	#Variation	ClinVar Variation Id	Allele Registry Id	HGVS Expressions	SYMBOL	Disease	Mondo Id	Mode of Inheritance	Assertion	Applied Evidence Codes (Met)	Applied Evidence Codes (Not Met)	Summary of interpretation	PubMed Articles	Expert Panel	Guideline	Approval Date	Published Date	Retracted	Evidence Repo Link	Uuid	mutation	AA1	AA_pos	AA2	Sequence	Length	uniprot_entry	AA2_symbol	diff_results
0	NM_206933.2(USH2A):c.15562A>G (p.Ser5188Gly)	48468	CA143409	NM_206933.2:c.15562A>G, NC_000001.11:g.215625828T>C, CM000663.2:g.215625828T>C, NC_000001.10:g.215799170T>C, CM000663.1:g.215799170T>C, NC_000001.9:g.213865793T>C, NG_009497.1:g.802569A>G, NM_206933.3:c.15562A>G, ENST00000307340.7:c.15562A>G, NM_206933.2(USH2A):c.15562A>G (p.Ser5188Gly)	USH2A	Usher syndrome	MONDO:0019501	Autosomal recessive inheritance	Benign	BA1		The filtering allele frequency of the p.Ser5188Gly variant in the USH2A gene is 6.8% (2200/30782) of South Asian chromosomes by the Genome Aggregation Database (http://gnomad.broadinstitute.org; calculated by using inverse allele frequency at https://www.cardiodb.org/allelefrequencyapp/), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive hearing loss variants (BA1).		Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2018-09-17	2019-07-17	False	https://erepo.genome.network/evrepo/ui/classification/CA143409/MONDO:0019501/005	6ea1fef2-f5b3-4739-8738-c6bf29fea20a	p.Ser5188Gly	Ser	5188	Gly	MNCPVLSLGSGFLFQVIEMLIFAYFASISLTESRGLFPRLENVGAFKKVSIVPTQAVCGLPDRSTFCHSSAAAESIQFCTQRFCIQDCPYRSSHPTYTALFSAGLSSCITPDKNDLHPNAHSNSASFIFGNHKSCFSSPPSPKLMASFTLAVWLKPEQQGVMCVIEKTVDGQIVFKLTISEKETMFYYRTVNGLQPPIKVMTLGRILVKKWIHLSVQVHQTKISFFINGVEKDHTPFNARTLSGSITDFASGTVQIGQSLNGLEQFVGRMQDFRLYQVALTNREILEVFSGDLLRLHAQSHCRCPGSHPRVHPLAQRYCIPNDAGDTADNRVSRLNPEAHPLSFVNDNDVGTSWVSNVFTNITQLNQGVTISVDLENGQYQVFYIIIQFFSPQPTEIRIQRKKENSLDWEDWQYFARNCGAFGMKNNGDLEKPDSVNCLQLSNFTPYSRGNVTFSILTPGPNYRPGYNNFYNTPSLQEFVKATQIRFHFHGQYYTTETAVNLRHRYYAVDEITISGRCQCHGHADNCDTTSQPYRCLCSQESFTEGLHCDRCLPLYNDKPFRQGDQVYAFNCKPCQCNSHSKSCHYNISVDPFPFEHFRGGGGVCDDCEHNTTGRNCELCKDYFFRQVGADPSAIDVCKPCDCDTVGTRNGSILCDQIGGQCNCKRHVSGRQCNQCQNGFYNLQELDPDGCSPCNCNTSGTVDGDITCHQNSGQCKCKANVIGLRCDHCNFGFKFLRSFNDVGCEPCQCNLHGSVNKFCNPHSGQCECKKEAKGLQCDTCRENFYGLDVTNCKACDCDTAGSLPGTVCNAKTGQCICKPNVEGRQCNKCLEGNFYLRQNNSFLCLPCNCDKTGTINGSLLCNKSTGQCPCKLGVTGLRCNQCEPHRYNLTIDNFQHCQMCECDSLGTLPGTICDPISGQCLCVPNRQGRRCNQCQPGFYISPGNATGCLPCSCHTTGAVNHICNSLTGQCVCQDASIAGQRCDQCKDHYFGFDPQTGRCQPCNCHLSGALNETCHLVTGQCFCKQFVTGSKCDACVPSASHLDVNNLLGCSKTPFQQPPPRGQVQSSSAINLSWSPPDSPNAHWLTYSLLRDGFEIYTTEDQYPYSIQYFLDTDLLPYTKYSYYIETTNVHGSTRSVAVTYKTKPGVPEGNLTLSYIIPIGSDSVTLTWTTLSNQSGPIEKYILSCAPLAGGQPCVSYEGHETSATIWNLVPFAKYDFSVQACTSGGCLHSLPITVTTAQAPPQRLSPPKMQKISSTELHVEWSPPAELNGIIIRYELYMRRLRSTKETTSEESRVFQSSGWLSPHSFVESANENALKPPQTMTTITGLEPYTKYEFRVLAVNMAGSVSSAWVSERTGESAPVFMIPPSVFPLSSYSLNISWEKPADNVTRGKVVGYDINMLSEQSPQQSIPMAFSQLLHTAKSQELSYTVEGLKPYRIYEFTITLCNSVGCVTSASGAGQTLAAAPAQLRPPLVKGINSTTIHLRWFPPEELNGPSPIYQLERRESSLPALMTTMMKGIRFIGNGYCKFPSSTHPVNTDFTGIKASFRTKVPEGLIVFAASPGNQEEYFALQLKKGRLYFLFDPQGSPVEVTTTNDHGKQYSDGKWHEIIAIRHQAFGQITLDGIYTGSSAILNGSTVIGDNTGVFLGGLPRSYTILRKDPEIIQKGFVGCLKDVHFMKNYNPSAIWEPLDWQSSEEQINVYNSWEGCPASLNEGAQFLGAGFLELHPYMFHGGMNFEISFKFRTDQLNGLLLFVYNKDGPDFLAMELKSGILTFRLNTSLAFTQVDLLLGLSYCNGKWNKVIIKKEGSFISASVNGLMKHASESGDQPLVVNSPVYVGGIPQELLNSYQHLCLEQGFGGCMKDVKFTRGAVVNLASVSSGAVRVNLDGCLSTDSAVNCRGNDSILVYQGKEQSVYEGGLQPFTEYLYRVIASHEGGSVYSDWSRGRTTGAAPQSVPTPSRVRSLNGYSIEVTWDEPVVRGVIEKYILKAYSEDSTRPPRMPSASAEFVNTSNLTGILTGLLPFKNYAVTLTACTLAGCTESSHALNISTPQEAPQEVQPPVAKSLPSSLLLSWNPPKKANGIITQYCLYMDGRLIYSGSEENYIVTDLAVFTPHQFLLSACTHVGCTNSSWVLLYTAQLPPEHVDSPVLTVLDSRTIHIQWKQPRKISGILERYVLYMSNHTHDFTIWSVIYNSTELFQDHMLQYVLPGNKYLIKLGACTGGGCTVSEASEALTDEDIPEGVPAPKAHSYSPDSFNVSWTEPEYPNGVITSYGLYLDGILIHNSSELSYRAYGFAPWSLHSFRVQACTAKGCALGPLVENRTLEAPPEGTVNVFVKTQGSRKAHVRWEAPFRPNGLLTHSVLFTGIFYVDPVGNNYTLLNVTKVMYSGEETNLWVLIDGLVPFTNYTVQVNISNSQGSLITDPITIAMPPGAPDGVLPPRLSSATPTSLQVVWSTPARNNAPGSPRYQLQMRSGDSTHGFLELFSNPSASLSYEVSDLQPYTEYMFRLVASNGFGSAHSSWIPFMTAEDKPGPVVPPILLDVKSRMMLVTWQHPRKSNGVITHYNIYLHGRLYLRTPGNVTNCTVMHLHPYTAYKFQVEACTSKGCSLSPESQTVWTLPGAPEGIPSPELFSDTPTSVIISWQPPTHPNGLVENFTIERRVKGKEEVTTLVTLPRSHSMRFIDKTSALSPWTKYEYRVLMSTLHGGTNSSAWVEVTTRPSRPAGVQPPVVTVLEPDAVQVTWKPPLIQNGDILSYEIHMPDPHITLTNVTSAVLSQKVTHLIPFTNYSVTIVACSGGNGYLGGCTESLPTYVTTHPTVPQNVGPLSVIPLSESYVVISWQPPSKPNGPNLRYELLRRKIQQPLASNPPEDLNRWHNIYSGTQWLYEDKGLSRFTTYEYMLFVHNSVGFTPSREVTVTTLAGLPERGANLTASVLNHTAIDVRWAKPTVQDLQGEVEYYTLFWSSATSNDSLKILPDVNSHVIGHLKPNTEYWIFISVFNGVHSINSAGLHATTCDGEPQGMLPPEVVIINSTAVRVIWTSPSNPNGVVTEYSIYVNNKLYKTGMNVPGSFILRDLSPFTIYDIQVEVCTIYACVKSNGTQITTVEDTPSDIPTPTIRGITSRSLQIDWVSPRKPNGIILGYDLLWKTWYPCAKTQKLVQDQSDELCKAVRCQKPESICGHICYSSEAKVCCNGVLYNPKPGHRCCEEKYIPFVLNSTGVCCGGRIQEAQPNHQCCSGYYARILPGEVCCPDEQHNRVSVGIGDSCCGRMPYSTSGNQICCAGRLHDGHGQKCCGRQIVSNDLECCGGEEGVVYNRLPGMFCCGQDYVNMSDTICCSASSGESKAHIKKNDPVPVKCCETELIPKSQKCCNGVGYNPLKYVCSDKISTGMMMKETKECRILCPASMEATEHCGRCDFNFTSHICTVIRGSHNSTGKASIEEMCSSAEETIHTGSVNTYSYTDVNLKPYMTYEYRISAWNSYGRGLSKAVRARTKEDVPQGVSPPTWTKIDNLEDTIVLNWRKPIQSNGPIIYYILLRNGIERFRGTSLSFSDKEGIQPFQEYSYQLKACTVAGCATSSKVVAATTQGVPESILPPSITALSAVALHLSWSVPEKSNGVIKEYQIRQVGKGLIHTDTTDRRQHTVTGLQPYTNYSFTLTACTSAGCTSSEPFLGQTLQAAPEGVWVTPRHIIINSTTVELYWSLPEKPNGLVSQYQLSRNGNLLFLGGSEEQNFTDKNLEPNSRYTYKLEVKTGGGSSASDDYIVQTPMSTPEEIYPPYNITVIGPYSIFVAWIPPGILIPEIPVEYNVLLNDGSVTPLAFSVGHHQSTLLENLTPFTQYEIRIQACQNGSCGVSSRMFVKTPEAAPMDLNSPVLKALGSACIEIKWMPPEKPNGIIINYFIYRRPAGIEEESVLFVWSEGALEFMDEGDTLRPFTLYEYRVRACNSKGSVESLWSLTQTLEAPPQDFPAPWAQATSAHSVLLNWTKPESPNGIISHYRVVYQERPDDPTFNSPTVHAFTVKGTSHQAHLYGLEPFTTYRIGVVAANHAGEILSPWTLIQTLESSPSGLRNFIVEQKENGRALLLQWSEPMRTNGVIKTYNIFSDGFLEYSGLNRQFLFRRLDPFTLYTLTLEACTRAGCAHSAPQPLWTDEAPPDSQLAPTVHSVKSTSVELSWSEPVNPNGKIIRYEVIRRCFEGKAWGNQTIQADEKIVFTEYNTERNTFMYNDTGLQPWTQCEYKIYTWNSAGHTCSSWNVVRTLQAPPEGLSPPVISYVSMNPQKLLISWIPPEQSNGIIQSYRLQRNEMLYPFSFDPVTFNYTDEELLPFSTYSYALQACTSGGCSTSKPTSITTLEAAPSEVSPPDLWAVSATQMNVCWSPPTVQNGKITKYLVRYDNKESLAGQGLCLLVSHLQPYSQYNFSLVACTNGGCTASVSKSAWTMEALPENMDSPTLQVTGSESIEITWKPPRNPNGQIRSYELRRDGTIVYTGLETRYRDFTLTPGVEYSYTVTASNSQGGILSPLVKDRTSPSAPSGMEPPKLQARGPQEILVNWDPPVRTNGDIINYTLFIRELFERETKIIHINTTHNSFGMQSYIVNQLKPFHRYEIRIQACTTLGCASSDWTFIQTPEIAPLMQPPPHLEVQMAPGGFQPTVSLLWTGPLQPNGKVLYYELYRRQIATQPRKSNPVLIYNGSSTSFIDSELLPFTEYEYQVWAVNSAGKAPSSWTWCRTGPAPPEGLRAPTFHVISSTQAVVNISAPGKPNGIVSLYRLFSSSAHGAETVLSEGMATQQTLHGLQAFTNYSIGVEACTCFNCCSKGPTAELRTHPAPPSGLSSPQIGTLASRTASFRWSPPMFPNGVIHSYELQFHVACPPDSALPCTPSQIETKYTGLGQKASLGGLQPYTTYKLRVVAHNEVGSTASEWISFTTQKELPQYRAPFSVDSNLSVVCVNWSDTFLLNGQLKEYVLTDGGRRVYSGLDTTLYIPRTADKTFFFQVICTTDEGSVKTPLIQYDTSTGLGLVLTTPGKKKGSRSKSTEFYSELWFIVLMAMLGLILLAIFLSLILQRKIHKEPYIRERPPLVPLQKRMSPLNVYPPGENHMGLADTKIPRSGTPVSIRSNRSACVLRIPSQNQTSLTYSQGSLHRSVSQLMDIQDKKVLMDNSLWEAIMGHNSGLYVDEEDLMNAIKDFSSVTKERTTFTDTHL	5202	O75445	G	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [3167, 3881], 'DISULFID_gain_score': array([0.000328  , 0.00131804]), 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [463, 4169, 4179, 4180], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.01517773, -0.02028877, -0.02481246, -0.02392626]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': [731], 'ZN_FING_gain_score': array([0.00185269])}
1	NM_000441.1(SLC26A4):c.1363A>T (p.Ile455Phe)	43507	CA132664	NM_000441.1:c.1363A>T, NC_000007.14:g.107694642A>T, CM000669.2:g.107694642A>T, NC_000007.13:g.107335087A>T, CM000669.1:g.107335087A>T, NC_000007.12:g.107122323A>T, NG_008489.1:g.39008A>T, XM_005250425.1:c.1363A>T, XM_005250425.2:c.1363A>T, XM_017012318.1:c.1285A>T, ENST00000265715.7:c.1363A>T, ENST00000460748.1:n.466A>T, ENST00000477350.5:n.210A>T, ENST00000480841.5:n.212A>T, ENST00000497446.5:n.378A>T, NM_000441.1(SLC26A4):c.1363A>T (p.Ile455Phe)	SLC26A4	Pendred syndrome	MONDO:0010134	Autosomal recessive inheritance	Benign	PP3, BA1	PS1, PM1, PM5	The filtering allele frequency of the p.Ile455Phe variant in the SLC26A4 gene is 3% (981/30778) of South Asian chromosomes by the Genome Aggregation Database (http://gnomad.broadinstitute.org; calculated by using inverse allele frequency at https://www.cardiodb.org/allelefrequencyapp/), which is a high frequency that is consistent with benign classification based on thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive hearing loss variants (BA1).		Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2018-09-28	2019-07-17	False	https://erepo.genome.network/evrepo/ui/classification/CA132664/MONDO:0010134/005	2b9fd19d-de91-41b2-a416-dc26fa5062e4	p.Ile455Phe	Ile	455	Phe	MAAPGGRSEPPQLPEYSCSYMVSRPVYSELAFQQQHERRLQERKTLRESLAKCCSCSRKRAFGVLKTLVPILEWLPKYRVKEWLLSDVISGVSTGLVATLQGMAYALLAAVPVGYGLYSAFFPILTYFIFGTSRHISVGPFPVVSLMVGSVVLSMAPDEHFLVSSSNGTVLNTTMIDTAARDTARVLIASALTLLVGIIQLIFGGLQIGFIVRYLADPLVGGFTTAAAFQVLVSQLKIVLNVSTKNYNGVLSIIYTLVEIFQNIGDTNLADFTAGLLTIVVCMAVKELNDRFRHKIPVPIPIEVIVTIIATAISYGANLEKNYNAGIVKSIPRGFLPPELPPVSLFSEMLAASFSIAVVAYAIAVSVGKVYATKYDYTIDGNQEFIAFGISNIFSGFFSCFVATTALSRTAVQESTGGKTQVAGIISAAIVMIAILALGKLLEPLQKSVLAAVVIANLKGMFMQLCDIPRLWRQNKIDAVIWVFTCIVSIILGLDLGLLAGLIFGLLTVVLRVQFPSWNGLGSIPSTDIYKSTKNYKNIEEPQGVKILRFSSPIFYGNVDGFKKCIKSTVGFDAIRVYNKRLKALRKIQKLIKSGQLRATKNGIISDAVSTNNAFEPDEDIEDLEELDIPTKEIEIQVDWNSELPVKVNVPKVPIHSLVLDCGAISFLDVVGVRSLRVIVKEFQRIDVNVYFASLQDYVIEKLEQCGFFDDNIRKDTFFLTVHDAILYLQNQVKSQEGQGSILETITLIQDCKDTLELIETELTEEELDVQDEAMRTLAS	780	O43511	F	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [344, 482], 'DNA_BIND_gain_score': array([0.00469792, 0.0023545 ]), 'TOPO_DOM_loss': [131, 132, 169], 'TOPO_DOM_gain': [], 'TOPO_DOM_loss_score': array([-0.00443423, -0.00413448, -0.01238739]), 'TRANSMEM_loss': [447], 'TRANSMEM_gain': [], 'TRANSMEM_loss_score': array([-0.04271233]), 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [561], 'DOMAIN_gain_score': array([0.01578605]), 'REGION_loss': [], 'REGION_gain': [615, 617], 'REGION_gain_score': array([0.00463057, 0.00484812]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
2	NM_000441.1(SLC26A4):c.565G>T (p.Ala189Ser)	43560	CA132732	NM_000441.1:c.565G>T, NC_000007.14:g.107674313G>T, CM000669.2:g.107674313G>T, NC_000007.13:g.107314758G>T, CM000669.1:g.107314758G>T, NC_000007.12:g.107101994G>T, NG_008489.1:g.18679G>T, XM_005250425.1:c.565G>T, XM_006716025.2:c.565G>T, XM_005250425.2:c.565G>T, XM_006716025.3:c.565G>T, XM_017012318.1:c.565G>T, ENST00000265715.7:c.565G>T, NM_000441.1(SLC26A4):c.565G>T (p.Ala189Ser)	SLC26A4	Pendred syndrome	MONDO:0010134	Autosomal recessive inheritance	Benign	BA1		The filtering allele frequency of the p.Ala1898Ser variant in the SLC26A4 gene is 1.2%  (324/24040) of African chromosomes by the Genome Aggregation Database (http://gnomad.broadinstitute.org; calculated by using inverse allele frequency at https://www.cardiodb.org/allelefrequencyapp/), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive hearing loss variants (BA1).		Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2018-09-28	2019-07-17	False	https://erepo.genome.network/evrepo/ui/classification/CA132732/MONDO:0010134/005	b905ae85-8973-4ed6-b603-52b3b342f2e0	p.Ala189Ser	Ala	189	Ser	MAAPGGRSEPPQLPEYSCSYMVSRPVYSELAFQQQHERRLQERKTLRESLAKCCSCSRKRAFGVLKTLVPILEWLPKYRVKEWLLSDVISGVSTGLVATLQGMAYALLAAVPVGYGLYSAFFPILTYFIFGTSRHISVGPFPVVSLMVGSVVLSMAPDEHFLVSSSNGTVLNTTMIDTAARDTARVLIASALTLLVGIIQLIFGGLQIGFIVRYLADPLVGGFTTAAAFQVLVSQLKIVLNVSTKNYNGVLSIIYTLVEIFQNIGDTNLADFTAGLLTIVVCMAVKELNDRFRHKIPVPIPIEVIVTIIATAISYGANLEKNYNAGIVKSIPRGFLPPELPPVSLFSEMLAASFSIAVVAYAIAVSVGKVYATKYDYTIDGNQEFIAFGISNIFSGFFSCFVATTALSRTAVQESTGGKTQVAGIISAAIVMIAILALGKLLEPLQKSVLAAVVIANLKGMFMQLCDIPRLWRQNKIDAVIWVFTCIVSIILGLDLGLLAGLIFGLLTVVLRVQFPSWNGLGSIPSTDIYKSTKNYKNIEEPQGVKILRFSSPIFYGNVDGFKKCIKSTVGFDAIRVYNKRLKALRKIQKLIKSGQLRATKNGIISDAVSTNNAFEPDEDIEDLEELDIPTKEIEIQVDWNSELPVKVNVPKVPIHSLVLDCGAISFLDVVGVRSLRVIVKEFQRIDVNVYFASLQDYVIEKLEQCGFFDDNIRKDTFFLTVHDAILYLQNQVKSQEGQGSILETITLIQDCKDTLELIETELTEEELDVQDEAMRTLAS	780	O43511	S	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [118, 434], 'DNA_BIND_gain': [], 'DNA_BIND_loss_score': array([-0.00735915, -0.00106102]), 'TOPO_DOM_loss': [131, 132, 161, 169, 170, 241, 257, 262, 287], 'TOPO_DOM_gain': [], 'TOPO_DOM_loss_score': array([-0.0225184 , -0.01455158, -0.01637238, -0.03226566, -0.03944385,
       -0.00538725, -0.0430885 , -0.0085696 , -0.00914037]), 'TRANSMEM_loss': [185, 188, 189, 482, 483], 'TRANSMEM_gain': [93, 206, 208, 209, 466], 'TRANSMEM_gain_score': array([0.01315469, 0.17592496, 0.20518589, 0.17680281, 0.00508606]), 'TRANSMEM_loss_score': array([-0.19610608, -0.35768336, -0.33171326, -0.00258875, -0.00299531]), 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [46], 'HELIX_gain': [157, 264], 'HELIX_gain_score': array([0.01623309, 0.02873641]), 'HELIX_loss_score': array([-0.00855398]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [420, 476, 487], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.00507486, -0.00756162, -0.00490123]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [364], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.00139064]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
3	NM_000257.4(MYH7):c.4130C>T (p.Thr1377Met)	42992	CA014494	NM_000257.4:c.4130C>T, NC_000014.9:g.23418249G>A, CM000676.2:g.23418249G>A, NC_000014.8:g.23887458G>A, CM000676.1:g.23887458G>A, NC_000014.7:g.22957298G>A, NG_007884.1:g.22413C>T, LRG_384:g.22413C>T, ENST00000355349.4:c.4130C>T, ENST00000355349.3:c.4130C>T, NM_000257.3:c.4130C>T, XM_017021340.1:c.4130C>T, NM_000257.4(MYH7):c.4130C>T (p.Thr1377Met)	MYH7	hypertrophic cardiomyopathy	MONDO:0005045	Autosomal dominant inheritance	Pathogenic	PS4, PM2, PP3, PP1_Strong	BS1, BS3, BS4, BP3, BP4, BP2, BP7, PS2, PS1, PM3, PS3, BA1, PM1, PM6, PM4, PM5, BS2	The NM_000257.4(MYH7):c.4130C>T (p.Thr1377Met) variant in MYH7 has been reported in >30 individuals with HCM (PS4; Richard 2003 PMID: 12707239; Van Driest 2004 PMID: 15358028; Girolami 2006 PMID: 16858239; Millat 2010 PMID: 20624503; Witjas-Paalberends 2013 PMID: 23674513; Berge 2014 PMID: 24111713; Helms 2014 PMID: 25031304; Adler 2016 PMID: 26743238; Montag 2017 PMID: 29101517; Pérez-Sánchez 2018 PMID: 28687478; Wang 2018 PMID: 29343710; Ambry pers. comm.; CHEO pers. comm.; GeneDx pers. comm., Invitae pers. comm.; LMM pers. comm.; Mayo pers. comm.; OMGL pers. comm.). This variant segregated with disease in >10 affected relatives with HCM in at least 4 families (PP1_strong; Pérez-Sánchez 2018 PMID: 28687478; Wang 2018 PMID: 29343710; LMM pers. comm.). This variant was identified in 0.0009% (1/113754) of European chromosomes by gnomAD v2.1.1 (PM2; https://gnomad.broadinstitute.org). Computational prediction tools and conservation analysis suggest that this variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for hypertrophic cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (PMID:29300372): PS4; PP1_Strong; PM2; PP3.		Cardiomyopathy VCEP		2021-11-23	2021-12-09	False	https://erepo.genome.network/evrepo/ui/classification/CA014494/MONDO:0005045/002	f4dea66d-87b3-467f-862c-c239472e6930	p.Thr1377Met	Thr	1377	Met	MGDSEMAVFGAAAPYLRKSEKERLEAQTRPFDLKKDVFVPDDKQEFVKAKIVSREGGKVTAETEYGKTVTVKEDQVMQQNPPKFDKIEDMAMLTFLHEPAVLYNLKDRYGSWMIYTYSGLFCVTVNPYKWLPVYTPEVVAAYRGKKRSEAPPHIFSISDNAYQYMLTDRENQSILITGESGAGKTVNTKRVIQYFAVIAAIGDRSKKDQSPGKGTLEDQIIQANPALEAFGNAKTVRNDNSSRFGKFIRIHFGATGKLASADIETYLLEKSRVIFQLKAERDYHIFYQILSNKKPELLDMLLITNNPYDYAFISQGETTVASIDDAEELMATDNAFDVLGFTSEEKNSMYKLTGAIMHFGNMKFKLKQREEQAEPDGTEEADKSAYLMGLNSADLLKGLCHPRVKVGNEYVTKGQNVQQVIYATGALAKAVYERMFNWMVTRINATLETKQPRQYFIGVLDIAGFEIFDFNSFEQLCINFTNEKLQQFFNHHMFVLEQEEYKKEGIEWTFIDFGMDLQACIDLIEKPMGIMSILEEECMFPKATDMTFKAKLFDNHLGKSANFQKPRNIKGKPEAHFSLIHYAGIVDYNIIGWLQKNKDPLNETVVGLYQKSSLKLLSTLFANYAGADAPIEKGKGKAKKGSSFQTVSALHRENLNKLMTNLRSTHPHFVRCIIPNETKSPGVMDNPLVMHQLRCNGVLEGIRICRKGFPNRILYGDFRQRYRILNPAAIPEGQFIDSRKGAEKLLSSLDIDHNQYKFGHTKVFFKAGLLGLLEEMRDERLSRIITRIQAQSRGVLARMEYKKLLERRDSLLVIQWNIRAFMGVKNWPWMKLYFKIKPLLKSAEREKEMASMKEEFTRLKEALEKSEARRKELEEKMVSLLQEKNDLQLQVQAEQDNLADAEERCDQLIKNKIQLEAKVKEMNERLEDEEEMNAELTAKKRKLEDECSELKRDIDDLELTLAKVEKEKHATENKVKNLTEEMAGLDEIIAKLTKEKKALQEAHQQALDDLQAEEDKVNTLTKAKVKLEQQVDDLEGSLEQEKKVRMDLERAKRKLEGDLKLTQESIMDLENDKQQLDERLKKKDFELNALNARIEDEQALGSQLQKKLKELQARIEELEEELEAERTARAKVEKLRSDLSRELEEISERLEEAGGATSVQIEMNKKREAEFQKMRRDLEEATLQHEATAAALRKKHADSVAELGEQIDNLQRVKQKLEKEKSEFKLELDDVTSNMEQIIKAKANLEKMCRTLEDQMNEHRSKAEETQRSVNDLTSQRAKLQTENGELSRQLDEKEALISQLTRGKLTYTQQLEDLKRQLEEEVKAKNALAHALQSARHDCDLLREQYEEETEAKAELQRVLSKANSEVAQWRTKYETDAIQRTEELEEAKKKLAQRLQEAEEAVEAVNAKCSSLEKTKHRLQNEIEDLMVDVERSNAAAAALDKKQRNFDKILAEWKQKYEESQSELESSQKEARSLSTELFKLKNAYEESLEHLETFKRENKNLQEEISDLTEQLGSSGKTIHELEKVRKQLEAEKMELQSALEEAEASLEHEEGKILRAQLEFNQIKAEIERKLAEKDEEMEQAKRNHLRVVDSLQTSLDAETRSRNEALRVKKKMEGDLNEMEIQLSHANRMAAEAQKQVKSLQSLLKDTQIQLDDAVRANDDLKENIAIVERRNNLLQAELEELRAVVEQTERSRKLAEQELIETSERVQLLHSQNTSLINQKKKMDADLSQLQTEVEEAVQECRNAEEKAKKAITDAAMMAEELKKEQDTSAHLERMKKNMEQTIKDLQHRLDEAEQIALKGGKKQLQKLEARVRELENELEAEQKRNAESVKGMRKSERRIKELTYQTEEDRKNLLRLQDLVDKLQLKVKAYKRQAEEAEEQANTNLSKFRKVQHELDEAEERADIAESQVNKLRAKSRDIGTKGLNEE	1935	P12883	M	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [149, 150, 151, 152, 153, 156, 157, 158, 159, 162, 163, 166, 168, 170], 'DOMAIN_gain_score': array([0.24199778, 0.25606072, 0.27471036, 0.22771114, 0.26296085,
       0.26886284, 0.28698754, 0.30672413, 0.31864518, 0.30717313,
       0.33919299, 0.28289211, 0.20040709, 0.29757994]), 'REGION_loss': [874], 'REGION_gain': [], 'REGION_loss_score': array([-0.00400066]), 'REPEAT_loss': [375, 879, 888, 980, 1009, 1111, 1122, 1156, 1841], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.00090849, -0.00425076, -0.00356412, -0.0015204 , -0.00230813,
       -0.00364977, -0.00399029, -0.00277781, -0.00197828]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
4	NM_000257.4(MYH7):c.4066G>A (p.Glu1356Lys)	164294	CA014400	NM_000257.4:c.4066G>A, NC_000014.9:g.23418313C>T, CM000676.2:g.23418313C>T, NC_000014.8:g.23887522C>T, CM000676.1:g.23887522C>T, NC_000014.7:g.22957362C>T, NG_007884.1:g.22349G>A, LRG_384:g.22349G>A, ENST00000355349.4:c.4066G>A, ENST00000355349.3:c.4066G>A, NM_000257.3:c.4066G>A, XM_017021340.1:c.4066G>A, NM_000257.4(MYH7):c.4066G>A (p.Glu1356Lys)	MYH7	hypertrophic cardiomyopathy	MONDO:0005045	Autosomal dominant inheritance	Pathogenic	PS4, PM2, PP3, PP1_Strong	BS3, PS1, PS2, PS3, PM5, PM1, PM6	The NM_000257.4(MYH7):c.4066G>A (p.Glu1356Lys) variant has been identified in at least 40 individuals with HCM, including 1 with features of RCM (PS4; Brito 2005 PMID: 16335287; Van Driest 2004 PMID: 15358028; Perrot 2005 PMID: 15856146; Theis 2009 PMID: 19808356; Brito 2012 PMID: 22857948; Zou 2013 PMID: 23283745; Lopes 2013 PMID: 23396983; Núñez 2013 PMID: 23782526; Captur 2014 PMID: 24704860; Homburger 2016 PMID: 27247418; Walsh 2017 PMID: 27532257; Mademont-Soler 2017 PMID: 28771489; Lu 2018 PMID: 30165862; Ambry pers. comm.; GeneDx pers. comm.; Invitae pers. comm.; LMM pers. comm.; OMGL pers. comm.). This variant segregates with HCM in at least 10 relatives from 5 families (PP1_Strong; LMM pers. comm.; OMGL pers. comm.; Stanford Inherited Heart Center pers. comm.). This variant was also reported to segregate with disease in a family with HCM, although details were not provided (Brito 2012 PMID: 22857948). This variant was absent from large population studies (PM2; gnomAD v2.1.1, http://gnomad.broadinstitute.org). In vitro functional studies provide some evidence that this variant alters protein function; however, this data is currently insufficient to establish functional impact and apply PS3 (Armel 2010 PMID: 19913502; Wolny 2013 PMID: 24047955). Computational prediction tools and conservation analysis suggest that this variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for hypertrophic cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (Kelly 2018 PMID:29300372): PS4, PP1_Strong, PM2, PP3.		Cardiomyopathy VCEP		2021-11-30	2021-12-09	False	https://erepo.genome.network/evrepo/ui/classification/CA014400/MONDO:0005045/002	8112b9be-baa4-485d-a686-c223e112af4e	p.Glu1356Lys	Glu	1356	Lys	MGDSEMAVFGAAAPYLRKSEKERLEAQTRPFDLKKDVFVPDDKQEFVKAKIVSREGGKVTAETEYGKTVTVKEDQVMQQNPPKFDKIEDMAMLTFLHEPAVLYNLKDRYGSWMIYTYSGLFCVTVNPYKWLPVYTPEVVAAYRGKKRSEAPPHIFSISDNAYQYMLTDRENQSILITGESGAGKTVNTKRVIQYFAVIAAIGDRSKKDQSPGKGTLEDQIIQANPALEAFGNAKTVRNDNSSRFGKFIRIHFGATGKLASADIETYLLEKSRVIFQLKAERDYHIFYQILSNKKPELLDMLLITNNPYDYAFISQGETTVASIDDAEELMATDNAFDVLGFTSEEKNSMYKLTGAIMHFGNMKFKLKQREEQAEPDGTEEADKSAYLMGLNSADLLKGLCHPRVKVGNEYVTKGQNVQQVIYATGALAKAVYERMFNWMVTRINATLETKQPRQYFIGVLDIAGFEIFDFNSFEQLCINFTNEKLQQFFNHHMFVLEQEEYKKEGIEWTFIDFGMDLQACIDLIEKPMGIMSILEEECMFPKATDMTFKAKLFDNHLGKSANFQKPRNIKGKPEAHFSLIHYAGIVDYNIIGWLQKNKDPLNETVVGLYQKSSLKLLSTLFANYAGADAPIEKGKGKAKKGSSFQTVSALHRENLNKLMTNLRSTHPHFVRCIIPNETKSPGVMDNPLVMHQLRCNGVLEGIRICRKGFPNRILYGDFRQRYRILNPAAIPEGQFIDSRKGAEKLLSSLDIDHNQYKFGHTKVFFKAGLLGLLEEMRDERLSRIITRIQAQSRGVLARMEYKKLLERRDSLLVIQWNIRAFMGVKNWPWMKLYFKIKPLLKSAEREKEMASMKEEFTRLKEALEKSEARRKELEEKMVSLLQEKNDLQLQVQAEQDNLADAEERCDQLIKNKIQLEAKVKEMNERLEDEEEMNAELTAKKRKLEDECSELKRDIDDLELTLAKVEKEKHATENKVKNLTEEMAGLDEIIAKLTKEKKALQEAHQQALDDLQAEEDKVNTLTKAKVKLEQQVDDLEGSLEQEKKVRMDLERAKRKLEGDLKLTQESIMDLENDKQQLDERLKKKDFELNALNARIEDEQALGSQLQKKLKELQARIEELEEELEAERTARAKVEKLRSDLSRELEEISERLEEAGGATSVQIEMNKKREAEFQKMRRDLEEATLQHEATAAALRKKHADSVAELGEQIDNLQRVKQKLEKEKSEFKLELDDVTSNMEQIIKAKANLEKMCRTLEDQMNEHRSKAEETQRSVNDLTSQRAKLQTENGELSRQLDEKEALISQLTRGKLTYTQQLEDLKRQLEEEVKAKNALAHALQSARHDCDLLREQYEEETEAKAELQRVLSKANSEVAQWRTKYETDAIQRTEELEEAKKKLAQRLQEAEEAVEAVNAKCSSLEKTKHRLQNEIEDLMVDVERSNAAAAALDKKQRNFDKILAEWKQKYEESQSELESSQKEARSLSTELFKLKNAYEESLEHLETFKRENKNLQEEISDLTEQLGSSGKTIHELEKVRKQLEAEKMELQSALEEAEASLEHEEGKILRAQLEFNQIKAEIERKLAEKDEEMEQAKRNHLRVVDSLQTSLDAETRSRNEALRVKKKMEGDLNEMEIQLSHANRMAAEAQKQVKSLQSLLKDTQIQLDDAVRANDDLKENIAIVERRNNLLQAELEELRAVVEQTERSRKLAEQELIETSERVQLLHSQNTSLINQKKKMDADLSQLQTEVEEAVQECRNAEEKAKKAITDAAMMAEELKKEQDTSAHLERMKKNMEQTIKDLQHRLDEAEQIALKGGKKQLQKLEARVRELENELEAEQKRNAESVKGMRKSERRIKELTYQTEEDRKNLLRLQDLVDKLQLKVKAYKRQAEEAEEQANTNLSKFRKVQHELDEAEERADIAESQVNKLRAKSRDIGTKGLNEE	1935	P12883	K	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [152], 'DOMAIN_gain_score': array([0.02941442]), 'REGION_loss': [874, 1264, 1271], 'REGION_gain': [], 'REGION_loss_score': array([-0.00559813, -0.00501704, -0.00457394]), 'REPEAT_loss': [888, 980, 1009, 1111, 1156, 1160], 'REPEAT_gain': [63, 79, 83, 92, 397], 'REPEAT_gain_score': array([0.00310147, 0.00296265, 0.00263131, 0.00242138, 0.00247145]), 'REPEAT_loss_score': array([-0.00309706, -0.00197119, -0.00240499, -0.00185359, -0.00545973,
       -0.00484395]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
5	NM_000257.4(MYH7):c.3158G>A (p.Arg1053Gln)	155814	CA013417	NM_000257.4:c.3158G>A, NC_000014.9:g.23422267C>T, CM000676.2:g.23422267C>T, NC_000014.8:g.23891476C>T, CM000676.1:g.23891476C>T, NC_000014.7:g.22961316C>T, NG_007884.1:g.18395G>A, LRG_384:g.18395G>A, ENST00000355349.4:c.3158G>A, ENST00000355349.3:c.3158G>A, NM_000257.3:c.3158G>A, XR_245686.3:n.3264G>A, XM_017021340.1:c.3158G>A, NM_000257.4(MYH7):c.3158G>A (p.Arg1053Gln)	MYH7	hypertrophic cardiomyopathy	MONDO:0005045	Autosomal dominant inheritance	Pathogenic	PS4, PP1_Strong, PM2, PP3	BS1, BS3, PS1, PS2, BP4, PM5, PM1, PM6, BA1, PS3	The NM_000257.4(MYH7):c.3158G>A (p.Arg1053Gln) variant in MYH7 has been reported in >35 individuals with hypertrophic cardiomyopathy (HCM), a large proportion of which are of Finnish ancestry (PS4; Kärkkäinen 2004 PMID:15556047; Jääskeläinen 2014 PMID:24888384; Walsh 2017 PMID:27532257; Ambry pers. comm.; GeneDx pers. comm., Invitae pers. comm.; LMM pers. comm.; OMGL pers. comm.). This variant segregated with disease in >15 affected individuals with HCM in 9 families (PP1_Moderate; Kärkkäinen 2004 PMID:15556047; GeneDx pers. comm.; OMGL pers. comm.). This variant was identified in 0.040% (FAF 95% CI; 16/25124) of Finnish chromosomes in gnomAD v2.1.1 (http://gnomad.broadinstitute.org), but was absent from other populations and is an established Finnish founder variant. Computational prediction tools and conservation analysis suggest that this variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for hypertrophic cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (Kelly 2018 PMID:29300372): PS4; PP1_Strong; PM2; PP3.	24888384, 27532257, 15556047, 15556047	Cardiomyopathy VCEP		2021-11-30	2021-12-09	False	https://erepo.genome.network/evrepo/ui/classification/CA013417/MONDO:0005045/002	da96f339-d77d-4caf-afe3-768754b0efca	p.Arg1053Gln	Arg	1053	Gln	MGDSEMAVFGAAAPYLRKSEKERLEAQTRPFDLKKDVFVPDDKQEFVKAKIVSREGGKVTAETEYGKTVTVKEDQVMQQNPPKFDKIEDMAMLTFLHEPAVLYNLKDRYGSWMIYTYSGLFCVTVNPYKWLPVYTPEVVAAYRGKKRSEAPPHIFSISDNAYQYMLTDRENQSILITGESGAGKTVNTKRVIQYFAVIAAIGDRSKKDQSPGKGTLEDQIIQANPALEAFGNAKTVRNDNSSRFGKFIRIHFGATGKLASADIETYLLEKSRVIFQLKAERDYHIFYQILSNKKPELLDMLLITNNPYDYAFISQGETTVASIDDAEELMATDNAFDVLGFTSEEKNSMYKLTGAIMHFGNMKFKLKQREEQAEPDGTEEADKSAYLMGLNSADLLKGLCHPRVKVGNEYVTKGQNVQQVIYATGALAKAVYERMFNWMVTRINATLETKQPRQYFIGVLDIAGFEIFDFNSFEQLCINFTNEKLQQFFNHHMFVLEQEEYKKEGIEWTFIDFGMDLQACIDLIEKPMGIMSILEEECMFPKATDMTFKAKLFDNHLGKSANFQKPRNIKGKPEAHFSLIHYAGIVDYNIIGWLQKNKDPLNETVVGLYQKSSLKLLSTLFANYAGADAPIEKGKGKAKKGSSFQTVSALHRENLNKLMTNLRSTHPHFVRCIIPNETKSPGVMDNPLVMHQLRCNGVLEGIRICRKGFPNRILYGDFRQRYRILNPAAIPEGQFIDSRKGAEKLLSSLDIDHNQYKFGHTKVFFKAGLLGLLEEMRDERLSRIITRIQAQSRGVLARMEYKKLLERRDSLLVIQWNIRAFMGVKNWPWMKLYFKIKPLLKSAEREKEMASMKEEFTRLKEALEKSEARRKELEEKMVSLLQEKNDLQLQVQAEQDNLADAEERCDQLIKNKIQLEAKVKEMNERLEDEEEMNAELTAKKRKLEDECSELKRDIDDLELTLAKVEKEKHATENKVKNLTEEMAGLDEIIAKLTKEKKALQEAHQQALDDLQAEEDKVNTLTKAKVKLEQQVDDLEGSLEQEKKVRMDLERAKRKLEGDLKLTQESIMDLENDKQQLDERLKKKDFELNALNARIEDEQALGSQLQKKLKELQARIEELEEELEAERTARAKVEKLRSDLSRELEEISERLEEAGGATSVQIEMNKKREAEFQKMRRDLEEATLQHEATAAALRKKHADSVAELGEQIDNLQRVKQKLEKEKSEFKLELDDVTSNMEQIIKAKANLEKMCRTLEDQMNEHRSKAEETQRSVNDLTSQRAKLQTENGELSRQLDEKEALISQLTRGKLTYTQQLEDLKRQLEEEVKAKNALAHALQSARHDCDLLREQYEEETEAKAELQRVLSKANSEVAQWRTKYETDAIQRTEELEEAKKKLAQRLQEAEEAVEAVNAKCSSLEKTKHRLQNEIEDLMVDVERSNAAAAALDKKQRNFDKILAEWKQKYEESQSELESSQKEARSLSTELFKLKNAYEESLEHLETFKRENKNLQEEISDLTEQLGSSGKTIHELEKVRKQLEAEKMELQSALEEAEASLEHEEGKILRAQLEFNQIKAEIERKLAEKDEEMEQAKRNHLRVVDSLQTSLDAETRSRNEALRVKKKMEGDLNEMEIQLSHANRMAAEAQKQVKSLQSLLKDTQIQLDDAVRANDDLKENIAIVERRNNLLQAELEELRAVVEQTERSRKLAEQELIETSERVQLLHSQNTSLINQKKKMDADLSQLQTEVEEAVQECRNAEEKAKKAITDAAMMAEELKKEQDTSAHLERMKKNMEQTIKDLQHRLDEAEQIALKGGKKQLQKLEARVRELENELEAEQKRNAESVKGMRKSERRIKELTYQTEEDRKNLLRLQDLVDKLQLKVKAYKRQAEEAEEQANTNLSKFRKVQHELDEAEERADIAESQVNKLRAKSRDIGTKGLNEE	1935	P12883	Q	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [1193, 1197, 1205], 'REGION_gain_score': array([0.00516224, 0.00467807, 0.0038625 ]), 'REPEAT_loss': [47, 87, 105, 375, 879, 888, 980, 1009, 1013, 1059, 1083, 1086, 1091, 1093, 1101, 1102, 1111, 1116, 1120, 1122, 1156, 1160, 1162], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.00161117, -0.00151235, -0.00139099, -0.00059903, -0.00584018,
       -0.00885385, -0.01030493, -0.01152068, -0.01039386, -0.03399616,
       -0.01064867, -0.01281255, -0.01710498, -0.01233524, -0.0233264 ,
       -0.02163917, -0.01643568, -0.01402855, -0.01042801, -0.01141745,
       -0.00951713, -0.00704741, -0.00762808]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
6	NM_000257.3(MYH7):c.2722C>G (p.Leu908Val)	14097	CA012953	NM_000257.3:c.2722C>G, NC_000014.9:g.23424107G>C, CM000676.2:g.23424107G>C, NC_000014.8:g.23893316G>C, CM000676.1:g.23893316G>C, NC_000014.7:g.22963156G>C, NG_007884.1:g.16555C>G, LRG_384:g.16555C>G, XR_245686.3:n.2828C>G, XM_017021340.1:c.2722C>G, NM_000257.4:c.2722C>G, ENST00000355349.3:c.2722C>G, NM_000257.3(MYH7):c.2722C>G (p.Leu908Val)	MYH7	hypertrophic cardiomyopathy	MONDO:0005045	Autosomal dominant inheritance	Pathogenic	PS4, PP3, PM1, PM2, PP1_Strong		The c.2722C>G (p.Leu908Val) variant in MYH7 has been reported in >20 individuals with hypertrophic cardiomyopathy (PS4; PMID:1638703; PMID:8483915 PMID:12473556; PMID:12975413; PMID:27532257; Partners LMM ClinVar SCV000059471.5; AGCMC Sydney ClinVar SCV000692499.1; SHaRe consortium, PMID: 30297972). This variant segregated with disease in >20 affected individuals (PP1_Strong; PMID:1638703; PMID:8483915; Partners LMM ClinVar SCV000059471.5). This variant was absent from large population studies (PM2; http://exac.broadinstitute.org). This variant lies in the head region of the protein (aa 181-937) and missense variants in this region are statistically more likely to be disease-associated (PM1; PMID:27532257). Computational prediction tools and conservation analysis suggest that this variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for hypertrophic cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (PMID:29300372): PS4; PP1_ Strong; PM1; PM2; PP3	27532257, 12473556, 8483915, 1638703, 12975413, 27532257, 8483915, 1638703	Cardiomyopathy VCEP		2016-12-15	2018-11-16	False	https://erepo.genome.network/evrepo/ui/classification/CA012953/MONDO:0005045/002	bd7ac89f-9ef0-4c1b-9884-893fd733703d	p.Leu908Val	Leu	908	Val	MGDSEMAVFGAAAPYLRKSEKERLEAQTRPFDLKKDVFVPDDKQEFVKAKIVSREGGKVTAETEYGKTVTVKEDQVMQQNPPKFDKIEDMAMLTFLHEPAVLYNLKDRYGSWMIYTYSGLFCVTVNPYKWLPVYTPEVVAAYRGKKRSEAPPHIFSISDNAYQYMLTDRENQSILITGESGAGKTVNTKRVIQYFAVIAAIGDRSKKDQSPGKGTLEDQIIQANPALEAFGNAKTVRNDNSSRFGKFIRIHFGATGKLASADIETYLLEKSRVIFQLKAERDYHIFYQILSNKKPELLDMLLITNNPYDYAFISQGETTVASIDDAEELMATDNAFDVLGFTSEEKNSMYKLTGAIMHFGNMKFKLKQREEQAEPDGTEEADKSAYLMGLNSADLLKGLCHPRVKVGNEYVTKGQNVQQVIYATGALAKAVYERMFNWMVTRINATLETKQPRQYFIGVLDIAGFEIFDFNSFEQLCINFTNEKLQQFFNHHMFVLEQEEYKKEGIEWTFIDFGMDLQACIDLIEKPMGIMSILEEECMFPKATDMTFKAKLFDNHLGKSANFQKPRNIKGKPEAHFSLIHYAGIVDYNIIGWLQKNKDPLNETVVGLYQKSSLKLLSTLFANYAGADAPIEKGKGKAKKGSSFQTVSALHRENLNKLMTNLRSTHPHFVRCIIPNETKSPGVMDNPLVMHQLRCNGVLEGIRICRKGFPNRILYGDFRQRYRILNPAAIPEGQFIDSRKGAEKLLSSLDIDHNQYKFGHTKVFFKAGLLGLLEEMRDERLSRIITRIQAQSRGVLARMEYKKLLERRDSLLVIQWNIRAFMGVKNWPWMKLYFKIKPLLKSAEREKEMASMKEEFTRLKEALEKSEARRKELEEKMVSLLQEKNDLQLQVQAEQDNLADAEERCDQLIKNKIQLEAKVKEMNERLEDEEEMNAELTAKKRKLEDECSELKRDIDDLELTLAKVEKEKHATENKVKNLTEEMAGLDEIIAKLTKEKKALQEAHQQALDDLQAEEDKVNTLTKAKVKLEQQVDDLEGSLEQEKKVRMDLERAKRKLEGDLKLTQESIMDLENDKQQLDERLKKKDFELNALNARIEDEQALGSQLQKKLKELQARIEELEEELEAERTARAKVEKLRSDLSRELEEISERLEEAGGATSVQIEMNKKREAEFQKMRRDLEEATLQHEATAAALRKKHADSVAELGEQIDNLQRVKQKLEKEKSEFKLELDDVTSNMEQIIKAKANLEKMCRTLEDQMNEHRSKAEETQRSVNDLTSQRAKLQTENGELSRQLDEKEALISQLTRGKLTYTQQLEDLKRQLEEEVKAKNALAHALQSARHDCDLLREQYEEETEAKAELQRVLSKANSEVAQWRTKYETDAIQRTEELEEAKKKLAQRLQEAEEAVEAVNAKCSSLEKTKHRLQNEIEDLMVDVERSNAAAAALDKKQRNFDKILAEWKQKYEESQSELESSQKEARSLSTELFKLKNAYEESLEHLETFKRENKNLQEEISDLTEQLGSSGKTIHELEKVRKQLEAEKMELQSALEEAEASLEHEEGKILRAQLEFNQIKAEIERKLAEKDEEMEQAKRNHLRVVDSLQTSLDAETRSRNEALRVKKKMEGDLNEMEIQLSHANRMAAEAQKQVKSLQSLLKDTQIQLDDAVRANDDLKENIAIVERRNNLLQAELEELRAVVEQTERSRKLAEQELIETSERVQLLHSQNTSLINQKKKMDADLSQLQTEVEEAVQECRNAEEKAKKAITDAAMMAEELKKEQDTSAHLERMKKNMEQTIKDLQHRLDEAEQIALKGGKKQLQKLEARVRELENELEAEQKRNAESVKGMRKSERRIKELTYQTEEDRKNLLRLQDLVDKLQLKVKAYKRQAEEAEEQANTNLSKFRKVQHELDEAEERADIAESQVNKLRAKSRDIGTKGLNEE	1935	P12883	V	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [866, 874, 876, 1264], 'REGION_gain': [], 'REGION_loss_score': array([-0.01504868, -0.01194566, -0.01317149, -0.00150222]), 'REPEAT_loss': [877, 879, 888, 890, 900, 902, 903, 909, 980, 996, 1000, 1009, 1013, 1079, 1083], 'REPEAT_gain': [63, 70, 76, 79, 83, 92, 93, 1115, 1150, 1168, 1178, 1192, 1193, 1194], 'REPEAT_gain_score': array([0.00374943, 0.00401574, 0.00404078, 0.00406551, 0.00391066,
       0.00405842, 0.00427413, 0.00642705, 0.00808853, 0.01154739,
       0.01815599, 0.02130264, 0.01700503, 0.01988447]), 'REPEAT_loss_score': array([-0.0181278 , -0.00530159, -0.01959431, -0.02485836, -0.05766046,
       -0.09700447, -0.13282758, -0.14546865, -0.01535666, -0.02557492,
       -0.02690566, -0.02660364, -0.02990961, -0.01994509, -0.00641096]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
7	NM_000257.3(MYH7):c.2717A>G (p.Asp906Gly)	14125	CA012936	NM_000257.3:c.2717A>G, XR_245686.3:n.2823A>G, XM_017021340.1:c.2717A>G, NM_000257.4:c.2717A>G, ENST00000355349.3:c.2717A>G, NC_000014.9:g.23424112T>C, CM000676.2:g.23424112T>C, NC_000014.8:g.23893321T>C, CM000676.1:g.23893321T>C, NC_000014.7:g.22963161T>C, NG_007884.1:g.16550A>G, LRG_384:g.16550A>G, NM_000257.3(MYH7):c.2717A>G (p.Asp906Gly)	MYH7	hypertrophic cardiomyopathy	MONDO:0005045	Autosomal dominant inheritance	Pathogenic	PS4, PP1_Strong, PM1, PM2		The c.2717A>G (p.Asp906Gly) variant in MYH7 has been reported in >20 individuals with hypertrophic cardiomyopathy (PS4; PMID:27532257; PMID:12081993; PMID:15528230; PMID:16267253; PMID:24510615; Partners LMM ClinVar SCV000059468.5). This variant segregated with disease in 10 affected individuals (PP1_Strong; PMID:12081993; PMID:15528230). This variant was absent from large population studies (PM2; http://exac.broadinstitute.org). This variant lies in the head region of the protein (aa 181-937) and missense variants in this region are statistically more likely to be disease-associated (PM1; PMID:27532257). In summary, this variant meets criteria to be classified as pathogenic for hypertrophic cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (PMID:29300372): PS4; PP1_ Strong; PM1; PM2	16267253, 15528230, 24510615, 12081993, 27532257, 15528230, 12081993, 27532257	Cardiomyopathy VCEP		2016-12-15	2018-11-16	False	https://erepo.genome.network/evrepo/ui/classification/CA012936/MONDO:0005045/002	6a11c78d-e05e-417f-8453-1e66356e09e9	p.Asp906Gly	Asp	906	Gly	MGDSEMAVFGAAAPYLRKSEKERLEAQTRPFDLKKDVFVPDDKQEFVKAKIVSREGGKVTAETEYGKTVTVKEDQVMQQNPPKFDKIEDMAMLTFLHEPAVLYNLKDRYGSWMIYTYSGLFCVTVNPYKWLPVYTPEVVAAYRGKKRSEAPPHIFSISDNAYQYMLTDRENQSILITGESGAGKTVNTKRVIQYFAVIAAIGDRSKKDQSPGKGTLEDQIIQANPALEAFGNAKTVRNDNSSRFGKFIRIHFGATGKLASADIETYLLEKSRVIFQLKAERDYHIFYQILSNKKPELLDMLLITNNPYDYAFISQGETTVASIDDAEELMATDNAFDVLGFTSEEKNSMYKLTGAIMHFGNMKFKLKQREEQAEPDGTEEADKSAYLMGLNSADLLKGLCHPRVKVGNEYVTKGQNVQQVIYATGALAKAVYERMFNWMVTRINATLETKQPRQYFIGVLDIAGFEIFDFNSFEQLCINFTNEKLQQFFNHHMFVLEQEEYKKEGIEWTFIDFGMDLQACIDLIEKPMGIMSILEEECMFPKATDMTFKAKLFDNHLGKSANFQKPRNIKGKPEAHFSLIHYAGIVDYNIIGWLQKNKDPLNETVVGLYQKSSLKLLSTLFANYAGADAPIEKGKGKAKKGSSFQTVSALHRENLNKLMTNLRSTHPHFVRCIIPNETKSPGVMDNPLVMHQLRCNGVLEGIRICRKGFPNRILYGDFRQRYRILNPAAIPEGQFIDSRKGAEKLLSSLDIDHNQYKFGHTKVFFKAGLLGLLEEMRDERLSRIITRIQAQSRGVLARMEYKKLLERRDSLLVIQWNIRAFMGVKNWPWMKLYFKIKPLLKSAEREKEMASMKEEFTRLKEALEKSEARRKELEEKMVSLLQEKNDLQLQVQAEQDNLADAEERCDQLIKNKIQLEAKVKEMNERLEDEEEMNAELTAKKRKLEDECSELKRDIDDLELTLAKVEKEKHATENKVKNLTEEMAGLDEIIAKLTKEKKALQEAHQQALDDLQAEEDKVNTLTKAKVKLEQQVDDLEGSLEQEKKVRMDLERAKRKLEGDLKLTQESIMDLENDKQQLDERLKKKDFELNALNARIEDEQALGSQLQKKLKELQARIEELEEELEAERTARAKVEKLRSDLSRELEEISERLEEAGGATSVQIEMNKKREAEFQKMRRDLEEATLQHEATAAALRKKHADSVAELGEQIDNLQRVKQKLEKEKSEFKLELDDVTSNMEQIIKAKANLEKMCRTLEDQMNEHRSKAEETQRSVNDLTSQRAKLQTENGELSRQLDEKEALISQLTRGKLTYTQQLEDLKRQLEEEVKAKNALAHALQSARHDCDLLREQYEEETEAKAELQRVLSKANSEVAQWRTKYETDAIQRTEELEEAKKKLAQRLQEAEEAVEAVNAKCSSLEKTKHRLQNEIEDLMVDVERSNAAAAALDKKQRNFDKILAEWKQKYEESQSELESSQKEARSLSTELFKLKNAYEESLEHLETFKRENKNLQEEISDLTEQLGSSGKTIHELEKVRKQLEAEKMELQSALEEAEASLEHEEGKILRAQLEFNQIKAEIERKLAEKDEEMEQAKRNHLRVVDSLQTSLDAETRSRNEALRVKKKMEGDLNEMEIQLSHANRMAAEAQKQVKSLQSLLKDTQIQLDDAVRANDDLKENIAIVERRNNLLQAELEELRAVVEQTERSRKLAEQELIETSERVQLLHSQNTSLINQKKKMDADLSQLQTEVEEAVQECRNAEEKAKKAITDAAMMAEELKKEQDTSAHLERMKKNMEQTIKDLQHRLDEAEQIALKGGKKQLQKLEARVRELENELEAEQKRNAESVKGMRKSERRIKELTYQTEEDRKNLLRLQDLVDKLQLKVKAYKRQAEEAEEQANTNLSKFRKVQHELDEAEERADIAESQVNKLRAKSRDIGTKGLNEE	1935	P12883	G	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [152], 'DOMAIN_gain_score': array([0.02191842]), 'REGION_loss': [874, 876, 1264], 'REGION_gain': [], 'REGION_loss_score': array([-0.01100755, -0.00951385, -0.00056779]), 'REPEAT_loss': [47, 87, 105, 373, 375, 400, 1156], 'REPEAT_gain': [897, 899, 901, 1095], 'REPEAT_gain_score': array([0.01728189, 0.02828777, 0.02751726, 0.00406921]), 'REPEAT_loss_score': array([-0.0020085 , -0.00187314, -0.00159568, -0.00158834, -0.00161088,
       -0.00218356, -0.00088239]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
8	NM_000257.3(MYH7):c.2681A>G (p.Glu894Gly)	42922	CA012832	NM_000257.3:c.2681A>G, NC_000014.9:g.23424148T>C, CM000676.2:g.23424148T>C, NC_000014.8:g.23893357T>C, CM000676.1:g.23893357T>C, NC_000014.7:g.22963197T>C, NG_007884.1:g.16514A>G, LRG_384:g.16514A>G, XR_245686.3:n.2787A>G, XM_017021340.1:c.2681A>G, NM_000257.4:c.2681A>G, ENST00000355349.3:c.2681A>G, NM_000257.3(MYH7):c.2681A>G (p.Glu894Gly)	MYH7	hypertrophic cardiomyopathy	MONDO:0005045	Autosomal dominant inheritance	Pathogenic	PP1_Moderate, PS4, PP3, PM1, PM2		The c.2681A>G (p.Glu894Gly) variant in MYH7 has been reported in >20 individuals with hypertrophic cardiomyopathy (PS4: PMID:PMID:27532257; PMID:15358028; PMID:15858117; PMID:21511876; PMID:23396983; PMID:24510615; SHaRe consortium, PMID: 30297972, Partners LMM ClinVar SCV000059463.5; AGCMC Sydney ClinVar SCV000212641.2; Invitae ClinVar SCV000253683.5). This variant segregated with disease in 6 affected individuals (PP1_Moderate: AGCMC Sydney ClinVar SCV000212641.2; Partners LMM ClinVar SCV000059463.5). This variant was absent from large population studies (PM2; http://exac.broadinstitute.org). This variant lies in the head region of the protein (aa 181-937) and missense variants in this region are statistically more likely to be disease-associated (PM1; PMID:27532257). Computational prediction tools and conservation analysis suggest that this variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for hypertrophic cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (PMID:29300372): PS4; PM1; PM2; PP1_Moderate; PP3	27532257, 27532257	Cardiomyopathy VCEP		2016-12-15	2018-11-16	False	https://erepo.genome.network/evrepo/ui/classification/CA012832/MONDO:0005045/002	f89b58e9-fd2b-41c7-9ca3-dd7cedfdd3ee	p.Glu894Gly	Glu	894	Gly	MGDSEMAVFGAAAPYLRKSEKERLEAQTRPFDLKKDVFVPDDKQEFVKAKIVSREGGKVTAETEYGKTVTVKEDQVMQQNPPKFDKIEDMAMLTFLHEPAVLYNLKDRYGSWMIYTYSGLFCVTVNPYKWLPVYTPEVVAAYRGKKRSEAPPHIFSISDNAYQYMLTDRENQSILITGESGAGKTVNTKRVIQYFAVIAAIGDRSKKDQSPGKGTLEDQIIQANPALEAFGNAKTVRNDNSSRFGKFIRIHFGATGKLASADIETYLLEKSRVIFQLKAERDYHIFYQILSNKKPELLDMLLITNNPYDYAFISQGETTVASIDDAEELMATDNAFDVLGFTSEEKNSMYKLTGAIMHFGNMKFKLKQREEQAEPDGTEEADKSAYLMGLNSADLLKGLCHPRVKVGNEYVTKGQNVQQVIYATGALAKAVYERMFNWMVTRINATLETKQPRQYFIGVLDIAGFEIFDFNSFEQLCINFTNEKLQQFFNHHMFVLEQEEYKKEGIEWTFIDFGMDLQACIDLIEKPMGIMSILEEECMFPKATDMTFKAKLFDNHLGKSANFQKPRNIKGKPEAHFSLIHYAGIVDYNIIGWLQKNKDPLNETVVGLYQKSSLKLLSTLFANYAGADAPIEKGKGKAKKGSSFQTVSALHRENLNKLMTNLRSTHPHFVRCIIPNETKSPGVMDNPLVMHQLRCNGVLEGIRICRKGFPNRILYGDFRQRYRILNPAAIPEGQFIDSRKGAEKLLSSLDIDHNQYKFGHTKVFFKAGLLGLLEEMRDERLSRIITRIQAQSRGVLARMEYKKLLERRDSLLVIQWNIRAFMGVKNWPWMKLYFKIKPLLKSAEREKEMASMKEEFTRLKEALEKSEARRKELEEKMVSLLQEKNDLQLQVQAEQDNLADAEERCDQLIKNKIQLEAKVKEMNERLEDEEEMNAELTAKKRKLEDECSELKRDIDDLELTLAKVEKEKHATENKVKNLTEEMAGLDEIIAKLTKEKKALQEAHQQALDDLQAEEDKVNTLTKAKVKLEQQVDDLEGSLEQEKKVRMDLERAKRKLEGDLKLTQESIMDLENDKQQLDERLKKKDFELNALNARIEDEQALGSQLQKKLKELQARIEELEEELEAERTARAKVEKLRSDLSRELEEISERLEEAGGATSVQIEMNKKREAEFQKMRRDLEEATLQHEATAAALRKKHADSVAELGEQIDNLQRVKQKLEKEKSEFKLELDDVTSNMEQIIKAKANLEKMCRTLEDQMNEHRSKAEETQRSVNDLTSQRAKLQTENGELSRQLDEKEALISQLTRGKLTYTQQLEDLKRQLEEEVKAKNALAHALQSARHDCDLLREQYEEETEAKAELQRVLSKANSEVAQWRTKYETDAIQRTEELEEAKKKLAQRLQEAEEAVEAVNAKCSSLEKTKHRLQNEIEDLMVDVERSNAAAAALDKKQRNFDKILAEWKQKYEESQSELESSQKEARSLSTELFKLKNAYEESLEHLETFKRENKNLQEEISDLTEQLGSSGKTIHELEKVRKQLEAEKMELQSALEEAEASLEHEEGKILRAQLEFNQIKAEIERKLAEKDEEMEQAKRNHLRVVDSLQTSLDAETRSRNEALRVKKKMEGDLNEMEIQLSHANRMAAEAQKQVKSLQSLLKDTQIQLDDAVRANDDLKENIAIVERRNNLLQAELEELRAVVEQTERSRKLAEQELIETSERVQLLHSQNTSLINQKKKMDADLSQLQTEVEEAVQECRNAEEKAKKAITDAAMMAEELKKEQDTSAHLERMKKNMEQTIKDLQHRLDEAEQIALKGGKKQLQKLEARVRELENELEAEQKRNAESVKGMRKSERRIKELTYQTEEDRKNLLRLQDLVDKLQLKVKAYKRQAEEAEEQANTNLSKFRKVQHELDEAEERADIAESQVNKLRAKSRDIGTKGLNEE	1935	P12883	G	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [866, 874, 876, 891, 892, 894, 897, 898, 899, 901, 904, 908, 909, 1264], 'REGION_gain': [], 'REGION_loss_score': array([-0.03714937, -0.02911752, -0.01900697, -0.03905302, -0.04608899,
       -0.08747381, -0.0698151 , -0.05004162, -0.047782  , -0.05120689,
       -0.03621548, -0.04046631, -0.03914785, -0.00060683]), 'REPEAT_loss': [47, 87, 105, 373, 375, 400, 876, 877, 879, 888, 890, 900, 1156], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.00253665, -0.0025205 , -0.00261557, -0.00218856, -0.0020957 ,
       -0.00202399, -0.03992903, -0.04651153, -0.03094882, -0.05123347,
       -0.04708248, -0.05352849, -0.00228047]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
9	NM_000257.3(MYH7):c.2609G>A (p.Arg870His)	14120	CA012740	NM_000257.3:c.2609G>A, NC_000014.9:g.23424839C>T, CM000676.2:g.23424839C>T, NC_000014.8:g.23894048C>T, CM000676.1:g.23894048C>T, NC_000014.7:g.22963888C>T, NG_007884.1:g.15823G>A, LRG_384:g.15823G>A, XR_245686.3:n.2715G>A, XM_017021340.1:c.2609G>A, NM_000257.4:c.2609G>A, ENST00000355349.3:c.2609G>A, NM_000257.3(MYH7):c.2609G>A (p.Arg870His)	MYH7	hypertrophic cardiomyopathy	MONDO:0005045	Autosomal dominant inheritance	Pathogenic	PS4, PM1, PM2, PP1_Strong		The c.2609G>A (p.Arg870His) variant in MYH7 has been reported in >20 individuals with hypertrophic cardiomyopathy (PS4; PMID:7796500; PMID:12974739; PMID:17703256; PMID:27532257; Partners LMM ClinVar SCV000059458.5; SHaRe consortium, PMID: 30297972). This variant segregated with disease in >10 affected individuals (PP1_Strong; PMID:7796500; PMID:12974739; PMID:17703256). This variant was identified in 1/66732 European chromosomes (PM2; http://exac.broadinstitute.org). This variant lies in the head region of the protein (aa 181-937) and missense variants in this region are statistically more likely to be disease-associated (PM1; PMID:27532257). In summary, this variant meets criteria to be classified as pathogenic for hypertrophic cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (PMID:29300372): PS4; PP1_ Strong; PM1; PM2	27532257, 7796500, 17703256, 12974739, 27532257, 7796500, 17703256, 12974739	Cardiomyopathy VCEP		2016-12-15	2018-11-16	False	https://erepo.genome.network/evrepo/ui/classification/CA012740/MONDO:0005045/002	2d09f591-2d8e-40af-a273-07a3ec1e0fc5	p.Arg870His	Arg	870	His	MGDSEMAVFGAAAPYLRKSEKERLEAQTRPFDLKKDVFVPDDKQEFVKAKIVSREGGKVTAETEYGKTVTVKEDQVMQQNPPKFDKIEDMAMLTFLHEPAVLYNLKDRYGSWMIYTYSGLFCVTVNPYKWLPVYTPEVVAAYRGKKRSEAPPHIFSISDNAYQYMLTDRENQSILITGESGAGKTVNTKRVIQYFAVIAAIGDRSKKDQSPGKGTLEDQIIQANPALEAFGNAKTVRNDNSSRFGKFIRIHFGATGKLASADIETYLLEKSRVIFQLKAERDYHIFYQILSNKKPELLDMLLITNNPYDYAFISQGETTVASIDDAEELMATDNAFDVLGFTSEEKNSMYKLTGAIMHFGNMKFKLKQREEQAEPDGTEEADKSAYLMGLNSADLLKGLCHPRVKVGNEYVTKGQNVQQVIYATGALAKAVYERMFNWMVTRINATLETKQPRQYFIGVLDIAGFEIFDFNSFEQLCINFTNEKLQQFFNHHMFVLEQEEYKKEGIEWTFIDFGMDLQACIDLIEKPMGIMSILEEECMFPKATDMTFKAKLFDNHLGKSANFQKPRNIKGKPEAHFSLIHYAGIVDYNIIGWLQKNKDPLNETVVGLYQKSSLKLLSTLFANYAGADAPIEKGKGKAKKGSSFQTVSALHRENLNKLMTNLRSTHPHFVRCIIPNETKSPGVMDNPLVMHQLRCNGVLEGIRICRKGFPNRILYGDFRQRYRILNPAAIPEGQFIDSRKGAEKLLSSLDIDHNQYKFGHTKVFFKAGLLGLLEEMRDERLSRIITRIQAQSRGVLARMEYKKLLERRDSLLVIQWNIRAFMGVKNWPWMKLYFKIKPLLKSAEREKEMASMKEEFTRLKEALEKSEARRKELEEKMVSLLQEKNDLQLQVQAEQDNLADAEERCDQLIKNKIQLEAKVKEMNERLEDEEEMNAELTAKKRKLEDECSELKRDIDDLELTLAKVEKEKHATENKVKNLTEEMAGLDEIIAKLTKEKKALQEAHQQALDDLQAEEDKVNTLTKAKVKLEQQVDDLEGSLEQEKKVRMDLERAKRKLEGDLKLTQESIMDLENDKQQLDERLKKKDFELNALNARIEDEQALGSQLQKKLKELQARIEELEEELEAERTARAKVEKLRSDLSRELEEISERLEEAGGATSVQIEMNKKREAEFQKMRRDLEEATLQHEATAAALRKKHADSVAELGEQIDNLQRVKQKLEKEKSEFKLELDDVTSNMEQIIKAKANLEKMCRTLEDQMNEHRSKAEETQRSVNDLTSQRAKLQTENGELSRQLDEKEALISQLTRGKLTYTQQLEDLKRQLEEEVKAKNALAHALQSARHDCDLLREQYEEETEAKAELQRVLSKANSEVAQWRTKYETDAIQRTEELEEAKKKLAQRLQEAEEAVEAVNAKCSSLEKTKHRLQNEIEDLMVDVERSNAAAAALDKKQRNFDKILAEWKQKYEESQSELESSQKEARSLSTELFKLKNAYEESLEHLETFKRENKNLQEEISDLTEQLGSSGKTIHELEKVRKQLEAEKMELQSALEEAEASLEHEEGKILRAQLEFNQIKAEIERKLAEKDEEMEQAKRNHLRVVDSLQTSLDAETRSRNEALRVKKKMEGDLNEMEIQLSHANRMAAEAQKQVKSLQSLLKDTQIQLDDAVRANDDLKENIAIVERRNNLLQAELEELRAVVEQTERSRKLAEQELIETSERVQLLHSQNTSLINQKKKMDADLSQLQTEVEEAVQECRNAEEKAKKAITDAAMMAEELKKEQDTSAHLERMKKNMEQTIKDLQHRLDEAEQIALKGGKKQLQKLEARVRELENELEAEQKRNAESVKGMRKSERRIKELTYQTEEDRKNLLRLQDLVDKLQLKVKAYKRQAEEAEEQANTNLSKFRKVQHELDEAEERADIAESQVNKLRAKSRDIGTKGLNEE	1935	P12883	H	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [152], 'DOMAIN_gain_score': array([0.02764183]), 'REGION_loss': [866, 872, 873, 874, 876, 886, 891, 892, 898, 899, 904], 'REGION_gain': [1205], 'REGION_gain_score': array([0.00300926]), 'REGION_loss_score': array([-0.09973669, -0.06332219, -0.07131785, -0.06425422, -0.07641095,
       -0.04568517, -0.0417099 , -0.03717643, -0.02531785, -0.01851082,
       -0.01489031]), 'REPEAT_loss': [47, 87, 91, 105, 373, 375, 400, 877, 879, 888, 1102, 1111, 1156], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.00455058, -0.00427884, -0.00459456, -0.00459206, -0.00373894,
       -0.00347459, -0.00414842, -0.02309614, -0.02144849, -0.00893039,
       -0.00532252, -0.0039314 , -0.00238436]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
10	NM_000257.3(MYH7):c.2539A>G (p.Lys847Glu)	177757	CA012578	NM_000257.3:c.2539A>G, NC_000014.9:g.23424909T>C, CM000676.2:g.23424909T>C, NC_000014.8:g.23894118T>C, CM000676.1:g.23894118T>C, NC_000014.7:g.22963958T>C, NG_007884.1:g.15753A>G, LRG_384:g.15753A>G, ENST00000355349.4:c.2539A>G, ENST00000355349.3:c.2539A>G, XR_245686.3:n.2645A>G, XM_017021340.1:c.2539A>G, NM_000257.4:c.2539A>G, NM_000257.4(MYH7):c.2539A>G (p.Lys847Glu), NM_000257.3(MYH7):c.2539A>G (p.Lys847Glu)	MYH7	hypertrophic cardiomyopathy	MONDO:0005045	Autosomal dominant inheritance	Pathogenic	PS4, PM2, PM1, PP1_Strong	BS1, BP4, BP2, BP5, PS2, PS1, PM3, PS3, BA1, PM6, PM5, PP3	The NM_000257.4(MYH7):c.2539A>G (p.Lys847Glu) variant has been identified in >50 individuals with HCM (PS4; Atiga 2000 PMID:10725281; Kaski 2009 PMID:20031618; Aletras 2011 PMID:21576279; Leung 2013 PMID:23271734; Nunez 2013 PMID:23782526; Homburger 2016 PMID:27247418; Walsh 2017 PMID:27532257; Ross 2017 PMID:28615295; Ambry pers. comm.; CHEO pers. comm.; GeneDx pers. comm.; Invitae pers. comm.; LMM pers. comm.; OMGL pers. comm.; Agnes Ginges Centre for Molecular Cardiology, Centenary Institute pers. comm.). This variant segregated with disease in 7 affected individuals with HCM in 5 families (PP1_Strong; Ross 2017 PMID:28615295; Invitae pers. comm.; OMGL pers. comm.). This variant was absent from large population studies (PM2; gnomAD v2.1.1, http://gnomad.broadinstitute.org). This variant lies in the head region of the protein (aa 181-937) and missense variants in this region are statistically more likely to be associated with HCM (PM1; Walsh 2017 PMID:27532257). Computational prediction tools and conservation analysis do not provide evidence for or against an impact to the protein. In summary, this variant meets criteria to be classified as pathogenic for hypertrophic cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (Kelly 2018 PMID:29300372): PS4, PP1_Strong, PM2, PM1.		Cardiomyopathy VCEP		2021-11-30	2021-12-09	False	https://erepo.genome.network/evrepo/ui/classification/CA012578/MONDO:0005045/002	5dd3f0f6-7736-4320-bd76-d07ae2cd679c	p.Lys847Glu	Lys	847	Glu	MGDSEMAVFGAAAPYLRKSEKERLEAQTRPFDLKKDVFVPDDKQEFVKAKIVSREGGKVTAETEYGKTVTVKEDQVMQQNPPKFDKIEDMAMLTFLHEPAVLYNLKDRYGSWMIYTYSGLFCVTVNPYKWLPVYTPEVVAAYRGKKRSEAPPHIFSISDNAYQYMLTDRENQSILITGESGAGKTVNTKRVIQYFAVIAAIGDRSKKDQSPGKGTLEDQIIQANPALEAFGNAKTVRNDNSSRFGKFIRIHFGATGKLASADIETYLLEKSRVIFQLKAERDYHIFYQILSNKKPELLDMLLITNNPYDYAFISQGETTVASIDDAEELMATDNAFDVLGFTSEEKNSMYKLTGAIMHFGNMKFKLKQREEQAEPDGTEEADKSAYLMGLNSADLLKGLCHPRVKVGNEYVTKGQNVQQVIYATGALAKAVYERMFNWMVTRINATLETKQPRQYFIGVLDIAGFEIFDFNSFEQLCINFTNEKLQQFFNHHMFVLEQEEYKKEGIEWTFIDFGMDLQACIDLIEKPMGIMSILEEECMFPKATDMTFKAKLFDNHLGKSANFQKPRNIKGKPEAHFSLIHYAGIVDYNIIGWLQKNKDPLNETVVGLYQKSSLKLLSTLFANYAGADAPIEKGKGKAKKGSSFQTVSALHRENLNKLMTNLRSTHPHFVRCIIPNETKSPGVMDNPLVMHQLRCNGVLEGIRICRKGFPNRILYGDFRQRYRILNPAAIPEGQFIDSRKGAEKLLSSLDIDHNQYKFGHTKVFFKAGLLGLLEEMRDERLSRIITRIQAQSRGVLARMEYKKLLERRDSLLVIQWNIRAFMGVKNWPWMKLYFKIKPLLKSAEREKEMASMKEEFTRLKEALEKSEARRKELEEKMVSLLQEKNDLQLQVQAEQDNLADAEERCDQLIKNKIQLEAKVKEMNERLEDEEEMNAELTAKKRKLEDECSELKRDIDDLELTLAKVEKEKHATENKVKNLTEEMAGLDEIIAKLTKEKKALQEAHQQALDDLQAEEDKVNTLTKAKVKLEQQVDDLEGSLEQEKKVRMDLERAKRKLEGDLKLTQESIMDLENDKQQLDERLKKKDFELNALNARIEDEQALGSQLQKKLKELQARIEELEEELEAERTARAKVEKLRSDLSRELEEISERLEEAGGATSVQIEMNKKREAEFQKMRRDLEEATLQHEATAAALRKKHADSVAELGEQIDNLQRVKQKLEKEKSEFKLELDDVTSNMEQIIKAKANLEKMCRTLEDQMNEHRSKAEETQRSVNDLTSQRAKLQTENGELSRQLDEKEALISQLTRGKLTYTQQLEDLKRQLEEEVKAKNALAHALQSARHDCDLLREQYEEETEAKAELQRVLSKANSEVAQWRTKYETDAIQRTEELEEAKKKLAQRLQEAEEAVEAVNAKCSSLEKTKHRLQNEIEDLMVDVERSNAAAAALDKKQRNFDKILAEWKQKYEESQSELESSQKEARSLSTELFKLKNAYEESLEHLETFKRENKNLQEEISDLTEQLGSSGKTIHELEKVRKQLEAEKMELQSALEEAEASLEHEEGKILRAQLEFNQIKAEIERKLAEKDEEMEQAKRNHLRVVDSLQTSLDAETRSRNEALRVKKKMEGDLNEMEIQLSHANRMAAEAQKQVKSLQSLLKDTQIQLDDAVRANDDLKENIAIVERRNNLLQAELEELRAVVEQTERSRKLAEQELIETSERVQLLHSQNTSLINQKKKMDADLSQLQTEVEEAVQECRNAEEKAKKAITDAAMMAEELKKEQDTSAHLERMKKNMEQTIKDLQHRLDEAEQIALKGGKKQLQKLEARVRELENELEAEQKRNAESVKGMRKSERRIKELTYQTEEDRKNLLRLQDLVDKLQLKVKAYKRQAEEAEEQANTNLSKFRKVQHELDEAEERADIAESQVNKLRAKSRDIGTKGLNEE	1935	P12883	E	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [152, 159], 'DOMAIN_gain_score': array([0.04377443, 0.06145567]), 'REGION_loss': [], 'REGION_gain': [868, 887, 902, 1205], 'REGION_gain_score': array([0.0074172 , 0.00815284, 0.00801957, 0.00307226]), 'REPEAT_loss': [888, 980, 1009], 'REPEAT_gain': [1168, 1178, 1192, 1194], 'REPEAT_gain_score': array([0.00244862, 0.00391906, 0.00272191, 0.00215161]), 'REPEAT_loss_score': array([-0.00278103, -0.00917017, -0.00328082]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
11	NM_000257.3(MYH7):c.2513C>T (p.Pro838Leu)	42910	CA012515	NM_000257.3:c.2513C>T, XR_245686.3:n.2619C>T, XM_017021340.1:c.2513C>T, NM_000257.4:c.2513C>T, ENST00000355349.3:c.2513C>T, NC_000014.9:g.23424935G>A, CM000676.2:g.23424935G>A, NC_000014.8:g.23894144G>A, CM000676.1:g.23894144G>A, NC_000014.7:g.22963984G>A, NG_007884.1:g.15727C>T, LRG_384:g.15727C>T, NM_000257.3(MYH7):c.2513C>T (p.Pro838Leu)	MYH7	restrictive cardiomyopathy	MONDO:0005201	Autosomal dominant inheritance	Pathogenic	PS4_Supporting, PS2, PP3, PM1, PM2		The c.2513C>T (p.Pro838Leu) variant in MYH7 has been reported as a de novo occurrence in two individuals with restrictive cardiomyopathy (PS4_Supporting and PS2: PMID:18380764; Partners LMM ClinVar SCV000059450.5). This variant was absent from large population studies (PM2; http://exac.broadinstitute.org). This variant lies in the head region of the protein (aa 181-937) and missense variants in this region are statistically more likely to be disease-associated (PM1; PMID:27532257). Computational prediction tools and conservation analysis suggest that this variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for restrictive cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (PMID:29300372): PS2; PM1; PM2; PP3; PS4_ Supporting	18380764, 18380764, 27532257	Cardiomyopathy VCEP		2016-12-15	2018-11-16	False	https://erepo.genome.network/evrepo/ui/classification/CA012515/MONDO:0005201/002	f43eef48-e44b-4436-b419-aee39de7c831	p.Pro838Leu	Pro	838	Leu	MGDSEMAVFGAAAPYLRKSEKERLEAQTRPFDLKKDVFVPDDKQEFVKAKIVSREGGKVTAETEYGKTVTVKEDQVMQQNPPKFDKIEDMAMLTFLHEPAVLYNLKDRYGSWMIYTYSGLFCVTVNPYKWLPVYTPEVVAAYRGKKRSEAPPHIFSISDNAYQYMLTDRENQSILITGESGAGKTVNTKRVIQYFAVIAAIGDRSKKDQSPGKGTLEDQIIQANPALEAFGNAKTVRNDNSSRFGKFIRIHFGATGKLASADIETYLLEKSRVIFQLKAERDYHIFYQILSNKKPELLDMLLITNNPYDYAFISQGETTVASIDDAEELMATDNAFDVLGFTSEEKNSMYKLTGAIMHFGNMKFKLKQREEQAEPDGTEEADKSAYLMGLNSADLLKGLCHPRVKVGNEYVTKGQNVQQVIYATGALAKAVYERMFNWMVTRINATLETKQPRQYFIGVLDIAGFEIFDFNSFEQLCINFTNEKLQQFFNHHMFVLEQEEYKKEGIEWTFIDFGMDLQACIDLIEKPMGIMSILEEECMFPKATDMTFKAKLFDNHLGKSANFQKPRNIKGKPEAHFSLIHYAGIVDYNIIGWLQKNKDPLNETVVGLYQKSSLKLLSTLFANYAGADAPIEKGKGKAKKGSSFQTVSALHRENLNKLMTNLRSTHPHFVRCIIPNETKSPGVMDNPLVMHQLRCNGVLEGIRICRKGFPNRILYGDFRQRYRILNPAAIPEGQFIDSRKGAEKLLSSLDIDHNQYKFGHTKVFFKAGLLGLLEEMRDERLSRIITRIQAQSRGVLARMEYKKLLERRDSLLVIQWNIRAFMGVKNWPWMKLYFKIKPLLKSAEREKEMASMKEEFTRLKEALEKSEARRKELEEKMVSLLQEKNDLQLQVQAEQDNLADAEERCDQLIKNKIQLEAKVKEMNERLEDEEEMNAELTAKKRKLEDECSELKRDIDDLELTLAKVEKEKHATENKVKNLTEEMAGLDEIIAKLTKEKKALQEAHQQALDDLQAEEDKVNTLTKAKVKLEQQVDDLEGSLEQEKKVRMDLERAKRKLEGDLKLTQESIMDLENDKQQLDERLKKKDFELNALNARIEDEQALGSQLQKKLKELQARIEELEEELEAERTARAKVEKLRSDLSRELEEISERLEEAGGATSVQIEMNKKREAEFQKMRRDLEEATLQHEATAAALRKKHADSVAELGEQIDNLQRVKQKLEKEKSEFKLELDDVTSNMEQIIKAKANLEKMCRTLEDQMNEHRSKAEETQRSVNDLTSQRAKLQTENGELSRQLDEKEALISQLTRGKLTYTQQLEDLKRQLEEEVKAKNALAHALQSARHDCDLLREQYEEETEAKAELQRVLSKANSEVAQWRTKYETDAIQRTEELEEAKKKLAQRLQEAEEAVEAVNAKCSSLEKTKHRLQNEIEDLMVDVERSNAAAAALDKKQRNFDKILAEWKQKYEESQSELESSQKEARSLSTELFKLKNAYEESLEHLETFKRENKNLQEEISDLTEQLGSSGKTIHELEKVRKQLEAEKMELQSALEEAEASLEHEEGKILRAQLEFNQIKAEIERKLAEKDEEMEQAKRNHLRVVDSLQTSLDAETRSRNEALRVKKKMEGDLNEMEIQLSHANRMAAEAQKQVKSLQSLLKDTQIQLDDAVRANDDLKENIAIVERRNNLLQAELEELRAVVEQTERSRKLAEQELIETSERVQLLHSQNTSLINQKKKMDADLSQLQTEVEEAVQECRNAEEKAKKAITDAAMMAEELKKEQDTSAHLERMKKNMEQTIKDLQHRLDEAEQIALKGGKKQLQKLEARVRELENELEAEQKRNAESVKGMRKSERRIKELTYQTEEDRKNLLRLQDLVDKLQLKVKAYKRQAEEAEEQANTNLSKFRKVQHELDEAEERADIAESQVNKLRAKSRDIGTKGLNEE	1935	P12883	L	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [169], 'DOMAIN_gain': [829], 'DOMAIN_gain_score': array([0.03741807]), 'DOMAIN_loss_score': array([-0.01567572]), 'REGION_loss': [], 'REGION_gain': [868, 887, 1193, 1197, 1205, 1208, 1212], 'REGION_gain_score': array([0.00723708, 0.00344896, 0.00768685, 0.00805509, 0.0071665 ,
       0.0072661 , 0.00700289]), 'REPEAT_loss': [47, 87, 105, 375, 980, 1009, 1083, 1102, 1111, 1122, 1156, 1160, 1162, 1841], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.00342172, -0.00293481, -0.0031504 , -0.00093573, -0.00169736,
       -0.00566018, -0.00416112, -0.00868964, -0.00670487, -0.00774044,
       -0.00899261, -0.00749594, -0.00757581, -0.00264001]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
12	NM_000257.3(MYH7):c.2221G>T (p.Gly741Trp)	177665	CA012022	NM_000257.3:c.2221G>T, XR_245686.3:n.2327G>T, XM_017021340.1:c.2221G>T, NM_000257.4:c.2221G>T, ENST00000355349.3:c.2221G>T, NC_000014.9:g.23425760C>A, CM000676.2:g.23425760C>A, NC_000014.8:g.23894969C>A, CM000676.1:g.23894969C>A, NC_000014.7:g.22964809C>A, NG_007884.1:g.14902G>T, LRG_384:g.14902G>T, NM_000257.3(MYH7):c.2221G>T (p.Gly741Trp)	MYH7	hypertrophic cardiomyopathy	MONDO:0005045	Autosomal dominant inheritance	Pathogenic	PP1_Moderate, PS4, PP3, PM1, PM5, PM2		The c.2221G>T (p.Gly741Trp) variant in MYH7 has been reported in >15 individuals with hypertrophic cardiomyopathy (PS4; PMID: 8533830; PMID:15856146; PMID:27532257; Partners LMM ClinVar SCV000203910.4; AGCMC Sydney ClinVar SCV000212638.1). This variant segregated with disease in 5 affected individuals (PP1_Moderate; PMID:15856146; AGCMC Sydney ClinVar SCV000212638.1). This variant was absent from large population studies (PM2; http://exac.broadinstitute.org). This variant lies in the head region of the protein (aa 181-937) and missense variants in this region are statistically more likely to be disease-associated (PM1; PMID:27532257). Computational prediction tools and conservation analysis suggest that this variant may impact the protein (PP3). A different pathogenic missense variant has been previously identified at this codon which may indicate that this residue is critical to the function of the protein (PM5; c.2221G>C p.Gly741Arg - Variation ID 14098). In summary, this variant meets criteria to be classified as pathogenic for hypertrophic cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (PMID:29300372): PS4; PM1; PM2; PM5; PP1_Moderate; PP3	15856146, 8533830, 27532257, 27532257	Cardiomyopathy VCEP		2016-12-15	2018-11-16	False	https://erepo.genome.network/evrepo/ui/classification/CA012022/MONDO:0005045/002	6c7676cc-a729-42ee-bc9c-580feb015c57	p.Gly741Trp	Gly	741	Trp	MGDSEMAVFGAAAPYLRKSEKERLEAQTRPFDLKKDVFVPDDKQEFVKAKIVSREGGKVTAETEYGKTVTVKEDQVMQQNPPKFDKIEDMAMLTFLHEPAVLYNLKDRYGSWMIYTYSGLFCVTVNPYKWLPVYTPEVVAAYRGKKRSEAPPHIFSISDNAYQYMLTDRENQSILITGESGAGKTVNTKRVIQYFAVIAAIGDRSKKDQSPGKGTLEDQIIQANPALEAFGNAKTVRNDNSSRFGKFIRIHFGATGKLASADIETYLLEKSRVIFQLKAERDYHIFYQILSNKKPELLDMLLITNNPYDYAFISQGETTVASIDDAEELMATDNAFDVLGFTSEEKNSMYKLTGAIMHFGNMKFKLKQREEQAEPDGTEEADKSAYLMGLNSADLLKGLCHPRVKVGNEYVTKGQNVQQVIYATGALAKAVYERMFNWMVTRINATLETKQPRQYFIGVLDIAGFEIFDFNSFEQLCINFTNEKLQQFFNHHMFVLEQEEYKKEGIEWTFIDFGMDLQACIDLIEKPMGIMSILEEECMFPKATDMTFKAKLFDNHLGKSANFQKPRNIKGKPEAHFSLIHYAGIVDYNIIGWLQKNKDPLNETVVGLYQKSSLKLLSTLFANYAGADAPIEKGKGKAKKGSSFQTVSALHRENLNKLMTNLRSTHPHFVRCIIPNETKSPGVMDNPLVMHQLRCNGVLEGIRICRKGFPNRILYGDFRQRYRILNPAAIPEGQFIDSRKGAEKLLSSLDIDHNQYKFGHTKVFFKAGLLGLLEEMRDERLSRIITRIQAQSRGVLARMEYKKLLERRDSLLVIQWNIRAFMGVKNWPWMKLYFKIKPLLKSAEREKEMASMKEEFTRLKEALEKSEARRKELEEKMVSLLQEKNDLQLQVQAEQDNLADAEERCDQLIKNKIQLEAKVKEMNERLEDEEEMNAELTAKKRKLEDECSELKRDIDDLELTLAKVEKEKHATENKVKNLTEEMAGLDEIIAKLTKEKKALQEAHQQALDDLQAEEDKVNTLTKAKVKLEQQVDDLEGSLEQEKKVRMDLERAKRKLEGDLKLTQESIMDLENDKQQLDERLKKKDFELNALNARIEDEQALGSQLQKKLKELQARIEELEEELEAERTARAKVEKLRSDLSRELEEISERLEEAGGATSVQIEMNKKREAEFQKMRRDLEEATLQHEATAAALRKKHADSVAELGEQIDNLQRVKQKLEKEKSEFKLELDDVTSNMEQIIKAKANLEKMCRTLEDQMNEHRSKAEETQRSVNDLTSQRAKLQTENGELSRQLDEKEALISQLTRGKLTYTQQLEDLKRQLEEEVKAKNALAHALQSARHDCDLLREQYEEETEAKAELQRVLSKANSEVAQWRTKYETDAIQRTEELEEAKKKLAQRLQEAEEAVEAVNAKCSSLEKTKHRLQNEIEDLMVDVERSNAAAAALDKKQRNFDKILAEWKQKYEESQSELESSQKEARSLSTELFKLKNAYEESLEHLETFKRENKNLQEEISDLTEQLGSSGKTIHELEKVRKQLEAEKMELQSALEEAEASLEHEEGKILRAQLEFNQIKAEIERKLAEKDEEMEQAKRNHLRVVDSLQTSLDAETRSRNEALRVKKKMEGDLNEMEIQLSHANRMAAEAQKQVKSLQSLLKDTQIQLDDAVRANDDLKENIAIVERRNNLLQAELEELRAVVEQTERSRKLAEQELIETSERVQLLHSQNTSLINQKKKMDADLSQLQTEVEEAVQECRNAEEKAKKAITDAAMMAEELKKEQDTSAHLERMKKNMEQTIKDLQHRLDEAEQIALKGGKKQLQKLEARVRELENELEAEQKRNAESVKGMRKSERRIKELTYQTEEDRKNLLRLQDLVDKLQLKVKAYKRQAEEAEEQANTNLSKFRKVQHELDEAEERADIAESQVNKLRAKSRDIGTKGLNEE	1935	P12883	W	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [493, 494, 547, 739, 740], 'HELIX_gain_score': array([0.01589757, 0.01556849, 0.02013874, 0.22863275, 0.17247438]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [1264], 'REGION_gain': [887, 902], 'REGION_gain_score': array([0.00558913, 0.00624424]), 'REGION_loss_score': array([-0.00179482]), 'REPEAT_loss': [373, 375, 381, 388, 400, 1841], 'REPEAT_gain': [63, 70, 76, 79, 83, 92, 1095, 1115, 1150, 1168, 1178, 1192, 1194], 'REPEAT_gain_score': array([0.0038504 , 0.00391823, 0.00384116, 0.00377184, 0.00325125,
       0.00316054, 0.00530243, 0.00620133, 0.00542849, 0.00361055,
       0.00410318, 0.00342673, 0.00320518]), 'REPEAT_loss_score': array([-0.00533432, -0.00533593, -0.00557196, -0.005678  , -0.00629133,
       -0.00342953]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
13	NM_000257.3(MYH7):c.2221G>C (p.Gly741Arg)	14098	CA012013	NM_000257.3:c.2221G>C, XR_245686.3:n.2327G>C, XM_017021340.1:c.2221G>C, NM_000257.4:c.2221G>C, ENST00000355349.3:c.2221G>C, NC_000014.9:g.23425760C>G, CM000676.2:g.23425760C>G, NC_000014.8:g.23894969C>G, CM000676.1:g.23894969C>G, NC_000014.7:g.22964809C>G, NG_007884.1:g.14902G>C, LRG_384:g.14902G>C, NM_000257.3(MYH7):c.2221G>C (p.Gly741Arg)	MYH7	hypertrophic cardiomyopathy	MONDO:0005045	Autosomal dominant inheritance	Pathogenic	PS4, PP1, PP3, PM6, PM5, PM1, PM2		The c.2221G>C (p.Gly741Arg) variant in MYH7 has been reported in >12 individuals with hypertrophic cardiomyopathy (PS4; PMID:8483915; PMID:15563892; PMID:20031618; PMID:15358028; Partners LMM ClinVar SCV000059430.5; SHaRe consortium, PMID: 30297972). This variant has been identified as a de novo occurrence in 1 proband with hypertrophic cardiomyopathy (PM6; PMID:15563892). This variant segregated with disease in 3 affected individuals (PP1; PMID:8483915; Partners LMM ClinVar SCV000059430.5). This variant was absent from large population studies (PM2; http://exac.broadinstitute.org). This variant lies in the head region of the protein (aa 181-937) and missense variants in this region are statistically more likely to be disease-associated (PM1; PMID:27532257). Computational prediction tools and conservation analysis suggest that this variant may impact the protein (PP3). A different pathogenic missense variant has been previously identified at this codon which may indicate that this residue is critical to the function of the protein (PM5; c.2221G>T p.Gly741Trp - Variation ID 177665). In summary, this variant meets criteria to be classified as pathogenic for hypertrophic cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (PMID:29300372): PS4; PM1; PM2; PM5; PM6; PP1; PP3	15358028, 20031618, 8483915, 15563892, 8483915, 15563892, 27532257	Cardiomyopathy VCEP		2016-12-15	2018-11-16	False	https://erepo.genome.network/evrepo/ui/classification/CA012013/MONDO:0005045/002	380d3ce8-4982-4df6-9bc5-6f4f7f75301c	p.Gly741Arg	Gly	741	Arg	MGDSEMAVFGAAAPYLRKSEKERLEAQTRPFDLKKDVFVPDDKQEFVKAKIVSREGGKVTAETEYGKTVTVKEDQVMQQNPPKFDKIEDMAMLTFLHEPAVLYNLKDRYGSWMIYTYSGLFCVTVNPYKWLPVYTPEVVAAYRGKKRSEAPPHIFSISDNAYQYMLTDRENQSILITGESGAGKTVNTKRVIQYFAVIAAIGDRSKKDQSPGKGTLEDQIIQANPALEAFGNAKTVRNDNSSRFGKFIRIHFGATGKLASADIETYLLEKSRVIFQLKAERDYHIFYQILSNKKPELLDMLLITNNPYDYAFISQGETTVASIDDAEELMATDNAFDVLGFTSEEKNSMYKLTGAIMHFGNMKFKLKQREEQAEPDGTEEADKSAYLMGLNSADLLKGLCHPRVKVGNEYVTKGQNVQQVIYATGALAKAVYERMFNWMVTRINATLETKQPRQYFIGVLDIAGFEIFDFNSFEQLCINFTNEKLQQFFNHHMFVLEQEEYKKEGIEWTFIDFGMDLQACIDLIEKPMGIMSILEEECMFPKATDMTFKAKLFDNHLGKSANFQKPRNIKGKPEAHFSLIHYAGIVDYNIIGWLQKNKDPLNETVVGLYQKSSLKLLSTLFANYAGADAPIEKGKGKAKKGSSFQTVSALHRENLNKLMTNLRSTHPHFVRCIIPNETKSPGVMDNPLVMHQLRCNGVLEGIRICRKGFPNRILYGDFRQRYRILNPAAIPEGQFIDSRKGAEKLLSSLDIDHNQYKFGHTKVFFKAGLLGLLEEMRDERLSRIITRIQAQSRGVLARMEYKKLLERRDSLLVIQWNIRAFMGVKNWPWMKLYFKIKPLLKSAEREKEMASMKEEFTRLKEALEKSEARRKELEEKMVSLLQEKNDLQLQVQAEQDNLADAEERCDQLIKNKIQLEAKVKEMNERLEDEEEMNAELTAKKRKLEDECSELKRDIDDLELTLAKVEKEKHATENKVKNLTEEMAGLDEIIAKLTKEKKALQEAHQQALDDLQAEEDKVNTLTKAKVKLEQQVDDLEGSLEQEKKVRMDLERAKRKLEGDLKLTQESIMDLENDKQQLDERLKKKDFELNALNARIEDEQALGSQLQKKLKELQARIEELEEELEAERTARAKVEKLRSDLSRELEEISERLEEAGGATSVQIEMNKKREAEFQKMRRDLEEATLQHEATAAALRKKHADSVAELGEQIDNLQRVKQKLEKEKSEFKLELDDVTSNMEQIIKAKANLEKMCRTLEDQMNEHRSKAEETQRSVNDLTSQRAKLQTENGELSRQLDEKEALISQLTRGKLTYTQQLEDLKRQLEEEVKAKNALAHALQSARHDCDLLREQYEEETEAKAELQRVLSKANSEVAQWRTKYETDAIQRTEELEEAKKKLAQRLQEAEEAVEAVNAKCSSLEKTKHRLQNEIEDLMVDVERSNAAAAALDKKQRNFDKILAEWKQKYEESQSELESSQKEARSLSTELFKLKNAYEESLEHLETFKRENKNLQEEISDLTEQLGSSGKTIHELEKVRKQLEAEKMELQSALEEAEASLEHEEGKILRAQLEFNQIKAEIERKLAEKDEEMEQAKRNHLRVVDSLQTSLDAETRSRNEALRVKKKMEGDLNEMEIQLSHANRMAAEAQKQVKSLQSLLKDTQIQLDDAVRANDDLKENIAIVERRNNLLQAELEELRAVVEQTERSRKLAEQELIETSERVQLLHSQNTSLINQKKKMDADLSQLQTEVEEAVQECRNAEEKAKKAITDAAMMAEELKKEQDTSAHLERMKKNMEQTIKDLQHRLDEAEQIALKGGKKQLQKLEARVRELENELEAEQKRNAESVKGMRKSERRIKELTYQTEEDRKNLLRLQDLVDKLQLKVKAYKRQAEEAEEQANTNLSKFRKVQHELDEAEERADIAESQVNKLRAKSRDIGTKGLNEE	1935	P12883	R	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [660], 'HELIX_gain': [494, 740], 'HELIX_gain_score': array([0.00318539, 0.07210422]), 'HELIX_loss_score': array([-0.00954634]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [161, 165, 169, 172], 'DOMAIN_gain': [1658], 'DOMAIN_gain_score': array([0.03216565]), 'DOMAIN_loss_score': array([-0.04806608, -0.05310541, -0.04558223, -0.05841047]), 'REGION_loss': [1264, 1271], 'REGION_gain': [], 'REGION_loss_score': array([-0.00269669, -0.0028373 ]), 'REPEAT_loss': [373, 375, 400, 888, 1841], 'REPEAT_gain': [63, 79, 83, 92, 93, 1168, 1178, 1192, 1194], 'REPEAT_gain_score': array([0.00259155, 0.00292993, 0.00310087, 0.00373936, 0.00349361,
       0.00231457, 0.00220901, 0.00170439, 0.00166875]), 'REPEAT_loss_score': array([-0.00155914, -0.00172812, -0.00225413, -0.00288498, -0.00193453]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
14	NM_000257.3(MYH7):c.2207T>C (p.Ile736Thr)	164342	CA011970	NM_000257.3:c.2207T>C, XR_245686.3:n.2313T>C, XM_017021340.1:c.2207T>C, NM_000257.4:c.2207T>C, ENST00000355349.3:c.2207T>C, NC_000014.9:g.23425774A>G, CM000676.2:g.23425774A>G, NC_000014.8:g.23894983A>G, CM000676.1:g.23894983A>G, NC_000014.7:g.22964823A>G, NG_007884.1:g.14888T>C, LRG_384:g.14888T>C, NM_000257.3(MYH7):c.2207T>C (p.Ile736Thr)	MYH7	hypertrophic cardiomyopathy	MONDO:0005045	Autosomal dominant inheritance	Pathogenic	PP1_Moderate, PS4, PM1, PM2		The c.2207T>C (p.Ile736Thr) variant in MYH7 has been reported in >20 individuals with hypertrophic cardiomyopathy (PS4; PMID:16630449; PMID:12974739; PMID:16199542; PMID:15856146; PMID:17125710; PMID:20738943; SHaRe consortium, PMID: 30297972; Partners LMM ClinVar SCV000199207.4; AGCMC Sydney ClinVar SCV000212631.2). This variant segregated with disease in 5 affected individuals (PP1_Moderate; PMID:15856146; PMID:17125710; Partners LMM ClinVar SCV000199207.4). This variant was absent from large population studies (PM2; http://exac.broadinstitute.org). This variant lies in the head region of the protein (aa 181-937) and missense variants in this region are statistically more likely to be disease-associated (PM1; PMID:27532257). In summary, this variant meets criteria to be classified as pathogenic for hypertrophic cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (PMID:29300372): PS4; PM1; PM2; PP1_Moderate	15856146, 17125710, 20738943, 15856146, 17125710, 12974739, 16630449, 16199542, 27532257, 27532257	Cardiomyopathy VCEP		2016-12-15	2018-11-16	False	https://erepo.genome.network/evrepo/ui/classification/CA011970/MONDO:0005045/002	e08a8c4f-f972-4f81-80b1-528cd4e6ca91	p.Ile736Thr	Ile	736	Thr	MGDSEMAVFGAAAPYLRKSEKERLEAQTRPFDLKKDVFVPDDKQEFVKAKIVSREGGKVTAETEYGKTVTVKEDQVMQQNPPKFDKIEDMAMLTFLHEPAVLYNLKDRYGSWMIYTYSGLFCVTVNPYKWLPVYTPEVVAAYRGKKRSEAPPHIFSISDNAYQYMLTDRENQSILITGESGAGKTVNTKRVIQYFAVIAAIGDRSKKDQSPGKGTLEDQIIQANPALEAFGNAKTVRNDNSSRFGKFIRIHFGATGKLASADIETYLLEKSRVIFQLKAERDYHIFYQILSNKKPELLDMLLITNNPYDYAFISQGETTVASIDDAEELMATDNAFDVLGFTSEEKNSMYKLTGAIMHFGNMKFKLKQREEQAEPDGTEEADKSAYLMGLNSADLLKGLCHPRVKVGNEYVTKGQNVQQVIYATGALAKAVYERMFNWMVTRINATLETKQPRQYFIGVLDIAGFEIFDFNSFEQLCINFTNEKLQQFFNHHMFVLEQEEYKKEGIEWTFIDFGMDLQACIDLIEKPMGIMSILEEECMFPKATDMTFKAKLFDNHLGKSANFQKPRNIKGKPEAHFSLIHYAGIVDYNIIGWLQKNKDPLNETVVGLYQKSSLKLLSTLFANYAGADAPIEKGKGKAKKGSSFQTVSALHRENLNKLMTNLRSTHPHFVRCIIPNETKSPGVMDNPLVMHQLRCNGVLEGIRICRKGFPNRILYGDFRQRYRILNPAAIPEGQFIDSRKGAEKLLSSLDIDHNQYKFGHTKVFFKAGLLGLLEEMRDERLSRIITRIQAQSRGVLARMEYKKLLERRDSLLVIQWNIRAFMGVKNWPWMKLYFKIKPLLKSAEREKEMASMKEEFTRLKEALEKSEARRKELEEKMVSLLQEKNDLQLQVQAEQDNLADAEERCDQLIKNKIQLEAKVKEMNERLEDEEEMNAELTAKKRKLEDECSELKRDIDDLELTLAKVEKEKHATENKVKNLTEEMAGLDEIIAKLTKEKKALQEAHQQALDDLQAEEDKVNTLTKAKVKLEQQVDDLEGSLEQEKKVRMDLERAKRKLEGDLKLTQESIMDLENDKQQLDERLKKKDFELNALNARIEDEQALGSQLQKKLKELQARIEELEEELEAERTARAKVEKLRSDLSRELEEISERLEEAGGATSVQIEMNKKREAEFQKMRRDLEEATLQHEATAAALRKKHADSVAELGEQIDNLQRVKQKLEKEKSEFKLELDDVTSNMEQIIKAKANLEKMCRTLEDQMNEHRSKAEETQRSVNDLTSQRAKLQTENGELSRQLDEKEALISQLTRGKLTYTQQLEDLKRQLEEEVKAKNALAHALQSARHDCDLLREQYEEETEAKAELQRVLSKANSEVAQWRTKYETDAIQRTEELEEAKKKLAQRLQEAEEAVEAVNAKCSSLEKTKHRLQNEIEDLMVDVERSNAAAAALDKKQRNFDKILAEWKQKYEESQSELESSQKEARSLSTELFKLKNAYEESLEHLETFKRENKNLQEEISDLTEQLGSSGKTIHELEKVRKQLEAEKMELQSALEEAEASLEHEEGKILRAQLEFNQIKAEIERKLAEKDEEMEQAKRNHLRVVDSLQTSLDAETRSRNEALRVKKKMEGDLNEMEIQLSHANRMAAEAQKQVKSLQSLLKDTQIQLDDAVRANDDLKENIAIVERRNNLLQAELEELRAVVEQTERSRKLAEQELIETSERVQLLHSQNTSLINQKKKMDADLSQLQTEVEEAVQECRNAEEKAKKAITDAAMMAEELKKEQDTSAHLERMKKNMEQTIKDLQHRLDEAEQIALKGGKKQLQKLEARVRELENELEAEQKRNAESVKGMRKSERRIKELTYQTEEDRKNLLRLQDLVDKLQLKVKAYKRQAEEAEEQANTNLSKFRKVQHELDEAEERADIAESQVNKLRAKSRDIGTKGLNEE	1935	P12883	T	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [494], 'HELIX_gain_score': array([0.0032773]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [152, 156, 157, 159], 'DOMAIN_gain_score': array([0.05081284, 0.06346047, 0.06585926, 0.07361209]), 'REGION_loss': [874, 876, 1264], 'REGION_gain': [], 'REGION_loss_score': array([-0.00977898, -0.00866228, -0.00198525]), 'REPEAT_loss': [47, 87, 375, 400, 888, 980, 1111, 1156], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.00102973, -0.00042474, -0.00085992, -0.00096983, -0.00060618,
       -0.00176501, -0.00213706, -0.00092518]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
15	NM_000257.3(MYH7):c.2167C>T (p.Arg723Cys)	14095	CA011851	NM_000257.3:c.2167C>T, XR_245686.3:n.2273C>T, XM_017021340.1:c.2167C>T, NM_000257.4:c.2167C>T, ENST00000355349.3:c.2167C>T, NC_000014.9:g.23425814G>A, CM000676.2:g.23425814G>A, NC_000014.8:g.23895023G>A, CM000676.1:g.23895023G>A, NC_000014.7:g.22964863G>A, NG_007884.1:g.14848C>T, LRG_384:g.14848C>T, NM_000257.3(MYH7):c.2167C>T (p.Arg723Cys)	MYH7	hypertrophic cardiomyopathy	MONDO:0005045	Autosomal dominant inheritance	Pathogenic	BP2, PS4, PP1_Strong, PP3, PM6, PM1, PM5, PM2		The c.2167C>T (p.Arg723Cys) variant in MYH7 has been reported in >20 individuals with hypertrophic cardiomyopathy (PS4; PMID:1430197; PMID:27532257; PMID:9829907; PMID:16199542; PMID:20359594; PMID:12707239; Partners LMM ClinVar SCV000059423.5; AGCMC Sydney ClinVar SCV000212630.1). Five of these probands carried additional variants in sarcomere genes (BP2; PMID:20359594; PMID:12707239; Partners LMM ClinVar SCV000059423.5). This variant has been identified as a de novo occurrence in 1 proband with hypertrophic cardiomyopathy (PM6; PMID:1430197). This variant segregated with disease in 7 affected individuals (PP1_Strong; PMID:9829907; Partners LMM ClinVar SCV000059423.5; AGCMC Sydney ClinVar SCV000212630.1). This variant was identified in 2/66738 European chromosomes (PM2; http://exac.broadinstitute.org). This variant lies in the head region of the protein (aa 181-937) and missense variants in this region are statistically more likely to be disease-associated (PM1; PMID:27532257). Computational prediction tools and conservation analysis suggest that this variant may impact the protein (PP3). A different pathogenic missense variant has been previously identified at this codon which may indicate that this residue is critical to the function of the protein (PM5; c.2167C>G p.Arg723Gly - ClinVar Variation ID 42885). In summary, this variant meets criteria to be classified as pathogenic for hypertrophic cardiomyopathy in an autosomal dominant manner. The benign evidence code BP2 was not considered to be in conflict with this conclusion given that presence of a second variant can be seen in individuals with cardiomyopathy and may contribute to the severity of disease. MYH7-specific ACMG/AMP criteria applied (PMID:29300372): PS4; PP1_ Strong; PM1; PM2; PM5; PM6; PP3; BP2	20359594, 20359594, 1430197, 9829907, 12707239, 16199542, 27532257, 9829907, 27532257	Cardiomyopathy VCEP		2016-12-15	2018-11-16	False	https://erepo.genome.network/evrepo/ui/classification/CA011851/MONDO:0005045/002	7cad6d45-ed00-44b9-a31d-225ff15a0c10	p.Arg723Cys	Arg	723	Cys	MGDSEMAVFGAAAPYLRKSEKERLEAQTRPFDLKKDVFVPDDKQEFVKAKIVSREGGKVTAETEYGKTVTVKEDQVMQQNPPKFDKIEDMAMLTFLHEPAVLYNLKDRYGSWMIYTYSGLFCVTVNPYKWLPVYTPEVVAAYRGKKRSEAPPHIFSISDNAYQYMLTDRENQSILITGESGAGKTVNTKRVIQYFAVIAAIGDRSKKDQSPGKGTLEDQIIQANPALEAFGNAKTVRNDNSSRFGKFIRIHFGATGKLASADIETYLLEKSRVIFQLKAERDYHIFYQILSNKKPELLDMLLITNNPYDYAFISQGETTVASIDDAEELMATDNAFDVLGFTSEEKNSMYKLTGAIMHFGNMKFKLKQREEQAEPDGTEEADKSAYLMGLNSADLLKGLCHPRVKVGNEYVTKGQNVQQVIYATGALAKAVYERMFNWMVTRINATLETKQPRQYFIGVLDIAGFEIFDFNSFEQLCINFTNEKLQQFFNHHMFVLEQEEYKKEGIEWTFIDFGMDLQACIDLIEKPMGIMSILEEECMFPKATDMTFKAKLFDNHLGKSANFQKPRNIKGKPEAHFSLIHYAGIVDYNIIGWLQKNKDPLNETVVGLYQKSSLKLLSTLFANYAGADAPIEKGKGKAKKGSSFQTVSALHRENLNKLMTNLRSTHPHFVRCIIPNETKSPGVMDNPLVMHQLRCNGVLEGIRICRKGFPNRILYGDFRQRYRILNPAAIPEGQFIDSRKGAEKLLSSLDIDHNQYKFGHTKVFFKAGLLGLLEEMRDERLSRIITRIQAQSRGVLARMEYKKLLERRDSLLVIQWNIRAFMGVKNWPWMKLYFKIKPLLKSAEREKEMASMKEEFTRLKEALEKSEARRKELEEKMVSLLQEKNDLQLQVQAEQDNLADAEERCDQLIKNKIQLEAKVKEMNERLEDEEEMNAELTAKKRKLEDECSELKRDIDDLELTLAKVEKEKHATENKVKNLTEEMAGLDEIIAKLTKEKKALQEAHQQALDDLQAEEDKVNTLTKAKVKLEQQVDDLEGSLEQEKKVRMDLERAKRKLEGDLKLTQESIMDLENDKQQLDERLKKKDFELNALNARIEDEQALGSQLQKKLKELQARIEELEEELEAERTARAKVEKLRSDLSRELEEISERLEEAGGATSVQIEMNKKREAEFQKMRRDLEEATLQHEATAAALRKKHADSVAELGEQIDNLQRVKQKLEKEKSEFKLELDDVTSNMEQIIKAKANLEKMCRTLEDQMNEHRSKAEETQRSVNDLTSQRAKLQTENGELSRQLDEKEALISQLTRGKLTYTQQLEDLKRQLEEEVKAKNALAHALQSARHDCDLLREQYEEETEAKAELQRVLSKANSEVAQWRTKYETDAIQRTEELEEAKKKLAQRLQEAEEAVEAVNAKCSSLEKTKHRLQNEIEDLMVDVERSNAAAAALDKKQRNFDKILAEWKQKYEESQSELESSQKEARSLSTELFKLKNAYEESLEHLETFKRENKNLQEEISDLTEQLGSSGKTIHELEKVRKQLEAEKMELQSALEEAEASLEHEEGKILRAQLEFNQIKAEIERKLAEKDEEMEQAKRNHLRVVDSLQTSLDAETRSRNEALRVKKKMEGDLNEMEIQLSHANRMAAEAQKQVKSLQSLLKDTQIQLDDAVRANDDLKENIAIVERRNNLLQAELEELRAVVEQTERSRKLAEQELIETSERVQLLHSQNTSLINQKKKMDADLSQLQTEVEEAVQECRNAEEKAKKAITDAAMMAEELKKEQDTSAHLERMKKNMEQTIKDLQHRLDEAEQIALKGGKKQLQKLEARVRELENELEAEQKRNAESVKGMRKSERRIKELTYQTEEDRKNLLRLQDLVDKLQLKVKAYKRQAEEAEEQANTNLSKFRKVQHELDEAEERADIAESQVNKLRAKSRDIGTKGLNEE	1935	P12883	C	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [722], 'DISULFID_gain_score': array([0.51960087]), 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [422, 494], 'HELIX_gain_score': array([0.02254766, 0.00782591]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [152, 1784], 'DOMAIN_gain_score': array([0.03265601, 0.0118013 ]), 'REGION_loss': [], 'REGION_gain': [868, 887, 902, 1193, 1197, 1205, 1206, 1208, 1212, 1265], 'REGION_gain_score': array([0.00780678, 0.00664937, 0.00550348, 0.01641107, 0.01760632,
       0.01552027, 0.01618922, 0.01613039, 0.01490623, 0.00824481]), 'REPEAT_loss': [1841], 'REPEAT_gain': [63, 70, 76, 79, 83, 92, 93, 1168, 1178, 1192, 1194], 'REPEAT_gain_score': array([0.0037359 , 0.00377846, 0.00398797, 0.00363672, 0.00388646,
       0.00356656, 0.0033952 , 0.00237495, 0.00180537, 0.00188482,
       0.00115228]), 'REPEAT_loss_score': array([-0.00288332]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
16	NM_000257.3(MYH7):c.2167C>G (p.Arg723Gly)	42885	CA011843	NM_000257.3:c.2167C>G, NC_000014.9:g.23425814G>C, CM000676.2:g.23425814G>C, NC_000014.8:g.23895023G>C, CM000676.1:g.23895023G>C, NC_000014.7:g.22964863G>C, NG_007884.1:g.14848C>G, LRG_384:g.14848C>G, XR_245686.3:n.2273C>G, XM_017021340.1:c.2167C>G, NM_000257.4:c.2167C>G, ENST00000355349.3:c.2167C>G, NM_000257.3(MYH7):c.2167C>G (p.Arg723Gly)	MYH7	hypertrophic cardiomyopathy	MONDO:0005045	Autosomal dominant inheritance	Pathogenic	PS4, PP1_Strong, PM1, PM5, PM2, PP3		The c.2167C>G (p.Arg723Gly) variant in MYH7 has been reported in 12 individuals with hypertrophic cardiomyopathy (PS4; PMID:11113006; PMID:19150014; PMID:17097032; Partners LMM ClinVar SCV000059422.5; SHaRe consortium, PMID: 30297972). This variant segregated with disease in >20 affected individuals (PP1_Strong; PMID:11113006). This variant was absent from large population studies (PM2; http://exac.broadinstitute.org). This variant lies in the head region of the protein (aa 181-937) and missense variants in this region are statistically more likely to be disease-associated (PM1; PMID:27532257). Computational prediction tools and conservation analysis suggest that this variant may impact the protein (PP3). A different pathogenic missense variant has been previously identified at this codon which may indicate that this residue is critical to the function of the protein (PM5; c.2167C>T p.Arg723Cys - ClinVar Variation ID 14095). In summary, this variant meets criteria to be classified as pathogenic for hypertrophic cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (PMID:29300372): PS4; PP1_ Strong; PM1; PM2; PM5; PP3	19150014, 27532257, 17097032, 11113006, 16630450, 27532257	Cardiomyopathy VCEP		2016-12-15	2018-11-16	False	https://erepo.genome.network/evrepo/ui/classification/CA011843/MONDO:0005045/002	6c2b587c-45cc-4fbc-bc0b-059a87ea6349	p.Arg723Gly	Arg	723	Gly	MGDSEMAVFGAAAPYLRKSEKERLEAQTRPFDLKKDVFVPDDKQEFVKAKIVSREGGKVTAETEYGKTVTVKEDQVMQQNPPKFDKIEDMAMLTFLHEPAVLYNLKDRYGSWMIYTYSGLFCVTVNPYKWLPVYTPEVVAAYRGKKRSEAPPHIFSISDNAYQYMLTDRENQSILITGESGAGKTVNTKRVIQYFAVIAAIGDRSKKDQSPGKGTLEDQIIQANPALEAFGNAKTVRNDNSSRFGKFIRIHFGATGKLASADIETYLLEKSRVIFQLKAERDYHIFYQILSNKKPELLDMLLITNNPYDYAFISQGETTVASIDDAEELMATDNAFDVLGFTSEEKNSMYKLTGAIMHFGNMKFKLKQREEQAEPDGTEEADKSAYLMGLNSADLLKGLCHPRVKVGNEYVTKGQNVQQVIYATGALAKAVYERMFNWMVTRINATLETKQPRQYFIGVLDIAGFEIFDFNSFEQLCINFTNEKLQQFFNHHMFVLEQEEYKKEGIEWTFIDFGMDLQACIDLIEKPMGIMSILEEECMFPKATDMTFKAKLFDNHLGKSANFQKPRNIKGKPEAHFSLIHYAGIVDYNIIGWLQKNKDPLNETVVGLYQKSSLKLLSTLFANYAGADAPIEKGKGKAKKGSSFQTVSALHRENLNKLMTNLRSTHPHFVRCIIPNETKSPGVMDNPLVMHQLRCNGVLEGIRICRKGFPNRILYGDFRQRYRILNPAAIPEGQFIDSRKGAEKLLSSLDIDHNQYKFGHTKVFFKAGLLGLLEEMRDERLSRIITRIQAQSRGVLARMEYKKLLERRDSLLVIQWNIRAFMGVKNWPWMKLYFKIKPLLKSAEREKEMASMKEEFTRLKEALEKSEARRKELEEKMVSLLQEKNDLQLQVQAEQDNLADAEERCDQLIKNKIQLEAKVKEMNERLEDEEEMNAELTAKKRKLEDECSELKRDIDDLELTLAKVEKEKHATENKVKNLTEEMAGLDEIIAKLTKEKKALQEAHQQALDDLQAEEDKVNTLTKAKVKLEQQVDDLEGSLEQEKKVRMDLERAKRKLEGDLKLTQESIMDLENDKQQLDERLKKKDFELNALNARIEDEQALGSQLQKKLKELQARIEELEEELEAERTARAKVEKLRSDLSRELEEISERLEEAGGATSVQIEMNKKREAEFQKMRRDLEEATLQHEATAAALRKKHADSVAELGEQIDNLQRVKQKLEKEKSEFKLELDDVTSNMEQIIKAKANLEKMCRTLEDQMNEHRSKAEETQRSVNDLTSQRAKLQTENGELSRQLDEKEALISQLTRGKLTYTQQLEDLKRQLEEEVKAKNALAHALQSARHDCDLLREQYEEETEAKAELQRVLSKANSEVAQWRTKYETDAIQRTEELEEAKKKLAQRLQEAEEAVEAVNAKCSSLEKTKHRLQNEIEDLMVDVERSNAAAAALDKKQRNFDKILAEWKQKYEESQSELESSQKEARSLSTELFKLKNAYEESLEHLETFKRENKNLQEEISDLTEQLGSSGKTIHELEKVRKQLEAEKMELQSALEEAEASLEHEEGKILRAQLEFNQIKAEIERKLAEKDEEMEQAKRNHLRVVDSLQTSLDAETRSRNEALRVKKKMEGDLNEMEIQLSHANRMAAEAQKQVKSLQSLLKDTQIQLDDAVRANDDLKENIAIVERRNNLLQAELEELRAVVEQTERSRKLAEQELIETSERVQLLHSQNTSLINQKKKMDADLSQLQTEVEEAVQECRNAEEKAKKAITDAAMMAEELKKEQDTSAHLERMKKNMEQTIKDLQHRLDEAEQIALKGGKKQLQKLEARVRELENELEAEQKRNAESVKGMRKSERRIKELTYQTEEDRKNLLRLQDLVDKLQLKVKAYKRQAEEAEEQANTNLSKFRKVQHELDEAEERADIAESQVNKLRAKSRDIGTKGLNEE	1935	P12883	G	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [887, 902], 'REGION_gain_score': array([0.00389701, 0.00354773]), 'REPEAT_loss': [888, 980, 1009, 1111, 1156], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.00180078, -0.00379127, -0.00275767, -0.00378835, -0.00424248]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
17	NM_000257.3(MYH7):c.3770A>G (p.Asn1257Ser)	188628	CA014062	NM_000257.3:c.3770A>G, XM_017021340.1:c.3770A>G, NM_000257.4:c.3770A>G, ENST00000355349.3:c.3770A>G, NC_000014.9:g.23419566T>C, CM000676.2:g.23419566T>C, NC_000014.8:g.23888775T>C, CM000676.1:g.23888775T>C, NC_000014.7:g.22958615T>C, NG_007884.1:g.21096A>G, LRG_384:g.21096A>G, NM_000257.3(MYH7):c.3770A>G (p.Asn1257Ser)	MYH7	cardiomyopathy	MONDO:0004994	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.3770A>G (p.Asn1257Ser) variant in the MYH7 gene is 0.17% (37/16512) of South Asian chromosomes by the Exome Aggregation Consortium (http://exac.broadinstitute.org), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Inherited Cardiomyopathy Expert Panel (BA1; PMID:29300372).		Cardiomyopathy VCEP		2016-12-16	2018-11-16	False	https://erepo.genome.network/evrepo/ui/classification/CA014062/MONDO:0004994/002	e2762d05-f514-4fde-90de-7e6983a078a7	p.Asn1257Ser	Asn	1257	Ser	MGDSEMAVFGAAAPYLRKSEKERLEAQTRPFDLKKDVFVPDDKQEFVKAKIVSREGGKVTAETEYGKTVTVKEDQVMQQNPPKFDKIEDMAMLTFLHEPAVLYNLKDRYGSWMIYTYSGLFCVTVNPYKWLPVYTPEVVAAYRGKKRSEAPPHIFSISDNAYQYMLTDRENQSILITGESGAGKTVNTKRVIQYFAVIAAIGDRSKKDQSPGKGTLEDQIIQANPALEAFGNAKTVRNDNSSRFGKFIRIHFGATGKLASADIETYLLEKSRVIFQLKAERDYHIFYQILSNKKPELLDMLLITNNPYDYAFISQGETTVASIDDAEELMATDNAFDVLGFTSEEKNSMYKLTGAIMHFGNMKFKLKQREEQAEPDGTEEADKSAYLMGLNSADLLKGLCHPRVKVGNEYVTKGQNVQQVIYATGALAKAVYERMFNWMVTRINATLETKQPRQYFIGVLDIAGFEIFDFNSFEQLCINFTNEKLQQFFNHHMFVLEQEEYKKEGIEWTFIDFGMDLQACIDLIEKPMGIMSILEEECMFPKATDMTFKAKLFDNHLGKSANFQKPRNIKGKPEAHFSLIHYAGIVDYNIIGWLQKNKDPLNETVVGLYQKSSLKLLSTLFANYAGADAPIEKGKGKAKKGSSFQTVSALHRENLNKLMTNLRSTHPHFVRCIIPNETKSPGVMDNPLVMHQLRCNGVLEGIRICRKGFPNRILYGDFRQRYRILNPAAIPEGQFIDSRKGAEKLLSSLDIDHNQYKFGHTKVFFKAGLLGLLEEMRDERLSRIITRIQAQSRGVLARMEYKKLLERRDSLLVIQWNIRAFMGVKNWPWMKLYFKIKPLLKSAEREKEMASMKEEFTRLKEALEKSEARRKELEEKMVSLLQEKNDLQLQVQAEQDNLADAEERCDQLIKNKIQLEAKVKEMNERLEDEEEMNAELTAKKRKLEDECSELKRDIDDLELTLAKVEKEKHATENKVKNLTEEMAGLDEIIAKLTKEKKALQEAHQQALDDLQAEEDKVNTLTKAKVKLEQQVDDLEGSLEQEKKVRMDLERAKRKLEGDLKLTQESIMDLENDKQQLDERLKKKDFELNALNARIEDEQALGSQLQKKLKELQARIEELEEELEAERTARAKVEKLRSDLSRELEEISERLEEAGGATSVQIEMNKKREAEFQKMRRDLEEATLQHEATAAALRKKHADSVAELGEQIDNLQRVKQKLEKEKSEFKLELDDVTSNMEQIIKAKANLEKMCRTLEDQMNEHRSKAEETQRSVNDLTSQRAKLQTENGELSRQLDEKEALISQLTRGKLTYTQQLEDLKRQLEEEVKAKNALAHALQSARHDCDLLREQYEEETEAKAELQRVLSKANSEVAQWRTKYETDAIQRTEELEEAKKKLAQRLQEAEEAVEAVNAKCSSLEKTKHRLQNEIEDLMVDVERSNAAAAALDKKQRNFDKILAEWKQKYEESQSELESSQKEARSLSTELFKLKNAYEESLEHLETFKRENKNLQEEISDLTEQLGSSGKTIHELEKVRKQLEAEKMELQSALEEAEASLEHEEGKILRAQLEFNQIKAEIERKLAEKDEEMEQAKRNHLRVVDSLQTSLDAETRSRNEALRVKKKMEGDLNEMEIQLSHANRMAAEAQKQVKSLQSLLKDTQIQLDDAVRANDDLKENIAIVERRNNLLQAELEELRAVVEQTERSRKLAEQELIETSERVQLLHSQNTSLINQKKKMDADLSQLQTEVEEAVQECRNAEEKAKKAITDAAMMAEELKKEQDTSAHLERMKKNMEQTIKDLQHRLDEAEQIALKGGKKQLQKLEARVRELENELEAEQKRNAESVKGMRKSERRIKELTYQTEEDRKNLLRLQDLVDKLQLKVKAYKRQAEEAEEQANTNLSKFRKVQHELDEAEERADIAESQVNKLRAKSRDIGTKGLNEE	1935	P12883	S	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [874], 'REGION_gain': [], 'REGION_loss_score': array([-0.0043571]), 'REPEAT_loss': [87, 375, 888, 980], 'REPEAT_gain': [1150, 1168, 1178, 1192, 1194], 'REPEAT_gain_score': array([0.00372928, 0.00629985, 0.01021343, 0.0048961 , 0.00393903]), 'REPEAT_loss_score': array([-0.00010478, -0.00063729, -0.00269425, -0.00063086]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
18	NM_000257.3(MYH7):c.4472C>G (p.Ser1491Cys)	43020	CA015008	NM_000257.3:c.4472C>G, NC_000014.9:g.23417200G>C, CM000676.2:g.23417200G>C, NC_000014.8:g.23886409G>C, CM000676.1:g.23886409G>C, NC_000014.7:g.22956249G>C, NG_007884.1:g.23462C>G, LRG_384:g.23462C>G, NR_126491.1:n.652-12G>C, XM_017021340.1:c.4472C>G, NM_000257.4:c.4472C>G, ENST00000355349.3:c.4472C>G, NM_000257.3(MYH7):c.4472C>G (p.Ser1491Cys)	MYH7	cardiomyopathy	MONDO:0004994	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.4472C>G (p.Ser1491Cys) variant in the MYH7 gene is 0.98% (698/66740) of European chromosomes by the Exome Aggregation Consortium (http://exac.broadinstitute.org), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Inherited Cardiomyopathy Expert Panel (BA1; PMID:29300372).		Cardiomyopathy VCEP		2016-12-15	2018-11-16	False	https://erepo.genome.network/evrepo/ui/classification/CA015008/MONDO:0004994/002	ccf7c102-ea2b-405d-80ab-65ce87901806	p.Ser1491Cys	Ser	1491	Cys	MGDSEMAVFGAAAPYLRKSEKERLEAQTRPFDLKKDVFVPDDKQEFVKAKIVSREGGKVTAETEYGKTVTVKEDQVMQQNPPKFDKIEDMAMLTFLHEPAVLYNLKDRYGSWMIYTYSGLFCVTVNPYKWLPVYTPEVVAAYRGKKRSEAPPHIFSISDNAYQYMLTDRENQSILITGESGAGKTVNTKRVIQYFAVIAAIGDRSKKDQSPGKGTLEDQIIQANPALEAFGNAKTVRNDNSSRFGKFIRIHFGATGKLASADIETYLLEKSRVIFQLKAERDYHIFYQILSNKKPELLDMLLITNNPYDYAFISQGETTVASIDDAEELMATDNAFDVLGFTSEEKNSMYKLTGAIMHFGNMKFKLKQREEQAEPDGTEEADKSAYLMGLNSADLLKGLCHPRVKVGNEYVTKGQNVQQVIYATGALAKAVYERMFNWMVTRINATLETKQPRQYFIGVLDIAGFEIFDFNSFEQLCINFTNEKLQQFFNHHMFVLEQEEYKKEGIEWTFIDFGMDLQACIDLIEKPMGIMSILEEECMFPKATDMTFKAKLFDNHLGKSANFQKPRNIKGKPEAHFSLIHYAGIVDYNIIGWLQKNKDPLNETVVGLYQKSSLKLLSTLFANYAGADAPIEKGKGKAKKGSSFQTVSALHRENLNKLMTNLRSTHPHFVRCIIPNETKSPGVMDNPLVMHQLRCNGVLEGIRICRKGFPNRILYGDFRQRYRILNPAAIPEGQFIDSRKGAEKLLSSLDIDHNQYKFGHTKVFFKAGLLGLLEEMRDERLSRIITRIQAQSRGVLARMEYKKLLERRDSLLVIQWNIRAFMGVKNWPWMKLYFKIKPLLKSAEREKEMASMKEEFTRLKEALEKSEARRKELEEKMVSLLQEKNDLQLQVQAEQDNLADAEERCDQLIKNKIQLEAKVKEMNERLEDEEEMNAELTAKKRKLEDECSELKRDIDDLELTLAKVEKEKHATENKVKNLTEEMAGLDEIIAKLTKEKKALQEAHQQALDDLQAEEDKVNTLTKAKVKLEQQVDDLEGSLEQEKKVRMDLERAKRKLEGDLKLTQESIMDLENDKQQLDERLKKKDFELNALNARIEDEQALGSQLQKKLKELQARIEELEEELEAERTARAKVEKLRSDLSRELEEISERLEEAGGATSVQIEMNKKREAEFQKMRRDLEEATLQHEATAAALRKKHADSVAELGEQIDNLQRVKQKLEKEKSEFKLELDDVTSNMEQIIKAKANLEKMCRTLEDQMNEHRSKAEETQRSVNDLTSQRAKLQTENGELSRQLDEKEALISQLTRGKLTYTQQLEDLKRQLEEEVKAKNALAHALQSARHDCDLLREQYEEETEAKAELQRVLSKANSEVAQWRTKYETDAIQRTEELEEAKKKLAQRLQEAEEAVEAVNAKCSSLEKTKHRLQNEIEDLMVDVERSNAAAAALDKKQRNFDKILAEWKQKYEESQSELESSQKEARSLSTELFKLKNAYEESLEHLETFKRENKNLQEEISDLTEQLGSSGKTIHELEKVRKQLEAEKMELQSALEEAEASLEHEEGKILRAQLEFNQIKAEIERKLAEKDEEMEQAKRNHLRVVDSLQTSLDAETRSRNEALRVKKKMEGDLNEMEIQLSHANRMAAEAQKQVKSLQSLLKDTQIQLDDAVRANDDLKENIAIVERRNNLLQAELEELRAVVEQTERSRKLAEQELIETSERVQLLHSQNTSLINQKKKMDADLSQLQTEVEEAVQECRNAEEKAKKAITDAAMMAEELKKEQDTSAHLERMKKNMEQTIKDLQHRLDEAEQIALKGGKKQLQKLEARVRELENELEAEQKRNAESVKGMRKSERRIKELTYQTEEDRKNLLRLQDLVDKLQLKVKAYKRQAEEAEEQANTNLSKFRKVQHELDEAEERADIAESQVNKLRAKSRDIGTKGLNEE	1935	P12883	C	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [422, 494, 547], 'HELIX_gain_score': array([0.02651471, 0.01287895, 0.01893097]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [1658], 'DOMAIN_gain_score': array([0.07262886]), 'REGION_loss': [], 'REGION_gain': [887, 902, 1193, 1197, 1205, 1208, 1212], 'REGION_gain_score': array([0.00492293, 0.00358564, 0.00961041, 0.01072723, 0.00925922,
       0.00982648, 0.00842512]), 'REPEAT_loss': [87, 105, 373, 375, 400], 'REPEAT_gain': [1095, 1115, 1150, 1168, 1178, 1192, 1194], 'REPEAT_gain_score': array([0.00560278, 0.00687754, 0.00361222, 0.0057444 , 0.00297558,
       0.00276667, 0.00171864]), 'REPEAT_loss_score': array([-0.00265157, -0.00305218, -0.00220656, -0.00185287, -0.00355345]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
19	NM_000257.3(MYH7):c.2945T>C (p.Met982Thr)	42941	CA013227	NM_000257.3:c.2945T>C, NC_000014.9:g.23423701A>G, CM000676.2:g.23423701A>G, NC_000014.8:g.23892910A>G, CM000676.1:g.23892910A>G, NC_000014.7:g.22962750A>G, NG_007884.1:g.16961T>C, LRG_384:g.16961T>C, XR_245686.3:n.3051T>C, XM_017021340.1:c.2945T>C, NM_000257.4:c.2945T>C, ENST00000355349.3:c.2945T>C, NM_000257.3(MYH7):c.2945T>C (p.Met982Thr)	MYH7	cardiomyopathy	MONDO:0004994	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.2945T>C (p.Met982Thr) variant in the MYH7 gene is 0.11% (88/66740) of European chromosomes by the Exome Aggregation Consortium (http://exac.broadinstitute.org), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Inherited Cardiomyopathy Expert Panel (BA1; PMID:29300372).		Cardiomyopathy VCEP		2016-12-15	2018-11-16	False	https://erepo.genome.network/evrepo/ui/classification/CA013227/MONDO:0004994/002	391d3665-b29c-4627-bf93-ca50435b06b4	p.Met982Thr	Met	982	Thr	MGDSEMAVFGAAAPYLRKSEKERLEAQTRPFDLKKDVFVPDDKQEFVKAKIVSREGGKVTAETEYGKTVTVKEDQVMQQNPPKFDKIEDMAMLTFLHEPAVLYNLKDRYGSWMIYTYSGLFCVTVNPYKWLPVYTPEVVAAYRGKKRSEAPPHIFSISDNAYQYMLTDRENQSILITGESGAGKTVNTKRVIQYFAVIAAIGDRSKKDQSPGKGTLEDQIIQANPALEAFGNAKTVRNDNSSRFGKFIRIHFGATGKLASADIETYLLEKSRVIFQLKAERDYHIFYQILSNKKPELLDMLLITNNPYDYAFISQGETTVASIDDAEELMATDNAFDVLGFTSEEKNSMYKLTGAIMHFGNMKFKLKQREEQAEPDGTEEADKSAYLMGLNSADLLKGLCHPRVKVGNEYVTKGQNVQQVIYATGALAKAVYERMFNWMVTRINATLETKQPRQYFIGVLDIAGFEIFDFNSFEQLCINFTNEKLQQFFNHHMFVLEQEEYKKEGIEWTFIDFGMDLQACIDLIEKPMGIMSILEEECMFPKATDMTFKAKLFDNHLGKSANFQKPRNIKGKPEAHFSLIHYAGIVDYNIIGWLQKNKDPLNETVVGLYQKSSLKLLSTLFANYAGADAPIEKGKGKAKKGSSFQTVSALHRENLNKLMTNLRSTHPHFVRCIIPNETKSPGVMDNPLVMHQLRCNGVLEGIRICRKGFPNRILYGDFRQRYRILNPAAIPEGQFIDSRKGAEKLLSSLDIDHNQYKFGHTKVFFKAGLLGLLEEMRDERLSRIITRIQAQSRGVLARMEYKKLLERRDSLLVIQWNIRAFMGVKNWPWMKLYFKIKPLLKSAEREKEMASMKEEFTRLKEALEKSEARRKELEEKMVSLLQEKNDLQLQVQAEQDNLADAEERCDQLIKNKIQLEAKVKEMNERLEDEEEMNAELTAKKRKLEDECSELKRDIDDLELTLAKVEKEKHATENKVKNLTEEMAGLDEIIAKLTKEKKALQEAHQQALDDLQAEEDKVNTLTKAKVKLEQQVDDLEGSLEQEKKVRMDLERAKRKLEGDLKLTQESIMDLENDKQQLDERLKKKDFELNALNARIEDEQALGSQLQKKLKELQARIEELEEELEAERTARAKVEKLRSDLSRELEEISERLEEAGGATSVQIEMNKKREAEFQKMRRDLEEATLQHEATAAALRKKHADSVAELGEQIDNLQRVKQKLEKEKSEFKLELDDVTSNMEQIIKAKANLEKMCRTLEDQMNEHRSKAEETQRSVNDLTSQRAKLQTENGELSRQLDEKEALISQLTRGKLTYTQQLEDLKRQLEEEVKAKNALAHALQSARHDCDLLREQYEEETEAKAELQRVLSKANSEVAQWRTKYETDAIQRTEELEEAKKKLAQRLQEAEEAVEAVNAKCSSLEKTKHRLQNEIEDLMVDVERSNAAAAALDKKQRNFDKILAEWKQKYEESQSELESSQKEARSLSTELFKLKNAYEESLEHLETFKRENKNLQEEISDLTEQLGSSGKTIHELEKVRKQLEAEKMELQSALEEAEASLEHEEGKILRAQLEFNQIKAEIERKLAEKDEEMEQAKRNHLRVVDSLQTSLDAETRSRNEALRVKKKMEGDLNEMEIQLSHANRMAAEAQKQVKSLQSLLKDTQIQLDDAVRANDDLKENIAIVERRNNLLQAELEELRAVVEQTERSRKLAEQELIETSERVQLLHSQNTSLINQKKKMDADLSQLQTEVEEAVQECRNAEEKAKKAITDAAMMAEELKKEQDTSAHLERMKKNMEQTIKDLQHRLDEAEQIALKGGKKQLQKLEARVRELENELEAEQKRNAESVKGMRKSERRIKELTYQTEEDRKNLLRLQDLVDKLQLKVKAYKRQAEEAEEQANTNLSKFRKVQHELDEAEERADIAESQVNKLRAKSRDIGTKGLNEE	1935	P12883	T	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [152, 1658], 'DOMAIN_gain_score': array([0.01975083, 0.03330582]), 'REGION_loss': [874, 1264], 'REGION_gain': [], 'REGION_loss_score': array([-0.00471801, -0.00178623]), 'REPEAT_loss': [981], 'REPEAT_gain': [63, 79, 83, 92, 886, 895, 897, 899, 982, 999, 1002, 1095, 1115], 'REPEAT_gain_score': array([0.00324404, 0.00281739, 0.00243098, 0.00221276, 0.02418232,
       0.01528555, 0.01163179, 0.01428169, 0.02212447, 0.0211693 ,
       0.02420795, 0.01145864, 0.00926387]), 'REPEAT_loss_score': array([-0.03209841]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
20	NM_000257.3(MYH7):c.77C>T (p.Ala26Val)	37375	CA016817	NM_000257.3:c.77C>T, XR_245686.3:n.183C>T, XM_017021340.1:c.77C>T, NM_000257.4:c.77C>T, ENST00000355349.3:c.77C>T, NC_000014.9:g.23433656G>A, CM000676.2:g.23433656G>A, NC_000014.8:g.23902865G>A, CM000676.1:g.23902865G>A, NC_000014.7:g.22972705G>A, NG_007884.1:g.7006C>T, LRG_384:g.7006C>T, NM_000257.3(MYH7):c.77C>T (p.Ala26Val)	MYH7	cardiomyopathy	MONDO:0004994	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.77C>T (p.Ala26Val) variant in the MYH7 gene is 0.55% (60/8646) of East Asian chromosomes by the Exome Aggregation Consortium (http://exac.broadinstitute.org), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Inherited Cardiomyopathy Expert Panel (BA1; PMID:29300372).		Cardiomyopathy VCEP		2016-12-15	2018-11-16	False	https://erepo.genome.network/evrepo/ui/classification/CA016817/MONDO:0004994/002	e26a6375-f03a-4542-9924-d09781723678	p.Ala26Val	Ala	26	Val	MGDSEMAVFGAAAPYLRKSEKERLEAQTRPFDLKKDVFVPDDKQEFVKAKIVSREGGKVTAETEYGKTVTVKEDQVMQQNPPKFDKIEDMAMLTFLHEPAVLYNLKDRYGSWMIYTYSGLFCVTVNPYKWLPVYTPEVVAAYRGKKRSEAPPHIFSISDNAYQYMLTDRENQSILITGESGAGKTVNTKRVIQYFAVIAAIGDRSKKDQSPGKGTLEDQIIQANPALEAFGNAKTVRNDNSSRFGKFIRIHFGATGKLASADIETYLLEKSRVIFQLKAERDYHIFYQILSNKKPELLDMLLITNNPYDYAFISQGETTVASIDDAEELMATDNAFDVLGFTSEEKNSMYKLTGAIMHFGNMKFKLKQREEQAEPDGTEEADKSAYLMGLNSADLLKGLCHPRVKVGNEYVTKGQNVQQVIYATGALAKAVYERMFNWMVTRINATLETKQPRQYFIGVLDIAGFEIFDFNSFEQLCINFTNEKLQQFFNHHMFVLEQEEYKKEGIEWTFIDFGMDLQACIDLIEKPMGIMSILEEECMFPKATDMTFKAKLFDNHLGKSANFQKPRNIKGKPEAHFSLIHYAGIVDYNIIGWLQKNKDPLNETVVGLYQKSSLKLLSTLFANYAGADAPIEKGKGKAKKGSSFQTVSALHRENLNKLMTNLRSTHPHFVRCIIPNETKSPGVMDNPLVMHQLRCNGVLEGIRICRKGFPNRILYGDFRQRYRILNPAAIPEGQFIDSRKGAEKLLSSLDIDHNQYKFGHTKVFFKAGLLGLLEEMRDERLSRIITRIQAQSRGVLARMEYKKLLERRDSLLVIQWNIRAFMGVKNWPWMKLYFKIKPLLKSAEREKEMASMKEEFTRLKEALEKSEARRKELEEKMVSLLQEKNDLQLQVQAEQDNLADAEERCDQLIKNKIQLEAKVKEMNERLEDEEEMNAELTAKKRKLEDECSELKRDIDDLELTLAKVEKEKHATENKVKNLTEEMAGLDEIIAKLTKEKKALQEAHQQALDDLQAEEDKVNTLTKAKVKLEQQVDDLEGSLEQEKKVRMDLERAKRKLEGDLKLTQESIMDLENDKQQLDERLKKKDFELNALNARIEDEQALGSQLQKKLKELQARIEELEEELEAERTARAKVEKLRSDLSRELEEISERLEEAGGATSVQIEMNKKREAEFQKMRRDLEEATLQHEATAAALRKKHADSVAELGEQIDNLQRVKQKLEKEKSEFKLELDDVTSNMEQIIKAKANLEKMCRTLEDQMNEHRSKAEETQRSVNDLTSQRAKLQTENGELSRQLDEKEALISQLTRGKLTYTQQLEDLKRQLEEEVKAKNALAHALQSARHDCDLLREQYEEETEAKAELQRVLSKANSEVAQWRTKYETDAIQRTEELEEAKKKLAQRLQEAEEAVEAVNAKCSSLEKTKHRLQNEIEDLMVDVERSNAAAAALDKKQRNFDKILAEWKQKYEESQSELESSQKEARSLSTELFKLKNAYEESLEHLETFKRENKNLQEEISDLTEQLGSSGKTIHELEKVRKQLEAEKMELQSALEEAEASLEHEEGKILRAQLEFNQIKAEIERKLAEKDEEMEQAKRNHLRVVDSLQTSLDAETRSRNEALRVKKKMEGDLNEMEIQLSHANRMAAEAQKQVKSLQSLLKDTQIQLDDAVRANDDLKENIAIVERRNNLLQAELEELRAVVEQTERSRKLAEQELIETSERVQLLHSQNTSLINQKKKMDADLSQLQTEVEEAVQECRNAEEKAKKAITDAAMMAEELKKEQDTSAHLERMKKNMEQTIKDLQHRLDEAEQIALKGGKKQLQKLEARVRELENELEAEQKRNAESVKGMRKSERRIKELTYQTEEDRKNLLRLQDLVDKLQLKVKAYKRQAEEAEEQANTNLSKFRKVQHELDEAEERADIAESQVNKLRAKSRDIGTKGLNEE	1935	P12883	V	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [152], 'DOMAIN_gain_score': array([0.03552294]), 'REGION_loss': [874, 1264], 'REGION_gain': [], 'REGION_loss_score': array([-0.00100738, -0.00060397]), 'REPEAT_loss': [375, 879, 888, 980, 1009, 1083, 1156], 'REPEAT_gain': [63, 70, 76, 79, 83, 92, 93], 'REPEAT_gain_score': array([0.0053032 , 0.00501472, 0.005256  , 0.00514936, 0.00384343,
       0.00439233, 0.00389361]), 'REPEAT_loss_score': array([-0.00066024, -0.00327241, -0.00342745, -0.0046556 , -0.00614733,
       -0.00309539, -0.00358212]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
21	NM_000257.3(MYH7):c.2156G>A (p.Arg719Gln)	14107	CA011785	NM_000257.3:c.2156G>A, XR_245686.3:n.2262G>A, XM_017021340.1:c.2156G>A, NM_000257.4:c.2156G>A, ENST00000355349.3:c.2156G>A, NC_000014.9:g.23425970C>T, CM000676.2:g.23425970C>T, NC_000014.8:g.23895179C>T, CM000676.1:g.23895179C>T, NC_000014.7:g.22965019C>T, NG_007884.1:g.14692G>A, LRG_384:g.14692G>A, NM_000257.3(MYH7):c.2156G>A (p.Arg719Gln)	MYH7	hypertrophic cardiomyopathy	MONDO:0005045	Autosomal dominant inheritance	Pathogenic	PS4, PP3, PM1, PM5, PM2, PP1_Strong		The c.2156G>A (p.Arg719Gln) variant in MYH7 has been reported in >30 individuals with hypertrophic cardiomyopathy (PS4; PMID:7848441; PMID:16199542; PMID:15358028; PMID:18411228; Partners LMM ClinVar SCV000059421.5; AGCMC Sydney ClinVar SCV000212634.1; SHaRe consortium, PMID: 30297972). This variant segregated with disease in 7 affected individuals (PP1_Strong; PMID:7848441; Partners LMM ClinVar SCV000059421.5). This variant was absent from large population studies (PM2; http://exac.broadinstitute.org). This variant lies in the head region of the protein (aa 181-937) and missense variants in this region are statistically more likely to be disease-associated (PM1; PMID:27532257). Computational prediction tools and conservation analysis suggest that this variant may impact the protein (PP3). A different pathogenic missense variant has been previously identified at this codon which may indicate that this residue is critical to the function of the protein (PM5; c.2155C>T p.Arg719Trp ClinVar Variation ID 14104). In summary, this variant meets criteria to be classified as pathogenic for hypertrophic cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (PMID:29300372): PS4; PP1_ Strong; PM1; PM2; PM5; PP3	18411228, 16199542, 15358028, 7848441, 15858117, 27532257, 7848441	Cardiomyopathy VCEP		2016-12-15	2018-11-16	False	https://erepo.genome.network/evrepo/ui/classification/CA011785/MONDO:0005045/002	3a4b002a-d683-41f1-9f5f-3211c2a7f950	p.Arg719Gln	Arg	719	Gln	MGDSEMAVFGAAAPYLRKSEKERLEAQTRPFDLKKDVFVPDDKQEFVKAKIVSREGGKVTAETEYGKTVTVKEDQVMQQNPPKFDKIEDMAMLTFLHEPAVLYNLKDRYGSWMIYTYSGLFCVTVNPYKWLPVYTPEVVAAYRGKKRSEAPPHIFSISDNAYQYMLTDRENQSILITGESGAGKTVNTKRVIQYFAVIAAIGDRSKKDQSPGKGTLEDQIIQANPALEAFGNAKTVRNDNSSRFGKFIRIHFGATGKLASADIETYLLEKSRVIFQLKAERDYHIFYQILSNKKPELLDMLLITNNPYDYAFISQGETTVASIDDAEELMATDNAFDVLGFTSEEKNSMYKLTGAIMHFGNMKFKLKQREEQAEPDGTEEADKSAYLMGLNSADLLKGLCHPRVKVGNEYVTKGQNVQQVIYATGALAKAVYERMFNWMVTRINATLETKQPRQYFIGVLDIAGFEIFDFNSFEQLCINFTNEKLQQFFNHHMFVLEQEEYKKEGIEWTFIDFGMDLQACIDLIEKPMGIMSILEEECMFPKATDMTFKAKLFDNHLGKSANFQKPRNIKGKPEAHFSLIHYAGIVDYNIIGWLQKNKDPLNETVVGLYQKSSLKLLSTLFANYAGADAPIEKGKGKAKKGSSFQTVSALHRENLNKLMTNLRSTHPHFVRCIIPNETKSPGVMDNPLVMHQLRCNGVLEGIRICRKGFPNRILYGDFRQRYRILNPAAIPEGQFIDSRKGAEKLLSSLDIDHNQYKFGHTKVFFKAGLLGLLEEMRDERLSRIITRIQAQSRGVLARMEYKKLLERRDSLLVIQWNIRAFMGVKNWPWMKLYFKIKPLLKSAEREKEMASMKEEFTRLKEALEKSEARRKELEEKMVSLLQEKNDLQLQVQAEQDNLADAEERCDQLIKNKIQLEAKVKEMNERLEDEEEMNAELTAKKRKLEDECSELKRDIDDLELTLAKVEKEKHATENKVKNLTEEMAGLDEIIAKLTKEKKALQEAHQQALDDLQAEEDKVNTLTKAKVKLEQQVDDLEGSLEQEKKVRMDLERAKRKLEGDLKLTQESIMDLENDKQQLDERLKKKDFELNALNARIEDEQALGSQLQKKLKELQARIEELEEELEAERTARAKVEKLRSDLSRELEEISERLEEAGGATSVQIEMNKKREAEFQKMRRDLEEATLQHEATAAALRKKHADSVAELGEQIDNLQRVKQKLEKEKSEFKLELDDVTSNMEQIIKAKANLEKMCRTLEDQMNEHRSKAEETQRSVNDLTSQRAKLQTENGELSRQLDEKEALISQLTRGKLTYTQQLEDLKRQLEEEVKAKNALAHALQSARHDCDLLREQYEEETEAKAELQRVLSKANSEVAQWRTKYETDAIQRTEELEEAKKKLAQRLQEAEEAVEAVNAKCSSLEKTKHRLQNEIEDLMVDVERSNAAAAALDKKQRNFDKILAEWKQKYEESQSELESSQKEARSLSTELFKLKNAYEESLEHLETFKRENKNLQEEISDLTEQLGSSGKTIHELEKVRKQLEAEKMELQSALEEAEASLEHEEGKILRAQLEFNQIKAEIERKLAEKDEEMEQAKRNHLRVVDSLQTSLDAETRSRNEALRVKKKMEGDLNEMEIQLSHANRMAAEAQKQVKSLQSLLKDTQIQLDDAVRANDDLKENIAIVERRNNLLQAELEELRAVVEQTERSRKLAEQELIETSERVQLLHSQNTSLINQKKKMDADLSQLQTEVEEAVQECRNAEEKAKKAITDAAMMAEELKKEQDTSAHLERMKKNMEQTIKDLQHRLDEAEQIALKGGKKQLQKLEARVRELENELEAEQKRNAESVKGMRKSERRIKELTYQTEEDRKNLLRLQDLVDKLQLKVKAYKRQAEEAEEQANTNLSKFRKVQHELDEAEERADIAESQVNKLRAKSRDIGTKGLNEE	1935	P12883	Q	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [152], 'DOMAIN_gain_score': array([0.02346802]), 'REGION_loss': [], 'REGION_gain': [887, 902], 'REGION_gain_score': array([0.00403911, 0.00317818]), 'REPEAT_loss': [47, 87, 879, 888, 980, 1111, 1156], 'REPEAT_gain': [397], 'REPEAT_gain_score': array([0.0025093]), 'REPEAT_loss_score': array([-0.00102961, -0.00084066, -0.00312978, -0.0024755 , -0.00240827,
       -0.00198734, -0.00200176]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
22	NM_000257.3(MYH7):c.2155C>T (p.Arg719Trp)	14104	CA011779	NM_000257.3:c.2155C>T, NC_000014.9:g.23425971G>A, CM000676.2:g.23425971G>A, NC_000014.8:g.23895180G>A, CM000676.1:g.23895180G>A, NC_000014.7:g.22965020G>A, NG_007884.1:g.14691C>T, LRG_384:g.14691C>T, XR_245686.3:n.2261C>T, XM_017021340.1:c.2155C>T, NM_000257.4:c.2155C>T, ENST00000355349.3:c.2155C>T, NM_000257.3(MYH7):c.2155C>T (p.Arg719Trp)	MYH7	hypertrophic cardiomyopathy	MONDO:0005045	Autosomal dominant inheritance	Pathogenic	PS2, PS4, PP3, PS3, PM1, PM5, PM2, PP1_Strong		The c.2155C>T (p.Arg719Trp) variant in MYH7 has been reported in >20 individuals with hypertrophic cardiomyopathy (PS4; PMID:9829907; PMID:8282798; PMID:9822100; PMID:12974739; PMID:22429680; PMID:23816408; PMID:12707239; PMID:19645038; PMID:27532257; SHaRe consortium, PMID: 30297972; Partners LMM ClinVar SCV000059419.5 ), including 1 de novo occurrence (PS2; 10957787). This variant was found to segregate with disease in 8 affected family members (PP1_Strong; PMID:9829907; PMID:8282798; PMID:9822100; PMID:12974739; SHaRe consortium, PMID: 30297972). A mouse model indicates that this variant disrupts the function of MYH7 and leads to a phenotype consistent with HCM (PS3: PMID:24829265). This variant was absent from large population studies (PM2; http://exac.broadinstitute.org). This variant lies in the head region of the protein (aa 181-937) and missense variants in this region are statistically more likely to be disease-associated (PM1; PMID:27532257). Computational prediction tools and conservation analysis suggest that this variant may impact the protein (PP3). A different pathogenic missense variant has been previously identified at this codon which may indicate that this residue is critical to the function of the protein (PM5; c.2156G>A p.Arg719Gln - Variation ID 14107). In summary, this variant meets criteria to be classified as pathogenic for hypertrophic cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (PMID:29300372): PS2; PS3; PS4; PP1_ Strong; PM1; PM2; PM5; PP3	10957787, 23816408, 19645038, 27532257, 12707239, 8282798, 22429680, 10957787, 12974739, 9822100, 24829265, 27532257, 8282798, 9829907, 12974739, 9822100	Cardiomyopathy VCEP		2016-12-15	2018-11-16	False	https://erepo.genome.network/evrepo/ui/classification/CA011779/MONDO:0005045/002	7b17a8bd-b169-46a1-8efa-b7388c4ecdef	p.Arg719Trp	Arg	719	Trp	MGDSEMAVFGAAAPYLRKSEKERLEAQTRPFDLKKDVFVPDDKQEFVKAKIVSREGGKVTAETEYGKTVTVKEDQVMQQNPPKFDKIEDMAMLTFLHEPAVLYNLKDRYGSWMIYTYSGLFCVTVNPYKWLPVYTPEVVAAYRGKKRSEAPPHIFSISDNAYQYMLTDRENQSILITGESGAGKTVNTKRVIQYFAVIAAIGDRSKKDQSPGKGTLEDQIIQANPALEAFGNAKTVRNDNSSRFGKFIRIHFGATGKLASADIETYLLEKSRVIFQLKAERDYHIFYQILSNKKPELLDMLLITNNPYDYAFISQGETTVASIDDAEELMATDNAFDVLGFTSEEKNSMYKLTGAIMHFGNMKFKLKQREEQAEPDGTEEADKSAYLMGLNSADLLKGLCHPRVKVGNEYVTKGQNVQQVIYATGALAKAVYERMFNWMVTRINATLETKQPRQYFIGVLDIAGFEIFDFNSFEQLCINFTNEKLQQFFNHHMFVLEQEEYKKEGIEWTFIDFGMDLQACIDLIEKPMGIMSILEEECMFPKATDMTFKAKLFDNHLGKSANFQKPRNIKGKPEAHFSLIHYAGIVDYNIIGWLQKNKDPLNETVVGLYQKSSLKLLSTLFANYAGADAPIEKGKGKAKKGSSFQTVSALHRENLNKLMTNLRSTHPHFVRCIIPNETKSPGVMDNPLVMHQLRCNGVLEGIRICRKGFPNRILYGDFRQRYRILNPAAIPEGQFIDSRKGAEKLLSSLDIDHNQYKFGHTKVFFKAGLLGLLEEMRDERLSRIITRIQAQSRGVLARMEYKKLLERRDSLLVIQWNIRAFMGVKNWPWMKLYFKIKPLLKSAEREKEMASMKEEFTRLKEALEKSEARRKELEEKMVSLLQEKNDLQLQVQAEQDNLADAEERCDQLIKNKIQLEAKVKEMNERLEDEEEMNAELTAKKRKLEDECSELKRDIDDLELTLAKVEKEKHATENKVKNLTEEMAGLDEIIAKLTKEKKALQEAHQQALDDLQAEEDKVNTLTKAKVKLEQQVDDLEGSLEQEKKVRMDLERAKRKLEGDLKLTQESIMDLENDKQQLDERLKKKDFELNALNARIEDEQALGSQLQKKLKELQARIEELEEELEAERTARAKVEKLRSDLSRELEEISERLEEAGGATSVQIEMNKKREAEFQKMRRDLEEATLQHEATAAALRKKHADSVAELGEQIDNLQRVKQKLEKEKSEFKLELDDVTSNMEQIIKAKANLEKMCRTLEDQMNEHRSKAEETQRSVNDLTSQRAKLQTENGELSRQLDEKEALISQLTRGKLTYTQQLEDLKRQLEEEVKAKNALAHALQSARHDCDLLREQYEEETEAKAELQRVLSKANSEVAQWRTKYETDAIQRTEELEEAKKKLAQRLQEAEEAVEAVNAKCSSLEKTKHRLQNEIEDLMVDVERSNAAAAALDKKQRNFDKILAEWKQKYEESQSELESSQKEARSLSTELFKLKNAYEESLEHLETFKRENKNLQEEISDLTEQLGSSGKTIHELEKVRKQLEAEKMELQSALEEAEASLEHEEGKILRAQLEFNQIKAEIERKLAEKDEEMEQAKRNHLRVVDSLQTSLDAETRSRNEALRVKKKMEGDLNEMEIQLSHANRMAAEAQKQVKSLQSLLKDTQIQLDDAVRANDDLKENIAIVERRNNLLQAELEELRAVVEQTERSRKLAEQELIETSERVQLLHSQNTSLINQKKKMDADLSQLQTEVEEAVQECRNAEEKAKKAITDAAMMAEELKKEQDTSAHLERMKKNMEQTIKDLQHRLDEAEQIALKGGKKQLQKLEARVRELENELEAEQKRNAESVKGMRKSERRIKELTYQTEEDRKNLLRLQDLVDKLQLKVKAYKRQAEEAEEQANTNLSKFRKVQHELDEAEERADIAESQVNKLRAKSRDIGTKGLNEE	1935	P12883	W	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [494, 547], 'HELIX_gain_score': array([0.01118648, 0.01841795]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [152, 168, 1784], 'DOMAIN_gain_score': array([0.02516097, 0.05764604, 0.0069474 ]), 'REGION_loss': [1264], 'REGION_gain': [], 'REGION_loss_score': array([-0.00091153]), 'REPEAT_loss': [373, 375, 400], 'REPEAT_gain': [63, 79, 83, 92, 93, 1178, 1192, 1194], 'REPEAT_gain_score': array([0.00308174, 0.00354195, 0.00294781, 0.00316477, 0.00286472,
       0.00201088, 0.00172061, 0.00150627]), 'REPEAT_loss_score': array([-0.00262856, -0.00235236, -0.00279021]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
23	NM_000257.3(MYH7):c.2146G>A (p.Gly716Arg)	14105	CA011770	NM_000257.3:c.2146G>A, XR_245686.3:n.2252G>A, XM_017021340.1:c.2146G>A, NM_000257.4:c.2146G>A, ENST00000355349.3:c.2146G>A, NC_000014.9:g.23425980C>T, CM000676.2:g.23425980C>T, NC_000014.8:g.23895189C>T, CM000676.1:g.23895189C>T, NC_000014.7:g.22965029C>T, NG_007884.1:g.14682G>A, LRG_384:g.14682G>A, NM_000257.3(MYH7):c.2146G>A (p.Gly716Arg)	MYH7	hypertrophic cardiomyopathy	MONDO:0005045	Autosomal dominant inheritance	Pathogenic	PS4, PP1_Strong, PP3, PM6, PM1, PM2		The c.2146G>A (p.Gly716Arg) variant in MYH7 has been reported in >30 individuals with hypertrophic cardiomyopathy (PS4; PMID:23074333; PMID:20641121; PMID:12084606; PMID:8282798; PMID:18953637; PMID:12707239; PMID:15358028; PMID:12975413; Partners LMM ClinVar SCV000059418.5; SHaRe consortium, PMID: 30297972). This variant has been identified as a de novo occurrence in 2 probands with hypertrophic cardiomyopathy (PM6; PMID:18953637; Partners LMM ClinVar SCV000059418.5). This variant segregated with disease in 11 affected individuals (PP1_Strong; PMID:8282798; PMID:20641121; Partners LMM ClinVar SCV000059418.5). This variant was absent from large population studies (PM2; http://exac.broadinstitute.org). This variant lies in the head region of the protein (aa 181-937) and missense variants in this region are statistically more likely to be disease-associated (PM1; PMID:27532257). Computational prediction tools and conservation analysis suggest that this variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for hypertrophic cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (PMID:29300372): PS4; PP1_ Strong; PM1; PM2; PM6; PP3	12084606, 23074333, 12975413, 20641121, 15358028, 12707239, 18953637, 8282798, 20641121, 8282798, 18953637, 27532257	Cardiomyopathy VCEP		2016-12-15	2018-11-16	False	https://erepo.genome.network/evrepo/ui/classification/CA011770/MONDO:0005045/002	768afef8-4fb0-47f1-980f-d95c2ab71447	p.Gly716Arg	Gly	716	Arg	MGDSEMAVFGAAAPYLRKSEKERLEAQTRPFDLKKDVFVPDDKQEFVKAKIVSREGGKVTAETEYGKTVTVKEDQVMQQNPPKFDKIEDMAMLTFLHEPAVLYNLKDRYGSWMIYTYSGLFCVTVNPYKWLPVYTPEVVAAYRGKKRSEAPPHIFSISDNAYQYMLTDRENQSILITGESGAGKTVNTKRVIQYFAVIAAIGDRSKKDQSPGKGTLEDQIIQANPALEAFGNAKTVRNDNSSRFGKFIRIHFGATGKLASADIETYLLEKSRVIFQLKAERDYHIFYQILSNKKPELLDMLLITNNPYDYAFISQGETTVASIDDAEELMATDNAFDVLGFTSEEKNSMYKLTGAIMHFGNMKFKLKQREEQAEPDGTEEADKSAYLMGLNSADLLKGLCHPRVKVGNEYVTKGQNVQQVIYATGALAKAVYERMFNWMVTRINATLETKQPRQYFIGVLDIAGFEIFDFNSFEQLCINFTNEKLQQFFNHHMFVLEQEEYKKEGIEWTFIDFGMDLQACIDLIEKPMGIMSILEEECMFPKATDMTFKAKLFDNHLGKSANFQKPRNIKGKPEAHFSLIHYAGIVDYNIIGWLQKNKDPLNETVVGLYQKSSLKLLSTLFANYAGADAPIEKGKGKAKKGSSFQTVSALHRENLNKLMTNLRSTHPHFVRCIIPNETKSPGVMDNPLVMHQLRCNGVLEGIRICRKGFPNRILYGDFRQRYRILNPAAIPEGQFIDSRKGAEKLLSSLDIDHNQYKFGHTKVFFKAGLLGLLEEMRDERLSRIITRIQAQSRGVLARMEYKKLLERRDSLLVIQWNIRAFMGVKNWPWMKLYFKIKPLLKSAEREKEMASMKEEFTRLKEALEKSEARRKELEEKMVSLLQEKNDLQLQVQAEQDNLADAEERCDQLIKNKIQLEAKVKEMNERLEDEEEMNAELTAKKRKLEDECSELKRDIDDLELTLAKVEKEKHATENKVKNLTEEMAGLDEIIAKLTKEKKALQEAHQQALDDLQAEEDKVNTLTKAKVKLEQQVDDLEGSLEQEKKVRMDLERAKRKLEGDLKLTQESIMDLENDKQQLDERLKKKDFELNALNARIEDEQALGSQLQKKLKELQARIEELEEELEAERTARAKVEKLRSDLSRELEEISERLEEAGGATSVQIEMNKKREAEFQKMRRDLEEATLQHEATAAALRKKHADSVAELGEQIDNLQRVKQKLEKEKSEFKLELDDVTSNMEQIIKAKANLEKMCRTLEDQMNEHRSKAEETQRSVNDLTSQRAKLQTENGELSRQLDEKEALISQLTRGKLTYTQQLEDLKRQLEEEVKAKNALAHALQSARHDCDLLREQYEEETEAKAELQRVLSKANSEVAQWRTKYETDAIQRTEELEEAKKKLAQRLQEAEEAVEAVNAKCSSLEKTKHRLQNEIEDLMVDVERSNAAAAALDKKQRNFDKILAEWKQKYEESQSELESSQKEARSLSTELFKLKNAYEESLEHLETFKRENKNLQEEISDLTEQLGSSGKTIHELEKVRKQLEAEKMELQSALEEAEASLEHEEGKILRAQLEFNQIKAEIERKLAEKDEEMEQAKRNHLRVVDSLQTSLDAETRSRNEALRVKKKMEGDLNEMEIQLSHANRMAAEAQKQVKSLQSLLKDTQIQLDDAVRANDDLKENIAIVERRNNLLQAELEELRAVVEQTERSRKLAEQELIETSERVQLLHSQNTSLINQKKKMDADLSQLQTEVEEAVQECRNAEEKAKKAITDAAMMAEELKKEQDTSAHLERMKKNMEQTIKDLQHRLDEAEQIALKGGKKQLQKLEARVRELENELEAEQKRNAESVKGMRKSERRIKELTYQTEEDRKNLLRLQDLVDKLQLKVKAYKRQAEEAEEQANTNLSKFRKVQHELDEAEERADIAESQVNKLRAKSRDIGTKGLNEE	1935	P12883	R	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [165, 169], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.0262205 , -0.02434278]), 'REGION_loss': [874, 1264], 'REGION_gain': [], 'REGION_loss_score': array([-0.0025956 , -0.00115526]), 'REPEAT_loss': [888], 'REPEAT_gain': [63, 79, 92, 397, 1168, 1178], 'REPEAT_gain_score': array([0.00188881, 0.00204211, 0.00220215, 0.00252396, 0.00198555,
       0.00138998]), 'REPEAT_loss_score': array([-0.00212282]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
24	NM_000257.3(MYH7):c.1988G>A (p.Arg663His)	42875	CA011552	NM_000257.3:c.1988G>A, XR_245686.3:n.2094G>A, XM_017021340.1:c.1988G>A, NM_000257.4:c.1988G>A, ENST00000355349.3:c.1988G>A, NC_000014.9:g.23426833C>T, CM000676.2:g.23426833C>T, NC_000014.8:g.23896042C>T, CM000676.1:g.23896042C>T, NC_000014.7:g.22965882C>T, NG_007884.1:g.13829G>A, LRG_384:g.13829G>A, NM_000257.3(MYH7):c.1988G>A (p.Arg663His)	MYH7	hypertrophic cardiomyopathy	MONDO:0005045	Autosomal dominant inheritance	Pathogenic	PS4, PM1, PM2, PP1_Strong		The c.1988G>A (p.Arg663His) variant in MYH7 has been reported in >30 individuals with hypertrophic cardiomyopathy (PS4; PMID:27532257; PMID:10750581; PMID:11133230; PMID:12707239; PMID:15563892; PMID:16199542; PMID:15358028; AGCMC Sydney ClinVar SCV000212629.1; Invitae ClinVar SCV000219103.7; Partners LMM ClinVar SCV000059409.5; SHaRe consortium, PMID: 30297972). This variant segregated with disease in >15 affected individuals (PP1_Strong; PMID:10750581; Partners LMM ClinVar SCV000059409.5; SHaRe consortium, PMID: 30297972). This variant was identified in 2/66718 European chromosomes (PM2; http://exac.broadinstitute.org). This variant lies in the head region of the protein (aa 181-937) and missense variants in this region are statistically more likely to be disease-associated (PM1; PMID:27532257). In summary, this variant meets criteria to be classified as pathogenic for hypertrophic cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (PMID:29300372): PS4; PP1_ Strong; PM1; PM2	27532257, 16199542, 15358028, 11133230, 10750581, 12707239, 15563892, 27532257, 10750581	Cardiomyopathy VCEP		2016-12-15	2018-11-16	False	https://erepo.genome.network/evrepo/ui/classification/CA011552/MONDO:0005045/002	b27a29bf-ad68-4066-b07a-e5dcac3e6944	p.Arg663His	Arg	663	His	MGDSEMAVFGAAAPYLRKSEKERLEAQTRPFDLKKDVFVPDDKQEFVKAKIVSREGGKVTAETEYGKTVTVKEDQVMQQNPPKFDKIEDMAMLTFLHEPAVLYNLKDRYGSWMIYTYSGLFCVTVNPYKWLPVYTPEVVAAYRGKKRSEAPPHIFSISDNAYQYMLTDRENQSILITGESGAGKTVNTKRVIQYFAVIAAIGDRSKKDQSPGKGTLEDQIIQANPALEAFGNAKTVRNDNSSRFGKFIRIHFGATGKLASADIETYLLEKSRVIFQLKAERDYHIFYQILSNKKPELLDMLLITNNPYDYAFISQGETTVASIDDAEELMATDNAFDVLGFTSEEKNSMYKLTGAIMHFGNMKFKLKQREEQAEPDGTEEADKSAYLMGLNSADLLKGLCHPRVKVGNEYVTKGQNVQQVIYATGALAKAVYERMFNWMVTRINATLETKQPRQYFIGVLDIAGFEIFDFNSFEQLCINFTNEKLQQFFNHHMFVLEQEEYKKEGIEWTFIDFGMDLQACIDLIEKPMGIMSILEEECMFPKATDMTFKAKLFDNHLGKSANFQKPRNIKGKPEAHFSLIHYAGIVDYNIIGWLQKNKDPLNETVVGLYQKSSLKLLSTLFANYAGADAPIEKGKGKAKKGSSFQTVSALHRENLNKLMTNLRSTHPHFVRCIIPNETKSPGVMDNPLVMHQLRCNGVLEGIRICRKGFPNRILYGDFRQRYRILNPAAIPEGQFIDSRKGAEKLLSSLDIDHNQYKFGHTKVFFKAGLLGLLEEMRDERLSRIITRIQAQSRGVLARMEYKKLLERRDSLLVIQWNIRAFMGVKNWPWMKLYFKIKPLLKSAEREKEMASMKEEFTRLKEALEKSEARRKELEEKMVSLLQEKNDLQLQVQAEQDNLADAEERCDQLIKNKIQLEAKVKEMNERLEDEEEMNAELTAKKRKLEDECSELKRDIDDLELTLAKVEKEKHATENKVKNLTEEMAGLDEIIAKLTKEKKALQEAHQQALDDLQAEEDKVNTLTKAKVKLEQQVDDLEGSLEQEKKVRMDLERAKRKLEGDLKLTQESIMDLENDKQQLDERLKKKDFELNALNARIEDEQALGSQLQKKLKELQARIEELEEELEAERTARAKVEKLRSDLSRELEEISERLEEAGGATSVQIEMNKKREAEFQKMRRDLEEATLQHEATAAALRKKHADSVAELGEQIDNLQRVKQKLEKEKSEFKLELDDVTSNMEQIIKAKANLEKMCRTLEDQMNEHRSKAEETQRSVNDLTSQRAKLQTENGELSRQLDEKEALISQLTRGKLTYTQQLEDLKRQLEEEVKAKNALAHALQSARHDCDLLREQYEEETEAKAELQRVLSKANSEVAQWRTKYETDAIQRTEELEEAKKKLAQRLQEAEEAVEAVNAKCSSLEKTKHRLQNEIEDLMVDVERSNAAAAALDKKQRNFDKILAEWKQKYEESQSELESSQKEARSLSTELFKLKNAYEESLEHLETFKRENKNLQEEISDLTEQLGSSGKTIHELEKVRKQLEAEKMELQSALEEAEASLEHEEGKILRAQLEFNQIKAEIERKLAEKDEEMEQAKRNHLRVVDSLQTSLDAETRSRNEALRVKKKMEGDLNEMEIQLSHANRMAAEAQKQVKSLQSLLKDTQIQLDDAVRANDDLKENIAIVERRNNLLQAELEELRAVVEQTERSRKLAEQELIETSERVQLLHSQNTSLINQKKKMDADLSQLQTEVEEAVQECRNAEEKAKKAITDAAMMAEELKKEQDTSAHLERMKKNMEQTIKDLQHRLDEAEQIALKGGKKQLQKLEARVRELENELEAEQKRNAESVKGMRKSERRIKELTYQTEEDRKNLLRLQDLVDKLQLKVKAYKRQAEEAEEQANTNLSKFRKVQHELDEAEERADIAESQVNKLRAKSRDIGTKGLNEE	1935	P12883	H	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [660], 'HELIX_gain': [494], 'HELIX_gain_score': array([0.00399071]), 'HELIX_loss_score': array([-0.00718015]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [152, 1784], 'DOMAIN_gain_score': array([0.02579463, 0.0064646 ]), 'REGION_loss': [], 'REGION_gain': [1205], 'REGION_gain_score': array([0.00368774]), 'REPEAT_loss': [47, 87, 105, 375, 879, 888, 980, 1009, 1083, 1111, 1156], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.00342715, -0.00287658, -0.0024935 , -0.0004071 , -0.00362688,
       -0.00305068, -0.00262707, -0.00304461, -0.00325084, -0.00338352,
       -0.00373834]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
25	NM_000257.3(MYH7):c.1750G>C (p.Gly584Arg)	14090	CA011186	NM_000257.3:c.1750G>C, NC_000014.9:g.23427723C>G, CM000676.2:g.23427723C>G, NC_000014.8:g.23896932C>G, CM000676.1:g.23896932C>G, NC_000014.7:g.22966772C>G, NG_007884.1:g.12939G>C, LRG_384:g.12939G>C, XR_245686.3:n.1856G>C, XM_017021340.1:c.1750G>C, NM_000257.4:c.1750G>C, ENST00000355349.3:c.1750G>C, NM_000257.3(MYH7):c.1750G>C (p.Gly584Arg)	MYH7	hypertrophic cardiomyopathy	MONDO:0005045	Autosomal dominant inheritance	Pathogenic	PP1_Moderate, PS4, PP3, PM1, PM2		The c.1750G>C (p.Gly584Arg) variant in MYH7 has been reported in >25 individuals with hypertrophic cardiomyopathy (PS4; PMID:1552912; PMID:10567705; PMID:24093860; Partners LMM ClinVar SCV000059395.5; SHaRe consortium, PMID: 30297972). This variant segregated with disease in >5 affected individuals (PP1_Moderate; PMID:1552912; Partners LMM ClinVar SCV000059395.5). This variant was absent from large population studies (PM2; http://exac.broadinstitute.org). This variant lies in the head region of the protein (aa 181-937) and missense variants in this region are statistically more likely to be disease-associated (PM1; PMID:27532257). Computational prediction tools and conservation analysis suggest that this variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for hypertrophic cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (PMID:29300372): PS4; PM1; PM2; PP1_Moderate; PP3	1552912, 10567705, 1552912, 24093860, 27532257	Cardiomyopathy VCEP		2016-12-15	2018-11-16	False	https://erepo.genome.network/evrepo/ui/classification/CA011186/MONDO:0005045/002	ad28d5b5-6c74-4aa4-a755-d1b21486fd81	p.Gly584Arg	Gly	584	Arg	MGDSEMAVFGAAAPYLRKSEKERLEAQTRPFDLKKDVFVPDDKQEFVKAKIVSREGGKVTAETEYGKTVTVKEDQVMQQNPPKFDKIEDMAMLTFLHEPAVLYNLKDRYGSWMIYTYSGLFCVTVNPYKWLPVYTPEVVAAYRGKKRSEAPPHIFSISDNAYQYMLTDRENQSILITGESGAGKTVNTKRVIQYFAVIAAIGDRSKKDQSPGKGTLEDQIIQANPALEAFGNAKTVRNDNSSRFGKFIRIHFGATGKLASADIETYLLEKSRVIFQLKAERDYHIFYQILSNKKPELLDMLLITNNPYDYAFISQGETTVASIDDAEELMATDNAFDVLGFTSEEKNSMYKLTGAIMHFGNMKFKLKQREEQAEPDGTEEADKSAYLMGLNSADLLKGLCHPRVKVGNEYVTKGQNVQQVIYATGALAKAVYERMFNWMVTRINATLETKQPRQYFIGVLDIAGFEIFDFNSFEQLCINFTNEKLQQFFNHHMFVLEQEEYKKEGIEWTFIDFGMDLQACIDLIEKPMGIMSILEEECMFPKATDMTFKAKLFDNHLGKSANFQKPRNIKGKPEAHFSLIHYAGIVDYNIIGWLQKNKDPLNETVVGLYQKSSLKLLSTLFANYAGADAPIEKGKGKAKKGSSFQTVSALHRENLNKLMTNLRSTHPHFVRCIIPNETKSPGVMDNPLVMHQLRCNGVLEGIRICRKGFPNRILYGDFRQRYRILNPAAIPEGQFIDSRKGAEKLLSSLDIDHNQYKFGHTKVFFKAGLLGLLEEMRDERLSRIITRIQAQSRGVLARMEYKKLLERRDSLLVIQWNIRAFMGVKNWPWMKLYFKIKPLLKSAEREKEMASMKEEFTRLKEALEKSEARRKELEEKMVSLLQEKNDLQLQVQAEQDNLADAEERCDQLIKNKIQLEAKVKEMNERLEDEEEMNAELTAKKRKLEDECSELKRDIDDLELTLAKVEKEKHATENKVKNLTEEMAGLDEIIAKLTKEKKALQEAHQQALDDLQAEEDKVNTLTKAKVKLEQQVDDLEGSLEQEKKVRMDLERAKRKLEGDLKLTQESIMDLENDKQQLDERLKKKDFELNALNARIEDEQALGSQLQKKLKELQARIEELEEELEAERTARAKVEKLRSDLSRELEEISERLEEAGGATSVQIEMNKKREAEFQKMRRDLEEATLQHEATAAALRKKHADSVAELGEQIDNLQRVKQKLEKEKSEFKLELDDVTSNMEQIIKAKANLEKMCRTLEDQMNEHRSKAEETQRSVNDLTSQRAKLQTENGELSRQLDEKEALISQLTRGKLTYTQQLEDLKRQLEEEVKAKNALAHALQSARHDCDLLREQYEEETEAKAELQRVLSKANSEVAQWRTKYETDAIQRTEELEEAKKKLAQRLQEAEEAVEAVNAKCSSLEKTKHRLQNEIEDLMVDVERSNAAAAALDKKQRNFDKILAEWKQKYEESQSELESSQKEARSLSTELFKLKNAYEESLEHLETFKRENKNLQEEISDLTEQLGSSGKTIHELEKVRKQLEAEKMELQSALEEAEASLEHEEGKILRAQLEFNQIKAEIERKLAEKDEEMEQAKRNHLRVVDSLQTSLDAETRSRNEALRVKKKMEGDLNEMEIQLSHANRMAAEAQKQVKSLQSLLKDTQIQLDDAVRANDDLKENIAIVERRNNLLQAELEELRAVVEQTERSRKLAEQELIETSERVQLLHSQNTSLINQKKKMDADLSQLQTEVEEAVQECRNAEEKAKKAITDAAMMAEELKKEQDTSAHLERMKKNMEQTIKDLQHRLDEAEQIALKGGKKQLQKLEARVRELENELEAEQKRNAESVKGMRKSERRIKELTYQTEEDRKNLLRLQDLVDKLQLKVKAYKRQAEEAEEQANTNLSKFRKVQHELDEAEERADIAESQVNKLRAKSRDIGTKGLNEE	1935	P12883	R	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [660], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.01276678]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [169, 1666], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.01402676, -0.05851614]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [888], 'REPEAT_gain': [63, 79, 83, 92, 93, 397, 1192, 1858], 'REPEAT_gain_score': array([0.00287038, 0.00308627, 0.00320649, 0.00329173, 0.0032953 ,
       0.00421166, 0.00077599, 0.00554729]), 'REPEAT_loss_score': array([-0.00063974]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
26	NM_000257.3(MYH7):c.1594T>C (p.Ser532Pro)	14108	CA011011	NM_000257.3:c.1594T>C, NC_000014.9:g.23427879A>G, CM000676.2:g.23427879A>G, NC_000014.8:g.23897088A>G, CM000676.1:g.23897088A>G, NC_000014.7:g.22966928A>G, NG_007884.1:g.12783T>C, LRG_384:g.12783T>C, XR_245686.3:n.1700T>C, XM_017021340.1:c.1594T>C, NM_000257.4:c.1594T>C, ENST00000355349.3:c.1594T>C, NM_000257.3(MYH7):c.1594T>C (p.Ser532Pro)	MYH7	dilated cardiomyopathy	MONDO:0005021	Autosomal dominant inheritance	Pathogenic	PS4_Supporting, PP1_Strong, PM1, PM2, PS3, PP3		The c.1594T>C (p.Ser532Pro) variant in MYH7 has been reported in 2 individuals with dilated cardiomyopathy (PS4_Supporting; PMID:11106718; PMID:22949430; Partners LMM ClinVar SCV000199219.4). This variant segregated with disease in >10 affected individuals (PP1_Strong; PMID:11106718; PMID:22949430). Mouse model indicates that this variant disrupts the function of MYH7 and leads to a phenotype consistent with DCM (PS3; PMID:16983074; PMID:23313350; PMID:17351073 ). This variant was absent from large population studies (PM2; http://exac.broadinstitute.org). This variant lies in the head region of the protein (aa 181-937) and missense variants in this region are statistically more likely to be disease-associated (PM1; PMID:27532257). Computational prediction tools and conservation analysis suggest that this variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for dilated cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (PMID:29300372): PS3; PP1_ Strong; PM1; PM2; PP3; PS4_Supporting	11106718, 22949430, 11106718, 22949430, 2753225, 16983074, 17351073, 23313350	Cardiomyopathy VCEP		2016-12-15	2018-11-16	False	https://erepo.genome.network/evrepo/ui/classification/CA011011/MONDO:0005021/002	9486153c-4de2-4686-927c-cbe960ccbc06	p.Ser532Pro	Ser	532	Pro	MGDSEMAVFGAAAPYLRKSEKERLEAQTRPFDLKKDVFVPDDKQEFVKAKIVSREGGKVTAETEYGKTVTVKEDQVMQQNPPKFDKIEDMAMLTFLHEPAVLYNLKDRYGSWMIYTYSGLFCVTVNPYKWLPVYTPEVVAAYRGKKRSEAPPHIFSISDNAYQYMLTDRENQSILITGESGAGKTVNTKRVIQYFAVIAAIGDRSKKDQSPGKGTLEDQIIQANPALEAFGNAKTVRNDNSSRFGKFIRIHFGATGKLASADIETYLLEKSRVIFQLKAERDYHIFYQILSNKKPELLDMLLITNNPYDYAFISQGETTVASIDDAEELMATDNAFDVLGFTSEEKNSMYKLTGAIMHFGNMKFKLKQREEQAEPDGTEEADKSAYLMGLNSADLLKGLCHPRVKVGNEYVTKGQNVQQVIYATGALAKAVYERMFNWMVTRINATLETKQPRQYFIGVLDIAGFEIFDFNSFEQLCINFTNEKLQQFFNHHMFVLEQEEYKKEGIEWTFIDFGMDLQACIDLIEKPMGIMSILEEECMFPKATDMTFKAKLFDNHLGKSANFQKPRNIKGKPEAHFSLIHYAGIVDYNIIGWLQKNKDPLNETVVGLYQKSSLKLLSTLFANYAGADAPIEKGKGKAKKGSSFQTVSALHRENLNKLMTNLRSTHPHFVRCIIPNETKSPGVMDNPLVMHQLRCNGVLEGIRICRKGFPNRILYGDFRQRYRILNPAAIPEGQFIDSRKGAEKLLSSLDIDHNQYKFGHTKVFFKAGLLGLLEEMRDERLSRIITRIQAQSRGVLARMEYKKLLERRDSLLVIQWNIRAFMGVKNWPWMKLYFKIKPLLKSAEREKEMASMKEEFTRLKEALEKSEARRKELEEKMVSLLQEKNDLQLQVQAEQDNLADAEERCDQLIKNKIQLEAKVKEMNERLEDEEEMNAELTAKKRKLEDECSELKRDIDDLELTLAKVEKEKHATENKVKNLTEEMAGLDEIIAKLTKEKKALQEAHQQALDDLQAEEDKVNTLTKAKVKLEQQVDDLEGSLEQEKKVRMDLERAKRKLEGDLKLTQESIMDLENDKQQLDERLKKKDFELNALNARIEDEQALGSQLQKKLKELQARIEELEEELEAERTARAKVEKLRSDLSRELEEISERLEEAGGATSVQIEMNKKREAEFQKMRRDLEEATLQHEATAAALRKKHADSVAELGEQIDNLQRVKQKLEKEKSEFKLELDDVTSNMEQIIKAKANLEKMCRTLEDQMNEHRSKAEETQRSVNDLTSQRAKLQTENGELSRQLDEKEALISQLTRGKLTYTQQLEDLKRQLEEEVKAKNALAHALQSARHDCDLLREQYEEETEAKAELQRVLSKANSEVAQWRTKYETDAIQRTEELEEAKKKLAQRLQEAEEAVEAVNAKCSSLEKTKHRLQNEIEDLMVDVERSNAAAAALDKKQRNFDKILAEWKQKYEESQSELESSQKEARSLSTELFKLKNAYEESLEHLETFKRENKNLQEEISDLTEQLGSSGKTIHELEKVRKQLEAEKMELQSALEEAEASLEHEEGKILRAQLEFNQIKAEIERKLAEKDEEMEQAKRNHLRVVDSLQTSLDAETRSRNEALRVKKKMEGDLNEMEIQLSHANRMAAEAQKQVKSLQSLLKDTQIQLDDAVRANDDLKENIAIVERRNNLLQAELEELRAVVEQTERSRKLAEQELIETSERVQLLHSQNTSLINQKKKMDADLSQLQTEVEEAVQECRNAEEKAKKAITDAAMMAEELKKEQDTSAHLERMKKNMEQTIKDLQHRLDEAEQIALKGGKKQLQKLEARVRELENELEAEQKRNAESVKGMRKSERRIKELTYQTEEDRKNLLRLQDLVDKLQLKVKAYKRQAEEAEEQANTNLSKFRKVQHELDEAEERADIAESQVNKLRAKSRDIGTKGLNEE	1935	P12883	P	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [531, 532], 'HELIX_gain': [494], 'HELIX_gain_score': array([0.00801873]), 'HELIX_loss_score': array([-0.11626101, -0.13651299]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [152, 159, 168, 1658, 1784], 'DOMAIN_gain_score': array([0.039316  , 0.0585835 , 0.04545355, 0.03025591, 0.01048642]), 'REGION_loss': [874, 1264, 1271], 'REGION_gain': [], 'REGION_loss_score': array([-0.00324357, -0.00300896, -0.00313359]), 'REPEAT_loss': [47, 373, 375, 400], 'REPEAT_gain': [1168, 1178, 1192, 1194], 'REPEAT_gain_score': array([0.00155616, 0.00181937, 0.00215477, 0.00218236]), 'REPEAT_loss_score': array([-0.00166333, -0.00294793, -0.00308156, -0.00439006]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
27	NM_000257.4(MYH7):c.5135G>A (p.Arg1712Gln)	36642	CA015727	NM_000257.4:c.5135G>A, NC_000014.9:g.23415651C>T, CM000676.2:g.23415651C>T, NC_000014.8:g.23884860C>T, CM000676.1:g.23884860C>T, NC_000014.7:g.22954700C>T, NG_007884.1:g.25011G>A, LRG_384:g.25011G>A, ENST00000355349.4:c.5135G>A, ENST00000355349.3:c.5135G>A, NM_000257.3:c.5135G>A, NR_126491.1:n.83C>T, XM_017021340.1:c.5135G>A, NM_000257.4(MYH7):c.5135G>A (p.Arg1712Gln)	MYH7	hypertrophic cardiomyopathy	MONDO:0005045	Autosomal dominant inheritance	Pathogenic	PS4, PP1_Strong, PM2	BS1, BS4, BS3, BP3, BP4, BP7, BP2, BP5, PS2, PS1, PVS1, PM1, PM4, PM6, PM5, PP3, BA1, PS3	The NM_000257.4(MYH7):c.5135G>A (p.Arg1712Gln) variant has been reported in >30 individuals with HCM (PS4; Miller 2013 PMID: 23054336; Mook 2013 PMID: 23785128; Glotov 2015 PMID: 25892673; Lopes 2015 PMID: 25351510; Helms 2016 PMID: 27688314; Mademont-Soler 2017 PMID: 28771489; Weissler-Snir 2017 PMID: 28193612; van Velzen 2017 PMID: 2879411; van Lint 2019 PMID: 30847666; Tran Vu 2019 PMID: 31308319; Ambry pers. comm.; CHEO pers. comm.; GeneDx pers. comm.; LMM pers. comm.; Mayo pers. comm.; OMGL pers. comm.). This variant segregated with disease in >15 affected relatives with HCM in at least 9  families (PP1_strong; GeneDx pers. comm.; LMM pers. comm.; OMGL pers. comm.). This variant has also been identified in 0.002% (FAF 95% CI; 6/128842) of European chromosomes by gnomAD v2.1.1 (PM2; https://gnomad.broadinstitute.org). Computational prediction tools and conservation analyses do not provide strong support for or against an impact to the protein. In summary, this variant meets criteria to be classified as  pathogenic for hypertrophic cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (PMID:29300372): PS4, PP1_strong, PM2.		Cardiomyopathy VCEP		2021-12-09	2021-12-09	False	https://erepo.genome.network/evrepo/ui/classification/CA015727/MONDO:0005045/002	96f084ee-5a31-4783-b4d4-aa2ffe4b4e45	p.Arg1712Gln	Arg	1712	Gln	MGDSEMAVFGAAAPYLRKSEKERLEAQTRPFDLKKDVFVPDDKQEFVKAKIVSREGGKVTAETEYGKTVTVKEDQVMQQNPPKFDKIEDMAMLTFLHEPAVLYNLKDRYGSWMIYTYSGLFCVTVNPYKWLPVYTPEVVAAYRGKKRSEAPPHIFSISDNAYQYMLTDRENQSILITGESGAGKTVNTKRVIQYFAVIAAIGDRSKKDQSPGKGTLEDQIIQANPALEAFGNAKTVRNDNSSRFGKFIRIHFGATGKLASADIETYLLEKSRVIFQLKAERDYHIFYQILSNKKPELLDMLLITNNPYDYAFISQGETTVASIDDAEELMATDNAFDVLGFTSEEKNSMYKLTGAIMHFGNMKFKLKQREEQAEPDGTEEADKSAYLMGLNSADLLKGLCHPRVKVGNEYVTKGQNVQQVIYATGALAKAVYERMFNWMVTRINATLETKQPRQYFIGVLDIAGFEIFDFNSFEQLCINFTNEKLQQFFNHHMFVLEQEEYKKEGIEWTFIDFGMDLQACIDLIEKPMGIMSILEEECMFPKATDMTFKAKLFDNHLGKSANFQKPRNIKGKPEAHFSLIHYAGIVDYNIIGWLQKNKDPLNETVVGLYQKSSLKLLSTLFANYAGADAPIEKGKGKAKKGSSFQTVSALHRENLNKLMTNLRSTHPHFVRCIIPNETKSPGVMDNPLVMHQLRCNGVLEGIRICRKGFPNRILYGDFRQRYRILNPAAIPEGQFIDSRKGAEKLLSSLDIDHNQYKFGHTKVFFKAGLLGLLEEMRDERLSRIITRIQAQSRGVLARMEYKKLLERRDSLLVIQWNIRAFMGVKNWPWMKLYFKIKPLLKSAEREKEMASMKEEFTRLKEALEKSEARRKELEEKMVSLLQEKNDLQLQVQAEQDNLADAEERCDQLIKNKIQLEAKVKEMNERLEDEEEMNAELTAKKRKLEDECSELKRDIDDLELTLAKVEKEKHATENKVKNLTEEMAGLDEIIAKLTKEKKALQEAHQQALDDLQAEEDKVNTLTKAKVKLEQQVDDLEGSLEQEKKVRMDLERAKRKLEGDLKLTQESIMDLENDKQQLDERLKKKDFELNALNARIEDEQALGSQLQKKLKELQARIEELEEELEAERTARAKVEKLRSDLSRELEEISERLEEAGGATSVQIEMNKKREAEFQKMRRDLEEATLQHEATAAALRKKHADSVAELGEQIDNLQRVKQKLEKEKSEFKLELDDVTSNMEQIIKAKANLEKMCRTLEDQMNEHRSKAEETQRSVNDLTSQRAKLQTENGELSRQLDEKEALISQLTRGKLTYTQQLEDLKRQLEEEVKAKNALAHALQSARHDCDLLREQYEEETEAKAELQRVLSKANSEVAQWRTKYETDAIQRTEELEEAKKKLAQRLQEAEEAVEAVNAKCSSLEKTKHRLQNEIEDLMVDVERSNAAAAALDKKQRNFDKILAEWKQKYEESQSELESSQKEARSLSTELFKLKNAYEESLEHLETFKRENKNLQEEISDLTEQLGSSGKTIHELEKVRKQLEAEKMELQSALEEAEASLEHEEGKILRAQLEFNQIKAEIERKLAEKDEEMEQAKRNHLRVVDSLQTSLDAETRSRNEALRVKKKMEGDLNEMEIQLSHANRMAAEAQKQVKSLQSLLKDTQIQLDDAVRANDDLKENIAIVERRNNLLQAELEELRAVVEQTERSRKLAEQELIETSERVQLLHSQNTSLINQKKKMDADLSQLQTEVEEAVQECRNAEEKAKKAITDAAMMAEELKKEQDTSAHLERMKKNMEQTIKDLQHRLDEAEQIALKGGKKQLQKLEARVRELENELEAEQKRNAESVKGMRKSERRIKELTYQTEEDRKNLLRLQDLVDKLQLKVKAYKRQAEEAEEQANTNLSKFRKVQHELDEAEERADIAESQVNKLRAKSRDIGTKGLNEE	1935	P12883	Q	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [161, 165, 169], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.03676462, -0.04054761, -0.02730221]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [87, 373, 375, 400, 888, 1156, 1841], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.00072914, -0.00173324, -0.00174659, -0.00131243, -0.00064766,
       -0.00188029, -0.00284559]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
28	NM_000257.3(MYH7):c.1208G>A (p.Arg403Gln)	14087	CA010365	NM_000257.3:c.1208G>A, NC_000014.9:g.23429278C>T, CM000676.2:g.23429278C>T, NC_000014.8:g.23898487C>T, CM000676.1:g.23898487C>T, NC_000014.7:g.22968327C>T, NG_007884.1:g.11384G>A, LRG_384:g.11384G>A, XR_245686.3:n.1314G>A, XM_017021340.1:c.1208G>A, NM_000257.4:c.1208G>A, ENST00000355349.3:c.1208G>A, NM_000257.3(MYH7):c.1208G>A (p.Arg403Gln)	MYH7	hypertrophic cardiomyopathy	MONDO:0005045	Autosomal dominant inheritance	Pathogenic	PS4, PP3, PS3, PM1, PM5, PM2, PP1_Strong		The c.1208G>A (p.Arg403Gln) variant in MYH7 has been reported in >30 individuals with hypertrophic cardiomyopathy and segregated with disease in >30 affected family members (PS4 and PP1_Strong; PMID:1638703; PMID:1975517; PMID:7789380; PMID:12975413; PMID:24268868; PMID:10725281; PMID:20800588; PMID:12707239; PMID:27532257; AGCMC Sydney ClinVar SCV000692503.1; Invitae ClinVar SCV000253815.4; Partners LMM ClinVar SCV000059359.5; SHaRe consortium, PMID: 30297972). Mouse model indicates that this variant disrupts the function of MYH7 and leads to a phenotype consistent with HCM (PS3: PMID:8614836). This variant was absent from large population studies (PM2; http://exac.broadinstitute.org). This variant lies in the head region of the protein (aa 181-937) and missense variants in this region are statistically more likely to be disease-associated (PM1; PMID:27532257). Computational prediction tools and conservation analysis suggest that this variant may impact the protein (PP3). A different pathogenic missense variant has been previously identified at this codon which may indicate that this residue is critical to the function of the protein (PM5; c.1207C>T (p.Arg403Trp) - Variation ID 14102). In summary, this variant meets criteria to be classified as pathogenic for hypertrophic cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (PMID:29300372): PS3; PS4; PP1_ Strong; PM1; PM2; PM5; PP3	27532257, 1975517, 12707239, 20800588, 7789380, 10725281, 24268868, 1638703, 12975413, 8614836, 27532257, 1975517, 1638703, 12975413	Cardiomyopathy VCEP		2016-12-15	2018-11-16	False	https://erepo.genome.network/evrepo/ui/classification/CA010365/MONDO:0005045/002	ae1c8298-2afe-4242-9a38-eea990986d41	p.Arg403Gln	Arg	403	Gln	MGDSEMAVFGAAAPYLRKSEKERLEAQTRPFDLKKDVFVPDDKQEFVKAKIVSREGGKVTAETEYGKTVTVKEDQVMQQNPPKFDKIEDMAMLTFLHEPAVLYNLKDRYGSWMIYTYSGLFCVTVNPYKWLPVYTPEVVAAYRGKKRSEAPPHIFSISDNAYQYMLTDRENQSILITGESGAGKTVNTKRVIQYFAVIAAIGDRSKKDQSPGKGTLEDQIIQANPALEAFGNAKTVRNDNSSRFGKFIRIHFGATGKLASADIETYLLEKSRVIFQLKAERDYHIFYQILSNKKPELLDMLLITNNPYDYAFISQGETTVASIDDAEELMATDNAFDVLGFTSEEKNSMYKLTGAIMHFGNMKFKLKQREEQAEPDGTEEADKSAYLMGLNSADLLKGLCHPRVKVGNEYVTKGQNVQQVIYATGALAKAVYERMFNWMVTRINATLETKQPRQYFIGVLDIAGFEIFDFNSFEQLCINFTNEKLQQFFNHHMFVLEQEEYKKEGIEWTFIDFGMDLQACIDLIEKPMGIMSILEEECMFPKATDMTFKAKLFDNHLGKSANFQKPRNIKGKPEAHFSLIHYAGIVDYNIIGWLQKNKDPLNETVVGLYQKSSLKLLSTLFANYAGADAPIEKGKGKAKKGSSFQTVSALHRENLNKLMTNLRSTHPHFVRCIIPNETKSPGVMDNPLVMHQLRCNGVLEGIRICRKGFPNRILYGDFRQRYRILNPAAIPEGQFIDSRKGAEKLLSSLDIDHNQYKFGHTKVFFKAGLLGLLEEMRDERLSRIITRIQAQSRGVLARMEYKKLLERRDSLLVIQWNIRAFMGVKNWPWMKLYFKIKPLLKSAEREKEMASMKEEFTRLKEALEKSEARRKELEEKMVSLLQEKNDLQLQVQAEQDNLADAEERCDQLIKNKIQLEAKVKEMNERLEDEEEMNAELTAKKRKLEDECSELKRDIDDLELTLAKVEKEKHATENKVKNLTEEMAGLDEIIAKLTKEKKALQEAHQQALDDLQAEEDKVNTLTKAKVKLEQQVDDLEGSLEQEKKVRMDLERAKRKLEGDLKLTQESIMDLENDKQQLDERLKKKDFELNALNARIEDEQALGSQLQKKLKELQARIEELEEELEAERTARAKVEKLRSDLSRELEEISERLEEAGGATSVQIEMNKKREAEFQKMRRDLEEATLQHEATAAALRKKHADSVAELGEQIDNLQRVKQKLEKEKSEFKLELDDVTSNMEQIIKAKANLEKMCRTLEDQMNEHRSKAEETQRSVNDLTSQRAKLQTENGELSRQLDEKEALISQLTRGKLTYTQQLEDLKRQLEEEVKAKNALAHALQSARHDCDLLREQYEEETEAKAELQRVLSKANSEVAQWRTKYETDAIQRTEELEEAKKKLAQRLQEAEEAVEAVNAKCSSLEKTKHRLQNEIEDLMVDVERSNAAAAALDKKQRNFDKILAEWKQKYEESQSELESSQKEARSLSTELFKLKNAYEESLEHLETFKRENKNLQEEISDLTEQLGSSGKTIHELEKVRKQLEAEKMELQSALEEAEASLEHEEGKILRAQLEFNQIKAEIERKLAEKDEEMEQAKRNHLRVVDSLQTSLDAETRSRNEALRVKKKMEGDLNEMEIQLSHANRMAAEAQKQVKSLQSLLKDTQIQLDDAVRANDDLKENIAIVERRNNLLQAELEELRAVVEQTERSRKLAEQELIETSERVQLLHSQNTSLINQKKKMDADLSQLQTEVEEAVQECRNAEEKAKKAITDAAMMAEELKKEQDTSAHLERMKKNMEQTIKDLQHRLDEAEQIALKGGKKQLQKLEARVRELENELEAEQKRNAESVKGMRKSERRIKELTYQTEEDRKNLLRLQDLVDKLQLKVKAYKRQAEEAEEQANTNLSKFRKVQHELDEAEERADIAESQVNKLRAKSRDIGTKGLNEE	1935	P12883	Q	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [169], 'DOMAIN_gain': [1784], 'DOMAIN_gain_score': array([0.00797504]), 'DOMAIN_loss_score': array([-0.01742101]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [47, 87, 105, 373, 375, 388, 400, 888, 980, 1111, 1156, 1841], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.00239658, -0.00257969, -0.0026229 , -0.00366867, -0.00334156,
       -0.00528693, -0.00906897, -0.00261617, -0.00275266, -0.00361711,
       -0.00256395, -0.00271839]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
29	NM_000257.3(MYH7):c.1207C>T (p.Arg403Trp)	14102	CA010360	NM_000257.3:c.1207C>T, NC_000014.9:g.23429279G>A, CM000676.2:g.23429279G>A, NC_000014.8:g.23898488G>A, CM000676.1:g.23898488G>A, NC_000014.7:g.22968328G>A, NG_007884.1:g.11383C>T, LRG_384:g.11383C>T, XR_245686.3:n.1313C>T, XM_017021340.1:c.1207C>T, NM_000257.4:c.1207C>T, ENST00000355349.3:c.1207C>T, NM_000257.3(MYH7):c.1207C>T (p.Arg403Trp)	MYH7	hypertrophic cardiomyopathy	MONDO:0005045	Autosomal dominant inheritance	Pathogenic	PS4, PP1_Strong, PM1, PM5, PM2, PP3		The c.1207C>T (p.Arg403Trp) variant in MYH7 has been reported in >20 individuals with hypertrophic cardiomyopathy and segregated with disease in >20 affected family members (PS4 and PP1_Strong; PMID:1052196; PMID:7662452; PMID:7848420; PMID:8254035; PMID:8268932; PMID:12707239; PMID:12974739; PMID:15010274; PMID:15856146; PMID:17612745; PMID:20428263; PMID:21239446; PMID:26383716; Partners LMM ClinVar SCV000059358.5; AGCMC Sydney ClinVar SCV000212643.1; SHaRe consortium, PMID: 30297972). This variant was absent from large population studies (PM2; http://exac.broadinstitute.org). This variant lies in the head region of the protein (aa 181-937) and missense variants in this region are statistically more likely to be disease-associated (PM1; PMID:27532257). Computational prediction tools and conservation analysis suggest that this variant may impact the protein (PP3). A different pathogenic missense variant has been previously identified at this codon which may indicate that this residue is critical to the function of the protein (PM5; c.1208G>A p.Arg403Gln - Variation ID 14087). In summary, this variant meets criteria to be classified as pathogenic for hypertrophic cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (PMID:29300372): PS4; PP1_Strong; PM1; PM2; PM5; PP3	7662452, 17612745, 8254035, 27532257	Cardiomyopathy VCEP		2016-12-15	2018-11-16	False	https://erepo.genome.network/evrepo/ui/classification/CA010360/MONDO:0005045/002	d065fb29-95bd-49a8-951e-f52b10fac57c	p.Arg403Trp	Arg	403	Trp	MGDSEMAVFGAAAPYLRKSEKERLEAQTRPFDLKKDVFVPDDKQEFVKAKIVSREGGKVTAETEYGKTVTVKEDQVMQQNPPKFDKIEDMAMLTFLHEPAVLYNLKDRYGSWMIYTYSGLFCVTVNPYKWLPVYTPEVVAAYRGKKRSEAPPHIFSISDNAYQYMLTDRENQSILITGESGAGKTVNTKRVIQYFAVIAAIGDRSKKDQSPGKGTLEDQIIQANPALEAFGNAKTVRNDNSSRFGKFIRIHFGATGKLASADIETYLLEKSRVIFQLKAERDYHIFYQILSNKKPELLDMLLITNNPYDYAFISQGETTVASIDDAEELMATDNAFDVLGFTSEEKNSMYKLTGAIMHFGNMKFKLKQREEQAEPDGTEEADKSAYLMGLNSADLLKGLCHPRVKVGNEYVTKGQNVQQVIYATGALAKAVYERMFNWMVTRINATLETKQPRQYFIGVLDIAGFEIFDFNSFEQLCINFTNEKLQQFFNHHMFVLEQEEYKKEGIEWTFIDFGMDLQACIDLIEKPMGIMSILEEECMFPKATDMTFKAKLFDNHLGKSANFQKPRNIKGKPEAHFSLIHYAGIVDYNIIGWLQKNKDPLNETVVGLYQKSSLKLLSTLFANYAGADAPIEKGKGKAKKGSSFQTVSALHRENLNKLMTNLRSTHPHFVRCIIPNETKSPGVMDNPLVMHQLRCNGVLEGIRICRKGFPNRILYGDFRQRYRILNPAAIPEGQFIDSRKGAEKLLSSLDIDHNQYKFGHTKVFFKAGLLGLLEEMRDERLSRIITRIQAQSRGVLARMEYKKLLERRDSLLVIQWNIRAFMGVKNWPWMKLYFKIKPLLKSAEREKEMASMKEEFTRLKEALEKSEARRKELEEKMVSLLQEKNDLQLQVQAEQDNLADAEERCDQLIKNKIQLEAKVKEMNERLEDEEEMNAELTAKKRKLEDECSELKRDIDDLELTLAKVEKEKHATENKVKNLTEEMAGLDEIIAKLTKEKKALQEAHQQALDDLQAEEDKVNTLTKAKVKLEQQVDDLEGSLEQEKKVRMDLERAKRKLEGDLKLTQESIMDLENDKQQLDERLKKKDFELNALNARIEDEQALGSQLQKKLKELQARIEELEEELEAERTARAKVEKLRSDLSRELEEISERLEEAGGATSVQIEMNKKREAEFQKMRRDLEEATLQHEATAAALRKKHADSVAELGEQIDNLQRVKQKLEKEKSEFKLELDDVTSNMEQIIKAKANLEKMCRTLEDQMNEHRSKAEETQRSVNDLTSQRAKLQTENGELSRQLDEKEALISQLTRGKLTYTQQLEDLKRQLEEEVKAKNALAHALQSARHDCDLLREQYEEETEAKAELQRVLSKANSEVAQWRTKYETDAIQRTEELEEAKKKLAQRLQEAEEAVEAVNAKCSSLEKTKHRLQNEIEDLMVDVERSNAAAAALDKKQRNFDKILAEWKQKYEESQSELESSQKEARSLSTELFKLKNAYEESLEHLETFKRENKNLQEEISDLTEQLGSSGKTIHELEKVRKQLEAEKMELQSALEEAEASLEHEEGKILRAQLEFNQIKAEIERKLAEKDEEMEQAKRNHLRVVDSLQTSLDAETRSRNEALRVKKKMEGDLNEMEIQLSHANRMAAEAQKQVKSLQSLLKDTQIQLDDAVRANDDLKENIAIVERRNNLLQAELEELRAVVEQTERSRKLAEQELIETSERVQLLHSQNTSLINQKKKMDADLSQLQTEVEEAVQECRNAEEKAKKAITDAAMMAEELKKEQDTSAHLERMKKNMEQTIKDLQHRLDEAEQIALKGGKKQLQKLEARVRELENELEAEQKRNAESVKGMRKSERRIKELTYQTEEDRKNLLRLQDLVDKLQLKVKAYKRQAEEAEEQANTNLSKFRKVQHELDEAEERADIAESQVNKLRAKSRDIGTKGLNEE	1935	P12883	W	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [421, 422, 493, 494, 547], 'HELIX_gain_score': array([0.03444469, 0.02567059, 0.01744777, 0.0189203 , 0.0289554 ]), 'COILED_loss': [1606], 'COILED_gain': [], 'COILED_loss_score': array([-0.01515549]), 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [152, 156, 157, 159, 162, 166, 168, 170, 1658, 1784], 'DOMAIN_gain_score': array([0.08107126, 0.12034786, 0.11642474, 0.14486635, 0.13808805,
       0.14252198, 0.1180259 , 0.13175702, 0.05052364, 0.01262611]), 'REGION_loss': [874], 'REGION_gain': [], 'REGION_loss_score': array([-0.0017314]), 'REPEAT_loss': [47, 87, 105, 362, 364, 367, 368, 370, 373, 375, 376, 381, 386, 388, 400, 1156], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.00468242, -0.00102222, -0.00138754, -0.01251853, -0.01254815,
       -0.0128336 , -0.01290292, -0.01430207, -0.01451236, -0.01466328,
       -0.01652747, -0.01872879, -0.02110624, -0.02169281, -0.04723704,
       -0.0028252 ]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
30	NM_000257.3(MYH7):c.1358G>A (p.Arg453His)	42838	CA010639	NM_000257.3:c.1358G>A, XR_245686.3:n.1464G>A, XM_017021340.1:c.1358G>A, NM_000257.4:c.1358G>A, ENST00000355349.3:c.1358G>A, NC_000014.9:g.23429004C>T, CM000676.2:g.23429004C>T, NC_000014.8:g.23898213C>T, CM000676.1:g.23898213C>T, NC_000014.7:g.22968053C>T, NG_007884.1:g.11658G>A, LRG_384:g.11658G>A, NM_000257.3(MYH7):c.1358G>A (p.Arg453His)	MYH7	hypertrophic cardiomyopathy	MONDO:0005045	Autosomal dominant inheritance	Pathogenic	PS4, PP3, PM6, PM5, PM1, PM2		The c.1358G>A (p.Arg453His) variant in MYH7 has been reported in >12 individuals with hypertrophic cardiomyopathy (PS4; PMID:27532257; PMID:20428263; PMID:15858117; PMID:20800588; PMID:21835320; PMID:22429680; Partners LMM ClinVar SCV000059369.5; Invitae ClinVar SCV000253816.4; SHaRe consortium, PMID: 30297972). This variant was been identified as a de novo occurrence in 1 proband with hypertrophic cardiomyopathy (PM6; PMID:20428263). This variant was absent from large population studies (PM2; http://exac.broadinstitute.org). This variant lies in the head region of the protein (aa 181-937) and missense variants in this region are statistically more likely to be disease-associated (PM1; PMID:27532257). Computational prediction tools and conservation analysis suggest that this variant may impact the protein (PP3). A different pathogenic missense variant has been previously identified at this codon which may indicate that this residue is critical to the function of the protein (PM5; c.1357C>T p.Arg453Cys; ClinVar Variation ID 14089). In summary, this variant meets criteria to be classified as pathogenic for hypertrophic cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (PMID:29300372): PS4; PM1; PM2; PM5; PM6; PP3	22429680, 21835320, 15858117, 20800588, 20428263, 20428263, 27532257	Cardiomyopathy VCEP		2016-12-15	2018-11-16	False	https://erepo.genome.network/evrepo/ui/classification/CA010639/MONDO:0005045/002	0be32c2f-1227-4089-b5fe-a3fd165b61d5	p.Arg453His	Arg	453	His	MGDSEMAVFGAAAPYLRKSEKERLEAQTRPFDLKKDVFVPDDKQEFVKAKIVSREGGKVTAETEYGKTVTVKEDQVMQQNPPKFDKIEDMAMLTFLHEPAVLYNLKDRYGSWMIYTYSGLFCVTVNPYKWLPVYTPEVVAAYRGKKRSEAPPHIFSISDNAYQYMLTDRENQSILITGESGAGKTVNTKRVIQYFAVIAAIGDRSKKDQSPGKGTLEDQIIQANPALEAFGNAKTVRNDNSSRFGKFIRIHFGATGKLASADIETYLLEKSRVIFQLKAERDYHIFYQILSNKKPELLDMLLITNNPYDYAFISQGETTVASIDDAEELMATDNAFDVLGFTSEEKNSMYKLTGAIMHFGNMKFKLKQREEQAEPDGTEEADKSAYLMGLNSADLLKGLCHPRVKVGNEYVTKGQNVQQVIYATGALAKAVYERMFNWMVTRINATLETKQPRQYFIGVLDIAGFEIFDFNSFEQLCINFTNEKLQQFFNHHMFVLEQEEYKKEGIEWTFIDFGMDLQACIDLIEKPMGIMSILEEECMFPKATDMTFKAKLFDNHLGKSANFQKPRNIKGKPEAHFSLIHYAGIVDYNIIGWLQKNKDPLNETVVGLYQKSSLKLLSTLFANYAGADAPIEKGKGKAKKGSSFQTVSALHRENLNKLMTNLRSTHPHFVRCIIPNETKSPGVMDNPLVMHQLRCNGVLEGIRICRKGFPNRILYGDFRQRYRILNPAAIPEGQFIDSRKGAEKLLSSLDIDHNQYKFGHTKVFFKAGLLGLLEEMRDERLSRIITRIQAQSRGVLARMEYKKLLERRDSLLVIQWNIRAFMGVKNWPWMKLYFKIKPLLKSAEREKEMASMKEEFTRLKEALEKSEARRKELEEKMVSLLQEKNDLQLQVQAEQDNLADAEERCDQLIKNKIQLEAKVKEMNERLEDEEEMNAELTAKKRKLEDECSELKRDIDDLELTLAKVEKEKHATENKVKNLTEEMAGLDEIIAKLTKEKKALQEAHQQALDDLQAEEDKVNTLTKAKVKLEQQVDDLEGSLEQEKKVRMDLERAKRKLEGDLKLTQESIMDLENDKQQLDERLKKKDFELNALNARIEDEQALGSQLQKKLKELQARIEELEEELEAERTARAKVEKLRSDLSRELEEISERLEEAGGATSVQIEMNKKREAEFQKMRRDLEEATLQHEATAAALRKKHADSVAELGEQIDNLQRVKQKLEKEKSEFKLELDDVTSNMEQIIKAKANLEKMCRTLEDQMNEHRSKAEETQRSVNDLTSQRAKLQTENGELSRQLDEKEALISQLTRGKLTYTQQLEDLKRQLEEEVKAKNALAHALQSARHDCDLLREQYEEETEAKAELQRVLSKANSEVAQWRTKYETDAIQRTEELEEAKKKLAQRLQEAEEAVEAVNAKCSSLEKTKHRLQNEIEDLMVDVERSNAAAAALDKKQRNFDKILAEWKQKYEESQSELESSQKEARSLSTELFKLKNAYEESLEHLETFKRENKNLQEEISDLTEQLGSSGKTIHELEKVRKQLEAEKMELQSALEEAEASLEHEEGKILRAQLEFNQIKAEIERKLAEKDEEMEQAKRNHLRVVDSLQTSLDAETRSRNEALRVKKKMEGDLNEMEIQLSHANRMAAEAQKQVKSLQSLLKDTQIQLDDAVRANDDLKENIAIVERRNNLLQAELEELRAVVEQTERSRKLAEQELIETSERVQLLHSQNTSLINQKKKMDADLSQLQTEVEEAVQECRNAEEKAKKAITDAAMMAEELKKEQDTSAHLERMKKNMEQTIKDLQHRLDEAEQIALKGGKKQLQKLEARVRELENELEAEQKRNAESVKGMRKSERRIKELTYQTEEDRKNLLRLQDLVDKLQLKVKAYKRQAEEAEEQANTNLSKFRKVQHELDEAEERADIAESQVNKLRAKSRDIGTKGLNEE	1935	P12883	H	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [421, 422, 424, 425, 426, 493, 494, 530, 547], 'HELIX_gain_score': array([0.04535526, 0.05311203, 0.05768943, 0.05249357, 0.05313259,
       0.03115475, 0.03076303, 0.0152539 , 0.03296012]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [152, 168, 1774, 1784], 'DOMAIN_gain_score': array([0.03597581, 0.04556882, 0.02822798, 0.04180562]), 'REGION_loss': [], 'REGION_gain': [1205], 'REGION_gain_score': array([0.00271481]), 'REPEAT_loss': [47, 87, 105, 373, 375, 400, 879, 888, 980, 1009, 1083, 1111, 1122, 1156, 1841], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.00464886, -0.00345021, -0.00327754, -0.00321627, -0.00273943,
       -0.00437123, -0.00387692, -0.00378412, -0.003591  , -0.00319803,
       -0.00279951, -0.00397116, -0.00368786, -0.00340796, -0.00374794]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
31	NM_000257.3(MYH7):c.788T>C (p.Ile263Thr)	43106	CA016824	NM_000257.3:c.788T>C, NC_000014.9:g.23431426A>G, CM000676.2:g.23431426A>G, NC_000014.8:g.23900635A>G, CM000676.1:g.23900635A>G, NC_000014.7:g.22970475A>G, NG_007884.1:g.9236T>C, LRG_384:g.9236T>C, XR_245686.3:n.894T>C, XM_017021340.1:c.788T>C, NM_000257.4:c.788T>C, ENST00000355349.3:c.788T>C, NM_000257.3(MYH7):c.788T>C (p.Ile263Thr)	MYH7	hypertrophic cardiomyopathy	MONDO:0005045	Autosomal dominant inheritance	Pathogenic	PS4, PP3, PM1, PM2, PP1_Strong		The c.788T>C (p.Ile263Thr) variant in MYH7 has been reported in >20 individuals with hypertrophic cardiomyopathy (PS4: PMID:15008060; PMID:9829907; PMID:12707239; PMID:22429680; PMID:20624503; Partners LMM ClinVar SCV000059656.5; SHaRe consortium, PMID: 30297972). This variant segregated with disease in 10 affected individuals (PP1_Strong: PMID:15008060; PMID:9829907). This variant was absent from large population studies (PM2; http://exac.broadinstitute.org). This variant lies in the head region of the protein (aa 181-937) and missense variants in this region are statistically more likely to be disease-associated (PM1; PMID:27532257). Computational prediction tools and conservation analysis suggest that this variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for hypertrophic cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (PMID:29300372): PS4, PP1_Strong, PM1, PM2, PP3	15008060, 9829907	Cardiomyopathy VCEP		2016-12-15	2018-11-16	False	https://erepo.genome.network/evrepo/ui/classification/CA016824/MONDO:0005045/002	da0ede45-78bd-43e3-8f1f-9ac160621dc4	p.Ile263Thr	Ile	263	Thr	MGDSEMAVFGAAAPYLRKSEKERLEAQTRPFDLKKDVFVPDDKQEFVKAKIVSREGGKVTAETEYGKTVTVKEDQVMQQNPPKFDKIEDMAMLTFLHEPAVLYNLKDRYGSWMIYTYSGLFCVTVNPYKWLPVYTPEVVAAYRGKKRSEAPPHIFSISDNAYQYMLTDRENQSILITGESGAGKTVNTKRVIQYFAVIAAIGDRSKKDQSPGKGTLEDQIIQANPALEAFGNAKTVRNDNSSRFGKFIRIHFGATGKLASADIETYLLEKSRVIFQLKAERDYHIFYQILSNKKPELLDMLLITNNPYDYAFISQGETTVASIDDAEELMATDNAFDVLGFTSEEKNSMYKLTGAIMHFGNMKFKLKQREEQAEPDGTEEADKSAYLMGLNSADLLKGLCHPRVKVGNEYVTKGQNVQQVIYATGALAKAVYERMFNWMVTRINATLETKQPRQYFIGVLDIAGFEIFDFNSFEQLCINFTNEKLQQFFNHHMFVLEQEEYKKEGIEWTFIDFGMDLQACIDLIEKPMGIMSILEEECMFPKATDMTFKAKLFDNHLGKSANFQKPRNIKGKPEAHFSLIHYAGIVDYNIIGWLQKNKDPLNETVVGLYQKSSLKLLSTLFANYAGADAPIEKGKGKAKKGSSFQTVSALHRENLNKLMTNLRSTHPHFVRCIIPNETKSPGVMDNPLVMHQLRCNGVLEGIRICRKGFPNRILYGDFRQRYRILNPAAIPEGQFIDSRKGAEKLLSSLDIDHNQYKFGHTKVFFKAGLLGLLEEMRDERLSRIITRIQAQSRGVLARMEYKKLLERRDSLLVIQWNIRAFMGVKNWPWMKLYFKIKPLLKSAEREKEMASMKEEFTRLKEALEKSEARRKELEEKMVSLLQEKNDLQLQVQAEQDNLADAEERCDQLIKNKIQLEAKVKEMNERLEDEEEMNAELTAKKRKLEDECSELKRDIDDLELTLAKVEKEKHATENKVKNLTEEMAGLDEIIAKLTKEKKALQEAHQQALDDLQAEEDKVNTLTKAKVKLEQQVDDLEGSLEQEKKVRMDLERAKRKLEGDLKLTQESIMDLENDKQQLDERLKKKDFELNALNARIEDEQALGSQLQKKLKELQARIEELEEELEAERTARAKVEKLRSDLSRELEEISERLEEAGGATSVQIEMNKKREAEFQKMRRDLEEATLQHEATAAALRKKHADSVAELGEQIDNLQRVKQKLEKEKSEFKLELDDVTSNMEQIIKAKANLEKMCRTLEDQMNEHRSKAEETQRSVNDLTSQRAKLQTENGELSRQLDEKEALISQLTRGKLTYTQQLEDLKRQLEEEVKAKNALAHALQSARHDCDLLREQYEEETEAKAELQRVLSKANSEVAQWRTKYETDAIQRTEELEEAKKKLAQRLQEAEEAVEAVNAKCSSLEKTKHRLQNEIEDLMVDVERSNAAAAALDKKQRNFDKILAEWKQKYEESQSELESSQKEARSLSTELFKLKNAYEESLEHLETFKRENKNLQEEISDLTEQLGSSGKTIHELEKVRKQLEAEKMELQSALEEAEASLEHEEGKILRAQLEFNQIKAEIERKLAEKDEEMEQAKRNHLRVVDSLQTSLDAETRSRNEALRVKKKMEGDLNEMEIQLSHANRMAAEAQKQVKSLQSLLKDTQIQLDDAVRANDDLKENIAIVERRNNLLQAELEELRAVVEQTERSRKLAEQELIETSERVQLLHSQNTSLINQKKKMDADLSQLQTEVEEAVQECRNAEEKAKKAITDAAMMAEELKKEQDTSAHLERMKKNMEQTIKDLQHRLDEAEQIALKGGKKQLQKLEARVRELENELEAEQKRNAESVKGMRKSERRIKELTYQTEEDRKNLLRLQDLVDKLQLKVKAYKRQAEEAEEQANTNLSKFRKVQHELDEAEERADIAESQVNKLRAKSRDIGTKGLNEE	1935	P12883	T	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [874, 1264, 1271], 'REGION_gain': [], 'REGION_loss_score': array([-0.00201118, -0.00633138, -0.00661767]), 'REPEAT_loss': [373, 375, 400, 888, 980, 1009, 1111], 'REPEAT_gain': [63, 79, 83], 'REPEAT_gain_score': array([0.00304985, 0.00205916, 0.00228298]), 'REPEAT_loss_score': array([-0.00169706, -0.00183743, -0.00388998, -0.0026511 , -0.00280201,
       -0.00246745, -0.00261414]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
32	NM_005343.3(HRAS):c.520C>T (p.Pro174Ser)	40448	CA135994	NM_005343.3:c.520C>T, NM_001130442.1:c.520C>T, NM_005343.2:c.520C>T, NM_176795.3:c.*89C>T, XM_011519875.1:c.-425+4349G>A, XM_011519877.1:c.-162+4349G>A, XR_242795.1:n.801C>T, NM_001130442.2:c.520C>T, NM_001318054.1:c.283C>T, NM_176795.4:c.*89C>T, XM_011519875.2:c.-425+4349G>A, XM_011519877.2:c.-162+4349G>A, XM_017017167.1:c.-500+4349G>A, XM_017017168.1:c.-500+4349G>A, NM_005343.4:c.520C>T, ENST00000311189.7:c.520C>T, ENST00000397594.5:c.*89C>T, ENST00000397596.6:c.520C>T, ENST00000417302.5:c.*89C>T, ENST00000451590.5:c.520C>T, ENST00000462734.1:n.295C>T, ENST00000478324.5:n.243-56C>T, ENST00000479482.1:n.441C>T, ENST00000493230.5:c.*89C>T, NC_000011.10:g.532686G>A, CM000673.2:g.532686G>A, NC_000011.9:g.532686G>A, CM000673.1:g.532686G>A, NC_000011.8:g.522686G>A, NG_007666.1:g.7865C>T, NM_005343.3(HRAS):c.520C>T (p.Pro174Ser)	LRRC56	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.520C>T (p.Pro174Ser) variant in the HRAS gene is 0.115% (20/11482) of Latino chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	False	https://erepo.genome.network/evrepo/ui/classification/CA135994/MONDO:0021060/004	d37c8250-6a81-4f7a-b0df-8e5eb3216e8a	p.Pro174Ser	Pro	174	Ser	MDLGWDRSRGPRRSTSSVRVRELSWQGLHNPCPQSKGPGSQRDRLGEQLVEEYLSPARLQALARVDDLRLVRTLEMCVDTREGSLGNFGVHLPNLDQLKLNGSHLGSLRDLGTSLGHLQVLWLARCGLADLDGIASLPALKELYASYNNISDLSPLCLLEQLEVLDLEGNSVEDLGQVRYLQLCPRLAMLTLEGNLVCLQPAPGPTNKVPRGYNYRAEVRKLIPQLQVLDEVPAAHTGPPAPPRLSQDWLAVKEAIKKGNGLPPLDCPRGAPIRRLDPELSLPETQSRASRPWPFSLLVRGGPLPEGLLSEDLAPEDNTSSLTHGAGQVLCGNPTKGLRERRHQCQAREPPEQLPQHRPGDPAASTSTPEPDPADSSDFLALAGLRAWREHGVRPLPYRHPESQQEGAVAPWGPRRVPEEQVHQAEPKTPSSPPSLASEPSGTSSQHLVPSPPKHPRPRDSGSSSPRWSTDLQSRGRRLRVLGSWGPGLGDGVAAVPVLRALEVASRLSPRAQGCPGPKPAPDAAARPPRAAELSHPSPVPT	542	Q8IYG6	S	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [0], 'TRANSIT_gain': [], 'TRANSIT_loss_score': array([-0.00536376]), 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [203], 'DOMAIN_gain_score': array([0.0228321]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [189], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.01253998]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
33	NM_005633.3(SOS1):c.553A>G (p.Ile185Val)	45374	CA136168	NM_005633.3:c.553A>G, LRG_754t1:c.553A>G, XM_005264515.3:c.553A>G, XM_011533060.1:c.646A>G, XM_011533061.1:c.646A>G, XM_011533062.1:c.532A>G, XM_011533063.1:c.529A>G, XM_011533064.1:c.382A>G, XM_011533065.1:c.646A>G, XM_005264515.4:c.553A>G, XM_011533062.2:c.532A>G, XM_011533064.2:c.382A>G, ENST00000395038.6:c.553A>G, ENST00000402219.6:c.553A>G, ENST00000426016.5:c.553A>G, NC_000002.12:g.39054781T>C, CM000664.2:g.39054781T>C, NC_000002.11:g.39281922T>C, CM000664.1:g.39281922T>C, NC_000002.10:g.39135426T>C, NG_007530.1:g.70683A>G, LRG_754:g.70683A>G, NM_005633.3(SOS1):c.553A>G (p.Ile185Val)	SOS1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.553A>G (p.Ile185Val) variant in the SOS1 gene is 0.087% (16/11574) of Latino chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	False	https://erepo.genome.network/evrepo/ui/classification/CA136168/MONDO:0021060/004	739972d5-a90d-4c3b-95f9-cf39b58d349c	p.Ile185Val	Ile	185	Val	MQAQQLPYEFFSEENAPKWRGLLVPALKKVQGQVHPTLESNDDALQYVEELILQLLNMLCQAQPRSASDVEERVQKSFPHPIDKWAIADAQSAIEKRKRRNPLSLPVEKIHPLLKEVLGYKIDHQVSVYIVAVLEYISADILKLVGNYVRNIRHYEITKQDIKVAMCADKVLMDMFHQDVEDINILSLTDEEPSTSGEQTYYDLVKAFMAEIRQYIRELNLIIKVFREPFVSNSKLFSANDVENIFSRIVDIHELSVKLLGHIEDTVEMTDEGSPHPLVGSCFEDLAEELAFDPYESYARDILRPGFHDRFLSQLSKPGAALYLQSIGEGFKEAVQYVLPRLLLAPVYHCLHYFELLKQLEEKSEDQEDKECLKQAITALLNVQSGMEKICSKSLAKRRLSESACRFYSQQMKGKQLAIKKMNEIQKNIDGWEGKDIGQCCNEFIMEGTLTRVGAKHERHIFLFDGLMICCKSNHGQPRLPGASNAEYRLKEKFFMRKVQINDKDDTNEYKHAFEIILKDENSVIFSAKSAEEKNNWMAALISLQYRSTLERMLDVTMLQEEKEEQMRLPSADVYRFAEPDSEENIIFEENMQPKAGIPIIKAGTVIKLIERLTYHMYADPNFVRTFLTTYRSFCKPQELLSLIIERFEIPEPEPTEADRIAIENGDQPLSAELKRFRKEYIQPVQLRVLNVCRHWVEHHFYDFERDAYLLQRMEEFIGTVRGKAMKKWVESITKIIQRKKIARDNGPGHNITFQSSPPTVEWHISRPGHIETFDLLTLHPIEIARQLTLLESDLYRAVQPSELVGSVWTKEDKEINSPNLLKMIRHTTNLTLWFEKCIVETENLEERVAVVSRIIEILQVFQELNNFNGVLEVVSAMNSSPVYRLDHTFEQIPSRQKKILEEAHELSEDHYKKYLAKLRSINPPCVPFFGIYLTNILKTEEGNPEVLKRHGKELINFSKRRKVAEITGEIQQYQNQPYCLRVESDIKRFFENLNPMGNSMEKEFTDYLFNKSLEIEPRNPKPLPRFPKKYSYPLKSPGVRPSNPRPGTMRHPTPLQQEPRKISYSRIPESETESTASAPNSPRTPLTPPPASGASSTTDVCSVFDSDHSSPFHSSNDTVFIQVTLPHGPRSASVSSISLTKGTDEVPVPPPVPPRRRPESAPAESSPSKIMSKHLDSPPAIPPRQPTSKAYSPRYSISDRTSISDPPESPPLLPPREPVRTPDVFSSSPLHLQPPPLGKKSDHGNAFFPNSPSPFTPPPPQTPSPHGTRRHLPSPPLTQEVDLHSIAGPPVPPRQSTSQHIPKLPPKTYKREHTHPSMHRDGPPLLENAHSS	1333	Q07889	V	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [1102], 'COMPBIAS_gain': [], 'COMPBIAS_loss_score': array([-0.00686717]), 'DOMAIN_loss': [], 'DOMAIN_gain': [782], 'DOMAIN_gain_score': array([0.00542831]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
34	NM_005633.3(SOS1):c.2010G>C (p.Leu670Phe)	448942	CA1624490	NM_005633.3:c.2010G>C, LRG_754t1:c.2010G>C, XM_005264515.3:c.2010G>C, XM_011533060.1:c.2103G>C, XM_011533061.1:c.2103G>C, XM_011533062.1:c.1989G>C, XM_011533063.1:c.1986G>C, XM_011533064.1:c.1839G>C, XM_011533065.1:c.2103G>C, XM_011533066.1:c.945G>C, XM_005264515.4:c.2010G>C, XM_011533062.2:c.1989G>C, XM_011533064.2:c.1839G>C, ENST00000395038.6:c.2010G>C, ENST00000402219.6:c.2010G>C, ENST00000426016.5:c.2010G>C, NC_000002.12:g.39013920C>G, CM000664.2:g.39013920C>G, NC_000002.11:g.39241061C>G, CM000664.1:g.39241061C>G, NC_000002.10:g.39094565C>G, NG_007530.1:g.111544G>C, LRG_754:g.111544G>C, NM_005633.3(SOS1):c.2010G>C (p.Leu670Phe)	SOS1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.2010G>C (p.Leu670Phe) variant in the SOS1 gene is 0.055% (9/8572) of East Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	False	https://erepo.genome.network/evrepo/ui/classification/CA1624490/MONDO:0021060/004	42ea487d-ec44-44f7-a90a-ac98312de0f1	p.Leu670Phe	Leu	670	Phe	MQAQQLPYEFFSEENAPKWRGLLVPALKKVQGQVHPTLESNDDALQYVEELILQLLNMLCQAQPRSASDVEERVQKSFPHPIDKWAIADAQSAIEKRKRRNPLSLPVEKIHPLLKEVLGYKIDHQVSVYIVAVLEYISADILKLVGNYVRNIRHYEITKQDIKVAMCADKVLMDMFHQDVEDINILSLTDEEPSTSGEQTYYDLVKAFMAEIRQYIRELNLIIKVFREPFVSNSKLFSANDVENIFSRIVDIHELSVKLLGHIEDTVEMTDEGSPHPLVGSCFEDLAEELAFDPYESYARDILRPGFHDRFLSQLSKPGAALYLQSIGEGFKEAVQYVLPRLLLAPVYHCLHYFELLKQLEEKSEDQEDKECLKQAITALLNVQSGMEKICSKSLAKRRLSESACRFYSQQMKGKQLAIKKMNEIQKNIDGWEGKDIGQCCNEFIMEGTLTRVGAKHERHIFLFDGLMICCKSNHGQPRLPGASNAEYRLKEKFFMRKVQINDKDDTNEYKHAFEIILKDENSVIFSAKSAEEKNNWMAALISLQYRSTLERMLDVTMLQEEKEEQMRLPSADVYRFAEPDSEENIIFEENMQPKAGIPIIKAGTVIKLIERLTYHMYADPNFVRTFLTTYRSFCKPQELLSLIIERFEIPEPEPTEADRIAIENGDQPLSAELKRFRKEYIQPVQLRVLNVCRHWVEHHFYDFERDAYLLQRMEEFIGTVRGKAMKKWVESITKIIQRKKIARDNGPGHNITFQSSPPTVEWHISRPGHIETFDLLTLHPIEIARQLTLLESDLYRAVQPSELVGSVWTKEDKEINSPNLLKMIRHTTNLTLWFEKCIVETENLEERVAVVSRIIEILQVFQELNNFNGVLEVVSAMNSSPVYRLDHTFEQIPSRQKKILEEAHELSEDHYKKYLAKLRSINPPCVPFFGIYLTNILKTEEGNPEVLKRHGKELINFSKRRKVAEITGEIQQYQNQPYCLRVESDIKRFFENLNPMGNSMEKEFTDYLFNKSLEIEPRNPKPLPRFPKKYSYPLKSPGVRPSNPRPGTMRHPTPLQQEPRKISYSRIPESETESTASAPNSPRTPLTPPPASGASSTTDVCSVFDSDHSSPFHSSNDTVFIQVTLPHGPRSASVSSISLTKGTDEVPVPPPVPPRRRPESAPAESSPSKIMSKHLDSPPAIPPRQPTSKAYSPRYSISDRTSISDPPESPPLLPPREPVRTPDVFSSSPLHLQPPPLGKKSDHGNAFFPNSPSPFTPPPPQTPSPHGTRRHLPSPPLTQEVDLHSIAGPPVPPRQSTSQHIPKLPPKTYKREHTHPSMHRDGPPLLENAHSS	1333	Q07889	F	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [516], 'STRAND_gain_score': array([0.0003131]), 'HELIX_loss': [296], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.00647283]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [778, 780, 781, 782, 872, 873, 875], 'DOMAIN_gain_score': array([0.11069232, 0.11625391, 0.10795641, 0.1041463 , 0.06585443,
       0.06590438, 0.05585182]), 'REGION_loss': [], 'REGION_gain': [1295], 'REGION_gain_score': array([0.00190222]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
35	NM_004333.4(BRAF):c.976A>G (p.Ile326Val)	417225	CA4516861	NM_004333.4:c.976A>G, LRG_299t1:c.976A>G, XM_005250045.1:c.976A>G, XM_005250046.1:c.976A>G, XM_011516529.1:c.976A>G, XM_011516530.1:c.976A>G, XR_242190.1:n.984A>G, XR_927520.1:n.984A>G, XR_927521.1:n.984A>G, XR_927522.1:n.984A>G, XR_927523.1:n.984A>G, NM_001354609.1:c.976A>G, NM_004333.5:c.976A>G, NR_148928.1:n.1281A>G, XM_017012558.1:c.976A>G, XM_017012559.1:c.976A>G, XR_001744857.1:n.984A>G, XR_001744858.1:n.984A>G, ENST00000288602.10:c.976A>G, ENST00000497784.1:n.1011A>G, NC_000007.14:g.140800366T>C, CM000669.2:g.140800366T>C, NC_000007.13:g.140500166T>C, CM000669.1:g.140500166T>C, NC_000007.12:g.140146635T>C, NG_007873.3:g.129399A>G, LRG_299:g.129399A>G, NM_004333.4(BRAF):c.976A>G (p.Ile326Val)	BRAF	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.1772A>G (p.Asn591Ser) variant in the SOS1 gene is 0.054% (11/11524) of Latino chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	False	https://erepo.genome.network/evrepo/ui/classification/CA4516861/MONDO:0021060/004	e46ee061-0859-4581-9333-f113c0784ab0	p.Ile326Val	Ile	326	Val	MAALSGGGGGGAEPGQALFNGDMEPEAGAGAGAAASSAADPAIPEEVWNIKQMIKLTQEHIEALLDKFGGEHNPPSIYLEAYEEYTSKLDALQQREQQLLESLGNGTDFSVSSSASMDTVTSSSSSSLSVLPSSLSVFQNPTDVARSNPKSPQKPIVRVFLPNKQRTVVPARCGVTVRDSLKKALMMRGLIPECCAVYRIQDGEKKPIGWDTDISWLTGEELHVEVLENVPLTTHNFVRKTFFTLAFCDFCRKLLFQGFRCQTCGYKFHQRCSTEVPLMCVNYDQLDLLFVSKFFEHHPIPQEEASLAETALTSGSSPSAPASDSIGPQILTSPSPSKSIPIPQPFRPADEDHRNQFGQRDRSSSAPNVHINTIEPVNIDDLIRDQGFRGDGGSTTGLSATPPASLPGSLTNVKALQKSPGPQRERKSSSSSEDRNRMKTLGRRDSSDDWEIPDGQITVGQRIGSGSFGTVYKGKWHGDVAVKMLNVTAPTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHHLHIIETKFEMIKLIDIARQTAQGMDYLHAKSIIHRDLKSNNIFLHEDLTVKIGDFGLATVKSRWSGSHQFEQLSGSILWMAPEVIRMQDKNPYSFQSDVYAFGIVLYELMTGQLPYSNINNRDQIIFMVGRGYLSPDLSKVRSNCPKAMKRLMAECLKKKRDERPLFPQILASIELLARSLPKIHRSASEPSLNRAGFQTEDFSLYACASPKTPIQAGGYGAFPVH	766	P15056	V	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [58, 61], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.00510275, -0.0055126 ]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [350, 359], 'COMPBIAS_gain': [339], 'COMPBIAS_gain_score': array([0.03814709]), 'COMPBIAS_loss_score': array([-0.00940728, -0.01064396]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [310], 'REGION_gain_score': array([0.08864093]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
36	NM_005633.3(SOS1):c.1772A>G (p.Asn591Ser)	448943	CA1624554	NM_005633.3:c.1772A>G, LRG_754t1:c.1772A>G, XM_005264515.3:c.1772A>G, XM_011533060.1:c.1865A>G, XM_011533061.1:c.1865A>G, XM_011533062.1:c.1751A>G, XM_011533063.1:c.1748A>G, XM_011533064.1:c.1601A>G, XM_011533065.1:c.1865A>G, XM_011533066.1:c.707A>G, XM_005264515.4:c.1772A>G, XM_011533062.2:c.1751A>G, XM_011533064.2:c.1601A>G, ENST00000395038.6:c.1772A>G, ENST00000402219.6:c.1772A>G, ENST00000426016.5:c.1772A>G, NC_000002.12:g.39022656T>C, CM000664.2:g.39022656T>C, NC_000002.11:g.39249797T>C, CM000664.1:g.39249797T>C, NC_000002.10:g.39103301T>C, NG_007530.1:g.102808A>G, LRG_754:g.102808A>G, NM_005633.3(SOS1):c.1772A>G (p.Asn591Ser)	SOS1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.1772A>G (p.Asn591Ser) variant in the SOS1 gene is 0.054% (11/11524) of Latino chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	False	https://erepo.genome.network/evrepo/ui/classification/CA1624554/MONDO:0021060/004	43130945-2556-414b-8804-afafb2608a11	p.Asn591Ser	Asn	591	Ser	MQAQQLPYEFFSEENAPKWRGLLVPALKKVQGQVHPTLESNDDALQYVEELILQLLNMLCQAQPRSASDVEERVQKSFPHPIDKWAIADAQSAIEKRKRRNPLSLPVEKIHPLLKEVLGYKIDHQVSVYIVAVLEYISADILKLVGNYVRNIRHYEITKQDIKVAMCADKVLMDMFHQDVEDINILSLTDEEPSTSGEQTYYDLVKAFMAEIRQYIRELNLIIKVFREPFVSNSKLFSANDVENIFSRIVDIHELSVKLLGHIEDTVEMTDEGSPHPLVGSCFEDLAEELAFDPYESYARDILRPGFHDRFLSQLSKPGAALYLQSIGEGFKEAVQYVLPRLLLAPVYHCLHYFELLKQLEEKSEDQEDKECLKQAITALLNVQSGMEKICSKSLAKRRLSESACRFYSQQMKGKQLAIKKMNEIQKNIDGWEGKDIGQCCNEFIMEGTLTRVGAKHERHIFLFDGLMICCKSNHGQPRLPGASNAEYRLKEKFFMRKVQINDKDDTNEYKHAFEIILKDENSVIFSAKSAEEKNNWMAALISLQYRSTLERMLDVTMLQEEKEEQMRLPSADVYRFAEPDSEENIIFEENMQPKAGIPIIKAGTVIKLIERLTYHMYADPNFVRTFLTTYRSFCKPQELLSLIIERFEIPEPEPTEADRIAIENGDQPLSAELKRFRKEYIQPVQLRVLNVCRHWVEHHFYDFERDAYLLQRMEEFIGTVRGKAMKKWVESITKIIQRKKIARDNGPGHNITFQSSPPTVEWHISRPGHIETFDLLTLHPIEIARQLTLLESDLYRAVQPSELVGSVWTKEDKEINSPNLLKMIRHTTNLTLWFEKCIVETENLEERVAVVSRIIEILQVFQELNNFNGVLEVVSAMNSSPVYRLDHTFEQIPSRQKKILEEAHELSEDHYKKYLAKLRSINPPCVPFFGIYLTNILKTEEGNPEVLKRHGKELINFSKRRKVAEITGEIQQYQNQPYCLRVESDIKRFFENLNPMGNSMEKEFTDYLFNKSLEIEPRNPKPLPRFPKKYSYPLKSPGVRPSNPRPGTMRHPTPLQQEPRKISYSRIPESETESTASAPNSPRTPLTPPPASGASSTTDVCSVFDSDHSSPFHSSNDTVFIQVTLPHGPRSASVSSISLTKGTDEVPVPPPVPPRRRPESAPAESSPSKIMSKHLDSPPAIPPRQPTSKAYSPRYSISDRTSISDPPESPPLLPPREPVRTPDVFSSSPLHLQPPPLGKKSDHGNAFFPNSPSPFTPPPPQTPSPHGTRRHLPSPPLTQEVDLHSIAGPPVPPRQSTSQHIPKLPPKTYKREHTHPSMHRDGPPLLENAHSS	1333	Q07889	S	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [516], 'STRAND_gain_score': array([0.00077432]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [783], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.01626539]), 'REGION_loss': [], 'REGION_gain': [1295], 'REGION_gain_score': array([0.00222951]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
37	NM_005633.3(SOS1):c.3032A>G (p.Asn1011Ser)	40716	CA136129	NM_005633.3:c.3032A>G, LRG_754t1:c.3032A>G, XM_005264515.3:c.3032A>G, XM_011533060.1:c.3125A>G, XM_011533061.1:c.3125A>G, XM_011533062.1:c.3011A>G, XM_011533063.1:c.3008A>G, XM_011533064.1:c.2861A>G, XM_011533065.1:c.3125A>G, XM_011533066.1:c.1967A>G, XM_005264515.4:c.3032A>G, XM_011533062.2:c.3011A>G, XM_011533064.2:c.2861A>G, ENST00000395038.6:c.3032A>G, ENST00000402219.6:c.3032A>G, ENST00000426016.5:c.3032A>G, NC_000002.12:g.38996971T>C, CM000664.2:g.38996971T>C, NC_000002.11:g.39224112T>C, CM000664.1:g.39224112T>C, NC_000002.10:g.39077616T>C, NG_007530.1:g.128493A>G, LRG_754:g.128493A>G, NM_005633.3(SOS1):c.3032A>G (p.Asn1011Ser)	SOS1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.3032A>G (p.Asn1011Ser) variant in the SOS1 gene is 0.26% for European (Non-Finnish) chromosomes by the Exome Aggregation Consortium (197/66620 with 95% CI), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert panel for autosomal dominant RASopathy variants (BA1).		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	False	https://erepo.genome.network/evrepo/ui/classification/CA136129/MONDO:0021060/004	8c759015-333c-4286-a49f-d6ca9f266789	p.Asn1011Ser	Asn	1011	Ser	MQAQQLPYEFFSEENAPKWRGLLVPALKKVQGQVHPTLESNDDALQYVEELILQLLNMLCQAQPRSASDVEERVQKSFPHPIDKWAIADAQSAIEKRKRRNPLSLPVEKIHPLLKEVLGYKIDHQVSVYIVAVLEYISADILKLVGNYVRNIRHYEITKQDIKVAMCADKVLMDMFHQDVEDINILSLTDEEPSTSGEQTYYDLVKAFMAEIRQYIRELNLIIKVFREPFVSNSKLFSANDVENIFSRIVDIHELSVKLLGHIEDTVEMTDEGSPHPLVGSCFEDLAEELAFDPYESYARDILRPGFHDRFLSQLSKPGAALYLQSIGEGFKEAVQYVLPRLLLAPVYHCLHYFELLKQLEEKSEDQEDKECLKQAITALLNVQSGMEKICSKSLAKRRLSESACRFYSQQMKGKQLAIKKMNEIQKNIDGWEGKDIGQCCNEFIMEGTLTRVGAKHERHIFLFDGLMICCKSNHGQPRLPGASNAEYRLKEKFFMRKVQINDKDDTNEYKHAFEIILKDENSVIFSAKSAEEKNNWMAALISLQYRSTLERMLDVTMLQEEKEEQMRLPSADVYRFAEPDSEENIIFEENMQPKAGIPIIKAGTVIKLIERLTYHMYADPNFVRTFLTTYRSFCKPQELLSLIIERFEIPEPEPTEADRIAIENGDQPLSAELKRFRKEYIQPVQLRVLNVCRHWVEHHFYDFERDAYLLQRMEEFIGTVRGKAMKKWVESITKIIQRKKIARDNGPGHNITFQSSPPTVEWHISRPGHIETFDLLTLHPIEIARQLTLLESDLYRAVQPSELVGSVWTKEDKEINSPNLLKMIRHTTNLTLWFEKCIVETENLEERVAVVSRIIEILQVFQELNNFNGVLEVVSAMNSSPVYRLDHTFEQIPSRQKKILEEAHELSEDHYKKYLAKLRSINPPCVPFFGIYLTNILKTEEGNPEVLKRHGKELINFSKRRKVAEITGEIQQYQNQPYCLRVESDIKRFFENLNPMGNSMEKEFTDYLFNKSLEIEPRNPKPLPRFPKKYSYPLKSPGVRPSNPRPGTMRHPTPLQQEPRKISYSRIPESETESTASAPNSPRTPLTPPPASGASSTTDVCSVFDSDHSSPFHSSNDTVFIQVTLPHGPRSASVSSISLTKGTDEVPVPPPVPPRRRPESAPAESSPSKIMSKHLDSPPAIPPRQPTSKAYSPRYSISDRTSISDPPESPPLLPPREPVRTPDVFSSSPLHLQPPPLGKKSDHGNAFFPNSPSPFTPPPPQTPSPHGTRRHLPSPPLTQEVDLHSIAGPPVPPRQSTSQHIPKLPPKTYKREHTHPSMHRDGPPLLENAHSS	1333	Q07889	S	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [516], 'STRAND_gain_score': array([0.00037134]), 'HELIX_loss': [856], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.01076597]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [782], 'DOMAIN_gain_score': array([0.01255929]), 'REGION_loss': [], 'REGION_gain': [1017, 1295], 'REGION_gain_score': array([0.04170626, 0.00231832]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
38	NM_005633.3(SOS1):c.73C>T (p.Pro25Ser)	40640	CA181527	NM_005633.3:c.73C>T, LRG_754t1:c.73C>T, XM_005264515.3:c.73C>T, XM_011533062.1:c.66+4314C>T, XM_005264515.4:c.73C>T, XM_011533062.2:c.66+4314C>T, ENST00000395038.6:c.73C>T, ENST00000402219.6:c.73C>T, ENST00000426016.5:c.73C>T, ENST00000451331.1:c.-85+3809C>T, NC_000002.12:g.39120350G>A, CM000664.2:g.39120350G>A, NC_000002.11:g.39347491G>A, CM000664.1:g.39347491G>A, NC_000002.10:g.39200995G>A, NG_007530.1:g.5114C>T, LRG_754:g.5114C>T, NM_005633.3(SOS1):c.73C>T (p.Pro25Ser)	SOS1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.73C>T (p.Pro25Ser) variant in the SOS1 gene is 0.23% for African chromosomes by the Exome Aggregation Consortium (21/6116 with 95% CI), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert panel for autosomal dominant RASopathy variants (BA1).		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	False	https://erepo.genome.network/evrepo/ui/classification/CA181527/MONDO:0021060/004	64e8b1a2-45eb-49be-932c-fc67eb53aae9	p.Pro25Ser	Pro	25	Ser	MQAQQLPYEFFSEENAPKWRGLLVPALKKVQGQVHPTLESNDDALQYVEELILQLLNMLCQAQPRSASDVEERVQKSFPHPIDKWAIADAQSAIEKRKRRNPLSLPVEKIHPLLKEVLGYKIDHQVSVYIVAVLEYISADILKLVGNYVRNIRHYEITKQDIKVAMCADKVLMDMFHQDVEDINILSLTDEEPSTSGEQTYYDLVKAFMAEIRQYIRELNLIIKVFREPFVSNSKLFSANDVENIFSRIVDIHELSVKLLGHIEDTVEMTDEGSPHPLVGSCFEDLAEELAFDPYESYARDILRPGFHDRFLSQLSKPGAALYLQSIGEGFKEAVQYVLPRLLLAPVYHCLHYFELLKQLEEKSEDQEDKECLKQAITALLNVQSGMEKICSKSLAKRRLSESACRFYSQQMKGKQLAIKKMNEIQKNIDGWEGKDIGQCCNEFIMEGTLTRVGAKHERHIFLFDGLMICCKSNHGQPRLPGASNAEYRLKEKFFMRKVQINDKDDTNEYKHAFEIILKDENSVIFSAKSAEEKNNWMAALISLQYRSTLERMLDVTMLQEEKEEQMRLPSADVYRFAEPDSEENIIFEENMQPKAGIPIIKAGTVIKLIERLTYHMYADPNFVRTFLTTYRSFCKPQELLSLIIERFEIPEPEPTEADRIAIENGDQPLSAELKRFRKEYIQPVQLRVLNVCRHWVEHHFYDFERDAYLLQRMEEFIGTVRGKAMKKWVESITKIIQRKKIARDNGPGHNITFQSSPPTVEWHISRPGHIETFDLLTLHPIEIARQLTLLESDLYRAVQPSELVGSVWTKEDKEINSPNLLKMIRHTTNLTLWFEKCIVETENLEERVAVVSRIIEILQVFQELNNFNGVLEVVSAMNSSPVYRLDHTFEQIPSRQKKILEEAHELSEDHYKKYLAKLRSINPPCVPFFGIYLTNILKTEEGNPEVLKRHGKELINFSKRRKVAEITGEIQQYQNQPYCLRVESDIKRFFENLNPMGNSMEKEFTDYLFNKSLEIEPRNPKPLPRFPKKYSYPLKSPGVRPSNPRPGTMRHPTPLQQEPRKISYSRIPESETESTASAPNSPRTPLTPPPASGASSTTDVCSVFDSDHSSPFHSSNDTVFIQVTLPHGPRSASVSSISLTKGTDEVPVPPPVPPRRRPESAPAESSPSKIMSKHLDSPPAIPPRQPTSKAYSPRYSISDRTSISDPPESPPLLPPREPVRTPDVFSSSPLHLQPPPLGKKSDHGNAFFPNSPSPFTPPPPQTPSPHGTRRHLPSPPLTQEVDLHSIAGPPVPPRQSTSQHIPKLPPKTYKREHTHPSMHRDGPPLLENAHSS	1333	Q07889	S	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [516], 'STRAND_gain_score': array([0.00244242]), 'HELIX_loss': [], 'HELIX_gain': [206], 'HELIX_gain_score': array([0.01186079]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [1102], 'COMPBIAS_gain': [1201], 'COMPBIAS_gain_score': array([0.01147109]), 'COMPBIAS_loss_score': array([-0.00495964]), 'DOMAIN_loss': [], 'DOMAIN_gain': [778, 780, 782], 'DOMAIN_gain_score': array([0.03241396, 0.04042578, 0.03303087]), 'REGION_loss': [], 'REGION_gain': [1295, 1300], 'REGION_gain_score': array([0.00754112, 0.0075798 ]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
39	NM_005633.3(SOS1):c.2122G>A (p.Ala708Thr)	40697	CA136094	NM_005633.3:c.2122G>A, LRG_754t1:c.2122G>A, XM_005264515.3:c.2122G>A, XM_011533060.1:c.2215G>A, XM_011533061.1:c.2215G>A, XM_011533062.1:c.2101G>A, XM_011533063.1:c.2098G>A, XM_011533064.1:c.1951G>A, XM_011533065.1:c.2215G>A, XM_011533066.1:c.1057G>A, XM_005264515.4:c.2122G>A, XM_011533062.2:c.2101G>A, XM_011533064.2:c.1951G>A, ENST00000395038.6:c.2122G>A, ENST00000402219.6:c.2122G>A, ENST00000426016.5:c.2122G>A, NC_000002.12:g.39013505C>T, CM000664.2:g.39013505C>T, NC_000002.11:g.39240646C>T, CM000664.1:g.39240646C>T, NC_000002.10:g.39094150C>T, NG_007530.1:g.111959G>A, LRG_754:g.111959G>A, NM_005633.3(SOS1):c.2122G>A (p.Ala708Thr)	SOS1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.2122G>A (p.Ala708Thr) variant in the SOS1 gene is 5.13% for Latino chromosomes by the Exome Aggregation Consortium (633/11554 with 95% CI), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert panel for autosomal dominant RASopathy variants (BA1).		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	False	https://erepo.genome.network/evrepo/ui/classification/CA136094/MONDO:0021060/004	0fc9c039-08e1-4b28-8161-1cb12bd63b04	p.Ala708Thr	Ala	708	Thr	MQAQQLPYEFFSEENAPKWRGLLVPALKKVQGQVHPTLESNDDALQYVEELILQLLNMLCQAQPRSASDVEERVQKSFPHPIDKWAIADAQSAIEKRKRRNPLSLPVEKIHPLLKEVLGYKIDHQVSVYIVAVLEYISADILKLVGNYVRNIRHYEITKQDIKVAMCADKVLMDMFHQDVEDINILSLTDEEPSTSGEQTYYDLVKAFMAEIRQYIRELNLIIKVFREPFVSNSKLFSANDVENIFSRIVDIHELSVKLLGHIEDTVEMTDEGSPHPLVGSCFEDLAEELAFDPYESYARDILRPGFHDRFLSQLSKPGAALYLQSIGEGFKEAVQYVLPRLLLAPVYHCLHYFELLKQLEEKSEDQEDKECLKQAITALLNVQSGMEKICSKSLAKRRLSESACRFYSQQMKGKQLAIKKMNEIQKNIDGWEGKDIGQCCNEFIMEGTLTRVGAKHERHIFLFDGLMICCKSNHGQPRLPGASNAEYRLKEKFFMRKVQINDKDDTNEYKHAFEIILKDENSVIFSAKSAEEKNNWMAALISLQYRSTLERMLDVTMLQEEKEEQMRLPSADVYRFAEPDSEENIIFEENMQPKAGIPIIKAGTVIKLIERLTYHMYADPNFVRTFLTTYRSFCKPQELLSLIIERFEIPEPEPTEADRIAIENGDQPLSAELKRFRKEYIQPVQLRVLNVCRHWVEHHFYDFERDAYLLQRMEEFIGTVRGKAMKKWVESITKIIQRKKIARDNGPGHNITFQSSPPTVEWHISRPGHIETFDLLTLHPIEIARQLTLLESDLYRAVQPSELVGSVWTKEDKEINSPNLLKMIRHTTNLTLWFEKCIVETENLEERVAVVSRIIEILQVFQELNNFNGVLEVVSAMNSSPVYRLDHTFEQIPSRQKKILEEAHELSEDHYKKYLAKLRSINPPCVPFFGIYLTNILKTEEGNPEVLKRHGKELINFSKRRKVAEITGEIQQYQNQPYCLRVESDIKRFFENLNPMGNSMEKEFTDYLFNKSLEIEPRNPKPLPRFPKKYSYPLKSPGVRPSNPRPGTMRHPTPLQQEPRKISYSRIPESETESTASAPNSPRTPLTPPPASGASSTTDVCSVFDSDHSSPFHSSNDTVFIQVTLPHGPRSASVSSISLTKGTDEVPVPPPVPPRRRPESAPAESSPSKIMSKHLDSPPAIPPRQPTSKAYSPRYSISDRTSISDPPESPPLLPPREPVRTPDVFSSSPLHLQPPPLGKKSDHGNAFFPNSPSPFTPPPPQTPSPHGTRRHLPSPPLTQEVDLHSIAGPPVPPRQSTSQHIPKLPPKTYKREHTHPSMHRDGPPLLENAHSS	1333	Q07889	T	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [778, 780, 781, 782, 872, 873, 875], 'DOMAIN_gain_score': array([0.0584963 , 0.07190758, 0.06010598, 0.06614351, 0.05477542,
       0.0588395 , 0.04869509]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
40	NM_005633.3(SOS1):c.2371C>A (p.Leu791Ile)	40702	CA136098	NM_005633.3:c.2371C>A, NC_000002.12:g.39012145G>T, CM000664.2:g.39012145G>T, NC_000002.11:g.39239286G>T, CM000664.1:g.39239286G>T, NC_000002.10:g.39092790G>T, NG_007530.1:g.113319C>A, LRG_754:g.113319C>A, LRG_754t1:c.2371C>A, XM_005264515.3:c.2371C>A, XM_011533060.1:c.2464C>A, XM_011533061.1:c.2464C>A, XM_011533062.1:c.2350C>A, XM_011533063.1:c.2347C>A, XM_011533064.1:c.2200C>A, XM_011533065.1:c.2464C>A, XM_011533066.1:c.1306C>A, XM_005264515.4:c.2371C>A, XM_011533062.2:c.2350C>A, XM_011533064.2:c.2200C>A, ENST00000395038.6:c.2371C>A, ENST00000402219.6:c.2371C>A, ENST00000426016.5:c.2371C>A, NM_005633.3(SOS1):c.2371C>A (p.Leu791Ile)	SOS1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.2371C>A (p.Leu791Ile) variant in the SOS1 gene is 0.081% for European (Non-Finnish) chromosomes by the Exome Aggregation Consortium (67/66688 with 95% CI), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert panel for autosomal dominant RASopathy variants (BA1).		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	False	https://erepo.genome.network/evrepo/ui/classification/CA136098/MONDO:0021060/004	5cdf91d2-4341-4b5c-9657-3a3132543f1a	p.Leu791Ile	Leu	791	Ile	MQAQQLPYEFFSEENAPKWRGLLVPALKKVQGQVHPTLESNDDALQYVEELILQLLNMLCQAQPRSASDVEERVQKSFPHPIDKWAIADAQSAIEKRKRRNPLSLPVEKIHPLLKEVLGYKIDHQVSVYIVAVLEYISADILKLVGNYVRNIRHYEITKQDIKVAMCADKVLMDMFHQDVEDINILSLTDEEPSTSGEQTYYDLVKAFMAEIRQYIRELNLIIKVFREPFVSNSKLFSANDVENIFSRIVDIHELSVKLLGHIEDTVEMTDEGSPHPLVGSCFEDLAEELAFDPYESYARDILRPGFHDRFLSQLSKPGAALYLQSIGEGFKEAVQYVLPRLLLAPVYHCLHYFELLKQLEEKSEDQEDKECLKQAITALLNVQSGMEKICSKSLAKRRLSESACRFYSQQMKGKQLAIKKMNEIQKNIDGWEGKDIGQCCNEFIMEGTLTRVGAKHERHIFLFDGLMICCKSNHGQPRLPGASNAEYRLKEKFFMRKVQINDKDDTNEYKHAFEIILKDENSVIFSAKSAEEKNNWMAALISLQYRSTLERMLDVTMLQEEKEEQMRLPSADVYRFAEPDSEENIIFEENMQPKAGIPIIKAGTVIKLIERLTYHMYADPNFVRTFLTTYRSFCKPQELLSLIIERFEIPEPEPTEADRIAIENGDQPLSAELKRFRKEYIQPVQLRVLNVCRHWVEHHFYDFERDAYLLQRMEEFIGTVRGKAMKKWVESITKIIQRKKIARDNGPGHNITFQSSPPTVEWHISRPGHIETFDLLTLHPIEIARQLTLLESDLYRAVQPSELVGSVWTKEDKEINSPNLLKMIRHTTNLTLWFEKCIVETENLEERVAVVSRIIEILQVFQELNNFNGVLEVVSAMNSSPVYRLDHTFEQIPSRQKKILEEAHELSEDHYKKYLAKLRSINPPCVPFFGIYLTNILKTEEGNPEVLKRHGKELINFSKRRKVAEITGEIQQYQNQPYCLRVESDIKRFFENLNPMGNSMEKEFTDYLFNKSLEIEPRNPKPLPRFPKKYSYPLKSPGVRPSNPRPGTMRHPTPLQQEPRKISYSRIPESETESTASAPNSPRTPLTPPPASGASSTTDVCSVFDSDHSSPFHSSNDTVFIQVTLPHGPRSASVSSISLTKGTDEVPVPPPVPPRRRPESAPAESSPSKIMSKHLDSPPAIPPRQPTSKAYSPRYSISDRTSISDPPESPPLLPPREPVRTPDVFSSSPLHLQPPPLGKKSDHGNAFFPNSPSPFTPPPPQTPSPHGTRRHLPSPPLTQEVDLHSIAGPPVPPRQSTSQHIPKLPPKTYKREHTHPSMHRDGPPLLENAHSS	1333	Q07889	I	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [516], 'STRAND_gain_score': array([0.00035214]), 'HELIX_loss': [], 'HELIX_gain': [859], 'HELIX_gain_score': array([0.0112887]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [778, 780, 782, 872, 873, 875], 'DOMAIN_gain_score': array([0.02208763, 0.052356  , 0.03422457, 0.0668506 , 0.07119662,
       0.06177831]), 'REGION_loss': [], 'REGION_gain': [1295], 'REGION_gain_score': array([0.0006066]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
41	NM_005633.3(SOS1):c.749T>C (p.Val250Ala)	40660	CA136183	NM_005633.3:c.749T>C, LRG_754t1:c.749T>C, XM_005264515.3:c.749T>C, XM_011533060.1:c.842T>C, XM_011533061.1:c.842T>C, XM_011533062.1:c.728T>C, XM_011533063.1:c.725T>C, XM_011533064.1:c.578T>C, XM_011533065.1:c.842T>C, XM_005264515.4:c.749T>C, XM_011533062.2:c.728T>C, XM_011533064.2:c.578T>C, ENST00000395038.6:c.749T>C, ENST00000402219.6:c.749T>C, ENST00000426016.5:c.749T>C, ENST00000461545.1:n.99T>C, NC_000002.12:g.39051259A>G, CM000664.2:g.39051259A>G, NC_000002.11:g.39278400A>G, CM000664.1:g.39278400A>G, NC_000002.10:g.39131904A>G, NG_007530.1:g.74205T>C, LRG_754:g.74205T>C, NM_005633.3(SOS1):c.749T>C (p.Val250Ala)	SOS1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.749T>C (p.Val250Ala) variant in the SOS1 gene is 0.089% for African chromosomes by the Exome Aggregation Consortium (15/10392 with 95% CI), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert panel for autosomal dominant RASopathy variants (BA1).		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	False	https://erepo.genome.network/evrepo/ui/classification/CA136183/MONDO:0021060/004	b29f4adc-7b22-4d66-89e7-1538798f3f2a	p.Val250Ala	Val	250	Ala	MQAQQLPYEFFSEENAPKWRGLLVPALKKVQGQVHPTLESNDDALQYVEELILQLLNMLCQAQPRSASDVEERVQKSFPHPIDKWAIADAQSAIEKRKRRNPLSLPVEKIHPLLKEVLGYKIDHQVSVYIVAVLEYISADILKLVGNYVRNIRHYEITKQDIKVAMCADKVLMDMFHQDVEDINILSLTDEEPSTSGEQTYYDLVKAFMAEIRQYIRELNLIIKVFREPFVSNSKLFSANDVENIFSRIVDIHELSVKLLGHIEDTVEMTDEGSPHPLVGSCFEDLAEELAFDPYESYARDILRPGFHDRFLSQLSKPGAALYLQSIGEGFKEAVQYVLPRLLLAPVYHCLHYFELLKQLEEKSEDQEDKECLKQAITALLNVQSGMEKICSKSLAKRRLSESACRFYSQQMKGKQLAIKKMNEIQKNIDGWEGKDIGQCCNEFIMEGTLTRVGAKHERHIFLFDGLMICCKSNHGQPRLPGASNAEYRLKEKFFMRKVQINDKDDTNEYKHAFEIILKDENSVIFSAKSAEEKNNWMAALISLQYRSTLERMLDVTMLQEEKEEQMRLPSADVYRFAEPDSEENIIFEENMQPKAGIPIIKAGTVIKLIERLTYHMYADPNFVRTFLTTYRSFCKPQELLSLIIERFEIPEPEPTEADRIAIENGDQPLSAELKRFRKEYIQPVQLRVLNVCRHWVEHHFYDFERDAYLLQRMEEFIGTVRGKAMKKWVESITKIIQRKKIARDNGPGHNITFQSSPPTVEWHISRPGHIETFDLLTLHPIEIARQLTLLESDLYRAVQPSELVGSVWTKEDKEINSPNLLKMIRHTTNLTLWFEKCIVETENLEERVAVVSRIIEILQVFQELNNFNGVLEVVSAMNSSPVYRLDHTFEQIPSRQKKILEEAHELSEDHYKKYLAKLRSINPPCVPFFGIYLTNILKTEEGNPEVLKRHGKELINFSKRRKVAEITGEIQQYQNQPYCLRVESDIKRFFENLNPMGNSMEKEFTDYLFNKSLEIEPRNPKPLPRFPKKYSYPLKSPGVRPSNPRPGTMRHPTPLQQEPRKISYSRIPESETESTASAPNSPRTPLTPPPASGASSTTDVCSVFDSDHSSPFHSSNDTVFIQVTLPHGPRSASVSSISLTKGTDEVPVPPPVPPRRRPESAPAESSPSKIMSKHLDSPPAIPPRQPTSKAYSPRYSISDRTSISDPPESPPLLPPREPVRTPDVFSSSPLHLQPPPLGKKSDHGNAFFPNSPSPFTPPPPQTPSPHGTRRHLPSPPLTQEVDLHSIAGPPVPPRQSTSQHIPKLPPKTYKREHTHPSMHRDGPPLLENAHSS	1333	Q07889	A	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [778, 780, 782], 'DOMAIN_gain_score': array([0.02582359, 0.03146774, 0.02599347]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
42	NM_005633.3(SOS1):c.322G>A (p.Glu108Lys)	40649	CA261739	NM_005633.3:c.322G>A, LRG_754t1:c.322G>A, XM_005264515.3:c.322G>A, XM_011533060.1:c.415G>A, XM_011533061.1:c.415G>A, XM_011533062.1:c.301G>A, XM_011533063.1:c.298G>A, XM_011533064.1:c.151G>A, XM_011533065.1:c.415G>A, XM_005264515.4:c.322G>A, XM_011533062.2:c.301G>A, XM_011533064.2:c.151G>A, ENST00000395038.6:c.322G>A, ENST00000402219.6:c.322G>A, ENST00000426016.5:c.322G>A, ENST00000451331.1:c.151G>A, NC_000002.12:g.39058696C>T, CM000664.2:g.39058696C>T, NC_000002.11:g.39285837C>T, CM000664.1:g.39285837C>T, NC_000002.10:g.39139341C>T, NG_007530.1:g.66768G>A, LRG_754:g.66768G>A, NM_005633.3(SOS1):c.322G>A (p.Glu108Lys)	SOS1	Noonan syndrome	MONDO:0018997	Autosomal dominant inheritance	Pathogenic	PM2, PM6, PP2, PS3, PS2, PS4_Moderate		The c.322G>A (p.Glu108Lys) variant in SOS1 has been reported as confirmed and unconfirmed occurrences in patients with clinical features of a RASopathy (PM6 and PS2; GeneDx, Partners LMM, APHP-Robert Debré Hospital internal data GTR Lab ID: 26957, 21766, 28338; ClinVar SCV000209088.9, SCV000062224.5, SCV000659144.2). The p.Glu108Lys variant has been identified in several independent occurrences in patients with clinical features of a RASopathy (PS4_Moderate; GeneDx, Partners LMM, APHP-Robert Debré Hospital internal data GTR Lab ID: 26957, 21766, 28338; ClinVar SCV000209088.9, SCV000062224.5, SCV000659144.2; PMID: 17143282; 23487764). In vitro functional studies provide some evidence that the p.Glu108Lys variant may impact protein function (PS3; PMID: 17143282, 23487764). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). The variant is located in the SOS1 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PS2, PS3, PM6, PS4_Moderate, PM2, PP2.	17143282, 23487764, 17143282, 23487764	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	False	https://erepo.genome.network/evrepo/ui/classification/CA261739/MONDO:0018997/004	31e0095f-919b-4660-81cd-4f5bf83b5bcb	p.Glu108Lys	Glu	108	Lys	MQAQQLPYEFFSEENAPKWRGLLVPALKKVQGQVHPTLESNDDALQYVEELILQLLNMLCQAQPRSASDVEERVQKSFPHPIDKWAIADAQSAIEKRKRRNPLSLPVEKIHPLLKEVLGYKIDHQVSVYIVAVLEYISADILKLVGNYVRNIRHYEITKQDIKVAMCADKVLMDMFHQDVEDINILSLTDEEPSTSGEQTYYDLVKAFMAEIRQYIRELNLIIKVFREPFVSNSKLFSANDVENIFSRIVDIHELSVKLLGHIEDTVEMTDEGSPHPLVGSCFEDLAEELAFDPYESYARDILRPGFHDRFLSQLSKPGAALYLQSIGEGFKEAVQYVLPRLLLAPVYHCLHYFELLKQLEEKSEDQEDKECLKQAITALLNVQSGMEKICSKSLAKRRLSESACRFYSQQMKGKQLAIKKMNEIQKNIDGWEGKDIGQCCNEFIMEGTLTRVGAKHERHIFLFDGLMICCKSNHGQPRLPGASNAEYRLKEKFFMRKVQINDKDDTNEYKHAFEIILKDENSVIFSAKSAEEKNNWMAALISLQYRSTLERMLDVTMLQEEKEEQMRLPSADVYRFAEPDSEENIIFEENMQPKAGIPIIKAGTVIKLIERLTYHMYADPNFVRTFLTTYRSFCKPQELLSLIIERFEIPEPEPTEADRIAIENGDQPLSAELKRFRKEYIQPVQLRVLNVCRHWVEHHFYDFERDAYLLQRMEEFIGTVRGKAMKKWVESITKIIQRKKIARDNGPGHNITFQSSPPTVEWHISRPGHIETFDLLTLHPIEIARQLTLLESDLYRAVQPSELVGSVWTKEDKEINSPNLLKMIRHTTNLTLWFEKCIVETENLEERVAVVSRIIEILQVFQELNNFNGVLEVVSAMNSSPVYRLDHTFEQIPSRQKKILEEAHELSEDHYKKYLAKLRSINPPCVPFFGIYLTNILKTEEGNPEVLKRHGKELINFSKRRKVAEITGEIQQYQNQPYCLRVESDIKRFFENLNPMGNSMEKEFTDYLFNKSLEIEPRNPKPLPRFPKKYSYPLKSPGVRPSNPRPGTMRHPTPLQQEPRKISYSRIPESETESTASAPNSPRTPLTPPPASGASSTTDVCSVFDSDHSSPFHSSNDTVFIQVTLPHGPRSASVSSISLTKGTDEVPVPPPVPPRRRPESAPAESSPSKIMSKHLDSPPAIPPRQPTSKAYSPRYSISDRTSISDPPESPPLLPPREPVRTPDVFSSSPLHLQPPPLGKKSDHGNAFFPNSPSPFTPPPPQTPSPHGTRRHLPSPPLTQEVDLHSIAGPPVPPRQSTSQHIPKLPPKTYKREHTHPSMHRDGPPLLENAHSS	1333	Q07889	K	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [856], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.00698668]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [783], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.01871651]), 'REGION_loss': [], 'REGION_gain': [1295], 'REGION_gain_score': array([0.00224185]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
43	NM_007373.3(SHOC2):c.10A>C (p.Ser4Arg)	40635	CA136657	NM_007373.3:c.10A>C, NM_001269039.1:c.10A>C, LRG_753t1:c.10A>C, XM_011540216.1:c.-380-21260A>C, NM_001269039.2:c.10A>C, NM_001324336.1:c.10A>C, NM_001324337.1:c.10A>C, NR_136749.1:n.116-21260A>C, ENST00000265277.9:c.10A>C, ENST00000369452.8:c.10A>C, ENST00000480155.1:n.494A>C, ENST00000489390.1:n.56-36047A>C, ENST00000489783.1:n.388A>C, NC_000010.11:g.110964368A>C, CM000672.2:g.110964368A>C, NC_000010.10:g.112724126A>C, CM000672.1:g.112724126A>C, NC_000010.9:g.112714116A>C, NG_028922.1:g.49826A>C, LRG_753:g.49826A>C, NM_007373.3(SHOC2):c.10A>C (p.Ser4Arg)	SHOC2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1, BP5	BP2	The c.10A>C variant in SHOC2 has been identified in a patient with an alternate molecular basis for disease (BP5; GeneDx, Partners LMM GTR Lab ID: 26957, 21766 internal data; ClinVar SCV000209046.7, SCV000062455.5). The filtering allele frequency of the c.10A>C (p.Ser4Arg) variant is 0.356% for Latino chromosomes by the Exome Aggregation Consortium (49/10712 with 95% CI), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert panel for autosomal dominant RASopathy variants (BA1). In summary, this variant meets criteria to be classified as benign. RASopathy-specific ACMG/AMP criteria applied (PMID:29493581): BA1, BP5.		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	False	https://erepo.genome.network/evrepo/ui/classification/CA136657/MONDO:0021060/004	f8ec95a4-b09f-4a17-984e-06b4098449c2	p.Ser4Arg	Ser	4	Arg	MSSSLGKEKDSKEKDPKVPSAKEREKEAKASGGFGKESKEKEPKTKGKDAKDGKKDSSAAQPGVAFSVDNTIKRPNPAPGTRKKSSNAEVIKELNKCREENSMRLDLSKRSIHILPSSIKELTQLTELYLYSNKLQSLPAEVGCLVNLMTLALSENSLTSLPDSLDNLKKLRMLDLRHNKLREIPSVVYRLDSLTTLYLRFNRITTVEKDIKNLSKLSMLSIRENKIKQLPAEIGELCNLITLDVAHNQLEHLPKEIGNCTQITNLDLQHNELLDLPDTIGNLSSLSRLGLRYNRLSAIPRSLAKCSALEELNLENNNISTLPESLLSSLVKLNSLTLARNCFQLYPVGGPSQFSTIYSLNMEHNRINKIPFGIFSRAKVLSKLNMKDNQLTSLPLDFGTWTSMVELNLATNQLTKIPEDVSGLVSLEVLILSNNLLKKLPHGLGNLRKLRELDLEENKLESLPNEIAYLKDLQKLVLTNNQLTTLPRGIGHLTNLTHLGLGENLLTHLPEEIGTLENLEELYLNDNPNLHSLPFELALCSKLSIMSIENCPLSHLPPQIVAGGPSFIIQFLKMQGPYRAMV	582	Q9UQ13	R	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
44	NM_007373.3(SHOC2):c.4A>G (p.Ser2Gly)	6821	CA118524	NM_007373.3:c.4A>G, NC_000010.11:g.110964362A>G, CM000672.2:g.110964362A>G, NC_000010.10:g.112724120A>G, CM000672.1:g.112724120A>G, NC_000010.9:g.112714110A>G, NG_028922.1:g.49820A>G, LRG_753:g.49820A>G, NM_001269039.1:c.4A>G, LRG_753t1:c.4A>G, XM_011540216.1:c.-380-21266A>G, NM_001269039.2:c.4A>G, NM_001324336.1:c.4A>G, NM_001324337.1:c.4A>G, NR_136749.1:n.116-21266A>G, ENST00000265277.9:c.4A>G, ENST00000369452.8:c.4A>G, ENST00000480155.1:n.488A>G, ENST00000489390.1:n.56-36053A>G, ENST00000489783.1:n.382A>G, NM_007373.3(SHOC2):c.4A>G (p.Ser2Gly)	SHOC2	Noonan syndrome-like disorder with loose anagen hair 1	MONDO:0054637	Autosomal dominant inheritance	Pathogenic	PM2, PS2_Very Strong, PP2, PS4, PS3		The c.4A>G (p.Ser2Gly) variant in SHOC2 has been reported as a confirmed de novo occurrence in multiple patients with clinical features of a RASopathy (PS2_VeryStrong; Partners LMM, Institute of Human Genetics, Otto von Guericke University Magdeburg, APHP-Robert Debré Hospital internal data; GTR ID's: 21766, 506381, 28338; ClinVar SCV000062456.5, SCV000209051.10, SCV000263045.1 PMID 19684605, 21548061, 23918763, 22528146). The p.Ser2Gly variant has been identified in at least 5 independent occurrences in patients with clinical features of a RASopathy (PS4; Institute of Human Genetics, Otto von Guericke University Magdeburg, APHP-Robert Debré Hospital internal data GTR ID's: 506381, 28338; PMID: 25563136, 24458587). In vitro functional studies provide some evidence that the p.Ser2Gly variant may impact protein function (PS3; PMID: 19684605). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). The variant is located in the SHOC2 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PS2_VeryStrong, PS3, PS4, PM2, PP2.	22528146, 23918763, 19684605, 21548061, 25563136, 24458587, 19684605	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	False	https://erepo.genome.network/evrepo/ui/classification/CA118524/MONDO:0054637/004	39b0e509-abdb-415d-87bd-98b7310bb1c0	p.Ser2Gly	Ser	2	Gly	MSSSLGKEKDSKEKDPKVPSAKEREKEAKASGGFGKESKEKEPKTKGKDAKDGKKDSSAAQPGVAFSVDNTIKRPNPAPGTRKKSSNAEVIKELNKCREENSMRLDLSKRSIHILPSSIKELTQLTELYLYSNKLQSLPAEVGCLVNLMTLALSENSLTSLPDSLDNLKKLRMLDLRHNKLREIPSVVYRLDSLTTLYLRFNRITTVEKDIKNLSKLSMLSIRENKIKQLPAEIGELCNLITLDVAHNQLEHLPKEIGNCTQITNLDLQHNELLDLPDTIGNLSSLSRLGLRYNRLSAIPRSLAKCSALEELNLENNNISTLPESLLSSLVKLNSLTLARNCFQLYPVGGPSQFSTIYSLNMEHNRINKIPFGIFSRAKVLSKLNMKDNQLTSLPLDFGTWTSMVELNLATNQLTKIPEDVSGLVSLEVLILSNNLLKKLPHGLGNLRKLRELDLEENKLESLPNEIAYLKDLQKLVLTNNQLTTLPRGIGHLTNLTHLGLGENLLTHLPEEIGTLENLEELYLNDNPNLHSLPFELALCSKLSIMSIENCPLSHLPPQIVAGGPSFIIQFLKMQGPYRAMV	582	Q9UQ13	G	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
45	NM_002880.3(RAF1):c.775T>A (p.Ser259Thr)	40601	CA261617	NM_002880.3:c.775T>A, NC_000003.12:g.12604195A>T, CM000665.2:g.12604195A>T, NC_000003.11:g.12645694A>T, CM000665.1:g.12645694A>T, NC_000003.10:g.12620694A>T, NG_007467.1:g.64985T>A, LRG_413:g.64985T>A, LRG_413t1:c.775T>A, XM_005265355.1:c.775T>A, XM_005265357.1:c.676T>A, XM_005265358.3:c.532T>A, XM_005265359.3:c.433T>A, XM_005265360.1:c.775T>A, XM_011533974.1:c.775T>A, XM_011533975.1:c.532T>A, NM_001354689.1:c.775T>A, NM_001354690.1:c.775T>A, NM_001354691.1:c.532T>A, NM_001354692.1:c.532T>A, NM_001354693.1:c.676T>A, NM_001354694.1:c.532T>A, NM_001354695.1:c.433T>A, NR_148940.1:n.1190T>A, NR_148941.1:n.1190T>A, NR_148942.1:n.1190T>A, XM_011533974.3:c.775T>A, XM_017006966.1:c.676T>A, XR_001740227.1:n.1007T>A, NM_001354689.3:c.775T>A, NM_001354690.2:c.775T>A, NM_001354691.2:c.532T>A, NM_001354692.2:c.532T>A, NM_001354693.2:c.676T>A, NM_001354694.2:c.532T>A, NM_001354695.2:c.433T>A, NR_148940.2:n.1106T>A, NR_148941.2:n.1106T>A, NR_148942.2:n.1106T>A, ENST00000251849.8:c.775T>A, ENST00000416093.1:c.*353T>A, ENST00000423275.5:c.*452T>A, ENST00000432427.2:n.412T>A, ENST00000442415.6:c.775T>A, ENST00000465826.5:n.19T>A, ENST00000491290.1:n.296T>A, NM_002880.3(RAF1):c.775T>A (p.Ser259Thr)	RAF1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Pathogenic	PM2, PP2, PP3, PP1, PM6_Strong, PS4_Supporting, PM1, PM5_Strong, PS3		The c.775T>A (p.Ser259Thr) variant in RAF1 has been reported in the literature in at least 2 unconfirmed de novo occurrences in patients with clinical features of a RASopathy (PM6_Strong; APHP-Robert Debré Hospital internal data; GTR ID's: 28338).  The p.Ser259Thr variant has been identified in at least 8 independent occurrences in patients with a RASopathy (PS4_Supporting; GeneDx, Partners LMM, Institute of Human Genetics, Otto von Guericke University Magdeburg internal data; GTR ID's: 26957, 21766, 506381 PMID: 21784453; ClinVar SCV000061360.5; SCV000209017.10). The p.Ser259Thr variant in RAF1 has been reported to segregate with clinical features of a RASopathy in at least 3 family members (PP1; GeneDx, Institute of Human Genetics, Otto von Guericke University Magdeburg internal data; GTR ID's: 26957, 506381; ClinVar SCV000209017.9). In vitro functional studies provide some evidence that the p.Ser259Thr variant may impact protein function (PS3; PMID: 21784453, 20052757). At least 2 other pathogenic missense variants have been previously identified at this codon of RAF1 which may indicate that this residue is critical to the function of the protein (PM5_Strong; ClinVar 40603, 40602, 228288). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of RAF1 (PM1; PMID 29493581). The variant is located in the RAF1 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Computational prediction tools and conservation analysis suggest that the p.Ser259Thr variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PM6_Strong, PS4_Supporting, PP1, PM5_Strong, PM2, PM1, PP2, PP3, PS3.	29493581	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2020-04-13	False	https://erepo.genome.network/evrepo/ui/classification/CA261617/MONDO:0021060/004	70e55828-a26c-447c-863d-156419f819e2	p.Ser259Thr	Ser	259	Thr	MEHIQGAWKTISNGFGFKDAVFDGSSCISPTIVQQFGYQRRASDDGKLTDPSKTSNTIRVFLPNKQRTVVNVRNGMSLHDCLMKALKVRGLQPECCAVFRLLHEHKGKKARLDWNTDAASLIGEELQVDFLDHVPLTTHNFARKTFLKLAFCDICQKFLLNGFRCQTCGYKFHEHCSTKVPTMCVDWSNIRQLLLFPNSTIGDSGVPALPSLTMRRMRESVSRMPVSSQHRYSTPHAFTFNTSSPSSEGSLSQRQRSTSTPNVHMVSTTLPVDSRMIEDAIRSHSESASPSALSSSPNNLSPTGWSQPKTPVPAQRERAPVSGTQEKNKIRPRGQRDSSYYWEIEASEVMLSTRIGSGSFGTVYKGKWHGDVAVKILKVVDPTPEQFQAFRNEVAVLRKTRHVNILLFMGYMTKDNLAIVTQWCEGSSLYKHLHVQETKFQMFQLIDIARQTAQGMDYLHAKNIIHRDMKSNNIFLHEGLTVKIGDFGLATVKSRWSGSQQVEQPTGSVLWMAPEVIRMQDNNPFSFQSDVYSYGIVLYELMTGELPYSHINNRDQIIFMVGRGYASPDLSKLYKNCPKAMKRLVADCVKKVKEERPLFPQILSSIELLQHSLPKINRSASEPSLHRAAHTEDINACTLTTSPRLPVF	648	P04049	T	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [131], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.00249964]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [240, 256, 283], 'COMPBIAS_gain': [], 'COMPBIAS_loss_score': array([-0.0255307 , -0.04810584, -0.02939147]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [266, 335], 'REGION_gain': [], 'REGION_loss_score': array([-0.05375618, -0.00505   ]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
46	NM_002880.3(RAF1):c.788T>G (p.Val263Gly)	40607	CA273745	NM_002880.3:c.788T>G, LRG_413t1:c.788T>G, XM_005265355.1:c.788T>G, XM_005265357.1:c.689T>G, XM_005265358.3:c.545T>G, XM_005265359.3:c.446T>G, XM_005265360.1:c.788T>G, XM_011533974.1:c.788T>G, XM_011533975.1:c.545T>G, NM_001354689.1:c.788T>G, NM_001354690.1:c.788T>G, NM_001354691.1:c.545T>G, NM_001354692.1:c.545T>G, NM_001354693.1:c.689T>G, NM_001354694.1:c.545T>G, NM_001354695.1:c.446T>G, NR_148940.1:n.1203T>G, NR_148941.1:n.1203T>G, NR_148942.1:n.1203T>G, XM_011533974.3:c.788T>G, XM_017006966.1:c.689T>G, XR_001740227.1:n.1020T>G, NM_001354689.3:c.788T>G, NM_001354690.2:c.788T>G, NM_001354691.2:c.545T>G, NM_001354692.2:c.545T>G, NM_001354693.2:c.689T>G, NM_001354694.2:c.545T>G, NM_001354695.2:c.446T>G, NR_148940.2:n.1119T>G, NR_148941.2:n.1119T>G, NR_148942.2:n.1119T>G, ENST00000251849.8:c.788T>G, ENST00000416093.1:c.*366T>G, ENST00000423275.5:c.*465T>G, ENST00000432427.2:n.425T>G, ENST00000442415.6:c.788T>G, ENST00000465826.5:n.32T>G, ENST00000491290.1:n.309T>G, NC_000003.12:g.12604182A>C, CM000665.2:g.12604182A>C, NC_000003.11:g.12645681A>C, CM000665.1:g.12645681A>C, NC_000003.10:g.12620681A>C, NG_007467.1:g.64998T>G, LRG_413:g.64998T>G, NM_002880.3(RAF1):c.788T>G (p.Val263Gly)	RAF1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Pathogenic	PM2, PP2, PP3, PM6_Strong, PM1, PS4	PM5	The c.788T>G (p.Val263Gly) variant in RAF1 has been reported as a de novo occurrence in at least two patients with clinical features of a RASopathy (PM6_Strong; PMID: 30732632; GeneDx internal data, ClinVar SCV000209021.10). The p.Val263Gly variant has been identified in at least 5 other independent occurrences in patients with a RASopathy (PS4; PMID: 30732632, 31560489, 31145547; Partners Laboratory for Molecular Medicine, Institute of Human Genetics, Otto von Guericke University Magdeburg internal data; ClinVar SCV000061370.6). This variant was absent from large population studies (PM2; gnomad.broadinstitute.org). Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of RAF1 (PM1; PMID 29493581). Different pathogenic missense variants have been previously identified at this codon of RAF1, which may indicate that this residue is critical to the function of the protein (PM5 not applied; ClinVar ID: 496189, 40608). The variant is located in the RAF1 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Computational prediction tools and conservation analysis suggest that the p.Val263Gly variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. RASopathy-specific ACMG/AMP criteria applied (PMID:29493581): PS4, PM6_Strong, PM1, PM2, PP2, PP3.	29493581	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2020-06-25	2020-07-01	False	https://erepo.genome.network/evrepo/ui/classification/CA273745/MONDO:0021060/004	fb3934fe-b004-493d-ac6a-987127cebac3	p.Val263Gly	Val	263	Gly	MEHIQGAWKTISNGFGFKDAVFDGSSCISPTIVQQFGYQRRASDDGKLTDPSKTSNTIRVFLPNKQRTVVNVRNGMSLHDCLMKALKVRGLQPECCAVFRLLHEHKGKKARLDWNTDAASLIGEELQVDFLDHVPLTTHNFARKTFLKLAFCDICQKFLLNGFRCQTCGYKFHEHCSTKVPTMCVDWSNIRQLLLFPNSTIGDSGVPALPSLTMRRMRESVSRMPVSSQHRYSTPHAFTFNTSSPSSEGSLSQRQRSTSTPNVHMVSTTLPVDSRMIEDAIRSHSESASPSALSSSPNNLSPTGWSQPKTPVPAQRERAPVSGTQEKNKIRPRGQRDSSYYWEIEASEVMLSTRIGSGSFGTVYKGKWHGDVAVKILKVVDPTPEQFQAFRNEVAVLRKTRHVNILLFMGYMTKDNLAIVTQWCEGSSLYKHLHVQETKFQMFQLIDIARQTAQGMDYLHAKNIIHRDMKSNNIFLHEGLTVKIGDFGLATVKSRWSGSQQVEQPTGSVLWMAPEVIRMQDNNPFSFQSDVYSYGIVLYELMTGELPYSHINNRDQIIFMVGRGYASPDLSKLYKNCPKAMKRLVADCVKKVKEERPLFPQILSSIELLQHSLPKINRSASEPSLHRAAHTEDINACTLTTSPRLPVF	648	P04049	G	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [235, 236, 237, 238, 239, 241, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 282, 309], 'COMPBIAS_gain_score': array([0.10569453, 0.13419861, 0.12049222, 0.13330173, 0.14936686,
       0.18283671, 0.30156296, 0.33537847, 0.32436681, 0.30327797,
       0.32245618, 0.3456744 , 0.31211823, 0.34799862, 0.32016021,
       0.31560904, 0.34712738, 0.07114279]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [226, 227, 267, 268, 269, 270, 271, 280], 'REGION_gain_score': array([0.01970589, 0.01733136, 0.32312322, 0.31335336, 0.30094111,
       0.24040282, 0.19777733, 0.13997501]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
47	NM_002880.3(RAF1):c.212A>G (p.Asn71Ser)	40588	CA134721	NM_002880.3:c.212A>G, LRG_413t1:c.212A>G, XM_005265355.1:c.212A>G, XM_005265357.1:c.212A>G, XM_005265358.3:c.78-2723A>G, XM_005265359.3:c.78-2723A>G, XM_005265360.1:c.212A>G, XM_011533974.1:c.212A>G, XM_011533975.1:c.78-2723A>G, NM_001354689.1:c.212A>G, NM_001354690.1:c.212A>G, NM_001354691.1:c.78-2723A>G, NM_001354692.1:c.78-2723A>G, NM_001354693.1:c.212A>G, NM_001354694.1:c.78-2723A>G, NM_001354695.1:c.78-2723A>G, NR_148940.1:n.627A>G, NR_148941.1:n.627A>G, NR_148942.1:n.627A>G, XM_011533974.3:c.212A>G, XM_017006966.1:c.212A>G, XR_001740227.1:n.543A>G, ENST00000251849.8:c.212A>G, ENST00000416093.1:c.208-2723A>G, ENST00000423275.5:c.208-2723A>G, ENST00000442415.6:c.212A>G, NC_000003.12:g.12612058T>C, CM000665.2:g.12612058T>C, NC_000003.11:g.12653557T>C, CM000665.1:g.12653557T>C, NC_000003.10:g.12628557T>C, NG_007467.1:g.57122A>G, LRG_413:g.57122A>G, NM_002880.3(RAF1):c.212A>G (p.Asn71Ser)	RAF1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.212A>G (p.Asn71Ser) variant in the RAF1 gene is 0.14% for Latino chromosomes by the Exome Aggregation Consortium (24/11578 with 95% CI), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert panel for autosomal dominant RASopathy variants (BA1).		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	False	https://erepo.genome.network/evrepo/ui/classification/CA134721/MONDO:0021060/004	bf556c8c-6cec-4e49-b9c7-2d92535a28ae	p.Asn71Ser	Asn	71	Ser	MEHIQGAWKTISNGFGFKDAVFDGSSCISPTIVQQFGYQRRASDDGKLTDPSKTSNTIRVFLPNKQRTVVNVRNGMSLHDCLMKALKVRGLQPECCAVFRLLHEHKGKKARLDWNTDAASLIGEELQVDFLDHVPLTTHNFARKTFLKLAFCDICQKFLLNGFRCQTCGYKFHEHCSTKVPTMCVDWSNIRQLLLFPNSTIGDSGVPALPSLTMRRMRESVSRMPVSSQHRYSTPHAFTFNTSSPSSEGSLSQRQRSTSTPNVHMVSTTLPVDSRMIEDAIRSHSESASPSALSSSPNNLSPTGWSQPKTPVPAQRERAPVSGTQEKNKIRPRGQRDSSYYWEIEASEVMLSTRIGSGSFGTVYKGKWHGDVAVKILKVVDPTPEQFQAFRNEVAVLRKTRHVNILLFMGYMTKDNLAIVTQWCEGSSLYKHLHVQETKFQMFQLIDIARQTAQGMDYLHAKNIIHRDMKSNNIFLHEGLTVKIGDFGLATVKSRWSGSQQVEQPTGSVLWMAPEVIRMQDNNPFSFQSDVYSYGIVLYELMTGELPYSHINNRDQIIFMVGRGYASPDLSKLYKNCPKAMKRLVADCVKKVKEERPLFPQILSSIELLQHSLPKINRSASEPSLHRAAHTEDINACTLTTSPRLPVF	648	P04049	S	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
48	NM_002880.3(RAF1):c.1082G>C (p.Gly361Ala)	40613	CA134687	NM_002880.3:c.1082G>C, NC_000003.12:g.12599717C>G, CM000665.2:g.12599717C>G, NC_000003.11:g.12641216C>G, CM000665.1:g.12641216C>G, NC_000003.10:g.12616216C>G, NG_007467.1:g.69463G>C, LRG_413:g.69463G>C, LRG_413t1:c.1082G>C, XM_005265355.1:c.1082G>C, XM_005265357.1:c.983G>C, XM_005265358.3:c.839G>C, XM_005265359.3:c.740G>C, XM_005265360.1:c.1082G>C, XM_011533974.1:c.1082G>C, XM_011533975.1:c.839G>C, NM_001354689.1:c.1142G>C, NM_001354690.1:c.1082G>C, NM_001354691.1:c.839G>C, NM_001354692.1:c.839G>C, NM_001354693.1:c.983G>C, NM_001354694.1:c.899G>C, NM_001354695.1:c.740G>C, NR_148940.1:n.1497G>C, NR_148941.1:n.1497G>C, NR_148942.1:n.1495G>C, XM_011533974.3:c.1082G>C, XM_017006966.1:c.983G>C, XR_001740227.1:n.1314G>C, ENST00000251849.8:c.1082G>C, ENST00000423275.5:c.*759G>C, ENST00000432427.2:n.719G>C, ENST00000442415.6:c.1142G>C, ENST00000460610.1:n.39G>C, ENST00000465826.5:n.326G>C, NM_002880.3(RAF1):c.1082G>C (p.Gly361Ala)	RAF1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Pathogenic	PM2, PP2, PP3, PM6_Strong, PS4_Moderate		The c.1082G>C (p.Gly361Ala) variant in RAF1 has been reported in the literature in at least 2 unconfirmed de novo occurrences in patients with clinical features of a RASopathy (PM6_Strong; GeneDx, Institute of Human Genetics, Otto von Guericke University Magdeburg internal data; GTR ID's: 26957, 506381 ClinVar SCV000209024.9). The p.Gly361Ala variant has been identified in at least 4 independent occurrences in patients with a RASopathy (PS4_Moderate; GeneDx, Partners LMM, Institute of Human Genetics, Otto von Guericke University Magdeburg internal data; GTR ID's: 26957, 21766, 506381;  SCV000209024.9, SCV000061333.5). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). The variant is located in the RAF1 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Computational prediction tools and conservation analysis suggest that the p.Gly361Ala variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as likely pathogenic for RASopathies in an autosomal dominant manner. RASopathy-specific ACMG/AMP criteria applied (PMID:29493581): PM6_Strong, PS4_Moderate, PM2, PP2, PP3.		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	False	https://erepo.genome.network/evrepo/ui/classification/CA134687/MONDO:0021060/004	04812bc6-1939-486b-9212-b10aa1e3260e	p.Gly361Ala	Gly	361	Ala	MEHIQGAWKTISNGFGFKDAVFDGSSCISPTIVQQFGYQRRASDDGKLTDPSKTSNTIRVFLPNKQRTVVNVRNGMSLHDCLMKALKVRGLQPECCAVFRLLHEHKGKKARLDWNTDAASLIGEELQVDFLDHVPLTTHNFARKTFLKLAFCDICQKFLLNGFRCQTCGYKFHEHCSTKVPTMCVDWSNIRQLLLFPNSTIGDSGVPALPSLTMRRMRESVSRMPVSSQHRYSTPHAFTFNTSSPSSEGSLSQRQRSTSTPNVHMVSTTLPVDSRMIEDAIRSHSESASPSALSSSPNNLSPTGWSQPKTPVPAQRERAPVSGTQEKNKIRPRGQRDSSYYWEIEASEVMLSTRIGSGSFGTVYKGKWHGDVAVKILKVVDPTPEQFQAFRNEVAVLRKTRHVNILLFMGYMTKDNLAIVTQWCEGSSLYKHLHVQETKFQMFQLIDIARQTAQGMDYLHAKNIIHRDMKSNNIFLHEGLTVKIGDFGLATVKSRWSGSQQVEQPTGSVLWMAPEVIRMQDNNPFSFQSDVYSYGIVLYELMTGELPYSHINNRDQIIFMVGRGYASPDLSKLYKNCPKAMKRLVADCVKKVKEERPLFPQILSSIELLQHSLPKINRSASEPSLHRAAHTEDINACTLTTSPRLPVF	648	P04049	A	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [131], 'STRAND_gain': [360, 377], 'STRAND_gain_score': array([0.12418818, 0.027511  ]), 'STRAND_loss_score': array([-0.00306064]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [335], 'REGION_gain': [], 'REGION_loss_score': array([-0.03740102]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
49	NM_002880.3(RAF1):c.119G>A (p.Arg40His)	40585	CA201617	NM_002880.3:c.119G>A, LRG_413t1:c.119G>A, XM_005265355.1:c.119G>A, XM_005265357.1:c.119G>A, XM_005265358.3:c.-12G>A, XM_005265359.3:c.-12G>A, XM_005265360.1:c.119G>A, XM_011533974.1:c.119G>A, XM_011533975.1:c.-12G>A, NM_001354689.1:c.119G>A, NM_001354690.1:c.119G>A, NM_001354691.1:c.-12G>A, NM_001354692.1:c.-12G>A, NM_001354693.1:c.119G>A, NM_001354694.1:c.-12G>A, NM_001354695.1:c.-12G>A, NR_148940.1:n.534G>A, NR_148941.1:n.534G>A, NR_148942.1:n.534G>A, XM_011533974.3:c.119G>A, XM_017006966.1:c.119G>A, XR_001740227.1:n.450G>A, ENST00000251849.8:c.119G>A, ENST00000416093.1:c.119G>A, ENST00000423275.5:c.119G>A, ENST00000442415.6:c.119G>A, NC_000003.12:g.12618603C>T, CM000665.2:g.12618603C>T, NC_000003.11:g.12660102C>T, CM000665.1:g.12660102C>T, NC_000003.10:g.12635102C>T, NG_007467.1:g.50577G>A, LRG_413:g.50577G>A, NM_002880.3(RAF1):c.119G>A (p.Arg40His)	RAF1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1, BP5, BS4		The filtering allele frequency of the c.119G>A (p.Arg40His) variant in the RAF1 gene is 0.082% for Latino chromosomes by the Exome Aggregation Consortium (112/11578 with 95% CI), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert panel for autosomal dominant RASopathy variants (BA1). Additionally, the variant did not segregate with disease in affected family members (BS4; GeneDx internal data; GTR ID: 26957; ClinVar SCV000171283.11; SCV000227278.4). This variant has been identified in a patient with an alternate molecular basis for disease (BP5; GeneDx internal data; GTR ID: 26957; SCV000171283.11). In summary, this variant meets criteria to be classified as benign. RASopathy-specific ACMG/AMP criteria applied (PMID:29493581): BA1, BS4, BP5.		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	False	https://erepo.genome.network/evrepo/ui/classification/CA201617/MONDO:0021060/004	e3a025b8-32a2-4d0f-92e0-d44516304ddc	p.Arg40His	Arg	40	His	MEHIQGAWKTISNGFGFKDAVFDGSSCISPTIVQQFGYQRRASDDGKLTDPSKTSNTIRVFLPNKQRTVVNVRNGMSLHDCLMKALKVRGLQPECCAVFRLLHEHKGKKARLDWNTDAASLIGEELQVDFLDHVPLTTHNFARKTFLKLAFCDICQKFLLNGFRCQTCGYKFHEHCSTKVPTMCVDWSNIRQLLLFPNSTIGDSGVPALPSLTMRRMRESVSRMPVSSQHRYSTPHAFTFNTSSPSSEGSLSQRQRSTSTPNVHMVSTTLPVDSRMIEDAIRSHSESASPSALSSSPNNLSPTGWSQPKTPVPAQRERAPVSGTQEKNKIRPRGQRDSSYYWEIEASEVMLSTRIGSGSFGTVYKGKWHGDVAVKILKVVDPTPEQFQAFRNEVAVLRKTRHVNILLFMGYMTKDNLAIVTQWCEGSSLYKHLHVQETKFQMFQLIDIARQTAQGMDYLHAKNIIHRDMKSNNIFLHEGLTVKIGDFGLATVKSRWSGSQQVEQPTGSVLWMAPEVIRMQDNNPFSFQSDVYSYGIVLYELMTGELPYSHINNRDQIIFMVGRGYASPDLSKLYKNCPKAMKRLVADCVKKVKEERPLFPQILSSIELLQHSLPKINRSASEPSLHRAAHTEDINACTLTTSPRLPVF	648	P04049	H	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [131], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.02135122]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [227], 'REGION_gain_score': array([0.00543934]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
50	NM_002834.4(PTPN11):c.781C>T (p.Leu261Phe)	40520	CA235373	NM_002834.4:c.781C>T, NM_002834.3:c.781C>T, LRG_614t1:c.781C>T, NM_080601.1:c.781C>T, XM_006719526.1:c.781C>T, XM_006719527.1:c.667C>T, XM_011538613.1:c.778C>T, NM_001330437.1:c.781C>T, NM_080601.2:c.781C>T, XM_011538613.2:c.778C>T, XM_017019722.1:c.778C>T, ENST00000351677.6:c.781C>T, ENST00000392597.5:c.781C>T, ENST00000635625.1:n.781C>T, NC_000012.12:g.112472968C>T, CM000674.2:g.112472968C>T, NC_000012.11:g.112910772C>T, CM000674.1:g.112910772C>T, NC_000012.10:g.111395155C>T, NG_007459.1:g.59237C>T, LRG_614:g.59237C>T, NM_002834.4(PTPN11):c.781C>T (p.Leu261Phe)	PTPN11	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Pathogenic	PM2, PP2, PM6_Strong, PM1, PS4_Moderate		The c.781C>T (p.Leu261Phe) variant in PTPN11 has been reported in the literature in at least 2 unconfirmed de novo occurrences in patients with clinical features of a RASopathy (PM6_Strong; PMID 22465605; GeneDx, Cave lab internal data ClinVar SCV000057404.12). The p.Leu261Phe variant has also been identified in at least 4 independent occurrences in patients with a RASopathy (PS4_Moderate; Partners LMM, Institute of Human Genetics, Otto von Guericke University Magdeburg,  APHP-Robert Debré Hospital internal data; GTR ID's: 21766, 506381, 28338; SCV000061319.5, SCV000207687.1 PMID: 22465605). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of PTPN11 (PM1; PMID 29493581). The variant is located in the PTPN11 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PM6_Strong, PS4_Moderate, PM2, PM1, PP2.	29493581, 22465605	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	False	https://erepo.genome.network/evrepo/ui/classification/CA235373/MONDO:0021060/004	90bd1343-a396-445b-985c-d23c393118d4	p.Leu261Phe	Leu	261	Phe	MTSRRWFHPNITGVEAENLLLTRGVDGSFLARPSKSNPGDFTLSVRRNGAVTHIKIQNTGDYYDLYGGEKFATLAELVQYYMEHHGQLKEKNGDVIELKYPLNCADPTSERWFHGHLSGKEAEKLLTEKGKHGSFLVRESQSHPGDFVLSVRTGDDKGESNDGKSKVTHVMIRCQELKYDVGGGERFDSLTDLVEHYKKNPMVETLGTVLQLKQPLNTTRINAAEIESRVRELSKLAETTDKVKQGFWEEFETLQQQECKLLYSRKEGQRQENKNKNRYKNILPFDHTRVVLHDGDPNEPVSDYINANIIMPEFETKCNNSKPKKSYIATQGCLQNTVNDFWRMVFQENSRVIVMTTKEVERGKSKCVKYWPDEYALKEYGVMRVRNVKESAAHDYTLRELKLSKVGQGNTERTVWQYHFRTWPDHGVPSDPGGVLDFLEEVHHKQESIMDAGPVVVHCSAGIGRTGTFIVIDILIDIIREKGVDCDIDVPKTIQMVRSQRSGMVQTEAQYRFIYMAVQHYIETLQRRIEEEQKSKRKGHEYTNIKYSLADQTSGDQSPLPPCTPTPPCAEMREDSARVYENVGLMQQQKSFR	593	Q06124	F	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [263], 'HELIX_gain': [528], 'HELIX_gain_score': array([0.00240356]), 'HELIX_loss_score': array([-0.04813355]), 'COILED_loss': [], 'COILED_gain': [215, 216], 'COILED_gain_score': array([0.02196485, 0.0234645 ]), 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [94], 'DOMAIN_gain_score': array([0.00214028]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
51	NM_002834.4(PTPN11):c.1658C>T (p.Thr553Met)	40570	CA134644	NM_002834.4:c.1658C>T, NM_002834.3:c.1658C>T, LRG_614t1:c.1658C>T, XM_006719526.1:c.1670C>T, XM_006719527.1:c.1556C>T, XM_011538613.1:c.1667C>T, NM_001330437.1:c.1670C>T, XM_011538613.2:c.1667C>T, XM_017019722.1:c.1655C>T, ENST00000351677.6:c.1658C>T, ENST00000635625.1:n.1670C>T, NC_000012.12:g.112502202C>T, CM000674.2:g.112502202C>T, NC_000012.11:g.112940006C>T, CM000674.1:g.112940006C>T, NC_000012.10:g.111424389C>T, NG_007459.1:g.88471C>T, LRG_614:g.88471C>T, NM_002834.4(PTPN11):c.1658C>T (p.Thr553Met)	PTPN11	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1, BP4		The filtering allele frequency of the c.1658C>T (p.Thr553Met) variant in the PTPN11 gene is 0.048% for European (Non-Finnish) chromosomes by the Exome Aggregation Consortium (49/66556 with 95% CI), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert panel for autosomal dominant RASopathy variants (BA1). Computational prediction tools and conservation analysis suggest that the p.Thr553Met variant does not impact the protein (BP4). In summary, this variant meets criteria to be classified as benign. RASopathy-specific ACMG/AMP criteria applied (PMID:29493581):  BA1, BP4.		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	False	https://erepo.genome.network/evrepo/ui/classification/CA134644/MONDO:0021060/004	8b509a72-e8ae-4215-92db-567fba446b08	p.Thr553Met	Thr	553	Met	MTSRRWFHPNITGVEAENLLLTRGVDGSFLARPSKSNPGDFTLSVRRNGAVTHIKIQNTGDYYDLYGGEKFATLAELVQYYMEHHGQLKEKNGDVIELKYPLNCADPTSERWFHGHLSGKEAEKLLTEKGKHGSFLVRESQSHPGDFVLSVRTGDDKGESNDGKSKVTHVMIRCQELKYDVGGGERFDSLTDLVEHYKKNPMVETLGTVLQLKQPLNTTRINAAEIESRVRELSKLAETTDKVKQGFWEEFETLQQQECKLLYSRKEGQRQENKNKNRYKNILPFDHTRVVLHDGDPNEPVSDYINANIIMPEFETKCNNSKPKKSYIATQGCLQNTVNDFWRMVFQENSRVIVMTTKEVERGKSKCVKYWPDEYALKEYGVMRVRNVKESAAHDYTLRELKLSKVGQGNTERTVWQYHFRTWPDHGVPSDPGGVLDFLEEVHHKQESIMDAGPVVVHCSAGIGRTGTFIVIDILIDIIREKGVDCDIDVPKTIQMVRSQRSGMVQTEAQYRFIYMAVQHYIETLQRRIEEEQKSKRKGHEYTNIKYSLADQTSGDQSPLPPCTPTPPCAEMREDSARVYENVGLMQQQKSFR	593	Q06124	M	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [303], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.00044686]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [564], 'COMPBIAS_gain_score': array([0.23685318]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [548, 549, 550, 551, 570, 571], 'REGION_gain': [], 'REGION_loss_score': array([-0.24410033, -0.34211081, -0.40932852, -0.39946461, -0.2737394 ,
       -0.13249874]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
52	NM_002834.4(PTPN11):c.1530G>C (p.Gln510His)	40567	CA220143	NM_002834.4:c.1530G>C, NC_000012.12:g.112489106G>C, CM000674.2:g.112489106G>C, NC_000012.11:g.112926910G>C, CM000674.1:g.112926910G>C, NC_000012.10:g.111411293G>C, NG_007459.1:g.75375G>C, LRG_614:g.75375G>C, NM_002834.3:c.1530G>C, LRG_614t1:c.1530G>C, XM_006719526.1:c.1542G>C, XM_006719527.1:c.1428G>C, XM_011538613.1:c.1539G>C, NM_001330437.1:c.1542G>C, XM_011538613.2:c.1539G>C, XM_017019722.1:c.1527G>C, ENST00000351677.6:c.1530G>C, ENST00000635625.1:n.1542G>C, ENST00000635652.1:n.543G>C, NM_002834.4(PTPN11):c.1530G>C (p.Gln510His)	PTPN11	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Pathogenic	PM2, PP2, PP3, PM6_Strong, PM5_Strong		The c.1530G>C (p.Gln510His) variant in PTPN11 has been reported in the literature in at least 2 unconfirmed de novo occurrences in patients with clinical features of a RASopathy (PM6_Strong; GeneDx, EGL, APHP-Robert Debré Hospital internal data; GTR ID's: 26957, 500060, 28338 ClinVar SCV000057460.11; SCV000331072.3). At least 2 other pathogenic missense variants have been previously identified at this codon of PTPN11 which may indicate that this residue is critical to the function of the protein (PM5_Strong; ClinVar 40566, 13345, 13344). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). The variant is located in the PTPN11 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Computational prediction tools and conservation analysis suggest that the p.Gln510His variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. ACMG/AMP criteria applied: PM6_Strong, PM5_Strong, PM2, PP3, PP2.		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	False	https://erepo.genome.network/evrepo/ui/classification/CA220143/MONDO:0021060/004	c1682ae1-ce46-41b9-b916-5efef827298a	p.Gln510His	Gln	510	His	MTSRRWFHPNITGVEAENLLLTRGVDGSFLARPSKSNPGDFTLSVRRNGAVTHIKIQNTGDYYDLYGGEKFATLAELVQYYMEHHGQLKEKNGDVIELKYPLNCADPTSERWFHGHLSGKEAEKLLTEKGKHGSFLVRESQSHPGDFVLSVRTGDDKGESNDGKSKVTHVMIRCQELKYDVGGGERFDSLTDLVEHYKKNPMVETLGTVLQLKQPLNTTRINAAEIESRVRELSKLAETTDKVKQGFWEEFETLQQQECKLLYSRKEGQRQENKNKNRYKNILPFDHTRVVLHDGDPNEPVSDYINANIIMPEFETKCNNSKPKKSYIATQGCLQNTVNDFWRMVFQENSRVIVMTTKEVERGKSKCVKYWPDEYALKEYGVMRVRNVKESAAHDYTLRELKLSKVGQGNTERTVWQYHFRTWPDHGVPSDPGGVLDFLEEVHHKQESIMDAGPVVVHCSAGIGRTGTFIVIDILIDIIREKGVDCDIDVPKTIQMVRSQRSGMVQTEAQYRFIYMAVQHYIETLQRRIEEEQKSKRKGHEYTNIKYSLADQTSGDQSPLPPCTPTPPCAEMREDSARVYENVGLMQQQKSFR	593	Q06124	H	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [527, 528], 'HELIX_gain_score': array([0.02103573, 0.0212    ]), 'COILED_loss': [], 'COILED_gain': [245], 'COILED_gain_score': array([0.00792575]), 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
53	NM_002834.4(PTPN11):c.925A>G (p.Ile309Val)	40536	CA177674	NM_002834.4:c.925A>G, NM_002834.3:c.925A>G, LRG_614t1:c.925A>G, NM_080601.1:c.925A>G, XM_006719526.1:c.925A>G, XM_006719527.1:c.811A>G, XM_011538613.1:c.922A>G, NM_001330437.1:c.925A>G, NM_080601.2:c.925A>G, XM_011538613.2:c.922A>G, XM_017019722.1:c.922A>G, ENST00000351677.6:c.925A>G, ENST00000392597.5:c.925A>G, ENST00000635625.1:n.925A>G, NC_000012.12:g.112477722A>G, CM000674.2:g.112477722A>G, NC_000012.11:g.112915526A>G, CM000674.1:g.112915526A>G, NC_000012.10:g.111399909A>G, NG_007459.1:g.63991A>G, LRG_614:g.63991A>G, NM_002834.4(PTPN11):c.925A>G (p.Ile309Val)	PTPN11	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.925A>G (p.Ile309Val) variant in the PTPN11 gene is 0.04% for European (Non-Finnish) chromosomes by the Exome Aggregation Consortium (46/66736 with 95% CI), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert panel for autosomal dominant RASopathy variants (BA1).		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	False	https://erepo.genome.network/evrepo/ui/classification/CA177674/MONDO:0021060/004	4cec7b98-aaab-4623-a50c-b195372c6afa	p.Ile309Val	Ile	309	Val	MTSRRWFHPNITGVEAENLLLTRGVDGSFLARPSKSNPGDFTLSVRRNGAVTHIKIQNTGDYYDLYGGEKFATLAELVQYYMEHHGQLKEKNGDVIELKYPLNCADPTSERWFHGHLSGKEAEKLLTEKGKHGSFLVRESQSHPGDFVLSVRTGDDKGESNDGKSKVTHVMIRCQELKYDVGGGERFDSLTDLVEHYKKNPMVETLGTVLQLKQPLNTTRINAAEIESRVRELSKLAETTDKVKQGFWEEFETLQQQECKLLYSRKEGQRQENKNKNRYKNILPFDHTRVVLHDGDPNEPVSDYINANIIMPEFETKCNNSKPKKSYIATQGCLQNTVNDFWRMVFQENSRVIVMTTKEVERGKSKCVKYWPDEYALKEYGVMRVRNVKESAAHDYTLRELKLSKVGQGNTERTVWQYHFRTWPDHGVPSDPGGVLDFLEEVHHKQESIMDAGPVVVHCSAGIGRTGTFIVIDILIDIIREKGVDCDIDVPKTIQMVRSQRSGMVQTEAQYRFIYMAVQHYIETLQRRIEEEQKSKRKGHEYTNIKYSLADQTSGDQSPLPPCTPTPPCAEMREDSARVYENVGLMQQQKSFR	593	Q06124	V	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [303], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.01176715]), 'HELIX_loss': [], 'HELIX_gain': [528], 'HELIX_gain_score': array([0.00049984]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [94], 'DOMAIN_gain_score': array([0.00656754]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
54	NM_002834.4(PTPN11):c.794G>A (p.Arg265Gln)	40522	CA234739	NM_002834.4:c.794G>A, NC_000012.12:g.112472981G>A, CM000674.2:g.112472981G>A, NC_000012.11:g.112910785G>A, CM000674.1:g.112910785G>A, NC_000012.10:g.111395168G>A, NG_007459.1:g.59250G>A, LRG_614:g.59250G>A, NM_002834.3:c.794G>A, LRG_614t1:c.794G>A, NM_080601.1:c.794G>A, XM_006719526.1:c.794G>A, XM_006719527.1:c.680G>A, XM_011538613.1:c.791G>A, NM_001330437.1:c.794G>A, NM_080601.2:c.794G>A, XM_011538613.2:c.791G>A, XM_017019722.1:c.791G>A, ENST00000351677.6:c.794G>A, ENST00000392597.5:c.794G>A, ENST00000635625.1:n.794G>A, NM_002834.4(PTPN11):c.794G>A (p.Arg265Gln)	PTPN11	Noonan syndrome	MONDO:0018997	Autosomal dominant inheritance	Pathogenic	PS2_Very Strong, PP2, PP1, PM1, PS4_Moderate, PS3		The c.794G>A p.Arg265Gln variant in PTPN11 has been reported as a confirmed de novo occurrence in at least 2 patients with clinical features of a RASopathy (PS2_VeryStrong; GeneDx, Partners LMM, Institute of Human Genetics, Otto von Guericke University Magdeburg, APHP-Robert Debré Hospital internal data; GTR ID's:26957, 21766, 506381, 28338; ClinVar SCV000203366.6; SCV000061320.5; SCV000057406.11; SCV000207688.1). The variant has been reported in the literature to segregate with clinical features of a RASopathy in at least 3 family members (PP1; APHP-Robert Debré Hospital internal data; GTR ID: 28338). The p.Arg265Gln variant has been identified in 2 independent occurrences in patients with a RASopathy (PS4_Moderate; GeneDx, LMM, Institute of Human Genetics, Otto von Guericke University Magdeburg, APHP-Robert Debré Hospital internal data; GTR Lab ID: 26957, 21766, 506381, 28338; SCV000203366.6; SCV000061320.5; SCV000057406.11; SCV000207688.1). In vitro functional studies provide some evidence that the p.Arg265Gln variant may impact protein function (PS3; PMID 28074573). Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of PTPN11 (PM1; PMID 29493581). The variant is located in the PTPN11 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. ACMG/AMP criteria applied: PS2_VeryStrong, PP1, PS4_Moderate, PS3, PM1, PP2.	29493581, 28074573	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	False	https://erepo.genome.network/evrepo/ui/classification/CA234739/MONDO:0018997/004	0478380b-41bf-443f-bb02-184b55a7aba8	p.Arg265Gln	Arg	265	Gln	MTSRRWFHPNITGVEAENLLLTRGVDGSFLARPSKSNPGDFTLSVRRNGAVTHIKIQNTGDYYDLYGGEKFATLAELVQYYMEHHGQLKEKNGDVIELKYPLNCADPTSERWFHGHLSGKEAEKLLTEKGKHGSFLVRESQSHPGDFVLSVRTGDDKGESNDGKSKVTHVMIRCQELKYDVGGGERFDSLTDLVEHYKKNPMVETLGTVLQLKQPLNTTRINAAEIESRVRELSKLAETTDKVKQGFWEEFETLQQQECKLLYSRKEGQRQENKNKNRYKNILPFDHTRVVLHDGDPNEPVSDYINANIIMPEFETKCNNSKPKKSYIATQGCLQNTVNDFWRMVFQENSRVIVMTTKEVERGKSKCVKYWPDEYALKEYGVMRVRNVKESAAHDYTLRELKLSKVGQGNTERTVWQYHFRTWPDHGVPSDPGGVLDFLEEVHHKQESIMDAGPVVVHCSAGIGRTGTFIVIDILIDIIREKGVDCDIDVPKTIQMVRSQRSGMVQTEAQYRFIYMAVQHYIETLQRRIEEEQKSKRKGHEYTNIKYSLADQTSGDQSPLPPCTPTPPCAEMREDSARVYENVGLMQQQKSFR	593	Q06124	Q	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [288, 303], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.01130146, -0.01644802]), 'HELIX_loss': [530], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.00688475]), 'COILED_loss': [], 'COILED_gain': [245], 'COILED_gain_score': array([0.00986189]), 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [94], 'DOMAIN_gain_score': array([0.00913757]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
55	NM_002834.4(PTPN11):c.1529A>C (p.Gln510Pro)	13344	CA256758	NM_002834.4:c.1529A>C, NM_002834.3:c.1529A>C, LRG_614t1:c.1529A>C, XM_006719526.1:c.1541A>C, XM_006719527.1:c.1427A>C, XM_011538613.1:c.1538A>C, NM_001330437.1:c.1541A>C, XM_011538613.2:c.1538A>C, XM_017019722.1:c.1526A>C, ENST00000351677.6:c.1529A>C, ENST00000635625.1:n.1541A>C, ENST00000635652.1:n.542A>C, NC_000012.12:g.112489105A>C, CM000674.2:g.112489105A>C, NC_000012.11:g.112926909A>C, CM000674.1:g.112926909A>C, NC_000012.10:g.111411292A>C, NG_007459.1:g.75374A>C, LRG_614:g.75374A>C, NM_002834.4(PTPN11):c.1529A>C (p.Gln510Pro)	PTPN11	Noonan syndrome with multiple lentigines	MONDO:0007893	Autosomal dominant inheritance	Pathogenic	PP1_Moderate, PS2_Very Strong, PM2, PP2, PP3, PS4_Supporting		The c.1529A>C (p.Gln510Pro) variant in PTPN11 has been reported as a confirmed de novo occurrence in at least 2 patients with clinical features of a RASopathy (PS2_VeryStrong; Partners LMM, GeneDx, Institute of Human Genetics, Otto von Guericke University Magdeburg internal data, APHP-Robert Debré Hospital; SCV000057459.14; SCV000200027.4; SCV000265844.1;. PMID 15520399, 20578946).  The p.Gln510Pro variant in PTPN11 has been reported in the literature to segregate with clinical features of a RASopathy in at least 4 family members (PP1_Moderate; APHP-Robert Debré Hospital: GTR Lab ID: 28338). The variant has also been identified in at least 2 independent occurrences in patients with clinical features of a RASopathy (PS4_Supporting; Partners LMM, GeneDx, Institute of Human Genetics, Otto von Guericke University Magdeburg internal data, APHP-Robert Debré Hospital; SCV000057459.14; SCV000200027.4; SCV000265844.1;. PMID 15520399, 20578946). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). The variant is in PTPN11, which has been defined by the ClinGen RASopathy Expert Panel as a gene with low rate of benign missense with missense variants commonly being pathogenic (PP2; PMID 29493581). Computational prediction tools and conservation analysis suggest that the p.Gln510Pro variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. ACMG/AMP criteria applied: PS2_VeryStrong, PP1_Moderate, PM2, PP2, PP3, PS4_Supporting.	20578946, 15520399	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	False	https://erepo.genome.network/evrepo/ui/classification/CA256758/MONDO:0007893/004	74aa9bfb-79b2-4d78-8440-29866a548c82	p.Gln510Pro	Gln	510	Pro	MTSRRWFHPNITGVEAENLLLTRGVDGSFLARPSKSNPGDFTLSVRRNGAVTHIKIQNTGDYYDLYGGEKFATLAELVQYYMEHHGQLKEKNGDVIELKYPLNCADPTSERWFHGHLSGKEAEKLLTEKGKHGSFLVRESQSHPGDFVLSVRTGDDKGESNDGKSKVTHVMIRCQELKYDVGGGERFDSLTDLVEHYKKNPMVETLGTVLQLKQPLNTTRINAAEIESRVRELSKLAETTDKVKQGFWEEFETLQQQECKLLYSRKEGQRQENKNKNRYKNILPFDHTRVVLHDGDPNEPVSDYINANIIMPEFETKCNNSKPKKSYIATQGCLQNTVNDFWRMVFQENSRVIVMTTKEVERGKSKCVKYWPDEYALKEYGVMRVRNVKESAAHDYTLRELKLSKVGQGNTERTVWQYHFRTWPDHGVPSDPGGVLDFLEEVHHKQESIMDAGPVVVHCSAGIGRTGTFIVIDILIDIIREKGVDCDIDVPKTIQMVRSQRSGMVQTEAQYRFIYMAVQHYIETLQRRIEEEQKSKRKGHEYTNIKYSLADQTSGDQSPLPPCTPTPPCAEMREDSARVYENVGLMQQQKSFR	593	Q06124	P	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [529, 530], 'HELIX_gain': [235], 'HELIX_gain_score': array([0.02352881]), 'HELIX_loss_score': array([-0.0452829 , -0.03272653]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [519], 'DOMAIN_gain': [94], 'DOMAIN_gain_score': array([0.01047409]), 'DOMAIN_loss_score': array([-0.0530802]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
56	NM_002834.4(PTPN11):c.155C>T (p.Thr52Ile)	40484	CA261555	NM_002834.4:c.155C>T, NM_002834.3:c.155C>T, LRG_614t1:c.155C>T, NM_080601.1:c.155C>T, XM_006719526.1:c.155C>T, XM_006719527.1:c.155C>T, XM_011538613.1:c.152C>T, NM_001330437.1:c.155C>T, NM_080601.2:c.155C>T, XM_011538613.2:c.152C>T, XM_017019722.1:c.152C>T, NM_001330437.2:c.155C>T, NM_001374625.1:c.152C>T, NM_002834.5:c.155C>T, NM_080601.3:c.155C>T, ENST00000351677.6:c.155C>T, ENST00000392597.5:c.155C>T, ENST00000635625.1:n.155C>T, NC_000012.12:g.112450335C>T, CM000674.2:g.112450335C>T, NC_000012.11:g.112888139C>T, CM000674.1:g.112888139C>T, NC_000012.10:g.111372522C>T, NG_007459.1:g.36604C>T, LRG_614:g.36604C>T, NM_002834.4(PTPN11):c.155C>T (p.Thr52Ile)	PTPN11	Noonan syndrome	MONDO:0018997	Autosomal dominant inheritance	Pathogenic	PM6, PM2, PP2, PP3, PS4		The c.155C>T (p.Thr52Ile) variant in PTPN11 has been identified in more than 5 independent occurrences in patients with a RASopathy (PS4; PMID: 22465605, 25804457, 32059087, GeneDx, Partners Laboratory for Molecular Medicine, Institute of Human Genetics, Otto von Guericke University Magdeburg internal data; ClinVar SCV000057357.11, SCV000061283.5). It was observed as a de novo occurrence without maternity or paternity confirmed in one proband with clinical features of a RASopathy (PM6; Hopital Universitaire Robert Debre internal data). This variant was absent from large population studies (PM2; gnomad.broadinstitute.org). Computational prediction tools and conservation analysis suggest that the p.Thr52Ile variant may impact the protein (PP3). The variant is located in the PTPN11 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. RASopathy-specific ACMG/AMP criteria applied (PMID:29493581): PS4, PM6_Strong, PM2, PP2, PP3.		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2020-05-18	2020-07-01	False	https://erepo.genome.network/evrepo/ui/classification/CA261555/MONDO:0018997/004	c650daaa-d00c-411a-9439-fe0b0570e53e	p.Thr52Ile	Thr	52	Ile	MTSRRWFHPNITGVEAENLLLTRGVDGSFLARPSKSNPGDFTLSVRRNGAVTHIKIQNTGDYYDLYGGEKFATLAELVQYYMEHHGQLKEKNGDVIELKYPLNCADPTSERWFHGHLSGKEAEKLLTEKGKHGSFLVRESQSHPGDFVLSVRTGDDKGESNDGKSKVTHVMIRCQELKYDVGGGERFDSLTDLVEHYKKNPMVETLGTVLQLKQPLNTTRINAAEIESRVRELSKLAETTDKVKQGFWEEFETLQQQECKLLYSRKEGQRQENKNKNRYKNILPFDHTRVVLHDGDPNEPVSDYINANIIMPEFETKCNNSKPKKSYIATQGCLQNTVNDFWRMVFQENSRVIVMTTKEVERGKSKCVKYWPDEYALKEYGVMRVRNVKESAAHDYTLRELKLSKVGQGNTERTVWQYHFRTWPDHGVPSDPGGVLDFLEEVHHKQESIMDAGPVVVHCSAGIGRTGTFIVIDILIDIIREKGVDCDIDVPKTIQMVRSQRSGMVQTEAQYRFIYMAVQHYIETLQRRIEEEQKSKRKGHEYTNIKYSLADQTSGDQSPLPPCTPTPPCAEMREDSARVYENVGLMQQQKSFR	593	Q06124	I	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [111, 303], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.01258582, -0.00418466]), 'HELIX_loss': [530], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.00821191]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [94, 95], 'DOMAIN_gain_score': array([0.12112927, 0.10834962]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
57	NM_030662.3(MAP2K2):c.1162C>T (p.Arg388Trp)	40843	CA180895	NM_030662.3:c.1162C>T, NC_000019.10:g.4090639G>A, CM000681.2:g.4090639G>A, NC_000019.9:g.4090637G>A, CM000681.1:g.4090637G>A, NC_000019.8:g.4041637G>A, NG_007996.1:g.38490C>T, LRG_750:g.38490C>T, LRG_750t1:c.1162C>T, XM_006722799.2:c.883C>T, XM_011528133.1:c.592C>T, ENST00000262948.9:c.1162C>T, ENST00000394867.8:c.871C>T, ENST00000597263.5:n.347C>T, ENST00000599021.1:n.272C>T, ENST00000600584.5:n.2611C>T, ENST00000601786.5:n.1463C>T, NM_030662.3(MAP2K2):c.1162C>T (p.Arg388Trp)	MAP2K2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.1162C>T (p.Arg388Trp) variant in the MAP2K2 gene is 0.125% for African chromosomes by the Exome Aggregation Consortium (25/2788 with 95% CI), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert panel for autosomal dominant RASopathy variants (BA1). Additional case-level data available: SCV000204180.4; SCV000252871.4.		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-05-09	2018-12-10	False	https://erepo.genome.network/evrepo/ui/classification/CA180895/MONDO:0021060/004	a8067cbf-1dd7-4aab-bdb7-dfb3edfdaedf	p.Arg388Trp	Arg	388	Trp	MLARRKPVLPALTINPTIAEGPSPTSEGASEANLVDLQKKLEELELDEQQKKRLEAFLTQKAKVGELKDDDFERISELGAGNGGVVTKVQHRPSGLIMARKLIHLEIKPAIRNQIIRELQVLHECNSPYIVGFYGAFYSDGEISICMEHMDGGSLDQVLKEAKRIPEEILGKVSIAVLRGLAYLREKHQIMHRDVKPSNILVNSRGEIKLCDFGVSGQLIDSMANSFVGTRSYMAPERLQGTHYSVQSDIWSMGLSLVELAVGRYPIPPPDAKELEAIFGRPVVDGEEGEPHSISPRPRPPGRPVSGHGMDSRPAMAIFELLDYIVNEPPPKLPNGVFTPDFQEFVNKCLIKNPAERADLKMLTNHTFIKRSEVEEVDFAGWLCKTLRLNQPGTPTRTAV	400	P36507	W	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [387], 'HELIX_gain_score': array([0.15793079]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [289], 'COMPBIAS_gain_score': array([0.06816095]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
58	NM_030662.3(MAP2K2):c.844C>T (p.Pro282Ser)	40826	CA137972	NM_030662.3:c.844C>T, LRG_750t1:c.844C>T, XM_006722799.2:c.705+1743C>T, XM_011528133.1:c.274C>T, XM_017026989.1:c.844C>T, XM_017026990.1:c.705+1743C>T, ENST00000262948.9:c.844C>T, ENST00000394867.8:c.553C>T, ENST00000593364.5:n.791C>T, ENST00000595715.1:n.659C>T, ENST00000597263.5:n.169+1743C>T, ENST00000599021.1:n.29+1743C>T, ENST00000600584.5:n.1404C>T, ENST00000601786.5:n.1145C>T, NC_000019.10:g.4099276G>A, CM000681.2:g.4099276G>A, NC_000019.9:g.4099274G>A, CM000681.1:g.4099274G>A, NC_000019.8:g.4050274G>A, NG_007996.1:g.29853C>T, LRG_750:g.29853C>T, NM_030662.3(MAP2K2):c.844C>T (p.Pro282Ser)	MAP2K2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1, BP5		The filtering allele frequency of the c.844C>T (p.Pro282Ser) variant in the MAP2K2 gene is 0.029% for African chromosomes by the Exome Aggregation Consortium (19/6048 with 95% CI), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert panel for autosomal dominant RASopathy variants (BA1).This variant has been identified in a patient with an alternate molecular basis for disease (BP5; GeneDx internal data; GTR ID's 26957; SCV000207963.8). In summary, this variant meets criteria to be classified as benign. RASopathy-specific ACMG/AMP criteria applied (PMID:29493581): BA1, BP5.		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-05-09	2018-12-10	False	https://erepo.genome.network/evrepo/ui/classification/CA137972/MONDO:0021060/004	413325d3-6867-4b66-a6a6-655f337675bc	p.Pro282Ser	Pro	282	Ser	MLARRKPVLPALTINPTIAEGPSPTSEGASEANLVDLQKKLEELELDEQQKKRLEAFLTQKAKVGELKDDDFERISELGAGNGGVVTKVQHRPSGLIMARKLIHLEIKPAIRNQIIRELQVLHECNSPYIVGFYGAFYSDGEISICMEHMDGGSLDQVLKEAKRIPEEILGKVSIAVLRGLAYLREKHQIMHRDVKPSNILVNSRGEIKLCDFGVSGQLIDSMANSFVGTRSYMAPERLQGTHYSVQSDIWSMGLSLVELAVGRYPIPPPDAKELEAIFGRPVVDGEEGEPHSISPRPRPPGRPVSGHGMDSRPAMAIFELLDYIVNEPPPKLPNGVFTPDFQEFVNKCLIKNPAERADLKMLTNHTFIKRSEVEEVDFAGWLCKTLRLNQPGTPTRTAV	400	P36507	S	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [37, 41], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.00462162, -0.00311685]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [290, 291], 'COMPBIAS_gain': [], 'COMPBIAS_loss_score': array([-0.13544452, -0.10826218]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [283], 'REGION_gain': [], 'REGION_loss_score': array([-0.30874521]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
59	NM_030662.3(MAP2K2):c.619G>A (p.Glu207Lys)	40813	CA180944	NM_030662.3:c.619G>A, LRG_750t1:c.619G>A, XM_006722799.2:c.619G>A, XM_011528133.1:c.49G>A, XM_017026989.1:c.619G>A, XM_017026990.1:c.619G>A, XM_017026991.1:c.619G>A, NM_030662.4:c.619G>A, ENST00000262948.9:c.619G>A, ENST00000394867.8:c.328G>A, ENST00000593364.5:n.566G>A, ENST00000597008.5:n.220G>A, ENST00000597263.5:n.83G>A, ENST00000599345.1:n.889G>A, ENST00000601786.5:n.920G>A, ENST00000602167.5:n.339G>A, NC_000019.10:g.4101105C>T, CM000681.2:g.4101105C>T, NC_000019.9:g.4101103C>T, CM000681.1:g.4101103C>T, NC_000019.8:g.4052103C>T, NG_007996.1:g.28024G>A, LRG_750:g.28024G>A, NM_030662.3(MAP2K2):c.619G>A (p.Glu207Lys)	MAP2K2	cardiofaciocutaneous syndrome	MONDO:0015280	Autosomal dominant inheritance	Pathogenic	PM2, PM6, PP2, PS4, PS2		The c.619G>A (p.Glu207Lys) variant in MAP2K2 was absent from large population studies (PM2; gnomAD.broadinstitute.org). It has been identified in 6 individuals with clinical features of a RASopathy (PS4; SCV000204213.4, SCV000207959.10, SCV000815593.1, Otto von Guericke University Magdeburg internal data). One of these cases was a confirmed de novo occurrence and another was an unconfirmed de novo occurrence (PS2; PM6; SCV000815593.1, Otto von Guericke University Magdeburg internal data). Additionally, the c.619G>A (p.Glu207Lys) is located in MAP2K2, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PS4, PS2, PM6, PM2, PP2.		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2020-06-25	2020-06-25	False	https://erepo.genome.network/evrepo/ui/classification/CA180944/MONDO:0015280/004	93491eab-4df5-480a-a62b-7022611f18ee	p.Glu207Lys	Glu	207	Lys	MLARRKPVLPALTINPTIAEGPSPTSEGASEANLVDLQKKLEELELDEQQKKRLEAFLTQKAKVGELKDDDFERISELGAGNGGVVTKVQHRPSGLIMARKLIHLEIKPAIRNQIIRELQVLHECNSPYIVGFYGAFYSDGEISICMEHMDGGSLDQVLKEAKRIPEEILGKVSIAVLRGLAYLREKHQIMHRDVKPSNILVNSRGEIKLCDFGVSGQLIDSMANSFVGTRSYMAPERLQGTHYSVQSDIWSMGLSLVELAVGRYPIPPPDAKELEAIFGRPVVDGEEGEPHSISPRPRPPGRPVSGHGMDSRPAMAIFELLDYIVNEPPPKLPNGVFTPDFQEFVNKCLIKNPAERADLKMLTNHTFIKRSEVEEVDFAGWLCKTLRLNQPGTPTRTAV	400	P36507	K	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [16], 'TRANSIT_gain': [], 'TRANSIT_loss_score': array([-0.00477368]), 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [37, 41], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.00655222, -0.00664651]), 'COILED_loss': [], 'COILED_gain': [62], 'COILED_gain_score': array([0.00817239]), 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
60	NM_002755.3(MAP2K1):c.169A>C (p.Lys57Gln)	40779	CA134595	NM_002755.3:c.169A>C, LRG_725t1:c.169A>C, XM_011521783.1:c.103A>C, XM_011521783.3:c.103A>C, XM_017022411.2:c.169A>C, XM_017022412.1:c.103A>C, NM_002755.4:c.169A>C, ENST00000307102.9:c.169A>C, ENST00000425818.2:n.680A>C, NC_000015.10:g.66435115A>C, CM000677.2:g.66435115A>C, NC_000015.9:g.66727453A>C, CM000677.1:g.66727453A>C, NC_000015.8:g.64514507A>C, NG_008305.1:g.53243A>C, LRG_725:g.53243A>C, NM_002755.3(MAP2K1):c.169A>C (p.Lys57Gln)	MAP2K1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Pathogenic	PM2, PM6, PP2, PP3, PM1, PS4_Moderate, PS2		The c.169A>C (p.Lys57Gln) variant in MAP2K1 was absent from large population studies (PM2; gnomAD.broadinstitute.org). It has been reported in 3 total patients with clinical features of a RASopathy (PS4_Moderate; SCV000061249.5; Otto von Guericke University Magdeburg internal data; Invitae internal data). One was a confirmed de novo occurrence and one was an unconfirmed de novo occurrence (PS2; PM6; SCV000061249.5; Otto von Guericke University Magdeburg internal data). The p.Lys57Gln variant is located in the negative regulatory region, which has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of MAP2K1 (PM1; PMID 29493581). Computational prediction tools and conservation analysis suggest that the p.Lys57Gln variant may impact the protein (PP3). Furthermore, the variant is located in MAP2K1, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic variants are common (PP2; PMID: 29493581). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PS2, PS4_Moderate, PM2, PM6, PM1, PP3, PP2.		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2020-06-25	2020-06-25	False	https://erepo.genome.network/evrepo/ui/classification/CA134595/MONDO:0021060/004	5fa3b275-1dad-4c57-bed5-dd904a8b11bb	p.Lys57Gln	Lys	57	Gln	MPKKKPTPIQLNPAPDGSAVNGTSSAETNLEALQKKLEELELDEQQRKRLEAFLTQKQKVGELKDDDFEKISELGAGNGGVVFKVSHKPSGLVMARKLIHLEIKPAIRNQIIRELQVLHECNSPYIVGFYGAFYSDGEISICMEHMDGGSLDQVLKKAGRIPEQILGKVSIAVIKGLTYLREKHKIMHRDVKPSNILVNSRGEIKLCDFGVSGQLIDSMANSFVGTRSYMSPERLQGTHYSVQSDIWSMGLSLVEMAVGRYPIPPPDAKELELMFGCQVEGDAAETPPRPRTPGRPLSSYGMDSRPPMAIFELLDYIVNEPPPKLPSGVFSLEFQDFVNKCLIKNPAERADLKQLMVHAFIKRSDAEEVDFAGWLCSTIGLNQPSTPTHAAGV	393	Q02750	Q	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
61	NM_005343.3(HRAS):c.257A>C (p.Asn86Thr)	40437	CA180888	NM_005343.3:c.257A>C, NM_001130442.1:c.257A>C, NM_005343.2:c.257A>C, NM_176795.3:c.257A>C, XM_011519875.1:c.-424-4799T>G, XM_011519877.1:c.-162+5462T>G, XR_242795.1:n.456A>C, NM_001130442.2:c.257A>C, NM_001318054.1:c.-63A>C, NM_176795.4:c.257A>C, XM_011519875.2:c.-424-4799T>G, XM_011519877.2:c.-162+5462T>G, XM_017017167.1:c.-499-4724T>G, XM_017017168.1:c.-499-4724T>G, NM_005343.4:c.257A>C, ENST00000311189.7:c.257A>C, ENST00000397594.5:c.257A>C, ENST00000397596.6:c.257A>C, ENST00000417302.5:c.257A>C, ENST00000451590.5:c.257A>C, ENST00000468682.2:n.745A>C, ENST00000479482.1:n.178A>C, ENST00000493230.5:c.257A>C, NC_000011.10:g.533799T>G, CM000673.2:g.533799T>G, NC_000011.9:g.533799T>G, CM000673.1:g.533799T>G, NC_000011.8:g.523799T>G, NG_007666.1:g.6752A>C, NM_005343.3(HRAS):c.257A>C (p.Asn86Thr)	LRRC56	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1, BP5		The filtering allele frequency of the c.257A>C (p.Asn86Thr) variant in the HRAS gene is 0.07% for African chromosomes by the Exome Aggregation Consortium (12/10342 with 95% CI), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert panel for autosomal dominant RASopathy variants (BA1).This variant has been identified in a patient with an alternate molecular basis for disease (BP5; Partners LMM, GeneDx internal data GTR ID: 21766, 26957 ClinVar SCV000204177.4; SCV000207861.7). In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied: BA1, BP5.		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	False	https://erepo.genome.network/evrepo/ui/classification/CA180888/MONDO:0021060/004	7a67f8eb-da68-4c6b-9d98-ee169176af3c	p.Asn86Thr	Asn	86	Thr	MDLGWDRSRGPRRSTSSVRVRELSWQGLHNPCPQSKGPGSQRDRLGEQLVEEYLSPARLQALARVDDLRLVRTLEMCVDTREGSLGNFGVHLPNLDQLKLNGSHLGSLRDLGTSLGHLQVLWLARCGLADLDGIASLPALKELYASYNNISDLSPLCLLEQLEVLDLEGNSVEDLGQVRYLQLCPRLAMLTLEGNLVCLQPAPGPTNKVPRGYNYRAEVRKLIPQLQVLDEVPAAHTGPPAPPRLSQDWLAVKEAIKKGNGLPPLDCPRGAPIRRLDPELSLPETQSRASRPWPFSLLVRGGPLPEGLLSEDLAPEDNTSSLTHGAGQVLCGNPTKGLRERRHQCQAREPPEQLPQHRPGDPAASTSTPEPDPADSSDFLALAGLRAWREHGVRPLPYRHPESQQEGAVAPWGPRRVPEEQVHQAEPKTPSSPPSLASEPSGTSSQHLVPSPPKHPRPRDSGSSSPRWSTDLQSRGRRLRVLGSWGPGLGDGVAAVPVLRALEVASRLSPRAQGCPGPKPAPDAAARPPRAAELSHPSPVPT	542	Q8IYG6	T	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [203], 'DOMAIN_gain_score': array([0.01612741]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
62	NM_004333.4(BRAF):c.1785T>G (p.Phe595Leu)	177672	CA280058	NM_004333.4:c.1785T>G, NC_000007.14:g.140753350A>C, CM000669.2:g.140753350A>C, NC_000007.13:g.140453150A>C, CM000669.1:g.140453150A>C, NC_000007.12:g.140099619A>C, NG_007873.3:g.176415T>G, LRG_299:g.176415T>G, LRG_299t1:c.1785T>G, XM_005250045.1:c.1785T>G, XM_005250046.1:c.1785T>G, XM_011516529.1:c.1785T>G, XM_011516530.1:c.1695-3932T>G, XR_242190.1:n.1793T>G, XR_927520.1:n.1793T>G, XR_927521.1:n.1793T>G, XR_927522.1:n.1703-3932T>G, XR_927523.1:n.1703-3932T>G, NM_001354609.1:c.1785T>G, NM_004333.5:c.1785T>G, NR_148928.1:n.2883T>G, XM_017012558.1:c.1905T>G, XM_017012559.1:c.1905T>G, XR_001744857.1:n.1913T>G, XR_001744858.1:n.1823-3932T>G, ENST00000288602.10:c.1785T>G, ENST00000479537.5:n.69T>G, ENST00000496384.6:n.608T>G, ENST00000497784.1:n.1820T>G, NM_004333.4(BRAF):c.1785T>G (p.Phe595Leu)	BRAF	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Pathogenic	PM2, PP2, PP3, PS4_Supporting, PM6_Strong, PM1		The c.1785T>G (p.Phe595Leu) variant in BRAF has been reported in the literature in at least 2 unconfirmed de novo occurrences in patients with clinical features of a RASopathy (PM6_Strong; PMID 19206169, 18042262; GTR ID's: 26957, 21766; ClinVar SCV000203922.4, SCV000207755.12). The variant has also been identified in at least 2 independent occurences in patients with clinical features of a RASopathy (PS4_Supporting; APHP-Robert Debré internal data; GTR ID 28338). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of BRAF (PM1; PMID 29493581, 16439621). The variant is located in the BRAF gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Computational prediction tools and conservation analysis suggest that the p.Phe595Leu variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. ACMG/AMP criteria applied: PM6_Strong, PM2, PM1, PP2, PP3, PS4_Supporting.	19206169, 8042262, 29493581, 16439621	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	False	https://erepo.genome.network/evrepo/ui/classification/CA280058/MONDO:0021060/004	020e6a22-3189-484a-8ca8-77cd1a08adba	p.Phe595Leu	Phe	595	Leu	MAALSGGGGGGAEPGQALFNGDMEPEAGAGAGAAASSAADPAIPEEVWNIKQMIKLTQEHIEALLDKFGGEHNPPSIYLEAYEEYTSKLDALQQREQQLLESLGNGTDFSVSSSASMDTVTSSSSSSLSVLPSSLSVFQNPTDVARSNPKSPQKPIVRVFLPNKQRTVVPARCGVTVRDSLKKALMMRGLIPECCAVYRIQDGEKKPIGWDTDISWLTGEELHVEVLENVPLTTHNFVRKTFFTLAFCDFCRKLLFQGFRCQTCGYKFHQRCSTEVPLMCVNYDQLDLLFVSKFFEHHPIPQEEASLAETALTSGSSPSAPASDSIGPQILTSPSPSKSIPIPQPFRPADEDHRNQFGQRDRSSSAPNVHINTIEPVNIDDLIRDQGFRGDGGSTTGLSATPPASLPGSLTNVKALQKSPGPQRERKSSSSSEDRNRMKTLGRRDSSDDWEIPDGQITVGQRIGSGSFGTVYKGKWHGDVAVKMLNVTAPTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHHLHIIETKFEMIKLIDIARQTAQGMDYLHAKSIIHRDLKSNNIFLHEDLTVKIGDFGLATVKSRWSGSHQFEQLSGSILWMAPEVIRMQDKNPYSFQSDVYAFGIVLYELMTGQLPYSNINNRDQIIFMVGRGYLSPDLSKVRSNCPKAMKRLMAECLKKKRDERPLFPQILASIELLARSLPKIHRSASEPSLNRAGFQTEDFSLYACASPKTPIQAGGYGAFPVH	766	P15056	L	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [617], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.02966303]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [374], 'REGION_gain': [], 'REGION_loss_score': array([-0.00191003]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
63	NM_004333.4(BRAF):c.968C>T (p.Ser323Leu)	44834	CA135149	NM_004333.4:c.968C>T, NC_000007.14:g.140800374G>A, CM000669.2:g.140800374G>A, NC_000007.13:g.140500174G>A, CM000669.1:g.140500174G>A, NC_000007.12:g.140146643G>A, NG_007873.3:g.129391C>T, LRG_299:g.129391C>T, LRG_299t1:c.968C>T, XM_005250045.1:c.968C>T, XM_005250046.1:c.968C>T, XM_011516529.1:c.968C>T, XM_011516530.1:c.968C>T, XR_242190.1:n.976C>T, XR_927520.1:n.976C>T, XR_927521.1:n.976C>T, XR_927522.1:n.976C>T, XR_927523.1:n.976C>T, NM_001354609.1:c.968C>T, NM_004333.5:c.968C>T, NR_148928.1:n.1273C>T, XM_017012558.1:c.968C>T, XM_017012559.1:c.968C>T, XR_001744857.1:n.976C>T, XR_001744858.1:n.976C>T, ENST00000288602.10:c.968C>T, ENST00000497784.1:n.1003C>T, NM_004333.4(BRAF):c.968C>T (p.Ser323Leu)	BRAF	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.968C>T (p.Ser323Leu) variant in the BRAF gene is 0.06% for South Asian chromosomes by the Exome Aggregation Consortium (17/16512 with 95% CI), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert panel for autosomal dominant RASopathy variants (BA1).		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	False	https://erepo.genome.network/evrepo/ui/classification/CA135149/MONDO:0021060/004	991935c6-c179-4715-b017-4dacb3dfd3ac	p.Ser323Leu	Ser	323	Leu	MAALSGGGGGGAEPGQALFNGDMEPEAGAGAGAAASSAADPAIPEEVWNIKQMIKLTQEHIEALLDKFGGEHNPPSIYLEAYEEYTSKLDALQQREQQLLESLGNGTDFSVSSSASMDTVTSSSSSSLSVLPSSLSVFQNPTDVARSNPKSPQKPIVRVFLPNKQRTVVPARCGVTVRDSLKKALMMRGLIPECCAVYRIQDGEKKPIGWDTDISWLTGEELHVEVLENVPLTTHNFVRKTFFTLAFCDFCRKLLFQGFRCQTCGYKFHQRCSTEVPLMCVNYDQLDLLFVSKFFEHHPIPQEEASLAETALTSGSSPSAPASDSIGPQILTSPSPSKSIPIPQPFRPADEDHRNQFGQRDRSSSAPNVHINTIEPVNIDDLIRDQGFRGDGGSTTGLSATPPASLPGSLTNVKALQKSPGPQRERKSSSSSEDRNRMKTLGRRDSSDDWEIPDGQITVGQRIGSGSFGTVYKGKWHGDVAVKMLNVTAPTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHHLHIIETKFEMIKLIDIARQTAQGMDYLHAKSIIHRDLKSNNIFLHEDLTVKIGDFGLATVKSRWSGSHQFEQLSGSILWMAPEVIRMQDKNPYSFQSDVYAFGIVLYELMTGQLPYSNINNRDQIIFMVGRGYLSPDLSKVRSNCPKAMKRLMAECLKKKRDERPLFPQILASIELLARSLPKIHRSASEPSLNRAGFQTEDFSLYACASPKTPIQAGGYGAFPVH	766	P15056	L	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [88], 'HELIX_gain_score': array([0.00251812]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [308, 309, 310, 311, 312, 313, 314, 315, 316], 'COMPBIAS_gain': [422, 447], 'COMPBIAS_gain_score': array([0.03512484, 0.0464021 ]), 'COMPBIAS_loss_score': array([-0.35533273, -0.3478682 , -0.34473044, -0.31999749, -0.34178424,
       -0.37936574, -0.38062137, -0.41280466, -0.46073562]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [311, 312, 313, 314, 315, 316, 374], 'REGION_gain': [], 'REGION_loss_score': array([-0.4103815 , -0.42251599, -0.47487617, -0.46240187, -0.49264491,
       -0.48380595, -0.03186166]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
64	NM_004333.4(BRAF):c.1787G>T (p.Gly596Val)	40387	CA220161	NM_004333.4:c.1787G>T, NC_000007.14:g.140753348C>A, CM000669.2:g.140753348C>A, NC_000007.13:g.140453148C>A, CM000669.1:g.140453148C>A, NC_000007.12:g.140099617C>A, NG_007873.3:g.176417G>T, LRG_299:g.176417G>T, LRG_299t1:c.1787G>T, XM_005250045.1:c.1787G>T, XM_005250046.1:c.1787G>T, XM_011516529.1:c.1787G>T, XM_011516530.1:c.1695-3930G>T, XR_242190.1:n.1795G>T, XR_927520.1:n.1795G>T, XR_927521.1:n.1795G>T, XR_927522.1:n.1703-3930G>T, XR_927523.1:n.1703-3930G>T, NM_001354609.1:c.1787G>T, NM_004333.5:c.1787G>T, NR_148928.1:n.2885G>T, XM_017012558.1:c.1907G>T, XM_017012559.1:c.1907G>T, XR_001744857.1:n.1915G>T, XR_001744858.1:n.1823-3930G>T, ENST00000288602.10:c.1787G>T, ENST00000479537.5:n.71G>T, ENST00000496384.6:n.610G>T, ENST00000497784.1:n.1822G>T, NM_004333.4(BRAF):c.1787G>T (p.Gly596Val)	BRAF	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Pathogenic	PM2, PP2, PP3, PM6_Strong, PM1, PS3		The c.1787G>T (p.Gly596Val) variant in BRAF has been reported in the literature in at least 2 unconfirmed de novo occurrences in patients with clinical features of a RASopathy (PM6_Strong; PMID 16439621, 25463315, Partners LMM and GeneDx internal data; GTR ID's: 21766, 26957; ClinVar SCV000197137, SCV000057237). In vitro functional studies provide some evidence that the p.Gly596Val variant may impact protein function (PS3; PMID 18413255). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). The variant is located in the BRAF gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common  (PP2; PMID 29493581). Computational prediction tools and conservation analysis suggest that the p.Gly596Val variant may impact the protein (PP3). Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of BRAF (PM1; PMID 29493581). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581):  PM6_Strong, PS3, PM2, PP2, PP3, PM1.	16439621, 25463315, 18413255	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2020-01-23	False	https://erepo.genome.network/evrepo/ui/classification/CA220161/MONDO:0021060/004	5fbeb559-b94f-4487-833a-8ea50dea3862	p.Gly596Val	Gly	596	Val	MAALSGGGGGGAEPGQALFNGDMEPEAGAGAGAAASSAADPAIPEEVWNIKQMIKLTQEHIEALLDKFGGEHNPPSIYLEAYEEYTSKLDALQQREQQLLESLGNGTDFSVSSSASMDTVTSSSSSSLSVLPSSLSVFQNPTDVARSNPKSPQKPIVRVFLPNKQRTVVPARCGVTVRDSLKKALMMRGLIPECCAVYRIQDGEKKPIGWDTDISWLTGEELHVEVLENVPLTTHNFVRKTFFTLAFCDFCRKLLFQGFRCQTCGYKFHQRCSTEVPLMCVNYDQLDLLFVSKFFEHHPIPQEEASLAETALTSGSSPSAPASDSIGPQILTSPSPSKSIPIPQPFRPADEDHRNQFGQRDRSSSAPNVHINTIEPVNIDDLIRDQGFRGDGGSTTGLSATPPASLPGSLTNVKALQKSPGPQRERKSSSSSEDRNRMKTLGRRDSSDDWEIPDGQITVGQRIGSGSFGTVYKGKWHGDVAVKMLNVTAPTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHHLHIIETKFEMIKLIDIARQTAQGMDYLHAKSIIHRDLKSNNIFLHEDLTVKIGDFGLATVKSRWSGSHQFEQLSGSILWMAPEVIRMQDKNPYSFQSDVYAFGIVLYELMTGQLPYSNINNRDQIIFMVGRGYLSPDLSKVRSNCPKAMKRLMAECLKKKRDERPLFPQILASIELLARSLPKIHRSASEPSLNRAGFQTEDFSLYACASPKTPIQAGGYGAFPVH	766	P15056	V	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [591], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.3331306]), 'HELIX_loss': [617], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.03622425]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [350], 'COMPBIAS_gain': [], 'COMPBIAS_loss_score': array([-0.00409651]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [374], 'REGION_gain': [], 'REGION_loss_score': array([-0.00766361]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
65	NM_176795.4(HRAS):c.173C>T (p.Thr58Ile)	12610	CA341206	NM_176795.4:c.173C>T, NM_001130442.1:c.173C>T, NM_005343.2:c.173C>T, NM_176795.3:c.173C>T, XM_011519875.1:c.-424-4715G>A, XM_011519877.1:c.-162+5546G>A, XR_242795.1:n.372C>T, NM_001130442.2:c.173C>T, NM_001318054.1:c.-147C>T, NM_005343.3:c.173C>T, XM_011519875.2:c.-424-4715G>A, XM_011519877.2:c.-162+5546G>A, XM_017017167.1:c.-499-4640G>A, XM_017017168.1:c.-499-4640G>A, NM_005343.4:c.173C>T, ENST00000311189.7:c.173C>T, ENST00000397594.5:c.173C>T, ENST00000397596.6:c.173C>T, ENST00000417302.5:c.173C>T, ENST00000451590.5:c.173C>T, ENST00000468682.2:n.661C>T, ENST00000479482.1:n.94C>T, ENST00000493230.5:c.173C>T, NC_000011.10:g.533883G>A, CM000673.2:g.533883G>A, NC_000011.9:g.533883G>A, CM000673.1:g.533883G>A, NC_000011.8:g.523883G>A, NG_007666.1:g.6668C>T, NM_176795.4(HRAS):c.173C>T (p.Thr58Ile)	LRRC56	Costello syndrome	MONDO:0009026	Autosomal dominant inheritance	Pathogenic	PM2, PM6, PP2, PP3, PS4_Supporting, PM1, PS1		The c.173C>T (p.Thr58Ile) variant in HRAS has been reported in the literature as an unconfirmed de novo occurrence in a patient with clinical features of a RASopathy (PM6; PMID 20112233, 16474405). Also, at least 2 independent occurrences of this variant have been detected in patients with a RASopathy (PS4_Supporting; PMID: 22488832, 18247425, 23321623, 20949621, 16921267). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). The p.Thr58Ile variant in HRAS is analogous to the same previously established amino acid change in the KRAS gene and the ClinGen RASopathy Expert Panel has defined that the pathogenicities of analogous variants in the HRAS and KRAS genes are correlated based on the assumption that a known functional residue in one gene is equivalent to other functions within that subgroup (PS1; 29493581). Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of HRAS (PM1; PMID 29493581).  The variant is in HRAS, which has been defined by the ClinGen RASopathy Expert Panel as a gene with low rate of benign missense with missense variants commonly being pathogenic (PP2; PMID 29493581). Computational prediction tools and conservation analysis suggest that the p.Thr58Ile variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PM6, PS4_Supporting, PM2, PS1, PM1, PP2, PP3.	20112233, 16474405, 18247425, 16921267, 23321623, 22488832, 20949621	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	False	https://erepo.genome.network/evrepo/ui/classification/CA341206/MONDO:0009026/004	4fa14d9d-3bce-4dd8-affa-771b6298c4fc	p.Thr58Ile	Thr	58	Ile	MDLGWDRSRGPRRSTSSVRVRELSWQGLHNPCPQSKGPGSQRDRLGEQLVEEYLSPARLQALARVDDLRLVRTLEMCVDTREGSLGNFGVHLPNLDQLKLNGSHLGSLRDLGTSLGHLQVLWLARCGLADLDGIASLPALKELYASYNNISDLSPLCLLEQLEVLDLEGNSVEDLGQVRYLQLCPRLAMLTLEGNLVCLQPAPGPTNKVPRGYNYRAEVRKLIPQLQVLDEVPAAHTGPPAPPRLSQDWLAVKEAIKKGNGLPPLDCPRGAPIRRLDPELSLPETQSRASRPWPFSLLVRGGPLPEGLLSEDLAPEDNTSSLTHGAGQVLCGNPTKGLRERRHQCQAREPPEQLPQHRPGDPAASTSTPEPDPADSSDFLALAGLRAWREHGVRPLPYRHPESQQEGAVAPWGPRRVPEEQVHQAEPKTPSSPPSLASEPSGTSSQHLVPSPPKHPRPRDSGSSSPRWSTDLQSRGRRLRVLGSWGPGLGDGVAAVPVLRALEVASRLSPRAQGCPGPKPAPDAAARPPRAAELSHPSPVPT	542	Q8IYG6	I	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [23, 25, 26], 'SIGNAL_gain_score': array([0.09156567, 0.09563559, 0.08422929]), 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [55, 56], 'HELIX_gain_score': array([0.07596886, 0.06924379]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [203, 236], 'DOMAIN_gain_score': array([0.00722462, 0.0456304 ]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
66	NM_005343.3(HRAS):c.34G>A (p.Gly12Ser)	12602	CA122549	NM_005343.3:c.34G>A, NC_000011.10:g.534289C>T, CM000673.2:g.534289C>T, NC_000011.9:g.534289C>T, CM000673.1:g.534289C>T, NC_000011.8:g.524289C>T, NG_007666.1:g.6262G>A, NM_001130442.1:c.34G>A, NM_005343.2:c.34G>A, NM_176795.3:c.34G>A, XM_011519875.1:c.-424-4309C>T, XM_011519877.1:c.-161-5291C>T, XR_242795.1:n.233G>A, NM_001130442.2:c.34G>A, NM_001318054.1:c.-286G>A, NM_176795.4:c.34G>A, XM_011519875.2:c.-424-4309C>T, XM_011519877.2:c.-161-5291C>T, XM_017017167.1:c.-499-4234C>T, XM_017017168.1:c.-499-4234C>T, NM_005343.4:c.34G>A, ENST00000311189.7:c.34G>A, ENST00000397594.5:c.34G>A, ENST00000397596.6:c.34G>A, ENST00000417302.5:c.34G>A, ENST00000451590.5:c.34G>A, ENST00000468682.2:n.522G>A, ENST00000482021.1:n.157G>A, ENST00000493230.5:c.34G>A, NM_005343.3(HRAS):c.34G>A (p.Gly12Ser)	LRRC56	Costello syndrome	MONDO:0009026	Autosomal dominant inheritance	Pathogenic	PM2, PS2_Very Strong, PP2, PP3, PM1, PS3, PS4		The c.34G>A (p.Gly12Ser) variant in HRAS has been reported as a confirmed de novo occurrence in at least 2 patients with clinical features of a RASopathy (PS2_VeryStrong; PMID 16170316, 16835863, 16443854, 16835863, 16881968, 17054105, 19669404). The p.Gly12Ser variant has been identified in >5 independent occurrences in patients with clinical features of a RASopathy (PS4; PMID: 20660566, 16372351, 16329078, 16969868, 18039947, 19371735, 19206176, 16835863). In vitro functional studies provide some evidence that the p.Gly12Ser variant may impact protein function (PS3; PMID: 17412879). Computational prediction tools and conservation analysis suggest that the p.Gly12Ser variant may impact the protein (PP3). Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of HRAS (PM1; PMID 29493581). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). The variant is located in the HRAS gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PS2_VeryStrong, PS4, PS3, PM1, PM2,  PP2, PP3.	17054105, 16443854, 19669404, 16170316, 16881968, 16835863, 29493581, 17412879, 19206176, 19371735, 16329078, 16372351, 16969868, 16835863, 20660566, 18039947	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	False	https://erepo.genome.network/evrepo/ui/classification/CA122549/MONDO:0009026/004	51947641-2e77-498f-93d6-ca73b8e343de	p.Gly12Ser	Gly	12	Ser	MDLGWDRSRGPRRSTSSVRVRELSWQGLHNPCPQSKGPGSQRDRLGEQLVEEYLSPARLQALARVDDLRLVRTLEMCVDTREGSLGNFGVHLPNLDQLKLNGSHLGSLRDLGTSLGHLQVLWLARCGLADLDGIASLPALKELYASYNNISDLSPLCLLEQLEVLDLEGNSVEDLGQVRYLQLCPRLAMLTLEGNLVCLQPAPGPTNKVPRGYNYRAEVRKLIPQLQVLDEVPAAHTGPPAPPRLSQDWLAVKEAIKKGNGLPPLDCPRGAPIRRLDPELSLPETQSRASRPWPFSLLVRGGPLPEGLLSEDLAPEDNTSSLTHGAGQVLCGNPTKGLRERRHQCQAREPPEQLPQHRPGDPAASTSTPEPDPADSSDFLALAGLRAWREHGVRPLPYRHPESQQEGAVAPWGPRRVPEEQVHQAEPKTPSSPPSLASEPSGTSSQHLVPSPPKHPRPRDSGSSSPRWSTDLQSRGRRLRVLGSWGPGLGDGVAAVPVLRALEVASRLSPRAQGCPGPKPAPDAAARPPRAAELSHPSPVPT	542	Q8IYG6	S	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [486], 'TRANSMEM_gain_score': array([0.01304436]), 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [22], 'SIGNAL_gain': [], 'SIGNAL_loss_score': array([-0.11973923]), 'TRANSIT_loss': [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12], 'TRANSIT_gain': [], 'TRANSIT_loss_score': array([-0.11929739, -0.19126409, -0.18123108, -0.20416534, -0.18996334,
       -0.19762623, -0.19385284, -0.22341681, -0.16352671, -0.24827892,
       -0.20898646, -0.2636596 , -0.1984399 ]), 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [154], 'HELIX_gain_score': array([0.01358879]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
67	NM_005343.3(HRAS):c.350A>G (p.Lys117Arg)	12605	CA256490	NM_005343.3:c.350A>G, NM_001130442.1:c.350A>G, NM_005343.2:c.350A>G, NM_176795.3:c.350A>G, XM_011519875.1:c.-424-5045T>C, XM_011519877.1:c.-162+5216T>C, XR_242795.1:n.549A>G, NM_001130442.2:c.350A>G, NM_001318054.1:c.31A>G, NM_176795.4:c.350A>G, XM_011519875.2:c.-424-5045T>C, XM_011519877.2:c.-162+5216T>C, XM_017017167.1:c.-499-4970T>C, XM_017017168.1:c.-499-4970T>C, NM_005343.4:c.350A>G, ENST00000311189.7:c.350A>G, ENST00000397594.5:c.350A>G, ENST00000397596.6:c.350A>G, ENST00000417302.5:c.350A>G, ENST00000451590.5:c.350A>G, ENST00000462734.1:n.43A>G, ENST00000478324.5:n.60A>G, ENST00000479482.1:n.271A>G, ENST00000493230.5:c.350A>G, NC_000011.10:g.533553T>C, CM000673.2:g.533553T>C, NC_000011.9:g.533553T>C, CM000673.1:g.533553T>C, NC_000011.8:g.523553T>C, NG_007666.1:g.6998A>G, NM_005343.3(HRAS):c.350A>G (p.Lys117Arg)	LRRC56	Costello syndrome	MONDO:0009026	Autosomal dominant inheritance	Pathogenic	PM2, PP3, PM6_Strong, PM1, PS3		The c.350A>G (p.Lys117Arg) variant in HRAS has been reported in the literature in at least 2 unconfirmed de novo occurrences in patients with clinical features of a RASopathy (PM6_Strong; PMID 16443854, 16155195). In vitro functional studies provide some evidence that the p.Lys117Arg variant may impact protein function (PS3; PMID 17979197, 21850009). Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of HRAS (PM1; PMID 29493581). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). Computational prediction tools and conservation analysis suggest that the p.Lys117Arg variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. ACMG/AMP criteria applied: PM6_Strong, PS3, PM1, PM2, PP3.	16443854, 29493581, 21850009	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	False	https://erepo.genome.network/evrepo/ui/classification/CA256490/MONDO:0009026/004	42e841f0-7121-4d9d-a2ae-ebc27adacd88	p.Lys117Arg	Lys	117	Arg	MDLGWDRSRGPRRSTSSVRVRELSWQGLHNPCPQSKGPGSQRDRLGEQLVEEYLSPARLQALARVDDLRLVRTLEMCVDTREGSLGNFGVHLPNLDQLKLNGSHLGSLRDLGTSLGHLQVLWLARCGLADLDGIASLPALKELYASYNNISDLSPLCLLEQLEVLDLEGNSVEDLGQVRYLQLCPRLAMLTLEGNLVCLQPAPGPTNKVPRGYNYRAEVRKLIPQLQVLDEVPAAHTGPPAPPRLSQDWLAVKEAIKKGNGLPPLDCPRGAPIRRLDPELSLPETQSRASRPWPFSLLVRGGPLPEGLLSEDLAPEDNTSSLTHGAGQVLCGNPTKGLRERRHQCQAREPPEQLPQHRPGDPAASTSTPEPDPADSSDFLALAGLRAWREHGVRPLPYRHPESQQEGAVAPWGPRRVPEEQVHQAEPKTPSSPPSLASEPSGTSSQHLVPSPPKHPRPRDSGSSSPRWSTDLQSRGRRLRVLGSWGPGLGDGVAAVPVLRALEVASRLSPRAQGCPGPKPAPDAAARPPRAAELSHPSPVPT	542	Q8IYG6	R	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [486], 'TRANSMEM_gain_score': array([0.00780189]), 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [174], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.00169331]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [203], 'DOMAIN_gain_score': array([0.00658017]), 'REGION_loss': [322], 'REGION_gain': [], 'REGION_loss_score': array([-0.00278467]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
68	NM_005343.3(HRAS):c.37G>T (p.Gly13Cys)	12606	CA295247	NM_005343.3:c.37G>T, NM_001130442.1:c.37G>T, NM_005343.2:c.37G>T, NM_176795.3:c.37G>T, XM_011519875.1:c.-424-4312C>A, XM_011519877.1:c.-161-5294C>A, XR_242795.1:n.236G>T, NM_001130442.2:c.37G>T, NM_001318054.1:c.-283G>T, NM_176795.4:c.37G>T, XM_011519875.2:c.-424-4312C>A, XM_011519877.2:c.-161-5294C>A, XM_017017167.1:c.-499-4237C>A, XM_017017168.1:c.-499-4237C>A, NM_005343.4:c.37G>T, ENST00000311189.7:c.37G>T, ENST00000397594.5:c.37G>T, ENST00000397596.6:c.37G>T, ENST00000417302.5:c.37G>T, ENST00000451590.5:c.37G>T, ENST00000468682.2:n.525G>T, ENST00000482021.1:n.160G>T, ENST00000493230.5:c.37G>T, NC_000011.10:g.534286C>A, CM000673.2:g.534286C>A, NC_000011.9:g.534286C>A, CM000673.1:g.534286C>A, NC_000011.8:g.524286C>A, NG_007666.1:g.6265G>T, NM_005343.3(HRAS):c.37G>T (p.Gly13Cys)	LRRC56	Noonan syndrome	MONDO:0018997	Autosomal dominant inheritance	Pathogenic	PM2, PS2_Very Strong, PP2, PP3, PM1, PS4_Moderate		The c.37G>T (p.Gly13Cys) variant in HRAS has been reported as a confirmed de novo occurrence in at least 2 patients with clinical features of a RASopathy (PS2_VeryStrong; PMID 21438134, 16329078). The p.Gly13Cys variant has been identified in at least 3 other independent occurrence in patients with clinical features of a RASopathy (PS4_Moderate; PMID: 16372351). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). The variant is located in the HRAS gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Computational prediction tools and conservation analysis suggest that the p.Gly13Cys variant may impact the protein (PP3). Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of HRAS (PM1; PMID 29493581). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID: 29493581): PP2, PP3, PM1, PM2, PS4_Moderate, PS2_VeryStrong.	16329078, 21438134, 29493581	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	False	https://erepo.genome.network/evrepo/ui/classification/CA295247/MONDO:0018997/004	77fd6395-3146-46f0-86ca-08fb626eb660	p.Gly13Cys	Gly	13	Cys	MDLGWDRSRGPRRSTSSVRVRELSWQGLHNPCPQSKGPGSQRDRLGEQLVEEYLSPARLQALARVDDLRLVRTLEMCVDTREGSLGNFGVHLPNLDQLKLNGSHLGSLRDLGTSLGHLQVLWLARCGLADLDGIASLPALKELYASYNNISDLSPLCLLEQLEVLDLEGNSVEDLGQVRYLQLCPRLAMLTLEGNLVCLQPAPGPTNKVPRGYNYRAEVRKLIPQLQVLDEVPAAHTGPPAPPRLSQDWLAVKEAIKKGNGLPPLDCPRGAPIRRLDPELSLPETQSRASRPWPFSLLVRGGPLPEGLLSEDLAPEDNTSSLTHGAGQVLCGNPTKGLRERRHQCQAREPPEQLPQHRPGDPAASTSTPEPDPADSSDFLALAGLRAWREHGVRPLPYRHPESQQEGAVAPWGPRRVPEEQVHQAEPKTPSSPPSLASEPSGTSSQHLVPSPPKHPRPRDSGSSSPRWSTDLQSRGRRLRVLGSWGPGLGDGVAAVPVLRALEVASRLSPRAQGCPGPKPAPDAAARPPRAAELSHPSPVPT	542	Q8IYG6	C	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [486], 'TRANSMEM_gain_score': array([0.00867552]), 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12], 'TRANSIT_gain': [], 'TRANSIT_loss_score': array([-0.09325707, -0.13874602, -0.13202733, -0.13861096, -0.13187695,
       -0.13105923, -0.14659727, -0.16245508, -0.15639049, -0.16357219,
       -0.16520888, -0.10448158, -0.20855594]), 'STRAND_loss': [], 'STRAND_gain': [163], 'STRAND_gain_score': array([0.02422571]), 'HELIX_loss': [], 'HELIX_gain': [154], 'HELIX_gain_score': array([0.0174793]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [320, 322], 'REGION_gain': [], 'REGION_loss_score': array([-0.00721353, -0.00546312]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
69	NM_005633.3(SOS1):c.1654A>G (p.Arg552Gly)	12871	CA235350	NM_005633.3:c.1654A>G, LRG_754t1:c.1654A>G, XM_005264515.3:c.1654A>G, XM_011533060.1:c.1747A>G, XM_011533061.1:c.1747A>G, XM_011533062.1:c.1633A>G, XM_011533063.1:c.1630A>G, XM_011533064.1:c.1483A>G, XM_011533065.1:c.1747A>G, XM_011533066.1:c.589A>G, XM_005264515.4:c.1654A>G, XM_011533062.2:c.1633A>G, XM_011533064.2:c.1483A>G, ENST00000395038.6:c.1654A>G, ENST00000402219.6:c.1654A>G, ENST00000426016.5:c.1654A>G, NC_000002.12:g.39022774T>C, CM000664.2:g.39022774T>C, NC_000002.11:g.39249915T>C, CM000664.1:g.39249915T>C, NC_000002.10:g.39103419T>C, NG_007530.1:g.102690A>G, LRG_754:g.102690A>G, NM_005633.3(SOS1):c.1654A>G (p.Arg552Gly)	SOS1	Noonan syndrome	MONDO:0018997	Autosomal dominant inheritance	Pathogenic	PS2_Very Strong, PM2, PP2, PP3, PM1, PS3		The c.1654A>G (p.Arg552Gly) variant in SOS1 has been reported as a confirmed de novo occurrence in at least 2 patients with clinical features of a RASopathy (PS2_VeryStrong; PMID 17143282). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). In vitro functional studies provide some evidence that the p.Arg552Gly variant may impact protein function (PS3; PMID: 17143282). The variant is located in the SOS1 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of SOS1 (PM1; PMID 29493581). Computational prediction tools and conservation analysis suggest that the p.Arg552Gly variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PP2, PP3, PM1, PM2, PS3, PS2_VeryStrong.		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	False	https://erepo.genome.network/evrepo/ui/classification/CA235350/MONDO:0018997/004	b5a21ed5-8cbc-465c-8a14-9be1d1d54011	p.Arg552Gly	Arg	552	Gly	MQAQQLPYEFFSEENAPKWRGLLVPALKKVQGQVHPTLESNDDALQYVEELILQLLNMLCQAQPRSASDVEERVQKSFPHPIDKWAIADAQSAIEKRKRRNPLSLPVEKIHPLLKEVLGYKIDHQVSVYIVAVLEYISADILKLVGNYVRNIRHYEITKQDIKVAMCADKVLMDMFHQDVEDINILSLTDEEPSTSGEQTYYDLVKAFMAEIRQYIRELNLIIKVFREPFVSNSKLFSANDVENIFSRIVDIHELSVKLLGHIEDTVEMTDEGSPHPLVGSCFEDLAEELAFDPYESYARDILRPGFHDRFLSQLSKPGAALYLQSIGEGFKEAVQYVLPRLLLAPVYHCLHYFELLKQLEEKSEDQEDKECLKQAITALLNVQSGMEKICSKSLAKRRLSESACRFYSQQMKGKQLAIKKMNEIQKNIDGWEGKDIGQCCNEFIMEGTLTRVGAKHERHIFLFDGLMICCKSNHGQPRLPGASNAEYRLKEKFFMRKVQINDKDDTNEYKHAFEIILKDENSVIFSAKSAEEKNNWMAALISLQYRSTLERMLDVTMLQEEKEEQMRLPSADVYRFAEPDSEENIIFEENMQPKAGIPIIKAGTVIKLIERLTYHMYADPNFVRTFLTTYRSFCKPQELLSLIIERFEIPEPEPTEADRIAIENGDQPLSAELKRFRKEYIQPVQLRVLNVCRHWVEHHFYDFERDAYLLQRMEEFIGTVRGKAMKKWVESITKIIQRKKIARDNGPGHNITFQSSPPTVEWHISRPGHIETFDLLTLHPIEIARQLTLLESDLYRAVQPSELVGSVWTKEDKEINSPNLLKMIRHTTNLTLWFEKCIVETENLEERVAVVSRIIEILQVFQELNNFNGVLEVVSAMNSSPVYRLDHTFEQIPSRQKKILEEAHELSEDHYKKYLAKLRSINPPCVPFFGIYLTNILKTEEGNPEVLKRHGKELINFSKRRKVAEITGEIQQYQNQPYCLRVESDIKRFFENLNPMGNSMEKEFTDYLFNKSLEIEPRNPKPLPRFPKKYSYPLKSPGVRPSNPRPGTMRHPTPLQQEPRKISYSRIPESETESTASAPNSPRTPLTPPPASGASSTTDVCSVFDSDHSSPFHSSNDTVFIQVTLPHGPRSASVSSISLTKGTDEVPVPPPVPPRRRPESAPAESSPSKIMSKHLDSPPAIPPRQPTSKAYSPRYSISDRTSISDPPESPPLLPPREPVRTPDVFSSSPLHLQPPPLGKKSDHGNAFFPNSPSPFTPPPPQTPSPHGTRRHLPSPPLTQEVDLHSIAGPPVPPRQSTSQHIPKLPPKTYKREHTHPSMHRDGPPLLENAHSS	1333	Q07889	G	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [516], 'STRAND_gain_score': array([0.01125723]), 'HELIX_loss': [849, 856], 'HELIX_gain': [534], 'HELIX_gain_score': array([0.01340634]), 'HELIX_loss_score': array([-0.01854777, -0.01754004]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [778, 780, 781, 782, 872, 873, 875], 'DOMAIN_gain_score': array([0.10004848, 0.1136021 , 0.09127325, 0.10209543, 0.07652581,
       0.07880253, 0.06656593]), 'REGION_loss': [], 'REGION_gain': [1295], 'REGION_gain_score': array([0.00124103]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
70	NM_005633.3(SOS1):c.1642A>C (p.Ser548Arg)	40678	CA234977	NM_005633.3:c.1642A>C, LRG_754t1:c.1642A>C, XM_005264515.3:c.1642A>C, XM_011533060.1:c.1735A>C, XM_011533061.1:c.1735A>C, XM_011533062.1:c.1621A>C, XM_011533063.1:c.1618A>C, XM_011533064.1:c.1471A>C, XM_011533065.1:c.1735A>C, XM_011533066.1:c.577A>C, XM_005264515.4:c.1642A>C, XM_011533062.2:c.1621A>C, XM_011533064.2:c.1471A>C, ENST00000395038.6:c.1642A>C, ENST00000402219.6:c.1642A>C, ENST00000426016.5:c.1642A>C, NC_000002.12:g.39022786T>G, CM000664.2:g.39022786T>G, NC_000002.11:g.39249927T>G, CM000664.1:g.39249927T>G, NC_000002.10:g.39103431T>G, NG_007530.1:g.102678A>C, LRG_754:g.102678A>C, NM_005633.3(SOS1):c.1642A>C (p.Ser548Arg)	SOS1	Noonan syndrome	MONDO:0018997	Autosomal dominant inheritance	Pathogenic	PM2, PS2_Very Strong, PP2, PP3, PM1, PS3		The c.1642A>C (p.Ser548Arg) variant in SOS1 has been reported as a confirmed de novo occurrence in a patient with clinical features of a RASopathy (PS2_VeryStrong; PMID 17143282). In vitro functional studies provide some evidence that the p.Ser548Arg variant may impact protein function (PS3; PMID 23487764). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). The variant is located in the SOS1 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of SOS1 (PM1; PMID 29493581). Computational prediction tools and conservation analysis suggest that the p.Ser548Arg variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID: 29493581): PP2, PP3, PM1, PM2, PS3 PS2_VeryStrong.	17143282, 29493581, 17143285	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	False	https://erepo.genome.network/evrepo/ui/classification/CA234977/MONDO:0018997/004	940ad8e1-71b4-424b-b085-ae78bed7e9d7	p.Ser548Arg	Ser	548	Arg	MQAQQLPYEFFSEENAPKWRGLLVPALKKVQGQVHPTLESNDDALQYVEELILQLLNMLCQAQPRSASDVEERVQKSFPHPIDKWAIADAQSAIEKRKRRNPLSLPVEKIHPLLKEVLGYKIDHQVSVYIVAVLEYISADILKLVGNYVRNIRHYEITKQDIKVAMCADKVLMDMFHQDVEDINILSLTDEEPSTSGEQTYYDLVKAFMAEIRQYIRELNLIIKVFREPFVSNSKLFSANDVENIFSRIVDIHELSVKLLGHIEDTVEMTDEGSPHPLVGSCFEDLAEELAFDPYESYARDILRPGFHDRFLSQLSKPGAALYLQSIGEGFKEAVQYVLPRLLLAPVYHCLHYFELLKQLEEKSEDQEDKECLKQAITALLNVQSGMEKICSKSLAKRRLSESACRFYSQQMKGKQLAIKKMNEIQKNIDGWEGKDIGQCCNEFIMEGTLTRVGAKHERHIFLFDGLMICCKSNHGQPRLPGASNAEYRLKEKFFMRKVQINDKDDTNEYKHAFEIILKDENSVIFSAKSAEEKNNWMAALISLQYRSTLERMLDVTMLQEEKEEQMRLPSADVYRFAEPDSEENIIFEENMQPKAGIPIIKAGTVIKLIERLTYHMYADPNFVRTFLTTYRSFCKPQELLSLIIERFEIPEPEPTEADRIAIENGDQPLSAELKRFRKEYIQPVQLRVLNVCRHWVEHHFYDFERDAYLLQRMEEFIGTVRGKAMKKWVESITKIIQRKKIARDNGPGHNITFQSSPPTVEWHISRPGHIETFDLLTLHPIEIARQLTLLESDLYRAVQPSELVGSVWTKEDKEINSPNLLKMIRHTTNLTLWFEKCIVETENLEERVAVVSRIIEILQVFQELNNFNGVLEVVSAMNSSPVYRLDHTFEQIPSRQKKILEEAHELSEDHYKKYLAKLRSINPPCVPFFGIYLTNILKTEEGNPEVLKRHGKELINFSKRRKVAEITGEIQQYQNQPYCLRVESDIKRFFENLNPMGNSMEKEFTDYLFNKSLEIEPRNPKPLPRFPKKYSYPLKSPGVRPSNPRPGTMRHPTPLQQEPRKISYSRIPESETESTASAPNSPRTPLTPPPASGASSTTDVCSVFDSDHSSPFHSSNDTVFIQVTLPHGPRSASVSSISLTKGTDEVPVPPPVPPRRRPESAPAESSPSKIMSKHLDSPPAIPPRQPTSKAYSPRYSISDRTSISDPPESPPLLPPREPVRTPDVFSSSPLHLQPPPLGKKSDHGNAFFPNSPSPFTPPPPQTPSPHGTRRHLPSPPLTQEVDLHSIAGPPVPPRQSTSQHIPKLPPKTYKREHTHPSMHRDGPPLLENAHSS	1333	Q07889	R	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [783, 874], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.04903787, -0.02560449]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
71	NM_005633.3(SOS1):c.806T>C (p.Met269Thr)	40662	CA235344	NM_005633.3:c.806T>C, NC_000002.12:g.39051202A>G, CM000664.2:g.39051202A>G, NC_000002.11:g.39278343A>G, CM000664.1:g.39278343A>G, NC_000002.10:g.39131847A>G, NG_007530.1:g.74262T>C, LRG_754:g.74262T>C, LRG_754t1:c.806T>C, XM_005264515.3:c.806T>C, XM_011533060.1:c.899T>C, XM_011533061.1:c.899T>C, XM_011533062.1:c.785T>C, XM_011533063.1:c.782T>C, XM_011533064.1:c.635T>C, XM_011533065.1:c.899T>C, XM_005264515.4:c.806T>C, XM_011533062.2:c.785T>C, XM_011533064.2:c.635T>C, ENST00000395038.6:c.806T>C, ENST00000402219.6:c.806T>C, ENST00000426016.5:c.806T>C, ENST00000461545.1:n.156T>C, NM_005633.3(SOS1):c.806T>C (p.Met269Thr)	SOS1	Noonan syndrome	MONDO:0018997	Autosomal dominant inheritance	Pathogenic	PM2, PS2_Very Strong, PP2, PP3, PM1		The c.806T>C (p.Met269Thr) variant in SOS1 has been reported in the literature in at least 2 unconfirmed and 1 confirmed de novo occurrences in patients with clinical features of a RASopathy (PS2_VeryStrong; PMID 17586837; 19953625, 20683980). It has also been reported as a confirmed de novo occurrence in a patient with clinical features of a RASoapthy (PMID: 20683980). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). The variant is in SOS1, which has been defined by the ClinGen RASopathy Expert Panel as a gene with low rate of benign missense with missense variants commonly being pathogenic (PP2; PMID 29493581). Computational prediction tools and conservation analysis suggest that the p.Met269Thr variant may impact the protein (PP3). Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of SOS1 (PM1; PMID 29493581). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID: 29493581): PP2, PP3, PM1, PM2, PS2_VeryStrong.	17586837, 19953625, 20683980	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	False	https://erepo.genome.network/evrepo/ui/classification/CA235344/MONDO:0018997/004	4536a40e-a4fc-474b-b83d-f63fa7e74a4a	p.Met269Thr	Met	269	Thr	MQAQQLPYEFFSEENAPKWRGLLVPALKKVQGQVHPTLESNDDALQYVEELILQLLNMLCQAQPRSASDVEERVQKSFPHPIDKWAIADAQSAIEKRKRRNPLSLPVEKIHPLLKEVLGYKIDHQVSVYIVAVLEYISADILKLVGNYVRNIRHYEITKQDIKVAMCADKVLMDMFHQDVEDINILSLTDEEPSTSGEQTYYDLVKAFMAEIRQYIRELNLIIKVFREPFVSNSKLFSANDVENIFSRIVDIHELSVKLLGHIEDTVEMTDEGSPHPLVGSCFEDLAEELAFDPYESYARDILRPGFHDRFLSQLSKPGAALYLQSIGEGFKEAVQYVLPRLLLAPVYHCLHYFELLKQLEEKSEDQEDKECLKQAITALLNVQSGMEKICSKSLAKRRLSESACRFYSQQMKGKQLAIKKMNEIQKNIDGWEGKDIGQCCNEFIMEGTLTRVGAKHERHIFLFDGLMICCKSNHGQPRLPGASNAEYRLKEKFFMRKVQINDKDDTNEYKHAFEIILKDENSVIFSAKSAEEKNNWMAALISLQYRSTLERMLDVTMLQEEKEEQMRLPSADVYRFAEPDSEENIIFEENMQPKAGIPIIKAGTVIKLIERLTYHMYADPNFVRTFLTTYRSFCKPQELLSLIIERFEIPEPEPTEADRIAIENGDQPLSAELKRFRKEYIQPVQLRVLNVCRHWVEHHFYDFERDAYLLQRMEEFIGTVRGKAMKKWVESITKIIQRKKIARDNGPGHNITFQSSPPTVEWHISRPGHIETFDLLTLHPIEIARQLTLLESDLYRAVQPSELVGSVWTKEDKEINSPNLLKMIRHTTNLTLWFEKCIVETENLEERVAVVSRIIEILQVFQELNNFNGVLEVVSAMNSSPVYRLDHTFEQIPSRQKKILEEAHELSEDHYKKYLAKLRSINPPCVPFFGIYLTNILKTEEGNPEVLKRHGKELINFSKRRKVAEITGEIQQYQNQPYCLRVESDIKRFFENLNPMGNSMEKEFTDYLFNKSLEIEPRNPKPLPRFPKKYSYPLKSPGVRPSNPRPGTMRHPTPLQQEPRKISYSRIPESETESTASAPNSPRTPLTPPPASGASSTTDVCSVFDSDHSSPFHSSNDTVFIQVTLPHGPRSASVSSISLTKGTDEVPVPPPVPPRRRPESAPAESSPSKIMSKHLDSPPAIPPRQPTSKAYSPRYSISDRTSISDPPESPPLLPPREPVRTPDVFSSSPLHLQPPPLGKKSDHGNAFFPNSPSPFTPPPPQTPSPHGTRRHLPSPPLTQEVDLHSIAGPPVPPRQSTSQHIPKLPPKTYKREHTHPSMHRDGPPLLENAHSS	1333	Q07889	T	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [516], 'STRAND_gain_score': array([0.00066417]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [783], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.01816827]), 'REGION_loss': [1298], 'REGION_gain': [], 'REGION_loss_score': array([-0.00419468]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
72	NM_005633.3(SOS1):c.2536G>A (p.Glu846Lys)	40706	CA261734	NM_005633.3:c.2536G>A, LRG_754t1:c.2536G>A, XM_005264515.3:c.2536G>A, XM_011533060.1:c.2629G>A, XM_011533061.1:c.2629G>A, XM_011533062.1:c.2515G>A, XM_011533063.1:c.2512G>A, XM_011533064.1:c.2365G>A, XM_011533065.1:c.2629G>A, XM_011533066.1:c.1471G>A, XM_005264515.4:c.2536G>A, XM_011533062.2:c.2515G>A, XM_011533064.2:c.2365G>A, ENST00000395038.6:c.2536G>A, ENST00000402219.6:c.2536G>A, ENST00000426016.5:c.2536G>A, ENST00000474390.1:n.332G>A, NC_000002.12:g.39007168C>T, CM000664.2:g.39007168C>T, NC_000002.11:g.39234309C>T, CM000664.1:g.39234309C>T, NC_000002.10:g.39087813C>T, NG_007530.1:g.118296G>A, LRG_754:g.118296G>A, NM_005633.3(SOS1):c.2536G>A (p.Glu846Lys)	SOS1	Noonan syndrome	MONDO:0018997	Autosomal dominant inheritance	Pathogenic	PM2, PM6, PP2, PP3, PM1, PS3	PS4	The c.2536G>A (p.Glu846Lys) variant in SOS1 has been reported in the literature as an unconfirmed de novo occurrence in a patient with clinical features of a RASopathy (PM6; PMID 23673306). It has also been reported in a patient diagnosed with HCM (PMID 22555271). In vitro functional studies provide some evidence that the p.Glu846Lys variant may impact protein function (PS3; PMID 17143285). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). Computational prediction tools and conservation analysis suggest that the p.Glu846Lys variant may impact the protein (PP3). The variant is located in the SOS1 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Furthermore, the variant is in a location that has been defined to be a mutational hotspot or domain of SOS1 (PM1; PMID 21387466). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PP2, PP3, PM1, PM2, PM6, PS3.	23673306, 17143285, 22555271	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	False	https://erepo.genome.network/evrepo/ui/classification/CA261734/MONDO:0018997/004	f2a2e5e9-f8ba-43a4-9776-40b192ce87cf	p.Glu846Lys	Glu	846	Lys	MQAQQLPYEFFSEENAPKWRGLLVPALKKVQGQVHPTLESNDDALQYVEELILQLLNMLCQAQPRSASDVEERVQKSFPHPIDKWAIADAQSAIEKRKRRNPLSLPVEKIHPLLKEVLGYKIDHQVSVYIVAVLEYISADILKLVGNYVRNIRHYEITKQDIKVAMCADKVLMDMFHQDVEDINILSLTDEEPSTSGEQTYYDLVKAFMAEIRQYIRELNLIIKVFREPFVSNSKLFSANDVENIFSRIVDIHELSVKLLGHIEDTVEMTDEGSPHPLVGSCFEDLAEELAFDPYESYARDILRPGFHDRFLSQLSKPGAALYLQSIGEGFKEAVQYVLPRLLLAPVYHCLHYFELLKQLEEKSEDQEDKECLKQAITALLNVQSGMEKICSKSLAKRRLSESACRFYSQQMKGKQLAIKKMNEIQKNIDGWEGKDIGQCCNEFIMEGTLTRVGAKHERHIFLFDGLMICCKSNHGQPRLPGASNAEYRLKEKFFMRKVQINDKDDTNEYKHAFEIILKDENSVIFSAKSAEEKNNWMAALISLQYRSTLERMLDVTMLQEEKEEQMRLPSADVYRFAEPDSEENIIFEENMQPKAGIPIIKAGTVIKLIERLTYHMYADPNFVRTFLTTYRSFCKPQELLSLIIERFEIPEPEPTEADRIAIENGDQPLSAELKRFRKEYIQPVQLRVLNVCRHWVEHHFYDFERDAYLLQRMEEFIGTVRGKAMKKWVESITKIIQRKKIARDNGPGHNITFQSSPPTVEWHISRPGHIETFDLLTLHPIEIARQLTLLESDLYRAVQPSELVGSVWTKEDKEINSPNLLKMIRHTTNLTLWFEKCIVETENLEERVAVVSRIIEILQVFQELNNFNGVLEVVSAMNSSPVYRLDHTFEQIPSRQKKILEEAHELSEDHYKKYLAKLRSINPPCVPFFGIYLTNILKTEEGNPEVLKRHGKELINFSKRRKVAEITGEIQQYQNQPYCLRVESDIKRFFENLNPMGNSMEKEFTDYLFNKSLEIEPRNPKPLPRFPKKYSYPLKSPGVRPSNPRPGTMRHPTPLQQEPRKISYSRIPESETESTASAPNSPRTPLTPPPASGASSTTDVCSVFDSDHSSPFHSSNDTVFIQVTLPHGPRSASVSSISLTKGTDEVPVPPPVPPRRRPESAPAESSPSKIMSKHLDSPPAIPPRQPTSKAYSPRYSISDRTSISDPPESPPLLPPREPVRTPDVFSSSPLHLQPPPLGKKSDHGNAFFPNSPSPFTPPPPQTPSPHGTRRHLPSPPLTQEVDLHSIAGPPVPPRQSTSQHIPKLPPKTYKREHTHPSMHRDGPPLLENAHSS	1333	Q07889	K	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [487, 489], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.00744802, -0.00891042]), 'HELIX_loss': [849, 852, 853, 856, 857, 858], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.08557141, -0.07098085, -0.05690646, -0.04578745, -0.04145181,
       -0.03618556]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [1102], 'COMPBIAS_gain': [], 'COMPBIAS_loss_score': array([-0.00574589]), 'DOMAIN_loss': [783, 784, 785, 786, 787, 788, 789, 790, 791, 792, 793, 794, 795, 796, 797, 798, 799, 800, 801, 802, 803, 804, 805, 807, 809, 810, 812, 813, 815, 816, 817, 819, 820, 863, 865, 866, 867, 868, 869, 870, 871, 874], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.24069798, -0.20913815, -0.20525193, -0.18728602, -0.21292955,
       -0.20941609, -0.19607687, -0.2109946 , -0.20773691, -0.17890543,
       -0.18815172, -0.20692444, -0.1744622 , -0.19799608, -0.15910906,
       -0.17037195, -0.17487323, -0.16874796, -0.17589343, -0.14523232,
       -0.12224126, -0.16291672, -0.14956349, -0.13810855, -0.13759333,
       -0.14861691, -0.14627528, -0.143255  , -0.14332455, -0.1748358 ,
       -0.17031473, -0.16770482, -0.18747085, -0.20853424, -0.20534116,
       -0.20705295, -0.21071339, -0.18444127, -0.21244115, -0.22554582,
       -0.19590789, -0.20132983]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
73	NM_005633.3(SOS1):c.508A>G (p.Lys170Glu)	40651	CA235342	NM_005633.3:c.508A>G, NC_000002.12:g.39056704T>C, CM000664.2:g.39056704T>C, NC_000002.11:g.39283845T>C, CM000664.1:g.39283845T>C, NC_000002.10:g.39137349T>C, NG_007530.1:g.68760A>G, LRG_754:g.68760A>G, LRG_754t1:c.508A>G, XM_005264515.3:c.508A>G, XM_011533060.1:c.601A>G, XM_011533061.1:c.601A>G, XM_011533062.1:c.487A>G, XM_011533063.1:c.484A>G, XM_011533064.1:c.337A>G, XM_011533065.1:c.601A>G, XM_005264515.4:c.508A>G, XM_011533062.2:c.487A>G, XM_011533064.2:c.337A>G, ENST00000395038.6:c.508A>G, ENST00000402219.6:c.508A>G, ENST00000426016.5:c.508A>G, NM_005633.3(SOS1):c.508A>G (p.Lys170Glu)	SOS1	Noonan syndrome	MONDO:0018997	Autosomal dominant inheritance	Pathogenic	PM2, PM6, PP2, PP3, PM1, PS3		The c.508A>G (p.Lys170Glu) variant in SOS1 has been reported in the literature as an unconfirmed de novo occurrence in a patient with clinical features of a RASopathy (PM6; PMID 19020799, 21387466). In vitro functional studies provide some evidence that the p.Lys170Glu variant may impact protein function (PS3; PMID 21784453, 23487764). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). The variant is located in the SOS1 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of SOS1 (PM1; PMID 29493581). Computational prediction tools and conservation analysis suggest that the p.Lys170Glu variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581):  PP2, PP3, PM1, PM2, PM6, PS3.	21387466, 19020799, 29493581, 21784453, 23487764	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	False	https://erepo.genome.network/evrepo/ui/classification/CA235342/MONDO:0018997/004	07b0e3e7-5c67-41c3-a988-3c438dfba738	p.Lys170Glu	Lys	170	Glu	MQAQQLPYEFFSEENAPKWRGLLVPALKKVQGQVHPTLESNDDALQYVEELILQLLNMLCQAQPRSASDVEERVQKSFPHPIDKWAIADAQSAIEKRKRRNPLSLPVEKIHPLLKEVLGYKIDHQVSVYIVAVLEYISADILKLVGNYVRNIRHYEITKQDIKVAMCADKVLMDMFHQDVEDINILSLTDEEPSTSGEQTYYDLVKAFMAEIRQYIRELNLIIKVFREPFVSNSKLFSANDVENIFSRIVDIHELSVKLLGHIEDTVEMTDEGSPHPLVGSCFEDLAEELAFDPYESYARDILRPGFHDRFLSQLSKPGAALYLQSIGEGFKEAVQYVLPRLLLAPVYHCLHYFELLKQLEEKSEDQEDKECLKQAITALLNVQSGMEKICSKSLAKRRLSESACRFYSQQMKGKQLAIKKMNEIQKNIDGWEGKDIGQCCNEFIMEGTLTRVGAKHERHIFLFDGLMICCKSNHGQPRLPGASNAEYRLKEKFFMRKVQINDKDDTNEYKHAFEIILKDENSVIFSAKSAEEKNNWMAALISLQYRSTLERMLDVTMLQEEKEEQMRLPSADVYRFAEPDSEENIIFEENMQPKAGIPIIKAGTVIKLIERLTYHMYADPNFVRTFLTTYRSFCKPQELLSLIIERFEIPEPEPTEADRIAIENGDQPLSAELKRFRKEYIQPVQLRVLNVCRHWVEHHFYDFERDAYLLQRMEEFIGTVRGKAMKKWVESITKIIQRKKIARDNGPGHNITFQSSPPTVEWHISRPGHIETFDLLTLHPIEIARQLTLLESDLYRAVQPSELVGSVWTKEDKEINSPNLLKMIRHTTNLTLWFEKCIVETENLEERVAVVSRIIEILQVFQELNNFNGVLEVVSAMNSSPVYRLDHTFEQIPSRQKKILEEAHELSEDHYKKYLAKLRSINPPCVPFFGIYLTNILKTEEGNPEVLKRHGKELINFSKRRKVAEITGEIQQYQNQPYCLRVESDIKRFFENLNPMGNSMEKEFTDYLFNKSLEIEPRNPKPLPRFPKKYSYPLKSPGVRPSNPRPGTMRHPTPLQQEPRKISYSRIPESETESTASAPNSPRTPLTPPPASGASSTTDVCSVFDSDHSSPFHSSNDTVFIQVTLPHGPRSASVSSISLTKGTDEVPVPPPVPPRRRPESAPAESSPSKIMSKHLDSPPAIPPRQPTSKAYSPRYSISDRTSISDPPESPPLLPPREPVRTPDVFSSSPLHLQPPPLGKKSDHGNAFFPNSPSPFTPPPPQTPSPHGTRRHLPSPPLTQEVDLHSIAGPPVPPRQSTSQHIPKLPPKTYKREHTHPSMHRDGPPLLENAHSS	1333	Q07889	E	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [516], 'STRAND_gain_score': array([0.00076634]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [783], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.02455795]), 'REGION_loss': [], 'REGION_gain': [1295], 'REGION_gain_score': array([0.00307256]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
74	NM_002880.3(RAF1):c.770C>T (p.Ser257Leu)	13957	CA235334	NM_002880.3:c.770C>T, LRG_413t1:c.770C>T, XM_005265355.1:c.770C>T, XM_005265357.1:c.671C>T, XM_005265358.3:c.527C>T, XM_005265359.3:c.428C>T, XM_005265360.1:c.770C>T, XM_011533974.1:c.770C>T, XM_011533975.1:c.527C>T, NM_001354689.1:c.770C>T, NM_001354690.1:c.770C>T, NM_001354691.1:c.527C>T, NM_001354692.1:c.527C>T, NM_001354693.1:c.671C>T, NM_001354694.1:c.527C>T, NM_001354695.1:c.428C>T, NR_148940.1:n.1185C>T, NR_148941.1:n.1185C>T, NR_148942.1:n.1185C>T, XM_011533974.3:c.770C>T, XM_017006966.1:c.671C>T, XR_001740227.1:n.1002C>T, ENST00000251849.8:c.770C>T, ENST00000416093.1:c.*348C>T, ENST00000423275.5:c.*447C>T, ENST00000432427.2:n.407C>T, ENST00000442415.6:c.770C>T, ENST00000465826.5:n.14C>T, ENST00000491290.1:n.291C>T, NC_000003.12:g.12604200G>A, CM000665.2:g.12604200G>A, NC_000003.11:g.12645699G>A, CM000665.1:g.12645699G>A, NC_000003.10:g.12620699G>A, NG_007467.1:g.64980C>T, LRG_413:g.64980C>T, NM_002880.3(RAF1):c.770C>T (p.Ser257Leu)	RAF1	Noonan syndrome	MONDO:0018997	Autosomal dominant inheritance	Pathogenic	PM2, PP2, PM6_Strong, PM1, PS3		The c.770C>T (p.Ser257Leu) variant in RAF1 has been reported in the literature in at least 2 unconfirmed de novo occurrences in patients with clinical features of a RASopathy (PM6_Strong; PMID 17603482,22389993, 23877478, 23312806, 25706034). In vitro functional studies provide some evidence that the p.Ser257Leu variant may impact protein function (PS3; PMID 17603482). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). The variant is located in the RAF1 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of RAF1 (PM1; PMID 29493581). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. ACMG/AMP criteria applied: PP2, PM1, PM2, PS3, PM6_Strong.	25706034, 17603482, 22389993, 23877478, 29493581, 17603482	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	False	https://erepo.genome.network/evrepo/ui/classification/CA235334/MONDO:0018997/004	6eb64962-8efe-49ca-a5e1-499e4cddd80f	p.Ser257Leu	Ser	257	Leu	MEHIQGAWKTISNGFGFKDAVFDGSSCISPTIVQQFGYQRRASDDGKLTDPSKTSNTIRVFLPNKQRTVVNVRNGMSLHDCLMKALKVRGLQPECCAVFRLLHEHKGKKARLDWNTDAASLIGEELQVDFLDHVPLTTHNFARKTFLKLAFCDICQKFLLNGFRCQTCGYKFHEHCSTKVPTMCVDWSNIRQLLLFPNSTIGDSGVPALPSLTMRRMRESVSRMPVSSQHRYSTPHAFTFNTSSPSSEGSLSQRQRSTSTPNVHMVSTTLPVDSRMIEDAIRSHSESASPSALSSSPNNLSPTGWSQPKTPVPAQRERAPVSGTQEKNKIRPRGQRDSSYYWEIEASEVMLSTRIGSGSFGTVYKGKWHGDVAVKILKVVDPTPEQFQAFRNEVAVLRKTRHVNILLFMGYMTKDNLAIVTQWCEGSSLYKHLHVQETKFQMFQLIDIARQTAQGMDYLHAKNIIHRDMKSNNIFLHEGLTVKIGDFGLATVKSRWSGSQQVEQPTGSVLWMAPEVIRMQDNNPFSFQSDVYSYGIVLYELMTGELPYSHINNRDQIIFMVGRGYASPDLSKLYKNCPKAMKRLVADCVKKVKEERPLFPQILSSIELLQHSLPKINRSASEPSLHRAAHTEDINACTLTTSPRLPVF	648	P04049	L	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [131], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.01317155]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [240, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 283], 'COMPBIAS_gain': [], 'COMPBIAS_loss_score': array([-0.12980509, -0.126095  , -0.10057867, -0.15925568, -0.15776044,
       -0.14801532, -0.16942686, -0.15804166, -0.18230569, -0.1573627 ,
       -0.18528855, -0.23369807, -0.21117437, -0.23724991, -0.21980119,
       -0.21555746, -0.05832034]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [228, 229, 230, 231, 232, 233, 234, 235, 237, 261, 262, 263, 264, 265, 266, 281, 335], 'REGION_gain': [], 'REGION_loss_score': array([-0.16038144, -0.15376633, -0.14253068, -0.15031052, -0.19754273,
       -0.19121796, -0.1967172 , -0.21888494, -0.2311244 , -0.37722999,
       -0.37408435, -0.351372  , -0.29520768, -0.26038712, -0.23388445,
       -0.13254279, -0.03535497]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
75	NM_002880.3(RAF1):c.781C>T (p.Pro261Ser)	13958	CA257062	NM_002880.3:c.781C>T, NC_000003.12:g.12604189G>A, CM000665.2:g.12604189G>A, NC_000003.11:g.12645688G>A, CM000665.1:g.12645688G>A, NC_000003.10:g.12620688G>A, NG_007467.1:g.64991C>T, LRG_413:g.64991C>T, LRG_413t1:c.781C>T, XM_005265355.1:c.781C>T, XM_005265357.1:c.682C>T, XM_005265358.3:c.538C>T, XM_005265359.3:c.439C>T, XM_005265360.1:c.781C>T, XM_011533974.1:c.781C>T, XM_011533975.1:c.538C>T, NM_001354689.1:c.781C>T, NM_001354690.1:c.781C>T, NM_001354691.1:c.538C>T, NM_001354692.1:c.538C>T, NM_001354693.1:c.682C>T, NM_001354694.1:c.538C>T, NM_001354695.1:c.439C>T, NR_148940.1:n.1196C>T, NR_148941.1:n.1196C>T, NR_148942.1:n.1196C>T, XM_011533974.3:c.781C>T, XM_017006966.1:c.682C>T, XR_001740227.1:n.1013C>T, ENST00000251849.8:c.781C>T, ENST00000416093.1:c.*359C>T, ENST00000423275.5:c.*458C>T, ENST00000432427.2:n.418C>T, ENST00000442415.6:c.781C>T, ENST00000465826.5:n.25C>T, ENST00000491290.1:n.302C>T, NM_002880.3(RAF1):c.781C>T (p.Pro261Ser)	RAF1	Noonan syndrome	MONDO:0018997	Autosomal dominant inheritance	Pathogenic	PM2, PP2, PM6_Strong, PM1, PS3		The c.781C>T (p.Pro261Ser) variant in RAF1 has been reported in the literature in at least 2 unconfirmed de novo occurrences in patients with clinical features of a RASopathy (PM6_Strong; PMID 17603482, 20683980). In vitro functional studies provide some evidence that the p.Pro261Leu variant may impact protein function (PS3; PMID 17603483, 17603482). Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of RAF1 (PM1; PMID 29493581). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). The variant is located in the RAF1 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. ACMG/AMP criteria applied: PP2, PM1, PM2, PS3, PM6_Strong.	20683980, 17603482, 17603482	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	False	https://erepo.genome.network/evrepo/ui/classification/CA257062/MONDO:0018997/004	563677cb-406b-41f7-9c7d-7fc9d73cbbe2	p.Pro261Ser	Pro	261	Ser	MEHIQGAWKTISNGFGFKDAVFDGSSCISPTIVQQFGYQRRASDDGKLTDPSKTSNTIRVFLPNKQRTVVNVRNGMSLHDCLMKALKVRGLQPECCAVFRLLHEHKGKKARLDWNTDAASLIGEELQVDFLDHVPLTTHNFARKTFLKLAFCDICQKFLLNGFRCQTCGYKFHEHCSTKVPTMCVDWSNIRQLLLFPNSTIGDSGVPALPSLTMRRMRESVSRMPVSSQHRYSTPHAFTFNTSSPSSEGSLSQRQRSTSTPNVHMVSTTLPVDSRMIEDAIRSHSESASPSALSSSPNNLSPTGWSQPKTPVPAQRERAPVSGTQEKNKIRPRGQRDSSYYWEIEASEVMLSTRIGSGSFGTVYKGKWHGDVAVKILKVVDPTPEQFQAFRNEVAVLRKTRHVNILLFMGYMTKDNLAIVTQWCEGSSLYKHLHVQETKFQMFQLIDIARQTAQGMDYLHAKNIIHRDMKSNNIFLHEGLTVKIGDFGLATVKSRWSGSQQVEQPTGSVLWMAPEVIRMQDNNPFSFQSDVYSYGIVLYELMTGELPYSHINNRDQIIFMVGRGYASPDLSKLYKNCPKAMKRLVADCVKKVKEERPLFPQILSSIELLQHSLPKINRSASEPSLHRAAHTEDINACTLTTSPRLPVF	648	P04049	S	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [131], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.00241619]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [240, 242, 243, 245, 246, 247, 253, 254, 255, 256, 283], 'COMPBIAS_gain': [], 'COMPBIAS_loss_score': array([-0.07075214, -0.07483101, -0.06338537, -0.07641846, -0.08559954,
       -0.08837563, -0.0820654 , -0.07468814, -0.07656354, -0.0700292 ,
       -0.01694107]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [266, 335], 'REGION_gain': [227], 'REGION_gain_score': array([0.00807643]), 'REGION_loss_score': array([-0.04507345, -0.00338858]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
76	NM_002880.3(RAF1):c.1837C>G (p.Leu613Val)	13960	CA257066	NM_002880.3:c.1837C>G, LRG_413t1:c.1837C>G, XM_005265355.1:c.1837C>G, XM_005265357.1:c.1738C>G, XM_005265358.3:c.1594C>G, XM_005265359.3:c.1495C>G, XM_011533974.1:c.1837C>G, XM_011533975.1:c.1594C>G, NM_001354689.1:c.1897C>G, NM_001354690.1:c.1837C>G, NM_001354691.1:c.1594C>G, NM_001354692.1:c.1594C>G, NM_001354693.1:c.1738C>G, NM_001354694.1:c.1654C>G, NM_001354695.1:c.1495C>G, NR_148940.1:n.2365C>G, NR_148941.1:n.2311C>G, NR_148942.1:n.2250C>G, XM_011533974.3:c.1837C>G, XM_017006966.1:c.1738C>G, ENST00000251849.8:c.1837C>G, ENST00000423275.5:c.*1514C>G, ENST00000432427.2:n.1474C>G, ENST00000442415.6:c.1897C>G, ENST00000471449.1:n.526C>G, NC_000003.12:g.12584624G>C, CM000665.2:g.12584624G>C, NC_000003.11:g.12626123G>C, CM000665.1:g.12626123G>C, NC_000003.10:g.12601123G>C, NG_007467.1:g.84556C>G, LRG_413:g.84556C>G, NM_002880.3(RAF1):c.1837C>G (p.Leu613Val)	RAF1	Noonan syndrome	MONDO:0018997	Autosomal dominant inheritance	Pathogenic	PM2, PP2, PS2, PS3		The c.1837C>G (p.Leu613Val) variant in RAF1 has been reported in at least one confirmed de novo case in an individual with clinical features of a RASopathy (PS2; PMID 17603483). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). The variant is located in the RAF1 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). In vitro functional studies provide some evidence that the p.Leu613Val variant may impact protein function (PS3; 17603482, 17603483, 22826437). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PP2, PM2, PS3, PS2.	17603483, 17603483, 17603482, 22826437	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	False	https://erepo.genome.network/evrepo/ui/classification/CA257066/MONDO:0018997/004	f8f03fe0-c539-40c8-ad23-64451f155a8c	p.Leu613Val	Leu	613	Val	MEHIQGAWKTISNGFGFKDAVFDGSSCISPTIVQQFGYQRRASDDGKLTDPSKTSNTIRVFLPNKQRTVVNVRNGMSLHDCLMKALKVRGLQPECCAVFRLLHEHKGKKARLDWNTDAASLIGEELQVDFLDHVPLTTHNFARKTFLKLAFCDICQKFLLNGFRCQTCGYKFHEHCSTKVPTMCVDWSNIRQLLLFPNSTIGDSGVPALPSLTMRRMRESVSRMPVSSQHRYSTPHAFTFNTSSPSSEGSLSQRQRSTSTPNVHMVSTTLPVDSRMIEDAIRSHSESASPSALSSSPNNLSPTGWSQPKTPVPAQRERAPVSGTQEKNKIRPRGQRDSSYYWEIEASEVMLSTRIGSGSFGTVYKGKWHGDVAVKILKVVDPTPEQFQAFRNEVAVLRKTRHVNILLFMGYMTKDNLAIVTQWCEGSSLYKHLHVQETKFQMFQLIDIARQTAQGMDYLHAKNIIHRDMKSNNIFLHEGLTVKIGDFGLATVKSRWSGSQQVEQPTGSVLWMAPEVIRMQDNNPFSFQSDVYSYGIVLYELMTGELPYSHINNRDQIIFMVGRGYASPDLSKLYKNCPKAMKRLVADCVKKVKEERPLFPQILSSIELLQHSLPKINRSASEPSLHRAAHTEDINACTLTTSPRLPVF	648	P04049	V	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
77	NM_002880.3(RAF1):c.1472C>T (p.Thr491Ile)	21342	CA261612	NM_002880.3:c.1472C>T, LRG_413t1:c.1472C>T, XM_005265355.1:c.1472C>T, XM_005265357.1:c.1373C>T, XM_005265358.3:c.1229C>T, XM_005265359.3:c.1130C>T, XM_005265360.1:c.1418-339C>T, XM_011533974.1:c.1472C>T, XM_011533975.1:c.1229C>T, NM_001354689.1:c.1532C>T, NM_001354690.1:c.1472C>T, NM_001354691.1:c.1229C>T, NM_001354692.1:c.1229C>T, NM_001354693.1:c.1373C>T, NM_001354694.1:c.1289C>T, NM_001354695.1:c.1130C>T, NR_148940.1:n.2000C>T, NR_148941.1:n.1946C>T, NR_148942.1:n.1885C>T, XM_011533974.3:c.1472C>T, XM_017006966.1:c.1373C>T, ENST00000251849.8:c.1472C>T, ENST00000423275.5:c.*1149C>T, ENST00000432427.2:n.1109C>T, ENST00000442415.6:c.1532C>T, ENST00000471449.1:n.161C>T, NC_000003.12:g.12585745G>A, CM000665.2:g.12585745G>A, NC_000003.11:g.12627244G>A, CM000665.1:g.12627244G>A, NC_000003.10:g.12602244G>A, NG_007467.1:g.83435C>T, LRG_413:g.83435C>T, NM_002880.3(RAF1):c.1472C>T (p.Thr491Ile)	RAF1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Pathogenic	PM2, PP2, PP3, PM1, PS3		The c.1472C>T (p.Thr491Ile) variant in RAF1 has been reported in the literature in at least one individual with clinical features of a RASopathy (PS4 not met; PMID 17603483). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). The variant is located in the RAF1 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common  (PP2; PMID 29493581). Computational prediction tools and conservation analysis suggest that the p.Thr491Ile variant may impact the protein (PP3). In vitro functional studies provide some evidence that the p.Thr491Ile variant may impact protein function (PS3; 20679480).  Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of RAF1 (PM1; PMID 29493581). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PP2, PP3, PM1, PM2, PS3.	29493581, 20679480	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	False	https://erepo.genome.network/evrepo/ui/classification/CA261612/MONDO:0021060/004	3d3d7a51-6ba9-4434-a6d9-ebf5e4b84ae4	p.Thr491Ile	Thr	491	Ile	MEHIQGAWKTISNGFGFKDAVFDGSSCISPTIVQQFGYQRRASDDGKLTDPSKTSNTIRVFLPNKQRTVVNVRNGMSLHDCLMKALKVRGLQPECCAVFRLLHEHKGKKARLDWNTDAASLIGEELQVDFLDHVPLTTHNFARKTFLKLAFCDICQKFLLNGFRCQTCGYKFHEHCSTKVPTMCVDWSNIRQLLLFPNSTIGDSGVPALPSLTMRRMRESVSRMPVSSQHRYSTPHAFTFNTSSPSSEGSLSQRQRSTSTPNVHMVSTTLPVDSRMIEDAIRSHSESASPSALSSSPNNLSPTGWSQPKTPVPAQRERAPVSGTQEKNKIRPRGQRDSSYYWEIEASEVMLSTRIGSGSFGTVYKGKWHGDVAVKILKVVDPTPEQFQAFRNEVAVLRKTRHVNILLFMGYMTKDNLAIVTQWCEGSSLYKHLHVQETKFQMFQLIDIARQTAQGMDYLHAKNIIHRDMKSNNIFLHEGLTVKIGDFGLATVKSRWSGSQQVEQPTGSVLWMAPEVIRMQDNNPFSFQSDVYSYGIVLYELMTGELPYSHINNRDQIIFMVGRGYASPDLSKLYKNCPKAMKRLVADCVKKVKEERPLFPQILSSIELLQHSLPKINRSASEPSLHRAAHTEDINACTLTTSPRLPVF	648	P04049	I	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
78	NM_002880.3(RAF1):c.768G>T (p.Arg256Ser)	40599	CA261625	NM_002880.3:c.768G>T, LRG_413t1:c.768G>T, XM_005265355.1:c.768G>T, XM_005265357.1:c.669G>T, XM_005265358.3:c.525G>T, XM_005265359.3:c.426G>T, XM_005265360.1:c.768G>T, XM_011533974.1:c.768G>T, XM_011533975.1:c.525G>T, NM_001354689.1:c.768G>T, NM_001354690.1:c.768G>T, NM_001354691.1:c.525G>T, NM_001354692.1:c.525G>T, NM_001354693.1:c.669G>T, NM_001354694.1:c.525G>T, NM_001354695.1:c.426G>T, NR_148940.1:n.1183G>T, NR_148941.1:n.1183G>T, NR_148942.1:n.1183G>T, XM_011533974.3:c.768G>T, XM_017006966.1:c.669G>T, XR_001740227.1:n.1000G>T, ENST00000251849.8:c.768G>T, ENST00000416093.1:c.*346G>T, ENST00000423275.5:c.*445G>T, ENST00000432427.2:n.405G>T, ENST00000442415.6:c.768G>T, ENST00000465826.5:n.12G>T, ENST00000491290.1:n.289G>T, NC_000003.12:g.12604202C>A, CM000665.2:g.12604202C>A, NC_000003.11:g.12645701C>A, CM000665.1:g.12645701C>A, NC_000003.10:g.12620701C>A, NG_007467.1:g.64978G>T, LRG_413:g.64978G>T, NM_002880.3(RAF1):c.768G>T (p.Arg256Ser)	RAF1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Pathogenic	PM2, PP2, PP3, PM1, PS3		The c.768G>T (p.Arg256Ser) variant in RAF1 has been reported in the literature in 1 individual with clinical features of Noonan syndrome and one individual with clinical features of Noonan syndrome with multiple lentigines. This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). The variant is located in the RAF1 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common  (PP2; PMID 29493581). Computational prediction tools and conservation analysis suggest that the p.Arg256Ser variant may impact the protein (PP3). In vitro functional studies provide some evidence that the p.Arg256Ser variant may impact protein function (PS3; 20679480).  Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of RAF1 (PM1; PMID 29493581). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PP2, PP3, PM1, PM2, PS3.		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	False	https://erepo.genome.network/evrepo/ui/classification/CA261625/MONDO:0021060/004	4f1ea3bf-fe0e-4be0-bb44-c2fbf8522598	p.Arg256Ser	Arg	256	Ser	MEHIQGAWKTISNGFGFKDAVFDGSSCISPTIVQQFGYQRRASDDGKLTDPSKTSNTIRVFLPNKQRTVVNVRNGMSLHDCLMKALKVRGLQPECCAVFRLLHEHKGKKARLDWNTDAASLIGEELQVDFLDHVPLTTHNFARKTFLKLAFCDICQKFLLNGFRCQTCGYKFHEHCSTKVPTMCVDWSNIRQLLLFPNSTIGDSGVPALPSLTMRRMRESVSRMPVSSQHRYSTPHAFTFNTSSPSSEGSLSQRQRSTSTPNVHMVSTTLPVDSRMIEDAIRSHSESASPSALSSSPNNLSPTGWSQPKTPVPAQRERAPVSGTQEKNKIRPRGQRDSSYYWEIEASEVMLSTRIGSGSFGTVYKGKWHGDVAVKILKVVDPTPEQFQAFRNEVAVLRKTRHVNILLFMGYMTKDNLAIVTQWCEGSSLYKHLHVQETKFQMFQLIDIARQTAQGMDYLHAKNIIHRDMKSNNIFLHEGLTVKIGDFGLATVKSRWSGSQQVEQPTGSVLWMAPEVIRMQDNNPFSFQSDVYSYGIVLYELMTGELPYSHINNRDQIIFMVGRGYASPDLSKLYKNCPKAMKRLVADCVKKVKEERPLFPQILSSIELLQHSLPKINRSASEPSLHRAAHTEDINACTLTTSPRLPVF	648	P04049	S	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [131], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.00079393]), 'HELIX_loss': [542], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.00327575]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [240, 242, 255, 256, 283], 'COMPBIAS_gain': [], 'COMPBIAS_loss_score': array([-0.04785925, -0.05195004, -0.07988787, -0.06508428, -0.02482492]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [335], 'REGION_gain': [], 'REGION_loss_score': array([-0.00599927]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
79	NM_002834.4(PTPN11):c.922A>G (p.Asn308Asp)	13326	CA220158	NM_002834.4:c.922A>G, NC_000012.12:g.112477719A>G, CM000674.2:g.112477719A>G, NC_000012.11:g.112915523A>G, CM000674.1:g.112915523A>G, NC_000012.10:g.111399906A>G, NG_007459.1:g.63988A>G, LRG_614:g.63988A>G, NM_002834.3:c.922A>G, LRG_614t1:c.922A>G, NM_080601.1:c.922A>G, XM_006719526.1:c.922A>G, XM_006719527.1:c.808A>G, XM_011538613.1:c.919A>G, NM_001330437.1:c.922A>G, NM_080601.2:c.922A>G, XM_011538613.2:c.919A>G, XM_017019722.1:c.919A>G, ENST00000351677.6:c.922A>G, ENST00000392597.5:c.922A>G, ENST00000635625.1:n.922A>G, NM_002834.4(PTPN11):c.922A>G (p.Asn308Asp)	PTPN11	Noonan syndrome	MONDO:0018997	Autosomal dominant inheritance	Pathogenic	PM2, PS2_Very Strong, PP2, PP3, PS3, PP1_Strong	PM6	The c.922A>G (p.Asn308Asp) variant in PTPN11 has been reported in the literature as a confirmed and unconfirmed de novo occurrence in 2 patients with clinical features of a RASopathy (PS2_VeryStrong; PMID 20979190, and 11704759, 22465605). The variant has co-segregated with disease in more than 7 family members (PP1_Strong; PMID: 11992261). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). The variant is located in the PTPN11 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common  (PP2; PMID 29493581). Computational prediction tools and conservation analysis suggest that the p.Asn308Asp variant may impact the protein (PP3). Additionally, at least 2  functional studies have been concordant in showing that this variant may be deleterious to the protein (PS3; PMID 14974085, 15987685, 19509418, 20308328). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PP2, PP3, PM2, PP1_Strong, PS2_VeryStrong, PS3.		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	False	https://erepo.genome.network/evrepo/ui/classification/CA220158/MONDO:0018997/004	6525f07c-2ebf-4229-9447-62d126ad46cd	p.Asn308Asp	Asn	308	Asp	MTSRRWFHPNITGVEAENLLLTRGVDGSFLARPSKSNPGDFTLSVRRNGAVTHIKIQNTGDYYDLYGGEKFATLAELVQYYMEHHGQLKEKNGDVIELKYPLNCADPTSERWFHGHLSGKEAEKLLTEKGKHGSFLVRESQSHPGDFVLSVRTGDDKGESNDGKSKVTHVMIRCQELKYDVGGGERFDSLTDLVEHYKKNPMVETLGTVLQLKQPLNTTRINAAEIESRVRELSKLAETTDKVKQGFWEEFETLQQQECKLLYSRKEGQRQENKNKNRYKNILPFDHTRVVLHDGDPNEPVSDYINANIIMPEFETKCNNSKPKKSYIATQGCLQNTVNDFWRMVFQENSRVIVMTTKEVERGKSKCVKYWPDEYALKEYGVMRVRNVKESAAHDYTLRELKLSKVGQGNTERTVWQYHFRTWPDHGVPSDPGGVLDFLEEVHHKQESIMDAGPVVVHCSAGIGRTGTFIVIDILIDIIREKGVDCDIDVPKTIQMVRSQRSGMVQTEAQYRFIYMAVQHYIETLQRRIEEEQKSKRKGHEYTNIKYSLADQTSGDQSPLPPCTPTPPCAEMREDSARVYENVGLMQQQKSFR	593	Q06124	D	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [94], 'DOMAIN_gain_score': array([0.01372331]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
80	NM_030662.3(MAP2K2):c.401A>G (p.Tyr134Cys)	177868	CA180890	NM_030662.3:c.401A>G, NC_000019.10:g.4110558T>C, CM000681.2:g.4110558T>C, NC_000019.9:g.4110556T>C, CM000681.1:g.4110556T>C, NC_000019.8:g.4061556T>C, NG_007996.1:g.18571A>G, LRG_750:g.18571A>G, LRG_750t1:c.401A>G, XM_006722799.2:c.401A>G, XM_017026989.1:c.401A>G, XM_017026990.1:c.401A>G, XM_017026991.1:c.401A>G, ENST00000262948.9:c.401A>G, ENST00000394867.8:c.110A>G, ENST00000599345.1:n.598A>G, NM_030662.3(MAP2K2):c.401A>G (p.Tyr134Cys)	MAP2K2	cardiofaciocutaneous syndrome	MONDO:0015280	Autosomal dominant inheritance	Pathogenic	PM2, PP2, PP3, PM1, PS3		The c.401A>G (p.Tyr134Cys) variant in MAP2K2 has been identified in one patient with clinical features of a RASopathy (PMID 18413255). In vitro functional studies provide some evidence that the p.Tyr134Cys variant may impact protein function (PS3; PMID 18413255). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). The variant is located in the MAP2K2 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common  (PP2; PMID 29493581). Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of MAP2K2 (PM1; PMID 29493581). Computational prediction tools and conservation analysis suggest that the p.Tyr134Cys variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PS3, PM2, PM1, PP2, PP3.	29493581, 18413255	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-05-09	2018-12-10	False	https://erepo.genome.network/evrepo/ui/classification/CA180890/MONDO:0015280/004	06d3c00a-69eb-4612-b456-062e6ac0a274	p.Tyr134Cys	Tyr	134	Cys	MLARRKPVLPALTINPTIAEGPSPTSEGASEANLVDLQKKLEELELDEQQKKRLEAFLTQKAKVGELKDDDFERISELGAGNGGVVTKVQHRPSGLIMARKLIHLEIKPAIRNQIIRELQVLHECNSPYIVGFYGAFYSDGEISICMEHMDGGSLDQVLKEAKRIPEEILGKVSIAVLRGLAYLREKHQIMHRDVKPSNILVNSRGEIKLCDFGVSGQLIDSMANSFVGTRSYMAPERLQGTHYSVQSDIWSMGLSLVELAVGRYPIPPPDAKELEAIFGRPVVDGEEGEPHSISPRPRPPGRPVSGHGMDSRPAMAIFELLDYIVNEPPPKLPNGVFTPDFQEFVNKCLIKNPAERADLKMLTNHTFIKRSEVEEVDFAGWLCKTLRLNQPGTPTRTAV	400	P36507	C	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [37], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.00433797]), 'COILED_loss': [], 'COILED_gain': [62], 'COILED_gain_score': array([0.00998533]), 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
81	NM_030662.3(MAP2K2):c.170T>G (p.Phe57Cys)	8272	CA279958	NM_030662.3:c.170T>G, LRG_750t1:c.170T>G, XM_006722799.2:c.170T>G, XM_017026989.1:c.170T>G, XM_017026990.1:c.170T>G, XM_017026991.1:c.170T>G, ENST00000262948.9:c.170T>G, ENST00000394867.8:c.-122T>G, ENST00000599345.1:n.367T>G, NC_000019.10:g.4117552A>C, CM000681.2:g.4117552A>C, NC_000019.9:g.4117550A>C, CM000681.1:g.4117550A>C, NC_000019.8:g.4068550A>C, NG_007996.1:g.11577T>G, LRG_750:g.11577T>G, NM_030662.3(MAP2K2):c.170T>G (p.Phe57Cys)	MAP2K2	cardiofaciocutaneous syndrome	MONDO:0015280	Autosomal dominant inheritance	Pathogenic	PM2, PM6, PP2, PP3, PM1, PM5, PS3		The c.170T>G (p.Phe57Cys) variant in MAP2K2 has been reported in the literature as an unconfirmed de novo occurrence in a patient with clinical features of a RASopathy (PM6; PMID 16439621). In vitro functional studies provide some evidence that the p.Phe57Cys variant may impact protein function (PS3; PMID 16439621). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). A different pathogenic missense variant has been previously identified at this codon of MAP2K2 (p.Phe57Val for malignant melanoma) which may indicate that this residue is critical to the function of the protein (PM5; ClinVar 8273). The variant is located in the MAP2K2 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common  (PP2; PMID 29493581). Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of MAP2K2 (PM1; PMID 29493581). Computational prediction tools and conservation analysis suggest that the p.Phe57Cys variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PM6, PS3, PM2, PM5, PP2, PM1, PP3.	16439621	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-05-09	2018-12-10	False	https://erepo.genome.network/evrepo/ui/classification/CA279958/MONDO:0015280/004	07aecf91-9cf2-48c7-b101-b21e809f57a4	p.Phe57Cys	Phe	57	Cys	MLARRKPVLPALTINPTIAEGPSPTSEGASEANLVDLQKKLEELELDEQQKKRLEAFLTQKAKVGELKDDDFERISELGAGNGGVVTKVQHRPSGLIMARKLIHLEIKPAIRNQIIRELQVLHECNSPYIVGFYGAFYSDGEISICMEHMDGGSLDQVLKEAKRIPEEILGKVSIAVLRGLAYLREKHQIMHRDVKPSNILVNSRGEIKLCDFGVSGQLIDSMANSFVGTRSYMAPERLQGTHYSVQSDIWSMGLSLVELAVGRYPIPPPDAKELEAIFGRPVVDGEEGEPHSISPRPRPPGRPVSGHGMDSRPAMAIFELLDYIVNEPPPKLPNGVFTPDFQEFVNKCLIKNPAERADLKMLTNHTFIKRSEVEEVDFAGWLCKTLRLNQPGTPTRTAV	400	P36507	C	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [16], 'TRANSIT_gain': [], 'TRANSIT_loss_score': array([-0.00923038]), 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [37, 41, 59], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.00178003, -0.00699526, -0.09487396]), 'COILED_loss': [], 'COILED_gain': [62], 'COILED_gain_score': array([0.08186078]), 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [0], 'REGION_gain': [], 'REGION_loss_score': array([-0.03530955]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
82	NM_030662.3(MAP2K2):c.383C>A (p.Pro128Gln)	8275	CA279962	NM_030662.3:c.383C>A, LRG_750t1:c.383C>A, XM_006722799.2:c.383C>A, XM_017026989.1:c.383C>A, XM_017026990.1:c.383C>A, XM_017026991.1:c.383C>A, ENST00000262948.9:c.383C>A, ENST00000394867.8:c.92C>A, ENST00000599345.1:n.580C>A, NC_000019.10:g.4110576G>T, CM000681.2:g.4110576G>T, NC_000019.9:g.4110574G>T, CM000681.1:g.4110574G>T, NC_000019.8:g.4061574G>T, NG_007996.1:g.18553C>A, LRG_750:g.18553C>A, NM_030662.3(MAP2K2):c.383C>A (p.Pro128Gln)	MAP2K2	cardiofaciocutaneous syndrome	MONDO:0015280	Autosomal dominant inheritance	Pathogenic	PM2, PP2, PP3, PP1, PM1, PS3		The c.383C>A (p.Pro128Gln) variant in MAP2K2 has been reported in the literature to segregate with clinical features of a RASopathy in at least 7 family members (PP1_Strong; 20358587). In vitro functional studies provide some evidence that the p.Pro128Gln variant may impact protein function (PS3; PMID 20358587). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). The variant is located in the MAP2K2 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID 29493581). Computational prediction tools and conservation analysis suggest that the p.Pro128Gln variant may impact the protein (PP3). Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of MAP2K2 (PM1; PMID 29493581). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PP1_Strong, PS3, PM1, PM2, PP2, PP3.	20358587	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-05-09	2018-12-10	False	https://erepo.genome.network/evrepo/ui/classification/CA279962/MONDO:0015280/004	307f4b6c-ef49-48bd-98e2-5cf382642800	p.Pro128Gln	Pro	128	Gln	MLARRKPVLPALTINPTIAEGPSPTSEGASEANLVDLQKKLEELELDEQQKKRLEAFLTQKAKVGELKDDDFERISELGAGNGGVVTKVQHRPSGLIMARKLIHLEIKPAIRNQIIRELQVLHECNSPYIVGFYGAFYSDGEISICMEHMDGGSLDQVLKEAKRIPEEILGKVSIAVLRGLAYLREKHQIMHRDVKPSNILVNSRGEIKLCDFGVSGQLIDSMANSFVGTRSYMAPERLQGTHYSVQSDIWSMGLSLVELAVGRYPIPPPDAKELEAIFGRPVVDGEEGEPHSISPRPRPPGRPVSGHGMDSRPAMAIFELLDYIVNEPPPKLPNGVFTPDFQEFVNKCLIKNPAERADLKMLTNHTFIKRSEVEEVDFAGWLCKTLRLNQPGTPTRTAV	400	P36507	Q	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [16], 'TRANSIT_gain': [], 'TRANSIT_loss_score': array([-0.00426406]), 'STRAND_loss': [], 'STRAND_gain': [151], 'STRAND_gain_score': array([0.03679347]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
83	NM_002755.3(MAP2K1):c.158T>C (p.Phe53Ser)	13350	CA279966	NM_002755.3:c.158T>C, LRG_725t1:c.158T>C, XM_011521783.1:c.92T>C, XM_011521783.3:c.92T>C, XM_017022411.2:c.158T>C, XM_017022412.1:c.92T>C, ENST00000307102.9:c.158T>C, ENST00000425818.2:n.669T>C, NC_000015.10:g.66435104T>C, CM000677.2:g.66435104T>C, NC_000015.9:g.66727442T>C, CM000677.1:g.66727442T>C, NC_000015.8:g.64514496T>C, NG_008305.1:g.53232T>C, LRG_725:g.53232T>C, NM_002755.3(MAP2K1):c.158T>C (p.Phe53Ser)	MAP2K1	cardiofaciocutaneous syndrome	MONDO:0015280	Autosomal dominant inheritance	Pathogenic	PM2, PM6, PP2, PP3, PM1, PS3		The c.158T>C (p.Phe53Ser) variant in MAP2K1 has been reported in the literature as an unconfirmed de novo occurrence in a patient with clinical features of a RASopathy (PM6; PMID 16439621). In vitro functional studies provide some evidence that the p.Phe53Ser variant may impact protein function (PS3; PMID 16439621). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). The variant is located in the MAP2K1 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID 29493581). Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of MAP2K1 (PM1; PMID 29493581). Computational prediction tools and conservation analysis suggest that the p.Phe53Ser variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID: 29493581):  PM6, PS3, PM2, PP2, PM1, PP3.	16439621, 16439621	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-05-09	2018-12-10	False	https://erepo.genome.network/evrepo/ui/classification/CA279966/MONDO:0015280/004	b78d797f-9630-4e8f-a1e3-8bf3ece401f5	p.Phe53Ser	Phe	53	Ser	MPKKKPTPIQLNPAPDGSAVNGTSSAETNLEALQKKLEELELDEQQRKRLEAFLTQKQKVGELKDDDFEKISELGAGNGGVVFKVSHKPSGLVMARKLIHLEIKPAIRNQIIRELQVLHECNSPYIVGFYGAFYSDGEISICMEHMDGGSLDQVLKKAGRIPEQILGKVSIAVIKGLTYLREKHKIMHRDVKPSNILVNSRGEIKLCDFGVSGQLIDSMANSFVGTRSYMSPERLQGTHYSVQSDIWSMGLSLVEMAVGRYPIPPPDAKELELMFGCQVEGDAAETPPRPRTPGRPLSSYGMDSRPPMAIFELLDYIVNEPPPKLPSGVFSLEFQDFVNKCLIKNPAERADLKQLMVHAFIKRSDAEEVDFAGWLCSTIGLNQPSTPTHAAGV	393	Q02750	S	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [30, 31, 32, 34, 35, 38, 55, 56], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.08618915, -0.07426465, -0.09409219, -0.09126389, -0.08274585,
       -0.07146752, -0.17886269, -0.20765734]), 'COILED_loss': [], 'COILED_gain': [59, 60], 'COILED_gain_score': array([0.284711, 0.312814]), 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
84	NM_002755.3(MAP2K1):c.199G>A (p.Asp67Asn)	40781	CA180743	NM_002755.3:c.199G>A, NC_000015.10:g.66435145G>A, CM000677.2:g.66435145G>A, NC_000015.9:g.66727483G>A, CM000677.1:g.66727483G>A, NC_000015.8:g.64514537G>A, NG_008305.1:g.53273G>A, LRG_725:g.53273G>A, LRG_725t1:c.199G>A, XM_011521783.1:c.133G>A, XM_011521783.3:c.133G>A, XM_017022411.2:c.199G>A, XM_017022412.1:c.133G>A, ENST00000307102.9:c.199G>A, ENST00000425818.2:n.710G>A, NM_002755.3(MAP2K1):c.199G>A (p.Asp67Asn)	MAP2K1	cardiofaciocutaneous syndrome	MONDO:0015280	Autosomal dominant inheritance	Pathogenic	PM2, PP2, PP3, PM6_Strong, PS3		The c.199G>A (p.Asp67Asn) variant in MAP2K1 has been reported in the literature in at least 2 unconfirmed de novo occurrences in patients with clinical features of a RASopathy (PM6_Strong; PMID 17704260). In vitro functional studies provide some evidence that the p.Asp67Asn variant may impact protein function (PS3; PMID 25049390). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). The variant is located in the MAP2K1 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Computational prediction tools and conservation analysis suggest that the p.Asp67Asn variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581):  PM6_Strong, PS3, PM2, PP2, PP3.	17704260, 25049390	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-05-09	2020-01-23	False	https://erepo.genome.network/evrepo/ui/classification/CA180743/MONDO:0015280/004	8197dee3-bc2e-49dc-88bc-d31b5fd7286f	p.Asp67Asn	Asp	67	Asn	MPKKKPTPIQLNPAPDGSAVNGTSSAETNLEALQKKLEELELDEQQRKRLEAFLTQKQKVGELKDDDFEKISELGAGNGGVVFKVSHKPSGLVMARKLIHLEIKPAIRNQIIRELQVLHECNSPYIVGFYGAFYSDGEISICMEHMDGGSLDQVLKKAGRIPEQILGKVSIAVIKGLTYLREKHKIMHRDVKPSNILVNSRGEIKLCDFGVSGQLIDSMANSFVGTRSYMSPERLQGTHYSVQSDIWSMGLSLVEMAVGRYPIPPPDAKELELMFGCQVEGDAAETPPRPRTPGRPLSSYGMDSRPPMAIFELLDYIVNEPPPKLPSGVFSLEFQDFVNKCLIKNPAERADLKQLMVHAFIKRSDAEEVDFAGWLCSTIGLNQPSTPTHAAGV	393	Q02750	N	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [59], 'COILED_gain_score': array([0.09131581]), 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
85	NM_002755.3(MAP2K1):c.388T>C (p.Tyr130His)	40747	CA279999	NM_002755.3:c.388T>C, LRG_725t1:c.388T>C, XM_011521783.1:c.322T>C, XM_011521783.3:c.322T>C, XM_017022411.2:c.388T>C, XM_017022412.1:c.322T>C, NM_002755.4:c.388T>C, ENST00000307102.9:c.388T>C, ENST00000425818.2:n.899T>C, NC_000015.10:g.66436842T>C, CM000677.2:g.66436842T>C, NC_000015.9:g.66729180T>C, CM000677.1:g.66729180T>C, NC_000015.8:g.64516234T>C, NG_008305.1:g.54970T>C, LRG_725:g.54970T>C, NM_002755.3(MAP2K1):c.388T>C (p.Tyr130His)	MAP2K1	cardiofaciocutaneous syndrome	MONDO:0015280	Autosomal dominant inheritance	Pathogenic	PM2, PP2, PP3, PM6_Strong, PS4_Supporting, PM5		The c.388T>C (p.Tyr130His) variant in MAP2K1 has been reported as an unconfirmed de novo occurrence in two probands with clinical features of a RASopathy (PM6_Strong; PMID: 1915617, Ambry Genetics internal data, ClinVar SCV000740998.1). One of these patients had a clinical diagnosis of cardiofaciocutaneous syndrome (PS4_Supporting). This variant was absent from large population studies (PM2; gnomad.broadinstitute.org). The variant is located in the MAP2K1 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID 29493581). The variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of MAP2K1 (PM1 not applied; PMID 29493581). Moreover, a different pathogenic missense variant has been previously identified at this codon of MAP2K1 which may indicate that this residue is critical to the function of the protein (PM5; ClinVar 13351). Computational prediction tools and conservation analysis suggest that the p.Tyr130His variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. RASopathy-specific ACMG/AMP criteria applied (PMID:29493581): PS4_Supporting, PM6_Strong, PM5, PM2, PP2, PP3.		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2020-05-18	2020-07-01	False	https://erepo.genome.network/evrepo/ui/classification/CA279999/MONDO:0015280/004	9f86afbc-b31d-472c-ac5d-ee0799f21c9c	p.Tyr130His	Tyr	130	His	MPKKKPTPIQLNPAPDGSAVNGTSSAETNLEALQKKLEELELDEQQRKRLEAFLTQKQKVGELKDDDFEKISELGAGNGGVVFKVSHKPSGLVMARKLIHLEIKPAIRNQIIRELQVLHECNSPYIVGFYGAFYSDGEISICMEHMDGGSLDQVLKKAGRIPEQILGKVSIAVIKGLTYLREKHKIMHRDVKPSNILVNSRGEIKLCDFGVSGQLIDSMANSFVGTRSYMSPERLQGTHYSVQSDIWSMGLSLVEMAVGRYPIPPPDAKELELMFGCQVEGDAAETPPRPRTPGRPLSSYGMDSRPPMAIFELLDYIVNEPPPKLPSGVFSLEFQDFVNKCLIKNPAERADLKQLMVHAFIKRSDAEEVDFAGWLCSTIGLNQPSTPTHAAGV	393	Q02750	H	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [241], 'HELIX_gain_score': array([0.00620592]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
86	NM_002755.3(MAP2K1):c.389A>G (p.Tyr130Cys)	13351	CA280036	NM_002755.3:c.389A>G, LRG_725t1:c.389A>G, XM_011521783.1:c.323A>G, XM_011521783.3:c.323A>G, XM_017022411.2:c.389A>G, XM_017022412.1:c.323A>G, ENST00000307102.9:c.389A>G, ENST00000425818.2:n.900A>G, NC_000015.10:g.66436843A>G, CM000677.2:g.66436843A>G, NC_000015.9:g.66729181A>G, CM000677.1:g.66729181A>G, NC_000015.8:g.64516235A>G, NG_008305.1:g.54971A>G, LRG_725:g.54971A>G, NM_002755.3(MAP2K1):c.389A>G (p.Tyr130Cys)	MAP2K1	cardiofaciocutaneous syndrome	MONDO:0015280	Autosomal dominant inheritance	Pathogenic	PS2_Very Strong, PM2, PP2, PP3, PM1, PS3		The c.389A>G (p.Tyr130Cys) variant in MAP2K1 has been reported as a confirmed de novo occurrence in at least 2 patients with clinical features of a RASopathy (PS2_VeryStong; PMID 16439621, 17551924, 18042262). In vitro functional studies provide some evidence that the p.Tyr130Cys variant may impact protein function (PS3; PMID 18413255, 23093928, 17981815). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). The variant is located in the MAP2K1 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common  (PP2; PMID 29493581). Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of MAP2K1 (PM1; PMID 29493581). Computational prediction tools and conservation analysis suggest that the p.Tyr130Cys variant may impact the protein (PP3).  In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PS2_VeryStrong, PP3, PS3, PM2, PP2, PM1.	16439621, 18042262, 17551924, 18413255, 17981815, 23093928	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-05-09	2018-12-10	False	https://erepo.genome.network/evrepo/ui/classification/CA280036/MONDO:0015280/004	1eaf4dad-ab0c-49ae-8548-22bad4210249	p.Tyr130Cys	Tyr	130	Cys	MPKKKPTPIQLNPAPDGSAVNGTSSAETNLEALQKKLEELELDEQQRKRLEAFLTQKQKVGELKDDDFEKISELGAGNGGVVFKVSHKPSGLVMARKLIHLEIKPAIRNQIIRELQVLHECNSPYIVGFYGAFYSDGEISICMEHMDGGSLDQVLKKAGRIPEQILGKVSIAVIKGLTYLREKHKIMHRDVKPSNILVNSRGEIKLCDFGVSGQLIDSMANSFVGTRSYMSPERLQGTHYSVQSDIWSMGLSLVEMAVGRYPIPPPDAKELELMFGCQVEGDAAETPPRPRTPGRPLSSYGMDSRPPMAIFELLDYIVNEPPPKLPSGVFSLEFQDFVNKCLIKNPAERADLKQLMVHAFIKRSDAEEVDFAGWLCSTIGLNQPSTPTHAAGV	393	Q02750	C	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [241], 'HELIX_gain_score': array([0.00678623]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
87	NM_004333.4(BRAF):c.1741A>G (p.Asn581Asp)	13979	CA279976	NM_004333.4:c.1741A>G, LRG_299t1:c.1741A>G, XM_005250045.1:c.1741A>G, XM_005250046.1:c.1741A>G, XM_011516529.1:c.1741A>G, XM_011516530.1:c.1695-4769A>G, XR_242190.1:n.1749A>G, XR_927520.1:n.1749A>G, XR_927521.1:n.1749A>G, XR_927522.1:n.1703-4769A>G, XR_927523.1:n.1703-4769A>G, NM_001354609.1:c.1741A>G, NM_004333.5:c.1741A>G, NR_148928.1:n.2046A>G, XM_017012558.1:c.1861A>G, XM_017012559.1:c.1861A>G, XR_001744857.1:n.1869A>G, XR_001744858.1:n.1823-4769A>G, ENST00000288602.10:c.1741A>G, ENST00000479537.5:n.25A>G, ENST00000496384.6:n.564A>G, ENST00000497784.1:n.1776A>G, NC_000007.14:g.140754187T>C, CM000669.2:g.140754187T>C, NC_000007.13:g.140453987T>C, CM000669.1:g.140453987T>C, NC_000007.12:g.140100456T>C, NG_007873.3:g.175578A>G, LRG_299:g.175578A>G, NM_004333.4(BRAF):c.1741A>G (p.Asn581Asp)	BRAF	cardiofaciocutaneous syndrome	MONDO:0015280	Autosomal dominant inheritance	Pathogenic	PM2, PP2, PP3, PM6_Strong, PM1, PS3		The c.1741A>G (p.Asn581Asp) variant in BRAF has been reported in the literature as a non-maternity/paternity confirmed de novo occurrence in at least 2 patients with clinical features of a RASopathy (PM6_Strong; PMID 25463315). In vitro functional studies provide some evidence that the p.Asn581Asp variant may impact protein function (PS3; 19376813, 16474404).  This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). The variant is located in the BRAF gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common  (PP2; PMID 29493581). Furthermore, this variant is located in the catalytic loop of BRAF (PM1; 16474404, 29493581).  Computational prediction tools and conservation analysis suggest that the p.Asn581Asp variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PP2, PP3, PM1, PM2, PM6_Strong, PS3.		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	False	https://erepo.genome.network/evrepo/ui/classification/CA279976/MONDO:0015280/004	f2cf40e6-1706-4a5e-b2f8-b7b396ddbde2	p.Asn581Asp	Asn	581	Asp	MAALSGGGGGGAEPGQALFNGDMEPEAGAGAGAAASSAADPAIPEEVWNIKQMIKLTQEHIEALLDKFGGEHNPPSIYLEAYEEYTSKLDALQQREQQLLESLGNGTDFSVSSSASMDTVTSSSSSSLSVLPSSLSVFQNPTDVARSNPKSPQKPIVRVFLPNKQRTVVPARCGVTVRDSLKKALMMRGLIPECCAVYRIQDGEKKPIGWDTDISWLTGEELHVEVLENVPLTTHNFVRKTFFTLAFCDFCRKLLFQGFRCQTCGYKFHQRCSTEVPLMCVNYDQLDLLFVSKFFEHHPIPQEEASLAETALTSGSSPSAPASDSIGPQILTSPSPSKSIPIPQPFRPADEDHRNQFGQRDRSSSAPNVHINTIEPVNIDDLIRDQGFRGDGGSTTGLSATPPASLPGSLTNVKALQKSPGPQRERKSSSSSEDRNRMKTLGRRDSSDDWEIPDGQITVGQRIGSGSFGTVYKGKWHGDVAVKMLNVTAPTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHHLHIIETKFEMIKLIDIARQTAQGMDYLHAKSIIHRDLKSNNIFLHEDLTVKIGDFGLATVKSRWSGSHQFEQLSGSILWMAPEVIRMQDKNPYSFQSDVYAFGIVLYELMTGQLPYSNINNRDQIIFMVGRGYLSPDLSKVRSNCPKAMKRLMAECLKKKRDERPLFPQILASIELLARSLPKIHRSASEPSLNRAGFQTEDFSLYACASPKTPIQAGGYGAFPVH	766	P15056	D	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [374], 'REGION_gain': [], 'REGION_loss_score': array([-0.00324529]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
88	NM_004333.4(BRAF):c.736G>C (p.Ala246Pro)	13965	CA279968	NM_004333.4:c.736G>C, NC_000007.14:g.140801536C>G, CM000669.2:g.140801536C>G, NC_000007.13:g.140501336C>G, CM000669.1:g.140501336C>G, NC_000007.12:g.140147805C>G, NG_007873.3:g.128229G>C, LRG_299:g.128229G>C, LRG_299t1:c.736G>C, XM_005250045.1:c.736G>C, XM_005250046.1:c.736G>C, XM_011516529.1:c.736G>C, XM_011516530.1:c.736G>C, XR_242190.1:n.744G>C, XR_927520.1:n.744G>C, XR_927521.1:n.744G>C, XR_927522.1:n.744G>C, XR_927523.1:n.744G>C, NM_001354609.1:c.736G>C, NM_004333.5:c.736G>C, NR_148928.1:n.1041G>C, XM_017012558.1:c.736G>C, XM_017012559.1:c.736G>C, XR_001744857.1:n.744G>C, XR_001744858.1:n.744G>C, ENST00000288602.10:c.736G>C, ENST00000497784.1:n.771G>C, NM_004333.4(BRAF):c.736G>C (p.Ala246Pro)	BRAF	cardiofaciocutaneous syndrome	MONDO:0015280	Autosomal dominant inheritance	Pathogenic	PM6, PM2, PP2, PP3, PM1, PS3, PS2		The c.736G>C (p.Ala246Pro) variant in BRAF has been reported in the literature as a de novo occurrence in at least 2 patients with clinical features of a RASopathy (PM6 and PS2; PMID 16474404 and 18042262). In vitro functional studies provide some evidence that the p.Ala246Pro variant may impact protein function (PS3; 16474404, 19376813).  This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). The variant is located in the BRAF gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID 29493581). This variant is in a location which has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of BRAF (PM1; PMID 29493581). Computational prediction tools and conservation analysis suggest that the p.Ala246Pro variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PP2, PP3, PM1, PM2, PM6, PS2, PS3.		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	False	https://erepo.genome.network/evrepo/ui/classification/CA279968/MONDO:0015280/004	2eac9953-9576-4ab4-8bd3-c9d0c1d40f0c	p.Ala246Pro	Ala	246	Pro	MAALSGGGGGGAEPGQALFNGDMEPEAGAGAGAAASSAADPAIPEEVWNIKQMIKLTQEHIEALLDKFGGEHNPPSIYLEAYEEYTSKLDALQQREQQLLESLGNGTDFSVSSSASMDTVTSSSSSSLSVLPSSLSVFQNPTDVARSNPKSPQKPIVRVFLPNKQRTVVPARCGVTVRDSLKKALMMRGLIPECCAVYRIQDGEKKPIGWDTDISWLTGEELHVEVLENVPLTTHNFVRKTFFTLAFCDFCRKLLFQGFRCQTCGYKFHQRCSTEVPLMCVNYDQLDLLFVSKFFEHHPIPQEEASLAETALTSGSSPSAPASDSIGPQILTSPSPSKSIPIPQPFRPADEDHRNQFGQRDRSSSAPNVHINTIEPVNIDDLIRDQGFRGDGGSTTGLSATPPASLPGSLTNVKALQKSPGPQRERKSSSSSEDRNRMKTLGRRDSSDDWEIPDGQITVGQRIGSGSFGTVYKGKWHGDVAVKMLNVTAPTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHHLHIIETKFEMIKLIDIARQTAQGMDYLHAKSIIHRDLKSNNIFLHEDLTVKIGDFGLATVKSRWSGSHQFEQLSGSILWMAPEVIRMQDKNPYSFQSDVYAFGIVLYELMTGQLPYSNINNRDQIIFMVGRGYLSPDLSKVRSNCPKAMKRLMAECLKKKRDERPLFPQILASIELLARSLPKIHRSASEPSLNRAGFQTEDFSLYACASPKTPIQAGGYGAFPVH	766	P15056	P	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [58], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.00695115]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
89	NM_004333.5(BRAF):c.1406G>A (p.Gly469Glu)	13974	CA279970	NM_004333.5:c.1406G>A, NM_004333.4:c.1406G>A, LRG_299t1:c.1406G>A, XM_005250045.1:c.1406G>A, XM_005250046.1:c.1406G>A, XM_011516529.1:c.1406G>A, XM_011516530.1:c.1406G>A, XR_242190.1:n.1414G>A, XR_927520.1:n.1414G>A, XR_927521.1:n.1414G>A, XR_927522.1:n.1414G>A, XR_927523.1:n.1414G>A, NM_001354609.1:c.1406G>A, NR_148928.1:n.1711G>A, XM_017012558.1:c.1526G>A, XM_017012559.1:c.1526G>A, XR_001744857.1:n.1534G>A, XR_001744858.1:n.1534G>A, ENST00000288602.10:c.1406G>A, ENST00000496384.6:n.229G>A, ENST00000497784.1:n.1441G>A, NC_000007.14:g.140781602C>T, CM000669.2:g.140781602C>T, NC_000007.13:g.140481402C>T, CM000669.1:g.140481402C>T, NC_000007.12:g.140127871C>T, NG_007873.3:g.148163G>A, LRG_299:g.148163G>A, NM_004333.5(BRAF):c.1406G>A (p.Gly469Glu)	BRAF	cardiofaciocutaneous syndrome	MONDO:0015280	Autosomal dominant inheritance	Pathogenic	PM2, PS2_Very Strong, PP2, PP3, PM1, PS3		The c.1406G>A (p.Gly469Glu) variant in BRAF has been reported in the literature as a confirmed de novo occurrence in at least 2 patients with clinical features of a RASopathy (PS2_VeryStrong; PMID 18042262, 16474404). In vitro functional studies provide some evidence that the p.Gly469Glu variant may impact protein function (PS3; 16474404). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). The variant is located in the BRAF gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID 29493581). Furthermore, this variant is in a location which has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of BRAF (PM1; PMID 29493581). Computational prediction tools and conservation analysis suggest that the p.Gly469Glu variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PP2, PP3, PM1, PM2, PS2_VeryStrong, PS3.		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	False	https://erepo.genome.network/evrepo/ui/classification/CA279970/MONDO:0015280/004	f75f3f8b-6c9c-41a1-9cee-4716d67229dd	p.Gly469Glu	Gly	469	Glu	MAALSGGGGGGAEPGQALFNGDMEPEAGAGAGAAASSAADPAIPEEVWNIKQMIKLTQEHIEALLDKFGGEHNPPSIYLEAYEEYTSKLDALQQREQQLLESLGNGTDFSVSSSASMDTVTSSSSSSLSVLPSSLSVFQNPTDVARSNPKSPQKPIVRVFLPNKQRTVVPARCGVTVRDSLKKALMMRGLIPECCAVYRIQDGEKKPIGWDTDISWLTGEELHVEVLENVPLTTHNFVRKTFFTLAFCDFCRKLLFQGFRCQTCGYKFHQRCSTEVPLMCVNYDQLDLLFVSKFFEHHPIPQEEASLAETALTSGSSPSAPASDSIGPQILTSPSPSKSIPIPQPFRPADEDHRNQFGQRDRSSSAPNVHINTIEPVNIDDLIRDQGFRGDGGSTTGLSATPPASLPGSLTNVKALQKSPGPQRERKSSSSSEDRNRMKTLGRRDSSDDWEIPDGQITVGQRIGSGSFGTVYKGKWHGDVAVKMLNVTAPTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHHLHIIETKFEMIKLIDIARQTAQGMDYLHAKSIIHRDLKSNNIFLHEDLTVKIGDFGLATVKSRWSGSHQFEQLSGSILWMAPEVIRMQDKNPYSFQSDVYAFGIVLYELMTGQLPYSNINNRDQIIFMVGRGYLSPDLSKVRSNCPKAMKRLMAECLKKKRDERPLFPQILASIELLARSLPKIHRSASEPSLNRAGFQTEDFSLYACASPKTPIQAGGYGAFPVH	766	P15056	E	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [467], 'STRAND_gain_score': array([0.08302057]), 'HELIX_loss': [58, 61], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.00242239, -0.00338751]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [350], 'COMPBIAS_gain': [], 'COMPBIAS_loss_score': array([-0.00330412]), 'DOMAIN_loss': [], 'DOMAIN_gain': [455], 'DOMAIN_gain_score': array([0.3107003]), 'REGION_loss': [374], 'REGION_gain': [], 'REGION_loss_score': array([-0.00176942]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
90	NM_004333.4(BRAF):c.730A>C (p.Thr244Pro)	40346	CA280025	NM_004333.4:c.730A>C, NC_000007.14:g.140801542T>G, CM000669.2:g.140801542T>G, NC_000007.13:g.140501342T>G, CM000669.1:g.140501342T>G, NC_000007.12:g.140147811T>G, NG_007873.3:g.128223A>C, LRG_299:g.128223A>C, LRG_299t1:c.730A>C, XM_005250045.1:c.730A>C, XM_005250046.1:c.730A>C, XM_011516529.1:c.730A>C, XM_011516530.1:c.730A>C, XR_242190.1:n.738A>C, XR_927520.1:n.738A>C, XR_927521.1:n.738A>C, XR_927522.1:n.738A>C, XR_927523.1:n.738A>C, NM_001354609.1:c.730A>C, NM_004333.5:c.730A>C, NR_148928.1:n.1035A>C, XM_017012558.1:c.730A>C, XM_017012559.1:c.730A>C, XR_001744857.1:n.738A>C, XR_001744858.1:n.738A>C, ENST00000288602.10:c.730A>C, ENST00000497784.1:n.765A>C, NM_004333.4(BRAF):c.730A>C (p.Thr244Pro)	BRAF	cardiofaciocutaneous syndrome	MONDO:0015280	Autosomal dominant inheritance	Pathogenic	PM6, PM2, PP2, PP3, PM1, PS2	PS3	The c.730A>C (p.Thr244Pro) variant in BRAF has been reported in the literature as a de novo occurrence in at least 2 patients with clinical features of a RASopathy (PM6 and PS2; PMID 17551924 and 18042262). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). The variant is located in the BRAF gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID 29493581). This variant is in a location which has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of BRAF (PM1; PMID 29493581). Computational prediction tools and conservation analysis suggest that the p.Thr244Pro variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581):  PP2, PP3, PM1, PM2, PM6, PS2.		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	False	https://erepo.genome.network/evrepo/ui/classification/CA280025/MONDO:0015280/004	4581b48f-d077-4114-baf4-9c4b42fd49c4	p.Thr244Pro	Thr	244	Pro	MAALSGGGGGGAEPGQALFNGDMEPEAGAGAGAAASSAADPAIPEEVWNIKQMIKLTQEHIEALLDKFGGEHNPPSIYLEAYEEYTSKLDALQQREQQLLESLGNGTDFSVSSSASMDTVTSSSSSSLSVLPSSLSVFQNPTDVARSNPKSPQKPIVRVFLPNKQRTVVPARCGVTVRDSLKKALMMRGLIPECCAVYRIQDGEKKPIGWDTDISWLTGEELHVEVLENVPLTTHNFVRKTFFTLAFCDFCRKLLFQGFRCQTCGYKFHQRCSTEVPLMCVNYDQLDLLFVSKFFEHHPIPQEEASLAETALTSGSSPSAPASDSIGPQILTSPSPSKSIPIPQPFRPADEDHRNQFGQRDRSSSAPNVHINTIEPVNIDDLIRDQGFRGDGGSTTGLSATPPASLPGSLTNVKALQKSPGPQRERKSSSSSEDRNRMKTLGRRDSSDDWEIPDGQITVGQRIGSGSFGTVYKGKWHGDVAVKMLNVTAPTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHHLHIIETKFEMIKLIDIARQTAQGMDYLHAKSIIHRDLKSNNIFLHEDLTVKIGDFGLATVKSRWSGSHQFEQLSGSILWMAPEVIRMQDKNPYSFQSDVYAFGIVLYELMTGQLPYSNINNRDQIIFMVGRGYLSPDLSKVRSNCPKAMKRLMAECLKKKRDERPLFPQILASIELLARSLPKIHRSASEPSLNRAGFQTEDFSLYACASPKTPIQAGGYGAFPVH	766	P15056	P	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [58, 61], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.00600117, -0.00403607]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
91	NM_002755.3(MAP2K1):c.848C>T (p.Ala283Val)	40756	CA134622	NM_002755.3:c.848C>T, NC_000015.10:g.66485144C>T, CM000677.2:g.66485144C>T, NC_000015.9:g.66777482C>T, CM000677.1:g.66777482C>T, NC_000015.8:g.64564536C>T, NG_008305.1:g.103272C>T, LRG_725:g.103272C>T, LRG_725t1:c.848C>T, XM_011521783.1:c.782C>T, XM_011521783.3:c.782C>T, XM_017022411.2:c.770C>T, XM_017022412.1:c.704C>T, XM_017022413.1:c.320C>T, ENST00000307102.9:c.848C>T, ENST00000566326.1:c.320C>T, NM_002755.3(MAP2K1):c.848C>T (p.Ala283Val)	MAP2K1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1, BP5		The filtering allele frequency of the c.848C>T (p.Ala283Val) variant in the MAP2K1 gene is 0.052% for African chromosomes by the Exome Aggregation Consortium (10/10366 with 95% CI), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert panel for autosomal dominant RASopathy variants (BA1). This variant has been identified in a patient with an alternate molecular basis for disease (BP5; Partners LMM, GeneDx internal data; GTR ID: 21766, 26957; ClinVar SCV000207935.12; SCV000061262.5). In summary, this variant meets criteria to be classified as benign. RASopathy-specific ACMG/AMP criteria applied (PMID:29493581): BA1, BP5.		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-05-09	2018-12-10	False	https://erepo.genome.network/evrepo/ui/classification/CA134622/MONDO:0021060/004	d798c554-02fa-4c7b-96d8-4fda7463f9de	p.Ala283Val	Ala	283	Val	MPKKKPTPIQLNPAPDGSAVNGTSSAETNLEALQKKLEELELDEQQRKRLEAFLTQKQKVGELKDDDFEKISELGAGNGGVVFKVSHKPSGLVMARKLIHLEIKPAIRNQIIRELQVLHECNSPYIVGFYGAFYSDGEISICMEHMDGGSLDQVLKKAGRIPEQILGKVSIAVIKGLTYLREKHKIMHRDVKPSNILVNSRGEIKLCDFGVSGQLIDSMANSFVGTRSYMSPERLQGTHYSVQSDIWSMGLSLVEMAVGRYPIPPPDAKELELMFGCQVEGDAAETPPRPRTPGRPLSSYGMDSRPPMAIFELLDYIVNEPPPKLPSGVFSLEFQDFVNKCLIKNPAERADLKQLMVHAFIKRSDAEEVDFAGWLCSTIGLNQPSTPTHAAGV	393	Q02750	V	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [241], 'HELIX_gain_score': array([0.01204771]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298], 'REGION_gain': [], 'REGION_loss_score': array([-0.38449061, -0.45595098, -0.39457607, -0.39796907, -0.39677089,
       -0.3379209 , -0.33191836, -0.3645221 , -0.38605934, -0.30328751,
       -0.39735156, -0.3017897 , -0.33947867, -0.41518921, -0.34508032,
       -0.28683513]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
92	NM_002755.3(MAP2K1):c.275T>G (p.Leu92Arg)	44588	CA134601	NM_002755.3:c.275T>G, LRG_725t1:c.275T>G, XM_011521783.1:c.209T>G, XM_011521783.3:c.209T>G, XM_017022411.2:c.275T>G, XM_017022412.1:c.209T>G, NM_002755.4:c.275T>G, ENST00000307102.9:c.275T>G, ENST00000425818.2:n.786T>G, NC_000015.10:g.66435221T>G, CM000677.2:g.66435221T>G, NC_000015.9:g.66727559T>G, CM000677.1:g.66727559T>G, NC_000015.8:g.64514613T>G, NG_008305.1:g.53349T>G, LRG_725:g.53349T>G, NM_002755.3(MAP2K1):c.275T>G (p.Leu92Arg)	MAP2K1	cardiofaciocutaneous syndrome	MONDO:0015280	Autosomal dominant inheritance	Pathogenic	PS2_Very Strong, PM2, PP2, PP3, PS4_Moderate	PM6	The c.275T>G (p.Leu92Arg) variant in MAP2K1 has been reported in at least 3 de novo occurrences, including 1 case with parental confirmation, in patients diagnosed with a RASopathy (PS2_VeryStrong, PS4_Moderate; GeneDx, APHP-Robert Debre hospital, Laboratory for Molecular Medicine internal data; ClinVar SCV000207940.11, SCV000965969.1, SCV000061251.5). This variant was absent from large population studies (PM2; gnomad.broadinstitute.org). The variant is located in the MAP2K1 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Computational prediction tools and conservation analysis suggest that the p.Leu92Arg variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. RASopathy-specific ACMG/AMP criteria applied (PMID:29493581): PS2_VeryStrong, PS4_Moderate, PM2, PP2, PP3.		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2020-06-25	2020-07-01	False	https://erepo.genome.network/evrepo/ui/classification/CA134601/MONDO:0015280/004	2986f8eb-3ee8-416d-a279-f72ff1c134a1	p.Leu92Arg	Leu	92	Arg	MPKKKPTPIQLNPAPDGSAVNGTSSAETNLEALQKKLEELELDEQQRKRLEAFLTQKQKVGELKDDDFEKISELGAGNGGVVFKVSHKPSGLVMARKLIHLEIKPAIRNQIIRELQVLHECNSPYIVGFYGAFYSDGEISICMEHMDGGSLDQVLKKAGRIPEQILGKVSIAVIKGLTYLREKHKIMHRDVKPSNILVNSRGEIKLCDFGVSGQLIDSMANSFVGTRSYMSPERLQGTHYSVQSDIWSMGLSLVEMAVGRYPIPPPDAKELELMFGCQVEGDAAETPPRPRTPGRPLSSYGMDSRPPMAIFELLDYIVNEPPPKLPSGVFSLEFQDFVNKCLIKNPAERADLKQLMVHAFIKRSDAEEVDFAGWLCSTIGLNQPSTPTHAAGV	393	Q02750	R	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
93	NM_004333.4(BRAF):c.770A>G (p.Gln257Arg)	13973	CA222583	NM_004333.4:c.770A>G, LRG_299t1:c.770A>G, XM_005250045.1:c.770A>G, XM_005250046.1:c.770A>G, XM_011516529.1:c.770A>G, XM_011516530.1:c.770A>G, XR_242190.1:n.778A>G, XR_927520.1:n.778A>G, XR_927521.1:n.778A>G, XR_927522.1:n.778A>G, XR_927523.1:n.778A>G, NM_001354609.1:c.770A>G, NM_004333.5:c.770A>G, NR_148928.1:n.1075A>G, XM_017012558.1:c.770A>G, XM_017012559.1:c.770A>G, XR_001744857.1:n.778A>G, XR_001744858.1:n.778A>G, ENST00000288602.10:c.770A>G, ENST00000497784.1:n.805A>G, NC_000007.14:g.140801502T>C, CM000669.2:g.140801502T>C, NC_000007.13:g.140501302T>C, CM000669.1:g.140501302T>C, NC_000007.12:g.140147771T>C, NG_007873.3:g.128263A>G, LRG_299:g.128263A>G, NM_004333.4(BRAF):c.770A>G (p.Gln257Arg)	BRAF	cardiofaciocutaneous syndrome	MONDO:0015280	Autosomal dominant inheritance	Pathogenic	PM2, PS2_Very Strong, PP2, PP3, PM1, PS3		The c.770A>G (p.Gln257Arg) variant in BRAF has been reported in the literature as a confirmed de novo occurrence in at least 2 patients with clinical features of a RASopathy (PS2_VeryStrong; PMID:18042262, PMID:17551924, PMID:16474404). In vitro functional studies provide some evidence that the p.Q257R variant may impact protein function (PS3; PMID:18413255; PMID:19376813).  This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). The variant is located in the BRAF gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID:29493581). Furthermore, this variant is located in exon 6, which has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of BRAF (PM1; PMID:29493581).  Computational prediction tools and conservation analysis suggest that the p.Q257R variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for cardio-facio-cutaneous syndrome in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PP2, PP3, PM1, PM2, PS3, PS2_VeryStrong.	18042262, 16474404, 17551924, 19376813, 18413255	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2018-12-10	False	https://erepo.genome.network/evrepo/ui/classification/CA222583/MONDO:0015280/004	5f9417cc-43e4-41be-b920-ae6db397bdaa	p.Gln257Arg	Gln	257	Arg	MAALSGGGGGGAEPGQALFNGDMEPEAGAGAGAAASSAADPAIPEEVWNIKQMIKLTQEHIEALLDKFGGEHNPPSIYLEAYEEYTSKLDALQQREQQLLESLGNGTDFSVSSSASMDTVTSSSSSSLSVLPSSLSVFQNPTDVARSNPKSPQKPIVRVFLPNKQRTVVPARCGVTVRDSLKKALMMRGLIPECCAVYRIQDGEKKPIGWDTDISWLTGEELHVEVLENVPLTTHNFVRKTFFTLAFCDFCRKLLFQGFRCQTCGYKFHQRCSTEVPLMCVNYDQLDLLFVSKFFEHHPIPQEEASLAETALTSGSSPSAPASDSIGPQILTSPSPSKSIPIPQPFRPADEDHRNQFGQRDRSSSAPNVHINTIEPVNIDDLIRDQGFRGDGGSTTGLSATPPASLPGSLTNVKALQKSPGPQRERKSSSSSEDRNRMKTLGRRDSSDDWEIPDGQITVGQRIGSGSFGTVYKGKWHGDVAVKMLNVTAPTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHHLHIIETKFEMIKLIDIARQTAQGMDYLHAKSIIHRDLKSNNIFLHEDLTVKIGDFGLATVKSRWSGSHQFEQLSGSILWMAPEVIRMQDKNPYSFQSDVYAFGIVLYELMTGQLPYSNINNRDQIIFMVGRGYLSPDLSKVRSNCPKAMKRLMAECLKKKRDERPLFPQILASIELLARSLPKIHRSASEPSLNRAGFQTEDFSLYACASPKTPIQAGGYGAFPVH	766	P15056	R	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
94	NM_002880.3(RAF1):c.923C>T (p.Pro308Leu)	40611	CA134762	NM_002880.3:c.923C>T, NC_000003.12:g.12600219G>A, CM000665.2:g.12600219G>A, NC_000003.11:g.12641718G>A, CM000665.1:g.12641718G>A, NC_000003.10:g.12616718G>A, NG_007467.1:g.68961C>T, LRG_413:g.68961C>T, LRG_413t1:c.923C>T, XM_005265355.1:c.923C>T, XM_005265357.1:c.824C>T, XM_005265358.3:c.680C>T, XM_005265359.3:c.581C>T, XM_005265360.1:c.923C>T, XM_011533974.1:c.923C>T, XM_011533975.1:c.680C>T, NM_001354689.1:c.983C>T, NM_001354690.1:c.923C>T, NM_001354691.1:c.680C>T, NM_001354692.1:c.680C>T, NM_001354693.1:c.824C>T, NM_001354694.1:c.740C>T, NM_001354695.1:c.581C>T, NR_148940.1:n.1338C>T, NR_148941.1:n.1338C>T, NR_148942.1:n.1338C>T, XM_011533974.3:c.923C>T, XM_017006966.1:c.824C>T, XR_001740227.1:n.1155C>T, ENST00000251849.8:c.923C>T, ENST00000423275.5:c.*600C>T, ENST00000432427.2:n.560C>T, ENST00000442415.6:c.983C>T, ENST00000465826.5:n.167C>T, ENST00000491290.1:n.552C>T, NM_002880.3(RAF1):c.923C>T (p.Pro308Leu)	RAF1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.923C>T (p.Pro308Leu) variant in the RAF1 gene is 1.516% (179/10394) of African chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	False	https://erepo.genome.network/evrepo/ui/classification/CA134762/MONDO:0021060/004	ed484574-9b2a-4dda-bd46-ea935a45f83c	p.Pro308Leu	Pro	308	Leu	MEHIQGAWKTISNGFGFKDAVFDGSSCISPTIVQQFGYQRRASDDGKLTDPSKTSNTIRVFLPNKQRTVVNVRNGMSLHDCLMKALKVRGLQPECCAVFRLLHEHKGKKARLDWNTDAASLIGEELQVDFLDHVPLTTHNFARKTFLKLAFCDICQKFLLNGFRCQTCGYKFHEHCSTKVPTMCVDWSNIRQLLLFPNSTIGDSGVPALPSLTMRRMRESVSRMPVSSQHRYSTPHAFTFNTSSPSSEGSLSQRQRSTSTPNVHMVSTTLPVDSRMIEDAIRSHSESASPSALSSSPNNLSPTGWSQPKTPVPAQRERAPVSGTQEKNKIRPRGQRDSSYYWEIEASEVMLSTRIGSGSFGTVYKGKWHGDVAVKILKVVDPTPEQFQAFRNEVAVLRKTRHVNILLFMGYMTKDNLAIVTQWCEGSSLYKHLHVQETKFQMFQLIDIARQTAQGMDYLHAKNIIHRDMKSNNIFLHEGLTVKIGDFGLATVKSRWSGSQQVEQPTGSVLWMAPEVIRMQDNNPFSFQSDVYSYGIVLYELMTGELPYSHINNRDQIIFMVGRGYASPDLSKLYKNCPKAMKRLVADCVKKVKEERPLFPQILSSIELLQHSLPKINRSASEPSLHRAAHTEDINACTLTTSPRLPVF	648	P04049	L	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [131], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.01491421]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [240, 256, 283], 'COMPBIAS_gain': [309], 'COMPBIAS_gain_score': array([0.15181309]), 'COMPBIAS_loss_score': array([-0.01553535, -0.01879585, -0.09849894]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [228, 229, 266, 281, 335], 'REGION_gain': [], 'REGION_loss_score': array([-0.03147721, -0.02691931, -0.04662901, -0.07446301, -0.0677138 ]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
95	NM_005633.3(SOS1):c.1964C>T (p.Pro655Leu)	40692	CA136088	NM_005633.3:c.1964C>T, NC_000002.12:g.39013966G>A, CM000664.2:g.39013966G>A, NC_000002.11:g.39241107G>A, CM000664.1:g.39241107G>A, NC_000002.10:g.39094611G>A, NG_007530.1:g.111498C>T, LRG_754:g.111498C>T, LRG_754t1:c.1964C>T, XM_005264515.3:c.1964C>T, XM_011533060.1:c.2057C>T, XM_011533061.1:c.2057C>T, XM_011533062.1:c.1943C>T, XM_011533063.1:c.1940C>T, XM_011533064.1:c.1793C>T, XM_011533065.1:c.2057C>T, XM_011533066.1:c.899C>T, XM_005264515.4:c.1964C>T, XM_011533062.2:c.1943C>T, XM_011533064.2:c.1793C>T, ENST00000395038.6:c.1964C>T, ENST00000402219.6:c.1964C>T, ENST00000426016.5:c.1964C>T, NM_005633.3(SOS1):c.1964C>T (p.Pro655Leu)	SOS1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.1964C>T (p.Pro655Leu) variant in the SOS1 gene is 1.153% (803/65674) of European chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	False	https://erepo.genome.network/evrepo/ui/classification/CA136088/MONDO:0021060/004	6a6d042c-678f-4246-a5be-507e028cd2fc	p.Pro655Leu	Pro	655	Leu	MQAQQLPYEFFSEENAPKWRGLLVPALKKVQGQVHPTLESNDDALQYVEELILQLLNMLCQAQPRSASDVEERVQKSFPHPIDKWAIADAQSAIEKRKRRNPLSLPVEKIHPLLKEVLGYKIDHQVSVYIVAVLEYISADILKLVGNYVRNIRHYEITKQDIKVAMCADKVLMDMFHQDVEDINILSLTDEEPSTSGEQTYYDLVKAFMAEIRQYIRELNLIIKVFREPFVSNSKLFSANDVENIFSRIVDIHELSVKLLGHIEDTVEMTDEGSPHPLVGSCFEDLAEELAFDPYESYARDILRPGFHDRFLSQLSKPGAALYLQSIGEGFKEAVQYVLPRLLLAPVYHCLHYFELLKQLEEKSEDQEDKECLKQAITALLNVQSGMEKICSKSLAKRRLSESACRFYSQQMKGKQLAIKKMNEIQKNIDGWEGKDIGQCCNEFIMEGTLTRVGAKHERHIFLFDGLMICCKSNHGQPRLPGASNAEYRLKEKFFMRKVQINDKDDTNEYKHAFEIILKDENSVIFSAKSAEEKNNWMAALISLQYRSTLERMLDVTMLQEEKEEQMRLPSADVYRFAEPDSEENIIFEENMQPKAGIPIIKAGTVIKLIERLTYHMYADPNFVRTFLTTYRSFCKPQELLSLIIERFEIPEPEPTEADRIAIENGDQPLSAELKRFRKEYIQPVQLRVLNVCRHWVEHHFYDFERDAYLLQRMEEFIGTVRGKAMKKWVESITKIIQRKKIARDNGPGHNITFQSSPPTVEWHISRPGHIETFDLLTLHPIEIARQLTLLESDLYRAVQPSELVGSVWTKEDKEINSPNLLKMIRHTTNLTLWFEKCIVETENLEERVAVVSRIIEILQVFQELNNFNGVLEVVSAMNSSPVYRLDHTFEQIPSRQKKILEEAHELSEDHYKKYLAKLRSINPPCVPFFGIYLTNILKTEEGNPEVLKRHGKELINFSKRRKVAEITGEIQQYQNQPYCLRVESDIKRFFENLNPMGNSMEKEFTDYLFNKSLEIEPRNPKPLPRFPKKYSYPLKSPGVRPSNPRPGTMRHPTPLQQEPRKISYSRIPESETESTASAPNSPRTPLTPPPASGASSTTDVCSVFDSDHSSPFHSSNDTVFIQVTLPHGPRSASVSSISLTKGTDEVPVPPPVPPRRRPESAPAESSPSKIMSKHLDSPPAIPPRQPTSKAYSPRYSISDRTSISDPPESPPLLPPREPVRTPDVFSSSPLHLQPPPLGKKSDHGNAFFPNSPSPFTPPPPQTPSPHGTRRHLPSPPLTQEVDLHSIAGPPVPPRQSTSQHIPKLPPKTYKREHTHPSMHRDGPPLLENAHSS	1333	Q07889	L	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [516], 'STRAND_gain_score': array([0.00738221]), 'HELIX_loss': [296], 'HELIX_gain': [859], 'HELIX_gain_score': array([0.00916171]), 'HELIX_loss_score': array([-0.00654256]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [642, 645, 646, 647, 648, 651, 654, 655, 656, 657, 658, 659, 661, 662, 663, 664, 665, 666, 667, 668, 669, 670, 671, 672, 673, 674, 675, 676, 677, 678, 679, 680, 681, 682, 683, 684, 685, 686, 687, 688, 689, 690, 691, 692, 693, 694, 695, 696, 697, 698, 699, 700, 701, 702, 703, 704, 705, 706, 707, 708, 709, 710, 711, 712, 713, 714, 715, 716, 717, 718, 719, 720, 721, 722, 723, 724, 726, 777, 778, 780, 781, 782, 872], 'DOMAIN_gain_score': array([0.50721687, 0.53208524, 0.6459884 , 0.56482774, 0.55180967,
       0.49316585, 0.50560594, 0.561113  , 0.49297667, 0.56943548,
       0.69745636, 0.64993155, 0.47780728, 0.55307961, 0.480874  ,
       0.48995513, 0.56936991, 0.70416999, 0.53068751, 0.48829705,
       0.6030193 , 0.62246871, 0.62982988, 0.65560079, 0.56284016,
       0.62570643, 0.63252431, 0.64134836, 0.61896622, 0.59577215,
       0.67467946, 0.70190811, 0.69462174, 0.64812094, 0.67260152,
       0.67653531, 0.70599747, 0.65351272, 0.59186572, 0.55884975,
       0.65135908, 0.59611446, 0.56841469, 0.61827511, 0.57741123,
       0.55271947, 0.56247866, 0.59976971, 0.58006632, 0.57343388,
       0.56814343, 0.57017243, 0.59309965, 0.57911623, 0.54722905,
       0.57672518, 0.49835849, 0.49911296, 0.46904671, 0.53118569,
       0.51278013, 0.48158199, 0.51282328, 0.48386467, 0.5774495 ,
       0.53669637, 0.539038  , 0.49229831, 0.48003185, 0.47270083,
       0.51061547, 0.46191031, 0.48607898, 0.43082982, 0.46610987,
       0.44364983, 0.38203233, 0.10341036, 0.08550256, 0.13380474,
       0.09388107, 0.11231673, 0.03514069]), 'REGION_loss': [], 'REGION_gain': [1295, 1300], 'REGION_gain_score': array([0.00334626, 0.00357991]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
96	NM_007373.3(SHOC2):c.1594A>G (p.Ser532Gly)	139110	CA293486	NM_007373.3:c.1594A>G, NM_001269039.1:c.1456A>G, LRG_753t1:c.1594A>G, XM_011540216.1:c.511A>G, NM_001269039.2:c.1456A>G, NM_001324336.1:c.1594A>G, NM_001324337.1:c.1594A>G, NR_136749.1:n.1006A>G, ENST00000265277.9:c.1456A>G, ENST00000369452.8:c.1594A>G, ENST00000451838.1:n.964A>G, ENST00000489390.1:n.808A>G, NC_000010.11:g.111011663A>G, CM000672.2:g.111011663A>G, NC_000010.10:g.112771421A>G, CM000672.1:g.112771421A>G, NC_000010.9:g.112761411A>G, NG_028922.1:g.97121A>G, LRG_753:g.97121A>G, NM_007373.3(SHOC2):c.1594A>G (p.Ser532Gly)	SHOC2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.1594A>G (p.Ser532Gly) variant in the SHOC2 gene is 1.147% (138/10402) of African chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	False	https://erepo.genome.network/evrepo/ui/classification/CA293486/MONDO:0021060/004	1bcfceba-23f2-4e97-8281-791f9602856c	p.Ser532Gly	Ser	532	Gly	MSSSLGKEKDSKEKDPKVPSAKEREKEAKASGGFGKESKEKEPKTKGKDAKDGKKDSSAAQPGVAFSVDNTIKRPNPAPGTRKKSSNAEVIKELNKCREENSMRLDLSKRSIHILPSSIKELTQLTELYLYSNKLQSLPAEVGCLVNLMTLALSENSLTSLPDSLDNLKKLRMLDLRHNKLREIPSVVYRLDSLTTLYLRFNRITTVEKDIKNLSKLSMLSIRENKIKQLPAEIGELCNLITLDVAHNQLEHLPKEIGNCTQITNLDLQHNELLDLPDTIGNLSSLSRLGLRYNRLSAIPRSLAKCSALEELNLENNNISTLPESLLSSLVKLNSLTLARNCFQLYPVGGPSQFSTIYSLNMEHNRINKIPFGIFSRAKVLSKLNMKDNQLTSLPLDFGTWTSMVELNLATNQLTKIPEDVSGLVSLEVLILSNNLLKKLPHGLGNLRKLRELDLEENKLESLPNEIAYLKDLQKLVLTNNQLTTLPRGIGHLTNLTHLGLGENLLTHLPEEIGTLENLEELYLNDNPNLHSLPFELALCSKLSIMSIENCPLSHLPPQIVAGGPSFIIQFLKMQGPYRAMV	582	Q9UQ13	G	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
97	NM_030662.3(MAP2K2):c.893C>T (p.Pro298Leu)	40832	CA180870	NM_030662.3:c.893C>T, LRG_750t1:c.893C>T, XM_006722799.2:c.705+1792C>T, XM_011528133.1:c.323C>T, XM_017026989.1:c.893C>T, XM_017026990.1:c.705+1792C>T, ENST00000262948.9:c.893C>T, ENST00000394867.8:c.602C>T, ENST00000593364.5:n.840C>T, ENST00000595715.1:n.708C>T, ENST00000597263.5:n.169+1792C>T, ENST00000599021.1:n.29+1792C>T, ENST00000600584.5:n.1453C>T, ENST00000601786.5:n.1194C>T, NC_000019.10:g.4099227G>A, CM000681.2:g.4099227G>A, NC_000019.9:g.4099225G>A, CM000681.1:g.4099225G>A, NC_000019.8:g.4050225G>A, NG_007996.1:g.29902C>T, LRG_750:g.29902C>T, NM_030662.3(MAP2K2):c.893C>T (p.Pro298Leu)	MAP2K2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.893C>T (p.Pro298Leu) variant in the MAP2K2 gene is 0.953% (68/5776) of East Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-05-09	2018-12-10	False	https://erepo.genome.network/evrepo/ui/classification/CA180870/MONDO:0021060/004	40ceccb2-5456-4905-8d02-1878c6fe945f	p.Pro298Leu	Pro	298	Leu	MLARRKPVLPALTINPTIAEGPSPTSEGASEANLVDLQKKLEELELDEQQKKRLEAFLTQKAKVGELKDDDFERISELGAGNGGVVTKVQHRPSGLIMARKLIHLEIKPAIRNQIIRELQVLHECNSPYIVGFYGAFYSDGEISICMEHMDGGSLDQVLKEAKRIPEEILGKVSIAVLRGLAYLREKHQIMHRDVKPSNILVNSRGEIKLCDFGVSGQLIDSMANSFVGTRSYMAPERLQGTHYSVQSDIWSMGLSLVELAVGRYPIPPPDAKELEAIFGRPVVDGEEGEPHSISPRPRPPGRPVSGHGMDSRPAMAIFELLDYIVNEPPPKLPNGVFTPDFQEFVNKCLIKNPAERADLKMLTNHTFIKRSEVEEVDFAGWLCKTLRLNQPGTPTRTAV	400	P36507	L	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [290, 291, 292, 298, 299, 301, 302, 303], 'COMPBIAS_gain': [], 'COMPBIAS_loss_score': array([-0.09543622, -0.10516232, -0.2104975 , -0.29376781, -0.29372495,
       -0.3452515 , -0.29447013, -0.30150235]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [283, 308], 'REGION_gain': [], 'REGION_loss_score': array([-0.24578613, -0.16479003]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
98	NM_002834.4(PTPN11):c.1052G>A (p.Arg351Gln)	40541	CA282114	NM_002834.4:c.1052G>A, NC_000012.12:g.112477975G>A, CM000674.2:g.112477975G>A, NC_000012.11:g.112915779G>A, CM000674.1:g.112915779G>A, NC_000012.10:g.111400162G>A, NG_007459.1:g.64244G>A, LRG_614:g.64244G>A, NM_002834.3:c.1052G>A, LRG_614t1:c.1052G>A, NM_080601.1:c.1052G>A, XM_006719526.1:c.1052G>A, XM_006719527.1:c.938G>A, XM_011538613.1:c.1049G>A, NM_001330437.1:c.1052G>A, NM_080601.2:c.1052G>A, XM_011538613.2:c.1049G>A, XM_017019722.1:c.1049G>A, ENST00000351677.6:c.1052G>A, ENST00000392597.5:c.1052G>A, ENST00000635625.1:n.1052G>A, ENST00000635652.1:n.44G>A, NM_002834.4(PTPN11):c.1052G>A (p.Arg351Gln)	PTPN11	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.1052G>A (p.Arg351Gln) variant in the PTPN11 gene is 0.263% (55/16488) of South Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	False	https://erepo.genome.network/evrepo/ui/classification/CA282114/MONDO:0021060/004	d67ff0bd-70c2-44c7-a7af-94d111f387e6	p.Arg351Gln	Arg	351	Gln	MTSRRWFHPNITGVEAENLLLTRGVDGSFLARPSKSNPGDFTLSVRRNGAVTHIKIQNTGDYYDLYGGEKFATLAELVQYYMEHHGQLKEKNGDVIELKYPLNCADPTSERWFHGHLSGKEAEKLLTEKGKHGSFLVRESQSHPGDFVLSVRTGDDKGESNDGKSKVTHVMIRCQELKYDVGGGERFDSLTDLVEHYKKNPMVETLGTVLQLKQPLNTTRINAAEIESRVRELSKLAETTDKVKQGFWEEFETLQQQECKLLYSRKEGQRQENKNKNRYKNILPFDHTRVVLHDGDPNEPVSDYINANIIMPEFETKCNNSKPKKSYIATQGCLQNTVNDFWRMVFQENSRVIVMTTKEVERGKSKCVKYWPDEYALKEYGVMRVRNVKESAAHDYTLRELKLSKVGQGNTERTVWQYHFRTWPDHGVPSDPGGVLDFLEEVHHKQESIMDAGPVVVHCSAGIGRTGTFIVIDILIDIIREKGVDCDIDVPKTIQMVRSQRSGMVQTEAQYRFIYMAVQHYIETLQRRIEEEQKSKRKGHEYTNIKYSLADQTSGDQSPLPPCTPTPPCAEMREDSARVYENVGLMQQQKSFR	593	Q06124	Q	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [94], 'DOMAIN_gain_score': array([0.00697017]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
99	NM_002880.3(RAF1):c.1141G>A (p.Asp381Asn)	181509	CA297118	NM_002880.3:c.1141G>A, LRG_413t1:c.1141G>A, XM_005265355.1:c.1141G>A, XM_005265357.1:c.1042G>A, XM_005265358.3:c.898G>A, XM_005265359.3:c.799G>A, XM_005265360.1:c.1141G>A, XM_011533974.1:c.1141G>A, XM_011533975.1:c.898G>A, NM_001354689.1:c.1201G>A, NM_001354690.1:c.1141G>A, NM_001354691.1:c.898G>A, NM_001354692.1:c.898G>A, NM_001354693.1:c.1042G>A, NM_001354694.1:c.958G>A, NM_001354695.1:c.799G>A, NR_148940.1:n.1669G>A, NR_148941.1:n.1615G>A, NR_148942.1:n.1554G>A, XM_011533974.3:c.1141G>A, XM_017006966.1:c.1042G>A, XR_001740227.1:n.1432G>A, ENST00000251849.8:c.1141G>A, ENST00000423275.5:c.*818G>A, ENST00000432427.2:n.778G>A, ENST00000442415.6:c.1201G>A, ENST00000460610.1:n.98G>A, ENST00000465826.5:n.498G>A, ENST00000475353.1:n.309G>A, ENST00000494557.1:n.157G>A, NC_000003.12:g.12591760C>T, CM000665.2:g.12591760C>T, NC_000003.11:g.12633259C>T, CM000665.1:g.12633259C>T, NC_000003.10:g.12608259C>T, NG_007467.1:g.77420G>A, LRG_413:g.77420G>A, NM_002880.3(RAF1):c.1141G>A (p.Asp381Asn)	RAF1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.1141G>A (p.Asp381Asn) variant in the RAF1 gene is 0.162% (36/16508) of South Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	False	https://erepo.genome.network/evrepo/ui/classification/CA297118/MONDO:0021060/004	f46177ab-5c80-48cf-bd17-6acc5668f182	p.Asp381Asn	Asp	381	Asn	MEHIQGAWKTISNGFGFKDAVFDGSSCISPTIVQQFGYQRRASDDGKLTDPSKTSNTIRVFLPNKQRTVVNVRNGMSLHDCLMKALKVRGLQPECCAVFRLLHEHKGKKARLDWNTDAASLIGEELQVDFLDHVPLTTHNFARKTFLKLAFCDICQKFLLNGFRCQTCGYKFHEHCSTKVPTMCVDWSNIRQLLLFPNSTIGDSGVPALPSLTMRRMRESVSRMPVSSQHRYSTPHAFTFNTSSPSSEGSLSQRQRSTSTPNVHMVSTTLPVDSRMIEDAIRSHSESASPSALSSSPNNLSPTGWSQPKTPVPAQRERAPVSGTQEKNKIRPRGQRDSSYYWEIEASEVMLSTRIGSGSFGTVYKGKWHGDVAVKILKVVDPTPEQFQAFRNEVAVLRKTRHVNILLFMGYMTKDNLAIVTQWCEGSSLYKHLHVQETKFQMFQLIDIARQTAQGMDYLHAKNIIHRDMKSNNIFLHEGLTVKIGDFGLATVKSRWSGSQQVEQPTGSVLWMAPEVIRMQDNNPFSFQSDVYSYGIVLYELMTGELPYSHINNRDQIIFMVGRGYASPDLSKLYKNCPKAMKRLVADCVKKVKEERPLFPQILSSIELLQHSLPKINRSASEPSLHRAAHTEDINACTLTTSPRLPVF	648	P04049	N	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [283], 'COMPBIAS_gain': [], 'COMPBIAS_loss_score': array([-0.00862414]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [335], 'REGION_gain': [], 'REGION_loss_score': array([-0.00555426]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
100	NM_002834.4(PTPN11):c.53A>G (p.Asn18Ser)	135112	CA161776	NM_002834.4:c.53A>G, NC_000012.12:g.112446314A>G, CM000674.2:g.112446314A>G, NC_000012.11:g.112884118A>G, CM000674.1:g.112884118A>G, NC_000012.10:g.111368501A>G, NG_007459.1:g.32583A>G, LRG_614:g.32583A>G, NM_002834.3:c.53A>G, LRG_614t1:c.53A>G, NM_080601.1:c.53A>G, XM_006719526.1:c.53A>G, XM_006719527.1:c.53A>G, XM_011538613.1:c.53A>G, NM_001330437.1:c.53A>G, NM_080601.2:c.53A>G, XM_011538613.2:c.53A>G, XM_017019722.1:c.53A>G, ENST00000351677.6:c.53A>G, ENST00000392597.5:c.53A>G, ENST00000635625.1:n.53A>G, NM_002834.4(PTPN11):c.53A>G (p.Asn18Ser)	PTPN11	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.53A>G (p.Asn18Ser) variant in the PTPN11 gene is 0.056% (15/16512) of South Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	False	https://erepo.genome.network/evrepo/ui/classification/CA161776/MONDO:0021060/004	b05eb983-c118-4f08-88a9-d168d803a9d0	p.Asn18Ser	Asn	18	Ser	MTSRRWFHPNITGVEAENLLLTRGVDGSFLARPSKSNPGDFTLSVRRNGAVTHIKIQNTGDYYDLYGGEKFATLAELVQYYMEHHGQLKEKNGDVIELKYPLNCADPTSERWFHGHLSGKEAEKLLTEKGKHGSFLVRESQSHPGDFVLSVRTGDDKGESNDGKSKVTHVMIRCQELKYDVGGGERFDSLTDLVEHYKKNPMVETLGTVLQLKQPLNTTRINAAEIESRVRELSKLAETTDKVKQGFWEEFETLQQQECKLLYSRKEGQRQENKNKNRYKNILPFDHTRVVLHDGDPNEPVSDYINANIIMPEFETKCNNSKPKKSYIATQGCLQNTVNDFWRMVFQENSRVIVMTTKEVERGKSKCVKYWPDEYALKEYGVMRVRNVKESAAHDYTLRELKLSKVGQGNTERTVWQYHFRTWPDHGVPSDPGGVLDFLEEVHHKQESIMDAGPVVVHCSAGIGRTGTFIVIDILIDIIREKGVDCDIDVPKTIQMVRSQRSGMVQTEAQYRFIYMAVQHYIETLQRRIEEEQKSKRKGHEYTNIKYSLADQTSGDQSPLPPCTPTPPCAEMREDSARVYENVGLMQQQKSFR	593	Q06124	S	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [23, 24, 25, 26], 'SIGNAL_gain_score': array([0.40305156, 0.55134207, 0.56343234, 0.38919276]), 'TRANSIT_loss': [], 'TRANSIT_gain': [7], 'TRANSIT_gain_score': array([0.07338631]), 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
101	NM_004333.5(BRAF):c.1150A>G (p.Arg384Gly)	448924	CA4516796	NM_004333.5:c.1150A>G, NM_004333.4:c.1150A>G, LRG_299t1:c.1150A>G, XM_005250045.1:c.1150A>G, XM_005250046.1:c.1150A>G, XM_011516529.1:c.1150A>G, XM_011516530.1:c.1150A>G, XR_242190.1:n.1158A>G, XR_927520.1:n.1158A>G, XR_927521.1:n.1158A>G, XR_927522.1:n.1158A>G, XR_927523.1:n.1158A>G, NM_001354609.1:c.1150A>G, NR_148928.1:n.1455A>G, XM_017012558.1:c.1150A>G, XM_017012559.1:c.1150A>G, XR_001744857.1:n.1158A>G, XR_001744858.1:n.1158A>G, ENST00000288602.10:c.1150A>G, ENST00000497784.1:n.1185A>G, NC_000007.14:g.140787575T>C, CM000669.2:g.140787575T>C, NC_000007.13:g.140487375T>C, CM000669.1:g.140487375T>C, NC_000007.12:g.140133844T>C, NG_007873.3:g.142190A>G, LRG_299:g.142190A>G, NM_004333.5(BRAF):c.1150A>G (p.Arg384Gly)	BRAF	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.1150A>G (p.Arg384Gly) variant in the BRAF gene is 0.116% (16/8646) of East Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	False	https://erepo.genome.network/evrepo/ui/classification/CA4516796/MONDO:0021060/004	2153a39b-818c-4cb1-b6e6-db1a736b545f	p.Arg384Gly	Arg	384	Gly	MAALSGGGGGGAEPGQALFNGDMEPEAGAGAGAAASSAADPAIPEEVWNIKQMIKLTQEHIEALLDKFGGEHNPPSIYLEAYEEYTSKLDALQQREQQLLESLGNGTDFSVSSSASMDTVTSSSSSSLSVLPSSLSVFQNPTDVARSNPKSPQKPIVRVFLPNKQRTVVPARCGVTVRDSLKKALMMRGLIPECCAVYRIQDGEKKPIGWDTDISWLTGEELHVEVLENVPLTTHNFVRKTFFTLAFCDFCRKLLFQGFRCQTCGYKFHQRCSTEVPLMCVNYDQLDLLFVSKFFEHHPIPQEEASLAETALTSGSSPSAPASDSIGPQILTSPSPSKSIPIPQPFRPADEDHRNQFGQRDRSSSAPNVHINTIEPVNIDDLIRDQGFRGDGGSTTGLSATPPASLPGSLTNVKALQKSPGPQRERKSSSSSEDRNRMKTLGRRDSSDDWEIPDGQITVGQRIGSGSFGTVYKGKWHGDVAVKMLNVTAPTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHHLHIIETKFEMIKLIDIARQTAQGMDYLHAKSIIHRDLKSNNIFLHEDLTVKIGDFGLATVKSRWSGSHQFEQLSGSILWMAPEVIRMQDKNPYSFQSDVYAFGIVLYELMTGQLPYSNINNRDQIIFMVGRGYLSPDLSKVRSNCPKAMKRLMAECLKKKRDERPLFPQILASIELLARSLPKIHRSASEPSLNRAGFQTEDFSLYACASPKTPIQAGGYGAFPVH	766	P15056	G	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [88], 'HELIX_gain_score': array([0.00198549]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [350], 'COMPBIAS_gain': [447], 'COMPBIAS_gain_score': array([0.01708829]), 'COMPBIAS_loss_score': array([-0.0572626]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [377, 379, 380, 381, 382], 'REGION_gain_score': array([0.08050025, 0.08665049, 0.08765566, 0.11077011, 0.14162594]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
102	NM_002834.4(PTPN11):c.1028G>A (p.Arg343Gln)	181766	CA297648	NM_002834.4:c.1028G>A, NC_000012.12:g.112477951G>A, CM000674.2:g.112477951G>A, NC_000012.11:g.112915755G>A, CM000674.1:g.112915755G>A, NC_000012.10:g.111400138G>A, NG_007459.1:g.64220G>A, LRG_614:g.64220G>A, NM_002834.3:c.1028G>A, LRG_614t1:c.1028G>A, NM_080601.1:c.1028G>A, XM_006719526.1:c.1028G>A, XM_006719527.1:c.914G>A, XM_011538613.1:c.1025G>A, NM_001330437.1:c.1028G>A, NM_080601.2:c.1028G>A, XM_011538613.2:c.1025G>A, XM_017019722.1:c.1025G>A, ENST00000351677.6:c.1028G>A, ENST00000392597.5:c.1028G>A, ENST00000635625.1:n.1028G>A, ENST00000635652.1:n.20G>A, NM_002834.4(PTPN11):c.1028G>A (p.Arg343Gln)	PTPN11	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.1028G>A (p.Arg343Gln) variant in the PTPN11 gene is 0.116% (27/16494) of South Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-18	2018-12-10	False	https://erepo.genome.network/evrepo/ui/classification/CA297648/MONDO:0021060/004	8d55f3e7-09d7-4c84-98a4-830352b7611a	p.Arg343Gln	Arg	343	Gln	MTSRRWFHPNITGVEAENLLLTRGVDGSFLARPSKSNPGDFTLSVRRNGAVTHIKIQNTGDYYDLYGGEKFATLAELVQYYMEHHGQLKEKNGDVIELKYPLNCADPTSERWFHGHLSGKEAEKLLTEKGKHGSFLVRESQSHPGDFVLSVRTGDDKGESNDGKSKVTHVMIRCQELKYDVGGGERFDSLTDLVEHYKKNPMVETLGTVLQLKQPLNTTRINAAEIESRVRELSKLAETTDKVKQGFWEEFETLQQQECKLLYSRKEGQRQENKNKNRYKNILPFDHTRVVLHDGDPNEPVSDYINANIIMPEFETKCNNSKPKKSYIATQGCLQNTVNDFWRMVFQENSRVIVMTTKEVERGKSKCVKYWPDEYALKEYGVMRVRNVKESAAHDYTLRELKLSKVGQGNTERTVWQYHFRTWPDHGVPSDPGGVLDFLEEVHHKQESIMDAGPVVVHCSAGIGRTGTFIVIDILIDIIREKGVDCDIDVPKTIQMVRSQRSGMVQTEAQYRFIYMAVQHYIETLQRRIEEEQKSKRKGHEYTNIKYSLADQTSGDQSPLPPCTPTPPCAEMREDSARVYENVGLMQQQKSFR	593	Q06124	Q	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [303], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.00609416]), 'HELIX_loss': [530], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.00281554]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [94], 'DOMAIN_gain_score': array([0.01153547]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
103	NM_004360.4(CDH1):c.2104G>A (p.Glu702Lys)	127921	CA288054	NM_004360.4:c.2104G>A, NC_000016.10:g.68823566G>A, CM000678.2:g.68823566G>A, NC_000016.9:g.68857469G>A, CM000678.1:g.68857469G>A, NC_000016.8:g.67414970G>A, NG_008021.1:g.91275G>A, LRG_301:g.91275G>A, ENST00000261769.10:c.2104G>A, ENST00000261769.9:c.2104G>A, ENST00000422392.6:c.1921G>A, ENST00000562118.1:n.322G>A, ENST00000562836.5:n.2175G>A, ENST00000566510.5:c.*770G>A, ENST00000566612.5:c.*344G>A, ENST00000611625.4:c.2167G>A, ENST00000612417.4:c.1830+1447G>A, ENST00000621016.4:c.1865+1412G>A, NM_004360.3:c.2104G>A, LRG_301t1:c.2104G>A, XM_011523488.1:c.1369G>A, XM_011523489.1:c.1369G>A, NM_001317184.1:c.1921G>A, NM_001317185.1:c.556G>A, NM_001317186.1:c.139G>A, NM_004360.5:c.2104G>A, NM_001317184.2:c.1921G>A, NM_001317185.2:c.556G>A, NM_001317186.2:c.139G>A, NM_004360.5(CDH1):c.2104G>A (p.Glu702Lys), NM_004360.4(CDH1):c.2104G>A (p.Glu702Lys)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Benign	BA1	BS2, PP3, PP2, PP1, PP4, PS1, PS3, PS4, PS2, BP4, BP1, BP3, BP2, PM5, PM4, PM1, PM3, BP7, BP5, BS1, BS3, BS4, PVS1, PM2, PM6	The c.2104G>A (p.GLu702Lys) variant has an allele frequency of 0.001714 (0.2%, 71/41,414 alleles) in the African subpopulation of the gnomAD cohort (BA1). Therefore, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): BA1.		CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-08	2023-08-08	False	https://erepo.genome.network/evrepo/ui/classification/CA288054/MONDO:0007648/007	89edf24d-5117-4ff9-8e40-1aad098773dd	p.Glu702Lys	Glu	702	Lys	MGPWSRSLSALLLLLQVSSWLCQEPEPCHPGFDAESYTFTVPRRHLERGRVLGRVNFEDCTGRQRTAYFSLDTRFKVGTDGVITVKRPLRFHNPQIHFLVYAWDSTYRKFSTKVTLNTVGHHHRPPPHQASVSGIQAELLTFPNSSPGLRRQKRDWVIPPISCPENEKGPFPKNLVQIKSNKDKEGKVFYSITGQGADTPPVGVFIIERETGWLKVTEPLDRERIATYTLFSHAVSSNGNAVEDPMEILITVTDQNDNKPEFTQEVFKGSVMEGALPGTSVMEVTATDADDDVNTYNAAIAYTILSQDPELPDKNMFTINRNTGVISVVTTGLDRESFPTYTLVVQAADLQGEGLSTTATAVITVTDTNDNPPIFNPTTYKGQVPENEANVVITTLKVTDADAPNTPAWEAVYTILNDDGGQFVVTTNPVNNDGILKTAKGLDFEAKQQYILHVAVTNVVPFEVSLTTSTATVTVDVLDVNEAPIFVPPEKRVEVSEDFGVGQEITSYTAQEPDTFMEQKITYRIWRDTANWLEINPDTGAISTRAELDREDFEHVKNSTYTALIIATDNGSPVATGTGTLLLILSDVNDNAPIPEPRTIFFCERNPKPQVINIIDADLPPNTSPFTAELTHGASANWTIQYNDPTQESIILKPKMALEVGDYKINLKLMDNQNKDQVTTLEVSVCDCEGAAGVCRKAQPVEAGLQIPAILGILGGILALLILILLLLLFLRRRAVVKEPLLPPEDDTRDNVYYYDEEGGGEEDQDFDLSQLHRGLDARPEVTRNDVAPTLMSVPRYLPRPANPDEIGNFIDENLKAADTDPTAPPYDSLLVFDYEGSGSEAASLSSLNSSESDKDQDYDYLNEWGNRFKKLADMYGGGEDD	882	P12830	K	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [1], 'TRANSIT_gain_score': array([0.00918663]), 'STRAND_loss': [503], 'STRAND_gain': [667, 678], 'STRAND_gain_score': array([0.00766414, 0.01208508]), 'STRAND_loss_score': array([-0.00068921]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
104	NM_004360.4(CDH1):c.1018A>G (p.Thr340Ala)	12245	CA288016	NM_004360.4:c.1018A>G, NC_000016.10:g.68812144A>G, CM000678.2:g.68812144A>G, NC_000016.9:g.68846047A>G, CM000678.1:g.68846047A>G, NC_000016.8:g.67403548A>G, NG_008021.1:g.79853A>G, LRG_301:g.79853A>G, ENST00000261769.10:c.1018A>G, ENST00000261769.9:c.1018A>G, ENST00000422392.6:c.1018A>G, ENST00000561751.1:c.640A>G, ENST00000562836.5:n.1089A>G, ENST00000565810.1:n.62A>G, ENST00000566510.5:c.862A>G, ENST00000566612.5:c.1018A>G, ENST00000611625.4:c.1018A>G, ENST00000612417.4:c.1018A>G, ENST00000621016.4:c.1018A>G, NM_004360.3:c.1018A>G, LRG_301t1:c.1018A>G, XM_011523488.1:c.283A>G, XM_011523489.1:c.283A>G, NM_001317184.1:c.1018A>G, NM_001317185.1:c.-598A>G, NM_001317186.1:c.-802A>G, NM_004360.5:c.1018A>G, NM_001317184.2:c.1018A>G, NM_001317185.2:c.-598A>G, NM_001317186.2:c.-802A>G, NM_004360.5(CDH1):c.1018A>G (p.Thr340Ala), NM_004360.4(CDH1):c.1018A>G (p.Thr340Ala)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Benign	BA1	PP3, PP2, PP1, PP4, BS2, PS1, PS3, PS4, PS2, BP4, BP1, BP3, BP2, PM5, PM4, PM1, PM3, PM2, PM6, PVS1, BP7, BP5, BS1, BS3, BS4	The c.1018A>G (p.Thr340Ala) variant has an allele frequency of 0.00360 (0.36%, 68/18,866 alleles) in the East Asian subpopulation of the gnomAD cohort (BA1). In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): BA1.		CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-08	2023-08-08	False	https://erepo.genome.network/evrepo/ui/classification/CA288016/MONDO:0007648/007	de5b0e27-fa33-4621-930e-61569417ceff	p.Thr340Ala	Thr	340	Ala	MGPWSRSLSALLLLLQVSSWLCQEPEPCHPGFDAESYTFTVPRRHLERGRVLGRVNFEDCTGRQRTAYFSLDTRFKVGTDGVITVKRPLRFHNPQIHFLVYAWDSTYRKFSTKVTLNTVGHHHRPPPHQASVSGIQAELLTFPNSSPGLRRQKRDWVIPPISCPENEKGPFPKNLVQIKSNKDKEGKVFYSITGQGADTPPVGVFIIERETGWLKVTEPLDRERIATYTLFSHAVSSNGNAVEDPMEILITVTDQNDNKPEFTQEVFKGSVMEGALPGTSVMEVTATDADDDVNTYNAAIAYTILSQDPELPDKNMFTINRNTGVISVVTTGLDRESFPTYTLVVQAADLQGEGLSTTATAVITVTDTNDNPPIFNPTTYKGQVPENEANVVITTLKVTDADAPNTPAWEAVYTILNDDGGQFVVTTNPVNNDGILKTAKGLDFEAKQQYILHVAVTNVVPFEVSLTTSTATVTVDVLDVNEAPIFVPPEKRVEVSEDFGVGQEITSYTAQEPDTFMEQKITYRIWRDTANWLEINPDTGAISTRAELDREDFEHVKNSTYTALIIATDNGSPVATGTGTLLLILSDVNDNAPIPEPRTIFFCERNPKPQVINIIDADLPPNTSPFTAELTHGASANWTIQYNDPTQESIILKPKMALEVGDYKINLKLMDNQNKDQVTTLEVSVCDCEGAAGVCRKAQPVEAGLQIPAILGILGGILALLILILLLLLFLRRRAVVKEPLLPPEDDTRDNVYYYDEEGGGEEDQDFDLSQLHRGLDARPEVTRNDVAPTLMSVPRYLPRPANPDEIGNFIDENLKAADTDPTAPPYDSLLVFDYEGSGSEAASLSSLNSSESDKDQDYDYLNEWGNRFKKLADMYGGGEDD	882	P12830	A	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [503], 'STRAND_gain': [175], 'STRAND_gain_score': array([0.00191736]), 'STRAND_loss_score': array([-0.00093603]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
105	NM_004360.5(CDH1):c.1409C>T (p.Thr470Ile)	127913	CA151518	NM_004360.5:c.1409C>T, NC_000016.10:g.68815603C>T, CM000678.2:g.68815603C>T, NC_000016.9:g.68849506C>T, CM000678.1:g.68849506C>T, NC_000016.8:g.67407007C>T, NG_008021.1:g.83312C>T, LRG_301:g.83312C>T, ENST00000261769.10:c.1409C>T, ENST00000261769.9:c.1409C>T, ENST00000422392.6:c.1226C>T, ENST00000562836.5:n.1480C>T, ENST00000566510.5:c.*75C>T, ENST00000566612.5:c.1409C>T, ENST00000611625.4:c.1472C>T, ENST00000612417.4:c.1409C>T, ENST00000621016.4:c.1409C>T, NM_004360.3:c.1409C>T, LRG_301t1:c.1409C>T, XM_011523488.1:c.674C>T, XM_011523489.1:c.674C>T, NM_001317184.1:c.1226C>T, NM_001317185.1:c.-140C>T, NM_001317186.1:c.-411C>T, NM_004360.4:c.1409C>T, NM_001317184.2:c.1226C>T, NM_001317185.2:c.-140C>T, NM_001317186.2:c.-411C>T, NM_004360.5(CDH1):c.1409C>T (p.Thr470Ile)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Benign	BS2, BP2_Strong	PP3, PP2, PP1, PP4, PS1, PS3, PS4, PS2, BP4, BP1, BP3, BA1, PM3, PM5, PM4, PM1, PM2, PM6, PVS1, BP5, BP7, BS1, BS4, BS3	The c.1409C>T (p.Thr470Ile) variant was observed in trans with a known pathogenic CDH1 variant with phase confirmed (BP2_Strong; PMID: 9537325). This variant was also observed in the homozygous state in at least 6 individuals without a personal and/or family history of diffuse gastric cancer, signet ring cell tumor or lobular breast cancer (BP2_Strong; internal laboratory contributors). Additionally, this variant has been observed in >10 individuals without a diagnosis of diffuse gastric cancer, signet ring tumor or lobular breast cancer and whose family histories do not suggest HDGC (BS2; internal laboratory contributors). In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): BP2_Strong, BS2.	9537325, 9537325	CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-10	2023-08-10	False	https://erepo.genome.network/evrepo/ui/classification/CA151518/MONDO:0007648/007	1149db17-78d8-4b2c-bbd4-e5f6b193a1eb	p.Thr470Ile	Thr	470	Ile	MGPWSRSLSALLLLLQVSSWLCQEPEPCHPGFDAESYTFTVPRRHLERGRVLGRVNFEDCTGRQRTAYFSLDTRFKVGTDGVITVKRPLRFHNPQIHFLVYAWDSTYRKFSTKVTLNTVGHHHRPPPHQASVSGIQAELLTFPNSSPGLRRQKRDWVIPPISCPENEKGPFPKNLVQIKSNKDKEGKVFYSITGQGADTPPVGVFIIERETGWLKVTEPLDRERIATYTLFSHAVSSNGNAVEDPMEILITVTDQNDNKPEFTQEVFKGSVMEGALPGTSVMEVTATDADDDVNTYNAAIAYTILSQDPELPDKNMFTINRNTGVISVVTTGLDRESFPTYTLVVQAADLQGEGLSTTATAVITVTDTNDNPPIFNPTTYKGQVPENEANVVITTLKVTDADAPNTPAWEAVYTILNDDGGQFVVTTNPVNNDGILKTAKGLDFEAKQQYILHVAVTNVVPFEVSLTTSTATVTVDVLDVNEAPIFVPPEKRVEVSEDFGVGQEITSYTAQEPDTFMEQKITYRIWRDTANWLEINPDTGAISTRAELDREDFEHVKNSTYTALIIATDNGSPVATGTGTLLLILSDVNDNAPIPEPRTIFFCERNPKPQVINIIDADLPPNTSPFTAELTHGASANWTIQYNDPTQESIILKPKMALEVGDYKINLKLMDNQNKDQVTTLEVSVCDCEGAAGVCRKAQPVEAGLQIPAILGILGGILALLILILLLLLFLRRRAVVKEPLLPPEDDTRDNVYYYDEEGGGEEDQDFDLSQLHRGLDARPEVTRNDVAPTLMSVPRYLPRPANPDEIGNFIDENLKAADTDPTAPPYDSLLVFDYEGSGSEAASLSSLNSSESDKDQDYDYLNEWGNRFKKLADMYGGGEDD	882	P12830	I	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [503], 'STRAND_gain': [175, 485], 'STRAND_gain_score': array([0.00123185, 0.02097315]), 'STRAND_loss_score': array([-0.00184232]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
106	NM_004360.4(CDH1):c.88C>A (p.Pro30Thr)	127933	CA151524	NM_004360.4:c.88C>A, NC_000016.10:g.68738336C>A, CM000678.2:g.68738336C>A, NC_000016.9:g.68772239C>A, CM000678.1:g.68772239C>A, NC_000016.8:g.67329740C>A, NG_008021.1:g.6045C>A, LRG_301:g.6045C>A, ENST00000261769.10:c.88C>A, ENST00000261769.9:c.88C>A, ENST00000422392.6:c.88C>A, ENST00000566510.5:c.88C>A, ENST00000566612.5:c.88C>A, ENST00000611625.4:c.88C>A, ENST00000612417.4:c.88C>A, ENST00000621016.4:c.88C>A, NM_004360.3:c.88C>A, LRG_301t1:c.88C>A, NM_001317184.1:c.88C>A, NM_001317185.1:c.-1528C>A, NM_001317186.1:c.-1732C>A, NM_004360.5:c.88C>A, NM_001317184.2:c.88C>A, NM_001317185.2:c.-1528C>A, NM_001317186.2:c.-1732C>A, NM_004360.5(CDH1):c.88C>A (p.Pro30Thr), NM_004360.4(CDH1):c.88C>A (p.Pro30Thr)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Benign	BS2, BA1	PP3, PP2, PP1, PP4, PS3, PS1, PS4, PS2, BP4, BP1, BP2, BP3, PM5, PM1, PM3, PM4, BP7, BP5, BS1, BS3, BS4, PM2, PM6, PVS1	The c.88C>A (p.Pro30Thr) variant has an allele frequency of 0.00249 (0.25%, 178/71372 alleles) in the European (non-Finnish) subpopulation of the gnomAD cohort (BA1). In addition to meeting stand along criteria for a benign classification, this variant has also been seen in >900 individuals without a diagnosis of diffuse gastric cancer, signet ring tumor or lobular breast cancer and whose family histories do not suggest HDGC (BS2; internal laboratory contributors).  In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): BA1, BS2.		CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-17	2023-08-17	False	https://erepo.genome.network/evrepo/ui/classification/CA151524/MONDO:0007648/007	d1e6757d-87b2-428c-a699-e2ac2893485c	p.Pro30Thr	Pro	30	Thr	MGPWSRSLSALLLLLQVSSWLCQEPEPCHPGFDAESYTFTVPRRHLERGRVLGRVNFEDCTGRQRTAYFSLDTRFKVGTDGVITVKRPLRFHNPQIHFLVYAWDSTYRKFSTKVTLNTVGHHHRPPPHQASVSGIQAELLTFPNSSPGLRRQKRDWVIPPISCPENEKGPFPKNLVQIKSNKDKEGKVFYSITGQGADTPPVGVFIIERETGWLKVTEPLDRERIATYTLFSHAVSSNGNAVEDPMEILITVTDQNDNKPEFTQEVFKGSVMEGALPGTSVMEVTATDADDDVNTYNAAIAYTILSQDPELPDKNMFTINRNTGVISVVTTGLDRESFPTYTLVVQAADLQGEGLSTTATAVITVTDTNDNPPIFNPTTYKGQVPENEANVVITTLKVTDADAPNTPAWEAVYTILNDDGGQFVVTTNPVNNDGILKTAKGLDFEAKQQYILHVAVTNVVPFEVSLTTSTATVTVDVLDVNEAPIFVPPEKRVEVSEDFGVGQEITSYTAQEPDTFMEQKITYRIWRDTANWLEINPDTGAISTRAELDREDFEHVKNSTYTALIIATDNGSPVATGTGTLLLILSDVNDNAPIPEPRTIFFCERNPKPQVINIIDADLPPNTSPFTAELTHGASANWTIQYNDPTQESIILKPKMALEVGDYKINLKLMDNQNKDQVTTLEVSVCDCEGAAGVCRKAQPVEAGLQIPAILGILGGILALLILILLLLLFLRRRAVVKEPLLPPEDDTRDNVYYYDEEGGGEEDQDFDLSQLHRGLDARPEVTRNDVAPTLMSVPRYLPRPANPDEIGNFIDENLKAADTDPTAPPYDSLLVFDYEGSGSEAASLSSLNSSESDKDQDYDYLNEWGNRFKKLADMYGGGEDD	882	P12830	T	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [84], 'STRAND_gain': [175, 260], 'STRAND_gain_score': array([0.00195354, 0.00308102]), 'STRAND_loss_score': array([-0.01400185]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
107	NM_004360.4(CDH1):c.1888C>G (p.Leu630Val)	133846	CA157951	NM_004360.4:c.1888C>G, NC_000016.10:g.68822177C>G, CM000678.2:g.68822177C>G, NC_000016.9:g.68856080C>G, CM000678.1:g.68856080C>G, NC_000016.8:g.67413581C>G, NG_008021.1:g.89886C>G, LRG_301:g.89886C>G, ENST00000261769.10:c.1888C>G, ENST00000261769.9:c.1888C>G, ENST00000422392.6:c.1705C>G, ENST00000562836.5:n.1959C>G, ENST00000566510.5:c.*554C>G, ENST00000566612.5:c.*128C>G, ENST00000611625.4:c.1951C>G, ENST00000612417.4:c.1830+58C>G, ENST00000621016.4:c.1865+23C>G, NM_004360.3:c.1888C>G, LRG_301t1:c.1888C>G, XM_011523488.1:c.1153C>G, XM_011523489.1:c.1153C>G, NM_001317184.1:c.1705C>G, NM_001317185.1:c.340C>G, NM_001317186.1:c.-78C>G, NM_004360.5:c.1888C>G, NM_001317184.2:c.1705C>G, NM_001317185.2:c.340C>G, NM_001317186.2:c.-78C>G, NM_004360.5(CDH1):c.1888C>G (p.Leu630Val), NM_004360.4(CDH1):c.1888C>G (p.Leu630Val)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Benign	BA1	PP3, PP2, PP1, PP4, BS2, PS1, PS3, PS4, PS2, BP4, BP1, BP3, BP2, PM5, PM4, PM1, PM3, BP7, BP5, BS1, BS3, BS4, PM2, PM6, PVS1	The c.1888C>G (p.Leu630Val) variant has an allele frequency of 0.00519 (0.52%, 98/18,866 alleles) in the East Asian subpopulation of the gnomAD cohort (BA1). In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): BA1.		CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-08	2023-08-08	False	https://erepo.genome.network/evrepo/ui/classification/CA157951/MONDO:0007648/007	98319533-e1cd-4555-9251-571e07d52e56	p.Leu630Val	Leu	630	Val	MGPWSRSLSALLLLLQVSSWLCQEPEPCHPGFDAESYTFTVPRRHLERGRVLGRVNFEDCTGRQRTAYFSLDTRFKVGTDGVITVKRPLRFHNPQIHFLVYAWDSTYRKFSTKVTLNTVGHHHRPPPHQASVSGIQAELLTFPNSSPGLRRQKRDWVIPPISCPENEKGPFPKNLVQIKSNKDKEGKVFYSITGQGADTPPVGVFIIERETGWLKVTEPLDRERIATYTLFSHAVSSNGNAVEDPMEILITVTDQNDNKPEFTQEVFKGSVMEGALPGTSVMEVTATDADDDVNTYNAAIAYTILSQDPELPDKNMFTINRNTGVISVVTTGLDRESFPTYTLVVQAADLQGEGLSTTATAVITVTDTNDNPPIFNPTTYKGQVPENEANVVITTLKVTDADAPNTPAWEAVYTILNDDGGQFVVTTNPVNNDGILKTAKGLDFEAKQQYILHVAVTNVVPFEVSLTTSTATVTVDVLDVNEAPIFVPPEKRVEVSEDFGVGQEITSYTAQEPDTFMEQKITYRIWRDTANWLEINPDTGAISTRAELDREDFEHVKNSTYTALIIATDNGSPVATGTGTLLLILSDVNDNAPIPEPRTIFFCERNPKPQVINIIDADLPPNTSPFTAELTHGASANWTIQYNDPTQESIILKPKMALEVGDYKINLKLMDNQNKDQVTTLEVSVCDCEGAAGVCRKAQPVEAGLQIPAILGILGGILALLILILLLLLFLRRRAVVKEPLLPPEDDTRDNVYYYDEEGGGEEDQDFDLSQLHRGLDARPEVTRNDVAPTLMSVPRYLPRPANPDEIGNFIDENLKAADTDPTAPPYDSLLVFDYEGSGSEAASLSSLNSSESDKDQDYDYLNEWGNRFKKLADMYGGGEDD	882	P12830	V	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [5], 'TRANSIT_gain': [], 'TRANSIT_loss_score': array([-0.00242639]), 'STRAND_loss': [], 'STRAND_gain': [175, 630, 667, 678], 'STRAND_gain_score': array([0.00183624, 0.07181096, 0.0156408 , 0.00726908]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
108	NM_004360.4(CDH1):c.2494G>A (p.Val832Met)	12246	CA157969	NM_004360.4:c.2494G>A, NC_000016.10:g.68833344G>A, CM000678.2:g.68833344G>A, NC_000016.9:g.68867247G>A, CM000678.1:g.68867247G>A, NC_000016.8:g.67424748G>A, NG_008021.1:g.101053G>A, LRG_301:g.101053G>A, ENST00000261769.10:c.2494G>A, ENST00000261769.9:c.2494G>A, ENST00000422392.6:c.2311G>A, ENST00000562118.1:n.712G>A, ENST00000562836.5:n.2565G>A, ENST00000566510.5:c.*1160G>A, ENST00000566612.5:c.*734G>A, ENST00000611625.4:c.2557G>A, ENST00000612417.4:c.1854-847G>A, ENST00000621016.4:c.1866-859G>A, NM_004360.3:c.2494G>A, LRG_301t1:c.2494G>A, XM_011523488.1:c.1759G>A, XM_011523489.1:c.1759G>A, NM_001317184.1:c.2311G>A, NM_001317185.1:c.946G>A, NM_001317186.1:c.529G>A, NM_004360.5:c.2494G>A, NM_001317184.2:c.2311G>A, NM_001317185.2:c.946G>A, NM_001317186.2:c.529G>A, NM_004360.5(CDH1):c.2494G>A (p.Val832Met), NM_004360.4(CDH1):c.2494G>A (p.Val832Met)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Benign	BS2, BS1	PP3, PP2, PP4, PP1, PS3, PS1, PS4, PS2, BP4, BP1, BP3, BP2, BA1, PM5, PM4, PM1, PM3, PM2, PM6, PVS1, BP5, BP7, BS4, BS3	The c.2494G>A (p.Val832Met) variant has an allele frequency of 0.00175 (0.175%, 33/18,868 alleles) in the East Asian subpopulation of the gnomAD cohort (BS1). This variant has been observed in >10 individuals without a diagnosis of diffuse gastric cancer, signet ring tumor or lobular breast cancer and whose family histories do not suggest HDGC (BS2; internal laboratory contributors). In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): BS1, BS2.	20921021, 12216071, 12216071, 17668349, 22850631, 19017792, 12944922, 12216071, 17668349, 22850631, 19017792, 12944922	CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-10	2023-08-10	False	https://erepo.genome.network/evrepo/ui/classification/CA157969/MONDO:0007648/007	fa3b9647-d4d2-4091-8d83-e4e2f0f16391	p.Val832Met	Val	832	Met	MGPWSRSLSALLLLLQVSSWLCQEPEPCHPGFDAESYTFTVPRRHLERGRVLGRVNFEDCTGRQRTAYFSLDTRFKVGTDGVITVKRPLRFHNPQIHFLVYAWDSTYRKFSTKVTLNTVGHHHRPPPHQASVSGIQAELLTFPNSSPGLRRQKRDWVIPPISCPENEKGPFPKNLVQIKSNKDKEGKVFYSITGQGADTPPVGVFIIERETGWLKVTEPLDRERIATYTLFSHAVSSNGNAVEDPMEILITVTDQNDNKPEFTQEVFKGSVMEGALPGTSVMEVTATDADDDVNTYNAAIAYTILSQDPELPDKNMFTINRNTGVISVVTTGLDRESFPTYTLVVQAADLQGEGLSTTATAVITVTDTNDNPPIFNPTTYKGQVPENEANVVITTLKVTDADAPNTPAWEAVYTILNDDGGQFVVTTNPVNNDGILKTAKGLDFEAKQQYILHVAVTNVVPFEVSLTTSTATVTVDVLDVNEAPIFVPPEKRVEVSEDFGVGQEITSYTAQEPDTFMEQKITYRIWRDTANWLEINPDTGAISTRAELDREDFEHVKNSTYTALIIATDNGSPVATGTGTLLLILSDVNDNAPIPEPRTIFFCERNPKPQVINIIDADLPPNTSPFTAELTHGASANWTIQYNDPTQESIILKPKMALEVGDYKINLKLMDNQNKDQVTTLEVSVCDCEGAAGVCRKAQPVEAGLQIPAILGILGGILALLILILLLLLFLRRRAVVKEPLLPPEDDTRDNVYYYDEEGGGEEDQDFDLSQLHRGLDARPEVTRNDVAPTLMSVPRYLPRPANPDEIGNFIDENLKAADTDPTAPPYDSLLVFDYEGSGSEAASLSSLNSSESDKDQDYDYLNEWGNRFKKLADMYGGGEDD	882	P12830	M	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [5], 'TRANSIT_gain': [], 'TRANSIT_loss_score': array([-0.00130844]), 'STRAND_loss': [], 'STRAND_gain': [175, 485, 678], 'STRAND_gain_score': array([0.00746918, 0.00368553, 0.00222021]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [855], 'COMPBIAS_gain_score': array([0.02356344]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
109	NM_004360.4(CDH1):c.1298A>G (p.Asp433Gly)	141810	CA294197	NM_004360.4:c.1298A>G, NC_000016.10:g.68813473A>G, CM000678.2:g.68813473A>G, NC_000016.9:g.68847376A>G, CM000678.1:g.68847376A>G, NC_000016.8:g.67404877A>G, NG_008021.1:g.81182A>G, LRG_301:g.81182A>G, ENST00000261769.10:c.1298A>G, ENST00000261769.9:c.1298A>G, ENST00000422392.6:c.1137+1210A>G, ENST00000562836.5:n.1369A>G, ENST00000566510.5:c.1142A>G, ENST00000566612.5:c.1298A>G, ENST00000611625.4:c.1298A>G, ENST00000612417.4:c.1298A>G, ENST00000621016.4:c.1298A>G, NM_004360.3:c.1298A>G, LRG_301t1:c.1298A>G, XM_011523488.1:c.563A>G, XM_011523489.1:c.563A>G, NM_001317184.1:c.1137+1210A>G, NM_001317185.1:c.-318A>G, NM_001317186.1:c.-522A>G, NM_004360.5:c.1298A>G, NM_001317184.2:c.1137+1210A>G, NM_001317185.2:c.-318A>G, NM_001317186.2:c.-522A>G, NM_004360.5(CDH1):c.1298A>G (p.Asp433Gly), NM_004360.4(CDH1):c.1298A>G (p.Asp433Gly)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Benign	BS2, BP2_Strong	PP3, PP2, PP4, PP1, PS1, PS3, PS4, PS2, BP4, BP1, BP3, BA1, PM5, PM3, PM4, PM1, PM2, PM6, PVS1, BP7, BP5, BS1, BS3, BS4	The c.1298A>G (p.Asp433Gly) variant was observed at least twice in the homozygous state in individuals without a personal and/or family history of diffuse gastric cancer, signet ring cell tumor or lobular breast cancer (BP2_Strong; SCV000253407.6). This variant has also been observed in >10 individuals without a diagnosis of diffuse gastric cancer, signet ring cell tumor or lobular breast cancer and whose family histories do not suggest HDGC (BS2; internal laboratory contributors). In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): BP2_Strong, BS2.	23435907, 20921021, 23435907, 20921021	CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-10	2023-08-10	False	https://erepo.genome.network/evrepo/ui/classification/CA294197/MONDO:0007648/007	13766caf-9ff5-48fb-a208-1ee4d81736e0	p.Asp433Gly	Asp	433	Gly	MGPWSRSLSALLLLLQVSSWLCQEPEPCHPGFDAESYTFTVPRRHLERGRVLGRVNFEDCTGRQRTAYFSLDTRFKVGTDGVITVKRPLRFHNPQIHFLVYAWDSTYRKFSTKVTLNTVGHHHRPPPHQASVSGIQAELLTFPNSSPGLRRQKRDWVIPPISCPENEKGPFPKNLVQIKSNKDKEGKVFYSITGQGADTPPVGVFIIERETGWLKVTEPLDRERIATYTLFSHAVSSNGNAVEDPMEILITVTDQNDNKPEFTQEVFKGSVMEGALPGTSVMEVTATDADDDVNTYNAAIAYTILSQDPELPDKNMFTINRNTGVISVVTTGLDRESFPTYTLVVQAADLQGEGLSTTATAVITVTDTNDNPPIFNPTTYKGQVPENEANVVITTLKVTDADAPNTPAWEAVYTILNDDGGQFVVTTNPVNNDGILKTAKGLDFEAKQQYILHVAVTNVVPFEVSLTTSTATVTVDVLDVNEAPIFVPPEKRVEVSEDFGVGQEITSYTAQEPDTFMEQKITYRIWRDTANWLEINPDTGAISTRAELDREDFEHVKNSTYTALIIATDNGSPVATGTGTLLLILSDVNDNAPIPEPRTIFFCERNPKPQVINIIDADLPPNTSPFTAELTHGASANWTIQYNDPTQESIILKPKMALEVGDYKINLKLMDNQNKDQVTTLEVSVCDCEGAAGVCRKAQPVEAGLQIPAILGILGGILALLILILLLLLFLRRRAVVKEPLLPPEDDTRDNVYYYDEEGGGEEDQDFDLSQLHRGLDARPEVTRNDVAPTLMSVPRYLPRPANPDEIGNFIDENLKAADTDPTAPPYDSLLVFDYEGSGSEAASLSSLNSSESDKDQDYDYLNEWGNRFKKLADMYGGGEDD	882	P12830	G	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [5], 'TRANSIT_gain': [], 'TRANSIT_loss_score': array([-0.0027557]), 'STRAND_loss': [503], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.00178069]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
110	NM_004360.4(CDH1):c.2413G>A (p.Asp805Asn)	127925	CA157966	NM_004360.4:c.2413G>A, NC_000016.10:g.68829771G>A, CM000678.2:g.68829771G>A, NC_000016.9:g.68863674G>A, CM000678.1:g.68863674G>A, NC_000016.8:g.67421175G>A, NG_008021.1:g.97480G>A, LRG_301:g.97480G>A, ENST00000261769.10:c.2413G>A, ENST00000261769.9:c.2413G>A, ENST00000422392.6:c.2230G>A, ENST00000562118.1:n.631G>A, ENST00000562836.5:n.2484G>A, ENST00000566510.5:c.*1079G>A, ENST00000566612.5:c.*653G>A, ENST00000611625.4:c.2476G>A, ENST00000612417.4:c.1853+3217G>A, ENST00000621016.4:c.1866-4432G>A, NM_004360.3:c.2413G>A, LRG_301t1:c.2413G>A, XM_011523488.1:c.1678G>A, XM_011523489.1:c.1678G>A, NM_001317184.1:c.2230G>A, NM_001317185.1:c.865G>A, NM_001317186.1:c.448G>A, NM_004360.5:c.2413G>A, NM_001317184.2:c.2230G>A, NM_001317185.2:c.865G>A, NM_001317186.2:c.448G>A, NM_004360.5(CDH1):c.2413G>A (p.Asp805Asn), NM_004360.4(CDH1):c.2413G>A (p.Asp805Asn)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Benign	BA1	PP3, PP2, PP4, PP1, BS2, PS3, PS1, PS4, PS2, BP4, BP1, BP2, BP3, PM5, PM3, PM4, PM1, PM2, PM6, PVS1, BP5, BP7, BS1, BS3, BS4	The c.2413G>A (p.Asp805Asn) variant has an allele frequency of 0.00207 (0.21%, 21/10,148 alleles) in the Ashkenazi Jewish subpopulation of the gnomAD cohort (BA1). In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): BA1.	26182300, 24728327, 25980754, 23197654, 23197654	CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-08	2023-08-08	False	https://erepo.genome.network/evrepo/ui/classification/CA157966/MONDO:0007648/007	8f3f955a-56d1-4528-83ec-f23b19eb3126	p.Asp805Asn	Asp	805	Asn	MGPWSRSLSALLLLLQVSSWLCQEPEPCHPGFDAESYTFTVPRRHLERGRVLGRVNFEDCTGRQRTAYFSLDTRFKVGTDGVITVKRPLRFHNPQIHFLVYAWDSTYRKFSTKVTLNTVGHHHRPPPHQASVSGIQAELLTFPNSSPGLRRQKRDWVIPPISCPENEKGPFPKNLVQIKSNKDKEGKVFYSITGQGADTPPVGVFIIERETGWLKVTEPLDRERIATYTLFSHAVSSNGNAVEDPMEILITVTDQNDNKPEFTQEVFKGSVMEGALPGTSVMEVTATDADDDVNTYNAAIAYTILSQDPELPDKNMFTINRNTGVISVVTTGLDRESFPTYTLVVQAADLQGEGLSTTATAVITVTDTNDNPPIFNPTTYKGQVPENEANVVITTLKVTDADAPNTPAWEAVYTILNDDGGQFVVTTNPVNNDGILKTAKGLDFEAKQQYILHVAVTNVVPFEVSLTTSTATVTVDVLDVNEAPIFVPPEKRVEVSEDFGVGQEITSYTAQEPDTFMEQKITYRIWRDTANWLEINPDTGAISTRAELDREDFEHVKNSTYTALIIATDNGSPVATGTGTLLLILSDVNDNAPIPEPRTIFFCERNPKPQVINIIDADLPPNTSPFTAELTHGASANWTIQYNDPTQESIILKPKMALEVGDYKINLKLMDNQNKDQVTTLEVSVCDCEGAAGVCRKAQPVEAGLQIPAILGILGGILALLILILLLLLFLRRRAVVKEPLLPPEDDTRDNVYYYDEEGGGEEDQDFDLSQLHRGLDARPEVTRNDVAPTLMSVPRYLPRPANPDEIGNFIDENLKAADTDPTAPPYDSLLVFDYEGSGSEAASLSSLNSSESDKDQDYDYLNEWGNRFKKLADMYGGGEDD	882	P12830	N	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [5], 'TRANSIT_gain': [], 'TRANSIT_loss_score': array([-0.00152212]), 'STRAND_loss': [], 'STRAND_gain': [175, 678], 'STRAND_gain_score': array([0.00106984, 0.00275499]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
111	NM_004360.4(CDH1):c.892G>A (p.Ala298Thr)	41787	CA211397	NM_004360.4:c.892G>A, NC_000016.10:g.68811743G>A, CM000678.2:g.68811743G>A, NC_000016.9:g.68845646G>A, CM000678.1:g.68845646G>A, NC_000016.8:g.67403147G>A, NG_008021.1:g.79452G>A, LRG_301:g.79452G>A, ENST00000261769.10:c.892G>A, ENST00000261769.9:c.892G>A, ENST00000422392.6:c.892G>A, ENST00000561751.1:n.514G>A, ENST00000562836.5:n.963G>A, ENST00000566510.5:c.736G>A, ENST00000566612.5:c.892G>A, ENST00000611625.4:c.892G>A, ENST00000612417.4:c.892G>A, ENST00000621016.4:c.892G>A, NM_004360.3:c.892G>A, LRG_301t1:c.892G>A, XM_011523488.1:c.157G>A, XM_011523489.1:c.157G>A, NM_001317184.1:c.892G>A, NM_001317185.1:c.-724G>A, NM_001317186.1:c.-928G>A, NM_004360.5:c.892G>A, NM_001317184.2:c.892G>A, NM_001317185.2:c.-724G>A, NM_001317186.2:c.-928G>A, NM_004360.5(CDH1):c.892G>A (p.Ala298Thr), NM_004360.4(CDH1):c.892G>A (p.Ala298Thr)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Benign	BS2, BS1	PP1, PP3, PP2, PP4, PS3, PS1, PS4, PS2, BP2, BP4, BP1, BP3, BA1, PM3, PM5, PM4, PM1, BP5, BP7, BS3, BS4, PVS1, PM2, PM6	The c.892G>A (p.Ala298Thr) variant has an allele frequency of 0.00133 (0.1%, 41/30,782 alleles) in the South Asian subpopulation of the gnomAD cohort (BS1). This variant has also been observed in >10 without a diagnosis of diffuse gastric cancer, signet ring tumor or lobular breast cancer and whose family histories do not suggest HDGC (BS2; internal laboratory contributors). In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): BS1, BS2.		CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-10	2023-08-10	False	https://erepo.genome.network/evrepo/ui/classification/CA211397/MONDO:0007648/007	1d1c6414-89d7-42c8-85d3-38f95b02cc08	p.Ala298Thr	Ala	298	Thr	MGPWSRSLSALLLLLQVSSWLCQEPEPCHPGFDAESYTFTVPRRHLERGRVLGRVNFEDCTGRQRTAYFSLDTRFKVGTDGVITVKRPLRFHNPQIHFLVYAWDSTYRKFSTKVTLNTVGHHHRPPPHQASVSGIQAELLTFPNSSPGLRRQKRDWVIPPISCPENEKGPFPKNLVQIKSNKDKEGKVFYSITGQGADTPPVGVFIIERETGWLKVTEPLDRERIATYTLFSHAVSSNGNAVEDPMEILITVTDQNDNKPEFTQEVFKGSVMEGALPGTSVMEVTATDADDDVNTYNAAIAYTILSQDPELPDKNMFTINRNTGVISVVTTGLDRESFPTYTLVVQAADLQGEGLSTTATAVITVTDTNDNPPIFNPTTYKGQVPENEANVVITTLKVTDADAPNTPAWEAVYTILNDDGGQFVVTTNPVNNDGILKTAKGLDFEAKQQYILHVAVTNVVPFEVSLTTSTATVTVDVLDVNEAPIFVPPEKRVEVSEDFGVGQEITSYTAQEPDTFMEQKITYRIWRDTANWLEINPDTGAISTRAELDREDFEHVKNSTYTALIIATDNGSPVATGTGTLLLILSDVNDNAPIPEPRTIFFCERNPKPQVINIIDADLPPNTSPFTAELTHGASANWTIQYNDPTQESIILKPKMALEVGDYKINLKLMDNQNKDQVTTLEVSVCDCEGAAGVCRKAQPVEAGLQIPAILGILGGILALLILILLLLLFLRRRAVVKEPLLPPEDDTRDNVYYYDEEGGGEEDQDFDLSQLHRGLDARPEVTRNDVAPTLMSVPRYLPRPANPDEIGNFIDENLKAADTDPTAPPYDSLLVFDYEGSGSEAASLSSLNSSESDKDQDYDYLNEWGNRFKKLADMYGGGEDD	882	P12830	T	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [5], 'TRANSIT_gain': [], 'TRANSIT_loss_score': array([-0.0066666]), 'STRAND_loss': [], 'STRAND_gain': [485, 678], 'STRAND_gain_score': array([0.00097287, 0.00135612]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
112	NM_004360.4(CDH1):c.1774G>A (p.Ala592Thr)	41783	CA157954	NM_004360.4:c.1774G>A, NC_000016.10:g.68822063G>A, CM000678.2:g.68822063G>A, NC_000016.9:g.68855966G>A, CM000678.1:g.68855966G>A, NC_000016.8:g.67413467G>A, NG_008021.1:g.89772G>A, LRG_301:g.89772G>A, ENST00000261769.10:c.1774G>A, ENST00000261769.9:c.1774G>A, ENST00000422392.6:c.1591G>A, ENST00000562836.5:n.1845G>A, ENST00000566510.5:c.*440G>A, ENST00000566612.5:c.*14G>A, ENST00000611625.4:c.1837G>A, ENST00000612417.4:c.1774G>A, ENST00000621016.4:c.1774G>A, NM_004360.3:c.1774G>A, LRG_301t1:c.1774G>A, XM_011523488.1:c.1039G>A, XM_011523489.1:c.1039G>A, NM_001317184.1:c.1591G>A, NM_001317185.1:c.226G>A, NM_001317186.1:c.-192G>A, NM_004360.5:c.1774G>A, NM_001317184.2:c.1591G>A, NM_001317185.2:c.226G>A, NM_001317186.2:c.-192G>A, NM_004360.5(CDH1):c.1774G>A (p.Ala592Thr), NM_004360.4(CDH1):c.1774G>A (p.Ala592Thr)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Benign	BA1	PP4, PP3, PP2, PP1, BS2, PS1, PS3, PS4, PS2, BP4, BP1, BP3, BP2, PM5, PM4, PM1, PM3, PM2, PM6, PVS1, BP7, BP5, BS1, BS3, BS4	The c.1774G>A  (p.Ala592Thr) variant has an allele frequency of 0.00481 (0.48%, 609/126,710 alleles) in the European (non-Finnish) subpopulation of the gnomAD cohort (BA1). In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): BA1.		CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-08	2023-08-08	False	https://erepo.genome.network/evrepo/ui/classification/CA157954/MONDO:0007648/007	ba6046f9-9dfa-4961-912e-d1cadcaa922d	p.Ala592Thr	Ala	592	Thr	MGPWSRSLSALLLLLQVSSWLCQEPEPCHPGFDAESYTFTVPRRHLERGRVLGRVNFEDCTGRQRTAYFSLDTRFKVGTDGVITVKRPLRFHNPQIHFLVYAWDSTYRKFSTKVTLNTVGHHHRPPPHQASVSGIQAELLTFPNSSPGLRRQKRDWVIPPISCPENEKGPFPKNLVQIKSNKDKEGKVFYSITGQGADTPPVGVFIIERETGWLKVTEPLDRERIATYTLFSHAVSSNGNAVEDPMEILITVTDQNDNKPEFTQEVFKGSVMEGALPGTSVMEVTATDADDDVNTYNAAIAYTILSQDPELPDKNMFTINRNTGVISVVTTGLDRESFPTYTLVVQAADLQGEGLSTTATAVITVTDTNDNPPIFNPTTYKGQVPENEANVVITTLKVTDADAPNTPAWEAVYTILNDDGGQFVVTTNPVNNDGILKTAKGLDFEAKQQYILHVAVTNVVPFEVSLTTSTATVTVDVLDVNEAPIFVPPEKRVEVSEDFGVGQEITSYTAQEPDTFMEQKITYRIWRDTANWLEINPDTGAISTRAELDREDFEHVKNSTYTALIIATDNGSPVATGTGTLLLILSDVNDNAPIPEPRTIFFCERNPKPQVINIIDADLPPNTSPFTAELTHGASANWTIQYNDPTQESIILKPKMALEVGDYKINLKLMDNQNKDQVTTLEVSVCDCEGAAGVCRKAQPVEAGLQIPAILGILGGILALLILILLLLLFLRRRAVVKEPLLPPEDDTRDNVYYYDEEGGGEEDQDFDLSQLHRGLDARPEVTRNDVAPTLMSVPRYLPRPANPDEIGNFIDENLKAADTDPTAPPYDSLLVFDYEGSGSEAASLSSLNSSESDKDQDYDYLNEWGNRFKKLADMYGGGEDD	882	P12830	T	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [5], 'TRANSIT_gain': [], 'TRANSIT_loss_score': array([-0.00239366]), 'STRAND_loss': [598, 683], 'STRAND_gain': [260], 'STRAND_gain_score': array([0.00530976]), 'STRAND_loss_score': array([-0.02730852, -0.03015661]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
113	NM_004360.4(CDH1):c.188G>A (p.Arg63Gln)	127919	CA288048	NM_004360.4:c.188G>A, NC_000016.10:g.68801694G>A, CM000678.2:g.68801694G>A, NC_000016.9:g.68835597G>A, CM000678.1:g.68835597G>A, NC_000016.8:g.67393098G>A, NG_008021.1:g.69403G>A, LRG_301:g.69403G>A, ENST00000261769.10:c.188G>A, ENST00000261769.9:c.188G>A, ENST00000422392.6:c.188G>A, ENST00000562836.5:n.259G>A, ENST00000564676.5:n.470G>A, ENST00000564745.1:n.183G>A, ENST00000566510.5:c.188G>A, ENST00000566612.5:c.188G>A, ENST00000611625.4:c.188G>A, ENST00000612417.4:c.188G>A, ENST00000621016.4:c.188G>A, NM_004360.3:c.188G>A, LRG_301t1:c.188G>A, XM_011523488.1:c.-548G>A, XM_011523489.1:c.-548G>A, NM_001317184.1:c.188G>A, NM_001317185.1:c.-1428G>A, NM_001317186.1:c.-1632G>A, NM_004360.5:c.188G>A, NM_001317184.2:c.188G>A, NM_001317185.2:c.-1428G>A, NM_001317186.2:c.-1632G>A, NM_004360.5(CDH1):c.188G>A (p.Arg63Gln), NM_004360.4(CDH1):c.188G>A (p.Arg63Gln)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Benign	BS2, BS1	PP3, PP2, PP1, PP4, PS1, PS3, PS4, PS2, BP4, BP1, BP3, BP2, BA1, PM5, PM4, PM1, PM3, BP5, BP7, BS3, BS4, PVS1, PM2, PM6	The c.188G>A (p.Arg63Gln) variant has an allele frequency of 0.00109 (0.11%, 6/5486 alleles) in the “Other” subpopulation of the gnomAD cohort (BS1). This variant has also been observed in >10 without a diagnosis of diffuse gastric cancer, signet ring tumor or lobular breast cancer and whose family histories do not suggest HDGC (BS2; internal laboratory contributors). In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): BS1, BS2.		CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-10	2023-08-10	False	https://erepo.genome.network/evrepo/ui/classification/CA288048/MONDO:0007648/007	4de15575-228f-4350-8bab-2e2dbfd23694	p.Arg63Gln	Arg	63	Gln	MGPWSRSLSALLLLLQVSSWLCQEPEPCHPGFDAESYTFTVPRRHLERGRVLGRVNFEDCTGRQRTAYFSLDTRFKVGTDGVITVKRPLRFHNPQIHFLVYAWDSTYRKFSTKVTLNTVGHHHRPPPHQASVSGIQAELLTFPNSSPGLRRQKRDWVIPPISCPENEKGPFPKNLVQIKSNKDKEGKVFYSITGQGADTPPVGVFIIERETGWLKVTEPLDRERIATYTLFSHAVSSNGNAVEDPMEILITVTDQNDNKPEFTQEVFKGSVMEGALPGTSVMEVTATDADDDVNTYNAAIAYTILSQDPELPDKNMFTINRNTGVISVVTTGLDRESFPTYTLVVQAADLQGEGLSTTATAVITVTDTNDNPPIFNPTTYKGQVPENEANVVITTLKVTDADAPNTPAWEAVYTILNDDGGQFVVTTNPVNNDGILKTAKGLDFEAKQQYILHVAVTNVVPFEVSLTTSTATVTVDVLDVNEAPIFVPPEKRVEVSEDFGVGQEITSYTAQEPDTFMEQKITYRIWRDTANWLEINPDTGAISTRAELDREDFEHVKNSTYTALIIATDNGSPVATGTGTLLLILSDVNDNAPIPEPRTIFFCERNPKPQVINIIDADLPPNTSPFTAELTHGASANWTIQYNDPTQESIILKPKMALEVGDYKINLKLMDNQNKDQVTTLEVSVCDCEGAAGVCRKAQPVEAGLQIPAILGILGGILALLILILLLLLFLRRRAVVKEPLLPPEDDTRDNVYYYDEEGGGEEDQDFDLSQLHRGLDARPEVTRNDVAPTLMSVPRYLPRPANPDEIGNFIDENLKAADTDPTAPPYDSLLVFDYEGSGSEAASLSSLNSSESDKDQDYDYLNEWGNRFKKLADMYGGGEDD	882	P12830	Q	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [5], 'TRANSIT_gain': [], 'TRANSIT_loss_score': array([-0.00572181]), 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
114	NM_004360.4(CDH1):c.604G>A (p.Val202Ile)	133853	CA163776	NM_004360.4:c.604G>A, NC_000016.10:g.68808765G>A, CM000678.2:g.68808765G>A, NC_000016.9:g.68842668G>A, CM000678.1:g.68842668G>A, NC_000016.8:g.67400169G>A, NG_008021.1:g.76474G>A, LRG_301:g.76474G>A, ENST00000261769.10:c.604G>A, ENST00000261769.9:c.604G>A, ENST00000422392.6:c.604G>A, ENST00000561751.1:c.371G>A, ENST00000562836.5:n.675G>A, ENST00000564676.5:n.886G>A, ENST00000566510.5:c.531+198G>A, ENST00000566612.5:c.604G>A, ENST00000567320.1:n.114G>A, ENST00000611625.4:c.604G>A, ENST00000612417.4:c.604G>A, ENST00000621016.4:c.604G>A, NM_004360.3:c.604G>A, LRG_301t1:c.604G>A, XM_011523488.1:c.-132G>A, XM_011523489.1:c.-132G>A, NM_001317184.1:c.604G>A, NM_001317185.1:c.-1012G>A, NM_001317186.1:c.-1216G>A, NM_004360.5:c.604G>A, NM_001317184.2:c.604G>A, NM_001317185.2:c.-1012G>A, NM_001317186.2:c.-1216G>A, NM_004360.5(CDH1):c.604G>A (p.Val202Ile), NM_004360.4(CDH1):c.604G>A (p.Val202Ile)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Benign	BA1	BS2, PP3, PP2, PP1, PP4, PS1, PS3, PS4, PS2, BP4, BP1, BP3, BP2, PM5, PM4, PM1, PM3, BP7, BP5, BS1, BS3, BS4, PVS1, PM2, PM6	The c.604G>A (p.Val202Ile) variant has an allele frequency of 0.00354 (0.35%, 109/30,772 alleles) in the South Asian subpopulation of the gnomAD cohort (BA1). In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): BA1.		CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-08	2023-08-08	False	https://erepo.genome.network/evrepo/ui/classification/CA163776/MONDO:0007648/007	4f56b139-4c6b-4107-aebc-4368f6c6f68b	p.Val202Ile	Val	202	Ile	MGPWSRSLSALLLLLQVSSWLCQEPEPCHPGFDAESYTFTVPRRHLERGRVLGRVNFEDCTGRQRTAYFSLDTRFKVGTDGVITVKRPLRFHNPQIHFLVYAWDSTYRKFSTKVTLNTVGHHHRPPPHQASVSGIQAELLTFPNSSPGLRRQKRDWVIPPISCPENEKGPFPKNLVQIKSNKDKEGKVFYSITGQGADTPPVGVFIIERETGWLKVTEPLDRERIATYTLFSHAVSSNGNAVEDPMEILITVTDQNDNKPEFTQEVFKGSVMEGALPGTSVMEVTATDADDDVNTYNAAIAYTILSQDPELPDKNMFTINRNTGVISVVTTGLDRESFPTYTLVVQAADLQGEGLSTTATAVITVTDTNDNPPIFNPTTYKGQVPENEANVVITTLKVTDADAPNTPAWEAVYTILNDDGGQFVVTTNPVNNDGILKTAKGLDFEAKQQYILHVAVTNVVPFEVSLTTSTATVTVDVLDVNEAPIFVPPEKRVEVSEDFGVGQEITSYTAQEPDTFMEQKITYRIWRDTANWLEINPDTGAISTRAELDREDFEHVKNSTYTALIIATDNGSPVATGTGTLLLILSDVNDNAPIPEPRTIFFCERNPKPQVINIIDADLPPNTSPFTAELTHGASANWTIQYNDPTQESIILKPKMALEVGDYKINLKLMDNQNKDQVTTLEVSVCDCEGAAGVCRKAQPVEAGLQIPAILGILGGILALLILILLLLLFLRRRAVVKEPLLPPEDDTRDNVYYYDEEGGGEEDQDFDLSQLHRGLDARPEVTRNDVAPTLMSVPRYLPRPANPDEIGNFIDENLKAADTDPTAPPYDSLLVFDYEGSGSEAASLSSLNSSESDKDQDYDYLNEWGNRFKKLADMYGGGEDD	882	P12830	I	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [503], 'STRAND_gain': [175], 'STRAND_gain_score': array([0.00586468]), 'STRAND_loss_score': array([-0.00020415]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
115	NM_004360.4(CDH1):c.1679C>G (p.Thr560Arg)	234554	CA10577547	NM_004360.4:c.1679C>G, NC_000016.10:g.68819393C>G, CM000678.2:g.68819393C>G, NC_000016.9:g.68853296C>G, CM000678.1:g.68853296C>G, NC_000016.8:g.67410797C>G, NG_008021.1:g.87102C>G, LRG_301:g.87102C>G, ENST00000261769.10:c.1679C>G, ENST00000261769.9:c.1679C>G, ENST00000422392.6:c.1496C>G, ENST00000562836.5:n.1750C>G, ENST00000566510.5:c.*345C>G, ENST00000566612.5:c.1566-2608C>G, ENST00000611625.4:c.1742C>G, ENST00000612417.4:c.1679C>G, ENST00000621016.4:c.1679C>G, NM_004360.3:c.1679C>G, LRG_301t1:c.1679C>G, XM_011523488.1:c.944C>G, XM_011523489.1:c.944C>G, NM_001317184.1:c.1496C>G, NM_001317185.1:c.131C>G, NM_001317186.1:c.-254-2608C>G, NM_004360.5:c.1679C>G, NM_001317184.2:c.1496C>G, NM_001317185.2:c.131C>G, NM_001317186.2:c.-254-2608C>G, NM_004360.5(CDH1):c.1679C>G (p.Thr560Arg), NM_004360.4(CDH1):c.1679C>G (p.Thr560Arg)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Pathogenic	PP3, PM2_Supporting, PS3, PS4, PP1_Strong	BS2, PP2, PP4, PS1, PS2, BA1, BP4, BP1, BP2, BP3, PM5, PM1, PM3, PM4, BS1, BS4, BS3, BP7, BP5, PVS1, PM6	The c.1679C>G (p.Thr560Arg) variant is absent in the gnomAD cohort (PM2_Supporting; http://gnomad.broadinstitute.org). There are at least 3 in silico predictors in agreement that this variant affects splicing (PP3). There is also an RNA assay demonstrating abnormal out-of-frame transcript (PS3; PMID: 27880784). Additionally, the variant was found to co-segregation with disease in multiple affected family members, with >7 meioses observed across at least 4 families (PP1_Strong; PMID: 27880784, 29769627). This variant has been reported in at least 4 families meeting HDGC clinical criteria (PS4; PMID: 27880784, 29769627, 23709761 and SCV000580704.2). In summary, this variant meets criteria to be classified as pathogenic based on the ACMG/AMP criteria applied as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): PM2_Supporting, PP3, PS3, PP1_Strong, PS4.	27880784, 29769627, 23709761, 29769627, 29769627	CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-29	2023-08-29	False	https://erepo.genome.network/evrepo/ui/classification/CA10577547/MONDO:0007648/007	89320d2b-848b-4794-bcc3-84d990e99660	p.Thr560Arg	Thr	560	Arg	MGPWSRSLSALLLLLQVSSWLCQEPEPCHPGFDAESYTFTVPRRHLERGRVLGRVNFEDCTGRQRTAYFSLDTRFKVGTDGVITVKRPLRFHNPQIHFLVYAWDSTYRKFSTKVTLNTVGHHHRPPPHQASVSGIQAELLTFPNSSPGLRRQKRDWVIPPISCPENEKGPFPKNLVQIKSNKDKEGKVFYSITGQGADTPPVGVFIIERETGWLKVTEPLDRERIATYTLFSHAVSSNGNAVEDPMEILITVTDQNDNKPEFTQEVFKGSVMEGALPGTSVMEVTATDADDDVNTYNAAIAYTILSQDPELPDKNMFTINRNTGVISVVTTGLDRESFPTYTLVVQAADLQGEGLSTTATAVITVTDTNDNPPIFNPTTYKGQVPENEANVVITTLKVTDADAPNTPAWEAVYTILNDDGGQFVVTTNPVNNDGILKTAKGLDFEAKQQYILHVAVTNVVPFEVSLTTSTATVTVDVLDVNEAPIFVPPEKRVEVSEDFGVGQEITSYTAQEPDTFMEQKITYRIWRDTANWLEINPDTGAISTRAELDREDFEHVKNSTYTALIIATDNGSPVATGTGTLLLILSDVNDNAPIPEPRTIFFCERNPKPQVINIIDADLPPNTSPFTAELTHGASANWTIQYNDPTQESIILKPKMALEVGDYKINLKLMDNQNKDQVTTLEVSVCDCEGAAGVCRKAQPVEAGLQIPAILGILGGILALLILILLLLLFLRRRAVVKEPLLPPEDDTRDNVYYYDEEGGGEEDQDFDLSQLHRGLDARPEVTRNDVAPTLMSVPRYLPRPANPDEIGNFIDENLKAADTDPTAPPYDSLLVFDYEGSGSEAASLSSLNSSESDKDQDYDYLNEWGNRFKKLADMYGGGEDD	882	P12830	R	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [1], 'TRANSIT_gain_score': array([0.01315403]), 'STRAND_loss': [], 'STRAND_gain': [485], 'STRAND_gain_score': array([0.00312823]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
116	NM_004360.4(CDH1):c.3G>A (p.Met1Ile)	239906	CA10583399	NM_004360.4:c.3G>A, NC_000016.10:g.68737418G>A, CM000678.2:g.68737418G>A, NC_000016.9:g.68771321G>A, CM000678.1:g.68771321G>A, NC_000016.8:g.67328822G>A, NG_008021.1:g.5127G>A, LRG_301:g.5127G>A, ENST00000261769.10:c.3G>A, ENST00000261769.9:c.3G>A, ENST00000422392.6:c.3G>A, ENST00000566510.5:c.3G>A, ENST00000566612.5:c.3G>A, ENST00000611625.4:c.3G>A, ENST00000612417.4:c.3G>A, ENST00000621016.4:c.3G>A, NM_004360.3:c.3G>A, LRG_301t1:c.3G>A, NM_001317184.1:c.3G>A, NM_001317185.1:c.-1613G>A, NM_001317186.1:c.-1817G>A, NM_004360.5:c.3G>A, NM_001317184.2:c.3G>A, NM_001317185.2:c.-1613G>A, NM_001317186.2:c.-1817G>A, NM_004360.5(CDH1):c.3G>A (p.Met1Ile), NM_004360.4(CDH1):c.3G>A (p.Met1Ile)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Pathogenic	PM2_Supporting, PS4, PP1_Moderate, PVS1	PP3, PP2, PP4, BS2, PS1, PS3, PS2, BA1, BP4, BP1, BP3, BP2, PM5, PM4, PM1, PM3, PM6, BP7, BP5, BS1, BS4, BS3	The c.3G>A (p.Met1Ile) variant causes a truncated or absent protein by altering the start codon of the coding sequence and is predicted to lead to the omission of a critical region of the protein (18726070, 2317870, 20066110) (PVS1). This variant is absent in the gnomAD cohort (PM2_Supporting; http://gnomad.broadinstitute.org). This variant was found to co-segregate with disease in multiple affected family members, with 5 or 6 meioses observed (PP1_Moderate; PMID:  28202063, 26182300). This variant has also been reported in at least 4 families meeting HDGC clinical criteria (PS4; PMID: 26182300, 20719348, clinical lab internal data). In summary, this variant meets criteria to be classified as pathogenic based on the ACMG/AMP Variant Interpretation Guidelines Version 3.1 as specified by the CDH1 Variant Curation Expert Panel: PVS1, PM2_Supporting, PP1_Moderate, PS4.		CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-29	2023-08-29	False	https://erepo.genome.network/evrepo/ui/classification/CA10583399/MONDO:0007648/007	d13fa937-98cf-4da0-956f-8d7d5543f0a3	p.Met1Ile	Met	1	Ile	MGPWSRSLSALLLLLQVSSWLCQEPEPCHPGFDAESYTFTVPRRHLERGRVLGRVNFEDCTGRQRTAYFSLDTRFKVGTDGVITVKRPLRFHNPQIHFLVYAWDSTYRKFSTKVTLNTVGHHHRPPPHQASVSGIQAELLTFPNSSPGLRRQKRDWVIPPISCPENEKGPFPKNLVQIKSNKDKEGKVFYSITGQGADTPPVGVFIIERETGWLKVTEPLDRERIATYTLFSHAVSSNGNAVEDPMEILITVTDQNDNKPEFTQEVFKGSVMEGALPGTSVMEVTATDADDDVNTYNAAIAYTILSQDPELPDKNMFTINRNTGVISVVTTGLDRESFPTYTLVVQAADLQGEGLSTTATAVITVTDTNDNPPIFNPTTYKGQVPENEANVVITTLKVTDADAPNTPAWEAVYTILNDDGGQFVVTTNPVNNDGILKTAKGLDFEAKQQYILHVAVTNVVPFEVSLTTSTATVTVDVLDVNEAPIFVPPEKRVEVSEDFGVGQEITSYTAQEPDTFMEQKITYRIWRDTANWLEINPDTGAISTRAELDREDFEHVKNSTYTALIIATDNGSPVATGTGTLLLILSDVNDNAPIPEPRTIFFCERNPKPQVINIIDADLPPNTSPFTAELTHGASANWTIQYNDPTQESIILKPKMALEVGDYKINLKLMDNQNKDQVTTLEVSVCDCEGAAGVCRKAQPVEAGLQIPAILGILGGILALLILILLLLLFLRRRAVVKEPLLPPEDDTRDNVYYYDEEGGGEEDQDFDLSQLHRGLDARPEVTRNDVAPTLMSVPRYLPRPANPDEIGNFIDENLKAADTDPTAPPYDSLLVFDYEGSGSEAASLSSLNSSESDKDQDYDYLNEWGNRFKKLADMYGGGEDD	882	P12830	I	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [3, 5], 'TRANSIT_gain': [], 'TRANSIT_loss_score': array([-0.31905496, -0.30514985]), 'STRAND_loss': [84, 503], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.01128298, -0.00805753]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
117	NM_004360.4(CDH1):c.1849G>A (p.Ala617Thr)	12232	CA121991	NM_004360.4:c.1849G>A, NC_000016.10:g.68822138G>A, CM000678.2:g.68822138G>A, NC_000016.9:g.68856041G>A, CM000678.1:g.68856041G>A, NC_000016.8:g.67413542G>A, NG_008021.1:g.89847G>A, LRG_301:g.89847G>A, ENST00000261769.10:c.1849G>A, ENST00000261769.9:c.1849G>A, ENST00000422392.6:c.1666G>A, ENST00000562836.5:n.1920G>A, ENST00000566510.5:c.*515G>A, ENST00000566612.5:c.*89G>A, ENST00000611625.4:c.1912G>A, ENST00000612417.4:c.1830+19G>A, ENST00000621016.4:c.1849G>A, NM_004360.3:c.1849G>A, LRG_301t1:c.1849G>A, XM_011523488.1:c.1114G>A, XM_011523489.1:c.1114G>A, NM_001317184.1:c.1666G>A, NM_001317185.1:c.301G>A, NM_001317186.1:c.-117G>A, NM_004360.5:c.1849G>A, NM_001317184.2:c.1666G>A, NM_001317185.2:c.301G>A, NM_001317186.2:c.-117G>A, NM_004360.5(CDH1):c.1849G>A (p.Ala617Thr), NM_004360.4(CDH1):c.1849G>A (p.Ala617Thr)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Benign	BA1	BS2, PP3, PP2, PP1, PP4, PS1, PS3, PS4, PS2, BP4, BP1, BP3, BP2, PM5, PM4, PM1, PM3, PVS1, PM2, PM6, BP7, BP5, BS1, BS3, BS4	The c.1849G>A (p.Ala617Thr) variant has an allele frequency of 0.04479 (4.5%, 1,076/24,022 alleles) in the African subpopulation of the gnomAD cohort (BA1). In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): BA1.		CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-08	2023-08-08	False	https://erepo.genome.network/evrepo/ui/classification/CA121991/MONDO:0007648/007	8fe2e0a3-670f-4cdb-bbf8-3836f7fc45e9	p.Ala617Thr	Ala	617	Thr	MGPWSRSLSALLLLLQVSSWLCQEPEPCHPGFDAESYTFTVPRRHLERGRVLGRVNFEDCTGRQRTAYFSLDTRFKVGTDGVITVKRPLRFHNPQIHFLVYAWDSTYRKFSTKVTLNTVGHHHRPPPHQASVSGIQAELLTFPNSSPGLRRQKRDWVIPPISCPENEKGPFPKNLVQIKSNKDKEGKVFYSITGQGADTPPVGVFIIERETGWLKVTEPLDRERIATYTLFSHAVSSNGNAVEDPMEILITVTDQNDNKPEFTQEVFKGSVMEGALPGTSVMEVTATDADDDVNTYNAAIAYTILSQDPELPDKNMFTINRNTGVISVVTTGLDRESFPTYTLVVQAADLQGEGLSTTATAVITVTDTNDNPPIFNPTTYKGQVPENEANVVITTLKVTDADAPNTPAWEAVYTILNDDGGQFVVTTNPVNNDGILKTAKGLDFEAKQQYILHVAVTNVVPFEVSLTTSTATVTVDVLDVNEAPIFVPPEKRVEVSEDFGVGQEITSYTAQEPDTFMEQKITYRIWRDTANWLEINPDTGAISTRAELDREDFEHVKNSTYTALIIATDNGSPVATGTGTLLLILSDVNDNAPIPEPRTIFFCERNPKPQVINIIDADLPPNTSPFTAELTHGASANWTIQYNDPTQESIILKPKMALEVGDYKINLKLMDNQNKDQVTTLEVSVCDCEGAAGVCRKAQPVEAGLQIPAILGILGGILALLILILLLLLFLRRRAVVKEPLLPPEDDTRDNVYYYDEEGGGEEDQDFDLSQLHRGLDARPEVTRNDVAPTLMSVPRYLPRPANPDEIGNFIDENLKAADTDPTAPPYDSLLVFDYEGSGSEAASLSSLNSSESDKDQDYDYLNEWGNRFKKLADMYGGGEDD	882	P12830	T	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [5], 'TRANSIT_gain': [], 'TRANSIT_loss_score': array([-0.00491029]), 'STRAND_loss': [], 'STRAND_gain': [667, 678], 'STRAND_gain_score': array([0.00936866, 0.00354141]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
118	NM_004360.4(CDH1):c.286A>G (p.Ile96Val)	220611	CA349520	NM_004360.4:c.286A>G, NC_000016.10:g.68801792A>G, CM000678.2:g.68801792A>G, NC_000016.9:g.68835695A>G, CM000678.1:g.68835695A>G, NC_000016.8:g.67393196A>G, NG_008021.1:g.69501A>G, LRG_301:g.69501A>G, ENST00000261769.10:c.286A>G, ENST00000261769.9:c.286A>G, ENST00000422392.6:c.286A>G, ENST00000561751.1:n.53A>G, ENST00000562836.5:n.357A>G, ENST00000564676.5:n.568A>G, ENST00000564745.1:n.281A>G, ENST00000566510.5:c.286A>G, ENST00000566612.5:c.286A>G, ENST00000611625.4:c.286A>G, ENST00000612417.4:c.286A>G, ENST00000621016.4:c.286A>G, NM_004360.3:c.286A>G, LRG_301t1:c.286A>G, XM_011523488.1:c.-450A>G, XM_011523489.1:c.-450A>G, NM_001317184.1:c.286A>G, NM_001317185.1:c.-1330A>G, NM_001317186.1:c.-1534A>G, NM_004360.5:c.286A>G, NM_001317184.2:c.286A>G, NM_001317185.2:c.-1330A>G, NM_001317186.2:c.-1534A>G, NM_004360.5(CDH1):c.286A>G (p.Ile96Val), NM_004360.4(CDH1):c.286A>G (p.Ile96Val)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Benign	BS2, BS1	PP3, PP2, PP1, PP4, PS1, PS3, PS4, PS2, BP4, BP1, BP2, BP3, BA1, PM5, PM3, PM1, PM4, PM2, PM6, PVS1, BP5, BP7, BS3, BS4	The c.286A>G (p.Ile96Val) variant has an allele frequency of 0.00122 (0.12%, 41/33,578 alleles) in the Latino subpopulation of the gnomAD cohort (BS1). This variant has also been observed in >10 without a diagnosis of diffuse gastric cancer, signet ring tumor or lobular breast cancer and whose family histories do not suggest HDGC (BS2; internal laboratory contributors). In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): BS1, BS2.	26182300	CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-10	2023-08-10	False	https://erepo.genome.network/evrepo/ui/classification/CA349520/MONDO:0007648/007	d9039763-3145-4298-b468-da3967101df3	p.Ile96Val	Ile	96	Val	MGPWSRSLSALLLLLQVSSWLCQEPEPCHPGFDAESYTFTVPRRHLERGRVLGRVNFEDCTGRQRTAYFSLDTRFKVGTDGVITVKRPLRFHNPQIHFLVYAWDSTYRKFSTKVTLNTVGHHHRPPPHQASVSGIQAELLTFPNSSPGLRRQKRDWVIPPISCPENEKGPFPKNLVQIKSNKDKEGKVFYSITGQGADTPPVGVFIIERETGWLKVTEPLDRERIATYTLFSHAVSSNGNAVEDPMEILITVTDQNDNKPEFTQEVFKGSVMEGALPGTSVMEVTATDADDDVNTYNAAIAYTILSQDPELPDKNMFTINRNTGVISVVTTGLDRESFPTYTLVVQAADLQGEGLSTTATAVITVTDTNDNPPIFNPTTYKGQVPENEANVVITTLKVTDADAPNTPAWEAVYTILNDDGGQFVVTTNPVNNDGILKTAKGLDFEAKQQYILHVAVTNVVPFEVSLTTSTATVTVDVLDVNEAPIFVPPEKRVEVSEDFGVGQEITSYTAQEPDTFMEQKITYRIWRDTANWLEINPDTGAISTRAELDREDFEHVKNSTYTALIIATDNGSPVATGTGTLLLILSDVNDNAPIPEPRTIFFCERNPKPQVINIIDADLPPNTSPFTAELTHGASANWTIQYNDPTQESIILKPKMALEVGDYKINLKLMDNQNKDQVTTLEVSVCDCEGAAGVCRKAQPVEAGLQIPAILGILGGILALLILILLLLLFLRRRAVVKEPLLPPEDDTRDNVYYYDEEGGGEEDQDFDLSQLHRGLDARPEVTRNDVAPTLMSVPRYLPRPANPDEIGNFIDENLKAADTDPTAPPYDSLLVFDYEGSGSEAASLSSLNSSESDKDQDYDYLNEWGNRFKKLADMYGGGEDD	882	P12830	V	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [678], 'STRAND_gain_score': array([0.00284153]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
119	NM_004360.4(CDH1):c.1162G>A (p.Glu388Lys)	127906	CA157986	NM_004360.4:c.1162G>A, NC_000016.10:g.68813337G>A, CM000678.2:g.68813337G>A, NC_000016.9:g.68847240G>A, CM000678.1:g.68847240G>A, NC_000016.8:g.67404741G>A, NG_008021.1:g.81046G>A, LRG_301:g.81046G>A, ENST00000261769.10:c.1162G>A, ENST00000261769.9:c.1162G>A, ENST00000422392.6:c.1137+1074G>A, ENST00000562836.5:n.1233G>A, ENST00000565810.1:n.206G>A, ENST00000566510.5:c.1006G>A, ENST00000566612.5:c.1162G>A, ENST00000611625.4:c.1162G>A, ENST00000612417.4:c.1162G>A, ENST00000621016.4:c.1162G>A, NM_004360.3:c.1162G>A, LRG_301t1:c.1162G>A, XM_011523488.1:c.427G>A, XM_011523489.1:c.427G>A, NM_001317184.1:c.1137+1074G>A, NM_001317185.1:c.-454G>A, NM_001317186.1:c.-658G>A, NM_004360.5:c.1162G>A, NM_001317184.2:c.1137+1074G>A, NM_001317185.2:c.-454G>A, NM_001317186.2:c.-658G>A, NM_004360.5(CDH1):c.1162G>A (p.Glu388Lys), NM_004360.4(CDH1):c.1162G>A (p.Glu388Lys)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Benign	BS2, BP2_Strong	PP3, PP2, PP1, PP4, PS1, PS3, PS4, PS2, BP4, BP1, BP3, BA1, PM5, PM4, PM1, PM3, PM2, PM6, PVS1, BP7, BP5, BS1, BS3, BS4	The c.1162G>A (p.Glu388Lys) variant was observed in the homozygous state in an individual without a personal and/or family history of diffuse gastric cancer, lobular breast cancer (BP2_Strong; SCV000254804.3). The variant has also been observed in >10 individuals without a diagnosis of diffuse gastric cancer, signet ring tumor or lobular breast cancer and whose family histories do not suggest HDGC (BS2; internal laboratory contributors). In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): BP2_Strong, BS2.		CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-10	2023-08-10	False	https://erepo.genome.network/evrepo/ui/classification/CA157986/MONDO:0007648/007	5c24cb6c-a751-4e76-83ab-baccc23c4caa	p.Glu388Lys	Glu	388	Lys	MGPWSRSLSALLLLLQVSSWLCQEPEPCHPGFDAESYTFTVPRRHLERGRVLGRVNFEDCTGRQRTAYFSLDTRFKVGTDGVITVKRPLRFHNPQIHFLVYAWDSTYRKFSTKVTLNTVGHHHRPPPHQASVSGIQAELLTFPNSSPGLRRQKRDWVIPPISCPENEKGPFPKNLVQIKSNKDKEGKVFYSITGQGADTPPVGVFIIERETGWLKVTEPLDRERIATYTLFSHAVSSNGNAVEDPMEILITVTDQNDNKPEFTQEVFKGSVMEGALPGTSVMEVTATDADDDVNTYNAAIAYTILSQDPELPDKNMFTINRNTGVISVVTTGLDRESFPTYTLVVQAADLQGEGLSTTATAVITVTDTNDNPPIFNPTTYKGQVPENEANVVITTLKVTDADAPNTPAWEAVYTILNDDGGQFVVTTNPVNNDGILKTAKGLDFEAKQQYILHVAVTNVVPFEVSLTTSTATVTVDVLDVNEAPIFVPPEKRVEVSEDFGVGQEITSYTAQEPDTFMEQKITYRIWRDTANWLEINPDTGAISTRAELDREDFEHVKNSTYTALIIATDNGSPVATGTGTLLLILSDVNDNAPIPEPRTIFFCERNPKPQVINIIDADLPPNTSPFTAELTHGASANWTIQYNDPTQESIILKPKMALEVGDYKINLKLMDNQNKDQVTTLEVSVCDCEGAAGVCRKAQPVEAGLQIPAILGILGGILALLILILLLLLFLRRRAVVKEPLLPPEDDTRDNVYYYDEEGGGEEDQDFDLSQLHRGLDARPEVTRNDVAPTLMSVPRYLPRPANPDEIGNFIDENLKAADTDPTAPPYDSLLVFDYEGSGSEAASLSSLNSSESDKDQDYDYLNEWGNRFKKLADMYGGGEDD	882	P12830	K	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [5], 'TRANSIT_gain': [], 'TRANSIT_loss_score': array([-0.00103831]), 'STRAND_loss': [503], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.00068593]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
120	NM_004360.4(CDH1):c.2195G>A (p.Arg732Gln)	406663	CA16615410	NM_004360.4:c.2195G>A, NC_000016.10:g.68828204G>A, CM000678.2:g.68828204G>A, NC_000016.9:g.68862107G>A, CM000678.1:g.68862107G>A, NC_000016.8:g.67419608G>A, NG_008021.1:g.95913G>A, LRG_301:g.95913G>A, ENST00000261769.10:c.2195G>A, ENST00000261769.9:c.2195G>A, ENST00000422392.6:c.2012G>A, ENST00000562118.1:n.413G>A, ENST00000562836.5:n.2266G>A, ENST00000566510.5:c.*861G>A, ENST00000566612.5:c.*435G>A, ENST00000611625.4:c.2258G>A, ENST00000612417.4:c.1853+1650G>A, ENST00000621016.4:c.1866-5999G>A, NM_004360.3:c.2195G>A, LRG_301t1:c.2195G>A, XM_011523488.1:c.1460G>A, XM_011523489.1:c.1460G>A, NM_001317184.1:c.2012G>A, NM_001317185.1:c.647G>A, NM_001317186.1:c.230G>A, NM_004360.5:c.2195G>A, NM_001317184.2:c.2012G>A, NM_001317185.2:c.647G>A, NM_001317186.2:c.230G>A, NM_004360.5(CDH1):c.2195G>A (p.Arg732Gln), NM_004360.4(CDH1):c.2195G>A (p.Arg732Gln)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Pathogenic	PM2_Supporting, PS3, PS4	BS2, PP3, PP2, PP1, PP4, PS1, PS2, BP4, BP1, BP2, BP3, BA1, PM5, PM1, PM3, PM4, PVS1, PM6, BP7, BP5, BS1, BS3, BS4	The c.2195G>A variant is absent in the gnomAD cohort (PM2_Supporting; http://gnomad.broadinstitute.org). There is an RNA assay demonstrating an abnormal out-of-frame transcript for this variant (PS3; PMID: 17545690 15235021). This variant has also been reported in at least 12 families with HDGC criteria (PS4; PMID: 17545690 15235021 and laboratory internal data). In summary, this variant meets criteria to be classified as pathogenic based on the ACMG/AMP criteria applied as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): PM2_Supporting, PS3, PS4.	17545690, 17545690, 15235021, 17545690, 15235021, 17545690, 26580448, 15235021, 17545690, 17545690, 17545690, 26580448	CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-11-27	2023-12-22	False	https://erepo.genome.network/evrepo/ui/classification/CA16615410/MONDO:0007648/007	0b968ecb-5432-4588-a812-7dd328f2b93d	p.Arg732Gln	Arg	732	Gln	MGPWSRSLSALLLLLQVSSWLCQEPEPCHPGFDAESYTFTVPRRHLERGRVLGRVNFEDCTGRQRTAYFSLDTRFKVGTDGVITVKRPLRFHNPQIHFLVYAWDSTYRKFSTKVTLNTVGHHHRPPPHQASVSGIQAELLTFPNSSPGLRRQKRDWVIPPISCPENEKGPFPKNLVQIKSNKDKEGKVFYSITGQGADTPPVGVFIIERETGWLKVTEPLDRERIATYTLFSHAVSSNGNAVEDPMEILITVTDQNDNKPEFTQEVFKGSVMEGALPGTSVMEVTATDADDDVNTYNAAIAYTILSQDPELPDKNMFTINRNTGVISVVTTGLDRESFPTYTLVVQAADLQGEGLSTTATAVITVTDTNDNPPIFNPTTYKGQVPENEANVVITTLKVTDADAPNTPAWEAVYTILNDDGGQFVVTTNPVNNDGILKTAKGLDFEAKQQYILHVAVTNVVPFEVSLTTSTATVTVDVLDVNEAPIFVPPEKRVEVSEDFGVGQEITSYTAQEPDTFMEQKITYRIWRDTANWLEINPDTGAISTRAELDREDFEHVKNSTYTALIIATDNGSPVATGTGTLLLILSDVNDNAPIPEPRTIFFCERNPKPQVINIIDADLPPNTSPFTAELTHGASANWTIQYNDPTQESIILKPKMALEVGDYKINLKLMDNQNKDQVTTLEVSVCDCEGAAGVCRKAQPVEAGLQIPAILGILGGILALLILILLLLLFLRRRAVVKEPLLPPEDDTRDNVYYYDEEGGGEEDQDFDLSQLHRGLDARPEVTRNDVAPTLMSVPRYLPRPANPDEIGNFIDENLKAADTDPTAPPYDSLLVFDYEGSGSEAASLSSLNSSESDKDQDYDYLNEWGNRFKKLADMYGGGEDD	882	P12830	Q	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [503], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.00260276]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
121	NM_004086.2(COCH):c.151C>T (p.Pro51Ser)	6611	CA253889	NM_004086.2:c.151C>T, NC_000014.9:g.30877640C>T, CM000676.2:g.30877640C>T, NC_000014.8:g.31346846C>T, CM000676.1:g.31346846C>T, NC_000014.7:g.30416597C>T, NG_008211.2:g.8106C>T, NM_001135058.1:c.151C>T, NR_038356.1:n.1618-1088G>A, XM_011536539.1:c.151C>T, NM_001347720.1:c.346C>T, XM_017021071.1:c.346C>T, XM_024449506.1:c.151C>T, NM_004086.3:c.151C>T, ENST00000216361.8:c.151C>T, ENST00000396618.7:c.151C>T, ENST00000460581.6:c.-186C>T, ENST00000475087.5:c.151C>T, ENST00000553772.5:c.151C>T, ENST00000553833.5:n.305C>T, ENST00000555881.5:c.82+2537C>T, ENST00000556908.5:c.103C>T, ENST00000557065.1:n.67C>T, NM_004086.2(COCH):c.151C>T (p.Pro51Ser)	COCH	nonsyndromic genetic deafness	MONDO:0019497	Autosomal dominant inheritance	Pathogenic	PS4, PP1_Strong, PM2, PP3	PS2, PS3, PS1, PM3, PM1, PM4, PM5, BS4, BS1, BP5, BP7, PVS1, PM6, BS2, PP4, BP2, BP3, BP4, BA1	The c.151C>T (p.Pro51Ser) variant in COCH has been reported to segregate with late onset progressive hearing loss and vestibular dysfunction in > 25 family members (PP1_S; PMID: 9931344, 11332404). The variant meets PM2 and has been observed in at least 15 affected probands (PS4, PMID: 28733840, 16151338, 11332404). The allele frequency of the p.Pro51Ser variant is 0.001% (1/111716) of European chromosomes by the Genome Aggregation Database (http://gnomad.broadinstitute.org), which is a low enough frequency to award PM2 based on the thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal dominant hearing loss (PM2). Computational prediction tools and conservation analysis suggest that the p.Pro51Ser variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for autosomal dominant hearing loss based on the ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel: PP1_S, PS4, PM2, PP3.	12928864, 25230692, 26256111, 16481359, 20228067, 28733840, 16151338, 11332404, 24662630, 9931344, 16151338, 24662630, 9931344, 16151338, 11332404	Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2018-09-19	2019-07-17	False	https://erepo.genome.network/evrepo/ui/classification/CA253889/MONDO:0019497/005	d4782d4a-27b7-4626-acc7-f8758d33384d	p.Pro51Ser	Pro	51	Ser	MSAAWIPALGLGVCLLLLPGPAGSEGAAPIAITCFTRGLDIRKEKADVLCPGGCPLEEFSVYGNIVYASVSSICGAAVHRGVISNSGGPVRVYSLPGRENYSSVDANGIQSQMLSRWSASFTVTKGKSSTQEATGQAVSTAHPPTGKRLKKTPEKKTGNKDCKADIAFLIDGSFNIGQRRFNLQKNFVGKVALMLGIGTEGPHVGLVQASEHPKIEFYLKNFTSAKDVLFAIKEVGFRGGNSNTGKALKHTAQKFFTVDAGVRKGIPKVVVVFIDGWPSDDIEEAGIVAREFGVNVFIVSVAKPIPEELGMVQDVTFVDKAVCRNNGFFSYHMPNWFGTTKYVKPLVQKLCTHEQMMCSKTCYNSVNIAFLIDGSSSVGDSNFRLMLEFVSNIAKTFEISDIGAKIAAVQFTYDQRTEFSFTDYSTKENVLAVIRNIRYMSGGTATGDAISFTVRNVFGPIRESPNKNFLVIVTDGQSYDDVQGPAAAAHDAGITIFSVGVAWAPLDDLKDMASKPKESHAFFTREFTGLEPIVSDVIRGICRDFLESQQ	550	O43405	S	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [126], 'PROPEP_gain_score': array([0.01061791]), 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [59, 60, 64, 68], 'STRAND_gain': [49], 'STRAND_gain_score': array([0.23553205]), 'STRAND_loss_score': array([-0.20249259, -0.14678317, -0.05624402, -0.04666501]), 'HELIX_loss': [187], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.01120847]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [25, 126], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.02597266, -0.1089834 ]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [258, 278], 'REPEAT_gain_score': array([0.00352269, 0.00033885]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
122	NM_206933.2(USH2A):c.5581G>A (p.Gly1861Ser)	48535	CA262105	NM_206933.2:c.5581G>A, NC_000001.11:g.216073292C>T, CM000663.2:g.216073292C>T, NC_000001.10:g.216246634C>T, CM000663.1:g.216246634C>T, NC_000001.9:g.214313257C>T, NG_009497.1:g.355105G>A, NR_125992.1:n.136+692C>T, NR_125993.1:n.136+692C>T, NM_206933.3:c.5581G>A, ENST00000307340.7:c.5581G>A, NM_206933.2(USH2A):c.5581G>A (p.Gly1861Ser)	USH2A	Usher syndrome	MONDO:0019501	Autosomal recessive inheritance	Pathogenic	PS4, PM3_Strong, PP4, PP1, PP3, PM2_Supporting	PS2, PS3, PS1, PM1, PM4, PM5, BP5, BP7, BS4, BS1, PVS1, PM6, BS2, BP3, BP2, BP4, BA1	The allele frequency of the p.Gly1861Ser variant in USH2A is 0.017% (3/17184) of East Asian chromosomes by the Genome Aggregation Database (http://gnomad.broadinstitute.org), which is a low enough frequency to award PM2_Supporting based on the thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive hearing loss (PM2_P). This variant was found to have a statistically higher prevalence in affected individuals over controls (PS4; PMIDs: 26310143, 26338283, 23737954, Partners LMM internal data SCV000065557.5). This variant has been detected in 4 patients with hearing loss in trans with pathogenic or suspected-pathogenic variants (PM3_S; PMIDs: 26310143, 26338283, 23737954, Partners LMM internal data SCV000065557.5). The variant has been reported to segregate with hearing loss in one affected family member (PP1, PMID: 26310143). At least one patient with a variant in this gene displayed features of mild to severe hearing loss and retinitis pigmentosa (PP4; PMID: PMIDs: 26310143, 26338283, 23737954, Partners LMM internal data SCV000065557.5). Computational prediction tools and conservation analysis suggest that the p.Gly1861Ser variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive Usher syndrome based on the ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel: PS4, PM2_P, PP3, PM3_S, PP1, PP4.	26338283, 26310143, 23737954, 25356976, 26310143, 26310143, 26338283, 26310143, 23737954, 25356976	Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2018-09-14	2019-07-17	False	https://erepo.genome.network/evrepo/ui/classification/CA262105/MONDO:0019501/005	16f373e0-f3cf-4ebe-91ea-6d1a22e44f9c	p.Gly1861Ser	Gly	1861	Ser	MNCPVLSLGSGFLFQVIEMLIFAYFASISLTESRGLFPRLENVGAFKKVSIVPTQAVCGLPDRSTFCHSSAAAESIQFCTQRFCIQDCPYRSSHPTYTALFSAGLSSCITPDKNDLHPNAHSNSASFIFGNHKSCFSSPPSPKLMASFTLAVWLKPEQQGVMCVIEKTVDGQIVFKLTISEKETMFYYRTVNGLQPPIKVMTLGRILVKKWIHLSVQVHQTKISFFINGVEKDHTPFNARTLSGSITDFASGTVQIGQSLNGLEQFVGRMQDFRLYQVALTNREILEVFSGDLLRLHAQSHCRCPGSHPRVHPLAQRYCIPNDAGDTADNRVSRLNPEAHPLSFVNDNDVGTSWVSNVFTNITQLNQGVTISVDLENGQYQVFYIIIQFFSPQPTEIRIQRKKENSLDWEDWQYFARNCGAFGMKNNGDLEKPDSVNCLQLSNFTPYSRGNVTFSILTPGPNYRPGYNNFYNTPSLQEFVKATQIRFHFHGQYYTTETAVNLRHRYYAVDEITISGRCQCHGHADNCDTTSQPYRCLCSQESFTEGLHCDRCLPLYNDKPFRQGDQVYAFNCKPCQCNSHSKSCHYNISVDPFPFEHFRGGGGVCDDCEHNTTGRNCELCKDYFFRQVGADPSAIDVCKPCDCDTVGTRNGSILCDQIGGQCNCKRHVSGRQCNQCQNGFYNLQELDPDGCSPCNCNTSGTVDGDITCHQNSGQCKCKANVIGLRCDHCNFGFKFLRSFNDVGCEPCQCNLHGSVNKFCNPHSGQCECKKEAKGLQCDTCRENFYGLDVTNCKACDCDTAGSLPGTVCNAKTGQCICKPNVEGRQCNKCLEGNFYLRQNNSFLCLPCNCDKTGTINGSLLCNKSTGQCPCKLGVTGLRCNQCEPHRYNLTIDNFQHCQMCECDSLGTLPGTICDPISGQCLCVPNRQGRRCNQCQPGFYISPGNATGCLPCSCHTTGAVNHICNSLTGQCVCQDASIAGQRCDQCKDHYFGFDPQTGRCQPCNCHLSGALNETCHLVTGQCFCKQFVTGSKCDACVPSASHLDVNNLLGCSKTPFQQPPPRGQVQSSSAINLSWSPPDSPNAHWLTYSLLRDGFEIYTTEDQYPYSIQYFLDTDLLPYTKYSYYIETTNVHGSTRSVAVTYKTKPGVPEGNLTLSYIIPIGSDSVTLTWTTLSNQSGPIEKYILSCAPLAGGQPCVSYEGHETSATIWNLVPFAKYDFSVQACTSGGCLHSLPITVTTAQAPPQRLSPPKMQKISSTELHVEWSPPAELNGIIIRYELYMRRLRSTKETTSEESRVFQSSGWLSPHSFVESANENALKPPQTMTTITGLEPYTKYEFRVLAVNMAGSVSSAWVSERTGESAPVFMIPPSVFPLSSYSLNISWEKPADNVTRGKVVGYDINMLSEQSPQQSIPMAFSQLLHTAKSQELSYTVEGLKPYRIYEFTITLCNSVGCVTSASGAGQTLAAAPAQLRPPLVKGINSTTIHLRWFPPEELNGPSPIYQLERRESSLPALMTTMMKGIRFIGNGYCKFPSSTHPVNTDFTGIKASFRTKVPEGLIVFAASPGNQEEYFALQLKKGRLYFLFDPQGSPVEVTTTNDHGKQYSDGKWHEIIAIRHQAFGQITLDGIYTGSSAILNGSTVIGDNTGVFLGGLPRSYTILRKDPEIIQKGFVGCLKDVHFMKNYNPSAIWEPLDWQSSEEQINVYNSWEGCPASLNEGAQFLGAGFLELHPYMFHGGMNFEISFKFRTDQLNGLLLFVYNKDGPDFLAMELKSGILTFRLNTSLAFTQVDLLLGLSYCNGKWNKVIIKKEGSFISASVNGLMKHASESGDQPLVVNSPVYVGGIPQELLNSYQHLCLEQGFGGCMKDVKFTRGAVVNLASVSSGAVRVNLDGCLSTDSAVNCRGNDSILVYQGKEQSVYEGGLQPFTEYLYRVIASHEGGSVYSDWSRGRTTGAAPQSVPTPSRVRSLNGYSIEVTWDEPVVRGVIEKYILKAYSEDSTRPPRMPSASAEFVNTSNLTGILTGLLPFKNYAVTLTACTLAGCTESSHALNISTPQEAPQEVQPPVAKSLPSSLLLSWNPPKKANGIITQYCLYMDGRLIYSGSEENYIVTDLAVFTPHQFLLSACTHVGCTNSSWVLLYTAQLPPEHVDSPVLTVLDSRTIHIQWKQPRKISGILERYVLYMSNHTHDFTIWSVIYNSTELFQDHMLQYVLPGNKYLIKLGACTGGGCTVSEASEALTDEDIPEGVPAPKAHSYSPDSFNVSWTEPEYPNGVITSYGLYLDGILIHNSSELSYRAYGFAPWSLHSFRVQACTAKGCALGPLVENRTLEAPPEGTVNVFVKTQGSRKAHVRWEAPFRPNGLLTHSVLFTGIFYVDPVGNNYTLLNVTKVMYSGEETNLWVLIDGLVPFTNYTVQVNISNSQGSLITDPITIAMPPGAPDGVLPPRLSSATPTSLQVVWSTPARNNAPGSPRYQLQMRSGDSTHGFLELFSNPSASLSYEVSDLQPYTEYMFRLVASNGFGSAHSSWIPFMTAEDKPGPVVPPILLDVKSRMMLVTWQHPRKSNGVITHYNIYLHGRLYLRTPGNVTNCTVMHLHPYTAYKFQVEACTSKGCSLSPESQTVWTLPGAPEGIPSPELFSDTPTSVIISWQPPTHPNGLVENFTIERRVKGKEEVTTLVTLPRSHSMRFIDKTSALSPWTKYEYRVLMSTLHGGTNSSAWVEVTTRPSRPAGVQPPVVTVLEPDAVQVTWKPPLIQNGDILSYEIHMPDPHITLTNVTSAVLSQKVTHLIPFTNYSVTIVACSGGNGYLGGCTESLPTYVTTHPTVPQNVGPLSVIPLSESYVVISWQPPSKPNGPNLRYELLRRKIQQPLASNPPEDLNRWHNIYSGTQWLYEDKGLSRFTTYEYMLFVHNSVGFTPSREVTVTTLAGLPERGANLTASVLNHTAIDVRWAKPTVQDLQGEVEYYTLFWSSATSNDSLKILPDVNSHVIGHLKPNTEYWIFISVFNGVHSINSAGLHATTCDGEPQGMLPPEVVIINSTAVRVIWTSPSNPNGVVTEYSIYVNNKLYKTGMNVPGSFILRDLSPFTIYDIQVEVCTIYACVKSNGTQITTVEDTPSDIPTPTIRGITSRSLQIDWVSPRKPNGIILGYDLLWKTWYPCAKTQKLVQDQSDELCKAVRCQKPESICGHICYSSEAKVCCNGVLYNPKPGHRCCEEKYIPFVLNSTGVCCGGRIQEAQPNHQCCSGYYARILPGEVCCPDEQHNRVSVGIGDSCCGRMPYSTSGNQICCAGRLHDGHGQKCCGRQIVSNDLECCGGEEGVVYNRLPGMFCCGQDYVNMSDTICCSASSGESKAHIKKNDPVPVKCCETELIPKSQKCCNGVGYNPLKYVCSDKISTGMMMKETKECRILCPASMEATEHCGRCDFNFTSHICTVIRGSHNSTGKASIEEMCSSAEETIHTGSVNTYSYTDVNLKPYMTYEYRISAWNSYGRGLSKAVRARTKEDVPQGVSPPTWTKIDNLEDTIVLNWRKPIQSNGPIIYYILLRNGIERFRGTSLSFSDKEGIQPFQEYSYQLKACTVAGCATSSKVVAATTQGVPESILPPSITALSAVALHLSWSVPEKSNGVIKEYQIRQVGKGLIHTDTTDRRQHTVTGLQPYTNYSFTLTACTSAGCTSSEPFLGQTLQAAPEGVWVTPRHIIINSTTVELYWSLPEKPNGLVSQYQLSRNGNLLFLGGSEEQNFTDKNLEPNSRYTYKLEVKTGGGSSASDDYIVQTPMSTPEEIYPPYNITVIGPYSIFVAWIPPGILIPEIPVEYNVLLNDGSVTPLAFSVGHHQSTLLENLTPFTQYEIRIQACQNGSCGVSSRMFVKTPEAAPMDLNSPVLKALGSACIEIKWMPPEKPNGIIINYFIYRRPAGIEEESVLFVWSEGALEFMDEGDTLRPFTLYEYRVRACNSKGSVESLWSLTQTLEAPPQDFPAPWAQATSAHSVLLNWTKPESPNGIISHYRVVYQERPDDPTFNSPTVHAFTVKGTSHQAHLYGLEPFTTYRIGVVAANHAGEILSPWTLIQTLESSPSGLRNFIVEQKENGRALLLQWSEPMRTNGVIKTYNIFSDGFLEYSGLNRQFLFRRLDPFTLYTLTLEACTRAGCAHSAPQPLWTDEAPPDSQLAPTVHSVKSTSVELSWSEPVNPNGKIIRYEVIRRCFEGKAWGNQTIQADEKIVFTEYNTERNTFMYNDTGLQPWTQCEYKIYTWNSAGHTCSSWNVVRTLQAPPEGLSPPVISYVSMNPQKLLISWIPPEQSNGIIQSYRLQRNEMLYPFSFDPVTFNYTDEELLPFSTYSYALQACTSGGCSTSKPTSITTLEAAPSEVSPPDLWAVSATQMNVCWSPPTVQNGKITKYLVRYDNKESLAGQGLCLLVSHLQPYSQYNFSLVACTNGGCTASVSKSAWTMEALPENMDSPTLQVTGSESIEITWKPPRNPNGQIRSYELRRDGTIVYTGLETRYRDFTLTPGVEYSYTVTASNSQGGILSPLVKDRTSPSAPSGMEPPKLQARGPQEILVNWDPPVRTNGDIINYTLFIRELFERETKIIHINTTHNSFGMQSYIVNQLKPFHRYEIRIQACTTLGCASSDWTFIQTPEIAPLMQPPPHLEVQMAPGGFQPTVSLLWTGPLQPNGKVLYYELYRRQIATQPRKSNPVLIYNGSSTSFIDSELLPFTEYEYQVWAVNSAGKAPSSWTWCRTGPAPPEGLRAPTFHVISSTQAVVNISAPGKPNGIVSLYRLFSSSAHGAETVLSEGMATQQTLHGLQAFTNYSIGVEACTCFNCCSKGPTAELRTHPAPPSGLSSPQIGTLASRTASFRWSPPMFPNGVIHSYELQFHVACPPDSALPCTPSQIETKYTGLGQKASLGGLQPYTTYKLRVVAHNEVGSTASEWISFTTQKELPQYRAPFSVDSNLSVVCVNWSDTFLLNGQLKEYVLTDGGRRVYSGLDTTLYIPRTADKTFFFQVICTTDEGSVKTPLIQYDTSTGLGLVLTTPGKKKGSRSKSTEFYSELWFIVLMAMLGLILLAIFLSLILQRKIHKEPYIRERPPLVPLQKRMSPLNVYPPGENHMGLADTKIPRSGTPVSIRSNRSACVLRIPSQNQTSLTYSQGSLHRSVSQLMDIQDKKVLMDNSLWEAIMGHNSGLYVDEEDLMNAIKDFSSVTKERTTFTDTHL	5202	O75445	S	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [4236], 'STRAND_gain_score': array([0.00070691]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [4174, 4286], 'DOMAIN_gain_score': array([0.00201976, 0.01292074]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [766], 'ZN_FING_gain': [], 'ZN_FING_loss_score': array([-0.00045305])}
123	NM_000441.1(SLC26A4):c.1229C>T (p.Thr410Met)	43498	CA261403	NM_000441.1:c.1229C>T, NC_000007.14:g.107690203C>T, CM000669.2:g.107690203C>T, NC_000007.13:g.107330648C>T, CM000669.1:g.107330648C>T, NC_000007.12:g.107117884C>T, NG_008489.1:g.34569C>T, XM_005250425.1:c.1229C>T, XM_006716025.2:c.1229C>T, XM_005250425.2:c.1229C>T, XM_006716025.3:c.1229C>T, XM_017012318.1:c.1229C>T, ENST00000265715.7:c.1229C>T, NM_000441.1(SLC26A4):c.1229C>T (p.Thr410Met)	SLC26A4	Pendred syndrome	MONDO:0010134	Autosomal recessive inheritance	Pathogenic	PP1_Strong, PS3_Supporting, PP4, PP3, PM3_Very Strong, PM2_Supporting	PS4, PS2, PS1, PM5, PM1, PM4, BS4, BS1, BP5, BP7, PVS1, PM6, BS2, BP2, BP3, BP4, BA1	This variant has been detected in patients with hearing loss in trans with at least 4 pathogenic or suspected-pathogenic variants (PM3_VeryStrong; PMID: 25372295, 23638949, 25468468, 24338212, 25394566, 19786220, 19017801, 27541434, 21366435, 17309986, 24007330, 24224479, 21961810, 2844304, 19509082, 15811013). The p.Thr410Met variant in SLC26A4 has been reported to segregate in an autosomal recessive pattern with hearing loss in at least 7 family members (PP1_Strong; PMID: 19017801, 9618167, 15811013). Computational prediction tools and conservation analysis suggest that the p.Thr410Met variant may impact the protein (PP3). At least one patient with a variant in this gene displayed features of EVA or Mondini malformation (PP4; PMID: 15355436, 15811013). The allele frequency of the p.Thr410Met variant in the SLC26A4 gene is 0.062% (19/30782) of South Asian chromosomes by the Genome Aggregation Database (http://gnomad.broadinstitute.org), which is a low enough frequency to award PM2_Supporting based on the thresholds defined by the ClinGen Hearing Loss Expert Panel for  autosomal recessive hearing loss (PM2_Supporting). In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive Pendred syndrome based on the ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel: PM3_VS, PP1_S, PP3, PS3_P, PM2_P, PP4.	26763877, 15905611, 22412181, 9618167, 15811013, 19017801, 9618167, 15811013, 19017801, 23266159, 11932316, 24007330, 15355436, 15811013, 25394566, 27541434, 17309986, 23638949, 28444304, 15355436, 25372295, 25468468, 24338212, 15811013, 19017801, 21366435, 19786220, 24224479, 21961810, 12676893, 24007330, 19509082, 25394566, 27541434, 17309986, 23638949, 28444304, 15355436, 25372295, 25468468, 24338212, 15811013, 19017801, 21366435, 19786220, 24224479, 21961810, 12676893, 24007330, 19509082	Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2018-09-17	2019-07-17	False	https://erepo.genome.network/evrepo/ui/classification/CA261403/MONDO:0010134/005	034f39b8-0469-47c1-b9ac-930299df3dc7	p.Thr410Met	Thr	410	Met	MAAPGGRSEPPQLPEYSCSYMVSRPVYSELAFQQQHERRLQERKTLRESLAKCCSCSRKRAFGVLKTLVPILEWLPKYRVKEWLLSDVISGVSTGLVATLQGMAYALLAAVPVGYGLYSAFFPILTYFIFGTSRHISVGPFPVVSLMVGSVVLSMAPDEHFLVSSSNGTVLNTTMIDTAARDTARVLIASALTLLVGIIQLIFGGLQIGFIVRYLADPLVGGFTTAAAFQVLVSQLKIVLNVSTKNYNGVLSIIYTLVEIFQNIGDTNLADFTAGLLTIVVCMAVKELNDRFRHKIPVPIPIEVIVTIIATAISYGANLEKNYNAGIVKSIPRGFLPPELPPVSLFSEMLAASFSIAVVAYAIAVSVGKVYATKYDYTIDGNQEFIAFGISNIFSGFFSCFVATTALSRTAVQESTGGKTQVAGIISAAIVMIAILALGKLLEPLQKSVLAAVVIANLKGMFMQLCDIPRLWRQNKIDAVIWVFTCIVSIILGLDLGLLAGLIFGLLTVVLRVQFPSWNGLGSIPSTDIYKSTKNYKNIEEPQGVKILRFSSPIFYGNVDGFKKCIKSTVGFDAIRVYNKRLKALRKIQKLIKSGQLRATKNGIISDAVSTNNAFEPDEDIEDLEELDIPTKEIEIQVDWNSELPVKVNVPKVPIHSLVLDCGAISFLDVVGVRSLRVIVKEFQRIDVNVYFASLQDYVIEKLEQCGFFDDNIRKDTFFLTVHDAILYLQNQVKSQEGQGSILETITLIQDCKDTLELIETELTEEELDVQDEAMRTLAS	780	O43511	M	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [344, 482], 'DNA_BIND_gain_score': array([0.00794411, 0.00523287]), 'TOPO_DOM_loss': [131, 169, 409], 'TOPO_DOM_gain': [242], 'TOPO_DOM_gain_score': array([0.03584141]), 'TOPO_DOM_loss_score': array([-0.00555134, -0.0152573 , -0.03707296]), 'TRANSMEM_loss': [447, 482, 483], 'TRANSMEM_gain': [101], 'TRANSMEM_gain_score': array([0.00153953]), 'TRANSMEM_loss_score': array([-0.03118789, -0.00868946, -0.008816  ]), 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [14], 'SIGNAL_gain': [], 'SIGNAL_loss_score': array([-0.00026911]), 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [157], 'HELIX_gain_score': array([0.01043588]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [447, 487], 'DOMAIN_gain': [561], 'DOMAIN_gain_score': array([0.03589988]), 'DOMAIN_loss_score': array([-0.01691812, -0.00620592]), 'REGION_loss': [624], 'REGION_gain': [], 'REGION_loss_score': array([-0.002271]), 'REPEAT_loss': [], 'REPEAT_gain': [379, 399], 'REPEAT_gain_score': array([0.0080412 , 0.00574464]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
124	NM_000441.1(SLC26A4):c.412G>T (p.Val138Phe)	4835	CA253312	NM_000441.1:c.412G>T, NC_000007.14:g.107672245G>T, CM000669.2:g.107672245G>T, NC_000007.13:g.107312690G>T, CM000669.1:g.107312690G>T, NC_000007.12:g.107099926G>T, NG_008489.1:g.16611G>T, XM_005250425.1:c.412G>T, XM_006716025.2:c.412G>T, XM_005250425.2:c.412G>T, XM_006716025.3:c.412G>T, XM_017012318.1:c.412G>T, ENST00000265715.7:c.412G>T, NM_000441.1(SLC26A4):c.412G>T (p.Val138Phe)	SLC26A4	Pendred syndrome	MONDO:0010134	Autosomal recessive inheritance	Pathogenic	PS4, PP1_Moderate, PS3_Supporting, PP4, PP3, PM3_Very Strong, PM2_Supporting	PS2, PS1, PM1, PM4, PM5, BP5, BP7, BS4, BS1, PVS1, PM6, BS2, BP2, BP3, BP4, BA1	The p.Val138Phe variant in SLC26A4 has been detected in over 4 patients with Pendred syndrome or hearing loss with enlarged vestibular aqueducts who harbored a pathogenic or suspected pathogenic variant in trans with p.Val138Phe (PM3_VS; PMID: 17503324, 15689455, 20597900, 18285825, 23965030, 24224479, 21551164, 23273637, 12788906, 16570074). This variant was found to have a statistically higher prevalence in affected individuals over controls (PS4; PMID: 25999548, 23336812, 26683941). The p.Val138Phe variant in SLC26A4 has been reported to segregate with hearing loss in at least 2 family members (PP1_M; PMID: 12788906). The allele frequency of the p.Val138Phe variant in the SLC26A4 gene is 0.03% (38/126540) of European chromosomes by the Genome Aggregation Database (http://gnomad.broadinstitute.org), which is a low enough frequency to award PM2_Supporting based on the thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive hearing loss (PM2_P). Computational prediction tools and conservation analysis suggest that the p.Val138Phe variant may impact the protein (PP3). At least one patient with a variant in this gene displayed features of EVA and/or Mondini malformation which are consistent with Pendred syndrome (PP4; PMID: 12788906, 23273637). A functional study performed in HeLa and human embryonic kidney cell lines demonstrated that pendrin harboring the p.Val138Phe variant did not localize to the cell membrane. However, there was no effect on iodide efflux (PS3_P; PMID: 11932316). In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive Pendred syndrome/EVA based on the ACMG/AMP criteria applied: PM3_VS, PS4, PP1_M, PM2_Supporting, PP3, PP4, PS3_P.	25999548, 23336812, 26683941, 12788906, 12788906, 11932316, 23273637, 12788906, 18285825, 21551164, 23965030, 23273637, 16570074, 15689455, 12788906, 24224479, 17503324, 20597900, 18285825, 21551164, 23965030, 23273637, 16570074, 15689455, 12788906, 24224479, 17503324, 20597900	Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2018-09-19	2019-07-17	False	https://erepo.genome.network/evrepo/ui/classification/CA253312/MONDO:0010134/005	c400a0f9-d38a-4d2e-9b96-5829547c6b19	p.Val138Phe	Val	138	Phe	MAAPGGRSEPPQLPEYSCSYMVSRPVYSELAFQQQHERRLQERKTLRESLAKCCSCSRKRAFGVLKTLVPILEWLPKYRVKEWLLSDVISGVSTGLVATLQGMAYALLAAVPVGYGLYSAFFPILTYFIFGTSRHISVGPFPVVSLMVGSVVLSMAPDEHFLVSSSNGTVLNTTMIDTAARDTARVLIASALTLLVGIIQLIFGGLQIGFIVRYLADPLVGGFTTAAAFQVLVSQLKIVLNVSTKNYNGVLSIIYTLVEIFQNIGDTNLADFTAGLLTIVVCMAVKELNDRFRHKIPVPIPIEVIVTIIATAISYGANLEKNYNAGIVKSIPRGFLPPELPPVSLFSEMLAASFSIAVVAYAIAVSVGKVYATKYDYTIDGNQEFIAFGISNIFSGFFSCFVATTALSRTAVQESTGGKTQVAGIISAAIVMIAILALGKLLEPLQKSVLAAVVIANLKGMFMQLCDIPRLWRQNKIDAVIWVFTCIVSIILGLDLGLLAGLIFGLLTVVLRVQFPSWNGLGSIPSTDIYKSTKNYKNIEEPQGVKILRFSSPIFYGNVDGFKKCIKSTVGFDAIRVYNKRLKALRKIQKLIKSGQLRATKNGIISDAVSTNNAFEPDEDIEDLEELDIPTKEIEIQVDWNSELPVKVNVPKVPIHSLVLDCGAISFLDVVGVRSLRVIVKEFQRIDVNVYFASLQDYVIEKLEQCGFFDDNIRKDTFFLTVHDAILYLQNQVKSQEGQGSILETITLIQDCKDTLELIETELTEEELDVQDEAMRTLAS	780	O43511	F	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [129, 344, 482], 'DNA_BIND_gain_score': array([0.01122385, 0.00664681, 0.00257593]), 'TOPO_DOM_loss': [131], 'TOPO_DOM_gain': [168], 'TOPO_DOM_gain_score': array([0.00895494]), 'TOPO_DOM_loss_score': array([-0.00268674]), 'TRANSMEM_loss': [88, 482, 483], 'TRANSMEM_gain': [101, 466], 'TRANSMEM_gain_score': array([0.00258803, 0.00238943]), 'TRANSMEM_loss_score': array([-0.01260257, -0.00036573, -0.00150752]), 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [48, 154, 157], 'HELIX_gain_score': array([0.01347256, 0.02273327, 0.01891142]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [129], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.02142966]), 'REGION_loss': [604, 624, 763, 764], 'REGION_gain': [], 'REGION_loss_score': array([-0.00312215, -0.00235784, -0.00250518, -0.00269687]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
125	NM_206933.2(USH2A):c.1036A>C (p.Asn346His)	48347	CA262054	NM_206933.2:c.1036A>C, NC_000001.11:g.216325412T>G, CM000663.2:g.216325412T>G, NC_000001.10:g.216498754T>G, CM000663.1:g.216498754T>G, NC_000001.9:g.214565377T>G, NG_009497.1:g.102985A>C, NM_007123.5:c.1036A>C, NM_206933.3:c.1036A>C, ENST00000307340.7:c.1036A>C, ENST00000366942.3:c.1036A>C, NM_206933.2(USH2A):c.1036A>C (p.Asn346His)	USH2A	Usher syndrome	MONDO:0019501	Autosomal recessive inheritance	Pathogenic	PP1_Strong, PP3, PP4, PM3_Very Strong, PM2_Supporting	PS3, PS1, PS2, PS4, PM4, PM1, PM5, BP7, BP5, BS4, BS1, PVS1, PM6, BS2, BP3, BP4, BP2, BA1	The allele frequency of the p.Asn346His variant in the USH2A gene is 0.016% (20/126318) of European (Non-Finnish) chromosomes by the Genome Aggregation Database (http://gnomad.broadinstitute.org), which is a low enough frequency to award PM2_Supporting based on the thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive Usher syndrome (PM2_Supporting). The p.Asn346His variant in USH2A has been reported to segregate with hearing loss in at least 7 families including 13 family members (PP1_S; 10729113, 15241801, 17405132, 25521520, 24160897, 22135276). This variant has been detected in patients with hearing loss in trans with at least 4 pathogenic or suspected-pathogenic variants (PM3_VS; PMID: 15241801, 24160897, 22135276, 26969326). At least one patient with a variant in this gene displayed features of mild to severe hearing loss and retinitis pigmentosa (PP4; PMID: 10729113, 15241801, 17405132, 25521520, 24160897, 22135276). Computational prediction tools and conservation analysis suggest that the p.Asn346His variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive Usher syndrome based on the ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel: PM2_Supporting, PP1_S, PM3_VS, PP4, PP3.	15241801, 24160897, 10729113, 17405132, 22135276, 25521520, 15241801, 24160897, 10729113, 17405132, 22135276, 25521520, 15241801, 24160897, 17405132, 10729113, 22135276, 25521520, 15241801, 24160897, 26969326, 22135276, 15241801, 24160897, 26969326, 22135276	Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2018-09-14	2019-07-17	False	https://erepo.genome.network/evrepo/ui/classification/CA262054/MONDO:0019501/005	211c3a9c-3789-42d9-ab55-04892c95f534	p.Asn346His	Asn	346	His	MNCPVLSLGSGFLFQVIEMLIFAYFASISLTESRGLFPRLENVGAFKKVSIVPTQAVCGLPDRSTFCHSSAAAESIQFCTQRFCIQDCPYRSSHPTYTALFSAGLSSCITPDKNDLHPNAHSNSASFIFGNHKSCFSSPPSPKLMASFTLAVWLKPEQQGVMCVIEKTVDGQIVFKLTISEKETMFYYRTVNGLQPPIKVMTLGRILVKKWIHLSVQVHQTKISFFINGVEKDHTPFNARTLSGSITDFASGTVQIGQSLNGLEQFVGRMQDFRLYQVALTNREILEVFSGDLLRLHAQSHCRCPGSHPRVHPLAQRYCIPNDAGDTADNRVSRLNPEAHPLSFVNDNDVGTSWVSNVFTNITQLNQGVTISVDLENGQYQVFYIIIQFFSPQPTEIRIQRKKENSLDWEDWQYFARNCGAFGMKNNGDLEKPDSVNCLQLSNFTPYSRGNVTFSILTPGPNYRPGYNNFYNTPSLQEFVKATQIRFHFHGQYYTTETAVNLRHRYYAVDEITISGRCQCHGHADNCDTTSQPYRCLCSQESFTEGLHCDRCLPLYNDKPFRQGDQVYAFNCKPCQCNSHSKSCHYNISVDPFPFEHFRGGGGVCDDCEHNTTGRNCELCKDYFFRQVGADPSAIDVCKPCDCDTVGTRNGSILCDQIGGQCNCKRHVSGRQCNQCQNGFYNLQELDPDGCSPCNCNTSGTVDGDITCHQNSGQCKCKANVIGLRCDHCNFGFKFLRSFNDVGCEPCQCNLHGSVNKFCNPHSGQCECKKEAKGLQCDTCRENFYGLDVTNCKACDCDTAGSLPGTVCNAKTGQCICKPNVEGRQCNKCLEGNFYLRQNNSFLCLPCNCDKTGTINGSLLCNKSTGQCPCKLGVTGLRCNQCEPHRYNLTIDNFQHCQMCECDSLGTLPGTICDPISGQCLCVPNRQGRRCNQCQPGFYISPGNATGCLPCSCHTTGAVNHICNSLTGQCVCQDASIAGQRCDQCKDHYFGFDPQTGRCQPCNCHLSGALNETCHLVTGQCFCKQFVTGSKCDACVPSASHLDVNNLLGCSKTPFQQPPPRGQVQSSSAINLSWSPPDSPNAHWLTYSLLRDGFEIYTTEDQYPYSIQYFLDTDLLPYTKYSYYIETTNVHGSTRSVAVTYKTKPGVPEGNLTLSYIIPIGSDSVTLTWTTLSNQSGPIEKYILSCAPLAGGQPCVSYEGHETSATIWNLVPFAKYDFSVQACTSGGCLHSLPITVTTAQAPPQRLSPPKMQKISSTELHVEWSPPAELNGIIIRYELYMRRLRSTKETTSEESRVFQSSGWLSPHSFVESANENALKPPQTMTTITGLEPYTKYEFRVLAVNMAGSVSSAWVSERTGESAPVFMIPPSVFPLSSYSLNISWEKPADNVTRGKVVGYDINMLSEQSPQQSIPMAFSQLLHTAKSQELSYTVEGLKPYRIYEFTITLCNSVGCVTSASGAGQTLAAAPAQLRPPLVKGINSTTIHLRWFPPEELNGPSPIYQLERRESSLPALMTTMMKGIRFIGNGYCKFPSSTHPVNTDFTGIKASFRTKVPEGLIVFAASPGNQEEYFALQLKKGRLYFLFDPQGSPVEVTTTNDHGKQYSDGKWHEIIAIRHQAFGQITLDGIYTGSSAILNGSTVIGDNTGVFLGGLPRSYTILRKDPEIIQKGFVGCLKDVHFMKNYNPSAIWEPLDWQSSEEQINVYNSWEGCPASLNEGAQFLGAGFLELHPYMFHGGMNFEISFKFRTDQLNGLLLFVYNKDGPDFLAMELKSGILTFRLNTSLAFTQVDLLLGLSYCNGKWNKVIIKKEGSFISASVNGLMKHASESGDQPLVVNSPVYVGGIPQELLNSYQHLCLEQGFGGCMKDVKFTRGAVVNLASVSSGAVRVNLDGCLSTDSAVNCRGNDSILVYQGKEQSVYEGGLQPFTEYLYRVIASHEGGSVYSDWSRGRTTGAAPQSVPTPSRVRSLNGYSIEVTWDEPVVRGVIEKYILKAYSEDSTRPPRMPSASAEFVNTSNLTGILTGLLPFKNYAVTLTACTLAGCTESSHALNISTPQEAPQEVQPPVAKSLPSSLLLSWNPPKKANGIITQYCLYMDGRLIYSGSEENYIVTDLAVFTPHQFLLSACTHVGCTNSSWVLLYTAQLPPEHVDSPVLTVLDSRTIHIQWKQPRKISGILERYVLYMSNHTHDFTIWSVIYNSTELFQDHMLQYVLPGNKYLIKLGACTGGGCTVSEASEALTDEDIPEGVPAPKAHSYSPDSFNVSWTEPEYPNGVITSYGLYLDGILIHNSSELSYRAYGFAPWSLHSFRVQACTAKGCALGPLVENRTLEAPPEGTVNVFVKTQGSRKAHVRWEAPFRPNGLLTHSVLFTGIFYVDPVGNNYTLLNVTKVMYSGEETNLWVLIDGLVPFTNYTVQVNISNSQGSLITDPITIAMPPGAPDGVLPPRLSSATPTSLQVVWSTPARNNAPGSPRYQLQMRSGDSTHGFLELFSNPSASLSYEVSDLQPYTEYMFRLVASNGFGSAHSSWIPFMTAEDKPGPVVPPILLDVKSRMMLVTWQHPRKSNGVITHYNIYLHGRLYLRTPGNVTNCTVMHLHPYTAYKFQVEACTSKGCSLSPESQTVWTLPGAPEGIPSPELFSDTPTSVIISWQPPTHPNGLVENFTIERRVKGKEEVTTLVTLPRSHSMRFIDKTSALSPWTKYEYRVLMSTLHGGTNSSAWVEVTTRPSRPAGVQPPVVTVLEPDAVQVTWKPPLIQNGDILSYEIHMPDPHITLTNVTSAVLSQKVTHLIPFTNYSVTIVACSGGNGYLGGCTESLPTYVTTHPTVPQNVGPLSVIPLSESYVVISWQPPSKPNGPNLRYELLRRKIQQPLASNPPEDLNRWHNIYSGTQWLYEDKGLSRFTTYEYMLFVHNSVGFTPSREVTVTTLAGLPERGANLTASVLNHTAIDVRWAKPTVQDLQGEVEYYTLFWSSATSNDSLKILPDVNSHVIGHLKPNTEYWIFISVFNGVHSINSAGLHATTCDGEPQGMLPPEVVIINSTAVRVIWTSPSNPNGVVTEYSIYVNNKLYKTGMNVPGSFILRDLSPFTIYDIQVEVCTIYACVKSNGTQITTVEDTPSDIPTPTIRGITSRSLQIDWVSPRKPNGIILGYDLLWKTWYPCAKTQKLVQDQSDELCKAVRCQKPESICGHICYSSEAKVCCNGVLYNPKPGHRCCEEKYIPFVLNSTGVCCGGRIQEAQPNHQCCSGYYARILPGEVCCPDEQHNRVSVGIGDSCCGRMPYSTSGNQICCAGRLHDGHGQKCCGRQIVSNDLECCGGEEGVVYNRLPGMFCCGQDYVNMSDTICCSASSGESKAHIKKNDPVPVKCCETELIPKSQKCCNGVGYNPLKYVCSDKISTGMMMKETKECRILCPASMEATEHCGRCDFNFTSHICTVIRGSHNSTGKASIEEMCSSAEETIHTGSVNTYSYTDVNLKPYMTYEYRISAWNSYGRGLSKAVRARTKEDVPQGVSPPTWTKIDNLEDTIVLNWRKPIQSNGPIIYYILLRNGIERFRGTSLSFSDKEGIQPFQEYSYQLKACTVAGCATSSKVVAATTQGVPESILPPSITALSAVALHLSWSVPEKSNGVIKEYQIRQVGKGLIHTDTTDRRQHTVTGLQPYTNYSFTLTACTSAGCTSSEPFLGQTLQAAPEGVWVTPRHIIINSTTVELYWSLPEKPNGLVSQYQLSRNGNLLFLGGSEEQNFTDKNLEPNSRYTYKLEVKTGGGSSASDDYIVQTPMSTPEEIYPPYNITVIGPYSIFVAWIPPGILIPEIPVEYNVLLNDGSVTPLAFSVGHHQSTLLENLTPFTQYEIRIQACQNGSCGVSSRMFVKTPEAAPMDLNSPVLKALGSACIEIKWMPPEKPNGIIINYFIYRRPAGIEEESVLFVWSEGALEFMDEGDTLRPFTLYEYRVRACNSKGSVESLWSLTQTLEAPPQDFPAPWAQATSAHSVLLNWTKPESPNGIISHYRVVYQERPDDPTFNSPTVHAFTVKGTSHQAHLYGLEPFTTYRIGVVAANHAGEILSPWTLIQTLESSPSGLRNFIVEQKENGRALLLQWSEPMRTNGVIKTYNIFSDGFLEYSGLNRQFLFRRLDPFTLYTLTLEACTRAGCAHSAPQPLWTDEAPPDSQLAPTVHSVKSTSVELSWSEPVNPNGKIIRYEVIRRCFEGKAWGNQTIQADEKIVFTEYNTERNTFMYNDTGLQPWTQCEYKIYTWNSAGHTCSSWNVVRTLQAPPEGLSPPVISYVSMNPQKLLISWIPPEQSNGIIQSYRLQRNEMLYPFSFDPVTFNYTDEELLPFSTYSYALQACTSGGCSTSKPTSITTLEAAPSEVSPPDLWAVSATQMNVCWSPPTVQNGKITKYLVRYDNKESLAGQGLCLLVSHLQPYSQYNFSLVACTNGGCTASVSKSAWTMEALPENMDSPTLQVTGSESIEITWKPPRNPNGQIRSYELRRDGTIVYTGLETRYRDFTLTPGVEYSYTVTASNSQGGILSPLVKDRTSPSAPSGMEPPKLQARGPQEILVNWDPPVRTNGDIINYTLFIRELFERETKIIHINTTHNSFGMQSYIVNQLKPFHRYEIRIQACTTLGCASSDWTFIQTPEIAPLMQPPPHLEVQMAPGGFQPTVSLLWTGPLQPNGKVLYYELYRRQIATQPRKSNPVLIYNGSSTSFIDSELLPFTEYEYQVWAVNSAGKAPSSWTWCRTGPAPPEGLRAPTFHVISSTQAVVNISAPGKPNGIVSLYRLFSSSAHGAETVLSEGMATQQTLHGLQAFTNYSIGVEACTCFNCCSKGPTAELRTHPAPPSGLSSPQIGTLASRTASFRWSPPMFPNGVIHSYELQFHVACPPDSALPCTPSQIETKYTGLGQKASLGGLQPYTTYKLRVVAHNEVGSTASEWISFTTQKELPQYRAPFSVDSNLSVVCVNWSDTFLLNGQLKEYVLTDGGRRVYSGLDTTLYIPRTADKTFFFQVICTTDEGSVKTPLIQYDTSTGLGLVLTTPGKKKGSRSKSTEFYSELWFIVLMAMLGLILLAIFLSLILQRKIHKEPYIRERPPLVPLQKRMSPLNVYPPGENHMGLADTKIPRSGTPVSIRSNRSACVLRIPSQNQTSLTYSQGSLHRSVSQLMDIQDKKVLMDNSLWEAIMGHNSGLYVDEEDLMNAIKDFSSVTKERTTFTDTHL	5202	O75445	H	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [4604], 'STRAND_gain_score': array([0.00072765]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [4174, 4286], 'DOMAIN_gain_score': array([0.00550449, 0.01886404]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': [731], 'ZN_FING_gain_score': array([0.00218153])}
126	NM_005633.3(SOS1):c.1018C>T (p.Pro340Ser)	40664	CA1624660	NM_005633.3:c.1018C>T, NC_000002.12:g.39035268G>A, CM000664.2:g.39035268G>A, NC_000002.11:g.39262409G>A, CM000664.1:g.39262409G>A, NC_000002.10:g.39115913G>A, NG_007530.1:g.90196C>T, LRG_754:g.90196C>T, LRG_754t1:c.1018C>T, XM_005264515.3:c.1018C>T, XM_011533060.1:c.1111C>T, XM_011533061.1:c.1111C>T, XM_011533062.1:c.997C>T, XM_011533063.1:c.994C>T, XM_011533064.1:c.847C>T, XM_011533065.1:c.1111C>T, XM_005264515.4:c.1018C>T, XM_011533062.2:c.997C>T, XM_011533064.2:c.847C>T, ENST00000395038.6:c.1018C>T, ENST00000402219.6:c.1018C>T, ENST00000426016.5:c.1018C>T, ENST00000461545.1:n.368C>T, NM_005633.3(SOS1):c.1018C>T (p.Pro340Ser)	SOS1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	PP2, BP5, BS4, BS1	PM6, PM2, BS2, PP1, PP3, PM1, PM4, PM5, BP3, BP2, BP4, BP1, BA1, PS3, PS4, PS2, PS1, BP7, BS3	The c.1018C>T (p.Pro340Ser) variant in the SOS1 gene has been found not to segregate in a family member of a patient who underwent testing for RASopathies as well as another adult who was unaffected (BS4; GeneDx, Invitae internal data; GTR Lab ID: 26957, 500031; SCV000514724.5, SCV000659124.2). This variant has also been identified in a patient with an alternate molecular basis of disease (BP5; PMID 22585553). The filtering allele frequency of the p.Pro340Ser variant is 0.022% for East Asian exomes in the gnomAD database (20/251276 with 95% CI), which is high enough frequency to be considered strong evidence for the variant being benign by the ClinGen RASopathy Expert Panel (BS1). In summary, this variant meets criteria to be classified as benign. RASopathy-specific ACMG/AMP criteria applied (PMID:29493581): BS4, BP5, BS1.	22585553	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2019-06-27	2019-06-28	False	https://erepo.genome.network/evrepo/ui/classification/CA1624660/MONDO:0021060/004	dc725e41-14fe-44e9-9d51-91ac14a1c2d3	p.Pro340Ser	Pro	340	Ser	MQAQQLPYEFFSEENAPKWRGLLVPALKKVQGQVHPTLESNDDALQYVEELILQLLNMLCQAQPRSASDVEERVQKSFPHPIDKWAIADAQSAIEKRKRRNPLSLPVEKIHPLLKEVLGYKIDHQVSVYIVAVLEYISADILKLVGNYVRNIRHYEITKQDIKVAMCADKVLMDMFHQDVEDINILSLTDEEPSTSGEQTYYDLVKAFMAEIRQYIRELNLIIKVFREPFVSNSKLFSANDVENIFSRIVDIHELSVKLLGHIEDTVEMTDEGSPHPLVGSCFEDLAEELAFDPYESYARDILRPGFHDRFLSQLSKPGAALYLQSIGEGFKEAVQYVLPRLLLAPVYHCLHYFELLKQLEEKSEDQEDKECLKQAITALLNVQSGMEKICSKSLAKRRLSESACRFYSQQMKGKQLAIKKMNEIQKNIDGWEGKDIGQCCNEFIMEGTLTRVGAKHERHIFLFDGLMICCKSNHGQPRLPGASNAEYRLKEKFFMRKVQINDKDDTNEYKHAFEIILKDENSVIFSAKSAEEKNNWMAALISLQYRSTLERMLDVTMLQEEKEEQMRLPSADVYRFAEPDSEENIIFEENMQPKAGIPIIKAGTVIKLIERLTYHMYADPNFVRTFLTTYRSFCKPQELLSLIIERFEIPEPEPTEADRIAIENGDQPLSAELKRFRKEYIQPVQLRVLNVCRHWVEHHFYDFERDAYLLQRMEEFIGTVRGKAMKKWVESITKIIQRKKIARDNGPGHNITFQSSPPTVEWHISRPGHIETFDLLTLHPIEIARQLTLLESDLYRAVQPSELVGSVWTKEDKEINSPNLLKMIRHTTNLTLWFEKCIVETENLEERVAVVSRIIEILQVFQELNNFNGVLEVVSAMNSSPVYRLDHTFEQIPSRQKKILEEAHELSEDHYKKYLAKLRSINPPCVPFFGIYLTNILKTEEGNPEVLKRHGKELINFSKRRKVAEITGEIQQYQNQPYCLRVESDIKRFFENLNPMGNSMEKEFTDYLFNKSLEIEPRNPKPLPRFPKKYSYPLKSPGVRPSNPRPGTMRHPTPLQQEPRKISYSRIPESETESTASAPNSPRTPLTPPPASGASSTTDVCSVFDSDHSSPFHSSNDTVFIQVTLPHGPRSASVSSISLTKGTDEVPVPPPVPPRRRPESAPAESSPSKIMSKHLDSPPAIPPRQPTSKAYSPRYSISDRTSISDPPESPPLLPPREPVRTPDVFSSSPLHLQPPPLGKKSDHGNAFFPNSPSPFTPPPPQTPSPHGTRRHLPSPPLTQEVDLHSIAGPPVPPRQSTSQHIPKLPPKTYKREHTHPSMHRDGPPLLENAHSS	1333	Q07889	S	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [487, 488, 489], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.01256418, -0.01217532, -0.00980181]), 'HELIX_loss': [296], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.01775712]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [778, 780, 782, 872], 'DOMAIN_gain_score': array([0.02693689, 0.03653997, 0.03431278, 0.02930617]), 'REGION_loss': [], 'REGION_gain': [1295], 'REGION_gain_score': array([0.00394207]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
127	NM_002880.3(RAF1):c.94A>G (p.Ile32Val)	40584	CA241481	NM_002880.3:c.94A>G, NC_000003.12:g.12618628T>C, CM000665.2:g.12618628T>C, NC_000003.11:g.12660127T>C, CM000665.1:g.12660127T>C, NC_000003.10:g.12635127T>C, NG_007467.1:g.50552A>G, LRG_413:g.50552A>G, LRG_413t1:c.94A>G, XM_005265355.1:c.94A>G, XM_005265357.1:c.94A>G, XM_005265358.3:c.-37A>G, XM_005265359.3:c.-37A>G, XM_005265360.1:c.94A>G, XM_011533974.1:c.94A>G, XM_011533975.1:c.-37A>G, NM_001354689.1:c.94A>G, NM_001354690.1:c.94A>G, NM_001354691.1:c.-37A>G, NM_001354692.1:c.-37A>G, NM_001354693.1:c.94A>G, NM_001354694.1:c.-37A>G, NM_001354695.1:c.-37A>G, NR_148940.1:n.509A>G, NR_148941.1:n.509A>G, NR_148942.1:n.509A>G, XM_011533974.3:c.94A>G, XM_017006966.1:c.94A>G, XR_001740227.1:n.425A>G, ENST00000251849.8:c.94A>G, ENST00000416093.1:c.94A>G, ENST00000423275.5:c.94A>G, ENST00000442415.6:c.94A>G, NM_002880.3(RAF1):c.94A>G (p.Ile32Val)	RAF1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	PP2, BS2, BP4, BS1, BP5	PM6, PM2, PP3, PP1, PM1, PM4, BP2, BP3, BP1, BA1, PS3, PS2, PS4, BS3, BS4, BP7	The c.94A>G (p.Ile32Val) variant in the RAF1 gene has been identified in patients who underwent testing for a RASopathy, however it has also been identified in multiple adults who did not have clinical features of a RASopathy (BS2, BP5; Invitae, EGL Diagnostics, GeneDx internal data; GTR Lab ID: 500031, 500060; SCV000287747.4, SCV000227277.5, SCV000209002.14). The filtering allele frequency of the p.Ile32Val variant is 0.017% for European (non-Finnish) genomes in the gnomAD database (8/31404 with 95% CI) which is a high enough frequency to be considered strong evidence that the variant is benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BS1). Computational prediction tools and conservation analysis suggest that the p.Ile32Val variant does not impact the protein (BP4). In summary, this variant meets criteria to be classified as benign. RASopathy-specific ACMG/AMP criteria applied (PMID:29493581): BS2, BP5, BS1, BP4.		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2019-06-27	2019-06-28	False	https://erepo.genome.network/evrepo/ui/classification/CA241481/MONDO:0021060/004	1128f941-c33c-438d-a44d-f5a0c76c3440	p.Ile32Val	Ile	32	Val	MEHIQGAWKTISNGFGFKDAVFDGSSCISPTIVQQFGYQRRASDDGKLTDPSKTSNTIRVFLPNKQRTVVNVRNGMSLHDCLMKALKVRGLQPECCAVFRLLHEHKGKKARLDWNTDAASLIGEELQVDFLDHVPLTTHNFARKTFLKLAFCDICQKFLLNGFRCQTCGYKFHEHCSTKVPTMCVDWSNIRQLLLFPNSTIGDSGVPALPSLTMRRMRESVSRMPVSSQHRYSTPHAFTFNTSSPSSEGSLSQRQRSTSTPNVHMVSTTLPVDSRMIEDAIRSHSESASPSALSSSPNNLSPTGWSQPKTPVPAQRERAPVSGTQEKNKIRPRGQRDSSYYWEIEASEVMLSTRIGSGSFGTVYKGKWHGDVAVKILKVVDPTPEQFQAFRNEVAVLRKTRHVNILLFMGYMTKDNLAIVTQWCEGSSLYKHLHVQETKFQMFQLIDIARQTAQGMDYLHAKNIIHRDMKSNNIFLHEGLTVKIGDFGLATVKSRWSGSQQVEQPTGSVLWMAPEVIRMQDNNPFSFQSDVYSYGIVLYELMTGELPYSHINNRDQIIFMVGRGYASPDLSKLYKNCPKAMKRLVADCVKKVKEERPLFPQILSSIELLQHSLPKINRSASEPSLHRAAHTEDINACTLTTSPRLPVF	648	P04049	V	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [131], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.01023811]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
128	NM_004333.4(BRAF):c.735A>C (p.Leu245Phe)	40347	CA280027	NM_004333.4:c.735A>C, NC_000007.14:g.140801537T>G, CM000669.2:g.140801537T>G, NC_000007.13:g.140501337T>G, CM000669.1:g.140501337T>G, NC_000007.12:g.140147806T>G, NG_007873.3:g.128228A>C, LRG_299:g.128228A>C, LRG_299t1:c.735A>C, XM_005250045.1:c.735A>C, XM_005250046.1:c.735A>C, XM_011516529.1:c.735A>C, XM_011516530.1:c.735A>C, XR_242190.1:n.743A>C, XR_927520.1:n.743A>C, XR_927521.1:n.743A>C, XR_927522.1:n.743A>C, XR_927523.1:n.743A>C, NM_001354609.1:c.735A>C, NM_004333.5:c.735A>C, NR_148928.1:n.1040A>C, XM_017012558.1:c.735A>C, XM_017012559.1:c.735A>C, XR_001744857.1:n.743A>C, XR_001744858.1:n.743A>C, ENST00000288602.10:c.735A>C, ENST00000497784.1:n.770A>C, NM_004333.4(BRAF):c.735A>C (p.Leu245Phe)	BRAF	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Pathogenic	PS2_Very Strong, PM2, PP3, PP2, PS4_Supporting, PM1	PM6, BS2, PP1, PM4, PM5, BP3, BP2, BP4, BP1, BA1, PS1, PS3, BS3, BS4, BS1, BP5, BP7	The c.735A>C (p.Leu245Phe) variant in BRAF has been reported as a a de novo occurrence, one of which was confirmed in at least 4 patients with clinical features of a RASopathy (PS2_VeryStrong; Partners LMM, GeneDx University Magdeburg GTR Lab ID's 21766, 26957, 506381; ClinVar SCV000061622.5, SCV000057188.16 PMID 19416762). This variant was absent from large population studies (PM2; gnomAD, http://gnomad.broadinstitute.org). Computational prediction tools and conservation analysis suggest that the p.Leu245Phe variant may impact the protein (PP3). The variant is located in the BRAF gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of BRAF (PM1; PMID 29493581). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PS2_VeryStrong, PM2, PM1, PP2, PP3, PS4_Supporting.		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2019-05-10	2019-06-28	False	https://erepo.genome.network/evrepo/ui/classification/CA280027/MONDO:0021060/004	cf6b44e4-40ca-4713-b35e-0ad194eb2f96	p.Leu245Phe	Leu	245	Phe	MAALSGGGGGGAEPGQALFNGDMEPEAGAGAGAAASSAADPAIPEEVWNIKQMIKLTQEHIEALLDKFGGEHNPPSIYLEAYEEYTSKLDALQQREQQLLESLGNGTDFSVSSSASMDTVTSSSSSSLSVLPSSLSVFQNPTDVARSNPKSPQKPIVRVFLPNKQRTVVPARCGVTVRDSLKKALMMRGLIPECCAVYRIQDGEKKPIGWDTDISWLTGEELHVEVLENVPLTTHNFVRKTFFTLAFCDFCRKLLFQGFRCQTCGYKFHQRCSTEVPLMCVNYDQLDLLFVSKFFEHHPIPQEEASLAETALTSGSSPSAPASDSIGPQILTSPSPSKSIPIPQPFRPADEDHRNQFGQRDRSSSAPNVHINTIEPVNIDDLIRDQGFRGDGGSTTGLSATPPASLPGSLTNVKALQKSPGPQRERKSSSSSEDRNRMKTLGRRDSSDDWEIPDGQITVGQRIGSGSFGTVYKGKWHGDVAVKMLNVTAPTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHHLHIIETKFEMIKLIDIARQTAQGMDYLHAKSIIHRDLKSNNIFLHEDLTVKIGDFGLATVKSRWSGSHQFEQLSGSILWMAPEVIRMQDKNPYSFQSDVYAFGIVLYELMTGQLPYSNINNRDQIIFMVGRGYLSPDLSKVRSNCPKAMKRLMAECLKKKRDERPLFPQILASIELLARSLPKIHRSASEPSLNRAGFQTEDFSLYACASPKTPIQAGGYGAFPVH	766	P15056	F	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [350], 'COMPBIAS_gain': [], 'COMPBIAS_loss_score': array([-0.00514007]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
129	NM_004333.4(BRAF):c.735A>T (p.Leu245Phe)	40348	CA280029	NM_004333.4:c.735A>T, NC_000007.14:g.140801537T>A, CM000669.2:g.140801537T>A, NC_000007.13:g.140501337T>A, CM000669.1:g.140501337T>A, NC_000007.12:g.140147806T>A, NG_007873.3:g.128228A>T, LRG_299:g.128228A>T, LRG_299t1:c.735A>T, XM_005250045.1:c.735A>T, XM_005250046.1:c.735A>T, XM_011516529.1:c.735A>T, XM_011516530.1:c.735A>T, XR_242190.1:n.743A>T, XR_927520.1:n.743A>T, XR_927521.1:n.743A>T, XR_927522.1:n.743A>T, XR_927523.1:n.743A>T, NM_001354609.1:c.735A>T, NM_004333.5:c.735A>T, NR_148928.1:n.1040A>T, XM_017012558.1:c.735A>T, XM_017012559.1:c.735A>T, XR_001744857.1:n.743A>T, XR_001744858.1:n.743A>T, ENST00000288602.10:c.735A>T, ENST00000497784.1:n.770A>T, NM_004333.4(BRAF):c.735A>T (p.Leu245Phe)	BRAF	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Pathogenic	PM6, PM2, PP3, PP2, PS4_Supporting, PM1, PS1	BS2, PP1, PM4, BP3, BP4, BP1, BP2, BA1, PS2, PS3, BP7, BP5, BS4, BS3, BS1	The c.735A>T p.Leu245Phe variant in BRAF has been identified in at least 2 independent occurrences, one of which was de novo, in patients with clinical features of a RASopathy (PM6, PS4_Supporting; Partners LMM, University Magdeburg internal data; GTR Lab IDs: 21766,  506381 PMID: 19206169, 22190897). This variant was absent from large population studies (PM2; gnomAD, http://gnomad.broadinstitute.org). Computational prediction tools and conservation analysis suggest that the p.Leu245Phe variant may impact the protein (PP3). The variant is located in the BRAF gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Of note, the p.Leu245Phe change has also been reported as a consequence of the c.735A>C variant in BRAF, which has been classified as pathogenic and therefore supports that this residue may be critical to protein function (PS1; ClinVar ID: 40347). Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of BRAF (PM1; PMID 29493581). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PS4_Supporting, PM6, PM1, PM2, PS1, PP2, PP3.	30820351, 19206169, 23763990, 22190897	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2019-05-10	2019-06-28	False	https://erepo.genome.network/evrepo/ui/classification/CA280029/MONDO:0021060/004	fc4fa86e-060f-49dc-8ade-c259aa8ad24b	p.Leu245Phe	Leu	245	Phe	MAALSGGGGGGAEPGQALFNGDMEPEAGAGAGAAASSAADPAIPEEVWNIKQMIKLTQEHIEALLDKFGGEHNPPSIYLEAYEEYTSKLDALQQREQQLLESLGNGTDFSVSSSASMDTVTSSSSSSLSVLPSSLSVFQNPTDVARSNPKSPQKPIVRVFLPNKQRTVVPARCGVTVRDSLKKALMMRGLIPECCAVYRIQDGEKKPIGWDTDISWLTGEELHVEVLENVPLTTHNFVRKTFFTLAFCDFCRKLLFQGFRCQTCGYKFHQRCSTEVPLMCVNYDQLDLLFVSKFFEHHPIPQEEASLAETALTSGSSPSAPASDSIGPQILTSPSPSKSIPIPQPFRPADEDHRNQFGQRDRSSSAPNVHINTIEPVNIDDLIRDQGFRGDGGSTTGLSATPPASLPGSLTNVKALQKSPGPQRERKSSSSSEDRNRMKTLGRRDSSDDWEIPDGQITVGQRIGSGSFGTVYKGKWHGDVAVKMLNVTAPTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHHLHIIETKFEMIKLIDIARQTAQGMDYLHAKSIIHRDLKSNNIFLHEDLTVKIGDFGLATVKSRWSGSHQFEQLSGSILWMAPEVIRMQDKNPYSFQSDVYAFGIVLYELMTGQLPYSNINNRDQIIFMVGRGYLSPDLSKVRSNCPKAMKRLMAECLKKKRDERPLFPQILASIELLARSLPKIHRSASEPSLNRAGFQTEDFSLYACASPKTPIQAGGYGAFPVH	766	P15056	F	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [350], 'COMPBIAS_gain': [], 'COMPBIAS_loss_score': array([-0.00514007]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
130	NM_004333.4(BRAF):c.739T>C (p.Phe247Leu)	180784	CA295904	NM_004333.4:c.739T>C, NC_000007.14:g.140801533A>G, CM000669.2:g.140801533A>G, NC_000007.13:g.140501333A>G, CM000669.1:g.140501333A>G, NC_000007.12:g.140147802A>G, NG_007873.3:g.128232T>C, LRG_299:g.128232T>C, LRG_299t1:c.739T>C, XM_005250045.1:c.739T>C, XM_005250046.1:c.739T>C, XM_011516529.1:c.739T>C, XM_011516530.1:c.739T>C, XR_242190.1:n.747T>C, XR_927520.1:n.747T>C, XR_927521.1:n.747T>C, XR_927522.1:n.747T>C, XR_927523.1:n.747T>C, NM_001354609.1:c.739T>C, NM_004333.5:c.739T>C, NR_148928.1:n.1044T>C, XM_017012558.1:c.739T>C, XM_017012559.1:c.739T>C, XR_001744857.1:n.747T>C, XR_001744858.1:n.747T>C, ENST00000288602.10:c.739T>C, ENST00000497784.1:n.774T>C, NM_004333.4(BRAF):c.739T>C (p.Phe247Leu)	BRAF	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Pathogenic	PM6, PM2, PP3, PP2, PM1, PS1, PS3	PP1, BS2, PM5, PM4, BP4, BP1, BP3, BP2, BA1, PS4, PS2, BS4, BS3, BS1, BP7, BP5	The c.739T>C (p.Phe247Leu) variant in BRAF has been reported in the literature as an unconfirmed de novo occurrence in a patient with clinical features of a RASopathy (PM6; GeneDx internal data; GTR Lab ID: 26957; ClinVar SCV000207748.12). This variant was absent from large population studies (PM2; gnomAD, http://gnomad.broadinstitute.org). In vitro functional studies provide some evidence that the p.Phe247Leu variant may impact protein function (PS3; PMID: 28512244). The c.739T>C variant results in the same amino acid change as the previously established pathogenic c.741T>G (p.Phe247Leu) variant (PS1; ClinVar ID 55793). Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of BRAF (PM1; PMID 29493581). The variant is located in the BRAF gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Computational prediction tools and conservation analysis suggest that the p.Phe247Leu variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PM6, PM2, PS3, PS1, PM1, PP2, PP3.	22899370, 26243863, 28512244	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2019-05-10	2019-06-28	False	https://erepo.genome.network/evrepo/ui/classification/CA295904/MONDO:0021060/004	9a18dc91-2016-4b25-ab42-a9f679412ae8	p.Phe247Leu	Phe	247	Leu	MAALSGGGGGGAEPGQALFNGDMEPEAGAGAGAAASSAADPAIPEEVWNIKQMIKLTQEHIEALLDKFGGEHNPPSIYLEAYEEYTSKLDALQQREQQLLESLGNGTDFSVSSSASMDTVTSSSSSSLSVLPSSLSVFQNPTDVARSNPKSPQKPIVRVFLPNKQRTVVPARCGVTVRDSLKKALMMRGLIPECCAVYRIQDGEKKPIGWDTDISWLTGEELHVEVLENVPLTTHNFVRKTFFTLAFCDFCRKLLFQGFRCQTCGYKFHQRCSTEVPLMCVNYDQLDLLFVSKFFEHHPIPQEEASLAETALTSGSSPSAPASDSIGPQILTSPSPSKSIPIPQPFRPADEDHRNQFGQRDRSSSAPNVHINTIEPVNIDDLIRDQGFRGDGGSTTGLSATPPASLPGSLTNVKALQKSPGPQRERKSSSSSEDRNRMKTLGRRDSSDDWEIPDGQITVGQRIGSGSFGTVYKGKWHGDVAVKMLNVTAPTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHHLHIIETKFEMIKLIDIARQTAQGMDYLHAKSIIHRDLKSNNIFLHEDLTVKIGDFGLATVKSRWSGSHQFEQLSGSILWMAPEVIRMQDKNPYSFQSDVYAFGIVLYELMTGQLPYSNINNRDQIIFMVGRGYLSPDLSKVRSNCPKAMKRLMAECLKKKRDERPLFPQILASIELLARSLPKIHRSASEPSLNRAGFQTEDFSLYACASPKTPIQAGGYGAFPVH	766	P15056	L	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
131	NM_004333.4(BRAF):c.741T>G (p.Phe247Leu)	55793	CA284654	NM_004333.4:c.741T>G, NC_000007.14:g.140801531A>C, CM000669.2:g.140801531A>C, NC_000007.13:g.140501331A>C, CM000669.1:g.140501331A>C, NC_000007.12:g.140147800A>C, NG_007873.3:g.128234T>G, LRG_299:g.128234T>G, LRG_299t1:c.741T>G, XM_005250045.1:c.741T>G, XM_005250046.1:c.741T>G, XM_011516529.1:c.741T>G, XM_011516530.1:c.741T>G, XR_242190.1:n.749T>G, XR_927520.1:n.749T>G, XR_927521.1:n.749T>G, XR_927522.1:n.749T>G, XR_927523.1:n.749T>G, NM_001354609.1:c.741T>G, NM_004333.5:c.741T>G, NR_148928.1:n.1046T>G, XM_017012558.1:c.741T>G, XM_017012559.1:c.741T>G, XR_001744857.1:n.749T>G, XR_001744858.1:n.749T>G, ENST00000288602.10:c.741T>G, ENST00000497784.1:n.776T>G, NM_004333.4(BRAF):c.741T>G (p.Phe247Leu)	BRAF	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Pathogenic	PM2, PM6, PP3, PP2, PS4_Supporting, PM1, PS3, PS2	PP1, BS2, PM5, PM4, BP3, BP2, BP4, BP1, BA1, PS1, BP7, BP5, BS4, BS1, BS3	The c.741T>G (p.Phe247Leu) variant in BRAF has been reported in the literature as a confirmed and unconfirmed de novo occurrence in 2 patients with clinical features of a RASopathy (PM6, PS2, PS4_Supporting; GeneDx internal data; GTR Lab ID 26957; SCV000077236.10). In vitro functional studies provide some evidence that the p.Phe247Leu variant may impact protein function (PS3; PMID: 28512244). Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of BRAF (PM1; PMID 29493581). This variant was absent from large population studies (PM2; gnomAD, http://gnomad.broadinstitute.org). The variant is located in the BRAF gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Computational prediction tools and conservation analysis suggest that the p.Phe247Leu variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PM6, PS2, PS3, PM1, PM2, PP2, PP3, PS4_Supporting.	28512244	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2019-05-10	2019-06-28	False	https://erepo.genome.network/evrepo/ui/classification/CA284654/MONDO:0021060/004	66924744-6ed6-4985-8479-1c8bab448ed0	p.Phe247Leu	Phe	247	Leu	MAALSGGGGGGAEPGQALFNGDMEPEAGAGAGAAASSAADPAIPEEVWNIKQMIKLTQEHIEALLDKFGGEHNPPSIYLEAYEEYTSKLDALQQREQQLLESLGNGTDFSVSSSASMDTVTSSSSSSLSVLPSSLSVFQNPTDVARSNPKSPQKPIVRVFLPNKQRTVVPARCGVTVRDSLKKALMMRGLIPECCAVYRIQDGEKKPIGWDTDISWLTGEELHVEVLENVPLTTHNFVRKTFFTLAFCDFCRKLLFQGFRCQTCGYKFHQRCSTEVPLMCVNYDQLDLLFVSKFFEHHPIPQEEASLAETALTSGSSPSAPASDSIGPQILTSPSPSKSIPIPQPFRPADEDHRNQFGQRDRSSSAPNVHINTIEPVNIDDLIRDQGFRGDGGSTTGLSATPPASLPGSLTNVKALQKSPGPQRERKSSSSSEDRNRMKTLGRRDSSDDWEIPDGQITVGQRIGSGSFGTVYKGKWHGDVAVKMLNVTAPTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHHLHIIETKFEMIKLIDIARQTAQGMDYLHAKSIIHRDLKSNNIFLHEDLTVKIGDFGLATVKSRWSGSHQFEQLSGSILWMAPEVIRMQDKNPYSFQSDVYAFGIVLYELMTGQLPYSNINNRDQIIFMVGRGYLSPDLSKVRSNCPKAMKRLMAECLKKKRDERPLFPQILASIELLARSLPKIHRSASEPSLNRAGFQTEDFSLYACASPKTPIQAGGYGAFPVH	766	P15056	L	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
132	NM_002834.4(PTPN11):c.166A>G (p.Ile56Val)	40485	CA180973	NM_002834.4:c.166A>G, NC_000012.12:g.112450346A>G, CM000674.2:g.112450346A>G, NC_000012.11:g.112888150A>G, CM000674.1:g.112888150A>G, NC_000012.10:g.111372533A>G, NG_007459.1:g.36615A>G, LRG_614:g.36615A>G, NM_002834.3:c.166A>G, LRG_614t1:c.166A>G, NM_080601.1:c.166A>G, XM_006719526.1:c.166A>G, XM_006719527.1:c.166A>G, XM_011538613.1:c.163A>G, NM_001330437.1:c.166A>G, NM_080601.2:c.166A>G, XM_011538613.2:c.163A>G, XM_017019722.1:c.163A>G, ENST00000351677.6:c.166A>G, ENST00000392597.5:c.166A>G, ENST00000635625.1:n.166A>G, NM_002834.4(PTPN11):c.166A>G (p.Ile56Val)	PTPN11	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Pathogenic	PM2, PP3, PP2, PS2, PS4	PM6, BS2, PM5, PM4, PM1, BP3, BP4, BP1, BP2, BA1, PS1, PS3, BS4, BS3, BS1, BP7, BP5	The c.166A>G (p.Ile56Val) variant in PTPN11 has been reported as a confirmed de novo occurrence in a patient with clinical features of a RASopathy (PS2; Invitae internal data; GTR Lab ID: 500031; ClinVar SCV000659037.2). The p.Ile56Val variant has been identified in at least 5 independent occurrences in patients with clinical features of a RASopathy (PS4; GeneDx, Partners LMM, Invitae, LabCorp internal data; GTR Lab IDs: 26957, 21766, 500031, 500026; ClinVar SCV SCV000057358.13, SCV000204234.4, SCV000659037.2, SCV000698061.1). This variant was absent from large population studies (PM2; gnomAD, http://gnomad.broadinstitute.org). Computational prediction tools and conservation analysis suggest that the p.Ile56Val variant may impact the protein (PP3). The variant is located in the PTPN11 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PS2, PS4, PM2, PP3, PP2.	19506109, 26817465, 26817465	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2019-05-10	2019-06-28	False	https://erepo.genome.network/evrepo/ui/classification/CA180973/MONDO:0021060/004	43db1167-715a-4f5d-8517-8487caffe8af	p.Ile56Val	Ile	56	Val	MTSRRWFHPNITGVEAENLLLTRGVDGSFLARPSKSNPGDFTLSVRRNGAVTHIKIQNTGDYYDLYGGEKFATLAELVQYYMEHHGQLKEKNGDVIELKYPLNCADPTSERWFHGHLSGKEAEKLLTEKGKHGSFLVRESQSHPGDFVLSVRTGDDKGESNDGKSKVTHVMIRCQELKYDVGGGERFDSLTDLVEHYKKNPMVETLGTVLQLKQPLNTTRINAAEIESRVRELSKLAETTDKVKQGFWEEFETLQQQECKLLYSRKEGQRQENKNKNRYKNILPFDHTRVVLHDGDPNEPVSDYINANIIMPEFETKCNNSKPKKSYIATQGCLQNTVNDFWRMVFQENSRVIVMTTKEVERGKSKCVKYWPDEYALKEYGVMRVRNVKESAAHDYTLRELKLSKVGQGNTERTVWQYHFRTWPDHGVPSDPGGVLDFLEEVHHKQESIMDAGPVVVHCSAGIGRTGTFIVIDILIDIIREKGVDCDIDVPKTIQMVRSQRSGMVQTEAQYRFIYMAVQHYIETLQRRIEEEQKSKRKGHEYTNIKYSLADQTSGDQSPLPPCTPTPPCAEMREDSARVYENVGLMQQQKSFR	593	Q06124	V	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [94], 'DOMAIN_gain_score': array([0.01582986]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
133	NM_002834.4(PTPN11):c.1510A>G (p.Met504Val)	40562	CA220140	NM_002834.4:c.1510A>G, NC_000012.12:g.112489086A>G, CM000674.2:g.112489086A>G, NC_000012.11:g.112926890A>G, CM000674.1:g.112926890A>G, NC_000012.10:g.111411273A>G, NG_007459.1:g.75355A>G, LRG_614:g.75355A>G, NM_002834.3:c.1510A>G, LRG_614t1:c.1510A>G, XM_006719526.1:c.1522A>G, XM_006719527.1:c.1408A>G, XM_011538613.1:c.1519A>G, NM_001330437.1:c.1522A>G, XM_011538613.2:c.1519A>G, XM_017019722.1:c.1507A>G, ENST00000351677.6:c.1510A>G, ENST00000635625.1:n.1522A>G, ENST00000635652.1:n.523A>G, NM_002834.4(PTPN11):c.1510A>G (p.Met504Val)	PTPN11	Noonan syndrome	MONDO:0018997	Autosomal dominant inheritance	Pathogenic	PP3, PP2, PM6_Strong, PS4_Moderate, PS3	PM2	The c.1510A>G (p.Met504Val) variant in PTPN11 has been reported in the literature in at least 2 unconfirmed de novo occurrences in patients and 3 independent occurrences in patients with clinical features of a RASopathy (PM6_Strong, PS4; GeneDx internal data; GTR Lab ID: 26957; SCV000057454.12; PMID: 15834506, 17661820, 17020470). In vitro functional studies provide some evidence that the p.Met504Val variant may impact protein function (PS3; PMID: 15834506). The variant is located in the PTPN11 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Computational prediction tools and conservation analysis suggest that the p.Met504Val variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PS3, PM6_Strong, PS4_Moderate, PP2, PP3.	15834506, 17661820, 17020470, 15834506	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2019-06-28	False	https://erepo.genome.network/evrepo/ui/classification/CA220140/MONDO:0018997/004	e9f2d6d1-62c8-49f8-89ca-4b2438d14afb	p.Met504Val	Met	504	Val	MTSRRWFHPNITGVEAENLLLTRGVDGSFLARPSKSNPGDFTLSVRRNGAVTHIKIQNTGDYYDLYGGEKFATLAELVQYYMEHHGQLKEKNGDVIELKYPLNCADPTSERWFHGHLSGKEAEKLLTEKGKHGSFLVRESQSHPGDFVLSVRTGDDKGESNDGKSKVTHVMIRCQELKYDVGGGERFDSLTDLVEHYKKNPMVETLGTVLQLKQPLNTTRINAAEIESRVRELSKLAETTDKVKQGFWEEFETLQQQECKLLYSRKEGQRQENKNKNRYKNILPFDHTRVVLHDGDPNEPVSDYINANIIMPEFETKCNNSKPKKSYIATQGCLQNTVNDFWRMVFQENSRVIVMTTKEVERGKSKCVKYWPDEYALKEYGVMRVRNVKESAAHDYTLRELKLSKVGQGNTERTVWQYHFRTWPDHGVPSDPGGVLDFLEEVHHKQESIMDAGPVVVHCSAGIGRTGTFIVIDILIDIIREKGVDCDIDVPKTIQMVRSQRSGMVQTEAQYRFIYMAVQHYIETLQRRIEEEQKSKRKGHEYTNIKYSLADQTSGDQSPLPPCTPTPPCAEMREDSARVYENVGLMQQQKSFR	593	Q06124	V	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [303], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.00076872]), 'HELIX_loss': [530], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.00473875]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
134	NM_002834.4(PTPN11):c.417G>C (p.Glu139Asp)	40513	CA177671	NM_002834.4:c.417G>C, NC_000012.12:g.112453279G>C, CM000674.2:g.112453279G>C, NC_000012.11:g.112891083G>C, CM000674.1:g.112891083G>C, NC_000012.10:g.111375466G>C, NG_007459.1:g.39548G>C, LRG_614:g.39548G>C, NM_002834.3:c.417G>C, LRG_614t1:c.417G>C, NM_080601.1:c.417G>C, XM_006719526.1:c.417G>C, XM_006719527.1:c.417G>C, XM_011538613.1:c.414G>C, NM_001330437.1:c.417G>C, NM_080601.2:c.417G>C, XM_011538613.2:c.414G>C, XM_017019722.1:c.414G>C, ENST00000351677.6:c.417G>C, ENST00000392597.5:c.417G>C, ENST00000635625.1:n.417G>C, NM_002834.4(PTPN11):c.417G>C (p.Glu139Asp)	PTPN11	Noonan syndrome	MONDO:0018997	Autosomal dominant inheritance	Pathogenic	PM2, PS2_Very Strong, PP2, PP3, PS4, PS3		The c.417G>C (p.Glu139Asp) variant in PTPN11 has been reported as a confirmed de novo occurrence in at least 2 patients and at least 5 other independent occurrences in patients with clinical features of a RASopathy (PS2_VeryStrong; PS4; GeneDx, Baylor, BC Children's internal data; SCV000057396.11, SCV000196664.1, SCV000803709.1; GTR Lab ID: 26957, 1006, 249401  PMID: 22315187, 17020470, 11992261). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). In vitro functional studies provide some evidence that the p.Glu139Asp variant may impact protein function (PS3; PMID: 23584145, 15987685, 18372317). The variant is located in the PTPN11 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Computational prediction tools and conservation analysis suggest that the c.417G>C (p.Glu139Asp) variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PS2_VeryStrong, PS3, PS4, PM2, PP2, PP3.	22315187, 11992261, 17020470, 18372317, 15987685, 23584145	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2019-06-28	False	https://erepo.genome.network/evrepo/ui/classification/CA177671/MONDO:0018997/004	d42e8a4a-ba52-4c29-8f18-11134760c93e	p.Glu139Asp	Glu	139	Asp	MTSRRWFHPNITGVEAENLLLTRGVDGSFLARPSKSNPGDFTLSVRRNGAVTHIKIQNTGDYYDLYGGEKFATLAELVQYYMEHHGQLKEKNGDVIELKYPLNCADPTSERWFHGHLSGKEAEKLLTEKGKHGSFLVRESQSHPGDFVLSVRTGDDKGESNDGKSKVTHVMIRCQELKYDVGGGERFDSLTDLVEHYKKNPMVETLGTVLQLKQPLNTTRINAAEIESRVRELSKLAETTDKVKQGFWEEFETLQQQECKLLYSRKEGQRQENKNKNRYKNILPFDHTRVVLHDGDPNEPVSDYINANIIMPEFETKCNNSKPKKSYIATQGCLQNTVNDFWRMVFQENSRVIVMTTKEVERGKSKCVKYWPDEYALKEYGVMRVRNVKESAAHDYTLRELKLSKVGQGNTERTVWQYHFRTWPDHGVPSDPGGVLDFLEEVHHKQESIMDAGPVVVHCSAGIGRTGTFIVIDILIDIIREKGVDCDIDVPKTIQMVRSQRSGMVQTEAQYRFIYMAVQHYIETLQRRIEEEQKSKRKGHEYTNIKYSLADQTSGDQSPLPPCTPTPPCAEMREDSARVYENVGLMQQQKSFR	593	Q06124	D	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [235, 528], 'HELIX_gain_score': array([0.03251171, 0.00023341]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
135	NM_030662.3(MAP2K2):c.169T>G (p.Phe57Val)	8273	CA279960	NM_030662.3:c.169T>G, NC_000019.10:g.4117553A>C, CM000681.2:g.4117553A>C, NC_000019.9:g.4117551A>C, CM000681.1:g.4117551A>C, NC_000019.8:g.4068551A>C, NG_007996.1:g.11576T>G, LRG_750:g.11576T>G, LRG_750t1:c.169T>G, XM_006722799.2:c.169T>G, XM_017026989.1:c.169T>G, XM_017026990.1:c.169T>G, XM_017026991.1:c.169T>G, ENST00000262948.9:c.169T>G, ENST00000394867.8:c.-123T>G, ENST00000599345.1:n.366T>G, NM_030662.3(MAP2K2):c.169T>G (p.Phe57Val)	MAP2K2	cardiofaciocutaneous syndrome	MONDO:0015280	Autosomal dominant inheritance	Pathogenic	PS2_Very Strong, PM2, PP3, PP2, PM1		The c.169T>G (p.Phe57Val) variant in MAP2K2 has been reported as a confirmed de novo occurrence in at least 2 patients with clinical features of a RASopathy (PS2_VeryStrong; PMID 18042262). The variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of MAP2K2 (PM1; PMID 29493581). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). The variant is located in the MAP2K2 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Computational prediction tools and conservation analysis suggest that the p.Phe57Val variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PS2_VeryStrong, PM1, PM2, PP2, PP3.	18042262	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-05-09	2019-07-15	False	https://erepo.genome.network/evrepo/ui/classification/CA279960/MONDO:0015280/004	ac054f0f-9da0-455d-8a0f-343d2f4ad540	p.Phe57Val	Phe	57	Val	MLARRKPVLPALTINPTIAEGPSPTSEGASEANLVDLQKKLEELELDEQQKKRLEAFLTQKAKVGELKDDDFERISELGAGNGGVVTKVQHRPSGLIMARKLIHLEIKPAIRNQIIRELQVLHECNSPYIVGFYGAFYSDGEISICMEHMDGGSLDQVLKEAKRIPEEILGKVSIAVLRGLAYLREKHQIMHRDVKPSNILVNSRGEIKLCDFGVSGQLIDSMANSFVGTRSYMAPERLQGTHYSVQSDIWSMGLSLVELAVGRYPIPPPDAKELEAIFGRPVVDGEEGEPHSISPRPRPPGRPVSGHGMDSRPAMAIFELLDYIVNEPPPKLPNGVFTPDFQEFVNKCLIKNPAERADLKMLTNHTFIKRSEVEEVDFAGWLCKTLRLNQPGTPTRTAV	400	P36507	V	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [37, 40, 41, 59], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.02281868, -0.03073138, -0.02562791, -0.09510815]), 'COILED_loss': [], 'COILED_gain': [62, 63], 'COILED_gain_score': array([0.15430474, 0.16008186]), 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
136	NM_002834.4(PTPN11):c.1403C>T (p.Thr468Met)	13331	CA220134	NM_002834.4:c.1403C>T, NC_000012.12:g.112488466C>T, CM000674.2:g.112488466C>T, NC_000012.11:g.112926270C>T, CM000674.1:g.112926270C>T, NC_000012.10:g.111410653C>T, NG_007459.1:g.74735C>T, LRG_614:g.74735C>T, NM_002834.3:c.1403C>T, LRG_614t1:c.1403C>T, XM_006719526.1:c.1415C>T, XM_006719527.1:c.1301C>T, XM_011538613.1:c.1412C>T, NM_001330437.1:c.1415C>T, XM_011538613.2:c.1412C>T, XM_017019722.1:c.1400C>T, ENST00000351677.6:c.1403C>T, ENST00000635625.1:n.1415C>T, ENST00000635652.1:n.416C>T, NM_002834.4(PTPN11):c.1403C>T (p.Thr468Met)	PTPN11	Noonan syndrome with multiple lentigines	MONDO:0007893	Autosomal dominant inheritance	Pathogenic	PP2, PP3, PM6_Strong, PM1, PS3, PS4, PP1_Strong	PM2	The c.1403C>T (p.Thr468Met) variant in PTPN11 has been reported in the literature in at least 2 unconfirmed de novo occurrences as well as more than 5 other independent occurances of patients with clinical features of a RASopathy (PM6_Strong, PS4; PMID 25884655, 19864201, PMIDs: 20883402, 15520399, 17935252, 24767283, 12058348, 15520399). The c.1403C>T (p.Thr468Met) variant in PTPN11 has been reported in the literature to segregate with clinical features of a RASopathy in at least 7 family members (PP1_Strong; 24767283, 17935252, 15520399, 20883402). In vitro functional studies provide some evidence that the p.Thr468Met variant may impact protein function (PS3; PMID: 24935154, 18372317, 16638574, 18849586). The variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of PTNP11 (PM1; PMID 29493581). The variant is located in the PTPN11 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Computational prediction tools and conservation analysis suggest that the p.Thr468Met variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PM6_Strong, PS4, PP1_Strong, PS3, PM1, PP2, PP3.	19864201, 25884655, 29493581, 24935154, 18849586, 18372317, 16638574, 24767283, 17935252, 12058348, 20883402, 15520399, 24767283, 17935252, 15520399, 20883402	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2019-07-15	False	https://erepo.genome.network/evrepo/ui/classification/CA220134/MONDO:0007893/004	e33078e1-353c-43ad-a6d9-93f2dab20e33	p.Thr468Met	Thr	468	Met	MTSRRWFHPNITGVEAENLLLTRGVDGSFLARPSKSNPGDFTLSVRRNGAVTHIKIQNTGDYYDLYGGEKFATLAELVQYYMEHHGQLKEKNGDVIELKYPLNCADPTSERWFHGHLSGKEAEKLLTEKGKHGSFLVRESQSHPGDFVLSVRTGDDKGESNDGKSKVTHVMIRCQELKYDVGGGERFDSLTDLVEHYKKNPMVETLGTVLQLKQPLNTTRINAAEIESRVRELSKLAETTDKVKQGFWEEFETLQQQECKLLYSRKEGQRQENKNKNRYKNILPFDHTRVVLHDGDPNEPVSDYINANIIMPEFETKCNNSKPKKSYIATQGCLQNTVNDFWRMVFQENSRVIVMTTKEVERGKSKCVKYWPDEYALKEYGVMRVRNVKESAAHDYTLRELKLSKVGQGNTERTVWQYHFRTWPDHGVPSDPGGVLDFLEEVHHKQESIMDAGPVVVHCSAGIGRTGTFIVIDILIDIIREKGVDCDIDVPKTIQMVRSQRSGMVQTEAQYRFIYMAVQHYIETLQRRIEEEQKSKRKGHEYTNIKYSLADQTSGDQSPLPPCTPTPPCAEMREDSARVYENVGLMQQQKSFR	593	Q06124	M	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [530], 'HELIX_gain': [528], 'HELIX_gain_score': array([0.00307816]), 'HELIX_loss_score': array([-0.0027827]), 'COILED_loss': [], 'COILED_gain': [216], 'COILED_gain_score': array([0.00881886]), 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
137	NM_002834.4(PTPN11):c.188A>G (p.Tyr63Cys)	13333	CA220146	NM_002834.4:c.188A>G, NC_000012.12:g.112450368A>G, CM000674.2:g.112450368A>G, NC_000012.11:g.112888172A>G, CM000674.1:g.112888172A>G, NC_000012.10:g.111372555A>G, NG_007459.1:g.36637A>G, LRG_614:g.36637A>G, NM_002834.3:c.188A>G, LRG_614t1:c.188A>G, NM_080601.1:c.188A>G, XM_006719526.1:c.188A>G, XM_006719527.1:c.188A>G, XM_011538613.1:c.185A>G, NM_001330437.1:c.188A>G, NM_080601.2:c.188A>G, XM_011538613.2:c.185A>G, XM_017019722.1:c.185A>G, ENST00000351677.6:c.188A>G, ENST00000392597.5:c.188A>G, ENST00000635625.1:n.188A>G, NM_002834.4(PTPN11):c.188A>G (p.Tyr63Cys)	PTPN11	Noonan syndrome	MONDO:0018997	Autosomal dominant inheritance	Pathogenic	PP3, PP2, PM1, PS4, PS3, PP1_Strong	PM2	The c.188A>G (p.Tyr63Cys) variant in PTPN11 has been reported in the literature in at least 6 unrelated individuals and has been found to segregate with clinical features of a RASopathy in at least 15 family members (PS4, PP1_Strong; 16498234, 12634870, 12325025, 11704759). In vitro functional studies provide some evidence that the p.Tyr63Cys variant may impact protein function (PS3; PMID: 22711529). The variant is located in the PTPN11 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Computational prediction tools and conservation analysis suggest that the p.Tyr63Cys variant may impact the protein (PP3). Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of PTPN11 (PM1; PMID 29493581). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PP1_Strong, PS4, PS3, PM1, PP2, PP3.	11704759, 24219368, 12634870, 12325025, 22711529, 12634870, 16498234, 12325025	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2017-04-03	2019-07-15	False	https://erepo.genome.network/evrepo/ui/classification/CA220146/MONDO:0018997/004	579af108-04e2-4cf7-9a40-35cbaa82b116	p.Tyr63Cys	Tyr	63	Cys	MTSRRWFHPNITGVEAENLLLTRGVDGSFLARPSKSNPGDFTLSVRRNGAVTHIKIQNTGDYYDLYGGEKFATLAELVQYYMEHHGQLKEKNGDVIELKYPLNCADPTSERWFHGHLSGKEAEKLLTEKGKHGSFLVRESQSHPGDFVLSVRTGDDKGESNDGKSKVTHVMIRCQELKYDVGGGERFDSLTDLVEHYKKNPMVETLGTVLQLKQPLNTTRINAAEIESRVRELSKLAETTDKVKQGFWEEFETLQQQECKLLYSRKEGQRQENKNKNRYKNILPFDHTRVVLHDGDPNEPVSDYINANIIMPEFETKCNNSKPKKSYIATQGCLQNTVNDFWRMVFQENSRVIVMTTKEVERGKSKCVKYWPDEYALKEYGVMRVRNVKESAAHDYTLRELKLSKVGQGNTERTVWQYHFRTWPDHGVPSDPGGVLDFLEEVHHKQESIMDAGPVVVHCSAGIGRTGTFIVIDILIDIIREKGVDCDIDVPKTIQMVRSQRSGMVQTEAQYRFIYMAVQHYIETLQRRIEEEQKSKRKGHEYTNIKYSLADQTSGDQSPLPPCTPTPPCAEMREDSARVYENVGLMQQQKSFR	593	Q06124	C	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [288, 303], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.01389533, -0.00188822]), 'HELIX_loss': [530], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.00688505]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
138	NM_022124.5(CDH23):c.3625A>G (p.Thr1209Ala)	4927	CA137387	NM_022124.5:c.3625A>G, NC_000010.11:g.71730514A>G, CM000672.2:g.71730514A>G, NC_000010.10:g.73490271A>G, CM000672.1:g.73490271A>G, NC_000010.9:g.73160277A>G, NG_008835.1:g.338568A>G, NM_001168390.1:c.-6+7214T>C, NM_001171930.1:c.3625A>G, XM_006717940.2:c.3820A>G, XM_006717942.2:c.3754A>G, XM_011540039.1:c.3820A>G, XM_011540040.1:c.3814A>G, XM_011540041.1:c.3760A>G, XM_011540042.1:c.3820A>G, XM_011540043.1:c.3820A>G, XM_011540044.1:c.3685A>G, XM_011540045.1:c.3820A>G, XM_011540046.1:c.3280A>G, XM_011540047.1:c.2638A>G, XM_011540048.1:c.3820A>G, XM_011540049.1:c.3820A>G, XM_011540050.1:c.3820A>G, XM_011540051.1:c.3820A>G, XM_011540052.1:c.148A>G, XM_011540053.1:c.3820A>G, XR_945796.1:n.4063A>G, ENST00000224721.10:c.3640A>G, ENST00000398786.2:c.-6+7214T>C, ENST00000398792.3:n.317A>G, ENST00000398809.8:c.3622A>G, ENST00000616684.4:c.3625A>G, ENST00000622827.4:c.3625A>G, NM_022124.5(CDH23):c.3625A>G (p.Thr1209Ala)	CDH23	Usher syndrome	MONDO:0019501	Autosomal recessive inheritance	Benign	BP4, BA1, BS3_Supporting	PS2, PS1, PS4, PS3, PM1, PM5, PM4, PM3, BS4, BS1, BP7, BP5, PVS1, PM6, PM2, BS2, PP4, PP1, PP3, BP3, BP2	The filtering allele frequency (the lower threshold of the 95% CI of 3442/23972) of the c.3625A>G (p.Thr1209Ala) variant in the CDH23 gene is 13.15% for African chromosomes by gnomAD, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive hearing loss variants (BA1). A splicing assay did not show any impact to splicing but BS3 was not applied given no assessment of protein function  (PMID:18273900). Computational prediction analysis using the metapredictor tool REVEL did not predict an impact the protein (BP4). Of note, this variant was reported in 3 patients with Usher syndrome (PMID: 15537665, 15660226, 12075507) though without any convincing evidence for pathogenicity (PM3 not met). In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel : BA1, BS3_Supporting, BP4.	16963483, 21569298, 21738395, 19683999, 15660226, 12075507, 15537665, 19683999, 15660226, 12075507, 15537665, 18273900	Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2019-05-28	2019-07-17	False	https://erepo.genome.network/evrepo/ui/classification/CA137387/MONDO:0019501/005	dfd4f5fa-53f6-478c-911d-6946d1680d38	p.Thr1209Ala	Thr	1209	Ala	MGRHVATSCHVAWLLVLISGCWGQVNRLPFFTNHFFDTYLLISEDTPVGSSVTQLLAQDMDNDPLVFGVSGEEASRFFAVEPDTGVVWLRQPLDRETKSEFTVEFSVSDHQGVITRKVNIQVGDVNDNAPTFHNQPYSVRIPENTPVGTPIFIVNATDPDLGAGGSVLYSFQPPSQFFAIDSARGIVTVIRELDYETTQAYQLTVNATDQDKTRPLSTLANLAIIITDVQDMDPIFINLPYSTNIYEHSPPGTTVRIITAIDQDKGRPRGIGYTIVSGNTNSIFALDYISGVLTLNGLLDRENPLYSHGFILTVKGTELNDDRTPSDATVTTTFNILVIDINDNAPEFNSSEYSVAITELAQVGFALPLFIQVVDKDENLGLNSMFEVYLVGNNSHHFIISPTSVQGKADIRIRVAIPLDYETVDRYDFDLFANESVPDHVGYAKVKITLINENDNRPIFSQPLYNISLYENVTVGTSVLTVLATDNDAGTFGEVSYFFSDDPDRFSLDKDTGLIMLIARLDYELIQRFTLTIIARDGGGEETTGRVRINVLDVNDNVPTFQKDAYVGALRENEPSVTQLVRLRATDEDSPPNNQITYSIVSASAFGSYFDISLYEGYGVISVSRPLDYEQISNGLIYLTVMAMDAGNPPLNSTVPVTIEVFDENDNPPTFSKPAYFVSVVENIMAGATVLFLNATDLDRSREYGQESIIYSLEGSTQFRINARSGEITTTSLLDRETKSEYILIVRAVDGGVGHNQKTGIATVNITLLDINDNHPTWKDAPYYINLVEMTPPDSDVTTVVAVDPDLGENGTLVYSIQPPNKFYSLNSTTGKIRTTHAMLDRENPDPHEAELMRKIVVSVTDCGRPPLKATSSATVFVNLLDLNDNDPTFQNLPFVAEVLEGIPAGVSIYQVVAIDLDEGLNGLVSYRMPVGMPRMDFLINSSSGVVVTTTELDRERIAEYQLRVVASDAGTPTKSSTSTLTIHVLDVNDETPTFFPAVYNVSVSEDVPREFRVVWLNCTDNDVGLNAELSYFITGGNVDGKFSVGYRDAVVRTVVGLDRETTAAYMLILEAIDNGPVGKRHTGTATVFVTVLDVNDNRPIFLQSSYEASVPEDIPEGHSILQLKATDADEGEFGRVWYRILHGNHGNNFRIHVSNGLLMRGPRPLDRERNSSHVLIVEAYNHDLGPMRSSVRVIVYVEDINDEAPVFTQQQYSRLGLRETAGIGTSVIVVQATDRDSGDGGLVNYRILSGAEGKFEIDESTGLIITVNYLDYETKTSYMMNVSATDQAPPFNQGFCSVYITLLNELDEAVQFSNASYEAAILENLALGTEIVRVQAYSIDNLNQITYRFNAYTSTQAKALFKIDAITGVITVQGLVDREKGDFYTLTVVADDGGPKVDSTVKVYITVLDENDNSPRFDFTSDSAVSIPEDCPVGQRVATVKAWDPDAGSNGQVVFSLASGNIAGAFEIVTTNDSIGEVFVARPLDREELDHYILQVVASDRGTPPRKKDHILQVTILDINDNPPVIESPFGYNVSVNENVGGGTAVVQVRATDRDIGINSVLSYYITEGNKDMAFRMDRISGEIATRPAPPDRERQSFYHLVATVEDEGTPTLSATTHVYVTIVDENDNAPMFQQPHYEVLLDEGPDTLNTSLITIQALDLDEGPNGTVTYAIVAGNIVNTFRIDRHMGVITAAKELDYEISHGRYTLIVTATDQCPILSHRLTSTTTVLVNVNDINDNVPTFPRDYEGPFEVTEGQPGPRVWTFLAHDRDSGPNGQVEYSIMDGDPLGEFVISPVEGVLRVRKDVELDRETIAFYNLTICARDRGMPPLSSTMLVGIRVLDINDNDPVLLNLPMNITISENSPVSSFVAHVLASDADSGCNARLTFNITAGNRERAFFINATTGIVTVNRPLDRERIPEYKLTISVKDNPENPRIARRDYDLLLIFLSDENDNHPLFTKSTYQAEVMENSPAGTPLTVLNGPILALDADQDIYAVVTYQLLGAQSGLFDINSSTGVVTVRSGVIIDREAFSPPILELLLLAEDIGLLNSTAHLLITILDDNDNRPTFSPATLTVHLLENCPPGFSVLQVTATDEDSGLNGELVYRIEAGAQDRFLIHLVTGVIRVGNATIDREEQESYRLTVVATDRGTVPLSGTAIVTILIDDINDSRPEFLNPIQTVSVLESAEPGTVIANITAIDHDLNPKLEYHIVGIVAKDDTDRLVPNQEDAFAVNINTGSVMVKSPMNRELVATYEVTLSVIDNASDLPERSVSVPNAKLTVNVLDVNDNTPQFKPFGITYYMERILEGATPGTTLIAVAAVDPDKGLNGLVTYTLLDLVPPGYVQLEDSSAGKVIANRTVDYEEVHWLNFTVRASDNGSPPRAAEIPVYLEIVDINDNNPIFDQPSYQEAVFEDVPVGTIILTVTATDADSGNFALIEYSLGDGESKFAINPTTGDIYVLSSLDREKKDHYILTALAKDNPGDVASNRRENSVQVVIQVLDVNDCRPQFSKPQFSTSVYENEPAGTSVITMMATDQDEGPNGELTYSLEGPGVEAFHVDMDSGLVTTQRPLQSYEKFSLTVVATDGGEPPLWGTTMLLVEVIDVNDNRPVFVRPPNGTILHIREEIPLRSNVYEVYATDKDEGLNGAVRYSFLKTAGNRDWEFFIIDPISGLIQTAQRLDRESQAVYSLILVASDLGQPVPYETMQPLQVALEDIDDNEPLFVRPPKGSPQYQLLTVPEHSPRGTLVGNVTGAVDADEGPNAIVYYFIAAGNEEKNFHLQPDGCLLVLRDLDREREAIFSFIVKASSNRSWTPPRGPSPTLDLVADLTLQEVRVVLEDINDQPPRFTKAEYTAGVATDAKVGSELIQVLALDADIGNNSLVFYSILAIHYFRALANDSEDVGQVFTMGSMDGILRTFDLFMAYSPGYFVVDIVARDLAGHNDTAIIGIYILRDDQRVKIVINEIPDRVRGFEEEFIHLLSNITGAIVNTDNVQFHVDKKGRVNFAQTELLIHVVNRDTNRILDVDRVIQMIDENKEQLRNLFRNYNVLDVQPAISVRLPDDMSALQMAIIVLAILLFLAAMLFVLMNWYYRTVHKRKLKAIVAGSAGNRGFIDIMDMPNTNKYSFDGANPVWLDPFCRNLELAAQAEHEDDLPENLSEIADLWNSPTRTHGTFGREPAAVKPDDDRYLRAAIQEYDNIAKLGQIIREGPIKGSLLKVVLEDYLRLKKLFAQRMVQKASSCHSSISELIQTELDEEPGDHSPGQGSLRFRHKPPVELKGPDGIHVVHGSTGTLLATDLNSLPEEDQKGLGRSLETLTAAEATAFERNARTESAKSTPLHKLRDVIMETPLEITEL	3354	Q9H251	A	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [368, 1149], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.00190222, -0.00211537]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [13, 251, 1807, 1812], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.049532  , -0.0152787 , -0.0094893 , -0.01281124]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
139	NM_004086.2(COCH):c.841G>A (p.Asp281Asn)	226529	CA7143202	NM_004086.2:c.841G>A, NC_000014.9:g.30885501G>A, CM000676.2:g.30885501G>A, NC_000014.8:g.31354707G>A, CM000676.1:g.31354707G>A, NC_000014.7:g.30424458G>A, NG_008211.2:g.15967G>A, NM_001135058.1:c.841G>A, NR_038356.1:n.1364C>T, XM_011536539.1:c.841G>A, NM_001347720.1:c.1036G>A, XM_017021071.1:c.1036G>A, XM_024449506.1:c.898G>A, NM_004086.3:c.841G>A, ENST00000216361.8:c.841G>A, ENST00000396618.7:c.841G>A, ENST00000460581.6:c.505G>A, ENST00000468826.2:n.492G>A, ENST00000475087.5:c.841G>A, ENST00000555881.5:c.487G>A, ENST00000557065.1:n.623G>A, NM_004086.2(COCH):c.841G>A (p.Asp281Asn)	COCH	nonsyndromic genetic deafness	MONDO:0019497	Autosomal dominant inheritance	Benign	BA1		The filtering allele frequency of the c.841G>A (p.Asp281Asn) variant in the COCH gene is 0.5% for African chromosomes by gnomAD (145/24032 with 95% CI), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal dominant hearing loss variants (BA1).		Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2019-02-25	2019-07-17	False	https://erepo.genome.network/evrepo/ui/classification/CA7143202/MONDO:0019497/005	f0ea27ae-e6f6-4144-a4b0-c916b38ecd23	p.Asp281Asn	Asp	281	Asn	MSAAWIPALGLGVCLLLLPGPAGSEGAAPIAITCFTRGLDIRKEKADVLCPGGCPLEEFSVYGNIVYASVSSICGAAVHRGVISNSGGPVRVYSLPGRENYSSVDANGIQSQMLSRWSASFTVTKGKSSTQEATGQAVSTAHPPTGKRLKKTPEKKTGNKDCKADIAFLIDGSFNIGQRRFNLQKNFVGKVALMLGIGTEGPHVGLVQASEHPKIEFYLKNFTSAKDVLFAIKEVGFRGGNSNTGKALKHTAQKFFTVDAGVRKGIPKVVVVFIDGWPSDDIEEAGIVAREFGVNVFIVSVAKPIPEELGMVQDVTFVDKAVCRNNGFFSYHMPNWFGTTKYVKPLVQKLCTHEQMMCSKTCYNSVNIAFLIDGSSSVGDSNFRLMLEFVSNIAKTFEISDIGAKIAAVQFTYDQRTEFSFTDYSTKENVLAVIRNIRYMSGGTATGDAISFTVRNVFGPIRESPNKNFLVIVTDGQSYDDVQGPAAAAHDAGITIFSVGVAWAPLDDLKDMASKPKESHAFFTREFTGLEPIVSDVIRGICRDFLESQQ	550	O43405	N	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [240, 297, 299, 392, 403, 413, 457], 'REPEAT_gain': [258], 'REPEAT_gain_score': array([0.00285119]), 'REPEAT_loss_score': array([-0.01564622, -0.04331732, -0.04619229, -0.01219714, -0.01015532,
       -0.00952303, -0.00616384]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
140	NM_000441.1(SLC26A4):c.1069G>A (p.Ala357Thr)	43491	CA132654	NM_000441.1:c.1069G>A, NC_000007.14:g.107689120G>A, CM000669.2:g.107689120G>A, NC_000007.13:g.107329565G>A, CM000669.1:g.107329565G>A, NC_000007.12:g.107116801G>A, NG_008489.1:g.33486G>A, XM_005250425.1:c.1069G>A, XM_006716025.2:c.1069G>A, XM_005250425.2:c.1069G>A, XM_006716025.3:c.1069G>A, XM_017012318.1:c.1069G>A, ENST00000265715.7:c.1069G>A, NM_000441.1(SLC26A4):c.1069G>A (p.Ala357Thr)	SLC26A4	Pendred syndrome	MONDO:0010134	Autosomal recessive inheritance	Benign	PP3, BA1	PS4, PS1, PM1, PM5, BP5, BP4	The filtering allele frequency of the p.Ala357Thr variant in the SLC26A4 gene is 0.47% for African chromosomes by gnomAD (136/24968 with 95% CI), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive Pendred syndrome variants (BA1). The REVEL computational prediction analysis tool produces a score of 0.849, which is above the threshold necessary to apply PP3; however, this information is not predictive of pathogenicity on its own and is not considered in conflict with evidence that supports a benign interpretation. In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel: BA1.		Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2019-02-25	2019-07-17	False	https://erepo.genome.network/evrepo/ui/classification/CA132654/MONDO:0010134/005	ff136dc4-4d43-4577-beb7-70c08e9c04ab	p.Ala357Thr	Ala	357	Thr	MAAPGGRSEPPQLPEYSCSYMVSRPVYSELAFQQQHERRLQERKTLRESLAKCCSCSRKRAFGVLKTLVPILEWLPKYRVKEWLLSDVISGVSTGLVATLQGMAYALLAAVPVGYGLYSAFFPILTYFIFGTSRHISVGPFPVVSLMVGSVVLSMAPDEHFLVSSSNGTVLNTTMIDTAARDTARVLIASALTLLVGIIQLIFGGLQIGFIVRYLADPLVGGFTTAAAFQVLVSQLKIVLNVSTKNYNGVLSIIYTLVEIFQNIGDTNLADFTAGLLTIVVCMAVKELNDRFRHKIPVPIPIEVIVTIIATAISYGANLEKNYNAGIVKSIPRGFLPPELPPVSLFSEMLAASFSIAVVAYAIAVSVGKVYATKYDYTIDGNQEFIAFGISNIFSGFFSCFVATTALSRTAVQESTGGKTQVAGIISAAIVMIAILALGKLLEPLQKSVLAAVVIANLKGMFMQLCDIPRLWRQNKIDAVIWVFTCIVSIILGLDLGLLAGLIFGLLTVVLRVQFPSWNGLGSIPSTDIYKSTKNYKNIEEPQGVKILRFSSPIFYGNVDGFKKCIKSTVGFDAIRVYNKRLKALRKIQKLIKSGQLRATKNGIISDAVSTNNAFEPDEDIEDLEELDIPTKEIEIQVDWNSELPVKVNVPKVPIHSLVLDCGAISFLDVVGVRSLRVIVKEFQRIDVNVYFASLQDYVIEKLEQCGFFDDNIRKDTFFLTVHDAILYLQNQVKSQEGQGSILETITLIQDCKDTLELIETELTEEELDVQDEAMRTLAS	780	O43511	T	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [356, 434], 'DNA_BIND_gain': [344], 'DNA_BIND_gain_score': array([0.01093441]), 'DNA_BIND_loss_score': array([-0.04333943, -0.00069541]), 'TOPO_DOM_loss': [131], 'TOPO_DOM_gain': [], 'TOPO_DOM_loss_score': array([-0.00214642]), 'TRANSMEM_loss': [], 'TRANSMEM_gain': [466], 'TRANSMEM_gain_score': array([0.00274801]), 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [14], 'SIGNAL_gain': [], 'SIGNAL_loss_score': array([-0.00430495]), 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [46], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.00666249]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [420, 476, 487], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.01276541, -0.01203448, -0.00959659]), 'REGION_loss': [], 'REGION_gain': [617], 'REGION_gain_score': array([0.00123286]), 'REPEAT_loss': [364], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.00746608]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
141	NM_001754.5(RUNX1):c.328A>G (p.Lys110Glu)	14465	CA248613	NM_001754.5:c.328A>G, NC_000021.9:g.34886866T>C, CM000683.2:g.34886866T>C, NC_000021.8:g.36259163T>C, CM000683.1:g.36259163T>C, NC_000021.7:g.35181033T>C, NG_011402.2:g.1102846A>G, LRG_482:g.1102846A>G, ENST00000675419.1:c.328A>G, ENST00000300305.7:c.328A>G, ENST00000344691.8:c.247A>G, ENST00000358356.9:c.247A>G, ENST00000399237.6:c.292A>G, ENST00000399240.5:c.247A>G, ENST00000437180.5:c.328A>G, ENST00000455571.5:c.289A>G, ENST00000482318.5:c.59-6153A>G, NM_001001890.2:c.247A>G, NM_001122607.1:c.247A>G, NM_001754.4:c.328A>G, LRG_482t1:c.328A>G, XM_005261068.3:c.292A>G, XM_005261069.3:c.328A>G, XM_011529766.1:c.328A>G, XM_011529767.1:c.289A>G, XM_011529768.1:c.289A>G, XM_011529770.1:c.328A>G, XR_937576.1:n.507A>G, XM_005261069.4:c.328A>G, XM_011529766.2:c.328A>G, XM_011529767.2:c.289A>G, XM_011529768.2:c.289A>G, XM_011529770.2:c.328A>G, XM_017028487.1:c.175A>G, XR_937576.2:n.554A>G, NM_001001890.3:c.247A>G, NM_001122607.2:c.247A>G, NM_001754.5(RUNX1):c.328A>G (p.Lys110Glu)	RUNX1	hereditary thrombocytopenia and hematologic cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Pathogenic	PM5_Supporting, PM1, PP3, PM2_Supporting, PS4_Supporting, PS3, PP1_Strong	PM6, PVS1, PM4, PM3, PP2, PP4, BS2, BA1, BP1, BP4, BP3, BP2, PS1, PS2, BS3, BS1, BS4, BP7, BP5	Transactivation assays demonstrate altered transactivation (<20% of wt) for the NM_001754.4:c.328A>G (p.Lys110Glu) variant and data from secondary assays demonstrate altered DNA binding, CBFβ binding and sub-cellular localization (PS3; PMID: 23848403; 17290219; 11830488). This variant was found to co-segregate with disease in multiple affected family members, with 7 meioses observed in one pedigree (PP1_Strong; PMID: 11830488). This variant affects one of the hotspot residues established by the MM-VCEP for RUNX1 (PM1). It is completely absent from all population databases with at least 20x coverage for RUNX1 (PM2_supporting). This missense variant has a REVEL score >0.75 (0.953) (PP3). This variant has been reported in one proband meeting at least one of the RUNX1-phenotypic criteria (PS4_Supporting; PMID: 11830488). This variant is a missense change at the same residue (p.K110) where a different missense change has been previously established as a pathogenic variant (ClinVar ID 1518631, 14465) based on MM-VCEP rules for RUNX1 and RNA data or agreement in splicing predictors (SSF and MES) show no splicing effects (PM5_Supporting). In summary, this variant meets criteria to be classified as pathogenic. ACMG/AMP criteria applied, as specified by the Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PS3, PP1_Strong, PM1, PM2_supporting, PP3, PS4_Supporting, PM5_supporting.	11830488, 23848403, 17290219, 11830488, 11830488, 11830488	Myeloid Malignancy VCEP	https://www.clinicalgenome.org/affiliation/50034/docs/assertion-criteria 	2024-03-26	2024-03-26	False	https://erepo.genome.network/evrepo/ui/classification/CA248613/MONDO:0011071/008	37efba9c-0430-4e4f-a3ce-fc8c501d717a	p.Lys110Glu	Lys	110	Glu	MRIPVDASTSRRFTPPSTALSPGKMSEALPLGAPDAGAALAGKLRSGDRSMVEVLADHPGELVRTDSPNFLCSVLPTHWRCNKTLPIAFKVVALGDVPDGTLVTVMAGNDENYSAELRNATAAMKNQVARFNDLRFVGRSGRGKSFTLTITVFTNPPQVATYHRAIKITVDGPREPRRHRQKLDDQTKPGSLSFSERLSELEQLRRTAMRVSPHHPAPTPNPRASLNHSTAFNPQPQSQMQDTRQIQPSPPWSYDQSYQYLGSIASPSVHPATPISPGRASGMTTLSAELSSRLSTAPDLTAFSDPRQFPALPSISDPRMHYPGAFTYSPTPVTSGIGIGMSAMGSATRYHTYLPPPYPGSSQAQGGPFQASSPSYHLYYGASAGSYQFSMVGGERSPPRILPPCTNASTGSALLNPSLPNQSDVVEAEGSHSNSPTNMAPSARLEEAVWRPY	453	Q01196	E	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [110], 'STRAND_gain_score': array([0.11832219]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [111, 114, 120], 'REGION_gain': [], 'REGION_loss_score': array([-0.00887793, -0.02189231, -0.00787795]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
142	NM_001754.5(RUNX1):c.400G>C (p.Ala134Pro)	14468	CA248623	NM_001754.5:c.400G>C, NC_000021.9:g.34880665C>G, CM000683.2:g.34880665C>G, NC_000021.8:g.36252962C>G, CM000683.1:g.36252962C>G, NC_000021.7:g.35174832C>G, NG_011402.2:g.1109047G>C, LRG_482:g.1109047G>C, ENST00000675419.1:c.400G>C, ENST00000300305.7:c.400G>C, ENST00000344691.8:c.319G>C, ENST00000358356.9:c.319G>C, ENST00000399237.6:c.364G>C, ENST00000399240.5:c.319G>C, ENST00000437180.5:c.400G>C, ENST00000455571.5:c.361G>C, ENST00000482318.5:c.107G>C, NM_001001890.2:c.319G>C, NM_001122607.1:c.319G>C, NM_001754.4:c.400G>C, LRG_482t1:c.400G>C, XM_005261068.3:c.364G>C, XM_005261069.3:c.400G>C, XM_011529766.1:c.400G>C, XM_011529767.1:c.361G>C, XM_011529768.1:c.361G>C, XM_011529770.1:c.400G>C, XR_937576.1:n.579G>C, XM_005261069.4:c.400G>C, XM_011529766.2:c.400G>C, XM_011529767.2:c.361G>C, XM_011529768.2:c.361G>C, XM_011529770.2:c.400G>C, XM_017028487.1:c.247G>C, XR_937576.2:n.626G>C, NM_001001890.3:c.319G>C, NM_001122607.2:c.319G>C, NM_001754.5(RUNX1):c.400G>C (p.Ala134Pro)	RUNX1	hereditary thrombocytopenia and hematologic cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Pathogenic	PM5_Supporting, PM1, PP3, PP1, PM2_Supporting, PS4_Supporting, PS3	PM6, PVS1, PM4, PM3, PP2, PP4, BS2, BP1, BP4, BP3, BP2, BA1, PS1, PS2, BS3, BS1, BS4, BP7, BP5	Transactivation assays demonstrate altered transactivation (<20% of wt) for the missense variant, NM_001754.4:c.400G>C (p.Ala134Pro) and data from secondary assays demonstrate altered CBFβ binding and sub-cellular localization.(PS3; PMID: 23848403). This variant affects one of the hotspot residues established by the MM-VCEP for RUNX1 (PM1). It is completely absent from all population databases with at least 20x coverage for RUNX1 (PM2_supporting). It has a REVEL score >0.75 (0.945) (PP3). This variant has been reported in one proband meeting at least one of the RUNX1-phenotypic criteria (PS4_ Supporting; PMID: 12060124). It was found to co-segregate with disease in multiple affected family members, with three meioses observed in one family (PP1; PMID: 12060124). This variant is a missense change at the same residue (p.A134) where a different missense change has been previously established as a likely pathogenic variant (ClinVar ID 1484777) based on MM-VCEP rules for RUNX1 and RNA data or agreement in splicing predictors (SSF and MES) show no splicing effects (PM5_Supporting). In summary, this variant meets criteria to be classified as pathogenic. ACMG/AMP criteria applied, as specified by the Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PS3, PM1, PM2_supporting, PP1, PP3, PS4_Supporting, PM5_Supporting.	12060124, 12060124, 23848403, 12060124	Myeloid Malignancy VCEP	https://www.clinicalgenome.org/affiliation/50034/docs/assertion-criteria 	2024-03-26	2024-03-26	False	https://erepo.genome.network/evrepo/ui/classification/CA248623/MONDO:0011071/008	d5e03ae0-3ff2-428d-87e3-ae93412f6bf1	p.Ala134Pro	Ala	134	Pro	MRIPVDASTSRRFTPPSTALSPGKMSEALPLGAPDAGAALAGKLRSGDRSMVEVLADHPGELVRTDSPNFLCSVLPTHWRCNKTLPIAFKVVALGDVPDGTLVTVMAGNDENYSAELRNATAAMKNQVARFNDLRFVGRSGRGKSFTLTITVFTNPPQVATYHRAIKITVDGPREPRRHRQKLDDQTKPGSLSFSERLSELEQLRRTAMRVSPHHPAPTPNPRASLNHSTAFNPQPQSQMQDTRQIQPSPPWSYDQSYQYLGSIASPSVHPATPISPGRASGMTTLSAELSSRLSTAPDLTAFSDPRQFPALPSISDPRMHYPGAFTYSPTPVTSGIGIGMSAMGSATRYHTYLPPPYPGSSQAQGGPFQASSPSYHLYYGASAGSYQFSMVGGERSPPRILPPCTNASTGSALLNPSLPNQSDVVEAEGSHSNSPTNMAPSARLEEAVWRPY	453	Q01196	P	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [56, 57, 179], 'DNA_BIND_gain_score': array([0.08052325, 0.02879316, 0.05990678]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [126, 158], 'STRAND_gain_score': array([0.09570986, 0.03941178]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [201, 204], 'COILED_gain_score': array([0.03383255, 0.03165257]), 'COMPBIAS_loss': [], 'COMPBIAS_gain': [188], 'COMPBIAS_gain_score': array([0.01981193]), 'DOMAIN_loss': [], 'DOMAIN_gain': [42], 'DOMAIN_gain_score': array([0.21935612]), 'REGION_loss': [111, 114, 118, 119, 120, 121, 122, 164, 165, 166], 'REGION_gain': [], 'REGION_loss_score': array([-0.02918965, -0.0334999 , -0.04607511, -0.04164875, -0.04797333,
       -0.05667281, -0.05431956, -0.02422845, -0.02566892, -0.0218612 ]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
143	NM_001754.4(RUNX1):c.497G>A (p.Arg166Gln)	417961	CA16616941	NM_001754.4:c.497G>A, NC_000021.9:g.34880568C>T, CM000683.2:g.34880568C>T, NC_000021.8:g.36252865C>T, CM000683.1:g.36252865C>T, NC_000021.7:g.35174735C>T, NG_011402.2:g.1109144G>A, LRG_482:g.1109144G>A, NM_001001890.2:c.416G>A, NM_001122607.1:c.416G>A, LRG_482t1:c.497G>A, XM_005261068.3:c.461G>A, XM_005261069.3:c.497G>A, XM_011529766.1:c.497G>A, XM_011529767.1:c.458G>A, XM_011529768.1:c.458G>A, XM_011529770.1:c.497G>A, XR_937576.1:n.676G>A, XM_005261069.4:c.497G>A, XM_011529766.2:c.497G>A, XM_011529767.2:c.458G>A, XM_011529768.2:c.458G>A, XM_011529770.2:c.497G>A, XM_017028487.1:c.344G>A, XR_937576.2:n.723G>A, ENST00000300305.7:c.497G>A, ENST00000344691.8:c.416G>A, ENST00000358356.9:c.416G>A, ENST00000399237.6:c.461G>A, ENST00000399240.5:c.416G>A, ENST00000437180.5:c.497G>A, ENST00000482318.5:c.*87G>A, NM_001754.4(RUNX1):c.497G>A (p.Arg166Gln)	RUNX1	hereditary thrombocytopenia with normal platelets-hematological cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Pathogenic	PM2, PM1, PP1, PP3, PS4_Moderate, PS3, PM6_Supporting	PVS1, PM4, PM5, BP2, BP4, BA1, PS1, BP7, BS1, BS4, BS3	Transactivation assays demonstrate altered transactivation (<20% of wt) for the NM_001754.4:c.497G>A (p.Arg166Gln) variant and data from a secondary assays demonstrate altered DNA binding, CBFβ binding and sub-cellular localization (PS3; PMID: 11830488,  25840971, 23848403). This variant affects one of the hotspot residues established by the MM-VCEP for RUNX1 (PM1). This variant has been reported in three probands meeting at least one of the RUNX1-phenotypic criteria (PS4_Moderate; PMID: 10508512, 28960434, 26175287). This variant is completely absent from all population databases with at least 20x coverage for RUNX1 (PM2). It has a REVEL score >0.75 (0.962) (PP3). There are two unrelated probands meeting at least one of the RUNX1- phenotypic criteria with assumed de novo occurrence (without confirmation of maternity and paternity) (PM6_ Supporting; PMID: 8960434, 26175287). This variant was found to co-segregate with disease in multiple affected family members, with three meioses observed in one family (PP1; PMID: 10508512). In summary, this variant meets criteria to be classified as pathogenic. ACMG/AMP criteria applied, as specified by the Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PS3, PM1, PS4_Moderate, PM2, PP3,  PM6_Supporting, PP1.	10508512, 10508512, 26175287, 28960434, 23848403, 11830488, 25840971, 26175287, 28960434, 10508512	Myeloid Malignancy VCEP	https://www.clinicalgenome.org/affiliation/50034/docs/assertion-criteria 	2019-07-30	2019-08-02	False	https://erepo.genome.network/evrepo/ui/classification/CA16616941/MONDO:0011071/008	ba8c0c9c-028c-473b-9259-a8316db5b16d	p.Arg166Gln	Arg	166	Gln	MRIPVDASTSRRFTPPSTALSPGKMSEALPLGAPDAGAALAGKLRSGDRSMVEVLADHPGELVRTDSPNFLCSVLPTHWRCNKTLPIAFKVVALGDVPDGTLVTVMAGNDENYSAELRNATAAMKNQVARFNDLRFVGRSGRGKSFTLTITVFTNPPQVATYHRAIKITVDGPREPRRHRQKLDDQTKPGSLSFSERLSELEQLRRTAMRVSPHHPAPTPNPRASLNHSTAFNPQPQSQMQDTRQIQPSPPWSYDQSYQYLGSIASPSVHPATPISPGRASGMTTLSAELSSRLSTAPDLTAFSDPRQFPALPSISDPRMHYPGAFTYSPTPVTSGIGIGMSAMGSATRYHTYLPPPYPGSSQAQGGPFQASSPSYHLYYGASAGSYQFSMVGGERSPPRILPPCTNASTGSALLNPSLPNQSDVVEAEGSHSNSPTNMAPSARLEEAVWRPY	453	Q01196	Q	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [175, 176, 177, 178], 'DNA_BIND_gain': [54, 56, 57], 'DNA_BIND_gain_score': array([0.07346338, 0.05010575, 0.08757609]), 'DNA_BIND_loss_score': array([-0.17122483, -0.14688337, -0.13271856, -0.10112607]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [50, 51, 52, 53, 107], 'STRAND_gain_score': array([0.20073038, 0.22517562, 0.23513353, 0.24046284, 0.07883197]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [169, 170, 188, 189], 'COMPBIAS_gain_score': array([0.43533802, 0.32918656, 0.08479148, 0.04445684]), 'DOMAIN_loss': [41, 43, 44, 179], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.11651224, -0.27103657, -0.17438537, -0.29524738]), 'REGION_loss': [111, 114, 120, 122, 355, 361, 362], 'REGION_gain': [32, 156, 161, 162], 'REGION_gain_score': array([0.01328593, 0.02284122, 0.06866509, 0.07573438]), 'REGION_loss_score': array([-0.00658453, -0.0077768 , -0.00623077, -0.01910079, -0.03081226,
       -0.04642802, -0.03758383]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
144	NM_001754.4(RUNX1):c.602G>A (p.Arg201Gln)	14464	CA248610	NM_001754.4:c.602G>A, NC_000021.9:g.34859485C>T, CM000683.2:g.34859485C>T, NC_000021.8:g.36231782C>T, CM000683.1:g.36231782C>T, NC_000021.7:g.35153652C>T, NG_011402.2:g.1130227G>A, LRG_482:g.1130227G>A, NM_001001890.2:c.521G>A, NM_001122607.1:c.521G>A, LRG_482t1:c.602G>A, XM_005261068.3:c.566G>A, XM_005261069.3:c.602G>A, XM_011529766.1:c.602G>A, XM_011529767.1:c.563G>A, XM_011529768.1:c.563G>A, XM_011529770.1:c.602G>A, XR_937576.1:n.781G>A, XM_005261069.4:c.602G>A, XM_011529766.2:c.602G>A, XM_011529767.2:c.563G>A, XM_011529768.2:c.563G>A, XM_011529770.2:c.602G>A, XM_017028487.1:c.449G>A, XR_937576.2:n.828G>A, ENST00000300305.7:c.602G>A, ENST00000344691.8:c.521G>A, ENST00000358356.9:c.521G>A, ENST00000399237.6:c.566G>A, ENST00000399240.5:c.521G>A, ENST00000437180.5:c.602G>A, ENST00000467577.1:n.94G>A, ENST00000482318.5:c.*192G>A, NM_001754.4(RUNX1):c.602G>A (p.Arg201Gln)	RUNX1	hereditary thrombocytopenia with normal platelets-hematological cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Pathogenic	PM2, PM1, PP1, PP3, PS4, PS3	PVS1, PM6, PM5, PM4, BP2, BP4, BA1, PS1, BP7, BS1, BS4, BS3	Transactivation assays demonstrate altered transactivation (<20% of wt) for the NM_001754.4:c.602G>A (p.Arg201Gln) variant  and data from a secondary assays demonstrate altered DNA binding, CBFβ binding and sub-cellular localization (PS3; PMID: 17290219, 11830488, 23817177, 22318203, 25840971,  23848403). This variant has been reported in four probands meeting at least one of the RUNX1-phenotypic criteria (PS4; PMID: 27112265, 28748566, 10508512). This variant affects one of the hotspot residues established by the MM-VCEP for RUNX1 (PM1). It is completely absent from all population databases with at least 20x coverage for RUNX1 (PM2). The variant has a REVEL score >0.75 (0.94) (PP3). It was found to co-segregate with disease in multiple affected family members, with four meioses observed in across 3 families (PP1; PMID:  27112265, 28748566, 10508512). In summary, this variant meets criteria to be classified as pathogenic. ACMG/AMP criteria applied, as specified by the Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PS3, PS4, PM1, PM2, PP1, PP3.	28748566, 10508512, 27112265, 10508512, 28748566, 27112265, 23817177, 11830488, 22318203, 23848403, 17290219, 25840971, 28748566, 10508512, 27112265	Myeloid Malignancy VCEP	https://www.clinicalgenome.org/affiliation/50034/docs/assertion-criteria 	2019-07-30	2019-08-02	False	https://erepo.genome.network/evrepo/ui/classification/CA248610/MONDO:0011071/008	52b9ca56-4641-4652-8c86-bee9650bacf2	p.Arg201Gln	Arg	201	Gln	MRIPVDASTSRRFTPPSTALSPGKMSEALPLGAPDAGAALAGKLRSGDRSMVEVLADHPGELVRTDSPNFLCSVLPTHWRCNKTLPIAFKVVALGDVPDGTLVTVMAGNDENYSAELRNATAAMKNQVARFNDLRFVGRSGRGKSFTLTITVFTNPPQVATYHRAIKITVDGPREPRRHRQKLDDQTKPGSLSFSERLSELEQLRRTAMRVSPHHPAPTPNPRASLNHSTAFNPQPQSQMQDTRQIQPSPPWSYDQSYQYLGSIASPSVHPATPISPGRASGMTTLSAELSSRLSTAPDLTAFSDPRQFPALPSISDPRMHYPGAFTYSPTPVTSGIGIGMSAMGSATRYHTYLPPPYPGSSQAQGGPFQASSPSYHLYYGASAGSYQFSMVGGERSPPRILPPCTNASTGSALLNPSLPNQSDVVEAEGSHSNSPTNMAPSARLEEAVWRPY	453	Q01196	Q	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [158], 'STRAND_gain_score': array([0.01388139]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [405, 407], 'COMPBIAS_gain': [170, 188, 189, 191], 'COMPBIAS_gain_score': array([0.10537094, 0.26800632, 0.2583462 , 0.27310222]), 'COMPBIAS_loss_score': array([-0.05073386, -0.04642355]), 'DOMAIN_loss': [44], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.0942992]), 'REGION_loss': [111, 114, 118, 119, 120, 121, 122, 163, 164, 165, 166, 167, 361], 'REGION_gain': [], 'REGION_loss_score': array([-0.03823495, -0.03787553, -0.03901339, -0.03592151, -0.03314054,
       -0.03411669, -0.0405134 , -0.09007668, -0.08616996, -0.11318672,
       -0.08401883, -0.10840291, -0.03159201]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
145	NM_001754.4(RUNX1):c.65T>A (p.Ile22Lys)	464002	CA10014634	NM_001754.4:c.65T>A, NC_000021.9:g.34892957A>T, CM000683.2:g.34892957A>T, NC_000021.8:g.36265254A>T, CM000683.1:g.36265254A>T, NC_000021.7:g.35187124A>T, NG_011402.2:g.1096755T>A, LRG_482:g.1096755T>A, LRG_482t1:c.65T>A, XM_005261069.3:c.65T>A, XM_011529766.1:c.65T>A, XM_011529767.1:c.59-5861T>A, XM_011529768.1:c.59-5861T>A, XM_011529770.1:c.65T>A, XR_937576.1:n.244T>A, XM_005261069.4:c.65T>A, XM_011529766.2:c.65T>A, XM_011529767.2:c.59-5861T>A, XM_011529768.2:c.59-5861T>A, XM_011529770.2:c.65T>A, XR_937576.2:n.291T>A, ENST00000300305.7:c.65T>A, ENST00000416754.1:c.65T>A, ENST00000437180.5:c.65T>A, ENST00000455571.5:c.59-5861T>A, ENST00000475045.6:c.65T>A, ENST00000482318.5:c.59-12244T>A, NM_001754.4(RUNX1):c.65T>A (p.Ile22Lys)	RUNX1	hereditary thrombocytopenia with normal platelets-hematological cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Benign	BA1	PM6, PM2, PVS1, PM1, PM4, PM5, PP1, PP3, BP2, BP4, PS4, PS3, PS1, BP7, BS4, BS1, BS3	The NM_001754.4:c.65T>A (p.Ile22Lys) variant has an MAF of 0.00201 (0.2%, 23/11436 alleles) in the Latino subpopulation of the ExAC cohort which is ≥ 0.0015 (0.15%) (BA1). In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the ClinGen Myeloid Malignancy Variant Curation Expert Panel for RUNX1: BA1.		Myeloid Malignancy VCEP	https://www.clinicalgenome.org/affiliation/50034/docs/assertion-criteria 	2019-08-02	2019-08-02	False	https://erepo.genome.network/evrepo/ui/classification/CA10014634/MONDO:0011071/008	6426c4e0-697d-4b39-a0dd-56f81c978e1a	p.Ile22Lys	Ile	22	Lys	MRIPVDASTSRRFTPPSTALSPGKMSEALPLGAPDAGAALAGKLRSGDRSMVEVLADHPGELVRTDSPNFLCSVLPTHWRCNKTLPIAFKVVALGDVPDGTLVTVMAGNDENYSAELRNATAAMKNQVARFNDLRFVGRSGRGKSFTLTITVFTNPPQVATYHRAIKITVDGPREPRRHRQKLDDQTKPGSLSFSERLSELEQLRRTAMRVSPHHPAPTPNPRASLNHSTAFNPQPQSQMQDTRQIQPSPPWSYDQSYQYLGSIASPSVHPATPISPGRASGMTTLSAELSSRLSTAPDLTAFSDPRQFPALPSISDPRMHYPGAFTYSPTPVTSGIGIGMSAMGSATRYHTYLPPPYPGSSQAQGGPFQASSPSYHLYYGASAGSYQFSMVGGERSPPRILPPCTNASTGSALLNPSLPNQSDVVEAEGSHSNSPTNMAPSARLEEAVWRPY	453	Q01196	K	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [53, 54, 55, 56, 57], 'DNA_BIND_gain_score': array([0.12979954, 0.13458359, 0.16758555, 0.16981781, 0.17187172]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [7, 9], 'TRANSIT_gain_score': array([0.09797448, 0.10048854]), 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [111, 114, 120, 122, 164, 165, 166], 'REGION_gain': [], 'REGION_loss_score': array([-0.01178092, -0.01222324, -0.01423913, -0.01504856, -0.01223588,
       -0.01120669, -0.01127791]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
146	NM_001754.4(RUNX1):c.824C>T (p.Pro275Leu)	464009	CA10014287	NM_001754.4:c.824C>T, NC_000021.9:g.34799444G>A, CM000683.2:g.34799444G>A, NC_000021.8:g.36171741G>A, CM000683.1:g.36171741G>A, NC_000021.7:g.35093611G>A, NG_011402.2:g.1190268C>T, LRG_482:g.1190268C>T, NM_001001890.2:c.743C>T, LRG_482t1:c.824C>T, XM_005261068.3:c.788C>T, XM_005261069.3:c.632C>T, XM_011529766.1:c.824C>T, XM_011529767.1:c.785C>T, XM_011529768.1:c.593C>T, XR_937576.1:n.1003C>T, XM_005261069.4:c.632C>T, XM_011529766.2:c.824C>T, XM_011529767.2:c.785C>T, XM_011529768.2:c.593C>T, XM_017028487.1:c.671C>T, XR_937576.2:n.1050C>T, ENST00000300305.7:c.824C>T, ENST00000344691.8:c.743C>T, ENST00000399240.5:c.551C>T, ENST00000437180.5:c.824C>T, ENST00000482318.5:c.*414C>T, NM_001754.4(RUNX1):c.824C>T (p.Pro275Leu)	RUNX1	hereditary thrombocytopenia with normal platelets-hematological cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Benign	BP4, BA1	PVS1, PM6, PM2, PM1, PM4, PM5, PP1, PP3, BP2, PS4, PS3, PS1, BS4, BS1, BS3, BP7	The NM_001754.4:c.824C>T (p.Pro275Leu) variant has an MAF of 0.00225 (0.2%, 26/11566 alleles) in the Latino subpopulation of the ExAC cohort that is ≥ 0.0015 (0.15%) (BA1). This missense variant has a REVEL score <0.15 (0.146) and SSF and MES predict either an increase in the canonical splice site score or a decrease of the canonical splice site score by no more than 10% and no putative cryptic splice sites are created (BP4). In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the ClinGen Myeloid Malignancy Variant Curation Expert Panel for RUNX1: BA1, BP4.		Myeloid Malignancy VCEP	https://www.clinicalgenome.org/affiliation/50034/docs/assertion-criteria 	2019-08-02	2019-08-02	False	https://erepo.genome.network/evrepo/ui/classification/CA10014287/MONDO:0011071/008	ed562b68-0918-4a40-899c-7000d16d5da8	p.Pro275Leu	Pro	275	Leu	MRIPVDASTSRRFTPPSTALSPGKMSEALPLGAPDAGAALAGKLRSGDRSMVEVLADHPGELVRTDSPNFLCSVLPTHWRCNKTLPIAFKVVALGDVPDGTLVTVMAGNDENYSAELRNATAAMKNQVARFNDLRFVGRSGRGKSFTLTITVFTNPPQVATYHRAIKITVDGPREPRRHRQKLDDQTKPGSLSFSERLSELEQLRRTAMRVSPHHPAPTPNPRASLNHSTAFNPQPQSQMQDTRQIQPSPPWSYDQSYQYLGSIASPSVHPATPISPGRASGMTTLSAELSSRLSTAPDLTAFSDPRQFPALPSISDPRMHYPGAFTYSPTPVTSGIGIGMSAMGSATRYHTYLPPPYPGSSQAQGGPFQASSPSYHLYYGASAGSYQFSMVGGERSPPRILPPCTNASTGSALLNPSLPNQSDVVEAEGSHSNSPTNMAPSARLEEAVWRPY	453	Q01196	L	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [114], 'REGION_gain': [], 'REGION_loss_score': array([-0.00238925]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
147	NM_001754.4(RUNX1):c.1005G>T (p.Gln335His)	239039	CA10014223	NM_001754.4:c.1005G>T, NC_000021.9:g.34792573C>A, CM000683.2:g.34792573C>A, NC_000021.8:g.36164870C>A, CM000683.1:g.36164870C>A, NC_000021.7:g.35086740C>A, NG_011402.2:g.1197139G>T, LRG_482:g.1197139G>T, NM_001001890.2:c.924G>T, LRG_482t1:c.1005G>T, XM_005261068.3:c.969G>T, XM_005261069.3:c.813G>T, XM_011529766.1:c.1005G>T, XM_011529767.1:c.966G>T, XM_011529768.1:c.774G>T, XR_937576.1:n.4609G>T, XM_005261069.4:c.813G>T, XM_011529766.2:c.1005G>T, XM_011529767.2:c.966G>T, XM_011529768.2:c.774G>T, XM_017028487.1:c.852G>T, XR_937576.2:n.4656G>T, ENST00000300305.7:c.1005G>T, ENST00000344691.8:c.924G>T, ENST00000399240.5:c.732G>T, ENST00000437180.5:c.1005G>T, ENST00000482318.5:c.*595G>T, NM_001754.4(RUNX1):c.1005G>T (p.Gln335His)	RUNX1	hereditary thrombocytopenia with normal platelets-hematological cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Benign	BA1	PVS1, PM6, PM2, PM1, PM4, PM5, PP1, PP3, BP2, BP4, PS4, PS3, PS1, BS4, BS1, BS3, BP7	The NM_001754.4:c.1005G>T (p.Gln335His) variant has a MAF of 0.00357 (0.357%, 15/4,206 alleles) in the East Asian subpopulation of the ExAC cohort that is ≥ 0.0015 (0.15%) (BA1). This missense variant has a REVEL score 0.4. In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the ClinGen Myeloid Malignancy Variant Curation Expert Panel for RUNX1: BA1.		Myeloid Malignancy VCEP	https://www.clinicalgenome.org/affiliation/50034/docs/assertion-criteria 	2019-07-26	2019-08-02	False	https://erepo.genome.network/evrepo/ui/classification/CA10014223/MONDO:0011071/008	1ef12dd0-41cd-4ff0-897f-dd0a414457bc	p.Gln335His	Gln	335	His	MRIPVDASTSRRFTPPSTALSPGKMSEALPLGAPDAGAALAGKLRSGDRSMVEVLADHPGELVRTDSPNFLCSVLPTHWRCNKTLPIAFKVVALGDVPDGTLVTVMAGNDENYSAELRNATAAMKNQVARFNDLRFVGRSGRGKSFTLTITVFTNPPQVATYHRAIKITVDGPREPRRHRQKLDDQTKPGSLSFSERLSELEQLRRTAMRVSPHHPAPTPNPRASLNHSTAFNPQPQSQMQDTRQIQPSPPWSYDQSYQYLGSIASPSVHPATPISPGRASGMTTLSAELSSRLSTAPDLTAFSDPRQFPALPSISDPRMHYPGAFTYSPTPVTSGIGIGMSAMGSATRYHTYLPPPYPGSSQAQGGPFQASSPSYHLYYGASAGSYQFSMVGGERSPPRILPPCTNASTGSALLNPSLPNQSDVVEAEGSHSNSPTNMAPSARLEEAVWRPY	453	Q01196	H	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [111, 114, 120, 122, 355, 361], 'REGION_gain': [], 'REGION_loss_score': array([-0.00798911, -0.00933492, -0.00687999, -0.01056778, -0.02739978,
       -0.04037911]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
148	NM_001754.4(RUNX1):c.1355T>G (p.Val452Gly)	339875	CA10014181	NM_001754.4:c.1355T>G, NC_000021.9:g.34792223A>C, CM000683.2:g.34792223A>C, NC_000021.8:g.36164520A>C, CM000683.1:g.36164520A>C, NC_000021.7:g.35086390A>C, NG_011402.2:g.1197489T>G, LRG_482:g.1197489T>G, NM_001001890.2:c.1274T>G, LRG_482t1:c.1355T>G, XM_005261068.3:c.1319T>G, XM_005261069.3:c.1163T>G, XM_011529766.1:c.1355T>G, XM_011529767.1:c.1316T>G, XM_011529768.1:c.1124T>G, XM_005261069.4:c.1163T>G, XM_011529766.2:c.1355T>G, XM_011529767.2:c.1316T>G, XM_011529768.2:c.1124T>G, XM_017028487.1:c.1202T>G, ENST00000300305.7:c.1355T>G, ENST00000344691.8:c.1274T>G, ENST00000399240.5:c.1082T>G, ENST00000437180.5:c.1355T>G, ENST00000482318.5:c.*945T>G, NM_001754.4(RUNX1):c.1355T>G (p.Val452Gly)	RUNX1	hereditary thrombocytopenia with normal platelets-hematological cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Benign	BP4, BA1, BS3	PM6, PM2, PVS1, PM1, PM4, PM5, PP1, PP3, BP2, PS4, PS3, PS1, BP7, BS4, BS1	The NM_001754.4:c.1355T>G (p.Val452Gly) variant has a MAF of 0.00177 (0.177%, 22/12,406 alleles) in the East Asian subpopulation of the gnomAD cohort that is ≥ 0.0015 (0.15%) (BA1). Transactivation assays demonstrating normal transactivation (80-115% of wt) and data from secondary assays demonstrate normal DNA binding and CBFβ binding (BS3; PMID: 25840971). This missense variant has a REVEL score <0.15 (0.046) and SSF and MES predict either an increase in the canonical splice site score or a decrease of the canonical splice site score by no more than 10% and no putative cryptic splice sites are created (BP4). In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the ClinGen Myeloid Malignancy Variant Curation Expert Panel for RUNX1: BA1, BS3, BP4.	25840971	Myeloid Malignancy VCEP	https://www.clinicalgenome.org/affiliation/50034/docs/assertion-criteria 	2019-07-26	2019-08-02	False	https://erepo.genome.network/evrepo/ui/classification/CA10014181/MONDO:0011071/008	1b105287-c135-44f7-b0a1-0719b8f91b20	p.Val452Gly	Val	452	Gly	MRIPVDASTSRRFTPPSTALSPGKMSEALPLGAPDAGAALAGKLRSGDRSMVEVLADHPGELVRTDSPNFLCSVLPTHWRCNKTLPIAFKVVALGDVPDGTLVTVMAGNDENYSAELRNATAAMKNQVARFNDLRFVGRSGRGKSFTLTITVFTNPPQVATYHRAIKITVDGPREPRRHRQKLDDQTKPGSLSFSERLSELEQLRRTAMRVSPHHPAPTPNPRASLNHSTAFNPQPQSQMQDTRQIQPSPPWSYDQSYQYLGSIASPSVHPATPISPGRASGMTTLSAELSSRLSTAPDLTAFSDPRQFPALPSISDPRMHYPGAFTYSPTPVTSGIGIGMSAMGSATRYHTYLPPPYPGSSQAQGGPFQASSPSYHLYYGASAGSYQFSMVGGERSPPRILPPCTNASTGSALLNPSLPNQSDVVEAEGSHSNSPTNMAPSARLEEAVWRPY	453	Q01196	G	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [407], 'COMPBIAS_gain': [], 'COMPBIAS_loss_score': array([-0.02987361]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [114, 444, 445, 446, 447, 448, 449, 450, 451, 452], 'REGION_gain': [368, 369], 'REGION_gain_score': array([0.00127381, 0.0042665 ]), 'REGION_loss_score': array([-0.00280929, -0.2157051 , -0.19857877, -0.19590181, -0.19276953,
       -0.19204092, -0.20735389, -0.16928357, -0.12974715, -0.18398798]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
149	NM_001754.4(RUNX1):c.167T>C (p.Leu56Ser)	239045	CA10014578	NM_001754.4:c.167T>C, NC_000021.9:g.34887027A>G, CM000683.2:g.34887027A>G, NC_000021.8:g.36259324A>G, CM000683.1:g.36259324A>G, NC_000021.7:g.35181194A>G, NG_011402.2:g.1102685T>C, LRG_482:g.1102685T>C, NM_001001890.2:c.86T>C, NM_001122607.1:c.86T>C, LRG_482t1:c.167T>C, XM_005261068.3:c.131T>C, XM_005261069.3:c.167T>C, XM_011529766.1:c.167T>C, XM_011529767.1:c.128T>C, XM_011529768.1:c.128T>C, XM_011529770.1:c.167T>C, XR_937576.1:n.346T>C, XM_005261069.4:c.167T>C, XM_011529766.2:c.167T>C, XM_011529767.2:c.128T>C, XM_011529768.2:c.128T>C, XM_011529770.2:c.167T>C, XM_017028487.1:c.14T>C, XR_937576.2:n.393T>C, ENST00000300305.7:c.167T>C, ENST00000344691.8:c.86T>C, ENST00000358356.9:c.86T>C, ENST00000399237.6:c.131T>C, ENST00000399240.5:c.86T>C, ENST00000437180.5:c.167T>C, ENST00000455571.5:c.128T>C, ENST00000482318.5:c.59-6314T>C, NM_001754.4(RUNX1):c.167T>C (p.Leu56Ser)	RUNX1	hereditary thrombocytopenia with normal platelets-hematological cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Benign	BP2, BA1, BS3	PM6, PM2, PVS1, PM1, PM4, PM5, PP1, PP3, BP4, PS4, PS3, PS1, BP7, BS4, BS1	The NM_001754.4:c.167T>C (p.Leu56Ser) variant has a MAF of 0.03259 (3.259%, 518/15,894 alleles) in the South Asian subpopulation of the ExAC cohort that is ≥ 0.0015 (0.15%) (BA1). This variant is detected in homozygous state (56) in gnomAD population database (BP2). Transactivation assays demonstrating normal transactivation (80-115% of wt) and data from secondary assays demonstrate normal DNA binding, CBFβ binding and sub-cellular localization (BS3; PMID: 23817177). Two patients reported in PMID:29365323 with AML. But PS4 can not apply in combined with BA1. In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the ClinGen Myeloid Malignancy Variant Curation Expert Panel for RUNX1: BA1, BS3, BP2.	23817177	Myeloid Malignancy VCEP	https://www.clinicalgenome.org/affiliation/50034/docs/assertion-criteria 	2019-07-26	2019-08-02	False	https://erepo.genome.network/evrepo/ui/classification/CA10014578/MONDO:0011071/008	36a19c90-310a-4c8f-ad1d-8f186170daaa	p.Leu56Ser	Leu	56	Ser	MRIPVDASTSRRFTPPSTALSPGKMSEALPLGAPDAGAALAGKLRSGDRSMVEVLADHPGELVRTDSPNFLCSVLPTHWRCNKTLPIAFKVVALGDVPDGTLVTVMAGNDENYSAELRNATAAMKNQVARFNDLRFVGRSGRGKSFTLTITVFTNPPQVATYHRAIKITVDGPREPRRHRQKLDDQTKPGSLSFSERLSELEQLRRTAMRVSPHHPAPTPNPRASLNHSTAFNPQPQSQMQDTRQIQPSPPWSYDQSYQYLGSIASPSVHPATPISPGRASGMTTLSAELSSRLSTAPDLTAFSDPRQFPALPSISDPRMHYPGAFTYSPTPVTSGIGIGMSAMGSATRYHTYLPPPYPGSSQAQGGPFQASSPSYHLYYGASAGSYQFSMVGGERSPPRILPPCTNASTGSALLNPSLPNQSDVVEAEGSHSNSPTNMAPSARLEEAVWRPY	453	Q01196	S	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [59], 'DNA_BIND_gain': [], 'DNA_BIND_loss_score': array([-0.10057449]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [8], 'TRANSIT_gain': [], 'TRANSIT_loss_score': array([-0.01375258]), 'STRAND_loss': [], 'STRAND_gain': [52], 'STRAND_gain_score': array([0.08828223]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [114], 'REGION_gain': [], 'REGION_loss_score': array([-0.00555158]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
150	NM_022124.5(CDH23):c.2866G>A (p.Glu956Lys)	444219	CA5544361	NM_022124.5:c.2866G>A, NC_000010.11:g.71705043G>A, CM000672.2:g.71705043G>A, NC_000010.10:g.73464800G>A, CM000672.1:g.73464800G>A, NC_000010.9:g.73134806G>A, NG_008835.1:g.313097G>A, ENST00000224721.12:c.2866G>A, ENST00000398809.9:c.2866G>A, ENST00000442677.4:c.2866G>A, ENST00000466757.8:c.2297G>A, ENST00000224721.10:c.2881G>A, ENST00000299366.11:c.2866G>A, ENST00000398809.8:c.2866G>A, ENST00000442677.3:c.1641G>A, ENST00000466757.7:c.2297G>A, ENST00000616684.4:c.2866G>A, ENST00000622827.4:c.2866G>A, NM_001171930.1:c.2866G>A, NM_001171931.1:c.2866G>A, XM_006717940.2:c.3061G>A, XM_006717942.2:c.2995G>A, XM_011540039.1:c.3061G>A, XM_011540040.1:c.3055G>A, XM_011540041.1:c.3001G>A, XM_011540042.1:c.3061G>A, XM_011540043.1:c.3061G>A, XM_011540044.1:c.2926G>A, XM_011540045.1:c.3061G>A, XM_011540046.1:c.2521G>A, XM_011540047.1:c.1879G>A, XM_011540048.1:c.3061G>A, XM_011540049.1:c.3061G>A, XM_011540050.1:c.3061G>A, XM_011540051.1:c.3061G>A, XM_011540053.1:c.3061G>A, XM_011540054.1:c.3001G>A, XR_945796.1:n.3304G>A, XR_946052.1:n.83-448C>T, NM_001171930.2:c.2866G>A, NM_001171931.2:c.2866G>A, NM_022124.6:c.2866G>A, NM_022124.6(CDH23):c.2866G>A (p.Glu956Lys), NM_022124.5(CDH23):c.2866G>A (p.Glu956Lys)	CDH23	sensorineural hearing loss disorder	MONDO:0020678	Autosomal recessive inheritance	Pathogenic	PM5, PP3, PM3_Very Strong	PM2, BP4	The p.Glu956Lys variant in CDH23 is a missense variant predicted to cause substitution of glutamic acid to lysine at amino acid 956. The highest population minor allele frequency in gnomAD v3.1.2 is 0.02895% (12/41444) in African/African American population which is greater than the PM2_Supporting thresholds defined by the ClinGen Hearing Loss Expert Panel (≤0.007%) and less than the BS1_supporting MAF of ≥0.0007 (0.07%) for autosomal recessive disorders (no codes met). The computational predictor REVEL produced a score of 0.616, which was just below the threshold to automatically apply PP3, but the Expert Panel decided to apply PP3 based upon manual review of alignments to examine homology. This variant has been detected in at least six probands with hearing loss without evidence of retinal disease (5 PM3_Very Strong points, PMID: 26763877,25963016, 22899989, Invitae Internal Data (SCV001228538.3)). Of those individuals, four harbored the p.Pro240Leu pathogenic variant in CDH23 with three individuals confirmed in trans (PMID 25963016, 22899989). The fifth individual harbored the p.Asp645Gly variant in CDH23, but phasing was not performed (PMID 25963016). The sixth proband carried a second pathogenic CDH23 variant in trans (Invitae Internal Data). 1 different missense variant, c.2867A>G (p.Glu956Gly) ClinVar Variation ID:1180655, in the same codon has been classified as likely pathogenic for AR sensorineural hearing loss by two submitters in ClinVar (PM5). In summary, this variant meets the criteria to be classified as pathogenic for AR hearing loss based on ACMG/AMP criteria applied, as specified by the ClinGen Hearing Loss VCEP; PP3, PM3_Very Strong, PM5. (The ClinGen Hearing Loss VCEP Specifications Version 2; 06/27/2023)		Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2023-06-27	2023-10-05	False	https://erepo.genome.network/evrepo/ui/classification/CA5544361/MONDO:0020678/005	ad55f8aa-c75a-44f6-9a6e-2344d0525a05	p.Glu956Lys	Glu	956	Lys	MGRHVATSCHVAWLLVLISGCWGQVNRLPFFTNHFFDTYLLISEDTPVGSSVTQLLAQDMDNDPLVFGVSGEEASRFFAVEPDTGVVWLRQPLDRETKSEFTVEFSVSDHQGVITRKVNIQVGDVNDNAPTFHNQPYSVRIPENTPVGTPIFIVNATDPDLGAGGSVLYSFQPPSQFFAIDSARGIVTVIRELDYETTQAYQLTVNATDQDKTRPLSTLANLAIIITDVQDMDPIFINLPYSTNIYEHSPPGTTVRIITAIDQDKGRPRGIGYTIVSGNTNSIFALDYISGVLTLNGLLDRENPLYSHGFILTVKGTELNDDRTPSDATVTTTFNILVIDINDNAPEFNSSEYSVAITELAQVGFALPLFIQVVDKDENLGLNSMFEVYLVGNNSHHFIISPTSVQGKADIRIRVAIPLDYETVDRYDFDLFANESVPDHVGYAKVKITLINENDNRPIFSQPLYNISLYENVTVGTSVLTVLATDNDAGTFGEVSYFFSDDPDRFSLDKDTGLIMLIARLDYELIQRFTLTIIARDGGGEETTGRVRINVLDVNDNVPTFQKDAYVGALRENEPSVTQLVRLRATDEDSPPNNQITYSIVSASAFGSYFDISLYEGYGVISVSRPLDYEQISNGLIYLTVMAMDAGNPPLNSTVPVTIEVFDENDNPPTFSKPAYFVSVVENIMAGATVLFLNATDLDRSREYGQESIIYSLEGSTQFRINARSGEITTTSLLDRETKSEYILIVRAVDGGVGHNQKTGIATVNITLLDINDNHPTWKDAPYYINLVEMTPPDSDVTTVVAVDPDLGENGTLVYSIQPPNKFYSLNSTTGKIRTTHAMLDRENPDPHEAELMRKIVVSVTDCGRPPLKATSSATVFVNLLDLNDNDPTFQNLPFVAEVLEGIPAGVSIYQVVAIDLDEGLNGLVSYRMPVGMPRMDFLINSSSGVVVTTTELDRERIAEYQLRVVASDAGTPTKSSTSTLTIHVLDVNDETPTFFPAVYNVSVSEDVPREFRVVWLNCTDNDVGLNAELSYFITGGNVDGKFSVGYRDAVVRTVVGLDRETTAAYMLILEAIDNGPVGKRHTGTATVFVTVLDVNDNRPIFLQSSYEASVPEDIPEGHSILQLKATDADEGEFGRVWYRILHGNHGNNFRIHVSNGLLMRGPRPLDRERNSSHVLIVEAYNHDLGPMRSSVRVIVYVEDINDEAPVFTQQQYSRLGLRETAGIGTSVIVVQATDRDSGDGGLVNYRILSGAEGKFEIDESTGLIITVNYLDYETKTSYMMNVSATDQAPPFNQGFCSVYITLLNELDEAVQFSNASYEAAILENLALGTEIVRVQAYSIDNLNQITYRFNAYTSTQAKALFKIDAITGVITVQGLVDREKGDFYTLTVVADDGGPKVDSTVKVYITVLDENDNSPRFDFTSDSAVSIPEDCPVGQRVATVKAWDPDAGSNGQVVFSLASGNIAGAFEIVTTNDSIGEVFVARPLDREELDHYILQVVASDRGTPPRKKDHILQVTILDINDNPPVIESPFGYNVSVNENVGGGTAVVQVRATDRDIGINSVLSYYITEGNKDMAFRMDRISGEIATRPAPPDRERQSFYHLVATVEDEGTPTLSATTHVYVTIVDENDNAPMFQQPHYEVLLDEGPDTLNTSLITIQALDLDEGPNGTVTYAIVAGNIVNTFRIDRHMGVITAAKELDYEISHGRYTLIVTATDQCPILSHRLTSTTTVLVNVNDINDNVPTFPRDYEGPFEVTEGQPGPRVWTFLAHDRDSGPNGQVEYSIMDGDPLGEFVISPVEGVLRVRKDVELDRETIAFYNLTICARDRGMPPLSSTMLVGIRVLDINDNDPVLLNLPMNITISENSPVSSFVAHVLASDADSGCNARLTFNITAGNRERAFFINATTGIVTVNRPLDRERIPEYKLTISVKDNPENPRIARRDYDLLLIFLSDENDNHPLFTKSTYQAEVMENSPAGTPLTVLNGPILALDADQDIYAVVTYQLLGAQSGLFDINSSTGVVTVRSGVIIDREAFSPPILELLLLAEDIGLLNSTAHLLITILDDNDNRPTFSPATLTVHLLENCPPGFSVLQVTATDEDSGLNGELVYRIEAGAQDRFLIHLVTGVIRVGNATIDREEQESYRLTVVATDRGTVPLSGTAIVTILIDDINDSRPEFLNPIQTVSVLESAEPGTVIANITAIDHDLNPKLEYHIVGIVAKDDTDRLVPNQEDAFAVNINTGSVMVKSPMNRELVATYEVTLSVIDNASDLPERSVSVPNAKLTVNVLDVNDNTPQFKPFGITYYMERILEGATPGTTLIAVAAVDPDKGLNGLVTYTLLDLVPPGYVQLEDSSAGKVIANRTVDYEEVHWLNFTVRASDNGSPPRAAEIPVYLEIVDINDNNPIFDQPSYQEAVFEDVPVGTIILTVTATDADSGNFALIEYSLGDGESKFAINPTTGDIYVLSSLDREKKDHYILTALAKDNPGDVASNRRENSVQVVIQVLDVNDCRPQFSKPQFSTSVYENEPAGTSVITMMATDQDEGPNGELTYSLEGPGVEAFHVDMDSGLVTTQRPLQSYEKFSLTVVATDGGEPPLWGTTMLLVEVIDVNDNRPVFVRPPNGTILHIREEIPLRSNVYEVYATDKDEGLNGAVRYSFLKTAGNRDWEFFIIDPISGLIQTAQRLDRESQAVYSLILVASDLGQPVPYETMQPLQVALEDIDDNEPLFVRPPKGSPQYQLLTVPEHSPRGTLVGNVTGAVDADEGPNAIVYYFIAAGNEEKNFHLQPDGCLLVLRDLDREREAIFSFIVKASSNRSWTPPRGPSPTLDLVADLTLQEVRVVLEDINDQPPRFTKAEYTAGVATDAKVGSELIQVLALDADIGNNSLVFYSILAIHYFRALANDSEDVGQVFTMGSMDGILRTFDLFMAYSPGYFVVDIVARDLAGHNDTAIIGIYILRDDQRVKIVINEIPDRVRGFEEEFIHLLSNITGAIVNTDNVQFHVDKKGRVNFAQTELLIHVVNRDTNRILDVDRVIQMIDENKEQLRNLFRNYNVLDVQPAISVRLPDDMSALQMAIIVLAILLFLAAMLFVLMNWYYRTVHKRKLKAIVAGSAGNRGFIDIMDMPNTNKYSFDGANPVWLDPFCRNLELAAQAEHEDDLPENLSEIADLWNSPTRTHGTFGREPAAVKPDDDRYLRAAIQEYDNIAKLGQIIREGPIKGSLLKVVLEDYLRLKKLFAQRMVQKASSCHSSISELIQTELDEEPGDHSPGQGSLRFRHKPPVELKGPDGIHVVHGSTGTLLATDLNSLPEEDQKGLGRSLETLTAAEATAFERNARTESAKSTPLHKLRDVIMETPLEITEL	3354	Q9H251	K	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [944, 1064, 1122, 2196], 'STRAND_gain': [2072, 2158, 2240, 2278, 2280, 2296, 2352], 'STRAND_gain_score': array([0.00799233, 0.12406468, 0.02842689, 0.01986271, 0.0166353 ,
       0.00173408, 0.00457454]), 'STRAND_loss_score': array([-0.0373134 , -0.00496459, -0.00212991, -0.0470643 ]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [251, 462, 1793, 1802, 1807, 1810, 1812, 1923, 1928, 2018, 2023, 2026, 2030, 2032, 2033, 2034, 2035, 2039, 2042, 2789, 3283, 3334, 3335, 3336, 3337, 3338, 3339], 'DOMAIN_gain': [2175, 2178, 2194, 2199, 2200, 2202, 2204, 2206, 2207, 2208, 2209, 2212, 2234, 2235, 2237, 2278, 2279], 'DOMAIN_gain_score': array([0.20798254, 0.16023266, 0.20276666, 0.2969318 , 0.24546236,
       0.13098443, 0.15815419, 0.22929031, 0.19554776, 0.2131753 ,
       0.21223927, 0.19578868, 0.04080856, 0.08317941, 0.11350763,
       0.14504892, 0.04987025]), 'DOMAIN_loss_score': array([-0.01852268, -0.0224182 , -0.01730913, -0.0154168 , -0.01855671,
       -0.03037208, -0.02970183, -0.02847821, -0.05274242, -0.07266891,
       -0.06540567, -0.06919712, -0.07321441, -0.09654963, -0.11482257,
       -0.1271587 , -0.12312561, -0.13063526, -0.12515134, -0.01143992,
       -0.02551663, -0.16451418, -0.19635636, -0.15614235, -0.11250514,
       -0.13673437, -0.11276448]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
151	NM_206933.2(USH2A):c.2276G>T (p.Cys759Phe)	2356	CA252233	NM_206933.2:c.2276G>T, NC_000001.11:g.216247118C>A, CM000663.2:g.216247118C>A, NC_000001.10:g.216420460C>A, CM000663.1:g.216420460C>A, NC_000001.9:g.214487083C>A, NG_009497.1:g.181279G>T, NM_007123.5:c.2276G>T, NM_206933.3:c.2276G>T, ENST00000307340.7:c.2276G>T, ENST00000366942.3:c.2276G>T, NM_206933.2(USH2A):c.2276G>T (p.Cys759Phe)	USH2A	Usher syndrome	MONDO:0019501	Autosomal recessive inheritance	Pathogenic	PS4, PM3_Strong, PP1_Strong, BS1, PP4, PP3	PS2, PS3, PS1, PM1, PM4, PM5, BP5, BP7, BS4, PVS1, PM6, PM2, BS2, BP2, BP3, BP4, BA1	The p.Cys759Phe variant in USH2A has been reported in 10 individuals with a clinical diagnosis of Usher Syndrome type II who were all confirmed compound heterozygous with a second pathogenic variant on the remaining allele (PMIDs: 16098008, 24944099, 29912909) (PM3_Strong). Note that scoring for PM3 was downgraded from PM3_VeryStrong to PM3_Strong since this variant has an allele frequency that meets criteria for BS1 (see below). Co-segregation with Usher II was demonstrated collectively in 2 affected and 13 unaffected siblings (LOD score: 2.23). When including all families affected with Usher II or an atypical Usher presentation (retinitis pigmentosa (RP) with some form of hearing loss), co-segregation can be identified in three affected and 26 unaffected siblings total (LOD score: 4.45) (PMID: 29912909) (PP1_Strong). When considering those patients who present with isolated RP, the variant segregated in an additional 15 affected and 32 unaffected siblings (LOD score: 12.43) (PMIDs:10775529, 12525556, 21151602, 29912909). The filtering allele frequency (the lower threshold of the 95% CI of 72/35410) of the p.Cys759Phe variant in the Latino population in gnomAD is 0.17% and it has also been observed at the filtering allele frequency (the lower threshold of the 95% CI of 17/2536) of 0.43% across several Spanish or Latino populations published in the literature (PMIDs: 12525556, 12112664, 25262649, 26764160, 25261458, 25823529; BS1). Although this allele frequency meets the threshold defined by the ClinGen Hearing Loss Expert Panel for considering strong evidence against pathogenicity for autosomal recessive hearing loss variants, other studies suggest it may still be associated with Usher syndrome, albeit with potentially reduced penetrance. The variant is statistically enriched in cohorts of Usher (2.00% (54/2704) in Usher patients compared to 0.67% (17/2536) as the highest and most ethnically matched published Spanish and Latino control populations; Fisher’s exact p value <0.0001) and RP patients (1.87% (109/5828) in RP patients compared to 0.71% in published Spanish and Latino controls; Chi-Square p value <0.0001) (PMIDs: 12525556, 12112664, 25262649, 26764160, 25261458, 25823529, 10909849, 12112664, 14970843, 15325563, 16098008, 17405132, 18273898, 19683999, 22004887, 21738395, 24944099, 25375654, 28041643, 29588463, 21151602, 25097241, 23591405, 25910913, 25649381, 29283788, 22135276, 22334370) (PS4).  The association with Usher syndrome is particularly clear when paired with a predicted loss-of-function or other pathogenic variant compared to homozygous individuals who are more at risk to develop non-syndromic RP (PMIDs: 29912909 and 25375654). There may also be evidence of reduced penetrance for both hearing loss and RP as two homozygous individuals were documented to have no evidence of any phenotype through their 6th decade (PMIDs: 16098008, 12525556). The PP4 rule has also been applied to this variant given the combination of hearing loss and RP that is seen in these patients and that most patients were screened for other Usher genes. Lastly, computational prediction tools and conservation analysis suggest that the p.Cys759Phe variant may impact the protein (REVEL: 0.902), and an analysis using the homologous mouse laminin gamma 1 chain concluded that this variant is likely to disrupt disulfide bonding with the cysteine at position 747 (PMID: 10909849) (PP3). In summary, the ClinGen Hearing Loss Expert Panel believes that the evidence for the pathogenicity of this variant for Usher Syndrome outweighs its higher than expected allele frequency in population databases and other general population cohorts. Therefore, the BS1 code will not contribute to the overall classification. In summary, this variant meets criteria to be classified as pathogenic for Usher syndrome (ACMG codes applied: BS1, PS4, PM3_Strong, PP1_Strong, PP4, and PP3). Please note that patients with this variant may present with either Usher syndrome or with isolated RP. Isolated RP presentations are more common when the variant is seen in homozygosity as opposed to combined with a distinct pathogenic USH2A variant.	25261458, 25823529, 26764160, 25262649	Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2019-07-28	2019-08-16	False	https://erepo.genome.network/evrepo/ui/classification/CA252233/MONDO:0019501/005	3b9c6310-7e67-431a-a1be-4962b9e7f495	p.Cys759Phe	Cys	759	Phe	MNCPVLSLGSGFLFQVIEMLIFAYFASISLTESRGLFPRLENVGAFKKVSIVPTQAVCGLPDRSTFCHSSAAAESIQFCTQRFCIQDCPYRSSHPTYTALFSAGLSSCITPDKNDLHPNAHSNSASFIFGNHKSCFSSPPSPKLMASFTLAVWLKPEQQGVMCVIEKTVDGQIVFKLTISEKETMFYYRTVNGLQPPIKVMTLGRILVKKWIHLSVQVHQTKISFFINGVEKDHTPFNARTLSGSITDFASGTVQIGQSLNGLEQFVGRMQDFRLYQVALTNREILEVFSGDLLRLHAQSHCRCPGSHPRVHPLAQRYCIPNDAGDTADNRVSRLNPEAHPLSFVNDNDVGTSWVSNVFTNITQLNQGVTISVDLENGQYQVFYIIIQFFSPQPTEIRIQRKKENSLDWEDWQYFARNCGAFGMKNNGDLEKPDSVNCLQLSNFTPYSRGNVTFSILTPGPNYRPGYNNFYNTPSLQEFVKATQIRFHFHGQYYTTETAVNLRHRYYAVDEITISGRCQCHGHADNCDTTSQPYRCLCSQESFTEGLHCDRCLPLYNDKPFRQGDQVYAFNCKPCQCNSHSKSCHYNISVDPFPFEHFRGGGGVCDDCEHNTTGRNCELCKDYFFRQVGADPSAIDVCKPCDCDTVGTRNGSILCDQIGGQCNCKRHVSGRQCNQCQNGFYNLQELDPDGCSPCNCNTSGTVDGDITCHQNSGQCKCKANVIGLRCDHCNFGFKFLRSFNDVGCEPCQCNLHGSVNKFCNPHSGQCECKKEAKGLQCDTCRENFYGLDVTNCKACDCDTAGSLPGTVCNAKTGQCICKPNVEGRQCNKCLEGNFYLRQNNSFLCLPCNCDKTGTINGSLLCNKSTGQCPCKLGVTGLRCNQCEPHRYNLTIDNFQHCQMCECDSLGTLPGTICDPISGQCLCVPNRQGRRCNQCQPGFYISPGNATGCLPCSCHTTGAVNHICNSLTGQCVCQDASIAGQRCDQCKDHYFGFDPQTGRCQPCNCHLSGALNETCHLVTGQCFCKQFVTGSKCDACVPSASHLDVNNLLGCSKTPFQQPPPRGQVQSSSAINLSWSPPDSPNAHWLTYSLLRDGFEIYTTEDQYPYSIQYFLDTDLLPYTKYSYYIETTNVHGSTRSVAVTYKTKPGVPEGNLTLSYIIPIGSDSVTLTWTTLSNQSGPIEKYILSCAPLAGGQPCVSYEGHETSATIWNLVPFAKYDFSVQACTSGGCLHSLPITVTTAQAPPQRLSPPKMQKISSTELHVEWSPPAELNGIIIRYELYMRRLRSTKETTSEESRVFQSSGWLSPHSFVESANENALKPPQTMTTITGLEPYTKYEFRVLAVNMAGSVSSAWVSERTGESAPVFMIPPSVFPLSSYSLNISWEKPADNVTRGKVVGYDINMLSEQSPQQSIPMAFSQLLHTAKSQELSYTVEGLKPYRIYEFTITLCNSVGCVTSASGAGQTLAAAPAQLRPPLVKGINSTTIHLRWFPPEELNGPSPIYQLERRESSLPALMTTMMKGIRFIGNGYCKFPSSTHPVNTDFTGIKASFRTKVPEGLIVFAASPGNQEEYFALQLKKGRLYFLFDPQGSPVEVTTTNDHGKQYSDGKWHEIIAIRHQAFGQITLDGIYTGSSAILNGSTVIGDNTGVFLGGLPRSYTILRKDPEIIQKGFVGCLKDVHFMKNYNPSAIWEPLDWQSSEEQINVYNSWEGCPASLNEGAQFLGAGFLELHPYMFHGGMNFEISFKFRTDQLNGLLLFVYNKDGPDFLAMELKSGILTFRLNTSLAFTQVDLLLGLSYCNGKWNKVIIKKEGSFISASVNGLMKHASESGDQPLVVNSPVYVGGIPQELLNSYQHLCLEQGFGGCMKDVKFTRGAVVNLASVSSGAVRVNLDGCLSTDSAVNCRGNDSILVYQGKEQSVYEGGLQPFTEYLYRVIASHEGGSVYSDWSRGRTTGAAPQSVPTPSRVRSLNGYSIEVTWDEPVVRGVIEKYILKAYSEDSTRPPRMPSASAEFVNTSNLTGILTGLLPFKNYAVTLTACTLAGCTESSHALNISTPQEAPQEVQPPVAKSLPSSLLLSWNPPKKANGIITQYCLYMDGRLIYSGSEENYIVTDLAVFTPHQFLLSACTHVGCTNSSWVLLYTAQLPPEHVDSPVLTVLDSRTIHIQWKQPRKISGILERYVLYMSNHTHDFTIWSVIYNSTELFQDHMLQYVLPGNKYLIKLGACTGGGCTVSEASEALTDEDIPEGVPAPKAHSYSPDSFNVSWTEPEYPNGVITSYGLYLDGILIHNSSELSYRAYGFAPWSLHSFRVQACTAKGCALGPLVENRTLEAPPEGTVNVFVKTQGSRKAHVRWEAPFRPNGLLTHSVLFTGIFYVDPVGNNYTLLNVTKVMYSGEETNLWVLIDGLVPFTNYTVQVNISNSQGSLITDPITIAMPPGAPDGVLPPRLSSATPTSLQVVWSTPARNNAPGSPRYQLQMRSGDSTHGFLELFSNPSASLSYEVSDLQPYTEYMFRLVASNGFGSAHSSWIPFMTAEDKPGPVVPPILLDVKSRMMLVTWQHPRKSNGVITHYNIYLHGRLYLRTPGNVTNCTVMHLHPYTAYKFQVEACTSKGCSLSPESQTVWTLPGAPEGIPSPELFSDTPTSVIISWQPPTHPNGLVENFTIERRVKGKEEVTTLVTLPRSHSMRFIDKTSALSPWTKYEYRVLMSTLHGGTNSSAWVEVTTRPSRPAGVQPPVVTVLEPDAVQVTWKPPLIQNGDILSYEIHMPDPHITLTNVTSAVLSQKVTHLIPFTNYSVTIVACSGGNGYLGGCTESLPTYVTTHPTVPQNVGPLSVIPLSESYVVISWQPPSKPNGPNLRYELLRRKIQQPLASNPPEDLNRWHNIYSGTQWLYEDKGLSRFTTYEYMLFVHNSVGFTPSREVTVTTLAGLPERGANLTASVLNHTAIDVRWAKPTVQDLQGEVEYYTLFWSSATSNDSLKILPDVNSHVIGHLKPNTEYWIFISVFNGVHSINSAGLHATTCDGEPQGMLPPEVVIINSTAVRVIWTSPSNPNGVVTEYSIYVNNKLYKTGMNVPGSFILRDLSPFTIYDIQVEVCTIYACVKSNGTQITTVEDTPSDIPTPTIRGITSRSLQIDWVSPRKPNGIILGYDLLWKTWYPCAKTQKLVQDQSDELCKAVRCQKPESICGHICYSSEAKVCCNGVLYNPKPGHRCCEEKYIPFVLNSTGVCCGGRIQEAQPNHQCCSGYYARILPGEVCCPDEQHNRVSVGIGDSCCGRMPYSTSGNQICCAGRLHDGHGQKCCGRQIVSNDLECCGGEEGVVYNRLPGMFCCGQDYVNMSDTICCSASSGESKAHIKKNDPVPVKCCETELIPKSQKCCNGVGYNPLKYVCSDKISTGMMMKETKECRILCPASMEATEHCGRCDFNFTSHICTVIRGSHNSTGKASIEEMCSSAEETIHTGSVNTYSYTDVNLKPYMTYEYRISAWNSYGRGLSKAVRARTKEDVPQGVSPPTWTKIDNLEDTIVLNWRKPIQSNGPIIYYILLRNGIERFRGTSLSFSDKEGIQPFQEYSYQLKACTVAGCATSSKVVAATTQGVPESILPPSITALSAVALHLSWSVPEKSNGVIKEYQIRQVGKGLIHTDTTDRRQHTVTGLQPYTNYSFTLTACTSAGCTSSEPFLGQTLQAAPEGVWVTPRHIIINSTTVELYWSLPEKPNGLVSQYQLSRNGNLLFLGGSEEQNFTDKNLEPNSRYTYKLEVKTGGGSSASDDYIVQTPMSTPEEIYPPYNITVIGPYSIFVAWIPPGILIPEIPVEYNVLLNDGSVTPLAFSVGHHQSTLLENLTPFTQYEIRIQACQNGSCGVSSRMFVKTPEAAPMDLNSPVLKALGSACIEIKWMPPEKPNGIIINYFIYRRPAGIEEESVLFVWSEGALEFMDEGDTLRPFTLYEYRVRACNSKGSVESLWSLTQTLEAPPQDFPAPWAQATSAHSVLLNWTKPESPNGIISHYRVVYQERPDDPTFNSPTVHAFTVKGTSHQAHLYGLEPFTTYRIGVVAANHAGEILSPWTLIQTLESSPSGLRNFIVEQKENGRALLLQWSEPMRTNGVIKTYNIFSDGFLEYSGLNRQFLFRRLDPFTLYTLTLEACTRAGCAHSAPQPLWTDEAPPDSQLAPTVHSVKSTSVELSWSEPVNPNGKIIRYEVIRRCFEGKAWGNQTIQADEKIVFTEYNTERNTFMYNDTGLQPWTQCEYKIYTWNSAGHTCSSWNVVRTLQAPPEGLSPPVISYVSMNPQKLLISWIPPEQSNGIIQSYRLQRNEMLYPFSFDPVTFNYTDEELLPFSTYSYALQACTSGGCSTSKPTSITTLEAAPSEVSPPDLWAVSATQMNVCWSPPTVQNGKITKYLVRYDNKESLAGQGLCLLVSHLQPYSQYNFSLVACTNGGCTASVSKSAWTMEALPENMDSPTLQVTGSESIEITWKPPRNPNGQIRSYELRRDGTIVYTGLETRYRDFTLTPGVEYSYTVTASNSQGGILSPLVKDRTSPSAPSGMEPPKLQARGPQEILVNWDPPVRTNGDIINYTLFIRELFERETKIIHINTTHNSFGMQSYIVNQLKPFHRYEIRIQACTTLGCASSDWTFIQTPEIAPLMQPPPHLEVQMAPGGFQPTVSLLWTGPLQPNGKVLYYELYRRQIATQPRKSNPVLIYNGSSTSFIDSELLPFTEYEYQVWAVNSAGKAPSSWTWCRTGPAPPEGLRAPTFHVISSTQAVVNISAPGKPNGIVSLYRLFSSSAHGAETVLSEGMATQQTLHGLQAFTNYSIGVEACTCFNCCSKGPTAELRTHPAPPSGLSSPQIGTLASRTASFRWSPPMFPNGVIHSYELQFHVACPPDSALPCTPSQIETKYTGLGQKASLGGLQPYTTYKLRVVAHNEVGSTASEWISFTTQKELPQYRAPFSVDSNLSVVCVNWSDTFLLNGQLKEYVLTDGGRRVYSGLDTTLYIPRTADKTFFFQVICTTDEGSVKTPLIQYDTSTGLGLVLTTPGKKKGSRSKSTEFYSELWFIVLMAMLGLILLAIFLSLILQRKIHKEPYIRERPPLVPLQKRMSPLNVYPPGENHMGLADTKIPRSGTPVSIRSNRSACVLRIPSQNQTSLTYSQGSLHRSVSQLMDIQDKKVLMDNSLWEAIMGHNSGLYVDEEDLMNAIKDFSSVTKERTTFTDTHL	5202	O75445	F	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [2607, 3167, 3881], 'DISULFID_gain_score': array([0.00195646, 0.00916815, 0.00221372]), 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [4190, 4477], 'STRAND_gain': [4604], 'STRAND_gain_score': array([0.00070536]), 'STRAND_loss_score': array([-0.00172645, -0.0010848 ]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [463, 4169, 4179, 4180, 4195], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.01925123, -0.03599435, -0.04185963, -0.04253709, -0.05059052]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [746, 748, 749, 752, 753, 754, 755, 756, 757, 758, 759, 760, 761, 762, 763, 764, 765, 766, 767, 768, 772], 'ZN_FING_gain': [675, 678, 681, 708, 714, 728, 731], 'ZN_FING_gain_score': array([0.02700192, 0.02527821, 0.02569354, 0.01686203, 0.01522279,
       0.01420206, 0.01361102]), 'ZN_FING_loss_score': array([-0.04324961, -0.04750443, -0.07789648, -0.11567783, -0.11568356,
       -0.10405523, -0.2116015 , -0.18882608, -0.08429867, -0.14447606,
       -0.16220033, -0.1175192 , -0.12413377, -0.10608262, -0.09134698,
       -0.14316201, -0.10780782, -0.06759757, -0.06554252, -0.07190794,
       -0.03352004])}"
152	NM_206933.4(USH2A):c.956G>A (p.Cys319Tyr)	2355	CA252231	NM_206933.4:c.956G>A, NC_000001.11:g.216325492C>T, CM000663.2:g.216325492C>T, NC_000001.10:g.216498834C>T, CM000663.1:g.216498834C>T, NC_000001.9:g.214565457C>T, NG_009497.1:g.102905G>A, NG_009497.2:g.102957G>A, ENST00000307340.8:c.956G>A, ENST00000674083.1:c.956G>A, ENST00000307340.7:c.956G>A, ENST00000366942.3:c.956G>A, NM_007123.5:c.956G>A, NM_206933.2:c.956G>A, NM_206933.3:c.956G>A, NM_007123.6:c.956G>A, NM_206933.4(USH2A):c.956G>A (p.Cys319Tyr)	USH2A	Usher syndrome	MONDO:0019501	Autosomal recessive inheritance	Pathogenic	PP1, PP4, PM3_Very Strong	BS1, PM2, PP3, BP4, BA1	The c.956G>A variant in USH2A is a missense variant predicted to cause substitution of cysteine by tyrosine at amino acid 319. The highest population minor allele frequency in gnomAD v2.1.1 is 0.0002679 (15/34508 alleles) in the Latino/Admixed American population (PM2_Supporting, BS1, and BA1 are not met). The computational predictor REVEL gives a score of 0.524, which is neither above nor below the thresholds predicting a damaging or benign impact on USH2A function. At least one patient was homozygous for this variant and displayed moderate to severe sensorineural hearing loss and progressive retinitis pigmentosa, which is highly specific for Usher syndrome (PP4, PMID:10729113). This variant has been detected in 5 individuals with Usher syndrome. For 5 of those individuals, 4 were compound heterozygous for the variant and a pathogenic or likely pathogenic variant and all of those were confirmed in trans by family testing (c.3408T>A (p.Ser1136Arg), c.12067-2A>G, c.5329C>T (p.Arg1777Trp), c.15089C>A (p.S5030X)), (4 PM3 points, PMID: 26969326, 33089500, LMM internal data, EGL internal data). One individual was homozygous for the variant (0.5 PM3 points, PMID:10729113) (PM3_VeryStrong). One of the individuals who was compound heterozygous for the variant and another pathogenic variant in USH2A (RCV000599950.1), had an affected sibling in whom both variants segregated (PP1). In summary, this variant meets the criteria to be classified as pathogenic for autosomal recessive Usher syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen Hearing Loss VCEP: PP4, PM3_VS, PP1 (Hearing Loss VCEP specifications version 2; 6/15/2022).	10729113, 26969326	Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2022-08-03	2022-08-03	False	https://erepo.genome.network/evrepo/ui/classification/CA252231/MONDO:0019501/005	de5c11cc-0c72-45e3-a3d9-8708277e343d	p.Cys319Tyr	Cys	319	Tyr	MNCPVLSLGSGFLFQVIEMLIFAYFASISLTESRGLFPRLENVGAFKKVSIVPTQAVCGLPDRSTFCHSSAAAESIQFCTQRFCIQDCPYRSSHPTYTALFSAGLSSCITPDKNDLHPNAHSNSASFIFGNHKSCFSSPPSPKLMASFTLAVWLKPEQQGVMCVIEKTVDGQIVFKLTISEKETMFYYRTVNGLQPPIKVMTLGRILVKKWIHLSVQVHQTKISFFINGVEKDHTPFNARTLSGSITDFASGTVQIGQSLNGLEQFVGRMQDFRLYQVALTNREILEVFSGDLLRLHAQSHCRCPGSHPRVHPLAQRYCIPNDAGDTADNRVSRLNPEAHPLSFVNDNDVGTSWVSNVFTNITQLNQGVTISVDLENGQYQVFYIIIQFFSPQPTEIRIQRKKENSLDWEDWQYFARNCGAFGMKNNGDLEKPDSVNCLQLSNFTPYSRGNVTFSILTPGPNYRPGYNNFYNTPSLQEFVKATQIRFHFHGQYYTTETAVNLRHRYYAVDEITISGRCQCHGHADNCDTTSQPYRCLCSQESFTEGLHCDRCLPLYNDKPFRQGDQVYAFNCKPCQCNSHSKSCHYNISVDPFPFEHFRGGGGVCDDCEHNTTGRNCELCKDYFFRQVGADPSAIDVCKPCDCDTVGTRNGSILCDQIGGQCNCKRHVSGRQCNQCQNGFYNLQELDPDGCSPCNCNTSGTVDGDITCHQNSGQCKCKANVIGLRCDHCNFGFKFLRSFNDVGCEPCQCNLHGSVNKFCNPHSGQCECKKEAKGLQCDTCRENFYGLDVTNCKACDCDTAGSLPGTVCNAKTGQCICKPNVEGRQCNKCLEGNFYLRQNNSFLCLPCNCDKTGTINGSLLCNKSTGQCPCKLGVTGLRCNQCEPHRYNLTIDNFQHCQMCECDSLGTLPGTICDPISGQCLCVPNRQGRRCNQCQPGFYISPGNATGCLPCSCHTTGAVNHICNSLTGQCVCQDASIAGQRCDQCKDHYFGFDPQTGRCQPCNCHLSGALNETCHLVTGQCFCKQFVTGSKCDACVPSASHLDVNNLLGCSKTPFQQPPPRGQVQSSSAINLSWSPPDSPNAHWLTYSLLRDGFEIYTTEDQYPYSIQYFLDTDLLPYTKYSYYIETTNVHGSTRSVAVTYKTKPGVPEGNLTLSYIIPIGSDSVTLTWTTLSNQSGPIEKYILSCAPLAGGQPCVSYEGHETSATIWNLVPFAKYDFSVQACTSGGCLHSLPITVTTAQAPPQRLSPPKMQKISSTELHVEWSPPAELNGIIIRYELYMRRLRSTKETTSEESRVFQSSGWLSPHSFVESANENALKPPQTMTTITGLEPYTKYEFRVLAVNMAGSVSSAWVSERTGESAPVFMIPPSVFPLSSYSLNISWEKPADNVTRGKVVGYDINMLSEQSPQQSIPMAFSQLLHTAKSQELSYTVEGLKPYRIYEFTITLCNSVGCVTSASGAGQTLAAAPAQLRPPLVKGINSTTIHLRWFPPEELNGPSPIYQLERRESSLPALMTTMMKGIRFIGNGYCKFPSSTHPVNTDFTGIKASFRTKVPEGLIVFAASPGNQEEYFALQLKKGRLYFLFDPQGSPVEVTTTNDHGKQYSDGKWHEIIAIRHQAFGQITLDGIYTGSSAILNGSTVIGDNTGVFLGGLPRSYTILRKDPEIIQKGFVGCLKDVHFMKNYNPSAIWEPLDWQSSEEQINVYNSWEGCPASLNEGAQFLGAGFLELHPYMFHGGMNFEISFKFRTDQLNGLLLFVYNKDGPDFLAMELKSGILTFRLNTSLAFTQVDLLLGLSYCNGKWNKVIIKKEGSFISASVNGLMKHASESGDQPLVVNSPVYVGGIPQELLNSYQHLCLEQGFGGCMKDVKFTRGAVVNLASVSSGAVRVNLDGCLSTDSAVNCRGNDSILVYQGKEQSVYEGGLQPFTEYLYRVIASHEGGSVYSDWSRGRTTGAAPQSVPTPSRVRSLNGYSIEVTWDEPVVRGVIEKYILKAYSEDSTRPPRMPSASAEFVNTSNLTGILTGLLPFKNYAVTLTACTLAGCTESSHALNISTPQEAPQEVQPPVAKSLPSSLLLSWNPPKKANGIITQYCLYMDGRLIYSGSEENYIVTDLAVFTPHQFLLSACTHVGCTNSSWVLLYTAQLPPEHVDSPVLTVLDSRTIHIQWKQPRKISGILERYVLYMSNHTHDFTIWSVIYNSTELFQDHMLQYVLPGNKYLIKLGACTGGGCTVSEASEALTDEDIPEGVPAPKAHSYSPDSFNVSWTEPEYPNGVITSYGLYLDGILIHNSSELSYRAYGFAPWSLHSFRVQACTAKGCALGPLVENRTLEAPPEGTVNVFVKTQGSRKAHVRWEAPFRPNGLLTHSVLFTGIFYVDPVGNNYTLLNVTKVMYSGEETNLWVLIDGLVPFTNYTVQVNISNSQGSLITDPITIAMPPGAPDGVLPPRLSSATPTSLQVVWSTPARNNAPGSPRYQLQMRSGDSTHGFLELFSNPSASLSYEVSDLQPYTEYMFRLVASNGFGSAHSSWIPFMTAEDKPGPVVPPILLDVKSRMMLVTWQHPRKSNGVITHYNIYLHGRLYLRTPGNVTNCTVMHLHPYTAYKFQVEACTSKGCSLSPESQTVWTLPGAPEGIPSPELFSDTPTSVIISWQPPTHPNGLVENFTIERRVKGKEEVTTLVTLPRSHSMRFIDKTSALSPWTKYEYRVLMSTLHGGTNSSAWVEVTTRPSRPAGVQPPVVTVLEPDAVQVTWKPPLIQNGDILSYEIHMPDPHITLTNVTSAVLSQKVTHLIPFTNYSVTIVACSGGNGYLGGCTESLPTYVTTHPTVPQNVGPLSVIPLSESYVVISWQPPSKPNGPNLRYELLRRKIQQPLASNPPEDLNRWHNIYSGTQWLYEDKGLSRFTTYEYMLFVHNSVGFTPSREVTVTTLAGLPERGANLTASVLNHTAIDVRWAKPTVQDLQGEVEYYTLFWSSATSNDSLKILPDVNSHVIGHLKPNTEYWIFISVFNGVHSINSAGLHATTCDGEPQGMLPPEVVIINSTAVRVIWTSPSNPNGVVTEYSIYVNNKLYKTGMNVPGSFILRDLSPFTIYDIQVEVCTIYACVKSNGTQITTVEDTPSDIPTPTIRGITSRSLQIDWVSPRKPNGIILGYDLLWKTWYPCAKTQKLVQDQSDELCKAVRCQKPESICGHICYSSEAKVCCNGVLYNPKPGHRCCEEKYIPFVLNSTGVCCGGRIQEAQPNHQCCSGYYARILPGEVCCPDEQHNRVSVGIGDSCCGRMPYSTSGNQICCAGRLHDGHGQKCCGRQIVSNDLECCGGEEGVVYNRLPGMFCCGQDYVNMSDTICCSASSGESKAHIKKNDPVPVKCCETELIPKSQKCCNGVGYNPLKYVCSDKISTGMMMKETKECRILCPASMEATEHCGRCDFNFTSHICTVIRGSHNSTGKASIEEMCSSAEETIHTGSVNTYSYTDVNLKPYMTYEYRISAWNSYGRGLSKAVRARTKEDVPQGVSPPTWTKIDNLEDTIVLNWRKPIQSNGPIIYYILLRNGIERFRGTSLSFSDKEGIQPFQEYSYQLKACTVAGCATSSKVVAATTQGVPESILPPSITALSAVALHLSWSVPEKSNGVIKEYQIRQVGKGLIHTDTTDRRQHTVTGLQPYTNYSFTLTACTSAGCTSSEPFLGQTLQAAPEGVWVTPRHIIINSTTVELYWSLPEKPNGLVSQYQLSRNGNLLFLGGSEEQNFTDKNLEPNSRYTYKLEVKTGGGSSASDDYIVQTPMSTPEEIYPPYNITVIGPYSIFVAWIPPGILIPEIPVEYNVLLNDGSVTPLAFSVGHHQSTLLENLTPFTQYEIRIQACQNGSCGVSSRMFVKTPEAAPMDLNSPVLKALGSACIEIKWMPPEKPNGIIINYFIYRRPAGIEEESVLFVWSEGALEFMDEGDTLRPFTLYEYRVRACNSKGSVESLWSLTQTLEAPPQDFPAPWAQATSAHSVLLNWTKPESPNGIISHYRVVYQERPDDPTFNSPTVHAFTVKGTSHQAHLYGLEPFTTYRIGVVAANHAGEILSPWTLIQTLESSPSGLRNFIVEQKENGRALLLQWSEPMRTNGVIKTYNIFSDGFLEYSGLNRQFLFRRLDPFTLYTLTLEACTRAGCAHSAPQPLWTDEAPPDSQLAPTVHSVKSTSVELSWSEPVNPNGKIIRYEVIRRCFEGKAWGNQTIQADEKIVFTEYNTERNTFMYNDTGLQPWTQCEYKIYTWNSAGHTCSSWNVVRTLQAPPEGLSPPVISYVSMNPQKLLISWIPPEQSNGIIQSYRLQRNEMLYPFSFDPVTFNYTDEELLPFSTYSYALQACTSGGCSTSKPTSITTLEAAPSEVSPPDLWAVSATQMNVCWSPPTVQNGKITKYLVRYDNKESLAGQGLCLLVSHLQPYSQYNFSLVACTNGGCTASVSKSAWTMEALPENMDSPTLQVTGSESIEITWKPPRNPNGQIRSYELRRDGTIVYTGLETRYRDFTLTPGVEYSYTVTASNSQGGILSPLVKDRTSPSAPSGMEPPKLQARGPQEILVNWDPPVRTNGDIINYTLFIRELFERETKIIHINTTHNSFGMQSYIVNQLKPFHRYEIRIQACTTLGCASSDWTFIQTPEIAPLMQPPPHLEVQMAPGGFQPTVSLLWTGPLQPNGKVLYYELYRRQIATQPRKSNPVLIYNGSSTSFIDSELLPFTEYEYQVWAVNSAGKAPSSWTWCRTGPAPPEGLRAPTFHVISSTQAVVNISAPGKPNGIVSLYRLFSSSAHGAETVLSEGMATQQTLHGLQAFTNYSIGVEACTCFNCCSKGPTAELRTHPAPPSGLSSPQIGTLASRTASFRWSPPMFPNGVIHSYELQFHVACPPDSALPCTPSQIETKYTGLGQKASLGGLQPYTTYKLRVVAHNEVGSTASEWISFTTQKELPQYRAPFSVDSNLSVVCVNWSDTFLLNGQLKEYVLTDGGRRVYSGLDTTLYIPRTADKTFFFQVICTTDEGSVKTPLIQYDTSTGLGLVLTTPGKKKGSRSKSTEFYSELWFIVLMAMLGLILLAIFLSLILQRKIHKEPYIRERPPLVPLQKRMSPLNVYPPGENHMGLADTKIPRSGTPVSIRSNRSACVLRIPSQNQTSLTYSQGSLHRSVSQLMDIQDKKVLMDNSLWEAIMGHNSGLYVDEEDLMNAIKDFSSVTKERTTFTDTHL	5202	O75445	Y	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [303, 318], 'DISULFID_gain': [3167, 3881], 'DISULFID_gain_score': array([0.00329274, 0.00223303]), 'DISULFID_loss_score': array([-0.03931069, -0.57922691]), 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [3940, 3998, 4000, 4190, 4477], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.00219065, -0.00316161, -0.00194108, -0.00279915, -0.00285459]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [393, 466, 4174, 4194, 4203, 4207, 4211, 4212, 4213, 4249, 4256, 4286], 'DOMAIN_gain_score': array([0.23470151, 0.07695293, 0.00290394, 0.0664919 , 0.05863869,
       0.06114149, 0.05256248, 0.04997492, 0.05538195, 0.03662711,
       0.06010312, 0.04043257]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': [675, 678, 681, 708, 714, 728, 731, 769], 'ZN_FING_gain_score': array([0.01014084, 0.01020759, 0.00969577, 0.01458383, 0.01097363,
       0.00875801, 0.01077867, 0.00579625])}"
153	NM_004360.5(CDH1):c.304G>A (p.Ala102Thr)	142578	CA294451	NM_004360.5:c.304G>A, NC_000016.10:g.68801810G>A, CM000678.2:g.68801810G>A, NC_000016.9:g.68835713G>A, CM000678.1:g.68835713G>A, NC_000016.8:g.67393214G>A, NG_008021.1:g.69519G>A, LRG_301:g.69519G>A, ENST00000261769.10:c.304G>A, ENST00000261769.9:c.304G>A, ENST00000422392.6:c.304G>A, ENST00000561751.1:n.71G>A, ENST00000562836.5:n.375G>A, ENST00000564676.5:n.586G>A, ENST00000564745.1:n.299G>A, ENST00000566510.5:c.304G>A, ENST00000566612.5:c.304G>A, ENST00000611625.4:c.304G>A, ENST00000612417.4:c.304G>A, ENST00000621016.4:c.304G>A, NM_004360.3:c.304G>A, LRG_301t1:c.304G>A, XM_011523488.1:c.-432G>A, XM_011523489.1:c.-432G>A, NM_001317184.1:c.304G>A, NM_001317185.1:c.-1312G>A, NM_001317186.1:c.-1516G>A, NM_004360.4:c.304G>A, NM_001317184.2:c.304G>A, NM_001317185.2:c.-1312G>A, NM_001317186.2:c.-1516G>A, NM_004360.5(CDH1):c.304G>A (p.Ala102Thr)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Benign	BS2, BP2, BS1	PP2, PP3, PP1, PP4, PS1, PS3, PS4, PS2, BP1, BP4, BP3, BA1, PM5, PM4, PM1, PM3, PVS1, PM2, PM6, BP5, BP7, BS3, BS4	The c.304G>A variant has an allele frequency of 0.00188 (0.19%, 58/30,780 alleles) in the South Asian subpopulation of the gnomAD 2.1.1 cohort (BS1; http://gnomad.broadinstitute.org). The variant was observed in the homozygous state in gnomAD 2.1.1 (BP2). The variant has also been observed in >10 individuals without a diagnosis of diffuse gastric cancer, signet ring tumor or lobular breast cancer and whose family histories do not suggest HDGC (BS2; SCV000210895.12; SCV000186827.5). Therefore, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): BS1, BS2, BP2 .	26911350	CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-10	2023-08-10	False	https://erepo.genome.network/evrepo/ui/classification/CA294451/MONDO:0007648/007	8f035f54-b2e9-48e3-9d30-9a4398d435a8	p.Ala102Thr	Ala	102	Thr	MGPWSRSLSALLLLLQVSSWLCQEPEPCHPGFDAESYTFTVPRRHLERGRVLGRVNFEDCTGRQRTAYFSLDTRFKVGTDGVITVKRPLRFHNPQIHFLVYAWDSTYRKFSTKVTLNTVGHHHRPPPHQASVSGIQAELLTFPNSSPGLRRQKRDWVIPPISCPENEKGPFPKNLVQIKSNKDKEGKVFYSITGQGADTPPVGVFIIERETGWLKVTEPLDRERIATYTLFSHAVSSNGNAVEDPMEILITVTDQNDNKPEFTQEVFKGSVMEGALPGTSVMEVTATDADDDVNTYNAAIAYTILSQDPELPDKNMFTINRNTGVISVVTTGLDRESFPTYTLVVQAADLQGEGLSTTATAVITVTDTNDNPPIFNPTTYKGQVPENEANVVITTLKVTDADAPNTPAWEAVYTILNDDGGQFVVTTNPVNNDGILKTAKGLDFEAKQQYILHVAVTNVVPFEVSLTTSTATVTVDVLDVNEAPIFVPPEKRVEVSEDFGVGQEITSYTAQEPDTFMEQKITYRIWRDTANWLEINPDTGAISTRAELDREDFEHVKNSTYTALIIATDNGSPVATGTGTLLLILSDVNDNAPIPEPRTIFFCERNPKPQVINIIDADLPPNTSPFTAELTHGASANWTIQYNDPTQESIILKPKMALEVGDYKINLKLMDNQNKDQVTTLEVSVCDCEGAAGVCRKAQPVEAGLQIPAILGILGGILALLILILLLLLFLRRRAVVKEPLLPPEDDTRDNVYYYDEEGGGEEDQDFDLSQLHRGLDARPEVTRNDVAPTLMSVPRYLPRPANPDEIGNFIDENLKAADTDPTAPPYDSLLVFDYEGSGSEAASLSSLNSSESDKDQDYDYLNEWGNRFKKLADMYGGGEDD	882	P12830	T	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [5], 'TRANSIT_gain': [], 'TRANSIT_loss_score': array([-0.00695556]), 'STRAND_loss': [52, 84], 'STRAND_gain': [678], 'STRAND_gain_score': array([0.00246465]), 'STRAND_loss_score': array([-0.11703593, -0.06541169]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
154	NM_022124.5(CDH23):c.719C>T (p.Pro240Leu)	4928	CA253338	NM_022124.5:c.719C>T, NC_000010.11:g.71570884C>T, CM000672.2:g.71570884C>T, NC_000010.10:g.73330641C>T, CM000672.1:g.73330641C>T, NC_000010.9:g.73000647C>T, NG_008835.1:g.178938C>T, NM_001171930.1:c.719C>T, NM_001171931.1:c.719C>T, NM_001171932.1:c.719C>T, NM_052836.3:c.719C>T, XM_006717940.2:c.854C>T, XM_006717942.2:c.854C>T, XM_011540039.1:c.854C>T, XM_011540040.1:c.854C>T, XM_011540041.1:c.854C>T, XM_011540042.1:c.854C>T, XM_011540043.1:c.854C>T, XM_011540044.1:c.719C>T, XM_011540045.1:c.854C>T, XM_011540046.1:c.314C>T, XM_011540048.1:c.854C>T, XM_011540049.1:c.854C>T, XM_011540050.1:c.854C>T, XM_011540051.1:c.854C>T, XM_011540053.1:c.854C>T, XM_011540054.1:c.854C>T, XR_246128.2:n.162-5750G>A, XR_945796.1:n.1097C>T, ENST00000224721.10:c.734C>T, ENST00000299366.11:c.719C>T, ENST00000398809.8:c.719C>T, ENST00000398842.7:c.470C>T, ENST00000461841.7:c.719C>T, ENST00000466757.7:n.90C>T, ENST00000616684.4:c.719C>T, ENST00000622827.4:c.719C>T, NM_022124.5(CDH23):c.719C>T (p.Pro240Leu)	CDH23	nonsyndromic genetic deafness	MONDO:0019497	Autosomal recessive inheritance	Pathogenic	PM3_Strong, PS4, PP1_Strong, PM2_Supporting	PP3, BP4	The allele frequency of the c.719C>T (p.Pro240Leu) variant in the CDH23 gene is 0.05% (10/17246) of East Asian chromosomes by gnomAD, which is a low enough frequency to apply PM2_Supporting based on the thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive hearing loss (PM2_Supporting). This variant has been reported in > 10 probands with hearing loss without evidence of retinal disease, including >5 homozygotes, at least 1 compound heterozygote with c.6712+1G>A variant, and >5 compound heterozygotes with rare variants of uncertain significance (PM3_Strong; PMID:24164807, 24618850, 25963016, 26264712, 17850630, 22899989). This variant has also segregated in 3 siblings with hearing loss (PP1_Strong, PMID: 17850630, 22899989). The variant was identified in the heterozygous state in a patient with Usher syndrome who also harbored a homozygous missense variant in MYO7A (PMID: 24618850). A case-control meta analysis found that the p.Pro240Leu variant was associated with a 12-fold higher risk of hearing loss compared to the wild-type allele (OR = 11.68; 95% CI = 3.16–43.24; PS4), though it should be noted that it appears that some probands were included in more than one study included in the meta-analysis (PMID 30367262). In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive hearing loss based on the ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel: PP1_Strong, PM3_Strong, PM2_Supporting, PS4.	25963016, 26264712, 24164807, 17850630, 24618850, 22899989, 30367262, 17850630, 22899989	Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2019-07-22	2019-10-17	False	https://erepo.genome.network/evrepo/ui/classification/CA253338/MONDO:0019497/005	bdc50191-a305-4375-b8cc-89088a4e5cac	p.Pro240Leu	Pro	240	Leu	MGRHVATSCHVAWLLVLISGCWGQVNRLPFFTNHFFDTYLLISEDTPVGSSVTQLLAQDMDNDPLVFGVSGEEASRFFAVEPDTGVVWLRQPLDRETKSEFTVEFSVSDHQGVITRKVNIQVGDVNDNAPTFHNQPYSVRIPENTPVGTPIFIVNATDPDLGAGGSVLYSFQPPSQFFAIDSARGIVTVIRELDYETTQAYQLTVNATDQDKTRPLSTLANLAIIITDVQDMDPIFINLPYSTNIYEHSPPGTTVRIITAIDQDKGRPRGIGYTIVSGNTNSIFALDYISGVLTLNGLLDRENPLYSHGFILTVKGTELNDDRTPSDATVTTTFNILVIDINDNAPEFNSSEYSVAITELAQVGFALPLFIQVVDKDENLGLNSMFEVYLVGNNSHHFIISPTSVQGKADIRIRVAIPLDYETVDRYDFDLFANESVPDHVGYAKVKITLINENDNRPIFSQPLYNISLYENVTVGTSVLTVLATDNDAGTFGEVSYFFSDDPDRFSLDKDTGLIMLIARLDYELIQRFTLTIIARDGGGEETTGRVRINVLDVNDNVPTFQKDAYVGALRENEPSVTQLVRLRATDEDSPPNNQITYSIVSASAFGSYFDISLYEGYGVISVSRPLDYEQISNGLIYLTVMAMDAGNPPLNSTVPVTIEVFDENDNPPTFSKPAYFVSVVENIMAGATVLFLNATDLDRSREYGQESIIYSLEGSTQFRINARSGEITTTSLLDRETKSEYILIVRAVDGGVGHNQKTGIATVNITLLDINDNHPTWKDAPYYINLVEMTPPDSDVTTVVAVDPDLGENGTLVYSIQPPNKFYSLNSTTGKIRTTHAMLDRENPDPHEAELMRKIVVSVTDCGRPPLKATSSATVFVNLLDLNDNDPTFQNLPFVAEVLEGIPAGVSIYQVVAIDLDEGLNGLVSYRMPVGMPRMDFLINSSSGVVVTTTELDRERIAEYQLRVVASDAGTPTKSSTSTLTIHVLDVNDETPTFFPAVYNVSVSEDVPREFRVVWLNCTDNDVGLNAELSYFITGGNVDGKFSVGYRDAVVRTVVGLDRETTAAYMLILEAIDNGPVGKRHTGTATVFVTVLDVNDNRPIFLQSSYEASVPEDIPEGHSILQLKATDADEGEFGRVWYRILHGNHGNNFRIHVSNGLLMRGPRPLDRERNSSHVLIVEAYNHDLGPMRSSVRVIVYVEDINDEAPVFTQQQYSRLGLRETAGIGTSVIVVQATDRDSGDGGLVNYRILSGAEGKFEIDESTGLIITVNYLDYETKTSYMMNVSATDQAPPFNQGFCSVYITLLNELDEAVQFSNASYEAAILENLALGTEIVRVQAYSIDNLNQITYRFNAYTSTQAKALFKIDAITGVITVQGLVDREKGDFYTLTVVADDGGPKVDSTVKVYITVLDENDNSPRFDFTSDSAVSIPEDCPVGQRVATVKAWDPDAGSNGQVVFSLASGNIAGAFEIVTTNDSIGEVFVARPLDREELDHYILQVVASDRGTPPRKKDHILQVTILDINDNPPVIESPFGYNVSVNENVGGGTAVVQVRATDRDIGINSVLSYYITEGNKDMAFRMDRISGEIATRPAPPDRERQSFYHLVATVEDEGTPTLSATTHVYVTIVDENDNAPMFQQPHYEVLLDEGPDTLNTSLITIQALDLDEGPNGTVTYAIVAGNIVNTFRIDRHMGVITAAKELDYEISHGRYTLIVTATDQCPILSHRLTSTTTVLVNVNDINDNVPTFPRDYEGPFEVTEGQPGPRVWTFLAHDRDSGPNGQVEYSIMDGDPLGEFVISPVEGVLRVRKDVELDRETIAFYNLTICARDRGMPPLSSTMLVGIRVLDINDNDPVLLNLPMNITISENSPVSSFVAHVLASDADSGCNARLTFNITAGNRERAFFINATTGIVTVNRPLDRERIPEYKLTISVKDNPENPRIARRDYDLLLIFLSDENDNHPLFTKSTYQAEVMENSPAGTPLTVLNGPILALDADQDIYAVVTYQLLGAQSGLFDINSSTGVVTVRSGVIIDREAFSPPILELLLLAEDIGLLNSTAHLLITILDDNDNRPTFSPATLTVHLLENCPPGFSVLQVTATDEDSGLNGELVYRIEAGAQDRFLIHLVTGVIRVGNATIDREEQESYRLTVVATDRGTVPLSGTAIVTILIDDINDSRPEFLNPIQTVSVLESAEPGTVIANITAIDHDLNPKLEYHIVGIVAKDDTDRLVPNQEDAFAVNINTGSVMVKSPMNRELVATYEVTLSVIDNASDLPERSVSVPNAKLTVNVLDVNDNTPQFKPFGITYYMERILEGATPGTTLIAVAAVDPDKGLNGLVTYTLLDLVPPGYVQLEDSSAGKVIANRTVDYEEVHWLNFTVRASDNGSPPRAAEIPVYLEIVDINDNNPIFDQPSYQEAVFEDVPVGTIILTVTATDADSGNFALIEYSLGDGESKFAINPTTGDIYVLSSLDREKKDHYILTALAKDNPGDVASNRRENSVQVVIQVLDVNDCRPQFSKPQFSTSVYENEPAGTSVITMMATDQDEGPNGELTYSLEGPGVEAFHVDMDSGLVTTQRPLQSYEKFSLTVVATDGGEPPLWGTTMLLVEVIDVNDNRPVFVRPPNGTILHIREEIPLRSNVYEVYATDKDEGLNGAVRYSFLKTAGNRDWEFFIIDPISGLIQTAQRLDRESQAVYSLILVASDLGQPVPYETMQPLQVALEDIDDNEPLFVRPPKGSPQYQLLTVPEHSPRGTLVGNVTGAVDADEGPNAIVYYFIAAGNEEKNFHLQPDGCLLVLRDLDREREAIFSFIVKASSNRSWTPPRGPSPTLDLVADLTLQEVRVVLEDINDQPPRFTKAEYTAGVATDAKVGSELIQVLALDADIGNNSLVFYSILAIHYFRALANDSEDVGQVFTMGSMDGILRTFDLFMAYSPGYFVVDIVARDLAGHNDTAIIGIYILRDDQRVKIVINEIPDRVRGFEEEFIHLLSNITGAIVNTDNVQFHVDKKGRVNFAQTELLIHVVNRDTNRILDVDRVIQMIDENKEQLRNLFRNYNVLDVQPAISVRLPDDMSALQMAIIVLAILLFLAAMLFVLMNWYYRTVHKRKLKAIVAGSAGNRGFIDIMDMPNTNKYSFDGANPVWLDPFCRNLELAAQAEHEDDLPENLSEIADLWNSPTRTHGTFGREPAAVKPDDDRYLRAAIQEYDNIAKLGQIIREGPIKGSLLKVVLEDYLRLKKLFAQRMVQKASSCHSSISELIQTELDEEPGDHSPGQGSLRFRHKPPVELKGPDGIHVVHGSTGTLLATDLNSLPEEDQKGLGRSLETLTAAEATAFERNARTESAKSTPLHKLRDVIMETPLEITEL	3354	Q9H251	L	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [368, 1122, 2833], 'STRAND_gain': [88, 237, 2866], 'STRAND_gain_score': array([0.00150365, 0.08233136, 0.00644088]), 'STRAND_loss_score': array([-0.00469089, -0.00060606, -0.00524372]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [251], 'DOMAIN_gain': [1808, 1822, 1823, 2790, 3275], 'DOMAIN_gain_score': array([0.00754458, 0.00795311, 0.01197064, 0.02486944, 0.00286263]), 'DOMAIN_loss_score': array([-0.02308649]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
155	NM_206933.2(USH2A):c.15433G>A (p.Val5145Ile)	48464	CA143401	NM_206933.2:c.15433G>A, NC_000001.11:g.215628900C>T, CM000663.2:g.215628900C>T, NC_000001.10:g.215802242C>T, CM000663.1:g.215802242C>T, NC_000001.9:g.213868865C>T, NG_009497.1:g.799497G>A, NM_206933.3:c.15433G>A, ENST00000307340.7:c.15433G>A, NM_206933.2(USH2A):c.15433G>A (p.Val5145Ile)	USH2A	Usher syndrome	MONDO:0019501	Autosomal recessive inheritance	Benign	BP4, BA1	PS4, PS2, PS3, PS1, PM3, PM1, PM4, PM5, BP5, BP7, BS4, BS1, PM6, PM2, PVS1, BS2, PP4, PP1, PP3, BP2, BP3	The p.Val5145Ile variant in USH2A has been identified in at least 5 individuals with Usher syndrome; however, in 3 individuals no variant on the second allele was identified and in two individuals, no information about the other allele was provided (PMIDs 28041643, 25999674, 20829743, 27353947, 23591405). Additionally, the p.Val5145Ile variant was identified in 2 alleles of 56 retinitis pigmentosa patients, however it is unclear in which one or two patients these alleles were found (PMID 20591486). The filtering allele frequency of the p.Val5145Ile variant in the USH2A gene is 0.7% for European (Finnish) chromosomes by gnomAD (201/25124 with 95% CI), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive hearing loss variants (BA1). Additionally, computational prediction analysis using the metapredictor tool REVEL suggests that the variant may not impact the protein (BP4) .In summary, this variant meets criteria to be classified as benign based primarily on population frequency data and the absence of cases with biallelic variants. ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel: BA1, BP4.	25999674, 28041643, 20591486, 23591405, 27353947, 20829743, 20507924	Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2019-01-14	2019-10-18	False	https://erepo.genome.network/evrepo/ui/classification/CA143401/MONDO:0019501/005	42b06ec9-1249-4155-a6ab-a61c363e6c5f	p.Val5145Ile	Val	5145	Ile	MNCPVLSLGSGFLFQVIEMLIFAYFASISLTESRGLFPRLENVGAFKKVSIVPTQAVCGLPDRSTFCHSSAAAESIQFCTQRFCIQDCPYRSSHPTYTALFSAGLSSCITPDKNDLHPNAHSNSASFIFGNHKSCFSSPPSPKLMASFTLAVWLKPEQQGVMCVIEKTVDGQIVFKLTISEKETMFYYRTVNGLQPPIKVMTLGRILVKKWIHLSVQVHQTKISFFINGVEKDHTPFNARTLSGSITDFASGTVQIGQSLNGLEQFVGRMQDFRLYQVALTNREILEVFSGDLLRLHAQSHCRCPGSHPRVHPLAQRYCIPNDAGDTADNRVSRLNPEAHPLSFVNDNDVGTSWVSNVFTNITQLNQGVTISVDLENGQYQVFYIIIQFFSPQPTEIRIQRKKENSLDWEDWQYFARNCGAFGMKNNGDLEKPDSVNCLQLSNFTPYSRGNVTFSILTPGPNYRPGYNNFYNTPSLQEFVKATQIRFHFHGQYYTTETAVNLRHRYYAVDEITISGRCQCHGHADNCDTTSQPYRCLCSQESFTEGLHCDRCLPLYNDKPFRQGDQVYAFNCKPCQCNSHSKSCHYNISVDPFPFEHFRGGGGVCDDCEHNTTGRNCELCKDYFFRQVGADPSAIDVCKPCDCDTVGTRNGSILCDQIGGQCNCKRHVSGRQCNQCQNGFYNLQELDPDGCSPCNCNTSGTVDGDITCHQNSGQCKCKANVIGLRCDHCNFGFKFLRSFNDVGCEPCQCNLHGSVNKFCNPHSGQCECKKEAKGLQCDTCRENFYGLDVTNCKACDCDTAGSLPGTVCNAKTGQCICKPNVEGRQCNKCLEGNFYLRQNNSFLCLPCNCDKTGTINGSLLCNKSTGQCPCKLGVTGLRCNQCEPHRYNLTIDNFQHCQMCECDSLGTLPGTICDPISGQCLCVPNRQGRRCNQCQPGFYISPGNATGCLPCSCHTTGAVNHICNSLTGQCVCQDASIAGQRCDQCKDHYFGFDPQTGRCQPCNCHLSGALNETCHLVTGQCFCKQFVTGSKCDACVPSASHLDVNNLLGCSKTPFQQPPPRGQVQSSSAINLSWSPPDSPNAHWLTYSLLRDGFEIYTTEDQYPYSIQYFLDTDLLPYTKYSYYIETTNVHGSTRSVAVTYKTKPGVPEGNLTLSYIIPIGSDSVTLTWTTLSNQSGPIEKYILSCAPLAGGQPCVSYEGHETSATIWNLVPFAKYDFSVQACTSGGCLHSLPITVTTAQAPPQRLSPPKMQKISSTELHVEWSPPAELNGIIIRYELYMRRLRSTKETTSEESRVFQSSGWLSPHSFVESANENALKPPQTMTTITGLEPYTKYEFRVLAVNMAGSVSSAWVSERTGESAPVFMIPPSVFPLSSYSLNISWEKPADNVTRGKVVGYDINMLSEQSPQQSIPMAFSQLLHTAKSQELSYTVEGLKPYRIYEFTITLCNSVGCVTSASGAGQTLAAAPAQLRPPLVKGINSTTIHLRWFPPEELNGPSPIYQLERRESSLPALMTTMMKGIRFIGNGYCKFPSSTHPVNTDFTGIKASFRTKVPEGLIVFAASPGNQEEYFALQLKKGRLYFLFDPQGSPVEVTTTNDHGKQYSDGKWHEIIAIRHQAFGQITLDGIYTGSSAILNGSTVIGDNTGVFLGGLPRSYTILRKDPEIIQKGFVGCLKDVHFMKNYNPSAIWEPLDWQSSEEQINVYNSWEGCPASLNEGAQFLGAGFLELHPYMFHGGMNFEISFKFRTDQLNGLLLFVYNKDGPDFLAMELKSGILTFRLNTSLAFTQVDLLLGLSYCNGKWNKVIIKKEGSFISASVNGLMKHASESGDQPLVVNSPVYVGGIPQELLNSYQHLCLEQGFGGCMKDVKFTRGAVVNLASVSSGAVRVNLDGCLSTDSAVNCRGNDSILVYQGKEQSVYEGGLQPFTEYLYRVIASHEGGSVYSDWSRGRTTGAAPQSVPTPSRVRSLNGYSIEVTWDEPVVRGVIEKYILKAYSEDSTRPPRMPSASAEFVNTSNLTGILTGLLPFKNYAVTLTACTLAGCTESSHALNISTPQEAPQEVQPPVAKSLPSSLLLSWNPPKKANGIITQYCLYMDGRLIYSGSEENYIVTDLAVFTPHQFLLSACTHVGCTNSSWVLLYTAQLPPEHVDSPVLTVLDSRTIHIQWKQPRKISGILERYVLYMSNHTHDFTIWSVIYNSTELFQDHMLQYVLPGNKYLIKLGACTGGGCTVSEASEALTDEDIPEGVPAPKAHSYSPDSFNVSWTEPEYPNGVITSYGLYLDGILIHNSSELSYRAYGFAPWSLHSFRVQACTAKGCALGPLVENRTLEAPPEGTVNVFVKTQGSRKAHVRWEAPFRPNGLLTHSVLFTGIFYVDPVGNNYTLLNVTKVMYSGEETNLWVLIDGLVPFTNYTVQVNISNSQGSLITDPITIAMPPGAPDGVLPPRLSSATPTSLQVVWSTPARNNAPGSPRYQLQMRSGDSTHGFLELFSNPSASLSYEVSDLQPYTEYMFRLVASNGFGSAHSSWIPFMTAEDKPGPVVPPILLDVKSRMMLVTWQHPRKSNGVITHYNIYLHGRLYLRTPGNVTNCTVMHLHPYTAYKFQVEACTSKGCSLSPESQTVWTLPGAPEGIPSPELFSDTPTSVIISWQPPTHPNGLVENFTIERRVKGKEEVTTLVTLPRSHSMRFIDKTSALSPWTKYEYRVLMSTLHGGTNSSAWVEVTTRPSRPAGVQPPVVTVLEPDAVQVTWKPPLIQNGDILSYEIHMPDPHITLTNVTSAVLSQKVTHLIPFTNYSVTIVACSGGNGYLGGCTESLPTYVTTHPTVPQNVGPLSVIPLSESYVVISWQPPSKPNGPNLRYELLRRKIQQPLASNPPEDLNRWHNIYSGTQWLYEDKGLSRFTTYEYMLFVHNSVGFTPSREVTVTTLAGLPERGANLTASVLNHTAIDVRWAKPTVQDLQGEVEYYTLFWSSATSNDSLKILPDVNSHVIGHLKPNTEYWIFISVFNGVHSINSAGLHATTCDGEPQGMLPPEVVIINSTAVRVIWTSPSNPNGVVTEYSIYVNNKLYKTGMNVPGSFILRDLSPFTIYDIQVEVCTIYACVKSNGTQITTVEDTPSDIPTPTIRGITSRSLQIDWVSPRKPNGIILGYDLLWKTWYPCAKTQKLVQDQSDELCKAVRCQKPESICGHICYSSEAKVCCNGVLYNPKPGHRCCEEKYIPFVLNSTGVCCGGRIQEAQPNHQCCSGYYARILPGEVCCPDEQHNRVSVGIGDSCCGRMPYSTSGNQICCAGRLHDGHGQKCCGRQIVSNDLECCGGEEGVVYNRLPGMFCCGQDYVNMSDTICCSASSGESKAHIKKNDPVPVKCCETELIPKSQKCCNGVGYNPLKYVCSDKISTGMMMKETKECRILCPASMEATEHCGRCDFNFTSHICTVIRGSHNSTGKASIEEMCSSAEETIHTGSVNTYSYTDVNLKPYMTYEYRISAWNSYGRGLSKAVRARTKEDVPQGVSPPTWTKIDNLEDTIVLNWRKPIQSNGPIIYYILLRNGIERFRGTSLSFSDKEGIQPFQEYSYQLKACTVAGCATSSKVVAATTQGVPESILPPSITALSAVALHLSWSVPEKSNGVIKEYQIRQVGKGLIHTDTTDRRQHTVTGLQPYTNYSFTLTACTSAGCTSSEPFLGQTLQAAPEGVWVTPRHIIINSTTVELYWSLPEKPNGLVSQYQLSRNGNLLFLGGSEEQNFTDKNLEPNSRYTYKLEVKTGGGSSASDDYIVQTPMSTPEEIYPPYNITVIGPYSIFVAWIPPGILIPEIPVEYNVLLNDGSVTPLAFSVGHHQSTLLENLTPFTQYEIRIQACQNGSCGVSSRMFVKTPEAAPMDLNSPVLKALGSACIEIKWMPPEKPNGIIINYFIYRRPAGIEEESVLFVWSEGALEFMDEGDTLRPFTLYEYRVRACNSKGSVESLWSLTQTLEAPPQDFPAPWAQATSAHSVLLNWTKPESPNGIISHYRVVYQERPDDPTFNSPTVHAFTVKGTSHQAHLYGLEPFTTYRIGVVAANHAGEILSPWTLIQTLESSPSGLRNFIVEQKENGRALLLQWSEPMRTNGVIKTYNIFSDGFLEYSGLNRQFLFRRLDPFTLYTLTLEACTRAGCAHSAPQPLWTDEAPPDSQLAPTVHSVKSTSVELSWSEPVNPNGKIIRYEVIRRCFEGKAWGNQTIQADEKIVFTEYNTERNTFMYNDTGLQPWTQCEYKIYTWNSAGHTCSSWNVVRTLQAPPEGLSPPVISYVSMNPQKLLISWIPPEQSNGIIQSYRLQRNEMLYPFSFDPVTFNYTDEELLPFSTYSYALQACTSGGCSTSKPTSITTLEAAPSEVSPPDLWAVSATQMNVCWSPPTVQNGKITKYLVRYDNKESLAGQGLCLLVSHLQPYSQYNFSLVACTNGGCTASVSKSAWTMEALPENMDSPTLQVTGSESIEITWKPPRNPNGQIRSYELRRDGTIVYTGLETRYRDFTLTPGVEYSYTVTASNSQGGILSPLVKDRTSPSAPSGMEPPKLQARGPQEILVNWDPPVRTNGDIINYTLFIRELFERETKIIHINTTHNSFGMQSYIVNQLKPFHRYEIRIQACTTLGCASSDWTFIQTPEIAPLMQPPPHLEVQMAPGGFQPTVSLLWTGPLQPNGKVLYYELYRRQIATQPRKSNPVLIYNGSSTSFIDSELLPFTEYEYQVWAVNSAGKAPSSWTWCRTGPAPPEGLRAPTFHVISSTQAVVNISAPGKPNGIVSLYRLFSSSAHGAETVLSEGMATQQTLHGLQAFTNYSIGVEACTCFNCCSKGPTAELRTHPAPPSGLSSPQIGTLASRTASFRWSPPMFPNGVIHSYELQFHVACPPDSALPCTPSQIETKYTGLGQKASLGGLQPYTTYKLRVVAHNEVGSTASEWISFTTQKELPQYRAPFSVDSNLSVVCVNWSDTFLLNGQLKEYVLTDGGRRVYSGLDTTLYIPRTADKTFFFQVICTTDEGSVKTPLIQYDTSTGLGLVLTTPGKKKGSRSKSTEFYSELWFIVLMAMLGLILLAIFLSLILQRKIHKEPYIRERPPLVPLQKRMSPLNVYPPGENHMGLADTKIPRSGTPVSIRSNRSACVLRIPSQNQTSLTYSQGSLHRSVSQLMDIQDKKVLMDNSLWEAIMGHNSGLYVDEEDLMNAIKDFSSVTKERTTFTDTHL	5202	O75445	I	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [3167, 3881], 'DISULFID_gain_score': array([9.75728035e-05, 5.57005405e-04]), 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [463, 4179], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.00951284, -0.01660067]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [766], 'ZN_FING_gain': [], 'ZN_FING_loss_score': array([-0.0003432])}
156	NM_206933.2(USH2A):c.3902G>T (p.Gly1301Val)	48509	CA143472	NM_206933.2:c.3902G>T, NC_000001.11:g.216198494C>A, CM000663.2:g.216198494C>A, NC_000001.10:g.216371836C>A, CM000663.1:g.216371836C>A, NC_000001.9:g.214438459C>A, NG_009497.1:g.229903G>T, NG_009497.2:g.229955G>T, ENST00000307340.8:c.3902G>T, ENST00000674083.1:c.3902G>T, ENST00000307340.7:c.3902G>T, ENST00000366942.3:c.3902G>T, NM_007123.5:c.3902G>T, XR_922595.1:n.354+2569C>A, XR_922596.1:n.354+2569C>A, XR_922597.1:n.354+2569C>A, XR_922598.1:n.484+2569C>A, XR_922595.3:n.1076+2569C>A, XR_922596.3:n.1076+2569C>A, NM_206933.3:c.3902G>T, NM_007123.6:c.3902G>T, NM_206933.4:c.3902G>T, NM_206933.2(USH2A):c.3902G>T (p.Gly1301Val)	USH2A	Usher syndrome	MONDO:0019501	Autosomal recessive inheritance	Benign	BA1	PS1, PS4, PM5, PM1, PM3, PM2, PP2, PP3, BP1, BP4	The c.3902G>T variant in USH2A is a missense variant predicted to cause substitution of glycine by valine at amino acid 1301 (p.Gly1301Val). The highest population filtering allele frequency with a confidence interval of 0.95 in gnomAD v4.0.0 is 0.5% (469/91078) with 4 homozygotes in the South Asian population, which meets the ClinGen Hearing Loss VCEP criteria for BA1 (≥0.5%). The computational predictor REVEL gives a score of 0.218, which is neither above nor below the thresholds predicting a damaging or benign impact on USH2A function. While this variant has been reported in several individuals with clinical features of USH2A-related disorders, there are no case-control studies and several affected individuals had an alternate cause of disease identified (PMID:21569298, 25649381, 26927203, 32531858). In summary, this variant meets the criteria to be classified as benign, based on the ACMG/AMP criteria applied, as specified by the ClinGen Hearing Loss VCEP (BA1, ClinGen Hearing Loss VCEP specifications version 2, 03.20.2024).		Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2024-03-20	2024-04-01	False	https://erepo.genome.network/evrepo/ui/classification/CA143472/MONDO:0019501/005	705d0fbc-b15a-4fc0-9f5e-c1ead022e87e	p.Gly1301Val	Gly	1301	Val	MNCPVLSLGSGFLFQVIEMLIFAYFASISLTESRGLFPRLENVGAFKKVSIVPTQAVCGLPDRSTFCHSSAAAESIQFCTQRFCIQDCPYRSSHPTYTALFSAGLSSCITPDKNDLHPNAHSNSASFIFGNHKSCFSSPPSPKLMASFTLAVWLKPEQQGVMCVIEKTVDGQIVFKLTISEKETMFYYRTVNGLQPPIKVMTLGRILVKKWIHLSVQVHQTKISFFINGVEKDHTPFNARTLSGSITDFASGTVQIGQSLNGLEQFVGRMQDFRLYQVALTNREILEVFSGDLLRLHAQSHCRCPGSHPRVHPLAQRYCIPNDAGDTADNRVSRLNPEAHPLSFVNDNDVGTSWVSNVFTNITQLNQGVTISVDLENGQYQVFYIIIQFFSPQPTEIRIQRKKENSLDWEDWQYFARNCGAFGMKNNGDLEKPDSVNCLQLSNFTPYSRGNVTFSILTPGPNYRPGYNNFYNTPSLQEFVKATQIRFHFHGQYYTTETAVNLRHRYYAVDEITISGRCQCHGHADNCDTTSQPYRCLCSQESFTEGLHCDRCLPLYNDKPFRQGDQVYAFNCKPCQCNSHSKSCHYNISVDPFPFEHFRGGGGVCDDCEHNTTGRNCELCKDYFFRQVGADPSAIDVCKPCDCDTVGTRNGSILCDQIGGQCNCKRHVSGRQCNQCQNGFYNLQELDPDGCSPCNCNTSGTVDGDITCHQNSGQCKCKANVIGLRCDHCNFGFKFLRSFNDVGCEPCQCNLHGSVNKFCNPHSGQCECKKEAKGLQCDTCRENFYGLDVTNCKACDCDTAGSLPGTVCNAKTGQCICKPNVEGRQCNKCLEGNFYLRQNNSFLCLPCNCDKTGTINGSLLCNKSTGQCPCKLGVTGLRCNQCEPHRYNLTIDNFQHCQMCECDSLGTLPGTICDPISGQCLCVPNRQGRRCNQCQPGFYISPGNATGCLPCSCHTTGAVNHICNSLTGQCVCQDASIAGQRCDQCKDHYFGFDPQTGRCQPCNCHLSGALNETCHLVTGQCFCKQFVTGSKCDACVPSASHLDVNNLLGCSKTPFQQPPPRGQVQSSSAINLSWSPPDSPNAHWLTYSLLRDGFEIYTTEDQYPYSIQYFLDTDLLPYTKYSYYIETTNVHGSTRSVAVTYKTKPGVPEGNLTLSYIIPIGSDSVTLTWTTLSNQSGPIEKYILSCAPLAGGQPCVSYEGHETSATIWNLVPFAKYDFSVQACTSGGCLHSLPITVTTAQAPPQRLSPPKMQKISSTELHVEWSPPAELNGIIIRYELYMRRLRSTKETTSEESRVFQSSGWLSPHSFVESANENALKPPQTMTTITGLEPYTKYEFRVLAVNMAGSVSSAWVSERTGESAPVFMIPPSVFPLSSYSLNISWEKPADNVTRGKVVGYDINMLSEQSPQQSIPMAFSQLLHTAKSQELSYTVEGLKPYRIYEFTITLCNSVGCVTSASGAGQTLAAAPAQLRPPLVKGINSTTIHLRWFPPEELNGPSPIYQLERRESSLPALMTTMMKGIRFIGNGYCKFPSSTHPVNTDFTGIKASFRTKVPEGLIVFAASPGNQEEYFALQLKKGRLYFLFDPQGSPVEVTTTNDHGKQYSDGKWHEIIAIRHQAFGQITLDGIYTGSSAILNGSTVIGDNTGVFLGGLPRSYTILRKDPEIIQKGFVGCLKDVHFMKNYNPSAIWEPLDWQSSEEQINVYNSWEGCPASLNEGAQFLGAGFLELHPYMFHGGMNFEISFKFRTDQLNGLLLFVYNKDGPDFLAMELKSGILTFRLNTSLAFTQVDLLLGLSYCNGKWNKVIIKKEGSFISASVNGLMKHASESGDQPLVVNSPVYVGGIPQELLNSYQHLCLEQGFGGCMKDVKFTRGAVVNLASVSSGAVRVNLDGCLSTDSAVNCRGNDSILVYQGKEQSVYEGGLQPFTEYLYRVIASHEGGSVYSDWSRGRTTGAAPQSVPTPSRVRSLNGYSIEVTWDEPVVRGVIEKYILKAYSEDSTRPPRMPSASAEFVNTSNLTGILTGLLPFKNYAVTLTACTLAGCTESSHALNISTPQEAPQEVQPPVAKSLPSSLLLSWNPPKKANGIITQYCLYMDGRLIYSGSEENYIVTDLAVFTPHQFLLSACTHVGCTNSSWVLLYTAQLPPEHVDSPVLTVLDSRTIHIQWKQPRKISGILERYVLYMSNHTHDFTIWSVIYNSTELFQDHMLQYVLPGNKYLIKLGACTGGGCTVSEASEALTDEDIPEGVPAPKAHSYSPDSFNVSWTEPEYPNGVITSYGLYLDGILIHNSSELSYRAYGFAPWSLHSFRVQACTAKGCALGPLVENRTLEAPPEGTVNVFVKTQGSRKAHVRWEAPFRPNGLLTHSVLFTGIFYVDPVGNNYTLLNVTKVMYSGEETNLWVLIDGLVPFTNYTVQVNISNSQGSLITDPITIAMPPGAPDGVLPPRLSSATPTSLQVVWSTPARNNAPGSPRYQLQMRSGDSTHGFLELFSNPSASLSYEVSDLQPYTEYMFRLVASNGFGSAHSSWIPFMTAEDKPGPVVPPILLDVKSRMMLVTWQHPRKSNGVITHYNIYLHGRLYLRTPGNVTNCTVMHLHPYTAYKFQVEACTSKGCSLSPESQTVWTLPGAPEGIPSPELFSDTPTSVIISWQPPTHPNGLVENFTIERRVKGKEEVTTLVTLPRSHSMRFIDKTSALSPWTKYEYRVLMSTLHGGTNSSAWVEVTTRPSRPAGVQPPVVTVLEPDAVQVTWKPPLIQNGDILSYEIHMPDPHITLTNVTSAVLSQKVTHLIPFTNYSVTIVACSGGNGYLGGCTESLPTYVTTHPTVPQNVGPLSVIPLSESYVVISWQPPSKPNGPNLRYELLRRKIQQPLASNPPEDLNRWHNIYSGTQWLYEDKGLSRFTTYEYMLFVHNSVGFTPSREVTVTTLAGLPERGANLTASVLNHTAIDVRWAKPTVQDLQGEVEYYTLFWSSATSNDSLKILPDVNSHVIGHLKPNTEYWIFISVFNGVHSINSAGLHATTCDGEPQGMLPPEVVIINSTAVRVIWTSPSNPNGVVTEYSIYVNNKLYKTGMNVPGSFILRDLSPFTIYDIQVEVCTIYACVKSNGTQITTVEDTPSDIPTPTIRGITSRSLQIDWVSPRKPNGIILGYDLLWKTWYPCAKTQKLVQDQSDELCKAVRCQKPESICGHICYSSEAKVCCNGVLYNPKPGHRCCEEKYIPFVLNSTGVCCGGRIQEAQPNHQCCSGYYARILPGEVCCPDEQHNRVSVGIGDSCCGRMPYSTSGNQICCAGRLHDGHGQKCCGRQIVSNDLECCGGEEGVVYNRLPGMFCCGQDYVNMSDTICCSASSGESKAHIKKNDPVPVKCCETELIPKSQKCCNGVGYNPLKYVCSDKISTGMMMKETKECRILCPASMEATEHCGRCDFNFTSHICTVIRGSHNSTGKASIEEMCSSAEETIHTGSVNTYSYTDVNLKPYMTYEYRISAWNSYGRGLSKAVRARTKEDVPQGVSPPTWTKIDNLEDTIVLNWRKPIQSNGPIIYYILLRNGIERFRGTSLSFSDKEGIQPFQEYSYQLKACTVAGCATSSKVVAATTQGVPESILPPSITALSAVALHLSWSVPEKSNGVIKEYQIRQVGKGLIHTDTTDRRQHTVTGLQPYTNYSFTLTACTSAGCTSSEPFLGQTLQAAPEGVWVTPRHIIINSTTVELYWSLPEKPNGLVSQYQLSRNGNLLFLGGSEEQNFTDKNLEPNSRYTYKLEVKTGGGSSASDDYIVQTPMSTPEEIYPPYNITVIGPYSIFVAWIPPGILIPEIPVEYNVLLNDGSVTPLAFSVGHHQSTLLENLTPFTQYEIRIQACQNGSCGVSSRMFVKTPEAAPMDLNSPVLKALGSACIEIKWMPPEKPNGIIINYFIYRRPAGIEEESVLFVWSEGALEFMDEGDTLRPFTLYEYRVRACNSKGSVESLWSLTQTLEAPPQDFPAPWAQATSAHSVLLNWTKPESPNGIISHYRVVYQERPDDPTFNSPTVHAFTVKGTSHQAHLYGLEPFTTYRIGVVAANHAGEILSPWTLIQTLESSPSGLRNFIVEQKENGRALLLQWSEPMRTNGVIKTYNIFSDGFLEYSGLNRQFLFRRLDPFTLYTLTLEACTRAGCAHSAPQPLWTDEAPPDSQLAPTVHSVKSTSVELSWSEPVNPNGKIIRYEVIRRCFEGKAWGNQTIQADEKIVFTEYNTERNTFMYNDTGLQPWTQCEYKIYTWNSAGHTCSSWNVVRTLQAPPEGLSPPVISYVSMNPQKLLISWIPPEQSNGIIQSYRLQRNEMLYPFSFDPVTFNYTDEELLPFSTYSYALQACTSGGCSTSKPTSITTLEAAPSEVSPPDLWAVSATQMNVCWSPPTVQNGKITKYLVRYDNKESLAGQGLCLLVSHLQPYSQYNFSLVACTNGGCTASVSKSAWTMEALPENMDSPTLQVTGSESIEITWKPPRNPNGQIRSYELRRDGTIVYTGLETRYRDFTLTPGVEYSYTVTASNSQGGILSPLVKDRTSPSAPSGMEPPKLQARGPQEILVNWDPPVRTNGDIINYTLFIRELFERETKIIHINTTHNSFGMQSYIVNQLKPFHRYEIRIQACTTLGCASSDWTFIQTPEIAPLMQPPPHLEVQMAPGGFQPTVSLLWTGPLQPNGKVLYYELYRRQIATQPRKSNPVLIYNGSSTSFIDSELLPFTEYEYQVWAVNSAGKAPSSWTWCRTGPAPPEGLRAPTFHVISSTQAVVNISAPGKPNGIVSLYRLFSSSAHGAETVLSEGMATQQTLHGLQAFTNYSIGVEACTCFNCCSKGPTAELRTHPAPPSGLSSPQIGTLASRTASFRWSPPMFPNGVIHSYELQFHVACPPDSALPCTPSQIETKYTGLGQKASLGGLQPYTTYKLRVVAHNEVGSTASEWISFTTQKELPQYRAPFSVDSNLSVVCVNWSDTFLLNGQLKEYVLTDGGRRVYSGLDTTLYIPRTADKTFFFQVICTTDEGSVKTPLIQYDTSTGLGLVLTTPGKKKGSRSKSTEFYSELWFIVLMAMLGLILLAIFLSLILQRKIHKEPYIRERPPLVPLQKRMSPLNVYPPGENHMGLADTKIPRSGTPVSIRSNRSACVLRIPSQNQTSLTYSQGSLHRSVSQLMDIQDKKVLMDNSLWEAIMGHNSGLYVDEEDLMNAIKDFSSVTKERTTFTDTHL	5202	O75445	V	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [4236, 4389, 4568, 4604], 'STRAND_gain_score': array([0.00301492, 0.00317419, 0.00212133, 0.0023455 ]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [466, 4174, 4207, 4211, 4212, 4213, 4256, 4286], 'DOMAIN_gain_score': array([0.02495843, 0.02844107, 0.04992247, 0.05171555, 0.04315478,
       0.04776961, 0.03505516, 0.04618639]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [766], 'ZN_FING_gain': [], 'ZN_FING_loss_score': array([-0.00076997])}"
157	NM_206933.3(USH2A):c.5012G>A (p.Gly1671Asp)	179773	CA185105	NM_206933.3:c.5012G>A, NC_000001.11:g.216084853C>T, CM000663.2:g.216084853C>T, NC_000001.10:g.216258195C>T, CM000663.1:g.216258195C>T, NC_000001.9:g.214324818C>T, NG_009497.1:g.343544G>A, NG_009497.2:g.343596G>A, ENST00000307340.8:c.5012G>A, ENST00000674083.1:c.5012G>A, ENST00000307340.7:c.5012G>A, ENST00000463147.1:n.256G>A, ENST00000481786.1:n.254G>A, NM_206933.2:c.5012G>A, NR_125992.1:n.266-1869C>T, NR_125993.1:n.137-1869C>T, NM_206933.4:c.5012G>A, NM_206933.4(USH2A):c.5012G>A (p.Gly1671Asp), NM_206933.3(USH2A):c.5012G>A (p.Gly1671Asp)	USH2A	inherited retinal dystrophy	MONDO:0019501	Autosomal recessive inheritance	Pathogenic	PP1_Strong, PP3, PM3_Very Strong	BP5, PM2, PP4	The c.5012G>A variant in USH2A is a missense variant predicted to cause substitution of glycine by aspartic acid at amino acid 1671 (p.Gly1671Asp). The highest population minor allele frequency in gnomAD v4 is 0.04% (51/91074 alleles) in the South Asian population (PM2_Supporting, BS1, and BA1 are not met). The computational predictor REVEL gives a score of 0.906, which is above the threshold of 0.7, evidence that correlates with impact to USH2A function (PP3). This variant has been detected in at least 10 individuals with retinitis pigmentosa or inherited retinal disease. Of those individuals, 9 were homozygous and 1 was compound heterozygous for the variant and a pathogenic or likely pathogenic variant with phase unknown (c.4251+1G>T, 5 PM3 points, PMID:26667666, 32581362, 33749171, 38219857, PM3_VeryStrong). Internal evidence from one laboratory indicates that this variant has been observed in trans with a likely pathogenic missense variant in an individual with optic neuropathy, night blindness, and sensorineural hearing loss and homozygous in one individual with hearing loss and hyperopia (Personal communication, SCV001789135.4). This suggests that there may be phenotypic variability with some individuals presenting with isolated retinal dystrophy, and some presenting with hearing loss and signs and/or symptoms of retinal dystrophy. Of note, many of these individuals were of South Asian ancestry, consistent with the population evidence from gnomAD (PMID:38219857). The variant has been reported to segregate with inherited retinal disease in 3 affected family members from 2 families (PP1_Strong; PMID: 38219857). In summary, this variant meets the criteria to be classified as Pathogenic for autosomal recessive USH2A-related inherited retinal dystrophy based on the ACMG/AMP criteria applied, as specified by the ClinGen Hearing Loss VCEP: PP3, PM3_VeryStrong, PP1_Strong. (ClinGen Hearing Loss VCEP specifications version 2, 02.27.2024).		Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2024-02-27	2024-04-01	False	https://erepo.genome.network/evrepo/ui/classification/CA185105/MONDO:0019501/005	24df34e2-4a6c-48b7-bc9a-24a20326902c	p.Gly1671Asp	Gly	1671	Asp	MNCPVLSLGSGFLFQVIEMLIFAYFASISLTESRGLFPRLENVGAFKKVSIVPTQAVCGLPDRSTFCHSSAAAESIQFCTQRFCIQDCPYRSSHPTYTALFSAGLSSCITPDKNDLHPNAHSNSASFIFGNHKSCFSSPPSPKLMASFTLAVWLKPEQQGVMCVIEKTVDGQIVFKLTISEKETMFYYRTVNGLQPPIKVMTLGRILVKKWIHLSVQVHQTKISFFINGVEKDHTPFNARTLSGSITDFASGTVQIGQSLNGLEQFVGRMQDFRLYQVALTNREILEVFSGDLLRLHAQSHCRCPGSHPRVHPLAQRYCIPNDAGDTADNRVSRLNPEAHPLSFVNDNDVGTSWVSNVFTNITQLNQGVTISVDLENGQYQVFYIIIQFFSPQPTEIRIQRKKENSLDWEDWQYFARNCGAFGMKNNGDLEKPDSVNCLQLSNFTPYSRGNVTFSILTPGPNYRPGYNNFYNTPSLQEFVKATQIRFHFHGQYYTTETAVNLRHRYYAVDEITISGRCQCHGHADNCDTTSQPYRCLCSQESFTEGLHCDRCLPLYNDKPFRQGDQVYAFNCKPCQCNSHSKSCHYNISVDPFPFEHFRGGGGVCDDCEHNTTGRNCELCKDYFFRQVGADPSAIDVCKPCDCDTVGTRNGSILCDQIGGQCNCKRHVSGRQCNQCQNGFYNLQELDPDGCSPCNCNTSGTVDGDITCHQNSGQCKCKANVIGLRCDHCNFGFKFLRSFNDVGCEPCQCNLHGSVNKFCNPHSGQCECKKEAKGLQCDTCRENFYGLDVTNCKACDCDTAGSLPGTVCNAKTGQCICKPNVEGRQCNKCLEGNFYLRQNNSFLCLPCNCDKTGTINGSLLCNKSTGQCPCKLGVTGLRCNQCEPHRYNLTIDNFQHCQMCECDSLGTLPGTICDPISGQCLCVPNRQGRRCNQCQPGFYISPGNATGCLPCSCHTTGAVNHICNSLTGQCVCQDASIAGQRCDQCKDHYFGFDPQTGRCQPCNCHLSGALNETCHLVTGQCFCKQFVTGSKCDACVPSASHLDVNNLLGCSKTPFQQPPPRGQVQSSSAINLSWSPPDSPNAHWLTYSLLRDGFEIYTTEDQYPYSIQYFLDTDLLPYTKYSYYIETTNVHGSTRSVAVTYKTKPGVPEGNLTLSYIIPIGSDSVTLTWTTLSNQSGPIEKYILSCAPLAGGQPCVSYEGHETSATIWNLVPFAKYDFSVQACTSGGCLHSLPITVTTAQAPPQRLSPPKMQKISSTELHVEWSPPAELNGIIIRYELYMRRLRSTKETTSEESRVFQSSGWLSPHSFVESANENALKPPQTMTTITGLEPYTKYEFRVLAVNMAGSVSSAWVSERTGESAPVFMIPPSVFPLSSYSLNISWEKPADNVTRGKVVGYDINMLSEQSPQQSIPMAFSQLLHTAKSQELSYTVEGLKPYRIYEFTITLCNSVGCVTSASGAGQTLAAAPAQLRPPLVKGINSTTIHLRWFPPEELNGPSPIYQLERRESSLPALMTTMMKGIRFIGNGYCKFPSSTHPVNTDFTGIKASFRTKVPEGLIVFAASPGNQEEYFALQLKKGRLYFLFDPQGSPVEVTTTNDHGKQYSDGKWHEIIAIRHQAFGQITLDGIYTGSSAILNGSTVIGDNTGVFLGGLPRSYTILRKDPEIIQKGFVGCLKDVHFMKNYNPSAIWEPLDWQSSEEQINVYNSWEGCPASLNEGAQFLGAGFLELHPYMFHGGMNFEISFKFRTDQLNGLLLFVYNKDGPDFLAMELKSGILTFRLNTSLAFTQVDLLLGLSYCNGKWNKVIIKKEGSFISASVNGLMKHASESGDQPLVVNSPVYVGGIPQELLNSYQHLCLEQGFGGCMKDVKFTRGAVVNLASVSSGAVRVNLDGCLSTDSAVNCRGNDSILVYQGKEQSVYEGGLQPFTEYLYRVIASHEGGSVYSDWSRGRTTGAAPQSVPTPSRVRSLNGYSIEVTWDEPVVRGVIEKYILKAYSEDSTRPPRMPSASAEFVNTSNLTGILTGLLPFKNYAVTLTACTLAGCTESSHALNISTPQEAPQEVQPPVAKSLPSSLLLSWNPPKKANGIITQYCLYMDGRLIYSGSEENYIVTDLAVFTPHQFLLSACTHVGCTNSSWVLLYTAQLPPEHVDSPVLTVLDSRTIHIQWKQPRKISGILERYVLYMSNHTHDFTIWSVIYNSTELFQDHMLQYVLPGNKYLIKLGACTGGGCTVSEASEALTDEDIPEGVPAPKAHSYSPDSFNVSWTEPEYPNGVITSYGLYLDGILIHNSSELSYRAYGFAPWSLHSFRVQACTAKGCALGPLVENRTLEAPPEGTVNVFVKTQGSRKAHVRWEAPFRPNGLLTHSVLFTGIFYVDPVGNNYTLLNVTKVMYSGEETNLWVLIDGLVPFTNYTVQVNISNSQGSLITDPITIAMPPGAPDGVLPPRLSSATPTSLQVVWSTPARNNAPGSPRYQLQMRSGDSTHGFLELFSNPSASLSYEVSDLQPYTEYMFRLVASNGFGSAHSSWIPFMTAEDKPGPVVPPILLDVKSRMMLVTWQHPRKSNGVITHYNIYLHGRLYLRTPGNVTNCTVMHLHPYTAYKFQVEACTSKGCSLSPESQTVWTLPGAPEGIPSPELFSDTPTSVIISWQPPTHPNGLVENFTIERRVKGKEEVTTLVTLPRSHSMRFIDKTSALSPWTKYEYRVLMSTLHGGTNSSAWVEVTTRPSRPAGVQPPVVTVLEPDAVQVTWKPPLIQNGDILSYEIHMPDPHITLTNVTSAVLSQKVTHLIPFTNYSVTIVACSGGNGYLGGCTESLPTYVTTHPTVPQNVGPLSVIPLSESYVVISWQPPSKPNGPNLRYELLRRKIQQPLASNPPEDLNRWHNIYSGTQWLYEDKGLSRFTTYEYMLFVHNSVGFTPSREVTVTTLAGLPERGANLTASVLNHTAIDVRWAKPTVQDLQGEVEYYTLFWSSATSNDSLKILPDVNSHVIGHLKPNTEYWIFISVFNGVHSINSAGLHATTCDGEPQGMLPPEVVIINSTAVRVIWTSPSNPNGVVTEYSIYVNNKLYKTGMNVPGSFILRDLSPFTIYDIQVEVCTIYACVKSNGTQITTVEDTPSDIPTPTIRGITSRSLQIDWVSPRKPNGIILGYDLLWKTWYPCAKTQKLVQDQSDELCKAVRCQKPESICGHICYSSEAKVCCNGVLYNPKPGHRCCEEKYIPFVLNSTGVCCGGRIQEAQPNHQCCSGYYARILPGEVCCPDEQHNRVSVGIGDSCCGRMPYSTSGNQICCAGRLHDGHGQKCCGRQIVSNDLECCGGEEGVVYNRLPGMFCCGQDYVNMSDTICCSASSGESKAHIKKNDPVPVKCCETELIPKSQKCCNGVGYNPLKYVCSDKISTGMMMKETKECRILCPASMEATEHCGRCDFNFTSHICTVIRGSHNSTGKASIEEMCSSAEETIHTGSVNTYSYTDVNLKPYMTYEYRISAWNSYGRGLSKAVRARTKEDVPQGVSPPTWTKIDNLEDTIVLNWRKPIQSNGPIIYYILLRNGIERFRGTSLSFSDKEGIQPFQEYSYQLKACTVAGCATSSKVVAATTQGVPESILPPSITALSAVALHLSWSVPEKSNGVIKEYQIRQVGKGLIHTDTTDRRQHTVTGLQPYTNYSFTLTACTSAGCTSSEPFLGQTLQAAPEGVWVTPRHIIINSTTVELYWSLPEKPNGLVSQYQLSRNGNLLFLGGSEEQNFTDKNLEPNSRYTYKLEVKTGGGSSASDDYIVQTPMSTPEEIYPPYNITVIGPYSIFVAWIPPGILIPEIPVEYNVLLNDGSVTPLAFSVGHHQSTLLENLTPFTQYEIRIQACQNGSCGVSSRMFVKTPEAAPMDLNSPVLKALGSACIEIKWMPPEKPNGIIINYFIYRRPAGIEEESVLFVWSEGALEFMDEGDTLRPFTLYEYRVRACNSKGSVESLWSLTQTLEAPPQDFPAPWAQATSAHSVLLNWTKPESPNGIISHYRVVYQERPDDPTFNSPTVHAFTVKGTSHQAHLYGLEPFTTYRIGVVAANHAGEILSPWTLIQTLESSPSGLRNFIVEQKENGRALLLQWSEPMRTNGVIKTYNIFSDGFLEYSGLNRQFLFRRLDPFTLYTLTLEACTRAGCAHSAPQPLWTDEAPPDSQLAPTVHSVKSTSVELSWSEPVNPNGKIIRYEVIRRCFEGKAWGNQTIQADEKIVFTEYNTERNTFMYNDTGLQPWTQCEYKIYTWNSAGHTCSSWNVVRTLQAPPEGLSPPVISYVSMNPQKLLISWIPPEQSNGIIQSYRLQRNEMLYPFSFDPVTFNYTDEELLPFSTYSYALQACTSGGCSTSKPTSITTLEAAPSEVSPPDLWAVSATQMNVCWSPPTVQNGKITKYLVRYDNKESLAGQGLCLLVSHLQPYSQYNFSLVACTNGGCTASVSKSAWTMEALPENMDSPTLQVTGSESIEITWKPPRNPNGQIRSYELRRDGTIVYTGLETRYRDFTLTPGVEYSYTVTASNSQGGILSPLVKDRTSPSAPSGMEPPKLQARGPQEILVNWDPPVRTNGDIINYTLFIRELFERETKIIHINTTHNSFGMQSYIVNQLKPFHRYEIRIQACTTLGCASSDWTFIQTPEIAPLMQPPPHLEVQMAPGGFQPTVSLLWTGPLQPNGKVLYYELYRRQIATQPRKSNPVLIYNGSSTSFIDSELLPFTEYEYQVWAVNSAGKAPSSWTWCRTGPAPPEGLRAPTFHVISSTQAVVNISAPGKPNGIVSLYRLFSSSAHGAETVLSEGMATQQTLHGLQAFTNYSIGVEACTCFNCCSKGPTAELRTHPAPPSGLSSPQIGTLASRTASFRWSPPMFPNGVIHSYELQFHVACPPDSALPCTPSQIETKYTGLGQKASLGGLQPYTTYKLRVVAHNEVGSTASEWISFTTQKELPQYRAPFSVDSNLSVVCVNWSDTFLLNGQLKEYVLTDGGRRVYSGLDTTLYIPRTADKTFFFQVICTTDEGSVKTPLIQYDTSTGLGLVLTTPGKKKGSRSKSTEFYSELWFIVLMAMLGLILLAIFLSLILQRKIHKEPYIRERPPLVPLQKRMSPLNVYPPGENHMGLADTKIPRSGTPVSIRSNRSACVLRIPSQNQTSLTYSQGSLHRSVSQLMDIQDKKVLMDNSLWEAIMGHNSGLYVDEEDLMNAIKDFSSVTKERTTFTDTHL	5202	O75445	D	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [1671], 'DISULFID_gain': [3167, 3881], 'DISULFID_gain_score': array([8.83340836e-05, 3.35395336e-04]), 'DISULFID_loss_score': array([-0.02795696]), 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [4236, 4254, 4389, 4604], 'STRAND_gain_score': array([0.00372291, 0.0075956 , 0.00204879, 0.00092018]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [466, 4163, 4168, 4174, 4194, 4199, 4202, 4203, 4207, 4211, 4212, 4213, 4249, 4256, 4286], 'DOMAIN_gain_score': array([0.02545178, 0.05767858, 0.08145642, 0.05938077, 0.09657812,
       0.06542146, 0.08800942, 0.09807801, 0.09427714, 0.10524863,
       0.08831674, 0.09448594, 0.05182636, 0.07284278, 0.04491979]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [766], 'ZN_FING_gain': [], 'ZN_FING_loss_score': array([-0.00082242])}"
158	NM_002834.4(PTPN11):c.205G>C (p.Glu69Gln)	40498	CA261565	NM_002834.4:c.205G>C, NC_000012.12:g.112450385G>C, CM000674.2:g.112450385G>C, NC_000012.11:g.112888189G>C, CM000674.1:g.112888189G>C, NC_000012.10:g.111372572G>C, NG_007459.1:g.36654G>C, LRG_614:g.36654G>C, NM_002834.3:c.205G>C, LRG_614t1:c.205G>C, NM_080601.1:c.205G>C, XM_006719526.1:c.205G>C, XM_006719527.1:c.205G>C, XM_011538613.1:c.202G>C, NM_001330437.1:c.205G>C, NM_080601.2:c.205G>C, XM_011538613.2:c.202G>C, XM_017019722.1:c.202G>C, ENST00000351677.6:c.205G>C, ENST00000392597.5:c.205G>C, ENST00000635625.1:n.205G>C, NM_002834.4(PTPN11):c.205G>C (p.Glu69Gln)	PTPN11	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Pathogenic	PS2_Very Strong, PM2, PP3, PP2, PM1, PS4	PP1, PM5	The c.205G>C (p.Glu69Gln) variant in PTPN11 has been observed in at least 25 probands diagnosed with autosomal dominant Noonan syndrome (NS) across 7 publications and 2 clinical labs (PS4; PMID: 12634870, 15001945, 20186801, 23624134, 25862627, 26607044, 31560489; Invitae internal data, SCV000659043.3; Institut Universitaire d'Hématologie internal data). This variant was identified as de novo in 6 cases and segregated with disease in 1 additional individual in 1 family (PM6_VS, PP1 not met; Institut Universitaire d'Hématologie internal data; Invitae internal data, SCV000659043.3). It has also been identified in 2 additional probands with NS for whom the cDNA change was not specified, as well as 1 de novo prenatal case (PMID: 26817465, 23321623). The p.Glu69Gln variant has also been seen by multiple clinical labs in several probands without a formal diagnosis of NS or another RASopathy. This variant was absent from large population databases (PM2; https://gnomad.broadinstitute.org). It occurs in the N-SH2 domain of the protein, which has been identified as a region important for protein function (PM1; PMID: 29493581). PTPN11 has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Computational prediction tools and conservation analyses suggest that this variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for autosomal dominant Noonan syndrome. ACMG/AMP criteria applied: PM6_VS, PS4, PM1, PM2, PP2, PP3.	23624134, 20186801, 31560489, 26607044, 12634870, 25862627, 15001945	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2019-12-05	2019-12-05	False	https://erepo.genome.network/evrepo/ui/classification/CA261565/MONDO:0021060/004	9d27348b-e93e-42e4-ad51-7528c854b07d	p.Glu69Gln	Glu	69	Gln	MTSRRWFHPNITGVEAENLLLTRGVDGSFLARPSKSNPGDFTLSVRRNGAVTHIKIQNTGDYYDLYGGEKFATLAELVQYYMEHHGQLKEKNGDVIELKYPLNCADPTSERWFHGHLSGKEAEKLLTEKGKHGSFLVRESQSHPGDFVLSVRTGDDKGESNDGKSKVTHVMIRCQELKYDVGGGERFDSLTDLVEHYKKNPMVETLGTVLQLKQPLNTTRINAAEIESRVRELSKLAETTDKVKQGFWEEFETLQQQECKLLYSRKEGQRQENKNKNRYKNILPFDHTRVVLHDGDPNEPVSDYINANIIMPEFETKCNNSKPKKSYIATQGCLQNTVNDFWRMVFQENSRVIVMTTKEVERGKSKCVKYWPDEYALKEYGVMRVRNVKESAAHDYTLRELKLSKVGQGNTERTVWQYHFRTWPDHGVPSDPGGVLDFLEEVHHKQESIMDAGPVVVHCSAGIGRTGTFIVIDILIDIIREKGVDCDIDVPKTIQMVRSQRSGMVQTEAQYRFIYMAVQHYIETLQRRIEEEQKSKRKGHEYTNIKYSLADQTSGDQSPLPPCTPTPPCAEMREDSARVYENVGLMQQQKSFR	593	Q06124	Q	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [303], 'STRAND_gain': [65], 'STRAND_gain_score': array([0.03896618]), 'STRAND_loss_score': array([-0.00010222]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
159	NM_007373.3(SHOC2):c.610A>G (p.Ile204Val)	240838	CA5689600	NM_007373.3:c.610A>G, NC_000010.11:g.110964968A>G, CM000672.2:g.110964968A>G, NC_000010.10:g.112724726A>G, CM000672.1:g.112724726A>G, NC_000010.9:g.112714716A>G, NG_028922.1:g.50426A>G, LRG_753:g.50426A>G, NM_001269039.1:c.610A>G, LRG_753t1:c.610A>G, XM_011540216.1:c.-380-20660A>G, NM_001269039.2:c.610A>G, NM_001324336.1:c.610A>G, NM_001324337.1:c.610A>G, NR_136749.1:n.116-20660A>G, ENST00000265277.9:c.610A>G, ENST00000369452.8:c.610A>G, ENST00000451838.1:n.118A>G, ENST00000489390.1:n.56-35447A>G, NM_007373.3(SHOC2):c.610A>G (p.Ile204Val)	SHOC2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BS2, BP4, BS4	PP1, PP2, PM1, BA1, PS4, BS1	The c.610A>G (p.Ile204Val) variant in SHOC2 is present in 0.01241% (16/128978) of non-Finnish European alleles in gnomAD. This variant was observed in 3 unaffected individuals as well as several individuals with varying clinical presentations lacking clear associations with a RASopathy (BS2; Invitae internal data, SCV000289856.3; Institut Universitaire d'Hématologie internal data). It was absent from the symptomatic sister of 1 proband with Noonan syndrome who carried this variant (BS4; Institut Universitaire d'Hématologie internal data). Computational analysis and splice site predictors suggest that this variant does not impact the protein (BP4). In summary, the p.Ile204Val variant meets criteria to be classified as benign for autosomal dominant RASopathy. RASopathy-specific ACMG/AMP Criteria applied (PMID:29493581): BS2, BS4, BP4.		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2020-01-13	2020-01-13	False	https://erepo.genome.network/evrepo/ui/classification/CA5689600/MONDO:0021060/004	bb194ef7-82a6-4738-913d-0bdd60ad44a4	p.Ile204Val	Ile	204	Val	MSSSLGKEKDSKEKDPKVPSAKEREKEAKASGGFGKESKEKEPKTKGKDAKDGKKDSSAAQPGVAFSVDNTIKRPNPAPGTRKKSSNAEVIKELNKCREENSMRLDLSKRSIHILPSSIKELTQLTELYLYSNKLQSLPAEVGCLVNLMTLALSENSLTSLPDSLDNLKKLRMLDLRHNKLREIPSVVYRLDSLTTLYLRFNRITTVEKDIKNLSKLSMLSIRENKIKQLPAEIGELCNLITLDVAHNQLEHLPKEIGNCTQITNLDLQHNELLDLPDTIGNLSSLSRLGLRYNRLSAIPRSLAKCSALEELNLENNNISTLPESLLSSLVKLNSLTLARNCFQLYPVGGPSQFSTIYSLNMEHNRINKIPFGIFSRAKVLSKLNMKDNQLTSLPLDFGTWTSMVELNLATNQLTKIPEDVSGLVSLEVLILSNNLLKKLPHGLGNLRKLRELDLEENKLESLPNEIAYLKDLQKLVLTNNQLTTLPRGIGHLTNLTHLGLGENLLTHLPEEIGTLENLEELYLNDNPNLHSLPFELALCSKLSIMSIENCPLSHLPPQIVAGGPSFIIQFLKMQGPYRAMV	582	Q9UQ13	V	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
160	NM_001754.5(RUNX1):c.611G>A (p.Arg204Gln)	561253	CA410207938	NM_001754.5:c.611G>A, NC_000021.9:g.34859476C>T, CM000683.2:g.34859476C>T, NC_000021.8:g.36231773C>T, CM000683.1:g.36231773C>T, NC_000021.7:g.35153643C>T, NG_011402.2:g.1130236G>A, LRG_482:g.1130236G>A, ENST00000675419.1:c.611G>A, ENST00000300305.7:c.611G>A, ENST00000344691.8:c.530G>A, ENST00000358356.9:c.530G>A, ENST00000399237.6:c.575G>A, ENST00000399240.5:c.530G>A, ENST00000437180.5:c.611G>A, ENST00000467577.1:n.103G>A, ENST00000482318.5:c.*201G>A, NM_001001890.2:c.530G>A, NM_001122607.1:c.530G>A, NM_001754.4:c.611G>A, LRG_482t1:c.611G>A, XM_005261068.3:c.575G>A, XM_005261069.3:c.611G>A, XM_011529766.1:c.611G>A, XM_011529767.1:c.572G>A, XM_011529768.1:c.572G>A, XM_011529770.1:c.611G>A, XR_937576.1:n.790G>A, XM_005261069.4:c.611G>A, XM_011529766.2:c.611G>A, XM_011529767.2:c.572G>A, XM_011529768.2:c.572G>A, XM_011529770.2:c.611G>A, XM_017028487.1:c.458G>A, XR_937576.2:n.837G>A, NM_001001890.3:c.530G>A, NM_001122607.2:c.530G>A, NM_001754.5(RUNX1):c.611G>A (p.Arg204Gln)	RUNX1	hereditary thrombocytopenia and hematologic cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Pathogenic	PM5_Supporting, PM1, PP3, PM2_Supporting, PS4_Moderate, PP1_Strong	PM6, PVS1, PM4, PM3, PP2, PP4, BS2, BP1, BP4, BP3, BP2, BA1, PS1, PS3, PS2, BS1, BS3, BS4, BP7, BP5	The NM_001754.4:c.611G>A (p.Arg204Gln) variant affects one of the 13 hotspot residues established by the MM-VCEP for RUNX1 (PM1). This variant is completely absent from all population databases with at least 20x coverage for RUNX1 (PM2_supporting). This missense variant has a REVEL score >0.75 (0.958) (PP3). This variant has been reported in three probands meeting at least one of the RUNX1-phenotypic criteria (PS4_ moderate; PMID: 19357396, PMID: 27112265, PMID: 26316320, PMID: 27479822). This variant was found to co-segregate with disease in multiple affected family members, with seven meioses observed across 3 families (PP1_strong; PMID: 19357396, PMID: 27112265, PMID: 26316320, PMID: 27479822). This variant is a missense change at the same residue (p.R204) where a different missense change has been previously established as a likely pathogenic variant (ClinVar ID 2177591) based on MM-VCEP rules for RUNX1 and RNA data or agreement in splicing predictors (SSF and MES) show no splicing effects (PM5_Supporting). In summary, this variant meets criteria to be classified as pathogenic. ACMG/AMP criteria applied, as specified by the ClinGen Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PP1_strong, PM1, PM2, PS4_moderate, PP3, PM5_supporting.	34166225, 27479822, 26316320, 27112265, 19357396, 27479822, 26316320, 27112265, 19357396, 34166225, 27479822, 26316320, 27112265, 19357396	Myeloid Malignancy VCEP	https://www.clinicalgenome.org/affiliation/50034/docs/assertion-criteria 	2024-03-26	2024-03-26	False	https://erepo.genome.network/evrepo/ui/classification/CA410207938/MONDO:0011071/008	ad45320e-ac57-472f-b6c0-f7a6ebda5841	p.Arg204Gln	Arg	204	Gln	MRIPVDASTSRRFTPPSTALSPGKMSEALPLGAPDAGAALAGKLRSGDRSMVEVLADHPGELVRTDSPNFLCSVLPTHWRCNKTLPIAFKVVALGDVPDGTLVTVMAGNDENYSAELRNATAAMKNQVARFNDLRFVGRSGRGKSFTLTITVFTNPPQVATYHRAIKITVDGPREPRRHRQKLDDQTKPGSLSFSERLSELEQLRRTAMRVSPHHPAPTPNPRASLNHSTAFNPQPQSQMQDTRQIQPSPPWSYDQSYQYLGSIASPSVHPATPISPGRASGMTTLSAELSSRLSTAPDLTAFSDPRQFPALPSISDPRMHYPGAFTYSPTPVTSGIGIGMSAMGSATRYHTYLPPPYPGSSQAQGGPFQASSPSYHLYYGASAGSYQFSMVGGERSPPRILPPCTNASTGSALLNPSLPNQSDVVEAEGSHSNSPTNMAPSARLEEAVWRPY	453	Q01196	Q	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [158], 'STRAND_gain_score': array([0.01538426]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210], 'COILED_gain_score': array([0.28742051, 0.27315551, 0.28203773, 0.36272001, 0.36123765,
       0.35002673, 0.37058866, 0.33656108, 0.35128593, 0.38532442,
       0.39347249, 0.3772288 , 0.37149882, 0.35467499, 0.29670954,
       0.36205471, 0.35336018, 0.4066025 , 0.41417909, 0.34031212,
       0.3359316 ]), 'COMPBIAS_loss': [405, 407], 'COMPBIAS_gain': [170, 188, 189], 'COMPBIAS_gain_score': array([0.09592003, 0.19561344, 0.17628431]), 'COMPBIAS_loss_score': array([-0.0492599 , -0.04566419]), 'DOMAIN_loss': [44, 179], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.08098817, -0.0735507 ]), 'REGION_loss': [114, 164, 165, 166], 'REGION_gain': [126], 'REGION_gain_score': array([0.00228125]), 'REGION_loss_score': array([-0.00190878, -0.023808  , -0.03275931, -0.02210468]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
161	NM_000152.4(GAA):c.668G>A (p.Arg223His)	92488	CA145791	NM_000152.4:c.668G>A, NC_000017.11:g.80105870G>A, CM000679.2:g.80105870G>A, NC_000017.10:g.78079669G>A, CM000679.1:g.78079669G>A, NC_000017.9:g.75694264G>A, NG_009822.1:g.9315G>A, LRG_673:g.9315G>A, NM_000152.3:c.668G>A, LRG_673t1:c.668G>A, NM_001079803.1:c.668G>A, NM_001079804.1:c.668G>A, XM_005257193.1:c.668G>A, XM_005257194.3:c.668G>A, NM_001079803.2:c.668G>A, NM_001079804.2:c.668G>A, XM_005257193.2:c.668G>A, XM_005257194.4:c.668G>A, NM_000152.5:c.668G>A, NM_001079803.3:c.668G>A, NM_001079804.3:c.668G>A, ENST00000302262.7:c.668G>A, ENST00000390015.7:c.668G>A, ENST00000570803.5:c.668G>A, NM_000152.4(GAA):c.668G>A (p.Arg223His)	GAA	glycogen storage disease II	MONDO:0009290	Autosomal recessive inheritance	Benign	BA1		The highest continental population minor allele frequency for c.668G>A (p.Arg223His) in gnomAD v2.1.1 is 0.74034 in the European non-Finnish population. This is higher than the ClinGen LSD VCEP’s BA1 threshold (>0.01), therefore meeting the BA1 criterion. There is a ClinVar entry for this variant (Variation ID: 92488; 2 star review status) with six submitters classifying the variant as benign, and one as likely benign. In summary, this variant meets the criteria to be classified as benign for Pompe disease. GAA-specific ACMG/AMP criteria applied, as specified by the ClinGen LSD VCEP: BA1.		Lysosomal Diseases VCEP	https://clinicalgenome.org/docs/clingen-lysosomal-storage-disorders-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-2/	2020-01-22	2020-05-19	False	https://erepo.genome.network/evrepo/ui/classification/CA145791/MONDO:0009290/010	5209e127-3f93-4166-b5f2-d98600bdd5c9	p.Arg223His	Arg	223	His	MGVRHPPCSHRLLAVCALVSLATAALLGHILLHDFLLVPRELSGSSPVLEETHPAHQQGASRPGPRDAQAHPGRPRAVPTQCDVPPNSRFDCAPDKAITQEQCEARGCCYIPAKQGLQGAQMGQPWCFFPPSYPSYKLENLSSSEMGYTATLTRTTPTFFPKDILTLRLDVMMETENRLHFTIKDPANRRYEVPLETPHVHSRAPSPLYSVEFSEEPFGVIVRRQLDGRVLLNTTVAPLFFADQFLQLSTSLPSQYITGLAEHLSPLMLSTSWTRITLWNRDLAPTPGANLYGSHPFYLALEDGGSAHGVFLLNSNAMDVVLQPSPALSWRSTGGILDVYIFLGPEPKSVVQQYLDVVGYPFMPPYWGLGFHLCRWGYSSTAITRQVVENMTRAHFPLDVQWNDLDYMDSRRDFTFNKDGFRDFPAMVQELHQGGRRYMMIVDPAISSSGPAGSYRPYDEGLRRGVFITNETGQPLIGKVWPGSTAFPDFTNPTALAWWEDMVAEFHDQVPFDGMWIDMNEPSNFIRGSEDGCPNNELENPPYVPGVVGGTLQAATICASSHQFLSTHYNLHNLYGLTEAIASHRALVKARGTRPFVISRSTFAGHGRYAGHWTGDVWSSWEQLASSVPEILQFNLLGVPLVGADVCGFLGNTSEELCVRWTQLGAFYPFMRNHNSLLSLPQEPYSFSEPAQQAMRKALTLRYALLPHLYTLFHQAHVAGETVARPLFLEFPKDSSTWTVDHQLLWGEALLITPVLQAGKAEVTGYFPLGTWYDLQTVPVEALGSLPPPPAAPREPAIHSEGQWVTLPAPLDTINVHLRAGYIIPLQGPGLTTTESRQQPMALAVALTKGGEARGELFWDDGESLEVLERGAYTQVIFLARNNTIVNELVRVTSEGAGLQLQKVTVLGVATAPQQVLSNGVPVSNFTYSPDTKVLDICVSLLMGEQFLVSWC	952	P10253	H	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [375], 'DNA_BIND_gain': [], 'DNA_BIND_loss_score': array([-0.00039071]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [214, 233, 240], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.05824828, -0.13346338, -0.03876567]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
162	NM_000152.4(GAA):c.1286A>G (p.Gln429Arg)	284497	CA8815250	NM_000152.4:c.1286A>G, NM_000152.3:c.1286A>G, LRG_673t1:c.1286A>G, NM_001079803.1:c.1286A>G, NM_001079804.1:c.1286A>G, XM_005257193.1:c.1286A>G, XM_005257194.3:c.1286A>G, NM_001079803.2:c.1286A>G, NM_001079804.2:c.1286A>G, XM_005257193.2:c.1286A>G, XM_005257194.4:c.1286A>G, NM_000152.5:c.1286A>G, NM_001079803.3:c.1286A>G, NM_001079804.3:c.1286A>G, ENST00000302262.7:c.1286A>G, ENST00000390015.7:c.1286A>G, NC_000017.11:g.80108788A>G, CM000679.2:g.80108788A>G, NC_000017.10:g.78082587A>G, CM000679.1:g.78082587A>G, NC_000017.9:g.75697182A>G, NG_009822.1:g.12233A>G, LRG_673:g.12233A>G, NM_000152.4(GAA):c.1286A>G (p.Gln429Arg)	GAA	glycogen storage disease II	MONDO:0009290	Autosomal recessive inheritance	Benign	BA1		The highest continental population minor allele frequency for c.1286A>G (p.Gln429Arg) in gnomAD v2.1.1 is 0.01028 in the East Asian population. This is higher than the ClinGen LSD VCEP’s BA1 threshold (>0.01), therefore meeting the BA1 criterion. There is a ClinVar entry for this variant (Variation ID: 284497; 2 star review status) with three submitters classifying the variant as benign and one as likely benign. In summary, this variant meets the criteria to be classified as benign for Pompe disease. GAA-specific ACMG/AMP criteria applied, as specified by the ClinGen LSD VCEP: BA1.		Lysosomal Diseases VCEP	https://clinicalgenome.org/docs/clingen-lysosomal-storage-disorders-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-2/	2020-01-22	2020-05-19	False	https://erepo.genome.network/evrepo/ui/classification/CA8815250/MONDO:0009290/010	a163d874-5535-499a-a421-67c8dfbbf089	p.Gln429Arg	Gln	429	Arg	MGVRHPPCSHRLLAVCALVSLATAALLGHILLHDFLLVPRELSGSSPVLEETHPAHQQGASRPGPRDAQAHPGRPRAVPTQCDVPPNSRFDCAPDKAITQEQCEARGCCYIPAKQGLQGAQMGQPWCFFPPSYPSYKLENLSSSEMGYTATLTRTTPTFFPKDILTLRLDVMMETENRLHFTIKDPANRRYEVPLETPHVHSRAPSPLYSVEFSEEPFGVIVRRQLDGRVLLNTTVAPLFFADQFLQLSTSLPSQYITGLAEHLSPLMLSTSWTRITLWNRDLAPTPGANLYGSHPFYLALEDGGSAHGVFLLNSNAMDVVLQPSPALSWRSTGGILDVYIFLGPEPKSVVQQYLDVVGYPFMPPYWGLGFHLCRWGYSSTAITRQVVENMTRAHFPLDVQWNDLDYMDSRRDFTFNKDGFRDFPAMVQELHQGGRRYMMIVDPAISSSGPAGSYRPYDEGLRRGVFITNETGQPLIGKVWPGSTAFPDFTNPTALAWWEDMVAEFHDQVPFDGMWIDMNEPSNFIRGSEDGCPNNELENPPYVPGVVGGTLQAATICASSHQFLSTHYNLHNLYGLTEAIASHRALVKARGTRPFVISRSTFAGHGRYAGHWTGDVWSSWEQLASSVPEILQFNLLGVPLVGADVCGFLGNTSEELCVRWTQLGAFYPFMRNHNSLLSLPQEPYSFSEPAQQAMRKALTLRYALLPHLYTLFHQAHVAGETVARPLFLEFPKDSSTWTVDHQLLWGEALLITPVLQAGKAEVTGYFPLGTWYDLQTVPVEALGSLPPPPAAPREPAIHSEGQWVTLPAPLDTINVHLRAGYIIPLQGPGLTTTESRQQPMALAVALTKGGEARGELFWDDGESLEVLERGAYTQVIFLARNNTIVNELVRVTSEGAGLQLQKVTVLGVATAPQQVLSNGVPVSNFTYSPDTKVLDICVSLLMGEQFLVSWC	952	P10253	R	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [423, 429, 707], 'DNA_BIND_gain_score': array([0.00636828, 0.00609583, 0.00109911]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
163	NM_206933.4(USH2A):c.3407G>A (p.Ser1136Asn)	133312	CA269917	NM_206933.4:c.3407G>A, NC_000001.11:g.216200031C>T, CM000663.2:g.216200031C>T, NC_000001.10:g.216373373C>T, CM000663.1:g.216373373C>T, NC_000001.9:g.214439996C>T, NG_009497.1:g.228366G>A, NG_009497.2:g.228418G>A, ENST00000307340.8:c.3407G>A, ENST00000674083.1:c.3407G>A, ENST00000307340.7:c.3407G>A, ENST00000366942.3:c.3407G>A, NM_007123.5:c.3407G>A, NM_206933.2:c.3407G>A, XR_922595.1:n.355-3999C>T, XR_922596.1:n.354+4106C>T, XR_922597.1:n.354+4106C>T, XR_922598.1:n.485-3999C>T, XR_922595.3:n.1077-3999C>T, XR_922596.3:n.1076+4106C>T, NM_206933.3:c.3407G>A, NM_007123.6:c.3407G>A, NM_206933.4(USH2A):c.3407G>A (p.Ser1136Asn)	USH2A	Usher syndrome	MONDO:0019501	Autosomal recessive inheritance	Pathogenic	PP4, PM3_Very Strong, PM2_Supporting	PP3, BP4	The c.3407G>A variant in USH2A is a missense variant predicted to cause substitution of serine to asparagine at amino acid 1136. This variant is absent from large population studies (PM2_Supporting, gnomAD v2.1.1). The computational predictor REVEL gives a score of 0.466 which is neither above nor below the thresholds predicting a damaging or benign impact on USH2A function. This variant has been reported in at least 6 probands with USH2A-related disorders, including four individuals with autosomal recessive Usher syndrome and two individuals with  isolated retinopathy. Of these individuals, the variant was confirmed in trans with a pathogenic variant in two individuals, but phase with a second pathogenic variant was unclear in the remaining 4 individuals (PM3_VeryStrong; PMID: 22135276, 25991456, 27957503, 36011334). Of note, the two individuals with isolated retinopathy harbored the pathogenic p.Cys759Phe variant, which is commonly found in individuals with an isolated retinopathy phenotype (SCV001334331.1). At least one patient with this variant was diagnosed with Usher syndrome (PP4). In summary, this variant meets the criteria to be classified as pathogenic for autosomal recessive USH2A-related disorders including Usher syndrome and isolated retinopathy based on ACMG/AMP criteria applied, as specified by the ClinGen Hearing Loss VCEP; PM2_Supporting, PM3_VeryStrong, PP4. (The ClinGen Hearing Loss VCEP Specifications Version 2; 09/26/2022)		Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2023-09-26	2023-10-05	False	https://erepo.genome.network/evrepo/ui/classification/CA269917/MONDO:0019501/005	20e08ce1-8604-4189-b5ef-0d710ecff19c	p.Ser1136Asn	Ser	1136	Asn	MNCPVLSLGSGFLFQVIEMLIFAYFASISLTESRGLFPRLENVGAFKKVSIVPTQAVCGLPDRSTFCHSSAAAESIQFCTQRFCIQDCPYRSSHPTYTALFSAGLSSCITPDKNDLHPNAHSNSASFIFGNHKSCFSSPPSPKLMASFTLAVWLKPEQQGVMCVIEKTVDGQIVFKLTISEKETMFYYRTVNGLQPPIKVMTLGRILVKKWIHLSVQVHQTKISFFINGVEKDHTPFNARTLSGSITDFASGTVQIGQSLNGLEQFVGRMQDFRLYQVALTNREILEVFSGDLLRLHAQSHCRCPGSHPRVHPLAQRYCIPNDAGDTADNRVSRLNPEAHPLSFVNDNDVGTSWVSNVFTNITQLNQGVTISVDLENGQYQVFYIIIQFFSPQPTEIRIQRKKENSLDWEDWQYFARNCGAFGMKNNGDLEKPDSVNCLQLSNFTPYSRGNVTFSILTPGPNYRPGYNNFYNTPSLQEFVKATQIRFHFHGQYYTTETAVNLRHRYYAVDEITISGRCQCHGHADNCDTTSQPYRCLCSQESFTEGLHCDRCLPLYNDKPFRQGDQVYAFNCKPCQCNSHSKSCHYNISVDPFPFEHFRGGGGVCDDCEHNTTGRNCELCKDYFFRQVGADPSAIDVCKPCDCDTVGTRNGSILCDQIGGQCNCKRHVSGRQCNQCQNGFYNLQELDPDGCSPCNCNTSGTVDGDITCHQNSGQCKCKANVIGLRCDHCNFGFKFLRSFNDVGCEPCQCNLHGSVNKFCNPHSGQCECKKEAKGLQCDTCRENFYGLDVTNCKACDCDTAGSLPGTVCNAKTGQCICKPNVEGRQCNKCLEGNFYLRQNNSFLCLPCNCDKTGTINGSLLCNKSTGQCPCKLGVTGLRCNQCEPHRYNLTIDNFQHCQMCECDSLGTLPGTICDPISGQCLCVPNRQGRRCNQCQPGFYISPGNATGCLPCSCHTTGAVNHICNSLTGQCVCQDASIAGQRCDQCKDHYFGFDPQTGRCQPCNCHLSGALNETCHLVTGQCFCKQFVTGSKCDACVPSASHLDVNNLLGCSKTPFQQPPPRGQVQSSSAINLSWSPPDSPNAHWLTYSLLRDGFEIYTTEDQYPYSIQYFLDTDLLPYTKYSYYIETTNVHGSTRSVAVTYKTKPGVPEGNLTLSYIIPIGSDSVTLTWTTLSNQSGPIEKYILSCAPLAGGQPCVSYEGHETSATIWNLVPFAKYDFSVQACTSGGCLHSLPITVTTAQAPPQRLSPPKMQKISSTELHVEWSPPAELNGIIIRYELYMRRLRSTKETTSEESRVFQSSGWLSPHSFVESANENALKPPQTMTTITGLEPYTKYEFRVLAVNMAGSVSSAWVSERTGESAPVFMIPPSVFPLSSYSLNISWEKPADNVTRGKVVGYDINMLSEQSPQQSIPMAFSQLLHTAKSQELSYTVEGLKPYRIYEFTITLCNSVGCVTSASGAGQTLAAAPAQLRPPLVKGINSTTIHLRWFPPEELNGPSPIYQLERRESSLPALMTTMMKGIRFIGNGYCKFPSSTHPVNTDFTGIKASFRTKVPEGLIVFAASPGNQEEYFALQLKKGRLYFLFDPQGSPVEVTTTNDHGKQYSDGKWHEIIAIRHQAFGQITLDGIYTGSSAILNGSTVIGDNTGVFLGGLPRSYTILRKDPEIIQKGFVGCLKDVHFMKNYNPSAIWEPLDWQSSEEQINVYNSWEGCPASLNEGAQFLGAGFLELHPYMFHGGMNFEISFKFRTDQLNGLLLFVYNKDGPDFLAMELKSGILTFRLNTSLAFTQVDLLLGLSYCNGKWNKVIIKKEGSFISASVNGLMKHASESGDQPLVVNSPVYVGGIPQELLNSYQHLCLEQGFGGCMKDVKFTRGAVVNLASVSSGAVRVNLDGCLSTDSAVNCRGNDSILVYQGKEQSVYEGGLQPFTEYLYRVIASHEGGSVYSDWSRGRTTGAAPQSVPTPSRVRSLNGYSIEVTWDEPVVRGVIEKYILKAYSEDSTRPPRMPSASAEFVNTSNLTGILTGLLPFKNYAVTLTACTLAGCTESSHALNISTPQEAPQEVQPPVAKSLPSSLLLSWNPPKKANGIITQYCLYMDGRLIYSGSEENYIVTDLAVFTPHQFLLSACTHVGCTNSSWVLLYTAQLPPEHVDSPVLTVLDSRTIHIQWKQPRKISGILERYVLYMSNHTHDFTIWSVIYNSTELFQDHMLQYVLPGNKYLIKLGACTGGGCTVSEASEALTDEDIPEGVPAPKAHSYSPDSFNVSWTEPEYPNGVITSYGLYLDGILIHNSSELSYRAYGFAPWSLHSFRVQACTAKGCALGPLVENRTLEAPPEGTVNVFVKTQGSRKAHVRWEAPFRPNGLLTHSVLFTGIFYVDPVGNNYTLLNVTKVMYSGEETNLWVLIDGLVPFTNYTVQVNISNSQGSLITDPITIAMPPGAPDGVLPPRLSSATPTSLQVVWSTPARNNAPGSPRYQLQMRSGDSTHGFLELFSNPSASLSYEVSDLQPYTEYMFRLVASNGFGSAHSSWIPFMTAEDKPGPVVPPILLDVKSRMMLVTWQHPRKSNGVITHYNIYLHGRLYLRTPGNVTNCTVMHLHPYTAYKFQVEACTSKGCSLSPESQTVWTLPGAPEGIPSPELFSDTPTSVIISWQPPTHPNGLVENFTIERRVKGKEEVTTLVTLPRSHSMRFIDKTSALSPWTKYEYRVLMSTLHGGTNSSAWVEVTTRPSRPAGVQPPVVTVLEPDAVQVTWKPPLIQNGDILSYEIHMPDPHITLTNVTSAVLSQKVTHLIPFTNYSVTIVACSGGNGYLGGCTESLPTYVTTHPTVPQNVGPLSVIPLSESYVVISWQPPSKPNGPNLRYELLRRKIQQPLASNPPEDLNRWHNIYSGTQWLYEDKGLSRFTTYEYMLFVHNSVGFTPSREVTVTTLAGLPERGANLTASVLNHTAIDVRWAKPTVQDLQGEVEYYTLFWSSATSNDSLKILPDVNSHVIGHLKPNTEYWIFISVFNGVHSINSAGLHATTCDGEPQGMLPPEVVIINSTAVRVIWTSPSNPNGVVTEYSIYVNNKLYKTGMNVPGSFILRDLSPFTIYDIQVEVCTIYACVKSNGTQITTVEDTPSDIPTPTIRGITSRSLQIDWVSPRKPNGIILGYDLLWKTWYPCAKTQKLVQDQSDELCKAVRCQKPESICGHICYSSEAKVCCNGVLYNPKPGHRCCEEKYIPFVLNSTGVCCGGRIQEAQPNHQCCSGYYARILPGEVCCPDEQHNRVSVGIGDSCCGRMPYSTSGNQICCAGRLHDGHGQKCCGRQIVSNDLECCGGEEGVVYNRLPGMFCCGQDYVNMSDTICCSASSGESKAHIKKNDPVPVKCCETELIPKSQKCCNGVGYNPLKYVCSDKISTGMMMKETKECRILCPASMEATEHCGRCDFNFTSHICTVIRGSHNSTGKASIEEMCSSAEETIHTGSVNTYSYTDVNLKPYMTYEYRISAWNSYGRGLSKAVRARTKEDVPQGVSPPTWTKIDNLEDTIVLNWRKPIQSNGPIIYYILLRNGIERFRGTSLSFSDKEGIQPFQEYSYQLKACTVAGCATSSKVVAATTQGVPESILPPSITALSAVALHLSWSVPEKSNGVIKEYQIRQVGKGLIHTDTTDRRQHTVTGLQPYTNYSFTLTACTSAGCTSSEPFLGQTLQAAPEGVWVTPRHIIINSTTVELYWSLPEKPNGLVSQYQLSRNGNLLFLGGSEEQNFTDKNLEPNSRYTYKLEVKTGGGSSASDDYIVQTPMSTPEEIYPPYNITVIGPYSIFVAWIPPGILIPEIPVEYNVLLNDGSVTPLAFSVGHHQSTLLENLTPFTQYEIRIQACQNGSCGVSSRMFVKTPEAAPMDLNSPVLKALGSACIEIKWMPPEKPNGIIINYFIYRRPAGIEEESVLFVWSEGALEFMDEGDTLRPFTLYEYRVRACNSKGSVESLWSLTQTLEAPPQDFPAPWAQATSAHSVLLNWTKPESPNGIISHYRVVYQERPDDPTFNSPTVHAFTVKGTSHQAHLYGLEPFTTYRIGVVAANHAGEILSPWTLIQTLESSPSGLRNFIVEQKENGRALLLQWSEPMRTNGVIKTYNIFSDGFLEYSGLNRQFLFRRLDPFTLYTLTLEACTRAGCAHSAPQPLWTDEAPPDSQLAPTVHSVKSTSVELSWSEPVNPNGKIIRYEVIRRCFEGKAWGNQTIQADEKIVFTEYNTERNTFMYNDTGLQPWTQCEYKIYTWNSAGHTCSSWNVVRTLQAPPEGLSPPVISYVSMNPQKLLISWIPPEQSNGIIQSYRLQRNEMLYPFSFDPVTFNYTDEELLPFSTYSYALQACTSGGCSTSKPTSITTLEAAPSEVSPPDLWAVSATQMNVCWSPPTVQNGKITKYLVRYDNKESLAGQGLCLLVSHLQPYSQYNFSLVACTNGGCTASVSKSAWTMEALPENMDSPTLQVTGSESIEITWKPPRNPNGQIRSYELRRDGTIVYTGLETRYRDFTLTPGVEYSYTVTASNSQGGILSPLVKDRTSPSAPSGMEPPKLQARGPQEILVNWDPPVRTNGDIINYTLFIRELFERETKIIHINTTHNSFGMQSYIVNQLKPFHRYEIRIQACTTLGCASSDWTFIQTPEIAPLMQPPPHLEVQMAPGGFQPTVSLLWTGPLQPNGKVLYYELYRRQIATQPRKSNPVLIYNGSSTSFIDSELLPFTEYEYQVWAVNSAGKAPSSWTWCRTGPAPPEGLRAPTFHVISSTQAVVNISAPGKPNGIVSLYRLFSSSAHGAETVLSEGMATQQTLHGLQAFTNYSIGVEACTCFNCCSKGPTAELRTHPAPPSGLSSPQIGTLASRTASFRWSPPMFPNGVIHSYELQFHVACPPDSALPCTPSQIETKYTGLGQKASLGGLQPYTTYKLRVVAHNEVGSTASEWISFTTQKELPQYRAPFSVDSNLSVVCVNWSDTFLLNGQLKEYVLTDGGRRVYSGLDTTLYIPRTADKTFFFQVICTTDEGSVKTPLIQYDTSTGLGLVLTTPGKKKGSRSKSTEFYSELWFIVLMAMLGLILLAIFLSLILQRKIHKEPYIRERPPLVPLQKRMSPLNVYPPGENHMGLADTKIPRSGTPVSIRSNRSACVLRIPSQNQTSLTYSQGSLHRSVSQLMDIQDKKVLMDNSLWEAIMGHNSGLYVDEEDLMNAIKDFSSVTKERTTFTDTHL	5202	O75445	N	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [3167, 3881], 'DISULFID_gain_score': array([0.00024253, 0.00043648]), 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
164	NM_000152.4(GAA):c.2338G>A (p.Val780Ile)	92476	CA145769	NM_000152.4:c.2338G>A, NC_000017.11:g.80117606G>A, CM000679.2:g.80117606G>A, NC_000017.10:g.78091405G>A, CM000679.1:g.78091405G>A, NC_000017.9:g.75706000G>A, NG_009822.1:g.21051G>A, LRG_673:g.21051G>A, NM_000152.3:c.2338G>A, LRG_673t1:c.2338G>A, NM_001079803.1:c.2338G>A, NM_001079804.1:c.2338G>A, XM_005257193.1:c.2338G>A, XM_005257194.3:c.2338G>A, NM_001079803.2:c.2338G>A, NM_001079804.2:c.2338G>A, XM_005257193.2:c.2338G>A, XM_005257194.4:c.2338G>A, NM_000152.5:c.2338G>A, NM_001079803.3:c.2338G>A, NM_001079804.3:c.2338G>A, ENST00000302262.7:c.2338G>A, ENST00000390015.7:c.2338G>A, ENST00000573556.1:n.291G>A, NM_000152.4(GAA):c.2338G>A (p.Val780Ile)	GAA	glycogen storage disease II	MONDO:0009290	Autosomal recessive inheritance	Benign	BA1		The highest continental population minor allele frequency for c.2338G>A (p.Val780Ile) in gnomAD v2.1.1 is 0.8129 in the South Asian population. This is higher than the ClinGen LSD VCEP’s BA1 threshold (>0.01), therefore meeting the BA1 criterion. There is a ClinVar entry for this variant (Variation ID: 92476; 2 star review status) with six submitters classifying the variant as benign. In summary, this variant meets the criteria to be classified as benign for Pompe disease. GAA-specific ACMG/AMP criteria applied, as specified by the ClinGen LSD VCEP: BA1.		Lysosomal Diseases VCEP	https://clinicalgenome.org/docs/clingen-lysosomal-storage-disorders-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-2/	2020-01-23	2020-05-19	False	https://erepo.genome.network/evrepo/ui/classification/CA145769/MONDO:0009290/010	69ccf2de-d1f6-4cf9-b273-379884a992c0	p.Val780Ile	Val	780	Ile	MGVRHPPCSHRLLAVCALVSLATAALLGHILLHDFLLVPRELSGSSPVLEETHPAHQQGASRPGPRDAQAHPGRPRAVPTQCDVPPNSRFDCAPDKAITQEQCEARGCCYIPAKQGLQGAQMGQPWCFFPPSYPSYKLENLSSSEMGYTATLTRTTPTFFPKDILTLRLDVMMETENRLHFTIKDPANRRYEVPLETPHVHSRAPSPLYSVEFSEEPFGVIVRRQLDGRVLLNTTVAPLFFADQFLQLSTSLPSQYITGLAEHLSPLMLSTSWTRITLWNRDLAPTPGANLYGSHPFYLALEDGGSAHGVFLLNSNAMDVVLQPSPALSWRSTGGILDVYIFLGPEPKSVVQQYLDVVGYPFMPPYWGLGFHLCRWGYSSTAITRQVVENMTRAHFPLDVQWNDLDYMDSRRDFTFNKDGFRDFPAMVQELHQGGRRYMMIVDPAISSSGPAGSYRPYDEGLRRGVFITNETGQPLIGKVWPGSTAFPDFTNPTALAWWEDMVAEFHDQVPFDGMWIDMNEPSNFIRGSEDGCPNNELENPPYVPGVVGGTLQAATICASSHQFLSTHYNLHNLYGLTEAIASHRALVKARGTRPFVISRSTFAGHGRYAGHWTGDVWSSWEQLASSVPEILQFNLLGVPLVGADVCGFLGNTSEELCVRWTQLGAFYPFMRNHNSLLSLPQEPYSFSEPAQQAMRKALTLRYALLPHLYTLFHQAHVAGETVARPLFLEFPKDSSTWTVDHQLLWGEALLITPVLQAGKAEVTGYFPLGTWYDLQTVPVEALGSLPPPPAAPREPAIHSEGQWVTLPAPLDTINVHLRAGYIIPLQGPGLTTTESRQQPMALAVALTKGGEARGELFWDDGESLEVLERGAYTQVIFLARNNTIVNELVRVTSEGAGLQLQKVTVLGVATAPQQVLSNGVPVSNFTYSPDTKVLDICVSLLMGEQFLVSWC	952	P10253	I	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [658, 707], 'DNA_BIND_gain_score': array([0.00197643, 0.0011878 ]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [806, 884, 885, 913], 'STRAND_gain_score': array([0.00699985, 0.00669742, 0.00745332, 0.00558609]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
165	NM_000152.4(GAA):c.2446G>A (p.Val816Ile)	92477	CA145772	NM_000152.4:c.2446G>A, NM_000152.3:c.2446G>A, LRG_673t1:c.2446G>A, NM_001079803.1:c.2446G>A, NM_001079804.1:c.2446G>A, XM_005257193.1:c.2446G>A, XM_005257194.3:c.2446G>A, NM_001079803.2:c.2446G>A, NM_001079804.2:c.2446G>A, XM_005257193.2:c.2446G>A, XM_005257194.4:c.2446G>A, NM_000152.5:c.2446G>A, NM_001079803.3:c.2446G>A, NM_001079804.3:c.2446G>A, ENST00000302262.7:c.2446G>A, ENST00000390015.7:c.2446G>A, ENST00000573556.1:n.399G>A, NC_000017.11:g.80117714G>A, CM000679.2:g.80117714G>A, NC_000017.10:g.78091513G>A, CM000679.1:g.78091513G>A, NC_000017.9:g.75706108G>A, NG_009822.1:g.21159G>A, LRG_673:g.21159G>A, NM_000152.4(GAA):c.2446G>A (p.Val816Ile)	GAA	glycogen storage disease II	MONDO:0009290	Autosomal recessive inheritance	Benign	BA1		The highest continental population minor allele frequency for c.2446G>A (p.Val816Ile) in gnomAD v2.1.1 is 0.14249 in the African population. This is higher than the ClinGen LSD VCEP’s BA1 threshold (>0.01), therefore meeting the BA1 criterion. There is a ClinVar entry for this variant (Variation ID: 92477; 2 star review status) with four submitters classifying the variant as benign, and two as likely benign. In summary, this variant meets the criteria to be classified as benign for Pompe disease. GAA-specific ACMG/AMP criteria applied, as specified by the ClinGen LSD VCEP: BA1.		Lysosomal Diseases VCEP	https://clinicalgenome.org/docs/clingen-lysosomal-storage-disorders-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-2/	2020-01-23	2020-05-19	False	https://erepo.genome.network/evrepo/ui/classification/CA145772/MONDO:0009290/010	b7701534-9880-4bd5-8371-0ca3b2250692	p.Val816Ile	Val	816	Ile	MGVRHPPCSHRLLAVCALVSLATAALLGHILLHDFLLVPRELSGSSPVLEETHPAHQQGASRPGPRDAQAHPGRPRAVPTQCDVPPNSRFDCAPDKAITQEQCEARGCCYIPAKQGLQGAQMGQPWCFFPPSYPSYKLENLSSSEMGYTATLTRTTPTFFPKDILTLRLDVMMETENRLHFTIKDPANRRYEVPLETPHVHSRAPSPLYSVEFSEEPFGVIVRRQLDGRVLLNTTVAPLFFADQFLQLSTSLPSQYITGLAEHLSPLMLSTSWTRITLWNRDLAPTPGANLYGSHPFYLALEDGGSAHGVFLLNSNAMDVVLQPSPALSWRSTGGILDVYIFLGPEPKSVVQQYLDVVGYPFMPPYWGLGFHLCRWGYSSTAITRQVVENMTRAHFPLDVQWNDLDYMDSRRDFTFNKDGFRDFPAMVQELHQGGRRYMMIVDPAISSSGPAGSYRPYDEGLRRGVFITNETGQPLIGKVWPGSTAFPDFTNPTALAWWEDMVAEFHDQVPFDGMWIDMNEPSNFIRGSEDGCPNNELENPPYVPGVVGGTLQAATICASSHQFLSTHYNLHNLYGLTEAIASHRALVKARGTRPFVISRSTFAGHGRYAGHWTGDVWSSWEQLASSVPEILQFNLLGVPLVGADVCGFLGNTSEELCVRWTQLGAFYPFMRNHNSLLSLPQEPYSFSEPAQQAMRKALTLRYALLPHLYTLFHQAHVAGETVARPLFLEFPKDSSTWTVDHQLLWGEALLITPVLQAGKAEVTGYFPLGTWYDLQTVPVEALGSLPPPPAAPREPAIHSEGQWVTLPAPLDTINVHLRAGYIIPLQGPGLTTTESRQQPMALAVALTKGGEARGELFWDDGESLEVLERGAYTQVIFLARNNTIVNELVRVTSEGAGLQLQKVTVLGVATAPQQVLSNGVPVSNFTYSPDTKVLDICVSLLMGEQFLVSWC	952	P10253	I	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [375, 420, 424], 'DNA_BIND_gain': [], 'DNA_BIND_loss_score': array([-0.00038695, -0.00053954, -0.00086987]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [806, 885], 'STRAND_gain_score': array([0.02740055, 0.00542563]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [386], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.00128585]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
166	NM_000152.4(GAA):c.2780C>T (p.Thr927Ile)	92482	CA145778	NM_000152.4:c.2780C>T, NC_000017.11:g.80118786C>T, CM000679.2:g.80118786C>T, NC_000017.10:g.78092585C>T, CM000679.1:g.78092585C>T, NC_000017.9:g.75707180C>T, NG_009822.1:g.22231C>T, LRG_673:g.22231C>T, NM_000152.3:c.2780C>T, LRG_673t1:c.2780C>T, NM_001079803.1:c.2780C>T, NM_001079804.1:c.2780C>T, XM_005257193.1:c.2780C>T, XM_005257194.3:c.2780C>T, NM_001079803.2:c.2780C>T, NM_001079804.2:c.2780C>T, XM_005257193.2:c.2780C>T, XM_005257194.4:c.2780C>T, NM_000152.5:c.2780C>T, NM_001079803.3:c.2780C>T, NM_001079804.3:c.2780C>T, ENST00000302262.7:c.2780C>T, ENST00000390015.7:c.2780C>T, ENST00000573556.1:n.733C>T, NM_000152.4(GAA):c.2780C>T (p.Thr927Ile)	GAA	glycogen storage disease II	MONDO:0009290	Autosomal recessive inheritance	Benign	BA1		The highest continental population minor allele frequency for c.2780C>T (p.Thr927Ile) in gnomAD v2.1.1 is 0.1317 in the African population. This is higher than the ClinGen LSD VCEP’s BA1 threshold (>0.01), therefore meeting the BA1 criterion. There is a ClinVar entry for this variant (Variation ID: 92482; 2 star review status) with six submitters classifying the variant as benign, and two as likely benign. In summary, this variant meets the criteria to be classified as benign for Pompe disease. GAA-specific ACMG/AMP criteria applied, as specified by the ClinGen LSD VCEP: BA1.		Lysosomal Diseases VCEP	https://clinicalgenome.org/docs/clingen-lysosomal-storage-disorders-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-2/	2020-01-23	2020-05-19	False	https://erepo.genome.network/evrepo/ui/classification/CA145778/MONDO:0009290/010	0dace307-d73d-4361-89ee-42f551fed0d7	p.Thr927Ile	Thr	927	Ile	MGVRHPPCSHRLLAVCALVSLATAALLGHILLHDFLLVPRELSGSSPVLEETHPAHQQGASRPGPRDAQAHPGRPRAVPTQCDVPPNSRFDCAPDKAITQEQCEARGCCYIPAKQGLQGAQMGQPWCFFPPSYPSYKLENLSSSEMGYTATLTRTTPTFFPKDILTLRLDVMMETENRLHFTIKDPANRRYEVPLETPHVHSRAPSPLYSVEFSEEPFGVIVRRQLDGRVLLNTTVAPLFFADQFLQLSTSLPSQYITGLAEHLSPLMLSTSWTRITLWNRDLAPTPGANLYGSHPFYLALEDGGSAHGVFLLNSNAMDVVLQPSPALSWRSTGGILDVYIFLGPEPKSVVQQYLDVVGYPFMPPYWGLGFHLCRWGYSSTAITRQVVENMTRAHFPLDVQWNDLDYMDSRRDFTFNKDGFRDFPAMVQELHQGGRRYMMIVDPAISSSGPAGSYRPYDEGLRRGVFITNETGQPLIGKVWPGSTAFPDFTNPTALAWWEDMVAEFHDQVPFDGMWIDMNEPSNFIRGSEDGCPNNELENPPYVPGVVGGTLQAATICASSHQFLSTHYNLHNLYGLTEAIASHRALVKARGTRPFVISRSTFAGHGRYAGHWTGDVWSSWEQLASSVPEILQFNLLGVPLVGADVCGFLGNTSEELCVRWTQLGAFYPFMRNHNSLLSLPQEPYSFSEPAQQAMRKALTLRYALLPHLYTLFHQAHVAGETVARPLFLEFPKDSSTWTVDHQLLWGEALLITPVLQAGKAEVTGYFPLGTWYDLQTVPVEALGSLPPPPAAPREPAIHSEGQWVTLPAPLDTINVHLRAGYIIPLQGPGLTTTESRQQPMALAVALTKGGEARGELFWDDGESLEVLERGAYTQVIFLARNNTIVNELVRVTSEGAGLQLQKVTVLGVATAPQQVLSNGVPVSNFTYSPDTKVLDICVSLLMGEQFLVSWC	952	P10253	I	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [424, 663, 704, 714, 716], 'DNA_BIND_gain': [], 'DNA_BIND_loss_score': array([-0.00088239, -0.00562125, -0.00046158, -0.00988722, -0.00192529]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [22], 'TRANSIT_gain_score': array([0.00996834]), 'STRAND_loss': [], 'STRAND_gain': [259, 806, 884, 913], 'STRAND_gain_score': array([0.00658017, 0.01462311, 0.00641268, 0.01600063]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
167	NM_000546.5(TP53):c.704A>G (p.Asn235Ser)	127821	CA000343	NM_000546.5:c.704A>G, NC_000017.11:g.7674259T>C, CM000679.2:g.7674259T>C, NC_000017.10:g.7577577T>C, CM000679.1:g.7577577T>C, NC_000017.9:g.7518302T>C, NG_017013.2:g.18292A>G, LRG_321:g.18292A>G, LRG_321t1:c.704A>G, NM_001126112.2:c.704A>G, LRG_321t2:c.704A>G, NM_001126113.2:c.704A>G, LRG_321t4:c.704A>G, NM_001126114.2:c.704A>G, LRG_321t3:c.704A>G, NM_001126115.1:c.308A>G, LRG_321t5:c.308A>G, NM_001126116.1:c.308A>G, LRG_321t6:c.308A>G, NM_001126117.1:c.308A>G, LRG_321t7:c.308A>G, NM_001126118.1:c.587A>G, LRG_321t8:c.587A>G, NM_001276695.1:c.587A>G, NM_001276696.1:c.587A>G, NM_001276697.1:c.227A>G, NM_001276698.1:c.227A>G, NM_001276699.1:c.227A>G, NM_001276760.1:c.587A>G, NM_001276761.1:c.587A>G, ENST00000269305.8:c.704A>G, ENST00000359597.8:n.704A>G, ENST00000413465.6:n.704A>G, ENST00000420246.6:c.704A>G, ENST00000445888.6:c.704A>G, ENST00000455263.6:c.704A>G, ENST00000504290.5:c.308A>G, ENST00000504937.5:c.308A>G, ENST00000509690.5:c.308A>G, ENST00000510385.5:c.308A>G, ENST00000514944.5:c.425A>G, ENST00000574684.1:n.99A>G, ENST00000610292.4:c.587A>G, ENST00000610538.4:c.587A>G, ENST00000610623.4:c.227A>G, ENST00000615910.4:n.671A>G, ENST00000617185.4:c.704A>G, ENST00000618944.4:c.227A>G, ENST00000619186.4:c.227A>G, ENST00000619485.4:c.587A>G, ENST00000620739.4:c.587A>G, ENST00000622645.4:c.587A>G, ENST00000635293.1:c.587A>G, NM_000546.5(TP53):c.704A>G (p.Asn235Ser)	TP53	Li-Fraumeni syndrome	MONDO:0018875	Autosomal dominant inheritance	Benign	BP2, BP4, BS2_Supporting, BS4, BS3, BS1		This variant has a minor allele frequency of 0.0003175 (0.03%, 41/129,118 alleles) in the European (non-Finnish) subpopulation of the gnomAD cohort (BS1). The variant has a BayesDel score < 0.16 and Align GVGD (Zebrafish) is Class C0 or Class C15 (BP4). Additionally, transactivation assays show retained function according to Kato, et al. and there is no evidence of a dominant negative effect or loss of function according to Giacomelli, et al. (BS3; PMID: 12826609, 30224644). This variant also segregates to the opposite side of a family who meets Li-Fraumeni syndrome criteria. (BS4; PMID: 17318340). The proband in this same family has a pathogenic variant (TP53 c.560-1G>A) in trans with this variant. (BP2; PMID: 17318340). Finally, this variant has been observed in at least 4 60+ year old females without a cancer diagnosis (BS2_Supporting; FLOSSIES database - https://whi.color.com).In summary, TP53 c.704A>G; p.Asn235Ser meets criteria to be classified as benign for Li-Fraumeni syndrome. ACMG/AMP criteria applied, as specified by the TP53 Variant Curation Expert Panel: BS1, BP4, BS3, BS4, BP2, BS2_Supporting.	30224644, 12826609	TP53 VCEP		2019-08-28	2020-01-24	False	https://erepo.genome.network/evrepo/ui/classification/CA000343/MONDO:0018875/009	38d9dfad-aa7b-409a-9fd8-3f6898fb8c57	p.Asn235Ser	Asn	235	Ser	MEEPQSDPSVEPPLSQETFSDLWKLLPENNVLSPLPSQAMDDLMLSPDDIEQWFTEDPGPDEAPRMPEAAPPVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFRHSVVVPYEPPEVGSDCTTIHYNYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNTSSSPQPKKKPLDGEYFTLQIRGRERFEMFRELNEALELKDAQAGKEPGGSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD	393	P04637	S	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [285], 'DNA_BIND_gain': [], 'DNA_BIND_loss_score': array([-0.02425587]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [121, 122, 300, 304, 305, 308, 311, 312, 318, 322, 365, 366, 369, 372, 377, 378], 'PROPEP_gain': [], 'PROPEP_loss_score': array([-0.00611991, -0.01876706, -0.02459663, -0.02027172, -0.02105105,
       -0.02299947, -0.02041161, -0.02133691, -0.02015758, -0.02638865,
       -0.02955288, -0.02962494, -0.03293502, -0.03164005, -0.03017068,
       -0.03011286]), 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [197, 199], 'STRAND_gain': [238], 'STRAND_gain_score': array([0.09744364]), 'STRAND_loss_score': array([-0.04733467, -0.03134388]), 'HELIX_loss': [239], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.11367971]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [131, 132, 133, 134, 135, 136], 'DOMAIN_gain_score': array([0.3140977 , 0.27686125, 0.28906959, 0.26113397, 0.25926894,
       0.26244456]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
168	NM_000546.5(TP53):c.537T>A (p.His179Gln)	406578	CA16615708	NM_000546.5:c.537T>A, NC_000017.11:g.7675075A>T, CM000679.2:g.7675075A>T, NC_000017.10:g.7578393A>T, CM000679.1:g.7578393A>T, NC_000017.9:g.7519118A>T, NG_017013.2:g.17476T>A, LRG_321:g.17476T>A, LRG_321t1:c.537T>A, NM_001126112.2:c.537T>A, LRG_321t2:c.537T>A, NM_001126113.2:c.537T>A, LRG_321t4:c.537T>A, NM_001126114.2:c.537T>A, LRG_321t3:c.537T>A, NM_001126115.1:c.141T>A, LRG_321t5:c.141T>A, NM_001126116.1:c.141T>A, LRG_321t6:c.141T>A, NM_001126117.1:c.141T>A, LRG_321t7:c.141T>A, NM_001126118.1:c.420T>A, LRG_321t8:c.420T>A, NM_001276695.1:c.420T>A, NM_001276696.1:c.420T>A, NM_001276697.1:c.60T>A, NM_001276698.1:c.60T>A, NM_001276699.1:c.60T>A, NM_001276760.1:c.420T>A, NM_001276761.1:c.420T>A, ENST00000269305.8:c.537T>A, ENST00000359597.8:n.537T>A, ENST00000413465.6:n.537T>A, ENST00000420246.6:c.537T>A, ENST00000445888.6:c.537T>A, ENST00000455263.6:c.537T>A, ENST00000504290.5:c.141T>A, ENST00000504937.5:c.141T>A, ENST00000505014.5:n.793T>A, ENST00000509690.5:c.141T>A, ENST00000510385.5:c.141T>A, ENST00000514944.5:c.258T>A, ENST00000574684.1:n.45T>A, ENST00000610292.4:c.420T>A, ENST00000610538.4:c.420T>A, ENST00000610623.4:c.60T>A, ENST00000615910.4:n.504T>A, ENST00000617185.4:c.537T>A, ENST00000618944.4:c.60T>A, ENST00000619186.4:c.60T>A, ENST00000619485.4:c.420T>A, ENST00000620739.4:c.420T>A, ENST00000622645.4:c.420T>A, ENST00000635293.1:c.420T>A, NM_000546.5(TP53):c.537T>A (p.His179Gln)	TP53	Li-Fraumeni syndrome	MONDO:0018875	Autosomal dominant inheritance	Pathogenic	PP3, PM2_Supporting, PM6, PS3, PM1	BP4, BA1, PS4, BS1	This variant is absent in the gnomAD cohort (PM2_Supporting; http://gnomad.broadinstitute.org). This variant has a BayesDel score > 0.16 and Align GVGD (Zebrafish) is Class 15 or higher (PP3). Transactivation assays show a low functioning allele according to Kato, et al. and there is evidence of a dominant negative effect and loss of function according to Giacomelli, et al. (PS3; PMID: 12826609, 30224644). This variant has >10 observations as a somatic hotspot variant in tumors (PM1; cancerhotspots.org v(2)). Additionally, there was a de novo observation in an individual with two Li-Fraumeni syndrome spectrum tumors under the age of 5 years without mention of maternal confirmation (PM6; PMID: 19556618). In summary, TP53 c.537T>A; p.His179Gln meets criteria to be classified as likely pathogenic for Li-Fraumeni syndrome.  ACMG/AMP criteria applied, as specified by the TP53 Variant Curation Expert Panel: PM2_Supporting, PP3, PS3, PM1, PM6.	30224644, 12826609	TP53 VCEP		2019-08-28	2020-01-24	False	https://erepo.genome.network/evrepo/ui/classification/CA16615708/MONDO:0018875/009	2f0057b7-4b8d-4b05-98bd-c7760ee4259c	p.His179Gln	His	179	Gln	MEEPQSDPSVEPPLSQETFSDLWKLLPENNVLSPLPSQAMDDLMLSPDDIEQWFTEDPGPDEAPRMPEAAPPVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFRHSVVVPYEPPEVGSDCTTIHYNYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNTSSSPQPKKKPLDGEYFTLQIRGRERFEMFRELNEALELKDAQAGKEPGGSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD	393	P04637	Q	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [134], 'BINDING_gain': [], 'BINDING_loss_score': array([-0.01499695]), 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [134], 'DISULFID_gain_score': array([0.00427443]), 'PROPEP_loss': [], 'PROPEP_gain': [303, 313, 364, 367, 371, 374, 379], 'PROPEP_gain_score': array([0.00495547, 0.00596094, 0.01378846, 0.01325393, 0.01617432,
       0.01613128, 0.01097214]), 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [169], 'STRAND_gain_score': array([0.05554193]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
169	NM_000546.5(TP53):c.659A>G (p.Tyr220Cys)	127819	CA000315	NM_000546.5:c.659A>G, NC_000017.11:g.7674872T>C, CM000679.2:g.7674872T>C, NC_000017.10:g.7578190T>C, CM000679.1:g.7578190T>C, NC_000017.9:g.7518915T>C, NG_017013.2:g.17679A>G, LRG_321:g.17679A>G, LRG_321t1:c.659A>G, NM_001126112.2:c.659A>G, LRG_321t2:c.659A>G, NM_001126113.2:c.659A>G, LRG_321t4:c.659A>G, NM_001126114.2:c.659A>G, LRG_321t3:c.659A>G, NM_001126115.1:c.263A>G, LRG_321t5:c.263A>G, NM_001126116.1:c.263A>G, LRG_321t6:c.263A>G, NM_001126117.1:c.263A>G, LRG_321t7:c.263A>G, NM_001126118.1:c.542A>G, LRG_321t8:c.542A>G, NM_001276695.1:c.542A>G, NM_001276696.1:c.542A>G, NM_001276697.1:c.182A>G, NM_001276698.1:c.182A>G, NM_001276699.1:c.182A>G, NM_001276760.1:c.542A>G, NM_001276761.1:c.542A>G, ENST00000269305.8:c.659A>G, ENST00000359597.8:n.659A>G, ENST00000413465.6:n.659A>G, ENST00000420246.6:c.659A>G, ENST00000445888.6:c.659A>G, ENST00000455263.6:c.659A>G, ENST00000504290.5:c.263A>G, ENST00000504937.5:c.263A>G, ENST00000505014.5:n.915A>G, ENST00000509690.5:c.263A>G, ENST00000510385.5:c.263A>G, ENST00000514944.5:c.380A>G, ENST00000574684.1:n.67+181A>G, ENST00000610292.4:c.542A>G, ENST00000610538.4:c.542A>G, ENST00000610623.4:c.182A>G, ENST00000615910.4:n.626A>G, ENST00000617185.4:c.659A>G, ENST00000618944.4:c.182A>G, ENST00000619186.4:c.182A>G, ENST00000619485.4:c.542A>G, ENST00000620739.4:c.542A>G, ENST00000622645.4:c.542A>G, ENST00000635293.1:c.542A>G, NM_000546.5(TP53):c.659A>G (p.Tyr220Cys)	TP53	Li-Fraumeni syndrome	MONDO:0018875	Autosomal dominant inheritance	Pathogenic	PP1_Strong, PP3_Moderate, PM6, PS4, PS3, PM1		This variant has a BayesDel score > 0.16 and Align GVGD (Zebrafish) is Class 65 (PP3_Moderate). This variant has >10 observations as a somatic hotspot variant in tumors (PM1; cancerhotspots.org v(2)). Transactivation assays show a low functioning allele according to Kato, et al., and there are two assays demonstrating loss of function. One study demonstrates a structural defect that destabilizes the protein and another study showed essentially no apoptosis activity in mutant cells (PS3; PMID: 12826609, 20516128, 15037740). This variant has been reported in at least 4 probands meeting Classic Li-Fraumeni syndrome criteria (PS4; PMID: 8118819, 10432928, 10589545, 15977174). This variant was found to co-segregate with disease in multiple affected family members, with >7 meioses observed across at least two families (PP1_Strong; PMID: 15977174, 9242456, 19101993, 10432928). Additionally, there was a de novo observation in an individual with 10 Classic Li-Fraumeni syndrome spectrum tumors without mention of parental confirmation (PM6; PMID: 18307025). In summary, TP53 c.659A>G; p.Tyr220Cys meets criteria to be classified as pathogenic for Li-Fraumeni syndrome.  ACMG/AMP criteria applied, as specified by the TP53 Variant Curation Expert Panel: PP3_Moderate, PM1, PS3, PS4, PP1_Strong, PM6.	10589545, 10432928, 8118819, 15977174, 12826609, 15037740, 30224644	TP53 VCEP		2019-08-28	2020-01-24	False	https://erepo.genome.network/evrepo/ui/classification/CA000315/MONDO:0018875/009	4795612b-c5d2-4229-a5ec-172fedfbcf55	p.Tyr220Cys	Tyr	220	Cys	MEEPQSDPSVEPPLSQETFSDLWKLLPENNVLSPLPSQAMDDLMLSPDDIEQWFTEDPGPDEAPRMPEAAPPVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFRHSVVVPYEPPEVGSDCTTIHYNYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNTSSSPQPKKKPLDGEYFTLQIRGRERFEMFRELNEALELKDAQAGKEPGGSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD	393	P04637	C	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [134, 219, 237], 'DISULFID_gain_score': array([0.08048993, 0.53483462, 0.11536705]), 'PROPEP_loss': [], 'PROPEP_gain': [128, 301, 302, 303, 307, 310, 313, 314, 323, 364, 367, 368, 370, 371, 373, 374, 375, 376, 379, 381, 382, 383, 384, 392], 'PROPEP_gain_score': array([0.00665259, 0.06130034, 0.05675793, 0.04851419, 0.06354553,
       0.06676775, 0.06951243, 0.07149595, 0.08202231, 0.08751106,
       0.07905692, 0.07512885, 0.08107966, 0.08243984, 0.08268213,
       0.08247316, 0.08759618, 0.08653307, 0.06649399, 0.0835256 ,
       0.08928484, 0.09689701, 0.06985611, 0.04439491]), 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [140], 'STRAND_gain': [229], 'STRAND_gain_score': array([0.01227081]), 'STRAND_loss_score': array([-0.02923995]), 'HELIX_loss': [279, 280, 335], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.10929894, -0.07813323, -0.0404166 ]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [132, 135, 136], 'DOMAIN_gain_score': array([0.21049285, 0.14425319, 0.14048821]), 'REGION_loss': [41, 327], 'REGION_gain': [], 'REGION_loss_score': array([-0.01351207, -0.02306116]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
170	NM_000546.5(TP53):c.455C>T (p.Pro152Leu)	142766	CA000204	NM_000546.5:c.455C>T, NC_000017.11:g.7675157G>A, CM000679.2:g.7675157G>A, NC_000017.10:g.7578475G>A, CM000679.1:g.7578475G>A, NC_000017.9:g.7519200G>A, NG_017013.2:g.17394C>T, LRG_321:g.17394C>T, LRG_321t1:c.455C>T, NM_001126112.2:c.455C>T, LRG_321t2:c.455C>T, NM_001126113.2:c.455C>T, LRG_321t4:c.455C>T, NM_001126114.2:c.455C>T, LRG_321t3:c.455C>T, NM_001126115.1:c.59C>T, LRG_321t5:c.59C>T, NM_001126116.1:c.59C>T, LRG_321t6:c.59C>T, NM_001126117.1:c.59C>T, LRG_321t7:c.59C>T, NM_001126118.1:c.338C>T, LRG_321t8:c.338C>T, NM_001276695.1:c.338C>T, NM_001276696.1:c.338C>T, NM_001276697.1:c.-23C>T, NM_001276698.1:c.-23C>T, NM_001276699.1:c.-23C>T, NM_001276760.1:c.338C>T, NM_001276761.1:c.338C>T, ENST00000269305.8:c.455C>T, ENST00000359597.8:n.455C>T, ENST00000413465.6:n.455C>T, ENST00000420246.6:c.455C>T, ENST00000445888.6:c.455C>T, ENST00000455263.6:c.455C>T, ENST00000504290.5:c.59C>T, ENST00000504937.5:c.59C>T, ENST00000505014.5:n.711C>T, ENST00000508793.5:c.455C>T, ENST00000509690.5:c.59C>T, ENST00000510385.5:c.59C>T, ENST00000514944.5:c.176C>T, ENST00000610292.4:c.338C>T, ENST00000610538.4:c.338C>T, ENST00000610623.4:c.-23C>T, ENST00000615910.4:n.422C>T, ENST00000617185.4:c.455C>T, ENST00000618944.4:c.-23C>T, ENST00000619186.4:c.-23C>T, ENST00000619485.4:c.338C>T, ENST00000620739.4:c.338C>T, ENST00000622645.4:c.338C>T, ENST00000635293.1:c.338C>T, NM_000546.5(TP53):c.455C>T (p.Pro152Leu)	TP53	Li-Fraumeni syndrome	MONDO:0018875	Autosomal dominant inheritance	Pathogenic	PP3_Moderate, PP1, PS4, PS3, PM1	BP4	This variant has a BayesDel score > 0.16 and Align GVGD (Zebrafish) is Class 65 (PP3_Moderate). The variant has >10 observations as a somatic hotspot variant in tumors (PM1; cancerhotspots.org v(2)). Transactivation assays show a low functioning allele according to Kato, et al. and there is evidence of a dominant negative effect and loss of function according to Giacomelli, et al. (PS3; PMID: 12826609, 30224644). This variant has been reported in at least 8 probands meeting Chompret criteria (PS4; PMID: 25584008, 10486318, 17308077, 15654279, 26014290). Additionally, this variant was found to co-segregate with disease in multiple affected family members, with at least 3 meioses observed (PP1; PMID: 10486318). In summary, TP53 c.455C>T; p.Pro152Leu meets criteria to be classified as pathogenic for Li-Fraumeni syndrome. ACMG/AMP criteria applied, as specified by the TP53 Variant Curation Expert Panel: PP3_Moderate, PM1, PS3, PS4, PP1.	10486318, 25584008, 12067251	TP53 VCEP		2019-08-28	2020-01-24	False	https://erepo.genome.network/evrepo/ui/classification/CA000204/MONDO:0018875/009	6bf64717-7983-4329-bddb-4b28f0690106	p.Pro152Leu	Pro	152	Leu	MEEPQSDPSVEPPLSQETFSDLWKLLPENNVLSPLPSQAMDDLMLSPDDIEQWFTEDPGPDEAPRMPEAAPPVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFRHSVVVPYEPPEVGSDCTTIHYNYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNTSSSPQPKKKPLDGEYFTLQIRGRERFEMFRELNEALELKDAQAGKEPGGSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD	393	P04637	L	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [134], 'BINDING_gain': [], 'BINDING_loss_score': array([-0.10841388]), 'DNA_BIND_loss': [104, 105, 106, 285], 'DNA_BIND_gain': [], 'DNA_BIND_loss_score': array([-0.05954462, -0.06039244, -0.05697334, -0.00829166]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [134], 'DISULFID_gain_score': array([0.01808596]), 'PROPEP_loss': [300, 305, 311, 312, 318, 322, 366, 377], 'PROPEP_gain': [120, 123, 124, 126, 128, 130, 133, 145, 146, 147, 150], 'PROPEP_gain_score': array([0.03657812, 0.03678828, 0.04238546, 0.03862447, 0.05152911,
       0.07039124, 0.08032036, 0.08395213, 0.075207  , 0.105865  ,
       0.10161287]), 'PROPEP_loss_score': array([-0.02100444, -0.01554823, -0.01771069, -0.01694483, -0.01530665,
       -0.01625335, -0.01423824, -0.01163042]), 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [106, 107, 140, 141, 165, 166, 167, 195, 197, 198, 199, 203, 204], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.14762086, -0.14660597, -0.06568491, -0.10281944, -0.0997048 ,
       -0.09165442, -0.12244284, -0.08362353, -0.09015328, -0.13550508,
       -0.11227822, -0.06566191, -0.0521971 ]), 'HELIX_loss': [239], 'HELIX_gain': [347], 'HELIX_gain_score': array([0.00598919]), 'HELIX_loss_score': array([-0.06144226]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
171	NM_000546.5(TP53):c.517G>A (p.Val173Met)	233951	CA10577579	NM_000546.5:c.517G>A, NC_000017.11:g.7675095C>T, CM000679.2:g.7675095C>T, NC_000017.10:g.7578413C>T, CM000679.1:g.7578413C>T, NC_000017.9:g.7519138C>T, NG_017013.2:g.17456G>A, LRG_321:g.17456G>A, LRG_321t1:c.517G>A, NM_001126112.2:c.517G>A, LRG_321t2:c.517G>A, NM_001126113.2:c.517G>A, LRG_321t4:c.517G>A, NM_001126114.2:c.517G>A, LRG_321t3:c.517G>A, NM_001126115.1:c.121G>A, LRG_321t5:c.121G>A, NM_001126116.1:c.121G>A, LRG_321t6:c.121G>A, NM_001126117.1:c.121G>A, LRG_321t7:c.121G>A, NM_001126118.1:c.400G>A, LRG_321t8:c.400G>A, NM_001276695.1:c.400G>A, NM_001276696.1:c.400G>A, NM_001276697.1:c.40G>A, NM_001276698.1:c.40G>A, NM_001276699.1:c.40G>A, NM_001276760.1:c.400G>A, NM_001276761.1:c.400G>A, ENST00000269305.8:c.517G>A, ENST00000359597.8:n.517G>A, ENST00000413465.6:n.517G>A, ENST00000420246.6:c.517G>A, ENST00000445888.6:c.517G>A, ENST00000455263.6:c.517G>A, ENST00000504290.5:c.121G>A, ENST00000504937.5:c.121G>A, ENST00000505014.5:n.773G>A, ENST00000509690.5:c.121G>A, ENST00000510385.5:c.121G>A, ENST00000514944.5:c.238G>A, ENST00000574684.1:n.25G>A, ENST00000610292.4:c.400G>A, ENST00000610538.4:c.400G>A, ENST00000610623.4:c.40G>A, ENST00000615910.4:n.484G>A, ENST00000617185.4:c.517G>A, ENST00000618944.4:c.40G>A, ENST00000619186.4:c.40G>A, ENST00000619485.4:c.400G>A, ENST00000620739.4:c.400G>A, ENST00000622645.4:c.400G>A, ENST00000635293.1:c.400G>A, NM_000546.5(TP53):c.517G>A (p.Val173Met)	TP53	Li-Fraumeni syndrome	MONDO:0018875	Autosomal dominant inheritance	Pathogenic	PP3, PS4_Supporting, PM2_Supporting, PS2, PS3, PM1		This variant is absent in the gnomAD cohort (PM2_Supporting; http://gnomad.broadinstitute.org). The variant has a BayesDel score > 0.16 and Align GVGD (Zebrafish) is Class 15 or higher (PP3). This variant has >10 observations as a somatic hotspot variant in tumors (PM1; cancerhotspots.org v(2)). Transactivation assays show a low functioning allele according to Kato, et al. and there is evidence of a dominant negative effect and loss of function according to Giacomelli, et al. (PS3; PMID: 12826609, 30224644). This variant has been reported in a proband meeting Classic Li-Fraumeni syndrome criteria (PS4_Supporting; PMID: 16494995). There is a de novo observation of a proband with a diagnosis of a sarcoma, breast cancer and thyroid cancers under the age of 26 years with parental confirmation (PS2; ClinVar SCV000545293.4). In summary, TP53 p.Val173Met meets criteria to be classified as pathogenic for Li-Fraumeni syndrome.  ACMG/AMP criteria applied, as specified by the TP53 Variant Curation Expert Panel: PM2_Supporting, PP3, PM1, PS3, PS4_Supporting, PS2.	16494995, 12826609, 15037740, 30224644	TP53 VCEP		2019-08-28	2020-01-24	False	https://erepo.genome.network/evrepo/ui/classification/CA10577579/MONDO:0018875/009	29aaaea7-f2a2-441a-911c-111485dd6b50	p.Val173Met	Val	173	Met	MEEPQSDPSVEPPLSQETFSDLWKLLPENNVLSPLPSQAMDDLMLSPDDIEQWFTEDPGPDEAPRMPEAAPPVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFRHSVVVPYEPPEVGSDCTTIHYNYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNTSSSPQPKKKPLDGEYFTLQIRGRERFEMFRELNEALELKDAQAGKEPGGSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD	393	P04637	M	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [134], 'BINDING_gain': [], 'BINDING_loss_score': array([-0.01266438]), 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [134], 'DISULFID_gain_score': array([0.00910366]), 'PROPEP_loss': [300, 311, 322], 'PROPEP_gain': [128], 'PROPEP_gain_score': array([0.01345664]), 'PROPEP_loss_score': array([-0.00242209, -0.00559312, -0.00370228]), 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [165, 166, 167], 'STRAND_gain': [136, 229, 238], 'STRAND_gain_score': array([0.02845562, 0.02109933, 0.01724941]), 'STRAND_loss_score': array([-0.06908524, -0.13425982, -0.30304903]), 'HELIX_loss': [], 'HELIX_gain': [168, 169, 170, 171, 172, 173, 347], 'HELIX_gain_score': array([0.33897257, 0.37590563, 0.37120014, 0.36725169, 0.32637203,
       0.26575375, 0.02209753]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
172	NM_000546.5(TP53):c.488A>G (p.Tyr163Cys)	127814	CA000240	NM_000546.5:c.488A>G, NC_000017.11:g.7675124T>C, CM000679.2:g.7675124T>C, NC_000017.10:g.7578442T>C, CM000679.1:g.7578442T>C, NC_000017.9:g.7519167T>C, NG_017013.2:g.17427A>G, LRG_321:g.17427A>G, LRG_321t1:c.488A>G, NM_001126112.2:c.488A>G, LRG_321t2:c.488A>G, NM_001126113.2:c.488A>G, LRG_321t4:c.488A>G, NM_001126114.2:c.488A>G, LRG_321t3:c.488A>G, NM_001126115.1:c.92A>G, LRG_321t5:c.92A>G, NM_001126116.1:c.92A>G, LRG_321t6:c.92A>G, NM_001126117.1:c.92A>G, LRG_321t7:c.92A>G, NM_001126118.1:c.371A>G, LRG_321t8:c.371A>G, NM_001276695.1:c.371A>G, NM_001276696.1:c.371A>G, NM_001276697.1:c.11A>G, NM_001276698.1:c.11A>G, NM_001276699.1:c.11A>G, NM_001276760.1:c.371A>G, NM_001276761.1:c.371A>G, ENST00000269305.8:c.488A>G, ENST00000359597.8:n.488A>G, ENST00000413465.6:n.488A>G, ENST00000420246.6:c.488A>G, ENST00000445888.6:c.488A>G, ENST00000455263.6:c.488A>G, ENST00000504290.5:c.92A>G, ENST00000504937.5:c.92A>G, ENST00000505014.5:n.744A>G, ENST00000508793.5:c.488A>G, ENST00000509690.5:c.92A>G, ENST00000510385.5:c.92A>G, ENST00000514944.5:c.209A>G, ENST00000610292.4:c.371A>G, ENST00000610538.4:c.371A>G, ENST00000610623.4:c.11A>G, ENST00000615910.4:n.455A>G, ENST00000617185.4:c.488A>G, ENST00000618944.4:c.11A>G, ENST00000619186.4:c.11A>G, ENST00000619485.4:c.371A>G, ENST00000620739.4:c.371A>G, ENST00000622645.4:c.371A>G, ENST00000635293.1:c.371A>G, NM_000546.5(TP53):c.488A>G (p.Tyr163Cys)	TP53	Li-Fraumeni syndrome	MONDO:0018875	Autosomal dominant inheritance	Pathogenic	PP3_Moderate, PM2_Supporting, PS4_Supporting, PS3, PS2_Moderate, PM1		This variant is absent in the gnomAD cohort (PM2_Supporting; http://gnomad.broadinstitute.org). This variant has a BayesDel score > 0.16 and Align GVGD (Zebrafish) is Class 65 (PP3_Moderate). This variant has >10 observations as a somatic hotspot variant in tumors (PM1; cancerhotspots.org v(2)). Transactivation assays show a low functioning allele according to Kato, et al. and there is evidence of a dominant negative effect and loss of function according to Giacomelli, et al. (PS3; PMID: 12826609, 30224644). This variant has been reported in at least 2 probands meeting Chompret criteria (PS4_Supporting; PMID: 21601526, 8164043). Additionally, there is one proband with a de novo observation of a Li-Fraumeni syndrome core cancer under the age of 5 years with parental confirmation (PS2_Moderate; PMID: 19556618). In summary, the clinical significance of TP53 c.488A>G; p.Tyr163Cys is pathogenic for Li-Fraumeni syndrome: PM2_Supporting, PP3_Moderate, PM1, PS3, PS4_Supporting, PS2_Moderate.	21601526, 8164043	TP53 VCEP		2019-08-28	2020-01-24	False	https://erepo.genome.network/evrepo/ui/classification/CA000240/MONDO:0018875/009	8a807387-daa0-4fb9-86e1-7e5ad3d1217f	p.Tyr163Cys	Tyr	163	Cys	MEEPQSDPSVEPPLSQETFSDLWKLLPENNVLSPLPSQAMDDLMLSPDDIEQWFTEDPGPDEAPRMPEAAPPVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFRHSVVVPYEPPEVGSDCTTIHYNYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNTSSSPQPKKKPLDGEYFTLQIRGRERFEMFRELNEALELKDAQAGKEPGGSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD	393	P04637	C	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [162, 177], 'BINDING_gain_score': array([0.76724273, 0.27026516]), 'DNA_BIND_loss': [285], 'DNA_BIND_gain': [], 'DNA_BIND_loss_score': array([-0.01640016]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [134], 'DISULFID_gain_score': array([0.08537698]), 'PROPEP_loss': [121, 122, 125, 127], 'PROPEP_gain': [302, 303, 307, 310, 313, 314, 323, 364, 367, 368, 370, 371, 373, 374, 375, 376, 379, 392], 'PROPEP_gain_score': array([0.04944825, 0.0382821 , 0.05177981, 0.04961312, 0.05241561,
       0.05607957, 0.06174511, 0.06687212, 0.06101185, 0.05997437,
       0.06176621, 0.06321079, 0.06118482, 0.06164896, 0.06521326,
       0.06402779, 0.05117804, 0.03362548]), 'PROPEP_loss_score': array([-0.06914157, -0.0752238 , -0.08381152, -0.09128201]), 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [135, 147, 148, 165, 166, 167, 197, 248], 'STRAND_gain': [229], 'STRAND_gain_score': array([0.03171754]), 'STRAND_loss_score': array([-0.22027248, -0.11800098, -0.11451507, -0.07062042, -0.10675645,
       -0.28228593, -0.02596641, -0.03434891]), 'HELIX_loss': [279, 280, 335], 'HELIX_gain': [170, 171, 347], 'HELIX_gain_score': array([0.15641493, 0.1537624 , 0.00126797]), 'HELIX_loss_score': array([-0.11752254, -0.08392996, -0.02552146]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 158, 161, 162, 163, 165, 167], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.62259698, -0.68445969, -0.65678054, -0.58974177, -0.63208455,
       -0.6748395 , -0.65722638, -0.64042228, -0.64175433, -0.66652983,
       -0.65003312, -0.65492713, -0.6771841 , -0.63608676, -0.68050206,
       -0.61501968, -0.64148766, -0.61572725, -0.56551647, -0.52371001,
       -0.50362808, -0.63206065, -0.57295161, -0.52654177, -0.47729915,
       -0.50645214]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
173	NM_000546.5(TP53):c.742C>T (p.Arg248Trp)	12347	CA000382	NM_000546.5:c.742C>T, NC_000017.11:g.7674221G>A, CM000679.2:g.7674221G>A, NC_000017.10:g.7577539G>A, CM000679.1:g.7577539G>A, NC_000017.9:g.7518264G>A, NG_017013.2:g.18330C>T, LRG_321:g.18330C>T, LRG_321t1:c.742C>T, NM_001126112.2:c.742C>T, LRG_321t2:c.742C>T, NM_001126113.2:c.742C>T, LRG_321t4:c.742C>T, NM_001126114.2:c.742C>T, LRG_321t3:c.742C>T, NM_001126115.1:c.346C>T, LRG_321t5:c.346C>T, NM_001126116.1:c.346C>T, LRG_321t6:c.346C>T, NM_001126117.1:c.346C>T, LRG_321t7:c.346C>T, NM_001126118.1:c.625C>T, LRG_321t8:c.625C>T, NM_001276695.1:c.625C>T, NM_001276696.1:c.625C>T, NM_001276697.1:c.265C>T, NM_001276698.1:c.265C>T, NM_001276699.1:c.265C>T, NM_001276760.1:c.625C>T, NM_001276761.1:c.625C>T, ENST00000269305.8:c.742C>T, ENST00000359597.8:n.742C>T, ENST00000413465.6:n.742C>T, ENST00000420246.6:c.742C>T, ENST00000445888.6:c.742C>T, ENST00000455263.6:c.742C>T, ENST00000504290.5:c.346C>T, ENST00000504937.5:c.346C>T, ENST00000509690.5:c.346C>T, ENST00000510385.5:c.346C>T, ENST00000514944.5:c.463C>T, ENST00000610292.4:c.625C>T, ENST00000610538.4:c.625C>T, ENST00000610623.4:c.265C>T, ENST00000615910.4:n.709C>T, ENST00000617185.4:c.742C>T, ENST00000618944.4:c.265C>T, ENST00000619186.4:c.265C>T, ENST00000619485.4:c.625C>T, ENST00000620739.4:c.625C>T, ENST00000622645.4:c.625C>T, ENST00000635293.1:c.625C>T, NM_000546.5(TP53):c.742C>T (p.Arg248Trp)	TP53	Li-Fraumeni syndrome	MONDO:0018875	Autosomal dominant inheritance	Pathogenic	PP1_Strong, PP3_Moderate, PS4, PS2, PS3, PM1		This variant is within a codon that is an established hotspot in the TP53 gene (PM1; PMID: 20182602). This variant has a BayesDel score > 0.16 and Align GVGD (Zebrafish) is Class 65 (PP3_Moderate). Transactivation assays show a low functioning allele according to Kato, et al. and there is evidence of a dominant negative effect and loss of function according to Giacomelli, et al. (PS3; PMID: 12826609, 30224644). This variant has been reported in at least 3 probands with Classic Li-Fraumeni syndrome criteria and 2 probands meeting Chrompret criteria (PS4; PMID: 8425176, 20522432, 23667202, 9242456). This variant was found to co-segregate with disease in multiple affected family members, with >7 meioses observed across at least two families (PP1_Strong; PMID: 1978757, 9825943). There is a de novo observation of a proband with a rhabdomyosarcoma with parental confirmation (PS2; PMID: 10089074). In summary, TP53 c.742C>T; p.Arg248Trp meets criteria to be classified as pathogenic for Li-Fraumeni syndrome.  ACMG/AMP criteria applied, as specified by the TP53 Variant Curation Expert Panel: PM1, PP3_Moderate, PS3, PS4, PP1_Strong, PS2.	23667202, 8425176, 20522432, 9242456	TP53 VCEP		2019-08-28	2020-01-24	False	https://erepo.genome.network/evrepo/ui/classification/CA000382/MONDO:0018875/009	55c3283e-f0f6-4e18-b837-99a275ea7d90	p.Arg248Trp	Arg	248	Trp	MEEPQSDPSVEPPLSQETFSDLWKLLPENNVLSPLPSQAMDDLMLSPDDIEQWFTEDPGPDEAPRMPEAAPPVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFRHSVVVPYEPPEVGSDCTTIHYNYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNTSSSPQPKKKPLDGEYFTLQIRGRERFEMFRELNEALELKDAQAGKEPGGSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD	393	P04637	W	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [286, 287], 'DNA_BIND_gain_score': array([0.03744471, 0.03630263]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [134], 'DISULFID_gain_score': array([0.02713352]), 'PROPEP_loss': [117, 118, 119, 121, 122, 125, 127, 300, 305, 311, 312, 318, 320, 322, 363, 365, 366, 369, 372, 377, 378], 'PROPEP_gain': [], 'PROPEP_loss_score': array([-0.09827107, -0.10440141, -0.10218507, -0.10731977, -0.11251736,
       -0.09845835, -0.10711527, -0.01000345, -0.00686592, -0.01667786,
       -0.01973009, -0.01880145, -0.02782637, -0.03195983, -0.04291427,
       -0.0449214 , -0.04322338, -0.04569966, -0.04563957, -0.0434643 ,
       -0.04600042]), 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [140], 'STRAND_gain': [238], 'STRAND_gain_score': array([0.07862961]), 'STRAND_loss_score': array([-0.02833927]), 'HELIX_loss': [239], 'HELIX_gain': [347], 'HELIX_gain_score': array([0.00949919]), 'HELIX_loss_score': array([-0.07761639]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [131, 132, 133, 134, 135, 136], 'DOMAIN_gain_score': array([0.50858402, 0.37218291, 0.47982925, 0.47786599, 0.49844533,
       0.43447429]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
174	NM_000546.5(TP53):c.743G>T (p.Arg248Leu)	230253	CA10580924	NM_000546.5:c.743G>T, NC_000017.11:g.7674220C>A, CM000679.2:g.7674220C>A, NC_000017.10:g.7577538C>A, CM000679.1:g.7577538C>A, NC_000017.9:g.7518263C>A, NG_017013.2:g.18331G>T, LRG_321:g.18331G>T, LRG_321t1:c.743G>T, NM_001126112.2:c.743G>T, LRG_321t2:c.743G>T, NM_001126113.2:c.743G>T, LRG_321t4:c.743G>T, NM_001126114.2:c.743G>T, LRG_321t3:c.743G>T, NM_001126115.1:c.347G>T, LRG_321t5:c.347G>T, NM_001126116.1:c.347G>T, LRG_321t6:c.347G>T, NM_001126117.1:c.347G>T, LRG_321t7:c.347G>T, NM_001126118.1:c.626G>T, LRG_321t8:c.626G>T, NM_001276695.1:c.626G>T, NM_001276696.1:c.626G>T, NM_001276697.1:c.266G>T, NM_001276698.1:c.266G>T, NM_001276699.1:c.266G>T, NM_001276760.1:c.626G>T, NM_001276761.1:c.626G>T, ENST00000269305.8:c.743G>T, ENST00000359597.8:n.743G>T, ENST00000413465.6:n.743G>T, ENST00000420246.6:c.743G>T, ENST00000445888.6:c.743G>T, ENST00000455263.6:c.743G>T, ENST00000504290.5:c.347G>T, ENST00000504937.5:c.347G>T, ENST00000509690.5:c.347G>T, ENST00000510385.5:c.347G>T, ENST00000514944.5:c.464G>T, ENST00000610292.4:c.626G>T, ENST00000610538.4:c.626G>T, ENST00000610623.4:c.266G>T, ENST00000615910.4:n.710G>T, ENST00000617185.4:c.743G>T, ENST00000618944.4:c.266G>T, ENST00000619186.4:c.266G>T, ENST00000619485.4:c.626G>T, ENST00000620739.4:c.626G>T, ENST00000622645.4:c.626G>T, ENST00000635293.1:c.626G>T, NM_000546.5(TP53):c.743G>T (p.Arg248Leu)	TP53	Li-Fraumeni syndrome	MONDO:0018875	Autosomal dominant inheritance	Pathogenic	PP3_Moderate, PM2_Supporting, PS4_Supporting, PS3, PM1	BP4	This variant is within a codon that is an established hotspot in the TP53 gene (PM1; PMID: 2046748). It is absent in the gnomAD cohort (PM2_Supporting; http://gnomad.broadinstitute.org). This variant has a BayesDel score > 0.16 and Align GVGD (Zebrafish) is Class 65 (PP3_Moderate). Transactivation assays show a low functioning allele according to Kato, et al. and there is evidence of a dominant negative effect and loss of function according to Giacomelli, et al. (PS3; PMID: 12826609, 30224644). This variant has been reported in 1 family meeting Classic Li-Fraumeni syndrome and 1 proband meeting Chompret criteria (PS4_Supporting; PMID: 1359493, 25584008). In summary, TP53 c.743G>T; p.Arg248Leu meets criteria to be classified as pathogenic for Li-Fraumeni syndrome. ACMG/AMP criteria applied, as specified by the TP53 Variant Curation Expert Panel: PM1, PM2_Supporting, PP3_Moderate, PS3, PS4_Supporting.	25584008, 1359493, 2046748	TP53 VCEP		2019-08-28	2020-01-24	False	https://erepo.genome.network/evrepo/ui/classification/CA10580924/MONDO:0018875/009	291eceb4-ecb0-489a-b637-b9ff4f5f34d5	p.Arg248Leu	Arg	248	Leu	MEEPQSDPSVEPPLSQETFSDLWKLLPENNVLSPLPSQAMDDLMLSPDDIEQWFTEDPGPDEAPRMPEAAPPVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFRHSVVVPYEPPEVGSDCTTIHYNYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNTSSSPQPKKKPLDGEYFTLQIRGRERFEMFRELNEALELKDAQAGKEPGGSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD	393	P04637	L	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [134], 'BINDING_gain': [], 'BINDING_loss_score': array([-0.03954601]), 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [134], 'DISULFID_gain_score': array([0.00792682]), 'PROPEP_loss': [121, 122, 300, 304, 305, 308, 311, 312, 316, 318, 320, 322, 324, 325, 365, 366, 369, 372, 377, 378], 'PROPEP_gain': [], 'PROPEP_loss_score': array([-0.01348269, -0.02072334, -0.02160382, -0.02201897, -0.02506459,
       -0.0254342 , -0.03226852, -0.03157997, -0.03573954, -0.02802008,
       -0.03329962, -0.03697336, -0.03800607, -0.0429529 , -0.03548169,
       -0.03511089, -0.03635174, -0.03559101, -0.03266507, -0.03438771]), 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [165, 197], 'STRAND_gain': [238], 'STRAND_gain_score': array([0.02545452]), 'STRAND_loss_score': array([-0.06661439, -0.02560091]), 'HELIX_loss': [], 'HELIX_gain': [347], 'HELIX_gain_score': array([0.00463295]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [131, 132, 133, 134, 135, 136], 'DOMAIN_gain_score': array([0.43050724, 0.3063525 , 0.4025051 , 0.41915512, 0.41157156,
       0.40202647]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
175	NM_000546.5(TP53):c.319T>C (p.Tyr107His)	140786	CA000104	NM_000546.5:c.319T>C, NC_000017.11:g.7676050A>G, CM000679.2:g.7676050A>G, NC_000017.10:g.7579368A>G, CM000679.1:g.7579368A>G, NC_000017.9:g.7520093A>G, NG_017013.2:g.16501T>C, LRG_321:g.16501T>C, LRG_321t1:c.319T>C, NM_001126112.2:c.319T>C, LRG_321t2:c.319T>C, NM_001126113.2:c.319T>C, LRG_321t4:c.319T>C, NM_001126114.2:c.319T>C, LRG_321t3:c.319T>C, NM_001126118.1:c.202T>C, LRG_321t8:c.202T>C, NM_001276695.1:c.202T>C, NM_001276696.1:c.202T>C, NM_001276760.1:c.202T>C, NM_001276761.1:c.202T>C, ENST00000269305.8:c.319T>C, ENST00000359597.8:n.319T>C, ENST00000413465.6:n.319T>C, ENST00000420246.6:c.319T>C, ENST00000445888.6:c.319T>C, ENST00000455263.6:c.319T>C, ENST00000503591.1:c.319T>C, ENST00000505014.5:n.575T>C, ENST00000508793.5:c.319T>C, ENST00000509690.5:c.-21-814T>C, ENST00000514944.5:c.96+332T>C, ENST00000604348.5:c.319T>C, ENST00000610292.4:c.202T>C, ENST00000610538.4:c.202T>C, ENST00000615910.4:n.319T>C, ENST00000617185.4:c.319T>C, ENST00000619485.4:c.202T>C, ENST00000620739.4:c.202T>C, ENST00000622645.4:c.202T>C, ENST00000635293.1:c.202T>C, NM_000546.5(TP53):c.319T>C (p.Tyr107His)	TP53	Li-Fraumeni syndrome	MONDO:0018875	Autosomal dominant inheritance	Benign	BP4, BS3_Supporting, BA1, BS2_Supporting	PP3, BS1	This variant has a minor allele frequency of 0.001122 (0.11%, 28/24,948 alleles) in the African subpopulation of the gnomAD cohort (BA1). The variant also has a BayesDel score < 0.16 and Align GVGD (Zebrafish) is Class C0 or Class C15 (BP4). Additionally, transactivation assays show partially functional variant according to Kato, et al. and there is no evidence of a dominant negative effect or loss of function according to Giacomelli, et al. (BS3_Supporting; PMID: 12826609, 30224644). Finally, this variant has been observed in at least 7 60+ year old females without a cancer diagnosis (BS2_Supporting; FLOSSIES database - https://whi.color.com). In summary, TP53 c.319T>C; p.Tyr107His meets criteria to be classified as benign for Li-Fraumeni syndrome. ACMG/AMP criteria applied, as specified by the TP53 Variant Curation Expert Panel: BA1, BP4, BS3_Supporting, BS2_Supporting.	12826609, 30224644	TP53 VCEP		2019-08-28	2020-01-24	False	https://erepo.genome.network/evrepo/ui/classification/CA000104/MONDO:0018875/009	b172bcbe-5cff-4ba5-9ba2-482b4e1e357d	p.Tyr107His	Tyr	107	His	MEEPQSDPSVEPPLSQETFSDLWKLLPENNVLSPLPSQAMDDLMLSPDDIEQWFTEDPGPDEAPRMPEAAPPVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFRHSVVVPYEPPEVGSDCTTIHYNYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNTSSSPQPKKKPLDGEYFTLQIRGRERFEMFRELNEALELKDAQAGKEPGGSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD	393	P04637	H	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [104, 105, 106], 'DNA_BIND_gain': [], 'DNA_BIND_loss_score': array([-0.10077262, -0.07681221, -0.05922037]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [120, 123, 124, 126, 128, 313, 367, 374], 'PROPEP_gain_score': array([0.06557161, 0.03418434, 0.05049676, 0.04471058, 0.04984504,
       0.00393087, 0.00639558, 0.00679201]), 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [106, 107, 140], 'STRAND_gain': [136, 229], 'STRAND_gain_score': array([0.02191848, 0.00875831]), 'STRAND_loss_score': array([-0.2624355 , -0.22368699, -0.02366936]), 'HELIX_loss': [], 'HELIX_gain': [347], 'HELIX_gain_score': array([0.00611407]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [99], 'REGION_gain_score': array([0.27832198]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
176	NM_000546.5(TP53):c.935C>G (p.Thr312Ser)	141102	CA000505	NM_000546.5:c.935C>G, NC_000017.11:g.7673593G>C, CM000679.2:g.7673593G>C, NC_000017.10:g.7576911G>C, CM000679.1:g.7576911G>C, NC_000017.9:g.7517636G>C, NG_017013.2:g.18958C>G, LRG_321:g.18958C>G, LRG_321t1:c.935C>G, NM_001126112.2:c.935C>G, LRG_321t2:c.935C>G, NM_001126113.2:c.935C>G, LRG_321t4:c.935C>G, NM_001126114.2:c.935C>G, LRG_321t3:c.935C>G, NM_001126115.1:c.539C>G, LRG_321t5:c.539C>G, NM_001126116.1:c.539C>G, LRG_321t6:c.539C>G, NM_001126117.1:c.539C>G, LRG_321t7:c.539C>G, NM_001126118.1:c.818C>G, LRG_321t8:c.818C>G, NM_001276695.1:c.818C>G, NM_001276696.1:c.818C>G, NM_001276697.1:c.458C>G, NM_001276698.1:c.458C>G, NM_001276699.1:c.458C>G, NM_001276760.1:c.818C>G, NM_001276761.1:c.818C>G, ENST00000269305.8:c.935C>G, ENST00000359597.8:n.935C>G, ENST00000413465.6:n.782+588C>G, ENST00000420246.6:c.935C>G, ENST00000445888.6:c.935C>G, ENST00000455263.6:c.935C>G, ENST00000504290.5:c.539C>G, ENST00000504937.5:c.539C>G, ENST00000509690.5:c.539C>G, ENST00000510385.5:c.539C>G, ENST00000610292.4:c.818C>G, ENST00000610538.4:c.818C>G, ENST00000610623.4:c.458C>G, ENST00000615910.4:n.902C>G, ENST00000617185.4:c.935C>G, ENST00000618944.4:c.458C>G, ENST00000619186.4:c.458C>G, ENST00000619485.4:c.818C>G, ENST00000620739.4:c.818C>G, ENST00000622645.4:c.818C>G, ENST00000635293.1:c.818C>G, NM_000546.5(TP53):c.935C>G (p.Thr312Ser)	TP53	Li-Fraumeni syndrome	MONDO:0018875	Autosomal dominant inheritance	Benign	BP4, BS3, BS1		This variant has an allele frequency of 0.0003605 (0.03%, 9/24,966 alleles) in the African subpopulation of the gnomAD cohort (BS1). This variant also has a BayesDel score < 0.16 and Align GVGD (Zebrafish) is Class C0 or Class C15 (BP4). Additionally, transactivation assays show retained function according to Kato, et al. and there is no evidence of a dominant negative effect or loss of function according to Giacomelli, et al. (BS3; PMID: 12826609, 30224644). In summary, TP53 c.935C>G; p.Thr312Ser meets criteria to be classified as benign for Li-Fraumeni syndrome. ACMG/AMP criteria applied, as specified by the TP53 Variant Curation Expert Panel: BS1, BP4, BS3.	12826609, 30224644	TP53 VCEP		2019-09-16	2020-01-24	False	https://erepo.genome.network/evrepo/ui/classification/CA000505/MONDO:0018875/009	c3655e4d-7f5e-4830-b702-3893ec9be6ac	p.Thr312Ser	Thr	312	Ser	MEEPQSDPSVEPPLSQETFSDLWKLLPENNVLSPLPSQAMDDLMLSPDDIEQWFTEDPGPDEAPRMPEAAPPVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFRHSVVVPYEPPEVGSDCTTIHYNYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNTSSSPQPKKKPLDGEYFTLQIRGRERFEMFRELNEALELKDAQAGKEPGGSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD	393	P04637	S	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [318, 322, 365, 366, 369, 377], 'PROPEP_gain': [303, 310, 313, 314], 'PROPEP_gain_score': array([0.00831139, 0.03139418, 0.00998539, 0.02526343]), 'PROPEP_loss_score': array([-0.00107062, -0.00599843, -0.01736772, -0.01468033, -0.01682734,
       -0.01663071]), 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [136], 'DOMAIN_gain_score': array([0.08675683]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
177	NM_000546.5(TP53):c.139C>T (p.Pro47Ser)	43588	CA000053	NM_000546.5:c.139C>T, NC_000017.11:g.7676230G>A, CM000679.2:g.7676230G>A, NC_000017.10:g.7579548G>A, CM000679.1:g.7579548G>A, NC_000017.9:g.7520273G>A, NG_017013.2:g.16321C>T, LRG_321:g.16321C>T, LRG_321t1:c.139C>T, NM_001126112.2:c.139C>T, LRG_321t2:c.139C>T, NM_001126113.2:c.139C>T, LRG_321t4:c.139C>T, NM_001126114.2:c.139C>T, LRG_321t3:c.139C>T, NM_001126118.1:c.22C>T, LRG_321t8:c.22C>T, NM_001276695.1:c.22C>T, NM_001276696.1:c.22C>T, NM_001276760.1:c.22C>T, NM_001276761.1:c.22C>T, ENST00000269305.8:c.139C>T, ENST00000359597.8:n.139C>T, ENST00000413465.6:n.139C>T, ENST00000420246.6:c.139C>T, ENST00000445888.6:c.139C>T, ENST00000455263.6:c.139C>T, ENST00000503591.1:c.139C>T, ENST00000505014.5:n.395C>T, ENST00000508793.5:c.139C>T, ENST00000509690.5:c.-21-994C>T, ENST00000514944.5:c.96+152C>T, ENST00000604348.5:c.139C>T, ENST00000610292.4:c.22C>T, ENST00000610538.4:c.22C>T, ENST00000615910.4:n.139C>T, ENST00000617185.4:c.139C>T, ENST00000619485.4:c.22C>T, ENST00000620739.4:c.22C>T, ENST00000622645.4:c.22C>T, ENST00000635293.1:c.22C>T, NM_000546.5(TP53):c.139C>T (p.Pro47Ser)	TP53	Li-Fraumeni syndrome	MONDO:0018875	Autosomal dominant inheritance	Benign	BS2, BA1, BP4, BS3	PP3, PS3, BS1	This variant has a minor allele frequency of 0.01645 (1.6%, 410/24,922 alleles) in the African subpopulation of the gnomAD cohort (BA1). The variant has a BayesDel score < 0.16 and Align GVGD (Zebrafish) is Class C0 or Class C15 (BP4). Additionally, transactivation assays show supertransactivation function according to Kato, et al. and there is no evidence of a dominant negative effect or loss of function according to Giacomelli, et al. (BS3; PMID: 12826609, 30224644). Finally, this variant has been observed in at least 105 60+ year old females without a cancer diagnosis (BS2; FLOSSIES database - https://whi.color.com). In summary, TP53 c.139C>T; p.Pro47Ser meets criteria to be classified as benign for Li-Fraumeni syndrome. ACMG/AMP criteria applied, as specified by the TP53 Variant Curation Expert Panel: BA1, BP4, BS3, BS2.	30224644, 27034505	TP53 VCEP		2019-08-28	2020-01-24	False	https://erepo.genome.network/evrepo/ui/classification/CA000053/MONDO:0018875/009	d9f1afe3-5f5c-4af4-8f96-d83399ee9404	p.Pro47Ser	Pro	47	Ser	MEEPQSDPSVEPPLSQETFSDLWKLLPENNVLSPLPSQAMDDLMLSPDDIEQWFTEDPGPDEAPRMPEAAPPVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFRHSVVVPYEPPEVGSDCTTIHYNYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNTSSSPQPKKKPLDGEYFTLQIRGRERFEMFRELNEALELKDAQAGKEPGGSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD	393	P04637	S	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [300, 305, 311, 312, 318, 322, 366], 'PROPEP_gain': [], 'PROPEP_loss_score': array([-0.01055443, -0.00832957, -0.01223469, -0.01211208, -0.01212245,
       -0.01243842, -0.00921255]), 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [47, 48, 50, 51], 'HELIX_gain': [347], 'HELIX_gain_score': array([0.0019148]), 'HELIX_loss_score': array([-0.14860374, -0.13735169, -0.05461186, -0.03369778]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [41, 44, 45], 'REGION_gain': [], 'REGION_loss_score': array([-0.03347743, -0.06054598, -0.06481624]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
178	NM_000546.5(TP53):c.818G>A (p.Arg273His)	12366	CA000434	NM_000546.5:c.818G>A, NC_000017.11:g.7673802C>T, CM000679.2:g.7673802C>T, NC_000017.10:g.7577120C>T, CM000679.1:g.7577120C>T, NC_000017.9:g.7517845C>T, NG_017013.2:g.18749G>A, LRG_321:g.18749G>A, LRG_321t1:c.818G>A, NM_001126112.2:c.818G>A, LRG_321t2:c.818G>A, NM_001126113.2:c.818G>A, LRG_321t4:c.818G>A, NM_001126114.2:c.818G>A, LRG_321t3:c.818G>A, NM_001126115.1:c.422G>A, LRG_321t5:c.422G>A, NM_001126116.1:c.422G>A, LRG_321t6:c.422G>A, NM_001126117.1:c.422G>A, LRG_321t7:c.422G>A, NM_001126118.1:c.701G>A, LRG_321t8:c.701G>A, NM_001276695.1:c.701G>A, NM_001276696.1:c.701G>A, NM_001276697.1:c.341G>A, NM_001276698.1:c.341G>A, NM_001276699.1:c.341G>A, NM_001276760.1:c.701G>A, NM_001276761.1:c.701G>A, ENST00000269305.8:c.818G>A, ENST00000359597.8:n.818G>A, ENST00000413465.6:n.782+379G>A, ENST00000420246.6:c.818G>A, ENST00000445888.6:c.818G>A, ENST00000455263.6:c.818G>A, ENST00000504290.5:c.422G>A, ENST00000504937.5:c.422G>A, ENST00000509690.5:c.422G>A, ENST00000510385.5:c.422G>A, ENST00000610292.4:c.701G>A, ENST00000610538.4:c.701G>A, ENST00000610623.4:c.341G>A, ENST00000615910.4:n.785G>A, ENST00000617185.4:c.818G>A, ENST00000618944.4:c.341G>A, ENST00000619186.4:c.341G>A, ENST00000619485.4:c.701G>A, ENST00000620739.4:c.701G>A, ENST00000622645.4:c.701G>A, ENST00000635293.1:c.701G>A, NM_000546.5(TP53):c.818G>A (p.Arg273His)	TP53	Li-Fraumeni syndrome	MONDO:0018875	Autosomal dominant inheritance	Pathogenic	PP3, PS4, PS2, PS3, PM1	BA1, BS1	This variant is within a codon that is an established hotspot in the TP53 gene (PM1; PMID: 2046748). This variant has a BayesDel score > 0.16 and Align GVGD (Zebrafish) is Class 15 or higher (PP3). Transactivation assays show a low functioning allele according to Kato, et al. and there is evidence of a dominant negative effect and loss of function according to Giacomelli, et al. (PS3; PMID: 12826609, 30224644). This variant has been reported in at least 2 probands meeting Classic Li-Fraumeni syndrome criteria and 4 probands meeting Chompret criteria (PS4; PMID: 16401470, 15390294, 9242456, 10864200, 1565144, 7732013). Additionally, there is a de novo observation of a proband with breast cancer at age 29 with parental confirmation (PS2; PMID: 12672316). In summary, TP53 c.818G>A; p.Arg273His meets criteria to be classified as pathogenic for Li-Fraumeni syndrome. ACMG/AMP criteria applied, as specified by the TP53 Variant Curation Expert Panel: PM1, PP3, PS3, PS4, PS2.	1565144, 7732013, 15390294, 10864200, 16401470, 9242456, 12672316, 30224644, 12826609	TP53 VCEP		2019-08-28	2020-01-24	False	https://erepo.genome.network/evrepo/ui/classification/CA000434/MONDO:0018875/009	8d32df42-16ac-41f2-9bf1-e2b9ce206190	p.Arg273His	Arg	273	His	MEEPQSDPSVEPPLSQETFSDLWKLLPENNVLSPLPSQAMDDLMLSPDDIEQWFTEDPGPDEAPRMPEAAPPVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFRHSVVVPYEPPEVGSDCTTIHYNYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNTSSSPQPKKKPLDGEYFTLQIRGRERFEMFRELNEALELKDAQAGKEPGGSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD	393	P04637	H	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [285], 'DNA_BIND_gain': [], 'DNA_BIND_loss_score': array([-0.016047]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [134], 'DISULFID_gain_score': array([0.01696783]), 'PROPEP_loss': [117, 118, 119, 121, 122, 125, 127, 299, 300, 304, 305, 306, 308, 309, 311, 312, 316, 317, 318, 319, 320, 322, 324, 325, 327, 331, 333, 343, 346, 358, 361, 363, 365, 366, 369, 372, 377, 378], 'PROPEP_gain': [], 'PROPEP_loss_score': array([-0.10104948, -0.11140138, -0.10191393, -0.1049211 , -0.12181151,
       -0.09452558, -0.11376691, -0.05713344, -0.04313058, -0.03719646,
       -0.03743404, -0.03916192, -0.04735506, -0.04342312, -0.03542948,
       -0.04238254, -0.05321264, -0.04498458, -0.04929763, -0.04865938,
       -0.05135453, -0.05452389, -0.05814224, -0.06053233, -0.0611043 ,
       -0.05915844, -0.05991715, -0.04873097, -0.05166072, -0.0515185 ,
       -0.05434781, -0.06426483, -0.06396836, -0.0631119 , -0.06821537,
       -0.06334883, -0.0641076 , -0.06418234]), 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [120, 136, 238], 'STRAND_gain_score': array([0.0201664 , 0.04438192, 0.03584915]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [137, 141, 142, 152], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.41142094, -0.32192034, -0.34559369, -0.31416184]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
179	NM_000546.5(TP53):c.743G>A (p.Arg248Gln)	12356	CA000387	NM_000546.5:c.743G>A, NC_000017.11:g.7674220C>T, CM000679.2:g.7674220C>T, NC_000017.10:g.7577538C>T, CM000679.1:g.7577538C>T, NC_000017.9:g.7518263C>T, NG_017013.2:g.18331G>A, LRG_321:g.18331G>A, LRG_321t1:c.743G>A, NM_001126112.2:c.743G>A, LRG_321t2:c.743G>A, NM_001126113.2:c.743G>A, LRG_321t4:c.743G>A, NM_001126114.2:c.743G>A, LRG_321t3:c.743G>A, NM_001126115.1:c.347G>A, LRG_321t5:c.347G>A, NM_001126116.1:c.347G>A, LRG_321t6:c.347G>A, NM_001126117.1:c.347G>A, LRG_321t7:c.347G>A, NM_001126118.1:c.626G>A, LRG_321t8:c.626G>A, NM_001276695.1:c.626G>A, NM_001276696.1:c.626G>A, NM_001276697.1:c.266G>A, NM_001276698.1:c.266G>A, NM_001276699.1:c.266G>A, NM_001276760.1:c.626G>A, NM_001276761.1:c.626G>A, ENST00000269305.8:c.743G>A, ENST00000359597.8:n.743G>A, ENST00000413465.6:n.743G>A, ENST00000420246.6:c.743G>A, ENST00000445888.6:c.743G>A, ENST00000455263.6:c.743G>A, ENST00000504290.5:c.347G>A, ENST00000504937.5:c.347G>A, ENST00000509690.5:c.347G>A, ENST00000510385.5:c.347G>A, ENST00000514944.5:c.464G>A, ENST00000610292.4:c.626G>A, ENST00000610538.4:c.626G>A, ENST00000610623.4:c.266G>A, ENST00000615910.4:n.710G>A, ENST00000617185.4:c.743G>A, ENST00000618944.4:c.266G>A, ENST00000619186.4:c.266G>A, ENST00000619485.4:c.626G>A, ENST00000620739.4:c.626G>A, ENST00000622645.4:c.626G>A, ENST00000635293.1:c.626G>A, NM_000546.5(TP53):c.743G>A (p.Arg248Gln)	TP53	Li-Fraumeni syndrome	MONDO:0018875	Autosomal dominant inheritance	Pathogenic	PP3, PS4, PS2, PS3, PM1	PP1, BP4, BA1, BS1	This variant is within a codon that is an established hotspot in the TP53 gene (PM1; PMID: 2046748). This variant has a BayesDel score > 0.16 and Align GVGD (Zebrafish) is Class 15 or higher (PP3). Transactivation assays show a low functioning allele according to Kato, et al. and there is evidence of a dominant negative effect and loss of function according to Giacomelli, et al. (PS3; PMID: 12826609, 30224644). This variant has been reported in at least 3 probands meeting Classic Li-Fraumeni syndrome and 2 probands meeting Chompret criteria (PS4; PMID: 1565143, 9242456, 15381368, 7887414). There is a de novo observation of a proband with adrenocortical carcinoma with parental confirmation (PS2; PMID: 15381368). In summary, TP53 c.743G>A; p.Arg248Gln meets criteria to be classified as pathogenic for Li-Fraumeni syndrome.  ACMG/AMP criteria applied, as specified by the TP53 Variant Curation Expert Panel: PM1, PP3, PS3, PS4, PS2.	7887414, 9242456, 1565143, 15381368, 7887414, 9242456, 15381368, 23538418	TP53 VCEP		2019-08-28	2020-01-24	False	https://erepo.genome.network/evrepo/ui/classification/CA000387/MONDO:0018875/009	cf887752-8539-4177-a74d-dc5c8f8a36ed	p.Arg248Gln	Arg	248	Gln	MEEPQSDPSVEPPLSQETFSDLWKLLPENNVLSPLPSQAMDDLMLSPDDIEQWFTEDPGPDEAPRMPEAAPPVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFRHSVVVPYEPPEVGSDCTTIHYNYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNTSSSPQPKKKPLDGEYFTLQIRGRERFEMFRELNEALELKDAQAGKEPGGSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD	393	P04637	Q	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [300, 305, 311, 318, 322], 'PROPEP_gain': [], 'PROPEP_loss_score': array([-0.0034672 , -0.00892258, -0.00677079, -0.00683719, -0.00466847]), 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [136, 238], 'STRAND_gain_score': array([0.0172776 , 0.02668834]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
180	NM_001126115.1(TP53):c.182A>C (p.His61Pro)	376612	CA16603033	NM_001126115.1:c.182A>C, NC_000017.11:g.7674953T>G, CM000679.2:g.7674953T>G, NC_000017.10:g.7578271T>G, CM000679.1:g.7578271T>G, NC_000017.9:g.7518996T>G, NG_017013.2:g.17598A>C, LRG_321:g.17598A>C, NM_000546.5:c.578A>C, LRG_321t1:c.578A>C, NM_001126112.2:c.578A>C, LRG_321t2:c.578A>C, NM_001126113.2:c.578A>C, LRG_321t4:c.578A>C, NM_001126114.2:c.578A>C, LRG_321t3:c.578A>C, LRG_321t5:c.182A>C, NM_001126116.1:c.182A>C, LRG_321t6:c.182A>C, NM_001126117.1:c.182A>C, LRG_321t7:c.182A>C, NM_001126118.1:c.461A>C, LRG_321t8:c.461A>C, NM_001276695.1:c.461A>C, NM_001276696.1:c.461A>C, NM_001276697.1:c.101A>C, NM_001276698.1:c.101A>C, NM_001276699.1:c.101A>C, NM_001276760.1:c.461A>C, NM_001276761.1:c.461A>C, ENST00000269305.8:c.578A>C, ENST00000359597.8:n.578A>C, ENST00000413465.6:n.578A>C, ENST00000420246.6:c.578A>C, ENST00000445888.6:c.578A>C, ENST00000455263.6:c.578A>C, ENST00000504290.5:c.182A>C, ENST00000504937.5:c.182A>C, ENST00000505014.5:n.834A>C, ENST00000509690.5:c.182A>C, ENST00000510385.5:c.182A>C, ENST00000514944.5:c.299A>C, ENST00000574684.1:n.67+100A>C, ENST00000610292.4:c.461A>C, ENST00000610538.4:c.461A>C, ENST00000610623.4:c.101A>C, ENST00000615910.4:n.545A>C, ENST00000617185.4:c.578A>C, ENST00000618944.4:c.101A>C, ENST00000619186.4:c.101A>C, ENST00000619485.4:c.461A>C, ENST00000620739.4:c.461A>C, ENST00000622645.4:c.461A>C, ENST00000635293.1:c.461A>C, NM_001126115.1(TP53):c.182A>C (p.His61Pro)	TP53	Li-Fraumeni syndrome	MONDO:0018875	Autosomal dominant inheritance	Pathogenic	PP3_Moderate, PS4_Supporting, PM2_Supporting, PM6, PS3	BP4	This variant is absent in the gnomAD cohort (PM2_Supporting; http://gnomad.broadinstitute.org). This variant has a BayesDel score > 0.16 and Align GVGD (Zebrafish) is Class 65 (PP3_Moderate). Transactivation assays show a low functioning allele according to Kato, et al. and there is evidence of a dominant negative effect and loss of function according to Giacomelli, et al. (PS3; PMID: 12826609, 30224644). This variant has been reported in at least 2 probands meeting Chompret criteria (PS4_Supporting; PMID: 28369373, 20308654). Additionally, there is one proband with a de novo observation of a Li-Fraumeni syndrome core cancer under the age of 5 years without parental confirmation (PM6; PMID: 25584008). In summary, the clinical significance of TP53 c.578A>C; p.His193Pro is pathogenic for Li-Fraumeni syndrome: PM2_Supporting, PP3_Moderate, PS3, PS4_Supporting, PM6.	28369373, 20308654	TP53 VCEP		2019-08-28	2020-01-24	False	https://erepo.genome.network/evrepo/ui/classification/CA16603033/MONDO:0018875/009	b7079914-1dfb-4bb9-8f67-f466a0532ac1	p.His61Pro	His	61	Pro	MEEPQSDPSVEPPLSQETFSDLWKLLPENNVLSPLPSQAMDDLMLSPDDIEQWFTEDPGPDEAPRMPEAAPPVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFRHSVVVPYEPPEVGSDCTTIHYNYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNTSSSPQPKKKPLDGEYFTLQIRGRERFEMFRELNEALELKDAQAGKEPGGSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD	393	P04637	P	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [134], 'BINDING_gain': [], 'BINDING_loss_score': array([-0.01006252]), 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [134], 'DISULFID_gain_score': array([0.01137888]), 'PROPEP_loss': [121, 122], 'PROPEP_gain': [303, 313, 364, 367, 371, 374], 'PROPEP_gain_score': array([0.0075528 , 0.00980484, 0.0104537 , 0.01125723, 0.01173204,
       0.01094431]), 'PROPEP_loss_score': array([-0.01334077, -0.01626378]), 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [50], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.01870477]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [88, 89, 388], 'COMPBIAS_gain': [61, 62, 63, 64, 65, 66], 'COMPBIAS_gain_score': array([0.65036768, 0.66124964, 0.71197087, 0.67572194, 0.56229895,
       0.51990205]), 'COMPBIAS_loss_score': array([-0.12153852, -0.10629684, -0.0213896 ]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [41], 'REGION_gain': [], 'REGION_loss_score': array([-0.01039529]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
181	NM_000546.5(TP53):c.869G>A (p.Arg290His)	127825	CA000468	NM_000546.5:c.869G>A, NC_000017.11:g.7673751C>T, CM000679.2:g.7673751C>T, NC_000017.10:g.7577069C>T, CM000679.1:g.7577069C>T, NC_000017.9:g.7517794C>T, NG_017013.2:g.18800G>A, LRG_321:g.18800G>A, LRG_321t1:c.869G>A, NM_001126112.2:c.869G>A, LRG_321t2:c.869G>A, NM_001126113.2:c.869G>A, LRG_321t4:c.869G>A, NM_001126114.2:c.869G>A, LRG_321t3:c.869G>A, NM_001126115.1:c.473G>A, LRG_321t5:c.473G>A, NM_001126116.1:c.473G>A, LRG_321t6:c.473G>A, NM_001126117.1:c.473G>A, LRG_321t7:c.473G>A, NM_001126118.1:c.752G>A, LRG_321t8:c.752G>A, NM_001276695.1:c.752G>A, NM_001276696.1:c.752G>A, NM_001276697.1:c.392G>A, NM_001276698.1:c.392G>A, NM_001276699.1:c.392G>A, NM_001276760.1:c.752G>A, NM_001276761.1:c.752G>A, ENST00000269305.8:c.869G>A, ENST00000359597.8:n.869G>A, ENST00000413465.6:n.782+430G>A, ENST00000420246.6:c.869G>A, ENST00000445888.6:c.869G>A, ENST00000455263.6:c.869G>A, ENST00000504290.5:c.473G>A, ENST00000504937.5:c.473G>A, ENST00000509690.5:c.473G>A, ENST00000510385.5:c.473G>A, ENST00000610292.4:c.752G>A, ENST00000610538.4:c.752G>A, ENST00000610623.4:c.392G>A, ENST00000615910.4:n.836G>A, ENST00000617185.4:c.869G>A, ENST00000618944.4:c.392G>A, ENST00000619186.4:c.392G>A, ENST00000619485.4:c.752G>A, ENST00000620739.4:c.752G>A, ENST00000622645.4:c.752G>A, ENST00000635293.1:c.752G>A, NM_000546.5(TP53):c.869G>A (p.Arg290His)	TP53	Li-Fraumeni syndrome	MONDO:0018875	Autosomal dominant inheritance	Benign	BP4, BS2_Supporting, BS1, BS3	PP4	This variant has a minor allele frequency of 0.0003583 (0.03%, 9/25,120 alleles) in the European Finnish subpopulation of the gnomAD cohort (BS1). Transactivation assays show super transactivation function according to Kato, et al. and there is no evidence of a dominant negative effect or loss of function according to Giacomelli, et al. (BS3; PMID: 12826609, 30224644). Additionally, this variant has a BayesDel score < 0.16 and Align GVGD (Zebrafish) is Class C0 or Class C15 (BP4). Finally, this variant has been observed in at least 7 60+ year old females without a cancer diagnosis (BS2_Supporting; FLOSSIES database - https://whi.color.com). In summary, TP53 c.869G>A; p.Arg290His meets criteria to be classified as benign for Li-Fraumeni syndrome. ACMG/AMP criteria applied, as specified by the TP53 Variant Curation Expert Panel: BS1, BS3, BP4, BS2_Supporting.	30224644, 12826609	TP53 VCEP		2019-09-16	2020-01-24	False	https://erepo.genome.network/evrepo/ui/classification/CA000468/MONDO:0018875/009	de5ede53-7b6d-40ad-8a0e-0b3aa4c7ecd8	p.Arg290His	Arg	290	His	MEEPQSDPSVEPPLSQETFSDLWKLLPENNVLSPLPSQAMDDLMLSPDDIEQWFTEDPGPDEAPRMPEAAPPVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFRHSVVVPYEPPEVGSDCTTIHYNYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNTSSSPQPKKKPLDGEYFTLQIRGRERFEMFRELNEALELKDAQAGKEPGGSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD	393	P04637	H	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [285], 'DNA_BIND_gain': [], 'DNA_BIND_loss_score': array([-0.02107257]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [120, 124, 126, 128, 145, 303, 307, 313, 364, 367, 368, 371, 374, 379], 'PROPEP_gain_score': array([0.033553  , 0.03241324, 0.03166324, 0.03306073, 0.03361577,
       0.0098052 , 0.01354659, 0.01003432, 0.02756578, 0.02442127,
       0.02697551, 0.03214228, 0.03284258, 0.02479494]), 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [248], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.03179121]), 'HELIX_loss': [279, 280, 288, 289, 290], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.1716128 , -0.15925884, -0.36391288, -0.41680139, -0.38437355]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
182	NM_002834.4(PTPN11):c.184T>G (p.Tyr62Asp)	13329	CA234749	NM_002834.4:c.184T>G, NM_002834.3:c.184T>G, LRG_614t1:c.184T>G, NM_080601.1:c.184T>G, XM_006719526.1:c.184T>G, XM_006719527.1:c.184T>G, XM_011538613.1:c.181T>G, NM_001330437.1:c.184T>G, NM_080601.2:c.184T>G, XM_011538613.2:c.181T>G, XM_017019722.1:c.181T>G, NM_001330437.2:c.184T>G, NM_001374625.1:c.181T>G, NM_002834.5:c.184T>G, NM_080601.3:c.184T>G, ENST00000351677.6:c.184T>G, ENST00000392597.5:c.184T>G, ENST00000635625.1:n.184T>G, NC_000012.12:g.112450364T>G, CM000674.2:g.112450364T>G, NC_000012.11:g.112888168T>G, CM000674.1:g.112888168T>G, NC_000012.10:g.111372551T>G, NG_007459.1:g.36633T>G, LRG_614:g.36633T>G, NM_002834.4(PTPN11):c.184T>G (p.Tyr62Asp)	PTPN11	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Pathogenic	PM6, PM2, PP3, PP2, PM1, PS4, PS3		The c.184T>G (p.Tyr62Asp) variant in PTPN11 is absent from gnomAD (PM2). This variant has been observed in multiple individuals with Noonan syndrome (PS4; SCV000659042.4, PMIDs: 26817465, 19352411, 17020470, 12325025, 11992261, 19077116, 17339163). It has also been reported in the literature as an unconfirmed de novo occurrence in a patient with clinical features of a RASopathy (PM6; PMID: 12325025). In vitro functional studies provide some evidence that the p.Tyr62Asp variant may impact protein function (PS3; PMID: 22711529). Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of PTPN11 (PM1; PMID: 29493581). Computational prediction tools and conservation analysis suggest the variant may impact the protein (PP3). Additionally, the p.Tyr62Asp variant is located in the PTPN11 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). In summary, the p.Tyr62Asp variant in PTPN11 meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID: 29493581): PM2, PS4, PM6, PS3, PM1, PP3, PP2.	12325025, 26817465, 11992261, 17020470, 19352411, 22711529	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2020-02-14	2020-02-18	False	https://erepo.genome.network/evrepo/ui/classification/CA234749/MONDO:0021060/004	f5564d77-9990-4f45-94f7-6ebb47bd39a9	p.Tyr62Asp	Tyr	62	Asp	MTSRRWFHPNITGVEAENLLLTRGVDGSFLARPSKSNPGDFTLSVRRNGAVTHIKIQNTGDYYDLYGGEKFATLAELVQYYMEHHGQLKEKNGDVIELKYPLNCADPTSERWFHGHLSGKEAEKLLTEKGKHGSFLVRESQSHPGDFVLSVRTGDDKGESNDGKSKVTHVMIRCQELKYDVGGGERFDSLTDLVEHYKKNPMVETLGTVLQLKQPLNTTRINAAEIESRVRELSKLAETTDKVKQGFWEEFETLQQQECKLLYSRKEGQRQENKNKNRYKNILPFDHTRVVLHDGDPNEPVSDYINANIIMPEFETKCNNSKPKKSYIATQGCLQNTVNDFWRMVFQENSRVIVMTTKEVERGKSKCVKYWPDEYALKEYGVMRVRNVKESAAHDYTLRELKLSKVGQGNTERTVWQYHFRTWPDHGVPSDPGGVLDFLEEVHHKQESIMDAGPVVVHCSAGIGRTGTFIVIDILIDIIREKGVDCDIDVPKTIQMVRSQRSGMVQTEAQYRFIYMAVQHYIETLQRRIEEEQKSKRKGHEYTNIKYSLADQTSGDQSPLPPCTPTPPCAEMREDSARVYENVGLMQQQKSFR	593	Q06124	D	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [23], 'SIGNAL_gain_score': array([0.05634785]), 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [61], 'STRAND_gain': [65], 'STRAND_gain_score': array([0.04350251]), 'STRAND_loss_score': array([-0.12932009]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [94], 'DOMAIN_gain_score': array([0.00331861]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
183	NM_000441.2(SLC26A4):c.1204G>A (p.Val402Met)	43495	CA261400	NM_000441.2:c.1204G>A, NM_000441.1:c.1204G>A, XM_005250425.1:c.1204G>A, XM_006716025.2:c.1204G>A, XM_005250425.2:c.1204G>A, XM_006716025.3:c.1204G>A, XM_017012318.1:c.1204G>A, ENST00000265715.7:c.1204G>A, NC_000007.14:g.107690178G>A, CM000669.2:g.107690178G>A, NC_000007.13:g.107330623G>A, CM000669.1:g.107330623G>A, NC_000007.12:g.107117859G>A, NG_008489.1:g.34544G>A, NM_000441.2(SLC26A4):c.1204G>A (p.Val402Met)	SLC26A4	Pendred syndrome	MONDO:0010134	Autosomal recessive inheritance	Pathogenic	PM3_Strong, PS3_Supporting, PM2, PP4, PP1, PP3		The p.Val402Met variant in SLC26A4 was absent from gnomAD v2.1.1 and v3 (PM2). This variant has been detected in 2 probands with hearing loss. For both patients, a pathogenic or suspected-pathogenic variant was observed in trans (PM3_Strong, PMID:19204907, Partners LMM unpublished data SCV000060082.6). The variant has been reported to segregate in one affected family member (PP1, PMID:19204907). At least one proband with this variant displayed features of sensorineural hearing loss and enlarged vestibular aqueduct, a phenotype specific for Pendred syndrome (PP4, LMM unpublished data SCV000060082.6). Functional studies including fluorescence assays have demonstrated that this variant impacts protein function (PS3_Supporting; PMID:19204907). The REVEL computational prediction analysis tool produced a score of 0.77, which is above the threshold necessary to apply PP3. In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive Pendred syndrome based on the ACMG/AMP criteria applied as specified by the Hearing Loss Expert Panel (PM3_Strong, PM2, PP1, PP3, PP4, PS3_Supporting).	19204907, 19204907	Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2020-02-19	2020-02-19	False	https://erepo.genome.network/evrepo/ui/classification/CA261400/MONDO:0010134/005	7741be8f-b9df-4fc1-9f8d-ebe650c2fce1	p.Val402Met	Val	402	Met	MAAPGGRSEPPQLPEYSCSYMVSRPVYSELAFQQQHERRLQERKTLRESLAKCCSCSRKRAFGVLKTLVPILEWLPKYRVKEWLLSDVISGVSTGLVATLQGMAYALLAAVPVGYGLYSAFFPILTYFIFGTSRHISVGPFPVVSLMVGSVVLSMAPDEHFLVSSSNGTVLNTTMIDTAARDTARVLIASALTLLVGIIQLIFGGLQIGFIVRYLADPLVGGFTTAAAFQVLVSQLKIVLNVSTKNYNGVLSIIYTLVEIFQNIGDTNLADFTAGLLTIVVCMAVKELNDRFRHKIPVPIPIEVIVTIIATAISYGANLEKNYNAGIVKSIPRGFLPPELPPVSLFSEMLAASFSIAVVAYAIAVSVGKVYATKYDYTIDGNQEFIAFGISNIFSGFFSCFVATTALSRTAVQESTGGKTQVAGIISAAIVMIAILALGKLLEPLQKSVLAAVVIANLKGMFMQLCDIPRLWRQNKIDAVIWVFTCIVSIILGLDLGLLAGLIFGLLTVVLRVQFPSWNGLGSIPSTDIYKSTKNYKNIEEPQGVKILRFSSPIFYGNVDGFKKCIKSTVGFDAIRVYNKRLKALRKIQKLIKSGQLRATKNGIISDAVSTNNAFEPDEDIEDLEELDIPTKEIEIQVDWNSELPVKVNVPKVPIHSLVLDCGAISFLDVVGVRSLRVIVKEFQRIDVNVYFASLQDYVIEKLEQCGFFDDNIRKDTFFLTVHDAILYLQNQVKSQEGQGSILETITLIQDCKDTLELIETELTEEELDVQDEAMRTLAS	780	O43511	M	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [344, 482], 'DNA_BIND_gain_score': array([0.00794894, 0.00432044]), 'TOPO_DOM_loss': [131, 132, 169, 241, 244, 262], 'TOPO_DOM_gain': [], 'TOPO_DOM_loss_score': array([-0.01617235, -0.01138759, -0.01854825, -0.01025069, -0.01567209,
       -0.00909793]), 'TRANSMEM_loss': [482, 483], 'TRANSMEM_gain': [101, 466], 'TRANSMEM_gain_score': array([0.00187314, 0.01743525]), 'TRANSMEM_loss_score': array([-0.00241858, -0.00038552]), 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [108], 'HELIX_gain': [157], 'HELIX_gain_score': array([0.01227862]), 'HELIX_loss_score': array([-0.00691378]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [359, 361, 457, 479, 489, 561], 'DOMAIN_gain_score': array([0.03152937, 0.0245623 , 0.03062654, 0.02225572, 0.02114725,
       0.02078646]), 'REGION_loss': [624, 763, 764], 'REGION_gain': [], 'REGION_loss_score': array([-0.00075501, -0.00148278, -0.00175196]), 'REPEAT_loss': [], 'REPEAT_gain': [379, 399], 'REPEAT_gain_score': array([0.00437468, 0.00296038]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
184	NM_206933.3(USH2A):c.1859G>T (p.Cys620Phe)	549981	CA1396372	NM_206933.3:c.1859G>T, NC_000001.11:g.216289392C>A, CM000663.2:g.216289392C>A, NC_000001.10:g.216462734C>A, CM000663.1:g.216462734C>A, NC_000001.9:g.214529357C>A, NG_009497.1:g.139005G>T, NG_009497.2:g.139057G>T, ENST00000307340.8:c.1859G>T, ENST00000674083.1:c.1859G>T, ENST00000307340.7:c.1859G>T, ENST00000366942.3:c.1859G>T, NM_007123.5:c.1859G>T, NM_206933.2:c.1859G>T, NM_007123.6:c.1859G>T, NM_206933.4:c.1859G>T, NM_206933.4(USH2A):c.1859G>T (p.Cys620Phe), NM_206933.3(USH2A):c.1859G>T (p.Cys620Phe)	USH2A	Usher syndrome	MONDO:0019501	Autosomal recessive inheritance	Pathogenic	PP3, PP4, PP1, PM3_Very Strong, PM2_Supporting	PS3	The c.1859G>T in USH2A is a missense variant predicted to cause a substitution of cysteine to phenylalanine at amino acid 620 (p.Cys620Phe) . The highest population minor allele frequency in gnomAD v2.1.1 is 0.004% (5/129062) in the European(non-Finnish) sub-population which is below the threshold defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive Usher syndrome (PM2_Supporting). The REVEL computational prediction analysis tool produced a score of 0.974 (PP3). This variant has been detected in at least four probands with other pathogenic or suspected-pathogenic variants confirmed in trans (4.0 PM3_Very Strong points; PMID: 22135276, 33089500, 36011334). The probands harbored these variants in USH2A: p.Trp1607*, p.Glu767Serfs*21, p.Cys759Phe, p.Gly3195*. At least one patient displayed features of hearing loss and retinitis pigmentosa, which is highly specific for USH2A and Usher syndrome (PP4; PMID: 22135276). The variant has been reported to segregate with AR Usher syndrome in one affected family member from one family (PP1; PMID: 36011334). In summary, this variant meets the criteria to be classified as pathogenic for AR Usher syndrome based on ACMG/AMP criteria applied, as specified by the ClinGen Hearing Loss VCEP; PM2_Supporting, PP3, PM3_Very Strong, PP4, PP1. (The ClinGen Hearing Loss VCEP Specifications Version 2; 06/27/2023).		Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2023-10-24	2023-10-25	False	https://erepo.genome.network/evrepo/ui/classification/CA1396372/MONDO:0019501/005	c6cc0a56-6e2d-4b2f-aa10-c7d1c4df0e45	p.Cys620Phe	Cys	620	Phe	MNCPVLSLGSGFLFQVIEMLIFAYFASISLTESRGLFPRLENVGAFKKVSIVPTQAVCGLPDRSTFCHSSAAAESIQFCTQRFCIQDCPYRSSHPTYTALFSAGLSSCITPDKNDLHPNAHSNSASFIFGNHKSCFSSPPSPKLMASFTLAVWLKPEQQGVMCVIEKTVDGQIVFKLTISEKETMFYYRTVNGLQPPIKVMTLGRILVKKWIHLSVQVHQTKISFFINGVEKDHTPFNARTLSGSITDFASGTVQIGQSLNGLEQFVGRMQDFRLYQVALTNREILEVFSGDLLRLHAQSHCRCPGSHPRVHPLAQRYCIPNDAGDTADNRVSRLNPEAHPLSFVNDNDVGTSWVSNVFTNITQLNQGVTISVDLENGQYQVFYIIIQFFSPQPTEIRIQRKKENSLDWEDWQYFARNCGAFGMKNNGDLEKPDSVNCLQLSNFTPYSRGNVTFSILTPGPNYRPGYNNFYNTPSLQEFVKATQIRFHFHGQYYTTETAVNLRHRYYAVDEITISGRCQCHGHADNCDTTSQPYRCLCSQESFTEGLHCDRCLPLYNDKPFRQGDQVYAFNCKPCQCNSHSKSCHYNISVDPFPFEHFRGGGGVCDDCEHNTTGRNCELCKDYFFRQVGADPSAIDVCKPCDCDTVGTRNGSILCDQIGGQCNCKRHVSGRQCNQCQNGFYNLQELDPDGCSPCNCNTSGTVDGDITCHQNSGQCKCKANVIGLRCDHCNFGFKFLRSFNDVGCEPCQCNLHGSVNKFCNPHSGQCECKKEAKGLQCDTCRENFYGLDVTNCKACDCDTAGSLPGTVCNAKTGQCICKPNVEGRQCNKCLEGNFYLRQNNSFLCLPCNCDKTGTINGSLLCNKSTGQCPCKLGVTGLRCNQCEPHRYNLTIDNFQHCQMCECDSLGTLPGTICDPISGQCLCVPNRQGRRCNQCQPGFYISPGNATGCLPCSCHTTGAVNHICNSLTGQCVCQDASIAGQRCDQCKDHYFGFDPQTGRCQPCNCHLSGALNETCHLVTGQCFCKQFVTGSKCDACVPSASHLDVNNLLGCSKTPFQQPPPRGQVQSSSAINLSWSPPDSPNAHWLTYSLLRDGFEIYTTEDQYPYSIQYFLDTDLLPYTKYSYYIETTNVHGSTRSVAVTYKTKPGVPEGNLTLSYIIPIGSDSVTLTWTTLSNQSGPIEKYILSCAPLAGGQPCVSYEGHETSATIWNLVPFAKYDFSVQACTSGGCLHSLPITVTTAQAPPQRLSPPKMQKISSTELHVEWSPPAELNGIIIRYELYMRRLRSTKETTSEESRVFQSSGWLSPHSFVESANENALKPPQTMTTITGLEPYTKYEFRVLAVNMAGSVSSAWVSERTGESAPVFMIPPSVFPLSSYSLNISWEKPADNVTRGKVVGYDINMLSEQSPQQSIPMAFSQLLHTAKSQELSYTVEGLKPYRIYEFTITLCNSVGCVTSASGAGQTLAAAPAQLRPPLVKGINSTTIHLRWFPPEELNGPSPIYQLERRESSLPALMTTMMKGIRFIGNGYCKFPSSTHPVNTDFTGIKASFRTKVPEGLIVFAASPGNQEEYFALQLKKGRLYFLFDPQGSPVEVTTTNDHGKQYSDGKWHEIIAIRHQAFGQITLDGIYTGSSAILNGSTVIGDNTGVFLGGLPRSYTILRKDPEIIQKGFVGCLKDVHFMKNYNPSAIWEPLDWQSSEEQINVYNSWEGCPASLNEGAQFLGAGFLELHPYMFHGGMNFEISFKFRTDQLNGLLLFVYNKDGPDFLAMELKSGILTFRLNTSLAFTQVDLLLGLSYCNGKWNKVIIKKEGSFISASVNGLMKHASESGDQPLVVNSPVYVGGIPQELLNSYQHLCLEQGFGGCMKDVKFTRGAVVNLASVSSGAVRVNLDGCLSTDSAVNCRGNDSILVYQGKEQSVYEGGLQPFTEYLYRVIASHEGGSVYSDWSRGRTTGAAPQSVPTPSRVRSLNGYSIEVTWDEPVVRGVIEKYILKAYSEDSTRPPRMPSASAEFVNTSNLTGILTGLLPFKNYAVTLTACTLAGCTESSHALNISTPQEAPQEVQPPVAKSLPSSLLLSWNPPKKANGIITQYCLYMDGRLIYSGSEENYIVTDLAVFTPHQFLLSACTHVGCTNSSWVLLYTAQLPPEHVDSPVLTVLDSRTIHIQWKQPRKISGILERYVLYMSNHTHDFTIWSVIYNSTELFQDHMLQYVLPGNKYLIKLGACTGGGCTVSEASEALTDEDIPEGVPAPKAHSYSPDSFNVSWTEPEYPNGVITSYGLYLDGILIHNSSELSYRAYGFAPWSLHSFRVQACTAKGCALGPLVENRTLEAPPEGTVNVFVKTQGSRKAHVRWEAPFRPNGLLTHSVLFTGIFYVDPVGNNYTLLNVTKVMYSGEETNLWVLIDGLVPFTNYTVQVNISNSQGSLITDPITIAMPPGAPDGVLPPRLSSATPTSLQVVWSTPARNNAPGSPRYQLQMRSGDSTHGFLELFSNPSASLSYEVSDLQPYTEYMFRLVASNGFGSAHSSWIPFMTAEDKPGPVVPPILLDVKSRMMLVTWQHPRKSNGVITHYNIYLHGRLYLRTPGNVTNCTVMHLHPYTAYKFQVEACTSKGCSLSPESQTVWTLPGAPEGIPSPELFSDTPTSVIISWQPPTHPNGLVENFTIERRVKGKEEVTTLVTLPRSHSMRFIDKTSALSPWTKYEYRVLMSTLHGGTNSSAWVEVTTRPSRPAGVQPPVVTVLEPDAVQVTWKPPLIQNGDILSYEIHMPDPHITLTNVTSAVLSQKVTHLIPFTNYSVTIVACSGGNGYLGGCTESLPTYVTTHPTVPQNVGPLSVIPLSESYVVISWQPPSKPNGPNLRYELLRRKIQQPLASNPPEDLNRWHNIYSGTQWLYEDKGLSRFTTYEYMLFVHNSVGFTPSREVTVTTLAGLPERGANLTASVLNHTAIDVRWAKPTVQDLQGEVEYYTLFWSSATSNDSLKILPDVNSHVIGHLKPNTEYWIFISVFNGVHSINSAGLHATTCDGEPQGMLPPEVVIINSTAVRVIWTSPSNPNGVVTEYSIYVNNKLYKTGMNVPGSFILRDLSPFTIYDIQVEVCTIYACVKSNGTQITTVEDTPSDIPTPTIRGITSRSLQIDWVSPRKPNGIILGYDLLWKTWYPCAKTQKLVQDQSDELCKAVRCQKPESICGHICYSSEAKVCCNGVLYNPKPGHRCCEEKYIPFVLNSTGVCCGGRIQEAQPNHQCCSGYYARILPGEVCCPDEQHNRVSVGIGDSCCGRMPYSTSGNQICCAGRLHDGHGQKCCGRQIVSNDLECCGGEEGVVYNRLPGMFCCGQDYVNMSDTICCSASSGESKAHIKKNDPVPVKCCETELIPKSQKCCNGVGYNPLKYVCSDKISTGMMMKETKECRILCPASMEATEHCGRCDFNFTSHICTVIRGSHNSTGKASIEEMCSSAEETIHTGSVNTYSYTDVNLKPYMTYEYRISAWNSYGRGLSKAVRARTKEDVPQGVSPPTWTKIDNLEDTIVLNWRKPIQSNGPIIYYILLRNGIERFRGTSLSFSDKEGIQPFQEYSYQLKACTVAGCATSSKVVAATTQGVPESILPPSITALSAVALHLSWSVPEKSNGVIKEYQIRQVGKGLIHTDTTDRRQHTVTGLQPYTNYSFTLTACTSAGCTSSEPFLGQTLQAAPEGVWVTPRHIIINSTTVELYWSLPEKPNGLVSQYQLSRNGNLLFLGGSEEQNFTDKNLEPNSRYTYKLEVKTGGGSSASDDYIVQTPMSTPEEIYPPYNITVIGPYSIFVAWIPPGILIPEIPVEYNVLLNDGSVTPLAFSVGHHQSTLLENLTPFTQYEIRIQACQNGSCGVSSRMFVKTPEAAPMDLNSPVLKALGSACIEIKWMPPEKPNGIIINYFIYRRPAGIEEESVLFVWSEGALEFMDEGDTLRPFTLYEYRVRACNSKGSVESLWSLTQTLEAPPQDFPAPWAQATSAHSVLLNWTKPESPNGIISHYRVVYQERPDDPTFNSPTVHAFTVKGTSHQAHLYGLEPFTTYRIGVVAANHAGEILSPWTLIQTLESSPSGLRNFIVEQKENGRALLLQWSEPMRTNGVIKTYNIFSDGFLEYSGLNRQFLFRRLDPFTLYTLTLEACTRAGCAHSAPQPLWTDEAPPDSQLAPTVHSVKSTSVELSWSEPVNPNGKIIRYEVIRRCFEGKAWGNQTIQADEKIVFTEYNTERNTFMYNDTGLQPWTQCEYKIYTWNSAGHTCSSWNVVRTLQAPPEGLSPPVISYVSMNPQKLLISWIPPEQSNGIIQSYRLQRNEMLYPFSFDPVTFNYTDEELLPFSTYSYALQACTSGGCSTSKPTSITTLEAAPSEVSPPDLWAVSATQMNVCWSPPTVQNGKITKYLVRYDNKESLAGQGLCLLVSHLQPYSQYNFSLVACTNGGCTASVSKSAWTMEALPENMDSPTLQVTGSESIEITWKPPRNPNGQIRSYELRRDGTIVYTGLETRYRDFTLTPGVEYSYTVTASNSQGGILSPLVKDRTSPSAPSGMEPPKLQARGPQEILVNWDPPVRTNGDIINYTLFIRELFERETKIIHINTTHNSFGMQSYIVNQLKPFHRYEIRIQACTTLGCASSDWTFIQTPEIAPLMQPPPHLEVQMAPGGFQPTVSLLWTGPLQPNGKVLYYELYRRQIATQPRKSNPVLIYNGSSTSFIDSELLPFTEYEYQVWAVNSAGKAPSSWTWCRTGPAPPEGLRAPTFHVISSTQAVVNISAPGKPNGIVSLYRLFSSSAHGAETVLSEGMATQQTLHGLQAFTNYSIGVEACTCFNCCSKGPTAELRTHPAPPSGLSSPQIGTLASRTASFRWSPPMFPNGVIHSYELQFHVACPPDSALPCTPSQIETKYTGLGQKASLGGLQPYTTYKLRVVAHNEVGSTASEWISFTTQKELPQYRAPFSVDSNLSVVCVNWSDTFLLNGQLKEYVLTDGGRRVYSGLDTTLYIPRTADKTFFFQVICTTDEGSVKTPLIQYDTSTGLGLVLTTPGKKKGSRSKSTEFYSELWFIVLMAMLGLILLAIFLSLILQRKIHKEPYIRERPPLVPLQKRMSPLNVYPPGENHMGLADTKIPRSGTPVSIRSNRSACVLRIPSQNQTSLTYSQGSLHRSVSQLMDIQDKKVLMDNSLWEAIMGHNSGLYVDEEDLMNAIKDFSSVTKERTTFTDTHL	5202	O75445	F	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [87, 571, 2607, 3167, 3881], 'DISULFID_gain_score': array([0.00563407, 0.01420784, 0.00356883, 0.02107692, 0.00176042]), 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [3940, 3998, 4000, 4190, 4477, 4565, 4673, 4862], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.00361794, -0.00499517, -0.00517941, -0.00482541, -0.00244194,
       -0.00584668, -0.00533897, -0.00386035]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [461, 463, 469, 473, 4165, 4169, 4172, 4173, 4175, 4178, 4179, 4180, 4195, 4210, 4218], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.061432  , -0.05768538, -0.06451225, -0.06341046, -0.07126439,
       -0.0813446 , -0.05292821, -0.072312  , -0.07042229, -0.08990037,
       -0.08775449, -0.08691472, -0.09845603, -0.105847  , -0.06027138]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [651, 704, 766], 'ZN_FING_gain': [769], 'ZN_FING_gain_score': array([0.00756276]), 'ZN_FING_loss_score': array([-0.04752684, -0.02449149, -0.00212157])}"
185	NM_004333.6(BRAF):c.1455G>T (p.Leu485Phe)	177844	CA280060	NM_004333.6:c.1455G>T, NM_004333.4:c.1455G>T, LRG_299t1:c.1455G>T, XM_005250045.1:c.1455G>T, XM_005250046.1:c.1455G>T, XM_011516529.1:c.1455G>T, XM_011516530.1:c.1455G>T, XR_242190.1:n.1463G>T, XR_927520.1:n.1463G>T, XR_927521.1:n.1463G>T, XR_927522.1:n.1463G>T, XR_927523.1:n.1463G>T, NM_001354609.1:c.1455G>T, NM_004333.5:c.1455G>T, NR_148928.1:n.1760G>T, XM_017012558.1:c.1575G>T, XM_017012559.1:c.1575G>T, XR_001744857.1:n.1583G>T, XR_001744858.1:n.1583G>T, NM_001354609.2:c.1455G>T, NM_001374244.1:c.1575G>T, NM_001374258.1:c.1575G>T, ENST00000288602.10:c.1455G>T, ENST00000496384.6:n.278G>T, ENST00000497784.1:n.1490G>T, NC_000007.14:g.140778053C>A, CM000669.2:g.140778053C>A, NC_000007.13:g.140477853C>A, CM000669.1:g.140477853C>A, NC_000007.12:g.140124322C>A, NG_007873.3:g.151712G>T, LRG_299:g.151712G>T, NM_004333.6(BRAF):c.1455G>T (p.Leu485Phe)	BRAF	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Pathogenic	PM2, PP3, PP2, PM6_Strong, PS4, PS3	PM5	The c.1455G>T (p.Leu485Phe) variant in BRAF is absent from gnomAD (PM2). It has been detected in at least 5 patients with clinical features of a RASopathy, 2 of which were reported as unconfirmed de novo cases (PS4; PM6_Strong; PMIDs: 18039235, 28524057, SCV000832735.1, SCV000204150.4, SCV000965953.1, Otto-von-Guericke-Universität Magdeburg internal communication). In vitro functional studies provide some evidence that the p.L485F variant may impact protein function (PS3; PMID: 18413255). The variant is located in the BRAF gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Additionally, computational prediction tools and conservation analysis suggest that this variant may affect the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PS4, PM6_Strong, PS3, PM2, PP2, PP3.	28524057, 18039235, 18413255	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2020-02-27	2020-02-27	False	https://erepo.genome.network/evrepo/ui/classification/CA280060/MONDO:0021060/004	a0d2f8e1-aad3-4fe8-b45c-4e716663a496	p.Leu485Phe	Leu	485	Phe	MAALSGGGGGGAEPGQALFNGDMEPEAGAGAGAAASSAADPAIPEEVWNIKQMIKLTQEHIEALLDKFGGEHNPPSIYLEAYEEYTSKLDALQQREQQLLESLGNGTDFSVSSSASMDTVTSSSSSSLSVLPSSLSVFQNPTDVARSNPKSPQKPIVRVFLPNKQRTVVPARCGVTVRDSLKKALMMRGLIPECCAVYRIQDGEKKPIGWDTDISWLTGEELHVEVLENVPLTTHNFVRKTFFTLAFCDFCRKLLFQGFRCQTCGYKFHQRCSTEVPLMCVNYDQLDLLFVSKFFEHHPIPQEEASLAETALTSGSSPSAPASDSIGPQILTSPSPSKSIPIPQPFRPADEDHRNQFGQRDRSSSAPNVHINTIEPVNIDDLIRDQGFRGDGGSTTGLSATPPASLPGSLTNVKALQKSPGPQRERKSSSSSEDRNRMKTLGRRDSSDDWEIPDGQITVGQRIGSGSFGTVYKGKWHGDVAVKMLNVTAPTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHHLHIIETKFEMIKLIDIARQTAQGMDYLHAKSIIHRDLKSNNIFLHEDLTVKIGDFGLATVKSRWSGSHQFEQLSGSILWMAPEVIRMQDKNPYSFQSDVYAFGIVLYELMTGQLPYSNINNRDQIIFMVGRGYLSPDLSKVRSNCPKAMKRLMAECLKKKRDERPLFPQILASIELLARSLPKIHRSASEPSLNRAGFQTEDFSLYACASPKTPIQAGGYGAFPVH	766	P15056	F	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [58, 61], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.00352943, -0.00401318]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [451], 'REGION_gain': [], 'REGION_loss_score': array([-0.02707797]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
186	NM_004333.6(BRAF):c.1455G>C (p.Leu485Phe)	13975	CA273414	NM_004333.6:c.1455G>C, NC_000007.14:g.140778053C>G, CM000669.2:g.140778053C>G, NC_000007.13:g.140477853C>G, CM000669.1:g.140477853C>G, NC_000007.12:g.140124322C>G, NG_007873.3:g.151712G>C, LRG_299:g.151712G>C, NM_004333.4:c.1455G>C, LRG_299t1:c.1455G>C, XM_005250045.1:c.1455G>C, XM_005250046.1:c.1455G>C, XM_011516529.1:c.1455G>C, XM_011516530.1:c.1455G>C, XR_242190.1:n.1463G>C, XR_927520.1:n.1463G>C, XR_927521.1:n.1463G>C, XR_927522.1:n.1463G>C, XR_927523.1:n.1463G>C, NM_001354609.1:c.1455G>C, NM_004333.5:c.1455G>C, NR_148928.1:n.1760G>C, XM_017012558.1:c.1575G>C, XM_017012559.1:c.1575G>C, XR_001744857.1:n.1583G>C, XR_001744858.1:n.1583G>C, NM_001354609.2:c.1455G>C, NM_001374244.1:c.1575G>C, NM_001374258.1:c.1575G>C, ENST00000288602.10:c.1455G>C, ENST00000496384.6:n.278G>C, ENST00000497784.1:n.1490G>C, NM_004333.6(BRAF):c.1455G>C (p.Leu485Phe)	BRAF	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Pathogenic	PM2, PP3, PP2, PS3, PS2, PS4_Moderate	PM5	The c.1455G>C (p.Leu485Phe) variant in BRAF is absent from gnomAD (PM2). It has been detected in at least 4 patients with clinical features of a RASopathy, 1 of which was reported as a de novo case with parentage confirmation (PS4_Moderate; PS2; 19206169, 16474404, SCV000197149.4). In vitro functional studies provide some evidence that the p.L485F variant may impact protein function (PS3; PMID: 18413255). The variant is located in the BRAF gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Additionally, computational prediction tools and conservation analysis suggest that this variant may affect the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PS4_Moderate, PS2, PS3, PM2, PP2, PP3.	18413255, 19206169, 16474404	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2020-02-27	2020-04-09	False	https://erepo.genome.network/evrepo/ui/classification/CA273414/MONDO:0021060/004	d7b34568-d590-44cf-a60c-e208532866d3	p.Leu485Phe	Leu	485	Phe	MAALSGGGGGGAEPGQALFNGDMEPEAGAGAGAAASSAADPAIPEEVWNIKQMIKLTQEHIEALLDKFGGEHNPPSIYLEAYEEYTSKLDALQQREQQLLESLGNGTDFSVSSSASMDTVTSSSSSSLSVLPSSLSVFQNPTDVARSNPKSPQKPIVRVFLPNKQRTVVPARCGVTVRDSLKKALMMRGLIPECCAVYRIQDGEKKPIGWDTDISWLTGEELHVEVLENVPLTTHNFVRKTFFTLAFCDFCRKLLFQGFRCQTCGYKFHQRCSTEVPLMCVNYDQLDLLFVSKFFEHHPIPQEEASLAETALTSGSSPSAPASDSIGPQILTSPSPSKSIPIPQPFRPADEDHRNQFGQRDRSSSAPNVHINTIEPVNIDDLIRDQGFRGDGGSTTGLSATPPASLPGSLTNVKALQKSPGPQRERKSSSSSEDRNRMKTLGRRDSSDDWEIPDGQITVGQRIGSGSFGTVYKGKWHGDVAVKMLNVTAPTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHHLHIIETKFEMIKLIDIARQTAQGMDYLHAKSIIHRDLKSNNIFLHEDLTVKIGDFGLATVKSRWSGSHQFEQLSGSILWMAPEVIRMQDKNPYSFQSDVYAFGIVLYELMTGQLPYSNINNRDQIIFMVGRGYLSPDLSKVRSNCPKAMKRLMAECLKKKRDERPLFPQILASIELLARSLPKIHRSASEPSLNRAGFQTEDFSLYACASPKTPIQAGGYGAFPVH	766	P15056	F	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [58, 61], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.00352943, -0.00401318]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [451], 'REGION_gain': [], 'REGION_loss_score': array([-0.02707797]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
187	NM_002834.4(PTPN11):c.215C>T (p.Ala72Val)	41443	CA215451	NM_002834.4:c.215C>T, NC_000012.12:g.112450395C>T, CM000674.2:g.112450395C>T, NC_000012.11:g.112888199C>T, CM000674.1:g.112888199C>T, NC_000012.10:g.111372582C>T, NG_007459.1:g.36664C>T, LRG_614:g.36664C>T, NM_002834.3:c.215C>T, LRG_614t1:c.215C>T, NM_080601.1:c.215C>T, XM_006719526.1:c.215C>T, XM_006719527.1:c.215C>T, XM_011538613.1:c.212C>T, NM_001330437.1:c.215C>T, NM_080601.2:c.215C>T, XM_011538613.2:c.212C>T, XM_017019722.1:c.212C>T, NM_001330437.2:c.215C>T, NM_001374625.1:c.212C>T, NM_002834.5:c.215C>T, NM_080601.3:c.215C>T, ENST00000351677.6:c.215C>T, ENST00000392597.5:c.215C>T, ENST00000635625.1:n.215C>T, NM_002834.4(PTPN11):c.215C>T (p.Ala72Val)	PTPN11	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Pathogenic	PM2, PP3, PP2, PS4_Supporting, PM1, PS3	PM4, BP3, BP4, BP1, BA1, BS1	The c.215C>T (p.Ala72Val) variant in PTPN11 has been reported in 1 patient clinically diagnosed with both Noonan syndrome and juvenile myelomonocytic leukemia (PS4_Supporting; PMID: 30896080). It was absent from large population studies (PM2; gnomad.broadinstitute.org). It occurs in the N-SH2 domain of the protein, which has been identified as a region important for protein function (PM1, 29493581). In vitro functional assays indicate that this variant may impact protein function (PS3; PMID: 30896080). Computational prediction tools and conservation analyses also suggest that this variant may impact the protein (PP3). The variant is located in the PTPN11 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic variants are common (PP2; PMID: 29493581). Of note, this variant has also been observed in association with somatic malignancies; however, analysis and classification of somatic variation is currently not used to inform germline classifications for the RASopathies. In summary, this variant meets criteria to be classified as pathogenic for autosomal dominant Noonan syndrome. RASopathy-specific ACMG/AMP criteria applied: PS3, PS4_Supporting, PM1, PM2, PP2, PP3.	20237506, 30896080, 17972951, 26619011, 29493581, 17177198	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2020-03-25	2020-03-25	False	https://erepo.genome.network/evrepo/ui/classification/CA215451/MONDO:0021060/004	4ec5038d-8e1d-4c2b-8b78-b4203d3b5c2d	p.Ala72Val	Ala	72	Val	MTSRRWFHPNITGVEAENLLLTRGVDGSFLARPSKSNPGDFTLSVRRNGAVTHIKIQNTGDYYDLYGGEKFATLAELVQYYMEHHGQLKEKNGDVIELKYPLNCADPTSERWFHGHLSGKEAEKLLTEKGKHGSFLVRESQSHPGDFVLSVRTGDDKGESNDGKSKVTHVMIRCQELKYDVGGGERFDSLTDLVEHYKKNPMVETLGTVLQLKQPLNTTRINAAEIESRVRELSKLAETTDKVKQGFWEEFETLQQQECKLLYSRKEGQRQENKNKNRYKNILPFDHTRVVLHDGDPNEPVSDYINANIIMPEFETKCNNSKPKKSYIATQGCLQNTVNDFWRMVFQENSRVIVMTTKEVERGKSKCVKYWPDEYALKEYGVMRVRNVKESAAHDYTLRELKLSKVGQGNTERTVWQYHFRTWPDHGVPSDPGGVLDFLEEVHHKQESIMDAGPVVVHCSAGIGRTGTFIVIDILIDIIREKGVDCDIDVPKTIQMVRSQRSGMVQTEAQYRFIYMAVQHYIETLQRRIEEEQKSKRKGHEYTNIKYSLADQTSGDQSPLPPCTPTPPCAEMREDSARVYENVGLMQQQKSFR	593	Q06124	V	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [288, 303], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.00639021, -0.00409919]), 'HELIX_loss': [530], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.00495666]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [94, 95], 'DOMAIN_gain_score': array([0.09003115, 0.0982554 ]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
188	NM_004333.6(BRAF):c.1391G>A (p.Gly464Glu)	13964	CA250636	NM_004333.6:c.1391G>A, NM_004333.4:c.1391G>A, LRG_299t1:c.1391G>A, XM_005250045.1:c.1391G>A, XM_005250046.1:c.1391G>A, XM_011516529.1:c.1391G>A, XM_011516530.1:c.1391G>A, XR_242190.1:n.1399G>A, XR_927520.1:n.1399G>A, XR_927521.1:n.1399G>A, XR_927522.1:n.1399G>A, XR_927523.1:n.1399G>A, NM_001354609.1:c.1391G>A, NM_004333.5:c.1391G>A, NR_148928.1:n.1696G>A, XM_017012558.1:c.1511G>A, XM_017012559.1:c.1511G>A, XR_001744857.1:n.1519G>A, XR_001744858.1:n.1519G>A, NM_001354609.2:c.1391G>A, NM_001374244.1:c.1511G>A, NM_001374258.1:c.1511G>A, ENST00000288602.10:c.1391G>A, ENST00000496384.6:n.214G>A, ENST00000497784.1:n.1426G>A, NC_000007.14:g.140781617C>T, CM000669.2:g.140781617C>T, NC_000007.13:g.140481417C>T, CM000669.1:g.140481417C>T, NC_000007.12:g.140127886C>T, NG_007873.3:g.148148G>A, LRG_299:g.148148G>A, NM_004333.6(BRAF):c.1391G>A (p.Gly464Glu)	BRAF	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Pathogenic	PM6, PM2, PP3, PP2, PS4_Supporting, PM1, PS3, PS2	PM5	The c.1391G>A (p.Gly464Glu) variant in BRAF has been observed in 2 probands with phenotypes consistent with cardiofaciocutaneous syndrome (PS4_Supporting; LMM internal data, SCV000197160.4; GeneDx internal data, SCV000057209.13). One of these cases was de novo with maternity and paternity confirmed, while the other was de novo without confirmation of maternity or paternity (PS2, PM6). The p.Gly464Glu variant was absent from large population studies (PM2; gnomad.broadinstitute.org). In vitro functional assays indicate that this variant may impact protein function (PS3; PMID: 25155755). It occurs in the P-loop domain of the protein, which has been identified as an important region for protein function (PM1; 29493581). Computational prediction tools and conservation analyses also suggest that this variant may impact the protein (PP3). The variant is located in the BRAF gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic variants are common (PP2; PMID: 29493581). Of note, this variant has also been observed in association with somatic malignancies; however, analysis and classification of somatic variation is currently not used to inform germline classifications for the RASopathies. In summary, this variant meets criteria to be classified as pathogenic for autosomal dominant RASopathy. RASopathy-specific ACMG/AMP criteria applied: PS2, PS3, PS4_Supporting, PM1, PM2, PM6, PP2, PP3.		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2020-03-09	2020-03-09	False	https://erepo.genome.network/evrepo/ui/classification/CA250636/MONDO:0021060/004	2731c1d0-461e-451c-b70b-9882166c553c	p.Gly464Glu	Gly	464	Glu	MAALSGGGGGGAEPGQALFNGDMEPEAGAGAGAAASSAADPAIPEEVWNIKQMIKLTQEHIEALLDKFGGEHNPPSIYLEAYEEYTSKLDALQQREQQLLESLGNGTDFSVSSSASMDTVTSSSSSSLSVLPSSLSVFQNPTDVARSNPKSPQKPIVRVFLPNKQRTVVPARCGVTVRDSLKKALMMRGLIPECCAVYRIQDGEKKPIGWDTDISWLTGEELHVEVLENVPLTTHNFVRKTFFTLAFCDFCRKLLFQGFRCQTCGYKFHQRCSTEVPLMCVNYDQLDLLFVSKFFEHHPIPQEEASLAETALTSGSSPSAPASDSIGPQILTSPSPSKSIPIPQPFRPADEDHRNQFGQRDRSSSAPNVHINTIEPVNIDDLIRDQGFRGDGGSTTGLSATPPASLPGSLTNVKALQKSPGPQRERKSSSSSEDRNRMKTLGRRDSSDDWEIPDGQITVGQRIGSGSFGTVYKGKWHGDVAVKMLNVTAPTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHHLHIIETKFEMIKLIDIARQTAQGMDYLHAKSIIHRDLKSNNIFLHEDLTVKIGDFGLATVKSRWSGSHQFEQLSGSILWMAPEVIRMQDKNPYSFQSDVYAFGIVLYELMTGQLPYSNINNRDQIIFMVGRGYLSPDLSKVRSNCPKAMKRLMAECLKKKRDERPLFPQILASIELLARSLPKIHRSASEPSLNRAGFQTEDFSLYACASPKTPIQAGGYGAFPVH	766	P15056	E	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [58, 61], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.00391471, -0.00564438]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [350], 'COMPBIAS_gain': [447], 'COMPBIAS_gain_score': array([0.00978035]), 'COMPBIAS_loss_score': array([-0.00280446]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
189	NM_005633.3(SOS1):c.512T>G (p.Val171Gly)	40654	CA136165	NM_005633.3:c.512T>G, NC_000002.12:g.39054822A>C, CM000664.2:g.39054822A>C, NC_000002.11:g.39281963A>C, CM000664.1:g.39281963A>C, NC_000002.10:g.39135467A>C, NG_007530.1:g.70642T>G, LRG_754:g.70642T>G, LRG_754t1:c.512T>G, XM_005264515.3:c.512T>G, XM_011533060.1:c.605T>G, XM_011533061.1:c.605T>G, XM_011533062.1:c.491T>G, XM_011533063.1:c.488T>G, XM_011533064.1:c.341T>G, XM_011533065.1:c.605T>G, XM_005264515.4:c.512T>G, XM_011533062.2:c.491T>G, XM_011533064.2:c.341T>G, ENST00000395038.6:c.512T>G, ENST00000402219.6:c.512T>G, ENST00000426016.5:c.512T>G, NM_005633.3(SOS1):c.512T>G (p.Val171Gly)	SOS1	Noonan syndrome	MONDO:0018997	Autosomal dominant inheritance	Pathogenic	PM2, PP2, PP3, PS4_Moderate, PS2	PM6, PP1, BS2, PM1, PM4, PM5, BA1, BP3, BP2, BP1, BP4, PS3, PS1, BS3, BS4, BS1, BP7, BP5	The c.512T>G (p.Val171Gly) variant has been identified in a patient with clinical features of a RASopathy in a de novo occurance (PS2; Ambry Genetics internal data, GTR ID: 61756, ClinVar SCV000742607.1) This variant has also been identified in two other independent occurrences in patients with clinical features of a RASopathy (PS4_Moderate PMID: 26918529, Partners LMM, Invitae internal data; GTR ID: 21766, 500031 ClinVar SCV000062241.5, SCV000553263.2). Of note, a different likely pathogenic missense variant (p.Val171Ala) has been previously identified at this codon of SOS1 (PM5 not met; ClinVar 45373). The p.Val171Gly variant in the SOS1 gene was absent from gnomAD (PM2). Computational prediction tools and conservation analysis suggest that the p.Val171Gly variant may impact the protein (PP3). Of note, the variant occurs at the second nucleotide of exon 5 (in-frame) but no functional evidence has indicated that the variant would cause skipping of the exon. The variant is located in the SOS1 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. RASopathy-specific ACMG/AMP criteria applied (PMID:29493581): PS2, PS4_Moderate, PM2, PP3, PP2.	26918529, 26918529	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2019-02-28	2020-03-12	False	https://erepo.genome.network/evrepo/ui/classification/CA136165/MONDO:0018997/004	2006faae-1689-4eab-b2b4-ad0ca1e3a543	p.Val171Gly	Val	171	Gly	MQAQQLPYEFFSEENAPKWRGLLVPALKKVQGQVHPTLESNDDALQYVEELILQLLNMLCQAQPRSASDVEERVQKSFPHPIDKWAIADAQSAIEKRKRRNPLSLPVEKIHPLLKEVLGYKIDHQVSVYIVAVLEYISADILKLVGNYVRNIRHYEITKQDIKVAMCADKVLMDMFHQDVEDINILSLTDEEPSTSGEQTYYDLVKAFMAEIRQYIRELNLIIKVFREPFVSNSKLFSANDVENIFSRIVDIHELSVKLLGHIEDTVEMTDEGSPHPLVGSCFEDLAEELAFDPYESYARDILRPGFHDRFLSQLSKPGAALYLQSIGEGFKEAVQYVLPRLLLAPVYHCLHYFELLKQLEEKSEDQEDKECLKQAITALLNVQSGMEKICSKSLAKRRLSESACRFYSQQMKGKQLAIKKMNEIQKNIDGWEGKDIGQCCNEFIMEGTLTRVGAKHERHIFLFDGLMICCKSNHGQPRLPGASNAEYRLKEKFFMRKVQINDKDDTNEYKHAFEIILKDENSVIFSAKSAEEKNNWMAALISLQYRSTLERMLDVTMLQEEKEEQMRLPSADVYRFAEPDSEENIIFEENMQPKAGIPIIKAGTVIKLIERLTYHMYADPNFVRTFLTTYRSFCKPQELLSLIIERFEIPEPEPTEADRIAIENGDQPLSAELKRFRKEYIQPVQLRVLNVCRHWVEHHFYDFERDAYLLQRMEEFIGTVRGKAMKKWVESITKIIQRKKIARDNGPGHNITFQSSPPTVEWHISRPGHIETFDLLTLHPIEIARQLTLLESDLYRAVQPSELVGSVWTKEDKEINSPNLLKMIRHTTNLTLWFEKCIVETENLEERVAVVSRIIEILQVFQELNNFNGVLEVVSAMNSSPVYRLDHTFEQIPSRQKKILEEAHELSEDHYKKYLAKLRSINPPCVPFFGIYLTNILKTEEGNPEVLKRHGKELINFSKRRKVAEITGEIQQYQNQPYCLRVESDIKRFFENLNPMGNSMEKEFTDYLFNKSLEIEPRNPKPLPRFPKKYSYPLKSPGVRPSNPRPGTMRHPTPLQQEPRKISYSRIPESETESTASAPNSPRTPLTPPPASGASSTTDVCSVFDSDHSSPFHSSNDTVFIQVTLPHGPRSASVSSISLTKGTDEVPVPPPVPPRRRPESAPAESSPSKIMSKHLDSPPAIPPRQPTSKAYSPRYSISDRTSISDPPESPPLLPPREPVRTPDVFSSSPLHLQPPPLGKKSDHGNAFFPNSPSPFTPPPPQTPSPHGTRRHLPSPPLTQEVDLHSIAGPPVPPRQSTSQHIPKLPPKTYKREHTHPSMHRDGPPLLENAHSS	1333	Q07889	G	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [144, 145, 147, 148, 149, 151, 154, 155, 157, 158, 160, 161, 778, 780, 782, 872, 873], 'DOMAIN_gain_score': array([0.36813265, 0.42416757, 0.38513464, 0.46679252, 0.42152429,
       0.43446535, 0.3744207 , 0.44828111, 0.41672283, 0.39820653,
       0.20019186, 0.29007077, 0.04566067, 0.05023932, 0.04894054,
       0.03527653, 0.03876966]), 'REGION_loss': [], 'REGION_gain': [1295, 1300], 'REGION_gain_score': array([0.01576352, 0.01666057]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
190	NM_206933.3(USH2A):c.7334C>T (p.Ser2445Phe)	48581	CA143592	NM_206933.3:c.7334C>T, NC_000001.11:g.215900872G>A, CM000663.2:g.215900872G>A, NC_000001.10:g.216074214G>A, CM000663.1:g.216074214G>A, NC_000001.9:g.214140837G>A, NG_009497.1:g.527525C>T, NG_009497.2:g.527577C>T, NM_206933.2:c.7334C>T, NM_206933.4:c.7334C>T, ENST00000307340.7:c.7334C>T, NM_206933.3(USH2A):c.7334C>T (p.Ser2445Phe)	USH2A	Usher syndrome	MONDO:0019501	Autosomal recessive inheritance	Benign	BA1	PM3, BP4	The filtering allele frequency (the lower threshold of the 95% CI of 197/30616) of the p.Ser2445Phe variant in the USH2A gene is 0.57% for South Asian chromosomes by gnomAD v2.1.1, which is  a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive hearing loss variants (BA1).		Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2020-03-18	2020-03-19	False	https://erepo.genome.network/evrepo/ui/classification/CA143592/MONDO:0019501/005	56dae361-9fdd-4622-a232-aaf252443c65	p.Ser2445Phe	Ser	2445	Phe	MNCPVLSLGSGFLFQVIEMLIFAYFASISLTESRGLFPRLENVGAFKKVSIVPTQAVCGLPDRSTFCHSSAAAESIQFCTQRFCIQDCPYRSSHPTYTALFSAGLSSCITPDKNDLHPNAHSNSASFIFGNHKSCFSSPPSPKLMASFTLAVWLKPEQQGVMCVIEKTVDGQIVFKLTISEKETMFYYRTVNGLQPPIKVMTLGRILVKKWIHLSVQVHQTKISFFINGVEKDHTPFNARTLSGSITDFASGTVQIGQSLNGLEQFVGRMQDFRLYQVALTNREILEVFSGDLLRLHAQSHCRCPGSHPRVHPLAQRYCIPNDAGDTADNRVSRLNPEAHPLSFVNDNDVGTSWVSNVFTNITQLNQGVTISVDLENGQYQVFYIIIQFFSPQPTEIRIQRKKENSLDWEDWQYFARNCGAFGMKNNGDLEKPDSVNCLQLSNFTPYSRGNVTFSILTPGPNYRPGYNNFYNTPSLQEFVKATQIRFHFHGQYYTTETAVNLRHRYYAVDEITISGRCQCHGHADNCDTTSQPYRCLCSQESFTEGLHCDRCLPLYNDKPFRQGDQVYAFNCKPCQCNSHSKSCHYNISVDPFPFEHFRGGGGVCDDCEHNTTGRNCELCKDYFFRQVGADPSAIDVCKPCDCDTVGTRNGSILCDQIGGQCNCKRHVSGRQCNQCQNGFYNLQELDPDGCSPCNCNTSGTVDGDITCHQNSGQCKCKANVIGLRCDHCNFGFKFLRSFNDVGCEPCQCNLHGSVNKFCNPHSGQCECKKEAKGLQCDTCRENFYGLDVTNCKACDCDTAGSLPGTVCNAKTGQCICKPNVEGRQCNKCLEGNFYLRQNNSFLCLPCNCDKTGTINGSLLCNKSTGQCPCKLGVTGLRCNQCEPHRYNLTIDNFQHCQMCECDSLGTLPGTICDPISGQCLCVPNRQGRRCNQCQPGFYISPGNATGCLPCSCHTTGAVNHICNSLTGQCVCQDASIAGQRCDQCKDHYFGFDPQTGRCQPCNCHLSGALNETCHLVTGQCFCKQFVTGSKCDACVPSASHLDVNNLLGCSKTPFQQPPPRGQVQSSSAINLSWSPPDSPNAHWLTYSLLRDGFEIYTTEDQYPYSIQYFLDTDLLPYTKYSYYIETTNVHGSTRSVAVTYKTKPGVPEGNLTLSYIIPIGSDSVTLTWTTLSNQSGPIEKYILSCAPLAGGQPCVSYEGHETSATIWNLVPFAKYDFSVQACTSGGCLHSLPITVTTAQAPPQRLSPPKMQKISSTELHVEWSPPAELNGIIIRYELYMRRLRSTKETTSEESRVFQSSGWLSPHSFVESANENALKPPQTMTTITGLEPYTKYEFRVLAVNMAGSVSSAWVSERTGESAPVFMIPPSVFPLSSYSLNISWEKPADNVTRGKVVGYDINMLSEQSPQQSIPMAFSQLLHTAKSQELSYTVEGLKPYRIYEFTITLCNSVGCVTSASGAGQTLAAAPAQLRPPLVKGINSTTIHLRWFPPEELNGPSPIYQLERRESSLPALMTTMMKGIRFIGNGYCKFPSSTHPVNTDFTGIKASFRTKVPEGLIVFAASPGNQEEYFALQLKKGRLYFLFDPQGSPVEVTTTNDHGKQYSDGKWHEIIAIRHQAFGQITLDGIYTGSSAILNGSTVIGDNTGVFLGGLPRSYTILRKDPEIIQKGFVGCLKDVHFMKNYNPSAIWEPLDWQSSEEQINVYNSWEGCPASLNEGAQFLGAGFLELHPYMFHGGMNFEISFKFRTDQLNGLLLFVYNKDGPDFLAMELKSGILTFRLNTSLAFTQVDLLLGLSYCNGKWNKVIIKKEGSFISASVNGLMKHASESGDQPLVVNSPVYVGGIPQELLNSYQHLCLEQGFGGCMKDVKFTRGAVVNLASVSSGAVRVNLDGCLSTDSAVNCRGNDSILVYQGKEQSVYEGGLQPFTEYLYRVIASHEGGSVYSDWSRGRTTGAAPQSVPTPSRVRSLNGYSIEVTWDEPVVRGVIEKYILKAYSEDSTRPPRMPSASAEFVNTSNLTGILTGLLPFKNYAVTLTACTLAGCTESSHALNISTPQEAPQEVQPPVAKSLPSSLLLSWNPPKKANGIITQYCLYMDGRLIYSGSEENYIVTDLAVFTPHQFLLSACTHVGCTNSSWVLLYTAQLPPEHVDSPVLTVLDSRTIHIQWKQPRKISGILERYVLYMSNHTHDFTIWSVIYNSTELFQDHMLQYVLPGNKYLIKLGACTGGGCTVSEASEALTDEDIPEGVPAPKAHSYSPDSFNVSWTEPEYPNGVITSYGLYLDGILIHNSSELSYRAYGFAPWSLHSFRVQACTAKGCALGPLVENRTLEAPPEGTVNVFVKTQGSRKAHVRWEAPFRPNGLLTHSVLFTGIFYVDPVGNNYTLLNVTKVMYSGEETNLWVLIDGLVPFTNYTVQVNISNSQGSLITDPITIAMPPGAPDGVLPPRLSSATPTSLQVVWSTPARNNAPGSPRYQLQMRSGDSTHGFLELFSNPSASLSYEVSDLQPYTEYMFRLVASNGFGSAHSSWIPFMTAEDKPGPVVPPILLDVKSRMMLVTWQHPRKSNGVITHYNIYLHGRLYLRTPGNVTNCTVMHLHPYTAYKFQVEACTSKGCSLSPESQTVWTLPGAPEGIPSPELFSDTPTSVIISWQPPTHPNGLVENFTIERRVKGKEEVTTLVTLPRSHSMRFIDKTSALSPWTKYEYRVLMSTLHGGTNSSAWVEVTTRPSRPAGVQPPVVTVLEPDAVQVTWKPPLIQNGDILSYEIHMPDPHITLTNVTSAVLSQKVTHLIPFTNYSVTIVACSGGNGYLGGCTESLPTYVTTHPTVPQNVGPLSVIPLSESYVVISWQPPSKPNGPNLRYELLRRKIQQPLASNPPEDLNRWHNIYSGTQWLYEDKGLSRFTTYEYMLFVHNSVGFTPSREVTVTTLAGLPERGANLTASVLNHTAIDVRWAKPTVQDLQGEVEYYTLFWSSATSNDSLKILPDVNSHVIGHLKPNTEYWIFISVFNGVHSINSAGLHATTCDGEPQGMLPPEVVIINSTAVRVIWTSPSNPNGVVTEYSIYVNNKLYKTGMNVPGSFILRDLSPFTIYDIQVEVCTIYACVKSNGTQITTVEDTPSDIPTPTIRGITSRSLQIDWVSPRKPNGIILGYDLLWKTWYPCAKTQKLVQDQSDELCKAVRCQKPESICGHICYSSEAKVCCNGVLYNPKPGHRCCEEKYIPFVLNSTGVCCGGRIQEAQPNHQCCSGYYARILPGEVCCPDEQHNRVSVGIGDSCCGRMPYSTSGNQICCAGRLHDGHGQKCCGRQIVSNDLECCGGEEGVVYNRLPGMFCCGQDYVNMSDTICCSASSGESKAHIKKNDPVPVKCCETELIPKSQKCCNGVGYNPLKYVCSDKISTGMMMKETKECRILCPASMEATEHCGRCDFNFTSHICTVIRGSHNSTGKASIEEMCSSAEETIHTGSVNTYSYTDVNLKPYMTYEYRISAWNSYGRGLSKAVRARTKEDVPQGVSPPTWTKIDNLEDTIVLNWRKPIQSNGPIIYYILLRNGIERFRGTSLSFSDKEGIQPFQEYSYQLKACTVAGCATSSKVVAATTQGVPESILPPSITALSAVALHLSWSVPEKSNGVIKEYQIRQVGKGLIHTDTTDRRQHTVTGLQPYTNYSFTLTACTSAGCTSSEPFLGQTLQAAPEGVWVTPRHIIINSTTVELYWSLPEKPNGLVSQYQLSRNGNLLFLGGSEEQNFTDKNLEPNSRYTYKLEVKTGGGSSASDDYIVQTPMSTPEEIYPPYNITVIGPYSIFVAWIPPGILIPEIPVEYNVLLNDGSVTPLAFSVGHHQSTLLENLTPFTQYEIRIQACQNGSCGVSSRMFVKTPEAAPMDLNSPVLKALGSACIEIKWMPPEKPNGIIINYFIYRRPAGIEEESVLFVWSEGALEFMDEGDTLRPFTLYEYRVRACNSKGSVESLWSLTQTLEAPPQDFPAPWAQATSAHSVLLNWTKPESPNGIISHYRVVYQERPDDPTFNSPTVHAFTVKGTSHQAHLYGLEPFTTYRIGVVAANHAGEILSPWTLIQTLESSPSGLRNFIVEQKENGRALLLQWSEPMRTNGVIKTYNIFSDGFLEYSGLNRQFLFRRLDPFTLYTLTLEACTRAGCAHSAPQPLWTDEAPPDSQLAPTVHSVKSTSVELSWSEPVNPNGKIIRYEVIRRCFEGKAWGNQTIQADEKIVFTEYNTERNTFMYNDTGLQPWTQCEYKIYTWNSAGHTCSSWNVVRTLQAPPEGLSPPVISYVSMNPQKLLISWIPPEQSNGIIQSYRLQRNEMLYPFSFDPVTFNYTDEELLPFSTYSYALQACTSGGCSTSKPTSITTLEAAPSEVSPPDLWAVSATQMNVCWSPPTVQNGKITKYLVRYDNKESLAGQGLCLLVSHLQPYSQYNFSLVACTNGGCTASVSKSAWTMEALPENMDSPTLQVTGSESIEITWKPPRNPNGQIRSYELRRDGTIVYTGLETRYRDFTLTPGVEYSYTVTASNSQGGILSPLVKDRTSPSAPSGMEPPKLQARGPQEILVNWDPPVRTNGDIINYTLFIRELFERETKIIHINTTHNSFGMQSYIVNQLKPFHRYEIRIQACTTLGCASSDWTFIQTPEIAPLMQPPPHLEVQMAPGGFQPTVSLLWTGPLQPNGKVLYYELYRRQIATQPRKSNPVLIYNGSSTSFIDSELLPFTEYEYQVWAVNSAGKAPSSWTWCRTGPAPPEGLRAPTFHVISSTQAVVNISAPGKPNGIVSLYRLFSSSAHGAETVLSEGMATQQTLHGLQAFTNYSIGVEACTCFNCCSKGPTAELRTHPAPPSGLSSPQIGTLASRTASFRWSPPMFPNGVIHSYELQFHVACPPDSALPCTPSQIETKYTGLGQKASLGGLQPYTTYKLRVVAHNEVGSTASEWISFTTQKELPQYRAPFSVDSNLSVVCVNWSDTFLLNGQLKEYVLTDGGRRVYSGLDTTLYIPRTADKTFFFQVICTTDEGSVKTPLIQYDTSTGLGLVLTTPGKKKGSRSKSTEFYSELWFIVLMAMLGLILLAIFLSLILQRKIHKEPYIRERPPLVPLQKRMSPLNVYPPGENHMGLADTKIPRSGTPVSIRSNRSACVLRIPSQNQTSLTYSQGSLHRSVSQLMDIQDKKVLMDNSLWEAIMGHNSGLYVDEEDLMNAIKDFSSVTKERTTFTDTHL	5202	O75445	F	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [3167, 3881], 'DISULFID_gain_score': array([0.00052023, 0.0009526 ]), 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [4236, 4604], 'STRAND_gain_score': array([0.00146788, 0.00092894]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': [731], 'ZN_FING_gain_score': array([0.00230771])}
191	NM_002755.3(MAP2K1):c.364A>G (p.Asn122Asp)	228273	CA10576999	NM_002755.3:c.364A>G, NC_000015.10:g.66436818A>G, CM000677.2:g.66436818A>G, NC_000015.9:g.66729156A>G, CM000677.1:g.66729156A>G, NC_000015.8:g.64516210A>G, NG_008305.1:g.54946A>G, LRG_725:g.54946A>G, LRG_725t1:c.364A>G, XM_011521783.1:c.298A>G, XM_011521783.3:c.298A>G, XM_017022411.2:c.364A>G, XM_017022412.1:c.298A>G, NM_002755.4:c.364A>G, ENST00000307102.9:c.364A>G, ENST00000425818.2:n.875A>G, NM_002755.3(MAP2K1):c.364A>G (p.Asn122Asp)	MAP2K1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Pathogenic	PS2_Very Strong, PM2, PP2, PS4_Supporting		The c.364A>G (p.Asn122Asp) variant in MAP2K1 was absent from gnomAD (PM2). It has been observed in 3 probands with clinical features of a RASopathy, including 1 de novo occurrence with maternity and paternity confirmed and 2 assumed de novo occurrences (PM2_VS; SCV000271240.2; Otto-von-Guericke-Universität Magdeburg internal communication; Invitae internal data, SCV000947966.1). Of these patients, 2 received a clinical diagnosis of either Noonan syndrome or cardiofaciocutaneous syndrome (PS4_Supporting). Of note, this variant was observed in 1 proband without clinical information who inherited it from a parent with unknown clinical status (GeneDx internal data). The c.364A>G (p.Asm122Asp) variant is located in MAP2K1, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). In summary, this variant meets criteria to be classified as pathogenic for autosomal dominant RASopathy based on RASopathy-specific ACMG/AMP criteria (PMID:29493581): PS2_VS, PS4_Supporting, PM2, PP2.		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2020-03-16	2020-03-24	False	https://erepo.genome.network/evrepo/ui/classification/CA10576999/MONDO:0021060/004	e13f1eb9-0fbc-4e6c-96cf-d06a0b166fca	p.Asn122Asp	Asn	122	Asp	MPKKKPTPIQLNPAPDGSAVNGTSSAETNLEALQKKLEELELDEQQRKRLEAFLTQKQKVGELKDDDFEKISELGAGNGGVVFKVSHKPSGLVMARKLIHLEIKPAIRNQIIRELQVLHECNSPYIVGFYGAFYSDGEISICMEHMDGGSLDQVLKKAGRIPEQILGKVSIAVIKGLTYLREKHKIMHRDVKPSNILVNSRGEIKLCDFGVSGQLIDSMANSFVGTRSYMSPERLQGTHYSVQSDIWSMGLSLVEMAVGRYPIPPPDAKELELMFGCQVEGDAAETPPRPRTPGRPLSSYGMDSRPPMAIFELLDYIVNEPPPKLPSGVFSLEFQDFVNKCLIKNPAERADLKQLMVHAFIKRSDAEEVDFAGWLCSTIGLNQPSTPTHAAGV	393	Q02750	D	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
192	NM_004333.6(BRAF):c.1796C>T (p.Thr599Ile)	40388	CA281995	NM_004333.6:c.1796C>T, NC_000007.14:g.140753339G>A, CM000669.2:g.140753339G>A, NC_000007.13:g.140453139G>A, CM000669.1:g.140453139G>A, NC_000007.12:g.140099608G>A, NG_007873.3:g.176426C>T, LRG_299:g.176426C>T, NM_004333.4:c.1796C>T, LRG_299t1:c.1796C>T, XM_005250045.1:c.1796C>T, XM_005250046.1:c.1796C>T, XM_011516529.1:c.1796C>T, XM_011516530.1:c.1695-3921C>T, XR_242190.1:n.1804C>T, XR_927520.1:n.1804C>T, XR_927521.1:n.1804C>T, XR_927522.1:n.1703-3921C>T, XR_927523.1:n.1703-3921C>T, NM_001354609.1:c.1796C>T, NM_004333.5:c.1796C>T, NR_148928.1:n.2894C>T, XM_017012558.1:c.1916C>T, XM_017012559.1:c.1916C>T, XR_001744857.1:n.1924C>T, XR_001744858.1:n.1823-3921C>T, NM_001354609.2:c.1796C>T, NM_001374244.1:c.1916C>T, NM_001374258.1:c.1916C>T, ENST00000288602.10:c.1796C>T, ENST00000479537.5:n.80C>T, ENST00000496384.6:n.619C>T, ENST00000497784.1:n.1831C>T, NM_004333.6(BRAF):c.1796C>T (p.Thr599Ile)	BRAF	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Pathogenic	PM6, PM2, PP3, PP2, PS4_Supporting, PM1, PS2	PM5	The c.1796C>T (p.Thr599Ille) variant in BRAF was absent from large population studies (PM2; gnomad.broadinstitute.org). It has been reported as a de novo occurrence with parentage confirmed in 1 proband diagnosed with cardiofaciocutaneous syndrome (PS2, PS4_Supporting; PMID 30732632). This variant was also observed as a de novo occurrence without parentage confirmed in proband with phenotypic features of a RASopathy but no clinical diagnosis (PM6; GeneDx internal data, SCV000057239.11). The variant occurs in the CR3 activation domain of BRAF, which has been defined by the ClinGen RASopathy Expert Panel as a region important for protein function (PM1; PMID 29493581). Computational prediction tools and conservation analysis suggest that the p.Thr599Ile variant may impact the protein (PP3). The variant is located in the BRAF gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Of note, this variant has also been observed in association with somatic malignancies; however, analysis and classification of somatic variation is currently not used to inform germline classifications for the RASopathies. In summary, this variant meets criteria to be classified as pathogenic for autosomal dominant RASopathy based on RASopathy-specific ACMG/AMP criteria applied (PMID:29493581): PS2, PS4_Supporting, PM1, PM2, PM6, PP2, PP3.	30732632	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2020-03-24	2020-03-24	False	https://erepo.genome.network/evrepo/ui/classification/CA281995/MONDO:0021060/004	afb07a14-6fd0-4901-bbfc-0a57329a227a	p.Thr599Ile	Thr	599	Ile	MAALSGGGGGGAEPGQALFNGDMEPEAGAGAGAAASSAADPAIPEEVWNIKQMIKLTQEHIEALLDKFGGEHNPPSIYLEAYEEYTSKLDALQQREQQLLESLGNGTDFSVSSSASMDTVTSSSSSSLSVLPSSLSVFQNPTDVARSNPKSPQKPIVRVFLPNKQRTVVPARCGVTVRDSLKKALMMRGLIPECCAVYRIQDGEKKPIGWDTDISWLTGEELHVEVLENVPLTTHNFVRKTFFTLAFCDFCRKLLFQGFRCQTCGYKFHQRCSTEVPLMCVNYDQLDLLFVSKFFEHHPIPQEEASLAETALTSGSSPSAPASDSIGPQILTSPSPSKSIPIPQPFRPADEDHRNQFGQRDRSSSAPNVHINTIEPVNIDDLIRDQGFRGDGGSTTGLSATPPASLPGSLTNVKALQKSPGPQRERKSSSSSEDRNRMKTLGRRDSSDDWEIPDGQITVGQRIGSGSFGTVYKGKWHGDVAVKMLNVTAPTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHHLHIIETKFEMIKLIDIARQTAQGMDYLHAKSIIHRDLKSNNIFLHEDLTVKIGDFGLATVKSRWSGSHQFEQLSGSILWMAPEVIRMQDKNPYSFQSDVYAFGIVLYELMTGQLPYSNINNRDQIIFMVGRGYLSPDLSKVRSNCPKAMKRLMAECLKKKRDERPLFPQILASIELLARSLPKIHRSASEPSLNRAGFQTEDFSLYACASPKTPIQAGGYGAFPVH	766	P15056	I	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [350], 'COMPBIAS_gain': [], 'COMPBIAS_loss_score': array([-0.0051505]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [374], 'REGION_gain': [], 'REGION_loss_score': array([-0.00257778]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
193	NM_004333.6(BRAF):c.1796C>G (p.Thr599Arg)	280033	CA10603019	NM_004333.6:c.1796C>G, NC_000007.14:g.140753339G>C, CM000669.2:g.140753339G>C, NC_000007.13:g.140453139G>C, CM000669.1:g.140453139G>C, NC_000007.12:g.140099608G>C, NG_007873.3:g.176426C>G, LRG_299:g.176426C>G, NM_004333.4:c.1796C>G, LRG_299t1:c.1796C>G, XM_005250045.1:c.1796C>G, XM_005250046.1:c.1796C>G, XM_011516529.1:c.1796C>G, XM_011516530.1:c.1695-3921C>G, XR_242190.1:n.1804C>G, XR_927520.1:n.1804C>G, XR_927521.1:n.1804C>G, XR_927522.1:n.1703-3921C>G, XR_927523.1:n.1703-3921C>G, NM_001354609.1:c.1796C>G, NM_004333.5:c.1796C>G, NR_148928.1:n.2894C>G, XM_017012558.1:c.1916C>G, XM_017012559.1:c.1916C>G, XR_001744857.1:n.1924C>G, XR_001744858.1:n.1823-3921C>G, NM_001354609.2:c.1796C>G, NM_001374244.1:c.1916C>G, NM_001374258.1:c.1916C>G, ENST00000288602.10:c.1796C>G, ENST00000479537.5:n.80C>G, ENST00000496384.6:n.619C>G, ENST00000497784.1:n.1831C>G, NM_004333.6(BRAF):c.1796C>G (p.Thr599Arg)	BRAF	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Pathogenic	PS2_Very Strong, PM2, PP2, PM1, PS4_Moderate, PS3	PP3, PM5	The c.1796C>G (p.Thr599Arg) variant in BRAF was absent from large population studies (PM2; gnomad.broadinstitute.org). It was observed in 3 probands diagnosed with cardiofaciocutaneous syndrome (PS4_Moderate; PMIDs: 19206169, 28650561; Otto-von-Guericke-Universität Magdeburg internal communication). In two of these patients, as well as one proband with phenotypic features suggestive of a RASopathy but no clinical diagnosis, the variant occurred de novo; parentage was confirmed in 2 of these cases (PS2_VS; PMIDs: 19206169, 28650561; GeneDx internal data, SCV000329761.7). The variant occurs in the CR3 activation domain of BRAF, which has been defined by the ClinGen RASopathy Expert Panel as a region important for protein function (PM1; PMID 29493581). In vitro functional studies provide some evidence that the p.Thr599Arg variant may impact protein function (PS3; PMID: 19206169). Additionally, the variant is located in BRAF, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PS2_VeryStrong, PS3, PS4_Moderate, PM1, PM2, PP2.	28650561, 19206169, 19206169	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2020-03-24	2020-03-24	False	https://erepo.genome.network/evrepo/ui/classification/CA10603019/MONDO:0021060/004	faecd415-c6bd-4898-b360-35d0ec408f2a	p.Thr599Arg	Thr	599	Arg	MAALSGGGGGGAEPGQALFNGDMEPEAGAGAGAAASSAADPAIPEEVWNIKQMIKLTQEHIEALLDKFGGEHNPPSIYLEAYEEYTSKLDALQQREQQLLESLGNGTDFSVSSSASMDTVTSSSSSSLSVLPSSLSVFQNPTDVARSNPKSPQKPIVRVFLPNKQRTVVPARCGVTVRDSLKKALMMRGLIPECCAVYRIQDGEKKPIGWDTDISWLTGEELHVEVLENVPLTTHNFVRKTFFTLAFCDFCRKLLFQGFRCQTCGYKFHQRCSTEVPLMCVNYDQLDLLFVSKFFEHHPIPQEEASLAETALTSGSSPSAPASDSIGPQILTSPSPSKSIPIPQPFRPADEDHRNQFGQRDRSSSAPNVHINTIEPVNIDDLIRDQGFRGDGGSTTGLSATPPASLPGSLTNVKALQKSPGPQRERKSSSSSEDRNRMKTLGRRDSSDDWEIPDGQITVGQRIGSGSFGTVYKGKWHGDVAVKMLNVTAPTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHHLHIIETKFEMIKLIDIARQTAQGMDYLHAKSIIHRDLKSNNIFLHEDLTVKIGDFGLATVKSRWSGSHQFEQLSGSILWMAPEVIRMQDKNPYSFQSDVYAFGIVLYELMTGQLPYSNINNRDQIIFMVGRGYLSPDLSKVRSNCPKAMKRLMAECLKKKRDERPLFPQILASIELLARSLPKIHRSASEPSLNRAGFQTEDFSLYACASPKTPIQAGGYGAFPVH	766	P15056	R	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [350], 'COMPBIAS_gain': [], 'COMPBIAS_loss_score': array([-0.00631702]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [374], 'REGION_gain': [], 'REGION_loss_score': array([-0.00174534]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
194	NM_002880.3(RAF1):c.776C>A (p.Ser259Tyr)	44633	CA134750	NM_002880.3:c.776C>A, NC_000003.12:g.12604194G>T, CM000665.2:g.12604194G>T, NC_000003.11:g.12645693G>T, CM000665.1:g.12645693G>T, NC_000003.10:g.12620693G>T, NG_007467.1:g.64986C>A, LRG_413:g.64986C>A, LRG_413t1:c.776C>A, XM_005265355.1:c.776C>A, XM_005265357.1:c.677C>A, XM_005265358.3:c.533C>A, XM_005265359.3:c.434C>A, XM_005265360.1:c.776C>A, XM_011533974.1:c.776C>A, XM_011533975.1:c.533C>A, NM_001354689.1:c.776C>A, NM_001354690.1:c.776C>A, NM_001354691.1:c.533C>A, NM_001354692.1:c.533C>A, NM_001354693.1:c.677C>A, NM_001354694.1:c.533C>A, NM_001354695.1:c.434C>A, NR_148940.1:n.1191C>A, NR_148941.1:n.1191C>A, NR_148942.1:n.1191C>A, XM_011533974.3:c.776C>A, XM_017006966.1:c.677C>A, XR_001740227.1:n.1008C>A, NM_001354689.3:c.776C>A, NM_001354690.2:c.776C>A, NM_001354691.2:c.533C>A, NM_001354692.2:c.533C>A, NM_001354693.2:c.677C>A, NM_001354694.2:c.533C>A, NM_001354695.2:c.434C>A, NR_148940.2:n.1107C>A, NR_148941.2:n.1107C>A, NR_148942.2:n.1107C>A, ENST00000251849.8:c.776C>A, ENST00000416093.1:c.*354C>A, ENST00000423275.5:c.*453C>A, ENST00000432427.2:n.413C>A, ENST00000442415.6:c.776C>A, ENST00000465826.5:n.20C>A, ENST00000491290.1:n.297C>A, NM_002880.3(RAF1):c.776C>A (p.Ser259Tyr)	RAF1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Pathogenic	PM2, PP2, PM1, PS2, PS4_Moderate	PM5	The c.776C>A (p.Ser259Tyr) variant in RAF1 was absent from large population studies (PM2; gnomAD, http://gnomad.broadinstitute.org). It has been reported in 3 probands with clinical features of Noonan syndrome (PS4_Moderate; PMIDs: 31030682, 26918529, GeneDx internal data). In one proband, the variant occurred de novo with parentage confirmation (PS2; PMID: 31030682). The c.776C>A (p.Ser259Tyr) variant occurs in the CR2 activation domain of RAF1, which has been defined by the ClinGen RASopathy Expert Panel as a region important for protein function (PM1; PMID 29493581). A different pathogenic missense variant has been previously identified at this codon of RAF1 supporting this residue is critical to the function of the protein (PM5 not applied; ClinVar 40601). The variant is located in RAF1, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PM2, PS4_Moderate, PS2, PM1, PP2.	26918529, 31030682	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2020-05-18	2020-05-21	False	https://erepo.genome.network/evrepo/ui/classification/CA134750/MONDO:0021060/004	b0b89194-26bd-44cc-967f-db86e0e33549	p.Ser259Tyr	Ser	259	Tyr	MEHIQGAWKTISNGFGFKDAVFDGSSCISPTIVQQFGYQRRASDDGKLTDPSKTSNTIRVFLPNKQRTVVNVRNGMSLHDCLMKALKVRGLQPECCAVFRLLHEHKGKKARLDWNTDAASLIGEELQVDFLDHVPLTTHNFARKTFLKLAFCDICQKFLLNGFRCQTCGYKFHEHCSTKVPTMCVDWSNIRQLLLFPNSTIGDSGVPALPSLTMRRMRESVSRMPVSSQHRYSTPHAFTFNTSSPSSEGSLSQRQRSTSTPNVHMVSTTLPVDSRMIEDAIRSHSESASPSALSSSPNNLSPTGWSQPKTPVPAQRERAPVSGTQEKNKIRPRGQRDSSYYWEIEASEVMLSTRIGSGSFGTVYKGKWHGDVAVKILKVVDPTPEQFQAFRNEVAVLRKTRHVNILLFMGYMTKDNLAIVTQWCEGSSLYKHLHVQETKFQMFQLIDIARQTAQGMDYLHAKNIIHRDMKSNNIFLHEGLTVKIGDFGLATVKSRWSGSQQVEQPTGSVLWMAPEVIRMQDNNPFSFQSDVYSYGIVLYELMTGELPYSHINNRDQIIFMVGRGYASPDLSKLYKNCPKAMKRLVADCVKKVKEERPLFPQILSSIELLQHSLPKINRSASEPSLHRAAHTEDINACTLTTSPRLPVF	648	P04049	Y	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [131], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.00748456]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [240, 242, 244, 245, 246, 247, 249, 250, 251, 252, 253, 254, 255, 256, 283], 'COMPBIAS_gain': [], 'COMPBIAS_loss_score': array([-0.09530151, -0.08037484, -0.10332513, -0.10384738, -0.10389334,
       -0.11942071, -0.14128906, -0.11149246, -0.13233697, -0.19531375,
       -0.1986413 , -0.21942025, -0.2189883 , -0.21350968, -0.081025  ]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [228, 229, 230, 231, 232, 233, 234, 235, 261, 262, 263, 264, 265, 266, 281, 335], 'REGION_gain': [], 'REGION_loss_score': array([-0.12638426, -0.12266678, -0.12221414, -0.12175852, -0.15595448,
       -0.15440321, -0.16290122, -0.18482846, -0.40783358, -0.42198038,
       -0.40712088, -0.3309145 , -0.30590624, -0.26148152, -0.14818299,
       -0.02943355]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
195	NM_004333.6(BRAF):c.1781A>T (p.Asp594Val)	375946	CA16602425	NM_004333.6:c.1781A>T, NC_000007.14:g.140753354T>A, CM000669.2:g.140753354T>A, NC_000007.13:g.140453154T>A, CM000669.1:g.140453154T>A, NC_000007.12:g.140099623T>A, NG_007873.3:g.176411A>T, LRG_299:g.176411A>T, NM_004333.4:c.1781A>T, LRG_299t1:c.1781A>T, XM_005250045.1:c.1781A>T, XM_005250046.1:c.1781A>T, XM_011516529.1:c.1781A>T, XM_011516530.1:c.1695-3936A>T, XR_242190.1:n.1789A>T, XR_927520.1:n.1789A>T, XR_927521.1:n.1789A>T, XR_927522.1:n.1703-3936A>T, XR_927523.1:n.1703-3936A>T, NM_001354609.1:c.1781A>T, NM_004333.5:c.1781A>T, NR_148928.1:n.2879A>T, XM_017012558.1:c.1901A>T, XM_017012559.1:c.1901A>T, XR_001744857.1:n.1909A>T, XR_001744858.1:n.1823-3936A>T, NM_001354609.2:c.1781A>T, NM_001374244.1:c.1901A>T, NM_001374258.1:c.1901A>T, ENST00000288602.10:c.1781A>T, ENST00000479537.5:n.65A>T, ENST00000496384.6:n.604A>T, ENST00000497784.1:n.1816A>T, NM_004333.6(BRAF):c.1781A>T (p.Asp594Val)	BRAF	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Pathogenic	PM2, PP3, PP2, PM1, PS2, PS4_Moderate		The c.1781A>T (p.Asp594Val) variant in BRAF was absent from large population studies (PM2; gnomAD, http://gnomad.broadinstitute.org). The variant has been reported in 3 probands with clinical features of a RASopathy (PS4_Moderate; SCV000935844.1, SCV000965957.1, GeneDx internal data). In one proband, the variant was reported as de novo with confirmed parentage (PS2). The c.1781A>T (p.Asp594Val) variant is located in the CR3 activation segment of BRAF, which has been defined by the ClinGen RASopathy Expert Panel as a region important for protein function (PM1; PMID 29493581). Computational prediction tools and conservation analysis suggest that the variant may impact protein function (PP3). Finally, c.1781A>T (p.Asp594Val) is located in the BRAF gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. RASopathy-specific ACMG/AMP criteria applied (PMID:29493581): PS2, PS4_Moderate, PM1, PM2, PP2, PP3,		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2020-05-18	2020-05-21	False	https://erepo.genome.network/evrepo/ui/classification/CA16602425/MONDO:0021060/004	8d88d5d7-5d83-4298-8db6-00da7b7db528	p.Asp594Val	Asp	594	Val	MAALSGGGGGGAEPGQALFNGDMEPEAGAGAGAAASSAADPAIPEEVWNIKQMIKLTQEHIEALLDKFGGEHNPPSIYLEAYEEYTSKLDALQQREQQLLESLGNGTDFSVSSSASMDTVTSSSSSSLSVLPSSLSVFQNPTDVARSNPKSPQKPIVRVFLPNKQRTVVPARCGVTVRDSLKKALMMRGLIPECCAVYRIQDGEKKPIGWDTDISWLTGEELHVEVLENVPLTTHNFVRKTFFTLAFCDFCRKLLFQGFRCQTCGYKFHQRCSTEVPLMCVNYDQLDLLFVSKFFEHHPIPQEEASLAETALTSGSSPSAPASDSIGPQILTSPSPSKSIPIPQPFRPADEDHRNQFGQRDRSSSAPNVHINTIEPVNIDDLIRDQGFRGDGGSTTGLSATPPASLPGSLTNVKALQKSPGPQRERKSSSSSEDRNRMKTLGRRDSSDDWEIPDGQITVGQRIGSGSFGTVYKGKWHGDVAVKMLNVTAPTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHHLHIIETKFEMIKLIDIARQTAQGMDYLHAKSIIHRDLKSNNIFLHEDLTVKIGDFGLATVKSRWSGSHQFEQLSGSILWMAPEVIRMQDKNPYSFQSDVYAFGIVLYELMTGQLPYSNINNRDQIIFMVGRGYLSPDLSKVRSNCPKAMKRLMAECLKKKRDERPLFPQILASIELLARSLPKIHRSASEPSLNRAGFQTEDFSLYACASPKTPIQAGGYGAFPVH	766	P15056	V	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [58, 61, 617], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.00948566, -0.00714082, -0.07256657]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [350], 'COMPBIAS_gain': [], 'COMPBIAS_loss_score': array([-0.00426567]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [374], 'REGION_gain': [], 'REGION_loss_score': array([-0.00771976]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
196	NM_206933.3(USH2A):c.12575G>A (p.Arg4192His)	166434	CA179511	NM_206933.3:c.12575G>A, NC_000001.11:g.215675336C>T, CM000663.2:g.215675336C>T, NC_000001.10:g.215848678C>T, CM000663.1:g.215848678C>T, NC_000001.9:g.213915301C>T, NG_009497.1:g.753061G>A, NG_009497.2:g.753113G>A, ENST00000307340.7:c.12575G>A, NM_206933.2:c.12575G>A, NM_206933.4:c.12575G>A, NM_206933.3(USH2A):c.12575G>A (p.Arg4192His)	USH2A	Usher syndrome	MONDO:0019501	Autosomal recessive inheritance	Benign	BA1, BP4		The filtering allele frequency (the lower threshold of the 95% CI of 39/3324) of the p.Arg4192His variant in the USH2A gene is 0.882% for Ashkenazi Jewish chromosomes by gnomAD v3, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive hearing loss variants (BA1). The variant is present in several individuals with retinitis pigmentosa but has not been associated with hearing loss (PM3 not met). Additionally, computational prediction analysis using the metapredictor tool REVEL (0.119) suggests that the variant may not impact the protein (BP4). In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel: BA1, BP4.		Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2020-03-19	2021-03-30	True	https://erepo.genome.network/evrepo/ui/classification/CA179511/MONDO:0019501/005	a38414ae-e328-4518-8105-9299e499fa90	p.Arg4192His	Arg	4192	His	MNCPVLSLGSGFLFQVIEMLIFAYFASISLTESRGLFPRLENVGAFKKVSIVPTQAVCGLPDRSTFCHSSAAAESIQFCTQRFCIQDCPYRSSHPTYTALFSAGLSSCITPDKNDLHPNAHSNSASFIFGNHKSCFSSPPSPKLMASFTLAVWLKPEQQGVMCVIEKTVDGQIVFKLTISEKETMFYYRTVNGLQPPIKVMTLGRILVKKWIHLSVQVHQTKISFFINGVEKDHTPFNARTLSGSITDFASGTVQIGQSLNGLEQFVGRMQDFRLYQVALTNREILEVFSGDLLRLHAQSHCRCPGSHPRVHPLAQRYCIPNDAGDTADNRVSRLNPEAHPLSFVNDNDVGTSWVSNVFTNITQLNQGVTISVDLENGQYQVFYIIIQFFSPQPTEIRIQRKKENSLDWEDWQYFARNCGAFGMKNNGDLEKPDSVNCLQLSNFTPYSRGNVTFSILTPGPNYRPGYNNFYNTPSLQEFVKATQIRFHFHGQYYTTETAVNLRHRYYAVDEITISGRCQCHGHADNCDTTSQPYRCLCSQESFTEGLHCDRCLPLYNDKPFRQGDQVYAFNCKPCQCNSHSKSCHYNISVDPFPFEHFRGGGGVCDDCEHNTTGRNCELCKDYFFRQVGADPSAIDVCKPCDCDTVGTRNGSILCDQIGGQCNCKRHVSGRQCNQCQNGFYNLQELDPDGCSPCNCNTSGTVDGDITCHQNSGQCKCKANVIGLRCDHCNFGFKFLRSFNDVGCEPCQCNLHGSVNKFCNPHSGQCECKKEAKGLQCDTCRENFYGLDVTNCKACDCDTAGSLPGTVCNAKTGQCICKPNVEGRQCNKCLEGNFYLRQNNSFLCLPCNCDKTGTINGSLLCNKSTGQCPCKLGVTGLRCNQCEPHRYNLTIDNFQHCQMCECDSLGTLPGTICDPISGQCLCVPNRQGRRCNQCQPGFYISPGNATGCLPCSCHTTGAVNHICNSLTGQCVCQDASIAGQRCDQCKDHYFGFDPQTGRCQPCNCHLSGALNETCHLVTGQCFCKQFVTGSKCDACVPSASHLDVNNLLGCSKTPFQQPPPRGQVQSSSAINLSWSPPDSPNAHWLTYSLLRDGFEIYTTEDQYPYSIQYFLDTDLLPYTKYSYYIETTNVHGSTRSVAVTYKTKPGVPEGNLTLSYIIPIGSDSVTLTWTTLSNQSGPIEKYILSCAPLAGGQPCVSYEGHETSATIWNLVPFAKYDFSVQACTSGGCLHSLPITVTTAQAPPQRLSPPKMQKISSTELHVEWSPPAELNGIIIRYELYMRRLRSTKETTSEESRVFQSSGWLSPHSFVESANENALKPPQTMTTITGLEPYTKYEFRVLAVNMAGSVSSAWVSERTGESAPVFMIPPSVFPLSSYSLNISWEKPADNVTRGKVVGYDINMLSEQSPQQSIPMAFSQLLHTAKSQELSYTVEGLKPYRIYEFTITLCNSVGCVTSASGAGQTLAAAPAQLRPPLVKGINSTTIHLRWFPPEELNGPSPIYQLERRESSLPALMTTMMKGIRFIGNGYCKFPSSTHPVNTDFTGIKASFRTKVPEGLIVFAASPGNQEEYFALQLKKGRLYFLFDPQGSPVEVTTTNDHGKQYSDGKWHEIIAIRHQAFGQITLDGIYTGSSAILNGSTVIGDNTGVFLGGLPRSYTILRKDPEIIQKGFVGCLKDVHFMKNYNPSAIWEPLDWQSSEEQINVYNSWEGCPASLNEGAQFLGAGFLELHPYMFHGGMNFEISFKFRTDQLNGLLLFVYNKDGPDFLAMELKSGILTFRLNTSLAFTQVDLLLGLSYCNGKWNKVIIKKEGSFISASVNGLMKHASESGDQPLVVNSPVYVGGIPQELLNSYQHLCLEQGFGGCMKDVKFTRGAVVNLASVSSGAVRVNLDGCLSTDSAVNCRGNDSILVYQGKEQSVYEGGLQPFTEYLYRVIASHEGGSVYSDWSRGRTTGAAPQSVPTPSRVRSLNGYSIEVTWDEPVVRGVIEKYILKAYSEDSTRPPRMPSASAEFVNTSNLTGILTGLLPFKNYAVTLTACTLAGCTESSHALNISTPQEAPQEVQPPVAKSLPSSLLLSWNPPKKANGIITQYCLYMDGRLIYSGSEENYIVTDLAVFTPHQFLLSACTHVGCTNSSWVLLYTAQLPPEHVDSPVLTVLDSRTIHIQWKQPRKISGILERYVLYMSNHTHDFTIWSVIYNSTELFQDHMLQYVLPGNKYLIKLGACTGGGCTVSEASEALTDEDIPEGVPAPKAHSYSPDSFNVSWTEPEYPNGVITSYGLYLDGILIHNSSELSYRAYGFAPWSLHSFRVQACTAKGCALGPLVENRTLEAPPEGTVNVFVKTQGSRKAHVRWEAPFRPNGLLTHSVLFTGIFYVDPVGNNYTLLNVTKVMYSGEETNLWVLIDGLVPFTNYTVQVNISNSQGSLITDPITIAMPPGAPDGVLPPRLSSATPTSLQVVWSTPARNNAPGSPRYQLQMRSGDSTHGFLELFSNPSASLSYEVSDLQPYTEYMFRLVASNGFGSAHSSWIPFMTAEDKPGPVVPPILLDVKSRMMLVTWQHPRKSNGVITHYNIYLHGRLYLRTPGNVTNCTVMHLHPYTAYKFQVEACTSKGCSLSPESQTVWTLPGAPEGIPSPELFSDTPTSVIISWQPPTHPNGLVENFTIERRVKGKEEVTTLVTLPRSHSMRFIDKTSALSPWTKYEYRVLMSTLHGGTNSSAWVEVTTRPSRPAGVQPPVVTVLEPDAVQVTWKPPLIQNGDILSYEIHMPDPHITLTNVTSAVLSQKVTHLIPFTNYSVTIVACSGGNGYLGGCTESLPTYVTTHPTVPQNVGPLSVIPLSESYVVISWQPPSKPNGPNLRYELLRRKIQQPLASNPPEDLNRWHNIYSGTQWLYEDKGLSRFTTYEYMLFVHNSVGFTPSREVTVTTLAGLPERGANLTASVLNHTAIDVRWAKPTVQDLQGEVEYYTLFWSSATSNDSLKILPDVNSHVIGHLKPNTEYWIFISVFNGVHSINSAGLHATTCDGEPQGMLPPEVVIINSTAVRVIWTSPSNPNGVVTEYSIYVNNKLYKTGMNVPGSFILRDLSPFTIYDIQVEVCTIYACVKSNGTQITTVEDTPSDIPTPTIRGITSRSLQIDWVSPRKPNGIILGYDLLWKTWYPCAKTQKLVQDQSDELCKAVRCQKPESICGHICYSSEAKVCCNGVLYNPKPGHRCCEEKYIPFVLNSTGVCCGGRIQEAQPNHQCCSGYYARILPGEVCCPDEQHNRVSVGIGDSCCGRMPYSTSGNQICCAGRLHDGHGQKCCGRQIVSNDLECCGGEEGVVYNRLPGMFCCGQDYVNMSDTICCSASSGESKAHIKKNDPVPVKCCETELIPKSQKCCNGVGYNPLKYVCSDKISTGMMMKETKECRILCPASMEATEHCGRCDFNFTSHICTVIRGSHNSTGKASIEEMCSSAEETIHTGSVNTYSYTDVNLKPYMTYEYRISAWNSYGRGLSKAVRARTKEDVPQGVSPPTWTKIDNLEDTIVLNWRKPIQSNGPIIYYILLRNGIERFRGTSLSFSDKEGIQPFQEYSYQLKACTVAGCATSSKVVAATTQGVPESILPPSITALSAVALHLSWSVPEKSNGVIKEYQIRQVGKGLIHTDTTDRRQHTVTGLQPYTNYSFTLTACTSAGCTSSEPFLGQTLQAAPEGVWVTPRHIIINSTTVELYWSLPEKPNGLVSQYQLSRNGNLLFLGGSEEQNFTDKNLEPNSRYTYKLEVKTGGGSSASDDYIVQTPMSTPEEIYPPYNITVIGPYSIFVAWIPPGILIPEIPVEYNVLLNDGSVTPLAFSVGHHQSTLLENLTPFTQYEIRIQACQNGSCGVSSRMFVKTPEAAPMDLNSPVLKALGSACIEIKWMPPEKPNGIIINYFIYRRPAGIEEESVLFVWSEGALEFMDEGDTLRPFTLYEYRVRACNSKGSVESLWSLTQTLEAPPQDFPAPWAQATSAHSVLLNWTKPESPNGIISHYRVVYQERPDDPTFNSPTVHAFTVKGTSHQAHLYGLEPFTTYRIGVVAANHAGEILSPWTLIQTLESSPSGLRNFIVEQKENGRALLLQWSEPMRTNGVIKTYNIFSDGFLEYSGLNRQFLFRRLDPFTLYTLTLEACTRAGCAHSAPQPLWTDEAPPDSQLAPTVHSVKSTSVELSWSEPVNPNGKIIRYEVIRRCFEGKAWGNQTIQADEKIVFTEYNTERNTFMYNDTGLQPWTQCEYKIYTWNSAGHTCSSWNVVRTLQAPPEGLSPPVISYVSMNPQKLLISWIPPEQSNGIIQSYRLQRNEMLYPFSFDPVTFNYTDEELLPFSTYSYALQACTSGGCSTSKPTSITTLEAAPSEVSPPDLWAVSATQMNVCWSPPTVQNGKITKYLVRYDNKESLAGQGLCLLVSHLQPYSQYNFSLVACTNGGCTASVSKSAWTMEALPENMDSPTLQVTGSESIEITWKPPRNPNGQIRSYELRRDGTIVYTGLETRYRDFTLTPGVEYSYTVTASNSQGGILSPLVKDRTSPSAPSGMEPPKLQARGPQEILVNWDPPVRTNGDIINYTLFIRELFERETKIIHINTTHNSFGMQSYIVNQLKPFHRYEIRIQACTTLGCASSDWTFIQTPEIAPLMQPPPHLEVQMAPGGFQPTVSLLWTGPLQPNGKVLYYELYRRQIATQPRKSNPVLIYNGSSTSFIDSELLPFTEYEYQVWAVNSAGKAPSSWTWCRTGPAPPEGLRAPTFHVISSTQAVVNISAPGKPNGIVSLYRLFSSSAHGAETVLSEGMATQQTLHGLQAFTNYSIGVEACTCFNCCSKGPTAELRTHPAPPSGLSSPQIGTLASRTASFRWSPPMFPNGVIHSYELQFHVACPPDSALPCTPSQIETKYTGLGQKASLGGLQPYTTYKLRVVAHNEVGSTASEWISFTTQKELPQYRAPFSVDSNLSVVCVNWSDTFLLNGQLKEYVLTDGGRRVYSGLDTTLYIPRTADKTFFFQVICTTDEGSVKTPLIQYDTSTGLGLVLTTPGKKKGSRSKSTEFYSELWFIVLMAMLGLILLAIFLSLILQRKIHKEPYIRERPPLVPLQKRMSPLNVYPPGENHMGLADTKIPRSGTPVSIRSNRSACVLRIPSQNQTSLTYSQGSLHRSVSQLMDIQDKKVLMDNSLWEAIMGHNSGLYVDEEDLMNAIKDFSSVTKERTTFTDTHL	5202	O75445	H	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [4189], 'STRAND_gain_score': array([0.00960457]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [461, 463, 473, 4164, 4165, 4169, 4171, 4172, 4173, 4175, 4177, 4178, 4179, 4180, 4181, 4195, 4208, 4210, 4214, 4216, 4218, 4283, 4295, 4296, 4297], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.06079721, -0.05318779, -0.05357325, -0.17536157, -0.1547007 ,
       -0.17489243, -0.16899937, -0.07559788, -0.17261887, -0.17980933,
       -0.20707041, -0.20138919, -0.18707466, -0.20094657, -0.18105274,
       -0.0721063 , -0.1923207 , -0.17726219, -0.17229933, -0.13027543,
       -0.1088047 , -0.07466483, -0.14041102, -0.12929076, -0.09272629]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [766], 'ZN_FING_gain': [], 'ZN_FING_loss_score': array([-0.00041485])}"
197	NM_000152.5(GAA):c.655G>A (p.Gly219Arg)	189065	CA274334	NM_000152.5:c.655G>A, NC_000017.11:g.80105857G>A, CM000679.2:g.80105857G>A, NC_000017.10:g.78079656G>A, CM000679.1:g.78079656G>A, NC_000017.9:g.75694251G>A, NG_009822.1:g.9302G>A, LRG_673:g.9302G>A, NM_000152.3:c.655G>A, LRG_673t1:c.655G>A, NM_001079803.1:c.655G>A, NM_001079804.1:c.655G>A, XM_005257193.1:c.655G>A, XM_005257194.3:c.655G>A, NM_000152.4:c.655G>A, NM_001079803.2:c.655G>A, NM_001079804.2:c.655G>A, XM_005257193.2:c.655G>A, XM_005257194.4:c.655G>A, NM_001079803.3:c.655G>A, NM_001079804.3:c.655G>A, ENST00000302262.7:c.655G>A, ENST00000390015.7:c.655G>A, ENST00000570803.5:c.655G>A, NM_000152.5(GAA):c.655G>A (p.Gly219Arg)	GAA	glycogen storage disease II	MONDO:0009290	Autosomal recessive inheritance	Pathogenic	PM3_Strong, PS3, PM2, PP3, PP4		This variant, c.655G>A (p.Gly219Arg), has been reported in at least eight individuals with Pompe disease and residual GAA activity meeting the ClinGen LSD VCEP’s specifications for PP4. Of these individuals, four are compound heterozygous for the variant and another pathogenic variant in GAA, including c.-32-13T>G (PMID 21550241, 24844452), c.169C>T (p.Gln57Ter) (PMID 29124014), or c.2560C>T (p.Arg854Ter)(PMID 23266370), and one is homozygous for the variant (PMID 25139343). This in trans data meets PM3_Strong. A further three individuals are compound heterozygous for the variant and either c.1735G>A (p.Glu579Lys) (PMIDs 23601496, 31193175), c.546G>A (PMID 25037089), or c.784G>A (p.Glu262Lys) (PMID 11738358). However, the in trans data for these patients will be used in the assessment of those respective variants and was not included here in order to avoid a circular argument. Additional patients have been reported but were not included because the residual GAA activity was not reported and therefore PP4 cannot be assessed, patients with the same genotype had already been included, or no cDNA sequence change was provided for the variant (PMIDs 14695532, 18429042, 20033296, 21550241, 23787031, 25139343, 27711114, 30023291, 30155607). The highest population minor allele frequency in gnomAD v2.1.1 is 0.00004024 in the African population, meeting PM2. When it was expressed in COS cells, this variant results in <2% wild type GAA activity and it is abnormally processed (PMIDs 14695532; 19862843), meeting PS3. The score for the REVEL in silico meta-predictor, 0.872, also supports that the variant has a deleterious impact on GAA function, meeting PP3. There is a ClinVar entry for this variant (Variation ID 189065; 2 star review status) with four submitters classifying the variant as pathogenic and one as likely pathogenic. In summary, this variant meets the criteria to be classified as pathogenic for Pompe disease. ACMG/AMP criteria met, based on the specifications of the ClinGen LSD VCEP: PS3, PM2, PM3_Strong, PP3, PP4.	23787031, 31193175, 25139343, 11738358, 23266370, 21550241, 30155607, 18429042, 14695532, 29289479, 20033296, 24844452, 27711114, 30023291, 25037089, 29124014, 23601496, 14695532, 19862843	Lysosomal Diseases VCEP	https://clinicalgenome.org/docs/clingen-lysosomal-storage-disorders-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-2/	2020-04-19	2020-05-26	False	https://erepo.genome.network/evrepo/ui/classification/CA274334/MONDO:0009290/010	0ef0c8e1-2dac-4aa5-b960-5bedcbc50b26	p.Gly219Arg	Gly	219	Arg	MGVRHPPCSHRLLAVCALVSLATAALLGHILLHDFLLVPRELSGSSPVLEETHPAHQQGASRPGPRDAQAHPGRPRAVPTQCDVPPNSRFDCAPDKAITQEQCEARGCCYIPAKQGLQGAQMGQPWCFFPPSYPSYKLENLSSSEMGYTATLTRTTPTFFPKDILTLRLDVMMETENRLHFTIKDPANRRYEVPLETPHVHSRAPSPLYSVEFSEEPFGVIVRRQLDGRVLLNTTVAPLFFADQFLQLSTSLPSQYITGLAEHLSPLMLSTSWTRITLWNRDLAPTPGANLYGSHPFYLALEDGGSAHGVFLLNSNAMDVVLQPSPALSWRSTGGILDVYIFLGPEPKSVVQQYLDVVGYPFMPPYWGLGFHLCRWGYSSTAITRQVVENMTRAHFPLDVQWNDLDYMDSRRDFTFNKDGFRDFPAMVQELHQGGRRYMMIVDPAISSSGPAGSYRPYDEGLRRGVFITNETGQPLIGKVWPGSTAFPDFTNPTALAWWEDMVAEFHDQVPFDGMWIDMNEPSNFIRGSEDGCPNNELENPPYVPGVVGGTLQAATICASSHQFLSTHYNLHNLYGLTEAIASHRALVKARGTRPFVISRSTFAGHGRYAGHWTGDVWSSWEQLASSVPEILQFNLLGVPLVGADVCGFLGNTSEELCVRWTQLGAFYPFMRNHNSLLSLPQEPYSFSEPAQQAMRKALTLRYALLPHLYTLFHQAHVAGETVARPLFLEFPKDSSTWTVDHQLLWGEALLITPVLQAGKAEVTGYFPLGTWYDLQTVPVEALGSLPPPPAAPREPAIHSEGQWVTLPAPLDTINVHLRAGYIIPLQGPGLTTTESRQQPMALAVALTKGGEARGELFWDDGESLEVLERGAYTQVIFLARNNTIVNELVRVTSEGAGLQLQKVTVLGVATAPQQVLSNGVPVSNFTYSPDTKVLDICVSLLMGEQFLVSWC	952	P10253	R	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [375], 'DNA_BIND_gain': [658], 'DNA_BIND_gain_score': array([0.00105321]), 'DNA_BIND_loss_score': array([-0.00165951]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [214, 239, 240], 'STRAND_gain': [217, 885, 913], 'STRAND_gain_score': array([0.34392011, 0.00521576, 0.00349528]), 'STRAND_loss_score': array([-0.28727823, -0.13446707, -0.12474531]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
198	NM_000152.3(GAA):c.1933G>A (p.Asp645Asn)	188728	CA273892	NM_000152.3:c.1933G>A, LRG_673t1:c.1933G>A, NM_001079803.1:c.1933G>A, NM_001079804.1:c.1933G>A, XM_005257193.1:c.1933G>A, XM_005257194.3:c.1933G>A, NM_000152.4:c.1933G>A, NM_001079803.2:c.1933G>A, NM_001079804.2:c.1933G>A, XM_005257193.2:c.1933G>A, XM_005257194.4:c.1933G>A, NM_000152.5:c.1933G>A, NM_001079803.3:c.1933G>A, NM_001079804.3:c.1933G>A, ENST00000302262.7:c.1933G>A, ENST00000390015.7:c.1933G>A, ENST00000570716.1:n.373G>A, ENST00000572080.1:n.352G>A, ENST00000572803.1:n.547G>A, NC_000017.11:g.80112920G>A, CM000679.2:g.80112920G>A, NC_000017.10:g.78086719G>A, CM000679.1:g.78086719G>A, NC_000017.9:g.75701314G>A, NG_009822.1:g.16365G>A, LRG_673:g.16365G>A, NM_000152.3(GAA):c.1933G>A (p.Asp645Asn)	GAA	glycogen storage disease II	MONDO:0009290	Autosomal recessive inheritance	Pathogenic	PM3_Strong, PS3, PM2, PP3, PP4, PM5		This variant, c.1933G>A (p.Asp645Asn), is a missense change which has been reported in least 11 individuals with deficient GAA activity meeting the ClinGen LSD VCEP's specifications for PP4 (PMIDs 9535769, 15145338, 16860134, 17723315, 23601496, 25139343, 26497565). Five of these individuals are homozygous for the variant have been reported to have infantile onset Pompe disease (PMIDs 16860134, 25139343, 26497565). This variant was also found in two patients who meet PP4 specifications, in compound heterozygosity, phase not confirmed, with a unique pathogenic variant in GAA, either c.2501_2502del or c.2242dup (PMIDs 9535769, 23601496). Based on data from homozygous and compound heterozygous patients, PM3_Strong is met. Additional compound heterozygous cases have been reported but the in trans data has been used in the assessment of the second variant and therefore is not included here in order to avoid circular logic (PMIDs 15145338, 17723315, 26497565). Other cases were not included because the residual GAA activity was not provided, and therefore PP4 cannot be assessed (PMIDs 18429042, 25455803, 27927596, 29122469, 30105547, 30155607). The highest population minor allele frequency in gnomAD is 0.00007 in the African population, meeting PM2. When expressed in GAA-deficient fibroblasts and COS cells, this variant results in virtually no GAA activity (PMIDs 9535769, 15145338), meeting PS3. The score for the in silico meta-predictor, REVEL, is 0.868 suggesting that the variant impacts the function of GAA, meeting PP3. Three other amino acid changes have been reported in patients with Pompe disease at the same amino acid position (c.1933G>C (p.Asp645His), c.1933G>T (p.Asp645Tyr), c.1935C>A (p.Asp645Glu). At least one of these variants, c.1935C>A (p.Asp645Glu), is pathogenic, meeting PM5. In summary, this variant meets the criteria to be specified as pathogenic for Pompe disease. ACMG/AMP criteria applied, as specified by the ClinGen LSD VCEP: PS3, PM2, PM3_Strong, PM5, PP4.	30155607, 18429042, 27927596, 23601496, 29122469, 9535769, 30105547, 26497565, 25455803, 15145338, 19862843, 17723315, 9535769, 15145338, 25139343, 16860134	Lysosomal Diseases VCEP	https://clinicalgenome.org/docs/clingen-lysosomal-storage-disorders-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-2/	2020-05-28	2020-05-28	False	https://erepo.genome.network/evrepo/ui/classification/CA273892/MONDO:0009290/010	de5d2dea-4287-467e-bb50-628cbd11edc8	p.Asp645Asn	Asp	645	Asn	MGVRHPPCSHRLLAVCALVSLATAALLGHILLHDFLLVPRELSGSSPVLEETHPAHQQGASRPGPRDAQAHPGRPRAVPTQCDVPPNSRFDCAPDKAITQEQCEARGCCYIPAKQGLQGAQMGQPWCFFPPSYPSYKLENLSSSEMGYTATLTRTTPTFFPKDILTLRLDVMMETENRLHFTIKDPANRRYEVPLETPHVHSRAPSPLYSVEFSEEPFGVIVRRQLDGRVLLNTTVAPLFFADQFLQLSTSLPSQYITGLAEHLSPLMLSTSWTRITLWNRDLAPTPGANLYGSHPFYLALEDGGSAHGVFLLNSNAMDVVLQPSPALSWRSTGGILDVYIFLGPEPKSVVQQYLDVVGYPFMPPYWGLGFHLCRWGYSSTAITRQVVENMTRAHFPLDVQWNDLDYMDSRRDFTFNKDGFRDFPAMVQELHQGGRRYMMIVDPAISSSGPAGSYRPYDEGLRRGVFITNETGQPLIGKVWPGSTAFPDFTNPTALAWWEDMVAEFHDQVPFDGMWIDMNEPSNFIRGSEDGCPNNELENPPYVPGVVGGTLQAATICASSHQFLSTHYNLHNLYGLTEAIASHRALVKARGTRPFVISRSTFAGHGRYAGHWTGDVWSSWEQLASSVPEILQFNLLGVPLVGADVCGFLGNTSEELCVRWTQLGAFYPFMRNHNSLLSLPQEPYSFSEPAQQAMRKALTLRYALLPHLYTLFHQAHVAGETVARPLFLEFPKDSSTWTVDHQLLWGEALLITPVLQAGKAEVTGYFPLGTWYDLQTVPVEALGSLPPPPAAPREPAIHSEGQWVTLPAPLDTINVHLRAGYIIPLQGPGLTTTESRQQPMALAVALTKGGEARGELFWDDGESLEVLERGAYTQVIFLARNNTIVNELVRVTSEGAGLQLQKVTVLGVATAPQQVLSNGVPVSNFTYSPDTKVLDICVSLLMGEQFLVSWC	952	P10253	N	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [599], 'BINDING_gain': [], 'BINDING_loss_score': array([-0.02755201]), 'DNA_BIND_loss': [659, 661, 663, 714, 716], 'DNA_BIND_gain': [601, 608, 611, 647, 707], 'DNA_BIND_gain_score': array([0.00672537, 0.00608283, 0.00615233, 0.02224547, 0.00367475]), 'DNA_BIND_loss_score': array([-0.01023257, -0.01985401, -0.02000272, -0.01858467, -0.00161815]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [259, 806], 'STRAND_gain_score': array([0.00318503, 0.01984662]), 'HELIX_loss': [727], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.02706748]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [623], 'REPEAT_gain': [579, 587, 598], 'REPEAT_gain_score': array([0.01457798, 0.01622277, 0.00637197]), 'REPEAT_loss_score': array([-0.00781471]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
199	NM_000152.4(GAA):c.925G>A (p.Gly309Arg)	188797	CA273972	NM_000152.4:c.925G>A, ENST00000302262.8:c.925G>A, ENST00000302262.7:c.925G>A, ENST00000390015.7:c.925G>A, NM_000152.3:c.925G>A, LRG_673t1:c.925G>A, NM_001079803.1:c.925G>A, NM_001079804.1:c.925G>A, XM_005257193.1:c.925G>A, XM_005257194.3:c.925G>A, NM_001079803.2:c.925G>A, NM_001079804.2:c.925G>A, XM_005257193.2:c.925G>A, XM_005257194.4:c.925G>A, NM_000152.5:c.925G>A, NM_001079803.3:c.925G>A, NM_001079804.3:c.925G>A, NC_000017.11:g.80107866G>A, CM000679.2:g.80107866G>A, NC_000017.10:g.78081665G>A, CM000679.1:g.78081665G>A, NC_000017.9:g.75696260G>A, NG_009822.1:g.11311G>A, LRG_673:g.11311G>A, NM_000152.4(GAA):c.925G>A (p.Gly309Arg)	GAA	glycogen storage disease II	MONDO:0009290	Autosomal recessive inheritance	Pathogenic	PS3, PP4_Moderate, PP3, PM2_Supporting, PM3_Very Strong		The NM_000152.5:c.925G>A variant in GAA is a missense variant predicted to cause substitution of glycine by arginine at amino acid 309 (p.Gly309Arg). In a cohort of 54 Dutch patients with Pompe disease, the allele frequency of the variant was 5.5%, and evidence suggests that it is a founder variant in that population (PMID 9660056). This variant has been reported in more than 13 individuals diagnosed with Pompe disease; for at least 6 individuals, residual GAA activity is available and is in the deficient range (PMIDs 9660056, 16838077, 23430847, 23601496, 24495340, 27189384), with some patients also reported to be on enzyme replacement therapy and/or to have documentation of symptoms consistent with infantile onset Pompe disease (PMID 23402890, 23430847, 23601496, 24495340) (PP4_Moderate). More data is available in the literature but the maximum strength of evidence for PP4, as specified by the ClinGen LSD VCEP, can already be applied.. Ten of these individuals are compound heterozygous for the variant and a pathogenic variant (PMID: 9660056, 16838077, 16917947, 23402890, 23430847), phase unknown in all cases, and one is homozygous (PMID: 23601496)(PM3_Very strong). The highest continental population minor allele frequency in gnomAD v2.1.1 is 0.00005 (European non-Finnish) which is lower than the ClinGen LSD VCEP threshold (<0.001) for PM2_Supporting. In functional studies, when expressed in COS cells, this variant resulted in no increase in GAA activity and showed evidence of abnormal processing (PMIDs 9660056, 19862843)(PS3_Moderate). The computational predictor REVEL gives a score of 0.963, which is above the threshold of 0.7, evidence that correlates with impact to GAA function (PP3). There is a ClinVar entry for this variant (Variation ID: 188797; 2 star review status) with 8 submitters all classifying the variant as pathogenic. In summary, this variant meets the criteria to be classified as pathogenic for Pompe disease. ACMG/AMP criteria applied, as specified by the ClinGen LSD VCEP (Specifications Version 2.0): PM3_Very Strong, PS3_Moderate, PP4_Moderate, PP3, PM2_Supporting.(Classification approved on August 17, 2021)		Lysosomal Diseases VCEP	https://clinicalgenome.org/docs/clingen-lysosomal-storage-disorders-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-2/	2021-09-07	2021-09-07	False	https://erepo.genome.network/evrepo/ui/classification/CA273972/MONDO:0009290/010	de8ae80b-693a-4177-8218-1d731456b97c	p.Gly309Arg	Gly	309	Arg	MGVRHPPCSHRLLAVCALVSLATAALLGHILLHDFLLVPRELSGSSPVLEETHPAHQQGASRPGPRDAQAHPGRPRAVPTQCDVPPNSRFDCAPDKAITQEQCEARGCCYIPAKQGLQGAQMGQPWCFFPPSYPSYKLENLSSSEMGYTATLTRTTPTFFPKDILTLRLDVMMETENRLHFTIKDPANRRYEVPLETPHVHSRAPSPLYSVEFSEEPFGVIVRRQLDGRVLLNTTVAPLFFADQFLQLSTSLPSQYITGLAEHLSPLMLSTSWTRITLWNRDLAPTPGANLYGSHPFYLALEDGGSAHGVFLLNSNAMDVVLQPSPALSWRSTGGILDVYIFLGPEPKSVVQQYLDVVGYPFMPPYWGLGFHLCRWGYSSTAITRQVVENMTRAHFPLDVQWNDLDYMDSRRDFTFNKDGFRDFPAMVQELHQGGRRYMMIVDPAISSSGPAGSYRPYDEGLRRGVFITNETGQPLIGKVWPGSTAFPDFTNPTALAWWEDMVAEFHDQVPFDGMWIDMNEPSNFIRGSEDGCPNNELENPPYVPGVVGGTLQAATICASSHQFLSTHYNLHNLYGLTEAIASHRALVKARGTRPFVISRSTFAGHGRYAGHWTGDVWSSWEQLASSVPEILQFNLLGVPLVGADVCGFLGNTSEELCVRWTQLGAFYPFMRNHNSLLSLPQEPYSFSEPAQQAMRKALTLRYALLPHLYTLFHQAHVAGETVARPLFLEFPKDSSTWTVDHQLLWGEALLITPVLQAGKAEVTGYFPLGTWYDLQTVPVEALGSLPPPPAAPREPAIHSEGQWVTLPAPLDTINVHLRAGYIIPLQGPGLTTTESRQQPMALAVALTKGGEARGELFWDDGESLEVLERGAYTQVIFLARNNTIVNELVRVTSEGAGLQLQKVTVLGVATAPQQVLSNGVPVSNFTYSPDTKVLDICVSLLMGEQFLVSWC	952	P10253	R	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [704], 'DNA_BIND_gain': [611, 658], 'DNA_BIND_gain_score': array([0.00052387, 0.00083089]), 'DNA_BIND_loss_score': array([-0.00045025]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [305], 'STRAND_gain': [278, 313, 806, 884, 885, 913], 'STRAND_gain_score': array([0.24188018, 0.24175751, 0.00600713, 0.00662363, 0.00764972,
       0.00795114]), 'STRAND_loss_score': array([-0.14232457]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [494], 'REPEAT_gain_score': array([0.00356549]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
200	NM_000152.4(GAA):c.1064T>C (p.Leu355Pro)	284093	CA8815136	NM_000152.4:c.1064T>C, NC_000017.11:g.80108398T>C, CM000679.2:g.80108398T>C, NC_000017.10:g.78082197T>C, CM000679.1:g.78082197T>C, NC_000017.9:g.75696792T>C, NG_009822.1:g.11843T>C, LRG_673:g.11843T>C, ENST00000302262.8:c.1064T>C, ENST00000302262.7:c.1064T>C, ENST00000390015.7:c.1064T>C, NM_000152.3:c.1064T>C, LRG_673t1:c.1064T>C, NM_001079803.1:c.1064T>C, NM_001079804.1:c.1064T>C, XM_005257193.1:c.1064T>C, XM_005257194.3:c.1064T>C, NM_001079803.2:c.1064T>C, NM_001079804.2:c.1064T>C, XM_005257193.2:c.1064T>C, XM_005257194.4:c.1064T>C, NM_000152.5:c.1064T>C, NM_001079803.3:c.1064T>C, NM_001079804.3:c.1064T>C, NM_000152.4(GAA):c.1064T>C (p.Leu355Pro)	GAA	glycogen storage disease II	MONDO:0009290	Autosomal recessive inheritance	Pathogenic	PM3_Strong, PP4_Moderate, PP3, PM2_Supporting, PS3_Moderate	PS1, PM5	The NM_000152.5:c.1064T>C variant in GAA is a missense variant predicted to cause substitution of leucine to proline at amino acid 355 (p.Leu355Pro). This variant has been reported in over 20 individuals with Pompe disease including at least 9 individuals with documented laboratory values showing GAA deficiency (PP4_Moderate) (PMIDs 14972326, 17213836, 17723315, 17213836, 23632174, 24016645, 30595407)(PP4_Moderate). The variant is homozygous in multiple patients (PMIDs 14972326, 16917947, 17213836, 17573812, 17723315, 18429042, 22658377, 23787031, 24016645, 30023291, 33325062). Three individuals are compound heterozygous for the variant and another variant that has been assessed as pathogenic by the ClinGen LSD VCEP; c.-32-13T>G in two patients (PMIDs 17643989, 21803581), and confirmed in trans with c.670C>T (p.Arg224Trp) in another patient (PMID 23632174; (PM3_Strong). p.Leu355Pro has also been reported in individuals with Pompe disease who are compound heterozygous for c.2041-2A>C (PMID 33325062), c.2303C>G (p.Pro768Arg) (PMID 17027861),  c.1210G>A (p.Asp404Asn) (PMID 22658377,  23787031), c.1120T>C (p.Cys374Arg) (PMID 14695532),  c.1927G>A (p.Gly643Arg) (PMID 18429042),  c.1106T >C (p.Leu369Pro) (PMID 23430493), and c.380G>T (p.Cys127Phe) (PMID  24016645). The in trans data from these patients will be used in the assessment of the other variant and was not included here in order to avoid circular logic. The highest population minor allele frequency in gnomAD v2.1.1 is 0.00003 (1/34580) in the Latino population, which is lower than the ClinGen LSD VCEP’s threshold for PM2_Supporting (<0.001), meeting this criterion (PM2_Supporting). When expressed in COS cells, this variant results in absent GAA activity, and there is evidence of abnormal synthesis and processing of GAA on Western blot (PMIDs 14695532, 14972326, 19862843) (PS3_Moderate). The computational predictor REVEL gives a score of 0.805 which is above the threshold of 0.7, evidence that correlates with impact to GAA function (PP3). There is a ClinVar entry for this variant (Variation ID: 284093, 2 star review status) with four submitters each classifying the variant as pathogenic. In summary, this variant meets the criteria to be classified as pathogenic for Pompe disease. GAA-specific ACMG/AMP criteria applied, as specified by the ClinGen LSD VCEP (Specifications Version 2.0): PM3_Strong, PS3_Moderate, PP4_Moderate, PP3, PM2_Supporting.(Classification approved August 17, 2021)		Lysosomal Diseases VCEP	https://clinicalgenome.org/docs/clingen-lysosomal-storage-disorders-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-2/	2021-09-07	2021-09-07	False	https://erepo.genome.network/evrepo/ui/classification/CA8815136/MONDO:0009290/010	7b23f882-c6fd-4d3b-b9ef-d2268a89f53a	p.Leu355Pro	Leu	355	Pro	MGVRHPPCSHRLLAVCALVSLATAALLGHILLHDFLLVPRELSGSSPVLEETHPAHQQGASRPGPRDAQAHPGRPRAVPTQCDVPPNSRFDCAPDKAITQEQCEARGCCYIPAKQGLQGAQMGQPWCFFPPSYPSYKLENLSSSEMGYTATLTRTTPTFFPKDILTLRLDVMMETENRLHFTIKDPANRRYEVPLETPHVHSRAPSPLYSVEFSEEPFGVIVRRQLDGRVLLNTTVAPLFFADQFLQLSTSLPSQYITGLAEHLSPLMLSTSWTRITLWNRDLAPTPGANLYGSHPFYLALEDGGSAHGVFLLNSNAMDVVLQPSPALSWRSTGGILDVYIFLGPEPKSVVQQYLDVVGYPFMPPYWGLGFHLCRWGYSSTAITRQVVENMTRAHFPLDVQWNDLDYMDSRRDFTFNKDGFRDFPAMVQELHQGGRRYMMIVDPAISSSGPAGSYRPYDEGLRRGVFITNETGQPLIGKVWPGSTAFPDFTNPTALAWWEDMVAEFHDQVPFDGMWIDMNEPSNFIRGSEDGCPNNELENPPYVPGVVGGTLQAATICASSHQFLSTHYNLHNLYGLTEAIASHRALVKARGTRPFVISRSTFAGHGRYAGHWTGDVWSSWEQLASSVPEILQFNLLGVPLVGADVCGFLGNTSEELCVRWTQLGAFYPFMRNHNSLLSLPQEPYSFSEPAQQAMRKALTLRYALLPHLYTLFHQAHVAGETVARPLFLEFPKDSSTWTVDHQLLWGEALLITPVLQAGKAEVTGYFPLGTWYDLQTVPVEALGSLPPPPAAPREPAIHSEGQWVTLPAPLDTINVHLRAGYIIPLQGPGLTTTESRQQPMALAVALTKGGEARGELFWDDGESLEVLERGAYTQVIFLARNNTIVNELVRVTSEGAGLQLQKVTVLGVATAPQQVLSNGVPVSNFTYSPDTKVLDICVSLLMGEQFLVSWC	952	P10253	P	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [354, 355, 375, 424], 'DNA_BIND_gain': [608, 611, 658, 707], 'DNA_BIND_gain_score': array([0.00348628, 0.00059623, 0.00490493, 0.00165421]), 'DNA_BIND_loss_score': array([-0.10131133, -0.03397703, -0.002518  , -0.00316733]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [913], 'STRAND_gain_score': array([0.00861079]), 'HELIX_loss': [367], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.09847361]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [386], 'REPEAT_gain': [494, 643], 'REPEAT_gain_score': array([0.00257021, 0.00110179]), 'REPEAT_loss_score': array([-0.0039438]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
201	NM_000152.5(GAA):c.1655T>C (p.Leu552Pro)	279811	CA8815429	NM_000152.5:c.1655T>C, NC_000017.11:g.80112001T>C, CM000679.2:g.80112001T>C, NC_000017.10:g.78085800T>C, CM000679.1:g.78085800T>C, NC_000017.9:g.75700395T>C, NG_009822.1:g.15446T>C, LRG_673:g.15446T>C, ENST00000302262.8:c.1655T>C, ENST00000302262.7:c.1655T>C, ENST00000390015.7:c.1655T>C, ENST00000572080.1:n.43T>C, ENST00000572803.1:n.269T>C, NM_000152.3:c.1655T>C, LRG_673t1:c.1655T>C, NM_001079803.1:c.1655T>C, NM_001079804.1:c.1655T>C, XM_005257193.1:c.1655T>C, XM_005257194.3:c.1655T>C, NM_000152.4:c.1655T>C, NM_001079803.2:c.1655T>C, NM_001079804.2:c.1655T>C, XM_005257193.2:c.1655T>C, XM_005257194.4:c.1655T>C, NM_001079803.3:c.1655T>C, NM_001079804.3:c.1655T>C, NM_000152.5(GAA):c.1655T>C (p.Leu552Pro)	GAA	glycogen storage disease II	MONDO:0009290	Autosomal recessive inheritance	Pathogenic	PP4_Moderate, PP3, PM2_Supporting, PS3_Moderate, PM3_Very Strong		The NM_000152.5: c.1655T>C variant in GAA is a missense variant predicted to cause substitution of leucine by proline at amino acid 552 (p.Leu552Pro). More than 10 individuals diagnosed with Pompe disease have been reported with this variant including at least 7 probands for whom laboratory data is published showing GAA activity in the deficient range (PMID 12923862, 18285536, 25681614, 27666774)(PP4_Moderate). Eight of these individuals were compound heterozygous for the variant and a pathogenic variant, phase unknown in all cases (PMID 12923862, 18285536, 18607768, 20033296, 25681614, 29122469 29422078, and two individuals were homozygotes (PMID 27666774)(PM3_Very strong). The highest population minor allele frequency in gnomAD v2.1.1 is 0.00007 (European non-Finnish) which is lower than the ClinGen LSD VCEP threshold (<0.001) for PM2_Supporting. In two functional studies, this variant has been shown to result in significantly decreased GAA activity (<5%) and abnormal processing when expressed in COS cells (PMIDs 14695532, 19862843)(PS3_Moderate). The computational predictor REVEL gives a score of 0.94, which is above the threshold of 0.7, evidence that correlates with impact to GAA function (PP3). There is a ClinVar entry for this variant (Variation ID: 279811, 2 star review status) with nine submitters all classifying the variant as pathogenic. In summary, the variant meets the criteria to be classified as pathogenic for Pompe disease. ACMG/AMP criteria met, as specified by the ClinGen LSD VCEP (Specifications Version 2.0): PM3_Very Strong, PS3_Moderate, PP4_Moderate, PM2_Supporting, PP3.(Classification approved August 17, 2021)		Lysosomal Diseases VCEP	https://clinicalgenome.org/docs/clingen-lysosomal-storage-disorders-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-2/	2021-09-07	2021-09-07	False	https://erepo.genome.network/evrepo/ui/classification/CA8815429/MONDO:0009290/010	e4b58c43-9d77-4025-86b8-ffa2f7a5b440	p.Leu552Pro	Leu	552	Pro	MGVRHPPCSHRLLAVCALVSLATAALLGHILLHDFLLVPRELSGSSPVLEETHPAHQQGASRPGPRDAQAHPGRPRAVPTQCDVPPNSRFDCAPDKAITQEQCEARGCCYIPAKQGLQGAQMGQPWCFFPPSYPSYKLENLSSSEMGYTATLTRTTPTFFPKDILTLRLDVMMETENRLHFTIKDPANRRYEVPLETPHVHSRAPSPLYSVEFSEEPFGVIVRRQLDGRVLLNTTVAPLFFADQFLQLSTSLPSQYITGLAEHLSPLMLSTSWTRITLWNRDLAPTPGANLYGSHPFYLALEDGGSAHGVFLLNSNAMDVVLQPSPALSWRSTGGILDVYIFLGPEPKSVVQQYLDVVGYPFMPPYWGLGFHLCRWGYSSTAITRQVVENMTRAHFPLDVQWNDLDYMDSRRDFTFNKDGFRDFPAMVQELHQGGRRYMMIVDPAISSSGPAGSYRPYDEGLRRGVFITNETGQPLIGKVWPGSTAFPDFTNPTALAWWEDMVAEFHDQVPFDGMWIDMNEPSNFIRGSEDGCPNNELENPPYVPGVVGGTLQAATICASSHQFLSTHYNLHNLYGLTEAIASHRALVKARGTRPFVISRSTFAGHGRYAGHWTGDVWSSWEQLASSVPEILQFNLLGVPLVGADVCGFLGNTSEELCVRWTQLGAFYPFMRNHNSLLSLPQEPYSFSEPAQQAMRKALTLRYALLPHLYTLFHQAHVAGETVARPLFLEFPKDSSTWTVDHQLLWGEALLITPVLQAGKAEVTGYFPLGTWYDLQTVPVEALGSLPPPPAAPREPAIHSEGQWVTLPAPLDTINVHLRAGYIIPLQGPGLTTTESRQQPMALAVALTKGGEARGELFWDDGESLEVLERGAYTQVIFLARNNTIVNELVRVTSEGAGLQLQKVTVLGVATAPQQVLSNGVPVSNFTYSPDTKVLDICVSLLMGEQFLVSWC	952	P10253	P	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [368, 658, 707], 'DNA_BIND_gain_score': array([0.00371236, 0.00867057, 0.00161839]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [468], 'STRAND_gain': [259], 'STRAND_gain_score': array([0.01086897]), 'STRAND_loss_score': array([-0.01095563]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [694], 'REPEAT_gain_score': array([0.0050692]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
202	NM_000152.4(GAA):c.1942G>A (p.Gly648Ser)	188902	CA274102	NM_000152.4:c.1942G>A, NC_000017.11:g.80112929G>A, CM000679.2:g.80112929G>A, NC_000017.10:g.78086728G>A, CM000679.1:g.78086728G>A, NC_000017.9:g.75701323G>A, NG_009822.1:g.16374G>A, LRG_673:g.16374G>A, ENST00000302262.8:c.1942G>A, ENST00000302262.7:c.1942G>A, ENST00000390015.7:c.1942G>A, ENST00000570716.1:n.382G>A, ENST00000572080.1:n.361G>A, ENST00000572803.1:n.556G>A, NM_000152.3:c.1942G>A, LRG_673t1:c.1942G>A, NM_001079803.1:c.1942G>A, NM_001079804.1:c.1942G>A, XM_005257193.1:c.1942G>A, XM_005257194.3:c.1942G>A, NM_001079803.2:c.1942G>A, NM_001079804.2:c.1942G>A, XM_005257193.2:c.1942G>A, XM_005257194.4:c.1942G>A, NM_000152.5:c.1942G>A, NM_001079803.3:c.1942G>A, NM_001079804.3:c.1942G>A, NM_000152.5(GAA):c.1942G>A (p.Gly648Ser), NM_000152.4(GAA):c.1942G>A (p.Gly648Ser)	GAA	glycogen storage disease II	MONDO:0009290	Autosomal recessive inheritance	Pathogenic	PS3_Supporting, PP4_Moderate, PP3, PM3_Very Strong, PM2_Supporting	PM5	"The NM_000152.5:c.1942G>A (p.Gly648Ser) variant in GAA is a missense variant with a highest population minor allele frequency  in gnomAD v2.1.1 of 0.00034  (10/29720 alleles) in the S. Asian population, which is lower than the ClinGen Lysosomal Diseases VCEP’s threshold for PM2_Supporting (<0.001), meeting this criterion (PM2_Supporting). At least 18 patients with a diagnosis of Pompe disease have been reported with this variant including those with documented deficient GAA activity and/or symptoms consistent with infantile onset Pompe disease and/or on enzyme replacment therapy (PMIDs 9535769, 17573812, 26497565, 29422078, 30214072, 31510962) (PP4_Moderate). In a study of the Maroon population of French Guiana, 9 out of 15 probands with """"""""""""""""enzymatically confirmed"""""""""""""""" infantile onset Pompe disease were compound heterozygous for c.1942G>A (p.Gly648Ser) and c.2560C>T (p.Arg854Ter), a variant which has been classified as pathogenic by the ClinGen LD VCEP. The two variants are assumed to be in trans based on the high carrier frequency of both variants in that population. The carrier frequency of c.1942G>A (p.Gly648Ser) was 1 in 47 (9/425 women tested) (PMID: 29637184). Patients have also been reported who are compound heterozygous for the variant and another variant in GAA that has been classified as pathogenic by the ClinGen LD VCEP including c.2214G>A (p.Trp768Ter) (PMID: 26575883) and c.-32-13T>G (2 patients, PMIDs: 17643989, 25455803, 27193587). In addition, at least 3 patients are homozygous for the variant (PMID: 26497565, 29122469, 29889338, 30214072) (PM3_VeryStrong). Patients compound heterozygous for the variant and c.1076-22T>G (17643989, 25455803), c.2646+2T>A (PMID: 29422078), and c.1099T>C (p.Trp367Arg) (PMID: 31510962) have also been reported. However, the in trans data from these patients will be used in the assessment of the second variant and was not included here in order to avoid circular logic. When expressed in SV40_immortalized GAA deficient fibroblasts, the enzyme activity was """"""""""""""""negligible"""""""""""""""" (PMID: 9535769), and when expressed in COS cells, the variant resulted in <2% wild type GAA activity (PMID: 19862843) (PS3_Supporting). The score for the REVEL meta-predictor, 0.98, also supports that the variant has a deleterious impact on GAA function (PP3). Another amino acid substitution at the same position has been reported in at least one individual with Pompe disease c.1943G>A (p.Gly648Asp) (PMIDs 22644586, 23146291, 23843830) (note that this data will be used in the classification of p.Gly648Asp and was not used here in order to avoid a circular argument). There is a ClinVar entry for this variant (Variation ID: 188902). In summary, this variant meets the criteria to be classified as pathogenic for Pompe disease. ACMG/AMP criteria met, as specified by the ClinGen Lysosomal Diseases VCEP (Specifications Version 2.0): PM3_VeryStrong, PP4_Moderate, PP3, PS3_Supporting, PM2_Supporting.(Classification approved by the ClinGen Lysosomal Diseases VCEP, July 3, 2023)"		Lysosomal Diseases VCEP	https://clinicalgenome.org/docs/clingen-lysosomal-storage-disorders-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-2/	2023-07-03	2023-09-05	False	https://erepo.genome.network/evrepo/ui/classification/CA274102/MONDO:0009290/010	2485e980-b2ce-432e-871f-861aec685091	p.Gly648Ser	Gly	648	Ser	MGVRHPPCSHRLLAVCALVSLATAALLGHILLHDFLLVPRELSGSSPVLEETHPAHQQGASRPGPRDAQAHPGRPRAVPTQCDVPPNSRFDCAPDKAITQEQCEARGCCYIPAKQGLQGAQMGQPWCFFPPSYPSYKLENLSSSEMGYTATLTRTTPTFFPKDILTLRLDVMMETENRLHFTIKDPANRRYEVPLETPHVHSRAPSPLYSVEFSEEPFGVIVRRQLDGRVLLNTTVAPLFFADQFLQLSTSLPSQYITGLAEHLSPLMLSTSWTRITLWNRDLAPTPGANLYGSHPFYLALEDGGSAHGVFLLNSNAMDVVLQPSPALSWRSTGGILDVYIFLGPEPKSVVQQYLDVVGYPFMPPYWGLGFHLCRWGYSSTAITRQVVENMTRAHFPLDVQWNDLDYMDSRRDFTFNKDGFRDFPAMVQELHQGGRRYMMIVDPAISSSGPAGSYRPYDEGLRRGVFITNETGQPLIGKVWPGSTAFPDFTNPTALAWWEDMVAEFHDQVPFDGMWIDMNEPSNFIRGSEDGCPNNELENPPYVPGVVGGTLQAATICASSHQFLSTHYNLHNLYGLTEAIASHRALVKARGTRPFVISRSTFAGHGRYAGHWTGDVWSSWEQLASSVPEILQFNLLGVPLVGADVCGFLGNTSEELCVRWTQLGAFYPFMRNHNSLLSLPQEPYSFSEPAQQAMRKALTLRYALLPHLYTLFHQAHVAGETVARPLFLEFPKDSSTWTVDHQLLWGEALLITPVLQAGKAEVTGYFPLGTWYDLQTVPVEALGSLPPPPAAPREPAIHSEGQWVTLPAPLDTINVHLRAGYIIPLQGPGLTTTESRQQPMALAVALTKGGEARGELFWDDGESLEVLERGAYTQVIFLARNNTIVNELVRVTSEGAGLQLQKVTVLGVATAPQQVLSNGVPVSNFTYSPDTKVLDICVSLLMGEQFLVSWC	952	P10253	S	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [599], 'BINDING_gain': [], 'BINDING_loss_score': array([-0.01843125]), 'DNA_BIND_loss': [], 'DNA_BIND_gain': [601, 611, 707], 'DNA_BIND_gain_score': array([0.00394607, 0.00239271, 0.00273609]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [259, 806, 885], 'STRAND_gain_score': array([0.00659972, 0.00880778, 0.00195688]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [647], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.02666104]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
203	NM_000152.4(GAA):c.670C>T (p.Arg224Trp)	189188	CA274477	NM_000152.4:c.670C>T, NM_000152.3:c.670C>T, LRG_673t1:c.670C>T, NM_001079803.1:c.670C>T, NM_001079804.1:c.670C>T, XM_005257193.1:c.670C>T, XM_005257194.3:c.670C>T, NM_001079803.2:c.670C>T, NM_001079804.2:c.670C>T, XM_005257193.2:c.670C>T, XM_005257194.4:c.670C>T, NM_000152.5:c.670C>T, NM_001079803.3:c.670C>T, NM_001079804.3:c.670C>T, ENST00000302262.7:c.670C>T, ENST00000390015.7:c.670C>T, ENST00000570803.5:c.670C>T, NC_000017.11:g.80105872C>T, CM000679.2:g.80105872C>T, NC_000017.10:g.78079671C>T, CM000679.1:g.78079671C>T, NC_000017.9:g.75694266C>T, NG_009822.1:g.9317C>T, LRG_673:g.9317C>T, NM_000152.4(GAA):c.670C>T (p.Arg224Trp)	GAA	glycogen storage disease II	MONDO:0009290	Autosomal recessive inheritance	Pathogenic	PM3_Strong, PS3, PM2, PP4	BP4, PP3	This variant, c.670C>T (p.Arg224Trp) has been reported in at least 6 individuals with Pompe disease and deficient GAA activity meeting the ClinGen LSD VCEP's PP4 specifications. All of these individuals are compound heterozygous for the variant and a unique pathogenic variant, including c.-32-13T>G (PMID 25673129; phase unknown), c.525delT (PMID 12923862; phase unknown), c.763C > T (p.Gln255Ter) (PMID 25026126, confirmed in trans), c.2237G>A (p.Trp746Ter) (PMID 12923862; phase unknown), c.1064T>C (p.Leu355Pro)(PMID 23632174; confirmed in trans), and c.1979G>A (p.Arg660His) (PMID 14643388; phase unknown). These data meet PM3_Strong. Note that the in trans data from the patients with c.1064T>C (p.Leu355Pro) and c.1979G>A (p.Arg660His) will be used in the assessment of those variants and was not used here in order to avoid a circular argument. The highest population minor allele frequency in gnomAD v2.1.1 is 0.00005 in the European non-Finnish population, meeting PM2. The score for the in silico meta-predictor REVEL, does not meet PP3 or BP4. However, when expressed in COS cells, this variant results in significantly reduced GAA activity, <10% of wild type (PMID 12923862, 14643388, 19862843), meeting PS3. There is a ClinVar entry for this variant (Variation ID: 189188, 1 star review status), with two submitters classifying the variant as pathogenic, one as likely pathogenic, and one as a variant of uncertain significance. In summary, the variant meets the criteria to be classified as pathogenic for Pompe disease. GAA-specific ACMG/AMP criteria applied, as specified by the ClinGen LSD VCEP: PS3, PM2, PM3_Strong, PP4.	25673129, 14643388, 23632174, 25026126, 12923862, 19862843, 14643388, 12923862	Lysosomal Diseases VCEP	https://clinicalgenome.org/docs/clingen-lysosomal-storage-disorders-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-2/	2020-05-03	2020-05-28	False	https://erepo.genome.network/evrepo/ui/classification/CA274477/MONDO:0009290/010	1f6327c8-2794-45a5-a3b1-4998dee695e7	p.Arg224Trp	Arg	224	Trp	MGVRHPPCSHRLLAVCALVSLATAALLGHILLHDFLLVPRELSGSSPVLEETHPAHQQGASRPGPRDAQAHPGRPRAVPTQCDVPPNSRFDCAPDKAITQEQCEARGCCYIPAKQGLQGAQMGQPWCFFPPSYPSYKLENLSSSEMGYTATLTRTTPTFFPKDILTLRLDVMMETENRLHFTIKDPANRRYEVPLETPHVHSRAPSPLYSVEFSEEPFGVIVRRQLDGRVLLNTTVAPLFFADQFLQLSTSLPSQYITGLAEHLSPLMLSTSWTRITLWNRDLAPTPGANLYGSHPFYLALEDGGSAHGVFLLNSNAMDVVLQPSPALSWRSTGGILDVYIFLGPEPKSVVQQYLDVVGYPFMPPYWGLGFHLCRWGYSSTAITRQVVENMTRAHFPLDVQWNDLDYMDSRRDFTFNKDGFRDFPAMVQELHQGGRRYMMIVDPAISSSGPAGSYRPYDEGLRRGVFITNETGQPLIGKVWPGSTAFPDFTNPTALAWWEDMVAEFHDQVPFDGMWIDMNEPSNFIRGSEDGCPNNELENPPYVPGVVGGTLQAATICASSHQFLSTHYNLHNLYGLTEAIASHRALVKARGTRPFVISRSTFAGHGRYAGHWTGDVWSSWEQLASSVPEILQFNLLGVPLVGADVCGFLGNTSEELCVRWTQLGAFYPFMRNHNSLLSLPQEPYSFSEPAQQAMRKALTLRYALLPHLYTLFHQAHVAGETVARPLFLEFPKDSSTWTVDHQLLWGEALLITPVLQAGKAEVTGYFPLGTWYDLQTVPVEALGSLPPPPAAPREPAIHSEGQWVTLPAPLDTINVHLRAGYIIPLQGPGLTTTESRQQPMALAVALTKGGEARGELFWDDGESLEVLERGAYTQVIFLARNNTIVNELVRVTSEGAGLQLQKVTVLGVATAPQQVLSNGVPVSNFTYSPDTKVLDICVSLLMGEQFLVSWC	952	P10253	W	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [375], 'DNA_BIND_gain': [658, 707], 'DNA_BIND_gain_score': array([0.00274014, 0.00061297]), 'DNA_BIND_loss_score': array([-0.00034833]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [224, 238, 241, 259], 'STRAND_gain_score': array([0.38406831, 0.19956326, 0.13909978, 0.05656892]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [494], 'REPEAT_gain_score': array([0.00353938]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
204	NM_004360.5(CDH1):c.2399G>A (p.Arg800His)	142363	CA294379	NM_004360.5:c.2399G>A, NC_000016.10:g.68829757G>A, CM000678.2:g.68829757G>A, NC_000016.9:g.68863660G>A, CM000678.1:g.68863660G>A, NC_000016.8:g.67421161G>A, NG_008021.1:g.97466G>A, LRG_301:g.97466G>A, ENST00000261769.10:c.2399G>A, ENST00000261769.9:c.2399G>A, ENST00000422392.6:c.2216G>A, ENST00000562118.1:n.617G>A, ENST00000562836.5:n.2470G>A, ENST00000566510.5:c.*1065G>A, ENST00000566612.5:c.*639G>A, ENST00000611625.4:c.2462G>A, ENST00000612417.4:c.1853+3203G>A, ENST00000621016.4:c.1866-4446G>A, NM_004360.3:c.2399G>A, LRG_301t1:c.2399G>A, XM_011523488.1:c.1664G>A, XM_011523489.1:c.1664G>A, NM_001317184.1:c.2216G>A, NM_001317185.1:c.851G>A, NM_001317186.1:c.434G>A, NM_004360.4:c.2399G>A, NM_001317184.2:c.2216G>A, NM_001317185.2:c.851G>A, NM_001317186.2:c.434G>A, NM_004360.5(CDH1):c.2399G>A (p.Arg800His)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Benign	BS2, BP2_Strong	PP2, PP3, PP4, PP1, PS1, PS3, PS2, PS4, BP1, BP4, BP3, BA1, PM5, PM4, PM1, PM3, PM2, PM6, PVS1, BP7, BP5, BS1, BS3, BS4	The c.2399G>A (p.Arg800His) variant has an allele frequency of 0.00003 (0.003%, 1/30,614 alleles) in the South Asian gnomAD subpopulation (http://gnomad.broadinstitute.org). The variant has been seen in >10 individuals without DCG, SRC tumors, or LBC and whose families do notsuggest HDGC (BS2; PMID: 26072394, SCV000186429.5, SCV000210876.13, SCV000254822.4). The variant has been identified in the homozygous state in an individual without personal and family history of DGC, LBC, or SRC tumors (BP2_Strong; SCV000186429.5). In summary, this variant meets criteria to be classified as benign based on the ACMG/AMP criteria applied as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): BS2, BP2_Strong.		CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-10	2023-08-10	False	https://erepo.genome.network/evrepo/ui/classification/CA294379/MONDO:0007648/007	df17608e-32cd-47b7-8dab-62c2935b5bbe	p.Arg800His	Arg	800	His	MGPWSRSLSALLLLLQVSSWLCQEPEPCHPGFDAESYTFTVPRRHLERGRVLGRVNFEDCTGRQRTAYFSLDTRFKVGTDGVITVKRPLRFHNPQIHFLVYAWDSTYRKFSTKVTLNTVGHHHRPPPHQASVSGIQAELLTFPNSSPGLRRQKRDWVIPPISCPENEKGPFPKNLVQIKSNKDKEGKVFYSITGQGADTPPVGVFIIERETGWLKVTEPLDRERIATYTLFSHAVSSNGNAVEDPMEILITVTDQNDNKPEFTQEVFKGSVMEGALPGTSVMEVTATDADDDVNTYNAAIAYTILSQDPELPDKNMFTINRNTGVISVVTTGLDRESFPTYTLVVQAADLQGEGLSTTATAVITVTDTNDNPPIFNPTTYKGQVPENEANVVITTLKVTDADAPNTPAWEAVYTILNDDGGQFVVTTNPVNNDGILKTAKGLDFEAKQQYILHVAVTNVVPFEVSLTTSTATVTVDVLDVNEAPIFVPPEKRVEVSEDFGVGQEITSYTAQEPDTFMEQKITYRIWRDTANWLEINPDTGAISTRAELDREDFEHVKNSTYTALIIATDNGSPVATGTGTLLLILSDVNDNAPIPEPRTIFFCERNPKPQVINIIDADLPPNTSPFTAELTHGASANWTIQYNDPTQESIILKPKMALEVGDYKINLKLMDNQNKDQVTTLEVSVCDCEGAAGVCRKAQPVEAGLQIPAILGILGGILALLILILLLLLFLRRRAVVKEPLLPPEDDTRDNVYYYDEEGGGEEDQDFDLSQLHRGLDARPEVTRNDVAPTLMSVPRYLPRPANPDEIGNFIDENLKAADTDPTAPPYDSLLVFDYEGSGSEAASLSSLNSSESDKDQDYDYLNEWGNRFKKLADMYGGGEDD	882	P12830	H	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [5], 'TRANSIT_gain': [], 'TRANSIT_loss_score': array([-0.00216174]), 'STRAND_loss': [503], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.00153142]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
205	NM_004333.6(BRAF):c.1799T>G (p.Val600Gly)	40389	CA281998	NM_004333.6:c.1799T>G, NM_004333.4:c.1799T>G, LRG_299t1:c.1799T>G, XM_005250045.1:c.1799T>G, XM_005250046.1:c.1799T>G, XM_011516529.1:c.1799T>G, XM_011516530.1:c.1695-3918T>G, XR_242190.1:n.1807T>G, XR_927520.1:n.1807T>G, XR_927521.1:n.1807T>G, XR_927522.1:n.1703-3918T>G, XR_927523.1:n.1703-3918T>G, NM_001354609.1:c.1799T>G, NM_004333.5:c.1799T>G, NR_148928.1:n.2897T>G, XM_017012558.1:c.1919T>G, XM_017012559.1:c.1919T>G, XR_001744857.1:n.1927T>G, XR_001744858.1:n.1823-3918T>G, NM_001354609.2:c.1799T>G, NM_001374244.1:c.1919T>G, NM_001374258.1:c.1919T>G, ENST00000288602.10:c.1799T>G, ENST00000479537.5:n.83T>G, ENST00000496384.6:n.622T>G, ENST00000497784.1:n.1834T>G, NC_000007.14:g.140753336A>C, CM000669.2:g.140753336A>C, NC_000007.13:g.140453136A>C, CM000669.1:g.140453136A>C, NC_000007.12:g.140099605A>C, NG_007873.3:g.176429T>G, LRG_299:g.176429T>G, NM_004333.6(BRAF):c.1799T>G (p.Val600Gly)	BRAF	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Pathogenic	PM6, PM2, PP3, PP2, PS4_Supporting, PM1, PS3		The c.1799T>G (p.Val600Gly) variant in BRAF is absent from gnomAD (PM2). It has been identified in one individual with Cardiofaciocutaneous syndrome (PS4_Supporting; PMID: 20735442). It has also been reported in the literature as an unconfirmed de novo occurrence (PM6; GeneDx internal communication). In vitro functional studies provide some evidence that the p.Val600Gly variant may impact protein function (PS3; PMID: 20735442). Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of BRAF (PM1; PMID 29493581). Computational prediction tools and conservation analysis suggest that the p.Val600Gly variant may impact the protein (PP3). Finally, the variant is located in BRAF, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PS3, PM1, PM2, PM6, PS4_Supporting, PP3, PP2.	20735442, 20735442	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2020-06-25	2020-06-25	False	https://erepo.genome.network/evrepo/ui/classification/CA281998/MONDO:0021060/004	33e1b46e-d087-4f11-a5d3-ab591b3261a1	p.Val600Gly	Val	600	Gly	MAALSGGGGGGAEPGQALFNGDMEPEAGAGAGAAASSAADPAIPEEVWNIKQMIKLTQEHIEALLDKFGGEHNPPSIYLEAYEEYTSKLDALQQREQQLLESLGNGTDFSVSSSASMDTVTSSSSSSLSVLPSSLSVFQNPTDVARSNPKSPQKPIVRVFLPNKQRTVVPARCGVTVRDSLKKALMMRGLIPECCAVYRIQDGEKKPIGWDTDISWLTGEELHVEVLENVPLTTHNFVRKTFFTLAFCDFCRKLLFQGFRCQTCGYKFHQRCSTEVPLMCVNYDQLDLLFVSKFFEHHPIPQEEASLAETALTSGSSPSAPASDSIGPQILTSPSPSKSIPIPQPFRPADEDHRNQFGQRDRSSSAPNVHINTIEPVNIDDLIRDQGFRGDGGSTTGLSATPPASLPGSLTNVKALQKSPGPQRERKSSSSSEDRNRMKTLGRRDSSDDWEIPDGQITVGQRIGSGSFGTVYKGKWHGDVAVKMLNVTAPTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHHLHIIETKFEMIKLIDIARQTAQGMDYLHAKSIIHRDLKSNNIFLHEDLTVKIGDFGLATVKSRWSGSHQFEQLSGSILWMAPEVIRMQDKNPYSFQSDVYAFGIVLYELMTGQLPYSNINNRDQIIFMVGRGYLSPDLSKVRSNCPKAMKRLMAECLKKKRDERPLFPQILASIELLARSLPKIHRSASEPSLNRAGFQTEDFSLYACASPKTPIQAGGYGAFPVH	766	P15056	G	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
206	NM_002834.5(PTPN11):c.209A>G (p.Lys70Arg)	44603	CA261568	NM_002834.5:c.209A>G, NM_002834.3:c.209A>G, LRG_614t1:c.209A>G, NM_080601.1:c.209A>G, XM_006719526.1:c.209A>G, XM_006719527.1:c.209A>G, XM_011538613.1:c.206A>G, NM_001330437.1:c.209A>G, NM_002834.4:c.209A>G, NM_080601.2:c.209A>G, XM_011538613.2:c.206A>G, XM_017019722.1:c.206A>G, NM_001330437.2:c.209A>G, NM_001374625.1:c.206A>G, NM_080601.3:c.209A>G, ENST00000351677.6:c.209A>G, ENST00000392597.5:c.209A>G, ENST00000635625.1:n.209A>G, NC_000012.12:g.112450389A>G, CM000674.2:g.112450389A>G, NC_000012.11:g.112888193A>G, CM000674.1:g.112888193A>G, NC_000012.10:g.111372576A>G, NG_007459.1:g.36658A>G, LRG_614:g.36658A>G, NM_002834.5(PTPN11):c.209A>G (p.Lys70Arg)	PTPN11	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Pathogenic	PM6, PM2, PP1, PP2, PM1, PS4		The c.2019A>G (p.Lys70Arg) variant in PTPN11 was absent from large population studies (PM2; gnomAD, http://gnomad.broadinstitute.org). It has been identified in at least 6 probands with Noonan syndrome (PS4; SCV000061296.6; PMID: 29084544).One case was described as an unconfirmed de novo occurrence (PM6; PMID: 29084544). It has been reported to segregate with clinical features of a RASopathy in at least 3 family members (PP1; SCV000061296.6). Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of PTPN11 (PM1; PMID: 29493581). Finally, PTPN11 has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PS4, PM6, PM1, PM2, PP1, PP2.	29084544	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2020-06-25	2020-06-25	False	https://erepo.genome.network/evrepo/ui/classification/CA261568/MONDO:0021060/004	3b04afbf-2784-4140-8597-2108c5253464	p.Lys70Arg	Lys	70	Arg	MTSRRWFHPNITGVEAENLLLTRGVDGSFLARPSKSNPGDFTLSVRRNGAVTHIKIQNTGDYYDLYGGEKFATLAELVQYYMEHHGQLKEKNGDVIELKYPLNCADPTSERWFHGHLSGKEAEKLLTEKGKHGSFLVRESQSHPGDFVLSVRTGDDKGESNDGKSKVTHVMIRCQELKYDVGGGERFDSLTDLVEHYKKNPMVETLGTVLQLKQPLNTTRINAAEIESRVRELSKLAETTDKVKQGFWEEFETLQQQECKLLYSRKEGQRQENKNKNRYKNILPFDHTRVVLHDGDPNEPVSDYINANIIMPEFETKCNNSKPKKSYIATQGCLQNTVNDFWRMVFQENSRVIVMTTKEVERGKSKCVKYWPDEYALKEYGVMRVRNVKESAAHDYTLRELKLSKVGQGNTERTVWQYHFRTWPDHGVPSDPGGVLDFLEEVHHKQESIMDAGPVVVHCSAGIGRTGTFIVIDILIDIIREKGVDCDIDVPKTIQMVRSQRSGMVQTEAQYRFIYMAVQHYIETLQRRIEEEQKSKRKGHEYTNIKYSLADQTSGDQSPLPPCTPTPPCAEMREDSARVYENVGLMQQQKSFR	593	Q06124	R	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [528], 'HELIX_gain_score': array([0.00285703]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [94], 'DOMAIN_gain_score': array([0.01238543]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
207	NM_001354689.3(RAF1):c.775T>G (p.Ser259Ala)	504514	CA351512423	NM_001354689.3:c.775T>G, NM_002880.3:c.775T>G, LRG_413t1:c.775T>G, XM_005265355.1:c.775T>G, XM_005265357.1:c.676T>G, XM_005265358.3:c.532T>G, XM_005265359.3:c.433T>G, XM_005265360.1:c.775T>G, XM_011533974.1:c.775T>G, XM_011533975.1:c.532T>G, NM_001354689.1:c.775T>G, NM_001354690.1:c.775T>G, NM_001354691.1:c.532T>G, NM_001354692.1:c.532T>G, NM_001354693.1:c.676T>G, NM_001354694.1:c.532T>G, NM_001354695.1:c.433T>G, NR_148940.1:n.1190T>G, NR_148941.1:n.1190T>G, NR_148942.1:n.1190T>G, XM_011533974.3:c.775T>G, XM_017006966.1:c.676T>G, XR_001740227.1:n.1007T>G, NM_001354690.2:c.775T>G, NM_001354691.2:c.532T>G, NM_001354692.2:c.532T>G, NM_001354693.2:c.676T>G, NM_001354694.2:c.532T>G, NM_001354695.2:c.433T>G, NR_148940.2:n.1106T>G, NR_148941.2:n.1106T>G, NR_148942.2:n.1106T>G, ENST00000251849.8:c.775T>G, ENST00000416093.1:c.*353T>G, ENST00000423275.5:c.*452T>G, ENST00000432427.2:n.412T>G, ENST00000442415.6:c.775T>G, ENST00000465826.5:n.19T>G, ENST00000491290.1:n.296T>G, NC_000003.12:g.12604195A>C, CM000665.2:g.12604195A>C, NC_000003.11:g.12645694A>C, CM000665.1:g.12645694A>C, NC_000003.10:g.12620694A>C, NG_007467.1:g.64985T>G, LRG_413:g.64985T>G, NM_001354689.3(RAF1):c.775T>G (p.Ser259Ala)	RAF1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Pathogenic	PS2_Very Strong, PM2, PP2, PS4_Supporting, PM5_Strong	PS3	The c.775T>G (p.Ser259Ala) variant in RAF1 was absent from large population studies (PM2; gnomAD, http://gnomad.broadinstitute.org). It has been reported as a confirmed de novo occurrence in 2 probands (PS2_VeryStrong; SCV000808501.1). The variant has been identified in 1 proband with Noonan syndrome (PS4_Supporting; SCV000710868.2). At least 2 other pathogenic missense variants have been previously identified at the Ser259 codon of RAF1 which may indicate that this residue is critical to the function of the protein (PM5_Strong; ClinVar 40601, 44633). A functional assay has been performed on c.775T>G (p.Ser259Ala), but given that it is not currently an approved assay outlined by the RASopathy VCEP, it has not been assessed for PS3 at this time (PMID:23391722). Finally, the variant is located in RAF1, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Of note, this variant has also been observed in association with somatic malignancies; however, analysis and classification of somatic variation is currently not used to inform germline classifications for the RASopathies. In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PS2_VeryStrong, PS4_Supporting, PM5_Strong, PM2, PP2.	23391722	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2020-06-25	2020-06-25	False	https://erepo.genome.network/evrepo/ui/classification/CA351512423/MONDO:0021060/004	b3cd9818-3e8f-4cc2-9125-611051be63a7	p.Ser259Ala	Ser	259	Ala	MEHIQGAWKTISNGFGFKDAVFDGSSCISPTIVQQFGYQRRASDDGKLTDPSKTSNTIRVFLPNKQRTVVNVRNGMSLHDCLMKALKVRGLQPECCAVFRLLHEHKGKKARLDWNTDAASLIGEELQVDFLDHVPLTTHNFARKTFLKLAFCDICQKFLLNGFRCQTCGYKFHEHCSTKVPTMCVDWSNIRQLLLFPNSTIGDSGVPALPSLTMRRMRESVSRMPVSSQHRYSTPHAFTFNTSSPSSEGSLSQRQRSTSTPNVHMVSTTLPVDSRMIEDAIRSHSESASPSALSSSPNNLSPTGWSQPKTPVPAQRERAPVSGTQEKNKIRPRGQRDSSYYWEIEASEVMLSTRIGSGSFGTVYKGKWHGDVAVKILKVVDPTPEQFQAFRNEVAVLRKTRHVNILLFMGYMTKDNLAIVTQWCEGSSLYKHLHVQETKFQMFQLIDIARQTAQGMDYLHAKNIIHRDMKSNNIFLHEGLTVKIGDFGLATVKSRWSGSQQVEQPTGSVLWMAPEVIRMQDNNPFSFQSDVYSYGIVLYELMTGELPYSHINNRDQIIFMVGRGYASPDLSKLYKNCPKAMKRLVADCVKKVKEERPLFPQILSSIELLQHSLPKINRSASEPSLHRAAHTEDINACTLTTSPRLPVF	648	P04049	A	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [131], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.00387079]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [240, 254, 255, 256, 283], 'COMPBIAS_gain': [], 'COMPBIAS_loss_score': array([-0.01471353, -0.07139724, -0.06940383, -0.07371807, -0.04834807]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [228, 229, 265, 266], 'REGION_gain': [], 'REGION_loss_score': array([-0.02992702, -0.03217328, -0.12133592, -0.10873669]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
208	NM_004333.6(BRAF):c.722C>A (p.Thr241Lys)	44829	CA261663	NM_004333.6:c.722C>A, NC_000007.14:g.140801550G>T, CM000669.2:g.140801550G>T, NC_000007.13:g.140501350G>T, CM000669.1:g.140501350G>T, NC_000007.12:g.140147819G>T, NG_007873.3:g.128215C>A, LRG_299:g.128215C>A, NM_004333.4:c.722C>A, LRG_299t1:c.722C>A, XM_005250045.1:c.722C>A, XM_005250046.1:c.722C>A, XM_011516529.1:c.722C>A, XM_011516530.1:c.722C>A, XR_242190.1:n.730C>A, XR_927520.1:n.730C>A, XR_927521.1:n.730C>A, XR_927522.1:n.730C>A, XR_927523.1:n.730C>A, NM_001354609.1:c.722C>A, NM_004333.5:c.722C>A, NR_148928.1:n.1027C>A, XM_017012558.1:c.722C>A, XM_017012559.1:c.722C>A, XR_001744857.1:n.730C>A, XR_001744858.1:n.730C>A, NM_001354609.2:c.722C>A, NM_001374244.1:c.722C>A, NM_001374258.1:c.722C>A, ENST00000288602.10:c.722C>A, ENST00000497784.1:n.757C>A, NM_004333.6(BRAF):c.722C>A (p.Thr241Lys)	BRAF	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Pathogenic	PM2, PP3, PP2, PS4_Supporting, PM6_Strong, PM1		The c.722C>A (p.Thr241Lys) variant in BRAF was absent from large population studies (PM2; gnomad.broadinstitute.org). It has been identified in 1 individual with Noonan syndrome and 1 individual with cardiofaciocutaneous syndrome (PS4_Supporting; Otto von Guericke University Magdeburg internal data, Laboratory for Molecular Medicine internal data; ClinVar SCV000061619.5). It has been reported at least twice as a de novo occurrence without confirmation of maternity or paternity (PM6_Strong; Fulgent Genetics, Laboratory for Molecular Medicine internal data, SCV000061619.5). Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of BRAF (PM1; 29493581). In addition, 3 other pathogenic or likely pathogenic variants have been identified at this codon (PM5 not applied; ClinVar ID: 29805, 29806, 29807). Computational prediction tools and conservation analysis suggest that the p.Thr241Lys variant in BRAF may impact the protein (PP3). This variant is located in BRAF, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic variants are common (PP2; PMID: 29493581). In summary, this variant meets criteria to be classified as pathogenic for autosomal dominant RASopathies. RASopathy-specific ACMG/AMP criteria applied (PMID: 29493581): PS4_Supporting, PM6_Strong, PM1, PM2, PP2, PP3.		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2020-06-25	2020-07-01	False	https://erepo.genome.network/evrepo/ui/classification/CA261663/MONDO:0021060/004	096bf007-b1b2-467c-a7b2-e9fbea9db17a	p.Thr241Lys	Thr	241	Lys	MAALSGGGGGGAEPGQALFNGDMEPEAGAGAGAAASSAADPAIPEEVWNIKQMIKLTQEHIEALLDKFGGEHNPPSIYLEAYEEYTSKLDALQQREQQLLESLGNGTDFSVSSSASMDTVTSSSSSSLSVLPSSLSVFQNPTDVARSNPKSPQKPIVRVFLPNKQRTVVPARCGVTVRDSLKKALMMRGLIPECCAVYRIQDGEKKPIGWDTDISWLTGEELHVEVLENVPLTTHNFVRKTFFTLAFCDFCRKLLFQGFRCQTCGYKFHQRCSTEVPLMCVNYDQLDLLFVSKFFEHHPIPQEEASLAETALTSGSSPSAPASDSIGPQILTSPSPSKSIPIPQPFRPADEDHRNQFGQRDRSSSAPNVHINTIEPVNIDDLIRDQGFRGDGGSTTGLSATPPASLPGSLTNVKALQKSPGPQRERKSSSSSEDRNRMKTLGRRDSSDDWEIPDGQITVGQRIGSGSFGTVYKGKWHGDVAVKMLNVTAPTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHHLHIIETKFEMIKLIDIARQTAQGMDYLHAKSIIHRDLKSNNIFLHEDLTVKIGDFGLATVKSRWSGSHQFEQLSGSILWMAPEVIRMQDKNPYSFQSDVYAFGIVLYELMTGQLPYSNINNRDQIIFMVGRGYLSPDLSKVRSNCPKAMKRLMAECLKKKRDERPLFPQILASIELLARSLPKIHRSASEPSLNRAGFQTEDFSLYACASPKTPIQAGGYGAFPVH	766	P15056	K	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [58], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.00404811]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [374], 'REGION_gain': [], 'REGION_loss_score': array([-0.0016709]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
209	NM_004333.6(BRAF):c.1411G>T (p.Val471Phe)	40367	CA281968	NM_004333.6:c.1411G>T, NM_004333.4:c.1411G>T, LRG_299t1:c.1411G>T, XM_005250045.1:c.1411G>T, XM_005250046.1:c.1411G>T, XM_011516529.1:c.1411G>T, XM_011516530.1:c.1411G>T, XR_242190.1:n.1419G>T, XR_927520.1:n.1419G>T, XR_927521.1:n.1419G>T, XR_927522.1:n.1419G>T, XR_927523.1:n.1419G>T, NM_001354609.1:c.1411G>T, NM_004333.5:c.1411G>T, NR_148928.1:n.1716G>T, XM_017012558.1:c.1531G>T, XM_017012559.1:c.1531G>T, XR_001744857.1:n.1539G>T, XR_001744858.1:n.1539G>T, NM_001354609.2:c.1411G>T, NM_001374244.1:c.1531G>T, NM_001374258.1:c.1531G>T, ENST00000288602.10:c.1411G>T, ENST00000496384.6:n.234G>T, ENST00000497784.1:n.1446G>T, NC_000007.14:g.140781597C>A, CM000669.2:g.140781597C>A, NC_000007.13:g.140481397C>A, CM000669.1:g.140481397C>A, NC_000007.12:g.140127866C>A, NG_007873.3:g.148168G>T, LRG_299:g.148168G>T, NM_004333.6(BRAF):c.1411G>T (p.Val471Phe)	BRAF	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Pathogenic	PM6, PM2, PP3, PP2, PS4_Supporting, PM1, PS3	PM5	The c.1411G>T (p.Val471Phe) variant in BRAF was absent from large population studies (PM2; gnomAD.broadinstitute.org). It has been identified in at least 2 individuals diagnosed with RASopathies (PS4_Supporting; PMID: 22495831, 30937965). One of these cases was shown to be a de novo occurrence without maternity or paternity confirmed (PM6). In vitro functional studies provide some evidence that the p.Val471Phe variant may impact protein function (PS3; PMID: 25348715). Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of BRAF (PM1; 29493581). Computational prediction tools and conservation analysis suggest that the p.Val471Phe variant in BRAF may impact the protein (PP3). This variant is located in BRAF, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). In summary, this variant meets criteria to be classified as pathogenic for autosomal dominant RASopathies. RASopathy-specific ACMG/AMP criteria applied (PMID: 29493581): PS3, PS4_Supporting, PM1, PM2, PM6, PP2, PP3.	30937965, 22495831, 25348715	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2020-06-25	2020-07-01	False	https://erepo.genome.network/evrepo/ui/classification/CA281968/MONDO:0021060/004	0fbf3e7d-b10c-48d4-8d20-1829cc00cf42	p.Val471Phe	Val	471	Phe	MAALSGGGGGGAEPGQALFNGDMEPEAGAGAGAAASSAADPAIPEEVWNIKQMIKLTQEHIEALLDKFGGEHNPPSIYLEAYEEYTSKLDALQQREQQLLESLGNGTDFSVSSSASMDTVTSSSSSSLSVLPSSLSVFQNPTDVARSNPKSPQKPIVRVFLPNKQRTVVPARCGVTVRDSLKKALMMRGLIPECCAVYRIQDGEKKPIGWDTDISWLTGEELHVEVLENVPLTTHNFVRKTFFTLAFCDFCRKLLFQGFRCQTCGYKFHQRCSTEVPLMCVNYDQLDLLFVSKFFEHHPIPQEEASLAETALTSGSSPSAPASDSIGPQILTSPSPSKSIPIPQPFRPADEDHRNQFGQRDRSSSAPNVHINTIEPVNIDDLIRDQGFRGDGGSTTGLSATPPASLPGSLTNVKALQKSPGPQRERKSSSSSEDRNRMKTLGRRDSSDDWEIPDGQITVGQRIGSGSFGTVYKGKWHGDVAVKMLNVTAPTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHHLHIIETKFEMIKLIDIARQTAQGMDYLHAKSIIHRDLKSNNIFLHEDLTVKIGDFGLATVKSRWSGSHQFEQLSGSILWMAPEVIRMQDKNPYSFQSDVYAFGIVLYELMTGQLPYSNINNRDQIIFMVGRGYLSPDLSKVRSNCPKAMKRLMAECLKKKRDERPLFPQILASIELLARSLPKIHRSASEPSLNRAGFQTEDFSLYACASPKTPIQAGGYGAFPVH	766	P15056	F	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [350], 'COMPBIAS_gain': [], 'COMPBIAS_loss_score': array([-0.00544113]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
210	NM_002755.3(MAP2K1):c.323G>T (p.Arg108Leu)	280446	CA10603467	NM_002755.3:c.323G>T, LRG_725t1:c.323G>T, XM_011521783.1:c.257G>T, XM_011521783.3:c.257G>T, XM_017022411.2:c.323G>T, XM_017022412.1:c.257G>T, NM_002755.4:c.323G>T, ENST00000307102.9:c.323G>T, ENST00000425818.2:n.834G>T, NC_000015.10:g.66436777G>T, CM000677.2:g.66436777G>T, NC_000015.9:g.66729115G>T, CM000677.1:g.66729115G>T, NC_000015.8:g.64516169G>T, NG_008305.1:g.54905G>T, LRG_725:g.54905G>T, NM_002755.3(MAP2K1):c.323G>T (p.Arg108Leu)	MAP2K1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Pathogenic	PM6, PM2, PP3, PP2, PS2	PM1, PM5	The c.323G>T (p.Arg108Leu) variant in MAP2K1 was absent from large population studies (PM2; gnomad.broadinstitute.org). It was observed as a de novo occurrence in 2 probands, one of whom had maternity and paternity confirmed (PS2, PM6; Fulgent Genetics and Baylor Genetics internal data, ClinVar SCV000894927.1). The variant is located in the MAP2K1 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Computational prediction tools and conservation analysis suggest that the p.Arg108Leu variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for autosomal dominant RASopathy. RASopathy-specific ACMG/AMP criteria applied (PMID:29493581): PS2, PM2, PM6, PP2, PP3.		RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2020-06-25	2020-07-01	False	https://erepo.genome.network/evrepo/ui/classification/CA10603467/MONDO:0021060/004	33491ca8-e49c-4685-80a6-287992b87237	p.Arg108Leu	Arg	108	Leu	MPKKKPTPIQLNPAPDGSAVNGTSSAETNLEALQKKLEELELDEQQRKRLEAFLTQKQKVGELKDDDFEKISELGAGNGGVVFKVSHKPSGLVMARKLIHLEIKPAIRNQIIRELQVLHECNSPYIVGFYGAFYSDGEISICMEHMDGGSLDQVLKKAGRIPEQILGKVSIAVIKGLTYLREKHKIMHRDVKPSNILVNSRGEIKLCDFGVSGQLIDSMANSFVGTRSYMSPERLQGTHYSVQSDIWSMGLSLVEMAVGRYPIPPPDAKELELMFGCQVEGDAAETPPRPRTPGRPLSSYGMDSRPPMAIFELLDYIVNEPPPKLPSGVFSLEFQDFVNKCLIKNPAERADLKQLMVHAFIKRSDAEEVDFAGWLCSTIGLNQPSTPTHAAGV	393	Q02750	L	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
211	NM_002755.3(MAP2K1):c.370C>T (p.Pro124Ser)	375981	CA16602456	NM_002755.3:c.370C>T, LRG_725t1:c.370C>T, XM_011521783.1:c.304C>T, XM_011521783.3:c.304C>T, XM_017022411.2:c.370C>T, XM_017022412.1:c.304C>T, NM_002755.4:c.370C>T, ENST00000307102.9:c.370C>T, ENST00000425818.2:n.881C>T, NC_000015.10:g.66436824C>T, CM000677.2:g.66436824C>T, NC_000015.9:g.66729162C>T, CM000677.1:g.66729162C>T, NC_000015.8:g.64516216C>T, NG_008305.1:g.54952C>T, LRG_725:g.54952C>T, NM_002755.3(MAP2K1):c.370C>T (p.Pro124Ser)	MAP2K1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Pathogenic	PS2_Very Strong, PM2, PP3, PP2, PM1, PS3		The c.370C>T (p.Pro124Ser) variant in MAP2K1 has been observed as a de novo occurrence with maternity and paternity confirmed in 2 probands with features of a RASopathy (PS2_VeryStrong; GeneDx internal data, ClinVar SCV000572401.5). In vitro functional studies provide some evidence that the p.Pro124Ser variant may impact protein function (PS3; PMID: 22197931). This variant was absent from large population studies (PM2; gnomad.broadinstitute.org). The p.Pro124Ser variant is located in the MAP2K1 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of MAP2K1 (PM1; PMID: 29493581). Computational prediction tools and conservation analysis suggest that the p.Leu92Arg variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. RASopathy-specific ACMG/AMP criteria applied (PMID: 29493581): PS2_VeryStrong, PS3, PM1, PM2, PP2, PP3.	22197931	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2020-07-02	2020-07-02	False	https://erepo.genome.network/evrepo/ui/classification/CA16602456/MONDO:0021060/004	5725ca85-ac7d-4884-bdcb-d5ee4a24cee6	p.Pro124Ser	Pro	124	Ser	MPKKKPTPIQLNPAPDGSAVNGTSSAETNLEALQKKLEELELDEQQRKRLEAFLTQKQKVGELKDDDFEKISELGAGNGGVVFKVSHKPSGLVMARKLIHLEIKPAIRNQIIRELQVLHECNSPYIVGFYGAFYSDGEISICMEHMDGGSLDQVLKKAGRIPEQILGKVSIAVIKGLTYLREKHKIMHRDVKPSNILVNSRGEIKLCDFGVSGQLIDSMANSFVGTRSYMSPERLQGTHYSVQSDIWSMGLSLVEMAVGRYPIPPPDAKELELMFGCQVEGDAAETPPRPRTPGRPLSSYGMDSRPPMAIFELLDYIVNEPPPKLPSGVFSLEFQDFVNKCLIKNPAERADLKQLMVHAFIKRSDAEEVDFAGWLCSTIGLNQPSTPTHAAGV	393	Q02750	S	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
212	NM_022124.6(CDH23):c.2263C>T (p.His755Tyr)	45891	CA137317	NM_022124.6:c.2263C>T, NC_000010.11:g.71694233C>T, CM000672.2:g.71694233C>T, NC_000010.10:g.73453990C>T, CM000672.1:g.73453990C>T, NC_000010.9:g.73123996C>T, NG_008835.1:g.302287C>T, NM_001171930.1:c.2263C>T, NM_001171931.1:c.2263C>T, NM_022124.5:c.2263C>T, XM_006717940.2:c.2458C>T, XM_006717942.2:c.2392C>T, XM_011540039.1:c.2458C>T, XM_011540040.1:c.2452C>T, XM_011540041.1:c.2398C>T, XM_011540042.1:c.2458C>T, XM_011540043.1:c.2458C>T, XM_011540044.1:c.2323C>T, XM_011540045.1:c.2458C>T, XM_011540046.1:c.1918C>T, XM_011540047.1:c.1276C>T, XM_011540048.1:c.2458C>T, XM_011540049.1:c.2458C>T, XM_011540050.1:c.2458C>T, XM_011540051.1:c.2458C>T, XM_011540053.1:c.2458C>T, XM_011540054.1:c.2398C>T, XR_945796.1:n.2701C>T, NM_001171930.2:c.2263C>T, NM_001171931.2:c.2263C>T, ENST00000224721.10:c.2278C>T, ENST00000299366.11:c.2263C>T, ENST00000398809.8:c.2263C>T, ENST00000442677.3:n.1038C>T, ENST00000466757.7:n.1694C>T, ENST00000616684.4:c.2263C>T, ENST00000622827.4:c.2263C>T, NM_022124.6(CDH23):c.2263C>T (p.His755Tyr)	CDH23	nonsyndromic genetic deafness	MONDO:0019497		Benign	BA1	BP4	The filtering allele frequency of the c.2263C>T (p.His755Tyr) variant in CDH23 is 0.73% (248/30558) for South Asian chromosomes by gnomAD v2.1.1, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive hearing loss variants (BA1). Of note, this variant was reported in 2 individuals with Usher syndrome, though without any evidence of pathogenicity (PM3 not met; PMID: 18429043, 21569298). In summary, this variant meets criteria to be classified as benign based on the ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel (BA1).		Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2020-01-15	2020-01-15	False	https://erepo.genome.network/evrepo/ui/classification/CA137317/MONDO:0019497/005	a25d23c2-e310-44b9-9600-d360176100dd	p.His755Tyr	His	755	Tyr	MGRHVATSCHVAWLLVLISGCWGQVNRLPFFTNHFFDTYLLISEDTPVGSSVTQLLAQDMDNDPLVFGVSGEEASRFFAVEPDTGVVWLRQPLDRETKSEFTVEFSVSDHQGVITRKVNIQVGDVNDNAPTFHNQPYSVRIPENTPVGTPIFIVNATDPDLGAGGSVLYSFQPPSQFFAIDSARGIVTVIRELDYETTQAYQLTVNATDQDKTRPLSTLANLAIIITDVQDMDPIFINLPYSTNIYEHSPPGTTVRIITAIDQDKGRPRGIGYTIVSGNTNSIFALDYISGVLTLNGLLDRENPLYSHGFILTVKGTELNDDRTPSDATVTTTFNILVIDINDNAPEFNSSEYSVAITELAQVGFALPLFIQVVDKDENLGLNSMFEVYLVGNNSHHFIISPTSVQGKADIRIRVAIPLDYETVDRYDFDLFANESVPDHVGYAKVKITLINENDNRPIFSQPLYNISLYENVTVGTSVLTVLATDNDAGTFGEVSYFFSDDPDRFSLDKDTGLIMLIARLDYELIQRFTLTIIARDGGGEETTGRVRINVLDVNDNVPTFQKDAYVGALRENEPSVTQLVRLRATDEDSPPNNQITYSIVSASAFGSYFDISLYEGYGVISVSRPLDYEQISNGLIYLTVMAMDAGNPPLNSTVPVTIEVFDENDNPPTFSKPAYFVSVVENIMAGATVLFLNATDLDRSREYGQESIIYSLEGSTQFRINARSGEITTTSLLDRETKSEYILIVRAVDGGVGHNQKTGIATVNITLLDINDNHPTWKDAPYYINLVEMTPPDSDVTTVVAVDPDLGENGTLVYSIQPPNKFYSLNSTTGKIRTTHAMLDRENPDPHEAELMRKIVVSVTDCGRPPLKATSSATVFVNLLDLNDNDPTFQNLPFVAEVLEGIPAGVSIYQVVAIDLDEGLNGLVSYRMPVGMPRMDFLINSSSGVVVTTTELDRERIAEYQLRVVASDAGTPTKSSTSTLTIHVLDVNDETPTFFPAVYNVSVSEDVPREFRVVWLNCTDNDVGLNAELSYFITGGNVDGKFSVGYRDAVVRTVVGLDRETTAAYMLILEAIDNGPVGKRHTGTATVFVTVLDVNDNRPIFLQSSYEASVPEDIPEGHSILQLKATDADEGEFGRVWYRILHGNHGNNFRIHVSNGLLMRGPRPLDRERNSSHVLIVEAYNHDLGPMRSSVRVIVYVEDINDEAPVFTQQQYSRLGLRETAGIGTSVIVVQATDRDSGDGGLVNYRILSGAEGKFEIDESTGLIITVNYLDYETKTSYMMNVSATDQAPPFNQGFCSVYITLLNELDEAVQFSNASYEAAILENLALGTEIVRVQAYSIDNLNQITYRFNAYTSTQAKALFKIDAITGVITVQGLVDREKGDFYTLTVVADDGGPKVDSTVKVYITVLDENDNSPRFDFTSDSAVSIPEDCPVGQRVATVKAWDPDAGSNGQVVFSLASGNIAGAFEIVTTNDSIGEVFVARPLDREELDHYILQVVASDRGTPPRKKDHILQVTILDINDNPPVIESPFGYNVSVNENVGGGTAVVQVRATDRDIGINSVLSYYITEGNKDMAFRMDRISGEIATRPAPPDRERQSFYHLVATVEDEGTPTLSATTHVYVTIVDENDNAPMFQQPHYEVLLDEGPDTLNTSLITIQALDLDEGPNGTVTYAIVAGNIVNTFRIDRHMGVITAAKELDYEISHGRYTLIVTATDQCPILSHRLTSTTTVLVNVNDINDNVPTFPRDYEGPFEVTEGQPGPRVWTFLAHDRDSGPNGQVEYSIMDGDPLGEFVISPVEGVLRVRKDVELDRETIAFYNLTICARDRGMPPLSSTMLVGIRVLDINDNDPVLLNLPMNITISENSPVSSFVAHVLASDADSGCNARLTFNITAGNRERAFFINATTGIVTVNRPLDRERIPEYKLTISVKDNPENPRIARRDYDLLLIFLSDENDNHPLFTKSTYQAEVMENSPAGTPLTVLNGPILALDADQDIYAVVTYQLLGAQSGLFDINSSTGVVTVRSGVIIDREAFSPPILELLLLAEDIGLLNSTAHLLITILDDNDNRPTFSPATLTVHLLENCPPGFSVLQVTATDEDSGLNGELVYRIEAGAQDRFLIHLVTGVIRVGNATIDREEQESYRLTVVATDRGTVPLSGTAIVTILIDDINDSRPEFLNPIQTVSVLESAEPGTVIANITAIDHDLNPKLEYHIVGIVAKDDTDRLVPNQEDAFAVNINTGSVMVKSPMNRELVATYEVTLSVIDNASDLPERSVSVPNAKLTVNVLDVNDNTPQFKPFGITYYMERILEGATPGTTLIAVAAVDPDKGLNGLVTYTLLDLVPPGYVQLEDSSAGKVIANRTVDYEEVHWLNFTVRASDNGSPPRAAEIPVYLEIVDINDNNPIFDQPSYQEAVFEDVPVGTIILTVTATDADSGNFALIEYSLGDGESKFAINPTTGDIYVLSSLDREKKDHYILTALAKDNPGDVASNRRENSVQVVIQVLDVNDCRPQFSKPQFSTSVYENEPAGTSVITMMATDQDEGPNGELTYSLEGPGVEAFHVDMDSGLVTTQRPLQSYEKFSLTVVATDGGEPPLWGTTMLLVEVIDVNDNRPVFVRPPNGTILHIREEIPLRSNVYEVYATDKDEGLNGAVRYSFLKTAGNRDWEFFIIDPISGLIQTAQRLDRESQAVYSLILVASDLGQPVPYETMQPLQVALEDIDDNEPLFVRPPKGSPQYQLLTVPEHSPRGTLVGNVTGAVDADEGPNAIVYYFIAAGNEEKNFHLQPDGCLLVLRDLDREREAIFSFIVKASSNRSWTPPRGPSPTLDLVADLTLQEVRVVLEDINDQPPRFTKAEYTAGVATDAKVGSELIQVLALDADIGNNSLVFYSILAIHYFRALANDSEDVGQVFTMGSMDGILRTFDLFMAYSPGYFVVDIVARDLAGHNDTAIIGIYILRDDQRVKIVINEIPDRVRGFEEEFIHLLSNITGAIVNTDNVQFHVDKKGRVNFAQTELLIHVVNRDTNRILDVDRVIQMIDENKEQLRNLFRNYNVLDVQPAISVRLPDDMSALQMAIIVLAILLFLAAMLFVLMNWYYRTVHKRKLKAIVAGSAGNRGFIDIMDMPNTNKYSFDGANPVWLDPFCRNLELAAQAEHEDDLPENLSEIADLWNSPTRTHGTFGREPAAVKPDDDRYLRAAIQEYDNIAKLGQIIREGPIKGSLLKVVLEDYLRLKKLFAQRMVQKASSCHSSISELIQTELDEEPGDHSPGQGSLRFRHKPPVELKGPDGIHVVHGSTGTLLATDLNSLPEEDQKGLGRSLETLTAAEATAFERNARTESAKSTPLHKLRDVIMETPLEITEL	3354	Q9H251	Y	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [2352], 'STRAND_gain_score': array([0.00105757]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [251, 1807, 1812, 2789, 3337], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.01560789, -0.01179081, -0.01370955, -0.01653385, -0.02609229]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
213	NM_005633.3(SOS1):c.1656G>C (p.Arg552Ser)	12872	CA256580	NM_005633.3:c.1656G>C, NC_000002.12:g.39022772C>G, CM000664.2:g.39022772C>G, NC_000002.11:g.39249913C>G, CM000664.1:g.39249913C>G, NC_000002.10:g.39103417C>G, NG_007530.1:g.102692G>C, LRG_754:g.102692G>C, LRG_754t1:c.1656G>C, XM_005264515.3:c.1656G>C, XM_011533060.1:c.1749G>C, XM_011533061.1:c.1749G>C, XM_011533062.1:c.1635G>C, XM_011533063.1:c.1632G>C, XM_011533064.1:c.1485G>C, XM_011533065.1:c.1749G>C, XM_011533066.1:c.591G>C, XM_005264515.4:c.1656G>C, XM_011533062.2:c.1635G>C, XM_011533064.2:c.1485G>C, ENST00000395038.6:c.1656G>C, ENST00000402219.6:c.1656G>C, ENST00000426016.5:c.1656G>C, NM_005633.3(SOS1):c.1656G>C (p.Arg552Ser)	SOS1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Pathogenic	PS2_Very Strong, PM2, PP3, PP2, PS4, PS3, PM1_Strong	PM6, BS2, PP1, PM5, PM4, BA1, BP3, BP4, BP1, BP2, PS1, BS4, BS3, BS1, BP7, BP5	The c.1656G>C (p.Arg552Ser) variant in SOS1 has been reported as a confirmed de novo occurrence in at least 2 patients with clinical features of a RASopathy (PS2_VeryStrong; PMID 17143282). This variant has also been identified in at least 7 independent occurrences in patients with clinical features of a RASopathy (PS4; PMIDs: 26297936, 25862627, 17143282, 21387466, 19020799, 23885229, 22190897, 19352411). This variant was absent from large population studies (PM2; gnomAD, http://gnomad.broadinstitute.org). In vitro functional studies provide some evidence that the p.Arg552Ser variant may impact protein function (PS3; PMID: 27304678). This residue has been identified as a hot spot. These variants would have received PM5_Strong but the RAS EP decided that PM1 and PM5 cannot be used simultaneously and therefore this rule has been upgraded with expert judgement (PM1_Strong). Computational prediction tools and conservation analysis suggest that the p.Arg552Ser variant may impact the protein (PP3). The variant is located in the SOS1 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PS2_VeryStrong, PS4, PM2, PS3, PM1_Strong, PP2, PP3.	17143282, 17143282, 23885229, 21387466, 26297936, 18925667, 25862627, 21784453, 22488759, 22190897, 19352411, 28378436, 19020799, 22465605, 17143282, 29625050, 29696744, 23885229, 27304678, 23885229	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2019-05-10	2019-06-28	False	https://erepo.genome.network/evrepo/ui/classification/CA256580/MONDO:0021060/004	7b69757f-5512-4640-93f6-c926e38cf7f9	p.Arg552Ser	Arg	552	Ser	MQAQQLPYEFFSEENAPKWRGLLVPALKKVQGQVHPTLESNDDALQYVEELILQLLNMLCQAQPRSASDVEERVQKSFPHPIDKWAIADAQSAIEKRKRRNPLSLPVEKIHPLLKEVLGYKIDHQVSVYIVAVLEYISADILKLVGNYVRNIRHYEITKQDIKVAMCADKVLMDMFHQDVEDINILSLTDEEPSTSGEQTYYDLVKAFMAEIRQYIRELNLIIKVFREPFVSNSKLFSANDVENIFSRIVDIHELSVKLLGHIEDTVEMTDEGSPHPLVGSCFEDLAEELAFDPYESYARDILRPGFHDRFLSQLSKPGAALYLQSIGEGFKEAVQYVLPRLLLAPVYHCLHYFELLKQLEEKSEDQEDKECLKQAITALLNVQSGMEKICSKSLAKRRLSESACRFYSQQMKGKQLAIKKMNEIQKNIDGWEGKDIGQCCNEFIMEGTLTRVGAKHERHIFLFDGLMICCKSNHGQPRLPGASNAEYRLKEKFFMRKVQINDKDDTNEYKHAFEIILKDENSVIFSAKSAEEKNNWMAALISLQYRSTLERMLDVTMLQEEKEEQMRLPSADVYRFAEPDSEENIIFEENMQPKAGIPIIKAGTVIKLIERLTYHMYADPNFVRTFLTTYRSFCKPQELLSLIIERFEIPEPEPTEADRIAIENGDQPLSAELKRFRKEYIQPVQLRVLNVCRHWVEHHFYDFERDAYLLQRMEEFIGTVRGKAMKKWVESITKIIQRKKIARDNGPGHNITFQSSPPTVEWHISRPGHIETFDLLTLHPIEIARQLTLLESDLYRAVQPSELVGSVWTKEDKEINSPNLLKMIRHTTNLTLWFEKCIVETENLEERVAVVSRIIEILQVFQELNNFNGVLEVVSAMNSSPVYRLDHTFEQIPSRQKKILEEAHELSEDHYKKYLAKLRSINPPCVPFFGIYLTNILKTEEGNPEVLKRHGKELINFSKRRKVAEITGEIQQYQNQPYCLRVESDIKRFFENLNPMGNSMEKEFTDYLFNKSLEIEPRNPKPLPRFPKKYSYPLKSPGVRPSNPRPGTMRHPTPLQQEPRKISYSRIPESETESTASAPNSPRTPLTPPPASGASSTTDVCSVFDSDHSSPFHSSNDTVFIQVTLPHGPRSASVSSISLTKGTDEVPVPPPVPPRRRPESAPAESSPSKIMSKHLDSPPAIPPRQPTSKAYSPRYSISDRTSISDPPESPPLLPPREPVRTPDVFSSSPLHLQPPPLGKKSDHGNAFFPNSPSPFTPPPPQTPSPHGTRRHLPSPPLTQEVDLHSIAGPPVPPRQSTSQHIPKLPPKTYKREHTHPSMHRDGPPLLENAHSS	1333	Q07889	S	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [516], 'STRAND_gain_score': array([0.00881422]), 'HELIX_loss': [], 'HELIX_gain': [534], 'HELIX_gain_score': array([0.01033378]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [778, 780, 782, 872], 'DOMAIN_gain_score': array([0.03422767, 0.04006362, 0.03551424, 0.027372  ]), 'REGION_loss': [], 'REGION_gain': [1295], 'REGION_gain_score': array([0.00247818]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
214	NM_005633.3(SOS1):c.1656G>T (p.Arg552Ser)	40684	CA261730	NM_005633.3:c.1656G>T, LRG_754t1:c.1656G>T, XM_005264515.3:c.1656G>T, XM_011533060.1:c.1749G>T, XM_011533061.1:c.1749G>T, XM_011533062.1:c.1635G>T, XM_011533063.1:c.1632G>T, XM_011533064.1:c.1485G>T, XM_011533065.1:c.1749G>T, XM_011533066.1:c.591G>T, XM_005264515.4:c.1656G>T, XM_011533062.2:c.1635G>T, XM_011533064.2:c.1485G>T, ENST00000395038.6:c.1656G>T, ENST00000402219.6:c.1656G>T, ENST00000426016.5:c.1656G>T, NC_000002.12:g.39022772C>A, CM000664.2:g.39022772C>A, NC_000002.11:g.39249913C>A, CM000664.1:g.39249913C>A, NC_000002.10:g.39103417C>A, NG_007530.1:g.102692G>T, LRG_754:g.102692G>T, NM_005633.3(SOS1):c.1656G>T (p.Arg552Ser)	SOS1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Pathogenic	PM2, PP3, PP2, PS4_Moderate, PS1, PS2, PM1_Strong	PM6, PP1, BS2, PM4, PM5, BP3, BP2, BP4, BP1, BA1, PS3, BP5, BP7, BS3, BS4, BS1	The c.1656G>T (p.Arg552Ser) variant in SOS1 has been reported as a confirmed de novo occurrence in one patient and 2 other probands with clinical features of a RASopathy (PS2, PS4_Moderate; PMID 17586837, 18854871). Of note, one of these cases was an affected mother-child duo (PP1 not met; PMID: 17586837). This variant was absent from large population studies (PM2; gnomAD, http://gnomad.broadinstitute.org). This amino acid residue has been designated as a hotspot. These variants would have received PM5_Strong but the RAS EP decided that PM1 and PM5 cannot be used simultaneously and therefore this rule has been upgraded with expert judgement (PM1_Strong). Of note, the p.Arg552Ser variant in SOS1 has also been a consequence of the c.1656G>C nucleotide change which has been classified as pathogenic (PS1; ClinVar ID 12872). Computational prediction tools and conservation analysis suggest that the p.Arg552Ser variant may impact the protein (PP3). The variant is located in the SOS1 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PS2, PS1, PM1_Strong, PM2, PS4_Moderate, PP2, PP3.	17586837, 17586837, 18854871, 17586837, 29625050, 17586837, 17586837	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2019-05-10	2019-06-28	False	https://erepo.genome.network/evrepo/ui/classification/CA261730/MONDO:0021060/004	b1bb4dae-8f06-4a91-b1c4-ccf1a3d0092f	p.Arg552Ser	Arg	552	Ser	MQAQQLPYEFFSEENAPKWRGLLVPALKKVQGQVHPTLESNDDALQYVEELILQLLNMLCQAQPRSASDVEERVQKSFPHPIDKWAIADAQSAIEKRKRRNPLSLPVEKIHPLLKEVLGYKIDHQVSVYIVAVLEYISADILKLVGNYVRNIRHYEITKQDIKVAMCADKVLMDMFHQDVEDINILSLTDEEPSTSGEQTYYDLVKAFMAEIRQYIRELNLIIKVFREPFVSNSKLFSANDVENIFSRIVDIHELSVKLLGHIEDTVEMTDEGSPHPLVGSCFEDLAEELAFDPYESYARDILRPGFHDRFLSQLSKPGAALYLQSIGEGFKEAVQYVLPRLLLAPVYHCLHYFELLKQLEEKSEDQEDKECLKQAITALLNVQSGMEKICSKSLAKRRLSESACRFYSQQMKGKQLAIKKMNEIQKNIDGWEGKDIGQCCNEFIMEGTLTRVGAKHERHIFLFDGLMICCKSNHGQPRLPGASNAEYRLKEKFFMRKVQINDKDDTNEYKHAFEIILKDENSVIFSAKSAEEKNNWMAALISLQYRSTLERMLDVTMLQEEKEEQMRLPSADVYRFAEPDSEENIIFEENMQPKAGIPIIKAGTVIKLIERLTYHMYADPNFVRTFLTTYRSFCKPQELLSLIIERFEIPEPEPTEADRIAIENGDQPLSAELKRFRKEYIQPVQLRVLNVCRHWVEHHFYDFERDAYLLQRMEEFIGTVRGKAMKKWVESITKIIQRKKIARDNGPGHNITFQSSPPTVEWHISRPGHIETFDLLTLHPIEIARQLTLLESDLYRAVQPSELVGSVWTKEDKEINSPNLLKMIRHTTNLTLWFEKCIVETENLEERVAVVSRIIEILQVFQELNNFNGVLEVVSAMNSSPVYRLDHTFEQIPSRQKKILEEAHELSEDHYKKYLAKLRSINPPCVPFFGIYLTNILKTEEGNPEVLKRHGKELINFSKRRKVAEITGEIQQYQNQPYCLRVESDIKRFFENLNPMGNSMEKEFTDYLFNKSLEIEPRNPKPLPRFPKKYSYPLKSPGVRPSNPRPGTMRHPTPLQQEPRKISYSRIPESETESTASAPNSPRTPLTPPPASGASSTTDVCSVFDSDHSSPFHSSNDTVFIQVTLPHGPRSASVSSISLTKGTDEVPVPPPVPPRRRPESAPAESSPSKIMSKHLDSPPAIPPRQPTSKAYSPRYSISDRTSISDPPESPPLLPPREPVRTPDVFSSSPLHLQPPPLGKKSDHGNAFFPNSPSPFTPPPPQTPSPHGTRRHLPSPPLTQEVDLHSIAGPPVPPRQSTSQHIPKLPPKTYKREHTHPSMHRDGPPLLENAHSS	1333	Q07889	S	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [516], 'STRAND_gain_score': array([0.00881422]), 'HELIX_loss': [], 'HELIX_gain': [534], 'HELIX_gain_score': array([0.01033378]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [778, 780, 782, 872], 'DOMAIN_gain_score': array([0.03422767, 0.04006362, 0.03551424, 0.027372  ]), 'REGION_loss': [], 'REGION_gain': [1295], 'REGION_gain_score': array([0.00247818]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
215	NM_005633.3(SOS1):c.1655G>C (p.Arg552Thr)	40682	CA261728	NM_005633.3:c.1655G>C, NC_000002.12:g.39022773C>G, CM000664.2:g.39022773C>G, NC_000002.11:g.39249914C>G, CM000664.1:g.39249914C>G, NC_000002.10:g.39103418C>G, NG_007530.1:g.102691G>C, LRG_754:g.102691G>C, LRG_754t1:c.1655G>C, XM_005264515.3:c.1655G>C, XM_011533060.1:c.1748G>C, XM_011533061.1:c.1748G>C, XM_011533062.1:c.1634G>C, XM_011533063.1:c.1631G>C, XM_011533064.1:c.1484G>C, XM_011533065.1:c.1748G>C, XM_011533066.1:c.590G>C, XM_005264515.4:c.1655G>C, XM_011533062.2:c.1634G>C, XM_011533064.2:c.1484G>C, NM_001382394.1:c.1634G>C, NM_001382395.1:c.1655G>C, NM_005633.4:c.1655G>C, ENST00000395038.6:c.1655G>C, ENST00000402219.6:c.1655G>C, ENST00000426016.5:c.1655G>C, NM_005633.3(SOS1):c.1655G>C (p.Arg552Thr)	SOS1	Noonan syndrome	MONDO:0018997	Autosomal dominant inheritance	Pathogenic	PM6, PM2, PP3, PP2, PS4_Moderate, PM1_Strong	PP1, BS2, PM5, PM4, BA1, BP3, BP2, BP4, BP1, PS2, PS1, PS3, BS4, BS3, BS1, BP5, BP7	The c.1655G>C (p.Arg552Thr) variant in SOS1 has been identified in at least 4 independent occurrences in patients with clinical features of a RASopathy, one of which was de novo (PS4_Moderate; GeneDx, St. George's Hospital, London internal data; GTR Lab ID: 26957 SCV000209121.12; PMID: 21387466, 19352411). This variant was absent from large population studies (PM2; gnomAD, http://gnomad.broadinstitute.org). The p.Arg552 residue has been defined as a hotspot by the RAS EP. These variants would have received PM5_Strong but the RAS EP decided that PM1 and PM5 cannot be used simultaneously and therefore this rule has been upgraded with expert judgement (PM1_Strong). The variant is located in the SOS1 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Computational prediction tools and conservation analysis suggest that the p.Arg552Thr variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PS4_Moderate, PM1_Strong, PM2, PM6, PP2, PP3.	19352411, 21387466	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2019-05-10	2019-06-28	False	https://erepo.genome.network/evrepo/ui/classification/CA261728/MONDO:0018997/004	29f14367-9d8d-4cd9-a97b-74d1d13b0a74	p.Arg552Thr	Arg	552	Thr	MQAQQLPYEFFSEENAPKWRGLLVPALKKVQGQVHPTLESNDDALQYVEELILQLLNMLCQAQPRSASDVEERVQKSFPHPIDKWAIADAQSAIEKRKRRNPLSLPVEKIHPLLKEVLGYKIDHQVSVYIVAVLEYISADILKLVGNYVRNIRHYEITKQDIKVAMCADKVLMDMFHQDVEDINILSLTDEEPSTSGEQTYYDLVKAFMAEIRQYIRELNLIIKVFREPFVSNSKLFSANDVENIFSRIVDIHELSVKLLGHIEDTVEMTDEGSPHPLVGSCFEDLAEELAFDPYESYARDILRPGFHDRFLSQLSKPGAALYLQSIGEGFKEAVQYVLPRLLLAPVYHCLHYFELLKQLEEKSEDQEDKECLKQAITALLNVQSGMEKICSKSLAKRRLSESACRFYSQQMKGKQLAIKKMNEIQKNIDGWEGKDIGQCCNEFIMEGTLTRVGAKHERHIFLFDGLMICCKSNHGQPRLPGASNAEYRLKEKFFMRKVQINDKDDTNEYKHAFEIILKDENSVIFSAKSAEEKNNWMAALISLQYRSTLERMLDVTMLQEEKEEQMRLPSADVYRFAEPDSEENIIFEENMQPKAGIPIIKAGTVIKLIERLTYHMYADPNFVRTFLTTYRSFCKPQELLSLIIERFEIPEPEPTEADRIAIENGDQPLSAELKRFRKEYIQPVQLRVLNVCRHWVEHHFYDFERDAYLLQRMEEFIGTVRGKAMKKWVESITKIIQRKKIARDNGPGHNITFQSSPPTVEWHISRPGHIETFDLLTLHPIEIARQLTLLESDLYRAVQPSELVGSVWTKEDKEINSPNLLKMIRHTTNLTLWFEKCIVETENLEERVAVVSRIIEILQVFQELNNFNGVLEVVSAMNSSPVYRLDHTFEQIPSRQKKILEEAHELSEDHYKKYLAKLRSINPPCVPFFGIYLTNILKTEEGNPEVLKRHGKELINFSKRRKVAEITGEIQQYQNQPYCLRVESDIKRFFENLNPMGNSMEKEFTDYLFNKSLEIEPRNPKPLPRFPKKYSYPLKSPGVRPSNPRPGTMRHPTPLQQEPRKISYSRIPESETESTASAPNSPRTPLTPPPASGASSTTDVCSVFDSDHSSPFHSSNDTVFIQVTLPHGPRSASVSSISLTKGTDEVPVPPPVPPRRRPESAPAESSPSKIMSKHLDSPPAIPPRQPTSKAYSPRYSISDRTSISDPPESPPLLPPREPVRTPDVFSSSPLHLQPPPLGKKSDHGNAFFPNSPSPFTPPPPQTPSPHGTRRHLPSPPLTQEVDLHSIAGPPVPPRQSTSQHIPKLPPKTYKREHTHPSMHRDGPPLLENAHSS	1333	Q07889	T	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [516], 'STRAND_gain_score': array([0.00503838]), 'HELIX_loss': [], 'HELIX_gain': [534], 'HELIX_gain_score': array([0.00930154]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [778, 780, 782, 872, 873], 'DOMAIN_gain_score': array([0.04852188, 0.05738777, 0.05002367, 0.03656888, 0.03630829]), 'REGION_loss': [], 'REGION_gain': [1295], 'REGION_gain_score': array([0.00206482]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
216	NM_005633.3(SOS1):c.1655G>A (p.Arg552Lys)	40683	CA261726	NM_005633.3:c.1655G>A, NC_000002.12:g.39022773C>T, CM000664.2:g.39022773C>T, NC_000002.11:g.39249914C>T, CM000664.1:g.39249914C>T, NC_000002.10:g.39103418C>T, NG_007530.1:g.102691G>A, LRG_754:g.102691G>A, LRG_754t1:c.1655G>A, XM_005264515.3:c.1655G>A, XM_011533060.1:c.1748G>A, XM_011533061.1:c.1748G>A, XM_011533062.1:c.1634G>A, XM_011533063.1:c.1631G>A, XM_011533064.1:c.1484G>A, XM_011533065.1:c.1748G>A, XM_011533066.1:c.590G>A, XM_005264515.4:c.1655G>A, XM_011533062.2:c.1634G>A, XM_011533064.2:c.1484G>A, ENST00000395038.6:c.1655G>A, ENST00000402219.6:c.1655G>A, ENST00000426016.5:c.1655G>A, NM_005633.3(SOS1):c.1655G>A (p.Arg552Lys)	SOS1	Noonan syndrome	MONDO:0018997	Autosomal dominant inheritance	Pathogenic	PS2_Very Strong, PM2, PP3, PP2, PS3, PS4, PM1_Strong	PM6, BS2, PP1, PM5, PM4, BA1, BP3, BP2, BP4, BP1, PS1, BS4, BS3, BS1, BP7, BP5	The c.1655G>A (p.Arg552Lys) variant in SOS1 has been reported as a confirmed de novo occurrence in at least 2 patients with clinical features of a RASopathy (PS2_VeryStrong; PMID 17586837, 17143282, 30266093, 26686981). This variant has been detected in at least 7 independent occurrences with clinical features of a RASopathy (PS4; PMIDs: 17586837, 22420426, 28378436, 29037749, 25337068, 21387466, 21784453, 26918529, 21274610). In vitro functional studies provide some evidence that the p.Arg552Lys variant may impact protein function (PS3; PMID: 21784453). This residue has been defined as a PM1 hotspot by the RAS VCEP. These variants would have received PM5_Strong but the RAS EP decided that PM1 and PM5 cannot be used simultaneously and therefore this rule has been upgraded with expert judgement (PM1_Strong). This variant was absent from large population studies (PM2; gnomAD, http://gnomad.broadinstitute.org). Computational prediction tools and conservation analysis suggest that the p.Arg552Lys variant may impact the protein (PP3). The variant is located in the SOS1 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PS2_VeryStrong, PS4, PS3, PM1_Strong, PM2, PP2, PP3.	30266093, 26686981, 30266093, 26686981, 28378436, 26214590, 27236105, 21784453, 21387466, 29037749, 25337068, 21274610, 30266093, 26918529	RASopathy VCEP	https://www.clinicalgenome.org/docs/clingen-rasopathy-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2019-05-10	2019-06-28	False	https://erepo.genome.network/evrepo/ui/classification/CA261726/MONDO:0018997/004	1065305a-be0c-4399-99c0-352adbd087b7	p.Arg552Lys	Arg	552	Lys	MQAQQLPYEFFSEENAPKWRGLLVPALKKVQGQVHPTLESNDDALQYVEELILQLLNMLCQAQPRSASDVEERVQKSFPHPIDKWAIADAQSAIEKRKRRNPLSLPVEKIHPLLKEVLGYKIDHQVSVYIVAVLEYISADILKLVGNYVRNIRHYEITKQDIKVAMCADKVLMDMFHQDVEDINILSLTDEEPSTSGEQTYYDLVKAFMAEIRQYIRELNLIIKVFREPFVSNSKLFSANDVENIFSRIVDIHELSVKLLGHIEDTVEMTDEGSPHPLVGSCFEDLAEELAFDPYESYARDILRPGFHDRFLSQLSKPGAALYLQSIGEGFKEAVQYVLPRLLLAPVYHCLHYFELLKQLEEKSEDQEDKECLKQAITALLNVQSGMEKICSKSLAKRRLSESACRFYSQQMKGKQLAIKKMNEIQKNIDGWEGKDIGQCCNEFIMEGTLTRVGAKHERHIFLFDGLMICCKSNHGQPRLPGASNAEYRLKEKFFMRKVQINDKDDTNEYKHAFEIILKDENSVIFSAKSAEEKNNWMAALISLQYRSTLERMLDVTMLQEEKEEQMRLPSADVYRFAEPDSEENIIFEENMQPKAGIPIIKAGTVIKLIERLTYHMYADPNFVRTFLTTYRSFCKPQELLSLIIERFEIPEPEPTEADRIAIENGDQPLSAELKRFRKEYIQPVQLRVLNVCRHWVEHHFYDFERDAYLLQRMEEFIGTVRGKAMKKWVESITKIIQRKKIARDNGPGHNITFQSSPPTVEWHISRPGHIETFDLLTLHPIEIARQLTLLESDLYRAVQPSELVGSVWTKEDKEINSPNLLKMIRHTTNLTLWFEKCIVETENLEERVAVVSRIIEILQVFQELNNFNGVLEVVSAMNSSPVYRLDHTFEQIPSRQKKILEEAHELSEDHYKKYLAKLRSINPPCVPFFGIYLTNILKTEEGNPEVLKRHGKELINFSKRRKVAEITGEIQQYQNQPYCLRVESDIKRFFENLNPMGNSMEKEFTDYLFNKSLEIEPRNPKPLPRFPKKYSYPLKSPGVRPSNPRPGTMRHPTPLQQEPRKISYSRIPESETESTASAPNSPRTPLTPPPASGASSTTDVCSVFDSDHSSPFHSSNDTVFIQVTLPHGPRSASVSSISLTKGTDEVPVPPPVPPRRRPESAPAESSPSKIMSKHLDSPPAIPPRQPTSKAYSPRYSISDRTSISDPPESPPLLPPREPVRTPDVFSSSPLHLQPPPLGKKSDHGNAFFPNSPSPFTPPPPQTPSPHGTRRHLPSPPLTQEVDLHSIAGPPVPPRQSTSQHIPKLPPKTYKREHTHPSMHRDGPPLLENAHSS	1333	Q07889	K	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [516], 'STRAND_gain_score': array([0.00211555]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [782], 'DOMAIN_gain_score': array([0.00621974]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
217	NM_000152.4(GAA):c.1841C>A (p.Thr614Lys)	167113	CA234050	NM_000152.4:c.1841C>A, NC_000017.11:g.80112664C>A, CM000679.2:g.80112664C>A, NC_000017.10:g.78086463C>A, CM000679.1:g.78086463C>A, NC_000017.9:g.75701058C>A, NG_009822.1:g.16109C>A, LRG_673:g.16109C>A, NM_000152.3:c.1841C>A, LRG_673t1:c.1841C>A, NM_001079803.1:c.1841C>A, NM_001079804.1:c.1841C>A, XM_005257193.1:c.1841C>A, XM_005257194.3:c.1841C>A, NM_001079803.2:c.1841C>A, NM_001079804.2:c.1841C>A, XM_005257193.2:c.1841C>A, XM_005257194.4:c.1841C>A, NM_000152.5:c.1841C>A, NM_001079803.3:c.1841C>A, NM_001079804.3:c.1841C>A, ENST00000302262.7:c.1841C>A, ENST00000390015.7:c.1841C>A, ENST00000570716.1:n.281C>A, ENST00000572080.1:n.229C>A, ENST00000572803.1:n.455C>A, NM_000152.4(GAA):c.1841C>A (p.Thr614Lys)	GAA	glycogen storage disease II	MONDO:0009290	Autosomal recessive inheritance	Pathogenic	PS3, PP3_Moderate, PP4_Moderate, PM2, PM3	PM5	This variant, c.1841C>A (p.Thr614Lys), has been found in two patients published in the literature and five patients in a clinical diagnostic laboratory who have Pompe disease and residual GAA activity meeting the ClinGen LSD VCEP's specifications for PP4. These patients are compound heterozygous for the variant and either c.1076–22T>G (PMID 21484825), c.-32-13T>G (PMID 24590251, 2 laboratory patients), c.2481+102_2646+31del (one patient), c.1402A>T (p.Ile468Phe) (one patient), and unconfirmed second variant (one patient). The phase of the variants is unknown for all patients. This in trans data meets PM3. Pseudodeficiency variants are absent in the patients identified in the clinical laboratory. Therefore, PP4_Moderate can be applied. When expressed in COS cells, this variant resulted in <5% wild type activity in cells and <2% wild type activity in medium, in addition to exhibiting abnormal synthesis and processing (PMID 22644586), meeting PS3. The score for the REVEL in silico predictor, 0.835, also suggests that the variant is deleterious, meeting PP3. The highest population minor allele frequency in gnomAD v2.1.1 is 0.00005 in the European non-Finnish population, meeting PM2. There is a ClinVar entry for this variant (Variation ID: 167113, 2 star review status) with one submitter classifying the variant as pathogenic and two as likely pathogenic. In summary, this variant meets the criteria to be classified as pathogenic for Pompe disease. ACMG/AMP criteria applied, as specified by the ClinGen LSD VCEP: PS3, PM2, PM3, PP3, PP4_Moderate.	22644586, 24590251, 30564623, 21484825, 25544546, 27708273	Lysosomal Diseases VCEP	https://clinicalgenome.org/docs/clingen-lysosomal-storage-disorders-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-2/	2020-04-21	2020-05-28	False	https://erepo.genome.network/evrepo/ui/classification/CA234050/MONDO:0009290/010	92ec254b-4a9f-4cac-929c-5b6222db49b4	p.Thr614Lys	Thr	614	Lys	MGVRHPPCSHRLLAVCALVSLATAALLGHILLHDFLLVPRELSGSSPVLEETHPAHQQGASRPGPRDAQAHPGRPRAVPTQCDVPPNSRFDCAPDKAITQEQCEARGCCYIPAKQGLQGAQMGQPWCFFPPSYPSYKLENLSSSEMGYTATLTRTTPTFFPKDILTLRLDVMMETENRLHFTIKDPANRRYEVPLETPHVHSRAPSPLYSVEFSEEPFGVIVRRQLDGRVLLNTTVAPLFFADQFLQLSTSLPSQYITGLAEHLSPLMLSTSWTRITLWNRDLAPTPGANLYGSHPFYLALEDGGSAHGVFLLNSNAMDVVLQPSPALSWRSTGGILDVYIFLGPEPKSVVQQYLDVVGYPFMPPYWGLGFHLCRWGYSSTAITRQVVENMTRAHFPLDVQWNDLDYMDSRRDFTFNKDGFRDFPAMVQELHQGGRRYMMIVDPAISSSGPAGSYRPYDEGLRRGVFITNETGQPLIGKVWPGSTAFPDFTNPTALAWWEDMVAEFHDQVPFDGMWIDMNEPSNFIRGSEDGCPNNELENPPYVPGVVGGTLQAATICASSHQFLSTHYNLHNLYGLTEAIASHRALVKARGTRPFVISRSTFAGHGRYAGHWTGDVWSSWEQLASSVPEILQFNLLGVPLVGADVCGFLGNTSEELCVRWTQLGAFYPFMRNHNSLLSLPQEPYSFSEPAQQAMRKALTLRYALLPHLYTLFHQAHVAGETVARPLFLEFPKDSSTWTVDHQLLWGEALLITPVLQAGKAEVTGYFPLGTWYDLQTVPVEALGSLPPPPAAPREPAIHSEGQWVTLPAPLDTINVHLRAGYIIPLQGPGLTTTESRQQPMALAVALTKGGEARGELFWDDGESLEVLERGAYTQVIFLARNNTIVNELVRVTSEGAGLQLQKVTVLGVATAPQQVLSNGVPVSNFTYSPDTKVLDICVSLLMGEQFLVSWC	952	P10253	K	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [599], 'BINDING_gain': [], 'BINDING_loss_score': array([-0.02036417]), 'DNA_BIND_loss': [375, 704, 716], 'DNA_BIND_gain': [585, 601, 608, 611, 615, 625, 628, 658, 707], 'DNA_BIND_gain_score': array([0.01180184, 0.00558168, 0.01320183, 0.00804055, 0.02110612,
       0.02007854, 0.01341742, 0.008488  , 0.00037545]), 'DNA_BIND_loss_score': array([-0.00024855, -0.0008164 , -0.00254184]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [22], 'TRANSIT_gain_score': array([0.00864851]), 'STRAND_loss': [], 'STRAND_gain': [913], 'STRAND_gain_score': array([0.00322443]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
218	NM_206933.2(USH2A):c.2522C>A (p.Ser841Tyr)	48487	CA248655	NM_206933.2:c.2522C>A, NM_007123.5:c.2522C>A, NM_206933.3:c.2522C>A, NM_007123.6:c.2522C>A, NM_206933.4:c.2522C>A, ENST00000307340.7:c.2522C>A, ENST00000366942.3:c.2522C>A, NC_000001.11:g.216246872G>T, CM000663.2:g.216246872G>T, NC_000001.10:g.216420214G>T, CM000663.1:g.216420214G>T, NC_000001.9:g.214486837G>T, NG_009497.1:g.181525C>A, NG_009497.2:g.181577C>A, NM_206933.2(USH2A):c.2522C>A (p.Ser841Tyr)	USH2A	Usher syndrome	MONDO:0019501	Autosomal recessive inheritance	Benign	BA1	PS3, PS4, PS2, PS1, PM1, PM3, PM4, PM5, BP5, BP7, BS4, BS1, PM6, PM2, PVS1, PP1, PP4, PP3, BS2, BP2, BP3, BP4	The p.Ser841Tyr variant in the USH2A gene has been identified in three individuals with Usher syndrome (PMIDs 19683999, 28944237, 28653555); however, in two of those individuals a variant on the second allele was not identified (PMIDs 19683999, 28944237) and in one (PMID 28653555), the variant found on the other alleles (p.Tyr1992Cys) did not have evidence to support pathogenicity and has a high allele frequency in gnomAD (of European (Finnish) chromosomes). The filtering allele frequency of the p.Ser841Tyr variant in the USH2A gene is 1.4% for European (Finnish) chromosomes by gnomAD (1144/128242 with 95% CI), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive hearing loss variants (BA1).	22004887, 25262649, 19683999, 25773295, 28944237, 28653555, 19683999, 25773295, 28944237, 28653555	Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2020-12-24	2020-12-24	False	https://erepo.genome.network/evrepo/ui/classification/CA248655/MONDO:0019501/005	7682e5e6-e0b4-41a9-a776-1e192a9bf66e	p.Ser841Tyr	Ser	841	Tyr	MNCPVLSLGSGFLFQVIEMLIFAYFASISLTESRGLFPRLENVGAFKKVSIVPTQAVCGLPDRSTFCHSSAAAESIQFCTQRFCIQDCPYRSSHPTYTALFSAGLSSCITPDKNDLHPNAHSNSASFIFGNHKSCFSSPPSPKLMASFTLAVWLKPEQQGVMCVIEKTVDGQIVFKLTISEKETMFYYRTVNGLQPPIKVMTLGRILVKKWIHLSVQVHQTKISFFINGVEKDHTPFNARTLSGSITDFASGTVQIGQSLNGLEQFVGRMQDFRLYQVALTNREILEVFSGDLLRLHAQSHCRCPGSHPRVHPLAQRYCIPNDAGDTADNRVSRLNPEAHPLSFVNDNDVGTSWVSNVFTNITQLNQGVTISVDLENGQYQVFYIIIQFFSPQPTEIRIQRKKENSLDWEDWQYFARNCGAFGMKNNGDLEKPDSVNCLQLSNFTPYSRGNVTFSILTPGPNYRPGYNNFYNTPSLQEFVKATQIRFHFHGQYYTTETAVNLRHRYYAVDEITISGRCQCHGHADNCDTTSQPYRCLCSQESFTEGLHCDRCLPLYNDKPFRQGDQVYAFNCKPCQCNSHSKSCHYNISVDPFPFEHFRGGGGVCDDCEHNTTGRNCELCKDYFFRQVGADPSAIDVCKPCDCDTVGTRNGSILCDQIGGQCNCKRHVSGRQCNQCQNGFYNLQELDPDGCSPCNCNTSGTVDGDITCHQNSGQCKCKANVIGLRCDHCNFGFKFLRSFNDVGCEPCQCNLHGSVNKFCNPHSGQCECKKEAKGLQCDTCRENFYGLDVTNCKACDCDTAGSLPGTVCNAKTGQCICKPNVEGRQCNKCLEGNFYLRQNNSFLCLPCNCDKTGTINGSLLCNKSTGQCPCKLGVTGLRCNQCEPHRYNLTIDNFQHCQMCECDSLGTLPGTICDPISGQCLCVPNRQGRRCNQCQPGFYISPGNATGCLPCSCHTTGAVNHICNSLTGQCVCQDASIAGQRCDQCKDHYFGFDPQTGRCQPCNCHLSGALNETCHLVTGQCFCKQFVTGSKCDACVPSASHLDVNNLLGCSKTPFQQPPPRGQVQSSSAINLSWSPPDSPNAHWLTYSLLRDGFEIYTTEDQYPYSIQYFLDTDLLPYTKYSYYIETTNVHGSTRSVAVTYKTKPGVPEGNLTLSYIIPIGSDSVTLTWTTLSNQSGPIEKYILSCAPLAGGQPCVSYEGHETSATIWNLVPFAKYDFSVQACTSGGCLHSLPITVTTAQAPPQRLSPPKMQKISSTELHVEWSPPAELNGIIIRYELYMRRLRSTKETTSEESRVFQSSGWLSPHSFVESANENALKPPQTMTTITGLEPYTKYEFRVLAVNMAGSVSSAWVSERTGESAPVFMIPPSVFPLSSYSLNISWEKPADNVTRGKVVGYDINMLSEQSPQQSIPMAFSQLLHTAKSQELSYTVEGLKPYRIYEFTITLCNSVGCVTSASGAGQTLAAAPAQLRPPLVKGINSTTIHLRWFPPEELNGPSPIYQLERRESSLPALMTTMMKGIRFIGNGYCKFPSSTHPVNTDFTGIKASFRTKVPEGLIVFAASPGNQEEYFALQLKKGRLYFLFDPQGSPVEVTTTNDHGKQYSDGKWHEIIAIRHQAFGQITLDGIYTGSSAILNGSTVIGDNTGVFLGGLPRSYTILRKDPEIIQKGFVGCLKDVHFMKNYNPSAIWEPLDWQSSEEQINVYNSWEGCPASLNEGAQFLGAGFLELHPYMFHGGMNFEISFKFRTDQLNGLLLFVYNKDGPDFLAMELKSGILTFRLNTSLAFTQVDLLLGLSYCNGKWNKVIIKKEGSFISASVNGLMKHASESGDQPLVVNSPVYVGGIPQELLNSYQHLCLEQGFGGCMKDVKFTRGAVVNLASVSSGAVRVNLDGCLSTDSAVNCRGNDSILVYQGKEQSVYEGGLQPFTEYLYRVIASHEGGSVYSDWSRGRTTGAAPQSVPTPSRVRSLNGYSIEVTWDEPVVRGVIEKYILKAYSEDSTRPPRMPSASAEFVNTSNLTGILTGLLPFKNYAVTLTACTLAGCTESSHALNISTPQEAPQEVQPPVAKSLPSSLLLSWNPPKKANGIITQYCLYMDGRLIYSGSEENYIVTDLAVFTPHQFLLSACTHVGCTNSSWVLLYTAQLPPEHVDSPVLTVLDSRTIHIQWKQPRKISGILERYVLYMSNHTHDFTIWSVIYNSTELFQDHMLQYVLPGNKYLIKLGACTGGGCTVSEASEALTDEDIPEGVPAPKAHSYSPDSFNVSWTEPEYPNGVITSYGLYLDGILIHNSSELSYRAYGFAPWSLHSFRVQACTAKGCALGPLVENRTLEAPPEGTVNVFVKTQGSRKAHVRWEAPFRPNGLLTHSVLFTGIFYVDPVGNNYTLLNVTKVMYSGEETNLWVLIDGLVPFTNYTVQVNISNSQGSLITDPITIAMPPGAPDGVLPPRLSSATPTSLQVVWSTPARNNAPGSPRYQLQMRSGDSTHGFLELFSNPSASLSYEVSDLQPYTEYMFRLVASNGFGSAHSSWIPFMTAEDKPGPVVPPILLDVKSRMMLVTWQHPRKSNGVITHYNIYLHGRLYLRTPGNVTNCTVMHLHPYTAYKFQVEACTSKGCSLSPESQTVWTLPGAPEGIPSPELFSDTPTSVIISWQPPTHPNGLVENFTIERRVKGKEEVTTLVTLPRSHSMRFIDKTSALSPWTKYEYRVLMSTLHGGTNSSAWVEVTTRPSRPAGVQPPVVTVLEPDAVQVTWKPPLIQNGDILSYEIHMPDPHITLTNVTSAVLSQKVTHLIPFTNYSVTIVACSGGNGYLGGCTESLPTYVTTHPTVPQNVGPLSVIPLSESYVVISWQPPSKPNGPNLRYELLRRKIQQPLASNPPEDLNRWHNIYSGTQWLYEDKGLSRFTTYEYMLFVHNSVGFTPSREVTVTTLAGLPERGANLTASVLNHTAIDVRWAKPTVQDLQGEVEYYTLFWSSATSNDSLKILPDVNSHVIGHLKPNTEYWIFISVFNGVHSINSAGLHATTCDGEPQGMLPPEVVIINSTAVRVIWTSPSNPNGVVTEYSIYVNNKLYKTGMNVPGSFILRDLSPFTIYDIQVEVCTIYACVKSNGTQITTVEDTPSDIPTPTIRGITSRSLQIDWVSPRKPNGIILGYDLLWKTWYPCAKTQKLVQDQSDELCKAVRCQKPESICGHICYSSEAKVCCNGVLYNPKPGHRCCEEKYIPFVLNSTGVCCGGRIQEAQPNHQCCSGYYARILPGEVCCPDEQHNRVSVGIGDSCCGRMPYSTSGNQICCAGRLHDGHGQKCCGRQIVSNDLECCGGEEGVVYNRLPGMFCCGQDYVNMSDTICCSASSGESKAHIKKNDPVPVKCCETELIPKSQKCCNGVGYNPLKYVCSDKISTGMMMKETKECRILCPASMEATEHCGRCDFNFTSHICTVIRGSHNSTGKASIEEMCSSAEETIHTGSVNTYSYTDVNLKPYMTYEYRISAWNSYGRGLSKAVRARTKEDVPQGVSPPTWTKIDNLEDTIVLNWRKPIQSNGPIIYYILLRNGIERFRGTSLSFSDKEGIQPFQEYSYQLKACTVAGCATSSKVVAATTQGVPESILPPSITALSAVALHLSWSVPEKSNGVIKEYQIRQVGKGLIHTDTTDRRQHTVTGLQPYTNYSFTLTACTSAGCTSSEPFLGQTLQAAPEGVWVTPRHIIINSTTVELYWSLPEKPNGLVSQYQLSRNGNLLFLGGSEEQNFTDKNLEPNSRYTYKLEVKTGGGSSASDDYIVQTPMSTPEEIYPPYNITVIGPYSIFVAWIPPGILIPEIPVEYNVLLNDGSVTPLAFSVGHHQSTLLENLTPFTQYEIRIQACQNGSCGVSSRMFVKTPEAAPMDLNSPVLKALGSACIEIKWMPPEKPNGIIINYFIYRRPAGIEEESVLFVWSEGALEFMDEGDTLRPFTLYEYRVRACNSKGSVESLWSLTQTLEAPPQDFPAPWAQATSAHSVLLNWTKPESPNGIISHYRVVYQERPDDPTFNSPTVHAFTVKGTSHQAHLYGLEPFTTYRIGVVAANHAGEILSPWTLIQTLESSPSGLRNFIVEQKENGRALLLQWSEPMRTNGVIKTYNIFSDGFLEYSGLNRQFLFRRLDPFTLYTLTLEACTRAGCAHSAPQPLWTDEAPPDSQLAPTVHSVKSTSVELSWSEPVNPNGKIIRYEVIRRCFEGKAWGNQTIQADEKIVFTEYNTERNTFMYNDTGLQPWTQCEYKIYTWNSAGHTCSSWNVVRTLQAPPEGLSPPVISYVSMNPQKLLISWIPPEQSNGIIQSYRLQRNEMLYPFSFDPVTFNYTDEELLPFSTYSYALQACTSGGCSTSKPTSITTLEAAPSEVSPPDLWAVSATQMNVCWSPPTVQNGKITKYLVRYDNKESLAGQGLCLLVSHLQPYSQYNFSLVACTNGGCTASVSKSAWTMEALPENMDSPTLQVTGSESIEITWKPPRNPNGQIRSYELRRDGTIVYTGLETRYRDFTLTPGVEYSYTVTASNSQGGILSPLVKDRTSPSAPSGMEPPKLQARGPQEILVNWDPPVRTNGDIINYTLFIRELFERETKIIHINTTHNSFGMQSYIVNQLKPFHRYEIRIQACTTLGCASSDWTFIQTPEIAPLMQPPPHLEVQMAPGGFQPTVSLLWTGPLQPNGKVLYYELYRRQIATQPRKSNPVLIYNGSSTSFIDSELLPFTEYEYQVWAVNSAGKAPSSWTWCRTGPAPPEGLRAPTFHVISSTQAVVNISAPGKPNGIVSLYRLFSSSAHGAETVLSEGMATQQTLHGLQAFTNYSIGVEACTCFNCCSKGPTAELRTHPAPPSGLSSPQIGTLASRTASFRWSPPMFPNGVIHSYELQFHVACPPDSALPCTPSQIETKYTGLGQKASLGGLQPYTTYKLRVVAHNEVGSTASEWISFTTQKELPQYRAPFSVDSNLSVVCVNWSDTFLLNGQLKEYVLTDGGRRVYSGLDTTLYIPRTADKTFFFQVICTTDEGSVKTPLIQYDTSTGLGLVLTTPGKKKGSRSKSTEFYSELWFIVLMAMLGLILLAIFLSLILQRKIHKEPYIRERPPLVPLQKRMSPLNVYPPGENHMGLADTKIPRSGTPVSIRSNRSACVLRIPSQNQTSLTYSQGSLHRSVSQLMDIQDKKVLMDNSLWEAIMGHNSGLYVDEEDLMNAIKDFSSVTKERTTFTDTHL	5202	O75445	Y	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [3167], 'DISULFID_gain_score': array([0.0002014]), 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [4236, 4568, 4604], 'STRAND_gain_score': array([0.00066829, 0.00194257, 0.00390774]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [463], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.01161367]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': [731], 'ZN_FING_gain_score': array([0.00125021])}
219	NM_001754.4(RUNX1):c.1396A>T (p.Met466Leu)	463982	CA10014176	NM_001754.4:c.1396A>T, NM_001001890.2:c.1315A>T, LRG_482t1:c.1396A>T, XM_005261068.3:c.1360A>T, XM_005261069.3:c.1204A>T, XM_011529766.1:c.1396A>T, XM_011529767.1:c.1357A>T, XM_011529768.1:c.1165A>T, XM_005261069.4:c.1204A>T, XM_011529766.2:c.1396A>T, XM_011529767.2:c.1357A>T, XM_011529768.2:c.1165A>T, XM_017028487.1:c.1243A>T, NM_001001890.3:c.1315A>T, NM_001754.5:c.1396A>T, ENST00000300305.7:c.1396A>T, ENST00000344691.8:c.1315A>T, ENST00000399240.5:c.1123A>T, ENST00000437180.5:c.1396A>T, ENST00000482318.5:c.*986A>T, NC_000021.9:g.34792182T>A, CM000683.2:g.34792182T>A, NC_000021.8:g.36164479T>A, CM000683.1:g.36164479T>A, NC_000021.7:g.35086349T>A, NG_011402.2:g.1197530A>T, LRG_482:g.1197530A>T, NM_001754.4(RUNX1):c.1396A>T (p.Met466Leu)	RUNX1	hereditary thrombocytopenia and hematologic cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Benign	BA1, BP4	PVS1, PM6, PM2, PM1, PM4, PM5, PP1, PP3, BP2, PS4, PS3, PS1, BP7, BS4, BS3, BS1	The NM_001754.4:c.1396A>T variant that results in a Met466Leu missense change has an MAF of 0.001761 (0.1%, 23/13058 alleles) in the East Asian subpopulation of the gnomAD v2.1.1 cohort, which is >0.0015 (0.15%) (BA1). This missense variant has a REVEL score <0.15 (0.149) and SSF and MES predict no effect on splicing (BP4). The variant has not been reported in the germ line of patients with familial platelet disorder with predisposition to hematologic malignancies in the literature, to the best of our knowledge. In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the Myeloid Malignancy Variant Curation Expert Panel for RUNX1: BA1, BP4.		Myeloid Malignancy VCEP	https://www.clinicalgenome.org/affiliation/50034/docs/assertion-criteria 	2021-01-11	2021-01-11	False	https://erepo.genome.network/evrepo/ui/classification/CA10014176/MONDO:0011071/008	2b0ab3a2-cbe9-4769-81a9-29dc6192cfb1	p.Met466Leu	Met	466	Leu	MRIPVDASTSRRFTPPSTALSPGKMSEALPLGAPDAGAALAGKLRSGDRSMVEVLADHPGELVRTDSPNFLCSVLPTHWRCNKTLPIAFKVVALGDVPDGTLVTVMAGNDENYSAELRNATAAMKNQVARFNDLRFVGRSGRGKSFTLTITVFTNPPQVATYHRAIKITVDGPREPRRHRQKLDDQTKPGSLSFSERLSELEQLRRTAMRVSPHHPAPTPNPRASLNHSTAFNPQPQSQMQDTRQIQPSPPWSYDQSYQYLGSIASPSVHPATPISPGRASGMTTLSAELSSRLSTAPDLTAFSDPRQFPALPSISDPRMHYPGAFTYSPTPVTSGIGIGMSAMGSATRYHTYLPPPYPGSSQAQGGPFQASSPSYHLYYGASAGSYQFSMVGGERSPPRILPPCTNASTGSALLNPSLPNQSDVVEAEGSHSNSPTNMAPSARLEEAVWRPY	453	Q01196	L	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [8], 'TRANSIT_gain': [], 'TRANSIT_loss_score': array([-0.01919663]), 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [405, 407, 441], 'COMPBIAS_gain': [], 'COMPBIAS_loss_score': array([-0.04940623, -0.04871958, -0.10376048]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [114, 361, 404, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452], 'REGION_gain': [], 'REGION_loss_score': array([-0.00468856, -0.02536446, -0.01762336, -0.22796005, -0.27495176,
       -0.2696268 , -0.25998139, -0.27012664, -0.27409703, -0.29643297,
       -0.26580387, -0.24672836, -0.27453399]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
220	NM_001754.4(RUNX1):c.179C>T (p.Ala60Val)	463986	CA10014576	NM_001754.4:c.179C>T, NC_000021.9:g.34887015G>A, CM000683.2:g.34887015G>A, NC_000021.8:g.36259312G>A, CM000683.1:g.36259312G>A, NC_000021.7:g.35181182G>A, NG_011402.2:g.1102697C>T, LRG_482:g.1102697C>T, NM_001001890.2:c.98C>T, NM_001122607.1:c.98C>T, LRG_482t1:c.179C>T, XM_005261068.3:c.143C>T, XM_005261069.3:c.179C>T, XM_011529766.1:c.179C>T, XM_011529767.1:c.140C>T, XM_011529768.1:c.140C>T, XM_011529770.1:c.179C>T, XR_937576.1:n.358C>T, XM_005261069.4:c.179C>T, XM_011529766.2:c.179C>T, XM_011529767.2:c.140C>T, XM_011529768.2:c.140C>T, XM_011529770.2:c.179C>T, XM_017028487.1:c.26C>T, XR_937576.2:n.405C>T, NM_001001890.3:c.98C>T, NM_001122607.2:c.98C>T, NM_001754.5:c.179C>T, ENST00000300305.7:c.179C>T, ENST00000344691.8:c.98C>T, ENST00000358356.9:c.98C>T, ENST00000399237.6:c.143C>T, ENST00000399240.5:c.98C>T, ENST00000437180.5:c.179C>T, ENST00000455571.5:c.140C>T, ENST00000482318.5:c.59-6302C>T, NM_001754.4(RUNX1):c.179C>T (p.Ala60Val)	RUNX1	hereditary thrombocytopenia and hematologic cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Benign	BS1, BS3	PVS1, PM6, PM2, PM1, PM4, PM5, PP1, PP3, BP2, BP4, BA1, PS4, PS1, PS3, BS4, BP7	The NM_001754.4:c.179C>T variant that results in the Ala60Val missense change has an MAF of 0.0002950 (0.02%, 10/33902 alleles) in the Latino subpopulation of the gnomAD v2.1.1 cohort, which is between 0.00015 (0.015%) and 0.0015 (0.15%) (BS1). Transactivation assays demonstrate normal transactivation (80-115% of wt) and data from a secondary EMSA demonstrate normal DNA binding (BS3; PMID: 23817177). The variant has not been reported in the germ line of patients with familial platelet disorder with predisposition to hematologic malignancies in the literature, to the best of our knowledge. In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the Myeloid Malignancy Variant Curation Expert Panel for RUNX1: BS1, BS3.	23817177	Myeloid Malignancy VCEP	https://www.clinicalgenome.org/affiliation/50034/docs/assertion-criteria 	2021-01-11	2021-01-11	False	https://erepo.genome.network/evrepo/ui/classification/CA10014576/MONDO:0011071/008	aa5c9149-1528-4fb7-84bd-9ee7b5f8857c	p.Ala60Val	Ala	60	Val	MRIPVDASTSRRFTPPSTALSPGKMSEALPLGAPDAGAALAGKLRSGDRSMVEVLADHPGELVRTDSPNFLCSVLPTHWRCNKTLPIAFKVVALGDVPDGTLVTVMAGNDENYSAELRNATAAMKNQVARFNDLRFVGRSGRGKSFTLTITVFTNPPQVATYHRAIKITVDGPREPRRHRQKLDDQTKPGSLSFSERLSELEQLRRTAMRVSPHHPAPTPNPRASLNHSTAFNPQPQSQMQDTRQIQPSPPWSYDQSYQYLGSIASPSVHPATPISPGRASGMTTLSAELSSRLSTAPDLTAFSDPRQFPALPSISDPRMHYPGAFTYSPTPVTSGIGIGMSAMGSATRYHTYLPPPYPGSSQAQGGPFQASSPSYHLYYGASAGSYQFSMVGGERSPPRILPPCTNASTGSALLNPSLPNQSDVVEAEGSHSNSPTNMAPSARLEEAVWRPY	453	Q01196	V	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [57], 'DNA_BIND_gain_score': array([0.07437563]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [204], 'COILED_gain_score': array([0.00852776]), 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [44], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.11008799]), 'REGION_loss': [], 'REGION_gain': [115, 125, 126, 368, 369], 'REGION_gain_score': array([0.00581068, 0.00749886, 0.0063141 , 0.00100613, 0.00237668]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
221	NM_001754.4(RUNX1):c.205G>C (p.Gly69Arg)	463990	CA10014569	NM_001754.4:c.205G>C, NM_001001890.2:c.124G>C, NM_001122607.1:c.124G>C, LRG_482t1:c.205G>C, XM_005261068.3:c.169G>C, XM_005261069.3:c.205G>C, XM_011529766.1:c.205G>C, XM_011529767.1:c.166G>C, XM_011529768.1:c.166G>C, XM_011529770.1:c.205G>C, XR_937576.1:n.384G>C, XM_005261069.4:c.205G>C, XM_011529766.2:c.205G>C, XM_011529767.2:c.166G>C, XM_011529768.2:c.166G>C, XM_011529770.2:c.205G>C, XM_017028487.1:c.52G>C, XR_937576.2:n.431G>C, NM_001001890.3:c.124G>C, NM_001122607.2:c.124G>C, NM_001754.5:c.205G>C, ENST00000300305.7:c.205G>C, ENST00000344691.8:c.124G>C, ENST00000358356.9:c.124G>C, ENST00000399237.6:c.169G>C, ENST00000399240.5:c.124G>C, ENST00000437180.5:c.205G>C, ENST00000455571.5:c.166G>C, ENST00000482318.5:c.59-6276G>C, NC_000021.9:g.34886989C>G, CM000683.2:g.34886989C>G, NC_000021.8:g.36259286C>G, CM000683.1:g.36259286C>G, NC_000021.7:g.35181156C>G, NG_011402.2:g.1102723G>C, LRG_482:g.1102723G>C, NM_001754.4(RUNX1):c.205G>C (p.Gly69Arg)	RUNX1	hereditary thrombocytopenia and hematologic cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Benign	BS3, BS1	PVS1, PM6, PM2, PM1, PM4, PM5, PP1, PP3, BA1, BP2, BP4, PS4, PS3, PS1, BS4, BP7	The NM_001754.4:c.205G>C variant that results in a Gly69Arg missense change has an MAF of 0.0003133 (0.03%, 6/19148 alleles) in the East Asian subpopulation of the gnomAD v2.1.1 cohort, which is between 0.00015 (0.015%) and 0.0015 (0.15%) (BS1). Transactivation assays demonstrate normal  transactivation as wild-type and normal DNA binding (BS3; PMIDs: 23817177 & 12393679). The variant has not been reported in the germ line of patients with familial platelet disorder with predisposition to hematologic malignancies in the literature, to the best of our knowledge. In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the Myeloid Malignancy Variant Curation Expert Panel for RUNX1: BS1, BS3.	12393679, 23817177	Myeloid Malignancy VCEP	https://www.clinicalgenome.org/affiliation/50034/docs/assertion-criteria 	2021-01-11	2021-01-11	False	https://erepo.genome.network/evrepo/ui/classification/CA10014569/MONDO:0011071/008	8ea17be0-3ed0-4d8a-b328-0a6493331461	p.Gly69Arg	Gly	69	Arg	MRIPVDASTSRRFTPPSTALSPGKMSEALPLGAPDAGAALAGKLRSGDRSMVEVLADHPGELVRTDSPNFLCSVLPTHWRCNKTLPIAFKVVALGDVPDGTLVTVMAGNDENYSAELRNATAAMKNQVARFNDLRFVGRSGRGKSFTLTITVFTNPPQVATYHRAIKITVDGPREPRRHRQKLDDQTKPGSLSFSERLSELEQLRRTAMRVSPHHPAPTPNPRASLNHSTAFNPQPQSQMQDTRQIQPSPPWSYDQSYQYLGSIASPSVHPATPISPGRASGMTTLSAELSSRLSTAPDLTAFSDPRQFPALPSISDPRMHYPGAFTYSPTPVTSGIGIGMSAMGSATRYHTYLPPPYPGSSQAQGGPFQASSPSYHLYYGASAGSYQFSMVGGERSPPRILPPCTNASTGSALLNPSLPNQSDVVEAEGSHSNSPTNMAPSARLEEAVWRPY	453	Q01196	R	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [53, 54, 55, 56, 57], 'DNA_BIND_gain_score': array([0.19099909, 0.20388049, 0.23616242, 0.23171359, 0.24370271]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [114], 'REGION_gain': [368, 369], 'REGION_gain_score': array([0.00867581, 0.00882524]), 'REGION_loss_score': array([-0.00266504]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
222	NM_001754.4(RUNX1):c.952T>G (p.Ser318Ala)	415833	CA10014261	NM_001754.4:c.952T>G, NM_001001890.2:c.871T>G, LRG_482t1:c.952T>G, XM_005261068.3:c.916T>G, XM_005261069.3:c.760T>G, XM_011529766.1:c.952T>G, XM_011529767.1:c.913T>G, XM_011529768.1:c.721T>G, XR_937576.1:n.1131T>G, XM_005261069.4:c.760T>G, XM_011529766.2:c.952T>G, XM_011529767.2:c.913T>G, XM_011529768.2:c.721T>G, XM_017028487.1:c.799T>G, XR_937576.2:n.1178T>G, NM_001001890.3:c.871T>G, NM_001754.5:c.952T>G, ENST00000300305.7:c.952T>G, ENST00000344691.8:c.871T>G, ENST00000399240.5:c.679T>G, ENST00000437180.5:c.952T>G, ENST00000482318.5:c.*542T>G, NC_000021.9:g.34799316A>C, CM000683.2:g.34799316A>C, NC_000021.8:g.36171613A>C, CM000683.1:g.36171613A>C, NC_000021.7:g.35093483A>C, NG_011402.2:g.1190396T>G, LRG_482:g.1190396T>G, NM_001754.4(RUNX1):c.952T>G (p.Ser318Ala)	RUNX1	hereditary thrombocytopenia and hematologic cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Benign	BA1, BP4	PVS1, PM6, PM2, PM4, PM5, PM1, PP1, PP3, BP2, PS3, PS1, PS4, BP7, BS4, BS3, BS1	This missense variant is present in gnomAD (v2) at an allele frequency 0.6377% >0.15% with 226 out of 35438 alleles in Latino subpopulation (BA1).  Additionally, this missense variant has a REVEL score <0.15 (0.093), and SSF and MES predict either an increase in the canonical splice site score or a decrease of the canonical splice site score by no more than 10% and no putative cryptic splice sites are created (BP4).  In summary, the clinical significance of this variant is benign. ACMG/AMP criteria applied, as specified by the ClinGen Myeloid Malignancy Variant Curation Expert Panel for RUNX1: BA1 and BP4.	30478137, 23753029, 27577878, 28933735	Myeloid Malignancy VCEP	https://www.clinicalgenome.org/affiliation/50034/docs/assertion-criteria 	2021-01-11	2021-01-11	False	https://erepo.genome.network/evrepo/ui/classification/CA10014261/MONDO:0011071/008	438020c8-369d-4532-9123-8f449f2ff97f	p.Ser318Ala	Ser	318	Ala	MRIPVDASTSRRFTPPSTALSPGKMSEALPLGAPDAGAALAGKLRSGDRSMVEVLADHPGELVRTDSPNFLCSVLPTHWRCNKTLPIAFKVVALGDVPDGTLVTVMAGNDENYSAELRNATAAMKNQVARFNDLRFVGRSGRGKSFTLTITVFTNPPQVATYHRAIKITVDGPREPRRHRQKLDDQTKPGSLSFSERLSELEQLRRTAMRVSPHHPAPTPNPRASLNHSTAFNPQPQSQMQDTRQIQPSPPWSYDQSYQYLGSIASPSVHPATPISPGRASGMTTLSAELSSRLSTAPDLTAFSDPRQFPALPSISDPRMHYPGAFTYSPTPVTSGIGIGMSAMGSATRYHTYLPPPYPGSSQAQGGPFQASSPSYHLYYGASAGSYQFSMVGGERSPPRILPPCTNASTGSALLNPSLPNQSDVVEAEGSHSNSPTNMAPSARLEEAVWRPY	453	Q01196	A	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [114, 120, 165], 'REGION_gain': [], 'REGION_loss_score': array([-0.00506955, -0.00609744, -0.00660139]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
223	NM_001754.5(RUNX1):c.484A>G (p.Arg162Gly)	376022	CA16602491	NM_001754.5:c.484A>G, NC_000021.9:g.34880581T>C, CM000683.2:g.34880581T>C, NC_000021.8:g.36252878T>C, CM000683.1:g.36252878T>C, NC_000021.7:g.35174748T>C, NG_011402.2:g.1109131A>G, LRG_482:g.1109131A>G, ENST00000675419.1:c.484A>G, ENST00000300305.7:c.484A>G, ENST00000344691.8:c.403A>G, ENST00000358356.9:c.403A>G, ENST00000399237.6:c.448A>G, ENST00000399240.5:c.403A>G, ENST00000437180.5:c.484A>G, ENST00000482318.5:c.*74A>G, NM_001001890.2:c.403A>G, NM_001122607.1:c.403A>G, NM_001754.4:c.484A>G, LRG_482t1:c.484A>G, XM_005261068.3:c.448A>G, XM_005261069.3:c.484A>G, XM_011529766.1:c.484A>G, XM_011529767.1:c.445A>G, XM_011529768.1:c.445A>G, XM_011529770.1:c.484A>G, XR_937576.1:n.663A>G, XM_005261069.4:c.484A>G, XM_011529766.2:c.484A>G, XM_011529767.2:c.445A>G, XM_011529768.2:c.445A>G, XM_011529770.2:c.484A>G, XM_017028487.1:c.331A>G, XR_937576.2:n.710A>G, NM_001001890.3:c.403A>G, NM_001122607.2:c.403A>G, NM_001754.5(RUNX1):c.484A>G (p.Arg162Gly)	RUNX1	hereditary thrombocytopenia and hematologic cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Pathogenic	PM5_Supporting, PM1, PP3, PP1, PS3_Moderate, PM2_Supporting, PS4_Supporting	PM6, PVS1, PM4, PM3, PP2, PP4, BS2, BP1, BP4, BP3, BP2, BA1, PS2, PS1, BS1, BS4, BS3, BP7, BP5	The c.484A>G variant in RUNX1 is a missense variant predicted to cause substitution of arginine by glycine at amino acid 162 (p.R162G), which is a residue that directly contacts DNA (PMID: 11276260, 12377125, 12393679, 12807882, 19808697, 28231333) and is considered a hotspot residue (PMID: 31648317, 27294619, 23958918), especially from a somatic perspective (PMID: 32208489) (PM1). This variant is absent from gnomAD v2 and v3 (PM2_Supporting), and has been reported in a proband meeting RUNX1-phenotypic criteria: history of bruising, menorrhagia, anemia, and a platelet defect with atypical platelet function tests, abnormal electron microscopy study, and atypical macrophages on bone marrow biopsy (PS4_Supporting; SCV001375396.1 and National Human Genome Research Institute). In addition, her older son (non-carrier) is unaffected, her younger son (carrier) has a history of thrombocytopenia (easy bleeding and bruising), frequent epistaxis, petechiae at 9 months, and an abnormal platelet electron microscopy study, and her mother (carrier) was diagnosed with AML at 45 (BMT done) and has a history of easy bleeding (PP1; National Human Genome Research Institute); finally, there is a supportive family history of AML in deceased relatives. Note that all other reports of the variant are not clearly germline (PMID: 19808697, 22689681, 24523240, 24659740, 25592059, 26273060, 27220669, 27534895, 28659335, 30373888, 31649132, 32045476, 32208489). Functionally, the variant demonstrates reduced DNA-binding and CBFβ-binding (PMID: 17290219), as well as impaired erythropoiesis (PMID: 17234761, 21725049 (PS3_Moderate), which is in line with computational evidence (REVEL score of 0.885 ≥ 0.88 threshold; PP3). In summary, this variant meets criteria to be classified as pathogenic. ACMG/AMP criteria applied, as specified by the ClinGen Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PS3_Moderate, PS4_Supporting, PM1, PM2_Supporting, PP1, and PP3.	19808697, 12377125, 28231333, 12807882, 12393679, 11276260, 27294619	Myeloid Malignancy VCEP	https://www.clinicalgenome.org/affiliation/50034/docs/assertion-criteria 	2024-03-26	2024-03-26	False	https://erepo.genome.network/evrepo/ui/classification/CA16602491/MONDO:0011071/008	2912edeb-f11c-4523-87b7-fb8694197de1	p.Arg162Gly	Arg	162	Gly	MRIPVDASTSRRFTPPSTALSPGKMSEALPLGAPDAGAALAGKLRSGDRSMVEVLADHPGELVRTDSPNFLCSVLPTHWRCNKTLPIAFKVVALGDVPDGTLVTVMAGNDENYSAELRNATAAMKNQVARFNDLRFVGRSGRGKSFTLTITVFTNPPQVATYHRAIKITVDGPREPRRHRQKLDDQTKPGSLSFSERLSELEQLRRTAMRVSPHHPAPTPNPRASLNHSTAFNPQPQSQMQDTRQIQPSPPWSYDQSYQYLGSIASPSVHPATPISPGRASGMTTLSAELSSRLSTAPDLTAFSDPRQFPALPSISDPRMHYPGAFTYSPTPVTSGIGIGMSAMGSATRYHTYLPPPYPGSSQAQGGPFQASSPSYHLYYGASAGSYQFSMVGGERSPPRILPPCTNASTGSALLNPSLPNQSDVVEAEGSHSNSPTNMAPSARLEEAVWRPY	453	Q01196	G	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [177], 'DNA_BIND_gain': [54, 56, 57], 'DNA_BIND_gain_score': array([0.082497  , 0.11039078, 0.08536178]), 'DNA_BIND_loss_score': array([-0.05884463]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [69, 85, 130], 'STRAND_gain': [50, 51, 52, 53, 107, 117, 158], 'STRAND_gain_score': array([0.2062735 , 0.22907662, 0.23350137, 0.24970239, 0.06394523,
       0.05696428, 0.17009449]), 'STRAND_loss_score': array([-0.22120464, -0.10685992, -0.03821152]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [204], 'COILED_gain_score': array([0.01199108]), 'COMPBIAS_loss': [], 'COMPBIAS_gain': [170, 188, 189], 'COMPBIAS_gain_score': array([0.18887556, 0.06988591, 0.04428405]), 'DOMAIN_loss': [43, 44, 179], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.26269239, -0.18449044, -0.12235713]), 'REGION_loss': [111, 114, 118, 119, 120, 121, 122], 'REGION_gain': [32, 159, 160, 161, 162, 368, 369], 'REGION_gain_score': array([0.01540124, 0.03898603, 0.0213452 , 0.07988811, 0.02538812,
       0.01034933, 0.00990659]), 'REGION_loss_score': array([-0.02793038, -0.02404988, -0.02952003, -0.02294457, -0.02189028,
       -0.02532434, -0.0314393 ]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
224	NM_000212.2(ITGB3):c.506G>A (p.Arg169Gln)	13557	CA123232	NM_000212.2:c.506G>A, NC_000017.11:g.47284587G>A, CM000679.2:g.47284587G>A, NC_000017.10:g.45361953G>A, CM000679.1:g.45361953G>A, NC_000017.9:g.42716952G>A, NG_008332.2:g.35746G>A, LRG_481:g.35746G>A, LRG_481t1:c.506G>A, NM_000212.3:c.506G>A, ENST00000559488.5:c.506G>A, ENST00000560629.1:n.471G>A, ENST00000571680.1:c.506G>A, NM_000212.2(ITGB3):c.506G>A (p.Arg169Gln)	ITGB3	Glanzmann's thrombasthenia	MONDO:0010119	Autosomal recessive inheritance	Benign	BA1, BS3	BP4, PM5, BS2	The c.506G>A (p.Arg169Gln) missense variant has been reported in the literature many times as the Penb antigenic epitope. However, this polymorphism has not been reported in association with Glanzmann thrombasthenia. It is present in a Latino control population at an allele frequency of 0.01439 and functional studies in CHO cells have shown no deleterious effect on surface expression or fibrinogen binding. In summary, this variant meets criteria to be classified as benign for GT. GT-specific criteria applied: BA1, BS3.	9787162, 1430225	Platelet Disorders VCEP	https://clinicalgenome.org/docs/clingen-platelet-disorders-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-2.1/	2019-08-07	2021-01-28	False	https://erepo.genome.network/evrepo/ui/classification/CA123232/MONDO:0010119/011	446275dc-0238-4035-8952-0d379747c458	p.Arg169Gln	Arg	169	Gln	MRARPRPRPLWATVLALGALAGVGVGGPNICTTRGVSSCQQCLAVSPMCAWCSDEALPLGSPRCDLKENLLKDNCAPESIEFPVSEARVLEDRPLSDKGSGDSSQVTQVSPQRIALRLRPDDSKNFSIQVRQVEDYPVDIYYLMDLSYSMKDDLWSIQNLGTKLATQMRKLTSNLRIGFGAFVDKPVSPYMYISPPEALENPCYDMKTTCLPMFGYKHVLTLTDQVTRFNEEVKKQSVSRNRDAPEGGFDAIMQATVCDEKIGWRNDASHLLVFTTDAKTHIALDGRLAGIVQPNDGQCHVGSDNHYSASTTMDYPSLGLMTEKLSQKNINLIFAVTENVVNLYQNYSELIPGTTVGVLSMDSSNVLQLIVDAYGKIRSKVELEVRDLPEELSLSFNATCLNNEVIPGLKSCMGLKIGDTVSFSIEAKVRGCPQEKEKSFTIKPVGFKDSLIVQVTFDCDCACQAQAEPNSHRCNNGNGTFECGVCRCGPGWLGSQCECSEEDYRPSQQDECSPREGQPVCSQRGECLCGQCVCHSSDFGKITGKYCECDDFSCVRYKGEMCSGHGQCSCGDCLCDSDWTGYYCNCTTRTDTCMSSNGLLCSGRGKCECGSCVCIQPGSYGDTCEKCPTCPDACTFKKECVECKKFDRGALHDENTCNRYCRDEIESVKELKDTGKDAVNCTYKNEDDCVVRFQYYEDSSGKSILYVVEEPECPKGPDILVVLLSVMGAILLIGLAALLIWKLLITIHDRKEFAKFEEERARAKWDTANNPLYKEATSTFTNITYRGT	788	P05106	Q	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [276], 'BINDING_gain': [], 'BINDING_loss_score': array([-0.00627273]), 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [174], 'STRAND_gain_score': array([0.00459439]), 'HELIX_loss': [], 'HELIX_gain': [150], 'HELIX_gain_score': array([0.01845127]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
225	NM_000212.2(ITGB3):c.40G>A (p.Val14Met)	235258	CA8622831	NM_000212.2:c.40G>A, LRG_481t1:c.40G>A, NM_000212.3:c.40G>A, ENST00000559488.5:c.40G>A, ENST00000560629.1:n.5G>A, ENST00000571680.1:c.40G>A, NC_000017.11:g.47253901G>A, CM000679.2:g.47253901G>A, NC_000017.10:g.45331267G>A, CM000679.1:g.45331267G>A, NC_000017.9:g.42686266G>A, NG_008332.2:g.5060G>A, LRG_481:g.5060G>A, NM_000212.2(ITGB3):c.40G>A (p.Val14Met)	ITGB3	Glanzmann's thrombasthenia	MONDO:0010119	Autosomal recessive inheritance	Benign	BA1, BP4		The c.40G>A; p.Val14Met missense variant has not been reported in the literature to our knowledge. It is present in an African population at an allele frequency of 0.03606. Computational evidence suggests no impact on the gene or gene product with a REVEL score of 0.115. In summary, this variant meets criteria  to be classified as benign for GT. GT-specific criteria applied: BA1 and BP4.		Platelet Disorders VCEP	https://clinicalgenome.org/docs/clingen-platelet-disorders-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-2.1/	2020-06-04	2021-01-28	False	https://erepo.genome.network/evrepo/ui/classification/CA8622831/MONDO:0010119/011	8be7bf22-cde0-4d3e-b643-a4adf46f69a3	p.Val14Met	Val	14	Met	MRARPRPRPLWATVLALGALAGVGVGGPNICTTRGVSSCQQCLAVSPMCAWCSDEALPLGSPRCDLKENLLKDNCAPESIEFPVSEARVLEDRPLSDKGSGDSSQVTQVSPQRIALRLRPDDSKNFSIQVRQVEDYPVDIYYLMDLSYSMKDDLWSIQNLGTKLATQMRKLTSNLRIGFGAFVDKPVSPYMYISPPEALENPCYDMKTTCLPMFGYKHVLTLTDQVTRFNEEVKKQSVSRNRDAPEGGFDAIMQATVCDEKIGWRNDASHLLVFTTDAKTHIALDGRLAGIVQPNDGQCHVGSDNHYSASTTMDYPSLGLMTEKLSQKNINLIFAVTENVVNLYQNYSELIPGTTVGVLSMDSSNVLQLIVDAYGKIRSKVELEVRDLPEELSLSFNATCLNNEVIPGLKSCMGLKIGDTVSFSIEAKVRGCPQEKEKSFTIKPVGFKDSLIVQVTFDCDCACQAQAEPNSHRCNNGNGTFECGVCRCGPGWLGSQCECSEEDYRPSQQDECSPREGQPVCSQRGECLCGQCVCHSSDFGKITGKYCECDDFSCVRYKGEMCSGHGQCSCGDCLCDSDWTGYYCNCTTRTDTCMSSNGLLCSGRGKCECGSCVCIQPGSYGDTCEKCPTCPDACTFKKECVECKKFDRGALHDENTCNRYCRDEIESVKELKDTGKDAVNCTYKNEDDCVVRFQYYEDSSGKSILYVVEEPECPKGPDILVVLLSVMGAILLIGLAALLIWKLLITIHDRKEFAKFEEERARAKWDTANNPLYKEATSTFTNITYRGT	788	P05106	M	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [32], 'TRANSIT_gain_score': array([0.0175308]), 'STRAND_loss': [], 'STRAND_gain': [174], 'STRAND_gain_score': array([0.00534248]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [642], 'REPEAT_gain_score': array([0.00478613]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
226	NM_000419.4(ITGA2B):c.641T>C (p.Leu214Pro)	2901	CA115848	NM_000419.4:c.641T>C, NM_000419.3:c.641T>C, LRG_479t1:c.641T>C, XM_011524749.1:c.641T>C, XM_011524750.1:c.641T>C, NM_000419.5:c.641T>C, ENST00000262407.5:c.641T>C, ENST00000589645.5:n.92T>C, ENST00000591990.5:n.3T>C, ENST00000592075.5:n.10T>C, ENST00000592226.5:n.10T>C, ENST00000592253.5:n.149T>C, ENST00000592944.1:n.323T>C, NC_000017.11:g.44385193A>G, CM000679.2:g.44385193A>G, NC_000017.10:g.42462561A>G, CM000679.1:g.42462561A>G, NC_000017.9:g.39818087A>G, NG_008331.1:g.9313T>C, LRG_479:g.9313T>C, NM_000419.4(ITGA2B):c.641T>C (p.Leu214Pro)	ITGA2B	Glanzmann's thrombasthenia	MONDO:0010119	Autosomal recessive inheritance	Pathogenic	PS3, PM3, PP4_Moderate, PP3, PM2_Supporting		The NM_000419.4:c.641T>C variant that results in the Leu214Pro amino acid change is reported in five homozygous individuals in the literature (PMID: 19691478, 9473221, 21113249). It is absent in population databases and is predicted damaging by in-silico tools. Experimental evidence shows moderate levels of surface expression of the GPIIb-IIIa complex, but impaired fibrinogen and PAC-1 binding. In summary, based on available evidence at this time, the Leu214Pro variant is classified as pathogenic. GT-specific criteria applied: PS3, PM2_supporting, PM3, PP3, PP4_moderate.	9473221, 27607598, 27696190, 19691478, 19691478, 9473221, 21113249	Platelet Disorders VCEP	https://clinicalgenome.org/docs/clingen-platelet-disorders-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-2.1/	2020-09-04	2021-01-28	False	https://erepo.genome.network/evrepo/ui/classification/CA115848/MONDO:0010119/011	99e33fc5-37e3-4481-a9c5-52cd04f26ea6	p.Leu214Pro	Leu	214	Pro	MARALCPLQALWLLEWVLLLLGPCAAPPAWALNLDPVQLTFYAGPNGSQFGFSLDFHKDSHGRVAIVVGAPRTLGPSQEETGGVFLCPWRAEGGQCPSLLFDLRDETRNVGSQTLQTFKARQGLGASVVSWSDVIVACAPWQHWNVLEKTEEAEKTPVGSCFLAQPESGRRAEYSPCRGNTLSRIYVENDFSWDKRYCEAGFSSVVTQAGELVLGAPGGYYFLGLLAQAPVADIFSSYRPGILLWHVSSQSLSFDSSNPEYFDGYWGYSVAVGEFDGDLNTTEYVVGAPTWSWTLGAVEILDSYYQRLHRLRGEQMASYFGHSVAVTDVNGDGRHDLLVGAPLYMESRADRKLAEVGRVYLFLQPRGPHALGAPSLLLTGTQLYGRFGSAIAPLGDLDRDGYNDIAVAAPYGGPSGRGQVLVFLGQSEGLRSRPSQVLDSPFPTGSAFGFSLRGAVDIDDNGYPDLIVGAYGANQVAVYRAQPVVKASVQLLVQDSLNPAVKSCVLPQTKTPVSCFNIQMCVGATGHNIPQKLSLNAELQLDRQKPRQGRRVLLLGSQQAGTTLNLDLGGKHSPICHTTMAFLRDEADFRDKLSPIVLSLNVSLPPTEAGMAPAVVLHGDTHVQEQTRIVLDCGEDDVCVPQLQLTASVTGSPLLVGADNVLELQMDAANEGEGAYEAELAVHLPQGAHYMRALSNVEGFERLICNQKKENETRVVLCELGNPMKKNAQIGIAMLVSVGNLEEAGESVSFQLQIRSKNSQNPNSKIVLLDVPVRAEAQVELRGNSFPASLVVAAEEGEREQNSLDSWGPKVEHTYELHNNGPGTVNGLHLSIHLPGQSQPSDLLYILDIQPQGGLQCFPQPPVNPLKVDWGLPIPSPSPIHPAHHKRDRRQIFLPEPEQPSRLQDPVLVSCDSAPCTVVQCDLQEMARGQRAMVTVLAFLWLPSLYQRPLDQFVLQSHAWFNVSSLPYAVPPLSLPRGEAQVWTQLLRALEERAIPIWWVLVGVLGGLLLLTILVLAMWKVGFFKRNRPPLEEDDEEGE	1039	P08514	P	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [453], 'STRAND_gain': [51, 182, 220, 221, 222, 235], 'STRAND_gain_score': array([0.01604718, 0.12887222, 0.36926419, 0.33396769, 0.25038964,
       0.15796918]), 'STRAND_loss_score': array([-0.01108503]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [785, 874], 'DOMAIN_gain': [422, 479, 483, 563], 'DOMAIN_gain_score': array([0.013017  , 0.02865916, 0.03088588, 0.01528764]), 'DOMAIN_loss_score': array([-0.00390792, -0.00410604]), 'REGION_loss': [], 'REGION_gain': [870], 'REGION_gain_score': array([0.00866401]), 'REPEAT_loss': [132, 199, 200, 201, 202, 203, 204, 205, 210, 211, 212, 213, 214, 215, 216, 217, 280], 'REPEAT_gain': [79], 'REPEAT_gain_score': array([0.01127994]), 'REPEAT_loss_score': array([-0.00811744, -0.21429712, -0.1583457 , -0.19106758, -0.21901363,
       -0.14881158, -0.1275112 , -0.10145897, -0.28033906, -0.19870216,
       -0.17875379, -0.19357002, -0.25719017, -0.28262395, -0.25482756,
       -0.26128638, -0.0188297 ]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
227	NM_000419.4(ITGA2B):c.2333A>C (p.Gln778Pro)	225393	CA290947544	NM_000419.4:c.2333A>C, NC_000017.11:g.44376323T>G, CM000679.2:g.44376323T>G, NC_000017.10:g.42453691T>G, CM000679.1:g.42453691T>G, NC_000017.9:g.39809217T>G, NG_008331.1:g.18183A>C, LRG_479:g.18183A>C, NM_000419.3:c.2333A>C, LRG_479t1:c.2333A>C, XM_011524749.1:c.2333A>C, XM_011524750.1:c.2333A>C, NM_000419.5:c.2333A>C, ENST00000262407.5:c.2333A>C, ENST00000592462.5:n.1128A>C, NM_000419.4(ITGA2B):c.2333A>C (p.Gln778Pro)	ITGA2B	Glanzmann's thrombasthenia	MONDO:0010119	Autosomal recessive inheritance	Pathogenic	PM3_Strong, PP4_Strong, PM2_Supporting	PS3, PP3	The NM_000419.4:c.2333A>C variant that results in the p.Gln778Pro amino acid change is reported in at least 5 homozygous and 6 compound heterozygous probands in the literature (PMID: 9722314, 22190468, 9763559, 29675921, 32237906). At least 5 variants in trans with Gln778Pro have been curated and evaluated for PM3 scoring. The variant is reported at frequency <0.0001 in the combined gnomAD v3 and v2.1.1 datasets. In summary, based on the available evidence at this time, the Gln778Pro variant is classified as pathogenic. GT-specific criteria applied: PM2_Supporting, PM3_Strong, PP4_Strong.	29675921, 9763559, 32237906, 12181054, 22190468, 9763559, 9722314, 9763559, 20020534, 9722314, 12181054, 22190468	Platelet Disorders VCEP	https://clinicalgenome.org/docs/clingen-platelet-disorders-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-2.1/	2020-09-08	2021-01-28	False	https://erepo.genome.network/evrepo/ui/classification/CA290947544/MONDO:0010119/011	c277c257-17ca-43c5-bfb7-913ae9e84528	p.Gln778Pro	Gln	778	Pro	MARALCPLQALWLLEWVLLLLGPCAAPPAWALNLDPVQLTFYAGPNGSQFGFSLDFHKDSHGRVAIVVGAPRTLGPSQEETGGVFLCPWRAEGGQCPSLLFDLRDETRNVGSQTLQTFKARQGLGASVVSWSDVIVACAPWQHWNVLEKTEEAEKTPVGSCFLAQPESGRRAEYSPCRGNTLSRIYVENDFSWDKRYCEAGFSSVVTQAGELVLGAPGGYYFLGLLAQAPVADIFSSYRPGILLWHVSSQSLSFDSSNPEYFDGYWGYSVAVGEFDGDLNTTEYVVGAPTWSWTLGAVEILDSYYQRLHRLRGEQMASYFGHSVAVTDVNGDGRHDLLVGAPLYMESRADRKLAEVGRVYLFLQPRGPHALGAPSLLLTGTQLYGRFGSAIAPLGDLDRDGYNDIAVAAPYGGPSGRGQVLVFLGQSEGLRSRPSQVLDSPFPTGSAFGFSLRGAVDIDDNGYPDLIVGAYGANQVAVYRAQPVVKASVQLLVQDSLNPAVKSCVLPQTKTPVSCFNIQMCVGATGHNIPQKLSLNAELQLDRQKPRQGRRVLLLGSQQAGTTLNLDLGGKHSPICHTTMAFLRDEADFRDKLSPIVLSLNVSLPPTEAGMAPAVVLHGDTHVQEQTRIVLDCGEDDVCVPQLQLTASVTGSPLLVGADNVLELQMDAANEGEGAYEAELAVHLPQGAHYMRALSNVEGFERLICNQKKENETRVVLCELGNPMKKNAQIGIAMLVSVGNLEEAGESVSFQLQIRSKNSQNPNSKIVLLDVPVRAEAQVELRGNSFPASLVVAAEEGEREQNSLDSWGPKVEHTYELHNNGPGTVNGLHLSIHLPGQSQPSDLLYILDIQPQGGLQCFPQPPVNPLKVDWGLPIPSPSPIHPAHHKRDRRQIFLPEPEQPSRLQDPVLVSCDSAPCTVVQCDLQEMARGQRAMVTVLAFLWLPSLYQRPLDQFVLQSHAWFNVSSLPYAVPPLSLPRGEAQVWTQLLRALEERAIPIWWVLVGVLGGLLLLTILVLAMWKVGFFKRNRPPLEEDDEEGE	1039	P08514	P	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [842], 'STRAND_gain_score': array([0.03878921]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [893], 'COMPBIAS_gain': [], 'COMPBIAS_loss_score': array([-0.01238316]), 'DOMAIN_loss': [], 'DOMAIN_gain': [422, 483, 563, 600, 603, 875], 'DOMAIN_gain_score': array([0.00627613, 0.00863379, 0.0136801 , 0.02182108, 0.03380507,
       0.04931378]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
228	NM_000212.2(ITGB3):c.433G>T (p.Asp145Tyr)	13554	CA123226	NM_000212.2:c.433G>T, NC_000017.11:g.47284514G>T, CM000679.2:g.47284514G>T, NC_000017.10:g.45361880G>T, CM000679.1:g.45361880G>T, NC_000017.9:g.42716879G>T, NG_008332.2:g.35673G>T, LRG_481:g.35673G>T, LRG_481t1:c.433G>T, NM_000212.3:c.433G>T, ENST00000559488.5:c.433G>T, ENST00000560629.1:n.398G>T, ENST00000571680.1:c.433G>T, NM_000212.2(ITGB3):c.433G>T (p.Asp145Tyr)	ITGB3	Glanzmann's thrombasthenia	MONDO:0010119	Autosomal recessive inheritance	Pathogenic	PS3, PM3_Supporting, PP4_Moderate, PP1, PP3, PM2_Supporting	PM5	The NM_000212.2(ITGB3):c.433G>T (p.Asp145Tyr) is a missense variant that is expressed normally on the platelet surface, but lacks the function of ligand binding (PMID: 2392682, PMID:15583747). It has been reported in 2 siblings with variant GT, in the homozygous state (PMIDs: 2428841, 2392682, 7520434) and a compound heterozygote (with Met150Val;PMID: 15583747). It is absent from population databases and has a REVEL score of 0.972 (threshold: >0.7).  In summary, based on the available evidence at this time, the variant is classified as Pathogenic. GT-specific criteria applied: PS3, PM2_Supporting, PP1, PP3, PP4_Moderate, PM3_Supporting.	2392682, 15583747, 2428841, 15583747, 2392682, 2428841, 30828542, 2428841	Platelet Disorders VCEP	https://clinicalgenome.org/docs/clingen-platelet-disorders-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-2.1/	2020-09-06	2021-01-28	False	https://erepo.genome.network/evrepo/ui/classification/CA123226/MONDO:0010119/011	5a88ad57-bb3d-49ef-8dd3-2e7628ef1a81	p.Asp145Tyr	Asp	145	Tyr	MRARPRPRPLWATVLALGALAGVGVGGPNICTTRGVSSCQQCLAVSPMCAWCSDEALPLGSPRCDLKENLLKDNCAPESIEFPVSEARVLEDRPLSDKGSGDSSQVTQVSPQRIALRLRPDDSKNFSIQVRQVEDYPVDIYYLMDLSYSMKDDLWSIQNLGTKLATQMRKLTSNLRIGFGAFVDKPVSPYMYISPPEALENPCYDMKTTCLPMFGYKHVLTLTDQVTRFNEEVKKQSVSRNRDAPEGGFDAIMQATVCDEKIGWRNDASHLLVFTTDAKTHIALDGRLAGIVQPNDGQCHVGSDNHYSASTTMDYPSLGLMTEKLSQKNINLIFAVTENVVNLYQNYSELIPGTTVGVLSMDSSNVLQLIVDAYGKIRSKVELEVRDLPEELSLSFNATCLNNEVIPGLKSCMGLKIGDTVSFSIEAKVRGCPQEKEKSFTIKPVGFKDSLIVQVTFDCDCACQAQAEPNSHRCNNGNGTFECGVCRCGPGWLGSQCECSEEDYRPSQQDECSPREGQPVCSQRGECLCGQCVCHSSDFGKITGKYCECDDFSCVRYKGEMCSGHGQCSCGDCLCDSDWTGYYCNCTTRTDTCMSSNGLLCSGRGKCECGSCVCIQPGSYGDTCEKCPTCPDACTFKKECVECKKFDRGALHDENTCNRYCRDEIESVKELKDTGKDAVNCTYKNEDDCVVRFQYYEDSSGKSILYVVEEPECPKGPDILVVLLSVMGAILLIGLAALLIWKLLITIHDRKEFAKFEEERARAKWDTANNPLYKEATSTFTNITYRGT	788	P05106	Y	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [151, 152, 276], 'BINDING_gain': [147, 249], 'BINDING_gain_score': array([0.54236871, 0.05080795]), 'BINDING_loss_score': array([-0.09763384, -0.18817675, -0.04515588]), 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [30], 'TRANSIT_gain': [], 'TRANSIT_loss_score': array([-0.03247863]), 'STRAND_loss': [115, 354, 404], 'STRAND_gain': [131], 'STRAND_gain_score': array([0.027924]), 'STRAND_loss_score': array([-0.08718485, -0.04267633, -0.01419103]), 'HELIX_loss': [371], 'HELIX_gain': [150], 'HELIX_gain_score': array([0.06581306]), 'HELIX_loss_score': array([-0.1154744]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [76], 'DOMAIN_gain_score': array([0.06675565]), 'REGION_loss': [103, 104, 105], 'REGION_gain': [], 'REGION_loss_score': array([-0.03329849, -0.04852581, -0.0391475 ]), 'REPEAT_loss': [146], 'REPEAT_gain': [642], 'REPEAT_gain_score': array([0.01516712]), 'REPEAT_loss_score': array([-0.23091978]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
229	NM_000419.4(ITGA2B):c.2944G>A (p.Val982Met)	381747	CA16608466	NM_000419.4:c.2944G>A, NC_000017.11:g.44374470C>T, CM000679.2:g.44374470C>T, NC_000017.10:g.42451838C>T, CM000679.1:g.42451838C>T, NC_000017.9:g.39807364C>T, NG_008331.1:g.20036G>A, LRG_479:g.20036G>A, NM_000419.3:c.2944G>A, LRG_479t1:c.2944G>A, XM_011524749.1:c.2842G>A, XM_011524750.1:c.2943+189G>A, NM_000419.5:c.2944G>A, ENST00000262407.5:c.2944G>A, ENST00000587295.5:n.253+1363G>A, ENST00000588098.1:n.37+189G>A, ENST00000592462.5:n.2643G>A, NM_000419.4(ITGA2B):c.2944G>A (p.Val982Met)	ITGA2B	Glanzmann's thrombasthenia	MONDO:0010119	Autosomal recessive inheritance	Pathogenic	PS2, PP4_Moderate, PM3, PP3, PM2_Supporting, PS3_Moderate		The c.2944G>A (p.Val982Met) missense variant has been reported in at least three compound heterozygous probands with a phenotype highly specific to GT (PMID: 28983057, 25539746,15099289); one of which was a de novo occurrence (PMID: 25539746). It is found at an extremely low frequency (MAF of 0.00006486 in the non-Finnish European population from gnomAD). This variant is predicted by HSF and MaxEntScan to result in a broken splice donor site. Flow cytometry found that this variant had a marked deleterious effect on αIIbβ3 expression (~25% of control levels) in COS-7 cells  (PMID: 15099289). In summary, this variant meets criteria to be classified as Pathogenic for GT. GT-specific criteria applied: PS2, PM3, PM2_supporting, PS3_Moderate, PP3, and PP4_moderate.	25539746, 15099289, 25539746, 28983057, 15099289, 25539746, 28983057, 15099289	Platelet Disorders VCEP	https://clinicalgenome.org/docs/clingen-platelet-disorders-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-2.1/	2020-09-06	2021-01-28	False	https://erepo.genome.network/evrepo/ui/classification/CA16608466/MONDO:0010119/011	7cd349a6-46e9-4a53-84cf-0c3313a6f570	p.Val982Met	Val	982	Met	MARALCPLQALWLLEWVLLLLGPCAAPPAWALNLDPVQLTFYAGPNGSQFGFSLDFHKDSHGRVAIVVGAPRTLGPSQEETGGVFLCPWRAEGGQCPSLLFDLRDETRNVGSQTLQTFKARQGLGASVVSWSDVIVACAPWQHWNVLEKTEEAEKTPVGSCFLAQPESGRRAEYSPCRGNTLSRIYVENDFSWDKRYCEAGFSSVVTQAGELVLGAPGGYYFLGLLAQAPVADIFSSYRPGILLWHVSSQSLSFDSSNPEYFDGYWGYSVAVGEFDGDLNTTEYVVGAPTWSWTLGAVEILDSYYQRLHRLRGEQMASYFGHSVAVTDVNGDGRHDLLVGAPLYMESRADRKLAEVGRVYLFLQPRGPHALGAPSLLLTGTQLYGRFGSAIAPLGDLDRDGYNDIAVAAPYGGPSGRGQVLVFLGQSEGLRSRPSQVLDSPFPTGSAFGFSLRGAVDIDDNGYPDLIVGAYGANQVAVYRAQPVVKASVQLLVQDSLNPAVKSCVLPQTKTPVSCFNIQMCVGATGHNIPQKLSLNAELQLDRQKPRQGRRVLLLGSQQAGTTLNLDLGGKHSPICHTTMAFLRDEADFRDKLSPIVLSLNVSLPPTEAGMAPAVVLHGDTHVQEQTRIVLDCGEDDVCVPQLQLTASVTGSPLLVGADNVLELQMDAANEGEGAYEAELAVHLPQGAHYMRALSNVEGFERLICNQKKENETRVVLCELGNPMKKNAQIGIAMLVSVGNLEEAGESVSFQLQIRSKNSQNPNSKIVLLDVPVRAEAQVELRGNSFPASLVVAAEEGEREQNSLDSWGPKVEHTYELHNNGPGTVNGLHLSIHLPGQSQPSDLLYILDIQPQGGLQCFPQPPVNPLKVDWGLPIPSPSPIHPAHHKRDRRQIFLPEPEQPSRLQDPVLVSCDSAPCTVVQCDLQEMARGQRAMVTVLAFLWLPSLYQRPLDQFVLQSHAWFNVSSLPYAVPPLSLPRGEAQVWTQLLRALEERAIPIWWVLVGVLGGLLLLTILVLAMWKVGFFKRNRPPLEEDDEEGE	1039	P08514	M	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [892, 893], 'COMPBIAS_gain': [], 'COMPBIAS_loss_score': array([-0.02101934, -0.02136147]), 'DOMAIN_loss': [], 'DOMAIN_gain': [483], 'DOMAIN_gain_score': array([0.00560778]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
230	NM_000419.4(ITGA2B):c.1234G>A (p.Gly412Arg)	381748	CA8603182	NM_000419.4:c.1234G>A, NC_000017.11:g.44381038C>T, CM000679.2:g.44381038C>T, NC_000017.10:g.42458406C>T, CM000679.1:g.42458406C>T, NC_000017.9:g.39813932C>T, NG_008331.1:g.13468G>A, LRG_479:g.13468G>A, ENST00000262407.6:c.1234G>A, ENST00000648408.1:n.665G>A, ENST00000262407.5:c.1234G>A, ENST00000592226.5:n.474G>A, ENST00000592462.5:n.29G>A, NM_000419.3:c.1234G>A, LRG_479t1:c.1234G>A, XM_011524749.1:c.1234G>A, XM_011524750.1:c.1234G>A, NM_000419.5:c.1234G>A, NM_000419.5(ITGA2B):c.1234G>A (p.Gly412Arg), NM_000419.4(ITGA2B):c.1234G>A (p.Gly412Arg)	ITGA2B	Glanzmann thrombasthenia	MONDO:0010119	Autosomal recessive inheritance	Pathogenic	PM3_Strong, PP4_Strong, PM2_Supporting	PP3	The c.1234G>A (p.Gly412Arg) variant has been reported  in at least six GT patients in the literature; at least 4 of them (from PMIDs: 29675921, 24418945, 19691478, 21557682) with a phenotype highly specific to GT. This includes 2 homozygotes and 4 compound heterozygotes. The variant is found at an extremely low frequency, with an the overall allele frequency on gnomAD is 0.00010 (5/49256)  alleles in the Latino population). In summary, this variant meets criteria to be classified as Pathogenic for GT. GT-specific criteria applied: PM3_Strong, PM2_Supporting, and PP4_Strong.	29675921, 19691478, 11798398, 27607598, 24418945, 21557682, 29675921, 19691478, 11798398, 27607598, 24418945, 21557682	Platelet Disorders VCEP	https://clinicalgenome.org/docs/clingen-platelet-disorders-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-2.1/	2021-12-23	2021-12-23	False	https://erepo.genome.network/evrepo/ui/classification/CA8603182/MONDO:0010119/011	d5a47ada-b724-415e-a81e-5d8e8e2fa322	p.Gly412Arg	Gly	412	Arg	MARALCPLQALWLLEWVLLLLGPCAAPPAWALNLDPVQLTFYAGPNGSQFGFSLDFHKDSHGRVAIVVGAPRTLGPSQEETGGVFLCPWRAEGGQCPSLLFDLRDETRNVGSQTLQTFKARQGLGASVVSWSDVIVACAPWQHWNVLEKTEEAEKTPVGSCFLAQPESGRRAEYSPCRGNTLSRIYVENDFSWDKRYCEAGFSSVVTQAGELVLGAPGGYYFLGLLAQAPVADIFSSYRPGILLWHVSSQSLSFDSSNPEYFDGYWGYSVAVGEFDGDLNTTEYVVGAPTWSWTLGAVEILDSYYQRLHRLRGEQMASYFGHSVAVTDVNGDGRHDLLVGAPLYMESRADRKLAEVGRVYLFLQPRGPHALGAPSLLLTGTQLYGRFGSAIAPLGDLDRDGYNDIAVAAPYGGPSGRGQVLVFLGQSEGLRSRPSQVLDSPFPTGSAFGFSLRGAVDIDDNGYPDLIVGAYGANQVAVYRAQPVVKASVQLLVQDSLNPAVKSCVLPQTKTPVSCFNIQMCVGATGHNIPQKLSLNAELQLDRQKPRQGRRVLLLGSQQAGTTLNLDLGGKHSPICHTTMAFLRDEADFRDKLSPIVLSLNVSLPPTEAGMAPAVVLHGDTHVQEQTRIVLDCGEDDVCVPQLQLTASVTGSPLLVGADNVLELQMDAANEGEGAYEAELAVHLPQGAHYMRALSNVEGFERLICNQKKENETRVVLCELGNPMKKNAQIGIAMLVSVGNLEEAGESVSFQLQIRSKNSQNPNSKIVLLDVPVRAEAQVELRGNSFPASLVVAAEEGEREQNSLDSWGPKVEHTYELHNNGPGTVNGLHLSIHLPGQSQPSDLLYILDIQPQGGLQCFPQPPVNPLKVDWGLPIPSPSPIHPAHHKRDRRQIFLPEPEQPSRLQDPVLVSCDSAPCTVVQCDLQEMARGQRAMVTVLAFLWLPSLYQRPLDQFVLQSHAWFNVSSLPYAVPPLSLPRGEAQVWTQLLRALEERAIPIWWVLVGVLGGLLLLTILVLAMWKVGFFKRNRPPLEEDDEEGE	1039	P08514	R	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [450, 453, 910], 'STRAND_gain': [418], 'STRAND_gain_score': array([0.01637191]), 'STRAND_loss_score': array([-0.00857192, -0.01485151, -0.00257385]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [893], 'COMPBIAS_gain': [], 'COMPBIAS_loss_score': array([-0.00270021]), 'DOMAIN_loss': [410, 554], 'DOMAIN_gain': [483], 'DOMAIN_gain_score': array([0.0228253]), 'DOMAIN_loss_score': array([-0.08154684, -0.02698034]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [211], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.00940818]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
231	NM_000419.4(ITGA2B):c.2614C>A (p.Leu872Met)	323544	CA8602631	NM_000419.4:c.2614C>A, NM_000419.3:c.2614C>A, LRG_479t1:c.2614C>A, XM_011524749.1:c.2614C>A, XM_011524750.1:c.2614C>A, NM_000419.5:c.2614C>A, ENST00000262407.5:c.2614C>A, ENST00000587295.5:n.253+129C>A, ENST00000592462.5:n.1409C>A, NC_000017.11:g.44375704G>T, CM000679.2:g.44375704G>T, NC_000017.10:g.42453072G>T, CM000679.1:g.42453072G>T, NC_000017.9:g.39808598G>T, NG_008331.1:g.18802C>A, LRG_479:g.18802C>A, NM_000419.4(ITGA2B):c.2614C>A (p.Leu872Met)	ITGA2B	Glanzmann's thrombasthenia	MONDO:0010119	Autosomal recessive inheritance	Benign	BA1, BP4, BS3		"The NM_000419.4:c.2614C>A variant that results in the Leu872Met amino acid change is reported at frequencies (2%; 0.02101 in the African subpopulation, with 5 homozygotes, in gnomAD) higher than the recommended threshold of 0.24%, in population databases. The variant is not reported in any GT patients in the literature. Experimental evidence suggests no impact  to expression or function of the αIIbβ3 complex. Computation evidence also suggests no impact with a REVEL score of 0.136. In summary, based on the available evidence, the Leu872Met variant is classified as """"""""""""""""benign"""""""""""""""". GT-specific criteria applied: BA1, BS3, and BP4."	22738334	Platelet Disorders VCEP	https://clinicalgenome.org/docs/clingen-platelet-disorders-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-2.1/	2020-06-04	2021-01-22	False	https://erepo.genome.network/evrepo/ui/classification/CA8602631/MONDO:0010119/011	13c5f175-a7d2-4a5c-8cea-f796b56c87d4	p.Leu872Met	Leu	872	Met	MARALCPLQALWLLEWVLLLLGPCAAPPAWALNLDPVQLTFYAGPNGSQFGFSLDFHKDSHGRVAIVVGAPRTLGPSQEETGGVFLCPWRAEGGQCPSLLFDLRDETRNVGSQTLQTFKARQGLGASVVSWSDVIVACAPWQHWNVLEKTEEAEKTPVGSCFLAQPESGRRAEYSPCRGNTLSRIYVENDFSWDKRYCEAGFSSVVTQAGELVLGAPGGYYFLGLLAQAPVADIFSSYRPGILLWHVSSQSLSFDSSNPEYFDGYWGYSVAVGEFDGDLNTTEYVVGAPTWSWTLGAVEILDSYYQRLHRLRGEQMASYFGHSVAVTDVNGDGRHDLLVGAPLYMESRADRKLAEVGRVYLFLQPRGPHALGAPSLLLTGTQLYGRFGSAIAPLGDLDRDGYNDIAVAAPYGGPSGRGQVLVFLGQSEGLRSRPSQVLDSPFPTGSAFGFSLRGAVDIDDNGYPDLIVGAYGANQVAVYRAQPVVKASVQLLVQDSLNPAVKSCVLPQTKTPVSCFNIQMCVGATGHNIPQKLSLNAELQLDRQKPRQGRRVLLLGSQQAGTTLNLDLGGKHSPICHTTMAFLRDEADFRDKLSPIVLSLNVSLPPTEAGMAPAVVLHGDTHVQEQTRIVLDCGEDDVCVPQLQLTASVTGSPLLVGADNVLELQMDAANEGEGAYEAELAVHLPQGAHYMRALSNVEGFERLICNQKKENETRVVLCELGNPMKKNAQIGIAMLVSVGNLEEAGESVSFQLQIRSKNSQNPNSKIVLLDVPVRAEAQVELRGNSFPASLVVAAEEGEREQNSLDSWGPKVEHTYELHNNGPGTVNGLHLSIHLPGQSQPSDLLYILDIQPQGGLQCFPQPPVNPLKVDWGLPIPSPSPIHPAHHKRDRRQIFLPEPEQPSRLQDPVLVSCDSAPCTVVQCDLQEMARGQRAMVTVLAFLWLPSLYQRPLDQFVLQSHAWFNVSSLPYAVPPLSLPRGEAQVWTQLLRALEERAIPIWWVLVGVLGGLLLLTILVLAMWKVGFFKRNRPPLEEDDEEGE	1039	P08514	M	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [874], 'DOMAIN_gain': [422, 483], 'DOMAIN_gain_score': array([0.00619411, 0.00416493]), 'DOMAIN_loss_score': array([-0.03341955]), 'REGION_loss': [], 'REGION_gain': [869, 870], 'REGION_gain_score': array([0.10551971, 0.08161891]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
232	NM_000419.5(ITGA2B):c.1945G>T (p.Val649Leu)	323549	CA8602902	NM_000419.5:c.1945G>T, NC_000017.11:g.44378644C>A, CM000679.2:g.44378644C>A, NC_000017.10:g.42456012C>A, CM000679.1:g.42456012C>A, NC_000017.9:g.39811538C>A, NG_008331.1:g.15862G>T, LRG_479:g.15862G>T, NM_000419.3:c.1945G>T, LRG_479t1:c.1945G>T, XM_011524749.1:c.1945G>T, XM_011524750.1:c.1945G>T, NM_000419.4:c.1945G>T, ENST00000262407.5:c.1945G>T, ENST00000592462.5:n.740G>T, NM_000419.5(ITGA2B):c.1945G>T (p.Val649Leu)	ITGA2B	Glanzmann's thrombasthenia	MONDO:0010119	Autosomal recessive inheritance	Benign	BA1, BP4		The NM_000419.5:c.1945G>T (p.Val649Leu) variant occurs at an allele frequency of 0.01773 in the gnomAD African population and is predicted by REVEL score of 0.035 to have no impact.  In summary, the variant is classified as benign. GT-specific criteria applied: BA1 and BP4.		Platelet Disorders VCEP	https://clinicalgenome.org/docs/clingen-platelet-disorders-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-2.1/	2020-06-04	2021-01-23	False	https://erepo.genome.network/evrepo/ui/classification/CA8602902/MONDO:0010119/011	de723507-813f-4853-952b-a696b4a3a991	p.Val649Leu	Val	649	Leu	MARALCPLQALWLLEWVLLLLGPCAAPPAWALNLDPVQLTFYAGPNGSQFGFSLDFHKDSHGRVAIVVGAPRTLGPSQEETGGVFLCPWRAEGGQCPSLLFDLRDETRNVGSQTLQTFKARQGLGASVVSWSDVIVACAPWQHWNVLEKTEEAEKTPVGSCFLAQPESGRRAEYSPCRGNTLSRIYVENDFSWDKRYCEAGFSSVVTQAGELVLGAPGGYYFLGLLAQAPVADIFSSYRPGILLWHVSSQSLSFDSSNPEYFDGYWGYSVAVGEFDGDLNTTEYVVGAPTWSWTLGAVEILDSYYQRLHRLRGEQMASYFGHSVAVTDVNGDGRHDLLVGAPLYMESRADRKLAEVGRVYLFLQPRGPHALGAPSLLLTGTQLYGRFGSAIAPLGDLDRDGYNDIAVAAPYGGPSGRGQVLVFLGQSEGLRSRPSQVLDSPFPTGSAFGFSLRGAVDIDDNGYPDLIVGAYGANQVAVYRAQPVVKASVQLLVQDSLNPAVKSCVLPQTKTPVSCFNIQMCVGATGHNIPQKLSLNAELQLDRQKPRQGRRVLLLGSQQAGTTLNLDLGGKHSPICHTTMAFLRDEADFRDKLSPIVLSLNVSLPPTEAGMAPAVVLHGDTHVQEQTRIVLDCGEDDVCVPQLQLTASVTGSPLLVGADNVLELQMDAANEGEGAYEAELAVHLPQGAHYMRALSNVEGFERLICNQKKENETRVVLCELGNPMKKNAQIGIAMLVSVGNLEEAGESVSFQLQIRSKNSQNPNSKIVLLDVPVRAEAQVELRGNSFPASLVVAAEEGEREQNSLDSWGPKVEHTYELHNNGPGTVNGLHLSIHLPGQSQPSDLLYILDIQPQGGLQCFPQPPVNPLKVDWGLPIPSPSPIHPAHHKRDRRQIFLPEPEQPSRLQDPVLVSCDSAPCTVVQCDLQEMARGQRAMVTVLAFLWLPSLYQRPLDQFVLQSHAWFNVSSLPYAVPPLSLPRGEAQVWTQLLRALEERAIPIWWVLVGVLGGLLLLTILVLAMWKVGFFKRNRPPLEEDDEEGE	1039	P08514	L	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [910], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.00350308]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [874], 'DOMAIN_gain': [483, 560, 563, 600, 603], 'DOMAIN_gain_score': array([0.01092821, 0.02214688, 0.02596813, 0.01588112, 0.02193385]), 'DOMAIN_loss_score': array([-0.00078452]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
233	NM_000419.5(ITGA2B):c.2621T>G (p.Ile874Ser)	2891	CA115831	NM_000419.5:c.2621T>G, NC_000017.11:g.44375697A>C, CM000679.2:g.44375697A>C, NC_000017.10:g.42453065A>C, CM000679.1:g.42453065A>C, NC_000017.9:g.39808591A>C, NG_008331.1:g.18809T>G, LRG_479:g.18809T>G, NM_000419.3:c.2621T>G, LRG_479t1:c.2621T>G, XM_011524749.1:c.2621T>G, XM_011524750.1:c.2621T>G, NM_000419.4:c.2621T>G, ENST00000262407.5:c.2621T>G, ENST00000587295.5:n.253+136T>G, ENST00000592462.5:n.1416T>G, NM_000419.5(ITGA2B):c.2621T>G (p.Ile874Ser)	ITGA2B	Glanzmann's thrombasthenia	MONDO:0010119	Autosomal recessive inheritance	Benign	BP2, BP4, BA1	BS2	The ITGA2B c.2621T>G (p.Ile874Ser) missense variant has been reported many times in the literature as an alloantigenic site. This variant has been observed in cis with several other Glanzmann thrombasthenia variants, including the pathogenic Tyr471Ter and c.1440-13_1440-1del ITGA2B variants and the Pro189Ser ITGB3 variant (PMID: 25728920). It is present in gnomAD at an  overall allele frequency of 0.39177 (and 0.43954 in the non-Finnish European population). Computational evidence suggest no impact on the gene/gene product, with a REVEL score of 0.055. In summary, this variant meets criteria to be classified as benign for GT. GT-specific criteria applied: BA1, BP2, BP4.		Platelet Disorders VCEP	https://clinicalgenome.org/docs/clingen-platelet-disorders-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-2.1/	2020-11-10	2021-01-22	False	https://erepo.genome.network/evrepo/ui/classification/CA115831/MONDO:0010119/011	9b68cd08-b338-44bf-bae0-7e8866b9a1b2	p.Ile874Ser	Ile	874	Ser	MARALCPLQALWLLEWVLLLLGPCAAPPAWALNLDPVQLTFYAGPNGSQFGFSLDFHKDSHGRVAIVVGAPRTLGPSQEETGGVFLCPWRAEGGQCPSLLFDLRDETRNVGSQTLQTFKARQGLGASVVSWSDVIVACAPWQHWNVLEKTEEAEKTPVGSCFLAQPESGRRAEYSPCRGNTLSRIYVENDFSWDKRYCEAGFSSVVTQAGELVLGAPGGYYFLGLLAQAPVADIFSSYRPGILLWHVSSQSLSFDSSNPEYFDGYWGYSVAVGEFDGDLNTTEYVVGAPTWSWTLGAVEILDSYYQRLHRLRGEQMASYFGHSVAVTDVNGDGRHDLLVGAPLYMESRADRKLAEVGRVYLFLQPRGPHALGAPSLLLTGTQLYGRFGSAIAPLGDLDRDGYNDIAVAAPYGGPSGRGQVLVFLGQSEGLRSRPSQVLDSPFPTGSAFGFSLRGAVDIDDNGYPDLIVGAYGANQVAVYRAQPVVKASVQLLVQDSLNPAVKSCVLPQTKTPVSCFNIQMCVGATGHNIPQKLSLNAELQLDRQKPRQGRRVLLLGSQQAGTTLNLDLGGKHSPICHTTMAFLRDEADFRDKLSPIVLSLNVSLPPTEAGMAPAVVLHGDTHVQEQTRIVLDCGEDDVCVPQLQLTASVTGSPLLVGADNVLELQMDAANEGEGAYEAELAVHLPQGAHYMRALSNVEGFERLICNQKKENETRVVLCELGNPMKKNAQIGIAMLVSVGNLEEAGESVSFQLQIRSKNSQNPNSKIVLLDVPVRAEAQVELRGNSFPASLVVAAEEGEREQNSLDSWGPKVEHTYELHNNGPGTVNGLHLSIHLPGQSQPSDLLYILDIQPQGGLQCFPQPPVNPLKVDWGLPIPSPSPIHPAHHKRDRRQIFLPEPEQPSRLQDPVLVSCDSAPCTVVQCDLQEMARGQRAMVTVLAFLWLPSLYQRPLDQFVLQSHAWFNVSSLPYAVPPLSLPRGEAQVWTQLLRALEERAIPIWWVLVGVLGGLLLLTILVLAMWKVGFFKRNRPPLEEDDEEGE	1039	P08514	S	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [175, 389], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.00355059, -0.00510442]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [880, 881, 894], 'COMPBIAS_gain_score': array([0.28605115, 0.27356648, 0.19076431]), 'DOMAIN_loss': [746], 'DOMAIN_gain': [483, 875], 'DOMAIN_gain_score': array([0.00069737, 0.05177045]), 'DOMAIN_loss_score': array([-0.0143494]), 'REGION_loss': [890, 891, 892, 893, 894, 895], 'REGION_gain': [868, 869, 870], 'REGION_gain_score': array([0.36952955, 0.42311394, 0.39121038]), 'REGION_loss_score': array([-0.14704025, -0.14246589, -0.14452463, -0.20185792, -0.21713483,
       -0.28486115]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
234	NM_000419.5(ITGA2B):c.1627C>T (p.Arg543Trp)	323553	CA8602998	NM_000419.5:c.1627C>T, NM_000419.3:c.1627C>T, LRG_479t1:c.1627C>T, XM_011524749.1:c.1627C>T, XM_011524750.1:c.1627C>T, NM_000419.4:c.1627C>T, ENST00000262407.5:c.1627C>T, ENST00000592226.5:n.1100C>T, ENST00000592462.5:n.422C>T, NC_000017.11:g.44380127G>A, CM000679.2:g.44380127G>A, NC_000017.10:g.42457495G>A, CM000679.1:g.42457495G>A, NC_000017.9:g.39813021G>A, NG_008331.1:g.14379C>T, LRG_479:g.14379C>T, NM_000419.5(ITGA2B):c.1627C>T (p.Arg543Trp)	ITGA2B	Glanzmann's thrombasthenia	MONDO:0010119	Autosomal recessive inheritance	Benign	BA1, BP4		The NM_000419.5:c.1627C>T (p.Arg543Trp) variant occurs at an allele frequency of 0.00968 in the gnomAD African population and is predicted by REVEL score of 0.229 to have no impact.  In summary, the variant is classified as benign. GT-specific criteria applied: BA1 and BP4.		Platelet Disorders VCEP	https://clinicalgenome.org/docs/clingen-platelet-disorders-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-2.1/	2020-06-04	2021-01-23	False	https://erepo.genome.network/evrepo/ui/classification/CA8602998/MONDO:0010119/011	db6c9b61-e7dd-4c62-a697-37118c6d4ab7	p.Arg543Trp	Arg	543	Trp	MARALCPLQALWLLEWVLLLLGPCAAPPAWALNLDPVQLTFYAGPNGSQFGFSLDFHKDSHGRVAIVVGAPRTLGPSQEETGGVFLCPWRAEGGQCPSLLFDLRDETRNVGSQTLQTFKARQGLGASVVSWSDVIVACAPWQHWNVLEKTEEAEKTPVGSCFLAQPESGRRAEYSPCRGNTLSRIYVENDFSWDKRYCEAGFSSVVTQAGELVLGAPGGYYFLGLLAQAPVADIFSSYRPGILLWHVSSQSLSFDSSNPEYFDGYWGYSVAVGEFDGDLNTTEYVVGAPTWSWTLGAVEILDSYYQRLHRLRGEQMASYFGHSVAVTDVNGDGRHDLLVGAPLYMESRADRKLAEVGRVYLFLQPRGPHALGAPSLLLTGTQLYGRFGSAIAPLGDLDRDGYNDIAVAAPYGGPSGRGQVLVFLGQSEGLRSRPSQVLDSPFPTGSAFGFSLRGAVDIDDNGYPDLIVGAYGANQVAVYRAQPVVKASVQLLVQDSLNPAVKSCVLPQTKTPVSCFNIQMCVGATGHNIPQKLSLNAELQLDRQKPRQGRRVLLLGSQQAGTTLNLDLGGKHSPICHTTMAFLRDEADFRDKLSPIVLSLNVSLPPTEAGMAPAVVLHGDTHVQEQTRIVLDCGEDDVCVPQLQLTASVTGSPLLVGADNVLELQMDAANEGEGAYEAELAVHLPQGAHYMRALSNVEGFERLICNQKKENETRVVLCELGNPMKKNAQIGIAMLVSVGNLEEAGESVSFQLQIRSKNSQNPNSKIVLLDVPVRAEAQVELRGNSFPASLVVAAEEGEREQNSLDSWGPKVEHTYELHNNGPGTVNGLHLSIHLPGQSQPSDLLYILDIQPQGGLQCFPQPPVNPLKVDWGLPIPSPSPIHPAHHKRDRRQIFLPEPEQPSRLQDPVLVSCDSAPCTVVQCDLQEMARGQRAMVTVLAFLWLPSLYQRPLDQFVLQSHAWFNVSSLPYAVPPLSLPRGEAQVWTQLLRALEERAIPIWWVLVGVLGGLLLLTILVLAMWKVGFFKRNRPPLEEDDEEGE	1039	P08514	W	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [175, 389, 594], 'STRAND_gain': [541], 'STRAND_gain_score': array([0.17982119]), 'STRAND_loss_score': array([-0.00258869, -0.00649875, -0.02224255]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [420, 874], 'DOMAIN_gain': [600], 'DOMAIN_gain_score': array([0.0142861]), 'DOMAIN_loss_score': array([-0.00576597, -0.0079478 ]), 'REGION_loss': [], 'REGION_gain': [870], 'REGION_gain_score': array([0.00598651]), 'REPEAT_loss': [], 'REPEAT_gain': [46, 79, 126], 'REPEAT_gain_score': array([0.01651961, 0.01242411, 0.00956017]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
235	NM_000212.2(ITGB3):c.1960G>A (p.Glu654Lys)	225395	CA8623406	NM_000212.2:c.1960G>A, NC_000017.11:g.47300524G>A, CM000679.2:g.47300524G>A, NC_000017.10:g.45377890G>A, CM000679.1:g.45377890G>A, NC_000017.9:g.42732889G>A, NG_008332.2:g.51683G>A, LRG_481:g.51683G>A, LRG_481t1:c.1960G>A, NM_000212.3:c.1960G>A, ENST00000559488.5:c.1960G>A, ENST00000560629.1:n.1925G>A, NM_000212.2(ITGB3):c.1960G>A (p.Glu654Lys)	ITGB3	Glanzmann's thrombasthenia	MONDO:0010119	Autosomal recessive inheritance	Benign	BA1	PP3	This missense, c.1960G>A (p.Glu654Lys) variant occurs at an overall allele frequency in gnomAD of 0.0006917 with a MAF of 0.0005056 (138/19954 alleles, including 1 homozygote) in the East Asian population. Computational evidence does not support a deleterious effect on the gene/gene product. This variant meets criteria to be classified as Benign by the ClinGen Platelet Disorders VCEP. GT-specific criteria met: BA1.		Platelet Disorders VCEP	https://clinicalgenome.org/docs/clingen-platelet-disorders-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-2.1/	2019-09-18	2021-01-23	False	https://erepo.genome.network/evrepo/ui/classification/CA8623406/MONDO:0010119/011	46ae73f6-57c9-49fe-9bfc-34734427d618	p.Glu654Lys	Glu	654	Lys	MRARPRPRPLWATVLALGALAGVGVGGPNICTTRGVSSCQQCLAVSPMCAWCSDEALPLGSPRCDLKENLLKDNCAPESIEFPVSEARVLEDRPLSDKGSGDSSQVTQVSPQRIALRLRPDDSKNFSIQVRQVEDYPVDIYYLMDLSYSMKDDLWSIQNLGTKLATQMRKLTSNLRIGFGAFVDKPVSPYMYISPPEALENPCYDMKTTCLPMFGYKHVLTLTDQVTRFNEEVKKQSVSRNRDAPEGGFDAIMQATVCDEKIGWRNDASHLLVFTTDAKTHIALDGRLAGIVQPNDGQCHVGSDNHYSASTTMDYPSLGLMTEKLSQKNINLIFAVTENVVNLYQNYSELIPGTTVGVLSMDSSNVLQLIVDAYGKIRSKVELEVRDLPEELSLSFNATCLNNEVIPGLKSCMGLKIGDTVSFSIEAKVRGCPQEKEKSFTIKPVGFKDSLIVQVTFDCDCACQAQAEPNSHRCNNGNGTFECGVCRCGPGWLGSQCECSEEDYRPSQQDECSPREGQPVCSQRGECLCGQCVCHSSDFGKITGKYCECDDFSCVRYKGEMCSGHGQCSCGDCLCDSDWTGYYCNCTTRTDTCMSSNGLLCSGRGKCECGSCVCIQPGSYGDTCEKCPTCPDACTFKKECVECKKFDRGALHDENTCNRYCRDEIESVKELKDTGKDAVNCTYKNEDDCVVRFQYYEDSSGKSILYVVEEPECPKGPDILVVLLSVMGAILLIGLAALLIWKLLITIHDRKEFAKFEEERARAKWDTANNPLYKEATSTFTNITYRGT	788	P05106	K	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
236	NM_000212.2(ITGB3):c.176T>C (p.Leu59Pro)	13558	CA123235	NM_000212.2:c.176T>C, NC_000017.11:g.47283364T>C, CM000679.2:g.47283364T>C, NC_000017.10:g.45360730T>C, CM000679.1:g.45360730T>C, NC_000017.9:g.42715729T>C, NG_008332.2:g.34523T>C, LRG_481:g.34523T>C, LRG_481t1:c.176T>C, NM_000212.3:c.176T>C, ENST00000559488.5:c.176T>C, ENST00000560629.1:n.141T>C, ENST00000571680.1:c.176T>C, NM_000212.2(ITGB3):c.176T>C (p.Leu59Pro)	ITGB3	Glanzmann's thrombasthenia	MONDO:0010119	Autosomal recessive inheritance	Benign	BP2, BP4, BA1, BS3	PM5, BS2	The ITGB3 c.176T>C (p.Leu59Pro) missense variant has been reported many times in the literature as an alloantigenic site. This variant has been observed in cis with several other Glanzmann thrombasthenia variants, including the pathogenic c.224del frameshift variant (PMID: 25728920). It is present in gnomAD at an overall allele frequency of 0.1223 (and 0.1550 in the non-Finnish European population). Computational evidence suggest no impact on the gene/gene product, with a REVEL score of 0.217. Functional studies in CHO cells have shown no deleterious effect on surface expression or fibrinogen binding (PMID: 10727448). In summary, this variant meets criteria to be classified as benign for GT. GT-specific criteria applied: BA1, BS3, BP2, BP4.	25728920, 10727448	Platelet Disorders VCEP	https://clinicalgenome.org/docs/clingen-platelet-disorders-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-2.1/	2020-06-18	2021-01-22	False	https://erepo.genome.network/evrepo/ui/classification/CA123235/MONDO:0010119/011	55e31015-4a08-43d4-8768-dba28433a961	p.Leu59Pro	Leu	59	Pro	MRARPRPRPLWATVLALGALAGVGVGGPNICTTRGVSSCQQCLAVSPMCAWCSDEALPLGSPRCDLKENLLKDNCAPESIEFPVSEARVLEDRPLSDKGSGDSSQVTQVSPQRIALRLRPDDSKNFSIQVRQVEDYPVDIYYLMDLSYSMKDDLWSIQNLGTKLATQMRKLTSNLRIGFGAFVDKPVSPYMYISPPEALENPCYDMKTTCLPMFGYKHVLTLTDQVTRFNEEVKKQSVSRNRDAPEGGFDAIMQATVCDEKIGWRNDASHLLVFTTDAKTHIALDGRLAGIVQPNDGQCHVGSDNHYSASTTMDYPSLGLMTEKLSQKNINLIFAVTENVVNLYQNYSELIPGTTVGVLSMDSSNVLQLIVDAYGKIRSKVELEVRDLPEELSLSFNATCLNNEVIPGLKSCMGLKIGDTVSFSIEAKVRGCPQEKEKSFTIKPVGFKDSLIVQVTFDCDCACQAQAEPNSHRCNNGNGTFECGVCRCGPGWLGSQCECSEEDYRPSQQDECSPREGQPVCSQRGECLCGQCVCHSSDFGKITGKYCECDDFSCVRYKGEMCSGHGQCSCGDCLCDSDWTGYYCNCTTRTDTCMSSNGLLCSGRGKCECGSCVCIQPGSYGDTCEKCPTCPDACTFKKECVECKKFDRGALHDENTCNRYCRDEIESVKELKDTGKDAVNCTYKNEDDCVVRFQYYEDSSGKSILYVVEEPECPKGPDILVVLLSVMGAILLIGLAALLIWKLLITIHDRKEFAKFEEERARAKWDTANNPLYKEATSTFTNITYRGT	788	P05106	P	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [115, 404], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.0578751 , -0.00650734]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [76], 'DOMAIN_gain_score': array([0.11150193]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
237	NM_000540.3(RYR1):c.1021G>A (p.Gly341Arg)	12969	CA023827	NM_000540.3:c.1021G>A, NC_000019.10:g.38448712G>A, CM000681.2:g.38448712G>A, NC_000019.9:g.38939352G>A, CM000681.1:g.38939352G>A, NC_000019.8:g.43631192G>A, NG_008866.1:g.20013G>A, LRG_766:g.20013G>A, ENST00000355481.8:c.1021G>A, ENST00000359596.7:n.1021G>A, ENST00000360985.7:c.1021G>A, NM_000540.2:c.1021G>A, LRG_766t1:c.1021G>A, NM_001042723.1:c.1021G>A, XM_006723317.1:c.1021G>A, XM_006723319.1:c.1021G>A, XM_011527204.1:c.1018G>A, XM_011527205.1:c.1021G>A, XM_006723317.2:c.1021G>A, XM_006723319.2:c.1021G>A, XM_011527205.2:c.1021G>A, NM_001042723.2:c.1021G>A, NM_000540.3(RYR1):c.1021G>A (p.Gly341Arg)	RYR1	malignant hyperthermia, susceptibility to, 1	MONDO:0007783	Autosomal dominant inheritance	Pathogenic	PS4, PS3_Moderate, BS2_Supporting, PM1, PP1_Strong, PP3_Moderate	BA1, BP4, BS1	This pathogenicity assessment is relevant only for malignant hyperthermia susceptibility (MHS) inherited in an autosomal dominant pattern. Variants in RYR1 can also cause other myopathies inherited in an autosomal dominant pattern or in an autosomal recessive pattern. Some of these disorders may predispose individuals to malignant hyperthermia. RYR1 variants may also contribute to a malignant hyperthermia reaction in combination with other genetic and non-genetic factors and the clinician needs to consider such factors in making management decisions. This sequence variant predicts a substitution of glycine with arginine at codon 341 of the RYR1 protein p.(Gly341Arg), c.1021G>A. This variant is not present in a large population database (gnomAD). This variant has been reported in 71 unrelated probands who have a personal or family history of a malignant hyperthermia reaction and a positive in vitro contracture test (IVCT) or caffeine halothane contracture test (CHCT) result (when the proband was unavailable for testing a positive diagnostic test result in a mutation positive relative was counted), PS4 ( PMID:30236257, PMID:16163667, PMID: 8012359 and others). Functional studies in HEK293 cells show an increased sensitivity to RYR1 agonists, PS3_Moderate (PMID:26115329). This variant resides in a region of RYR1 considered to be a hotspot for pathogenic variants that contribute to MHS, PM1 (PMID: 21118704). This variant segregates with MHS in 66 individuals, PP1_Strong ( PMID: 8012359, PMID:9106529, PMID:17710899 and others). A REVEL score > 0.85 supports pathogenicity,PP3_Moderate. Based on using Bayes to combine criteria this variant is assessed as Pathogenic, (PMID: 29300386). Criteria implemented: PS4, PS3_Moderate, PM1, PP1_Strong, PP3_Moderate, BS2_Moderate. 	26115329	Malignant Hyperthermia Susceptibility VCEP	https://clinicalgenome.org/docs/clingen-malignant-hyperthermia-susceptibility-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-for/	2021-03-18	2021-03-31	False	https://erepo.genome.network/evrepo/ui/classification/CA023827/MONDO:0007783/012	9fd209aa-12fb-400e-9b0f-37a7981de6b7	p.Gly341Arg	Gly	341	Arg	MGDAEGEDEVQFLRTDDEVVLQCSATVLKEQLKLCLAAEGFGNRLCFLEPTSNAQNVPPDLAICCFVLEQSLSVRALQEMLANTVEAGVESSQGGGHRTLLYGHAILLRHAHSRMYLSCLTTSRSMTDKLAFDVGLQEDATGEACWWTMHPASKQRSEGEKVRVGDDIILVSVSSERYLHLSTASGELQVDASFMQTLWNMNPICSRCEEGFVTGGHVLRLFHGHMDECLTISPADSDDQRRLVYYEGGAVCTHARSLWRLEPLRISWSGSHLRWGQPLRVRHVTTGQYLALTEDQGLVVVDASKAHTKATSFCFRISKEKLDVAPKRDVEGMGPPEIKYGESLCFVQHVASGLWLTYAAPDPKALRLGVLKKKAMLHQEGHMDDALSLTRCQQEESQAARMIHSTNGLYNQFIKSLDSFSGKPRGSGPPAGTALPIEGVILSLQDLIIYFEPPSEDLQHEEKQSKLRSLRNRQSLFQEEGMLSMVLNCIDRLNVYTTAAHFAEFAGEEAAESWKEIVNLLYELLASLIRGNRSNCALFSTNLDWLVSKLDRLEASSGILEVLYCVLIESPEVLNIIQENHIKSIISLLDKHGRNHKVLDVLCSLCVCNGVAVRSNQDLITENLLPGRELLLQTNLINYVTSIRPNIFVGRAEGTTQYSKWYFEVMVDEVTPFLTAQATHLRVGWALTEGYTPYPGAGEGWGGNGVGDDLYSYGFDGLHLWTGHVARPVTSPGQHLLAPEDVISCCLDLSVPSISFRINGCPVQGVFESFNLDGLFFPVVSFSAGVKVRFLLGGRHGEFKFLPPPGYAPCHEAVLPRERLHLEPIKEYRREGPRGPHLVGPSRCLSHTDFVPCPVDTVQIVLPPHLERIREKLAENIHELWALTRIEQGWTYGPVRDDNKRLHPCLVDFHSLPEPERNYNLQMSGETLKTLLALGCHVGMADEKAEDNLKKTKLPKTYMMSNGYKPAPLDLSHVRLTPAQTTLVDRLAENGHNVWARDRVGQGWSYSAVQDIPARRNPRLVPYRLLDEATKRSNRDSLCQAVRTLLGYGYNIEPPDQEPSQVENQSRCDRVRIFRAEKSYTVQSGRWYFEFEAVTTGEMRVGWARPELRPDVELGADELAYVFNGHRGQRWHLGSEPFGRPWQPGDVVGCMIDLTENTIIFTLNGEVLMSDSGSETAFREIEIGDGFLPVCSLGPGQVGHLNLGQDVSSLRFFAICGLQEGFEPFAINMQRPVTTWFSKGLPQFEPVPLEHPHYEVSRVDGTVDTPPCLRLTHRTWGSQNSLVEMLFLRLSLPVQFHQHFRCTAGATPLAPPGLQPPAEDEARAAEPDPDYENLRRSAGGWSEAENGKEGTAKEGAPGGTPQAGGEAQPARAENEKDATTEKNKKRGFLFKAKKVAMMTQPPATPTLPRLPHDVVPADNRDDPEIILNTTTYYYSVRVFAGQEPSCVWAGWVTPDYHQHDMSFDLSKVRVVTVTMGDEQGNVHSSLKCSNCYMVWGGDFVSPGQQGRISHTDLVIGCLVDLATGLMTFTANGKESNTFFQVEPNTKLFPAVFVLPTHQNVIQFELGKQKNIMPLSAAMFQSERKNPAPQCPPRLEMQMLMPVSWSRMPNHFLQVETRRAGERLGWAVQCQEPLTMMALHIPEENRCMDILELSERLDLQRFHSHTLRLYRAVCALGNNRVAHALCSHVDQAQLLHALEDAHLPGPLRAGYYDLLISIHLESACRSRRSMLSEYIVPLTPETRAITLFPPGRSTENGHPRHGLPGVGVTTSLRPPHHFSPPCFVAALPAAGAAEAPARLSPAIPLEALRDKALRMLGEAVRDGGQHARDPVGGSVEFQFVPVLKLVSTLLVMGIFGDEDVKQILKMIEPEVFTEEEEEEDEEEEGEEEDEEEKEEDEEETAQEKEDEEKEEEEAAEGEKEEGLEEGLLQMKLPESVKLQMCHLLEYFCDQELQHRVESLAAFAERYVDKLQANQRSRYGLLIKAFSMTAAETARRTREFRSPPQEQINMLLQFKDGTDEEDCPLPEEIRQDLLDFHQDLLAHCGIQLDGEEEEPEEETTLGSRLMSLLEKVRLVKKKEEKPEEERSAEESKPRSLQELVSHMVVRWAQEDFVQSPELVRAMFSLLHRQYDGLGELLRALPRAYTISPSSVEDTMSLLECLGQIRSLLIVQMGPQEENLMIQSIGNIMNNKVFYQHPNLMRALGMHETVMEVMVNVLGGGESKEIRFPKMVTSCCRFLCYFCRISRQNQRSMFDHLSYLLENSGIGLGMQGSTPLDVAAASVIDNNELALALQEQDLEKVVSYLAGCGLQSCPMLVAKGYPDIGWNPCGGERYLDFLRFAVFVNGESVEENANVVVRLLIRKPECFGPALRGEGGSGLLAAIEEAIRISEDPARDGPGIRRDRRREHFGEEPPEENRVHLGHAIMSFYAALIDLLGRCAPEMHLIQAGKGEALRIRAILRSLVPLEDLVGIISLPLQIPTLGKDGALVQPKMSASFVPDHKASMVLFLDRVYGIENQDFLLHVLDVGFLPDMRAAASLDTATFSTTEMALALNRYLCLAVLPLITKCAPLFAGTEHRAIMVDSMLHTVYRLSRGRSLTKAQRDVIEDCLMSLCRYIRPSMLQHLLRRLVFDVPILNEFAKMPLKLLTNHYERCWKYYCLPTGWANFGVTSEEELHLTRKLFWGIFDSLAHKKYDPELYRMAMPCLCAIAGALPPDYVDASYSSKAEKKATVDAEGNFDPRPVETLNVIIPEKLDSFINKFAEYTHEKWAFDKIQNNWSYGENIDEELKTHPMLRPYKTFSEKDKEIYRWPIKESLKAMIAWEWTIEKAREGEEEKTEKKKTRKISQSAQTYDPREGYNPQPPDLSAVTLSRELQAMAEQLAENYHNTWGRKKKQELEAKGGGTHPLLVPYDTLTAKEKARDREKAQELLKFLQMNGYAVTRGLKDMELDSSSIEKRFAFGFLQQLLRWMDISQEFIAHLEAVVSSGRVEKSPHEQEIKFFAKILLPLINQYFTNHCLYFLSTPAKVLGSGGHASNKEKEMITSLFCKLAALVRHRVSLFGTDAPAVVNCLHILARSLDARTVMKSGPEIVKAGLRSFFESASEDIEKMVENLRLGKVSQARTQVKGVGQNLTYTTVALLPVLTTLFQHIAQHQFGDDVILDDVQVSCYRTLCSIYSLGTTKNTYVEKLRPALGECLARLAAAMPVAFLEPQLNEYNACSVYTTKSPRERAILGLPNSVEEMCPDIPVLERLMADIGGLAESGARYTEMPHVIEITLPMLCSYLPRWWERGPEAPPSALPAGAPPPCTAVTSDHLNSLLGNILRIIVNNLGIDEASWMKRLAVFAQPIVSRARPELLQSHFIPTIGRLRKRAGKVVSEEEQLRLEAKAEAQEGELLVRDEFSVLCRDLYALYPLLIRYVDNNRAQWLTEPNPSAEELFRMVGEIFIYWSKSHNFKREEQNFVVQNEINNMSFLTADNKSKMAKAGDIQSGGSDQERTKKKRRGDRYSVQTSLIVATLKKMLPIGLNMCAPTDQDLITLAKTRYALKDTDEEVREFLHNNLHLQGKVEGSPSLRWQMALYRGVPGREEDADDPEKIVRRVQEVSAVLYYLDQTEHPYKSKKAVWHKLLSKQRRRAVVACFRMTPLYNLPTHRACNMFLESYKAAWILTEDHSFEDRMIDDLSKAGEQEEEEEEVEEKKPDPLHQLVLHFSRTALTEKSKLDEDYLYMAYADIMAKSCHLEEGGENGEAEEEVEVSFEEKQMEKQRLLYQQARLHTRGAAEMVLQMISACKGETGAMVSSTLKLGISILNGGNAEVQQKMLDYLKDKKEVGFFQSIQALMQTCSVLDLNAFERQNKAEGLGMVNEDGTVINRQNGEKVMADDEFTQDLFRFLQLLCEGHNNDFQNYLRTQTGNTTTINIIICTVDYLLRLQESISDFYWYYSGKDVIEEQGKRNFSKAMSVAKQVFNSLTEYIQGPCTGNQQSLAHSRLWDAVVGFLHVFAHMMMKLAQDSSQIELLKELLDLQKDMVVMLLSLLEGNVVNGMIARQMVDMLVESSSNVEMILKFFDMFLKLKDIVGSEAFQDYVTDPRGLISKKDFQKAMDSQKQFSGPEIQFLLSCSEADENEMINCEEFANRFQEPARDIGFNVAVLLTNLSEHVPHDPRLHNFLELAESILEYFRPYLGRIEIMGASRRIERIYFEISETNRAQWEMPQVKESKRQFIFDVVNEGGEAEKMELFVSFCEDTIFEMQIAAQISEPEGEPETDEDEGAGAAEAGAEGAEEGAAGLEGTAATAAAGATARVVAAAGRALRGLSYRSLRRRVRRLRRLTAREAATAVAALLWAAVTRAGAAGAGAAAGALGLLWGSLFGGGLVEGAKKVTVTELLAGMPDPTSDEVHGEQPAGPGGDADGEGASEGAGDAAEGAGDEEEAVHEAGPGGADGAVAVTDGGPFRPEGAGGLGDMGDTTPAEPPTPEGSPILKRKLGVDGVEEELPPEPEPEPEPELEPEKADAENGEKEEVPEPTPEPPKKQAPPSPPPKKEEAGGEFWGELEVQRVKFLNYLSRNFYTLRFLALFLAFAINFILLFYKVSDSPPGEDDMEGSAAGDVSGAGSGGSSGWGLGAGEEAEGDEDENMVYYFLEESTGYMEPALRCLSLLHTLVAFLCIIGYNCLKVPLVIFKREKELARKLEFDGLYITEQPEDDDVKGQWDRLVLNTPSFPSNYWDKFVKRKVLDKHGDIYGRERIAELLGMDLATLEITAHNERKPNPPPGLLTWLMSIDVKYQIWKFGVIFTDNSFLYLGWYMVMSLLGHYNNFFFAAHLLDIAMGVKTLRTILSSVTHNGKQLVMTVGLLAVVVYLYTVVAFNFFRKFYNKSEDEDEPDMKCDDMMTCYLFHMYVGVRAGGGIGDEIEDPAGDEYELYRVVFDITFFFFVIVILLAIIQGLIIDAFGELRDQQEQVKEDMETKCFICGIGSDYFDTTPHGFETHTLEEHNLANYMFFLMYLINKDETEHTGQESYVWKMYQERCWDFFPAGDCFRKQYEDQLS	5038	P21817	R	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
238	NM_000540.3(RYR1):c.1565A>C (p.Tyr522Ser)	12993	CA024286	NM_000540.3:c.1565A>C, NC_000019.10:g.38455359A>C, CM000681.2:g.38455359A>C, NC_000019.9:g.38945999A>C, CM000681.1:g.38945999A>C, NC_000019.8:g.43637839A>C, NG_008866.1:g.26660A>C, LRG_766:g.26660A>C, ENST00000355481.8:c.1565A>C, ENST00000359596.7:n.1565A>C, ENST00000360985.7:c.1565A>C, NM_000540.2:c.1565A>C, LRG_766t1:c.1565A>C, NM_001042723.1:c.1565A>C, XM_006723317.1:c.1565A>C, XM_006723319.1:c.1565A>C, XM_011527204.1:c.1562A>C, XM_011527205.1:c.1565A>C, XM_006723317.2:c.1565A>C, XM_006723319.2:c.1565A>C, XM_011527205.2:c.1565A>C, NM_001042723.2:c.1565A>C, NM_000540.3(RYR1):c.1565A>C (p.Tyr522Ser)	RYR1	malignant hyperthermia, susceptibility to, 1	MONDO:0007783	Autosomal dominant inheritance	Pathogenic	PP1, PS3, PS4_Supporting, PM1, PP3_Moderate	BA1, BS1	This pathogenicity assessment is relevant only for malignant hyperthermia susceptibility (MHS) inherited in an autosomal dominant pattern. Variants in RYR1 can also cause other myopathies inherited in an autosomal dominant pattern or in an autosomal recessive pattern. Some of these disorders may predispose individuals to malignant hyperthermia. RYR1 variants may also contribute to a malignant hyperthermia reaction in combination with other genetic and non-genetic factors and the clinician needs to consider such factors in making management decisions. This sequence variant predicts a substitution of tyrosine with serine at codon 522 of the RYR1 protein, p.(Tyr522Ser). The maximum allele frequency for this variant among the six major gnomAD populations is EAS: 0.00005, a frequency consistent with pathogenicity for MHS. This variant has been reported in two unrelated individuals who have a personal or family history of a malignant hyperthermia reaction, one of these individuals had a positive in vitro contracture test (IVCT) or caffeine halothane contracture test (CHCT) result (if the proband was unavailable for testing, a positive diagnostic test result in a mutation-positive relative was counted), PS4_Supporting (PMID:7829078, PMID:19020143). Functional studies in HEK293 cells show an increased sensitivity to RYR1 agonists. A knock-in mouse model supports pathogenicity of this variant demonstrating a malignant hyperthermia reaction in response to agonist, as well ex vivo studies showed increased response to agonist with increased calcium release, PS3 (PMID:31607937, PMID:9334205).This variant resides in a region of RYR1 considered to be a hotspot for pathogenic variants that contribute to MHS, PM1 (PMID: 21118704). This variant segregates with MHS in three individuals, PP1 ( PMID:7829078). A REVEL score >0.85 supports a pathogenic status for this variant, PP3_Moderate. This variant has been classified as Pathogenic. Criteria implemented: PS4_Supporting, PS3, PM1, PP1, PP3_Moderate. 		Malignant Hyperthermia Susceptibility VCEP	https://clinicalgenome.org/docs/clingen-malignant-hyperthermia-susceptibility-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-for/	2021-03-18	2021-03-31	False	https://erepo.genome.network/evrepo/ui/classification/CA024286/MONDO:0007783/012	3dabd68e-7090-43d8-9cbb-77ae98ef977d	p.Tyr522Ser	Tyr	522	Ser	MGDAEGEDEVQFLRTDDEVVLQCSATVLKEQLKLCLAAEGFGNRLCFLEPTSNAQNVPPDLAICCFVLEQSLSVRALQEMLANTVEAGVESSQGGGHRTLLYGHAILLRHAHSRMYLSCLTTSRSMTDKLAFDVGLQEDATGEACWWTMHPASKQRSEGEKVRVGDDIILVSVSSERYLHLSTASGELQVDASFMQTLWNMNPICSRCEEGFVTGGHVLRLFHGHMDECLTISPADSDDQRRLVYYEGGAVCTHARSLWRLEPLRISWSGSHLRWGQPLRVRHVTTGQYLALTEDQGLVVVDASKAHTKATSFCFRISKEKLDVAPKRDVEGMGPPEIKYGESLCFVQHVASGLWLTYAAPDPKALRLGVLKKKAMLHQEGHMDDALSLTRCQQEESQAARMIHSTNGLYNQFIKSLDSFSGKPRGSGPPAGTALPIEGVILSLQDLIIYFEPPSEDLQHEEKQSKLRSLRNRQSLFQEEGMLSMVLNCIDRLNVYTTAAHFAEFAGEEAAESWKEIVNLLYELLASLIRGNRSNCALFSTNLDWLVSKLDRLEASSGILEVLYCVLIESPEVLNIIQENHIKSIISLLDKHGRNHKVLDVLCSLCVCNGVAVRSNQDLITENLLPGRELLLQTNLINYVTSIRPNIFVGRAEGTTQYSKWYFEVMVDEVTPFLTAQATHLRVGWALTEGYTPYPGAGEGWGGNGVGDDLYSYGFDGLHLWTGHVARPVTSPGQHLLAPEDVISCCLDLSVPSISFRINGCPVQGVFESFNLDGLFFPVVSFSAGVKVRFLLGGRHGEFKFLPPPGYAPCHEAVLPRERLHLEPIKEYRREGPRGPHLVGPSRCLSHTDFVPCPVDTVQIVLPPHLERIREKLAENIHELWALTRIEQGWTYGPVRDDNKRLHPCLVDFHSLPEPERNYNLQMSGETLKTLLALGCHVGMADEKAEDNLKKTKLPKTYMMSNGYKPAPLDLSHVRLTPAQTTLVDRLAENGHNVWARDRVGQGWSYSAVQDIPARRNPRLVPYRLLDEATKRSNRDSLCQAVRTLLGYGYNIEPPDQEPSQVENQSRCDRVRIFRAEKSYTVQSGRWYFEFEAVTTGEMRVGWARPELRPDVELGADELAYVFNGHRGQRWHLGSEPFGRPWQPGDVVGCMIDLTENTIIFTLNGEVLMSDSGSETAFREIEIGDGFLPVCSLGPGQVGHLNLGQDVSSLRFFAICGLQEGFEPFAINMQRPVTTWFSKGLPQFEPVPLEHPHYEVSRVDGTVDTPPCLRLTHRTWGSQNSLVEMLFLRLSLPVQFHQHFRCTAGATPLAPPGLQPPAEDEARAAEPDPDYENLRRSAGGWSEAENGKEGTAKEGAPGGTPQAGGEAQPARAENEKDATTEKNKKRGFLFKAKKVAMMTQPPATPTLPRLPHDVVPADNRDDPEIILNTTTYYYSVRVFAGQEPSCVWAGWVTPDYHQHDMSFDLSKVRVVTVTMGDEQGNVHSSLKCSNCYMVWGGDFVSPGQQGRISHTDLVIGCLVDLATGLMTFTANGKESNTFFQVEPNTKLFPAVFVLPTHQNVIQFELGKQKNIMPLSAAMFQSERKNPAPQCPPRLEMQMLMPVSWSRMPNHFLQVETRRAGERLGWAVQCQEPLTMMALHIPEENRCMDILELSERLDLQRFHSHTLRLYRAVCALGNNRVAHALCSHVDQAQLLHALEDAHLPGPLRAGYYDLLISIHLESACRSRRSMLSEYIVPLTPETRAITLFPPGRSTENGHPRHGLPGVGVTTSLRPPHHFSPPCFVAALPAAGAAEAPARLSPAIPLEALRDKALRMLGEAVRDGGQHARDPVGGSVEFQFVPVLKLVSTLLVMGIFGDEDVKQILKMIEPEVFTEEEEEEDEEEEGEEEDEEEKEEDEEETAQEKEDEEKEEEEAAEGEKEEGLEEGLLQMKLPESVKLQMCHLLEYFCDQELQHRVESLAAFAERYVDKLQANQRSRYGLLIKAFSMTAAETARRTREFRSPPQEQINMLLQFKDGTDEEDCPLPEEIRQDLLDFHQDLLAHCGIQLDGEEEEPEEETTLGSRLMSLLEKVRLVKKKEEKPEEERSAEESKPRSLQELVSHMVVRWAQEDFVQSPELVRAMFSLLHRQYDGLGELLRALPRAYTISPSSVEDTMSLLECLGQIRSLLIVQMGPQEENLMIQSIGNIMNNKVFYQHPNLMRALGMHETVMEVMVNVLGGGESKEIRFPKMVTSCCRFLCYFCRISRQNQRSMFDHLSYLLENSGIGLGMQGSTPLDVAAASVIDNNELALALQEQDLEKVVSYLAGCGLQSCPMLVAKGYPDIGWNPCGGERYLDFLRFAVFVNGESVEENANVVVRLLIRKPECFGPALRGEGGSGLLAAIEEAIRISEDPARDGPGIRRDRRREHFGEEPPEENRVHLGHAIMSFYAALIDLLGRCAPEMHLIQAGKGEALRIRAILRSLVPLEDLVGIISLPLQIPTLGKDGALVQPKMSASFVPDHKASMVLFLDRVYGIENQDFLLHVLDVGFLPDMRAAASLDTATFSTTEMALALNRYLCLAVLPLITKCAPLFAGTEHRAIMVDSMLHTVYRLSRGRSLTKAQRDVIEDCLMSLCRYIRPSMLQHLLRRLVFDVPILNEFAKMPLKLLTNHYERCWKYYCLPTGWANFGVTSEEELHLTRKLFWGIFDSLAHKKYDPELYRMAMPCLCAIAGALPPDYVDASYSSKAEKKATVDAEGNFDPRPVETLNVIIPEKLDSFINKFAEYTHEKWAFDKIQNNWSYGENIDEELKTHPMLRPYKTFSEKDKEIYRWPIKESLKAMIAWEWTIEKAREGEEEKTEKKKTRKISQSAQTYDPREGYNPQPPDLSAVTLSRELQAMAEQLAENYHNTWGRKKKQELEAKGGGTHPLLVPYDTLTAKEKARDREKAQELLKFLQMNGYAVTRGLKDMELDSSSIEKRFAFGFLQQLLRWMDISQEFIAHLEAVVSSGRVEKSPHEQEIKFFAKILLPLINQYFTNHCLYFLSTPAKVLGSGGHASNKEKEMITSLFCKLAALVRHRVSLFGTDAPAVVNCLHILARSLDARTVMKSGPEIVKAGLRSFFESASEDIEKMVENLRLGKVSQARTQVKGVGQNLTYTTVALLPVLTTLFQHIAQHQFGDDVILDDVQVSCYRTLCSIYSLGTTKNTYVEKLRPALGECLARLAAAMPVAFLEPQLNEYNACSVYTTKSPRERAILGLPNSVEEMCPDIPVLERLMADIGGLAESGARYTEMPHVIEITLPMLCSYLPRWWERGPEAPPSALPAGAPPPCTAVTSDHLNSLLGNILRIIVNNLGIDEASWMKRLAVFAQPIVSRARPELLQSHFIPTIGRLRKRAGKVVSEEEQLRLEAKAEAQEGELLVRDEFSVLCRDLYALYPLLIRYVDNNRAQWLTEPNPSAEELFRMVGEIFIYWSKSHNFKREEQNFVVQNEINNMSFLTADNKSKMAKAGDIQSGGSDQERTKKKRRGDRYSVQTSLIVATLKKMLPIGLNMCAPTDQDLITLAKTRYALKDTDEEVREFLHNNLHLQGKVEGSPSLRWQMALYRGVPGREEDADDPEKIVRRVQEVSAVLYYLDQTEHPYKSKKAVWHKLLSKQRRRAVVACFRMTPLYNLPTHRACNMFLESYKAAWILTEDHSFEDRMIDDLSKAGEQEEEEEEVEEKKPDPLHQLVLHFSRTALTEKSKLDEDYLYMAYADIMAKSCHLEEGGENGEAEEEVEVSFEEKQMEKQRLLYQQARLHTRGAAEMVLQMISACKGETGAMVSSTLKLGISILNGGNAEVQQKMLDYLKDKKEVGFFQSIQALMQTCSVLDLNAFERQNKAEGLGMVNEDGTVINRQNGEKVMADDEFTQDLFRFLQLLCEGHNNDFQNYLRTQTGNTTTINIIICTVDYLLRLQESISDFYWYYSGKDVIEEQGKRNFSKAMSVAKQVFNSLTEYIQGPCTGNQQSLAHSRLWDAVVGFLHVFAHMMMKLAQDSSQIELLKELLDLQKDMVVMLLSLLEGNVVNGMIARQMVDMLVESSSNVEMILKFFDMFLKLKDIVGSEAFQDYVTDPRGLISKKDFQKAMDSQKQFSGPEIQFLLSCSEADENEMINCEEFANRFQEPARDIGFNVAVLLTNLSEHVPHDPRLHNFLELAESILEYFRPYLGRIEIMGASRRIERIYFEISETNRAQWEMPQVKESKRQFIFDVVNEGGEAEKMELFVSFCEDTIFEMQIAAQISEPEGEPETDEDEGAGAAEAGAEGAEEGAAGLEGTAATAAAGATARVVAAAGRALRGLSYRSLRRRVRRLRRLTAREAATAVAALLWAAVTRAGAAGAGAAAGALGLLWGSLFGGGLVEGAKKVTVTELLAGMPDPTSDEVHGEQPAGPGGDADGEGASEGAGDAAEGAGDEEEAVHEAGPGGADGAVAVTDGGPFRPEGAGGLGDMGDTTPAEPPTPEGSPILKRKLGVDGVEEELPPEPEPEPEPELEPEKADAENGEKEEVPEPTPEPPKKQAPPSPPPKKEEAGGEFWGELEVQRVKFLNYLSRNFYTLRFLALFLAFAINFILLFYKVSDSPPGEDDMEGSAAGDVSGAGSGGSSGWGLGAGEEAEGDEDENMVYYFLEESTGYMEPALRCLSLLHTLVAFLCIIGYNCLKVPLVIFKREKELARKLEFDGLYITEQPEDDDVKGQWDRLVLNTPSFPSNYWDKFVKRKVLDKHGDIYGRERIAELLGMDLATLEITAHNERKPNPPPGLLTWLMSIDVKYQIWKFGVIFTDNSFLYLGWYMVMSLLGHYNNFFFAAHLLDIAMGVKTLRTILSSVTHNGKQLVMTVGLLAVVVYLYTVVAFNFFRKFYNKSEDEDEPDMKCDDMMTCYLFHMYVGVRAGGGIGDEIEDPAGDEYELYRVVFDITFFFFVIVILLAIIQGLIIDAFGELRDQQEQVKEDMETKCFICGIGSDYFDTTPHGFETHTLEEHNLANYMFFLMYLINKDETEHTGQESYVWKMYQERCWDFFPAGDCFRKQYEDQLS	5038	P21817	S	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
239	NM_000540.2(RYR1):c.1841G>T (p.Arg614Leu)	133108	CA024313	NM_000540.2:c.1841G>T, NC_000019.10:g.38457546G>T, CM000681.2:g.38457546G>T, NC_000019.9:g.38948186G>T, CM000681.1:g.38948186G>T, NC_000019.8:g.43640026G>T, NG_008866.1:g.28847G>T, LRG_766:g.28847G>T, ENST00000355481.8:c.1841G>T, ENST00000359596.7:n.1841G>T, ENST00000360985.7:c.1841G>T, LRG_766t1:c.1841G>T, NM_001042723.1:c.1841G>T, XM_006723317.1:c.1841G>T, XM_006723319.1:c.1841G>T, XM_011527204.1:c.1838G>T, XM_011527205.1:c.1841G>T, XM_006723317.2:c.1841G>T, XM_006723319.2:c.1841G>T, XM_011527205.2:c.1841G>T, NM_000540.3:c.1841G>T, NM_001042723.2:c.1841G>T, NM_000540.2(RYR1):c.1841G>T (p.Arg614Leu)	RYR1	malignant hyperthermia, susceptibility to, 1	MONDO:0007783	Autosomal dominant inheritance	Pathogenic	PS4, PS3_Moderate, PP1_Strong, PP3_Moderate	BA1, BS1, PM1, PM5	This pathogenicity assessment is relevant only for malignant hyperthermia susceptibility (MHS) inherited in an autosomal dominant pattern. Variants in RYR1 can also cause other myopathies inherited in an autosomal dominant pattern or in an autosomal recessive pattern. Some of these disorders may predispose individuals to malignant hyperthermia. RYR1 variants may also contribute to a malignant hyperthermia reaction in combination with other genetic and non-genetic factors and the clinician needs to consider such factors in making management decisions.This sequence variant predicts a substitution of Arginine with Leucine at codon 614 of the RYR1 protein, p.(Arg614Leu). This variant was not present in a large population database (gnomAD) at the time this variant was interpreted. This variant has been reported in nine unrelated individuals who have a personal or family history of a malignant hyperthermia reaction, all of these individuals had a positive in vitro contracture test (IVCT) or caffeine halothane contracture test (CHCT) result (if the proband was unavailable for testing, a positive diagnostic test result in a mutation-positive relative was counted), PS4 (PMID:10051009; PMID:17710899; PMID:10484775 and others). Functional studies in HEK293 cells show an increased sensitivity to RYR1 agonists, PS3_Moderate (PMID:9334205). This variant does not reside in a hotspot for pathogenic variants that contribute to MHS. This variant segregates with MHS in seven individuals, PP1_Strong (PMID:9389851; PMID:17710899). A REVEL score >0.85 supports a pathogenic status for this variant, PP3_Moderate. This variant has been classified as Pathogenic. Criteria implemented: PS4, PS3_Moderate, PP1_Strong, PP3_Moderate.		Malignant Hyperthermia Susceptibility VCEP	https://clinicalgenome.org/docs/clingen-malignant-hyperthermia-susceptibility-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-for/	2021-03-18	2021-03-31	False	https://erepo.genome.network/evrepo/ui/classification/CA024313/MONDO:0007783/012	2d50f12d-53e1-4c3b-bea8-d307ab18043a	p.Arg614Leu	Arg	614	Leu	MGDAEGEDEVQFLRTDDEVVLQCSATVLKEQLKLCLAAEGFGNRLCFLEPTSNAQNVPPDLAICCFVLEQSLSVRALQEMLANTVEAGVESSQGGGHRTLLYGHAILLRHAHSRMYLSCLTTSRSMTDKLAFDVGLQEDATGEACWWTMHPASKQRSEGEKVRVGDDIILVSVSSERYLHLSTASGELQVDASFMQTLWNMNPICSRCEEGFVTGGHVLRLFHGHMDECLTISPADSDDQRRLVYYEGGAVCTHARSLWRLEPLRISWSGSHLRWGQPLRVRHVTTGQYLALTEDQGLVVVDASKAHTKATSFCFRISKEKLDVAPKRDVEGMGPPEIKYGESLCFVQHVASGLWLTYAAPDPKALRLGVLKKKAMLHQEGHMDDALSLTRCQQEESQAARMIHSTNGLYNQFIKSLDSFSGKPRGSGPPAGTALPIEGVILSLQDLIIYFEPPSEDLQHEEKQSKLRSLRNRQSLFQEEGMLSMVLNCIDRLNVYTTAAHFAEFAGEEAAESWKEIVNLLYELLASLIRGNRSNCALFSTNLDWLVSKLDRLEASSGILEVLYCVLIESPEVLNIIQENHIKSIISLLDKHGRNHKVLDVLCSLCVCNGVAVRSNQDLITENLLPGRELLLQTNLINYVTSIRPNIFVGRAEGTTQYSKWYFEVMVDEVTPFLTAQATHLRVGWALTEGYTPYPGAGEGWGGNGVGDDLYSYGFDGLHLWTGHVARPVTSPGQHLLAPEDVISCCLDLSVPSISFRINGCPVQGVFESFNLDGLFFPVVSFSAGVKVRFLLGGRHGEFKFLPPPGYAPCHEAVLPRERLHLEPIKEYRREGPRGPHLVGPSRCLSHTDFVPCPVDTVQIVLPPHLERIREKLAENIHELWALTRIEQGWTYGPVRDDNKRLHPCLVDFHSLPEPERNYNLQMSGETLKTLLALGCHVGMADEKAEDNLKKTKLPKTYMMSNGYKPAPLDLSHVRLTPAQTTLVDRLAENGHNVWARDRVGQGWSYSAVQDIPARRNPRLVPYRLLDEATKRSNRDSLCQAVRTLLGYGYNIEPPDQEPSQVENQSRCDRVRIFRAEKSYTVQSGRWYFEFEAVTTGEMRVGWARPELRPDVELGADELAYVFNGHRGQRWHLGSEPFGRPWQPGDVVGCMIDLTENTIIFTLNGEVLMSDSGSETAFREIEIGDGFLPVCSLGPGQVGHLNLGQDVSSLRFFAICGLQEGFEPFAINMQRPVTTWFSKGLPQFEPVPLEHPHYEVSRVDGTVDTPPCLRLTHRTWGSQNSLVEMLFLRLSLPVQFHQHFRCTAGATPLAPPGLQPPAEDEARAAEPDPDYENLRRSAGGWSEAENGKEGTAKEGAPGGTPQAGGEAQPARAENEKDATTEKNKKRGFLFKAKKVAMMTQPPATPTLPRLPHDVVPADNRDDPEIILNTTTYYYSVRVFAGQEPSCVWAGWVTPDYHQHDMSFDLSKVRVVTVTMGDEQGNVHSSLKCSNCYMVWGGDFVSPGQQGRISHTDLVIGCLVDLATGLMTFTANGKESNTFFQVEPNTKLFPAVFVLPTHQNVIQFELGKQKNIMPLSAAMFQSERKNPAPQCPPRLEMQMLMPVSWSRMPNHFLQVETRRAGERLGWAVQCQEPLTMMALHIPEENRCMDILELSERLDLQRFHSHTLRLYRAVCALGNNRVAHALCSHVDQAQLLHALEDAHLPGPLRAGYYDLLISIHLESACRSRRSMLSEYIVPLTPETRAITLFPPGRSTENGHPRHGLPGVGVTTSLRPPHHFSPPCFVAALPAAGAAEAPARLSPAIPLEALRDKALRMLGEAVRDGGQHARDPVGGSVEFQFVPVLKLVSTLLVMGIFGDEDVKQILKMIEPEVFTEEEEEEDEEEEGEEEDEEEKEEDEEETAQEKEDEEKEEEEAAEGEKEEGLEEGLLQMKLPESVKLQMCHLLEYFCDQELQHRVESLAAFAERYVDKLQANQRSRYGLLIKAFSMTAAETARRTREFRSPPQEQINMLLQFKDGTDEEDCPLPEEIRQDLLDFHQDLLAHCGIQLDGEEEEPEEETTLGSRLMSLLEKVRLVKKKEEKPEEERSAEESKPRSLQELVSHMVVRWAQEDFVQSPELVRAMFSLLHRQYDGLGELLRALPRAYTISPSSVEDTMSLLECLGQIRSLLIVQMGPQEENLMIQSIGNIMNNKVFYQHPNLMRALGMHETVMEVMVNVLGGGESKEIRFPKMVTSCCRFLCYFCRISRQNQRSMFDHLSYLLENSGIGLGMQGSTPLDVAAASVIDNNELALALQEQDLEKVVSYLAGCGLQSCPMLVAKGYPDIGWNPCGGERYLDFLRFAVFVNGESVEENANVVVRLLIRKPECFGPALRGEGGSGLLAAIEEAIRISEDPARDGPGIRRDRRREHFGEEPPEENRVHLGHAIMSFYAALIDLLGRCAPEMHLIQAGKGEALRIRAILRSLVPLEDLVGIISLPLQIPTLGKDGALVQPKMSASFVPDHKASMVLFLDRVYGIENQDFLLHVLDVGFLPDMRAAASLDTATFSTTEMALALNRYLCLAVLPLITKCAPLFAGTEHRAIMVDSMLHTVYRLSRGRSLTKAQRDVIEDCLMSLCRYIRPSMLQHLLRRLVFDVPILNEFAKMPLKLLTNHYERCWKYYCLPTGWANFGVTSEEELHLTRKLFWGIFDSLAHKKYDPELYRMAMPCLCAIAGALPPDYVDASYSSKAEKKATVDAEGNFDPRPVETLNVIIPEKLDSFINKFAEYTHEKWAFDKIQNNWSYGENIDEELKTHPMLRPYKTFSEKDKEIYRWPIKESLKAMIAWEWTIEKAREGEEEKTEKKKTRKISQSAQTYDPREGYNPQPPDLSAVTLSRELQAMAEQLAENYHNTWGRKKKQELEAKGGGTHPLLVPYDTLTAKEKARDREKAQELLKFLQMNGYAVTRGLKDMELDSSSIEKRFAFGFLQQLLRWMDISQEFIAHLEAVVSSGRVEKSPHEQEIKFFAKILLPLINQYFTNHCLYFLSTPAKVLGSGGHASNKEKEMITSLFCKLAALVRHRVSLFGTDAPAVVNCLHILARSLDARTVMKSGPEIVKAGLRSFFESASEDIEKMVENLRLGKVSQARTQVKGVGQNLTYTTVALLPVLTTLFQHIAQHQFGDDVILDDVQVSCYRTLCSIYSLGTTKNTYVEKLRPALGECLARLAAAMPVAFLEPQLNEYNACSVYTTKSPRERAILGLPNSVEEMCPDIPVLERLMADIGGLAESGARYTEMPHVIEITLPMLCSYLPRWWERGPEAPPSALPAGAPPPCTAVTSDHLNSLLGNILRIIVNNLGIDEASWMKRLAVFAQPIVSRARPELLQSHFIPTIGRLRKRAGKVVSEEEQLRLEAKAEAQEGELLVRDEFSVLCRDLYALYPLLIRYVDNNRAQWLTEPNPSAEELFRMVGEIFIYWSKSHNFKREEQNFVVQNEINNMSFLTADNKSKMAKAGDIQSGGSDQERTKKKRRGDRYSVQTSLIVATLKKMLPIGLNMCAPTDQDLITLAKTRYALKDTDEEVREFLHNNLHLQGKVEGSPSLRWQMALYRGVPGREEDADDPEKIVRRVQEVSAVLYYLDQTEHPYKSKKAVWHKLLSKQRRRAVVACFRMTPLYNLPTHRACNMFLESYKAAWILTEDHSFEDRMIDDLSKAGEQEEEEEEVEEKKPDPLHQLVLHFSRTALTEKSKLDEDYLYMAYADIMAKSCHLEEGGENGEAEEEVEVSFEEKQMEKQRLLYQQARLHTRGAAEMVLQMISACKGETGAMVSSTLKLGISILNGGNAEVQQKMLDYLKDKKEVGFFQSIQALMQTCSVLDLNAFERQNKAEGLGMVNEDGTVINRQNGEKVMADDEFTQDLFRFLQLLCEGHNNDFQNYLRTQTGNTTTINIIICTVDYLLRLQESISDFYWYYSGKDVIEEQGKRNFSKAMSVAKQVFNSLTEYIQGPCTGNQQSLAHSRLWDAVVGFLHVFAHMMMKLAQDSSQIELLKELLDLQKDMVVMLLSLLEGNVVNGMIARQMVDMLVESSSNVEMILKFFDMFLKLKDIVGSEAFQDYVTDPRGLISKKDFQKAMDSQKQFSGPEIQFLLSCSEADENEMINCEEFANRFQEPARDIGFNVAVLLTNLSEHVPHDPRLHNFLELAESILEYFRPYLGRIEIMGASRRIERIYFEISETNRAQWEMPQVKESKRQFIFDVVNEGGEAEKMELFVSFCEDTIFEMQIAAQISEPEGEPETDEDEGAGAAEAGAEGAEEGAAGLEGTAATAAAGATARVVAAAGRALRGLSYRSLRRRVRRLRRLTAREAATAVAALLWAAVTRAGAAGAGAAAGALGLLWGSLFGGGLVEGAKKVTVTELLAGMPDPTSDEVHGEQPAGPGGDADGEGASEGAGDAAEGAGDEEEAVHEAGPGGADGAVAVTDGGPFRPEGAGGLGDMGDTTPAEPPTPEGSPILKRKLGVDGVEEELPPEPEPEPEPELEPEKADAENGEKEEVPEPTPEPPKKQAPPSPPPKKEEAGGEFWGELEVQRVKFLNYLSRNFYTLRFLALFLAFAINFILLFYKVSDSPPGEDDMEGSAAGDVSGAGSGGSSGWGLGAGEEAEGDEDENMVYYFLEESTGYMEPALRCLSLLHTLVAFLCIIGYNCLKVPLVIFKREKELARKLEFDGLYITEQPEDDDVKGQWDRLVLNTPSFPSNYWDKFVKRKVLDKHGDIYGRERIAELLGMDLATLEITAHNERKPNPPPGLLTWLMSIDVKYQIWKFGVIFTDNSFLYLGWYMVMSLLGHYNNFFFAAHLLDIAMGVKTLRTILSSVTHNGKQLVMTVGLLAVVVYLYTVVAFNFFRKFYNKSEDEDEPDMKCDDMMTCYLFHMYVGVRAGGGIGDEIEDPAGDEYELYRVVFDITFFFFVIVILLAIIQGLIIDAFGELRDQQEQVKEDMETKCFICGIGSDYFDTTPHGFETHTLEEHNLANYMFFLMYLINKDETEHTGQESYVWKMYQERCWDFFPAGDCFRKQYEDQLS	5038	P21817	L	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
240	NM_000540.2(RYR1):c.12884C>T (p.Ala4295Val)	133043	CA024018	NM_000540.2:c.12884C>T, NC_000019.10:g.38565218C>T, CM000681.2:g.38565218C>T, NC_000019.9:g.39055858C>T, CM000681.1:g.39055858C>T, NC_000019.8:g.43747698C>T, NG_008866.1:g.136519C>T, LRG_766:g.136519C>T, ENST00000355481.8:c.12869C>T, ENST00000359596.7:n.12884C>T, ENST00000360985.7:c.12866C>T, LRG_766t1:c.12884C>T, NM_001042723.1:c.12869C>T, XM_006723317.1:c.12866C>T, XM_006723319.1:c.12851C>T, XM_011527204.1:c.12881C>T, XM_011527205.1:c.12884C>T, XM_006723317.2:c.12866C>T, XM_006723319.2:c.12851C>T, XM_011527205.2:c.12884C>T, NM_000540.3:c.12884C>T, NM_001042723.2:c.12869C>T, NM_000540.2(RYR1):c.12884C>T (p.Ala4295Val)	RYR1	malignant hyperthermia, susceptibility to, 1	MONDO:0007783	Autosomal dominant inheritance	Benign	BP4, BP2, BS2_Supporting, BS1	PP3, BA1, PS4, PM1	This pathogenicity assessment is relevant only for malignant hyperthermia susceptibility (MHS) inherited in an autosomal dominant pattern. Variants in RYR1 can also cause other myopathies inherited in an autosomal dominant pattern or in an autosomal recessive pattern. Some of these disorders may predispose individuals to malignant hyperthermia. RYR1 variants may also contribute to a malignant hyperthermia reaction in combination with other genetic and non-genetic factors and the clinician needs to consider such factors in making management decisions.This sequence variant predicts a substitution of Alanine with Valine at codon 4295 of the RYR1 protein, p.(Ala4295Val). The maximum allele frequency for this variant among the six major gnomAD populations is NFE: 0.0019, this is considered to be more common than expected for a pathogenic variant causing autosomal dominantly inherited MHS, BS1. This variant has been reported in two unrelated individuals who have a personal or family history of a malignant hyperthermia reaction, both of these individuals had a positive in vitro contracture test (IVCT) or caffeine halothane contracture test (CHCT) result (if the proband was unavailable for testing, a positive diagnostic test result in a mutation-positive relative was counted), (PMID:30236257). However, the high MAF in the NFE population in gnomAD precludes the use of PS4. This variant has been identified in an individual with a negative IVCT/CHCT result, BS2_Moderate, (PMID:25658027). No functional studies were identified for this variant. This variant does not reside in a hotspot for pathogenic variants that contribute to MHS. This variant was observed in cis with a variant assessed as pathogenic, p.(Arg2435His), BP2 (PMID:19513315). A REVEL score <0.5 (0.152) supports a benign status for this variant, BP4. Based on using Bayes to combine criteria this variant is assessed as Benign, (PMID: 29300386). Criteria implemented: BS1, BS2_Moderate, BP2, BP4.		Malignant Hyperthermia Susceptibility VCEP	https://clinicalgenome.org/docs/clingen-malignant-hyperthermia-susceptibility-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-for/	2021-03-18	2021-03-31	False	https://erepo.genome.network/evrepo/ui/classification/CA024018/MONDO:0007783/012	ee8cf8a1-7193-4be2-92d4-4ee287b0fdf0	p.Ala4295Val	Ala	4295	Val	MGDAEGEDEVQFLRTDDEVVLQCSATVLKEQLKLCLAAEGFGNRLCFLEPTSNAQNVPPDLAICCFVLEQSLSVRALQEMLANTVEAGVESSQGGGHRTLLYGHAILLRHAHSRMYLSCLTTSRSMTDKLAFDVGLQEDATGEACWWTMHPASKQRSEGEKVRVGDDIILVSVSSERYLHLSTASGELQVDASFMQTLWNMNPICSRCEEGFVTGGHVLRLFHGHMDECLTISPADSDDQRRLVYYEGGAVCTHARSLWRLEPLRISWSGSHLRWGQPLRVRHVTTGQYLALTEDQGLVVVDASKAHTKATSFCFRISKEKLDVAPKRDVEGMGPPEIKYGESLCFVQHVASGLWLTYAAPDPKALRLGVLKKKAMLHQEGHMDDALSLTRCQQEESQAARMIHSTNGLYNQFIKSLDSFSGKPRGSGPPAGTALPIEGVILSLQDLIIYFEPPSEDLQHEEKQSKLRSLRNRQSLFQEEGMLSMVLNCIDRLNVYTTAAHFAEFAGEEAAESWKEIVNLLYELLASLIRGNRSNCALFSTNLDWLVSKLDRLEASSGILEVLYCVLIESPEVLNIIQENHIKSIISLLDKHGRNHKVLDVLCSLCVCNGVAVRSNQDLITENLLPGRELLLQTNLINYVTSIRPNIFVGRAEGTTQYSKWYFEVMVDEVTPFLTAQATHLRVGWALTEGYTPYPGAGEGWGGNGVGDDLYSYGFDGLHLWTGHVARPVTSPGQHLLAPEDVISCCLDLSVPSISFRINGCPVQGVFESFNLDGLFFPVVSFSAGVKVRFLLGGRHGEFKFLPPPGYAPCHEAVLPRERLHLEPIKEYRREGPRGPHLVGPSRCLSHTDFVPCPVDTVQIVLPPHLERIREKLAENIHELWALTRIEQGWTYGPVRDDNKRLHPCLVDFHSLPEPERNYNLQMSGETLKTLLALGCHVGMADEKAEDNLKKTKLPKTYMMSNGYKPAPLDLSHVRLTPAQTTLVDRLAENGHNVWARDRVGQGWSYSAVQDIPARRNPRLVPYRLLDEATKRSNRDSLCQAVRTLLGYGYNIEPPDQEPSQVENQSRCDRVRIFRAEKSYTVQSGRWYFEFEAVTTGEMRVGWARPELRPDVELGADELAYVFNGHRGQRWHLGSEPFGRPWQPGDVVGCMIDLTENTIIFTLNGEVLMSDSGSETAFREIEIGDGFLPVCSLGPGQVGHLNLGQDVSSLRFFAICGLQEGFEPFAINMQRPVTTWFSKGLPQFEPVPLEHPHYEVSRVDGTVDTPPCLRLTHRTWGSQNSLVEMLFLRLSLPVQFHQHFRCTAGATPLAPPGLQPPAEDEARAAEPDPDYENLRRSAGGWSEAENGKEGTAKEGAPGGTPQAGGEAQPARAENEKDATTEKNKKRGFLFKAKKVAMMTQPPATPTLPRLPHDVVPADNRDDPEIILNTTTYYYSVRVFAGQEPSCVWAGWVTPDYHQHDMSFDLSKVRVVTVTMGDEQGNVHSSLKCSNCYMVWGGDFVSPGQQGRISHTDLVIGCLVDLATGLMTFTANGKESNTFFQVEPNTKLFPAVFVLPTHQNVIQFELGKQKNIMPLSAAMFQSERKNPAPQCPPRLEMQMLMPVSWSRMPNHFLQVETRRAGERLGWAVQCQEPLTMMALHIPEENRCMDILELSERLDLQRFHSHTLRLYRAVCALGNNRVAHALCSHVDQAQLLHALEDAHLPGPLRAGYYDLLISIHLESACRSRRSMLSEYIVPLTPETRAITLFPPGRSTENGHPRHGLPGVGVTTSLRPPHHFSPPCFVAALPAAGAAEAPARLSPAIPLEALRDKALRMLGEAVRDGGQHARDPVGGSVEFQFVPVLKLVSTLLVMGIFGDEDVKQILKMIEPEVFTEEEEEEDEEEEGEEEDEEEKEEDEEETAQEKEDEEKEEEEAAEGEKEEGLEEGLLQMKLPESVKLQMCHLLEYFCDQELQHRVESLAAFAERYVDKLQANQRSRYGLLIKAFSMTAAETARRTREFRSPPQEQINMLLQFKDGTDEEDCPLPEEIRQDLLDFHQDLLAHCGIQLDGEEEEPEEETTLGSRLMSLLEKVRLVKKKEEKPEEERSAEESKPRSLQELVSHMVVRWAQEDFVQSPELVRAMFSLLHRQYDGLGELLRALPRAYTISPSSVEDTMSLLECLGQIRSLLIVQMGPQEENLMIQSIGNIMNNKVFYQHPNLMRALGMHETVMEVMVNVLGGGESKEIRFPKMVTSCCRFLCYFCRISRQNQRSMFDHLSYLLENSGIGLGMQGSTPLDVAAASVIDNNELALALQEQDLEKVVSYLAGCGLQSCPMLVAKGYPDIGWNPCGGERYLDFLRFAVFVNGESVEENANVVVRLLIRKPECFGPALRGEGGSGLLAAIEEAIRISEDPARDGPGIRRDRRREHFGEEPPEENRVHLGHAIMSFYAALIDLLGRCAPEMHLIQAGKGEALRIRAILRSLVPLEDLVGIISLPLQIPTLGKDGALVQPKMSASFVPDHKASMVLFLDRVYGIENQDFLLHVLDVGFLPDMRAAASLDTATFSTTEMALALNRYLCLAVLPLITKCAPLFAGTEHRAIMVDSMLHTVYRLSRGRSLTKAQRDVIEDCLMSLCRYIRPSMLQHLLRRLVFDVPILNEFAKMPLKLLTNHYERCWKYYCLPTGWANFGVTSEEELHLTRKLFWGIFDSLAHKKYDPELYRMAMPCLCAIAGALPPDYVDASYSSKAEKKATVDAEGNFDPRPVETLNVIIPEKLDSFINKFAEYTHEKWAFDKIQNNWSYGENIDEELKTHPMLRPYKTFSEKDKEIYRWPIKESLKAMIAWEWTIEKAREGEEEKTEKKKTRKISQSAQTYDPREGYNPQPPDLSAVTLSRELQAMAEQLAENYHNTWGRKKKQELEAKGGGTHPLLVPYDTLTAKEKARDREKAQELLKFLQMNGYAVTRGLKDMELDSSSIEKRFAFGFLQQLLRWMDISQEFIAHLEAVVSSGRVEKSPHEQEIKFFAKILLPLINQYFTNHCLYFLSTPAKVLGSGGHASNKEKEMITSLFCKLAALVRHRVSLFGTDAPAVVNCLHILARSLDARTVMKSGPEIVKAGLRSFFESASEDIEKMVENLRLGKVSQARTQVKGVGQNLTYTTVALLPVLTTLFQHIAQHQFGDDVILDDVQVSCYRTLCSIYSLGTTKNTYVEKLRPALGECLARLAAAMPVAFLEPQLNEYNACSVYTTKSPRERAILGLPNSVEEMCPDIPVLERLMADIGGLAESGARYTEMPHVIEITLPMLCSYLPRWWERGPEAPPSALPAGAPPPCTAVTSDHLNSLLGNILRIIVNNLGIDEASWMKRLAVFAQPIVSRARPELLQSHFIPTIGRLRKRAGKVVSEEEQLRLEAKAEAQEGELLVRDEFSVLCRDLYALYPLLIRYVDNNRAQWLTEPNPSAEELFRMVGEIFIYWSKSHNFKREEQNFVVQNEINNMSFLTADNKSKMAKAGDIQSGGSDQERTKKKRRGDRYSVQTSLIVATLKKMLPIGLNMCAPTDQDLITLAKTRYALKDTDEEVREFLHNNLHLQGKVEGSPSLRWQMALYRGVPGREEDADDPEKIVRRVQEVSAVLYYLDQTEHPYKSKKAVWHKLLSKQRRRAVVACFRMTPLYNLPTHRACNMFLESYKAAWILTEDHSFEDRMIDDLSKAGEQEEEEEEVEEKKPDPLHQLVLHFSRTALTEKSKLDEDYLYMAYADIMAKSCHLEEGGENGEAEEEVEVSFEEKQMEKQRLLYQQARLHTRGAAEMVLQMISACKGETGAMVSSTLKLGISILNGGNAEVQQKMLDYLKDKKEVGFFQSIQALMQTCSVLDLNAFERQNKAEGLGMVNEDGTVINRQNGEKVMADDEFTQDLFRFLQLLCEGHNNDFQNYLRTQTGNTTTINIIICTVDYLLRLQESISDFYWYYSGKDVIEEQGKRNFSKAMSVAKQVFNSLTEYIQGPCTGNQQSLAHSRLWDAVVGFLHVFAHMMMKLAQDSSQIELLKELLDLQKDMVVMLLSLLEGNVVNGMIARQMVDMLVESSSNVEMILKFFDMFLKLKDIVGSEAFQDYVTDPRGLISKKDFQKAMDSQKQFSGPEIQFLLSCSEADENEMINCEEFANRFQEPARDIGFNVAVLLTNLSEHVPHDPRLHNFLELAESILEYFRPYLGRIEIMGASRRIERIYFEISETNRAQWEMPQVKESKRQFIFDVVNEGGEAEKMELFVSFCEDTIFEMQIAAQISEPEGEPETDEDEGAGAAEAGAEGAEEGAAGLEGTAATAAAGATARVVAAAGRALRGLSYRSLRRRVRRLRRLTAREAATAVAALLWAAVTRAGAAGAGAAAGALGLLWGSLFGGGLVEGAKKVTVTELLAGMPDPTSDEVHGEQPAGPGGDADGEGASEGAGDAAEGAGDEEEAVHEAGPGGADGAVAVTDGGPFRPEGAGGLGDMGDTTPAEPPTPEGSPILKRKLGVDGVEEELPPEPEPEPEPELEPEKADAENGEKEEVPEPTPEPPKKQAPPSPPPKKEEAGGEFWGELEVQRVKFLNYLSRNFYTLRFLALFLAFAINFILLFYKVSDSPPGEDDMEGSAAGDVSGAGSGGSSGWGLGAGEEAEGDEDENMVYYFLEESTGYMEPALRCLSLLHTLVAFLCIIGYNCLKVPLVIFKREKELARKLEFDGLYITEQPEDDDVKGQWDRLVLNTPSFPSNYWDKFVKRKVLDKHGDIYGRERIAELLGMDLATLEITAHNERKPNPPPGLLTWLMSIDVKYQIWKFGVIFTDNSFLYLGWYMVMSLLGHYNNFFFAAHLLDIAMGVKTLRTILSSVTHNGKQLVMTVGLLAVVVYLYTVVAFNFFRKFYNKSEDEDEPDMKCDDMMTCYLFHMYVGVRAGGGIGDEIEDPAGDEYELYRVVFDITFFFFVIVILLAIIQGLIIDAFGELRDQQEQVKEDMETKCFICGIGSDYFDTTPHGFETHTLEEHNLANYMFFLMYLINKDETEHTGQESYVWKMYQERCWDFFPAGDCFRKQYEDQLS	5038	P21817	V	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
241	NM_000540.2(RYR1):c.1202G>A (p.Arg401His)	133030	CA023959	NM_000540.2:c.1202G>A, NC_000019.10:g.38451843G>A, CM000681.2:g.38451843G>A, NC_000019.9:g.38942483G>A, CM000681.1:g.38942483G>A, NC_000019.8:g.43634323G>A, NG_008866.1:g.23144G>A, LRG_766:g.23144G>A, ENST00000355481.8:c.1202G>A, ENST00000359596.7:n.1202G>A, ENST00000360985.7:c.1202G>A, LRG_766t1:c.1202G>A, NM_001042723.1:c.1202G>A, XM_006723317.1:c.1202G>A, XM_006723319.1:c.1202G>A, XM_011527204.1:c.1199G>A, XM_011527205.1:c.1202G>A, XM_006723317.2:c.1202G>A, XM_006723319.2:c.1202G>A, XM_011527205.2:c.1202G>A, NM_000540.3:c.1202G>A, NM_001042723.2:c.1202G>A, NM_000540.2(RYR1):c.1202G>A (p.Arg401His)	RYR1	malignant hyperthermia, susceptibility to, 1	MONDO:0007783	Autosomal dominant inheritance	Pathogenic	PP1, PS4, PS3_Moderate, PM1, PP3_Moderate	BA1, BP4, BS1	This pathogenicity assessment is relevant only for malignant hyperthermia susceptibility (MHS) inherited in an autosomal dominant pattern. Variants in RYR1 can also cause other myopathies inherited in an autosomal dominant pattern or in an autosomal recessive pattern. Some of these disorders may predispose individuals to malignant hyperthermia. RYR1 variants may also contribute to a malignant hyperthermia reaction in combination with other genetic and non-genetic factors and the clinician needs to consider such factors in making management decisions. This sequence variant predicts a substitution of arginine with histidine at codon 401 of the RYR1 protein, p.(Arg401His). The maximum allele frequency for this variant in the Finish population in gnomAD was 0.000046 with one alternate allele. This variant was not identified in any of the six continental populations in gnomAD. This is consistent with pathogenicity. This variant has been reported in eight unrelated individuals who have a personal or family history of a malignant hyperthermia reaction, eight of these individuals had a positive in vitro contracture test (IVCT) or caffeine halothane contracture test (CHCT) result (if the proband was unavailable for testing, a positive diagnostic test result in a mutation-positive relative was counted), PS4 (PMID:12059893, PMID:16163667, PMID:30236257, PMID:23460944, PMID:24433488). This variant segregates with MHS in three individuals, PP1_Supporting ( PMID:12059893). Functional studies in HEK293 cells show an increased sensitivity to RYR1 agonists PS3_Moderate (PMID:26115329, PMID:31841587). This variant resides in a region of RYR1 considered to be a hotspot for pathogenic variants that contribute to MHS, PM1 (PMID: 21118704). This variant segregates with MHS in three individuals, PP1_Supporting (PMID:12059893). A REVEL score >0.85 (0.903) supports a pathogenic status for this variant, PP3_Moderate. This variant has been classified as Pathogenic. Criteria implemented: PS3_Moderate, PS4, PM1, PP1_Supporting, PP3_Moderate. 		Malignant Hyperthermia Susceptibility VCEP	https://clinicalgenome.org/docs/clingen-malignant-hyperthermia-susceptibility-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-for/	2021-03-18	2021-03-31	False	https://erepo.genome.network/evrepo/ui/classification/CA023959/MONDO:0007783/012	29fc611a-ac33-4a31-aa55-7f0ae887a359	p.Arg401His	Arg	401	His	MGDAEGEDEVQFLRTDDEVVLQCSATVLKEQLKLCLAAEGFGNRLCFLEPTSNAQNVPPDLAICCFVLEQSLSVRALQEMLANTVEAGVESSQGGGHRTLLYGHAILLRHAHSRMYLSCLTTSRSMTDKLAFDVGLQEDATGEACWWTMHPASKQRSEGEKVRVGDDIILVSVSSERYLHLSTASGELQVDASFMQTLWNMNPICSRCEEGFVTGGHVLRLFHGHMDECLTISPADSDDQRRLVYYEGGAVCTHARSLWRLEPLRISWSGSHLRWGQPLRVRHVTTGQYLALTEDQGLVVVDASKAHTKATSFCFRISKEKLDVAPKRDVEGMGPPEIKYGESLCFVQHVASGLWLTYAAPDPKALRLGVLKKKAMLHQEGHMDDALSLTRCQQEESQAARMIHSTNGLYNQFIKSLDSFSGKPRGSGPPAGTALPIEGVILSLQDLIIYFEPPSEDLQHEEKQSKLRSLRNRQSLFQEEGMLSMVLNCIDRLNVYTTAAHFAEFAGEEAAESWKEIVNLLYELLASLIRGNRSNCALFSTNLDWLVSKLDRLEASSGILEVLYCVLIESPEVLNIIQENHIKSIISLLDKHGRNHKVLDVLCSLCVCNGVAVRSNQDLITENLLPGRELLLQTNLINYVTSIRPNIFVGRAEGTTQYSKWYFEVMVDEVTPFLTAQATHLRVGWALTEGYTPYPGAGEGWGGNGVGDDLYSYGFDGLHLWTGHVARPVTSPGQHLLAPEDVISCCLDLSVPSISFRINGCPVQGVFESFNLDGLFFPVVSFSAGVKVRFLLGGRHGEFKFLPPPGYAPCHEAVLPRERLHLEPIKEYRREGPRGPHLVGPSRCLSHTDFVPCPVDTVQIVLPPHLERIREKLAENIHELWALTRIEQGWTYGPVRDDNKRLHPCLVDFHSLPEPERNYNLQMSGETLKTLLALGCHVGMADEKAEDNLKKTKLPKTYMMSNGYKPAPLDLSHVRLTPAQTTLVDRLAENGHNVWARDRVGQGWSYSAVQDIPARRNPRLVPYRLLDEATKRSNRDSLCQAVRTLLGYGYNIEPPDQEPSQVENQSRCDRVRIFRAEKSYTVQSGRWYFEFEAVTTGEMRVGWARPELRPDVELGADELAYVFNGHRGQRWHLGSEPFGRPWQPGDVVGCMIDLTENTIIFTLNGEVLMSDSGSETAFREIEIGDGFLPVCSLGPGQVGHLNLGQDVSSLRFFAICGLQEGFEPFAINMQRPVTTWFSKGLPQFEPVPLEHPHYEVSRVDGTVDTPPCLRLTHRTWGSQNSLVEMLFLRLSLPVQFHQHFRCTAGATPLAPPGLQPPAEDEARAAEPDPDYENLRRSAGGWSEAENGKEGTAKEGAPGGTPQAGGEAQPARAENEKDATTEKNKKRGFLFKAKKVAMMTQPPATPTLPRLPHDVVPADNRDDPEIILNTTTYYYSVRVFAGQEPSCVWAGWVTPDYHQHDMSFDLSKVRVVTVTMGDEQGNVHSSLKCSNCYMVWGGDFVSPGQQGRISHTDLVIGCLVDLATGLMTFTANGKESNTFFQVEPNTKLFPAVFVLPTHQNVIQFELGKQKNIMPLSAAMFQSERKNPAPQCPPRLEMQMLMPVSWSRMPNHFLQVETRRAGERLGWAVQCQEPLTMMALHIPEENRCMDILELSERLDLQRFHSHTLRLYRAVCALGNNRVAHALCSHVDQAQLLHALEDAHLPGPLRAGYYDLLISIHLESACRSRRSMLSEYIVPLTPETRAITLFPPGRSTENGHPRHGLPGVGVTTSLRPPHHFSPPCFVAALPAAGAAEAPARLSPAIPLEALRDKALRMLGEAVRDGGQHARDPVGGSVEFQFVPVLKLVSTLLVMGIFGDEDVKQILKMIEPEVFTEEEEEEDEEEEGEEEDEEEKEEDEEETAQEKEDEEKEEEEAAEGEKEEGLEEGLLQMKLPESVKLQMCHLLEYFCDQELQHRVESLAAFAERYVDKLQANQRSRYGLLIKAFSMTAAETARRTREFRSPPQEQINMLLQFKDGTDEEDCPLPEEIRQDLLDFHQDLLAHCGIQLDGEEEEPEEETTLGSRLMSLLEKVRLVKKKEEKPEEERSAEESKPRSLQELVSHMVVRWAQEDFVQSPELVRAMFSLLHRQYDGLGELLRALPRAYTISPSSVEDTMSLLECLGQIRSLLIVQMGPQEENLMIQSIGNIMNNKVFYQHPNLMRALGMHETVMEVMVNVLGGGESKEIRFPKMVTSCCRFLCYFCRISRQNQRSMFDHLSYLLENSGIGLGMQGSTPLDVAAASVIDNNELALALQEQDLEKVVSYLAGCGLQSCPMLVAKGYPDIGWNPCGGERYLDFLRFAVFVNGESVEENANVVVRLLIRKPECFGPALRGEGGSGLLAAIEEAIRISEDPARDGPGIRRDRRREHFGEEPPEENRVHLGHAIMSFYAALIDLLGRCAPEMHLIQAGKGEALRIRAILRSLVPLEDLVGIISLPLQIPTLGKDGALVQPKMSASFVPDHKASMVLFLDRVYGIENQDFLLHVLDVGFLPDMRAAASLDTATFSTTEMALALNRYLCLAVLPLITKCAPLFAGTEHRAIMVDSMLHTVYRLSRGRSLTKAQRDVIEDCLMSLCRYIRPSMLQHLLRRLVFDVPILNEFAKMPLKLLTNHYERCWKYYCLPTGWANFGVTSEEELHLTRKLFWGIFDSLAHKKYDPELYRMAMPCLCAIAGALPPDYVDASYSSKAEKKATVDAEGNFDPRPVETLNVIIPEKLDSFINKFAEYTHEKWAFDKIQNNWSYGENIDEELKTHPMLRPYKTFSEKDKEIYRWPIKESLKAMIAWEWTIEKAREGEEEKTEKKKTRKISQSAQTYDPREGYNPQPPDLSAVTLSRELQAMAEQLAENYHNTWGRKKKQELEAKGGGTHPLLVPYDTLTAKEKARDREKAQELLKFLQMNGYAVTRGLKDMELDSSSIEKRFAFGFLQQLLRWMDISQEFIAHLEAVVSSGRVEKSPHEQEIKFFAKILLPLINQYFTNHCLYFLSTPAKVLGSGGHASNKEKEMITSLFCKLAALVRHRVSLFGTDAPAVVNCLHILARSLDARTVMKSGPEIVKAGLRSFFESASEDIEKMVENLRLGKVSQARTQVKGVGQNLTYTTVALLPVLTTLFQHIAQHQFGDDVILDDVQVSCYRTLCSIYSLGTTKNTYVEKLRPALGECLARLAAAMPVAFLEPQLNEYNACSVYTTKSPRERAILGLPNSVEEMCPDIPVLERLMADIGGLAESGARYTEMPHVIEITLPMLCSYLPRWWERGPEAPPSALPAGAPPPCTAVTSDHLNSLLGNILRIIVNNLGIDEASWMKRLAVFAQPIVSRARPELLQSHFIPTIGRLRKRAGKVVSEEEQLRLEAKAEAQEGELLVRDEFSVLCRDLYALYPLLIRYVDNNRAQWLTEPNPSAEELFRMVGEIFIYWSKSHNFKREEQNFVVQNEINNMSFLTADNKSKMAKAGDIQSGGSDQERTKKKRRGDRYSVQTSLIVATLKKMLPIGLNMCAPTDQDLITLAKTRYALKDTDEEVREFLHNNLHLQGKVEGSPSLRWQMALYRGVPGREEDADDPEKIVRRVQEVSAVLYYLDQTEHPYKSKKAVWHKLLSKQRRRAVVACFRMTPLYNLPTHRACNMFLESYKAAWILTEDHSFEDRMIDDLSKAGEQEEEEEEVEEKKPDPLHQLVLHFSRTALTEKSKLDEDYLYMAYADIMAKSCHLEEGGENGEAEEEVEVSFEEKQMEKQRLLYQQARLHTRGAAEMVLQMISACKGETGAMVSSTLKLGISILNGGNAEVQQKMLDYLKDKKEVGFFQSIQALMQTCSVLDLNAFERQNKAEGLGMVNEDGTVINRQNGEKVMADDEFTQDLFRFLQLLCEGHNNDFQNYLRTQTGNTTTINIIICTVDYLLRLQESISDFYWYYSGKDVIEEQGKRNFSKAMSVAKQVFNSLTEYIQGPCTGNQQSLAHSRLWDAVVGFLHVFAHMMMKLAQDSSQIELLKELLDLQKDMVVMLLSLLEGNVVNGMIARQMVDMLVESSSNVEMILKFFDMFLKLKDIVGSEAFQDYVTDPRGLISKKDFQKAMDSQKQFSGPEIQFLLSCSEADENEMINCEEFANRFQEPARDIGFNVAVLLTNLSEHVPHDPRLHNFLELAESILEYFRPYLGRIEIMGASRRIERIYFEISETNRAQWEMPQVKESKRQFIFDVVNEGGEAEKMELFVSFCEDTIFEMQIAAQISEPEGEPETDEDEGAGAAEAGAEGAEEGAAGLEGTAATAAAGATARVVAAAGRALRGLSYRSLRRRVRRLRRLTAREAATAVAALLWAAVTRAGAAGAGAAAGALGLLWGSLFGGGLVEGAKKVTVTELLAGMPDPTSDEVHGEQPAGPGGDADGEGASEGAGDAAEGAGDEEEAVHEAGPGGADGAVAVTDGGPFRPEGAGGLGDMGDTTPAEPPTPEGSPILKRKLGVDGVEEELPPEPEPEPEPELEPEKADAENGEKEEVPEPTPEPPKKQAPPSPPPKKEEAGGEFWGELEVQRVKFLNYLSRNFYTLRFLALFLAFAINFILLFYKVSDSPPGEDDMEGSAAGDVSGAGSGGSSGWGLGAGEEAEGDEDENMVYYFLEESTGYMEPALRCLSLLHTLVAFLCIIGYNCLKVPLVIFKREKELARKLEFDGLYITEQPEDDDVKGQWDRLVLNTPSFPSNYWDKFVKRKVLDKHGDIYGRERIAELLGMDLATLEITAHNERKPNPPPGLLTWLMSIDVKYQIWKFGVIFTDNSFLYLGWYMVMSLLGHYNNFFFAAHLLDIAMGVKTLRTILSSVTHNGKQLVMTVGLLAVVVYLYTVVAFNFFRKFYNKSEDEDEPDMKCDDMMTCYLFHMYVGVRAGGGIGDEIEDPAGDEYELYRVVFDITFFFFVIVILLAIIQGLIIDAFGELRDQQEQVKEDMETKCFICGIGSDYFDTTPHGFETHTLEEHNLANYMFFLMYLINKDETEHTGQESYVWKMYQERCWDFFPAGDCFRKQYEDQLS	5038	P21817	H	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
242	NM_000540.2(RYR1):c.10747G>C (p.Glu3583Gln)	132999	CA023858	NM_000540.2:c.10747G>C, NC_000019.10:g.38527707G>C, CM000681.2:g.38527707G>C, NC_000019.9:g.39018347G>C, CM000681.1:g.39018347G>C, NC_000019.8:g.43710187G>C, NG_008866.1:g.99008G>C, LRG_766:g.99008G>C, ENST00000355481.8:c.10732G>C, ENST00000359596.7:n.10747G>C, ENST00000360985.7:c.10729G>C, LRG_766t1:c.10747G>C, NM_001042723.1:c.10732G>C, XM_006723317.1:c.10747G>C, XM_006723319.1:c.10732G>C, XM_011527204.1:c.10744G>C, XM_011527205.1:c.10747G>C, XM_006723317.2:c.10747G>C, XM_006723319.2:c.10732G>C, XM_011527205.2:c.10747G>C, NM_000540.3:c.10747G>C, NM_001042723.2:c.10732G>C, NM_000540.2(RYR1):c.10747G>C (p.Glu3583Gln)	RYR1	malignant hyperthermia, susceptibility to, 1	MONDO:0007783	Autosomal dominant inheritance	Benign	BA1		This pathogenicity assessment is relevant only for malignant hyperthermia susceptibility (MHS) inherited in an autosomal dominant pattern. Variants in RYR1 can also cause other myopathies inherited in an autosomal dominant pattern or in an autosomal recessive pattern. Some of these disorders may predispose individuals to malignant hyperthermia. RYR1 variants may also contribute to a malignant hyperthermia reaction in combination with other genetic and non-genetic factors and the clinician needs to consider such factors in making management decisions.This sequence variant predicts a substitution of Glutamic Acid with Glutamine at codon 3583 of the RYR1 protein, p.(Glu3583Gln). The maximum allele frequency for this variant among the six major gnomAD populations is SAS: 0.0241, which is considered to be too common for a pathogenic variant causing autosomal dominantly inherited MHS, BA1. This variant has been classified as Benign. Criteria implemented: BA1.		Malignant Hyperthermia Susceptibility VCEP	https://clinicalgenome.org/docs/clingen-malignant-hyperthermia-susceptibility-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-for/	2021-03-17	2021-03-31	False	https://erepo.genome.network/evrepo/ui/classification/CA023858/MONDO:0007783/012	fc4aa821-2122-48cd-a503-bebf86b45e59	p.Glu3583Gln	Glu	3583	Gln	MGDAEGEDEVQFLRTDDEVVLQCSATVLKEQLKLCLAAEGFGNRLCFLEPTSNAQNVPPDLAICCFVLEQSLSVRALQEMLANTVEAGVESSQGGGHRTLLYGHAILLRHAHSRMYLSCLTTSRSMTDKLAFDVGLQEDATGEACWWTMHPASKQRSEGEKVRVGDDIILVSVSSERYLHLSTASGELQVDASFMQTLWNMNPICSRCEEGFVTGGHVLRLFHGHMDECLTISPADSDDQRRLVYYEGGAVCTHARSLWRLEPLRISWSGSHLRWGQPLRVRHVTTGQYLALTEDQGLVVVDASKAHTKATSFCFRISKEKLDVAPKRDVEGMGPPEIKYGESLCFVQHVASGLWLTYAAPDPKALRLGVLKKKAMLHQEGHMDDALSLTRCQQEESQAARMIHSTNGLYNQFIKSLDSFSGKPRGSGPPAGTALPIEGVILSLQDLIIYFEPPSEDLQHEEKQSKLRSLRNRQSLFQEEGMLSMVLNCIDRLNVYTTAAHFAEFAGEEAAESWKEIVNLLYELLASLIRGNRSNCALFSTNLDWLVSKLDRLEASSGILEVLYCVLIESPEVLNIIQENHIKSIISLLDKHGRNHKVLDVLCSLCVCNGVAVRSNQDLITENLLPGRELLLQTNLINYVTSIRPNIFVGRAEGTTQYSKWYFEVMVDEVTPFLTAQATHLRVGWALTEGYTPYPGAGEGWGGNGVGDDLYSYGFDGLHLWTGHVARPVTSPGQHLLAPEDVISCCLDLSVPSISFRINGCPVQGVFESFNLDGLFFPVVSFSAGVKVRFLLGGRHGEFKFLPPPGYAPCHEAVLPRERLHLEPIKEYRREGPRGPHLVGPSRCLSHTDFVPCPVDTVQIVLPPHLERIREKLAENIHELWALTRIEQGWTYGPVRDDNKRLHPCLVDFHSLPEPERNYNLQMSGETLKTLLALGCHVGMADEKAEDNLKKTKLPKTYMMSNGYKPAPLDLSHVRLTPAQTTLVDRLAENGHNVWARDRVGQGWSYSAVQDIPARRNPRLVPYRLLDEATKRSNRDSLCQAVRTLLGYGYNIEPPDQEPSQVENQSRCDRVRIFRAEKSYTVQSGRWYFEFEAVTTGEMRVGWARPELRPDVELGADELAYVFNGHRGQRWHLGSEPFGRPWQPGDVVGCMIDLTENTIIFTLNGEVLMSDSGSETAFREIEIGDGFLPVCSLGPGQVGHLNLGQDVSSLRFFAICGLQEGFEPFAINMQRPVTTWFSKGLPQFEPVPLEHPHYEVSRVDGTVDTPPCLRLTHRTWGSQNSLVEMLFLRLSLPVQFHQHFRCTAGATPLAPPGLQPPAEDEARAAEPDPDYENLRRSAGGWSEAENGKEGTAKEGAPGGTPQAGGEAQPARAENEKDATTEKNKKRGFLFKAKKVAMMTQPPATPTLPRLPHDVVPADNRDDPEIILNTTTYYYSVRVFAGQEPSCVWAGWVTPDYHQHDMSFDLSKVRVVTVTMGDEQGNVHSSLKCSNCYMVWGGDFVSPGQQGRISHTDLVIGCLVDLATGLMTFTANGKESNTFFQVEPNTKLFPAVFVLPTHQNVIQFELGKQKNIMPLSAAMFQSERKNPAPQCPPRLEMQMLMPVSWSRMPNHFLQVETRRAGERLGWAVQCQEPLTMMALHIPEENRCMDILELSERLDLQRFHSHTLRLYRAVCALGNNRVAHALCSHVDQAQLLHALEDAHLPGPLRAGYYDLLISIHLESACRSRRSMLSEYIVPLTPETRAITLFPPGRSTENGHPRHGLPGVGVTTSLRPPHHFSPPCFVAALPAAGAAEAPARLSPAIPLEALRDKALRMLGEAVRDGGQHARDPVGGSVEFQFVPVLKLVSTLLVMGIFGDEDVKQILKMIEPEVFTEEEEEEDEEEEGEEEDEEEKEEDEEETAQEKEDEEKEEEEAAEGEKEEGLEEGLLQMKLPESVKLQMCHLLEYFCDQELQHRVESLAAFAERYVDKLQANQRSRYGLLIKAFSMTAAETARRTREFRSPPQEQINMLLQFKDGTDEEDCPLPEEIRQDLLDFHQDLLAHCGIQLDGEEEEPEEETTLGSRLMSLLEKVRLVKKKEEKPEEERSAEESKPRSLQELVSHMVVRWAQEDFVQSPELVRAMFSLLHRQYDGLGELLRALPRAYTISPSSVEDTMSLLECLGQIRSLLIVQMGPQEENLMIQSIGNIMNNKVFYQHPNLMRALGMHETVMEVMVNVLGGGESKEIRFPKMVTSCCRFLCYFCRISRQNQRSMFDHLSYLLENSGIGLGMQGSTPLDVAAASVIDNNELALALQEQDLEKVVSYLAGCGLQSCPMLVAKGYPDIGWNPCGGERYLDFLRFAVFVNGESVEENANVVVRLLIRKPECFGPALRGEGGSGLLAAIEEAIRISEDPARDGPGIRRDRRREHFGEEPPEENRVHLGHAIMSFYAALIDLLGRCAPEMHLIQAGKGEALRIRAILRSLVPLEDLVGIISLPLQIPTLGKDGALVQPKMSASFVPDHKASMVLFLDRVYGIENQDFLLHVLDVGFLPDMRAAASLDTATFSTTEMALALNRYLCLAVLPLITKCAPLFAGTEHRAIMVDSMLHTVYRLSRGRSLTKAQRDVIEDCLMSLCRYIRPSMLQHLLRRLVFDVPILNEFAKMPLKLLTNHYERCWKYYCLPTGWANFGVTSEEELHLTRKLFWGIFDSLAHKKYDPELYRMAMPCLCAIAGALPPDYVDASYSSKAEKKATVDAEGNFDPRPVETLNVIIPEKLDSFINKFAEYTHEKWAFDKIQNNWSYGENIDEELKTHPMLRPYKTFSEKDKEIYRWPIKESLKAMIAWEWTIEKAREGEEEKTEKKKTRKISQSAQTYDPREGYNPQPPDLSAVTLSRELQAMAEQLAENYHNTWGRKKKQELEAKGGGTHPLLVPYDTLTAKEKARDREKAQELLKFLQMNGYAVTRGLKDMELDSSSIEKRFAFGFLQQLLRWMDISQEFIAHLEAVVSSGRVEKSPHEQEIKFFAKILLPLINQYFTNHCLYFLSTPAKVLGSGGHASNKEKEMITSLFCKLAALVRHRVSLFGTDAPAVVNCLHILARSLDARTVMKSGPEIVKAGLRSFFESASEDIEKMVENLRLGKVSQARTQVKGVGQNLTYTTVALLPVLTTLFQHIAQHQFGDDVILDDVQVSCYRTLCSIYSLGTTKNTYVEKLRPALGECLARLAAAMPVAFLEPQLNEYNACSVYTTKSPRERAILGLPNSVEEMCPDIPVLERLMADIGGLAESGARYTEMPHVIEITLPMLCSYLPRWWERGPEAPPSALPAGAPPPCTAVTSDHLNSLLGNILRIIVNNLGIDEASWMKRLAVFAQPIVSRARPELLQSHFIPTIGRLRKRAGKVVSEEEQLRLEAKAEAQEGELLVRDEFSVLCRDLYALYPLLIRYVDNNRAQWLTEPNPSAEELFRMVGEIFIYWSKSHNFKREEQNFVVQNEINNMSFLTADNKSKMAKAGDIQSGGSDQERTKKKRRGDRYSVQTSLIVATLKKMLPIGLNMCAPTDQDLITLAKTRYALKDTDEEVREFLHNNLHLQGKVEGSPSLRWQMALYRGVPGREEDADDPEKIVRRVQEVSAVLYYLDQTEHPYKSKKAVWHKLLSKQRRRAVVACFRMTPLYNLPTHRACNMFLESYKAAWILTEDHSFEDRMIDDLSKAGEQEEEEEEVEEKKPDPLHQLVLHFSRTALTEKSKLDEDYLYMAYADIMAKSCHLEEGGENGEAEEEVEVSFEEKQMEKQRLLYQQARLHTRGAAEMVLQMISACKGETGAMVSSTLKLGISILNGGNAEVQQKMLDYLKDKKEVGFFQSIQALMQTCSVLDLNAFERQNKAEGLGMVNEDGTVINRQNGEKVMADDEFTQDLFRFLQLLCEGHNNDFQNYLRTQTGNTTTINIIICTVDYLLRLQESISDFYWYYSGKDVIEEQGKRNFSKAMSVAKQVFNSLTEYIQGPCTGNQQSLAHSRLWDAVVGFLHVFAHMMMKLAQDSSQIELLKELLDLQKDMVVMLLSLLEGNVVNGMIARQMVDMLVESSSNVEMILKFFDMFLKLKDIVGSEAFQDYVTDPRGLISKKDFQKAMDSQKQFSGPEIQFLLSCSEADENEMINCEEFANRFQEPARDIGFNVAVLLTNLSEHVPHDPRLHNFLELAESILEYFRPYLGRIEIMGASRRIERIYFEISETNRAQWEMPQVKESKRQFIFDVVNEGGEAEKMELFVSFCEDTIFEMQIAAQISEPEGEPETDEDEGAGAAEAGAEGAEEGAAGLEGTAATAAAGATARVVAAAGRALRGLSYRSLRRRVRRLRRLTAREAATAVAALLWAAVTRAGAAGAGAAAGALGLLWGSLFGGGLVEGAKKVTVTELLAGMPDPTSDEVHGEQPAGPGGDADGEGASEGAGDAAEGAGDEEEAVHEAGPGGADGAVAVTDGGPFRPEGAGGLGDMGDTTPAEPPTPEGSPILKRKLGVDGVEEELPPEPEPEPEPELEPEKADAENGEKEEVPEPTPEPPKKQAPPSPPPKKEEAGGEFWGELEVQRVKFLNYLSRNFYTLRFLALFLAFAINFILLFYKVSDSPPGEDDMEGSAAGDVSGAGSGGSSGWGLGAGEEAEGDEDENMVYYFLEESTGYMEPALRCLSLLHTLVAFLCIIGYNCLKVPLVIFKREKELARKLEFDGLYITEQPEDDDVKGQWDRLVLNTPSFPSNYWDKFVKRKVLDKHGDIYGRERIAELLGMDLATLEITAHNERKPNPPPGLLTWLMSIDVKYQIWKFGVIFTDNSFLYLGWYMVMSLLGHYNNFFFAAHLLDIAMGVKTLRTILSSVTHNGKQLVMTVGLLAVVVYLYTVVAFNFFRKFYNKSEDEDEPDMKCDDMMTCYLFHMYVGVRAGGGIGDEIEDPAGDEYELYRVVFDITFFFFVIVILLAIIQGLIIDAFGELRDQQEQVKEDMETKCFICGIGSDYFDTTPHGFETHTLEEHNLANYMFFLMYLINKDETEHTGQESYVWKMYQERCWDFFPAGDCFRKQYEDQLS	5038	P21817	Q	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
243	NM_000540.3(RYR1):c.13513G>C (p.Asp4505His)	93252	CA024057	NM_000540.3:c.13513G>C, NC_000019.10:g.38566986G>C, CM000681.2:g.38566986G>C, NC_000019.9:g.39057626G>C, CM000681.1:g.39057626G>C, NC_000019.8:g.43749466G>C, NG_008866.1:g.138287G>C, LRG_766:g.138287G>C, ENST00000355481.8:c.13498G>C, ENST00000359596.7:n.13513G>C, ENST00000360985.7:c.13495G>C, NM_000540.2:c.13513G>C, LRG_766t1:c.13513G>C, NM_001042723.1:c.13498G>C, XM_006723317.1:c.13495G>C, XM_006723319.1:c.13480G>C, XM_011527204.1:c.13510G>C, XM_011527205.1:c.13513G>C, XM_006723317.2:c.13495G>C, XM_006723319.2:c.13480G>C, XM_011527205.2:c.13513G>C, NM_001042723.2:c.13498G>C, NM_000540.3(RYR1):c.13513G>C (p.Asp4505His)	RYR1	malignant hyperthermia, susceptibility to, 1	MONDO:0007783	Autosomal dominant inheritance	Benign	BA1		This pathogenicity assessment is relevant only for malignant hyperthermia susceptibility (MHS) inherited in an autosomal dominant pattern. Variants in RYR1 can also cause other myopathies inherited in an autosomal dominant pattern or in an autosomal recessive pattern. Some of these disorders may predispose individuals to malignant hyperthermia. RYR1 variants may also contribute to a malignant hyperthermia reaction in combination with other genetic and non-genetic factors and the clinician needs to consider such factors in making management decisions.This sequence variant predicts a substitution of Aspartic Acid with Histidine at codon 4505 of the RYR1 protein, p.(Asp4505His). The maximum allele frequency for this variant among the six major gnomAD populations is NFE: 0.0054, which is considered to be too common for a pathogenic variant causing autosomal dominantly inherited MHS, BA1. This variant has been classified as Benign. Criteria implemented: BA1.		Malignant Hyperthermia Susceptibility VCEP	https://clinicalgenome.org/docs/clingen-malignant-hyperthermia-susceptibility-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-for/	2021-03-17	2021-03-31	False	https://erepo.genome.network/evrepo/ui/classification/CA024057/MONDO:0007783/012	a51fdb33-f111-476c-aa86-949409f77623	p.Asp4505His	Asp	4505	His	MGDAEGEDEVQFLRTDDEVVLQCSATVLKEQLKLCLAAEGFGNRLCFLEPTSNAQNVPPDLAICCFVLEQSLSVRALQEMLANTVEAGVESSQGGGHRTLLYGHAILLRHAHSRMYLSCLTTSRSMTDKLAFDVGLQEDATGEACWWTMHPASKQRSEGEKVRVGDDIILVSVSSERYLHLSTASGELQVDASFMQTLWNMNPICSRCEEGFVTGGHVLRLFHGHMDECLTISPADSDDQRRLVYYEGGAVCTHARSLWRLEPLRISWSGSHLRWGQPLRVRHVTTGQYLALTEDQGLVVVDASKAHTKATSFCFRISKEKLDVAPKRDVEGMGPPEIKYGESLCFVQHVASGLWLTYAAPDPKALRLGVLKKKAMLHQEGHMDDALSLTRCQQEESQAARMIHSTNGLYNQFIKSLDSFSGKPRGSGPPAGTALPIEGVILSLQDLIIYFEPPSEDLQHEEKQSKLRSLRNRQSLFQEEGMLSMVLNCIDRLNVYTTAAHFAEFAGEEAAESWKEIVNLLYELLASLIRGNRSNCALFSTNLDWLVSKLDRLEASSGILEVLYCVLIESPEVLNIIQENHIKSIISLLDKHGRNHKVLDVLCSLCVCNGVAVRSNQDLITENLLPGRELLLQTNLINYVTSIRPNIFVGRAEGTTQYSKWYFEVMVDEVTPFLTAQATHLRVGWALTEGYTPYPGAGEGWGGNGVGDDLYSYGFDGLHLWTGHVARPVTSPGQHLLAPEDVISCCLDLSVPSISFRINGCPVQGVFESFNLDGLFFPVVSFSAGVKVRFLLGGRHGEFKFLPPPGYAPCHEAVLPRERLHLEPIKEYRREGPRGPHLVGPSRCLSHTDFVPCPVDTVQIVLPPHLERIREKLAENIHELWALTRIEQGWTYGPVRDDNKRLHPCLVDFHSLPEPERNYNLQMSGETLKTLLALGCHVGMADEKAEDNLKKTKLPKTYMMSNGYKPAPLDLSHVRLTPAQTTLVDRLAENGHNVWARDRVGQGWSYSAVQDIPARRNPRLVPYRLLDEATKRSNRDSLCQAVRTLLGYGYNIEPPDQEPSQVENQSRCDRVRIFRAEKSYTVQSGRWYFEFEAVTTGEMRVGWARPELRPDVELGADELAYVFNGHRGQRWHLGSEPFGRPWQPGDVVGCMIDLTENTIIFTLNGEVLMSDSGSETAFREIEIGDGFLPVCSLGPGQVGHLNLGQDVSSLRFFAICGLQEGFEPFAINMQRPVTTWFSKGLPQFEPVPLEHPHYEVSRVDGTVDTPPCLRLTHRTWGSQNSLVEMLFLRLSLPVQFHQHFRCTAGATPLAPPGLQPPAEDEARAAEPDPDYENLRRSAGGWSEAENGKEGTAKEGAPGGTPQAGGEAQPARAENEKDATTEKNKKRGFLFKAKKVAMMTQPPATPTLPRLPHDVVPADNRDDPEIILNTTTYYYSVRVFAGQEPSCVWAGWVTPDYHQHDMSFDLSKVRVVTVTMGDEQGNVHSSLKCSNCYMVWGGDFVSPGQQGRISHTDLVIGCLVDLATGLMTFTANGKESNTFFQVEPNTKLFPAVFVLPTHQNVIQFELGKQKNIMPLSAAMFQSERKNPAPQCPPRLEMQMLMPVSWSRMPNHFLQVETRRAGERLGWAVQCQEPLTMMALHIPEENRCMDILELSERLDLQRFHSHTLRLYRAVCALGNNRVAHALCSHVDQAQLLHALEDAHLPGPLRAGYYDLLISIHLESACRSRRSMLSEYIVPLTPETRAITLFPPGRSTENGHPRHGLPGVGVTTSLRPPHHFSPPCFVAALPAAGAAEAPARLSPAIPLEALRDKALRMLGEAVRDGGQHARDPVGGSVEFQFVPVLKLVSTLLVMGIFGDEDVKQILKMIEPEVFTEEEEEEDEEEEGEEEDEEEKEEDEEETAQEKEDEEKEEEEAAEGEKEEGLEEGLLQMKLPESVKLQMCHLLEYFCDQELQHRVESLAAFAERYVDKLQANQRSRYGLLIKAFSMTAAETARRTREFRSPPQEQINMLLQFKDGTDEEDCPLPEEIRQDLLDFHQDLLAHCGIQLDGEEEEPEEETTLGSRLMSLLEKVRLVKKKEEKPEEERSAEESKPRSLQELVSHMVVRWAQEDFVQSPELVRAMFSLLHRQYDGLGELLRALPRAYTISPSSVEDTMSLLECLGQIRSLLIVQMGPQEENLMIQSIGNIMNNKVFYQHPNLMRALGMHETVMEVMVNVLGGGESKEIRFPKMVTSCCRFLCYFCRISRQNQRSMFDHLSYLLENSGIGLGMQGSTPLDVAAASVIDNNELALALQEQDLEKVVSYLAGCGLQSCPMLVAKGYPDIGWNPCGGERYLDFLRFAVFVNGESVEENANVVVRLLIRKPECFGPALRGEGGSGLLAAIEEAIRISEDPARDGPGIRRDRRREHFGEEPPEENRVHLGHAIMSFYAALIDLLGRCAPEMHLIQAGKGEALRIRAILRSLVPLEDLVGIISLPLQIPTLGKDGALVQPKMSASFVPDHKASMVLFLDRVYGIENQDFLLHVLDVGFLPDMRAAASLDTATFSTTEMALALNRYLCLAVLPLITKCAPLFAGTEHRAIMVDSMLHTVYRLSRGRSLTKAQRDVIEDCLMSLCRYIRPSMLQHLLRRLVFDVPILNEFAKMPLKLLTNHYERCWKYYCLPTGWANFGVTSEEELHLTRKLFWGIFDSLAHKKYDPELYRMAMPCLCAIAGALPPDYVDASYSSKAEKKATVDAEGNFDPRPVETLNVIIPEKLDSFINKFAEYTHEKWAFDKIQNNWSYGENIDEELKTHPMLRPYKTFSEKDKEIYRWPIKESLKAMIAWEWTIEKAREGEEEKTEKKKTRKISQSAQTYDPREGYNPQPPDLSAVTLSRELQAMAEQLAENYHNTWGRKKKQELEAKGGGTHPLLVPYDTLTAKEKARDREKAQELLKFLQMNGYAVTRGLKDMELDSSSIEKRFAFGFLQQLLRWMDISQEFIAHLEAVVSSGRVEKSPHEQEIKFFAKILLPLINQYFTNHCLYFLSTPAKVLGSGGHASNKEKEMITSLFCKLAALVRHRVSLFGTDAPAVVNCLHILARSLDARTVMKSGPEIVKAGLRSFFESASEDIEKMVENLRLGKVSQARTQVKGVGQNLTYTTVALLPVLTTLFQHIAQHQFGDDVILDDVQVSCYRTLCSIYSLGTTKNTYVEKLRPALGECLARLAAAMPVAFLEPQLNEYNACSVYTTKSPRERAILGLPNSVEEMCPDIPVLERLMADIGGLAESGARYTEMPHVIEITLPMLCSYLPRWWERGPEAPPSALPAGAPPPCTAVTSDHLNSLLGNILRIIVNNLGIDEASWMKRLAVFAQPIVSRARPELLQSHFIPTIGRLRKRAGKVVSEEEQLRLEAKAEAQEGELLVRDEFSVLCRDLYALYPLLIRYVDNNRAQWLTEPNPSAEELFRMVGEIFIYWSKSHNFKREEQNFVVQNEINNMSFLTADNKSKMAKAGDIQSGGSDQERTKKKRRGDRYSVQTSLIVATLKKMLPIGLNMCAPTDQDLITLAKTRYALKDTDEEVREFLHNNLHLQGKVEGSPSLRWQMALYRGVPGREEDADDPEKIVRRVQEVSAVLYYLDQTEHPYKSKKAVWHKLLSKQRRRAVVACFRMTPLYNLPTHRACNMFLESYKAAWILTEDHSFEDRMIDDLSKAGEQEEEEEEVEEKKPDPLHQLVLHFSRTALTEKSKLDEDYLYMAYADIMAKSCHLEEGGENGEAEEEVEVSFEEKQMEKQRLLYQQARLHTRGAAEMVLQMISACKGETGAMVSSTLKLGISILNGGNAEVQQKMLDYLKDKKEVGFFQSIQALMQTCSVLDLNAFERQNKAEGLGMVNEDGTVINRQNGEKVMADDEFTQDLFRFLQLLCEGHNNDFQNYLRTQTGNTTTINIIICTVDYLLRLQESISDFYWYYSGKDVIEEQGKRNFSKAMSVAKQVFNSLTEYIQGPCTGNQQSLAHSRLWDAVVGFLHVFAHMMMKLAQDSSQIELLKELLDLQKDMVVMLLSLLEGNVVNGMIARQMVDMLVESSSNVEMILKFFDMFLKLKDIVGSEAFQDYVTDPRGLISKKDFQKAMDSQKQFSGPEIQFLLSCSEADENEMINCEEFANRFQEPARDIGFNVAVLLTNLSEHVPHDPRLHNFLELAESILEYFRPYLGRIEIMGASRRIERIYFEISETNRAQWEMPQVKESKRQFIFDVVNEGGEAEKMELFVSFCEDTIFEMQIAAQISEPEGEPETDEDEGAGAAEAGAEGAEEGAAGLEGTAATAAAGATARVVAAAGRALRGLSYRSLRRRVRRLRRLTAREAATAVAALLWAAVTRAGAAGAGAAAGALGLLWGSLFGGGLVEGAKKVTVTELLAGMPDPTSDEVHGEQPAGPGGDADGEGASEGAGDAAEGAGDEEEAVHEAGPGGADGAVAVTDGGPFRPEGAGGLGDMGDTTPAEPPTPEGSPILKRKLGVDGVEEELPPEPEPEPEPELEPEKADAENGEKEEVPEPTPEPPKKQAPPSPPPKKEEAGGEFWGELEVQRVKFLNYLSRNFYTLRFLALFLAFAINFILLFYKVSDSPPGEDDMEGSAAGDVSGAGSGGSSGWGLGAGEEAEGDEDENMVYYFLEESTGYMEPALRCLSLLHTLVAFLCIIGYNCLKVPLVIFKREKELARKLEFDGLYITEQPEDDDVKGQWDRLVLNTPSFPSNYWDKFVKRKVLDKHGDIYGRERIAELLGMDLATLEITAHNERKPNPPPGLLTWLMSIDVKYQIWKFGVIFTDNSFLYLGWYMVMSLLGHYNNFFFAAHLLDIAMGVKTLRTILSSVTHNGKQLVMTVGLLAVVVYLYTVVAFNFFRKFYNKSEDEDEPDMKCDDMMTCYLFHMYVGVRAGGGIGDEIEDPAGDEYELYRVVFDITFFFFVIVILLAIIQGLIIDAFGELRDQQEQVKEDMETKCFICGIGSDYFDTTPHGFETHTLEEHNLANYMFFLMYLINKDETEHTGQESYVWKMYQERCWDFFPAGDCFRKQYEDQLS	5038	P21817	H	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
244	NM_000540.2(RYR1):c.2797G>A (p.Ala933Thr)	161363	CA024368	NM_000540.2:c.2797G>A, NC_000019.10:g.38464649G>A, CM000681.2:g.38464649G>A, NC_000019.9:g.38955289G>A, CM000681.1:g.38955289G>A, NC_000019.8:g.43647129G>A, NG_008866.1:g.35950G>A, LRG_766:g.35950G>A, ENST00000355481.8:c.2797G>A, ENST00000359596.7:n.2797G>A, ENST00000360985.7:c.2797G>A, LRG_766t1:c.2797G>A, NM_001042723.1:c.2797G>A, XM_006723317.1:c.2797G>A, XM_006723319.1:c.2797G>A, XM_011527204.1:c.2794G>A, XM_011527205.1:c.2797G>A, XM_006723317.2:c.2797G>A, XM_006723319.2:c.2797G>A, XM_011527205.2:c.2797G>A, NM_000540.3:c.2797G>A, NM_001042723.2:c.2797G>A, NM_000540.2(RYR1):c.2797G>A (p.Ala933Thr)	RYR1	malignant hyperthermia, susceptibility to, 1	MONDO:0007783	Autosomal dominant inheritance	Benign	BA1		This pathogenicity assessment is relevant only for malignant hyperthermia susceptibility (MHS) inherited in an autosomal dominant pattern. Variants in RYR1 can also cause other myopathies inherited in an autosomal dominant pattern or in an autosomal recessive pattern. Some of these disorders may predispose individuals to malignant hyperthermia. RYR1 variants may also contribute to a malignant hyperthermia reaction in combination with other genetic and non-genetic factors and the clinician needs to consider such factors in making management decisions.This sequence variant predicts a substitution of Alanine with Threonine at codon 933 of the RYR1 protein, p.(Ala933Thr). The maximum allele frequency for this variant among the six major gnomAD populations is AFR: 0.00388, which is considered to be too common for a pathogenic variant causing autosomal dominantly inherited MHS, BA1. This variant has been classified as Benign. Criteria implemented: BA1.		Malignant Hyperthermia Susceptibility VCEP	https://clinicalgenome.org/docs/clingen-malignant-hyperthermia-susceptibility-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-for/	2021-03-17	2021-03-31	False	https://erepo.genome.network/evrepo/ui/classification/CA024368/MONDO:0007783/012	eb6330aa-4971-4922-a249-cc526e76e611	p.Ala933Thr	Ala	933	Thr	MGDAEGEDEVQFLRTDDEVVLQCSATVLKEQLKLCLAAEGFGNRLCFLEPTSNAQNVPPDLAICCFVLEQSLSVRALQEMLANTVEAGVESSQGGGHRTLLYGHAILLRHAHSRMYLSCLTTSRSMTDKLAFDVGLQEDATGEACWWTMHPASKQRSEGEKVRVGDDIILVSVSSERYLHLSTASGELQVDASFMQTLWNMNPICSRCEEGFVTGGHVLRLFHGHMDECLTISPADSDDQRRLVYYEGGAVCTHARSLWRLEPLRISWSGSHLRWGQPLRVRHVTTGQYLALTEDQGLVVVDASKAHTKATSFCFRISKEKLDVAPKRDVEGMGPPEIKYGESLCFVQHVASGLWLTYAAPDPKALRLGVLKKKAMLHQEGHMDDALSLTRCQQEESQAARMIHSTNGLYNQFIKSLDSFSGKPRGSGPPAGTALPIEGVILSLQDLIIYFEPPSEDLQHEEKQSKLRSLRNRQSLFQEEGMLSMVLNCIDRLNVYTTAAHFAEFAGEEAAESWKEIVNLLYELLASLIRGNRSNCALFSTNLDWLVSKLDRLEASSGILEVLYCVLIESPEVLNIIQENHIKSIISLLDKHGRNHKVLDVLCSLCVCNGVAVRSNQDLITENLLPGRELLLQTNLINYVTSIRPNIFVGRAEGTTQYSKWYFEVMVDEVTPFLTAQATHLRVGWALTEGYTPYPGAGEGWGGNGVGDDLYSYGFDGLHLWTGHVARPVTSPGQHLLAPEDVISCCLDLSVPSISFRINGCPVQGVFESFNLDGLFFPVVSFSAGVKVRFLLGGRHGEFKFLPPPGYAPCHEAVLPRERLHLEPIKEYRREGPRGPHLVGPSRCLSHTDFVPCPVDTVQIVLPPHLERIREKLAENIHELWALTRIEQGWTYGPVRDDNKRLHPCLVDFHSLPEPERNYNLQMSGETLKTLLALGCHVGMADEKAEDNLKKTKLPKTYMMSNGYKPAPLDLSHVRLTPAQTTLVDRLAENGHNVWARDRVGQGWSYSAVQDIPARRNPRLVPYRLLDEATKRSNRDSLCQAVRTLLGYGYNIEPPDQEPSQVENQSRCDRVRIFRAEKSYTVQSGRWYFEFEAVTTGEMRVGWARPELRPDVELGADELAYVFNGHRGQRWHLGSEPFGRPWQPGDVVGCMIDLTENTIIFTLNGEVLMSDSGSETAFREIEIGDGFLPVCSLGPGQVGHLNLGQDVSSLRFFAICGLQEGFEPFAINMQRPVTTWFSKGLPQFEPVPLEHPHYEVSRVDGTVDTPPCLRLTHRTWGSQNSLVEMLFLRLSLPVQFHQHFRCTAGATPLAPPGLQPPAEDEARAAEPDPDYENLRRSAGGWSEAENGKEGTAKEGAPGGTPQAGGEAQPARAENEKDATTEKNKKRGFLFKAKKVAMMTQPPATPTLPRLPHDVVPADNRDDPEIILNTTTYYYSVRVFAGQEPSCVWAGWVTPDYHQHDMSFDLSKVRVVTVTMGDEQGNVHSSLKCSNCYMVWGGDFVSPGQQGRISHTDLVIGCLVDLATGLMTFTANGKESNTFFQVEPNTKLFPAVFVLPTHQNVIQFELGKQKNIMPLSAAMFQSERKNPAPQCPPRLEMQMLMPVSWSRMPNHFLQVETRRAGERLGWAVQCQEPLTMMALHIPEENRCMDILELSERLDLQRFHSHTLRLYRAVCALGNNRVAHALCSHVDQAQLLHALEDAHLPGPLRAGYYDLLISIHLESACRSRRSMLSEYIVPLTPETRAITLFPPGRSTENGHPRHGLPGVGVTTSLRPPHHFSPPCFVAALPAAGAAEAPARLSPAIPLEALRDKALRMLGEAVRDGGQHARDPVGGSVEFQFVPVLKLVSTLLVMGIFGDEDVKQILKMIEPEVFTEEEEEEDEEEEGEEEDEEEKEEDEEETAQEKEDEEKEEEEAAEGEKEEGLEEGLLQMKLPESVKLQMCHLLEYFCDQELQHRVESLAAFAERYVDKLQANQRSRYGLLIKAFSMTAAETARRTREFRSPPQEQINMLLQFKDGTDEEDCPLPEEIRQDLLDFHQDLLAHCGIQLDGEEEEPEEETTLGSRLMSLLEKVRLVKKKEEKPEEERSAEESKPRSLQELVSHMVVRWAQEDFVQSPELVRAMFSLLHRQYDGLGELLRALPRAYTISPSSVEDTMSLLECLGQIRSLLIVQMGPQEENLMIQSIGNIMNNKVFYQHPNLMRALGMHETVMEVMVNVLGGGESKEIRFPKMVTSCCRFLCYFCRISRQNQRSMFDHLSYLLENSGIGLGMQGSTPLDVAAASVIDNNELALALQEQDLEKVVSYLAGCGLQSCPMLVAKGYPDIGWNPCGGERYLDFLRFAVFVNGESVEENANVVVRLLIRKPECFGPALRGEGGSGLLAAIEEAIRISEDPARDGPGIRRDRRREHFGEEPPEENRVHLGHAIMSFYAALIDLLGRCAPEMHLIQAGKGEALRIRAILRSLVPLEDLVGIISLPLQIPTLGKDGALVQPKMSASFVPDHKASMVLFLDRVYGIENQDFLLHVLDVGFLPDMRAAASLDTATFSTTEMALALNRYLCLAVLPLITKCAPLFAGTEHRAIMVDSMLHTVYRLSRGRSLTKAQRDVIEDCLMSLCRYIRPSMLQHLLRRLVFDVPILNEFAKMPLKLLTNHYERCWKYYCLPTGWANFGVTSEEELHLTRKLFWGIFDSLAHKKYDPELYRMAMPCLCAIAGALPPDYVDASYSSKAEKKATVDAEGNFDPRPVETLNVIIPEKLDSFINKFAEYTHEKWAFDKIQNNWSYGENIDEELKTHPMLRPYKTFSEKDKEIYRWPIKESLKAMIAWEWTIEKAREGEEEKTEKKKTRKISQSAQTYDPREGYNPQPPDLSAVTLSRELQAMAEQLAENYHNTWGRKKKQELEAKGGGTHPLLVPYDTLTAKEKARDREKAQELLKFLQMNGYAVTRGLKDMELDSSSIEKRFAFGFLQQLLRWMDISQEFIAHLEAVVSSGRVEKSPHEQEIKFFAKILLPLINQYFTNHCLYFLSTPAKVLGSGGHASNKEKEMITSLFCKLAALVRHRVSLFGTDAPAVVNCLHILARSLDARTVMKSGPEIVKAGLRSFFESASEDIEKMVENLRLGKVSQARTQVKGVGQNLTYTTVALLPVLTTLFQHIAQHQFGDDVILDDVQVSCYRTLCSIYSLGTTKNTYVEKLRPALGECLARLAAAMPVAFLEPQLNEYNACSVYTTKSPRERAILGLPNSVEEMCPDIPVLERLMADIGGLAESGARYTEMPHVIEITLPMLCSYLPRWWERGPEAPPSALPAGAPPPCTAVTSDHLNSLLGNILRIIVNNLGIDEASWMKRLAVFAQPIVSRARPELLQSHFIPTIGRLRKRAGKVVSEEEQLRLEAKAEAQEGELLVRDEFSVLCRDLYALYPLLIRYVDNNRAQWLTEPNPSAEELFRMVGEIFIYWSKSHNFKREEQNFVVQNEINNMSFLTADNKSKMAKAGDIQSGGSDQERTKKKRRGDRYSVQTSLIVATLKKMLPIGLNMCAPTDQDLITLAKTRYALKDTDEEVREFLHNNLHLQGKVEGSPSLRWQMALYRGVPGREEDADDPEKIVRRVQEVSAVLYYLDQTEHPYKSKKAVWHKLLSKQRRRAVVACFRMTPLYNLPTHRACNMFLESYKAAWILTEDHSFEDRMIDDLSKAGEQEEEEEEVEEKKPDPLHQLVLHFSRTALTEKSKLDEDYLYMAYADIMAKSCHLEEGGENGEAEEEVEVSFEEKQMEKQRLLYQQARLHTRGAAEMVLQMISACKGETGAMVSSTLKLGISILNGGNAEVQQKMLDYLKDKKEVGFFQSIQALMQTCSVLDLNAFERQNKAEGLGMVNEDGTVINRQNGEKVMADDEFTQDLFRFLQLLCEGHNNDFQNYLRTQTGNTTTINIIICTVDYLLRLQESISDFYWYYSGKDVIEEQGKRNFSKAMSVAKQVFNSLTEYIQGPCTGNQQSLAHSRLWDAVVGFLHVFAHMMMKLAQDSSQIELLKELLDLQKDMVVMLLSLLEGNVVNGMIARQMVDMLVESSSNVEMILKFFDMFLKLKDIVGSEAFQDYVTDPRGLISKKDFQKAMDSQKQFSGPEIQFLLSCSEADENEMINCEEFANRFQEPARDIGFNVAVLLTNLSEHVPHDPRLHNFLELAESILEYFRPYLGRIEIMGASRRIERIYFEISETNRAQWEMPQVKESKRQFIFDVVNEGGEAEKMELFVSFCEDTIFEMQIAAQISEPEGEPETDEDEGAGAAEAGAEGAEEGAAGLEGTAATAAAGATARVVAAAGRALRGLSYRSLRRRVRRLRRLTAREAATAVAALLWAAVTRAGAAGAGAAAGALGLLWGSLFGGGLVEGAKKVTVTELLAGMPDPTSDEVHGEQPAGPGGDADGEGASEGAGDAAEGAGDEEEAVHEAGPGGADGAVAVTDGGPFRPEGAGGLGDMGDTTPAEPPTPEGSPILKRKLGVDGVEEELPPEPEPEPEPELEPEKADAENGEKEEVPEPTPEPPKKQAPPSPPPKKEEAGGEFWGELEVQRVKFLNYLSRNFYTLRFLALFLAFAINFILLFYKVSDSPPGEDDMEGSAAGDVSGAGSGGSSGWGLGAGEEAEGDEDENMVYYFLEESTGYMEPALRCLSLLHTLVAFLCIIGYNCLKVPLVIFKREKELARKLEFDGLYITEQPEDDDVKGQWDRLVLNTPSFPSNYWDKFVKRKVLDKHGDIYGRERIAELLGMDLATLEITAHNERKPNPPPGLLTWLMSIDVKYQIWKFGVIFTDNSFLYLGWYMVMSLLGHYNNFFFAAHLLDIAMGVKTLRTILSSVTHNGKQLVMTVGLLAVVVYLYTVVAFNFFRKFYNKSEDEDEPDMKCDDMMTCYLFHMYVGVRAGGGIGDEIEDPAGDEYELYRVVFDITFFFFVIVILLAIIQGLIIDAFGELRDQQEQVKEDMETKCFICGIGSDYFDTTPHGFETHTLEEHNLANYMFFLMYLINKDETEHTGQESYVWKMYQERCWDFFPAGDCFRKQYEDQLS	5038	P21817	T	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
245	NM_000540.2(RYR1):c.4999C>T (p.Arg1667Cys)	224380	CA212170	NM_000540.2:c.4999C>T, NC_000019.10:g.38485654C>T, CM000681.2:g.38485654C>T, NC_000019.9:g.38976294C>T, CM000681.1:g.38976294C>T, NC_000019.8:g.43668134C>T, NG_008866.1:g.56955C>T, LRG_766:g.56955C>T, ENST00000355481.8:c.4999C>T, ENST00000359596.7:n.4999C>T, ENST00000360985.7:c.4996C>T, LRG_766t1:c.4999C>T, NM_001042723.1:c.4999C>T, XM_006723317.1:c.4999C>T, XM_006723319.1:c.4999C>T, XM_011527204.1:c.4996C>T, XM_011527205.1:c.4999C>T, XM_006723317.2:c.4999C>T, XM_006723319.2:c.4999C>T, XM_011527205.2:c.4999C>T, NM_000540.3:c.4999C>T, NM_001042723.2:c.4999C>T, NM_000540.2(RYR1):c.4999C>T (p.Arg1667Cys)	RYR1	malignant hyperthermia, susceptibility to, 1	MONDO:0007783	Autosomal dominant inheritance	Benign	BA1		This pathogenicity assessment is relevant only for malignant hyperthermia susceptibility (MHS) inherited in an autosomal dominant pattern. Variants in RYR1 can also cause other myopathies inherited in an autosomal dominant pattern or in an autosomal recessive pattern. Some of these disorders may predispose individuals to malignant hyperthermia. RYR1 variants may also contribute to a malignant hyperthermia reaction in combination with other genetic and non-genetic factors and the clinician needs to consider such factors in making management decisions.This sequence variant predicts a substitution of Arginine with Cysteine at codon 1667 of the RYR1 protein, p.(Arg1667Cys). The maximum allele frequency for this variant among the six major gnomAD populations is EAS: 0.0051, which is considered to be too common for a pathogenic variant causing autosomal dominantly inherited MHS, BA1. This variant has been classified as Benign. Criteria implemented: BA1.		Malignant Hyperthermia Susceptibility VCEP	https://clinicalgenome.org/docs/clingen-malignant-hyperthermia-susceptibility-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-for/	2021-03-17	2021-03-31	False	https://erepo.genome.network/evrepo/ui/classification/CA212170/MONDO:0007783/012	3b67716e-0df3-49da-be62-066d465873c5	p.Arg1667Cys	Arg	1667	Cys	MGDAEGEDEVQFLRTDDEVVLQCSATVLKEQLKLCLAAEGFGNRLCFLEPTSNAQNVPPDLAICCFVLEQSLSVRALQEMLANTVEAGVESSQGGGHRTLLYGHAILLRHAHSRMYLSCLTTSRSMTDKLAFDVGLQEDATGEACWWTMHPASKQRSEGEKVRVGDDIILVSVSSERYLHLSTASGELQVDASFMQTLWNMNPICSRCEEGFVTGGHVLRLFHGHMDECLTISPADSDDQRRLVYYEGGAVCTHARSLWRLEPLRISWSGSHLRWGQPLRVRHVTTGQYLALTEDQGLVVVDASKAHTKATSFCFRISKEKLDVAPKRDVEGMGPPEIKYGESLCFVQHVASGLWLTYAAPDPKALRLGVLKKKAMLHQEGHMDDALSLTRCQQEESQAARMIHSTNGLYNQFIKSLDSFSGKPRGSGPPAGTALPIEGVILSLQDLIIYFEPPSEDLQHEEKQSKLRSLRNRQSLFQEEGMLSMVLNCIDRLNVYTTAAHFAEFAGEEAAESWKEIVNLLYELLASLIRGNRSNCALFSTNLDWLVSKLDRLEASSGILEVLYCVLIESPEVLNIIQENHIKSIISLLDKHGRNHKVLDVLCSLCVCNGVAVRSNQDLITENLLPGRELLLQTNLINYVTSIRPNIFVGRAEGTTQYSKWYFEVMVDEVTPFLTAQATHLRVGWALTEGYTPYPGAGEGWGGNGVGDDLYSYGFDGLHLWTGHVARPVTSPGQHLLAPEDVISCCLDLSVPSISFRINGCPVQGVFESFNLDGLFFPVVSFSAGVKVRFLLGGRHGEFKFLPPPGYAPCHEAVLPRERLHLEPIKEYRREGPRGPHLVGPSRCLSHTDFVPCPVDTVQIVLPPHLERIREKLAENIHELWALTRIEQGWTYGPVRDDNKRLHPCLVDFHSLPEPERNYNLQMSGETLKTLLALGCHVGMADEKAEDNLKKTKLPKTYMMSNGYKPAPLDLSHVRLTPAQTTLVDRLAENGHNVWARDRVGQGWSYSAVQDIPARRNPRLVPYRLLDEATKRSNRDSLCQAVRTLLGYGYNIEPPDQEPSQVENQSRCDRVRIFRAEKSYTVQSGRWYFEFEAVTTGEMRVGWARPELRPDVELGADELAYVFNGHRGQRWHLGSEPFGRPWQPGDVVGCMIDLTENTIIFTLNGEVLMSDSGSETAFREIEIGDGFLPVCSLGPGQVGHLNLGQDVSSLRFFAICGLQEGFEPFAINMQRPVTTWFSKGLPQFEPVPLEHPHYEVSRVDGTVDTPPCLRLTHRTWGSQNSLVEMLFLRLSLPVQFHQHFRCTAGATPLAPPGLQPPAEDEARAAEPDPDYENLRRSAGGWSEAENGKEGTAKEGAPGGTPQAGGEAQPARAENEKDATTEKNKKRGFLFKAKKVAMMTQPPATPTLPRLPHDVVPADNRDDPEIILNTTTYYYSVRVFAGQEPSCVWAGWVTPDYHQHDMSFDLSKVRVVTVTMGDEQGNVHSSLKCSNCYMVWGGDFVSPGQQGRISHTDLVIGCLVDLATGLMTFTANGKESNTFFQVEPNTKLFPAVFVLPTHQNVIQFELGKQKNIMPLSAAMFQSERKNPAPQCPPRLEMQMLMPVSWSRMPNHFLQVETRRAGERLGWAVQCQEPLTMMALHIPEENRCMDILELSERLDLQRFHSHTLRLYRAVCALGNNRVAHALCSHVDQAQLLHALEDAHLPGPLRAGYYDLLISIHLESACRSRRSMLSEYIVPLTPETRAITLFPPGRSTENGHPRHGLPGVGVTTSLRPPHHFSPPCFVAALPAAGAAEAPARLSPAIPLEALRDKALRMLGEAVRDGGQHARDPVGGSVEFQFVPVLKLVSTLLVMGIFGDEDVKQILKMIEPEVFTEEEEEEDEEEEGEEEDEEEKEEDEEETAQEKEDEEKEEEEAAEGEKEEGLEEGLLQMKLPESVKLQMCHLLEYFCDQELQHRVESLAAFAERYVDKLQANQRSRYGLLIKAFSMTAAETARRTREFRSPPQEQINMLLQFKDGTDEEDCPLPEEIRQDLLDFHQDLLAHCGIQLDGEEEEPEEETTLGSRLMSLLEKVRLVKKKEEKPEEERSAEESKPRSLQELVSHMVVRWAQEDFVQSPELVRAMFSLLHRQYDGLGELLRALPRAYTISPSSVEDTMSLLECLGQIRSLLIVQMGPQEENLMIQSIGNIMNNKVFYQHPNLMRALGMHETVMEVMVNVLGGGESKEIRFPKMVTSCCRFLCYFCRISRQNQRSMFDHLSYLLENSGIGLGMQGSTPLDVAAASVIDNNELALALQEQDLEKVVSYLAGCGLQSCPMLVAKGYPDIGWNPCGGERYLDFLRFAVFVNGESVEENANVVVRLLIRKPECFGPALRGEGGSGLLAAIEEAIRISEDPARDGPGIRRDRRREHFGEEPPEENRVHLGHAIMSFYAALIDLLGRCAPEMHLIQAGKGEALRIRAILRSLVPLEDLVGIISLPLQIPTLGKDGALVQPKMSASFVPDHKASMVLFLDRVYGIENQDFLLHVLDVGFLPDMRAAASLDTATFSTTEMALALNRYLCLAVLPLITKCAPLFAGTEHRAIMVDSMLHTVYRLSRGRSLTKAQRDVIEDCLMSLCRYIRPSMLQHLLRRLVFDVPILNEFAKMPLKLLTNHYERCWKYYCLPTGWANFGVTSEEELHLTRKLFWGIFDSLAHKKYDPELYRMAMPCLCAIAGALPPDYVDASYSSKAEKKATVDAEGNFDPRPVETLNVIIPEKLDSFINKFAEYTHEKWAFDKIQNNWSYGENIDEELKTHPMLRPYKTFSEKDKEIYRWPIKESLKAMIAWEWTIEKAREGEEEKTEKKKTRKISQSAQTYDPREGYNPQPPDLSAVTLSRELQAMAEQLAENYHNTWGRKKKQELEAKGGGTHPLLVPYDTLTAKEKARDREKAQELLKFLQMNGYAVTRGLKDMELDSSSIEKRFAFGFLQQLLRWMDISQEFIAHLEAVVSSGRVEKSPHEQEIKFFAKILLPLINQYFTNHCLYFLSTPAKVLGSGGHASNKEKEMITSLFCKLAALVRHRVSLFGTDAPAVVNCLHILARSLDARTVMKSGPEIVKAGLRSFFESASEDIEKMVENLRLGKVSQARTQVKGVGQNLTYTTVALLPVLTTLFQHIAQHQFGDDVILDDVQVSCYRTLCSIYSLGTTKNTYVEKLRPALGECLARLAAAMPVAFLEPQLNEYNACSVYTTKSPRERAILGLPNSVEEMCPDIPVLERLMADIGGLAESGARYTEMPHVIEITLPMLCSYLPRWWERGPEAPPSALPAGAPPPCTAVTSDHLNSLLGNILRIIVNNLGIDEASWMKRLAVFAQPIVSRARPELLQSHFIPTIGRLRKRAGKVVSEEEQLRLEAKAEAQEGELLVRDEFSVLCRDLYALYPLLIRYVDNNRAQWLTEPNPSAEELFRMVGEIFIYWSKSHNFKREEQNFVVQNEINNMSFLTADNKSKMAKAGDIQSGGSDQERTKKKRRGDRYSVQTSLIVATLKKMLPIGLNMCAPTDQDLITLAKTRYALKDTDEEVREFLHNNLHLQGKVEGSPSLRWQMALYRGVPGREEDADDPEKIVRRVQEVSAVLYYLDQTEHPYKSKKAVWHKLLSKQRRRAVVACFRMTPLYNLPTHRACNMFLESYKAAWILTEDHSFEDRMIDDLSKAGEQEEEEEEVEEKKPDPLHQLVLHFSRTALTEKSKLDEDYLYMAYADIMAKSCHLEEGGENGEAEEEVEVSFEEKQMEKQRLLYQQARLHTRGAAEMVLQMISACKGETGAMVSSTLKLGISILNGGNAEVQQKMLDYLKDKKEVGFFQSIQALMQTCSVLDLNAFERQNKAEGLGMVNEDGTVINRQNGEKVMADDEFTQDLFRFLQLLCEGHNNDFQNYLRTQTGNTTTINIIICTVDYLLRLQESISDFYWYYSGKDVIEEQGKRNFSKAMSVAKQVFNSLTEYIQGPCTGNQQSLAHSRLWDAVVGFLHVFAHMMMKLAQDSSQIELLKELLDLQKDMVVMLLSLLEGNVVNGMIARQMVDMLVESSSNVEMILKFFDMFLKLKDIVGSEAFQDYVTDPRGLISKKDFQKAMDSQKQFSGPEIQFLLSCSEADENEMINCEEFANRFQEPARDIGFNVAVLLTNLSEHVPHDPRLHNFLELAESILEYFRPYLGRIEIMGASRRIERIYFEISETNRAQWEMPQVKESKRQFIFDVVNEGGEAEKMELFVSFCEDTIFEMQIAAQISEPEGEPETDEDEGAGAAEAGAEGAEEGAAGLEGTAATAAAGATARVVAAAGRALRGLSYRSLRRRVRRLRRLTAREAATAVAALLWAAVTRAGAAGAGAAAGALGLLWGSLFGGGLVEGAKKVTVTELLAGMPDPTSDEVHGEQPAGPGGDADGEGASEGAGDAAEGAGDEEEAVHEAGPGGADGAVAVTDGGPFRPEGAGGLGDMGDTTPAEPPTPEGSPILKRKLGVDGVEEELPPEPEPEPEPELEPEKADAENGEKEEVPEPTPEPPKKQAPPSPPPKKEEAGGEFWGELEVQRVKFLNYLSRNFYTLRFLALFLAFAINFILLFYKVSDSPPGEDDMEGSAAGDVSGAGSGGSSGWGLGAGEEAEGDEDENMVYYFLEESTGYMEPALRCLSLLHTLVAFLCIIGYNCLKVPLVIFKREKELARKLEFDGLYITEQPEDDDVKGQWDRLVLNTPSFPSNYWDKFVKRKVLDKHGDIYGRERIAELLGMDLATLEITAHNERKPNPPPGLLTWLMSIDVKYQIWKFGVIFTDNSFLYLGWYMVMSLLGHYNNFFFAAHLLDIAMGVKTLRTILSSVTHNGKQLVMTVGLLAVVVYLYTVVAFNFFRKFYNKSEDEDEPDMKCDDMMTCYLFHMYVGVRAGGGIGDEIEDPAGDEYELYRVVFDITFFFFVIVILLAIIQGLIIDAFGELRDQQEQVKEDMETKCFICGIGSDYFDTTPHGFETHTLEEHNLANYMFFLMYLINKDETEHTGQESYVWKMYQERCWDFFPAGDCFRKQYEDQLS	5038	P21817	C	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
246	NM_000540.2(RYR1):c.9353C>T (p.Ala3118Val)	329088	CA073512	NM_000540.2:c.9353C>T, NC_000019.10:g.38512364C>T, CM000681.2:g.38512364C>T, NC_000019.9:g.39003004C>T, CM000681.1:g.39003004C>T, NC_000019.8:g.43694844C>T, NG_008866.1:g.83665C>T, LRG_766:g.83665C>T, ENST00000355481.8:c.9353C>T, ENST00000359596.7:n.9353C>T, ENST00000360985.7:c.9350C>T, LRG_766t1:c.9353C>T, NM_001042723.1:c.9353C>T, XM_006723317.1:c.9353C>T, XM_006723319.1:c.9353C>T, XM_011527204.1:c.9350C>T, XM_011527205.1:c.9353C>T, XM_006723317.2:c.9353C>T, XM_006723319.2:c.9353C>T, XM_011527205.2:c.9353C>T, NM_000540.3:c.9353C>T, NM_001042723.2:c.9353C>T, NM_000540.2(RYR1):c.9353C>T (p.Ala3118Val)	RYR1	malignant hyperthermia, susceptibility to, 1	MONDO:0007783	Autosomal dominant inheritance	Benign	BA1		This pathogenicity assessment is relevant only for malignant hyperthermia susceptibility (MHS) inherited in an autosomal dominant pattern. Variants in RYR1 can also cause other myopathies inherited in an autosomal dominant pattern or in an autosomal recessive pattern. Some of these disorders may predispose individuals to malignant hyperthermia. RYR1 variants may also contribute to a malignant hyperthermia reaction in combination with other genetic and non-genetic factors and the clinician needs to consider such factors in making management decisions.This sequence variant predicts a substitution of Alanine with Valine at codon 3118 of the RYR1 protein, p.(Ala3118Val). The maximum allele frequency for this variant among the six major gnomAD populations is AFR: 0.0063, which is considered to be too common for a pathogenic variant causing autosomal dominantly inherited MHS, BA1. This variant has been classified as Benign. Criteria implemented: BA1.		Malignant Hyperthermia Susceptibility VCEP	https://clinicalgenome.org/docs/clingen-malignant-hyperthermia-susceptibility-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-for/	2021-03-17	2021-03-31	False	https://erepo.genome.network/evrepo/ui/classification/CA073512/MONDO:0007783/012	ff550456-5053-40d7-86de-84e32f5b1636	p.Ala3118Val	Ala	3118	Val	MGDAEGEDEVQFLRTDDEVVLQCSATVLKEQLKLCLAAEGFGNRLCFLEPTSNAQNVPPDLAICCFVLEQSLSVRALQEMLANTVEAGVESSQGGGHRTLLYGHAILLRHAHSRMYLSCLTTSRSMTDKLAFDVGLQEDATGEACWWTMHPASKQRSEGEKVRVGDDIILVSVSSERYLHLSTASGELQVDASFMQTLWNMNPICSRCEEGFVTGGHVLRLFHGHMDECLTISPADSDDQRRLVYYEGGAVCTHARSLWRLEPLRISWSGSHLRWGQPLRVRHVTTGQYLALTEDQGLVVVDASKAHTKATSFCFRISKEKLDVAPKRDVEGMGPPEIKYGESLCFVQHVASGLWLTYAAPDPKALRLGVLKKKAMLHQEGHMDDALSLTRCQQEESQAARMIHSTNGLYNQFIKSLDSFSGKPRGSGPPAGTALPIEGVILSLQDLIIYFEPPSEDLQHEEKQSKLRSLRNRQSLFQEEGMLSMVLNCIDRLNVYTTAAHFAEFAGEEAAESWKEIVNLLYELLASLIRGNRSNCALFSTNLDWLVSKLDRLEASSGILEVLYCVLIESPEVLNIIQENHIKSIISLLDKHGRNHKVLDVLCSLCVCNGVAVRSNQDLITENLLPGRELLLQTNLINYVTSIRPNIFVGRAEGTTQYSKWYFEVMVDEVTPFLTAQATHLRVGWALTEGYTPYPGAGEGWGGNGVGDDLYSYGFDGLHLWTGHVARPVTSPGQHLLAPEDVISCCLDLSVPSISFRINGCPVQGVFESFNLDGLFFPVVSFSAGVKVRFLLGGRHGEFKFLPPPGYAPCHEAVLPRERLHLEPIKEYRREGPRGPHLVGPSRCLSHTDFVPCPVDTVQIVLPPHLERIREKLAENIHELWALTRIEQGWTYGPVRDDNKRLHPCLVDFHSLPEPERNYNLQMSGETLKTLLALGCHVGMADEKAEDNLKKTKLPKTYMMSNGYKPAPLDLSHVRLTPAQTTLVDRLAENGHNVWARDRVGQGWSYSAVQDIPARRNPRLVPYRLLDEATKRSNRDSLCQAVRTLLGYGYNIEPPDQEPSQVENQSRCDRVRIFRAEKSYTVQSGRWYFEFEAVTTGEMRVGWARPELRPDVELGADELAYVFNGHRGQRWHLGSEPFGRPWQPGDVVGCMIDLTENTIIFTLNGEVLMSDSGSETAFREIEIGDGFLPVCSLGPGQVGHLNLGQDVSSLRFFAICGLQEGFEPFAINMQRPVTTWFSKGLPQFEPVPLEHPHYEVSRVDGTVDTPPCLRLTHRTWGSQNSLVEMLFLRLSLPVQFHQHFRCTAGATPLAPPGLQPPAEDEARAAEPDPDYENLRRSAGGWSEAENGKEGTAKEGAPGGTPQAGGEAQPARAENEKDATTEKNKKRGFLFKAKKVAMMTQPPATPTLPRLPHDVVPADNRDDPEIILNTTTYYYSVRVFAGQEPSCVWAGWVTPDYHQHDMSFDLSKVRVVTVTMGDEQGNVHSSLKCSNCYMVWGGDFVSPGQQGRISHTDLVIGCLVDLATGLMTFTANGKESNTFFQVEPNTKLFPAVFVLPTHQNVIQFELGKQKNIMPLSAAMFQSERKNPAPQCPPRLEMQMLMPVSWSRMPNHFLQVETRRAGERLGWAVQCQEPLTMMALHIPEENRCMDILELSERLDLQRFHSHTLRLYRAVCALGNNRVAHALCSHVDQAQLLHALEDAHLPGPLRAGYYDLLISIHLESACRSRRSMLSEYIVPLTPETRAITLFPPGRSTENGHPRHGLPGVGVTTSLRPPHHFSPPCFVAALPAAGAAEAPARLSPAIPLEALRDKALRMLGEAVRDGGQHARDPVGGSVEFQFVPVLKLVSTLLVMGIFGDEDVKQILKMIEPEVFTEEEEEEDEEEEGEEEDEEEKEEDEEETAQEKEDEEKEEEEAAEGEKEEGLEEGLLQMKLPESVKLQMCHLLEYFCDQELQHRVESLAAFAERYVDKLQANQRSRYGLLIKAFSMTAAETARRTREFRSPPQEQINMLLQFKDGTDEEDCPLPEEIRQDLLDFHQDLLAHCGIQLDGEEEEPEEETTLGSRLMSLLEKVRLVKKKEEKPEEERSAEESKPRSLQELVSHMVVRWAQEDFVQSPELVRAMFSLLHRQYDGLGELLRALPRAYTISPSSVEDTMSLLECLGQIRSLLIVQMGPQEENLMIQSIGNIMNNKVFYQHPNLMRALGMHETVMEVMVNVLGGGESKEIRFPKMVTSCCRFLCYFCRISRQNQRSMFDHLSYLLENSGIGLGMQGSTPLDVAAASVIDNNELALALQEQDLEKVVSYLAGCGLQSCPMLVAKGYPDIGWNPCGGERYLDFLRFAVFVNGESVEENANVVVRLLIRKPECFGPALRGEGGSGLLAAIEEAIRISEDPARDGPGIRRDRRREHFGEEPPEENRVHLGHAIMSFYAALIDLLGRCAPEMHLIQAGKGEALRIRAILRSLVPLEDLVGIISLPLQIPTLGKDGALVQPKMSASFVPDHKASMVLFLDRVYGIENQDFLLHVLDVGFLPDMRAAASLDTATFSTTEMALALNRYLCLAVLPLITKCAPLFAGTEHRAIMVDSMLHTVYRLSRGRSLTKAQRDVIEDCLMSLCRYIRPSMLQHLLRRLVFDVPILNEFAKMPLKLLTNHYERCWKYYCLPTGWANFGVTSEEELHLTRKLFWGIFDSLAHKKYDPELYRMAMPCLCAIAGALPPDYVDASYSSKAEKKATVDAEGNFDPRPVETLNVIIPEKLDSFINKFAEYTHEKWAFDKIQNNWSYGENIDEELKTHPMLRPYKTFSEKDKEIYRWPIKESLKAMIAWEWTIEKAREGEEEKTEKKKTRKISQSAQTYDPREGYNPQPPDLSAVTLSRELQAMAEQLAENYHNTWGRKKKQELEAKGGGTHPLLVPYDTLTAKEKARDREKAQELLKFLQMNGYAVTRGLKDMELDSSSIEKRFAFGFLQQLLRWMDISQEFIAHLEAVVSSGRVEKSPHEQEIKFFAKILLPLINQYFTNHCLYFLSTPAKVLGSGGHASNKEKEMITSLFCKLAALVRHRVSLFGTDAPAVVNCLHILARSLDARTVMKSGPEIVKAGLRSFFESASEDIEKMVENLRLGKVSQARTQVKGVGQNLTYTTVALLPVLTTLFQHIAQHQFGDDVILDDVQVSCYRTLCSIYSLGTTKNTYVEKLRPALGECLARLAAAMPVAFLEPQLNEYNACSVYTTKSPRERAILGLPNSVEEMCPDIPVLERLMADIGGLAESGARYTEMPHVIEITLPMLCSYLPRWWERGPEAPPSALPAGAPPPCTAVTSDHLNSLLGNILRIIVNNLGIDEASWMKRLAVFAQPIVSRARPELLQSHFIPTIGRLRKRAGKVVSEEEQLRLEAKAEAQEGELLVRDEFSVLCRDLYALYPLLIRYVDNNRAQWLTEPNPSAEELFRMVGEIFIYWSKSHNFKREEQNFVVQNEINNMSFLTADNKSKMAKAGDIQSGGSDQERTKKKRRGDRYSVQTSLIVATLKKMLPIGLNMCAPTDQDLITLAKTRYALKDTDEEVREFLHNNLHLQGKVEGSPSLRWQMALYRGVPGREEDADDPEKIVRRVQEVSAVLYYLDQTEHPYKSKKAVWHKLLSKQRRRAVVACFRMTPLYNLPTHRACNMFLESYKAAWILTEDHSFEDRMIDDLSKAGEQEEEEEEVEEKKPDPLHQLVLHFSRTALTEKSKLDEDYLYMAYADIMAKSCHLEEGGENGEAEEEVEVSFEEKQMEKQRLLYQQARLHTRGAAEMVLQMISACKGETGAMVSSTLKLGISILNGGNAEVQQKMLDYLKDKKEVGFFQSIQALMQTCSVLDLNAFERQNKAEGLGMVNEDGTVINRQNGEKVMADDEFTQDLFRFLQLLCEGHNNDFQNYLRTQTGNTTTINIIICTVDYLLRLQESISDFYWYYSGKDVIEEQGKRNFSKAMSVAKQVFNSLTEYIQGPCTGNQQSLAHSRLWDAVVGFLHVFAHMMMKLAQDSSQIELLKELLDLQKDMVVMLLSLLEGNVVNGMIARQMVDMLVESSSNVEMILKFFDMFLKLKDIVGSEAFQDYVTDPRGLISKKDFQKAMDSQKQFSGPEIQFLLSCSEADENEMINCEEFANRFQEPARDIGFNVAVLLTNLSEHVPHDPRLHNFLELAESILEYFRPYLGRIEIMGASRRIERIYFEISETNRAQWEMPQVKESKRQFIFDVVNEGGEAEKMELFVSFCEDTIFEMQIAAQISEPEGEPETDEDEGAGAAEAGAEGAEEGAAGLEGTAATAAAGATARVVAAAGRALRGLSYRSLRRRVRRLRRLTAREAATAVAALLWAAVTRAGAAGAGAAAGALGLLWGSLFGGGLVEGAKKVTVTELLAGMPDPTSDEVHGEQPAGPGGDADGEGASEGAGDAAEGAGDEEEAVHEAGPGGADGAVAVTDGGPFRPEGAGGLGDMGDTTPAEPPTPEGSPILKRKLGVDGVEEELPPEPEPEPEPELEPEKADAENGEKEEVPEPTPEPPKKQAPPSPPPKKEEAGGEFWGELEVQRVKFLNYLSRNFYTLRFLALFLAFAINFILLFYKVSDSPPGEDDMEGSAAGDVSGAGSGGSSGWGLGAGEEAEGDEDENMVYYFLEESTGYMEPALRCLSLLHTLVAFLCIIGYNCLKVPLVIFKREKELARKLEFDGLYITEQPEDDDVKGQWDRLVLNTPSFPSNYWDKFVKRKVLDKHGDIYGRERIAELLGMDLATLEITAHNERKPNPPPGLLTWLMSIDVKYQIWKFGVIFTDNSFLYLGWYMVMSLLGHYNNFFFAAHLLDIAMGVKTLRTILSSVTHNGKQLVMTVGLLAVVVYLYTVVAFNFFRKFYNKSEDEDEPDMKCDDMMTCYLFHMYVGVRAGGGIGDEIEDPAGDEYELYRVVFDITFFFFVIVILLAIIQGLIIDAFGELRDQQEQVKEDMETKCFICGIGSDYFDTTPHGFETHTLEEHNLANYMFFLMYLINKDETEHTGQESYVWKMYQERCWDFFPAGDCFRKQYEDQLS	5038	P21817	V	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
247	NM_000540.2(RYR1):c.12881C>T (p.Thr4294Met)	159834	CA024017	NM_000540.2:c.12881C>T, NC_000019.10:g.38565215C>T, CM000681.2:g.38565215C>T, NC_000019.9:g.39055855C>T, CM000681.1:g.39055855C>T, NC_000019.8:g.43747695C>T, NG_008866.1:g.136516C>T, LRG_766:g.136516C>T, ENST00000355481.8:c.12866C>T, ENST00000359596.7:n.12881C>T, ENST00000360985.7:c.12863C>T, LRG_766t1:c.12881C>T, NM_001042723.1:c.12866C>T, XM_006723317.1:c.12863C>T, XM_006723319.1:c.12848C>T, XM_011527204.1:c.12878C>T, XM_011527205.1:c.12881C>T, XM_006723317.2:c.12863C>T, XM_006723319.2:c.12848C>T, XM_011527205.2:c.12881C>T, NM_000540.3:c.12881C>T, NM_001042723.2:c.12866C>T, NM_000540.2(RYR1):c.12881C>T (p.Thr4294Met)	RYR1	malignant hyperthermia, susceptibility to, 1	MONDO:0007783	Autosomal dominant inheritance	Benign	BA1		This pathogenicity assessment is relevant only for malignant hyperthermia susceptibility (MHS) inherited in an autosomal dominant pattern. Variants in RYR1 can also cause other myopathies inherited in an autosomal dominant pattern or in an autosomal recessive pattern. Some of these disorders may predispose individuals to malignant hyperthermia. RYR1 variants may also contribute to a malignant hyperthermia reaction in combination with other genetic and non-genetic factors and the clinician needs to consider such factors in making management decisions.This sequence variant predicts a substitution of Threonine with Methionine at codon 4294 of the RYR1 protein, p.(Thr4294Met). The maximum allele frequency for this variant among the six major gnomAD populations is AFR: 0.0193, which is considered to be too common for a pathogenic variant causing autosomal dominantly inherited MHS, BA1. This variant has been classified as Benign. Criteria implemented: BA1.		Malignant Hyperthermia Susceptibility VCEP	https://clinicalgenome.org/docs/clingen-malignant-hyperthermia-susceptibility-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-for/	2021-03-17	2021-03-31	False	https://erepo.genome.network/evrepo/ui/classification/CA024017/MONDO:0007783/012	13e778b6-fc1c-4a97-9c49-0878bad4f887	p.Thr4294Met	Thr	4294	Met	MGDAEGEDEVQFLRTDDEVVLQCSATVLKEQLKLCLAAEGFGNRLCFLEPTSNAQNVPPDLAICCFVLEQSLSVRALQEMLANTVEAGVESSQGGGHRTLLYGHAILLRHAHSRMYLSCLTTSRSMTDKLAFDVGLQEDATGEACWWTMHPASKQRSEGEKVRVGDDIILVSVSSERYLHLSTASGELQVDASFMQTLWNMNPICSRCEEGFVTGGHVLRLFHGHMDECLTISPADSDDQRRLVYYEGGAVCTHARSLWRLEPLRISWSGSHLRWGQPLRVRHVTTGQYLALTEDQGLVVVDASKAHTKATSFCFRISKEKLDVAPKRDVEGMGPPEIKYGESLCFVQHVASGLWLTYAAPDPKALRLGVLKKKAMLHQEGHMDDALSLTRCQQEESQAARMIHSTNGLYNQFIKSLDSFSGKPRGSGPPAGTALPIEGVILSLQDLIIYFEPPSEDLQHEEKQSKLRSLRNRQSLFQEEGMLSMVLNCIDRLNVYTTAAHFAEFAGEEAAESWKEIVNLLYELLASLIRGNRSNCALFSTNLDWLVSKLDRLEASSGILEVLYCVLIESPEVLNIIQENHIKSIISLLDKHGRNHKVLDVLCSLCVCNGVAVRSNQDLITENLLPGRELLLQTNLINYVTSIRPNIFVGRAEGTTQYSKWYFEVMVDEVTPFLTAQATHLRVGWALTEGYTPYPGAGEGWGGNGVGDDLYSYGFDGLHLWTGHVARPVTSPGQHLLAPEDVISCCLDLSVPSISFRINGCPVQGVFESFNLDGLFFPVVSFSAGVKVRFLLGGRHGEFKFLPPPGYAPCHEAVLPRERLHLEPIKEYRREGPRGPHLVGPSRCLSHTDFVPCPVDTVQIVLPPHLERIREKLAENIHELWALTRIEQGWTYGPVRDDNKRLHPCLVDFHSLPEPERNYNLQMSGETLKTLLALGCHVGMADEKAEDNLKKTKLPKTYMMSNGYKPAPLDLSHVRLTPAQTTLVDRLAENGHNVWARDRVGQGWSYSAVQDIPARRNPRLVPYRLLDEATKRSNRDSLCQAVRTLLGYGYNIEPPDQEPSQVENQSRCDRVRIFRAEKSYTVQSGRWYFEFEAVTTGEMRVGWARPELRPDVELGADELAYVFNGHRGQRWHLGSEPFGRPWQPGDVVGCMIDLTENTIIFTLNGEVLMSDSGSETAFREIEIGDGFLPVCSLGPGQVGHLNLGQDVSSLRFFAICGLQEGFEPFAINMQRPVTTWFSKGLPQFEPVPLEHPHYEVSRVDGTVDTPPCLRLTHRTWGSQNSLVEMLFLRLSLPVQFHQHFRCTAGATPLAPPGLQPPAEDEARAAEPDPDYENLRRSAGGWSEAENGKEGTAKEGAPGGTPQAGGEAQPARAENEKDATTEKNKKRGFLFKAKKVAMMTQPPATPTLPRLPHDVVPADNRDDPEIILNTTTYYYSVRVFAGQEPSCVWAGWVTPDYHQHDMSFDLSKVRVVTVTMGDEQGNVHSSLKCSNCYMVWGGDFVSPGQQGRISHTDLVIGCLVDLATGLMTFTANGKESNTFFQVEPNTKLFPAVFVLPTHQNVIQFELGKQKNIMPLSAAMFQSERKNPAPQCPPRLEMQMLMPVSWSRMPNHFLQVETRRAGERLGWAVQCQEPLTMMALHIPEENRCMDILELSERLDLQRFHSHTLRLYRAVCALGNNRVAHALCSHVDQAQLLHALEDAHLPGPLRAGYYDLLISIHLESACRSRRSMLSEYIVPLTPETRAITLFPPGRSTENGHPRHGLPGVGVTTSLRPPHHFSPPCFVAALPAAGAAEAPARLSPAIPLEALRDKALRMLGEAVRDGGQHARDPVGGSVEFQFVPVLKLVSTLLVMGIFGDEDVKQILKMIEPEVFTEEEEEEDEEEEGEEEDEEEKEEDEEETAQEKEDEEKEEEEAAEGEKEEGLEEGLLQMKLPESVKLQMCHLLEYFCDQELQHRVESLAAFAERYVDKLQANQRSRYGLLIKAFSMTAAETARRTREFRSPPQEQINMLLQFKDGTDEEDCPLPEEIRQDLLDFHQDLLAHCGIQLDGEEEEPEEETTLGSRLMSLLEKVRLVKKKEEKPEEERSAEESKPRSLQELVSHMVVRWAQEDFVQSPELVRAMFSLLHRQYDGLGELLRALPRAYTISPSSVEDTMSLLECLGQIRSLLIVQMGPQEENLMIQSIGNIMNNKVFYQHPNLMRALGMHETVMEVMVNVLGGGESKEIRFPKMVTSCCRFLCYFCRISRQNQRSMFDHLSYLLENSGIGLGMQGSTPLDVAAASVIDNNELALALQEQDLEKVVSYLAGCGLQSCPMLVAKGYPDIGWNPCGGERYLDFLRFAVFVNGESVEENANVVVRLLIRKPECFGPALRGEGGSGLLAAIEEAIRISEDPARDGPGIRRDRRREHFGEEPPEENRVHLGHAIMSFYAALIDLLGRCAPEMHLIQAGKGEALRIRAILRSLVPLEDLVGIISLPLQIPTLGKDGALVQPKMSASFVPDHKASMVLFLDRVYGIENQDFLLHVLDVGFLPDMRAAASLDTATFSTTEMALALNRYLCLAVLPLITKCAPLFAGTEHRAIMVDSMLHTVYRLSRGRSLTKAQRDVIEDCLMSLCRYIRPSMLQHLLRRLVFDVPILNEFAKMPLKLLTNHYERCWKYYCLPTGWANFGVTSEEELHLTRKLFWGIFDSLAHKKYDPELYRMAMPCLCAIAGALPPDYVDASYSSKAEKKATVDAEGNFDPRPVETLNVIIPEKLDSFINKFAEYTHEKWAFDKIQNNWSYGENIDEELKTHPMLRPYKTFSEKDKEIYRWPIKESLKAMIAWEWTIEKAREGEEEKTEKKKTRKISQSAQTYDPREGYNPQPPDLSAVTLSRELQAMAEQLAENYHNTWGRKKKQELEAKGGGTHPLLVPYDTLTAKEKARDREKAQELLKFLQMNGYAVTRGLKDMELDSSSIEKRFAFGFLQQLLRWMDISQEFIAHLEAVVSSGRVEKSPHEQEIKFFAKILLPLINQYFTNHCLYFLSTPAKVLGSGGHASNKEKEMITSLFCKLAALVRHRVSLFGTDAPAVVNCLHILARSLDARTVMKSGPEIVKAGLRSFFESASEDIEKMVENLRLGKVSQARTQVKGVGQNLTYTTVALLPVLTTLFQHIAQHQFGDDVILDDVQVSCYRTLCSIYSLGTTKNTYVEKLRPALGECLARLAAAMPVAFLEPQLNEYNACSVYTTKSPRERAILGLPNSVEEMCPDIPVLERLMADIGGLAESGARYTEMPHVIEITLPMLCSYLPRWWERGPEAPPSALPAGAPPPCTAVTSDHLNSLLGNILRIIVNNLGIDEASWMKRLAVFAQPIVSRARPELLQSHFIPTIGRLRKRAGKVVSEEEQLRLEAKAEAQEGELLVRDEFSVLCRDLYALYPLLIRYVDNNRAQWLTEPNPSAEELFRMVGEIFIYWSKSHNFKREEQNFVVQNEINNMSFLTADNKSKMAKAGDIQSGGSDQERTKKKRRGDRYSVQTSLIVATLKKMLPIGLNMCAPTDQDLITLAKTRYALKDTDEEVREFLHNNLHLQGKVEGSPSLRWQMALYRGVPGREEDADDPEKIVRRVQEVSAVLYYLDQTEHPYKSKKAVWHKLLSKQRRRAVVACFRMTPLYNLPTHRACNMFLESYKAAWILTEDHSFEDRMIDDLSKAGEQEEEEEEVEEKKPDPLHQLVLHFSRTALTEKSKLDEDYLYMAYADIMAKSCHLEEGGENGEAEEEVEVSFEEKQMEKQRLLYQQARLHTRGAAEMVLQMISACKGETGAMVSSTLKLGISILNGGNAEVQQKMLDYLKDKKEVGFFQSIQALMQTCSVLDLNAFERQNKAEGLGMVNEDGTVINRQNGEKVMADDEFTQDLFRFLQLLCEGHNNDFQNYLRTQTGNTTTINIIICTVDYLLRLQESISDFYWYYSGKDVIEEQGKRNFSKAMSVAKQVFNSLTEYIQGPCTGNQQSLAHSRLWDAVVGFLHVFAHMMMKLAQDSSQIELLKELLDLQKDMVVMLLSLLEGNVVNGMIARQMVDMLVESSSNVEMILKFFDMFLKLKDIVGSEAFQDYVTDPRGLISKKDFQKAMDSQKQFSGPEIQFLLSCSEADENEMINCEEFANRFQEPARDIGFNVAVLLTNLSEHVPHDPRLHNFLELAESILEYFRPYLGRIEIMGASRRIERIYFEISETNRAQWEMPQVKESKRQFIFDVVNEGGEAEKMELFVSFCEDTIFEMQIAAQISEPEGEPETDEDEGAGAAEAGAEGAEEGAAGLEGTAATAAAGATARVVAAAGRALRGLSYRSLRRRVRRLRRLTAREAATAVAALLWAAVTRAGAAGAGAAAGALGLLWGSLFGGGLVEGAKKVTVTELLAGMPDPTSDEVHGEQPAGPGGDADGEGASEGAGDAAEGAGDEEEAVHEAGPGGADGAVAVTDGGPFRPEGAGGLGDMGDTTPAEPPTPEGSPILKRKLGVDGVEEELPPEPEPEPEPELEPEKADAENGEKEEVPEPTPEPPKKQAPPSPPPKKEEAGGEFWGELEVQRVKFLNYLSRNFYTLRFLALFLAFAINFILLFYKVSDSPPGEDDMEGSAAGDVSGAGSGGSSGWGLGAGEEAEGDEDENMVYYFLEESTGYMEPALRCLSLLHTLVAFLCIIGYNCLKVPLVIFKREKELARKLEFDGLYITEQPEDDDVKGQWDRLVLNTPSFPSNYWDKFVKRKVLDKHGDIYGRERIAELLGMDLATLEITAHNERKPNPPPGLLTWLMSIDVKYQIWKFGVIFTDNSFLYLGWYMVMSLLGHYNNFFFAAHLLDIAMGVKTLRTILSSVTHNGKQLVMTVGLLAVVVYLYTVVAFNFFRKFYNKSEDEDEPDMKCDDMMTCYLFHMYVGVRAGGGIGDEIEDPAGDEYELYRVVFDITFFFFVIVILLAIIQGLIIDAFGELRDQQEQVKEDMETKCFICGIGSDYFDTTPHGFETHTLEEHNLANYMFFLMYLINKDETEHTGQESYVWKMYQERCWDFFPAGDCFRKQYEDQLS	5038	P21817	M	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [1490], 'DISULFID_gain': [], 'DISULFID_loss_score': array([-0.00120902]), 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
248	NM_000540.2(RYR1):c.11266C>G (p.Gln3756Glu)	133011	CA023907	NM_000540.2:c.11266C>G, NC_000019.10:g.38534726C>G, CM000681.2:g.38534726C>G, NC_000019.9:g.39025366C>G, CM000681.1:g.39025366C>G, NC_000019.8:g.43717206C>G, NG_008866.1:g.106027C>G, LRG_766:g.106027C>G, ENST00000355481.8:c.11251C>G, ENST00000359596.7:n.11266C>G, ENST00000360985.7:c.11248C>G, ENST00000601514.5:n.547C>G, LRG_766t1:c.11266C>G, NM_001042723.1:c.11251C>G, XM_006723317.1:c.11266C>G, XM_006723319.1:c.11251C>G, XM_011527204.1:c.11263C>G, XM_011527205.1:c.11266C>G, XM_006723317.2:c.11266C>G, XM_006723319.2:c.11251C>G, XM_011527205.2:c.11266C>G, NM_000540.3:c.11266C>G, NM_001042723.2:c.11251C>G, NM_000540.2(RYR1):c.11266C>G (p.Gln3756Glu)	RYR1	malignant hyperthermia, susceptibility to, 1	MONDO:0007783	Autosomal dominant inheritance	Benign	BA1		This pathogenicity assessment is relevant only for malignant hyperthermia susceptibility (MHS) inherited in an autosomal dominant pattern. Variants in RYR1 can also cause other myopathies inherited in an autosomal dominant pattern or in an autosomal recessive pattern. Some of these disorders may predispose individuals to malignant hyperthermia. RYR1 variants may also contribute to a malignant hyperthermia reaction in combination with other genetic and non-genetic factors and the clinician needs to consider such factors in making management decisions.This sequence variant predicts a substitution of Glutamine with Glutamic Acid at codon 3756 of the RYR1 protein, p.(Gln3756Glu). The maximum allele frequency for this variant among the six major gnomAD populations is AMR: 0.1085, which is considered to be too common for a pathogenic variant causing autosomal dominantly inherited MHS, BA1. This variant has been classified as Benign. Criteria implemented: BA1.		Malignant Hyperthermia Susceptibility VCEP	https://clinicalgenome.org/docs/clingen-malignant-hyperthermia-susceptibility-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-for/	2021-03-17	2021-03-31	False	https://erepo.genome.network/evrepo/ui/classification/CA023907/MONDO:0007783/012	84e67b58-13bd-412d-89ff-e40986b35baf	p.Gln3756Glu	Gln	3756	Glu	MGDAEGEDEVQFLRTDDEVVLQCSATVLKEQLKLCLAAEGFGNRLCFLEPTSNAQNVPPDLAICCFVLEQSLSVRALQEMLANTVEAGVESSQGGGHRTLLYGHAILLRHAHSRMYLSCLTTSRSMTDKLAFDVGLQEDATGEACWWTMHPASKQRSEGEKVRVGDDIILVSVSSERYLHLSTASGELQVDASFMQTLWNMNPICSRCEEGFVTGGHVLRLFHGHMDECLTISPADSDDQRRLVYYEGGAVCTHARSLWRLEPLRISWSGSHLRWGQPLRVRHVTTGQYLALTEDQGLVVVDASKAHTKATSFCFRISKEKLDVAPKRDVEGMGPPEIKYGESLCFVQHVASGLWLTYAAPDPKALRLGVLKKKAMLHQEGHMDDALSLTRCQQEESQAARMIHSTNGLYNQFIKSLDSFSGKPRGSGPPAGTALPIEGVILSLQDLIIYFEPPSEDLQHEEKQSKLRSLRNRQSLFQEEGMLSMVLNCIDRLNVYTTAAHFAEFAGEEAAESWKEIVNLLYELLASLIRGNRSNCALFSTNLDWLVSKLDRLEASSGILEVLYCVLIESPEVLNIIQENHIKSIISLLDKHGRNHKVLDVLCSLCVCNGVAVRSNQDLITENLLPGRELLLQTNLINYVTSIRPNIFVGRAEGTTQYSKWYFEVMVDEVTPFLTAQATHLRVGWALTEGYTPYPGAGEGWGGNGVGDDLYSYGFDGLHLWTGHVARPVTSPGQHLLAPEDVISCCLDLSVPSISFRINGCPVQGVFESFNLDGLFFPVVSFSAGVKVRFLLGGRHGEFKFLPPPGYAPCHEAVLPRERLHLEPIKEYRREGPRGPHLVGPSRCLSHTDFVPCPVDTVQIVLPPHLERIREKLAENIHELWALTRIEQGWTYGPVRDDNKRLHPCLVDFHSLPEPERNYNLQMSGETLKTLLALGCHVGMADEKAEDNLKKTKLPKTYMMSNGYKPAPLDLSHVRLTPAQTTLVDRLAENGHNVWARDRVGQGWSYSAVQDIPARRNPRLVPYRLLDEATKRSNRDSLCQAVRTLLGYGYNIEPPDQEPSQVENQSRCDRVRIFRAEKSYTVQSGRWYFEFEAVTTGEMRVGWARPELRPDVELGADELAYVFNGHRGQRWHLGSEPFGRPWQPGDVVGCMIDLTENTIIFTLNGEVLMSDSGSETAFREIEIGDGFLPVCSLGPGQVGHLNLGQDVSSLRFFAICGLQEGFEPFAINMQRPVTTWFSKGLPQFEPVPLEHPHYEVSRVDGTVDTPPCLRLTHRTWGSQNSLVEMLFLRLSLPVQFHQHFRCTAGATPLAPPGLQPPAEDEARAAEPDPDYENLRRSAGGWSEAENGKEGTAKEGAPGGTPQAGGEAQPARAENEKDATTEKNKKRGFLFKAKKVAMMTQPPATPTLPRLPHDVVPADNRDDPEIILNTTTYYYSVRVFAGQEPSCVWAGWVTPDYHQHDMSFDLSKVRVVTVTMGDEQGNVHSSLKCSNCYMVWGGDFVSPGQQGRISHTDLVIGCLVDLATGLMTFTANGKESNTFFQVEPNTKLFPAVFVLPTHQNVIQFELGKQKNIMPLSAAMFQSERKNPAPQCPPRLEMQMLMPVSWSRMPNHFLQVETRRAGERLGWAVQCQEPLTMMALHIPEENRCMDILELSERLDLQRFHSHTLRLYRAVCALGNNRVAHALCSHVDQAQLLHALEDAHLPGPLRAGYYDLLISIHLESACRSRRSMLSEYIVPLTPETRAITLFPPGRSTENGHPRHGLPGVGVTTSLRPPHHFSPPCFVAALPAAGAAEAPARLSPAIPLEALRDKALRMLGEAVRDGGQHARDPVGGSVEFQFVPVLKLVSTLLVMGIFGDEDVKQILKMIEPEVFTEEEEEEDEEEEGEEEDEEEKEEDEEETAQEKEDEEKEEEEAAEGEKEEGLEEGLLQMKLPESVKLQMCHLLEYFCDQELQHRVESLAAFAERYVDKLQANQRSRYGLLIKAFSMTAAETARRTREFRSPPQEQINMLLQFKDGTDEEDCPLPEEIRQDLLDFHQDLLAHCGIQLDGEEEEPEEETTLGSRLMSLLEKVRLVKKKEEKPEEERSAEESKPRSLQELVSHMVVRWAQEDFVQSPELVRAMFSLLHRQYDGLGELLRALPRAYTISPSSVEDTMSLLECLGQIRSLLIVQMGPQEENLMIQSIGNIMNNKVFYQHPNLMRALGMHETVMEVMVNVLGGGESKEIRFPKMVTSCCRFLCYFCRISRQNQRSMFDHLSYLLENSGIGLGMQGSTPLDVAAASVIDNNELALALQEQDLEKVVSYLAGCGLQSCPMLVAKGYPDIGWNPCGGERYLDFLRFAVFVNGESVEENANVVVRLLIRKPECFGPALRGEGGSGLLAAIEEAIRISEDPARDGPGIRRDRRREHFGEEPPEENRVHLGHAIMSFYAALIDLLGRCAPEMHLIQAGKGEALRIRAILRSLVPLEDLVGIISLPLQIPTLGKDGALVQPKMSASFVPDHKASMVLFLDRVYGIENQDFLLHVLDVGFLPDMRAAASLDTATFSTTEMALALNRYLCLAVLPLITKCAPLFAGTEHRAIMVDSMLHTVYRLSRGRSLTKAQRDVIEDCLMSLCRYIRPSMLQHLLRRLVFDVPILNEFAKMPLKLLTNHYERCWKYYCLPTGWANFGVTSEEELHLTRKLFWGIFDSLAHKKYDPELYRMAMPCLCAIAGALPPDYVDASYSSKAEKKATVDAEGNFDPRPVETLNVIIPEKLDSFINKFAEYTHEKWAFDKIQNNWSYGENIDEELKTHPMLRPYKTFSEKDKEIYRWPIKESLKAMIAWEWTIEKAREGEEEKTEKKKTRKISQSAQTYDPREGYNPQPPDLSAVTLSRELQAMAEQLAENYHNTWGRKKKQELEAKGGGTHPLLVPYDTLTAKEKARDREKAQELLKFLQMNGYAVTRGLKDMELDSSSIEKRFAFGFLQQLLRWMDISQEFIAHLEAVVSSGRVEKSPHEQEIKFFAKILLPLINQYFTNHCLYFLSTPAKVLGSGGHASNKEKEMITSLFCKLAALVRHRVSLFGTDAPAVVNCLHILARSLDARTVMKSGPEIVKAGLRSFFESASEDIEKMVENLRLGKVSQARTQVKGVGQNLTYTTVALLPVLTTLFQHIAQHQFGDDVILDDVQVSCYRTLCSIYSLGTTKNTYVEKLRPALGECLARLAAAMPVAFLEPQLNEYNACSVYTTKSPRERAILGLPNSVEEMCPDIPVLERLMADIGGLAESGARYTEMPHVIEITLPMLCSYLPRWWERGPEAPPSALPAGAPPPCTAVTSDHLNSLLGNILRIIVNNLGIDEASWMKRLAVFAQPIVSRARPELLQSHFIPTIGRLRKRAGKVVSEEEQLRLEAKAEAQEGELLVRDEFSVLCRDLYALYPLLIRYVDNNRAQWLTEPNPSAEELFRMVGEIFIYWSKSHNFKREEQNFVVQNEINNMSFLTADNKSKMAKAGDIQSGGSDQERTKKKRRGDRYSVQTSLIVATLKKMLPIGLNMCAPTDQDLITLAKTRYALKDTDEEVREFLHNNLHLQGKVEGSPSLRWQMALYRGVPGREEDADDPEKIVRRVQEVSAVLYYLDQTEHPYKSKKAVWHKLLSKQRRRAVVACFRMTPLYNLPTHRACNMFLESYKAAWILTEDHSFEDRMIDDLSKAGEQEEEEEEVEEKKPDPLHQLVLHFSRTALTEKSKLDEDYLYMAYADIMAKSCHLEEGGENGEAEEEVEVSFEEKQMEKQRLLYQQARLHTRGAAEMVLQMISACKGETGAMVSSTLKLGISILNGGNAEVQQKMLDYLKDKKEVGFFQSIQALMQTCSVLDLNAFERQNKAEGLGMVNEDGTVINRQNGEKVMADDEFTQDLFRFLQLLCEGHNNDFQNYLRTQTGNTTTINIIICTVDYLLRLQESISDFYWYYSGKDVIEEQGKRNFSKAMSVAKQVFNSLTEYIQGPCTGNQQSLAHSRLWDAVVGFLHVFAHMMMKLAQDSSQIELLKELLDLQKDMVVMLLSLLEGNVVNGMIARQMVDMLVESSSNVEMILKFFDMFLKLKDIVGSEAFQDYVTDPRGLISKKDFQKAMDSQKQFSGPEIQFLLSCSEADENEMINCEEFANRFQEPARDIGFNVAVLLTNLSEHVPHDPRLHNFLELAESILEYFRPYLGRIEIMGASRRIERIYFEISETNRAQWEMPQVKESKRQFIFDVVNEGGEAEKMELFVSFCEDTIFEMQIAAQISEPEGEPETDEDEGAGAAEAGAEGAEEGAAGLEGTAATAAAGATARVVAAAGRALRGLSYRSLRRRVRRLRRLTAREAATAVAALLWAAVTRAGAAGAGAAAGALGLLWGSLFGGGLVEGAKKVTVTELLAGMPDPTSDEVHGEQPAGPGGDADGEGASEGAGDAAEGAGDEEEAVHEAGPGGADGAVAVTDGGPFRPEGAGGLGDMGDTTPAEPPTPEGSPILKRKLGVDGVEEELPPEPEPEPEPELEPEKADAENGEKEEVPEPTPEPPKKQAPPSPPPKKEEAGGEFWGELEVQRVKFLNYLSRNFYTLRFLALFLAFAINFILLFYKVSDSPPGEDDMEGSAAGDVSGAGSGGSSGWGLGAGEEAEGDEDENMVYYFLEESTGYMEPALRCLSLLHTLVAFLCIIGYNCLKVPLVIFKREKELARKLEFDGLYITEQPEDDDVKGQWDRLVLNTPSFPSNYWDKFVKRKVLDKHGDIYGRERIAELLGMDLATLEITAHNERKPNPPPGLLTWLMSIDVKYQIWKFGVIFTDNSFLYLGWYMVMSLLGHYNNFFFAAHLLDIAMGVKTLRTILSSVTHNGKQLVMTVGLLAVVVYLYTVVAFNFFRKFYNKSEDEDEPDMKCDDMMTCYLFHMYVGVRAGGGIGDEIEDPAGDEYELYRVVFDITFFFFVIVILLAIIQGLIIDAFGELRDQQEQVKEDMETKCFICGIGSDYFDTTPHGFETHTLEEHNLANYMFFLMYLINKDETEHTGQESYVWKMYQERCWDFFPAGDCFRKQYEDQLS	5038	P21817	E	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
249	NM_000540.2(RYR1):c.6178G>T (p.Gly2060Cys)	93279	CA024556	NM_000540.2:c.6178G>T, NC_000019.10:g.38492540G>T, CM000681.2:g.38492540G>T, NC_000019.9:g.38983180G>T, CM000681.1:g.38983180G>T, NC_000019.8:g.43675020G>T, NG_008866.1:g.63841G>T, LRG_766:g.63841G>T, ENST00000355481.8:c.6178G>T, ENST00000359596.7:n.6178G>T, ENST00000360985.7:c.6175G>T, LRG_766t1:c.6178G>T, NM_001042723.1:c.6178G>T, XM_006723317.1:c.6178G>T, XM_006723319.1:c.6178G>T, XM_011527204.1:c.6175G>T, XM_011527205.1:c.6178G>T, XM_006723317.2:c.6178G>T, XM_006723319.2:c.6178G>T, XM_011527205.2:c.6178G>T, NM_000540.3:c.6178G>T, NM_001042723.2:c.6178G>T, NM_000540.2(RYR1):c.6178G>T (p.Gly2060Cys)	RYR1	malignant hyperthermia, susceptibility to, 1	MONDO:0007783	Autosomal dominant inheritance	Benign	BA1		This pathogenicity assessment is relevant only for malignant hyperthermia susceptibility (MHS) inherited in an autosomal dominant pattern. Variants in RYR1 can also cause other myopathies inherited in an autosomal dominant pattern or in an autosomal recessive pattern. Some of these disorders may predispose individuals to malignant hyperthermia. RYR1 variants may also contribute to a malignant hyperthermia reaction in combination with other genetic and non-genetic factors and the clinician needs to consider such factors in making management decisions.This sequence variant predicts a substitution of Glycine with Cysteine at codon 2060 of the RYR1 protein, p.(Gly2060Cys). The maximum allele frequency for this variant among the six major gnomAD populations is SAS: 0.1562, which is considered to be too common for a pathogenic variant causing autosomal dominantly inherited MHS, BA1. This variant has been classified as Benign. Criteria implemented: BA1.		Malignant Hyperthermia Susceptibility VCEP	https://clinicalgenome.org/docs/clingen-malignant-hyperthermia-susceptibility-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-for/	2021-03-17	2021-03-31	False	https://erepo.genome.network/evrepo/ui/classification/CA024556/MONDO:0007783/012	5b192993-1d6e-4e4e-badb-ba67fbaecc13	p.Gly2060Cys	Gly	2060	Cys	MGDAEGEDEVQFLRTDDEVVLQCSATVLKEQLKLCLAAEGFGNRLCFLEPTSNAQNVPPDLAICCFVLEQSLSVRALQEMLANTVEAGVESSQGGGHRTLLYGHAILLRHAHSRMYLSCLTTSRSMTDKLAFDVGLQEDATGEACWWTMHPASKQRSEGEKVRVGDDIILVSVSSERYLHLSTASGELQVDASFMQTLWNMNPICSRCEEGFVTGGHVLRLFHGHMDECLTISPADSDDQRRLVYYEGGAVCTHARSLWRLEPLRISWSGSHLRWGQPLRVRHVTTGQYLALTEDQGLVVVDASKAHTKATSFCFRISKEKLDVAPKRDVEGMGPPEIKYGESLCFVQHVASGLWLTYAAPDPKALRLGVLKKKAMLHQEGHMDDALSLTRCQQEESQAARMIHSTNGLYNQFIKSLDSFSGKPRGSGPPAGTALPIEGVILSLQDLIIYFEPPSEDLQHEEKQSKLRSLRNRQSLFQEEGMLSMVLNCIDRLNVYTTAAHFAEFAGEEAAESWKEIVNLLYELLASLIRGNRSNCALFSTNLDWLVSKLDRLEASSGILEVLYCVLIESPEVLNIIQENHIKSIISLLDKHGRNHKVLDVLCSLCVCNGVAVRSNQDLITENLLPGRELLLQTNLINYVTSIRPNIFVGRAEGTTQYSKWYFEVMVDEVTPFLTAQATHLRVGWALTEGYTPYPGAGEGWGGNGVGDDLYSYGFDGLHLWTGHVARPVTSPGQHLLAPEDVISCCLDLSVPSISFRINGCPVQGVFESFNLDGLFFPVVSFSAGVKVRFLLGGRHGEFKFLPPPGYAPCHEAVLPRERLHLEPIKEYRREGPRGPHLVGPSRCLSHTDFVPCPVDTVQIVLPPHLERIREKLAENIHELWALTRIEQGWTYGPVRDDNKRLHPCLVDFHSLPEPERNYNLQMSGETLKTLLALGCHVGMADEKAEDNLKKTKLPKTYMMSNGYKPAPLDLSHVRLTPAQTTLVDRLAENGHNVWARDRVGQGWSYSAVQDIPARRNPRLVPYRLLDEATKRSNRDSLCQAVRTLLGYGYNIEPPDQEPSQVENQSRCDRVRIFRAEKSYTVQSGRWYFEFEAVTTGEMRVGWARPELRPDVELGADELAYVFNGHRGQRWHLGSEPFGRPWQPGDVVGCMIDLTENTIIFTLNGEVLMSDSGSETAFREIEIGDGFLPVCSLGPGQVGHLNLGQDVSSLRFFAICGLQEGFEPFAINMQRPVTTWFSKGLPQFEPVPLEHPHYEVSRVDGTVDTPPCLRLTHRTWGSQNSLVEMLFLRLSLPVQFHQHFRCTAGATPLAPPGLQPPAEDEARAAEPDPDYENLRRSAGGWSEAENGKEGTAKEGAPGGTPQAGGEAQPARAENEKDATTEKNKKRGFLFKAKKVAMMTQPPATPTLPRLPHDVVPADNRDDPEIILNTTTYYYSVRVFAGQEPSCVWAGWVTPDYHQHDMSFDLSKVRVVTVTMGDEQGNVHSSLKCSNCYMVWGGDFVSPGQQGRISHTDLVIGCLVDLATGLMTFTANGKESNTFFQVEPNTKLFPAVFVLPTHQNVIQFELGKQKNIMPLSAAMFQSERKNPAPQCPPRLEMQMLMPVSWSRMPNHFLQVETRRAGERLGWAVQCQEPLTMMALHIPEENRCMDILELSERLDLQRFHSHTLRLYRAVCALGNNRVAHALCSHVDQAQLLHALEDAHLPGPLRAGYYDLLISIHLESACRSRRSMLSEYIVPLTPETRAITLFPPGRSTENGHPRHGLPGVGVTTSLRPPHHFSPPCFVAALPAAGAAEAPARLSPAIPLEALRDKALRMLGEAVRDGGQHARDPVGGSVEFQFVPVLKLVSTLLVMGIFGDEDVKQILKMIEPEVFTEEEEEEDEEEEGEEEDEEEKEEDEEETAQEKEDEEKEEEEAAEGEKEEGLEEGLLQMKLPESVKLQMCHLLEYFCDQELQHRVESLAAFAERYVDKLQANQRSRYGLLIKAFSMTAAETARRTREFRSPPQEQINMLLQFKDGTDEEDCPLPEEIRQDLLDFHQDLLAHCGIQLDGEEEEPEEETTLGSRLMSLLEKVRLVKKKEEKPEEERSAEESKPRSLQELVSHMVVRWAQEDFVQSPELVRAMFSLLHRQYDGLGELLRALPRAYTISPSSVEDTMSLLECLGQIRSLLIVQMGPQEENLMIQSIGNIMNNKVFYQHPNLMRALGMHETVMEVMVNVLGGGESKEIRFPKMVTSCCRFLCYFCRISRQNQRSMFDHLSYLLENSGIGLGMQGSTPLDVAAASVIDNNELALALQEQDLEKVVSYLAGCGLQSCPMLVAKGYPDIGWNPCGGERYLDFLRFAVFVNGESVEENANVVVRLLIRKPECFGPALRGEGGSGLLAAIEEAIRISEDPARDGPGIRRDRRREHFGEEPPEENRVHLGHAIMSFYAALIDLLGRCAPEMHLIQAGKGEALRIRAILRSLVPLEDLVGIISLPLQIPTLGKDGALVQPKMSASFVPDHKASMVLFLDRVYGIENQDFLLHVLDVGFLPDMRAAASLDTATFSTTEMALALNRYLCLAVLPLITKCAPLFAGTEHRAIMVDSMLHTVYRLSRGRSLTKAQRDVIEDCLMSLCRYIRPSMLQHLLRRLVFDVPILNEFAKMPLKLLTNHYERCWKYYCLPTGWANFGVTSEEELHLTRKLFWGIFDSLAHKKYDPELYRMAMPCLCAIAGALPPDYVDASYSSKAEKKATVDAEGNFDPRPVETLNVIIPEKLDSFINKFAEYTHEKWAFDKIQNNWSYGENIDEELKTHPMLRPYKTFSEKDKEIYRWPIKESLKAMIAWEWTIEKAREGEEEKTEKKKTRKISQSAQTYDPREGYNPQPPDLSAVTLSRELQAMAEQLAENYHNTWGRKKKQELEAKGGGTHPLLVPYDTLTAKEKARDREKAQELLKFLQMNGYAVTRGLKDMELDSSSIEKRFAFGFLQQLLRWMDISQEFIAHLEAVVSSGRVEKSPHEQEIKFFAKILLPLINQYFTNHCLYFLSTPAKVLGSGGHASNKEKEMITSLFCKLAALVRHRVSLFGTDAPAVVNCLHILARSLDARTVMKSGPEIVKAGLRSFFESASEDIEKMVENLRLGKVSQARTQVKGVGQNLTYTTVALLPVLTTLFQHIAQHQFGDDVILDDVQVSCYRTLCSIYSLGTTKNTYVEKLRPALGECLARLAAAMPVAFLEPQLNEYNACSVYTTKSPRERAILGLPNSVEEMCPDIPVLERLMADIGGLAESGARYTEMPHVIEITLPMLCSYLPRWWERGPEAPPSALPAGAPPPCTAVTSDHLNSLLGNILRIIVNNLGIDEASWMKRLAVFAQPIVSRARPELLQSHFIPTIGRLRKRAGKVVSEEEQLRLEAKAEAQEGELLVRDEFSVLCRDLYALYPLLIRYVDNNRAQWLTEPNPSAEELFRMVGEIFIYWSKSHNFKREEQNFVVQNEINNMSFLTADNKSKMAKAGDIQSGGSDQERTKKKRRGDRYSVQTSLIVATLKKMLPIGLNMCAPTDQDLITLAKTRYALKDTDEEVREFLHNNLHLQGKVEGSPSLRWQMALYRGVPGREEDADDPEKIVRRVQEVSAVLYYLDQTEHPYKSKKAVWHKLLSKQRRRAVVACFRMTPLYNLPTHRACNMFLESYKAAWILTEDHSFEDRMIDDLSKAGEQEEEEEEVEEKKPDPLHQLVLHFSRTALTEKSKLDEDYLYMAYADIMAKSCHLEEGGENGEAEEEVEVSFEEKQMEKQRLLYQQARLHTRGAAEMVLQMISACKGETGAMVSSTLKLGISILNGGNAEVQQKMLDYLKDKKEVGFFQSIQALMQTCSVLDLNAFERQNKAEGLGMVNEDGTVINRQNGEKVMADDEFTQDLFRFLQLLCEGHNNDFQNYLRTQTGNTTTINIIICTVDYLLRLQESISDFYWYYSGKDVIEEQGKRNFSKAMSVAKQVFNSLTEYIQGPCTGNQQSLAHSRLWDAVVGFLHVFAHMMMKLAQDSSQIELLKELLDLQKDMVVMLLSLLEGNVVNGMIARQMVDMLVESSSNVEMILKFFDMFLKLKDIVGSEAFQDYVTDPRGLISKKDFQKAMDSQKQFSGPEIQFLLSCSEADENEMINCEEFANRFQEPARDIGFNVAVLLTNLSEHVPHDPRLHNFLELAESILEYFRPYLGRIEIMGASRRIERIYFEISETNRAQWEMPQVKESKRQFIFDVVNEGGEAEKMELFVSFCEDTIFEMQIAAQISEPEGEPETDEDEGAGAAEAGAEGAEEGAAGLEGTAATAAAGATARVVAAAGRALRGLSYRSLRRRVRRLRRLTAREAATAVAALLWAAVTRAGAAGAGAAAGALGLLWGSLFGGGLVEGAKKVTVTELLAGMPDPTSDEVHGEQPAGPGGDADGEGASEGAGDAAEGAGDEEEAVHEAGPGGADGAVAVTDGGPFRPEGAGGLGDMGDTTPAEPPTPEGSPILKRKLGVDGVEEELPPEPEPEPEPELEPEKADAENGEKEEVPEPTPEPPKKQAPPSPPPKKEEAGGEFWGELEVQRVKFLNYLSRNFYTLRFLALFLAFAINFILLFYKVSDSPPGEDDMEGSAAGDVSGAGSGGSSGWGLGAGEEAEGDEDENMVYYFLEESTGYMEPALRCLSLLHTLVAFLCIIGYNCLKVPLVIFKREKELARKLEFDGLYITEQPEDDDVKGQWDRLVLNTPSFPSNYWDKFVKRKVLDKHGDIYGRERIAELLGMDLATLEITAHNERKPNPPPGLLTWLMSIDVKYQIWKFGVIFTDNSFLYLGWYMVMSLLGHYNNFFFAAHLLDIAMGVKTLRTILSSVTHNGKQLVMTVGLLAVVVYLYTVVAFNFFRKFYNKSEDEDEPDMKCDDMMTCYLFHMYVGVRAGGGIGDEIEDPAGDEYELYRVVFDITFFFFVIVILLAIIQGLIIDAFGELRDQQEQVKEDMETKCFICGIGSDYFDTTPHGFETHTLEEHNLANYMFFLMYLINKDETEHTGQESYVWKMYQERCWDFFPAGDCFRKQYEDQLS	5038	P21817	C	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
250	NM_000540.2(RYR1):c.5360C>T (p.Pro1787Leu)	133149	CA024515	NM_000540.2:c.5360C>T, NC_000019.10:g.38486015C>T, CM000681.2:g.38486015C>T, NC_000019.9:g.38976655C>T, CM000681.1:g.38976655C>T, NC_000019.8:g.43668495C>T, NG_008866.1:g.57316C>T, LRG_766:g.57316C>T, ENST00000355481.8:c.5360C>T, ENST00000359596.7:n.5360C>T, ENST00000360985.7:c.5357C>T, LRG_766t1:c.5360C>T, NM_001042723.1:c.5360C>T, XM_006723317.1:c.5360C>T, XM_006723319.1:c.5360C>T, XM_011527204.1:c.5357C>T, XM_011527205.1:c.5360C>T, XM_006723317.2:c.5360C>T, XM_006723319.2:c.5360C>T, XM_011527205.2:c.5360C>T, NM_000540.3:c.5360C>T, NM_001042723.2:c.5360C>T, NM_000540.2(RYR1):c.5360C>T (p.Pro1787Leu)	RYR1	malignant hyperthermia, susceptibility to, 1	MONDO:0007783	Autosomal dominant inheritance	Benign	BA1		This pathogenicity assessment is relevant only for malignant hyperthermia susceptibility (MHS) inherited in an autosomal dominant pattern. Variants in RYR1 can also cause other myopathies inherited in an autosomal dominant pattern or in an autosomal recessive pattern. Some of these disorders may predispose individuals to malignant hyperthermia. RYR1 variants may also contribute to a malignant hyperthermia reaction in combination with other genetic and non-genetic factors and the clinician needs to consider such factors in making management decisions.This sequence variant predicts a substitution of Proline with Leucine at codon 1787 of the RYR1 protein, p.(Pro1787Leu). The maximum allele frequency for this variant among the six major gnomAD populations is SAS: 0.0413, which is considered to be too common for a pathogenic variant causing autosomal dominantly inherited MHS, BA1. This variant has been classified as Benign. Criteria implemented: BA1.		Malignant Hyperthermia Susceptibility VCEP	https://clinicalgenome.org/docs/clingen-malignant-hyperthermia-susceptibility-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-for/	2021-03-17	2021-03-31	False	https://erepo.genome.network/evrepo/ui/classification/CA024515/MONDO:0007783/012	03ac6f63-5c67-4f58-9c5d-f8c57d7fc777	p.Pro1787Leu	Pro	1787	Leu	MGDAEGEDEVQFLRTDDEVVLQCSATVLKEQLKLCLAAEGFGNRLCFLEPTSNAQNVPPDLAICCFVLEQSLSVRALQEMLANTVEAGVESSQGGGHRTLLYGHAILLRHAHSRMYLSCLTTSRSMTDKLAFDVGLQEDATGEACWWTMHPASKQRSEGEKVRVGDDIILVSVSSERYLHLSTASGELQVDASFMQTLWNMNPICSRCEEGFVTGGHVLRLFHGHMDECLTISPADSDDQRRLVYYEGGAVCTHARSLWRLEPLRISWSGSHLRWGQPLRVRHVTTGQYLALTEDQGLVVVDASKAHTKATSFCFRISKEKLDVAPKRDVEGMGPPEIKYGESLCFVQHVASGLWLTYAAPDPKALRLGVLKKKAMLHQEGHMDDALSLTRCQQEESQAARMIHSTNGLYNQFIKSLDSFSGKPRGSGPPAGTALPIEGVILSLQDLIIYFEPPSEDLQHEEKQSKLRSLRNRQSLFQEEGMLSMVLNCIDRLNVYTTAAHFAEFAGEEAAESWKEIVNLLYELLASLIRGNRSNCALFSTNLDWLVSKLDRLEASSGILEVLYCVLIESPEVLNIIQENHIKSIISLLDKHGRNHKVLDVLCSLCVCNGVAVRSNQDLITENLLPGRELLLQTNLINYVTSIRPNIFVGRAEGTTQYSKWYFEVMVDEVTPFLTAQATHLRVGWALTEGYTPYPGAGEGWGGNGVGDDLYSYGFDGLHLWTGHVARPVTSPGQHLLAPEDVISCCLDLSVPSISFRINGCPVQGVFESFNLDGLFFPVVSFSAGVKVRFLLGGRHGEFKFLPPPGYAPCHEAVLPRERLHLEPIKEYRREGPRGPHLVGPSRCLSHTDFVPCPVDTVQIVLPPHLERIREKLAENIHELWALTRIEQGWTYGPVRDDNKRLHPCLVDFHSLPEPERNYNLQMSGETLKTLLALGCHVGMADEKAEDNLKKTKLPKTYMMSNGYKPAPLDLSHVRLTPAQTTLVDRLAENGHNVWARDRVGQGWSYSAVQDIPARRNPRLVPYRLLDEATKRSNRDSLCQAVRTLLGYGYNIEPPDQEPSQVENQSRCDRVRIFRAEKSYTVQSGRWYFEFEAVTTGEMRVGWARPELRPDVELGADELAYVFNGHRGQRWHLGSEPFGRPWQPGDVVGCMIDLTENTIIFTLNGEVLMSDSGSETAFREIEIGDGFLPVCSLGPGQVGHLNLGQDVSSLRFFAICGLQEGFEPFAINMQRPVTTWFSKGLPQFEPVPLEHPHYEVSRVDGTVDTPPCLRLTHRTWGSQNSLVEMLFLRLSLPVQFHQHFRCTAGATPLAPPGLQPPAEDEARAAEPDPDYENLRRSAGGWSEAENGKEGTAKEGAPGGTPQAGGEAQPARAENEKDATTEKNKKRGFLFKAKKVAMMTQPPATPTLPRLPHDVVPADNRDDPEIILNTTTYYYSVRVFAGQEPSCVWAGWVTPDYHQHDMSFDLSKVRVVTVTMGDEQGNVHSSLKCSNCYMVWGGDFVSPGQQGRISHTDLVIGCLVDLATGLMTFTANGKESNTFFQVEPNTKLFPAVFVLPTHQNVIQFELGKQKNIMPLSAAMFQSERKNPAPQCPPRLEMQMLMPVSWSRMPNHFLQVETRRAGERLGWAVQCQEPLTMMALHIPEENRCMDILELSERLDLQRFHSHTLRLYRAVCALGNNRVAHALCSHVDQAQLLHALEDAHLPGPLRAGYYDLLISIHLESACRSRRSMLSEYIVPLTPETRAITLFPPGRSTENGHPRHGLPGVGVTTSLRPPHHFSPPCFVAALPAAGAAEAPARLSPAIPLEALRDKALRMLGEAVRDGGQHARDPVGGSVEFQFVPVLKLVSTLLVMGIFGDEDVKQILKMIEPEVFTEEEEEEDEEEEGEEEDEEEKEEDEEETAQEKEDEEKEEEEAAEGEKEEGLEEGLLQMKLPESVKLQMCHLLEYFCDQELQHRVESLAAFAERYVDKLQANQRSRYGLLIKAFSMTAAETARRTREFRSPPQEQINMLLQFKDGTDEEDCPLPEEIRQDLLDFHQDLLAHCGIQLDGEEEEPEEETTLGSRLMSLLEKVRLVKKKEEKPEEERSAEESKPRSLQELVSHMVVRWAQEDFVQSPELVRAMFSLLHRQYDGLGELLRALPRAYTISPSSVEDTMSLLECLGQIRSLLIVQMGPQEENLMIQSIGNIMNNKVFYQHPNLMRALGMHETVMEVMVNVLGGGESKEIRFPKMVTSCCRFLCYFCRISRQNQRSMFDHLSYLLENSGIGLGMQGSTPLDVAAASVIDNNELALALQEQDLEKVVSYLAGCGLQSCPMLVAKGYPDIGWNPCGGERYLDFLRFAVFVNGESVEENANVVVRLLIRKPECFGPALRGEGGSGLLAAIEEAIRISEDPARDGPGIRRDRRREHFGEEPPEENRVHLGHAIMSFYAALIDLLGRCAPEMHLIQAGKGEALRIRAILRSLVPLEDLVGIISLPLQIPTLGKDGALVQPKMSASFVPDHKASMVLFLDRVYGIENQDFLLHVLDVGFLPDMRAAASLDTATFSTTEMALALNRYLCLAVLPLITKCAPLFAGTEHRAIMVDSMLHTVYRLSRGRSLTKAQRDVIEDCLMSLCRYIRPSMLQHLLRRLVFDVPILNEFAKMPLKLLTNHYERCWKYYCLPTGWANFGVTSEEELHLTRKLFWGIFDSLAHKKYDPELYRMAMPCLCAIAGALPPDYVDASYSSKAEKKATVDAEGNFDPRPVETLNVIIPEKLDSFINKFAEYTHEKWAFDKIQNNWSYGENIDEELKTHPMLRPYKTFSEKDKEIYRWPIKESLKAMIAWEWTIEKAREGEEEKTEKKKTRKISQSAQTYDPREGYNPQPPDLSAVTLSRELQAMAEQLAENYHNTWGRKKKQELEAKGGGTHPLLVPYDTLTAKEKARDREKAQELLKFLQMNGYAVTRGLKDMELDSSSIEKRFAFGFLQQLLRWMDISQEFIAHLEAVVSSGRVEKSPHEQEIKFFAKILLPLINQYFTNHCLYFLSTPAKVLGSGGHASNKEKEMITSLFCKLAALVRHRVSLFGTDAPAVVNCLHILARSLDARTVMKSGPEIVKAGLRSFFESASEDIEKMVENLRLGKVSQARTQVKGVGQNLTYTTVALLPVLTTLFQHIAQHQFGDDVILDDVQVSCYRTLCSIYSLGTTKNTYVEKLRPALGECLARLAAAMPVAFLEPQLNEYNACSVYTTKSPRERAILGLPNSVEEMCPDIPVLERLMADIGGLAESGARYTEMPHVIEITLPMLCSYLPRWWERGPEAPPSALPAGAPPPCTAVTSDHLNSLLGNILRIIVNNLGIDEASWMKRLAVFAQPIVSRARPELLQSHFIPTIGRLRKRAGKVVSEEEQLRLEAKAEAQEGELLVRDEFSVLCRDLYALYPLLIRYVDNNRAQWLTEPNPSAEELFRMVGEIFIYWSKSHNFKREEQNFVVQNEINNMSFLTADNKSKMAKAGDIQSGGSDQERTKKKRRGDRYSVQTSLIVATLKKMLPIGLNMCAPTDQDLITLAKTRYALKDTDEEVREFLHNNLHLQGKVEGSPSLRWQMALYRGVPGREEDADDPEKIVRRVQEVSAVLYYLDQTEHPYKSKKAVWHKLLSKQRRRAVVACFRMTPLYNLPTHRACNMFLESYKAAWILTEDHSFEDRMIDDLSKAGEQEEEEEEVEEKKPDPLHQLVLHFSRTALTEKSKLDEDYLYMAYADIMAKSCHLEEGGENGEAEEEVEVSFEEKQMEKQRLLYQQARLHTRGAAEMVLQMISACKGETGAMVSSTLKLGISILNGGNAEVQQKMLDYLKDKKEVGFFQSIQALMQTCSVLDLNAFERQNKAEGLGMVNEDGTVINRQNGEKVMADDEFTQDLFRFLQLLCEGHNNDFQNYLRTQTGNTTTINIIICTVDYLLRLQESISDFYWYYSGKDVIEEQGKRNFSKAMSVAKQVFNSLTEYIQGPCTGNQQSLAHSRLWDAVVGFLHVFAHMMMKLAQDSSQIELLKELLDLQKDMVVMLLSLLEGNVVNGMIARQMVDMLVESSSNVEMILKFFDMFLKLKDIVGSEAFQDYVTDPRGLISKKDFQKAMDSQKQFSGPEIQFLLSCSEADENEMINCEEFANRFQEPARDIGFNVAVLLTNLSEHVPHDPRLHNFLELAESILEYFRPYLGRIEIMGASRRIERIYFEISETNRAQWEMPQVKESKRQFIFDVVNEGGEAEKMELFVSFCEDTIFEMQIAAQISEPEGEPETDEDEGAGAAEAGAEGAEEGAAGLEGTAATAAAGATARVVAAAGRALRGLSYRSLRRRVRRLRRLTAREAATAVAALLWAAVTRAGAAGAGAAAGALGLLWGSLFGGGLVEGAKKVTVTELLAGMPDPTSDEVHGEQPAGPGGDADGEGASEGAGDAAEGAGDEEEAVHEAGPGGADGAVAVTDGGPFRPEGAGGLGDMGDTTPAEPPTPEGSPILKRKLGVDGVEEELPPEPEPEPEPELEPEKADAENGEKEEVPEPTPEPPKKQAPPSPPPKKEEAGGEFWGELEVQRVKFLNYLSRNFYTLRFLALFLAFAINFILLFYKVSDSPPGEDDMEGSAAGDVSGAGSGGSSGWGLGAGEEAEGDEDENMVYYFLEESTGYMEPALRCLSLLHTLVAFLCIIGYNCLKVPLVIFKREKELARKLEFDGLYITEQPEDDDVKGQWDRLVLNTPSFPSNYWDKFVKRKVLDKHGDIYGRERIAELLGMDLATLEITAHNERKPNPPPGLLTWLMSIDVKYQIWKFGVIFTDNSFLYLGWYMVMSLLGHYNNFFFAAHLLDIAMGVKTLRTILSSVTHNGKQLVMTVGLLAVVVYLYTVVAFNFFRKFYNKSEDEDEPDMKCDDMMTCYLFHMYVGVRAGGGIGDEIEDPAGDEYELYRVVFDITFFFFVIVILLAIIQGLIIDAFGELRDQQEQVKEDMETKCFICGIGSDYFDTTPHGFETHTLEEHNLANYMFFLMYLINKDETEHTGQESYVWKMYQERCWDFFPAGDCFRKQYEDQLS	5038	P21817	L	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [1490], 'DISULFID_gain': [], 'DISULFID_loss_score': array([-0.00169218]), 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
251	NM_000540.2(RYR1):c.5317C>T (p.Pro1773Ser)	224382	CA066877	NM_000540.2:c.5317C>T, NC_000019.10:g.38485972C>T, CM000681.2:g.38485972C>T, NC_000019.9:g.38976612C>T, CM000681.1:g.38976612C>T, NC_000019.8:g.43668452C>T, NG_008866.1:g.57273C>T, LRG_766:g.57273C>T, ENST00000355481.8:c.5317C>T, ENST00000359596.7:n.5317C>T, ENST00000360985.7:c.5314C>T, LRG_766t1:c.5317C>T, NM_001042723.1:c.5317C>T, XM_006723317.1:c.5317C>T, XM_006723319.1:c.5317C>T, XM_011527204.1:c.5314C>T, XM_011527205.1:c.5317C>T, XM_006723317.2:c.5317C>T, XM_006723319.2:c.5317C>T, XM_011527205.2:c.5317C>T, NM_000540.3:c.5317C>T, NM_001042723.2:c.5317C>T, NM_000540.2(RYR1):c.5317C>T (p.Pro1773Ser)	RYR1	malignant hyperthermia, susceptibility to, 1	MONDO:0007783	Autosomal dominant inheritance	Benign	BA1		This pathogenicity assessment is relevant only for malignant hyperthermia susceptibility (MHS) inherited in an autosomal dominant pattern. Variants in RYR1 can also cause other myopathies inherited in an autosomal dominant pattern or in an autosomal recessive pattern. Some of these disorders may predispose individuals to malignant hyperthermia. RYR1 variants may also contribute to a malignant hyperthermia reaction in combination with other genetic and non-genetic factors and the clinician needs to consider such factors in making management decisions.This sequence variant predicts a substitution of Proline with Serine at codon 1773 of the RYR1 protein, p.(Pro1773Ser). The maximum allele frequency for this variant among the six major gnomAD populations is EAS: 0.0147, which is considered to be too common for a pathogenic variant causing autosomal dominantly inherited MHS, BA1. This variant has been classified as Benign. Criteria implemented: BA1.		Malignant Hyperthermia Susceptibility VCEP	https://clinicalgenome.org/docs/clingen-malignant-hyperthermia-susceptibility-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-for/	2021-03-17	2021-03-31	False	https://erepo.genome.network/evrepo/ui/classification/CA066877/MONDO:0007783/012	956cb8ac-494d-487e-a743-3619f2cea15e	p.Pro1773Ser	Pro	1773	Ser	MGDAEGEDEVQFLRTDDEVVLQCSATVLKEQLKLCLAAEGFGNRLCFLEPTSNAQNVPPDLAICCFVLEQSLSVRALQEMLANTVEAGVESSQGGGHRTLLYGHAILLRHAHSRMYLSCLTTSRSMTDKLAFDVGLQEDATGEACWWTMHPASKQRSEGEKVRVGDDIILVSVSSERYLHLSTASGELQVDASFMQTLWNMNPICSRCEEGFVTGGHVLRLFHGHMDECLTISPADSDDQRRLVYYEGGAVCTHARSLWRLEPLRISWSGSHLRWGQPLRVRHVTTGQYLALTEDQGLVVVDASKAHTKATSFCFRISKEKLDVAPKRDVEGMGPPEIKYGESLCFVQHVASGLWLTYAAPDPKALRLGVLKKKAMLHQEGHMDDALSLTRCQQEESQAARMIHSTNGLYNQFIKSLDSFSGKPRGSGPPAGTALPIEGVILSLQDLIIYFEPPSEDLQHEEKQSKLRSLRNRQSLFQEEGMLSMVLNCIDRLNVYTTAAHFAEFAGEEAAESWKEIVNLLYELLASLIRGNRSNCALFSTNLDWLVSKLDRLEASSGILEVLYCVLIESPEVLNIIQENHIKSIISLLDKHGRNHKVLDVLCSLCVCNGVAVRSNQDLITENLLPGRELLLQTNLINYVTSIRPNIFVGRAEGTTQYSKWYFEVMVDEVTPFLTAQATHLRVGWALTEGYTPYPGAGEGWGGNGVGDDLYSYGFDGLHLWTGHVARPVTSPGQHLLAPEDVISCCLDLSVPSISFRINGCPVQGVFESFNLDGLFFPVVSFSAGVKVRFLLGGRHGEFKFLPPPGYAPCHEAVLPRERLHLEPIKEYRREGPRGPHLVGPSRCLSHTDFVPCPVDTVQIVLPPHLERIREKLAENIHELWALTRIEQGWTYGPVRDDNKRLHPCLVDFHSLPEPERNYNLQMSGETLKTLLALGCHVGMADEKAEDNLKKTKLPKTYMMSNGYKPAPLDLSHVRLTPAQTTLVDRLAENGHNVWARDRVGQGWSYSAVQDIPARRNPRLVPYRLLDEATKRSNRDSLCQAVRTLLGYGYNIEPPDQEPSQVENQSRCDRVRIFRAEKSYTVQSGRWYFEFEAVTTGEMRVGWARPELRPDVELGADELAYVFNGHRGQRWHLGSEPFGRPWQPGDVVGCMIDLTENTIIFTLNGEVLMSDSGSETAFREIEIGDGFLPVCSLGPGQVGHLNLGQDVSSLRFFAICGLQEGFEPFAINMQRPVTTWFSKGLPQFEPVPLEHPHYEVSRVDGTVDTPPCLRLTHRTWGSQNSLVEMLFLRLSLPVQFHQHFRCTAGATPLAPPGLQPPAEDEARAAEPDPDYENLRRSAGGWSEAENGKEGTAKEGAPGGTPQAGGEAQPARAENEKDATTEKNKKRGFLFKAKKVAMMTQPPATPTLPRLPHDVVPADNRDDPEIILNTTTYYYSVRVFAGQEPSCVWAGWVTPDYHQHDMSFDLSKVRVVTVTMGDEQGNVHSSLKCSNCYMVWGGDFVSPGQQGRISHTDLVIGCLVDLATGLMTFTANGKESNTFFQVEPNTKLFPAVFVLPTHQNVIQFELGKQKNIMPLSAAMFQSERKNPAPQCPPRLEMQMLMPVSWSRMPNHFLQVETRRAGERLGWAVQCQEPLTMMALHIPEENRCMDILELSERLDLQRFHSHTLRLYRAVCALGNNRVAHALCSHVDQAQLLHALEDAHLPGPLRAGYYDLLISIHLESACRSRRSMLSEYIVPLTPETRAITLFPPGRSTENGHPRHGLPGVGVTTSLRPPHHFSPPCFVAALPAAGAAEAPARLSPAIPLEALRDKALRMLGEAVRDGGQHARDPVGGSVEFQFVPVLKLVSTLLVMGIFGDEDVKQILKMIEPEVFTEEEEEEDEEEEGEEEDEEEKEEDEEETAQEKEDEEKEEEEAAEGEKEEGLEEGLLQMKLPESVKLQMCHLLEYFCDQELQHRVESLAAFAERYVDKLQANQRSRYGLLIKAFSMTAAETARRTREFRSPPQEQINMLLQFKDGTDEEDCPLPEEIRQDLLDFHQDLLAHCGIQLDGEEEEPEEETTLGSRLMSLLEKVRLVKKKEEKPEEERSAEESKPRSLQELVSHMVVRWAQEDFVQSPELVRAMFSLLHRQYDGLGELLRALPRAYTISPSSVEDTMSLLECLGQIRSLLIVQMGPQEENLMIQSIGNIMNNKVFYQHPNLMRALGMHETVMEVMVNVLGGGESKEIRFPKMVTSCCRFLCYFCRISRQNQRSMFDHLSYLLENSGIGLGMQGSTPLDVAAASVIDNNELALALQEQDLEKVVSYLAGCGLQSCPMLVAKGYPDIGWNPCGGERYLDFLRFAVFVNGESVEENANVVVRLLIRKPECFGPALRGEGGSGLLAAIEEAIRISEDPARDGPGIRRDRRREHFGEEPPEENRVHLGHAIMSFYAALIDLLGRCAPEMHLIQAGKGEALRIRAILRSLVPLEDLVGIISLPLQIPTLGKDGALVQPKMSASFVPDHKASMVLFLDRVYGIENQDFLLHVLDVGFLPDMRAAASLDTATFSTTEMALALNRYLCLAVLPLITKCAPLFAGTEHRAIMVDSMLHTVYRLSRGRSLTKAQRDVIEDCLMSLCRYIRPSMLQHLLRRLVFDVPILNEFAKMPLKLLTNHYERCWKYYCLPTGWANFGVTSEEELHLTRKLFWGIFDSLAHKKYDPELYRMAMPCLCAIAGALPPDYVDASYSSKAEKKATVDAEGNFDPRPVETLNVIIPEKLDSFINKFAEYTHEKWAFDKIQNNWSYGENIDEELKTHPMLRPYKTFSEKDKEIYRWPIKESLKAMIAWEWTIEKAREGEEEKTEKKKTRKISQSAQTYDPREGYNPQPPDLSAVTLSRELQAMAEQLAENYHNTWGRKKKQELEAKGGGTHPLLVPYDTLTAKEKARDREKAQELLKFLQMNGYAVTRGLKDMELDSSSIEKRFAFGFLQQLLRWMDISQEFIAHLEAVVSSGRVEKSPHEQEIKFFAKILLPLINQYFTNHCLYFLSTPAKVLGSGGHASNKEKEMITSLFCKLAALVRHRVSLFGTDAPAVVNCLHILARSLDARTVMKSGPEIVKAGLRSFFESASEDIEKMVENLRLGKVSQARTQVKGVGQNLTYTTVALLPVLTTLFQHIAQHQFGDDVILDDVQVSCYRTLCSIYSLGTTKNTYVEKLRPALGECLARLAAAMPVAFLEPQLNEYNACSVYTTKSPRERAILGLPNSVEEMCPDIPVLERLMADIGGLAESGARYTEMPHVIEITLPMLCSYLPRWWERGPEAPPSALPAGAPPPCTAVTSDHLNSLLGNILRIIVNNLGIDEASWMKRLAVFAQPIVSRARPELLQSHFIPTIGRLRKRAGKVVSEEEQLRLEAKAEAQEGELLVRDEFSVLCRDLYALYPLLIRYVDNNRAQWLTEPNPSAEELFRMVGEIFIYWSKSHNFKREEQNFVVQNEINNMSFLTADNKSKMAKAGDIQSGGSDQERTKKKRRGDRYSVQTSLIVATLKKMLPIGLNMCAPTDQDLITLAKTRYALKDTDEEVREFLHNNLHLQGKVEGSPSLRWQMALYRGVPGREEDADDPEKIVRRVQEVSAVLYYLDQTEHPYKSKKAVWHKLLSKQRRRAVVACFRMTPLYNLPTHRACNMFLESYKAAWILTEDHSFEDRMIDDLSKAGEQEEEEEEVEEKKPDPLHQLVLHFSRTALTEKSKLDEDYLYMAYADIMAKSCHLEEGGENGEAEEEVEVSFEEKQMEKQRLLYQQARLHTRGAAEMVLQMISACKGETGAMVSSTLKLGISILNGGNAEVQQKMLDYLKDKKEVGFFQSIQALMQTCSVLDLNAFERQNKAEGLGMVNEDGTVINRQNGEKVMADDEFTQDLFRFLQLLCEGHNNDFQNYLRTQTGNTTTINIIICTVDYLLRLQESISDFYWYYSGKDVIEEQGKRNFSKAMSVAKQVFNSLTEYIQGPCTGNQQSLAHSRLWDAVVGFLHVFAHMMMKLAQDSSQIELLKELLDLQKDMVVMLLSLLEGNVVNGMIARQMVDMLVESSSNVEMILKFFDMFLKLKDIVGSEAFQDYVTDPRGLISKKDFQKAMDSQKQFSGPEIQFLLSCSEADENEMINCEEFANRFQEPARDIGFNVAVLLTNLSEHVPHDPRLHNFLELAESILEYFRPYLGRIEIMGASRRIERIYFEISETNRAQWEMPQVKESKRQFIFDVVNEGGEAEKMELFVSFCEDTIFEMQIAAQISEPEGEPETDEDEGAGAAEAGAEGAEEGAAGLEGTAATAAAGATARVVAAAGRALRGLSYRSLRRRVRRLRRLTAREAATAVAALLWAAVTRAGAAGAGAAAGALGLLWGSLFGGGLVEGAKKVTVTELLAGMPDPTSDEVHGEQPAGPGGDADGEGASEGAGDAAEGAGDEEEAVHEAGPGGADGAVAVTDGGPFRPEGAGGLGDMGDTTPAEPPTPEGSPILKRKLGVDGVEEELPPEPEPEPEPELEPEKADAENGEKEEVPEPTPEPPKKQAPPSPPPKKEEAGGEFWGELEVQRVKFLNYLSRNFYTLRFLALFLAFAINFILLFYKVSDSPPGEDDMEGSAAGDVSGAGSGGSSGWGLGAGEEAEGDEDENMVYYFLEESTGYMEPALRCLSLLHTLVAFLCIIGYNCLKVPLVIFKREKELARKLEFDGLYITEQPEDDDVKGQWDRLVLNTPSFPSNYWDKFVKRKVLDKHGDIYGRERIAELLGMDLATLEITAHNERKPNPPPGLLTWLMSIDVKYQIWKFGVIFTDNSFLYLGWYMVMSLLGHYNNFFFAAHLLDIAMGVKTLRTILSSVTHNGKQLVMTVGLLAVVVYLYTVVAFNFFRKFYNKSEDEDEPDMKCDDMMTCYLFHMYVGVRAGGGIGDEIEDPAGDEYELYRVVFDITFFFFVIVILLAIIQGLIIDAFGELRDQQEQVKEDMETKCFICGIGSDYFDTTPHGFETHTLEEHNLANYMFFLMYLINKDETEHTGQESYVWKMYQERCWDFFPAGDCFRKQYEDQLS	5038	P21817	S	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
252	NM_000540.2(RYR1):c.13502C>T (p.Pro4501Leu)	224403	CA059964	NM_000540.2:c.13502C>T, NC_000019.10:g.38566975C>T, CM000681.2:g.38566975C>T, NC_000019.9:g.39057615C>T, CM000681.1:g.39057615C>T, NC_000019.8:g.43749455C>T, NG_008866.1:g.138276C>T, LRG_766:g.138276C>T, ENST00000355481.8:c.13487C>T, ENST00000359596.7:n.13502C>T, ENST00000360985.7:c.13484C>T, LRG_766t1:c.13502C>T, NM_001042723.1:c.13487C>T, XM_006723317.1:c.13484C>T, XM_006723319.1:c.13469C>T, XM_011527204.1:c.13499C>T, XM_011527205.1:c.13502C>T, XM_006723317.2:c.13484C>T, XM_006723319.2:c.13469C>T, XM_011527205.2:c.13502C>T, NM_000540.3:c.13502C>T, NM_001042723.2:c.13487C>T, NM_000540.2(RYR1):c.13502C>T (p.Pro4501Leu)	RYR1	malignant hyperthermia, susceptibility to, 1	MONDO:0007783	Autosomal dominant inheritance	Benign	BA1		This pathogenicity assessment is relevant only for malignant hyperthermia susceptibility (MHS) inherited in an autosomal dominant pattern. Variants in RYR1 can also cause other myopathies inherited in an autosomal dominant pattern or in an autosomal recessive pattern. Some of these disorders may predispose individuals to malignant hyperthermia. RYR1 variants may also contribute to a malignant hyperthermia reaction in combination with other genetic and non-genetic factors and the clinician needs to consider such factors in making management decisions.This sequence variant predicts a substitution of Proline with Leucine at codon 4501 of the RYR1 protein, p.(Pro4501Leu). The maximum allele frequency for this variant among the six major gnomAD populations is AFR: 0.0181, which is considered to be too common for a pathogenic variant causing autosomal dominantly inherited MHS, BA1. This variant has been classified as Benign. Criteria implemented: BA1.		Malignant Hyperthermia Susceptibility VCEP	https://clinicalgenome.org/docs/clingen-malignant-hyperthermia-susceptibility-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-for/	2021-03-16	2021-03-31	False	https://erepo.genome.network/evrepo/ui/classification/CA059964/MONDO:0007783/012	8af9da9e-f9d6-4adb-8482-a4870cad8cfc	p.Pro4501Leu	Pro	4501	Leu	MGDAEGEDEVQFLRTDDEVVLQCSATVLKEQLKLCLAAEGFGNRLCFLEPTSNAQNVPPDLAICCFVLEQSLSVRALQEMLANTVEAGVESSQGGGHRTLLYGHAILLRHAHSRMYLSCLTTSRSMTDKLAFDVGLQEDATGEACWWTMHPASKQRSEGEKVRVGDDIILVSVSSERYLHLSTASGELQVDASFMQTLWNMNPICSRCEEGFVTGGHVLRLFHGHMDECLTISPADSDDQRRLVYYEGGAVCTHARSLWRLEPLRISWSGSHLRWGQPLRVRHVTTGQYLALTEDQGLVVVDASKAHTKATSFCFRISKEKLDVAPKRDVEGMGPPEIKYGESLCFVQHVASGLWLTYAAPDPKALRLGVLKKKAMLHQEGHMDDALSLTRCQQEESQAARMIHSTNGLYNQFIKSLDSFSGKPRGSGPPAGTALPIEGVILSLQDLIIYFEPPSEDLQHEEKQSKLRSLRNRQSLFQEEGMLSMVLNCIDRLNVYTTAAHFAEFAGEEAAESWKEIVNLLYELLASLIRGNRSNCALFSTNLDWLVSKLDRLEASSGILEVLYCVLIESPEVLNIIQENHIKSIISLLDKHGRNHKVLDVLCSLCVCNGVAVRSNQDLITENLLPGRELLLQTNLINYVTSIRPNIFVGRAEGTTQYSKWYFEVMVDEVTPFLTAQATHLRVGWALTEGYTPYPGAGEGWGGNGVGDDLYSYGFDGLHLWTGHVARPVTSPGQHLLAPEDVISCCLDLSVPSISFRINGCPVQGVFESFNLDGLFFPVVSFSAGVKVRFLLGGRHGEFKFLPPPGYAPCHEAVLPRERLHLEPIKEYRREGPRGPHLVGPSRCLSHTDFVPCPVDTVQIVLPPHLERIREKLAENIHELWALTRIEQGWTYGPVRDDNKRLHPCLVDFHSLPEPERNYNLQMSGETLKTLLALGCHVGMADEKAEDNLKKTKLPKTYMMSNGYKPAPLDLSHVRLTPAQTTLVDRLAENGHNVWARDRVGQGWSYSAVQDIPARRNPRLVPYRLLDEATKRSNRDSLCQAVRTLLGYGYNIEPPDQEPSQVENQSRCDRVRIFRAEKSYTVQSGRWYFEFEAVTTGEMRVGWARPELRPDVELGADELAYVFNGHRGQRWHLGSEPFGRPWQPGDVVGCMIDLTENTIIFTLNGEVLMSDSGSETAFREIEIGDGFLPVCSLGPGQVGHLNLGQDVSSLRFFAICGLQEGFEPFAINMQRPVTTWFSKGLPQFEPVPLEHPHYEVSRVDGTVDTPPCLRLTHRTWGSQNSLVEMLFLRLSLPVQFHQHFRCTAGATPLAPPGLQPPAEDEARAAEPDPDYENLRRSAGGWSEAENGKEGTAKEGAPGGTPQAGGEAQPARAENEKDATTEKNKKRGFLFKAKKVAMMTQPPATPTLPRLPHDVVPADNRDDPEIILNTTTYYYSVRVFAGQEPSCVWAGWVTPDYHQHDMSFDLSKVRVVTVTMGDEQGNVHSSLKCSNCYMVWGGDFVSPGQQGRISHTDLVIGCLVDLATGLMTFTANGKESNTFFQVEPNTKLFPAVFVLPTHQNVIQFELGKQKNIMPLSAAMFQSERKNPAPQCPPRLEMQMLMPVSWSRMPNHFLQVETRRAGERLGWAVQCQEPLTMMALHIPEENRCMDILELSERLDLQRFHSHTLRLYRAVCALGNNRVAHALCSHVDQAQLLHALEDAHLPGPLRAGYYDLLISIHLESACRSRRSMLSEYIVPLTPETRAITLFPPGRSTENGHPRHGLPGVGVTTSLRPPHHFSPPCFVAALPAAGAAEAPARLSPAIPLEALRDKALRMLGEAVRDGGQHARDPVGGSVEFQFVPVLKLVSTLLVMGIFGDEDVKQILKMIEPEVFTEEEEEEDEEEEGEEEDEEEKEEDEEETAQEKEDEEKEEEEAAEGEKEEGLEEGLLQMKLPESVKLQMCHLLEYFCDQELQHRVESLAAFAERYVDKLQANQRSRYGLLIKAFSMTAAETARRTREFRSPPQEQINMLLQFKDGTDEEDCPLPEEIRQDLLDFHQDLLAHCGIQLDGEEEEPEEETTLGSRLMSLLEKVRLVKKKEEKPEEERSAEESKPRSLQELVSHMVVRWAQEDFVQSPELVRAMFSLLHRQYDGLGELLRALPRAYTISPSSVEDTMSLLECLGQIRSLLIVQMGPQEENLMIQSIGNIMNNKVFYQHPNLMRALGMHETVMEVMVNVLGGGESKEIRFPKMVTSCCRFLCYFCRISRQNQRSMFDHLSYLLENSGIGLGMQGSTPLDVAAASVIDNNELALALQEQDLEKVVSYLAGCGLQSCPMLVAKGYPDIGWNPCGGERYLDFLRFAVFVNGESVEENANVVVRLLIRKPECFGPALRGEGGSGLLAAIEEAIRISEDPARDGPGIRRDRRREHFGEEPPEENRVHLGHAIMSFYAALIDLLGRCAPEMHLIQAGKGEALRIRAILRSLVPLEDLVGIISLPLQIPTLGKDGALVQPKMSASFVPDHKASMVLFLDRVYGIENQDFLLHVLDVGFLPDMRAAASLDTATFSTTEMALALNRYLCLAVLPLITKCAPLFAGTEHRAIMVDSMLHTVYRLSRGRSLTKAQRDVIEDCLMSLCRYIRPSMLQHLLRRLVFDVPILNEFAKMPLKLLTNHYERCWKYYCLPTGWANFGVTSEEELHLTRKLFWGIFDSLAHKKYDPELYRMAMPCLCAIAGALPPDYVDASYSSKAEKKATVDAEGNFDPRPVETLNVIIPEKLDSFINKFAEYTHEKWAFDKIQNNWSYGENIDEELKTHPMLRPYKTFSEKDKEIYRWPIKESLKAMIAWEWTIEKAREGEEEKTEKKKTRKISQSAQTYDPREGYNPQPPDLSAVTLSRELQAMAEQLAENYHNTWGRKKKQELEAKGGGTHPLLVPYDTLTAKEKARDREKAQELLKFLQMNGYAVTRGLKDMELDSSSIEKRFAFGFLQQLLRWMDISQEFIAHLEAVVSSGRVEKSPHEQEIKFFAKILLPLINQYFTNHCLYFLSTPAKVLGSGGHASNKEKEMITSLFCKLAALVRHRVSLFGTDAPAVVNCLHILARSLDARTVMKSGPEIVKAGLRSFFESASEDIEKMVENLRLGKVSQARTQVKGVGQNLTYTTVALLPVLTTLFQHIAQHQFGDDVILDDVQVSCYRTLCSIYSLGTTKNTYVEKLRPALGECLARLAAAMPVAFLEPQLNEYNACSVYTTKSPRERAILGLPNSVEEMCPDIPVLERLMADIGGLAESGARYTEMPHVIEITLPMLCSYLPRWWERGPEAPPSALPAGAPPPCTAVTSDHLNSLLGNILRIIVNNLGIDEASWMKRLAVFAQPIVSRARPELLQSHFIPTIGRLRKRAGKVVSEEEQLRLEAKAEAQEGELLVRDEFSVLCRDLYALYPLLIRYVDNNRAQWLTEPNPSAEELFRMVGEIFIYWSKSHNFKREEQNFVVQNEINNMSFLTADNKSKMAKAGDIQSGGSDQERTKKKRRGDRYSVQTSLIVATLKKMLPIGLNMCAPTDQDLITLAKTRYALKDTDEEVREFLHNNLHLQGKVEGSPSLRWQMALYRGVPGREEDADDPEKIVRRVQEVSAVLYYLDQTEHPYKSKKAVWHKLLSKQRRRAVVACFRMTPLYNLPTHRACNMFLESYKAAWILTEDHSFEDRMIDDLSKAGEQEEEEEEVEEKKPDPLHQLVLHFSRTALTEKSKLDEDYLYMAYADIMAKSCHLEEGGENGEAEEEVEVSFEEKQMEKQRLLYQQARLHTRGAAEMVLQMISACKGETGAMVSSTLKLGISILNGGNAEVQQKMLDYLKDKKEVGFFQSIQALMQTCSVLDLNAFERQNKAEGLGMVNEDGTVINRQNGEKVMADDEFTQDLFRFLQLLCEGHNNDFQNYLRTQTGNTTTINIIICTVDYLLRLQESISDFYWYYSGKDVIEEQGKRNFSKAMSVAKQVFNSLTEYIQGPCTGNQQSLAHSRLWDAVVGFLHVFAHMMMKLAQDSSQIELLKELLDLQKDMVVMLLSLLEGNVVNGMIARQMVDMLVESSSNVEMILKFFDMFLKLKDIVGSEAFQDYVTDPRGLISKKDFQKAMDSQKQFSGPEIQFLLSCSEADENEMINCEEFANRFQEPARDIGFNVAVLLTNLSEHVPHDPRLHNFLELAESILEYFRPYLGRIEIMGASRRIERIYFEISETNRAQWEMPQVKESKRQFIFDVVNEGGEAEKMELFVSFCEDTIFEMQIAAQISEPEGEPETDEDEGAGAAEAGAEGAEEGAAGLEGTAATAAAGATARVVAAAGRALRGLSYRSLRRRVRRLRRLTAREAATAVAALLWAAVTRAGAAGAGAAAGALGLLWGSLFGGGLVEGAKKVTVTELLAGMPDPTSDEVHGEQPAGPGGDADGEGASEGAGDAAEGAGDEEEAVHEAGPGGADGAVAVTDGGPFRPEGAGGLGDMGDTTPAEPPTPEGSPILKRKLGVDGVEEELPPEPEPEPEPELEPEKADAENGEKEEVPEPTPEPPKKQAPPSPPPKKEEAGGEFWGELEVQRVKFLNYLSRNFYTLRFLALFLAFAINFILLFYKVSDSPPGEDDMEGSAAGDVSGAGSGGSSGWGLGAGEEAEGDEDENMVYYFLEESTGYMEPALRCLSLLHTLVAFLCIIGYNCLKVPLVIFKREKELARKLEFDGLYITEQPEDDDVKGQWDRLVLNTPSFPSNYWDKFVKRKVLDKHGDIYGRERIAELLGMDLATLEITAHNERKPNPPPGLLTWLMSIDVKYQIWKFGVIFTDNSFLYLGWYMVMSLLGHYNNFFFAAHLLDIAMGVKTLRTILSSVTHNGKQLVMTVGLLAVVVYLYTVVAFNFFRKFYNKSEDEDEPDMKCDDMMTCYLFHMYVGVRAGGGIGDEIEDPAGDEYELYRVVFDITFFFFVIVILLAIIQGLIIDAFGELRDQQEQVKEDMETKCFICGIGSDYFDTTPHGFETHTLEEHNLANYMFFLMYLINKDETEHTGQESYVWKMYQERCWDFFPAGDCFRKQYEDQLS	5038	P21817	L	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [1490], 'DISULFID_gain': [], 'DISULFID_loss_score': array([-0.00109166]), 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
253	NM_000540.2(RYR1):c.4024A>G (p.Ser1342Gly)	93265	CA024415	NM_000540.2:c.4024A>G, NC_000019.10:g.38473635A>G, CM000681.2:g.38473635A>G, NC_000019.9:g.38964275A>G, CM000681.1:g.38964275A>G, NC_000019.8:g.43656115A>G, NG_008866.1:g.44936A>G, LRG_766:g.44936A>G, ENST00000355481.8:c.4024A>G, ENST00000359596.7:n.4024A>G, ENST00000360985.7:c.4024A>G, LRG_766t1:c.4024A>G, NM_001042723.1:c.4024A>G, XM_006723317.1:c.4024A>G, XM_006723319.1:c.4024A>G, XM_011527204.1:c.4021A>G, XM_011527205.1:c.4024A>G, XM_006723317.2:c.4024A>G, XM_006723319.2:c.4024A>G, XM_011527205.2:c.4024A>G, NM_000540.3:c.4024A>G, NM_001042723.2:c.4024A>G, NM_000540.2(RYR1):c.4024A>G (p.Ser1342Gly)	RYR1	malignant hyperthermia, susceptibility to, 1	MONDO:0007783	Autosomal dominant inheritance	Benign	BA1		This pathogenicity assessment is relevant only for malignant hyperthermia susceptibility (MHS) inherited in an autosomal dominant pattern. Variants in RYR1 can also cause other myopathies inherited in an autosomal dominant pattern or in an autosomal recessive pattern. Some of these disorders may predispose individuals to malignant hyperthermia. RYR1 variants may also contribute to a malignant hyperthermia reaction in combination with other genetic and non-genetic factors and the clinician needs to consider such factors in making management decisions.This sequence variant predicts a substitution of Serine with Glycine at codon 1342 of the RYR1 protein, p.(Ser1342Gly). The maximum allele frequency for this variant among the six major gnomAD populations is AFR: 0.1566, which is considered to be too common for a pathogenic variant causing autosomal dominantly inherited MHS, BA1. This variant has been classified as Benign. Criteria implemented: BA1.		Malignant Hyperthermia Susceptibility VCEP	https://clinicalgenome.org/docs/clingen-malignant-hyperthermia-susceptibility-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-for/	2021-03-17	2021-03-31	False	https://erepo.genome.network/evrepo/ui/classification/CA024415/MONDO:0007783/012	9aa53598-a119-4051-9fee-0525aa89851d	p.Ser1342Gly	Ser	1342	Gly	MGDAEGEDEVQFLRTDDEVVLQCSATVLKEQLKLCLAAEGFGNRLCFLEPTSNAQNVPPDLAICCFVLEQSLSVRALQEMLANTVEAGVESSQGGGHRTLLYGHAILLRHAHSRMYLSCLTTSRSMTDKLAFDVGLQEDATGEACWWTMHPASKQRSEGEKVRVGDDIILVSVSSERYLHLSTASGELQVDASFMQTLWNMNPICSRCEEGFVTGGHVLRLFHGHMDECLTISPADSDDQRRLVYYEGGAVCTHARSLWRLEPLRISWSGSHLRWGQPLRVRHVTTGQYLALTEDQGLVVVDASKAHTKATSFCFRISKEKLDVAPKRDVEGMGPPEIKYGESLCFVQHVASGLWLTYAAPDPKALRLGVLKKKAMLHQEGHMDDALSLTRCQQEESQAARMIHSTNGLYNQFIKSLDSFSGKPRGSGPPAGTALPIEGVILSLQDLIIYFEPPSEDLQHEEKQSKLRSLRNRQSLFQEEGMLSMVLNCIDRLNVYTTAAHFAEFAGEEAAESWKEIVNLLYELLASLIRGNRSNCALFSTNLDWLVSKLDRLEASSGILEVLYCVLIESPEVLNIIQENHIKSIISLLDKHGRNHKVLDVLCSLCVCNGVAVRSNQDLITENLLPGRELLLQTNLINYVTSIRPNIFVGRAEGTTQYSKWYFEVMVDEVTPFLTAQATHLRVGWALTEGYTPYPGAGEGWGGNGVGDDLYSYGFDGLHLWTGHVARPVTSPGQHLLAPEDVISCCLDLSVPSISFRINGCPVQGVFESFNLDGLFFPVVSFSAGVKVRFLLGGRHGEFKFLPPPGYAPCHEAVLPRERLHLEPIKEYRREGPRGPHLVGPSRCLSHTDFVPCPVDTVQIVLPPHLERIREKLAENIHELWALTRIEQGWTYGPVRDDNKRLHPCLVDFHSLPEPERNYNLQMSGETLKTLLALGCHVGMADEKAEDNLKKTKLPKTYMMSNGYKPAPLDLSHVRLTPAQTTLVDRLAENGHNVWARDRVGQGWSYSAVQDIPARRNPRLVPYRLLDEATKRSNRDSLCQAVRTLLGYGYNIEPPDQEPSQVENQSRCDRVRIFRAEKSYTVQSGRWYFEFEAVTTGEMRVGWARPELRPDVELGADELAYVFNGHRGQRWHLGSEPFGRPWQPGDVVGCMIDLTENTIIFTLNGEVLMSDSGSETAFREIEIGDGFLPVCSLGPGQVGHLNLGQDVSSLRFFAICGLQEGFEPFAINMQRPVTTWFSKGLPQFEPVPLEHPHYEVSRVDGTVDTPPCLRLTHRTWGSQNSLVEMLFLRLSLPVQFHQHFRCTAGATPLAPPGLQPPAEDEARAAEPDPDYENLRRSAGGWSEAENGKEGTAKEGAPGGTPQAGGEAQPARAENEKDATTEKNKKRGFLFKAKKVAMMTQPPATPTLPRLPHDVVPADNRDDPEIILNTTTYYYSVRVFAGQEPSCVWAGWVTPDYHQHDMSFDLSKVRVVTVTMGDEQGNVHSSLKCSNCYMVWGGDFVSPGQQGRISHTDLVIGCLVDLATGLMTFTANGKESNTFFQVEPNTKLFPAVFVLPTHQNVIQFELGKQKNIMPLSAAMFQSERKNPAPQCPPRLEMQMLMPVSWSRMPNHFLQVETRRAGERLGWAVQCQEPLTMMALHIPEENRCMDILELSERLDLQRFHSHTLRLYRAVCALGNNRVAHALCSHVDQAQLLHALEDAHLPGPLRAGYYDLLISIHLESACRSRRSMLSEYIVPLTPETRAITLFPPGRSTENGHPRHGLPGVGVTTSLRPPHHFSPPCFVAALPAAGAAEAPARLSPAIPLEALRDKALRMLGEAVRDGGQHARDPVGGSVEFQFVPVLKLVSTLLVMGIFGDEDVKQILKMIEPEVFTEEEEEEDEEEEGEEEDEEEKEEDEEETAQEKEDEEKEEEEAAEGEKEEGLEEGLLQMKLPESVKLQMCHLLEYFCDQELQHRVESLAAFAERYVDKLQANQRSRYGLLIKAFSMTAAETARRTREFRSPPQEQINMLLQFKDGTDEEDCPLPEEIRQDLLDFHQDLLAHCGIQLDGEEEEPEEETTLGSRLMSLLEKVRLVKKKEEKPEEERSAEESKPRSLQELVSHMVVRWAQEDFVQSPELVRAMFSLLHRQYDGLGELLRALPRAYTISPSSVEDTMSLLECLGQIRSLLIVQMGPQEENLMIQSIGNIMNNKVFYQHPNLMRALGMHETVMEVMVNVLGGGESKEIRFPKMVTSCCRFLCYFCRISRQNQRSMFDHLSYLLENSGIGLGMQGSTPLDVAAASVIDNNELALALQEQDLEKVVSYLAGCGLQSCPMLVAKGYPDIGWNPCGGERYLDFLRFAVFVNGESVEENANVVVRLLIRKPECFGPALRGEGGSGLLAAIEEAIRISEDPARDGPGIRRDRRREHFGEEPPEENRVHLGHAIMSFYAALIDLLGRCAPEMHLIQAGKGEALRIRAILRSLVPLEDLVGIISLPLQIPTLGKDGALVQPKMSASFVPDHKASMVLFLDRVYGIENQDFLLHVLDVGFLPDMRAAASLDTATFSTTEMALALNRYLCLAVLPLITKCAPLFAGTEHRAIMVDSMLHTVYRLSRGRSLTKAQRDVIEDCLMSLCRYIRPSMLQHLLRRLVFDVPILNEFAKMPLKLLTNHYERCWKYYCLPTGWANFGVTSEEELHLTRKLFWGIFDSLAHKKYDPELYRMAMPCLCAIAGALPPDYVDASYSSKAEKKATVDAEGNFDPRPVETLNVIIPEKLDSFINKFAEYTHEKWAFDKIQNNWSYGENIDEELKTHPMLRPYKTFSEKDKEIYRWPIKESLKAMIAWEWTIEKAREGEEEKTEKKKTRKISQSAQTYDPREGYNPQPPDLSAVTLSRELQAMAEQLAENYHNTWGRKKKQELEAKGGGTHPLLVPYDTLTAKEKARDREKAQELLKFLQMNGYAVTRGLKDMELDSSSIEKRFAFGFLQQLLRWMDISQEFIAHLEAVVSSGRVEKSPHEQEIKFFAKILLPLINQYFTNHCLYFLSTPAKVLGSGGHASNKEKEMITSLFCKLAALVRHRVSLFGTDAPAVVNCLHILARSLDARTVMKSGPEIVKAGLRSFFESASEDIEKMVENLRLGKVSQARTQVKGVGQNLTYTTVALLPVLTTLFQHIAQHQFGDDVILDDVQVSCYRTLCSIYSLGTTKNTYVEKLRPALGECLARLAAAMPVAFLEPQLNEYNACSVYTTKSPRERAILGLPNSVEEMCPDIPVLERLMADIGGLAESGARYTEMPHVIEITLPMLCSYLPRWWERGPEAPPSALPAGAPPPCTAVTSDHLNSLLGNILRIIVNNLGIDEASWMKRLAVFAQPIVSRARPELLQSHFIPTIGRLRKRAGKVVSEEEQLRLEAKAEAQEGELLVRDEFSVLCRDLYALYPLLIRYVDNNRAQWLTEPNPSAEELFRMVGEIFIYWSKSHNFKREEQNFVVQNEINNMSFLTADNKSKMAKAGDIQSGGSDQERTKKKRRGDRYSVQTSLIVATLKKMLPIGLNMCAPTDQDLITLAKTRYALKDTDEEVREFLHNNLHLQGKVEGSPSLRWQMALYRGVPGREEDADDPEKIVRRVQEVSAVLYYLDQTEHPYKSKKAVWHKLLSKQRRRAVVACFRMTPLYNLPTHRACNMFLESYKAAWILTEDHSFEDRMIDDLSKAGEQEEEEEEVEEKKPDPLHQLVLHFSRTALTEKSKLDEDYLYMAYADIMAKSCHLEEGGENGEAEEEVEVSFEEKQMEKQRLLYQQARLHTRGAAEMVLQMISACKGETGAMVSSTLKLGISILNGGNAEVQQKMLDYLKDKKEVGFFQSIQALMQTCSVLDLNAFERQNKAEGLGMVNEDGTVINRQNGEKVMADDEFTQDLFRFLQLLCEGHNNDFQNYLRTQTGNTTTINIIICTVDYLLRLQESISDFYWYYSGKDVIEEQGKRNFSKAMSVAKQVFNSLTEYIQGPCTGNQQSLAHSRLWDAVVGFLHVFAHMMMKLAQDSSQIELLKELLDLQKDMVVMLLSLLEGNVVNGMIARQMVDMLVESSSNVEMILKFFDMFLKLKDIVGSEAFQDYVTDPRGLISKKDFQKAMDSQKQFSGPEIQFLLSCSEADENEMINCEEFANRFQEPARDIGFNVAVLLTNLSEHVPHDPRLHNFLELAESILEYFRPYLGRIEIMGASRRIERIYFEISETNRAQWEMPQVKESKRQFIFDVVNEGGEAEKMELFVSFCEDTIFEMQIAAQISEPEGEPETDEDEGAGAAEAGAEGAEEGAAGLEGTAATAAAGATARVVAAAGRALRGLSYRSLRRRVRRLRRLTAREAATAVAALLWAAVTRAGAAGAGAAAGALGLLWGSLFGGGLVEGAKKVTVTELLAGMPDPTSDEVHGEQPAGPGGDADGEGASEGAGDAAEGAGDEEEAVHEAGPGGADGAVAVTDGGPFRPEGAGGLGDMGDTTPAEPPTPEGSPILKRKLGVDGVEEELPPEPEPEPEPELEPEKADAENGEKEEVPEPTPEPPKKQAPPSPPPKKEEAGGEFWGELEVQRVKFLNYLSRNFYTLRFLALFLAFAINFILLFYKVSDSPPGEDDMEGSAAGDVSGAGSGGSSGWGLGAGEEAEGDEDENMVYYFLEESTGYMEPALRCLSLLHTLVAFLCIIGYNCLKVPLVIFKREKELARKLEFDGLYITEQPEDDDVKGQWDRLVLNTPSFPSNYWDKFVKRKVLDKHGDIYGRERIAELLGMDLATLEITAHNERKPNPPPGLLTWLMSIDVKYQIWKFGVIFTDNSFLYLGWYMVMSLLGHYNNFFFAAHLLDIAMGVKTLRTILSSVTHNGKQLVMTVGLLAVVVYLYTVVAFNFFRKFYNKSEDEDEPDMKCDDMMTCYLFHMYVGVRAGGGIGDEIEDPAGDEYELYRVVFDITFFFFVIVILLAIIQGLIIDAFGELRDQQEQVKEDMETKCFICGIGSDYFDTTPHGFETHTLEEHNLANYMFFLMYLINKDETEHTGQESYVWKMYQERCWDFFPAGDCFRKQYEDQLS	5038	P21817	G	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
254	NM_000540.3(RYR1):c.7048G>A (p.Ala2350Thr)	133182	CA024690	NM_000540.3:c.7048G>A, NC_000019.10:g.38499655G>A, CM000681.2:g.38499655G>A, NC_000019.9:g.38990295G>A, CM000681.1:g.38990295G>A, NC_000019.8:g.43682135G>A, NG_008866.1:g.70956G>A, LRG_766:g.70956G>A, ENST00000355481.8:c.7048G>A, ENST00000359596.7:n.7048G>A, ENST00000360985.7:c.7045G>A, NM_000540.2:c.7048G>A, LRG_766t1:c.7048G>A, NM_001042723.1:c.7048G>A, XM_006723317.1:c.7048G>A, XM_006723319.1:c.7048G>A, XM_011527204.1:c.7045G>A, XM_011527205.1:c.7048G>A, XM_006723317.2:c.7048G>A, XM_006723319.2:c.7048G>A, XM_011527205.2:c.7048G>A, NM_001042723.2:c.7048G>A, NM_000540.3(RYR1):c.7048G>A (p.Ala2350Thr)	RYR1	malignant hyperthermia, susceptibility to, 1	MONDO:0007783	Autosomal dominant inheritance	Pathogenic	PS4, PS3_Moderate, PM1, PP1_Strong, PP3_Moderate	BA1, BS1	This pathogenicity assessment is relevant only for malignant hyperthermia susceptibility (MHS) inherited in an autosomal dominant pattern. Variants in RYR1 can also cause other myopathies inherited in an autosomal dominant pattern or in an autosomal recessive pattern. Some of these disorders may predispose individuals to malignant hyperthermia. RYR1 variants may also contribute to a malignant hyperthermia reaction in combination with other genetic and non-genetic factors and the clinician needs to consider such factors in making management decisions.This sequence variant predicts a substitution of Alanine with Threonine at codon 2350 of the RYR1 protein, p.(Ala2350Thr). This variant was not present in a large population database (gnomAD) at the time this variant was interpreted. This variant has been reported in 19 unrelated individuals who have a personal or family history of a malignant hyperthermia reaction, 17 of these individuals had a positive in vitro contracture test (IVCT) or caffeine halothane contracture test (CHCT) result (if the proband was unavailable for testing, a positive diagnostic test result in a mutation-positive relative was counted), PS4, (PMID:30236257, PMID:16163667, PMID:11525881, PMID:12434264, and others). Functional studies in HEK293 cells show an increased sensitivity to RYR1 agonists, PS3_Moderate (PMID:11525881).  An ex vivo study in myotubes from a single patient also showed increased sensitivity to RYR1 agonists, (PMID:15210166). This variant resides in a region of RYR1 considered to be a hotspot for pathogenic variants that contribute to MHS, PM1 (PMID: 21118704). This variant segregates with MHS in 7 individuals PP1_Strong (PMID:11525881, PMID:25960145). A REVEL score >0.85 (0.952) supports a pathogenic status for this variant, PP3_Moderate. This variant has been classified as Pathogenic. Criteria implemented: PS3_Moderate, PS4, PM1, PP1_Strong, PP3_Moderate.		Malignant Hyperthermia Susceptibility VCEP	https://clinicalgenome.org/docs/clingen-malignant-hyperthermia-susceptibility-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-for/	2021-03-17	2021-03-31	False	https://erepo.genome.network/evrepo/ui/classification/CA024690/MONDO:0007783/012	efb7116e-4296-4306-a153-395080a0a23e	p.Ala2350Thr	Ala	2350	Thr	MGDAEGEDEVQFLRTDDEVVLQCSATVLKEQLKLCLAAEGFGNRLCFLEPTSNAQNVPPDLAICCFVLEQSLSVRALQEMLANTVEAGVESSQGGGHRTLLYGHAILLRHAHSRMYLSCLTTSRSMTDKLAFDVGLQEDATGEACWWTMHPASKQRSEGEKVRVGDDIILVSVSSERYLHLSTASGELQVDASFMQTLWNMNPICSRCEEGFVTGGHVLRLFHGHMDECLTISPADSDDQRRLVYYEGGAVCTHARSLWRLEPLRISWSGSHLRWGQPLRVRHVTTGQYLALTEDQGLVVVDASKAHTKATSFCFRISKEKLDVAPKRDVEGMGPPEIKYGESLCFVQHVASGLWLTYAAPDPKALRLGVLKKKAMLHQEGHMDDALSLTRCQQEESQAARMIHSTNGLYNQFIKSLDSFSGKPRGSGPPAGTALPIEGVILSLQDLIIYFEPPSEDLQHEEKQSKLRSLRNRQSLFQEEGMLSMVLNCIDRLNVYTTAAHFAEFAGEEAAESWKEIVNLLYELLASLIRGNRSNCALFSTNLDWLVSKLDRLEASSGILEVLYCVLIESPEVLNIIQENHIKSIISLLDKHGRNHKVLDVLCSLCVCNGVAVRSNQDLITENLLPGRELLLQTNLINYVTSIRPNIFVGRAEGTTQYSKWYFEVMVDEVTPFLTAQATHLRVGWALTEGYTPYPGAGEGWGGNGVGDDLYSYGFDGLHLWTGHVARPVTSPGQHLLAPEDVISCCLDLSVPSISFRINGCPVQGVFESFNLDGLFFPVVSFSAGVKVRFLLGGRHGEFKFLPPPGYAPCHEAVLPRERLHLEPIKEYRREGPRGPHLVGPSRCLSHTDFVPCPVDTVQIVLPPHLERIREKLAENIHELWALTRIEQGWTYGPVRDDNKRLHPCLVDFHSLPEPERNYNLQMSGETLKTLLALGCHVGMADEKAEDNLKKTKLPKTYMMSNGYKPAPLDLSHVRLTPAQTTLVDRLAENGHNVWARDRVGQGWSYSAVQDIPARRNPRLVPYRLLDEATKRSNRDSLCQAVRTLLGYGYNIEPPDQEPSQVENQSRCDRVRIFRAEKSYTVQSGRWYFEFEAVTTGEMRVGWARPELRPDVELGADELAYVFNGHRGQRWHLGSEPFGRPWQPGDVVGCMIDLTENTIIFTLNGEVLMSDSGSETAFREIEIGDGFLPVCSLGPGQVGHLNLGQDVSSLRFFAICGLQEGFEPFAINMQRPVTTWFSKGLPQFEPVPLEHPHYEVSRVDGTVDTPPCLRLTHRTWGSQNSLVEMLFLRLSLPVQFHQHFRCTAGATPLAPPGLQPPAEDEARAAEPDPDYENLRRSAGGWSEAENGKEGTAKEGAPGGTPQAGGEAQPARAENEKDATTEKNKKRGFLFKAKKVAMMTQPPATPTLPRLPHDVVPADNRDDPEIILNTTTYYYSVRVFAGQEPSCVWAGWVTPDYHQHDMSFDLSKVRVVTVTMGDEQGNVHSSLKCSNCYMVWGGDFVSPGQQGRISHTDLVIGCLVDLATGLMTFTANGKESNTFFQVEPNTKLFPAVFVLPTHQNVIQFELGKQKNIMPLSAAMFQSERKNPAPQCPPRLEMQMLMPVSWSRMPNHFLQVETRRAGERLGWAVQCQEPLTMMALHIPEENRCMDILELSERLDLQRFHSHTLRLYRAVCALGNNRVAHALCSHVDQAQLLHALEDAHLPGPLRAGYYDLLISIHLESACRSRRSMLSEYIVPLTPETRAITLFPPGRSTENGHPRHGLPGVGVTTSLRPPHHFSPPCFVAALPAAGAAEAPARLSPAIPLEALRDKALRMLGEAVRDGGQHARDPVGGSVEFQFVPVLKLVSTLLVMGIFGDEDVKQILKMIEPEVFTEEEEEEDEEEEGEEEDEEEKEEDEEETAQEKEDEEKEEEEAAEGEKEEGLEEGLLQMKLPESVKLQMCHLLEYFCDQELQHRVESLAAFAERYVDKLQANQRSRYGLLIKAFSMTAAETARRTREFRSPPQEQINMLLQFKDGTDEEDCPLPEEIRQDLLDFHQDLLAHCGIQLDGEEEEPEEETTLGSRLMSLLEKVRLVKKKEEKPEEERSAEESKPRSLQELVSHMVVRWAQEDFVQSPELVRAMFSLLHRQYDGLGELLRALPRAYTISPSSVEDTMSLLECLGQIRSLLIVQMGPQEENLMIQSIGNIMNNKVFYQHPNLMRALGMHETVMEVMVNVLGGGESKEIRFPKMVTSCCRFLCYFCRISRQNQRSMFDHLSYLLENSGIGLGMQGSTPLDVAAASVIDNNELALALQEQDLEKVVSYLAGCGLQSCPMLVAKGYPDIGWNPCGGERYLDFLRFAVFVNGESVEENANVVVRLLIRKPECFGPALRGEGGSGLLAAIEEAIRISEDPARDGPGIRRDRRREHFGEEPPEENRVHLGHAIMSFYAALIDLLGRCAPEMHLIQAGKGEALRIRAILRSLVPLEDLVGIISLPLQIPTLGKDGALVQPKMSASFVPDHKASMVLFLDRVYGIENQDFLLHVLDVGFLPDMRAAASLDTATFSTTEMALALNRYLCLAVLPLITKCAPLFAGTEHRAIMVDSMLHTVYRLSRGRSLTKAQRDVIEDCLMSLCRYIRPSMLQHLLRRLVFDVPILNEFAKMPLKLLTNHYERCWKYYCLPTGWANFGVTSEEELHLTRKLFWGIFDSLAHKKYDPELYRMAMPCLCAIAGALPPDYVDASYSSKAEKKATVDAEGNFDPRPVETLNVIIPEKLDSFINKFAEYTHEKWAFDKIQNNWSYGENIDEELKTHPMLRPYKTFSEKDKEIYRWPIKESLKAMIAWEWTIEKAREGEEEKTEKKKTRKISQSAQTYDPREGYNPQPPDLSAVTLSRELQAMAEQLAENYHNTWGRKKKQELEAKGGGTHPLLVPYDTLTAKEKARDREKAQELLKFLQMNGYAVTRGLKDMELDSSSIEKRFAFGFLQQLLRWMDISQEFIAHLEAVVSSGRVEKSPHEQEIKFFAKILLPLINQYFTNHCLYFLSTPAKVLGSGGHASNKEKEMITSLFCKLAALVRHRVSLFGTDAPAVVNCLHILARSLDARTVMKSGPEIVKAGLRSFFESASEDIEKMVENLRLGKVSQARTQVKGVGQNLTYTTVALLPVLTTLFQHIAQHQFGDDVILDDVQVSCYRTLCSIYSLGTTKNTYVEKLRPALGECLARLAAAMPVAFLEPQLNEYNACSVYTTKSPRERAILGLPNSVEEMCPDIPVLERLMADIGGLAESGARYTEMPHVIEITLPMLCSYLPRWWERGPEAPPSALPAGAPPPCTAVTSDHLNSLLGNILRIIVNNLGIDEASWMKRLAVFAQPIVSRARPELLQSHFIPTIGRLRKRAGKVVSEEEQLRLEAKAEAQEGELLVRDEFSVLCRDLYALYPLLIRYVDNNRAQWLTEPNPSAEELFRMVGEIFIYWSKSHNFKREEQNFVVQNEINNMSFLTADNKSKMAKAGDIQSGGSDQERTKKKRRGDRYSVQTSLIVATLKKMLPIGLNMCAPTDQDLITLAKTRYALKDTDEEVREFLHNNLHLQGKVEGSPSLRWQMALYRGVPGREEDADDPEKIVRRVQEVSAVLYYLDQTEHPYKSKKAVWHKLLSKQRRRAVVACFRMTPLYNLPTHRACNMFLESYKAAWILTEDHSFEDRMIDDLSKAGEQEEEEEEVEEKKPDPLHQLVLHFSRTALTEKSKLDEDYLYMAYADIMAKSCHLEEGGENGEAEEEVEVSFEEKQMEKQRLLYQQARLHTRGAAEMVLQMISACKGETGAMVSSTLKLGISILNGGNAEVQQKMLDYLKDKKEVGFFQSIQALMQTCSVLDLNAFERQNKAEGLGMVNEDGTVINRQNGEKVMADDEFTQDLFRFLQLLCEGHNNDFQNYLRTQTGNTTTINIIICTVDYLLRLQESISDFYWYYSGKDVIEEQGKRNFSKAMSVAKQVFNSLTEYIQGPCTGNQQSLAHSRLWDAVVGFLHVFAHMMMKLAQDSSQIELLKELLDLQKDMVVMLLSLLEGNVVNGMIARQMVDMLVESSSNVEMILKFFDMFLKLKDIVGSEAFQDYVTDPRGLISKKDFQKAMDSQKQFSGPEIQFLLSCSEADENEMINCEEFANRFQEPARDIGFNVAVLLTNLSEHVPHDPRLHNFLELAESILEYFRPYLGRIEIMGASRRIERIYFEISETNRAQWEMPQVKESKRQFIFDVVNEGGEAEKMELFVSFCEDTIFEMQIAAQISEPEGEPETDEDEGAGAAEAGAEGAEEGAAGLEGTAATAAAGATARVVAAAGRALRGLSYRSLRRRVRRLRRLTAREAATAVAALLWAAVTRAGAAGAGAAAGALGLLWGSLFGGGLVEGAKKVTVTELLAGMPDPTSDEVHGEQPAGPGGDADGEGASEGAGDAAEGAGDEEEAVHEAGPGGADGAVAVTDGGPFRPEGAGGLGDMGDTTPAEPPTPEGSPILKRKLGVDGVEEELPPEPEPEPEPELEPEKADAENGEKEEVPEPTPEPPKKQAPPSPPPKKEEAGGEFWGELEVQRVKFLNYLSRNFYTLRFLALFLAFAINFILLFYKVSDSPPGEDDMEGSAAGDVSGAGSGGSSGWGLGAGEEAEGDEDENMVYYFLEESTGYMEPALRCLSLLHTLVAFLCIIGYNCLKVPLVIFKREKELARKLEFDGLYITEQPEDDDVKGQWDRLVLNTPSFPSNYWDKFVKRKVLDKHGDIYGRERIAELLGMDLATLEITAHNERKPNPPPGLLTWLMSIDVKYQIWKFGVIFTDNSFLYLGWYMVMSLLGHYNNFFFAAHLLDIAMGVKTLRTILSSVTHNGKQLVMTVGLLAVVVYLYTVVAFNFFRKFYNKSEDEDEPDMKCDDMMTCYLFHMYVGVRAGGGIGDEIEDPAGDEYELYRVVFDITFFFFVIVILLAIIQGLIIDAFGELRDQQEQVKEDMETKCFICGIGSDYFDTTPHGFETHTLEEHNLANYMFFLMYLINKDETEHTGQESYVWKMYQERCWDFFPAGDCFRKQYEDQLS	5038	P21817	T	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
255	NM_000540.2(RYR1):c.1597C>T (p.Arg533Cys)	133102	CA024293	NM_000540.2:c.1597C>T, NC_000019.10:g.38455471C>T, CM000681.2:g.38455471C>T, NC_000019.9:g.38946111C>T, CM000681.1:g.38946111C>T, NC_000019.8:g.43637951C>T, NG_008866.1:g.26772C>T, LRG_766:g.26772C>T, ENST00000355481.8:c.1597C>T, ENST00000359596.7:n.1597C>T, ENST00000360985.7:c.1597C>T, LRG_766t1:c.1597C>T, NM_001042723.1:c.1597C>T, XM_006723317.1:c.1597C>T, XM_006723319.1:c.1597C>T, XM_011527204.1:c.1594C>T, XM_011527205.1:c.1597C>T, XM_006723317.2:c.1597C>T, XM_006723319.2:c.1597C>T, XM_011527205.2:c.1597C>T, NM_000540.3:c.1597C>T, NM_001042723.2:c.1597C>T, NM_000540.2(RYR1):c.1597C>T (p.Arg533Cys)	RYR1	malignant hyperthermia, susceptibility to, 1	MONDO:0007783	Autosomal dominant inheritance	Pathogenic	PS3_Moderate, PS4_Supporting, PM1, PP1_Strong, PP3_Moderate	BP4	This pathogenicity assessment is relevant only for malignant hyperthermia susceptibility (MHS) inherited in an autosomal dominant pattern. Variants in RYR1 can also cause other myopathies inherited in an autosomal dominant pattern or in an autosomal recessive pattern. Some of these disorders may predispose individuals to malignant hyperthermia. RYR1 variants may also contribute to a malignant hyperthermia reaction in combination with other genetic and non-genetic factors and the clinician needs to consider such factors in making management decisions.This sequence variant predicts a substitution of Arginine with Cysteine at codon 533 of the RYR1 protein, p.(Arg533Cys). This variant is not present in a large population database (gnomAD) at the time this variant was interpreted. This variant has been reported in an individual with a personal or family history of an MH episode and a positive in vitro contracture test (IVCT) or caffeine halothane contracture test (CHCT) result (if the proband was unavailable for testing, a positive diagnostic test result in a mutation-positive relative was counted), PS4_Supporting (PMID:12709367). Functional studies in HEK293 cells show an increased sensitivity to RYR1 agonists, PS3_Moderate (PMID:23459219). This variant resides in a region of RYR1 considered to be a hotspot for pathogenic variants that contribute to MHS, PM1 (PMID: 21118704). This variant segregates with MHS in 8 individuals PP1_Strong (PMID:12709367). A REVEL score >0.85 supports a pathogenic status for this variant, PP3_Moderate. This variant has been classified as Pathogenic. Criteria implemented: PS4_Supporting, PS3_Moderate, PM1, PP1_Strong, PP3_Moderate.		Malignant Hyperthermia Susceptibility VCEP	https://clinicalgenome.org/docs/clingen-malignant-hyperthermia-susceptibility-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-for/	2021-03-17	2021-03-31	False	https://erepo.genome.network/evrepo/ui/classification/CA024293/MONDO:0007783/012	5ac26bd0-a5a1-4e1c-99c8-8fd8264d8656	p.Arg533Cys	Arg	533	Cys	MGDAEGEDEVQFLRTDDEVVLQCSATVLKEQLKLCLAAEGFGNRLCFLEPTSNAQNVPPDLAICCFVLEQSLSVRALQEMLANTVEAGVESSQGGGHRTLLYGHAILLRHAHSRMYLSCLTTSRSMTDKLAFDVGLQEDATGEACWWTMHPASKQRSEGEKVRVGDDIILVSVSSERYLHLSTASGELQVDASFMQTLWNMNPICSRCEEGFVTGGHVLRLFHGHMDECLTISPADSDDQRRLVYYEGGAVCTHARSLWRLEPLRISWSGSHLRWGQPLRVRHVTTGQYLALTEDQGLVVVDASKAHTKATSFCFRISKEKLDVAPKRDVEGMGPPEIKYGESLCFVQHVASGLWLTYAAPDPKALRLGVLKKKAMLHQEGHMDDALSLTRCQQEESQAARMIHSTNGLYNQFIKSLDSFSGKPRGSGPPAGTALPIEGVILSLQDLIIYFEPPSEDLQHEEKQSKLRSLRNRQSLFQEEGMLSMVLNCIDRLNVYTTAAHFAEFAGEEAAESWKEIVNLLYELLASLIRGNRSNCALFSTNLDWLVSKLDRLEASSGILEVLYCVLIESPEVLNIIQENHIKSIISLLDKHGRNHKVLDVLCSLCVCNGVAVRSNQDLITENLLPGRELLLQTNLINYVTSIRPNIFVGRAEGTTQYSKWYFEVMVDEVTPFLTAQATHLRVGWALTEGYTPYPGAGEGWGGNGVGDDLYSYGFDGLHLWTGHVARPVTSPGQHLLAPEDVISCCLDLSVPSISFRINGCPVQGVFESFNLDGLFFPVVSFSAGVKVRFLLGGRHGEFKFLPPPGYAPCHEAVLPRERLHLEPIKEYRREGPRGPHLVGPSRCLSHTDFVPCPVDTVQIVLPPHLERIREKLAENIHELWALTRIEQGWTYGPVRDDNKRLHPCLVDFHSLPEPERNYNLQMSGETLKTLLALGCHVGMADEKAEDNLKKTKLPKTYMMSNGYKPAPLDLSHVRLTPAQTTLVDRLAENGHNVWARDRVGQGWSYSAVQDIPARRNPRLVPYRLLDEATKRSNRDSLCQAVRTLLGYGYNIEPPDQEPSQVENQSRCDRVRIFRAEKSYTVQSGRWYFEFEAVTTGEMRVGWARPELRPDVELGADELAYVFNGHRGQRWHLGSEPFGRPWQPGDVVGCMIDLTENTIIFTLNGEVLMSDSGSETAFREIEIGDGFLPVCSLGPGQVGHLNLGQDVSSLRFFAICGLQEGFEPFAINMQRPVTTWFSKGLPQFEPVPLEHPHYEVSRVDGTVDTPPCLRLTHRTWGSQNSLVEMLFLRLSLPVQFHQHFRCTAGATPLAPPGLQPPAEDEARAAEPDPDYENLRRSAGGWSEAENGKEGTAKEGAPGGTPQAGGEAQPARAENEKDATTEKNKKRGFLFKAKKVAMMTQPPATPTLPRLPHDVVPADNRDDPEIILNTTTYYYSVRVFAGQEPSCVWAGWVTPDYHQHDMSFDLSKVRVVTVTMGDEQGNVHSSLKCSNCYMVWGGDFVSPGQQGRISHTDLVIGCLVDLATGLMTFTANGKESNTFFQVEPNTKLFPAVFVLPTHQNVIQFELGKQKNIMPLSAAMFQSERKNPAPQCPPRLEMQMLMPVSWSRMPNHFLQVETRRAGERLGWAVQCQEPLTMMALHIPEENRCMDILELSERLDLQRFHSHTLRLYRAVCALGNNRVAHALCSHVDQAQLLHALEDAHLPGPLRAGYYDLLISIHLESACRSRRSMLSEYIVPLTPETRAITLFPPGRSTENGHPRHGLPGVGVTTSLRPPHHFSPPCFVAALPAAGAAEAPARLSPAIPLEALRDKALRMLGEAVRDGGQHARDPVGGSVEFQFVPVLKLVSTLLVMGIFGDEDVKQILKMIEPEVFTEEEEEEDEEEEGEEEDEEEKEEDEEETAQEKEDEEKEEEEAAEGEKEEGLEEGLLQMKLPESVKLQMCHLLEYFCDQELQHRVESLAAFAERYVDKLQANQRSRYGLLIKAFSMTAAETARRTREFRSPPQEQINMLLQFKDGTDEEDCPLPEEIRQDLLDFHQDLLAHCGIQLDGEEEEPEEETTLGSRLMSLLEKVRLVKKKEEKPEEERSAEESKPRSLQELVSHMVVRWAQEDFVQSPELVRAMFSLLHRQYDGLGELLRALPRAYTISPSSVEDTMSLLECLGQIRSLLIVQMGPQEENLMIQSIGNIMNNKVFYQHPNLMRALGMHETVMEVMVNVLGGGESKEIRFPKMVTSCCRFLCYFCRISRQNQRSMFDHLSYLLENSGIGLGMQGSTPLDVAAASVIDNNELALALQEQDLEKVVSYLAGCGLQSCPMLVAKGYPDIGWNPCGGERYLDFLRFAVFVNGESVEENANVVVRLLIRKPECFGPALRGEGGSGLLAAIEEAIRISEDPARDGPGIRRDRRREHFGEEPPEENRVHLGHAIMSFYAALIDLLGRCAPEMHLIQAGKGEALRIRAILRSLVPLEDLVGIISLPLQIPTLGKDGALVQPKMSASFVPDHKASMVLFLDRVYGIENQDFLLHVLDVGFLPDMRAAASLDTATFSTTEMALALNRYLCLAVLPLITKCAPLFAGTEHRAIMVDSMLHTVYRLSRGRSLTKAQRDVIEDCLMSLCRYIRPSMLQHLLRRLVFDVPILNEFAKMPLKLLTNHYERCWKYYCLPTGWANFGVTSEEELHLTRKLFWGIFDSLAHKKYDPELYRMAMPCLCAIAGALPPDYVDASYSSKAEKKATVDAEGNFDPRPVETLNVIIPEKLDSFINKFAEYTHEKWAFDKIQNNWSYGENIDEELKTHPMLRPYKTFSEKDKEIYRWPIKESLKAMIAWEWTIEKAREGEEEKTEKKKTRKISQSAQTYDPREGYNPQPPDLSAVTLSRELQAMAEQLAENYHNTWGRKKKQELEAKGGGTHPLLVPYDTLTAKEKARDREKAQELLKFLQMNGYAVTRGLKDMELDSSSIEKRFAFGFLQQLLRWMDISQEFIAHLEAVVSSGRVEKSPHEQEIKFFAKILLPLINQYFTNHCLYFLSTPAKVLGSGGHASNKEKEMITSLFCKLAALVRHRVSLFGTDAPAVVNCLHILARSLDARTVMKSGPEIVKAGLRSFFESASEDIEKMVENLRLGKVSQARTQVKGVGQNLTYTTVALLPVLTTLFQHIAQHQFGDDVILDDVQVSCYRTLCSIYSLGTTKNTYVEKLRPALGECLARLAAAMPVAFLEPQLNEYNACSVYTTKSPRERAILGLPNSVEEMCPDIPVLERLMADIGGLAESGARYTEMPHVIEITLPMLCSYLPRWWERGPEAPPSALPAGAPPPCTAVTSDHLNSLLGNILRIIVNNLGIDEASWMKRLAVFAQPIVSRARPELLQSHFIPTIGRLRKRAGKVVSEEEQLRLEAKAEAQEGELLVRDEFSVLCRDLYALYPLLIRYVDNNRAQWLTEPNPSAEELFRMVGEIFIYWSKSHNFKREEQNFVVQNEINNMSFLTADNKSKMAKAGDIQSGGSDQERTKKKRRGDRYSVQTSLIVATLKKMLPIGLNMCAPTDQDLITLAKTRYALKDTDEEVREFLHNNLHLQGKVEGSPSLRWQMALYRGVPGREEDADDPEKIVRRVQEVSAVLYYLDQTEHPYKSKKAVWHKLLSKQRRRAVVACFRMTPLYNLPTHRACNMFLESYKAAWILTEDHSFEDRMIDDLSKAGEQEEEEEEVEEKKPDPLHQLVLHFSRTALTEKSKLDEDYLYMAYADIMAKSCHLEEGGENGEAEEEVEVSFEEKQMEKQRLLYQQARLHTRGAAEMVLQMISACKGETGAMVSSTLKLGISILNGGNAEVQQKMLDYLKDKKEVGFFQSIQALMQTCSVLDLNAFERQNKAEGLGMVNEDGTVINRQNGEKVMADDEFTQDLFRFLQLLCEGHNNDFQNYLRTQTGNTTTINIIICTVDYLLRLQESISDFYWYYSGKDVIEEQGKRNFSKAMSVAKQVFNSLTEYIQGPCTGNQQSLAHSRLWDAVVGFLHVFAHMMMKLAQDSSQIELLKELLDLQKDMVVMLLSLLEGNVVNGMIARQMVDMLVESSSNVEMILKFFDMFLKLKDIVGSEAFQDYVTDPRGLISKKDFQKAMDSQKQFSGPEIQFLLSCSEADENEMINCEEFANRFQEPARDIGFNVAVLLTNLSEHVPHDPRLHNFLELAESILEYFRPYLGRIEIMGASRRIERIYFEISETNRAQWEMPQVKESKRQFIFDVVNEGGEAEKMELFVSFCEDTIFEMQIAAQISEPEGEPETDEDEGAGAAEAGAEGAEEGAAGLEGTAATAAAGATARVVAAAGRALRGLSYRSLRRRVRRLRRLTAREAATAVAALLWAAVTRAGAAGAGAAAGALGLLWGSLFGGGLVEGAKKVTVTELLAGMPDPTSDEVHGEQPAGPGGDADGEGASEGAGDAAEGAGDEEEAVHEAGPGGADGAVAVTDGGPFRPEGAGGLGDMGDTTPAEPPTPEGSPILKRKLGVDGVEEELPPEPEPEPEPELEPEKADAENGEKEEVPEPTPEPPKKQAPPSPPPKKEEAGGEFWGELEVQRVKFLNYLSRNFYTLRFLALFLAFAINFILLFYKVSDSPPGEDDMEGSAAGDVSGAGSGGSSGWGLGAGEEAEGDEDENMVYYFLEESTGYMEPALRCLSLLHTLVAFLCIIGYNCLKVPLVIFKREKELARKLEFDGLYITEQPEDDDVKGQWDRLVLNTPSFPSNYWDKFVKRKVLDKHGDIYGRERIAELLGMDLATLEITAHNERKPNPPPGLLTWLMSIDVKYQIWKFGVIFTDNSFLYLGWYMVMSLLGHYNNFFFAAHLLDIAMGVKTLRTILSSVTHNGKQLVMTVGLLAVVVYLYTVVAFNFFRKFYNKSEDEDEPDMKCDDMMTCYLFHMYVGVRAGGGIGDEIEDPAGDEYELYRVVFDITFFFFVIVILLAIIQGLIIDAFGELRDQQEQVKEDMETKCFICGIGSDYFDTTPHGFETHTLEEHNLANYMFFLMYLINKDETEHTGQESYVWKMYQERCWDFFPAGDCFRKQYEDQLS	5038	P21817	C	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
256	NM_000540.3(RYR1):c.1840C>T (p.Arg614Cys)	12964	CA024311	NM_000540.3:c.1840C>T, NC_000019.10:g.38457545C>T, CM000681.2:g.38457545C>T, NC_000019.9:g.38948185C>T, CM000681.1:g.38948185C>T, NC_000019.8:g.43640025C>T, NG_008866.1:g.28846C>T, LRG_766:g.28846C>T, ENST00000355481.8:c.1840C>T, ENST00000359596.7:n.1840C>T, ENST00000360985.7:c.1840C>T, NM_000540.2:c.1840C>T, LRG_766t1:c.1840C>T, NM_001042723.1:c.1840C>T, XM_006723317.1:c.1840C>T, XM_006723319.1:c.1840C>T, XM_011527204.1:c.1837C>T, XM_011527205.1:c.1840C>T, XM_006723317.2:c.1840C>T, XM_006723319.2:c.1840C>T, XM_011527205.2:c.1840C>T, NM_001042723.2:c.1840C>T, NM_000540.3(RYR1):c.1840C>T (p.Arg614Cys)	RYR1	malignant hyperthermia, susceptibility to, 1	MONDO:0007783	Autosomal dominant inheritance	Pathogenic	PS4, PS3_Moderate, BS2_Supporting, PM5, PP1_Strong, PP3_Moderate	BA1, BS1, PM1	This pathogenicity assessment is relevant only for malignant hyperthermia susceptibility (MHS) inherited in an autosomal dominant pattern. Variants in RYR1 can also cause other myopathies inherited in an autosomal dominant pattern or in an autosomal recessive pattern. Some of these disorders may predispose individuals to malignant hyperthermia. RYR1 variants may also contribute to a malignant hyperthermia reaction in combination with other genetic and non-genetic factors and the clinician needs to consider such factors in making management decisions.This sequence variant predicts a substitution of Arginine with Cysteine at codon 614 of the RYR1 protein, p.(Arg614Cys). The maximum allele frequency for this variant among the six major gnomAD populations is NFE: 0.00019, a frequency consistent with pathogenicity for MHS. This variant has been reported in over 100 unrelated individuals who have a personal or family history of a malignant hyperthermia reaction, over 100 of these individuals had a positive in vitro contracture test (IVCT) or caffeine halothane contracture test (CHCT) result (if the proband was unavailable for testing, a positive diagnostic test result in a mutation-positive relative was counted), PS4 (PMID:24433488, PMID:16163667, PMID:30236257, and others). This variant has been identified in an individual with negative IVCT/CHCT results, BS2_Moderate (PMID:10484775). Functional studies in HEK293 cells show an increased sensitivity to RYR1 agonists, PS3_Moderate (PMID:26115329). This variant does not reside in a hotspot for pathogenic variants that contribute to MHS (PMID: 21118704). Another variant that has been assessed as pathogenic occurs at this codon, p.(Arg614Leu), PM5 (PMID:16917943). p.(Arg614Cys) segregates with MHS in 38 individuals PP1_Strong, (PMID:25960145, PMID:7586638, PMID:11493496 and others). A REVEL score >0.85 supports a pathogenic status for this variant, PP3_Moderate. Criteria implemented: PS3_Moderate, PS4, PM5, PP1_Strong, PP3_Moderate, BS2_Moderate. Based on using Bayes to combine criteria this variant is assessed as Pathogenic, (PMID: 29300386).		Malignant Hyperthermia Susceptibility VCEP	https://clinicalgenome.org/docs/clingen-malignant-hyperthermia-susceptibility-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-for/	2021-03-17	2021-03-31	False	https://erepo.genome.network/evrepo/ui/classification/CA024311/MONDO:0007783/012	db1e9a13-5143-462b-8d02-86b85ab5b1c4	p.Arg614Cys	Arg	614	Cys	MGDAEGEDEVQFLRTDDEVVLQCSATVLKEQLKLCLAAEGFGNRLCFLEPTSNAQNVPPDLAICCFVLEQSLSVRALQEMLANTVEAGVESSQGGGHRTLLYGHAILLRHAHSRMYLSCLTTSRSMTDKLAFDVGLQEDATGEACWWTMHPASKQRSEGEKVRVGDDIILVSVSSERYLHLSTASGELQVDASFMQTLWNMNPICSRCEEGFVTGGHVLRLFHGHMDECLTISPADSDDQRRLVYYEGGAVCTHARSLWRLEPLRISWSGSHLRWGQPLRVRHVTTGQYLALTEDQGLVVVDASKAHTKATSFCFRISKEKLDVAPKRDVEGMGPPEIKYGESLCFVQHVASGLWLTYAAPDPKALRLGVLKKKAMLHQEGHMDDALSLTRCQQEESQAARMIHSTNGLYNQFIKSLDSFSGKPRGSGPPAGTALPIEGVILSLQDLIIYFEPPSEDLQHEEKQSKLRSLRNRQSLFQEEGMLSMVLNCIDRLNVYTTAAHFAEFAGEEAAESWKEIVNLLYELLASLIRGNRSNCALFSTNLDWLVSKLDRLEASSGILEVLYCVLIESPEVLNIIQENHIKSIISLLDKHGRNHKVLDVLCSLCVCNGVAVRSNQDLITENLLPGRELLLQTNLINYVTSIRPNIFVGRAEGTTQYSKWYFEVMVDEVTPFLTAQATHLRVGWALTEGYTPYPGAGEGWGGNGVGDDLYSYGFDGLHLWTGHVARPVTSPGQHLLAPEDVISCCLDLSVPSISFRINGCPVQGVFESFNLDGLFFPVVSFSAGVKVRFLLGGRHGEFKFLPPPGYAPCHEAVLPRERLHLEPIKEYRREGPRGPHLVGPSRCLSHTDFVPCPVDTVQIVLPPHLERIREKLAENIHELWALTRIEQGWTYGPVRDDNKRLHPCLVDFHSLPEPERNYNLQMSGETLKTLLALGCHVGMADEKAEDNLKKTKLPKTYMMSNGYKPAPLDLSHVRLTPAQTTLVDRLAENGHNVWARDRVGQGWSYSAVQDIPARRNPRLVPYRLLDEATKRSNRDSLCQAVRTLLGYGYNIEPPDQEPSQVENQSRCDRVRIFRAEKSYTVQSGRWYFEFEAVTTGEMRVGWARPELRPDVELGADELAYVFNGHRGQRWHLGSEPFGRPWQPGDVVGCMIDLTENTIIFTLNGEVLMSDSGSETAFREIEIGDGFLPVCSLGPGQVGHLNLGQDVSSLRFFAICGLQEGFEPFAINMQRPVTTWFSKGLPQFEPVPLEHPHYEVSRVDGTVDTPPCLRLTHRTWGSQNSLVEMLFLRLSLPVQFHQHFRCTAGATPLAPPGLQPPAEDEARAAEPDPDYENLRRSAGGWSEAENGKEGTAKEGAPGGTPQAGGEAQPARAENEKDATTEKNKKRGFLFKAKKVAMMTQPPATPTLPRLPHDVVPADNRDDPEIILNTTTYYYSVRVFAGQEPSCVWAGWVTPDYHQHDMSFDLSKVRVVTVTMGDEQGNVHSSLKCSNCYMVWGGDFVSPGQQGRISHTDLVIGCLVDLATGLMTFTANGKESNTFFQVEPNTKLFPAVFVLPTHQNVIQFELGKQKNIMPLSAAMFQSERKNPAPQCPPRLEMQMLMPVSWSRMPNHFLQVETRRAGERLGWAVQCQEPLTMMALHIPEENRCMDILELSERLDLQRFHSHTLRLYRAVCALGNNRVAHALCSHVDQAQLLHALEDAHLPGPLRAGYYDLLISIHLESACRSRRSMLSEYIVPLTPETRAITLFPPGRSTENGHPRHGLPGVGVTTSLRPPHHFSPPCFVAALPAAGAAEAPARLSPAIPLEALRDKALRMLGEAVRDGGQHARDPVGGSVEFQFVPVLKLVSTLLVMGIFGDEDVKQILKMIEPEVFTEEEEEEDEEEEGEEEDEEEKEEDEEETAQEKEDEEKEEEEAAEGEKEEGLEEGLLQMKLPESVKLQMCHLLEYFCDQELQHRVESLAAFAERYVDKLQANQRSRYGLLIKAFSMTAAETARRTREFRSPPQEQINMLLQFKDGTDEEDCPLPEEIRQDLLDFHQDLLAHCGIQLDGEEEEPEEETTLGSRLMSLLEKVRLVKKKEEKPEEERSAEESKPRSLQELVSHMVVRWAQEDFVQSPELVRAMFSLLHRQYDGLGELLRALPRAYTISPSSVEDTMSLLECLGQIRSLLIVQMGPQEENLMIQSIGNIMNNKVFYQHPNLMRALGMHETVMEVMVNVLGGGESKEIRFPKMVTSCCRFLCYFCRISRQNQRSMFDHLSYLLENSGIGLGMQGSTPLDVAAASVIDNNELALALQEQDLEKVVSYLAGCGLQSCPMLVAKGYPDIGWNPCGGERYLDFLRFAVFVNGESVEENANVVVRLLIRKPECFGPALRGEGGSGLLAAIEEAIRISEDPARDGPGIRRDRRREHFGEEPPEENRVHLGHAIMSFYAALIDLLGRCAPEMHLIQAGKGEALRIRAILRSLVPLEDLVGIISLPLQIPTLGKDGALVQPKMSASFVPDHKASMVLFLDRVYGIENQDFLLHVLDVGFLPDMRAAASLDTATFSTTEMALALNRYLCLAVLPLITKCAPLFAGTEHRAIMVDSMLHTVYRLSRGRSLTKAQRDVIEDCLMSLCRYIRPSMLQHLLRRLVFDVPILNEFAKMPLKLLTNHYERCWKYYCLPTGWANFGVTSEEELHLTRKLFWGIFDSLAHKKYDPELYRMAMPCLCAIAGALPPDYVDASYSSKAEKKATVDAEGNFDPRPVETLNVIIPEKLDSFINKFAEYTHEKWAFDKIQNNWSYGENIDEELKTHPMLRPYKTFSEKDKEIYRWPIKESLKAMIAWEWTIEKAREGEEEKTEKKKTRKISQSAQTYDPREGYNPQPPDLSAVTLSRELQAMAEQLAENYHNTWGRKKKQELEAKGGGTHPLLVPYDTLTAKEKARDREKAQELLKFLQMNGYAVTRGLKDMELDSSSIEKRFAFGFLQQLLRWMDISQEFIAHLEAVVSSGRVEKSPHEQEIKFFAKILLPLINQYFTNHCLYFLSTPAKVLGSGGHASNKEKEMITSLFCKLAALVRHRVSLFGTDAPAVVNCLHILARSLDARTVMKSGPEIVKAGLRSFFESASEDIEKMVENLRLGKVSQARTQVKGVGQNLTYTTVALLPVLTTLFQHIAQHQFGDDVILDDVQVSCYRTLCSIYSLGTTKNTYVEKLRPALGECLARLAAAMPVAFLEPQLNEYNACSVYTTKSPRERAILGLPNSVEEMCPDIPVLERLMADIGGLAESGARYTEMPHVIEITLPMLCSYLPRWWERGPEAPPSALPAGAPPPCTAVTSDHLNSLLGNILRIIVNNLGIDEASWMKRLAVFAQPIVSRARPELLQSHFIPTIGRLRKRAGKVVSEEEQLRLEAKAEAQEGELLVRDEFSVLCRDLYALYPLLIRYVDNNRAQWLTEPNPSAEELFRMVGEIFIYWSKSHNFKREEQNFVVQNEINNMSFLTADNKSKMAKAGDIQSGGSDQERTKKKRRGDRYSVQTSLIVATLKKMLPIGLNMCAPTDQDLITLAKTRYALKDTDEEVREFLHNNLHLQGKVEGSPSLRWQMALYRGVPGREEDADDPEKIVRRVQEVSAVLYYLDQTEHPYKSKKAVWHKLLSKQRRRAVVACFRMTPLYNLPTHRACNMFLESYKAAWILTEDHSFEDRMIDDLSKAGEQEEEEEEVEEKKPDPLHQLVLHFSRTALTEKSKLDEDYLYMAYADIMAKSCHLEEGGENGEAEEEVEVSFEEKQMEKQRLLYQQARLHTRGAAEMVLQMISACKGETGAMVSSTLKLGISILNGGNAEVQQKMLDYLKDKKEVGFFQSIQALMQTCSVLDLNAFERQNKAEGLGMVNEDGTVINRQNGEKVMADDEFTQDLFRFLQLLCEGHNNDFQNYLRTQTGNTTTINIIICTVDYLLRLQESISDFYWYYSGKDVIEEQGKRNFSKAMSVAKQVFNSLTEYIQGPCTGNQQSLAHSRLWDAVVGFLHVFAHMMMKLAQDSSQIELLKELLDLQKDMVVMLLSLLEGNVVNGMIARQMVDMLVESSSNVEMILKFFDMFLKLKDIVGSEAFQDYVTDPRGLISKKDFQKAMDSQKQFSGPEIQFLLSCSEADENEMINCEEFANRFQEPARDIGFNVAVLLTNLSEHVPHDPRLHNFLELAESILEYFRPYLGRIEIMGASRRIERIYFEISETNRAQWEMPQVKESKRQFIFDVVNEGGEAEKMELFVSFCEDTIFEMQIAAQISEPEGEPETDEDEGAGAAEAGAEGAEEGAAGLEGTAATAAAGATARVVAAAGRALRGLSYRSLRRRVRRLRRLTAREAATAVAALLWAAVTRAGAAGAGAAAGALGLLWGSLFGGGLVEGAKKVTVTELLAGMPDPTSDEVHGEQPAGPGGDADGEGASEGAGDAAEGAGDEEEAVHEAGPGGADGAVAVTDGGPFRPEGAGGLGDMGDTTPAEPPTPEGSPILKRKLGVDGVEEELPPEPEPEPEPELEPEKADAENGEKEEVPEPTPEPPKKQAPPSPPPKKEEAGGEFWGELEVQRVKFLNYLSRNFYTLRFLALFLAFAINFILLFYKVSDSPPGEDDMEGSAAGDVSGAGSGGSSGWGLGAGEEAEGDEDENMVYYFLEESTGYMEPALRCLSLLHTLVAFLCIIGYNCLKVPLVIFKREKELARKLEFDGLYITEQPEDDDVKGQWDRLVLNTPSFPSNYWDKFVKRKVLDKHGDIYGRERIAELLGMDLATLEITAHNERKPNPPPGLLTWLMSIDVKYQIWKFGVIFTDNSFLYLGWYMVMSLLGHYNNFFFAAHLLDIAMGVKTLRTILSSVTHNGKQLVMTVGLLAVVVYLYTVVAFNFFRKFYNKSEDEDEPDMKCDDMMTCYLFHMYVGVRAGGGIGDEIEDPAGDEYELYRVVFDITFFFFVIVILLAIIQGLIIDAFGELRDQQEQVKEDMETKCFICGIGSDYFDTTPHGFETHTLEEHNLANYMFFLMYLINKDETEHTGQESYVWKMYQERCWDFFPAGDCFRKQYEDQLS	5038	P21817	C	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
257	NM_000540.2(RYR1):c.529C>T (p.Arg177Cys)	133147	CA024503	NM_000540.2:c.529C>T, NC_000019.10:g.38444253C>T, CM000681.2:g.38444253C>T, NC_000019.9:g.38934893C>T, CM000681.1:g.38934893C>T, NC_000019.8:g.43626733C>T, NG_008866.1:g.15554C>T, LRG_766:g.15554C>T, ENST00000355481.8:c.529C>T, ENST00000359596.7:n.529C>T, ENST00000360985.7:c.529C>T, LRG_766t1:c.529C>T, NM_001042723.1:c.529C>T, XM_006723317.1:c.529C>T, XM_006723319.1:c.529C>T, XM_011527204.1:c.529C>T, XM_011527205.1:c.529C>T, XM_006723317.2:c.529C>T, XM_006723319.2:c.529C>T, XM_011527205.2:c.529C>T, NM_000540.3:c.529C>T, NM_001042723.2:c.529C>T, NM_000540.2(RYR1):c.529C>T (p.Arg177Cys)	RYR1	malignant hyperthermia, susceptibility to, 1	MONDO:0007783	Autosomal dominant inheritance	Pathogenic	PS4, BS2_Supporting, PM1, PS2_Moderate, PP1_Strong, PP3_Moderate	BA1, BP4, BS1	This pathogenicity assessment is relevant only for malignant hyperthermia susceptibility (MHS) inherited in an autosomal dominant pattern. Variants in RYR1 can also cause other myopathies inherited in an autosomal dominant pattern or in an autosomal recessive pattern. Some of these disorders may predispose individuals to malignant hyperthermia. RYR1 variants may also contribute to a malignant hyperthermia reaction in combination with other genetic and non-genetic factors and the clinician needs to consider such factors in making management decisions.This sequence variant predicts a substitution of arginine with cysteine at codon 177 of the RYR1 protein, p.(Arg177Cys). This variant was not present in the six major gnomAD populations at the time this variant was interpreted. This variant has been reported in 11 unrelated individuals who have a personal or family history of a malignant hyperthermia reaction, 11 of these individuals had a positive in vitro contracture test (IVCT) or caffeine halothane contracture test (CHCT) result (if the proband was unavailable for testing, a positive diagnostic test result in a mutation-positive relative was counted), PS4 (PMID:30236257, PMID:16163667). This variant has been identified an individual with a negative IVCT/CHCT result BS2_Moderate. In one individuals the variant was determined to be de novo with confirmed parentage PS2_Moderate. No functional studies were identified for this variant. This variant resides in a region of RYR1 considered to be a hotspot for pathogenic variants that contribute to MHS, PM1 (PMID: 21118704). This variant segregates with MHS in at least 7 individuals PP1_Strong (PMID:19648156). A REVEL score >0.85 (0.931) supports a pathogenic status for this variant, PP3_Moderate. Based on using Bayes to combine criteria this variant is assessed as Pathogenic, (PMID: 29300386). Criteria implemented: PS2_Moderate, PS4, PM1, PP1_Strong, PP3_Moderate, BS2_Moderate.		Malignant Hyperthermia Susceptibility VCEP	https://clinicalgenome.org/docs/clingen-malignant-hyperthermia-susceptibility-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-for/	2021-03-16	2021-03-31	False	https://erepo.genome.network/evrepo/ui/classification/CA024503/MONDO:0007783/012	daad25c5-6f40-4afa-af24-8c0d61ebc301	p.Arg177Cys	Arg	177	Cys	MGDAEGEDEVQFLRTDDEVVLQCSATVLKEQLKLCLAAEGFGNRLCFLEPTSNAQNVPPDLAICCFVLEQSLSVRALQEMLANTVEAGVESSQGGGHRTLLYGHAILLRHAHSRMYLSCLTTSRSMTDKLAFDVGLQEDATGEACWWTMHPASKQRSEGEKVRVGDDIILVSVSSERYLHLSTASGELQVDASFMQTLWNMNPICSRCEEGFVTGGHVLRLFHGHMDECLTISPADSDDQRRLVYYEGGAVCTHARSLWRLEPLRISWSGSHLRWGQPLRVRHVTTGQYLALTEDQGLVVVDASKAHTKATSFCFRISKEKLDVAPKRDVEGMGPPEIKYGESLCFVQHVASGLWLTYAAPDPKALRLGVLKKKAMLHQEGHMDDALSLTRCQQEESQAARMIHSTNGLYNQFIKSLDSFSGKPRGSGPPAGTALPIEGVILSLQDLIIYFEPPSEDLQHEEKQSKLRSLRNRQSLFQEEGMLSMVLNCIDRLNVYTTAAHFAEFAGEEAAESWKEIVNLLYELLASLIRGNRSNCALFSTNLDWLVSKLDRLEASSGILEVLYCVLIESPEVLNIIQENHIKSIISLLDKHGRNHKVLDVLCSLCVCNGVAVRSNQDLITENLLPGRELLLQTNLINYVTSIRPNIFVGRAEGTTQYSKWYFEVMVDEVTPFLTAQATHLRVGWALTEGYTPYPGAGEGWGGNGVGDDLYSYGFDGLHLWTGHVARPVTSPGQHLLAPEDVISCCLDLSVPSISFRINGCPVQGVFESFNLDGLFFPVVSFSAGVKVRFLLGGRHGEFKFLPPPGYAPCHEAVLPRERLHLEPIKEYRREGPRGPHLVGPSRCLSHTDFVPCPVDTVQIVLPPHLERIREKLAENIHELWALTRIEQGWTYGPVRDDNKRLHPCLVDFHSLPEPERNYNLQMSGETLKTLLALGCHVGMADEKAEDNLKKTKLPKTYMMSNGYKPAPLDLSHVRLTPAQTTLVDRLAENGHNVWARDRVGQGWSYSAVQDIPARRNPRLVPYRLLDEATKRSNRDSLCQAVRTLLGYGYNIEPPDQEPSQVENQSRCDRVRIFRAEKSYTVQSGRWYFEFEAVTTGEMRVGWARPELRPDVELGADELAYVFNGHRGQRWHLGSEPFGRPWQPGDVVGCMIDLTENTIIFTLNGEVLMSDSGSETAFREIEIGDGFLPVCSLGPGQVGHLNLGQDVSSLRFFAICGLQEGFEPFAINMQRPVTTWFSKGLPQFEPVPLEHPHYEVSRVDGTVDTPPCLRLTHRTWGSQNSLVEMLFLRLSLPVQFHQHFRCTAGATPLAPPGLQPPAEDEARAAEPDPDYENLRRSAGGWSEAENGKEGTAKEGAPGGTPQAGGEAQPARAENEKDATTEKNKKRGFLFKAKKVAMMTQPPATPTLPRLPHDVVPADNRDDPEIILNTTTYYYSVRVFAGQEPSCVWAGWVTPDYHQHDMSFDLSKVRVVTVTMGDEQGNVHSSLKCSNCYMVWGGDFVSPGQQGRISHTDLVIGCLVDLATGLMTFTANGKESNTFFQVEPNTKLFPAVFVLPTHQNVIQFELGKQKNIMPLSAAMFQSERKNPAPQCPPRLEMQMLMPVSWSRMPNHFLQVETRRAGERLGWAVQCQEPLTMMALHIPEENRCMDILELSERLDLQRFHSHTLRLYRAVCALGNNRVAHALCSHVDQAQLLHALEDAHLPGPLRAGYYDLLISIHLESACRSRRSMLSEYIVPLTPETRAITLFPPGRSTENGHPRHGLPGVGVTTSLRPPHHFSPPCFVAALPAAGAAEAPARLSPAIPLEALRDKALRMLGEAVRDGGQHARDPVGGSVEFQFVPVLKLVSTLLVMGIFGDEDVKQILKMIEPEVFTEEEEEEDEEEEGEEEDEEEKEEDEEETAQEKEDEEKEEEEAAEGEKEEGLEEGLLQMKLPESVKLQMCHLLEYFCDQELQHRVESLAAFAERYVDKLQANQRSRYGLLIKAFSMTAAETARRTREFRSPPQEQINMLLQFKDGTDEEDCPLPEEIRQDLLDFHQDLLAHCGIQLDGEEEEPEEETTLGSRLMSLLEKVRLVKKKEEKPEEERSAEESKPRSLQELVSHMVVRWAQEDFVQSPELVRAMFSLLHRQYDGLGELLRALPRAYTISPSSVEDTMSLLECLGQIRSLLIVQMGPQEENLMIQSIGNIMNNKVFYQHPNLMRALGMHETVMEVMVNVLGGGESKEIRFPKMVTSCCRFLCYFCRISRQNQRSMFDHLSYLLENSGIGLGMQGSTPLDVAAASVIDNNELALALQEQDLEKVVSYLAGCGLQSCPMLVAKGYPDIGWNPCGGERYLDFLRFAVFVNGESVEENANVVVRLLIRKPECFGPALRGEGGSGLLAAIEEAIRISEDPARDGPGIRRDRRREHFGEEPPEENRVHLGHAIMSFYAALIDLLGRCAPEMHLIQAGKGEALRIRAILRSLVPLEDLVGIISLPLQIPTLGKDGALVQPKMSASFVPDHKASMVLFLDRVYGIENQDFLLHVLDVGFLPDMRAAASLDTATFSTTEMALALNRYLCLAVLPLITKCAPLFAGTEHRAIMVDSMLHTVYRLSRGRSLTKAQRDVIEDCLMSLCRYIRPSMLQHLLRRLVFDVPILNEFAKMPLKLLTNHYERCWKYYCLPTGWANFGVTSEEELHLTRKLFWGIFDSLAHKKYDPELYRMAMPCLCAIAGALPPDYVDASYSSKAEKKATVDAEGNFDPRPVETLNVIIPEKLDSFINKFAEYTHEKWAFDKIQNNWSYGENIDEELKTHPMLRPYKTFSEKDKEIYRWPIKESLKAMIAWEWTIEKAREGEEEKTEKKKTRKISQSAQTYDPREGYNPQPPDLSAVTLSRELQAMAEQLAENYHNTWGRKKKQELEAKGGGTHPLLVPYDTLTAKEKARDREKAQELLKFLQMNGYAVTRGLKDMELDSSSIEKRFAFGFLQQLLRWMDISQEFIAHLEAVVSSGRVEKSPHEQEIKFFAKILLPLINQYFTNHCLYFLSTPAKVLGSGGHASNKEKEMITSLFCKLAALVRHRVSLFGTDAPAVVNCLHILARSLDARTVMKSGPEIVKAGLRSFFESASEDIEKMVENLRLGKVSQARTQVKGVGQNLTYTTVALLPVLTTLFQHIAQHQFGDDVILDDVQVSCYRTLCSIYSLGTTKNTYVEKLRPALGECLARLAAAMPVAFLEPQLNEYNACSVYTTKSPRERAILGLPNSVEEMCPDIPVLERLMADIGGLAESGARYTEMPHVIEITLPMLCSYLPRWWERGPEAPPSALPAGAPPPCTAVTSDHLNSLLGNILRIIVNNLGIDEASWMKRLAVFAQPIVSRARPELLQSHFIPTIGRLRKRAGKVVSEEEQLRLEAKAEAQEGELLVRDEFSVLCRDLYALYPLLIRYVDNNRAQWLTEPNPSAEELFRMVGEIFIYWSKSHNFKREEQNFVVQNEINNMSFLTADNKSKMAKAGDIQSGGSDQERTKKKRRGDRYSVQTSLIVATLKKMLPIGLNMCAPTDQDLITLAKTRYALKDTDEEVREFLHNNLHLQGKVEGSPSLRWQMALYRGVPGREEDADDPEKIVRRVQEVSAVLYYLDQTEHPYKSKKAVWHKLLSKQRRRAVVACFRMTPLYNLPTHRACNMFLESYKAAWILTEDHSFEDRMIDDLSKAGEQEEEEEEVEEKKPDPLHQLVLHFSRTALTEKSKLDEDYLYMAYADIMAKSCHLEEGGENGEAEEEVEVSFEEKQMEKQRLLYQQARLHTRGAAEMVLQMISACKGETGAMVSSTLKLGISILNGGNAEVQQKMLDYLKDKKEVGFFQSIQALMQTCSVLDLNAFERQNKAEGLGMVNEDGTVINRQNGEKVMADDEFTQDLFRFLQLLCEGHNNDFQNYLRTQTGNTTTINIIICTVDYLLRLQESISDFYWYYSGKDVIEEQGKRNFSKAMSVAKQVFNSLTEYIQGPCTGNQQSLAHSRLWDAVVGFLHVFAHMMMKLAQDSSQIELLKELLDLQKDMVVMLLSLLEGNVVNGMIARQMVDMLVESSSNVEMILKFFDMFLKLKDIVGSEAFQDYVTDPRGLISKKDFQKAMDSQKQFSGPEIQFLLSCSEADENEMINCEEFANRFQEPARDIGFNVAVLLTNLSEHVPHDPRLHNFLELAESILEYFRPYLGRIEIMGASRRIERIYFEISETNRAQWEMPQVKESKRQFIFDVVNEGGEAEKMELFVSFCEDTIFEMQIAAQISEPEGEPETDEDEGAGAAEAGAEGAEEGAAGLEGTAATAAAGATARVVAAAGRALRGLSYRSLRRRVRRLRRLTAREAATAVAALLWAAVTRAGAAGAGAAAGALGLLWGSLFGGGLVEGAKKVTVTELLAGMPDPTSDEVHGEQPAGPGGDADGEGASEGAGDAAEGAGDEEEAVHEAGPGGADGAVAVTDGGPFRPEGAGGLGDMGDTTPAEPPTPEGSPILKRKLGVDGVEEELPPEPEPEPEPELEPEKADAENGEKEEVPEPTPEPPKKQAPPSPPPKKEEAGGEFWGELEVQRVKFLNYLSRNFYTLRFLALFLAFAINFILLFYKVSDSPPGEDDMEGSAAGDVSGAGSGGSSGWGLGAGEEAEGDEDENMVYYFLEESTGYMEPALRCLSLLHTLVAFLCIIGYNCLKVPLVIFKREKELARKLEFDGLYITEQPEDDDVKGQWDRLVLNTPSFPSNYWDKFVKRKVLDKHGDIYGRERIAELLGMDLATLEITAHNERKPNPPPGLLTWLMSIDVKYQIWKFGVIFTDNSFLYLGWYMVMSLLGHYNNFFFAAHLLDIAMGVKTLRTILSSVTHNGKQLVMTVGLLAVVVYLYTVVAFNFFRKFYNKSEDEDEPDMKCDDMMTCYLFHMYVGVRAGGGIGDEIEDPAGDEYELYRVVFDITFFFFVIVILLAIIQGLIIDAFGELRDQQEQVKEDMETKCFICGIGSDYFDTTPHGFETHTLEEHNLANYMFFLMYLINKDETEHTGQESYVWKMYQERCWDFFPAGDCFRKQYEDQLS	5038	P21817	C	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [1490], 'DISULFID_gain': [], 'DISULFID_loss_score': array([-0.00338668]), 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
258	NM_000540.3(RYR1):c.6487C>T (p.Arg2163Cys)	12973	CA024590	NM_000540.3:c.6487C>T, NC_000019.10:g.38494564C>T, CM000681.2:g.38494564C>T, NC_000019.9:g.38985204C>T, CM000681.1:g.38985204C>T, NC_000019.8:g.43677044C>T, NG_008866.1:g.65865C>T, LRG_766:g.65865C>T, ENST00000359596.8:c.6487C>T, ENST00000355481.8:c.6487C>T, ENST00000359596.7:n.6487C>T, ENST00000360985.7:c.6484C>T, NM_000540.2:c.6487C>T, LRG_766t1:c.6487C>T, NM_001042723.1:c.6487C>T, XM_006723317.1:c.6487C>T, XM_006723319.1:c.6487C>T, XM_011527204.1:c.6484C>T, XM_011527205.1:c.6487C>T, XM_006723317.2:c.6487C>T, XM_006723319.2:c.6487C>T, XM_011527205.2:c.6487C>T, XR_001753735.1:n.6570C>T, NM_001042723.2:c.6487C>T, NM_000540.3(RYR1):c.6487C>T (p.Arg2163Cys)	RYR1	malignant hyperthermia, susceptibility to, 1	MONDO:0007783	Autosomal dominant inheritance	Pathogenic	PM1_Supporting, PS4_Moderate, PS3_Moderate, BS2_Supporting, PP1_Strong, PP3_Moderate, PM5		This pathogenicity assessment is relevant only for malignant hyperthermia susceptibility (MHS) inherited in an autosomal dominant pattern. Variants in RYR1 can also cause other myopathies inherited in an autosomal dominant pattern or in an autosomal recessive pattern. Some of these disorders may predispose individuals to malignant hyperthermia. RYR1 variants may also contribute to a malignant hyperthermia reaction in combination with other genetic and non-genetic factors and the clinician needs to consider such factors in making management decisions.This sequence variant predicts a substitution of Arginine with Cysteine at codon 2163 of the RYR1 protein, p.(Arg2163Cys). The maximum allele frequency for this variant among the six major gnomAD populations is SAS: 0.000033, a frequency consistent with pathogenicity for MHS. This variant has been reported in three unrelated individuals who have a personal or family history of a malignant hyperthermia reaction, three of these individuals had a positive in vitro contracture test (IVCT) or caffeine halothane contracture test (CHCT) result (if the proband was unavailable for testing, a positive diagnostic test result in a mutation-positive relative was counted), PS4_Moderate (PMID:10484775, PMID:30236257, PMID:9497245). This variant has been identified in an individual with a negative IVCT/CHCT result, BS2_Moderate. Functional studies in HEK293 cells show an increased sensitivity to RYR1 agonists, PS3_Moderate (PMID:9873004). Another variant has been assessed as pathogenic at this codon, p.(Arg2163His), PM5 (PMID:30236257 ). This variant resides in a region of RYR1 considered to be a hotspot for pathogenic variants that contribute to MHS, use PM1_Supporting to avoid overweighting with PM5 (PMID: 21118704). This variant segregates with MHS in over 15 individuals PP1_Strong, (PMID:9497245, PMID:30236257, PMID:10484775). A REVEL score >0.85 supports a pathogenic status for this variant, PP3_Moderate. Based on using Bayes to combine criteria this variant is assessed as Pathogenic, (PMID: 29300386). Criteria implemented: PS3_Moderate, PS4_Moderate, PM1_Supporting, PM5, PP1_Strong, PP3_Moderate, BS2_Moderate.		Malignant Hyperthermia Susceptibility VCEP	https://clinicalgenome.org/docs/clingen-malignant-hyperthermia-susceptibility-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-for/	2022-03-14	2022-03-14	False	https://erepo.genome.network/evrepo/ui/classification/CA024590/MONDO:0007783/012	a1cc0bc5-bb8b-405b-985d-a85e26b6d2d8	p.Arg2163Cys	Arg	2163	Cys	MGDAEGEDEVQFLRTDDEVVLQCSATVLKEQLKLCLAAEGFGNRLCFLEPTSNAQNVPPDLAICCFVLEQSLSVRALQEMLANTVEAGVESSQGGGHRTLLYGHAILLRHAHSRMYLSCLTTSRSMTDKLAFDVGLQEDATGEACWWTMHPASKQRSEGEKVRVGDDIILVSVSSERYLHLSTASGELQVDASFMQTLWNMNPICSRCEEGFVTGGHVLRLFHGHMDECLTISPADSDDQRRLVYYEGGAVCTHARSLWRLEPLRISWSGSHLRWGQPLRVRHVTTGQYLALTEDQGLVVVDASKAHTKATSFCFRISKEKLDVAPKRDVEGMGPPEIKYGESLCFVQHVASGLWLTYAAPDPKALRLGVLKKKAMLHQEGHMDDALSLTRCQQEESQAARMIHSTNGLYNQFIKSLDSFSGKPRGSGPPAGTALPIEGVILSLQDLIIYFEPPSEDLQHEEKQSKLRSLRNRQSLFQEEGMLSMVLNCIDRLNVYTTAAHFAEFAGEEAAESWKEIVNLLYELLASLIRGNRSNCALFSTNLDWLVSKLDRLEASSGILEVLYCVLIESPEVLNIIQENHIKSIISLLDKHGRNHKVLDVLCSLCVCNGVAVRSNQDLITENLLPGRELLLQTNLINYVTSIRPNIFVGRAEGTTQYSKWYFEVMVDEVTPFLTAQATHLRVGWALTEGYTPYPGAGEGWGGNGVGDDLYSYGFDGLHLWTGHVARPVTSPGQHLLAPEDVISCCLDLSVPSISFRINGCPVQGVFESFNLDGLFFPVVSFSAGVKVRFLLGGRHGEFKFLPPPGYAPCHEAVLPRERLHLEPIKEYRREGPRGPHLVGPSRCLSHTDFVPCPVDTVQIVLPPHLERIREKLAENIHELWALTRIEQGWTYGPVRDDNKRLHPCLVDFHSLPEPERNYNLQMSGETLKTLLALGCHVGMADEKAEDNLKKTKLPKTYMMSNGYKPAPLDLSHVRLTPAQTTLVDRLAENGHNVWARDRVGQGWSYSAVQDIPARRNPRLVPYRLLDEATKRSNRDSLCQAVRTLLGYGYNIEPPDQEPSQVENQSRCDRVRIFRAEKSYTVQSGRWYFEFEAVTTGEMRVGWARPELRPDVELGADELAYVFNGHRGQRWHLGSEPFGRPWQPGDVVGCMIDLTENTIIFTLNGEVLMSDSGSETAFREIEIGDGFLPVCSLGPGQVGHLNLGQDVSSLRFFAICGLQEGFEPFAINMQRPVTTWFSKGLPQFEPVPLEHPHYEVSRVDGTVDTPPCLRLTHRTWGSQNSLVEMLFLRLSLPVQFHQHFRCTAGATPLAPPGLQPPAEDEARAAEPDPDYENLRRSAGGWSEAENGKEGTAKEGAPGGTPQAGGEAQPARAENEKDATTEKNKKRGFLFKAKKVAMMTQPPATPTLPRLPHDVVPADNRDDPEIILNTTTYYYSVRVFAGQEPSCVWAGWVTPDYHQHDMSFDLSKVRVVTVTMGDEQGNVHSSLKCSNCYMVWGGDFVSPGQQGRISHTDLVIGCLVDLATGLMTFTANGKESNTFFQVEPNTKLFPAVFVLPTHQNVIQFELGKQKNIMPLSAAMFQSERKNPAPQCPPRLEMQMLMPVSWSRMPNHFLQVETRRAGERLGWAVQCQEPLTMMALHIPEENRCMDILELSERLDLQRFHSHTLRLYRAVCALGNNRVAHALCSHVDQAQLLHALEDAHLPGPLRAGYYDLLISIHLESACRSRRSMLSEYIVPLTPETRAITLFPPGRSTENGHPRHGLPGVGVTTSLRPPHHFSPPCFVAALPAAGAAEAPARLSPAIPLEALRDKALRMLGEAVRDGGQHARDPVGGSVEFQFVPVLKLVSTLLVMGIFGDEDVKQILKMIEPEVFTEEEEEEDEEEEGEEEDEEEKEEDEEETAQEKEDEEKEEEEAAEGEKEEGLEEGLLQMKLPESVKLQMCHLLEYFCDQELQHRVESLAAFAERYVDKLQANQRSRYGLLIKAFSMTAAETARRTREFRSPPQEQINMLLQFKDGTDEEDCPLPEEIRQDLLDFHQDLLAHCGIQLDGEEEEPEEETTLGSRLMSLLEKVRLVKKKEEKPEEERSAEESKPRSLQELVSHMVVRWAQEDFVQSPELVRAMFSLLHRQYDGLGELLRALPRAYTISPSSVEDTMSLLECLGQIRSLLIVQMGPQEENLMIQSIGNIMNNKVFYQHPNLMRALGMHETVMEVMVNVLGGGESKEIRFPKMVTSCCRFLCYFCRISRQNQRSMFDHLSYLLENSGIGLGMQGSTPLDVAAASVIDNNELALALQEQDLEKVVSYLAGCGLQSCPMLVAKGYPDIGWNPCGGERYLDFLRFAVFVNGESVEENANVVVRLLIRKPECFGPALRGEGGSGLLAAIEEAIRISEDPARDGPGIRRDRRREHFGEEPPEENRVHLGHAIMSFYAALIDLLGRCAPEMHLIQAGKGEALRIRAILRSLVPLEDLVGIISLPLQIPTLGKDGALVQPKMSASFVPDHKASMVLFLDRVYGIENQDFLLHVLDVGFLPDMRAAASLDTATFSTTEMALALNRYLCLAVLPLITKCAPLFAGTEHRAIMVDSMLHTVYRLSRGRSLTKAQRDVIEDCLMSLCRYIRPSMLQHLLRRLVFDVPILNEFAKMPLKLLTNHYERCWKYYCLPTGWANFGVTSEEELHLTRKLFWGIFDSLAHKKYDPELYRMAMPCLCAIAGALPPDYVDASYSSKAEKKATVDAEGNFDPRPVETLNVIIPEKLDSFINKFAEYTHEKWAFDKIQNNWSYGENIDEELKTHPMLRPYKTFSEKDKEIYRWPIKESLKAMIAWEWTIEKAREGEEEKTEKKKTRKISQSAQTYDPREGYNPQPPDLSAVTLSRELQAMAEQLAENYHNTWGRKKKQELEAKGGGTHPLLVPYDTLTAKEKARDREKAQELLKFLQMNGYAVTRGLKDMELDSSSIEKRFAFGFLQQLLRWMDISQEFIAHLEAVVSSGRVEKSPHEQEIKFFAKILLPLINQYFTNHCLYFLSTPAKVLGSGGHASNKEKEMITSLFCKLAALVRHRVSLFGTDAPAVVNCLHILARSLDARTVMKSGPEIVKAGLRSFFESASEDIEKMVENLRLGKVSQARTQVKGVGQNLTYTTVALLPVLTTLFQHIAQHQFGDDVILDDVQVSCYRTLCSIYSLGTTKNTYVEKLRPALGECLARLAAAMPVAFLEPQLNEYNACSVYTTKSPRERAILGLPNSVEEMCPDIPVLERLMADIGGLAESGARYTEMPHVIEITLPMLCSYLPRWWERGPEAPPSALPAGAPPPCTAVTSDHLNSLLGNILRIIVNNLGIDEASWMKRLAVFAQPIVSRARPELLQSHFIPTIGRLRKRAGKVVSEEEQLRLEAKAEAQEGELLVRDEFSVLCRDLYALYPLLIRYVDNNRAQWLTEPNPSAEELFRMVGEIFIYWSKSHNFKREEQNFVVQNEINNMSFLTADNKSKMAKAGDIQSGGSDQERTKKKRRGDRYSVQTSLIVATLKKMLPIGLNMCAPTDQDLITLAKTRYALKDTDEEVREFLHNNLHLQGKVEGSPSLRWQMALYRGVPGREEDADDPEKIVRRVQEVSAVLYYLDQTEHPYKSKKAVWHKLLSKQRRRAVVACFRMTPLYNLPTHRACNMFLESYKAAWILTEDHSFEDRMIDDLSKAGEQEEEEEEVEEKKPDPLHQLVLHFSRTALTEKSKLDEDYLYMAYADIMAKSCHLEEGGENGEAEEEVEVSFEEKQMEKQRLLYQQARLHTRGAAEMVLQMISACKGETGAMVSSTLKLGISILNGGNAEVQQKMLDYLKDKKEVGFFQSIQALMQTCSVLDLNAFERQNKAEGLGMVNEDGTVINRQNGEKVMADDEFTQDLFRFLQLLCEGHNNDFQNYLRTQTGNTTTINIIICTVDYLLRLQESISDFYWYYSGKDVIEEQGKRNFSKAMSVAKQVFNSLTEYIQGPCTGNQQSLAHSRLWDAVVGFLHVFAHMMMKLAQDSSQIELLKELLDLQKDMVVMLLSLLEGNVVNGMIARQMVDMLVESSSNVEMILKFFDMFLKLKDIVGSEAFQDYVTDPRGLISKKDFQKAMDSQKQFSGPEIQFLLSCSEADENEMINCEEFANRFQEPARDIGFNVAVLLTNLSEHVPHDPRLHNFLELAESILEYFRPYLGRIEIMGASRRIERIYFEISETNRAQWEMPQVKESKRQFIFDVVNEGGEAEKMELFVSFCEDTIFEMQIAAQISEPEGEPETDEDEGAGAAEAGAEGAEEGAAGLEGTAATAAAGATARVVAAAGRALRGLSYRSLRRRVRRLRRLTAREAATAVAALLWAAVTRAGAAGAGAAAGALGLLWGSLFGGGLVEGAKKVTVTELLAGMPDPTSDEVHGEQPAGPGGDADGEGASEGAGDAAEGAGDEEEAVHEAGPGGADGAVAVTDGGPFRPEGAGGLGDMGDTTPAEPPTPEGSPILKRKLGVDGVEEELPPEPEPEPEPELEPEKADAENGEKEEVPEPTPEPPKKQAPPSPPPKKEEAGGEFWGELEVQRVKFLNYLSRNFYTLRFLALFLAFAINFILLFYKVSDSPPGEDDMEGSAAGDVSGAGSGGSSGWGLGAGEEAEGDEDENMVYYFLEESTGYMEPALRCLSLLHTLVAFLCIIGYNCLKVPLVIFKREKELARKLEFDGLYITEQPEDDDVKGQWDRLVLNTPSFPSNYWDKFVKRKVLDKHGDIYGRERIAELLGMDLATLEITAHNERKPNPPPGLLTWLMSIDVKYQIWKFGVIFTDNSFLYLGWYMVMSLLGHYNNFFFAAHLLDIAMGVKTLRTILSSVTHNGKQLVMTVGLLAVVVYLYTVVAFNFFRKFYNKSEDEDEPDMKCDDMMTCYLFHMYVGVRAGGGIGDEIEDPAGDEYELYRVVFDITFFFFVIVILLAIIQGLIIDAFGELRDQQEQVKEDMETKCFICGIGSDYFDTTPHGFETHTLEEHNLANYMFFLMYLINKDETEHTGQESYVWKMYQERCWDFFPAGDCFRKQYEDQLS	5038	P21817	C	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
259	NM_000540.3(RYR1):c.103T>C (p.Cys35Arg)	132995	CA023838	NM_000540.3:c.103T>C, NC_000019.10:g.38440802T>C, CM000681.2:g.38440802T>C, NC_000019.9:g.38931442T>C, CM000681.1:g.38931442T>C, NC_000019.8:g.43623282T>C, NG_008866.1:g.12103T>C, LRG_766:g.12103T>C, ENST00000355481.8:c.103T>C, ENST00000359596.7:n.103T>C, ENST00000360985.7:c.103T>C, NM_000540.2:c.103T>C, LRG_766t1:c.103T>C, NM_001042723.1:c.103T>C, XM_006723317.1:c.103T>C, XM_006723319.1:c.103T>C, XM_011527204.1:c.103T>C, XM_011527205.1:c.103T>C, XM_006723317.2:c.103T>C, XM_006723319.2:c.103T>C, XM_011527205.2:c.103T>C, NM_001042723.2:c.103T>C, NM_000540.3(RYR1):c.103T>C (p.Cys35Arg)	RYR1	malignant hyperthermia, susceptibility to, 1	MONDO:0007783	Autosomal dominant inheritance	Pathogenic	PS4_Moderate, PM1, PP1_Strong, PP3_Moderate	BA1, BP4, PS3, BS1, BS3	This pathogenicity assessment is relevant only for malignant hyperthermia susceptibility (MHS) inherited in an autosomal dominant pattern. Variants in RYR1 can also cause other myopathies inherited in an autosomal dominant pattern or in an autosomal recessive pattern. Some of these disorders may predispose individuals to malignant hyperthermia. RYR1 variants may also contribute to a malignant hyperthermia reaction in combination with other genetic and non-genetic factors and the clinician needs to consider such factors in making management decisions. This sequence variant predicts a substitution of cysteine with arginine at codon 35 of the RYR1 protein, p.(Cys35Arg). The maximum allele frequency for this variant among the six major gnomAD populations is NFE: 0.000009, a frequency consistent with pathogenicity for MHS. This variant has been reported in three unrelated individuals who have a personal or family history of a malignant hyperthermia reaction and positive in vitro contracture test (IVCT) or caffeine halothane contracture test (CHCT) result (when the proband was unavailable for testing a positive diagnostic test result in a mutation positive relative was counted), PS4_Moderate (PMID:17710899, PMID:20681998, PMID:9066328). Functional studies in HEK293 cells show conflicting data regarding sensitivity to RYR1 agonists, PS3/BS3 were not implemented (PMID:9334205, PMID:26115329). This variant resides in a region of RYR1 considered to be a hotspot for pathogenic variants that contribute to MHS, PM1 (PMID: 21118704). This variant segregates with MHS in 11 individuals, PP1_Strong (PMID:9066328). A REVEL score > 0.85 supports pathogenicity, PP3_Moderate. Criteria implemented: PS4_Moderate, PM1, PP3_Moderate, PP1_Strong. Based on using Bayes to combine criteria this variant is assessed as Pathogenic, (PMID: 29300386).	26115329, 9334205, 26115329, 9334205	Malignant Hyperthermia Susceptibility VCEP	https://clinicalgenome.org/docs/clingen-malignant-hyperthermia-susceptibility-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-for/	2021-03-18	2021-03-31	False	https://erepo.genome.network/evrepo/ui/classification/CA023838/MONDO:0007783/012	8410e5b5-ba69-4c4b-a83f-f2bbb062586d	p.Cys35Arg	Cys	35	Arg	MGDAEGEDEVQFLRTDDEVVLQCSATVLKEQLKLCLAAEGFGNRLCFLEPTSNAQNVPPDLAICCFVLEQSLSVRALQEMLANTVEAGVESSQGGGHRTLLYGHAILLRHAHSRMYLSCLTTSRSMTDKLAFDVGLQEDATGEACWWTMHPASKQRSEGEKVRVGDDIILVSVSSERYLHLSTASGELQVDASFMQTLWNMNPICSRCEEGFVTGGHVLRLFHGHMDECLTISPADSDDQRRLVYYEGGAVCTHARSLWRLEPLRISWSGSHLRWGQPLRVRHVTTGQYLALTEDQGLVVVDASKAHTKATSFCFRISKEKLDVAPKRDVEGMGPPEIKYGESLCFVQHVASGLWLTYAAPDPKALRLGVLKKKAMLHQEGHMDDALSLTRCQQEESQAARMIHSTNGLYNQFIKSLDSFSGKPRGSGPPAGTALPIEGVILSLQDLIIYFEPPSEDLQHEEKQSKLRSLRNRQSLFQEEGMLSMVLNCIDRLNVYTTAAHFAEFAGEEAAESWKEIVNLLYELLASLIRGNRSNCALFSTNLDWLVSKLDRLEASSGILEVLYCVLIESPEVLNIIQENHIKSIISLLDKHGRNHKVLDVLCSLCVCNGVAVRSNQDLITENLLPGRELLLQTNLINYVTSIRPNIFVGRAEGTTQYSKWYFEVMVDEVTPFLTAQATHLRVGWALTEGYTPYPGAGEGWGGNGVGDDLYSYGFDGLHLWTGHVARPVTSPGQHLLAPEDVISCCLDLSVPSISFRINGCPVQGVFESFNLDGLFFPVVSFSAGVKVRFLLGGRHGEFKFLPPPGYAPCHEAVLPRERLHLEPIKEYRREGPRGPHLVGPSRCLSHTDFVPCPVDTVQIVLPPHLERIREKLAENIHELWALTRIEQGWTYGPVRDDNKRLHPCLVDFHSLPEPERNYNLQMSGETLKTLLALGCHVGMADEKAEDNLKKTKLPKTYMMSNGYKPAPLDLSHVRLTPAQTTLVDRLAENGHNVWARDRVGQGWSYSAVQDIPARRNPRLVPYRLLDEATKRSNRDSLCQAVRTLLGYGYNIEPPDQEPSQVENQSRCDRVRIFRAEKSYTVQSGRWYFEFEAVTTGEMRVGWARPELRPDVELGADELAYVFNGHRGQRWHLGSEPFGRPWQPGDVVGCMIDLTENTIIFTLNGEVLMSDSGSETAFREIEIGDGFLPVCSLGPGQVGHLNLGQDVSSLRFFAICGLQEGFEPFAINMQRPVTTWFSKGLPQFEPVPLEHPHYEVSRVDGTVDTPPCLRLTHRTWGSQNSLVEMLFLRLSLPVQFHQHFRCTAGATPLAPPGLQPPAEDEARAAEPDPDYENLRRSAGGWSEAENGKEGTAKEGAPGGTPQAGGEAQPARAENEKDATTEKNKKRGFLFKAKKVAMMTQPPATPTLPRLPHDVVPADNRDDPEIILNTTTYYYSVRVFAGQEPSCVWAGWVTPDYHQHDMSFDLSKVRVVTVTMGDEQGNVHSSLKCSNCYMVWGGDFVSPGQQGRISHTDLVIGCLVDLATGLMTFTANGKESNTFFQVEPNTKLFPAVFVLPTHQNVIQFELGKQKNIMPLSAAMFQSERKNPAPQCPPRLEMQMLMPVSWSRMPNHFLQVETRRAGERLGWAVQCQEPLTMMALHIPEENRCMDILELSERLDLQRFHSHTLRLYRAVCALGNNRVAHALCSHVDQAQLLHALEDAHLPGPLRAGYYDLLISIHLESACRSRRSMLSEYIVPLTPETRAITLFPPGRSTENGHPRHGLPGVGVTTSLRPPHHFSPPCFVAALPAAGAAEAPARLSPAIPLEALRDKALRMLGEAVRDGGQHARDPVGGSVEFQFVPVLKLVSTLLVMGIFGDEDVKQILKMIEPEVFTEEEEEEDEEEEGEEEDEEEKEEDEEETAQEKEDEEKEEEEAAEGEKEEGLEEGLLQMKLPESVKLQMCHLLEYFCDQELQHRVESLAAFAERYVDKLQANQRSRYGLLIKAFSMTAAETARRTREFRSPPQEQINMLLQFKDGTDEEDCPLPEEIRQDLLDFHQDLLAHCGIQLDGEEEEPEEETTLGSRLMSLLEKVRLVKKKEEKPEEERSAEESKPRSLQELVSHMVVRWAQEDFVQSPELVRAMFSLLHRQYDGLGELLRALPRAYTISPSSVEDTMSLLECLGQIRSLLIVQMGPQEENLMIQSIGNIMNNKVFYQHPNLMRALGMHETVMEVMVNVLGGGESKEIRFPKMVTSCCRFLCYFCRISRQNQRSMFDHLSYLLENSGIGLGMQGSTPLDVAAASVIDNNELALALQEQDLEKVVSYLAGCGLQSCPMLVAKGYPDIGWNPCGGERYLDFLRFAVFVNGESVEENANVVVRLLIRKPECFGPALRGEGGSGLLAAIEEAIRISEDPARDGPGIRRDRRREHFGEEPPEENRVHLGHAIMSFYAALIDLLGRCAPEMHLIQAGKGEALRIRAILRSLVPLEDLVGIISLPLQIPTLGKDGALVQPKMSASFVPDHKASMVLFLDRVYGIENQDFLLHVLDVGFLPDMRAAASLDTATFSTTEMALALNRYLCLAVLPLITKCAPLFAGTEHRAIMVDSMLHTVYRLSRGRSLTKAQRDVIEDCLMSLCRYIRPSMLQHLLRRLVFDVPILNEFAKMPLKLLTNHYERCWKYYCLPTGWANFGVTSEEELHLTRKLFWGIFDSLAHKKYDPELYRMAMPCLCAIAGALPPDYVDASYSSKAEKKATVDAEGNFDPRPVETLNVIIPEKLDSFINKFAEYTHEKWAFDKIQNNWSYGENIDEELKTHPMLRPYKTFSEKDKEIYRWPIKESLKAMIAWEWTIEKAREGEEEKTEKKKTRKISQSAQTYDPREGYNPQPPDLSAVTLSRELQAMAEQLAENYHNTWGRKKKQELEAKGGGTHPLLVPYDTLTAKEKARDREKAQELLKFLQMNGYAVTRGLKDMELDSSSIEKRFAFGFLQQLLRWMDISQEFIAHLEAVVSSGRVEKSPHEQEIKFFAKILLPLINQYFTNHCLYFLSTPAKVLGSGGHASNKEKEMITSLFCKLAALVRHRVSLFGTDAPAVVNCLHILARSLDARTVMKSGPEIVKAGLRSFFESASEDIEKMVENLRLGKVSQARTQVKGVGQNLTYTTVALLPVLTTLFQHIAQHQFGDDVILDDVQVSCYRTLCSIYSLGTTKNTYVEKLRPALGECLARLAAAMPVAFLEPQLNEYNACSVYTTKSPRERAILGLPNSVEEMCPDIPVLERLMADIGGLAESGARYTEMPHVIEITLPMLCSYLPRWWERGPEAPPSALPAGAPPPCTAVTSDHLNSLLGNILRIIVNNLGIDEASWMKRLAVFAQPIVSRARPELLQSHFIPTIGRLRKRAGKVVSEEEQLRLEAKAEAQEGELLVRDEFSVLCRDLYALYPLLIRYVDNNRAQWLTEPNPSAEELFRMVGEIFIYWSKSHNFKREEQNFVVQNEINNMSFLTADNKSKMAKAGDIQSGGSDQERTKKKRRGDRYSVQTSLIVATLKKMLPIGLNMCAPTDQDLITLAKTRYALKDTDEEVREFLHNNLHLQGKVEGSPSLRWQMALYRGVPGREEDADDPEKIVRRVQEVSAVLYYLDQTEHPYKSKKAVWHKLLSKQRRRAVVACFRMTPLYNLPTHRACNMFLESYKAAWILTEDHSFEDRMIDDLSKAGEQEEEEEEVEEKKPDPLHQLVLHFSRTALTEKSKLDEDYLYMAYADIMAKSCHLEEGGENGEAEEEVEVSFEEKQMEKQRLLYQQARLHTRGAAEMVLQMISACKGETGAMVSSTLKLGISILNGGNAEVQQKMLDYLKDKKEVGFFQSIQALMQTCSVLDLNAFERQNKAEGLGMVNEDGTVINRQNGEKVMADDEFTQDLFRFLQLLCEGHNNDFQNYLRTQTGNTTTINIIICTVDYLLRLQESISDFYWYYSGKDVIEEQGKRNFSKAMSVAKQVFNSLTEYIQGPCTGNQQSLAHSRLWDAVVGFLHVFAHMMMKLAQDSSQIELLKELLDLQKDMVVMLLSLLEGNVVNGMIARQMVDMLVESSSNVEMILKFFDMFLKLKDIVGSEAFQDYVTDPRGLISKKDFQKAMDSQKQFSGPEIQFLLSCSEADENEMINCEEFANRFQEPARDIGFNVAVLLTNLSEHVPHDPRLHNFLELAESILEYFRPYLGRIEIMGASRRIERIYFEISETNRAQWEMPQVKESKRQFIFDVVNEGGEAEKMELFVSFCEDTIFEMQIAAQISEPEGEPETDEDEGAGAAEAGAEGAEEGAAGLEGTAATAAAGATARVVAAAGRALRGLSYRSLRRRVRRLRRLTAREAATAVAALLWAAVTRAGAAGAGAAAGALGLLWGSLFGGGLVEGAKKVTVTELLAGMPDPTSDEVHGEQPAGPGGDADGEGASEGAGDAAEGAGDEEEAVHEAGPGGADGAVAVTDGGPFRPEGAGGLGDMGDTTPAEPPTPEGSPILKRKLGVDGVEEELPPEPEPEPEPELEPEKADAENGEKEEVPEPTPEPPKKQAPPSPPPKKEEAGGEFWGELEVQRVKFLNYLSRNFYTLRFLALFLAFAINFILLFYKVSDSPPGEDDMEGSAAGDVSGAGSGGSSGWGLGAGEEAEGDEDENMVYYFLEESTGYMEPALRCLSLLHTLVAFLCIIGYNCLKVPLVIFKREKELARKLEFDGLYITEQPEDDDVKGQWDRLVLNTPSFPSNYWDKFVKRKVLDKHGDIYGRERIAELLGMDLATLEITAHNERKPNPPPGLLTWLMSIDVKYQIWKFGVIFTDNSFLYLGWYMVMSLLGHYNNFFFAAHLLDIAMGVKTLRTILSSVTHNGKQLVMTVGLLAVVVYLYTVVAFNFFRKFYNKSEDEDEPDMKCDDMMTCYLFHMYVGVRAGGGIGDEIEDPAGDEYELYRVVFDITFFFFVIVILLAIIQGLIIDAFGELRDQQEQVKEDMETKCFICGIGSDYFDTTPHGFETHTLEEHNLANYMFFLMYLINKDETEHTGQESYVWKMYQERCWDFFPAGDCFRKQYEDQLS	5038	P21817	R	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [34, 118, 1490], 'DISULFID_gain': [], 'DISULFID_loss_score': array([-0.53175586, -0.00461048, -0.00127685]), 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
260	NM_000540.2(RYR1):c.1021G>C (p.Gly341Arg)	132992	CA023828	NM_000540.2:c.1021G>C, NC_000019.10:g.38448712G>C, CM000681.2:g.38448712G>C, NC_000019.9:g.38939352G>C, CM000681.1:g.38939352G>C, NC_000019.8:g.43631192G>C, NG_008866.1:g.20013G>C, LRG_766:g.20013G>C, ENST00000359596.8:c.1021G>C, ENST00000355481.8:c.1021G>C, ENST00000359596.7:n.1021G>C, ENST00000360985.7:c.1021G>C, LRG_766t1:c.1021G>C, NM_001042723.1:c.1021G>C, XM_006723317.1:c.1021G>C, XM_006723319.1:c.1021G>C, XM_011527204.1:c.1018G>C, XM_011527205.1:c.1021G>C, XM_006723317.2:c.1021G>C, XM_006723319.2:c.1021G>C, XM_011527205.2:c.1021G>C, XR_001753735.1:n.1104G>C, NM_000540.3:c.1021G>C, NM_001042723.2:c.1021G>C, NM_000540.3(RYR1):c.1021G>C (p.Gly341Arg), NM_000540.2(RYR1):c.1021G>C (p.Gly341Arg)	RYR1	malignant hyperthermia, susceptibility to, 1	MONDO:0007783	Autosomal dominant inheritance	Pathogenic	PP1_Moderate, PS4_Moderate, PS1, PM1_Supporting, PS3_Moderate, PP3_Moderate	BA1, BS1	This pathogenicity assessment is relevant only for malignant hyperthermia susceptibility (MHS) inherited in an autosomal dominant pattern. Variants in RYR1 can also cause other myopathies inherited in an autosomal dominant pattern or in an autosomal recessive pattern. Some of these disorders may predispose individuals to malignant hyperthermia. RYR1 variants may also contribute to a malignant hyperthermia reaction in combination with other genetic and non-genetic factors and the clinician needs to consider such factors in making management decisions. This sequence variant predicts a substitution of Glycine with Arginine at codon 341 of the RYR1 protein, p.(Gly341Arg), c.1021G>C. This variant was not present in a large population database (gnomAD) at the time this variant was interpreted. This variant has been reported in five unrelated individuals who have a personal or family history of a malignant hyperthermia reaction, four of these individuals had a positive in vitro contracture test (IVCT) or caffeine halothane contracture test (CHCT) result (if the proband was unavailable for testing, a positive diagnostic test result in a mutation-positive relative was counted), PS4_Moderate (PMID:12059893, PMID:16163667, PMID:30236257 ). This variant segregates with MHS in five individuals/families, PP1_Moderate (PMID:12059893, PMID:12411788). Functional studies in HEK293 cells show an increased sensitivity to RYR1 agonists, PS3_Moderate (PMID:9334205). This variant resides in a region of RYR1 considered to be a hotspot for pathogenic variants that contribute to MHS, use PM1_Supporting to avoid overweighting with PS1 (PMID: 21118704). Another variant has been assessed as pathogenic occurs at this codon, p.(Gly341Arg, c.1021G>A), PS1. This variant segregates with MHS in two individuals (PMID:12059893). A REVEL score >0.85 (0.876) supports a pathogenic status for this variant, PP3_Moderate. This variant has been classified as Pathogenic. Criteria implemented: PS4_Moderate, PS3_Moderate, PM1_Supporting, PS1, PP3_Moderate. 		Malignant Hyperthermia Susceptibility VCEP	https://clinicalgenome.org/docs/clingen-malignant-hyperthermia-susceptibility-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-for/	2022-03-14	2022-03-14	False	https://erepo.genome.network/evrepo/ui/classification/CA023828/MONDO:0007783/012	abeb9b28-e15a-48a6-8e72-e677bdac5968	p.Gly341Arg	Gly	341	Arg	MGDAEGEDEVQFLRTDDEVVLQCSATVLKEQLKLCLAAEGFGNRLCFLEPTSNAQNVPPDLAICCFVLEQSLSVRALQEMLANTVEAGVESSQGGGHRTLLYGHAILLRHAHSRMYLSCLTTSRSMTDKLAFDVGLQEDATGEACWWTMHPASKQRSEGEKVRVGDDIILVSVSSERYLHLSTASGELQVDASFMQTLWNMNPICSRCEEGFVTGGHVLRLFHGHMDECLTISPADSDDQRRLVYYEGGAVCTHARSLWRLEPLRISWSGSHLRWGQPLRVRHVTTGQYLALTEDQGLVVVDASKAHTKATSFCFRISKEKLDVAPKRDVEGMGPPEIKYGESLCFVQHVASGLWLTYAAPDPKALRLGVLKKKAMLHQEGHMDDALSLTRCQQEESQAARMIHSTNGLYNQFIKSLDSFSGKPRGSGPPAGTALPIEGVILSLQDLIIYFEPPSEDLQHEEKQSKLRSLRNRQSLFQEEGMLSMVLNCIDRLNVYTTAAHFAEFAGEEAAESWKEIVNLLYELLASLIRGNRSNCALFSTNLDWLVSKLDRLEASSGILEVLYCVLIESPEVLNIIQENHIKSIISLLDKHGRNHKVLDVLCSLCVCNGVAVRSNQDLITENLLPGRELLLQTNLINYVTSIRPNIFVGRAEGTTQYSKWYFEVMVDEVTPFLTAQATHLRVGWALTEGYTPYPGAGEGWGGNGVGDDLYSYGFDGLHLWTGHVARPVTSPGQHLLAPEDVISCCLDLSVPSISFRINGCPVQGVFESFNLDGLFFPVVSFSAGVKVRFLLGGRHGEFKFLPPPGYAPCHEAVLPRERLHLEPIKEYRREGPRGPHLVGPSRCLSHTDFVPCPVDTVQIVLPPHLERIREKLAENIHELWALTRIEQGWTYGPVRDDNKRLHPCLVDFHSLPEPERNYNLQMSGETLKTLLALGCHVGMADEKAEDNLKKTKLPKTYMMSNGYKPAPLDLSHVRLTPAQTTLVDRLAENGHNVWARDRVGQGWSYSAVQDIPARRNPRLVPYRLLDEATKRSNRDSLCQAVRTLLGYGYNIEPPDQEPSQVENQSRCDRVRIFRAEKSYTVQSGRWYFEFEAVTTGEMRVGWARPELRPDVELGADELAYVFNGHRGQRWHLGSEPFGRPWQPGDVVGCMIDLTENTIIFTLNGEVLMSDSGSETAFREIEIGDGFLPVCSLGPGQVGHLNLGQDVSSLRFFAICGLQEGFEPFAINMQRPVTTWFSKGLPQFEPVPLEHPHYEVSRVDGTVDTPPCLRLTHRTWGSQNSLVEMLFLRLSLPVQFHQHFRCTAGATPLAPPGLQPPAEDEARAAEPDPDYENLRRSAGGWSEAENGKEGTAKEGAPGGTPQAGGEAQPARAENEKDATTEKNKKRGFLFKAKKVAMMTQPPATPTLPRLPHDVVPADNRDDPEIILNTTTYYYSVRVFAGQEPSCVWAGWVTPDYHQHDMSFDLSKVRVVTVTMGDEQGNVHSSLKCSNCYMVWGGDFVSPGQQGRISHTDLVIGCLVDLATGLMTFTANGKESNTFFQVEPNTKLFPAVFVLPTHQNVIQFELGKQKNIMPLSAAMFQSERKNPAPQCPPRLEMQMLMPVSWSRMPNHFLQVETRRAGERLGWAVQCQEPLTMMALHIPEENRCMDILELSERLDLQRFHSHTLRLYRAVCALGNNRVAHALCSHVDQAQLLHALEDAHLPGPLRAGYYDLLISIHLESACRSRRSMLSEYIVPLTPETRAITLFPPGRSTENGHPRHGLPGVGVTTSLRPPHHFSPPCFVAALPAAGAAEAPARLSPAIPLEALRDKALRMLGEAVRDGGQHARDPVGGSVEFQFVPVLKLVSTLLVMGIFGDEDVKQILKMIEPEVFTEEEEEEDEEEEGEEEDEEEKEEDEEETAQEKEDEEKEEEEAAEGEKEEGLEEGLLQMKLPESVKLQMCHLLEYFCDQELQHRVESLAAFAERYVDKLQANQRSRYGLLIKAFSMTAAETARRTREFRSPPQEQINMLLQFKDGTDEEDCPLPEEIRQDLLDFHQDLLAHCGIQLDGEEEEPEEETTLGSRLMSLLEKVRLVKKKEEKPEEERSAEESKPRSLQELVSHMVVRWAQEDFVQSPELVRAMFSLLHRQYDGLGELLRALPRAYTISPSSVEDTMSLLECLGQIRSLLIVQMGPQEENLMIQSIGNIMNNKVFYQHPNLMRALGMHETVMEVMVNVLGGGESKEIRFPKMVTSCCRFLCYFCRISRQNQRSMFDHLSYLLENSGIGLGMQGSTPLDVAAASVIDNNELALALQEQDLEKVVSYLAGCGLQSCPMLVAKGYPDIGWNPCGGERYLDFLRFAVFVNGESVEENANVVVRLLIRKPECFGPALRGEGGSGLLAAIEEAIRISEDPARDGPGIRRDRRREHFGEEPPEENRVHLGHAIMSFYAALIDLLGRCAPEMHLIQAGKGEALRIRAILRSLVPLEDLVGIISLPLQIPTLGKDGALVQPKMSASFVPDHKASMVLFLDRVYGIENQDFLLHVLDVGFLPDMRAAASLDTATFSTTEMALALNRYLCLAVLPLITKCAPLFAGTEHRAIMVDSMLHTVYRLSRGRSLTKAQRDVIEDCLMSLCRYIRPSMLQHLLRRLVFDVPILNEFAKMPLKLLTNHYERCWKYYCLPTGWANFGVTSEEELHLTRKLFWGIFDSLAHKKYDPELYRMAMPCLCAIAGALPPDYVDASYSSKAEKKATVDAEGNFDPRPVETLNVIIPEKLDSFINKFAEYTHEKWAFDKIQNNWSYGENIDEELKTHPMLRPYKTFSEKDKEIYRWPIKESLKAMIAWEWTIEKAREGEEEKTEKKKTRKISQSAQTYDPREGYNPQPPDLSAVTLSRELQAMAEQLAENYHNTWGRKKKQELEAKGGGTHPLLVPYDTLTAKEKARDREKAQELLKFLQMNGYAVTRGLKDMELDSSSIEKRFAFGFLQQLLRWMDISQEFIAHLEAVVSSGRVEKSPHEQEIKFFAKILLPLINQYFTNHCLYFLSTPAKVLGSGGHASNKEKEMITSLFCKLAALVRHRVSLFGTDAPAVVNCLHILARSLDARTVMKSGPEIVKAGLRSFFESASEDIEKMVENLRLGKVSQARTQVKGVGQNLTYTTVALLPVLTTLFQHIAQHQFGDDVILDDVQVSCYRTLCSIYSLGTTKNTYVEKLRPALGECLARLAAAMPVAFLEPQLNEYNACSVYTTKSPRERAILGLPNSVEEMCPDIPVLERLMADIGGLAESGARYTEMPHVIEITLPMLCSYLPRWWERGPEAPPSALPAGAPPPCTAVTSDHLNSLLGNILRIIVNNLGIDEASWMKRLAVFAQPIVSRARPELLQSHFIPTIGRLRKRAGKVVSEEEQLRLEAKAEAQEGELLVRDEFSVLCRDLYALYPLLIRYVDNNRAQWLTEPNPSAEELFRMVGEIFIYWSKSHNFKREEQNFVVQNEINNMSFLTADNKSKMAKAGDIQSGGSDQERTKKKRRGDRYSVQTSLIVATLKKMLPIGLNMCAPTDQDLITLAKTRYALKDTDEEVREFLHNNLHLQGKVEGSPSLRWQMALYRGVPGREEDADDPEKIVRRVQEVSAVLYYLDQTEHPYKSKKAVWHKLLSKQRRRAVVACFRMTPLYNLPTHRACNMFLESYKAAWILTEDHSFEDRMIDDLSKAGEQEEEEEEVEEKKPDPLHQLVLHFSRTALTEKSKLDEDYLYMAYADIMAKSCHLEEGGENGEAEEEVEVSFEEKQMEKQRLLYQQARLHTRGAAEMVLQMISACKGETGAMVSSTLKLGISILNGGNAEVQQKMLDYLKDKKEVGFFQSIQALMQTCSVLDLNAFERQNKAEGLGMVNEDGTVINRQNGEKVMADDEFTQDLFRFLQLLCEGHNNDFQNYLRTQTGNTTTINIIICTVDYLLRLQESISDFYWYYSGKDVIEEQGKRNFSKAMSVAKQVFNSLTEYIQGPCTGNQQSLAHSRLWDAVVGFLHVFAHMMMKLAQDSSQIELLKELLDLQKDMVVMLLSLLEGNVVNGMIARQMVDMLVESSSNVEMILKFFDMFLKLKDIVGSEAFQDYVTDPRGLISKKDFQKAMDSQKQFSGPEIQFLLSCSEADENEMINCEEFANRFQEPARDIGFNVAVLLTNLSEHVPHDPRLHNFLELAESILEYFRPYLGRIEIMGASRRIERIYFEISETNRAQWEMPQVKESKRQFIFDVVNEGGEAEKMELFVSFCEDTIFEMQIAAQISEPEGEPETDEDEGAGAAEAGAEGAEEGAAGLEGTAATAAAGATARVVAAAGRALRGLSYRSLRRRVRRLRRLTAREAATAVAALLWAAVTRAGAAGAGAAAGALGLLWGSLFGGGLVEGAKKVTVTELLAGMPDPTSDEVHGEQPAGPGGDADGEGASEGAGDAAEGAGDEEEAVHEAGPGGADGAVAVTDGGPFRPEGAGGLGDMGDTTPAEPPTPEGSPILKRKLGVDGVEEELPPEPEPEPEPELEPEKADAENGEKEEVPEPTPEPPKKQAPPSPPPKKEEAGGEFWGELEVQRVKFLNYLSRNFYTLRFLALFLAFAINFILLFYKVSDSPPGEDDMEGSAAGDVSGAGSGGSSGWGLGAGEEAEGDEDENMVYYFLEESTGYMEPALRCLSLLHTLVAFLCIIGYNCLKVPLVIFKREKELARKLEFDGLYITEQPEDDDVKGQWDRLVLNTPSFPSNYWDKFVKRKVLDKHGDIYGRERIAELLGMDLATLEITAHNERKPNPPPGLLTWLMSIDVKYQIWKFGVIFTDNSFLYLGWYMVMSLLGHYNNFFFAAHLLDIAMGVKTLRTILSSVTHNGKQLVMTVGLLAVVVYLYTVVAFNFFRKFYNKSEDEDEPDMKCDDMMTCYLFHMYVGVRAGGGIGDEIEDPAGDEYELYRVVFDITFFFFVIVILLAIIQGLIIDAFGELRDQQEQVKEDMETKCFICGIGSDYFDTTPHGFETHTLEEHNLANYMFFLMYLINKDETEHTGQESYVWKMYQERCWDFFPAGDCFRKQYEDQLS	5038	P21817	R	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
261	NM_000540.2(RYR1):c.488G>T (p.Arg163Leu)	133137	CA024467	NM_000540.2:c.488G>T, NC_000019.10:g.38444212G>T, CM000681.2:g.38444212G>T, NC_000019.9:g.38934852G>T, CM000681.1:g.38934852G>T, NC_000019.8:g.43626692G>T, NG_008866.1:g.15513G>T, LRG_766:g.15513G>T, ENST00000599547.6:n.488G>T, ENST00000359596.8:c.488G>T, ENST00000355481.8:c.488G>T, ENST00000359596.7:n.488G>T, ENST00000360985.7:c.488G>T, LRG_766t1:c.488G>T, NM_001042723.1:c.488G>T, XM_006723317.1:c.488G>T, XM_006723319.1:c.488G>T, XM_011527204.1:c.488G>T, XM_011527205.1:c.488G>T, XM_006723317.2:c.488G>T, XM_006723319.2:c.488G>T, XM_011527205.2:c.488G>T, XR_001753735.1:n.571G>T, NM_000540.3:c.488G>T, NM_001042723.2:c.488G>T, NM_000540.3(RYR1):c.488G>T (p.Arg163Leu), NM_000540.2(RYR1):c.488G>T (p.Arg163Leu)	RYR1	malignant hyperthermia, susceptibility to, 1	MONDO:0007783	Autosomal dominant inheritance	Pathogenic	PP1_Moderate, PS4_Moderate, PS3_Moderate, PM1, PP3_Moderate	BA1, BS3, BS1, PM5	This pathogenicity assessment is relevant only for malignant hyperthermia susceptibility (MHS) inherited in an autosomal dominant pattern. Variants in RYR1 can also cause other myopathies inherited in an autosomal dominant pattern or in an autosomal recessive pattern. Some of these disorders may predispose individuals to malignant hyperthermia. RYR1 variants may also contribute to a malignant hyperthermia reaction in combination with other genetic and non-genetic factors and the clinician needs to consider such factors in making management decisions.This sequence variant predicts a substitution of arginine with leucine at codon 163 of the RYR1 protein p.(Arg163Leu). This variant is absent from a large population databases (gnomAD). This variant has been reported in three unrelated individuals who have a personal or family history of a malignant hyperthermia reaction, two of these individuals had a positive in vitro contracture test (IVCT) or caffeine halothane contracture test (CHCT) result (when the proband was unavailable for testing a positive diagnostic test result in a mutation positive relative was counted), PS4_Moderate (PMID:30236257, PMID:16163667). This variant segregates with MHS in five individuals, PP1_Moderate (PMID:35718563). Functional studies in HEK293 cells show an increased sensitivity to RYR1 agonists, PS3_Moderate (PMID:16163667, PMID:26115329). This variant resides in a region of RYR1 considered to be a hotspot for pathogenic variants that contribute to MHS, PM1 (PMID:21118704). Another variant assessed as pathogenic occurs at this codon, p.(Arg163Cys), however PM5 was not applied as Arg→Cys is predicted to be more disruptive based on a higher Grantham score as compared to Arg→Leu. A REVEL score > 0.85 supports pathogenicity, PP3_Moderate. Based on using Bayes to combine criteria this variant is assessed as Pathogenic, (PMID:29300386). Criteria implemented: PS4_Moderate, PS3_Moderate, PM1, PP1_Moderate, PP3_Moderate.	26115329, 16163667	Malignant Hyperthermia Susceptibility VCEP	https://clinicalgenome.org/docs/clingen-malignant-hyperthermia-susceptibility-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-for/	2023-05-22	2023-05-22	False	https://erepo.genome.network/evrepo/ui/classification/CA024467/MONDO:0007783/012	d3963666-0d28-46a5-88d3-0f7a9f6005f6	p.Arg163Leu	Arg	163	Leu	MGDAEGEDEVQFLRTDDEVVLQCSATVLKEQLKLCLAAEGFGNRLCFLEPTSNAQNVPPDLAICCFVLEQSLSVRALQEMLANTVEAGVESSQGGGHRTLLYGHAILLRHAHSRMYLSCLTTSRSMTDKLAFDVGLQEDATGEACWWTMHPASKQRSEGEKVRVGDDIILVSVSSERYLHLSTASGELQVDASFMQTLWNMNPICSRCEEGFVTGGHVLRLFHGHMDECLTISPADSDDQRRLVYYEGGAVCTHARSLWRLEPLRISWSGSHLRWGQPLRVRHVTTGQYLALTEDQGLVVVDASKAHTKATSFCFRISKEKLDVAPKRDVEGMGPPEIKYGESLCFVQHVASGLWLTYAAPDPKALRLGVLKKKAMLHQEGHMDDALSLTRCQQEESQAARMIHSTNGLYNQFIKSLDSFSGKPRGSGPPAGTALPIEGVILSLQDLIIYFEPPSEDLQHEEKQSKLRSLRNRQSLFQEEGMLSMVLNCIDRLNVYTTAAHFAEFAGEEAAESWKEIVNLLYELLASLIRGNRSNCALFSTNLDWLVSKLDRLEASSGILEVLYCVLIESPEVLNIIQENHIKSIISLLDKHGRNHKVLDVLCSLCVCNGVAVRSNQDLITENLLPGRELLLQTNLINYVTSIRPNIFVGRAEGTTQYSKWYFEVMVDEVTPFLTAQATHLRVGWALTEGYTPYPGAGEGWGGNGVGDDLYSYGFDGLHLWTGHVARPVTSPGQHLLAPEDVISCCLDLSVPSISFRINGCPVQGVFESFNLDGLFFPVVSFSAGVKVRFLLGGRHGEFKFLPPPGYAPCHEAVLPRERLHLEPIKEYRREGPRGPHLVGPSRCLSHTDFVPCPVDTVQIVLPPHLERIREKLAENIHELWALTRIEQGWTYGPVRDDNKRLHPCLVDFHSLPEPERNYNLQMSGETLKTLLALGCHVGMADEKAEDNLKKTKLPKTYMMSNGYKPAPLDLSHVRLTPAQTTLVDRLAENGHNVWARDRVGQGWSYSAVQDIPARRNPRLVPYRLLDEATKRSNRDSLCQAVRTLLGYGYNIEPPDQEPSQVENQSRCDRVRIFRAEKSYTVQSGRWYFEFEAVTTGEMRVGWARPELRPDVELGADELAYVFNGHRGQRWHLGSEPFGRPWQPGDVVGCMIDLTENTIIFTLNGEVLMSDSGSETAFREIEIGDGFLPVCSLGPGQVGHLNLGQDVSSLRFFAICGLQEGFEPFAINMQRPVTTWFSKGLPQFEPVPLEHPHYEVSRVDGTVDTPPCLRLTHRTWGSQNSLVEMLFLRLSLPVQFHQHFRCTAGATPLAPPGLQPPAEDEARAAEPDPDYENLRRSAGGWSEAENGKEGTAKEGAPGGTPQAGGEAQPARAENEKDATTEKNKKRGFLFKAKKVAMMTQPPATPTLPRLPHDVVPADNRDDPEIILNTTTYYYSVRVFAGQEPSCVWAGWVTPDYHQHDMSFDLSKVRVVTVTMGDEQGNVHSSLKCSNCYMVWGGDFVSPGQQGRISHTDLVIGCLVDLATGLMTFTANGKESNTFFQVEPNTKLFPAVFVLPTHQNVIQFELGKQKNIMPLSAAMFQSERKNPAPQCPPRLEMQMLMPVSWSRMPNHFLQVETRRAGERLGWAVQCQEPLTMMALHIPEENRCMDILELSERLDLQRFHSHTLRLYRAVCALGNNRVAHALCSHVDQAQLLHALEDAHLPGPLRAGYYDLLISIHLESACRSRRSMLSEYIVPLTPETRAITLFPPGRSTENGHPRHGLPGVGVTTSLRPPHHFSPPCFVAALPAAGAAEAPARLSPAIPLEALRDKALRMLGEAVRDGGQHARDPVGGSVEFQFVPVLKLVSTLLVMGIFGDEDVKQILKMIEPEVFTEEEEEEDEEEEGEEEDEEEKEEDEEETAQEKEDEEKEEEEAAEGEKEEGLEEGLLQMKLPESVKLQMCHLLEYFCDQELQHRVESLAAFAERYVDKLQANQRSRYGLLIKAFSMTAAETARRTREFRSPPQEQINMLLQFKDGTDEEDCPLPEEIRQDLLDFHQDLLAHCGIQLDGEEEEPEEETTLGSRLMSLLEKVRLVKKKEEKPEEERSAEESKPRSLQELVSHMVVRWAQEDFVQSPELVRAMFSLLHRQYDGLGELLRALPRAYTISPSSVEDTMSLLECLGQIRSLLIVQMGPQEENLMIQSIGNIMNNKVFYQHPNLMRALGMHETVMEVMVNVLGGGESKEIRFPKMVTSCCRFLCYFCRISRQNQRSMFDHLSYLLENSGIGLGMQGSTPLDVAAASVIDNNELALALQEQDLEKVVSYLAGCGLQSCPMLVAKGYPDIGWNPCGGERYLDFLRFAVFVNGESVEENANVVVRLLIRKPECFGPALRGEGGSGLLAAIEEAIRISEDPARDGPGIRRDRRREHFGEEPPEENRVHLGHAIMSFYAALIDLLGRCAPEMHLIQAGKGEALRIRAILRSLVPLEDLVGIISLPLQIPTLGKDGALVQPKMSASFVPDHKASMVLFLDRVYGIENQDFLLHVLDVGFLPDMRAAASLDTATFSTTEMALALNRYLCLAVLPLITKCAPLFAGTEHRAIMVDSMLHTVYRLSRGRSLTKAQRDVIEDCLMSLCRYIRPSMLQHLLRRLVFDVPILNEFAKMPLKLLTNHYERCWKYYCLPTGWANFGVTSEEELHLTRKLFWGIFDSLAHKKYDPELYRMAMPCLCAIAGALPPDYVDASYSSKAEKKATVDAEGNFDPRPVETLNVIIPEKLDSFINKFAEYTHEKWAFDKIQNNWSYGENIDEELKTHPMLRPYKTFSEKDKEIYRWPIKESLKAMIAWEWTIEKAREGEEEKTEKKKTRKISQSAQTYDPREGYNPQPPDLSAVTLSRELQAMAEQLAENYHNTWGRKKKQELEAKGGGTHPLLVPYDTLTAKEKARDREKAQELLKFLQMNGYAVTRGLKDMELDSSSIEKRFAFGFLQQLLRWMDISQEFIAHLEAVVSSGRVEKSPHEQEIKFFAKILLPLINQYFTNHCLYFLSTPAKVLGSGGHASNKEKEMITSLFCKLAALVRHRVSLFGTDAPAVVNCLHILARSLDARTVMKSGPEIVKAGLRSFFESASEDIEKMVENLRLGKVSQARTQVKGVGQNLTYTTVALLPVLTTLFQHIAQHQFGDDVILDDVQVSCYRTLCSIYSLGTTKNTYVEKLRPALGECLARLAAAMPVAFLEPQLNEYNACSVYTTKSPRERAILGLPNSVEEMCPDIPVLERLMADIGGLAESGARYTEMPHVIEITLPMLCSYLPRWWERGPEAPPSALPAGAPPPCTAVTSDHLNSLLGNILRIIVNNLGIDEASWMKRLAVFAQPIVSRARPELLQSHFIPTIGRLRKRAGKVVSEEEQLRLEAKAEAQEGELLVRDEFSVLCRDLYALYPLLIRYVDNNRAQWLTEPNPSAEELFRMVGEIFIYWSKSHNFKREEQNFVVQNEINNMSFLTADNKSKMAKAGDIQSGGSDQERTKKKRRGDRYSVQTSLIVATLKKMLPIGLNMCAPTDQDLITLAKTRYALKDTDEEVREFLHNNLHLQGKVEGSPSLRWQMALYRGVPGREEDADDPEKIVRRVQEVSAVLYYLDQTEHPYKSKKAVWHKLLSKQRRRAVVACFRMTPLYNLPTHRACNMFLESYKAAWILTEDHSFEDRMIDDLSKAGEQEEEEEEVEEKKPDPLHQLVLHFSRTALTEKSKLDEDYLYMAYADIMAKSCHLEEGGENGEAEEEVEVSFEEKQMEKQRLLYQQARLHTRGAAEMVLQMISACKGETGAMVSSTLKLGISILNGGNAEVQQKMLDYLKDKKEVGFFQSIQALMQTCSVLDLNAFERQNKAEGLGMVNEDGTVINRQNGEKVMADDEFTQDLFRFLQLLCEGHNNDFQNYLRTQTGNTTTINIIICTVDYLLRLQESISDFYWYYSGKDVIEEQGKRNFSKAMSVAKQVFNSLTEYIQGPCTGNQQSLAHSRLWDAVVGFLHVFAHMMMKLAQDSSQIELLKELLDLQKDMVVMLLSLLEGNVVNGMIARQMVDMLVESSSNVEMILKFFDMFLKLKDIVGSEAFQDYVTDPRGLISKKDFQKAMDSQKQFSGPEIQFLLSCSEADENEMINCEEFANRFQEPARDIGFNVAVLLTNLSEHVPHDPRLHNFLELAESILEYFRPYLGRIEIMGASRRIERIYFEISETNRAQWEMPQVKESKRQFIFDVVNEGGEAEKMELFVSFCEDTIFEMQIAAQISEPEGEPETDEDEGAGAAEAGAEGAEEGAAGLEGTAATAAAGATARVVAAAGRALRGLSYRSLRRRVRRLRRLTAREAATAVAALLWAAVTRAGAAGAGAAAGALGLLWGSLFGGGLVEGAKKVTVTELLAGMPDPTSDEVHGEQPAGPGGDADGEGASEGAGDAAEGAGDEEEAVHEAGPGGADGAVAVTDGGPFRPEGAGGLGDMGDTTPAEPPTPEGSPILKRKLGVDGVEEELPPEPEPEPEPELEPEKADAENGEKEEVPEPTPEPPKKQAPPSPPPKKEEAGGEFWGELEVQRVKFLNYLSRNFYTLRFLALFLAFAINFILLFYKVSDSPPGEDDMEGSAAGDVSGAGSGGSSGWGLGAGEEAEGDEDENMVYYFLEESTGYMEPALRCLSLLHTLVAFLCIIGYNCLKVPLVIFKREKELARKLEFDGLYITEQPEDDDVKGQWDRLVLNTPSFPSNYWDKFVKRKVLDKHGDIYGRERIAELLGMDLATLEITAHNERKPNPPPGLLTWLMSIDVKYQIWKFGVIFTDNSFLYLGWYMVMSLLGHYNNFFFAAHLLDIAMGVKTLRTILSSVTHNGKQLVMTVGLLAVVVYLYTVVAFNFFRKFYNKSEDEDEPDMKCDDMMTCYLFHMYVGVRAGGGIGDEIEDPAGDEYELYRVVFDITFFFFVIVILLAIIQGLIIDAFGELRDQQEQVKEDMETKCFICGIGSDYFDTTPHGFETHTLEEHNLANYMFFLMYLINKDETEHTGQESYVWKMYQERCWDFFPAGDCFRKQYEDQLS	5038	P21817	L	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [118], 'DISULFID_gain': [], 'DISULFID_loss_score': array([-0.00434494]), 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
262	NM_000540.3(RYR1):c.6961A>G (p.Ile2321Val)	133173	CA024659	NM_000540.3:c.6961A>G, NC_000019.10:g.38499177A>G, CM000681.2:g.38499177A>G, NC_000019.9:g.38989817A>G, CM000681.1:g.38989817A>G, NC_000019.8:g.43681657A>G, NG_008866.1:g.70478A>G, LRG_766:g.70478A>G, ENST00000355481.8:c.6961A>G, ENST00000359596.7:n.6961A>G, ENST00000360985.7:c.6958A>G, NM_000540.2:c.6961A>G, LRG_766t1:c.6961A>G, NM_001042723.1:c.6961A>G, XM_006723317.1:c.6961A>G, XM_006723319.1:c.6961A>G, XM_011527204.1:c.6958A>G, XM_011527205.1:c.6961A>G, XM_006723317.2:c.6961A>G, XM_006723319.2:c.6961A>G, XM_011527205.2:c.6961A>G, NM_001042723.2:c.6961A>G, NM_000540.3(RYR1):c.6961A>G (p.Ile2321Val)	RYR1	malignant hyperthermia, susceptibility to, 1	MONDO:0007783	Autosomal dominant inheritance	Benign	BS2, BS3_Supporting, BS1, PM1	PP3, BA1, BP4, PS4, PS3	This pathogenicity assessment is relevant only for malignant hyperthermia susceptibility (MHS) inherited in an autosomal dominant pattern. Variants in RYR1 can also cause other myopathies inherited in an autosomal dominant pattern or in an autosomal recessive pattern. Some of these disorders may predispose individuals to malignant hyperthermia. RYR1 variants may also contribute to a malignant hyperthermia reaction in combination with other genetic and non-genetic factors and the clinician needs to consider such factors in making management decisions.This sequence variant predicts a substitution of isoleucine with valine at codon 2321 of the RYR1 protein p.(Ile2321Val). The maximum allele frequency for this variant among the six major gnomAD populations is NFE: 0.00081, this is considered to be more common than expected for a pathogenic variant causing autosomal dominant MHS, BS1. This variant has been reported in four unrelated individuals who have a personal or family history of a malignant hyperthermia reaction, all of these individuals had a positive in vitro contracture test (IVCT) or caffeine halothane contracture test (CHCT) result (when the proband was unavailable for testing a positive diagnostic test result in a mutation positive relative was counted) (PMID:30236257; PMID:23558838). However, the high MAF in the NFE population in gnomAD precludes the use of PS4. This variant has been identified in families with genotype positive/ phenotype negative individuals (IVCT) supporting a benign status, BS2 (PMID:30236257, personal communications). Variant did not show increased sensitivity to RYR1 agonists in HEK293 assay (personal communication), BS3_Supporting. This variant resides in a region of RYR1 considered to be a hotspot for pathogenic variants that contribute to MHS, PM1 (PMID: 21118704). A REVEL score of 0.712 does not support pathogenic or a benign status. This variant has been classified as Benign. Criteria implemented: BS1, BS2, BS3_Supporting, PM1.		Malignant Hyperthermia Susceptibility VCEP	https://clinicalgenome.org/docs/clingen-malignant-hyperthermia-susceptibility-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-for/	2021-03-18	2021-03-31	False	https://erepo.genome.network/evrepo/ui/classification/CA024659/MONDO:0007783/012	0edf33d7-7e9e-41a8-988b-c2f21bde9e8a	p.Ile2321Val	Ile	2321	Val	MGDAEGEDEVQFLRTDDEVVLQCSATVLKEQLKLCLAAEGFGNRLCFLEPTSNAQNVPPDLAICCFVLEQSLSVRALQEMLANTVEAGVESSQGGGHRTLLYGHAILLRHAHSRMYLSCLTTSRSMTDKLAFDVGLQEDATGEACWWTMHPASKQRSEGEKVRVGDDIILVSVSSERYLHLSTASGELQVDASFMQTLWNMNPICSRCEEGFVTGGHVLRLFHGHMDECLTISPADSDDQRRLVYYEGGAVCTHARSLWRLEPLRISWSGSHLRWGQPLRVRHVTTGQYLALTEDQGLVVVDASKAHTKATSFCFRISKEKLDVAPKRDVEGMGPPEIKYGESLCFVQHVASGLWLTYAAPDPKALRLGVLKKKAMLHQEGHMDDALSLTRCQQEESQAARMIHSTNGLYNQFIKSLDSFSGKPRGSGPPAGTALPIEGVILSLQDLIIYFEPPSEDLQHEEKQSKLRSLRNRQSLFQEEGMLSMVLNCIDRLNVYTTAAHFAEFAGEEAAESWKEIVNLLYELLASLIRGNRSNCALFSTNLDWLVSKLDRLEASSGILEVLYCVLIESPEVLNIIQENHIKSIISLLDKHGRNHKVLDVLCSLCVCNGVAVRSNQDLITENLLPGRELLLQTNLINYVTSIRPNIFVGRAEGTTQYSKWYFEVMVDEVTPFLTAQATHLRVGWALTEGYTPYPGAGEGWGGNGVGDDLYSYGFDGLHLWTGHVARPVTSPGQHLLAPEDVISCCLDLSVPSISFRINGCPVQGVFESFNLDGLFFPVVSFSAGVKVRFLLGGRHGEFKFLPPPGYAPCHEAVLPRERLHLEPIKEYRREGPRGPHLVGPSRCLSHTDFVPCPVDTVQIVLPPHLERIREKLAENIHELWALTRIEQGWTYGPVRDDNKRLHPCLVDFHSLPEPERNYNLQMSGETLKTLLALGCHVGMADEKAEDNLKKTKLPKTYMMSNGYKPAPLDLSHVRLTPAQTTLVDRLAENGHNVWARDRVGQGWSYSAVQDIPARRNPRLVPYRLLDEATKRSNRDSLCQAVRTLLGYGYNIEPPDQEPSQVENQSRCDRVRIFRAEKSYTVQSGRWYFEFEAVTTGEMRVGWARPELRPDVELGADELAYVFNGHRGQRWHLGSEPFGRPWQPGDVVGCMIDLTENTIIFTLNGEVLMSDSGSETAFREIEIGDGFLPVCSLGPGQVGHLNLGQDVSSLRFFAICGLQEGFEPFAINMQRPVTTWFSKGLPQFEPVPLEHPHYEVSRVDGTVDTPPCLRLTHRTWGSQNSLVEMLFLRLSLPVQFHQHFRCTAGATPLAPPGLQPPAEDEARAAEPDPDYENLRRSAGGWSEAENGKEGTAKEGAPGGTPQAGGEAQPARAENEKDATTEKNKKRGFLFKAKKVAMMTQPPATPTLPRLPHDVVPADNRDDPEIILNTTTYYYSVRVFAGQEPSCVWAGWVTPDYHQHDMSFDLSKVRVVTVTMGDEQGNVHSSLKCSNCYMVWGGDFVSPGQQGRISHTDLVIGCLVDLATGLMTFTANGKESNTFFQVEPNTKLFPAVFVLPTHQNVIQFELGKQKNIMPLSAAMFQSERKNPAPQCPPRLEMQMLMPVSWSRMPNHFLQVETRRAGERLGWAVQCQEPLTMMALHIPEENRCMDILELSERLDLQRFHSHTLRLYRAVCALGNNRVAHALCSHVDQAQLLHALEDAHLPGPLRAGYYDLLISIHLESACRSRRSMLSEYIVPLTPETRAITLFPPGRSTENGHPRHGLPGVGVTTSLRPPHHFSPPCFVAALPAAGAAEAPARLSPAIPLEALRDKALRMLGEAVRDGGQHARDPVGGSVEFQFVPVLKLVSTLLVMGIFGDEDVKQILKMIEPEVFTEEEEEEDEEEEGEEEDEEEKEEDEEETAQEKEDEEKEEEEAAEGEKEEGLEEGLLQMKLPESVKLQMCHLLEYFCDQELQHRVESLAAFAERYVDKLQANQRSRYGLLIKAFSMTAAETARRTREFRSPPQEQINMLLQFKDGTDEEDCPLPEEIRQDLLDFHQDLLAHCGIQLDGEEEEPEEETTLGSRLMSLLEKVRLVKKKEEKPEEERSAEESKPRSLQELVSHMVVRWAQEDFVQSPELVRAMFSLLHRQYDGLGELLRALPRAYTISPSSVEDTMSLLECLGQIRSLLIVQMGPQEENLMIQSIGNIMNNKVFYQHPNLMRALGMHETVMEVMVNVLGGGESKEIRFPKMVTSCCRFLCYFCRISRQNQRSMFDHLSYLLENSGIGLGMQGSTPLDVAAASVIDNNELALALQEQDLEKVVSYLAGCGLQSCPMLVAKGYPDIGWNPCGGERYLDFLRFAVFVNGESVEENANVVVRLLIRKPECFGPALRGEGGSGLLAAIEEAIRISEDPARDGPGIRRDRRREHFGEEPPEENRVHLGHAIMSFYAALIDLLGRCAPEMHLIQAGKGEALRIRAILRSLVPLEDLVGIISLPLQIPTLGKDGALVQPKMSASFVPDHKASMVLFLDRVYGIENQDFLLHVLDVGFLPDMRAAASLDTATFSTTEMALALNRYLCLAVLPLITKCAPLFAGTEHRAIMVDSMLHTVYRLSRGRSLTKAQRDVIEDCLMSLCRYIRPSMLQHLLRRLVFDVPILNEFAKMPLKLLTNHYERCWKYYCLPTGWANFGVTSEEELHLTRKLFWGIFDSLAHKKYDPELYRMAMPCLCAIAGALPPDYVDASYSSKAEKKATVDAEGNFDPRPVETLNVIIPEKLDSFINKFAEYTHEKWAFDKIQNNWSYGENIDEELKTHPMLRPYKTFSEKDKEIYRWPIKESLKAMIAWEWTIEKAREGEEEKTEKKKTRKISQSAQTYDPREGYNPQPPDLSAVTLSRELQAMAEQLAENYHNTWGRKKKQELEAKGGGTHPLLVPYDTLTAKEKARDREKAQELLKFLQMNGYAVTRGLKDMELDSSSIEKRFAFGFLQQLLRWMDISQEFIAHLEAVVSSGRVEKSPHEQEIKFFAKILLPLINQYFTNHCLYFLSTPAKVLGSGGHASNKEKEMITSLFCKLAALVRHRVSLFGTDAPAVVNCLHILARSLDARTVMKSGPEIVKAGLRSFFESASEDIEKMVENLRLGKVSQARTQVKGVGQNLTYTTVALLPVLTTLFQHIAQHQFGDDVILDDVQVSCYRTLCSIYSLGTTKNTYVEKLRPALGECLARLAAAMPVAFLEPQLNEYNACSVYTTKSPRERAILGLPNSVEEMCPDIPVLERLMADIGGLAESGARYTEMPHVIEITLPMLCSYLPRWWERGPEAPPSALPAGAPPPCTAVTSDHLNSLLGNILRIIVNNLGIDEASWMKRLAVFAQPIVSRARPELLQSHFIPTIGRLRKRAGKVVSEEEQLRLEAKAEAQEGELLVRDEFSVLCRDLYALYPLLIRYVDNNRAQWLTEPNPSAEELFRMVGEIFIYWSKSHNFKREEQNFVVQNEINNMSFLTADNKSKMAKAGDIQSGGSDQERTKKKRRGDRYSVQTSLIVATLKKMLPIGLNMCAPTDQDLITLAKTRYALKDTDEEVREFLHNNLHLQGKVEGSPSLRWQMALYRGVPGREEDADDPEKIVRRVQEVSAVLYYLDQTEHPYKSKKAVWHKLLSKQRRRAVVACFRMTPLYNLPTHRACNMFLESYKAAWILTEDHSFEDRMIDDLSKAGEQEEEEEEVEEKKPDPLHQLVLHFSRTALTEKSKLDEDYLYMAYADIMAKSCHLEEGGENGEAEEEVEVSFEEKQMEKQRLLYQQARLHTRGAAEMVLQMISACKGETGAMVSSTLKLGISILNGGNAEVQQKMLDYLKDKKEVGFFQSIQALMQTCSVLDLNAFERQNKAEGLGMVNEDGTVINRQNGEKVMADDEFTQDLFRFLQLLCEGHNNDFQNYLRTQTGNTTTINIIICTVDYLLRLQESISDFYWYYSGKDVIEEQGKRNFSKAMSVAKQVFNSLTEYIQGPCTGNQQSLAHSRLWDAVVGFLHVFAHMMMKLAQDSSQIELLKELLDLQKDMVVMLLSLLEGNVVNGMIARQMVDMLVESSSNVEMILKFFDMFLKLKDIVGSEAFQDYVTDPRGLISKKDFQKAMDSQKQFSGPEIQFLLSCSEADENEMINCEEFANRFQEPARDIGFNVAVLLTNLSEHVPHDPRLHNFLELAESILEYFRPYLGRIEIMGASRRIERIYFEISETNRAQWEMPQVKESKRQFIFDVVNEGGEAEKMELFVSFCEDTIFEMQIAAQISEPEGEPETDEDEGAGAAEAGAEGAEEGAAGLEGTAATAAAGATARVVAAAGRALRGLSYRSLRRRVRRLRRLTAREAATAVAALLWAAVTRAGAAGAGAAAGALGLLWGSLFGGGLVEGAKKVTVTELLAGMPDPTSDEVHGEQPAGPGGDADGEGASEGAGDAAEGAGDEEEAVHEAGPGGADGAVAVTDGGPFRPEGAGGLGDMGDTTPAEPPTPEGSPILKRKLGVDGVEEELPPEPEPEPEPELEPEKADAENGEKEEVPEPTPEPPKKQAPPSPPPKKEEAGGEFWGELEVQRVKFLNYLSRNFYTLRFLALFLAFAINFILLFYKVSDSPPGEDDMEGSAAGDVSGAGSGGSSGWGLGAGEEAEGDEDENMVYYFLEESTGYMEPALRCLSLLHTLVAFLCIIGYNCLKVPLVIFKREKELARKLEFDGLYITEQPEDDDVKGQWDRLVLNTPSFPSNYWDKFVKRKVLDKHGDIYGRERIAELLGMDLATLEITAHNERKPNPPPGLLTWLMSIDVKYQIWKFGVIFTDNSFLYLGWYMVMSLLGHYNNFFFAAHLLDIAMGVKTLRTILSSVTHNGKQLVMTVGLLAVVVYLYTVVAFNFFRKFYNKSEDEDEPDMKCDDMMTCYLFHMYVGVRAGGGIGDEIEDPAGDEYELYRVVFDITFFFFVIVILLAIIQGLIIDAFGELRDQQEQVKEDMETKCFICGIGSDYFDTTPHGFETHTLEEHNLANYMFFLMYLINKDETEHTGQESYVWKMYQERCWDFFPAGDCFRKQYEDQLS	5038	P21817	V	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
263	NM_000419.4(ITGA2B):c.1073G>A (p.Arg358His)	2896	CA115839	NM_000419.4:c.1073G>A, NC_000017.11:g.44383630C>T, CM000679.2:g.44383630C>T, NC_000017.10:g.42460998C>T, CM000679.1:g.42460998C>T, NC_000017.9:g.39816524C>T, NG_008331.1:g.10876G>A, LRG_479:g.10876G>A, ENST00000262407.6:c.1073G>A, ENST00000648408.1:n.504G>A, ENST00000262407.5:c.1073G>A, ENST00000592226.5:n.313G>A, NM_000419.3:c.1073G>A, LRG_479t1:c.1073G>A, XM_011524749.1:c.1073G>A, XM_011524750.1:c.1073G>A, NM_000419.5:c.1073G>A, NM_000419.4(ITGA2B):c.1073G>A (p.Arg358His)	ITGA2B	Glanzmann's thrombasthenia	MONDO:0010119	Autosomal recessive inheritance	Pathogenic	PM3_Strong, PP4_Strong, PM2_Supporting	PS3, PM5, PP3	The c.1073G>A (p.Arg358His) variant has been reported, in the homozygous state, in at least four probands (PMIDs: 8883261, 25728920, 19691478, 7706461) and once in a compound heterozygous case (PMID: 21557682), several of whom meet all diagnostic criteria for a phenotype highly specific to GT. This variant is absent from ExAC and gnomAD. In summary, this variant meets criteria to be classified as pathogenic for GT. GT-specific criteria applied: PM2_supporting, PM3_strong, and PP4_strong.	8883261, 7706461, 8883261, 19691478, 25728920, 7706461, 8883261, 21557682, 19691478, 25728920, 7706461	Platelet Disorders VCEP	https://clinicalgenome.org/docs/clingen-platelet-disorders-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-2.1/	2021-03-05	2021-08-20	False	https://erepo.genome.network/evrepo/ui/classification/CA115839/MONDO:0010119/011	a6fd9573-676f-4b4d-bbd9-49eea0ffdd23	p.Arg358His	Arg	358	His	MARALCPLQALWLLEWVLLLLGPCAAPPAWALNLDPVQLTFYAGPNGSQFGFSLDFHKDSHGRVAIVVGAPRTLGPSQEETGGVFLCPWRAEGGQCPSLLFDLRDETRNVGSQTLQTFKARQGLGASVVSWSDVIVACAPWQHWNVLEKTEEAEKTPVGSCFLAQPESGRRAEYSPCRGNTLSRIYVENDFSWDKRYCEAGFSSVVTQAGELVLGAPGGYYFLGLLAQAPVADIFSSYRPGILLWHVSSQSLSFDSSNPEYFDGYWGYSVAVGEFDGDLNTTEYVVGAPTWSWTLGAVEILDSYYQRLHRLRGEQMASYFGHSVAVTDVNGDGRHDLLVGAPLYMESRADRKLAEVGRVYLFLQPRGPHALGAPSLLLTGTQLYGRFGSAIAPLGDLDRDGYNDIAVAAPYGGPSGRGQVLVFLGQSEGLRSRPSQVLDSPFPTGSAFGFSLRGAVDIDDNGYPDLIVGAYGANQVAVYRAQPVVKASVQLLVQDSLNPAVKSCVLPQTKTPVSCFNIQMCVGATGHNIPQKLSLNAELQLDRQKPRQGRRVLLLGSQQAGTTLNLDLGGKHSPICHTTMAFLRDEADFRDKLSPIVLSLNVSLPPTEAGMAPAVVLHGDTHVQEQTRIVLDCGEDDVCVPQLQLTASVTGSPLLVGADNVLELQMDAANEGEGAYEAELAVHLPQGAHYMRALSNVEGFERLICNQKKENETRVVLCELGNPMKKNAQIGIAMLVSVGNLEEAGESVSFQLQIRSKNSQNPNSKIVLLDVPVRAEAQVELRGNSFPASLVVAAEEGEREQNSLDSWGPKVEHTYELHNNGPGTVNGLHLSIHLPGQSQPSDLLYILDIQPQGGLQCFPQPPVNPLKVDWGLPIPSPSPIHPAHHKRDRRQIFLPEPEQPSRLQDPVLVSCDSAPCTVVQCDLQEMARGQRAMVTVLAFLWLPSLYQRPLDQFVLQSHAWFNVSSLPYAVPPLSLPRGEAQVWTQLLRALEERAIPIWWVLVGVLGGLLLLTILVLAMWKVGFFKRNRPPLEEDDEEGE	1039	P08514	H	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [356], 'STRAND_gain_score': array([0.02157766]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [420], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.00367379]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
264	NM_004360.5(CDH1):c.715G>A (p.Gly239Arg)	132709	CA298980	NM_004360.5:c.715G>A, NC_000016.10:g.68810224G>A, CM000678.2:g.68810224G>A, NC_000016.9:g.68844127G>A, CM000678.1:g.68844127G>A, NC_000016.8:g.67401628G>A, NG_008021.1:g.77933G>A, LRG_301:g.77933G>A, ENST00000261769.10:c.715G>A, ENST00000261769.9:c.715G>A, ENST00000422392.6:c.715G>A, ENST00000561751.1:n.454+1376G>A, ENST00000562836.5:n.786G>A, ENST00000566510.5:c.559G>A, ENST00000566612.5:c.715G>A, ENST00000611625.4:c.715G>A, ENST00000612417.4:c.715G>A, ENST00000621016.4:c.715G>A, NM_004360.3:c.715G>A, LRG_301t1:c.715G>A, XM_011523488.1:c.-21G>A, XM_011523489.1:c.-21G>A, NM_001317184.1:c.715G>A, NM_001317185.1:c.-901G>A, NM_001317186.1:c.-1105G>A, NM_004360.4:c.715G>A, NM_001317184.2:c.715G>A, NM_001317185.2:c.-901G>A, NM_001317186.2:c.-1105G>A, NM_004360.5(CDH1):c.715G>A (p.Gly239Arg)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Pathogenic	PP3, PM2_Supporting, PS4, PS3	PP2, PP4, PP1, BS2, PS1, PS2, BP1, BP4, BP3, BP2, BA1, PM1, PM4, PM3, PM5, BP5, BP7, BS3, BS1, BS4, PM6, PVS1	The c.715G>A (p.Gly239Arg) variant is absent in the gnomAD cohort (PM2_supporting; http://gnomad.broadinstitute.org). This variant has been reported in at least 16 families (18) meeting HDGC clinical criteria (PS4_very strong; PMID: 17545690, 23264079, 23264079, 26182300; SCV000153869.9, SCV000273881.6, internal laboratory contributors). This variant is predicted to affect splicing by at least 3 in silico splicing predictors in agreement (PP3). There are RNA assays demonstrating an abnormal out-of-frame transcript for this variant (PS3; PMID: 17545690, 33619332). In summary, this variant meets criteria to be classified as pathogenic based on the ACMG/AMP criteria applied as specified by the CDH1 Variant Curation Expert Panel (v3.1): PS4_very strong, PS3, PM2_supporting, PP3.		CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-29	2023-08-29	False	https://erepo.genome.network/evrepo/ui/classification/CA298980/MONDO:0007648/007	ed68928a-1184-400b-9e8e-8f8e92950551	p.Gly239Arg	Gly	239	Arg	MGPWSRSLSALLLLLQVSSWLCQEPEPCHPGFDAESYTFTVPRRHLERGRVLGRVNFEDCTGRQRTAYFSLDTRFKVGTDGVITVKRPLRFHNPQIHFLVYAWDSTYRKFSTKVTLNTVGHHHRPPPHQASVSGIQAELLTFPNSSPGLRRQKRDWVIPPISCPENEKGPFPKNLVQIKSNKDKEGKVFYSITGQGADTPPVGVFIIERETGWLKVTEPLDRERIATYTLFSHAVSSNGNAVEDPMEILITVTDQNDNKPEFTQEVFKGSVMEGALPGTSVMEVTATDADDDVNTYNAAIAYTILSQDPELPDKNMFTINRNTGVISVVTTGLDRESFPTYTLVVQAADLQGEGLSTTATAVITVTDTNDNPPIFNPTTYKGQVPENEANVVITTLKVTDADAPNTPAWEAVYTILNDDGGQFVVTTNPVNNDGILKTAKGLDFEAKQQYILHVAVTNVVPFEVSLTTSTATVTVDVLDVNEAPIFVPPEKRVEVSEDFGVGQEITSYTAQEPDTFMEQKITYRIWRDTANWLEINPDTGAISTRAELDREDFEHVKNSTYTALIIATDNGSPVATGTGTLLLILSDVNDNAPIPEPRTIFFCERNPKPQVINIIDADLPPNTSPFTAELTHGASANWTIQYNDPTQESIILKPKMALEVGDYKINLKLMDNQNKDQVTTLEVSVCDCEGAAGVCRKAQPVEAGLQIPAILGILGGILALLILILLLLLFLRRRAVVKEPLLPPEDDTRDNVYYYDEEGGGEEDQDFDLSQLHRGLDARPEVTRNDVAPTLMSVPRYLPRPANPDEIGNFIDENLKAADTDPTAPPYDSLLVFDYEGSGSEAASLSSLNSSESDKDQDYDYLNEWGNRFKKLADMYGGGEDD	882	P12830	R	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [5], 'TRANSIT_gain': [], 'TRANSIT_loss_score': array([-0.00135911]), 'STRAND_loss': [], 'STRAND_gain': [175, 260, 678], 'STRAND_gain_score': array([0.0140388 , 0.00292021, 0.00402933]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
265	NM_004360.5(CDH1):c.2T>G (p.Met1Arg)	532474	CA396451182	NM_004360.5:c.2T>G, NC_000016.10:g.68737417T>G, CM000678.2:g.68737417T>G, NC_000016.9:g.68771320T>G, CM000678.1:g.68771320T>G, NC_000016.8:g.67328821T>G, NG_008021.1:g.5126T>G, LRG_301:g.5126T>G, ENST00000261769.10:c.2T>G, ENST00000261769.9:c.2T>G, ENST00000422392.6:c.2T>G, ENST00000566510.5:c.2T>G, ENST00000566612.5:c.2T>G, ENST00000611625.4:c.2T>G, ENST00000612417.4:c.2T>G, ENST00000621016.4:c.2T>G, NM_004360.3:c.2T>G, LRG_301t1:c.2T>G, NM_001317184.1:c.2T>G, NM_001317185.1:c.-1614T>G, NM_001317186.1:c.-1818T>G, NM_004360.4:c.2T>G, NM_001317184.2:c.2T>G, NM_001317185.2:c.-1614T>G, NM_001317186.2:c.-1818T>G, NM_004360.5(CDH1):c.2T>G (p.Met1Arg)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Pathogenic	PM2_Supporting, PS4_Moderate, PVS1	PP1, PP4, PP2, PP3, BS2, PS3, PS2, PS1, BP2, BP1, BP4, BP3, BA1, PM3, PM5, PM1, PM4, BP5, BP7, BS3, BS4, BS1, PM6	The c.2T>G (p.Met1Arg) variant alters the start codon of the CDH1 coding sequence and is predicted to lead to an absent protein (PVS1). This variant is absent in the gnomAD cohort (PM2_supporting; http://gnomad.broadinstitute.org). This variant has been reported in two probands/families meeting HDGC clinical criteria (PS4_Moderate; SCV000760846.2 and internal laboratory contributor). In summary, this variant meets criteria to be classified as pathogenic based on the ACMG/AMP Variant Interpretation Guidelines Version 2 as specified by the CDH1 Variant Curation Expert Panel (v3.1): PVS1, PM2_supporting, PS4_Moderate.		CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-25	2023-08-25	False	https://erepo.genome.network/evrepo/ui/classification/CA396451182/MONDO:0007648/007	24665ae3-8d6a-4ac8-a7b2-70d9d379c8dd	p.Met1Arg	Met	1	Arg	MGPWSRSLSALLLLLQVSSWLCQEPEPCHPGFDAESYTFTVPRRHLERGRVLGRVNFEDCTGRQRTAYFSLDTRFKVGTDGVITVKRPLRFHNPQIHFLVYAWDSTYRKFSTKVTLNTVGHHHRPPPHQASVSGIQAELLTFPNSSPGLRRQKRDWVIPPISCPENEKGPFPKNLVQIKSNKDKEGKVFYSITGQGADTPPVGVFIIERETGWLKVTEPLDRERIATYTLFSHAVSSNGNAVEDPMEILITVTDQNDNKPEFTQEVFKGSVMEGALPGTSVMEVTATDADDDVNTYNAAIAYTILSQDPELPDKNMFTINRNTGVISVVTTGLDRESFPTYTLVVQAADLQGEGLSTTATAVITVTDTNDNPPIFNPTTYKGQVPENEANVVITTLKVTDADAPNTPAWEAVYTILNDDGGQFVVTTNPVNNDGILKTAKGLDFEAKQQYILHVAVTNVVPFEVSLTTSTATVTVDVLDVNEAPIFVPPEKRVEVSEDFGVGQEITSYTAQEPDTFMEQKITYRIWRDTANWLEINPDTGAISTRAELDREDFEHVKNSTYTALIIATDNGSPVATGTGTLLLILSDVNDNAPIPEPRTIFFCERNPKPQVINIIDADLPPNTSPFTAELTHGASANWTIQYNDPTQESIILKPKMALEVGDYKINLKLMDNQNKDQVTTLEVSVCDCEGAAGVCRKAQPVEAGLQIPAILGILGGILALLILILLLLLFLRRRAVVKEPLLPPEDDTRDNVYYYDEEGGGEEDQDFDLSQLHRGLDARPEVTRNDVAPTLMSVPRYLPRPANPDEIGNFIDENLKAADTDPTAPPYDSLLVFDYEGSGSEAASLSSLNSSESDKDQDYDYLNEWGNRFKKLADMYGGGEDD	882	P12830	R	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [3, 5], 'TRANSIT_gain': [], 'TRANSIT_loss_score': array([-0.33835328, -0.30453271]), 'STRAND_loss': [52, 84, 162, 503, 683], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.06370074, -0.02715558, -0.01793945, -0.01122206, -0.03107405]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
266	NM_004360.5(CDH1):c.1A>G (p.Met1Val)	532457	CA396451176	NM_004360.5:c.1A>G, NC_000016.10:g.68737416A>G, CM000678.2:g.68737416A>G, NC_000016.9:g.68771319A>G, CM000678.1:g.68771319A>G, NC_000016.8:g.67328820A>G, NG_008021.1:g.5125A>G, LRG_301:g.5125A>G, ENST00000261769.10:c.1A>G, ENST00000261769.9:c.1A>G, ENST00000422392.6:c.1A>G, ENST00000566510.5:c.1A>G, ENST00000566612.5:c.1A>G, ENST00000611625.4:c.1A>G, ENST00000612417.4:c.1A>G, ENST00000621016.4:c.1A>G, NM_004360.3:c.1A>G, LRG_301t1:c.1A>G, NM_001317184.1:c.1A>G, NM_001317185.1:c.-1615A>G, NM_001317186.1:c.-1819A>G, NM_004360.4:c.1A>G, NM_001317184.2:c.1A>G, NM_001317185.2:c.-1615A>G, NM_001317186.2:c.-1819A>G, NM_004360.5(CDH1):c.1A>G (p.Met1Val)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Pathogenic	PP1, PS4_Supporting, PM2_Supporting, PVS1	BS2, PP4, PP2, PP3, PS3, PS2, PS1, BP2, BP1, BP4, BP3, BA1, PM1, PM3, PM5, PM4, PM6, BP5, BP7, BS4, BS3, BS1	The c.1A>G (p.Met1Val) variant alters the start codon of the CDH1 coding sequence and is predicted to lead to an absent protein (PVS1). This variant is absent in the gnomAD cohort (PM2_supporting; http://gnomad.broadinstitute.org). This variant has been reported in at least one proband meeting HDGC clinical criteria (PS4_supporting; SCV000760810.2). This variant was also found to co-segregate with disease in multiple affected family members (PP1; SCV000760810.2). In summary, this variant meets criteria to be classified as pathogenic based on the ACMG/AMP Variant Interpretation Guidelines Version 3.1 as specified by the CDH1 Variant Curation Expert Panel: PVS1, PS4_supporting, PM2_supporting, PP1.		CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-25	2023-08-25	False	https://erepo.genome.network/evrepo/ui/classification/CA396451176/MONDO:0007648/007	6d19d5b0-c34b-4794-89e5-d0173e561a83	p.Met1Val	Met	1	Val	MGPWSRSLSALLLLLQVSSWLCQEPEPCHPGFDAESYTFTVPRRHLERGRVLGRVNFEDCTGRQRTAYFSLDTRFKVGTDGVITVKRPLRFHNPQIHFLVYAWDSTYRKFSTKVTLNTVGHHHRPPPHQASVSGIQAELLTFPNSSPGLRRQKRDWVIPPISCPENEKGPFPKNLVQIKSNKDKEGKVFYSITGQGADTPPVGVFIIERETGWLKVTEPLDRERIATYTLFSHAVSSNGNAVEDPMEILITVTDQNDNKPEFTQEVFKGSVMEGALPGTSVMEVTATDADDDVNTYNAAIAYTILSQDPELPDKNMFTINRNTGVISVVTTGLDRESFPTYTLVVQAADLQGEGLSTTATAVITVTDTNDNPPIFNPTTYKGQVPENEANVVITTLKVTDADAPNTPAWEAVYTILNDDGGQFVVTTNPVNNDGILKTAKGLDFEAKQQYILHVAVTNVVPFEVSLTTSTATVTVDVLDVNEAPIFVPPEKRVEVSEDFGVGQEITSYTAQEPDTFMEQKITYRIWRDTANWLEINPDTGAISTRAELDREDFEHVKNSTYTALIIATDNGSPVATGTGTLLLILSDVNDNAPIPEPRTIFFCERNPKPQVINIIDADLPPNTSPFTAELTHGASANWTIQYNDPTQESIILKPKMALEVGDYKINLKLMDNQNKDQVTTLEVSVCDCEGAAGVCRKAQPVEAGLQIPAILGILGGILALLILILLLLLFLRRRAVVKEPLLPPEDDTRDNVYYYDEEGGGEEDQDFDLSQLHRGLDARPEVTRNDVAPTLMSVPRYLPRPANPDEIGNFIDENLKAADTDPTAPPYDSLLVFDYEGSGSEAASLSSLNSSESDKDQDYDYLNEWGNRFKKLADMYGGGEDD	882	P12830	V	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [3, 5], 'TRANSIT_gain': [], 'TRANSIT_loss_score': array([-0.32732558, -0.31346631]), 'STRAND_loss': [52, 84, 503], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.03917146, -0.01461565, -0.00392741]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
267	NM_004360.5(CDH1):c.2T>C (p.Met1Thr)	486826	CA396451185	NM_004360.5:c.2T>C, NC_000016.10:g.68737417T>C, CM000678.2:g.68737417T>C, NC_000016.9:g.68771320T>C, CM000678.1:g.68771320T>C, NC_000016.8:g.67328821T>C, NG_008021.1:g.5126T>C, LRG_301:g.5126T>C, ENST00000261769.10:c.2T>C, ENST00000261769.9:c.2T>C, ENST00000422392.6:c.2T>C, ENST00000566510.5:c.2T>C, ENST00000566612.5:c.2T>C, ENST00000611625.4:c.2T>C, ENST00000612417.4:c.2T>C, ENST00000621016.4:c.2T>C, NM_004360.3:c.2T>C, LRG_301t1:c.2T>C, NM_001317184.1:c.2T>C, NM_001317185.1:c.-1614T>C, NM_001317186.1:c.-1818T>C, NM_004360.4:c.2T>C, NM_001317184.2:c.2T>C, NM_001317185.2:c.-1614T>C, NM_001317186.2:c.-1818T>C, NM_004360.5(CDH1):c.2T>C (p.Met1Thr)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Pathogenic	PM2_Supporting, PS4_Moderate, PVS1	BS2, PP2, PP3, PP1, PP4, PS1, PS3, PS2, BP3, BP1, BP4, BP2, BA1, PM4, PM5, PM1, PM3, BP7, BP5, BS1, BS3, BS4, PM6	The c.2T>C (p.Met1Thr) variant alters the start codon of the CDH1 coding sequence and is predicted to lead to an absent protein (PVS1). This variant is absent in the gnomAD cohort (PM2_supporting; http://gnomad.broadinstitute.org). This variant has been reported in at least 2 probands/families meeting HDGC clinical criteria (PS4_moderate; PMID: 20373070, SCV000760804.3). In summary, this variant meets criteria to be classified as pathogenic based on the ACMG/AMP Variant Interpretation Guidelines Version 3.1 as specified by the CDH1 Variant Curation Expert Panel: PVS1, PS4_moderate, PM2_supporting.		CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-25	2023-08-25	False	https://erepo.genome.network/evrepo/ui/classification/CA396451185/MONDO:0007648/007	3f6e0f9d-ae4a-4d07-a4a1-4f43338d71eb	p.Met1Thr	Met	1	Thr	MGPWSRSLSALLLLLQVSSWLCQEPEPCHPGFDAESYTFTVPRRHLERGRVLGRVNFEDCTGRQRTAYFSLDTRFKVGTDGVITVKRPLRFHNPQIHFLVYAWDSTYRKFSTKVTLNTVGHHHRPPPHQASVSGIQAELLTFPNSSPGLRRQKRDWVIPPISCPENEKGPFPKNLVQIKSNKDKEGKVFYSITGQGADTPPVGVFIIERETGWLKVTEPLDRERIATYTLFSHAVSSNGNAVEDPMEILITVTDQNDNKPEFTQEVFKGSVMEGALPGTSVMEVTATDADDDVNTYNAAIAYTILSQDPELPDKNMFTINRNTGVISVVTTGLDRESFPTYTLVVQAADLQGEGLSTTATAVITVTDTNDNPPIFNPTTYKGQVPENEANVVITTLKVTDADAPNTPAWEAVYTILNDDGGQFVVTTNPVNNDGILKTAKGLDFEAKQQYILHVAVTNVVPFEVSLTTSTATVTVDVLDVNEAPIFVPPEKRVEVSEDFGVGQEITSYTAQEPDTFMEQKITYRIWRDTANWLEINPDTGAISTRAELDREDFEHVKNSTYTALIIATDNGSPVATGTGTLLLILSDVNDNAPIPEPRTIFFCERNPKPQVINIIDADLPPNTSPFTAELTHGASANWTIQYNDPTQESIILKPKMALEVGDYKINLKLMDNQNKDQVTTLEVSVCDCEGAAGVCRKAQPVEAGLQIPAILGILGGILALLILILLLLLFLRRRAVVKEPLLPPEDDTRDNVYYYDEEGGGEEDQDFDLSQLHRGLDARPEVTRNDVAPTLMSVPRYLPRPANPDEIGNFIDENLKAADTDPTAPPYDSLLVFDYEGSGSEAASLSSLNSSESDKDQDYDYLNEWGNRFKKLADMYGGGEDD	882	P12830	T	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [3, 5], 'TRANSIT_gain': [], 'TRANSIT_loss_score': array([-0.36649185, -0.35447663]), 'STRAND_loss': [52, 84, 503], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.04712313, -0.02420235, -0.00447541]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
268	NM_004360.5(CDH1):c.546A>C (p.Lys182Asn)	140853	CA163740	NM_004360.5:c.546A>C, NC_000016.10:g.68808707A>C, CM000678.2:g.68808707A>C, NC_000016.9:g.68842610A>C, CM000678.1:g.68842610A>C, NC_000016.8:g.67400111A>C, NG_008021.1:g.76416A>C, LRG_301:g.76416A>C, ENST00000261769.10:c.546A>C, ENST00000261769.9:c.546A>C, ENST00000422392.6:c.546A>C, ENST00000561751.1:n.313A>C, ENST00000562836.5:n.617A>C, ENST00000564676.5:n.828A>C, ENST00000564745.1:n.541A>C, ENST00000566510.5:c.531+140A>C, ENST00000566612.5:c.546A>C, ENST00000567320.1:n.56A>C, ENST00000611625.4:c.546A>C, ENST00000612417.4:c.546A>C, ENST00000621016.4:c.546A>C, NM_004360.3:c.546A>C, LRG_301t1:c.546A>C, XM_011523488.1:c.-190A>C, XM_011523489.1:c.-190A>C, NM_001317184.1:c.546A>C, NM_001317185.1:c.-1070A>C, NM_001317186.1:c.-1274A>C, NM_004360.4:c.546A>C, NM_001317184.2:c.546A>C, NM_001317185.2:c.-1070A>C, NM_001317186.2:c.-1274A>C, NM_004360.5(CDH1):c.546A>C (p.Lys182Asn)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Benign	BS2, BS1	PP1, PP2, PP3, PP4, PS3, PS1, PS2, PS4, BP1, BP4, BP3, BP2, BA1, PM4, PM3, PM1, PM5, PM2, PM6, PVS1, BP5, BP7, BS3, BS4	The c.546A>C (p.Lys182Asn) variant has an allele frequency of 0.00104 (>0.1%, 9 out of 8628 alleles) in the East Asian subpopulation of the ExAC cohort (BS1). The variant has also been observed in >10 (56) individuals without a diagnosis of diffuse gastric cancer, signet ring tumor or lobular breast cancer and whose family histories do not suggest HDGC (BS2; SCV000637839.5; SCV000566004.5). Therefore, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): BS1, BS2.		CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-10	2023-08-10	False	https://erepo.genome.network/evrepo/ui/classification/CA163740/MONDO:0007648/007	4dbe4a4e-01f1-4566-96b5-4c9d2a05ba36	p.Lys182Asn	Lys	182	Asn	MGPWSRSLSALLLLLQVSSWLCQEPEPCHPGFDAESYTFTVPRRHLERGRVLGRVNFEDCTGRQRTAYFSLDTRFKVGTDGVITVKRPLRFHNPQIHFLVYAWDSTYRKFSTKVTLNTVGHHHRPPPHQASVSGIQAELLTFPNSSPGLRRQKRDWVIPPISCPENEKGPFPKNLVQIKSNKDKEGKVFYSITGQGADTPPVGVFIIERETGWLKVTEPLDRERIATYTLFSHAVSSNGNAVEDPMEILITVTDQNDNKPEFTQEVFKGSVMEGALPGTSVMEVTATDADDDVNTYNAAIAYTILSQDPELPDKNMFTINRNTGVISVVTTGLDRESFPTYTLVVQAADLQGEGLSTTATAVITVTDTNDNPPIFNPTTYKGQVPENEANVVITTLKVTDADAPNTPAWEAVYTILNDDGGQFVVTTNPVNNDGILKTAKGLDFEAKQQYILHVAVTNVVPFEVSLTTSTATVTVDVLDVNEAPIFVPPEKRVEVSEDFGVGQEITSYTAQEPDTFMEQKITYRIWRDTANWLEINPDTGAISTRAELDREDFEHVKNSTYTALIIATDNGSPVATGTGTLLLILSDVNDNAPIPEPRTIFFCERNPKPQVINIIDADLPPNTSPFTAELTHGASANWTIQYNDPTQESIILKPKMALEVGDYKINLKLMDNQNKDQVTTLEVSVCDCEGAAGVCRKAQPVEAGLQIPAILGILGGILALLILILLLLLFLRRRAVVKEPLLPPEDDTRDNVYYYDEEGGGEEDQDFDLSQLHRGLDARPEVTRNDVAPTLMSVPRYLPRPANPDEIGNFIDENLKAADTDPTAPPYDSLLVFDYEGSGSEAASLSSLNSSESDKDQDYDYLNEWGNRFKKLADMYGGGEDD	882	P12830	N	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [5], 'TRANSIT_gain': [], 'TRANSIT_loss_score': array([-0.00575238]), 'STRAND_loss': [], 'STRAND_gain': [175, 176, 678], 'STRAND_gain_score': array([0.03104919, 0.03979892, 0.00286382]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
269	NM_004360.5(CDH1):c.671G>A (p.Arg224His)	41786	CA165387	NM_004360.5:c.671G>A, NC_000016.10:g.68808832G>A, CM000678.2:g.68808832G>A, NC_000016.9:g.68842735G>A, CM000678.1:g.68842735G>A, NC_000016.8:g.67400236G>A, NG_008021.1:g.76541G>A, LRG_301:g.76541G>A, ENST00000261769.10:c.671G>A, ENST00000261769.9:c.671G>A, ENST00000422392.6:c.671G>A, ENST00000561751.1:n.438G>A, ENST00000562836.5:n.742G>A, ENST00000564676.5:n.953G>A, ENST00000566510.5:c.531+265G>A, ENST00000566612.5:c.671G>A, ENST00000567320.1:n.181G>A, ENST00000611625.4:c.671G>A, ENST00000612417.4:c.671G>A, ENST00000621016.4:c.671G>A, NM_004360.3:c.671G>A, LRG_301t1:c.671G>A, XM_011523488.1:c.-65G>A, XM_011523489.1:c.-65G>A, NM_001317184.1:c.671G>A, NM_001317185.1:c.-945G>A, NM_001317186.1:c.-1149G>A, NM_004360.4:c.671G>A, NM_001317184.2:c.671G>A, NM_001317185.2:c.-945G>A, NM_001317186.2:c.-1149G>A, NM_004360.5(CDH1):c.671G>A (p.Arg224His)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Benign	BS2, BP2_Strong	PP2, PP3, PP1, PP4, PS1, PS3, PS4, PS2, BP1, BP4, BP3, BA1, PM5, PM4, PM1, PM3, PM2, PM6, PVS1, BP7, BP5, BS1, BS3, BS4	The c.671G>A (p.Arg224His) missense variant has a frequency of 0. 0.00003189 (8 of 250,850) in the gnomAD v2.1.1 cohort, with a maximum non-founder allele frequency of 0.00006179 (7 of 113,278) in the African subpopulation (http://gnomad.broadinstitute.org). This variant has been observed in >50 individuals w/o DCG, SRC tumors, or LBC & whose families do not suggest HDGC (BS2; SCV000637843.5, SCV000278911.9). This variant was observed in the homozygous state in an individual without DGC, SRC tumors or LBC and whose family does not suggest HDGC (BP2_Strong, internal laboratory contributor). In summary, the clinical significance of this variant is classified as benign based the ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): BS2, BP2_Strong.		CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-09	2023-08-10	False	https://erepo.genome.network/evrepo/ui/classification/CA165387/MONDO:0007648/007	55957b0c-748d-4efe-8c6d-60dee2cb6bac	p.Arg224His	Arg	224	His	MGPWSRSLSALLLLLQVSSWLCQEPEPCHPGFDAESYTFTVPRRHLERGRVLGRVNFEDCTGRQRTAYFSLDTRFKVGTDGVITVKRPLRFHNPQIHFLVYAWDSTYRKFSTKVTLNTVGHHHRPPPHQASVSGIQAELLTFPNSSPGLRRQKRDWVIPPISCPENEKGPFPKNLVQIKSNKDKEGKVFYSITGQGADTPPVGVFIIERETGWLKVTEPLDRERIATYTLFSHAVSSNGNAVEDPMEILITVTDQNDNKPEFTQEVFKGSVMEGALPGTSVMEVTATDADDDVNTYNAAIAYTILSQDPELPDKNMFTINRNTGVISVVTTGLDRESFPTYTLVVQAADLQGEGLSTTATAVITVTDTNDNPPIFNPTTYKGQVPENEANVVITTLKVTDADAPNTPAWEAVYTILNDDGGQFVVTTNPVNNDGILKTAKGLDFEAKQQYILHVAVTNVVPFEVSLTTSTATVTVDVLDVNEAPIFVPPEKRVEVSEDFGVGQEITSYTAQEPDTFMEQKITYRIWRDTANWLEINPDTGAISTRAELDREDFEHVKNSTYTALIIATDNGSPVATGTGTLLLILSDVNDNAPIPEPRTIFFCERNPKPQVINIIDADLPPNTSPFTAELTHGASANWTIQYNDPTQESIILKPKMALEVGDYKINLKLMDNQNKDQVTTLEVSVCDCEGAAGVCRKAQPVEAGLQIPAILGILGGILALLILILLLLLFLRRRAVVKEPLLPPEDDTRDNVYYYDEEGGGEEDQDFDLSQLHRGLDARPEVTRNDVAPTLMSVPRYLPRPANPDEIGNFIDENLKAADTDPTAPPYDSLLVFDYEGSGSEAASLSSLNSSESDKDQDYDYLNEWGNRFKKLADMYGGGEDD	882	P12830	H	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [5], 'TRANSIT_gain': [], 'TRANSIT_loss_score': array([-0.00358105]), 'STRAND_loss': [503], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.00062209]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
270	NM_005249.4(FOXG1):c.799G>A (p.Gly267Ser)	158602	CA172199	NM_005249.4:c.799G>A, ENST00000313071.7:c.799G>A, ENST00000313071.6:c.799G>A, NM_005249.5:c.799G>A, NC_000014.9:g.28768078G>A, CM000676.2:g.28768078G>A, NC_000014.8:g.29237284G>A, CM000676.1:g.29237284G>A, NC_000014.7:g.28307035G>A, NG_009367.1:g.5998G>A, NM_005249.4(FOXG1):c.799G>A (p.Gly267Ser)	FOXG1	FOXG1 disorder	MONDO:0100040	Autosomal dominant inheritance	Pathogenic	PP3, PM2_Supporting, PS2_Very Strong, PM1		The p.Gly267Ser variant in FOXG1 has been reported as a de novo occurrence (biological parenthood confirmed) in at least 2 individuals with FOXG1 disorder (internal database - GeneDx) (PS2_very strong). The p.Gly267Ser variant occurs in the well-characterized Fork-head functional domain of the FOXG1 gene (PM1). The p.Gly267Ser variant in FOXG1 is absent from gnomAD (PM2_supporting). Computational prediction analysis tools suggests a deleterious impact; however, this information does not predict clinical significance on its own (PP3). In summary, the p.Gly267Ser variant in FOXG1 is classified as Pathogenic for FOXG1 disorder based on the ACMG/AMP criteria (PS2_very strong, PM1, PM2_supporting, PP3).		Rett and Angelman-like Disorders VCEP	https://clinicalgenome.org/site/assets/files/7339/clingen_rettas_acmg_specifications_v2.pdf	2021-03-24	2021-05-10	False	https://erepo.genome.network/evrepo/ui/classification/CA172199/MONDO:0100040/016	27df47a8-b4c0-4855-b601-8b7a887dd00a	p.Gly267Ser	Gly	267	Ser	MLDMGDRKEVKMIPKSSFSINSLVPEAVQNDNHHASHGHHNSHHPQHHHHHHHHHHHPPPPAPQPPPPPQQQQPPPPPPPAPQPPQTRGAPAADDDKGPQQLLLPPPPPPPPAAALDGAKADGLGGKGEPGGGPGELAPVGPDEKEKGAGAGGEEKKGAGEGGKDGEGGKEGEKKNGKYEKPPFSYNALIMMAIRQSPEKRLTLNGIYEFIMKNFPYYRENKQGWQNSIRHNLSLNKCFVKVPRHYDDPGKGNYWMLDPSSDDVFIGGTTGKLRRRSTTSRAKLAFKRGARLTSTGLTFMDRAGSLYWPMSPFLSLHHPRASSTLSYNGTTSAYPSHPMPYSSVLTQNSLGNNHSFSTANGLSVDRLVNGEIPYATHHLTAAALAASVPCGLSVPCSGTYSLNPCSVNLLAGQTSYFFPHVPHPSMTSQSSTSMSARAASSSTSPQAPSTLPCESLRPSLPSFTTGLSGGLSDYFTHQNQGSSSNPLIH	489	P55316	S	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [218], 'DOMAIN_gain_score': array([0.02392757]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
271	NM_005249.4(FOXG1):c.561C>A (p.Asn187Lys)	205485	CA204685	NM_005249.4:c.561C>A, NC_000014.9:g.28767840C>A, CM000676.2:g.28767840C>A, NC_000014.8:g.29237046C>A, CM000676.1:g.29237046C>A, NC_000014.7:g.28306797C>A, NG_009367.1:g.5760C>A, ENST00000313071.7:c.561C>A, ENST00000313071.6:c.561C>A, NM_005249.5:c.561C>A, NM_005249.4(FOXG1):c.561C>A (p.Asn187Lys)	FOXG1	FOXG1 disorder	MONDO:0100040	Autosomal dominant inheritance	Pathogenic	PM2_Supporting, PS2_Very Strong, PS4, PM1		The p.Asn187Lys variant in FOXG1 has been reported as a de novo occurrence (biological parenthood confirmed) in at least 2 individuals with FOXG1 disorder (PMID 26795593, 28661489) (PS2_very strong). The p.Asn187Lys variant in FOXG1 has been observed in at least 5 other individuals with FOXG1 disorder (PMID 26795593, 25356970, 28661489) (PS4). This variant occurs in the well-characterized Forkhead functional domain of the FOXG1 (PM1). The p.Asn187Lys variant in FOXG1 is absent from gnomAD (PM2_supporting). In summary, the p.Asn187Lys variant in FOXG1 is classified as Pathogenic for FOXG1 disorder based on the ACMG/AMP criteria (PS2_very strong, PS4, PM1, PM2_supporting).		Rett and Angelman-like Disorders VCEP	https://clinicalgenome.org/site/assets/files/7339/clingen_rettas_acmg_specifications_v2.pdf	2021-03-25	2021-05-10	False	https://erepo.genome.network/evrepo/ui/classification/CA204685/MONDO:0100040/016	021968c7-1749-4560-b21e-7deb642bfa60	p.Asn187Lys	Asn	187	Lys	MLDMGDRKEVKMIPKSSFSINSLVPEAVQNDNHHASHGHHNSHHPQHHHHHHHHHHHPPPPAPQPPPPPQQQQPPPPPPPAPQPPQTRGAPAADDDKGPQQLLLPPPPPPPPAAALDGAKADGLGGKGEPGGGPGELAPVGPDEKEKGAGAGGEEKKGAGEGGKDGEGGKEGEKKNGKYEKPPFSYNALIMMAIRQSPEKRLTLNGIYEFIMKNFPYYRENKQGWQNSIRHNLSLNKCFVKVPRHYDDPGKGNYWMLDPSSDDVFIGGTTGKLRRRSTTSRAKLAFKRGARLTSTGLTFMDRAGSLYWPMSPFLSLHHPRASSTLSYNGTTSAYPSHPMPYSSVLTQNSLGNNHSFSTANGLSVDRLVNGEIPYATHHLTAAALAASVPCGLSVPCSGTYSLNPCSVNLLAGQTSYFFPHVPHPSMTSQSSTSMSARAASSSTSPQAPSTLPCESLRPSLPSFTTGLSGGLSDYFTHQNQGSSSNPLIH	489	P55316	K	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [192, 197, 218], 'DOMAIN_gain_score': array([0.10098374, 0.10722995, 0.03932965]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
272	NM_000284.4(PDHA1):c.506C>T (p.Ala169Val)	214941	CA323959	NM_000284.4:c.506C>T, ENST00000422285.7:c.506C>T, ENST00000355808.9:c.527C>T, ENST00000379805.3:c.506C>T, ENST00000379806.9:c.620C>T, ENST00000422285.6:c.506C>T, ENST00000479146.1:n.341C>T, ENST00000540249.5:c.506C>T, ENST00000545074.5:c.527C>T, NM_000284.3:c.506C>T, NM_001173454.1:c.620C>T, NM_001173455.1:c.527C>T, NM_001173456.1:c.506C>T, XM_011545531.1:c.641C>T, XM_011545532.1:c.641C>T, XM_017029574.2:c.620C>T, NM_001173454.2:c.620C>T, NM_001173455.2:c.527C>T, NM_001173456.2:c.506C>T, NC_000023.11:g.19353169C>T, CM000685.2:g.19353169C>T, NC_000023.10:g.19371287C>T, CM000685.1:g.19371287C>T, NC_000023.9:g.19281208C>T, NG_016781.1:g.14277C>T, NM_000284.4(PDHA1):c.506C>T (p.Ala169Val)	PDHA1	pyruvate dehydrogenase deficiency	MONDO:0019169	X-linked inheritance	Pathogenic	PP3, PP4, PS2, PM2, PM1	BS2, BA1, PS1, BS1, PM5	The c.506C>T variant in the PDHA1 gene is a missense mutation occurring in a hotspot domain (aa position A169, located in α β heterodimer interface (PM1). This variant is absent from population databases (PM2). This variant has been reported in three individuals in the literature with presentations consistent with PDHA1-related disease. These three cases include two assumed de novo cases (PMID: 20002461 and PMID: 21914562), and one maternity confirmed de novo case via exome sequencing in PMID: 31683770 (PS2). PMID: 20002461 Western Blot studies showed reduced E1a, and Imbard et al 2011 PDC studies indicate activity <3rd percentile in fibroblasts (PP4). In silico predictors suggest a deleterious effect (REVEL score – 0.946; PP3). In summary, this variant meets criteria to be classified as a pathogenic of PDHA1- related pyruvate dehydrogenase deficiency in an X-linked manner. PDHA1-specific ACMG/AMP criteria applied: (PM1, PM2, PS2, PP3, PP4). This was reviewed with the PDHA1 expert panel on 4/6/2021 and approved on 4/6/2021.		Mitochondrial Diseases VCEP	https://www.clinicalgenome.org/affiliation/50027/docs/assertion-criteria	2021-05-06	2021-05-06	False	https://erepo.genome.network/evrepo/ui/classification/CA323959/MONDO:0019169/014	dc5261dd-3db5-4b9d-a01b-0c4006234082	p.Ala169Val	Ala	169	Val	MRKMLAAVSRVLSGASQKPASRVLVASRNFANDATFEIKKCDLHRLEEGPPVTTVLTREDGLKYYRMMQTVRRMELKADQLYKQKIIRGFCHLCDGQEACCVGLEAGINPTDHLITAYRAHGFTFTRGLSVREILAELTGRKGGCAKGKGGSMHMYAKNFYGGNGIVGAQVPLGAGIALACKYNGKDEVCLTLYGDGAANQGQIFEAYNMAALWKLPCIFICENNRYGMGTSVERAAASTDYYKRGDFIPGLRVDGMDILCVREATRFAAAYCRSGKGPILMELQTYRYHGHSMSDPGVSYRTREEIQEVRSKSDPIMLLKDRMVNSNLASVEELKEIDVEVRKEIEDAAQFATADPEPPLEELGYHIYSSDPPFEVRGANQWIKFKSVS	390	P08559	V	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [282], 'BINDING_gain_score': array([0.0079999]), 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [81], 'DOMAIN_gain_score': array([0.00681144]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [180], 'REPEAT_gain_score': array([0.0055005]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
273	NM_000284.4(PDHA1):c.999A>C (p.Glu333Asp)	378343	CA10363173	NM_000284.4:c.999A>C, ENST00000422285.7:c.999A>C, ENST00000379804.1:c.156A>C, ENST00000379806.9:c.1113A>C, ENST00000422285.6:c.999A>C, ENST00000478795.1:n.438A>C, ENST00000481733.1:n.427A>C, ENST00000540249.5:c.906A>C, ENST00000545074.5:c.1020A>C, NM_000284.3:c.999A>C, NM_001173454.1:c.1113A>C, NM_001173455.1:c.1020A>C, NM_001173456.1:c.906A>C, XM_011545531.1:c.1134A>C, XM_011545532.1:c.1041A>C, XM_017029574.2:c.1020A>C, NM_001173454.2:c.1113A>C, NM_001173455.2:c.1020A>C, NM_001173456.2:c.906A>C, NC_000023.11:g.19359015A>C, CM000685.2:g.19359015A>C, NC_000023.10:g.19377133A>C, CM000685.1:g.19377133A>C, NC_000023.9:g.19287054A>C, NG_016781.1:g.20123A>C, NG_021184.1:g.161247T>G, NM_000284.4(PDHA1):c.999A>C (p.Glu333Asp)	PDHA1	pyruvate dehydrogenase deficiency	MONDO:0019169	X-linked inheritance	Benign	BS2, BS1	PP3, BA1, BP4, PS1, PVS1, PM2, PM1, PM5	The allele frequency of the c.999A>C variant in the PDHA1 gene is 0.044% in gnomAD, including 25 hemizygotes. This allele frequency, and the frequency with which it is seen in hemizygotes in the general population are high enough to be classified as benign based on thresholds defined by the ClinGen PDHA1 Variant Curation Expert Panel (>0.0092%- BS1; gnomAD >16 hemizygotes- BS2). In silico predictors provide a conflicting score (REVEL score 0.509). In summary, this variant meets criteria to be classified as benign for PDHA1- related pyruvate dehydrogenase deficiency in an X-linked manner. PDHA1-specific ACMG/AMP criteria applied: (BS1, BS2). This was reviewed with the PDHA1 expert panel on 4/6/2021 and approved on 4/6/2021.		Mitochondrial Diseases VCEP	https://www.clinicalgenome.org/affiliation/50027/docs/assertion-criteria	2021-05-06	2021-05-06	False	https://erepo.genome.network/evrepo/ui/classification/CA10363173/MONDO:0019169/014	b000cfe0-fa2b-4a64-89d9-917fee0b821c	p.Glu333Asp	Glu	333	Asp	MRKMLAAVSRVLSGASQKPASRVLVASRNFANDATFEIKKCDLHRLEEGPPVTTVLTREDGLKYYRMMQTVRRMELKADQLYKQKIIRGFCHLCDGQEACCVGLEAGINPTDHLITAYRAHGFTFTRGLSVREILAELTGRKGGCAKGKGGSMHMYAKNFYGGNGIVGAQVPLGAGIALACKYNGKDEVCLTLYGDGAANQGQIFEAYNMAALWKLPCIFICENNRYGMGTSVERAAASTDYYKRGDFIPGLRVDGMDILCVREATRFAAAYCRSGKGPILMELQTYRYHGHSMSDPGVSYRTREEIQEVRSKSDPIMLLKDRMVNSNLASVEELKEIDVEVRKEIEDAAQFATADPEPPLEELGYHIYSSDPPFEVRGANQWIKFKSVS	390	P08559	D	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [245], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.00426257]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [84], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.00038272]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [180], 'REPEAT_gain_score': array([0.00277436]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
274	NM_000284.4(PDHA1):c.844A>C (p.Met282Leu)	10885	CA121220	NM_000284.4:c.844A>C, ENST00000422285.7:c.844A>C, ENST00000379804.1:c.1A>C, ENST00000379806.9:c.958A>C, ENST00000422285.6:c.844A>C, ENST00000478795.1:n.283A>C, ENST00000481733.1:n.272A>C, ENST00000540249.5:c.751A>C, ENST00000545074.5:c.865A>C, NM_000284.3:c.844A>C, NM_001173454.1:c.958A>C, NM_001173455.1:c.865A>C, NM_001173456.1:c.751A>C, XM_011545531.1:c.979A>C, XM_011545532.1:c.886A>C, XM_017029574.2:c.865A>C, NM_001173454.2:c.958A>C, NM_001173455.2:c.865A>C, NM_001173456.2:c.751A>C, NC_000023.11:g.19357664A>C, CM000685.2:g.19357664A>C, NC_000023.10:g.19375782A>C, CM000685.1:g.19375782A>C, NC_000023.9:g.19285703A>C, NG_016781.1:g.18772A>C, NM_000284.4(PDHA1):c.844A>C (p.Met282Leu)	PDHA1	pyruvate dehydrogenase deficiency	MONDO:0019169	X-linked inheritance	Benign	BS2, BA1	PP3, BP4, PM2, PM5, PM1	The allele frequency of the c.844A>C; p. M282L variant in the PDHA1 gene is 0.207% in gnomAD, including 1,436 hemizygotes. This allele frequency, and the frequency with which it is seen in hemizygotes in the general population are high enough to be classified as benign based on thresholds defined by the ClinGen PDHA1 Variant Curation Expert Panel (>0.092%; gnomAD >16 hemizygotes). In summary, this variant meets criteria to be classified as benign for PDHA1- related pyruvate dehydrogenase deficiency in an X-linked manner. PDHA1-specific ACMG/AMP criteria applied: (BA1, BS2). This was reviewed with the PDHA1 expert panel on 2/16/2021 and approved on 2/16/2021.		Mitochondrial Diseases VCEP	https://www.clinicalgenome.org/affiliation/50027/docs/assertion-criteria	2021-04-02	2021-05-06	False	https://erepo.genome.network/evrepo/ui/classification/CA121220/MONDO:0019169/014	9b20eee9-ea40-4e89-b0d2-b35d745e803a	p.Met282Leu	Met	282	Leu	MRKMLAAVSRVLSGASQKPASRVLVASRNFANDATFEIKKCDLHRLEEGPPVTTVLTREDGLKYYRMMQTVRRMELKADQLYKQKIIRGFCHLCDGQEACCVGLEAGINPTDHLITAYRAHGFTFTRGLSVREILAELTGRKGGCAKGKGGSMHMYAKNFYGGNGIVGAQVPLGAGIALACKYNGKDEVCLTLYGDGAANQGQIFEAYNMAALWKLPCIFICENNRYGMGTSVERAAASTDYYKRGDFIPGLRVDGMDILCVREATRFAAAYCRSGKGPILMELQTYRYHGHSMSDPGVSYRTREEIQEVRSKSDPIMLLKDRMVNSNLASVEELKEIDVEVRKEIEDAAQFATADPEPPLEELGYHIYSSDPPFEVRGANQWIKFKSVS	390	P08559	L	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [282], 'BINDING_gain_score': array([0.0439958]), 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [84], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.00435495]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [190], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.00258642]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
275	NM_014297.5(ETHE1):c.487C>T (p.Arg163Trp)	2317	CA115479	NM_014297.5:c.487C>T, ENST00000292147.7:c.487C>T, ENST00000292147.6:c.487C>T, ENST00000594342.5:c.*50C>T, ENST00000598330.1:c.*50C>T, ENST00000600651.5:c.487C>T, NM_014297.3:c.487C>T, XM_005258687.2:c.406C>T, XM_005258688.2:c.118C>T, XM_011526685.1:c.227-2591C>T, NM_001320867.1:c.454C>T, NM_001320868.1:c.118C>T, NM_001320869.1:c.193C>T, NM_014297.4:c.487C>T, XM_005258687.4:c.406C>T, NM_001320867.2:c.454C>T, NM_001320868.2:c.118C>T, NM_001320869.2:c.193C>T, NC_000019.10:g.43511455G>A, CM000681.2:g.43511455G>A, NC_000019.9:g.44015607G>A, CM000681.1:g.44015607G>A, NC_000019.8:g.48707447G>A, NG_008141.1:g.20790C>T, NM_014297.5(ETHE1):c.487C>T (p.Arg163Trp)	ETHE1	ethylmalonic encephalopathy	MONDO:0011229	Autosomal recessive inheritance	Pathogenic	PP3, PP1_Strong, PM3_Strong, PP4_Moderate, PS3_Supporting, PM5	BS2, PP2, BA1, BP2, BP1, BP4, PS4, PS1, PM2, BS4, BS1	The ETHE1 c.487C>T mutation is a missense mutation at the 163 amino acid position where one other pathogenic mutation has been reported (c.488G>A) indicating that this residue is critical to the function of the protein (PM5_moderate). There are multiple lines of computational evidence supporting a deleterious effect (PP3_supporting). Functional studies performed in ETHE1 isolated from E-coli cells demonstrated 10 fold reduced ETHE1 catalytic activity when compared to controls (PS3_supporting; PMID:25198162). The c.487C>T mutation has been reported in four unrelated affected individuals including three who were homozygous for the mutation (PMID:16183799; PMID:16828325; PMID:28698729) and one proband where the c. 487C>T was found in trans with another reportedly pathogenic ETHE1 mutation (PMID:18593870) (PM3_strong). One of these patients demonstrated a clinical phenotype specific to ethylmalonic encephalopathy including chronic diarrhea, petechiae, acrocyanosis, and developmental delay in addition to the biochemical findings urinary ethylmalonic acid and elevated blood C4-acylcarnitine esters and blood C5-acylcarnitines (PP4_moderate; PMID: 16828325). A larger family including 7 children has been reported where homozygous c.487C>T mutation was identified in the three affected siblings and segregated with disease in the unaffected siblings (PP1_strong; PMID:14732903). In summary, this variant meets criteria to be classified as pathogenic for ethylmalonic encephalopathy in an autosomal recessive manner. ETHE1-specific ACMG/AMP criteria applied PM5_moderate; PP3_supporting; PS3_supporting; PM3_strong; PP4_moderate; PP1_strong.		Mitochondrial Diseases VCEP	https://www.clinicalgenome.org/affiliation/50027/docs/assertion-criteria	2021-05-06	2021-05-06	False	https://erepo.genome.network/evrepo/ui/classification/CA115479/MONDO:0011229/014	fee72906-744e-40b2-a972-1025f79f0db5	p.Arg163Trp	Arg	163	Trp	MAEAVLRVARRQLSQRGGSGAPILLRQMFEPVSCTFTYLLGDRESREAVLIDPVLETAPRDAQLIKELGLRLLYAVNTHCHADHITGSGLLRSLLPGCQSVISRLSGAQADLHIEDGDSIRFGRFALETRASPGHTPGCVTFVLNDHSMAFTGDALLIRGCGRTDFQQGCAKTLYHSVHEKIFTLPGDCLIYPAHDYHGFTVSTVEEERTLNPRLTLSCEEFVKIMGNLNLPKPQQIDFAVPANMRCGVQTPTA	254	O95571	W	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [17], 'SIGNAL_gain': [], 'SIGNAL_loss_score': array([-0.03195834]), 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [226], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.01547831]), 'REGION_loss': [81, 125, 130, 133], 'REGION_gain': [], 'REGION_loss_score': array([-0.00508606, -0.0253405 , -0.02592373, -0.02315921]), 'REPEAT_loss': [137, 151, 152], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.00893706, -0.02335674, -0.01251888]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
276	NM_014297.5(ETHE1):c.61G>T (p.Ala21Ser)	137240	CA290780	NM_014297.5:c.61G>T, ENST00000292147.7:c.61G>T, ENST00000292147.6:c.61G>T, ENST00000458714.2:c.135+491C>A, ENST00000594342.5:c.61G>T, ENST00000595115.1:n.114G>T, ENST00000598330.1:c.61G>T, ENST00000600651.5:c.61G>T, ENST00000602138.1:c.61G>T, NM_014297.3:c.61G>T, XM_005258687.2:c.-181G>T, XM_005258688.2:c.-160G>T, XM_011526685.1:c.61G>T, NM_001320867.1:c.61G>T, NM_001320868.1:c.-160G>T, NM_001320869.1:c.61G>T, NM_014297.4:c.61G>T, XM_005258687.4:c.-181G>T, NM_001320867.2:c.61G>T, NM_001320868.2:c.-160G>T, NM_001320869.2:c.61G>T, NC_000019.10:g.43527117C>A, CM000681.2:g.43527117C>A, NC_000019.9:g.44031269C>A, CM000681.1:g.44031269C>A, NC_000019.8:g.48723109C>A, NG_008141.1:g.5128G>T, NM_014297.5(ETHE1):c.61G>T (p.Ala21Ser)	ETHE1	ethylmalonic encephalopathy	MONDO:0011229	Autosomal recessive inheritance	Benign	BS2, BA1	PP3, PP4, BP4, PS2, PS1, PS3, PM2, PM6, PVS1, BP5, BS3, PM5	The allele frequency of the c.61G>T variant in the ETHE1 gene is 0.7%  in gnomAD, including 33 homozygotes which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen ETHE1 Variant Curation Expert Panel (>0.1% in gnomAD- BA1 and BS2). In summary, this variant meets criteria to be classified as benign for ETHE1-related ethylmalonic encephalopathy. ETHE1 specific ACMG/AMP criteria applied: (BA1, BS2). This was reviewed with the ETHE1 expert panel on 2/23/2021 and approved on 2/23/2021.		Mitochondrial Diseases VCEP	https://www.clinicalgenome.org/affiliation/50027/docs/assertion-criteria	2021-05-06	2021-05-06	False	https://erepo.genome.network/evrepo/ui/classification/CA290780/MONDO:0011229/014	24885ccf-9898-4dd2-9697-2788635e2099	p.Ala21Ser	Ala	21	Ser	MAEAVLRVARRQLSQRGGSGAPILLRQMFEPVSCTFTYLLGDRESREAVLIDPVLETAPRDAQLIKELGLRLLYAVNTHCHADHITGSGLLRSLLPGCQSVISRLSGAQADLHIEDGDSIRFGRFALETRASPGHTPGCVTFVLNDHSMAFTGDALLIRGCGRTDFQQGCAKTLYHSVHEKIFTLPGDCLIYPAHDYHGFTVSTVEEERTLNPRLTLSCEEFVKIMGNLNLPKPQQIDFAVPANMRCGVQTPTA	254	O95571	S	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [17], 'SIGNAL_gain': [], 'SIGNAL_loss_score': array([-0.03013694]), 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [226], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.01722282]), 'REGION_loss': [81, 133], 'REGION_gain': [], 'REGION_loss_score': array([-0.01886582, -0.00197244]), 'REPEAT_loss': [137, 151], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.0099715 , -0.01211905]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
277	NM_003159.2(CDKL5):c.533G>A (p.Arg178Gln)	94113	CA199289	NM_003159.2:c.533G>A, ENST00000623535.2:c.533G>A, ENST00000635828.1:c.533G>A, ENST00000637881.1:c.533G>A, ENST00000674046.1:c.533G>A, ENST00000379989.6:c.533G>A, ENST00000379996.7:c.533G>A, ENST00000463994.4:c.533G>A, ENST00000623535.1:n.533G>A, NM_001037343.1:c.533G>A, XM_011545569.1:c.533G>A, XM_011545570.1:c.401G>A, XR_950484.1:n.785G>A, NM_001323289.1:c.533G>A, NM_001323289.2:c.533G>A, NM_001037343.2:c.533G>A, NM_003159.3:c.533G>A, NC_000023.11:g.18584332G>A, CM000685.2:g.18584332G>A, NC_000023.10:g.18602452G>A, CM000685.1:g.18602452G>A, NC_000023.9:g.18512373G>A, NG_008475.1:g.163728G>A, NM_003159.2(CDKL5):c.533G>A (p.Arg178Gln)	CDKL5	CDKL5 disorder	MONDO:0100039	X-linked inheritance (dominant (HP:0001423))	Pathogenic	PM2_Supporting, PS2_Very Strong, PS4, PM5_Strong	PP3	The p.Arg178Gln variant in CDKL5 has been reported in at least 4 de novo occurrences (biological parentage unconfirmed) in patients with CDKL5 disorder (PMID 26482601, 21770923, 29852413, 29190809, 24564546, 26482601) (PM6_very strong). The variant was present in the mosaic state in one patient, confirming its de novo nature (PMID 26482601) (PS2). The p.Arg178Gln variant in CDKL5 has been reported in at least 7 other individuals with CDKL5 disorder (PMID 26482601, 21770923, 29852413, 29190809, 24564546) (PS4). Multiple pathogenic missense variants have been previously identified within this codon which indicates that this residue is critical to the function of the protein (PMID 29100083, 22430159, 19793311, 18809835, 30182498) (PM5_strong). The p.Arg178Gln variant in CDKL5 is absent from gnomAD (PM2_supporting). In summary, the p.Arg178Gln variant in CDKL5 is classified as Pathogenic for CDKL5 disorder based on the ACMG/AMP criteria (PM6_very strong, PS2, PS4, PM5_strong, PM2_supporting).	29852413, 24564546, 21770923, 29190809, 26482601, 29852413, 24564546, 21770923, 29190809	Rett and Angelman-like Disorders VCEP	https://clinicalgenome.org/site/assets/files/7339/clingen_rettas_acmg_specifications_v2.pdf	2021-03-25	2021-05-10	False	https://erepo.genome.network/evrepo/ui/classification/CA199289/MONDO:0100039/016	1bf4c21f-9836-4b36-9366-021907530816	p.Arg178Gln	Arg	178	Gln	MKIPNIGNVMNKFEILGVVGEGAYGVVLKCRHKETHEIVAIKKFKDSEENEEVKETTLRELKMLRTLKQENIVELKEAFRRRGKLYLVFEYVEKNMLELLEEMPNGVPPEKVKSYIYQLIKAIHWCHKNDIVHRDIKPENLLISHNDVLKLCDFGFARNLSEGNNANYTEYVATRWYRSPELLLGAPYGKSVDMWSVGCILGELSDGQPLFPGESEIDQLFTIQKVLGPLPSEQMKLFYSNPRFHGLRFPAVNHPQSLERRYLGILNSVLLDLMKNLLKLDPADRYLTEQCLNHPTFQTQRLLDRSPSRSAKRKPYHVESSTLSNRNQAGKSTALQSHHRSNSKDIQNLSVGLPRADEGLPANESFLNGNLAGASLSPLHTKTYQASSQPGSTSKDLTNNNIPHLLSPKEAKSKTEFDFNIDPKPSEGPGTKYLKSNSRSQQNRHSFMESSQSKAGTLQPNEKQSRHSYIDTIPQSSRSPSYRTKAKSHGALSDSKSVSNLSEARAQIAEPSTSRYFPSSCLDLNSPTSPTPTRHSDTRTLLSPSGRNNRNEGTLDSRRTTTRHSKTMEELKLPEHMDSSHSHSLSAPHESFSYGLGYTSPFSSQQRPHRHSMYVTRDKVRAKGLDGSLSIGQGMAARANSLQLLSPQPGEQLPPEMTVARSSVKETSREGTSSFHTRQKSEGGVYHDPHSDDGTAPKENRHLYNDPVPRRVGSFYRVPSPRPDNSFHENNVSTRVSSLPSESSSGTNHSKRQPAFDPWKSPENISHSEQLKEKEKQGFFRSMKKKKKKSQTVPNSDSPDLLTLQKSIHSASTPSSRPKEWRPEKISDLQTQSQPLKSLRKLLHLSSASNHPASSDPRFQPLTAQQTKNSFSEIRIHPLSQASGGSSNIRQEPAPKGRPALQLPGQMDPGWHVSSVTRSATEGPSYSEQLGAKSGPNGHPYNRTNRSRMPNLNDLKETAL	960	O76039	Q	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [16], 'SIGNAL_gain': [], 'SIGNAL_loss_score': array([-0.01060319]), 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
278	NM_004992.3(MECP2):c.1180G>A (p.Glu394Lys)	143421	CA170197	NM_004992.3:c.1180G>A, ENST00000303391.11:c.1180G>A, ENST00000453960.7:c.1216G>A, ENST00000303391.10:c.1180G>A, ENST00000407218.5:c.*552G>A, ENST00000453960.6:c.1216G>A, ENST00000619732.4:c.1180G>A, ENST00000628176.2:c.*552G>A, NM_001110792.1:c.1216G>A, NM_001316337.1:c.901G>A, XM_005274681.3:c.1180G>A, XM_005274682.3:c.901G>A, XM_005274683.3:c.901G>A, XM_006724819.2:c.511G>A, XM_011531166.1:c.901G>A, XM_006724819.3:c.511G>A, XM_011531166.2:c.901G>A, XM_024452383.1:c.901G>A, XM_024452384.1:c.901G>A, NM_001110792.2:c.1216G>A, NM_001316337.2:c.901G>A, NM_001369391.2:c.901G>A, NM_001369392.2:c.901G>A, NM_001369393.2:c.901G>A, NM_001369394.1:c.901G>A, NM_001369394.2:c.901G>A, NM_001386137.1:c.511G>A, NM_001386138.1:c.511G>A, NM_001386139.1:c.511G>A, NM_004992.4:c.1180G>A, NC_000023.11:g.154030648C>T, CM000685.2:g.154030648C>T, NC_000023.10:g.153296099C>T, CM000685.1:g.153296099C>T, NC_000023.9:g.152949293C>T, NG_007107.2:g.111480G>A, NG_007107.3:g.111456G>A, NM_004992.3(MECP2):c.1180G>A (p.Glu394Lys)	MECP2	Rett syndrome	MONDO:0010726	X-linked inheritance	Benign	BS2, BA1, BP4, BP5		The allele frequency of the p.Glu394Lys variant in MECP2 is 0.035% in East Asian sub population in gnomAD, which is high enough to be classified as benign based on thresholds defined by the ClinGen Rett/Angelman-like Expert Panel for Rett/AS-like conditions (BA1). The p.Glu394Lys variant is observed in at least 2 unaffected individuals (internal database) (BS2). Computational analysis prediction tools suggest that the p.Glu394Lys variant does not have a deleterious impact; however this information does not predict clinical significance on its own (BP4). The p.Glu394Lys variant is found in a patient with an alternate molecular basis of disease (internal database) (BP5). In summary, the p.Glu394Lys variant in MECP2 is classified as benign based on the ACMG/AMP criteria (BA1, BS2, BP4, BP5).		Rett and Angelman-like Disorders VCEP	https://clinicalgenome.org/site/assets/files/7339/clingen_rettas_acmg_specifications_v2.pdf	2021-03-26	2021-05-17	False	https://erepo.genome.network/evrepo/ui/classification/CA170197/MONDO:0010726/016	cb6d3431-d972-4851-bc8e-700dee1752ff	p.Glu394Lys	Glu	394	Lys	MVAGMLGLREEKSEDQDLQGLKDKPLKFKKVKKDKKEEKEGKHEPVQPSAHHSAEPAEAGKAETSEGSGSAPAVPEASASPKQRRSIIRDRGPMYDDPTLPEGWTRKLKQRKSGRSAGKYDVYLINPQGKAFRSKVELIAYFEKVGDTSLDPNDFDFTVTGRGSPSRREQKPPKKPKSPKAPGTGRGRGRPKGSGTTRPKAATSEGVQVKRVLEKSPGKLLVKMPFQTSPGGKAEGGGATTSTQVMVIKRPGRKRKAEADPQAIPKKRGRKPGSVVAAAAAEAKKKAVKESSIRSVQETVLPIKKRKTRETVSIEVKEVVKPLLVSTLGEKSGKGLKTCKSPGRKSKESSPKGRSSSASSPPKKEHHHHHHHSESPKAPVPLLPPLPPPPPEPESSEDPTSPPEPQDLSSSVCKEEKMPRGGSLESDGCPKEPAKTQPAVATAATAAEKYKHRGEGERKDIVSSSMPRPNREEPVDSRTPVTERVS	486	P51608	K	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [374], 'COMPBIAS_gain_score': array([0.03034419]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
279	NM_003159.2(CDKL5):c.2896G>A (p.Val966Ile)	210646	CA209185	NM_003159.2:c.2896G>A, ENST00000379984.4:c.185-3176C>T, ENST00000673617.1:n.168G>A, ENST00000379984.3:c.185-3176C>T, ENST00000379989.6:c.2896G>A, ENST00000379996.7:c.2896G>A, ENST00000476595.1:n.30C>T, NM_000330.3:c.185-3176C>T, LRG_702t1:c.185-3176C>T, NM_001037343.1:c.2896G>A, XM_011545569.1:c.2968G>A, XM_011545570.1:c.2887G>A, XR_950484.1:n.3271G>A, NM_000330.4:c.185-3176C>T, NM_001037343.2:c.2896G>A, NM_003159.3:c.2896G>A, NC_000023.11:g.18650508G>A, CM000685.2:g.18650508G>A, NC_000023.10:g.18668628G>A, CM000685.1:g.18668628G>A, NC_000023.9:g.18578549G>A, NG_008475.1:g.229904G>A, NG_008659.3:g.31941C>T, LRG_702:g.31941C>T, NM_003159.2(CDKL5):c.2896G>A (p.Val966Ile)	CDKL5	CDKL5 disorder	MONDO:0100039	X-linked inheritance	Benign	BA1, BP4, BS2_Supporting, BP5		The allele frequency of the p.Val966Ile variant in CDKL5 is 0.03% in South Asian sub population in gnomAD, which is high enough to be classified as benign based on thresholds defined by the ClinGen Rett/Angelman-like Expert Panel for Rett/AS-like conditions (BA1). The p.Val966Ile variant is observed in at least 1 unaffected individual (internal database) (BS2_supporting). Computational analysis prediction tools suggest that the p.Val966Ile variant does not have a deleterious impact; however this information does not predict clinical significance on its own (BP4). The p.Val966Ile variant is found in a patient with an alternate molecular basis of disease (internal database) (BP5). In summary, the p.Val966Ile variant in CDKL5 is classified as benign based on the ACMG/AMP criteria applied (BA1, BS2_supporting, BP4, BP5).		Rett and Angelman-like Disorders VCEP	https://clinicalgenome.org/site/assets/files/7339/clingen_rettas_acmg_specifications_v2.pdf	2021-03-26	2021-05-17	False	https://erepo.genome.network/evrepo/ui/classification/CA209185/MONDO:0100039/016	6358edd6-1663-4d8a-9784-64f135a14164	p.Val966Ile	Val	966	Ile	MKIPNIGNVMNKFEILGVVGEGAYGVVLKCRHKETHEIVAIKKFKDSEENEEVKETTLRELKMLRTLKQENIVELKEAFRRRGKLYLVFEYVEKNMLELLEEMPNGVPPEKVKSYIYQLIKAIHWCHKNDIVHRDIKPENLLISHNDVLKLCDFGFARNLSEGNNANYTEYVATRWYRSPELLLGAPYGKSVDMWSVGCILGELSDGQPLFPGESEIDQLFTIQKVLGPLPSEQMKLFYSNPRFHGLRFPAVNHPQSLERRYLGILNSVLLDLMKNLLKLDPADRYLTEQCLNHPTFQTQRLLDRSPSRSAKRKPYHVESSTLSNRNQAGKSTALQSHHRSNSKDIQNLSVGLPRADEGLPANESFLNGNLAGASLSPLHTKTYQASSQPGSTSKDLTNNNIPHLLSPKEAKSKTEFDFNIDPKPSEGPGTKYLKSNSRSQQNRHSFMESSQSKAGTLQPNEKQSRHSYIDTIPQSSRSPSYRTKAKSHGALSDSKSVSNLSEARAQIAEPSTSRYFPSSCLDLNSPTSPTPTRHSDTRTLLSPSGRNNRNEGTLDSRRTTTRHSKTMEELKLPEHMDSSHSHSLSAPHESFSYGLGYTSPFSSQQRPHRHSMYVTRDKVRAKGLDGSLSIGQGMAARANSLQLLSPQPGEQLPPEMTVARSSVKETSREGTSSFHTRQKSEGGVYHDPHSDDGTAPKENRHLYNDPVPRRVGSFYRVPSPRPDNSFHENNVSTRVSSLPSESSSGTNHSKRQPAFDPWKSPENISHSEQLKEKEKQGFFRSMKKKKKKSQTVPNSDSPDLLTLQKSIHSASTPSSRPKEWRPEKISDLQTQSQPLKSLRKLLHLSSASNHPASSDPRFQPLTAQQTKNSFSEIRIHPLSQASGGSSNIRQEPAPKGRPALQLPGQMDPGWHVSSVTRSATEGPSYSEQLGAKSGPNGHPYNRTNRSRMPNLNDLKETAL	960	O76039	I	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [241], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.00147331]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [950, 951, 952], 'COMPBIAS_gain': [], 'COMPBIAS_loss_score': array([-0.13358134, -0.1380794 , -0.24757403]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
280	NM_004992.3(MECP2):c.608C>T (p.Thr203Met)	95198	CA148319	NM_004992.3:c.608C>T, NC_000023.11:g.154031220G>A, CM000685.2:g.154031220G>A, NC_000023.10:g.153296671G>A, CM000685.1:g.153296671G>A, NC_000023.9:g.152949865G>A, NG_007107.2:g.110908C>T, NG_007107.3:g.110884C>T, ENST00000303391.11:c.608C>T, ENST00000453960.7:c.644C>T, ENST00000637917.1:n.65+176C>T, ENST00000303391.10:c.608C>T, ENST00000407218.5:c.535C>T, ENST00000453960.6:c.644C>T, ENST00000619732.4:c.608C>T, ENST00000622433.4:c.596C>T, ENST00000628176.2:c.499C>T, NM_001110792.1:c.644C>T, NM_001316337.1:c.329C>T, XM_005274681.3:c.608C>T, XM_005274682.3:c.329C>T, XM_005274683.3:c.329C>T, XM_006724819.2:c.-62C>T, XM_011531166.1:c.329C>T, XM_006724819.3:c.-62C>T, XM_011531166.2:c.329C>T, XM_024452383.1:c.329C>T, XM_024452384.1:c.329C>T, NM_001110792.2:c.644C>T, NM_001316337.2:c.329C>T, NM_001369391.2:c.329C>T, NM_001369392.2:c.329C>T, NM_001369393.2:c.329C>T, NM_001369394.1:c.329C>T, NM_001369394.2:c.329C>T, NM_001386137.1:c.-62C>T, NM_001386138.1:c.-62C>T, NM_001386139.1:c.-62C>T, NM_004992.4:c.608C>T, NM_004992.3(MECP2):c.608C>T (p.Thr203Met)	MECP2	Rett syndrome	MONDO:0010726	X-linked inheritance	Benign	BS2, BA1, BP4, BP5		The allele frequency of the p.Thr203Met variant in MECP2 is 0.07% in gnomAD, which is high enough to be classified as benign based on thresholds defined by the ClinGen Rett/Angelman-like Expert Panel for Rett/AS-like conditions (BA1). The p.Thr203Met variant is observed in at least 2 unaffected individuals (internal database) (BS2). Computational analysis prediction tools suggest that the p.Thr203Met variant does not have a deleterious impact; however this information does not predict clinical significance on its own (BP4). The p.Thr203Met variant is found in a patient with an alternate molecular basis of disease (internal database) (BP5). In summary, the p.Thr203Met variant in MECP2 is classified as benign based on the ACMG/AMP criteria (BA1, BS2, BP4, BP5).		Rett and Angelman-like Disorders VCEP	https://clinicalgenome.org/site/assets/files/7339/clingen_rettas_acmg_specifications_v2.pdf	2021-03-26	2021-05-17	False	https://erepo.genome.network/evrepo/ui/classification/CA148319/MONDO:0010726/016	49670d6c-9ef7-465b-a280-333556f92e42	p.Thr203Met	Thr	203	Met	MVAGMLGLREEKSEDQDLQGLKDKPLKFKKVKKDKKEEKEGKHEPVQPSAHHSAEPAEAGKAETSEGSGSAPAVPEASASPKQRRSIIRDRGPMYDDPTLPEGWTRKLKQRKSGRSAGKYDVYLINPQGKAFRSKVELIAYFEKVGDTSLDPNDFDFTVTGRGSPSRREQKPPKKPKSPKAPGTGRGRGRPKGSGTTRPKAATSEGVQVKRVLEKSPGKLLVKMPFQTSPGGKAEGGGATTSTQVMVIKRPGRKRKAEADPQAIPKKRGRKPGSVVAAAAAEAKKKAVKESSIRSVQETVLPIKKRKTRETVSIEVKEVVKPLLVSTLGEKSGKGLKTCKSPGRKSKESSPKGRSSSASSPPKKEHHHHHHHSESPKAPVPLLPPLPPPPPEPESSEDPTSPPEPQDLSSSVCKEEKMPRGGSLESDGCPKEPAKTQPAVATAATAAEKYKHRGEGERKDIVSSSMPRPNREEPVDSRTPVTERVS	486	P51608	M	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
281	NM_001083962.2(TCF4):c.269A>G (p.Asn90Ser)	167731	CA234991	NM_001083962.2:c.269A>G, NC_000018.10:g.55461054T>C, CM000680.2:g.55461054T>C, NC_000018.9:g.53128285T>C, CM000680.1:g.53128285T>C, NC_000018.8:g.51279283T>C, NG_011716.1:g.132576A>G, NG_011716.2:g.179940A>G, ENST00000354452.8:c.269A>G, ENST00000635822.2:c.269A>G, ENST00000636400.2:c.197A>G, ENST00000636751.2:c.197A>G, ENST00000637115.2:c.*159A>G, ENST00000637239.2:n.336A>G, ENST00000638154.3:c.299A>G, ENST00000674598.1:n.739A>G, ENST00000674764.1:c.143A>G, ENST00000354452.7:c.269A>G, ENST00000356073.8:c.269A>G, ENST00000398339.5:c.575A>G, ENST00000537578.5:c.197A>G, ENST00000540999.5:c.197A>G, ENST00000543082.5:c.143A>G, ENST00000562543.5:c.269A>G, ENST00000562847.5:c.32A>G, ENST00000563686.5:n.124A>G, ENST00000563824.5:c.197A>G, ENST00000563888.6:c.197A>G, ENST00000564343.5:c.197A>G, ENST00000564403.6:c.269A>G, ENST00000564999.5:c.269A>G, ENST00000565018.6:c.197A>G, ENST00000565580.3:n.198A>G, ENST00000565908.6:c.197A>G, ENST00000566279.5:c.269A>G, ENST00000566286.5:n.263A>G, ENST00000566514.5:c.230A>G, ENST00000567880.5:n.269A>G, ENST00000568147.5:c.233A>G, ENST00000568169.5:c.281A>G, ENST00000568673.5:c.197A>G, ENST00000568740.5:c.197A>G, ENST00000569357.4:n.478A>G, ENST00000616053.4:c.197A>G, ENST00000625716.2:n.199A>G, ENST00000626425.2:c.197A>G, ENST00000626595.2:c.269A>G, ENST00000627136.2:n.243A>G, ENST00000627320.2:c.*199A>G, ENST00000627685.2:c.197A>G, ENST00000627784.2:c.269A>G, ENST00000629387.2:c.269A>G, ENST00000630319.2:c.74-57536A>G, NM_001083962.1:c.269A>G, NM_001243226.2:c.575A>G, NM_001243227.1:c.197A>G, NM_001243228.1:c.269A>G, NM_001243230.1:c.263A>G, NM_001243231.1:c.143A>G, NM_001306207.1:c.197A>G, NM_003199.2:c.269A>G, NR_132985.1:n.178+8344T>C, XM_005266739.3:c.197A>G, XM_005266741.3:c.269A>G, XM_005266743.3:c.197A>G, XM_005266744.3:c.197A>G, XM_005266745.3:c.197A>G, XM_005266747.3:c.143A>G, XM_006722536.2:c.269A>G, XM_006722537.2:c.269A>G, XM_006722538.2:c.197A>G, XM_011526154.1:c.575A>G, XM_011526155.1:c.575A>G, XM_011526156.1:c.575A>G, XM_011526157.1:c.575A>G, XM_011526158.1:c.263A>G, NM_001330604.2:c.269A>G, NM_001348211.1:c.143A>G, NM_001348217.1:c.197A>G, NM_001348218.1:c.197A>G, NM_001348219.1:c.197A>G, NM_001348220.1:c.197A>G, XM_005266739.4:c.197A>G, XM_005266741.4:c.269A>G, XM_005266745.4:c.197A>G, XM_006722536.3:c.269A>G, XM_006722537.3:c.269A>G, XM_006722538.3:c.197A>G, XM_017025934.2:c.197A>G, XM_017025935.2:c.197A>G, XM_017025936.2:c.197A>G, XM_017025937.2:c.197A>G, XM_017025938.2:c.269A>G, XM_017025940.2:c.269A>G, XM_017025941.2:c.269A>G, XM_017025942.2:c.269A>G, XM_017025943.2:c.269A>G, XM_017025944.2:c.197A>G, XM_017025945.2:c.197A>G, XM_017025946.2:c.197A>G, XM_017025948.2:c.197A>G, XM_017025950.2:c.197A>G, XM_017025951.2:c.143A>G, XM_024451240.1:c.197A>G, XM_024451241.1:c.32A>G, NM_001243226.3:c.575A>G, NM_001243227.2:c.197A>G, NM_001243228.2:c.269A>G, NM_001243231.2:c.143A>G, NM_001330604.3:c.269A>G, NM_001348211.2:c.143A>G, NM_001348218.2:c.197A>G, NM_001348219.2:c.197A>G, NM_001369567.1:c.269A>G, NM_001369568.1:c.269A>G, NM_001369569.1:c.269A>G, NM_001369570.1:c.269A>G, NM_001369571.1:c.269A>G, NM_001369572.1:c.269A>G, NM_001369573.1:c.269A>G, NM_001369574.1:c.269A>G, NM_001369575.1:c.197A>G, NM_001369576.1:c.197A>G, NM_001369577.1:c.197A>G, NM_001369578.1:c.197A>G, NM_001369579.1:c.197A>G, NM_001369580.1:c.197A>G, NM_001369581.1:c.197A>G, NM_001369582.1:c.197A>G, NM_001369583.1:c.197A>G, NM_001369584.1:c.197A>G, NM_001369585.1:c.197A>G, NM_001369586.1:c.197A>G, NM_003199.3:c.269A>G, NM_001243230.2:c.263A>G, NM_001083962.2(TCF4):c.269A>G (p.Asn90Ser)	TCF4	Pitt-Hopkins syndrome	MONDO:0012589	Autosomal dominant inheritance	Benign	BS2, BA1, BP4		The allele frequency of the p.Asn90Ser variant in TCF4 is 1.5% in Ashkenazi Jewish sub population in gnomAD, which is high enough to be classified as benign based on thresholds defined by the ClinGen Rett/Angelman-like Expert Panel for Rett/AS-like conditions (BA1). The p.Asn90Ser variant is observed in at least 2 unaffected individuals (internal database) (BS2). Computational analysis prediction tools suggest that the p.Asn90Ser variant does not have a deleterious impact; however this information does not predict clinical significance on its own (BP4). In summary, the p.Asn90Ser variant in TCF4 is classified as benign based on the ACMG/AMP criteria (BA1, BS2, BP4).		Rett and Angelman-like Disorders VCEP	https://clinicalgenome.org/site/assets/files/7339/clingen_rettas_acmg_specifications_v2.pdf	2021-03-26	2021-05-17	False	https://erepo.genome.network/evrepo/ui/classification/CA234991/MONDO:0012589/016	8ab7cf89-4df9-4ee4-ac6a-8b22d634ebb3	p.Asn90Ser	Asn	90	Ser	MHHQQRMAALGTDKELSDLLDFSAMFSPPVSSGKNGPTSLASGHFTGSNVEDRSSSGSWGNGGHPSPSRNYGDGTPYDHMTSRDLGSHDNLSPPFVNSRIQSKTERGSYSSYGRESNLQGCHQQSLLGGDMDMGNPGTLSPTKPGSQYYQYSSNNPRRRPLHSSAMEVQTKKVRKVPPGLPSSVYAPSASTADYNRDSPGYPSSKPATSTFPSSFFMQDGHHSSDPWSSSSGMNQPGYAGMLGNSSHIPQSSSYCSLHPHERLSYPSHSSADINSSLPPMSTFHRSGTNHYSTSSCTPPANGTDSIMANRGSGAAGSSQTGDALGKALASIYSPDHTNNSFSSNPSTPVGSPPSLSAGTAVWSRNGGQASSSPNYEGPLHSLQSRIEDRLERLDDAIHVLRNHAVGPSTAMPGGHGDMHGIIGPSHNGAMGGLGSGYGTGLLSANRHSLMVGTHREDGVALRGSHSLLPNQVPVPQLPVQSATSPDLNPPQDPYRGMPPGLQGQSVSSGSSEIKSDDEGDENLQDTKSSEDKKLDDDKKDIKSITSNNDDEDLTPEQKAEREKERRMANNARERLRVRDINEAFKELGRMVQLHLKSDKPQTKLLILHQAVAVILSLEQQVRERNLNPKAACLKRREEEKVSSEPPPLSLAGPHPGMGDASNHMGQM	667	P15884	S	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [88, 227, 230], 'COMPBIAS_gain_score': array([0.04015362, 0.00497353, 0.00555211]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
282	NM_001083962.2(TCF4):c.944C>T (p.Ala315Val)	160091	CA239802	NM_001083962.2:c.944C>T, ENST00000354452.8:c.944C>T, ENST00000630720.3:c.464C>T, ENST00000635822.2:c.944C>T, ENST00000635990.2:n.624C>T, ENST00000636400.2:c.872C>T, ENST00000636751.2:c.*652C>T, ENST00000636822.2:c.554C>T, ENST00000637115.2:c.*834C>T, ENST00000637169.2:c.296C>T, ENST00000637239.2:n.1011C>T, ENST00000637250.2:n.638C>T, ENST00000637923.2:n.542C>T, ENST00000638154.3:c.974C>T, ENST00000643689.1:c.554C>T, ENST00000674764.1:c.*555C>T, ENST00000675707.1:c.554C>T, ENST00000354452.7:c.944C>T, ENST00000356073.8:c.944C>T, ENST00000398339.5:c.1250C>T, ENST00000457482.7:c.464C>T, ENST00000537578.5:c.872C>T, ENST00000537856.7:c.554C>T, ENST00000540999.5:c.872C>T, ENST00000543082.5:c.818C>T, ENST00000544241.6:c.731C>T, ENST00000561831.7:c.464C>T, ENST00000561992.5:c.554C>T, ENST00000562680.5:n.1035C>T, ENST00000563760.5:n.536C>T, ENST00000564228.5:n.731C>T, ENST00000564403.6:c.962C>T, ENST00000564999.5:c.944C>T, ENST00000565018.6:c.692C>T, ENST00000566279.5:c.764C>T, ENST00000566286.5:n.938C>T, ENST00000567880.5:n.764C>T, ENST00000568673.5:c.872C>T, ENST00000568740.5:c.869C>T, ENST00000570146.3:n.208C>T, ENST00000570177.6:c.554C>T, ENST00000570287.6:c.464C>T, ENST00000616053.4:c.692C>T, ENST00000626584.2:c.296C>T, ENST00000627136.2:n.545C>T, ENST00000628078.2:c.554C>T, ENST00000628360.1:n.41C>T, ENST00000628636.2:c.554C>T, ENST00000628689.2:c.*87C>T, ENST00000629343.2:c.554C>T, ENST00000629387.2:c.944C>T, ENST00000630720.2:c.464C>T, NM_001083962.1:c.944C>T, NM_001243226.2:c.1250C>T, NM_001243227.1:c.872C>T, NM_001243228.1:c.962C>T, NM_001243230.1:c.938C>T, NM_001243231.1:c.818C>T, NM_001243232.1:c.731C>T, NM_001243233.1:c.554C>T, NM_001243234.1:c.464C>T, NM_001243235.1:c.464C>T, NM_001243236.1:c.464C>T, NM_001306207.1:c.872C>T, NM_001306208.1:c.731C>T, NM_003199.2:c.944C>T, XM_005266739.3:c.872C>T, XM_005266741.3:c.941C>T, XM_005266743.3:c.872C>T, XM_005266744.3:c.872C>T, XM_005266745.3:c.869C>T, XM_005266747.3:c.818C>T, XM_005266749.3:c.734C>T, XM_005266752.3:c.554C>T, XM_005266754.3:c.554C>T, XM_005266755.3:c.554C>T, XM_005266761.3:c.464C>T, XM_006722536.2:c.944C>T, XM_006722537.2:c.944C>T, XM_006722538.2:c.869C>T, XM_006722539.2:c.554C>T, XM_006722540.2:c.554C>T, XM_011526154.1:c.1247C>T, XM_011526155.1:c.1250C>T, XM_011526156.1:c.1250C>T, XM_011526157.1:c.1247C>T, XM_011526158.1:c.938C>T, XM_011526159.1:c.554C>T, XM_011526160.1:c.554C>T, XM_011526161.1:c.554C>T, XM_011526162.1:c.554C>T, XM_011526163.1:c.554C>T, XM_011526164.1:c.554C>T, NM_001330604.2:c.944C>T, NM_001330605.2:c.554C>T, NM_001348211.1:c.818C>T, NM_001348212.1:c.554C>T, NM_001348213.1:c.554C>T, NM_001348214.1:c.464C>T, NM_001348215.1:c.296C>T, NM_001348216.1:c.464C>T, NM_001348217.1:c.872C>T, NM_001348218.1:c.872C>T, NM_001348219.1:c.872C>T, NM_001348220.1:c.869C>T, XM_005266739.4:c.872C>T, XM_005266741.4:c.941C>T, XM_005266745.4:c.869C>T, XM_005266749.4:c.734C>T, XM_005266752.5:c.554C>T, XM_005266755.5:c.554C>T, XM_005266761.4:c.464C>T, XM_006722536.3:c.944C>T, XM_006722537.3:c.944C>T, XM_006722538.3:c.869C>T, XM_017025934.2:c.869C>T, XM_017025935.2:c.872C>T, XM_017025936.2:c.872C>T, XM_017025937.2:c.869C>T, XM_017025938.2:c.941C>T, XM_017025940.2:c.944C>T, XM_017025941.2:c.944C>T, XM_017025942.2:c.941C>T, XM_017025943.2:c.944C>T, XM_017025944.2:c.869C>T, XM_017025945.2:c.872C>T, XM_017025946.2:c.872C>T, XM_017025948.2:c.869C>T, XM_017025950.2:c.869C>T, XM_017025951.2:c.818C>T, XM_017025952.2:c.731C>T, XM_017025953.2:c.734C>T, XM_017025954.2:c.554C>T, XM_017025956.2:c.554C>T, XM_024451240.1:c.872C>T, XM_024451241.1:c.707C>T, NM_001243226.3:c.1250C>T, NM_001243227.2:c.872C>T, NM_001243228.2:c.962C>T, NM_001243231.2:c.818C>T, NM_001243233.2:c.554C>T, NM_001243234.2:c.464C>T, NM_001243235.2:c.464C>T, NM_001243236.2:c.464C>T, NM_001330604.3:c.944C>T, NM_001330605.3:c.554C>T, NM_001348211.2:c.818C>T, NM_001348212.2:c.554C>T, NM_001348213.2:c.554C>T, NM_001348214.2:c.464C>T, NM_001348215.2:c.296C>T, NM_001348216.2:c.464C>T, NM_001348218.2:c.872C>T, NM_001348219.2:c.872C>T, NM_001369567.1:c.944C>T, NM_001369568.1:c.944C>T, NM_001369569.1:c.941C>T, NM_001369570.1:c.941C>T, NM_001369571.1:c.944C>T, NM_001369572.1:c.944C>T, NM_001369573.1:c.941C>T, NM_001369574.1:c.944C>T, NM_001369575.1:c.872C>T, NM_001369576.1:c.869C>T, NM_001369577.1:c.872C>T, NM_001369578.1:c.869C>T, NM_001369579.1:c.872C>T, NM_001369580.1:c.872C>T, NM_001369581.1:c.869C>T, NM_001369582.1:c.872C>T, NM_001369583.1:c.872C>T, NM_001369584.1:c.869C>T, NM_001369585.1:c.869C>T, NM_001369586.1:c.872C>T, NM_003199.3:c.944C>T, NM_001243230.2:c.938C>T, NC_000018.10:g.55261512G>A, CM000680.2:g.55261512G>A, NC_000018.9:g.52928743G>A, CM000680.1:g.52928743G>A, NC_000018.8:g.51079741G>A, NG_011716.1:g.332118C>T, NG_011716.2:g.379482C>T, NM_001083962.2(TCF4):c.944C>T (p.Ala315Val)	TCF4	Pitt-Hopkins syndrome	MONDO:0012589	Autosomal dominant inheritance	Benign	BS2, BA1, BP5		The allele frequency of the p.Ala315Val variant in TCF4 is 0.1% in European (Non-Finnish) sub population in gnomAD, which is high enough to be classified as benign based on thresholds defined by the ClinGen Rett/Angelman-like Expert Panel for Rett/AS-like conditions (BA1). The p.Ala315Val variant is observed in at least 2 unaffected individuals (internal database) (BS2). The p.Ala315Val variant is found in a patient with an alternate molecular basis of disease (internal database) (BP5). In summary, the p.Ala315Val variant in TCF4 is classified as benign based on the ACMG/AMP criteria (BA1, BS2, BP5).		Rett and Angelman-like Disorders VCEP	https://clinicalgenome.org/site/assets/files/7339/clingen_rettas_acmg_specifications_v2.pdf	2021-03-26	2021-05-17	False	https://erepo.genome.network/evrepo/ui/classification/CA239802/MONDO:0012589/016	644b4eae-91ea-4cc2-ae5a-abc981bf920f	p.Ala315Val	Ala	315	Val	MHHQQRMAALGTDKELSDLLDFSAMFSPPVSSGKNGPTSLASGHFTGSNVEDRSSSGSWGNGGHPSPSRNYGDGTPYDHMTSRDLGSHDNLSPPFVNSRIQSKTERGSYSSYGRESNLQGCHQQSLLGGDMDMGNPGTLSPTKPGSQYYQYSSNNPRRRPLHSSAMEVQTKKVRKVPPGLPSSVYAPSASTADYNRDSPGYPSSKPATSTFPSSFFMQDGHHSSDPWSSSSGMNQPGYAGMLGNSSHIPQSSSYCSLHPHERLSYPSHSSADINSSLPPMSTFHRSGTNHYSTSSCTPPANGTDSIMANRGSGAAGSSQTGDALGKALASIYSPDHTNNSFSSNPSTPVGSPPSLSAGTAVWSRNGGQASSSPNYEGPLHSLQSRIEDRLERLDDAIHVLRNHAVGPSTAMPGGHGDMHGIIGPSHNGAMGGLGSGYGTGLLSANRHSLMVGTHREDGVALRGSHSLLPNQVPVPQLPVQSATSPDLNPPQDPYRGMPPGLQGQSVSSGSSEIKSDDEGDENLQDTKSSEDKKLDDDKKDIKSITSNNDDEDLTPEQKAEREKERRMANNARERLRVRDINEAFKELGRMVQLHLKSDKPQTKLLILHQAVAVILSLEQQVRERNLNPKAACLKRREEEKVSSEPPPLSLAGPHPGMGDASNHMGQM	667	P15884	V	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [220, 224, 228, 229, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 343, 345, 350, 354, 369, 370, 373], 'COMPBIAS_gain': [566], 'COMPBIAS_gain_score': array([0.00124365]), 'COMPBIAS_loss_score': array([-0.01766151, -0.0231002 , -0.02106237, -0.02767348, -0.07843798,
       -0.09119147, -0.08535206, -0.07589012, -0.08897626, -0.09114099,
       -0.083588  , -0.09325272, -0.08774209, -0.0958885 , -0.10356367,
       -0.09553987, -0.10313016, -0.11453706, -0.10539228, -0.09741849,
       -0.11045629, -0.06115699, -0.05869812, -0.04126096, -0.04172462,
       -0.04353088, -0.0408327 , -0.04208654]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [264, 316, 317, 318, 319, 320, 332, 379], 'REGION_gain': [], 'REGION_loss_score': array([-0.03954893, -0.20257455, -0.19506949, -0.22118616, -0.1809122 ,
       -0.16192108, -0.08200908, -0.02466923]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
283	NM_005249.5(FOXG1):c.503G>C (p.Gly168Ala)	205474	CA314588	NM_005249.5:c.503G>C, NC_000014.9:g.28767782G>C, CM000676.2:g.28767782G>C, NC_000014.8:g.29236988G>C, CM000676.1:g.29236988G>C, NC_000014.7:g.28306739G>C, NG_009367.1:g.5702G>C, ENST00000313071.7:c.503G>C, ENST00000313071.6:c.503G>C, NM_005249.4:c.503G>C, NM_005249.5(FOXG1):c.503G>C (p.Gly168Ala)	FOXG1	FOXG1 disorder	MONDO:0100040	Autosomal dominant inheritance	Benign	BA1, BP4		The allele frequency of the p.Gly168Ala variant in FOXG1 is 0.18% in African sub population in gnomAD, which is high enough to be classified as benign based on thresholds defined by the ClinGen Rett/Angelman-like Expert Panel for Rett/AS-like conditions (BA1). Computational analysis prediction tools suggest that the p.Gly168Ala variant does not have a deleterious impact; however this information does not predict clinical significance on its own (BP4). In summary, the p.Gly168Ala variant in FOXG1 is classified as benign based on the ACMG/AMP criteria (BA1, BP4).		Rett and Angelman-like Disorders VCEP	https://clinicalgenome.org/site/assets/files/7339/clingen_rettas_acmg_specifications_v2.pdf	2021-03-26	2021-05-17	False	https://erepo.genome.network/evrepo/ui/classification/CA314588/MONDO:0100040/016	19e24439-dc92-487e-996e-15f701bd41d8	p.Gly168Ala	Gly	168	Ala	MLDMGDRKEVKMIPKSSFSINSLVPEAVQNDNHHASHGHHNSHHPQHHHHHHHHHHHPPPPAPQPPPPPQQQQPPPPPPPAPQPPQTRGAPAADDDKGPQQLLLPPPPPPPPAAALDGAKADGLGGKGEPGGGPGELAPVGPDEKEKGAGAGGEEKKGAGEGGKDGEGGKEGEKKNGKYEKPPFSYNALIMMAIRQSPEKRLTLNGIYEFIMKNFPYYRENKQGWQNSIRHNLSLNKCFVKVPRHYDDPGKGNYWMLDPSSDDVFIGGTTGKLRRRSTTSRAKLAFKRGARLTSTGLTFMDRAGSLYWPMSPFLSLHHPRASSTLSYNGTTSAYPSHPMPYSSVLTQNSLGNNHSFSTANGLSVDRLVNGEIPYATHHLTAAALAASVPCGLSVPCSGTYSLNPCSVNLLAGQTSYFFPHVPHPSMTSQSSTSMSARAASSSTSPQAPSTLPCESLRPSLPSFTTGLSGGLSDYFTHQNQGSSSNPLIH	489	P55316	A	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [224], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.00396907]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
284	NM_004992.3(MECP2):c.1030C>T (p.Arg344Trp)	143309	CA270179	NM_004992.3:c.1030C>T, NC_000023.11:g.154030798G>A, CM000685.2:g.154030798G>A, NC_000023.10:g.153296249G>A, CM000685.1:g.153296249G>A, NC_000023.9:g.152949443G>A, NG_007107.2:g.111330C>T, NG_007107.3:g.111306C>T, ENST00000303391.11:c.1030C>T, ENST00000453960.7:c.1066C>T, ENST00000303391.10:c.1030C>T, ENST00000407218.5:c.*402C>T, ENST00000453960.6:c.1066C>T, ENST00000619732.4:c.1030C>T, ENST00000628176.2:c.*402C>T, NM_001110792.1:c.1066C>T, NM_001316337.1:c.751C>T, XM_005274681.3:c.1030C>T, XM_005274682.3:c.751C>T, XM_005274683.3:c.751C>T, XM_006724819.2:c.361C>T, XM_011531166.1:c.751C>T, XM_006724819.3:c.361C>T, XM_011531166.2:c.751C>T, XM_024452383.1:c.751C>T, XM_024452384.1:c.751C>T, NM_001110792.2:c.1066C>T, NM_001316337.2:c.751C>T, NM_001369391.2:c.751C>T, NM_001369392.2:c.751C>T, NM_001369393.2:c.751C>T, NM_001369394.1:c.751C>T, NM_001369394.2:c.751C>T, NM_001386137.1:c.361C>T, NM_001386138.1:c.361C>T, NM_001386139.1:c.361C>T, NM_004992.4:c.1030C>T, NM_004992.3(MECP2):c.1030C>T (p.Arg344Trp)	MECP2	Rett syndrome	MONDO:0010726	X-linked inheritance	Benign	BS2, BS1	PP4, PM2, PS4	The allele frequency of the p.R344W variant in MECP2 is 0.01% in South Asian sub population in gnomAD, which is high enough to be classified as likely benign based on thresholds defined by the ClinGen Rett/Angelman-like Expert Panel for Rett/AS-like conditions (BS1). The p.R344W variant is observed in at least 2 unaffected individuals (internal database) (BS2). In summary, the p.R344W variant in MECP2 is classified as benign based on the ACMG/AMP criteria (BS1, BS2).		Rett and Angelman-like Disorders VCEP	https://clinicalgenome.org/site/assets/files/7339/clingen_rettas_acmg_specifications_v2.pdf	2021-03-26	2021-05-17	False	https://erepo.genome.network/evrepo/ui/classification/CA270179/MONDO:0010726/016	21ffb64d-8c26-49f1-b485-49b92c825bfc	p.Arg344Trp	Arg	344	Trp	MVAGMLGLREEKSEDQDLQGLKDKPLKFKKVKKDKKEEKEGKHEPVQPSAHHSAEPAEAGKAETSEGSGSAPAVPEASASPKQRRSIIRDRGPMYDDPTLPEGWTRKLKQRKSGRSAGKYDVYLINPQGKAFRSKVELIAYFEKVGDTSLDPNDFDFTVTGRGSPSRREQKPPKKPKSPKAPGTGRGRGRPKGSGTTRPKAATSEGVQVKRVLEKSPGKLLVKMPFQTSPGGKAEGGGATTSTQVMVIKRPGRKRKAEADPQAIPKKRGRKPGSVVAAAAAEAKKKAVKESSIRSVQETVLPIKKRKTRETVSIEVKEVVKPLLVSTLGEKSGKGLKTCKSPGRKSKESSPKGRSSSASSPPKKEHHHHHHHSESPKAPVPLLPPLPPPPPEPESSEDPTSPPEPQDLSSSVCKEEKMPRGGSLESDGCPKEPAKTQPAVATAATAAEKYKHRGEGERKDIVSSSMPRPNREEPVDSRTPVTERVS	486	P51608	W	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [300, 301, 303, 324, 325], 'REGION_gain': [], 'REGION_loss_score': array([-0.06958705, -0.06450754, -0.06342191, -0.11959058, -0.13812798]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
285	NM_004992.3(MECP2):c.916C>T (p.Arg306Cys)	11824	CA212529	NM_004992.3:c.916C>T, NC_000023.11:g.154030912G>A, CM000685.2:g.154030912G>A, NC_000023.10:g.153296363G>A, CM000685.1:g.153296363G>A, NC_000023.9:g.152949557G>A, NG_007107.2:g.111216C>T, NG_007107.3:g.111192C>T, ENST00000303391.11:c.916C>T, ENST00000453960.7:c.952C>T, ENST00000637917.1:n.90C>T, ENST00000303391.10:c.916C>T, ENST00000407218.5:c.*288C>T, ENST00000453960.6:c.952C>T, ENST00000619732.4:c.916C>T, ENST00000622433.4:c.902C>T, ENST00000628176.2:c.*288C>T, NM_001110792.1:c.952C>T, NM_001316337.1:c.637C>T, XM_005274681.3:c.916C>T, XM_005274682.3:c.637C>T, XM_005274683.3:c.637C>T, XM_006724819.2:c.247C>T, XM_011531166.1:c.637C>T, XM_006724819.3:c.247C>T, XM_011531166.2:c.637C>T, XM_024452383.1:c.637C>T, XM_024452384.1:c.637C>T, NM_001110792.2:c.952C>T, NM_001316337.2:c.637C>T, NM_001369391.2:c.637C>T, NM_001369392.2:c.637C>T, NM_001369393.2:c.637C>T, NM_001369394.1:c.637C>T, NM_001369394.2:c.637C>T, NM_001386137.1:c.247C>T, NM_001386138.1:c.247C>T, NM_001386139.1:c.247C>T, NM_004992.4:c.916C>T, NM_004992.3(MECP2):c.916C>T (p.Arg306Cys)	MECP2	Rett syndrome	MONDO:0010726	X-linked inheritance (dominant (HP:0001423))	Pathogenic	PP1, PM2_Supporting, PS2_Very Strong, PS4, PS3_Supporting, PM1		The p.Arg306Cys variant in MECP2 has been reported as a de novo occurrence (biological parentage both confirmed and unconfirmed) in at least 3 individuals with Rett Syndrome (PMID 10577905, 11309679, 19189931; internal database, GeneDx) (PS2_very strong). This variant has been observed in at least 4 other individuals with Rett syndrome (PMID 24511209, 23238081, RettBase) (PS4). The p.Arg306Cys variant occurs in the well-characterized transcriptional repression domain (TRD) functional domain of MECP2 (PMID 21326358, 23770565) (PM1). This variant is absent in gnomAD (PM2_supporting). Computational prediction analysis tools suggests a deleterious impact; however, this information does not predict clinical significance on its own (PP3). In summary, p.Arg306Cys variant in MECP2 is classified as Pathogenic for Rett syndrome based on the ACMG/AMP criteria (PS2_very strong, PS4, PM1, PM2_supporting, PP3).		Rett and Angelman-like Disorders VCEP	https://clinicalgenome.org/site/assets/files/7339/clingen_rettas_acmg_specifications_v2.pdf	2021-03-26	2021-05-17	False	https://erepo.genome.network/evrepo/ui/classification/CA212529/MONDO:0010726/016	306280ba-f29e-479c-a220-4d3eb2bc93d9	p.Arg306Cys	Arg	306	Cys	MVAGMLGLREEKSEDQDLQGLKDKPLKFKKVKKDKKEEKEGKHEPVQPSAHHSAEPAEAGKAETSEGSGSAPAVPEASASPKQRRSIIRDRGPMYDDPTLPEGWTRKLKQRKSGRSAGKYDVYLINPQGKAFRSKVELIAYFEKVGDTSLDPNDFDFTVTGRGSPSRREQKPPKKPKSPKAPGTGRGRGRPKGSGTTRPKAATSEGVQVKRVLEKSPGKLLVKMPFQTSPGGKAEGGGATTSTQVMVIKRPGRKRKAEADPQAIPKKRGRKPGSVVAAAAAEAKKKAVKESSIRSVQETVLPIKKRKTRETVSIEVKEVVKPLLVSTLGEKSGKGLKTCKSPGRKSKESSPKGRSSSASSPPKKEHHHHHHHSESPKAPVPLLPPLPPPPPEPESSEDPTSPPEPQDLSSSVCKEEKMPRGGSLESDGCPKEPAKTQPAVATAATAAEKYKHRGEGERKDIVSSSMPRPNREEPVDSRTPVTERVS	486	P51608	C	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [252, 264], 'COMPBIAS_gain_score': array([0.01922923, 0.02131128]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 303, 324, 325], 'REGION_gain': [], 'REGION_loss_score': array([-0.24654722, -0.27896148, -0.26665968, -0.30649006, -0.35133713,
       -0.39612693, -0.34109855, -0.38654894, -0.38392013, -0.36697114,
       -0.33031446, -0.27595437, -0.32436943, -0.20391297, -0.20489049]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
286	NM_003159.2(CDKL5):c.215T>C (p.Ile72Thr)	11503	CA121523	NM_003159.2:c.215T>C, ENST00000623535.2:c.215T>C, ENST00000635828.1:c.215T>C, ENST00000637881.1:c.215T>C, ENST00000674046.1:c.215T>C, ENST00000379989.6:c.215T>C, ENST00000379996.7:c.215T>C, ENST00000463994.4:c.215T>C, ENST00000623535.1:n.215T>C, NM_001037343.1:c.215T>C, XM_011545569.1:c.215T>C, XM_011545570.1:c.83T>C, XR_950484.1:n.467T>C, NM_001323289.1:c.215T>C, NM_001323289.2:c.215T>C, NM_001037343.2:c.215T>C, NM_003159.3:c.215T>C, NC_000023.11:g.18575423T>C, CM000685.2:g.18575423T>C, NC_000023.10:g.18593543T>C, CM000685.1:g.18593543T>C, NC_000023.9:g.18503464T>C, NG_008475.1:g.154819T>C, NM_003159.2(CDKL5):c.215T>C (p.Ile72Thr)	CDKL5	CDKL5 disorder	MONDO:0100039	X-linked inheritance (dominant (HP:0001423))	Pathogenic	PP3, PM2_Supporting, PM6, PM5_Strong, PS4_Moderate, PS3_Supporting		The p.Ile72Thr variant in CDKL5 has been reported as a de novo occurrence (biological parentage unconfirmed) in an individual with CDKL5 disease (PMID 19396824, 19241098) (PM6). The p.Ile72Thr variant in CDKL5 has been reported in at least 3 other individuals with CDKL5 disease (PMID 19396824, 19241098, 25657822, ClinVar) (PS4_moderate). The p.Ile72Thr variant in CDKL5 is absent from gnomAD (PM2). Multiple likely pathogenic missense variants have been previously identified within this codon (p.Ile72Asn; p.Ile72Met) which indicates that this residue is critical to the function of the protein (PMID 28074849, 27779742, 16015284) (PM5_strong). Phosphoproteomic screening of the cellular substrates of CDKL5 (MAP1S, CEP131 and DLG5) has shown that the p.Ile72Thr variant impacts protein function (PMID 30266825) (PS3_supporting). Computational prediction analysis tools suggests a deleterious impact; however, this information does not predict clinical significance on its own(PP3). In summary, the p.Ile72Thr variant in CDKL5 is classified as Pathogenic for CDKL5 disease based on the ACMG/AMP criteria (PM5_strong, PM6, PS4_moderate, PS3_supporting, PM2_supporting, PP3).	19396824, 19241098, 25657822, 19396824	Rett and Angelman-like Disorders VCEP	https://clinicalgenome.org/site/assets/files/7339/clingen_rettas_acmg_specifications_v2.pdf	2021-03-26	2021-05-17	False	https://erepo.genome.network/evrepo/ui/classification/CA121523/MONDO:0100039/016	52d0dedf-0fba-4aeb-b0db-0185cef7c6dd	p.Ile72Thr	Ile	72	Thr	MKIPNIGNVMNKFEILGVVGEGAYGVVLKCRHKETHEIVAIKKFKDSEENEEVKETTLRELKMLRTLKQENIVELKEAFRRRGKLYLVFEYVEKNMLELLEEMPNGVPPEKVKSYIYQLIKAIHWCHKNDIVHRDIKPENLLISHNDVLKLCDFGFARNLSEGNNANYTEYVATRWYRSPELLLGAPYGKSVDMWSVGCILGELSDGQPLFPGESEIDQLFTIQKVLGPLPSEQMKLFYSNPRFHGLRFPAVNHPQSLERRYLGILNSVLLDLMKNLLKLDPADRYLTEQCLNHPTFQTQRLLDRSPSRSAKRKPYHVESSTLSNRNQAGKSTALQSHHRSNSKDIQNLSVGLPRADEGLPANESFLNGNLAGASLSPLHTKTYQASSQPGSTSKDLTNNNIPHLLSPKEAKSKTEFDFNIDPKPSEGPGTKYLKSNSRSQQNRHSFMESSQSKAGTLQPNEKQSRHSYIDTIPQSSRSPSYRTKAKSHGALSDSKSVSNLSEARAQIAEPSTSRYFPSSCLDLNSPTSPTPTRHSDTRTLLSPSGRNNRNEGTLDSRRTTTRHSKTMEELKLPEHMDSSHSHSLSAPHESFSYGLGYTSPFSSQQRPHRHSMYVTRDKVRAKGLDGSLSIGQGMAARANSLQLLSPQPGEQLPPEMTVARSSVKETSREGTSSFHTRQKSEGGVYHDPHSDDGTAPKENRHLYNDPVPRRVGSFYRVPSPRPDNSFHENNVSTRVSSLPSESSSGTNHSKRQPAFDPWKSPENISHSEQLKEKEKQGFFRSMKKKKKKSQTVPNSDSPDLLTLQKSIHSASTPSSRPKEWRPEKISDLQTQSQPLKSLRKLLHLSSASNHPASSDPRFQPLTAQQTKNSFSEIRIHPLSQASGGSSNIRQEPAPKGRPALQLPGQMDPGWHVSSVTRSATEGPSYSEQLGAKSGPNGHPYNRTNRSRMPNLNDLKETAL	960	O76039	T	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [94], 'STRAND_gain_score': array([0.00854671]), 'HELIX_loss': [6, 241], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.02388287, -0.00209218]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [583], 'REGION_gain': [], 'REGION_loss_score': array([-0.00358814]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
287	NM_001083962.1(TCF4):c.1739G>A (p.Arg580Gln)	7371	CA254162	NM_001083962.1:c.1739G>A, ENST00000354452.8:c.1739G>A, ENST00000635822.2:c.1619G>A, ENST00000635990.2:n.1419G>A, ENST00000636400.2:c.1667G>A, ENST00000636751.2:c.*1447G>A, ENST00000636822.2:c.1349G>A, ENST00000637115.2:c.*1617G>A, ENST00000637169.2:c.1091G>A, ENST00000637239.2:n.1794G>A, ENST00000637250.2:n.1433G>A, ENST00000637923.2:n.1337G>A, ENST00000638154.3:c.1766G>A, ENST00000643689.1:c.1349G>A, ENST00000674764.1:c.*1350G>A, ENST00000675707.1:c.1349G>A, ENST00000354452.7:c.1739G>A, ENST00000356073.8:c.1727G>A, ENST00000398339.5:c.2045G>A, ENST00000457482.7:c.1259G>A, ENST00000537578.5:c.1667G>A, ENST00000537856.7:c.1337G>A, ENST00000540999.5:c.1655G>A, ENST00000543082.5:c.1601G>A, ENST00000544241.6:c.1526G>A, ENST00000561831.7:c.1247G>A, ENST00000561992.5:c.1337G>A, ENST00000562680.5:n.5262G>A, ENST00000564228.5:n.1514G>A, ENST00000564403.6:c.1757G>A, ENST00000564999.5:c.1727G>A, ENST00000565018.6:c.1475G>A, ENST00000566279.5:c.1559G>A, ENST00000566286.5:n.1718G>A, ENST00000567880.5:n.1547G>A, ENST00000568673.5:c.1667G>A, ENST00000568740.5:c.1652G>A, ENST00000570177.6:c.1337G>A, ENST00000570287.6:c.1247G>A, ENST00000616053.4:c.1475G>A, ENST00000626466.1:n.762G>A, ENST00000626584.2:c.1079G>A, ENST00000629387.2:c.1739G>A, NM_001243226.2:c.2045G>A, NM_001243227.1:c.1667G>A, NM_001243228.1:c.1757G>A, NM_001243230.1:c.1718G>A, NM_001243231.1:c.1601G>A, NM_001243232.1:c.1526G>A, NM_001243233.1:c.1337G>A, NM_001243234.1:c.1259G>A, NM_001243235.1:c.1247G>A, NM_001243236.1:c.1247G>A, NM_001306207.1:c.1655G>A, NM_001306208.1:c.1514G>A, NM_003199.2:c.1727G>A, XM_005266739.3:c.1667G>A, XM_005266741.3:c.1736G>A, XM_005266743.3:c.1667G>A, XM_005266744.3:c.1667G>A, XM_005266745.3:c.1664G>A, XM_005266747.3:c.1613G>A, XM_005266749.3:c.1529G>A, XM_005266752.3:c.1349G>A, XM_005266754.3:c.1349G>A, XM_005266755.3:c.1349G>A, XM_005266761.3:c.1256G>A, XM_006722536.2:c.1739G>A, XM_006722537.2:c.1739G>A, XM_006722538.2:c.1664G>A, XM_006722539.2:c.1349G>A, XM_006722540.2:c.1337G>A, XM_011526154.1:c.2042G>A, XM_011526155.1:c.2042G>A, XM_011526156.1:c.2033G>A, XM_011526157.1:c.2030G>A, XM_011526158.1:c.1733G>A, XM_011526159.1:c.1349G>A, XM_011526160.1:c.1349G>A, XM_011526161.1:c.1349G>A, XM_011526162.1:c.1349G>A, XM_011526163.1:c.1349G>A, XM_011526164.1:c.1337G>A, NM_001330604.2:c.1736G>A, NM_001330605.2:c.1349G>A, NM_001348211.1:c.1613G>A, NM_001348212.1:c.1337G>A, NM_001348213.1:c.1349G>A, NM_001348214.1:c.1244G>A, NM_001348215.1:c.1091G>A, NM_001348216.1:c.1259G>A, NM_001348217.1:c.1667G>A, NM_001348218.1:c.1667G>A, NM_001348219.1:c.1655G>A, NM_001348220.1:c.1652G>A, XM_005266739.4:c.1667G>A, XM_005266741.4:c.1736G>A, XM_005266745.4:c.1664G>A, XM_005266749.4:c.1529G>A, XM_005266752.5:c.1349G>A, XM_005266755.5:c.1349G>A, XM_005266761.4:c.1256G>A, XM_006722536.3:c.1739G>A, XM_006722537.3:c.1739G>A, XM_006722538.3:c.1664G>A, XM_017025934.2:c.1664G>A, XM_017025935.2:c.1664G>A, XM_017025936.2:c.1655G>A, XM_017025937.2:c.1652G>A, XM_017025938.2:c.1736G>A, XM_017025940.2:c.1727G>A, XM_017025941.2:c.1727G>A, XM_017025942.2:c.1724G>A, XM_017025943.2:c.1724G>A, XM_017025944.2:c.1664G>A, XM_017025945.2:c.1664G>A, XM_017025946.2:c.1655G>A, XM_017025948.2:c.1652G>A, XM_017025950.2:c.1649G>A, XM_017025951.2:c.1610G>A, XM_017025952.2:c.1523G>A, XM_017025953.2:c.1517G>A, XM_017025954.2:c.1346G>A, XM_017025956.2:c.1337G>A, XM_024451240.1:c.1664G>A, XM_024451241.1:c.1502G>A, NM_001083962.2:c.1739G>A, NM_001243226.3:c.2045G>A, NM_001243227.2:c.1667G>A, NM_001243228.2:c.1757G>A, NM_001243231.2:c.1601G>A, NM_001243233.2:c.1337G>A, NM_001243234.2:c.1259G>A, NM_001243235.2:c.1247G>A, NM_001243236.2:c.1247G>A, NM_001330604.3:c.1736G>A, NM_001330605.3:c.1349G>A, NM_001348211.2:c.1613G>A, NM_001348212.2:c.1337G>A, NM_001348213.2:c.1349G>A, NM_001348214.2:c.1244G>A, NM_001348215.2:c.1091G>A, NM_001348216.2:c.1259G>A, NM_001348218.2:c.1667G>A, NM_001348219.2:c.1655G>A, NM_001369567.1:c.1739G>A, NM_001369568.1:c.1739G>A, NM_001369569.1:c.1736G>A, NM_001369570.1:c.1736G>A, NM_001369571.1:c.1727G>A, NM_001369572.1:c.1727G>A, NM_001369573.1:c.1724G>A, NM_001369574.1:c.1724G>A, NM_001369575.1:c.1667G>A, NM_001369576.1:c.1664G>A, NM_001369577.1:c.1664G>A, NM_001369578.1:c.1664G>A, NM_001369579.1:c.1664G>A, NM_001369580.1:c.1664G>A, NM_001369581.1:c.1664G>A, NM_001369582.1:c.1655G>A, NM_001369583.1:c.1655G>A, NM_001369584.1:c.1652G>A, NM_001369585.1:c.1652G>A, NM_001369586.1:c.1670G>A, NM_003199.3:c.1727G>A, NM_001243230.2:c.1718G>A, NC_000018.10:g.55228987C>T, CM000680.2:g.55228987C>T, NC_000018.9:g.52896218C>T, CM000680.1:g.52896218C>T, NC_000018.8:g.51047216C>T, NG_011716.1:g.364643G>A, NG_011716.2:g.412007G>A, NM_001083962.1(TCF4):c.1739G>A (p.Arg580Gln)	TCF4	Pitt-Hopkins syndrome	MONDO:0012589	Autosomal dominant inheritance	Pathogenic	PP3, PP4, PS4_Supporting, PM6_Strong, PM2_Supporting, PS3_Supporting, PM1		The p.Arg580Gln variant in TCF4 has been reported in at least 2 de novo occurrences (biological parentage unconfirmed) in individuals with Pitt-Hopkins syndrome (PMID 22045651, 17436254) (PM6_strong, PS4_supporting, PP4).  Transcriptional reporter assay has shown that this variant impacts protein function (PMID 19235238) (PS3_supporting). The p.Arg580Gln variant occurs in the well-characterized basic Helix-Loop-Helix domain of TCF4 (PM1). Computational prediction analysis tools suggests a deleterious impact; however, this information does not predict clinical significance on its own (PP3). In summary, the p.Arg580Gln variant in TCF4 is classified as Pathogenic for autosomal dominant Pitt-Hopkins syndrome based on the ACMG/AMP criteria (PM6_strong, PM1, PS4_supporting, PP1, PP3, PP4).	17436254, 22045651, 17436254, 22045651, 17436254, 22045651, 19235238	Rett and Angelman-like Disorders VCEP	https://clinicalgenome.org/site/assets/files/7339/clingen_rettas_acmg_specifications_v2.pdf	2021-03-26	2021-05-17	False	https://erepo.genome.network/evrepo/ui/classification/CA254162/MONDO:0012589/016	23eb4bab-14dd-4fbb-aebc-7c755b2976ea	p.Arg580Gln	Arg	580	Gln	MHHQQRMAALGTDKELSDLLDFSAMFSPPVSSGKNGPTSLASGHFTGSNVEDRSSSGSWGNGGHPSPSRNYGDGTPYDHMTSRDLGSHDNLSPPFVNSRIQSKTERGSYSSYGRESNLQGCHQQSLLGGDMDMGNPGTLSPTKPGSQYYQYSSNNPRRRPLHSSAMEVQTKKVRKVPPGLPSSVYAPSASTADYNRDSPGYPSSKPATSTFPSSFFMQDGHHSSDPWSSSSGMNQPGYAGMLGNSSHIPQSSSYCSLHPHERLSYPSHSSADINSSLPPMSTFHRSGTNHYSTSSCTPPANGTDSIMANRGSGAAGSSQTGDALGKALASIYSPDHTNNSFSSNPSTPVGSPPSLSAGTAVWSRNGGQASSSPNYEGPLHSLQSRIEDRLERLDDAIHVLRNHAVGPSTAMPGGHGDMHGIIGPSHNGAMGGLGSGYGTGLLSANRHSLMVGTHREDGVALRGSHSLLPNQVPVPQLPVQSATSPDLNPPQDPYRGMPPGLQGQSVSSGSSEIKSDDEGDENLQDTKSSEDKKLDDDKKDIKSITSNNDDEDLTPEQKAEREKERRMANNARERLRVRDINEAFKELGRMVQLHLKSDKPQTKLLILHQAVAVILSLEQQVRERNLNPKAACLKRREEEKVSSEPPPLSLAGPHPGMGDASNHMGQM	667	P15884	Q	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [592, 593], 'DNA_BIND_gain': [], 'DNA_BIND_loss_score': array([-0.06800878, -0.06277758]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [18], 'SIGNAL_gain': [], 'SIGNAL_loss_score': array([-0.0778321]), 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [569], 'HELIX_gain_score': array([0.03207499]), 'COILED_loss': [], 'COILED_gain': [580, 581], 'COILED_gain_score': array([0.2784766 , 0.33126009]), 'COMPBIAS_loss': [], 'COMPBIAS_gain': [472, 566, 567, 568, 569], 'COMPBIAS_gain_score': array([0.00887436, 0.1629445 , 0.16475046, 0.1838569 , 0.16150361]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [320, 332], 'REGION_gain': [571, 572, 573, 629], 'REGION_gain_score': array([0.38933283, 0.32852685, 0.41791302, 0.02703595]), 'REGION_loss_score': array([-0.01096803, -0.03014338]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
288	NM_130838.1(UBE3A):c.2T>C (p.Met1Thr)	136199	CA333472	NM_130838.1:c.2T>C, ENST00000438097.6:c.2T>C, ENST00000625778.3:c.2T>C, ENST00000635914.1:c.2T>C, ENST00000637886.1:c.62T>C, ENST00000638011.1:c.-112T>C, ENST00000638155.1:c.2T>C, ENST00000648336.2:c.62T>C, ENST00000649550.1:c.2T>C, ENST00000650110.1:c.71T>C, ENST00000675000.1:n.737T>C, ENST00000675038.1:n.797T>C, ENST00000675177.1:c.-115-29698T>C, ENST00000675593.1:n.2758T>C, ENST00000232165.7:c.2T>C, ENST00000397954.6:c.71T>C, ENST00000428984.6:c.2T>C, ENST00000438097.5:c.2T>C, ENST00000566215.5:c.2T>C, ENST00000614096.4:c.62T>C, ENST00000625778.2:c.2T>C, ENST00000626068.2:c.83T>C, ENST00000626793.2:n.309T>C, ENST00000628267.2:c.2T>C, ENST00000628733.2:c.62T>C, ENST00000628890.1:c.62T>C, ENST00000629252.2:c.2T>C, ENST00000629886.2:c.62T>C, ENST00000630424.2:c.2T>C, ENST00000630607.2:c.2T>C, ENST00000630907.2:c.62T>C, NM_000462.3:c.71T>C, LRG_15t1:c.2T>C, NM_130839.2:c.62T>C, XM_005268267.3:c.2T>C, XM_005268268.3:c.2T>C, XM_005268269.3:c.2T>C, XM_005268270.3:c.2T>C, XM_005268271.3:c.2T>C, XM_006720673.2:c.62T>C, XM_006720674.2:c.62T>C, XM_006720675.2:c.2T>C, XM_006720676.2:c.2T>C, XM_011521994.1:c.71T>C, XM_011521995.1:c.71T>C, XM_011521996.1:c.2T>C, NM_000462.5:c.71T>C, NM_001354505.1:c.62T>C, NM_001354506.1:c.2T>C, NM_001354507.1:c.2T>C, NM_001354508.1:c.2T>C, NM_001354509.1:c.2T>C, NM_001354511.1:c.2T>C, NM_001354512.1:c.2T>C, NM_001354513.1:c.2T>C, NM_001354523.1:c.-112T>C, NM_001354526.1:c.2T>C, NM_001354538.1:c.62T>C, NM_001354539.1:c.2T>C, NM_001354540.1:c.2T>C, NM_001354541.1:c.2T>C, NM_001354542.1:c.2T>C, NM_001354543.1:c.2T>C, NM_001354544.1:c.2T>C, NM_001354545.1:c.62T>C, NM_001354546.1:c.-115-29698T>C, NM_001354547.1:c.2T>C, NM_001354548.1:c.2T>C, NM_001354549.1:c.2T>C, NM_001354550.1:c.62T>C, NM_001354551.1:c.2T>C, NM_130838.3:c.2T>C, NM_130839.4:c.62T>C, NR_146177.1:n.18589-13327A>G, NR_148916.1:n.610T>C, XM_011521995.3:c.71T>C, XM_017022547.2:c.62T>C, XM_017022548.2:c.62T>C, XM_017022550.2:c.62T>C, XM_017022556.2:c.71T>C, XM_024450043.1:c.71T>C, XM_024450044.1:c.2T>C, NM_001354506.2:c.2T>C, NM_001354507.2:c.2T>C, NM_001354508.2:c.2T>C, NM_001354509.2:c.2T>C, NM_001354511.2:c.2T>C, NM_001354512.2:c.2T>C, NM_001354513.2:c.2T>C, NM_001354523.2:c.-112T>C, NM_001354538.2:c.62T>C, NM_001354539.2:c.2T>C, NM_001354540.2:c.2T>C, NM_001354541.2:c.2T>C, NM_001354542.2:c.2T>C, NM_001354543.2:c.2T>C, NM_001354544.2:c.2T>C, NM_001354545.2:c.62T>C, NM_001354546.2:c.-115-29698T>C, NM_001354547.2:c.2T>C, NM_001354548.2:c.2T>C, NM_001354549.2:c.2T>C, NM_001354550.2:c.62T>C, NM_001354551.2:c.2T>C, NM_001374461.1:c.2T>C, NM_130838.4:c.2T>C, NM_130839.5:c.62T>C, NR_148916.2:n.578T>C, NC_000015.10:g.25405461A>G, CM000677.2:g.25405461A>G, NC_000015.9:g.25650608A>G, CM000677.1:g.25650608A>G, NC_000015.8:g.23201701A>G, NG_009268.1:g.38521T>C, LRG_15:g.38521T>C, NM_130838.1(UBE3A):c.2T>C (p.Met1Thr)	UBE3A	Angelman syndrome	MONDO:0007113	Autosomal dominant inheritance (with paternal imprinting (HP:0012274))	Pathogenic	PP4, PP1, PM2_Supporting, PM6, PVS1, PS4_Moderate		The p.M1? variant in UBE3A is predicted to cause a truncated or absent protein by altering the start codon of the coding sequence in a UBE3A where loss-of-function is an established disease mechanism. Pathogenic variants affecting the start site have been described in affected patients (PVS1). The p.M1? variant has been observed in 3 other individuals with Angelman syndrome (PMID 29737008, 25212744) (PS4_Moderate). The p.M1? variant in UBE3A is absent from gnomAD (PM2_Supporting). The p.M1? variant in UBE3A has been reported as a de novo occurrence (biological parentage unconfirmed) in an individual with Angelman syndrome (PMID 29737008) (PM6). The variant has been reported to segregate in two informative meioses (PP1). The p.M1? variant in UBE3A has been reported in an individual with a clinical phenotype suggestive of Angelman syndrome (PMID 29737008, 25212744) (PP4). In summary, the p.M1? variant in UBE3A is classified as pathogenic for Angelman syndrome based on the ACMG/AMP criteria (PVS1, PS4_moderate, PM2_supporting, PM6, PP1, PP4).	29737008, 25212744, 29737008	Rett and Angelman-like Disorders VCEP	https://clinicalgenome.org/site/assets/files/7339/clingen_rettas_acmg_specifications_v2.pdf	2021-03-26	2021-05-17	False	https://erepo.genome.network/evrepo/ui/classification/CA333472/MONDO:0007113/016	ca3b17bd-94fc-4e26-a127-06213fba2385	p.Met1Thr	Met	1	Thr	MEKLHQCYWKSGEPQSDDIEASRMKRAAAKHLIERYYHQLTEGCGNEACTNEFCASCPTFLRMDNNAAAIKALELYKINAKLCDPHPSKKGASSAYLENSKGAPNNSCSEIKMNKKGARIDFKDVTYLTEEKVYEILELCREREDYSPLIRVIGRVFSSAEALVQSFRKVKQHTKEELKSLQAKDEDKDEDEKEKAACSAAAMEEDSEASSSRIGDSSQGDNNLQKLGPDDVSVDIDAIRRVYTRLLSNEKIETAFLNALVYLSPNVECDLTYHNVYSRDPNYLNLFIIVMENRNLHSPEYLEMALPLFCKAMSKLPLAAQGKLIRLWSKYNADQIRRMMETFQQLITYKVISNEFNSRNLVNDDDAIVAASKCLKMVYYANVVGGEVDTNHNEEDDEEPIPESSELTLQELLGEERRNKKGPRVDPLETELGVKTLDCRKPLIPFEEFINEPLNEVLEMDKDYTFFKVETENKFSFMTCPFILNAVTKNLGLYYDNRIRMYSERRITVLYSLVQGQQLNPYLRLKVRRDHIIDDALVRLEMIAMENPADLKKQLYVEFEGEQGVDEGGVSKEFFQLVVEEIFNPDIGMFTYDESTKLFWFNPSSFETEGQFTLIGIVLGLAIYNNCILDVHFPMVVYRKLMGKKGTFRDLGDSHPVLYQSLKDLLEYEGNVEDDMMITFQISQTDLFGNPMMYDLKENGDKIPITNENRKEFVNLYSDYILNKSVEKQFKAFRRGFHMVTNESPLKYLFRPEEIELLICGSRNLDFQALEETTEYDGGYTRDSVLIREFWEIVHSFTDEQKRLFLQFTTGTDRAPVGGLGKLKMIIAKNGPDTERLPTSHTCFNVLLLPEYSSKEKLKERLLKAITYAKGFGML	875	Q05086	T	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [616], 'TOPO_DOM_gain_score': array([0.07590181]), 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13], 'SIGNAL_gain': [], 'SIGNAL_loss_score': array([-0.49777234, -0.53991258, -0.69074315, -0.63386756, -0.69893044,
       -0.7044118 , -0.66404361, -0.57928151, -0.71500438, -0.68362081,
       -0.63897097, -0.58281684, -0.49108559]), 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [678, 682], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.04821086, -0.02392328]), 'HELIX_loss': [39, 77, 174, 246, 378, 455, 485, 547, 609, 744], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.01808703, -0.02609438, -0.0072192 , -0.04356563, -0.02775043,
       -0.02906686, -0.06942797, -0.039087  , -0.09132141, -0.01085734]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [175], 'REGION_gain': [], 'REGION_loss_score': array([-0.01888293]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
289	NM_004992.3(MECP2):c.301C>T (p.Pro101Ser)	143524	CA270328	NM_004992.3:c.301C>T, ENST00000303391.11:c.301C>T, ENST00000453960.7:c.337C>T, ENST00000303391.10:c.301C>T, ENST00000369957.5:c.*355C>T, ENST00000407218.5:c.337C>T, ENST00000453960.6:c.337C>T, ENST00000486506.5:n.2649C>T, ENST00000611468.1:c.289C>T, ENST00000619732.4:c.301C>T, ENST00000622433.4:c.289C>T, ENST00000628176.2:c.301C>T, NM_001110792.1:c.337C>T, NM_001316337.1:c.22C>T, XM_005274681.3:c.301C>T, XM_005274682.3:c.22C>T, XM_005274683.3:c.22C>T, XM_011531166.1:c.22C>T, XM_006724819.3:c.-260C>T, XM_011531166.2:c.22C>T, XM_024452383.1:c.22C>T, XM_024452384.1:c.22C>T, NM_001110792.2:c.337C>T, NM_001316337.2:c.22C>T, NM_001369391.2:c.22C>T, NM_001369392.2:c.22C>T, NM_001369393.2:c.22C>T, NM_001369394.1:c.22C>T, NM_001369394.2:c.22C>T, NM_001386137.1:c.-260C>T, NM_001386138.1:c.-260C>T, NM_001386139.1:c.-260C>T, NM_004992.4:c.301C>T, NC_000023.11:g.154032283G>A, CM000685.2:g.154032283G>A, NC_000023.10:g.153297734G>A, CM000685.1:g.153297734G>A, NC_000023.9:g.152950928G>A, NG_007107.2:g.109845C>T, NG_007107.3:g.109821C>T, NM_004992.3(MECP2):c.301C>T (p.Pro101Ser)	MECP2	Rett syndrome	MONDO:0010726	X-linked inheritance	Pathogenic	PP4, PP3, PM2_Supporting, PM5_Strong, PS4, PM1		The p.Pro101Ser variant has been observed in at least 4 other individuals with Rett syndrome (RettBASE, internal database) (PS4). Multiple pathogenic missense variants have been previously identified within this codon which indicates that this residue is critical to the function of the protein (PMID 10767337, 31439979) (PM5_Strong). The p.Pro101Ser variant in MECP2 is absent from gnomAD (PM2_Supporting). Computational prediction analysis tools suggests a deleterious impact; however, this information does not predict clinical significance on its own (PP3). The p.Pro101Ser variant in MECP2 has been reported in an individual with a clinical phenotype suggestive of Rett syndrome (PMID 11269512) (PP4). In summary, the p.Pro101Ser variant in MECP2 is classified as pathogenic for Rett syndrome based on the ACMG/AMP criteria (PS4, PM5_strong, PM2_supporting, PP3, PP4).		Rett and Angelman-like Disorders VCEP	https://clinicalgenome.org/site/assets/files/7339/clingen_rettas_acmg_specifications_v2.pdf	2021-03-26	2021-05-17	False	https://erepo.genome.network/evrepo/ui/classification/CA270328/MONDO:0010726/016	2b8ace0a-d687-49ca-a70c-e5ca323bc4b3	p.Pro101Ser	Pro	101	Ser	MVAGMLGLREEKSEDQDLQGLKDKPLKFKKVKKDKKEEKEGKHEPVQPSAHHSAEPAEAGKAETSEGSGSAPAVPEASASPKQRRSIIRDRGPMYDDPTLPEGWTRKLKQRKSGRSAGKYDVYLINPQGKAFRSKVELIAYFEKVGDTSLDPNDFDFTVTGRGSPSRREQKPPKKPKSPKAPGTGRGRGRPKGSGTTRPKAATSEGVQVKRVLEKSPGKLLVKMPFQTSPGGKAEGGGATTSTQVMVIKRPGRKRKAEADPQAIPKKRGRKPGSVVAAAAAEAKKKAVKESSIRSVQETVLPIKKRKTRETVSIEVKEVVKPLLVSTLGEKSGKGLKTCKSPGRKSKESSPKGRSSSASSPPKKEHHHHHHHSESPKAPVPLLPPLPPPPPEPESSEDPTSPPEPQDLSSSVCKEEKMPRGGSLESDGCPKEPAKTQPAVATAATAAEKYKHRGEGERKDIVSSSMPRPNREEPVDSRTPVTERVS	486	P51608	S	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [100], 'COMPBIAS_gain': [], 'COMPBIAS_loss_score': array([-0.0827865]), 'DOMAIN_loss': [86], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.03500813]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
290	NM_130838.1(UBE3A):c.317C>A (p.Thr106Lys)	155994	CA333390	NM_130838.1:c.317C>A, ENST00000438097.6:c.317C>A, ENST00000625778.3:c.317C>A, ENST00000635914.1:c.317C>A, ENST00000637886.1:c.377C>A, ENST00000638011.1:c.317C>A, ENST00000638155.1:c.317C>A, ENST00000648336.2:c.377C>A, ENST00000649550.1:c.317C>A, ENST00000650110.1:c.386C>A, ENST00000675000.1:n.1052C>A, ENST00000675177.1:c.200C>A, ENST00000675593.1:n.3073C>A, ENST00000232165.7:c.317C>A, ENST00000397954.6:c.386C>A, ENST00000428984.6:c.317C>A, ENST00000438097.5:c.317C>A, ENST00000566215.5:c.317C>A, ENST00000614096.4:c.377C>A, ENST00000625778.2:c.317C>A, ENST00000626068.2:c.398C>A, ENST00000626793.2:n.428C>A, ENST00000628733.2:c.377C>A, ENST00000630424.2:c.317C>A, ENST00000630907.2:c.377C>A, NM_000462.3:c.386C>A, LRG_15t1:c.317C>A, NM_130839.2:c.377C>A, XM_005268267.3:c.317C>A, XM_005268268.3:c.317C>A, XM_005268269.3:c.317C>A, XM_005268270.3:c.317C>A, XM_005268271.3:c.317C>A, XM_006720673.2:c.377C>A, XM_006720674.2:c.377C>A, XM_006720675.2:c.317C>A, XM_006720676.2:c.317C>A, XM_011521994.1:c.386C>A, XM_011521995.1:c.386C>A, XM_011521996.1:c.317C>A, NM_000462.5:c.386C>A, NM_001354505.1:c.377C>A, NM_001354506.1:c.317C>A, NM_001354507.1:c.317C>A, NM_001354508.1:c.317C>A, NM_001354509.1:c.317C>A, NM_001354511.1:c.317C>A, NM_001354512.1:c.317C>A, NM_001354513.1:c.317C>A, NM_001354523.1:c.317C>A, NM_001354526.1:c.317C>A, NM_001354538.1:c.377C>A, NM_001354539.1:c.317C>A, NM_001354540.1:c.317C>A, NM_001354541.1:c.317C>A, NM_001354542.1:c.317C>A, NM_001354543.1:c.317C>A, NM_001354544.1:c.317C>A, NM_001354545.1:c.377C>A, NM_001354546.1:c.200C>A, NM_001354547.1:c.317C>A, NM_001354548.1:c.317C>A, NM_001354549.1:c.317C>A, NM_001354550.1:c.361+3668C>A, NM_001354551.1:c.301+3668C>A, NM_130838.3:c.317C>A, NM_130839.4:c.377C>A, NR_146177.1:n.18393-19799G>T, NR_148916.1:n.925C>A, XM_011521995.3:c.386C>A, XM_017022547.2:c.377C>A, XM_017022548.2:c.377C>A, XM_017022550.2:c.377C>A, XM_017022556.2:c.386C>A, XM_024450043.1:c.386C>A, XM_024450044.1:c.317C>A, NM_001354506.2:c.317C>A, NM_001354507.2:c.317C>A, NM_001354508.2:c.317C>A, NM_001354509.2:c.317C>A, NM_001354511.2:c.317C>A, NM_001354512.2:c.317C>A, NM_001354513.2:c.317C>A, NM_001354523.2:c.317C>A, NM_001354538.2:c.377C>A, NM_001354539.2:c.317C>A, NM_001354540.2:c.317C>A, NM_001354541.2:c.317C>A, NM_001354542.2:c.317C>A, NM_001354543.2:c.317C>A, NM_001354544.2:c.317C>A, NM_001354545.2:c.377C>A, NM_001354546.2:c.200C>A, NM_001354547.2:c.317C>A, NM_001354548.2:c.317C>A, NM_001354549.2:c.317C>A, NM_001354550.2:c.361+3668C>A, NM_001354551.2:c.301+3668C>A, NM_001374461.1:c.317C>A, NM_130838.4:c.317C>A, NM_130839.5:c.377C>A, NR_148916.2:n.893C>A, NC_000015.10:g.25371797G>T, CM000677.2:g.25371797G>T, NC_000015.9:g.25616944G>T, CM000677.1:g.25616944G>T, NC_000015.8:g.23168037G>T, NG_009268.1:g.72185C>A, LRG_15:g.72185C>A, NM_130838.1(UBE3A):c.317C>A (p.Thr106Lys)	UBE3A	Angelman syndrome	MONDO:0007113	Autosomal dominant inheritance (with paternal imprinting (HP:0012274))	Pathogenic	PP3, PM2_Supporting, PS4_Supporting, PS3_Supporting, PM5, PP1_Strong		The variant has been reported to segregate in at least five informative meioses (PMID 25212744, internal database) (PP1_Strong). A pathogenic missense variant (p.Thr106Pro) has been previously identified within this codon which indicates that this residue is critical to the function of the protein (PMID 15054837) (PM5). Protein expression analysis in transfected cell lines has shown that this variant reduces protein function (PMID 26255772) PS3_Supporting). The p.Thr106Lys variant has been observed in at least 1 other individual with Angelman syndrome (PMID 25212744) (PS4_Supporting). The p.Thr106Lys variant in UBE3A is absent from gnomAD (PM2_Supporting). Computational prediction analysis tools suggests a deleterious impact; however, this information does not predict clinical significance on its own (PP3). In summary, the p.Thr106Lys variant in UBE3A is classified as pathogenic for Angelman syndrome based on the ACMG/AMP criteria (PP1_strong, PM5, PS3_supporting, PS4_supporting, PM2_supporting, PP3).	25212744, 26255772, 25212744	Rett and Angelman-like Disorders VCEP	https://clinicalgenome.org/site/assets/files/7339/clingen_rettas_acmg_specifications_v2.pdf	2021-03-26	2021-05-17	False	https://erepo.genome.network/evrepo/ui/classification/CA333390/MONDO:0007113/016	ab249ad8-9000-4fe3-b765-33904af0119f	p.Thr106Lys	Thr	106	Lys	MEKLHQCYWKSGEPQSDDIEASRMKRAAAKHLIERYYHQLTEGCGNEACTNEFCASCPTFLRMDNNAAAIKALELYKINAKLCDPHPSKKGASSAYLENSKGAPNNSCSEIKMNKKGARIDFKDVTYLTEEKVYEILELCREREDYSPLIRVIGRVFSSAEALVQSFRKVKQHTKEELKSLQAKDEDKDEDEKEKAACSAAAMEEDSEASSSRIGDSSQGDNNLQKLGPDDVSVDIDAIRRVYTRLLSNEKIETAFLNALVYLSPNVECDLTYHNVYSRDPNYLNLFIIVMENRNLHSPEYLEMALPLFCKAMSKLPLAAQGKLIRLWSKYNADQIRRMMETFQQLITYKVISNEFNSRNLVNDDDAIVAASKCLKMVYYANVVGGEVDTNHNEEDDEEPIPESSELTLQELLGEERRNKKGPRVDPLETELGVKTLDCRKPLIPFEEFINEPLNEVLEMDKDYTFFKVETENKFSFMTCPFILNAVTKNLGLYYDNRIRMYSERRITVLYSLVQGQQLNPYLRLKVRRDHIIDDALVRLEMIAMENPADLKKQLYVEFEGEQGVDEGGVSKEFFQLVVEEIFNPDIGMFTYDESTKLFWFNPSSFETEGQFTLIGIVLGLAIYNNCILDVHFPMVVYRKLMGKKGTFRDLGDSHPVLYQSLKDLLEYEGNVEDDMMITFQISQTDLFGNPMMYDLKENGDKIPITNENRKEFVNLYSDYILNKSVEKQFKAFRRGFHMVTNESPLKYLFRPEEIELLICGSRNLDFQALEETTEYDGGYTRDSVLIREFWEIVHSFTDEQKRLFLQFTTGTDRAPVGGLGKLKMIIAKNGPDTERLPTSHTCFNVLLLPEYSSKEKLKERLLKAITYAKGFGML	875	Q05086	K	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [616], 'TOPO_DOM_gain_score': array([0.02132773]), 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [39, 174], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.01100886, -0.00371623]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
291	NM_001083962.2(TCF4):c.1733G>A (p.Arg578His)	93542	CA266820	NM_001083962.2:c.1733G>A, ENST00000354452.8:c.1733G>A, ENST00000635822.2:c.1613G>A, ENST00000635990.2:n.1413G>A, ENST00000636400.2:c.1661G>A, ENST00000636751.2:c.*1441G>A, ENST00000636822.2:c.1343G>A, ENST00000637115.2:c.*1611G>A, ENST00000637169.2:c.1085G>A, ENST00000637239.2:n.1788G>A, ENST00000637250.2:n.1427G>A, ENST00000637923.2:n.1331G>A, ENST00000638154.3:c.1760G>A, ENST00000643689.1:c.1343G>A, ENST00000674764.1:c.*1344G>A, ENST00000675707.1:c.1343G>A, ENST00000354452.7:c.1733G>A, ENST00000356073.8:c.1721G>A, ENST00000398339.5:c.2039G>A, ENST00000457482.7:c.1253G>A, ENST00000537578.5:c.1661G>A, ENST00000537856.7:c.1331G>A, ENST00000540999.5:c.1649G>A, ENST00000543082.5:c.1595G>A, ENST00000544241.6:c.1520G>A, ENST00000561831.7:c.1241G>A, ENST00000561992.5:c.1331G>A, ENST00000562680.5:n.5256G>A, ENST00000564228.5:n.1508G>A, ENST00000564403.6:c.1751G>A, ENST00000564999.5:c.1721G>A, ENST00000565018.6:c.1469G>A, ENST00000566279.5:c.1553G>A, ENST00000566286.5:n.1712G>A, ENST00000567880.5:n.1541G>A, ENST00000568673.5:c.1661G>A, ENST00000568740.5:c.1646G>A, ENST00000570177.6:c.1331G>A, ENST00000570287.6:c.1241G>A, ENST00000616053.4:c.1469G>A, ENST00000626466.1:n.756G>A, ENST00000626584.2:c.1073G>A, ENST00000629387.2:c.1733G>A, NM_001083962.1:c.1733G>A, NM_001243226.2:c.2039G>A, NM_001243227.1:c.1661G>A, NM_001243228.1:c.1751G>A, NM_001243230.1:c.1712G>A, NM_001243231.1:c.1595G>A, NM_001243232.1:c.1520G>A, NM_001243233.1:c.1331G>A, NM_001243234.1:c.1253G>A, NM_001243235.1:c.1241G>A, NM_001243236.1:c.1241G>A, NM_001306207.1:c.1649G>A, NM_001306208.1:c.1508G>A, NM_003199.2:c.1721G>A, XM_005266739.3:c.1661G>A, XM_005266741.3:c.1730G>A, XM_005266743.3:c.1661G>A, XM_005266744.3:c.1661G>A, XM_005266745.3:c.1658G>A, XM_005266747.3:c.1607G>A, XM_005266749.3:c.1523G>A, XM_005266752.3:c.1343G>A, XM_005266754.3:c.1343G>A, XM_005266755.3:c.1343G>A, XM_005266761.3:c.1250G>A, XM_006722536.2:c.1733G>A, XM_006722537.2:c.1733G>A, XM_006722538.2:c.1658G>A, XM_006722539.2:c.1343G>A, XM_006722540.2:c.1331G>A, XM_011526154.1:c.2036G>A, XM_011526155.1:c.2036G>A, XM_011526156.1:c.2027G>A, XM_011526157.1:c.2024G>A, XM_011526158.1:c.1727G>A, XM_011526159.1:c.1343G>A, XM_011526160.1:c.1343G>A, XM_011526161.1:c.1343G>A, XM_011526162.1:c.1343G>A, XM_011526163.1:c.1343G>A, XM_011526164.1:c.1331G>A, NM_001330604.2:c.1730G>A, NM_001330605.2:c.1343G>A, NM_001348211.1:c.1607G>A, NM_001348212.1:c.1331G>A, NM_001348213.1:c.1343G>A, NM_001348214.1:c.1238G>A, NM_001348215.1:c.1085G>A, NM_001348216.1:c.1253G>A, NM_001348217.1:c.1661G>A, NM_001348218.1:c.1661G>A, NM_001348219.1:c.1649G>A, NM_001348220.1:c.1646G>A, XM_005266739.4:c.1661G>A, XM_005266741.4:c.1730G>A, XM_005266745.4:c.1658G>A, XM_005266749.4:c.1523G>A, XM_005266752.5:c.1343G>A, XM_005266755.5:c.1343G>A, XM_005266761.4:c.1250G>A, XM_006722536.3:c.1733G>A, XM_006722537.3:c.1733G>A, XM_006722538.3:c.1658G>A, XM_017025934.2:c.1658G>A, XM_017025935.2:c.1658G>A, XM_017025936.2:c.1649G>A, XM_017025937.2:c.1646G>A, XM_017025938.2:c.1730G>A, XM_017025940.2:c.1721G>A, XM_017025941.2:c.1721G>A, XM_017025942.2:c.1718G>A, XM_017025943.2:c.1718G>A, XM_017025944.2:c.1658G>A, XM_017025945.2:c.1658G>A, XM_017025946.2:c.1649G>A, XM_017025948.2:c.1646G>A, XM_017025950.2:c.1643G>A, XM_017025951.2:c.1604G>A, XM_017025952.2:c.1517G>A, XM_017025953.2:c.1511G>A, XM_017025954.2:c.1340G>A, XM_017025956.2:c.1331G>A, XM_024451240.1:c.1658G>A, XM_024451241.1:c.1496G>A, NM_001243226.3:c.2039G>A, NM_001243227.2:c.1661G>A, NM_001243228.2:c.1751G>A, NM_001243231.2:c.1595G>A, NM_001243233.2:c.1331G>A, NM_001243234.2:c.1253G>A, NM_001243235.2:c.1241G>A, NM_001243236.2:c.1241G>A, NM_001330604.3:c.1730G>A, NM_001330605.3:c.1343G>A, NM_001348211.2:c.1607G>A, NM_001348212.2:c.1331G>A, NM_001348213.2:c.1343G>A, NM_001348214.2:c.1238G>A, NM_001348215.2:c.1085G>A, NM_001348216.2:c.1253G>A, NM_001348218.2:c.1661G>A, NM_001348219.2:c.1649G>A, NM_001369567.1:c.1733G>A, NM_001369568.1:c.1733G>A, NM_001369569.1:c.1730G>A, NM_001369570.1:c.1730G>A, NM_001369571.1:c.1721G>A, NM_001369572.1:c.1721G>A, NM_001369573.1:c.1718G>A, NM_001369574.1:c.1718G>A, NM_001369575.1:c.1661G>A, NM_001369576.1:c.1658G>A, NM_001369577.1:c.1658G>A, NM_001369578.1:c.1658G>A, NM_001369579.1:c.1658G>A, NM_001369580.1:c.1658G>A, NM_001369581.1:c.1658G>A, NM_001369582.1:c.1649G>A, NM_001369583.1:c.1649G>A, NM_001369584.1:c.1646G>A, NM_001369585.1:c.1646G>A, NM_001369586.1:c.1664G>A, NM_003199.3:c.1721G>A, NM_001243230.2:c.1712G>A, NC_000018.10:g.55228993C>T, CM000680.2:g.55228993C>T, NC_000018.9:g.52896224C>T, CM000680.1:g.52896224C>T, NC_000018.8:g.51047222C>T, NG_011716.1:g.364637G>A, NG_011716.2:g.412001G>A, NM_001083962.2(TCF4):c.1733G>A (p.Arg578His)	TCF4	Pitt-Hopkins syndrome	MONDO:0012589	Autosomal dominant inheritance	Pathogenic	PP4, PP3, PM6_Strong, PM2_Supporting, PS4_Moderate, PS3_Supporting, PM1		The p.Arg578His variant in TCF4 has been reported in an individual with a clinical phenotype suggestive of Pitt-Hopkins syndrome (PMID 18728071) (PP4). This variant appears to be de novo in this patient and has been reported in the de novo state (biological parentage unconfirmed) in at least two additional patients with Pitt-Hopkins syndrome (PMID 21671391) (PM6_strong, PS4_moderate). In vitro binding assays have shown that this variant impacts impacts protein function (PMID 22460224) (PS3_supporting). This variant is located in the basic Helix-Loop-Helix domain (bHLH) (PMID 17436254, 22045651) (PM1). Computational prediction analysis tools suggests a deleterious impact; however, this information does not predict clinical significance on its own (PP3). The p.Arg578His variant in TCF4 is absent from gnomAD (PM2_supporting). In summary, the Arg578His variant in TCF4 is classified as Pathogenic for Pitt-Hopkins syndrome based on the ACMG/AMP criteria (PM6_strong, PS4_moderate, PM1, PM2_supporting, PP3, PP4).	21671391, 18728071, 21671391, 18728071, 21671391, 18728071	Rett and Angelman-like Disorders VCEP	https://clinicalgenome.org/site/assets/files/7339/clingen_rettas_acmg_specifications_v2.pdf	2021-03-26	2021-05-17	False	https://erepo.genome.network/evrepo/ui/classification/CA266820/MONDO:0012589/016	b545bd8e-c8f6-4437-a1d0-ce19966d9ce7	p.Arg578His	Arg	578	His	MHHQQRMAALGTDKELSDLLDFSAMFSPPVSSGKNGPTSLASGHFTGSNVEDRSSSGSWGNGGHPSPSRNYGDGTPYDHMTSRDLGSHDNLSPPFVNSRIQSKTERGSYSSYGRESNLQGCHQQSLLGGDMDMGNPGTLSPTKPGSQYYQYSSNNPRRRPLHSSAMEVQTKKVRKVPPGLPSSVYAPSASTADYNRDSPGYPSSKPATSTFPSSFFMQDGHHSSDPWSSSSGMNQPGYAGMLGNSSHIPQSSSYCSLHPHERLSYPSHSSADINSSLPPMSTFHRSGTNHYSTSSCTPPANGTDSIMANRGSGAAGSSQTGDALGKALASIYSPDHTNNSFSSNPSTPVGSPPSLSAGTAVWSRNGGQASSSPNYEGPLHSLQSRIEDRLERLDDAIHVLRNHAVGPSTAMPGGHGDMHGIIGPSHNGAMGGLGSGYGTGLLSANRHSLMVGTHREDGVALRGSHSLLPNQVPVPQLPVQSATSPDLNPPQDPYRGMPPGLQGQSVSSGSSEIKSDDEGDENLQDTKSSEDKKLDDDKKDIKSITSNNDDEDLTPEQKAEREKERRMANNARERLRVRDINEAFKELGRMVQLHLKSDKPQTKLLILHQAVAVILSLEQQVRERNLNPKAACLKRREEEKVSSEPPPLSLAGPHPGMGDASNHMGQM	667	P15884	H	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [220, 224, 285], 'COMPBIAS_gain': [], 'COMPBIAS_loss_score': array([-0.00585139, -0.0064497 , -0.0032742 ]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [570], 'REGION_gain': [], 'REGION_loss_score': array([-0.09646189]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
292	NM_001083962.1(TCF4):c.1727G>A (p.Arg576Gln)	381549	CA16607615	NM_001083962.1:c.1727G>A, NC_000018.10:g.55228999C>T, CM000680.2:g.55228999C>T, NC_000018.9:g.52896230C>T, CM000680.1:g.52896230C>T, NC_000018.8:g.51047228C>T, NG_011716.1:g.364631G>A, NG_011716.2:g.411995G>A, ENST00000354452.8:c.1727G>A, ENST00000635822.2:c.1607G>A, ENST00000635990.2:n.1407G>A, ENST00000636400.2:c.1655G>A, ENST00000636751.2:c.*1435G>A, ENST00000636822.2:c.1337G>A, ENST00000637115.2:c.*1605G>A, ENST00000637169.2:c.1079G>A, ENST00000637239.2:n.1782G>A, ENST00000637250.2:n.1421G>A, ENST00000637923.2:n.1325G>A, ENST00000638154.3:c.1754G>A, ENST00000643689.1:c.1337G>A, ENST00000674764.1:c.*1338G>A, ENST00000675707.1:c.1337G>A, ENST00000354452.7:c.1727G>A, ENST00000356073.8:c.1715G>A, ENST00000398339.5:c.2033G>A, ENST00000457482.7:c.1247G>A, ENST00000537578.5:c.1655G>A, ENST00000537856.7:c.1325G>A, ENST00000540999.5:c.1643G>A, ENST00000543082.5:c.1589G>A, ENST00000544241.6:c.1514G>A, ENST00000561831.7:c.1235G>A, ENST00000561992.5:c.1325G>A, ENST00000562680.5:n.5250G>A, ENST00000564228.5:n.1502G>A, ENST00000564403.6:c.1745G>A, ENST00000564999.5:c.1715G>A, ENST00000565018.6:c.1463G>A, ENST00000566279.5:c.1547G>A, ENST00000566286.5:n.1706G>A, ENST00000567880.5:n.1535G>A, ENST00000568673.5:c.1655G>A, ENST00000568740.5:c.1640G>A, ENST00000570177.6:c.1325G>A, ENST00000570287.6:c.1235G>A, ENST00000616053.4:c.1463G>A, ENST00000626466.1:n.750G>A, ENST00000626584.2:c.1067G>A, ENST00000629387.2:c.1727G>A, NM_001243226.2:c.2033G>A, NM_001243227.1:c.1655G>A, NM_001243228.1:c.1745G>A, NM_001243230.1:c.1706G>A, NM_001243231.1:c.1589G>A, NM_001243232.1:c.1514G>A, NM_001243233.1:c.1325G>A, NM_001243234.1:c.1247G>A, NM_001243235.1:c.1235G>A, NM_001243236.1:c.1235G>A, NM_001306207.1:c.1643G>A, NM_001306208.1:c.1502G>A, NM_003199.2:c.1715G>A, XM_005266739.3:c.1655G>A, XM_005266741.3:c.1724G>A, XM_005266743.3:c.1655G>A, XM_005266744.3:c.1655G>A, XM_005266745.3:c.1652G>A, XM_005266747.3:c.1601G>A, XM_005266749.3:c.1517G>A, XM_005266752.3:c.1337G>A, XM_005266754.3:c.1337G>A, XM_005266755.3:c.1337G>A, XM_005266761.3:c.1244G>A, XM_006722536.2:c.1727G>A, XM_006722537.2:c.1727G>A, XM_006722538.2:c.1652G>A, XM_006722539.2:c.1337G>A, XM_006722540.2:c.1325G>A, XM_011526154.1:c.2030G>A, XM_011526155.1:c.2030G>A, XM_011526156.1:c.2021G>A, XM_011526157.1:c.2018G>A, XM_011526158.1:c.1721G>A, XM_011526159.1:c.1337G>A, XM_011526160.1:c.1337G>A, XM_011526161.1:c.1337G>A, XM_011526162.1:c.1337G>A, XM_011526163.1:c.1337G>A, XM_011526164.1:c.1325G>A, NM_001330604.2:c.1724G>A, NM_001330605.2:c.1337G>A, NM_001348211.1:c.1601G>A, NM_001348212.1:c.1325G>A, NM_001348213.1:c.1337G>A, NM_001348214.1:c.1232G>A, NM_001348215.1:c.1079G>A, NM_001348216.1:c.1247G>A, NM_001348217.1:c.1655G>A, NM_001348218.1:c.1655G>A, NM_001348219.1:c.1643G>A, NM_001348220.1:c.1640G>A, XM_005266739.4:c.1655G>A, XM_005266741.4:c.1724G>A, XM_005266745.4:c.1652G>A, XM_005266749.4:c.1517G>A, XM_005266752.5:c.1337G>A, XM_005266755.5:c.1337G>A, XM_005266761.4:c.1244G>A, XM_006722536.3:c.1727G>A, XM_006722537.3:c.1727G>A, XM_006722538.3:c.1652G>A, XM_017025934.2:c.1652G>A, XM_017025935.2:c.1652G>A, XM_017025936.2:c.1643G>A, XM_017025937.2:c.1640G>A, XM_017025938.2:c.1724G>A, XM_017025940.2:c.1715G>A, XM_017025941.2:c.1715G>A, XM_017025942.2:c.1712G>A, XM_017025943.2:c.1712G>A, XM_017025944.2:c.1652G>A, XM_017025945.2:c.1652G>A, XM_017025946.2:c.1643G>A, XM_017025948.2:c.1640G>A, XM_017025950.2:c.1637G>A, XM_017025951.2:c.1598G>A, XM_017025952.2:c.1511G>A, XM_017025953.2:c.1505G>A, XM_017025954.2:c.1334G>A, XM_017025956.2:c.1325G>A, XM_024451240.1:c.1652G>A, XM_024451241.1:c.1490G>A, NM_001083962.2:c.1727G>A, NM_001243226.3:c.2033G>A, NM_001243227.2:c.1655G>A, NM_001243228.2:c.1745G>A, NM_001243231.2:c.1589G>A, NM_001243233.2:c.1325G>A, NM_001243234.2:c.1247G>A, NM_001243235.2:c.1235G>A, NM_001243236.2:c.1235G>A, NM_001330604.3:c.1724G>A, NM_001330605.3:c.1337G>A, NM_001348211.2:c.1601G>A, NM_001348212.2:c.1325G>A, NM_001348213.2:c.1337G>A, NM_001348214.2:c.1232G>A, NM_001348215.2:c.1079G>A, NM_001348216.2:c.1247G>A, NM_001348218.2:c.1655G>A, NM_001348219.2:c.1643G>A, NM_001369567.1:c.1727G>A, NM_001369568.1:c.1727G>A, NM_001369569.1:c.1724G>A, NM_001369570.1:c.1724G>A, NM_001369571.1:c.1715G>A, NM_001369572.1:c.1715G>A, NM_001369573.1:c.1712G>A, NM_001369574.1:c.1712G>A, NM_001369575.1:c.1655G>A, NM_001369576.1:c.1652G>A, NM_001369577.1:c.1652G>A, NM_001369578.1:c.1652G>A, NM_001369579.1:c.1652G>A, NM_001369580.1:c.1652G>A, NM_001369581.1:c.1652G>A, NM_001369582.1:c.1643G>A, NM_001369583.1:c.1643G>A, NM_001369584.1:c.1640G>A, NM_001369585.1:c.1640G>A, NM_001369586.1:c.1658G>A, NM_003199.3:c.1715G>A, NM_001243230.2:c.1706G>A, NM_001083962.1(TCF4):c.1727G>A (p.Arg576Gln)	TCF4	Pitt-Hopkins syndrome	MONDO:0012589	Autosomal dominant inheritance	Pathogenic	PP3, PP4, PM2_Supporting, PS4_Supporting, PS2_Very Strong, PS3_Supporting, PM1		The p.Arg576Gln variant in TCF4 has been reported as a de novo occurrence (biological parentage confirmed) in at least 2 individuals with Pitt-Hopkins syndrome (PMID 23033978, 28726809) (PS2_VS, PS4_supporting, PP4). The p.Arg576Gln variant in TCF4 is absent from gnomAD (PM2_supporting). In vitro binding assays have shown that this variant impacts protein function (PMID 22460224) (PS3_supporting). The p.Arg576Gln variant occurs in the well-characterized basic Helix-Loop-Helix domain of TCF4 (PM1). Computational prediction analysis tools suggests a deleterious impact; however, this information does not predict clinical significance on its own (PP3). In summary, the p.Arg576Gln variant in TCF4 is classified as Pathogenic for Pitt-Hopkins syndrome based on the ACMG/AMP criteria (PS2_VS, PM1, PS4_supporting, PM2_supporting, PP3, PP4).	28726809, 23033978, 23033978, 28726809, 28726809, 23033978	Rett and Angelman-like Disorders VCEP	https://clinicalgenome.org/site/assets/files/7339/clingen_rettas_acmg_specifications_v2.pdf	2021-03-26	2021-05-17	False	https://erepo.genome.network/evrepo/ui/classification/CA16607615/MONDO:0012589/016	b79ddda3-bf1e-4cee-8b49-6cc1423ac1a7	p.Arg576Gln	Arg	576	Gln	MHHQQRMAALGTDKELSDLLDFSAMFSPPVSSGKNGPTSLASGHFTGSNVEDRSSSGSWGNGGHPSPSRNYGDGTPYDHMTSRDLGSHDNLSPPFVNSRIQSKTERGSYSSYGRESNLQGCHQQSLLGGDMDMGNPGTLSPTKPGSQYYQYSSNNPRRRPLHSSAMEVQTKKVRKVPPGLPSSVYAPSASTADYNRDSPGYPSSKPATSTFPSSFFMQDGHHSSDPWSSSSGMNQPGYAGMLGNSSHIPQSSSYCSLHPHERLSYPSHSSADINSSLPPMSTFHRSGTNHYSTSSCTPPANGTDSIMANRGSGAAGSSQTGDALGKALASIYSPDHTNNSFSSNPSTPVGSPPSLSAGTAVWSRNGGQASSSPNYEGPLHSLQSRIEDRLERLDDAIHVLRNHAVGPSTAMPGGHGDMHGIIGPSHNGAMGGLGSGYGTGLLSANRHSLMVGTHREDGVALRGSHSLLPNQVPVPQLPVQSATSPDLNPPQDPYRGMPPGLQGQSVSSGSSEIKSDDEGDENLQDTKSSEDKKLDDDKKDIKSITSNNDDEDLTPEQKAEREKERRMANNARERLRVRDINEAFKELGRMVQLHLKSDKPQTKLLILHQAVAVILSLEQQVRERNLNPKAACLKRREEEKVSSEPPPLSLAGPHPGMGDASNHMGQM	667	P15884	Q	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [560, 590, 591, 592, 593], 'DNA_BIND_gain': [], 'DNA_BIND_loss_score': array([-0.16744435, -0.14780122, -0.15849203, -0.13484627, -0.13893104]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [220, 285], 'COMPBIAS_gain': [566], 'COMPBIAS_gain_score': array([0.02779001]), 'COMPBIAS_loss_score': array([-0.00320596, -0.00269312]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [630], 'REGION_gain': [571], 'REGION_gain_score': array([0.12608647]), 'REGION_loss_score': array([-0.02286541]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
293	NM_001083962.1(TCF4):c.1738C>T (p.Arg580Trp)	7370	CA254160	NM_001083962.1:c.1738C>T, ENST00000354452.8:c.1738C>T, ENST00000635822.2:c.1618C>T, ENST00000635990.2:n.1418C>T, ENST00000636400.2:c.1666C>T, ENST00000636751.2:c.*1446C>T, ENST00000636822.2:c.1348C>T, ENST00000637115.2:c.*1616C>T, ENST00000637169.2:c.1090C>T, ENST00000637239.2:n.1793C>T, ENST00000637250.2:n.1432C>T, ENST00000637923.2:n.1336C>T, ENST00000638154.3:c.1765C>T, ENST00000643689.1:c.1348C>T, ENST00000674764.1:c.*1349C>T, ENST00000675707.1:c.1348C>T, ENST00000354452.7:c.1738C>T, ENST00000356073.8:c.1726C>T, ENST00000398339.5:c.2044C>T, ENST00000457482.7:c.1258C>T, ENST00000537578.5:c.1666C>T, ENST00000537856.7:c.1336C>T, ENST00000540999.5:c.1654C>T, ENST00000543082.5:c.1600C>T, ENST00000544241.6:c.1525C>T, ENST00000561831.7:c.1246C>T, ENST00000561992.5:c.1336C>T, ENST00000562680.5:n.5261C>T, ENST00000564228.5:n.1513C>T, ENST00000564403.6:c.1756C>T, ENST00000564999.5:c.1726C>T, ENST00000565018.6:c.1474C>T, ENST00000566279.5:c.1558C>T, ENST00000566286.5:n.1717C>T, ENST00000567880.5:n.1546C>T, ENST00000568673.5:c.1666C>T, ENST00000568740.5:c.1651C>T, ENST00000570177.6:c.1336C>T, ENST00000570287.6:c.1246C>T, ENST00000616053.4:c.1474C>T, ENST00000626466.1:n.761C>T, ENST00000626584.2:c.1078C>T, ENST00000629387.2:c.1738C>T, NM_001243226.2:c.2044C>T, NM_001243227.1:c.1666C>T, NM_001243228.1:c.1756C>T, NM_001243230.1:c.1717C>T, NM_001243231.1:c.1600C>T, NM_001243232.1:c.1525C>T, NM_001243233.1:c.1336C>T, NM_001243234.1:c.1258C>T, NM_001243235.1:c.1246C>T, NM_001243236.1:c.1246C>T, NM_001306207.1:c.1654C>T, NM_001306208.1:c.1513C>T, NM_003199.2:c.1726C>T, XM_005266739.3:c.1666C>T, XM_005266741.3:c.1735C>T, XM_005266743.3:c.1666C>T, XM_005266744.3:c.1666C>T, XM_005266745.3:c.1663C>T, XM_005266747.3:c.1612C>T, XM_005266749.3:c.1528C>T, XM_005266752.3:c.1348C>T, XM_005266754.3:c.1348C>T, XM_005266755.3:c.1348C>T, XM_005266761.3:c.1255C>T, XM_006722536.2:c.1738C>T, XM_006722537.2:c.1738C>T, XM_006722538.2:c.1663C>T, XM_006722539.2:c.1348C>T, XM_006722540.2:c.1336C>T, XM_011526154.1:c.2041C>T, XM_011526155.1:c.2041C>T, XM_011526156.1:c.2032C>T, XM_011526157.1:c.2029C>T, XM_011526158.1:c.1732C>T, XM_011526159.1:c.1348C>T, XM_011526160.1:c.1348C>T, XM_011526161.1:c.1348C>T, XM_011526162.1:c.1348C>T, XM_011526163.1:c.1348C>T, XM_011526164.1:c.1336C>T, NM_001330604.2:c.1735C>T, NM_001330605.2:c.1348C>T, NM_001348211.1:c.1612C>T, NM_001348212.1:c.1336C>T, NM_001348213.1:c.1348C>T, NM_001348214.1:c.1243C>T, NM_001348215.1:c.1090C>T, NM_001348216.1:c.1258C>T, NM_001348217.1:c.1666C>T, NM_001348218.1:c.1666C>T, NM_001348219.1:c.1654C>T, NM_001348220.1:c.1651C>T, XM_005266739.4:c.1666C>T, XM_005266741.4:c.1735C>T, XM_005266745.4:c.1663C>T, XM_005266749.4:c.1528C>T, XM_005266752.5:c.1348C>T, XM_005266755.5:c.1348C>T, XM_005266761.4:c.1255C>T, XM_006722536.3:c.1738C>T, XM_006722537.3:c.1738C>T, XM_006722538.3:c.1663C>T, XM_017025934.2:c.1663C>T, XM_017025935.2:c.1663C>T, XM_017025936.2:c.1654C>T, XM_017025937.2:c.1651C>T, XM_017025938.2:c.1735C>T, XM_017025940.2:c.1726C>T, XM_017025941.2:c.1726C>T, XM_017025942.2:c.1723C>T, XM_017025943.2:c.1723C>T, XM_017025944.2:c.1663C>T, XM_017025945.2:c.1663C>T, XM_017025946.2:c.1654C>T, XM_017025948.2:c.1651C>T, XM_017025950.2:c.1648C>T, XM_017025951.2:c.1609C>T, XM_017025952.2:c.1522C>T, XM_017025953.2:c.1516C>T, XM_017025954.2:c.1345C>T, XM_017025956.2:c.1336C>T, XM_024451240.1:c.1663C>T, XM_024451241.1:c.1501C>T, NM_001083962.2:c.1738C>T, NM_001243226.3:c.2044C>T, NM_001243227.2:c.1666C>T, NM_001243228.2:c.1756C>T, NM_001243231.2:c.1600C>T, NM_001243233.2:c.1336C>T, NM_001243234.2:c.1258C>T, NM_001243235.2:c.1246C>T, NM_001243236.2:c.1246C>T, NM_001330604.3:c.1735C>T, NM_001330605.3:c.1348C>T, NM_001348211.2:c.1612C>T, NM_001348212.2:c.1336C>T, NM_001348213.2:c.1348C>T, NM_001348214.2:c.1243C>T, NM_001348215.2:c.1090C>T, NM_001348216.2:c.1258C>T, NM_001348218.2:c.1666C>T, NM_001348219.2:c.1654C>T, NM_001369567.1:c.1738C>T, NM_001369568.1:c.1738C>T, NM_001369569.1:c.1735C>T, NM_001369570.1:c.1735C>T, NM_001369571.1:c.1726C>T, NM_001369572.1:c.1726C>T, NM_001369573.1:c.1723C>T, NM_001369574.1:c.1723C>T, NM_001369575.1:c.1666C>T, NM_001369576.1:c.1663C>T, NM_001369577.1:c.1663C>T, NM_001369578.1:c.1663C>T, NM_001369579.1:c.1663C>T, NM_001369580.1:c.1663C>T, NM_001369581.1:c.1663C>T, NM_001369582.1:c.1654C>T, NM_001369583.1:c.1654C>T, NM_001369584.1:c.1651C>T, NM_001369585.1:c.1651C>T, NM_001369586.1:c.1669C>T, NM_003199.3:c.1726C>T, NM_001243230.2:c.1717C>T, NC_000018.10:g.55228988G>A, CM000680.2:g.55228988G>A, NC_000018.9:g.52896219G>A, CM000680.1:g.52896219G>A, NC_000018.8:g.51047217G>A, NG_011716.1:g.364642C>T, NG_011716.2:g.412006C>T, NM_001083962.1(TCF4):c.1738C>T (p.Arg580Trp)	TCF4	Pitt-Hopkins syndrome	MONDO:0012589	Autosomal dominant inheritance	Pathogenic	PP3, PP4, PM6_Strong, PS4_Supporting, PM2_Supporting, PS3_Supporting, PM1		The p.Arg580Trp variant in TCF4 has been reported in at least 2 de novo occurrences (biological parentage unconfirmed) in individuals with Pitt-Hopkins syndrome (PMID 17436254, 22045651) (PM6_strong, PS4_supporting, PP4). The p.Arg580Trp in TCF4 is absent from gnomAD (PM2_supporting). The p.Arg580Trp variant occurs in the well-characterized basic Helix-Loop-Helix domain of TCF4 (PM1). In vitro binding assays have shown that this variant impacts protein function (PMID 22460224) (PS3_supporting). Computational prediction analysis tools suggests a deleterious impact; however, this information does not predict clinical significance on its own (PP3). In summary, the p.Arg580Trp variant in TCF4 is classified as Pathogenic for Pitt-Hopkins syndrome based on the ACMG/AMP criteria (PM6_strong, PM1, PM2_supporting, PS4_supporting, PP3, PP4).	17436254, 17436254, 17436254	Rett and Angelman-like Disorders VCEP	https://clinicalgenome.org/site/assets/files/7339/clingen_rettas_acmg_specifications_v2.pdf	2021-03-26	2021-05-17	False	https://erepo.genome.network/evrepo/ui/classification/CA254160/MONDO:0012589/016	b4b4e028-4434-4362-a57e-8a50ad94182f	p.Arg580Trp	Arg	580	Trp	MHHQQRMAALGTDKELSDLLDFSAMFSPPVSSGKNGPTSLASGHFTGSNVEDRSSSGSWGNGGHPSPSRNYGDGTPYDHMTSRDLGSHDNLSPPFVNSRIQSKTERGSYSSYGRESNLQGCHQQSLLGGDMDMGNPGTLSPTKPGSQYYQYSSNNPRRRPLHSSAMEVQTKKVRKVPPGLPSSVYAPSASTADYNRDSPGYPSSKPATSTFPSSFFMQDGHHSSDPWSSSSGMNQPGYAGMLGNSSHIPQSSSYCSLHPHERLSYPSHSSADINSSLPPMSTFHRSGTNHYSTSSCTPPANGTDSIMANRGSGAAGSSQTGDALGKALASIYSPDHTNNSFSSNPSTPVGSPPSLSAGTAVWSRNGGQASSSPNYEGPLHSLQSRIEDRLERLDDAIHVLRNHAVGPSTAMPGGHGDMHGIIGPSHNGAMGGLGSGYGTGLLSANRHSLMVGTHREDGVALRGSHSLLPNQVPVPQLPVQSATSPDLNPPQDPYRGMPPGLQGQSVSSGSSEIKSDDEGDENLQDTKSSEDKKLDDDKKDIKSITSNNDDEDLTPEQKAEREKERRMANNARERLRVRDINEAFKELGRMVQLHLKSDKPQTKLLILHQAVAVILSLEQQVRERNLNPKAACLKRREEEKVSSEPPPLSLAGPHPGMGDASNHMGQM	667	P15884	W	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [592, 593], 'DNA_BIND_gain': [], 'DNA_BIND_loss_score': array([-0.06259853, -0.06547993]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [18], 'SIGNAL_gain': [], 'SIGNAL_loss_score': array([-0.05660141]), 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [569], 'HELIX_gain_score': array([0.03536421]), 'COILED_loss': [579], 'COILED_gain': [], 'COILED_loss_score': array([-0.06355023]), 'COMPBIAS_loss': [285], 'COMPBIAS_gain': [188, 189, 472], 'COMPBIAS_gain_score': array([0.01300025, 0.01317364, 0.00465542]), 'COMPBIAS_loss_score': array([-0.00612622]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
294	NM_003159.2(CDKL5):c.119C>T (p.Ala40Val)	11502	CA121521	NM_003159.2:c.119C>T, ENST00000623535.2:c.119C>T, ENST00000635828.1:c.119C>T, ENST00000637881.1:c.119C>T, ENST00000674046.1:c.119C>T, ENST00000379989.6:c.119C>T, ENST00000379996.7:c.119C>T, ENST00000463994.4:c.119C>T, ENST00000623364.3:c.119C>T, ENST00000623535.1:n.119C>T, ENST00000624700.3:c.119C>T, NM_001037343.1:c.119C>T, XM_011545569.1:c.119C>T, XM_011545570.1:c.14-10858C>T, XR_950484.1:n.371C>T, NM_001323289.1:c.119C>T, NM_001323289.2:c.119C>T, NM_001037343.2:c.119C>T, NM_003159.3:c.119C>T, NC_000023.11:g.18564496C>T, CM000685.2:g.18564496C>T, NC_000023.10:g.18582616C>T, CM000685.1:g.18582616C>T, NC_000023.9:g.18492537C>T, NG_008475.1:g.143892C>T, NM_003159.2(CDKL5):c.119C>T (p.Ala40Val)	CDKL5	CDKL5 disorder	MONDO:0100039	X-linked inheritance	Pathogenic	PP3, PM2_Supporting, PS2_Very Strong, PS4, PM1		The p.Ala40Val variant in CDKL5 has been reported in at least 4 unconfirmed de novo occurrences in patients with CDKL5 disorder (PMID 27779742, 17993579, 22678952, 19793311) (PM6_VS).  It is also reported in the mosaic state in a male patient with CDKL5 disorder (PMID 25819767) and therefore confirmed to be de novo (PS2). The p.Ala40Val variant has been observed in at least 10 other individuals with CDKL5 disorder (27779742, 25819767, 17993579, 22678952, 19793311, 21309761, 19780792) (PS4). The variant is absent in gnomAD (PM2_supporting). The variant is located in a well-characterized (ATP binding region: aa 19-43) functional domain of CDKL5 (PMID: 28544139, 17993579, 23064044, 29264392) (PM1). Computational prediction analysis tools suggests a deleterious impact; however, this information does not predict clinical significance on its own (PP3). In summary, the p.Ala40Val in CDKL5 is classified as Pathogenic based on the ACMG/AMP criteria (PM6_very strong, PS2, PS4_strong, PM1, PM2_supporting, PP3).		Rett and Angelman-like Disorders VCEP	https://clinicalgenome.org/site/assets/files/7339/clingen_rettas_acmg_specifications_v2.pdf	2021-03-30	2021-05-17	False	https://erepo.genome.network/evrepo/ui/classification/CA121521/MONDO:0100039/016	0e323081-868b-43b4-974c-8893a942d274	p.Ala40Val	Ala	40	Val	MKIPNIGNVMNKFEILGVVGEGAYGVVLKCRHKETHEIVAIKKFKDSEENEEVKETTLRELKMLRTLKQENIVELKEAFRRRGKLYLVFEYVEKNMLELLEEMPNGVPPEKVKSYIYQLIKAIHWCHKNDIVHRDIKPENLLISHNDVLKLCDFGFARNLSEGNNANYTEYVATRWYRSPELLLGAPYGKSVDMWSVGCILGELSDGQPLFPGESEIDQLFTIQKVLGPLPSEQMKLFYSNPRFHGLRFPAVNHPQSLERRYLGILNSVLLDLMKNLLKLDPADRYLTEQCLNHPTFQTQRLLDRSPSRSAKRKPYHVESSTLSNRNQAGKSTALQSHHRSNSKDIQNLSVGLPRADEGLPANESFLNGNLAGASLSPLHTKTYQASSQPGSTSKDLTNNNIPHLLSPKEAKSKTEFDFNIDPKPSEGPGTKYLKSNSRSQQNRHSFMESSQSKAGTLQPNEKQSRHSYIDTIPQSSRSPSYRTKAKSHGALSDSKSVSNLSEARAQIAEPSTSRYFPSSCLDLNSPTSPTPTRHSDTRTLLSPSGRNNRNEGTLDSRRTTTRHSKTMEELKLPEHMDSSHSHSLSAPHESFSYGLGYTSPFSSQQRPHRHSMYVTRDKVRAKGLDGSLSIGQGMAARANSLQLLSPQPGEQLPPEMTVARSSVKETSREGTSSFHTRQKSEGGVYHDPHSDDGTAPKENRHLYNDPVPRRVGSFYRVPSPRPDNSFHENNVSTRVSSLPSESSSGTNHSKRQPAFDPWKSPENISHSEQLKEKEKQGFFRSMKKKKKKSQTVPNSDSPDLLTLQKSIHSASTPSSRPKEWRPEKISDLQTQSQPLKSLRKLLHLSSASNHPASSDPRFQPLTAQQTKNSFSEIRIHPLSQASGGSSNIRQEPAPKGRPALQLPGQMDPGWHVSSVTRSATEGPSYSEQLGAKSGPNGHPYNRTNRSRMPNLNDLKETAL	960	O76039	V	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [16], 'SIGNAL_gain': [], 'SIGNAL_loss_score': array([-0.11035991]), 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [583], 'REGION_gain': [], 'REGION_loss_score': array([-0.00318307]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
295	NM_004360.5(CDH1):c.820G>A (p.Gly274Ser)	186326	CA194486	NM_004360.5:c.820G>A, NC_000016.10:g.68810329G>A, CM000678.2:g.68810329G>A, NC_000016.9:g.68844232G>A, CM000678.1:g.68844232G>A, NC_000016.8:g.67401733G>A, NG_008021.1:g.78038G>A, LRG_301:g.78038G>A, ENST00000261769.10:c.820G>A, ENST00000261769.9:c.820G>A, ENST00000422392.6:c.820G>A, ENST00000561751.1:n.455-1355G>A, ENST00000562836.5:n.891G>A, ENST00000566510.5:c.664G>A, ENST00000566612.5:c.820G>A, ENST00000611625.4:c.820G>A, ENST00000612417.4:c.820G>A, ENST00000621016.4:c.820G>A, NM_004360.3:c.820G>A, LRG_301t1:c.820G>A, XM_011523488.1:c.85G>A, XM_011523489.1:c.85G>A, NM_001317184.1:c.820G>A, NM_001317185.1:c.-796G>A, NM_001317186.1:c.-1000G>A, NM_004360.4:c.820G>A, NM_001317184.2:c.820G>A, NM_001317185.2:c.-796G>A, NM_001317186.2:c.-1000G>A, NM_004360.5(CDH1):c.820G>A (p.Gly274Ser)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Benign	BS2, BP2_Strong, BS1	PP2, PP3, PP4, PP1, PS3, PS1, PS4, PS2, BP1, BP4, BP3, BA1, PM1, PM3, PM4, PM5, PM2, PM6, PVS1, BP5, BP7, BS3, BS4	The c.820G>A (p.Gly274Ser) variant has been observed in >10 (25) individuals without a diagnosis of diffuse gastric cancer, signet ring tumor or lobular breast cancer and whose family histories do not suggest HDGC (BS2; SCV000760786.3, SCV000216659.5 and SCV000520889.4). This variant was observed in the homozygous state in an individual without a personal and/or family history of diffuse gastric cancer or lobular breast cancer (BP2_Strong; SCV000520889.4). The c.820G>A variant has an allele frequency of 0.001037 (0.1037%, 5/4822 alleles) in the South Asian subpopulation of the gnomAD v.3.1 cohort (BS1). In summary, the clinical significance of this variant is benign, ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): BS2, BP2_Strong, BS1.		CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-09	2023-08-10	False	https://erepo.genome.network/evrepo/ui/classification/CA194486/MONDO:0007648/007	a5aaee48-e09b-460f-91c0-455f0065cfa0	p.Gly274Ser	Gly	274	Ser	MGPWSRSLSALLLLLQVSSWLCQEPEPCHPGFDAESYTFTVPRRHLERGRVLGRVNFEDCTGRQRTAYFSLDTRFKVGTDGVITVKRPLRFHNPQIHFLVYAWDSTYRKFSTKVTLNTVGHHHRPPPHQASVSGIQAELLTFPNSSPGLRRQKRDWVIPPISCPENEKGPFPKNLVQIKSNKDKEGKVFYSITGQGADTPPVGVFIIERETGWLKVTEPLDRERIATYTLFSHAVSSNGNAVEDPMEILITVTDQNDNKPEFTQEVFKGSVMEGALPGTSVMEVTATDADDDVNTYNAAIAYTILSQDPELPDKNMFTINRNTGVISVVTTGLDRESFPTYTLVVQAADLQGEGLSTTATAVITVTDTNDNPPIFNPTTYKGQVPENEANVVITTLKVTDADAPNTPAWEAVYTILNDDGGQFVVTTNPVNNDGILKTAKGLDFEAKQQYILHVAVTNVVPFEVSLTTSTATVTVDVLDVNEAPIFVPPEKRVEVSEDFGVGQEITSYTAQEPDTFMEQKITYRIWRDTANWLEINPDTGAISTRAELDREDFEHVKNSTYTALIIATDNGSPVATGTGTLLLILSDVNDNAPIPEPRTIFFCERNPKPQVINIIDADLPPNTSPFTAELTHGASANWTIQYNDPTQESIILKPKMALEVGDYKINLKLMDNQNKDQVTTLEVSVCDCEGAAGVCRKAQPVEAGLQIPAILGILGGILALLILILLLLLFLRRRAVVKEPLLPPEDDTRDNVYYYDEEGGGEEDQDFDLSQLHRGLDARPEVTRNDVAPTLMSVPRYLPRPANPDEIGNFIDENLKAADTDPTAPPYDSLLVFDYEGSGSEAASLSSLNSSESDKDQDYDYLNEWGNRFKKLADMYGGGEDD	882	P12830	S	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [260], 'STRAND_gain_score': array([0.01136523]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
296	NM_000257.4(MYH7):c.1322C>T (p.Thr441Met)	14122	CA010543	NM_000257.4:c.1322C>T, ENST00000355349.4:c.1322C>T, ENST00000355349.3:c.1322C>T, NM_000257.3:c.1322C>T, XR_245686.3:n.1428C>T, XM_017021340.1:c.1322C>T, NC_000014.9:g.23429040G>A, CM000676.2:g.23429040G>A, NC_000014.8:g.23898249G>A, CM000676.1:g.23898249G>A, NC_000014.7:g.22968089G>A, NG_007884.1:g.11622C>T, LRG_384:g.11622C>T, NM_000257.4(MYH7):c.1322C>T (p.Thr441Met)	MYH7	cardiomyopathy	MONDO:0004994	Autosomal dominant inheritance	Benign	PM1, BA1	BP1, BP3, BS1, BS3, BS4, PS1, PS4, PS2, BP4, BP7, BP2, BP5, PVS1, PM3, BS2, PP2, PP4, PM2, PM5, PM4, PS3, PM6, PP3, PP1	The c.1322C>T (p.Thr441Met) in MYH7 has been identified in 0.2% (FAF 95% CI; 47/18394) of East Asian chromosomes in gnomAD (BA1; https://gnomad.broadinstitute.org). While this variant lies in the head region of the protein (aa 181-937), where missense variants are statistically more likely to be disease-associated (PM1; Walsh 2017 PMID:27532257), this is not considered to be in conflict with BA1 since benign variation within this region was considered during that analysis. In summary, this variant meets criteria to be is classified as benign for cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (Kelly 2018 PMID:29300372): BA1, PM1.	17548557, 17548557	Cardiomyopathy VCEP		2021-06-16	2021-06-16	False	https://erepo.genome.network/evrepo/ui/classification/CA010543/MONDO:0004994/002	001b25ad-349a-401e-8256-78899c1526f5	p.Thr441Met	Thr	441	Met	MGDSEMAVFGAAAPYLRKSEKERLEAQTRPFDLKKDVFVPDDKQEFVKAKIVSREGGKVTAETEYGKTVTVKEDQVMQQNPPKFDKIEDMAMLTFLHEPAVLYNLKDRYGSWMIYTYSGLFCVTVNPYKWLPVYTPEVVAAYRGKKRSEAPPHIFSISDNAYQYMLTDRENQSILITGESGAGKTVNTKRVIQYFAVIAAIGDRSKKDQSPGKGTLEDQIIQANPALEAFGNAKTVRNDNSSRFGKFIRIHFGATGKLASADIETYLLEKSRVIFQLKAERDYHIFYQILSNKKPELLDMLLITNNPYDYAFISQGETTVASIDDAEELMATDNAFDVLGFTSEEKNSMYKLTGAIMHFGNMKFKLKQREEQAEPDGTEEADKSAYLMGLNSADLLKGLCHPRVKVGNEYVTKGQNVQQVIYATGALAKAVYERMFNWMVTRINATLETKQPRQYFIGVLDIAGFEIFDFNSFEQLCINFTNEKLQQFFNHHMFVLEQEEYKKEGIEWTFIDFGMDLQACIDLIEKPMGIMSILEEECMFPKATDMTFKAKLFDNHLGKSANFQKPRNIKGKPEAHFSLIHYAGIVDYNIIGWLQKNKDPLNETVVGLYQKSSLKLLSTLFANYAGADAPIEKGKGKAKKGSSFQTVSALHRENLNKLMTNLRSTHPHFVRCIIPNETKSPGVMDNPLVMHQLRCNGVLEGIRICRKGFPNRILYGDFRQRYRILNPAAIPEGQFIDSRKGAEKLLSSLDIDHNQYKFGHTKVFFKAGLLGLLEEMRDERLSRIITRIQAQSRGVLARMEYKKLLERRDSLLVIQWNIRAFMGVKNWPWMKLYFKIKPLLKSAEREKEMASMKEEFTRLKEALEKSEARRKELEEKMVSLLQEKNDLQLQVQAEQDNLADAEERCDQLIKNKIQLEAKVKEMNERLEDEEEMNAELTAKKRKLEDECSELKRDIDDLELTLAKVEKEKHATENKVKNLTEEMAGLDEIIAKLTKEKKALQEAHQQALDDLQAEEDKVNTLTKAKVKLEQQVDDLEGSLEQEKKVRMDLERAKRKLEGDLKLTQESIMDLENDKQQLDERLKKKDFELNALNARIEDEQALGSQLQKKLKELQARIEELEEELEAERTARAKVEKLRSDLSRELEEISERLEEAGGATSVQIEMNKKREAEFQKMRRDLEEATLQHEATAAALRKKHADSVAELGEQIDNLQRVKQKLEKEKSEFKLELDDVTSNMEQIIKAKANLEKMCRTLEDQMNEHRSKAEETQRSVNDLTSQRAKLQTENGELSRQLDEKEALISQLTRGKLTYTQQLEDLKRQLEEEVKAKNALAHALQSARHDCDLLREQYEEETEAKAELQRVLSKANSEVAQWRTKYETDAIQRTEELEEAKKKLAQRLQEAEEAVEAVNAKCSSLEKTKHRLQNEIEDLMVDVERSNAAAAALDKKQRNFDKILAEWKQKYEESQSELESSQKEARSLSTELFKLKNAYEESLEHLETFKRENKNLQEEISDLTEQLGSSGKTIHELEKVRKQLEAEKMELQSALEEAEASLEHEEGKILRAQLEFNQIKAEIERKLAEKDEEMEQAKRNHLRVVDSLQTSLDAETRSRNEALRVKKKMEGDLNEMEIQLSHANRMAAEAQKQVKSLQSLLKDTQIQLDDAVRANDDLKENIAIVERRNNLLQAELEELRAVVEQTERSRKLAEQELIETSERVQLLHSQNTSLINQKKKMDADLSQLQTEVEEAVQECRNAEEKAKKAITDAAMMAEELKKEQDTSAHLERMKKNMEQTIKDLQHRLDEAEQIALKGGKKQLQKLEARVRELENELEAEQKRNAESVKGMRKSERRIKELTYQTEEDRKNLLRLQDLVDKLQLKVKAYKRQAEEAEEQANTNLSKFRKVQHELDEAEERADIAESQVNKLRAKSRDIGTKGLNEE	1935	P12883	M	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [660], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.00780642]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [161, 164, 165, 169, 172, 1666, 1773, 1786], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.05513507, -0.06468129, -0.05919766, -0.06330568, -0.05679196,
       -0.05492812, -0.01909614, -0.0264101 ]), 'REGION_loss': [874], 'REGION_gain': [], 'REGION_loss_score': array([-0.00245798]), 'REPEAT_loss': [47, 87, 105, 373, 375, 400, 1111, 1156, 1841], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.00281584, -0.00191665, -0.00217938, -0.00214028, -0.00227743,
       -0.0020479 , -0.00188649, -0.00275952, -0.00433004]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
297	NM_000257.4(MYH7):c.1357C>A (p.Arg453Ser)	14129	CA010621	NM_000257.4:c.1357C>A, NC_000014.9:g.23429005G>T, CM000676.2:g.23429005G>T, NC_000014.8:g.23898214G>T, CM000676.1:g.23898214G>T, NC_000014.7:g.22968054G>T, NG_007884.1:g.11657C>A, LRG_384:g.11657C>A, ENST00000355349.4:c.1357C>A, ENST00000355349.3:c.1357C>A, NM_000257.3:c.1357C>A, XR_245686.3:n.1463C>A, XM_017021340.1:c.1357C>A, NM_000257.4(MYH7):c.1357C>A (p.Arg453Ser)	MYH7	hypertrophic cardiomyopathy	MONDO:0005045	Autosomal dominant inheritance	Pathogenic	PS4_Supporting, PM2, PM5, PP1_Strong, PP3	BS1, BS3, BS4, BP3, PS1, PS2, BP4, BP2, BP5, PVS1, PM1, PM6, PM4, PS3, BA1	The c.1357C>A (p.Arg453Ser) variant in MYH7 has been identified in 3 individuals with HCM, including 1 individual with early onset HCM (<20 yo; PS4_Supporting; Frazier 2008 PMID:18175163; Walsh 2017 PMID:27532257; Centenary Institute Sydney pers. comm.; LMM pers. comm.) and segregated with disease in 9 affected relatives with HCM from 2 families (PP1_Strong; Centenary Institute Sydney pers. comm.; LMM pers. comm.). This variant was absent from large population studies (PM2; http:/gnomad.broadinstitute.org, v2.1.1). Computational prediction tools and conservation analysis suggest that this variant may impact the protein (PP3). Two different missense variants that have been classified as pathogenic by this expert panel have been previously identified at this codon, which indicate that this residue may be critical to the function of the protein (PM5; c.1358G>T, p.Arg453His - Variation ID 42838 and c.1357C>T, p.Arg453Cys - Variation ID 14089). This variant lies in the head region of the protein (aa 181-937) and missense variants in this region are statistically more likely to be disease-associated (PM1; Walsh 2017 PMID:27532257); however, because the other pathogenic variants at this codon were used to establish this enrichment, PM1 cannot be used in combination with PM5. In summary, this variant meets criteria to be classified as likely pathogenic for hypertrophic cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (Kelly 2018 PMID:29300372): PS4_Supporting; PP1_Strong; PM2; PP3; PM5.		Cardiomyopathy VCEP		2021-06-16	2021-10-13	True	https://erepo.genome.network/evrepo/ui/classification/CA010621/MONDO:0005045/002	e324a6b6-6afc-422c-895f-6f899dc1576a	p.Arg453Ser	Arg	453	Ser	MGDSEMAVFGAAAPYLRKSEKERLEAQTRPFDLKKDVFVPDDKQEFVKAKIVSREGGKVTAETEYGKTVTVKEDQVMQQNPPKFDKIEDMAMLTFLHEPAVLYNLKDRYGSWMIYTYSGLFCVTVNPYKWLPVYTPEVVAAYRGKKRSEAPPHIFSISDNAYQYMLTDRENQSILITGESGAGKTVNTKRVIQYFAVIAAIGDRSKKDQSPGKGTLEDQIIQANPALEAFGNAKTVRNDNSSRFGKFIRIHFGATGKLASADIETYLLEKSRVIFQLKAERDYHIFYQILSNKKPELLDMLLITNNPYDYAFISQGETTVASIDDAEELMATDNAFDVLGFTSEEKNSMYKLTGAIMHFGNMKFKLKQREEQAEPDGTEEADKSAYLMGLNSADLLKGLCHPRVKVGNEYVTKGQNVQQVIYATGALAKAVYERMFNWMVTRINATLETKQPRQYFIGVLDIAGFEIFDFNSFEQLCINFTNEKLQQFFNHHMFVLEQEEYKKEGIEWTFIDFGMDLQACIDLIEKPMGIMSILEEECMFPKATDMTFKAKLFDNHLGKSANFQKPRNIKGKPEAHFSLIHYAGIVDYNIIGWLQKNKDPLNETVVGLYQKSSLKLLSTLFANYAGADAPIEKGKGKAKKGSSFQTVSALHRENLNKLMTNLRSTHPHFVRCIIPNETKSPGVMDNPLVMHQLRCNGVLEGIRICRKGFPNRILYGDFRQRYRILNPAAIPEGQFIDSRKGAEKLLSSLDIDHNQYKFGHTKVFFKAGLLGLLEEMRDERLSRIITRIQAQSRGVLARMEYKKLLERRDSLLVIQWNIRAFMGVKNWPWMKLYFKIKPLLKSAEREKEMASMKEEFTRLKEALEKSEARRKELEEKMVSLLQEKNDLQLQVQAEQDNLADAEERCDQLIKNKIQLEAKVKEMNERLEDEEEMNAELTAKKRKLEDECSELKRDIDDLELTLAKVEKEKHATENKVKNLTEEMAGLDEIIAKLTKEKKALQEAHQQALDDLQAEEDKVNTLTKAKVKLEQQVDDLEGSLEQEKKVRMDLERAKRKLEGDLKLTQESIMDLENDKQQLDERLKKKDFELNALNARIEDEQALGSQLQKKLKELQARIEELEEELEAERTARAKVEKLRSDLSRELEEISERLEEAGGATSVQIEMNKKREAEFQKMRRDLEEATLQHEATAAALRKKHADSVAELGEQIDNLQRVKQKLEKEKSEFKLELDDVTSNMEQIIKAKANLEKMCRTLEDQMNEHRSKAEETQRSVNDLTSQRAKLQTENGELSRQLDEKEALISQLTRGKLTYTQQLEDLKRQLEEEVKAKNALAHALQSARHDCDLLREQYEEETEAKAELQRVLSKANSEVAQWRTKYETDAIQRTEELEEAKKKLAQRLQEAEEAVEAVNAKCSSLEKTKHRLQNEIEDLMVDVERSNAAAAALDKKQRNFDKILAEWKQKYEESQSELESSQKEARSLSTELFKLKNAYEESLEHLETFKRENKNLQEEISDLTEQLGSSGKTIHELEKVRKQLEAEKMELQSALEEAEASLEHEEGKILRAQLEFNQIKAEIERKLAEKDEEMEQAKRNHLRVVDSLQTSLDAETRSRNEALRVKKKMEGDLNEMEIQLSHANRMAAEAQKQVKSLQSLLKDTQIQLDDAVRANDDLKENIAIVERRNNLLQAELEELRAVVEQTERSRKLAEQELIETSERVQLLHSQNTSLINQKKKMDADLSQLQTEVEEAVQECRNAEEKAKKAITDAAMMAEELKKEQDTSAHLERMKKNMEQTIKDLQHRLDEAEQIALKGGKKQLQKLEARVRELENELEAEQKRNAESVKGMRKSERRIKELTYQTEEDRKNLLRLQDLVDKLQLKVKAYKRQAEEAEEQANTNLSKFRKVQHELDEAEERADIAESQVNKLRAKSRDIGTKGLNEE	1935	P12883	S	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [421, 422, 424, 425, 426, 493, 494, 547], 'HELIX_gain_score': array([0.02855533, 0.03284794, 0.03774798, 0.03359008, 0.03431833,
       0.02038181, 0.02079356, 0.02174866]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [1774, 1784], 'DOMAIN_gain_score': array([0.02239954, 0.0329088 ]), 'REGION_loss': [], 'REGION_gain': [1205], 'REGION_gain_score': array([0.00236607]), 'REPEAT_loss': [47, 87, 373, 375, 400, 888, 980, 1009, 1083, 1111, 1156, 1841], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.00187039, -0.00088906, -0.00379235, -0.00369239, -0.00443769,
       -0.00338686, -0.00457215, -0.0046289 , -0.00253946, -0.00340217,
       -0.00243145, -0.00341105]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
298	NM_000546.5(TP53):c.814G>A (p.Val272Met)	185814	CA000427	NM_000546.5:c.814G>A, NC_000017.11:g.7673806C>T, CM000679.2:g.7673806C>T, NC_000017.10:g.7577124C>T, CM000679.1:g.7577124C>T, NC_000017.9:g.7517849C>T, NG_017013.2:g.18745G>A, LRG_321:g.18745G>A, ENST00000269305.9:c.814G>A, ENST00000269305.8:c.814G>A, ENST00000359597.8:n.814G>A, ENST00000413465.6:n.782+375G>A, ENST00000420246.6:c.814G>A, ENST00000445888.6:c.814G>A, ENST00000455263.6:c.814G>A, ENST00000504290.5:c.418G>A, ENST00000504937.5:c.418G>A, ENST00000509690.5:c.418G>A, ENST00000510385.5:c.418G>A, ENST00000610292.4:c.697G>A, ENST00000610538.4:c.697G>A, ENST00000610623.4:c.337G>A, ENST00000615910.4:n.781G>A, ENST00000617185.4:c.814G>A, ENST00000618944.4:c.337G>A, ENST00000619186.4:c.337G>A, ENST00000619485.4:c.697G>A, ENST00000620739.4:c.697G>A, ENST00000622645.4:c.697G>A, ENST00000635293.1:c.697G>A, LRG_321t1:c.814G>A, NM_001126112.2:c.814G>A, LRG_321t2:c.814G>A, NM_001126113.2:c.814G>A, LRG_321t4:c.814G>A, NM_001126114.2:c.814G>A, LRG_321t3:c.814G>A, NM_001126115.1:c.418G>A, LRG_321t5:c.418G>A, NM_001126116.1:c.418G>A, LRG_321t6:c.418G>A, NM_001126117.1:c.418G>A, LRG_321t7:c.418G>A, NM_001126118.1:c.697G>A, LRG_321t8:c.697G>A, NM_001276695.1:c.697G>A, NM_001276696.1:c.697G>A, NM_001276697.1:c.337G>A, NM_001276698.1:c.337G>A, NM_001276699.1:c.337G>A, NM_001276760.1:c.697G>A, NM_001276761.1:c.697G>A, NM_001276695.2:c.697G>A, NM_001276696.2:c.697G>A, NM_001276697.2:c.337G>A, NM_001276698.2:c.337G>A, NM_001276699.2:c.337G>A, NM_001276760.2:c.697G>A, NM_001276761.2:c.697G>A, NM_000546.6:c.814G>A, NM_001126112.3:c.814G>A, NM_001126113.3:c.814G>A, NM_001126114.3:c.814G>A, NM_001126115.2:c.418G>A, NM_001126116.2:c.418G>A, NM_001126117.2:c.418G>A, NM_001126118.2:c.697G>A, NM_001276695.3:c.697G>A, NM_001276696.3:c.697G>A, NM_001276697.3:c.337G>A, NM_001276698.3:c.337G>A, NM_001276699.3:c.337G>A, NM_001276760.3:c.697G>A, NM_001276761.3:c.697G>A, NM_000546.6(TP53):c.814G>A (p.Val272Met), NM_000546.5(TP53):c.814G>A (p.Val272Met)	TP53	Li-Fraumeni syndrome 1	MONDO:0007903	Autosomal dominant inheritance	Pathogenic	PM6_Strong, PS3, PS4_Moderate, PM1	BS2, PP3, PM2, BP4, BA1, PS1, PM5, BS1, BS3	This variant has >10 observations as a somatic hotspot variant in tumors (PM1; cancerhotspots.org v(2)). Transactivation assays show a low functioning allele according to Kato, et al. and there is evidence of a dominant negative effect and loss of function according to Giacomelli, et al. (PS3; PMID: 12826609, 30224644). This variant has been reported in 4 probands meeting Chompret criteria (PS4_Moderate; PMID: 25584008, 23175693, IARC, NIH). There are de novo observations in 2 probands with childhood rhabdomyosarcoma, osteosarcoma, without parental confirmation (PM6_Strong; PMID: IARC, NIH). In summary, TP53 c.814G>A (p.Val272Met) meets criteria to be classified as pathogenic for Li-Fraumeni syndrome.  ACMG/AMP criteria applied, as specified by the TP53 Variant Curation Expert Panel: PM1, PS3, PS4_Moderate, PM6_Strong.		TP53 VCEP		2022-03-18	2022-03-18	False	https://erepo.genome.network/evrepo/ui/classification/CA000427/MONDO:0007903/009	f3006a48-5b31-4ef1-8f3d-575a86c78f1b	p.Val272Met	Val	272	Met	MEEPQSDPSVEPPLSQETFSDLWKLLPENNVLSPLPSQAMDDLMLSPDDIEQWFTEDPGPDEAPRMPEAAPPVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFRHSVVVPYEPPEVGSDCTTIHYNYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNTSSSPQPKKKPLDGEYFTLQIRGRERFEMFRELNEALELKDAQAGKEPGGSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD	393	P04637	M	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [285], 'DNA_BIND_gain': [], 'DNA_BIND_loss_score': array([-0.00658798]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [134], 'DISULFID_gain_score': array([0.02311385]), 'PROPEP_loss': [117, 118, 119, 121, 122, 125, 127, 300, 304, 305, 308, 309, 311, 312, 316, 317, 318, 319, 320, 322, 324, 325, 327, 328, 329, 331, 333, 335, 336, 339, 342, 343, 346, 349, 350, 356, 357, 358, 359, 360, 361, 362, 363, 365, 366, 369, 372, 377, 378], 'PROPEP_gain': [], 'PROPEP_loss_score': array([-0.10783243, -0.10888606, -0.10523963, -0.10508722, -0.11214715,
       -0.10263741, -0.10609651, -0.03141212, -0.02819991, -0.03415924,
       -0.05506968, -0.05295038, -0.0458045 , -0.05636549, -0.0616262 ,
       -0.05113256, -0.05059034, -0.05038488, -0.06594628, -0.08055389,
       -0.07642955, -0.0797891 , -0.07424122, -0.07403857, -0.07157725,
       -0.08102924, -0.0847075 , -0.07979178, -0.08904994, -0.08192939,
       -0.08514136, -0.06903505, -0.08233368, -0.07905692, -0.08504462,
       -0.09242779, -0.09182256, -0.09335762, -0.09088773, -0.09236473,
       -0.09594107, -0.10514539, -0.11428618, -0.115659  , -0.10992372,
       -0.12606364, -0.11680096, -0.10857856, -0.1092416 ]), 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [140, 248], 'STRAND_gain': [136, 229], 'STRAND_gain_score': array([0.09227461, 0.04839295]), 'STRAND_loss_score': array([-0.02118808, -0.03143871]), 'HELIX_loss': [239], 'HELIX_gain': [347], 'HELIX_gain_score': array([0.03706938]), 'HELIX_loss_score': array([-0.04298097]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [137, 138, 139, 140, 141, 142, 152], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.42706907, -0.50633085, -0.52101421, -0.4840163 , -0.4803955 ,
       -0.47024387, -0.36558002]), 'REGION_loss': [41, 327], 'REGION_gain': [], 'REGION_loss_score': array([-0.01300693, -0.02365994]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
299	NM_001126112.2(TP53):c.380C>A (p.Ser127Tyr)	656751	CA397843908	NM_001126112.2:c.380C>A, NC_000017.11:g.7675232G>T, CM000679.2:g.7675232G>T, NC_000017.10:g.7578550G>T, CM000679.1:g.7578550G>T, NC_000017.9:g.7519275G>T, NG_017013.2:g.17319C>A, LRG_321:g.17319C>A, ENST00000269305.9:c.380C>A, ENST00000269305.8:c.380C>A, ENST00000359597.8:n.380C>A, ENST00000413465.6:n.380C>A, ENST00000420246.6:c.380C>A, ENST00000445888.6:c.380C>A, ENST00000455263.6:c.380C>A, ENST00000503591.1:c.380C>A, ENST00000504290.5:c.-17C>A, ENST00000504937.5:c.-17C>A, ENST00000505014.5:n.636C>A, ENST00000508793.5:c.380C>A, ENST00000509690.5:c.-17C>A, ENST00000510385.5:c.-17C>A, ENST00000514944.5:c.101C>A, ENST00000604348.5:c.376-17C>A, ENST00000610292.4:c.263C>A, ENST00000610538.4:c.263C>A, ENST00000610623.4:c.-98C>A, ENST00000615910.4:n.347C>A, ENST00000617185.4:c.380C>A, ENST00000618944.4:c.-98C>A, ENST00000619186.4:c.-98C>A, ENST00000619485.4:c.263C>A, ENST00000620739.4:c.263C>A, ENST00000622645.4:c.263C>A, ENST00000635293.1:c.263C>A, NM_000546.5:c.380C>A, LRG_321t1:c.380C>A, LRG_321t2:c.380C>A, NM_001126113.2:c.380C>A, LRG_321t4:c.380C>A, NM_001126114.2:c.380C>A, LRG_321t3:c.380C>A, NM_001126115.1:c.-17C>A, LRG_321t5:c.-17C>A, NM_001126116.1:c.-17C>A, LRG_321t6:c.-17C>A, NM_001126117.1:c.-17C>A, LRG_321t7:c.-17C>A, NM_001126118.1:c.263C>A, LRG_321t8:c.263C>A, NM_001276695.1:c.263C>A, NM_001276696.1:c.263C>A, NM_001276697.1:c.-98C>A, NM_001276698.1:c.-98C>A, NM_001276699.1:c.-98C>A, NM_001276760.1:c.263C>A, NM_001276761.1:c.263C>A, NM_001276695.2:c.263C>A, NM_001276696.2:c.263C>A, NM_001276697.2:c.-98C>A, NM_001276698.2:c.-98C>A, NM_001276699.2:c.-98C>A, NM_001276760.2:c.263C>A, NM_001276761.2:c.263C>A, NM_000546.6:c.380C>A, NM_001126112.3:c.380C>A, NM_001126113.3:c.380C>A, NM_001126114.3:c.380C>A, NM_001126115.2:c.-17C>A, NM_001126116.2:c.-17C>A, NM_001126117.2:c.-17C>A, NM_001126118.2:c.263C>A, NM_001276695.3:c.263C>A, NM_001276696.3:c.263C>A, NM_001276697.3:c.-98C>A, NM_001276698.3:c.-98C>A, NM_001276699.3:c.-98C>A, NM_001276760.3:c.263C>A, NM_001276761.3:c.263C>A, NM_001126112.2(TP53):c.380C>A (p.Ser127Tyr)	TP53	Li-Fraumeni syndrome 1	MONDO:0007903	Autosomal dominant inheritance	Pathogenic	PP3_Moderate, PP1, PM2_Supporting, PS4_Supporting, PS3, PM1	BS2, BP4, PS1, BS3	This variant is absent in the gnomAD cohort (PM2_Supporting; http://gnomad.broadinstitute.org). This variant has a BayesDel score > 0.16 and Align GVGD (Zebrafish) is Class 65 (PP3_Moderate). This variant has >10 observations as a somatic hotspot variant in tumors (PM1; cancerhotspots.org v(2)). Transactivation assays show a low functioning allele according to Kato, et al. and there is an in vitro proliferation assay demonstrating loss of function (PS3; PMID: 12826609, PMID: 25584008). This variant has been reported in 2 probands meeting Chompret criteria (PS4; internal laboratory contributors). This variant was found to co-segregate with disease in multiple affected family members, with 3 meioses observed (PP1; internal laboratory contributor). In summary, TP53 c.380C>A (p.Ser127Tyr) meets criteria to be classified as Pathogenic for Li-Fraumeni syndrome.  ACMG/AMP criteria applied, as specified by the TP53 Variant Curation Expert Panel: PM2_Supporting, PP3_Moderate, PM1, PS3, PS4_Supporting, PP1.		TP53 VCEP		2021-04-20	2021-06-16	False	https://erepo.genome.network/evrepo/ui/classification/CA397843908/MONDO:0007903/009	69da5ddc-e144-48e0-aa76-30754f54757b	p.Ser127Tyr	Ser	127	Tyr	MEEPQSDPSVEPPLSQETFSDLWKLLPENNVLSPLPSQAMDDLMLSPDDIEQWFTEDPGPDEAPRMPEAAPPVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFRHSVVVPYEPPEVGSDCTTIHYNYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNTSSSPQPKKKPLDGEYFTLQIRGRERFEMFRELNEALELKDAQAGKEPGGSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD	393	P04637	Y	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [140], 'BINDING_gain_score': array([0.27450049]), 'DNA_BIND_loss': [285], 'DNA_BIND_gain': [], 'DNA_BIND_loss_score': array([-0.02389479]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [134], 'DISULFID_gain_score': array([0.06016713]), 'PROPEP_loss': [117, 118, 119, 121, 122, 125, 127], 'PROPEP_gain': [], 'PROPEP_loss_score': array([-0.06797945, -0.08287817, -0.09522343, -0.11308181, -0.11425012,
       -0.08213389, -0.14207101]), 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [197, 199, 204], 'STRAND_gain': [126, 136], 'STRAND_gain_score': array([0.18834943, 0.02335662]), 'STRAND_loss_score': array([-0.03616905, -0.04984099, -0.0307287 ]), 'HELIX_loss': [239], 'HELIX_gain': [347], 'HELIX_gain_score': array([0.00332952]), 'HELIX_loss_score': array([-0.03384084]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [131, 132, 134, 135, 136], 'DOMAIN_gain_score': array([0.34635222, 0.2663759 , 0.21668577, 0.30828887, 0.3813647 ]), 'REGION_loss': [41], 'REGION_gain': [], 'REGION_loss_score': array([-0.01381046]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
300	NM_001126112.2(TP53):c.711G>A (p.Met237Ile)	142714	CA000349	NM_001126112.2:c.711G>A, ENST00000269305.9:c.711G>A, ENST00000269305.8:c.711G>A, ENST00000359597.8:n.711G>A, ENST00000413465.6:n.711G>A, ENST00000420246.6:c.711G>A, ENST00000445888.6:c.711G>A, ENST00000455263.6:c.711G>A, ENST00000504290.5:c.315G>A, ENST00000504937.5:c.315G>A, ENST00000509690.5:c.315G>A, ENST00000510385.5:c.315G>A, ENST00000514944.5:c.432G>A, ENST00000610292.4:c.594G>A, ENST00000610538.4:c.594G>A, ENST00000610623.4:c.234G>A, ENST00000615910.4:n.678G>A, ENST00000617185.4:c.711G>A, ENST00000618944.4:c.234G>A, ENST00000619186.4:c.234G>A, ENST00000619485.4:c.594G>A, ENST00000620739.4:c.594G>A, ENST00000622645.4:c.594G>A, ENST00000635293.1:c.594G>A, NM_000546.5:c.711G>A, LRG_321t1:c.711G>A, LRG_321t2:c.711G>A, NM_001126113.2:c.711G>A, LRG_321t4:c.711G>A, NM_001126114.2:c.711G>A, LRG_321t3:c.711G>A, NM_001126115.1:c.315G>A, LRG_321t5:c.315G>A, NM_001126116.1:c.315G>A, LRG_321t6:c.315G>A, NM_001126117.1:c.315G>A, LRG_321t7:c.315G>A, NM_001126118.1:c.594G>A, LRG_321t8:c.594G>A, NM_001276695.1:c.594G>A, NM_001276696.1:c.594G>A, NM_001276697.1:c.234G>A, NM_001276698.1:c.234G>A, NM_001276699.1:c.234G>A, NM_001276760.1:c.594G>A, NM_001276761.1:c.594G>A, NM_001276695.2:c.594G>A, NM_001276696.2:c.594G>A, NM_001276697.2:c.234G>A, NM_001276698.2:c.234G>A, NM_001276699.2:c.234G>A, NM_001276760.2:c.594G>A, NM_001276761.2:c.594G>A, NM_000546.6:c.711G>A, NM_001126112.3:c.711G>A, NM_001126113.3:c.711G>A, NM_001126114.3:c.711G>A, NM_001126115.2:c.315G>A, NM_001126116.2:c.315G>A, NM_001126117.2:c.315G>A, NM_001126118.2:c.594G>A, NM_001276695.3:c.594G>A, NM_001276696.3:c.594G>A, NM_001276697.3:c.234G>A, NM_001276698.3:c.234G>A, NM_001276699.3:c.234G>A, NM_001276760.3:c.594G>A, NM_001276761.3:c.594G>A, NC_000017.11:g.7674252C>T, CM000679.2:g.7674252C>T, NC_000017.10:g.7577570C>T, CM000679.1:g.7577570C>T, NC_000017.9:g.7518295C>T, NG_017013.2:g.18299G>A, LRG_321:g.18299G>A, NM_001126112.2(TP53):c.711G>A (p.Met237Ile)	TP53	Li-Fraumeni syndrome 1	MONDO:0007903	Autosomal dominant inheritance	Pathogenic	PP1_Moderate, PM6_Supporting, PS3, PS4, PM1	BS2, PP3, PM2, BA1, BP4, BS1, BS3, PM5	This variant has >10 observations as a somatic hotspot variant in tumors (PM1; cancerhotspots.org v(2)). Transactivation assays show a low functioning allele according to Kato, et al. and there is evidence of a dominant negative effect and loss of function according to Giacomelli, et al. (PS3; PMID: 12826609, 30224644). This variant has been reported in 1 proband meeting Classic LFS criteria and 4 probands meeting Chompret criteria (PS4; PMID: 11370630, 25945745, NIH, Invitae, Ambry). This variant was found to co-segregate with disease in multiple affected family members, with 5 or 6 meioses observed (PP1_Moderate; NIH, Invitae). There is one de novo observation in a proband with breast and thyroid cancer in her 30s without parental confirmation (PM6_Supporting; GeneDx).  In summary, TP53 c.711G>A (p.Met237Ile) meets criteria to be classified as pathogenic for Li-Fraumeni syndrome.  ACMG/AMP criteria applied, as specified by the TP53 Variant Curation Expert Panel: PM1, PS3, PS4, PP1_Moderate, PM6_Supporting.		TP53 VCEP		2021-04-20	2021-06-16	False	https://erepo.genome.network/evrepo/ui/classification/CA000349/MONDO:0007903/009	98acfed4-de66-4a8c-b6ba-bc9a67cd4189	p.Met237Ile	Met	237	Ile	MEEPQSDPSVEPPLSQETFSDLWKLLPENNVLSPLPSQAMDDLMLSPDDIEQWFTEDPGPDEAPRMPEAAPPVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFRHSVVVPYEPPEVGSDCTTIHYNYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNTSSSPQPKKKPLDGEYFTLQIRGRERFEMFRELNEALELKDAQAGKEPGGSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD	393	P04637	I	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [237], 'BINDING_gain': [], 'BINDING_loss_score': array([-0.22883314]), 'DNA_BIND_loss': [285], 'DNA_BIND_gain': [], 'DNA_BIND_loss_score': array([-0.00382298]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [300, 305, 311, 312, 318, 322, 366], 'PROPEP_gain': [], 'PROPEP_loss_score': array([-0.01048326, -0.01055866, -0.0100472 , -0.00963324, -0.01387644,
       -0.01183099, -0.01012284]), 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [140, 197, 248], 'STRAND_gain': [238], 'STRAND_gain_score': array([0.02937907]), 'STRAND_loss_score': array([-0.02069694, -0.01540971, -0.02069283]), 'HELIX_loss': [239], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.03459549]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [136], 'DOMAIN_gain_score': array([0.05656767]), 'REGION_loss': [], 'REGION_gain': [43], 'REGION_gain_score': array([0.00356883]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
301	NM_000527.5(LDLR):c.970G>A (p.Gly324Ser)	161263	CA023801	NM_000527.5:c.970G>A, NC_000019.10:g.11110681G>A, CM000681.2:g.11110681G>A, NC_000019.9:g.11221357G>A, CM000681.1:g.11221357G>A, NC_000019.8:g.11082357G>A, NG_009060.1:g.26301G>A, LRG_274:g.26301G>A, ENST00000558518.6:c.970G>A, ENST00000252444.9:n.1224G>A, ENST00000455727.6:c.466G>A, ENST00000535915.5:c.847G>A, ENST00000545707.5:c.589G>A, ENST00000557933.5:c.970G>A, ENST00000558013.5:c.970G>A, ENST00000558518.5:c.970G>A, ENST00000560467.1:n.541-833G>A, NM_000527.4:c.970G>A, LRG_274t1:c.970G>A, NM_001195798.1:c.970G>A, NM_001195799.1:c.847G>A, NM_001195800.1:c.466G>A, NM_001195803.1:c.589G>A, XM_011528010.1:c.970G>A, XM_011528011.1:c.589G>A, XR_244074.2:n.1120G>A, XM_011528010.2:c.970G>A, XR_001753685.2:n.1087G>A, XR_001753686.2:n.1087G>A, NM_001195798.2:c.970G>A, NM_001195799.2:c.847G>A, NM_001195800.2:c.466G>A, NM_001195803.2:c.589G>A, NM_000527.5(LDLR):c.970G>A (p.Gly324Ser)	LDLR	hypercholesterolemia, familial	MONDO:0007750	Semidominant inheritance	Benign	PP3, PP1, BS2, BA1, BP2	PS3, PS1, PS4, PS2, PM5, PM1, PM4, PM3, BP7, BP5, BS1, BS4, BS3, PM2, PM6, PVS1, PP2, PP4, BP1, BP4, BP3	The NM_000527.5(LDLR):c.970G>A (p.Gly324Ser) variant is classified as Benign for Familial Hypercholesterolemia by applying evidence codes (BA1, BS2, BP2, PP1 and PP3) as defined by the ClinGen Familial Hypercholesterolemia Expert Panel LDLR-specific variant curation guidelines (https://doi.org/10.1101/2021.03.17.21252755). The supporting evidence is as follows: BA1 - FAF = 0.01153 (1.153%) in African/African American exomes (gnomAD v2.1.1). BS2 - Identified in 4 heterozygous non-affected family members from different labs.BP2 - variant identified 1 index case with heterozygous FH phenotype who is double heterozygous with NM_000384.3(APOB):c.10580G>A p.Arg3527Gln (ClinVar ID 17890) - classified as Pathogenic by the general ACMG guidelines (Chora et al., 2018).PP1 - variant segregates with phenotype in 2 informative meiosis in 1 family from Cardiovascular Research Group,Instituto Nacional de Saude Doutor Ricardo Jorge.PP3 - REVEL = 0.815.Variant has 1 stand alone, 1 Strong and 1 Supporting evidence codes towards Benign, enough to classify as Benign, and only 2 Supporting codes towards Pathogenic. The Benign criteria overwhelms the Pathogenic criteria, so we are confident in classifying this variant as Benign.		Familial Hypercholesterolemia VCEP	https://clinicalgenome.org/docs/clingen-familial-hypercholesterolemia-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1-2/	2021-06-23	2021-06-24	False	https://erepo.genome.network/evrepo/ui/classification/CA023801/MONDO:0007750/013	ffcac230-1fce-4800-8865-926e499ad6fc	p.Gly324Ser	Gly	324	Ser	MGPWGWKLRWTVALLLAAAGTAVGDRCERNEFQCQDGKCISYKWVCDGSAECQDGSDESQETCLSVTCKSGDFSCGGRVNRCIPQFWRCDGQVDCDNGSDEQGCPPKTCSQDEFRCHDGKCISRQFVCDSDRDCLDGSDEASCPVLTCGPASFQCNSSTCIPQLWACDNDPDCEDGSDEWPQRCRGLYVFQGDSSPCSAFEFHCLSGECIHSSWRCDGGPDCKDKSDEENCAVATCRPDEFQCSDGNCIHGSRQCDREYDCKDMSDEVGCVNVTLCEGPNKFKCHSGECITLDKVCNMARDCRDWSDEPIKECGTNECLDNNGGCSHVCNDLKIGYECLCPDGFQLVAQRRCEDIDECQDPDTCSQLCVNLEGGYKCQCEEGFQLDPHTKACKAVGSIAYLFFTNRHEVRKMTLDRSEYTSLIPNLRNVVALDTEVASNRIYWSDLSQRMICSTQLDRAHGVSSYDTVISRDIQAPDGLAVDWIHSNIYWTDSVLGTVSVADTKGVKRKTLFRENGSKPRAIVVDPVHGFMYWTDWGTPAKIKKGGLNGVDIYSLVTENIQWPNGITLDLLSGRLYWVDSKLHSISSIDVNGGNRKTILEDEKRLAHPFSLAVFEDKVFWTDIINEAIFSANRLTGSDVNLLAENLLSPEDMVLFHNLTQPRGVNWCERTTLSNGGCQYLCLPAPQINPHSPKFTCACPDGMLLARDMRSCLTEAEAAVATQETSTVRLKVSSTAVRTQHTTTRPVPDTSRLPGATPGLTTVEIVTMSHQALGDVAGRGNEKKPSSVRALSIVLPIVLLVFLCLGVFLLWKNWRLKNINSINFDNPVYQKTTEDEVHICHNQDGYSYPSRQMVSLEDDVA	860	P01130	S	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [74], 'ZN_FING_gain': [], 'ZN_FING_loss_score': array([-0.00078934])}
302	NM_000527.5(LDLR):c.1171G>A (p.Ala391Thr)	183138	CA023426	NM_000527.5:c.1171G>A, ENST00000558518.6:c.1171G>A, ENST00000252444.9:n.1425G>A, ENST00000455727.6:c.667G>A, ENST00000535915.5:c.1048G>A, ENST00000545707.5:c.790G>A, ENST00000557933.5:c.1171G>A, ENST00000558013.5:c.1171G>A, ENST00000558518.5:c.1171G>A, ENST00000560173.1:n.170G>A, ENST00000560467.1:n.651G>A, NM_000527.4:c.1171G>A, LRG_274t1:c.1171G>A, NM_001195798.1:c.1171G>A, NM_001195799.1:c.1048G>A, NM_001195800.1:c.667G>A, NM_001195803.1:c.790G>A, XM_011528010.1:c.1171G>A, XM_011528011.1:c.790G>A, XR_244074.2:n.1321G>A, XM_011528010.2:c.1171G>A, XR_001753685.2:n.1288G>A, XR_001753686.2:n.1288G>A, NM_001195798.2:c.1171G>A, NM_001195799.2:c.1048G>A, NM_001195800.2:c.667G>A, NM_001195803.2:c.790G>A, NC_000019.10:g.11111624G>A, CM000681.2:g.11111624G>A, NC_000019.9:g.11222300G>A, CM000681.1:g.11222300G>A, NC_000019.8:g.11083300G>A, NG_009060.1:g.27244G>A, LRG_274:g.27244G>A, NM_000527.5(LDLR):c.1171G>A (p.Ala391Thr)	LDLR	hypercholesterolemia, familial	MONDO:0007750	Semidominant inheritance	Benign	BS2, BA1, BP4, BP2	PS3, PS4, PS2, PS1, PM4, PM1, PM3, PM5, BP7, BP5, BS1, BS3, BS4, PVS1, PM2, PM6, PP2, PP3, PP1, PP4, BP1, BP3	The NM_000527.5(LDLR):c.1171G>A (p.Ala391Thr) variant is classified as Benign for Familial Hypercholesterolemia by applying evidence codes BA1, BS2, BP2 and BP4 as defined by the ClinGen Familial Hypercholesterolemia Expert Panel LDLR-specific variant curation guidelines (https://doi.org/10.1101/2021.03.17.21252755). The supporting evidence is as follows: BA1 - FAF = 0.1752 (17.52%) in African exomes (gnomAD v2.1.1); frequency meets BA1 >0.5%BS2 - Case-level data in VCI indicates this variant is identified in heterozygosity in 1894 normolipidemic individuals, as well as in homozygosity in 58 normolipidemic individuals.BP2 - Case-level data present in VCI indicates this variant has been identified to co-occur with Pathogenic LDLR variants in at least 3 index cases with heterozygous FH phenotype.BP4 - REVEL = 0.309; score is below BP4 threshold of <0.50. splicing evaluation is required. Functional data on splicing not available. A) not on limits B) does not create GT C) no nearby GT.		Familial Hypercholesterolemia VCEP	https://clinicalgenome.org/docs/clingen-familial-hypercholesterolemia-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1-2/	2021-06-23	2021-06-24	False	https://erepo.genome.network/evrepo/ui/classification/CA023426/MONDO:0007750/013	7235c54a-6e6c-4107-b0ea-465ee2900bc7	p.Ala391Thr	Ala	391	Thr	MGPWGWKLRWTVALLLAAAGTAVGDRCERNEFQCQDGKCISYKWVCDGSAECQDGSDESQETCLSVTCKSGDFSCGGRVNRCIPQFWRCDGQVDCDNGSDEQGCPPKTCSQDEFRCHDGKCISRQFVCDSDRDCLDGSDEASCPVLTCGPASFQCNSSTCIPQLWACDNDPDCEDGSDEWPQRCRGLYVFQGDSSPCSAFEFHCLSGECIHSSWRCDGGPDCKDKSDEENCAVATCRPDEFQCSDGNCIHGSRQCDREYDCKDMSDEVGCVNVTLCEGPNKFKCHSGECITLDKVCNMARDCRDWSDEPIKECGTNECLDNNGGCSHVCNDLKIGYECLCPDGFQLVAQRRCEDIDECQDPDTCSQLCVNLEGGYKCQCEEGFQLDPHTKACKAVGSIAYLFFTNRHEVRKMTLDRSEYTSLIPNLRNVVALDTEVASNRIYWSDLSQRMICSTQLDRAHGVSSYDTVISRDIQAPDGLAVDWIHSNIYWTDSVLGTVSVADTKGVKRKTLFRENGSKPRAIVVDPVHGFMYWTDWGTPAKIKKGGLNGVDIYSLVTENIQWPNGITLDLLSGRLYWVDSKLHSISSIDVNGGNRKTILEDEKRLAHPFSLAVFEDKVFWTDIINEAIFSANRLTGSDVNLLAENLLSPEDMVLFHNLTQPRGVNWCERTTLSNGGCQYLCLPAPQINPHSPKFTCACPDGMLLARDMRSCLTEAEAAVATQETSTVRLKVSSTAVRTQHTTTRPVPDTSRLPGATPGLTTVEIVTMSHQALGDVAGRGNEKKPSSVRALSIVLPIVLLVFLCLGVFLLWKNWRLKNINSINFDNPVYQKTTEDEVHICHNQDGYSYPSRQMVSLEDDVA	860	P01130	T	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
303	NM_000527.5(LDLR):c.2043C>G (p.Cys681Trp)	252188	CA10585743	NM_000527.5:c.2043C>G, ENST00000558518.6:c.2043C>G, ENST00000252444.9:n.2297C>G, ENST00000455727.6:c.1539C>G, ENST00000535915.5:c.1920C>G, ENST00000545707.5:c.1606+192C>G, ENST00000557933.5:c.2043C>G, ENST00000558013.5:c.2043C>G, ENST00000558518.5:c.2043C>G, NM_000527.4:c.2043C>G, LRG_274t1:c.2043C>G, NM_001195798.1:c.2043C>G, NM_001195799.1:c.1920C>G, NM_001195800.1:c.1539C>G, NM_001195803.1:c.1606+192C>G, XM_011528010.1:c.2043C>G, XM_011528011.1:c.1662C>G, XR_244074.2:n.2053C>G, XM_011528010.2:c.2043C>G, XR_001753685.2:n.2160C>G, XR_001753686.2:n.2020C>G, NM_001195798.2:c.2043C>G, NM_001195799.2:c.1920C>G, NM_001195800.2:c.1539C>G, NM_001195803.2:c.1606+192C>G, NC_000019.10:g.11120425C>G, CM000681.2:g.11120425C>G, NC_000019.9:g.11231101C>G, CM000681.1:g.11231101C>G, NC_000019.8:g.11092101C>G, NG_009060.1:g.36045C>G, LRG_274:g.36045C>G, NM_000527.5(LDLR):c.2043C>G (p.Cys681Trp)	LDLR	hypercholesterolemia, familial	MONDO:0007750	Semidominant inheritance	Pathogenic	PP1_Strong, PM1, PM2, PP3, PP4	PS1, PS3, PS4, PS2, PM5, PM4, PM3, BP7, BP5, BS1, BS3, BS4, PVS1, PM6, PP2, BS2, BA1, BP1, BP4, BP3, BP2	NM_000527.5(LDLR):c.2043C>G (p.Cys681Trp) variant is classified as Pathogenic for Familial Hypercholesterolemia by applying evidence codes (PP1_Strong, PM1, PM2, PP3 and PP4) as defined by the ClinGen Familial Hypercholesterolemia Expert Panel LDLR-specific variant curation guidelines (https://doi.org/10.1101/2021.03.17.21252755). The supporting evidence is as follows: PP1_strong - Variant segregates with FH phenotype in 7 informative meioses in 1 family from PMID: 16092059.PM1 - Variant meets PM2 and is one of listed Cysteine. PM2 - No population data was found for this allele in gnomAD (gnomAD v2.1.1).PP3 - REVEL: 0,83. PP4 - Variant meet PM2. PMID: 16092059 - 1 case who fulfills Simon-Broome criteria for FH.		Familial Hypercholesterolemia VCEP	https://clinicalgenome.org/docs/clingen-familial-hypercholesterolemia-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1-2/	2021-06-18	2021-06-24	False	https://erepo.genome.network/evrepo/ui/classification/CA10585743/MONDO:0007750/013	c12a6a0d-1d06-4705-8036-67b2e5a31e81	p.Cys681Trp	Cys	681	Trp	MGPWGWKLRWTVALLLAAAGTAVGDRCERNEFQCQDGKCISYKWVCDGSAECQDGSDESQETCLSVTCKSGDFSCGGRVNRCIPQFWRCDGQVDCDNGSDEQGCPPKTCSQDEFRCHDGKCISRQFVCDSDRDCLDGSDEASCPVLTCGPASFQCNSSTCIPQLWACDNDPDCEDGSDEWPQRCRGLYVFQGDSSPCSAFEFHCLSGECIHSSWRCDGGPDCKDKSDEENCAVATCRPDEFQCSDGNCIHGSRQCDREYDCKDMSDEVGCVNVTLCEGPNKFKCHSGECITLDKVCNMARDCRDWSDEPIKECGTNECLDNNGGCSHVCNDLKIGYECLCPDGFQLVAQRRCEDIDECQDPDTCSQLCVNLEGGYKCQCEEGFQLDPHTKACKAVGSIAYLFFTNRHEVRKMTLDRSEYTSLIPNLRNVVALDTEVASNRIYWSDLSQRMICSTQLDRAHGVSSYDTVISRDIQAPDGLAVDWIHSNIYWTDSVLGTVSVADTKGVKRKTLFRENGSKPRAIVVDPVHGFMYWTDWGTPAKIKKGGLNGVDIYSLVTENIQWPNGITLDLLSGRLYWVDSKLHSISSIDVNGGNRKTILEDEKRLAHPFSLAVFEDKVFWTDIINEAIFSANRLTGSDVNLLAENLLSPEDMVLFHNLTQPRGVNWCERTTLSNGGCQYLCLPAPQINPHSPKFTCACPDGMLLARDMRSCLTEAEAAVATQETSTVRLKVSSTAVRTQHTTTRPVPDTSRLPGATPGLTTVEIVTMSHQALGDVAGRGNEKKPSSVRALSIVLPIVLLVFLCLGVFLLWKNWRLKNINSINFDNPVYQKTTEDEVHICHNQDGYSYPSRQMVSLEDDVA	860	P01130	W	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [666, 680, 695, 697], 'DISULFID_gain': [], 'DISULFID_loss_score': array([-0.24235547, -0.93757069, -0.32792014, -0.42615002]), 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [681, 682], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.11419606, -0.08616072]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [663, 712], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.33699363, -0.29129863]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [661, 662, 664], 'REPEAT_gain_score': array([0.16935438, 0.25724155, 0.38753927]), 'ZN_FING_loss': [675, 676, 677, 678, 679, 681, 682, 699, 700, 701], 'ZN_FING_gain': [108], 'ZN_FING_gain_score': array([0.0053485]), 'ZN_FING_loss_score': array([-0.3476851 , -0.14351338, -0.31463534, -0.20924836, -0.24036276,
       -0.27314103, -0.37358367, -0.16055697, -0.08503848, -0.1317668 ])}"
304	NM_000527.5(LDLR):c.1783C>T (p.Arg595Trp)	161290	CA023581	NM_000527.5:c.1783C>T, NC_000019.10:g.11116936C>T, CM000681.2:g.11116936C>T, NC_000019.9:g.11227612C>T, CM000681.1:g.11227612C>T, NC_000019.8:g.11088612C>T, NG_009060.1:g.32556C>T, LRG_274:g.32556C>T, ENST00000558518.6:c.1783C>T, ENST00000252444.9:n.2037C>T, ENST00000455727.6:c.1279C>T, ENST00000535915.5:c.1660C>T, ENST00000545707.5:c.1402C>T, ENST00000557933.5:c.1783C>T, ENST00000558013.5:c.1783C>T, ENST00000558518.5:c.1783C>T, ENST00000559340.1:n.426+724C>T, NM_000527.4:c.1783C>T, LRG_274t1:c.1783C>T, NM_001195798.1:c.1783C>T, NM_001195799.1:c.1660C>T, NM_001195800.1:c.1279C>T, NM_001195803.1:c.1402C>T, XM_011528010.1:c.1783C>T, XM_011528011.1:c.1402C>T, XR_244074.2:n.1855+724C>T, XM_011528010.2:c.1783C>T, XR_001753685.2:n.1900C>T, XR_001753686.2:n.1822+724C>T, NM_001195798.2:c.1783C>T, NM_001195799.2:c.1660C>T, NM_001195800.2:c.1279C>T, NM_001195803.2:c.1402C>T, NM_000527.5(LDLR):c.1783C>T (p.Arg595Trp)	LDLR	hypercholesterolemia, familial	MONDO:0007750	Semidominant inheritance	Pathogenic	PS4, PP1_Strong, PM2, PP3, PP4	PS1, PS3, PS2, PM5, PM4, PM1, PM3, BP7, BP5, BS1, BS3, BS4, PM6, PVS1, PP2, BS2, BA1, BP1, BP4, BP3, BP2	NM_000527.5(LDLR):c.1783C>T (p.Arg595Trp) variant is classified as Pathogenic for Familial Hypercholesterolemia by applying evidence codes (PS4, PP1_Strong, PM2, PP3 and PP4) as defined by the ClinGen Familial Hypercholesterolemia Expert Panel LDLR-specific variant curation guidelines (https://doi.org/10.1101/2021.03.17.21252755). The supporting evidence is as follows: PS4 - Variant meets PM2. Variant identified in 12 index cases.PP1_strong - 10 informative meioses identified by Laboratory of Genetics and Molecular Cardiology.PM2 - PopMax MAF = 0.00001548 (0.0015%) in European non-Finnish (gnomAD v2.1.1). PP3 - REVEL: 0,89. PP4 - Variant meets PM2. Variant identified in 12 index cases fulfilling validated clinical criteria for FH (6 cases with Simon-Broome or DLCN criteria from Ambry Genetics; 2 cases with Simon-Broome from Color laboratory; 3 cases with Simon-Broome criteria from Laboratory of Genetics and Molecular Cardiology; 1 case with Simon-Broome criteria from GeneDx).		Familial Hypercholesterolemia VCEP	https://clinicalgenome.org/docs/clingen-familial-hypercholesterolemia-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1-2/	2021-06-09	2021-06-24	False	https://erepo.genome.network/evrepo/ui/classification/CA023581/MONDO:0007750/013	ba5d5793-ffd3-48df-89c0-24c7600a8a6d	p.Arg595Trp	Arg	595	Trp	MGPWGWKLRWTVALLLAAAGTAVGDRCERNEFQCQDGKCISYKWVCDGSAECQDGSDESQETCLSVTCKSGDFSCGGRVNRCIPQFWRCDGQVDCDNGSDEQGCPPKTCSQDEFRCHDGKCISRQFVCDSDRDCLDGSDEASCPVLTCGPASFQCNSSTCIPQLWACDNDPDCEDGSDEWPQRCRGLYVFQGDSSPCSAFEFHCLSGECIHSSWRCDGGPDCKDKSDEENCAVATCRPDEFQCSDGNCIHGSRQCDREYDCKDMSDEVGCVNVTLCEGPNKFKCHSGECITLDKVCNMARDCRDWSDEPIKECGTNECLDNNGGCSHVCNDLKIGYECLCPDGFQLVAQRRCEDIDECQDPDTCSQLCVNLEGGYKCQCEEGFQLDPHTKACKAVGSIAYLFFTNRHEVRKMTLDRSEYTSLIPNLRNVVALDTEVASNRIYWSDLSQRMICSTQLDRAHGVSSYDTVISRDIQAPDGLAVDWIHSNIYWTDSVLGTVSVADTKGVKRKTLFRENGSKPRAIVVDPVHGFMYWTDWGTPAKIKKGGLNGVDIYSLVTENIQWPNGITLDLLSGRLYWVDSKLHSISSIDVNGGNRKTILEDEKRLAHPFSLAVFEDKVFWTDIINEAIFSANRLTGSDVNLLAENLLSPEDMVLFHNLTQPRGVNWCERTTLSNGGCQYLCLPAPQINPHSPKFTCACPDGMLLARDMRSCLTEAEAAVATQETSTVRLKVSSTAVRTQHTTTRPVPDTSRLPGATPGLTTVEIVTMSHQALGDVAGRGNEKKPSSVRALSIVLPIVLLVFLCLGVFLLWKNWRLKNINSINFDNPVYQKTTEDEVHICHNQDGYSYPSRQMVSLEDDVA	860	P01130	W	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [661], 'REPEAT_gain_score': array([0.0250442]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
305	NM_000527.5(LDLR):c.1775G>A (p.Gly592Glu)	161271	CA023577	NM_000527.5:c.1775G>A, ENST00000558518.6:c.1775G>A, ENST00000252444.9:n.2029G>A, ENST00000455727.6:c.1271G>A, ENST00000535915.5:c.1652G>A, ENST00000545707.5:c.1394G>A, ENST00000557933.5:c.1775G>A, ENST00000558013.5:c.1775G>A, ENST00000558518.5:c.1775G>A, ENST00000559340.1:n.426+716G>A, NM_000527.4:c.1775G>A, LRG_274t1:c.1775G>A, NM_001195798.1:c.1775G>A, NM_001195799.1:c.1652G>A, NM_001195800.1:c.1271G>A, NM_001195803.1:c.1394G>A, XM_011528010.1:c.1775G>A, XM_011528011.1:c.1394G>A, XR_244074.2:n.1855+716G>A, XM_011528010.2:c.1775G>A, XR_001753685.2:n.1892G>A, XR_001753686.2:n.1822+716G>A, NM_001195798.2:c.1775G>A, NM_001195799.2:c.1652G>A, NM_001195800.2:c.1271G>A, NM_001195803.2:c.1394G>A, NC_000019.10:g.11116928G>A, CM000681.2:g.11116928G>A, NC_000019.9:g.11227604G>A, CM000681.1:g.11227604G>A, NC_000019.8:g.11088604G>A, NG_009060.1:g.32548G>A, LRG_274:g.32548G>A, NM_000527.5(LDLR):c.1775G>A (p.Gly592Glu)	LDLR	hypercholesterolemia, familial	MONDO:0007750	Semidominant inheritance	Pathogenic	PS4, PP1_Strong, PM2, PP3, PP4, PS3_Moderate	PS1, PS2, PM5, PM4, PM1, PM3, BP7, BP5, BS1, BS3, BS4, PVS1, PM6, PP2, BS2, BA1, BP1, BP4, BP3, BP2	NM_000527.5(LDLR):c.1775G>A (p.Gly592Glu) variant is classified as Pathogenic for Familial Hypercholesterolemia by applying evidence codes (PS4, PP1_Strong, PM2, PS3_Moderate, PP3 and PP4) as defined by the ClinGen Familial Hypercholesterolemia Expert Panel LDLR-specific variant curation guidelines (https://doi.org/10.1101/2021.03.17.21252755). The supporting evidence is as follows: PS4 - Variant meets PM2. Variant identified in 239 index cases.PP1_strong - 130 informative meioses (1 from Robarts Research Institute; 83 from Molecular Genetics Laboratory (Centre for Cardiovascular Surgery and Transplantation); 19 from Laboratory of Genetics and Molecular Cardiology; 2 from University of British Columbia; 25 from Cardiovascular Research Group,Instituto Nacional de Saude Doutor Ricardo Jorge).PM2 - PopMax MAF = 0.0001161 (0.012%) in European non-Finnish exomes (gnomAD v2.1.1). PS3_moderate - Level 2 assay - PMID:21865347 - study on hmz patient's lymphocytes, FACS, LDLR activity value range: 39-53%.PP3 - REVEL: 0,938. PP4 - Variant meets PM2. Variant identified in 239 index cases fulfill specific clinical criteria for FH (3 cases with Simon-Broome from Color laboratory; 189 cases with MedPed criteria from Molecular Genetics Laboratory (Centre for Cardiovascular Surgery and Transplantation); 5 cases with Simon-Broome criteria from GeneDx; 15 cases with Siom-Broome criteria from Laboratory of Genetics and Molecular Cardiology; 2 cases with DLCN criteria from Cardiovascular Genetics Laboratory (PathWest Laboratory Medicine WA); 6 cases with DLCN criteria from University of British Columbia; 19 cases with Simon-Broome criteria from Cardiovascular Research Group,Instituto Nacional de Saude Doutor Ricardo Jorge).		Familial Hypercholesterolemia VCEP	https://clinicalgenome.org/docs/clingen-familial-hypercholesterolemia-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1-2/	2021-06-09	2021-06-24	False	https://erepo.genome.network/evrepo/ui/classification/CA023577/MONDO:0007750/013	cd0c4aea-7158-4181-83f0-1c4cce449e45	p.Gly592Glu	Gly	592	Glu	MGPWGWKLRWTVALLLAAAGTAVGDRCERNEFQCQDGKCISYKWVCDGSAECQDGSDESQETCLSVTCKSGDFSCGGRVNRCIPQFWRCDGQVDCDNGSDEQGCPPKTCSQDEFRCHDGKCISRQFVCDSDRDCLDGSDEASCPVLTCGPASFQCNSSTCIPQLWACDNDPDCEDGSDEWPQRCRGLYVFQGDSSPCSAFEFHCLSGECIHSSWRCDGGPDCKDKSDEENCAVATCRPDEFQCSDGNCIHGSRQCDREYDCKDMSDEVGCVNVTLCEGPNKFKCHSGECITLDKVCNMARDCRDWSDEPIKECGTNECLDNNGGCSHVCNDLKIGYECLCPDGFQLVAQRRCEDIDECQDPDTCSQLCVNLEGGYKCQCEEGFQLDPHTKACKAVGSIAYLFFTNRHEVRKMTLDRSEYTSLIPNLRNVVALDTEVASNRIYWSDLSQRMICSTQLDRAHGVSSYDTVISRDIQAPDGLAVDWIHSNIYWTDSVLGTVSVADTKGVKRKTLFRENGSKPRAIVVDPVHGFMYWTDWGTPAKIKKGGLNGVDIYSLVTENIQWPNGITLDLLSGRLYWVDSKLHSISSIDVNGGNRKTILEDEKRLAHPFSLAVFEDKVFWTDIINEAIFSANRLTGSDVNLLAENLLSPEDMVLFHNLTQPRGVNWCERTTLSNGGCQYLCLPAPQINPHSPKFTCACPDGMLLARDMRSCLTEAEAAVATQETSTVRLKVSSTAVRTQHTTTRPVPDTSRLPGATPGLTTVEIVTMSHQALGDVAGRGNEKKPSSVRALSIVLPIVLLVFLCLGVFLLWKNWRLKNINSINFDNPVYQKTTEDEVHICHNQDGYSYPSRQMVSLEDDVA	860	P01130	E	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [587, 594], 'STRAND_gain_score': array([0.1307497 , 0.17246491]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [661], 'REPEAT_gain_score': array([0.00739896]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
306	NM_000527.5(LDLR):c.1322T>C (p.Ile441Thr)	251783	CA10585400	NM_000527.5:c.1322T>C, ENST00000558518.6:c.1322T>C, ENST00000252444.9:n.1576T>C, ENST00000455727.6:c.818T>C, ENST00000535915.5:c.1199T>C, ENST00000545707.5:c.941T>C, ENST00000557933.5:c.1322T>C, ENST00000558013.5:c.1322T>C, ENST00000558518.5:c.1322T>C, ENST00000559340.1:n.43T>C, ENST00000560173.1:n.321T>C, ENST00000560467.1:n.802T>C, NM_000527.4:c.1322T>C, LRG_274t1:c.1322T>C, NM_001195798.1:c.1322T>C, NM_001195799.1:c.1199T>C, NM_001195800.1:c.818T>C, NM_001195803.1:c.941T>C, XM_011528010.1:c.1322T>C, XM_011528011.1:c.941T>C, XR_244074.2:n.1472T>C, XM_011528010.2:c.1322T>C, XR_001753685.2:n.1439T>C, XR_001753686.2:n.1439T>C, NM_001195798.2:c.1322T>C, NM_001195799.2:c.1199T>C, NM_001195800.2:c.818T>C, NM_001195803.2:c.941T>C, NC_000019.10:g.11113413T>C, CM000681.2:g.11113413T>C, NC_000019.9:g.11224089T>C, CM000681.1:g.11224089T>C, NC_000019.8:g.11085089T>C, NG_009060.1:g.29033T>C, LRG_274:g.29033T>C, NM_000527.5(LDLR):c.1322T>C (p.Ile441Thr)	LDLR	hypercholesterolemia, familial	MONDO:0007750	Semidominant inheritance	Pathogenic	PS3, PS4_Moderate, PP1_Strong, PM2, PP3, PP4	PS1, PS2, PM5, PM4, PM1, PM3, BP7, BP5, BS1, BS3, BS4, PVS1, PM6, PP2, BS2, BA1, BP1, BP4, BP3, BP2	NM_000527.5(LDLR):c.1322T>C (p.Ile441Thr) variant is classified as Pathogenic for Familial Hypercholesterolemia by applying evidence codes (PS3, PP1_Strong, PM2, PS4_Moderate, PP3 and PP4) as defined by the ClinGen Familial Hypercholesterolemia Expert Panel LDLR-specific variant curation guidelines (https://doi.org/10.1101/2021.03.17.21252755). The supporting evidence is as follows: PS3 - Level 1 assay - PMID:25741862 - CHO cells, WB+FACS+CLSM, 7% low-density lipoprotein particle receptor biosynthetic process; 5% low-density lipoprotein particle binding; 10% low-density lipoprotein particle clearance.PP1_strong - 6 informative meioses in 3 families identified by Cardiovascular Research Group,Instituto Nacional de Saude Doutor Ricardo Jorge.PM2 - No population data was found for this allele in gnomAD (gnomAD v2.1.1).PS4_moderate - Variant meets PM2. Variant identified in 9 index cases.PP3 - REVEL: 0,907. PP4 - Variant meets PM2. Variant identified in 9 index cases fulfilling specific clinical criteria for FH (6 cases with Simon-Broome from Cardiovascular Research Group,Instituto Nacional de Saude Doutor Ricardo Jorge; 3 cases with Simon-Broome criteria published in PMID: 20538126).		Familial Hypercholesterolemia VCEP	https://clinicalgenome.org/docs/clingen-familial-hypercholesterolemia-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1-2/	2021-06-09	2021-06-24	False	https://erepo.genome.network/evrepo/ui/classification/CA10585400/MONDO:0007750/013	c86aaf4e-cc4f-448f-a070-bdbdce293339	p.Ile441Thr	Ile	441	Thr	MGPWGWKLRWTVALLLAAAGTAVGDRCERNEFQCQDGKCISYKWVCDGSAECQDGSDESQETCLSVTCKSGDFSCGGRVNRCIPQFWRCDGQVDCDNGSDEQGCPPKTCSQDEFRCHDGKCISRQFVCDSDRDCLDGSDEASCPVLTCGPASFQCNSSTCIPQLWACDNDPDCEDGSDEWPQRCRGLYVFQGDSSPCSAFEFHCLSGECIHSSWRCDGGPDCKDKSDEENCAVATCRPDEFQCSDGNCIHGSRQCDREYDCKDMSDEVGCVNVTLCEGPNKFKCHSGECITLDKVCNMARDCRDWSDEPIKECGTNECLDNNGGCSHVCNDLKIGYECLCPDGFQLVAQRRCEDIDECQDPDTCSQLCVNLEGGYKCQCEEGFQLDPHTKACKAVGSIAYLFFTNRHEVRKMTLDRSEYTSLIPNLRNVVALDTEVASNRIYWSDLSQRMICSTQLDRAHGVSSYDTVISRDIQAPDGLAVDWIHSNIYWTDSVLGTVSVADTKGVKRKTLFRENGSKPRAIVVDPVHGFMYWTDWGTPAKIKKGGLNGVDIYSLVTENIQWPNGITLDLLSGRLYWVDSKLHSISSIDVNGGNRKTILEDEKRLAHPFSLAVFEDKVFWTDIINEAIFSANRLTGSDVNLLAENLLSPEDMVLFHNLTQPRGVNWCERTTLSNGGCQYLCLPAPQINPHSPKFTCACPDGMLLARDMRSCLTEAEAAVATQETSTVRLKVSSTAVRTQHTTTRPVPDTSRLPGATPGLTTVEIVTMSHQALGDVAGRGNEKKPSSVRALSIVLPIVLLVFLCLGVFLLWKNWRLKNINSINFDNPVYQKTTEDEVHICHNQDGYSYPSRQMVSLEDDVA	860	P01130	T	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [419, 450, 453], 'STRAND_gain': [609], 'STRAND_gain_score': array([0.01645148]), 'STRAND_loss_score': array([-0.12503642, -0.05235976, -0.05164701]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [399, 400, 401, 402, 403, 404, 405, 406, 409, 411, 415, 416, 417, 418], 'REPEAT_gain': [661], 'REPEAT_gain_score': array([0.00266975]), 'REPEAT_loss_score': array([-0.15903896, -0.1504758 , -0.14388198, -0.19499773, -0.1935057 ,
       -0.23525023, -0.21847916, -0.21870947, -0.21676445, -0.16944647,
       -0.16598642, -0.14596552, -0.13862985, -0.13631839]), 'ZN_FING_loss': [74], 'ZN_FING_gain': [], 'ZN_FING_loss_score': array([-0.00208384])}"
307	NM_000527.5(LDLR):c.862G>A (p.Glu288Lys)	161268	CA023783	NM_000527.5:c.862G>A, ENST00000558518.6:c.862G>A, ENST00000252444.9:n.1116G>A, ENST00000455727.6:c.358G>A, ENST00000535915.5:c.739G>A, ENST00000545707.5:c.481G>A, ENST00000557933.5:c.862G>A, ENST00000558013.5:c.862G>A, ENST00000558518.5:c.862G>A, ENST00000558528.1:n.377G>A, ENST00000560467.1:n.462G>A, NM_000527.4:c.862G>A, LRG_274t1:c.862G>A, NM_001195798.1:c.862G>A, NM_001195799.1:c.739G>A, NM_001195800.1:c.358G>A, NM_001195803.1:c.481G>A, XM_011528010.1:c.862G>A, XM_011528011.1:c.481G>A, XR_244074.2:n.1012G>A, XM_011528010.2:c.862G>A, XR_001753685.2:n.979G>A, XR_001753686.2:n.979G>A, NM_001195798.2:c.862G>A, NM_001195799.2:c.739G>A, NM_001195800.2:c.358G>A, NM_001195803.2:c.481G>A, NC_000019.10:g.11107436G>A, CM000681.2:g.11107436G>A, NC_000019.9:g.11218112G>A, CM000681.1:g.11218112G>A, NC_000019.8:g.11079112G>A, NG_009060.1:g.23056G>A, LRG_274:g.23056G>A, NM_000527.5(LDLR):c.862G>A (p.Glu288Lys)	LDLR	hypercholesterolemia, familial	MONDO:0007750	Semidominant inheritance	Pathogenic	PS4_Moderate, PP1_Strong, PS3_Supporting, PM2, PP3, PP4	PS1, PS2, PM5, PM1, PM4, PM3, BP7, BP5, BS4, BS1, BS3, PVS1, PM6, PP2, BS2, BA1, BP1, BP4, BP3, BP2	The NM_000527.5(LDLR):c.862G>A (p.Glu288Lys) variant is classified as Pathogenic for Familial Hypercholesterolemia by applying evidence codes (PP1_Strong, PM2, PS4_Moderate, PP3, PP4 and PS3_Supporting) as defined by the ClinGen Familial Hypercholesterolemia Expert Panel LDLR-specific variant curation guidelines (https://doi.org/10.1101/2021.03.17.21252755). The supporting evidence is as follows: PP1_strong - variant segregates with FH phenotype in 13 informative meiosis in at least 6 families from different labs.PM2 - PopMax MAF = 0.0001960 (0.0196%) in South Asian exomes (gnomAD v2.1.1).PS4_moderate - Variant meets PM2. Variant identified in at least 7 unrelated index cases with Simon-Broome criteria for FH from Cardiovascular Research Group, Instituto Nacional de Saude Doutor Ricardo Jorge. PP3 - REVEL = 0.85. PP4 - Variant meets PM2. Identified in 7 unrelated index cases who fulfill Simon-Broome criteria for FH from Cardiovascular Research Group,Instituto Nacional de Saude Doutor Ricardo Jorge.PS3_supporting - Level 3 assays: PMID 21990180: Htz Patient lymphocytes, FACS assays - results - normal (90%) cell surface LDLR, 50% LDL-LDLR binding and 45% LDL uptake ---- results are below 85% of wild-type activity, so PS3_supporting is Met.		Familial Hypercholesterolemia VCEP	https://clinicalgenome.org/docs/clingen-familial-hypercholesterolemia-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1-2/	2021-06-08	2021-06-24	False	https://erepo.genome.network/evrepo/ui/classification/CA023783/MONDO:0007750/013	dbff12fe-9b22-41d6-9fbd-31ef930eaeb1	p.Glu288Lys	Glu	288	Lys	MGPWGWKLRWTVALLLAAAGTAVGDRCERNEFQCQDGKCISYKWVCDGSAECQDGSDESQETCLSVTCKSGDFSCGGRVNRCIPQFWRCDGQVDCDNGSDEQGCPPKTCSQDEFRCHDGKCISRQFVCDSDRDCLDGSDEASCPVLTCGPASFQCNSSTCIPQLWACDNDPDCEDGSDEWPQRCRGLYVFQGDSSPCSAFEFHCLSGECIHSSWRCDGGPDCKDKSDEENCAVATCRPDEFQCSDGNCIHGSRQCDREYDCKDMSDEVGCVNVTLCEGPNKFKCHSGECITLDKVCNMARDCRDWSDEPIKECGTNECLDNNGGCSHVCNDLKIGYECLCPDGFQLVAQRRCEDIDECQDPDTCSQLCVNLEGGYKCQCEEGFQLDPHTKACKAVGSIAYLFFTNRHEVRKMTLDRSEYTSLIPNLRNVVALDTEVASNRIYWSDLSQRMICSTQLDRAHGVSSYDTVISRDIQAPDGLAVDWIHSNIYWTDSVLGTVSVADTKGVKRKTLFRENGSKPRAIVVDPVHGFMYWTDWGTPAKIKKGGLNGVDIYSLVTENIQWPNGITLDLLSGRLYWVDSKLHSISSIDVNGGNRKTILEDEKRLAHPFSLAVFEDKVFWTDIINEAIFSANRLTGSDVNLLAENLLSPEDMVLFHNLTQPRGVNWCERTTLSNGGCQYLCLPAPQINPHSPKFTCACPDGMLLARDMRSCLTEAEAAVATQETSTVRLKVSSTAVRTQHTTTRPVPDTSRLPGATPGLTTVEIVTMSHQALGDVAGRGNEKKPSSVRALSIVLPIVLLVFLCLGVFLLWKNWRLKNINSINFDNPVYQKTTEDEVHICHNQDGYSYPSRQMVSLEDDVA	860	P01130	K	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': [268, 302], 'ZN_FING_gain_score': array([0.00226337, 0.00505936])}
308	NM_000527.5(LDLR):c.798T>A (p.Asp266Glu)	161287	CA023765	NM_000527.5:c.798T>A, ENST00000558518.6:c.798T>A, ENST00000252444.9:n.1052T>A, ENST00000455727.6:c.314-724T>A, ENST00000535915.5:c.675T>A, ENST00000545707.5:c.417T>A, ENST00000557933.5:c.798T>A, ENST00000558013.5:c.798T>A, ENST00000558518.5:c.798T>A, ENST00000558528.1:n.313T>A, ENST00000560467.1:n.398T>A, NM_000527.4:c.798T>A, LRG_274t1:c.798T>A, NM_001195798.1:c.798T>A, NM_001195799.1:c.675T>A, NM_001195800.1:c.314-724T>A, NM_001195803.1:c.417T>A, XM_011528010.1:c.798T>A, XM_011528011.1:c.417T>A, XR_244074.2:n.948T>A, XM_011528010.2:c.798T>A, XR_001753685.2:n.915T>A, XR_001753686.2:n.915T>A, NM_001195798.2:c.798T>A, NM_001195799.2:c.675T>A, NM_001195800.2:c.314-724T>A, NM_001195803.2:c.417T>A, NC_000019.10:g.11106668T>A, CM000681.2:g.11106668T>A, NC_000019.9:g.11217344T>A, CM000681.1:g.11217344T>A, NC_000019.8:g.11078344T>A, NG_009060.1:g.22288T>A, LRG_274:g.22288T>A, NM_000527.5(LDLR):c.798T>A (p.Asp266Glu)	LDLR	hypercholesterolemia, familial	MONDO:0007750	Semidominant inheritance	Pathogenic	PS4, PM5_Strong, PP1_Strong, PM2, PP4, PS3_Moderate	PS1, PS2, PM1, PM4, PM3, BP7, BP5, BS4, BS1, BS3, PM6, PVS1, BS2, PP2, PP3, BA1, BP3, BP2, BP1, BP4	The NM_000527.5(LDLR):c.798T>A (p.Asp266Glu) variant is classified as Pathogenic for Familial Hypercholesterolemia by applying evidence codes (PS4, PP1_Strong, PM5_Strong, PM2, PS3_Moderate and PP4) as defined by the ClinGen Familial Hypercholesterolemia Expert Panel LDLR-specific variant curation guidelines (https://doi.org/10.1101/2021.03.17.21252755). The supporting evidence is as follows: PS4 - Variant meets PM2. Identified in over 10 unrelated index cases from Center of molecular biology and gene therapy with FH diagnosis.PP1_strong - variant segregates with phenotype in over 30 informative meiosis in several families from different laboratories.PM5_strong - Four more missense variants described in same codon:  --- 3 variants classified as Pathogenic, so PM5_Strong is met.PM2 - PopMax MAF = 0.00007740 (0.008%) in european non-finnish exomes (gnomAD v2.1.1).PS3_moderate - Level 2 assay: PMID 1301956: Hmz patients' fibroblasts, 125I-LDL assays - results - 15-30% LDLR activity (but all cycle was tested) ---- Overall LDLR activity is below 70% of wild-type activity, so PS3_moderate is Met.PP4 - Variant meets PM2. Identified in over 10 unrelated index cases from Center of molecular biology and gene therapy with FH diagnosis.		Familial Hypercholesterolemia VCEP	https://clinicalgenome.org/docs/clingen-familial-hypercholesterolemia-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1-2/	2021-06-07	2021-06-24	False	https://erepo.genome.network/evrepo/ui/classification/CA023765/MONDO:0007750/013	da36a90c-1718-424e-83fa-5e42e5af70fa	p.Asp266Glu	Asp	266	Glu	MGPWGWKLRWTVALLLAAAGTAVGDRCERNEFQCQDGKCISYKWVCDGSAECQDGSDESQETCLSVTCKSGDFSCGGRVNRCIPQFWRCDGQVDCDNGSDEQGCPPKTCSQDEFRCHDGKCISRQFVCDSDRDCLDGSDEASCPVLTCGPASFQCNSSTCIPQLWACDNDPDCEDGSDEWPQRCRGLYVFQGDSSPCSAFEFHCLSGECIHSSWRCDGGPDCKDKSDEENCAVATCRPDEFQCSDGNCIHGSRQCDREYDCKDMSDEVGCVNVTLCEGPNKFKCHSGECITLDKVCNMARDCRDWSDEPIKECGTNECLDNNGGCSHVCNDLKIGYECLCPDGFQLVAQRRCEDIDECQDPDTCSQLCVNLEGGYKCQCEEGFQLDPHTKACKAVGSIAYLFFTNRHEVRKMTLDRSEYTSLIPNLRNVVALDTEVASNRIYWSDLSQRMICSTQLDRAHGVSSYDTVISRDIQAPDGLAVDWIHSNIYWTDSVLGTVSVADTKGVKRKTLFRENGSKPRAIVVDPVHGFMYWTDWGTPAKIKKGGLNGVDIYSLVTENIQWPNGITLDLLSGRLYWVDSKLHSISSIDVNGGNRKTILEDEKRLAHPFSLAVFEDKVFWTDIINEAIFSANRLTGSDVNLLAENLLSPEDMVLFHNLTQPRGVNWCERTTLSNGGCQYLCLPAPQINPHSPKFTCACPDGMLLARDMRSCLTEAEAAVATQETSTVRLKVSSTAVRTQHTTTRPVPDTSRLPGATPGLTTVEIVTMSHQALGDVAGRGNEKKPSSVRALSIVLPIVLLVFLCLGVFLLWKNWRLKNINSINFDNPVYQKTTEDEVHICHNQDGYSYPSRQMVSLEDDVA	860	P01130	E	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [24], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.00453919]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [181, 228, 261, 266], 'ZN_FING_gain': [], 'ZN_FING_loss_score': array([-0.0037806 , -0.01338333, -0.01680768, -0.03299689])}
309	NM_000527.5(LDLR):c.259T>G (p.Trp87Gly)	3685	CA023683	NM_000527.5:c.259T>G, ENST00000558518.6:c.259T>G, ENST00000252444.9:n.513T>G, ENST00000455727.6:c.259T>G, ENST00000535915.5:c.190+2387T>G, ENST00000545707.5:c.259T>G, ENST00000557933.5:c.259T>G, ENST00000557958.1:n.345T>G, ENST00000558013.5:c.259T>G, ENST00000558518.5:c.259T>G, NM_000527.4:c.259T>G, LRG_274t1:c.259T>G, NM_001195798.1:c.259T>G, NM_001195799.1:c.190+2387T>G, NM_001195800.1:c.259T>G, NM_001195803.1:c.259T>G, XM_011528010.1:c.259T>G, XM_011528011.1:c.259T>G, XR_244074.2:n.409T>G, XM_011528010.2:c.259T>G, XR_001753685.2:n.376T>G, XR_001753686.2:n.376T>G, NM_001195798.2:c.259T>G, NM_001195799.2:c.190+2387T>G, NM_001195800.2:c.259T>G, NM_001195803.2:c.259T>G, NC_000019.10:g.11102732T>G, CM000681.2:g.11102732T>G, NC_000019.9:g.11213408T>G, CM000681.1:g.11213408T>G, NC_000019.8:g.11074408T>G, NG_009060.1:g.18352T>G, LRG_274:g.18352T>G, NM_000527.5(LDLR):c.259T>G (p.Trp87Gly)	LDLR	hypercholesterolemia, familial	MONDO:0007750	Semidominant inheritance	Pathogenic	PS4, PS3, PP1_Moderate, PM2, PP3, PP4	PS1, PS2, PM5, PM1, PM4, PM3, BP7, BP5, BS3, BS4, BS1, PVS1, PM6, PP2, BS2, BA1, BP1, BP4, BP3, BP2	The NM_000527.5(LDLR):c.259T>G (p.Trp87Gly) variant is classified as Pathogenic for Familial Hypercholesterolemia by applying evidence codes (PS3, PS4, PP1_Moderate, PM2, PP3 and PP4) as defined by the ClinGen Familial Hypercholesterolemia Expert Panel LDLR-specific variant curation guidelines (https://doi.org/10.1101/2021.03.17.21252755).The supporting evidence is as follows: PS3 - Level 1/2 assays: PMID 31578082: Hmz patients' lymphocytes, FACS assays and Heterologous cells (CHO), WB, FACS and CLSM assays - results - lymphocytes: normal cell surface LDLR, 40% LDL-LDLR binding, 35% uptake; CHO: normal (100%) LDLR expression, 20% LDL-LDLR binding, 35% uptake ---- binding and uptake are below 70% of wild-type, so PS3 is Met.PS4 - Variant meets PM2. Variant identified in at least 13 unrelated index cases with Dutch Lipid Clinic score equal or above 6 from different labs.PP1_moderate - variant segregates with FH phenotype in 5 informative meiosis in 2 families from different labs.PM2 - PopMax MAF = 0.00005418 (0.0054%) in european non-finnish exomes (gnomAD v2.1.1).PP3 - REVEL = 0.892. PP4 - Variant meets PM2. Identified in 13 unrelated index cases with Dutch Lipid Clinic score equal or above 6 from different labs.		Familial Hypercholesterolemia VCEP	https://clinicalgenome.org/docs/clingen-familial-hypercholesterolemia-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1-2/	2021-06-07	2021-06-24	False	https://erepo.genome.network/evrepo/ui/classification/CA023683/MONDO:0007750/013	fe3c7d4d-c876-42cf-b2ec-d228ee2c5d24	p.Trp87Gly	Trp	87	Gly	MGPWGWKLRWTVALLLAAAGTAVGDRCERNEFQCQDGKCISYKWVCDGSAECQDGSDESQETCLSVTCKSGDFSCGGRVNRCIPQFWRCDGQVDCDNGSDEQGCPPKTCSQDEFRCHDGKCISRQFVCDSDRDCLDGSDEASCPVLTCGPASFQCNSSTCIPQLWACDNDPDCEDGSDEWPQRCRGLYVFQGDSSPCSAFEFHCLSGECIHSSWRCDGGPDCKDKSDEENCAVATCRPDEFQCSDGNCIHGSRQCDREYDCKDMSDEVGCVNVTLCEGPNKFKCHSGECITLDKVCNMARDCRDWSDEPIKECGTNECLDNNGGCSHVCNDLKIGYECLCPDGFQLVAQRRCEDIDECQDPDTCSQLCVNLEGGYKCQCEEGFQLDPHTKACKAVGSIAYLFFTNRHEVRKMTLDRSEYTSLIPNLRNVVALDTEVASNRIYWSDLSQRMICSTQLDRAHGVSSYDTVISRDIQAPDGLAVDWIHSNIYWTDSVLGTVSVADTKGVKRKTLFRENGSKPRAIVVDPVHGFMYWTDWGTPAKIKKGGLNGVDIYSLVTENIQWPNGITLDLLSGRLYWVDSKLHSISSIDVNGGNRKTILEDEKRLAHPFSLAVFEDKVFWTDIINEAIFSANRLTGSDVNLLAENLLSPEDMVLFHNLTQPRGVNWCERTTLSNGGCQYLCLPAPQINPHSPKFTCACPDGMLLARDMRSCLTEAEAAVATQETSTVRLKVSSTAVRTQHTTTRPVPDTSRLPGATPGLTTVEIVTMSHQALGDVAGRGNEKKPSSVRALSIVLPIVLLVFLCLGVFLLWKNWRLKNINSINFDNPVYQKTTEDEVHICHNQDGYSYPSRQMVSLEDDVA	860	P01130	G	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [84], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.12628871]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [70, 74, 77, 97, 100, 110, 181], 'ZN_FING_gain': [], 'ZN_FING_loss_score': array([-0.04596704, -0.06444049, -0.03482139, -0.03441554, -0.00885528,
       -0.00563693, -0.00460857])}"
310	NM_000527.5(LDLR):c.58G>A (p.Gly20Arg)	161272	CA023728	NM_000527.5:c.58G>A, NC_000019.10:g.11089606G>A, CM000681.2:g.11089606G>A, NC_000019.9:g.11200282G>A, CM000681.1:g.11200282G>A, NC_000019.8:g.11061282G>A, NG_009060.1:g.5226G>A, LRG_274:g.5226G>A, ENST00000558518.6:c.58G>A, ENST00000455727.6:c.58G>A, ENST00000535915.5:c.58G>A, ENST00000545707.5:c.58G>A, ENST00000557933.5:c.58G>A, ENST00000557958.1:n.144G>A, ENST00000558013.5:c.58G>A, ENST00000558518.5:c.58G>A, ENST00000560502.5:n.144G>A, NM_000527.4:c.58G>A, LRG_274t1:c.58G>A, NM_001195798.1:c.58G>A, NM_001195799.1:c.58G>A, NM_001195800.1:c.58G>A, NM_001195803.1:c.58G>A, XM_011528010.1:c.58G>A, XM_011528011.1:c.58G>A, XR_244074.2:n.208G>A, XM_011528010.2:c.58G>A, XR_001753685.2:n.175G>A, XR_001753686.2:n.175G>A, NM_001195798.2:c.58G>A, NM_001195799.2:c.58G>A, NM_001195800.2:c.58G>A, NM_001195803.2:c.58G>A, NR_163945.1:n.54C>T, NM_000527.5(LDLR):c.58G>A (p.Gly20Arg)	LDLR	hypercholesterolemia, familial	MONDO:0007750	Semidominant inheritance	Benign	BS3, BS4, PP1_Moderate, BS2	PS3, PS1, PS4, PS2, PM5, PM1, PM4, PM3, BP7, BP5, BS1, PM2, PM6, PVS1, PP2, PP3, PP4, BA1, BP3, BP2, BP1, BP4	The NM_000527.5(LDLR):c.58G>A (p.Gly20Arg) variant is classified as Benign for Familial Hypercholesterolemia by applying evidence codes (BS2, BS3, BS4 and PP1_Moderate) as defined by the ClinGen Familial Hypercholesterolemia Expert Panel LDLR-specific variant curation guidelines (https://doi.org/10.1101/2021.03.17.21252755). The supporting evidence is as follows: BS2 - Variant identified in 5 unaffected relatives from Centre of molecular biology and gene therapy and 1 elderly heterozygous from the ABraOM database.BS3 - Level 1 assays: PMID 27175606: Heterologous cells (CHO), CLSM assays - result - normal cell surface LDLR, normal LDL-LDLR binding. ---- although not quantified, assume whole cycle is above 90% of wild-type, so BS3 is Met.BS4 - Variant does not segregate with FH phenotype in 8 informative meiosis from at least 3 families from different labs (Centre of molecular biology and gene therapy, University of British Columbia and Cardiovascular Research Group,Instituto Nacional de Saude Doutor Ricardo Jorge).PP1_moderate - variant segregates with FH phenotype in 5 informative meiosis from Centre of molecular biology and gene therapy.Variant has 3 strong evidence codes towards Benign, enough to classify as Benign, and only 1 moderate evidence code towards Pathogenic. The Benign criteria overwhelms the Pathogenic criteria, so we are confident in classifying this variant as Benign.		Familial Hypercholesterolemia VCEP	https://clinicalgenome.org/docs/clingen-familial-hypercholesterolemia-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1-2/	2021-06-07	2021-06-24	False	https://erepo.genome.network/evrepo/ui/classification/CA023728/MONDO:0007750/013	be4b2a4c-4d4f-4372-99c1-a538940653d5	p.Gly20Arg	Gly	20	Arg	MGPWGWKLRWTVALLLAAAGTAVGDRCERNEFQCQDGKCISYKWVCDGSAECQDGSDESQETCLSVTCKSGDFSCGGRVNRCIPQFWRCDGQVDCDNGSDEQGCPPKTCSQDEFRCHDGKCISRQFVCDSDRDCLDGSDEASCPVLTCGPASFQCNSSTCIPQLWACDNDPDCEDGSDEWPQRCRGLYVFQGDSSPCSAFEFHCLSGECIHSSWRCDGGPDCKDKSDEENCAVATCRPDEFQCSDGNCIHGSRQCDREYDCKDMSDEVGCVNVTLCEGPNKFKCHSGECITLDKVCNMARDCRDWSDEPIKECGTNECLDNNGGCSHVCNDLKIGYECLCPDGFQLVAQRRCEDIDECQDPDTCSQLCVNLEGGYKCQCEEGFQLDPHTKACKAVGSIAYLFFTNRHEVRKMTLDRSEYTSLIPNLRNVVALDTEVASNRIYWSDLSQRMICSTQLDRAHGVSSYDTVISRDIQAPDGLAVDWIHSNIYWTDSVLGTVSVADTKGVKRKTLFRENGSKPRAIVVDPVHGFMYWTDWGTPAKIKKGGLNGVDIYSLVTENIQWPNGITLDLLSGRLYWVDSKLHSISSIDVNGGNRKTILEDEKRLAHPFSLAVFEDKVFWTDIINEAIFSANRLTGSDVNLLAENLLSPEDMVLFHNLTQPRGVNWCERTTLSNGGCQYLCLPAPQINPHSPKFTCACPDGMLLARDMRSCLTEAEAAVATQETSTVRLKVSSTAVRTQHTTTRPVPDTSRLPGATPGLTTVEIVTMSHQALGDVAGRGNEKKPSSVRALSIVLPIVLLVFLCLGVFLLWKNWRLKNINSINFDNPVYQKTTEDEVHICHNQDGYSYPSRQMVSLEDDVA	860	P01130	R	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [400, 401], 'STRAND_gain_score': array([0.04595202, 0.04794884]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [24], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.00822049]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': [268], 'ZN_FING_gain_score': array([0.00284374])}
311	NM_000527.5(LDLR):c.1A>T (p.Met1Leu)	250968	CA10584720	NM_000527.5:c.1A>T, NC_000019.10:g.11089549A>T, CM000681.2:g.11089549A>T, NC_000019.9:g.11200225A>T, CM000681.1:g.11200225A>T, NC_000019.8:g.11061225A>T, NG_009060.1:g.5169A>T, LRG_274:g.5169A>T, ENST00000558518.6:c.1A>T, ENST00000455727.6:c.1A>T, ENST00000535915.5:c.1A>T, ENST00000545707.5:c.1A>T, ENST00000557933.5:c.1A>T, ENST00000557958.1:n.87A>T, ENST00000558013.5:c.1A>T, ENST00000558518.5:c.1A>T, ENST00000560502.5:n.87A>T, NM_000527.4:c.1A>T, LRG_274t1:c.1A>T, NM_001195798.1:c.1A>T, NM_001195799.1:c.1A>T, NM_001195800.1:c.1A>T, NM_001195803.1:c.1A>T, XM_011528010.1:c.1A>T, XM_011528011.1:c.1A>T, XR_244074.2:n.151A>T, XM_011528010.2:c.1A>T, XR_001753685.2:n.118A>T, XR_001753686.2:n.118A>T, NM_001195798.2:c.1A>T, NM_001195799.2:c.1A>T, NM_001195800.2:c.1A>T, NM_001195803.2:c.1A>T, NR_163945.1:n.111T>A, NM_000527.5(LDLR):c.1A>T (p.Met1Leu)	LDLR	hypercholesterolemia, familial	MONDO:0007750	Semidominant inheritance	Pathogenic	PS3, PS1, PVS1_Moderate, PM2, PP4, PS4_Supporting	PS2, PM5, PM1, PM4, PM3, BS1, BS3, BS4, BP5, BP7, PM6, BS2, PP1, PP2, PP3, BA1, BP3, BP2, BP1, BP4	The NM_000527.5(LDLR):c.1A>T (p.Met1Leu) variant is classified as Pathogenic for Familial Hypercholesterolemia by applying evidence codes PS1, PS3, PM2, PVS1_Moderate, PP4 and PS4_Supporting as defined by the ClinGen Familial Hypercholesterolemia Expert Panel LDLR-specific variant curation guidelines (https://doi.org/10.1016/j.gim.2021.09.012).The supporting evidence is as follows:PS1 - One more missense variant that leads to the same amino acid change: (1)NM_000527.5(LDLR):c.1A>C (p.Met1Leu) (ClinVar ID 250966) - Pathogenic by these guidelines--- variant is classified as Pathogenic, so PS1 is Met.PS3 - Level 1 (and other levels) FS: Graça et al., 2021 (PMID 34572405) Heterologous cells (CHO), FACS, luciferase and microscopy assays: FACS: 10% cell surface LDLR, 3% binding and 8% uptake; luciferase : 1% luciferase construct activity; microscopy: 5-10% LDLR expression and 5-10% LDLR activity.--- functional study in heterologous cells results in expression, binding and uptake less than 70% of wild-type, so PS3 is met.PM2 - This variant was not identified in gnomAD (gnomAD v2.1.1), so PM2 is met.PVS1_moderate - Variant is in initiation codon, so PVS1_Moderate is Met.PS4_supporting - Variant meets PM2 and was identified in:- 1 index case with DLCN score above 6 from University of British Columbia, Canada;- 1 index case with Simon-Broome criteria of possible FH from Centre de Génétique Moléculaire et Chromosomique, Unité de génétique de l'Obésité et des Dyslipidémies (APHP.Sorbonne Université, Hôpital de la Pitié-Salpêtrière), France;- 1 index case with Simon-Broome criteria of possible FH (Inclusion: LDL-C level>95th percentile for age and gender and autosomal dominant inheritance pattern of hypercholesterolemia, and a family history of hypercholesterolemia and cardiovascular disease) from PMID: 21382890 (van der Graaf et al., 2011), The Netherlands;- 1 index case with Simon-Broome criteria of at least possible FH from PMID: 17094996 (Tosi et al., 2007), UK.--- 4 cases, so PS4_Supporting is MetPP4 - Variant meets PM2 and was identified in 4 unrelated index cases who fulfill clinical FH criteria from different labs (see PS4 for details), so PP4 is Met.		Familial Hypercholesterolemia VCEP	https://clinicalgenome.org/docs/clingen-familial-hypercholesterolemia-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1-2/	2022-03-17	2022-07-12	False	https://erepo.genome.network/evrepo/ui/classification/CA10584720/MONDO:0007750/013	be29245c-5ccb-4a73-8acb-9d5bb0810775	p.Met1Leu	Met	1	Leu	MGPWGWKLRWTVALLLAAAGTAVGDRCERNEFQCQDGKCISYKWVCDGSAECQDGSDESQETCLSVTCKSGDFSCGGRVNRCIPQFWRCDGQVDCDNGSDEQGCPPKTCSQDEFRCHDGKCISRQFVCDSDRDCLDGSDEASCPVLTCGPASFQCNSSTCIPQLWACDNDPDCEDGSDEWPQRCRGLYVFQGDSSPCSAFEFHCLSGECIHSSWRCDGGPDCKDKSDEENCAVATCRPDEFQCSDGNCIHGSRQCDREYDCKDMSDEVGCVNVTLCEGPNKFKCHSGECITLDKVCNMARDCRDWSDEPIKECGTNECLDNNGGCSHVCNDLKIGYECLCPDGFQLVAQRRCEDIDECQDPDTCSQLCVNLEGGYKCQCEEGFQLDPHTKACKAVGSIAYLFFTNRHEVRKMTLDRSEYTSLIPNLRNVVALDTEVASNRIYWSDLSQRMICSTQLDRAHGVSSYDTVISRDIQAPDGLAVDWIHSNIYWTDSVLGTVSVADTKGVKRKTLFRENGSKPRAIVVDPVHGFMYWTDWGTPAKIKKGGLNGVDIYSLVTENIQWPNGITLDLLSGRLYWVDSKLHSISSIDVNGGNRKTILEDEKRLAHPFSLAVFEDKVFWTDIINEAIFSANRLTGSDVNLLAENLLSPEDMVLFHNLTQPRGVNWCERTTLSNGGCQYLCLPAPQINPHSPKFTCACPDGMLLARDMRSCLTEAEAAVATQETSTVRLKVSSTAVRTQHTTTRPVPDTSRLPGATPGLTTVEIVTMSHQALGDVAGRGNEKKPSSVRALSIVLPIVLLVFLCLGVFLLWKNWRLKNINSINFDNPVYQKTTEDEVHICHNQDGYSYPSRQMVSLEDDVA	860	P01130	L	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [710], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.01552969]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [74, 77], 'ZN_FING_gain': [], 'ZN_FING_loss_score': array([-0.00574875, -0.00481629])}
312	NM_014297.5(ETHE1):c.488G>A (p.Arg163Gln)	214322	CA320215	NM_014297.5:c.488G>A, ENST00000292147.7:c.488G>A, ENST00000292147.6:c.488G>A, ENST00000594342.5:c.*51G>A, ENST00000598330.1:c.*51G>A, ENST00000600651.5:c.488G>A, NM_014297.3:c.488G>A, XM_005258687.2:c.407G>A, XM_005258688.2:c.119G>A, XM_011526685.1:c.227-2590G>A, NM_001320867.1:c.455G>A, NM_001320868.1:c.119G>A, NM_001320869.1:c.194G>A, NM_014297.4:c.488G>A, XM_005258687.4:c.407G>A, NM_001320867.2:c.455G>A, NM_001320868.2:c.119G>A, NM_001320869.2:c.194G>A, NC_000019.10:g.43511454C>T, CM000681.2:g.43511454C>T, NC_000019.9:g.44015606C>T, CM000681.1:g.44015606C>T, NC_000019.8:g.48707446C>T, NG_008141.1:g.20791G>A, NM_014297.5(ETHE1):c.488G>A (p.Arg163Gln)	ETHE1	ethylmalonic encephalopathy	MONDO:0011229	Autosomal recessive inheritance	Pathogenic	PP3, PM3_Strong, PP4_Moderate, PM5, PS3_Supporting	BS2, BA1, BP4, BP2, PS1, PS2, PVS1, PM6, PM2, BP5, BS1	The c.488G>A (NM_014297.5) variant in ETHE1 is a missense variant predicted to cause substitution of arginine by glutamine at amino acid 163 (p.R163Q). The highest population minor allele frequency for this variant in gnomAD v2.1.1 is 0.00005 (13/251,458 alleles) in the general population, which is higher than the ClinGen ETHE1 threshold < 0.00002 for PM2, thus it does not meet this criterion. This variant was originally reported in two compound heterozygous (c.131_132delAG; p. E44fsX105) relatives who both had developmental delay, petechiae, orthostatic acrocyanosis, chronic diarrhea, and ethylmalonic aciduria which is a phenotype highly specific to ethylmalonic encephalopathy (PP4_moderate; PMID: 14732903). This variant has been detected in at least 9 patients reported in the literature with ethylmalonic encephalopathy, however, many of the cases are not scoreable according to the SVI recommendation for in trans criterion for PM3, as parental phasing was not performed or the second variant was a VUS (PMID: 18593870; PMID: 16183799, PMID: 30298498). After review of scoreable cases, it was determined by the ETHE1 VCEP that four reported cases were scorable. A single relative from family L from PMID: 14732903 was awarded 1.0 as this patient was a compound heterozygote for an upstream truncating variant (c.131_132delAG; p. E44fsX105), which was confirmed in trans by segregation analysis. Additionally, while the p.E44fsX105 has not been formally curated at this time, given that the p.E44fsX105 is a truncating variant that is predicted to undergo nonsense mediated decay, it is also a strong candidate for a pathogenic classification; the VCEP agreed that this was justification to score this case as 1.0. Patients reported in PMID: 22020834 and PMID: 27771676 were each awarded 0.25 for their respective VUS’s, which were also confirmed in trans. A homozygous patient reported in PMID: 27391121 in whom homozygosity was confirmed via trio WES including parental samples was scored 0.5. This was confirmed by Baylor Genetics who performed the testing for this study (PM3_Strong; Total score- 2.0). ETHE1 encodes persulfide dioxygenase.  Persulfide dioxygenase activity measured in recombinant human ETHE1 proteins (both wild-type and p.R163Q) expressed in E.Coli (purified to homogeneity) showed that the p.R163Q recombinant E.Coli only exhibited ~10% of wild-type catalytic activity, indicating that this variant impacts protein function (PS3_supporting; PMID: 25198162). One other missense variant [c.487C>T, p.R163W; PMID 14732903, PMID 16828325, PMID 16183799, PMID 28698729; ClinVar Variation ID: 2317], in the same codon has been classified as pathogenic for ethylmalonic encephalopathy by the ClinGen ETHE1 VCEP (PM5). The computational predictor [REVEL] gives a score of 0.928, which is above the threshold of 0.75, evidence that correlates with impact on ETHE1 function (PP3). In summary, this variant meets the criteria to be classified as pathogenic for Autosomal Recessive Ethylmalonic Encephalopathy. ACMG/AMP criteria applied, as specified by the ClinGen ETHE1 VCEP (version 1.0): PM3_strong, PP4_Moderate, PS3_supporting, PM5, PP3. Approved 7/12/2021.		Mitochondrial Diseases VCEP	https://www.clinicalgenome.org/affiliation/50027/docs/assertion-criteria	2021-07-27	2021-07-27	False	https://erepo.genome.network/evrepo/ui/classification/CA320215/MONDO:0011229/014	00257c9e-b540-4286-aa0e-f1a6c0e40cef	p.Arg163Gln	Arg	163	Gln	MAEAVLRVARRQLSQRGGSGAPILLRQMFEPVSCTFTYLLGDRESREAVLIDPVLETAPRDAQLIKELGLRLLYAVNTHCHADHITGSGLLRSLLPGCQSVISRLSGAQADLHIEDGDSIRFGRFALETRASPGHTPGCVTFVLNDHSMAFTGDALLIRGCGRTDFQQGCAKTLYHSVHEKIFTLPGDCLIYPAHDYHGFTVSTVEEERTLNPRLTLSCEEFVKIMGNLNLPKPQQIDFAVPANMRCGVQTPTA	254	O95571	Q	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [222, 225, 227], 'DOMAIN_gain_score': array([0.04039168, 0.03138262, 0.02761656]), 'REGION_loss': [], 'REGION_gain': [138], 'REGION_gain_score': array([0.0175004]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
313	NM_000212.2(ITGB3):c.719G>A (p.Arg240Gln)	13553	CA123224	NM_000212.2:c.719G>A, NC_000017.11:g.47286364G>A, CM000679.2:g.47286364G>A, NC_000017.10:g.45363730G>A, CM000679.1:g.45363730G>A, NC_000017.9:g.42718729G>A, NG_008332.2:g.37523G>A, LRG_481:g.37523G>A, ENST00000559488.7:c.719G>A, ENST00000559488.5:c.719G>A, ENST00000560629.1:n.684G>A, ENST00000571680.1:c.719G>A, LRG_481t1:c.719G>A, NM_000212.3:c.719G>A, NM_000212.2(ITGB3):c.719G>A (p.Arg240Gln)	ITGB3	Glanzmann thrombasthenia	MONDO:0100326	Autosomal recessive inheritance	Pathogenic	PS3, PM3, PP4_Moderate, PP3, PM2_Supporting	PM5	The NM_000212.2(ITGB3):c.719G>A (p.Arg240Gln) missense variant has been reported in at least four patients (PMIDs: 1371279, 29084015, 29675921, 30138987) with a phenotype highly specific to GT. This variant is absent from all population cohorts in gnomAD, ExAC, 1000 Genomes, and ESP and is predicted to have a deleterious effect (REVEL score 0.819). The functional impact has been assessed by transfection in CHO cells, showing normal αIIbβ3 surface expression with a deficiency in binding of fibrinogen and PAC-1 in response to mAb 62 stimulation (PMID: 1371279). In summary this variant meets criteria to be classified as Pathogenic for GT. GT-specific criteria applied: PS3, PM2_Supporting, PM3, PP3, and PP4_Moderate.		Platelet Disorders VCEP	https://clinicalgenome.org/docs/clingen-platelet-disorders-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-2.1/	2021-07-08	2021-08-19	False	https://erepo.genome.network/evrepo/ui/classification/CA123224/MONDO:0100326/011	896337ce-7c9e-40dc-89f7-3550c3ed61e6	p.Arg240Gln	Arg	240	Gln	MRARPRPRPLWATVLALGALAGVGVGGPNICTTRGVSSCQQCLAVSPMCAWCSDEALPLGSPRCDLKENLLKDNCAPESIEFPVSEARVLEDRPLSDKGSGDSSQVTQVSPQRIALRLRPDDSKNFSIQVRQVEDYPVDIYYLMDLSYSMKDDLWSIQNLGTKLATQMRKLTSNLRIGFGAFVDKPVSPYMYISPPEALENPCYDMKTTCLPMFGYKHVLTLTDQVTRFNEEVKKQSVSRNRDAPEGGFDAIMQATVCDEKIGWRNDASHLLVFTTDAKTHIALDGRLAGIVQPNDGQCHVGSDNHYSASTTMDYPSLGLMTEKLSQKNINLIFAVTENVVNLYQNYSELIPGTTVGVLSMDSSNVLQLIVDAYGKIRSKVELEVRDLPEELSLSFNATCLNNEVIPGLKSCMGLKIGDTVSFSIEAKVRGCPQEKEKSFTIKPVGFKDSLIVQVTFDCDCACQAQAEPNSHRCNNGNGTFECGVCRCGPGWLGSQCECSEEDYRPSQQDECSPREGQPVCSQRGECLCGQCVCHSSDFGKITGKYCECDDFSCVRYKGEMCSGHGQCSCGDCLCDSDWTGYYCNCTTRTDTCMSSNGLLCSGRGKCECGSCVCIQPGSYGDTCEKCPTCPDACTFKKECVECKKFDRGALHDENTCNRYCRDEIESVKELKDTGKDAVNCTYKNEDDCVVRFQYYEDSSGKSILYVVEEPECPKGPDILVVLLSVMGAILLIGLAALLIWKLLITIHDRKEFAKFEEERARAKWDTANNPLYKEATSTFTNITYRGT	788	P05106	Q	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [239, 276], 'BINDING_gain': [], 'BINDING_loss_score': array([-0.4125222 , -0.01144522]), 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [113, 174], 'STRAND_gain_score': array([0.01558429, 0.00365007]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
314	NM_000212.2(ITGB3):c.1544G>A (p.Arg515Gln)	13561	CA123241	NM_000212.2:c.1544G>A, NC_000017.11:g.47292422G>A, CM000679.2:g.47292422G>A, NC_000017.10:g.45369788G>A, CM000679.1:g.45369788G>A, NC_000017.9:g.42724787G>A, NG_008332.2:g.43581G>A, LRG_481:g.43581G>A, ENST00000559488.7:c.1544G>A, ENST00000559488.5:c.1544G>A, ENST00000560629.1:n.1509G>A, LRG_481t1:c.1544G>A, NM_000212.3:c.1544G>A, NM_000212.2(ITGB3):c.1544G>A (p.Arg515Gln)	ITGB3	Glanzmann's thrombasthenia	MONDO:0010119	Autosomal recessive inheritance	Benign	BA1, BP4	BS2	The NM_000212.3(ITGB3):c.1544G>A (p.Arg515Gln) missense variant occurs at an allele frequency of 0.02211 in the gnomAD East Asian population and is predicted, by REVEL score of 0.183, to have no impact on the gene or gene product. This variant has been reported in the literature multiple times (including PMIDs:  7694683 and 8457479) as the alloantigenic site HPA-6 (formerly known as Ca/Tu). In summary, the variant is classified as benign for GT. GT-specific criteria applied: BA1 and BP4.		Platelet Disorders VCEP	https://clinicalgenome.org/docs/clingen-platelet-disorders-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-2.1/	2021-05-07	2021-08-20	False	https://erepo.genome.network/evrepo/ui/classification/CA123241/MONDO:0010119/011	f8ea8df0-2867-4351-8d44-52a3d6cf1b73	p.Arg515Gln	Arg	515	Gln	MRARPRPRPLWATVLALGALAGVGVGGPNICTTRGVSSCQQCLAVSPMCAWCSDEALPLGSPRCDLKENLLKDNCAPESIEFPVSEARVLEDRPLSDKGSGDSSQVTQVSPQRIALRLRPDDSKNFSIQVRQVEDYPVDIYYLMDLSYSMKDDLWSIQNLGTKLATQMRKLTSNLRIGFGAFVDKPVSPYMYISPPEALENPCYDMKTTCLPMFGYKHVLTLTDQVTRFNEEVKKQSVSRNRDAPEGGFDAIMQATVCDEKIGWRNDASHLLVFTTDAKTHIALDGRLAGIVQPNDGQCHVGSDNHYSASTTMDYPSLGLMTEKLSQKNINLIFAVTENVVNLYQNYSELIPGTTVGVLSMDSSNVLQLIVDAYGKIRSKVELEVRDLPEELSLSFNATCLNNEVIPGLKSCMGLKIGDTVSFSIEAKVRGCPQEKEKSFTIKPVGFKDSLIVQVTFDCDCACQAQAEPNSHRCNNGNGTFECGVCRCGPGWLGSQCECSEEDYRPSQQDECSPREGQPVCSQRGECLCGQCVCHSSDFGKITGKYCECDDFSCVRYKGEMCSGHGQCSCGDCLCDSDWTGYYCNCTTRTDTCMSSNGLLCSGRGKCECGSCVCIQPGSYGDTCEKCPTCPDACTFKKECVECKKFDRGALHDENTCNRYCRDEIESVKELKDTGKDAVNCTYKNEDDCVVRFQYYEDSSGKSILYVVEEPECPKGPDILVVLLSVMGAILLIGLAALLIWKLLITIHDRKEFAKFEEERARAKWDTANNPLYKEATSTFTNITYRGT	788	P05106	Q	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [642], 'REPEAT_gain_score': array([0.00471568]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
315	NM_000419.4(ITGA2B):c.1878G>C (p.Gln626His)	2903	CA115852	NM_000419.4:c.1878G>C, ENST00000262407.6:c.1878G>C, ENST00000648408.1:n.1309G>C, ENST00000262407.5:c.1878G>C, ENST00000592462.5:n.673G>C, NM_000419.3:c.1878G>C, LRG_479t1:c.1878G>C, XM_011524749.1:c.1878G>C, XM_011524750.1:c.1878G>C, NM_000419.5:c.1878G>C, NC_000017.11:g.44379689C>G, CM000679.2:g.44379689C>G, NC_000017.10:g.42457057C>G, CM000679.1:g.42457057C>G, NC_000017.9:g.39812583C>G, NG_008331.1:g.14817G>C, LRG_479:g.14817G>C, NM_000419.4(ITGA2B):c.1878G>C (p.Gln626His)	ITGA2B	Glanzmann's thrombasthenia	MONDO:0010119	Autosomal recessive inheritance	Pathogenic	PP4_Strong, PM3, PM4, PP3, PP1, PM2_Supporting	PS3	The c.1878G>C; p.Gln626His splicing variant has been reported in at least 5 GT probands (PMIDs: 20020534, 22513797, 25728920, 21113249, 29474205) and co-segregated in one additional affected family member (PMID: 22513797). It is absent from ExAC and gnomAD. Flow cytometric studies of the mutant protein expressed in COS-7 cells showed that the mutation did not prevent expression of the GPIIb/IIIa complex on the cell surface (PMID: 20020534). However, the mutation was found to result in a splice site error, skipping of exon 18, which could explain the absence of mRNA in the patients (PMID: 20020534). Splicing predictors, HSF and MaxEntScan, agree that there is alteration to the WT donor site, most likely affecting splicing. In summary, this variant meets criteria to be classified as pathogenic for GT. GT-specific criteria applied: PM2_Supporting, PM3, PM4, PP3, PP4_Strong, and PP1.		Platelet Disorders VCEP	https://clinicalgenome.org/docs/clingen-platelet-disorders-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-2.1/	2020-09-04	2021-08-20	False	https://erepo.genome.network/evrepo/ui/classification/CA115852/MONDO:0010119/011	57f0837e-2d71-4368-b20e-a9445687d83d	p.Gln626His	Gln	626	His	MARALCPLQALWLLEWVLLLLGPCAAPPAWALNLDPVQLTFYAGPNGSQFGFSLDFHKDSHGRVAIVVGAPRTLGPSQEETGGVFLCPWRAEGGQCPSLLFDLRDETRNVGSQTLQTFKARQGLGASVVSWSDVIVACAPWQHWNVLEKTEEAEKTPVGSCFLAQPESGRRAEYSPCRGNTLSRIYVENDFSWDKRYCEAGFSSVVTQAGELVLGAPGGYYFLGLLAQAPVADIFSSYRPGILLWHVSSQSLSFDSSNPEYFDGYWGYSVAVGEFDGDLNTTEYVVGAPTWSWTLGAVEILDSYYQRLHRLRGEQMASYFGHSVAVTDVNGDGRHDLLVGAPLYMESRADRKLAEVGRVYLFLQPRGPHALGAPSLLLTGTQLYGRFGSAIAPLGDLDRDGYNDIAVAAPYGGPSGRGQVLVFLGQSEGLRSRPSQVLDSPFPTGSAFGFSLRGAVDIDDNGYPDLIVGAYGANQVAVYRAQPVVKASVQLLVQDSLNPAVKSCVLPQTKTPVSCFNIQMCVGATGHNIPQKLSLNAELQLDRQKPRQGRRVLLLGSQQAGTTLNLDLGGKHSPICHTTMAFLRDEADFRDKLSPIVLSLNVSLPPTEAGMAPAVVLHGDTHVQEQTRIVLDCGEDDVCVPQLQLTASVTGSPLLVGADNVLELQMDAANEGEGAYEAELAVHLPQGAHYMRALSNVEGFERLICNQKKENETRVVLCELGNPMKKNAQIGIAMLVSVGNLEEAGESVSFQLQIRSKNSQNPNSKIVLLDVPVRAEAQVELRGNSFPASLVVAAEEGEREQNSLDSWGPKVEHTYELHNNGPGTVNGLHLSIHLPGQSQPSDLLYILDIQPQGGLQCFPQPPVNPLKVDWGLPIPSPSPIHPAHHKRDRRQIFLPEPEQPSRLQDPVLVSCDSAPCTVVQCDLQEMARGQRAMVTVLAFLWLPSLYQRPLDQFVLQSHAWFNVSSLPYAVPPLSLPRGEAQVWTQLLRALEERAIPIWWVLVGVLGGLLLLTILVLAMWKVGFFKRNRPPLEEDDEEGE	1039	P08514	H	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [619, 910], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.03053939, -0.00224316]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [893], 'COMPBIAS_gain': [], 'COMPBIAS_loss_score': array([-0.00732899]), 'DOMAIN_loss': [874], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.00178778]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
316	NM_000212.3(ITGB3):c.197T>G (p.Leu66Arg)	695335	CA8622895	NM_000212.3:c.197T>G, NC_000017.11:g.47283385T>G, CM000679.2:g.47283385T>G, NC_000017.10:g.45360751T>G, CM000679.1:g.45360751T>G, NC_000017.9:g.42715750T>G, NG_008332.2:g.34544T>G, LRG_481:g.34544T>G, ENST00000559488.7:c.197T>G, ENST00000559488.5:c.197T>G, ENST00000560629.1:c.162T>G, ENST00000571680.1:c.197T>G, NM_000212.2:c.197T>G, LRG_481t1:c.197T>G, NM_000212.3(ITGB3):c.197T>G (p.Leu66Arg)	ITGB3	Glanzmann thrombasthenia	MONDO:0010119	Autosomal recessive inheritance	Benign	BA1	BP4, BS2, PP3, PP4	The NM_000212.3(ITGB3):c.197T>G (p.Leu66Arg) missense variant was observed by Illumina as part of a predisposition screen in an ostensibly healthy population and has been reported in the literature in a blood donor cohort (PMID: 32110192) but has not been reported in a GT patient. There is not consensus among computational evidence as to whether there is an effect on the gene or gene product. The variant occurs at a frequency in gnomAD v4.0.0 of 0.002756 (3252/1180038 alleles) in the European (non-Finnish) population, which is higher than the ClinGen PD VCEP BA1 threshold (>0.0024), and therefore meets this criterion (BA1). In summary this variant meets criteria for classification as Benign for Glanzmann thrombasthenia. GT-specific criteria applied: BA1.		Platelet Disorders VCEP	https://clinicalgenome.org/docs/clingen-platelet-disorders-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-2.1/	2023-12-19	2023-12-19	False	https://erepo.genome.network/evrepo/ui/classification/CA8622895/MONDO:0010119/011	d9b94a86-212e-420f-98f5-7157dba80330	p.Leu66Arg	Leu	66	Arg	MRARPRPRPLWATVLALGALAGVGVGGPNICTTRGVSSCQQCLAVSPMCAWCSDEALPLGSPRCDLKENLLKDNCAPESIEFPVSEARVLEDRPLSDKGSGDSSQVTQVSPQRIALRLRPDDSKNFSIQVRQVEDYPVDIYYLMDLSYSMKDDLWSIQNLGTKLATQMRKLTSNLRIGFGAFVDKPVSPYMYISPPEALENPCYDMKTTCLPMFGYKHVLTLTDQVTRFNEEVKKQSVSRNRDAPEGGFDAIMQATVCDEKIGWRNDASHLLVFTTDAKTHIALDGRLAGIVQPNDGQCHVGSDNHYSASTTMDYPSLGLMTEKLSQKNINLIFAVTENVVNLYQNYSELIPGTTVGVLSMDSSNVLQLIVDAYGKIRSKVELEVRDLPEELSLSFNATCLNNEVIPGLKSCMGLKIGDTVSFSIEAKVRGCPQEKEKSFTIKPVGFKDSLIVQVTFDCDCACQAQAEPNSHRCNNGNGTFECGVCRCGPGWLGSQCECSEEDYRPSQQDECSPREGQPVCSQRGECLCGQCVCHSSDFGKITGKYCECDDFSCVRYKGEMCSGHGQCSCGDCLCDSDWTGYYCNCTTRTDTCMSSNGLLCSGRGKCECGSCVCIQPGSYGDTCEKCPTCPDACTFKKECVECKKFDRGALHDENTCNRYCRDEIESVKELKDTGKDAVNCTYKNEDDCVVRFQYYEDSSGKSILYVVEEPECPKGPDILVVLLSVMGAILLIGLAALLIWKLLITIHDRKEFAKFEEERARAKWDTANNPLYKEATSTFTNITYRGT	788	P05106	R	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [77], 'DOMAIN_gain': [76], 'DOMAIN_gain_score': array([0.01105636]), 'DOMAIN_loss_score': array([-0.01891696]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
317	NM_000419.5(ITGA2B):c.1063G>A (p.Glu355Lys)	2899	CA115844	NM_000419.5:c.1063G>A, NC_000017.11:g.44383640C>T, CM000679.2:g.44383640C>T, NC_000017.10:g.42461008C>T, CM000679.1:g.42461008C>T, NC_000017.9:g.39816534C>T, NG_008331.1:g.10866G>A, LRG_479:g.10866G>A, ENST00000262407.6:c.1063G>A, ENST00000648408.1:n.494G>A, ENST00000262407.5:c.1063G>A, ENST00000592226.5:n.303G>A, NM_000419.3:c.1063G>A, LRG_479t1:c.1063G>A, XM_011524749.1:c.1063G>A, XM_011524750.1:c.1063G>A, NM_000419.4:c.1063G>A, NM_000419.5(ITGA2B):c.1063G>A (p.Glu355Lys)	ITGA2B	Glanzmann's thrombasthenia	MONDO:0010119	Autosomal recessive inheritance	Pathogenic	PS3, PP4_Moderate, PM3, PP3, PM2_Supporting		The NM_000419.5(ITGA2B):c.1063G>A (p.Glu355Lys) missense variant has been reported in several patients (PMIDs: 11122161, 9722314, 9215749, 22250950, 9734640) with a phenotype highly specific to GT. It is occurs at a very low allele frequency of  0.00001978 (2/101,102 alleles) in the non-Finnish European gnomAD population. The variant is predicted to have a deleterious effect (REVEL score 0.793). The functional impact has been assessed by transfection in CHO cells, showing lack of αIIbβ3 surface expression with the Glu355Lys mutant (PMIDs: 11122161, 12362239). In summary this variant meets criteria to be classified as Pathogenic for GT. GT-specific criteria applied: PS3, PM2_Supporting, PM3, PP3, and PP4_Moderate.		Platelet Disorders VCEP	https://clinicalgenome.org/docs/clingen-platelet-disorders-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-2.1/	2021-02-10	2021-08-20	False	https://erepo.genome.network/evrepo/ui/classification/CA115844/MONDO:0010119/011	4fb9bbea-ef5f-4224-a74d-fbf5b546f159	p.Glu355Lys	Glu	355	Lys	MARALCPLQALWLLEWVLLLLGPCAAPPAWALNLDPVQLTFYAGPNGSQFGFSLDFHKDSHGRVAIVVGAPRTLGPSQEETGGVFLCPWRAEGGQCPSLLFDLRDETRNVGSQTLQTFKARQGLGASVVSWSDVIVACAPWQHWNVLEKTEEAEKTPVGSCFLAQPESGRRAEYSPCRGNTLSRIYVENDFSWDKRYCEAGFSSVVTQAGELVLGAPGGYYFLGLLAQAPVADIFSSYRPGILLWHVSSQSLSFDSSNPEYFDGYWGYSVAVGEFDGDLNTTEYVVGAPTWSWTLGAVEILDSYYQRLHRLRGEQMASYFGHSVAVTDVNGDGRHDLLVGAPLYMESRADRKLAEVGRVYLFLQPRGPHALGAPSLLLTGTQLYGRFGSAIAPLGDLDRDGYNDIAVAAPYGGPSGRGQVLVFLGQSEGLRSRPSQVLDSPFPTGSAFGFSLRGAVDIDDNGYPDLIVGAYGANQVAVYRAQPVVKASVQLLVQDSLNPAVKSCVLPQTKTPVSCFNIQMCVGATGHNIPQKLSLNAELQLDRQKPRQGRRVLLLGSQQAGTTLNLDLGGKHSPICHTTMAFLRDEADFRDKLSPIVLSLNVSLPPTEAGMAPAVVLHGDTHVQEQTRIVLDCGEDDVCVPQLQLTASVTGSPLLVGADNVLELQMDAANEGEGAYEAELAVHLPQGAHYMRALSNVEGFERLICNQKKENETRVVLCELGNPMKKNAQIGIAMLVSVGNLEEAGESVSFQLQIRSKNSQNPNSKIVLLDVPVRAEAQVELRGNSFPASLVVAAEEGEREQNSLDSWGPKVEHTYELHNNGPGTVNGLHLSIHLPGQSQPSDLLYILDIQPQGGLQCFPQPPVNPLKVDWGLPIPSPSPIHPAHHKRDRRQIFLPEPEQPSRLQDPVLVSCDSAPCTVVQCDLQEMARGQRAMVTVLAFLWLPSLYQRPLDQFVLQSHAWFNVSSLPYAVPPLSLPRGEAQVWTQLLRALEERAIPIWWVLVGVLGGLLLLTILVLAMWKVGFFKRNRPPLEEDDEEGE	1039	P08514	K	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [356], 'STRAND_gain_score': array([0.02695239]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [893], 'COMPBIAS_gain': [], 'COMPBIAS_loss_score': array([-0.00310463]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [126], 'REPEAT_gain_score': array([0.0064224]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
318	NM_000540.2(RYR1):c.14627A>G (p.Lys4876Arg)	133081	CA024200	NM_000540.2:c.14627A>G, NC_000019.10:g.38580485A>G, CM000681.2:g.38580485A>G, NC_000019.9:g.39071125A>G, CM000681.1:g.39071125A>G, NC_000019.8:g.43762965A>G, NG_008866.1:g.151786A>G, LRG_766:g.151786A>G, ENST00000593677.2:c.1563A>G, ENST00000688602.1:c.2960A>G, ENST00000689936.1:c.2932A>G, ENST00000359596.8:c.14627A>G, ENST00000355481.8:c.14612A>G, ENST00000359596.7:c.14627A>G, ENST00000360985.7:c.14609A>G, LRG_766t1:c.14627A>G, NM_001042723.1:c.14612A>G, XM_006723317.1:c.14609A>G, XM_006723319.1:c.14594A>G, XM_011527204.1:c.14624A>G, XM_011527205.1:c.14540A>G, XM_006723317.2:c.14609A>G, XM_006723319.2:c.14594A>G, XM_011527205.2:c.14540A>G, NM_000540.3:c.14627A>G, NM_001042723.2:c.14612A>G, NM_000540.3(RYR1):c.14627A>G (p.Lys4876Arg), NM_000540.2(RYR1):c.14627A>G (p.Lys4876Arg)	RYR1	malignant hyperthermia of anesthesia	MONDO:0018493	Autosomal dominant inheritance	Pathogenic	PS4_Moderate, PM1_Supporting, PS3_Moderate, PP1_Strong, PP3_Moderate		This pathogenicity assessment is relevant only for malignant hyperthermia susceptibility (MHS) inherited in an autosomal dominant pattern. Variants in RYR1 can also cause other myopathies inherited in an autosomal dominant pattern or in an autosomal recessive pattern. Some of these disorders may predispose individuals to malignant hyperthermia. RYR1 variants may also contribute to a malignant hyperthermia reaction in combination with other genetic and non-genetic factors and the clinician needs to consider such factors in making management decisions.This sequence variant predicts a substitution of lysine with arginine at codon 4876 of the RYR1 protein, p.(Lys4876Arg). This variant was not present in a large population database (gnomAD) at the time this variant was interpreted. This variant has been reported in four unrelated individuals who have a personal or family history of a malignant hyperthermia reaction, all of these individuals had a positive in vitro contracture test (IVCT) or caffeine halothane contracture test (CHCT) result (if the proband was unavailable for testing, a positive diagnostic test result in a mutation-positive relative was counted), PS4_Moderate (PMID:15731587, PMID:16163667, PMID:19191329, PMID:24433488). This variant segregates with MHS in seven individuals, PP1_Strong (PMID:27854207, Noda et al. 2023). Functional studies in HEK293 cells show an increased sensitivity to RYR1 agonists, PS3_Moderate (Noda et al. 2023). This variant resides in a region of RYR1 considered to be a hotspot for pathogenic variants that contribute to MHS, PM1_Supporting (PMID: 21118704). A REVEL score >0.85 (0.912) supports a pathogenic status for this variant, PP3_Moderate. This variant has been classified as Pathogenic. Criteria implemented: PS3_Moderate, PS4_Moderate, PM1_Supporting, PP1_Strong, PP3_Moderate.		Malignant Hyperthermia Susceptibility VCEP	https://clinicalgenome.org/docs/clingen-malignant-hyperthermia-susceptibility-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-for/	2023-12-15	2023-12-15	False	https://erepo.genome.network/evrepo/ui/classification/CA024200/MONDO:0018493/012	c0331ac2-972c-4b78-ad2a-8ceb6915a9db	p.Lys4876Arg	Lys	4876	Arg	MGDAEGEDEVQFLRTDDEVVLQCSATVLKEQLKLCLAAEGFGNRLCFLEPTSNAQNVPPDLAICCFVLEQSLSVRALQEMLANTVEAGVESSQGGGHRTLLYGHAILLRHAHSRMYLSCLTTSRSMTDKLAFDVGLQEDATGEACWWTMHPASKQRSEGEKVRVGDDIILVSVSSERYLHLSTASGELQVDASFMQTLWNMNPICSRCEEGFVTGGHVLRLFHGHMDECLTISPADSDDQRRLVYYEGGAVCTHARSLWRLEPLRISWSGSHLRWGQPLRVRHVTTGQYLALTEDQGLVVVDASKAHTKATSFCFRISKEKLDVAPKRDVEGMGPPEIKYGESLCFVQHVASGLWLTYAAPDPKALRLGVLKKKAMLHQEGHMDDALSLTRCQQEESQAARMIHSTNGLYNQFIKSLDSFSGKPRGSGPPAGTALPIEGVILSLQDLIIYFEPPSEDLQHEEKQSKLRSLRNRQSLFQEEGMLSMVLNCIDRLNVYTTAAHFAEFAGEEAAESWKEIVNLLYELLASLIRGNRSNCALFSTNLDWLVSKLDRLEASSGILEVLYCVLIESPEVLNIIQENHIKSIISLLDKHGRNHKVLDVLCSLCVCNGVAVRSNQDLITENLLPGRELLLQTNLINYVTSIRPNIFVGRAEGTTQYSKWYFEVMVDEVTPFLTAQATHLRVGWALTEGYTPYPGAGEGWGGNGVGDDLYSYGFDGLHLWTGHVARPVTSPGQHLLAPEDVISCCLDLSVPSISFRINGCPVQGVFESFNLDGLFFPVVSFSAGVKVRFLLGGRHGEFKFLPPPGYAPCHEAVLPRERLHLEPIKEYRREGPRGPHLVGPSRCLSHTDFVPCPVDTVQIVLPPHLERIREKLAENIHELWALTRIEQGWTYGPVRDDNKRLHPCLVDFHSLPEPERNYNLQMSGETLKTLLALGCHVGMADEKAEDNLKKTKLPKTYMMSNGYKPAPLDLSHVRLTPAQTTLVDRLAENGHNVWARDRVGQGWSYSAVQDIPARRNPRLVPYRLLDEATKRSNRDSLCQAVRTLLGYGYNIEPPDQEPSQVENQSRCDRVRIFRAEKSYTVQSGRWYFEFEAVTTGEMRVGWARPELRPDVELGADELAYVFNGHRGQRWHLGSEPFGRPWQPGDVVGCMIDLTENTIIFTLNGEVLMSDSGSETAFREIEIGDGFLPVCSLGPGQVGHLNLGQDVSSLRFFAICGLQEGFEPFAINMQRPVTTWFSKGLPQFEPVPLEHPHYEVSRVDGTVDTPPCLRLTHRTWGSQNSLVEMLFLRLSLPVQFHQHFRCTAGATPLAPPGLQPPAEDEARAAEPDPDYENLRRSAGGWSEAENGKEGTAKEGAPGGTPQAGGEAQPARAENEKDATTEKNKKRGFLFKAKKVAMMTQPPATPTLPRLPHDVVPADNRDDPEIILNTTTYYYSVRVFAGQEPSCVWAGWVTPDYHQHDMSFDLSKVRVVTVTMGDEQGNVHSSLKCSNCYMVWGGDFVSPGQQGRISHTDLVIGCLVDLATGLMTFTANGKESNTFFQVEPNTKLFPAVFVLPTHQNVIQFELGKQKNIMPLSAAMFQSERKNPAPQCPPRLEMQMLMPVSWSRMPNHFLQVETRRAGERLGWAVQCQEPLTMMALHIPEENRCMDILELSERLDLQRFHSHTLRLYRAVCALGNNRVAHALCSHVDQAQLLHALEDAHLPGPLRAGYYDLLISIHLESACRSRRSMLSEYIVPLTPETRAITLFPPGRSTENGHPRHGLPGVGVTTSLRPPHHFSPPCFVAALPAAGAAEAPARLSPAIPLEALRDKALRMLGEAVRDGGQHARDPVGGSVEFQFVPVLKLVSTLLVMGIFGDEDVKQILKMIEPEVFTEEEEEEDEEEEGEEEDEEEKEEDEEETAQEKEDEEKEEEEAAEGEKEEGLEEGLLQMKLPESVKLQMCHLLEYFCDQELQHRVESLAAFAERYVDKLQANQRSRYGLLIKAFSMTAAETARRTREFRSPPQEQINMLLQFKDGTDEEDCPLPEEIRQDLLDFHQDLLAHCGIQLDGEEEEPEEETTLGSRLMSLLEKVRLVKKKEEKPEEERSAEESKPRSLQELVSHMVVRWAQEDFVQSPELVRAMFSLLHRQYDGLGELLRALPRAYTISPSSVEDTMSLLECLGQIRSLLIVQMGPQEENLMIQSIGNIMNNKVFYQHPNLMRALGMHETVMEVMVNVLGGGESKEIRFPKMVTSCCRFLCYFCRISRQNQRSMFDHLSYLLENSGIGLGMQGSTPLDVAAASVIDNNELALALQEQDLEKVVSYLAGCGLQSCPMLVAKGYPDIGWNPCGGERYLDFLRFAVFVNGESVEENANVVVRLLIRKPECFGPALRGEGGSGLLAAIEEAIRISEDPARDGPGIRRDRRREHFGEEPPEENRVHLGHAIMSFYAALIDLLGRCAPEMHLIQAGKGEALRIRAILRSLVPLEDLVGIISLPLQIPTLGKDGALVQPKMSASFVPDHKASMVLFLDRVYGIENQDFLLHVLDVGFLPDMRAAASLDTATFSTTEMALALNRYLCLAVLPLITKCAPLFAGTEHRAIMVDSMLHTVYRLSRGRSLTKAQRDVIEDCLMSLCRYIRPSMLQHLLRRLVFDVPILNEFAKMPLKLLTNHYERCWKYYCLPTGWANFGVTSEEELHLTRKLFWGIFDSLAHKKYDPELYRMAMPCLCAIAGALPPDYVDASYSSKAEKKATVDAEGNFDPRPVETLNVIIPEKLDSFINKFAEYTHEKWAFDKIQNNWSYGENIDEELKTHPMLRPYKTFSEKDKEIYRWPIKESLKAMIAWEWTIEKAREGEEEKTEKKKTRKISQSAQTYDPREGYNPQPPDLSAVTLSRELQAMAEQLAENYHNTWGRKKKQELEAKGGGTHPLLVPYDTLTAKEKARDREKAQELLKFLQMNGYAVTRGLKDMELDSSSIEKRFAFGFLQQLLRWMDISQEFIAHLEAVVSSGRVEKSPHEQEIKFFAKILLPLINQYFTNHCLYFLSTPAKVLGSGGHASNKEKEMITSLFCKLAALVRHRVSLFGTDAPAVVNCLHILARSLDARTVMKSGPEIVKAGLRSFFESASEDIEKMVENLRLGKVSQARTQVKGVGQNLTYTTVALLPVLTTLFQHIAQHQFGDDVILDDVQVSCYRTLCSIYSLGTTKNTYVEKLRPALGECLARLAAAMPVAFLEPQLNEYNACSVYTTKSPRERAILGLPNSVEEMCPDIPVLERLMADIGGLAESGARYTEMPHVIEITLPMLCSYLPRWWERGPEAPPSALPAGAPPPCTAVTSDHLNSLLGNILRIIVNNLGIDEASWMKRLAVFAQPIVSRARPELLQSHFIPTIGRLRKRAGKVVSEEEQLRLEAKAEAQEGELLVRDEFSVLCRDLYALYPLLIRYVDNNRAQWLTEPNPSAEELFRMVGEIFIYWSKSHNFKREEQNFVVQNEINNMSFLTADNKSKMAKAGDIQSGGSDQERTKKKRRGDRYSVQTSLIVATLKKMLPIGLNMCAPTDQDLITLAKTRYALKDTDEEVREFLHNNLHLQGKVEGSPSLRWQMALYRGVPGREEDADDPEKIVRRVQEVSAVLYYLDQTEHPYKSKKAVWHKLLSKQRRRAVVACFRMTPLYNLPTHRACNMFLESYKAAWILTEDHSFEDRMIDDLSKAGEQEEEEEEVEEKKPDPLHQLVLHFSRTALTEKSKLDEDYLYMAYADIMAKSCHLEEGGENGEAEEEVEVSFEEKQMEKQRLLYQQARLHTRGAAEMVLQMISACKGETGAMVSSTLKLGISILNGGNAEVQQKMLDYLKDKKEVGFFQSIQALMQTCSVLDLNAFERQNKAEGLGMVNEDGTVINRQNGEKVMADDEFTQDLFRFLQLLCEGHNNDFQNYLRTQTGNTTTINIIICTVDYLLRLQESISDFYWYYSGKDVIEEQGKRNFSKAMSVAKQVFNSLTEYIQGPCTGNQQSLAHSRLWDAVVGFLHVFAHMMMKLAQDSSQIELLKELLDLQKDMVVMLLSLLEGNVVNGMIARQMVDMLVESSSNVEMILKFFDMFLKLKDIVGSEAFQDYVTDPRGLISKKDFQKAMDSQKQFSGPEIQFLLSCSEADENEMINCEEFANRFQEPARDIGFNVAVLLTNLSEHVPHDPRLHNFLELAESILEYFRPYLGRIEIMGASRRIERIYFEISETNRAQWEMPQVKESKRQFIFDVVNEGGEAEKMELFVSFCEDTIFEMQIAAQISEPEGEPETDEDEGAGAAEAGAEGAEEGAAGLEGTAATAAAGATARVVAAAGRALRGLSYRSLRRRVRRLRRLTAREAATAVAALLWAAVTRAGAAGAGAAAGALGLLWGSLFGGGLVEGAKKVTVTELLAGMPDPTSDEVHGEQPAGPGGDADGEGASEGAGDAAEGAGDEEEAVHEAGPGGADGAVAVTDGGPFRPEGAGGLGDMGDTTPAEPPTPEGSPILKRKLGVDGVEEELPPEPEPEPEPELEPEKADAENGEKEEVPEPTPEPPKKQAPPSPPPKKEEAGGEFWGELEVQRVKFLNYLSRNFYTLRFLALFLAFAINFILLFYKVSDSPPGEDDMEGSAAGDVSGAGSGGSSGWGLGAGEEAEGDEDENMVYYFLEESTGYMEPALRCLSLLHTLVAFLCIIGYNCLKVPLVIFKREKELARKLEFDGLYITEQPEDDDVKGQWDRLVLNTPSFPSNYWDKFVKRKVLDKHGDIYGRERIAELLGMDLATLEITAHNERKPNPPPGLLTWLMSIDVKYQIWKFGVIFTDNSFLYLGWYMVMSLLGHYNNFFFAAHLLDIAMGVKTLRTILSSVTHNGKQLVMTVGLLAVVVYLYTVVAFNFFRKFYNKSEDEDEPDMKCDDMMTCYLFHMYVGVRAGGGIGDEIEDPAGDEYELYRVVFDITFFFFVIVILLAIIQGLIIDAFGELRDQQEQVKEDMETKCFICGIGSDYFDTTPHGFETHTLEEHNLANYMFFLMYLINKDETEHTGQESYVWKMYQERCWDFFPAGDCFRKQYEDQLS	5038	P21817	R	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
319	NM_000152.5(GAA):c.784G>A (p.Glu262Lys)	188806	CA273984	NM_000152.5:c.784G>A, ENST00000302262.8:c.784G>A, ENST00000302262.7:c.784G>A, ENST00000390015.7:c.784G>A, ENST00000570803.5:c.784G>A, NM_000152.3:c.784G>A, LRG_673t1:c.784G>A, NM_001079803.1:c.784G>A, NM_001079804.1:c.784G>A, XM_005257193.1:c.784G>A, XM_005257194.3:c.784G>A, NM_000152.4:c.784G>A, NM_001079803.2:c.784G>A, NM_001079804.2:c.784G>A, XM_005257193.2:c.784G>A, XM_005257194.4:c.784G>A, NM_001079803.3:c.784G>A, NM_001079804.3:c.784G>A, NC_000017.11:g.80107648G>A, CM000679.2:g.80107648G>A, NC_000017.10:g.78081447G>A, CM000679.1:g.78081447G>A, NC_000017.9:g.75696042G>A, NG_009822.1:g.11093G>A, LRG_673:g.11093G>A, NM_000152.5(GAA):c.784G>A (p.Glu262Lys)	GAA	glycogen storage disease II	MONDO:0009290	Autosomal recessive inheritance	Pathogenic	PP4_Moderate, PP3, PM2_Supporting, PM3_Very Strong	PM5	This variant, NM_000152.5(GAA):c.784G>A, is predicted to result in the substitution of glutamate to lysine at amino acid 262 (p.Glu262Lys). This variant represented 6.8% of alleles in an Italian case series of 29 infants with Pompe disease (PMID: 18429042). This variant has been reported in at least 20 individuals with Pompe disease, including at least 12 individuals with documented laboratory data showing deficiency of GAA activity and/or clinical symptoms consistent with infantile onset Pompe disease (cardiomegaly and muscle weakness), and/or on treated with enzyme replacement therapy (ERT) meeting the ClinGen LSD VCEP’s specifications for PP4_Moderate  (PMID 11738358, 18285536, 19588081, 19948615, 25455803, 26497565, 27344650, 29181627, 29422078, 30023291, 31193175 31915562, 33228748)(PP4_Moderate). The variant has been reported in compound heterozygosity with a pathogenic variant in at least 8 patients, phase unconfirmed (PMID: 11738358, 18285536, 19948615, 24269976, 25455803, 29181627, 29422078, 29880332), and in at least 5 homozygous patients diagnosed with Pompe disease (PMIDs: 18429042, 26497565, 29422078, 33228748, 33325062) (PM3_Very Strong). More data is available in the literature but the maximum evidence for PM3_Very Strong has been reached. The highest population minor allele frequency in gnomAD v2.1.1 is 0.00005 in the East Asian population, which is lower than the ClinGen LSD VCEP threshold (<0.001) for PM2_Supporting, allowing this criterion to be applied (PM2_Supporting). The computational predictor REVEL gives a score of 0.888 which is above the threshold of 0.7, evidence that correlates with impact to GAA function (PP3). To our knowledge, the results of functional studies have not been reported for this variant. There is a ClinVar entry for this variant (ClinVar variation ID: 188806) with 3 submitters classifying the variant as pathogenic and two as likely pathogenic. In summary, this variant meets the criteria to be classified as pathogenic for Pompe disease. ACMG/AMP criteria met, as specified by the ClinGen LSD VCEP (Specification Version 2.0): PM3_Very Strong, PP4_Moderate, PP3, PM2_Supporting. (Classification approved: August 17, 2021)		Lysosomal Diseases VCEP	https://clinicalgenome.org/docs/clingen-lysosomal-storage-disorders-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-2/	2021-08-25	2021-09-07	False	https://erepo.genome.network/evrepo/ui/classification/CA273984/MONDO:0009290/010	b5e75561-1400-4069-9027-2a7c802ad249	p.Glu262Lys	Glu	262	Lys	MGVRHPPCSHRLLAVCALVSLATAALLGHILLHDFLLVPRELSGSSPVLEETHPAHQQGASRPGPRDAQAHPGRPRAVPTQCDVPPNSRFDCAPDKAITQEQCEARGCCYIPAKQGLQGAQMGQPWCFFPPSYPSYKLENLSSSEMGYTATLTRTTPTFFPKDILTLRLDVMMETENRLHFTIKDPANRRYEVPLETPHVHSRAPSPLYSVEFSEEPFGVIVRRQLDGRVLLNTTVAPLFFADQFLQLSTSLPSQYITGLAEHLSPLMLSTSWTRITLWNRDLAPTPGANLYGSHPFYLALEDGGSAHGVFLLNSNAMDVVLQPSPALSWRSTGGILDVYIFLGPEPKSVVQQYLDVVGYPFMPPYWGLGFHLCRWGYSSTAITRQVVENMTRAHFPLDVQWNDLDYMDSRRDFTFNKDGFRDFPAMVQELHQGGRRYMMIVDPAISSSGPAGSYRPYDEGLRRGVFITNETGQPLIGKVWPGSTAFPDFTNPTALAWWEDMVAEFHDQVPFDGMWIDMNEPSNFIRGSEDGCPNNELENPPYVPGVVGGTLQAATICASSHQFLSTHYNLHNLYGLTEAIASHRALVKARGTRPFVISRSTFAGHGRYAGHWTGDVWSSWEQLASSVPEILQFNLLGVPLVGADVCGFLGNTSEELCVRWTQLGAFYPFMRNHNSLLSLPQEPYSFSEPAQQAMRKALTLRYALLPHLYTLFHQAHVAGETVARPLFLEFPKDSSTWTVDHQLLWGEALLITPVLQAGKAEVTGYFPLGTWYDLQTVPVEALGSLPPPPAAPREPAIHSEGQWVTLPAPLDTINVHLRAGYIIPLQGPGLTTTESRQQPMALAVALTKGGEARGELFWDDGESLEVLERGAYTQVIFLARNNTIVNELVRVTSEGAGLQLQKVTVLGVATAPQQVLSNGVPVSNFTYSPDTKVLDICVSLLMGEQFLVSWC	952	P10253	K	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [375, 704], 'DNA_BIND_gain': [], 'DNA_BIND_loss_score': array([-0.00089067, -0.00051212]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [22], 'TRANSIT_gain_score': array([0.01225424]), 'STRAND_loss': [], 'STRAND_gain': [913], 'STRAND_gain_score': array([0.00328469]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
320	NM_000152.5(GAA):c.1802C>T (p.Ser601Leu)	194154	CA274982	NM_000152.5:c.1802C>T, NC_000017.11:g.80112625C>T, CM000679.2:g.80112625C>T, NC_000017.10:g.78086424C>T, CM000679.1:g.78086424C>T, NC_000017.9:g.75701019C>T, NG_009822.1:g.16070C>T, LRG_673:g.16070C>T, ENST00000302262.8:c.1802C>T, ENST00000302262.7:c.1802C>T, ENST00000390015.7:c.1802C>T, ENST00000570716.1:n.242C>T, ENST00000572080.1:n.190C>T, ENST00000572803.1:n.416C>T, NM_000152.3:c.1802C>T, LRG_673t1:c.1802C>T, NM_001079803.1:c.1802C>T, NM_001079804.1:c.1802C>T, XM_005257193.1:c.1802C>T, XM_005257194.3:c.1802C>T, NM_000152.4:c.1802C>T, NM_001079803.2:c.1802C>T, NM_001079804.2:c.1802C>T, XM_005257193.2:c.1802C>T, XM_005257194.4:c.1802C>T, NM_001079803.3:c.1802C>T, NM_001079804.3:c.1802C>T, NM_000152.5(GAA):c.1802C>T (p.Ser601Leu)	GAA	glycogen storage disease II	MONDO:0009290	Autosomal recessive inheritance	Pathogenic	PM3_Strong, PP4_Moderate, PP3, PM2_Supporting, PS3_Moderate	PM5	"The NM_000152.5:c. c.1802C>T variant in GAA is a missense variant predicted to cause substitution of serine by leucine at amino acid 601 (p.Ser601Leu). At least eight patients with this variant have been reported to have Pompe disease including three with clinical features consistent with infantile onset Pompe disease and on enzyme replacement therapy (PMID 22538254, 30023291), and one with GAA deficiency reported in the affected range in lymphocytes (PMID 22676651), as well as four patients reported to be diagnosed with the condition (PMID 28394184) (PP4_Moderate). Of note, in one patient, with features of infantile onset Pompe disease and on ERT, the variant was reported to be in cis with pseudodeficiency variants c.1726G>A and c.2065G>A (PMID 22538254). Of these patients, four were compound heterozygous for the variant and a variant that has been classified as pathogenic or likely pathogenic by the ClinGen LSD VCEP (PMID 22676651, 28394184, 30023291) One patient was homozygous for the variant (PMID 30023291) (PM3_Strong). In addition, three patients were compound heterozygous for the variant and a missense variant (PMID 22538254, 28394184). The in trans data from these patients will be used in the assessment of the second variant and is not included here in order to avoid circular logic. The highest population minor allele frequency in gnomAD is 0.00064 in the East Asian population, which is lower than the ClinGen LSD VCEP threshold (<0.001) for PM2_Supporting, meeting this criterion (PM2_Supporting). Expression of the variant in COS cells resulted in 0.5% wild type GAA activity in cells and medium, and evidence of abnormal GAA synthesis and processing, leading the variant to be described as Class B (“potentially less severe""""""""""""""""). This indicates that the variant may impact protein function (PMID: 22644586) (PS3_Moderate). The computational predictor REVEL gives a score of 0.961, which is above the threshold of 0.7, evidence that correlates with impact to GAA function (PP3). Another missense variant, c.1802C>G (p.Ser601Trp), in the same codon has been reported in patients with Pompe disease (PMID 17056254, 29422078). However, the data for p.Ser601Leu will be used in the assessment of p.Ser601Trp and therefore PM5 is not met here in order to avoid circular logic (PM5 not met). The is a ClinVar entry for this variant (Variation ID: 194154). In summary, this variant meets the criteria to be classified at pathogenic for Pompe disease. ACMG/AMP criteria met, as specified by the ClinGen Lysosomal Storage Disorders Variant Curation Expert Panel (Specification version 2.0): PM3_Strong; PS3_Moderate, PP4_Moderate, PM2_Supporting, PP3.(Classification approved on August 17, 2021)"		Lysosomal Diseases VCEP	https://clinicalgenome.org/docs/clingen-lysosomal-storage-disorders-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-2/	2021-09-07	2021-09-07	False	https://erepo.genome.network/evrepo/ui/classification/CA274982/MONDO:0009290/010	8b322e84-d5bb-4038-bce4-875136c7e6cd	p.Ser601Leu	Ser	601	Leu	MGVRHPPCSHRLLAVCALVSLATAALLGHILLHDFLLVPRELSGSSPVLEETHPAHQQGASRPGPRDAQAHPGRPRAVPTQCDVPPNSRFDCAPDKAITQEQCEARGCCYIPAKQGLQGAQMGQPWCFFPPSYPSYKLENLSSSEMGYTATLTRTTPTFFPKDILTLRLDVMMETENRLHFTIKDPANRRYEVPLETPHVHSRAPSPLYSVEFSEEPFGVIVRRQLDGRVLLNTTVAPLFFADQFLQLSTSLPSQYITGLAEHLSPLMLSTSWTRITLWNRDLAPTPGANLYGSHPFYLALEDGGSAHGVFLLNSNAMDVVLQPSPALSWRSTGGILDVYIFLGPEPKSVVQQYLDVVGYPFMPPYWGLGFHLCRWGYSSTAITRQVVENMTRAHFPLDVQWNDLDYMDSRRDFTFNKDGFRDFPAMVQELHQGGRRYMMIVDPAISSSGPAGSYRPYDEGLRRGVFITNETGQPLIGKVWPGSTAFPDFTNPTALAWWEDMVAEFHDQVPFDGMWIDMNEPSNFIRGSEDGCPNNELENPPYVPGVVGGTLQAATICASSHQFLSTHYNLHNLYGLTEAIASHRALVKARGTRPFVISRSTFAGHGRYAGHWTGDVWSSWEQLASSVPEILQFNLLGVPLVGADVCGFLGNTSEELCVRWTQLGAFYPFMRNHNSLLSLPQEPYSFSEPAQQAMRKALTLRYALLPHLYTLFHQAHVAGETVARPLFLEFPKDSSTWTVDHQLLWGEALLITPVLQAGKAEVTGYFPLGTWYDLQTVPVEALGSLPPPPAAPREPAIHSEGQWVTLPAPLDTINVHLRAGYIIPLQGPGLTTTESRQQPMALAVALTKGGEARGELFWDDGESLEVLERGAYTQVIFLARNNTIVNELVRVTSEGAGLQLQKVTVLGVATAPQQVLSNGVPVSNFTYSPDTKVLDICVSLLMGEQFLVSWC	952	P10253	L	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [599], 'BINDING_gain': [], 'BINDING_loss_score': array([-0.26109624]), 'DNA_BIND_loss': [375], 'DNA_BIND_gain': [601, 611, 628, 658], 'DNA_BIND_gain_score': array([0.00783545, 0.00607681, 0.01144248, 0.0047726 ]), 'DNA_BIND_loss_score': array([-0.0002318]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [606, 727], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.07632762, -0.02001816]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [386, 623], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.00090003, -0.00706166]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
321	NM_000152.5(GAA):c.1935C>A (p.Asp645Glu)	4029	CA116610	NM_000152.5:c.1935C>A, ENST00000302262.8:c.1935C>A, ENST00000302262.7:c.1935C>A, ENST00000390015.7:c.1935C>A, ENST00000570716.1:n.375C>A, ENST00000572080.1:n.354C>A, ENST00000572803.1:n.549C>A, NM_000152.3:c.1935C>A, LRG_673t1:c.1935C>A, NM_001079803.1:c.1935C>A, NM_001079804.1:c.1935C>A, XM_005257193.1:c.1935C>A, XM_005257194.3:c.1935C>A, NM_000152.4:c.1935C>A, NM_001079803.2:c.1935C>A, NM_001079804.2:c.1935C>A, XM_005257193.2:c.1935C>A, XM_005257194.4:c.1935C>A, NM_001079803.3:c.1935C>A, NM_001079804.3:c.1935C>A, NC_000017.11:g.80112922C>A, CM000679.2:g.80112922C>A, NC_000017.10:g.78086721C>A, CM000679.1:g.78086721C>A, NC_000017.9:g.75701316C>A, NG_009822.1:g.16367C>A, LRG_673:g.16367C>A, NM_000152.5(GAA):c.1935C>A (p.Asp645Glu)	GAA	glycogen storage disease II	MONDO:0009290	Autosomal recessive inheritance	Pathogenic	PP4_Moderate, PP3, PS3_Moderate, PM3_Very Strong, PM5	PM2	The NM_000152.5:c.1935C>A variant in GAA is a missense variant predicted to cause substitution of aspartate by glutamate at amino acid 645 (p.Asp645Glu).  At least 50 individuals with this variant have been reported with GAA activity in the affected range for Pompe disease in fibroblasts, lymphocytes, or dried blood spots (PMID: 8094613, 9554747, 18458862). This variant is reported to be the most common variant identified in patients with infantile onset Pompe disease from China, Taiwan, and Thailand (PMID 9554747, 18458862, 21039225, 31342611), although it has also been reported in other populations (PMID: 8094613). It has been found to be associated with a specific haplotype, which includes the pseudodeficiency variant, indicating that it is a founder variant (PMID: 9554747). However, other studies have not found an association with this specific haplotype (PMID: 8094613, 18458862) (PP4_Moderate). This variant was found in compound heterozygosity with a pathogenic variant in 5 patients (PMID: 8094613, 9554747, 18458862, 28394184), as well as over 30 homozygotes (PMID: 9554747, 18458862, 28394184). More data is available in the literature but the maximum amount of evidence required for PM3_Strong has been reached. The highest population minor allele frequency in gnomAD is 0.001729 in the East Asian population. This is higher than the ClinGen LSD VCEP threshold (<0.001) for PM2, and therefore does not meet this criterion. The computational predictor REVEL gives a score of 0.8, which is above the threshold of 0.7, evidence that correlates with impact to GAA function (PP3). Measurement of GAA activity in COS cells transfected with the variant showed <10% normal GAA activity indicating that this variant impacts protein function (PMID: 8094613, 19862843). In addition, little to no mature 76 kDa protein was detected by pulse-chase analysis, suggesting abnormal synthesis and/or processing of the protein (PMID: 8094613) (PS3_Moderate). Another missense variant, c.1933G>A (p.Asp645Asn) (ClinVar Variation ID: 188728) in the same codon has been classified as pathogenic for Pompe disease by the ClinGen Lysosomal Storage Disorders VCEP (PM5). There is a ClinVar entry for this variant (Variation ID 4029; 2 star review status) with seven laboratory submitters classifying the variant as pathogenic. In summary, this variant meets the criteria to be classified as pathogenic for Pompe disease. GAA-specific ACMG/AMP criteria met, based on the specifications of the ClinGen LSD VCEP (Specifications Version 2.0): PM3_Very Strong, PM5, PS3_Moderate, PP4_Moderate, PP3.(Classification approved on August 17, 2021)		Lysosomal Diseases VCEP	https://clinicalgenome.org/docs/clingen-lysosomal-storage-disorders-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-2/	2021-09-07	2021-09-07	False	https://erepo.genome.network/evrepo/ui/classification/CA116610/MONDO:0009290/010	e2861e0f-9989-4040-822a-dcdb1255a3b0	p.Asp645Glu	Asp	645	Glu	MGVRHPPCSHRLLAVCALVSLATAALLGHILLHDFLLVPRELSGSSPVLEETHPAHQQGASRPGPRDAQAHPGRPRAVPTQCDVPPNSRFDCAPDKAITQEQCEARGCCYIPAKQGLQGAQMGQPWCFFPPSYPSYKLENLSSSEMGYTATLTRTTPTFFPKDILTLRLDVMMETENRLHFTIKDPANRRYEVPLETPHVHSRAPSPLYSVEFSEEPFGVIVRRQLDGRVLLNTTVAPLFFADQFLQLSTSLPSQYITGLAEHLSPLMLSTSWTRITLWNRDLAPTPGANLYGSHPFYLALEDGGSAHGVFLLNSNAMDVVLQPSPALSWRSTGGILDVYIFLGPEPKSVVQQYLDVVGYPFMPPYWGLGFHLCRWGYSSTAITRQVVENMTRAHFPLDVQWNDLDYMDSRRDFTFNKDGFRDFPAMVQELHQGGRRYMMIVDPAISSSGPAGSYRPYDEGLRRGVFITNETGQPLIGKVWPGSTAFPDFTNPTALAWWEDMVAEFHDQVPFDGMWIDMNEPSNFIRGSEDGCPNNELENPPYVPGVVGGTLQAATICASSHQFLSTHYNLHNLYGLTEAIASHRALVKARGTRPFVISRSTFAGHGRYAGHWTGDVWSSWEQLASSVPEILQFNLLGVPLVGADVCGFLGNTSEELCVRWTQLGAFYPFMRNHNSLLSLPQEPYSFSEPAQQAMRKALTLRYALLPHLYTLFHQAHVAGETVARPLFLEFPKDSSTWTVDHQLLWGEALLITPVLQAGKAEVTGYFPLGTWYDLQTVPVEALGSLPPPPAAPREPAIHSEGQWVTLPAPLDTINVHLRAGYIIPLQGPGLTTTESRQQPMALAVALTKGGEARGELFWDDGESLEVLERGAYTQVIFLARNNTIVNELVRVTSEGAGLQLQKVTVLGVATAPQQVLSNGVPVSNFTYSPDTKVLDICVSLLMGEQFLVSWC	952	P10253	E	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [599], 'BINDING_gain': [], 'BINDING_loss_score': array([-0.03109485]), 'DNA_BIND_loss': [420, 424, 508, 584, 588, 614, 618, 620, 659, 660, 661, 663, 714, 716], 'DNA_BIND_gain': [707], 'DNA_BIND_gain_score': array([0.00121695]), 'DNA_BIND_loss_score': array([-0.00131589, -0.00151318, -0.00381875, -0.0097881 , -0.01414967,
       -0.00779378, -0.01915741, -0.00765258, -0.02274138, -0.01628464,
       -0.02841842, -0.02786326, -0.03590679, -0.0041793 ]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [806], 'STRAND_gain_score': array([0.01546139]), 'HELIX_loss': [606, 727], 'HELIX_gain': [665], 'HELIX_gain_score': array([0.05150479]), 'HELIX_loss_score': array([-0.04319406, -0.05525786]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [656, 666, 710], 'REPEAT_gain': [643], 'REPEAT_gain_score': array([0.00158685]), 'REPEAT_loss_score': array([-0.02131689, -0.01685482, -0.0130915 ]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
322	NM_000257.4(MYH7):c.2710C>T (p.Arg904Cys)	164316	CA012904	NM_000257.4:c.2710C>T, NC_000014.9:g.23424119G>A, CM000676.2:g.23424119G>A, NC_000014.8:g.23893328G>A, CM000676.1:g.23893328G>A, NC_000014.7:g.22963168G>A, NG_007884.1:g.16543C>T, LRG_384:g.16543C>T, ENST00000355349.4:c.2710C>T, ENST00000355349.3:c.2710C>T, NM_000257.3:c.2710C>T, XR_245686.3:n.2816C>T, XM_017021340.1:c.2710C>T, NM_000257.4(MYH7):c.2710C>T (p.Arg904Cys)	MYH7	dilated cardiomyopathy	MONDO:0005021	Autosomal dominant inheritance	Pathogenic	PS4_Moderate, PM2, PM6, PM5, PP3, PP1_Strong	BP3, BS4, BS1, BS3, PS2, PS1, BP4, BP2, BP5, BP7, PVS1, PM3, PP4, BS2, PM1, PM4, PS3, BA1	The NM_000257.4:c.2710C>T (p.Arg904Cys) variant in MYH7 has been identified in 4 individuals with DCM in the literature (1 of whom also had LVNC; van Spaendonck-Zwarts 2013 PMID:23349452; van der Zwaag 2011 PMID:20573160; Walsh 2017 PMID:27532257; Miller 2017 PMID29212898) and 3 individuals with LVNC (2 of which were pediatric; Yang 2014 PMID:25326635; Wang 2017 PMID:28855170; van Waning 2018 PMID:29447731). This variant was identified in 8 individuals with DCM and 1 proband with LVNC by clinical laboratories (GeneDx pers. comm.; Invitae pers. comm.; LMM pers. comm.; OMGL pers comm.). Only probands with DCM are counted towards PS4 (n=12; PS4_Moderate). This variant segregated with DCM in 15 affected individuals from 4 families (PP1_Strong; van der Zwaag 2011 PMID:20573160; GeneDx pers. comm.; LMM pers. comm.; OMGL pers. comm.) and was assumed de novo in 1 of the above cases (PM6; GeneDx pers. comm.). This variant has been identified in 0.010% (1/10080) of Ashkenazi Jewish chromosomes by gnomAD v2.1.1 (https://gnomad.broadinstitute.org), but was absent from all other populations. A different pathogenic missense variant has been previously identified at this codon, which indicates that this residue may be critical to the function of the protein (PM5; c.2711G>A p.Arg904His - Variation ID 42926). Computational prediction tools and conservation analysis suggest that this variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for dilated cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (Kelly 2018 PMID:29300372): PS4_Moderate, PP1_Strong, PM6, PM2, PM5, PP3.		Cardiomyopathy VCEP		2021-09-27	2021-10-01	False	https://erepo.genome.network/evrepo/ui/classification/CA012904/MONDO:0005021/002	6106a59d-ad87-4369-8ac2-364ff07935c4	p.Arg904Cys	Arg	904	Cys	MGDSEMAVFGAAAPYLRKSEKERLEAQTRPFDLKKDVFVPDDKQEFVKAKIVSREGGKVTAETEYGKTVTVKEDQVMQQNPPKFDKIEDMAMLTFLHEPAVLYNLKDRYGSWMIYTYSGLFCVTVNPYKWLPVYTPEVVAAYRGKKRSEAPPHIFSISDNAYQYMLTDRENQSILITGESGAGKTVNTKRVIQYFAVIAAIGDRSKKDQSPGKGTLEDQIIQANPALEAFGNAKTVRNDNSSRFGKFIRIHFGATGKLASADIETYLLEKSRVIFQLKAERDYHIFYQILSNKKPELLDMLLITNNPYDYAFISQGETTVASIDDAEELMATDNAFDVLGFTSEEKNSMYKLTGAIMHFGNMKFKLKQREEQAEPDGTEEADKSAYLMGLNSADLLKGLCHPRVKVGNEYVTKGQNVQQVIYATGALAKAVYERMFNWMVTRINATLETKQPRQYFIGVLDIAGFEIFDFNSFEQLCINFTNEKLQQFFNHHMFVLEQEEYKKEGIEWTFIDFGMDLQACIDLIEKPMGIMSILEEECMFPKATDMTFKAKLFDNHLGKSANFQKPRNIKGKPEAHFSLIHYAGIVDYNIIGWLQKNKDPLNETVVGLYQKSSLKLLSTLFANYAGADAPIEKGKGKAKKGSSFQTVSALHRENLNKLMTNLRSTHPHFVRCIIPNETKSPGVMDNPLVMHQLRCNGVLEGIRICRKGFPNRILYGDFRQRYRILNPAAIPEGQFIDSRKGAEKLLSSLDIDHNQYKFGHTKVFFKAGLLGLLEEMRDERLSRIITRIQAQSRGVLARMEYKKLLERRDSLLVIQWNIRAFMGVKNWPWMKLYFKIKPLLKSAEREKEMASMKEEFTRLKEALEKSEARRKELEEKMVSLLQEKNDLQLQVQAEQDNLADAEERCDQLIKNKIQLEAKVKEMNERLEDEEEMNAELTAKKRKLEDECSELKRDIDDLELTLAKVEKEKHATENKVKNLTEEMAGLDEIIAKLTKEKKALQEAHQQALDDLQAEEDKVNTLTKAKVKLEQQVDDLEGSLEQEKKVRMDLERAKRKLEGDLKLTQESIMDLENDKQQLDERLKKKDFELNALNARIEDEQALGSQLQKKLKELQARIEELEEELEAERTARAKVEKLRSDLSRELEEISERLEEAGGATSVQIEMNKKREAEFQKMRRDLEEATLQHEATAAALRKKHADSVAELGEQIDNLQRVKQKLEKEKSEFKLELDDVTSNMEQIIKAKANLEKMCRTLEDQMNEHRSKAEETQRSVNDLTSQRAKLQTENGELSRQLDEKEALISQLTRGKLTYTQQLEDLKRQLEEEVKAKNALAHALQSARHDCDLLREQYEEETEAKAELQRVLSKANSEVAQWRTKYETDAIQRTEELEEAKKKLAQRLQEAEEAVEAVNAKCSSLEKTKHRLQNEIEDLMVDVERSNAAAAALDKKQRNFDKILAEWKQKYEESQSELESSQKEARSLSTELFKLKNAYEESLEHLETFKRENKNLQEEISDLTEQLGSSGKTIHELEKVRKQLEAEKMELQSALEEAEASLEHEEGKILRAQLEFNQIKAEIERKLAEKDEEMEQAKRNHLRVVDSLQTSLDAETRSRNEALRVKKKMEGDLNEMEIQLSHANRMAAEAQKQVKSLQSLLKDTQIQLDDAVRANDDLKENIAIVERRNNLLQAELEELRAVVEQTERSRKLAEQELIETSERVQLLHSQNTSLINQKKKMDADLSQLQTEVEEAVQECRNAEEKAKKAITDAAMMAEELKKEQDTSAHLERMKKNMEQTIKDLQHRLDEAEQIALKGGKKQLQKLEARVRELENELEAEQKRNAESVKGMRKSERRIKELTYQTEEDRKNLLRLQDLVDKLQLKVKAYKRQAEEAEEQANTNLSKFRKVQHELDEAEERADIAESQVNKLRAKSRDIGTKGLNEE	1935	P12883	C	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [152], 'DOMAIN_gain_score': array([0.03284723]), 'REGION_loss': [866, 874, 876, 886, 891, 892, 893, 894, 897, 898, 899, 900, 901, 903, 904, 906, 908, 909, 911, 912, 916], 'REGION_gain': [1193, 1197, 1205], 'REGION_gain_score': array([0.00613219, 0.00642973, 0.00599086]), 'REGION_loss_score': array([-0.03306317, -0.03513151, -0.03665793, -0.05452746, -0.0727191 ,
       -0.07078397, -0.07015043, -0.09366655, -0.09912318, -0.08560455,
       -0.06857872, -0.11074907, -0.08759195, -0.07883757, -0.08211929,
       -0.07238239, -0.07111835, -0.0704121 , -0.05832762, -0.06497222,
       -0.06462812]), 'REPEAT_loss': [47, 87, 105, 373, 375, 388, 400], 'REPEAT_gain': [895, 896, 897, 899, 901, 982, 999, 1002, 1011, 1078, 1087, 1088, 1095, 1098, 1099, 1115, 1168], 'REPEAT_gain_score': array([0.02524298, 0.02402997, 0.02638835, 0.0454123 , 0.02899754,
       0.0343107 , 0.03266317, 0.03195745, 0.02685708, 0.02065325,
       0.02130306, 0.02083105, 0.02651697, 0.01776159, 0.02470601,
       0.01019454, 0.00279796]), 'REPEAT_loss_score': array([-0.00196481, -0.00186145, -0.00253612, -0.00404447, -0.00409788,
       -0.00427002, -0.00523603]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
323	NM_000257.4(MYH7):c.2711G>A (p.Arg904His)	42926	CA012913	NM_000257.4:c.2711G>A, ENST00000355349.4:c.2711G>A, ENST00000355349.3:c.2711G>A, NM_000257.3:c.2711G>A, XR_245686.3:n.2817G>A, XM_017021340.1:c.2711G>A, NC_000014.9:g.23424118C>T, CM000676.2:g.23424118C>T, NC_000014.8:g.23893327C>T, CM000676.1:g.23893327C>T, NC_000014.7:g.22963167C>T, NG_007884.1:g.16544G>A, LRG_384:g.16544G>A, NM_000257.4(MYH7):c.2711G>A (p.Arg904His)	MYH7	dilated cardiomyopathy	MONDO:0005021	Autosomal dominant inheritance	Pathogenic	PS4, PM2, PP3, PP1_Strong, PM6_Strong	BS4, BS3, BP1, PS2, PS1, BP4, PM5, PM1, PS3, PP2	The NM_000257.4(MYH7):c.2711G>A (p.Arg904His) variant has been identified in at least 14 individuals with DCM in the literature (PS4; Waldmüller 2011 PMID:21750094; Lakdawala 2012 PMID:22464770; Pugh 2014 PMID:24503780; Chami 2014 PMID:25448463; Walsh 2017 PMID:27532257; Gigli 2019 PMID:31514951; Ambry pers. comm.; GeneDx pers. comm.; Invitae pers. comm.). In 3 of theses cases, the variant was identified as an unconfirmed de novo occurrence (PM6_Strong; Lakdawala 2012 PMID:22464770; GeneDx pers. comm.; OMGL pers. comm.). This variant also segregated with disease in 7 affected individuals with DCM across 4 families (PP1_Strong; Chami 2014 PMID:25448463; GeneDx pers. comm.; OMGL pers. comm.). This variant was absent from large population studies (PM2; gnomAD v2.1.1, http://gnomad.broadinstitute.org). While this variant lies in the head region of the protein (aa 181-937), where missense variants are statistically more likely to be associated with HCM (Walsh 2017 PMID:27532257), location in this region cannot be used to support pathogenicity for other phenotypes; therefore PM1 is not applicable. Finally, computational prediction tools and conservation analysis suggest that this variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for dilated cardiomyopathy (DCM) in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (Kelly 2018 PMID:29300372): PS4, PM6_Strong, PP1_Strong, PM2, PP3.		Cardiomyopathy VCEP		2021-09-27	2021-10-01	False	https://erepo.genome.network/evrepo/ui/classification/CA012913/MONDO:0005021/002	87568204-0e45-42e8-b9e9-3488c811c4d5	p.Arg904His	Arg	904	His	MGDSEMAVFGAAAPYLRKSEKERLEAQTRPFDLKKDVFVPDDKQEFVKAKIVSREGGKVTAETEYGKTVTVKEDQVMQQNPPKFDKIEDMAMLTFLHEPAVLYNLKDRYGSWMIYTYSGLFCVTVNPYKWLPVYTPEVVAAYRGKKRSEAPPHIFSISDNAYQYMLTDRENQSILITGESGAGKTVNTKRVIQYFAVIAAIGDRSKKDQSPGKGTLEDQIIQANPALEAFGNAKTVRNDNSSRFGKFIRIHFGATGKLASADIETYLLEKSRVIFQLKAERDYHIFYQILSNKKPELLDMLLITNNPYDYAFISQGETTVASIDDAEELMATDNAFDVLGFTSEEKNSMYKLTGAIMHFGNMKFKLKQREEQAEPDGTEEADKSAYLMGLNSADLLKGLCHPRVKVGNEYVTKGQNVQQVIYATGALAKAVYERMFNWMVTRINATLETKQPRQYFIGVLDIAGFEIFDFNSFEQLCINFTNEKLQQFFNHHMFVLEQEEYKKEGIEWTFIDFGMDLQACIDLIEKPMGIMSILEEECMFPKATDMTFKAKLFDNHLGKSANFQKPRNIKGKPEAHFSLIHYAGIVDYNIIGWLQKNKDPLNETVVGLYQKSSLKLLSTLFANYAGADAPIEKGKGKAKKGSSFQTVSALHRENLNKLMTNLRSTHPHFVRCIIPNETKSPGVMDNPLVMHQLRCNGVLEGIRICRKGFPNRILYGDFRQRYRILNPAAIPEGQFIDSRKGAEKLLSSLDIDHNQYKFGHTKVFFKAGLLGLLEEMRDERLSRIITRIQAQSRGVLARMEYKKLLERRDSLLVIQWNIRAFMGVKNWPWMKLYFKIKPLLKSAEREKEMASMKEEFTRLKEALEKSEARRKELEEKMVSLLQEKNDLQLQVQAEQDNLADAEERCDQLIKNKIQLEAKVKEMNERLEDEEEMNAELTAKKRKLEDECSELKRDIDDLELTLAKVEKEKHATENKVKNLTEEMAGLDEIIAKLTKEKKALQEAHQQALDDLQAEEDKVNTLTKAKVKLEQQVDDLEGSLEQEKKVRMDLERAKRKLEGDLKLTQESIMDLENDKQQLDERLKKKDFELNALNARIEDEQALGSQLQKKLKELQARIEELEEELEAERTARAKVEKLRSDLSRELEEISERLEEAGGATSVQIEMNKKREAEFQKMRRDLEEATLQHEATAAALRKKHADSVAELGEQIDNLQRVKQKLEKEKSEFKLELDDVTSNMEQIIKAKANLEKMCRTLEDQMNEHRSKAEETQRSVNDLTSQRAKLQTENGELSRQLDEKEALISQLTRGKLTYTQQLEDLKRQLEEEVKAKNALAHALQSARHDCDLLREQYEEETEAKAELQRVLSKANSEVAQWRTKYETDAIQRTEELEEAKKKLAQRLQEAEEAVEAVNAKCSSLEKTKHRLQNEIEDLMVDVERSNAAAAALDKKQRNFDKILAEWKQKYEESQSELESSQKEARSLSTELFKLKNAYEESLEHLETFKRENKNLQEEISDLTEQLGSSGKTIHELEKVRKQLEAEKMELQSALEEAEASLEHEEGKILRAQLEFNQIKAEIERKLAEKDEEMEQAKRNHLRVVDSLQTSLDAETRSRNEALRVKKKMEGDLNEMEIQLSHANRMAAEAQKQVKSLQSLLKDTQIQLDDAVRANDDLKENIAIVERRNNLLQAELEELRAVVEQTERSRKLAEQELIETSERVQLLHSQNTSLINQKKKMDADLSQLQTEVEEAVQECRNAEEKAKKAITDAAMMAEELKKEQDTSAHLERMKKNMEQTIKDLQHRLDEAEQIALKGGKKQLQKLEARVRELENELEAEQKRNAESVKGMRKSERRIKELTYQTEEDRKNLLRLQDLVDKLQLKVKAYKRQAEEAEEQANTNLSKFRKVQHELDEAEERADIAESQVNKLRAKSRDIGTKGLNEE	1935	P12883	H	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [874, 876, 891, 898, 899, 901, 904], 'REGION_gain': [1205], 'REGION_gain_score': array([0.00221384]), 'REGION_loss_score': array([-0.00929874, -0.01216173, -0.0203253 , -0.02574337, -0.03090793,
       -0.02917331, -0.03704578]), 'REPEAT_loss': [47, 87, 105, 373, 375, 400, 1156], 'REPEAT_gain': [886, 895, 896, 897, 899, 999, 1002, 1095], 'REPEAT_gain_score': array([0.02131021, 0.03256613, 0.02964669, 0.02906805, 0.02850562,
       0.01275098, 0.01522851, 0.00882936]), 'REPEAT_loss_score': array([-0.00344199, -0.00346416, -0.00368136, -0.00317746, -0.00310493,
       -0.00332302, -0.00181335]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
324	NM_005027.4(PIK3R2):c.160G>A (p.Val54Met)	468317	CA9306657	NM_005027.4:c.160G>A, NC_000019.10:g.18156039G>A, CM000681.2:g.18156039G>A, NC_000019.9:g.18266849G>A, CM000681.1:g.18266849G>A, NC_000019.8:g.18127849G>A, NG_033010.1:g.7862G>A, NG_033010.2:g.7862G>A, ENST00000222254.13:c.160G>A, ENST00000617130.5:c.160G>A, ENST00000617642.2:c.160G>A, ENST00000222254.12:c.160G>A, ENST00000426902.5:c.160G>A, ENST00000593731.1:c.160G>A, ENST00000617130.4:n.160G>A, ENST00000617642.1:n.160G>A, NM_005027.3:c.160G>A, NR_073517.1:n.700G>A, NR_073517.2:n.715G>A, NR_162071.1:n.715G>A, NM_005027.4(PIK3R2):c.160G>A (p.Val54Met)	PIK3R2	overgrowth syndrome and/or cerebral malformations due to abnormalities in MTOR pathway genes	MONDO:0100283	Autosomal dominant inheritance (mosaic)	Benign	BA1	PP2	The c.160G>A (NM_005027.4) variant in PIK3R2 is a missense variant predicted to cause substitution of (p.Val54Met).  The highest population minor allele frequency in gnomAD v2.1.1 is 0.004092 in the European (non Finnish) population, which is higher than the ClinGen BMEP threshold ([>=0.00185]) for BA1, and therefore meets this criterion (BA1).  In summary, this variant meets the criteria to be classified as Benign for mosaic autosomal dominant overgrowth with or without cerebral malformations due to abnormalities in MTOR-pathway genes based on the ACMG/AMP criteria applied, as specified by the ClinGen Brain Malformations Expert Panel: BA1; -8 points (VCEP specifications version 1; Approved: 1/31/2021)		Brain Malformations VCEP	https://clinicalgenome.org/docs/clingen-brain-malformations-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1.1/	2022-02-11	2022-02-11	False	https://erepo.genome.network/evrepo/ui/classification/CA9306657/MONDO:0100283/018	01200966-ff55-4274-8597-25b027b3187e	p.Val54Met	Val	54	Met	MAGPEGFQYRALYPFRRERPEDLELLPGDVLVVSRAALQALGVAEGGERCPQSVGWMPGLNERTRQRGDFPGTYVEFLGPVALARPGPRPRGPRPLPARPRDGAPEPGLTLPDLPEQFSPPDVAPPLLVKLVEAIERTGLDSESHYRPELPAPRTDWSLSDVDQWDTAALADGIKSFLLALPAPLVTPEASAEARRALREAAGPVGPALEPPTLPLHRALTLRFLLQHLGRVASRAPALGPAVRALGATFGPLLLRAPPPPSSPPPGGAPDGSEPSPDFPALLVEKLLQEHLEEQEVAPPALPPKPPKAKPASTVLANGGSPPSLQDAEWYWGDISREEVNEKLRDTPDGTFLVRDASSKIQGEYTLTLRKGGNNKLIKVFHRDGHYGFSEPLTFCSVVDLINHYRHESLAQYNAKLDTRLLYPVSKYQQDQIVKEDSVEAVGAQLKVYHQQYQDKSREYDQLYEEYTRTSQELQMKRTAIEAFNETIKIFEEQGQTQEKCSKEYLERFRREGNEKEMQRILLNSERLKSRIAEIHESRTKLEQQLRAQASDNREIDKRMNSLKPDLMQLRKIRDQYLVWLTQKGARQKKINEWLGIKNETEDQYALMEDEDDLPHHEERTWYVGKINRTQAEEMLSGKRDGTFLIRESSQRGCYACSVVVDGDTKHCVIYRTATGFGFAEPYNLYGSLKELVLHYQHASLVQHNDALTVTLAHPVRAPGPGPPPAAR	728	O00459	M	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [0, 4], 'TRANSIT_gain': [], 'TRANSIT_loss_score': array([-0.00427115, -0.01074803]), 'STRAND_loss': [676], 'STRAND_gain': [55], 'STRAND_gain_score': array([0.03601927]), 'STRAND_loss_score': array([-0.00198269]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [83], 'REGION_gain_score': array([0.05027604]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
325	NM_005027.4(PIK3R2):c.1117G>A (p.Gly373Arg)	39808	CA130573	NM_005027.4:c.1117G>A, NC_000019.10:g.18162974G>A, CM000681.2:g.18162974G>A, NC_000019.9:g.18273784G>A, CM000681.1:g.18273784G>A, NC_000019.8:g.18134784G>A, NG_033010.1:g.14797G>A, NG_033010.2:g.14797G>A, ENST00000222254.13:c.1117G>A, ENST00000617130.5:c.*96G>A, ENST00000617642.2:c.*96G>A, ENST00000675271.1:n.63G>A, ENST00000222254.12:c.1117G>A, ENST00000426902.5:c.1117G>A, ENST00000593731.1:c.1117G>A, ENST00000617130.4:n.1117G>A, ENST00000617642.1:n.1117G>A, NM_005027.3:c.1117G>A, NR_073517.1:n.1657G>A, NR_073517.2:n.1672G>A, NR_162071.1:n.1455G>A, NM_005027.4(PIK3R2):c.1117G>A (p.Gly373Arg)	PIK3R2	overgrowth syndrome and/or cerebral malformations due to abnormalities in MTOR pathway genes	MONDO:0016054	Autosomal dominant inheritance (mosaic)	Pathogenic	PM2_Supporting, PM1_Supporting, PS4, PS2_Moderate	PP2, PP3, PP1, PP4, BS2, BA1, BP1, BP4, BP3, BP2, PS1, PS3, PM5, PM4, PM3, BS1, BS3, BS4, BP7, BP5, PVS1, PM6	The c.1117G>A (NM_005027.4) variant in PIK3R2 is a missense variant predicted to cause substitution of (p.Gly373Arg). This variant is absent from gnomAD v2.1.1 (PM2_Supporting). This variant resides within the PIK3R2 SH2, sequence homology 2 domain of  PIK3R2 that is defined as a critical functional domain by the ClinGen BMEP (PMID: 26860062) (PM1_Supporting). The prevalence of the variant in affected individuals is significantly increased compared with the prevalence in controls (PS4_VS; identified in 2 individuals with macrocephaly (>=2 SD) and Developmental Delay or Intellectual disability with cortical malformation, 13 individuals with a clinical diagnosis of megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome; (MPPH) or megalencephaly-capillary malformation-polymicrogyria syndrome; (MCAP), it has been shown to significantly increase phosphorylation levels in patient cell lines (PMID: 22729224), and has been identified in over 15 tumor samples in the literature and COSMIC (PMID: 28086757,22729224, 28502725)). This variant has been identified as a de novo occurrence with confirmed parental relationships (PS2_moderate; PMID: 22729224). In summary, this variant meets the criteria to be classified as Pathogenic for mosaic autosomal dominant overgrowth with or without cerebral malformations due to abnormalities in MTOR-pathway genes based on the ACMG/AMP criteria applied, as specified by the ClinGen Brain Malformations Expert Panel: PM2_P, PM1_P, PS4_VS, PS2_M; 13 points (VCEP specifications version 1; Approved: 1/31/2021)	22729224, 28086757, 22729224, 22729224, 22729224, 22729224	Brain Malformations VCEP	https://clinicalgenome.org/docs/clingen-brain-malformations-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1.1/	2022-02-17	2022-02-17	False	https://erepo.genome.network/evrepo/ui/classification/CA130573/MONDO:0016054/018	421e7cec-5414-46bc-82b2-ecde31fd73a0	p.Gly373Arg	Gly	373	Arg	MAGPEGFQYRALYPFRRERPEDLELLPGDVLVVSRAALQALGVAEGGERCPQSVGWMPGLNERTRQRGDFPGTYVEFLGPVALARPGPRPRGPRPLPARPRDGAPEPGLTLPDLPEQFSPPDVAPPLLVKLVEAIERTGLDSESHYRPELPAPRTDWSLSDVDQWDTAALADGIKSFLLALPAPLVTPEASAEARRALREAAGPVGPALEPPTLPLHRALTLRFLLQHLGRVASRAPALGPAVRALGATFGPLLLRAPPPPSSPPPGGAPDGSEPSPDFPALLVEKLLQEHLEEQEVAPPALPPKPPKAKPASTVLANGGSPPSLQDAEWYWGDISREEVNEKLRDTPDGTFLVRDASSKIQGEYTLTLRKGGNNKLIKVFHRDGHYGFSEPLTFCSVVDLINHYRHESLAQYNAKLDTRLLYPVSKYQQDQIVKEDSVEAVGAQLKVYHQQYQDKSREYDQLYEEYTRTSQELQMKRTAIEAFNETIKIFEEQGQTQEKCSKEYLERFRREGNEKEMQRILLNSERLKSRIAEIHESRTKLEQQLRAQASDNREIDKRMNSLKPDLMQLRKIRDQYLVWLTQKGARQKKINEWLGIKNETEDQYALMEDEDDLPHHEERTWYVGKINRTQAEEMLSGKRDGTFLIRESSQRGCYACSVVVDGDTKHCVIYRTATGFGFAEPYNLYGSLKELVLHYQHASLVQHNDALTVTLAHPVRAPGPGPPPAAR	728	O00459	R	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [654, 676], 'STRAND_gain': [664], 'STRAND_gain_score': array([0.00213009]), 'STRAND_loss_score': array([-0.00559324, -0.00533539]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
326	NM_006218.3(PIK3CA):c.2198A>G (p.Lys733Arg)	456537	CA2710903	NM_006218.3:c.2198A>G, NC_000003.12:g.179224091A>G, CM000665.2:g.179224091A>G, NC_000003.11:g.178941879A>G, CM000665.1:g.178941879A>G, NC_000003.10:g.180424573A>G, NG_012113.2:g.80569A>G, LRG_310:g.80569A>G, ENST00000263967.4:c.2198A>G, ENST00000462255.2:n.660A>G, ENST00000643187.1:c.2198A>G, ENST00000674534.1:n.3106A>G, ENST00000674622.1:n.619A>G, ENST00000675467.1:n.5005A>G, ENST00000675786.1:c.*765A>G, ENST00000263967.3:c.2198A>G, ENST00000462255.1:n.472A>G, NM_006218.2:c.2198A>G, LRG_310t1:c.2198A>G, XM_006713658.2:c.2198A>G, XM_011512894.1:c.2198A>G, XM_006713658.4:c.2198A>G, XM_011512894.2:c.2198A>G, NM_006218.4:c.2198A>G, NM_006218.4(PIK3CA):c.2198A>G (p.Lys733Arg), NM_006218.3(PIK3CA):c.2198A>G (p.Lys733Arg)	PIK3CA	overgrowth syndrome and/or cerebral malformations due to abnormalities in MTOR pathway genes	MONDO:0016054	Autosomal dominant inheritance (mosaic)	Benign	PP2, BA1	BS2, PP3, PP1, PP4, BP1, BP4, BP3, BP2, PS1, PS3, PS4, PS2, PM5, PM4, PM1, PM3, BS1, BS3, BS4, BP7, BP5, PVS1, PM2, PM6	The c.2198A>G (NM_006218.4) variant in PIK3CA is a missense variant predicted to cause substitution of (p.Lys733Arg). The highest population minor allele frequency in gnomAD v2.1.1 is 0.005643 in the East Asian population, which is higher than the ClinGen BMEP threshold ([>=0.00185]) for BA1, and therefore meets this criterion (BA1).  PIK3CA, in which the variant was identified, is defined by the ClinGen Brain Malformations Expert Panel as a gene that has a low rate of benign missense variation and where pathogenic missense variants are a common mechanism of disease (PP2).  In summary, this variant meets the criteria to be classified as Benign for mosaic autosomal dominant overgrowth with or without cerebral malformations due to abnormalities in MTOR-pathway genes based on the ACMG/AMP criteria applied, as specified by the ClinGen Brain Malformations Expert Panel: BA1, PP2; -7 points (VCEP specifications version 1; Approved: 1/31/2021)		Brain Malformations VCEP	https://clinicalgenome.org/docs/clingen-brain-malformations-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1.1/	2022-02-12	2022-02-12	False	https://erepo.genome.network/evrepo/ui/classification/CA2710903/MONDO:0016054/018	5b3b96cd-ec1e-4db0-9843-d360ef02fbd0	p.Lys733Arg	Lys	733	Arg	MPPRPSSGELWGIHLMPPRILVECLLPNGMIVTLECLREATLITIKHELFKEARKYPLHQLLQDESSYIFVSVTQEAEREEFFDETRRLCDLRLFQPFLKVIEPVGNREEKILNREIGFAIGMPVCEFDMVKDPEVQDFRRNILNVCKEAVDLRDLNSPHSRAMYVYPPNVESSPELPKHIYNKLDKGQIIVVIWVIVSPNNDKQKYTLKINHDCVPEQVIAEAIRKKTRSMLLSSEQLKLCVLEYQGKYILKVCGCDEYFLEKYPLSQYKYIRSCIMLGRMPNLMLMAKESLYSQLPMDCFTMPSYSRRISTATPYMNGETSTKSLWVINSALRIKILCATYVNVNIRDIDKIYVRTGIYHGGEPLCDNVNTQRVPCSNPRWNEWLNYDIYIPDLPRAARLCLSICSVKGRKGAKEEHCPLAWGNINLFDYTDTLVSGKMALNLWPVPHGLEDLLNPIGVTGSNPNKETPCLELEFDWFSSVVKFPDMSVIEEHANWSVSREAGFSYSHAGLSNRLARDNELRENDKEQLKAISTRDPLSEITEQEKDFLWSHRHYCVTIPEILPKLLLSVKWNSRDEVAQMYCLVKDWPPIKPEQAMELLDCNYPDPMVRGFAVRCLEKYLTDDKLSQYLIQLVQVLKYEQYLDNLLVRFLLKKALTNQRIGHFFFWHLKSEMHNKTVSQRFGLLLESYCRACGMYLKHLNRQVEAMEKLINLTDILKQEKKDETQKVQMKFLVEQMRRPDFMDALQGFLSPLNPAHQLGNLRLEECRIMSSAKRPLWLNWENPDIMSELLFQNNEIIFKNGDDLRQDMLTLQIIRIMENIWQNQGLDLRMLPYGCLSIGDCVGLIEVVRNSHTIMQIQCKGGLKGALQFNSHTLHQWLKDKNKGEIYDAAIDLFTRSCAGYCVATFILGIGDRHNSNIMVKDDGQLFHIDFGHFLDHKKKKFGYKRERVPFVLTQDFLIVISKGAQECTKTREFERFQEMCYKAYLAIRQHANLFINLFSMMLGSGMPELQSFDDIAYIRKTLALDKTEQEALEYFMKQMNDAHHGGWTTKMDWIFHTIKQHALN	1068	P42336	R	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [911], 'BINDING_gain_score': array([0.00312823]), 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [178, 747], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.00202614, -0.02245665]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [41], 'REGION_gain': [], 'REGION_loss_score': array([-0.00059009]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
327	NM_006218.4(PIK3CA):c.1624G>A (p.Glu542Lys)	31944	CA333572	NM_006218.4:c.1624G>A, NC_000003.12:g.179218294G>A, CM000665.2:g.179218294G>A, NC_000003.11:g.178936082G>A, CM000665.1:g.178936082G>A, NC_000003.10:g.180418776G>A, NG_012113.2:g.74772G>A, LRG_310:g.74772G>A, ENST00000263967.4:c.1624G>A, ENST00000462255.2:n.86G>A, ENST00000643187.1:c.1624G>A, ENST00000674534.1:n.1378G>A, ENST00000674622.1:n.127G>A, ENST00000675467.1:n.4431G>A, ENST00000675786.1:c.*191G>A, ENST00000263967.3:c.1624G>A, NM_006218.2:c.1624G>A, LRG_310t1:c.1624G>A, XM_006713658.2:c.1624G>A, XM_011512894.1:c.1624G>A, NM_006218.3:c.1624G>A, XM_006713658.4:c.1624G>A, XM_011512894.2:c.1624G>A, NM_006218.4(PIK3CA):c.1624G>A (p.Glu542Lys)	PIK3CA	overgrowth syndrome and/or cerebral malformations due to abnormalities in MTOR pathway genes	MONDO:0016054	Autosomal dominant inheritance (mosaic)	Pathogenic	PP2, PM2_Supporting, PS4, PS2_Moderate	PP1, PP3, PP4, BS2, BA1, BP2, BP3, BP1, BP4, PS1, PS3, PM5, PM1, PM3, PM4, BP5, BP7, BS3, BS1, BS4, PVS1, PM6	The c.1624G>A (NM_006218.4) variant in PIK3CA is a missense variant predicted to cause substitution of (p.Glu542Lys). Testing of unaffected and affected tissue show variable allelic fractions consistent with a post-zygotic event (PS2_Moderate; PMID: 22658544). The prevalence of the variant in affected individuals is significantly increased compared with the prevalence in controls (PS4_VS; PMIDs: 25722288, 25681199, 22658544, 29446767, 26851524, 25292196, 23100325; identified in 1 individual with neuroimaging demonstrating at least one large cerebral hemisphere with cortical malformation, at least 6 individuals with a clinical diagnosis of megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome; (MPPH) or megalencephaly-capillary malformation-polymicrogyria syndrome; (MCAP), at least 9 individuals with segmental overgrowth or vascular malformation of a limb or region of the body, and at least 9 tumor samples in the literature and COSMIC). This variant is absent from gnomAD v2.1.1 (PM2_Supporting). PIK3CA, in which the variant was identified, is defined by the ClinGen Brain Malformations Expert Panel as a gene that has a low rate of benign missense variation and where pathogenic missense variants are a common mechanism of disease (PP2).  In summary, this variant meets the criteria to be classified as Pathogenic for mosaic autosomal dominant overgrowth with or without cerebral malformations due to abnormalities in MTOR-pathway genes based on the ACMG/AMP criteria applied, as specified by the ClinGen Brain Malformations Expert Panel: PS2_M, PS4_VS, PM2_P, PP2; 12 points (VCEP specifications version 1; Approved: 1/31/2021)		Brain Malformations VCEP	https://clinicalgenome.org/docs/clingen-brain-malformations-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1.1/	2022-02-12	2022-02-12	False	https://erepo.genome.network/evrepo/ui/classification/CA333572/MONDO:0016054/018	7ffcf400-d46a-4637-be35-8721447aa249	p.Glu542Lys	Glu	542	Lys	MPPRPSSGELWGIHLMPPRILVECLLPNGMIVTLECLREATLITIKHELFKEARKYPLHQLLQDESSYIFVSVTQEAEREEFFDETRRLCDLRLFQPFLKVIEPVGNREEKILNREIGFAIGMPVCEFDMVKDPEVQDFRRNILNVCKEAVDLRDLNSPHSRAMYVYPPNVESSPELPKHIYNKLDKGQIIVVIWVIVSPNNDKQKYTLKINHDCVPEQVIAEAIRKKTRSMLLSSEQLKLCVLEYQGKYILKVCGCDEYFLEKYPLSQYKYIRSCIMLGRMPNLMLMAKESLYSQLPMDCFTMPSYSRRISTATPYMNGETSTKSLWVINSALRIKILCATYVNVNIRDIDKIYVRTGIYHGGEPLCDNVNTQRVPCSNPRWNEWLNYDIYIPDLPRAARLCLSICSVKGRKGAKEEHCPLAWGNINLFDYTDTLVSGKMALNLWPVPHGLEDLLNPIGVTGSNPNKETPCLELEFDWFSSVVKFPDMSVIEEHANWSVSREAGFSYSHAGLSNRLARDNELRENDKEQLKAISTRDPLSEITEQEKDFLWSHRHYCVTIPEILPKLLLSVKWNSRDEVAQMYCLVKDWPPIKPEQAMELLDCNYPDPMVRGFAVRCLEKYLTDDKLSQYLIQLVQVLKYEQYLDNLLVRFLLKKALTNQRIGHFFFWHLKSEMHNKTVSQRFGLLLESYCRACGMYLKHLNRQVEAMEKLINLTDILKQEKKDETQKVQMKFLVEQMRRPDFMDALQGFLSPLNPAHQLGNLRLEECRIMSSAKRPLWLNWENPDIMSELLFQNNEIIFKNGDDLRQDMLTLQIIRIMENIWQNQGLDLRMLPYGCLSIGDCVGLIEVVRNSHTIMQIQCKGGLKGALQFNSHTLHQWLKDKNKGEIYDAAIDLFTRSCAGYCVATFILGIGDRHNSNIMVKDDGQLFHIDFGHFLDHKKKKFGYKRERVPFVLTQDFLIVISKGAQECTKTREFERFQEMCYKAYLAIRQHANLFINLFSMMLGSGMPELQSFDDIAYIRKTLALDKTEQEALEYFMKQMNDAHHGGWTTKMDWIFHTIKQHALN	1068	P42336	K	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [406], 'STRAND_gain_score': array([0.0017885]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [175], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.01475859]), 'REGION_loss': [], 'REGION_gain': [30], 'REGION_gain_score': array([0.00148618]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
328	NM_006218.3(PIK3CA):c.2740G>A (p.Gly914Arg)	39703	CA130467	NM_006218.3:c.2740G>A, NC_000003.12:g.179230077G>A, CM000665.2:g.179230077G>A, NC_000003.11:g.178947865G>A, CM000665.1:g.178947865G>A, NC_000003.10:g.180430559G>A, NG_012113.2:g.86555G>A, LRG_310:g.86555G>A, ENST00000263967.4:c.2740G>A, ENST00000462255.2:n.1763G>A, ENST00000643187.1:c.2740G>A, ENST00000674534.1:n.3648G>A, ENST00000674622.1:n.1161G>A, ENST00000675467.1:n.5547G>A, ENST00000675786.1:c.*1307G>A, ENST00000675796.1:n.2635G>A, ENST00000263967.3:c.2740G>A, NM_006218.2:c.2740G>A, LRG_310t1:c.2740G>A, XM_006713658.2:c.2740G>A, XM_011512894.1:c.2740G>A, XM_006713658.4:c.2740G>A, XM_011512894.2:c.2740G>A, NM_006218.4:c.2740G>A, NM_006218.4(PIK3CA):c.2740G>A (p.Gly914Arg), NM_006218.3(PIK3CA):c.2740G>A (p.Gly914Arg)	PIK3CA	overgrowth syndrome and/or cerebral malformations due to abnormalities in MTOR pathway genes	MONDO:0016054	Autosomal dominant inheritance (mosaic)	Pathogenic	PP2, PM2_Supporting, PM1_Supporting, PS4, PS2	PP3, PP1, PP4, BS2, BA1, BP1, BP4, BP3, BP2, PS3, PS1, PM4, PM5, PM3, BP7, BP5, BS1, BS3, BS4, PVS1, PM6	The c.2740G>A (NM_006218.4) variant in PIK3CA is a missense variant predicted to cause substitution of (p.Gly914Arg).  This variant is absent from gnomAD v2.1.1 (PM2_Supporting). PIK3CA, in which the variant was identified, is defined by the ClinGen Brain Malformations Expert Panel as a gene that has a low rate of benign missense variation and where pathogenic missense variants are a common mechanism of disease (PP2).  This variant resides within the kinase domain of  PIK3CA that is defined as a critical functional domain by the ClinGen BMEP (PMIDs: 26637981, 24459181, 27631024) (PM1_Supporting). The prevalence of the variant in affected individuals is significantly increased compared with the prevalence in controls (PS4; identified in 5 individuals with a clinical diagnosis of megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome; (MPPH) or megalencephaly-capillary malformation-polymicrogyria syndrome; (MCAP), and in 4 individuals with segmental overgrowth or vascular malformation of a limb or region of the body, it has been shown to significantly increase phosphorylation levels in patient cell lines (PMID: 22729224), and it was identified in 2 tumor samples in COSMIC (PMID: 22729224, PMID: 28151489, PMID: 28502725, PMID: 30231930).  This variant has been confirmed de novo and has been identified with variable allelic fractions consistent with a post-zygotic event (PS2_Strong; PMID: 22729224).  In summary, this variant meets the criteria to be classified as Pathogenic for mosaic autosomal dominant overgrowth with or without cerebral malformations due to abnormalities in MTOR-pathway genes based on the ACMG/AMP criteria applied, as specified by the ClinGen Brain Malformations Expert Panel: PM2_P, PP2, PM1_P, PS4, PS2; 11 points (VCEP specifications version 1; Approved: 1/31/2021)	22729224, 28151489, 22729224, 28502725, 30231930, 22729224, 28737257, 22729224, 22729224	Brain Malformations VCEP	https://clinicalgenome.org/docs/clingen-brain-malformations-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1.1/	2022-02-12	2022-02-12	False	https://erepo.genome.network/evrepo/ui/classification/CA130467/MONDO:0016054/018	857fcdd5-3e4e-4d8c-bc86-6586a8591ded	p.Gly914Arg	Gly	914	Arg	MPPRPSSGELWGIHLMPPRILVECLLPNGMIVTLECLREATLITIKHELFKEARKYPLHQLLQDESSYIFVSVTQEAEREEFFDETRRLCDLRLFQPFLKVIEPVGNREEKILNREIGFAIGMPVCEFDMVKDPEVQDFRRNILNVCKEAVDLRDLNSPHSRAMYVYPPNVESSPELPKHIYNKLDKGQIIVVIWVIVSPNNDKQKYTLKINHDCVPEQVIAEAIRKKTRSMLLSSEQLKLCVLEYQGKYILKVCGCDEYFLEKYPLSQYKYIRSCIMLGRMPNLMLMAKESLYSQLPMDCFTMPSYSRRISTATPYMNGETSTKSLWVINSALRIKILCATYVNVNIRDIDKIYVRTGIYHGGEPLCDNVNTQRVPCSNPRWNEWLNYDIYIPDLPRAARLCLSICSVKGRKGAKEEHCPLAWGNINLFDYTDTLVSGKMALNLWPVPHGLEDLLNPIGVTGSNPNKETPCLELEFDWFSSVVKFPDMSVIEEHANWSVSREAGFSYSHAGLSNRLARDNELRENDKEQLKAISTRDPLSEITEQEKDFLWSHRHYCVTIPEILPKLLLSVKWNSRDEVAQMYCLVKDWPPIKPEQAMELLDCNYPDPMVRGFAVRCLEKYLTDDKLSQYLIQLVQVLKYEQYLDNLLVRFLLKKALTNQRIGHFFFWHLKSEMHNKTVSQRFGLLLESYCRACGMYLKHLNRQVEAMEKLINLTDILKQEKKDETQKVQMKFLVEQMRRPDFMDALQGFLSPLNPAHQLGNLRLEECRIMSSAKRPLWLNWENPDIMSELLFQNNEIIFKNGDDLRQDMLTLQIIRIMENIWQNQGLDLRMLPYGCLSIGDCVGLIEVVRNSHTIMQIQCKGGLKGALQFNSHTLHQWLKDKNKGEIYDAAIDLFTRSCAGYCVATFILGIGDRHNSNIMVKDDGQLFHIDFGHFLDHKKKKFGYKRERVPFVLTQDFLIVISKGAQECTKTREFERFQEMCYKAYLAIRQHANLFINLFSMMLGSGMPELQSFDDIAYIRKTLALDKTEQEALEYFMKQMNDAHHGGWTTKMDWIFHTIKQHALN	1068	P42336	R	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [911, 912, 913, 916, 933, 935], 'BINDING_gain_score': array([0.03504944, 0.05559188, 0.08972377, 0.24845469, 0.18469864,
       0.12315494]), 'DNA_BIND_loss': [906, 909, 924, 933, 937], 'DNA_BIND_gain': [], 'DNA_BIND_loss_score': array([-0.01840746, -0.02001041, -0.02715939, -0.02324593, -0.03262079]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [208, 386], 'STRAND_gain': [406], 'STRAND_gain_score': array([0.00328571]), 'STRAND_loss_score': array([-0.004103  , -0.00472546]), 'HELIX_loss': [47, 178, 646, 677, 745, 746, 747, 867], 'HELIX_gain': [882, 1045, 1063], 'HELIX_gain_score': array([0.04338402, 0.10080653, 0.03715414]), 'HELIX_loss_score': array([-0.00952607, -0.01181757, -0.01516789, -0.02812248, -0.05990088,
       -0.06451142, -0.05259818, -0.09602714]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [174, 175], 'DOMAIN_gain': [1057, 1058], 'DOMAIN_gain_score': array([0.09611189, 0.09031469]), 'DOMAIN_loss_score': array([-0.01633155, -0.01244301]), 'REGION_loss': [34, 41, 47, 48, 52, 53], 'REGION_gain': [], 'REGION_loss_score': array([-0.00426978, -0.00346875, -0.00293094, -0.00367475, -0.00278968,
       -0.00295925]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [903, 904, 905, 907], 'ZN_FING_gain': [], 'ZN_FING_loss_score': array([-0.05878568, -0.0484556 , -0.0647577 , -0.05451435])}"
329	NM_006218.4(PIK3CA):c.2176G>A (p.Glu726Lys)	376476	CA16602910	NM_006218.4:c.2176G>A, NC_000003.12:g.179221146G>A, CM000665.2:g.179221146G>A, NC_000003.11:g.178938934G>A, CM000665.1:g.178938934G>A, NC_000003.10:g.180421628G>A, NG_012113.2:g.77624G>A, LRG_310:g.77624G>A, ENST00000263967.4:c.2176G>A, ENST00000462255.2:n.638G>A, ENST00000643187.1:c.2176G>A, ENST00000674534.1:n.3084G>A, ENST00000674622.1:n.597G>A, ENST00000675467.1:n.4983G>A, ENST00000675786.1:c.*743G>A, ENST00000263967.3:c.2176G>A, ENST00000462255.1:n.450G>A, NM_006218.2:c.2176G>A, LRG_310t1:c.2176G>A, XM_006713658.2:c.2176G>A, XM_011512894.1:c.2176G>A, NM_006218.3:c.2176G>A, XM_006713658.4:c.2176G>A, XM_011512894.2:c.2176G>A, NM_006218.4(PIK3CA):c.2176G>A (p.Glu726Lys)	PIK3CA	overgrowth syndrome and/or cerebral malformations due to abnormalities in MTOR pathway genes	MONDO:0016054	Autosomal dominant inheritance (mosaic)	Pathogenic	PP2, PM2_Supporting, PS4, PS2	PP3, PP1, PP4, BS2, BA1, BP1, BP4, BP2, BP3, PS1, PS3, PM5, PM1, PM3, PM4, BP5, BP7, BS1, BS3, BS4, PVS1, PM6	The c.2176G>A (NM_006218.4) variant in PIK3CA is a missense variant predicted to cause substitution of (p.Glu726Lys).  This variant is absent from gnomAD v2.1.1 (PM2_Supporting). PIK3CA, in which the variant was identified, is defined by the ClinGen Brain Malformations Expert Panel as a gene that has a low rate of benign missense variation and where pathogenic missense variants are a common mechanism of disease (PP2).  The prevalence of the variant in affected individuals is significantly increased compared with the prevalence in controls (PS4_VS; identified in at least 15 individuals with a clinical diagnosis of megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome; (MPPH) or megalencephaly-capillary malformation-polymicrogyria syndrome; (MCAP), it has been shown to significantly increase phosphorylation levels in patient cell lines (PMID: 28566443), and is in at least 15 tumor samples in the literature and COSMIC  (PMID: 22729224, PMID: 28941273, PMID: 24497998 )).  This variant has been confirmed de novo and has been identified with variable allelic fractions consistent with a post-zygotic event (PS2_Strong; PMIDs: 22729224, 22729224).  In summary, this variant meets the criteria to be classified as Pathogenic for mosaic autosomal dominant overgrowth with or without cerebral malformations due to abnormalities in MTOR-pathway genes based on the ACMG/AMP criteria applied, as specified by the ClinGen Brain Malformations Expert Panel: PM2_P, PP2, PS4_VS, PS2; 14 points (VCEP specifications version 1; Approved: 1/31/2021)	28566443, 22729224, 27631024, 28941273, 22729224, 28566443, 22729224	Brain Malformations VCEP	https://clinicalgenome.org/docs/clingen-brain-malformations-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1.1/	2022-02-12	2022-02-12	False	https://erepo.genome.network/evrepo/ui/classification/CA16602910/MONDO:0016054/018	8d9a648c-9ee0-4820-8635-a9b83415906d	p.Glu726Lys	Glu	726	Lys	MPPRPSSGELWGIHLMPPRILVECLLPNGMIVTLECLREATLITIKHELFKEARKYPLHQLLQDESSYIFVSVTQEAEREEFFDETRRLCDLRLFQPFLKVIEPVGNREEKILNREIGFAIGMPVCEFDMVKDPEVQDFRRNILNVCKEAVDLRDLNSPHSRAMYVYPPNVESSPELPKHIYNKLDKGQIIVVIWVIVSPNNDKQKYTLKINHDCVPEQVIAEAIRKKTRSMLLSSEQLKLCVLEYQGKYILKVCGCDEYFLEKYPLSQYKYIRSCIMLGRMPNLMLMAKESLYSQLPMDCFTMPSYSRRISTATPYMNGETSTKSLWVINSALRIKILCATYVNVNIRDIDKIYVRTGIYHGGEPLCDNVNTQRVPCSNPRWNEWLNYDIYIPDLPRAARLCLSICSVKGRKGAKEEHCPLAWGNINLFDYTDTLVSGKMALNLWPVPHGLEDLLNPIGVTGSNPNKETPCLELEFDWFSSVVKFPDMSVIEEHANWSVSREAGFSYSHAGLSNRLARDNELRENDKEQLKAISTRDPLSEITEQEKDFLWSHRHYCVTIPEILPKLLLSVKWNSRDEVAQMYCLVKDWPPIKPEQAMELLDCNYPDPMVRGFAVRCLEKYLTDDKLSQYLIQLVQVLKYEQYLDNLLVRFLLKKALTNQRIGHFFFWHLKSEMHNKTVSQRFGLLLESYCRACGMYLKHLNRQVEAMEKLINLTDILKQEKKDETQKVQMKFLVEQMRRPDFMDALQGFLSPLNPAHQLGNLRLEECRIMSSAKRPLWLNWENPDIMSELLFQNNEIIFKNGDDLRQDMLTLQIIRIMENIWQNQGLDLRMLPYGCLSIGDCVGLIEVVRNSHTIMQIQCKGGLKGALQFNSHTLHQWLKDKNKGEIYDAAIDLFTRSCAGYCVATFILGIGDRHNSNIMVKDDGQLFHIDFGHFLDHKKKKFGYKRERVPFVLTQDFLIVISKGAQECTKTREFERFQEMCYKAYLAIRQHANLFINLFSMMLGSGMPELQSFDDIAYIRKTLALDKTEQEALEYFMKQMNDAHHGGWTTKMDWIFHTIKQHALN	1068	P42336	K	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [725], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.16084397]), 'COILED_loss': [], 'COILED_gain': [722], 'COILED_gain_score': array([0.01709265]), 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
330	NM_006218.4(PIK3CA):c.1173A>G (p.Ile391Met)	135038	CA161490	NM_006218.4:c.1173A>G, NC_000003.12:g.179209622A>G, CM000665.2:g.179209622A>G, NC_000003.11:g.178927410A>G, CM000665.1:g.178927410A>G, NC_000003.10:g.180410104A>G, NG_012113.2:g.66100A>G, LRG_310:g.66100A>G, ENST00000263967.4:c.1173A>G, ENST00000643187.1:c.1173A>G, ENST00000674534.1:n.927A>G, ENST00000675467.1:n.3980A>G, ENST00000675786.1:c.1173A>G, ENST00000263967.3:c.1173A>G, NM_006218.2:c.1173A>G, LRG_310t1:c.1173A>G, XM_006713658.2:c.1173A>G, XM_011512894.1:c.1173A>G, NM_006218.3:c.1173A>G, XM_006713658.4:c.1173A>G, XM_011512894.2:c.1173A>G, NM_006218.4(PIK3CA):c.1173A>G (p.Ile391Met)	PIK3CA	overgrowth syndrome and/or cerebral malformations due to abnormalities in MTOR pathway genes	MONDO:0100283	Autosomal dominant inheritance	Benign	BS2, PP2, BA1, PM1_Supporting		The c.1173A>G (NM_006218.4) variant in PIK3CA is a missense variant predicted to cause substitution of (p.Ile391Met).  This variant resides within the kinase domain of  PIK3CA that is defined as a critical functional domain by the ClinGen BMEP (PMIDs: 26637981, 24459181, 27631024) (PM1_Supporting).  The highest population minor allele frequency in gnomAD v2.1.1 is 0.2113 in African/African American population, which is higher than the ClinGen BMEP threshold ([>=0.00185]) for BA1, and therefore meets this criterion (BA1). This variant was identified the homozygous state in >3 individuals within control databases (BS2). PIK3CA, in which the variant was identified, is defined by the ClinGen Brain Malformations Expert Panel as a gene that has a low rate of benign missense variation and where pathogenic missense variants are a common mechanism of disease (PP2).  In summary, this variant meets the criteria to be classified as Benign for mosaic autosomal dominant overgrowth with or without cerebral malformations due to abnormalities in MTOR-pathway genes based on the ACMG/AMP criteria applied, as specified by the ClinGen Brain Malformations Expert Panel: PM1_P, BA1, BS2, PP2; -10 points (VCEP specifications version 1; Approved: 1/31/2021)		Brain Malformations VCEP	https://clinicalgenome.org/docs/clingen-brain-malformations-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1.1/	2022-02-17	2022-02-17	False	https://erepo.genome.network/evrepo/ui/classification/CA161490/MONDO:0100283/018	b2be4058-24f0-4813-a90c-a8752970cfd2	p.Ile391Met	Ile	391	Met	MPPRPSSGELWGIHLMPPRILVECLLPNGMIVTLECLREATLITIKHELFKEARKYPLHQLLQDESSYIFVSVTQEAEREEFFDETRRLCDLRLFQPFLKVIEPVGNREEKILNREIGFAIGMPVCEFDMVKDPEVQDFRRNILNVCKEAVDLRDLNSPHSRAMYVYPPNVESSPELPKHIYNKLDKGQIIVVIWVIVSPNNDKQKYTLKINHDCVPEQVIAEAIRKKTRSMLLSSEQLKLCVLEYQGKYILKVCGCDEYFLEKYPLSQYKYIRSCIMLGRMPNLMLMAKESLYSQLPMDCFTMPSYSRRISTATPYMNGETSTKSLWVINSALRIKILCATYVNVNIRDIDKIYVRTGIYHGGEPLCDNVNTQRVPCSNPRWNEWLNYDIYIPDLPRAARLCLSICSVKGRKGAKEEHCPLAWGNINLFDYTDTLVSGKMALNLWPVPHGLEDLLNPIGVTGSNPNKETPCLELEFDWFSSVVKFPDMSVIEEHANWSVSREAGFSYSHAGLSNRLARDNELRENDKEQLKAISTRDPLSEITEQEKDFLWSHRHYCVTIPEILPKLLLSVKWNSRDEVAQMYCLVKDWPPIKPEQAMELLDCNYPDPMVRGFAVRCLEKYLTDDKLSQYLIQLVQVLKYEQYLDNLLVRFLLKKALTNQRIGHFFFWHLKSEMHNKTVSQRFGLLLESYCRACGMYLKHLNRQVEAMEKLINLTDILKQEKKDETQKVQMKFLVEQMRRPDFMDALQGFLSPLNPAHQLGNLRLEECRIMSSAKRPLWLNWENPDIMSELLFQNNEIIFKNGDDLRQDMLTLQIIRIMENIWQNQGLDLRMLPYGCLSIGDCVGLIEVVRNSHTIMQIQCKGGLKGALQFNSHTLHQWLKDKNKGEIYDAAIDLFTRSCAGYCVATFILGIGDRHNSNIMVKDDGQLFHIDFGHFLDHKKKKFGYKRERVPFVLTQDFLIVISKGAQECTKTREFERFQEMCYKAYLAIRQHANLFINLFSMMLGSGMPELQSFDDIAYIRKTLALDKTEQEALEYFMKQMNDAHHGGWTTKMDWIFHTIKQHALN	1068	P42336	M	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [911], 'BINDING_gain_score': array([0.00237483]), 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [389], 'STRAND_gain': [406], 'STRAND_gain_score': array([0.01492023]), 'STRAND_loss_score': array([-0.07453918]), 'HELIX_loss': [], 'HELIX_gain': [224], 'HELIX_gain_score': array([0.00411677]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [151, 153, 163, 166, 167, 169, 171], 'DOMAIN_gain_score': array([0.0544492 , 0.05348188, 0.04639292, 0.04317665, 0.04713166,
       0.05091965, 0.04855585]), 'REGION_loss': [], 'REGION_gain': [30, 46, 51, 69, 86], 'REGION_gain_score': array([0.006589  , 0.00744307, 0.0071879 , 0.00735819, 0.00963259]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
331	NM_006218.4(PIK3CA):c.3140A>G (p.His1047Arg)	13652	CA123326	NM_006218.4:c.3140A>G, NC_000003.12:g.179234297A>G, CM000665.2:g.179234297A>G, NC_000003.11:g.178952085A>G, CM000665.1:g.178952085A>G, NC_000003.10:g.180434779A>G, NG_012113.2:g.90775A>G, LRG_310:g.90775A>G, ENST00000263967.4:c.3140A>G, ENST00000462255.2:n.2163A>G, ENST00000643187.1:c.*220A>G, ENST00000674534.1:n.4048A>G, ENST00000674622.1:n.1561A>G, ENST00000675467.1:n.5947A>G, ENST00000675786.1:c.*1707A>G, ENST00000675796.1:n.3035A>G, ENST00000263967.3:c.3140A>G, NM_006218.2:c.3140A>G, LRG_310t1:c.3140A>G, XM_006713658.2:c.3140A>G, XM_011512894.1:c.3140A>G, NM_006218.3:c.3140A>G, XM_006713658.4:c.3140A>G, XM_011512894.2:c.3140A>G, NM_006218.4(PIK3CA):c.3140A>G (p.His1047Arg)	PIK3CA	overgrowth syndrome and/or cerebral malformations due to abnormalities in MTOR pathway genes	MONDO:0016054	Autosomal dominant inheritance (mosaic)	Pathogenic	PP2, PM2_Supporting, PS3_Moderate, PM1_Supporting, PS4, PS2_Moderate	BS2, PP1, PP4, PP3, BP2, BP1, BP4, BP3, BA1, PS1, PM3, PM5, PM4, BP5, BP7, BS1, BS4, BS3, PVS1, PM6	The c.3140A>G (NM_006218.4) variant in PIK3CA is a missense variant predicted to cause substitution of (p.His1047Arg). This variant is present in one individual in gnomAD v2.1.1 (PM2_Supporting).  The prevalence of the variant in affected individuals is significantly increased compared with the prevalence in controls (PS4_VS; PMIDs: 27191687, 28328134, 25292196, 22729222, 25424831, 465 entries in COSMIC, Segmental overgrowth or vascular malformation of a limb or region of the body, present in patient derived cell lines). 60 independent Ba/F3 and 57 independent MCF10A experiments showed this variant has a proliferative effect indicating that this variant impacts protein function (PMID:29533785 ) (PS3_Moderate).  This variant resides within the kinase domain of  PIK3CA that is defined as a critical functional domain by the ClinGen BMEP (PMIDs: 26637981, 24459181, 27631024) (PM1_Supporting).  PIK3CA, in which the variant was identified, is defined by the ClinGen Brain Malformations Expert Panel as a gene that has a low rate of benign missense variation and where pathogenic missense variants are a common mechanism of disease (PP2). Testing of unaffected and affected tissue show variable allelic fractions consistent with a post-zygotic event (PS2_Moderate; PMID: 25424831). In summary, this variant meets the criteria to be classified as Pathogenic for mosaic autosomal dominant overgrowth with or without cerebral malformations due to abnormalities in MTOR-pathway genes based on the ACMG/AMP criteria applied, as specified by the ClinGen Brain Malformations Expert Panel: PM2_P, PS4_VS, PS3_M, PM1_P, PP2, PS2_M; 15 points (VCEP specifications version 1; Approved: 1/31/2021)	22370636, 23066039, 29988677, 29988677, 29988677	Brain Malformations VCEP	https://clinicalgenome.org/docs/clingen-brain-malformations-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1.1/	2022-02-11	2022-02-11	False	https://erepo.genome.network/evrepo/ui/classification/CA123326/MONDO:0016054/018	f4d8f50e-a120-47e5-8b69-0a8921149fde	p.His1047Arg	His	1047	Arg	MPPRPSSGELWGIHLMPPRILVECLLPNGMIVTLECLREATLITIKHELFKEARKYPLHQLLQDESSYIFVSVTQEAEREEFFDETRRLCDLRLFQPFLKVIEPVGNREEKILNREIGFAIGMPVCEFDMVKDPEVQDFRRNILNVCKEAVDLRDLNSPHSRAMYVYPPNVESSPELPKHIYNKLDKGQIIVVIWVIVSPNNDKQKYTLKINHDCVPEQVIAEAIRKKTRSMLLSSEQLKLCVLEYQGKYILKVCGCDEYFLEKYPLSQYKYIRSCIMLGRMPNLMLMAKESLYSQLPMDCFTMPSYSRRISTATPYMNGETSTKSLWVINSALRIKILCATYVNVNIRDIDKIYVRTGIYHGGEPLCDNVNTQRVPCSNPRWNEWLNYDIYIPDLPRAARLCLSICSVKGRKGAKEEHCPLAWGNINLFDYTDTLVSGKMALNLWPVPHGLEDLLNPIGVTGSNPNKETPCLELEFDWFSSVVKFPDMSVIEEHANWSVSREAGFSYSHAGLSNRLARDNELRENDKEQLKAISTRDPLSEITEQEKDFLWSHRHYCVTIPEILPKLLLSVKWNSRDEVAQMYCLVKDWPPIKPEQAMELLDCNYPDPMVRGFAVRCLEKYLTDDKLSQYLIQLVQVLKYEQYLDNLLVRFLLKKALTNQRIGHFFFWHLKSEMHNKTVSQRFGLLLESYCRACGMYLKHLNRQVEAMEKLINLTDILKQEKKDETQKVQMKFLVEQMRRPDFMDALQGFLSPLNPAHQLGNLRLEECRIMSSAKRPLWLNWENPDIMSELLFQNNEIIFKNGDDLRQDMLTLQIIRIMENIWQNQGLDLRMLPYGCLSIGDCVGLIEVVRNSHTIMQIQCKGGLKGALQFNSHTLHQWLKDKNKGEIYDAAIDLFTRSCAGYCVATFILGIGDRHNSNIMVKDDGQLFHIDFGHFLDHKKKKFGYKRERVPFVLTQDFLIVISKGAQECTKTREFERFQEMCYKAYLAIRQHANLFINLFSMMLGSGMPELQSFDDIAYIRKTLALDKTEQEALEYFMKQMNDAHHGGWTTKMDWIFHTIKQHALN	1068	P42336	R	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [918], 'BINDING_gain': [], 'BINDING_loss_score': array([-0.00504249]), 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [1056], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.07667482]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
332	NM_000284.3(PDHA1):c.1132C>T (p.Arg378Cys)	214936	CA323094	NM_000284.3:c.1132C>T, NC_000023.11:g.19359612C>T, CM000685.2:g.19359612C>T, NC_000023.10:g.19377730C>T, CM000685.1:g.19377730C>T, NC_000023.9:g.19287651C>T, NG_016781.1:g.20720C>T, NG_021184.1:g.160650G>A, ENST00000422285.7:c.1132C>T, ENST00000379804.1:c.289C>T, ENST00000379806.9:c.1246C>T, ENST00000422285.6:c.1132C>T, ENST00000478795.1:n.571C>T, ENST00000540249.5:c.1039C>T, ENST00000545074.5:c.1153C>T, NM_001173454.1:c.1246C>T, NM_001173455.1:c.1153C>T, NM_001173456.1:c.1039C>T, XM_011545531.1:c.1267C>T, XM_011545532.1:c.1174C>T, XM_017029574.2:c.1153C>T, NM_000284.4:c.1132C>T, NM_001173454.2:c.1246C>T, NM_001173455.2:c.1153C>T, NM_001173456.2:c.1039C>T, NM_000284.4(PDHA1):c.1132C>T (p.Arg378Cys), NM_000284.3(PDHA1):c.1132C>T (p.Arg378Cys)	PDHA1	pyruvate dehydrogenase deficiency	MONDO:0019169	X-linked inheritance	Pathogenic	PP3, PP4, PM6_Strong, PM2, PM5	PP1, BA1, PS1, PVS1, BS1, PM1, PM4	The c.1132C>T (p.R378C) variant in PDHA1 has been reported in multiples males and females with pyruvate dehydrogenase deficiency and is one of the more common pathogenic variants seen in this cohort (PMID: 22896851). It has been seen in at least three individuals with decreased pyruvate dehydrogenase activity (PP4; Patient 6 in PMID: 8962591; Subject M-7 in PMID: 20002461; Subject 35-2 in PMID: 10679936). This variant has been identified as a de novo occurrence (unconfirmed parental relationships) in at least 4 unrelated individuals with pyruvate dehydrogenase deficiency [PM6_Strong; utilized ClinGen SVI de novo scoring guidance (phenotype consistent but not highly specific); PMID: 10679936, subject 35-2; PMID: 20002461, subject M-7; PMID: 21914562, subject AM8; PMID: 21914562, subject AF22]. Of note, to our knowledge, there are no reports of this variant being inherited from a healthy mother, however it is important to note that not all cases reported in the literature had mothers who were tested. This variant is absent from gnomAD v2.1.1 (PM2). Another missense variant at this position [c.1133G>A, p.R378H] has been reported in at least six other probands (PM5; PMIDs: 8032855 - 1 case, 7887409 - 2 cases, 9409363 - 3 cases) and is a known pathogenic variant. The computational predictor REVEL gives a score of 0.907, which is above the threshold of 0.75, evidence that correlates with impact to PDHA1 function (PP3). In summary, this variant meets criteria to be classified as pathogenic for pyruvate dehydrogenase deficiency inherited in an X-linked manner. This classification was approved by the NICHD U24 Mitochondrial Disease Variant Curation Expert Panel on May 20, 2020. PDHA1-specific ACMG/AMP criteria applied: PM2, PM5, PM6_strong, PP3, PP4.	8962591	Mitochondrial Diseases VCEP	https://www.clinicalgenome.org/affiliation/50027/docs/assertion-criteria	2021-10-25	2021-10-25	False	https://erepo.genome.network/evrepo/ui/classification/CA323094/MONDO:0019169/014	ce28d7f7-3561-4601-9603-7bb8aa198a9e	p.Arg378Cys	Arg	378	Cys	MRKMLAAVSRVLSGASQKPASRVLVASRNFANDATFEIKKCDLHRLEEGPPVTTVLTREDGLKYYRMMQTVRRMELKADQLYKQKIIRGFCHLCDGQEACCVGLEAGINPTDHLITAYRAHGFTFTRGLSVREILAELTGRKGGCAKGKGGSMHMYAKNFYGGNGIVGAQVPLGAGIALACKYNGKDEVCLTLYGDGAANQGQIFEAYNMAALWKLPCIFICENNRYGMGTSVERAAASTDYYKRGDFIPGLRVDGMDILCVREATRFAAAYCRSGKGPILMELQTYRYHGHSMSDPGVSYRTREEIQEVRSKSDPIMLLKDRMVNSNLASVEELKEIDVEVRKEIEDAAQFATADPEPPLEELGYHIYSSDPPFEVRGANQWIKFKSVS	390	P08559	C	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [385], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.08566827]), 'HELIX_loss': [245], 'HELIX_gain': [382], 'HELIX_gain_score': array([0.12918234]), 'HELIX_loss_score': array([-0.00425208]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [84], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.00172967]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
333	NM_000152.5(GAA):c.871C>T (p.Leu291Phe)	956209	CA8815079	NM_000152.5:c.871C>T, NC_000017.11:g.80107812C>T, CM000679.2:g.80107812C>T, NC_000017.10:g.78081611C>T, CM000679.1:g.78081611C>T, NC_000017.9:g.75696206C>T, NG_009822.1:g.11257C>T, LRG_673:g.11257C>T, ENST00000302262.8:c.871C>T, ENST00000302262.7:c.871C>T, ENST00000390015.7:c.871C>T, NM_000152.3:c.871C>T, LRG_673t1:c.871C>T, NM_001079803.1:c.871C>T, NM_001079804.1:c.871C>T, XM_005257193.1:c.871C>T, XM_005257194.3:c.871C>T, NM_000152.4:c.871C>T, NM_001079803.2:c.871C>T, NM_001079804.2:c.871C>T, XM_005257193.2:c.871C>T, XM_005257194.4:c.871C>T, NM_001079803.3:c.871C>T, NM_001079804.3:c.871C>T, NM_000152.5(GAA):c.871C>T (p.Leu291Phe)	GAA	glycogen storage disease II	MONDO:0009290	Autosomal recessive inheritance	Pathogenic	PM3_Strong, PP4_Moderate, PP3, PM2_Supporting, PS3_Moderate, PM5		The NM_000152.5:c.871C>T variant in GAA is a missense variant predicted to cause substitution of leucine by phenylalanine at amino acid 291 (p.Leu291Phe). Five patients with Pompe disease and this variant have been reported, four with characteristics specific for Pompe disease including published laboratory values showing deficient GAA activity and/or on enzyme replacement therapy and/or with documented symptoms consistent with infantile onset Pompe disease (PMID 25526786, 30737479, 31086307, 32849613) (PP4_Moderate). Four of these patients are compound heterozygous for the variant and a pathogenic variant in GAA, phase unknown, including c.716delT (PMID 32849613; 0.5 points), c.1798C>T (p.Arg600Cys)(PMID 26253708; 0.5 points), c.2238G>C (p.Trp746Cys)(PMID 25526786; 0.5 points), and c.2481+102_2646+31del (PMID 31086307; 0.5 points). One patient who is homozygous for the variant, due to uniparental disomy, has also been reported (PMID 30737479; 0.5 points). Total 2.5 points (PM3_Strong). The highest population minor allele frequency in gnomAD v2.1.1 is 0.00006378 in the African population, which is lower than the ClinGen LSD VCEP threshold (<0.001) for PM2_Supporting, meeting this criterion (PM2_Supporting). When expressed in COS cells, this variant had <5% wild type GAA activity and showed evidence of abnormal synthesis and processing on Western blot (PMID 22644586) (PS3_Moderate). The computational predictor REVEL gives a score of 0.701 which is above the threshold of 0.7, evidence that correlates with impact to GAA function (PP3). Two other missense changes, c.872T>C (p.Leu291Pro) and c.872T>A (p.Leu291His), at the same amino acid residue have been reported; c.872T>C (p.Leu291Pro) has been classified as pathogenic based on the specifications of the ClinGen LSD VCEP (CAID: CA401363854)(PM5). The data for this variant, c.871C>T (p.Leu291Phe, will be used in the assessment of p.Leu291His and is not included here to avoid circular logic. There is a ClinVar entry for this variant (Variation ID 956209; 1 star review status) with two submitters classifying the variant as pathogenic. In summary, this variant meets the criteria to be classified as pathogenic for Pompe disease. GAA-specific ACMG/AMP criteria met, as specified by the ClinGen LSD VCEP (Specifications Version 2.0): PM5, PP3, PS3_Moderate, PM3_Strong, PM2_Supporting, PP4_Moderate. (Classification approved by the ClinGen LSD VCEP - Oct. 19, 2021).		Lysosomal Diseases VCEP	https://clinicalgenome.org/docs/clingen-lysosomal-storage-disorders-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-2/	2021-10-26	2021-10-26	False	https://erepo.genome.network/evrepo/ui/classification/CA8815079/MONDO:0009290/010	eba501a5-9784-427b-9832-ea88a774417b	p.Leu291Phe	Leu	291	Phe	MGVRHPPCSHRLLAVCALVSLATAALLGHILLHDFLLVPRELSGSSPVLEETHPAHQQGASRPGPRDAQAHPGRPRAVPTQCDVPPNSRFDCAPDKAITQEQCEARGCCYIPAKQGLQGAQMGQPWCFFPPSYPSYKLENLSSSEMGYTATLTRTTPTFFPKDILTLRLDVMMETENRLHFTIKDPANRRYEVPLETPHVHSRAPSPLYSVEFSEEPFGVIVRRQLDGRVLLNTTVAPLFFADQFLQLSTSLPSQYITGLAEHLSPLMLSTSWTRITLWNRDLAPTPGANLYGSHPFYLALEDGGSAHGVFLLNSNAMDVVLQPSPALSWRSTGGILDVYIFLGPEPKSVVQQYLDVVGYPFMPPYWGLGFHLCRWGYSSTAITRQVVENMTRAHFPLDVQWNDLDYMDSRRDFTFNKDGFRDFPAMVQELHQGGRRYMMIVDPAISSSGPAGSYRPYDEGLRRGVFITNETGQPLIGKVWPGSTAFPDFTNPTALAWWEDMVAEFHDQVPFDGMWIDMNEPSNFIRGSEDGCPNNELENPPYVPGVVGGTLQAATICASSHQFLSTHYNLHNLYGLTEAIASHRALVKARGTRPFVISRSTFAGHGRYAGHWTGDVWSSWEQLASSVPEILQFNLLGVPLVGADVCGFLGNTSEELCVRWTQLGAFYPFMRNHNSLLSLPQEPYSFSEPAQQAMRKALTLRYALLPHLYTLFHQAHVAGETVARPLFLEFPKDSSTWTVDHQLLWGEALLITPVLQAGKAEVTGYFPLGTWYDLQTVPVEALGSLPPPPAAPREPAIHSEGQWVTLPAPLDTINVHLRAGYIIPLQGPGLTTTESRQQPMALAVALTKGGEARGELFWDDGESLEVLERGAYTQVIFLARNNTIVNELVRVTSEGAGLQLQKVTVLGVATAPQQVLSNGVPVSNFTYSPDTKVLDICVSLLMGEQFLVSWC	952	P10253	F	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [429, 658], 'DNA_BIND_gain_score': array([0.00153631, 0.00365776]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
334	NM_000152.4(GAA):c.2238G>C (p.Trp746Cys)	265160	CA8815665	NM_000152.4:c.2238G>C, NC_000017.11:g.80117016G>C, CM000679.2:g.80117016G>C, NC_000017.10:g.78090815G>C, CM000679.1:g.78090815G>C, NC_000017.9:g.75705410G>C, NG_009822.1:g.20461G>C, LRG_673:g.20461G>C, ENST00000302262.8:c.2238G>C, ENST00000302262.7:c.2238G>C, ENST00000390015.7:c.2238G>C, ENST00000572080.1:n.657G>C, ENST00000573556.1:n.191G>C, NM_000152.3:c.2238G>C, LRG_673t1:c.2238G>C, NM_001079803.1:c.2238G>C, NM_001079804.1:c.2238G>C, XM_005257193.1:c.2238G>C, XM_005257194.3:c.2238G>C, NM_001079803.2:c.2238G>C, NM_001079804.2:c.2238G>C, XM_005257193.2:c.2238G>C, XM_005257194.4:c.2238G>C, NM_000152.5:c.2238G>C, NM_001079803.3:c.2238G>C, NM_001079804.3:c.2238G>C, NM_000152.5(GAA):c.2238G>C (p.Trp746Cys), NM_000152.4(GAA):c.2238G>C (p.Trp746Cys)	GAA	glycogen storage disease II	MONDO:0009290	Autosomal recessive inheritance	Pathogenic	PS3_Supporting, PP4_Moderate, PP3, PM3_Very Strong, PM2_Supporting	PM5	The NM_000152.5:c.2238G>C variant in GAA is a missense variant predicted to cause substitution of tryptophan by cysteine at amino acid 746 (p.Trp746Cys). This variant is one of the most commonly reported variants in patients with late onset Pompe disease from East Asia (PMIDs 21757382, 31076647) and has been reported in more than 30 patients with Pompe disease (PMIDs 7981676, 18458862, 21232767, 21757382, 25093132, 25526786, 27099502, 27692865, 28433475, 29095275, 29120458, 30360039, 30897595). Because the variant often occurs in cis with pseudodeficiency variants, a conservative approach was taken when assessing data for PP4 and PM3. When pseudodeficiency variants were present or not confirmed to be absent, GAA deficiency was not used to apply PP4, and allelic data was not used for PM3 unless there was convincing evidence that the patient has Pompe disease in addition to GAA deficiency and molecular results. At least 7 Chinese patients have been reported to have the variant and were confirmed to not carry either of the pseudodeficiency variants that are common in East Asian populations (c.1726G>A (p.Gly576Ser) and c.2065G>A (p.Glu689Lys))(PMID 25526786). The patients all had documented laboratory values showing deficiency of GAA activity (PP4_Moderate). In addition, at least 4 patients with the variant and one or both pseudodeficiency variants were reported to have clinical features consistent with Pompe disease and improvements on enzyme replacement therapy (PMIDs 21232767, 25093132, 30360039). Of these patients, 8 were compound heterozygous for the variant and a GAA variant classified as pathogenic by the ClinGen LSD VCEP, phase unknown, including c.444C>G (p.Tyr148Ter), phase unknown, (PMID 25093132), c.1356delC (note that nomenclature in the paper is c.1355delC), phase unknown, (ClinVar SCV SCV001443295.1), c.1935C>A (p.Asp645Glu)(three patients, one confirmed in trans)(PMIDs 21232767, 25526786), c.2662G>T (p.Glu888Ter)(2 patients, one confirmed in trans)(ClinVar SCV001371767.1 (PMIDs 21232767, 25526786), and c.241C>T (p.Gln81Ter), phase unknown (ClinVar SCV001443296.1)(PMID 25526786)(PM3_Very Strong). The highest population minor allele frequency in gnomAD is 0.00057 (European non-Finnish) which is lower than the ClinGen LSD VCEP threshold (<0.001) for PM2, meeting this criterion (PM2_Supporting). When expressed in cultured cells, this variant has been reported to reduce GAA activity, ranging from 5-29% of the wild type activity (PMIDs 7981676, 21757382, 23430493)(PS3_Supporting). The computational predictor REVEL gives a score of 0.896, which is above the threshold of 0.7, evidence that correlates with impact to GAA function (PP3). Other missense substitutions at this amino acid position reported in patients with Pompe disease include c.2236T>C (p.Trp746Arg), c.2237G>C (p.Trp746Ser), and c.2237G>T (p.Trp746Leu). The classification for p.Trp746Cys will be used in the assessment of these other variants and therefore PM5 is not met here in order to avoid circular logic. There is a ClinVar entry for this variant (Variation ID: 265160; 2 star review status) with 14 submitters classifying the variant as pathogenic and two as likely pathogenic. In summary, this variant meets the criteria to be classified as pathogenic for Pompe disease. GAA-specific ACMG/AMP criteria met, as specified by the ClinGen LSD VCEP (Specifications Version 2.0): PM3_Very Strong, PP3, PP4_Moderate, PS3_Supporting, PM2_Supporting. (Classification approved by the ClinGen LSD VCEP - Oct. 19, 2021).		Lysosomal Diseases VCEP	https://clinicalgenome.org/docs/clingen-lysosomal-storage-disorders-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-2/	2021-10-26	2021-10-27	False	https://erepo.genome.network/evrepo/ui/classification/CA8815665/MONDO:0009290/010	ad2e847c-b962-45a9-9153-2be48be47e3e	p.Trp746Cys	Trp	746	Cys	MGVRHPPCSHRLLAVCALVSLATAALLGHILLHDFLLVPRELSGSSPVLEETHPAHQQGASRPGPRDAQAHPGRPRAVPTQCDVPPNSRFDCAPDKAITQEQCEARGCCYIPAKQGLQGAQMGQPWCFFPPSYPSYKLENLSSSEMGYTATLTRTTPTFFPKDILTLRLDVMMETENRLHFTIKDPANRRYEVPLETPHVHSRAPSPLYSVEFSEEPFGVIVRRQLDGRVLLNTTVAPLFFADQFLQLSTSLPSQYITGLAEHLSPLMLSTSWTRITLWNRDLAPTPGANLYGSHPFYLALEDGGSAHGVFLLNSNAMDVVLQPSPALSWRSTGGILDVYIFLGPEPKSVVQQYLDVVGYPFMPPYWGLGFHLCRWGYSSTAITRQVVENMTRAHFPLDVQWNDLDYMDSRRDFTFNKDGFRDFPAMVQELHQGGRRYMMIVDPAISSSGPAGSYRPYDEGLRRGVFITNETGQPLIGKVWPGSTAFPDFTNPTALAWWEDMVAEFHDQVPFDGMWIDMNEPSNFIRGSEDGCPNNELENPPYVPGVVGGTLQAATICASSHQFLSTHYNLHNLYGLTEAIASHRALVKARGTRPFVISRSTFAGHGRYAGHWTGDVWSSWEQLASSVPEILQFNLLGVPLVGADVCGFLGNTSEELCVRWTQLGAFYPFMRNHNSLLSLPQEPYSFSEPAQQAMRKALTLRYALLPHLYTLFHQAHVAGETVARPLFLEFPKDSSTWTVDHQLLWGEALLITPVLQAGKAEVTGYFPLGTWYDLQTVPVEALGSLPPPPAAPREPAIHSEGQWVTLPAPLDTINVHLRAGYIIPLQGPGLTTTESRQQPMALAVALTKGGEARGELFWDDGESLEVLERGAYTQVIFLARNNTIVNELVRVTSEGAGLQLQKVTVLGVATAPQQVLSNGVPVSNFTYSPDTKVLDICVSLLMGEQFLVSWC	952	P10253	C	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [599], 'BINDING_gain': [], 'BINDING_loss_score': array([-0.01942891]), 'DNA_BIND_loss': [375, 704], 'DNA_BIND_gain': [], 'DNA_BIND_loss_score': array([-0.00143242, -0.00197184]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [22], 'TRANSIT_gain_score': array([0.01543254]), 'STRAND_loss': [], 'STRAND_gain': [806, 884, 885, 913], 'STRAND_gain_score': array([0.00889689, 0.01377207, 0.02055204, 0.00709665]), 'HELIX_loss': [738], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.02648854]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [666], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.00152564]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
335	NM_000545.6(HNF1A):c.391C>T (p.Arg131Trp)	14943	CA124478	NM_000545.6:c.391C>T, NC_000012.12:g.120988897C>T, CM000674.2:g.120988897C>T, NC_000012.11:g.121426700C>T, CM000674.1:g.121426700C>T, NC_000012.10:g.119911083C>T, NG_011731.2:g.15152C>T, LRG_522:g.15152C>T, ENST00000257555.11:c.391C>T, ENST00000257555.10:c.391C>T, ENST00000400024.6:c.391C>T, ENST00000402929.5:n.526C>T, ENST00000535955.5:n.43-8594C>T, ENST00000538626.2:n.191-8594C>T, ENST00000538646.5:c.391C>T, ENST00000540108.1:c.327-4623C>T, ENST00000541395.5:c.391C>T, ENST00000541924.5:c.391C>T, ENST00000543427.5:c.391C>T, ENST00000544413.2:c.391C>T, ENST00000544574.5:c.73-7720C>T, ENST00000560968.5:n.534C>T, ENST00000615446.4:c.-257-7365C>T, ENST00000617366.4:c.391C>T, NM_000545.5:c.391C>T, LRG_522t1:c.391C>T, NM_001306179.1:c.391C>T, XM_005253931.2:c.391C>T, XM_024449168.1:c.391C>T, NM_000545.8:c.391C>T, NM_001306179.2:c.391C>T, NM_000545.8(HNF1A):c.391C>T (p.Arg131Trp), NM_000545.6(HNF1A):c.391C>T (p.Arg131Trp)	HNF1A	monogenic diabetes	MONDO:0015967	Autosomal dominant inheritance	Pathogenic	PS4, PM5, PM1, PP1_Strong, PP3, PM2_Supporting	PP4	The c.391C>T variant in the HNF1 homeobox A gene, HNF1A, causes an amino acid change of arginine to tryptophan at codon 131 (p.(R131W)) of NM_000545.8. This variant resides in an amino acid within the HNF1α DNA binding domain that directly binds DNA, which is defined as critical for the protein’s function by the ClinGen MDEP (PM1). and is predicted to be deleterious by computational evidence, with a REVEL score of 0.903, which is greater than the MDEP threshold of 0.70 (PP3). Another missense variant, c.392G>A (p.Arg131Gln) has been interpreted as pathogenic by the ClinGen MDEP and p.Arg131Trp has an equal or greater Grantham distance. (PM5). This variant is absent from gnomAD v2.1.1 (PM2_Supporting), and was identified in at least 44 unrelated individuals with non-autoimmune and non-absolute/near-absolute insulin-deficient diabetes (PS4; PMID:9166684, PMID:9075818, PMID:22060211, internal lab contributors). However, the MODY probability is unable to be calculated due to lack of clinical information (PMID:9166684, PMID:9075818, PMID:22060211 internal lab contributors). This variant segregated with disease with 11 informative meioses in six families with MODY (PP1_Strong, internal lab contributor). Taken together, this evidence supports the classification of this variant as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP VCEP (specification version 1.0): PP1_Strong, PS4, PM1, PM5, PP3, PM2_Supporting).		Monogenic Diabetes VCEP		2021-08-18	2021-10-29	False	https://erepo.genome.network/evrepo/ui/classification/CA124478/MONDO:0015967/017	fc4594a0-686e-4161-8a58-8284386b1743	p.Arg131Trp	Arg	131	Trp	MVSKLSQLQTELLAALLESGLSKEALIQALGEPGPYLLAGEGPLDKGESCGGGRGELAELPNGLGETRGSEDETDDDGEDFTPPILKELENLSPEEAAHQKAVVETLLQEDPWRVAKMVKSYLQQHNIPQREVVDTTGLNQSHLSQHLNKGTPMKTQKRAALYTWYVRKQREVAQQFTHAGQGGLIEEPTGDELPTKKGRRNRFKWGPASQQILFQAYERQKNPSKEERETLVEECNRAECIQRGVSPSQAQGLGSNLVTEVRVYNWFANRRKEEAFRHKLAMDTYSGPPPGPGPGPALPAHSSPGLPPPALSPSKVHGVRYGQPATSETAEVPSSSGGPLVTVSTPLHQVSPTGLEPSHSLLSTEAKLVSAAGGPLPPVSTLTALHSLEQTSPGLNQQPQNLIMASLPGVMTIGPGEPASLGPTFTNTGASTLVIGLASTQAQSVPVINSMGSSLTTLQPVQFSQPLHPSYQQPLMPPVQSHVTQSPFMATMAQLQSPHALYSHKPEVAQYTHTGLLPQTMLITDTTNLSALASLTPTKQVFTSDTEASSESGLHTPASQATTLHVPSQDPAGIQHLQPAHRLSASPTVSSSSLVLYQSSDSSNGQSHLLPSNHSVIETFISTQMASSSQ	631	P20823	W	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [230], 'DNA_BIND_gain': [], 'DNA_BIND_loss_score': array([-0.04492939]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [98, 99, 100, 101, 102, 103, 104, 105, 107], 'HELIX_gain_score': array([0.07672948, 0.08036679, 0.08784306, 0.10078615, 0.09651577,
       0.09214473, 0.08945352, 0.08905035, 0.09819984]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [77], 'COMPBIAS_gain': [], 'COMPBIAS_loss_score': array([-0.01147366]), 'DOMAIN_loss': [5, 33, 34, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 179, 180, 181], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.07164049, -0.07077163, -0.07512391, -0.28019553, -0.30813313,
       -0.28649908, -0.39392054, -0.36066562, -0.37870938, -0.39514542,
       -0.46709013, -0.36773705, -0.38828164, -0.54356146, -0.3769756 ,
       -0.3451215 , -0.16605538]), 'REGION_loss': [180], 'REGION_gain': [], 'REGION_loss_score': array([-0.0350911]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
336	NM_000545.6(HNF1A):c.392G>A (p.Arg131Gln)	562373	CA6831746	NM_000545.6(HNF1A):c.392G>A, NM_000545.6:c.392G>A, NC_000012.12:g.120988898G>A, CM000674.2:g.120988898G>A, NC_000012.11:g.121426701G>A, CM000674.1:g.121426701G>A, NC_000012.10:g.119911084G>A, NG_011731.2:g.15153G>A, LRG_522:g.15153G>A, ENST00000257555.11:c.392G>A, ENST00000257555.10:c.392G>A, ENST00000400024.6:c.392G>A, ENST00000402929.5:n.527G>A, ENST00000535955.5:n.43-8593G>A, ENST00000538626.2:n.191-8593G>A, ENST00000538646.5:c.392G>A, ENST00000540108.1:c.327-4622G>A, ENST00000541395.5:c.392G>A, ENST00000541924.5:c.392G>A, ENST00000543427.5:c.392G>A, ENST00000544413.2:c.392G>A, ENST00000544574.5:c.73-7719G>A, ENST00000560968.5:n.535G>A, ENST00000615446.4:c.-257-7364G>A, ENST00000617366.4:c.392G>A, NM_000545.5:c.392G>A, LRG_522t1:c.392G>A, NM_001306179.1:c.392G>A, XM_005253931.2:c.392G>A, XM_024449168.1:c.392G>A, NM_000545.8:c.392G>A, NM_001306179.2:c.392G>A, NM_000545.8(HNF1A):c.392G>A (p.Arg131Gln), NM_000545.6(HNF1A):c.392G>A (p.Arg131Gln)	HNF1A	monogenic diabetes	MONDO:0015967	Autosomal dominant inheritance	Pathogenic	PS4, PS2, PM1, PP1_Strong, PS3_Supporting, PP4_Moderate, PP3, PM2_Supporting		The c.392G>A variant in the HNF1 homeobox A gene, HNF1A, causes an amino acid change of arginine to glutamine at codon 131 (p.(R131Q)) of NM_000545.8. This variant has a minor allele frequency of 0.000008795 in the gnomAD v2.1.1 European non-Finnish population and no copies in another subpopulation, which is less than the ClinGen MDEP threshold for PM2_Supporting (≤0.00002 and ≤1 copy in any other subpopulation) (PM2_Supporting). This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.985, which is greater than the MDEP threshold of 0.70 (PP3), which is supported by functional studies that demonstrated the p.Arg131Gln protein has abnormal nuclear localization and transactivation below 40% of wildtype (PMID: 32910913 and PMID: 10585442) (PS3_Supporting). This variant resides in an amino acid within the HNF1α DNA binding domain that directly binds DNA, which is defined as critical for the protein’s function by the ClinGen MDEP (PM1). This variant was identified in at least 40 unrelated individuals with non- autoimmune and non-absolute/near-absolute insulin-deficient diabetes (PS4; PMID:9287053, PMID:10447526, PMID:894547, PMID:9032114, PMID:1115175, PMID:11315851, PMID:12442290, PMID:162495, PMID:19754856, PMID:2095039, ClinVar ID: 562373, internal lab contributors). This variant segregated with diabetes, with at least 20 informative meioses in 6 families with MODY (PP1_Strong; PMID:10447526, PMID:894547, PMID:9032114, PMID:11315851, internal lab contributors). This variant was identified as a de novo occurrence with confirmed parental relationships in 2 individuals with diabetes, but whose clinical picture is not highly specific for HNF1A-MODY (MODY probability calculator results <50%)(PS2; PMID:24323243). Additionally, at least 2 individuals have a clinical history highly specific for HNF1A-MODY (MODY probability calculator result >50%, negative genetic testing for HNF4A, and sulfonylurea sensitive) (PP4_Moderate; internal lab contributors). Taken together, this evidence supports the classification of this variant as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP VCEP: PP1_Strong, PS2, PS4, PP4_Moderate, PM1, PP3, PM2_Supporting, PS3_Supporting.		Monogenic Diabetes VCEP		2021-08-11	2021-10-29	False	https://erepo.genome.network/evrepo/ui/classification/CA6831746/MONDO:0015967/017	650e4d16-b761-4c10-ac4d-479b2c98013e	p.Arg131Gln	Arg	131	Gln	MVSKLSQLQTELLAALLESGLSKEALIQALGEPGPYLLAGEGPLDKGESCGGGRGELAELPNGLGETRGSEDETDDDGEDFTPPILKELENLSPEEAAHQKAVVETLLQEDPWRVAKMVKSYLQQHNIPQREVVDTTGLNQSHLSQHLNKGTPMKTQKRAALYTWYVRKQREVAQQFTHAGQGGLIEEPTGDELPTKKGRRNRFKWGPASQQILFQAYERQKNPSKEERETLVEECNRAECIQRGVSPSQAQGLGSNLVTEVRVYNWFANRRKEEAFRHKLAMDTYSGPPPGPGPGPALPAHSSPGLPPPALSPSKVHGVRYGQPATSETAEVPSSSGGPLVTVSTPLHQVSPTGLEPSHSLLSTEAKLVSAAGGPLPPVSTLTALHSLEQTSPGLNQQPQNLIMASLPGVMTIGPGEPASLGPTFTNTGASTLVIGLASTQAQSVPVINSMGSSLTTLQPVQFSQPLHPSYQQPLMPPVQSHVTQSPFMATMAQLQSPHALYSHKPEVAQYTHTGLLPQTMLITDTTNLSALASLTPTKQVFTSDTEASSESGLHTPASQATTLHVPSQDPAGIQHLQPAHRLSASPTVSSSSLVLYQSSDSSNGQSHLLPSNHSVIETFISTQMASSSQ	631	P20823	Q	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [222, 227, 229], 'DNA_BIND_gain_score': array([0.04350972, 0.05125225, 0.03737867]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [102, 103, 104, 105], 'HELIX_gain_score': array([0.03871286, 0.04203832, 0.04768515, 0.04638046]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [77], 'COMPBIAS_gain': [], 'COMPBIAS_loss_score': array([-0.00776905]), 'DOMAIN_loss': [5, 81, 82, 83], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.02543044, -0.10880733, -0.11339164, -0.10767543]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
337	NM_004360.5(CDH1):c.1223C>T (p.Ala408Val)	127908	CA288022	NM_004360.5:c.1223C>T, NC_000016.10:g.68813398C>T, CM000678.2:g.68813398C>T, NC_000016.9:g.68847301C>T, CM000678.1:g.68847301C>T, NC_000016.8:g.67404802C>T, NG_008021.1:g.81107C>T, LRG_301:g.81107C>T, ENST00000261769.10:c.1223C>T, ENST00000261769.9:c.1223C>T, ENST00000422392.6:c.1137+1135C>T, ENST00000562836.5:n.1294C>T, ENST00000565810.1:n.267C>T, ENST00000566510.5:c.1067C>T, ENST00000566612.5:c.1223C>T, ENST00000611625.4:c.1223C>T, ENST00000612417.4:c.1223C>T, ENST00000621016.4:c.1223C>T, NM_004360.3:c.1223C>T, LRG_301t1:c.1223C>T, XM_011523488.1:c.488C>T, XM_011523489.1:c.488C>T, NM_001317184.1:c.1137+1135C>T, NM_001317185.1:c.-393C>T, NM_001317186.1:c.-597C>T, NM_004360.4:c.1223C>T, NM_001317184.2:c.1137+1135C>T, NM_001317185.2:c.-393C>T, NM_001317186.2:c.-597C>T, NM_004360.5(CDH1):c.1223C>T (p.Ala408Val)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Benign	BS2, BS1	PP2, PP3, PP4, PP1, PS1, PS4, PS3, PS2, BP1, BP4, BP2, BP3, BA1, PM1, PM3, PM4, PM5, PVS1, PM2, PM6, BP5, BP7, BS3, BS4	The c.1223C>T (p.Ala408Val) missense variant has a frequency of 0.114% (>0.1%) in South Asians (35 of 30616 alleles) in the gnomAD v2.1.1 cohort (BS1). This variant has been observed in ≥10 (122) individuals without DGC, SRC tumours or LBC and whose families do not suggest HDGC (BS2; SCV000260430.7, SCV000186167.6). In summary, the clinical significance of this variant is classified as of benign based the ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): BS1, BS2.		CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-10	2023-08-10	False	https://erepo.genome.network/evrepo/ui/classification/CA288022/MONDO:0007648/007	de121013-db34-4461-8027-65ef657a9e2a	p.Ala408Val	Ala	408	Val	MGPWSRSLSALLLLLQVSSWLCQEPEPCHPGFDAESYTFTVPRRHLERGRVLGRVNFEDCTGRQRTAYFSLDTRFKVGTDGVITVKRPLRFHNPQIHFLVYAWDSTYRKFSTKVTLNTVGHHHRPPPHQASVSGIQAELLTFPNSSPGLRRQKRDWVIPPISCPENEKGPFPKNLVQIKSNKDKEGKVFYSITGQGADTPPVGVFIIERETGWLKVTEPLDRERIATYTLFSHAVSSNGNAVEDPMEILITVTDQNDNKPEFTQEVFKGSVMEGALPGTSVMEVTATDADDDVNTYNAAIAYTILSQDPELPDKNMFTINRNTGVISVVTTGLDRESFPTYTLVVQAADLQGEGLSTTATAVITVTDTNDNPPIFNPTTYKGQVPENEANVVITTLKVTDADAPNTPAWEAVYTILNDDGGQFVVTTNPVNNDGILKTAKGLDFEAKQQYILHVAVTNVVPFEVSLTTSTATVTVDVLDVNEAPIFVPPEKRVEVSEDFGVGQEITSYTAQEPDTFMEQKITYRIWRDTANWLEINPDTGAISTRAELDREDFEHVKNSTYTALIIATDNGSPVATGTGTLLLILSDVNDNAPIPEPRTIFFCERNPKPQVINIIDADLPPNTSPFTAELTHGASANWTIQYNDPTQESIILKPKMALEVGDYKINLKLMDNQNKDQVTTLEVSVCDCEGAAGVCRKAQPVEAGLQIPAILGILGGILALLILILLLLLFLRRRAVVKEPLLPPEDDTRDNVYYYDEEGGGEEDQDFDLSQLHRGLDARPEVTRNDVAPTLMSVPRYLPRPANPDEIGNFIDENLKAADTDPTAPPYDSLLVFDYEGSGSEAASLSSLNSSESDKDQDYDYLNEWGNRFKKLADMYGGGEDD	882	P12830	V	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [5], 'TRANSIT_gain': [], 'TRANSIT_loss_score': array([-0.00210959]), 'STRAND_loss': [503], 'STRAND_gain': [678], 'STRAND_gain_score': array([0.00440443]), 'STRAND_loss_score': array([-0.00022942]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
338	NM_004360.5(CDH1):c.808T>G (p.Ser270Ala)	142011	CA294235	NM_004360.5:c.808T>G, NC_000016.10:g.68810317T>G, CM000678.2:g.68810317T>G, NC_000016.9:g.68844220T>G, CM000678.1:g.68844220T>G, NC_000016.8:g.67401721T>G, NG_008021.1:g.78026T>G, LRG_301:g.78026T>G, ENST00000261769.10:c.808T>G, ENST00000261769.9:c.808T>G, ENST00000422392.6:c.808T>G, ENST00000561751.1:n.455-1367T>G, ENST00000562836.5:n.879T>G, ENST00000566510.5:c.652T>G, ENST00000566612.5:c.808T>G, ENST00000611625.4:c.808T>G, ENST00000612417.4:c.808T>G, ENST00000621016.4:c.808T>G, NM_004360.3:c.808T>G, LRG_301t1:c.808T>G, XM_011523488.1:c.73T>G, XM_011523489.1:c.73T>G, NM_001317184.1:c.808T>G, NM_001317185.1:c.-808T>G, NM_001317186.1:c.-1012T>G, NM_004360.4:c.808T>G, NM_001317184.2:c.808T>G, NM_001317185.2:c.-808T>G, NM_001317186.2:c.-1012T>G, NM_004360.5(CDH1):c.808T>G (p.Ser270Ala)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0007648	Autosomal dominant inheritance	Benign	BS2, BA1	PP2, PP3, PP4, PP1, PS1, PS4, PS3, PS2, BP1, BP4, BP2, BP3, PM1, PM3, PM4, PM5, PM2, PM6, PVS1, BP5, BP7, BS1, BS3, BS4	The c.808T>G (p.Ser270Ala) variant has a maximum subpopulation frequency of 0.002269 (0.2269%, 57 of 25124 alleles) in the European (Finnish) subpopulation of the gnomAD v2.1.1 cohort (BA1). This variant has also has been observed in more than 10 individuals without a diagnosis of diffuse gastric cancer, signet ring tumor or lobular breast cancer and whose family histories do not suggest HDGC (BS2; SCV000185687.6, SCV000254832.8). In summary, this variant meets criteria to be classified as benign based the ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): BA1, BS2.	27582386, 27582386	CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-17	2023-08-17	False	https://erepo.genome.network/evrepo/ui/classification/CA294235/MONDO:0007648/007	f736f74f-a045-4573-aa21-41c5dfa9dd12	p.Ser270Ala	Ser	270	Ala	MGPWSRSLSALLLLLQVSSWLCQEPEPCHPGFDAESYTFTVPRRHLERGRVLGRVNFEDCTGRQRTAYFSLDTRFKVGTDGVITVKRPLRFHNPQIHFLVYAWDSTYRKFSTKVTLNTVGHHHRPPPHQASVSGIQAELLTFPNSSPGLRRQKRDWVIPPISCPENEKGPFPKNLVQIKSNKDKEGKVFYSITGQGADTPPVGVFIIERETGWLKVTEPLDRERIATYTLFSHAVSSNGNAVEDPMEILITVTDQNDNKPEFTQEVFKGSVMEGALPGTSVMEVTATDADDDVNTYNAAIAYTILSQDPELPDKNMFTINRNTGVISVVTTGLDRESFPTYTLVVQAADLQGEGLSTTATAVITVTDTNDNPPIFNPTTYKGQVPENEANVVITTLKVTDADAPNTPAWEAVYTILNDDGGQFVVTTNPVNNDGILKTAKGLDFEAKQQYILHVAVTNVVPFEVSLTTSTATVTVDVLDVNEAPIFVPPEKRVEVSEDFGVGQEITSYTAQEPDTFMEQKITYRIWRDTANWLEINPDTGAISTRAELDREDFEHVKNSTYTALIIATDNGSPVATGTGTLLLILSDVNDNAPIPEPRTIFFCERNPKPQVINIIDADLPPNTSPFTAELTHGASANWTIQYNDPTQESIILKPKMALEVGDYKINLKLMDNQNKDQVTTLEVSVCDCEGAAGVCRKAQPVEAGLQIPAILGILGGILALLILILLLLLFLRRRAVVKEPLLPPEDDTRDNVYYYDEEGGGEEDQDFDLSQLHRGLDARPEVTRNDVAPTLMSVPRYLPRPANPDEIGNFIDENLKAADTDPTAPPYDSLLVFDYEGSGSEAASLSSLNSSESDKDQDYDYLNEWGNRFKKLADMYGGGEDD	882	P12830	A	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [270], 'STRAND_gain': [175, 678], 'STRAND_gain_score': array([0.00183874, 0.00321448]), 'STRAND_loss_score': array([-0.05912817]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
339	NM_000152.5(GAA):c.1798C>T (p.Arg600Cys)	640911	CA8815481	NM_000152.5:c.1798C>T, NC_000017.11:g.80112621C>T, CM000679.2:g.80112621C>T, NC_000017.10:g.78086420C>T, CM000679.1:g.78086420C>T, NC_000017.9:g.75701015C>T, NG_009822.1:g.16066C>T, LRG_673:g.16066C>T, ENST00000302262.8:c.1798C>T, ENST00000302262.7:c.1798C>T, ENST00000390015.7:c.1798C>T, ENST00000570716.1:n.238C>T, ENST00000572080.1:n.186C>T, ENST00000572803.1:n.412C>T, NM_000152.3:c.1798C>T, LRG_673t1:c.1798C>T, NM_001079803.1:c.1798C>T, NM_001079804.1:c.1798C>T, XM_005257193.1:c.1798C>T, XM_005257194.3:c.1798C>T, NM_000152.4:c.1798C>T, NM_001079803.2:c.1798C>T, NM_001079804.2:c.1798C>T, XM_005257193.2:c.1798C>T, XM_005257194.4:c.1798C>T, NM_001079803.3:c.1798C>T, NM_001079804.3:c.1798C>T, NM_000152.5(GAA):c.1798C>T (p.Arg600Cys)	GAA	glycogen storage disease II	MONDO:0009290	Autosomal recessive inheritance	Pathogenic	PM3_Strong, PP4_Moderate, PP3, PM2_Supporting, PS3_Moderate, PM1, PM5	BA1	The NM_000152.5:c.1798C>T variant in GAA is a missense variant predicted to cause substitution of arginine by cysteine at amino acid 600 (p.Arg600Cys). At least 15 patients with Pompe disease have been reported with this variant. Of these patients, at least 8 have documented laboratory values showing GAA deficiency, some of whom also have documentation of symptoms consistent with infantile onset Pompe disease, and/or on enzyme replacement therapy, meeting the ClinGen LSD VCEP’s specifications for PP4_Moderate (PMID 14695532, 18458862, 19609281, 21984055, 24384324, 26497565, 29124014) (PP4_Moderate). Additional patients were reported to be on enzyme replacement therapy, without GAA activity values provided, meeting PP4 (PMID 20202878), and others were reported to have Pompe disease but did not have sufficient data for PP4 to be applied (PMID 11053688, 14643388, 26253708, 27417441, 29124014). The patients with Pompe disease and this variant include three patients who are compound heterozygous for the variant and a pathogenic variant in GAA, either c.525delT (PMID 14695532; phase unknown), or c.546G>T (PMID 20202878, 21984055; phase unknown in both cases), and one homozygote (PMID 11053688)(PM3_Strong). The variant was also reported to be in cis with c.199G>A (p.Asp67Asn) and in trans with c.546G>T in one patient; this data was not counted for PM3 due to the presence of the in cis variant, which is rare and has not yet been assessed by the LSD VCEP (PMID 19609281). In addition, the variant was found in compound heterozygosity with the following variants; the allelic data for the following patients will be used in the assessment of the second variant and is not included here to avoid circular logic - c.871C>T (p.Leu291Phe)(PMID 26253708, 27417441), c.872T>C (p.Leu291Pro)(PMID 18458862), c.1211A>G (p.Asp404Gly)(PMID 24384324), c.1309C>T (p.Arg437Cys)(PMID 29124014), c.1316T>A (p.Met439Lys)(PMID 20202878), c.1857C>G (p.Ser619Arg)(PMID 29124014), c.1979G>A (p.Arg660His)(PMID 14643388), c.2105G>T (p.Arg702Leu)(PMID 26497565), c.2481+1G>A (PMID 29124014). The highest population minor allele frequency in gnomAD v2.1.1 is 0.00003 in the South Asian population, which is lower than the ClinGen LSD VCEP’s threshold for PM2_Supporting (<0.001), meeting this criterion (PM2_Supporting). This variant alters an amino acid, Arg600, that has been deduced to be important in the active site architecture of GAA, based on the crystal structure of native and recombinant GAA (PMID: 29061980; DOI 10.1101/212837)(PM1). Indeed, when expressed in either COS cells or GAA-deficient SV40 immortalized fibroblasts, the variant had <1% wild type GAA activity, and Western blot showed abnormal synthesis and processing of the enzyme (PMID 11053688, 14695532) (PS3_Moderate). The computational predictor REVEL gives a score of 0.915 which is above the threshold of 0.7, evidence that correlates with impact to GAA function (PP3). Three additional missense changes in the same codon have been reported in patients with Pompe disease; c.1799G>A (p.Arg600His) is pathogenic based on assessment by the ClinGen LSD VCEP (PM5); c.1799G>C (p.Arg600Pro) and c.1799G>T (p.Arg600Leu) have also been reported. There is a ClinVar entry for this variant (Variant ID 640911; 2 star review status) with three submitters classifying the variant as pathogenic. In summary, this variant meets the criteria to be classified as pathogenic for Pompe disease. GAA-specific ACMG/AMP criteria met, as specified by the ClinGen LSD VCEP (Specifications Version 2.0): PM1, PM5, PP3, PS3_Moderate, PM3_Strong, PM2_Supporting, PP4_Moderate.		Lysosomal Diseases VCEP	https://clinicalgenome.org/docs/clingen-lysosomal-storage-disorders-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-2/	2021-09-30	2021-12-02	False	https://erepo.genome.network/evrepo/ui/classification/CA8815481/MONDO:0009290/010	c36e7ac5-eb57-42af-9970-5ed94590f028	p.Arg600Cys	Arg	600	Cys	MGVRHPPCSHRLLAVCALVSLATAALLGHILLHDFLLVPRELSGSSPVLEETHPAHQQGASRPGPRDAQAHPGRPRAVPTQCDVPPNSRFDCAPDKAITQEQCEARGCCYIPAKQGLQGAQMGQPWCFFPPSYPSYKLENLSSSEMGYTATLTRTTPTFFPKDILTLRLDVMMETENRLHFTIKDPANRRYEVPLETPHVHSRAPSPLYSVEFSEEPFGVIVRRQLDGRVLLNTTVAPLFFADQFLQLSTSLPSQYITGLAEHLSPLMLSTSWTRITLWNRDLAPTPGANLYGSHPFYLALEDGGSAHGVFLLNSNAMDVVLQPSPALSWRSTGGILDVYIFLGPEPKSVVQQYLDVVGYPFMPPYWGLGFHLCRWGYSSTAITRQVVENMTRAHFPLDVQWNDLDYMDSRRDFTFNKDGFRDFPAMVQELHQGGRRYMMIVDPAISSSGPAGSYRPYDEGLRRGVFITNETGQPLIGKVWPGSTAFPDFTNPTALAWWEDMVAEFHDQVPFDGMWIDMNEPSNFIRGSEDGCPNNELENPPYVPGVVGGTLQAATICASSHQFLSTHYNLHNLYGLTEAIASHRALVKARGTRPFVISRSTFAGHGRYAGHWTGDVWSSWEQLASSVPEILQFNLLGVPLVGADVCGFLGNTSEELCVRWTQLGAFYPFMRNHNSLLSLPQEPYSFSEPAQQAMRKALTLRYALLPHLYTLFHQAHVAGETVARPLFLEFPKDSSTWTVDHQLLWGEALLITPVLQAGKAEVTGYFPLGTWYDLQTVPVEALGSLPPPPAAPREPAIHSEGQWVTLPAPLDTINVHLRAGYIIPLQGPGLTTTESRQQPMALAVALTKGGEARGELFWDDGESLEVLERGAYTQVIFLARNNTIVNELVRVTSEGAGLQLQKVTVLGVATAPQQVLSNGVPVSNFTYSPDTKVLDICVSLLMGEQFLVSWC	952	P10253	C	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [599], 'BINDING_gain': [], 'BINDING_loss_score': array([-0.48051989]), 'DNA_BIND_loss': [588, 614, 704], 'DNA_BIND_gain': [423, 601, 611, 612, 658, 707], 'DNA_BIND_gain_score': array([0.00442058, 0.01069981, 0.00148559, 0.01258302, 0.00813466,
       0.00071985]), 'DNA_BIND_loss_score': array([-0.01744616, -0.00771862, -0.00160468]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [468], 'STRAND_gain': [259, 595, 806, 884, 885], 'STRAND_gain_score': array([0.00409371, 0.09908694, 0.00683534, 0.00945526, 0.01291049]), 'STRAND_loss_score': array([-0.009431]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [584, 710], 'REPEAT_gain': [598, 643], 'REPEAT_gain_score': array([0.02512956, 0.0024938 ]), 'REPEAT_loss_score': array([-0.03064907, -0.00572491]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
340	NM_000545.6(HNF1A):c.92G>A (p.Gly31Asp)	14948	CA124487	NM_000545.6:c.92G>A, NC_000012.12:g.120978860G>A, CM000674.2:g.120978860G>A, NC_000012.11:g.121416663G>A, CM000674.1:g.121416663G>A, NC_000012.10:g.119901046G>A, NG_011731.2:g.5115G>A, LRG_522:g.5115G>A, ENST00000257555.11:c.92G>A, ENST00000257555.10:c.92G>A, ENST00000400024.6:c.92G>A, ENST00000402929.5:n.227G>A, ENST00000535955.5:n.42+168G>A, ENST00000538626.2:n.190+20G>A, ENST00000538646.5:c.92G>A, ENST00000540108.1:c.92G>A, ENST00000541395.5:c.92G>A, ENST00000541924.5:c.92G>A, ENST00000543427.5:c.92G>A, ENST00000544413.2:c.92G>A, ENST00000544574.5:c.72+20G>A, ENST00000560968.5:n.235G>A, ENST00000615446.4:c.-258+149G>A, ENST00000617366.4:c.92G>A, NM_000545.5:c.92G>A, LRG_522t1:c.92G>A, NM_001306179.1:c.92G>A, XM_005253931.2:c.92G>A, XM_024449168.1:c.92G>A, NM_000545.8:c.92G>A, NM_001306179.2:c.92G>A, NM_000545.8(HNF1A):c.92G>A (p.Gly31Asp), NM_000545.6(HNF1A):c.92G>A (p.Gly31Asp)	HNF1A	monogenic diabetes	MONDO:0015967	Autosomal dominant inheritance	Benign	PM1_Supporting, BA1, BS3_Supporting	PS4, PP3, PP4	The c.92G>A variant in the HNF1 homeobox A gene, HNF1A, causes an amino acid change of glycine to aspartic acid at codon 31 (p.(Gly31Asp)) of NM_000545.8. This variant is located within the dimerization domain (codons 1-32) of HNF1A, which is defined as critical for the protein’s function by the ClinGen MDEP (PM1_Supporting). While it has been noted to be a pathogenic variant in the literature, there are numerous pieces of evidence that refute this classification. Functional studies demonstrated the p.Gly31Asp protein has DNA binding above 75% of wild type, indicating that this variant does not impact protein function (PMID: 32910913) (BS3_Supporting). This variant has a REVEL score of 0.591, which is between the ClinGen MDEP thresholds predicting neither a damaging nor benign impact on HNF1A function. The variant has a Popmax Filtering allele frequency in gnomAD 2.1.1 of 0.000772 (0.0772%), which is greater than the MDEP threshold for BA1 (≥0.0001) (BA1). It has been was identified in >30 unrelated individuals with diabetes; however, PS4 cannot be applied because the variant MAF in gnomAD is above the ClinGen MDEP PM2_Supporting cutoff (PMID: 31365591, 31638168, 19169489, 26431509, 28395978, 20950394, 26059258, 19929997, 22432108, 27899486, 23551881, 24041679, 16917892, 21696527, and others). In summary, c.92G>A meets the criteria to be classified as benign for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.1, approved 6/4/2021): BA1, BS3_Supporting, PM1_Supporting.		Monogenic Diabetes VCEP		2021-12-15	2022-07-11	False	https://erepo.genome.network/evrepo/ui/classification/CA124487/MONDO:0015967/017	90aedfd1-3bfc-4e66-9183-7fa83800e4df	p.Gly31Asp	Gly	31	Asp	MVSKLSQLQTELLAALLESGLSKEALIQALGEPGPYLLAGEGPLDKGESCGGGRGELAELPNGLGETRGSEDETDDDGEDFTPPILKELENLSPEEAAHQKAVVETLLQEDPWRVAKMVKSYLQQHNIPQREVVDTTGLNQSHLSQHLNKGTPMKTQKRAALYTWYVRKQREVAQQFTHAGQGGLIEEPTGDELPTKKGRRNRFKWGPASQQILFQAYERQKNPSKEERETLVEECNRAECIQRGVSPSQAQGLGSNLVTEVRVYNWFANRRKEEAFRHKLAMDTYSGPPPGPGPGPALPAHSSPGLPPPALSPSKVHGVRYGQPATSETAEVPSSSGGPLVTVSTPLHQVSPTGLEPSHSLLSTEAKLVSAAGGPLPPVSTLTALHSLEQTSPGLNQQPQNLIMASLPGVMTIGPGEPASLGPTFTNTGASTLVIGLASTQAQSVPVINSMGSSLTTLQPVQFSQPLHPSYQQPLMPPVQSHVTQSPFMATMAQLQSPHALYSHKPEVAQYTHTGLLPQTMLITDTTNLSALASLTPTKQVFTSDTEASSESGLHTPASQATTLHVPSQDPAGIQHLQPAHRLSASPTVSSSSLVLYQSSDSSNGQSHLLPSNHSVIETFISTQMASSSQ	631	P20823	D	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [4, 6, 35, 36], 'DOMAIN_gain_score': array([0.13358498, 0.13663805, 0.09480006, 0.10472518]), 'REGION_loss': [], 'REGION_gain': [37, 38], 'REGION_gain_score': array([0.15514547, 0.15839165]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
341	NM_000540.2(RYR1):c.14210G>A (p.Arg4737Gln)	133061	-	NM_000540.2:c.14210G>A, NM_000540.3(RYR1):c.14210G>A (p.Arg4737Gln), NM_000540.2(RYR1):c.14210G>A (p.Arg4737Gln)	RYR1	malignant hyperthermia of anesthesia	MONDO:0018493	Autosomal dominant inheritance	Pathogenic	PS4, PM1_Supporting, PS3_Moderate, BS2_Supporting, PP1_Strong, PP3_Moderate		This pathogenicity assessment is relevant only for malignant hyperthermia susceptibility (MHS) inherited in an autosomal dominant pattern. Variants in RYR1 can also cause other myopathies inherited in an autosomal dominant pattern or in an autosomal recessive pattern. Some of these disorders may predispose individuals to malignant hyperthermia. RYR1 variants may also contribute to a malignant hyperthermia reaction in combination with other genetic and non-genetic factors and the clinician needs to consider such factors in making management decisions.This sequence variant predicts a substitution of arginine with glutamine at codon 4737 of the RYR1 protein, p.(Arg4737Gln). The maximum allele frequency for this variant among the six major gnomAD populations is NFE: 0.000009, a frequency consistent with pathogenicity for MHS. This variant has been reported in 14 unrelated individuals who have a personal or family history of a malignant hyperthermia reaction, all of these individuals had a positive in vitro contracture test (IVCT) or caffeine halothane contracture test (CHCT) result (if the proband was unavailable for testing, a positive diagnostic test result in a mutation-positive relative was counted), PS4 (PMID:30236257, PMID:16163667, PMID:18564801, PMID:24433488, NZ MH investigation unit, MH Investigation Unit (MHIU), UHN, Toronto). This variant segregates with MHS in >6 meioses, PP1_Strong, (PMID:30236257 , PMID:18564801, MH Investigation Unit (MHIU), UHN, Toronto). However, in a different family two genotype positive/phenotype negative (IVCT-) individuals were identified, BS2_Moderate. Functional studies in HEK293 cells show an increased sensitivity to RYR1 agonists, PS3_Moderate, (PMID:36208971). This variant resides in a region of RYR1 considered to be a hotspot for pathogenic variants that contribute to MHS, PM1_Supporting (PMID: 21118704). A REVEL score >0.85 (0.89) supports a pathogenic status for this variant, PP3_Moderate. Based on using Bayes to combine criteria this variant is assessed as Pathogenic, (PMID: 29300386). Criteria implemented: PS3_Moderate, PS4, PM1_Supporting, PP1_Strong, PP3_Moderate, BS2_Moderate.		Malignant Hyperthermia Susceptibility VCEP	https://clinicalgenome.org/docs/clingen-malignant-hyperthermia-susceptibility-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-for/	2023-05-20	2023-05-20	False	https://erepo.genome.network/evrepo/ui/classification/CV133061/MONDO:0018493/012	48f6f132-4979-4c5c-a072-974c09b7dff8	p.Arg4737Gln	Arg	4737	Gln	MGDAEGEDEVQFLRTDDEVVLQCSATVLKEQLKLCLAAEGFGNRLCFLEPTSNAQNVPPDLAICCFVLEQSLSVRALQEMLANTVEAGVESSQGGGHRTLLYGHAILLRHAHSRMYLSCLTTSRSMTDKLAFDVGLQEDATGEACWWTMHPASKQRSEGEKVRVGDDIILVSVSSERYLHLSTASGELQVDASFMQTLWNMNPICSRCEEGFVTGGHVLRLFHGHMDECLTISPADSDDQRRLVYYEGGAVCTHARSLWRLEPLRISWSGSHLRWGQPLRVRHVTTGQYLALTEDQGLVVVDASKAHTKATSFCFRISKEKLDVAPKRDVEGMGPPEIKYGESLCFVQHVASGLWLTYAAPDPKALRLGVLKKKAMLHQEGHMDDALSLTRCQQEESQAARMIHSTNGLYNQFIKSLDSFSGKPRGSGPPAGTALPIEGVILSLQDLIIYFEPPSEDLQHEEKQSKLRSLRNRQSLFQEEGMLSMVLNCIDRLNVYTTAAHFAEFAGEEAAESWKEIVNLLYELLASLIRGNRSNCALFSTNLDWLVSKLDRLEASSGILEVLYCVLIESPEVLNIIQENHIKSIISLLDKHGRNHKVLDVLCSLCVCNGVAVRSNQDLITENLLPGRELLLQTNLINYVTSIRPNIFVGRAEGTTQYSKWYFEVMVDEVTPFLTAQATHLRVGWALTEGYTPYPGAGEGWGGNGVGDDLYSYGFDGLHLWTGHVARPVTSPGQHLLAPEDVISCCLDLSVPSISFRINGCPVQGVFESFNLDGLFFPVVSFSAGVKVRFLLGGRHGEFKFLPPPGYAPCHEAVLPRERLHLEPIKEYRREGPRGPHLVGPSRCLSHTDFVPCPVDTVQIVLPPHLERIREKLAENIHELWALTRIEQGWTYGPVRDDNKRLHPCLVDFHSLPEPERNYNLQMSGETLKTLLALGCHVGMADEKAEDNLKKTKLPKTYMMSNGYKPAPLDLSHVRLTPAQTTLVDRLAENGHNVWARDRVGQGWSYSAVQDIPARRNPRLVPYRLLDEATKRSNRDSLCQAVRTLLGYGYNIEPPDQEPSQVENQSRCDRVRIFRAEKSYTVQSGRWYFEFEAVTTGEMRVGWARPELRPDVELGADELAYVFNGHRGQRWHLGSEPFGRPWQPGDVVGCMIDLTENTIIFTLNGEVLMSDSGSETAFREIEIGDGFLPVCSLGPGQVGHLNLGQDVSSLRFFAICGLQEGFEPFAINMQRPVTTWFSKGLPQFEPVPLEHPHYEVSRVDGTVDTPPCLRLTHRTWGSQNSLVEMLFLRLSLPVQFHQHFRCTAGATPLAPPGLQPPAEDEARAAEPDPDYENLRRSAGGWSEAENGKEGTAKEGAPGGTPQAGGEAQPARAENEKDATTEKNKKRGFLFKAKKVAMMTQPPATPTLPRLPHDVVPADNRDDPEIILNTTTYYYSVRVFAGQEPSCVWAGWVTPDYHQHDMSFDLSKVRVVTVTMGDEQGNVHSSLKCSNCYMVWGGDFVSPGQQGRISHTDLVIGCLVDLATGLMTFTANGKESNTFFQVEPNTKLFPAVFVLPTHQNVIQFELGKQKNIMPLSAAMFQSERKNPAPQCPPRLEMQMLMPVSWSRMPNHFLQVETRRAGERLGWAVQCQEPLTMMALHIPEENRCMDILELSERLDLQRFHSHTLRLYRAVCALGNNRVAHALCSHVDQAQLLHALEDAHLPGPLRAGYYDLLISIHLESACRSRRSMLSEYIVPLTPETRAITLFPPGRSTENGHPRHGLPGVGVTTSLRPPHHFSPPCFVAALPAAGAAEAPARLSPAIPLEALRDKALRMLGEAVRDGGQHARDPVGGSVEFQFVPVLKLVSTLLVMGIFGDEDVKQILKMIEPEVFTEEEEEEDEEEEGEEEDEEEKEEDEEETAQEKEDEEKEEEEAAEGEKEEGLEEGLLQMKLPESVKLQMCHLLEYFCDQELQHRVESLAAFAERYVDKLQANQRSRYGLLIKAFSMTAAETARRTREFRSPPQEQINMLLQFKDGTDEEDCPLPEEIRQDLLDFHQDLLAHCGIQLDGEEEEPEEETTLGSRLMSLLEKVRLVKKKEEKPEEERSAEESKPRSLQELVSHMVVRWAQEDFVQSPELVRAMFSLLHRQYDGLGELLRALPRAYTISPSSVEDTMSLLECLGQIRSLLIVQMGPQEENLMIQSIGNIMNNKVFYQHPNLMRALGMHETVMEVMVNVLGGGESKEIRFPKMVTSCCRFLCYFCRISRQNQRSMFDHLSYLLENSGIGLGMQGSTPLDVAAASVIDNNELALALQEQDLEKVVSYLAGCGLQSCPMLVAKGYPDIGWNPCGGERYLDFLRFAVFVNGESVEENANVVVRLLIRKPECFGPALRGEGGSGLLAAIEEAIRISEDPARDGPGIRRDRRREHFGEEPPEENRVHLGHAIMSFYAALIDLLGRCAPEMHLIQAGKGEALRIRAILRSLVPLEDLVGIISLPLQIPTLGKDGALVQPKMSASFVPDHKASMVLFLDRVYGIENQDFLLHVLDVGFLPDMRAAASLDTATFSTTEMALALNRYLCLAVLPLITKCAPLFAGTEHRAIMVDSMLHTVYRLSRGRSLTKAQRDVIEDCLMSLCRYIRPSMLQHLLRRLVFDVPILNEFAKMPLKLLTNHYERCWKYYCLPTGWANFGVTSEEELHLTRKLFWGIFDSLAHKKYDPELYRMAMPCLCAIAGALPPDYVDASYSSKAEKKATVDAEGNFDPRPVETLNVIIPEKLDSFINKFAEYTHEKWAFDKIQNNWSYGENIDEELKTHPMLRPYKTFSEKDKEIYRWPIKESLKAMIAWEWTIEKAREGEEEKTEKKKTRKISQSAQTYDPREGYNPQPPDLSAVTLSRELQAMAEQLAENYHNTWGRKKKQELEAKGGGTHPLLVPYDTLTAKEKARDREKAQELLKFLQMNGYAVTRGLKDMELDSSSIEKRFAFGFLQQLLRWMDISQEFIAHLEAVVSSGRVEKSPHEQEIKFFAKILLPLINQYFTNHCLYFLSTPAKVLGSGGHASNKEKEMITSLFCKLAALVRHRVSLFGTDAPAVVNCLHILARSLDARTVMKSGPEIVKAGLRSFFESASEDIEKMVENLRLGKVSQARTQVKGVGQNLTYTTVALLPVLTTLFQHIAQHQFGDDVILDDVQVSCYRTLCSIYSLGTTKNTYVEKLRPALGECLARLAAAMPVAFLEPQLNEYNACSVYTTKSPRERAILGLPNSVEEMCPDIPVLERLMADIGGLAESGARYTEMPHVIEITLPMLCSYLPRWWERGPEAPPSALPAGAPPPCTAVTSDHLNSLLGNILRIIVNNLGIDEASWMKRLAVFAQPIVSRARPELLQSHFIPTIGRLRKRAGKVVSEEEQLRLEAKAEAQEGELLVRDEFSVLCRDLYALYPLLIRYVDNNRAQWLTEPNPSAEELFRMVGEIFIYWSKSHNFKREEQNFVVQNEINNMSFLTADNKSKMAKAGDIQSGGSDQERTKKKRRGDRYSVQTSLIVATLKKMLPIGLNMCAPTDQDLITLAKTRYALKDTDEEVREFLHNNLHLQGKVEGSPSLRWQMALYRGVPGREEDADDPEKIVRRVQEVSAVLYYLDQTEHPYKSKKAVWHKLLSKQRRRAVVACFRMTPLYNLPTHRACNMFLESYKAAWILTEDHSFEDRMIDDLSKAGEQEEEEEEVEEKKPDPLHQLVLHFSRTALTEKSKLDEDYLYMAYADIMAKSCHLEEGGENGEAEEEVEVSFEEKQMEKQRLLYQQARLHTRGAAEMVLQMISACKGETGAMVSSTLKLGISILNGGNAEVQQKMLDYLKDKKEVGFFQSIQALMQTCSVLDLNAFERQNKAEGLGMVNEDGTVINRQNGEKVMADDEFTQDLFRFLQLLCEGHNNDFQNYLRTQTGNTTTINIIICTVDYLLRLQESISDFYWYYSGKDVIEEQGKRNFSKAMSVAKQVFNSLTEYIQGPCTGNQQSLAHSRLWDAVVGFLHVFAHMMMKLAQDSSQIELLKELLDLQKDMVVMLLSLLEGNVVNGMIARQMVDMLVESSSNVEMILKFFDMFLKLKDIVGSEAFQDYVTDPRGLISKKDFQKAMDSQKQFSGPEIQFLLSCSEADENEMINCEEFANRFQEPARDIGFNVAVLLTNLSEHVPHDPRLHNFLELAESILEYFRPYLGRIEIMGASRRIERIYFEISETNRAQWEMPQVKESKRQFIFDVVNEGGEAEKMELFVSFCEDTIFEMQIAAQISEPEGEPETDEDEGAGAAEAGAEGAEEGAAGLEGTAATAAAGATARVVAAAGRALRGLSYRSLRRRVRRLRRLTAREAATAVAALLWAAVTRAGAAGAGAAAGALGLLWGSLFGGGLVEGAKKVTVTELLAGMPDPTSDEVHGEQPAGPGGDADGEGASEGAGDAAEGAGDEEEAVHEAGPGGADGAVAVTDGGPFRPEGAGGLGDMGDTTPAEPPTPEGSPILKRKLGVDGVEEELPPEPEPEPEPELEPEKADAENGEKEEVPEPTPEPPKKQAPPSPPPKKEEAGGEFWGELEVQRVKFLNYLSRNFYTLRFLALFLAFAINFILLFYKVSDSPPGEDDMEGSAAGDVSGAGSGGSSGWGLGAGEEAEGDEDENMVYYFLEESTGYMEPALRCLSLLHTLVAFLCIIGYNCLKVPLVIFKREKELARKLEFDGLYITEQPEDDDVKGQWDRLVLNTPSFPSNYWDKFVKRKVLDKHGDIYGRERIAELLGMDLATLEITAHNERKPNPPPGLLTWLMSIDVKYQIWKFGVIFTDNSFLYLGWYMVMSLLGHYNNFFFAAHLLDIAMGVKTLRTILSSVTHNGKQLVMTVGLLAVVVYLYTVVAFNFFRKFYNKSEDEDEPDMKCDDMMTCYLFHMYVGVRAGGGIGDEIEDPAGDEYELYRVVFDITFFFFVIVILLAIIQGLIIDAFGELRDQQEQVKEDMETKCFICGIGSDYFDTTPHGFETHTLEEHNLANYMFFLMYLINKDETEHTGQESYVWKMYQERCWDFFPAGDCFRKQYEDQLS	5038	P21817	Q	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
342	NM_000540.2(RYR1):c.8360C>G (p.Thr2787Ser)	133223	CA024914	NM_000540.2:c.8360C>G, NC_000019.10:g.38505358C>G, CM000681.2:g.38505358C>G, NC_000019.9:g.38995998C>G, CM000681.1:g.38995998C>G, NC_000019.8:g.43687838C>G, NG_008866.1:g.76659C>G, LRG_766:g.76659C>G, ENST00000359596.8:c.8360C>G, ENST00000355481.8:c.8360C>G, ENST00000359596.7:n.8360C>G, ENST00000360985.7:c.8357C>G, ENST00000594335.5:n.1812C>G, LRG_766t1:c.8360C>G, NM_001042723.1:c.8360C>G, XM_006723317.1:c.8360C>G, XM_006723319.1:c.8360C>G, XM_011527204.1:c.8357C>G, XM_011527205.1:c.8360C>G, XM_006723317.2:c.8360C>G, XM_006723319.2:c.8360C>G, XM_011527205.2:c.8360C>G, XR_001753735.1:n.8443C>G, NM_000540.3:c.8360C>G, NM_001042723.2:c.8360C>G, NM_000540.3(RYR1):c.8360C>G (p.Thr2787Ser), NM_000540.2(RYR1):c.8360C>G (p.Thr2787Ser)	RYR1	malignant hyperthermia of anesthesia	MONDO:0018493	Autosomal dominant inheritance	Benign	BA1		This pathogenicity assessment is relevant only for malignant hyperthermia susceptibility (MHS) inherited in an autosomal dominant pattern. Variants in RYR1 can also cause other myopathies inherited in an autosomal dominant pattern or in an autosomal recessive pattern. Some of these disorders may predispose individuals to malignant hyperthermia. RYR1 variants may also contribute to a malignant hyperthermia reaction in combination with other genetic and non-genetic factors and the clinician needs to consider such factors in making management decisions.This sequence variant predicts a substitution of threonine with serine at codon 2787 of the RYR1 protein, p.(Thr2787Ser). The maximum allele frequency for this variant among the six major gnomAD populations is AFR: 0.029867, which is considered to be too common for a pathogenic variant causing autosomal dominantly inherited MHS, BA1. This variant has been classified as Benign. Criteria implemented: BA1.		Malignant Hyperthermia Susceptibility VCEP	https://clinicalgenome.org/docs/clingen-malignant-hyperthermia-susceptibility-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-for/	2021-12-22	2021-12-22	False	https://erepo.genome.network/evrepo/ui/classification/CA024914/MONDO:0018493/012	2e9567be-422b-4d6b-bc4a-371a26dcb0f9	p.Thr2787Ser	Thr	2787	Ser	MGDAEGEDEVQFLRTDDEVVLQCSATVLKEQLKLCLAAEGFGNRLCFLEPTSNAQNVPPDLAICCFVLEQSLSVRALQEMLANTVEAGVESSQGGGHRTLLYGHAILLRHAHSRMYLSCLTTSRSMTDKLAFDVGLQEDATGEACWWTMHPASKQRSEGEKVRVGDDIILVSVSSERYLHLSTASGELQVDASFMQTLWNMNPICSRCEEGFVTGGHVLRLFHGHMDECLTISPADSDDQRRLVYYEGGAVCTHARSLWRLEPLRISWSGSHLRWGQPLRVRHVTTGQYLALTEDQGLVVVDASKAHTKATSFCFRISKEKLDVAPKRDVEGMGPPEIKYGESLCFVQHVASGLWLTYAAPDPKALRLGVLKKKAMLHQEGHMDDALSLTRCQQEESQAARMIHSTNGLYNQFIKSLDSFSGKPRGSGPPAGTALPIEGVILSLQDLIIYFEPPSEDLQHEEKQSKLRSLRNRQSLFQEEGMLSMVLNCIDRLNVYTTAAHFAEFAGEEAAESWKEIVNLLYELLASLIRGNRSNCALFSTNLDWLVSKLDRLEASSGILEVLYCVLIESPEVLNIIQENHIKSIISLLDKHGRNHKVLDVLCSLCVCNGVAVRSNQDLITENLLPGRELLLQTNLINYVTSIRPNIFVGRAEGTTQYSKWYFEVMVDEVTPFLTAQATHLRVGWALTEGYTPYPGAGEGWGGNGVGDDLYSYGFDGLHLWTGHVARPVTSPGQHLLAPEDVISCCLDLSVPSISFRINGCPVQGVFESFNLDGLFFPVVSFSAGVKVRFLLGGRHGEFKFLPPPGYAPCHEAVLPRERLHLEPIKEYRREGPRGPHLVGPSRCLSHTDFVPCPVDTVQIVLPPHLERIREKLAENIHELWALTRIEQGWTYGPVRDDNKRLHPCLVDFHSLPEPERNYNLQMSGETLKTLLALGCHVGMADEKAEDNLKKTKLPKTYMMSNGYKPAPLDLSHVRLTPAQTTLVDRLAENGHNVWARDRVGQGWSYSAVQDIPARRNPRLVPYRLLDEATKRSNRDSLCQAVRTLLGYGYNIEPPDQEPSQVENQSRCDRVRIFRAEKSYTVQSGRWYFEFEAVTTGEMRVGWARPELRPDVELGADELAYVFNGHRGQRWHLGSEPFGRPWQPGDVVGCMIDLTENTIIFTLNGEVLMSDSGSETAFREIEIGDGFLPVCSLGPGQVGHLNLGQDVSSLRFFAICGLQEGFEPFAINMQRPVTTWFSKGLPQFEPVPLEHPHYEVSRVDGTVDTPPCLRLTHRTWGSQNSLVEMLFLRLSLPVQFHQHFRCTAGATPLAPPGLQPPAEDEARAAEPDPDYENLRRSAGGWSEAENGKEGTAKEGAPGGTPQAGGEAQPARAENEKDATTEKNKKRGFLFKAKKVAMMTQPPATPTLPRLPHDVVPADNRDDPEIILNTTTYYYSVRVFAGQEPSCVWAGWVTPDYHQHDMSFDLSKVRVVTVTMGDEQGNVHSSLKCSNCYMVWGGDFVSPGQQGRISHTDLVIGCLVDLATGLMTFTANGKESNTFFQVEPNTKLFPAVFVLPTHQNVIQFELGKQKNIMPLSAAMFQSERKNPAPQCPPRLEMQMLMPVSWSRMPNHFLQVETRRAGERLGWAVQCQEPLTMMALHIPEENRCMDILELSERLDLQRFHSHTLRLYRAVCALGNNRVAHALCSHVDQAQLLHALEDAHLPGPLRAGYYDLLISIHLESACRSRRSMLSEYIVPLTPETRAITLFPPGRSTENGHPRHGLPGVGVTTSLRPPHHFSPPCFVAALPAAGAAEAPARLSPAIPLEALRDKALRMLGEAVRDGGQHARDPVGGSVEFQFVPVLKLVSTLLVMGIFGDEDVKQILKMIEPEVFTEEEEEEDEEEEGEEEDEEEKEEDEEETAQEKEDEEKEEEEAAEGEKEEGLEEGLLQMKLPESVKLQMCHLLEYFCDQELQHRVESLAAFAERYVDKLQANQRSRYGLLIKAFSMTAAETARRTREFRSPPQEQINMLLQFKDGTDEEDCPLPEEIRQDLLDFHQDLLAHCGIQLDGEEEEPEEETTLGSRLMSLLEKVRLVKKKEEKPEEERSAEESKPRSLQELVSHMVVRWAQEDFVQSPELVRAMFSLLHRQYDGLGELLRALPRAYTISPSSVEDTMSLLECLGQIRSLLIVQMGPQEENLMIQSIGNIMNNKVFYQHPNLMRALGMHETVMEVMVNVLGGGESKEIRFPKMVTSCCRFLCYFCRISRQNQRSMFDHLSYLLENSGIGLGMQGSTPLDVAAASVIDNNELALALQEQDLEKVVSYLAGCGLQSCPMLVAKGYPDIGWNPCGGERYLDFLRFAVFVNGESVEENANVVVRLLIRKPECFGPALRGEGGSGLLAAIEEAIRISEDPARDGPGIRRDRRREHFGEEPPEENRVHLGHAIMSFYAALIDLLGRCAPEMHLIQAGKGEALRIRAILRSLVPLEDLVGIISLPLQIPTLGKDGALVQPKMSASFVPDHKASMVLFLDRVYGIENQDFLLHVLDVGFLPDMRAAASLDTATFSTTEMALALNRYLCLAVLPLITKCAPLFAGTEHRAIMVDSMLHTVYRLSRGRSLTKAQRDVIEDCLMSLCRYIRPSMLQHLLRRLVFDVPILNEFAKMPLKLLTNHYERCWKYYCLPTGWANFGVTSEEELHLTRKLFWGIFDSLAHKKYDPELYRMAMPCLCAIAGALPPDYVDASYSSKAEKKATVDAEGNFDPRPVETLNVIIPEKLDSFINKFAEYTHEKWAFDKIQNNWSYGENIDEELKTHPMLRPYKTFSEKDKEIYRWPIKESLKAMIAWEWTIEKAREGEEEKTEKKKTRKISQSAQTYDPREGYNPQPPDLSAVTLSRELQAMAEQLAENYHNTWGRKKKQELEAKGGGTHPLLVPYDTLTAKEKARDREKAQELLKFLQMNGYAVTRGLKDMELDSSSIEKRFAFGFLQQLLRWMDISQEFIAHLEAVVSSGRVEKSPHEQEIKFFAKILLPLINQYFTNHCLYFLSTPAKVLGSGGHASNKEKEMITSLFCKLAALVRHRVSLFGTDAPAVVNCLHILARSLDARTVMKSGPEIVKAGLRSFFESASEDIEKMVENLRLGKVSQARTQVKGVGQNLTYTTVALLPVLTTLFQHIAQHQFGDDVILDDVQVSCYRTLCSIYSLGTTKNTYVEKLRPALGECLARLAAAMPVAFLEPQLNEYNACSVYTTKSPRERAILGLPNSVEEMCPDIPVLERLMADIGGLAESGARYTEMPHVIEITLPMLCSYLPRWWERGPEAPPSALPAGAPPPCTAVTSDHLNSLLGNILRIIVNNLGIDEASWMKRLAVFAQPIVSRARPELLQSHFIPTIGRLRKRAGKVVSEEEQLRLEAKAEAQEGELLVRDEFSVLCRDLYALYPLLIRYVDNNRAQWLTEPNPSAEELFRMVGEIFIYWSKSHNFKREEQNFVVQNEINNMSFLTADNKSKMAKAGDIQSGGSDQERTKKKRRGDRYSVQTSLIVATLKKMLPIGLNMCAPTDQDLITLAKTRYALKDTDEEVREFLHNNLHLQGKVEGSPSLRWQMALYRGVPGREEDADDPEKIVRRVQEVSAVLYYLDQTEHPYKSKKAVWHKLLSKQRRRAVVACFRMTPLYNLPTHRACNMFLESYKAAWILTEDHSFEDRMIDDLSKAGEQEEEEEEVEEKKPDPLHQLVLHFSRTALTEKSKLDEDYLYMAYADIMAKSCHLEEGGENGEAEEEVEVSFEEKQMEKQRLLYQQARLHTRGAAEMVLQMISACKGETGAMVSSTLKLGISILNGGNAEVQQKMLDYLKDKKEVGFFQSIQALMQTCSVLDLNAFERQNKAEGLGMVNEDGTVINRQNGEKVMADDEFTQDLFRFLQLLCEGHNNDFQNYLRTQTGNTTTINIIICTVDYLLRLQESISDFYWYYSGKDVIEEQGKRNFSKAMSVAKQVFNSLTEYIQGPCTGNQQSLAHSRLWDAVVGFLHVFAHMMMKLAQDSSQIELLKELLDLQKDMVVMLLSLLEGNVVNGMIARQMVDMLVESSSNVEMILKFFDMFLKLKDIVGSEAFQDYVTDPRGLISKKDFQKAMDSQKQFSGPEIQFLLSCSEADENEMINCEEFANRFQEPARDIGFNVAVLLTNLSEHVPHDPRLHNFLELAESILEYFRPYLGRIEIMGASRRIERIYFEISETNRAQWEMPQVKESKRQFIFDVVNEGGEAEKMELFVSFCEDTIFEMQIAAQISEPEGEPETDEDEGAGAAEAGAEGAEEGAAGLEGTAATAAAGATARVVAAAGRALRGLSYRSLRRRVRRLRRLTAREAATAVAALLWAAVTRAGAAGAGAAAGALGLLWGSLFGGGLVEGAKKVTVTELLAGMPDPTSDEVHGEQPAGPGGDADGEGASEGAGDAAEGAGDEEEAVHEAGPGGADGAVAVTDGGPFRPEGAGGLGDMGDTTPAEPPTPEGSPILKRKLGVDGVEEELPPEPEPEPEPELEPEKADAENGEKEEVPEPTPEPPKKQAPPSPPPKKEEAGGEFWGELEVQRVKFLNYLSRNFYTLRFLALFLAFAINFILLFYKVSDSPPGEDDMEGSAAGDVSGAGSGGSSGWGLGAGEEAEGDEDENMVYYFLEESTGYMEPALRCLSLLHTLVAFLCIIGYNCLKVPLVIFKREKELARKLEFDGLYITEQPEDDDVKGQWDRLVLNTPSFPSNYWDKFVKRKVLDKHGDIYGRERIAELLGMDLATLEITAHNERKPNPPPGLLTWLMSIDVKYQIWKFGVIFTDNSFLYLGWYMVMSLLGHYNNFFFAAHLLDIAMGVKTLRTILSSVTHNGKQLVMTVGLLAVVVYLYTVVAFNFFRKFYNKSEDEDEPDMKCDDMMTCYLFHMYVGVRAGGGIGDEIEDPAGDEYELYRVVFDITFFFFVIVILLAIIQGLIIDAFGELRDQQEQVKEDMETKCFICGIGSDYFDTTPHGFETHTLEEHNLANYMFFLMYLINKDETEHTGQESYVWKMYQERCWDFFPAGDCFRKQYEDQLS	5038	P21817	S	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
343	NM_000545.6(HNF1A):c.475C>T (p.Arg159Trp)	429750	CA244529794	NM_000545.6:c.475C>T, NC_000012.12:g.120988981C>T, CM000674.2:g.120988981C>T, NC_000012.11:g.121426784C>T, CM000674.1:g.121426784C>T, NC_000012.10:g.119911167C>T, NG_011731.2:g.15236C>T, LRG_522:g.15236C>T, ENST00000257555.11:c.475C>T, ENST00000257555.10:c.475C>T, ENST00000400024.6:c.475C>T, ENST00000402929.5:n.610C>T, ENST00000535955.5:n.43-8510C>T, ENST00000538626.2:n.191-8510C>T, ENST00000538646.5:c.475C>T, ENST00000540108.1:c.327-4539C>T, ENST00000541395.5:c.475C>T, ENST00000541924.5:c.475C>T, ENST00000543427.5:c.475C>T, ENST00000544413.2:c.475C>T, ENST00000544574.5:c.73-7636C>T, ENST00000560968.5:n.618C>T, ENST00000615446.4:c.-257-7281C>T, ENST00000617366.4:c.475C>T, NM_000545.5:c.475C>T, LRG_522t1:c.475C>T, NM_001306179.1:c.475C>T, XM_005253931.2:c.475C>T, XM_024449168.1:c.475C>T, NM_000545.8:c.475C>T, NM_001306179.2:c.475C>T, NM_000545.8(HNF1A):c.475C>T (p.Arg159Trp), NM_000545.6(HNF1A):c.475C>T (p.Arg159Trp)	HNF1A	monogenic diabetes	MONDO:0015967	Autosomal dominant inheritance	Pathogenic	PS4, PM1, PM5, PP1_Strong, PP3, PP4, PM2_Supporting		The c.475C>T  variant in the HNF1 homeobox A gene, HNF1A, causes an amino acid change of arginine to tryptophan at codon 159 (p.(Arg159Trp)) of  NM_000545.8.  This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.907, which is greater than or equal to the MDEP VCEP threshold of 0.70 (PP3). Additionally, this variant was identified in multiple individuals with a clinical history highly specific for HNF1A-MODY (MODY probability calculator result >50%, negative genetic testing for HNF4A) (PP4).  This variant is located within a conserved region of the DNA binding domain (codons 107-174 and 201-280) of HNF1A, which is defined as critical for the protein’s function by the ClinGen MDEP (PM1_Supporting) and is absent from gnomAD v2.1.1 (PM2_Supporting). Another missense variant, c.476G>A, p.(Arg159Gln), has been interpreted as pathogenic by the ClinGen MDEP and p.Arg159Trp has an equal or greater Grantham distance. (PM5). This variant was identified in thirteen unrelated families with non- autoimmune and non-absolute/near-absolute insulin-deficient diabetes (PS4; [internal lab contributors; Exeter, BMRC, Paris]). Lastly, this variant segregated with diabetes, with eight informative meioses in five families with MODY (PP1_Strong; [internal lab contributors; Exeter]). In summary, c.475C>T meets the criteria to be classified as pathogneic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.0, approved 6/4/2021): PP3,  PP4, PM1_Supporting, PM2_Supporting, PM5, PS4, PP1_Strong.		Monogenic Diabetes VCEP		2021-12-22	2021-12-22	False	https://erepo.genome.network/evrepo/ui/classification/CA244529794/MONDO:0015967/017	cb08fbb4-f6a7-453e-8d69-a7c412e82e90	p.Arg159Trp	Arg	159	Trp	MVSKLSQLQTELLAALLESGLSKEALIQALGEPGPYLLAGEGPLDKGESCGGGRGELAELPNGLGETRGSEDETDDDGEDFTPPILKELENLSPEEAAHQKAVVETLLQEDPWRVAKMVKSYLQQHNIPQREVVDTTGLNQSHLSQHLNKGTPMKTQKRAALYTWYVRKQREVAQQFTHAGQGGLIEEPTGDELPTKKGRRNRFKWGPASQQILFQAYERQKNPSKEERETLVEECNRAECIQRGVSPSQAQGLGSNLVTEVRVYNWFANRRKEEAFRHKLAMDTYSGPPPGPGPGPALPAHSSPGLPPPALSPSKVHGVRYGQPATSETAEVPSSSGGPLVTVSTPLHQVSPTGLEPSHSLLSTEAKLVSAAGGPLPPVSTLTALHSLEQTSPGLNQQPQNLIMASLPGVMTIGPGEPASLGPTFTNTGASTLVIGLASTQAQSVPVINSMGSSLTTLQPVQFSQPLHPSYQQPLMPPVQSHVTQSPFMATMAQLQSPHALYSHKPEVAQYTHTGLLPQTMLITDTTNLSALASLTPTKQVFTSDTEASSESGLHTPASQATTLHVPSQDPAGIQHLQPAHRLSASPTVSSSSLVLYQSSDSSNGQSHLLPSNHSVIETFISTQMASSSQ	631	P20823	W	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [230], 'DNA_BIND_gain': [], 'DNA_BIND_loss_score': array([-0.07541704]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [97, 106, 111, 154, 171], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.03091377, -0.03739774, -0.06422526, -0.1239267 , -0.05701792]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [77], 'COMPBIAS_gain': [], 'COMPBIAS_loss_score': array([-0.01040524]), 'DOMAIN_loss': [5, 34, 81, 83], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.04650199, -0.06199962, -0.06347942, -0.07039994]), 'REGION_loss': [179, 180, 181], 'REGION_gain': [], 'REGION_loss_score': array([-0.08409256, -0.08868301, -0.10760856]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
344	NM_001110792.2(MECP2):c.1250C>T (p.Pro417Leu)	143438	CA199322	NM_001110792.2:c.1250C>T, NC_000023.11:g.154030614G>A, CM000685.2:g.154030614G>A, NC_000023.10:g.153296065G>A, CM000685.1:g.153296065G>A, NC_000023.9:g.152949259G>A, NG_007107.2:g.111514C>T, NG_007107.3:g.111490C>T, ENST00000303391.11:c.1214C>T, ENST00000453960.7:c.1250C>T, ENST00000303391.10:c.1214C>T, ENST00000407218.5:c.*586C>T, ENST00000453960.6:c.1250C>T, ENST00000619732.4:c.1214C>T, ENST00000628176.2:c.*586C>T, NM_001110792.1:c.1250C>T, NM_001316337.1:c.935C>T, NM_004992.3:c.1214C>T, XM_005274681.3:c.1214C>T, XM_005274682.3:c.935C>T, XM_005274683.3:c.935C>T, XM_006724819.2:c.545C>T, XM_011531166.1:c.935C>T, XM_006724819.3:c.545C>T, XM_011531166.2:c.935C>T, XM_024452383.1:c.935C>T, XM_024452384.1:c.935C>T, NM_001316337.2:c.935C>T, NM_001369391.2:c.935C>T, NM_001369392.2:c.935C>T, NM_001369393.2:c.935C>T, NM_001369394.1:c.935C>T, NM_001369394.2:c.935C>T, NM_001386137.1:c.545C>T, NM_001386138.1:c.545C>T, NM_001386139.1:c.545C>T, NM_004992.4:c.1214C>T, NM_001110792.2(MECP2):c.1250C>T (p.Pro417Leu)	MECP2	Rett syndrome	MONDO:0010726	X-linked inheritance	Benign	BS1, BS2_Stand Alone	BA1	The allele frequency of the p.Pro405Leu (NM_004992.3) variant in MECP2 is 0.029% in Latino sub population in gnomAD, which is high enough to meet the BS1 criteria based on thresholds defined by the ClinGen Rett/Angelman-like Expert Panel for Rett/AS-like conditions (BS1). The p.Pro405Leu variant is observed in at least 2 unaffected individuals (GeneDx internal database)(BS2). In summary, the p.Pro405Leu variant in MECP2 is classified as benign based on the ACMG/AMP criteria (BS1, BS2).		Rett and Angelman-like Disorders VCEP		2021-12-22	2024-02-23	True	https://erepo.genome.network/evrepo/ui/classification/CA199322/MONDO:0010726/036	88dbea59-2fc0-49e6-9200-9a675d39f17a	p.Pro417Leu	Pro	417	Leu	MVAGMLGLREEKSEDQDLQGLKDKPLKFKKVKKDKKEEKEGKHEPVQPSAHHSAEPAEAGKAETSEGSGSAPAVPEASASPKQRRSIIRDRGPMYDDPTLPEGWTRKLKQRKSGRSAGKYDVYLINPQGKAFRSKVELIAYFEKVGDTSLDPNDFDFTVTGRGSPSRREQKPPKKPKSPKAPGTGRGRGRPKGSGTTRPKAATSEGVQVKRVLEKSPGKLLVKMPFQTSPGGKAEGGGATTSTQVMVIKRPGRKRKAEADPQAIPKKRGRKPGSVVAAAAAEAKKKAVKESSIRSVQETVLPIKKRKTRETVSIEVKEVVKPLLVSTLGEKSGKGLKTCKSPGRKSKESSPKGRSSSASSPPKKEHHHHHHHSESPKAPVPLLPPLPPPPPEPESSEDPTSPPEPQDLSSSVCKEEKMPRGGSLESDGCPKEPAKTQPAVATAATAAEKYKHRGEGERKDIVSSSMPRPNREEPVDSRTPVTERVS	486	P51608	L	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [264, 360, 374, 399, 401], 'COMPBIAS_gain_score': array([0.00984865, 0.02922463, 0.0322094 , 0.11271173, 0.095599  ]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [324], 'REGION_gain': [], 'REGION_loss_score': array([-0.01436484]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
345	NM_001110792.2(MECP2):c.1198C>T (p.Pro400Ser)	143393	CA274535	NM_001110792.2:c.1198C>T, NC_000023.11:g.154030666G>A, CM000685.2:g.154030666G>A, NC_000023.10:g.153296117G>A, CM000685.1:g.153296117G>A, NC_000023.9:g.152949311G>A, NG_007107.2:g.111462C>T, NG_007107.3:g.111438C>T, ENST00000303391.11:c.1162C>T, ENST00000453960.7:c.1198C>T, ENST00000303391.10:c.1162C>T, ENST00000407218.5:c.*534C>T, ENST00000453960.6:c.1198C>T, ENST00000619732.4:c.1162C>T, ENST00000628176.2:c.*534C>T, NM_001110792.1:c.1198C>T, NM_001316337.1:c.883C>T, NM_004992.3:c.1162C>T, XM_005274681.3:c.1162C>T, XM_005274682.3:c.883C>T, XM_005274683.3:c.883C>T, XM_006724819.2:c.493C>T, XM_011531166.1:c.883C>T, XM_006724819.3:c.493C>T, XM_011531166.2:c.883C>T, XM_024452383.1:c.883C>T, XM_024452384.1:c.883C>T, NM_001316337.2:c.883C>T, NM_001369391.2:c.883C>T, NM_001369392.2:c.883C>T, NM_001369393.2:c.883C>T, NM_001369394.1:c.883C>T, NM_001369394.2:c.883C>T, NM_001386137.1:c.493C>T, NM_001386138.1:c.493C>T, NM_001386139.1:c.493C>T, NM_004992.4:c.1162C>T, NM_001110792.2(MECP2):c.1198C>T (p.Pro400Ser)	MECP2	Rett syndrome	MONDO:0010726	X-linked inheritance	Benign	BA1		The allele frequency of the p.Pro388Ser (NM_004992.3) variant in MECP2 is 0.039% in a sub population in gnomAD, which is high enough to be classified as benign based on thresholds defined by the ClinGen Rett/Angelman-like Expert Panel for Rett/AS-like conditions (BA1). In summary, the p.Pro388Ser variant in MECP2 is classified as benign based on the ACMG/AMP criteria (BA1).		Rett and Angelman-like Disorders VCEP	https://clinicalgenome.org/site/assets/files/7339/clingen_rettas_acmg_specifications_v2.pdf	2021-12-22	2021-12-27	False	https://erepo.genome.network/evrepo/ui/classification/CA274535/MONDO:0010726/016	788bd61d-e448-4487-aa28-328c5b73f0d1	p.Pro400Ser	Pro	400	Ser	MVAGMLGLREEKSEDQDLQGLKDKPLKFKKVKKDKKEEKEGKHEPVQPSAHHSAEPAEAGKAETSEGSGSAPAVPEASASPKQRRSIIRDRGPMYDDPTLPEGWTRKLKQRKSGRSAGKYDVYLINPQGKAFRSKVELIAYFEKVGDTSLDPNDFDFTVTGRGSPSRREQKPPKKPKSPKAPGTGRGRGRPKGSGTTRPKAATSEGVQVKRVLEKSPGKLLVKMPFQTSPGGKAEGGGATTSTQVMVIKRPGRKRKAEADPQAIPKKRGRKPGSVVAAAAAEAKKKAVKESSIRSVQETVLPIKKRKTRETVSIEVKEVVKPLLVSTLGEKSGKGLKTCKSPGRKSKESSPKGRSSSASSPPKKEHHHHHHHSESPKAPVPLLPPLPPPPPEPESSEDPTSPPEPQDLSSSVCKEEKMPRGGSLESDGCPKEPAKTQPAVATAATAAEKYKHRGEGERKDIVSSSMPRPNREEPVDSRTPVTERVS	486	P51608	S	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [399], 'COMPBIAS_gain_score': array([0.05268604]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
346	NM_001110792.2(MECP2):c.1375G>A (p.Ala459Thr)	143465	CA170236	NM_001110792.2:c.1375G>A, NC_000023.11:g.154030489C>T, CM000685.2:g.154030489C>T, NC_000023.10:g.153295940C>T, CM000685.1:g.153295940C>T, NC_000023.9:g.152949134C>T, NG_007107.2:g.111639G>A, NG_007107.3:g.111615G>A, ENST00000303391.11:c.1339G>A, ENST00000453960.7:c.1375G>A, ENST00000303391.10:c.1339G>A, ENST00000453960.6:c.1375G>A, ENST00000619732.4:c.1339G>A, ENST00000628176.2:c.*711G>A, NM_001110792.1:c.1375G>A, NM_001316337.1:c.1060G>A, NM_004992.3:c.1339G>A, XM_005274681.3:c.1339G>A, XM_005274682.3:c.1060G>A, XM_005274683.3:c.1060G>A, XM_006724819.2:c.670G>A, XM_011531166.1:c.1060G>A, XM_006724819.3:c.670G>A, XM_011531166.2:c.1060G>A, XM_024452383.1:c.1060G>A, XM_024452384.1:c.1060G>A, NM_001316337.2:c.1060G>A, NM_001369391.2:c.1060G>A, NM_001369392.2:c.1060G>A, NM_001369393.2:c.1060G>A, NM_001369394.1:c.1060G>A, NM_001369394.2:c.1060G>A, NM_001386137.1:c.670G>A, NM_001386138.1:c.670G>A, NM_001386139.1:c.670G>A, NM_004992.4:c.1339G>A, NM_001110792.2(MECP2):c.1375G>A (p.Ala459Thr)	MECP2	Rett syndrome	MONDO:0010726	X-linked inheritance	Benign	BS2, BS1		The allele frequency of the p.Ala447Thr (NM_004992.3) variant in MECP2 is 0.02% in East Asian sub population in gnomAD, which is high enough to be classified as likely benign based on thresholds defined by the ClinGen Rett/Angelman-like Expert Panel for Rett/AS-like conditions (BS1). The p.Ala447Thr variant is observed in at least 2 unaffected individuals (GeneDx internal database) (BS2).  In summary, the p.Ala447Thr variant in MECP2 is classified as benign based on the ACMG/AMP criteria (BS1, BS2).		Rett and Angelman-like Disorders VCEP	https://clinicalgenome.org/site/assets/files/7339/clingen_rettas_acmg_specifications_v2.pdf	2021-12-13	2021-12-27	False	https://erepo.genome.network/evrepo/ui/classification/CA170236/MONDO:0010726/016	9f25c8eb-711e-405f-8efd-73e14e35627c	p.Ala459Thr	Ala	459	Thr	MVAGMLGLREEKSEDQDLQGLKDKPLKFKKVKKDKKEEKEGKHEPVQPSAHHSAEPAEAGKAETSEGSGSAPAVPEASASPKQRRSIIRDRGPMYDDPTLPEGWTRKLKQRKSGRSAGKYDVYLINPQGKAFRSKVELIAYFEKVGDTSLDPNDFDFTVTGRGSPSRREQKPPKKPKSPKAPGTGRGRGRPKGSGTTRPKAATSEGVQVKRVLEKSPGKLLVKMPFQTSPGGKAEGGGATTSTQVMVIKRPGRKRKAEADPQAIPKKRGRKPGSVVAAAAAEAKKKAVKESSIRSVQETVLPIKKRKTRETVSIEVKEVVKPLLVSTLGEKSGKGLKTCKSPGRKSKESSPKGRSSSASSPPKKEHHHHHHHSESPKAPVPLLPPLPPPPPEPESSEDPTSPPEPQDLSSSVCKEEKMPRGGSLESDGCPKEPAKTQPAVATAATAAEKYKHRGEGERKDIVSSSMPRPNREEPVDSRTPVTERVS	486	P51608	T	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [447], 'COMPBIAS_gain': [], 'COMPBIAS_loss_score': array([-0.20344377]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
347	NM_001110792.2(MECP2):c.1199C>T (p.Pro400Leu)	143398	CA270246	NM_001110792.2:c.1199C>T, NC_000023.11:g.154030665G>A, CM000685.2:g.154030665G>A, NC_000023.10:g.153296116G>A, CM000685.1:g.153296116G>A, NC_000023.9:g.152949310G>A, NG_007107.2:g.111463C>T, NG_007107.3:g.111439C>T, ENST00000303391.11:c.1163C>T, ENST00000453960.7:c.1199C>T, ENST00000303391.10:c.1163C>T, ENST00000407218.5:c.*535C>T, ENST00000453960.6:c.1199C>T, ENST00000619732.4:c.1163C>T, ENST00000628176.2:c.*535C>T, NM_001110792.1:c.1199C>T, NM_001316337.1:c.884C>T, NM_004992.3:c.1163C>T, XM_005274681.3:c.1163C>T, XM_005274682.3:c.884C>T, XM_005274683.3:c.884C>T, XM_006724819.2:c.494C>T, XM_011531166.1:c.884C>T, XM_006724819.3:c.494C>T, XM_011531166.2:c.884C>T, XM_024452383.1:c.884C>T, XM_024452384.1:c.884C>T, NM_001316337.2:c.884C>T, NM_001369391.2:c.884C>T, NM_001369392.2:c.884C>T, NM_001369393.2:c.884C>T, NM_001369394.1:c.884C>T, NM_001369394.2:c.884C>T, NM_001386137.1:c.494C>T, NM_001386138.1:c.494C>T, NM_001386139.1:c.494C>T, NM_004992.4:c.1163C>T, NM_001110792.2(MECP2):c.1199C>T (p.Pro400Leu)	MECP2	Rett syndrome	MONDO:0010726	X-linked inheritance	Benign	BS2, BS1		The allele frequency of the p.Pro388Leu (NM_004992.3) variant in MECP2 is 0.014% in Latino sub population in gnomAD, which is high enough to be classified as likely benign based on thresholds defined by the ClinGen Rett/Angelman-like Expert Panel for Rett/AS-like conditions (BS1). Thep.Pro388Leu variant is observed in at least 2 unaffected individuals (GeneDx internal database) (BS2). In summary, the p.Pro388Leu variant in MECP2 is classified as benign based on the ACMG/AMP criteria (BS1, BS2).		Rett and Angelman-like Disorders VCEP	https://clinicalgenome.org/site/assets/files/7339/clingen_rettas_acmg_specifications_v2.pdf	2021-12-13	2021-12-27	False	https://erepo.genome.network/evrepo/ui/classification/CA270246/MONDO:0010726/016	c9f8a43d-6228-4bee-8416-b26cbcfdb0e4	p.Pro400Leu	Pro	400	Leu	MVAGMLGLREEKSEDQDLQGLKDKPLKFKKVKKDKKEEKEGKHEPVQPSAHHSAEPAEAGKAETSEGSGSAPAVPEASASPKQRRSIIRDRGPMYDDPTLPEGWTRKLKQRKSGRSAGKYDVYLINPQGKAFRSKVELIAYFEKVGDTSLDPNDFDFTVTGRGSPSRREQKPPKKPKSPKAPGTGRGRGRPKGSGTTRPKAATSEGVQVKRVLEKSPGKLLVKMPFQTSPGGKAEGGGATTSTQVMVIKRPGRKRKAEADPQAIPKKRGRKPGSVVAAAAAEAKKKAVKESSIRSVQETVLPIKKRKTRETVSIEVKEVVKPLLVSTLGEKSGKGLKTCKSPGRKSKESSPKGRSSSASSPPKKEHHHHHHHSESPKAPVPLLPPLPPPPPEPESSEDPTSPPEPQDLSSSVCKEEKMPRGGSLESDGCPKEPAKTQPAVATAATAAEKYKHRGEGERKDIVSSSMPRPNREEPVDSRTPVTERVS	486	P51608	L	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [398], 'COMPBIAS_gain': [], 'COMPBIAS_loss_score': array([-0.18469191]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [324], 'REGION_gain': [], 'REGION_loss_score': array([-0.01710534]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
348	NM_001110792.2(MECP2):c.1196C>T (p.Pro399Leu)	143383	CA170185	NM_001110792.2:c.1196C>T, NC_000023.11:g.154030668G>A, CM000685.2:g.154030668G>A, NC_000023.10:g.153296119G>A, CM000685.1:g.153296119G>A, NC_000023.9:g.152949313G>A, NG_007107.2:g.111460C>T, NG_007107.3:g.111436C>T, ENST00000303391.11:c.1160C>T, ENST00000453960.7:c.1196C>T, ENST00000303391.10:c.1160C>T, ENST00000407218.5:c.*532C>T, ENST00000453960.6:c.1196C>T, ENST00000619732.4:c.1160C>T, ENST00000628176.2:c.*532C>T, NM_001110792.1:c.1196C>T, NM_001316337.1:c.881C>T, NM_004992.3:c.1160C>T, XM_005274681.3:c.1160C>T, XM_005274682.3:c.881C>T, XM_005274683.3:c.881C>T, XM_006724819.2:c.491C>T, XM_011531166.1:c.881C>T, XM_006724819.3:c.491C>T, XM_011531166.2:c.881C>T, XM_024452383.1:c.881C>T, XM_024452384.1:c.881C>T, NM_001316337.2:c.881C>T, NM_001369391.2:c.881C>T, NM_001369392.2:c.881C>T, NM_001369393.2:c.881C>T, NM_001369394.1:c.881C>T, NM_001369394.2:c.881C>T, NM_001386137.1:c.491C>T, NM_001386138.1:c.491C>T, NM_001386139.1:c.491C>T, NM_004992.4:c.1160C>T, NM_001110792.2(MECP2):c.1196C>T (p.Pro399Leu)	MECP2	Rett syndrome	MONDO:0010726	X-linked inheritance	Benign	BS2, BS1		The allele frequency of the p.Pro387Leu (NM_004992.3) variant in MECP2 is 0.026% in South Asian sub population in gnomAD, which is high enough to be classified as likely benign based on thresholds defined by the ClinGen Rett/Angelman-like Expert Panel for Rett/AS-like conditions (BS1). The p.Pro387Leu variant is observed in at least 2 unaffected individuals (PMID 12161600, GeneDx internal database) (BS2). In summary, the p.Pro387Leu variant in MECP2 is classified as benign based on the ACMG/AMP criteria (BS1, BS2).		Rett and Angelman-like Disorders VCEP	https://clinicalgenome.org/site/assets/files/7339/clingen_rettas_acmg_specifications_v2.pdf	2021-12-13	2021-12-27	False	https://erepo.genome.network/evrepo/ui/classification/CA170185/MONDO:0010726/016	2895aad2-34d6-4d56-8c6b-e11d15c61d64	p.Pro399Leu	Pro	399	Leu	MVAGMLGLREEKSEDQDLQGLKDKPLKFKKVKKDKKEEKEGKHEPVQPSAHHSAEPAEAGKAETSEGSGSAPAVPEASASPKQRRSIIRDRGPMYDDPTLPEGWTRKLKQRKSGRSAGKYDVYLINPQGKAFRSKVELIAYFEKVGDTSLDPNDFDFTVTGRGSPSRREQKPPKKPKSPKAPGTGRGRGRPKGSGTTRPKAATSEGVQVKRVLEKSPGKLLVKMPFQTSPGGKAEGGGATTSTQVMVIKRPGRKRKAEADPQAIPKKRGRKPGSVVAAAAAEAKKKAVKESSIRSVQETVLPIKKRKTRETVSIEVKEVVKPLLVSTLGEKSGKGLKTCKSPGRKSKESSPKGRSSSASSPPKKEHHHHHHHSESPKAPVPLLPPLPPPPPEPESSEDPTSPPEPQDLSSSVCKEEKMPRGGSLESDGCPKEPAKTQPAVATAATAAEKYKHRGEGERKDIVSSSMPRPNREEPVDSRTPVTERVS	486	P51608	L	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [397, 398], 'COMPBIAS_gain': [], 'COMPBIAS_loss_score': array([-0.34803975, -0.29835659]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [300, 301, 324], 'REGION_gain': [], 'REGION_loss_score': array([-0.02336121, -0.02199548, -0.02977037]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
349	NM_001110792.2(MECP2):c.1174G>A (p.Val392Met)	143344	CA199319	NM_001110792.2:c.1174G>A, NC_000023.11:g.154030690C>T, CM000685.2:g.154030690C>T, NC_000023.10:g.153296141C>T, CM000685.1:g.153296141C>T, NC_000023.9:g.152949335C>T, NG_007107.2:g.111438G>A, NG_007107.3:g.111414G>A, ENST00000303391.11:c.1138G>A, ENST00000453960.7:c.1174G>A, ENST00000303391.10:c.1138G>A, ENST00000407218.5:c.*510G>A, ENST00000453960.6:c.1174G>A, ENST00000619732.4:c.1138G>A, ENST00000628176.2:c.*510G>A, NM_001110792.1:c.1174G>A, NM_001316337.1:c.859G>A, NM_004992.3:c.1138G>A, XM_005274681.3:c.1138G>A, XM_005274682.3:c.859G>A, XM_005274683.3:c.859G>A, XM_006724819.2:c.469G>A, XM_011531166.1:c.859G>A, XM_006724819.3:c.469G>A, XM_011531166.2:c.859G>A, XM_024452383.1:c.859G>A, XM_024452384.1:c.859G>A, NM_001316337.2:c.859G>A, NM_001369391.2:c.859G>A, NM_001369392.2:c.859G>A, NM_001369393.2:c.859G>A, NM_001369394.1:c.859G>A, NM_001369394.2:c.859G>A, NM_001386137.1:c.469G>A, NM_001386138.1:c.469G>A, NM_001386139.1:c.469G>A, NM_004992.4:c.1138G>A, NM_001110792.2(MECP2):c.1174G>A (p.Val392Met)	MECP2	Rett syndrome	MONDO:0010726	X-linked inheritance	Benign	BA1		The allele frequency of the p.Val380Met (NM_004992.3) variant in MECP2 is 0.138% in Latino sub population in gnomAD, which is high enough to be classified as benign based on thresholds defined by the ClinGen Rett/Angelman-like Expert Panel for Rett/AS-like conditions (BA1). In summary, the p.Val380Met variant in MECP2 is classified as benign based on the ACMG/AMP criteria (BA1).		Rett and Angelman-like Disorders VCEP	https://clinicalgenome.org/site/assets/files/7339/clingen_rettas_acmg_specifications_v2.pdf	2021-12-13	2021-12-27	False	https://erepo.genome.network/evrepo/ui/classification/CA199319/MONDO:0010726/016	b26119fb-9e22-4462-a5e1-932df26bc559	p.Val392Met	Val	392	Met	MVAGMLGLREEKSEDQDLQGLKDKPLKFKKVKKDKKEEKEGKHEPVQPSAHHSAEPAEAGKAETSEGSGSAPAVPEASASPKQRRSIIRDRGPMYDDPTLPEGWTRKLKQRKSGRSAGKYDVYLINPQGKAFRSKVELIAYFEKVGDTSLDPNDFDFTVTGRGSPSRREQKPPKKPKSPKAPGTGRGRGRPKGSGTTRPKAATSEGVQVKRVLEKSPGKLLVKMPFQTSPGGKAEGGGATTSTQVMVIKRPGRKRKAEADPQAIPKKRGRKPGSVVAAAAAEAKKKAVKESSIRSVQETVLPIKKRKTRETVSIEVKEVVKPLLVSTLGEKSGKGLKTCKSPGRKSKESSPKGRSSSASSPPKKEHHHHHHHSESPKAPVPLLPPLPPPPPEPESSEDPTSPPEPQDLSSSVCKEEKMPRGGSLESDGCPKEPAKTQPAVATAATAAEKYKHRGEGERKDIVSSSMPRPNREEPVDSRTPVTERVS	486	P51608	M	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [360, 399], 'COMPBIAS_gain_score': array([0.03106564, 0.09255975]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [300, 301, 324], 'REGION_gain': [], 'REGION_loss_score': array([-0.02220863, -0.0223304 , -0.02720261]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
350	NM_001110792.2(MECP2):c.915C>G (p.Ile305Met)	156671	CA294722	NM_001110792.2:c.915C>G, NC_000023.11:g.154030949G>C, CM000685.2:g.154030949G>C, NC_000023.10:g.153296400G>C, CM000685.1:g.153296400G>C, NC_000023.9:g.152949594G>C, NG_007107.2:g.111179C>G, NG_007107.3:g.111155C>G, ENST00000303391.11:c.879C>G, ENST00000453960.7:c.915C>G, ENST00000637917.1:n.66-13C>G, ENST00000303391.10:c.879C>G, ENST00000407218.5:c.*251C>G, ENST00000453960.6:c.915C>G, ENST00000619732.4:c.879C>G, ENST00000622433.4:c.865C>G, ENST00000628176.2:c.*251C>G, NM_001110792.1:c.915C>G, NM_001316337.1:c.600C>G, NM_004992.3:c.879C>G, XM_005274681.3:c.879C>G, XM_005274682.3:c.600C>G, XM_005274683.3:c.600C>G, XM_006724819.2:c.210C>G, XM_011531166.1:c.600C>G, XM_006724819.3:c.210C>G, XM_011531166.2:c.600C>G, XM_024452383.1:c.600C>G, XM_024452384.1:c.600C>G, NM_001316337.2:c.600C>G, NM_001369391.2:c.600C>G, NM_001369392.2:c.600C>G, NM_001369393.2:c.600C>G, NM_001369394.1:c.600C>G, NM_001369394.2:c.600C>G, NM_001386137.1:c.210C>G, NM_001386138.1:c.210C>G, NM_001386139.1:c.210C>G, NM_004992.4:c.879C>G, NM_001110792.2(MECP2):c.915C>G (p.Ile305Met)	MECP2	Rett syndrome	MONDO:0010726	X-linked inheritance	Benign	BS2, BP5, BS1		The p.Ile293Met variant (NM_004992.3) is observed in at least 2 unaffected individuals (GeneDx internal database) (BS2). The p.Ile305Met variant is found in a patient with an alternate molecular basis of disease (GeneDx internal database) (BP5). The allele frequency of the p.Ile293Met variant in MECP2 is 0.00027% in the East Asian sub population in gnomAD, which is high enough to be classified as likely benign based on thresholds defined by the ClinGen Rett/Angelman-like Expert Panel for Rett/AS-like conditions (BS1). In summary, the p.Ile293Met variant in MECP2 is classified as likely benign based on the ACMG/AMP criteria (BS2, BP5, BS1).		Rett and Angelman-like Disorders VCEP	https://clinicalgenome.org/site/assets/files/7339/clingen_rettas_acmg_specifications_v2.pdf	2021-12-13	2021-12-27	False	https://erepo.genome.network/evrepo/ui/classification/CA294722/MONDO:0010726/016	8b0ed6a7-76cf-44dc-8cb6-0606f5cb85d7	p.Ile305Met	Ile	305	Met	MVAGMLGLREEKSEDQDLQGLKDKPLKFKKVKKDKKEEKEGKHEPVQPSAHHSAEPAEAGKAETSEGSGSAPAVPEASASPKQRRSIIRDRGPMYDDPTLPEGWTRKLKQRKSGRSAGKYDVYLINPQGKAFRSKVELIAYFEKVGDTSLDPNDFDFTVTGRGSPSRREQKPPKKPKSPKAPGTGRGRGRPKGSGTTRPKAATSEGVQVKRVLEKSPGKLLVKMPFQTSPGGKAEGGGATTSTQVMVIKRPGRKRKAEADPQAIPKKRGRKPGSVVAAAAAEAKKKAVKESSIRSVQETVLPIKKRKTRETVSIEVKEVVKPLLVSTLGEKSGKGLKTCKSPGRKSKESSPKGRSSSASSPPKKEHHHHHHHSESPKAPVPLLPPLPPPPPEPESSEDPTSPPEPQDLSSSVCKEEKMPRGGSLESDGCPKEPAKTQPAVATAATAAEKYKHRGEGERKDIVSSSMPRPNREEPVDSRTPVTERVS	486	P51608	M	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [264], 'COMPBIAS_gain_score': array([0.00940132]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [293, 294, 295, 296, 297, 298, 299, 300, 301, 303, 324, 325], 'REGION_gain': [], 'REGION_loss_score': array([-0.23871219, -0.27901435, -0.32469016, -0.28492612, -0.33202159,
       -0.34166986, -0.34099036, -0.2951206 , -0.25397092, -0.27416879,
       -0.1348477 , -0.13804179]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
351	NM_001110792.2(MECP2):c.437C>T (p.Ser146Phe)	143563	CA270398	NM_001110792.2:c.437C>T, NC_000023.11:g.154031427G>A, CM000685.2:g.154031427G>A, NC_000023.10:g.153296878G>A, CM000685.1:g.153296878G>A, NC_000023.9:g.152950072G>A, NG_007107.2:g.110701C>T, NG_007107.3:g.110677C>T, ENST00000303391.11:c.401C>T, ENST00000453960.7:c.437C>T, ENST00000637917.1:n.34C>T, ENST00000303391.10:c.401C>T, ENST00000369957.5:c.*455C>T, ENST00000407218.5:c.437C>T, ENST00000453960.6:c.437C>T, ENST00000486506.5:n.2749C>T, ENST00000611468.1:c.389C>T, ENST00000619732.4:c.401C>T, ENST00000622433.4:c.389C>T, ENST00000628176.2:c.401C>T, NM_001110792.1:c.437C>T, NM_001316337.1:c.122C>T, NM_004992.3:c.401C>T, XM_005274681.3:c.401C>T, XM_005274682.3:c.122C>T, XM_005274683.3:c.122C>T, XM_006724819.2:c.-160C>T, XM_011531166.1:c.122C>T, XM_006724819.3:c.-160C>T, XM_011531166.2:c.122C>T, XM_024452383.1:c.122C>T, XM_024452384.1:c.122C>T, NM_001316337.2:c.122C>T, NM_001369391.2:c.122C>T, NM_001369392.2:c.122C>T, NM_001369393.2:c.122C>T, NM_001369394.1:c.122C>T, NM_001369394.2:c.122C>T, NM_001386137.1:c.-160C>T, NM_001386138.1:c.-160C>T, NM_001386139.1:c.-160C>T, NM_004992.4:c.401C>T, NM_001110792.2(MECP2):c.437C>T (p.Ser146Phe)	MECP2	Rett syndrome	MONDO:0010726	X-linked inheritance	Pathogenic	PP3, PP4, PM2_Supporting, PS4_Moderate, PS2, PM5, PM1		The p.Ser134Phe variant in MECP2 (NM_004992.3) has been reported as a de novo occurrence (biological parentage both confirmed and unconfirmed) in at least 2 individuals with Rett syndrome (PMID 15737703, internal database - GeneDx) (PS2, PP4). The p.Ser134Phe variant has been observed in at least 1 other individual with Rett syndrome (PMID 21160487) (PS4_moderate). A pathogenic missense variant (p.Ser134Cys) has been previously identified within this codon which indicates that this residue is critical to the function of the protein (PMID 10814718, 11738864, 17089071, 12655490, 21160487, 11738883, 18337588, 10767337, 23696494, 22182064) (PM5). The p.Ser134Phe variant occurs in the well-characterized methyl-binding domain (MBD) functional domain of MECP2 (PMID 1326358, 23770565) (PM1). The p.Ser134Phe variant in MECP2 is absent from gnomAD (PM2_supporting). Computational prediction analysis tools suggests a deleterious impact; however, this information does not predict clinical significance on its own (PP3). In summary, the p.Ser134Phe variant in MECP2 is classified as Pathogenic for Rett syndrome based on the ACMG/AMP criteria (PS2, PS4_moderate, PM1, PM5, PM2_supporting, PP3, PP4).		Rett and Angelman-like Disorders VCEP	https://clinicalgenome.org/site/assets/files/7339/clingen_rettas_acmg_specifications_v2.pdf	2021-10-26	2021-12-27	False	https://erepo.genome.network/evrepo/ui/classification/CA270398/MONDO:0010726/016	cdabb0b8-00e6-4545-a4b7-f8005af1d548	p.Ser146Phe	Ser	146	Phe	MVAGMLGLREEKSEDQDLQGLKDKPLKFKKVKKDKKEEKEGKHEPVQPSAHHSAEPAEAGKAETSEGSGSAPAVPEASASPKQRRSIIRDRGPMYDDPTLPEGWTRKLKQRKSGRSAGKYDVYLINPQGKAFRSKVELIAYFEKVGDTSLDPNDFDFTVTGRGSPSRREQKPPKKPKSPKAPGTGRGRGRPKGSGTTRPKAATSEGVQVKRVLEKSPGKLLVKMPFQTSPGGKAEGGGATTSTQVMVIKRPGRKRKAEADPQAIPKKRGRKPGSVVAAAAAEAKKKAVKESSIRSVQETVLPIKKRKTRETVSIEVKEVVKPLLVSTLGEKSGKGLKTCKSPGRKSKESSPKGRSSSASSPPKKEHHHHHHHSESPKAPVPLLPPLPPPPPEPESSEDPTSPPEPQDLSSSVCKEEKMPRGGSLESDGCPKEPAKTQPAVATAATAAEKYKHRGEGERKDIVSSSMPRPNREEPVDSRTPVTERVS	486	P51608	F	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [157, 158], 'STRAND_gain_score': array([0.05092394, 0.05994934]), 'HELIX_loss': [], 'HELIX_gain': [144], 'HELIX_gain_score': array([0.32816136]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [102], 'COMPBIAS_gain': [], 'COMPBIAS_loss_score': array([-0.0234918]), 'DOMAIN_loss': [86, 163], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.02880234, -0.05733895]), 'REGION_loss': [149, 150, 151, 324], 'REGION_gain': [], 'REGION_loss_score': array([-0.20330501, -0.20460814, -0.26907212, -0.01537561]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
352	NM_001110792.2(MECP2):c.508A>G (p.Thr170Ala)	143590	CA270438	NM_001110792.2:c.508A>G, NC_000023.11:g.154031356T>C, CM000685.2:g.154031356T>C, NC_000023.10:g.153296807T>C, CM000685.1:g.153296807T>C, NC_000023.9:g.152950001T>C, NG_007107.2:g.110772A>G, NG_007107.3:g.110748A>G, ENST00000303391.11:c.472A>G, ENST00000453960.7:c.508A>G, ENST00000637917.1:n.65+40A>G, ENST00000303391.10:c.472A>G, ENST00000407218.5:c.468+40A>G, ENST00000453960.6:c.508A>G, ENST00000486506.5:n.2820A>G, ENST00000611468.1:c.460A>G, ENST00000619732.4:c.472A>G, ENST00000622433.4:c.460A>G, ENST00000628176.2:c.432+40A>G, NM_001110792.1:c.508A>G, NM_001316337.1:c.193A>G, NM_004992.3:c.472A>G, XM_005274681.3:c.472A>G, XM_005274682.3:c.193A>G, XM_005274683.3:c.193A>G, XM_006724819.2:c.-129+40A>G, XM_011531166.1:c.193A>G, XM_006724819.3:c.-129+40A>G, XM_011531166.2:c.193A>G, XM_024452383.1:c.193A>G, XM_024452384.1:c.193A>G, NM_001316337.2:c.193A>G, NM_001369391.2:c.193A>G, NM_001369392.2:c.193A>G, NM_001369393.2:c.193A>G, NM_001369394.1:c.193A>G, NM_001369394.2:c.193A>G, NM_001386137.1:c.-129+40A>G, NM_001386138.1:c.-129+40A>G, NM_001386139.1:c.-129+40A>G, NM_004992.4:c.472A>G, NM_001110792.2(MECP2):c.508A>G (p.Thr170Ala)	MECP2	Rett syndrome	MONDO:0010726	X-linked inheritance	Pathogenic	PP3, PP4, PM2_Supporting, PM6, PS4_Moderate, PM5_Strong, PS3_Supporting		The p.Thr158Ala variant in MECP2 (NM_004992.3) has been reported as a de novo occurrence (biological parentage unconfirmed) in an individual with preserved speech variant Rett syndrome (PMID 11269512) (PM6). The p.Thr158Ala variant has been observed in 2 other individuals with Rett syndrome (PMID 18842453, 15057977) (PS4_moderate, PP4). Multiple pathogenic missense variants have been previously identified within this codon which indicates that this residue is critical to the function of the protein (PMID 18337588, 23270700, 23421866, 10508514, internal database - Invitae) (PM5_strong). The p.Thr158Ala variant in MECP2 is absent from gnomAD (PM2_supporting). Heterochromatin binding and in vitro transcription repression assays have shown that this variant impacts protein function (PMID 12843318) (PS3_supporting). Computational prediction analysis tools suggests a deleterious impact; however, this information does not predict clinical significance on its own (PP3). In summary, the p.Thr158Ala variant in MECP2 is classified as Pathogenic for Rett syndrome based on the ACMG/AMP criteria (PM5_strong, PM6, PS4_moderate, PS3_supporting, PM2_supporting, PP3, PP4).		Rett and Angelman-like Disorders VCEP	https://clinicalgenome.org/site/assets/files/7339/clingen_rettas_acmg_specifications_v2.pdf	2021-10-26	2021-12-27	False	https://erepo.genome.network/evrepo/ui/classification/CA270438/MONDO:0010726/016	7c0d60c3-3c7d-4eaa-9029-8f79030fa221	p.Thr170Ala	Thr	170	Ala	MVAGMLGLREEKSEDQDLQGLKDKPLKFKKVKKDKKEEKEGKHEPVQPSAHHSAEPAEAGKAETSEGSGSAPAVPEASASPKQRRSIIRDRGPMYDDPTLPEGWTRKLKQRKSGRSAGKYDVYLINPQGKAFRSKVELIAYFEKVGDTSLDPNDFDFTVTGRGSPSRREQKPPKKPKSPKAPGTGRGRGRPKGSGTTRPKAATSEGVQVKRVLEKSPGKLLVKMPFQTSPGGKAEGGGATTSTQVMVIKRPGRKRKAEADPQAIPKKRGRKPGSVVAAAAAEAKKKAVKESSIRSVQETVLPIKKRKTRETVSIEVKEVVKPLLVSTLGEKSGKGLKTCKSPGRKSKESSPKGRSSSASSPPKKEHHHHHHHSESPKAPVPLLPPLPPPPPEPESSEDPTSPPEPQDLSSSVCKEEKMPRGGSLESDGCPKEPAKTQPAVATAATAAEKYKHRGEGERKDIVSSSMPRPNREEPVDSRTPVTERVS	486	P51608	A	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [264], 'COMPBIAS_gain_score': array([0.02761012]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
353	NM_001110792.2(MECP2):c.503A>G (p.Asp168Gly)	143583	CA270431	NM_001110792.2:c.503A>G, NC_000023.11:g.154031361T>C, CM000685.2:g.154031361T>C, NC_000023.10:g.153296812T>C, CM000685.1:g.153296812T>C, NC_000023.9:g.152950006T>C, NG_007107.2:g.110767A>G, NG_007107.3:g.110743A>G, ENST00000303391.11:c.467A>G, ENST00000453960.7:c.503A>G, ENST00000637917.1:n.65+35A>G, ENST00000303391.10:c.467A>G, ENST00000407218.5:c.468+35A>G, ENST00000453960.6:c.503A>G, ENST00000486506.5:n.2815A>G, ENST00000611468.1:c.455A>G, ENST00000619732.4:c.467A>G, ENST00000622433.4:c.455A>G, ENST00000628176.2:c.432+35A>G, NM_001110792.1:c.503A>G, NM_001316337.1:c.188A>G, NM_004992.3:c.467A>G, XM_005274681.3:c.467A>G, XM_005274682.3:c.188A>G, XM_005274683.3:c.188A>G, XM_006724819.2:c.-129+35A>G, XM_011531166.1:c.188A>G, XM_006724819.3:c.-129+35A>G, XM_011531166.2:c.188A>G, XM_024452383.1:c.188A>G, XM_024452384.1:c.188A>G, NM_001316337.2:c.188A>G, NM_001369391.2:c.188A>G, NM_001369392.2:c.188A>G, NM_001369393.2:c.188A>G, NM_001369394.1:c.188A>G, NM_001369394.2:c.188A>G, NM_001386137.1:c.-129+35A>G, NM_001386138.1:c.-129+35A>G, NM_001386139.1:c.-129+35A>G, NM_004992.4:c.467A>G, NM_001110792.2(MECP2):c.503A>G (p.Asp168Gly)	MECP2	Rett syndrome	MONDO:0010726	X-linked inheritance	Pathogenic	PP3, PM6_Strong, PM2, PS4_Moderate, PS3_Supporting, PM1, PM5	PP4	The p.Asp156Gly variant in MECP2 (NM_004992.3) has been reported in at least 2 de novo occurrences (biological parentage unconfirmed) in individuals with phenotype consistent with Rett syndrome (PMID 11309679, 11241840) (PM6_strong). The p.Asp156Gly variant in MECP2 has been observed in at least 2 other individuals with clinical features of Rett syndrome (PMID 11309679, 11241840) (PS4_moderate). The p.Asp156Gly variant occurs in the well-characterized methyl-binding domain (MBD) functional domain of MECP2 (PMID 1326358, 23770565) (PM1). A pathogenic missense variant (p.Asp156Glu) has been previously identified within this codon which indicates that this residue is critical to the function of the protein (PMID 11524741, 15737703, 26984561, 27354166, 12843318, 26418480, internal database - Invitae) (PM5). The p.Asp156Gly variant in MECP2 is absent from gnomAD (PM2_supporting). Chromatin binding and in vitro transcription repression assays have shown that this variant impacts protein function (PMID 12843318) (PS3_supporting). Computational prediction analysis tools suggests a deleterious impact; however, this information does not predict clinical significance on its own (PP3).  In summary, the p.Asp156Gly variant in MECP2 is classified as Pathogenic for Rett syndrome based on the ACMG/AMP criteria (PM6_strong, PS4_moderate, PM1, PM5, PS3_supporting, PM2_supporting, PP3).		Rett and Angelman-like Disorders VCEP	https://clinicalgenome.org/site/assets/files/7339/clingen_rettas_acmg_specifications_v2.pdf	2021-10-26	2021-12-27	False	https://erepo.genome.network/evrepo/ui/classification/CA270431/MONDO:0010726/016	1cb2470d-8a34-48e7-a854-6aae0154359d	p.Asp168Gly	Asp	168	Gly	MVAGMLGLREEKSEDQDLQGLKDKPLKFKKVKKDKKEEKEGKHEPVQPSAHHSAEPAEAGKAETSEGSGSAPAVPEASASPKQRRSIIRDRGPMYDDPTLPEGWTRKLKQRKSGRSAGKYDVYLINPQGKAFRSKVELIAYFEKVGDTSLDPNDFDFTVTGRGSPSRREQKPPKKPKSPKAPGTGRGRGRPKGSGTTRPKAATSEGVQVKRVLEKSPGKLLVKMPFQTSPGGKAEGGGATTSTQVMVIKRPGRKRKAEADPQAIPKKRGRKPGSVVAAAAAEAKKKAVKESSIRSVQETVLPIKKRKTRETVSIEVKEVVKPLLVSTLGEKSGKGLKTCKSPGRKSKESSPKGRSSSASSPPKKEHHHHHHHSESPKAPVPLLPPLPPPPPEPESSEDPTSPPEPQDLSSSVCKEEKMPRGGSLESDGCPKEPAKTQPAVATAATAAEKYKHRGEGERKDIVSSSMPRPNREEPVDSRTPVTERVS	486	P51608	G	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [163], 'DOMAIN_gain': [85], 'DOMAIN_gain_score': array([0.01531124]), 'DOMAIN_loss_score': array([-0.06380516]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
354	NM_001110792.2(MECP2):c.491C>G (p.Pro164Arg)	143579	CA270424	NM_001110792.2:c.491C>G, NC_000023.11:g.154031373G>C, CM000685.2:g.154031373G>C, NC_000023.10:g.153296824G>C, CM000685.1:g.153296824G>C, NC_000023.9:g.152950018G>C, NG_007107.2:g.110755C>G, NG_007107.3:g.110731C>G, ENST00000303391.11:c.455C>G, ENST00000453960.7:c.491C>G, ENST00000637917.1:n.65+23C>G, ENST00000303391.10:c.455C>G, ENST00000369957.5:c.*509C>G, ENST00000407218.5:c.468+23C>G, ENST00000453960.6:c.491C>G, ENST00000486506.5:n.2803C>G, ENST00000611468.1:c.443C>G, ENST00000619732.4:c.455C>G, ENST00000622433.4:c.443C>G, ENST00000628176.2:c.432+23C>G, NM_001110792.1:c.491C>G, NM_001316337.1:c.176C>G, NM_004992.3:c.455C>G, XM_005274681.3:c.455C>G, XM_005274682.3:c.176C>G, XM_005274683.3:c.176C>G, XM_006724819.2:c.-129+23C>G, XM_011531166.1:c.176C>G, XM_006724819.3:c.-129+23C>G, XM_011531166.2:c.176C>G, XM_024452383.1:c.176C>G, XM_024452384.1:c.176C>G, NM_001316337.2:c.176C>G, NM_001369391.2:c.176C>G, NM_001369392.2:c.176C>G, NM_001369393.2:c.176C>G, NM_001369394.1:c.176C>G, NM_001369394.2:c.176C>G, NM_001386137.1:c.-129+23C>G, NM_001386138.1:c.-129+23C>G, NM_001386139.1:c.-129+23C>G, NM_004992.4:c.455C>G, NM_001110792.2(MECP2):c.491C>G (p.Pro164Arg)	MECP2	Rett syndrome	MONDO:0010726	X-linked inheritance	Pathogenic	PP4, PP3, PM2_Supporting, PS2_Very Strong, PS4, PS3_Supporting, PM1, PM5		The p.Pro152Arg variant in MECP2 (NM_004992.3) has been reported in at least 6 de novo occurrences (biological parentage unconfirmed) in patients with Rett syndrome (PMID 10767337, 10814718, 11241840) and in at least 4 other individuals with clinical features of Rett syndrome (PMID 11055898, 2385859, RettBASE) (PM6_very strong, PP4, PS4). The p.Pro152Arg variant occurs in the well-characterized methyl-DNA binding (MDB) functional domain of MECP2 (PM1). A pathogenic missense variant (p.Pro152Ala) has been previously identified within this codon which indicates that this residue is critical to the function of the protein (PMID 18989701, 18989701, 27929079, 26842955, ClinVar) (PM5). Computational prediction analysis tools suggests a deleterious impact; however, this information does not predict clinical significance on its own (PP3). Immunofluorescence assays have shown that the p.Pro152Arg variant in MECP2 impacts heterochromatin clustering (PMID 21831886, 22923521) (PS3_supporting). The p.Pro152Arg variant in MECP2 is absent from gnomAD (PM2_supporting). In summary, the p.Pro152Arg variant in MECP2 is classified as Pathogenic for Rett syndrome based on the ACMG/AMP criteria (PM6_very strong, PS4, PM1, PM5, PS3_supporting, PM2_supporting, PP3, PP4).		Rett and Angelman-like Disorders VCEP	https://clinicalgenome.org/site/assets/files/7339/clingen_rettas_acmg_specifications_v2.pdf	2021-10-26	2021-12-27	False	https://erepo.genome.network/evrepo/ui/classification/CA270424/MONDO:0010726/016	6d7ad90d-38fc-4fab-9db8-b6da72e59655	p.Pro164Arg	Pro	164	Arg	MVAGMLGLREEKSEDQDLQGLKDKPLKFKKVKKDKKEEKEGKHEPVQPSAHHSAEPAEAGKAETSEGSGSAPAVPEASASPKQRRSIIRDRGPMYDDPTLPEGWTRKLKQRKSGRSAGKYDVYLINPQGKAFRSKVELIAYFEKVGDTSLDPNDFDFTVTGRGSPSRREQKPPKKPKSPKAPGTGRGRGRPKGSGTTRPKAATSEGVQVKRVLEKSPGKLLVKMPFQTSPGGKAEGGGATTSTQVMVIKRPGRKRKAEADPQAIPKKRGRKPGSVVAAAAAEAKKKAVKESSIRSVQETVLPIKKRKTRETVSIEVKEVVKPLLVSTLGEKSGKGLKTCKSPGRKSKESSPKGRSSSASSPPKKEHHHHHHHSESPKAPVPLLPPLPPPPPEPESSEDPTSPPEPQDLSSSVCKEEKMPRGGSLESDGCPKEPAKTQPAVATAATAAEKYKHRGEGERKDIVSSSMPRPNREEPVDSRTPVTERVS	486	P51608	R	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [166, 167, 168, 170, 171, 173, 264], 'COMPBIAS_gain_score': array([0.38098145, 0.39233238, 0.40792018, 0.40635991, 0.35670942,
       0.39190269, 0.01044136]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
355	NM_001110792.2(MECP2):c.439A>G (p.Lys147Glu)	143564	CA270401	NM_001110792.2:c.439A>G, NC_000023.11:g.154031425T>C, CM000685.2:g.154031425T>C, NC_000023.10:g.153296876T>C, CM000685.1:g.153296876T>C, NC_000023.9:g.152950070T>C, NG_007107.2:g.110703A>G, NG_007107.3:g.110679A>G, ENST00000303391.11:c.403A>G, ENST00000453960.7:c.439A>G, ENST00000637917.1:n.36A>G, ENST00000303391.10:c.403A>G, ENST00000369957.5:c.*457A>G, ENST00000407218.5:c.439A>G, ENST00000453960.6:c.439A>G, ENST00000486506.5:n.2751A>G, ENST00000611468.1:c.391A>G, ENST00000619732.4:c.403A>G, ENST00000622433.4:c.391A>G, ENST00000628176.2:c.403A>G, NM_001110792.1:c.439A>G, NM_001316337.1:c.124A>G, NM_004992.3:c.403A>G, XM_005274681.3:c.403A>G, XM_005274682.3:c.124A>G, XM_005274683.3:c.124A>G, XM_006724819.2:c.-158A>G, XM_011531166.1:c.124A>G, XM_006724819.3:c.-158A>G, XM_011531166.2:c.124A>G, XM_024452383.1:c.124A>G, XM_024452384.1:c.124A>G, NM_001316337.2:c.124A>G, NM_001369391.2:c.124A>G, NM_001369392.2:c.124A>G, NM_001369393.2:c.124A>G, NM_001369394.1:c.124A>G, NM_001369394.2:c.124A>G, NM_001386137.1:c.-158A>G, NM_001386138.1:c.-158A>G, NM_001386139.1:c.-158A>G, NM_004992.4:c.403A>G, NM_001110792.2(MECP2):c.439A>G (p.Lys147Glu)	MECP2	Rett syndrome	MONDO:0010726	X-linked inheritance	Pathogenic	PP3, PP4, PM2_Supporting, PM6, PS4, PS3_Supporting, PM1		The p.Lys135Glu variant in MECP2 (NM_004992.3) has been reported as a de novo occurrence (biological parentage unconfirmed) in an individual with Rett syndrome (PMID 22182064) (PM6). The p.Lys135Glu variant has been observed in at least 6 other individuals with Rett syndrome (PMID 11241840, 22982301, 18842453, 16473305, 17387578) (PS4 and PP4). The p.Lys135Glu variant occurs in the well-characterized methyl-binding domain (MBD) functional domain of MECP2 (PMID 1326358, 23770565) (PM1). The p.Lys135Glu variant in MECP2 is absent from gnomAD (PM2_supporting). Computational prediction analysis tools suggest a deleterious impact; however, this information does not predict clinical significance on its own (PP3). MECP2 chromatin binding assays and in vitro transcription repression assays have shown that this variant impacts protein function (PMID 21831886, 12843318) (PS3_supporting). In summary, the p.Lys135Glu variant in MECP2 is classified as Pathogenic for Rett syndrome based on the ACMG/AMP criteria (PS4, PM1, PM6, PM2_supporting, PS3_supporting, PP3, PP4).		Rett and Angelman-like Disorders VCEP	https://clinicalgenome.org/site/assets/files/7339/clingen_rettas_acmg_specifications_v2.pdf	2021-10-26	2021-12-27	False	https://erepo.genome.network/evrepo/ui/classification/CA270401/MONDO:0010726/016	4cc0ea18-84f8-4a59-b14d-908303cbe14c	p.Lys147Glu	Lys	147	Glu	MVAGMLGLREEKSEDQDLQGLKDKPLKFKKVKKDKKEEKEGKHEPVQPSAHHSAEPAEAGKAETSEGSGSAPAVPEASASPKQRRSIIRDRGPMYDDPTLPEGWTRKLKQRKSGRSAGKYDVYLINPQGKAFRSKVELIAYFEKVGDTSLDPNDFDFTVTGRGSPSRREQKPPKKPKSPKAPGTGRGRGRPKGSGTTRPKAATSEGVQVKRVLEKSPGKLLVKMPFQTSPGGKAEGGGATTSTQVMVIKRPGRKRKAEADPQAIPKKRGRKPGSVVAAAAAEAKKKAVKESSIRSVQETVLPIKKRKTRETVSIEVKEVVKPLLVSTLGEKSGKGLKTCKSPGRKSKESSPKGRSSSASSPPKKEHHHHHHHSESPKAPVPLLPPLPPPPPEPESSEDPTSPPEPQDLSSSVCKEEKMPRGGSLESDGCPKEPAKTQPAVATAATAAEKYKHRGEGERKDIVSSSMPRPNREEPVDSRTPVTERVS	486	P51608	E	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [163], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.04918873]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
356	NM_001110792.2(MECP2):c.434G>A (p.Arg145His)	143559	CA274538	NM_001110792.2:c.434G>A, NC_000023.11:g.154031430C>T, CM000685.2:g.154031430C>T, NC_000023.10:g.153296881C>T, CM000685.1:g.153296881C>T, NC_000023.9:g.152950075C>T, NG_007107.2:g.110698G>A, NG_007107.3:g.110674G>A, ENST00000303391.11:c.398G>A, ENST00000453960.7:c.434G>A, ENST00000637917.1:n.31G>A, ENST00000303391.10:c.398G>A, ENST00000369957.5:c.*452G>A, ENST00000407218.5:c.434G>A, ENST00000453960.6:c.434G>A, ENST00000486506.5:n.2746G>A, ENST00000611468.1:c.386G>A, ENST00000619732.4:c.398G>A, ENST00000622433.4:c.386G>A, ENST00000628176.2:c.398G>A, NM_001110792.1:c.434G>A, NM_001316337.1:c.119G>A, NM_004992.3:c.398G>A, XM_005274681.3:c.398G>A, XM_005274682.3:c.119G>A, XM_005274683.3:c.119G>A, XM_006724819.2:c.-163G>A, XM_011531166.1:c.119G>A, XM_006724819.3:c.-163G>A, XM_011531166.2:c.119G>A, XM_024452383.1:c.119G>A, XM_024452384.1:c.119G>A, NM_001316337.2:c.119G>A, NM_001369391.2:c.119G>A, NM_001369392.2:c.119G>A, NM_001369393.2:c.119G>A, NM_001369394.1:c.119G>A, NM_001369394.2:c.119G>A, NM_001386137.1:c.-163G>A, NM_001386138.1:c.-163G>A, NM_001386139.1:c.-163G>A, NM_004992.4:c.398G>A, NM_001110792.2(MECP2):c.434G>A (p.Arg145His)	MECP2	Rett syndrome	MONDO:0010726	X-linked inheritance	Pathogenic	PP4, PP3, PM2_Supporting, PS2_Very Strong, PM5_Strong, PS4, PS3_Supporting, PM1		The p.Arg133His variant in MECP2 (NM_004992.3) has been reported as a de novo occurrence (biological parentage both confirmed and unconfirmed) in at least 4 individuals with classic or atypical Rett syndrome (PMID 30569584, 17089071, 30945278) (PS2_very strong, PP4). The p.Arg133His variant has been observed in at least 3 other individuals with classic or atypical Rett syndrome (PMID 16473305, RettBASE) (PS4). Four additional pathogenic missense variants (p.Arg133Cys, p.Arg133Leu, p.Arg133Pro, p.Arg133Gly) have been previously identified within this codon which indicates that this residue is critical to the function of the protein (PMID 23421866, 11738879, 26418480, 16473305, 22368975, 10854091, 11960578, 12180070, Invitae - internal database) (PM5_Strong). Computational prediction analysis tools suggests a deleterious impact; however, this information does not predict clinical significance on its own (PP3). Luciferase reporter and immunofluorescence assays have shown that this variant impacts protein function (PMID 21831886, 12843318) (PS3_supporting). The p.Arg133His variant in MECP2 is absent from gnomAD (PM2_supporting). In summary, the p.Arg133His variant in MECP2 is classified as Pathogenic for Rett syndrome based on the ACMG/AMP criteria (PS2_very strong, PS4, PM5_strong, PS3_supporting, PM2_supporting, PP3, PP4).		Rett and Angelman-like Disorders VCEP	https://clinicalgenome.org/site/assets/files/7339/clingen_rettas_acmg_specifications_v2.pdf	2021-10-26	2021-12-27	False	https://erepo.genome.network/evrepo/ui/classification/CA274538/MONDO:0010726/016	0fb2669b-a028-460e-a61d-84f544baf3a5	p.Arg145His	Arg	145	His	MVAGMLGLREEKSEDQDLQGLKDKPLKFKKVKKDKKEEKEGKHEPVQPSAHHSAEPAEAGKAETSEGSGSAPAVPEASASPKQRRSIIRDRGPMYDDPTLPEGWTRKLKQRKSGRSAGKYDVYLINPQGKAFRSKVELIAYFEKVGDTSLDPNDFDFTVTGRGSPSRREQKPPKKPKSPKAPGTGRGRGRPKGSGTTRPKAATSEGVQVKRVLEKSPGKLLVKMPFQTSPGGKAEGGGATTSTQVMVIKRPGRKRKAEADPQAIPKKRGRKPGSVVAAAAAEAKKKAVKESSIRSVQETVLPIKKRKTRETVSIEVKEVVKPLLVSTLGEKSGKGLKTCKSPGRKSKESSPKGRSSSASSPPKKEHHHHHHHSESPKAPVPLLPPLPPPPPEPESSEDPTSPPEPQDLSSSVCKEEKMPRGGSLESDGCPKEPAKTQPAVATAATAAEKYKHRGEGERKDIVSSSMPRPNREEPVDSRTPVTERVS	486	P51608	H	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [86, 163], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.03345072, -0.11548483]), 'REGION_loss': [], 'REGION_gain': [147, 148], 'REGION_gain_score': array([0.2188682, 0.2377404]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
357	NM_001110792.2(MECP2):c.416C>T (p.Pro139Leu)	143552	CA270373	NM_001110792.2:c.416C>T, NC_000023.11:g.154031448G>A, CM000685.2:g.154031448G>A, NC_000023.10:g.153296899G>A, CM000685.1:g.153296899G>A, NC_000023.9:g.152950093G>A, NG_007107.2:g.110680C>T, NG_007107.3:g.110656C>T, ENST00000303391.11:c.380C>T, ENST00000453960.7:c.416C>T, ENST00000637917.1:n.13C>T, ENST00000303391.10:c.380C>T, ENST00000369957.5:c.*434C>T, ENST00000407218.5:c.416C>T, ENST00000453960.6:c.416C>T, ENST00000486506.5:n.2728C>T, ENST00000611468.1:c.368C>T, ENST00000619732.4:c.380C>T, ENST00000622433.4:c.368C>T, ENST00000628176.2:c.380C>T, NM_001110792.1:c.416C>T, NM_001316337.1:c.101C>T, NM_004992.3:c.380C>T, XM_005274681.3:c.380C>T, XM_005274682.3:c.101C>T, XM_005274683.3:c.101C>T, XM_006724819.2:c.-181C>T, XM_011531166.1:c.101C>T, XM_006724819.3:c.-181C>T, XM_011531166.2:c.101C>T, XM_024452383.1:c.101C>T, XM_024452384.1:c.101C>T, NM_001316337.2:c.101C>T, NM_001369391.2:c.101C>T, NM_001369392.2:c.101C>T, NM_001369393.2:c.101C>T, NM_001369394.1:c.101C>T, NM_001369394.2:c.101C>T, NM_001386137.1:c.-181C>T, NM_001386138.1:c.-181C>T, NM_001386139.1:c.-181C>T, NM_004992.4:c.380C>T, NM_001110792.2(MECP2):c.416C>T (p.Pro139Leu)	MECP2	Rett syndrome	MONDO:0010726	X-linked inheritance	Pathogenic	PP3, PP4, PM2_Supporting, PM6_Strong, PS4, PM1	PS3	The p.Pro127Leu variant in MECP2 (NM_004992.3) has been reported in at least 2 de novo occurrences (biological parentage unconfirmed) in individuals with Rett syndrome (PMID: 16225173, 22182064) (PM6_strong, PP4). This variant has been observed in at least 5 other individuals with Rett syndrome (PMID: 11245712, 16473305, 11960578, internal database - Invitae) (PS4). The p.Pro127Leu variant occurs in the well-characterized methyl binding domain (MBD) functional domain of MECP2 (PMID: 21326358, 23770565) (PM1). The p.Pro127Leu variant in MECP2 is absent from gnomAD (PM2_supporting). Computational prediction analysis tools suggests a deleterious impact; however, this information does not predict clinical significance on its own (PP3). In summary, the p.Pro127Leu variant in MECP2 is classified as Pathogenic for Rett syndrome based on the ACMG/AMP criteria (PM6_strong, PS4, PM1, PM2_supporting, PP3, PP4).		Rett and Angelman-like Disorders VCEP	https://clinicalgenome.org/site/assets/files/7339/clingen_rettas_acmg_specifications_v2.pdf	2021-10-26	2021-12-27	False	https://erepo.genome.network/evrepo/ui/classification/CA270373/MONDO:0010726/016	2161318a-9364-40db-a371-c3dd56921992	p.Pro139Leu	Pro	139	Leu	MVAGMLGLREEKSEDQDLQGLKDKPLKFKKVKKDKKEEKEGKHEPVQPSAHHSAEPAEAGKAETSEGSGSAPAVPEASASPKQRRSIIRDRGPMYDDPTLPEGWTRKLKQRKSGRSAGKYDVYLINPQGKAFRSKVELIAYFEKVGDTSLDPNDFDFTVTGRGSPSRREQKPPKKPKSPKAPGTGRGRGRPKGSGTTRPKAATSEGVQVKRVLEKSPGKLLVKMPFQTSPGGKAEGGGATTSTQVMVIKRPGRKRKAEADPQAIPKKRGRKPGSVVAAAAAEAKKKAVKESSIRSVQETVLPIKKRKTRETVSIEVKEVVKPLLVSTLGEKSGKGLKTCKSPGRKSKESSPKGRSSSASSPPKKEHHHHHHHSESPKAPVPLLPPLPPPPPEPESSEDPTSPPEPQDLSSSVCKEEKMPRGGSLESDGCPKEPAKTQPAVATAATAAEKYKHRGEGERKDIVSSSMPRPNREEPVDSRTPVTERVS	486	P51608	L	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [103], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.01891196]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [163], 'DOMAIN_gain': [85], 'DOMAIN_gain_score': array([0.01685286]), 'DOMAIN_loss_score': array([-0.04032344]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
358	NM_001110792.2(MECP2):c.400G>A (p.Val134Met)	143546	CA270366	NM_001110792.2:c.400G>A, NC_000023.11:g.154032220C>T, CM000685.2:g.154032220C>T, NC_000023.10:g.153297671C>T, CM000685.1:g.153297671C>T, NC_000023.9:g.152950865C>T, NG_007107.2:g.109908G>A, NG_007107.3:g.109884G>A, ENST00000303391.11:c.364G>A, ENST00000453960.7:c.400G>A, ENST00000303391.10:c.364G>A, ENST00000369957.5:c.*418G>A, ENST00000407218.5:c.400G>A, ENST00000453960.6:c.400G>A, ENST00000486506.5:n.2712G>A, ENST00000611468.1:c.352G>A, ENST00000619732.4:c.364G>A, ENST00000622433.4:c.352G>A, ENST00000628176.2:c.364G>A, NM_001110792.1:c.400G>A, NM_001316337.1:c.85G>A, NM_004992.3:c.364G>A, XM_005274681.3:c.364G>A, XM_005274682.3:c.85G>A, XM_005274683.3:c.85G>A, XM_006724819.2:c.-197G>A, XM_011531166.1:c.85G>A, XM_006724819.3:c.-197G>A, XM_011531166.2:c.85G>A, XM_024452383.1:c.85G>A, XM_024452384.1:c.85G>A, NM_001316337.2:c.85G>A, NM_001369391.2:c.85G>A, NM_001369392.2:c.85G>A, NM_001369393.2:c.85G>A, NM_001369394.1:c.85G>A, NM_001369394.2:c.85G>A, NM_001386137.1:c.-197G>A, NM_001386138.1:c.-197G>A, NM_001386139.1:c.-197G>A, NM_004992.4:c.364G>A, NM_001110792.2(MECP2):c.400G>A (p.Val134Met)	MECP2	Rett syndrome	MONDO:0010726	X-linked inheritance	Pathogenic	PP3, PP4, PM2_Supporting, PS4_Supporting, PS2, PM1		The p.Val122Met variant in MECP2 (NM_004992.3) has been reported in an individual with a clinical phenotype suggestive of Rett syndrome (PMID: 17089071) (PP4). The p.Val122Met variant in MECP2 occurs in the de novo state (biological parentage unconfirmed) in this individual. It is also reported in the mosaic state in a male patient with clinical features of Rett syndrome (PMID 28837158, internal database - GeneDx) and therefore confirmed to be de novo (PS2, PS4_supporting). The p.Val122Met variant occurs in the well-characterized methyl-DNA binding (MDB) functional domain of MECP2 (PM1). Computational prediction analysis tools suggests a deleterious impact; however, this information does not predict clinical significance on its own (PP3). The p.Val122Met variant in MECP2 is absent from gnomAD (PM2_supporting).  In summary, the p.Val122Met variant in MECP2 is classified as Pathogenic for Rett syndrome based on the ACMG/AMP criteria (PS2, PM1, PS4_supporting, PM2_supporting, PP3, PP4).		Rett and Angelman-like Disorders VCEP	https://clinicalgenome.org/site/assets/files/7339/clingen_rettas_acmg_specifications_v2.pdf	2021-10-26	2021-12-27	False	https://erepo.genome.network/evrepo/ui/classification/CA270366/MONDO:0010726/016	524c0c15-0c45-4f53-a9b3-ab6d2536879f	p.Val134Met	Val	134	Met	MVAGMLGLREEKSEDQDLQGLKDKPLKFKKVKKDKKEEKEGKHEPVQPSAHHSAEPAEAGKAETSEGSGSAPAVPEASASPKQRRSIIRDRGPMYDDPTLPEGWTRKLKQRKSGRSAGKYDVYLINPQGKAFRSKVELIAYFEKVGDTSLDPNDFDFTVTGRGSPSRREQKPPKKPKSPKAPGTGRGRGRPKGSGTTRPKAATSEGVQVKRVLEKSPGKLLVKMPFQTSPGGKAEGGGATTSTQVMVIKRPGRKRKAEADPQAIPKKRGRKPGSVVAAAAAEAKKKAVKESSIRSVQETVLPIKKRKTRETVSIEVKEVVKPLLVSTLGEKSGKGLKTCKSPGRKSKESSPKGRSSSASSPPKKEHHHHHHHSESPKAPVPLLPPLPPPPPEPESSEDPTSPPEPQDLSSSVCKEEKMPRGGSLESDGCPKEPAKTQPAVATAATAAEKYKHRGEGERKDIVSSSMPRPNREEPVDSRTPVTERVS	486	P51608	M	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [102], 'COMPBIAS_gain': [], 'COMPBIAS_loss_score': array([-0.03188181]), 'DOMAIN_loss': [], 'DOMAIN_gain': [82, 83, 84, 85, 164, 165], 'DOMAIN_gain_score': array([0.23150378, 0.26056641, 0.28110075, 0.29028034, 0.15425569,
       0.13805419]), 'REGION_loss': [324], 'REGION_gain': [], 'REGION_loss_score': array([-0.02858192]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
359	NM_000545.6(HNF1A):c.476G>A (p.Arg159Gln)	586792	CA386960413	NM_000545.6:c.476G>A, NC_000012.12:g.120988982G>A, CM000674.2:g.120988982G>A, NC_000012.11:g.121426785G>A, CM000674.1:g.121426785G>A, NC_000012.10:g.119911168G>A, NG_011731.2:g.15237G>A, LRG_522:g.15237G>A, ENST00000257555.11:c.476G>A, ENST00000257555.10:c.476G>A, ENST00000400024.6:c.476G>A, ENST00000402929.5:n.611G>A, ENST00000535955.5:n.43-8509G>A, ENST00000538626.2:n.191-8509G>A, ENST00000538646.5:c.476G>A, ENST00000540108.1:c.327-4538G>A, ENST00000541395.5:c.476G>A, ENST00000541924.5:c.476G>A, ENST00000543427.5:c.476G>A, ENST00000544413.2:c.476G>A, ENST00000544574.5:c.73-7635G>A, ENST00000560968.5:n.619G>A, ENST00000615446.4:c.-257-7280G>A, ENST00000617366.4:c.476G>A, NM_000545.5:c.476G>A, LRG_522t1:c.476G>A, NM_001306179.1:c.476G>A, XM_005253931.2:c.476G>A, XM_024449168.1:c.476G>A, NM_000545.8:c.476G>A, NM_001306179.2:c.476G>A, NM_000545.8(HNF1A):c.476G>A (p.Arg159Gln), NM_000545.6(HNF1A):c.476G>A (p.Arg159Gln)	HNF1A	monogenic diabetes	MONDO:0015967	Autosomal dominant inheritance	Pathogenic	PM1, PS4, PP4_Moderate, PP3, PP1, PM2_Supporting		The c.476G>A variant in the HNF1 homeobox A gene, HNF1A, causes an amino acid change of arginine to glutamine at codon 159 (p.Arg159Gln) of NM_000545.8. This variant was identified in more than 10 unrelated individuals with non- autoimmune and non-absolute/near-absolute insulin-deficient diabetes (PS4; PMIDS: 10078571, 12488961, 15928245, 20132997, 9097962, 10754480, internal lab contributors). Also, this variant segregated with diabetes, with at least 11 informative meioses in 17 families with MODY (PP1_Strong; PMIDs: 9097962, 10754480, internal lab contributors). This variant is located within a conserved region of the DNA binding domain (codons 107-174 and 201-280) of HNF1A, which is defined as critical for the protein’s function by the ClinGen MDEP (PM1_Supporting). This variant is also absent from gnomAD v2.1.1 (PM2_Supporting). Additionally, this variant was identified in an individual with a clinical history highly specific for HNF1A-MODY (MODY probability calculator result >50%, negative genetic testing for HNF4A, and response to low-dose sulfonylureas) (PP4_Moderate; internal lab contributors). This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.976, which is greater than or equal to the MDEP VCEP threshold of 0.70 (PP3). Lastly, functional studies demonstrated the p.Arg159Gln protein has DNA binding below 40% of wild type, indicating that this variant impacts protein function (PS3_Supporting; PMID: 10585442). In summary, c.476G>A meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.1, approved 6/4/2021): PS4, PP1_Strong, PM1_Supporting, PM2_Supporting, PP4_Moderate, PP3, PS3_Supporting		Monogenic Diabetes VCEP		2021-12-30	2021-12-30	False	https://erepo.genome.network/evrepo/ui/classification/CA386960413/MONDO:0015967/017	ed6e9cb1-5384-4744-a9d9-e7febc7b5765	p.Arg159Gln	Arg	159	Gln	MVSKLSQLQTELLAALLESGLSKEALIQALGEPGPYLLAGEGPLDKGESCGGGRGELAELPNGLGETRGSEDETDDDGEDFTPPILKELENLSPEEAAHQKAVVETLLQEDPWRVAKMVKSYLQQHNIPQREVVDTTGLNQSHLSQHLNKGTPMKTQKRAALYTWYVRKQREVAQQFTHAGQGGLIEEPTGDELPTKKGRRNRFKWGPASQQILFQAYERQKNPSKEERETLVEECNRAECIQRGVSPSQAQGLGSNLVTEVRVYNWFANRRKEEAFRHKLAMDTYSGPPPGPGPGPALPAHSSPGLPPPALSPSKVHGVRYGQPATSETAEVPSSSGGPLVTVSTPLHQVSPTGLEPSHSLLSTEAKLVSAAGGPLPPVSTLTALHSLEQTSPGLNQQPQNLIMASLPGVMTIGPGEPASLGPTFTNTGASTLVIGLASTQAQSVPVINSMGSSLTTLQPVQFSQPLHPSYQQPLMPPVQSHVTQSPFMATMAQLQSPHALYSHKPEVAQYTHTGLLPQTMLITDTTNLSALASLTPTKQVFTSDTEASSESGLHTPASQATTLHVPSQDPAGIQHLQPAHRLSASPTVSSSSLVLYQSSDSSNGQSHLLPSNHSVIETFISTQMASSSQ	631	P20823	Q	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [97, 154, 171], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.00573748, -0.091456  , -0.0117296 ]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [81], 'DOMAIN_gain': [6, 35], 'DOMAIN_gain_score': array([0.02628589, 0.03126419]), 'DOMAIN_loss_score': array([-0.03759962]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
360	NM_000545.6(HNF1A):c.1340C>T (p.Pro447Leu)	14928	CA124454	NM_000545.6:c.1340C>T, NC_000012.12:g.120997504C>T, CM000674.2:g.120997504C>T, NC_000012.11:g.121435307C>T, CM000674.1:g.121435307C>T, NC_000012.10:g.119919690C>T, NG_011731.2:g.23759C>T, LRG_522:g.23759C>T, ENST00000257555.11:c.1340C>T, ENST00000257555.10:c.1340C>T, ENST00000400024.6:c.1340C>T, ENST00000402929.5:n.2206C>T, ENST00000535955.5:n.56C>T, ENST00000538626.2:n.204C>T, ENST00000538646.5:c.*316C>T, ENST00000540108.1:c.*780C>T, ENST00000541395.5:c.1340C>T, ENST00000541924.5:c.*354C>T, ENST00000543255.1:n.384C>T, ENST00000543427.5:c.803C>T, ENST00000544413.2:c.1340C>T, ENST00000544574.5:c.*103C>T, ENST00000560968.5:n.1157C>T, ENST00000615446.4:c.128C>T, ENST00000617366.4:c.587-130C>T, NM_000545.5:c.1340C>T, LRG_522t1:c.1340C>T, NM_001306179.1:c.1340C>T, XM_005253931.2:c.1340C>T, XM_024449168.1:c.1340C>T, NM_000545.8:c.1340C>T, NM_001306179.2:c.1340C>T, NM_000545.8(HNF1A):c.1340C>T (p.Pro447Leu), NM_000545.6(HNF1A):c.1340C>T (p.Pro447Leu)	HNF1A	monogenic diabetes	MONDO:0015967	Autosomal dominant inheritance	Pathogenic	PS4, PP1_Strong, PS2_Supporting, PP4, PP3, PM2_Supporting, PS3_Moderate		The c.1340C>T variant in the HNF1 homeobox A gene, HNF1A, causes an amino acid change of proline to leucine at codon 447 (p.(Pro447Leu)) of NM_000545.8. This variant was identified as a de novo occurrence with unconfirmed parental relationships in an individual with diabetes, but whose clinical picture is not highly specific for HNF1A-MODY ([MODY probability calculator result <50%/HNF4A not tested) (PS2_Supporting;  internal lab contributors). A luciferase assay meeting the ClinGen MDEP quality control specifications demonstrated that the p.Pro447Leu protein has transactivation activity below 40% of wildtype, indicating that this variant impacts protein function (PS3_Moderate, PMIDs: 27899486, 12530534, 10585442, 32910913, 32910913).  This variant was identified in 11 unrelated individuals with non- autoimmune and non-absolute/near-absolute insulin-deficient diabetes (PS4; internal lab contributors) and  is absent from gnomAD v2.1.1 (PM2_Supporting).  This variant segregated with diabetes, with at least 15 informative meioses in families with MODY (PP1_Strong;  internal lab contributors), and is predicted to be deleterious by computational evidence, with a REVEL score of 0.957, which is greater than or equal to the MDEP VCEP threshold of 0.70 (PP3). Lastly, this variant was identified in at least two individuals with a clinical history highly specific for HNF1A-MODY (MODY probability calculator result >50%, negative genetic testing for HNF4A) (PP4; internal lab contributors).  In summary, c.1340C>T meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.1, approved 6/4/2021): PS4, PP1_Strong, PP3, PP4, PS2_Supporting, PM2_Supporting, PS3_Moderate.	10585442, 12530534, 27899486	Monogenic Diabetes VCEP		2021-12-31	2022-07-11	False	https://erepo.genome.network/evrepo/ui/classification/CA124454/MONDO:0015967/017	c0326a24-f74a-4d2d-8623-525b5be1ae24	p.Pro447Leu	Pro	447	Leu	MVSKLSQLQTELLAALLESGLSKEALIQALGEPGPYLLAGEGPLDKGESCGGGRGELAELPNGLGETRGSEDETDDDGEDFTPPILKELENLSPEEAAHQKAVVETLLQEDPWRVAKMVKSYLQQHNIPQREVVDTTGLNQSHLSQHLNKGTPMKTQKRAALYTWYVRKQREVAQQFTHAGQGGLIEEPTGDELPTKKGRRNRFKWGPASQQILFQAYERQKNPSKEERETLVEECNRAECIQRGVSPSQAQGLGSNLVTEVRVYNWFANRRKEEAFRHKLAMDTYSGPPPGPGPGPALPAHSSPGLPPPALSPSKVHGVRYGQPATSETAEVPSSSGGPLVTVSTPLHQVSPTGLEPSHSLLSTEAKLVSAAGGPLPPVSTLTALHSLEQTSPGLNQQPQNLIMASLPGVMTIGPGEPASLGPTFTNTGASTLVIGLASTQAQSVPVINSMGSSLTTLQPVQFSQPLHPSYQQPLMPPVQSHVTQSPFMATMAQLQSPHALYSHKPEVAQYTHTGLLPQTMLITDTTNLSALASLTPTKQVFTSDTEASSESGLHTPASQATTLHVPSQDPAGIQHLQPAHRLSASPTVSSSSLVLYQSSDSSNGQSHLLPSNHSVIETFISTQMASSSQ	631	P20823	L	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [97], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.00324953]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [580], 'REGION_gain': [], 'REGION_loss_score': array([-0.02112645]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
361	NM_000527.5(LDLR):c.301G>A (p.Glu101Lys)	161266	CA023687	NM_000527.5:c.301G>A, NC_000019.10:g.11102774G>A, CM000681.2:g.11102774G>A, NC_000019.9:g.11213450G>A, CM000681.1:g.11213450G>A, NC_000019.8:g.11074450G>A, NG_009060.1:g.18394G>A, LRG_274:g.18394G>A, ENST00000558518.6:c.301G>A, ENST00000252444.9:n.555G>A, ENST00000455727.6:c.301G>A, ENST00000535915.5:c.190+2429G>A, ENST00000545707.5:c.301G>A, ENST00000557933.5:c.301G>A, ENST00000557958.1:n.387G>A, ENST00000558013.5:c.301G>A, ENST00000558518.5:c.301G>A, NM_000527.4:c.301G>A, LRG_274t1:c.301G>A, NM_001195798.1:c.301G>A, NM_001195799.1:c.190+2429G>A, NM_001195800.1:c.301G>A, NM_001195803.1:c.301G>A, XM_011528010.1:c.301G>A, XM_011528011.1:c.301G>A, XR_244074.2:n.451G>A, XM_011528010.2:c.301G>A, XR_001753685.2:n.418G>A, XR_001753686.2:n.418G>A, NM_001195798.2:c.301G>A, NM_001195799.2:c.190+2429G>A, NM_001195800.2:c.301G>A, NM_001195803.2:c.301G>A, NM_000527.5(LDLR):c.301G>A (p.Glu101Lys)	LDLR	hypercholesterolemia, familial	MONDO:0007750	Semidominant inheritance	Pathogenic	PS4, PP1_Strong, PM3, PM2, PP3, PP4, PS3_Moderate	PS1, PS2, PM5, PM4, PM1, BP7, BP5, BS1, BS3, BS4, PVS1, PM6, BS2, PP2, BP1, BP4, BP3, BP2, BA1	The NM_000527.5(LDLR):c.301G>A (p.Glu101Lys) variant is classified as Pathogenic for Familial Hypercholesterolemia by applying evidence codes (PP1_Strong, PS4, PM2, PM3, PS3_Moderate, PP3 and PP4) as defined by the ClinGen Familial Hypercholesterolemia Expert Panel LDLR-specific variant curation guidelines (https://doi.org/10.1101/2021.03.17.21252755). The supporting evidence is as follows: PP1_strong - variant segregates with the FH phenotype in at least 19 relatives with the variant and LDL-C above the 75th percentile from several labs (Centre de Génétique Moléculaire et Chromosomique, Unité de génétique de l'Obésité et des Dyslipidémies, Ambry, Robarts Research Institute), so PP1_Strong is met.PS4 - variant meets PM2 and is identified in at least 16 index cases who fulfill validated clinical criteria for FH from several labs (SB criteria from Cardiovascular Research Group,Instituto Nacional de Saude Doutor Ricardo Jorge and DLCN >=6 from Color, Cardiovascular Genetics Laboratory (PathWest Laboratory Medicine WA) and Robarts Research Institute), so PS4 is met.PM2 - PopMax MAF = 0.00003266 (0.003%) in south asian exomes (gnomAD v2.1.1). It is below 0.02%, so PM2 is met.PM3 - variant meets PM2 and was identified in 1 index case with LDL 16.2 mmol/L and also LDLR exon 15 deletion from Cardiovascular Genetics Laboratory (PathWest Laboratory Medicine WA) - Likely pathogenic by these guidelines, so PM3 is metPS3_moderate - Level 2 FS: Hobbs et al., 1992 (PMID 1301956): Hmz patient fibroblast, 125I-LDL assays - results: 15-30% LDLR activity. Activity is below 70% of wild-type, so PS3_Moderate is met.PP3 - REVEL = 0.896. It is above 0.75, so PP3 is met.PP4 - variant meets PM2 and is identified in at least 1 index case who fulfills SB criteria from Cardiovascular Research Group,Instituto Nacional de Saude Doutor Ricardo Jorge. so, PP4 is met		Familial Hypercholesterolemia VCEP	https://clinicalgenome.org/docs/clingen-familial-hypercholesterolemia-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1-2/	2021-12-13	2022-07-11	False	https://erepo.genome.network/evrepo/ui/classification/CA023687/MONDO:0007750/013	07409e96-2c49-47c8-8e87-1e15283ee370	p.Glu101Lys	Glu	101	Lys	MGPWGWKLRWTVALLLAAAGTAVGDRCERNEFQCQDGKCISYKWVCDGSAECQDGSDESQETCLSVTCKSGDFSCGGRVNRCIPQFWRCDGQVDCDNGSDEQGCPPKTCSQDEFRCHDGKCISRQFVCDSDRDCLDGSDEASCPVLTCGPASFQCNSSTCIPQLWACDNDPDCEDGSDEWPQRCRGLYVFQGDSSPCSAFEFHCLSGECIHSSWRCDGGPDCKDKSDEENCAVATCRPDEFQCSDGNCIHGSRQCDREYDCKDMSDEVGCVNVTLCEGPNKFKCHSGECITLDKVCNMARDCRDWSDEPIKECGTNECLDNNGGCSHVCNDLKIGYECLCPDGFQLVAQRRCEDIDECQDPDTCSQLCVNLEGGYKCQCEEGFQLDPHTKACKAVGSIAYLFFTNRHEVRKMTLDRSEYTSLIPNLRNVVALDTEVASNRIYWSDLSQRMICSTQLDRAHGVSSYDTVISRDIQAPDGLAVDWIHSNIYWTDSVLGTVSVADTKGVKRKTLFRENGSKPRAIVVDPVHGFMYWTDWGTPAKIKKGGLNGVDIYSLVTENIQWPNGITLDLLSGRLYWVDSKLHSISSIDVNGGNRKTILEDEKRLAHPFSLAVFEDKVFWTDIINEAIFSANRLTGSDVNLLAENLLSPEDMVLFHNLTQPRGVNWCERTTLSNGGCQYLCLPAPQINPHSPKFTCACPDGMLLARDMRSCLTEAEAAVATQETSTVRLKVSSTAVRTQHTTTRPVPDTSRLPGATPGLTTVEIVTMSHQALGDVAGRGNEKKPSSVRALSIVLPIVLLVFLCLGVFLLWKNWRLKNINSINFDNPVYQKTTEDEVHICHNQDGYSYPSRQMVSLEDDVA	860	P01130	K	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [74, 77, 97, 100], 'ZN_FING_gain': [], 'ZN_FING_loss_score': array([-0.01141018, -0.0076642 , -0.00892276, -0.02825868])}
362	NM_000527.5(LDLR):c.418G>A (p.Glu140Lys)	251213	CA10584911	NM_000527.5:c.418G>A, NC_000019.10:g.11105324G>A, CM000681.2:g.11105324G>A, NC_000019.9:g.11216000G>A, CM000681.1:g.11216000G>A, NC_000019.8:g.11077000G>A, NG_009060.1:g.20944G>A, LRG_274:g.20944G>A, ENST00000558518.6:c.418G>A, ENST00000252444.9:n.672G>A, ENST00000455727.6:c.314-2068G>A, ENST00000535915.5:c.295G>A, ENST00000545707.5:c.314-1241G>A, ENST00000557933.5:c.418G>A, ENST00000558013.5:c.418G>A, ENST00000558518.5:c.418G>A, ENST00000560467.1:n.18G>A, NM_000527.4:c.418G>A, LRG_274t1:c.418G>A, NM_001195798.1:c.418G>A, NM_001195799.1:c.295G>A, NM_001195800.1:c.314-2068G>A, NM_001195803.1:c.314-1241G>A, XM_011528010.1:c.418G>A, XM_011528011.1:c.314-1241G>A, XR_244074.2:n.568G>A, XM_011528010.2:c.418G>A, XR_001753685.2:n.535G>A, XR_001753686.2:n.535G>A, NM_001195798.2:c.418G>A, NM_001195799.2:c.295G>A, NM_001195800.2:c.314-2068G>A, NM_001195803.2:c.314-1241G>A, NM_000527.5(LDLR):c.418G>A (p.Glu140Lys)	LDLR	hypercholesterolemia, familial	MONDO:0007750	Semidominant inheritance	Pathogenic	PP1_Strong, PM1, PM2, PP3, PP4, PS4_Supporting	PS1, PS3, PS2, PM5, PM4, PM3, BP7, BP5, BS1, BS3, BS4, PVS1, PM6, BS2, PP2, BP1, BP4, BP3, BP2, BA1	The NM_000527.5(LDLR):c.418G>A (p.Glu140Lys) variant is classified as Pathogenic for Familial Hypercholesterolemia by applying evidence codes (PP1_Strong, PM1, PM2, PP3, PP4 and PS4_Supporting) as defined by the ClinGen Familial Hypercholesterolemia Expert Panel LDLR-specific variant curation guidelines (https://doi.org/10.1016/j.gim.2021.09.012). The supporting evidence is as follows: PP1_strong - variant segregates with FH phenotype in 8 informative meioses from 4 families from Instituto Nacional de Saude Doutor Ricardo Jorge and Laboratory of Genetics and Molecular Cardiology, so PP1_Strong is met.PM1 - variant is missense in exon 4 and meets PM2 criteria, so PM1 is met.PM2 - This variant is absent from gnomAD (gnomAD v2.1.1), so PM2 is met.PP3 - REVEL = 0.965, it is above 0.75, so PP3 is met.PP4 - Variant meets PM2 and was identified in 2 unrelated index cases who fulfill SB criteria from Instituto Nacional de Saude Doutor Ricardo Jorge, so PP4 is met.PS4_supporting - variant meets PM2. Identified in 2 unrelated index cases who fulfill SB criteria from Instituto Nacional de Saude Doutor Ricardo Jorge, PS4_supporting is met.		Familial Hypercholesterolemia VCEP	https://clinicalgenome.org/docs/clingen-familial-hypercholesterolemia-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1-2/	2021-12-13	2022-07-11	False	https://erepo.genome.network/evrepo/ui/classification/CA10584911/MONDO:0007750/013	d63fb472-1e90-49ec-afe1-e4d3de7005aa	p.Glu140Lys	Glu	140	Lys	MGPWGWKLRWTVALLLAAAGTAVGDRCERNEFQCQDGKCISYKWVCDGSAECQDGSDESQETCLSVTCKSGDFSCGGRVNRCIPQFWRCDGQVDCDNGSDEQGCPPKTCSQDEFRCHDGKCISRQFVCDSDRDCLDGSDEASCPVLTCGPASFQCNSSTCIPQLWACDNDPDCEDGSDEWPQRCRGLYVFQGDSSPCSAFEFHCLSGECIHSSWRCDGGPDCKDKSDEENCAVATCRPDEFQCSDGNCIHGSRQCDREYDCKDMSDEVGCVNVTLCEGPNKFKCHSGECITLDKVCNMARDCRDWSDEPIKECGTNECLDNNGGCSHVCNDLKIGYECLCPDGFQLVAQRRCEDIDECQDPDTCSQLCVNLEGGYKCQCEEGFQLDPHTKACKAVGSIAYLFFTNRHEVRKMTLDRSEYTSLIPNLRNVVALDTEVASNRIYWSDLSQRMICSTQLDRAHGVSSYDTVISRDIQAPDGLAVDWIHSNIYWTDSVLGTVSVADTKGVKRKTLFRENGSKPRAIVVDPVHGFMYWTDWGTPAKIKKGGLNGVDIYSLVTENIQWPNGITLDLLSGRLYWVDSKLHSISSIDVNGGNRKTILEDEKRLAHPFSLAVFEDKVFWTDIINEAIFSANRLTGSDVNLLAENLLSPEDMVLFHNLTQPRGVNWCERTTLSNGGCQYLCLPAPQINPHSPKFTCACPDGMLLARDMRSCLTEAEAAVATQETSTVRLKVSSTAVRTQHTTTRPVPDTSRLPGATPGLTTVEIVTMSHQALGDVAGRGNEKKPSSVRALSIVLPIVLLVFLCLGVFLLWKNWRLKNINSINFDNPVYQKTTEDEVHICHNQDGYSYPSRQMVSLEDDVA	860	P01130	K	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [143], 'ZN_FING_gain': [], 'ZN_FING_loss_score': array([-0.02042204])}
363	NM_000527.5(LDLR):c.1024G>A (p.Asp342Asn)	161274	CA023404	NM_000527.5:c.1024G>A, NC_000019.10:g.11110735G>A, CM000681.2:g.11110735G>A, NC_000019.9:g.11221411G>A, CM000681.1:g.11221411G>A, NC_000019.8:g.11082411G>A, NG_009060.1:g.26355G>A, LRG_274:g.26355G>A, ENST00000558518.6:c.1024G>A, ENST00000252444.9:n.1278G>A, ENST00000455727.6:c.520G>A, ENST00000535915.5:c.901G>A, ENST00000545707.5:c.643G>A, ENST00000557933.5:c.1024G>A, ENST00000558013.5:c.1024G>A, ENST00000558518.5:c.1024G>A, ENST00000560173.1:n.23G>A, ENST00000560467.1:n.541-779G>A, NM_000527.4:c.1024G>A, LRG_274t1:c.1024G>A, NM_001195798.1:c.1024G>A, NM_001195799.1:c.901G>A, NM_001195800.1:c.520G>A, NM_001195803.1:c.643G>A, XM_011528010.1:c.1024G>A, XM_011528011.1:c.643G>A, XR_244074.2:n.1174G>A, XM_011528010.2:c.1024G>A, XR_001753685.2:n.1141G>A, XR_001753686.2:n.1141G>A, NM_001195798.2:c.1024G>A, NM_001195799.2:c.901G>A, NM_001195800.2:c.520G>A, NM_001195803.2:c.643G>A, NM_000527.5(LDLR):c.1024G>A (p.Asp342Asn)	LDLR	hypercholesterolemia, familial	MONDO:0007750	Semidominant inheritance	Benign	BP4, BA1	PS1, PS3, PS4, PS2, PM5, PM4, PM1, PM3, BP7, BP5, BS1, BS3, BS4, PVS1, PM2, PM6, BS2, PP2, PP3, PP1, PP4, BP1, BP3, BP2	The NM_000527.5(LDLR):c.1024G>A (p.Asp342Asn) variant is classified as Benign for Familial Hypercholesterolemia by applying evidence codes (BA1 and BP4) as defined by the ClinGen Familial Hypercholesterolemia Expert Panel LDLR-specific variant curation guidelines (https://doi.org/10.1101/2021.03.17.21252755). The supporting evidence is as follows: BA1 - FAF = 0.005579 (0.56%) in African exomes (gnomAD v2.1.1). It is above 0.5%, so BA1 is met.BP4 - REVEL = 0.283. it is below 0.50, splicing evaluation required. Functional data on splicing not available. A) not on limits B) variant is exonic and at least 50bp downstream from canonical acceptor site but it does not create GT. Variant is not predicted to alter splicing, so BP4 is met.		Familial Hypercholesterolemia VCEP	https://clinicalgenome.org/docs/clingen-familial-hypercholesterolemia-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1-2/	2021-12-13	2022-01-01	False	https://erepo.genome.network/evrepo/ui/classification/CA023404/MONDO:0007750/013	ce995e23-c06d-45fb-9806-e3589bf1dff2	p.Asp342Asn	Asp	342	Asn	MGPWGWKLRWTVALLLAAAGTAVGDRCERNEFQCQDGKCISYKWVCDGSAECQDGSDESQETCLSVTCKSGDFSCGGRVNRCIPQFWRCDGQVDCDNGSDEQGCPPKTCSQDEFRCHDGKCISRQFVCDSDRDCLDGSDEASCPVLTCGPASFQCNSSTCIPQLWACDNDPDCEDGSDEWPQRCRGLYVFQGDSSPCSAFEFHCLSGECIHSSWRCDGGPDCKDKSDEENCAVATCRPDEFQCSDGNCIHGSRQCDREYDCKDMSDEVGCVNVTLCEGPNKFKCHSGECITLDKVCNMARDCRDWSDEPIKECGTNECLDNNGGCSHVCNDLKIGYECLCPDGFQLVAQRRCEDIDECQDPDTCSQLCVNLEGGYKCQCEEGFQLDPHTKACKAVGSIAYLFFTNRHEVRKMTLDRSEYTSLIPNLRNVVALDTEVASNRIYWSDLSQRMICSTQLDRAHGVSSYDTVISRDIQAPDGLAVDWIHSNIYWTDSVLGTVSVADTKGVKRKTLFRENGSKPRAIVVDPVHGFMYWTDWGTPAKIKKGGLNGVDIYSLVTENIQWPNGITLDLLSGRLYWVDSKLHSISSIDVNGGNRKTILEDEKRLAHPFSLAVFEDKVFWTDIINEAIFSANRLTGSDVNLLAENLLSPEDMVLFHNLTQPRGVNWCERTTLSNGGCQYLCLPAPQINPHSPKFTCACPDGMLLARDMRSCLTEAEAAVATQETSTVRLKVSSTAVRTQHTTTRPVPDTSRLPGATPGLTTVEIVTMSHQALGDVAGRGNEKKPSSVRALSIVLPIVLLVFLCLGVFLLWKNWRLKNINSINFDNPVYQKTTEDEVHICHNQDGYSYPSRQMVSLEDDVA	860	P01130	N	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
364	NM_000527.5(LDLR):c.1432G>A (p.Gly478Arg)	161277	CA023495	NM_000527.5:c.1432G>A, NC_000019.10:g.11113608G>A, CM000681.2:g.11113608G>A, NC_000019.9:g.11224284G>A, CM000681.1:g.11224284G>A, NC_000019.8:g.11085284G>A, NG_009060.1:g.29228G>A, LRG_274:g.29228G>A, ENST00000558518.6:c.1432G>A, ENST00000252444.9:n.1686G>A, ENST00000455727.6:c.928G>A, ENST00000535915.5:c.1309G>A, ENST00000545707.5:c.1051G>A, ENST00000557933.5:c.1432G>A, ENST00000558013.5:c.1432G>A, ENST00000558518.5:c.1432G>A, ENST00000559340.1:n.153G>A, ENST00000560467.1:n.912G>A, NM_000527.4:c.1432G>A, LRG_274t1:c.1432G>A, NM_001195798.1:c.1432G>A, NM_001195799.1:c.1309G>A, NM_001195800.1:c.928G>A, NM_001195803.1:c.1051G>A, XM_011528010.1:c.1432G>A, XM_011528011.1:c.1051G>A, XR_244074.2:n.1582G>A, XM_011528010.2:c.1432G>A, XR_001753685.2:n.1549G>A, XR_001753686.2:n.1549G>A, NM_001195798.2:c.1432G>A, NM_001195799.2:c.1309G>A, NM_001195800.2:c.928G>A, NM_001195803.2:c.1051G>A, NM_000527.5(LDLR):c.1432G>A (p.Gly478Arg)	LDLR	hypercholesterolemia, familial	MONDO:0007750	Semidominant inheritance	Pathogenic	PS4, PP1_Strong, PM2, PP3, PP4	PS1, PS3, PS2, PM5, PM4, PM1, PM3, BP7, BP5, BS1, BS3, BS4, PVS1, PM6, PP2, BS2, BA1, BP1, BP4, BP3, BP2	The NM_000527.5(LDLR):c.1432G>A (p.Gly478Arg) variant is classified as Pathogenic for Familial Hypercholesterolemia by applying evidence codes (PP1_strong, PS4, PM2, PP3 and PP4) as defined by the ClinGen Familial Hypercholesterolemia Expert Panel LDLR-specific variant curation guidelines (https://doi.org/10.1016/j.gim.2021.09.012). The supporting evidence is as follows: PP1_strong - variant segregates with FH phenotype in 10 informative meiosis from 4 families from 2 labs:- Laboratory of Genetics and Molecular Cardiology - Data from 1 family: 2 relatives positive for variant with LDL-C >75th percentile, 1 relative negative for variant with LDL-C <50th percentile;- Cardiovascular Research Group, Instituto Nacional de Saude Doutor Ricardo Jorge -  Data from 3 families. F1: 3 relatives with the phenotype are positive for the variant plus 1 relative without the phenotype is negative for the variant. F2: 1 relative with the phenotype and positive for the variant plus 1 relative without the phenotype is negative for the variant. F3: 1 relative with the phenotype  is positive for the variant.so PP1_Strong is metPS4 - variant meets PM2 and was identified in at least 11 unrelated index cases who fulfill clinical FH criteria from different labs:- 1 case with Simon-Broome criteria from Molecular Genetics Laboratory (Centre for Cardiovascular Surgery and Transplantation); - 1 case with DLCN score >= 6 from Color Health, Inc; - 4 unrelated cases with DLCN score >= 6 from Cardiovascular Genetics Laboratory (PathWest Laboratory Medicine WA); - 4 unrelated cases with Simon-Broome criteria from Cardiovascular Research Group, Instituto Nacional de Saude Doutor Ricardo Jorge; - 1 case with DLCN score >= 6 from Mayo Clinic Atherosclerosis and Lipid Genomics Laboratory),so PS4 is metPM2 - PopMax MAF = 0.0001234 (0.01234%) in African/African-American exomes (gnomAD v2.1.1). It is below 0.02%, so PM2 is met.PP3 - REVEL = 0.985. It is above 0.75, so PP3 is met.PP4 - variant meets PM2 and was identified in at least 11 unrelated index cases who fulfill clinical FH criteria from different labs (see details in PS4), so PP4 is met.		Familial Hypercholesterolemia VCEP	https://clinicalgenome.org/docs/clingen-familial-hypercholesterolemia-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1-2/	2021-12-14	2022-07-11	False	https://erepo.genome.network/evrepo/ui/classification/CA023495/MONDO:0007750/013	d3424058-b37e-4bce-b932-0695abc3af1d	p.Gly478Arg	Gly	478	Arg	MGPWGWKLRWTVALLLAAAGTAVGDRCERNEFQCQDGKCISYKWVCDGSAECQDGSDESQETCLSVTCKSGDFSCGGRVNRCIPQFWRCDGQVDCDNGSDEQGCPPKTCSQDEFRCHDGKCISRQFVCDSDRDCLDGSDEASCPVLTCGPASFQCNSSTCIPQLWACDNDPDCEDGSDEWPQRCRGLYVFQGDSSPCSAFEFHCLSGECIHSSWRCDGGPDCKDKSDEENCAVATCRPDEFQCSDGNCIHGSRQCDREYDCKDMSDEVGCVNVTLCEGPNKFKCHSGECITLDKVCNMARDCRDWSDEPIKECGTNECLDNNGGCSHVCNDLKIGYECLCPDGFQLVAQRRCEDIDECQDPDTCSQLCVNLEGGYKCQCEEGFQLDPHTKACKAVGSIAYLFFTNRHEVRKMTLDRSEYTSLIPNLRNVVALDTEVASNRIYWSDLSQRMICSTQLDRAHGVSSYDTVISRDIQAPDGLAVDWIHSNIYWTDSVLGTVSVADTKGVKRKTLFRENGSKPRAIVVDPVHGFMYWTDWGTPAKIKKGGLNGVDIYSLVTENIQWPNGITLDLLSGRLYWVDSKLHSISSIDVNGGNRKTILEDEKRLAHPFSLAVFEDKVFWTDIINEAIFSANRLTGSDVNLLAENLLSPEDMVLFHNLTQPRGVNWCERTTLSNGGCQYLCLPAPQINPHSPKFTCACPDGMLLARDMRSCLTEAEAAVATQETSTVRLKVSSTAVRTQHTTTRPVPDTSRLPGATPGLTTVEIVTMSHQALGDVAGRGNEKKPSSVRALSIVLPIVLLVFLCLGVFLLWKNWRLKNINSINFDNPVYQKTTEDEVHICHNQDGYSYPSRQMVSLEDDVA	860	P01130	R	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
365	NM_000527.5(LDLR):c.269A>G (p.Asp90Gly)	226313	CA042622	NM_000527.5:c.269A>G, NC_000019.10:g.11102742A>G, CM000681.2:g.11102742A>G, NC_000019.9:g.11213418A>G, CM000681.1:g.11213418A>G, NC_000019.8:g.11074418A>G, NG_009060.1:g.18362A>G, LRG_274:g.18362A>G, ENST00000558518.6:c.269A>G, ENST00000252444.9:n.523A>G, ENST00000455727.6:c.269A>G, ENST00000535915.5:c.190+2397A>G, ENST00000545707.5:c.269A>G, ENST00000557933.5:c.269A>G, ENST00000557958.1:n.355A>G, ENST00000558013.5:c.269A>G, ENST00000558518.5:c.269A>G, NM_000527.4:c.269A>G, LRG_274t1:c.269A>G, NM_001195798.1:c.269A>G, NM_001195799.1:c.190+2397A>G, NM_001195800.1:c.269A>G, NM_001195803.1:c.269A>G, XM_011528010.1:c.269A>G, XM_011528011.1:c.269A>G, XR_244074.2:n.419A>G, XM_011528010.2:c.269A>G, XR_001753685.2:n.386A>G, XR_001753686.2:n.386A>G, NM_001195798.2:c.269A>G, NM_001195799.2:c.190+2397A>G, NM_001195800.2:c.269A>G, NM_001195803.2:c.269A>G, NM_000527.5(LDLR):c.269A>G (p.Asp90Gly)	LDLR	hypercholesterolemia, familial	MONDO:0007750	Semidominant inheritance	Pathogenic	PS4, PM5, PM3, PP1_Moderate, PM2, PP3, PP4	PS1, PS3, PS2, PM4, PM1, BS1, BS3, BS4, BP7, BP5, PM6, PVS1, BS2, PP2, BA1, BP1, BP4, BP3, BP2	The NM_000527.5(LDLR):c.269A>G (p.Asp90Gly) variant is classified as Pathogenic for Familial Hypercholesterolemia by applying evidence codes PS4, PP1_Moderate, PM2, PM3, PM5, PP3 and PP4 as defined by the ClinGen Familial Hypercholesterolemia Expert Panel LDLR-specific variant curation guidelines (https://doi.org/10.1101/2021.03.17.21252755). The supporting evidence is as follows: PS4 - variant meets PM2 and was identified in at least 14 unrelated index cases with clinical criteria of FH:- 4 unrelated index cases with DLCN >=6 from Cardiovascular Genetics Laboratory (PathWest Laboratory Medicine WA), Australia;- at least 1 index case with DLCN probable FH from U4M - Lille University & CHRU Lille, Université de Lille - CHRU de Lille (SCV000583646.1), France;- 8 unrelated index cases (7 with DLCN>=6 and 1 SB possible) from Centre de Génétique Moléculaire et Chromosomique, Unité de génétique de l'Obésité et des Dyslipidémies (APHP.Sorbonne Université, Hôpital de la Pitié-Salpêtrière), France;- at least 1 index case with SB criteria for FH (plasma cholesterol of >8.0 mmol/L and family histories of hypercholesterolemia and/or classical clinical stigmata of FH) from PMID 11857755 (Bunn et al., 2002), New Zeland;- 1 index case with SB criteria for FH (grossly increased plasma cholesterol concentration and the presence of xanthomata in childhood and cardiovascular involvement by puberty in the proband, together with hypercholesterolemia in both parents; this index case died at 31years, had cholesterol of 20.7mmol/L and CVD) from PMID 9026534 (Webb et al., 1996), UKso PS4 is met.PP1_moderate - Variant segregates with FH phenotype in 5 informative meiosis from 3 families:- 2 affected family members have the variant, from Cardiovascular Genetics Laboratory (PathWest Laboratory Medicine WA);- 3 affected family members have the variant, from Centre de Génétique Moléculaire et Chromosomique, Unité de génétique de l'Obésité et des Dyslipidémies (APHP.Sorbonne Université, Hôpital de la Pitié-Salpêtrière),so PP1_Moderate is met.PM2 - This variant is absent from gnomAD (gnomAD v2.1.1), so PM2 is met.PM3 - variant meets PM2 and was identified in- 1 index case with phenotype of homozygous FH (cholesterol of 20.7mmol/L) and also NM_000527.5(LDLR):c.912C>G (p.Asp304Glu), Likely pathogenic by these guidelines, from PMID 9026534 (Webb et al., 1996), UKso PM3 is metPM5 - 4 other missense variants is the same codon:- NM_000527.5(LDLR):c.268G>A (p.Asp90Asn) - Likely pathogenic by these guidelines- NM_000527.5(LDLR):c.268G>T (p.Asp90Tyr) - classified as Likely pathogenic​ by the FH VCEP, with these guidelines- NM_000527.5(LDLR):c.269A>C (p.Asp90Ala) - Likely pathogenic by these guidelines- NM_000527.5(LDLR):c.270T>A (p.Asp90Glu) - Pathogenic by these guidelinesThere is 1 variant classified as Pathogenic by these guidelines, so PM5 is met.PP3 - REVEL = 0.957. It is above 0.75, so PP3 is metPP4 - variant meets PM2 and was identified in at least 14 unrelated index cases with clinical criteria of FH (see PS4 for details), so PP4 is met		Familial Hypercholesterolemia VCEP	https://clinicalgenome.org/docs/clingen-familial-hypercholesterolemia-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1-2/	2021-12-30	2022-07-11	False	https://erepo.genome.network/evrepo/ui/classification/CA042622/MONDO:0007750/013	243fe145-86fd-48f6-98dd-c946485388c0	p.Asp90Gly	Asp	90	Gly	MGPWGWKLRWTVALLLAAAGTAVGDRCERNEFQCQDGKCISYKWVCDGSAECQDGSDESQETCLSVTCKSGDFSCGGRVNRCIPQFWRCDGQVDCDNGSDEQGCPPKTCSQDEFRCHDGKCISRQFVCDSDRDCLDGSDEASCPVLTCGPASFQCNSSTCIPQLWACDNDPDCEDGSDEWPQRCRGLYVFQGDSSPCSAFEFHCLSGECIHSSWRCDGGPDCKDKSDEENCAVATCRPDEFQCSDGNCIHGSRQCDREYDCKDMSDEVGCVNVTLCEGPNKFKCHSGECITLDKVCNMARDCRDWSDEPIKECGTNECLDNNGGCSHVCNDLKIGYECLCPDGFQLVAQRRCEDIDECQDPDTCSQLCVNLEGGYKCQCEEGFQLDPHTKACKAVGSIAYLFFTNRHEVRKMTLDRSEYTSLIPNLRNVVALDTEVASNRIYWSDLSQRMICSTQLDRAHGVSSYDTVISRDIQAPDGLAVDWIHSNIYWTDSVLGTVSVADTKGVKRKTLFRENGSKPRAIVVDPVHGFMYWTDWGTPAKIKKGGLNGVDIYSLVTENIQWPNGITLDLLSGRLYWVDSKLHSISSIDVNGGNRKTILEDEKRLAHPFSLAVFEDKVFWTDIINEAIFSANRLTGSDVNLLAENLLSPEDMVLFHNLTQPRGVNWCERTTLSNGGCQYLCLPAPQINPHSPKFTCACPDGMLLARDMRSCLTEAEAAVATQETSTVRLKVSSTAVRTQHTTTRPVPDTSRLPGATPGLTTVEIVTMSHQALGDVAGRGNEKKPSSVRALSIVLPIVLLVFLCLGVFLLWKNWRLKNINSINFDNPVYQKTTEDEVHICHNQDGYSYPSRQMVSLEDDVA	860	P01130	G	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [74, 77, 97, 100], 'ZN_FING_gain': [], 'ZN_FING_loss_score': array([-0.01378685, -0.00940835, -0.03479177, -0.01058501])}
366	NM_000527.5(LDLR):c.270T>A (p.Asp90Glu)	251107	CA10584821	NM_000527.5:c.270T>A, NC_000019.10:g.11102743T>A, CM000681.2:g.11102743T>A, NC_000019.9:g.11213419T>A, CM000681.1:g.11213419T>A, NC_000019.8:g.11074419T>A, NG_009060.1:g.18363T>A, LRG_274:g.18363T>A, ENST00000558518.6:c.270T>A, ENST00000252444.9:n.524T>A, ENST00000455727.6:c.270T>A, ENST00000535915.5:c.190+2398T>A, ENST00000545707.5:c.270T>A, ENST00000557933.5:c.270T>A, ENST00000557958.1:n.356T>A, ENST00000558013.5:c.270T>A, ENST00000558518.5:c.270T>A, NM_000527.4:c.270T>A, LRG_274t1:c.270T>A, NM_001195798.1:c.270T>A, NM_001195799.1:c.190+2398T>A, NM_001195800.1:c.270T>A, NM_001195803.1:c.270T>A, XM_011528010.1:c.270T>A, XM_011528011.1:c.270T>A, XR_244074.2:n.420T>A, XM_011528010.2:c.270T>A, XR_001753685.2:n.387T>A, XR_001753686.2:n.387T>A, NM_001195798.2:c.270T>A, NM_001195799.2:c.190+2398T>A, NM_001195800.2:c.270T>A, NM_001195803.2:c.270T>A, NM_000527.5(LDLR):c.270T>A (p.Asp90Glu)	LDLR	hypercholesterolemia, familial	MONDO:0007750	Semidominant inheritance	Pathogenic	PP1_Strong, PM5, PM2, PP3, PP4, PS4_Supporting	PS1, PS3, PS2, PM4, PM1, PM3, BP7, BP5, BS1, BS3, BS4, PVS1, PM6, BS2, PP2, BP1, BP4, BP3, BP2, BA1	The NM_000527.5(LDLR):c.270T>A (p.Asp90Glu) variant is classified as Pathogenic for Familial Hypercholesterolemia by applying evidence PP1_Strong, PM2, PM5, PP3, PP4 and PS4_Supporting as defined by the ClinGen Familial Hypercholesterolemia Expert Panel LDLR-specific variant curation guidelines (https://doi.org/10.1101/2021.03.17.21252755). The supporting evidence is as follows: PP1_strong - variant segregates with FH phenotype in 11 informative meiosis from 2 families from PMID 20809525 (Marduel et al., 2010): F1: 4 affected relatives have the variant and 3 unaffected relatives do not have the variant; F2: 3 affected relatives have the variant and 1 unaffected relative does not have the variant, so PP1_Strong is met.PM2 - This variant was not identified in gnomAD (gnomAD v2.1.1), so PM2 is met.PM5 - 4 other missense variants is the same codon:- NM_000527.5(LDLR):c.268G>A (p.Asp90Asn) - Likely pathogenic by these guidelines- NM_000527.5(LDLR):c.268G>T (p.Asp90Tyr) - classified as Likely pathogenic​ by the FH VCEP, with these guidelines- NM_000527.5(LDLR):c.269A>C (p.Asp90Ala) - Likely pathogenic by these guidelines- NM_000527.5(LDLR):c.269A>G (p.Asp90Gly) - Pathogenic by these guidelinesThere is 1 variant classified as Pathogenic by these guidelines, so PM5 is met.PP3 - REVEL = 0.833. It is above 0.75, so PP3 is met.PP4 - variant meets PM2 and was identified in 4 index cases with SB criteria of FH (total and LDL-cholesterol levels above the 95th percentile of a sex and age-matched French population and autosomal dominant transmission of hypercholesterolemia in the family) from PMID 20809525 (Marduel et al., 2010), so PP4 is met.PS4_supporting - variant meets PM2 and was identified in 4 index cases with SB criteria of FH from PMID 20809525 (Marduel et al., 2010), (see PP4 for details), so PS4_Supporting is met.		Familial Hypercholesterolemia VCEP	https://clinicalgenome.org/docs/clingen-familial-hypercholesterolemia-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1-2/	2021-12-30	2022-07-11	False	https://erepo.genome.network/evrepo/ui/classification/CA10584821/MONDO:0007750/013	c59d43d0-b343-44d0-b9cb-f1b7f782876f	p.Asp90Glu	Asp	90	Glu	MGPWGWKLRWTVALLLAAAGTAVGDRCERNEFQCQDGKCISYKWVCDGSAECQDGSDESQETCLSVTCKSGDFSCGGRVNRCIPQFWRCDGQVDCDNGSDEQGCPPKTCSQDEFRCHDGKCISRQFVCDSDRDCLDGSDEASCPVLTCGPASFQCNSSTCIPQLWACDNDPDCEDGSDEWPQRCRGLYVFQGDSSPCSAFEFHCLSGECIHSSWRCDGGPDCKDKSDEENCAVATCRPDEFQCSDGNCIHGSRQCDREYDCKDMSDEVGCVNVTLCEGPNKFKCHSGECITLDKVCNMARDCRDWSDEPIKECGTNECLDNNGGCSHVCNDLKIGYECLCPDGFQLVAQRRCEDIDECQDPDTCSQLCVNLEGGYKCQCEEGFQLDPHTKACKAVGSIAYLFFTNRHEVRKMTLDRSEYTSLIPNLRNVVALDTEVASNRIYWSDLSQRMICSTQLDRAHGVSSYDTVISRDIQAPDGLAVDWIHSNIYWTDSVLGTVSVADTKGVKRKTLFRENGSKPRAIVVDPVHGFMYWTDWGTPAKIKKGGLNGVDIYSLVTENIQWPNGITLDLLSGRLYWVDSKLHSISSIDVNGGNRKTILEDEKRLAHPFSLAVFEDKVFWTDIINEAIFSANRLTGSDVNLLAENLLSPEDMVLFHNLTQPRGVNWCERTTLSNGGCQYLCLPAPQINPHSPKFTCACPDGMLLARDMRSCLTEAEAAVATQETSTVRLKVSSTAVRTQHTTTRPVPDTSRLPGATPGLTTVEIVTMSHQALGDVAGRGNEKKPSSVRALSIVLPIVLLVFLCLGVFLLWKNWRLKNINSINFDNPVYQKTTEDEVHICHNQDGYSYPSRQMVSLEDDVA	860	P01130	E	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [86], 'HELIX_gain_score': array([0.07101101]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [74, 77, 97, 100, 110], 'ZN_FING_gain': [], 'ZN_FING_loss_score': array([-0.01994795, -0.01714319, -0.01732945, -0.00943446, -0.00577623])}
367	NM_000540.2(RYR1):c.4178A>G (p.Lys1393Arg)	93269	CA024433	NM_000540.2:c.4178A>G, NC_000019.10:g.38475335A>G, CM000681.2:g.38475335A>G, NC_000019.9:g.38965975A>G, CM000681.1:g.38965975A>G, NC_000019.8:g.43657815A>G, NG_008866.1:g.46636A>G, LRG_766:g.46636A>G, ENST00000359596.8:c.4178A>G, ENST00000355481.8:c.4178A>G, ENST00000359596.7:n.4178A>G, ENST00000360985.7:c.4175A>G, LRG_766t1:c.4178A>G, NM_001042723.1:c.4178A>G, XM_006723317.1:c.4178A>G, XM_006723319.1:c.4178A>G, XM_011527204.1:c.4175A>G, XM_011527205.1:c.4178A>G, XM_006723317.2:c.4178A>G, XM_006723319.2:c.4178A>G, XM_011527205.2:c.4178A>G, XR_001753735.1:n.4261A>G, NM_000540.3:c.4178A>G, NM_001042723.2:c.4178A>G, NM_000540.3(RYR1):c.4178A>G (p.Lys1393Arg), NM_000540.2(RYR1):c.4178A>G (p.Lys1393Arg)	RYR1	malignant hyperthermia of anesthesia	MONDO:0018493	Autosomal dominant inheritance	Benign	BA1		This pathogenicity assessment is relevant only for malignant hyperthermia susceptibility (MHS) inherited in an autosomal dominant pattern. Variants in RYR1 can also cause other myopathies inherited in an autosomal dominant pattern or in an autosomal recessive pattern. Some of these disorders may predispose individuals to malignant hyperthermia. RYR1 variants may also contribute to a malignant hyperthermia reaction in combination with other genetic and non-genetic factors and the clinician needs to consider such factors in making management decisions.This sequence variant predicts a substitution of lysine with arginine at codon 1393 of the RYR1 protein, p.(Lys1393Arg). The maximum allele frequency for this variant among the six major gnomAD populations is NFE: 0.0046, which is considered to be too common for a pathogenic variant causing autosomal dominantly inherited MHS, BA1. This variant has been classified as Benign. Criteria implemented: BA1.		Malignant Hyperthermia Susceptibility VCEP	https://clinicalgenome.org/docs/clingen-malignant-hyperthermia-susceptibility-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-for/	2022-01-03	2022-01-03	False	https://erepo.genome.network/evrepo/ui/classification/CA024433/MONDO:0018493/012	0ad43115-8d40-4a4c-a50a-51fdcb7351ca	p.Lys1393Arg	Lys	1393	Arg	MGDAEGEDEVQFLRTDDEVVLQCSATVLKEQLKLCLAAEGFGNRLCFLEPTSNAQNVPPDLAICCFVLEQSLSVRALQEMLANTVEAGVESSQGGGHRTLLYGHAILLRHAHSRMYLSCLTTSRSMTDKLAFDVGLQEDATGEACWWTMHPASKQRSEGEKVRVGDDIILVSVSSERYLHLSTASGELQVDASFMQTLWNMNPICSRCEEGFVTGGHVLRLFHGHMDECLTISPADSDDQRRLVYYEGGAVCTHARSLWRLEPLRISWSGSHLRWGQPLRVRHVTTGQYLALTEDQGLVVVDASKAHTKATSFCFRISKEKLDVAPKRDVEGMGPPEIKYGESLCFVQHVASGLWLTYAAPDPKALRLGVLKKKAMLHQEGHMDDALSLTRCQQEESQAARMIHSTNGLYNQFIKSLDSFSGKPRGSGPPAGTALPIEGVILSLQDLIIYFEPPSEDLQHEEKQSKLRSLRNRQSLFQEEGMLSMVLNCIDRLNVYTTAAHFAEFAGEEAAESWKEIVNLLYELLASLIRGNRSNCALFSTNLDWLVSKLDRLEASSGILEVLYCVLIESPEVLNIIQENHIKSIISLLDKHGRNHKVLDVLCSLCVCNGVAVRSNQDLITENLLPGRELLLQTNLINYVTSIRPNIFVGRAEGTTQYSKWYFEVMVDEVTPFLTAQATHLRVGWALTEGYTPYPGAGEGWGGNGVGDDLYSYGFDGLHLWTGHVARPVTSPGQHLLAPEDVISCCLDLSVPSISFRINGCPVQGVFESFNLDGLFFPVVSFSAGVKVRFLLGGRHGEFKFLPPPGYAPCHEAVLPRERLHLEPIKEYRREGPRGPHLVGPSRCLSHTDFVPCPVDTVQIVLPPHLERIREKLAENIHELWALTRIEQGWTYGPVRDDNKRLHPCLVDFHSLPEPERNYNLQMSGETLKTLLALGCHVGMADEKAEDNLKKTKLPKTYMMSNGYKPAPLDLSHVRLTPAQTTLVDRLAENGHNVWARDRVGQGWSYSAVQDIPARRNPRLVPYRLLDEATKRSNRDSLCQAVRTLLGYGYNIEPPDQEPSQVENQSRCDRVRIFRAEKSYTVQSGRWYFEFEAVTTGEMRVGWARPELRPDVELGADELAYVFNGHRGQRWHLGSEPFGRPWQPGDVVGCMIDLTENTIIFTLNGEVLMSDSGSETAFREIEIGDGFLPVCSLGPGQVGHLNLGQDVSSLRFFAICGLQEGFEPFAINMQRPVTTWFSKGLPQFEPVPLEHPHYEVSRVDGTVDTPPCLRLTHRTWGSQNSLVEMLFLRLSLPVQFHQHFRCTAGATPLAPPGLQPPAEDEARAAEPDPDYENLRRSAGGWSEAENGKEGTAKEGAPGGTPQAGGEAQPARAENEKDATTEKNKKRGFLFKAKKVAMMTQPPATPTLPRLPHDVVPADNRDDPEIILNTTTYYYSVRVFAGQEPSCVWAGWVTPDYHQHDMSFDLSKVRVVTVTMGDEQGNVHSSLKCSNCYMVWGGDFVSPGQQGRISHTDLVIGCLVDLATGLMTFTANGKESNTFFQVEPNTKLFPAVFVLPTHQNVIQFELGKQKNIMPLSAAMFQSERKNPAPQCPPRLEMQMLMPVSWSRMPNHFLQVETRRAGERLGWAVQCQEPLTMMALHIPEENRCMDILELSERLDLQRFHSHTLRLYRAVCALGNNRVAHALCSHVDQAQLLHALEDAHLPGPLRAGYYDLLISIHLESACRSRRSMLSEYIVPLTPETRAITLFPPGRSTENGHPRHGLPGVGVTTSLRPPHHFSPPCFVAALPAAGAAEAPARLSPAIPLEALRDKALRMLGEAVRDGGQHARDPVGGSVEFQFVPVLKLVSTLLVMGIFGDEDVKQILKMIEPEVFTEEEEEEDEEEEGEEEDEEEKEEDEEETAQEKEDEEKEEEEAAEGEKEEGLEEGLLQMKLPESVKLQMCHLLEYFCDQELQHRVESLAAFAERYVDKLQANQRSRYGLLIKAFSMTAAETARRTREFRSPPQEQINMLLQFKDGTDEEDCPLPEEIRQDLLDFHQDLLAHCGIQLDGEEEEPEEETTLGSRLMSLLEKVRLVKKKEEKPEEERSAEESKPRSLQELVSHMVVRWAQEDFVQSPELVRAMFSLLHRQYDGLGELLRALPRAYTISPSSVEDTMSLLECLGQIRSLLIVQMGPQEENLMIQSIGNIMNNKVFYQHPNLMRALGMHETVMEVMVNVLGGGESKEIRFPKMVTSCCRFLCYFCRISRQNQRSMFDHLSYLLENSGIGLGMQGSTPLDVAAASVIDNNELALALQEQDLEKVVSYLAGCGLQSCPMLVAKGYPDIGWNPCGGERYLDFLRFAVFVNGESVEENANVVVRLLIRKPECFGPALRGEGGSGLLAAIEEAIRISEDPARDGPGIRRDRRREHFGEEPPEENRVHLGHAIMSFYAALIDLLGRCAPEMHLIQAGKGEALRIRAILRSLVPLEDLVGIISLPLQIPTLGKDGALVQPKMSASFVPDHKASMVLFLDRVYGIENQDFLLHVLDVGFLPDMRAAASLDTATFSTTEMALALNRYLCLAVLPLITKCAPLFAGTEHRAIMVDSMLHTVYRLSRGRSLTKAQRDVIEDCLMSLCRYIRPSMLQHLLRRLVFDVPILNEFAKMPLKLLTNHYERCWKYYCLPTGWANFGVTSEEELHLTRKLFWGIFDSLAHKKYDPELYRMAMPCLCAIAGALPPDYVDASYSSKAEKKATVDAEGNFDPRPVETLNVIIPEKLDSFINKFAEYTHEKWAFDKIQNNWSYGENIDEELKTHPMLRPYKTFSEKDKEIYRWPIKESLKAMIAWEWTIEKAREGEEEKTEKKKTRKISQSAQTYDPREGYNPQPPDLSAVTLSRELQAMAEQLAENYHNTWGRKKKQELEAKGGGTHPLLVPYDTLTAKEKARDREKAQELLKFLQMNGYAVTRGLKDMELDSSSIEKRFAFGFLQQLLRWMDISQEFIAHLEAVVSSGRVEKSPHEQEIKFFAKILLPLINQYFTNHCLYFLSTPAKVLGSGGHASNKEKEMITSLFCKLAALVRHRVSLFGTDAPAVVNCLHILARSLDARTVMKSGPEIVKAGLRSFFESASEDIEKMVENLRLGKVSQARTQVKGVGQNLTYTTVALLPVLTTLFQHIAQHQFGDDVILDDVQVSCYRTLCSIYSLGTTKNTYVEKLRPALGECLARLAAAMPVAFLEPQLNEYNACSVYTTKSPRERAILGLPNSVEEMCPDIPVLERLMADIGGLAESGARYTEMPHVIEITLPMLCSYLPRWWERGPEAPPSALPAGAPPPCTAVTSDHLNSLLGNILRIIVNNLGIDEASWMKRLAVFAQPIVSRARPELLQSHFIPTIGRLRKRAGKVVSEEEQLRLEAKAEAQEGELLVRDEFSVLCRDLYALYPLLIRYVDNNRAQWLTEPNPSAEELFRMVGEIFIYWSKSHNFKREEQNFVVQNEINNMSFLTADNKSKMAKAGDIQSGGSDQERTKKKRRGDRYSVQTSLIVATLKKMLPIGLNMCAPTDQDLITLAKTRYALKDTDEEVREFLHNNLHLQGKVEGSPSLRWQMALYRGVPGREEDADDPEKIVRRVQEVSAVLYYLDQTEHPYKSKKAVWHKLLSKQRRRAVVACFRMTPLYNLPTHRACNMFLESYKAAWILTEDHSFEDRMIDDLSKAGEQEEEEEEVEEKKPDPLHQLVLHFSRTALTEKSKLDEDYLYMAYADIMAKSCHLEEGGENGEAEEEVEVSFEEKQMEKQRLLYQQARLHTRGAAEMVLQMISACKGETGAMVSSTLKLGISILNGGNAEVQQKMLDYLKDKKEVGFFQSIQALMQTCSVLDLNAFERQNKAEGLGMVNEDGTVINRQNGEKVMADDEFTQDLFRFLQLLCEGHNNDFQNYLRTQTGNTTTINIIICTVDYLLRLQESISDFYWYYSGKDVIEEQGKRNFSKAMSVAKQVFNSLTEYIQGPCTGNQQSLAHSRLWDAVVGFLHVFAHMMMKLAQDSSQIELLKELLDLQKDMVVMLLSLLEGNVVNGMIARQMVDMLVESSSNVEMILKFFDMFLKLKDIVGSEAFQDYVTDPRGLISKKDFQKAMDSQKQFSGPEIQFLLSCSEADENEMINCEEFANRFQEPARDIGFNVAVLLTNLSEHVPHDPRLHNFLELAESILEYFRPYLGRIEIMGASRRIERIYFEISETNRAQWEMPQVKESKRQFIFDVVNEGGEAEKMELFVSFCEDTIFEMQIAAQISEPEGEPETDEDEGAGAAEAGAEGAEEGAAGLEGTAATAAAGATARVVAAAGRALRGLSYRSLRRRVRRLRRLTAREAATAVAALLWAAVTRAGAAGAGAAAGALGLLWGSLFGGGLVEGAKKVTVTELLAGMPDPTSDEVHGEQPAGPGGDADGEGASEGAGDAAEGAGDEEEAVHEAGPGGADGAVAVTDGGPFRPEGAGGLGDMGDTTPAEPPTPEGSPILKRKLGVDGVEEELPPEPEPEPEPELEPEKADAENGEKEEVPEPTPEPPKKQAPPSPPPKKEEAGGEFWGELEVQRVKFLNYLSRNFYTLRFLALFLAFAINFILLFYKVSDSPPGEDDMEGSAAGDVSGAGSGGSSGWGLGAGEEAEGDEDENMVYYFLEESTGYMEPALRCLSLLHTLVAFLCIIGYNCLKVPLVIFKREKELARKLEFDGLYITEQPEDDDVKGQWDRLVLNTPSFPSNYWDKFVKRKVLDKHGDIYGRERIAELLGMDLATLEITAHNERKPNPPPGLLTWLMSIDVKYQIWKFGVIFTDNSFLYLGWYMVMSLLGHYNNFFFAAHLLDIAMGVKTLRTILSSVTHNGKQLVMTVGLLAVVVYLYTVVAFNFFRKFYNKSEDEDEPDMKCDDMMTCYLFHMYVGVRAGGGIGDEIEDPAGDEYELYRVVFDITFFFFVIVILLAIIQGLIIDAFGELRDQQEQVKEDMETKCFICGIGSDYFDTTPHGFETHTLEEHNLANYMFFLMYLINKDETEHTGQESYVWKMYQERCWDFFPAGDCFRKQYEDQLS	5038	P21817	R	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
368	NM_000540.3(RYR1):c.6617C>G (p.Thr2206Arg)	133164	CA024620	NM_000540.3:c.6617C>G, NC_000019.10:g.38496283C>G, CM000681.2:g.38496283C>G, NC_000019.9:g.38986923C>G, CM000681.1:g.38986923C>G, NC_000019.8:g.43678763C>G, NG_008866.1:g.67584C>G, LRG_766:g.67584C>G, ENST00000359596.8:c.6617C>G, ENST00000355481.8:c.6617C>G, ENST00000359596.7:n.6617C>G, ENST00000360985.7:c.6614C>G, ENST00000594335.5:n.69C>G, NM_000540.2:c.6617C>G, LRG_766t1:c.6617C>G, NM_001042723.1:c.6617C>G, XM_006723317.1:c.6617C>G, XM_006723319.1:c.6617C>G, XM_011527204.1:c.6614C>G, XM_011527205.1:c.6617C>G, XM_006723317.2:c.6617C>G, XM_006723319.2:c.6617C>G, XM_011527205.2:c.6617C>G, XR_001753735.1:n.6700C>G, NM_001042723.2:c.6617C>G, NM_000540.3(RYR1):c.6617C>G (p.Thr2206Arg)	RYR1	malignant hyperthermia, susceptibility to, 1	MONDO:0007783	Autosomal dominant inheritance	Pathogenic	PP1_Moderate, PS4_Moderate, PS3_Moderate, PM1, PP3_Moderate	BA1, BS1	This pathogenicity assessment is relevant only for malignant hyperthermia susceptibility (MHS) inherited in an autosomal dominant pattern. Variants in RYR1 can also cause other myopathies inherited in an autosomal dominant pattern or in an autosomal recessive pattern. Some of these disorders may predispose individuals to malignant hyperthermia. RYR1 variants may also contribute to a malignant hyperthermia reaction in combination with other genetic and non-genetic factors and the clinician needs to consider such factors in making management decisions.This sequence variant predicts a substitution of threonine with arginine at codon 2206 of the RYR1 protein, p.(Thr2206Arg). This variant was not present in a large population database (gnomAD) at the time this variant was interpreted. This variant has been reported in four unrelated individuals who have a personal or family history of a malignant hyperthermia reaction, two of these individuals had a positive in vitro contracture test (IVCT) or caffeine halothane contracture test (CHCT) result (if the proband was unavailable for testing, a positive diagnostic test result in a mutation-positive relative was counted), PS4_Moderate (PMID: 10484775, 30236257, 16244001). This variant segregates with MHS in six individuals, PP1_Moderate (PMID: 10484775). A functional study in HEK293 cells shows an increased sensitivity to RYR1 agonists PS3_Moderate (PMID: 16163667). This variant resides in a region of RYR1 considered to be a hotspot for pathogenic variants that contribute to MHS, PM1 (PMID: 21118704). A REVEL score >0.85 (0.968) supports a pathogenic status for this variant, PP3_Moderate. 75e1f85c-b5bd-4e59-83c6-5d22ed39b50e75e1f85c-b5bd-4e59-83c6-5d22ed39b50eRYR1NC_000019.10g.38543551A>GNM_000540.2(RYR1):c.11798A>G|p.Tyr3933CysMONDOMONDO:0007783Likely Benign2022-01-04assertion-criteriaAutosomal dominant inheritancehttps://erepo.clinicalgenome.org/evrepo/ui/interpretation/75e1f85c-b5bd-4e59-83c6-5d22ed39b50eThis pathogenicity assessment is relevant only for malignant hyperthermia susceptibility (MHS) inherited in an autosomal dominant pattern. Variants in RYR1 can also cause other myopathies inherited in an autosomal dominant pattern or in an autosomal recessive pattern. Some of these disorders may predispose individuals to malignant hyperthermia. RYR1 variants may also contribute to a malignant hyperthermia reaction in combination with other genetic and non-genetic factors and the clinician needs to consider such factors in making management decisions. This sequence variant predicts a substitution of tyrosine with cysteine at codon 3933 of the RYR1 protein, p.(Tyr3933Cys). The maximum allele frequency for this variant among the six major gnomAD populations is NFE: 0.001332, this is considered to be more common than expected for a pathogenic variant causing autosomal dominantly inherited MHS, BS1. This variant has been reported in six unrelated individuals who have a personal or family history of a malignant hyperthermia reaction, all of these individuals had a positive in vitro contracture test (IVCT) or caffeine halothane contracture test (CHCT) result (if the proband was unavailable for testing, a positive diagnostic test result in a mutation-positive relative was counted) (PMID: 25958340, 20681998, 23558838, 25658027, 25735680). However, the high MAF in the NFE population in gnomAD precludes the use of PS4. No functional studies were identified for this variant. This variant does not reside in a hotspot for pathogenic variants that contribute to MHS. A REVEL score >0.85 (0.983) supports a pathogenic status for this variant, PP3_Moderate. Based on using Bayes to combine criteria this variant is classified as Pathogenic, (PMID: 29300386). Criteria implemented: PS3_Moderate, PS4_Moderate, PM1, PP1_Moderate, PP3_Moderate.		Malignant Hyperthermia Susceptibility VCEP	https://clinicalgenome.org/docs/clingen-malignant-hyperthermia-susceptibility-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-for/	2022-01-04	2022-01-04	False	https://erepo.genome.network/evrepo/ui/classification/CA024620/MONDO:0007783/012	2f6f441a-8500-48e4-a792-48d8c1ca7a17	p.Thr2206Arg	Thr	2206	Arg	MGDAEGEDEVQFLRTDDEVVLQCSATVLKEQLKLCLAAEGFGNRLCFLEPTSNAQNVPPDLAICCFVLEQSLSVRALQEMLANTVEAGVESSQGGGHRTLLYGHAILLRHAHSRMYLSCLTTSRSMTDKLAFDVGLQEDATGEACWWTMHPASKQRSEGEKVRVGDDIILVSVSSERYLHLSTASGELQVDASFMQTLWNMNPICSRCEEGFVTGGHVLRLFHGHMDECLTISPADSDDQRRLVYYEGGAVCTHARSLWRLEPLRISWSGSHLRWGQPLRVRHVTTGQYLALTEDQGLVVVDASKAHTKATSFCFRISKEKLDVAPKRDVEGMGPPEIKYGESLCFVQHVASGLWLTYAAPDPKALRLGVLKKKAMLHQEGHMDDALSLTRCQQEESQAARMIHSTNGLYNQFIKSLDSFSGKPRGSGPPAGTALPIEGVILSLQDLIIYFEPPSEDLQHEEKQSKLRSLRNRQSLFQEEGMLSMVLNCIDRLNVYTTAAHFAEFAGEEAAESWKEIVNLLYELLASLIRGNRSNCALFSTNLDWLVSKLDRLEASSGILEVLYCVLIESPEVLNIIQENHIKSIISLLDKHGRNHKVLDVLCSLCVCNGVAVRSNQDLITENLLPGRELLLQTNLINYVTSIRPNIFVGRAEGTTQYSKWYFEVMVDEVTPFLTAQATHLRVGWALTEGYTPYPGAGEGWGGNGVGDDLYSYGFDGLHLWTGHVARPVTSPGQHLLAPEDVISCCLDLSVPSISFRINGCPVQGVFESFNLDGLFFPVVSFSAGVKVRFLLGGRHGEFKFLPPPGYAPCHEAVLPRERLHLEPIKEYRREGPRGPHLVGPSRCLSHTDFVPCPVDTVQIVLPPHLERIREKLAENIHELWALTRIEQGWTYGPVRDDNKRLHPCLVDFHSLPEPERNYNLQMSGETLKTLLALGCHVGMADEKAEDNLKKTKLPKTYMMSNGYKPAPLDLSHVRLTPAQTTLVDRLAENGHNVWARDRVGQGWSYSAVQDIPARRNPRLVPYRLLDEATKRSNRDSLCQAVRTLLGYGYNIEPPDQEPSQVENQSRCDRVRIFRAEKSYTVQSGRWYFEFEAVTTGEMRVGWARPELRPDVELGADELAYVFNGHRGQRWHLGSEPFGRPWQPGDVVGCMIDLTENTIIFTLNGEVLMSDSGSETAFREIEIGDGFLPVCSLGPGQVGHLNLGQDVSSLRFFAICGLQEGFEPFAINMQRPVTTWFSKGLPQFEPVPLEHPHYEVSRVDGTVDTPPCLRLTHRTWGSQNSLVEMLFLRLSLPVQFHQHFRCTAGATPLAPPGLQPPAEDEARAAEPDPDYENLRRSAGGWSEAENGKEGTAKEGAPGGTPQAGGEAQPARAENEKDATTEKNKKRGFLFKAKKVAMMTQPPATPTLPRLPHDVVPADNRDDPEIILNTTTYYYSVRVFAGQEPSCVWAGWVTPDYHQHDMSFDLSKVRVVTVTMGDEQGNVHSSLKCSNCYMVWGGDFVSPGQQGRISHTDLVIGCLVDLATGLMTFTANGKESNTFFQVEPNTKLFPAVFVLPTHQNVIQFELGKQKNIMPLSAAMFQSERKNPAPQCPPRLEMQMLMPVSWSRMPNHFLQVETRRAGERLGWAVQCQEPLTMMALHIPEENRCMDILELSERLDLQRFHSHTLRLYRAVCALGNNRVAHALCSHVDQAQLLHALEDAHLPGPLRAGYYDLLISIHLESACRSRRSMLSEYIVPLTPETRAITLFPPGRSTENGHPRHGLPGVGVTTSLRPPHHFSPPCFVAALPAAGAAEAPARLSPAIPLEALRDKALRMLGEAVRDGGQHARDPVGGSVEFQFVPVLKLVSTLLVMGIFGDEDVKQILKMIEPEVFTEEEEEEDEEEEGEEEDEEEKEEDEEETAQEKEDEEKEEEEAAEGEKEEGLEEGLLQMKLPESVKLQMCHLLEYFCDQELQHRVESLAAFAERYVDKLQANQRSRYGLLIKAFSMTAAETARRTREFRSPPQEQINMLLQFKDGTDEEDCPLPEEIRQDLLDFHQDLLAHCGIQLDGEEEEPEEETTLGSRLMSLLEKVRLVKKKEEKPEEERSAEESKPRSLQELVSHMVVRWAQEDFVQSPELVRAMFSLLHRQYDGLGELLRALPRAYTISPSSVEDTMSLLECLGQIRSLLIVQMGPQEENLMIQSIGNIMNNKVFYQHPNLMRALGMHETVMEVMVNVLGGGESKEIRFPKMVTSCCRFLCYFCRISRQNQRSMFDHLSYLLENSGIGLGMQGSTPLDVAAASVIDNNELALALQEQDLEKVVSYLAGCGLQSCPMLVAKGYPDIGWNPCGGERYLDFLRFAVFVNGESVEENANVVVRLLIRKPECFGPALRGEGGSGLLAAIEEAIRISEDPARDGPGIRRDRRREHFGEEPPEENRVHLGHAIMSFYAALIDLLGRCAPEMHLIQAGKGEALRIRAILRSLVPLEDLVGIISLPLQIPTLGKDGALVQPKMSASFVPDHKASMVLFLDRVYGIENQDFLLHVLDVGFLPDMRAAASLDTATFSTTEMALALNRYLCLAVLPLITKCAPLFAGTEHRAIMVDSMLHTVYRLSRGRSLTKAQRDVIEDCLMSLCRYIRPSMLQHLLRRLVFDVPILNEFAKMPLKLLTNHYERCWKYYCLPTGWANFGVTSEEELHLTRKLFWGIFDSLAHKKYDPELYRMAMPCLCAIAGALPPDYVDASYSSKAEKKATVDAEGNFDPRPVETLNVIIPEKLDSFINKFAEYTHEKWAFDKIQNNWSYGENIDEELKTHPMLRPYKTFSEKDKEIYRWPIKESLKAMIAWEWTIEKAREGEEEKTEKKKTRKISQSAQTYDPREGYNPQPPDLSAVTLSRELQAMAEQLAENYHNTWGRKKKQELEAKGGGTHPLLVPYDTLTAKEKARDREKAQELLKFLQMNGYAVTRGLKDMELDSSSIEKRFAFGFLQQLLRWMDISQEFIAHLEAVVSSGRVEKSPHEQEIKFFAKILLPLINQYFTNHCLYFLSTPAKVLGSGGHASNKEKEMITSLFCKLAALVRHRVSLFGTDAPAVVNCLHILARSLDARTVMKSGPEIVKAGLRSFFESASEDIEKMVENLRLGKVSQARTQVKGVGQNLTYTTVALLPVLTTLFQHIAQHQFGDDVILDDVQVSCYRTLCSIYSLGTTKNTYVEKLRPALGECLARLAAAMPVAFLEPQLNEYNACSVYTTKSPRERAILGLPNSVEEMCPDIPVLERLMADIGGLAESGARYTEMPHVIEITLPMLCSYLPRWWERGPEAPPSALPAGAPPPCTAVTSDHLNSLLGNILRIIVNNLGIDEASWMKRLAVFAQPIVSRARPELLQSHFIPTIGRLRKRAGKVVSEEEQLRLEAKAEAQEGELLVRDEFSVLCRDLYALYPLLIRYVDNNRAQWLTEPNPSAEELFRMVGEIFIYWSKSHNFKREEQNFVVQNEINNMSFLTADNKSKMAKAGDIQSGGSDQERTKKKRRGDRYSVQTSLIVATLKKMLPIGLNMCAPTDQDLITLAKTRYALKDTDEEVREFLHNNLHLQGKVEGSPSLRWQMALYRGVPGREEDADDPEKIVRRVQEVSAVLYYLDQTEHPYKSKKAVWHKLLSKQRRRAVVACFRMTPLYNLPTHRACNMFLESYKAAWILTEDHSFEDRMIDDLSKAGEQEEEEEEVEEKKPDPLHQLVLHFSRTALTEKSKLDEDYLYMAYADIMAKSCHLEEGGENGEAEEEVEVSFEEKQMEKQRLLYQQARLHTRGAAEMVLQMISACKGETGAMVSSTLKLGISILNGGNAEVQQKMLDYLKDKKEVGFFQSIQALMQTCSVLDLNAFERQNKAEGLGMVNEDGTVINRQNGEKVMADDEFTQDLFRFLQLLCEGHNNDFQNYLRTQTGNTTTINIIICTVDYLLRLQESISDFYWYYSGKDVIEEQGKRNFSKAMSVAKQVFNSLTEYIQGPCTGNQQSLAHSRLWDAVVGFLHVFAHMMMKLAQDSSQIELLKELLDLQKDMVVMLLSLLEGNVVNGMIARQMVDMLVESSSNVEMILKFFDMFLKLKDIVGSEAFQDYVTDPRGLISKKDFQKAMDSQKQFSGPEIQFLLSCSEADENEMINCEEFANRFQEPARDIGFNVAVLLTNLSEHVPHDPRLHNFLELAESILEYFRPYLGRIEIMGASRRIERIYFEISETNRAQWEMPQVKESKRQFIFDVVNEGGEAEKMELFVSFCEDTIFEMQIAAQISEPEGEPETDEDEGAGAAEAGAEGAEEGAAGLEGTAATAAAGATARVVAAAGRALRGLSYRSLRRRVRRLRRLTAREAATAVAALLWAAVTRAGAAGAGAAAGALGLLWGSLFGGGLVEGAKKVTVTELLAGMPDPTSDEVHGEQPAGPGGDADGEGASEGAGDAAEGAGDEEEAVHEAGPGGADGAVAVTDGGPFRPEGAGGLGDMGDTTPAEPPTPEGSPILKRKLGVDGVEEELPPEPEPEPEPELEPEKADAENGEKEEVPEPTPEPPKKQAPPSPPPKKEEAGGEFWGELEVQRVKFLNYLSRNFYTLRFLALFLAFAINFILLFYKVSDSPPGEDDMEGSAAGDVSGAGSGGSSGWGLGAGEEAEGDEDENMVYYFLEESTGYMEPALRCLSLLHTLVAFLCIIGYNCLKVPLVIFKREKELARKLEFDGLYITEQPEDDDVKGQWDRLVLNTPSFPSNYWDKFVKRKVLDKHGDIYGRERIAELLGMDLATLEITAHNERKPNPPPGLLTWLMSIDVKYQIWKFGVIFTDNSFLYLGWYMVMSLLGHYNNFFFAAHLLDIAMGVKTLRTILSSVTHNGKQLVMTVGLLAVVVYLYTVVAFNFFRKFYNKSEDEDEPDMKCDDMMTCYLFHMYVGVRAGGGIGDEIEDPAGDEYELYRVVFDITFFFFVIVILLAIIQGLIIDAFGELRDQQEQVKEDMETKCFICGIGSDYFDTTPHGFETHTLEEHNLANYMFFLMYLINKDETEHTGQESYVWKMYQERCWDFFPAGDCFRKQYEDQLS	5038	P21817	R	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
369	NM_000540.3(RYR1):c.14545G>A (p.Val4849Ile)	12984	CA024171	NM_000540.3:c.14545G>A, NC_000019.10:g.38580403G>A, CM000681.2:g.38580403G>A, NC_000019.9:g.39071043G>A, CM000681.1:g.39071043G>A, NC_000019.8:g.43762883G>A, NG_008866.1:g.151704G>A, LRG_766:g.151704G>A, ENST00000359596.8:c.14545G>A, ENST00000355481.8:c.14530G>A, ENST00000359596.7:n.14545G>A, ENST00000360985.7:c.14527G>A, NM_000540.2:c.14545G>A, LRG_766t1:c.14545G>A, NM_001042723.1:c.14530G>A, XM_006723317.1:c.14527G>A, XM_006723319.1:c.14512G>A, XM_011527204.1:c.14542G>A, XM_011527205.1:c.14458G>A, XM_006723317.2:c.14527G>A, XM_006723319.2:c.14512G>A, XM_011527205.2:c.14458G>A, NM_001042723.2:c.14530G>A, NM_000540.3(RYR1):c.14545G>A (p.Val4849Ile)	RYR1	malignant hyperthermia, susceptibility to, 1	MONDO:0007783	Autosomal dominant inheritance	Pathogenic	PM1_Supporting, PS4, PS3_Moderate, PP1_Strong	PP3, BP4, BA1, BS1	This pathogenicity assessment is relevant only for malignant hyperthermia susceptibility (MHS) inherited in an autosomal dominant pattern. Variants in RYR1 can also cause other myopathies inherited in an autosomal dominant pattern or in an autosomal recessive pattern. Some of these disorders may predispose individuals to malignant hyperthermia. RYR1 variants may also contribute to a malignant hyperthermia reaction in combination with other genetic and non-genetic factors and the clinician needs to consider such factors in making management decisions.This sequence variant predicts a substitution of valine with isoleucine at codon 4849 of the RYR1 protein, p.(Val4849Ile). The maximum allele frequency for this variant among the six major gnomAD populations is AFR: 0.00004, a frequency consistent with pathogenicity for MHS. This variant has been reported in 31 unrelated individuals who have a personal or family history of a malignant hyperthermia reaction, all of these individuals had a positive in vitro contracture test (IVCT) or caffeine halothane contracture test (CHCT) result (if the proband was unavailable for testing, a positive diagnostic test result in a mutation-positive relative was counted), PS4 (PMID: 25960145, 30236257, 23558838, 24433488, 16163667, 28527222, 15731587, 19346234, 21455645). Functional studies in HEK293 cells show an increased sensitivity to RYR1 agonists PS3_Moderate (PMID: 28403410). This variant resides in a region of RYR1 considered to be a hotspot for pathogenic variants that contribute to MHS, PM1_Sup (PMID: 21118704). This variant segregates with MHS in 23 individuals, PP1_Strong (PMID: 25960145, 28527222). A REVEL score of 0.817 supports neither a pathogenic nor a benign status for this variant. This variant has been classified as Pathogenic. Criteria implemented: PS3_Moderate, PS4, PM1_Supporting, PP1_Strong.		Malignant Hyperthermia Susceptibility VCEP	https://clinicalgenome.org/docs/clingen-malignant-hyperthermia-susceptibility-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-for/	2021-03-22	2022-01-04	False	https://erepo.genome.network/evrepo/ui/classification/CA024171/MONDO:0007783/012	c9c5046f-3680-4d56-bc13-8c1ec15d32a5	p.Val4849Ile	Val	4849	Ile	MGDAEGEDEVQFLRTDDEVVLQCSATVLKEQLKLCLAAEGFGNRLCFLEPTSNAQNVPPDLAICCFVLEQSLSVRALQEMLANTVEAGVESSQGGGHRTLLYGHAILLRHAHSRMYLSCLTTSRSMTDKLAFDVGLQEDATGEACWWTMHPASKQRSEGEKVRVGDDIILVSVSSERYLHLSTASGELQVDASFMQTLWNMNPICSRCEEGFVTGGHVLRLFHGHMDECLTISPADSDDQRRLVYYEGGAVCTHARSLWRLEPLRISWSGSHLRWGQPLRVRHVTTGQYLALTEDQGLVVVDASKAHTKATSFCFRISKEKLDVAPKRDVEGMGPPEIKYGESLCFVQHVASGLWLTYAAPDPKALRLGVLKKKAMLHQEGHMDDALSLTRCQQEESQAARMIHSTNGLYNQFIKSLDSFSGKPRGSGPPAGTALPIEGVILSLQDLIIYFEPPSEDLQHEEKQSKLRSLRNRQSLFQEEGMLSMVLNCIDRLNVYTTAAHFAEFAGEEAAESWKEIVNLLYELLASLIRGNRSNCALFSTNLDWLVSKLDRLEASSGILEVLYCVLIESPEVLNIIQENHIKSIISLLDKHGRNHKVLDVLCSLCVCNGVAVRSNQDLITENLLPGRELLLQTNLINYVTSIRPNIFVGRAEGTTQYSKWYFEVMVDEVTPFLTAQATHLRVGWALTEGYTPYPGAGEGWGGNGVGDDLYSYGFDGLHLWTGHVARPVTSPGQHLLAPEDVISCCLDLSVPSISFRINGCPVQGVFESFNLDGLFFPVVSFSAGVKVRFLLGGRHGEFKFLPPPGYAPCHEAVLPRERLHLEPIKEYRREGPRGPHLVGPSRCLSHTDFVPCPVDTVQIVLPPHLERIREKLAENIHELWALTRIEQGWTYGPVRDDNKRLHPCLVDFHSLPEPERNYNLQMSGETLKTLLALGCHVGMADEKAEDNLKKTKLPKTYMMSNGYKPAPLDLSHVRLTPAQTTLVDRLAENGHNVWARDRVGQGWSYSAVQDIPARRNPRLVPYRLLDEATKRSNRDSLCQAVRTLLGYGYNIEPPDQEPSQVENQSRCDRVRIFRAEKSYTVQSGRWYFEFEAVTTGEMRVGWARPELRPDVELGADELAYVFNGHRGQRWHLGSEPFGRPWQPGDVVGCMIDLTENTIIFTLNGEVLMSDSGSETAFREIEIGDGFLPVCSLGPGQVGHLNLGQDVSSLRFFAICGLQEGFEPFAINMQRPVTTWFSKGLPQFEPVPLEHPHYEVSRVDGTVDTPPCLRLTHRTWGSQNSLVEMLFLRLSLPVQFHQHFRCTAGATPLAPPGLQPPAEDEARAAEPDPDYENLRRSAGGWSEAENGKEGTAKEGAPGGTPQAGGEAQPARAENEKDATTEKNKKRGFLFKAKKVAMMTQPPATPTLPRLPHDVVPADNRDDPEIILNTTTYYYSVRVFAGQEPSCVWAGWVTPDYHQHDMSFDLSKVRVVTVTMGDEQGNVHSSLKCSNCYMVWGGDFVSPGQQGRISHTDLVIGCLVDLATGLMTFTANGKESNTFFQVEPNTKLFPAVFVLPTHQNVIQFELGKQKNIMPLSAAMFQSERKNPAPQCPPRLEMQMLMPVSWSRMPNHFLQVETRRAGERLGWAVQCQEPLTMMALHIPEENRCMDILELSERLDLQRFHSHTLRLYRAVCALGNNRVAHALCSHVDQAQLLHALEDAHLPGPLRAGYYDLLISIHLESACRSRRSMLSEYIVPLTPETRAITLFPPGRSTENGHPRHGLPGVGVTTSLRPPHHFSPPCFVAALPAAGAAEAPARLSPAIPLEALRDKALRMLGEAVRDGGQHARDPVGGSVEFQFVPVLKLVSTLLVMGIFGDEDVKQILKMIEPEVFTEEEEEEDEEEEGEEEDEEEKEEDEEETAQEKEDEEKEEEEAAEGEKEEGLEEGLLQMKLPESVKLQMCHLLEYFCDQELQHRVESLAAFAERYVDKLQANQRSRYGLLIKAFSMTAAETARRTREFRSPPQEQINMLLQFKDGTDEEDCPLPEEIRQDLLDFHQDLLAHCGIQLDGEEEEPEEETTLGSRLMSLLEKVRLVKKKEEKPEEERSAEESKPRSLQELVSHMVVRWAQEDFVQSPELVRAMFSLLHRQYDGLGELLRALPRAYTISPSSVEDTMSLLECLGQIRSLLIVQMGPQEENLMIQSIGNIMNNKVFYQHPNLMRALGMHETVMEVMVNVLGGGESKEIRFPKMVTSCCRFLCYFCRISRQNQRSMFDHLSYLLENSGIGLGMQGSTPLDVAAASVIDNNELALALQEQDLEKVVSYLAGCGLQSCPMLVAKGYPDIGWNPCGGERYLDFLRFAVFVNGESVEENANVVVRLLIRKPECFGPALRGEGGSGLLAAIEEAIRISEDPARDGPGIRRDRRREHFGEEPPEENRVHLGHAIMSFYAALIDLLGRCAPEMHLIQAGKGEALRIRAILRSLVPLEDLVGIISLPLQIPTLGKDGALVQPKMSASFVPDHKASMVLFLDRVYGIENQDFLLHVLDVGFLPDMRAAASLDTATFSTTEMALALNRYLCLAVLPLITKCAPLFAGTEHRAIMVDSMLHTVYRLSRGRSLTKAQRDVIEDCLMSLCRYIRPSMLQHLLRRLVFDVPILNEFAKMPLKLLTNHYERCWKYYCLPTGWANFGVTSEEELHLTRKLFWGIFDSLAHKKYDPELYRMAMPCLCAIAGALPPDYVDASYSSKAEKKATVDAEGNFDPRPVETLNVIIPEKLDSFINKFAEYTHEKWAFDKIQNNWSYGENIDEELKTHPMLRPYKTFSEKDKEIYRWPIKESLKAMIAWEWTIEKAREGEEEKTEKKKTRKISQSAQTYDPREGYNPQPPDLSAVTLSRELQAMAEQLAENYHNTWGRKKKQELEAKGGGTHPLLVPYDTLTAKEKARDREKAQELLKFLQMNGYAVTRGLKDMELDSSSIEKRFAFGFLQQLLRWMDISQEFIAHLEAVVSSGRVEKSPHEQEIKFFAKILLPLINQYFTNHCLYFLSTPAKVLGSGGHASNKEKEMITSLFCKLAALVRHRVSLFGTDAPAVVNCLHILARSLDARTVMKSGPEIVKAGLRSFFESASEDIEKMVENLRLGKVSQARTQVKGVGQNLTYTTVALLPVLTTLFQHIAQHQFGDDVILDDVQVSCYRTLCSIYSLGTTKNTYVEKLRPALGECLARLAAAMPVAFLEPQLNEYNACSVYTTKSPRERAILGLPNSVEEMCPDIPVLERLMADIGGLAESGARYTEMPHVIEITLPMLCSYLPRWWERGPEAPPSALPAGAPPPCTAVTSDHLNSLLGNILRIIVNNLGIDEASWMKRLAVFAQPIVSRARPELLQSHFIPTIGRLRKRAGKVVSEEEQLRLEAKAEAQEGELLVRDEFSVLCRDLYALYPLLIRYVDNNRAQWLTEPNPSAEELFRMVGEIFIYWSKSHNFKREEQNFVVQNEINNMSFLTADNKSKMAKAGDIQSGGSDQERTKKKRRGDRYSVQTSLIVATLKKMLPIGLNMCAPTDQDLITLAKTRYALKDTDEEVREFLHNNLHLQGKVEGSPSLRWQMALYRGVPGREEDADDPEKIVRRVQEVSAVLYYLDQTEHPYKSKKAVWHKLLSKQRRRAVVACFRMTPLYNLPTHRACNMFLESYKAAWILTEDHSFEDRMIDDLSKAGEQEEEEEEVEEKKPDPLHQLVLHFSRTALTEKSKLDEDYLYMAYADIMAKSCHLEEGGENGEAEEEVEVSFEEKQMEKQRLLYQQARLHTRGAAEMVLQMISACKGETGAMVSSTLKLGISILNGGNAEVQQKMLDYLKDKKEVGFFQSIQALMQTCSVLDLNAFERQNKAEGLGMVNEDGTVINRQNGEKVMADDEFTQDLFRFLQLLCEGHNNDFQNYLRTQTGNTTTINIIICTVDYLLRLQESISDFYWYYSGKDVIEEQGKRNFSKAMSVAKQVFNSLTEYIQGPCTGNQQSLAHSRLWDAVVGFLHVFAHMMMKLAQDSSQIELLKELLDLQKDMVVMLLSLLEGNVVNGMIARQMVDMLVESSSNVEMILKFFDMFLKLKDIVGSEAFQDYVTDPRGLISKKDFQKAMDSQKQFSGPEIQFLLSCSEADENEMINCEEFANRFQEPARDIGFNVAVLLTNLSEHVPHDPRLHNFLELAESILEYFRPYLGRIEIMGASRRIERIYFEISETNRAQWEMPQVKESKRQFIFDVVNEGGEAEKMELFVSFCEDTIFEMQIAAQISEPEGEPETDEDEGAGAAEAGAEGAEEGAAGLEGTAATAAAGATARVVAAAGRALRGLSYRSLRRRVRRLRRLTAREAATAVAALLWAAVTRAGAAGAGAAAGALGLLWGSLFGGGLVEGAKKVTVTELLAGMPDPTSDEVHGEQPAGPGGDADGEGASEGAGDAAEGAGDEEEAVHEAGPGGADGAVAVTDGGPFRPEGAGGLGDMGDTTPAEPPTPEGSPILKRKLGVDGVEEELPPEPEPEPEPELEPEKADAENGEKEEVPEPTPEPPKKQAPPSPPPKKEEAGGEFWGELEVQRVKFLNYLSRNFYTLRFLALFLAFAINFILLFYKVSDSPPGEDDMEGSAAGDVSGAGSGGSSGWGLGAGEEAEGDEDENMVYYFLEESTGYMEPALRCLSLLHTLVAFLCIIGYNCLKVPLVIFKREKELARKLEFDGLYITEQPEDDDVKGQWDRLVLNTPSFPSNYWDKFVKRKVLDKHGDIYGRERIAELLGMDLATLEITAHNERKPNPPPGLLTWLMSIDVKYQIWKFGVIFTDNSFLYLGWYMVMSLLGHYNNFFFAAHLLDIAMGVKTLRTILSSVTHNGKQLVMTVGLLAVVVYLYTVVAFNFFRKFYNKSEDEDEPDMKCDDMMTCYLFHMYVGVRAGGGIGDEIEDPAGDEYELYRVVFDITFFFFVIVILLAIIQGLIIDAFGELRDQQEQVKEDMETKCFICGIGSDYFDTTPHGFETHTLEEHNLANYMFFLMYLINKDETEHTGQESYVWKMYQERCWDFFPAGDCFRKQYEDQLS	5038	P21817	I	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
370	NM_000540.3(RYR1):c.7373G>A (p.Arg2458His)	12972	CA024787	NM_000540.3:c.7373G>A, NC_000019.10:g.38500655G>A, CM000681.2:g.38500655G>A, NC_000019.9:g.38991295G>A, CM000681.1:g.38991295G>A, NC_000019.8:g.43683135G>A, NG_008866.1:g.71956G>A, LRG_766:g.71956G>A, ENST00000359596.8:c.7373G>A, ENST00000355481.8:c.7373G>A, ENST00000359596.7:n.7373G>A, ENST00000360985.7:c.7370G>A, ENST00000594335.5:n.825G>A, NM_000540.2:c.7373G>A, LRG_766t1:c.7373G>A, NM_001042723.1:c.7373G>A, XM_006723317.1:c.7373G>A, XM_006723319.1:c.7373G>A, XM_011527204.1:c.7370G>A, XM_011527205.1:c.7373G>A, XM_006723317.2:c.7373G>A, XM_006723319.2:c.7373G>A, XM_011527205.2:c.7373G>A, XR_001753735.1:n.7456G>A, NM_001042723.2:c.7373G>A, NM_000540.3(RYR1):c.7373G>A (p.Arg2458His)	RYR1	malignant hyperthermia, susceptibility to, 1	MONDO:0007783	Autosomal dominant inheritance	Pathogenic	PS4, PS3_Moderate, PM1, PP1_Strong, PP3_Moderate	BA1, BS1	This pathogenicity assessment is relevant only for malignant hyperthermia susceptibility (MHS) inherited in an autosomal dominant pattern. Variants in RYR1 can also cause other myopathies inherited in an autosomal dominant pattern or in an autosomal recessive pattern. Some of these disorders may predispose individuals to malignant hyperthermia. RYR1 variants may also contribute to a malignant hyperthermia reaction in combination with other genetic and non-genetic factors and the clinician needs to consider such factors in making management decisions.This sequence variant predicts a substitution of arginine with histidine at codon 2458 of the RYR1 protein, p.(Arg2458His). The maximum allele frequency for this variant among the six major gnomAD populations is EAS: 0.000054, a frequency consistent with pathogenicity for MHS. This variant has been reported in 26 unrelated individuals who have a personal or family history of a malignant hyperthermia reaction, 23 of these individuals had a positive in vitro contracture test (IVCT) or caffeine halothane contracture test (CHCT) result (if the proband was unavailable for testing, a positive diagnostic test result in a mutation-positive relative was counted), PS4 (PMID: 30236257, 16163667, 22415532, 9450902, 16732084, 21157159 and others). This variant segregates with MHS in 10 individuals, PP1_Strong (PMID:30236257). Functional studies in HEK293 cells and dyspedic myotubes show an increased sensitivity to RYR1 agonists, PS3_Moderate (PMID:27586648, 12732639). This variant resides in a region of RYR1 considered to be a hotspot for pathogenic variants that contribute to MHS, PM1 (PMID: 21118704). A REVEL score >0.85 (0.959) supports a pathogenic status for this variant, PP3_Moderate. This variant has been classified as Pathogenic. Criteria implemented: PS3_Moderate, PS4, PM1, PP1_Strong, PP3_Moderate.		Malignant Hyperthermia Susceptibility VCEP	https://clinicalgenome.org/docs/clingen-malignant-hyperthermia-susceptibility-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-for/	2022-01-04	2022-01-04	False	https://erepo.genome.network/evrepo/ui/classification/CA024787/MONDO:0007783/012	3778fd48-227a-4d54-b8c6-095bf4d41315	p.Arg2458His	Arg	2458	His	MGDAEGEDEVQFLRTDDEVVLQCSATVLKEQLKLCLAAEGFGNRLCFLEPTSNAQNVPPDLAICCFVLEQSLSVRALQEMLANTVEAGVESSQGGGHRTLLYGHAILLRHAHSRMYLSCLTTSRSMTDKLAFDVGLQEDATGEACWWTMHPASKQRSEGEKVRVGDDIILVSVSSERYLHLSTASGELQVDASFMQTLWNMNPICSRCEEGFVTGGHVLRLFHGHMDECLTISPADSDDQRRLVYYEGGAVCTHARSLWRLEPLRISWSGSHLRWGQPLRVRHVTTGQYLALTEDQGLVVVDASKAHTKATSFCFRISKEKLDVAPKRDVEGMGPPEIKYGESLCFVQHVASGLWLTYAAPDPKALRLGVLKKKAMLHQEGHMDDALSLTRCQQEESQAARMIHSTNGLYNQFIKSLDSFSGKPRGSGPPAGTALPIEGVILSLQDLIIYFEPPSEDLQHEEKQSKLRSLRNRQSLFQEEGMLSMVLNCIDRLNVYTTAAHFAEFAGEEAAESWKEIVNLLYELLASLIRGNRSNCALFSTNLDWLVSKLDRLEASSGILEVLYCVLIESPEVLNIIQENHIKSIISLLDKHGRNHKVLDVLCSLCVCNGVAVRSNQDLITENLLPGRELLLQTNLINYVTSIRPNIFVGRAEGTTQYSKWYFEVMVDEVTPFLTAQATHLRVGWALTEGYTPYPGAGEGWGGNGVGDDLYSYGFDGLHLWTGHVARPVTSPGQHLLAPEDVISCCLDLSVPSISFRINGCPVQGVFESFNLDGLFFPVVSFSAGVKVRFLLGGRHGEFKFLPPPGYAPCHEAVLPRERLHLEPIKEYRREGPRGPHLVGPSRCLSHTDFVPCPVDTVQIVLPPHLERIREKLAENIHELWALTRIEQGWTYGPVRDDNKRLHPCLVDFHSLPEPERNYNLQMSGETLKTLLALGCHVGMADEKAEDNLKKTKLPKTYMMSNGYKPAPLDLSHVRLTPAQTTLVDRLAENGHNVWARDRVGQGWSYSAVQDIPARRNPRLVPYRLLDEATKRSNRDSLCQAVRTLLGYGYNIEPPDQEPSQVENQSRCDRVRIFRAEKSYTVQSGRWYFEFEAVTTGEMRVGWARPELRPDVELGADELAYVFNGHRGQRWHLGSEPFGRPWQPGDVVGCMIDLTENTIIFTLNGEVLMSDSGSETAFREIEIGDGFLPVCSLGPGQVGHLNLGQDVSSLRFFAICGLQEGFEPFAINMQRPVTTWFSKGLPQFEPVPLEHPHYEVSRVDGTVDTPPCLRLTHRTWGSQNSLVEMLFLRLSLPVQFHQHFRCTAGATPLAPPGLQPPAEDEARAAEPDPDYENLRRSAGGWSEAENGKEGTAKEGAPGGTPQAGGEAQPARAENEKDATTEKNKKRGFLFKAKKVAMMTQPPATPTLPRLPHDVVPADNRDDPEIILNTTTYYYSVRVFAGQEPSCVWAGWVTPDYHQHDMSFDLSKVRVVTVTMGDEQGNVHSSLKCSNCYMVWGGDFVSPGQQGRISHTDLVIGCLVDLATGLMTFTANGKESNTFFQVEPNTKLFPAVFVLPTHQNVIQFELGKQKNIMPLSAAMFQSERKNPAPQCPPRLEMQMLMPVSWSRMPNHFLQVETRRAGERLGWAVQCQEPLTMMALHIPEENRCMDILELSERLDLQRFHSHTLRLYRAVCALGNNRVAHALCSHVDQAQLLHALEDAHLPGPLRAGYYDLLISIHLESACRSRRSMLSEYIVPLTPETRAITLFPPGRSTENGHPRHGLPGVGVTTSLRPPHHFSPPCFVAALPAAGAAEAPARLSPAIPLEALRDKALRMLGEAVRDGGQHARDPVGGSVEFQFVPVLKLVSTLLVMGIFGDEDVKQILKMIEPEVFTEEEEEEDEEEEGEEEDEEEKEEDEEETAQEKEDEEKEEEEAAEGEKEEGLEEGLLQMKLPESVKLQMCHLLEYFCDQELQHRVESLAAFAERYVDKLQANQRSRYGLLIKAFSMTAAETARRTREFRSPPQEQINMLLQFKDGTDEEDCPLPEEIRQDLLDFHQDLLAHCGIQLDGEEEEPEEETTLGSRLMSLLEKVRLVKKKEEKPEEERSAEESKPRSLQELVSHMVVRWAQEDFVQSPELVRAMFSLLHRQYDGLGELLRALPRAYTISPSSVEDTMSLLECLGQIRSLLIVQMGPQEENLMIQSIGNIMNNKVFYQHPNLMRALGMHETVMEVMVNVLGGGESKEIRFPKMVTSCCRFLCYFCRISRQNQRSMFDHLSYLLENSGIGLGMQGSTPLDVAAASVIDNNELALALQEQDLEKVVSYLAGCGLQSCPMLVAKGYPDIGWNPCGGERYLDFLRFAVFVNGESVEENANVVVRLLIRKPECFGPALRGEGGSGLLAAIEEAIRISEDPARDGPGIRRDRRREHFGEEPPEENRVHLGHAIMSFYAALIDLLGRCAPEMHLIQAGKGEALRIRAILRSLVPLEDLVGIISLPLQIPTLGKDGALVQPKMSASFVPDHKASMVLFLDRVYGIENQDFLLHVLDVGFLPDMRAAASLDTATFSTTEMALALNRYLCLAVLPLITKCAPLFAGTEHRAIMVDSMLHTVYRLSRGRSLTKAQRDVIEDCLMSLCRYIRPSMLQHLLRRLVFDVPILNEFAKMPLKLLTNHYERCWKYYCLPTGWANFGVTSEEELHLTRKLFWGIFDSLAHKKYDPELYRMAMPCLCAIAGALPPDYVDASYSSKAEKKATVDAEGNFDPRPVETLNVIIPEKLDSFINKFAEYTHEKWAFDKIQNNWSYGENIDEELKTHPMLRPYKTFSEKDKEIYRWPIKESLKAMIAWEWTIEKAREGEEEKTEKKKTRKISQSAQTYDPREGYNPQPPDLSAVTLSRELQAMAEQLAENYHNTWGRKKKQELEAKGGGTHPLLVPYDTLTAKEKARDREKAQELLKFLQMNGYAVTRGLKDMELDSSSIEKRFAFGFLQQLLRWMDISQEFIAHLEAVVSSGRVEKSPHEQEIKFFAKILLPLINQYFTNHCLYFLSTPAKVLGSGGHASNKEKEMITSLFCKLAALVRHRVSLFGTDAPAVVNCLHILARSLDARTVMKSGPEIVKAGLRSFFESASEDIEKMVENLRLGKVSQARTQVKGVGQNLTYTTVALLPVLTTLFQHIAQHQFGDDVILDDVQVSCYRTLCSIYSLGTTKNTYVEKLRPALGECLARLAAAMPVAFLEPQLNEYNACSVYTTKSPRERAILGLPNSVEEMCPDIPVLERLMADIGGLAESGARYTEMPHVIEITLPMLCSYLPRWWERGPEAPPSALPAGAPPPCTAVTSDHLNSLLGNILRIIVNNLGIDEASWMKRLAVFAQPIVSRARPELLQSHFIPTIGRLRKRAGKVVSEEEQLRLEAKAEAQEGELLVRDEFSVLCRDLYALYPLLIRYVDNNRAQWLTEPNPSAEELFRMVGEIFIYWSKSHNFKREEQNFVVQNEINNMSFLTADNKSKMAKAGDIQSGGSDQERTKKKRRGDRYSVQTSLIVATLKKMLPIGLNMCAPTDQDLITLAKTRYALKDTDEEVREFLHNNLHLQGKVEGSPSLRWQMALYRGVPGREEDADDPEKIVRRVQEVSAVLYYLDQTEHPYKSKKAVWHKLLSKQRRRAVVACFRMTPLYNLPTHRACNMFLESYKAAWILTEDHSFEDRMIDDLSKAGEQEEEEEEVEEKKPDPLHQLVLHFSRTALTEKSKLDEDYLYMAYADIMAKSCHLEEGGENGEAEEEVEVSFEEKQMEKQRLLYQQARLHTRGAAEMVLQMISACKGETGAMVSSTLKLGISILNGGNAEVQQKMLDYLKDKKEVGFFQSIQALMQTCSVLDLNAFERQNKAEGLGMVNEDGTVINRQNGEKVMADDEFTQDLFRFLQLLCEGHNNDFQNYLRTQTGNTTTINIIICTVDYLLRLQESISDFYWYYSGKDVIEEQGKRNFSKAMSVAKQVFNSLTEYIQGPCTGNQQSLAHSRLWDAVVGFLHVFAHMMMKLAQDSSQIELLKELLDLQKDMVVMLLSLLEGNVVNGMIARQMVDMLVESSSNVEMILKFFDMFLKLKDIVGSEAFQDYVTDPRGLISKKDFQKAMDSQKQFSGPEIQFLLSCSEADENEMINCEEFANRFQEPARDIGFNVAVLLTNLSEHVPHDPRLHNFLELAESILEYFRPYLGRIEIMGASRRIERIYFEISETNRAQWEMPQVKESKRQFIFDVVNEGGEAEKMELFVSFCEDTIFEMQIAAQISEPEGEPETDEDEGAGAAEAGAEGAEEGAAGLEGTAATAAAGATARVVAAAGRALRGLSYRSLRRRVRRLRRLTAREAATAVAALLWAAVTRAGAAGAGAAAGALGLLWGSLFGGGLVEGAKKVTVTELLAGMPDPTSDEVHGEQPAGPGGDADGEGASEGAGDAAEGAGDEEEAVHEAGPGGADGAVAVTDGGPFRPEGAGGLGDMGDTTPAEPPTPEGSPILKRKLGVDGVEEELPPEPEPEPEPELEPEKADAENGEKEEVPEPTPEPPKKQAPPSPPPKKEEAGGEFWGELEVQRVKFLNYLSRNFYTLRFLALFLAFAINFILLFYKVSDSPPGEDDMEGSAAGDVSGAGSGGSSGWGLGAGEEAEGDEDENMVYYFLEESTGYMEPALRCLSLLHTLVAFLCIIGYNCLKVPLVIFKREKELARKLEFDGLYITEQPEDDDVKGQWDRLVLNTPSFPSNYWDKFVKRKVLDKHGDIYGRERIAELLGMDLATLEITAHNERKPNPPPGLLTWLMSIDVKYQIWKFGVIFTDNSFLYLGWYMVMSLLGHYNNFFFAAHLLDIAMGVKTLRTILSSVTHNGKQLVMTVGLLAVVVYLYTVVAFNFFRKFYNKSEDEDEPDMKCDDMMTCYLFHMYVGVRAGGGIGDEIEDPAGDEYELYRVVFDITFFFFVIVILLAIIQGLIIDAFGELRDQQEQVKEDMETKCFICGIGSDYFDTTPHGFETHTLEEHNLANYMFFLMYLINKDETEHTGQESYVWKMYQERCWDFFPAGDCFRKQYEDQLS	5038	P21817	H	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
371	NM_000152.5(GAA):c.2014C>T (p.Arg672Trp)	188773	CA273939	NM_000152.5:c.2014C>T, NM_000152.5(GAA):c.2014C>T, NC_000017.11:g.80113001C>T, CM000679.2:g.80113001C>T, NC_000017.10:g.78086800C>T, CM000679.1:g.78086800C>T, NC_000017.9:g.75701395C>T, NG_009822.1:g.16446C>T, LRG_673:g.16446C>T, ENST00000302262.8:c.2014C>T, ENST00000302262.7:c.2014C>T, ENST00000390015.7:c.2014C>T, ENST00000570716.1:n.454C>T, ENST00000572080.1:n.433C>T, NM_000152.3:c.2014C>T, LRG_673t1:c.2014C>T, NM_001079803.1:c.2014C>T, NM_001079804.1:c.2014C>T, XM_005257193.1:c.2014C>T, XM_005257194.3:c.2014C>T, NM_000152.4:c.2014C>T, NM_001079803.2:c.2014C>T, NM_001079804.2:c.2014C>T, XM_005257193.2:c.2014C>T, XM_005257194.4:c.2014C>T, NM_001079803.3:c.2014C>T, NM_001079804.3:c.2014C>T, NM_000152.5(GAA):c.2014C>T (p.Arg672Trp)	GAA	glycogen storage disease II	MONDO:0009290	Autosomal recessive inheritance	Pathogenic	PM3_Strong, PM5_Supporting, PS3_Supporting, PP4_Moderate, PP3, PM2_Supporting		The NM_000152.5:c.2014C>T variant in GAA is a missense variant predicted to cause substitution of arginine by tryptophan at amino acid 672 (p.Arg672Trp). The variant has been reported in 5 patients with a diagnosis of Pompe disease supported by <10% normal GAA activity in muscle (PMID 9535769), <1% GAA activity in cultured fibroblasts (PMID 16917947), or GAA activity in the affected range in leukocytes or lymphocytes (PMID 22676651, 25526786) in addition to at least 5 patients stated to have symptoms consistent with Pompe disease and deficient GAA activity but values not provided (PMID 16917947, 21803581, 27692865)(PP4_Moderate). At least 5 patients are compound heterozygous for the variant and a variant in GAA classified as pathogenic by the ClinGen LSD VCEP, phase unknown - c.-32-13T>G (PMID 16917947), c.2385delG (PMID 21484825), c.1411_1414del (PMID 27692865), c.766_785delinsC (PMID 9535769), and c.1951_1952insT (clinical laboratory data) (PM3_Strong). The variant has also been reported in compound heterozygotes with c.1748C>T(p.Ser583Phe)(PMID 21484825), c.323G>A (p.Cys108Tyr) (PMID 25526786), c.1465G>A (p.Asp489Asn)(PMID 16917947), c.1703A>T (p.His568Leu)(PMID 17027861, 22676651), c.2474C>G (p.Pro825Arg)(PMID 30564623). The in trans data from these patients will be used in the assessment of the second variant and is not included here in order to avoid circular logic. The highest population minor allele frequency in gnomAD v2.1.1 is 0.00003 (1/29806 alleles) in the South Asian population, which is lower than the ClinGen LSD VCEP’s threshold for PM2_Supporting (<0.001), meeting this criterion (PM2_Supporting). Expression of the variant in SV40-immortalized GAA-deficient fibroblasts revealed activity of <1% of the control value (PMID 9535769), and <2% activity in COS cells (PMID 19862843) (PS3_Supporting). The computational predictor REVEL gives a score of 0.9 which is above the threshold of 0.7, evidence that correlates with impact to GAA function (PP3). Another missense variant c.2015G>A (p.Arg672Gln)(see Table 1 in PMID 33578445) in the same codon has been classified as pathogenic for Pompe disease by the ClinGen LSD VCEP (likely pathogenic without PM5 data from c.2014C>T (p.Arg672Trp) PM5_Supporting). c.2015G>T (p.Arg672Leu) has also been reported but has not yet met the criteria to be classified as pathogenic or likely pathogenic. There is a ClinVar entry for this variant (Variation ID: 188773; 2 star status) with 5 submitters classifying the variant as pathogenic and one as likely pathogenic. In summary, this variant meets the criteria to be classified as pathogenic for Pompe disease. ACMG/AMP criteria met, as specified by the ClinGen Lysosomal Storage Disorders VCEP: PM3_Strong, PP4_Moderate, PP3, PS3_Supporting, PM2_Supporting, PM5_Supporting.		Lysosomal Diseases VCEP	https://clinicalgenome.org/docs/clingen-lysosomal-storage-disorders-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-2/	2022-01-04	2022-01-04	False	https://erepo.genome.network/evrepo/ui/classification/CA273939/MONDO:0009290/010	0010f825-8714-4490-bdb6-1919f2f2a555	p.Arg672Trp	Arg	672	Trp	MGVRHPPCSHRLLAVCALVSLATAALLGHILLHDFLLVPRELSGSSPVLEETHPAHQQGASRPGPRDAQAHPGRPRAVPTQCDVPPNSRFDCAPDKAITQEQCEARGCCYIPAKQGLQGAQMGQPWCFFPPSYPSYKLENLSSSEMGYTATLTRTTPTFFPKDILTLRLDVMMETENRLHFTIKDPANRRYEVPLETPHVHSRAPSPLYSVEFSEEPFGVIVRRQLDGRVLLNTTVAPLFFADQFLQLSTSLPSQYITGLAEHLSPLMLSTSWTRITLWNRDLAPTPGANLYGSHPFYLALEDGGSAHGVFLLNSNAMDVVLQPSPALSWRSTGGILDVYIFLGPEPKSVVQQYLDVVGYPFMPPYWGLGFHLCRWGYSSTAITRQVVENMTRAHFPLDVQWNDLDYMDSRRDFTFNKDGFRDFPAMVQELHQGGRRYMMIVDPAISSSGPAGSYRPYDEGLRRGVFITNETGQPLIGKVWPGSTAFPDFTNPTALAWWEDMVAEFHDQVPFDGMWIDMNEPSNFIRGSEDGCPNNELENPPYVPGVVGGTLQAATICASSHQFLSTHYNLHNLYGLTEAIASHRALVKARGTRPFVISRSTFAGHGRYAGHWTGDVWSSWEQLASSVPEILQFNLLGVPLVGADVCGFLGNTSEELCVRWTQLGAFYPFMRNHNSLLSLPQEPYSFSEPAQQAMRKALTLRYALLPHLYTLFHQAHVAGETVARPLFLEFPKDSSTWTVDHQLLWGEALLITPVLQAGKAEVTGYFPLGTWYDLQTVPVEALGSLPPPPAAPREPAIHSEGQWVTLPAPLDTINVHLRAGYIIPLQGPGLTTTESRQQPMALAVALTKGGEARGELFWDDGESLEVLERGAYTQVIFLARNNTIVNELVRVTSEGAGLQLQKVTVLGVATAPQQVLSNGVPVSNFTYSPDTKVLDICVSLLMGEQFLVSWC	952	P10253	W	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [707], 'DNA_BIND_gain_score': array([0.00177735]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [665], 'HELIX_gain_score': array([0.04693681]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [386, 623], 'REPEAT_gain': [643, 670], 'REPEAT_gain_score': array([0.00188249, 0.02602464]), 'REPEAT_loss_score': array([-0.00064433, -0.00589782]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
372	NM_000540.3(RYR1):c.6617C>T (p.Thr2206Met)	12977	CA024622	NM_000540.3:c.6617C>T, NC_000019.10:g.38496283C>T, CM000681.2:g.38496283C>T, NC_000019.9:g.38986923C>T, CM000681.1:g.38986923C>T, NC_000019.8:g.43678763C>T, NG_008866.1:g.67584C>T, LRG_766:g.67584C>T, ENST00000359596.8:c.6617C>T, ENST00000355481.8:c.6617C>T, ENST00000359596.7:n.6617C>T, ENST00000360985.7:c.6614C>T, ENST00000594335.5:n.69C>T, NM_000540.2:c.6617C>T, LRG_766t1:c.6617C>T, NM_001042723.1:c.6617C>T, XM_006723317.1:c.6617C>T, XM_006723319.1:c.6617C>T, XM_011527204.1:c.6614C>T, XM_011527205.1:c.6617C>T, XM_006723317.2:c.6617C>T, XM_006723319.2:c.6617C>T, XM_011527205.2:c.6617C>T, XR_001753735.1:n.6700C>T, NM_001042723.2:c.6617C>T, NM_000540.3(RYR1):c.6617C>T (p.Thr2206Met)	RYR1	malignant hyperthermia, susceptibility to, 1	MONDO:0007783	Autosomal dominant inheritance	Pathogenic	BS2, PM1_Supporting, PS4, PS3_Moderate, PM5, PP3_Moderate, PP1_Strong	BA1, BS1	This pathogenicity assessment is relevant only for malignant hyperthermia susceptibility (MHS) inherited in an autosomal dominant pattern. Variants in RYR1 can also cause other myopathies inherited in an autosomal dominant pattern or in an autosomal recessive pattern. Some of these disorders may predispose individuals to malignant hyperthermia. RYR1 variants may also contribute to a malignant hyperthermia reaction in combination with other genetic and non-genetic factors and the clinician needs to consider such factors in making management decisions.This sequence variant predicts a substitution of threonine with methionine at codon 2206 of the RYR1 protein, p.(Thr2206Met). The maximum allele frequency for this variant among the six major gnomAD populations is EAS: 0.00005, a frequency consistent with pathogenicity for MHS. This variant has been reported in 67 unrelated individuals who have a personal or family history of a malignant hyperthermia reaction, 63 of these individuals had a positive in vitro contracture test (IVCT) or caffeine halothane contracture test (CHCT) result (if the proband was unavailable for testing, a positive diagnostic test result in a mutation-positive relative was counted), PS4 (PMID: 30236257, 12059893, 24433488, 23558838, 10484775, 25735680, 25960145, 16163667, 11575529, 12220451, 12434264, 15731587, 17081152, 18505122, 22696611, 9497245, 25268394, 31559918). This variant has been identified in at least three individuals with negative IVCT/CHCT results, BS2 (PMID: 30236257). Functional studies in HEK293 cells show an increased sensitivity to RYR1 agonists PS3_Moderate (PMID: 27586648). An ex vivo assay in patient derived myotubes from two related individuals showed an increased sensitivity to RYR1 agonists (PMID: 12220451). This variant resides in a region of RYR1 considered to be a hotspot for pathogenic variants that contribute to MHS, use PM1_Supporting to avoid overweighting with PM5 (PMID: 21118704). Another variant that has been assessed as pathogenic occurs at this codon, p.(Thr2206Arg), PM5. This variant segregates with MHS in nine individuals, PP1_Strong (PMID: 12059893, 25960145). A REVEL score >0.85 (0.95) supports a pathogenic status for this variant, PP3_Moderate. Based on using Bayes to combine criteria this variant is assessed as Pathogenic, (PMID: 29300386). Criteria implemented: PS4, PS3_Moderate, PM1_Supporting, PM5, PP1_Strong, PP3_Moderate, BS2.		Malignant Hyperthermia Susceptibility VCEP	https://clinicalgenome.org/docs/clingen-malignant-hyperthermia-susceptibility-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-for/	2022-03-14	2022-03-14	False	https://erepo.genome.network/evrepo/ui/classification/CA024622/MONDO:0007783/012	ecd64388-7fbd-43cd-8605-0d6feb7dbe20	p.Thr2206Met	Thr	2206	Met	MGDAEGEDEVQFLRTDDEVVLQCSATVLKEQLKLCLAAEGFGNRLCFLEPTSNAQNVPPDLAICCFVLEQSLSVRALQEMLANTVEAGVESSQGGGHRTLLYGHAILLRHAHSRMYLSCLTTSRSMTDKLAFDVGLQEDATGEACWWTMHPASKQRSEGEKVRVGDDIILVSVSSERYLHLSTASGELQVDASFMQTLWNMNPICSRCEEGFVTGGHVLRLFHGHMDECLTISPADSDDQRRLVYYEGGAVCTHARSLWRLEPLRISWSGSHLRWGQPLRVRHVTTGQYLALTEDQGLVVVDASKAHTKATSFCFRISKEKLDVAPKRDVEGMGPPEIKYGESLCFVQHVASGLWLTYAAPDPKALRLGVLKKKAMLHQEGHMDDALSLTRCQQEESQAARMIHSTNGLYNQFIKSLDSFSGKPRGSGPPAGTALPIEGVILSLQDLIIYFEPPSEDLQHEEKQSKLRSLRNRQSLFQEEGMLSMVLNCIDRLNVYTTAAHFAEFAGEEAAESWKEIVNLLYELLASLIRGNRSNCALFSTNLDWLVSKLDRLEASSGILEVLYCVLIESPEVLNIIQENHIKSIISLLDKHGRNHKVLDVLCSLCVCNGVAVRSNQDLITENLLPGRELLLQTNLINYVTSIRPNIFVGRAEGTTQYSKWYFEVMVDEVTPFLTAQATHLRVGWALTEGYTPYPGAGEGWGGNGVGDDLYSYGFDGLHLWTGHVARPVTSPGQHLLAPEDVISCCLDLSVPSISFRINGCPVQGVFESFNLDGLFFPVVSFSAGVKVRFLLGGRHGEFKFLPPPGYAPCHEAVLPRERLHLEPIKEYRREGPRGPHLVGPSRCLSHTDFVPCPVDTVQIVLPPHLERIREKLAENIHELWALTRIEQGWTYGPVRDDNKRLHPCLVDFHSLPEPERNYNLQMSGETLKTLLALGCHVGMADEKAEDNLKKTKLPKTYMMSNGYKPAPLDLSHVRLTPAQTTLVDRLAENGHNVWARDRVGQGWSYSAVQDIPARRNPRLVPYRLLDEATKRSNRDSLCQAVRTLLGYGYNIEPPDQEPSQVENQSRCDRVRIFRAEKSYTVQSGRWYFEFEAVTTGEMRVGWARPELRPDVELGADELAYVFNGHRGQRWHLGSEPFGRPWQPGDVVGCMIDLTENTIIFTLNGEVLMSDSGSETAFREIEIGDGFLPVCSLGPGQVGHLNLGQDVSSLRFFAICGLQEGFEPFAINMQRPVTTWFSKGLPQFEPVPLEHPHYEVSRVDGTVDTPPCLRLTHRTWGSQNSLVEMLFLRLSLPVQFHQHFRCTAGATPLAPPGLQPPAEDEARAAEPDPDYENLRRSAGGWSEAENGKEGTAKEGAPGGTPQAGGEAQPARAENEKDATTEKNKKRGFLFKAKKVAMMTQPPATPTLPRLPHDVVPADNRDDPEIILNTTTYYYSVRVFAGQEPSCVWAGWVTPDYHQHDMSFDLSKVRVVTVTMGDEQGNVHSSLKCSNCYMVWGGDFVSPGQQGRISHTDLVIGCLVDLATGLMTFTANGKESNTFFQVEPNTKLFPAVFVLPTHQNVIQFELGKQKNIMPLSAAMFQSERKNPAPQCPPRLEMQMLMPVSWSRMPNHFLQVETRRAGERLGWAVQCQEPLTMMALHIPEENRCMDILELSERLDLQRFHSHTLRLYRAVCALGNNRVAHALCSHVDQAQLLHALEDAHLPGPLRAGYYDLLISIHLESACRSRRSMLSEYIVPLTPETRAITLFPPGRSTENGHPRHGLPGVGVTTSLRPPHHFSPPCFVAALPAAGAAEAPARLSPAIPLEALRDKALRMLGEAVRDGGQHARDPVGGSVEFQFVPVLKLVSTLLVMGIFGDEDVKQILKMIEPEVFTEEEEEEDEEEEGEEEDEEEKEEDEEETAQEKEDEEKEEEEAAEGEKEEGLEEGLLQMKLPESVKLQMCHLLEYFCDQELQHRVESLAAFAERYVDKLQANQRSRYGLLIKAFSMTAAETARRTREFRSPPQEQINMLLQFKDGTDEEDCPLPEEIRQDLLDFHQDLLAHCGIQLDGEEEEPEEETTLGSRLMSLLEKVRLVKKKEEKPEEERSAEESKPRSLQELVSHMVVRWAQEDFVQSPELVRAMFSLLHRQYDGLGELLRALPRAYTISPSSVEDTMSLLECLGQIRSLLIVQMGPQEENLMIQSIGNIMNNKVFYQHPNLMRALGMHETVMEVMVNVLGGGESKEIRFPKMVTSCCRFLCYFCRISRQNQRSMFDHLSYLLENSGIGLGMQGSTPLDVAAASVIDNNELALALQEQDLEKVVSYLAGCGLQSCPMLVAKGYPDIGWNPCGGERYLDFLRFAVFVNGESVEENANVVVRLLIRKPECFGPALRGEGGSGLLAAIEEAIRISEDPARDGPGIRRDRRREHFGEEPPEENRVHLGHAIMSFYAALIDLLGRCAPEMHLIQAGKGEALRIRAILRSLVPLEDLVGIISLPLQIPTLGKDGALVQPKMSASFVPDHKASMVLFLDRVYGIENQDFLLHVLDVGFLPDMRAAASLDTATFSTTEMALALNRYLCLAVLPLITKCAPLFAGTEHRAIMVDSMLHTVYRLSRGRSLTKAQRDVIEDCLMSLCRYIRPSMLQHLLRRLVFDVPILNEFAKMPLKLLTNHYERCWKYYCLPTGWANFGVTSEEELHLTRKLFWGIFDSLAHKKYDPELYRMAMPCLCAIAGALPPDYVDASYSSKAEKKATVDAEGNFDPRPVETLNVIIPEKLDSFINKFAEYTHEKWAFDKIQNNWSYGENIDEELKTHPMLRPYKTFSEKDKEIYRWPIKESLKAMIAWEWTIEKAREGEEEKTEKKKTRKISQSAQTYDPREGYNPQPPDLSAVTLSRELQAMAEQLAENYHNTWGRKKKQELEAKGGGTHPLLVPYDTLTAKEKARDREKAQELLKFLQMNGYAVTRGLKDMELDSSSIEKRFAFGFLQQLLRWMDISQEFIAHLEAVVSSGRVEKSPHEQEIKFFAKILLPLINQYFTNHCLYFLSTPAKVLGSGGHASNKEKEMITSLFCKLAALVRHRVSLFGTDAPAVVNCLHILARSLDARTVMKSGPEIVKAGLRSFFESASEDIEKMVENLRLGKVSQARTQVKGVGQNLTYTTVALLPVLTTLFQHIAQHQFGDDVILDDVQVSCYRTLCSIYSLGTTKNTYVEKLRPALGECLARLAAAMPVAFLEPQLNEYNACSVYTTKSPRERAILGLPNSVEEMCPDIPVLERLMADIGGLAESGARYTEMPHVIEITLPMLCSYLPRWWERGPEAPPSALPAGAPPPCTAVTSDHLNSLLGNILRIIVNNLGIDEASWMKRLAVFAQPIVSRARPELLQSHFIPTIGRLRKRAGKVVSEEEQLRLEAKAEAQEGELLVRDEFSVLCRDLYALYPLLIRYVDNNRAQWLTEPNPSAEELFRMVGEIFIYWSKSHNFKREEQNFVVQNEINNMSFLTADNKSKMAKAGDIQSGGSDQERTKKKRRGDRYSVQTSLIVATLKKMLPIGLNMCAPTDQDLITLAKTRYALKDTDEEVREFLHNNLHLQGKVEGSPSLRWQMALYRGVPGREEDADDPEKIVRRVQEVSAVLYYLDQTEHPYKSKKAVWHKLLSKQRRRAVVACFRMTPLYNLPTHRACNMFLESYKAAWILTEDHSFEDRMIDDLSKAGEQEEEEEEVEEKKPDPLHQLVLHFSRTALTEKSKLDEDYLYMAYADIMAKSCHLEEGGENGEAEEEVEVSFEEKQMEKQRLLYQQARLHTRGAAEMVLQMISACKGETGAMVSSTLKLGISILNGGNAEVQQKMLDYLKDKKEVGFFQSIQALMQTCSVLDLNAFERQNKAEGLGMVNEDGTVINRQNGEKVMADDEFTQDLFRFLQLLCEGHNNDFQNYLRTQTGNTTTINIIICTVDYLLRLQESISDFYWYYSGKDVIEEQGKRNFSKAMSVAKQVFNSLTEYIQGPCTGNQQSLAHSRLWDAVVGFLHVFAHMMMKLAQDSSQIELLKELLDLQKDMVVMLLSLLEGNVVNGMIARQMVDMLVESSSNVEMILKFFDMFLKLKDIVGSEAFQDYVTDPRGLISKKDFQKAMDSQKQFSGPEIQFLLSCSEADENEMINCEEFANRFQEPARDIGFNVAVLLTNLSEHVPHDPRLHNFLELAESILEYFRPYLGRIEIMGASRRIERIYFEISETNRAQWEMPQVKESKRQFIFDVVNEGGEAEKMELFVSFCEDTIFEMQIAAQISEPEGEPETDEDEGAGAAEAGAEGAEEGAAGLEGTAATAAAGATARVVAAAGRALRGLSYRSLRRRVRRLRRLTAREAATAVAALLWAAVTRAGAAGAGAAAGALGLLWGSLFGGGLVEGAKKVTVTELLAGMPDPTSDEVHGEQPAGPGGDADGEGASEGAGDAAEGAGDEEEAVHEAGPGGADGAVAVTDGGPFRPEGAGGLGDMGDTTPAEPPTPEGSPILKRKLGVDGVEEELPPEPEPEPEPELEPEKADAENGEKEEVPEPTPEPPKKQAPPSPPPKKEEAGGEFWGELEVQRVKFLNYLSRNFYTLRFLALFLAFAINFILLFYKVSDSPPGEDDMEGSAAGDVSGAGSGGSSGWGLGAGEEAEGDEDENMVYYFLEESTGYMEPALRCLSLLHTLVAFLCIIGYNCLKVPLVIFKREKELARKLEFDGLYITEQPEDDDVKGQWDRLVLNTPSFPSNYWDKFVKRKVLDKHGDIYGRERIAELLGMDLATLEITAHNERKPNPPPGLLTWLMSIDVKYQIWKFGVIFTDNSFLYLGWYMVMSLLGHYNNFFFAAHLLDIAMGVKTLRTILSSVTHNGKQLVMTVGLLAVVVYLYTVVAFNFFRKFYNKSEDEDEPDMKCDDMMTCYLFHMYVGVRAGGGIGDEIEDPAGDEYELYRVVFDITFFFFVIVILLAIIQGLIIDAFGELRDQQEQVKEDMETKCFICGIGSDYFDTTPHGFETHTLEEHNLANYMFFLMYLINKDETEHTGQESYVWKMYQERCWDFFPAGDCFRKQYEDQLS	5038	P21817	M	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
373	NM_000527.5(LDLR):c.1784G>A (p.Arg595Gln)	183126	CA023585	NM_000527.5:c.1784G>A, NC_000019.10:g.11116937G>A, CM000681.2:g.11116937G>A, NC_000019.9:g.11227613G>A, CM000681.1:g.11227613G>A, NC_000019.8:g.11088613G>A, NG_009060.1:g.32557G>A, LRG_274:g.32557G>A, ENST00000558518.6:c.1784G>A, ENST00000252444.9:n.2038G>A, ENST00000455727.6:c.1280G>A, ENST00000535915.5:c.1661G>A, ENST00000545707.5:c.1403G>A, ENST00000557933.5:c.1784G>A, ENST00000558013.5:c.1784G>A, ENST00000558518.5:c.1784G>A, ENST00000559340.1:n.426+725G>A, NM_000527.4:c.1784G>A, LRG_274t1:c.1784G>A, NM_001195798.1:c.1784G>A, NM_001195799.1:c.1661G>A, NM_001195800.1:c.1280G>A, NM_001195803.1:c.1403G>A, XM_011528010.1:c.1784G>A, XM_011528011.1:c.1403G>A, XR_244074.2:n.1855+725G>A, XM_011528010.2:c.1784G>A, XR_001753685.2:n.1901G>A, XR_001753686.2:n.1822+725G>A, NM_001195798.2:c.1784G>A, NM_001195799.2:c.1661G>A, NM_001195800.2:c.1280G>A, NM_001195803.2:c.1403G>A, NM_000527.5(LDLR):c.1784G>A (p.Arg595Gln)	LDLR	hypercholesterolemia, familial	MONDO:0007750	Semidominant inheritance	Pathogenic	PS4, PM5, PM3, PS3_Supporting, PM2, PP3, PP4	PS1, PS2, PM4, PM1, BS1, BS3, BS4, BP7, PM6, PVS1, BS2, PP1, BA1, BP4, BP2	The NM_000527.5(LDLR):c.1784G>A (p.Arg595Gln) variant is classified as Pathogenic for Familial Hypercholesterolemia by applying evidence codes (PM2, PP3, PM5, PS3_supporting, PS4, PP4, PM3) as defined by the ClinGen Familial Hypercholesterolemia Expert Panel LDLR-specific variant curation guidelines (https://doi.org/10.1016/j.gim.2021.09.012). The supporting evidence is as follows:PM2 - PopMax MAF = 0.0002389 (0.02389%) in European (Finnish) exomes+genomes (gnomAD v2.1.1), since this is a founder effect variant in Finnish population (PMID: 11585102) we can consider PopMax MAF = 0.00005012 (0.005012%) in East Asian exomes+genomes (gnomAD v2.1.1), so PM2 is Met.PP3 - REVEL = 0.956.It is above 0.75, so PP3 is Met.PM5 - 2 other missense variants in the same codon:- NM_000527.5(LDLR):c.1783C>T (p.Arg595Trp) (ClinVar ID: 161290)    - Pathogenic by these guidelines- NM_000527.5(LDLR):c.1784G>T (p.Arg595Leu) (ClinVar ID: 252029)    - Likely pathogenic by these guidelinesThere is 1 variant in the same codon classified as Pathogenic by these guidelines, so PM5 is Met.PS3_supporting - Level 3 assay:  PMID 11585102:Heterozygous patient cells, 125I-LDL assays - result - 70% LDL-LDLR binding, 54-49% LDL-LDLR uptake and degradation.---- functional study is consistent with damaging effect, so PS3_Supporting is Met.PS4 - Variant meets PM2 and is identified in 11 unrelated index cases: 1 index case with Simon Broome definite criteria from Molecular Genetics Laboratory (Centre for Cardiovascular Surgery and Transplantation), 4 index cases with DLCN criteria for FH (LDL > 95th percentile and presence of tendon xanthomas) from Finland (PMID: 11585102), 1 index case with FH criteria suggested by the Japan Atherosclerosis Society (TC > 260 mg/dL with tendon xanthomas OR TC > 260 mg/dL and TC > 260 mg/dL with tendon xanthomas in first or second degree relatives) from Japan ( PMID: 18718593), 1 index case with DLCN criteria for FH (score=8) from Sweden (PMID: 29974534), 1 index case with DLCN criteria for FH (score>=6) from Argentina (PMID: 30270055), 2 index cases with DLCN criteria for FH (score>=6) from Russia (PMID: 33418990), 1 index case with homozygous FH phenotype (LDL = 16 mmol/L) from The Netherlands (PMID: 24585268), so PS4 is Met.PP4 - Variant meets PM2 and is identified in 11 unrelated index cases as described before, so PP4 is Met.PM3 - Variant meets PM2 and is identified in an index case with homozygous FH phenotype (LDL = 16 mmol/L) and LDLR variant c.(1705+1_1706-1)_(*2514_?)del (described as 16kb deletion exon 12-18) (PMID: 24585268), classified as Pathogenic by these guidelines, in trans, so PM3 is Met.		Familial Hypercholesterolemia VCEP	https://clinicalgenome.org/docs/clingen-familial-hypercholesterolemia-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1-2/	2022-02-02	2022-07-11	False	https://erepo.genome.network/evrepo/ui/classification/CA023585/MONDO:0007750/013	812ea6ba-58f9-4dc4-b88d-13dc9626d34f	p.Arg595Gln	Arg	595	Gln	MGPWGWKLRWTVALLLAAAGTAVGDRCERNEFQCQDGKCISYKWVCDGSAECQDGSDESQETCLSVTCKSGDFSCGGRVNRCIPQFWRCDGQVDCDNGSDEQGCPPKTCSQDEFRCHDGKCISRQFVCDSDRDCLDGSDEASCPVLTCGPASFQCNSSTCIPQLWACDNDPDCEDGSDEWPQRCRGLYVFQGDSSPCSAFEFHCLSGECIHSSWRCDGGPDCKDKSDEENCAVATCRPDEFQCSDGNCIHGSRQCDREYDCKDMSDEVGCVNVTLCEGPNKFKCHSGECITLDKVCNMARDCRDWSDEPIKECGTNECLDNNGGCSHVCNDLKIGYECLCPDGFQLVAQRRCEDIDECQDPDTCSQLCVNLEGGYKCQCEEGFQLDPHTKACKAVGSIAYLFFTNRHEVRKMTLDRSEYTSLIPNLRNVVALDTEVASNRIYWSDLSQRMICSTQLDRAHGVSSYDTVISRDIQAPDGLAVDWIHSNIYWTDSVLGTVSVADTKGVKRKTLFRENGSKPRAIVVDPVHGFMYWTDWGTPAKIKKGGLNGVDIYSLVTENIQWPNGITLDLLSGRLYWVDSKLHSISSIDVNGGNRKTILEDEKRLAHPFSLAVFEDKVFWTDIINEAIFSANRLTGSDVNLLAENLLSPEDMVLFHNLTQPRGVNWCERTTLSNGGCQYLCLPAPQINPHSPKFTCACPDGMLLARDMRSCLTEAEAAVATQETSTVRLKVSSTAVRTQHTTTRPVPDTSRLPGATPGLTTVEIVTMSHQALGDVAGRGNEKKPSSVRALSIVLPIVLLVFLCLGVFLLWKNWRLKNINSINFDNPVYQKTTEDEVHICHNQDGYSYPSRQMVSLEDDVA	860	P01130	Q	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
374	NM_000152.5(GAA):c.1979G>A (p.Arg660His)	189172	CA274455	NM_000152.5:c.1979G>A, NC_000017.11:g.80112966G>A, CM000679.2:g.80112966G>A, NC_000017.10:g.78086765G>A, CM000679.1:g.78086765G>A, NC_000017.9:g.75701360G>A, NG_009822.1:g.16411G>A, LRG_673:g.16411G>A, ENST00000302262.8:c.1979G>A, ENST00000302262.7:c.1979G>A, ENST00000390015.7:c.1979G>A, ENST00000570716.1:n.419G>A, ENST00000572080.1:n.398G>A, NM_000152.3:c.1979G>A, LRG_673t1:c.1979G>A, NM_001079803.1:c.1979G>A, NM_001079804.1:c.1979G>A, XM_005257193.1:c.1979G>A, XM_005257194.3:c.1979G>A, NM_000152.4:c.1979G>A, NM_001079803.2:c.1979G>A, NM_001079804.2:c.1979G>A, XM_005257193.2:c.1979G>A, XM_005257194.4:c.1979G>A, NM_001079803.3:c.1979G>A, NM_001079804.3:c.1979G>A, NM_000152.5(GAA):c.1979G>A (p.Arg660His)	GAA	glycogen storage disease II	MONDO:0009290	Autosomal recessive inheritance	Pathogenic	PS3_Supporting, PP4_Moderate, PP3, PM3_Very Strong, PM2_Supporting	PM5	The NM_000152.5: c.1979G>A variant in GAA is a missense variant predicted to cause substitution of arginine by histidine at amino acid 660 (p.Arg660His). More than nine individuals with features consistent with Pompe disease have been reported with this variant. Of these patients 3 probands (and two siblings) have documented laboratory values indicating GAA deficiency in the affected range in dried blood spot, or muscle, or <1% activity in cultured skin fibroblasts (PMID: 21484825, 25037089, 27649523), and three probands are reported to have low GAA activity and to be on enzyme replacement therapy (PP4_Moderate). Six patients are compound heterozygous for the variant and a variant classified as pathogenic by the ClinGen LSD VCEP. For two patients, the second variant was confirmed in trans by parental testing - c.525delT (PMID: 30559630, possibly same case in PMID: 30214072), and c.670C>T (p.Arg224Trp) (PMID: 14643388) – and in four patients the phase of the second variant is unconfirmed - c.655G>A (p.Gly219Arg) (PMID: 29122469), c.1082C>T (p.Pro361Leu) (PMID: 21484825), c.1998C>T (p.Arg600Cys) (PMID: 14643388), and c.2560C>T (p.Arg854Ter) (PMID: 30214072). Two homozygous siblings have also been reported (PMID: 27649523) (PM3_Very Strong). Two probands have been reported who are compound heterozygous for the variant and either c.-32-17_-32-10del8ins30 (PMID: 25037089; two affected siblings), or c.1114C>T (p.His372Tyr) (PMID: 30214072). The allelic data from these patients will be used in the classification of the second variant and is not included here to avoid circular logic. The highest population minor allele frequency in gnomAD v2.1.1 is 0.00025 (6/23566) in the African population, which is lower than the ClinGen LSD VCEP’s threshold for PM2_Supporting (<0.001), meeting this criterion (PM2_Supporting). In two independent studies, in which the variant was expressed in COS cells, the GAA activity was <2% wild type, indicating that the variant has a damaging effect on GAA function (PS3_Supporting). The computational predictor REVEL gives a score of 0.976 which is above the threshold of 0.7, evidence that correlates with impact to GAA function (PP3). Another variant, c.1978C>T (p.Arg660Cys), has been reported at this position. p.Arg660His will be used to support the classification of p.Arg660Cys and thus PM5 is not applied here, in order to avoid circular logic. There is a ClinVar entry for this variant (Variation ID: 189172; 2 star review status) with nine submitters classifying the variant as pathogenic, and three as likely pathogenic. In summary, this variant meets the criteria to be classified as Pathogenic for Pompe disease. GAA-specific ACMG/AMP criteria met, based on the specifications of the ClinGen LSD VCEP (Specifications Version 2.0): PM3_VeryStrong, PP4_Moderate, PP3, PS3_Supporting, PM2_Supporting.(Approved by LSD VCEP on Feb 15, 2022).		Lysosomal Diseases VCEP	https://clinicalgenome.org/docs/clingen-lysosomal-storage-disorders-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-2/	2022-03-01	2022-07-11	False	https://erepo.genome.network/evrepo/ui/classification/CA274455/MONDO:0009290/010	02045fc7-d300-46b1-a6c6-515f7ec9f666	p.Arg660His	Arg	660	His	MGVRHPPCSHRLLAVCALVSLATAALLGHILLHDFLLVPRELSGSSPVLEETHPAHQQGASRPGPRDAQAHPGRPRAVPTQCDVPPNSRFDCAPDKAITQEQCEARGCCYIPAKQGLQGAQMGQPWCFFPPSYPSYKLENLSSSEMGYTATLTRTTPTFFPKDILTLRLDVMMETENRLHFTIKDPANRRYEVPLETPHVHSRAPSPLYSVEFSEEPFGVIVRRQLDGRVLLNTTVAPLFFADQFLQLSTSLPSQYITGLAEHLSPLMLSTSWTRITLWNRDLAPTPGANLYGSHPFYLALEDGGSAHGVFLLNSNAMDVVLQPSPALSWRSTGGILDVYIFLGPEPKSVVQQYLDVVGYPFMPPYWGLGFHLCRWGYSSTAITRQVVENMTRAHFPLDVQWNDLDYMDSRRDFTFNKDGFRDFPAMVQELHQGGRRYMMIVDPAISSSGPAGSYRPYDEGLRRGVFITNETGQPLIGKVWPGSTAFPDFTNPTALAWWEDMVAEFHDQVPFDGMWIDMNEPSNFIRGSEDGCPNNELENPPYVPGVVGGTLQAATICASSHQFLSTHYNLHNLYGLTEAIASHRALVKARGTRPFVISRSTFAGHGRYAGHWTGDVWSSWEQLASSVPEILQFNLLGVPLVGADVCGFLGNTSEELCVRWTQLGAFYPFMRNHNSLLSLPQEPYSFSEPAQQAMRKALTLRYALLPHLYTLFHQAHVAGETVARPLFLEFPKDSSTWTVDHQLLWGEALLITPVLQAGKAEVTGYFPLGTWYDLQTVPVEALGSLPPPPAAPREPAIHSEGQWVTLPAPLDTINVHLRAGYIIPLQGPGLTTTESRQQPMALAVALTKGGEARGELFWDDGESLEVLERGAYTQVIFLARNNTIVNELVRVTSEGAGLQLQKVTVLGVATAPQQVLSNGVPVSNFTYSPDTKVLDICVSLLMGEQFLVSWC	952	P10253	H	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [420, 620, 661, 663, 704, 714, 716], 'DNA_BIND_gain': [], 'DNA_BIND_loss_score': array([-0.00084043, -0.00422609, -0.02190846, -0.00867784, -0.00183934,
       -0.01614749, -0.00205785]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [386, 666], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.00119072, -0.01272589]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
375	NM_000152.5(GAA):c.1978C>T (p.Arg660Cys)	558604	CA8815561	NM_000152.5:c.1978C>T, NC_000017.11:g.80112965C>T, CM000679.2:g.80112965C>T, NC_000017.10:g.78086764C>T, CM000679.1:g.78086764C>T, NC_000017.9:g.75701359C>T, NG_009822.1:g.16410C>T, LRG_673:g.16410C>T, ENST00000302262.8:c.1978C>T, ENST00000302262.7:c.1978C>T, ENST00000390015.7:c.1978C>T, ENST00000570716.1:n.418C>T, ENST00000572080.1:n.397C>T, NM_000152.3:c.1978C>T, LRG_673t1:c.1978C>T, NM_001079803.1:c.1978C>T, NM_001079804.1:c.1978C>T, XM_005257193.1:c.1978C>T, XM_005257194.3:c.1978C>T, NM_000152.4:c.1978C>T, NM_001079803.2:c.1978C>T, NM_001079804.2:c.1978C>T, XM_005257193.2:c.1978C>T, XM_005257194.4:c.1978C>T, NM_001079803.3:c.1978C>T, NM_001079804.3:c.1978C>T, NM_000152.5(GAA):c.1978C>T (p.Arg660Cys)	GAA	glycogen storage disease II	MONDO:0009290	Autosomal recessive inheritance	Pathogenic	PM3_Strong, PS3_Supporting, PP4_Moderate, PP3, PM2_Supporting, PM5		The NM_000152.5:c.1978C>T variant in GAA is a missense variant predicted to cause substitution of arginine by cysteine at amino acid 660 (p.Arg660Cys). At least 6 patients with clinical features consistent with Pompe disease have been reported with this variant; three with documented laboratory data showing deficiency of GAA in dried blood spot, or lymphocytes and muscle (PMID: 17056254, 31193175, clinical laboratory data), and two reported to have deficient GAA activity and to be on enzyme replacement therapy on enzyme replacement therapy (PMID: 25626711, 29122469, 31904026) (PP4_Moderate). Three of these patients are compound heterozygous, phase unknown, for the variant and a variant classified as pathogenic by the ClinGen LSD VCEP, either c.784G>A (p.Glu262Lys) (PMID 31193175), c.1082C>T (p.Pro361Leu) (clinical laboratory data), or c.546G>T (PMID: 29124014) and another patient is homozygous (PMID: 25626711) (PM3_Strong). An additional two patients are compound heterozygous for the variant and [c.1477C>T; c.2221G>A] ([p.Pro493Ser; p.Asp741Asn)] (PMID:  29122469, 31904026), or c.1397T>G (p.Val466Gly) (PMID: 17056254). The allelic data from the latter 2 patients will be used in the classification of the second variant and is not included here to avoid circular logic. The highest population minor allele frequency in gnomAD v2.1.1 is 0.00006 (1/18006 alleles) in the East Asian population, which is lower than the ClinGen LSD VCEP’s threshold for PM2_Supporting (<0.001), meeting this criterion (PM2_Supporting). When expressed in COS cells, the variant results in <2% normal GAA activity (PMID 19862843) (PS3_Supporting). The computational predictor REVEL gives a score of 0.966 which is above the threshold of 0.7, evidence that correlates with impact to GAA function (PP3). Another variant at this amino acid position, c.1979G>A (p.Arg660His) has been classified as pathogenic by the ClinGen LSD VCEP (PM5). There is a ClinVar entry for this variant (Variation ID: 558604; 2 star review status) with four submitters classifying the variant as pathogenic, and two as likely pathogenic. In summary, this variant meets the criteria to be classified as Pathogenic for Pompe disease. GAA-specific ACMG/AMP criteria met, based on the specifications of the ClinGen LSD VCEP (Specifications Version 2.0): PM5, PM3_Strong, PP4_Moderate, PS3_Supporting, PM2_Supporting.(Approved by LSD VCEP on Feb 15, 2022).		Lysosomal Diseases VCEP	https://clinicalgenome.org/docs/clingen-lysosomal-storage-disorders-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-2/	2022-03-01	2022-07-11	False	https://erepo.genome.network/evrepo/ui/classification/CA8815561/MONDO:0009290/010	55109263-57b6-46d4-879a-dd022f1ae61c	p.Arg660Cys	Arg	660	Cys	MGVRHPPCSHRLLAVCALVSLATAALLGHILLHDFLLVPRELSGSSPVLEETHPAHQQGASRPGPRDAQAHPGRPRAVPTQCDVPPNSRFDCAPDKAITQEQCEARGCCYIPAKQGLQGAQMGQPWCFFPPSYPSYKLENLSSSEMGYTATLTRTTPTFFPKDILTLRLDVMMETENRLHFTIKDPANRRYEVPLETPHVHSRAPSPLYSVEFSEEPFGVIVRRQLDGRVLLNTTVAPLFFADQFLQLSTSLPSQYITGLAEHLSPLMLSTSWTRITLWNRDLAPTPGANLYGSHPFYLALEDGGSAHGVFLLNSNAMDVVLQPSPALSWRSTGGILDVYIFLGPEPKSVVQQYLDVVGYPFMPPYWGLGFHLCRWGYSSTAITRQVVENMTRAHFPLDVQWNDLDYMDSRRDFTFNKDGFRDFPAMVQELHQGGRRYMMIVDPAISSSGPAGSYRPYDEGLRRGVFITNETGQPLIGKVWPGSTAFPDFTNPTALAWWEDMVAEFHDQVPFDGMWIDMNEPSNFIRGSEDGCPNNELENPPYVPGVVGGTLQAATICASSHQFLSTHYNLHNLYGLTEAIASHRALVKARGTRPFVISRSTFAGHGRYAGHWTGDVWSSWEQLASSVPEILQFNLLGVPLVGADVCGFLGNTSEELCVRWTQLGAFYPFMRNHNSLLSLPQEPYSFSEPAQQAMRKALTLRYALLPHLYTLFHQAHVAGETVARPLFLEFPKDSSTWTVDHQLLWGEALLITPVLQAGKAEVTGYFPLGTWYDLQTVPVEALGSLPPPPAAPREPAIHSEGQWVTLPAPLDTINVHLRAGYIIPLQGPGLTTTESRQQPMALAVALTKGGEARGELFWDDGESLEVLERGAYTQVIFLARNNTIVNELVRVTSEGAGLQLQKVTVLGVATAPQQVLSNGVPVSNFTYSPDTKVLDICVSLLMGEQFLVSWC	952	P10253	C	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [599], 'BINDING_gain': [], 'BINDING_loss_score': array([-0.02321637]), 'DNA_BIND_loss': [420, 424, 508, 584, 588, 614, 620, 656, 661, 663, 704, 714, 716], 'DNA_BIND_gain': [], 'DNA_BIND_loss_score': array([-0.0016802 , -0.00131661, -0.00419801, -0.01298994, -0.01385492,
       -0.00974184, -0.00912929, -0.04175293, -0.0880062 , -0.03161395,
       -0.00837004, -0.03511673, -0.00927722]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [659], 'DISULFID_gain_score': array([0.57504904]), 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [214], 'STRAND_gain': [806], 'STRAND_gain_score': array([0.00670308]), 'STRAND_loss_score': array([-0.03729719]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [386, 505, 623, 656, 662, 666, 710], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.0027988 , -0.00310081, -0.01398671, -0.04376096, -0.03891647,
       -0.04622877, -0.00814283]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
376	NM_000545.6(HNF1A):c.1A>G (p.Met1Val)	36814	CA214292	NM_000545.6:c.1A>G, NC_000012.12:g.120978769A>G, CM000674.2:g.120978769A>G, NC_000012.11:g.121416572A>G, CM000674.1:g.121416572A>G, NC_000012.10:g.119900955A>G, NG_011731.2:g.5024A>G, LRG_522:g.5024A>G, ENST00000257555.11:c.1A>G, ENST00000257555.10:c.1A>G, ENST00000400024.6:c.1A>G, ENST00000402929.5:n.136A>G, ENST00000535955.5:n.42+77A>G, ENST00000538626.2:n.119A>G, ENST00000538646.5:c.1A>G, ENST00000540108.1:c.1A>G, ENST00000541395.5:c.1A>G, ENST00000541924.5:c.1A>G, ENST00000543427.5:c.1A>G, ENST00000544413.2:c.1A>G, ENST00000544574.5:c.1A>G, ENST00000560968.5:n.144A>G, ENST00000615446.4:c.-258+58A>G, ENST00000617366.4:c.1A>G, NM_000545.5:c.1A>G, LRG_522t1:c.1A>G, NM_001306179.1:c.1A>G, XM_005253931.2:c.1A>G, XM_024449168.1:c.1A>G, NM_000545.8:c.1A>G, NM_001306179.2:c.1A>G, NM_000545.8(HNF1A):c.1A>G (p.Met1Val), NM_000545.6(HNF1A):c.1A>G (p.Met1Val)	HNF1A	monogenic diabetes	MONDO:0015967	Autosomal dominant inheritance	Pathogenic	PP4_Moderate, PVS1, PM2_Supporting		The c.1A>G variant in the HNF1 homeobox A gene, HNF1A, results in the loss of the initiation codon (p.Met1Val) of NM_000545.8. By altering the start codon of the coding sequence, this variant is predicted to cause a truncated or absent protein in a gene in which loss-of-function is an established disease mechanism (PVS1; PMID: 23348805). This variant is absent from gnomAD v2.1.1 (PM2_Supporting). This variant was identified in an individual with a clinical history highly specific for HNF1A-MODY (MODY probability calculator result >50%, negative genetic testing for HNF4A, antibody negative) (PP4_Moderate; internal lab contributor). In summary, c.1A>G meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.0, approved 9/30/2021): PVS1, PM2_Supporting, PP4_Moderate		Monogenic Diabetes VCEP		2022-03-04	2022-07-11	False	https://erepo.genome.network/evrepo/ui/classification/CA214292/MONDO:0015967/017	7c508e24-1f72-4f67-a59e-36cd9ef980bd	p.Met1Val	Met	1	Val	MVSKLSQLQTELLAALLESGLSKEALIQALGEPGPYLLAGEGPLDKGESCGGGRGELAELPNGLGETRGSEDETDDDGEDFTPPILKELENLSPEEAAHQKAVVETLLQEDPWRVAKMVKSYLQQHNIPQREVVDTTGLNQSHLSQHLNKGTPMKTQKRAALYTWYVRKQREVAQQFTHAGQGGLIEEPTGDELPTKKGRRNRFKWGPASQQILFQAYERQKNPSKEERETLVEECNRAECIQRGVSPSQAQGLGSNLVTEVRVYNWFANRRKEEAFRHKLAMDTYSGPPPGPGPGPALPAHSSPGLPPPALSPSKVHGVRYGQPATSETAEVPSSSGGPLVTVSTPLHQVSPTGLEPSHSLLSTEAKLVSAAGGPLPPVSTLTALHSLEQTSPGLNQQPQNLIMASLPGVMTIGPGEPASLGPTFTNTGASTLVIGLASTQAQSVPVINSMGSSLTTLQPVQFSQPLHPSYQQPLMPPVQSHVTQSPFMATMAQLQSPHALYSHKPEVAQYTHTGLLPQTMLITDTTNLSALASLTPTKQVFTSDTEASSESGLHTPASQATTLHVPSQDPAGIQHLQPAHRLSASPTVSSSSLVLYQSSDSSNGQSHLLPSNHSVIETFISTQMASSSQ	631	P20823	V	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [19, 20, 21], 'SIGNAL_gain': [], 'SIGNAL_loss_score': array([-0.44108343, -0.48667097, -0.47266865]), 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [97, 171], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.00990993, -0.02512574]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [77], 'COMPBIAS_gain': [], 'COMPBIAS_loss_score': array([-0.02159035]), 'DOMAIN_loss': [5, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.362679  , -0.43435454, -0.45432192, -0.42236704, -0.47351444,
       -0.4629367 , -0.47396994, -0.45184922, -0.44990563, -0.44384491,
       -0.45573413, -0.49135184, -0.49008828, -0.49193054, -0.46076798,
       -0.48081923, -0.48584056, -0.48243958, -0.45551544, -0.41749322,
       -0.4425537 , -0.45654649, -0.44055933, -0.44284791, -0.47529083,
       -0.44239402, -0.42994612, -0.4023785 , -0.37900311]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
377	NM_000545.6(HNF1A):c.1A>T (p.Met1Leu)	502525	CA386951973	NM_000545.6:c.1A>T, NC_000012.12:g.120978769A>T, CM000674.2:g.120978769A>T, NC_000012.11:g.121416572A>T, CM000674.1:g.121416572A>T, NC_000012.10:g.119900955A>T, NG_011731.2:g.5024A>T, LRG_522:g.5024A>T, ENST00000257555.11:c.1A>T, ENST00000257555.10:c.1A>T, ENST00000400024.6:c.1A>T, ENST00000402929.5:n.136A>T, ENST00000535955.5:n.42+77A>T, ENST00000538626.2:n.119A>T, ENST00000538646.5:c.1A>T, ENST00000540108.1:c.1A>T, ENST00000541395.5:c.1A>T, ENST00000541924.5:c.1A>T, ENST00000543427.5:c.1A>T, ENST00000544413.2:c.1A>T, ENST00000544574.5:c.1A>T, ENST00000560968.5:n.144A>T, ENST00000615446.4:c.-258+58A>T, ENST00000617366.4:c.1A>T, NM_000545.5:c.1A>T, LRG_522t1:c.1A>T, NM_001306179.1:c.1A>T, XM_005253931.2:c.1A>T, XM_024449168.1:c.1A>T, NM_000545.8:c.1A>T, NM_001306179.2:c.1A>T, NM_000545.8(HNF1A):c.1A>T (p.Met1Leu), NM_000545.6(HNF1A):c.1A>T (p.Met1Leu)	HNF1A	monogenic diabetes	MONDO:0015967	Autosomal dominant inheritance	Pathogenic	PVS1, PP4_Moderate, PM2_Supporting		The c.1A>T variant in the HNF1 homeobox A gene, HNF1A, results in the loss of the initiation codon (p.Met1Leu) of transcript NM_000545.8. By altering the start codon of the coding sequence, this variant is predicted to cause a truncated or absent protein in a gene in which loss-of-function is an established disease mechanism (PVS1; PMID: 23348805). This variant is absent from gnomAD v2.1.1 (PM2_Supporting). This variant was identified in an individual with a clinical history highly specific for HNF1A-MODY (MODY probability calculator result >50%, negative genetic testing for HNF4A, sulfonylurea-responsive, and antibody negative) (PP4_Moderate; internal lab contributor). In summary, c.1A>T meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.1, approved 9/30/2021): PVS1, PM2_Supporting and PP4_Moderate.		Monogenic Diabetes VCEP		2022-03-04	2022-07-11	False	https://erepo.genome.network/evrepo/ui/classification/CA386951973/MONDO:0015967/017	9119b620-1951-443c-96fd-5a29455f8200	p.Met1Leu	Met	1	Leu	MVSKLSQLQTELLAALLESGLSKEALIQALGEPGPYLLAGEGPLDKGESCGGGRGELAELPNGLGETRGSEDETDDDGEDFTPPILKELENLSPEEAAHQKAVVETLLQEDPWRVAKMVKSYLQQHNIPQREVVDTTGLNQSHLSQHLNKGTPMKTQKRAALYTWYVRKQREVAQQFTHAGQGGLIEEPTGDELPTKKGRRNRFKWGPASQQILFQAYERQKNPSKEERETLVEECNRAECIQRGVSPSQAQGLGSNLVTEVRVYNWFANRRKEEAFRHKLAMDTYSGPPPGPGPGPALPAHSSPGLPPPALSPSKVHGVRYGQPATSETAEVPSSSGGPLVTVSTPLHQVSPTGLEPSHSLLSTEAKLVSAAGGPLPPVSTLTALHSLEQTSPGLNQQPQNLIMASLPGVMTIGPGEPASLGPTFTNTGASTLVIGLASTQAQSVPVINSMGSSLTTLQPVQFSQPLHPSYQQPLMPPVQSHVTQSPFMATMAQLQSPHALYSHKPEVAQYTHTGLLPQTMLITDTTNLSALASLTPTKQVFTSDTEASSESGLHTPASQATTLHVPSQDPAGIQHLQPAHRLSASPTVSSSSLVLYQSSDSSNGQSHLLPSNHSVIETFISTQMASSSQ	631	P20823	L	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [19, 20, 21], 'SIGNAL_gain': [], 'SIGNAL_loss_score': array([-0.46070361, -0.50633317, -0.48040897]), 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [97, 171], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.0057596, -0.0240041]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [77], 'COMPBIAS_gain': [], 'COMPBIAS_loss_score': array([-0.01934415]), 'DOMAIN_loss': [5, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.44304186, -0.53957242, -0.55589318, -0.53220838, -0.59381348,
       -0.58798456, -0.60223407, -0.5678317 , -0.57887721, -0.57862723,
       -0.55956513, -0.59666556, -0.61565459, -0.61381507, -0.58981484,
       -0.61549842, -0.59918308, -0.59032726, -0.57852757, -0.53037637,
       -0.56123435, -0.55793184, -0.54960835, -0.53735429, -0.55869406,
       -0.52163249, -0.50964028, -0.4802137 , -0.44497383]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
378	NM_000261.2(MYOC):c.227G>A (p.Arg76Lys)	193066	CA200294	NM_000261.2:c.227G>A, NC_000001.11:g.171652385C>T, CM000663.2:g.171652385C>T, NC_000001.10:g.171621525C>T, CM000663.1:g.171621525C>T, NC_000001.9:g.169888148C>T, NG_008859.1:g.5249G>A, ENST00000037502.11:c.227G>A, ENST00000638471.1:c.130+97G>A, ENST00000037502.10:c.227G>A, ENST00000614688.1:c.227G>A, NM_000261.1:c.227G>A, NM_000261.2(MYOC):c.227G>A (p.Arg76Lys)	MYOC	juvenile open angle glaucoma	MONDO:0020367	Autosomal dominant inheritance	Benign	BA1, BS3_Supporting	PP3, PP1, PM4, PM5, PS4, PS3, PS1, PS2, BP4, PM2, PM6, BS1, BP7	The c.227G>A variant in MYOC is a missense variant predicted to cause substitution of Arginine by Lysine at amino acid 76 (p.Arg76Lys). The highest minor allele frequency of this variant was in the South Asian population of gnomAD (v2.1.1) = 0.3468, which met the ≥ 0.01 threshold set for BA1 (10,613 alleles out of 30,602, meeting the threshold of  ≥ 5 of at least 2,000 observed alleles). The REVEL score = 0.203, which was neither above nor below the thresholds for PP3 (≥ 0.7) or BP4 (≤ 0.15), predicting a damaging or benign impact on MYOC function. Previous studies (PMIDs: 16466712 and 35196929) demonstrated that the Arg76Lys protein had similar solubility and secretion levels to wild type myocilin protein and met the OddsPath threshold for BS3_Moderate (< 0.23), indicating that this variant did not impact protein function. As BA1 was met, PP1 did not apply and segregations were not counted. Although probands with juvenile or primary open angle glaucoma have been reported carrying this variant, PM2_Supporting was not met, therefore PS4 did not apply. In summary, this variant was classified as benign (BA1 is a stand-alone criterion for a benign level of pathogenicity) for juvenile open angle glaucoma based on the ACMG/AMP criteria met, as specified by the ClinGen Glaucoma VCEP (v1, 12 Oct 2021): BA1, BS3_Moderate.	35196929, 16466712	Glaucoma VCEP	https://clinicalgenome.org/docs/clingen-glaucoma-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2022-03-06	2022-07-11	False	https://erepo.genome.network/evrepo/ui/classification/CA200294/MONDO:0020367/019	cdc28e4e-311a-4cfa-9a12-640c62d568e2	p.Arg76Lys	Arg	76	Lys	MRFFCARCCSFGPEMPAVQLLLLACLVWDVGARTAQLRKANDQSGRCQYTFSVASPNESSCPEQSQAMSVIHNLQRDSSTQRLDLEATKARLSSLESLLHQLTLDQAARPQETQEGLQRELGTLRRERDQLETQTRELETAYSNLLRDKSVLEEEKKRLRQENENLARRLESSSQEVARLRRGQCPQTRDTARAVPPGSREVSTWNLDTLAFQELKSELTEVPASRILKESPSGYLRSGEGDTGCGELVWVGEPLTLRTAETITGKYGVWMRDPKPTYPYTQETTWRIDTVGTDVRQVFEYDLISQFMQGYPSKVHILPRPLESTGAVVYSGSLYFQGAESRTVIRYELNTETVKAEKEIPGAGYHGQFPYSWGGYTDIDLAVDEAGLWVIYSTDEAKGAIVLSKLNPENLELEQTWETNIRKQSVANAFIICGTLYTVSSYTSADATVNFAYDTGTGISKTLTIPFKNRYKYSSMIDYNPLEKKLFAWDNLNMVTYDIKLSKM	504	Q99972	K	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [46], 'TRANSIT_gain_score': array([0.00324678]), 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [192], 'COMPBIAS_gain': [], 'COMPBIAS_loss_score': array([-0.01077676]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
379	NM_000261.2(MYOC):c.1109C>T (p.Pro370Leu)	7948	CA119171	NM_000261.2:c.1109C>T, NC_000001.11:g.171636331G>A, CM000663.2:g.171636331G>A, NC_000001.10:g.171605471G>A, CM000663.1:g.171605471G>A, NC_000001.9:g.169872094G>A, NG_008859.1:g.21303C>T, ENST00000037502.11:c.1109C>T, ENST00000637303.1:c.235-2299G>A, ENST00000638471.1:c.*447C>T, ENST00000037502.10:c.1109C>T, ENST00000614688.1:c.*73C>T, NM_000261.1:c.1109C>T, NM_000261.2(MYOC):c.1109C>T (p.Pro370Leu)	MYOC	juvenile open angle glaucoma	MONDO:0020367	Autosomal dominant inheritance	Pathogenic	PP3, PM2_Supporting, PS3_Moderate, PS4, PP1_Strong	PM4, PM5, PS1, PS2, BP4, BA1, PM6, BP7, BS1, BS3	The c.1109C>T variant in MYOC is a missense variant predicted to cause substitution of Proline by Leucine at amino acid 370 (p.Pro370Leu). This variant was not found in any population of gnomAD (v2.1.1), meeting the ≤ 0.0001 threshold set for PM2_Supporting in a population of at least 10,000 alleles. The REVEL score = 0.89, which met the ≥ 0.7 threshold for PP3, predicting a damaging effect on MYOC function. A previous study (PMID: 16466712) demonstrated that the Pro370Leu protein had reduced secretion levels compared to wild type myocilin protein and met the OddsPath threshold for PS3_Moderate (> 4.3), indicating that this variant did impact protein function. 21 segregations in 2 families, with juvenile or primary open angle glaucoma (JOAG or POAG), have been reported (PMIDs: 9490287, 9772276), which fulfilled PP1_Strong (≥7 meioses in >1 family). 15 probands with JOAG or POAG have been reported carrying this variant (PMIDs: 9345106, 9328473, 11774072, 28564705, 12447164, 22194650, 9792882, 23453510, 29540704, 30484747, 9490287, 9772276), which met PS4 (≥ 15 probands). There were many more probands and families published than presented here. In summary, this variant met the criteria to receive a score of 12 and to be classified as pathogenic (pathogenic classification ≥ 10) for juvenile open angle glaucoma based on the ACMG/AMP criteria met, as specified by the ClinGen Glaucoma VCEP (v1, 12 Oct 2021): PS4, PP1_Strong, PS3_Moderate, PP3, PM2_Supporting	15069026, 11004290, 19234343	Glaucoma VCEP	https://clinicalgenome.org/docs/clingen-glaucoma-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2022-03-07	2022-07-11	False	https://erepo.genome.network/evrepo/ui/classification/CA119171/MONDO:0020367/019	924d6dc0-3570-496f-a90d-2cb4cd205f2f	p.Pro370Leu	Pro	370	Leu	MRFFCARCCSFGPEMPAVQLLLLACLVWDVGARTAQLRKANDQSGRCQYTFSVASPNESSCPEQSQAMSVIHNLQRDSSTQRLDLEATKARLSSLESLLHQLTLDQAARPQETQEGLQRELGTLRRERDQLETQTRELETAYSNLLRDKSVLEEEKKRLRQENENLARRLESSSQEVARLRRGQCPQTRDTARAVPPGSREVSTWNLDTLAFQELKSELTEVPASRILKESPSGYLRSGEGDTGCGELVWVGEPLTLRTAETITGKYGVWMRDPKPTYPYTQETTWRIDTVGTDVRQVFEYDLISQFMQGYPSKVHILPRPLESTGAVVYSGSLYFQGAESRTVIRYELNTETVKAEKEIPGAGYHGQFPYSWGGYTDIDLAVDEAGLWVIYSTDEAKGAIVLSKLNPENLELEQTWETNIRKQSVANAFIICGTLYTVSSYTSADATVNFAYDTGTGISKTLTIPFKNRYKYSSMIDYNPLEKKLFAWDNLNMVTYDIKLSKM	504	Q99972	L	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [426], 'STRAND_gain': [398, 441, 499], 'STRAND_gain_score': array([0.01370597, 0.01325202, 0.01314503]), 'STRAND_loss_score': array([-0.03230917]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [370, 374, 375, 376, 380, 469, 470, 472, 473, 475, 476], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.03897691, -0.06959796, -0.0969283 , -0.08826238, -0.06015867,
       -0.04554439, -0.05028522, -0.04163551, -0.03529292, -0.05012125,
       -0.04800868]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
380	NM_000261.2(MYOC):c.1309T>C (p.Tyr437His)	7946	CA119169	NM_000261.2:c.1309T>C, NC_000001.11:g.171636131A>G, CM000663.2:g.171636131A>G, NC_000001.10:g.171605271A>G, CM000663.1:g.171605271A>G, NC_000001.9:g.169871894A>G, NG_008859.1:g.21503T>C, ENST00000037502.11:c.1309T>C, ENST00000637303.1:c.235-2499A>G, ENST00000638471.1:c.*647T>C, ENST00000037502.10:c.1309T>C, ENST00000614688.1:c.*273T>C, NM_000261.1:c.1309T>C, NM_000261.2(MYOC):c.1309T>C (p.Tyr437His)	MYOC	juvenile open angle glaucoma	MONDO:0020367	Autosomal dominant inheritance	Pathogenic	PP3, PM2_Supporting, PS3_Moderate, PS4_Moderate, PP1_Strong	PM4, PM5, PS1, PS2, BA1, BP4, PM6, BS1, BS3, BP7	The c.1309T>C variant in MYOC is a missense variant predicted to cause substitution of Tyrosine by Histidine at amino acid 437 (p.Tyr437His). This variant was not found in any population of gnomAD (v2.1.1), meeting the ≤ 0.0001 threshold set for PM2_Supporting in a population of at least 10,000 alleles. The REVEL score = 0.966, which met the ≥ 0.7 threshold for PP3, predicting a damaging effect on MYOC function. Previous studies (PMIDs: 16466712 and 35196929) demonstrated that the Tyr437His protein had increased insolubility and reduced secretion levels compared to wild type myocilin protein and met the OddsPath threshold for PS3_Moderate (> 4.3), indicating that this variant did impact protein function. 39 segregations in 3 families, with juvenile or primary open angle glaucoma (JOAG or POAG), have been reported (PMIDs: 9535666, 30612094), which fulfilled PP1_Strong (≥ 7 meioses in > 1 family). 6 probands with JOAG or POAG have been reported carrying this variant (PMIDs: 10196380, 9792882, 30612094), which met PS4_Moderate (≥ 6 probands). In summary, this variant met the criteria to receive a score of 10 and to be classified as pathogenic (pathogenic classification ≥ 10) for juvenile open angle glaucoma based on the ACMG/AMP criteria met, as specified by the ClinGen Glaucoma VCEP (v1, 12 Oct 2021): PP1_Strong, PS3_Moderate, PS4_Moderate, PP3, PM2_Supporting.	19234343, 35196929, 15069026	Glaucoma VCEP	https://clinicalgenome.org/docs/clingen-glaucoma-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2022-03-07	2022-07-11	False	https://erepo.genome.network/evrepo/ui/classification/CA119169/MONDO:0020367/019	49b3b4bf-7c55-4a5d-b01c-2c1d71639162	p.Tyr437His	Tyr	437	His	MRFFCARCCSFGPEMPAVQLLLLACLVWDVGARTAQLRKANDQSGRCQYTFSVASPNESSCPEQSQAMSVIHNLQRDSSTQRLDLEATKARLSSLESLLHQLTLDQAARPQETQEGLQRELGTLRRERDQLETQTRELETAYSNLLRDKSVLEEEKKRLRQENENLARRLESSSQEVARLRRGQCPQTRDTARAVPPGSREVSTWNLDTLAFQELKSELTEVPASRILKESPSGYLRSGEGDTGCGELVWVGEPLTLRTAETITGKYGVWMRDPKPTYPYTQETTWRIDTVGTDVRQVFEYDLISQFMQGYPSKVHILPRPLESTGAVVYSGSLYFQGAESRTVIRYELNTETVKAEKEIPGAGYHGQFPYSWGGYTDIDLAVDEAGLWVIYSTDEAKGAIVLSKLNPENLELEQTWETNIRKQSVANAFIICGTLYTVSSYTSADATVNFAYDTGTGISKTLTIPFKNRYKYSSMIDYNPLEKKLFAWDNLNMVTYDIKLSKM	504	Q99972	H	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [46], 'TRANSIT_gain_score': array([0.00664246]), 'STRAND_loss': [254], 'STRAND_gain': [394, 398, 441], 'STRAND_gain_score': array([0.01089376, 0.01389182, 0.05428207]), 'STRAND_loss_score': array([-0.09042412]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [244, 245], 'DOMAIN_gain_score': array([0.16837537, 0.15023208]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [323, 324, 326, 327, 368, 369, 370, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 384, 385, 388, 389, 391, 393, 395, 442, 443, 444, 467, 468, 469, 470, 472, 473, 474, 475, 476], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.14560634, -0.15499026, -0.13230622, -0.13116819, -0.15112907,
       -0.15729421, -0.12301618, -0.17014378, -0.17314839, -0.18534911,
       -0.1995557 , -0.18720549, -0.19564885, -0.17573297, -0.16095275,
       -0.13999522, -0.14807355, -0.16760069, -0.16081029, -0.14739811,
       -0.14204103, -0.15110952, -0.15514284, -0.16758353, -0.20328116,
       -0.20156235, -0.2305252 , -0.21798915, -0.11213416, -0.09585887,
       -0.10926098, -0.11061376, -0.13128376, -0.11833274, -0.12615007,
       -0.15199691, -0.13190228]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
381	NM_000018.4(ACADVL):c.194C>T (p.Pro65Leu)	38798	CA285292	NM_000018.4:c.194C>T, NC_000017.11:g.7220519C>T, CM000679.2:g.7220519C>T, NC_000017.10:g.7123838C>T, CM000679.1:g.7123838C>T, NC_000017.9:g.7064562C>T, NG_007975.1:g.5686C>T, NG_008391.2:g.4532G>A, ENST00000356839.10:c.194C>T, ENST00000322910.9:c.*149C>T, ENST00000350303.9:c.139-85C>T, ENST00000356839.9:c.194C>T, ENST00000543245.6:c.263C>T, ENST00000577191.5:n.271C>T, ENST00000577433.5:n.328C>T, ENST00000577857.5:n.229-247C>T, ENST00000578269.5:n.567C>T, ENST00000578421.1:n.328C>T, ENST00000579286.5:n.301C>T, ENST00000579886.2:c.194C>T, ENST00000580263.5:n.284C>T, ENST00000581562.5:n.241C>T, ENST00000582056.5:n.284C>T, ENST00000582166.1:n.82C>T, ENST00000582356.5:n.319C>T, ENST00000583312.5:c.194C>T, ENST00000584103.5:c.194C>T, NM_000018.3:c.194C>T, NM_001033859.2:c.139-85C>T, NM_001270447.1:c.263C>T, NM_001270448.1:c.-35C>T, XM_006721516.2:c.194C>T, XM_011523829.1:c.194C>T, XM_011523830.1:c.194C>T, XR_934021.1:n.301C>T, XR_934022.1:n.301C>T, XR_934023.1:n.301C>T, XM_006721516.3:c.194C>T, XM_011523829.2:c.194C>T, XM_011523830.2:c.194C>T, XM_024450741.1:c.194C>T, XR_934021.2:n.253C>T, XR_934022.2:n.253C>T, XR_934023.2:n.253C>T, NM_001033859.3:c.139-85C>T, NM_001270447.2:c.263C>T, NM_001270448.2:c.-35C>T, NM_000018.4(ACADVL):c.194C>T (p.Pro65Leu)	ACADVL	very long chain acyl-CoA dehydrogenase deficiency	MONDO:0008723	Autosomal recessive inheritance	Benign	BS3_Supporting, BA1, BP4	BP2, PS3	The c.194C>T variant in ACADVL is a missense variant predicted to cause substitution of proline by leucine at amino acid 65 (p.Pro65Leu). The highest population minor allele frequency in gnomAD v2.1.1 is 0.1129 in the African/African American population, which is higher than the ClinGen ACADVL Variant Curation Expert Panel threshold (≥0.007) for BA1, and therefore meets this criterion (BA1). Palmitoyl-CoA dehydrogenase activity in VLCAD-null fibroblasts transfected with c.194C>T cDNA showed activity comparable to the cells transfected with wild-type cDNA indicating that this variant does not impact protein function (PMID: 10790204, BS3_supporting). The computational predictor REVEL gives a score of 0.276, which is below the threshold of 0.5, evidence that does not predict a damaging effect on ACADVL function (BP4). In summary, this variant meets the criteria to be classified as benign for autosomal recessive very long chain acyl-CoA dehydrogenase (VLCAD) deficiency based on the ACMG/AMP criteria applied, as specified by the ClinGen ACADVL Variant Curation Expert Panel: BA1, BS3_supporting, BP4 (VCEP specifications v2.0, approved on 09/16/2021).		ACADVL VCEP	https://clinicalgenome.org/site/assets/files/7380/clingen_acadvl_acmg_specifications_v1.pdf	2022-03-08	2022-03-08	False	https://erepo.genome.network/evrepo/ui/classification/CA285292/MONDO:0008723/021	fc9045f6-6b42-44b3-91a2-bb334c06b05f	p.Pro65Leu	Pro	65	Leu	MQAARMAASLGRQLLRLGGGSSRLTALLGQPRPGPARRPYAGGAAQLALDKSDSHPSDALTRKKPAKAESKSFAVGMFKGQLTTDQVFPYPSVLNEEQTQFLKELVEPVSRFFEEVNDPAKNDALEMVEETTWQGLKELGAFGLQVPSELGGVGLCNTQYARLVEIVGMHDLGVGITLGAHQSIGFKGILLFGTKAQKEKYLPKLASGETVAAFCLTEPSSGSDAASIRTSAVPSPCGKYYTLNGSKLWISNGGLADIFTVFAKTPVTDPATGAVKEKITAFVVERGFGGITHGPPEKKMGIKASNTAEVFFDGVRVPSENVLGEVGSGFKVAMHILNNGRFGMAAALAGTMRGIIAKAVDHATNRTQFGEKIHNFGLIQEKLARMVMLQYVTESMAYMVSANMDQGATDFQIEAAISKIFGSEAAWKVTDECIQIMGGMGFMKEPGVERVLRDLRIFRIFEGTNDILRLFVALQGCMDKGKELSGLGSALKNPFGNAGLLLGEAGKQLRRRAGLGSGLSLSGLVHPELSRSGELAVRALEQFATVVEAKLIKHKKGIVNEQFLLQRLADGAIDLYAMVVVLSRASRSLSEGHPTAQHEKMLCDTWCIEAAARIREGMAALQSDPWQQELYRNFKSISKALVERGGVVTSNPLGF	655	P49748	L	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [45], 'PROPEP_gain_score': array([0.02290964]), 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [523], 'HELIX_gain': [58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 71, 72, 73, 74, 75, 77, 337], 'HELIX_gain_score': array([0.58877671, 0.67265618, 0.78258163, 0.78769881, 0.79803342,
       0.83944649, 0.81060165, 0.78044337, 0.6667645 , 0.6502685 ,
       0.51418209, 0.45233941, 0.65994942, 0.74086821, 0.70691788,
       0.61791527, 0.40815789, 0.01110446]), 'HELIX_loss_score': array([-0.01980358]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65], 'COMPBIAS_gain': [], 'COMPBIAS_loss_score': array([-0.57013345, -0.60494411, -0.67996138, -0.66962922, -0.69050008,
       -0.73720735, -0.708426  , -0.67623258, -0.66047996, -0.6315484 ,
       -0.61198479, -0.57574755, -0.52032191]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [33, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65], 'REGION_gain': [290], 'REGION_gain_score': array([0.49085504]), 'REGION_loss_score': array([-0.11944306, -0.15855241, -0.18647391, -0.19909918, -0.2112118 ,
       -0.19811219, -0.23550522, -0.25251496, -0.26375133, -0.26814336,
       -0.31078827, -0.37383765, -0.39221042, -0.42937815, -0.41292369,
       -0.55400676, -0.57390887, -0.62317616, -0.66229212, -0.71229738,
       -0.68545723, -0.68553323, -0.66291451, -0.72475994, -0.77202356,
       -0.72136748, -0.69916874, -0.68734127, -0.62119502, -0.50602627,
       -0.45992446, -0.44911903]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
382	NM_000018.4(ACADVL):c.68G>A (p.Arg23Gln)	21023	CA341524	NM_000018.4:c.68G>A, NC_000017.11:g.7220127G>A, CM000679.2:g.7220127G>A, NC_000017.10:g.7123446G>A, CM000679.1:g.7123446G>A, NC_000017.9:g.7064170G>A, NG_007975.1:g.5294G>A, NG_008391.2:g.4924C>T, ENST00000356839.10:c.68G>A, ENST00000322910.9:c.*23G>A, ENST00000350303.9:c.68G>A, ENST00000356839.9:c.68G>A, ENST00000543245.6:c.137G>A, ENST00000577191.5:n.145G>A, ENST00000577857.5:n.158G>A, ENST00000578269.5:n.175G>A, ENST00000578421.1:n.202G>A, ENST00000579286.5:n.175G>A, ENST00000579886.2:c.68G>A, ENST00000580263.5:n.158G>A, ENST00000581562.5:n.115G>A, ENST00000582056.5:n.158G>A, ENST00000582356.5:n.193G>A, ENST00000583312.5:c.68G>A, ENST00000584103.5:c.68G>A, NM_000018.3:c.68G>A, NM_001033859.2:c.68G>A, NM_001270447.1:c.137G>A, NM_001270448.1:c.-161G>A, XM_006721516.2:c.68G>A, XM_011523829.1:c.68G>A, XM_011523830.1:c.68G>A, XR_934021.1:n.175G>A, XR_934022.1:n.175G>A, XR_934023.1:n.175G>A, XM_006721516.3:c.68G>A, XM_011523829.2:c.68G>A, XM_011523830.2:c.68G>A, XM_024450741.1:c.68G>A, XR_934021.2:n.127G>A, XR_934022.2:n.127G>A, XR_934023.2:n.127G>A, NM_001033859.3:c.68G>A, NM_001270447.2:c.137G>A, NM_001270448.2:c.-161G>A, NM_000018.4(ACADVL):c.68G>A (p.Arg23Gln)	ACADVL	very long chain acyl-CoA dehydrogenase deficiency	MONDO:0008723	Autosomal recessive inheritance	Benign	BA1, BP4		The c.68G>A variant in ACADVL is a missense variant predicted to cause the substitution of arginine by glutamine at amino acid 23 (p.Arg23Gln). The highest population minor allele frequency in gnomAD v2.1.1 is 0.01223 in the Latino population, which is higher than the ClinGen ACADVL Variant Curation Expert Panel threshold (≥0.007) for BA1, and therefore meets this criterion (BA1). The computational predictor REVEL gives a score of 0.123, which is below the threshold of 0.5, evidence that does not predict a damaging effect on ACADVL function (BP4). In summary, this variant meets the criteria to be classified as benign for autosomal recessive very long chain acyl-CoA dehydrogenase (VLCAD) deficiency based on the ACMG/AMP criteria applied, as specified by the ClinGen ACADVL Variant Curation Expert Panel: BA1, BP4 (VCEP specifications v2.0, approved on 09/16/2021).		ACADVL VCEP	https://clinicalgenome.org/site/assets/files/7380/clingen_acadvl_acmg_specifications_v1.pdf	2022-03-08	2022-03-08	False	https://erepo.genome.network/evrepo/ui/classification/CA341524/MONDO:0008723/021	038283e9-ea63-4bf8-82f7-d0b03faebaad	p.Arg23Gln	Arg	23	Gln	MQAARMAASLGRQLLRLGGGSSRLTALLGQPRPGPARRPYAGGAAQLALDKSDSHPSDALTRKKPAKAESKSFAVGMFKGQLTTDQVFPYPSVLNEEQTQFLKELVEPVSRFFEEVNDPAKNDALEMVEETTWQGLKELGAFGLQVPSELGGVGLCNTQYARLVEIVGMHDLGVGITLGAHQSIGFKGILLFGTKAQKEKYLPKLASGETVAAFCLTEPSSGSDAASIRTSAVPSPCGKYYTLNGSKLWISNGGLADIFTVFAKTPVTDPATGAVKEKITAFVVERGFGGITHGPPEKKMGIKASNTAEVFFDGVRVPSENVLGEVGSGFKVAMHILNNGRFGMAAALAGTMRGIIAKAVDHATNRTQFGEKIHNFGLIQEKLARMVMLQYVTESMAYMVSANMDQGATDFQIEAAISKIFGSEAAWKVTDECIQIMGGMGFMKEPGVERVLRDLRIFRIFEGTNDILRLFVALQGCMDKGKELSGLGSALKNPFGNAGLLLGEAGKQLRRRAGLGSGLSLSGLVHPELSRSGELAVRALEQFATVVEAKLIKHKKGIVNEQFLLQRLADGAIDLYAMVVVLSRASRSLSEGHPTAQHEKMLCDTWCIEAAARIREGMAALQSDPWQQELYRNFKSISKALVERGGVVTSNPLGF	655	P49748	Q	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [46, 48], 'PROPEP_gain': [], 'PROPEP_loss_score': array([-0.01135337, -0.00965858]), 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [65], 'COMPBIAS_gain': [], 'COMPBIAS_loss_score': array([-0.05368471]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [33], 'REGION_gain': [], 'REGION_loss_score': array([-0.02278179]), 'REPEAT_loss': [396, 398], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.00782013, -0.00745517]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
383	NM_000051.3(ATM):c.3118A>G (p.Met1040Val)	3027	CA151920	NM_000051.3:c.3118A>G, NC_000011.10:g.108272572A>G, CM000673.2:g.108272572A>G, NC_000011.9:g.108143299A>G, CM000673.1:g.108143299A>G, NC_000011.8:g.107648509A>G, NG_009830.1:g.54741A>G, LRG_135:g.54741A>G, ENST00000278616.9:c.3118A>G, ENST00000683174.1:n.3268A>G, ENST00000527805.6:c.3118A>G, ENST00000675595.1:c.2953A>G, ENST00000675843.1:c.3118A>G, ENST00000278616.8:c.3118A>G, ENST00000452508.6:c.3118A>G, ENST00000527805.5:c.3118A>G, LRG_135t1:c.3118A>G, XM_005271561.3:c.3118A>G, XM_005271562.3:c.3118A>G, XM_006718843.2:c.3118A>G, XM_011542840.1:c.3118A>G, XM_011542841.1:c.3118A>G, XM_011542842.1:c.2953A>G, XM_011542843.1:c.3118A>G, XM_011542844.1:c.2074A>G, XM_011542845.1:c.1810A>G, XM_011542846.1:c.3118A>G, NM_001351834.1:c.3118A>G, XM_005271562.5:c.3118A>G, XM_006718843.4:c.3118A>G, XM_011542840.3:c.3118A>G, XM_011542842.3:c.2953A>G, XM_011542843.2:c.3118A>G, XM_011542844.3:c.2074A>G, XM_011542845.2:c.1810A>G, XM_017017789.2:c.3118A>G, XM_017017790.2:c.3118A>G, XM_017017791.1:c.3118A>G, XM_017017792.2:c.3118A>G, XR_002957150.1:n.3851A>G, NM_001351834.2:c.3118A>G, NM_000051.4:c.3118A>G, NM_000051.4(ATM):c.3118A>G (p.Met1040Val), NM_000051.3(ATM):c.3118A>G (p.Met1040Val)	ATM	hereditary breast cancer	MONDO:0016419	Autosomal dominant inheritance	Benign	BP2_Strong, BA1, BP4	PM2, BS1	The ATM c.3118A>G (p.Met1040Val) variant has a GnomAD (v2.1.1) filtering allele frequency of 4.2% (AFR) which is above the ATM BA1 threshold of 0.5% (BA1). This variant has been observed in a homozygous state in multiple individuals without Ataxia-Telangiectasia (BP2_Strong, GTR Lab IDs: 500031, 61756). In silico protein predictors (BayesDel, score:-0.45, AGVGD, Class C0) predict that this alteration is not deleterious (BP4). In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the HBOP Variant Curation Expert Panel.		Hereditary Breast, Ovarian and Pancreatic Cancer VCEP		2022-03-09	2022-07-11	False	https://erepo.genome.network/evrepo/ui/classification/CA151920/MONDO:0016419/020	26ac1fa7-faca-44e7-9ae0-cb81579c10ae	p.Met1040Val	Met	1040	Val	MSLVLNDLLICCRQLEHDRATERKKEVEKFKRLIRDPETIKHLDRHSDSKQGKYLNWDAVFRFLQKYIQKETECLRIAKPNVSASTQASRQKKMQEISSLVKYFIKCANRRAPRLKCQELLNYIMDTVKDSSNGAIYGADCSNILLKDILSVRKYWCEISQQQWLELFSVYFRLYLKPSQDVHRVLVARIIHAVTKGCCSQTDGLNSKFLDFFSKAIQCARQEKSSSGLNHILAALTIFLKTLAVNFRIRVCELGDEILPTLLYIWTQHRLNDSLKEVIIELFQLQIYIHHPKGAKTQEKGAYESTKWRSILYNLYDLLVNEISHIGSRGKYSSGFRNIAVKENLIELMADICHQVFNEDTRSLEISQSYTTTQRESSDYSVPCKRKKIELGWEVIKDHLQKSQNDFDLVPWLQIATQLISKYPASLPNCELSPLLMILSQLLPQQRHGERTPYVLRCLTEVALCQDKRSNLESSQKSDLLKLWNKIWCITFRGISSEQIQAENFGLLGAIIQGSLVEVDREFWKLFTGSACRPSCPAVCCLTLALTTSIVPGTVKMGIEQNMCEVNRSFSLKESIMKWLLFYQLEGDLENSTEVPPILHSNFPHLVLEKILVSLTMKNCKAAMNFFQSVPECEHHQKDKEELSFSEVEELFLQTTFDKMDFLTIVRECGIEKHQSSIGFSVHQNLKESLDRCLLGLSEQLLNNYSSEITNSETLVRCSRLLVGVLGCYCYMGVIAEEEAYKSELFQKAKSLMQCAGESITLFKNKTNEEFRIGSLRNMMQLCTRCLSNCTKKSPNKIASGFFLRLLTSKLMNDIADICKSLASFIKKPFDRGEVESMEDDTNGNLMEVEDQSSMNLFNDYPDSSVSDANEPGESQSTIGAINPLAEEYLSKQDLLFLDMLKFLCLCVTTAQTNTVSFRAADIRRKLLMLIDSSTLEPTKSLHLHMYLMLLKELPGEEYPLPMEDVLELLKPLSNVCSLYRRDQDVCKTILNHVLHVVKNLGQSNMDSENTRDAQGQFLTVIGAFWHLTKERKYIFSVRMALVNCLKTLLEADPYSKWAILNVMGKDFPVNEVFTQFLADNHHQVRMLAAESINRLFQDTKGDSSRLLKALPLKLQQTAFENAYLKAQEGMREMSHSAENPETLDEIYNRKSVLLTLIAVVLSCSPICEKQALFALCKSVKENGLEPHLVKKVLEKVSETFGYRRLEDFMASHLDYLVLEWLNLQDTEYNLSSFPFILLNYTNIEDFYRSCYKVLIPHLVIRSHFDEVKSIANQIQEDWKSLLTDCFPKILVNILPYFAYEGTRDSGMAQQRETATKVYDMLKSENLLGKQIDHLFISNLPEIVVELLMTLHEPANSSASQSTDLCDFSGDLDPAPNPPHFPSHVIKATFAYISNCHKTKLKSILEILSKSPDSYQKILLAICEQAAETNNVYKKHRILKIYHLFVSLLLKDIKSGLGGAWAFVLRDVIYTLIHYINQRPSCIMDVSLRSFSLCCDLLSQVCQTAVTYCKDALENHLHVIVGTLIPLVYEQVEVQKQVLDLLKYLVIDNKDNENLYITIKLLDPFPDHVVFKDLRITQQKIKYSRGPFSLLEEINHFLSVSVYDALPLTRLEGLKDLRRQLELHKDQMVDIMRASQDNPQDGIMVKLVVNLLQLSKMAINHTGEKEVLEAVGSCLGEVGPIDFSTIAIQHSKDASYTKALKLFEDKELQWTFIMLTYLNNTLVEDCVKVRSAAVTCLKNILATKTGHSFWEIYKMTTDPMLAYLQPFRTSRKKFLEVPRFDKENPFEGLDDINLWIPLSENHDIWIKTLTCAFLDSGGTKCEILQLLKPMCEVKTDFCQTVLPYLIHDILLQDTNESWRNLLSTHVQGFFTSCLRHFSQTSRSTTPANLDSESEHFFRCCLDKKSQRTMLAVVDYMRRQKRPSSGTIFNDAFWLDLNYLEVAKVAQSCAAHFTALLYAEIYADKKSMDDQEKRSLAFEEGSQSTTISSLSEKSKEETGISLQDLLLEIYRSIGEPDSLYGCGGGKMLQPITRLRTYEHEAMWGKALVTYDLETAIPSSTRQAGIIQALQNLGLCHILSVYLKGLDYENKDWCPELEELHYQAAWRNMQWDHCTSVSKEVEGTSYHESLYNALQSLRDREFSTFYESLKYARVKEVEEMCKRSLESVYSLYPTLSRLQAIGELESIGELFSRSVTHRQLSEVYIKWQKHSQLLKDSDFSFQEPIMALRTVILEILMEKEMDNSQRECIKDILTKHLVELSILARTFKNTQLPERAIFQIKQYNSVSCGVSEWQLEEAQVFWAKKEQSLALSILKQMIKKLDASCAANNPSLKLTYTECLRVCGNWLAETCLENPAVIMQTYLEKAVEVAGNYDGESSDELRNGKMKAFLSLARFSDTQYQRIENYMKSSEFENKQALLKRAKEEVGLLREHKIQTNRYTVKVQRELELDELALRALKEDRKRFLCKAVENYINCLLSGEEHDMWVFRLCSLWLENSGVSEVNGMMKRDGMKIPTYKFLPLMYQLAARMGTKMMGGLGFHEVLNNLISRISMDHPHHTLFIILALANANRDEFLTKPEVARRSRITKNVPKQSSQLDEDRTEAANRIICTIRSRRPQMVRSVEALCDAYIILANLDATQWKTQRKGINIPADQPITKLKNLEDVVVPTMEIKVDHTGEYGNLVTIQSFKAEFRLAGGVNLPKIIDCVGSDGKERRQLVKGRDDLRQDAVMQQVFQMCNTLLQRNTETRKRKLTICTYKVVPLSQRSGVLEWCTGTVPIGEFLVNNEDGAHKRYRPNDFSAFQCQKKMMEVQKKSFEEKYEVFMDVCQNFQPVFRYFCMEKFLDPAIWFEKRLAYTRSVATSSIVGYILGLGDRHVQNILINEQSAELVHIDLGVAFEQGKILPTPETVPFRLTRDIVDGMGITGVEGVFRRCCEKTMEVMRNSQETLLTIVEVLLYDPLFDWTMNPLKALYLQQRPEDETELHPTLNADDQECKRNLSDIDQSFNKVAERVLMRLQEKLKGVEEGTVLSVGGQVNLLIQQAIDPKNLSRLFPGWKAWV	3056	Q13315	V	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [622, 649, 762, 938, 1606, 2281, 2320], 'HELIX_gain_score': array([0.00335401, 0.00343645, 0.00436467, 0.00460529, 0.00250882,
       0.00404364, 0.00383562]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [2088], 'REPEAT_gain_score': array([0.00130725]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
384	NM_000051.3(ATM):c.146C>G (p.Ser49Cys)	3048	CA202190	NM_000051.3:c.146C>G, NC_000011.10:g.108227849C>G, CM000673.2:g.108227849C>G, NC_000011.9:g.108098576C>G, CM000673.1:g.108098576C>G, NC_000011.8:g.107603786C>G, NG_009830.1:g.10018C>G, LRG_135:g.10018C>G, ENST00000278616.9:c.146C>G, ENST00000682147.1:n.276C>G, ENST00000682430.1:n.245C>G, ENST00000682465.1:c.146C>G, ENST00000682516.1:n.280C>G, ENST00000682956.1:n.280C>G, ENST00000683150.1:c.146C>G, ENST00000683174.1:n.296C>G, ENST00000683468.1:c.146C>G, ENST00000683488.1:n.4806C>G, ENST00000683914.1:c.146C>G, ENST00000684029.1:c.146C>G, ENST00000684037.1:c.146C>G, ENST00000684061.1:n.280C>G, ENST00000684179.1:n.280C>G, ENST00000527805.6:c.146C>G, ENST00000638443.1:c.146C>G, ENST00000639240.1:c.146C>G, ENST00000639953.1:c.146C>G, ENST00000640388.1:c.146C>G, ENST00000675595.1:c.146C>G, ENST00000675843.1:c.146C>G, ENST00000278616.8:c.146C>G, ENST00000452508.6:c.146C>G, ENST00000526567.5:c.146C>G, ENST00000527805.5:c.146C>G, ENST00000527891.5:c.146C>G, ENST00000530958.5:c.146C>G, ENST00000532931.5:c.146C>G, ENST00000601453.2:c.146C>G, LRG_135t1:c.146C>G, XM_005271561.3:c.146C>G, XM_005271562.3:c.146C>G, XM_006718843.2:c.146C>G, XM_011542840.1:c.146C>G, XM_011542841.1:c.146C>G, XM_011542842.1:c.146C>G, XM_011542843.1:c.146C>G, XM_011542846.1:c.146C>G, NM_001351834.1:c.146C>G, NM_001351835.1:c.146C>G, NM_001351836.1:c.146C>G, XM_005271562.5:c.146C>G, XM_006718843.4:c.146C>G, XM_011542840.3:c.146C>G, XM_011542842.3:c.146C>G, XM_011542843.2:c.146C>G, XM_011542844.3:c.-877C>G, XM_017017789.2:c.146C>G, XM_017017790.2:c.146C>G, XM_017017791.1:c.146C>G, XM_017017792.2:c.146C>G, XR_002957150.1:n.879C>G, NM_001351834.2:c.146C>G, NM_000051.4:c.146C>G, NM_001351835.2:c.146C>G, NM_001351836.2:c.146C>G, NM_000051.4(ATM):c.146C>G (p.Ser49Cys), NM_000051.3(ATM):c.146C>G (p.Ser49Cys)	ATM	hereditary breast cancer	MONDO:0016419	Autosomal dominant inheritance	Benign	BP2_Strong, BA1	PP3, BP4	The ATM c.146C>G (p.Ser49Cys) variant has a GnomAD (v2.1.1) filtering allele frequency of 1.208% (NFE) which is above the ATM BA1 threshold of .5% (BA1). This variant has been observed in a homozygous and/or compound heterozygous state (presumed) in multiple individuals without Ataxia-Telangiectasia (Laboratory data) (BP2_Strong). In summary, this variant meets criteria to be classified as benign based on the ACMG/AMP criteria applied as specified by the HBOP Variant Curation Expert Panel.		Hereditary Breast, Ovarian and Pancreatic Cancer VCEP		2022-03-09	2022-07-11	False	https://erepo.genome.network/evrepo/ui/classification/CA202190/MONDO:0016419/020	0ea617e8-2bed-480f-9f56-843da825a738	p.Ser49Cys	Ser	49	Cys	MSLVLNDLLICCRQLEHDRATERKKEVEKFKRLIRDPETIKHLDRHSDSKQGKYLNWDAVFRFLQKYIQKETECLRIAKPNVSASTQASRQKKMQEISSLVKYFIKCANRRAPRLKCQELLNYIMDTVKDSSNGAIYGADCSNILLKDILSVRKYWCEISQQQWLELFSVYFRLYLKPSQDVHRVLVARIIHAVTKGCCSQTDGLNSKFLDFFSKAIQCARQEKSSSGLNHILAALTIFLKTLAVNFRIRVCELGDEILPTLLYIWTQHRLNDSLKEVIIELFQLQIYIHHPKGAKTQEKGAYESTKWRSILYNLYDLLVNEISHIGSRGKYSSGFRNIAVKENLIELMADICHQVFNEDTRSLEISQSYTTTQRESSDYSVPCKRKKIELGWEVIKDHLQKSQNDFDLVPWLQIATQLISKYPASLPNCELSPLLMILSQLLPQQRHGERTPYVLRCLTEVALCQDKRSNLESSQKSDLLKLWNKIWCITFRGISSEQIQAENFGLLGAIIQGSLVEVDREFWKLFTGSACRPSCPAVCCLTLALTTSIVPGTVKMGIEQNMCEVNRSFSLKESIMKWLLFYQLEGDLENSTEVPPILHSNFPHLVLEKILVSLTMKNCKAAMNFFQSVPECEHHQKDKEELSFSEVEELFLQTTFDKMDFLTIVRECGIEKHQSSIGFSVHQNLKESLDRCLLGLSEQLLNNYSSEITNSETLVRCSRLLVGVLGCYCYMGVIAEEEAYKSELFQKAKSLMQCAGESITLFKNKTNEEFRIGSLRNMMQLCTRCLSNCTKKSPNKIASGFFLRLLTSKLMNDIADICKSLASFIKKPFDRGEVESMEDDTNGNLMEVEDQSSMNLFNDYPDSSVSDANEPGESQSTIGAINPLAEEYLSKQDLLFLDMLKFLCLCVTTAQTNTVSFRAADIRRKLLMLIDSSTLEPTKSLHLHMYLMLLKELPGEEYPLPMEDVLELLKPLSNVCSLYRRDQDVCKTILNHVLHVVKNLGQSNMDSENTRDAQGQFLTVIGAFWHLTKERKYIFSVRMALVNCLKTLLEADPYSKWAILNVMGKDFPVNEVFTQFLADNHHQVRMLAAESINRLFQDTKGDSSRLLKALPLKLQQTAFENAYLKAQEGMREMSHSAENPETLDEIYNRKSVLLTLIAVVLSCSPICEKQALFALCKSVKENGLEPHLVKKVLEKVSETFGYRRLEDFMASHLDYLVLEWLNLQDTEYNLSSFPFILLNYTNIEDFYRSCYKVLIPHLVIRSHFDEVKSIANQIQEDWKSLLTDCFPKILVNILPYFAYEGTRDSGMAQQRETATKVYDMLKSENLLGKQIDHLFISNLPEIVVELLMTLHEPANSSASQSTDLCDFSGDLDPAPNPPHFPSHVIKATFAYISNCHKTKLKSILEILSKSPDSYQKILLAICEQAAETNNVYKKHRILKIYHLFVSLLLKDIKSGLGGAWAFVLRDVIYTLIHYINQRPSCIMDVSLRSFSLCCDLLSQVCQTAVTYCKDALENHLHVIVGTLIPLVYEQVEVQKQVLDLLKYLVIDNKDNENLYITIKLLDPFPDHVVFKDLRITQQKIKYSRGPFSLLEEINHFLSVSVYDALPLTRLEGLKDLRRQLELHKDQMVDIMRASQDNPQDGIMVKLVVNLLQLSKMAINHTGEKEVLEAVGSCLGEVGPIDFSTIAIQHSKDASYTKALKLFEDKELQWTFIMLTYLNNTLVEDCVKVRSAAVTCLKNILATKTGHSFWEIYKMTTDPMLAYLQPFRTSRKKFLEVPRFDKENPFEGLDDINLWIPLSENHDIWIKTLTCAFLDSGGTKCEILQLLKPMCEVKTDFCQTVLPYLIHDILLQDTNESWRNLLSTHVQGFFTSCLRHFSQTSRSTTPANLDSESEHFFRCCLDKKSQRTMLAVVDYMRRQKRPSSGTIFNDAFWLDLNYLEVAKVAQSCAAHFTALLYAEIYADKKSMDDQEKRSLAFEEGSQSTTISSLSEKSKEETGISLQDLLLEIYRSIGEPDSLYGCGGGKMLQPITRLRTYEHEAMWGKALVTYDLETAIPSSTRQAGIIQALQNLGLCHILSVYLKGLDYENKDWCPELEELHYQAAWRNMQWDHCTSVSKEVEGTSYHESLYNALQSLRDREFSTFYESLKYARVKEVEEMCKRSLESVYSLYPTLSRLQAIGELESIGELFSRSVTHRQLSEVYIKWQKHSQLLKDSDFSFQEPIMALRTVILEILMEKEMDNSQRECIKDILTKHLVELSILARTFKNTQLPERAIFQIKQYNSVSCGVSEWQLEEAQVFWAKKEQSLALSILKQMIKKLDASCAANNPSLKLTYTECLRVCGNWLAETCLENPAVIMQTYLEKAVEVAGNYDGESSDELRNGKMKAFLSLARFSDTQYQRIENYMKSSEFENKQALLKRAKEEVGLLREHKIQTNRYTVKVQRELELDELALRALKEDRKRFLCKAVENYINCLLSGEEHDMWVFRLCSLWLENSGVSEVNGMMKRDGMKIPTYKFLPLMYQLAARMGTKMMGGLGFHEVLNNLISRISMDHPHHTLFIILALANANRDEFLTKPEVARRSRITKNVPKQSSQLDEDRTEAANRIICTIRSRRPQMVRSVEALCDAYIILANLDATQWKTQRKGINIPADQPITKLKNLEDVVVPTMEIKVDHTGEYGNLVTIQSFKAEFRLAGGVNLPKIIDCVGSDGKERRQLVKGRDDLRQDAVMQQVFQMCNTLLQRNTETRKRKLTICTYKVVPLSQRSGVLEWCTGTVPIGEFLVNNEDGAHKRYRPNDFSAFQCQKKMMEVQKKSFEEKYEVFMDVCQNFQPVFRYFCMEKFLDPAIWFEKRLAYTRSVATSSIVGYILGLGDRHVQNILINEQSAELVHIDLGVAFEQGKILPTPETVPFRLTRDIVDGMGITGVEGVFRRCCEKTMEVMRNSQETLLTIVEVLLYDPLFDWTMNPLKALYLQQRPEDETELHPTLNADDQECKRNLSDIDQSFNKVAERVLMRLQEKLKGVEEGTVLSVGGQVNLLIQQAIDPKNLSRLFPGWKAWV	3056	Q13315	C	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [238, 544, 623, 797, 1314, 1407, 1824, 1859, 2124, 2196], 'HELIX_gain': [2915], 'HELIX_gain_score': array([0.01101547]), 'HELIX_loss_score': array([-0.00832224, -0.006172  , -0.00420976, -0.00420451, -0.0028066 ,
       -0.00502813, -0.00387585, -0.00432616, -0.00283778, -0.00130939]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
385	NM_000051.3(ATM):c.6995T>C (p.Leu2332Pro)	133631	CA157165	NM_000051.3:c.6995T>C, NC_000011.10:g.108327664T>C, CM000673.2:g.108327664T>C, NC_000011.9:g.108198391T>C, CM000673.1:g.108198391T>C, NC_000011.8:g.107703601T>C, NG_009830.1:g.109833T>C, LRG_135:g.109833T>C, NG_054724.1:g.147169A>G, ENST00000278616.9:c.6995T>C, ENST00000525056.2:n.1414T>C, ENST00000682286.1:n.1752T>C, ENST00000682302.1:n.1413T>C, ENST00000683174.1:n.8479T>C, ENST00000683524.1:n.2219T>C, ENST00000684152.1:n.2709T>C, ENST00000684447.1:n.1458T>C, ENST00000527805.6:c.*2059T>C, ENST00000675595.1:c.*2130T>C, ENST00000675843.1:c.6995T>C, ENST00000278616.8:c.6995T>C, ENST00000452508.6:c.6995T>C, ENST00000524792.5:n.3210T>C, ENST00000525537.2:n.271T>C, ENST00000525729.5:c.641-18593A>G, ENST00000527389.2:n.20T>C, ENST00000533690.5:n.2399T>C, LRG_135t1:c.6995T>C, XM_005271561.3:c.6995T>C, XM_005271562.3:c.6995T>C, XM_006718843.2:c.6995T>C, XM_006718845.1:c.2951T>C, XM_011542840.1:c.6995T>C, XM_011542841.1:c.6995T>C, XM_011542842.1:c.6830T>C, XM_011542843.1:c.6995T>C, XM_011542844.1:c.5951T>C, XM_011542845.1:c.5687T>C, XM_011542847.1:c.2066T>C, NM_001330368.1:c.641-18593A>G, NM_001351110.1:c.*38+7556A>G, NM_001351834.1:c.6995T>C, XM_005271562.5:c.6995T>C, XM_006718843.4:c.6995T>C, XM_006718845.2:c.2951T>C, XM_011542840.3:c.6995T>C, XM_011542842.3:c.6830T>C, XM_011542843.2:c.6995T>C, XM_011542844.3:c.5951T>C, XM_011542845.2:c.5687T>C, XM_017017789.2:c.6995T>C, XM_017017790.2:c.6995T>C, NM_001330368.2:c.641-18593A>G, NM_001351110.2:c.*38+7556A>G, NM_001351834.2:c.6995T>C, NM_000051.4:c.6995T>C, NM_000051.4(ATM):c.6995T>C (p.Leu2332Pro), NM_000051.3(ATM):c.6995T>C (p.Leu2332Pro)	ATM	hereditary breast cancer	MONDO:0016419	Autosomal dominant inheritance	Benign	BP2_Strong, BP4, BA1	PM2, BS1, PP3, PS1	The ATM c.6995T>C (p.Leu2332Pro) variant has a gnomAD v2.1.1 filtering allele frequency of 2.062% (African/African-American; exomes) which exceeds the ATM BA1 threshold of 0.50% (BA1). This variant has been observed in a homozygous and compound heterozygous state (presumed) in multiple individuals without biallelic disease (BP2_Strong; GTR Lab IDs: 61756, 500031). In silico protein predictors (ALIGN GVGD: Class C25; REVEL: 0.193; SIFT: tolerated; PolyPhen2: benign) predict that this alteration is not deleterious and in silico splicing predictors (SpliceAI: AL 0.01/DL 0.00/AG 0.00/DG 0.00; MaxEntScan: 0.00% (wild type = 9.04, variant = 9.04)) find that this variant is unlikely to affect splicing (BP4). In summary, this variant meets criteria to be classified as benign based on the ACMG/AMP criteria applied as specified by the HBOP Variant Curation Expert Panel.		Hereditary Breast, Ovarian and Pancreatic Cancer VCEP		2022-03-09	2022-07-11	False	https://erepo.genome.network/evrepo/ui/classification/CA157165/MONDO:0016419/020	d85e41f7-7a25-4f0c-b2eb-530a536f48f4	p.Leu2332Pro	Leu	2332	Pro	MSLVLNDLLICCRQLEHDRATERKKEVEKFKRLIRDPETIKHLDRHSDSKQGKYLNWDAVFRFLQKYIQKETECLRIAKPNVSASTQASRQKKMQEISSLVKYFIKCANRRAPRLKCQELLNYIMDTVKDSSNGAIYGADCSNILLKDILSVRKYWCEISQQQWLELFSVYFRLYLKPSQDVHRVLVARIIHAVTKGCCSQTDGLNSKFLDFFSKAIQCARQEKSSSGLNHILAALTIFLKTLAVNFRIRVCELGDEILPTLLYIWTQHRLNDSLKEVIIELFQLQIYIHHPKGAKTQEKGAYESTKWRSILYNLYDLLVNEISHIGSRGKYSSGFRNIAVKENLIELMADICHQVFNEDTRSLEISQSYTTTQRESSDYSVPCKRKKIELGWEVIKDHLQKSQNDFDLVPWLQIATQLISKYPASLPNCELSPLLMILSQLLPQQRHGERTPYVLRCLTEVALCQDKRSNLESSQKSDLLKLWNKIWCITFRGISSEQIQAENFGLLGAIIQGSLVEVDREFWKLFTGSACRPSCPAVCCLTLALTTSIVPGTVKMGIEQNMCEVNRSFSLKESIMKWLLFYQLEGDLENSTEVPPILHSNFPHLVLEKILVSLTMKNCKAAMNFFQSVPECEHHQKDKEELSFSEVEELFLQTTFDKMDFLTIVRECGIEKHQSSIGFSVHQNLKESLDRCLLGLSEQLLNNYSSEITNSETLVRCSRLLVGVLGCYCYMGVIAEEEAYKSELFQKAKSLMQCAGESITLFKNKTNEEFRIGSLRNMMQLCTRCLSNCTKKSPNKIASGFFLRLLTSKLMNDIADICKSLASFIKKPFDRGEVESMEDDTNGNLMEVEDQSSMNLFNDYPDSSVSDANEPGESQSTIGAINPLAEEYLSKQDLLFLDMLKFLCLCVTTAQTNTVSFRAADIRRKLLMLIDSSTLEPTKSLHLHMYLMLLKELPGEEYPLPMEDVLELLKPLSNVCSLYRRDQDVCKTILNHVLHVVKNLGQSNMDSENTRDAQGQFLTVIGAFWHLTKERKYIFSVRMALVNCLKTLLEADPYSKWAILNVMGKDFPVNEVFTQFLADNHHQVRMLAAESINRLFQDTKGDSSRLLKALPLKLQQTAFENAYLKAQEGMREMSHSAENPETLDEIYNRKSVLLTLIAVVLSCSPICEKQALFALCKSVKENGLEPHLVKKVLEKVSETFGYRRLEDFMASHLDYLVLEWLNLQDTEYNLSSFPFILLNYTNIEDFYRSCYKVLIPHLVIRSHFDEVKSIANQIQEDWKSLLTDCFPKILVNILPYFAYEGTRDSGMAQQRETATKVYDMLKSENLLGKQIDHLFISNLPEIVVELLMTLHEPANSSASQSTDLCDFSGDLDPAPNPPHFPSHVIKATFAYISNCHKTKLKSILEILSKSPDSYQKILLAICEQAAETNNVYKKHRILKIYHLFVSLLLKDIKSGLGGAWAFVLRDVIYTLIHYINQRPSCIMDVSLRSFSLCCDLLSQVCQTAVTYCKDALENHLHVIVGTLIPLVYEQVEVQKQVLDLLKYLVIDNKDNENLYITIKLLDPFPDHVVFKDLRITQQKIKYSRGPFSLLEEINHFLSVSVYDALPLTRLEGLKDLRRQLELHKDQMVDIMRASQDNPQDGIMVKLVVNLLQLSKMAINHTGEKEVLEAVGSCLGEVGPIDFSTIAIQHSKDASYTKALKLFEDKELQWTFIMLTYLNNTLVEDCVKVRSAAVTCLKNILATKTGHSFWEIYKMTTDPMLAYLQPFRTSRKKFLEVPRFDKENPFEGLDDINLWIPLSENHDIWIKTLTCAFLDSGGTKCEILQLLKPMCEVKTDFCQTVLPYLIHDILLQDTNESWRNLLSTHVQGFFTSCLRHFSQTSRSTTPANLDSESEHFFRCCLDKKSQRTMLAVVDYMRRQKRPSSGTIFNDAFWLDLNYLEVAKVAQSCAAHFTALLYAEIYADKKSMDDQEKRSLAFEEGSQSTTISSLSEKSKEETGISLQDLLLEIYRSIGEPDSLYGCGGGKMLQPITRLRTYEHEAMWGKALVTYDLETAIPSSTRQAGIIQALQNLGLCHILSVYLKGLDYENKDWCPELEELHYQAAWRNMQWDHCTSVSKEVEGTSYHESLYNALQSLRDREFSTFYESLKYARVKEVEEMCKRSLESVYSLYPTLSRLQAIGELESIGELFSRSVTHRQLSEVYIKWQKHSQLLKDSDFSFQEPIMALRTVILEILMEKEMDNSQRECIKDILTKHLVELSILARTFKNTQLPERAIFQIKQYNSVSCGVSEWQLEEAQVFWAKKEQSLALSILKQMIKKLDASCAANNPSLKLTYTECLRVCGNWLAETCLENPAVIMQTYLEKAVEVAGNYDGESSDELRNGKMKAFLSLARFSDTQYQRIENYMKSSEFENKQALLKRAKEEVGLLREHKIQTNRYTVKVQRELELDELALRALKEDRKRFLCKAVENYINCLLSGEEHDMWVFRLCSLWLENSGVSEVNGMMKRDGMKIPTYKFLPLMYQLAARMGTKMMGGLGFHEVLNNLISRISMDHPHHTLFIILALANANRDEFLTKPEVARRSRITKNVPKQSSQLDEDRTEAANRIICTIRSRRPQMVRSVEALCDAYIILANLDATQWKTQRKGINIPADQPITKLKNLEDVVVPTMEIKVDHTGEYGNLVTIQSFKAEFRLAGGVNLPKIIDCVGSDGKERRQLVKGRDDLRQDAVMQQVFQMCNTLLQRNTETRKRKLTICTYKVVPLSQRSGVLEWCTGTVPIGEFLVNNEDGAHKRYRPNDFSAFQCQKKMMEVQKKSFEEKYEVFMDVCQNFQPVFRYFCMEKFLDPAIWFEKRLAYTRSVATSSIVGYILGLGDRHVQNILINEQSAELVHIDLGVAFEQGKILPTPETVPFRLTRDIVDGMGITGVEGVFRRCCEKTMEVMRNSQETLLTIVEVLLYDPLFDWTMNPLKALYLQQRPEDETELHPTLNADDQECKRNLSDIDQSFNKVAERVLMRLQEKLKGVEEGTVLSVGGQVNLLIQQAIDPKNLSRLFPGWKAWV	3056	Q13315	P	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [2886], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.00463283]), 'HELIX_loss': [2124, 2196, 2441, 2727], 'HELIX_gain': [615, 622, 649, 762, 1109, 2281, 2319, 2320, 2345, 2346], 'HELIX_gain_score': array([0.00423992, 0.00483173, 0.00494093, 0.00293636, 0.008856  ,
       0.00513196, 0.0284788 , 0.01269531, 0.06451726, 0.05248153]), 'HELIX_loss_score': array([-0.00105274, -0.00207889, -0.0058862 , -0.00142074]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [175, 400], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.01781601, -0.009278  ]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [2088], 'REPEAT_gain_score': array([0.00116771]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
386	NM_000051.3(ATM):c.1073A>G (p.Asn358Ser)	127329	CA286708	NM_000051.3:c.1073A>G, NC_000011.10:g.108248940A>G, CM000673.2:g.108248940A>G, NC_000011.9:g.108119667A>G, CM000673.1:g.108119667A>G, NC_000011.8:g.107624877A>G, NG_009830.1:g.31109A>G, LRG_135:g.31109A>G, ENST00000278616.9:c.1073A>G, ENST00000682516.1:n.1207A>G, ENST00000682956.1:n.1207A>G, ENST00000683174.1:n.1223A>G, ENST00000683605.1:n.568A>G, ENST00000684037.1:c.*8A>G, ENST00000684061.1:n.1207A>G, ENST00000684179.1:n.1042A>G, ENST00000527805.6:c.1073A>G, ENST00000675595.1:c.908A>G, ENST00000675843.1:c.1073A>G, ENST00000278616.8:c.1073A>G, ENST00000452508.6:c.1073A>G, ENST00000527805.5:c.1073A>G, LRG_135t1:c.1073A>G, XM_005271561.3:c.1073A>G, XM_005271562.3:c.1073A>G, XM_006718843.2:c.1073A>G, XM_011542840.1:c.1073A>G, XM_011542841.1:c.1073A>G, XM_011542842.1:c.908A>G, XM_011542843.1:c.1073A>G, XM_011542844.1:c.29A>G, XM_011542845.1:c.-73-1761A>G, XM_011542846.1:c.1073A>G, NM_001351834.1:c.1073A>G, XM_005271562.5:c.1073A>G, XM_006718843.4:c.1073A>G, XM_011542840.3:c.1073A>G, XM_011542842.3:c.908A>G, XM_011542843.2:c.1073A>G, XM_011542844.3:c.29A>G, XM_011542845.2:c.-73-1761A>G, XM_017017789.2:c.1073A>G, XM_017017790.2:c.1073A>G, XM_017017791.1:c.1073A>G, XM_017017792.2:c.1073A>G, XR_002957150.1:n.1806A>G, NM_001351834.2:c.1073A>G, NM_000051.4:c.1073A>G, NM_000051.4(ATM):c.1073A>G (p.Asn358Ser), NM_000051.3(ATM):c.1073A>G (p.Asn358Ser)	ATM	hereditary breast cancer	MONDO:0016419	Autosomal dominant inheritance	Benign	BS1, BP2_Strong, BP4	PM2, PP3, BA1, PS1	The ATM  c.1073A>G (p.Asn358Ser) variant has a gnomAD v2.1.1 filtering allele frequency of 0.1523% (African/African-American; exomes) which exceeds the ATM BS1 threshold of 0.05% (BS1). This variant has been observed in a homozygous and compound heterozygous state (presumed) in multiple individuals without biallelic disease (BP2_Strong; GTR Lab IDs: 500031, 61756). In silico protein predictors (ALIGN GVGD: Class C0; REVEL: 0.054; SIFT: tolerated; PolyPhen2: benign) predict that this alteration is not deleterious and in silico splicing predictors (SpliceAI: AL 0.13/DL 0.00/AG 0.00/DG 0.00; MaxEntScan: 0.00% (wild type = 10.82, variant = 10.82)) find that this variant is unlikely to affect splicing (BP4). In summary, this variant meets criteria to be classified as benign based on the ACMG/AMP criteria applied as specified by the HBOP Variant Curation Expert Panel.		Hereditary Breast, Ovarian and Pancreatic Cancer VCEP		2022-03-09	2022-07-11	False	https://erepo.genome.network/evrepo/ui/classification/CA286708/MONDO:0016419/020	e78376c1-7f08-4335-87ea-e4c47d2801ff	p.Asn358Ser	Asn	358	Ser	MSLVLNDLLICCRQLEHDRATERKKEVEKFKRLIRDPETIKHLDRHSDSKQGKYLNWDAVFRFLQKYIQKETECLRIAKPNVSASTQASRQKKMQEISSLVKYFIKCANRRAPRLKCQELLNYIMDTVKDSSNGAIYGADCSNILLKDILSVRKYWCEISQQQWLELFSVYFRLYLKPSQDVHRVLVARIIHAVTKGCCSQTDGLNSKFLDFFSKAIQCARQEKSSSGLNHILAALTIFLKTLAVNFRIRVCELGDEILPTLLYIWTQHRLNDSLKEVIIELFQLQIYIHHPKGAKTQEKGAYESTKWRSILYNLYDLLVNEISHIGSRGKYSSGFRNIAVKENLIELMADICHQVFNEDTRSLEISQSYTTTQRESSDYSVPCKRKKIELGWEVIKDHLQKSQNDFDLVPWLQIATQLISKYPASLPNCELSPLLMILSQLLPQQRHGERTPYVLRCLTEVALCQDKRSNLESSQKSDLLKLWNKIWCITFRGISSEQIQAENFGLLGAIIQGSLVEVDREFWKLFTGSACRPSCPAVCCLTLALTTSIVPGTVKMGIEQNMCEVNRSFSLKESIMKWLLFYQLEGDLENSTEVPPILHSNFPHLVLEKILVSLTMKNCKAAMNFFQSVPECEHHQKDKEELSFSEVEELFLQTTFDKMDFLTIVRECGIEKHQSSIGFSVHQNLKESLDRCLLGLSEQLLNNYSSEITNSETLVRCSRLLVGVLGCYCYMGVIAEEEAYKSELFQKAKSLMQCAGESITLFKNKTNEEFRIGSLRNMMQLCTRCLSNCTKKSPNKIASGFFLRLLTSKLMNDIADICKSLASFIKKPFDRGEVESMEDDTNGNLMEVEDQSSMNLFNDYPDSSVSDANEPGESQSTIGAINPLAEEYLSKQDLLFLDMLKFLCLCVTTAQTNTVSFRAADIRRKLLMLIDSSTLEPTKSLHLHMYLMLLKELPGEEYPLPMEDVLELLKPLSNVCSLYRRDQDVCKTILNHVLHVVKNLGQSNMDSENTRDAQGQFLTVIGAFWHLTKERKYIFSVRMALVNCLKTLLEADPYSKWAILNVMGKDFPVNEVFTQFLADNHHQVRMLAAESINRLFQDTKGDSSRLLKALPLKLQQTAFENAYLKAQEGMREMSHSAENPETLDEIYNRKSVLLTLIAVVLSCSPICEKQALFALCKSVKENGLEPHLVKKVLEKVSETFGYRRLEDFMASHLDYLVLEWLNLQDTEYNLSSFPFILLNYTNIEDFYRSCYKVLIPHLVIRSHFDEVKSIANQIQEDWKSLLTDCFPKILVNILPYFAYEGTRDSGMAQQRETATKVYDMLKSENLLGKQIDHLFISNLPEIVVELLMTLHEPANSSASQSTDLCDFSGDLDPAPNPPHFPSHVIKATFAYISNCHKTKLKSILEILSKSPDSYQKILLAICEQAAETNNVYKKHRILKIYHLFVSLLLKDIKSGLGGAWAFVLRDVIYTLIHYINQRPSCIMDVSLRSFSLCCDLLSQVCQTAVTYCKDALENHLHVIVGTLIPLVYEQVEVQKQVLDLLKYLVIDNKDNENLYITIKLLDPFPDHVVFKDLRITQQKIKYSRGPFSLLEEINHFLSVSVYDALPLTRLEGLKDLRRQLELHKDQMVDIMRASQDNPQDGIMVKLVVNLLQLSKMAINHTGEKEVLEAVGSCLGEVGPIDFSTIAIQHSKDASYTKALKLFEDKELQWTFIMLTYLNNTLVEDCVKVRSAAVTCLKNILATKTGHSFWEIYKMTTDPMLAYLQPFRTSRKKFLEVPRFDKENPFEGLDDINLWIPLSENHDIWIKTLTCAFLDSGGTKCEILQLLKPMCEVKTDFCQTVLPYLIHDILLQDTNESWRNLLSTHVQGFFTSCLRHFSQTSRSTTPANLDSESEHFFRCCLDKKSQRTMLAVVDYMRRQKRPSSGTIFNDAFWLDLNYLEVAKVAQSCAAHFTALLYAEIYADKKSMDDQEKRSLAFEEGSQSTTISSLSEKSKEETGISLQDLLLEIYRSIGEPDSLYGCGGGKMLQPITRLRTYEHEAMWGKALVTYDLETAIPSSTRQAGIIQALQNLGLCHILSVYLKGLDYENKDWCPELEELHYQAAWRNMQWDHCTSVSKEVEGTSYHESLYNALQSLRDREFSTFYESLKYARVKEVEEMCKRSLESVYSLYPTLSRLQAIGELESIGELFSRSVTHRQLSEVYIKWQKHSQLLKDSDFSFQEPIMALRTVILEILMEKEMDNSQRECIKDILTKHLVELSILARTFKNTQLPERAIFQIKQYNSVSCGVSEWQLEEAQVFWAKKEQSLALSILKQMIKKLDASCAANNPSLKLTYTECLRVCGNWLAETCLENPAVIMQTYLEKAVEVAGNYDGESSDELRNGKMKAFLSLARFSDTQYQRIENYMKSSEFENKQALLKRAKEEVGLLREHKIQTNRYTVKVQRELELDELALRALKEDRKRFLCKAVENYINCLLSGEEHDMWVFRLCSLWLENSGVSEVNGMMKRDGMKIPTYKFLPLMYQLAARMGTKMMGGLGFHEVLNNLISRISMDHPHHTLFIILALANANRDEFLTKPEVARRSRITKNVPKQSSQLDEDRTEAANRIICTIRSRRPQMVRSVEALCDAYIILANLDATQWKTQRKGINIPADQPITKLKNLEDVVVPTMEIKVDHTGEYGNLVTIQSFKAEFRLAGGVNLPKIIDCVGSDGKERRQLVKGRDDLRQDAVMQQVFQMCNTLLQRNTETRKRKLTICTYKVVPLSQRSGVLEWCTGTVPIGEFLVNNEDGAHKRYRPNDFSAFQCQKKMMEVQKKSFEEKYEVFMDVCQNFQPVFRYFCMEKFLDPAIWFEKRLAYTRSVATSSIVGYILGLGDRHVQNILINEQSAELVHIDLGVAFEQGKILPTPETVPFRLTRDIVDGMGITGVEGVFRRCCEKTMEVMRNSQETLLTIVEVLLYDPLFDWTMNPLKALYLQQRPEDETELHPTLNADDQECKRNLSDIDQSFNKVAERVLMRLQEKLKGVEEGTVLSVGGQVNLLIQQAIDPKNLSRLFPGWKAWV	3056	Q13315	S	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [2886], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.00688612]), 'HELIX_loss': [355, 623, 1824, 1859, 2124, 2196, 2727, 2944, 2945], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.01201338, -0.00338089, -0.00412059, -0.00292653, -0.00130862,
       -0.00105906, -0.00339371, -0.00641346, -0.00739634]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [2088], 'REPEAT_gain_score': array([0.00102425]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
387	NM_000051.3(ATM):c.7271T>G (p.Val2424Gly)	3023	CA115930	NM_000051.3:c.7271T>G, NC_000011.10:g.108329202T>G, CM000673.2:g.108329202T>G, NC_000011.9:g.108199929T>G, CM000673.1:g.108199929T>G, NC_000011.8:g.107705139T>G, NG_009830.1:g.111371T>G, LRG_135:g.111371T>G, NG_054724.1:g.145631A>C, ENST00000278616.9:c.7271T>G, ENST00000525056.2:n.1690T>G, ENST00000525537.3:n.228T>G, ENST00000638786.2:n.108T>G, ENST00000682286.1:n.2028T>G, ENST00000682302.1:n.1689T>G, ENST00000683174.1:n.8755T>G, ENST00000683524.1:n.2495T>G, ENST00000684152.1:n.2985T>G, ENST00000684447.1:n.1734T>G, ENST00000527805.6:c.*2335T>G, ENST00000675595.1:c.*2406T>G, ENST00000675843.1:c.7271T>G, ENST00000278616.8:c.7271T>G, ENST00000452508.6:c.7271T>G, ENST00000524792.5:n.3486T>G, ENST00000525537.2:n.547T>G, ENST00000525729.5:c.641-20131A>C, ENST00000527389.2:n.296T>G, ENST00000533690.5:n.2675T>G, LRG_135t1:c.7271T>G, XM_005271561.3:c.7271T>G, XM_005271562.3:c.7271T>G, XM_006718843.2:c.7271T>G, XM_006718845.1:c.3227T>G, XM_011542840.1:c.7271T>G, XM_011542841.1:c.7271T>G, XM_011542842.1:c.7106T>G, XM_011542843.1:c.7271T>G, XM_011542844.1:c.6227T>G, XM_011542845.1:c.5963T>G, XM_011542847.1:c.2342T>G, NM_001330368.1:c.641-20131A>C, NM_001351110.1:c.*38+6018A>C, NM_001351834.1:c.7271T>G, XM_005271562.5:c.7271T>G, XM_006718843.4:c.7271T>G, XM_006718845.2:c.3227T>G, XM_011542840.3:c.7271T>G, XM_011542842.3:c.7106T>G, XM_011542843.2:c.7271T>G, XM_011542844.3:c.6227T>G, XM_011542845.2:c.5963T>G, XM_017017789.2:c.7271T>G, XM_017017790.2:c.7271T>G, NM_001330368.2:c.641-20131A>C, NM_001351110.2:c.*38+6018A>C, NM_001351834.2:c.7271T>G, NM_000051.4:c.7271T>G, NM_000051.4(ATM):c.7271T>G (p.Val2424Gly), NM_000051.3(ATM):c.7271T>G (p.Val2424Gly)	ATM	hereditary breast cancer	MONDO:0016419	Autosomal dominant inheritance	Pathogenic	PS3_Moderate, PM3_Very Strong, PP3, PP1, PS4	PM2, PP4	The ATM c.7271T>G (p.Val2424Gly) variant has a GnomAD (v2.1.1) allele frequency of 0.004124% (NFE) which is above the PM2 threshold of .001% but below the BS1 threshold of .05%. This variant is predicted deleterious by multiple protein in silico tools (PP3). This variant is non-functional in multiple different protein assays (PMIDs:19431188,18634022) (PS3_Moderate). The prevalence of the variant in affected individuals is significantly increased compared to the prevalence in controls in a case control study with lower CI ≥1.5 (PMIDs: 16958054, 21787400) (PS4). This variant has been observed in a homozygous and/or compound heterozygous state (presumed and/or confirmed) in multiple individuals with ataxia-telangiectasia (GeneDx, PMIDs: 9463314, 18575927, 27528516) (>8 points - PM3_Very strong). This variant co-segregated with ataxia-telangiectasia in multiple affected family members (PMID: 18575927) (PP1). In summary, this variant meets criteria to be classified as pathogenic based on the ACMG/AMP criteria applied as specified by the HBOP Variant Curation Expert Panel.		Hereditary Breast, Ovarian and Pancreatic Cancer VCEP		2022-03-09	2022-07-11	False	https://erepo.genome.network/evrepo/ui/classification/CA115930/MONDO:0016419/020	36ae7580-8da9-4ce9-9040-32e7eee1bb34	p.Val2424Gly	Val	2424	Gly	MSLVLNDLLICCRQLEHDRATERKKEVEKFKRLIRDPETIKHLDRHSDSKQGKYLNWDAVFRFLQKYIQKETECLRIAKPNVSASTQASRQKKMQEISSLVKYFIKCANRRAPRLKCQELLNYIMDTVKDSSNGAIYGADCSNILLKDILSVRKYWCEISQQQWLELFSVYFRLYLKPSQDVHRVLVARIIHAVTKGCCSQTDGLNSKFLDFFSKAIQCARQEKSSSGLNHILAALTIFLKTLAVNFRIRVCELGDEILPTLLYIWTQHRLNDSLKEVIIELFQLQIYIHHPKGAKTQEKGAYESTKWRSILYNLYDLLVNEISHIGSRGKYSSGFRNIAVKENLIELMADICHQVFNEDTRSLEISQSYTTTQRESSDYSVPCKRKKIELGWEVIKDHLQKSQNDFDLVPWLQIATQLISKYPASLPNCELSPLLMILSQLLPQQRHGERTPYVLRCLTEVALCQDKRSNLESSQKSDLLKLWNKIWCITFRGISSEQIQAENFGLLGAIIQGSLVEVDREFWKLFTGSACRPSCPAVCCLTLALTTSIVPGTVKMGIEQNMCEVNRSFSLKESIMKWLLFYQLEGDLENSTEVPPILHSNFPHLVLEKILVSLTMKNCKAAMNFFQSVPECEHHQKDKEELSFSEVEELFLQTTFDKMDFLTIVRECGIEKHQSSIGFSVHQNLKESLDRCLLGLSEQLLNNYSSEITNSETLVRCSRLLVGVLGCYCYMGVIAEEEAYKSELFQKAKSLMQCAGESITLFKNKTNEEFRIGSLRNMMQLCTRCLSNCTKKSPNKIASGFFLRLLTSKLMNDIADICKSLASFIKKPFDRGEVESMEDDTNGNLMEVEDQSSMNLFNDYPDSSVSDANEPGESQSTIGAINPLAEEYLSKQDLLFLDMLKFLCLCVTTAQTNTVSFRAADIRRKLLMLIDSSTLEPTKSLHLHMYLMLLKELPGEEYPLPMEDVLELLKPLSNVCSLYRRDQDVCKTILNHVLHVVKNLGQSNMDSENTRDAQGQFLTVIGAFWHLTKERKYIFSVRMALVNCLKTLLEADPYSKWAILNVMGKDFPVNEVFTQFLADNHHQVRMLAAESINRLFQDTKGDSSRLLKALPLKLQQTAFENAYLKAQEGMREMSHSAENPETLDEIYNRKSVLLTLIAVVLSCSPICEKQALFALCKSVKENGLEPHLVKKVLEKVSETFGYRRLEDFMASHLDYLVLEWLNLQDTEYNLSSFPFILLNYTNIEDFYRSCYKVLIPHLVIRSHFDEVKSIANQIQEDWKSLLTDCFPKILVNILPYFAYEGTRDSGMAQQRETATKVYDMLKSENLLGKQIDHLFISNLPEIVVELLMTLHEPANSSASQSTDLCDFSGDLDPAPNPPHFPSHVIKATFAYISNCHKTKLKSILEILSKSPDSYQKILLAICEQAAETNNVYKKHRILKIYHLFVSLLLKDIKSGLGGAWAFVLRDVIYTLIHYINQRPSCIMDVSLRSFSLCCDLLSQVCQTAVTYCKDALENHLHVIVGTLIPLVYEQVEVQKQVLDLLKYLVIDNKDNENLYITIKLLDPFPDHVVFKDLRITQQKIKYSRGPFSLLEEINHFLSVSVYDALPLTRLEGLKDLRRQLELHKDQMVDIMRASQDNPQDGIMVKLVVNLLQLSKMAINHTGEKEVLEAVGSCLGEVGPIDFSTIAIQHSKDASYTKALKLFEDKELQWTFIMLTYLNNTLVEDCVKVRSAAVTCLKNILATKTGHSFWEIYKMTTDPMLAYLQPFRTSRKKFLEVPRFDKENPFEGLDDINLWIPLSENHDIWIKTLTCAFLDSGGTKCEILQLLKPMCEVKTDFCQTVLPYLIHDILLQDTNESWRNLLSTHVQGFFTSCLRHFSQTSRSTTPANLDSESEHFFRCCLDKKSQRTMLAVVDYMRRQKRPSSGTIFNDAFWLDLNYLEVAKVAQSCAAHFTALLYAEIYADKKSMDDQEKRSLAFEEGSQSTTISSLSEKSKEETGISLQDLLLEIYRSIGEPDSLYGCGGGKMLQPITRLRTYEHEAMWGKALVTYDLETAIPSSTRQAGIIQALQNLGLCHILSVYLKGLDYENKDWCPELEELHYQAAWRNMQWDHCTSVSKEVEGTSYHESLYNALQSLRDREFSTFYESLKYARVKEVEEMCKRSLESVYSLYPTLSRLQAIGELESIGELFSRSVTHRQLSEVYIKWQKHSQLLKDSDFSFQEPIMALRTVILEILMEKEMDNSQRECIKDILTKHLVELSILARTFKNTQLPERAIFQIKQYNSVSCGVSEWQLEEAQVFWAKKEQSLALSILKQMIKKLDASCAANNPSLKLTYTECLRVCGNWLAETCLENPAVIMQTYLEKAVEVAGNYDGESSDELRNGKMKAFLSLARFSDTQYQRIENYMKSSEFENKQALLKRAKEEVGLLREHKIQTNRYTVKVQRELELDELALRALKEDRKRFLCKAVENYINCLLSGEEHDMWVFRLCSLWLENSGVSEVNGMMKRDGMKIPTYKFLPLMYQLAARMGTKMMGGLGFHEVLNNLISRISMDHPHHTLFIILALANANRDEFLTKPEVARRSRITKNVPKQSSQLDEDRTEAANRIICTIRSRRPQMVRSVEALCDAYIILANLDATQWKTQRKGINIPADQPITKLKNLEDVVVPTMEIKVDHTGEYGNLVTIQSFKAEFRLAGGVNLPKIIDCVGSDGKERRQLVKGRDDLRQDAVMQQVFQMCNTLLQRNTETRKRKLTICTYKVVPLSQRSGVLEWCTGTVPIGEFLVNNEDGAHKRYRPNDFSAFQCQKKMMEVQKKSFEEKYEVFMDVCQNFQPVFRYFCMEKFLDPAIWFEKRLAYTRSVATSSIVGYILGLGDRHVQNILINEQSAELVHIDLGVAFEQGKILPTPETVPFRLTRDIVDGMGITGVEGVFRRCCEKTMEVMRNSQETLLTIVEVLLYDPLFDWTMNPLKALYLQQRPEDETELHPTLNADDQECKRNLSDIDQSFNKVAERVLMRLQEKLKGVEEGTVLSVGGQVNLLIQQAIDPKNLSRLFPGWKAWV	3056	Q13315	G	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [2420, 2421, 2422, 2423, 2424, 2425, 2455], 'HELIX_gain': [762, 938, 1274, 2281, 2320, 2377, 2626, 2915], 'HELIX_gain_score': array([0.00117522, 0.00397974, 0.00520885, 0.00397676, 0.00237781,
       0.01150435, 0.00383872, 0.0063557 ]), 'HELIX_loss_score': array([-0.12827694, -0.17703098, -0.2373355 , -0.20511818, -0.23041582,
       -0.16582823, -0.0083468 ]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [2088], 'REPEAT_gain_score': array([0.0021013]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
388	NM_000051.3(ATM):c.2T>C (p.Met1Thr)	187275	CA197209	NM_000051.3:c.2T>C, NC_000011.10:g.108227626T>C, CM000673.2:g.108227626T>C, NC_000011.9:g.108098353T>C, CM000673.1:g.108098353T>C, NC_000011.8:g.107603563T>C, NG_009830.1:g.9795T>C, LRG_135:g.9795T>C, ENST00000278616.9:c.2T>C, ENST00000682147.1:n.136T>C, ENST00000682430.1:n.101T>C, ENST00000682465.1:c.2T>C, ENST00000682516.1:n.136T>C, ENST00000682956.1:n.136T>C, ENST00000683150.1:c.2T>C, ENST00000683174.1:n.152T>C, ENST00000683468.1:c.2T>C, ENST00000683488.1:n.4583T>C, ENST00000683914.1:c.2T>C, ENST00000684029.1:c.2T>C, ENST00000684037.1:c.2T>C, ENST00000684061.1:n.136T>C, ENST00000684179.1:n.136T>C, ENST00000527805.6:c.2T>C, ENST00000638443.1:c.2T>C, ENST00000639240.1:c.2T>C, ENST00000639953.1:c.2T>C, ENST00000640388.1:c.2T>C, ENST00000675595.1:c.2T>C, ENST00000675843.1:c.2T>C, ENST00000278616.8:c.2T>C, ENST00000452508.6:c.2T>C, ENST00000526567.5:c.2T>C, ENST00000527805.5:c.2T>C, ENST00000527891.5:c.2T>C, ENST00000530958.5:c.2T>C, ENST00000532931.5:c.2T>C, ENST00000601453.2:c.2T>C, LRG_135t1:c.2T>C, XM_005271561.3:c.2T>C, XM_005271562.3:c.2T>C, XM_006718843.2:c.2T>C, XM_011542840.1:c.2T>C, XM_011542841.1:c.2T>C, XM_011542842.1:c.2T>C, XM_011542843.1:c.2T>C, XM_011542846.1:c.2T>C, NM_001351834.1:c.2T>C, NM_001351835.1:c.2T>C, NM_001351836.1:c.2T>C, XM_005271562.5:c.2T>C, XM_006718843.4:c.2T>C, XM_011542840.3:c.2T>C, XM_011542842.3:c.2T>C, XM_011542843.2:c.2T>C, XM_011542844.3:c.-1021T>C, XM_017017789.2:c.2T>C, XM_017017790.2:c.2T>C, XM_017017791.1:c.2T>C, XM_017017792.2:c.2T>C, XR_002957150.1:n.735T>C, NM_001351834.2:c.2T>C, NM_000051.4:c.2T>C, NM_001351835.2:c.2T>C, NM_001351836.2:c.2T>C, NM_000051.4(ATM):c.2T>C (p.Met1Thr), NM_000051.3(ATM):c.2T>C (p.Met1Thr)	ATM	hereditary breast cancer	MONDO:0016419	Autosomal dominant inheritance	Pathogenic	PVS1, PM2_Supporting, PM3_Very Strong		The ATM c.2T>C (p.M1?) variant impacts the initiation codon and is not expected to produce a fully functional protein (PVS1). This variant has been observed in a compound heterozygous state in multiple individuals with Ataxia-Telangiectasia (PMIDs: 22146522, 3054930, 12552559, PM3_VeryStrong).  This alteration has an allele frequency below 0.001% in the European (non-Finnish) subpopulation in GnomAD (PM2_Supporting). In summary, this variant meets criteria to be classified as pathogenic. ACMG/AMP criteria applied, as specified by the HBOP Variant Curation Expert Panel.		Hereditary Breast, Ovarian and Pancreatic Cancer VCEP		2022-03-16	2022-07-12	False	https://erepo.genome.network/evrepo/ui/classification/CA197209/MONDO:0016419/020	af70c135-df1b-4c1e-becb-96e5c6882dd5	p.Met1Thr	Met	1	Thr	MSLVLNDLLICCRQLEHDRATERKKEVEKFKRLIRDPETIKHLDRHSDSKQGKYLNWDAVFRFLQKYIQKETECLRIAKPNVSASTQASRQKKMQEISSLVKYFIKCANRRAPRLKCQELLNYIMDTVKDSSNGAIYGADCSNILLKDILSVRKYWCEISQQQWLELFSVYFRLYLKPSQDVHRVLVARIIHAVTKGCCSQTDGLNSKFLDFFSKAIQCARQEKSSSGLNHILAALTIFLKTLAVNFRIRVCELGDEILPTLLYIWTQHRLNDSLKEVIIELFQLQIYIHHPKGAKTQEKGAYESTKWRSILYNLYDLLVNEISHIGSRGKYSSGFRNIAVKENLIELMADICHQVFNEDTRSLEISQSYTTTQRESSDYSVPCKRKKIELGWEVIKDHLQKSQNDFDLVPWLQIATQLISKYPASLPNCELSPLLMILSQLLPQQRHGERTPYVLRCLTEVALCQDKRSNLESSQKSDLLKLWNKIWCITFRGISSEQIQAENFGLLGAIIQGSLVEVDREFWKLFTGSACRPSCPAVCCLTLALTTSIVPGTVKMGIEQNMCEVNRSFSLKESIMKWLLFYQLEGDLENSTEVPPILHSNFPHLVLEKILVSLTMKNCKAAMNFFQSVPECEHHQKDKEELSFSEVEELFLQTTFDKMDFLTIVRECGIEKHQSSIGFSVHQNLKESLDRCLLGLSEQLLNNYSSEITNSETLVRCSRLLVGVLGCYCYMGVIAEEEAYKSELFQKAKSLMQCAGESITLFKNKTNEEFRIGSLRNMMQLCTRCLSNCTKKSPNKIASGFFLRLLTSKLMNDIADICKSLASFIKKPFDRGEVESMEDDTNGNLMEVEDQSSMNLFNDYPDSSVSDANEPGESQSTIGAINPLAEEYLSKQDLLFLDMLKFLCLCVTTAQTNTVSFRAADIRRKLLMLIDSSTLEPTKSLHLHMYLMLLKELPGEEYPLPMEDVLELLKPLSNVCSLYRRDQDVCKTILNHVLHVVKNLGQSNMDSENTRDAQGQFLTVIGAFWHLTKERKYIFSVRMALVNCLKTLLEADPYSKWAILNVMGKDFPVNEVFTQFLADNHHQVRMLAAESINRLFQDTKGDSSRLLKALPLKLQQTAFENAYLKAQEGMREMSHSAENPETLDEIYNRKSVLLTLIAVVLSCSPICEKQALFALCKSVKENGLEPHLVKKVLEKVSETFGYRRLEDFMASHLDYLVLEWLNLQDTEYNLSSFPFILLNYTNIEDFYRSCYKVLIPHLVIRSHFDEVKSIANQIQEDWKSLLTDCFPKILVNILPYFAYEGTRDSGMAQQRETATKVYDMLKSENLLGKQIDHLFISNLPEIVVELLMTLHEPANSSASQSTDLCDFSGDLDPAPNPPHFPSHVIKATFAYISNCHKTKLKSILEILSKSPDSYQKILLAICEQAAETNNVYKKHRILKIYHLFVSLLLKDIKSGLGGAWAFVLRDVIYTLIHYINQRPSCIMDVSLRSFSLCCDLLSQVCQTAVTYCKDALENHLHVIVGTLIPLVYEQVEVQKQVLDLLKYLVIDNKDNENLYITIKLLDPFPDHVVFKDLRITQQKIKYSRGPFSLLEEINHFLSVSVYDALPLTRLEGLKDLRRQLELHKDQMVDIMRASQDNPQDGIMVKLVVNLLQLSKMAINHTGEKEVLEAVGSCLGEVGPIDFSTIAIQHSKDASYTKALKLFEDKELQWTFIMLTYLNNTLVEDCVKVRSAAVTCLKNILATKTGHSFWEIYKMTTDPMLAYLQPFRTSRKKFLEVPRFDKENPFEGLDDINLWIPLSENHDIWIKTLTCAFLDSGGTKCEILQLLKPMCEVKTDFCQTVLPYLIHDILLQDTNESWRNLLSTHVQGFFTSCLRHFSQTSRSTTPANLDSESEHFFRCCLDKKSQRTMLAVVDYMRRQKRPSSGTIFNDAFWLDLNYLEVAKVAQSCAAHFTALLYAEIYADKKSMDDQEKRSLAFEEGSQSTTISSLSEKSKEETGISLQDLLLEIYRSIGEPDSLYGCGGGKMLQPITRLRTYEHEAMWGKALVTYDLETAIPSSTRQAGIIQALQNLGLCHILSVYLKGLDYENKDWCPELEELHYQAAWRNMQWDHCTSVSKEVEGTSYHESLYNALQSLRDREFSTFYESLKYARVKEVEEMCKRSLESVYSLYPTLSRLQAIGELESIGELFSRSVTHRQLSEVYIKWQKHSQLLKDSDFSFQEPIMALRTVILEILMEKEMDNSQRECIKDILTKHLVELSILARTFKNTQLPERAIFQIKQYNSVSCGVSEWQLEEAQVFWAKKEQSLALSILKQMIKKLDASCAANNPSLKLTYTECLRVCGNWLAETCLENPAVIMQTYLEKAVEVAGNYDGESSDELRNGKMKAFLSLARFSDTQYQRIENYMKSSEFENKQALLKRAKEEVGLLREHKIQTNRYTVKVQRELELDELALRALKEDRKRFLCKAVENYINCLLSGEEHDMWVFRLCSLWLENSGVSEVNGMMKRDGMKIPTYKFLPLMYQLAARMGTKMMGGLGFHEVLNNLISRISMDHPHHTLFIILALANANRDEFLTKPEVARRSRITKNVPKQSSQLDEDRTEAANRIICTIRSRRPQMVRSVEALCDAYIILANLDATQWKTQRKGINIPADQPITKLKNLEDVVVPTMEIKVDHTGEYGNLVTIQSFKAEFRLAGGVNLPKIIDCVGSDGKERRQLVKGRDDLRQDAVMQQVFQMCNTLLQRNTETRKRKLTICTYKVVPLSQRSGVLEWCTGTVPIGEFLVNNEDGAHKRYRPNDFSAFQCQKKMMEVQKKSFEEKYEVFMDVCQNFQPVFRYFCMEKFLDPAIWFEKRLAYTRSVATSSIVGYILGLGDRHVQNILINEQSAELVHIDLGVAFEQGKILPTPETVPFRLTRDIVDGMGITGVEGVFRRCCEKTMEVMRNSQETLLTIVEVLLYDPLFDWTMNPLKALYLQQRPEDETELHPTLNADDQECKRNLSDIDQSFNKVAERVLMRLQEKLKGVEEGTVLSVGGQVNLLIQQAIDPKNLSRLFPGWKAWV	3056	Q13315	T	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [8, 1314, 1407, 2196], 'HELIX_gain': [1606, 2320, 2915], 'HELIX_gain_score': array([0.00274479, 0.00142658, 0.00763112]), 'HELIX_loss_score': array([-0.0325222 , -0.00455081, -0.00303775, -0.00027907]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [2088], 'REPEAT_gain_score': array([0.00096452]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
389	NM_000051.4(ATM):c.3925G>A (p.Ala1309Thr)	127377	CA242620	NM_000051.4:c.3925G>A, NC_000011.10:g.108284405G>A, CM000673.2:g.108284405G>A, NC_000011.9:g.108155132G>A, CM000673.1:g.108155132G>A, NC_000011.8:g.107660342G>A, NG_009830.1:g.66574G>A, LRG_135:g.66574G>A, ENST00000278616.9:c.3925G>A, ENST00000682289.1:n.272G>A, ENST00000683174.1:n.4075G>A, ENST00000527805.6:c.3925G>A, ENST00000675595.1:c.3760G>A, ENST00000675843.1:c.3925G>A, ENST00000278616.8:c.3925G>A, ENST00000452508.6:c.3925G>A, ENST00000527805.5:c.3925G>A, NM_000051.3:c.3925G>A, LRG_135t1:c.3925G>A, XM_005271561.3:c.3925G>A, XM_005271562.3:c.3925G>A, XM_006718843.2:c.3925G>A, XM_011542840.1:c.3925G>A, XM_011542841.1:c.3925G>A, XM_011542842.1:c.3760G>A, XM_011542843.1:c.3925G>A, XM_011542844.1:c.2881G>A, XM_011542845.1:c.2617G>A, XM_011542846.1:c.3925G>A, NM_001351834.1:c.3925G>A, XM_005271562.5:c.3925G>A, XM_006718843.4:c.3925G>A, XM_011542840.3:c.3925G>A, XM_011542842.3:c.3760G>A, XM_011542843.2:c.3925G>A, XM_011542844.3:c.2881G>A, XM_011542845.2:c.2617G>A, XM_017017789.2:c.3925G>A, XM_017017790.2:c.3925G>A, XM_017017791.1:c.3925G>A, XM_017017792.2:c.3925G>A, XR_002957150.1:n.4658G>A, NM_001351834.2:c.3925G>A, NM_000051.4(ATM):c.3925G>A (p.Ala1309Thr)	ATM	hereditary breast cancer	MONDO:0016419	Autosomal dominant inheritance	Benign	BS1, BP2_Strong, BP4	PM2, BA1	The ATM c.3925G>A (p.Ala1309Thr) variant has a GnomAD (v2.1.1) filtering allele frequency of 0.1050% (NFE) which is above the ATM BS1 threshold of .05% (BS1). This variant has been observed in a homozygous and compound heterozygous state in multiple individuals without ataxia-telangiectasia (Internal laboratory contributions; BP2_strong). Multiple in silico protein predictors predict that this alteration is not deleterious (BP4). In summary, this variant meets criteria to be classified as benign based on the ACMG/AMP criteria applied, as specified by the HBOP Variant Curation Expert Panel.		Hereditary Breast, Ovarian and Pancreatic Cancer VCEP		2022-03-09	2022-07-11	False	https://erepo.genome.network/evrepo/ui/classification/CA242620/MONDO:0016419/020	65d2266d-93af-405f-b678-b9b808d3bbe1	p.Ala1309Thr	Ala	1309	Thr	MSLVLNDLLICCRQLEHDRATERKKEVEKFKRLIRDPETIKHLDRHSDSKQGKYLNWDAVFRFLQKYIQKETECLRIAKPNVSASTQASRQKKMQEISSLVKYFIKCANRRAPRLKCQELLNYIMDTVKDSSNGAIYGADCSNILLKDILSVRKYWCEISQQQWLELFSVYFRLYLKPSQDVHRVLVARIIHAVTKGCCSQTDGLNSKFLDFFSKAIQCARQEKSSSGLNHILAALTIFLKTLAVNFRIRVCELGDEILPTLLYIWTQHRLNDSLKEVIIELFQLQIYIHHPKGAKTQEKGAYESTKWRSILYNLYDLLVNEISHIGSRGKYSSGFRNIAVKENLIELMADICHQVFNEDTRSLEISQSYTTTQRESSDYSVPCKRKKIELGWEVIKDHLQKSQNDFDLVPWLQIATQLISKYPASLPNCELSPLLMILSQLLPQQRHGERTPYVLRCLTEVALCQDKRSNLESSQKSDLLKLWNKIWCITFRGISSEQIQAENFGLLGAIIQGSLVEVDREFWKLFTGSACRPSCPAVCCLTLALTTSIVPGTVKMGIEQNMCEVNRSFSLKESIMKWLLFYQLEGDLENSTEVPPILHSNFPHLVLEKILVSLTMKNCKAAMNFFQSVPECEHHQKDKEELSFSEVEELFLQTTFDKMDFLTIVRECGIEKHQSSIGFSVHQNLKESLDRCLLGLSEQLLNNYSSEITNSETLVRCSRLLVGVLGCYCYMGVIAEEEAYKSELFQKAKSLMQCAGESITLFKNKTNEEFRIGSLRNMMQLCTRCLSNCTKKSPNKIASGFFLRLLTSKLMNDIADICKSLASFIKKPFDRGEVESMEDDTNGNLMEVEDQSSMNLFNDYPDSSVSDANEPGESQSTIGAINPLAEEYLSKQDLLFLDMLKFLCLCVTTAQTNTVSFRAADIRRKLLMLIDSSTLEPTKSLHLHMYLMLLKELPGEEYPLPMEDVLELLKPLSNVCSLYRRDQDVCKTILNHVLHVVKNLGQSNMDSENTRDAQGQFLTVIGAFWHLTKERKYIFSVRMALVNCLKTLLEADPYSKWAILNVMGKDFPVNEVFTQFLADNHHQVRMLAAESINRLFQDTKGDSSRLLKALPLKLQQTAFENAYLKAQEGMREMSHSAENPETLDEIYNRKSVLLTLIAVVLSCSPICEKQALFALCKSVKENGLEPHLVKKVLEKVSETFGYRRLEDFMASHLDYLVLEWLNLQDTEYNLSSFPFILLNYTNIEDFYRSCYKVLIPHLVIRSHFDEVKSIANQIQEDWKSLLTDCFPKILVNILPYFAYEGTRDSGMAQQRETATKVYDMLKSENLLGKQIDHLFISNLPEIVVELLMTLHEPANSSASQSTDLCDFSGDLDPAPNPPHFPSHVIKATFAYISNCHKTKLKSILEILSKSPDSYQKILLAICEQAAETNNVYKKHRILKIYHLFVSLLLKDIKSGLGGAWAFVLRDVIYTLIHYINQRPSCIMDVSLRSFSLCCDLLSQVCQTAVTYCKDALENHLHVIVGTLIPLVYEQVEVQKQVLDLLKYLVIDNKDNENLYITIKLLDPFPDHVVFKDLRITQQKIKYSRGPFSLLEEINHFLSVSVYDALPLTRLEGLKDLRRQLELHKDQMVDIMRASQDNPQDGIMVKLVVNLLQLSKMAINHTGEKEVLEAVGSCLGEVGPIDFSTIAIQHSKDASYTKALKLFEDKELQWTFIMLTYLNNTLVEDCVKVRSAAVTCLKNILATKTGHSFWEIYKMTTDPMLAYLQPFRTSRKKFLEVPRFDKENPFEGLDDINLWIPLSENHDIWIKTLTCAFLDSGGTKCEILQLLKPMCEVKTDFCQTVLPYLIHDILLQDTNESWRNLLSTHVQGFFTSCLRHFSQTSRSTTPANLDSESEHFFRCCLDKKSQRTMLAVVDYMRRQKRPSSGTIFNDAFWLDLNYLEVAKVAQSCAAHFTALLYAEIYADKKSMDDQEKRSLAFEEGSQSTTISSLSEKSKEETGISLQDLLLEIYRSIGEPDSLYGCGGGKMLQPITRLRTYEHEAMWGKALVTYDLETAIPSSTRQAGIIQALQNLGLCHILSVYLKGLDYENKDWCPELEELHYQAAWRNMQWDHCTSVSKEVEGTSYHESLYNALQSLRDREFSTFYESLKYARVKEVEEMCKRSLESVYSLYPTLSRLQAIGELESIGELFSRSVTHRQLSEVYIKWQKHSQLLKDSDFSFQEPIMALRTVILEILMEKEMDNSQRECIKDILTKHLVELSILARTFKNTQLPERAIFQIKQYNSVSCGVSEWQLEEAQVFWAKKEQSLALSILKQMIKKLDASCAANNPSLKLTYTECLRVCGNWLAETCLENPAVIMQTYLEKAVEVAGNYDGESSDELRNGKMKAFLSLARFSDTQYQRIENYMKSSEFENKQALLKRAKEEVGLLREHKIQTNRYTVKVQRELELDELALRALKEDRKRFLCKAVENYINCLLSGEEHDMWVFRLCSLWLENSGVSEVNGMMKRDGMKIPTYKFLPLMYQLAARMGTKMMGGLGFHEVLNNLISRISMDHPHHTLFIILALANANRDEFLTKPEVARRSRITKNVPKQSSQLDEDRTEAANRIICTIRSRRPQMVRSVEALCDAYIILANLDATQWKTQRKGINIPADQPITKLKNLEDVVVPTMEIKVDHTGEYGNLVTIQSFKAEFRLAGGVNLPKIIDCVGSDGKERRQLVKGRDDLRQDAVMQQVFQMCNTLLQRNTETRKRKLTICTYKVVPLSQRSGVLEWCTGTVPIGEFLVNNEDGAHKRYRPNDFSAFQCQKKMMEVQKKSFEEKYEVFMDVCQNFQPVFRYFCMEKFLDPAIWFEKRLAYTRSVATSSIVGYILGLGDRHVQNILINEQSAELVHIDLGVAFEQGKILPTPETVPFRLTRDIVDGMGITGVEGVFRRCCEKTMEVMRNSQETLLTIVEVLLYDPLFDWTMNPLKALYLQQRPEDETELHPTLNADDQECKRNLSDIDQSFNKVAERVLMRLQEKLKGVEEGTVLSVGGQVNLLIQQAIDPKNLSRLFPGWKAWV	3056	Q13315	T	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [2886], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.00909412]), 'HELIX_loss': [1312, 1314, 1315, 2945], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.04222971, -0.02464622, -0.02227652, -0.0035764 ]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [173, 175, 400, 1734, 2693], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.025033  , -0.02928716, -0.01121032, -0.00909728, -0.02262807]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [2088], 'REPEAT_gain_score': array([0.00113779]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
390	NM_000051.3(ATM):c.2614C>T (p.Pro872Ser)	133610	CA157083	NM_000051.3:c.2614C>T, NC_000011.10:g.108267318C>T, CM000673.2:g.108267318C>T, NC_000011.9:g.108138045C>T, CM000673.1:g.108138045C>T, NC_000011.8:g.107643255C>T, NG_009830.1:g.49487C>T, LRG_135:g.49487C>T, ENST00000278616.9:c.2614C>T, ENST00000682516.1:n.2748C>T, ENST00000683174.1:n.2764C>T, ENST00000683605.1:n.2109C>T, ENST00000684037.1:c.*1549C>T, ENST00000527805.6:c.2614C>T, ENST00000675595.1:c.2449C>T, ENST00000675843.1:c.2614C>T, ENST00000278616.8:c.2614C>T, ENST00000452508.6:c.2614C>T, ENST00000527805.5:c.2614C>T, LRG_135t1:c.2614C>T, XM_005271561.3:c.2614C>T, XM_005271562.3:c.2614C>T, XM_006718843.2:c.2614C>T, XM_011542840.1:c.2614C>T, XM_011542841.1:c.2614C>T, XM_011542842.1:c.2449C>T, XM_011542843.1:c.2614C>T, XM_011542844.1:c.1570C>T, XM_011542845.1:c.1306C>T, XM_011542846.1:c.2614C>T, NM_001351834.1:c.2614C>T, XM_005271562.5:c.2614C>T, XM_006718843.4:c.2614C>T, XM_011542840.3:c.2614C>T, XM_011542842.3:c.2449C>T, XM_011542843.2:c.2614C>T, XM_011542844.3:c.1570C>T, XM_011542845.2:c.1306C>T, XM_017017789.2:c.2614C>T, XM_017017790.2:c.2614C>T, XM_017017791.1:c.2614C>T, XM_017017792.2:c.2614C>T, XR_002957150.1:n.3347C>T, NM_001351834.2:c.2614C>T, NM_000051.4:c.2614C>T, NM_000051.4(ATM):c.2614C>T (p.Pro872Ser), NM_000051.3(ATM):c.2614C>T (p.Pro872Ser)	ATM	hereditary breast cancer	MONDO:0016419	Autosomal dominant inheritance	Benign	BP2_Strong, BP4, BA1		The ATM c.2614C>T (p.Pro872Ser) variant has a GnomAD FAF 4.6% (AFR) exceeding ATM BA1 threshold of .5% (BA1). This variant has been observed in a homozygous or compound heterozygous state (presumed and/or confirmed) in multiple individuals without Ataxia-Telangiectasia (BP2_Strong, Clinical Diagnostic Laboratories). This variant is predicted tolerated by multiple protein in silico tools (BP4). In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the HBOP Variant Curation Expert Panel.		Hereditary Breast, Ovarian and Pancreatic Cancer VCEP		2022-03-09	2022-07-11	False	https://erepo.genome.network/evrepo/ui/classification/CA157083/MONDO:0016419/020	9323445f-3f23-4566-ae93-d2d61e92076d	p.Pro872Ser	Pro	872	Ser	MSLVLNDLLICCRQLEHDRATERKKEVEKFKRLIRDPETIKHLDRHSDSKQGKYLNWDAVFRFLQKYIQKETECLRIAKPNVSASTQASRQKKMQEISSLVKYFIKCANRRAPRLKCQELLNYIMDTVKDSSNGAIYGADCSNILLKDILSVRKYWCEISQQQWLELFSVYFRLYLKPSQDVHRVLVARIIHAVTKGCCSQTDGLNSKFLDFFSKAIQCARQEKSSSGLNHILAALTIFLKTLAVNFRIRVCELGDEILPTLLYIWTQHRLNDSLKEVIIELFQLQIYIHHPKGAKTQEKGAYESTKWRSILYNLYDLLVNEISHIGSRGKYSSGFRNIAVKENLIELMADICHQVFNEDTRSLEISQSYTTTQRESSDYSVPCKRKKIELGWEVIKDHLQKSQNDFDLVPWLQIATQLISKYPASLPNCELSPLLMILSQLLPQQRHGERTPYVLRCLTEVALCQDKRSNLESSQKSDLLKLWNKIWCITFRGISSEQIQAENFGLLGAIIQGSLVEVDREFWKLFTGSACRPSCPAVCCLTLALTTSIVPGTVKMGIEQNMCEVNRSFSLKESIMKWLLFYQLEGDLENSTEVPPILHSNFPHLVLEKILVSLTMKNCKAAMNFFQSVPECEHHQKDKEELSFSEVEELFLQTTFDKMDFLTIVRECGIEKHQSSIGFSVHQNLKESLDRCLLGLSEQLLNNYSSEITNSETLVRCSRLLVGVLGCYCYMGVIAEEEAYKSELFQKAKSLMQCAGESITLFKNKTNEEFRIGSLRNMMQLCTRCLSNCTKKSPNKIASGFFLRLLTSKLMNDIADICKSLASFIKKPFDRGEVESMEDDTNGNLMEVEDQSSMNLFNDYPDSSVSDANEPGESQSTIGAINPLAEEYLSKQDLLFLDMLKFLCLCVTTAQTNTVSFRAADIRRKLLMLIDSSTLEPTKSLHLHMYLMLLKELPGEEYPLPMEDVLELLKPLSNVCSLYRRDQDVCKTILNHVLHVVKNLGQSNMDSENTRDAQGQFLTVIGAFWHLTKERKYIFSVRMALVNCLKTLLEADPYSKWAILNVMGKDFPVNEVFTQFLADNHHQVRMLAAESINRLFQDTKGDSSRLLKALPLKLQQTAFENAYLKAQEGMREMSHSAENPETLDEIYNRKSVLLTLIAVVLSCSPICEKQALFALCKSVKENGLEPHLVKKVLEKVSETFGYRRLEDFMASHLDYLVLEWLNLQDTEYNLSSFPFILLNYTNIEDFYRSCYKVLIPHLVIRSHFDEVKSIANQIQEDWKSLLTDCFPKILVNILPYFAYEGTRDSGMAQQRETATKVYDMLKSENLLGKQIDHLFISNLPEIVVELLMTLHEPANSSASQSTDLCDFSGDLDPAPNPPHFPSHVIKATFAYISNCHKTKLKSILEILSKSPDSYQKILLAICEQAAETNNVYKKHRILKIYHLFVSLLLKDIKSGLGGAWAFVLRDVIYTLIHYINQRPSCIMDVSLRSFSLCCDLLSQVCQTAVTYCKDALENHLHVIVGTLIPLVYEQVEVQKQVLDLLKYLVIDNKDNENLYITIKLLDPFPDHVVFKDLRITQQKIKYSRGPFSLLEEINHFLSVSVYDALPLTRLEGLKDLRRQLELHKDQMVDIMRASQDNPQDGIMVKLVVNLLQLSKMAINHTGEKEVLEAVGSCLGEVGPIDFSTIAIQHSKDASYTKALKLFEDKELQWTFIMLTYLNNTLVEDCVKVRSAAVTCLKNILATKTGHSFWEIYKMTTDPMLAYLQPFRTSRKKFLEVPRFDKENPFEGLDDINLWIPLSENHDIWIKTLTCAFLDSGGTKCEILQLLKPMCEVKTDFCQTVLPYLIHDILLQDTNESWRNLLSTHVQGFFTSCLRHFSQTSRSTTPANLDSESEHFFRCCLDKKSQRTMLAVVDYMRRQKRPSSGTIFNDAFWLDLNYLEVAKVAQSCAAHFTALLYAEIYADKKSMDDQEKRSLAFEEGSQSTTISSLSEKSKEETGISLQDLLLEIYRSIGEPDSLYGCGGGKMLQPITRLRTYEHEAMWGKALVTYDLETAIPSSTRQAGIIQALQNLGLCHILSVYLKGLDYENKDWCPELEELHYQAAWRNMQWDHCTSVSKEVEGTSYHESLYNALQSLRDREFSTFYESLKYARVKEVEEMCKRSLESVYSLYPTLSRLQAIGELESIGELFSRSVTHRQLSEVYIKWQKHSQLLKDSDFSFQEPIMALRTVILEILMEKEMDNSQRECIKDILTKHLVELSILARTFKNTQLPERAIFQIKQYNSVSCGVSEWQLEEAQVFWAKKEQSLALSILKQMIKKLDASCAANNPSLKLTYTECLRVCGNWLAETCLENPAVIMQTYLEKAVEVAGNYDGESSDELRNGKMKAFLSLARFSDTQYQRIENYMKSSEFENKQALLKRAKEEVGLLREHKIQTNRYTVKVQRELELDELALRALKEDRKRFLCKAVENYINCLLSGEEHDMWVFRLCSLWLENSGVSEVNGMMKRDGMKIPTYKFLPLMYQLAARMGTKMMGGLGFHEVLNNLISRISMDHPHHTLFIILALANANRDEFLTKPEVARRSRITKNVPKQSSQLDEDRTEAANRIICTIRSRRPQMVRSVEALCDAYIILANLDATQWKTQRKGINIPADQPITKLKNLEDVVVPTMEIKVDHTGEYGNLVTIQSFKAEFRLAGGVNLPKIIDCVGSDGKERRQLVKGRDDLRQDAVMQQVFQMCNTLLQRNTETRKRKLTICTYKVVPLSQRSGVLEWCTGTVPIGEFLVNNEDGAHKRYRPNDFSAFQCQKKMMEVQKKSFEEKYEVFMDVCQNFQPVFRYFCMEKFLDPAIWFEKRLAYTRSVATSSIVGYILGLGDRHVQNILINEQSAELVHIDLGVAFEQGKILPTPETVPFRLTRDIVDGMGITGVEGVFRRCCEKTMEVMRNSQETLLTIVEVLLYDPLFDWTMNPLKALYLQQRPEDETELHPTLNADDQECKRNLSDIDQSFNKVAERVLMRLQEKLKGVEEGTVLSVGGQVNLLIQQAIDPKNLSRLFPGWKAWV	3056	Q13315	S	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [623, 1407, 1824, 1859, 2124, 2196, 2203, 2945], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.00423801, -0.00131792, -0.00400376, -0.00414205, -0.00195408,
       -0.00446528, -0.00613463, -0.00389409]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [2088], 'REPEAT_gain_score': array([0.00287306]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
391	NM_000540.3(RYR1):c.6502G>A (p.Val2168Met)	12976	CA024603	NM_000540.3:c.6502G>A, NC_000019.10:g.38494579G>A, CM000681.2:g.38494579G>A, NC_000019.9:g.38985219G>A, CM000681.1:g.38985219G>A, NC_000019.8:g.43677059G>A, NG_008866.1:g.65880G>A, LRG_766:g.65880G>A, ENST00000359596.8:c.6502G>A, ENST00000355481.8:c.6502G>A, ENST00000359596.7:n.6502G>A, ENST00000360985.7:c.6499G>A, NM_000540.2:c.6502G>A, LRG_766t1:c.6502G>A, NM_001042723.1:c.6502G>A, XM_006723317.1:c.6502G>A, XM_006723319.1:c.6502G>A, XM_011527204.1:c.6499G>A, XM_011527205.1:c.6502G>A, XM_006723317.2:c.6502G>A, XM_006723319.2:c.6502G>A, XM_011527205.2:c.6502G>A, XR_001753735.1:n.6585G>A, NM_001042723.2:c.6502G>A, NM_000540.3(RYR1):c.6502G>A (p.Val2168Met)	RYR1	malignant hyperthermia, susceptibility to, 1	MONDO:0007783	Autosomal dominant inheritance	Pathogenic	PS4, PS3_Moderate, PM1, PP1_Strong, PP3_Moderate		This pathogenicity assessment is relevant only for malignant hyperthermia susceptibility (MHS) inherited in an autosomal dominant pattern. Variants in RYR1 can also cause other myopathies inherited in an autosomal dominant pattern or in an autosomal recessive pattern. Some of these disorders may predispose individuals to malignant hyperthermia. RYR1 variants may also contribute to a malignant hyperthermia reaction in combination with other genetic and non-genetic factors and the clinician needs to consider such factors in making management decisions.This sequence variant predicts a substitution of Valine with Methionine at codon 2168 of the RYR1 protein, p.(Val2168Met). This variant is not present in a large population database (gnomAD) at the time this variant was interpreted. This variant has been reported in over 25 unrelated individuals who have a personal or family history of a malignant hyperthermia reaction, over 25 of these individuals had a positive in vitro contracture test (IVCT) or caffeine halothane contracture test (CHCT) result (if the proband was unavailable for testing, a positive diagnostic test result in a mutation-positive relative was counted), PS4 (PMID:11668625; PMID:30236257; PMID:20681998 and others). Functional studies in human myotubes from nine individuals (5 families) showed an increased sensitivity to RYR1 agonists, PS3_Moderate (PMID:15299003). This variant resides in a region of RYR1 considered to be a hotspot for pathogenic variants that contribute to MHS, PM1 (PMID: 21118704).This variant segregates with MHS eight individuals PP1_Strong (PMID:12434264, PMID:11575529). A REVEL score >0.85 (0.896)supports a pathogenic status for this variant, PP3_Moderate. This variant has been classified as Pathogenic. Criteria implemented: PS3_Moderate, PS4, PM1, PP1_Strong, PP3_Moderate.		Malignant Hyperthermia Susceptibility VCEP	https://clinicalgenome.org/docs/clingen-malignant-hyperthermia-susceptibility-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-for/	2022-03-29	2022-03-29	False	https://erepo.genome.network/evrepo/ui/classification/CA024603/MONDO:0007783/012	ba9df0d1-d974-42fd-9d62-e1fe3355bb7c	p.Val2168Met	Val	2168	Met	MGDAEGEDEVQFLRTDDEVVLQCSATVLKEQLKLCLAAEGFGNRLCFLEPTSNAQNVPPDLAICCFVLEQSLSVRALQEMLANTVEAGVESSQGGGHRTLLYGHAILLRHAHSRMYLSCLTTSRSMTDKLAFDVGLQEDATGEACWWTMHPASKQRSEGEKVRVGDDIILVSVSSERYLHLSTASGELQVDASFMQTLWNMNPICSRCEEGFVTGGHVLRLFHGHMDECLTISPADSDDQRRLVYYEGGAVCTHARSLWRLEPLRISWSGSHLRWGQPLRVRHVTTGQYLALTEDQGLVVVDASKAHTKATSFCFRISKEKLDVAPKRDVEGMGPPEIKYGESLCFVQHVASGLWLTYAAPDPKALRLGVLKKKAMLHQEGHMDDALSLTRCQQEESQAARMIHSTNGLYNQFIKSLDSFSGKPRGSGPPAGTALPIEGVILSLQDLIIYFEPPSEDLQHEEKQSKLRSLRNRQSLFQEEGMLSMVLNCIDRLNVYTTAAHFAEFAGEEAAESWKEIVNLLYELLASLIRGNRSNCALFSTNLDWLVSKLDRLEASSGILEVLYCVLIESPEVLNIIQENHIKSIISLLDKHGRNHKVLDVLCSLCVCNGVAVRSNQDLITENLLPGRELLLQTNLINYVTSIRPNIFVGRAEGTTQYSKWYFEVMVDEVTPFLTAQATHLRVGWALTEGYTPYPGAGEGWGGNGVGDDLYSYGFDGLHLWTGHVARPVTSPGQHLLAPEDVISCCLDLSVPSISFRINGCPVQGVFESFNLDGLFFPVVSFSAGVKVRFLLGGRHGEFKFLPPPGYAPCHEAVLPRERLHLEPIKEYRREGPRGPHLVGPSRCLSHTDFVPCPVDTVQIVLPPHLERIREKLAENIHELWALTRIEQGWTYGPVRDDNKRLHPCLVDFHSLPEPERNYNLQMSGETLKTLLALGCHVGMADEKAEDNLKKTKLPKTYMMSNGYKPAPLDLSHVRLTPAQTTLVDRLAENGHNVWARDRVGQGWSYSAVQDIPARRNPRLVPYRLLDEATKRSNRDSLCQAVRTLLGYGYNIEPPDQEPSQVENQSRCDRVRIFRAEKSYTVQSGRWYFEFEAVTTGEMRVGWARPELRPDVELGADELAYVFNGHRGQRWHLGSEPFGRPWQPGDVVGCMIDLTENTIIFTLNGEVLMSDSGSETAFREIEIGDGFLPVCSLGPGQVGHLNLGQDVSSLRFFAICGLQEGFEPFAINMQRPVTTWFSKGLPQFEPVPLEHPHYEVSRVDGTVDTPPCLRLTHRTWGSQNSLVEMLFLRLSLPVQFHQHFRCTAGATPLAPPGLQPPAEDEARAAEPDPDYENLRRSAGGWSEAENGKEGTAKEGAPGGTPQAGGEAQPARAENEKDATTEKNKKRGFLFKAKKVAMMTQPPATPTLPRLPHDVVPADNRDDPEIILNTTTYYYSVRVFAGQEPSCVWAGWVTPDYHQHDMSFDLSKVRVVTVTMGDEQGNVHSSLKCSNCYMVWGGDFVSPGQQGRISHTDLVIGCLVDLATGLMTFTANGKESNTFFQVEPNTKLFPAVFVLPTHQNVIQFELGKQKNIMPLSAAMFQSERKNPAPQCPPRLEMQMLMPVSWSRMPNHFLQVETRRAGERLGWAVQCQEPLTMMALHIPEENRCMDILELSERLDLQRFHSHTLRLYRAVCALGNNRVAHALCSHVDQAQLLHALEDAHLPGPLRAGYYDLLISIHLESACRSRRSMLSEYIVPLTPETRAITLFPPGRSTENGHPRHGLPGVGVTTSLRPPHHFSPPCFVAALPAAGAAEAPARLSPAIPLEALRDKALRMLGEAVRDGGQHARDPVGGSVEFQFVPVLKLVSTLLVMGIFGDEDVKQILKMIEPEVFTEEEEEEDEEEEGEEEDEEEKEEDEEETAQEKEDEEKEEEEAAEGEKEEGLEEGLLQMKLPESVKLQMCHLLEYFCDQELQHRVESLAAFAERYVDKLQANQRSRYGLLIKAFSMTAAETARRTREFRSPPQEQINMLLQFKDGTDEEDCPLPEEIRQDLLDFHQDLLAHCGIQLDGEEEEPEEETTLGSRLMSLLEKVRLVKKKEEKPEEERSAEESKPRSLQELVSHMVVRWAQEDFVQSPELVRAMFSLLHRQYDGLGELLRALPRAYTISPSSVEDTMSLLECLGQIRSLLIVQMGPQEENLMIQSIGNIMNNKVFYQHPNLMRALGMHETVMEVMVNVLGGGESKEIRFPKMVTSCCRFLCYFCRISRQNQRSMFDHLSYLLENSGIGLGMQGSTPLDVAAASVIDNNELALALQEQDLEKVVSYLAGCGLQSCPMLVAKGYPDIGWNPCGGERYLDFLRFAVFVNGESVEENANVVVRLLIRKPECFGPALRGEGGSGLLAAIEEAIRISEDPARDGPGIRRDRRREHFGEEPPEENRVHLGHAIMSFYAALIDLLGRCAPEMHLIQAGKGEALRIRAILRSLVPLEDLVGIISLPLQIPTLGKDGALVQPKMSASFVPDHKASMVLFLDRVYGIENQDFLLHVLDVGFLPDMRAAASLDTATFSTTEMALALNRYLCLAVLPLITKCAPLFAGTEHRAIMVDSMLHTVYRLSRGRSLTKAQRDVIEDCLMSLCRYIRPSMLQHLLRRLVFDVPILNEFAKMPLKLLTNHYERCWKYYCLPTGWANFGVTSEEELHLTRKLFWGIFDSLAHKKYDPELYRMAMPCLCAIAGALPPDYVDASYSSKAEKKATVDAEGNFDPRPVETLNVIIPEKLDSFINKFAEYTHEKWAFDKIQNNWSYGENIDEELKTHPMLRPYKTFSEKDKEIYRWPIKESLKAMIAWEWTIEKAREGEEEKTEKKKTRKISQSAQTYDPREGYNPQPPDLSAVTLSRELQAMAEQLAENYHNTWGRKKKQELEAKGGGTHPLLVPYDTLTAKEKARDREKAQELLKFLQMNGYAVTRGLKDMELDSSSIEKRFAFGFLQQLLRWMDISQEFIAHLEAVVSSGRVEKSPHEQEIKFFAKILLPLINQYFTNHCLYFLSTPAKVLGSGGHASNKEKEMITSLFCKLAALVRHRVSLFGTDAPAVVNCLHILARSLDARTVMKSGPEIVKAGLRSFFESASEDIEKMVENLRLGKVSQARTQVKGVGQNLTYTTVALLPVLTTLFQHIAQHQFGDDVILDDVQVSCYRTLCSIYSLGTTKNTYVEKLRPALGECLARLAAAMPVAFLEPQLNEYNACSVYTTKSPRERAILGLPNSVEEMCPDIPVLERLMADIGGLAESGARYTEMPHVIEITLPMLCSYLPRWWERGPEAPPSALPAGAPPPCTAVTSDHLNSLLGNILRIIVNNLGIDEASWMKRLAVFAQPIVSRARPELLQSHFIPTIGRLRKRAGKVVSEEEQLRLEAKAEAQEGELLVRDEFSVLCRDLYALYPLLIRYVDNNRAQWLTEPNPSAEELFRMVGEIFIYWSKSHNFKREEQNFVVQNEINNMSFLTADNKSKMAKAGDIQSGGSDQERTKKKRRGDRYSVQTSLIVATLKKMLPIGLNMCAPTDQDLITLAKTRYALKDTDEEVREFLHNNLHLQGKVEGSPSLRWQMALYRGVPGREEDADDPEKIVRRVQEVSAVLYYLDQTEHPYKSKKAVWHKLLSKQRRRAVVACFRMTPLYNLPTHRACNMFLESYKAAWILTEDHSFEDRMIDDLSKAGEQEEEEEEVEEKKPDPLHQLVLHFSRTALTEKSKLDEDYLYMAYADIMAKSCHLEEGGENGEAEEEVEVSFEEKQMEKQRLLYQQARLHTRGAAEMVLQMISACKGETGAMVSSTLKLGISILNGGNAEVQQKMLDYLKDKKEVGFFQSIQALMQTCSVLDLNAFERQNKAEGLGMVNEDGTVINRQNGEKVMADDEFTQDLFRFLQLLCEGHNNDFQNYLRTQTGNTTTINIIICTVDYLLRLQESISDFYWYYSGKDVIEEQGKRNFSKAMSVAKQVFNSLTEYIQGPCTGNQQSLAHSRLWDAVVGFLHVFAHMMMKLAQDSSQIELLKELLDLQKDMVVMLLSLLEGNVVNGMIARQMVDMLVESSSNVEMILKFFDMFLKLKDIVGSEAFQDYVTDPRGLISKKDFQKAMDSQKQFSGPEIQFLLSCSEADENEMINCEEFANRFQEPARDIGFNVAVLLTNLSEHVPHDPRLHNFLELAESILEYFRPYLGRIEIMGASRRIERIYFEISETNRAQWEMPQVKESKRQFIFDVVNEGGEAEKMELFVSFCEDTIFEMQIAAQISEPEGEPETDEDEGAGAAEAGAEGAEEGAAGLEGTAATAAAGATARVVAAAGRALRGLSYRSLRRRVRRLRRLTAREAATAVAALLWAAVTRAGAAGAGAAAGALGLLWGSLFGGGLVEGAKKVTVTELLAGMPDPTSDEVHGEQPAGPGGDADGEGASEGAGDAAEGAGDEEEAVHEAGPGGADGAVAVTDGGPFRPEGAGGLGDMGDTTPAEPPTPEGSPILKRKLGVDGVEEELPPEPEPEPEPELEPEKADAENGEKEEVPEPTPEPPKKQAPPSPPPKKEEAGGEFWGELEVQRVKFLNYLSRNFYTLRFLALFLAFAINFILLFYKVSDSPPGEDDMEGSAAGDVSGAGSGGSSGWGLGAGEEAEGDEDENMVYYFLEESTGYMEPALRCLSLLHTLVAFLCIIGYNCLKVPLVIFKREKELARKLEFDGLYITEQPEDDDVKGQWDRLVLNTPSFPSNYWDKFVKRKVLDKHGDIYGRERIAELLGMDLATLEITAHNERKPNPPPGLLTWLMSIDVKYQIWKFGVIFTDNSFLYLGWYMVMSLLGHYNNFFFAAHLLDIAMGVKTLRTILSSVTHNGKQLVMTVGLLAVVVYLYTVVAFNFFRKFYNKSEDEDEPDMKCDDMMTCYLFHMYVGVRAGGGIGDEIEDPAGDEYELYRVVFDITFFFFVIVILLAIIQGLIIDAFGELRDQQEQVKEDMETKCFICGIGSDYFDTTPHGFETHTLEEHNLANYMFFLMYLINKDETEHTGQESYVWKMYQERCWDFFPAGDCFRKQYEDQLS	5038	P21817	M	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
392	NM_000540.3(RYR1):c.487C>T (p.Arg163Cys)	12967	CA018598	NM_000540.3:c.487C>T, NC_000019.10:g.38444211C>T, CM000681.2:g.38444211C>T, NC_000019.9:g.38934851C>T, CM000681.1:g.38934851C>T, NC_000019.8:g.43626691C>T, NG_008866.1:g.15512C>T, LRG_766:g.15512C>T, ENST00000359596.8:c.487C>T, ENST00000355481.8:c.487C>T, ENST00000359596.7:n.487C>T, ENST00000360985.7:c.487C>T, NM_000540.2:c.487C>T, LRG_766t1:c.487C>T, NM_001042723.1:c.487C>T, XM_006723317.1:c.487C>T, XM_006723319.1:c.487C>T, XM_011527204.1:c.487C>T, XM_011527205.1:c.487C>T, XM_006723317.2:c.487C>T, XM_006723319.2:c.487C>T, XM_011527205.2:c.487C>T, XR_001753735.1:n.570C>T, NM_001042723.2:c.487C>T, NM_000540.3(RYR1):c.487C>T (p.Arg163Cys)	RYR1	malignant hyperthermia, susceptibility to, 1	MONDO:0007783	Autosomal dominant inheritance	Pathogenic	PM5_Supporting, PS3, PS4, PM1_Supporting, BS2_Supporting, PP1_Strong, PP3_Moderate	BA1, BP4, BS1, BS3	This pathogenicity assessment is relevant only for malignant hyperthermia susceptibility (MHS) inherited in an autosomal dominant pattern. Variants in RYR1 can also cause other myopathies inherited in an autosomal dominant pattern or in an autosomal recessive pattern. Some of these disorders may predispose individuals to malignant hyperthermia. RYR1 variants may also contribute to a malignant hyperthermia reaction in combination with other genetic and non-genetic factors and the clinician needs to consider such factors in making management decisions.This sequence variant predicts a substitution of arginine with cysteine at codon 163 of the RYR1 protein p.(Arg163Cys). This variant is not present in a large population databases (gnomAD). This variant has been reported in over 40 unrelated individuals who have a personal or family history of a malignant hyperthermia reaction and a positive in vitro contracture test (IVCT) or caffeine halothane contracture test (CHCT) result (when the proband was unavailable for testing a positive diagnostic test result in a mutation positive relative was counted), PS4 (PMID:30236257, PMID:12151923, PMID:16163667, PMID:8220423, PMID:11575529, PMID:12059893, PMID:23558838 and others). This variant has been identified in 1 individual with negative IVCT/CHCT results, BS2_Moderate (PMID:30236257). Functional studies in HEK293 cells show an increased sensitivity to RYR1 agonists. A knock-in mouse model supports pathogenicity of this variant demonstrating a malignant hyperthermia reaction in response to agonist, as well ex vivo studies show increased response to agonist with increased calcium release, PS3 (PMID:20461000, PMID:9334205, PMID:17122579). Another variant assessed as likely pathogenic occurs at this codon, p.(Arg163Leu), PM5_Supporting. This variant resides in a region of RYR1 considered to be a hotspot for pathogenic variants that contribute to MHS, use PM1_Supporting to avoid overweighting with PM5 (PMID: 21118704). This variant segregates with MHS over seven individuals, PP1_Strong (PMID:30236257, PMID:12059893, PMID:7889656). A REVEL score > 0.85 (0.959) supports pathogenicity, PP3_Moderate. Based on using Bayes to combine criteria this variant is assessed as Pathogenic, (PMID: 29300386). Criteria implemented: PS4, PS3, PM1_Supporting, PM5_Supporting, PP1_Strong, PP3_Moderate, BS2_Moderate.		Malignant Hyperthermia Susceptibility VCEP	https://clinicalgenome.org/docs/clingen-malignant-hyperthermia-susceptibility-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-for/	2022-03-29	2022-03-29	False	https://erepo.genome.network/evrepo/ui/classification/CA018598/MONDO:0007783/012	b2c419cf-7cdb-484f-8504-880aa4d39370	p.Arg163Cys	Arg	163	Cys	MGDAEGEDEVQFLRTDDEVVLQCSATVLKEQLKLCLAAEGFGNRLCFLEPTSNAQNVPPDLAICCFVLEQSLSVRALQEMLANTVEAGVESSQGGGHRTLLYGHAILLRHAHSRMYLSCLTTSRSMTDKLAFDVGLQEDATGEACWWTMHPASKQRSEGEKVRVGDDIILVSVSSERYLHLSTASGELQVDASFMQTLWNMNPICSRCEEGFVTGGHVLRLFHGHMDECLTISPADSDDQRRLVYYEGGAVCTHARSLWRLEPLRISWSGSHLRWGQPLRVRHVTTGQYLALTEDQGLVVVDASKAHTKATSFCFRISKEKLDVAPKRDVEGMGPPEIKYGESLCFVQHVASGLWLTYAAPDPKALRLGVLKKKAMLHQEGHMDDALSLTRCQQEESQAARMIHSTNGLYNQFIKSLDSFSGKPRGSGPPAGTALPIEGVILSLQDLIIYFEPPSEDLQHEEKQSKLRSLRNRQSLFQEEGMLSMVLNCIDRLNVYTTAAHFAEFAGEEAAESWKEIVNLLYELLASLIRGNRSNCALFSTNLDWLVSKLDRLEASSGILEVLYCVLIESPEVLNIIQENHIKSIISLLDKHGRNHKVLDVLCSLCVCNGVAVRSNQDLITENLLPGRELLLQTNLINYVTSIRPNIFVGRAEGTTQYSKWYFEVMVDEVTPFLTAQATHLRVGWALTEGYTPYPGAGEGWGGNGVGDDLYSYGFDGLHLWTGHVARPVTSPGQHLLAPEDVISCCLDLSVPSISFRINGCPVQGVFESFNLDGLFFPVVSFSAGVKVRFLLGGRHGEFKFLPPPGYAPCHEAVLPRERLHLEPIKEYRREGPRGPHLVGPSRCLSHTDFVPCPVDTVQIVLPPHLERIREKLAENIHELWALTRIEQGWTYGPVRDDNKRLHPCLVDFHSLPEPERNYNLQMSGETLKTLLALGCHVGMADEKAEDNLKKTKLPKTYMMSNGYKPAPLDLSHVRLTPAQTTLVDRLAENGHNVWARDRVGQGWSYSAVQDIPARRNPRLVPYRLLDEATKRSNRDSLCQAVRTLLGYGYNIEPPDQEPSQVENQSRCDRVRIFRAEKSYTVQSGRWYFEFEAVTTGEMRVGWARPELRPDVELGADELAYVFNGHRGQRWHLGSEPFGRPWQPGDVVGCMIDLTENTIIFTLNGEVLMSDSGSETAFREIEIGDGFLPVCSLGPGQVGHLNLGQDVSSLRFFAICGLQEGFEPFAINMQRPVTTWFSKGLPQFEPVPLEHPHYEVSRVDGTVDTPPCLRLTHRTWGSQNSLVEMLFLRLSLPVQFHQHFRCTAGATPLAPPGLQPPAEDEARAAEPDPDYENLRRSAGGWSEAENGKEGTAKEGAPGGTPQAGGEAQPARAENEKDATTEKNKKRGFLFKAKKVAMMTQPPATPTLPRLPHDVVPADNRDDPEIILNTTTYYYSVRVFAGQEPSCVWAGWVTPDYHQHDMSFDLSKVRVVTVTMGDEQGNVHSSLKCSNCYMVWGGDFVSPGQQGRISHTDLVIGCLVDLATGLMTFTANGKESNTFFQVEPNTKLFPAVFVLPTHQNVIQFELGKQKNIMPLSAAMFQSERKNPAPQCPPRLEMQMLMPVSWSRMPNHFLQVETRRAGERLGWAVQCQEPLTMMALHIPEENRCMDILELSERLDLQRFHSHTLRLYRAVCALGNNRVAHALCSHVDQAQLLHALEDAHLPGPLRAGYYDLLISIHLESACRSRRSMLSEYIVPLTPETRAITLFPPGRSTENGHPRHGLPGVGVTTSLRPPHHFSPPCFVAALPAAGAAEAPARLSPAIPLEALRDKALRMLGEAVRDGGQHARDPVGGSVEFQFVPVLKLVSTLLVMGIFGDEDVKQILKMIEPEVFTEEEEEEDEEEEGEEEDEEEKEEDEEETAQEKEDEEKEEEEAAEGEKEEGLEEGLLQMKLPESVKLQMCHLLEYFCDQELQHRVESLAAFAERYVDKLQANQRSRYGLLIKAFSMTAAETARRTREFRSPPQEQINMLLQFKDGTDEEDCPLPEEIRQDLLDFHQDLLAHCGIQLDGEEEEPEEETTLGSRLMSLLEKVRLVKKKEEKPEEERSAEESKPRSLQELVSHMVVRWAQEDFVQSPELVRAMFSLLHRQYDGLGELLRALPRAYTISPSSVEDTMSLLECLGQIRSLLIVQMGPQEENLMIQSIGNIMNNKVFYQHPNLMRALGMHETVMEVMVNVLGGGESKEIRFPKMVTSCCRFLCYFCRISRQNQRSMFDHLSYLLENSGIGLGMQGSTPLDVAAASVIDNNELALALQEQDLEKVVSYLAGCGLQSCPMLVAKGYPDIGWNPCGGERYLDFLRFAVFVNGESVEENANVVVRLLIRKPECFGPALRGEGGSGLLAAIEEAIRISEDPARDGPGIRRDRRREHFGEEPPEENRVHLGHAIMSFYAALIDLLGRCAPEMHLIQAGKGEALRIRAILRSLVPLEDLVGIISLPLQIPTLGKDGALVQPKMSASFVPDHKASMVLFLDRVYGIENQDFLLHVLDVGFLPDMRAAASLDTATFSTTEMALALNRYLCLAVLPLITKCAPLFAGTEHRAIMVDSMLHTVYRLSRGRSLTKAQRDVIEDCLMSLCRYIRPSMLQHLLRRLVFDVPILNEFAKMPLKLLTNHYERCWKYYCLPTGWANFGVTSEEELHLTRKLFWGIFDSLAHKKYDPELYRMAMPCLCAIAGALPPDYVDASYSSKAEKKATVDAEGNFDPRPVETLNVIIPEKLDSFINKFAEYTHEKWAFDKIQNNWSYGENIDEELKTHPMLRPYKTFSEKDKEIYRWPIKESLKAMIAWEWTIEKAREGEEEKTEKKKTRKISQSAQTYDPREGYNPQPPDLSAVTLSRELQAMAEQLAENYHNTWGRKKKQELEAKGGGTHPLLVPYDTLTAKEKARDREKAQELLKFLQMNGYAVTRGLKDMELDSSSIEKRFAFGFLQQLLRWMDISQEFIAHLEAVVSSGRVEKSPHEQEIKFFAKILLPLINQYFTNHCLYFLSTPAKVLGSGGHASNKEKEMITSLFCKLAALVRHRVSLFGTDAPAVVNCLHILARSLDARTVMKSGPEIVKAGLRSFFESASEDIEKMVENLRLGKVSQARTQVKGVGQNLTYTTVALLPVLTTLFQHIAQHQFGDDVILDDVQVSCYRTLCSIYSLGTTKNTYVEKLRPALGECLARLAAAMPVAFLEPQLNEYNACSVYTTKSPRERAILGLPNSVEEMCPDIPVLERLMADIGGLAESGARYTEMPHVIEITLPMLCSYLPRWWERGPEAPPSALPAGAPPPCTAVTSDHLNSLLGNILRIIVNNLGIDEASWMKRLAVFAQPIVSRARPELLQSHFIPTIGRLRKRAGKVVSEEEQLRLEAKAEAQEGELLVRDEFSVLCRDLYALYPLLIRYVDNNRAQWLTEPNPSAEELFRMVGEIFIYWSKSHNFKREEQNFVVQNEINNMSFLTADNKSKMAKAGDIQSGGSDQERTKKKRRGDRYSVQTSLIVATLKKMLPIGLNMCAPTDQDLITLAKTRYALKDTDEEVREFLHNNLHLQGKVEGSPSLRWQMALYRGVPGREEDADDPEKIVRRVQEVSAVLYYLDQTEHPYKSKKAVWHKLLSKQRRRAVVACFRMTPLYNLPTHRACNMFLESYKAAWILTEDHSFEDRMIDDLSKAGEQEEEEEEVEEKKPDPLHQLVLHFSRTALTEKSKLDEDYLYMAYADIMAKSCHLEEGGENGEAEEEVEVSFEEKQMEKQRLLYQQARLHTRGAAEMVLQMISACKGETGAMVSSTLKLGISILNGGNAEVQQKMLDYLKDKKEVGFFQSIQALMQTCSVLDLNAFERQNKAEGLGMVNEDGTVINRQNGEKVMADDEFTQDLFRFLQLLCEGHNNDFQNYLRTQTGNTTTINIIICTVDYLLRLQESISDFYWYYSGKDVIEEQGKRNFSKAMSVAKQVFNSLTEYIQGPCTGNQQSLAHSRLWDAVVGFLHVFAHMMMKLAQDSSQIELLKELLDLQKDMVVMLLSLLEGNVVNGMIARQMVDMLVESSSNVEMILKFFDMFLKLKDIVGSEAFQDYVTDPRGLISKKDFQKAMDSQKQFSGPEIQFLLSCSEADENEMINCEEFANRFQEPARDIGFNVAVLLTNLSEHVPHDPRLHNFLELAESILEYFRPYLGRIEIMGASRRIERIYFEISETNRAQWEMPQVKESKRQFIFDVVNEGGEAEKMELFVSFCEDTIFEMQIAAQISEPEGEPETDEDEGAGAAEAGAEGAEEGAAGLEGTAATAAAGATARVVAAAGRALRGLSYRSLRRRVRRLRRLTAREAATAVAALLWAAVTRAGAAGAGAAAGALGLLWGSLFGGGLVEGAKKVTVTELLAGMPDPTSDEVHGEQPAGPGGDADGEGASEGAGDAAEGAGDEEEAVHEAGPGGADGAVAVTDGGPFRPEGAGGLGDMGDTTPAEPPTPEGSPILKRKLGVDGVEEELPPEPEPEPEPELEPEKADAENGEKEEVPEPTPEPPKKQAPPSPPPKKEEAGGEFWGELEVQRVKFLNYLSRNFYTLRFLALFLAFAINFILLFYKVSDSPPGEDDMEGSAAGDVSGAGSGGSSGWGLGAGEEAEGDEDENMVYYFLEESTGYMEPALRCLSLLHTLVAFLCIIGYNCLKVPLVIFKREKELARKLEFDGLYITEQPEDDDVKGQWDRLVLNTPSFPSNYWDKFVKRKVLDKHGDIYGRERIAELLGMDLATLEITAHNERKPNPPPGLLTWLMSIDVKYQIWKFGVIFTDNSFLYLGWYMVMSLLGHYNNFFFAAHLLDIAMGVKTLRTILSSVTHNGKQLVMTVGLLAVVVYLYTVVAFNFFRKFYNKSEDEDEPDMKCDDMMTCYLFHMYVGVRAGGGIGDEIEDPAGDEYELYRVVFDITFFFFVIVILLAIIQGLIIDAFGELRDQQEQVKEDMETKCFICGIGSDYFDTTPHGFETHTLEEHNLANYMFFLMYLINKDETEHTGQESYVWKMYQERCWDFFPAGDCFRKQYEDQLS	5038	P21817	C	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [1490], 'DISULFID_gain': [162], 'DISULFID_gain_score': array([0.57329392]), 'DISULFID_loss_score': array([-0.00095433]), 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
393	NM_000540.3(RYR1):c.1201C>T (p.Arg401Cys)	133029	CA023956	NM_000540.3:c.1201C>T, NC_000019.10:g.38451842C>T, CM000681.2:g.38451842C>T, NC_000019.9:g.38942482C>T, CM000681.1:g.38942482C>T, NC_000019.8:g.43634322C>T, NG_008866.1:g.23143C>T, LRG_766:g.23143C>T, ENST00000359596.8:c.1201C>T, ENST00000355481.8:c.1201C>T, ENST00000359596.7:n.1201C>T, ENST00000360985.7:c.1201C>T, NM_000540.2:c.1201C>T, LRG_766t1:c.1201C>T, NM_001042723.1:c.1201C>T, XM_006723317.1:c.1201C>T, XM_006723319.1:c.1201C>T, XM_011527204.1:c.1198C>T, XM_011527205.1:c.1201C>T, XM_006723317.2:c.1201C>T, XM_006723319.2:c.1201C>T, XM_011527205.2:c.1201C>T, XR_001753735.1:n.1284C>T, NM_001042723.2:c.1201C>T, NM_000540.3(RYR1):c.1201C>T (p.Arg401Cys)	RYR1	malignant hyperthermia, susceptibility to, 1	MONDO:0007783	Autosomal dominant inheritance	Pathogenic	PP1, PS4_Moderate, PM1_Supporting, PS3_Moderate, PM5, PP3_Moderate	BA1, BP4, BS1	This pathogenicity assessment is relevant only for malignant hyperthermia susceptibility (MHS) inherited in an autosomal dominant pattern. Variants in RYR1 can also cause other myopathies inherited in an autosomal dominant pattern or in an autosomal recessive pattern. Some of these disorders may predispose individuals to malignant hyperthermia. RYR1 variants may also contribute to a malignant hyperthermia reaction in combination with other genetic and non-genetic factors and the clinician needs to consider such factors in making management decisions.This sequence variant predicts a substitution of arginine with cysteine at codon 401 of the RYR1 protein p.(Arg401Cys). The maximum allele frequency for this variant among the six major gnomAD populations is EAS: 0.00005, a frequency consistent with pathogenicity for MHS. This variant has been reported in five unrelated individuals who have a personal or family history of a malignant hyperthermia reaction and a positive in vitro contracture test (IVCT) or caffeine halothane contracture test (CHCT) result (when the proband was unavailable for testing a positive diagnostic test result in a mutation positive relative was counted), PS4_Moderate ( PMID:30236257, PMID:12434264, PMID:24433488, PMID:25735680). This variant segregates with MHS in three individuals, PP1 (PMID:12066726, PMID:18564801). Functional studies in HEK293 cells show an increased sensitivity to RYR1 agonists PS3_Moderate, (PMID:23459219). Another variant has been assessed as pathogenic occurs at this codon, p.(Arg401His), PM5 (PMID:16917943). This variant resides in a region of RYR1 considered to be a hotspot for pathogenic variants that contribute to MHS, use PM1_Supporting to avoid overweighting with PM5  (PMID: 21118704). A REVEL score > 0.85 (0.886) supports pathogenicity, PP3_Moderate. Criteria implemented: PS4_Moderate, PS3_Moderate, PM1_Supporting, PM5, PP1, PP3_Moderate. Based on using Bayes to combine criteria this variant is assessed as Pathogenic, (PMID: 29300386).	23459219	Malignant Hyperthermia Susceptibility VCEP	https://clinicalgenome.org/docs/clingen-malignant-hyperthermia-susceptibility-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-for/	2022-03-29	2022-03-29	False	https://erepo.genome.network/evrepo/ui/classification/CA023956/MONDO:0007783/012	61f449cf-05e9-4bd2-b696-05dcefd57769	p.Arg401Cys	Arg	401	Cys	MGDAEGEDEVQFLRTDDEVVLQCSATVLKEQLKLCLAAEGFGNRLCFLEPTSNAQNVPPDLAICCFVLEQSLSVRALQEMLANTVEAGVESSQGGGHRTLLYGHAILLRHAHSRMYLSCLTTSRSMTDKLAFDVGLQEDATGEACWWTMHPASKQRSEGEKVRVGDDIILVSVSSERYLHLSTASGELQVDASFMQTLWNMNPICSRCEEGFVTGGHVLRLFHGHMDECLTISPADSDDQRRLVYYEGGAVCTHARSLWRLEPLRISWSGSHLRWGQPLRVRHVTTGQYLALTEDQGLVVVDASKAHTKATSFCFRISKEKLDVAPKRDVEGMGPPEIKYGESLCFVQHVASGLWLTYAAPDPKALRLGVLKKKAMLHQEGHMDDALSLTRCQQEESQAARMIHSTNGLYNQFIKSLDSFSGKPRGSGPPAGTALPIEGVILSLQDLIIYFEPPSEDLQHEEKQSKLRSLRNRQSLFQEEGMLSMVLNCIDRLNVYTTAAHFAEFAGEEAAESWKEIVNLLYELLASLIRGNRSNCALFSTNLDWLVSKLDRLEASSGILEVLYCVLIESPEVLNIIQENHIKSIISLLDKHGRNHKVLDVLCSLCVCNGVAVRSNQDLITENLLPGRELLLQTNLINYVTSIRPNIFVGRAEGTTQYSKWYFEVMVDEVTPFLTAQATHLRVGWALTEGYTPYPGAGEGWGGNGVGDDLYSYGFDGLHLWTGHVARPVTSPGQHLLAPEDVISCCLDLSVPSISFRINGCPVQGVFESFNLDGLFFPVVSFSAGVKVRFLLGGRHGEFKFLPPPGYAPCHEAVLPRERLHLEPIKEYRREGPRGPHLVGPSRCLSHTDFVPCPVDTVQIVLPPHLERIREKLAENIHELWALTRIEQGWTYGPVRDDNKRLHPCLVDFHSLPEPERNYNLQMSGETLKTLLALGCHVGMADEKAEDNLKKTKLPKTYMMSNGYKPAPLDLSHVRLTPAQTTLVDRLAENGHNVWARDRVGQGWSYSAVQDIPARRNPRLVPYRLLDEATKRSNRDSLCQAVRTLLGYGYNIEPPDQEPSQVENQSRCDRVRIFRAEKSYTVQSGRWYFEFEAVTTGEMRVGWARPELRPDVELGADELAYVFNGHRGQRWHLGSEPFGRPWQPGDVVGCMIDLTENTIIFTLNGEVLMSDSGSETAFREIEIGDGFLPVCSLGPGQVGHLNLGQDVSSLRFFAICGLQEGFEPFAINMQRPVTTWFSKGLPQFEPVPLEHPHYEVSRVDGTVDTPPCLRLTHRTWGSQNSLVEMLFLRLSLPVQFHQHFRCTAGATPLAPPGLQPPAEDEARAAEPDPDYENLRRSAGGWSEAENGKEGTAKEGAPGGTPQAGGEAQPARAENEKDATTEKNKKRGFLFKAKKVAMMTQPPATPTLPRLPHDVVPADNRDDPEIILNTTTYYYSVRVFAGQEPSCVWAGWVTPDYHQHDMSFDLSKVRVVTVTMGDEQGNVHSSLKCSNCYMVWGGDFVSPGQQGRISHTDLVIGCLVDLATGLMTFTANGKESNTFFQVEPNTKLFPAVFVLPTHQNVIQFELGKQKNIMPLSAAMFQSERKNPAPQCPPRLEMQMLMPVSWSRMPNHFLQVETRRAGERLGWAVQCQEPLTMMALHIPEENRCMDILELSERLDLQRFHSHTLRLYRAVCALGNNRVAHALCSHVDQAQLLHALEDAHLPGPLRAGYYDLLISIHLESACRSRRSMLSEYIVPLTPETRAITLFPPGRSTENGHPRHGLPGVGVTTSLRPPHHFSPPCFVAALPAAGAAEAPARLSPAIPLEALRDKALRMLGEAVRDGGQHARDPVGGSVEFQFVPVLKLVSTLLVMGIFGDEDVKQILKMIEPEVFTEEEEEEDEEEEGEEEDEEEKEEDEEETAQEKEDEEKEEEEAAEGEKEEGLEEGLLQMKLPESVKLQMCHLLEYFCDQELQHRVESLAAFAERYVDKLQANQRSRYGLLIKAFSMTAAETARRTREFRSPPQEQINMLLQFKDGTDEEDCPLPEEIRQDLLDFHQDLLAHCGIQLDGEEEEPEEETTLGSRLMSLLEKVRLVKKKEEKPEEERSAEESKPRSLQELVSHMVVRWAQEDFVQSPELVRAMFSLLHRQYDGLGELLRALPRAYTISPSSVEDTMSLLECLGQIRSLLIVQMGPQEENLMIQSIGNIMNNKVFYQHPNLMRALGMHETVMEVMVNVLGGGESKEIRFPKMVTSCCRFLCYFCRISRQNQRSMFDHLSYLLENSGIGLGMQGSTPLDVAAASVIDNNELALALQEQDLEKVVSYLAGCGLQSCPMLVAKGYPDIGWNPCGGERYLDFLRFAVFVNGESVEENANVVVRLLIRKPECFGPALRGEGGSGLLAAIEEAIRISEDPARDGPGIRRDRRREHFGEEPPEENRVHLGHAIMSFYAALIDLLGRCAPEMHLIQAGKGEALRIRAILRSLVPLEDLVGIISLPLQIPTLGKDGALVQPKMSASFVPDHKASMVLFLDRVYGIENQDFLLHVLDVGFLPDMRAAASLDTATFSTTEMALALNRYLCLAVLPLITKCAPLFAGTEHRAIMVDSMLHTVYRLSRGRSLTKAQRDVIEDCLMSLCRYIRPSMLQHLLRRLVFDVPILNEFAKMPLKLLTNHYERCWKYYCLPTGWANFGVTSEEELHLTRKLFWGIFDSLAHKKYDPELYRMAMPCLCAIAGALPPDYVDASYSSKAEKKATVDAEGNFDPRPVETLNVIIPEKLDSFINKFAEYTHEKWAFDKIQNNWSYGENIDEELKTHPMLRPYKTFSEKDKEIYRWPIKESLKAMIAWEWTIEKAREGEEEKTEKKKTRKISQSAQTYDPREGYNPQPPDLSAVTLSRELQAMAEQLAENYHNTWGRKKKQELEAKGGGTHPLLVPYDTLTAKEKARDREKAQELLKFLQMNGYAVTRGLKDMELDSSSIEKRFAFGFLQQLLRWMDISQEFIAHLEAVVSSGRVEKSPHEQEIKFFAKILLPLINQYFTNHCLYFLSTPAKVLGSGGHASNKEKEMITSLFCKLAALVRHRVSLFGTDAPAVVNCLHILARSLDARTVMKSGPEIVKAGLRSFFESASEDIEKMVENLRLGKVSQARTQVKGVGQNLTYTTVALLPVLTTLFQHIAQHQFGDDVILDDVQVSCYRTLCSIYSLGTTKNTYVEKLRPALGECLARLAAAMPVAFLEPQLNEYNACSVYTTKSPRERAILGLPNSVEEMCPDIPVLERLMADIGGLAESGARYTEMPHVIEITLPMLCSYLPRWWERGPEAPPSALPAGAPPPCTAVTSDHLNSLLGNILRIIVNNLGIDEASWMKRLAVFAQPIVSRARPELLQSHFIPTIGRLRKRAGKVVSEEEQLRLEAKAEAQEGELLVRDEFSVLCRDLYALYPLLIRYVDNNRAQWLTEPNPSAEELFRMVGEIFIYWSKSHNFKREEQNFVVQNEINNMSFLTADNKSKMAKAGDIQSGGSDQERTKKKRRGDRYSVQTSLIVATLKKMLPIGLNMCAPTDQDLITLAKTRYALKDTDEEVREFLHNNLHLQGKVEGSPSLRWQMALYRGVPGREEDADDPEKIVRRVQEVSAVLYYLDQTEHPYKSKKAVWHKLLSKQRRRAVVACFRMTPLYNLPTHRACNMFLESYKAAWILTEDHSFEDRMIDDLSKAGEQEEEEEEVEEKKPDPLHQLVLHFSRTALTEKSKLDEDYLYMAYADIMAKSCHLEEGGENGEAEEEVEVSFEEKQMEKQRLLYQQARLHTRGAAEMVLQMISACKGETGAMVSSTLKLGISILNGGNAEVQQKMLDYLKDKKEVGFFQSIQALMQTCSVLDLNAFERQNKAEGLGMVNEDGTVINRQNGEKVMADDEFTQDLFRFLQLLCEGHNNDFQNYLRTQTGNTTTINIIICTVDYLLRLQESISDFYWYYSGKDVIEEQGKRNFSKAMSVAKQVFNSLTEYIQGPCTGNQQSLAHSRLWDAVVGFLHVFAHMMMKLAQDSSQIELLKELLDLQKDMVVMLLSLLEGNVVNGMIARQMVDMLVESSSNVEMILKFFDMFLKLKDIVGSEAFQDYVTDPRGLISKKDFQKAMDSQKQFSGPEIQFLLSCSEADENEMINCEEFANRFQEPARDIGFNVAVLLTNLSEHVPHDPRLHNFLELAESILEYFRPYLGRIEIMGASRRIERIYFEISETNRAQWEMPQVKESKRQFIFDVVNEGGEAEKMELFVSFCEDTIFEMQIAAQISEPEGEPETDEDEGAGAAEAGAEGAEEGAAGLEGTAATAAAGATARVVAAAGRALRGLSYRSLRRRVRRLRRLTAREAATAVAALLWAAVTRAGAAGAGAAAGALGLLWGSLFGGGLVEGAKKVTVTELLAGMPDPTSDEVHGEQPAGPGGDADGEGASEGAGDAAEGAGDEEEAVHEAGPGGADGAVAVTDGGPFRPEGAGGLGDMGDTTPAEPPTPEGSPILKRKLGVDGVEEELPPEPEPEPEPELEPEKADAENGEKEEVPEPTPEPPKKQAPPSPPPKKEEAGGEFWGELEVQRVKFLNYLSRNFYTLRFLALFLAFAINFILLFYKVSDSPPGEDDMEGSAAGDVSGAGSGGSSGWGLGAGEEAEGDEDENMVYYFLEESTGYMEPALRCLSLLHTLVAFLCIIGYNCLKVPLVIFKREKELARKLEFDGLYITEQPEDDDVKGQWDRLVLNTPSFPSNYWDKFVKRKVLDKHGDIYGRERIAELLGMDLATLEITAHNERKPNPPPGLLTWLMSIDVKYQIWKFGVIFTDNSFLYLGWYMVMSLLGHYNNFFFAAHLLDIAMGVKTLRTILSSVTHNGKQLVMTVGLLAVVVYLYTVVAFNFFRKFYNKSEDEDEPDMKCDDMMTCYLFHMYVGVRAGGGIGDEIEDPAGDEYELYRVVFDITFFFFVIVILLAIIQGLIIDAFGELRDQQEQVKEDMETKCFICGIGSDYFDTTPHGFETHTLEEHNLANYMFFLMYLINKDETEHTGQESYVWKMYQERCWDFFPAGDCFRKQYEDQLS	5038	P21817	C	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [391, 400], 'DISULFID_gain_score': array([0.16973549, 0.54014224]), 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
394	NM_000540.3(RYR1):c.6488G>A (p.Arg2163His)	12974	CA024593	NM_000540.3:c.6488G>A, NC_000019.10:g.38494565G>A, CM000681.2:g.38494565G>A, NC_000019.9:g.38985205G>A, CM000681.1:g.38985205G>A, NC_000019.8:g.43677045G>A, NG_008866.1:g.65866G>A, LRG_766:g.65866G>A, ENST00000359596.8:c.6488G>A, ENST00000355481.8:c.6488G>A, ENST00000359596.7:n.6488G>A, ENST00000360985.7:c.6485G>A, NM_000540.2:c.6488G>A, LRG_766t1:c.6488G>A, NM_001042723.1:c.6488G>A, XM_006723317.1:c.6488G>A, XM_006723319.1:c.6488G>A, XM_011527204.1:c.6485G>A, XM_011527205.1:c.6488G>A, XM_006723317.2:c.6488G>A, XM_006723319.2:c.6488G>A, XM_011527205.2:c.6488G>A, XR_001753735.1:n.6571G>A, NM_001042723.2:c.6488G>A, NM_000540.3(RYR1):c.6488G>A (p.Arg2163His)	RYR1	malignant hyperthermia, susceptibility to, 1	MONDO:0007783	Autosomal dominant inheritance	Pathogenic	BS2, PS4, PS3_Moderate, PM1, PP1_Strong, PP3_Moderate	BA1, BS1	This pathogenicity assessment is relevant only for malignant hyperthermia susceptibility (MHS) inherited in an autosomal dominant pattern. Variants in RYR1 can also cause other myopathies inherited in an autosomal dominant pattern or in an autosomal recessive pattern. Some of these disorders may predispose individuals to malignant hyperthermia. RYR1 variants may also contribute to a malignant hyperthermia reaction in combination with other genetic and non-genetic factors and the clinician needs to consider such factors in making management decisions.This sequence variant predicts a substitution of Arginine with Histidine at codon 2163 of the RYR1 protein, p.(Arg2163His). This variant is not present in a large population database (gnomAD) at the time this variant was interpreted. This variant has been reported in 16 unrelated individuals who have a personal or family history of a malignant hyperthermia reaction, 14 of these individuals had a positive in vitro contracture test (IVCT) or caffeine halothane contracture test (CHCT) result (if the proband was unavailable for testing, a positive diagnostic test result in a mutation-positive relative was counted), PS4 (PMID:30236257, PMID:9497245, PMID:21455645, PMID:15731587, PMID:23558838). This variant has been identified in three individuals with negative IVCT/CHCT results, BS2 (PMID:30236257). Functional studies in HEK293 cells show an increased sensitivity to RYR1 agonists, PS3_Moderate (PMID:9334205). Additional functional studies in dyspedic myotubes were published for this variant, this assay is not considered a standard assay by the ClinGen RYR1 VCEP for MHS (PMID:12732639, PMID:15347586). This variant resides in a region of RYR1 considered to be a hotspot for pathogenic variants that contribute to MHS, PM1 (PMID: 21118704). This variant segregates with MHS in seven families, PP1_Strong (PMID:30236257, PMID:9497245). A REVEL score >0.85 (0.933) supports a pathogenic status for this variant, PP3_Moderate. Based on using Bayes to combine criteria this variant is assessed as Pathogenic, (PMID: 29300386). Criteria implemented: PS3_Moderate, PS4, PM1, PP1_Strong, PP3_Moderate, BS2.		Malignant Hyperthermia Susceptibility VCEP	https://clinicalgenome.org/docs/clingen-malignant-hyperthermia-susceptibility-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-for/	2022-03-29	2022-03-29	False	https://erepo.genome.network/evrepo/ui/classification/CA024593/MONDO:0007783/012	55c04060-0210-46df-b5b8-319c520d93a5	p.Arg2163His	Arg	2163	His	MGDAEGEDEVQFLRTDDEVVLQCSATVLKEQLKLCLAAEGFGNRLCFLEPTSNAQNVPPDLAICCFVLEQSLSVRALQEMLANTVEAGVESSQGGGHRTLLYGHAILLRHAHSRMYLSCLTTSRSMTDKLAFDVGLQEDATGEACWWTMHPASKQRSEGEKVRVGDDIILVSVSSERYLHLSTASGELQVDASFMQTLWNMNPICSRCEEGFVTGGHVLRLFHGHMDECLTISPADSDDQRRLVYYEGGAVCTHARSLWRLEPLRISWSGSHLRWGQPLRVRHVTTGQYLALTEDQGLVVVDASKAHTKATSFCFRISKEKLDVAPKRDVEGMGPPEIKYGESLCFVQHVASGLWLTYAAPDPKALRLGVLKKKAMLHQEGHMDDALSLTRCQQEESQAARMIHSTNGLYNQFIKSLDSFSGKPRGSGPPAGTALPIEGVILSLQDLIIYFEPPSEDLQHEEKQSKLRSLRNRQSLFQEEGMLSMVLNCIDRLNVYTTAAHFAEFAGEEAAESWKEIVNLLYELLASLIRGNRSNCALFSTNLDWLVSKLDRLEASSGILEVLYCVLIESPEVLNIIQENHIKSIISLLDKHGRNHKVLDVLCSLCVCNGVAVRSNQDLITENLLPGRELLLQTNLINYVTSIRPNIFVGRAEGTTQYSKWYFEVMVDEVTPFLTAQATHLRVGWALTEGYTPYPGAGEGWGGNGVGDDLYSYGFDGLHLWTGHVARPVTSPGQHLLAPEDVISCCLDLSVPSISFRINGCPVQGVFESFNLDGLFFPVVSFSAGVKVRFLLGGRHGEFKFLPPPGYAPCHEAVLPRERLHLEPIKEYRREGPRGPHLVGPSRCLSHTDFVPCPVDTVQIVLPPHLERIREKLAENIHELWALTRIEQGWTYGPVRDDNKRLHPCLVDFHSLPEPERNYNLQMSGETLKTLLALGCHVGMADEKAEDNLKKTKLPKTYMMSNGYKPAPLDLSHVRLTPAQTTLVDRLAENGHNVWARDRVGQGWSYSAVQDIPARRNPRLVPYRLLDEATKRSNRDSLCQAVRTLLGYGYNIEPPDQEPSQVENQSRCDRVRIFRAEKSYTVQSGRWYFEFEAVTTGEMRVGWARPELRPDVELGADELAYVFNGHRGQRWHLGSEPFGRPWQPGDVVGCMIDLTENTIIFTLNGEVLMSDSGSETAFREIEIGDGFLPVCSLGPGQVGHLNLGQDVSSLRFFAICGLQEGFEPFAINMQRPVTTWFSKGLPQFEPVPLEHPHYEVSRVDGTVDTPPCLRLTHRTWGSQNSLVEMLFLRLSLPVQFHQHFRCTAGATPLAPPGLQPPAEDEARAAEPDPDYENLRRSAGGWSEAENGKEGTAKEGAPGGTPQAGGEAQPARAENEKDATTEKNKKRGFLFKAKKVAMMTQPPATPTLPRLPHDVVPADNRDDPEIILNTTTYYYSVRVFAGQEPSCVWAGWVTPDYHQHDMSFDLSKVRVVTVTMGDEQGNVHSSLKCSNCYMVWGGDFVSPGQQGRISHTDLVIGCLVDLATGLMTFTANGKESNTFFQVEPNTKLFPAVFVLPTHQNVIQFELGKQKNIMPLSAAMFQSERKNPAPQCPPRLEMQMLMPVSWSRMPNHFLQVETRRAGERLGWAVQCQEPLTMMALHIPEENRCMDILELSERLDLQRFHSHTLRLYRAVCALGNNRVAHALCSHVDQAQLLHALEDAHLPGPLRAGYYDLLISIHLESACRSRRSMLSEYIVPLTPETRAITLFPPGRSTENGHPRHGLPGVGVTTSLRPPHHFSPPCFVAALPAAGAAEAPARLSPAIPLEALRDKALRMLGEAVRDGGQHARDPVGGSVEFQFVPVLKLVSTLLVMGIFGDEDVKQILKMIEPEVFTEEEEEEDEEEEGEEEDEEEKEEDEEETAQEKEDEEKEEEEAAEGEKEEGLEEGLLQMKLPESVKLQMCHLLEYFCDQELQHRVESLAAFAERYVDKLQANQRSRYGLLIKAFSMTAAETARRTREFRSPPQEQINMLLQFKDGTDEEDCPLPEEIRQDLLDFHQDLLAHCGIQLDGEEEEPEEETTLGSRLMSLLEKVRLVKKKEEKPEEERSAEESKPRSLQELVSHMVVRWAQEDFVQSPELVRAMFSLLHRQYDGLGELLRALPRAYTISPSSVEDTMSLLECLGQIRSLLIVQMGPQEENLMIQSIGNIMNNKVFYQHPNLMRALGMHETVMEVMVNVLGGGESKEIRFPKMVTSCCRFLCYFCRISRQNQRSMFDHLSYLLENSGIGLGMQGSTPLDVAAASVIDNNELALALQEQDLEKVVSYLAGCGLQSCPMLVAKGYPDIGWNPCGGERYLDFLRFAVFVNGESVEENANVVVRLLIRKPECFGPALRGEGGSGLLAAIEEAIRISEDPARDGPGIRRDRRREHFGEEPPEENRVHLGHAIMSFYAALIDLLGRCAPEMHLIQAGKGEALRIRAILRSLVPLEDLVGIISLPLQIPTLGKDGALVQPKMSASFVPDHKASMVLFLDRVYGIENQDFLLHVLDVGFLPDMRAAASLDTATFSTTEMALALNRYLCLAVLPLITKCAPLFAGTEHRAIMVDSMLHTVYRLSRGRSLTKAQRDVIEDCLMSLCRYIRPSMLQHLLRRLVFDVPILNEFAKMPLKLLTNHYERCWKYYCLPTGWANFGVTSEEELHLTRKLFWGIFDSLAHKKYDPELYRMAMPCLCAIAGALPPDYVDASYSSKAEKKATVDAEGNFDPRPVETLNVIIPEKLDSFINKFAEYTHEKWAFDKIQNNWSYGENIDEELKTHPMLRPYKTFSEKDKEIYRWPIKESLKAMIAWEWTIEKAREGEEEKTEKKKTRKISQSAQTYDPREGYNPQPPDLSAVTLSRELQAMAEQLAENYHNTWGRKKKQELEAKGGGTHPLLVPYDTLTAKEKARDREKAQELLKFLQMNGYAVTRGLKDMELDSSSIEKRFAFGFLQQLLRWMDISQEFIAHLEAVVSSGRVEKSPHEQEIKFFAKILLPLINQYFTNHCLYFLSTPAKVLGSGGHASNKEKEMITSLFCKLAALVRHRVSLFGTDAPAVVNCLHILARSLDARTVMKSGPEIVKAGLRSFFESASEDIEKMVENLRLGKVSQARTQVKGVGQNLTYTTVALLPVLTTLFQHIAQHQFGDDVILDDVQVSCYRTLCSIYSLGTTKNTYVEKLRPALGECLARLAAAMPVAFLEPQLNEYNACSVYTTKSPRERAILGLPNSVEEMCPDIPVLERLMADIGGLAESGARYTEMPHVIEITLPMLCSYLPRWWERGPEAPPSALPAGAPPPCTAVTSDHLNSLLGNILRIIVNNLGIDEASWMKRLAVFAQPIVSRARPELLQSHFIPTIGRLRKRAGKVVSEEEQLRLEAKAEAQEGELLVRDEFSVLCRDLYALYPLLIRYVDNNRAQWLTEPNPSAEELFRMVGEIFIYWSKSHNFKREEQNFVVQNEINNMSFLTADNKSKMAKAGDIQSGGSDQERTKKKRRGDRYSVQTSLIVATLKKMLPIGLNMCAPTDQDLITLAKTRYALKDTDEEVREFLHNNLHLQGKVEGSPSLRWQMALYRGVPGREEDADDPEKIVRRVQEVSAVLYYLDQTEHPYKSKKAVWHKLLSKQRRRAVVACFRMTPLYNLPTHRACNMFLESYKAAWILTEDHSFEDRMIDDLSKAGEQEEEEEEVEEKKPDPLHQLVLHFSRTALTEKSKLDEDYLYMAYADIMAKSCHLEEGGENGEAEEEVEVSFEEKQMEKQRLLYQQARLHTRGAAEMVLQMISACKGETGAMVSSTLKLGISILNGGNAEVQQKMLDYLKDKKEVGFFQSIQALMQTCSVLDLNAFERQNKAEGLGMVNEDGTVINRQNGEKVMADDEFTQDLFRFLQLLCEGHNNDFQNYLRTQTGNTTTINIIICTVDYLLRLQESISDFYWYYSGKDVIEEQGKRNFSKAMSVAKQVFNSLTEYIQGPCTGNQQSLAHSRLWDAVVGFLHVFAHMMMKLAQDSSQIELLKELLDLQKDMVVMLLSLLEGNVVNGMIARQMVDMLVESSSNVEMILKFFDMFLKLKDIVGSEAFQDYVTDPRGLISKKDFQKAMDSQKQFSGPEIQFLLSCSEADENEMINCEEFANRFQEPARDIGFNVAVLLTNLSEHVPHDPRLHNFLELAESILEYFRPYLGRIEIMGASRRIERIYFEISETNRAQWEMPQVKESKRQFIFDVVNEGGEAEKMELFVSFCEDTIFEMQIAAQISEPEGEPETDEDEGAGAAEAGAEGAEEGAAGLEGTAATAAAGATARVVAAAGRALRGLSYRSLRRRVRRLRRLTAREAATAVAALLWAAVTRAGAAGAGAAAGALGLLWGSLFGGGLVEGAKKVTVTELLAGMPDPTSDEVHGEQPAGPGGDADGEGASEGAGDAAEGAGDEEEAVHEAGPGGADGAVAVTDGGPFRPEGAGGLGDMGDTTPAEPPTPEGSPILKRKLGVDGVEEELPPEPEPEPEPELEPEKADAENGEKEEVPEPTPEPPKKQAPPSPPPKKEEAGGEFWGELEVQRVKFLNYLSRNFYTLRFLALFLAFAINFILLFYKVSDSPPGEDDMEGSAAGDVSGAGSGGSSGWGLGAGEEAEGDEDENMVYYFLEESTGYMEPALRCLSLLHTLVAFLCIIGYNCLKVPLVIFKREKELARKLEFDGLYITEQPEDDDVKGQWDRLVLNTPSFPSNYWDKFVKRKVLDKHGDIYGRERIAELLGMDLATLEITAHNERKPNPPPGLLTWLMSIDVKYQIWKFGVIFTDNSFLYLGWYMVMSLLGHYNNFFFAAHLLDIAMGVKTLRTILSSVTHNGKQLVMTVGLLAVVVYLYTVVAFNFFRKFYNKSEDEDEPDMKCDDMMTCYLFHMYVGVRAGGGIGDEIEDPAGDEYELYRVVFDITFFFFVIVILLAIIQGLIIDAFGELRDQQEQVKEDMETKCFICGIGSDYFDTTPHGFETHTLEEHNLANYMFFLMYLINKDETEHTGQESYVWKMYQERCWDFFPAGDCFRKQYEDQLS	5038	P21817	H	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
395	NM_000527.5(LDLR):c.977C>G (p.Ser326Cys)	251581	CA10585235	NM_000527.5:c.977C>G, NC_000019.10:g.11110688C>G, CM000681.2:g.11110688C>G, NC_000019.9:g.11221364C>G, CM000681.1:g.11221364C>G, NC_000019.8:g.11082364C>G, NG_009060.1:g.26308C>G, LRG_274:g.26308C>G, ENST00000558518.6:c.977C>G, ENST00000252444.9:n.1231C>G, ENST00000455727.6:c.473C>G, ENST00000535915.5:c.854C>G, ENST00000545707.5:c.596C>G, ENST00000557933.5:c.977C>G, ENST00000558013.5:c.977C>G, ENST00000558518.5:c.977C>G, ENST00000560467.1:n.541-826C>G, NM_000527.4:c.977C>G, LRG_274t1:c.977C>G, NM_001195798.1:c.977C>G, NM_001195799.1:c.854C>G, NM_001195800.1:c.473C>G, NM_001195803.1:c.596C>G, XM_011528010.1:c.977C>G, XM_011528011.1:c.596C>G, XR_244074.2:n.1127C>G, XM_011528010.2:c.977C>G, XR_001753685.2:n.1094C>G, XR_001753686.2:n.1094C>G, NM_001195798.2:c.977C>G, NM_001195799.2:c.854C>G, NM_001195800.2:c.473C>G, NM_001195803.2:c.596C>G, NM_000527.5(LDLR):c.977C>G (p.Ser326Cys)	LDLR	hypercholesterolemia, familial	MONDO:0007750	Semidominant inheritance	Pathogenic	PS3, PP1_Strong, PM2, PP3, PP4, PS4_Supporting	BS3, BS1, BS4, BP4, BA1	PP1_strong: Variant segregates with FH phenotype in at least 28 informative meiosis (minimum 2) from 9 families from different labs (Laboratory of Genetics and Molecular Cardiology). PS3: PMID: 32015373. Level 1 assay. Heterologous cells (CHO), FACS assays. Normal cell surface LDLR (90%), 50% binding and 48% uptake.PS4_supporting: variant meets PM2 and is identified in 1 index case who fulfills SB criteria of definite FH from Molecular Genetics Laboratory (Centre for Cardiovascular Surgery and Transplantation) and 1 index case with DLCN >6 from PMID 30270055, Corral et al., 2018 (Argentina) so PS4_Supporting is met PM2: No population data was found for this variant in gnomAD (gnomAD version 2.1.1). PP3: REVEL = 0.927. PP4: Variant meets PM2 and is identified in 1 index case who fulfils SB for FH from different labs (Molecular Genetics Laboratory (Centre for Cardiovascular Surgery and Transplantation) and Laboratory of Genetics and Molecular Cardiology).		Familial Hypercholesterolemia VCEP	https://clinicalgenome.org/docs/clingen-familial-hypercholesterolemia-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1-2/	2022-04-05	2022-04-05	False	https://erepo.genome.network/evrepo/ui/classification/CA10585235/MONDO:0007750/013	68761f1c-ea68-4c34-8226-2b2de6723855	p.Ser326Cys	Ser	326	Cys	MGPWGWKLRWTVALLLAAAGTAVGDRCERNEFQCQDGKCISYKWVCDGSAECQDGSDESQETCLSVTCKSGDFSCGGRVNRCIPQFWRCDGQVDCDNGSDEQGCPPKTCSQDEFRCHDGKCISRQFVCDSDRDCLDGSDEASCPVLTCGPASFQCNSSTCIPQLWACDNDPDCEDGSDEWPQRCRGLYVFQGDSSPCSAFEFHCLSGECIHSSWRCDGGPDCKDKSDEENCAVATCRPDEFQCSDGNCIHGSRQCDREYDCKDMSDEVGCVNVTLCEGPNKFKCHSGECITLDKVCNMARDCRDWSDEPIKECGTNECLDNNGGCSHVCNDLKIGYECLCPDGFQLVAQRRCEDIDECQDPDTCSQLCVNLEGGYKCQCEEGFQLDPHTKACKAVGSIAYLFFTNRHEVRKMTLDRSEYTSLIPNLRNVVALDTEVASNRIYWSDLSQRMICSTQLDRAHGVSSYDTVISRDIQAPDGLAVDWIHSNIYWTDSVLGTVSVADTKGVKRKTLFRENGSKPRAIVVDPVHGFMYWTDWGTPAKIKKGGLNGVDIYSLVTENIQWPNGITLDLLSGRLYWVDSKLHSISSIDVNGGNRKTILEDEKRLAHPFSLAVFEDKVFWTDIINEAIFSANRLTGSDVNLLAENLLSPEDMVLFHNLTQPRGVNWCERTTLSNGGCQYLCLPAPQINPHSPKFTCACPDGMLLARDMRSCLTEAEAAVATQETSTVRLKVSSTAVRTQHTTTRPVPDTSRLPGATPGLTTVEIVTMSHQALGDVAGRGNEKKPSSVRALSIVLPIVLLVFLCLGVFLLWKNWRLKNINSINFDNPVYQKTTEDEVHICHNQDGYSYPSRQMVSLEDDVA	860	P01130	C	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [325], 'DISULFID_gain_score': array([0.84989369]), 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [401], 'STRAND_gain_score': array([0.02495188]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [24, 274, 275, 276], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.00721592, -0.11495173, -0.15372783, -0.10857838]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [74, 168, 181, 228, 232, 318], 'ZN_FING_gain': [], 'ZN_FING_loss_score': array([-0.00149238, -0.00744879, -0.00912976, -0.00764227, -0.00805187,
       -0.02166271])}"
396	NM_000527.5(LDLR):c.910G>A (p.Asp304Asn)	3692	CA023792	NM_000527.5:c.910G>A, NC_000019.10:g.11107484G>A, CM000681.2:g.11107484G>A, NC_000019.9:g.11218160G>A, CM000681.1:g.11218160G>A, NC_000019.8:g.11079160G>A, NG_009060.1:g.23104G>A, LRG_274:g.23104G>A, ENST00000558518.6:c.910G>A, ENST00000252444.9:n.1164G>A, ENST00000455727.6:c.406G>A, ENST00000535915.5:c.787G>A, ENST00000545707.5:c.529G>A, ENST00000557933.5:c.910G>A, ENST00000558013.5:c.910G>A, ENST00000558518.5:c.910G>A, ENST00000558528.1:n.425G>A, ENST00000560467.1:n.510G>A, NM_000527.4:c.910G>A, LRG_274t1:c.910G>A, NM_001195798.1:c.910G>A, NM_001195799.1:c.787G>A, NM_001195800.1:c.406G>A, NM_001195803.1:c.529G>A, XM_011528010.1:c.910G>A, XM_011528011.1:c.529G>A, XR_244074.2:n.1060G>A, XM_011528010.2:c.910G>A, XR_001753685.2:n.1027G>A, XR_001753686.2:n.1027G>A, NM_001195798.2:c.910G>A, NM_001195799.2:c.787G>A, NM_001195800.2:c.406G>A, NM_001195803.2:c.529G>A, NM_000527.5(LDLR):c.910G>A (p.Asp304Asn)	LDLR	hypercholesterolemia, familial	MONDO:0007750	Semidominant inheritance	Pathogenic	PS4, PP1_Strong, PM3, PM2, PP3, PP4, PS3_Moderate	PS1, PS2, PM5, PM4, PM1, BS1, BS3, BS4, BP7, PVS1, PM6, BS2, BA1, BP4, BP2	The NM_000527.5(LDLR):c.910G>A (p.Asp304Asn) variant is classified as Pathogenic for Familial Hypercholesterolemia by applying evidence codes PM2, PP3, PS3_moderate, PS4, PP1_strong, PM3 and PP4 as defined by the ClinGen Familial Hypercholesterolemia Expert Panel LDLR-specific variant curation guidelines (https://doi.org/10.1101/2021.03.17.21252755). The supporting evidence is as follows:PM2 - PopMax MAF = 0.0001203 (0.01203%) in African/African American genomes (gnomAD v2.1.1), so PM2 is Met.PP3 - REVEL = 0.883.It is above 0.75, so PP3 is Met.PS3_moderate - 2 Level 2 assays performed by different labs:PMID 2088165:Homozygous patient cells, 125I-LDL assays - result - 5-15% LDLR activity.PMID 6438436:Homozygous patient cells, 125I-LDL assays - result - 5-10% LDLR activity.2 Level 3 assays performed by different labs:PMID 4061492:Heterozygous patient cells, 125I-LDL assays - result - 20-30% LDLR activityPMID 6438436:Heterozygous patient cells, 125I-LDL assays - result - 25-50% LDLR activity---- all functional studies are consistent with damaging effect, so PS3_Moderate is Met.PS4 - Variant meets PM2 and is identified in at least 14 unrelated index cases: 4 index cases who fulfill Simon-Broome criteria for FH from Molecular Genetics Laboratory (Centre for Cardiovascular Surgery and Transplantation); 7 unrelated index cases who fulfill Simon-Broome criteria for FH from Malaysia (Al-Khateeb et al, 2011) (PMID: 21418584); 1 index case who fulfills modified Simon-Broome criteria for FH (pretreatment   LDL-C  >95th percentile for age and sex, with (1)  tendon  xanthoma  (proband  or  first-degree  relative) or (2) either first-degree relative with premature CHD (<55 years of age in men or 65 years of age in women) or pretreatment LDL-C >95th  percentile  for  age  and  sex) from Dallas, TX, USA (Ahmad et al, 2011) (PMID: 23064986); 1 index case who fulfils Simon-Broome criteria from MRC Clinical Sciences Centre, London UK (Tosi et al, 2007)(PMID: 17094996); and 1 index case with clinical diagnosis of FH (based on (1) a plasma LDL cholesterol concentration  above  the  95th  percentile  for  age  and  sex and (2) the presence of xanthoma or coronary heart disease in the proband or at least one first degree relative with type IIa hypercholesterolemia, xanthoma, or CVD) from France (Amsellem et al, 2002) (PMID: 12436241), so PS4 is Met.PP1_strong - Variant segregates with FH phenotype in at least 6 informative meiosis from 3 families from Molecular Genetics Laboratory (Centre for Cardiovascular Surgery and Transplantation): 6  affected family members have the variant, so PP1_Strong is Met.PM3 - Variant meets PM2 and is identified in an index case from Molecular Genetics Laboratory (Centre for Cardiovascular Surgery and Transplantation) with homozygous FH phenotype (14.9 mmol/L) and LDLR c.761A>C/p.(Gln254Pro), classified as Likely pathogenic by these guidelines, in trans, so PM3 is Met.PP4 - Variant meets PM2 and is identified in at least 14 unrelated index cases as described in PS4, PP4 is Met.		Familial Hypercholesterolemia VCEP	https://clinicalgenome.org/docs/clingen-familial-hypercholesterolemia-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1-2/	2021-12-17	2022-04-05	False	https://erepo.genome.network/evrepo/ui/classification/CA023792/MONDO:0007750/013	586da900-0f67-479c-89aa-50f096de6db6	p.Asp304Asn	Asp	304	Asn	MGPWGWKLRWTVALLLAAAGTAVGDRCERNEFQCQDGKCISYKWVCDGSAECQDGSDESQETCLSVTCKSGDFSCGGRVNRCIPQFWRCDGQVDCDNGSDEQGCPPKTCSQDEFRCHDGKCISRQFVCDSDRDCLDGSDEASCPVLTCGPASFQCNSSTCIPQLWACDNDPDCEDGSDEWPQRCRGLYVFQGDSSPCSAFEFHCLSGECIHSSWRCDGGPDCKDKSDEENCAVATCRPDEFQCSDGNCIHGSRQCDREYDCKDMSDEVGCVNVTLCEGPNKFKCHSGECITLDKVCNMARDCRDWSDEPIKECGTNECLDNNGGCSHVCNDLKIGYECLCPDGFQLVAQRRCEDIDECQDPDTCSQLCVNLEGGYKCQCEEGFQLDPHTKACKAVGSIAYLFFTNRHEVRKMTLDRSEYTSLIPNLRNVVALDTEVASNRIYWSDLSQRMICSTQLDRAHGVSSYDTVISRDIQAPDGLAVDWIHSNIYWTDSVLGTVSVADTKGVKRKTLFRENGSKPRAIVVDPVHGFMYWTDWGTPAKIKKGGLNGVDIYSLVTENIQWPNGITLDLLSGRLYWVDSKLHSISSIDVNGGNRKTILEDEKRLAHPFSLAVFEDKVFWTDIINEAIFSANRLTGSDVNLLAENLLSPEDMVLFHNLTQPRGVNWCERTTLSNGGCQYLCLPAPQINPHSPKFTCACPDGMLLARDMRSCLTEAEAAVATQETSTVRLKVSSTAVRTQHTTTRPVPDTSRLPGATPGLTTVEIVTMSHQALGDVAGRGNEKKPSSVRALSIVLPIVLLVFLCLGVFLLWKNWRLKNINSINFDNPVYQKTTEDEVHICHNQDGYSYPSRQMVSLEDDVA	860	P01130	N	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [24, 274, 275, 276], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.00401896, -0.11686265, -0.15378386, -0.12247479]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [181], 'ZN_FING_gain': [], 'ZN_FING_loss_score': array([-0.00299096])}
397	NM_000527.5(LDLR):c.718G>A (p.Glu240Lys)	200920	CA023755	NM_000527.5:c.718G>A, NC_000019.10:g.11106588G>A, CM000681.2:g.11106588G>A, NC_000019.9:g.11217264G>A, CM000681.1:g.11217264G>A, NC_000019.8:g.11078264G>A, NG_009060.1:g.22208G>A, LRG_274:g.22208G>A, ENST00000558518.6:c.718G>A, ENST00000252444.9:n.972G>A, ENST00000455727.6:c.314-804G>A, ENST00000535915.5:c.595G>A, ENST00000545707.5:c.337G>A, ENST00000557933.5:c.718G>A, ENST00000558013.5:c.718G>A, ENST00000558518.5:c.718G>A, ENST00000558528.1:n.233G>A, ENST00000560467.1:n.318G>A, NM_000527.4:c.718G>A, LRG_274t1:c.718G>A, NM_001195798.1:c.718G>A, NM_001195799.1:c.595G>A, NM_001195800.1:c.314-804G>A, NM_001195803.1:c.337G>A, XM_011528010.1:c.718G>A, XM_011528011.1:c.337G>A, XR_244074.2:n.868G>A, XM_011528010.2:c.718G>A, XR_001753685.2:n.835G>A, XR_001753686.2:n.835G>A, NM_001195798.2:c.718G>A, NM_001195799.2:c.595G>A, NM_001195800.2:c.314-804G>A, NM_001195803.2:c.337G>A, NM_000527.5(LDLR):c.718G>A (p.Glu240Lys)	LDLR	hypercholesterolemia, familial	MONDO:0007750	Semidominant inheritance	Pathogenic	PS4, PM3, PM2, PP3, PP4	PS1, PS3, PS2, PM5, PM4, PM1, BS1, BS3, BS4, BP7, PM6, PVS1, BS2, PP1, BA1, BP4, BP2	The NM_000527.5(LDLR):c.718G>A (p.Glu240Lys) variant is classified as U Pathogenic for Familial Hypercholesterolemia by applying evidence codes PP3, PM2, PS4, PM3, PP4 as defined by the ClinGen Familial Hypercholesterolemia Expert Panel LDLR-specific variant curation guidelines (https://doi.org/10.1016/j.gim.2021.09.012). The supporting evidence is as follows:PP3 - REVEL = 0.865.It is above 0.75, so PP3 is Met.PM2 - PopMax MAF = 0.00005418 (0.005418%) in European (non-Finnish) exomes+genomes (gnomAD v2.1.1), so PM2 is Met.PS4 - Variant meets PM2 and is identified in at least 11 unrelated index cases: 2 index cases with Simon Broome possible from Centre de Génétique Moléculaire et Chromosomique, Unité de génétique de l'Obésité et des Dyslipidémies (APHP.Sorbonne Université, Hôpital de la Pitié-Salpêtrière); 1 index case with DLCN>6 from Cardiovascular Genetics Laboratory (PathWest Laboratory Medicine WA); 2 index cases with DLCN>6 from Robarts Research Institute; 2 index cases with DLCN>6 from Color Health, Inc; 2 index cases fulfilling the following criteria: children with a) TC >200 mg/dl or LDL >120 mg/dl and b) presence of primary hypercholesterolemia in 1st degree relatives with autosomal dominant mode of inheritance or c) family history of pCHD or d) presence of xanthomas in proband or in parents, from Greece (PMID: 25463123); at least 1 index case with Simon Broome criteria from China (PMID: 28235710); 1 index case with Definite FH (LDL >13 mmol/l and presence of xanthomas and hypercholesterolemia in both parents) from Italy (PMID: 32977124), so PS4 is Met.PM3 - Variant meets PM2 and is identified in an italian index case with homozygous FH phenotype (LDL>13 mmol/l) with another LDLR variant, in trans (PMID: 32977124). In PMID: 28965616 is identified an italian index case (phenotype not reported) with LDLR variant c.304C>T (p.Gln102*), classified as Pathogenic by these guidelines, but cannot determine if the variants are in trans (PMID: 28965616). Assuming that is the same homozygous index case (same lab), PM3 is Met.PP4 - Variant meets PM2 and is identified in at least 11 unrelated index cases as reported above, so PP4 is Met.		Familial Hypercholesterolemia VCEP	https://clinicalgenome.org/docs/clingen-familial-hypercholesterolemia-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1-2/	2022-02-14	2022-07-12	False	https://erepo.genome.network/evrepo/ui/classification/CA023755/MONDO:0007750/013	54c170e0-5a9b-4b98-b1d4-806c3082ce85	p.Glu240Lys	Glu	240	Lys	MGPWGWKLRWTVALLLAAAGTAVGDRCERNEFQCQDGKCISYKWVCDGSAECQDGSDESQETCLSVTCKSGDFSCGGRVNRCIPQFWRCDGQVDCDNGSDEQGCPPKTCSQDEFRCHDGKCISRQFVCDSDRDCLDGSDEASCPVLTCGPASFQCNSSTCIPQLWACDNDPDCEDGSDEWPQRCRGLYVFQGDSSPCSAFEFHCLSGECIHSSWRCDGGPDCKDKSDEENCAVATCRPDEFQCSDGNCIHGSRQCDREYDCKDMSDEVGCVNVTLCEGPNKFKCHSGECITLDKVCNMARDCRDWSDEPIKECGTNECLDNNGGCSHVCNDLKIGYECLCPDGFQLVAQRRCEDIDECQDPDTCSQLCVNLEGGYKCQCEEGFQLDPHTKACKAVGSIAYLFFTNRHEVRKMTLDRSEYTSLIPNLRNVVALDTEVASNRIYWSDLSQRMICSTQLDRAHGVSSYDTVISRDIQAPDGLAVDWIHSNIYWTDSVLGTVSVADTKGVKRKTLFRENGSKPRAIVVDPVHGFMYWTDWGTPAKIKKGGLNGVDIYSLVTENIQWPNGITLDLLSGRLYWVDSKLHSISSIDVNGGNRKTILEDEKRLAHPFSLAVFEDKVFWTDIINEAIFSANRLTGSDVNLLAENLLSPEDMVLFHNLTQPRGVNWCERTTLSNGGCQYLCLPAPQINPHSPKFTCACPDGMLLARDMRSCLTEAEAAVATQETSTVRLKVSSTAVRTQHTTTRPVPDTSRLPGATPGLTTVEIVTMSHQALGDVAGRGNEKKPSSVRALSIVLPIVLLVFLCLGVFLLWKNWRLKNINSINFDNPVYQKTTEDEVHICHNQDGYSYPSRQMVSLEDDVA	860	P01130	K	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
398	NM_000545.8(HNF1A):c.335C>T (p.Pro112Leu)	14942	CA124475	NM_000545.8:c.335C>T, NC_000012.12:g.120988841C>T, CM000674.2:g.120988841C>T, NC_000012.11:g.121426644C>T, CM000674.1:g.121426644C>T, NC_000012.10:g.119911027C>T, NG_011731.2:g.15096C>T, LRG_522:g.15096C>T, ENST00000257555.11:c.335C>T, ENST00000257555.10:c.335C>T, ENST00000400024.6:c.335C>T, ENST00000402929.5:n.470C>T, ENST00000535955.5:n.43-8650C>T, ENST00000538626.2:n.191-8650C>T, ENST00000538646.5:c.335C>T, ENST00000540108.1:c.327-4679C>T, ENST00000541395.5:c.335C>T, ENST00000541924.5:c.335C>T, ENST00000543427.5:c.335C>T, ENST00000544413.2:c.335C>T, ENST00000544574.5:c.73-7776C>T, ENST00000560968.5:n.478C>T, ENST00000615446.4:c.-257-7421C>T, ENST00000617366.4:c.335C>T, NM_000545.5:c.335C>T, LRG_522t1:c.335C>T, NM_000545.6:c.335C>T, NM_001306179.1:c.335C>T, XM_005253931.2:c.335C>T, XM_024449168.1:c.335C>T, NM_001306179.2:c.335C>T, NM_000545.8(HNF1A):c.335C>T (p.Pro112Leu)	HNF1A	monogenic diabetes	MONDO:0015967	Autosomal dominant inheritance	Pathogenic	PM1, PS3, PS4_Moderate, PP1_Strong, PP4_Moderate, PP3, PM2_Supporting		The c.335C>T variant in the HNF1 homeobox A gene, HNF1A, causes an amino acid change of proline to leucine at codon 112 (p.(Pro112Leu)) of NM_000545.8.  This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.966, which is greater than the MDEP VCEP threshold of 0.70 (PP3) and is absent from gnomAD v2.1.1 (PM2_Supporting). Additionally, this variant is located within a conserved region of the DNA binding domain (codons 107-174 and 201-280) of HNF1A, which is defined as critical for the protein’s function by the ClinGen MDEP (PM1_Supporting). This variant was identified in six unrelated individuals with non- autoimmune and non-absolute/near-absolute insulin-deficient diabetes (PS4_Moderate; internal lab contributors). This variant was identified in two individuals with a clinical history highly specific for HNF1A-MODY (MODY probability calculator result >50%, negative genetic testing for HNF4A, and response to low dose sulfonylureas) (PP4_Moderate; internal lab contributors). A luciferase assay meeting the ClinGen MDEP quality control specifications demonstrated that the p.Pro112Leu protein has transactivation activity below 40% of wildtype, indicating that this variant impacts protein function (PS3_Moderate, PMID: 32910913). Lastly, this variant segregated with diabetes, with 11 informative meioses in six families with MODY (PP1_Strong; internal lab contributors). In summary, c.335C>T meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.1, approved 9/30/21): PP3, PM1_Supporting, PM2_Supporting, PP4_Moderate, PS4_Moderate,PS3_Moderate, PP1_Strong.		Monogenic Diabetes VCEP		2022-04-08	2022-07-12	False	https://erepo.genome.network/evrepo/ui/classification/CA124475/MONDO:0015967/017	53a9fce0-d78f-477d-9a67-dfcbda28884c	p.Pro112Leu	Pro	112	Leu	MVSKLSQLQTELLAALLESGLSKEALIQALGEPGPYLLAGEGPLDKGESCGGGRGELAELPNGLGETRGSEDETDDDGEDFTPPILKELENLSPEEAAHQKAVVETLLQEDPWRVAKMVKSYLQQHNIPQREVVDTTGLNQSHLSQHLNKGTPMKTQKRAALYTWYVRKQREVAQQFTHAGQGGLIEEPTGDELPTKKGRRNRFKWGPASQQILFQAYERQKNPSKEERETLVEECNRAECIQRGVSPSQAQGLGSNLVTEVRVYNWFANRRKEEAFRHKLAMDTYSGPPPGPGPGPALPAHSSPGLPPPALSPSKVHGVRYGQPATSETAEVPSSSGGPLVTVSTPLHQVSPTGLEPSHSLLSTEAKLVSAAGGPLPPVSTLTALHSLEQTSPGLNQQPQNLIMASLPGVMTIGPGEPASLGPTFTNTGASTLVIGLASTQAQSVPVINSMGSSLTTLQPVQFSQPLHPSYQQPLMPPVQSHVTQSPFMATMAQLQSPHALYSHKPEVAQYTHTGLLPQTMLITDTTNLSALASLTPTKQVFTSDTEASSESGLHTPASQATTLHVPSQDPAGIQHLQPAHRLSASPTVSSSSLVLYQSSDSSNGQSHLLPSNHSVIETFISTQMASSSQ	631	P20823	L	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [97, 106], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.02998102, -0.17315185]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [77], 'COMPBIAS_gain': [], 'COMPBIAS_loss_score': array([-0.01918638]), 'DOMAIN_loss': [5, 33, 34, 81, 179, 180], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.11260974, -0.08382201, -0.09667331, -0.0287624 , -0.31409246,
       -0.2393918 ]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
399	NM_000545.8(HNF1A):c.434C>T (p.Ser145Phe)	447489	CA386959990	NM_000545.8:c.434C>T, NC_000012.12:g.120988940C>T, CM000674.2:g.120988940C>T, NC_000012.11:g.121426743C>T, CM000674.1:g.121426743C>T, NC_000012.10:g.119911126C>T, NG_011731.2:g.15195C>T, LRG_522:g.15195C>T, ENST00000257555.11:c.434C>T, ENST00000257555.10:c.434C>T, ENST00000400024.6:c.434C>T, ENST00000402929.5:n.569C>T, ENST00000535955.5:n.43-8551C>T, ENST00000538626.2:n.191-8551C>T, ENST00000538646.5:c.434C>T, ENST00000540108.1:c.327-4580C>T, ENST00000541395.5:c.434C>T, ENST00000541924.5:c.434C>T, ENST00000543427.5:c.434C>T, ENST00000544413.2:c.434C>T, ENST00000544574.5:c.73-7677C>T, ENST00000560968.5:n.577C>T, ENST00000615446.4:c.-257-7322C>T, ENST00000617366.4:c.434C>T, NM_000545.5:c.434C>T, LRG_522t1:c.434C>T, NM_000545.6:c.434C>T, NM_001306179.1:c.434C>T, XM_005253931.2:c.434C>T, XM_024449168.1:c.434C>T, NM_001306179.2:c.434C>T, NM_000545.8(HNF1A):c.434C>T (p.Ser145Phe)	HNF1A	monogenic diabetes	MONDO:0015967	Autosomal dominant inheritance	Pathogenic	PM1, PS4_Moderate, PP1_Strong, PP3, PM2_Supporting	PM5, PP4	The c.434C>T variant in the HNF1 homeobox A gene, HNF1A, causes an amino acid change of serine to phenylalanine at codon 145 (p.(Ser145Phe)) of NM_000545.8. This variant was identified in six unrelated individuals with non- autoimmune and non-absolute/near-absolute insulin-deficient diabetes (PS4_Moderate; PMID: 28701371, internal lab contributors). This variant segregated with diabetes, with 4 informative meioses in 2 families with MODY (PP1_Strong; PMID: 28701371, internal lab contributors). This variant resides in an amino acid within the HNF1α DNA binding domain that directly binds DNA, which is defined as critical for the protein’s function by the ClinGen MDEP (PM1). This variant is absent from gnomAD v2.1.1 (PM2_Supporting). This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.989, which is greater than the MDEP threshold of 0.70 (PP3).  Another missense variant, c.433T>C (p.(Ser145Pro)), has been classified as a VUS by the ClinGen MDEP; therefore, PM5 will not be applied.  This variant was identified in at least six individuals with diabetes; however, the MODY probability is unable to be calculated due to lack of clinical information, and PP4 cannot be applied (PMID:28701371, internal lab contributors).  In summary, c.434C>T meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.1, approved September 30, 2021): PP3, PM1, PM2_Supporting, PS4_Moderate, PP1_Strong.		Monogenic Diabetes VCEP		2022-04-08	2022-07-12	False	https://erepo.genome.network/evrepo/ui/classification/CA386959990/MONDO:0015967/017	e182ccbb-ffe1-4d68-9dfa-81ce551eed87	p.Ser145Phe	Ser	145	Phe	MVSKLSQLQTELLAALLESGLSKEALIQALGEPGPYLLAGEGPLDKGESCGGGRGELAELPNGLGETRGSEDETDDDGEDFTPPILKELENLSPEEAAHQKAVVETLLQEDPWRVAKMVKSYLQQHNIPQREVVDTTGLNQSHLSQHLNKGTPMKTQKRAALYTWYVRKQREVAQQFTHAGQGGLIEEPTGDELPTKKGRRNRFKWGPASQQILFQAYERQKNPSKEERETLVEECNRAECIQRGVSPSQAQGLGSNLVTEVRVYNWFANRRKEEAFRHKLAMDTYSGPPPGPGPGPALPAHSSPGLPPPALSPSKVHGVRYGQPATSETAEVPSSSGGPLVTVSTPLHQVSPTGLEPSHSLLSTEAKLVSAAGGPLPPVSTLTALHSLEQTSPGLNQQPQNLIMASLPGVMTIGPGEPASLGPTFTNTGASTLVIGLASTQAQSVPVINSMGSSLTTLQPVQFSQPLHPSYQQPLMPPVQSHVTQSPFMATMAQLQSPHALYSHKPEVAQYTHTGLLPQTMLITDTTNLSALASLTPTKQVFTSDTEASSESGLHTPASQATTLHVPSQDPAGIQHLQPAHRLSASPTVSSSSLVLYQSSDSSNGQSHLLPSNHSVIETFISTQMASSSQ	631	P20823	F	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [230], 'DNA_BIND_gain': [], 'DNA_BIND_loss_score': array([-0.03916985]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [111, 171], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.06962848, -0.01372755]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [77], 'COMPBIAS_gain': [], 'COMPBIAS_loss_score': array([-0.00875604]), 'DOMAIN_loss': [5, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 81, 82, 83, 84, 85], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.30745727, -0.33814383, -0.33459878, -0.32953143, -0.34904087,
       -0.32962972, -0.38940716, -0.3417595 , -0.32870537, -0.33484298,
       -0.31899548, -0.36896682, -0.35380876, -0.34844917, -0.31003577,
       -0.31665856, -0.34592551, -0.33799255, -0.32345557, -0.29451108,
       -0.296004  , -0.30403829, -0.29154927, -0.28887612, -0.31229091,
       -0.32004052, -0.30925572, -0.2840783 , -0.29201758, -0.19623345,
       -0.18568951, -0.18659943, -0.20100045, -0.19956928]), 'REGION_loss': [179, 180, 181], 'REGION_gain': [], 'REGION_loss_score': array([-0.05956018, -0.0652023 , -0.05982757]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
400	NM_000545.5(HNF1A):c.598C>T (p.Arg200Trp)	36824	CA214311	NC_000012.12:g.120993591C>T, CM000674.2:g.120993591C>T, NC_000012.11:g.121431394C>T, CM000674.1:g.121431394C>T, NC_000012.10:g.119915777C>T, NG_011731.2:g.19846C>T, LRG_522:g.19846C>T, ENST00000257555.11:c.598C>T, ENST00000257555.10:c.598C>T, ENST00000400024.6:c.598C>T, ENST00000402929.5:n.733C>T, ENST00000535955.5:n.43-3900C>T, ENST00000538626.2:n.191-3900C>T, ENST00000538646.5:c.527-573C>T, ENST00000540108.1:c.*38C>T, ENST00000541395.5:c.598C>T, ENST00000541924.5:c.598C>T, ENST00000543427.5:c.598C>T, ENST00000544413.2:c.598C>T, ENST00000544574.5:c.73-3026C>T, ENST00000560968.5:n.741C>T, ENST00000615446.4:c.-257-2671C>T, ENST00000617366.4:c.586+12C>T, NM_000545.5:c.598C>T, LRG_522t1:c.598C>T, NM_000545.6:c.598C>T, NM_001306179.1:c.598C>T, XM_005253931.2:c.598C>T, XM_024449168.1:c.598C>T, NM_000545.8:c.598C>T, NM_001306179.2:c.598C>T, NM_000545.5(HNF1A):c.598C>T (p.Arg200Trp)	HNF1A	monogenic diabetes	MONDO:0015967	Autosomal dominant inheritance	Pathogenic	PM5, PS4, PP1_Strong, PP4_Moderate, PP3, PM2_Supporting		The c.598C>T variant in the HNF1 homeobox A gene, HNF1A, causes an amino acid change of arginine to tryptophan at codon 200 (p.(Arg200Trp)) of NM_000545.8. This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.775, which is greater than the MDEP VCEP threshold of 0.70 (PP3) and is absent from gnomAD v2.1.1 (PM2_Supporting).  Another missense variant, c.599G>A, p.(Arg200Gln), has been interpreted as pathogenic by the ClinGen MDEP, and p.Arg200Trp has a greater Grantham distance (PM5). This variant was identified in an individual with a clinical history highly specific for HNF1A-MODY (MODY probability calculator result >50%, negative genetic testing for HNF4A, and negative autoantibodies) (PP4_Moderate; PMID: 32238361).  This variant was identified in at least ten unrelated individuals with non- autoimmune and non-absolute/near-absolute insulin-deficient diabetes (PS4; PMIDs: 17440016, 9754819, 29927023, 32238361; internal lab contributors). Lastly, this variant segregated with diabetes, with five informative meioses in five  families with MODY (PP1_Strong; internal lab contributors). In summary, c.598C>T meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.1, approved 9/30/2021): PP1_Strong, PM2_Supporting, PP3, PS4, PP4_Moderate, PM5.		Monogenic Diabetes VCEP		2022-04-10	2022-07-12	False	https://erepo.genome.network/evrepo/ui/classification/CA214311/MONDO:0015967/017	12591884-428f-498d-95c2-6e7b98985cdf	p.Arg200Trp	Arg	200	Trp	MVSKLSQLQTELLAALLESGLSKEALIQALGEPGPYLLAGEGPLDKGESCGGGRGELAELPNGLGETRGSEDETDDDGEDFTPPILKELENLSPEEAAHQKAVVETLLQEDPWRVAKMVKSYLQQHNIPQREVVDTTGLNQSHLSQHLNKGTPMKTQKRAALYTWYVRKQREVAQQFTHAGQGGLIEEPTGDELPTKKGRRNRFKWGPASQQILFQAYERQKNPSKEERETLVEECNRAECIQRGVSPSQAQGLGSNLVTEVRVYNWFANRRKEEAFRHKLAMDTYSGPPPGPGPGPALPAHSSPGLPPPALSPSKVHGVRYGQPATSETAEVPSSSGGPLVTVSTPLHQVSPTGLEPSHSLLSTEAKLVSAAGGPLPPVSTLTALHSLEQTSPGLNQQPQNLIMASLPGVMTIGPGEPASLGPTFTNTGASTLVIGLASTQAQSVPVINSMGSSLTTLQPVQFSQPLHPSYQQPLMPPVQSHVTQSPFMATMAQLQSPHALYSHKPEVAQYTHTGLLPQTMLITDTTNLSALASLTPTKQVFTSDTEASSESGLHTPASQATTLHVPSQDPAGIQHLQPAHRLSASPTVSSSSLVLYQSSDSSNGQSHLLPSNHSVIETFISTQMASSSQ	631	P20823	W	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [228, 230], 'DNA_BIND_gain': [], 'DNA_BIND_loss_score': array([-0.10966426, -0.08262634]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [94, 96, 97, 106, 111, 154, 171], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.05142099, -0.04999906, -0.04744202, -0.05079216, -0.03612113,
       -0.09490907, -0.05423492]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [77], 'COMPBIAS_gain': [], 'COMPBIAS_loss_score': array([-0.02829409]), 'DOMAIN_loss': [], 'DOMAIN_gain': [6, 35, 36], 'DOMAIN_gain_score': array([0.02401149, 0.07132995, 0.08692342]), 'REGION_loss': [179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201], 'REGION_gain': [], 'REGION_loss_score': array([-0.3914184 , -0.38138545, -0.41291821, -0.49371904, -0.54700196,
       -0.59195852, -0.56003976, -0.58746302, -0.59854448, -0.60357106,
       -0.57486808, -0.52872026, -0.55899823, -0.58071554, -0.66132236,
       -0.65175617, -0.6686812 , -0.63336223, -0.6426025 , -0.725061  ,
       -0.70820737, -0.6882695 , -0.64076477]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
401	NM_000545.8(HNF1A):c.599G>A (p.Arg200Gln)	381588	CA16606474	NM_000545.8:c.599G>A, NC_000012.12:g.120993592G>A, CM000674.2:g.120993592G>A, NC_000012.11:g.121431395G>A, CM000674.1:g.121431395G>A, NC_000012.10:g.119915778G>A, NG_011731.2:g.19847G>A, LRG_522:g.19847G>A, ENST00000257555.11:c.599G>A, ENST00000257555.10:c.599G>A, ENST00000400024.6:c.599G>A, ENST00000402929.5:n.734G>A, ENST00000535955.5:n.43-3899G>A, ENST00000538626.2:n.191-3899G>A, ENST00000538646.5:c.527-572G>A, ENST00000540108.1:c.*39G>A, ENST00000541395.5:c.599G>A, ENST00000541924.5:c.599G>A, ENST00000543427.5:c.599G>A, ENST00000544413.2:c.599G>A, ENST00000544574.5:c.73-3025G>A, ENST00000560968.5:n.742G>A, ENST00000615446.4:c.-257-2670G>A, ENST00000617366.4:c.586+13G>A, NM_000545.5:c.599G>A, LRG_522t1:c.599G>A, NM_000545.6:c.599G>A, NM_001306179.1:c.599G>A, XM_005253931.2:c.599G>A, XM_024449168.1:c.599G>A, NM_001306179.2:c.599G>A, NM_000545.8(HNF1A):c.599G>A (p.Arg200Gln)	HNF1A	monogenic diabetes	MONDO:0015967	Autosomal dominant inheritance	Pathogenic	PS4, PP1_Strong, PS3_Supporting, PP4_Moderate, PP3, PM2_Supporting	PM5	The c.599G>A variant in the HNF1 homeobox A gene, HNF1A, causes an amino acid change of arginine to glutamine at codon 200 (p.(Arg200Gln)) of transcript, e.g. NM_000545.8. This variant segregated with diabetes, with 11 informative meioses in six families with MODY (PP1_Strong; internal lab contributors). Additionally, this variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.926, which is greater than the MDEP VCEP threshold of 0.70 (PP3) and is absent from gnomAD v2.1.1 (PM2_Supporting).  This variant was identified in nine unrelated individuals with non- autoimmune and non-absolute/near-absolute insulin-deficient diabetes (PS4; PMID: 23517481; internal lab contributors). Functional studies demonstrated the p.Arg200Gln protein has transactivation 40% of wildtype, indicating that this variant impacts protein function (PS3_Supporting, PMID: 15522234).  Lastly, this variant was identified in at least three individuals from one family with a clinical history highly specific for HNF1A-MODY (MODY probability calculator result >50%, negative genetic testing for HNF4A, and negative antibodies) (PP4_Moderate; internal lab contributors).  In summary, c.599G>A meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.1, approved 9/30/2021): PP1_Strong, PP3, PM2_Supporting, PS3_Supporting, PS4, PP4_Moderate.		Monogenic Diabetes VCEP		2022-04-10	2022-07-12	False	https://erepo.genome.network/evrepo/ui/classification/CA16606474/MONDO:0015967/017	3494780c-5e33-4e9a-bd0b-b8754e5d04e1	p.Arg200Gln	Arg	200	Gln	MVSKLSQLQTELLAALLESGLSKEALIQALGEPGPYLLAGEGPLDKGESCGGGRGELAELPNGLGETRGSEDETDDDGEDFTPPILKELENLSPEEAAHQKAVVETLLQEDPWRVAKMVKSYLQQHNIPQREVVDTTGLNQSHLSQHLNKGTPMKTQKRAALYTWYVRKQREVAQQFTHAGQGGLIEEPTGDELPTKKGRRNRFKWGPASQQILFQAYERQKNPSKEERETLVEECNRAECIQRGVSPSQAQGLGSNLVTEVRVYNWFANRRKEEAFRHKLAMDTYSGPPPGPGPGPALPAHSSPGLPPPALSPSKVHGVRYGQPATSETAEVPSSSGGPLVTVSTPLHQVSPTGLEPSHSLLSTEAKLVSAAGGPLPPVSTLTALHSLEQTSPGLNQQPQNLIMASLPGVMTIGPGEPASLGPTFTNTGASTLVIGLASTQAQSVPVINSMGSSLTTLQPVQFSQPLHPSYQQPLMPPVQSHVTQSPFMATMAQLQSPHALYSHKPEVAQYTHTGLLPQTMLITDTTNLSALASLTPTKQVFTSDTEASSESGLHTPASQATTLHVPSQDPAGIQHLQPAHRLSASPTVSSSSLVLYQSSDSSNGQSHLLPSNHSVIETFISTQMASSSQ	631	P20823	Q	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [230], 'DNA_BIND_gain': [], 'DNA_BIND_loss_score': array([-0.05879647]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [97, 106, 111, 171], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.02951008, -0.02836013, -0.0197885 , -0.02812666]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [77], 'COMPBIAS_gain': [], 'COMPBIAS_loss_score': array([-0.01214582]), 'DOMAIN_loss': [], 'DOMAIN_gain': [6, 35, 36], 'DOMAIN_gain_score': array([0.07342631, 0.07219309, 0.08107609]), 'REGION_loss': [179, 180, 181], 'REGION_gain': [], 'REGION_loss_score': array([-0.07214189, -0.06336021, -0.06693923]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
402	NM_000545.6(HNF1A):c.608G>A (p.Arg203His)	129235	CA153100	NM_000545.6:c.608G>A, NC_000012.12:g.120993601G>A, CM000674.2:g.120993601G>A, NC_000012.11:g.121431404G>A, CM000674.1:g.121431404G>A, NC_000012.10:g.119915787G>A, NG_011731.2:g.19856G>A, LRG_522:g.19856G>A, ENST00000257555.11:c.608G>A, ENST00000257555.10:c.608G>A, ENST00000400024.6:c.608G>A, ENST00000402929.5:n.743G>A, ENST00000535955.5:n.43-3890G>A, ENST00000538626.2:n.191-3890G>A, ENST00000538646.5:c.527-563G>A, ENST00000540108.1:c.*48G>A, ENST00000541395.5:c.608G>A, ENST00000541924.5:c.608G>A, ENST00000543427.5:c.608G>A, ENST00000544413.2:c.608G>A, ENST00000544574.5:c.73-3016G>A, ENST00000560968.5:n.751G>A, ENST00000615446.4:c.-257-2661G>A, ENST00000617366.4:c.586+22G>A, NM_000545.5:c.608G>A, LRG_522t1:c.608G>A, NM_001306179.1:c.608G>A, XM_005253931.2:c.608G>A, XM_024449168.1:c.608G>A, NM_000545.8:c.608G>A, NM_001306179.2:c.608G>A, NM_000545.8(HNF1A):c.608G>A (p.Arg203His), NM_000545.6(HNF1A):c.608G>A (p.Arg203His)	HNF1A	monogenic diabetes	MONDO:0015967	Autosomal dominant inheritance	Pathogenic	PM1, PS4, PP1_Strong, PS3_Supporting, PP4_Moderate, PP3, PM2_Supporting	BS3	The c.608G>A variant in the HNF1 homeobox A gene, HNF1A, causes an amino acid change of arginine to histidine at codon 203 (p.(Arg203His)) of NM_000545.8. This variant segregated with diabetes, in more than 10 families with MODY (PP1_Strong; internal lab contributors). Additionally, this variant was identified in at least 15 unrelated individuals with non- autoimmune and non-absolute/near-absolute insulin-deficient diabetes (PS4; PMIDs: 23348805, 27913849, internal lab contributors). This variant resides in an amino acid within the HNF1α DNA binding domain that directly binds DNA, which is defined as critical for the protein’s function by the ClinGen MDEP (PM1) and is absent from gnomAD v2.1.1 (PM2_Supporting). This variant is also predicted to be deleterious by computational evidence, with a REVEL score of 0.958, which is greater than the MDEP VCEP threshold of 0.70 (PP3). Functional studies demonstrated the p.Arg203His protein has abnormal nuclear localization  below 40% of wildtype, indicating that this variant impacts protein function (PMID: 32910913) (PS3_Supporting). Lastly, this variant was identified in an individual with a clinical history highly specific for HNF1A-MODY (MODY probability calculator result >50%, negative genetic testing for HNF4A, and antibody negative) (PP4_Moderate; PMID:27913849). In summary, c.608G>A meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.0, approved 9/30/21): PS4, PP1_Strong, PM1, PM2_Supporting, PP4_Moderate,PP3, PS3_Supporting.		Monogenic Diabetes VCEP		2022-04-11	2022-07-12	False	https://erepo.genome.network/evrepo/ui/classification/CA153100/MONDO:0015967/017	72ad3997-eb69-48ef-8b9c-c9fb9facd124	p.Arg203His	Arg	203	His	MVSKLSQLQTELLAALLESGLSKEALIQALGEPGPYLLAGEGPLDKGESCGGGRGELAELPNGLGETRGSEDETDDDGEDFTPPILKELENLSPEEAAHQKAVVETLLQEDPWRVAKMVKSYLQQHNIPQREVVDTTGLNQSHLSQHLNKGTPMKTQKRAALYTWYVRKQREVAQQFTHAGQGGLIEEPTGDELPTKKGRRNRFKWGPASQQILFQAYERQKNPSKEERETLVEECNRAECIQRGVSPSQAQGLGSNLVTEVRVYNWFANRRKEEAFRHKLAMDTYSGPPPGPGPGPALPAHSSPGLPPPALSPSKVHGVRYGQPATSETAEVPSSSGGPLVTVSTPLHQVSPTGLEPSHSLLSTEAKLVSAAGGPLPPVSTLTALHSLEQTSPGLNQQPQNLIMASLPGVMTIGPGEPASLGPTFTNTGASTLVIGLASTQAQSVPVINSMGSSLTTLQPVQFSQPLHPSYQQPLMPPVQSHVTQSPFMATMAQLQSPHALYSHKPEVAQYTHTGLLPQTMLITDTTNLSALASLTPTKQVFTSDTEASSESGLHTPASQATTLHVPSQDPAGIQHLQPAHRLSASPTVSSSSLVLYQSSDSSNGQSHLLPSNHSVIETFISTQMASSSQ	631	P20823	H	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [230], 'DNA_BIND_gain': [], 'DNA_BIND_loss_score': array([-0.0772751]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [97, 171], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.0063796 , -0.01542455]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [77], 'COMPBIAS_gain': [], 'COMPBIAS_loss_score': array([-0.0092932]), 'DOMAIN_loss': [], 'DOMAIN_gain': [6, 35], 'DOMAIN_gain_score': array([0.05107486, 0.05536205]), 'REGION_loss': [179, 180, 181, 182, 201], 'REGION_gain': [], 'REGION_loss_score': array([-0.13477015, -0.13310516, -0.15056497, -0.16338348, -0.27515304]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
403	NM_000545.8(HNF1A):c.686G>A (p.Arg229Gln)	379904	CA16606085	NM_000545.8:c.686G>A, NC_000012.12:g.120993679G>A, CM000674.2:g.120993679G>A, NC_000012.11:g.121431482G>A, CM000674.1:g.121431482G>A, NC_000012.10:g.119915865G>A, NG_011731.2:g.19934G>A, LRG_522:g.19934G>A, ENST00000257555.11:c.686G>A, ENST00000257555.10:c.686G>A, ENST00000400024.6:c.686G>A, ENST00000402929.5:n.821G>A, ENST00000535955.5:n.43-3812G>A, ENST00000538626.2:n.191-3812G>A, ENST00000538646.5:c.527-485G>A, ENST00000540108.1:c.*126G>A, ENST00000541395.5:c.686G>A, ENST00000541924.5:c.686G>A, ENST00000543427.5:c.633+53G>A, ENST00000544413.2:c.686G>A, ENST00000544574.5:c.73-2938G>A, ENST00000560968.5:n.829G>A, ENST00000615446.4:c.-257-2583G>A, ENST00000617366.4:c.586+100G>A, NM_000545.5:c.686G>A, LRG_522t1:c.686G>A, NM_000545.6:c.686G>A, NM_001306179.1:c.686G>A, XM_005253931.2:c.686G>A, XM_024449168.1:c.686G>A, NM_001306179.2:c.686G>A, NM_000545.8(HNF1A):c.686G>A (p.Arg229Gln)	HNF1A	monogenic diabetes	MONDO:0015967	Autosomal dominant inheritance	Pathogenic	PM1_Supporting, PS4, PP1_Strong, PS3_Supporting, PP4_Moderate, PP3, PM2_Supporting		The c.686G>A variant in the HNF1 homeobox A gene, HNF1A, causes an amino acid change of arginine to glutamine at codon 229 (p.(Arg229Gln)) of  NM_000545.8. This variant is located within a conserved region of the DNA binding domain (codons 107-174 and 201-280) of HNF1A, which is defined as critical for the protein’s function by the ClinGen MDEP (PM1_Supporting) and is absent from gnomAD v2.1.1 (PM2_Supporting). Additionally, this variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.953, which is greater than the MDEP VCEP threshold of 0.70 (PP3). This variant was identified in at two individuals with a clinical history highly specific for HNF1A-MODY (MODY probability calculator result >50%, negative genetic testing for HNF4A, and negative antibodies in both and positive C-peptide in one) (PP4_Moderate; PMID: 27913849). The c.686G>A variant was identified in 27 unrelated individuals with non- autoimmune and non-absolute/near-absolute insulin-deficient diabetes (PS4; PMIDs: 29927023, 28395978, 27913849, 9032114, 18513305, internal lab contributors). Functional studies demonstrated the p.Arg229Gln protein has transactivation below 40% of wildtype, indicating that this variant impacts protein function (PS3_Supporting; PMIDs: 12530534, 12574234). Lastly, this variant segregated with diabetes, with at least 17 informative meioses in at more than three families with MODY (PP1_Strong; PMID: 18513305; internal lab contributors). In summary, c.686G>A meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.1, approved 9/30/21): PS3_Supporting, PP1_strong, PS4, PM1_Supporting, PM2_Supporting, PP4_Moderate, PP3.		Monogenic Diabetes VCEP		2022-04-12	2022-07-12	False	https://erepo.genome.network/evrepo/ui/classification/CA16606085/MONDO:0015967/017	e739ac30-b1d8-481c-9382-de08bbb585f6	p.Arg229Gln	Arg	229	Gln	MVSKLSQLQTELLAALLESGLSKEALIQALGEPGPYLLAGEGPLDKGESCGGGRGELAELPNGLGETRGSEDETDDDGEDFTPPILKELENLSPEEAAHQKAVVETLLQEDPWRVAKMVKSYLQQHNIPQREVVDTTGLNQSHLSQHLNKGTPMKTQKRAALYTWYVRKQREVAQQFTHAGQGGLIEEPTGDELPTKKGRRNRFKWGPASQQILFQAYERQKNPSKEERETLVEECNRAECIQRGVSPSQAQGLGSNLVTEVRVYNWFANRRKEEAFRHKLAMDTYSGPPPGPGPGPALPAHSSPGLPPPALSPSKVHGVRYGQPATSETAEVPSSSGGPLVTVSTPLHQVSPTGLEPSHSLLSTEAKLVSAAGGPLPPVSTLTALHSLEQTSPGLNQQPQNLIMASLPGVMTIGPGEPASLGPTFTNTGASTLVIGLASTQAQSVPVINSMGSSLTTLQPVQFSQPLHPSYQQPLMPPVQSHVTQSPFMATMAQLQSPHALYSHKPEVAQYTHTGLLPQTMLITDTTNLSALASLTPTKQVFTSDTEASSESGLHTPASQATTLHVPSQDPAGIQHLQPAHRLSASPTVSSSSLVLYQSSDSSNGQSHLLPSNHSVIETFISTQMASSSQ	631	P20823	Q	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [228, 230], 'DNA_BIND_gain': [], 'DNA_BIND_loss_score': array([-0.22044247, -0.06951642]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [97, 111], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.00258476, -0.01419216]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [5], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.01558489]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
404	NM_000545.6(HNF1A):c.779C>T (p.Thr260Met)	265436	CA10588543	NM_000545.6:c.779C>T, NC_000012.12:g.120994229C>T, CM000674.2:g.120994229C>T, NC_000012.11:g.121432032C>T, CM000674.1:g.121432032C>T, NC_000012.10:g.119916415C>T, NG_011731.2:g.20484C>T, LRG_522:g.20484C>T, ENST00000257555.11:c.779C>T, ENST00000257555.10:c.779C>T, ENST00000400024.6:c.779C>T, ENST00000402929.5:n.914C>T, ENST00000535955.5:n.43-3262C>T, ENST00000538626.2:n.191-3262C>T, ENST00000538646.5:c.592C>T, ENST00000540108.1:c.*219C>T, ENST00000541395.5:c.779C>T, ENST00000541924.5:c.713+523C>T, ENST00000543427.5:c.633+603C>T, ENST00000544413.2:c.779C>T, ENST00000544574.5:c.73-2388C>T, ENST00000560968.5:n.893+29C>T, ENST00000615446.4:c.-257-2033C>T, ENST00000617366.4:c.586+650C>T, NM_000545.5:c.779C>T, LRG_522t1:c.779C>T, NM_001306179.1:c.779C>T, XM_005253931.2:c.779C>T, XM_024449168.1:c.779C>T, NM_000545.8:c.779C>T, NM_001306179.2:c.779C>T, NM_000545.8(HNF1A):c.779C>T (p.Thr260Met), NM_000545.6(HNF1A):c.779C>T (p.Thr260Met)	HNF1A	monogenic diabetes	MONDO:0015967	Autosomal dominant inheritance	Pathogenic	PM1_Supporting, PS4, PP1_Strong, PP4_Moderate, PP3, PM2_Supporting, PS3_Moderate		The c.779C>T variant in the HNF1 homeobox A gene, HNF1A, causes an amino acid change of threonine to methionine at codon 260 (p.(Thr260Met)) of NM_000545.8. This variant is located within a conserved region of the DNA binding domain (107-174 and 201-280) of HNF1A, which is defined as critical for the protein’s function by the ClinGen MDEP (PM1_Supporting). Additionally, variant is absent from gnomAD v2.1.1 (PM2_Supporting). This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.956, which is greater than the MDEP VCEP threshold of 0.70 (PP3). This variant was identified in at least 28 unrelated individuals with non- autoimmune and non-absolute/near-absolute insulin-deficient diabetes (PMIDs: 30760653, 29927023, 30663027, 29207974, 28105082, internal lab contributors).  At least two of these individuals had a clinical history highly specific for HNF1A-MODY (MODY probability calculator result >50% and negative genetic testing for HNF4A, and both were antibody negative and one responded to low dose sulfonylureas) (PP4_Moderate; PMIDs: 30760653, 281505082).  This variant segregated with diabetes, with 16 informative meioses in multiple families with MODY (PP1_Strong; PMIDs: 30760653. 28105082, internal lab contributors).  A luciferase assay meeting the ClinGen MDEP quality control specifications demonstrated that the p.Thr260Met protein has transactivation activity below 40% of wildtype, indicating that this variant impacts protein function (PS3_Moderate; PMID: 32910913).  In summary, c.779C>T meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.1, approved 9/30/2021): PM1_supporting, PM2_Supporting, PP3, PS4, PP4_Moderate, PP1_Strong, PS3_Moderate.		Monogenic Diabetes VCEP		2022-04-14	2022-07-12	False	https://erepo.genome.network/evrepo/ui/classification/CA10588543/MONDO:0015967/017	b5943d8b-4ba3-402c-879f-9049fe2f8a98	p.Thr260Met	Thr	260	Met	MVSKLSQLQTELLAALLESGLSKEALIQALGEPGPYLLAGEGPLDKGESCGGGRGELAELPNGLGETRGSEDETDDDGEDFTPPILKELENLSPEEAAHQKAVVETLLQEDPWRVAKMVKSYLQQHNIPQREVVDTTGLNQSHLSQHLNKGTPMKTQKRAALYTWYVRKQREVAQQFTHAGQGGLIEEPTGDELPTKKGRRNRFKWGPASQQILFQAYERQKNPSKEERETLVEECNRAECIQRGVSPSQAQGLGSNLVTEVRVYNWFANRRKEEAFRHKLAMDTYSGPPPGPGPGPALPAHSSPGLPPPALSPSKVHGVRYGQPATSETAEVPSSSGGPLVTVSTPLHQVSPTGLEPSHSLLSTEAKLVSAAGGPLPPVSTLTALHSLEQTSPGLNQQPQNLIMASLPGVMTIGPGEPASLGPTFTNTGASTLVIGLASTQAQSVPVINSMGSSLTTLQPVQFSQPLHPSYQQPLMPPVQSHVTQSPFMATMAQLQSPHALYSHKPEVAQYTHTGLLPQTMLITDTTNLSALASLTPTKQVFTSDTEASSESGLHTPASQATTLHVPSQDPAGIQHLQPAHRLSASPTVSSSSLVLYQSSDSSNGQSHLLPSNHSVIETFISTQMASSSQ	631	P20823	M	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [230], 'DNA_BIND_gain': [], 'DNA_BIND_loss_score': array([-0.04664236]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [102, 277], 'HELIX_gain_score': array([0.01198012, 0.04478848]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [5, 34], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.01560634, -0.02360713]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
405	NM_000545.6(HNF1A):c.787C>T (p.Arg263Cys)	562367	CA6831834	NM_000545.6:c.787C>T, NC_000012.12:g.120994237C>T, CM000674.2:g.120994237C>T, NC_000012.11:g.121432040C>T, CM000674.1:g.121432040C>T, NC_000012.10:g.119916423C>T, NG_011731.2:g.20492C>T, LRG_522:g.20492C>T, ENST00000257555.11:c.787C>T, ENST00000257555.10:c.787C>T, ENST00000400024.6:c.787C>T, ENST00000402929.5:n.922C>T, ENST00000535955.5:n.43-3254C>T, ENST00000538626.2:n.191-3254C>T, ENST00000538646.5:c.600C>T, ENST00000540108.1:c.*227C>T, ENST00000541395.5:c.787C>T, ENST00000541924.5:c.713+531C>T, ENST00000543427.5:c.633+611C>T, ENST00000544413.2:c.787C>T, ENST00000544574.5:c.73-2380C>T, ENST00000560968.5:n.893+37C>T, ENST00000615446.4:c.-257-2025C>T, ENST00000617366.4:c.586+658C>T, NM_000545.5:c.787C>T, LRG_522t1:c.787C>T, NM_001306179.1:c.787C>T, XM_005253931.2:c.787C>T, XM_024449168.1:c.787C>T, NM_000545.8:c.787C>T, NM_001306179.2:c.787C>T, NM_000545.8(HNF1A):c.787C>T (p.Arg263Cys), NM_000545.6(HNF1A):c.787C>T (p.Arg263Cys)	HNF1A	monogenic diabetes	MONDO:0015967	Autosomal dominant inheritance	Pathogenic	PM1, PM5, PS4, PP1_Strong, PS3_Supporting, PP4_Moderate, PP3, PM2_Supporting		The c.787C>T variant in the HNF1 homeobox A] gene, HNF1A, causes an amino acid change of arginine to cysteine at codon 263 (p.Arg263Cys) of NM_000545.8. This variant resides in an amino acid within the HNF1α DNA binding domain that directly binds DNA, which is defined as critical for the protein’s function by the ClinGen MDEP (PM1). This variant is absent in the gnomAD v2.1.1 European non-Finnish population, and there is one copy in another subpopulation, which is less than the ClinGen MDEP threshold for PM2_Supporting (≤0.00002 and ≤1 copy in any other subpopulation) (PM2_Supporting). This variant is also predicted to be deleterious by computational evidence, with a REVEL score of 0.948, which is greater than the MDEP VCEP threshold of 0.70 (PP3). This variant was identified in at least 21 unrelated individuals with non- autoimmune and non-absolute/near-absolute insulin-deficient diabetes (PS4; PMIDs: 30155490, 12574234, 25414397, 9287053; internal lab contributors). Additionally, another missense variant, c.788G>A (p.Arg263His), has been interpreted as pathogenic by the ClinGen MDEP and p.Arg263Cys has a greater Grantham distance (PM5). Functional studies demonstrated the p.Arg263Cys protein has DNA binding and transactivation activity below 40% of wild type, indicating that this variant impacts protein function (PS3_Supporting; PMID: 12574234). Also, this variant was identified in an individual with a clinical history highly specific for HNF1A-MODY (MODY probability calculator result >50%, negative genetic testing for HNF4A, and response to low dose sulfonylureas) (PP4_Moderate; internal lab contributors). Lastly, this variant segregated with diabetes, with 7 informative meioses in 2 families with MODY (PP1_Strong; PMID: 12574234, internal lab contributors). In summary, c.787C>T meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.1, approved 9/30/2021): PM1, PM2_Supporting, PP3, PS4, PM5, PS3_Supporting, PP4_Moderate, PP1_Strong.		Monogenic Diabetes VCEP		2022-04-14	2022-07-12	False	https://erepo.genome.network/evrepo/ui/classification/CA6831834/MONDO:0015967/017	dfa508d2-1967-4ee6-b589-b0d5dce61488	p.Arg263Cys	Arg	263	Cys	MVSKLSQLQTELLAALLESGLSKEALIQALGEPGPYLLAGEGPLDKGESCGGGRGELAELPNGLGETRGSEDETDDDGEDFTPPILKELENLSPEEAAHQKAVVETLLQEDPWRVAKMVKSYLQQHNIPQREVVDTTGLNQSHLSQHLNKGTPMKTQKRAALYTWYVRKQREVAQQFTHAGQGGLIEEPTGDELPTKKGRRNRFKWGPASQQILFQAYERQKNPSKEERETLVEECNRAECIQRGVSPSQAQGLGSNLVTEVRVYNWFANRRKEEAFRHKLAMDTYSGPPPGPGPGPALPAHSSPGLPPPALSPSKVHGVRYGQPATSETAEVPSSSGGPLVTVSTPLHQVSPTGLEPSHSLLSTEAKLVSAAGGPLPPVSTLTALHSLEQTSPGLNQQPQNLIMASLPGVMTIGPGEPASLGPTFTNTGASTLVIGLASTQAQSVPVINSMGSSLTTLQPVQFSQPLHPSYQQPLMPPVQSHVTQSPFMATMAQLQSPHALYSHKPEVAQYTHTGLLPQTMLITDTTNLSALASLTPTKQVFTSDTEASSESGLHTPASQATTLHVPSQDPAGIQHLQPAHRLSASPTVSSSSLVLYQSSDSSNGQSHLLPSNHSVIETFISTQMASSSQ	631	P20823	C	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [228, 230], 'DNA_BIND_gain': [], 'DNA_BIND_loss_score': array([-0.13481754, -0.12764144]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [97, 171], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.01263577, -0.04887599]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [77], 'COMPBIAS_gain': [], 'COMPBIAS_loss_score': array([-0.0060997]), 'DOMAIN_loss': [34], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.01690489]), 'REGION_loss': [179, 180, 281], 'REGION_gain': [], 'REGION_loss_score': array([-0.04606009, -0.04403216, -0.22237271]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
406	NM_000545.8(HNF1A):c.788G>A (p.Arg263His)	379138	CA16606475	NM_000545.8:c.788G>A, NC_000012.12:g.120994238G>A, CM000674.2:g.120994238G>A, NC_000012.11:g.121432041G>A, CM000674.1:g.121432041G>A, NC_000012.10:g.119916424G>A, NG_011731.2:g.20493G>A, LRG_522:g.20493G>A, ENST00000257555.11:c.788G>A, ENST00000257555.10:c.788G>A, ENST00000400024.6:c.788G>A, ENST00000402929.5:n.923G>A, ENST00000535955.5:n.43-3253G>A, ENST00000538626.2:n.191-3253G>A, ENST00000538646.5:c.601G>A, ENST00000540108.1:c.*228G>A, ENST00000541395.5:c.788G>A, ENST00000541924.5:c.713+532G>A, ENST00000543427.5:c.633+612G>A, ENST00000544413.2:c.788G>A, ENST00000544574.5:c.73-2379G>A, ENST00000560968.5:n.893+38G>A, ENST00000615446.4:c.-257-2024G>A, ENST00000617366.4:c.586+659G>A, NM_000545.5:c.788G>A, LRG_522t1:c.788G>A, NM_000545.6:c.788G>A, NM_001306179.1:c.788G>A, XM_005253931.2:c.788G>A, XM_024449168.1:c.788G>A, NM_001306179.2:c.788G>A, NM_000545.8(HNF1A):c.788G>A (p.Arg263His)	HNF1A	monogenic diabetes	MONDO:0015967	Autosomal dominant inheritance	Pathogenic	PS4, PM1, PP1_Strong, PS3_Supporting, PP4_Moderate, PP3, PM2_Supporting	PM5	The c.788G>A variant in the HNF1 homeobox A gene, HNF1A, causes an amino acid change of arginine to histidine at codon 263 (p.Arg263His) of NM_000545.8. This variant resides in an amino acid within the HNF1α DNA binding domain that directly binds DNA, which is defined as critical for the protein’s function by the ClinGen MDEP (PM1). This variant is absent from gnomAD v2.1.1 (PM2_Supporting). This variant is also predicted to be deleterious by computational evidence, with a REVEL score of 0.957, which is greater thanthe MDEP VCEP threshold of 0.70 (PP3). This variant was identified in at least 16 unrelated individuals with non- autoimmune and non-absolute/near-absolute insulin-deficient diabetes (PS4; PMIDs: 19336507, 26853433, 28012402, 29927023, 31166087, internal lab contributors). Additionally, functional studies demonstrated the p.Arg263His protein has DNA binding and nuclear localization below 40% of wild type, indicating that this variant impacts protein function (PS3_Supporting; PMID: 26853433). This variant was identified in an individual with a clinical history highly specific for HNF1A-MODY (MODY probability calculator result >50%, negative genetic testing for HNF4A, and response to low dose sulfonylureas) (PP4_Moderate; internal lab contributors). Finally, this variant segregated with diabetes, with 9 informative meioses in multiple families with MODY (PP1_Strong; 19336507, internal lab contributors).  While two additional missense variants, c.787C>T (p.Arg263His) and c.788G>T (p.Arg263Leu) have been classified as pathogenic by the ClinGen MDEP, p.Arg263His has the lowest Grantham distance and was used as the base variant to apply PM5 to Arg263Cys and PM5_Strong to Arg263Leu and thus PM5 is not applied to p.Arg263His. In summary, c.788G>A meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.1, approved 9/30/2021): PM1, PM2_Supporting, PP3, PS4, PS3_Supporting, PP4_Moderate, PP1_Strong.		Monogenic Diabetes VCEP		2022-04-14	2022-07-12	False	https://erepo.genome.network/evrepo/ui/classification/CA16606475/MONDO:0015967/017	e613a19a-b574-44b5-9300-22020e589dd7	p.Arg263His	Arg	263	His	MVSKLSQLQTELLAALLESGLSKEALIQALGEPGPYLLAGEGPLDKGESCGGGRGELAELPNGLGETRGSEDETDDDGEDFTPPILKELENLSPEEAAHQKAVVETLLQEDPWRVAKMVKSYLQQHNIPQREVVDTTGLNQSHLSQHLNKGTPMKTQKRAALYTWYVRKQREVAQQFTHAGQGGLIEEPTGDELPTKKGRRNRFKWGPASQQILFQAYERQKNPSKEERETLVEECNRAECIQRGVSPSQAQGLGSNLVTEVRVYNWFANRRKEEAFRHKLAMDTYSGPPPGPGPGPALPAHSSPGLPPPALSPSKVHGVRYGQPATSETAEVPSSSGGPLVTVSTPLHQVSPTGLEPSHSLLSTEAKLVSAAGGPLPPVSTLTALHSLEQTSPGLNQQPQNLIMASLPGVMTIGPGEPASLGPTFTNTGASTLVIGLASTQAQSVPVINSMGSSLTTLQPVQFSQPLHPSYQQPLMPPVQSHVTQSPFMATMAQLQSPHALYSHKPEVAQYTHTGLLPQTMLITDTTNLSALASLTPTKQVFTSDTEASSESGLHTPASQATTLHVPSQDPAGIQHLQPAHRLSASPTVSSSSLVLYQSSDSSNGQSHLLPSNHSVIETFISTQMASSSQ	631	P20823	H	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [5, 34, 81, 83], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.0474636 , -0.04634291, -0.06671548, -0.06645298]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
407	NM_000545.6(HNF1A):c.811C>T (p.Arg271Trp)	265193	CA10588544	NM_000545.6:c.811C>T, NC_000012.12:g.120994261C>T, CM000674.2:g.120994261C>T, NC_000012.11:g.121432064C>T, CM000674.1:g.121432064C>T, NC_000012.10:g.119916447C>T, NG_011731.2:g.20516C>T, LRG_522:g.20516C>T, ENST00000257555.11:c.811C>T, ENST00000257555.10:c.811C>T, ENST00000400024.6:c.811C>T, ENST00000402929.5:n.946C>T, ENST00000535955.5:n.43-3230C>T, ENST00000538626.2:n.191-3230C>T, ENST00000538646.5:c.624C>T, ENST00000540108.1:c.*251C>T, ENST00000541395.5:c.811C>T, ENST00000541924.5:c.713+555C>T, ENST00000543427.5:c.633+635C>T, ENST00000544413.2:c.811C>T, ENST00000544574.5:c.73-2356C>T, ENST00000560968.5:n.893+61C>T, ENST00000615446.4:c.-257-2001C>T, ENST00000617366.4:c.586+682C>T, NM_000545.5:c.811C>T, LRG_522t1:c.811C>T, NM_001306179.1:c.811C>T, XM_005253931.2:c.811C>T, XM_024449168.1:c.811C>T, NM_000545.8:c.811C>T, NM_001306179.2:c.811C>T, NM_000545.8(HNF1A):c.811C>T (p.Arg271Trp), NM_000545.6(HNF1A):c.811C>T (p.Arg271Trp)	HNF1A	monogenic diabetes	MONDO:0015967	Autosomal dominant inheritance	Pathogenic	PM1, PM5, PS4, PP1_Strong, PS3_Supporting, PP4_Moderate, PP3, PM2_Supporting		The c.811C>T variant in the HNF1 homeobox A gene, HNF1A, causes an amino acid change of arginine to tryptophan at codon 271 (p.(Arg271Trp) of transcript, e.g. NM_000545.8. This variant was identified in over 26 unrelated individuals with non- autoimmune and non-absolute/near-absolute insulin-deficient diabetes (PS4; internal lab contributors).  Additionally, this variant segregated with diabetes, with at least four informative meioses in multiple families with MODY (PP1_Strong; internal lab contributors). Functional studies demonstrated the p.Arg271Trp protein has transactivation below 40% of wildtype, indicating that this variant impacts protein function (PMID: 21170474) (PS3_Supporting). This variant resides in an amino acid within the HNF1α DNA binding domain that directly binds DNA, which is defined as critical for the protein’s function by the ClinGen MDEP (PM1). Another missense variant, c. 812G>A (p.Arg271Gln), has been interpreted as pathogenic by the ClinGen MDEP and p. Arg271Trp has a greater Grantham distance (PM5). The variant was identified in at least 8 individuals with a clinical history highly specific for HNF1A-MODY (MODY probability calculator result >50%, negative genetic testing for HNF4A, and autoantibody negative) (PP4_Moderate). This variant failed QC in gnomAD v2.1.1.  The variant was absent other than two heterozygotes filtered out due to poor quality which even if real would place the frequency below the ClinGen MDEP cutoff for PM2_Supporting (PM2_Supporting).  Lastly, this variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.93, which is greater than the MDEP VCEP threshold of 0.70 (PP3) and is absent from gnomAD v2.1.1 (PM2_Supporting). In summary, c.814C>A meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.1, approved 9/30/2021): PS4, PP1_Strong, PS3_Supporting, PM1,  PM5,  PP4_Moderate,  PP3, PM2_Supporting.		Monogenic Diabetes VCEP		2022-04-14	2022-07-12	False	https://erepo.genome.network/evrepo/ui/classification/CA10588544/MONDO:0015967/017	b52c71ef-1a30-4439-b5ec-d4ec00c3c8a1	p.Arg271Trp	Arg	271	Trp	MVSKLSQLQTELLAALLESGLSKEALIQALGEPGPYLLAGEGPLDKGESCGGGRGELAELPNGLGETRGSEDETDDDGEDFTPPILKELENLSPEEAAHQKAVVETLLQEDPWRVAKMVKSYLQQHNIPQREVVDTTGLNQSHLSQHLNKGTPMKTQKRAALYTWYVRKQREVAQQFTHAGQGGLIEEPTGDELPTKKGRRNRFKWGPASQQILFQAYERQKNPSKEERETLVEECNRAECIQRGVSPSQAQGLGSNLVTEVRVYNWFANRRKEEAFRHKLAMDTYSGPPPGPGPGPALPAHSSPGLPPPALSPSKVHGVRYGQPATSETAEVPSSSGGPLVTVSTPLHQVSPTGLEPSHSLLSTEAKLVSAAGGPLPPVSTLTALHSLEQTSPGLNQQPQNLIMASLPGVMTIGPGEPASLGPTFTNTGASTLVIGLASTQAQSVPVINSMGSSLTTLQPVQFSQPLHPSYQQPLMPPVQSHVTQSPFMATMAQLQSPHALYSHKPEVAQYTHTGLLPQTMLITDTTNLSALASLTPTKQVFTSDTEASSESGLHTPASQATTLHVPSQDPAGIQHLQPAHRLSASPTVSSSSLVLYQSSDSSNGQSHLLPSNHSVIETFISTQMASSSQ	631	P20823	W	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [230, 277], 'DNA_BIND_gain': [], 'DNA_BIND_loss_score': array([-0.08265811, -0.10911065]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [171, 237], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.03270131, -0.04481739]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [345], 'COMPBIAS_gain': [69], 'COMPBIAS_gain_score': array([0.00819939]), 'COMPBIAS_loss_score': array([-0.02415949]), 'DOMAIN_loss': [179, 180, 181], 'DOMAIN_gain': [4, 6, 35], 'DOMAIN_gain_score': array([0.11127794, 0.10858387, 0.05190414]), 'DOMAIN_loss_score': array([-0.57977229, -0.54739332, -0.40274543]), 'REGION_loss': [179, 180, 181, 281, 282], 'REGION_gain': [], 'REGION_loss_score': array([-0.07769394, -0.07438225, -0.06944531, -0.45546335, -0.39299709]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
408	NM_000545.6(HNF1A):c.814C>T (p.Arg272Cys)	447503	CA386966363	NM_000545.6:c.814C>T, NC_000012.12:g.120994264C>T, CM000674.2:g.120994264C>T, NC_000012.11:g.121432067C>T, CM000674.1:g.121432067C>T, NC_000012.10:g.119916450C>T, NG_011731.2:g.20519C>T, LRG_522:g.20519C>T, ENST00000257555.11:c.814C>T, ENST00000257555.10:c.814C>T, ENST00000400024.6:c.814C>T, ENST00000402929.5:n.949C>T, ENST00000535955.5:n.43-3227C>T, ENST00000538626.2:n.191-3227C>T, ENST00000538646.5:c.627C>T, ENST00000540108.1:c.*254C>T, ENST00000541395.5:c.814C>T, ENST00000541924.5:c.713+558C>T, ENST00000543427.5:c.633+638C>T, ENST00000544413.2:c.814C>T, ENST00000544574.5:c.73-2353C>T, ENST00000560968.5:n.893+64C>T, ENST00000615446.4:c.-257-1998C>T, ENST00000617366.4:c.586+685C>T, NM_000545.5:c.814C>T, LRG_522t1:c.814C>T, NM_001306179.1:c.814C>T, XM_005253931.2:c.814C>T, XM_024449168.1:c.814C>T, NM_000545.8:c.814C>T, NM_001306179.2:c.814C>T, NM_000545.8(HNF1A):c.814C>T (p.Arg272Cys), NM_000545.6(HNF1A):c.814C>T (p.Arg272Cys)	HNF1A	monogenic diabetes	MONDO:0015967	Autosomal dominant inheritance	Pathogenic	PM5, PM1, PS4, PP1_Strong, PS3_Supporting, PP4_Moderate, PP3, PM2_Supporting		The c.814C>T variant in the HNF1 homeobox A gene, HNF1A, causes an amino acid change of arginine to cystine at codon 272 (p.(Arg272Cys) of transcript, e.g. NM_000545.8.  This variant resides in an amino acid within the HNF1α DNA binding domain that directly binds DNA, which is defined as critical for the protein’s function by the ClinGen MDEP (PM1) and is absent from gnomAD v2.1.1 (PM2_Supporting). Additionally, this variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.941, which is greater than  the MDEP VCEP threshold of 0.70 (PP3). This variant was identified in at least 17 unrelated individuals with non- autoimmune and non-absolute/near-absolute insulin-deficient diabetes (PS4; PMIDs: 18003757, 28701371, 25414397, 11719843, 10447526; internal lab contributors). The variant segregated with diabetes, with at least fifteen informative meioses in at least sixteen families with MODY (PP1_Strong; internal lab contributors). Another missense variant, c. 815G>A, p.Arg272His, has been interpreted as pathogenic by the ClinGen MDEP and p.Arg272Cys has a greater Grantham distance (PM5). Functional studies demonstrated the p.Arg272Cys protein has DNA binding below 40% of wild type and transactivation below 40% of wildtype, indicating that this variant impacts protein function (PS3_Supporting; PMID: 10333057). Lastly, this variant was identified in at least five individuals with a clinical history highly specific for HNF1A-MODY (MODY probability calculator result >50%, negative genetic testing for HNF4A, and response to low dose sulfonylurea) (PP4_Moderate; internal lab contributors).  In summary, c.814C>T, meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.1, approved 9/30/2021): PM1, PM2_Supporting,  PP3,  PS4, PP1_Strong, PM5, PS3_Supporting,  PP4_Moderate.		Monogenic Diabetes VCEP		2022-04-15	2022-04-15	False	https://erepo.genome.network/evrepo/ui/classification/CA386966363/MONDO:0015967/017	0f1ff5b2-ff32-42cb-adcd-bc25b95b14cf	p.Arg272Cys	Arg	272	Cys	MVSKLSQLQTELLAALLESGLSKEALIQALGEPGPYLLAGEGPLDKGESCGGGRGELAELPNGLGETRGSEDETDDDGEDFTPPILKELENLSPEEAAHQKAVVETLLQEDPWRVAKMVKSYLQQHNIPQREVVDTTGLNQSHLSQHLNKGTPMKTQKRAALYTWYVRKQREVAQQFTHAGQGGLIEEPTGDELPTKKGRRNRFKWGPASQQILFQAYERQKNPSKEERETLVEECNRAECIQRGVSPSQAQGLGSNLVTEVRVYNWFANRRKEEAFRHKLAMDTYSGPPPGPGPGPALPAHSSPGLPPPALSPSKVHGVRYGQPATSETAEVPSSSGGPLVTVSTPLHQVSPTGLEPSHSLLSTEAKLVSAAGGPLPPVSTLTALHSLEQTSPGLNQQPQNLIMASLPGVMTIGPGEPASLGPTFTNTGASTLVIGLASTQAQSVPVINSMGSSLTTLQPVQFSQPLHPSYQQPLMPPVQSHVTQSPFMATMAQLQSPHALYSHKPEVAQYTHTGLLPQTMLITDTTNLSALASLTPTKQVFTSDTEASSESGLHTPASQATTLHVPSQDPAGIQHLQPAHRLSASPTVSSSSLVLYQSSDSSNGQSHLLPSNHSVIETFISTQMASSSQ	631	P20823	C	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [228, 230, 277], 'DNA_BIND_gain': [], 'DNA_BIND_loss_score': array([-0.17441005, -0.18232292, -0.14869338]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [87, 88, 98, 102, 103, 104, 105, 277], 'HELIX_gain_score': array([0.04200667, 0.04655772, 0.03587949, 0.03530675, 0.03564703,
       0.03892666, 0.03329754, 0.05121875]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [179, 180, 181], 'DOMAIN_gain': [6], 'DOMAIN_gain_score': array([0.06312686]), 'DOMAIN_loss_score': array([-0.40174085, -0.35017073, -0.24407047]), 'REGION_loss': [179, 180, 181, 281, 282], 'REGION_gain': [], 'REGION_loss_score': array([-0.04643017, -0.04886365, -0.04926664, -0.43793589, -0.43233413]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
409	NM_000545.6(HNF1A):c.812G>A (p.Arg271Gln)	449403	CA6831835	NM_000545.6:c.812G>A, NC_000012.12:g.120994262G>A, CM000674.2:g.120994262G>A, NC_000012.11:g.121432065G>A, CM000674.1:g.121432065G>A, NC_000012.10:g.119916448G>A, NG_011731.2:g.20517G>A, LRG_522:g.20517G>A, ENST00000257555.11:c.812G>A, ENST00000257555.10:c.812G>A, ENST00000400024.6:c.812G>A, ENST00000402929.5:n.947G>A, ENST00000535955.5:n.43-3229G>A, ENST00000538626.2:n.191-3229G>A, ENST00000538646.5:c.625G>A, ENST00000540108.1:c.*252G>A, ENST00000541395.5:c.812G>A, ENST00000541924.5:c.713+556G>A, ENST00000543427.5:c.633+636G>A, ENST00000544413.2:c.812G>A, ENST00000544574.5:c.73-2355G>A, ENST00000560968.5:n.893+62G>A, ENST00000615446.4:c.-257-2000G>A, ENST00000617366.4:c.586+683G>A, NM_000545.5:c.812G>A, LRG_522t1:c.812G>A, NM_001306179.1:c.812G>A, XM_005253931.2:c.812G>A, XM_024449168.1:c.812G>A, NM_000545.8:c.812G>A, NM_001306179.2:c.812G>A, NM_000545.8(HNF1A):c.812G>A (p.Arg271Gln), NM_000545.6(HNF1A):c.812G>A (p.Arg271Gln)	HNF1A	monogenic diabetes	MONDO:0015967	Autosomal dominant inheritance	Pathogenic	PM1, PS4, PP1_Strong, PP4_Moderate, PP3, PM2_Supporting	PM5, PS3	The c.812G>A variant in the HNF1 homeobox A gene, HNF1A, causes an amino acid change of arginine to glutamine at codon 271 (p.(Arg271Gln) of NM_000545.8. This variant was identified in 19 unrelated individuals with non- autoimmune and non-absolute/near-absolute insulin-deficient diabetes (PS4; internal lab contributors). Additionally, this variant segregated with diabetes, with four informative meioses in two families with MODY (PP1_Strong; internal lab contributors). This variant resides in an amino acid within the HNF1α DNA binding domain that directly binds DNA, which is defined as critical for the protein’s function by the ClinGen MDEP (PM1). This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.945, which is greater than the MDEP VCEP threshold of 0.70 (PP3) and is absent from gnomAD v2.1.1 (PM2_Supporting).  Functional studies demonstrated the p.Arg271Gln protein has DNA binding 110% of wild type and transactivation 50-60% of wildtype; however, this is between the ClinGen MDEP cutoffs for PS3 and BS3 (PMID: 26853433).  The p.Arg271Trp and p.Arg271Gly variants have been interpreted as pathogenic and likely pathogenic, respectively, by the MDEP.  Arg271Gln has a lower Grantham distance than both and was used as the base variant to apply PM5, and therefore, PM5 will not be applied to Arg271Gln.  In summary, c.814C>A meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.1, approved 9/30/2021): PS4, PP1_Strong, PM1, PP3, PM2_Supporting, PP4_Moderate.		Monogenic Diabetes VCEP		2022-04-15	2022-07-12	False	https://erepo.genome.network/evrepo/ui/classification/CA6831835/MONDO:0015967/017	38c10de3-40b2-4def-bf4e-c08f9d43f223	p.Arg271Gln	Arg	271	Gln	MVSKLSQLQTELLAALLESGLSKEALIQALGEPGPYLLAGEGPLDKGESCGGGRGELAELPNGLGETRGSEDETDDDGEDFTPPILKELENLSPEEAAHQKAVVETLLQEDPWRVAKMVKSYLQQHNIPQREVVDTTGLNQSHLSQHLNKGTPMKTQKRAALYTWYVRKQREVAQQFTHAGQGGLIEEPTGDELPTKKGRRNRFKWGPASQQILFQAYERQKNPSKEERETLVEECNRAECIQRGVSPSQAQGLGSNLVTEVRVYNWFANRRKEEAFRHKLAMDTYSGPPPGPGPGPALPAHSSPGLPPPALSPSKVHGVRYGQPATSETAEVPSSSGGPLVTVSTPLHQVSPTGLEPSHSLLSTEAKLVSAAGGPLPPVSTLTALHSLEQTSPGLNQQPQNLIMASLPGVMTIGPGEPASLGPTFTNTGASTLVIGLASTQAQSVPVINSMGSSLTTLQPVQFSQPLHPSYQQPLMPPVQSHVTQSPFMATMAQLQSPHALYSHKPEVAQYTHTGLLPQTMLITDTTNLSALASLTPTKQVFTSDTEASSESGLHTPASQATTLHVPSQDPAGIQHLQPAHRLSASPTVSSSSLVLYQSSDSSNGQSHLLPSNHSVIETFISTQMASSSQ	631	P20823	Q	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [277], 'DNA_BIND_gain': [222, 227, 229], 'DNA_BIND_gain_score': array([0.08331436, 0.08329779, 0.03754002]), 'DNA_BIND_loss_score': array([-0.1599291]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [88, 98, 102, 103, 104, 105, 243, 277], 'HELIX_gain_score': array([0.03163785, 0.02016222, 0.01815784, 0.01846611, 0.02086228,
       0.01900017, 0.01200128, 0.01463276]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [179, 180, 181], 'DOMAIN_gain': [4, 6, 35], 'DOMAIN_gain_score': array([0.10989523, 0.10843986, 0.06099361]), 'DOMAIN_loss_score': array([-0.36617315, -0.30779302, -0.18569809]), 'REGION_loss': [], 'REGION_gain': [202], 'REGION_gain_score': array([0.04238945]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
410	NM_000545.8(HNF1A):c.1720A>G (p.Ser574Gly)	36810	CA214285	NM_000545.8:c.1720A>G, NC_000012.12:g.120999579A>G, CM000674.2:g.120999579A>G, NC_000012.11:g.121437382A>G, CM000674.1:g.121437382A>G, NC_000012.10:g.119921765A>G, ENST00000257555.11:c.1720A>G, ENST00000257555.10:c.1720A>G, ENST00000540108.1:c.*1160A>G, ENST00000541395.5:c.1813A>G, ENST00000543427.5:c.1183A>G, ENST00000544413.2:c.1741A>G, ENST00000560968.5:n.1537A>G, ENST00000615446.4:c.508A>G, ENST00000617366.4:c.*129A>G, XM_005253931.2:c.1813A>G, XM_024449168.1:c.1813A>G, NM_001306179.2:c.1741A>G, NM_000545.8(HNF1A):c.1720A>G (p.Ser574Gly)	HNF1A	monogenic diabetes	MONDO:0015967	Autosomal dominant inheritance	Benign	BP5, BA1		The c.1720A>G variant in the HNF1 homeobox A gene, HNF1A, causes an amino acid change of serine to glycine at codon 574 (p.(Ser574Gly)) of NM_000545.8.  This variant has a Popmax Filtering allele frequency in gnomAD 2.1.1 of 0.996; however, given that the G (Gly) alternate allele has frequencies ≥95% in all subpopulations, we have recalculated the Popmax Filtering allele frequency based on the highest prevalence of the A (Ser) reference allele being found in the African/African-American subpopulation (1144/24164 = 0.0473).  The newly calculated Popmax Filtering allele frequency is 0.0447, which is greater than the MDEP threshold for BA1 (≥0.0001) (BA1). Additionally, this variant was identified in a patient with an alternate molecular basis for disease (BP5; internal lab contributors). In summary, c.1720A>G meets the criteria to be classified as benign for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.1, approved 9/30/2021): BA1, BP5.		Monogenic Diabetes VCEP		2022-04-18	2022-04-18	False	https://erepo.genome.network/evrepo/ui/classification/CA214285/MONDO:0015967/017	e85181fe-8c0d-4882-8417-cd3f34b7ab9f	p.Ser574Gly	Ser	574	Gly	MVSKLSQLQTELLAALLESGLSKEALIQALGEPGPYLLAGEGPLDKGESCGGGRGELAELPNGLGETRGSEDETDDDGEDFTPPILKELENLSPEEAAHQKAVVETLLQEDPWRVAKMVKSYLQQHNIPQREVVDTTGLNQSHLSQHLNKGTPMKTQKRAALYTWYVRKQREVAQQFTHAGQGGLIEEPTGDELPTKKGRRNRFKWGPASQQILFQAYERQKNPSKEERETLVEECNRAECIQRGVSPSQAQGLGSNLVTEVRVYNWFANRRKEEAFRHKLAMDTYSGPPPGPGPGPALPAHSSPGLPPPALSPSKVHGVRYGQPATSETAEVPSSSGGPLVTVSTPLHQVSPTGLEPSHSLLSTEAKLVSAAGGPLPPVSTLTALHSLEQTSPGLNQQPQNLIMASLPGVMTIGPGEPASLGPTFTNTGASTLVIGLASTQAQSVPVINSMGSSLTTLQPVQFSQPLHPSYQQPLMPPVQSHVTQSPFMATMAQLQSPHALYSHKPEVAQYTHTGLLPQTMLITDTTNLSALASLTPTKQVFTSDTEASSESGLHTPASQATTLHVPSQDPAGIQHLQPAHRLSASPTVSSSSLVLYQSSDSSNGQSHLLPSNHSVIETFISTQMASSSQ	631	P20823	G	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
411	NM_000545.8(HNF1A):c.827C>A (p.Ala276Asp)	14945	CA124481	NM_000545.8:c.827C>A, NC_000012.12:g.120994277C>A, CM000674.2:g.120994277C>A, NC_000012.11:g.121432080C>A, CM000674.1:g.121432080C>A, NC_000012.10:g.119916463C>A, NG_011731.2:g.20532C>A, LRG_522:g.20532C>A, ENST00000257555.11:c.827C>A, ENST00000257555.10:c.827C>A, ENST00000400024.6:c.827C>A, ENST00000402929.5:n.962C>A, ENST00000535955.5:n.43-3214C>A, ENST00000538626.2:n.191-3214C>A, ENST00000538646.5:c.640C>A, ENST00000540108.1:c.*267C>A, ENST00000541395.5:c.827C>A, ENST00000541924.5:c.713+571C>A, ENST00000543427.5:c.633+651C>A, ENST00000544413.2:c.827C>A, ENST00000544574.5:c.73-2340C>A, ENST00000560968.5:n.893+77C>A, ENST00000615446.4:c.-257-1985C>A, ENST00000617366.4:c.586+698C>A, NM_000545.5:c.827C>A, LRG_522t1:c.827C>A, NM_000545.6:c.827C>A, NM_001306179.1:c.827C>A, XM_005253931.2:c.827C>A, XM_024449168.1:c.827C>A, NM_001306179.2:c.827C>A, NM_000545.8(HNF1A):c.827C>A (p.Ala276Asp)	HNF1A	monogenic diabetes	MONDO:0015967	Autosomal dominant inheritance	Pathogenic	PM1_Supporting, PP1_Strong, PS3_Supporting, PM5_Supporting, PP4_Moderate, PP3	PS4, PM2	The c.827C>A variant in the HNF1 homeobox A gene, HNF1A, causes an amino acid change of alanine to aspartic acid at codon 276 (p.(Ala276Asp)) of NM_000545.8. This variant is located within a conserved region of the DNA binding domain (107-174 and 201-280) of HNF1A, which is defined as critical for the protein’s function by the ClinGen MDEP (PM1_Supporting).  Additionally, this variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.956, which is greater than the MDEP VCEP threshold of 0.70 (PP3). This variant was identified in two individuals with a clinical history highly specific for HNF1A-MODY (MODY probability calculator result >50%, negative genetic testing for HNF4A, antibody-negative, and response to low-dose sulfonylurea (PP4_Moderate, internal lab contributors). Another missense variant, c.827C>G (p.Ala276Gly), has been classified as likely pathogenic by the ClinGen MDEP (PM5_Supporting).  Also, the variant segregated with diabetes, with four informative meioses in two families with MODY (PP1_Strong; internal lab contributors).   Functional studies demonstrated abnormal nuclear localization, DNA binding less than 40% of wildtype, and normal transactivation (PS3_Supporting; PMID:12574234).  This variant is absent from the gnomAD European non-Finnish population, but two copies are present in the African population; therefore PM2_Supporting cannot be applied.  This variant was identified in at least 12 unrelated individuals with non- autoimmune and non-absolute/near-absolute insulin-deficient diabetes; however, PS4 cannot be applied because the variant MAF in gnomAD is above the ClinGen MDEP PM2_Supporting cutoff (PMID: 12574234, internal lab contributors). In summary, c.827C>A meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.1, approved 9/30/2021):  PP1_Strong, PP4_Moderate, PP3, PM1_Supporting, PM5_Supporting, PS3_Supporting.		Monogenic Diabetes VCEP		2022-04-18	2022-04-18	False	https://erepo.genome.network/evrepo/ui/classification/CA124481/MONDO:0015967/017	b1ec8b81-961e-47de-94da-be293288ac39	p.Ala276Asp	Ala	276	Asp	MVSKLSQLQTELLAALLESGLSKEALIQALGEPGPYLLAGEGPLDKGESCGGGRGELAELPNGLGETRGSEDETDDDGEDFTPPILKELENLSPEEAAHQKAVVETLLQEDPWRVAKMVKSYLQQHNIPQREVVDTTGLNQSHLSQHLNKGTPMKTQKRAALYTWYVRKQREVAQQFTHAGQGGLIEEPTGDELPTKKGRRNRFKWGPASQQILFQAYERQKNPSKEERETLVEECNRAECIQRGVSPSQAQGLGSNLVTEVRVYNWFANRRKEEAFRHKLAMDTYSGPPPGPGPGPALPAHSSPGLPPPALSPSKVHGVRYGQPATSETAEVPSSSGGPLVTVSTPLHQVSPTGLEPSHSLLSTEAKLVSAAGGPLPPVSTLTALHSLEQTSPGLNQQPQNLIMASLPGVMTIGPGEPASLGPTFTNTGASTLVIGLASTQAQSVPVINSMGSSLTTLQPVQFSQPLHPSYQQPLMPPVQSHVTQSPFMATMAQLQSPHALYSHKPEVAQYTHTGLLPQTMLITDTTNLSALASLTPTKQVFTSDTEASSESGLHTPASQATTLHVPSQDPAGIQHLQPAHRLSASPTVSSSSLVLYQSSDSSNGQSHLLPSNHSVIETFISTQMASSSQ	631	P20823	D	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [277], 'DNA_BIND_gain': [], 'DNA_BIND_loss_score': array([-0.03845447]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [102], 'HELIX_gain_score': array([0.00766677]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [77], 'COMPBIAS_gain': [], 'COMPBIAS_loss_score': array([-0.00531173]), 'DOMAIN_loss': [], 'DOMAIN_gain': [6], 'DOMAIN_gain_score': array([0.01135725]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
412	NM_000527.5(LDLR):c.1216C>T (p.Arg406Trp)	226351	CA033073	NM_000527.5:c.1216C>T, NC_000019.10:g.11113307C>T, CM000681.2:g.11113307C>T, NC_000019.9:g.11223983C>T, CM000681.1:g.11223983C>T, NC_000019.8:g.11084983C>T, NG_009060.1:g.28927C>T, LRG_274:g.28927C>T, ENST00000558518.6:c.1216C>T, ENST00000252444.9:n.1470C>T, ENST00000455727.6:c.712C>T, ENST00000535915.5:c.1093C>T, ENST00000545707.5:c.835C>T, ENST00000557933.5:c.1216C>T, ENST00000558013.5:c.1216C>T, ENST00000558518.5:c.1216C>T, ENST00000560173.1:n.215C>T, ENST00000560467.1:n.696C>T, NM_000527.4:c.1216C>T, LRG_274t1:c.1216C>T, NM_001195798.1:c.1216C>T, NM_001195799.1:c.1093C>T, NM_001195800.1:c.712C>T, NM_001195803.1:c.835C>T, XM_011528010.1:c.1216C>T, XM_011528011.1:c.835C>T, XR_244074.2:n.1366C>T, XM_011528010.2:c.1216C>T, XR_001753685.2:n.1333C>T, XR_001753686.2:n.1333C>T, NM_001195798.2:c.1216C>T, NM_001195799.2:c.1093C>T, NM_001195800.2:c.712C>T, NM_001195803.2:c.835C>T, NM_000527.5(LDLR):c.1216C>T (p.Arg406Trp)	LDLR	hypercholesterolemia, familial	MONDO:0007750	Semidominant inheritance	Pathogenic	PS3, PS4, PP1_Strong, PM2, PP3, PP4	PS1, PS2, BP7, BS1, BS3, BS4, PM5, PM4, PM1, PM3, PM6, PVS1, BS2, BP4, BP2, BA1	The NM_000527.5(LDLR):c1216C>T (p.Arg406Trp) variant is classified as Pathogenic for Familial Hypercholesterolemia by applying evidence codes PM2, PP3, PS3, PS4, PP1_Strong, and PP4 as defined by the ClinGen Familial Hypercholesterolemia Expert Panel LDLR-specific variant curation guidelines (https://doi.org/10.1101/2021.03.17.21252755). The supporting evidence is as follows:PM2 - PopMax MAF = 0.000097 (0.0097%) in Ashkenazi Jewish exomes+genomes (gnomAD v2.1.1).PP3 - REVEL = 0.88, which is above the threshold of 0.75. PS3 – Level 1 functional studies: PMID: 2574186; Heterologous cells (CHO), FACS assays - variant results in 60-65% LDLR expression/biosynthesis, LDL binding and LDL internalization compared to wild-type; results meet <70% threshold.PS4 – Variant meets PM2 and is identified in at least 19 unrelated index cases who fulfill clinical criteria for FH (1 case with DLCN criteria from PathWest Laboratory Medicine WA – FH VCEP member lab; 18 cases with SB criteria from Cardiovascular Research Group, Instituto Nacional de Saude Doutor Ricardo Jorge – FH VCEP member lab).PP1_Strong – Variant segregates with phenotype in 31 informative meioses from 15 families in data provided by FH VCEP member labs (Cardiovascular Research Group, Instituto Nacional de Saude Doutor Ricardo Jorge – 11 families: 23 affected with the variant and 1 unaffected without the variant; Laboratory of Genetics and Molecular Cardiology – 4 families: 4 affected with the variant and 3 unaffected without the variant).PP4 - Variant meets PM2. Identified in >1 case who met clinical criteria for FH after alternative causes for high cholesterol were excluded.Note: two other missense variants at this same codon have been reported: 1) NM_000527.5(LDLR):c.1217G>A (p.Arg406Gln) – Likely pathogenic by these guidelines.2) NM_000527.5(LDLR):c.1217G>C (p.Arg406Pro) – Likely pathogenic by these guidelines. -PM5 not applicable as such variants must be Pathogenic.		Familial Hypercholesterolemia VCEP	https://clinicalgenome.org/docs/clingen-familial-hypercholesterolemia-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1-2/	2022-05-19	2022-05-19	False	https://erepo.genome.network/evrepo/ui/classification/CA033073/MONDO:0007750/013	20341145-6ce8-4ebf-bf2f-1b567994c9fb	p.Arg406Trp	Arg	406	Trp	MGPWGWKLRWTVALLLAAAGTAVGDRCERNEFQCQDGKCISYKWVCDGSAECQDGSDESQETCLSVTCKSGDFSCGGRVNRCIPQFWRCDGQVDCDNGSDEQGCPPKTCSQDEFRCHDGKCISRQFVCDSDRDCLDGSDEASCPVLTCGPASFQCNSSTCIPQLWACDNDPDCEDGSDEWPQRCRGLYVFQGDSSPCSAFEFHCLSGECIHSSWRCDGGPDCKDKSDEENCAVATCRPDEFQCSDGNCIHGSRQCDREYDCKDMSDEVGCVNVTLCEGPNKFKCHSGECITLDKVCNMARDCRDWSDEPIKECGTNECLDNNGGCSHVCNDLKIGYECLCPDGFQLVAQRRCEDIDECQDPDTCSQLCVNLEGGYKCQCEEGFQLDPHTKACKAVGSIAYLFFTNRHEVRKMTLDRSEYTSLIPNLRNVVALDTEVASNRIYWSDLSQRMICSTQLDRAHGVSSYDTVISRDIQAPDGLAVDWIHSNIYWTDSVLGTVSVADTKGVKRKTLFRENGSKPRAIVVDPVHGFMYWTDWGTPAKIKKGGLNGVDIYSLVTENIQWPNGITLDLLSGRLYWVDSKLHSISSIDVNGGNRKTILEDEKRLAHPFSLAVFEDKVFWTDIINEAIFSANRLTGSDVNLLAENLLSPEDMVLFHNLTQPRGVNWCERTTLSNGGCQYLCLPAPQINPHSPKFTCACPDGMLLARDMRSCLTEAEAAVATQETSTVRLKVSSTAVRTQHTTTRPVPDTSRLPGATPGLTTVEIVTMSHQALGDVAGRGNEKKPSSVRALSIVLPIVLLVFLCLGVFLLWKNWRLKNINSINFDNPVYQKTTEDEVHICHNQDGYSYPSRQMVSLEDDVA	860	P01130	W	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [401], 'STRAND_gain_score': array([0.01329362]), 'HELIX_loss': [], 'HELIX_gain': [357], 'HELIX_gain_score': array([0.01320302]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [661], 'REPEAT_gain_score': array([0.00412947]), 'ZN_FING_loss': [], 'ZN_FING_gain': [268], 'ZN_FING_gain_score': array([0.00330007])}
413	NM_000527.5(LDLR):c.1A>C (p.Met1Leu)	250966	CA10584718	NM_000527.5:c.1A>C, NC_000019.10:g.11089549A>C, CM000681.2:g.11089549A>C, NC_000019.9:g.11200225A>C, CM000681.1:g.11200225A>C, NC_000019.8:g.11061225A>C, NG_009060.1:g.5169A>C, LRG_274:g.5169A>C, ENST00000558518.6:c.1A>C, ENST00000455727.6:c.1A>C, ENST00000535915.5:c.1A>C, ENST00000545707.5:c.1A>C, ENST00000557933.5:c.1A>C, ENST00000557958.1:n.87A>C, ENST00000558013.5:c.1A>C, ENST00000558518.5:c.1A>C, ENST00000560502.5:n.87A>C, NM_000527.4:c.1A>C, LRG_274t1:c.1A>C, NM_001195798.1:c.1A>C, NM_001195799.1:c.1A>C, NM_001195800.1:c.1A>C, NM_001195803.1:c.1A>C, XM_011528010.1:c.1A>C, XM_011528011.1:c.1A>C, XR_244074.2:n.151A>C, XM_011528010.2:c.1A>C, XR_001753685.2:n.118A>C, XR_001753686.2:n.118A>C, NM_001195798.2:c.1A>C, NM_001195799.2:c.1A>C, NM_001195800.2:c.1A>C, NM_001195803.2:c.1A>C, NR_163945.1:n.111T>G, NM_000527.5(LDLR):c.1A>C (p.Met1Leu)	LDLR	hypercholesterolemia, familial	MONDO:0007750	Semidominant inheritance	Pathogenic	PS3, PVS1_Moderate, PP1_Moderate, PM2, PP4, PS4_Supporting	PS2, PS1, BS1, BS3, BS4, BP7, PM4, PM3, PM5, PM6, PP3, BA1, BP4, BP2	The NM_000527.5(LDLR):c.1A>C (p.Met1Leu) variant is classified as Pathogenic for Familial Hypercholesterolemia by applying evidence codes as PM2, PVS1_Moderate, PS3, PS4_Supporting, PP1_Moderate, and PP4 as defined by the ClinGen Familial Hypercholesterolemia Expert Panel LDLR-specific variant curation guidelines (https://doi.org/10.1016/j.gim.2021.09.012). The supporting evidence is as follows:PM2 - variant is absent from gnomAD (v2.1.1).PVS1_Moderate – variant is predicted to affect the initiation codon.PS3 - Level 1 functional studies performed - Heterologous cells (CHO), FACS: results of 60% cell surface LDLR, 59% LDL binding and 66% LDL uptake, compared to wild-type. Note - Level 3 luciferase reporter assays were also performed: results of 5% luciferase construct activity compared to wild-type. Both studies performed in PMID: 34572405.PS4_Supporting - variant meets PM2 and is identified in 4 unrelated index cases who fulfill clinical criteria for FH (4 cases with SB criteria from Cardiovascular Research Group, Instituto Nacional de Saude Doutor Ricardo Jorge – FH VCEP member lab).PP1_Moderate – variant segregates with phenotype in 4 informative meioses in 3 families (Cardiovascular Research Group, Instituto Nacional de Saude Doutor Ricardo Jorge – 3 families: 4 affected relatives with the variant).PP4 - variant meets PM2 and is identified in >1 case who met clinical criteria for FH after alternative causes for high cholesterol were excluded.Note: four other missense variants at this same codon have been reported: 1) NM_000527.5(LDLR):c.1A>G (p.Met1Val) – Likely pathogenic by these guidelines.2) NM_000527.4(LDLR):c.2T>C (p.Met1Thr) - Likely pathogenic by these guidelines.3) NM_000527.4(LDLR):c.3G>A (p.Met1Ile) - Likely pathogenic by these guidelines.4)  NM_000527.5(LDLR):c.3G>T (p.Met1Ile) - Likely pathogenic by these guidelines.  -PM5 not applicable as such variants must be Pathogenic.		Familial Hypercholesterolemia VCEP	https://clinicalgenome.org/docs/clingen-familial-hypercholesterolemia-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1-2/	2022-05-19	2022-05-19	False	https://erepo.genome.network/evrepo/ui/classification/CA10584718/MONDO:0007750/013	e7450868-fc21-439a-949f-f84feae9c98d	p.Met1Leu	Met	1	Leu	MGPWGWKLRWTVALLLAAAGTAVGDRCERNEFQCQDGKCISYKWVCDGSAECQDGSDESQETCLSVTCKSGDFSCGGRVNRCIPQFWRCDGQVDCDNGSDEQGCPPKTCSQDEFRCHDGKCISRQFVCDSDRDCLDGSDEASCPVLTCGPASFQCNSSTCIPQLWACDNDPDCEDGSDEWPQRCRGLYVFQGDSSPCSAFEFHCLSGECIHSSWRCDGGPDCKDKSDEENCAVATCRPDEFQCSDGNCIHGSRQCDREYDCKDMSDEVGCVNVTLCEGPNKFKCHSGECITLDKVCNMARDCRDWSDEPIKECGTNECLDNNGGCSHVCNDLKIGYECLCPDGFQLVAQRRCEDIDECQDPDTCSQLCVNLEGGYKCQCEEGFQLDPHTKACKAVGSIAYLFFTNRHEVRKMTLDRSEYTSLIPNLRNVVALDTEVASNRIYWSDLSQRMICSTQLDRAHGVSSYDTVISRDIQAPDGLAVDWIHSNIYWTDSVLGTVSVADTKGVKRKTLFRENGSKPRAIVVDPVHGFMYWTDWGTPAKIKKGGLNGVDIYSLVTENIQWPNGITLDLLSGRLYWVDSKLHSISSIDVNGGNRKTILEDEKRLAHPFSLAVFEDKVFWTDIINEAIFSANRLTGSDVNLLAENLLSPEDMVLFHNLTQPRGVNWCERTTLSNGGCQYLCLPAPQINPHSPKFTCACPDGMLLARDMRSCLTEAEAAVATQETSTVRLKVSSTAVRTQHTTTRPVPDTSRLPGATPGLTTVEIVTMSHQALGDVAGRGNEKKPSSVRALSIVLPIVLLVFLCLGVFLLWKNWRLKNINSINFDNPVYQKTTEDEVHICHNQDGYSYPSRQMVSLEDDVA	860	P01130	L	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [710], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.01552969]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [74, 77], 'ZN_FING_gain': [], 'ZN_FING_loss_score': array([-0.00574875, -0.00481629])}
414	NM_000527.5(LDLR):c.551G>A (p.Cys184Tyr)	3739	CA023721	NM_000527.5:c.551G>A, NC_000019.10:g.11105457G>A, CM000681.2:g.11105457G>A, NC_000019.9:g.11216133G>A, CM000681.1:g.11216133G>A, NC_000019.8:g.11077133G>A, NG_009060.1:g.21077G>A, LRG_274:g.21077G>A, ENST00000558518.6:c.551G>A, ENST00000252444.9:n.805G>A, ENST00000455727.6:c.314-1935G>A, ENST00000535915.5:c.428G>A, ENST00000545707.5:c.314-1108G>A, ENST00000557933.5:c.551G>A, ENST00000558013.5:c.551G>A, ENST00000558518.5:c.551G>A, ENST00000560467.1:n.151G>A, NM_000527.4:c.551G>A, LRG_274t1:c.551G>A, NM_001195798.1:c.551G>A, NM_001195799.1:c.428G>A, NM_001195800.1:c.314-1935G>A, NM_001195803.1:c.314-1108G>A, XM_011528010.1:c.551G>A, XM_011528011.1:c.314-1108G>A, XR_244074.2:n.701G>A, XM_011528010.2:c.551G>A, XR_001753685.2:n.668G>A, XR_001753686.2:n.668G>A, NM_001195798.2:c.551G>A, NM_001195799.2:c.428G>A, NM_001195800.2:c.314-1935G>A, NM_001195803.2:c.314-1108G>A, NM_000527.5(LDLR):c.551G>A (p.Cys184Tyr)	LDLR	hypercholesterolemia, familial	MONDO:0007750	Semidominant inheritance	Pathogenic	PS3, PS4, PP1_Strong, PM1, PM2, PP4	PS2, BS1, BS3, BS4, PM6, BA1	The NM_000527.5(LDLR):c.551G>A (p.Cys184Tyr) variant is classified as Pathogenic for Familial Hypercholesterolemia by applying evidence codes PM2, PP3, PM1, PS3, PS4, PP1_Strong, and PP4 as defined by the ClinGen Familial Hypercholesterolemia Expert Panel LDLR-specific variant curation guidelines (https://doi.org/10.1016/j.gim.2021.09.012). The supporting evidence is as follows:PM2 - PopMax MAF = 0.00019 (0.019%) in European Non-Finnish genomes (gnomAD v2.1.1).PP3 - REVEL = 0.85, which is above the threshold of 0.75.PM1 - variant meets PM2 and is located in exon 4.PS3 - Level 1 functional studies performed - Heterologous cells (CHO), FACS: Result of normal cell surface LDLR (100%), 4% LDL binding and 18% LDL uptake, compared to wild-type (PMID: 34167030).PS4 - Variant meets PM2 and is identified in at least 22 unrelated index cases who fulfill clinical criteria for FH (8 cases with SB criteria from Cardiovascular Research Group, Instituto Nacional de Saude Doutor Ricardo Jorge; 6 cases with DLCN criteria from Robarts Research Institute; 5 cases with DLCN criteria from PathWest Laboratory Medicine WA; 2 cases with DLCN criteria from Color; 1 case with MEDPED criteria from Mayo Clinic Atherosclerosis and Lipid Genomics Laboratory).PP1_Strong - Variant segregates with phenotype in 14 informative meioses from 8 families (Cardiovascular Research Group, Instituto Nacional de Saude Doutor Ricardo Jorge – 4 families: 8 relatives affected with the variant and 1 relative unaffected without the variant; Robarts Research Institute – 2 families: 2 relatives affected with the variant; PathWest Laboratory Medicine WA – 2 families: 2 affected relative with the variant and 1 unaffected relative without the variant)PP4 - variant meets PM2 and is identified in >1 case who met clinical criteria for FH after alternative causes for high cholesterol were excluded.		Familial Hypercholesterolemia VCEP	https://clinicalgenome.org/docs/clingen-familial-hypercholesterolemia-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1-2/	2022-04-22	2022-04-22	False	https://erepo.genome.network/evrepo/ui/classification/CA023721/MONDO:0007750/013	2f05ce00-876a-478f-b36c-26dfc18742c8	p.Cys184Tyr	Cys	184	Tyr	MGPWGWKLRWTVALLLAAAGTAVGDRCERNEFQCQDGKCISYKWVCDGSAECQDGSDESQETCLSVTCKSGDFSCGGRVNRCIPQFWRCDGQVDCDNGSDEQGCPPKTCSQDEFRCHDGKCISRQFVCDSDRDCLDGSDEASCPVLTCGPASFQCNSSTCIPQLWACDNDPDCEDGSDEWPQRCRGLYVFQGDSSPCSAFEFHCLSGECIHSSWRCDGGPDCKDKSDEENCAVATCRPDEFQCSDGNCIHGSRQCDREYDCKDMSDEVGCVNVTLCEGPNKFKCHSGECITLDKVCNMARDCRDWSDEPIKECGTNECLDNNGGCSHVCNDLKIGYECLCPDGFQLVAQRRCEDIDECQDPDTCSQLCVNLEGGYKCQCEEGFQLDPHTKACKAVGSIAYLFFTNRHEVRKMTLDRSEYTSLIPNLRNVVALDTEVASNRIYWSDLSQRMICSTQLDRAHGVSSYDTVISRDIQAPDGLAVDWIHSNIYWTDSVLGTVSVADTKGVKRKTLFRENGSKPRAIVVDPVHGFMYWTDWGTPAKIKKGGLNGVDIYSLVTENIQWPNGITLDLLSGRLYWVDSKLHSISSIDVNGGNRKTILEDEKRLAHPFSLAVFEDKVFWTDIINEAIFSANRLTGSDVNLLAENLLSPEDMVLFHNLTQPRGVNWCERTTLSNGGCQYLCLPAPQINPHSPKFTCACPDGMLLARDMRSCLTEAEAAVATQETSTVRLKVSSTAVRTQHTTTRPVPDTSRLPGATPGLTTVEIVTMSHQALGDVAGRGNEKKPSSVRALSIVLPIVLLVFLCLGVFLLWKNWRLKNINSINFDNPVYQKTTEDEVHICHNQDGYSYPSRQMVSLEDDVA	860	P01130	Y	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [183], 'DISULFID_gain': [], 'DISULFID_loss_score': array([-0.93444413]), 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [401], 'STRAND_gain_score': array([0.02569604]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [183], 'DOMAIN_gain': [194], 'DOMAIN_gain_score': array([0.12475955]), 'DOMAIN_loss_score': array([-0.44436431]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [138, 155, 168, 180, 181], 'ZN_FING_gain': [268], 'ZN_FING_gain_score': array([0.00468689]), 'ZN_FING_loss_score': array([-0.00997734, -0.03705996, -0.01548922, -0.06438267, -0.12913436])}
415	NM_000527.5(LDLR):c.682G>A (p.Glu228Lys)	3691	CA023749	NM_000527.5:c.682G>A, NC_000019.10:g.11105588G>A, CM000681.2:g.11105588G>A, NC_000019.9:g.11216264G>A, CM000681.1:g.11216264G>A, NC_000019.8:g.11077264G>A, NG_009060.1:g.21208G>A, LRG_274:g.21208G>A, ENST00000558518.6:c.682G>A, ENST00000252444.9:n.936G>A, ENST00000455727.6:c.314-1804G>A, ENST00000535915.5:c.559G>A, ENST00000545707.5:c.314-977G>A, ENST00000557933.5:c.682G>A, ENST00000558013.5:c.682G>A, ENST00000558518.5:c.682G>A, ENST00000560467.1:n.282G>A, NM_000527.4:c.682G>A, LRG_274t1:c.682G>A, NM_001195798.1:c.682G>A, NM_001195799.1:c.559G>A, NM_001195800.1:c.314-1804G>A, NM_001195803.1:c.314-977G>A, XM_011528010.1:c.682G>A, XM_011528011.1:c.314-977G>A, XR_244074.2:n.832G>A, XM_011528010.2:c.682G>A, XR_001753685.2:n.799G>A, XR_001753686.2:n.799G>A, NM_001195798.2:c.682G>A, NM_001195799.2:c.559G>A, NM_001195800.2:c.314-1804G>A, NM_001195803.2:c.314-977G>A, NM_000527.5(LDLR):c.682G>A (p.Glu228Lys)	LDLR	hypercholesterolemia, familial	MONDO:0007750	Semidominant inheritance	Pathogenic	PS3, PS4, PP1_Strong, PM1, PM2, PP3, PP4		NM_000527.5(LDLR):c.682G>A (p.Glu228Lys) variant is classified as pathogenic for Familial Hypercholesterolemia by applying evidence code PS3, PS4, PM1, PM2, PP1_Strong, PP3 and PP4 as defined by the ClinGen Familial Hypercholesterolemia Expert Panel LDLR-specific variant curation guidelines (https://doi.org/10.1016/j.gim.2021.09.012).The supporting evidence is as follows:PM2 - PopMax MAF = 0.0001105 (0.01%) in East Asian exomes (gnomAD v2.1.1).PP3 - REVEL = 0.972. It is above 0.75.PM1 - Variant meets PM2 and is missense located in exon 4 .PS3 - Three studies contribute to PS3 attribution. One (PMID: 10978268) report a level 3 assay performed on heterozygous patient's fibroblasts with radiolabeled LDL consistent with damaging effect of the variant (50% LDLR activity). The second reports a level 2 assay perfomed on homozygous patient's fibroblasts with radiolabeled LDL consistent with damaging effect of the variant (< 2% LDLR activity).The third is permformed on Heterologous cells (COS-7). FACS, CLSM and WB results in 24% LDLR expression and 21% LDL clearance. LDLR is retained in the ER.PS4 - Variant meets PM2 and is identified in 13 index cases who fulfil SB criteria for FH (n=1 CGMC, UFGOD, APHP.Sorbonne Université, Hôpital de la Pitié-Salpêtrière; n=1 Cardiovascular Research Group,Instituto Nacional de Saude Doutor Ricardo Jorge; n=1 Molecular Genetics Laboratory (Centre for Cardiovascular Surgery and Transplantation)) or DLCN criteria for FH (n=1 Robarts Research Institute; n=9 CGMC, UFGOD, APHP.Sorbonne Université, Hôpital de la Pitié-Salpêtrière).PP1_Strong - Variant segregate with FH in 10 informatives meiosis (6 relatives positive LDL-C > 75th percentile and 4 relatives negative LDLC < 50th percentile) from 2 families from Laboratory of Genetics and Molecular Cardiology, University of São Paulo and in 1 relative positive for variant  (LDL-C > 75th percentile) from Cardiovascular Research Group,Instituto Nacional de Saude Doutor Ricardo Jorge. PP4 - Variant meets PM2 and is identified in 13 index cases who fulfil SB criteria for FH (n=1 CGMC, UFGOD, APHP.Sorbonne Université, Hôpital de la Pitié-Salpêtrière; n=1 Cardiovascular Research Group,Instituto Nacional de Saude Doutor Ricardo Jorge; n=1 Molecular Genetics Laboratory (Centre for Cardiovascular Surgery and Transplantation)) or DLCN criteria for FH (n=1 Robarts Research Institute; n=9 CGMC, UFGOD, APHP.Sorbonne Université, Hôpital de la Pitié-Salpêtrière).		Familial Hypercholesterolemia VCEP	https://clinicalgenome.org/docs/clingen-familial-hypercholesterolemia-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1-2/	2022-06-21	2022-06-21	False	https://erepo.genome.network/evrepo/ui/classification/CA023749/MONDO:0007750/013	e72e629f-1640-40bb-97c4-aed2ca36bbe3	p.Glu228Lys	Glu	228	Lys	MGPWGWKLRWTVALLLAAAGTAVGDRCERNEFQCQDGKCISYKWVCDGSAECQDGSDESQETCLSVTCKSGDFSCGGRVNRCIPQFWRCDGQVDCDNGSDEQGCPPKTCSQDEFRCHDGKCISRQFVCDSDRDCLDGSDEASCPVLTCGPASFQCNSSTCIPQLWACDNDPDCEDGSDEWPQRCRGLYVFQGDSSPCSAFEFHCLSGECIHSSWRCDGGPDCKDKSDEENCAVATCRPDEFQCSDGNCIHGSRQCDREYDCKDMSDEVGCVNVTLCEGPNKFKCHSGECITLDKVCNMARDCRDWSDEPIKECGTNECLDNNGGCSHVCNDLKIGYECLCPDGFQLVAQRRCEDIDECQDPDTCSQLCVNLEGGYKCQCEEGFQLDPHTKACKAVGSIAYLFFTNRHEVRKMTLDRSEYTSLIPNLRNVVALDTEVASNRIYWSDLSQRMICSTQLDRAHGVSSYDTVISRDIQAPDGLAVDWIHSNIYWTDSVLGTVSVADTKGVKRKTLFRENGSKPRAIVVDPVHGFMYWTDWGTPAKIKKGGLNGVDIYSLVTENIQWPNGITLDLLSGRLYWVDSKLHSISSIDVNGGNRKTILEDEKRLAHPFSLAVFEDKVFWTDIINEAIFSANRLTGSDVNLLAENLLSPEDMVLFHNLTQPRGVNWCERTTLSNGGCQYLCLPAPQINPHSPKFTCACPDGMLLARDMRSCLTEAEAAVATQETSTVRLKVSSTAVRTQHTTTRPVPDTSRLPGATPGLTTVEIVTMSHQALGDVAGRGNEKKPSSVRALSIVLPIVLLVFLCLGVFLLWKNWRLKNINSINFDNPVYQKTTEDEVHICHNQDGYSYPSRQMVSLEDDVA	860	P01130	K	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [181, 228, 232], 'ZN_FING_gain': [], 'ZN_FING_loss_score': array([-0.00617903, -0.00732756, -0.00788093])}
416	NM_000545.8(HNF1A):c.1849G>A (p.Val617Ile)	972765	CA6832205	NM_000545.8:c.1849G>A, NC_000012.12:g.121001145G>A, CM000674.2:g.121001145G>A, NC_000012.11:g.121438948G>A, CM000674.1:g.121438948G>A, NC_000012.10:g.119923331G>A, NG_011731.2:g.27400G>A, LRG_522:g.27400G>A, ENST00000257555.11:c.1849G>A, ENST00000257555.10:c.1849G>A, ENST00000288757.7:c.*3008C>T, ENST00000540108.1:c.*1289G>A, ENST00000541395.5:c.1942G>A, ENST00000543427.5:c.1312G>A, ENST00000544413.2:c.1870G>A, ENST00000560968.5:n.1666G>A, ENST00000615446.4:c.637G>A, ENST00000617366.4:c.*258G>A, NM_000545.5:c.1849G>A, LRG_522t1:c.1849G>A, NM_000545.6:c.1849G>A, NM_001306179.1:c.1870G>A, XM_005253931.2:c.1942G>A, XM_024449168.1:c.1942G>A, NM_001286191.2:c.*3008C>T, NM_001286196.2:c.*3008C>T, NM_001306179.2:c.1870G>A, NM_022895.3:c.*3008C>T, NM_000545.8(HNF1A):c.1849G>A (p.Val617Ile)	HNF1A	monogenic diabetes	MONDO:0015967	Autosomal dominant inheritance	Benign	BS1, BS2, PP4	PS3, PS4, PP1	The c.1849G>A variant in the HNF1 homeobox A gene, HNF1A, causes an amino acid change of valine to isoleucine at codon 617 (p.(Val617Ile)) of NM_000545.8. This variant has a Popmax Filtering allele frequency in gnomAD 2.1.1 of 0.00003429, which is greater than the MDEP threshold for BS1 (≥0.000033) (BS1). This variant also was identified in a normoglycemic individual >70 years old, and the expected penetrance for HNF1A-MODY is 95% by age 70 (internal lab contributors) (BS2). This variant was identified in an individual with a clinical history highly specific for HNF1A-MODY (MODY probability calculator result >50%, negative genetic testing for HNF4A) (PP4; internal lab contributors). This variant was identified in two unrelated individuals with non-autoimmune and non-absolute/near-absolute insulin-deficient diabetes; however, PS4_Moderate cannot be applied because this number is below the ClinGen MDEP threshold, and PM2_Supporting is not met (PMID: 12488962, internal lab contributors).  This variant segregated with diabetes with one informative meiosis in a single family; however, this does not meet the thresholds for PP1 set by the ClinGen MDEP (PMIDs: 27236918, 12488962).  Transactivation activity (COS-7 cells) was 63% of wildtype, which was between ClinGen MDEP thresholds for PS3_Supporting and BS3_Supporting (PMID: 12488962).  In summary, c.1849G>A meets the criteria to be classified as benign for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.1, approved 9/30/2021): BS1, BS2, PP4.		Monogenic Diabetes VCEP		2022-05-02	2022-05-02	False	https://erepo.genome.network/evrepo/ui/classification/CA6832205/MONDO:0015967/017	8be5dbda-26ba-4f58-af5a-6c61209c89a7	p.Val617Ile	Val	617	Ile	MVSKLSQLQTELLAALLESGLSKEALIQALGEPGPYLLAGEGPLDKGESCGGGRGELAELPNGLGETRGSEDETDDDGEDFTPPILKELENLSPEEAAHQKAVVETLLQEDPWRVAKMVKSYLQQHNIPQREVVDTTGLNQSHLSQHLNKGTPMKTQKRAALYTWYVRKQREVAQQFTHAGQGGLIEEPTGDELPTKKGRRNRFKWGPASQQILFQAYERQKNPSKEERETLVEECNRAECIQRGVSPSQAQGLGSNLVTEVRVYNWFANRRKEEAFRHKLAMDTYSGPPPGPGPGPALPAHSSPGLPPPALSPSKVHGVRYGQPATSETAEVPSSSGGPLVTVSTPLHQVSPTGLEPSHSLLSTEAKLVSAAGGPLPPVSTLTALHSLEQTSPGLNQQPQNLIMASLPGVMTIGPGEPASLGPTFTNTGASTLVIGLASTQAQSVPVINSMGSSLTTLQPVQFSQPLHPSYQQPLMPPVQSHVTQSPFMATMAQLQSPHALYSHKPEVAQYTHTGLLPQTMLITDTTNLSALASLTPTKQVFTSDTEASSESGLHTPASQATTLHVPSQDPAGIQHLQPAHRLSASPTVSSSSLVLYQSSDSSNGQSHLLPSNHSVIETFISTQMASSSQ	631	P20823	I	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [5, 34], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.01565945, -0.00927234]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
417	NM_000545.8(HNF1A):c.155_156delinsCT (p.Gly52Ala)	134503	CA159995	NM_000545.8:c.155_156delinsCT, NC_000012.12:g.120978923_120978924delinsCT, CM000674.2:g.120978923_120978924delinsCT, NC_000012.11:g.121416726_121416727delinsCT, CM000674.1:g.121416726_121416727delinsCT, NC_000012.10:g.119901109_119901110delinsCT, NG_011731.2:g.5178_5179delinsCT, LRG_522:g.5178_5179delinsCT, ENST00000257555.11:c.155_156delinsCT, ENST00000257555.10:c.155_156delinsCT, ENST00000400024.6:c.155_156delinsCT, ENST00000402929.5:n.290_291delinsCT, ENST00000535955.5:n.42+231_42+232delinsCT, ENST00000538626.2:n.190+83_190+84delinsCT, ENST00000538646.5:c.155_156delinsCT, ENST00000540108.1:c.155_156delinsCT, ENST00000541395.5:c.155_156delinsCT, ENST00000541924.5:c.155_156delinsCT, ENST00000543427.5:c.155_156delinsCT, ENST00000544413.2:c.155_156delinsCT, ENST00000544574.5:c.72+83_72+84delinsCT, ENST00000560968.5:n.298_299delinsCT, ENST00000615446.4:c.-258+212_-258+213delinsCT, ENST00000617366.4:c.155_156delinsCT, NM_000545.5:c.155_156delinsCT, LRG_522t1:c.155_156delinsCT, NM_000545.6:c.155_156delinsCT, NM_001306179.1:c.155_156delinsCT, XM_005253931.2:c.155_156delinsCT, XM_024449168.1:c.155_156delinsCT, NM_001306179.2:c.155_156delinsCT, NM_000545.8(HNF1A):c.155_156delinsCT (p.Gly52Ala)	HNF1A	monogenic diabetes	MONDO:0015967	Autosomal dominant inheritance	Benign	BA1	PS4, PM2, PP3, PP1	The c.155_156delinsCT variant in the HNF1 homeobox A gene, HNF1A, causes an amino acid change of Glycine to Alanine at codon 52 (p.(Gly52Ala)) of transcript NM_000545.8. This variant has a Popmax Filtering allele frequency in gnomAD 2.1.1 of 0.0024, which is greater than the MDEP threshold for BA1 (≥0.0001) (BA1).  In summary, c.155_156delinsCT meets the criteria to be classified as benign for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.1, approved 9/30/2021): BA1.	25555642, 10690959	Monogenic Diabetes VCEP		2022-05-03	2022-05-03	False	https://erepo.genome.network/evrepo/ui/classification/CA159995/MONDO:0015967/017	2abbfbc5-058c-45f2-b93f-1bb4d15351f1	p.Gly52Ala	Gly	52	Ala	MVSKLSQLQTELLAALLESGLSKEALIQALGEPGPYLLAGEGPLDKGESCGGGRGELAELPNGLGETRGSEDETDDDGEDFTPPILKELENLSPEEAAHQKAVVETLLQEDPWRVAKMVKSYLQQHNIPQREVVDTTGLNQSHLSQHLNKGTPMKTQKRAALYTWYVRKQREVAQQFTHAGQGGLIEEPTGDELPTKKGRRNRFKWGPASQQILFQAYERQKNPSKEERETLVEECNRAECIQRGVSPSQAQGLGSNLVTEVRVYNWFANRRKEEAFRHKLAMDTYSGPPPGPGPGPALPAHSSPGLPPPALSPSKVHGVRYGQPATSETAEVPSSSGGPLVTVSTPLHQVSPTGLEPSHSLLSTEAKLVSAAGGPLPPVSTLTALHSLEQTSPGLNQQPQNLIMASLPGVMTIGPGEPASLGPTFTNTGASTLVIGLASTQAQSVPVINSMGSSLTTLQPVQFSQPLHPSYQQPLMPPVQSHVTQSPFMATMAQLQSPHALYSHKPEVAQYTHTGLLPQTMLITDTTNLSALASLTPTKQVFTSDTEASSESGLHTPASQATTLHVPSQDPAGIQHLQPAHRLSASPTVSSSSLVLYQSSDSSNGQSHLLPSNHSVIETFISTQMASSSQ	631	P20823	A	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [102], 'HELIX_gain_score': array([0.00762755]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [77], 'COMPBIAS_gain': [], 'COMPBIAS_loss_score': array([-0.04090345]), 'DOMAIN_loss': [5, 34], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.02651685, -0.02887553]), 'REGION_loss': [39], 'REGION_gain': [], 'REGION_loss_score': array([-0.15428466]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
418	NM_000152.5(GAA):c.896T>C (p.Leu299Pro)	180144	CA273686	NM_000152.5:c.896T>C, NC_000017.11:g.80107837T>C, CM000679.2:g.80107837T>C, NC_000017.10:g.78081636T>C, CM000679.1:g.78081636T>C, NC_000017.9:g.75696231T>C, NG_009822.1:g.11282T>C, LRG_673:g.11282T>C, ENST00000302262.8:c.896T>C, ENST00000302262.7:c.896T>C, ENST00000390015.7:c.896T>C, NM_000152.3:c.896T>C, LRG_673t1:c.896T>C, NM_001079803.1:c.896T>C, NM_001079804.1:c.896T>C, XM_005257193.1:c.896T>C, XM_005257194.3:c.896T>C, NM_000152.4:c.896T>C, NM_001079803.2:c.896T>C, NM_001079804.2:c.896T>C, XM_005257193.2:c.896T>C, XM_005257194.4:c.896T>C, NM_001079803.3:c.896T>C, NM_001079804.3:c.896T>C, NM_000152.5(GAA):c.896T>C (p.Leu299Pro)	GAA	glycogen storage disease II	MONDO:0009290	Autosomal recessive inheritance	Pathogenic	PS3, PP4_Moderate, PP3, PM2_Supporting, PM3	PM5	The NM_000152.5:c.896T>C variant in GAA is a missense variant predicted to cause substitution of Leucine by Proline at amino acid 299 (p.Leu299Pro). At least 4 individuals have been reported with this variant and either diagnosis of Pompe disease with ERT treatment or GAA activity <10% normal in lymphocytes/leukocytes/muscle samples/unknown tissue (PMIDs 26622091, 26873529, 25626711,29422078). Another patient was homozygous for this variant and identified by newborn screening for Pompe disease (PMID: 22133539). This meets the criteria for PP4_Moderate. This variant has been detected in at least 7 individuals with Pompe disease or identified by newborn screening for Pompe disease. Of those individuals, 4 were compound heterozygous for the variant and a pathogenic variant, c.-32-13T>G (PMID:18757064, 26622091, 26873529). At least 1 individual was homozygous for the variant (PMID: 22133539,25626711). Criteria for PM3 were met. This variant is absent in gnomAD v2.1.1 (PM2_Supporting). Expression of the variant in COS cells resulted in 0% wild type GAA activity and evidence of abnormal synthesis and processing on Western blots leading the variant to be described as Class B (“potentially less severe”, indicating that this variant may impact protein function (PMID:18425781)(PS3). REVEL Score = 0.952 which is higher than the LSD VCEP threshold for PP3 (>0.7) and therefore meets this criterion. There is a ClinVar entry for this variant (Variation ID: 180144, 2 star review status) with 5 submitters classifying the variant as Pathogenic. In summary, this variant meets the criteria to be classified as Pathogenic for Pompe disease based on the ACMG/AMP criteria applied, as specified by the ClinGen Lysosomal Storage Disorders Variant Curation Expert panel (specifications Version 2.0): PS3, PP4_Moderate, PM3, PM2_Supporting, PP3		Lysosomal Diseases VCEP	https://clinicalgenome.org/docs/clingen-lysosomal-storage-disorders-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-2/	2022-05-11	2022-05-11	False	https://erepo.genome.network/evrepo/ui/classification/CA273686/MONDO:0009290/010	f6e2a5b8-6227-4d3b-b770-cadd3638fb54	p.Leu299Pro	Leu	299	Pro	MGVRHPPCSHRLLAVCALVSLATAALLGHILLHDFLLVPRELSGSSPVLEETHPAHQQGASRPGPRDAQAHPGRPRAVPTQCDVPPNSRFDCAPDKAITQEQCEARGCCYIPAKQGLQGAQMGQPWCFFPPSYPSYKLENLSSSEMGYTATLTRTTPTFFPKDILTLRLDVMMETENRLHFTIKDPANRRYEVPLETPHVHSRAPSPLYSVEFSEEPFGVIVRRQLDGRVLLNTTVAPLFFADQFLQLSTSLPSQYITGLAEHLSPLMLSTSWTRITLWNRDLAPTPGANLYGSHPFYLALEDGGSAHGVFLLNSNAMDVVLQPSPALSWRSTGGILDVYIFLGPEPKSVVQQYLDVVGYPFMPPYWGLGFHLCRWGYSSTAITRQVVENMTRAHFPLDVQWNDLDYMDSRRDFTFNKDGFRDFPAMVQELHQGGRRYMMIVDPAISSSGPAGSYRPYDEGLRRGVFITNETGQPLIGKVWPGSTAFPDFTNPTALAWWEDMVAEFHDQVPFDGMWIDMNEPSNFIRGSEDGCPNNELENPPYVPGVVGGTLQAATICASSHQFLSTHYNLHNLYGLTEAIASHRALVKARGTRPFVISRSTFAGHGRYAGHWTGDVWSSWEQLASSVPEILQFNLLGVPLVGADVCGFLGNTSEELCVRWTQLGAFYPFMRNHNSLLSLPQEPYSFSEPAQQAMRKALTLRYALLPHLYTLFHQAHVAGETVARPLFLEFPKDSSTWTVDHQLLWGEALLITPVLQAGKAEVTGYFPLGTWYDLQTVPVEALGSLPPPPAAPREPAIHSEGQWVTLPAPLDTINVHLRAGYIIPLQGPGLTTTESRQQPMALAVALTKGGEARGELFWDDGESLEVLERGAYTQVIFLARNNTIVNELVRVTSEGAGLQLQKVTVLGVATAPQQVLSNGVPVSNFTYSPDTKVLDICVSLLMGEQFLVSWC	952	P10253	P	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [367, 368, 611, 707], 'DNA_BIND_gain_score': array([0.00407016, 0.00440586, 0.00263077, 0.00123739]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [305], 'STRAND_gain': [259], 'STRAND_gain_score': array([0.0383417]), 'STRAND_loss_score': array([-0.21122247]), 'HELIX_loss': [], 'HELIX_gain': [364], 'HELIX_gain_score': array([0.02796942]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
419	NM_016239.4(MYO15A):c.2238G>T (p.Arg746Ser)	226780	CA8423237	NM_016239.4:c.2238G>T, NC_000017.11:g.18121038G>T, CM000679.2:g.18121038G>T, NC_000017.10:g.18024352G>T, CM000679.1:g.18024352G>T, NC_000017.9:g.17965077G>T, NG_011634.1:g.17333G>T, NG_011634.2:g.17333G>T, ENST00000647165.2:c.2238G>T, ENST00000205890.9:c.2238G>T, ENST00000583079.1:n.1871G>T, ENST00000615845.4:c.2238G>T, NM_016239.3:c.2238G>T, XM_011523917.1:c.2238G>T, XM_011523918.1:c.2238G>T, XM_011523919.1:c.2238G>T, XM_011523920.1:c.2238G>T, XM_011523921.1:c.2238G>T, XR_934037.1:n.2897G>T, XR_934038.1:n.2897G>T, XR_934039.1:n.2897G>T, XM_011523918.2:c.2238G>T, XM_017024714.2:c.2238G>T, XM_017024715.2:c.2238G>T, XM_024450780.1:c.2238G>T, XM_024450781.1:c.2238G>T, XM_024450782.1:c.2238G>T, XR_934039.2:n.2936G>T, NM_016239.4(MYO15A):c.2238G>T (p.Arg746Ser)	MYO15A	nonsyndromic genetic deafness	MONDO:0019497	Autosomal recessive inheritance	Benign	BP4, BA1		The filtering allele frequency (the lower threshold of the 95% CI of 511/11092) of the p.Arg746Ser variant in the MYO15A gene is 4.27% for African chromosomes (including 8 homozygous observations) by gnomAD, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive hearing loss variants (BA1). Additionally, computational prediction analysis using the metapredictor tool REVEL suggests that the variant may not impact the protein (BP4). In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel : BA1, BP4.		Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2021-06-15	2022-05-13	False	https://erepo.genome.network/evrepo/ui/classification/CA8423237/MONDO:0019497/005	c106e1bb-b977-487c-8f1d-a99424ff232a	p.Arg746Ser	Arg	746	Ser	MAKEEDEEKKAKKGKKGKKAPEPEKPKRSLKGTSRLFMGFRDRTPKISKKGQFRSASAFFWGLHTGPQKTKRKRKARTVLKSTSKLMTQMRMGKKKRAMKGKKPSFMVIRFPGRRGYGRLRPRARSLSKASTAINWLTKKFLLKKAEESGSEQATVDAWLQRSSSRMGSRKLPFPSGAEILRPGGRLRRFPRSRSIYASGEPLGFLPFEDEAPFHHSGSRKSLYGLEGFQDLGEYYDYHRDGDDYYDRQSLHRYEEQEPYLAGLGPYSPAWPPYGDHYYGYPPEDPYDYYHPDYYGGPFDPGYTYGYGYDDYEPPYAPPSGYSSPYSYHDGYEGEAHPYGYYLDPYAPYDAPYPPYDLPYHTPYDVPYFDPYGVHYTVPYAEGVYGGGDEAIYPPEVPYFYPEESASAFVYPWVPPPIPSPHNPYAHAMDDIAELEEPEDAGVERQGTSFRLPSAAFFEQQGMDKPARSKLSLIRKFRLFPRPQVKLFGKEKLEVPLPPSLDIPLPLGDADEEEDEEELPPVSAVPYGHPFWGFLTPRQRNLQRALSAFGAHRGLGFGPEFGRPVPRPATSLARFLKKTLSEKKPIARLRGSQKARAGGPAVREAAYKRFGYKLAGMDPEKPGTPIVLRRAQPRARSSNDARRPPAPQPAPRTLSHWSALLSPPVPPRPPSSGPPPAPPLSPALSGLPRPASPYGSLRRHPPPWAAPAHVPPAPQASWWAFVEPPAVSPEVPPDLLAFPGPRPSFRGSRRRGAAFGFPGASPRASRRRAWSPLASPQPSLRSSPGLGYCSPLAPPSPQLSLRTGPFQPPFLPPARRPRSLQESPAPRRAAGRLGPPGSPLPGSPRPPSPPLGLCHSPRRSSLNLPSRLPHTWRRLSEPPTRAVKPQVRLPFHRPPRAGAWRAPLEHRESPREPEDSETPWTVPPLAPSWDVDMPPTQRPPSPWPGGAGSRRGFSRPPPVPENPFLQLLGPVPSPTLQPEDPAADMTRVFLGRHHEPGPGQLTKSAGPTPEKPEEEATLGDPQLPAETKPPTPAPPKDVTPPKDITPPKDVLPEQKTLRPSLSYPLAACDQTRATWPPWHRWGTLPQAAAPLAPIRAPEPLPKGGERRQAAPGRFAVVMPRVQKLSSFQRVGPATLKPQVQPIQDPKPRACSLRWSCLWLRADAYGPWPRVHTHPQSCHLGPGAACLSLRGSWEEVGPPSWRNKMHSIRNLPSMRFREQHGEDGVEDMTQLEDLQETTVLSNLKIRFERNLIYTYIGSILVSVNPYQMFGIYGPEQVQQYNGRALGENPPHLFAVANLAFAKMLDAKQNQCIIISGESGSGKTEATKLILRYLAAMNQKREVMQQIKILEATPLLESFGNAKTVRNDNSSRFGKFVEIFLEGGVISGAITSQYLLEKSRIVFQAKNERNYHIFYELLAGLPAQLRQAFSLQEAETYYYLNQGGNCEIAGKSDADDFRRLLAAMEVLGFSSEDQDSIFRILASILHLGNVYFEKYETDAQEVASVVSAREIQAVAELLQISPEGLQKAITFKVTETMREKIFTPLTVESAVDARDAIAKVLYALLFSWLITRVNALVSPRQDTLSIAILDIYGFEDLSFNSFEQLCINYANENLQYLFNKIVFQEEQEEYIREQIDWQEITFADNQPCINLISLKPYGILRILDDQCCFPQATDHTFLQKCHYHHGANPLYSKPKMPLPEFTIKHYAGKVTYQVHKFLDKNHDQVRQDVLDLFVRSRTRVVAHLFSSHAPQAAPQRLGKSSSVTRLYKAHTVAAKFQQSLLDLVEKMERCNPLFMRCLKPNHKKEPGLFEPDVVMAQLRYSGVLETVRIRKEGFPVRLPFQGFIDRYCCLVALKHDLPANGDMCVSVLSRLCKVMPNMYRVGVSKLFLKEHLYQLLESMREHVLNLAALTLQRCLRGFFIKRRFRSLRHKIILLQSRARGYLARQRYQQMRRSLVKFRSLVHAYVSRRRYLKLRAEWRCQVEGALLWEQEELSKREVVAVGHLEVPAELAGLLQAVAGLGLAQVPQVAPVRTPRLQAEPRVTLPLDINNYPMAKFVQCHFKEPAFGMLTVPLRTPLTQLPAEHHAEAVSIFKLILRFMGDPHLHGARENIFGNYIVQKGLAVPELRDEILAQLANQVWHNHNAHNAERGWLLLAACLSGFAPSPCFNKYLLKFVSDYGRNGFQAVCQHRLMQAMGRAQQQGSGAARTLPPTQLEWTATYEKASMALDVGCFNGDQFSCPVHSWSTGEEVAGDILRHRGLADGWRGWTVAMKNGVQWAELAGHDYVLDLVSDLELLRDFPRQKSYFIVGTEGPAASRGGPKVVFGNSWDSDEDMSTRPQPQEHMPKVLDSDGYSSHNQDGTNGETEAQRGTATHQESDSLGEPAVPHKGLDCYLDSLFDPVLSYGDADLEKPTAIAYRMKGGGQPGGGSSSGTEDTPRRPPEPKPIPGLDASTLALQQAFIHKQAVLLAREMTLQATALQQQPLSAALRSLPAEKPPAPEAQPTSVGTGPPAKPVLLRATPKPLAPAPLAKAPRLPIKPVAAPVLAQDQASPETTSPSPELVRYSTLNSEHFPQPTQQIKNIVRQYQQPFRGGRPEALRKDGGKVFMKRPDPHEEALMILKGQMTHLAAAPGTQVSREAVALVKPVTSAPRPSMAPTSALPSRSLEPPEELTQTRLHRLINPNFYGYQDAPWKIFLRKEVFYPKDSYSHPVQLDLLFRQILHDTLSEACLRISEDERLRMKALFAQNQLDTQKPLVTESVKRAVVSTARDTWEVYFSRIFPATGSVGTGVQLLAVSHVGIKLLRMVKGGQEAGGQLRVLRAYSFADILFVTMPSQNMLEFNLASEKVILFSARAHQVKTLVDDFILELKKDSDYVVAVRNFLPEDPALLAFHKGDIIHLQPLEPPRVGYSAGCVVRRKVVYLEELRRRGPDFGWRFGTIHGRVGRFPSELVQPAAAPDFLQLPTEPGRGRAAAVAAAVASAAAAQEVGRRREGPPVRARSADHGEDALALPPYTMLEFAQKYFRDPQRRPQDGLRLKSKEPRESRTLEDMLCFTKTPLQESLIELSDSSLSKMATDMFLAVMRFMGDAPLKGQSDLDVLCNLLKLCGDHEVMRDECYCQVVKQITDNTSSKQDSCQRGWRLLYIVTAYHSCSEVLHPHLTRFLQDVSRTPGLPFQGIAKACEQNLQKTLRFGGRLELPSSIELRAMLAGRSSKRQLFLLPGGLERHLKIKTCTVALDVVEEICAEMALTRPEAFNEYVIFVVTNRGQHVCPLSRRAYILDVASEMEQVDGGYMLWFRRVLWDQPLKFENELYVTMHYNQVLPDYLKGLFSSVPASRPSEQLLQQVSKLASLQHRAKDHFYLPSVREVQEYIPAQLYRTTAGSTWLNLVSQHRQQTQALSPHQARAQFLGLLSALPMFGSSFFFIQSCSNIAVPAPCILAINHNGLNFLSTETHELMVKFPLKEIQSTRTQRPTANSSYPYVEIALGDVAAQRTLQLQLEQGLELCRVVAVHVENLLSAHEKRLTLPPSEITLL	3530	Q9UKN7	S	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [1006], 'REGION_gain_score': array([0.00189817]), 'REPEAT_loss': [], 'REPEAT_gain': [819, 822, 844, 846, 850, 1224, 2020, 2158, 2160, 2168, 2453, 2459, 2556, 3427, 3429, 3433, 3515, 3516], 'REPEAT_gain_score': array([0.0017426 , 0.00257409, 0.00340688, 0.00344688, 0.00309849,
       0.0023964 , 0.00283611, 0.00344467, 0.00352412, 0.00345033,
       0.00261974, 0.00244302, 0.00197113, 0.00248367, 0.00261897,
       0.0026288 , 0.00242078, 0.00227892]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
420	NM_016239.4(MYO15A):c.5929T>C (p.Cys1977Arg)	45753	CA136998	NM_016239.4:c.5929T>C, NC_000017.11:g.18143584T>C, CM000679.2:g.18143584T>C, NC_000017.10:g.18046898T>C, CM000679.1:g.18046898T>C, NC_000017.9:g.17987623T>C, NG_011634.1:g.39879T>C, NG_011634.2:g.39879T>C, ENST00000647165.2:c.5929T>C, ENST00000205890.9:c.5929T>C, ENST00000615845.4:c.5929T>C, NM_016239.3:c.5929T>C, XM_011523917.1:c.5905-131T>C, XM_011523918.1:c.5905-131T>C, XM_011523919.1:c.5905-131T>C, XM_011523920.1:c.*36T>C, XM_011523921.1:c.5923T>C, XR_934037.1:n.6564-131T>C, XR_934038.1:n.6564-131T>C, XR_934039.1:n.6821T>C, XM_011523918.2:c.5905-131T>C, XM_017024714.2:c.5905-131T>C, XM_017024715.2:c.5932T>C, XM_024450780.1:c.5905-131T>C, XM_024450781.1:c.5905-131T>C, XM_024450782.1:c.*36T>C, XR_934039.2:n.6860T>C, NM_016239.4(MYO15A):c.5929T>C (p.Cys1977Arg)	MYO15A	nonsyndromic genetic deafness	MONDO:0019497	Autosomal recessive inheritance	Benign	BA1	BP4	The filtering allele frequency (the lower threshold of the 95% CI of 15730/17934) of the p.Cys1977Arg variant in the MYO15A gene is 86.6% for African chromosomes (including 6913 homozygous observations) by gnomAD v2.1, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive hearing loss variants (BA1). ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel : BA1.		Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2021-06-16	2022-05-13	False	https://erepo.genome.network/evrepo/ui/classification/CA136998/MONDO:0019497/005	068fa8a8-3311-4a6b-9a51-fb53e2168f9e	p.Cys1977Arg	Cys	1977	Arg	MAKEEDEEKKAKKGKKGKKAPEPEKPKRSLKGTSRLFMGFRDRTPKISKKGQFRSASAFFWGLHTGPQKTKRKRKARTVLKSTSKLMTQMRMGKKKRAMKGKKPSFMVIRFPGRRGYGRLRPRARSLSKASTAINWLTKKFLLKKAEESGSEQATVDAWLQRSSSRMGSRKLPFPSGAEILRPGGRLRRFPRSRSIYASGEPLGFLPFEDEAPFHHSGSRKSLYGLEGFQDLGEYYDYHRDGDDYYDRQSLHRYEEQEPYLAGLGPYSPAWPPYGDHYYGYPPEDPYDYYHPDYYGGPFDPGYTYGYGYDDYEPPYAPPSGYSSPYSYHDGYEGEAHPYGYYLDPYAPYDAPYPPYDLPYHTPYDVPYFDPYGVHYTVPYAEGVYGGGDEAIYPPEVPYFYPEESASAFVYPWVPPPIPSPHNPYAHAMDDIAELEEPEDAGVERQGTSFRLPSAAFFEQQGMDKPARSKLSLIRKFRLFPRPQVKLFGKEKLEVPLPPSLDIPLPLGDADEEEDEEELPPVSAVPYGHPFWGFLTPRQRNLQRALSAFGAHRGLGFGPEFGRPVPRPATSLARFLKKTLSEKKPIARLRGSQKARAGGPAVREAAYKRFGYKLAGMDPEKPGTPIVLRRAQPRARSSNDARRPPAPQPAPRTLSHWSALLSPPVPPRPPSSGPPPAPPLSPALSGLPRPASPYGSLRRHPPPWAAPAHVPPAPQASWWAFVEPPAVSPEVPPDLLAFPGPRPSFRGSRRRGAAFGFPGASPRASRRRAWSPLASPQPSLRSSPGLGYCSPLAPPSPQLSLRTGPFQPPFLPPARRPRSLQESPAPRRAAGRLGPPGSPLPGSPRPPSPPLGLCHSPRRSSLNLPSRLPHTWRRLSEPPTRAVKPQVRLPFHRPPRAGAWRAPLEHRESPREPEDSETPWTVPPLAPSWDVDMPPTQRPPSPWPGGAGSRRGFSRPPPVPENPFLQLLGPVPSPTLQPEDPAADMTRVFLGRHHEPGPGQLTKSAGPTPEKPEEEATLGDPQLPAETKPPTPAPPKDVTPPKDITPPKDVLPEQKTLRPSLSYPLAACDQTRATWPPWHRWGTLPQAAAPLAPIRAPEPLPKGGERRQAAPGRFAVVMPRVQKLSSFQRVGPATLKPQVQPIQDPKPRACSLRWSCLWLRADAYGPWPRVHTHPQSCHLGPGAACLSLRGSWEEVGPPSWRNKMHSIRNLPSMRFREQHGEDGVEDMTQLEDLQETTVLSNLKIRFERNLIYTYIGSILVSVNPYQMFGIYGPEQVQQYNGRALGENPPHLFAVANLAFAKMLDAKQNQCIIISGESGSGKTEATKLILRYLAAMNQKREVMQQIKILEATPLLESFGNAKTVRNDNSSRFGKFVEIFLEGGVISGAITSQYLLEKSRIVFQAKNERNYHIFYELLAGLPAQLRQAFSLQEAETYYYLNQGGNCEIAGKSDADDFRRLLAAMEVLGFSSEDQDSIFRILASILHLGNVYFEKYETDAQEVASVVSAREIQAVAELLQISPEGLQKAITFKVTETMREKIFTPLTVESAVDARDAIAKVLYALLFSWLITRVNALVSPRQDTLSIAILDIYGFEDLSFNSFEQLCINYANENLQYLFNKIVFQEEQEEYIREQIDWQEITFADNQPCINLISLKPYGILRILDDQCCFPQATDHTFLQKCHYHHGANPLYSKPKMPLPEFTIKHYAGKVTYQVHKFLDKNHDQVRQDVLDLFVRSRTRVVAHLFSSHAPQAAPQRLGKSSSVTRLYKAHTVAAKFQQSLLDLVEKMERCNPLFMRCLKPNHKKEPGLFEPDVVMAQLRYSGVLETVRIRKEGFPVRLPFQGFIDRYCCLVALKHDLPANGDMCVSVLSRLCKVMPNMYRVGVSKLFLKEHLYQLLESMREHVLNLAALTLQRCLRGFFIKRRFRSLRHKIILLQSRARGYLARQRYQQMRRSLVKFRSLVHAYVSRRRYLKLRAEWRCQVEGALLWEQEELSKREVVAVGHLEVPAELAGLLQAVAGLGLAQVPQVAPVRTPRLQAEPRVTLPLDINNYPMAKFVQCHFKEPAFGMLTVPLRTPLTQLPAEHHAEAVSIFKLILRFMGDPHLHGARENIFGNYIVQKGLAVPELRDEILAQLANQVWHNHNAHNAERGWLLLAACLSGFAPSPCFNKYLLKFVSDYGRNGFQAVCQHRLMQAMGRAQQQGSGAARTLPPTQLEWTATYEKASMALDVGCFNGDQFSCPVHSWSTGEEVAGDILRHRGLADGWRGWTVAMKNGVQWAELAGHDYVLDLVSDLELLRDFPRQKSYFIVGTEGPAASRGGPKVVFGNSWDSDEDMSTRPQPQEHMPKVLDSDGYSSHNQDGTNGETEAQRGTATHQESDSLGEPAVPHKGLDCYLDSLFDPVLSYGDADLEKPTAIAYRMKGGGQPGGGSSSGTEDTPRRPPEPKPIPGLDASTLALQQAFIHKQAVLLAREMTLQATALQQQPLSAALRSLPAEKPPAPEAQPTSVGTGPPAKPVLLRATPKPLAPAPLAKAPRLPIKPVAAPVLAQDQASPETTSPSPELVRYSTLNSEHFPQPTQQIKNIVRQYQQPFRGGRPEALRKDGGKVFMKRPDPHEEALMILKGQMTHLAAAPGTQVSREAVALVKPVTSAPRPSMAPTSALPSRSLEPPEELTQTRLHRLINPNFYGYQDAPWKIFLRKEVFYPKDSYSHPVQLDLLFRQILHDTLSEACLRISEDERLRMKALFAQNQLDTQKPLVTESVKRAVVSTARDTWEVYFSRIFPATGSVGTGVQLLAVSHVGIKLLRMVKGGQEAGGQLRVLRAYSFADILFVTMPSQNMLEFNLASEKVILFSARAHQVKTLVDDFILELKKDSDYVVAVRNFLPEDPALLAFHKGDIIHLQPLEPPRVGYSAGCVVRRKVVYLEELRRRGPDFGWRFGTIHGRVGRFPSELVQPAAAPDFLQLPTEPGRGRAAAVAAAVASAAAAQEVGRRREGPPVRARSADHGEDALALPPYTMLEFAQKYFRDPQRRPQDGLRLKSKEPRESRTLEDMLCFTKTPLQESLIELSDSSLSKMATDMFLAVMRFMGDAPLKGQSDLDVLCNLLKLCGDHEVMRDECYCQVVKQITDNTSSKQDSCQRGWRLLYIVTAYHSCSEVLHPHLTRFLQDVSRTPGLPFQGIAKACEQNLQKTLRFGGRLELPSSIELRAMLAGRSSKRQLFLLPGGLERHLKIKTCTVALDVVEEICAEMALTRPEAFNEYVIFVVTNRGQHVCPLSRRAYILDVASEMEQVDGGYMLWFRRVLWDQPLKFENELYVTMHYNQVLPDYLKGLFSSVPASRPSEQLLQQVSKLASLQHRAKDHFYLPSVREVQEYIPAQLYRTTAGSTWLNLVSQHRQQTQALSPHQARAQFLGLLSALPMFGSSFFFIQSCSNIAVPAPCILAINHNGLNFLSTETHELMVKFPLKEIQSTRTQRPTANSSYPYVEIALGDVAAQRTLQLQLEQGLELCRVVAVHVENLLSAHEKRLTLPPSEITLL	3530	Q9UKN7	R	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [3423], 'DISULFID_gain': [], 'DISULFID_loss_score': array([-0.00114244]), 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [11, 1221], 'REPEAT_gain': [819, 822, 850, 2020], 'REPEAT_gain_score': array([0.00253904, 0.00276822, 0.0019232 , 0.00154942]), 'REPEAT_loss_score': array([-0.00137931, -0.00125843]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
421	NM_016239.4(MYO15A):c.4198G>A (p.Val1400Met)	632271	CA8423796	NM_016239.4:c.4198G>A, NC_000017.11:g.18131523G>A, CM000679.2:g.18131523G>A, NC_000017.10:g.18034837G>A, CM000679.1:g.18034837G>A, NC_000017.9:g.17975562G>A, NG_011634.1:g.27818G>A, NG_011634.2:g.27818G>A, ENST00000647165.2:c.4198G>A, ENST00000205890.9:c.4198G>A, ENST00000615845.4:c.4198G>A, NM_016239.3:c.4198G>A, XM_011523917.1:c.4192G>A, XM_011523918.1:c.4192G>A, XM_011523919.1:c.4192G>A, XM_011523920.1:c.4192G>A, XM_011523921.1:c.4192G>A, XR_934037.1:n.4851G>A, XR_934038.1:n.4851G>A, XR_934039.1:n.4851G>A, XM_011523918.2:c.4192G>A, XM_017024714.2:c.4192G>A, XM_017024715.2:c.4201G>A, XM_024450780.1:c.4192G>A, XM_024450781.1:c.4192G>A, XM_024450782.1:c.4192G>A, XR_934039.2:n.4890G>A, NM_016239.4(MYO15A):c.4198G>A (p.Val1400Met)	MYO15A	nonsyndromic genetic deafness	MONDO:0019497	Autosomal recessive inheritance	Pathogenic	PM3_Strong, PP1_Strong, PP3	PM2	The allele frequency of the c.4198G>A (p.Val1400Met) variant in the MYO15A gene is 0.01980% (7/35356) of African/African-American chromosomes by gnomAD. This variant has been reported to segregate with hearing loss in at least 3 separate families (PP1_Strong; PMIDs: 27870113, 20642360; Partners LMM internal data SCV000966848.2). This variant has been detected in 10 probands with nonsyndromic hearing loss. For 2 of those probands, a pathogenic or suspected-pathogenic variant was observed in trans, in 1 a rare variant of unknown significance was observed in trans, and in 7 the variant was observed in the homozygous state (PM3_Strong; PMIDs: 27870113, 20642360; Partners LMM internal data SCV000966848.2). Additionally, the REVEL computational prediction analysis tool produced a score of 0.891, which is above the threshold necessary to apply PP3. In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive nonsyndromic hearing loss based on the ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel: PP1_Strong, PM3_Strong, PP3.		Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2021-07-27	2022-05-13	False	https://erepo.genome.network/evrepo/ui/classification/CA8423796/MONDO:0019497/005	429026a9-22bf-43c4-8735-e5fb87686291	p.Val1400Met	Val	1400	Met	MAKEEDEEKKAKKGKKGKKAPEPEKPKRSLKGTSRLFMGFRDRTPKISKKGQFRSASAFFWGLHTGPQKTKRKRKARTVLKSTSKLMTQMRMGKKKRAMKGKKPSFMVIRFPGRRGYGRLRPRARSLSKASTAINWLTKKFLLKKAEESGSEQATVDAWLQRSSSRMGSRKLPFPSGAEILRPGGRLRRFPRSRSIYASGEPLGFLPFEDEAPFHHSGSRKSLYGLEGFQDLGEYYDYHRDGDDYYDRQSLHRYEEQEPYLAGLGPYSPAWPPYGDHYYGYPPEDPYDYYHPDYYGGPFDPGYTYGYGYDDYEPPYAPPSGYSSPYSYHDGYEGEAHPYGYYLDPYAPYDAPYPPYDLPYHTPYDVPYFDPYGVHYTVPYAEGVYGGGDEAIYPPEVPYFYPEESASAFVYPWVPPPIPSPHNPYAHAMDDIAELEEPEDAGVERQGTSFRLPSAAFFEQQGMDKPARSKLSLIRKFRLFPRPQVKLFGKEKLEVPLPPSLDIPLPLGDADEEEDEEELPPVSAVPYGHPFWGFLTPRQRNLQRALSAFGAHRGLGFGPEFGRPVPRPATSLARFLKKTLSEKKPIARLRGSQKARAGGPAVREAAYKRFGYKLAGMDPEKPGTPIVLRRAQPRARSSNDARRPPAPQPAPRTLSHWSALLSPPVPPRPPSSGPPPAPPLSPALSGLPRPASPYGSLRRHPPPWAAPAHVPPAPQASWWAFVEPPAVSPEVPPDLLAFPGPRPSFRGSRRRGAAFGFPGASPRASRRRAWSPLASPQPSLRSSPGLGYCSPLAPPSPQLSLRTGPFQPPFLPPARRPRSLQESPAPRRAAGRLGPPGSPLPGSPRPPSPPLGLCHSPRRSSLNLPSRLPHTWRRLSEPPTRAVKPQVRLPFHRPPRAGAWRAPLEHRESPREPEDSETPWTVPPLAPSWDVDMPPTQRPPSPWPGGAGSRRGFSRPPPVPENPFLQLLGPVPSPTLQPEDPAADMTRVFLGRHHEPGPGQLTKSAGPTPEKPEEEATLGDPQLPAETKPPTPAPPKDVTPPKDITPPKDVLPEQKTLRPSLSYPLAACDQTRATWPPWHRWGTLPQAAAPLAPIRAPEPLPKGGERRQAAPGRFAVVMPRVQKLSSFQRVGPATLKPQVQPIQDPKPRACSLRWSCLWLRADAYGPWPRVHTHPQSCHLGPGAACLSLRGSWEEVGPPSWRNKMHSIRNLPSMRFREQHGEDGVEDMTQLEDLQETTVLSNLKIRFERNLIYTYIGSILVSVNPYQMFGIYGPEQVQQYNGRALGENPPHLFAVANLAFAKMLDAKQNQCIIISGESGSGKTEATKLILRYLAAMNQKREVMQQIKILEATPLLESFGNAKTVRNDNSSRFGKFVEIFLEGGVISGAITSQYLLEKSRIVFQAKNERNYHIFYELLAGLPAQLRQAFSLQEAETYYYLNQGGNCEIAGKSDADDFRRLLAAMEVLGFSSEDQDSIFRILASILHLGNVYFEKYETDAQEVASVVSAREIQAVAELLQISPEGLQKAITFKVTETMREKIFTPLTVESAVDARDAIAKVLYALLFSWLITRVNALVSPRQDTLSIAILDIYGFEDLSFNSFEQLCINYANENLQYLFNKIVFQEEQEEYIREQIDWQEITFADNQPCINLISLKPYGILRILDDQCCFPQATDHTFLQKCHYHHGANPLYSKPKMPLPEFTIKHYAGKVTYQVHKFLDKNHDQVRQDVLDLFVRSRTRVVAHLFSSHAPQAAPQRLGKSSSVTRLYKAHTVAAKFQQSLLDLVEKMERCNPLFMRCLKPNHKKEPGLFEPDVVMAQLRYSGVLETVRIRKEGFPVRLPFQGFIDRYCCLVALKHDLPANGDMCVSVLSRLCKVMPNMYRVGVSKLFLKEHLYQLLESMREHVLNLAALTLQRCLRGFFIKRRFRSLRHKIILLQSRARGYLARQRYQQMRRSLVKFRSLVHAYVSRRRYLKLRAEWRCQVEGALLWEQEELSKREVVAVGHLEVPAELAGLLQAVAGLGLAQVPQVAPVRTPRLQAEPRVTLPLDINNYPMAKFVQCHFKEPAFGMLTVPLRTPLTQLPAEHHAEAVSIFKLILRFMGDPHLHGARENIFGNYIVQKGLAVPELRDEILAQLANQVWHNHNAHNAERGWLLLAACLSGFAPSPCFNKYLLKFVSDYGRNGFQAVCQHRLMQAMGRAQQQGSGAARTLPPTQLEWTATYEKASMALDVGCFNGDQFSCPVHSWSTGEEVAGDILRHRGLADGWRGWTVAMKNGVQWAELAGHDYVLDLVSDLELLRDFPRQKSYFIVGTEGPAASRGGPKVVFGNSWDSDEDMSTRPQPQEHMPKVLDSDGYSSHNQDGTNGETEAQRGTATHQESDSLGEPAVPHKGLDCYLDSLFDPVLSYGDADLEKPTAIAYRMKGGGQPGGGSSSGTEDTPRRPPEPKPIPGLDASTLALQQAFIHKQAVLLAREMTLQATALQQQPLSAALRSLPAEKPPAPEAQPTSVGTGPPAKPVLLRATPKPLAPAPLAKAPRLPIKPVAAPVLAQDQASPETTSPSPELVRYSTLNSEHFPQPTQQIKNIVRQYQQPFRGGRPEALRKDGGKVFMKRPDPHEEALMILKGQMTHLAAAPGTQVSREAVALVKPVTSAPRPSMAPTSALPSRSLEPPEELTQTRLHRLINPNFYGYQDAPWKIFLRKEVFYPKDSYSHPVQLDLLFRQILHDTLSEACLRISEDERLRMKALFAQNQLDTQKPLVTESVKRAVVSTARDTWEVYFSRIFPATGSVGTGVQLLAVSHVGIKLLRMVKGGQEAGGQLRVLRAYSFADILFVTMPSQNMLEFNLASEKVILFSARAHQVKTLVDDFILELKKDSDYVVAVRNFLPEDPALLAFHKGDIIHLQPLEPPRVGYSAGCVVRRKVVYLEELRRRGPDFGWRFGTIHGRVGRFPSELVQPAAAPDFLQLPTEPGRGRAAAVAAAVASAAAAQEVGRRREGPPVRARSADHGEDALALPPYTMLEFAQKYFRDPQRRPQDGLRLKSKEPRESRTLEDMLCFTKTPLQESLIELSDSSLSKMATDMFLAVMRFMGDAPLKGQSDLDVLCNLLKLCGDHEVMRDECYCQVVKQITDNTSSKQDSCQRGWRLLYIVTAYHSCSEVLHPHLTRFLQDVSRTPGLPFQGIAKACEQNLQKTLRFGGRLELPSSIELRAMLAGRSSKRQLFLLPGGLERHLKIKTCTVALDVVEEICAEMALTRPEAFNEYVIFVVTNRGQHVCPLSRRAYILDVASEMEQVDGGYMLWFRRVLWDQPLKFENELYVTMHYNQVLPDYLKGLFSSVPASRPSEQLLQQVSKLASLQHRAKDHFYLPSVREVQEYIPAQLYRTTAGSTWLNLVSQHRQQTQALSPHQARAQFLGLLSALPMFGSSFFFIQSCSNIAVPAPCILAINHNGLNFLSTETHELMVKFPLKEIQSTRTQRPTANSSYPYVEIALGDVAAQRTLQLQLEQGLELCRVVAVHVENLLSAHEKRLTLPPSEITLL	3530	Q9UKN7	M	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [1007], 'REGION_gain': [], 'REGION_loss_score': array([-0.00062621]), 'REPEAT_loss': [11], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.00152439]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
422	NM_000261.2(MYOC):c.1099G>A (p.Gly367Arg)	7952	CA119176	NM_000261.2:c.1099G>A, NC_000001.11:g.171636341C>T, CM000663.2:g.171636341C>T, NC_000001.10:g.171605481C>T, CM000663.1:g.171605481C>T, NC_000001.9:g.169872104C>T, NG_008859.1:g.21293G>A, ENST00000037502.11:c.1099G>A, ENST00000637303.1:c.235-2289C>T, ENST00000638471.1:c.*437G>A, ENST00000037502.10:c.1099G>A, ENST00000614688.1:c.*63G>A, NM_000261.1:c.1099G>A, NM_000261.2(MYOC):c.1099G>A (p.Gly367Arg)	MYOC	juvenile open angle glaucoma	MONDO:0020367	Autosomal dominant inheritance	Pathogenic	PP3, PS3_Moderate, PM2_Supporting, PS4, PP1_Strong	PM4, PM5, PS1, PS2, BA1, BP4, PM6, BP7, BS1, BS3	The c.1099G>A variant in MYOC is a missense variant predicted to cause substitution of Glycine by Arginine at amino acid 367 (p.Gly367Arg). This variant was not found in any population of gnomAD (v2.1.1), meeting the ≤ 0.0001 threshold set for PM2_Supporting in a population of at least 10,000 alleles. The REVEL score = 0.787, which met the ≥ 0.7 threshold for PP3, predicting a damaging effect on MYOC function. Previous studies (PMIDs: 16466712, 35196929) demonstrated that the Gly367Arg protein had increased insolubility and reduced secretion levels compared to wild type myocilin protein and met the OddsPath threshold for PS3_Moderate (> 4.3), indicating that this variant did impact protein function. 35 segregations in 7 families, with juvenile or primary open angle glaucoma (JOAG or POAG), have been reported (PMIDs: 17304254, 32300215, 12189160, 11815346), which fulfilled PP1_Strong (≥7 meioses in >1 family). 16 probands with JOAG or POAG have been reported carrying this variant (PMIDs: 32300215, 12189160, 11774072, 9345106, 23453510, 12872267, 14627955, 12442283), which met PS4 (≥ 15 probands). There were many more probands and families published than presented here. In summary, this variant met the criteria to receive a score of 12 and to be classified as pathogenic (pathogenic classification ≥ 10) for juvenile open angle glaucoma based on the ACMG/AMP criteria met, as specified by the ClinGen Glaucoma VCEP (v1, 12 Oct 2021): PS4, PP1_Strong, PS3_Moderate, PP3, PM2_Supporting	35196929	Glaucoma VCEP	https://clinicalgenome.org/docs/clingen-glaucoma-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2022-05-10	2022-05-25	False	https://erepo.genome.network/evrepo/ui/classification/CA119176/MONDO:0020367/019	75e7b7fd-1db7-4c60-8dd5-07f1be2fa1f2	p.Gly367Arg	Gly	367	Arg	MRFFCARCCSFGPEMPAVQLLLLACLVWDVGARTAQLRKANDQSGRCQYTFSVASPNESSCPEQSQAMSVIHNLQRDSSTQRLDLEATKARLSSLESLLHQLTLDQAARPQETQEGLQRELGTLRRERDQLETQTRELETAYSNLLRDKSVLEEEKKRLRQENENLARRLESSSQEVARLRRGQCPQTRDTARAVPPGSREVSTWNLDTLAFQELKSELTEVPASRILKESPSGYLRSGEGDTGCGELVWVGEPLTLRTAETITGKYGVWMRDPKPTYPYTQETTWRIDTVGTDVRQVFEYDLISQFMQGYPSKVHILPRPLESTGAVVYSGSLYFQGAESRTVIRYELNTETVKAEKEIPGAGYHGQFPYSWGGYTDIDLAVDEAGLWVIYSTDEAKGAIVLSKLNPENLELEQTWETNIRKQSVANAFIICGTLYTVSSYTSADATVNFAYDTGTGISKTLTIPFKNRYKYSSMIDYNPLEKKLFAWDNLNMVTYDIKLSKM	504	Q99972	R	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [319, 471, 477], 'REPEAT_gain_score': array([0.02661824, 0.04018885, 0.02675945]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
423	NM_000261.2(MYOC):c.1297T>C (p.Cys433Arg)	7956	CA119181	NM_000261.2:c.1297T>C, NC_000001.11:g.171636143A>G, CM000663.2:g.171636143A>G, NC_000001.10:g.171605283A>G, CM000663.1:g.171605283A>G, NC_000001.9:g.169871906A>G, NG_008859.1:g.21491T>C, ENST00000037502.11:c.1297T>C, ENST00000637303.1:c.235-2487A>G, ENST00000638471.1:c.*635T>C, ENST00000037502.10:c.1297T>C, ENST00000614688.1:c.*261T>C, NM_000261.1:c.1297T>C, NM_000261.2(MYOC):c.1297T>C (p.Cys433Arg)	MYOC	juvenile open angle glaucoma	MONDO:0020367	Autosomal dominant inheritance	Pathogenic	PP3, PS3_Moderate, PM2_Supporting, PS4, PP1_Strong	PM5, PM4, PS1, PS2, BA1, BP4, BS1, BS3, BP7, PM6	The c.1297T>C variant in MYOC is a missense variant predicted to cause substitution of Cysteine by Arginine at amino acid 433 (p.Cys433Arg). This variant was not found in any population of gnomAD (v2.1.1), meeting the ≤ 0.0001 threshold set for PM2_Supporting in a population of at least 10,000 alleles. The REVEL score = 0.913, which met the ≥ 0.7 threshold for PP3, predicting a damaging effect on MYOC function. A previous study (PMID: 16466712) demonstrated that the Cys433Arg protein had reduced secretion levels compared to wild type myocilin protein and met the OddsPath threshold for PS3_Moderate (> 4.3), indicating that this variant did impact protein function. 23 segregations in 4 families, with juvenile or primary open angle glaucoma (JOAG or POAG), have been reported (PMIDs: 10819638, 16936947, 12671463), which fulfilled PP1_Strong (≥ 7 meioses in > 1 family). 30 probands with JOAG or POAG have been reported carrying this variant (PMIDs: 30484747, 10819638, 16936947, 12671463), which met PS4 (≥ 15 probands). In summary, this variant met the criteria to receive a score of 12 and to be classified as pathogenic (pathogenic classification ≥ 10) for juvenile open angle glaucoma based on the ACMG/AMP criteria met, as specified by the ClinGen Glaucoma VCEP (v1, 12 Oct 2021): PS4, PP1_Strong, PS3_Moderate, PP3, PM2_Supporting.		Glaucoma VCEP	https://clinicalgenome.org/docs/clingen-glaucoma-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2022-05-10	2022-05-25	False	https://erepo.genome.network/evrepo/ui/classification/CA119181/MONDO:0020367/019	17a16a8f-7d35-4be9-9c5a-125f169a53f3	p.Cys433Arg	Cys	433	Arg	MRFFCARCCSFGPEMPAVQLLLLACLVWDVGARTAQLRKANDQSGRCQYTFSVASPNESSCPEQSQAMSVIHNLQRDSSTQRLDLEATKARLSSLESLLHQLTLDQAARPQETQEGLQRELGTLRRERDQLETQTRELETAYSNLLRDKSVLEEEKKRLRQENENLARRLESSSQEVARLRRGQCPQTRDTARAVPPGSREVSTWNLDTLAFQELKSELTEVPASRILKESPSGYLRSGEGDTGCGELVWVGEPLTLRTAETITGKYGVWMRDPKPTYPYTQETTWRIDTVGTDVRQVFEYDLISQFMQGYPSKVHILPRPLESTGAVVYSGSLYFQGAESRTVIRYELNTETVKAEKEIPGAGYHGQFPYSWGGYTDIDLAVDEAGLWVIYSTDEAKGAIVLSKLNPENLELEQTWETNIRKQSVANAFIICGTLYTVSSYTSADATVNFAYDTGTGISKTLTIPFKNRYKYSSMIDYNPLEKKLFAWDNLNMVTYDIKLSKM	504	Q99972	R	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [432], 'DISULFID_gain': [], 'DISULFID_loss_score': array([-0.55813038]), 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [426], 'STRAND_gain': [398, 441], 'STRAND_gain_score': array([0.00730407, 0.01620084]), 'STRAND_loss_score': array([-0.0279128]), 'HELIX_loss': [], 'HELIX_gain': [304], 'HELIX_gain_score': array([0.01522464]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [244, 245], 'DOMAIN_gain_score': array([0.08106756, 0.08547223]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [319, 322, 371, 471, 477], 'REPEAT_gain_score': array([0.03860426, 0.03536755, 0.05658281, 0.03219539, 0.05931187]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
424	NM_000261.2(MYOC):c.1440C>A (p.Asn480Lys)	7951	CA119175	NM_000261.2:c.1440C>A, NC_000001.11:g.171636000G>T, CM000663.2:g.171636000G>T, NC_000001.10:g.171605140G>T, CM000663.1:g.171605140G>T, NC_000001.9:g.169871763G>T, NG_008859.1:g.21634C>A, ENST00000037502.11:c.1440C>A, ENST00000637303.1:c.235-2630G>T, ENST00000638471.1:c.*778C>A, ENST00000037502.10:c.1440C>A, ENST00000614688.1:c.*404C>A, NM_000261.1:c.1440C>A, NM_000261.2(MYOC):c.1440C>A (p.Asn480Lys)	MYOC	juvenile open angle glaucoma	MONDO:0020367	Autosomal dominant inheritance	Pathogenic	PP3, PS3_Moderate, PM2_Supporting, PS4_Moderate, PP1_Strong	PM4, PM5, PS1, PS2, BA1, BP4, BS1, BS3, BP7, PM6	The c.1440C>A variant in MYOC is a missense variant predicted to cause substitution of Asparagine by Lysine at amino acid 480 (p.Asn480Lys). This variant was not found in any population of gnomAD (v2.1.1), meeting the ≤ 0.0001 threshold set for PM2_Supporting in a population of at least 10,000 alleles. The REVEL score = 0.784, which met the ≥ 0.7 threshold for PP3, predicting a damaging effect on MYOC function. Previous studies (PMIDs: 16466712 and 35196929) demonstrated that the Asn480Lys protein had increased insolubility and reduced secretion levels compared to wild type myocilin protein and met the OddsPath threshold for PS3_Moderate (> 4.3), indicating that this variant did impact protein function. Over 90 segregations in 8 families, with juvenile or primary open angle glaucoma (JOAG or POAG), have been reported (PMIDs: 12107514, 24883016, 9556305), which fulfilled PP1_Strong (≥ 7 meioses in > 1 family). 13 probands with JOAG or POAG have been reported carrying this variant (PMIDs: pers. communication E Souzeau, 22194650, 12872267, 12107514, 24883016, 9556305), which met PS4_Moderate (≥ 6 probands). In summary, this variant met the criteria to receive a score of 10 and to be classified as pathogenic (pathogenic classification ≥ 10) for juvenile open angle glaucoma based on the ACMG/AMP criteria met, as specified by the ClinGen Glaucoma VCEP (v1, 12 Oct 2021): PP1_Strong, PS3_Moderate, PS4_Moderate, PP3, PM2_Supporting.	35196929	Glaucoma VCEP	https://clinicalgenome.org/docs/clingen-glaucoma-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2022-05-10	2022-05-25	False	https://erepo.genome.network/evrepo/ui/classification/CA119175/MONDO:0020367/019	d0adf58d-a397-461c-b1cd-9d3a527bd978	p.Asn480Lys	Asn	480	Lys	MRFFCARCCSFGPEMPAVQLLLLACLVWDVGARTAQLRKANDQSGRCQYTFSVASPNESSCPEQSQAMSVIHNLQRDSSTQRLDLEATKARLSSLESLLHQLTLDQAARPQETQEGLQRELGTLRRERDQLETQTRELETAYSNLLRDKSVLEEEKKRLRQENENLARRLESSSQEVARLRRGQCPQTRDTARAVPPGSREVSTWNLDTLAFQELKSELTEVPASRILKESPSGYLRSGEGDTGCGELVWVGEPLTLRTAETITGKYGVWMRDPKPTYPYTQETTWRIDTVGTDVRQVFEYDLISQFMQGYPSKVHILPRPLESTGAVVYSGSLYFQGAESRTVIRYELNTETVKAEKEIPGAGYHGQFPYSWGGYTDIDLAVDEAGLWVIYSTDEAKGAIVLSKLNPENLELEQTWETNIRKQSVANAFIICGTLYTVSSYTSADATVNFAYDTGTGISKTLTIPFKNRYKYSSMIDYNPLEKKLFAWDNLNMVTYDIKLSKM	504	Q99972	K	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [46], 'TRANSIT_gain_score': array([0.0037055]), 'STRAND_loss': [], 'STRAND_gain': [441, 472, 473, 474, 499], 'STRAND_gain_score': array([0.01122785, 0.07292253, 0.04999924, 0.05607885, 0.01977354]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [503], 'DOMAIN_gain': [245], 'DOMAIN_gain_score': array([0.03364164]), 'DOMAIN_loss_score': array([-0.26975429]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [324, 326, 370, 372, 374, 375, 467, 468, 469, 470, 472, 473, 474, 475, 476], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.07261789, -0.0631628 , -0.05124545, -0.05002338, -0.06168824,
       -0.07301128, -0.19928718, -0.18876505, -0.22744828, -0.21669775,
       -0.28451532, -0.33569741, -0.38569194, -0.39690465, -0.37226653]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
425	NM_000545.8(HNF1A):c.185A>G (p.Asn62Ser)	447485	CA6831682	NM_000545.8:c.185A>G, NC_000012.12:g.120978953A>G, CM000674.2:g.120978953A>G, NC_000012.11:g.121416756A>G, CM000674.1:g.121416756A>G, NC_000012.10:g.119901139A>G, NG_011731.2:g.5208A>G, LRG_522:g.5208A>G, ENST00000257555.11:c.185A>G, ENST00000257555.10:c.185A>G, ENST00000400024.6:c.185A>G, ENST00000402929.5:n.320A>G, ENST00000535955.5:n.42+261A>G, ENST00000538626.2:n.190+113A>G, ENST00000538646.5:c.185A>G, ENST00000540108.1:c.185A>G, ENST00000541395.5:c.185A>G, ENST00000541924.5:c.185A>G, ENST00000543427.5:c.185A>G, ENST00000544413.2:c.185A>G, ENST00000544574.5:c.72+113A>G, ENST00000560968.5:n.328A>G, ENST00000615446.4:c.-258+242A>G, ENST00000617366.4:c.185A>G, NM_000545.5:c.185A>G, LRG_522t1:c.185A>G, NM_000545.6:c.185A>G, NM_001306179.1:c.185A>G, XM_005253931.2:c.185A>G, XM_024449168.1:c.185A>G, NM_001306179.2:c.185A>G, NM_000545.8(HNF1A):c.185A>G (p.Asn62Ser)	HNF1A	monogenic diabetes	MONDO:0015967	Autosomal dominant inheritance	Benign	BP5, BA1	PM1, BS3, PP3, PP4	The c.185A>G variant in the HNF1 homeobox A gene, HNF1A, causes an amino acid change of asparagine to serine at codon 62 (p.(Asn62Ser)) of NM_000545.8. This variant has a Popmax Filtering allele frequency in gnomAD 2.1.1 of 0.00019, which is greater than the MDEP threshold for BA1 (≥0.0001) (BA1). Furthermore, this variant was identified in a patient with an alternate molecular basis for disease (BP5; internal lab contributors).  In summary, c.185A>G meets the criteria to be classified as benign for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.1, approved 9/30/21): BA1, BP5.	27899486	Monogenic Diabetes VCEP		2022-06-03	2022-06-03	False	https://erepo.genome.network/evrepo/ui/classification/CA6831682/MONDO:0015967/017	7e62708e-dd55-42f5-9e0a-e6bdb1c0b199	p.Asn62Ser	Asn	62	Ser	MVSKLSQLQTELLAALLESGLSKEALIQALGEPGPYLLAGEGPLDKGESCGGGRGELAELPNGLGETRGSEDETDDDGEDFTPPILKELENLSPEEAAHQKAVVETLLQEDPWRVAKMVKSYLQQHNIPQREVVDTTGLNQSHLSQHLNKGTPMKTQKRAALYTWYVRKQREVAQQFTHAGQGGLIEEPTGDELPTKKGRRNRFKWGPASQQILFQAYERQKNPSKEERETLVEECNRAECIQRGVSPSQAQGLGSNLVTEVRVYNWFANRRKEEAFRHKLAMDTYSGPPPGPGPGPALPAHSSPGLPPPALSPSKVHGVRYGQPATSETAEVPSSSGGPLVTVSTPLHQVSPTGLEPSHSLLSTEAKLVSAAGGPLPPVSTLTALHSLEQTSPGLNQQPQNLIMASLPGVMTIGPGEPASLGPTFTNTGASTLVIGLASTQAQSVPVINSMGSSLTTLQPVQFSQPLHPSYQQPLMPPVQSHVTQSPFMATMAQLQSPHALYSHKPEVAQYTHTGLLPQTMLITDTTNLSALASLTPTKQVFTSDTEASSESGLHTPASQATTLHVPSQDPAGIQHLQPAHRLSASPTVSSSSLVLYQSSDSSNGQSHLLPSNHSVIETFISTQMASSSQ	631	P20823	S	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [97], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.00800419]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [69, 73], 'COMPBIAS_gain_score': array([0.03207862, 0.02721024]), 'DOMAIN_loss': [5], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.01223785]), 'REGION_loss': [], 'REGION_gain': [38, 84], 'REGION_gain_score': array([0.11791861, 0.04314202]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
426	NM_000152.5(GAA):c.2297A>C (p.Tyr766Ser)	420102	CA8815680	NM_000152.5:c.2297A>C, NC_000017.11:g.80117075A>C, CM000679.2:g.80117075A>C, NC_000017.10:g.78090874A>C, CM000679.1:g.78090874A>C, NC_000017.9:g.75705469A>C, NG_009822.1:g.20520A>C, LRG_673:g.20520A>C, ENST00000302262.8:c.2297A>C, ENST00000302262.7:c.2297A>C, ENST00000390015.7:c.2297A>C, ENST00000572080.1:n.716A>C, ENST00000573556.1:n.250A>C, NM_000152.3:c.2297A>C, LRG_673t1:c.2297A>C, NM_001079803.1:c.2297A>C, NM_001079804.1:c.2297A>C, XM_005257193.1:c.2297A>C, XM_005257194.3:c.2297A>C, NM_000152.4:c.2297A>C, NM_001079803.2:c.2297A>C, NM_001079804.2:c.2297A>C, XM_005257193.2:c.2297A>C, XM_005257194.4:c.2297A>C, NM_001079803.3:c.2297A>C, NM_001079804.3:c.2297A>C, NM_000152.5(GAA):c.2297A>C (p.Tyr766Ser)	GAA	glycogen storage disease II	MONDO:0009290	Autosomal recessive inheritance	Pathogenic	PP4_Moderate, PP3, PM2_Supporting, PM3_Very Strong	PM5	The NM_000152.5: c.2297A>C variant in GAA is a missense variant predicted to cause substitution of tyrosine by serine at amino acid 766 (p.Tyr766Ser). At least 12 patients with this variant have been reported including 7 with documented GAA deficiency with <1% of normal mean control level of GAA activity in cultured fibroblasts or GAA activity in the affected leukocytes or dried blood spot (PMID: 22538254, 22521436, 31875618, Clinical Laboratory data), one noted to have deficient GAA activity but results were not provided (PMID: 28394184), and two reported to have Pompe disease with no further details (PMID: 26693141). At least three of these patients are receiving enzyme replacement therapy (PMID: 22521436, 22538254, 26693141 29289479, 30214072, 31899940) (PP4_Moderate). Of the reported patients, at least three are homozygous (PMID: 22521436, 22538254, 26693141 29289479, 31899940, Clinical Laboratory data, and seven were compound heterozygous for the variant and a variant classified as pathogenic by the ClinGen LSD VCEP including c.1309C>T (p.Arg437Cys) (PMID: 22521436), c.-32-13T>G (Clinical Laboratory Data), c.2608C>T (p.Arg870Ter) (Clinical Laboratory Data), c.525delT (PMID: 30214072), all phase unknown, and c.1822C>T (p.Arg608Ter), confirmed in trans by parental testing (PMID: 31875618) (PM3_Very Strong). Two other individuals are compound heterozygous for the variant and either c.1118T>G (p.Leu373Arg) (Clinical Laboratory data) or c.2105G>A (p.Arg702His) (PMID: 28394184) but the allelic data from these patients will be used in the classification of the second variant and is not included here to avoid circular logic. The highest population minor allele frequency in gnomAD v2.1.1 is 0.00005441 (1/18378 alleles) in the East Asian population, which is lower than the ClinGen LSD VCEP’s threshold for PM2_Supporting (<0.001), meeting this criterion. The computational predictor REVEL gives a score of 0.98 which is above the threshold of 0.7, evidence that correlates with impact to GAA function (PP3). To our knowledge, the results of functional studies for this variant have not been published. Two other missense variants, c.2297A>G (p.Tyr766Cys) and 2296T>A (p.Tyr766Asn), in the same codon have been reported in patients with Pompe disease. The classification of c.2297A>C (p.Tyr766Ser) will be used to apply PM5 for those other variants and is not included here to avoid circular logic. There is a ClinVar entry for this variant (Variation ID: 420102; 2 star review status) with five submitters classifying the variant as pathogenic and one as likely pathogenic. In summary, this variant meets the criteria to be classified as pathogenic for Pompe disease. ACMG/AMP criteria met, as specified by the ClinGen Lysosomal Storage Disorders Expert Panel: PM3_VeryStrong, PP4_Moderate, PP3, PM2_Supporting.Classification approved by the ClinGen LSD VCEP on May 16, 2022.		Lysosomal Diseases VCEP	https://clinicalgenome.org/docs/clingen-lysosomal-storage-disorders-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-2/	2022-06-03	2022-06-03	False	https://erepo.genome.network/evrepo/ui/classification/CA8815680/MONDO:0009290/010	ad356d09-5ea4-40e4-920a-d04aa5815cbf	p.Tyr766Ser	Tyr	766	Ser	MGVRHPPCSHRLLAVCALVSLATAALLGHILLHDFLLVPRELSGSSPVLEETHPAHQQGASRPGPRDAQAHPGRPRAVPTQCDVPPNSRFDCAPDKAITQEQCEARGCCYIPAKQGLQGAQMGQPWCFFPPSYPSYKLENLSSSEMGYTATLTRTTPTFFPKDILTLRLDVMMETENRLHFTIKDPANRRYEVPLETPHVHSRAPSPLYSVEFSEEPFGVIVRRQLDGRVLLNTTVAPLFFADQFLQLSTSLPSQYITGLAEHLSPLMLSTSWTRITLWNRDLAPTPGANLYGSHPFYLALEDGGSAHGVFLLNSNAMDVVLQPSPALSWRSTGGILDVYIFLGPEPKSVVQQYLDVVGYPFMPPYWGLGFHLCRWGYSSTAITRQVVENMTRAHFPLDVQWNDLDYMDSRRDFTFNKDGFRDFPAMVQELHQGGRRYMMIVDPAISSSGPAGSYRPYDEGLRRGVFITNETGQPLIGKVWPGSTAFPDFTNPTALAWWEDMVAEFHDQVPFDGMWIDMNEPSNFIRGSEDGCPNNELENPPYVPGVVGGTLQAATICASSHQFLSTHYNLHNLYGLTEAIASHRALVKARGTRPFVISRSTFAGHGRYAGHWTGDVWSSWEQLASSVPEILQFNLLGVPLVGADVCGFLGNTSEELCVRWTQLGAFYPFMRNHNSLLSLPQEPYSFSEPAQQAMRKALTLRYALLPHLYTLFHQAHVAGETVARPLFLEFPKDSSTWTVDHQLLWGEALLITPVLQAGKAEVTGYFPLGTWYDLQTVPVEALGSLPPPPAAPREPAIHSEGQWVTLPAPLDTINVHLRAGYIIPLQGPGLTTTESRQQPMALAVALTKGGEARGELFWDDGESLEVLERGAYTQVIFLARNNTIVNELVRVTSEGAGLQLQKVTVLGVATAPQQVLSNGVPVSNFTYSPDTKVLDICVSLLMGEQFLVSWC	952	P10253	S	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [599], 'BINDING_gain': [], 'BINDING_loss_score': array([-0.02304971]), 'DNA_BIND_loss': [420, 663, 704, 714, 716], 'DNA_BIND_gain': [611], 'DNA_BIND_gain_score': array([0.00245357]), 'DNA_BIND_loss_score': array([-0.00079346, -0.0086056 , -0.00819266, -0.03247899, -0.01949465]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [760], 'STRAND_gain': [806, 872, 893, 899, 913], 'STRAND_gain_score': array([0.01572049, 0.01891828, 0.01282406, 0.02990806, 0.02576965]), 'STRAND_loss_score': array([-0.03812426]), 'HELIX_loss': [], 'HELIX_gain': [729], 'HELIX_gain_score': array([0.01428151]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [505, 666, 710], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.00341201, -0.00485027, -0.00377345]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
427	NM_000152.5(GAA):c.1316T>A (p.Met439Lys)	371305	CA8815258	NM_000152.5:c.1316T>A, NC_000017.11:g.80108818T>A, CM000679.2:g.80108818T>A, NC_000017.10:g.78082617T>A, CM000679.1:g.78082617T>A, NC_000017.9:g.75697212T>A, NG_009822.1:g.12263T>A, LRG_673:g.12263T>A, ENST00000302262.8:c.1316T>A, ENST00000302262.7:c.1316T>A, ENST00000390015.7:c.1316T>A, NM_000152.3:c.1316T>A, LRG_673t1:c.1316T>A, NM_001079803.1:c.1316T>A, NM_001079804.1:c.1316T>A, XM_005257193.1:c.1316T>A, XM_005257194.3:c.1316T>A, NM_000152.4:c.1316T>A, NM_001079803.2:c.1316T>A, NM_001079804.2:c.1316T>A, XM_005257193.2:c.1316T>A, XM_005257194.4:c.1316T>A, NM_001079803.3:c.1316T>A, NM_001079804.3:c.1316T>A, NM_000152.5(GAA):c.1316T>A (p.Met439Lys)	GAA	glycogen storage disease II	MONDO:0009290	Autosomal recessive inheritance	Pathogenic	PP4_Moderate, PP3, PM3_Very Strong, PM2_Supporting, PS3_Moderate	PS1, PM5	The NM_000152.5:c.1316T>A variant in GAA is a missense variant predicted to cause substitution of methionine by lysine at amino acid 439 (p.Met439Lys). At least 14 patients have been reported with this variant and features consistent with Pompe disease. This includes 7 patients with documented laboratory values showing deficiency of GAA activity, below the reference range for normal activity in leukocytes (PMIDs: 17092519, 21940687, 23884227, 25388776, 28433475, 30360039), some of whom are also reported to have histological features of Pompe disease in muscle (PMID: 20202878, 30894207), and/or documented features of infantile onset Pompe disease including muscle weakness and cardiomyoapthy (PMID: 33344388) and/or on enzyme replacement therapy (PMID: 30894207, 31193175) (PP4_Moderate). Note that pseudodeficiency variants, (p.Gly576Ser and p.Glu689Lys) were confirmed to be absent in at least one of these cases (PMID 28433475). Of these patients, 7 are compound heterozygous for the variant and a variant classified as pathogenic or likely pathogenic by the ClinGen LSD VCEP including c.1798C>T (p.Arg600Cys) (PMID: 20202878; phase unknown, 0.5 points), c.2238G>C (p.Trp746Cys) (PMID: 30894207, confirmed in trans, 1 point) (PMID: 25388776, unknown phase, 0.5 points), c.546G>T (PMID: 28433475, unknown phase, 0.5 points), c.2407_2413del (p.Gln803Ter) (PMID: 23884227, unknown phase, 0.5 points), and c.1579_1580del (p.Arg527GlyfsTer3) (PMID: 30360039, phase unknown, 0.5 points), and c.1225dup (PMID: 29869463; phase unknown, 0.25 points); and one patient is homozygous (PMID: 29124014) (0.5 points). Total 4.25 points (PM3_VeryStrong). Additional patients have been reported who are compound heterozygous for the variant and c.796C>T (p.Pro266Ser) (PMID: 17092519, 29044175, 31850350), c.1225dup (PMID: 29869463), and c.1309C>T (p.Arg437Cys) (PMID: 25388776) but the allelic data from these patients will be used in the assessment of the second variant and is not included here to avoid circular logic. Additional data was not included due to uncertainty about the nomenclature of the second variant (PMIDs: 20202878, 21940687). The highest population minor allele frequency in gnomAD is 0.00038 (6/15644 alleles) in the East Asian population, which is lower than the ClinGen LSD VCEP threshold (<0.001) for PM2_Supporting, meeting this criterion. When expressed in COS cells the variant has <2% normal activity and does not show mature GAA protein on western blot (PMID 19862843) (PM3_Moderate). The computational predictor REVEL gives a score of 0.784 which is above the threshold of 0.7, evidence that correlates with impact to GAA function (PP3). There is a ClinVar entry for this variant (Variation ID: 371305, 2 star review status) with 3 submitters classifying the variant as pathogenic and 4 as likely pathogenic. In summary, this variant meets the criteria to be classified as pathogenic for Pompe disease. GAA-specific ACMG-AMP criteria met, as specified by the ClinGen LSD VCEP (Specifications version 2): PM3_VeryStrong, PP4_Moderate, PS3_Moderate, PP3, PM2_Supporting.Classification approved by the ClinGen LSD VCEP on May 16, 2022.		Lysosomal Diseases VCEP	https://clinicalgenome.org/docs/clingen-lysosomal-storage-disorders-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-2/	2022-06-03	2022-06-03	False	https://erepo.genome.network/evrepo/ui/classification/CA8815258/MONDO:0009290/010	aecc4442-0d8c-4bbd-a5ce-42bee4bda6e9	p.Met439Lys	Met	439	Lys	MGVRHPPCSHRLLAVCALVSLATAALLGHILLHDFLLVPRELSGSSPVLEETHPAHQQGASRPGPRDAQAHPGRPRAVPTQCDVPPNSRFDCAPDKAITQEQCEARGCCYIPAKQGLQGAQMGQPWCFFPPSYPSYKLENLSSSEMGYTATLTRTTPTFFPKDILTLRLDVMMETENRLHFTIKDPANRRYEVPLETPHVHSRAPSPLYSVEFSEEPFGVIVRRQLDGRVLLNTTVAPLFFADQFLQLSTSLPSQYITGLAEHLSPLMLSTSWTRITLWNRDLAPTPGANLYGSHPFYLALEDGGSAHGVFLLNSNAMDVVLQPSPALSWRSTGGILDVYIFLGPEPKSVVQQYLDVVGYPFMPPYWGLGFHLCRWGYSSTAITRQVVENMTRAHFPLDVQWNDLDYMDSRRDFTFNKDGFRDFPAMVQELHQGGRRYMMIVDPAISSSGPAGSYRPYDEGLRRGVFITNETGQPLIGKVWPGSTAFPDFTNPTALAWWEDMVAEFHDQVPFDGMWIDMNEPSNFIRGSEDGCPNNELENPPYVPGVVGGTLQAATICASSHQFLSTHYNLHNLYGLTEAIASHRALVKARGTRPFVISRSTFAGHGRYAGHWTGDVWSSWEQLASSVPEILQFNLLGVPLVGADVCGFLGNTSEELCVRWTQLGAFYPFMRNHNSLLSLPQEPYSFSEPAQQAMRKALTLRYALLPHLYTLFHQAHVAGETVARPLFLEFPKDSSTWTVDHQLLWGEALLITPVLQAGKAEVTGYFPLGTWYDLQTVPVEALGSLPPPPAAPREPAIHSEGQWVTLPAPLDTINVHLRAGYIIPLQGPGLTTTESRQQPMALAVALTKGGEARGELFWDDGESLEVLERGAYTQVIFLARNNTIVNELVRVTSEGAGLQLQKVTVLGVATAPQQVLSNGVPVSNFTYSPDTKVLDICVSLLMGEQFLVSWC	952	P10253	K	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [375, 420, 424, 584, 663, 704, 714, 716], 'DNA_BIND_gain': [], 'DNA_BIND_loss_score': array([-0.00081116, -0.00070602, -0.00279355, -0.00966531, -0.01056367,
       -0.00255889, -0.01124001, -0.00140131]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [22], 'TRANSIT_gain_score': array([0.01148939]), 'STRAND_loss': [], 'STRAND_gain': [259, 806], 'STRAND_gain_score': array([0.00930703, 0.00785828]), 'HELIX_loss': [727], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.0129559]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [427], 'REPEAT_gain': [383], 'REPEAT_gain_score': array([0.01286817]), 'REPEAT_loss_score': array([-0.00448215]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
428	NM_000152.5(GAA):c.1082C>T (p.Pro361Leu)	403712	CA8815163	NM_000152.5:c.1082C>T, NC_000017.11:g.80108495C>T, CM000679.2:g.80108495C>T, NC_000017.10:g.78082294C>T, CM000679.1:g.78082294C>T, NC_000017.9:g.75696889C>T, NG_009822.1:g.11940C>T, LRG_673:g.11940C>T, ENST00000302262.8:c.1082C>T, ENST00000302262.7:c.1082C>T, ENST00000390015.7:c.1082C>T, NM_000152.3:c.1082C>T, LRG_673t1:c.1082C>T, NM_001079803.1:c.1082C>T, NM_001079804.1:c.1082C>T, XM_005257193.1:c.1082C>T, XM_005257194.3:c.1082C>T, NM_000152.4:c.1082C>T, NM_001079803.2:c.1082C>T, NM_001079804.2:c.1082C>T, XM_005257193.2:c.1082C>T, XM_005257194.4:c.1082C>T, NM_001079803.3:c.1082C>T, NM_001079804.3:c.1082C>T, NM_000152.5(GAA):c.1082C>T (p.Pro361Leu)	GAA	glycogen storage disease II	MONDO:0009290	Autosomal recessive inheritance	Pathogenic	PM3_Strong, PP4_Moderate, PP3, PM2_Supporting, PS3_Moderate	PM5	The NM_000152.5:c.1082C>T variant in GAA is a missense variant predicted to cause substitution of proline by leucine at amino acid 361 (p.Pro361Leu). This variant has been reported in at least 13 individuals with clinical symptoms consistent with Pompe disease including 6 individuals with documented laboratory values showing deficiency of GAA activity below normal range in leukocytes or <1% activity in fibroblasts or another tissue, many of whom were also reported to be showing improvement on enzyme replacement therapy and/or had specific features reported for infantile onset Pompe disease including cardiomyopathy and motor delay (PMID: 21484825, 25139343, 25526786, 26497565, 27344650, 31439017, 31915562) and another patient with features specific for infantile onset Pompe disease, on enzyme replacement therapy (PMID: 30023291). Pseudodeficiency variants, c.1726G>A and c.2065G>A, were reported to be absent in at least one of these patients (PMID: 25526786) (PP4_Moderate). Of the patients reported with this variant, four are compound heterozygous for the variant and another variant in GAA classified as pathogenic by the ClinGen LSD VCEP including c.784G>A (p.Glu262Lys) (PMID: 31915562; confirmed in trans by parental DNA testing) and c.1933G>A (p.Asp645Asn) (PMID: 26497565, 27344650; phase unknown), c.1935C>A (p.Asp645Glu) (PMID: 31439017; phase unknown), and c.2238G>C (p.Trp746Cys) (PMID: 35123860; phase unknown). In addition, two homozygotes have been reported (PMID: 30023291, 31931849), one of whom was identified by next generation sequencing panel for limb girdle muscle weakness, and not counted due to no report of follow up enzyme studies to confirm diagnosis of Pompe disease (PMID: 31931849) (PM3_Strong). Additional patients have been reported with the variant in compound heterozygosity with another variant including c.503G>C (p.Arg168Pro) (PMID: 25526786), c.953T>C (p.Met318Thr) (PMID: 25139343), c.1309C>T (p.Arg437Cys) (PMID: 12601120, 27692865), c.1432G>A (p.Gly478Arg) (PMID: 25213570), c.1979G>A (p.Arg660His) (PMID:  21484825), and c.1551+1G>C (PMID: 16917947). In these cases, the allelic data will be used in the assessment of the second variant and was not applied to PM3 here in order to avoid circular logic. The highest population minor allele frequency in gnomAD v2.1.1 is 0.00006 in the Latino population which is lower than the ClinGen LSD VCEP threshold (<0.001) for PM2_Supporting, meeting this criterion. When expressed in COS cells and GAA deficient fibroblasts, this variant resulted in <4% wild type GAA activity in three different studies (PMID: 12601120, 19862843, 22644586) and showed evidence of abnormal synthesis and processing on Western blot (PMID: 22644586) (PS3_Moderate). The computational predictor REVEL gives a score of 0.951 which is above the threshold of 0.7, evidence that correlates with impact to GAA function (PP3). Another variant at the same codon, c.1082C>A (p.Pro361Arg) has been reported (PMID: 31076647). The classification of p.Pro163Leu will be used in the assessment of p.Pro361Arg and, therefore, PM5 is not applied here. There is a ClinVar entry for this variant (Variation ID: 403712, 2 star review status) with four submitters classifying the variant as pathogenic and two as likely pathogenic. In summary, this variant meets the criteria to be classified as pathogenic for Pompe disease. GAA-specific ACMG/AMP criteria applied, as specified by the ClinGen LSD VCEP: PM3_Strong, PS3_Moderate, PP4_Moderate, PP3, PM2_Supporting.Classification approved by the ClinGen LSD VCEP on May 16, 2022.		Lysosomal Diseases VCEP	https://clinicalgenome.org/docs/clingen-lysosomal-storage-disorders-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-2/	2022-06-03	2022-06-03	False	https://erepo.genome.network/evrepo/ui/classification/CA8815163/MONDO:0009290/010	9f8dfb67-c941-448e-9f21-0942d1c57fab	p.Pro361Leu	Pro	361	Leu	MGVRHPPCSHRLLAVCALVSLATAALLGHILLHDFLLVPRELSGSSPVLEETHPAHQQGASRPGPRDAQAHPGRPRAVPTQCDVPPNSRFDCAPDKAITQEQCEARGCCYIPAKQGLQGAQMGQPWCFFPPSYPSYKLENLSSSEMGYTATLTRTTPTFFPKDILTLRLDVMMETENRLHFTIKDPANRRYEVPLETPHVHSRAPSPLYSVEFSEEPFGVIVRRQLDGRVLLNTTVAPLFFADQFLQLSTSLPSQYITGLAEHLSPLMLSTSWTRITLWNRDLAPTPGANLYGSHPFYLALEDGGSAHGVFLLNSNAMDVVLQPSPALSWRSTGGILDVYIFLGPEPKSVVQQYLDVVGYPFMPPYWGLGFHLCRWGYSSTAITRQVVENMTRAHFPLDVQWNDLDYMDSRRDFTFNKDGFRDFPAMVQELHQGGRRYMMIVDPAISSSGPAGSYRPYDEGLRRGVFITNETGQPLIGKVWPGSTAFPDFTNPTALAWWEDMVAEFHDQVPFDGMWIDMNEPSNFIRGSEDGCPNNELENPPYVPGVVGGTLQAATICASSHQFLSTHYNLHNLYGLTEAIASHRALVKARGTRPFVISRSTFAGHGRYAGHWTGDVWSSWEQLASSVPEILQFNLLGVPLVGADVCGFLGNTSEELCVRWTQLGAFYPFMRNHNSLLSLPQEPYSFSEPAQQAMRKALTLRYALLPHLYTLFHQAHVAGETVARPLFLEFPKDSSTWTVDHQLLWGEALLITPVLQAGKAEVTGYFPLGTWYDLQTVPVEALGSLPPPPAAPREPAIHSEGQWVTLPAPLDTINVHLRAGYIIPLQGPGLTTTESRQQPMALAVALTKGGEARGELFWDDGESLEVLERGAYTQVIFLARNNTIVNELVRVTSEGAGLQLQKVTVLGVATAPQQVLSNGVPVSNFTYSPDTKVLDICVSLLMGEQFLVSWC	952	P10253	L	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [355, 375, 420, 424, 431, 507, 508, 584, 663, 704, 714, 716], 'DNA_BIND_gain': [], 'DNA_BIND_loss_score': array([-0.00492996, -0.00523305, -0.00057113, -0.00188738, -0.00558954,
       -0.00481194, -0.00524777, -0.00855929, -0.00628787, -0.0013786 ,
       -0.01145995, -0.00376678]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [71], 'PROPEP_gain': [], 'PROPEP_loss_score': array([-0.0119434]), 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [468], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.00818419]), 'HELIX_loss': [], 'HELIX_gain': [364], 'HELIX_gain_score': array([0.03963161]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [386, 427, 505, 666], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.00333375, -0.00560921, -0.00269735, -0.00185597]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
429	NM_000545.8(HNF1A):c.620G>A (p.Gly207Asp)	447496	CA386964424	NM_000545.8:c.620G>A, NC_000012.12:g.120993613G>A, CM000674.2:g.120993613G>A, NC_000012.11:g.121431416G>A, CM000674.1:g.121431416G>A, NC_000012.10:g.119915799G>A, NG_011731.2:g.19868G>A, LRG_522:g.19868G>A, ENST00000257555.11:c.620G>A, ENST00000257555.10:c.620G>A, ENST00000400024.6:c.620G>A, ENST00000402929.5:n.755G>A, ENST00000535955.5:n.43-3878G>A, ENST00000538626.2:n.191-3878G>A, ENST00000538646.5:c.527-551G>A, ENST00000540108.1:c.*60G>A, ENST00000541395.5:c.620G>A, ENST00000541924.5:c.620G>A, ENST00000543427.5:c.620G>A, ENST00000544413.2:c.620G>A, ENST00000544574.5:c.73-3004G>A, ENST00000560968.5:n.763G>A, ENST00000615446.4:c.-257-2649G>A, ENST00000617366.4:c.586+34G>A, NM_000545.5:c.620G>A, LRG_522t1:c.620G>A, NM_000545.6:c.620G>A, NM_001306179.1:c.620G>A, XM_005253931.2:c.620G>A, XM_024449168.1:c.620G>A, NM_001306179.2:c.620G>A, NM_000545.8(HNF1A):c.620G>A (p.Gly207Asp)	HNF1A	monogenic diabetes	MONDO:0015967	Autosomal dominant inheritance	Pathogenic	PM1_Supporting, PS4_Moderate, PP1_Strong, PP4_Moderate, PP3, PM2_Supporting	BS1, BA1, BP4	The c.620G>A variant in the HNF1 Homeobox A gene, HNF1A, causes an amino acid change of glycine to aspartic acid at codon 207 (p.(Gly207Asp)) of NM_000545.8. This variant was identified in an individual with a clinical history highly specific for HNF1A-MODY (MODY probability calculator result >50%, negative genetic testing for HNF4A, and response to low dose sulfonylurea) (PP4_Moderate). This variant was identified in six unrelated individuals with non- autoimmune and non-absolute/near-absolute insulin-deficient diabetes (PS4_Moderate). Furthermore, this variant segregated with diabetes, with 10 informative meioses, in one family with MODY (PP1_Strong). The glycine at the 207 codon position is located within a conserved region of the DNA binding domain (codons 107-174 and 201-280) of HNF1A, which is defined as critical for the protein’s function by the ClinGen MDEP (PM1_Supporting). This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.937, which is greater than the MDEP VCEP threshold of 0.70 (PP3).  In summary, c.620G>A meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.1, approved 9/30/2021): PP1_Strong, PM1_Supporting, PM2_Supporting, PS4_Moderate, PP4_Moderate, PP3.	1985954, 12453420, 21683639, 16917892, 23674172	Monogenic Diabetes VCEP		2022-06-10	2022-06-10	False	https://erepo.genome.network/evrepo/ui/classification/CA386964424/MONDO:0015967/017	9e82deb5-70f5-4b33-a7f6-22f6883030d8	p.Gly207Asp	Gly	207	Asp	MVSKLSQLQTELLAALLESGLSKEALIQALGEPGPYLLAGEGPLDKGESCGGGRGELAELPNGLGETRGSEDETDDDGEDFTPPILKELENLSPEEAAHQKAVVETLLQEDPWRVAKMVKSYLQQHNIPQREVVDTTGLNQSHLSQHLNKGTPMKTQKRAALYTWYVRKQREVAQQFTHAGQGGLIEEPTGDELPTKKGRRNRFKWGPASQQILFQAYERQKNPSKEERETLVEECNRAECIQRGVSPSQAQGLGSNLVTEVRVYNWFANRRKEEAFRHKLAMDTYSGPPPGPGPGPALPAHSSPGLPPPALSPSKVHGVRYGQPATSETAEVPSSSGGPLVTVSTPLHQVSPTGLEPSHSLLSTEAKLVSAAGGPLPPVSTLTALHSLEQTSPGLNQQPQNLIMASLPGVMTIGPGEPASLGPTFTNTGASTLVIGLASTQAQSVPVINSMGSSLTTLQPVQFSQPLHPSYQQPLMPPVQSHVTQSPFMATMAQLQSPHALYSHKPEVAQYTHTGLLPQTMLITDTTNLSALASLTPTKQVFTSDTEASSESGLHTPASQATTLHVPSQDPAGIQHLQPAHRLSASPTVSSSSLVLYQSSDSSNGQSHLLPSNHSVIETFISTQMASSSQ	631	P20823	D	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [277], 'DNA_BIND_gain': [222, 227, 229], 'DNA_BIND_gain_score': array([0.04972398, 0.04716212, 0.03269023]), 'DNA_BIND_loss_score': array([-0.06122631]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [97], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.00315326]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [81, 179], 'DOMAIN_gain': [6], 'DOMAIN_gain_score': array([0.02780205]), 'DOMAIN_loss_score': array([-0.03567123, -0.21213609]), 'REGION_loss': [], 'REGION_gain': [202], 'REGION_gain_score': array([0.08583415]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
430	NM_001110792.2(MECP2):c.1241C>T (p.Pro414Leu)	138195	CA199300	NM_001110792.2:c.1241C>T, NC_000023.11:g.154030623G>A, CM000685.2:g.154030623G>A, NC_000023.10:g.153296074G>A, CM000685.1:g.153296074G>A, NC_000023.9:g.152949268G>A, NG_007107.2:g.111505C>T, NG_007107.3:g.111481C>T, ENST00000303391.11:c.1205C>T, ENST00000453960.7:c.1241C>T, ENST00000303391.10:c.1205C>T, ENST00000407218.5:c.*577C>T, ENST00000453960.6:c.1241C>T, ENST00000619732.4:c.1205C>T, ENST00000628176.2:c.*577C>T, NM_001110792.1:c.1241C>T, NM_001316337.1:c.926C>T, NM_004992.3:c.1205C>T, XM_005274681.3:c.1205C>T, XM_005274682.3:c.926C>T, XM_005274683.3:c.926C>T, XM_006724819.2:c.536C>T, XM_011531166.1:c.926C>T, XM_006724819.3:c.536C>T, XM_011531166.2:c.926C>T, XM_024452383.1:c.926C>T, XM_024452384.1:c.926C>T, NM_001316337.2:c.926C>T, NM_001369391.2:c.926C>T, NM_001369392.2:c.926C>T, NM_001369393.2:c.926C>T, NM_001369394.1:c.926C>T, NM_001369394.2:c.926C>T, NM_001386137.1:c.536C>T, NM_001386138.1:c.536C>T, NM_001386139.1:c.536C>T, NM_004992.4:c.1205C>T, NM_001110792.2(MECP2):c.1241C>T (p.Pro414Leu)	MECP2	Rett syndrome	MONDO:0010726	X-linked inheritance	Benign	BS2, BS1	BA1	The allele frequency of the p.Pro402Leu variant in MECP2 (NM_004992) is 0.011% in European (Non-Finnish) sub population in gnomAD, which is high enough to meet the BS1 criteria based on thresholds defined by the ClinGen Rett/Angelman-like Expert Panel for Rett/AS-like conditions (BS1). The p.Pro402Leu variant is observed in at least 4 unaffected individuals (PMID 12384770) (BS2). In summary the p.Pro402Leu variant in MECP2 is classified as Benign for Rett syndrome disorder based on the ACMG/AMP criteria (BS1, BS2).		Rett and Angelman-like Disorders VCEP	https://clinicalgenome.org/site/assets/files/7339/clingen_rettas_acmg_specifications_v2.pdf	2022-05-11	2022-06-28	False	https://erepo.genome.network/evrepo/ui/classification/CA199300/MONDO:0010726/016	64da92b7-700b-4545-b33f-9ca6adb678d5	p.Pro414Leu	Pro	414	Leu	MVAGMLGLREEKSEDQDLQGLKDKPLKFKKVKKDKKEEKEGKHEPVQPSAHHSAEPAEAGKAETSEGSGSAPAVPEASASPKQRRSIIRDRGPMYDDPTLPEGWTRKLKQRKSGRSAGKYDVYLINPQGKAFRSKVELIAYFEKVGDTSLDPNDFDFTVTGRGSPSRREQKPPKKPKSPKAPGTGRGRGRPKGSGTTRPKAATSEGVQVKRVLEKSPGKLLVKMPFQTSPGGKAEGGGATTSTQVMVIKRPGRKRKAEADPQAIPKKRGRKPGSVVAAAAAEAKKKAVKESSIRSVQETVLPIKKRKTRETVSIEVKEVVKPLLVSTLGEKSGKGLKTCKSPGRKSKESSPKGRSSSASSPPKKEHHHHHHHSESPKAPVPLLPPLPPPPPEPESSEDPTSPPEPQDLSSSVCKEEKMPRGGSLESDGCPKEPAKTQPAVATAATAAEKYKHRGEGERKDIVSSSMPRPNREEPVDSRTPVTERVS	486	P51608	L	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [252, 264, 360, 374, 399], 'COMPBIAS_gain_score': array([0.01049829, 0.01026517, 0.02962846, 0.03266877, 0.08332759]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [324], 'REGION_gain': [], 'REGION_loss_score': array([-0.02049226]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
431	NM_001110792.2(MECP2):c.1225G>A (p.Glu409Lys)	95187	CA211306	NM_001110792.2:c.1225G>A, NC_000023.11:g.154030639C>T, CM000685.2:g.154030639C>T, NC_000023.10:g.153296090C>T, CM000685.1:g.153296090C>T, NC_000023.9:g.152949284C>T, NG_007107.2:g.111489G>A, NG_007107.3:g.111465G>A, ENST00000303391.11:c.1189G>A, ENST00000453960.7:c.1225G>A, ENST00000303391.10:c.1189G>A, ENST00000407218.5:c.*561G>A, ENST00000453960.6:c.1225G>A, ENST00000619732.4:c.1189G>A, ENST00000628176.2:c.*561G>A, NM_001110792.1:c.1225G>A, NM_001316337.1:c.910G>A, NM_004992.3:c.1189G>A, XM_005274681.3:c.1189G>A, XM_005274682.3:c.910G>A, XM_005274683.3:c.910G>A, XM_006724819.2:c.520G>A, XM_011531166.1:c.910G>A, XM_006724819.3:c.520G>A, XM_011531166.2:c.910G>A, XM_024452383.1:c.910G>A, XM_024452384.1:c.910G>A, NM_001316337.2:c.910G>A, NM_001369391.2:c.910G>A, NM_001369392.2:c.910G>A, NM_001369393.2:c.910G>A, NM_001369394.1:c.910G>A, NM_001369394.2:c.910G>A, NM_001386137.1:c.520G>A, NM_001386138.1:c.520G>A, NM_001386139.1:c.520G>A, NM_004992.4:c.1189G>A, NM_001110792.2(MECP2):c.1225G>A (p.Glu409Lys)	MECP2	Rett syndrome	MONDO:0010726	X-linked inheritance	Benign	BS2, BA1		The allele frequency of the p.Glu397Lys variant in MECP2 (NM_004992) is 0.393% in European (Non-Finnish) sub population in gnomAD, which is high enough to be classified as Benign based on thresholds defined by the ClinGen Rett/Angelman-like Expert Panel for Rett/AS-like conditions (BA1). The p.Glu397Lys variant is observed in at least 2 unaffected individuals (PMID 10577905,12384770, RettBASE) (BS2). In summary, the p.Glu397Lys variant in MECP2 is classified as Benign based on the ACMG/AMP criteria applied (BA1, BS2).		Rett and Angelman-like Disorders VCEP	https://clinicalgenome.org/site/assets/files/7339/clingen_rettas_acmg_specifications_v2.pdf	2022-05-10	2022-06-28	False	https://erepo.genome.network/evrepo/ui/classification/CA211306/MONDO:0010726/016	9117a511-01ac-4ea0-85db-858db41ea9d3	p.Glu409Lys	Glu	409	Lys	MVAGMLGLREEKSEDQDLQGLKDKPLKFKKVKKDKKEEKEGKHEPVQPSAHHSAEPAEAGKAETSEGSGSAPAVPEASASPKQRRSIIRDRGPMYDDPTLPEGWTRKLKQRKSGRSAGKYDVYLINPQGKAFRSKVELIAYFEKVGDTSLDPNDFDFTVTGRGSPSRREQKPPKKPKSPKAPGTGRGRGRPKGSGTTRPKAATSEGVQVKRVLEKSPGKLLVKMPFQTSPGGKAEGGGATTSTQVMVIKRPGRKRKAEADPQAIPKKRGRKPGSVVAAAAAEAKKKAVKESSIRSVQETVLPIKKRKTRETVSIEVKEVVKPLLVSTLGEKSGKGLKTCKSPGRKSKESSPKGRSSSASSPPKKEHHHHHHHSESPKAPVPLLPPLPPPPPEPESSEDPTSPPEPQDLSSSVCKEEKMPRGGSLESDGCPKEPAKTQPAVATAATAAEKYKHRGEGERKDIVSSSMPRPNREEPVDSRTPVTERVS	486	P51608	K	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [398], 'COMPBIAS_gain': [409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420], 'COMPBIAS_gain_score': array([0.37172621, 0.41209072, 0.55396664, 0.51896042, 0.50620258,
       0.51974022, 0.52610886, 0.47243541, 0.48368764, 0.46239269,
       0.46993834, 0.43502021]), 'COMPBIAS_loss_score': array([-0.24456114]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
432	NM_001110792.2(MECP2):c.638C>T (p.Ala213Val)	138188	CA211932	NM_001110792.2:c.638C>T, NC_000023.11:g.154031226G>A, CM000685.2:g.154031226G>A, NC_000023.10:g.153296677G>A, CM000685.1:g.153296677G>A, NC_000023.9:g.152949871G>A, NG_007107.2:g.110902C>T, NG_007107.3:g.110878C>T, ENST00000303391.11:c.602C>T, ENST00000453960.7:c.638C>T, ENST00000637917.1:n.65+170C>T, ENST00000303391.10:c.602C>T, ENST00000407218.5:c.529C>T, ENST00000453960.6:c.638C>T, ENST00000619732.4:c.602C>T, ENST00000622433.4:c.590C>T, ENST00000628176.2:c.493C>T, NM_001110792.1:c.638C>T, NM_001316337.1:c.323C>T, NM_004992.3:c.602C>T, XM_005274681.3:c.602C>T, XM_005274682.3:c.323C>T, XM_005274683.3:c.323C>T, XM_006724819.2:c.-68C>T, XM_011531166.1:c.323C>T, XM_006724819.3:c.-68C>T, XM_011531166.2:c.323C>T, XM_024452383.1:c.323C>T, XM_024452384.1:c.323C>T, NM_001316337.2:c.323C>T, NM_001369391.2:c.323C>T, NM_001369392.2:c.323C>T, NM_001369393.2:c.323C>T, NM_001369394.1:c.323C>T, NM_001369394.2:c.323C>T, NM_001386137.1:c.-68C>T, NM_001386138.1:c.-68C>T, NM_001386139.1:c.-68C>T, NM_004992.4:c.602C>T, NM_001110792.2(MECP2):c.638C>T (p.Ala213Val)	MECP2	Rett syndrome	MONDO:0010726	X-linked inheritance	Benign	BA1		The allele frequency of the p.Ala201Val (NM_004992) variant in MECP2 is 1.045% in East Asian sub population in gnomAD, which is high enough to be classified as Benign based on thresholds defined by the ClinGen Rett/Angelman-like Expert Panel for Rett/AS-like conditions (BA1). In summary, the p.Ala201Val variant in MECP2 is classified as Benign based on the ACMG/AMP criteria (BA1).		Rett and Angelman-like Disorders VCEP	https://clinicalgenome.org/site/assets/files/7339/clingen_rettas_acmg_specifications_v2.pdf	2022-05-10	2022-06-28	False	https://erepo.genome.network/evrepo/ui/classification/CA211932/MONDO:0010726/016	f9b818a7-0eb3-40ed-a6e6-fa82aecaff83	p.Ala213Val	Ala	213	Val	MVAGMLGLREEKSEDQDLQGLKDKPLKFKKVKKDKKEEKEGKHEPVQPSAHHSAEPAEAGKAETSEGSGSAPAVPEASASPKQRRSIIRDRGPMYDDPTLPEGWTRKLKQRKSGRSAGKYDVYLINPQGKAFRSKVELIAYFEKVGDTSLDPNDFDFTVTGRGSPSRREQKPPKKPKSPKAPGTGRGRGRPKGSGTTRPKAATSEGVQVKRVLEKSPGKLLVKMPFQTSPGGKAEGGGATTSTQVMVIKRPGRKRKAEADPQAIPKKRGRKPGSVVAAAAAEAKKKAVKESSIRSVQETVLPIKKRKTRETVSIEVKEVVKPLLVSTLGEKSGKGLKTCKSPGRKSKESSPKGRSSSASSPPKKEHHHHHHHSESPKAPVPLLPPLPPPPPEPESSEDPTSPPEPQDLSSSVCKEEKMPRGGSLESDGCPKEPAKTQPAVATAATAAEKYKHRGEGERKDIVSSSMPRPNREEPVDSRTPVTERVS	486	P51608	V	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [264], 'COMPBIAS_gain_score': array([0.00695831]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
433	NM_001110792.2(MECP2):c.1169C>T (p.Ala390Val)	143341	CA170175	NM_001110792.2:c.1169C>T, NC_000023.11:g.154030695G>A, CM000685.2:g.154030695G>A, NC_000023.10:g.153296146G>A, CM000685.1:g.153296146G>A, NC_000023.9:g.152949340G>A, NG_007107.2:g.111433C>T, NG_007107.3:g.111409C>T, ENST00000303391.11:c.1133C>T, ENST00000453960.7:c.1169C>T, ENST00000303391.10:c.1133C>T, ENST00000407218.5:c.*505C>T, ENST00000453960.6:c.1169C>T, ENST00000619732.4:c.1133C>T, ENST00000628176.2:c.*505C>T, NM_001110792.1:c.1169C>T, NM_001316337.1:c.854C>T, NM_004992.3:c.1133C>T, XM_005274681.3:c.1133C>T, XM_005274682.3:c.854C>T, XM_005274683.3:c.854C>T, XM_006724819.2:c.464C>T, XM_011531166.1:c.854C>T, XM_006724819.3:c.464C>T, XM_011531166.2:c.854C>T, XM_024452383.1:c.854C>T, XM_024452384.1:c.854C>T, NM_001316337.2:c.854C>T, NM_001369391.2:c.854C>T, NM_001369392.2:c.854C>T, NM_001369393.2:c.854C>T, NM_001369394.1:c.854C>T, NM_001369394.2:c.854C>T, NM_001386137.1:c.464C>T, NM_001386138.1:c.464C>T, NM_001386139.1:c.464C>T, NM_004992.4:c.1133C>T, NM_001110792.2(MECP2):c.1169C>T (p.Ala390Val)	MECP2	Rett syndrome	MONDO:0010726	X-linked inheritance	Benign	BS2, BS1	BP4	The allele frequency of the p.Ala378Val (NM_004992) variant in MECP2 is 0.014% in East Asian sub population in gnomAD, which is high enough to meet BS1 criteria based on thresholds defined by the ClinGen Rett/Angelman-like Expert Panel for Rett/AS-like conditions (BS1). The p.Ala378Val variant is observed in at least 2 unaffected individuals (PMID 15737703)(BS2). In summary, the p.Ala378Val  variant in MECP2 is classified as Benign based on the ACMG/AMP criteria (BS1, BS2).		Rett and Angelman-like Disorders VCEP	https://clinicalgenome.org/site/assets/files/7339/clingen_rettas_acmg_specifications_v2.pdf	2022-05-10	2022-06-28	False	https://erepo.genome.network/evrepo/ui/classification/CA170175/MONDO:0010726/016	48fda9a4-d1f4-4f66-a6a1-63af8a81c8b4	p.Ala390Val	Ala	390	Val	MVAGMLGLREEKSEDQDLQGLKDKPLKFKKVKKDKKEEKEGKHEPVQPSAHHSAEPAEAGKAETSEGSGSAPAVPEASASPKQRRSIIRDRGPMYDDPTLPEGWTRKLKQRKSGRSAGKYDVYLINPQGKAFRSKVELIAYFEKVGDTSLDPNDFDFTVTGRGSPSRREQKPPKKPKSPKAPGTGRGRGRPKGSGTTRPKAATSEGVQVKRVLEKSPGKLLVKMPFQTSPGGKAEGGGATTSTQVMVIKRPGRKRKAEADPQAIPKKRGRKPGSVVAAAAAEAKKKAVKESSIRSVQETVLPIKKRKTRETVSIEVKEVVKPLLVSTLGEKSGKGLKTCKSPGRKSKESSPKGRSSSASSPPKKEHHHHHHHSESPKAPVPLLPPLPPPPPEPESSEDPTSPPEPQDLSSSVCKEEKMPRGGSLESDGCPKEPAKTQPAVATAATAAEKYKHRGEGERKDIVSSSMPRPNREEPVDSRTPVTERVS	486	P51608	V	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [376, 398], 'COMPBIAS_gain': [], 'COMPBIAS_loss_score': array([-0.06359452, -0.12532699]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [300, 301, 324], 'REGION_gain': [], 'REGION_loss_score': array([-0.02617562, -0.02513057, -0.03135657]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
434	NM_001110792.2(MECP2):c.334C>G (p.Leu112Val)	11835	CA198822	NM_001110792.2:c.334C>G, NC_000023.11:g.154032286G>C, CM000685.2:g.154032286G>C, NC_000023.10:g.153297737G>C, CM000685.1:g.153297737G>C, NC_000023.9:g.152950931G>C, NG_007107.2:g.109842C>G, NG_007107.3:g.109818C>G, ENST00000303391.11:c.298C>G, ENST00000453960.7:c.334C>G, ENST00000303391.10:c.298C>G, ENST00000369957.5:c.*352C>G, ENST00000407218.5:c.334C>G, ENST00000453960.6:c.334C>G, ENST00000486506.5:n.2646C>G, ENST00000611468.1:c.286C>G, ENST00000619732.4:c.298C>G, ENST00000622433.4:c.286C>G, ENST00000628176.2:c.298C>G, NM_001110792.1:c.334C>G, NM_001316337.1:c.19C>G, NM_004992.3:c.298C>G, XM_005274681.3:c.298C>G, XM_005274682.3:c.19C>G, XM_005274683.3:c.19C>G, XM_011531166.1:c.19C>G, XM_006724819.3:c.-263C>G, XM_011531166.2:c.19C>G, XM_024452383.1:c.19C>G, XM_024452384.1:c.19C>G, NM_001316337.2:c.19C>G, NM_001369391.2:c.19C>G, NM_001369392.2:c.19C>G, NM_001369393.2:c.19C>G, NM_001369394.1:c.19C>G, NM_001369394.2:c.19C>G, NM_001386137.1:c.-263C>G, NM_001386138.1:c.-263C>G, NM_001386139.1:c.-263C>G, NM_004992.4:c.298C>G, NM_001110792.2(MECP2):c.334C>G (p.Leu112Val)	MECP2	Rett syndrome	MONDO:0010726	X-linked inheritance	Pathogenic	PP3, PM2_Supporting, PM6, PS4, PM1	BP4	The p.Leu100Val (NM_004992) variant has been observed in at least 5 other individuals with Rett Syndrome (PMID: 22476991, 16672765, 12966522, 11913567, 11055898, RettBASE) (PS4). The p.Leu100Val variant occurs in the well-characterized Methyl-DNA binding [MBD] functional domain of the MECP2 (PM1). The p.Leu100Val variant in MECP2 is absent from gnomAD (PM2_supporting). The p.Leu100Val variant in MECP2 occurs in the de novo state (biological parentage unconfirmed) in an individual with mild atypical Rett syndrome (PMID: 12966522)(PM6). Computational prediction analysis tools suggests a deleterious impact; however, this information does not predict clinical significance on its own (PP3). In summary, the p.Leu100Val variant in MECP2 is classified as Pathogenic for Rett syndrome based on the ACMG/AMP criteria (PS4, PM1, PM6, PM2_supporting, PP3).		Rett and Angelman-like Disorders VCEP	https://clinicalgenome.org/site/assets/files/7339/clingen_rettas_acmg_specifications_v2.pdf	2022-05-10	2022-06-28	False	https://erepo.genome.network/evrepo/ui/classification/CA198822/MONDO:0010726/016	e3bdc1b4-4132-4891-9922-81a05eb5f882	p.Leu112Val	Leu	112	Val	MVAGMLGLREEKSEDQDLQGLKDKPLKFKKVKKDKKEEKEGKHEPVQPSAHHSAEPAEAGKAETSEGSGSAPAVPEASASPKQRRSIIRDRGPMYDDPTLPEGWTRKLKQRKSGRSAGKYDVYLINPQGKAFRSKVELIAYFEKVGDTSLDPNDFDFTVTGRGSPSRREQKPPKKPKSPKAPGTGRGRGRPKGSGTTRPKAATSEGVQVKRVLEKSPGKLLVKMPFQTSPGGKAEGGGATTSTQVMVIKRPGRKRKAEADPQAIPKKRGRKPGSVVAAAAAEAKKKAVKESSIRSVQETVLPIKKRKTRETVSIEVKEVVKPLLVSTLGEKSGKGLKTCKSPGRKSKESSPKGRSSSASSPPKKEHHHHHHHSESPKAPVPLLPPLPPPPPEPESSEDPTSPPEPQDLSSSVCKEEKMPRGGSLESDGCPKEPAKTQPAVATAATAAEKYKHRGEGERKDIVSSSMPRPNREEPVDSRTPVTERVS	486	P51608	V	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [103], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.03740561]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [99, 100, 101, 102], 'COMPBIAS_gain': [264], 'COMPBIAS_gain_score': array([0.01308149]), 'COMPBIAS_loss_score': array([-0.23185217, -0.21506661, -0.24472862, -0.28587431]), 'DOMAIN_loss': [86], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.03113842]), 'REGION_loss': [115, 116, 117, 118, 119], 'REGION_gain': [], 'REGION_loss_score': array([-0.48168254, -0.51943612, -0.53618008, -0.3686952 , -0.40546536]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
435	NM_001110792.2(MECP2):c.1318G>A (p.Gly440Ser)	11831	CA121707	NM_001110792.2:c.1318G>A, NC_000023.11:g.154030546C>T, CM000685.2:g.154030546C>T, NC_000023.10:g.153295997C>T, CM000685.1:g.153295997C>T, NC_000023.9:g.152949191C>T, NG_007107.2:g.111582G>A, NG_007107.3:g.111558G>A, ENST00000303391.11:c.1282G>A, ENST00000453960.7:c.1318G>A, ENST00000303391.10:c.1282G>A, ENST00000453960.6:c.1318G>A, ENST00000619732.4:c.1282G>A, ENST00000628176.2:c.*654G>A, NM_001110792.1:c.1318G>A, NM_001316337.1:c.1003G>A, NM_004992.3:c.1282G>A, XM_005274681.3:c.1282G>A, XM_005274682.3:c.1003G>A, XM_005274683.3:c.1003G>A, XM_006724819.2:c.613G>A, XM_011531166.1:c.1003G>A, XM_006724819.3:c.613G>A, XM_011531166.2:c.1003G>A, XM_024452383.1:c.1003G>A, XM_024452384.1:c.1003G>A, NM_001316337.2:c.1003G>A, NM_001369391.2:c.1003G>A, NM_001369392.2:c.1003G>A, NM_001369393.2:c.1003G>A, NM_001369394.1:c.1003G>A, NM_001369394.2:c.1003G>A, NM_001386137.1:c.613G>A, NM_001386138.1:c.613G>A, NM_001386139.1:c.613G>A, NM_004992.4:c.1282G>A, NM_001110792.2(MECP2):c.1318G>A (p.Gly440Ser)	MECP2	Rett syndrome	MONDO:0010726	X-linked inheritance	Benign	BS2, BS1	PP3	The allele frequency of the p.Gly428Ser (NM_004992) variant in MECP2 is 0.014% in gnomAD, which is high enough to meet BS1 criteria based on thresholds defined by the ClinGen Rett/Angelman-like Expert Panel for Rett/AS-like conditions (BS1). The p.Gly428Ser variant is observed in at least 2 unaffected individuals (PMID: 11238684, PMID: 12161600) (BS2). In summary the p.Gly428Ser variant in MECP2 is classified as Benign for Rett Syndrome based on the ACMG/AMP criteria (BS1, BS2).		Rett and Angelman-like Disorders VCEP	https://clinicalgenome.org/site/assets/files/7339/clingen_rettas_acmg_specifications_v2.pdf	2022-05-10	2022-06-28	False	https://erepo.genome.network/evrepo/ui/classification/CA121707/MONDO:0010726/016	e4f79d84-f9c0-4e1b-84c1-fb00225eea4d	p.Gly440Ser	Gly	440	Ser	MVAGMLGLREEKSEDQDLQGLKDKPLKFKKVKKDKKEEKEGKHEPVQPSAHHSAEPAEAGKAETSEGSGSAPAVPEASASPKQRRSIIRDRGPMYDDPTLPEGWTRKLKQRKSGRSAGKYDVYLINPQGKAFRSKVELIAYFEKVGDTSLDPNDFDFTVTGRGSPSRREQKPPKKPKSPKAPGTGRGRGRPKGSGTTRPKAATSEGVQVKRVLEKSPGKLLVKMPFQTSPGGKAEGGGATTSTQVMVIKRPGRKRKAEADPQAIPKKRGRKPGSVVAAAAAEAKKKAVKESSIRSVQETVLPIKKRKTRETVSIEVKEVVKPLLVSTLGEKSGKGLKTCKSPGRKSKESSPKGRSSSASSPPKKEHHHHHHHSESPKAPVPLLPPLPPPPPEPESSEDPTSPPEPQDLSSSVCKEEKMPRGGSLESDGCPKEPAKTQPAVATAATAAEKYKHRGEGERKDIVSSSMPRPNREEPVDSRTPVTERVS	486	P51608	S	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
436	NM_001110792.2(MECP2):c.433C>T (p.Arg145Cys)	11809	CA211250	NM_001110792.2:c.433C>T, NC_000023.11:g.154031431G>A, CM000685.2:g.154031431G>A, NC_000023.10:g.153296882G>A, CM000685.1:g.153296882G>A, NC_000023.9:g.152950076G>A, NG_007107.2:g.110697C>T, NG_007107.3:g.110673C>T, ENST00000303391.11:c.397C>T, ENST00000453960.7:c.433C>T, ENST00000637917.1:n.30C>T, ENST00000303391.10:c.397C>T, ENST00000369957.5:c.*451C>T, ENST00000407218.5:c.433C>T, ENST00000453960.6:c.433C>T, ENST00000486506.5:n.2745C>T, ENST00000611468.1:c.385C>T, ENST00000619732.4:c.397C>T, ENST00000622433.4:c.385C>T, ENST00000628176.2:c.397C>T, NM_001110792.1:c.433C>T, NM_001316337.1:c.118C>T, NM_004992.3:c.397C>T, XM_005274681.3:c.397C>T, XM_005274682.3:c.118C>T, XM_005274683.3:c.118C>T, XM_006724819.2:c.-164C>T, XM_011531166.1:c.118C>T, XM_006724819.3:c.-164C>T, XM_011531166.2:c.118C>T, XM_024452383.1:c.118C>T, XM_024452384.1:c.118C>T, NM_001316337.2:c.118C>T, NM_001369391.2:c.118C>T, NM_001369392.2:c.118C>T, NM_001369393.2:c.118C>T, NM_001369394.1:c.118C>T, NM_001369394.2:c.118C>T, NM_001386137.1:c.-164C>T, NM_001386138.1:c.-164C>T, NM_001386139.1:c.-164C>T, NM_004992.4:c.397C>T, NM_001110792.2(MECP2):c.433C>T (p.Arg145Cys)	MECP2	Rett syndrome	MONDO:0010726	X-linked inheritance	Pathogenic	PP3, PM2_Supporting, PS2_Very Strong, PS4, PM1		The p.Arg133Cys (NM_004992) variant in MECP2 has been reported as an assumed de novo occurrence in at least 4 individuals with Rett Syndrome (PMID: 10814718, PMID: 10991688, PMID: 12707946) (PS2_very-strong). The p.Arg133Cys variant has been observed in at least 4 other individuals with Rett Syndrome (PMID: 10814718, PMID: 10991688, PMID: 12707946, PMID: 17387578, PMID: 16473305) (PS4). The p.Arg133Cys variant occurs in the well-characterized (Methyl-DNA binding [MDB]: aa 90-162) functional domain of the MECP2 (PM1). Computational prediction analysis tools suggests a deleterious impact; however, this information does not predict clinical significance on its own (PP3). The p.Arg133Cys variant in MECP2 is absent from gnomAD (PM2_Supporting). In summary the p.Arg133Cys variant in MECP2 is classified as Pathogenic for Rett Syndrome based on the ACMG/AMP criteria (PS2_very-strong, PS4, PM1, PP3, PM2_supporting).		Rett and Angelman-like Disorders VCEP	https://clinicalgenome.org/site/assets/files/7339/clingen_rettas_acmg_specifications_v2.pdf	2022-05-10	2022-07-25	False	https://erepo.genome.network/evrepo/ui/classification/CA211250/MONDO:0010726/016	9b84fa8c-1789-41fa-a192-056f88af3907	p.Arg145Cys	Arg	145	Cys	MVAGMLGLREEKSEDQDLQGLKDKPLKFKKVKKDKKEEKEGKHEPVQPSAHHSAEPAEAGKAETSEGSGSAPAVPEASASPKQRRSIIRDRGPMYDDPTLPEGWTRKLKQRKSGRSAGKYDVYLINPQGKAFRSKVELIAYFEKVGDTSLDPNDFDFTVTGRGSPSRREQKPPKKPKSPKAPGTGRGRGRPKGSGTTRPKAATSEGVQVKRVLEKSPGKLLVKMPFQTSPGGKAEGGGATTSTQVMVIKRPGRKRKAEADPQAIPKKRGRKPGSVVAAAAAEAKKKAVKESSIRSVQETVLPIKKRKTRETVSIEVKEVVKPLLVSTLGEKSGKGLKTCKSPGRKSKESSPKGRSSSASSPPKKEHHHHHHHSESPKAPVPLLPPLPPPPPEPESSEDPTSPPEPQDLSSSVCKEEKMPRGGSLESDGCPKEPAKTQPAVATAATAAEKYKHRGEGERKDIVSSSMPRPNREEPVDSRTPVTERVS	486	P51608	C	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [102], 'COMPBIAS_gain': [], 'COMPBIAS_loss_score': array([-0.03316593]), 'DOMAIN_loss': [163], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.06311154]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
437	NM_001110792.2(MECP2):c.1162C>T (p.Pro388Ser)	95184	CA148292	NM_001110792.2:c.1162C>T, NC_000023.11:g.154030702G>A, CM000685.2:g.154030702G>A, NC_000023.10:g.153296153G>A, CM000685.1:g.153296153G>A, NC_000023.9:g.152949347G>A, NG_007107.2:g.111426C>T, NG_007107.3:g.111402C>T, ENST00000303391.11:c.1126C>T, ENST00000453960.7:c.1162C>T, ENST00000303391.10:c.1126C>T, ENST00000407218.5:c.*498C>T, ENST00000453960.6:c.1162C>T, ENST00000619732.4:c.1126C>T, ENST00000628176.2:c.*498C>T, NM_001110792.1:c.1162C>T, NM_001316337.1:c.847C>T, NM_004992.3:c.1126C>T, XM_005274681.3:c.1126C>T, XM_005274682.3:c.847C>T, XM_005274683.3:c.847C>T, XM_006724819.2:c.457C>T, XM_011531166.1:c.847C>T, XM_006724819.3:c.457C>T, XM_011531166.2:c.847C>T, XM_024452383.1:c.847C>T, XM_024452384.1:c.847C>T, NM_001316337.2:c.847C>T, NM_001369391.2:c.847C>T, NM_001369392.2:c.847C>T, NM_001369393.2:c.847C>T, NM_001369394.1:c.847C>T, NM_001369394.2:c.847C>T, NM_001386137.1:c.457C>T, NM_001386138.1:c.457C>T, NM_001386139.1:c.457C>T, NM_004992.4:c.1126C>T, NM_001110792.2(MECP2):c.1162C>T (p.Pro388Ser)	MECP2	Rett syndrome	MONDO:0010726	X-linked inheritance	Benign	BS2, BA1		The allele frequency of the c.1126C>T, p.(Pro376Ser)  variant in MECP2(NM_004992.4) is 0.13% in European (Non-Finnish) sub population in gnomAD, which is high enough to be classified as benign based on thresholds defined by the ClinGen Rett/Angelman-like Expert Panel for Rett/AS-like conditions (BA1). The p.(Pro376Ser) variant is observed in at least 2 unaffected individuals (PMID 10944854, PMID 14560307, RettBASE) (BS1). In summary, the p.(Pro376Ser) variant in MECP2 is classified as Benign based on the ACMG/AMP criteria applied (BA1, BS2).		Rett and Angelman-like Disorders VCEP	https://clinicalgenome.org/site/assets/files/7339/clingen_rettas_acmg_specifications_v2.pdf	2022-04-28	2022-06-28	False	https://erepo.genome.network/evrepo/ui/classification/CA148292/MONDO:0010726/016	42ed0077-9bfb-41a6-9c0b-f3dedb097940	p.Pro388Ser	Pro	388	Ser	MVAGMLGLREEKSEDQDLQGLKDKPLKFKKVKKDKKEEKEGKHEPVQPSAHHSAEPAEAGKAETSEGSGSAPAVPEASASPKQRRSIIRDRGPMYDDPTLPEGWTRKLKQRKSGRSAGKYDVYLINPQGKAFRSKVELIAYFEKVGDTSLDPNDFDFTVTGRGSPSRREQKPPKKPKSPKAPGTGRGRGRPKGSGTTRPKAATSEGVQVKRVLEKSPGKLLVKMPFQTSPGGKAEGGGATTSTQVMVIKRPGRKRKAEADPQAIPKKRGRKPGSVVAAAAAEAKKKAVKESSIRSVQETVLPIKKRKTRETVSIEVKEVVKPLLVSTLGEKSGKGLKTCKSPGRKSKESSPKGRSSSASSPPKKEHHHHHHHSESPKAPVPLLPPLPPPPPEPESSEDPTSPPEPQDLSSSVCKEEKMPRGGSLESDGCPKEPAKTQPAVATAATAAEKYKHRGEGERKDIVSSSMPRPNREEPVDSRTPVTERVS	486	P51608	S	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [252, 264, 360, 399], 'COMPBIAS_gain_score': array([0.00991213, 0.0110116 , 0.02596158, 0.07004821]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
438	NM_001110792.2(MECP2):c.1291C>T (p.Pro431Ser)	156634	CA198850	NM_001110792.2:c.1291C>T, NC_000023.11:g.154030573G>A, CM000685.2:g.154030573G>A, NC_000023.10:g.153296024G>A, CM000685.1:g.153296024G>A, NC_000023.9:g.152949218G>A, NG_007107.2:g.111555C>T, NG_007107.3:g.111531C>T, ENST00000303391.11:c.1255C>T, ENST00000453960.7:c.1291C>T, ENST00000303391.10:c.1255C>T, ENST00000453960.6:c.1291C>T, ENST00000619732.4:c.1255C>T, ENST00000628176.2:c.*627C>T, NM_001110792.1:c.1291C>T, NM_001316337.1:c.976C>T, NM_004992.3:c.1255C>T, XM_005274681.3:c.1255C>T, XM_005274682.3:c.976C>T, XM_005274683.3:c.976C>T, XM_006724819.2:c.586C>T, XM_011531166.1:c.976C>T, XM_006724819.3:c.586C>T, XM_011531166.2:c.976C>T, XM_024452383.1:c.976C>T, XM_024452384.1:c.976C>T, NM_001316337.2:c.976C>T, NM_001369391.2:c.976C>T, NM_001369392.2:c.976C>T, NM_001369393.2:c.976C>T, NM_001369394.1:c.976C>T, NM_001369394.2:c.976C>T, NM_001386137.1:c.586C>T, NM_001386138.1:c.586C>T, NM_001386139.1:c.586C>T, NM_004992.4:c.1255C>T, NM_001110792.2(MECP2):c.1291C>T (p.Pro431Ser)	MECP2	Rett syndrome	MONDO:0010726	X-linked inheritance	Benign	BS2, PS4_Supporting, BP5, BS1		"The allele frequency of the p.Pro419Ser variant in MECP2 (NM_004992.3) is 0.02% in """"""""""""""""Other"""""""""""""""" sub population in gnomAD, which is high enough to meet the BS1 criteria based on thresholds defined by the ClinGen Rett/Angelman-like Expert Panel for Rett/AS-like conditions (BS1) and additionally is present in three male individuals in gnomAD. The p.Pro419Ser variant is observed in at least 7 unaffected individuals (Baylor Genetic internal database, GeneDx internal database, PMID 16225173) (BS2). The p.Pro419Ser variant is found in a patient with an alternate molecular basis of disease (Invitae internal database) (BP5). The p.Pro419Ser variant has been observed in at least 2 individuals with neurodevelopmental disorders (PMID 32457807, 16225173) (PS4_supporting), however in these studies MECP2 was the only gene sequenced. In summary the p.Pro419Ser variant in MECP2 is classified as benign for Rett Syndrome based on the ACMG/AMP criteria (BS1, BS2, BP5) and the PS4_supporting evidence is not considered inconsistent with the final benign classification."		Rett and Angelman-like Disorders VCEP	https://clinicalgenome.org/site/assets/files/7339/clingen_rettas_acmg_specifications_v2.pdf	2022-04-28	2022-06-28	False	https://erepo.genome.network/evrepo/ui/classification/CA198850/MONDO:0010726/016	e8117af8-b1e2-44b8-b051-c56e78e83078	p.Pro431Ser	Pro	431	Ser	MVAGMLGLREEKSEDQDLQGLKDKPLKFKKVKKDKKEEKEGKHEPVQPSAHHSAEPAEAGKAETSEGSGSAPAVPEASASPKQRRSIIRDRGPMYDDPTLPEGWTRKLKQRKSGRSAGKYDVYLINPQGKAFRSKVELIAYFEKVGDTSLDPNDFDFTVTGRGSPSRREQKPPKKPKSPKAPGTGRGRGRPKGSGTTRPKAATSEGVQVKRVLEKSPGKLLVKMPFQTSPGGKAEGGGATTSTQVMVIKRPGRKRKAEADPQAIPKKRGRKPGSVVAAAAAEAKKKAVKESSIRSVQETVLPIKKRKTRETVSIEVKEVVKPLLVSTLGEKSGKGLKTCKSPGRKSKESSPKGRSSSASSPPKKEHHHHHHHSESPKAPVPLLPPLPPPPPEPESSEDPTSPPEPQDLSSSVCKEEKMPRGGSLESDGCPKEPAKTQPAVATAATAAEKYKHRGEGERKDIVSSSMPRPNREEPVDSRTPVTERVS	486	P51608	S	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [264, 374], 'COMPBIAS_gain_score': array([0.01249272, 0.02142698]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
439	NM_000152.5(GAA):c.1309C>T (p.Arg437Cys)	189082	CA274356	NM_000152.5:c.1309C>T, NC_000017.11:g.80108811C>T, CM000679.2:g.80108811C>T, NC_000017.10:g.78082610C>T, CM000679.1:g.78082610C>T, NC_000017.9:g.75697205C>T, NG_009822.1:g.12256C>T, LRG_673:g.12256C>T, ENST00000302262.8:c.1309C>T, ENST00000302262.7:c.1309C>T, ENST00000390015.7:c.1309C>T, NM_000152.3:c.1309C>T, LRG_673t1:c.1309C>T, NM_001079803.1:c.1309C>T, NM_001079804.1:c.1309C>T, XM_005257193.1:c.1309C>T, XM_005257194.3:c.1309C>T, NM_000152.4:c.1309C>T, NM_001079803.2:c.1309C>T, NM_001079804.2:c.1309C>T, XM_005257193.2:c.1309C>T, XM_005257194.4:c.1309C>T, NM_001079803.3:c.1309C>T, NM_001079804.3:c.1309C>T, NM_000152.5(GAA):c.1309C>T (p.Arg437Cys)	GAA	glycogen storage disease II	MONDO:0009290	Autosomal recessive inheritance	Pathogenic	PS3_Supporting, PP4_Moderate, PP3, PM2_Supporting, PM3_Very Strong	PM5	The NM_000152.5:c.1309C>T variant in GAA is a missense variant predicted to cause substitution of arginine by cysteine at amino acid 437 (p.Arg437Cys). This variant has been reported in at least 16 East Asian individuals with late onset Pompe disease (PMID: 34356580) including 11 individuals with documented laboratory values reporting GAA activity <10% normal in muscle or skin fibroblasts or in the affected range in a clinically validated dried blood spot assay and/or histological features consistent with Pompe disease in muscle, and/or on enzyme replacement therapy for Pompe disease (PMID 22521436, 29786057, 27692865, 30360039)(PP4_Moderate). Ten individuals are reported to be compound heterozygous for the variant and another variant in GAA that has been classified as pathogenic by the ClinGen LSD VCEP including one confirmed in trans, c.1082C>T (p.Pro361Leu) (PMID: 12601120), and 9 phase unknown, c.796C>T (p.Pro266Ser) (PMID: 25526786), c.1082C>T (p.Pro361Leu) (PMID: 27692865), c.1316T>A (p.Met439Lys) (PMID: 25388776), c.1822C>T (p.Arg608Ter) (PMID: 30360039), c.1978C>T (p.Arg600Cys) (PMID: 29124014, 3 probands), c.2238G>C (p.Trp746Cys) (PMID: 27692865), c.2297A>G (p.Tyr766Cys) (PMID: 29124014) (PM3_VeryStrong). The variant has also been reported in compound heterozygosity with c.1544T>A (p.Met515Lys) (PMID: 24190153), c.1562A>T (p.Glu521Val) (PMID: 29786057), c.1857C>G (p.Ser619Arg) (PMID: 291240140, c.2051C>A (p.Pro684Gln) (PMID: 29451150), c.2177C>G (p.Pro726Arg) (PMID: 29124014), and c.2297A>C (p.Tyr766Ser) (PMID: 22521436). The allelic data from these patients will be used in the classification of the second variant and is not included here in order to avoid circular logic. Additional patients have also been reported but the data was not included because the cDNA sequences of the variants was not included (PMID: 18495398, 21471980, 21704464). The highest population minor allele frequency in gnomAD v2.1.1 is 0.00009 (2/21914 alleles) in the African population, which is lower than the ClinGen LSD VCEP’s threshold for PM2_Supporting (<0.001), meeting this criterion (PM2_Supporting). Expression of the variant in Ad5-SV40 immortalized human GAA-deficient fibroblast cells showed no detectable GAA enzyme activity, and another study showed abnormal synthesis and processing of GAA when the variant was expressed in COS cells, indicating that this variant may impact protein function (PMID: 12601120, 19862843)(PS3_Supporting). The computational predictor REVEL gives a score of 0.782, which is above the threshold of 0.7, evidence that correlates with impact to GAA function (PP3). A novel variant at the same amino acid position, c.1310G>A (p.Arg437His) has been reported in a patient with Pompe disease (PMID: 25681614) but has not yet been classified as pathogenic or likely pathogenic by the ClinGen LSD VCEP and, therefore, PM5 is not applied. There is a ClinVar entry for this variant (Variation ID: 189082, 2 star review status) with 6 submitters classifying the variant as pathogenic and two as likely pathogenic). In summary, this variant meets the criteria to be classified as pathogenic for Pompe disease. GAA-specific ACMG/AMP criteria applied, as specified by the ClinGen LSD VCEP (Specifications Version 2.0): PM3_VeryStrong, PP4_Moderate, PP3, PS3_Supporting, PM2_Supporting.	19862843	Lysosomal Diseases VCEP	https://clinicalgenome.org/docs/clingen-lysosomal-storage-disorders-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-2/	2022-06-30	2022-06-30	False	https://erepo.genome.network/evrepo/ui/classification/CA274356/MONDO:0009290/010	0dbf1624-9409-4543-ab0b-0d66118a2e88	p.Arg437Cys	Arg	437	Cys	MGVRHPPCSHRLLAVCALVSLATAALLGHILLHDFLLVPRELSGSSPVLEETHPAHQQGASRPGPRDAQAHPGRPRAVPTQCDVPPNSRFDCAPDKAITQEQCEARGCCYIPAKQGLQGAQMGQPWCFFPPSYPSYKLENLSSSEMGYTATLTRTTPTFFPKDILTLRLDVMMETENRLHFTIKDPANRRYEVPLETPHVHSRAPSPLYSVEFSEEPFGVIVRRQLDGRVLLNTTVAPLFFADQFLQLSTSLPSQYITGLAEHLSPLMLSTSWTRITLWNRDLAPTPGANLYGSHPFYLALEDGGSAHGVFLLNSNAMDVVLQPSPALSWRSTGGILDVYIFLGPEPKSVVQQYLDVVGYPFMPPYWGLGFHLCRWGYSSTAITRQVVENMTRAHFPLDVQWNDLDYMDSRRDFTFNKDGFRDFPAMVQELHQGGRRYMMIVDPAISSSGPAGSYRPYDEGLRRGVFITNETGQPLIGKVWPGSTAFPDFTNPTALAWWEDMVAEFHDQVPFDGMWIDMNEPSNFIRGSEDGCPNNELENPPYVPGVVGGTLQAATICASSHQFLSTHYNLHNLYGLTEAIASHRALVKARGTRPFVISRSTFAGHGRYAGHWTGDVWSSWEQLASSVPEILQFNLLGVPLVGADVCGFLGNTSEELCVRWTQLGAFYPFMRNHNSLLSLPQEPYSFSEPAQQAMRKALTLRYALLPHLYTLFHQAHVAGETVARPLFLEFPKDSSTWTVDHQLLWGEALLITPVLQAGKAEVTGYFPLGTWYDLQTVPVEALGSLPPPPAAPREPAIHSEGQWVTLPAPLDTINVHLRAGYIIPLQGPGLTTTESRQQPMALAVALTKGGEARGELFWDDGESLEVLERGAYTQVIFLARNNTIVNELVRVTSEGAGLQLQKVTVLGVATAPQQVLSNGVPVSNFTYSPDTKVLDICVSLLMGEQFLVSWC	952	P10253	C	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [355, 375, 426, 508, 584, 663, 704, 714, 716], 'DNA_BIND_gain': [611], 'DNA_BIND_gain_score': array([0.00150377]), 'DNA_BIND_loss_score': array([-0.00427252, -0.00280386, -0.00942355, -0.00379133, -0.00749201,
       -0.00459689, -0.00285816, -0.01081556, -0.00304008]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [240, 468], 'STRAND_gain': [806, 885], 'STRAND_gain_score': array([0.00553787, 0.00514573]), 'STRAND_loss_score': array([-0.02492565, -0.02610272]), 'HELIX_loss': [453], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.04164702]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [386, 408, 426, 427, 434, 505], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.01143289, -0.01819617, -0.02648944, -0.0256865 , -0.02815312,
       -0.01459563]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
440	NM_001110792.2(MECP2):c.941C>T (p.Pro314Leu)	143738	CA270574	NM_001110792.2:c.941C>T, NC_000023.11:g.154030923G>A, CM000685.2:g.154030923G>A, NC_000023.10:g.153296374G>A, CM000685.1:g.153296374G>A, NC_000023.9:g.152949568G>A, NG_007107.2:g.111205C>T, NG_007107.3:g.111181C>T, ENST00000303391.11:c.905C>T, ENST00000453960.7:c.941C>T, ENST00000637917.1:n.79C>T, ENST00000303391.10:c.905C>T, ENST00000407218.5:c.*277C>T, ENST00000453960.6:c.941C>T, ENST00000619732.4:c.905C>T, ENST00000622433.4:c.891C>T, ENST00000628176.2:c.*277C>T, NM_001110792.1:c.941C>T, NM_001316337.1:c.626C>T, NM_004992.3:c.905C>T, XM_005274681.3:c.905C>T, XM_005274682.3:c.626C>T, XM_005274683.3:c.626C>T, XM_006724819.2:c.236C>T, XM_011531166.1:c.626C>T, XM_006724819.3:c.236C>T, XM_011531166.2:c.626C>T, XM_024452383.1:c.626C>T, XM_024452384.1:c.626C>T, NM_001316337.2:c.626C>T, NM_001369391.2:c.626C>T, NM_001369392.2:c.626C>T, NM_001369393.2:c.626C>T, NM_001369394.1:c.626C>T, NM_001369394.2:c.626C>T, NM_001386137.1:c.236C>T, NM_001386138.1:c.236C>T, NM_001386139.1:c.236C>T, NM_004992.4:c.905C>T, NM_001110792.2(MECP2):c.941C>T (p.Pro314Leu)	MECP2	Rett syndrome	MONDO:0010726	X-linked inheritance	Pathogenic	PP3, PP4, PM6_Strong, PM2_Supporting, PS4, PM1, PM5		The c.905C>T p.(Pro302Leu) variant in MECP2 (NM_004992.3) is absent from gnomAD (PM2_supporting). The p.(Pro302Leu) variant has been observed in at least 5 individuals with Rett syndrome or severe neonatal encephalopathy (PMID: 10767337, 30377382, 23696494, 11313756, 16473305, 32472557) (PS4, PP4), where it has been reported as a de novo occurrence (biological parentage unconfirmed) in at least 4 of these individuals (PMID: 10767337, 30377382, 23696494, 11313756) (PM6_very strong). The p.(Pro302Leu) variant occurs in the well-characterized transcriptional repression domain (TRD: aa 302-306) of the MECP2 gene (PM1). Computational prediction analysis tools suggests a deleterious impact; however, this information does not predict clinical significance on its own (PP3). Multiple pathogenic missense variants have been previously identified within this codon which indicates that this residue is critical to the function of the protein (PMID: 10814718, 10814719, 10944854, 17387578, 15737703) (PM5). In summary, the c.905C>T p.(Pro302Leu) variant in MECP2 is classified as Pathogenic for Rett syndrome based on the ACMG/AMP criteria (PM6_very strong, PS4, PM1, PM5, PP3, PP4, PM2_supporting).		Rett and Angelman-like Disorders VCEP	https://clinicalgenome.org/site/assets/files/7339/clingen_rettas_acmg_specifications_v2.pdf	2022-06-30	2022-06-30	False	https://erepo.genome.network/evrepo/ui/classification/CA270574/MONDO:0010726/016	5440749b-7ac5-4fba-8a4a-70847f234b72	p.Pro314Leu	Pro	314	Leu	MVAGMLGLREEKSEDQDLQGLKDKPLKFKKVKKDKKEEKEGKHEPVQPSAHHSAEPAEAGKAETSEGSGSAPAVPEASASPKQRRSIIRDRGPMYDDPTLPEGWTRKLKQRKSGRSAGKYDVYLINPQGKAFRSKVELIAYFEKVGDTSLDPNDFDFTVTGRGSPSRREQKPPKKPKSPKAPGTGRGRGRPKGSGTTRPKAATSEGVQVKRVLEKSPGKLLVKMPFQTSPGGKAEGGGATTSTQVMVIKRPGRKRKAEADPQAIPKKRGRKPGSVVAAAAAEAKKKAVKESSIRSVQETVLPIKKRKTRETVSIEVKEVVKPLLVSTLGEKSGKGLKTCKSPGRKSKESSPKGRSSSASSPPKKEHHHHHHHSESPKAPVPLLPPLPPPPPEPESSEDPTSPPEPQDLSSSVCKEEKMPRGGSLESDGCPKEPAKTQPAVATAATAAEKYKHRGEGERKDIVSSSMPRPNREEPVDSRTPVTERVS	486	P51608	L	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [252, 264], 'COMPBIAS_gain_score': array([0.00916117, 0.01091254]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
441	NM_130839.5(UBE3A):c.1064G>C (p.Ser355Thr)	156132	CA333425	NM_130839.5:c.1064G>C, NC_000015.10:g.25371110C>G, CM000677.2:g.25371110C>G, NC_000015.9:g.25616257C>G, CM000677.1:g.25616257C>G, NC_000015.8:g.23167350C>G, NG_009268.1:g.72872G>C, LRG_15:g.72872G>C, ENST00000438097.6:c.1004G>C, ENST00000625778.3:c.1004G>C, ENST00000635914.1:c.1004G>C, ENST00000637886.1:c.1064G>C, ENST00000638011.1:c.1004G>C, ENST00000638155.1:c.1004G>C, ENST00000648336.2:c.1064G>C, ENST00000649550.1:c.1004G>C, ENST00000650110.1:c.1073G>C, ENST00000675000.1:n.1739G>C, ENST00000675177.1:c.887G>C, ENST00000675593.1:n.3760G>C, ENST00000232165.7:c.1004G>C, ENST00000397954.6:c.1073G>C, ENST00000428984.6:c.1004G>C, ENST00000438097.5:c.1004G>C, ENST00000566215.5:c.1004G>C, ENST00000614096.4:c.1064G>C, ENST00000625778.2:c.1004G>C, ENST00000630424.2:c.1004G>C, NM_000462.3:c.1073G>C, NM_130838.1:c.1004G>C, LRG_15t1:c.1004G>C, NM_130839.2:c.1064G>C, XM_005268267.3:c.1004G>C, XM_005268268.3:c.1004G>C, XM_005268269.3:c.1004G>C, XM_005268270.3:c.1004G>C, XM_005268271.3:c.1004G>C, XM_006720673.2:c.1064G>C, XM_006720674.2:c.1064G>C, XM_006720675.2:c.1004G>C, XM_006720676.2:c.1004G>C, XM_011521994.1:c.1073G>C, XM_011521995.1:c.1073G>C, XM_011521996.1:c.1004G>C, NM_000462.5:c.1073G>C, NM_001354505.1:c.1064G>C, NM_001354506.1:c.1004G>C, NM_001354507.1:c.1004G>C, NM_001354508.1:c.1004G>C, NM_001354509.1:c.1004G>C, NM_001354511.1:c.1004G>C, NM_001354512.1:c.1004G>C, NM_001354513.1:c.1004G>C, NM_001354523.1:c.1004G>C, NM_001354526.1:c.1004G>C, NM_001354538.1:c.1064G>C, NM_001354539.1:c.1004G>C, NM_001354540.1:c.1004G>C, NM_001354541.1:c.1004G>C, NM_001354542.1:c.1004G>C, NM_001354543.1:c.1004G>C, NM_001354544.1:c.1004G>C, NM_001354545.1:c.1064G>C, NM_001354546.1:c.887G>C, NM_001354547.1:c.1004G>C, NM_001354548.1:c.1004G>C, NM_001354549.1:c.1004G>C, NM_001354550.1:c.361+4355G>C, NM_001354551.1:c.301+4355G>C, NM_130838.3:c.1004G>C, NM_130839.4:c.1064G>C, NR_146177.1:n.18393-20486C>G, NR_148916.1:n.1612G>C, XM_011521995.3:c.1073G>C, XM_017022547.2:c.1064G>C, XM_017022548.2:c.1064G>C, XM_017022550.2:c.1064G>C, XM_017022556.2:c.1073G>C, XM_024450043.1:c.1073G>C, XM_024450044.1:c.1004G>C, NM_001354506.2:c.1004G>C, NM_001354507.2:c.1004G>C, NM_001354508.2:c.1004G>C, NM_001354509.2:c.1004G>C, NM_001354511.2:c.1004G>C, NM_001354512.2:c.1004G>C, NM_001354513.2:c.1004G>C, NM_001354523.2:c.1004G>C, NM_001354538.2:c.1064G>C, NM_001354539.2:c.1004G>C, NM_001354540.2:c.1004G>C, NM_001354541.2:c.1004G>C, NM_001354542.2:c.1004G>C, NM_001354543.2:c.1004G>C, NM_001354544.2:c.1004G>C, NM_001354545.2:c.1064G>C, NM_001354546.2:c.887G>C, NM_001354547.2:c.1004G>C, NM_001354548.2:c.1004G>C, NM_001354549.2:c.1004G>C, NM_001354550.2:c.361+4355G>C, NM_001354551.2:c.301+4355G>C, NM_001374461.1:c.1004G>C, NM_130838.4:c.1004G>C, NR_148916.2:n.1580G>C, NM_130839.5(UBE3A):c.1064G>C (p.Ser355Thr)	UBE3A	Angelman syndrome	MONDO:0007113	Autosomal dominant inheritance (with paternal imprinting (HP:0012274))	Benign	BA1, BP4		The allele frequency of the c.1064G>C p.(Ser355Thr) variant in UBE3A (NM_130839.5) is 0.078% in the South Asian sub population in gnomAD, which is high enough to be classified as benign based on thresholds defined by the ClinGen Rett/Angelman-like Expert Panel for Rett/AS-like conditions (BA1). In summary, the c.1064G>C p.(Ser355Thr) variant in UBE3A is classified as Benign based on the ACMG/AMP criteria (BA1).		Rett and Angelman-like Disorders VCEP	https://clinicalgenome.org/site/assets/files/7339/clingen_rettas_acmg_specifications_v2.pdf	2022-06-30	2022-06-30	False	https://erepo.genome.network/evrepo/ui/classification/CA333425/MONDO:0007113/016	4f1d9c1a-3719-42b4-a7cc-c1a2acb499c8	p.Ser355Thr	Ser	355	Thr	MEKLHQCYWKSGEPQSDDIEASRMKRAAAKHLIERYYHQLTEGCGNEACTNEFCASCPTFLRMDNNAAAIKALELYKINAKLCDPHPSKKGASSAYLENSKGAPNNSCSEIKMNKKGARIDFKDVTYLTEEKVYEILELCREREDYSPLIRVIGRVFSSAEALVQSFRKVKQHTKEELKSLQAKDEDKDEDEKEKAACSAAAMEEDSEASSSRIGDSSQGDNNLQKLGPDDVSVDIDAIRRVYTRLLSNEKIETAFLNALVYLSPNVECDLTYHNVYSRDPNYLNLFIIVMENRNLHSPEYLEMALPLFCKAMSKLPLAAQGKLIRLWSKYNADQIRRMMETFQQLITYKVISNEFNSRNLVNDDDAIVAASKCLKMVYYANVVGGEVDTNHNEEDDEEPIPESSELTLQELLGEERRNKKGPRVDPLETELGVKTLDCRKPLIPFEEFINEPLNEVLEMDKDYTFFKVETENKFSFMTCPFILNAVTKNLGLYYDNRIRMYSERRITVLYSLVQGQQLNPYLRLKVRRDHIIDDALVRLEMIAMENPADLKKQLYVEFEGEQGVDEGGVSKEFFQLVVEEIFNPDIGMFTYDESTKLFWFNPSSFETEGQFTLIGIVLGLAIYNNCILDVHFPMVVYRKLMGKKGTFRDLGDSHPVLYQSLKDLLEYEGNVEDDMMITFQISQTDLFGNPMMYDLKENGDKIPITNENRKEFVNLYSDYILNKSVEKQFKAFRRGFHMVTNESPLKYLFRPEEIELLICGSRNLDFQALEETTEYDGGYTRDSVLIREFWEIVHSFTDEQKRLFLQFTTGTDRAPVGGLGKLKMIIAKNGPDTERLPTSHTCFNVLLLPEYSSKEKLKERLLKAITYAKGFGML	875	Q05086	T	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [614], 'TOPO_DOM_gain': [], 'TOPO_DOM_loss_score': array([-0.01152498]), 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [13], 'SIGNAL_gain': [], 'SIGNAL_loss_score': array([-0.01006132]), 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [378, 755], 'HELIX_gain': [294, 295], 'HELIX_gain_score': array([0.02166975, 0.00977677]), 'HELIX_loss_score': array([-0.01002383, -0.0176248 ]), 'COILED_loss': [], 'COILED_gain': [197], 'COILED_gain_score': array([0.00844538]), 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [735], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.02277821]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
442	NM_001754.5(RUNX1):c.1415T>C (p.Leu472Pro)	463984	CA10014174	NM_001754.5:c.1415T>C, NC_000021.9:g.34792163A>G, CM000683.2:g.34792163A>G, NC_000021.8:g.36164460A>G, CM000683.1:g.36164460A>G, NC_000021.7:g.35086330A>G, NG_011402.2:g.1197549T>C, LRG_482:g.1197549T>C, ENST00000675419.1:c.1415T>C, ENST00000300305.7:c.1415T>C, ENST00000344691.8:c.1334T>C, ENST00000399240.5:c.1142T>C, ENST00000437180.5:c.1415T>C, ENST00000482318.5:c.*1005T>C, NM_001001890.2:c.1334T>C, NM_001754.4:c.1415T>C, LRG_482t1:c.1415T>C, XM_005261068.3:c.1379T>C, XM_005261069.3:c.1223T>C, XM_011529766.1:c.1415T>C, XM_011529767.1:c.1376T>C, XM_011529768.1:c.1184T>C, XM_005261069.4:c.1223T>C, XM_011529766.2:c.1415T>C, XM_011529767.2:c.1376T>C, XM_011529768.2:c.1184T>C, XM_017028487.1:c.1262T>C, NM_001001890.3:c.1334T>C, NM_001754.5(RUNX1):c.1415T>C (p.Leu472Pro)	RUNX1	hereditary thrombocytopenia and hematologic cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Benign	BA1, BP4	PM2, PVS1, PM3, PM4, PM1, PM5, BS2, PP4, PP2, PP3, PP1, BP2, BP3, BP1, PS3, PS1, PS2, PS4, BS1, BS3, BS4, BP5, BP7	NM_001754.5(RUNX1):c.1415T>C (p.Leu472Pro) is a  missense variant in the final exon of the protein. MAF of 0.002289 (0.2289%, 23/10046 alleles, gnomad v2.11) in South East Asian population: cohort is ≥ 0.0015 (0.15%) (BA1). The REVEL score= 0.414 (≤0.50) and SpliceAI is ≤0.20 (0.00) (BP4). In summary, this variant meets the criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the  Myeloid Malignancy Variant Curation Expert Panel for RUNX1: BA1, BP4		Myeloid Malignancy VCEP	https://www.clinicalgenome.org/affiliation/50034/docs/assertion-criteria 	2022-04-08	2022-06-30	False	https://erepo.genome.network/evrepo/ui/classification/CA10014174/MONDO:0011071/008	2b491571-516e-4909-a1ca-1d034807cf15	p.Leu472Pro	Leu	472	Pro	MRIPVDASTSRRFTPPSTALSPGKMSEALPLGAPDAGAALAGKLRSGDRSMVEVLADHPGELVRTDSPNFLCSVLPTHWRCNKTLPIAFKVVALGDVPDGTLVTVMAGNDENYSAELRNATAAMKNQVARFNDLRFVGRSGRGKSFTLTITVFTNPPQVATYHRAIKITVDGPREPRRHRQKLDDQTKPGSLSFSERLSELEQLRRTAMRVSPHHPAPTPNPRASLNHSTAFNPQPQSQMQDTRQIQPSPPWSYDQSYQYLGSIASPSVHPATPISPGRASGMTTLSAELSSRLSTAPDLTAFSDPRQFPALPSISDPRMHYPGAFTYSPTPVTSGIGIGMSAMGSATRYHTYLPPPYPGSSQAQGGPFQASSPSYHLYYGASAGSYQFSMVGGERSPPRILPPCTNASTGSALLNPSLPNQSDVVEAEGSHSNSPTNMAPSARLEEAVWRPY	453	Q01196	P	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [8], 'TRANSIT_gain': [], 'TRANSIT_loss_score': array([-0.01202691]), 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [404, 406, 409], 'COMPBIAS_gain_score': array([0.03374624, 0.02795899, 0.04160565]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [400], 'REGION_gain_score': array([0.01649261]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
443	NM_000527.5(LDLR):c.796G>A (p.Asp266Asn)	226334	CA10576288	NM_000527.5:c.796G>A, NC_000019.10:g.11106666G>A, CM000681.2:g.11106666G>A, NC_000019.9:g.11217342G>A, CM000681.1:g.11217342G>A, NC_000019.8:g.11078342G>A, NG_009060.1:g.22286G>A, LRG_274:g.22286G>A, ENST00000558518.6:c.796G>A, ENST00000252444.9:n.1050G>A, ENST00000455727.6:c.314-726G>A, ENST00000535915.5:c.673G>A, ENST00000545707.5:c.415G>A, ENST00000557933.5:c.796G>A, ENST00000558013.5:c.796G>A, ENST00000558518.5:c.796G>A, ENST00000558528.1:n.311G>A, ENST00000560467.1:n.396G>A, NM_000527.4:c.796G>A, LRG_274t1:c.796G>A, NM_001195798.1:c.796G>A, NM_001195799.1:c.673G>A, NM_001195800.1:c.314-726G>A, NM_001195803.1:c.415G>A, XM_011528010.1:c.796G>A, XM_011528011.1:c.415G>A, XR_244074.2:n.946G>A, XM_011528010.2:c.796G>A, XR_001753685.2:n.913G>A, XR_001753686.2:n.913G>A, NM_001195798.2:c.796G>A, NM_001195799.2:c.673G>A, NM_001195800.2:c.314-726G>A, NM_001195803.2:c.415G>A, NM_000527.5(LDLR):c.796G>A (p.Asp266Asn)	LDLR	hypercholesterolemia, familial	MONDO:0007750	Semidominant inheritance	Pathogenic	PM5_Strong, PS4, PM2, PP3, PP1, PP4, PS3_Moderate	PS2, PS1, BS1, BS3, BS4, BP5, BP7, PM1, PM3, PM4, PM6, PVS1, BS2, PP2, BA1, BP1, BP4, BP2, BP3	The NM_000527.5(LDLR):c. c.796G>A (p.Asp266Asn) variant is classified as Pathogenic for Familial Hypercholesterolemia by applying evidence codes PS4, PM2, PM5_Strong, PS3_Moderate, PP1, PP3 and PP4 as defined by the ClinGen Familial Hypercholesterolemia Expert Panel LDLR-specific variant curation guidelines (https://doi.org/10.1101/2021.03.17.21252755). The supporting evidence is as follows: PS4 - Variant meets PM2. Variant identified in 10 unrelated index cases (1 case fulfilling Simon-Broome criteria published in PMID: 12414836; 1 case probably fulfilling Simon-Broome criteria published in PMID: 12417285; 1 case with DLCN criteria from Cardiovascular Genetics Laboratory (PathWest Laboratory Medicine WA); 4 cases with Simon-Broome criteria from Molecular Genetics Laboratory (Centre for Cardiovascular Surgery and Transplantation); 3 cases with DLCN criteria from Mayo Clinic Atherosclerosis and Lipid Genomics Laboratory);PM2 - PopMax MAF = 0.00006533 (0.006533%) in South Asian  exomes (gnomAD v2.1.1);PM5_Strong - 4 other missense variants in the same codon: - NM_000527.5(LDLR): c.796G>T (p.Asp266Tyr) (ClinVar ID 251456) - Pathogenic by these guidelines. - NM_000527.5(LDLR): c.797A>T (p.Asp266Val) (ClinVar ID 251458) - Likely Pathogenic by these guidelines. - NM_001195803.2(LDLR):c.797A>G (p.Asp266Gly) (ClinVar ID 251457) - Likely pathogenic by these guidelines. - NM_001195803.2(LDLR): c.798T>A (p.Asp266Glu) - (ClinVar ID 161287) - Pathogenic by these guidelines.There are 2 variants in the same codon classified as Pathogenic by these guidelines.PS3_Moderate - Level 2 assay: PMID 12414836: Homozygous patient cells, 125I assays - result - <2% LDL-LDLR binding and internalisation. Functional study is consistent with damaging effect;PP1 - 3 informative meioses identified by Molecular Genetics Laboratory (Centre for Cardiovascular Surgery and Transplantation);PP3 - REVEL = 0,83;PP4 - Variant meets PM2. Identified in at least 1 FH case fulfilling Simon-Broome criteria published in PMID 12414836.		Familial Hypercholesterolemia VCEP	https://clinicalgenome.org/docs/clingen-familial-hypercholesterolemia-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1-2/	2022-05-04	2022-06-30	False	https://erepo.genome.network/evrepo/ui/classification/CA10576288/MONDO:0007750/013	febc36e7-3293-4e52-8666-7a907e25a4a9	p.Asp266Asn	Asp	266	Asn	MGPWGWKLRWTVALLLAAAGTAVGDRCERNEFQCQDGKCISYKWVCDGSAECQDGSDESQETCLSVTCKSGDFSCGGRVNRCIPQFWRCDGQVDCDNGSDEQGCPPKTCSQDEFRCHDGKCISRQFVCDSDRDCLDGSDEASCPVLTCGPASFQCNSSTCIPQLWACDNDPDCEDGSDEWPQRCRGLYVFQGDSSPCSAFEFHCLSGECIHSSWRCDGGPDCKDKSDEENCAVATCRPDEFQCSDGNCIHGSRQCDREYDCKDMSDEVGCVNVTLCEGPNKFKCHSGECITLDKVCNMARDCRDWSDEPIKECGTNECLDNNGGCSHVCNDLKIGYECLCPDGFQLVAQRRCEDIDECQDPDTCSQLCVNLEGGYKCQCEEGFQLDPHTKACKAVGSIAYLFFTNRHEVRKMTLDRSEYTSLIPNLRNVVALDTEVASNRIYWSDLSQRMICSTQLDRAHGVSSYDTVISRDIQAPDGLAVDWIHSNIYWTDSVLGTVSVADTKGVKRKTLFRENGSKPRAIVVDPVHGFMYWTDWGTPAKIKKGGLNGVDIYSLVTENIQWPNGITLDLLSGRLYWVDSKLHSISSIDVNGGNRKTILEDEKRLAHPFSLAVFEDKVFWTDIINEAIFSANRLTGSDVNLLAENLLSPEDMVLFHNLTQPRGVNWCERTTLSNGGCQYLCLPAPQINPHSPKFTCACPDGMLLARDMRSCLTEAEAAVATQETSTVRLKVSSTAVRTQHTTTRPVPDTSRLPGATPGLTTVEIVTMSHQALGDVAGRGNEKKPSSVRALSIVLPIVLLVFLCLGVFLLWKNWRLKNINSINFDNPVYQKTTEDEVHICHNQDGYSYPSRQMVSLEDDVA	860	P01130	N	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [24], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.00727499]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [266], 'ZN_FING_gain': [260], 'ZN_FING_gain_score': array([0.00314987]), 'ZN_FING_loss_score': array([-0.03843486])}
444	NM_000527.5(LDLR):c.796G>T (p.Asp266Tyr)	251456	CA10585134	NM_000527.5:c.796G>T, NC_000019.10:g.11106666G>T, CM000681.2:g.11106666G>T, NC_000019.9:g.11217342G>T, CM000681.1:g.11217342G>T, NC_000019.8:g.11078342G>T, NG_009060.1:g.22286G>T, LRG_274:g.22286G>T, ENST00000558518.6:c.796G>T, ENST00000252444.9:n.1050G>T, ENST00000455727.6:c.314-726G>T, ENST00000535915.5:c.673G>T, ENST00000545707.5:c.415G>T, ENST00000557933.5:c.796G>T, ENST00000558013.5:c.796G>T, ENST00000558518.5:c.796G>T, ENST00000558528.1:n.311G>T, ENST00000560467.1:n.396G>T, NM_000527.4:c.796G>T, LRG_274t1:c.796G>T, NM_001195798.1:c.796G>T, NM_001195799.1:c.673G>T, NM_001195800.1:c.314-726G>T, NM_001195803.1:c.415G>T, XM_011528010.1:c.796G>T, XM_011528011.1:c.415G>T, XR_244074.2:n.946G>T, XM_011528010.2:c.796G>T, XR_001753685.2:n.913G>T, XR_001753686.2:n.913G>T, NM_001195798.2:c.796G>T, NM_001195799.2:c.673G>T, NM_001195800.2:c.314-726G>T, NM_001195803.2:c.415G>T, NM_000527.5(LDLR):c.796G>T (p.Asp266Tyr)	LDLR	hypercholesterolemia, familial	MONDO:0007750	Semidominant inheritance	Pathogenic	PM5_Strong, PP1_Moderate, PM2, PP3, PP4	PS1, PS3, PS4, PS2, PM1, PM3, PM4, BP5, BP7, BS1, BS3, BS4, PVS1, PM6, PP2, BS2, BA1, BP1, BP4, BP2, BP3	The NM_000527.5(LDLR): c.796G>T (p.Asp266Tyr) variant is classified as Pathogenic for Familial Hypercholesterolemia by applying evidence codes PM5_Strong, PM2, PP1_Moderate, PP3 and PP4 as defined by the ClinGen Familial Hypercholesterolemia Expert Panel LDLR-specific variant curation guidelines (https://doi.org/10.1101/2021.03.17.21252755). The supporting evidence is as follows: PM5_Strong - 4 other missense variants in the same codon:- NM_000527.5(LDLR): c.796G>T (p.Asp266Asn) (ClinVar ID 226334) - Pathogenic by these guidelines,- NM_000527.5(LDLR): c.797A>T (p.Asp266Val) (ClinVar ID 251458) - Likely pathogenic by these guidelines,- NM_000527.5(LDLR):  c.797A>G (p.Asp266Gly) (ClinVar ID 251457) - Likely pathogenic by these guidelines,- NM_000527.5(LDLR): c.798T>A (p.Asp266Glu) - (ClinVar ID 161287) - Pathogenic by these guidelines.There are 2 variants in the same codon classified as Pathogenic by these guidelines;PM2 - This variant is absent from gnomAD (gnomAD v2.1.1);PP1_Moderate - 5 informative meioses published in PMID 11196104.PP3 – REVEL = 0.97;PP4 - Variant meets PM2. Identified in 1 FH case fulfilling MEDPED criteria published in PMID 11196104.		Familial Hypercholesterolemia VCEP	https://clinicalgenome.org/docs/clingen-familial-hypercholesterolemia-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1-2/	2022-05-05	2022-06-30	False	https://erepo.genome.network/evrepo/ui/classification/CA10585134/MONDO:0007750/013	02855998-6cea-4d61-ab76-99c4e0737e92	p.Asp266Tyr	Asp	266	Tyr	MGPWGWKLRWTVALLLAAAGTAVGDRCERNEFQCQDGKCISYKWVCDGSAECQDGSDESQETCLSVTCKSGDFSCGGRVNRCIPQFWRCDGQVDCDNGSDEQGCPPKTCSQDEFRCHDGKCISRQFVCDSDRDCLDGSDEASCPVLTCGPASFQCNSSTCIPQLWACDNDPDCEDGSDEWPQRCRGLYVFQGDSSPCSAFEFHCLSGECIHSSWRCDGGPDCKDKSDEENCAVATCRPDEFQCSDGNCIHGSRQCDREYDCKDMSDEVGCVNVTLCEGPNKFKCHSGECITLDKVCNMARDCRDWSDEPIKECGTNECLDNNGGCSHVCNDLKIGYECLCPDGFQLVAQRRCEDIDECQDPDTCSQLCVNLEGGYKCQCEEGFQLDPHTKACKAVGSIAYLFFTNRHEVRKMTLDRSEYTSLIPNLRNVVALDTEVASNRIYWSDLSQRMICSTQLDRAHGVSSYDTVISRDIQAPDGLAVDWIHSNIYWTDSVLGTVSVADTKGVKRKTLFRENGSKPRAIVVDPVHGFMYWTDWGTPAKIKKGGLNGVDIYSLVTENIQWPNGITLDLLSGRLYWVDSKLHSISSIDVNGGNRKTILEDEKRLAHPFSLAVFEDKVFWTDIINEAIFSANRLTGSDVNLLAENLLSPEDMVLFHNLTQPRGVNWCERTTLSNGGCQYLCLPAPQINPHSPKFTCACPDGMLLARDMRSCLTEAEAAVATQETSTVRLKVSSTAVRTQHTTTRPVPDTSRLPGATPGLTTVEIVTMSHQALGDVAGRGNEKKPSSVRALSIVLPIVLLVFLCLGVFLLWKNWRLKNINSINFDNPVYQKTTEDEVHICHNQDGYSYPSRQMVSLEDDVA	860	P01130	Y	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [252], 'HELIX_gain_score': array([0.06218654]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [228, 237, 261, 266], 'ZN_FING_gain': [], 'ZN_FING_loss_score': array([-0.01338267, -0.02055848, -0.00917113, -0.01728612])}
445	NM_000527.5(LDLR):c.530C>T (p.Ser177Leu)	3686	CA023715	NM_000527.5:c.530C>T, NC_000019.10:g.11105436C>T, CM000681.2:g.11105436C>T, NC_000019.9:g.11216112C>T, CM000681.1:g.11216112C>T, NC_000019.8:g.11077112C>T, NG_009060.1:g.21056C>T, LRG_274:g.21056C>T, ENST00000558518.6:c.530C>T, ENST00000252444.9:n.784C>T, ENST00000455727.6:c.314-1956C>T, ENST00000535915.5:c.407C>T, ENST00000545707.5:c.314-1129C>T, ENST00000557933.5:c.530C>T, ENST00000558013.5:c.530C>T, ENST00000558518.5:c.530C>T, ENST00000560467.1:n.130C>T, NM_000527.4:c.530C>T, LRG_274t1:c.530C>T, NM_001195798.1:c.530C>T, NM_001195799.1:c.407C>T, NM_001195800.1:c.314-1956C>T, NM_001195803.1:c.314-1129C>T, XM_011528010.1:c.530C>T, XM_011528011.1:c.314-1129C>T, XR_244074.2:n.680C>T, XM_011528010.2:c.530C>T, XR_001753685.2:n.647C>T, XR_001753686.2:n.647C>T, NM_001195798.2:c.530C>T, NM_001195799.2:c.407C>T, NM_001195800.2:c.314-1956C>T, NM_001195803.2:c.314-1129C>T, NM_000527.5(LDLR):c.530C>T (p.Ser177Leu)	LDLR	hypercholesterolemia, familial	MONDO:0007750	Semidominant inheritance	Pathogenic	PS3, PS4, PP1_Strong, PM1, PM3, BS4, PM2, PP3, PP4	PS1, PS2, PM5, PM4, BP7, BP5, BS1, BS3, PVS1, PM6, BS2, PP2, BP1, BP4, BP3, BP2, BA1	NM_000527.5(LDLR): c.530C>T (p.Ser177Leu) variant is classified as Pathogenic for Familial Hypercholesterolemia by applying evidence codes (PS3, PS4, PM1, PM2, PM3, PP1_Strong, PP3, PP4 and BS4) as defined by the ClinGen Familial Hypercholesterolemia Expert Panel LDLR-specific variant curation guidelines (https://doi.org/10.1016/j.gim.2021.09.012).The supporting evidence is as follows:PS3 - PMID: 31578082 - Level 1 assay - Heterologous cells (CHO), FACS assays and CLSM: 65% cell surface LDLR, 10% binding and <2% uptake.  PMID: 2760205 - Level 2 assay - Homozygous patient fibroblast, 125I-LDL assays: <2% LDLR activity. PMID: 25647241 - Level 3 assay - Heterologous cells (HeLa), CLSM assays: LDLR activity decreased compared to WT - considered as disruptive.PS4 - Variant meets PM2. Variant identified in 30 unrelated index cases (5 cases (2 with DLCN≥6; 3 with Simon-Broome possible) from Centre de Génétique Moléculaire et Chromosomique, Unité de génétique de l'Obésité et des Dyslipidémies (APHP.Sorbonne Université, Hôpital de la Pitié-Salpêtrière); 1 case with Simon-Broome possible from GeneDx Inc.; 11 cases with Simon-Broome possible from Cardiovascular Research Group,Instituto Nacional de Saude Doutor Ricardo Jorge; 13 cases with Simon-Broome possible/definite from Molecular Genetics Laboratory (Centre for Cardiovascular Surgery and Transplantation).PM1 - Variant meets PM2 and is missense in exon 4.PM2 - PopMax MAF = 0.00006533 (0.006533%) in South Asian exomes+genomes (gnomAD v2.1.1).PM3 - Patient 3 from PMID: 18263977 has LDL = 19.7 mmol/l and also LDLR p.Arg350* in trans - Pathogenic by these guidelines. Two true homozygotes (FHF23 and FHF57) published in PMID: 27816806 had LDL = 16.2 mmol/l and 22.6 mmol/l, respectively.PP1_Strong - Variant segregates with FH phenotype in 52 informative meiosis in 26 families from different labs (Laboratory of Genetics and Molecular Cardiology, University of São Paulo; Centre de Génétique Moléculaire et Chromosomique, Unité de génétique de l'Obésité et des Dyslipidémies (APHP.Sorbonne Université, Hôpital de la Pitié-Salpêtrière); Molecular Genetics Laboratory (Centre for Cardiovascular Surgery and Transplantation); Cardiovascular Research Group,Instituto Nacional de Saude Doutor Ricardo Jorge): 43 relatives tested positive had LDL-C >75th percentile + 9 relatives tested negative had  LDL-C <50th percentile.PP3 - REVEL = 0.886.PP4 - Variant meets PM2. Variant identified in 30 unrelated index cases who fulfill clinical criteria for FH from several labs (see PS4 for details).BS4 - Variant does not segregate with phenotype in 14 informative meiosis from at least 6 families from different labs (Laboratory of Genetics and Molecular Cardiology, University of São Paulo; Molecular Genetics Laboratory (Centre for Cardiovascular Surgery and Transplantation); Cardiovascular Research Group,Instituto Nacional de Saude Doutor Ricardo Jorge): 13 relatives tested negative but had LDL-C >75th percentile + 1 relative tested positive but LDL-C <50th percentile.Variant has 3 Strong, 3 Moderate and 2 Supporting evidence codes towards Pathogenic, enough to classify as Pathogenic, and only 1 Strong evidence codes towards Benign. The Pathogenic criteria overwhelms the Benign criteria, so we are confident in classifying this variant as Pathogenic.		Familial Hypercholesterolemia VCEP	https://clinicalgenome.org/docs/clingen-familial-hypercholesterolemia-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1-2/	2022-06-03	2022-06-30	False	https://erepo.genome.network/evrepo/ui/classification/CA023715/MONDO:0007750/013	50f0c43e-cc4f-40fa-b9f2-0e1dbe5c246a	p.Ser177Leu	Ser	177	Leu	MGPWGWKLRWTVALLLAAAGTAVGDRCERNEFQCQDGKCISYKWVCDGSAECQDGSDESQETCLSVTCKSGDFSCGGRVNRCIPQFWRCDGQVDCDNGSDEQGCPPKTCSQDEFRCHDGKCISRQFVCDSDRDCLDGSDEASCPVLTCGPASFQCNSSTCIPQLWACDNDPDCEDGSDEWPQRCRGLYVFQGDSSPCSAFEFHCLSGECIHSSWRCDGGPDCKDKSDEENCAVATCRPDEFQCSDGNCIHGSRQCDREYDCKDMSDEVGCVNVTLCEGPNKFKCHSGECITLDKVCNMARDCRDWSDEPIKECGTNECLDNNGGCSHVCNDLKIGYECLCPDGFQLVAQRRCEDIDECQDPDTCSQLCVNLEGGYKCQCEEGFQLDPHTKACKAVGSIAYLFFTNRHEVRKMTLDRSEYTSLIPNLRNVVALDTEVASNRIYWSDLSQRMICSTQLDRAHGVSSYDTVISRDIQAPDGLAVDWIHSNIYWTDSVLGTVSVADTKGVKRKTLFRENGSKPRAIVVDPVHGFMYWTDWGTPAKIKKGGLNGVDIYSLVTENIQWPNGITLDLLSGRLYWVDSKLHSISSIDVNGGNRKTILEDEKRLAHPFSLAVFEDKVFWTDIINEAIFSANRLTGSDVNLLAENLLSPEDMVLFHNLTQPRGVNWCERTTLSNGGCQYLCLPAPQINPHSPKFTCACPDGMLLARDMRSCLTEAEAAVATQETSTVRLKVSSTAVRTQHTTTRPVPDTSRLPGATPGLTTVEIVTMSHQALGDVAGRGNEKKPSSVRALSIVLPIVLLVFLCLGVFLLWKNWRLKNINSINFDNPVYQKTTEDEVHICHNQDGYSYPSRQMVSLEDDVA	860	P01130	L	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [661], 'REPEAT_gain_score': array([0.00336319]), 'ZN_FING_loss': [155, 168], 'ZN_FING_gain': [], 'ZN_FING_loss_score': array([-0.03502572, -0.02481979])}
446	NM_000527.5(LDLR):c.661G>T (p.Asp221Tyr)	251356	CA10585046	NM_000527.5:c.661G>T, NC_000019.10:g.11105567G>T, CM000681.2:g.11105567G>T, NC_000019.9:g.11216243G>T, CM000681.1:g.11216243G>T, NC_000019.8:g.11077243G>T, NG_009060.1:g.21187G>T, LRG_274:g.21187G>T, ENST00000558518.6:c.661G>T, ENST00000252444.9:n.915G>T, ENST00000455727.6:c.314-1825G>T, ENST00000535915.5:c.538G>T, ENST00000545707.5:c.314-998G>T, ENST00000557933.5:c.661G>T, ENST00000558013.5:c.661G>T, ENST00000558518.5:c.661G>T, ENST00000560467.1:n.261G>T, NM_000527.4:c.661G>T, LRG_274t1:c.661G>T, NM_001195798.1:c.661G>T, NM_001195799.1:c.538G>T, NM_001195800.1:c.314-1825G>T, NM_001195803.1:c.314-998G>T, XM_011528010.1:c.661G>T, XM_011528011.1:c.314-998G>T, XR_244074.2:n.811G>T, XM_011528010.2:c.661G>T, XR_001753685.2:n.778G>T, XR_001753686.2:n.778G>T, NM_001195798.2:c.661G>T, NM_001195799.2:c.538G>T, NM_001195800.2:c.314-1825G>T, NM_001195803.2:c.314-998G>T, NM_000527.5(LDLR):c.661G>T (p.Asp221Tyr)	LDLR	hypercholesterolemia, familial	MONDO:0007750	Semidominant inheritance	Pathogenic	PS4_Moderate, PS3, PP1_Strong, PM1, PM2, PP3, PP4	PS1, PS2, BP7, BP5, BS1, BS3, BS4, PM5, PM4, PM3, PVS1, PM6, BS2, PP2, BP1, BP4, BP3, BP2, BA1	NM_000527.5(LDLR):c.661G>T (p.Asp221Tyr) variant is classified as Pathogenic for Familial Hypercholesterolemia by applying evidence codes (PP1_Strong, PS3, PM1, PM2, PS4_Moderate, PP3 and PP4) as defined by the ClinGen Familial Hypercholesterolemia Expert Panel LDLR-specific variant curation guidelines (https://doi.org/10.1016/j.gim.2021.09.012).The supporting evidence is as follows:PP1_Strong - Variant segregates with phenotype in 7 informative meiosis in at least 4 families from different labs (Cardiovascular Research Group,Instituto Nacional de Saude Doutor Ricardo Jorge; Centre de Génétique Moléculaire et Chromosomique, Unité de génétique de l'Obésité et des Dyslipidémies (APHP.Sorbonne Université, Hôpital de la Pitié-Salpêtrière)): 6 affected family members have the variant and 1 non-affected family members do not have the variant.PS3 - PMID: 34167030 - Level 1 assay - Heterologous cells (CHO), FACS: Normal cell surface LDLR, 5% LDL-LDLR binding and 8% uptake.PM1 - Missense at codon 221. PM2 is Met and it is exon 4.PM2 - This variant is absent from gnomAD (gnomAD v2.1.1).PS4_moderate - Variant meets PM2. Variant identified in 9 unrelated index cases (1 case with Simon-Broome published in PMID 32331935; 2 cases with Simon Broome criteria from Cardiovascular Research Group,Instituto Nacional de Saude Doutor Ricardo Jorge; 6 cases with DLCN/Simon Broome criteria from Centre de Génétique Moléculaire et Chromosomique, Unité de génétique de l'Obésité et des Dyslipidémies (APHP.Sorbonne Université, Hôpital de la Pitié-Salpêtrière).PP3 - REVEL = 0.978.PP4 - Variant meets PM2. Variant identified in 9 unrelated index cases (1 case with Simon-Broome published in PMID 32331935; 2 cases with Simon Broome criteria from Cardiovascular Research Group,Instituto Nacional de Saude Doutor Ricardo Jorge; 6 cases with DLCN/Simon Broome criteria from Centre de Génétique Moléculaire et Chromosomique, Unité de génétique de l'Obésité et des Dyslipidémies (APHP.Sorbonne Université, Hôpital de la Pitié-Salpêtrière).		Familial Hypercholesterolemia VCEP	https://clinicalgenome.org/docs/clingen-familial-hypercholesterolemia-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1-2/	2022-06-01	2022-06-30	False	https://erepo.genome.network/evrepo/ui/classification/CA10585046/MONDO:0007750/013	0c078f82-bf62-4550-a36c-aa3db8e89b02	p.Asp221Tyr	Asp	221	Tyr	MGPWGWKLRWTVALLLAAAGTAVGDRCERNEFQCQDGKCISYKWVCDGSAECQDGSDESQETCLSVTCKSGDFSCGGRVNRCIPQFWRCDGQVDCDNGSDEQGCPPKTCSQDEFRCHDGKCISRQFVCDSDRDCLDGSDEASCPVLTCGPASFQCNSSTCIPQLWACDNDPDCEDGSDEWPQRCRGLYVFQGDSSPCSAFEFHCLSGECIHSSWRCDGGPDCKDKSDEENCAVATCRPDEFQCSDGNCIHGSRQCDREYDCKDMSDEVGCVNVTLCEGPNKFKCHSGECITLDKVCNMARDCRDWSDEPIKECGTNECLDNNGGCSHVCNDLKIGYECLCPDGFQLVAQRRCEDIDECQDPDTCSQLCVNLEGGYKCQCEEGFQLDPHTKACKAVGSIAYLFFTNRHEVRKMTLDRSEYTSLIPNLRNVVALDTEVASNRIYWSDLSQRMICSTQLDRAHGVSSYDTVISRDIQAPDGLAVDWIHSNIYWTDSVLGTVSVADTKGVKRKTLFRENGSKPRAIVVDPVHGFMYWTDWGTPAKIKKGGLNGVDIYSLVTENIQWPNGITLDLLSGRLYWVDSKLHSISSIDVNGGNRKTILEDEKRLAHPFSLAVFEDKVFWTDIINEAIFSANRLTGSDVNLLAENLLSPEDMVLFHNLTQPRGVNWCERTTLSNGGCQYLCLPAPQINPHSPKFTCACPDGMLLARDMRSCLTEAEAAVATQETSTVRLKVSSTAVRTQHTTTRPVPDTSRLPGATPGLTTVEIVTMSHQALGDVAGRGNEKKPSSVRALSIVLPIVLLVFLCLGVFLLWKNWRLKNINSINFDNPVYQKTTEDEVHICHNQDGYSYPSRQMVSLEDDVA	860	P01130	Y	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [181, 228, 237], 'ZN_FING_gain': [260, 268, 302], 'ZN_FING_gain_score': array([0.00356346, 0.00734067, 0.00372213]), 'ZN_FING_loss_score': array([-0.00550145, -0.013942  , -0.02138466])}
447	NM_000527.5(LDLR):c.662A>G (p.Asp221Gly)	183092	CA023739	NM_000527.5:c.662A>G, NC_000019.10:g.11105568A>G, CM000681.2:g.11105568A>G, NC_000019.9:g.11216244A>G, CM000681.1:g.11216244A>G, NC_000019.8:g.11077244A>G, NG_009060.1:g.21188A>G, LRG_274:g.21188A>G, ENST00000558518.6:c.662A>G, ENST00000252444.9:n.916A>G, ENST00000455727.6:c.314-1824A>G, ENST00000535915.5:c.539A>G, ENST00000545707.5:c.314-997A>G, ENST00000557933.5:c.662A>G, ENST00000558013.5:c.662A>G, ENST00000558518.5:c.662A>G, ENST00000560467.1:n.262A>G, NM_000527.4:c.662A>G, LRG_274t1:c.662A>G, NM_001195798.1:c.662A>G, NM_001195799.1:c.539A>G, NM_001195800.1:c.314-1824A>G, NM_001195803.1:c.314-997A>G, XM_011528010.1:c.662A>G, XM_011528011.1:c.314-997A>G, XR_244074.2:n.812A>G, XM_011528010.2:c.662A>G, XR_001753685.2:n.779A>G, XR_001753686.2:n.779A>G, NM_001195798.2:c.662A>G, NM_001195799.2:c.539A>G, NM_001195800.2:c.314-1824A>G, NM_001195803.2:c.314-997A>G, NM_000527.5(LDLR):c.662A>G (p.Asp221Gly)	LDLR	hypercholesterolemia, familial	MONDO:0007750	Semidominant inheritance	Pathogenic	PS4, PP1_Strong, BS4, PM1, PM3, PM2, PP3, PP4, PS3_Moderate	PS1, PS2, BS1, BS3, BP7, BP5, PM5, PM4, PM6, PVS1, BS2, PP2, BA1, BP1, BP4, BP3, BP2	NM_000527.5(LDLR): c.662A>G (p.Asp221Gly) variant is classified as Pathogenic for Familial Hypercholesterolemia by applying evidence codes (PP1_strong, PS3_moderate, PS4, PM1, PM2, PM3, PP3, PP4 and BS4) as defined by the ClinGen Familial Hypercholesterolemia Expert Panel LDLR-specific variant curation guidelines (https://doi.org/10.1016/j.gim.2021.09.012). The supporting evidence is as follows:PP1_strong - Variant segregates with FH phenotype in 92 informative meiosis in at least 37 families from different labs (Robarts Research Institute; Laboratory of Genetics and Molecular Cardiology, University of São Paulo; Centre de Génétique Moléculaire et Chromosomique, Unité de génétique de l'Obésité et des Dyslipidémies (APHP.Sorbonne Université, Hôpital de la Pitié-Salpêtrière); Molecular Genetics Laboratory (Centre for Cardiovascular Surgery and Transplantation); Cardiovascular Research Group,Instituto Nacional de Saude Doutor Ricardo Jorge; Cardiovascular Genetics Laboratory (PathWest Laboratory Medicine WA)): 55 affected family members have the variant, 37 unaffected family members don’t have the variant.PS3_moderate - PMID: 9974426 - Level 2 assay - Homozygous patients' fibroblasts, 125I-LDL assays: 8% LDLR activity;  PMID: 25647241 - Level 3 assay - Heterologous cells (HeLa), CLSM assay:  most of mutant LDLR is in ER, LDLR activity decreased compared to WT - considered as disruptive.PS4 - Variant meets PM2. Variant identified in 48 unrelated index cases (2 cases with DLCN≥6 from Robarts Research Institute; 21 cases (13 patients with DLCN≥6, and 8 patients with possible FH (Simon Broome)) from Centre de Génétique Moléculaire et Chromosomique, Unité de génétique de l'Obésité et des Dyslipidémies (APHP.Sorbonne Université, Hôpital de la Pitié-Salpêtrière); 17 cases with possible/definite FH (Simon-Broome) from Molecular Genetics Laboratory (Centre for Cardiovascular Surgery and Transplantation); 1 case with Possible FH (Simon-Broome) from Cardiovascular Research Group,Instituto Nacional de Saude Doutor Ricardo Jorge; 5 cases with DLCN≥6 from Cardiovascular Genetics Laboratory (PathWest Laboratory Medicine WA); 2 cases with DLCN≥6 from Color Health, Inc.PM1 - Variant meets PM2 and is missense in exon 4.PM2 - PopMax MAF = 0.0001152 (0.01152%) in European (non-Finnish) exomes+genomes (gnomAD v2.1.1).PM3 - Index case from Ambry Genetics has LDL = 750 mg/dl and also LDLR c.2140+1G>T (pathogenic by these guidelines, confirmed to be in trans).PP3 - REVEL = 0.986.PP4 - Variant meets PM2. Identified in 48 FH cases from different labs (for list see PS4) with clinical Dutch Lipid Clinic Network Criteria score ≥ 6 or Simon-Broome possible/definite FH, after alternative causes of high cholesterol were excluded.BS4 - 30 nonsegregations in 12 families (Laboratory of Genetics and Molecular Cardiology, University of São Paulo).Variant has 2 Strong plus 4 Moderate plus 2 Supporting evidence codes towards Pathogenic, enough to classify as Pathogenic, and only 1 Strong evidence codes towards Benign. The Pathogenic criteria overwhelms the Benign criteria, so we are confident in classifying this variant as Pathogenic.		Familial Hypercholesterolemia VCEP	https://clinicalgenome.org/docs/clingen-familial-hypercholesterolemia-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1-2/	2022-05-30	2022-06-30	False	https://erepo.genome.network/evrepo/ui/classification/CA023739/MONDO:0007750/013	f2f41bd9-ad4d-4237-b618-832f5cbc6885	p.Asp221Gly	Asp	221	Gly	MGPWGWKLRWTVALLLAAAGTAVGDRCERNEFQCQDGKCISYKWVCDGSAECQDGSDESQETCLSVTCKSGDFSCGGRVNRCIPQFWRCDGQVDCDNGSDEQGCPPKTCSQDEFRCHDGKCISRQFVCDSDRDCLDGSDEASCPVLTCGPASFQCNSSTCIPQLWACDNDPDCEDGSDEWPQRCRGLYVFQGDSSPCSAFEFHCLSGECIHSSWRCDGGPDCKDKSDEENCAVATCRPDEFQCSDGNCIHGSRQCDREYDCKDMSDEVGCVNVTLCEGPNKFKCHSGECITLDKVCNMARDCRDWSDEPIKECGTNECLDNNGGCSHVCNDLKIGYECLCPDGFQLVAQRRCEDIDECQDPDTCSQLCVNLEGGYKCQCEEGFQLDPHTKACKAVGSIAYLFFTNRHEVRKMTLDRSEYTSLIPNLRNVVALDTEVASNRIYWSDLSQRMICSTQLDRAHGVSSYDTVISRDIQAPDGLAVDWIHSNIYWTDSVLGTVSVADTKGVKRKTLFRENGSKPRAIVVDPVHGFMYWTDWGTPAKIKKGGLNGVDIYSLVTENIQWPNGITLDLLSGRLYWVDSKLHSISSIDVNGGNRKTILEDEKRLAHPFSLAVFEDKVFWTDIINEAIFSANRLTGSDVNLLAENLLSPEDMVLFHNLTQPRGVNWCERTTLSNGGCQYLCLPAPQINPHSPKFTCACPDGMLLARDMRSCLTEAEAAVATQETSTVRLKVSSTAVRTQHTTTRPVPDTSRLPGATPGLTTVEIVTMSHQALGDVAGRGNEKKPSSVRALSIVLPIVLLVFLCLGVFLLWKNWRLKNINSINFDNPVYQKTTEDEVHICHNQDGYSYPSRQMVSLEDDVA	860	P01130	G	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [181, 200, 202, 203], 'ZN_FING_gain': [260, 268], 'ZN_FING_gain_score': array([0.00583494, 0.00421411]), 'ZN_FING_loss_score': array([-0.00417757, -0.0733937 , -0.03029418, -0.05212355])}
448	NM_000545.8(HNF1A):c.1781G>T (p.Ser594Ile)	1315998	CA386940977	NM_000545.8:c.1781G>T, NC_000012.12:g.121001077G>T, CM000674.2:g.121001077G>T, NC_000012.11:g.121438880G>T, CM000674.1:g.121438880G>T, NC_000012.10:g.119923263G>T, NG_011731.2:g.27332G>T, LRG_522:g.27332G>T, ENST00000257555.11:c.1781G>T, ENST00000257555.10:c.1781G>T, ENST00000288757.7:c.*3076C>A, ENST00000540108.1:c.*1221G>T, ENST00000541395.5:c.1874G>T, ENST00000543427.5:c.1244G>T, ENST00000544413.2:c.1802G>T, ENST00000560968.5:n.1598G>T, ENST00000615446.4:c.569G>T, ENST00000617366.4:c.*190G>T, NM_000545.5:c.1781G>T, LRG_522t1:c.1781G>T, NM_000545.6:c.1781G>T, NM_001306179.1:c.1802G>T, XM_005253931.2:c.1874G>T, XM_024449168.1:c.1874G>T, NM_001286191.2:c.*3076C>A, NM_001286196.2:c.*3076C>A, NM_001306179.2:c.1802G>T, NM_022895.3:c.*3076C>A, NM_000545.8(HNF1A):c.1781G>T (p.Ser594Ile)	HNF1A	monogenic diabetes	MONDO:0015967	Autosomal dominant inheritance	Pathogenic	PS4, PP1_Strong, PP3, PP4, PM2_Supporting		The c.1781G>T variant in the HNF1 homeobox A gene, HNF1A, causes an amino acid change of serine to isoleucine at codon 594 (p.(Ser594Ile)) of  NM_000545.8. This variant is predicted to be deleterious by computational evidence, with a REVEL score of  0.73, which is greater than the MDEP VCEP threshold of 0.70 (PP3) and is absent from gnomAD v2.1.1 (PM2_Supporting).  Additionally, this variant was identified in at least 8 unrelated individuals with non- autoimmune and non-absolute/near-absolute insulin-deficient diabetes (PS4; PMID: 9392505, internal lab contributors). This variant segregated with diabetes, with at least 5 informative meioses in four families with MODY (PP1_Strong; internal lab contributors). Lastly, this variant was identified in  at least one individual with a clinical history highly specific for HNF1A-MODY (MODY probability calculator result <50% but antibody-negative and sulfonylurea-sensitive, negative genetic testing for HNF4A) (PP4; PMID: internal lab contributors). In summary, c.1781G>T meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.0, approved 9/30/21): PP3, PM2_Supporting, PS4, PP1_Strong, PP4.		Monogenic Diabetes VCEP		2022-07-01	2022-07-01	False	https://erepo.genome.network/evrepo/ui/classification/CA386940977/MONDO:0015967/017	e4592074-d88e-48ee-8e72-bc40c284f533	p.Ser594Ile	Ser	594	Ile	MVSKLSQLQTELLAALLESGLSKEALIQALGEPGPYLLAGEGPLDKGESCGGGRGELAELPNGLGETRGSEDETDDDGEDFTPPILKELENLSPEEAAHQKAVVETLLQEDPWRVAKMVKSYLQQHNIPQREVVDTTGLNQSHLSQHLNKGTPMKTQKRAALYTWYVRKQREVAQQFTHAGQGGLIEEPTGDELPTKKGRRNRFKWGPASQQILFQAYERQKNPSKEERETLVEECNRAECIQRGVSPSQAQGLGSNLVTEVRVYNWFANRRKEEAFRHKLAMDTYSGPPPGPGPGPALPAHSSPGLPPPALSPSKVHGVRYGQPATSETAEVPSSSGGPLVTVSTPLHQVSPTGLEPSHSLLSTEAKLVSAAGGPLPPVSTLTALHSLEQTSPGLNQQPQNLIMASLPGVMTIGPGEPASLGPTFTNTGASTLVIGLASTQAQSVPVINSMGSSLTTLQPVQFSQPLHPSYQQPLMPPVQSHVTQSPFMATMAQLQSPHALYSHKPEVAQYTHTGLLPQTMLITDTTNLSALASLTPTKQVFTSDTEASSESGLHTPASQATTLHVPSQDPAGIQHLQPAHRLSASPTVSSSSLVLYQSSDSSNGQSHLLPSNHSVIETFISTQMASSSQ	631	P20823	I	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [69], 'COMPBIAS_gain_score': array([0.01072621]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [575, 577, 579, 580], 'REGION_gain': [543], 'REGION_gain_score': array([0.04401451]), 'REGION_loss_score': array([-0.06103492, -0.04833263, -0.10350412, -0.12688082]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
449	NM_000545.6(HNF1A):c.815G>A (p.Arg272His)	14931	CA124460	NM_000545.6:c.815G>A, NC_000012.12:g.120994265G>A, CM000674.2:g.120994265G>A, NC_000012.11:g.121432068G>A, CM000674.1:g.121432068G>A, NC_000012.10:g.119916451G>A, NG_011731.2:g.20520G>A, LRG_522:g.20520G>A, ENST00000257555.11:c.815G>A, ENST00000257555.10:c.815G>A, ENST00000400024.6:c.815G>A, ENST00000402929.5:n.950G>A, ENST00000535955.5:n.43-3226G>A, ENST00000538626.2:n.191-3226G>A, ENST00000538646.5:c.628G>A, ENST00000540108.1:c.*255G>A, ENST00000541395.5:c.815G>A, ENST00000541924.5:c.713+559G>A, ENST00000543427.5:c.633+639G>A, ENST00000544413.2:c.815G>A, ENST00000544574.5:c.73-2352G>A, ENST00000560968.5:n.893+65G>A, ENST00000615446.4:c.-257-1997G>A, ENST00000617366.4:c.586+686G>A, NM_000545.5:c.815G>A, LRG_522t1:c.815G>A, NM_001306179.1:c.815G>A, XM_005253931.2:c.815G>A, XM_024449168.1:c.815G>A, NM_000545.8:c.815G>A, NM_001306179.2:c.815G>A, NM_000545.8(HNF1A):c.815G>A (p.Arg272His), NM_000545.6(HNF1A):c.815G>A (p.Arg272His)	HNF1A	monogenic diabetes	MONDO:0015967	Autosomal dominant inheritance	Pathogenic	PM1, PS4, PP1_Strong, PS3_Supporting, PP3, PM2_Supporting	PM5, BS3, BS1, BP4, BA1	The c.815G>A variant in the  HNF1 homeobox A gene, HNF1A, causes an amino acid change of arginine to histidine at codon 272 (p.(Arg272His)) of NM_000545.8. This variant resides in an amino acid within the HNF1α DNA binding domain that directly binds DNA, which is defined as critical for the protein’s function by the ClinGen MDEP (PM1). Also, this variant is absent from gnomAD v2.1.1 (PM2_Supporting). This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.961, which is greater than the MDEP VCEP threshold of 0.70 (PP3). Additionally, this variant was identified in at least 18  unrelated individuals with non- autoimmune and non-absolute/near-absolute insulin-deficient diabetes (PS4; PMID:31166087, PMID:18003757, PMID:24905847, PMID:31483937, PMID:29439679, PMID:23610083, PMID:21989397, PMID:21395678, PMID:21224407, PMID:15114102, ClinVar ID 14931, internal lab contributors). This variant segregated with diabetes, with 13 informative meioses in multiple families with MODY (PP1_Strong; PMID:15114102, internal lab contributors). Functional studies demonstrated the p.Arg272His protein has transactivation below 40% of wildtype, indicating that this variant impacts protein function (PS3_Supporting; PMID: 16781669). In summary, c.815G>A meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.1, approved 9/30/2021): PP1_Strong, PS4, PM1, PP3, PM2_Supporting, PS3_Supporting.	16562587, 18003757, 10333057, 28701371, 10447526, 25414397, 11719843, 15726414, 9032114, 11393552, 15114102, 9166684, 10585442	Monogenic Diabetes VCEP		2022-07-05	2022-07-05	False	https://erepo.genome.network/evrepo/ui/classification/CA124460/MONDO:0015967/017	d5d2e5b3-43bd-4c42-a38d-791aad7cd241	p.Arg272His	Arg	272	His	MVSKLSQLQTELLAALLESGLSKEALIQALGEPGPYLLAGEGPLDKGESCGGGRGELAELPNGLGETRGSEDETDDDGEDFTPPILKELENLSPEEAAHQKAVVETLLQEDPWRVAKMVKSYLQQHNIPQREVVDTTGLNQSHLSQHLNKGTPMKTQKRAALYTWYVRKQREVAQQFTHAGQGGLIEEPTGDELPTKKGRRNRFKWGPASQQILFQAYERQKNPSKEERETLVEECNRAECIQRGVSPSQAQGLGSNLVTEVRVYNWFANRRKEEAFRHKLAMDTYSGPPPGPGPGPALPAHSSPGLPPPALSPSKVHGVRYGQPATSETAEVPSSSGGPLVTVSTPLHQVSPTGLEPSHSLLSTEAKLVSAAGGPLPPVSTLTALHSLEQTSPGLNQQPQNLIMASLPGVMTIGPGEPASLGPTFTNTGASTLVIGLASTQAQSVPVINSMGSSLTTLQPVQFSQPLHPSYQQPLMPPVQSHVTQSPFMATMAQLQSPHALYSHKPEVAQYTHTGLLPQTMLITDTTNLSALASLTPTKQVFTSDTEASSESGLHTPASQATTLHVPSQDPAGIQHLQPAHRLSASPTVSSSSLVLYQSSDSSNGQSHLLPSNHSVIETFISTQMASSSQ	631	P20823	H	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [230, 277], 'DNA_BIND_gain': [222], 'DNA_BIND_gain_score': array([0.02932513]), 'DNA_BIND_loss_score': array([-0.0532515 , -0.14041907]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [88, 98, 102, 103, 104, 105, 277], 'HELIX_gain_score': array([0.03499842, 0.02776814, 0.02714157, 0.02575171, 0.02944744,
       0.02561545, 0.02498674]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [179, 180, 181], 'DOMAIN_gain': [4, 6, 35, 36], 'DOMAIN_gain_score': array([0.15202117, 0.14357173, 0.08388215, 0.06386656]), 'DOMAIN_loss_score': array([-0.45620942, -0.35231137, -0.20193326]), 'REGION_loss': [281], 'REGION_gain': [202], 'REGION_gain_score': array([0.05923772]), 'REGION_loss_score': array([-0.24089319]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
450	NM_001754.4(RUNX1):c.1190A>G (p.Gln397Arg)	532673	CA10014193	NM_001754.4:c.1190A>G, NC_000021.9:g.34792388T>C, CM000683.2:g.34792388T>C, NC_000021.8:g.36164685T>C, CM000683.1:g.36164685T>C, NC_000021.7:g.35086555T>C, NG_011402.2:g.1197324A>G, LRG_482:g.1197324A>G, ENST00000675419.1:c.1190A>G, ENST00000300305.7:c.1190A>G, ENST00000344691.8:c.1109A>G, ENST00000399240.5:c.917A>G, ENST00000437180.5:c.1190A>G, ENST00000482318.5:c.*780A>G, NM_001001890.2:c.1109A>G, LRG_482t1:c.1190A>G, XM_005261068.3:c.1154A>G, XM_005261069.3:c.998A>G, XM_011529766.1:c.1190A>G, XM_011529767.1:c.1151A>G, XM_011529768.1:c.959A>G, XM_005261069.4:c.998A>G, XM_011529766.2:c.1190A>G, XM_011529767.2:c.1151A>G, XM_011529768.2:c.959A>G, XM_017028487.1:c.1037A>G, NM_001001890.3:c.1109A>G, NM_001754.5:c.1190A>G, NM_001754.5(RUNX1):c.1190A>G (p.Gln397Arg), NM_001754.4(RUNX1):c.1190A>G (p.Gln397Arg)	RUNX1	hereditary thrombocytopenia and hematologic cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Benign	BP4, BA1	PVS1, PM2, PM6, PM4, PM3, PM1, PM5, BS2, PP2, PP3, PP4, PP1, BP1, BP3, BP2, PS4, PS2, PS1, PS3, BP7, BP5, BS1, BS4, BS3	This c.1190A>G (p.Gln397Arg) missense variant has a MAF of 0.003624 (0.3624%, 53/14624, 202938 alleles) in the East Asian subpopulation of the gnomAD v2 cohort, which is ≥ 0.0015 (0.15%) (BA1). The high allele frequency accounts for reports of this variant in affected individuals: 2 heterozygous patients with AML (PMID: 19808697), a homozygous patient with personal and family history of thrombocytopenia (PMID: 30103613), and other reports of this variant in patients with MDS, AML, and T-ALL that have not been confirmed to be of germline origin (PMID: 17910630, 24523240, 24792891, 24850867, 28157215, 29279377). Furthermore, an abstract indicated that a dual luciferase assay used to assess this variant's transactivation ability in K562 cells was normal, although this data was not published in a peer-reviewed format (Huang et al., 2009, ASH Abstract 3468 - https://ashpublications.org/blood/article/114/22/3468/132805/High-Frequency-of-C-Terminal-Frame-Shift-Mutations). This missense variant have a REVEL score <0.5 (0.238), and is not predicted by SpliceAI, MES, or SSF-like to have a splicing impact (BP4). In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the ClinGen Myeloid Malignancy Variant Curation Expert Panel for RUNX1: BA1 and BP4.		Myeloid Malignancy VCEP	https://www.clinicalgenome.org/affiliation/50034/docs/assertion-criteria 	2022-07-07	2022-07-07	False	https://erepo.genome.network/evrepo/ui/classification/CA10014193/MONDO:0011071/008	c12e966a-f7a4-468b-9c26-af1bd643dee1	p.Gln397Arg	Gln	397	Arg	MRIPVDASTSRRFTPPSTALSPGKMSEALPLGAPDAGAALAGKLRSGDRSMVEVLADHPGELVRTDSPNFLCSVLPTHWRCNKTLPIAFKVVALGDVPDGTLVTVMAGNDENYSAELRNATAAMKNQVARFNDLRFVGRSGRGKSFTLTITVFTNPPQVATYHRAIKITVDGPREPRRHRQKLDDQTKPGSLSFSERLSELEQLRRTAMRVSPHHPAPTPNPRASLNHSTAFNPQPQSQMQDTRQIQPSPPWSYDQSYQYLGSIASPSVHPATPISPGRASGMTTLSAELSSRLSTAPDLTAFSDPRQFPALPSISDPRMHYPGAFTYSPTPVTSGIGIGMSAMGSATRYHTYLPPPYPGSSQAQGGPFQASSPSYHLYYGASAGSYQFSMVGGERSPPRILPPCTNASTGSALLNPSLPNQSDVVEAEGSHSNSPTNMAPSARLEEAVWRPY	453	Q01196	R	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [204], 'COILED_gain_score': array([0.00335443]), 'COMPBIAS_loss': [], 'COMPBIAS_gain': [406, 409], 'COMPBIAS_gain_score': array([0.04301101, 0.0868839 ]), 'DOMAIN_loss': [179], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.04833007]), 'REGION_loss': [111, 114, 120, 122, 164, 165], 'REGION_gain': [], 'REGION_loss_score': array([-0.01164901, -0.01082772, -0.0109883 , -0.01048607, -0.01226211,
       -0.01238847]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
451	NM_030621.4(DICER1):c.5125G>A (p.Asp1709Asn)	690480	CA390865395	NM_030621.4:c.5125G>A, NC_000014.9:g.95094127C>T, CM000676.2:g.95094127C>T, NC_000014.8:g.95560464C>T, CM000676.1:g.95560464C>T, NC_000014.7:g.94630217C>T, NG_016311.1:g.68296G>A, LRG_492:g.68296G>A, ENST00000343455.8:c.5125G>A, ENST00000393063.6:c.5125G>A, ENST00000526495.6:c.5125G>A, ENST00000556045.6:c.5125G>A, ENST00000675540.1:n.2870G>A, ENST00000675995.1:c.*3441G>A, ENST00000343455.7:c.5125G>A, ENST00000393063.5:c.5125G>A, ENST00000526495.5:c.5125G>A, ENST00000527414.5:c.5125G>A, ENST00000541352.5:c.5125G>A, ENST00000556045.5:c.1819G>A, NM_001195573.1:c.5125G>A, NM_001271282.2:c.5125G>A, NM_001291628.1:c.5125G>A, NM_177438.2:c.5125G>A, LRG_492t1:c.5125G>A, XM_011536599.1:c.5125G>A, XM_011536600.1:c.5125G>A, XM_011536601.1:c.5125G>A, XM_011536602.1:c.5125G>A, XM_011536603.1:c.5125G>A, XM_011536604.1:c.4720G>A, XM_011536605.1:c.3646G>A, XM_011536599.2:c.5125G>A, XM_011536600.3:c.5125G>A, XM_011536601.3:c.5125G>A, XM_011536602.3:c.5125G>A, XM_011536604.2:c.4720G>A, XM_011536605.2:c.3646G>A, XM_017021120.2:c.5125G>A, XM_017021121.2:c.5125G>A, XM_017021122.2:c.4720G>A, XM_017021123.2:c.4720G>A, NM_001271282.3:c.5125G>A, NM_001291628.2:c.5125G>A, NM_177438.3:c.5125G>A, NM_001395677.1:c.5125G>A, NM_001395678.1:c.5125G>A, NM_001395679.1:c.5125G>A, NM_001395680.1:c.5125G>A, NM_001395682.1:c.5125G>A, NM_001395683.1:c.5125G>A, NM_001395684.1:c.5125G>A, NM_001395685.1:c.5125G>A, NM_001395686.1:c.4843G>A, NM_001395687.1:c.4720G>A, NM_001395688.1:c.4720G>A, NM_001395689.1:c.4720G>A, NM_001395690.1:c.4720G>A, NM_001395691.1:c.4558G>A, NM_001395697.1:c.3442G>A, NR_172715.1:n.5543G>A, NR_172716.1:n.5727G>A, NR_172717.1:n.5637G>A, NR_172718.1:n.5560G>A, NR_172719.1:n.5393G>A, NR_172720.1:n.5470G>A, NM_177438.3(DICER1):c.5125G>A (p.Asp1709Asn), NM_030621.4(DICER1):c.5125G>A (p.Asp1709Asn)	DICER1	dicer1 syndrome	MONDO:0017288	Autosomal dominant inheritance	Pathogenic	PS3_Supporting, PS2_Very Strong, PP3, PM2_Supporting, PS4_Moderate, PM1	PP1, PP4, BP4, BP2, BA1, PS1, PM5, BS1, BS3, BS4	The NM_177438.2:c.5125G>A variant in DICER1 is a missense variant predicted to cause substitution of aspartic acid by asparagine at amino acid 1709 (p.Asp1709Asn). This variant received a total of 2 phenotype points across 2 unrelated probands meeting DICER1 VCEP phenotype specificity scoring criteria of 2-3.5 points (PS4_Moderate, PMIDs: 26925222, 26475046). In both probands, this variant was identified as a de novo occurrence with constitutional mosaicism (PS2_Very Strong; PMIDs: 26925222, 26475046). This variant is absent from gnomAD v2.1.1 and v3.1.1 (non-cancer) (PM2_Supporting). In vitro cleavage assays in HEK293 cells showed that this variant fails to produce 5p microRNAs from a pre-miRNA, indicating that this variant impacts protein function (PS3_Supporting, PMIDs: 22187960, 26545620). The computational predictor REVEL gives a score of 0.868, which is above the threshold of 0.75, evidence that correlates with impact to DICER1 function (PP3). This variant resides in the p.D1709 metal ion-binding residue located in the RNase IIIb domain of DICER1, that is defined as a mutational hotspot and critical functional domain by the ClinGen DICER1 VCEP (PM1, PMID: 31342592). In summary, this variant meets the criteria to be classified as PATHOGENIC for DICER1 syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen DICER1 VCEP: PS4_Moderate, PS2_Very Strong, PM2_Supporting, PS3_Supporting, PP3, PM1. (Bayesian Points: 15; VCEP specifications version 1; 02/11/2022)		DICER1 and miRNA-Processing Gene VCEP		2022-05-17	2022-07-08	False	https://erepo.genome.network/evrepo/ui/classification/CA390865395/MONDO:0017288/024	d7bb7946-aea7-4885-9715-4a46a61fd29f	p.Asp1709Asn	Asp	1709	Asn	MKSPALQPLSMAGLQLMTPASSPMGPFFGLPWQQEAIHDNIYTPRKYQVELLEAALDHNTIVCLNTGSGKTFIAVLLTKELSYQIRGDFSRNGKRTVFLVNSANQVAQQVSAVRTHSDLKVGEYSNLEVNASWTKERWNQEFTKHQVLIMTCYVALNVLKNGYLSLSDINLLVFDECHLAILDHPYREIMKLCENCPSCPRILGLTASILNGKCDPEELEEKIQKLEKILKSNAETATDLVVLDRYTSQPCEIVVDCGPFTDRSGLYERLLMELEEALNFINDCNISVHSKERDSTLISKQILSDCRAVLVVLGPWCADKVAGMMVRELQKYIKHEQEELHRKFLLFTDTFLRKIHALCEEHFSPASLDLKFVTPKVIKLLEILRKYKPYERQQFESVEWYNNRNQDNYVSWSDSEDDDEDEEIEEKEKPETNFPSPFTNILCGIIFVERRYTAVVLNRLIKEAGKQDPELAYISSNFITGHGIGKNQPRNKQMEAEFRKQEEVLRKFRAHETNLLIATSIVEEGVDIPKCNLVVRFDLPTEYRSYVQSKGRARAPISNYIMLADTDKIKSFEEDLKTYKAIEKILRNKCSKSVDTGETDIDPVMDDDDVFPPYVLRPDDGGPRVTINTAIGHINRYCARLPSDPFTHLAPKCRTRELPDGTFYSTLYLPINSPLRASIVGPPMSCVRLAERVVALICCEKLHKIGELDDHLMPVGKETVKYEEELDLHDEEETSVPGRPGSTKRRQCYPKAIPECLRDSYPRPDQPCYLYVIGMVLTTPLPDELNFRRRKLYPPEDTTRCFGILTAKPIPQIPHFPVYTRSGEVTISIELKKSGFMLSLQMLELITRLHQYIFSHILRLEKPALEFKPTDADSAYCVLPLNVVNDSSTLDIDFKFMEDIEKSEARIGIPSTKYTKETPFVFKLEDYQDAVIIPRYRNFDQPHRFYVADVYTDLTPLSKFPSPEYETFAEYYKTKYNLDLTNLNQPLLDVDHTSSRLNLLTPRHLNQKGKALPLSSAEKRKAKWESLQNKQILVPELCAIHPIPASLWRKAVCLPSILYRLHCLLTAEELRAQTASDAGVGVRSLPADFRYPNLDFGWKKSIDSKSFISISNSSSAENDNYCKHSTIVPENAAHQGANRTSSLENHDQMSVNCRTLLSESPGKLHVEVSADLTAINGLSYNQNLANGSYDLANRDFCQGNQLNYYKQEIPVQPTTSYSIQNLYSYENQPQPSDECTLLSNKYLDGNANKSTSDGSPVMAVMPGTTDTIQVLKGRMDSEQSPSIGYSSRTLGPNPGLILQALTLSNASDGFNLERLEMLGDSFLKHAITTYLFCTYPDAHEGRLSYMRSKKVSNCNLYRLGKKKGLPSRMVVSIFDPPVNWLPPGYVVNQDKSNTDKWEKDEMTKDCMLANGKLDEDYEEEDEEEESLMWRAPKEEADYEDDFLEYDQEHIRFIDNMLMGSGAFVKKISLSPFSTTDSAYEWKMPKKSSLGSMPFSSDFEDFDYSSWDAMCYLDPSKAVEEDDFVVGFWNPSEENCGVDTGKQSISYDLHTEQCIADKSIADCVEALLGCYLTSCGERAAQLFLCSLGLKVLPVIKRTDREKALCPTRENFNSQQKNLSVSCAAASVASSRSSVLKDSEYGCLKIPPRCMFDHPDADKTLNHLISGFENFEKKINYRFKNKAYLLQAFTHASYHYNTITDCYQRLEFLGDAILDYLITKHLYEDPRQHSPGVLTDLRSALVNNTIFASLAVKYDYHKYFKAVSPELFHVIDDFVQFQLEKNEMQGMDSELRRSEEDEEKEEDIEVPKAMGDIFESLAGAIYMDSGMSLETVWQVYYPMMRPLIEKFSANVPRSPVRELLEMEPETAKFSPAERTYDGKVRVTVEVVGKGKFKGVGRSYRIAKSAAARRALRSLKANQPQVPNS	1922	Q9UPY3	N	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [1695, 1696, 1698], 'BINDING_gain': [], 'BINDING_loss_score': array([-0.3202095, -0.3076871, -0.0838145]), 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [563], 'STRAND_gain': [445], 'STRAND_gain_score': array([0.22982091]), 'STRAND_loss_score': array([-0.01142192]), 'HELIX_loss': [45, 548, 571, 574, 577, 578, 1325, 1709, 1710, 1763, 1764], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.00511134, -0.28575552, -0.04494536, -0.04366332, -0.03305143,
       -0.03385556, -0.04496819, -0.43405986, -0.39558762, -0.23747516,
       -0.25108182]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [190, 558, 559, 1387, 1685, 1686, 1687, 1688, 1689, 1690, 1691, 1692, 1693, 1694, 1695, 1696, 1697, 1698, 1699, 1700, 1701, 1702, 1703, 1705, 1758], 'DOMAIN_gain': [453, 454, 455, 464, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 561, 562, 564, 565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578, 579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, 1763, 1769, 1770, 1771, 1772], 'DOMAIN_gain_score': array([0.50975239, 0.57739246, 0.55223769, 0.46977013, 0.46435839,
       0.56463891, 0.50154978, 0.54031235, 0.60274136, 0.64669359,
       0.69130808, 0.76345551, 0.84626198, 0.81404626, 0.85420495,
       0.83891976, 0.84647077, 0.82585311, 0.8451848 , 0.80409181,
       0.85578531, 0.77119458, 0.77308667, 0.75806022, 0.78620893,
       0.7460292 , 0.77381885, 0.75289768, 0.76663673, 0.7620939 ,
       0.76979625, 0.72564632, 0.53206819, 0.61586082, 0.6646207 ,
       0.6810174 , 0.49723071, 0.19137913, 0.30079621, 0.36332059,
       0.46835226, 0.42063099, 0.48450488, 0.48544359, 0.47286791,
       0.53563929, 0.45197755, 0.4235729 , 0.47632432, 0.47267014,
       0.416291  , 0.42469364, 0.50620997, 0.49813038, 0.48278534,
       0.59553838, 0.55874842, 0.49923986, 0.59116   , 0.57120502,
       0.51826268, 0.54127115, 0.54465735, 0.47558975, 0.57051581,
       0.61051565, 0.59246761, 0.52519143, 0.51528847, 0.45143062,
       0.43889195, 0.17966342, 0.25292206, 0.37931204, 0.41727358,
       0.4162783 ]), 'DOMAIN_loss_score': array([-0.04040021, -0.30772853, -0.13638622, -0.0046674 , -0.69894028,
       -0.73645371, -0.76148546, -0.6907711 , -0.72680473, -0.83599293,
       -0.84742665, -0.8178314 , -0.85157996, -0.85135543, -0.81923896,
       -0.78734767, -0.87898648, -0.84987473, -0.72328472, -0.65444785,
       -0.74801195, -0.68628508, -0.57508624, -0.72682387, -0.10066986]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
452	NM_030621.4(DICER1):c.5441C>T (p.Ser1814Leu)	412119	CA16614268	NM_030621.4:c.5441C>T, NC_000014.9:g.95091289G>A, CM000676.2:g.95091289G>A, NC_000014.8:g.95557626G>A, CM000676.1:g.95557626G>A, NC_000014.7:g.94627379G>A, NG_016311.1:g.71134C>T, LRG_492:g.71134C>T, ENST00000343455.8:c.5441C>T, ENST00000393063.6:c.5441C>T, ENST00000526495.6:c.5441C>T, ENST00000556045.6:c.*158C>T, ENST00000675540.1:n.3186C>T, ENST00000675995.1:c.*3757C>T, ENST00000343455.7:c.5441C>T, ENST00000393063.5:c.5441C>T, ENST00000526495.5:c.5441C>T, ENST00000527414.5:c.5441C>T, ENST00000527416.2:n.34C>T, ENST00000527554.2:n.134C>T, ENST00000541352.5:c.5365-180C>T, ENST00000556045.5:c.2135C>T, NM_001195573.1:c.5365-180C>T, NM_001271282.2:c.5441C>T, NM_001291628.1:c.5441C>T, NM_177438.2:c.5441C>T, LRG_492t1:c.5441C>T, XM_011536599.1:c.5441C>T, XM_011536600.1:c.5441C>T, XM_011536601.1:c.5441C>T, XM_011536602.1:c.5441C>T, XM_011536603.1:c.5441C>T, XM_011536604.1:c.5036C>T, XM_011536605.1:c.3962C>T, XM_011536599.2:c.5441C>T, XM_011536600.3:c.5441C>T, XM_011536601.3:c.5441C>T, XM_011536602.3:c.5441C>T, XM_011536604.2:c.5036C>T, XM_011536605.2:c.3962C>T, XM_017021120.2:c.5441C>T, XM_017021121.2:c.5441C>T, XM_017021122.2:c.5036C>T, XM_017021123.2:c.5036C>T, NM_001271282.3:c.5441C>T, NM_001291628.2:c.5441C>T, NM_177438.3:c.5441C>T, NM_001395677.1:c.5441C>T, NM_001395678.1:c.5441C>T, NM_001395679.1:c.5441C>T, NM_001395680.1:c.5441C>T, NM_001395682.1:c.5441C>T, NM_001395683.1:c.5441C>T, NM_001395684.1:c.5441C>T, NM_001395685.1:c.5441C>T, NM_001395686.1:c.5159C>T, NM_001395687.1:c.5036C>T, NM_001395688.1:c.5036C>T, NM_001395689.1:c.5036C>T, NM_001395690.1:c.5036C>T, NM_001395691.1:c.4874C>T, NM_001395697.1:c.3758C>T, NR_172715.1:n.5859C>T, NR_172716.1:n.6043C>T, NR_172717.1:n.5953C>T, NR_172718.1:n.5876C>T, NR_172719.1:n.5709C>T, NR_172720.1:n.5912C>T, NM_177438.3(DICER1):c.5441C>T (p.Ser1814Leu), NM_030621.4(DICER1):c.5441C>T (p.Ser1814Leu)	DICER1	dicer1 syndrome	MONDO:0017288	Autosomal dominant inheritance	Pathogenic	PS3_Supporting, PP3, PP4, PM2_Supporting, PS4, PM1_Supporting, PP1_Strong	PM6, BP4, BA1, PS1, PS2, PM5, BS1, BS3, BS4	NM_177438.2(DICER1):c.5441C>T variant in DICER1 is a missense variant predicted to cause substitution of serine by leucine at amino acid 1814 (p.Ser1814Leu). This variant received a total of 4.5 phenotype points across 5 unrelated probands/families meeting DICER1 VCEP phenotype specificity scoring criteria of >4 points (PS4; PMIDs: 26545620, 26555935, ClinVar GTRs: 239772, 500031, 500086). At least one patient with this variant was found to have a somatic second hit in a recognized DICER1 hotspot codon on tumor sequencing, which is highly specific for DICER1 syndrome (PP4, PMIDs: 26555935). The variant has been reported to segregate with disease in multiple affected family members with 7 meioses from 3 families (PP1_Strong; PMIDs: 26555935, ClinVar SCVs: SCV000553579.6). This variant is absent from gnomAD v2.1.1 and v3.1.1 (non-cancer)(PM2_Supporting). In vitro cleavage assay in HEK293 cells showed that this variant reduces the capacity of the protein to produce 5p/3p microRNAs from a pre-miRNA, indicating that this variant impacts protein function (PS3_Supporting; PMIDs: 26545620). This variant resides within the RNase IIIb domain of DICER1, a mutational hotspot domain with critical functional as defined by the ClinGen DICER1 VCEP (PM1_Supporting; PMID: 31342592). The computational predictor REVEL gives a score of 0.889, which is above the threshold of 0.75, evidence that correlates with impact to DICER1 function (PP3). In summary, this variant meets the criteria to be classified as Pathogenic for DICER1 syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen DICER1 VCEP:  PS4, PP4, PP1_Strong, PM2_Supporting, PS3_Supporting, PM1_Supporting, PP3 (Bayesian Points: 13; VCEP specifications version 1; 02/11/2022).		DICER1 and miRNA-Processing Gene VCEP		2022-05-18	2022-07-08	False	https://erepo.genome.network/evrepo/ui/classification/CA16614268/MONDO:0017288/024	8e7cfae4-6aa0-43c2-bd8e-ac97698ead21	p.Ser1814Leu	Ser	1814	Leu	MKSPALQPLSMAGLQLMTPASSPMGPFFGLPWQQEAIHDNIYTPRKYQVELLEAALDHNTIVCLNTGSGKTFIAVLLTKELSYQIRGDFSRNGKRTVFLVNSANQVAQQVSAVRTHSDLKVGEYSNLEVNASWTKERWNQEFTKHQVLIMTCYVALNVLKNGYLSLSDINLLVFDECHLAILDHPYREIMKLCENCPSCPRILGLTASILNGKCDPEELEEKIQKLEKILKSNAETATDLVVLDRYTSQPCEIVVDCGPFTDRSGLYERLLMELEEALNFINDCNISVHSKERDSTLISKQILSDCRAVLVVLGPWCADKVAGMMVRELQKYIKHEQEELHRKFLLFTDTFLRKIHALCEEHFSPASLDLKFVTPKVIKLLEILRKYKPYERQQFESVEWYNNRNQDNYVSWSDSEDDDEDEEIEEKEKPETNFPSPFTNILCGIIFVERRYTAVVLNRLIKEAGKQDPELAYISSNFITGHGIGKNQPRNKQMEAEFRKQEEVLRKFRAHETNLLIATSIVEEGVDIPKCNLVVRFDLPTEYRSYVQSKGRARAPISNYIMLADTDKIKSFEEDLKTYKAIEKILRNKCSKSVDTGETDIDPVMDDDDVFPPYVLRPDDGGPRVTINTAIGHINRYCARLPSDPFTHLAPKCRTRELPDGTFYSTLYLPINSPLRASIVGPPMSCVRLAERVVALICCEKLHKIGELDDHLMPVGKETVKYEEELDLHDEEETSVPGRPGSTKRRQCYPKAIPECLRDSYPRPDQPCYLYVIGMVLTTPLPDELNFRRRKLYPPEDTTRCFGILTAKPIPQIPHFPVYTRSGEVTISIELKKSGFMLSLQMLELITRLHQYIFSHILRLEKPALEFKPTDADSAYCVLPLNVVNDSSTLDIDFKFMEDIEKSEARIGIPSTKYTKETPFVFKLEDYQDAVIIPRYRNFDQPHRFYVADVYTDLTPLSKFPSPEYETFAEYYKTKYNLDLTNLNQPLLDVDHTSSRLNLLTPRHLNQKGKALPLSSAEKRKAKWESLQNKQILVPELCAIHPIPASLWRKAVCLPSILYRLHCLLTAEELRAQTASDAGVGVRSLPADFRYPNLDFGWKKSIDSKSFISISNSSSAENDNYCKHSTIVPENAAHQGANRTSSLENHDQMSVNCRTLLSESPGKLHVEVSADLTAINGLSYNQNLANGSYDLANRDFCQGNQLNYYKQEIPVQPTTSYSIQNLYSYENQPQPSDECTLLSNKYLDGNANKSTSDGSPVMAVMPGTTDTIQVLKGRMDSEQSPSIGYSSRTLGPNPGLILQALTLSNASDGFNLERLEMLGDSFLKHAITTYLFCTYPDAHEGRLSYMRSKKVSNCNLYRLGKKKGLPSRMVVSIFDPPVNWLPPGYVVNQDKSNTDKWEKDEMTKDCMLANGKLDEDYEEEDEEEESLMWRAPKEEADYEDDFLEYDQEHIRFIDNMLMGSGAFVKKISLSPFSTTDSAYEWKMPKKSSLGSMPFSSDFEDFDYSSWDAMCYLDPSKAVEEDDFVVGFWNPSEENCGVDTGKQSISYDLHTEQCIADKSIADCVEALLGCYLTSCGERAAQLFLCSLGLKVLPVIKRTDREKALCPTRENFNSQQKNLSVSCAAASVASSRSSVLKDSEYGCLKIPPRCMFDHPDADKTLNHLISGFENFEKKINYRFKNKAYLLQAFTHASYHYNTITDCYQRLEFLGDAILDYLITKHLYEDPRQHSPGVLTDLRSALVNNTIFASLAVKYDYHKYFKAVSPELFHVIDDFVQFQLEKNEMQGMDSELRRSEEDEEKEEDIEVPKAMGDIFESLAGAIYMDSGMSLETVWQVYYPMMRPLIEKFSANVPRSPVRELLEMEPETAKFSPAERTYDGKVRVTVEVVGKGKFKGVGRSYRIAKSAAARRALRSLKANQPQVPNS	1922	Q9UPY3	L	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [309], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.01588076]), 'HELIX_loss': [], 'HELIX_gain': [503, 1704], 'HELIX_gain_score': array([0.00637752, 0.01102728]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
453	NM_177438.2(DICER1):c.2614G>A (p.Ala872Thr)	133967	CA158264	NM_177438.2:c.2614G>A, NC_000014.9:g.95107916C>T, CM000676.2:g.95107916C>T, NC_000014.8:g.95574253C>T, CM000676.1:g.95574253C>T, NC_000014.7:g.94644006C>T, NG_016311.1:g.54507G>A, LRG_492:g.54507G>A, ENST00000343455.8:c.2614G>A, ENST00000393063.6:c.2614G>A, ENST00000526495.6:c.2614G>A, ENST00000532939.3:c.2614G>A, ENST00000556045.6:c.2614G>A, ENST00000675540.1:n.436G>A, ENST00000675995.1:c.*930G>A, ENST00000343455.7:c.2614G>A, ENST00000393063.5:c.2614G>A, ENST00000526495.5:c.2614G>A, ENST00000527414.5:c.2614G>A, ENST00000541352.5:c.2614G>A, NM_001195573.1:c.2614G>A, NM_001271282.2:c.2614G>A, NM_001291628.1:c.2614G>A, NM_030621.4:c.2614G>A, LRG_492t1:c.2614G>A, XM_011536599.1:c.2614G>A, XM_011536600.1:c.2614G>A, XM_011536601.1:c.2614G>A, XM_011536602.1:c.2614G>A, XM_011536603.1:c.2614G>A, XM_011536604.1:c.2209G>A, XM_011536605.1:c.1135G>A, XM_011536599.2:c.2614G>A, XM_011536600.3:c.2614G>A, XM_011536601.3:c.2614G>A, XM_011536602.3:c.2614G>A, XM_011536604.2:c.2209G>A, XM_011536605.2:c.1135G>A, XM_017021120.2:c.2614G>A, XM_017021121.2:c.2614G>A, XM_017021122.2:c.2209G>A, XM_017021123.2:c.2209G>A, NM_001271282.3:c.2614G>A, NM_001291628.2:c.2614G>A, NM_177438.3:c.2614G>A, NM_001395677.1:c.2614G>A, NM_001395678.1:c.2614G>A, NM_001395679.1:c.2614G>A, NM_001395680.1:c.2614G>A, NM_001395682.1:c.2614G>A, NM_001395683.1:c.2614G>A, NM_001395684.1:c.2614G>A, NM_001395685.1:c.2614G>A, NM_001395686.1:c.2332G>A, NM_001395687.1:c.2209G>A, NM_001395688.1:c.2209G>A, NM_001395689.1:c.2209G>A, NM_001395690.1:c.2209G>A, NM_001395691.1:c.2047G>A, NM_001395692.1:c.2614G>A, NM_001395693.1:c.2614G>A, NM_001395694.1:c.2614G>A, NM_001395695.1:c.2614G>A, NM_001395696.1:c.2209G>A, NM_001395697.1:c.931G>A, NR_172715.1:n.3032G>A, NR_172716.1:n.2959G>A, NR_172717.1:n.3126G>A, NR_172718.1:n.3126G>A, NR_172719.1:n.2959G>A, NR_172720.1:n.2959G>A, NM_177438.3(DICER1):c.2614G>A (p.Ala872Thr), NM_177438.2(DICER1):c.2614G>A (p.Ala872Thr)	DICER1	dicer1 syndrome	MONDO:0017288	Autosomal dominant inheritance	Benign	BS2, BP4, BS3_Supporting, BS1	PM2, PM6, PP3, PP4, PP1, BP2, BA1, PS1, PS3, PS4, PS2, PM5, PM1, BS4	The NM_177438.2:c.2614G>A (p.Ala872Thr) variant in DICER1 has the highest population minor allele frequency in gnomAD v2.1.1 is 0.00119 in non-Finnish European population, which is higher than the ClinGen DICER1 VCEP threshold (>0.0003) for BS1, and therefore meets this criterion (BS1). This variant has been observed in 40 or more unrelated females without tumors through age 50 in at least one testing laboratory (Internal lab contributors: 61756, 500031) and has been observed in a homozygous state in 5 healthy individuals (Internal lab contributors: 26957, 500031)(BS2). In vitro cleavage assay in HEK293 cells showed that this variant produces both 5p and 3p microRNAs from a pre-miRNA, indicating that this variant is unlikely to impact protein function (PMID: 31342592)(BS3_Supporting). The computational predictor REVEL gives a score of 0.488, which is below the threshold of 0.5, and the splice site predictors MaxEntScan and SpliceAI indicate that the variant has no impact on splicing, evidence that does not predict a damaging effect on DICER1 function (BP4). In summary, this variant meets the criteria to be classified as benign for DICER1 syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen DICER1 VCEP: BS1, BS2, BS3_Supporting, BP4. (Bayesian Points: -10; VCEP specifications version 1; 02/11/2022).	31342592	DICER1 and miRNA-Processing Gene VCEP		2022-05-18	2022-07-08	False	https://erepo.genome.network/evrepo/ui/classification/CA158264/MONDO:0017288/024	d0180ab5-21d7-45b9-bb2f-91f305099d4f	p.Ala872Thr	Ala	872	Thr	MKSPALQPLSMAGLQLMTPASSPMGPFFGLPWQQEAIHDNIYTPRKYQVELLEAALDHNTIVCLNTGSGKTFIAVLLTKELSYQIRGDFSRNGKRTVFLVNSANQVAQQVSAVRTHSDLKVGEYSNLEVNASWTKERWNQEFTKHQVLIMTCYVALNVLKNGYLSLSDINLLVFDECHLAILDHPYREIMKLCENCPSCPRILGLTASILNGKCDPEELEEKIQKLEKILKSNAETATDLVVLDRYTSQPCEIVVDCGPFTDRSGLYERLLMELEEALNFINDCNISVHSKERDSTLISKQILSDCRAVLVVLGPWCADKVAGMMVRELQKYIKHEQEELHRKFLLFTDTFLRKIHALCEEHFSPASLDLKFVTPKVIKLLEILRKYKPYERQQFESVEWYNNRNQDNYVSWSDSEDDDEDEEIEEKEKPETNFPSPFTNILCGIIFVERRYTAVVLNRLIKEAGKQDPELAYISSNFITGHGIGKNQPRNKQMEAEFRKQEEVLRKFRAHETNLLIATSIVEEGVDIPKCNLVVRFDLPTEYRSYVQSKGRARAPISNYIMLADTDKIKSFEEDLKTYKAIEKILRNKCSKSVDTGETDIDPVMDDDDVFPPYVLRPDDGGPRVTINTAIGHINRYCARLPSDPFTHLAPKCRTRELPDGTFYSTLYLPINSPLRASIVGPPMSCVRLAERVVALICCEKLHKIGELDDHLMPVGKETVKYEEELDLHDEEETSVPGRPGSTKRRQCYPKAIPECLRDSYPRPDQPCYLYVIGMVLTTPLPDELNFRRRKLYPPEDTTRCFGILTAKPIPQIPHFPVYTRSGEVTISIELKKSGFMLSLQMLELITRLHQYIFSHILRLEKPALEFKPTDADSAYCVLPLNVVNDSSTLDIDFKFMEDIEKSEARIGIPSTKYTKETPFVFKLEDYQDAVIIPRYRNFDQPHRFYVADVYTDLTPLSKFPSPEYETFAEYYKTKYNLDLTNLNQPLLDVDHTSSRLNLLTPRHLNQKGKALPLSSAEKRKAKWESLQNKQILVPELCAIHPIPASLWRKAVCLPSILYRLHCLLTAEELRAQTASDAGVGVRSLPADFRYPNLDFGWKKSIDSKSFISISNSSSAENDNYCKHSTIVPENAAHQGANRTSSLENHDQMSVNCRTLLSESPGKLHVEVSADLTAINGLSYNQNLANGSYDLANRDFCQGNQLNYYKQEIPVQPTTSYSIQNLYSYENQPQPSDECTLLSNKYLDGNANKSTSDGSPVMAVMPGTTDTIQVLKGRMDSEQSPSIGYSSRTLGPNPGLILQALTLSNASDGFNLERLEMLGDSFLKHAITTYLFCTYPDAHEGRLSYMRSKKVSNCNLYRLGKKKGLPSRMVVSIFDPPVNWLPPGYVVNQDKSNTDKWEKDEMTKDCMLANGKLDEDYEEEDEEEESLMWRAPKEEADYEDDFLEYDQEHIRFIDNMLMGSGAFVKKISLSPFSTTDSAYEWKMPKKSSLGSMPFSSDFEDFDYSSWDAMCYLDPSKAVEEDDFVVGFWNPSEENCGVDTGKQSISYDLHTEQCIADKSIADCVEALLGCYLTSCGERAAQLFLCSLGLKVLPVIKRTDREKALCPTRENFNSQQKNLSVSCAAASVASSRSSVLKDSEYGCLKIPPRCMFDHPDADKTLNHLISGFENFEKKINYRFKNKAYLLQAFTHASYHYNTITDCYQRLEFLGDAILDYLITKHLYEDPRQHSPGVLTDLRSALVNNTIFASLAVKYDYHKYFKAVSPELFHVIDDFVQFQLEKNEMQGMDSELRRSEEDEEKEEDIEVPKAMGDIFESLAGAIYMDSGMSLETVWQVYYPMMRPLIEKFSANVPRSPVRELLEMEPETAKFSPAERTYDGKVRVTVEVVGKGKFKGVGRSYRIAKSAAARRALRSLKANQPQVPNS	1922	Q9UPY3	T	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
454	NM_177438.2(DICER1):c.4910C>T (p.Ser1637Leu)	242127	CA7330772	NM_177438.2:c.4910C>T, NC_000014.9:g.95096010G>A, CM000676.2:g.95096010G>A, NC_000014.8:g.95562347G>A, CM000676.1:g.95562347G>A, NC_000014.7:g.94632100G>A, NG_016311.1:g.66413C>T, LRG_492:g.66413C>T, ENST00000343455.8:c.4910C>T, ENST00000393063.6:c.4910C>T, ENST00000526495.6:c.4910C>T, ENST00000532939.3:c.4910C>T, ENST00000556045.6:c.4910C>T, ENST00000675540.1:n.2655C>T, ENST00000675995.1:c.*3226C>T, ENST00000343455.7:c.4910C>T, ENST00000393063.5:c.4910C>T, ENST00000526495.5:c.4910C>T, ENST00000527414.5:c.4910C>T, ENST00000532939.2:n.945C>T, ENST00000541352.5:c.4910C>T, ENST00000556045.5:c.1604C>T, NM_001195573.1:c.4910C>T, NM_001271282.2:c.4910C>T, NM_001291628.1:c.4910C>T, NM_030621.4:c.4910C>T, LRG_492t1:c.4910C>T, XM_011536599.1:c.4910C>T, XM_011536600.1:c.4910C>T, XM_011536601.1:c.4910C>T, XM_011536602.1:c.4910C>T, XM_011536603.1:c.4910C>T, XM_011536604.1:c.4505C>T, XM_011536605.1:c.3431C>T, XM_011536599.2:c.4910C>T, XM_011536600.3:c.4910C>T, XM_011536601.3:c.4910C>T, XM_011536602.3:c.4910C>T, XM_011536604.2:c.4505C>T, XM_011536605.2:c.3431C>T, XM_017021120.2:c.4910C>T, XM_017021121.2:c.4910C>T, XM_017021122.2:c.4505C>T, XM_017021123.2:c.4505C>T, NM_001271282.3:c.4910C>T, NM_001291628.2:c.4910C>T, NM_177438.3:c.4910C>T, NM_001395677.1:c.4910C>T, NM_001395678.1:c.4910C>T, NM_001395679.1:c.4910C>T, NM_001395680.1:c.4910C>T, NM_001395682.1:c.4910C>T, NM_001395683.1:c.4910C>T, NM_001395684.1:c.4910C>T, NM_001395685.1:c.4910C>T, NM_001395686.1:c.4628C>T, NM_001395687.1:c.4505C>T, NM_001395688.1:c.4505C>T, NM_001395689.1:c.4505C>T, NM_001395690.1:c.4505C>T, NM_001395691.1:c.4343C>T, NM_001395692.1:c.4910C>T, NM_001395693.1:c.4910C>T, NM_001395694.1:c.4910C>T, NM_001395695.1:c.4910C>T, NM_001395696.1:c.4505C>T, NM_001395697.1:c.3227C>T, NR_172715.1:n.5328C>T, NR_172716.1:n.5512C>T, NR_172717.1:n.5422C>T, NR_172718.1:n.5345C>T, NR_172719.1:n.5178C>T, NR_172720.1:n.5255C>T, NM_177438.3(DICER1):c.4910C>T (p.Ser1637Leu), NM_177438.2(DICER1):c.4910C>T (p.Ser1637Leu)	DICER1	dicer1 syndrome	MONDO:0017288	Autosomal dominant inheritance	Benign	BS2, BP4, BS1	PM2, PM6, PP1, PP4, BA1, PS1, PS3, PS2, PM5, BS3, BS4	NM_177438.2(DICER1):c.4910C>T variant in DICER1 is a missense variant predicted to cause substitution of serine by leucine at amino acid 1637 (p.Ser1637Leu). The highest population minor allele frequency in gnomAD v2.1.1 non-cancer is 0.0026 (61/23614 alleles) in African/African-American population, which is higher than the ClinGen DICER1 VCEP threshold (>0.0003) for BS1, and therefore meets this criterion (BS1). This variant has been seen in 40 or more unrelated females without tumors through age 50 in at least one testing laboratory (BS2; Internal lab contributors/GTRs: 61756, 500031). The computational predictor REVEL gives a score of 0.065, which is below the threshold of 0.5, and the splice site predictors MaxEntScan and SpliceAI indicate that the variant has no impact on splicing, evidence that does not predict a damaging effect on DICER1 function (BP4). In summary, this variant meets the criteria to be classified as Benign for DICER1 syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen DICER1 VCEP: BS1, BS2, BP4 (Bayesian Points: -9; VCEP specifications version 1; 02/11/2022).		DICER1 and miRNA-Processing Gene VCEP		2022-05-18	2022-07-08	False	https://erepo.genome.network/evrepo/ui/classification/CA7330772/MONDO:0017288/024	c9daa85f-dbd7-4827-94cc-e41a19904f0c	p.Ser1637Leu	Ser	1637	Leu	MKSPALQPLSMAGLQLMTPASSPMGPFFGLPWQQEAIHDNIYTPRKYQVELLEAALDHNTIVCLNTGSGKTFIAVLLTKELSYQIRGDFSRNGKRTVFLVNSANQVAQQVSAVRTHSDLKVGEYSNLEVNASWTKERWNQEFTKHQVLIMTCYVALNVLKNGYLSLSDINLLVFDECHLAILDHPYREIMKLCENCPSCPRILGLTASILNGKCDPEELEEKIQKLEKILKSNAETATDLVVLDRYTSQPCEIVVDCGPFTDRSGLYERLLMELEEALNFINDCNISVHSKERDSTLISKQILSDCRAVLVVLGPWCADKVAGMMVRELQKYIKHEQEELHRKFLLFTDTFLRKIHALCEEHFSPASLDLKFVTPKVIKLLEILRKYKPYERQQFESVEWYNNRNQDNYVSWSDSEDDDEDEEIEEKEKPETNFPSPFTNILCGIIFVERRYTAVVLNRLIKEAGKQDPELAYISSNFITGHGIGKNQPRNKQMEAEFRKQEEVLRKFRAHETNLLIATSIVEEGVDIPKCNLVVRFDLPTEYRSYVQSKGRARAPISNYIMLADTDKIKSFEEDLKTYKAIEKILRNKCSKSVDTGETDIDPVMDDDDVFPPYVLRPDDGGPRVTINTAIGHINRYCARLPSDPFTHLAPKCRTRELPDGTFYSTLYLPINSPLRASIVGPPMSCVRLAERVVALICCEKLHKIGELDDHLMPVGKETVKYEEELDLHDEEETSVPGRPGSTKRRQCYPKAIPECLRDSYPRPDQPCYLYVIGMVLTTPLPDELNFRRRKLYPPEDTTRCFGILTAKPIPQIPHFPVYTRSGEVTISIELKKSGFMLSLQMLELITRLHQYIFSHILRLEKPALEFKPTDADSAYCVLPLNVVNDSSTLDIDFKFMEDIEKSEARIGIPSTKYTKETPFVFKLEDYQDAVIIPRYRNFDQPHRFYVADVYTDLTPLSKFPSPEYETFAEYYKTKYNLDLTNLNQPLLDVDHTSSRLNLLTPRHLNQKGKALPLSSAEKRKAKWESLQNKQILVPELCAIHPIPASLWRKAVCLPSILYRLHCLLTAEELRAQTASDAGVGVRSLPADFRYPNLDFGWKKSIDSKSFISISNSSSAENDNYCKHSTIVPENAAHQGANRTSSLENHDQMSVNCRTLLSESPGKLHVEVSADLTAINGLSYNQNLANGSYDLANRDFCQGNQLNYYKQEIPVQPTTSYSIQNLYSYENQPQPSDECTLLSNKYLDGNANKSTSDGSPVMAVMPGTTDTIQVLKGRMDSEQSPSIGYSSRTLGPNPGLILQALTLSNASDGFNLERLEMLGDSFLKHAITTYLFCTYPDAHEGRLSYMRSKKVSNCNLYRLGKKKGLPSRMVVSIFDPPVNWLPPGYVVNQDKSNTDKWEKDEMTKDCMLANGKLDEDYEEEDEEEESLMWRAPKEEADYEDDFLEYDQEHIRFIDNMLMGSGAFVKKISLSPFSTTDSAYEWKMPKKSSLGSMPFSSDFEDFDYSSWDAMCYLDPSKAVEEDDFVVGFWNPSEENCGVDTGKQSISYDLHTEQCIADKSIADCVEALLGCYLTSCGERAAQLFLCSLGLKVLPVIKRTDREKALCPTRENFNSQQKNLSVSCAAASVASSRSSVLKDSEYGCLKIPPRCMFDHPDADKTLNHLISGFENFEKKINYRFKNKAYLLQAFTHASYHYNTITDCYQRLEFLGDAILDYLITKHLYEDPRQHSPGVLTDLRSALVNNTIFASLAVKYDYHKYFKAVSPELFHVIDDFVQFQLEKNEMQGMDSELRRSEEDEEKEEDIEVPKAMGDIFESLAGAIYMDSGMSLETVWQVYYPMMRPLIEKFSANVPRSPVRELLEMEPETAKFSPAERTYDGKVRVTVEVVGKGKFKGVGRSYRIAKSAAARRALRSLKANQPQVPNS	1922	Q9UPY3	L	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [308, 309], 'STRAND_gain': [123], 'STRAND_gain_score': array([0.00985891]), 'STRAND_loss_score': array([-0.04501629, -0.04288876]), 'HELIX_loss': [634], 'HELIX_gain': [1328], 'HELIX_gain_score': array([0.00509554]), 'HELIX_loss_score': array([-0.00614208]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
455	NM_177438.2(DICER1):c.3428T>C (p.Leu1143Pro)	220594	CA349475	NM_177438.2:c.3428T>C, NC_000014.9:g.95103968A>G, CM000676.2:g.95103968A>G, NC_000014.8:g.95570305A>G, CM000676.1:g.95570305A>G, NC_000014.7:g.94640058A>G, NG_016311.1:g.58455T>C, LRG_492:g.58455T>C, ENST00000343455.8:c.3428T>C, ENST00000393063.6:c.3428T>C, ENST00000526495.6:c.3428T>C, ENST00000532939.3:c.3428T>C, ENST00000556045.6:c.3428T>C, ENST00000675540.1:n.1173T>C, ENST00000675995.1:c.*1744T>C, ENST00000343455.7:c.3428T>C, ENST00000393063.5:c.3428T>C, ENST00000526495.5:c.3428T>C, ENST00000527414.5:c.3428T>C, ENST00000541352.5:c.3428T>C, ENST00000554367.1:n.637T>C, ENST00000556045.5:c.122T>C, NM_001195573.1:c.3428T>C, NM_001271282.2:c.3428T>C, NM_001291628.1:c.3428T>C, NM_030621.4:c.3428T>C, LRG_492t1:c.3428T>C, XM_011536599.1:c.3428T>C, XM_011536600.1:c.3428T>C, XM_011536601.1:c.3428T>C, XM_011536602.1:c.3428T>C, XM_011536603.1:c.3428T>C, XM_011536604.1:c.3023T>C, XM_011536605.1:c.1949T>C, XM_011536599.2:c.3428T>C, XM_011536600.3:c.3428T>C, XM_011536601.3:c.3428T>C, XM_011536602.3:c.3428T>C, XM_011536604.2:c.3023T>C, XM_011536605.2:c.1949T>C, XM_017021120.2:c.3428T>C, XM_017021121.2:c.3428T>C, XM_017021122.2:c.3023T>C, XM_017021123.2:c.3023T>C, NM_001271282.3:c.3428T>C, NM_001291628.2:c.3428T>C, NM_177438.3:c.3428T>C, NM_001395677.1:c.3428T>C, NM_001395678.1:c.3428T>C, NM_001395679.1:c.3428T>C, NM_001395680.1:c.3428T>C, NM_001395682.1:c.3428T>C, NM_001395683.1:c.3428T>C, NM_001395684.1:c.3428T>C, NM_001395685.1:c.3428T>C, NM_001395686.1:c.3146T>C, NM_001395687.1:c.3023T>C, NM_001395688.1:c.3023T>C, NM_001395689.1:c.3023T>C, NM_001395690.1:c.3023T>C, NM_001395691.1:c.2861T>C, NM_001395692.1:c.3428T>C, NM_001395693.1:c.3428T>C, NM_001395694.1:c.3428T>C, NM_001395695.1:c.3428T>C, NM_001395696.1:c.3023T>C, NM_001395697.1:c.1745T>C, NR_172715.1:n.3846T>C, NR_172716.1:n.4030T>C, NR_172717.1:n.3940T>C, NR_172718.1:n.3863T>C, NR_172719.1:n.3696T>C, NR_172720.1:n.3773T>C, NM_177438.3(DICER1):c.3428T>C (p.Leu1143Pro), NM_177438.2(DICER1):c.3428T>C (p.Leu1143Pro)	DICER1	dicer1 syndrome	MONDO:0017288	Autosomal dominant inheritance	Benign	BS2, BP4, BS1	PM2, PM6, PP3, PP1, PP4, BP2, BA1, PS1, PS3, PS4, PS2, BS3, BS4, PM5, PM1	The NM_177438.2:c.3428T>C variant in DICER1 is a missense variant predicted to cause substitution of leucine by proline at amino acid 1143 (p.Leu1143Pro). This variant has been seen in 40 or more unrelated females without tumors through age 50 in at least one testing laboratory (BS2; GTRs: 500031, 61756). The highest population minor allele frequency in gnomAD v2.1.1 (non-cancer) is 0.0029 (69/23442 alleles; FAF=0.0020) in African/African-American population, which is higher than the ClinGen DICER1 VCEP threshold (>0.0003) for BS1, and therefore meets this criterion (BS1). The computational predictor REVEL gives a score of 0.102, which is below the threshold of 0.5, and the splice site predictors MaxEntScan and SpliceAI indicate that the variant has no impact on splicing, evidence that does not predict a damaging effect on DICER1 function (BP4). In summary, this variant meets the criteria to be classified as BENIGN for DICER1 syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen DICER1 VCEP: BS2, BS1, BP4. (Bayesian Points: -9; VCEP specifications version 1; 02/11/2022)		DICER1 and miRNA-Processing Gene VCEP		2022-05-18	2022-07-08	False	https://erepo.genome.network/evrepo/ui/classification/CA349475/MONDO:0017288/024	6cde00c2-e953-4b0e-8669-393eef83e7fd	p.Leu1143Pro	Leu	1143	Pro	MKSPALQPLSMAGLQLMTPASSPMGPFFGLPWQQEAIHDNIYTPRKYQVELLEAALDHNTIVCLNTGSGKTFIAVLLTKELSYQIRGDFSRNGKRTVFLVNSANQVAQQVSAVRTHSDLKVGEYSNLEVNASWTKERWNQEFTKHQVLIMTCYVALNVLKNGYLSLSDINLLVFDECHLAILDHPYREIMKLCENCPSCPRILGLTASILNGKCDPEELEEKIQKLEKILKSNAETATDLVVLDRYTSQPCEIVVDCGPFTDRSGLYERLLMELEEALNFINDCNISVHSKERDSTLISKQILSDCRAVLVVLGPWCADKVAGMMVRELQKYIKHEQEELHRKFLLFTDTFLRKIHALCEEHFSPASLDLKFVTPKVIKLLEILRKYKPYERQQFESVEWYNNRNQDNYVSWSDSEDDDEDEEIEEKEKPETNFPSPFTNILCGIIFVERRYTAVVLNRLIKEAGKQDPELAYISSNFITGHGIGKNQPRNKQMEAEFRKQEEVLRKFRAHETNLLIATSIVEEGVDIPKCNLVVRFDLPTEYRSYVQSKGRARAPISNYIMLADTDKIKSFEEDLKTYKAIEKILRNKCSKSVDTGETDIDPVMDDDDVFPPYVLRPDDGGPRVTINTAIGHINRYCARLPSDPFTHLAPKCRTRELPDGTFYSTLYLPINSPLRASIVGPPMSCVRLAERVVALICCEKLHKIGELDDHLMPVGKETVKYEEELDLHDEEETSVPGRPGSTKRRQCYPKAIPECLRDSYPRPDQPCYLYVIGMVLTTPLPDELNFRRRKLYPPEDTTRCFGILTAKPIPQIPHFPVYTRSGEVTISIELKKSGFMLSLQMLELITRLHQYIFSHILRLEKPALEFKPTDADSAYCVLPLNVVNDSSTLDIDFKFMEDIEKSEARIGIPSTKYTKETPFVFKLEDYQDAVIIPRYRNFDQPHRFYVADVYTDLTPLSKFPSPEYETFAEYYKTKYNLDLTNLNQPLLDVDHTSSRLNLLTPRHLNQKGKALPLSSAEKRKAKWESLQNKQILVPELCAIHPIPASLWRKAVCLPSILYRLHCLLTAEELRAQTASDAGVGVRSLPADFRYPNLDFGWKKSIDSKSFISISNSSSAENDNYCKHSTIVPENAAHQGANRTSSLENHDQMSVNCRTLLSESPGKLHVEVSADLTAINGLSYNQNLANGSYDLANRDFCQGNQLNYYKQEIPVQPTTSYSIQNLYSYENQPQPSDECTLLSNKYLDGNANKSTSDGSPVMAVMPGTTDTIQVLKGRMDSEQSPSIGYSSRTLGPNPGLILQALTLSNASDGFNLERLEMLGDSFLKHAITTYLFCTYPDAHEGRLSYMRSKKVSNCNLYRLGKKKGLPSRMVVSIFDPPVNWLPPGYVVNQDKSNTDKWEKDEMTKDCMLANGKLDEDYEEEDEEEESLMWRAPKEEADYEDDFLEYDQEHIRFIDNMLMGSGAFVKKISLSPFSTTDSAYEWKMPKKSSLGSMPFSSDFEDFDYSSWDAMCYLDPSKAVEEDDFVVGFWNPSEENCGVDTGKQSISYDLHTEQCIADKSIADCVEALLGCYLTSCGERAAQLFLCSLGLKVLPVIKRTDREKALCPTRENFNSQQKNLSVSCAAASVASSRSSVLKDSEYGCLKIPPRCMFDHPDADKTLNHLISGFENFEKKINYRFKNKAYLLQAFTHASYHYNTITDCYQRLEFLGDAILDYLITKHLYEDPRQHSPGVLTDLRSALVNNTIFASLAVKYDYHKYFKAVSPELFHVIDDFVQFQLEKNEMQGMDSELRRSEEDEEKEEDIEVPKAMGDIFESLAGAIYMDSGMSLETVWQVYYPMMRPLIEKFSANVPRSPVRELLEMEPETAKFSPAERTYDGKVRVTVEVVGKGKFKGVGRSYRIAKSAAARRALRSLKANQPQVPNS	1922	Q9UPY3	P	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [309], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.00701725]), 'HELIX_loss': [634], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.00435889]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [576], 'DOMAIN_gain_score': array([0.01439095]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
456	NM_177438.2(DICER1):c.1825G>T (p.Asp609Tyr)	133965	CA158261	NM_177438.2:c.1825G>T, NC_000014.9:g.95115749C>A, CM000676.2:g.95115749C>A, NC_000014.8:g.95582086C>A, CM000676.1:g.95582086C>A, NC_000014.7:g.94651839C>A, NG_016311.1:g.46674G>T, LRG_492:g.46674G>T, ENST00000343455.8:c.1825G>T, ENST00000393063.6:c.1825G>T, ENST00000526495.6:c.1825G>T, ENST00000532939.3:c.1825G>T, ENST00000556045.6:c.1825G>T, ENST00000675995.1:c.*141G>T, ENST00000343455.7:c.1825G>T, ENST00000393063.5:c.1825G>T, ENST00000526495.5:c.1825G>T, ENST00000527414.5:c.1825G>T, ENST00000532458.1:n.414G>T, ENST00000541352.5:c.1825G>T, NM_001195573.1:c.1825G>T, NM_001271282.2:c.1825G>T, NM_001291628.1:c.1825G>T, NM_030621.4:c.1825G>T, LRG_492t1:c.1825G>T, XM_011536599.1:c.1825G>T, XM_011536600.1:c.1825G>T, XM_011536601.1:c.1825G>T, XM_011536602.1:c.1825G>T, XM_011536603.1:c.1825G>T, XM_011536604.1:c.1420G>T, XM_011536605.1:c.346G>T, XM_011536599.2:c.1825G>T, XM_011536600.3:c.1825G>T, XM_011536601.3:c.1825G>T, XM_011536602.3:c.1825G>T, XM_011536604.2:c.1420G>T, XM_011536605.2:c.346G>T, XM_017021120.2:c.1825G>T, XM_017021121.2:c.1825G>T, XM_017021122.2:c.1420G>T, XM_017021123.2:c.1420G>T, NM_001271282.3:c.1825G>T, NM_001291628.2:c.1825G>T, NM_177438.3:c.1825G>T, NM_001395677.1:c.1825G>T, NM_001395678.1:c.1825G>T, NM_001395679.1:c.1825G>T, NM_001395680.1:c.1825G>T, NM_001395682.1:c.1825G>T, NM_001395683.1:c.1825G>T, NM_001395684.1:c.1825G>T, NM_001395685.1:c.1825G>T, NM_001395686.1:c.1543G>T, NM_001395687.1:c.1420G>T, NM_001395688.1:c.1420G>T, NM_001395689.1:c.1420G>T, NM_001395690.1:c.1420G>T, NM_001395691.1:c.1258G>T, NM_001395692.1:c.1825G>T, NM_001395693.1:c.1825G>T, NM_001395694.1:c.1825G>T, NM_001395695.1:c.1825G>T, NM_001395696.1:c.1420G>T, NM_001395697.1:c.142G>T, NM_001395698.1:c.1420G>T, NR_172715.1:n.2243G>T, NR_172716.1:n.2170G>T, NR_172717.1:n.2337G>T, NR_172718.1:n.2337G>T, NR_172719.1:n.2170G>T, NR_172720.1:n.2170G>T, NM_177438.3(DICER1):c.1825G>T (p.Asp609Tyr), NM_177438.2(DICER1):c.1825G>T (p.Asp609Tyr)	DICER1	dicer1 syndrome	MONDO:0017288	Autosomal dominant inheritance	Benign	BS2, BA1, BP4	PM2, PM6, PP3, PP1, PP4, BP2, PS1, PS3, PS4, PS2, PM5, PM1, BS1, BS3, BS4	The NM_177438.2:c.1825G>T variant in DICER1 is a missense variant predicted to cause substitution of Aspartic Acid by Tyrosine at amino acid 609 (p.Asp609Tyr). The highest population minor allele frequency in gnomAD non cancer dataset v2.1.1 is 0.006310 (149/23614 alleles) in the African population, which is higher than the ClinGen DICER1 VCEP threshold (>0.003) for BA1, and therefore meets this criterion (BA1).  In summary, this variant meets the criteria to be classified as Benign for DICER1 syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen DICER1 VCEP: BA1. (Bayesian Points: NA; VCEP specifications version 1; 02/11/2022)		DICER1 and miRNA-Processing Gene VCEP		2022-05-18	2022-07-08	False	https://erepo.genome.network/evrepo/ui/classification/CA158261/MONDO:0017288/024	ce2a208e-7e58-4c57-84aa-e9d89f32b6c7	p.Asp609Tyr	Asp	609	Tyr	MKSPALQPLSMAGLQLMTPASSPMGPFFGLPWQQEAIHDNIYTPRKYQVELLEAALDHNTIVCLNTGSGKTFIAVLLTKELSYQIRGDFSRNGKRTVFLVNSANQVAQQVSAVRTHSDLKVGEYSNLEVNASWTKERWNQEFTKHQVLIMTCYVALNVLKNGYLSLSDINLLVFDECHLAILDHPYREIMKLCENCPSCPRILGLTASILNGKCDPEELEEKIQKLEKILKSNAETATDLVVLDRYTSQPCEIVVDCGPFTDRSGLYERLLMELEEALNFINDCNISVHSKERDSTLISKQILSDCRAVLVVLGPWCADKVAGMMVRELQKYIKHEQEELHRKFLLFTDTFLRKIHALCEEHFSPASLDLKFVTPKVIKLLEILRKYKPYERQQFESVEWYNNRNQDNYVSWSDSEDDDEDEEIEEKEKPETNFPSPFTNILCGIIFVERRYTAVVLNRLIKEAGKQDPELAYISSNFITGHGIGKNQPRNKQMEAEFRKQEEVLRKFRAHETNLLIATSIVEEGVDIPKCNLVVRFDLPTEYRSYVQSKGRARAPISNYIMLADTDKIKSFEEDLKTYKAIEKILRNKCSKSVDTGETDIDPVMDDDDVFPPYVLRPDDGGPRVTINTAIGHINRYCARLPSDPFTHLAPKCRTRELPDGTFYSTLYLPINSPLRASIVGPPMSCVRLAERVVALICCEKLHKIGELDDHLMPVGKETVKYEEELDLHDEEETSVPGRPGSTKRRQCYPKAIPECLRDSYPRPDQPCYLYVIGMVLTTPLPDELNFRRRKLYPPEDTTRCFGILTAKPIPQIPHFPVYTRSGEVTISIELKKSGFMLSLQMLELITRLHQYIFSHILRLEKPALEFKPTDADSAYCVLPLNVVNDSSTLDIDFKFMEDIEKSEARIGIPSTKYTKETPFVFKLEDYQDAVIIPRYRNFDQPHRFYVADVYTDLTPLSKFPSPEYETFAEYYKTKYNLDLTNLNQPLLDVDHTSSRLNLLTPRHLNQKGKALPLSSAEKRKAKWESLQNKQILVPELCAIHPIPASLWRKAVCLPSILYRLHCLLTAEELRAQTASDAGVGVRSLPADFRYPNLDFGWKKSIDSKSFISISNSSSAENDNYCKHSTIVPENAAHQGANRTSSLENHDQMSVNCRTLLSESPGKLHVEVSADLTAINGLSYNQNLANGSYDLANRDFCQGNQLNYYKQEIPVQPTTSYSIQNLYSYENQPQPSDECTLLSNKYLDGNANKSTSDGSPVMAVMPGTTDTIQVLKGRMDSEQSPSIGYSSRTLGPNPGLILQALTLSNASDGFNLERLEMLGDSFLKHAITTYLFCTYPDAHEGRLSYMRSKKVSNCNLYRLGKKKGLPSRMVVSIFDPPVNWLPPGYVVNQDKSNTDKWEKDEMTKDCMLANGKLDEDYEEEDEEEESLMWRAPKEEADYEDDFLEYDQEHIRFIDNMLMGSGAFVKKISLSPFSTTDSAYEWKMPKKSSLGSMPFSSDFEDFDYSSWDAMCYLDPSKAVEEDDFVVGFWNPSEENCGVDTGKQSISYDLHTEQCIADKSIADCVEALLGCYLTSCGERAAQLFLCSLGLKVLPVIKRTDREKALCPTRENFNSQQKNLSVSCAAASVASSRSSVLKDSEYGCLKIPPRCMFDHPDADKTLNHLISGFENFEKKINYRFKNKAYLLQAFTHASYHYNTITDCYQRLEFLGDAILDYLITKHLYEDPRQHSPGVLTDLRSALVNNTIFASLAVKYDYHKYFKAVSPELFHVIDDFVQFQLEKNEMQGMDSELRRSEEDEEKEEDIEVPKAMGDIFESLAGAIYMDSGMSLETVWQVYYPMMRPLIEKFSANVPRSPVRELLEMEPETAKFSPAERTYDGKVRVTVEVVGKGKFKGVGRSYRIAKSAAARRALRSLKANQPQVPNS	1922	Q9UPY3	Y	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [563], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.00683004]), 'HELIX_loss': [571], 'HELIX_gain': [632, 633, 635, 1704], 'HELIX_gain_score': array([0.06075144, 0.05267835, 0.05618334, 0.00529981]), 'HELIX_loss_score': array([-0.00736386]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
457	NM_030621.4(DICER1):c.884C>G (p.Ser295Cys)	242151	CA7331562	NM_030621.4:c.884C>G, NC_000014.9:g.95126599G>C, CM000676.2:g.95126599G>C, NC_000014.8:g.95592936G>C, CM000676.1:g.95592936G>C, NC_000014.7:g.94662689G>C, NG_016311.1:g.35824C>G, LRG_492:g.35824C>G, ENST00000343455.8:c.884C>G, ENST00000393063.6:c.884C>G, ENST00000526495.6:c.884C>G, ENST00000532939.3:c.884C>G, ENST00000556045.6:c.884C>G, ENST00000674628.1:c.884C>G, ENST00000675995.1:c.884C>G, ENST00000343455.7:c.884C>G, ENST00000393063.5:c.884C>G, ENST00000526495.5:c.884C>G, ENST00000527414.5:c.884C>G, ENST00000541352.5:c.884C>G, NM_001195573.1:c.884C>G, NM_001271282.2:c.884C>G, NM_001291628.1:c.884C>G, NM_177438.2:c.884C>G, LRG_492t1:c.884C>G, XM_011536599.1:c.884C>G, XM_011536600.1:c.884C>G, XM_011536601.1:c.884C>G, XM_011536602.1:c.884C>G, XM_011536603.1:c.884C>G, XM_011536604.1:c.479C>G, XM_011536599.2:c.884C>G, XM_011536600.3:c.884C>G, XM_011536601.3:c.884C>G, XM_011536602.3:c.884C>G, XM_011536604.2:c.479C>G, XM_017021120.2:c.884C>G, XM_017021121.2:c.884C>G, XM_017021122.2:c.479C>G, XM_017021123.2:c.479C>G, NM_001271282.3:c.884C>G, NM_001291628.2:c.884C>G, NM_177438.3:c.884C>G, NM_001395677.1:c.884C>G, NM_001395678.1:c.884C>G, NM_001395679.1:c.884C>G, NM_001395680.1:c.884C>G, NM_001395682.1:c.884C>G, NM_001395683.1:c.884C>G, NM_001395684.1:c.884C>G, NM_001395685.1:c.884C>G, NM_001395686.1:c.602C>G, NM_001395687.1:c.479C>G, NM_001395688.1:c.479C>G, NM_001395689.1:c.479C>G, NM_001395690.1:c.479C>G, NM_001395691.1:c.317C>G, NM_001395692.1:c.884C>G, NM_001395693.1:c.884C>G, NM_001395694.1:c.884C>G, NM_001395695.1:c.884C>G, NM_001395696.1:c.479C>G, NM_001395697.1:c.-685C>G, NM_001395698.1:c.479C>G, NM_001395699.1:c.884C>G, NM_001395700.1:c.884C>G, NR_172715.1:n.1098C>G, NR_172716.1:n.1229C>G, NR_172717.1:n.1396C>G, NR_172718.1:n.1396C>G, NR_172719.1:n.1229C>G, NR_172720.1:n.1229C>G, NM_177438.3(DICER1):c.884C>G (p.Ser295Cys), NM_030621.4(DICER1):c.884C>G (p.Ser295Cys)	DICER1	dicer1 syndrome	MONDO:0017288	Autosomal dominant inheritance	Benign	BS2, BA1, BP4		The NM_177438.2:c.884C>G variant in DICER1 is a missense variant predicted to cause substitution of serine by cysteine at amino acid 295 (p.Ser295Cys). The highest population minor allele frequency in gnomAD v2.1.1 (non-cancer) is 0.0072 (219/30496 alleles; FAF=0.0064) in the South Asian population, which is higher than the ClinGen DICER1 VCEP threshold (>0.003) for BA1, and therefore meets this criterion (BA1). In summary, this variant meets the criteria to be classified as BENIGN for DICER1 syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen DICER1 VCEP: BA1. (Bayesian Points: NA; VCEP specifications version 1; 02/11/2022)		DICER1 and miRNA-Processing Gene VCEP		2022-05-18	2022-07-08	False	https://erepo.genome.network/evrepo/ui/classification/CA7331562/MONDO:0017288/024	01250ee6-c3f3-4f76-a436-492940d394a4	p.Ser295Cys	Ser	295	Cys	MKSPALQPLSMAGLQLMTPASSPMGPFFGLPWQQEAIHDNIYTPRKYQVELLEAALDHNTIVCLNTGSGKTFIAVLLTKELSYQIRGDFSRNGKRTVFLVNSANQVAQQVSAVRTHSDLKVGEYSNLEVNASWTKERWNQEFTKHQVLIMTCYVALNVLKNGYLSLSDINLLVFDECHLAILDHPYREIMKLCENCPSCPRILGLTASILNGKCDPEELEEKIQKLEKILKSNAETATDLVVLDRYTSQPCEIVVDCGPFTDRSGLYERLLMELEEALNFINDCNISVHSKERDSTLISKQILSDCRAVLVVLGPWCADKVAGMMVRELQKYIKHEQEELHRKFLLFTDTFLRKIHALCEEHFSPASLDLKFVTPKVIKLLEILRKYKPYERQQFESVEWYNNRNQDNYVSWSDSEDDDEDEEIEEKEKPETNFPSPFTNILCGIIFVERRYTAVVLNRLIKEAGKQDPELAYISSNFITGHGIGKNQPRNKQMEAEFRKQEEVLRKFRAHETNLLIATSIVEEGVDIPKCNLVVRFDLPTEYRSYVQSKGRARAPISNYIMLADTDKIKSFEEDLKTYKAIEKILRNKCSKSVDTGETDIDPVMDDDDVFPPYVLRPDDGGPRVTINTAIGHINRYCARLPSDPFTHLAPKCRTRELPDGTFYSTLYLPINSPLRASIVGPPMSCVRLAERVVALICCEKLHKIGELDDHLMPVGKETVKYEEELDLHDEEETSVPGRPGSTKRRQCYPKAIPECLRDSYPRPDQPCYLYVIGMVLTTPLPDELNFRRRKLYPPEDTTRCFGILTAKPIPQIPHFPVYTRSGEVTISIELKKSGFMLSLQMLELITRLHQYIFSHILRLEKPALEFKPTDADSAYCVLPLNVVNDSSTLDIDFKFMEDIEKSEARIGIPSTKYTKETPFVFKLEDYQDAVIIPRYRNFDQPHRFYVADVYTDLTPLSKFPSPEYETFAEYYKTKYNLDLTNLNQPLLDVDHTSSRLNLLTPRHLNQKGKALPLSSAEKRKAKWESLQNKQILVPELCAIHPIPASLWRKAVCLPSILYRLHCLLTAEELRAQTASDAGVGVRSLPADFRYPNLDFGWKKSIDSKSFISISNSSSAENDNYCKHSTIVPENAAHQGANRTSSLENHDQMSVNCRTLLSESPGKLHVEVSADLTAINGLSYNQNLANGSYDLANRDFCQGNQLNYYKQEIPVQPTTSYSIQNLYSYENQPQPSDECTLLSNKYLDGNANKSTSDGSPVMAVMPGTTDTIQVLKGRMDSEQSPSIGYSSRTLGPNPGLILQALTLSNASDGFNLERLEMLGDSFLKHAITTYLFCTYPDAHEGRLSYMRSKKVSNCNLYRLGKKKGLPSRMVVSIFDPPVNWLPPGYVVNQDKSNTDKWEKDEMTKDCMLANGKLDEDYEEEDEEEESLMWRAPKEEADYEDDFLEYDQEHIRFIDNMLMGSGAFVKKISLSPFSTTDSAYEWKMPKKSSLGSMPFSSDFEDFDYSSWDAMCYLDPSKAVEEDDFVVGFWNPSEENCGVDTGKQSISYDLHTEQCIADKSIADCVEALLGCYLTSCGERAAQLFLCSLGLKVLPVIKRTDREKALCPTRENFNSQQKNLSVSCAAASVASSRSSVLKDSEYGCLKIPPRCMFDHPDADKTLNHLISGFENFEKKINYRFKNKAYLLQAFTHASYHYNTITDCYQRLEFLGDAILDYLITKHLYEDPRQHSPGVLTDLRSALVNNTIFASLAVKYDYHKYFKAVSPELFHVIDDFVQFQLEKNEMQGMDSELRRSEEDEEKEEDIEVPKAMGDIFESLAGAIYMDSGMSLETVWQVYYPMMRPLIEKFSANVPRSPVRELLEMEPETAKFSPAERTYDGKVRVTVEVVGKGKFKGVGRSYRIAKSAAARRALRSLKANQPQVPNS	1922	Q9UPY3	C	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [308, 309], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.12213904, -0.11534375]), 'HELIX_loss': [45, 634], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.00926262, -0.00515676]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [1387], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.00875306]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
458	NM_177438.2(DICER1):c.59C>T (p.Ala20Val)	133964	CA332140	NM_177438.2:c.59C>T, NC_000014.9:g.95133400G>A, CM000676.2:g.95133400G>A, NC_000014.8:g.95599737G>A, CM000676.1:g.95599737G>A, NC_000014.7:g.94669490G>A, NG_016311.1:g.29023C>T, LRG_492:g.29023C>T, ENST00000343455.8:c.59C>T, ENST00000393063.6:c.59C>T, ENST00000526495.6:c.59C>T, ENST00000531162.6:c.59C>T, ENST00000532939.3:c.59C>T, ENST00000556045.6:c.59C>T, ENST00000674628.1:c.59C>T, ENST00000675995.1:c.59C>T, ENST00000343455.7:c.59C>T, ENST00000393063.5:c.59C>T, ENST00000526495.5:c.59C>T, ENST00000527414.5:c.59C>T, ENST00000529206.1:n.200C>T, ENST00000529720.1:c.59C>T, ENST00000531162.5:c.59C>T, ENST00000541352.5:c.59C>T, NM_001195573.1:c.59C>T, NM_001271282.2:c.59C>T, NM_001291628.1:c.59C>T, NM_030621.4:c.59C>T, LRG_492t1:c.59C>T, XM_011536599.1:c.59C>T, XM_011536600.1:c.59C>T, XM_011536601.1:c.59C>T, XM_011536602.1:c.59C>T, XM_011536603.1:c.59C>T, XM_011536604.1:c.-216C>T, XM_011536599.2:c.59C>T, XM_011536600.3:c.59C>T, XM_011536601.3:c.59C>T, XM_011536602.3:c.59C>T, XM_011536604.2:c.-216C>T, XM_017021120.2:c.59C>T, XM_017021121.2:c.59C>T, XM_017021122.2:c.-216C>T, XM_017021123.2:c.-216C>T, NM_001271282.3:c.59C>T, NM_001291628.2:c.59C>T, NM_177438.3:c.59C>T, NM_001395677.1:c.59C>T, NM_001395678.1:c.59C>T, NM_001395679.1:c.59C>T, NM_001395680.1:c.59C>T, NM_001395682.1:c.59C>T, NM_001395683.1:c.59C>T, NM_001395684.1:c.59C>T, NM_001395685.1:c.59C>T, NM_001395686.1:c.-216C>T, NM_001395687.1:c.-130-723C>T, NM_001395688.1:c.-216C>T, NM_001395689.1:c.-216C>T, NM_001395690.1:c.-216C>T, NM_001395691.1:c.-400C>T, NM_001395692.1:c.59C>T, NM_001395693.1:c.59C>T, NM_001395694.1:c.59C>T, NM_001395695.1:c.59C>T, NM_001395696.1:c.-216C>T, NM_001395697.1:c.-1510C>T, NM_001395698.1:c.-216C>T, NM_001395699.1:c.59C>T, NM_001395700.1:c.59C>T, NR_172715.1:n.404C>T, NR_172716.1:n.404C>T, NR_172717.1:n.571C>T, NR_172718.1:n.571C>T, NR_172719.1:n.404C>T, NR_172720.1:n.404C>T, NM_177438.3(DICER1):c.59C>T (p.Ala20Val), NM_177438.2(DICER1):c.59C>T (p.Ala20Val)	DICER1	dicer1 syndrome	MONDO:0017288	Autosomal dominant inheritance	Benign	BS2, BP4, BS1	PM2, PM6, PP3, PP4, PP1, BP2, BA1, PS3, PS1, PS4, PS2, BS3, BS4, PM1, PM5	The NM_177438.2:c.59C>T is a missense variant in DICER1 predicted to cause substitution of Alanine by Valine at amino acid 20 (p.Ala20Val). The highest population minor allele frequency in gnomAD v2.1.1 is 0.0009673 in the non-Finnish European population, which is higher than the ClinGen DICER1 VCEP threshold (>0.0003) for BS1, and therefore meets this criterion (BS1). This variant has been observed in 40 or more unrelated females without tumors through age 50 in at least one testing laboratory (Internal lab contributors GTRs: 61756, 500031) and has been observed in a homozygous state in 3 healthy individuals (Internal lab contributors GTR: 500031)(BS2). The computational predictor REVEL gives a score of 0.302, which is below the threshold of 0.5, and the splice site predictors MaxEntScan and SpliceAI indicate that the variant has no impact on splicing, evidence that does not predict a damaging effect on DICER1 function (BP4). In summary, this variant meets the criteria to be classified as benign for DICER1 syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen DICER1 VCEP: BS1, BS2, BP4. (Bayesian Points: -9; VCEP specifications version 1; 02/11/2022).		DICER1 and miRNA-Processing Gene VCEP		2022-05-18	2022-07-08	False	https://erepo.genome.network/evrepo/ui/classification/CA332140/MONDO:0017288/024	c125e21b-58b1-464c-9b3e-4a627e10bf8a	p.Ala20Val	Ala	20	Val	MKSPALQPLSMAGLQLMTPASSPMGPFFGLPWQQEAIHDNIYTPRKYQVELLEAALDHNTIVCLNTGSGKTFIAVLLTKELSYQIRGDFSRNGKRTVFLVNSANQVAQQVSAVRTHSDLKVGEYSNLEVNASWTKERWNQEFTKHQVLIMTCYVALNVLKNGYLSLSDINLLVFDECHLAILDHPYREIMKLCENCPSCPRILGLTASILNGKCDPEELEEKIQKLEKILKSNAETATDLVVLDRYTSQPCEIVVDCGPFTDRSGLYERLLMELEEALNFINDCNISVHSKERDSTLISKQILSDCRAVLVVLGPWCADKVAGMMVRELQKYIKHEQEELHRKFLLFTDTFLRKIHALCEEHFSPASLDLKFVTPKVIKLLEILRKYKPYERQQFESVEWYNNRNQDNYVSWSDSEDDDEDEEIEEKEKPETNFPSPFTNILCGIIFVERRYTAVVLNRLIKEAGKQDPELAYISSNFITGHGIGKNQPRNKQMEAEFRKQEEVLRKFRAHETNLLIATSIVEEGVDIPKCNLVVRFDLPTEYRSYVQSKGRARAPISNYIMLADTDKIKSFEEDLKTYKAIEKILRNKCSKSVDTGETDIDPVMDDDDVFPPYVLRPDDGGPRVTINTAIGHINRYCARLPSDPFTHLAPKCRTRELPDGTFYSTLYLPINSPLRASIVGPPMSCVRLAERVVALICCEKLHKIGELDDHLMPVGKETVKYEEELDLHDEEETSVPGRPGSTKRRQCYPKAIPECLRDSYPRPDQPCYLYVIGMVLTTPLPDELNFRRRKLYPPEDTTRCFGILTAKPIPQIPHFPVYTRSGEVTISIELKKSGFMLSLQMLELITRLHQYIFSHILRLEKPALEFKPTDADSAYCVLPLNVVNDSSTLDIDFKFMEDIEKSEARIGIPSTKYTKETPFVFKLEDYQDAVIIPRYRNFDQPHRFYVADVYTDLTPLSKFPSPEYETFAEYYKTKYNLDLTNLNQPLLDVDHTSSRLNLLTPRHLNQKGKALPLSSAEKRKAKWESLQNKQILVPELCAIHPIPASLWRKAVCLPSILYRLHCLLTAEELRAQTASDAGVGVRSLPADFRYPNLDFGWKKSIDSKSFISISNSSSAENDNYCKHSTIVPENAAHQGANRTSSLENHDQMSVNCRTLLSESPGKLHVEVSADLTAINGLSYNQNLANGSYDLANRDFCQGNQLNYYKQEIPVQPTTSYSIQNLYSYENQPQPSDECTLLSNKYLDGNANKSTSDGSPVMAVMPGTTDTIQVLKGRMDSEQSPSIGYSSRTLGPNPGLILQALTLSNASDGFNLERLEMLGDSFLKHAITTYLFCTYPDAHEGRLSYMRSKKVSNCNLYRLGKKKGLPSRMVVSIFDPPVNWLPPGYVVNQDKSNTDKWEKDEMTKDCMLANGKLDEDYEEEDEEEESLMWRAPKEEADYEDDFLEYDQEHIRFIDNMLMGSGAFVKKISLSPFSTTDSAYEWKMPKKSSLGSMPFSSDFEDFDYSSWDAMCYLDPSKAVEEDDFVVGFWNPSEENCGVDTGKQSISYDLHTEQCIADKSIADCVEALLGCYLTSCGERAAQLFLCSLGLKVLPVIKRTDREKALCPTRENFNSQQKNLSVSCAAASVASSRSSVLKDSEYGCLKIPPRCMFDHPDADKTLNHLISGFENFEKKINYRFKNKAYLLQAFTHASYHYNTITDCYQRLEFLGDAILDYLITKHLYEDPRQHSPGVLTDLRSALVNNTIFASLAVKYDYHKYFKAVSPELFHVIDDFVQFQLEKNEMQGMDSELRRSEEDEEKEEDIEVPKAMGDIFESLAGAIYMDSGMSLETVWQVYYPMMRPLIEKFSANVPRSPVRELLEMEPETAKFSPAERTYDGKVRVTVEVVGKGKFKGVGRSYRIAKSAAARRALRSLKANQPQVPNS	1922	Q9UPY3	V	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [45, 548, 1325, 1763], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.00857651, -0.01160198, -0.00736153, -0.00566059]), 'COILED_loss': [211], 'COILED_gain': [], 'COILED_loss_score': array([-0.00231385]), 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [1387], 'DOMAIN_gain': [576], 'DOMAIN_gain_score': array([0.02375817]), 'DOMAIN_loss_score': array([-0.01752317]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
459	NM_000540.3(RYR1):c.7360C>T (p.Arg2454Cys)	133202	CA024778	NM_000540.3:c.7360C>T, NC_000019.10:g.38500642C>T, CM000681.2:g.38500642C>T, NC_000019.9:g.38991282C>T, CM000681.1:g.38991282C>T, NC_000019.8:g.43683122C>T, NG_008866.1:g.71943C>T, LRG_766:g.71943C>T, ENST00000599547.6:n.7360C>T, ENST00000359596.8:c.7360C>T, ENST00000355481.8:c.7360C>T, ENST00000359596.7:n.7360C>T, ENST00000360985.7:c.7357C>T, ENST00000594335.5:n.812C>T, NM_000540.2:c.7360C>T, LRG_766t1:c.7360C>T, NM_001042723.1:c.7360C>T, XM_006723317.1:c.7360C>T, XM_006723319.1:c.7360C>T, XM_011527204.1:c.7357C>T, XM_011527205.1:c.7360C>T, XM_006723317.2:c.7360C>T, XM_006723319.2:c.7360C>T, XM_011527205.2:c.7360C>T, XR_001753735.1:n.7443C>T, NM_001042723.2:c.7360C>T, NM_000540.3(RYR1):c.7360C>T (p.Arg2454Cys)	RYR1	malignant hyperthermia, susceptibility to, 1	MONDO:0007783	Autosomal dominant inheritance	Pathogenic	PP1, PM1_Supporting, PS4_Moderate, PS3_Moderate, PM5, PP3_Moderate		This pathogenicity assessment is relevant only for malignant hyperthermia susceptibility (MHS) inherited in an autosomal dominant pattern. Variants in RYR1 can also cause other myopathies inherited in an autosomal dominant pattern or in an autosomal recessive pattern. Some of these disorders may predispose individuals to malignant hyperthermia. RYR1 variants may also contribute to a malignant hyperthermia reaction in combination with other genetic and non-genetic factors and the clinician needs to consider such factors in making management decisions.This sequence variant predicts a substitution of arginine with cysteine at codon 2454 of the RYR1 protein, p.(Arg2454Cys). The maximum allele frequency for this variant among the six major gnomAD populations is SAS: 0.000065. This variant has been reported in three unrelated individuals who have a personal or family history of a malignant hyperthermia reaction, all of these individuals had a positive in vitro contracture test (IVCT) or caffeine halothane contracture test (CHCT) result (if the proband was unavailable for testing, a positive diagnostic test result in a mutation-positive relative was counted), PS4_Moderate (PMID: 10484775, 10612851, 16163667). This variant segregates with MHS in 3 individuals, PP1 (PMI: 10484775). A functional study in HEK293 cells shows an increased sensitivity to RYR1 agonists, PS3_Moderate (PMID: 27586648). This variant resides in a region of RYR1 considered to be a hotspot for pathogenic variants that contribute to MHS, use PM1_Supporting to avoid overweighting with PM5 (PMID: 21118704). Another variant that has been assessed as pathogenic occurs at this codon, p.(Arg2454His), PM5 (PMID: 26951757). A REVEL score >0.85 (0.913) supports a pathogenic status for this variant, PP3_Moderate. This variant has been classified as Pathogenic. Criteria implemented: PS3_Moderate, PS4_Moderate, PM1_Supporting, PM5, PP1, PP3_Moderate.		Malignant Hyperthermia Susceptibility VCEP	https://clinicalgenome.org/docs/clingen-malignant-hyperthermia-susceptibility-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-for/	2022-03-11	2022-07-10	False	https://erepo.genome.network/evrepo/ui/classification/CA024778/MONDO:0007783/012	d6ebf9fe-9589-48d9-a56a-c0af6613211f	p.Arg2454Cys	Arg	2454	Cys	MGDAEGEDEVQFLRTDDEVVLQCSATVLKEQLKLCLAAEGFGNRLCFLEPTSNAQNVPPDLAICCFVLEQSLSVRALQEMLANTVEAGVESSQGGGHRTLLYGHAILLRHAHSRMYLSCLTTSRSMTDKLAFDVGLQEDATGEACWWTMHPASKQRSEGEKVRVGDDIILVSVSSERYLHLSTASGELQVDASFMQTLWNMNPICSRCEEGFVTGGHVLRLFHGHMDECLTISPADSDDQRRLVYYEGGAVCTHARSLWRLEPLRISWSGSHLRWGQPLRVRHVTTGQYLALTEDQGLVVVDASKAHTKATSFCFRISKEKLDVAPKRDVEGMGPPEIKYGESLCFVQHVASGLWLTYAAPDPKALRLGVLKKKAMLHQEGHMDDALSLTRCQQEESQAARMIHSTNGLYNQFIKSLDSFSGKPRGSGPPAGTALPIEGVILSLQDLIIYFEPPSEDLQHEEKQSKLRSLRNRQSLFQEEGMLSMVLNCIDRLNVYTTAAHFAEFAGEEAAESWKEIVNLLYELLASLIRGNRSNCALFSTNLDWLVSKLDRLEASSGILEVLYCVLIESPEVLNIIQENHIKSIISLLDKHGRNHKVLDVLCSLCVCNGVAVRSNQDLITENLLPGRELLLQTNLINYVTSIRPNIFVGRAEGTTQYSKWYFEVMVDEVTPFLTAQATHLRVGWALTEGYTPYPGAGEGWGGNGVGDDLYSYGFDGLHLWTGHVARPVTSPGQHLLAPEDVISCCLDLSVPSISFRINGCPVQGVFESFNLDGLFFPVVSFSAGVKVRFLLGGRHGEFKFLPPPGYAPCHEAVLPRERLHLEPIKEYRREGPRGPHLVGPSRCLSHTDFVPCPVDTVQIVLPPHLERIREKLAENIHELWALTRIEQGWTYGPVRDDNKRLHPCLVDFHSLPEPERNYNLQMSGETLKTLLALGCHVGMADEKAEDNLKKTKLPKTYMMSNGYKPAPLDLSHVRLTPAQTTLVDRLAENGHNVWARDRVGQGWSYSAVQDIPARRNPRLVPYRLLDEATKRSNRDSLCQAVRTLLGYGYNIEPPDQEPSQVENQSRCDRVRIFRAEKSYTVQSGRWYFEFEAVTTGEMRVGWARPELRPDVELGADELAYVFNGHRGQRWHLGSEPFGRPWQPGDVVGCMIDLTENTIIFTLNGEVLMSDSGSETAFREIEIGDGFLPVCSLGPGQVGHLNLGQDVSSLRFFAICGLQEGFEPFAINMQRPVTTWFSKGLPQFEPVPLEHPHYEVSRVDGTVDTPPCLRLTHRTWGSQNSLVEMLFLRLSLPVQFHQHFRCTAGATPLAPPGLQPPAEDEARAAEPDPDYENLRRSAGGWSEAENGKEGTAKEGAPGGTPQAGGEAQPARAENEKDATTEKNKKRGFLFKAKKVAMMTQPPATPTLPRLPHDVVPADNRDDPEIILNTTTYYYSVRVFAGQEPSCVWAGWVTPDYHQHDMSFDLSKVRVVTVTMGDEQGNVHSSLKCSNCYMVWGGDFVSPGQQGRISHTDLVIGCLVDLATGLMTFTANGKESNTFFQVEPNTKLFPAVFVLPTHQNVIQFELGKQKNIMPLSAAMFQSERKNPAPQCPPRLEMQMLMPVSWSRMPNHFLQVETRRAGERLGWAVQCQEPLTMMALHIPEENRCMDILELSERLDLQRFHSHTLRLYRAVCALGNNRVAHALCSHVDQAQLLHALEDAHLPGPLRAGYYDLLISIHLESACRSRRSMLSEYIVPLTPETRAITLFPPGRSTENGHPRHGLPGVGVTTSLRPPHHFSPPCFVAALPAAGAAEAPARLSPAIPLEALRDKALRMLGEAVRDGGQHARDPVGGSVEFQFVPVLKLVSTLLVMGIFGDEDVKQILKMIEPEVFTEEEEEEDEEEEGEEEDEEEKEEDEEETAQEKEDEEKEEEEAAEGEKEEGLEEGLLQMKLPESVKLQMCHLLEYFCDQELQHRVESLAAFAERYVDKLQANQRSRYGLLIKAFSMTAAETARRTREFRSPPQEQINMLLQFKDGTDEEDCPLPEEIRQDLLDFHQDLLAHCGIQLDGEEEEPEEETTLGSRLMSLLEKVRLVKKKEEKPEEERSAEESKPRSLQELVSHMVVRWAQEDFVQSPELVRAMFSLLHRQYDGLGELLRALPRAYTISPSSVEDTMSLLECLGQIRSLLIVQMGPQEENLMIQSIGNIMNNKVFYQHPNLMRALGMHETVMEVMVNVLGGGESKEIRFPKMVTSCCRFLCYFCRISRQNQRSMFDHLSYLLENSGIGLGMQGSTPLDVAAASVIDNNELALALQEQDLEKVVSYLAGCGLQSCPMLVAKGYPDIGWNPCGGERYLDFLRFAVFVNGESVEENANVVVRLLIRKPECFGPALRGEGGSGLLAAIEEAIRISEDPARDGPGIRRDRRREHFGEEPPEENRVHLGHAIMSFYAALIDLLGRCAPEMHLIQAGKGEALRIRAILRSLVPLEDLVGIISLPLQIPTLGKDGALVQPKMSASFVPDHKASMVLFLDRVYGIENQDFLLHVLDVGFLPDMRAAASLDTATFSTTEMALALNRYLCLAVLPLITKCAPLFAGTEHRAIMVDSMLHTVYRLSRGRSLTKAQRDVIEDCLMSLCRYIRPSMLQHLLRRLVFDVPILNEFAKMPLKLLTNHYERCWKYYCLPTGWANFGVTSEEELHLTRKLFWGIFDSLAHKKYDPELYRMAMPCLCAIAGALPPDYVDASYSSKAEKKATVDAEGNFDPRPVETLNVIIPEKLDSFINKFAEYTHEKWAFDKIQNNWSYGENIDEELKTHPMLRPYKTFSEKDKEIYRWPIKESLKAMIAWEWTIEKAREGEEEKTEKKKTRKISQSAQTYDPREGYNPQPPDLSAVTLSRELQAMAEQLAENYHNTWGRKKKQELEAKGGGTHPLLVPYDTLTAKEKARDREKAQELLKFLQMNGYAVTRGLKDMELDSSSIEKRFAFGFLQQLLRWMDISQEFIAHLEAVVSSGRVEKSPHEQEIKFFAKILLPLINQYFTNHCLYFLSTPAKVLGSGGHASNKEKEMITSLFCKLAALVRHRVSLFGTDAPAVVNCLHILARSLDARTVMKSGPEIVKAGLRSFFESASEDIEKMVENLRLGKVSQARTQVKGVGQNLTYTTVALLPVLTTLFQHIAQHQFGDDVILDDVQVSCYRTLCSIYSLGTTKNTYVEKLRPALGECLARLAAAMPVAFLEPQLNEYNACSVYTTKSPRERAILGLPNSVEEMCPDIPVLERLMADIGGLAESGARYTEMPHVIEITLPMLCSYLPRWWERGPEAPPSALPAGAPPPCTAVTSDHLNSLLGNILRIIVNNLGIDEASWMKRLAVFAQPIVSRARPELLQSHFIPTIGRLRKRAGKVVSEEEQLRLEAKAEAQEGELLVRDEFSVLCRDLYALYPLLIRYVDNNRAQWLTEPNPSAEELFRMVGEIFIYWSKSHNFKREEQNFVVQNEINNMSFLTADNKSKMAKAGDIQSGGSDQERTKKKRRGDRYSVQTSLIVATLKKMLPIGLNMCAPTDQDLITLAKTRYALKDTDEEVREFLHNNLHLQGKVEGSPSLRWQMALYRGVPGREEDADDPEKIVRRVQEVSAVLYYLDQTEHPYKSKKAVWHKLLSKQRRRAVVACFRMTPLYNLPTHRACNMFLESYKAAWILTEDHSFEDRMIDDLSKAGEQEEEEEEVEEKKPDPLHQLVLHFSRTALTEKSKLDEDYLYMAYADIMAKSCHLEEGGENGEAEEEVEVSFEEKQMEKQRLLYQQARLHTRGAAEMVLQMISACKGETGAMVSSTLKLGISILNGGNAEVQQKMLDYLKDKKEVGFFQSIQALMQTCSVLDLNAFERQNKAEGLGMVNEDGTVINRQNGEKVMADDEFTQDLFRFLQLLCEGHNNDFQNYLRTQTGNTTTINIIICTVDYLLRLQESISDFYWYYSGKDVIEEQGKRNFSKAMSVAKQVFNSLTEYIQGPCTGNQQSLAHSRLWDAVVGFLHVFAHMMMKLAQDSSQIELLKELLDLQKDMVVMLLSLLEGNVVNGMIARQMVDMLVESSSNVEMILKFFDMFLKLKDIVGSEAFQDYVTDPRGLISKKDFQKAMDSQKQFSGPEIQFLLSCSEADENEMINCEEFANRFQEPARDIGFNVAVLLTNLSEHVPHDPRLHNFLELAESILEYFRPYLGRIEIMGASRRIERIYFEISETNRAQWEMPQVKESKRQFIFDVVNEGGEAEKMELFVSFCEDTIFEMQIAAQISEPEGEPETDEDEGAGAAEAGAEGAEEGAAGLEGTAATAAAGATARVVAAAGRALRGLSYRSLRRRVRRLRRLTAREAATAVAALLWAAVTRAGAAGAGAAAGALGLLWGSLFGGGLVEGAKKVTVTELLAGMPDPTSDEVHGEQPAGPGGDADGEGASEGAGDAAEGAGDEEEAVHEAGPGGADGAVAVTDGGPFRPEGAGGLGDMGDTTPAEPPTPEGSPILKRKLGVDGVEEELPPEPEPEPEPELEPEKADAENGEKEEVPEPTPEPPKKQAPPSPPPKKEEAGGEFWGELEVQRVKFLNYLSRNFYTLRFLALFLAFAINFILLFYKVSDSPPGEDDMEGSAAGDVSGAGSGGSSGWGLGAGEEAEGDEDENMVYYFLEESTGYMEPALRCLSLLHTLVAFLCIIGYNCLKVPLVIFKREKELARKLEFDGLYITEQPEDDDVKGQWDRLVLNTPSFPSNYWDKFVKRKVLDKHGDIYGRERIAELLGMDLATLEITAHNERKPNPPPGLLTWLMSIDVKYQIWKFGVIFTDNSFLYLGWYMVMSLLGHYNNFFFAAHLLDIAMGVKTLRTILSSVTHNGKQLVMTVGLLAVVVYLYTVVAFNFFRKFYNKSEDEDEPDMKCDDMMTCYLFHMYVGVRAGGGIGDEIEDPAGDEYELYRVVFDITFFFFVIVILLAIIQGLIIDAFGELRDQQEQVKEDMETKCFICGIGSDYFDTTPHGFETHTLEEHNLANYMFFLMYLINKDETEHTGQESYVWKMYQERCWDFFPAGDCFRKQYEDQLS	5038	P21817	C	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [1101], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.0105865]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
460	NM_000540.3(RYR1):c.7007G>A (p.Arg2336His)	133174	CA024662	NM_000540.3:c.7007G>A, NC_000019.10:g.38499223G>A, CM000681.2:g.38499223G>A, NC_000019.9:g.38989863G>A, CM000681.1:g.38989863G>A, NC_000019.8:g.43681703G>A, NG_008866.1:g.70524G>A, LRG_766:g.70524G>A, ENST00000599547.6:n.7007G>A, ENST00000359596.8:c.7007G>A, ENST00000355481.8:c.7007G>A, ENST00000359596.7:n.7007G>A, ENST00000360985.7:c.7004G>A, ENST00000594335.5:n.459G>A, NM_000540.2:c.7007G>A, LRG_766t1:c.7007G>A, NM_001042723.1:c.7007G>A, XM_006723317.1:c.7007G>A, XM_006723319.1:c.7007G>A, XM_011527204.1:c.7004G>A, XM_011527205.1:c.7007G>A, XM_006723317.2:c.7007G>A, XM_006723319.2:c.7007G>A, XM_011527205.2:c.7007G>A, XR_001753735.1:n.7090G>A, NM_001042723.2:c.7007G>A, NM_000540.3(RYR1):c.7007G>A (p.Arg2336His)	RYR1	malignant hyperthermia, susceptibility to, 1	MONDO:0007783	Autosomal dominant inheritance	Pathogenic	PS4, PS3_Moderate, PM1, PP1_Strong, PP3_Moderate	BA1, BS1	This pathogenicity assessment is relevant only for malignant hyperthermia susceptibility (MHS) inherited in an autosomal dominant pattern. Variants in RYR1 can also cause other myopathies inherited in an autosomal dominant pattern or in an autosomal recessive pattern. Some of these disorders may predispose individuals to malignant hyperthermia. RYR1 variants may also contribute to a malignant hyperthermia reaction in combination with other genetic and non-genetic factors and the clinician needs to consider such factors in making management decisions.This sequence variant predicts a substitution of arginine with histidine at codon 2336 of the RYR1 protein, p.(Arg2336His). This variant was not present in a large population database (gnomAD) at the time this variant was interpreted. This variant has been reported in 26 individuals with a personal or family history of an MH episode and a positive in vitro contracture test (IVCT) or caffeine halothane contracture test (CHCT) result (if the proband was unavailable for testing, a positive diagnostic test result in a mutation-positive relative was counted), PS4 (PMID: 30236257, 19191329, 24433488, 21455645, 23460944, 23558838, 23736090, 31559918). This variant segregates with IVCT status in over 10 individuals (PMID: 30236257, 19191329, 24433488). Functional study in HEK293 cells showed an increased sensitivity to RYR1 agonists, PS3_Moderate (PMID: 28403410). This variant resides in a region of RYR1 considered to be a hotspot for pathogenic variants that contribute to MHS, PM1 (PMID: 21118704). A REVEL score >0.85 (0.903) supports a pathogenic status for this variant, PP3_Moderate. This variant has been classified as Pathogenic. Criteria implemented: PS3_Moderate, PS4, PM1, PP1_Strong, PP3_Moderate.		Malignant Hyperthermia Susceptibility VCEP	https://clinicalgenome.org/docs/clingen-malignant-hyperthermia-susceptibility-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-for/	2022-07-10	2022-07-10	False	https://erepo.genome.network/evrepo/ui/classification/CA024662/MONDO:0007783/012	bad792cf-612e-4479-be9c-80fc5475d572	p.Arg2336His	Arg	2336	His	MGDAEGEDEVQFLRTDDEVVLQCSATVLKEQLKLCLAAEGFGNRLCFLEPTSNAQNVPPDLAICCFVLEQSLSVRALQEMLANTVEAGVESSQGGGHRTLLYGHAILLRHAHSRMYLSCLTTSRSMTDKLAFDVGLQEDATGEACWWTMHPASKQRSEGEKVRVGDDIILVSVSSERYLHLSTASGELQVDASFMQTLWNMNPICSRCEEGFVTGGHVLRLFHGHMDECLTISPADSDDQRRLVYYEGGAVCTHARSLWRLEPLRISWSGSHLRWGQPLRVRHVTTGQYLALTEDQGLVVVDASKAHTKATSFCFRISKEKLDVAPKRDVEGMGPPEIKYGESLCFVQHVASGLWLTYAAPDPKALRLGVLKKKAMLHQEGHMDDALSLTRCQQEESQAARMIHSTNGLYNQFIKSLDSFSGKPRGSGPPAGTALPIEGVILSLQDLIIYFEPPSEDLQHEEKQSKLRSLRNRQSLFQEEGMLSMVLNCIDRLNVYTTAAHFAEFAGEEAAESWKEIVNLLYELLASLIRGNRSNCALFSTNLDWLVSKLDRLEASSGILEVLYCVLIESPEVLNIIQENHIKSIISLLDKHGRNHKVLDVLCSLCVCNGVAVRSNQDLITENLLPGRELLLQTNLINYVTSIRPNIFVGRAEGTTQYSKWYFEVMVDEVTPFLTAQATHLRVGWALTEGYTPYPGAGEGWGGNGVGDDLYSYGFDGLHLWTGHVARPVTSPGQHLLAPEDVISCCLDLSVPSISFRINGCPVQGVFESFNLDGLFFPVVSFSAGVKVRFLLGGRHGEFKFLPPPGYAPCHEAVLPRERLHLEPIKEYRREGPRGPHLVGPSRCLSHTDFVPCPVDTVQIVLPPHLERIREKLAENIHELWALTRIEQGWTYGPVRDDNKRLHPCLVDFHSLPEPERNYNLQMSGETLKTLLALGCHVGMADEKAEDNLKKTKLPKTYMMSNGYKPAPLDLSHVRLTPAQTTLVDRLAENGHNVWARDRVGQGWSYSAVQDIPARRNPRLVPYRLLDEATKRSNRDSLCQAVRTLLGYGYNIEPPDQEPSQVENQSRCDRVRIFRAEKSYTVQSGRWYFEFEAVTTGEMRVGWARPELRPDVELGADELAYVFNGHRGQRWHLGSEPFGRPWQPGDVVGCMIDLTENTIIFTLNGEVLMSDSGSETAFREIEIGDGFLPVCSLGPGQVGHLNLGQDVSSLRFFAICGLQEGFEPFAINMQRPVTTWFSKGLPQFEPVPLEHPHYEVSRVDGTVDTPPCLRLTHRTWGSQNSLVEMLFLRLSLPVQFHQHFRCTAGATPLAPPGLQPPAEDEARAAEPDPDYENLRRSAGGWSEAENGKEGTAKEGAPGGTPQAGGEAQPARAENEKDATTEKNKKRGFLFKAKKVAMMTQPPATPTLPRLPHDVVPADNRDDPEIILNTTTYYYSVRVFAGQEPSCVWAGWVTPDYHQHDMSFDLSKVRVVTVTMGDEQGNVHSSLKCSNCYMVWGGDFVSPGQQGRISHTDLVIGCLVDLATGLMTFTANGKESNTFFQVEPNTKLFPAVFVLPTHQNVIQFELGKQKNIMPLSAAMFQSERKNPAPQCPPRLEMQMLMPVSWSRMPNHFLQVETRRAGERLGWAVQCQEPLTMMALHIPEENRCMDILELSERLDLQRFHSHTLRLYRAVCALGNNRVAHALCSHVDQAQLLHALEDAHLPGPLRAGYYDLLISIHLESACRSRRSMLSEYIVPLTPETRAITLFPPGRSTENGHPRHGLPGVGVTTSLRPPHHFSPPCFVAALPAAGAAEAPARLSPAIPLEALRDKALRMLGEAVRDGGQHARDPVGGSVEFQFVPVLKLVSTLLVMGIFGDEDVKQILKMIEPEVFTEEEEEEDEEEEGEEEDEEEKEEDEEETAQEKEDEEKEEEEAAEGEKEEGLEEGLLQMKLPESVKLQMCHLLEYFCDQELQHRVESLAAFAERYVDKLQANQRSRYGLLIKAFSMTAAETARRTREFRSPPQEQINMLLQFKDGTDEEDCPLPEEIRQDLLDFHQDLLAHCGIQLDGEEEEPEEETTLGSRLMSLLEKVRLVKKKEEKPEEERSAEESKPRSLQELVSHMVVRWAQEDFVQSPELVRAMFSLLHRQYDGLGELLRALPRAYTISPSSVEDTMSLLECLGQIRSLLIVQMGPQEENLMIQSIGNIMNNKVFYQHPNLMRALGMHETVMEVMVNVLGGGESKEIRFPKMVTSCCRFLCYFCRISRQNQRSMFDHLSYLLENSGIGLGMQGSTPLDVAAASVIDNNELALALQEQDLEKVVSYLAGCGLQSCPMLVAKGYPDIGWNPCGGERYLDFLRFAVFVNGESVEENANVVVRLLIRKPECFGPALRGEGGSGLLAAIEEAIRISEDPARDGPGIRRDRRREHFGEEPPEENRVHLGHAIMSFYAALIDLLGRCAPEMHLIQAGKGEALRIRAILRSLVPLEDLVGIISLPLQIPTLGKDGALVQPKMSASFVPDHKASMVLFLDRVYGIENQDFLLHVLDVGFLPDMRAAASLDTATFSTTEMALALNRYLCLAVLPLITKCAPLFAGTEHRAIMVDSMLHTVYRLSRGRSLTKAQRDVIEDCLMSLCRYIRPSMLQHLLRRLVFDVPILNEFAKMPLKLLTNHYERCWKYYCLPTGWANFGVTSEEELHLTRKLFWGIFDSLAHKKYDPELYRMAMPCLCAIAGALPPDYVDASYSSKAEKKATVDAEGNFDPRPVETLNVIIPEKLDSFINKFAEYTHEKWAFDKIQNNWSYGENIDEELKTHPMLRPYKTFSEKDKEIYRWPIKESLKAMIAWEWTIEKAREGEEEKTEKKKTRKISQSAQTYDPREGYNPQPPDLSAVTLSRELQAMAEQLAENYHNTWGRKKKQELEAKGGGTHPLLVPYDTLTAKEKARDREKAQELLKFLQMNGYAVTRGLKDMELDSSSIEKRFAFGFLQQLLRWMDISQEFIAHLEAVVSSGRVEKSPHEQEIKFFAKILLPLINQYFTNHCLYFLSTPAKVLGSGGHASNKEKEMITSLFCKLAALVRHRVSLFGTDAPAVVNCLHILARSLDARTVMKSGPEIVKAGLRSFFESASEDIEKMVENLRLGKVSQARTQVKGVGQNLTYTTVALLPVLTTLFQHIAQHQFGDDVILDDVQVSCYRTLCSIYSLGTTKNTYVEKLRPALGECLARLAAAMPVAFLEPQLNEYNACSVYTTKSPRERAILGLPNSVEEMCPDIPVLERLMADIGGLAESGARYTEMPHVIEITLPMLCSYLPRWWERGPEAPPSALPAGAPPPCTAVTSDHLNSLLGNILRIIVNNLGIDEASWMKRLAVFAQPIVSRARPELLQSHFIPTIGRLRKRAGKVVSEEEQLRLEAKAEAQEGELLVRDEFSVLCRDLYALYPLLIRYVDNNRAQWLTEPNPSAEELFRMVGEIFIYWSKSHNFKREEQNFVVQNEINNMSFLTADNKSKMAKAGDIQSGGSDQERTKKKRRGDRYSVQTSLIVATLKKMLPIGLNMCAPTDQDLITLAKTRYALKDTDEEVREFLHNNLHLQGKVEGSPSLRWQMALYRGVPGREEDADDPEKIVRRVQEVSAVLYYLDQTEHPYKSKKAVWHKLLSKQRRRAVVACFRMTPLYNLPTHRACNMFLESYKAAWILTEDHSFEDRMIDDLSKAGEQEEEEEEVEEKKPDPLHQLVLHFSRTALTEKSKLDEDYLYMAYADIMAKSCHLEEGGENGEAEEEVEVSFEEKQMEKQRLLYQQARLHTRGAAEMVLQMISACKGETGAMVSSTLKLGISILNGGNAEVQQKMLDYLKDKKEVGFFQSIQALMQTCSVLDLNAFERQNKAEGLGMVNEDGTVINRQNGEKVMADDEFTQDLFRFLQLLCEGHNNDFQNYLRTQTGNTTTINIIICTVDYLLRLQESISDFYWYYSGKDVIEEQGKRNFSKAMSVAKQVFNSLTEYIQGPCTGNQQSLAHSRLWDAVVGFLHVFAHMMMKLAQDSSQIELLKELLDLQKDMVVMLLSLLEGNVVNGMIARQMVDMLVESSSNVEMILKFFDMFLKLKDIVGSEAFQDYVTDPRGLISKKDFQKAMDSQKQFSGPEIQFLLSCSEADENEMINCEEFANRFQEPARDIGFNVAVLLTNLSEHVPHDPRLHNFLELAESILEYFRPYLGRIEIMGASRRIERIYFEISETNRAQWEMPQVKESKRQFIFDVVNEGGEAEKMELFVSFCEDTIFEMQIAAQISEPEGEPETDEDEGAGAAEAGAEGAEEGAAGLEGTAATAAAGATARVVAAAGRALRGLSYRSLRRRVRRLRRLTAREAATAVAALLWAAVTRAGAAGAGAAAGALGLLWGSLFGGGLVEGAKKVTVTELLAGMPDPTSDEVHGEQPAGPGGDADGEGASEGAGDAAEGAGDEEEAVHEAGPGGADGAVAVTDGGPFRPEGAGGLGDMGDTTPAEPPTPEGSPILKRKLGVDGVEEELPPEPEPEPEPELEPEKADAENGEKEEVPEPTPEPPKKQAPPSPPPKKEEAGGEFWGELEVQRVKFLNYLSRNFYTLRFLALFLAFAINFILLFYKVSDSPPGEDDMEGSAAGDVSGAGSGGSSGWGLGAGEEAEGDEDENMVYYFLEESTGYMEPALRCLSLLHTLVAFLCIIGYNCLKVPLVIFKREKELARKLEFDGLYITEQPEDDDVKGQWDRLVLNTPSFPSNYWDKFVKRKVLDKHGDIYGRERIAELLGMDLATLEITAHNERKPNPPPGLLTWLMSIDVKYQIWKFGVIFTDNSFLYLGWYMVMSLLGHYNNFFFAAHLLDIAMGVKTLRTILSSVTHNGKQLVMTVGLLAVVVYLYTVVAFNFFRKFYNKSEDEDEPDMKCDDMMTCYLFHMYVGVRAGGGIGDEIEDPAGDEYELYRVVFDITFFFFVIVILLAIIQGLIIDAFGELRDQQEQVKEDMETKCFICGIGSDYFDTTPHGFETHTLEEHNLANYMFFLMYLINKDETEHTGQESYVWKMYQERCWDFFPAGDCFRKQYEDQLS	5038	P21817	H	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
461	NM_000540.3(RYR1):c.14477C>T (p.Thr4826Ile)	12978	CA024154	NM_000540.3:c.14477C>T, NC_000019.10:g.38580094C>T, CM000681.2:g.38580094C>T, NC_000019.9:g.39070734C>T, CM000681.1:g.39070734C>T, NC_000019.8:g.43762574C>T, NG_008866.1:g.151395C>T, LRG_766:g.151395C>T, ENST00000593677.2:n.1413C>T, ENST00000688602.1:n.2810C>T, ENST00000689936.1:n.2782C>T, ENST00000359596.8:c.14477C>T, ENST00000355481.8:c.14462C>T, ENST00000359596.7:n.14477C>T, ENST00000360985.7:c.14459C>T, NM_000540.2:c.14477C>T, LRG_766t1:c.14477C>T, NM_001042723.1:c.14462C>T, XM_006723317.1:c.14459C>T, XM_006723319.1:c.14444C>T, XM_011527204.1:c.14474C>T, XM_011527205.1:c.14390C>T, XM_006723317.2:c.14459C>T, XM_006723319.2:c.14444C>T, XM_011527205.2:c.14390C>T, NM_001042723.2:c.14462C>T, NM_000540.3(RYR1):c.14477C>T (p.Thr4826Ile)	RYR1	malignant hyperthermia, susceptibility to, 1	MONDO:0007783	Autosomal dominant inheritance	Pathogenic	PM1_Supporting, PS4, PS3, PP1_Strong, PP3_Moderate	BA1, BS1	This pathogenicity assessment is relevant only for malignant hyperthermia susceptibility (MHS) inherited in an autosomal dominant pattern. Variants in RYR1 can also cause other myopathies inherited in an autosomal dominant pattern or in an autosomal recessive pattern. Some of these disorders may predispose individuals to malignant hyperthermia. RYR1 variants may also contribute to a malignant hyperthermia reaction in combination with other genetic and non-genetic factors and the clinician needs to consider such factors in making management decisions.This sequence variant predicts a substitution of threonine with isoleucine at codon 4826 of the RYR1 protein, p.(Thr4826Ile). The maximum allele frequency for this variant among the six major gnomAD populations is NFE: 0.000009, a frequency consistent with pathogenicity for MHS. This variant has been reported in 14 unrelated individuals who have a personal or family history of a malignant hyperthermia reaction, all of these individuals had a positive in vitro contracture test (IVCT) or caffeine halothane contracture test (CHCT) result (if the proband was unavailable for testing, a positive diagnostic test result in a mutation-positive relative was counted), PS4 (PMID: 30236257, 10888602, 16163667, 18564801, 25960145). This variant segregates with MHS in seven families, PP1_Strong ( PMID: 30236257). Two studies using a knock-in mouse model support pathogenicity of this variant. One study demonstrated a malignant hyperthermia reaction in response to agonist (PMID: 22131268). The other ex vivo study showed increased response to agonist with increased calcium release (PMID: 22139840), PS3_Strong. Studies in dyspedic myotubes also show increased sensitivity to RYR1 agonists (PMID: 12732639, 15347586). This variant resides in a region of RYR1 considered to be a hotspot for pathogenic variants that contribute to MHS, PM1_Sup (PMID: 21118704). A REVEL score >0.85 (0.977) supports a pathogenic status for this variant, PP3_Moderate. This variant has been classified as Pathogenic. Criteria implemented: PS3, PS4, PM1_Supporting, PP1_Strong, PP3_Moderate.		Malignant Hyperthermia Susceptibility VCEP	https://clinicalgenome.org/docs/clingen-malignant-hyperthermia-susceptibility-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-for/	2021-03-22	2022-07-11	False	https://erepo.genome.network/evrepo/ui/classification/CA024154/MONDO:0007783/012	ef1c927e-3971-4640-8125-a82897971b0c	p.Thr4826Ile	Thr	4826	Ile	MGDAEGEDEVQFLRTDDEVVLQCSATVLKEQLKLCLAAEGFGNRLCFLEPTSNAQNVPPDLAICCFVLEQSLSVRALQEMLANTVEAGVESSQGGGHRTLLYGHAILLRHAHSRMYLSCLTTSRSMTDKLAFDVGLQEDATGEACWWTMHPASKQRSEGEKVRVGDDIILVSVSSERYLHLSTASGELQVDASFMQTLWNMNPICSRCEEGFVTGGHVLRLFHGHMDECLTISPADSDDQRRLVYYEGGAVCTHARSLWRLEPLRISWSGSHLRWGQPLRVRHVTTGQYLALTEDQGLVVVDASKAHTKATSFCFRISKEKLDVAPKRDVEGMGPPEIKYGESLCFVQHVASGLWLTYAAPDPKALRLGVLKKKAMLHQEGHMDDALSLTRCQQEESQAARMIHSTNGLYNQFIKSLDSFSGKPRGSGPPAGTALPIEGVILSLQDLIIYFEPPSEDLQHEEKQSKLRSLRNRQSLFQEEGMLSMVLNCIDRLNVYTTAAHFAEFAGEEAAESWKEIVNLLYELLASLIRGNRSNCALFSTNLDWLVSKLDRLEASSGILEVLYCVLIESPEVLNIIQENHIKSIISLLDKHGRNHKVLDVLCSLCVCNGVAVRSNQDLITENLLPGRELLLQTNLINYVTSIRPNIFVGRAEGTTQYSKWYFEVMVDEVTPFLTAQATHLRVGWALTEGYTPYPGAGEGWGGNGVGDDLYSYGFDGLHLWTGHVARPVTSPGQHLLAPEDVISCCLDLSVPSISFRINGCPVQGVFESFNLDGLFFPVVSFSAGVKVRFLLGGRHGEFKFLPPPGYAPCHEAVLPRERLHLEPIKEYRREGPRGPHLVGPSRCLSHTDFVPCPVDTVQIVLPPHLERIREKLAENIHELWALTRIEQGWTYGPVRDDNKRLHPCLVDFHSLPEPERNYNLQMSGETLKTLLALGCHVGMADEKAEDNLKKTKLPKTYMMSNGYKPAPLDLSHVRLTPAQTTLVDRLAENGHNVWARDRVGQGWSYSAVQDIPARRNPRLVPYRLLDEATKRSNRDSLCQAVRTLLGYGYNIEPPDQEPSQVENQSRCDRVRIFRAEKSYTVQSGRWYFEFEAVTTGEMRVGWARPELRPDVELGADELAYVFNGHRGQRWHLGSEPFGRPWQPGDVVGCMIDLTENTIIFTLNGEVLMSDSGSETAFREIEIGDGFLPVCSLGPGQVGHLNLGQDVSSLRFFAICGLQEGFEPFAINMQRPVTTWFSKGLPQFEPVPLEHPHYEVSRVDGTVDTPPCLRLTHRTWGSQNSLVEMLFLRLSLPVQFHQHFRCTAGATPLAPPGLQPPAEDEARAAEPDPDYENLRRSAGGWSEAENGKEGTAKEGAPGGTPQAGGEAQPARAENEKDATTEKNKKRGFLFKAKKVAMMTQPPATPTLPRLPHDVVPADNRDDPEIILNTTTYYYSVRVFAGQEPSCVWAGWVTPDYHQHDMSFDLSKVRVVTVTMGDEQGNVHSSLKCSNCYMVWGGDFVSPGQQGRISHTDLVIGCLVDLATGLMTFTANGKESNTFFQVEPNTKLFPAVFVLPTHQNVIQFELGKQKNIMPLSAAMFQSERKNPAPQCPPRLEMQMLMPVSWSRMPNHFLQVETRRAGERLGWAVQCQEPLTMMALHIPEENRCMDILELSERLDLQRFHSHTLRLYRAVCALGNNRVAHALCSHVDQAQLLHALEDAHLPGPLRAGYYDLLISIHLESACRSRRSMLSEYIVPLTPETRAITLFPPGRSTENGHPRHGLPGVGVTTSLRPPHHFSPPCFVAALPAAGAAEAPARLSPAIPLEALRDKALRMLGEAVRDGGQHARDPVGGSVEFQFVPVLKLVSTLLVMGIFGDEDVKQILKMIEPEVFTEEEEEEDEEEEGEEEDEEEKEEDEEETAQEKEDEEKEEEEAAEGEKEEGLEEGLLQMKLPESVKLQMCHLLEYFCDQELQHRVESLAAFAERYVDKLQANQRSRYGLLIKAFSMTAAETARRTREFRSPPQEQINMLLQFKDGTDEEDCPLPEEIRQDLLDFHQDLLAHCGIQLDGEEEEPEEETTLGSRLMSLLEKVRLVKKKEEKPEEERSAEESKPRSLQELVSHMVVRWAQEDFVQSPELVRAMFSLLHRQYDGLGELLRALPRAYTISPSSVEDTMSLLECLGQIRSLLIVQMGPQEENLMIQSIGNIMNNKVFYQHPNLMRALGMHETVMEVMVNVLGGGESKEIRFPKMVTSCCRFLCYFCRISRQNQRSMFDHLSYLLENSGIGLGMQGSTPLDVAAASVIDNNELALALQEQDLEKVVSYLAGCGLQSCPMLVAKGYPDIGWNPCGGERYLDFLRFAVFVNGESVEENANVVVRLLIRKPECFGPALRGEGGSGLLAAIEEAIRISEDPARDGPGIRRDRRREHFGEEPPEENRVHLGHAIMSFYAALIDLLGRCAPEMHLIQAGKGEALRIRAILRSLVPLEDLVGIISLPLQIPTLGKDGALVQPKMSASFVPDHKASMVLFLDRVYGIENQDFLLHVLDVGFLPDMRAAASLDTATFSTTEMALALNRYLCLAVLPLITKCAPLFAGTEHRAIMVDSMLHTVYRLSRGRSLTKAQRDVIEDCLMSLCRYIRPSMLQHLLRRLVFDVPILNEFAKMPLKLLTNHYERCWKYYCLPTGWANFGVTSEEELHLTRKLFWGIFDSLAHKKYDPELYRMAMPCLCAIAGALPPDYVDASYSSKAEKKATVDAEGNFDPRPVETLNVIIPEKLDSFINKFAEYTHEKWAFDKIQNNWSYGENIDEELKTHPMLRPYKTFSEKDKEIYRWPIKESLKAMIAWEWTIEKAREGEEEKTEKKKTRKISQSAQTYDPREGYNPQPPDLSAVTLSRELQAMAEQLAENYHNTWGRKKKQELEAKGGGTHPLLVPYDTLTAKEKARDREKAQELLKFLQMNGYAVTRGLKDMELDSSSIEKRFAFGFLQQLLRWMDISQEFIAHLEAVVSSGRVEKSPHEQEIKFFAKILLPLINQYFTNHCLYFLSTPAKVLGSGGHASNKEKEMITSLFCKLAALVRHRVSLFGTDAPAVVNCLHILARSLDARTVMKSGPEIVKAGLRSFFESASEDIEKMVENLRLGKVSQARTQVKGVGQNLTYTTVALLPVLTTLFQHIAQHQFGDDVILDDVQVSCYRTLCSIYSLGTTKNTYVEKLRPALGECLARLAAAMPVAFLEPQLNEYNACSVYTTKSPRERAILGLPNSVEEMCPDIPVLERLMADIGGLAESGARYTEMPHVIEITLPMLCSYLPRWWERGPEAPPSALPAGAPPPCTAVTSDHLNSLLGNILRIIVNNLGIDEASWMKRLAVFAQPIVSRARPELLQSHFIPTIGRLRKRAGKVVSEEEQLRLEAKAEAQEGELLVRDEFSVLCRDLYALYPLLIRYVDNNRAQWLTEPNPSAEELFRMVGEIFIYWSKSHNFKREEQNFVVQNEINNMSFLTADNKSKMAKAGDIQSGGSDQERTKKKRRGDRYSVQTSLIVATLKKMLPIGLNMCAPTDQDLITLAKTRYALKDTDEEVREFLHNNLHLQGKVEGSPSLRWQMALYRGVPGREEDADDPEKIVRRVQEVSAVLYYLDQTEHPYKSKKAVWHKLLSKQRRRAVVACFRMTPLYNLPTHRACNMFLESYKAAWILTEDHSFEDRMIDDLSKAGEQEEEEEEVEEKKPDPLHQLVLHFSRTALTEKSKLDEDYLYMAYADIMAKSCHLEEGGENGEAEEEVEVSFEEKQMEKQRLLYQQARLHTRGAAEMVLQMISACKGETGAMVSSTLKLGISILNGGNAEVQQKMLDYLKDKKEVGFFQSIQALMQTCSVLDLNAFERQNKAEGLGMVNEDGTVINRQNGEKVMADDEFTQDLFRFLQLLCEGHNNDFQNYLRTQTGNTTTINIIICTVDYLLRLQESISDFYWYYSGKDVIEEQGKRNFSKAMSVAKQVFNSLTEYIQGPCTGNQQSLAHSRLWDAVVGFLHVFAHMMMKLAQDSSQIELLKELLDLQKDMVVMLLSLLEGNVVNGMIARQMVDMLVESSSNVEMILKFFDMFLKLKDIVGSEAFQDYVTDPRGLISKKDFQKAMDSQKQFSGPEIQFLLSCSEADENEMINCEEFANRFQEPARDIGFNVAVLLTNLSEHVPHDPRLHNFLELAESILEYFRPYLGRIEIMGASRRIERIYFEISETNRAQWEMPQVKESKRQFIFDVVNEGGEAEKMELFVSFCEDTIFEMQIAAQISEPEGEPETDEDEGAGAAEAGAEGAEEGAAGLEGTAATAAAGATARVVAAAGRALRGLSYRSLRRRVRRLRRLTAREAATAVAALLWAAVTRAGAAGAGAAAGALGLLWGSLFGGGLVEGAKKVTVTELLAGMPDPTSDEVHGEQPAGPGGDADGEGASEGAGDAAEGAGDEEEAVHEAGPGGADGAVAVTDGGPFRPEGAGGLGDMGDTTPAEPPTPEGSPILKRKLGVDGVEEELPPEPEPEPEPELEPEKADAENGEKEEVPEPTPEPPKKQAPPSPPPKKEEAGGEFWGELEVQRVKFLNYLSRNFYTLRFLALFLAFAINFILLFYKVSDSPPGEDDMEGSAAGDVSGAGSGGSSGWGLGAGEEAEGDEDENMVYYFLEESTGYMEPALRCLSLLHTLVAFLCIIGYNCLKVPLVIFKREKELARKLEFDGLYITEQPEDDDVKGQWDRLVLNTPSFPSNYWDKFVKRKVLDKHGDIYGRERIAELLGMDLATLEITAHNERKPNPPPGLLTWLMSIDVKYQIWKFGVIFTDNSFLYLGWYMVMSLLGHYNNFFFAAHLLDIAMGVKTLRTILSSVTHNGKQLVMTVGLLAVVVYLYTVVAFNFFRKFYNKSEDEDEPDMKCDDMMTCYLFHMYVGVRAGGGIGDEIEDPAGDEYELYRVVFDITFFFFVIVILLAIIQGLIIDAFGELRDQQEQVKEDMETKCFICGIGSDYFDTTPHGFETHTLEEHNLANYMFFLMYLINKDETEHTGQESYVWKMYQERCWDFFPAGDCFRKQYEDQLS	5038	P21817	I	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [1490], 'DISULFID_gain': [], 'DISULFID_loss_score': array([-0.00212955]), 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
462	NM_000540.3(RYR1):c.7361G>A (p.Arg2454His)	65980	CA024781	NM_000540.3:c.7361G>A, NC_000019.10:g.38500643G>A, CM000681.2:g.38500643G>A, NC_000019.9:g.38991283G>A, CM000681.1:g.38991283G>A, NC_000019.8:g.43683123G>A, NG_008866.1:g.71944G>A, LRG_766:g.71944G>A, ENST00000599547.6:n.7361G>A, ENST00000359596.8:c.7361G>A, ENST00000355481.8:c.7361G>A, ENST00000359596.7:n.7361G>A, ENST00000360985.7:c.7358G>A, ENST00000594335.5:n.813G>A, NM_000540.2:c.7361G>A, LRG_766t1:c.7361G>A, NM_001042723.1:c.7361G>A, XM_006723317.1:c.7361G>A, XM_006723319.1:c.7361G>A, XM_011527204.1:c.7358G>A, XM_011527205.1:c.7361G>A, XM_006723317.2:c.7361G>A, XM_006723319.2:c.7361G>A, XM_011527205.2:c.7361G>A, XR_001753735.1:n.7444G>A, NM_001042723.2:c.7361G>A, NM_000540.3(RYR1):c.7361G>A (p.Arg2454His)	RYR1	malignant hyperthermia, susceptibility to, 1	MONDO:0007783	Autosomal dominant inheritance	Pathogenic	PS4, PS3_Moderate, BS2_Supporting, PM1, PP1_Strong, PP3_Moderate		This pathogenicity assessment is relevant only for malignant hyperthermia susceptibility (MHS) inherited in an autosomal dominant pattern. Variants in RYR1 can also cause other myopathies inherited in an autosomal dominant pattern or in an autosomal recessive pattern. Some of these disorders may predispose individuals to malignant hyperthermia. RYR1 variants may also contribute to a malignant hyperthermia reaction in combination with other genetic and non-genetic factors and the clinician needs to consider such factors in making management decisions.This sequence variant predicts a substitution of arginine with histidine at codon 2454 of the RYR1 protein, p.(Arg2454His). The maximum allele frequency for this variant among the six major gnomAD populations is AFR: 0.000062, a frequency consistent with pathogenicity for MHS. This variant has been reported in 34 unrelated individuals who have a personal or family history of a malignant hyperthermia reaction, all of these individuals had a positive in vitro contracture test (IVCT) or caffeine halothane contracture test (CHCT) result (if the proband was unavailable for testing, a positive diagnostic test result in a mutation-positive relative was counted, PS4 (PMID: 30236257, 12059893, 16163667, 24433488, 11575529, 10051009, 10823104, 17081152, 20618998, 21455645, 23460944, 23558838, 25960145). This variant has been identified in an individual with a negative IVCT/CHCT result, BS2_Moderate (PMID: 30236257).Functional studies in HEK293 cells show an increased sensitivity to RYR1 agonists, PS3_Moderate (PMID: 27586648). An ex vivo assay in patient derived immortalized lymphoblastoid cells also shows an increased sensitivity to RYR1 agonists (PMID: 19191333). This variant resides in a region of RYR1 considered to be a hotspot for pathogenic variants that contribute to MHS, PM1 (PMID: 21118704). This variant segregates with MHS in at least 11 individuals/families PP1_Strong (PMID: 12059893, 10051009). A REVEL score >0.85 (0.923) supports a pathogenic status for this variant, PP3_Moderate. Based on using Bayes to combine criteria this variant is assessed as Pathogenic, (PMID: 29300386). Criteria implemented: PS3_Moderate, PS4, PM1, PP1_Strong, PP3_Moderate, BS2_Moderate.		Malignant Hyperthermia Susceptibility VCEP	https://clinicalgenome.org/docs/clingen-malignant-hyperthermia-susceptibility-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-for/	2021-03-19	2022-07-11	False	https://erepo.genome.network/evrepo/ui/classification/CA024781/MONDO:0007783/012	bcdaf173-ea83-4748-b137-4d59e12e9e65	p.Arg2454His	Arg	2454	His	MGDAEGEDEVQFLRTDDEVVLQCSATVLKEQLKLCLAAEGFGNRLCFLEPTSNAQNVPPDLAICCFVLEQSLSVRALQEMLANTVEAGVESSQGGGHRTLLYGHAILLRHAHSRMYLSCLTTSRSMTDKLAFDVGLQEDATGEACWWTMHPASKQRSEGEKVRVGDDIILVSVSSERYLHLSTASGELQVDASFMQTLWNMNPICSRCEEGFVTGGHVLRLFHGHMDECLTISPADSDDQRRLVYYEGGAVCTHARSLWRLEPLRISWSGSHLRWGQPLRVRHVTTGQYLALTEDQGLVVVDASKAHTKATSFCFRISKEKLDVAPKRDVEGMGPPEIKYGESLCFVQHVASGLWLTYAAPDPKALRLGVLKKKAMLHQEGHMDDALSLTRCQQEESQAARMIHSTNGLYNQFIKSLDSFSGKPRGSGPPAGTALPIEGVILSLQDLIIYFEPPSEDLQHEEKQSKLRSLRNRQSLFQEEGMLSMVLNCIDRLNVYTTAAHFAEFAGEEAAESWKEIVNLLYELLASLIRGNRSNCALFSTNLDWLVSKLDRLEASSGILEVLYCVLIESPEVLNIIQENHIKSIISLLDKHGRNHKVLDVLCSLCVCNGVAVRSNQDLITENLLPGRELLLQTNLINYVTSIRPNIFVGRAEGTTQYSKWYFEVMVDEVTPFLTAQATHLRVGWALTEGYTPYPGAGEGWGGNGVGDDLYSYGFDGLHLWTGHVARPVTSPGQHLLAPEDVISCCLDLSVPSISFRINGCPVQGVFESFNLDGLFFPVVSFSAGVKVRFLLGGRHGEFKFLPPPGYAPCHEAVLPRERLHLEPIKEYRREGPRGPHLVGPSRCLSHTDFVPCPVDTVQIVLPPHLERIREKLAENIHELWALTRIEQGWTYGPVRDDNKRLHPCLVDFHSLPEPERNYNLQMSGETLKTLLALGCHVGMADEKAEDNLKKTKLPKTYMMSNGYKPAPLDLSHVRLTPAQTTLVDRLAENGHNVWARDRVGQGWSYSAVQDIPARRNPRLVPYRLLDEATKRSNRDSLCQAVRTLLGYGYNIEPPDQEPSQVENQSRCDRVRIFRAEKSYTVQSGRWYFEFEAVTTGEMRVGWARPELRPDVELGADELAYVFNGHRGQRWHLGSEPFGRPWQPGDVVGCMIDLTENTIIFTLNGEVLMSDSGSETAFREIEIGDGFLPVCSLGPGQVGHLNLGQDVSSLRFFAICGLQEGFEPFAINMQRPVTTWFSKGLPQFEPVPLEHPHYEVSRVDGTVDTPPCLRLTHRTWGSQNSLVEMLFLRLSLPVQFHQHFRCTAGATPLAPPGLQPPAEDEARAAEPDPDYENLRRSAGGWSEAENGKEGTAKEGAPGGTPQAGGEAQPARAENEKDATTEKNKKRGFLFKAKKVAMMTQPPATPTLPRLPHDVVPADNRDDPEIILNTTTYYYSVRVFAGQEPSCVWAGWVTPDYHQHDMSFDLSKVRVVTVTMGDEQGNVHSSLKCSNCYMVWGGDFVSPGQQGRISHTDLVIGCLVDLATGLMTFTANGKESNTFFQVEPNTKLFPAVFVLPTHQNVIQFELGKQKNIMPLSAAMFQSERKNPAPQCPPRLEMQMLMPVSWSRMPNHFLQVETRRAGERLGWAVQCQEPLTMMALHIPEENRCMDILELSERLDLQRFHSHTLRLYRAVCALGNNRVAHALCSHVDQAQLLHALEDAHLPGPLRAGYYDLLISIHLESACRSRRSMLSEYIVPLTPETRAITLFPPGRSTENGHPRHGLPGVGVTTSLRPPHHFSPPCFVAALPAAGAAEAPARLSPAIPLEALRDKALRMLGEAVRDGGQHARDPVGGSVEFQFVPVLKLVSTLLVMGIFGDEDVKQILKMIEPEVFTEEEEEEDEEEEGEEEDEEEKEEDEEETAQEKEDEEKEEEEAAEGEKEEGLEEGLLQMKLPESVKLQMCHLLEYFCDQELQHRVESLAAFAERYVDKLQANQRSRYGLLIKAFSMTAAETARRTREFRSPPQEQINMLLQFKDGTDEEDCPLPEEIRQDLLDFHQDLLAHCGIQLDGEEEEPEEETTLGSRLMSLLEKVRLVKKKEEKPEEERSAEESKPRSLQELVSHMVVRWAQEDFVQSPELVRAMFSLLHRQYDGLGELLRALPRAYTISPSSVEDTMSLLECLGQIRSLLIVQMGPQEENLMIQSIGNIMNNKVFYQHPNLMRALGMHETVMEVMVNVLGGGESKEIRFPKMVTSCCRFLCYFCRISRQNQRSMFDHLSYLLENSGIGLGMQGSTPLDVAAASVIDNNELALALQEQDLEKVVSYLAGCGLQSCPMLVAKGYPDIGWNPCGGERYLDFLRFAVFVNGESVEENANVVVRLLIRKPECFGPALRGEGGSGLLAAIEEAIRISEDPARDGPGIRRDRRREHFGEEPPEENRVHLGHAIMSFYAALIDLLGRCAPEMHLIQAGKGEALRIRAILRSLVPLEDLVGIISLPLQIPTLGKDGALVQPKMSASFVPDHKASMVLFLDRVYGIENQDFLLHVLDVGFLPDMRAAASLDTATFSTTEMALALNRYLCLAVLPLITKCAPLFAGTEHRAIMVDSMLHTVYRLSRGRSLTKAQRDVIEDCLMSLCRYIRPSMLQHLLRRLVFDVPILNEFAKMPLKLLTNHYERCWKYYCLPTGWANFGVTSEEELHLTRKLFWGIFDSLAHKKYDPELYRMAMPCLCAIAGALPPDYVDASYSSKAEKKATVDAEGNFDPRPVETLNVIIPEKLDSFINKFAEYTHEKWAFDKIQNNWSYGENIDEELKTHPMLRPYKTFSEKDKEIYRWPIKESLKAMIAWEWTIEKAREGEEEKTEKKKTRKISQSAQTYDPREGYNPQPPDLSAVTLSRELQAMAEQLAENYHNTWGRKKKQELEAKGGGTHPLLVPYDTLTAKEKARDREKAQELLKFLQMNGYAVTRGLKDMELDSSSIEKRFAFGFLQQLLRWMDISQEFIAHLEAVVSSGRVEKSPHEQEIKFFAKILLPLINQYFTNHCLYFLSTPAKVLGSGGHASNKEKEMITSLFCKLAALVRHRVSLFGTDAPAVVNCLHILARSLDARTVMKSGPEIVKAGLRSFFESASEDIEKMVENLRLGKVSQARTQVKGVGQNLTYTTVALLPVLTTLFQHIAQHQFGDDVILDDVQVSCYRTLCSIYSLGTTKNTYVEKLRPALGECLARLAAAMPVAFLEPQLNEYNACSVYTTKSPRERAILGLPNSVEEMCPDIPVLERLMADIGGLAESGARYTEMPHVIEITLPMLCSYLPRWWERGPEAPPSALPAGAPPPCTAVTSDHLNSLLGNILRIIVNNLGIDEASWMKRLAVFAQPIVSRARPELLQSHFIPTIGRLRKRAGKVVSEEEQLRLEAKAEAQEGELLVRDEFSVLCRDLYALYPLLIRYVDNNRAQWLTEPNPSAEELFRMVGEIFIYWSKSHNFKREEQNFVVQNEINNMSFLTADNKSKMAKAGDIQSGGSDQERTKKKRRGDRYSVQTSLIVATLKKMLPIGLNMCAPTDQDLITLAKTRYALKDTDEEVREFLHNNLHLQGKVEGSPSLRWQMALYRGVPGREEDADDPEKIVRRVQEVSAVLYYLDQTEHPYKSKKAVWHKLLSKQRRRAVVACFRMTPLYNLPTHRACNMFLESYKAAWILTEDHSFEDRMIDDLSKAGEQEEEEEEVEEKKPDPLHQLVLHFSRTALTEKSKLDEDYLYMAYADIMAKSCHLEEGGENGEAEEEVEVSFEEKQMEKQRLLYQQARLHTRGAAEMVLQMISACKGETGAMVSSTLKLGISILNGGNAEVQQKMLDYLKDKKEVGFFQSIQALMQTCSVLDLNAFERQNKAEGLGMVNEDGTVINRQNGEKVMADDEFTQDLFRFLQLLCEGHNNDFQNYLRTQTGNTTTINIIICTVDYLLRLQESISDFYWYYSGKDVIEEQGKRNFSKAMSVAKQVFNSLTEYIQGPCTGNQQSLAHSRLWDAVVGFLHVFAHMMMKLAQDSSQIELLKELLDLQKDMVVMLLSLLEGNVVNGMIARQMVDMLVESSSNVEMILKFFDMFLKLKDIVGSEAFQDYVTDPRGLISKKDFQKAMDSQKQFSGPEIQFLLSCSEADENEMINCEEFANRFQEPARDIGFNVAVLLTNLSEHVPHDPRLHNFLELAESILEYFRPYLGRIEIMGASRRIERIYFEISETNRAQWEMPQVKESKRQFIFDVVNEGGEAEKMELFVSFCEDTIFEMQIAAQISEPEGEPETDEDEGAGAAEAGAEGAEEGAAGLEGTAATAAAGATARVVAAAGRALRGLSYRSLRRRVRRLRRLTAREAATAVAALLWAAVTRAGAAGAGAAAGALGLLWGSLFGGGLVEGAKKVTVTELLAGMPDPTSDEVHGEQPAGPGGDADGEGASEGAGDAAEGAGDEEEAVHEAGPGGADGAVAVTDGGPFRPEGAGGLGDMGDTTPAEPPTPEGSPILKRKLGVDGVEEELPPEPEPEPEPELEPEKADAENGEKEEVPEPTPEPPKKQAPPSPPPKKEEAGGEFWGELEVQRVKFLNYLSRNFYTLRFLALFLAFAINFILLFYKVSDSPPGEDDMEGSAAGDVSGAGSGGSSGWGLGAGEEAEGDEDENMVYYFLEESTGYMEPALRCLSLLHTLVAFLCIIGYNCLKVPLVIFKREKELARKLEFDGLYITEQPEDDDVKGQWDRLVLNTPSFPSNYWDKFVKRKVLDKHGDIYGRERIAELLGMDLATLEITAHNERKPNPPPGLLTWLMSIDVKYQIWKFGVIFTDNSFLYLGWYMVMSLLGHYNNFFFAAHLLDIAMGVKTLRTILSSVTHNGKQLVMTVGLLAVVVYLYTVVAFNFFRKFYNKSEDEDEPDMKCDDMMTCYLFHMYVGVRAGGGIGDEIEDPAGDEYELYRVVFDITFFFFVIVILLAIIQGLIIDAFGELRDQQEQVKEDMETKCFICGIGSDYFDTTPHGFETHTLEEHNLANYMFFLMYLINKDETEHTGQESYVWKMYQERCWDFFPAGDCFRKQYEDQLS	5038	P21817	H	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
463	NM_000540.3(RYR1):c.7304G>A (p.Arg2435His)	12966	CA024750	NM_000540.3:c.7304G>A, NC_000019.10:g.38499997G>A, CM000681.2:g.38499997G>A, NC_000019.9:g.38990637G>A, CM000681.1:g.38990637G>A, NC_000019.8:g.43682477G>A, NG_008866.1:g.71298G>A, LRG_766:g.71298G>A, ENST00000599547.6:n.7304G>A, ENST00000359596.8:c.7304G>A, ENST00000355481.8:c.7304G>A, ENST00000359596.7:n.7304G>A, ENST00000360985.7:c.7301G>A, ENST00000594335.5:n.756G>A, NM_000540.2:c.7304G>A, LRG_766t1:c.7304G>A, NM_001042723.1:c.7304G>A, XM_006723317.1:c.7304G>A, XM_006723319.1:c.7304G>A, XM_011527204.1:c.7301G>A, XM_011527205.1:c.7304G>A, XM_006723317.2:c.7304G>A, XM_006723319.2:c.7304G>A, XM_011527205.2:c.7304G>A, XR_001753735.1:n.7387G>A, NM_001042723.2:c.7304G>A, NM_000540.3(RYR1):c.7304G>A (p.Arg2435His)	RYR1	malignant hyperthermia, susceptibility to, 1	MONDO:0007783	Autosomal dominant inheritance	Pathogenic	PS4, PS3_Moderate, PM1, PP3_Moderate, PP1_Strong	BA1, BS1	This pathogenicity assessment is relevant only for malignant hyperthermia susceptibility (MHS) inherited in an autosomal dominant pattern. Variants in RYR1 can also cause other myopathies inherited in an autosomal dominant pattern or in an autosomal recessive pattern. Some of these disorders may predispose individuals to malignant hyperthermia. RYR1 variants may also contribute to a malignant hyperthermia reaction in combination with other genetic and non-genetic factors and the clinician needs to consider such factors in making management decisions.This sequence variant predicts a substitution of arginine with histidine at codon 2435 of the RYR1 protein, p.(Arg2435His). This variant was not present in a large population database (gnomAD) at the time this variant was interpreted. This variant has been reported in 26 unrelated individuals who have a personal or family history of a malignant hyperthermia reaction, 24 of these individuals had a positive in vitro contracture test (IVCT) or caffeine halothane contracture test (CHCT) result (if the proband was unavailable for testing, a positive diagnostic test result in a mutation-positive relative was counted), PS4 (PMID: 30236257, 16163667, 21965348, 23842196, 12059893, 17081152, 17710899, 20681998, 31559918, 16732084, 19513315). Functional studies in HEK293 cells shows an increased sensitivity to RYR1 agonists, PS3_Moderate (PMID: 9334205, 27586648). This variant resides in a region of RYR1 considered to be a hotspot for pathogenic variants that contribute to MHS, PM1 (PMID: 21118704). This variant segregates with MHS in at least 10 families individuals, PP1_Strong (PMID: 12059893, 30236257, 32919876). A REVEL score >0.85 (0.944) supports a pathogenic status for this variant, PP3_Moderate. This variant has been classified as Pathogenic. Criteria implemented: PS3_Moderate, PS4, PM1, PP1_Strong, PP3_Moderate.		Malignant Hyperthermia Susceptibility VCEP	https://clinicalgenome.org/docs/clingen-malignant-hyperthermia-susceptibility-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-for/	2021-03-19	2022-07-11	False	https://erepo.genome.network/evrepo/ui/classification/CA024750/MONDO:0007783/012	5a42695d-2628-48e3-9733-9c50063e0ed0	p.Arg2435His	Arg	2435	His	MGDAEGEDEVQFLRTDDEVVLQCSATVLKEQLKLCLAAEGFGNRLCFLEPTSNAQNVPPDLAICCFVLEQSLSVRALQEMLANTVEAGVESSQGGGHRTLLYGHAILLRHAHSRMYLSCLTTSRSMTDKLAFDVGLQEDATGEACWWTMHPASKQRSEGEKVRVGDDIILVSVSSERYLHLSTASGELQVDASFMQTLWNMNPICSRCEEGFVTGGHVLRLFHGHMDECLTISPADSDDQRRLVYYEGGAVCTHARSLWRLEPLRISWSGSHLRWGQPLRVRHVTTGQYLALTEDQGLVVVDASKAHTKATSFCFRISKEKLDVAPKRDVEGMGPPEIKYGESLCFVQHVASGLWLTYAAPDPKALRLGVLKKKAMLHQEGHMDDALSLTRCQQEESQAARMIHSTNGLYNQFIKSLDSFSGKPRGSGPPAGTALPIEGVILSLQDLIIYFEPPSEDLQHEEKQSKLRSLRNRQSLFQEEGMLSMVLNCIDRLNVYTTAAHFAEFAGEEAAESWKEIVNLLYELLASLIRGNRSNCALFSTNLDWLVSKLDRLEASSGILEVLYCVLIESPEVLNIIQENHIKSIISLLDKHGRNHKVLDVLCSLCVCNGVAVRSNQDLITENLLPGRELLLQTNLINYVTSIRPNIFVGRAEGTTQYSKWYFEVMVDEVTPFLTAQATHLRVGWALTEGYTPYPGAGEGWGGNGVGDDLYSYGFDGLHLWTGHVARPVTSPGQHLLAPEDVISCCLDLSVPSISFRINGCPVQGVFESFNLDGLFFPVVSFSAGVKVRFLLGGRHGEFKFLPPPGYAPCHEAVLPRERLHLEPIKEYRREGPRGPHLVGPSRCLSHTDFVPCPVDTVQIVLPPHLERIREKLAENIHELWALTRIEQGWTYGPVRDDNKRLHPCLVDFHSLPEPERNYNLQMSGETLKTLLALGCHVGMADEKAEDNLKKTKLPKTYMMSNGYKPAPLDLSHVRLTPAQTTLVDRLAENGHNVWARDRVGQGWSYSAVQDIPARRNPRLVPYRLLDEATKRSNRDSLCQAVRTLLGYGYNIEPPDQEPSQVENQSRCDRVRIFRAEKSYTVQSGRWYFEFEAVTTGEMRVGWARPELRPDVELGADELAYVFNGHRGQRWHLGSEPFGRPWQPGDVVGCMIDLTENTIIFTLNGEVLMSDSGSETAFREIEIGDGFLPVCSLGPGQVGHLNLGQDVSSLRFFAICGLQEGFEPFAINMQRPVTTWFSKGLPQFEPVPLEHPHYEVSRVDGTVDTPPCLRLTHRTWGSQNSLVEMLFLRLSLPVQFHQHFRCTAGATPLAPPGLQPPAEDEARAAEPDPDYENLRRSAGGWSEAENGKEGTAKEGAPGGTPQAGGEAQPARAENEKDATTEKNKKRGFLFKAKKVAMMTQPPATPTLPRLPHDVVPADNRDDPEIILNTTTYYYSVRVFAGQEPSCVWAGWVTPDYHQHDMSFDLSKVRVVTVTMGDEQGNVHSSLKCSNCYMVWGGDFVSPGQQGRISHTDLVIGCLVDLATGLMTFTANGKESNTFFQVEPNTKLFPAVFVLPTHQNVIQFELGKQKNIMPLSAAMFQSERKNPAPQCPPRLEMQMLMPVSWSRMPNHFLQVETRRAGERLGWAVQCQEPLTMMALHIPEENRCMDILELSERLDLQRFHSHTLRLYRAVCALGNNRVAHALCSHVDQAQLLHALEDAHLPGPLRAGYYDLLISIHLESACRSRRSMLSEYIVPLTPETRAITLFPPGRSTENGHPRHGLPGVGVTTSLRPPHHFSPPCFVAALPAAGAAEAPARLSPAIPLEALRDKALRMLGEAVRDGGQHARDPVGGSVEFQFVPVLKLVSTLLVMGIFGDEDVKQILKMIEPEVFTEEEEEEDEEEEGEEEDEEEKEEDEEETAQEKEDEEKEEEEAAEGEKEEGLEEGLLQMKLPESVKLQMCHLLEYFCDQELQHRVESLAAFAERYVDKLQANQRSRYGLLIKAFSMTAAETARRTREFRSPPQEQINMLLQFKDGTDEEDCPLPEEIRQDLLDFHQDLLAHCGIQLDGEEEEPEEETTLGSRLMSLLEKVRLVKKKEEKPEEERSAEESKPRSLQELVSHMVVRWAQEDFVQSPELVRAMFSLLHRQYDGLGELLRALPRAYTISPSSVEDTMSLLECLGQIRSLLIVQMGPQEENLMIQSIGNIMNNKVFYQHPNLMRALGMHETVMEVMVNVLGGGESKEIRFPKMVTSCCRFLCYFCRISRQNQRSMFDHLSYLLENSGIGLGMQGSTPLDVAAASVIDNNELALALQEQDLEKVVSYLAGCGLQSCPMLVAKGYPDIGWNPCGGERYLDFLRFAVFVNGESVEENANVVVRLLIRKPECFGPALRGEGGSGLLAAIEEAIRISEDPARDGPGIRRDRRREHFGEEPPEENRVHLGHAIMSFYAALIDLLGRCAPEMHLIQAGKGEALRIRAILRSLVPLEDLVGIISLPLQIPTLGKDGALVQPKMSASFVPDHKASMVLFLDRVYGIENQDFLLHVLDVGFLPDMRAAASLDTATFSTTEMALALNRYLCLAVLPLITKCAPLFAGTEHRAIMVDSMLHTVYRLSRGRSLTKAQRDVIEDCLMSLCRYIRPSMLQHLLRRLVFDVPILNEFAKMPLKLLTNHYERCWKYYCLPTGWANFGVTSEEELHLTRKLFWGIFDSLAHKKYDPELYRMAMPCLCAIAGALPPDYVDASYSSKAEKKATVDAEGNFDPRPVETLNVIIPEKLDSFINKFAEYTHEKWAFDKIQNNWSYGENIDEELKTHPMLRPYKTFSEKDKEIYRWPIKESLKAMIAWEWTIEKAREGEEEKTEKKKTRKISQSAQTYDPREGYNPQPPDLSAVTLSRELQAMAEQLAENYHNTWGRKKKQELEAKGGGTHPLLVPYDTLTAKEKARDREKAQELLKFLQMNGYAVTRGLKDMELDSSSIEKRFAFGFLQQLLRWMDISQEFIAHLEAVVSSGRVEKSPHEQEIKFFAKILLPLINQYFTNHCLYFLSTPAKVLGSGGHASNKEKEMITSLFCKLAALVRHRVSLFGTDAPAVVNCLHILARSLDARTVMKSGPEIVKAGLRSFFESASEDIEKMVENLRLGKVSQARTQVKGVGQNLTYTTVALLPVLTTLFQHIAQHQFGDDVILDDVQVSCYRTLCSIYSLGTTKNTYVEKLRPALGECLARLAAAMPVAFLEPQLNEYNACSVYTTKSPRERAILGLPNSVEEMCPDIPVLERLMADIGGLAESGARYTEMPHVIEITLPMLCSYLPRWWERGPEAPPSALPAGAPPPCTAVTSDHLNSLLGNILRIIVNNLGIDEASWMKRLAVFAQPIVSRARPELLQSHFIPTIGRLRKRAGKVVSEEEQLRLEAKAEAQEGELLVRDEFSVLCRDLYALYPLLIRYVDNNRAQWLTEPNPSAEELFRMVGEIFIYWSKSHNFKREEQNFVVQNEINNMSFLTADNKSKMAKAGDIQSGGSDQERTKKKRRGDRYSVQTSLIVATLKKMLPIGLNMCAPTDQDLITLAKTRYALKDTDEEVREFLHNNLHLQGKVEGSPSLRWQMALYRGVPGREEDADDPEKIVRRVQEVSAVLYYLDQTEHPYKSKKAVWHKLLSKQRRRAVVACFRMTPLYNLPTHRACNMFLESYKAAWILTEDHSFEDRMIDDLSKAGEQEEEEEEVEEKKPDPLHQLVLHFSRTALTEKSKLDEDYLYMAYADIMAKSCHLEEGGENGEAEEEVEVSFEEKQMEKQRLLYQQARLHTRGAAEMVLQMISACKGETGAMVSSTLKLGISILNGGNAEVQQKMLDYLKDKKEVGFFQSIQALMQTCSVLDLNAFERQNKAEGLGMVNEDGTVINRQNGEKVMADDEFTQDLFRFLQLLCEGHNNDFQNYLRTQTGNTTTINIIICTVDYLLRLQESISDFYWYYSGKDVIEEQGKRNFSKAMSVAKQVFNSLTEYIQGPCTGNQQSLAHSRLWDAVVGFLHVFAHMMMKLAQDSSQIELLKELLDLQKDMVVMLLSLLEGNVVNGMIARQMVDMLVESSSNVEMILKFFDMFLKLKDIVGSEAFQDYVTDPRGLISKKDFQKAMDSQKQFSGPEIQFLLSCSEADENEMINCEEFANRFQEPARDIGFNVAVLLTNLSEHVPHDPRLHNFLELAESILEYFRPYLGRIEIMGASRRIERIYFEISETNRAQWEMPQVKESKRQFIFDVVNEGGEAEKMELFVSFCEDTIFEMQIAAQISEPEGEPETDEDEGAGAAEAGAEGAEEGAAGLEGTAATAAAGATARVVAAAGRALRGLSYRSLRRRVRRLRRLTAREAATAVAALLWAAVTRAGAAGAGAAAGALGLLWGSLFGGGLVEGAKKVTVTELLAGMPDPTSDEVHGEQPAGPGGDADGEGASEGAGDAAEGAGDEEEAVHEAGPGGADGAVAVTDGGPFRPEGAGGLGDMGDTTPAEPPTPEGSPILKRKLGVDGVEEELPPEPEPEPEPELEPEKADAENGEKEEVPEPTPEPPKKQAPPSPPPKKEEAGGEFWGELEVQRVKFLNYLSRNFYTLRFLALFLAFAINFILLFYKVSDSPPGEDDMEGSAAGDVSGAGSGGSSGWGLGAGEEAEGDEDENMVYYFLEESTGYMEPALRCLSLLHTLVAFLCIIGYNCLKVPLVIFKREKELARKLEFDGLYITEQPEDDDVKGQWDRLVLNTPSFPSNYWDKFVKRKVLDKHGDIYGRERIAELLGMDLATLEITAHNERKPNPPPGLLTWLMSIDVKYQIWKFGVIFTDNSFLYLGWYMVMSLLGHYNNFFFAAHLLDIAMGVKTLRTILSSVTHNGKQLVMTVGLLAVVVYLYTVVAFNFFRKFYNKSEDEDEPDMKCDDMMTCYLFHMYVGVRAGGGIGDEIEDPAGDEYELYRVVFDITFFFFVIVILLAIIQGLIIDAFGELRDQQEQVKEDMETKCFICGIGSDYFDTTPHGFETHTLEEHNLANYMFFLMYLINKDETEHTGQESYVWKMYQERCWDFFPAGDCFRKQYEDQLS	5038	P21817	H	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
464	NM_000540.3(RYR1):c.7300G>A (p.Gly2434Arg)	12970	CA024747	NM_000540.3:c.7300G>A, NC_000019.10:g.38499993G>A, CM000681.2:g.38499993G>A, NC_000019.9:g.38990633G>A, CM000681.1:g.38990633G>A, NC_000019.8:g.43682473G>A, NG_008866.1:g.71294G>A, LRG_766:g.71294G>A, ENST00000599547.6:n.7300G>A, ENST00000359596.8:c.7300G>A, ENST00000355481.8:c.7300G>A, ENST00000359596.7:n.7300G>A, ENST00000360985.7:c.7297G>A, ENST00000594335.5:n.752G>A, NM_000540.2:c.7300G>A, LRG_766t1:c.7300G>A, NM_001042723.1:c.7300G>A, XM_006723317.1:c.7300G>A, XM_006723319.1:c.7300G>A, XM_011527204.1:c.7297G>A, XM_011527205.1:c.7300G>A, XM_006723317.2:c.7300G>A, XM_006723319.2:c.7300G>A, XM_011527205.2:c.7300G>A, XR_001753735.1:n.7383G>A, NM_001042723.2:c.7300G>A, NM_000540.3(RYR1):c.7300G>A (p.Gly2434Arg)	RYR1	malignant hyperthermia, susceptibility to, 1	MONDO:0007783	Autosomal dominant inheritance	Pathogenic	BS2, PS4, PS3, PM1, PP1_Strong, PP3_Moderate	BA1, BS1	This pathogenicity assessment is relevant only for malignant hyperthermia susceptibility (MHS) inherited in an autosomal dominant pattern. Variants in RYR1 can also cause other myopathies inherited in an autosomal dominant pattern or in an autosomal recessive pattern. Some of these disorders may predispose individuals to malignant hyperthermia. RYR1 variants may also contribute to a malignant hyperthermia reaction in combination with other genetic and non-genetic factors and the clinician needs to consider such factors in making management decisions.This sequence variant predicts a substitution of glycine with arginine at codon 2434 of the RYR1 protein, p.(Gly2434Arg). The maximum allele frequency for this variant among the six major gnomAD populations is NFE: 0.000078, a frequency consistent with pathogenicity for MHS. This variant has been reported in 178 unrelated individuals who have a personal or family history of a malignant hyperthermia reaction, 174 of these individuals had a positive in vitro contracture test (IVCT) or caffeine halothane contracture test (CHCT) result (if the proband was unavailable for testing, a positive diagnostic test result in a mutation-positive relative was counted, PS4 (PMID: 30236257, 10484775, 23558838, 16163667, 21455645, 23842196, 7849712, 7881417, 11575529, 15731587, 11668625, 12059893, 12151923, 31559918, 10700782, 17081125, 18564801, 20681998, 21965348, 23460944, 25735680, 25960145, 9030597, 25268394, 17667681). This variant has been identified in six individuals with negative IVCT/CHCT results, BS2 (PMID:30236257). A functional study in HEK293 cells shows an increased sensitivity to RYR1 agonists (PMID: 27586648). p.(Gly2434Arg) knock-in mice are susceptible to malignant hyperthermia due to volatile anesthetics and ex vivo assays demonstrate increased sensitivity to RYR1 agonists for knock-in myotubes, PS3 (PMID:30236258). This variant resides in a region of RYR1 considered to be a hotspot for pathogenic variants that contribute to MHS, PM1 (PMID: 21118704). This variant segregates with MHS in at least 20 individuals, PP1_Strong (PMID: 7849712, 11575529, 12059893, 25960145). A REVEL score >0.85 (0.956) supports a pathogenic status for this variant, PP3_Moderate. Based on using Bayes to combine criteria this variant is assessed as Pathogenic, (PMID: 29300386).  Criteria implemented: PS3, PS4, PM1, PP1_Strong, PP3_Moderate, BS2.		Malignant Hyperthermia Susceptibility VCEP	https://clinicalgenome.org/docs/clingen-malignant-hyperthermia-susceptibility-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-for/	2022-07-11	2022-07-11	False	https://erepo.genome.network/evrepo/ui/classification/CA024747/MONDO:0007783/012	1436fa1b-2178-480a-9711-337815571f93	p.Gly2434Arg	Gly	2434	Arg	MGDAEGEDEVQFLRTDDEVVLQCSATVLKEQLKLCLAAEGFGNRLCFLEPTSNAQNVPPDLAICCFVLEQSLSVRALQEMLANTVEAGVESSQGGGHRTLLYGHAILLRHAHSRMYLSCLTTSRSMTDKLAFDVGLQEDATGEACWWTMHPASKQRSEGEKVRVGDDIILVSVSSERYLHLSTASGELQVDASFMQTLWNMNPICSRCEEGFVTGGHVLRLFHGHMDECLTISPADSDDQRRLVYYEGGAVCTHARSLWRLEPLRISWSGSHLRWGQPLRVRHVTTGQYLALTEDQGLVVVDASKAHTKATSFCFRISKEKLDVAPKRDVEGMGPPEIKYGESLCFVQHVASGLWLTYAAPDPKALRLGVLKKKAMLHQEGHMDDALSLTRCQQEESQAARMIHSTNGLYNQFIKSLDSFSGKPRGSGPPAGTALPIEGVILSLQDLIIYFEPPSEDLQHEEKQSKLRSLRNRQSLFQEEGMLSMVLNCIDRLNVYTTAAHFAEFAGEEAAESWKEIVNLLYELLASLIRGNRSNCALFSTNLDWLVSKLDRLEASSGILEVLYCVLIESPEVLNIIQENHIKSIISLLDKHGRNHKVLDVLCSLCVCNGVAVRSNQDLITENLLPGRELLLQTNLINYVTSIRPNIFVGRAEGTTQYSKWYFEVMVDEVTPFLTAQATHLRVGWALTEGYTPYPGAGEGWGGNGVGDDLYSYGFDGLHLWTGHVARPVTSPGQHLLAPEDVISCCLDLSVPSISFRINGCPVQGVFESFNLDGLFFPVVSFSAGVKVRFLLGGRHGEFKFLPPPGYAPCHEAVLPRERLHLEPIKEYRREGPRGPHLVGPSRCLSHTDFVPCPVDTVQIVLPPHLERIREKLAENIHELWALTRIEQGWTYGPVRDDNKRLHPCLVDFHSLPEPERNYNLQMSGETLKTLLALGCHVGMADEKAEDNLKKTKLPKTYMMSNGYKPAPLDLSHVRLTPAQTTLVDRLAENGHNVWARDRVGQGWSYSAVQDIPARRNPRLVPYRLLDEATKRSNRDSLCQAVRTLLGYGYNIEPPDQEPSQVENQSRCDRVRIFRAEKSYTVQSGRWYFEFEAVTTGEMRVGWARPELRPDVELGADELAYVFNGHRGQRWHLGSEPFGRPWQPGDVVGCMIDLTENTIIFTLNGEVLMSDSGSETAFREIEIGDGFLPVCSLGPGQVGHLNLGQDVSSLRFFAICGLQEGFEPFAINMQRPVTTWFSKGLPQFEPVPLEHPHYEVSRVDGTVDTPPCLRLTHRTWGSQNSLVEMLFLRLSLPVQFHQHFRCTAGATPLAPPGLQPPAEDEARAAEPDPDYENLRRSAGGWSEAENGKEGTAKEGAPGGTPQAGGEAQPARAENEKDATTEKNKKRGFLFKAKKVAMMTQPPATPTLPRLPHDVVPADNRDDPEIILNTTTYYYSVRVFAGQEPSCVWAGWVTPDYHQHDMSFDLSKVRVVTVTMGDEQGNVHSSLKCSNCYMVWGGDFVSPGQQGRISHTDLVIGCLVDLATGLMTFTANGKESNTFFQVEPNTKLFPAVFVLPTHQNVIQFELGKQKNIMPLSAAMFQSERKNPAPQCPPRLEMQMLMPVSWSRMPNHFLQVETRRAGERLGWAVQCQEPLTMMALHIPEENRCMDILELSERLDLQRFHSHTLRLYRAVCALGNNRVAHALCSHVDQAQLLHALEDAHLPGPLRAGYYDLLISIHLESACRSRRSMLSEYIVPLTPETRAITLFPPGRSTENGHPRHGLPGVGVTTSLRPPHHFSPPCFVAALPAAGAAEAPARLSPAIPLEALRDKALRMLGEAVRDGGQHARDPVGGSVEFQFVPVLKLVSTLLVMGIFGDEDVKQILKMIEPEVFTEEEEEEDEEEEGEEEDEEEKEEDEEETAQEKEDEEKEEEEAAEGEKEEGLEEGLLQMKLPESVKLQMCHLLEYFCDQELQHRVESLAAFAERYVDKLQANQRSRYGLLIKAFSMTAAETARRTREFRSPPQEQINMLLQFKDGTDEEDCPLPEEIRQDLLDFHQDLLAHCGIQLDGEEEEPEEETTLGSRLMSLLEKVRLVKKKEEKPEEERSAEESKPRSLQELVSHMVVRWAQEDFVQSPELVRAMFSLLHRQYDGLGELLRALPRAYTISPSSVEDTMSLLECLGQIRSLLIVQMGPQEENLMIQSIGNIMNNKVFYQHPNLMRALGMHETVMEVMVNVLGGGESKEIRFPKMVTSCCRFLCYFCRISRQNQRSMFDHLSYLLENSGIGLGMQGSTPLDVAAASVIDNNELALALQEQDLEKVVSYLAGCGLQSCPMLVAKGYPDIGWNPCGGERYLDFLRFAVFVNGESVEENANVVVRLLIRKPECFGPALRGEGGSGLLAAIEEAIRISEDPARDGPGIRRDRRREHFGEEPPEENRVHLGHAIMSFYAALIDLLGRCAPEMHLIQAGKGEALRIRAILRSLVPLEDLVGIISLPLQIPTLGKDGALVQPKMSASFVPDHKASMVLFLDRVYGIENQDFLLHVLDVGFLPDMRAAASLDTATFSTTEMALALNRYLCLAVLPLITKCAPLFAGTEHRAIMVDSMLHTVYRLSRGRSLTKAQRDVIEDCLMSLCRYIRPSMLQHLLRRLVFDVPILNEFAKMPLKLLTNHYERCWKYYCLPTGWANFGVTSEEELHLTRKLFWGIFDSLAHKKYDPELYRMAMPCLCAIAGALPPDYVDASYSSKAEKKATVDAEGNFDPRPVETLNVIIPEKLDSFINKFAEYTHEKWAFDKIQNNWSYGENIDEELKTHPMLRPYKTFSEKDKEIYRWPIKESLKAMIAWEWTIEKAREGEEEKTEKKKTRKISQSAQTYDPREGYNPQPPDLSAVTLSRELQAMAEQLAENYHNTWGRKKKQELEAKGGGTHPLLVPYDTLTAKEKARDREKAQELLKFLQMNGYAVTRGLKDMELDSSSIEKRFAFGFLQQLLRWMDISQEFIAHLEAVVSSGRVEKSPHEQEIKFFAKILLPLINQYFTNHCLYFLSTPAKVLGSGGHASNKEKEMITSLFCKLAALVRHRVSLFGTDAPAVVNCLHILARSLDARTVMKSGPEIVKAGLRSFFESASEDIEKMVENLRLGKVSQARTQVKGVGQNLTYTTVALLPVLTTLFQHIAQHQFGDDVILDDVQVSCYRTLCSIYSLGTTKNTYVEKLRPALGECLARLAAAMPVAFLEPQLNEYNACSVYTTKSPRERAILGLPNSVEEMCPDIPVLERLMADIGGLAESGARYTEMPHVIEITLPMLCSYLPRWWERGPEAPPSALPAGAPPPCTAVTSDHLNSLLGNILRIIVNNLGIDEASWMKRLAVFAQPIVSRARPELLQSHFIPTIGRLRKRAGKVVSEEEQLRLEAKAEAQEGELLVRDEFSVLCRDLYALYPLLIRYVDNNRAQWLTEPNPSAEELFRMVGEIFIYWSKSHNFKREEQNFVVQNEINNMSFLTADNKSKMAKAGDIQSGGSDQERTKKKRRGDRYSVQTSLIVATLKKMLPIGLNMCAPTDQDLITLAKTRYALKDTDEEVREFLHNNLHLQGKVEGSPSLRWQMALYRGVPGREEDADDPEKIVRRVQEVSAVLYYLDQTEHPYKSKKAVWHKLLSKQRRRAVVACFRMTPLYNLPTHRACNMFLESYKAAWILTEDHSFEDRMIDDLSKAGEQEEEEEEVEEKKPDPLHQLVLHFSRTALTEKSKLDEDYLYMAYADIMAKSCHLEEGGENGEAEEEVEVSFEEKQMEKQRLLYQQARLHTRGAAEMVLQMISACKGETGAMVSSTLKLGISILNGGNAEVQQKMLDYLKDKKEVGFFQSIQALMQTCSVLDLNAFERQNKAEGLGMVNEDGTVINRQNGEKVMADDEFTQDLFRFLQLLCEGHNNDFQNYLRTQTGNTTTINIIICTVDYLLRLQESISDFYWYYSGKDVIEEQGKRNFSKAMSVAKQVFNSLTEYIQGPCTGNQQSLAHSRLWDAVVGFLHVFAHMMMKLAQDSSQIELLKELLDLQKDMVVMLLSLLEGNVVNGMIARQMVDMLVESSSNVEMILKFFDMFLKLKDIVGSEAFQDYVTDPRGLISKKDFQKAMDSQKQFSGPEIQFLLSCSEADENEMINCEEFANRFQEPARDIGFNVAVLLTNLSEHVPHDPRLHNFLELAESILEYFRPYLGRIEIMGASRRIERIYFEISETNRAQWEMPQVKESKRQFIFDVVNEGGEAEKMELFVSFCEDTIFEMQIAAQISEPEGEPETDEDEGAGAAEAGAEGAEEGAAGLEGTAATAAAGATARVVAAAGRALRGLSYRSLRRRVRRLRRLTAREAATAVAALLWAAVTRAGAAGAGAAAGALGLLWGSLFGGGLVEGAKKVTVTELLAGMPDPTSDEVHGEQPAGPGGDADGEGASEGAGDAAEGAGDEEEAVHEAGPGGADGAVAVTDGGPFRPEGAGGLGDMGDTTPAEPPTPEGSPILKRKLGVDGVEEELPPEPEPEPEPELEPEKADAENGEKEEVPEPTPEPPKKQAPPSPPPKKEEAGGEFWGELEVQRVKFLNYLSRNFYTLRFLALFLAFAINFILLFYKVSDSPPGEDDMEGSAAGDVSGAGSGGSSGWGLGAGEEAEGDEDENMVYYFLEESTGYMEPALRCLSLLHTLVAFLCIIGYNCLKVPLVIFKREKELARKLEFDGLYITEQPEDDDVKGQWDRLVLNTPSFPSNYWDKFVKRKVLDKHGDIYGRERIAELLGMDLATLEITAHNERKPNPPPGLLTWLMSIDVKYQIWKFGVIFTDNSFLYLGWYMVMSLLGHYNNFFFAAHLLDIAMGVKTLRTILSSVTHNGKQLVMTVGLLAVVVYLYTVVAFNFFRKFYNKSEDEDEPDMKCDDMMTCYLFHMYVGVRAGGGIGDEIEDPAGDEYELYRVVFDITFFFFVIVILLAIIQGLIIDAFGELRDQQEQVKEDMETKCFICGIGSDYFDTTPHGFETHTLEEHNLANYMFFLMYLINKDETEHTGQESYVWKMYQERCWDFFPAGDCFRKQYEDQLS	5038	P21817	R	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
465	NM_000540.3(RYR1):c.7124G>C (p.Gly2375Ala)	133189	CA024718	NM_000540.3:c.7124G>C, NC_000019.10:g.38499731G>C, CM000681.2:g.38499731G>C, NC_000019.9:g.38990371G>C, CM000681.1:g.38990371G>C, NC_000019.8:g.43682211G>C, NG_008866.1:g.71032G>C, LRG_766:g.71032G>C, ENST00000599547.6:n.7124G>C, ENST00000359596.8:c.7124G>C, ENST00000355481.8:c.7124G>C, ENST00000359596.7:n.7124G>C, ENST00000360985.7:c.7121G>C, ENST00000594335.5:n.576G>C, NM_000540.2:c.7124G>C, LRG_766t1:c.7124G>C, NM_001042723.1:c.7124G>C, XM_006723317.1:c.7124G>C, XM_006723319.1:c.7124G>C, XM_011527204.1:c.7121G>C, XM_011527205.1:c.7124G>C, XM_006723317.2:c.7124G>C, XM_006723319.2:c.7124G>C, XM_011527205.2:c.7124G>C, XR_001753735.1:n.7207G>C, NM_001042723.2:c.7124G>C, NM_000540.3(RYR1):c.7124G>C (p.Gly2375Ala)	RYR1	malignant hyperthermia, susceptibility to, 1	MONDO:0007783	Autosomal dominant inheritance	Pathogenic	PP1_Moderate, PS4_Moderate, PS3_Moderate, PM1, PP3_Moderate	BA1, BS1	This pathogenicity assessment is relevant only for malignant hyperthermia susceptibility (MHS) inherited in an autosomal dominant pattern. Variants in RYR1 can also cause other myopathies inherited in an autosomal dominant pattern or in an autosomal recessive pattern. Some of these disorders may predispose individuals to malignant hyperthermia. RYR1 variants may also contribute to a malignant hyperthermia reaction in combination with other genetic and non-genetic factors and the clinician needs to consider such factors in making management decisions.This sequence variant predicts a substitution of glycine with alanine at codon 2375 of the RYR1 protein, p.(Gly2375Ala). This variant was not present in a large population database (gnomAD) at the time this variant was interpreted. This variant has been reported in five unrelated individuals who have a personal or family history of a malignant hyperthermia reaction, four of these individuals had a positive in vitro contracture test (IVCT) or caffeine halothane contracture test (CHCT) result (if the proband was unavailable for testing, a positive diagnostic test result in a mutation-positive relative was counted), PS4_Moderate (PMID: 12434264, 24433488, 25268394). This variant segregates with MHS in six individuals, PP1_Moderate (PMID:12434264, 14641996). Functional studies in HEK293 cells and patient myotubes showed an increased sensitivity to RYR1 agonists, PS3_Moderate (PMID: 27586648, 15210166). This variant resides in a region of RYR1 considered to be a hotspot for pathogenic variants that contribute to MHS, PM1 (PMID: 21118704). A REVEL score >0.85 (0.905) supports a pathogenic status for this variant, PP3_Moderate. This variant has been classified as Pathogenic. Criteria implemented: PS3_Moderate, PS4_Moderate, PM1, PP1_Moderate, PP3_Moderate.		Malignant Hyperthermia Susceptibility VCEP	https://clinicalgenome.org/docs/clingen-malignant-hyperthermia-susceptibility-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-for/	2022-07-11	2022-07-11	False	https://erepo.genome.network/evrepo/ui/classification/CA024718/MONDO:0007783/012	dc449eb6-2adf-42e5-9acc-d6d8c6d0118b	p.Gly2375Ala	Gly	2375	Ala	MGDAEGEDEVQFLRTDDEVVLQCSATVLKEQLKLCLAAEGFGNRLCFLEPTSNAQNVPPDLAICCFVLEQSLSVRALQEMLANTVEAGVESSQGGGHRTLLYGHAILLRHAHSRMYLSCLTTSRSMTDKLAFDVGLQEDATGEACWWTMHPASKQRSEGEKVRVGDDIILVSVSSERYLHLSTASGELQVDASFMQTLWNMNPICSRCEEGFVTGGHVLRLFHGHMDECLTISPADSDDQRRLVYYEGGAVCTHARSLWRLEPLRISWSGSHLRWGQPLRVRHVTTGQYLALTEDQGLVVVDASKAHTKATSFCFRISKEKLDVAPKRDVEGMGPPEIKYGESLCFVQHVASGLWLTYAAPDPKALRLGVLKKKAMLHQEGHMDDALSLTRCQQEESQAARMIHSTNGLYNQFIKSLDSFSGKPRGSGPPAGTALPIEGVILSLQDLIIYFEPPSEDLQHEEKQSKLRSLRNRQSLFQEEGMLSMVLNCIDRLNVYTTAAHFAEFAGEEAAESWKEIVNLLYELLASLIRGNRSNCALFSTNLDWLVSKLDRLEASSGILEVLYCVLIESPEVLNIIQENHIKSIISLLDKHGRNHKVLDVLCSLCVCNGVAVRSNQDLITENLLPGRELLLQTNLINYVTSIRPNIFVGRAEGTTQYSKWYFEVMVDEVTPFLTAQATHLRVGWALTEGYTPYPGAGEGWGGNGVGDDLYSYGFDGLHLWTGHVARPVTSPGQHLLAPEDVISCCLDLSVPSISFRINGCPVQGVFESFNLDGLFFPVVSFSAGVKVRFLLGGRHGEFKFLPPPGYAPCHEAVLPRERLHLEPIKEYRREGPRGPHLVGPSRCLSHTDFVPCPVDTVQIVLPPHLERIREKLAENIHELWALTRIEQGWTYGPVRDDNKRLHPCLVDFHSLPEPERNYNLQMSGETLKTLLALGCHVGMADEKAEDNLKKTKLPKTYMMSNGYKPAPLDLSHVRLTPAQTTLVDRLAENGHNVWARDRVGQGWSYSAVQDIPARRNPRLVPYRLLDEATKRSNRDSLCQAVRTLLGYGYNIEPPDQEPSQVENQSRCDRVRIFRAEKSYTVQSGRWYFEFEAVTTGEMRVGWARPELRPDVELGADELAYVFNGHRGQRWHLGSEPFGRPWQPGDVVGCMIDLTENTIIFTLNGEVLMSDSGSETAFREIEIGDGFLPVCSLGPGQVGHLNLGQDVSSLRFFAICGLQEGFEPFAINMQRPVTTWFSKGLPQFEPVPLEHPHYEVSRVDGTVDTPPCLRLTHRTWGSQNSLVEMLFLRLSLPVQFHQHFRCTAGATPLAPPGLQPPAEDEARAAEPDPDYENLRRSAGGWSEAENGKEGTAKEGAPGGTPQAGGEAQPARAENEKDATTEKNKKRGFLFKAKKVAMMTQPPATPTLPRLPHDVVPADNRDDPEIILNTTTYYYSVRVFAGQEPSCVWAGWVTPDYHQHDMSFDLSKVRVVTVTMGDEQGNVHSSLKCSNCYMVWGGDFVSPGQQGRISHTDLVIGCLVDLATGLMTFTANGKESNTFFQVEPNTKLFPAVFVLPTHQNVIQFELGKQKNIMPLSAAMFQSERKNPAPQCPPRLEMQMLMPVSWSRMPNHFLQVETRRAGERLGWAVQCQEPLTMMALHIPEENRCMDILELSERLDLQRFHSHTLRLYRAVCALGNNRVAHALCSHVDQAQLLHALEDAHLPGPLRAGYYDLLISIHLESACRSRRSMLSEYIVPLTPETRAITLFPPGRSTENGHPRHGLPGVGVTTSLRPPHHFSPPCFVAALPAAGAAEAPARLSPAIPLEALRDKALRMLGEAVRDGGQHARDPVGGSVEFQFVPVLKLVSTLLVMGIFGDEDVKQILKMIEPEVFTEEEEEEDEEEEGEEEDEEEKEEDEEETAQEKEDEEKEEEEAAEGEKEEGLEEGLLQMKLPESVKLQMCHLLEYFCDQELQHRVESLAAFAERYVDKLQANQRSRYGLLIKAFSMTAAETARRTREFRSPPQEQINMLLQFKDGTDEEDCPLPEEIRQDLLDFHQDLLAHCGIQLDGEEEEPEEETTLGSRLMSLLEKVRLVKKKEEKPEEERSAEESKPRSLQELVSHMVVRWAQEDFVQSPELVRAMFSLLHRQYDGLGELLRALPRAYTISPSSVEDTMSLLECLGQIRSLLIVQMGPQEENLMIQSIGNIMNNKVFYQHPNLMRALGMHETVMEVMVNVLGGGESKEIRFPKMVTSCCRFLCYFCRISRQNQRSMFDHLSYLLENSGIGLGMQGSTPLDVAAASVIDNNELALALQEQDLEKVVSYLAGCGLQSCPMLVAKGYPDIGWNPCGGERYLDFLRFAVFVNGESVEENANVVVRLLIRKPECFGPALRGEGGSGLLAAIEEAIRISEDPARDGPGIRRDRRREHFGEEPPEENRVHLGHAIMSFYAALIDLLGRCAPEMHLIQAGKGEALRIRAILRSLVPLEDLVGIISLPLQIPTLGKDGALVQPKMSASFVPDHKASMVLFLDRVYGIENQDFLLHVLDVGFLPDMRAAASLDTATFSTTEMALALNRYLCLAVLPLITKCAPLFAGTEHRAIMVDSMLHTVYRLSRGRSLTKAQRDVIEDCLMSLCRYIRPSMLQHLLRRLVFDVPILNEFAKMPLKLLTNHYERCWKYYCLPTGWANFGVTSEEELHLTRKLFWGIFDSLAHKKYDPELYRMAMPCLCAIAGALPPDYVDASYSSKAEKKATVDAEGNFDPRPVETLNVIIPEKLDSFINKFAEYTHEKWAFDKIQNNWSYGENIDEELKTHPMLRPYKTFSEKDKEIYRWPIKESLKAMIAWEWTIEKAREGEEEKTEKKKTRKISQSAQTYDPREGYNPQPPDLSAVTLSRELQAMAEQLAENYHNTWGRKKKQELEAKGGGTHPLLVPYDTLTAKEKARDREKAQELLKFLQMNGYAVTRGLKDMELDSSSIEKRFAFGFLQQLLRWMDISQEFIAHLEAVVSSGRVEKSPHEQEIKFFAKILLPLINQYFTNHCLYFLSTPAKVLGSGGHASNKEKEMITSLFCKLAALVRHRVSLFGTDAPAVVNCLHILARSLDARTVMKSGPEIVKAGLRSFFESASEDIEKMVENLRLGKVSQARTQVKGVGQNLTYTTVALLPVLTTLFQHIAQHQFGDDVILDDVQVSCYRTLCSIYSLGTTKNTYVEKLRPALGECLARLAAAMPVAFLEPQLNEYNACSVYTTKSPRERAILGLPNSVEEMCPDIPVLERLMADIGGLAESGARYTEMPHVIEITLPMLCSYLPRWWERGPEAPPSALPAGAPPPCTAVTSDHLNSLLGNILRIIVNNLGIDEASWMKRLAVFAQPIVSRARPELLQSHFIPTIGRLRKRAGKVVSEEEQLRLEAKAEAQEGELLVRDEFSVLCRDLYALYPLLIRYVDNNRAQWLTEPNPSAEELFRMVGEIFIYWSKSHNFKREEQNFVVQNEINNMSFLTADNKSKMAKAGDIQSGGSDQERTKKKRRGDRYSVQTSLIVATLKKMLPIGLNMCAPTDQDLITLAKTRYALKDTDEEVREFLHNNLHLQGKVEGSPSLRWQMALYRGVPGREEDADDPEKIVRRVQEVSAVLYYLDQTEHPYKSKKAVWHKLLSKQRRRAVVACFRMTPLYNLPTHRACNMFLESYKAAWILTEDHSFEDRMIDDLSKAGEQEEEEEEVEEKKPDPLHQLVLHFSRTALTEKSKLDEDYLYMAYADIMAKSCHLEEGGENGEAEEEVEVSFEEKQMEKQRLLYQQARLHTRGAAEMVLQMISACKGETGAMVSSTLKLGISILNGGNAEVQQKMLDYLKDKKEVGFFQSIQALMQTCSVLDLNAFERQNKAEGLGMVNEDGTVINRQNGEKVMADDEFTQDLFRFLQLLCEGHNNDFQNYLRTQTGNTTTINIIICTVDYLLRLQESISDFYWYYSGKDVIEEQGKRNFSKAMSVAKQVFNSLTEYIQGPCTGNQQSLAHSRLWDAVVGFLHVFAHMMMKLAQDSSQIELLKELLDLQKDMVVMLLSLLEGNVVNGMIARQMVDMLVESSSNVEMILKFFDMFLKLKDIVGSEAFQDYVTDPRGLISKKDFQKAMDSQKQFSGPEIQFLLSCSEADENEMINCEEFANRFQEPARDIGFNVAVLLTNLSEHVPHDPRLHNFLELAESILEYFRPYLGRIEIMGASRRIERIYFEISETNRAQWEMPQVKESKRQFIFDVVNEGGEAEKMELFVSFCEDTIFEMQIAAQISEPEGEPETDEDEGAGAAEAGAEGAEEGAAGLEGTAATAAAGATARVVAAAGRALRGLSYRSLRRRVRRLRRLTAREAATAVAALLWAAVTRAGAAGAGAAAGALGLLWGSLFGGGLVEGAKKVTVTELLAGMPDPTSDEVHGEQPAGPGGDADGEGASEGAGDAAEGAGDEEEAVHEAGPGGADGAVAVTDGGPFRPEGAGGLGDMGDTTPAEPPTPEGSPILKRKLGVDGVEEELPPEPEPEPEPELEPEKADAENGEKEEVPEPTPEPPKKQAPPSPPPKKEEAGGEFWGELEVQRVKFLNYLSRNFYTLRFLALFLAFAINFILLFYKVSDSPPGEDDMEGSAAGDVSGAGSGGSSGWGLGAGEEAEGDEDENMVYYFLEESTGYMEPALRCLSLLHTLVAFLCIIGYNCLKVPLVIFKREKELARKLEFDGLYITEQPEDDDVKGQWDRLVLNTPSFPSNYWDKFVKRKVLDKHGDIYGRERIAELLGMDLATLEITAHNERKPNPPPGLLTWLMSIDVKYQIWKFGVIFTDNSFLYLGWYMVMSLLGHYNNFFFAAHLLDIAMGVKTLRTILSSVTHNGKQLVMTVGLLAVVVYLYTVVAFNFFRKFYNKSEDEDEPDMKCDDMMTCYLFHMYVGVRAGGGIGDEIEDPAGDEYELYRVVFDITFFFFVIVILLAIIQGLIIDAFGELRDQQEQVKEDMETKCFICGIGSDYFDTTPHGFETHTLEEHNLANYMFFLMYLINKDETEHTGQESYVWKMYQERCWDFFPAGDCFRKQYEDQLS	5038	P21817	A	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
466	NM_000540.3(RYR1):c.7063C>T (p.Arg2355Trp)	133183	CA024693	NM_000540.3:c.7063C>T, NC_000019.10:g.38499670C>T, CM000681.2:g.38499670C>T, NC_000019.9:g.38990310C>T, CM000681.1:g.38990310C>T, NC_000019.8:g.43682150C>T, NG_008866.1:g.70971C>T, LRG_766:g.70971C>T, ENST00000599547.6:n.7063C>T, ENST00000359596.8:c.7063C>T, ENST00000355481.8:c.7063C>T, ENST00000359596.7:n.7063C>T, ENST00000360985.7:c.7060C>T, ENST00000594335.5:n.515C>T, NM_000540.2:c.7063C>T, LRG_766t1:c.7063C>T, NM_001042723.1:c.7063C>T, XM_006723317.1:c.7063C>T, XM_006723319.1:c.7063C>T, XM_011527204.1:c.7060C>T, XM_011527205.1:c.7063C>T, XM_006723317.2:c.7063C>T, XM_006723319.2:c.7063C>T, XM_011527205.2:c.7063C>T, XR_001753735.1:n.7146C>T, NM_001042723.2:c.7063C>T, NM_000540.3(RYR1):c.7063C>T (p.Arg2355Trp)	RYR1	malignant hyperthermia, susceptibility to, 1	MONDO:0007783	Autosomal dominant inheritance	Pathogenic	PS4, PS3_Moderate, PM1, PP1_Strong, PP3_Moderate	BA1, BS1	This pathogenicity assessment is relevant only for malignant hyperthermia susceptibility (MHS) inherited in an autosomal dominant pattern. Variants in RYR1 can also cause other myopathies inherited in an autosomal dominant pattern or in an autosomal recessive pattern. Some of these disorders may predispose individuals to malignant hyperthermia. RYR1 variants may also contribute to a malignant hyperthermia reaction in combination with other genetic and non-genetic factors and the clinician needs to consider such factors in making management decisions.This sequence variant predicts a substitution of arginine with tryptophan at codon 2355 of the RYR1 protein, p.(Arg2355Trp). The maximum allele frequency for this variant among the six major gnomAD populations is NFE: .000036, a frequency consistent with pathogenicity for MHS. This variant has been reported in 18 unrelated individuals who have a personal or family history of a malignant hyperthermia reaction, 17 of these individuals had a positive in vitro contracture test (IVCT) or caffeine halothane contracture test (CHCT) result (if the proband was unavailable for testing, a positive diagnostic test result in a mutation-positive relative was counted), PS4 (PMID: 30236257, 23558838, 24361844, 12123492, 15210166, 23460944, 25256590, 22473935). This variant segregates with MHS in at least 12 individuals, PP1_Strong (PMID: 30236257, 24361844). Functional studies in HEK293 cells show an increased sensitivity to RYR1 agonists, PS3_Moderate (PMID: 28403410). Additionally, two ex vivo studies using myotubes and B-lymphocytes, showed increased sensitivity to RYR1 agonists in multiple unrelated individuals (PMID: 15210166, 24361844). This variant resides in a region of RYR1 considered to be a hotspot for pathogenic variants that contribute to MHS, PM1 (PMID: 21118704). A REVEL score >0.85 (0.861) supports a pathogenic status for this variant, PP3_Moderate. This variant has been classified as Pathogenic. Criteria implemented: PS3_Moderate, PS4, PM1, PP1_Strong, PP3_Moderate.		Malignant Hyperthermia Susceptibility VCEP	https://clinicalgenome.org/docs/clingen-malignant-hyperthermia-susceptibility-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-for/	2021-03-19	2022-07-11	False	https://erepo.genome.network/evrepo/ui/classification/CA024693/MONDO:0007783/012	b0889437-dc2e-4a8f-b0e4-59876af6b15b	p.Arg2355Trp	Arg	2355	Trp	MGDAEGEDEVQFLRTDDEVVLQCSATVLKEQLKLCLAAEGFGNRLCFLEPTSNAQNVPPDLAICCFVLEQSLSVRALQEMLANTVEAGVESSQGGGHRTLLYGHAILLRHAHSRMYLSCLTTSRSMTDKLAFDVGLQEDATGEACWWTMHPASKQRSEGEKVRVGDDIILVSVSSERYLHLSTASGELQVDASFMQTLWNMNPICSRCEEGFVTGGHVLRLFHGHMDECLTISPADSDDQRRLVYYEGGAVCTHARSLWRLEPLRISWSGSHLRWGQPLRVRHVTTGQYLALTEDQGLVVVDASKAHTKATSFCFRISKEKLDVAPKRDVEGMGPPEIKYGESLCFVQHVASGLWLTYAAPDPKALRLGVLKKKAMLHQEGHMDDALSLTRCQQEESQAARMIHSTNGLYNQFIKSLDSFSGKPRGSGPPAGTALPIEGVILSLQDLIIYFEPPSEDLQHEEKQSKLRSLRNRQSLFQEEGMLSMVLNCIDRLNVYTTAAHFAEFAGEEAAESWKEIVNLLYELLASLIRGNRSNCALFSTNLDWLVSKLDRLEASSGILEVLYCVLIESPEVLNIIQENHIKSIISLLDKHGRNHKVLDVLCSLCVCNGVAVRSNQDLITENLLPGRELLLQTNLINYVTSIRPNIFVGRAEGTTQYSKWYFEVMVDEVTPFLTAQATHLRVGWALTEGYTPYPGAGEGWGGNGVGDDLYSYGFDGLHLWTGHVARPVTSPGQHLLAPEDVISCCLDLSVPSISFRINGCPVQGVFESFNLDGLFFPVVSFSAGVKVRFLLGGRHGEFKFLPPPGYAPCHEAVLPRERLHLEPIKEYRREGPRGPHLVGPSRCLSHTDFVPCPVDTVQIVLPPHLERIREKLAENIHELWALTRIEQGWTYGPVRDDNKRLHPCLVDFHSLPEPERNYNLQMSGETLKTLLALGCHVGMADEKAEDNLKKTKLPKTYMMSNGYKPAPLDLSHVRLTPAQTTLVDRLAENGHNVWARDRVGQGWSYSAVQDIPARRNPRLVPYRLLDEATKRSNRDSLCQAVRTLLGYGYNIEPPDQEPSQVENQSRCDRVRIFRAEKSYTVQSGRWYFEFEAVTTGEMRVGWARPELRPDVELGADELAYVFNGHRGQRWHLGSEPFGRPWQPGDVVGCMIDLTENTIIFTLNGEVLMSDSGSETAFREIEIGDGFLPVCSLGPGQVGHLNLGQDVSSLRFFAICGLQEGFEPFAINMQRPVTTWFSKGLPQFEPVPLEHPHYEVSRVDGTVDTPPCLRLTHRTWGSQNSLVEMLFLRLSLPVQFHQHFRCTAGATPLAPPGLQPPAEDEARAAEPDPDYENLRRSAGGWSEAENGKEGTAKEGAPGGTPQAGGEAQPARAENEKDATTEKNKKRGFLFKAKKVAMMTQPPATPTLPRLPHDVVPADNRDDPEIILNTTTYYYSVRVFAGQEPSCVWAGWVTPDYHQHDMSFDLSKVRVVTVTMGDEQGNVHSSLKCSNCYMVWGGDFVSPGQQGRISHTDLVIGCLVDLATGLMTFTANGKESNTFFQVEPNTKLFPAVFVLPTHQNVIQFELGKQKNIMPLSAAMFQSERKNPAPQCPPRLEMQMLMPVSWSRMPNHFLQVETRRAGERLGWAVQCQEPLTMMALHIPEENRCMDILELSERLDLQRFHSHTLRLYRAVCALGNNRVAHALCSHVDQAQLLHALEDAHLPGPLRAGYYDLLISIHLESACRSRRSMLSEYIVPLTPETRAITLFPPGRSTENGHPRHGLPGVGVTTSLRPPHHFSPPCFVAALPAAGAAEAPARLSPAIPLEALRDKALRMLGEAVRDGGQHARDPVGGSVEFQFVPVLKLVSTLLVMGIFGDEDVKQILKMIEPEVFTEEEEEEDEEEEGEEEDEEEKEEDEEETAQEKEDEEKEEEEAAEGEKEEGLEEGLLQMKLPESVKLQMCHLLEYFCDQELQHRVESLAAFAERYVDKLQANQRSRYGLLIKAFSMTAAETARRTREFRSPPQEQINMLLQFKDGTDEEDCPLPEEIRQDLLDFHQDLLAHCGIQLDGEEEEPEEETTLGSRLMSLLEKVRLVKKKEEKPEEERSAEESKPRSLQELVSHMVVRWAQEDFVQSPELVRAMFSLLHRQYDGLGELLRALPRAYTISPSSVEDTMSLLECLGQIRSLLIVQMGPQEENLMIQSIGNIMNNKVFYQHPNLMRALGMHETVMEVMVNVLGGGESKEIRFPKMVTSCCRFLCYFCRISRQNQRSMFDHLSYLLENSGIGLGMQGSTPLDVAAASVIDNNELALALQEQDLEKVVSYLAGCGLQSCPMLVAKGYPDIGWNPCGGERYLDFLRFAVFVNGESVEENANVVVRLLIRKPECFGPALRGEGGSGLLAAIEEAIRISEDPARDGPGIRRDRRREHFGEEPPEENRVHLGHAIMSFYAALIDLLGRCAPEMHLIQAGKGEALRIRAILRSLVPLEDLVGIISLPLQIPTLGKDGALVQPKMSASFVPDHKASMVLFLDRVYGIENQDFLLHVLDVGFLPDMRAAASLDTATFSTTEMALALNRYLCLAVLPLITKCAPLFAGTEHRAIMVDSMLHTVYRLSRGRSLTKAQRDVIEDCLMSLCRYIRPSMLQHLLRRLVFDVPILNEFAKMPLKLLTNHYERCWKYYCLPTGWANFGVTSEEELHLTRKLFWGIFDSLAHKKYDPELYRMAMPCLCAIAGALPPDYVDASYSSKAEKKATVDAEGNFDPRPVETLNVIIPEKLDSFINKFAEYTHEKWAFDKIQNNWSYGENIDEELKTHPMLRPYKTFSEKDKEIYRWPIKESLKAMIAWEWTIEKAREGEEEKTEKKKTRKISQSAQTYDPREGYNPQPPDLSAVTLSRELQAMAEQLAENYHNTWGRKKKQELEAKGGGTHPLLVPYDTLTAKEKARDREKAQELLKFLQMNGYAVTRGLKDMELDSSSIEKRFAFGFLQQLLRWMDISQEFIAHLEAVVSSGRVEKSPHEQEIKFFAKILLPLINQYFTNHCLYFLSTPAKVLGSGGHASNKEKEMITSLFCKLAALVRHRVSLFGTDAPAVVNCLHILARSLDARTVMKSGPEIVKAGLRSFFESASEDIEKMVENLRLGKVSQARTQVKGVGQNLTYTTVALLPVLTTLFQHIAQHQFGDDVILDDVQVSCYRTLCSIYSLGTTKNTYVEKLRPALGECLARLAAAMPVAFLEPQLNEYNACSVYTTKSPRERAILGLPNSVEEMCPDIPVLERLMADIGGLAESGARYTEMPHVIEITLPMLCSYLPRWWERGPEAPPSALPAGAPPPCTAVTSDHLNSLLGNILRIIVNNLGIDEASWMKRLAVFAQPIVSRARPELLQSHFIPTIGRLRKRAGKVVSEEEQLRLEAKAEAQEGELLVRDEFSVLCRDLYALYPLLIRYVDNNRAQWLTEPNPSAEELFRMVGEIFIYWSKSHNFKREEQNFVVQNEINNMSFLTADNKSKMAKAGDIQSGGSDQERTKKKRRGDRYSVQTSLIVATLKKMLPIGLNMCAPTDQDLITLAKTRYALKDTDEEVREFLHNNLHLQGKVEGSPSLRWQMALYRGVPGREEDADDPEKIVRRVQEVSAVLYYLDQTEHPYKSKKAVWHKLLSKQRRRAVVACFRMTPLYNLPTHRACNMFLESYKAAWILTEDHSFEDRMIDDLSKAGEQEEEEEEVEEKKPDPLHQLVLHFSRTALTEKSKLDEDYLYMAYADIMAKSCHLEEGGENGEAEEEVEVSFEEKQMEKQRLLYQQARLHTRGAAEMVLQMISACKGETGAMVSSTLKLGISILNGGNAEVQQKMLDYLKDKKEVGFFQSIQALMQTCSVLDLNAFERQNKAEGLGMVNEDGTVINRQNGEKVMADDEFTQDLFRFLQLLCEGHNNDFQNYLRTQTGNTTTINIIICTVDYLLRLQESISDFYWYYSGKDVIEEQGKRNFSKAMSVAKQVFNSLTEYIQGPCTGNQQSLAHSRLWDAVVGFLHVFAHMMMKLAQDSSQIELLKELLDLQKDMVVMLLSLLEGNVVNGMIARQMVDMLVESSSNVEMILKFFDMFLKLKDIVGSEAFQDYVTDPRGLISKKDFQKAMDSQKQFSGPEIQFLLSCSEADENEMINCEEFANRFQEPARDIGFNVAVLLTNLSEHVPHDPRLHNFLELAESILEYFRPYLGRIEIMGASRRIERIYFEISETNRAQWEMPQVKESKRQFIFDVVNEGGEAEKMELFVSFCEDTIFEMQIAAQISEPEGEPETDEDEGAGAAEAGAEGAEEGAAGLEGTAATAAAGATARVVAAAGRALRGLSYRSLRRRVRRLRRLTAREAATAVAALLWAAVTRAGAAGAGAAAGALGLLWGSLFGGGLVEGAKKVTVTELLAGMPDPTSDEVHGEQPAGPGGDADGEGASEGAGDAAEGAGDEEEAVHEAGPGGADGAVAVTDGGPFRPEGAGGLGDMGDTTPAEPPTPEGSPILKRKLGVDGVEEELPPEPEPEPEPELEPEKADAENGEKEEVPEPTPEPPKKQAPPSPPPKKEEAGGEFWGELEVQRVKFLNYLSRNFYTLRFLALFLAFAINFILLFYKVSDSPPGEDDMEGSAAGDVSGAGSGGSSGWGLGAGEEAEGDEDENMVYYFLEESTGYMEPALRCLSLLHTLVAFLCIIGYNCLKVPLVIFKREKELARKLEFDGLYITEQPEDDDVKGQWDRLVLNTPSFPSNYWDKFVKRKVLDKHGDIYGRERIAELLGMDLATLEITAHNERKPNPPPGLLTWLMSIDVKYQIWKFGVIFTDNSFLYLGWYMVMSLLGHYNNFFFAAHLLDIAMGVKTLRTILSSVTHNGKQLVMTVGLLAVVVYLYTVVAFNFFRKFYNKSEDEDEPDMKCDDMMTCYLFHMYVGVRAGGGIGDEIEDPAGDEYELYRVVFDITFFFFVIVILLAIIQGLIIDAFGELRDQQEQVKEDMETKCFICGIGSDYFDTTPHGFETHTLEEHNLANYMFFLMYLINKDETEHTGQESYVWKMYQERCWDFFPAGDCFRKQYEDQLS	5038	P21817	W	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
467	NM_000257.4(MYH7):c.427C>T (p.Arg143Trp)	164401	CA014751	NM_000257.4:c.427C>T, NC_000014.9:g.23432714G>A, CM000676.2:g.23432714G>A, NC_000014.8:g.23901923G>A, CM000676.1:g.23901923G>A, NC_000014.7:g.22971763G>A, NG_007884.1:g.7948C>T, LRG_384:g.7948C>T, ENST00000355349.4:c.427C>T, ENST00000355349.3:c.427C>T, NM_000257.3:c.427C>T, XR_245686.3:n.533C>T, XM_017021340.1:c.427C>T, NM_000257.4(MYH7):c.427C>T (p.Arg143Trp)	MYH7	hypertrophic cardiomyopathy	MONDO:0005045	Autosomal dominant inheritance	Pathogenic	PS4, PP3, PM2, PP1_Strong	BP3, BS1, BS3, BS4, BP4, BP7, BP5, PS1, PS2, PVS1, BA1, PM5, PM4, PM1, PS3, PM6	The NM_000257.4(MYH7):c.427C>T (p.Arg143Trp) variant in MYH7 has been identified in >40 individuals with HCM, including 1 individual in which it was observed in the homozygous state  (PS4; Mohiddin 2003 PMID: 12820698; Erdmann 2003 PMID: 12974739; Maron 2012 PMID: 21839045; Curila 2012 PMID: 22455086; Liu 2013 PMID: 23711808; Kapplinger 2014 PMID: 24510615; Chiou 2015 PMID: 25086479; Weissler-Snir 2017 PMID: 28193612; Mademont-Soler 2017 PMID: 28771489; Hershkovitz 2019 PMID: 30588760; Gao 2020 PMID: 32344918;  Ambry pers. comm.; CHEO pers. comm.; GeneDx pers. comm.; Invitae pers. comm.; LMM pers. comm.; OMGL pers. comm.; Centenary Institute Sydney pers. comm.) and segregated with disease in >9 affected relatives from three families (Mademont-Soler 2017 PMID: 28771489 GeneDx pers. comm.; OMGL pers. comm.). It was also identified in 2 infants with DCM that had loss of function variants in MYH7 and both variants segregated with DCM in one affected infant sibling (Ambry pers. comm; LMM pers. comm.). This variant has been identified in 0.002% (FAF 95% CI, 2/18394) of East Asian chromosomes and 0.001% (FAF 95% CI, 4/113754) of European chromosomes in gnomAD v2.1.1 (http://gnomad.broadinstitute.org). Computational prediction tools and conservation analysis suggest that this variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for hypertrophic cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (Kelly 2018 PMID:29300372): PS4; PP1_Strong; PM2; PP3.		Cardiomyopathy VCEP		2022-07-30	2022-07-30	False	https://erepo.genome.network/evrepo/ui/classification/CA014751/MONDO:0005045/002	a5d5ca4d-e48c-4e60-8ec0-83141a9d091a	p.Arg143Trp	Arg	143	Trp	MGDSEMAVFGAAAPYLRKSEKERLEAQTRPFDLKKDVFVPDDKQEFVKAKIVSREGGKVTAETEYGKTVTVKEDQVMQQNPPKFDKIEDMAMLTFLHEPAVLYNLKDRYGSWMIYTYSGLFCVTVNPYKWLPVYTPEVVAAYRGKKRSEAPPHIFSISDNAYQYMLTDRENQSILITGESGAGKTVNTKRVIQYFAVIAAIGDRSKKDQSPGKGTLEDQIIQANPALEAFGNAKTVRNDNSSRFGKFIRIHFGATGKLASADIETYLLEKSRVIFQLKAERDYHIFYQILSNKKPELLDMLLITNNPYDYAFISQGETTVASIDDAEELMATDNAFDVLGFTSEEKNSMYKLTGAIMHFGNMKFKLKQREEQAEPDGTEEADKSAYLMGLNSADLLKGLCHPRVKVGNEYVTKGQNVQQVIYATGALAKAVYERMFNWMVTRINATLETKQPRQYFIGVLDIAGFEIFDFNSFEQLCINFTNEKLQQFFNHHMFVLEQEEYKKEGIEWTFIDFGMDLQACIDLIEKPMGIMSILEEECMFPKATDMTFKAKLFDNHLGKSANFQKPRNIKGKPEAHFSLIHYAGIVDYNIIGWLQKNKDPLNETVVGLYQKSSLKLLSTLFANYAGADAPIEKGKGKAKKGSSFQTVSALHRENLNKLMTNLRSTHPHFVRCIIPNETKSPGVMDNPLVMHQLRCNGVLEGIRICRKGFPNRILYGDFRQRYRILNPAAIPEGQFIDSRKGAEKLLSSLDIDHNQYKFGHTKVFFKAGLLGLLEEMRDERLSRIITRIQAQSRGVLARMEYKKLLERRDSLLVIQWNIRAFMGVKNWPWMKLYFKIKPLLKSAEREKEMASMKEEFTRLKEALEKSEARRKELEEKMVSLLQEKNDLQLQVQAEQDNLADAEERCDQLIKNKIQLEAKVKEMNERLEDEEEMNAELTAKKRKLEDECSELKRDIDDLELTLAKVEKEKHATENKVKNLTEEMAGLDEIIAKLTKEKKALQEAHQQALDDLQAEEDKVNTLTKAKVKLEQQVDDLEGSLEQEKKVRMDLERAKRKLEGDLKLTQESIMDLENDKQQLDERLKKKDFELNALNARIEDEQALGSQLQKKLKELQARIEELEEELEAERTARAKVEKLRSDLSRELEEISERLEEAGGATSVQIEMNKKREAEFQKMRRDLEEATLQHEATAAALRKKHADSVAELGEQIDNLQRVKQKLEKEKSEFKLELDDVTSNMEQIIKAKANLEKMCRTLEDQMNEHRSKAEETQRSVNDLTSQRAKLQTENGELSRQLDEKEALISQLTRGKLTYTQQLEDLKRQLEEEVKAKNALAHALQSARHDCDLLREQYEEETEAKAELQRVLSKANSEVAQWRTKYETDAIQRTEELEEAKKKLAQRLQEAEEAVEAVNAKCSSLEKTKHRLQNEIEDLMVDVERSNAAAAALDKKQRNFDKILAEWKQKYEESQSELESSQKEARSLSTELFKLKNAYEESLEHLETFKRENKNLQEEISDLTEQLGSSGKTIHELEKVRKQLEAEKMELQSALEEAEASLEHEEGKILRAQLEFNQIKAEIERKLAEKDEEMEQAKRNHLRVVDSLQTSLDAETRSRNEALRVKKKMEGDLNEMEIQLSHANRMAAEAQKQVKSLQSLLKDTQIQLDDAVRANDDLKENIAIVERRNNLLQAELEELRAVVEQTERSRKLAEQELIETSERVQLLHSQNTSLINQKKKMDADLSQLQTEVEEAVQECRNAEEKAKKAITDAAMMAEELKKEQDTSAHLERMKKNMEQTIKDLQHRLDEAEQIALKGGKKQLQKLEARVRELENELEAEQKRNAESVKGMRKSERRIKELTYQTEEDRKNLLRLQDLVDKLQLKVKAYKRQAEEAEEQANTNLSKFRKVQHELDEAEERADIAESQVNKLRAKSRDIGTKGLNEE	1935	P12883	W	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [494], 'HELIX_gain_score': array([0.00583035]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [150, 152, 156, 157, 159, 162, 166, 168], 'DOMAIN_gain_score': array([0.13264114, 0.09793574, 0.1177541 , 0.09662616, 0.11840832,
       0.0949825 , 0.13471568, 0.12337208]), 'REGION_loss': [874, 1264], 'REGION_gain': [], 'REGION_loss_score': array([-0.00141668, -0.00061291]), 'REPEAT_loss': [42, 47, 75, 80, 87, 91, 94, 105, 123, 128, 140, 1156], 'REPEAT_gain': [899, 1095, 1858], 'REPEAT_gain_score': array([0.0067963 , 0.00353438, 0.00371325]), 'REPEAT_loss_score': array([-0.01119286, -0.01234925, -0.0099386 , -0.00935584, -0.01123798,
       -0.01219654, -0.01031077, -0.01542306, -0.02116972, -0.02062482,
       -0.02889591, -0.00149363]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
468	NM_000018.4(ACADVL):c.1376G>A (p.Arg459Gln)	203585	CA312275	NM_000018.4:c.1376G>A, NC_000017.11:g.7224011G>A, CM000679.2:g.7224011G>A, NC_000017.10:g.7127330G>A, CM000679.1:g.7127330G>A, NC_000017.9:g.7068054G>A, NG_007975.1:g.9178G>A, NG_008391.2:g.1040C>T, NG_033038.1:g.15534C>T, ENST00000356839.10:c.1376G>A, ENST00000322910.9:c.*1331G>A, ENST00000350303.9:c.1310G>A, ENST00000356839.9:c.1376G>A, ENST00000542255.6:n.234G>A, ENST00000543245.6:c.1445G>A, ENST00000578711.1:n.507G>A, ENST00000579425.5:n.492G>A, ENST00000579546.1:n.213G>A, ENST00000579894.5:n.87G>A, ENST00000583074.5:n.95G>A, ENST00000583850.5:n.151G>A, ENST00000583858.5:n.405G>A, ENST00000585203.6:n.567G>A, NM_000018.3:c.1376G>A, NM_001033859.2:c.1310G>A, NM_001270447.1:c.1445G>A, NM_001270448.1:c.1148G>A, XM_006721516.2:c.1376G>A, XM_011523829.1:c.1376G>A, XM_011523830.1:c.1376G>A, XR_934021.1:n.1483G>A, XR_934022.1:n.1483G>A, XR_934023.1:n.1483G>A, XM_006721516.3:c.1376G>A, XM_011523829.2:c.1376G>A, XM_011523830.2:c.1376G>A, XM_024450741.1:c.1376G>A, XR_934021.2:n.1435G>A, XR_934022.2:n.1435G>A, XR_934023.2:n.1435G>A, NM_001033859.3:c.1310G>A, NM_001270447.2:c.1445G>A, NM_001270448.2:c.1148G>A, NM_000018.4(ACADVL):c.1376G>A (p.Arg459Gln)	ACADVL	very long chain acyl-CoA dehydrogenase deficiency	MONDO:0008723	Autosomal recessive inheritance	Pathogenic	PP4_Moderate, PP3, PM2_Supporting, PM1, PM3_Strong	PM5	The c.1376G>A variant is a missense variant predicted to cause substitution of arginine by glutamine at amino acid 459 (p.Arg459Gln). This variant has been reported in at least 11 individuals with very long chain acyl-CoA dehydrogenase (VLCAD) deficiency in the literature with either significantly reduced VLCAD activity or increased C14:1 acylcarnitine levels, with two individuals displaying both reduced VLCAD activity and increased C14:1 acylcarnitine levels, which is highly specific for VLCAD deficiency (PP4_moderate; PMID: 30194637; PMID: 21429517; PMID: 19327992). In these individuals, the variant was detected three times in the homozygous state plus 1 confirmed in-trans and 5 not confirmed in-trans with the pathogenic variant c.848T>C (PM3_strong; PMID: 30194637; PMID: 21429517). The highest population minor allele frequency in gnomAD v2.1.1 is 0.00004646 in the European (non-Finnish) population, which is lower than the ClinGen ACADVL Variant Curation Expert Panel threshold (<0.001) for PM2_Supporting, meeting this criterion (PM2_Supporting). The variant is located in a well-studied dimerization domain which is critical for the protein's dimer interaction (PM1; PMID: 14517516). The computational predictor REVEL gives a score of 0.864, which is above the threshold of 0.75, evidence that correlates with impact to ACADVL function (PP3). In summary, this variant meets the criteria to be classified as pathogenic for autosomal recessive VLCAD deficiency based on the ACMG/AMP criteria applied, as specified by the ClinGen ACADVL Variant Curation Expert Panel: PP4_Moderate; PM3_Strong; PM2_Supporting; PM1; PP3  (ACADVL VCEP specifications version 1; approved November 8, 2021).		ACADVL VCEP	https://clinicalgenome.org/site/assets/files/7380/clingen_acadvl_acmg_specifications_v1.pdf	2022-08-09	2022-08-09	False	https://erepo.genome.network/evrepo/ui/classification/CA312275/MONDO:0008723/021	10b5273f-7a1b-4007-882c-82d17b0ed875	p.Arg459Gln	Arg	459	Gln	MQAARMAASLGRQLLRLGGGSSRLTALLGQPRPGPARRPYAGGAAQLALDKSDSHPSDALTRKKPAKAESKSFAVGMFKGQLTTDQVFPYPSVLNEEQTQFLKELVEPVSRFFEEVNDPAKNDALEMVEETTWQGLKELGAFGLQVPSELGGVGLCNTQYARLVEIVGMHDLGVGITLGAHQSIGFKGILLFGTKAQKEKYLPKLASGETVAAFCLTEPSSGSDAASIRTSAVPSPCGKYYTLNGSKLWISNGGLADIFTVFAKTPVTDPATGAVKEKITAFVVERGFGGITHGPPEKKMGIKASNTAEVFFDGVRVPSENVLGEVGSGFKVAMHILNNGRFGMAAALAGTMRGIIAKAVDHATNRTQFGEKIHNFGLIQEKLARMVMLQYVTESMAYMVSANMDQGATDFQIEAAISKIFGSEAAWKVTDECIQIMGGMGFMKEPGVERVLRDLRIFRIFEGTNDILRLFVALQGCMDKGKELSGLGSALKNPFGNAGLLLGEAGKQLRRRAGLGSGLSLSGLVHPELSRSGELAVRALEQFATVVEAKLIKHKKGIVNEQFLLQRLADGAIDLYAMVVVLSRASRSLSEGHPTAQHEKMLCDTWCIEAAARIREGMAALQSDPWQQELYRNFKSISKALVERGGVVTSNPLGF	655	P49748	Q	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [339], 'BINDING_gain': [], 'BINDING_loss_score': array([-0.00505382]), 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
469	NM_000018.4(ACADVL):c.848T>C (p.Val283Ala)	21025	CA285294	NM_000018.4:c.848T>C, NC_000017.11:g.7222272T>C, CM000679.2:g.7222272T>C, NC_000017.10:g.7125591T>C, CM000679.1:g.7125591T>C, NC_000017.9:g.7066315T>C, NG_007975.1:g.7439T>C, NG_008391.2:g.2779A>G, ENST00000356839.10:c.848T>C, ENST00000322910.9:c.*803T>C, ENST00000350303.9:c.782T>C, ENST00000356839.9:c.848T>C, ENST00000543245.6:c.917T>C, ENST00000577191.5:n.1020T>C, ENST00000581378.5:n.566T>C, ENST00000582379.1:n.232T>C, NM_000018.3:c.848T>C, NM_001033859.2:c.782T>C, NM_001270447.1:c.917T>C, NM_001270448.1:c.620T>C, XM_006721516.2:c.848T>C, XM_011523829.1:c.848T>C, XM_011523830.1:c.848T>C, XR_934021.1:n.955T>C, XR_934022.1:n.955T>C, XR_934023.1:n.955T>C, XM_006721516.3:c.848T>C, XM_011523829.2:c.848T>C, XM_011523830.2:c.848T>C, XM_024450741.1:c.848T>C, XR_934021.2:n.907T>C, XR_934022.2:n.907T>C, XR_934023.2:n.907T>C, NM_001033859.3:c.782T>C, NM_001270447.2:c.917T>C, NM_001270448.2:c.620T>C, NM_000018.4(ACADVL):c.848T>C (p.Val283Ala)	ACADVL	very long chain acyl-CoA dehydrogenase deficiency	MONDO:0008723	Autosomal recessive inheritance	Pathogenic	PS3_Supporting, PP4_Moderate, PP3, PM1, PM3_Strong	PM2	The c.848T>C variant in ACADVL is a missense variant predicted to cause substitution of valine by alanine at amino acid 283 (p.Val283Ala). This variant is also known as Val243Ala when numbered from the mature peptide. The variant accounts for up to 29% of individuals with very long chain acyl-CoA dehydrogenase (VLCAD) deficiency identified by newborn screen (PMID:20301763). This variant has been reported in at least 12 individuals with VLCAD in the literature with either significantly reduced VLCAD activity or increased C14:1 acylcarnitine levels, which is highly specific for VLCAD deficiency (PP4_moderate; PMID: 17999356, 26385305, 20107901, 14517516). The variant was detected at least 9 times in the homozygous state as well as at least 1 confirmed in-trans with another pathogenic variant (PM3_Strong; PMID: 20107901; 17999356, 17999356). In vitro expression showed 20-25% residual enzyme activity when expressed in COS7 cells (PS3_supporting; PMID: 9973285). The highest population minor allele frequency in gnomAD v2.1.1 is 0.002238 in the European (non-Finnish) population (PM2_Supporting, BS1, and BA1 are not met). The variant is located in a well-studied outer loop with structural importance with high homology to medium-chain acyl-CoA dehydrogenase (PM1; PMID: 14517516). The computational predictor REVEL gives a score of 0.905, which is above the threshold of 0.75, evidence that correlates with impact to ACADVL function (PP3). In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive VLCAD deficiency based on the ACMG/AMP criteria applied, as specified by the ClinGen ACADVL Variant Curation Expert Panel: PP4_Moderate, PM3_Strong, PM1, PP3, PS3_supporting (ACADVL specifications version 1; approved November 8, 2021)		ACADVL VCEP	https://clinicalgenome.org/site/assets/files/7380/clingen_acadvl_acmg_specifications_v1.pdf	2022-08-23	2022-08-23	False	https://erepo.genome.network/evrepo/ui/classification/CA285294/MONDO:0008723/021	7d9f7051-1a9d-4a3d-970a-d2e863e8a7c2	p.Val283Ala	Val	283	Ala	MQAARMAASLGRQLLRLGGGSSRLTALLGQPRPGPARRPYAGGAAQLALDKSDSHPSDALTRKKPAKAESKSFAVGMFKGQLTTDQVFPYPSVLNEEQTQFLKELVEPVSRFFEEVNDPAKNDALEMVEETTWQGLKELGAFGLQVPSELGGVGLCNTQYARLVEIVGMHDLGVGITLGAHQSIGFKGILLFGTKAQKEKYLPKLASGETVAAFCLTEPSSGSDAASIRTSAVPSPCGKYYTLNGSKLWISNGGLADIFTVFAKTPVTDPATGAVKEKITAFVVERGFGGITHGPPEKKMGIKASNTAEVFFDGVRVPSENVLGEVGSGFKVAMHILNNGRFGMAAALAGTMRGIIAKAVDHATNRTQFGEKIHNFGLIQEKLARMVMLQYVTESMAYMVSANMDQGATDFQIEAAISKIFGSEAAWKVTDECIQIMGGMGFMKEPGVERVLRDLRIFRIFEGTNDILRLFVALQGCMDKGKELSGLGSALKNPFGNAGLLLGEAGKQLRRRAGLGSGLSLSGLVHPELSRSGELAVRALEQFATVVEAKLIKHKKGIVNEQFLLQRLADGAIDLYAMVVVLSRASRSLSEGHPTAQHEKMLCDTWCIEAAARIREGMAALQSDPWQQELYRNFKSISKALVERGGVVTSNPLGF	655	P49748	A	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [46], 'PROPEP_gain': [], 'PROPEP_loss_score': array([-0.00524461]), 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [255], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.02867264]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [382], 'REPEAT_gain_score': array([0.00235111]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
470	NM_000527.5(LDLR):c.268G>A (p.Asp90Asn)	251105	CA042604	NM_000527.5:c.268G>A, NC_000019.10:g.11102741G>A, CM000681.2:g.11102741G>A, NC_000019.9:g.11213417G>A, CM000681.1:g.11213417G>A, NC_000019.8:g.11074417G>A, NG_009060.1:g.18361G>A, LRG_274:g.18361G>A, ENST00000558518.6:c.268G>A, ENST00000252444.9:n.522G>A, ENST00000455727.6:c.268G>A, ENST00000535915.5:c.190+2396G>A, ENST00000545707.5:c.268G>A, ENST00000557933.5:c.268G>A, ENST00000557958.1:n.354G>A, ENST00000558013.5:c.268G>A, ENST00000558518.5:c.268G>A, NM_000527.4:c.268G>A, LRG_274t1:c.268G>A, NM_001195798.1:c.268G>A, NM_001195799.1:c.190+2396G>A, NM_001195800.1:c.268G>A, NM_001195803.1:c.268G>A, XM_011528010.1:c.268G>A, XM_011528011.1:c.268G>A, XR_244074.2:n.418G>A, XM_011528010.2:c.268G>A, XR_001753685.2:n.385G>A, XR_001753686.2:n.385G>A, NM_001195798.2:c.268G>A, NM_001195799.2:c.190+2396G>A, NM_001195800.2:c.268G>A, NM_001195803.2:c.268G>A, NM_000527.5(LDLR):c.268G>A (p.Asp90Asn)	LDLR	hypercholesterolemia, familial	MONDO:0007750	Semidominant inheritance	Pathogenic	PM5_Strong, PS4_Moderate, PP1_Moderate, PM2, PP4, PS3_Moderate	PS1, PS2, PM4, PM1, PM3, BP7, BP5, BS1, BS3, BS4, PVS1, PM6, PP2, PP3, BS2, BP1, BP4, BP3, BP2, BA1	The NM_000527.5(LDLR):c.268G>A (p.Asp90Asn) variant is classified as Pathogenic for Familial Hypercholesterolemia by applying evidence codes PM5_Strong, PM2, PP1_Moderate, PS3_Moderate, PS4_Moderate and PP4 as defined by the ClinGen Familial Hypercholesterolemia Expert Panel LDLR-specific variant curation guidelines (https://doi.org/10.1101/2021.03.17.21252755). The supporting evidence is as follows: PM5_strong - there are 4 other missense variants is the same codon:- NM_000527.5(LDLR):c.268G>T (p.Asp90Tyr) - classified as Likely pathogenic​ by the FH VCEP, with these guidelines- NM_000527.5(LDLR):c.269A>C (p.Asp90Ala) - Likely pathogenic by these guidelines- NM_000527.5(LDLR):c.269A>G (p.Asp90Gly) - Pathogenic by these guidelines- NM_000527.5(LDLR):c.270T>A (p.Asp90Glu) - Pathogenic by these guidelines--- There are 2 variants classified as Pathogenic, so PM5_Strong is met.PP1_moderate - Variant segregates with phenotype in 4 informative meiosis from different labs: - 1 unaffected family member does not have the variant, from Molecular Genetics Laboratory (Centre for Cardiovascular Surgery and Transplantation);- 3 informative meiosis from 1 family from PMID 12837857 (Chang et al. 2003): 1 relative has the variant and phenotype (III:1), plus 2 relatives do not have the variant and do not have the phenotype (II:1 and III:2)4 informative meiosis, so PP1_Moderate is met.PM2 - PopMax MAF = 0.0008019 (0.08019%) in East Asian (gnomAD v2.1.1), but this is a founder variant in East Asian populations, so PM2 can be met in this instance.PS3_moderate - Level 2 FS: Chang et al., 2003 (PMID:12837857): Heterologous cells (COS-7), FACS assays - results: 55% LDLR cell surface and uptake. Binding is not studied, so not all cycle is studied (level 2 and not level 1)---- functional study is consistent with damaging effect, activity is below 70% of wild-type, so PS3_Moderate is met.PS4_moderate - variant meets PM2 and was identified in:- 1 index case who fulfills Simon Broome criteria of possible FH from Molecular Genetics Laboratory (Centre for Cardiovascular Surgery and Transplantation), Czech Republic;- 3 unrelated index cases, all with Dutch lipid clinic network >=6, from Robarts Research Institute, Canada;- at least 1 index case with DLCN score of definite FH from U4M - Lille University & CHRU Lille, Université de Lille - CHRU de Lille (SCV000583645.1 in ClinVar), France;- 1 index case who fulfills SB criteria of at least possible FH from PMID 9259195 (Day et al., 1997), UK;- 1 index case who fulfills SB criteria of at least possible FH from PMID 25962062 (Han et al., 2015), Korea;- 2 unrelated index cases who fulfill SB criteria of possible FH (TC>8mmol/L, plus CAD) from PMID 12837857 (Chang et al., 2003), Taiwan, China;9 cases, so PS4_Moderate is met.PP4 - variant meets PM2 and was identified in 9 unrelated index cases from different labs (see PS4 for details), so PP4 is met.		Familial Hypercholesterolemia VCEP	https://clinicalgenome.org/docs/clingen-familial-hypercholesterolemia-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1-2/	2022-08-28	2022-08-28	False	https://erepo.genome.network/evrepo/ui/classification/CA042604/MONDO:0007750/013	5eb6bd54-ae4e-4b33-9b7c-222467e9a8f8	p.Asp90Asn	Asp	90	Asn	MGPWGWKLRWTVALLLAAAGTAVGDRCERNEFQCQDGKCISYKWVCDGSAECQDGSDESQETCLSVTCKSGDFSCGGRVNRCIPQFWRCDGQVDCDNGSDEQGCPPKTCSQDEFRCHDGKCISRQFVCDSDRDCLDGSDEASCPVLTCGPASFQCNSSTCIPQLWACDNDPDCEDGSDEWPQRCRGLYVFQGDSSPCSAFEFHCLSGECIHSSWRCDGGPDCKDKSDEENCAVATCRPDEFQCSDGNCIHGSRQCDREYDCKDMSDEVGCVNVTLCEGPNKFKCHSGECITLDKVCNMARDCRDWSDEPIKECGTNECLDNNGGCSHVCNDLKIGYECLCPDGFQLVAQRRCEDIDECQDPDTCSQLCVNLEGGYKCQCEEGFQLDPHTKACKAVGSIAYLFFTNRHEVRKMTLDRSEYTSLIPNLRNVVALDTEVASNRIYWSDLSQRMICSTQLDRAHGVSSYDTVISRDIQAPDGLAVDWIHSNIYWTDSVLGTVSVADTKGVKRKTLFRENGSKPRAIVVDPVHGFMYWTDWGTPAKIKKGGLNGVDIYSLVTENIQWPNGITLDLLSGRLYWVDSKLHSISSIDVNGGNRKTILEDEKRLAHPFSLAVFEDKVFWTDIINEAIFSANRLTGSDVNLLAENLLSPEDMVLFHNLTQPRGVNWCERTTLSNGGCQYLCLPAPQINPHSPKFTCACPDGMLLARDMRSCLTEAEAAVATQETSTVRLKVSSTAVRTQHTTTRPVPDTSRLPGATPGLTTVEIVTMSHQALGDVAGRGNEKKPSSVRALSIVLPIVLLVFLCLGVFLLWKNWRLKNINSINFDNPVYQKTTEDEVHICHNQDGYSYPSRQMVSLEDDVA	860	P01130	N	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [74, 77, 97, 100], 'ZN_FING_gain': [], 'ZN_FING_loss_score': array([-0.00349182, -0.00526923, -0.01564682, -0.00836247])}
471	NM_000527.5(LDLR):c.1291G>A (p.Ala431Thr)	3695	CA023445	NM_000527.5:c.1291G>A, NC_000019.10:g.11113382G>A, CM000681.2:g.11113382G>A, NC_000019.9:g.11224058G>A, CM000681.1:g.11224058G>A, NC_000019.8:g.11085058G>A, NG_009060.1:g.29002G>A, LRG_274:g.29002G>A, ENST00000558518.6:c.1291G>A, ENST00000252444.9:n.1545G>A, ENST00000455727.6:c.787G>A, ENST00000535915.5:c.1168G>A, ENST00000545707.5:c.910G>A, ENST00000557933.5:c.1291G>A, ENST00000558013.5:c.1291G>A, ENST00000558518.5:c.1291G>A, ENST00000559340.1:n.12G>A, ENST00000560173.1:n.290G>A, ENST00000560467.1:n.771G>A, NM_000527.4:c.1291G>A, LRG_274t1:c.1291G>A, NM_001195798.1:c.1291G>A, NM_001195799.1:c.1168G>A, NM_001195800.1:c.787G>A, NM_001195803.1:c.910G>A, XM_011528010.1:c.1291G>A, XM_011528011.1:c.910G>A, XR_244074.2:n.1441G>A, XM_011528010.2:c.1291G>A, XR_001753685.2:n.1408G>A, XR_001753686.2:n.1408G>A, NM_001195798.2:c.1291G>A, NM_001195799.2:c.1168G>A, NM_001195800.2:c.787G>A, NM_001195803.2:c.910G>A, NM_000527.5(LDLR):c.1291G>A (p.Ala431Thr)	LDLR	hypercholesterolemia, familial	MONDO:0007750	Semidominant inheritance	Pathogenic	PS3, PS4, PP1_Strong, PM3, PM2, PP3, PP4	PS1, PS2, BP7, BP5, BS1, BS3, BS4, PM5, PM4, PM1, PVS1, PM6, PP2, BS2, BA1, BP1, BP4, BP3, BP2	The NM_000527.5(LDLR):c.1291G>A (p.Ala431Thr) variant is classified as Pathogenic for Familial Hypercholesterolemia by applying evidence codes PS3, PS4, PP1_Strong, PM2, PM3, PP3, PP4 as defined by the ClinGen Familial Hypercholesterolemia Expert Panel LDLR-specific variant curation guidelines (https://doi.org/10.1016/j.gim.2021.09.012). The supporting evidence is as follows: PS3 - Level 1 FS: Chang et al., 2003 (PMID 12837857): Heterologous cells (COS), FACS and WB assays - results: 22% LDLR expression, 20% LDL-LDLR binding and internalization, LDLR retained in endosomal/lysosomal regions. Activity is below 70% of wild-type, so PS3 is met. PS4 - variant meets PM2 and was identified in - 7 unrelated index cases (1 index case with Simon Broome possible FH and 6 index cases with DLCN >=6) from Centre de Génétique Moléculaire et Chromosomique, Unité de génétique de l'Obésité et des Dyslipidémies (APHP.Sorbonne Université, Hôpital de la Pitié-Salpêtrière), France;- 1 index case with Simon Broome possible FH (high chol in child w/ family hx) from Ambry Genetics, USA;- 1 index case with Simon Broome possible FH (LDL-C high, family history of high cholesterol) from GeneDx Inc, USA;- 47 unrelated index cases w/ Simon Broome possible FH from Cardiovascular Research Group, Instituto Nacional de Saude Doutor Ricardo Jorge, Portugal;- 1 index case with Simon Broome possible FH from Molecular Genetics Laboratory (Centre for Cardiovascular Surgery and Transplantation), reported in Tichy et al. 2012 PMID: 22698793, Czech Republic;at least 57 unrelated cases, so PS4 is met.PP1_strong - variant segregates with FH phenotype in 72 informative meiosis from 28 families:- 10 informative meiosis from 3 families from Centre de Génétique Moléculaire et Chromosomique, Unité de génétique de l'Obésité et des Dyslipidémies (APHP.Sorbonne Université, Hôpital de la Pitié-Salpêtrière): F1: 6 relatives with the variant have LDL >75th percentile, F2: 3 relatives with the variant have LDL >75th percentile, F3: 1 relative with the variant has LDL >75th percentile.- 28 informative meiosis from 14 families from Cardiovascular Research Group,Instituto Nacional de Saude Doutor Ricardo Jorge: in total, 21 relatives with the variant have LDL-C >75th percentile, and 7 relatives without the variant have LDL-C <50th percentile. The greatest # segregations occurring within a family is 5;- 34 informative meiosis from 11 families from Laboratory of Genetics and Molecular Cardiology, University of São Paulo: in total, 20 relatives with the variant have LDL-C >75th percentile, and 14 relatives without the variant have LDL-C <50th percentile. The greatest number of segregations occurring in a family was 9 (6 relatives positive for variant w/ phenotype, and 3 relatives negative for variant w/o phenotype).--- 72 informative meiosis support co-segregation, so PP1_Strong is metPM2 - PopMax MAF = 0.00005439 (0.005%) in East Asian exomes (gnomAD v2.1.1). It is below 0.02%, so PM2 is met. PM3 - Variant meets PM2 and was identified in - 1 index case homozygous for the variant under curation and untreated LDL = 512mg/dL from Cardiovascular Research Group,Instituto Nacional de Saude Doutor Ricardo Jorge.----- it is an homozygous patient with an homozygous phenotype, so PM3 is met.PP3 - REVEL = 0.914. It is above 0.75, so PP3 is met.PP4 - variant meets PM2 and was identified in at least 57 unrelated cases (see PS4 for details), so PP4 is met.		Familial Hypercholesterolemia VCEP	https://clinicalgenome.org/docs/clingen-familial-hypercholesterolemia-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1-2/	2022-08-28	2022-08-28	False	https://erepo.genome.network/evrepo/ui/classification/CA023445/MONDO:0007750/013	77e0bdaf-bfa7-44ce-9ab5-62ba16365a7c	p.Ala431Thr	Ala	431	Thr	MGPWGWKLRWTVALLLAAAGTAVGDRCERNEFQCQDGKCISYKWVCDGSAECQDGSDESQETCLSVTCKSGDFSCGGRVNRCIPQFWRCDGQVDCDNGSDEQGCPPKTCSQDEFRCHDGKCISRQFVCDSDRDCLDGSDEASCPVLTCGPASFQCNSSTCIPQLWACDNDPDCEDGSDEWPQRCRGLYVFQGDSSPCSAFEFHCLSGECIHSSWRCDGGPDCKDKSDEENCAVATCRPDEFQCSDGNCIHGSRQCDREYDCKDMSDEVGCVNVTLCEGPNKFKCHSGECITLDKVCNMARDCRDWSDEPIKECGTNECLDNNGGCSHVCNDLKIGYECLCPDGFQLVAQRRCEDIDECQDPDTCSQLCVNLEGGYKCQCEEGFQLDPHTKACKAVGSIAYLFFTNRHEVRKMTLDRSEYTSLIPNLRNVVALDTEVASNRIYWSDLSQRMICSTQLDRAHGVSSYDTVISRDIQAPDGLAVDWIHSNIYWTDSVLGTVSVADTKGVKRKTLFRENGSKPRAIVVDPVHGFMYWTDWGTPAKIKKGGLNGVDIYSLVTENIQWPNGITLDLLSGRLYWVDSKLHSISSIDVNGGNRKTILEDEKRLAHPFSLAVFEDKVFWTDIINEAIFSANRLTGSDVNLLAENLLSPEDMVLFHNLTQPRGVNWCERTTLSNGGCQYLCLPAPQINPHSPKFTCACPDGMLLARDMRSCLTEAEAAVATQETSTVRLKVSSTAVRTQHTTTRPVPDTSRLPGATPGLTTVEIVTMSHQALGDVAGRGNEKKPSSVRALSIVLPIVLLVFLCLGVFLLWKNWRLKNINSINFDNPVYQKTTEDEVHICHNQDGYSYPSRQMVSLEDDVA	860	P01130	T	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [345, 419, 421, 450, 453], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.0025425 , -0.10785425, -0.09411842, -0.04044598, -0.03182143]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [399, 405], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.09475625, -0.11831427]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
472	NM_000527.5(LDLR):c.1618G>A (p.Ala540Thr)	226363	CA035437	NM_000527.5:c.1618G>A, NC_000019.10:g.11116125G>A, CM000681.2:g.11116125G>A, NC_000019.9:g.11226801G>A, CM000681.1:g.11226801G>A, NC_000019.8:g.11087801G>A, NG_009060.1:g.31745G>A, LRG_274:g.31745G>A, ENST00000558518.6:c.1618G>A, ENST00000252444.9:n.1872G>A, ENST00000455727.6:c.1114G>A, ENST00000535915.5:c.1495G>A, ENST00000545707.5:c.1237G>A, ENST00000557933.5:c.1618G>A, ENST00000558013.5:c.1618G>A, ENST00000558518.5:c.1618G>A, ENST00000559340.1:n.339G>A, NM_000527.4:c.1618G>A, LRG_274t1:c.1618G>A, NM_001195798.1:c.1618G>A, NM_001195799.1:c.1495G>A, NM_001195800.1:c.1114G>A, NM_001195803.1:c.1237G>A, XM_011528010.1:c.1618G>A, XM_011528011.1:c.1237G>A, XR_244074.2:n.1768G>A, XM_011528010.2:c.1618G>A, XR_001753685.2:n.1735G>A, XR_001753686.2:n.1735G>A, NM_001195798.2:c.1618G>A, NM_001195799.2:c.1495G>A, NM_001195800.2:c.1114G>A, NM_001195803.2:c.1237G>A, NM_000527.5(LDLR):c.1618G>A (p.Ala540Thr)	LDLR	hypercholesterolemia, familial	MONDO:0007750	Semidominant inheritance	Pathogenic	PS4, PP1_Strong, PM3, PS3_Supporting, PM2, PP3, PP4	PS1, PS2, PM5, PM4, PM1, BP7, BP5, BS1, BS3, BS4, PVS1, PM6, PP2, BS2, BP1, BP4, BP3, BP2, BA1	The NM_000527.5(LDLR):c.1618G>A (p.Ala540Thr) variant is classified as Pathogenic for Familial Hypercholesterolemia by applying evidence codes PS4, PP1_Strong, PM2, PM3, PP3, PP4, PS3_Supporting as defined by the ClinGen Familial Hypercholesterolemia Expert Panel LDLR-specific variant curation guidelines (https://doi.org/10.1016/j.gim.2021.09.012). The supporting evidence is as follows: PS4 - variant meets PM2 and was identified in:- at least 1 index case with DLCN at least 8 (TC =700mg/dl) from Ambry Genetics, USA;- 14 unrelated index cases, all with DLCN >=6 from Centre de Génétique Moléculaire et Chromosomique, Unité de génétique de l'Obésité et des Dyslipidémies (APHP.Sorbonne Université, Hôpital de la Pitié-Salpêtrière), France;- at least 5 unrelated index cases (3 with Simon Broome definite FH, 2 with Simon Broome possible FH) from Molecular Genetics Laboratory (Centre for Cardiovascular Surgery and Transplantation), Czech Republic;- 2 unrelated index cases who fulfill SB criteria of possible FH from Cardiovascular Research Group,Instituto Nacional de Saude Doutor Ricardo Jorge, Portugal;- 4 unrelated index cases, all with DLCN >=6 from Cardiovascular Genetics Laboratory (PathWest Laboratory Medicine WA), Australia;- 2 unrelated index cases, all with Dutch lipid clinic network >=6 from Robarts Research Institute, Canada;- at least 1 index case with DLCN>=6 from PMID 19318025 (Alonso et al., 2009), Spain;- at least 1 index case with SB criteria for FH from PMID 21376320 Chiou et al., 2011), Taiwan,--- 30 cases, so PS4 is metPP1_strong - variant segregates with the FH phenotype in 39 informative meiosis from at least 14 families:- 20 informative meiosis from 7 families from Laboratory of Genetics and Molecular Cardiology, University of São Paulo: 16 relatives with the variant have LDL-C >75th percentile, and 4 relatives without the variant have LDL-C <50th percentile;- 1 informative meiosis from Centre de Génétique Moléculaire et Chromosomique, Unité de génétique de l'Obésité et des Dyslipidémies (APHP.Sorbonne Université, Hôpital de la Pitié-Salpêtrière): 1 relative positive for variant had LDL-C >75th percentile;- 8 informative meiosis from 3 families from Molecular Genetics Laboratory (Centre for Cardiovascular Surgery and Transplantation): F1 with 2 relatives positive for variant and having LDL-C >75th percentile, and 2 relatives negative for variant and having LDL-C <50th percentile, F2: 1 relative who was positive for the variant and had LDL-C >75th percentile, F3: 2 relatives who were positive for variant with LDL-C >75th percentile, and 1 relative who was negative for the variant with LDL-C <50th percentile;- 2 informative meiosis from 2 families from Cardiovascular Research Group,Instituto Nacional de Saude Doutor Ricardo Jorge: 1 relative positive for variant with LDL-C >75th percentile in each family;- 8 informative meiosis (unknown how many families) from Cardiovascular Genetics Laboratory (PathWest Laboratory Medicine WA): 5 relatives positive for variant with LDL-C >75th percentile, and 3 relatives were negative for variant with LDL-C <50th percentile.--- 39 segregations, so PP1_Strong is metPM2 - PopMax MAF = 0.00006533 (0.007%) in South Asian exomes (gnomAD v2.1.1). It is below than 0.02%, so PM2 is met.PM3 - variant meets PM2 and was identified in:- 1 index case homozygous for the variant with TC = 700mg/dl at 7 years old from Ambry Genetics. ---> individual is homozygous for variant and has an homozygous phenotype, so PM3 is met.- 2 unrelated index cases, both homozygous for the variant, with LDL-C 352mg/dL under statin treatment (352/0.7 = 503mg/dl) and LDL-C=409mg/dl under statin treatment (409/0.7 = 584mg/dl), respectively, both from Centre de Génétique Moléculaire et Chromosomique, Unité de génétique de l'Obésité et des Dyslipidémies (APHP.Sorbonne Université, Hôpital de la Pitié-Salpêtrière) ---> individuals are homozygous for variant and have an homozygous phenotype, so PM3 is met.PP3 - REVEL = 0.888. It is above 0.75, so PP3 is met.PP4 - variant meets PM2 and was identified in at least 30 unrelated index cases who fulfill clinical FH criteria (see PS4 for details), so PP4 is met.PS3_supporting - Level 3 FS: Sun et al., 1997 (PMID 9409298) - Htz patients' fibroblasts, immunoblot and 125I-LDL assays - results: 40-50% LDLR activity, cell surface LDLR 40-50% LDLR.--- Activity is below 85%, so PS3_Supporting is met.		Familial Hypercholesterolemia VCEP	https://clinicalgenome.org/docs/clingen-familial-hypercholesterolemia-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1-2/	2022-08-28	2022-08-28	False	https://erepo.genome.network/evrepo/ui/classification/CA035437/MONDO:0007750/013	10b60a8f-b6e6-40ce-bf9a-7a99e5b2a35b	p.Ala540Thr	Ala	540	Thr	MGPWGWKLRWTVALLLAAAGTAVGDRCERNEFQCQDGKCISYKWVCDGSAECQDGSDESQETCLSVTCKSGDFSCGGRVNRCIPQFWRCDGQVDCDNGSDEQGCPPKTCSQDEFRCHDGKCISRQFVCDSDRDCLDGSDEASCPVLTCGPASFQCNSSTCIPQLWACDNDPDCEDGSDEWPQRCRGLYVFQGDSSPCSAFEFHCLSGECIHSSWRCDGGPDCKDKSDEENCAVATCRPDEFQCSDGNCIHGSRQCDREYDCKDMSDEVGCVNVTLCEGPNKFKCHSGECITLDKVCNMARDCRDWSDEPIKECGTNECLDNNGGCSHVCNDLKIGYECLCPDGFQLVAQRRCEDIDECQDPDTCSQLCVNLEGGYKCQCEEGFQLDPHTKACKAVGSIAYLFFTNRHEVRKMTLDRSEYTSLIPNLRNVVALDTEVASNRIYWSDLSQRMICSTQLDRAHGVSSYDTVISRDIQAPDGLAVDWIHSNIYWTDSVLGTVSVADTKGVKRKTLFRENGSKPRAIVVDPVHGFMYWTDWGTPAKIKKGGLNGVDIYSLVTENIQWPNGITLDLLSGRLYWVDSKLHSISSIDVNGGNRKTILEDEKRLAHPFSLAVFEDKVFWTDIINEAIFSANRLTGSDVNLLAENLLSPEDMVLFHNLTQPRGVNWCERTTLSNGGCQYLCLPAPQINPHSPKFTCACPDGMLLARDMRSCLTEAEAAVATQETSTVRLKVSSTAVRTQHTTTRPVPDTSRLPGATPGLTTVEIVTMSHQALGDVAGRGNEKKPSSVRALSIVLPIVLLVFLCLGVFLLWKNWRLKNINSINFDNPVYQKTTEDEVHICHNQDGYSYPSRQMVSLEDDVA	860	P01130	T	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [401], 'STRAND_gain_score': array([0.02138466]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
473	NM_130839.5(UBE3A):c.815A>G (p.Asn272Ser)	156141	CA333443	NM_130839.5:c.815A>G, NC_000015.10:g.25371359T>C, CM000677.2:g.25371359T>C, NC_000015.9:g.25616506T>C, CM000677.1:g.25616506T>C, NC_000015.8:g.23167599T>C, NG_009268.1:g.72623A>G, LRG_15:g.72623A>G, ENST00000438097.6:c.755A>G, ENST00000625778.3:c.755A>G, ENST00000635914.1:c.755A>G, ENST00000637886.1:c.815A>G, ENST00000638011.1:c.755A>G, ENST00000638155.1:c.755A>G, ENST00000648336.2:c.815A>G, ENST00000649550.1:c.755A>G, ENST00000650110.1:c.824A>G, ENST00000675000.1:n.1490A>G, ENST00000675177.1:c.638A>G, ENST00000675593.1:n.3511A>G, ENST00000232165.7:c.755A>G, ENST00000397954.6:c.824A>G, ENST00000428984.6:c.755A>G, ENST00000438097.5:c.755A>G, ENST00000566215.5:c.755A>G, ENST00000614096.4:c.815A>G, ENST00000625778.2:c.755A>G, ENST00000630424.2:c.755A>G, NM_000462.3:c.824A>G, NM_130838.1:c.755A>G, LRG_15t1:c.755A>G, NM_130839.2:c.815A>G, XM_005268267.3:c.755A>G, XM_005268268.3:c.755A>G, XM_005268269.3:c.755A>G, XM_005268270.3:c.755A>G, XM_005268271.3:c.755A>G, XM_006720673.2:c.815A>G, XM_006720674.2:c.815A>G, XM_006720675.2:c.755A>G, XM_006720676.2:c.755A>G, XM_011521994.1:c.824A>G, XM_011521995.1:c.824A>G, XM_011521996.1:c.755A>G, NM_000462.5:c.824A>G, NM_001354505.1:c.815A>G, NM_001354506.1:c.755A>G, NM_001354507.1:c.755A>G, NM_001354508.1:c.755A>G, NM_001354509.1:c.755A>G, NM_001354511.1:c.755A>G, NM_001354512.1:c.755A>G, NM_001354513.1:c.755A>G, NM_001354523.1:c.755A>G, NM_001354526.1:c.755A>G, NM_001354538.1:c.815A>G, NM_001354539.1:c.755A>G, NM_001354540.1:c.755A>G, NM_001354541.1:c.755A>G, NM_001354542.1:c.755A>G, NM_001354543.1:c.755A>G, NM_001354544.1:c.755A>G, NM_001354545.1:c.815A>G, NM_001354546.1:c.638A>G, NM_001354547.1:c.755A>G, NM_001354548.1:c.755A>G, NM_001354549.1:c.755A>G, NM_001354550.1:c.361+4106A>G, NM_001354551.1:c.301+4106A>G, NM_130838.3:c.755A>G, NM_130839.4:c.815A>G, NR_146177.1:n.18393-20237T>C, NR_148916.1:n.1363A>G, XM_011521995.3:c.824A>G, XM_017022547.2:c.815A>G, XM_017022548.2:c.815A>G, XM_017022550.2:c.815A>G, XM_017022556.2:c.824A>G, XM_024450043.1:c.824A>G, XM_024450044.1:c.755A>G, NM_001354506.2:c.755A>G, NM_001354507.2:c.755A>G, NM_001354508.2:c.755A>G, NM_001354509.2:c.755A>G, NM_001354511.2:c.755A>G, NM_001354512.2:c.755A>G, NM_001354513.2:c.755A>G, NM_001354523.2:c.755A>G, NM_001354538.2:c.815A>G, NM_001354539.2:c.755A>G, NM_001354540.2:c.755A>G, NM_001354541.2:c.755A>G, NM_001354542.2:c.755A>G, NM_001354543.2:c.755A>G, NM_001354544.2:c.755A>G, NM_001354545.2:c.815A>G, NM_001354546.2:c.638A>G, NM_001354547.2:c.755A>G, NM_001354548.2:c.755A>G, NM_001354549.2:c.755A>G, NM_001354550.2:c.361+4106A>G, NM_001354551.2:c.301+4106A>G, NM_001374461.1:c.755A>G, NM_130838.4:c.755A>G, NR_148916.2:n.1331A>G, NM_130839.5(UBE3A):c.815A>G (p.Asn272Ser)	UBE3A	Angelman syndrome	MONDO:0007113	Autosomal dominant inheritance	Benign	BS2, BP4, BS1		The allele frequency of the p.Asn272Ser variant in UBE3A is 0.013% in European (Non-Finnish) sub population in gnomAD, which is high enough to be classified as likely benign based on thresholds defined by the ClinGen Rett/Angelman-like Expert Panel for Rett/AS-like conditions (BS1). The p.Asn272Ser variant is observed in at least 4 unaffected individuals (internal database) (BS2). Computational analysis prediction tools suggest that the p.Asn272Ser variant does not have a deleterious impact; however this information does not predict clinical significance on its own (BP4). In summary, the p.Asn272Ser variant in UBE3A is classified as benign based on the ACMG/AMP criteria (BS1, BS2, BP4).		Rett and Angelman-like Disorders VCEP	https://clinicalgenome.org/site/assets/files/7339/clingen_rettas_acmg_specifications_v2.pdf	2022-08-25	2022-09-06	False	https://erepo.genome.network/evrepo/ui/classification/CA333443/MONDO:0007113/016	bbc83c7e-03be-4647-b643-35aaeb0773ae	p.Asn272Ser	Asn	272	Ser	MEKLHQCYWKSGEPQSDDIEASRMKRAAAKHLIERYYHQLTEGCGNEACTNEFCASCPTFLRMDNNAAAIKALELYKINAKLCDPHPSKKGASSAYLENSKGAPNNSCSEIKMNKKGARIDFKDVTYLTEEKVYEILELCREREDYSPLIRVIGRVFSSAEALVQSFRKVKQHTKEELKSLQAKDEDKDEDEKEKAACSAAAMEEDSEASSSRIGDSSQGDNNLQKLGPDDVSVDIDAIRRVYTRLLSNEKIETAFLNALVYLSPNVECDLTYHNVYSRDPNYLNLFIIVMENRNLHSPEYLEMALPLFCKAMSKLPLAAQGKLIRLWSKYNADQIRRMMETFQQLITYKVISNEFNSRNLVNDDDAIVAASKCLKMVYYANVVGGEVDTNHNEEDDEEPIPESSELTLQELLGEERRNKKGPRVDPLETELGVKTLDCRKPLIPFEEFINEPLNEVLEMDKDYTFFKVETENKFSFMTCPFILNAVTKNLGLYYDNRIRMYSERRITVLYSLVQGQQLNPYLRLKVRRDHIIDDALVRLEMIAMENPADLKKQLYVEFEGEQGVDEGGVSKEFFQLVVEEIFNPDIGMFTYDESTKLFWFNPSSFETEGQFTLIGIVLGLAIYNNCILDVHFPMVVYRKLMGKKGTFRDLGDSHPVLYQSLKDLLEYEGNVEDDMMITFQISQTDLFGNPMMYDLKENGDKIPITNENRKEFVNLYSDYILNKSVEKQFKAFRRGFHMVTNESPLKYLFRPEEIELLICGSRNLDFQALEETTEYDGGYTRDSVLIREFWEIVHSFTDEQKRLFLQFTTGTDRAPVGGLGKLKMIIAKNGPDTERLPTSHTCFNVLLLPEYSSKEKLKERLLKAITYAKGFGML	875	Q05086	S	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
474	NM_001323289.2(CDKL5):c.1892T>C (p.Ile631Thr)	143786	CA170457	NM_001323289.2:c.1892T>C, NC_000023.11:g.18604816T>C, CM000685.2:g.18604816T>C, NC_000023.10:g.18622936T>C, CM000685.1:g.18622936T>C, NC_000023.9:g.18532857T>C, NG_008475.1:g.184212T>C, ENST00000623535.2:c.1892T>C, ENST00000635828.1:c.1892T>C, ENST00000674046.1:c.1892T>C, ENST00000379989.6:c.1892T>C, ENST00000379996.7:c.1892T>C, ENST00000463994.4:c.1892T>C, ENST00000623535.1:n.1892T>C, NM_001037343.1:c.1892T>C, NM_003159.2:c.1892T>C, XM_011545569.1:c.1841T>C, XM_011545570.1:c.1760T>C, XR_950484.1:n.2144T>C, NM_001323289.1:c.1892T>C, NM_001037343.2:c.1892T>C, NM_003159.3:c.1892T>C, NM_001323289.2(CDKL5):c.1892T>C (p.Ile631Thr)	CDKL5	CDKL5 disorder	MONDO:0100039	X-linked inheritance	Benign	BS2, BA1, BP2		The allele frequency of the p.Ile631Thr variant in CDKL5 is 0.03% in African sub population in gnomAD, which is high enough to be classified as benign based on thresholds defined by the ClinGen Rett/Angelman-like Expert Panel for Rett/AS-like conditions (BA1). The p.Ile631Thr variant is observed in at least 2 unaffected individuals (internal database) (BS2). The p.Ile631Thr variant is observed in the CDKL5 gene where a second pathogenic variant in the same gene is present in the patient (PMID 19793311) (BP2). In summary, the p.Ile631Thr variant in CDKL5 is classified as benign based on the ACMG/AMP criteria (BA1, BS2, BP2).		Rett and Angelman-like Disorders VCEP	https://clinicalgenome.org/site/assets/files/7339/clingen_rettas_acmg_specifications_v2.pdf	2022-08-25	2022-09-06	False	https://erepo.genome.network/evrepo/ui/classification/CA170457/MONDO:0100039/016	cf916b16-4fcd-40e2-96b2-4e26fb1d5f95	p.Ile631Thr	Ile	631	Thr	MKIPNIGNVMNKFEILGVVGEGAYGVVLKCRHKETHEIVAIKKFKDSEENEEVKETTLRELKMLRTLKQENIVELKEAFRRRGKLYLVFEYVEKNMLELLEEMPNGVPPEKVKSYIYQLIKAIHWCHKNDIVHRDIKPENLLISHNDVLKLCDFGFARNLSEGNNANYTEYVATRWYRSPELLLGAPYGKSVDMWSVGCILGELSDGQPLFPGESEIDQLFTIQKVLGPLPSEQMKLFYSNPRFHGLRFPAVNHPQSLERRYLGILNSVLLDLMKNLLKLDPADRYLTEQCLNHPTFQTQRLLDRSPSRSAKRKPYHVESSTLSNRNQAGKSTALQSHHRSNSKDIQNLSVGLPRADEGLPANESFLNGNLAGASLSPLHTKTYQASSQPGSTSKDLTNNNIPHLLSPKEAKSKTEFDFNIDPKPSEGPGTKYLKSNSRSQQNRHSFMESSQSKAGTLQPNEKQSRHSYIDTIPQSSRSPSYRTKAKSHGALSDSKSVSNLSEARAQIAEPSTSRYFPSSCLDLNSPTSPTPTRHSDTRTLLSPSGRNNRNEGTLDSRRTTTRHSKTMEELKLPEHMDSSHSHSLSAPHESFSYGLGYTSPFSSQQRPHRHSMYVTRDKVRAKGLDGSLSIGQGMAARANSLQLLSPQPGEQLPPEMTVARSSVKETSREGTSSFHTRQKSEGGVYHDPHSDDGTAPKENRHLYNDPVPRRVGSFYRVPSPRPDNSFHENNVSTRVSSLPSESSSGTNHSKRQPAFDPWKSPENISHSEQLKEKEKQGFFRSMKKKKKKSQTVPNSDSPDLLTLQKSIHSASTPSSRPKEWRPEKISDLQTQSQPLKSLRKLLHLSSASNHPASSDPRFQPLTAQQTKNSFSEIRIHPLSQASGGSSNIRQEPAPKGRPALQLPGQMDPGWHVSSVTRSATEGPSYSEQLGAKSGPNGHPYNRTNRSRMPNLNDLKETAL	960	O76039	T	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [16], 'SIGNAL_gain': [], 'SIGNAL_loss_score': array([-0.01463085]), 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [241], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.00448292]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [578, 633, 634, 635, 636, 637, 638, 639, 640, 641, 642, 643, 659, 829], 'COMPBIAS_gain_score': array([0.02604437, 0.52127916, 0.53102571, 0.58244699, 0.59924597,
       0.64272875, 0.55659038, 0.55904651, 0.46952999, 0.46518129,
       0.49312228, 0.46651715, 0.05341274, 0.00814062]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [584, 586, 642], 'REGION_gain_score': array([0.09198147, 0.0855186 , 0.13927186]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
475	NM_001323289.2(CDKL5):c.1523T>C (p.Ile508Thr)	143778	CA170449	NM_001323289.2:c.1523T>C, NC_000023.11:g.18604447T>C, CM000685.2:g.18604447T>C, NC_000023.10:g.18622567T>C, CM000685.1:g.18622567T>C, NC_000023.9:g.18532488T>C, NG_008475.1:g.183843T>C, ENST00000623535.2:c.1523T>C, ENST00000635828.1:c.1523T>C, ENST00000674046.1:c.1523T>C, ENST00000379989.6:c.1523T>C, ENST00000379996.7:c.1523T>C, ENST00000463994.4:c.1523T>C, ENST00000623535.1:n.1523T>C, NM_001037343.1:c.1523T>C, NM_003159.2:c.1523T>C, XM_011545569.1:c.1472T>C, XM_011545570.1:c.1391T>C, XR_950484.1:n.1775T>C, NM_001323289.1:c.1523T>C, NM_001037343.2:c.1523T>C, NM_003159.3:c.1523T>C, NM_001323289.2(CDKL5):c.1523T>C (p.Ile508Thr)	CDKL5	CDKL5 disorder	MONDO:0100039	X-linked inheritance	Benign	BS2, BP4, BS1		The allele frequency of the p.Ile508Thr variant in CDKL5 is 0.018% in European (Non-Finnish) sub population in gnomAD, which is high enough to be classified as likely benign based on thresholds defined by the ClinGen Rett/Angelman-like Expert Panel for Rett/AS-like conditions (BS1). The p.Ile508Thr variant is observed in at least 2 unaffected individuals (internal database) (BS2). Computational analysis prediction tools suggest that the p.Ile508Thr variant does not have a deleterious impact; however this information does not predict clinical significance on its own (BP4). In summary, the p.Ile508Thr variant in CDKL5 is classified as benign based on the ACMG/AMP criteria (BS1, BS2, BP4).		Rett and Angelman-like Disorders VCEP	https://clinicalgenome.org/site/assets/files/7339/clingen_rettas_acmg_specifications_v2.pdf	2022-08-25	2022-09-06	False	https://erepo.genome.network/evrepo/ui/classification/CA170449/MONDO:0100039/016	5f5fb003-d8d4-436f-ac53-e36731ee6396	p.Ile508Thr	Ile	508	Thr	MKIPNIGNVMNKFEILGVVGEGAYGVVLKCRHKETHEIVAIKKFKDSEENEEVKETTLRELKMLRTLKQENIVELKEAFRRRGKLYLVFEYVEKNMLELLEEMPNGVPPEKVKSYIYQLIKAIHWCHKNDIVHRDIKPENLLISHNDVLKLCDFGFARNLSEGNNANYTEYVATRWYRSPELLLGAPYGKSVDMWSVGCILGELSDGQPLFPGESEIDQLFTIQKVLGPLPSEQMKLFYSNPRFHGLRFPAVNHPQSLERRYLGILNSVLLDLMKNLLKLDPADRYLTEQCLNHPTFQTQRLLDRSPSRSAKRKPYHVESSTLSNRNQAGKSTALQSHHRSNSKDIQNLSVGLPRADEGLPANESFLNGNLAGASLSPLHTKTYQASSQPGSTSKDLTNNNIPHLLSPKEAKSKTEFDFNIDPKPSEGPGTKYLKSNSRSQQNRHSFMESSQSKAGTLQPNEKQSRHSYIDTIPQSSRSPSYRTKAKSHGALSDSKSVSNLSEARAQIAEPSTSRYFPSSCLDLNSPTSPTPTRHSDTRTLLSPSGRNNRNEGTLDSRRTTTRHSKTMEELKLPEHMDSSHSHSLSAPHESFSYGLGYTSPFSSQQRPHRHSMYVTRDKVRAKGLDGSLSIGQGMAARANSLQLLSPQPGEQLPPEMTVARSSVKETSREGTSSFHTRQKSEGGVYHDPHSDDGTAPKENRHLYNDPVPRRVGSFYRVPSPRPDNSFHENNVSTRVSSLPSESSSGTNHSKRQPAFDPWKSPENISHSEQLKEKEKQGFFRSMKKKKKKSQTVPNSDSPDLLTLQKSIHSASTPSSRPKEWRPEKISDLQTQSQPLKSLRKLLHLSSASNHPASSDPRFQPLTAQQTKNSFSEIRIHPLSQASGGSSNIRQEPAPKGRPALQLPGQMDPGWHVSSVTRSATEGPSYSEQLGAKSGPNGHPYNRTNRSRMPNLNDLKETAL	960	O76039	T	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [16], 'SIGNAL_gain': [], 'SIGNAL_loss_score': array([-0.00381035]), 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [241], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.00325596]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [404], 'COMPBIAS_gain_score': array([0.01624709]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
476	NM_001110792.2(MECP2):c.961C>T (p.Arg321Trp)	143749	CA199325	NM_001110792.2:c.961C>T, NC_000023.11:g.154030903G>A, CM000685.2:g.154030903G>A, NC_000023.10:g.153296354G>A, CM000685.1:g.153296354G>A, NC_000023.9:g.152949548G>A, NG_007107.2:g.111225C>T, NG_007107.3:g.111201C>T, ENST00000303391.11:c.925C>T, ENST00000453960.7:c.961C>T, ENST00000637917.1:n.99C>T, ENST00000303391.10:c.925C>T, ENST00000407218.5:c.*297C>T, ENST00000453960.6:c.961C>T, ENST00000619732.4:c.925C>T, ENST00000622433.4:c.911C>T, ENST00000628176.2:c.*297C>T, NM_001110792.1:c.961C>T, NM_001316337.1:c.646C>T, NM_004992.3:c.925C>T, XM_005274681.3:c.925C>T, XM_005274682.3:c.646C>T, XM_005274683.3:c.646C>T, XM_006724819.2:c.256C>T, XM_011531166.1:c.646C>T, XM_006724819.3:c.256C>T, XM_011531166.2:c.646C>T, XM_024452383.1:c.646C>T, XM_024452384.1:c.646C>T, NM_001316337.2:c.646C>T, NM_001369391.2:c.646C>T, NM_001369392.2:c.646C>T, NM_001369393.2:c.646C>T, NM_001369394.1:c.646C>T, NM_001369394.2:c.646C>T, NM_001386137.1:c.256C>T, NM_001386138.1:c.256C>T, NM_001386139.1:c.256C>T, NM_004992.4:c.925C>T, NM_001110792.2(MECP2):c.961C>T (p.Arg321Trp)	MECP2	Rett syndrome	MONDO:0010726	X-linked inheritance	Pathogenic	PP4, PM2_Supporting, PS2_Very Strong, PS4	PP3, BP4, PM1	The c.925C>T p.(Arg309Trp) variant in MECP2 (NM_004992.3) is absent from gnomAD (PM2_supporting). The p.(Arg309Trp) variant has been observed in at least 5 individuals, including males, with variable neurodevelopmental phenotypes consistent with MECP2-related disease (PMID 26936630, 29655203, 29720203, 28837158, 31178897, 30536762, 32214227) (PS4, PP4). One of the reported individuals with this variant was also found to be heterozygous for a de novo (biological parentage confirmed) SMC3 frameshift variant (PMID 31178897). The p.(Arg309Trp) variant has been reported as a de novo occurrence (biological parentage both confirmed and unconfirmed) in at least 3 of these individuals (PMID 31178897, 26936630) (PS2_very strong). Additional family studies have found the p.(Arg309Trp) variant to be maternally inherited in at least 2 cases (PMID 29720203, 26936630), and inherited from an unaffected mosaic parent in at least 1 case (PMID 28837158). Computational prediction analysis tools are inconclusive for this variant. In summary, the c.925C>T p.(Arg309Trp) variant in MECP2 is classified as Pathogenic for MECP2-related disease based on the ACMG/AMP criteria (PS2_very strong, PS4, PM2_supporting, PP4).		Rett and Angelman-like Disorders VCEP	https://clinicalgenome.org/site/assets/files/7339/clingen_rettas_acmg_specifications_v2.pdf	2022-07-28	2022-09-06	False	https://erepo.genome.network/evrepo/ui/classification/CA199325/MONDO:0010726/016	431d1239-3305-42a4-967d-adae00522f20	p.Arg321Trp	Arg	321	Trp	MVAGMLGLREEKSEDQDLQGLKDKPLKFKKVKKDKKEEKEGKHEPVQPSAHHSAEPAEAGKAETSEGSGSAPAVPEASASPKQRRSIIRDRGPMYDDPTLPEGWTRKLKQRKSGRSAGKYDVYLINPQGKAFRSKVELIAYFEKVGDTSLDPNDFDFTVTGRGSPSRREQKPPKKPKSPKAPGTGRGRGRPKGSGTTRPKAATSEGVQVKRVLEKSPGKLLVKMPFQTSPGGKAEGGGATTSTQVMVIKRPGRKRKAEADPQAIPKKRGRKPGSVVAAAAAEAKKKAVKESSIRSVQETVLPIKKRKTRETVSIEVKEVVKPLLVSTLGEKSGKGLKTCKSPGRKSKESSPKGRSSSASSPPKKEHHHHHHHSESPKAPVPLLPPLPPPPPEPESSEDPTSPPEPQDLSSSVCKEEKMPRGGSLESDGCPKEPAKTQPAVATAATAAEKYKHRGEGERKDIVSSSMPRPNREEPVDSRTPVTERVS	486	P51608	W	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [299, 300, 301, 303, 324, 325, 326], 'REGION_gain': [], 'REGION_loss_score': array([-0.10338581, -0.10250992, -0.09192628, -0.06823736, -0.30784768,
       -0.37565935, -0.38340467]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
477	NM_001110792.2(MECP2):c.1001C>T (p.Pro334Leu)	143754	CA270591	NM_001110792.2:c.1001C>T, NC_000023.11:g.154030863G>A, CM000685.2:g.154030863G>A, NC_000023.10:g.153296314G>A, CM000685.1:g.153296314G>A, NC_000023.9:g.152949508G>A, NG_007107.2:g.111265C>T, NG_007107.3:g.111241C>T, ENST00000303391.11:c.965C>T, ENST00000453960.7:c.1001C>T, ENST00000637917.1:n.139C>T, ENST00000303391.10:c.965C>T, ENST00000407218.5:c.*337C>T, ENST00000453960.6:c.1001C>T, ENST00000619732.4:c.965C>T, ENST00000622433.4:c.951C>T, ENST00000628176.2:c.*337C>T, NM_001110792.1:c.1001C>T, NM_001316337.1:c.686C>T, NM_004992.3:c.965C>T, XM_005274681.3:c.965C>T, XM_005274682.3:c.686C>T, XM_005274683.3:c.686C>T, XM_006724819.2:c.296C>T, XM_011531166.1:c.686C>T, XM_006724819.3:c.296C>T, XM_011531166.2:c.686C>T, XM_024452383.1:c.686C>T, XM_024452384.1:c.686C>T, NM_001316337.2:c.686C>T, NM_001369391.2:c.686C>T, NM_001369392.2:c.686C>T, NM_001369393.2:c.686C>T, NM_001369394.1:c.686C>T, NM_001369394.2:c.686C>T, NM_001386137.1:c.296C>T, NM_001386138.1:c.296C>T, NM_001386139.1:c.296C>T, NM_004992.4:c.965C>T, NM_001110792.2(MECP2):c.1001C>T (p.Pro334Leu)	MECP2	Rett syndrome	MONDO:0010726	X-linked inheritance	Pathogenic	PP4, PM2_Supporting, PM6_Strong, PS4, PM5	PP3, BP4, PM1	The c.965C>T p.(Pro322Leu) variant in MECP2 (NM_004992.3) is absent from gnomAD (PM2_supporting). The p.(Pro322Leu) variant has been observed in at least 5 individuals with Rett syndrome (PMID: 10814718, 19722030, 17089071, 16672765, 11402105, 16473305) (PS4, PP4), where it has been reported in as de novo occurrences (biological parentage unconfirmed) in at least 2 individuals (PMID 10814718, 11402105) (PM6_strong). Multiple missense variants have been previously identified within this codon, at least one of which is classified as pathogenic; this indicates that this residue is critical to the function of the protein (PMID 10814719, 16966553, 16225173, 32820509) (PM5). In summary, the c.965C>T p.(Pro322Leu) variant in MECP2 is classified as Pathogenic for Rett syndrome based on the ACMG/AMP criteria (PS4, PM6_strong, PP4, PM5).		Rett and Angelman-like Disorders VCEP	https://clinicalgenome.org/site/assets/files/7339/clingen_rettas_acmg_specifications_v2.pdf	2022-07-05	2022-09-06	False	https://erepo.genome.network/evrepo/ui/classification/CA270591/MONDO:0010726/016	4e3a5fc4-323d-4a09-8c72-f46d04b0eeb7	p.Pro334Leu	Pro	334	Leu	MVAGMLGLREEKSEDQDLQGLKDKPLKFKKVKKDKKEEKEGKHEPVQPSAHHSAEPAEAGKAETSEGSGSAPAVPEASASPKQRRSIIRDRGPMYDDPTLPEGWTRKLKQRKSGRSAGKYDVYLINPQGKAFRSKVELIAYFEKVGDTSLDPNDFDFTVTGRGSPSRREQKPPKKPKSPKAPGTGRGRGRPKGSGTTRPKAATSEGVQVKRVLEKSPGKLLVKMPFQTSPGGKAEGGGATTSTQVMVIKRPGRKRKAEADPQAIPKKRGRKPGSVVAAAAAEAKKKAVKESSIRSVQETVLPIKKRKTRETVSIEVKEVVKPLLVSTLGEKSGKGLKTCKSPGRKSKESSPKGRSSSASSPPKKEHHHHHHHSESPKAPVPLLPPLPPPPPEPESSEDPTSPPEPQDLSSSVCKEEKMPRGGSLESDGCPKEPAKTQPAVATAATAAEKYKHRGEGERKDIVSSSMPRPNREEPVDSRTPVTERVS	486	P51608	L	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [300, 301, 303, 324, 325, 326], 'REGION_gain': [], 'REGION_loss_score': array([-0.05733091, -0.0554297 , -0.05312294, -0.22559124, -0.27924496,
       -0.29799002]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
478	NM_000540.3(RYR1):c.11969G>T (p.Gly3990Val)	133027	CA023953	NM_000540.3:c.11969G>T, NC_000019.10:g.38543832G>T, CM000681.2:g.38543832G>T, NC_000019.9:g.39034472G>T, CM000681.1:g.39034472G>T, NC_000019.8:g.43726312G>T, NG_008866.1:g.115133G>T, LRG_766:g.115133G>T, ENST00000688602.1:n.379G>T, ENST00000689936.1:n.361G>T, ENST00000359596.8:c.11969G>T, ENST00000355481.8:c.11954G>T, ENST00000359596.7:n.11969G>T, ENST00000360985.7:c.11951G>T, ENST00000593322.1:n.578G>T, ENST00000594335.5:n.5338G>T, NM_000540.2:c.11969G>T, LRG_766t1:c.11969G>T, NM_001042723.1:c.11954G>T, XM_006723317.1:c.11951G>T, XM_006723319.1:c.11936G>T, XM_011527204.1:c.11966G>T, XM_011527205.1:c.11969G>T, XM_006723317.2:c.11951G>T, XM_006723319.2:c.11936G>T, XM_011527205.2:c.11969G>T, NM_001042723.2:c.11954G>T, NM_000540.3(RYR1):c.11969G>T (p.Gly3990Val)	RYR1	malignant hyperthermia, susceptibility to, 1	MONDO:0007783	Autosomal dominant inheritance	Pathogenic	PS4, PS3_Moderate, PP1_Strong	PP3, BA1, BP4, BS1, PM1	This pathogenicity assessment is relevant only for malignant hyperthermia susceptibility (MHS) inherited in an autosomal dominant pattern. Variants in RYR1 can also cause other myopathies inherited in an autosomal dominant pattern or in an autosomal recessive pattern. Some of these disorders may predispose individuals to malignant hyperthermia. RYR1 variants may also contribute to a malignant hyperthermia reaction in combination with other genetic and non-genetic factors and the clinician needs to consider such factors in making management decisions.This sequence variant predicts a substitution of glycine with valine at codon 3990 of the RYR1 protein, p.(Gly3990Val). This variant is not present in a large population database (gnomAD) at the time this variant was interpreted. This variant has been reported in 11 unrelated individuals who have a personal or family history of a malignant hyperthermia reaction, 11 of these individuals had a positive in vitro contracture test (IVCT) or caffeine halothane contracture test (CHCT) result (if the proband was unavailable for testing, a positive diagnostic test result in a mutation-positive relative was counted), PS4 (PMID:30236257). Functional studies in HEK293 cells show an increased sensitivity to RYR1 agonists, PS3_Moderate (PMID:28403410). This variant does not reside in a hotspot for pathogenic variants that contribute to MHS. This variant segregates with MHS in 10 individuals,  PP1_Strong (PMID:28403410). A REVEL score of 0.75 supports neither a pathogenic nor a benign status for this variant. This variant has been classified as Pathogenic. Criteria implemented: PS3_Moderate, PS4, PP1_Strong.		Malignant Hyperthermia Susceptibility VCEP	https://clinicalgenome.org/docs/clingen-malignant-hyperthermia-susceptibility-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-for/	2022-09-08	2022-09-08	False	https://erepo.genome.network/evrepo/ui/classification/CA023953/MONDO:0007783/012	478a28f0-a907-4bb4-8130-2e4d90fcaca8	p.Gly3990Val	Gly	3990	Val	MGDAEGEDEVQFLRTDDEVVLQCSATVLKEQLKLCLAAEGFGNRLCFLEPTSNAQNVPPDLAICCFVLEQSLSVRALQEMLANTVEAGVESSQGGGHRTLLYGHAILLRHAHSRMYLSCLTTSRSMTDKLAFDVGLQEDATGEACWWTMHPASKQRSEGEKVRVGDDIILVSVSSERYLHLSTASGELQVDASFMQTLWNMNPICSRCEEGFVTGGHVLRLFHGHMDECLTISPADSDDQRRLVYYEGGAVCTHARSLWRLEPLRISWSGSHLRWGQPLRVRHVTTGQYLALTEDQGLVVVDASKAHTKATSFCFRISKEKLDVAPKRDVEGMGPPEIKYGESLCFVQHVASGLWLTYAAPDPKALRLGVLKKKAMLHQEGHMDDALSLTRCQQEESQAARMIHSTNGLYNQFIKSLDSFSGKPRGSGPPAGTALPIEGVILSLQDLIIYFEPPSEDLQHEEKQSKLRSLRNRQSLFQEEGMLSMVLNCIDRLNVYTTAAHFAEFAGEEAAESWKEIVNLLYELLASLIRGNRSNCALFSTNLDWLVSKLDRLEASSGILEVLYCVLIESPEVLNIIQENHIKSIISLLDKHGRNHKVLDVLCSLCVCNGVAVRSNQDLITENLLPGRELLLQTNLINYVTSIRPNIFVGRAEGTTQYSKWYFEVMVDEVTPFLTAQATHLRVGWALTEGYTPYPGAGEGWGGNGVGDDLYSYGFDGLHLWTGHVARPVTSPGQHLLAPEDVISCCLDLSVPSISFRINGCPVQGVFESFNLDGLFFPVVSFSAGVKVRFLLGGRHGEFKFLPPPGYAPCHEAVLPRERLHLEPIKEYRREGPRGPHLVGPSRCLSHTDFVPCPVDTVQIVLPPHLERIREKLAENIHELWALTRIEQGWTYGPVRDDNKRLHPCLVDFHSLPEPERNYNLQMSGETLKTLLALGCHVGMADEKAEDNLKKTKLPKTYMMSNGYKPAPLDLSHVRLTPAQTTLVDRLAENGHNVWARDRVGQGWSYSAVQDIPARRNPRLVPYRLLDEATKRSNRDSLCQAVRTLLGYGYNIEPPDQEPSQVENQSRCDRVRIFRAEKSYTVQSGRWYFEFEAVTTGEMRVGWARPELRPDVELGADELAYVFNGHRGQRWHLGSEPFGRPWQPGDVVGCMIDLTENTIIFTLNGEVLMSDSGSETAFREIEIGDGFLPVCSLGPGQVGHLNLGQDVSSLRFFAICGLQEGFEPFAINMQRPVTTWFSKGLPQFEPVPLEHPHYEVSRVDGTVDTPPCLRLTHRTWGSQNSLVEMLFLRLSLPVQFHQHFRCTAGATPLAPPGLQPPAEDEARAAEPDPDYENLRRSAGGWSEAENGKEGTAKEGAPGGTPQAGGEAQPARAENEKDATTEKNKKRGFLFKAKKVAMMTQPPATPTLPRLPHDVVPADNRDDPEIILNTTTYYYSVRVFAGQEPSCVWAGWVTPDYHQHDMSFDLSKVRVVTVTMGDEQGNVHSSLKCSNCYMVWGGDFVSPGQQGRISHTDLVIGCLVDLATGLMTFTANGKESNTFFQVEPNTKLFPAVFVLPTHQNVIQFELGKQKNIMPLSAAMFQSERKNPAPQCPPRLEMQMLMPVSWSRMPNHFLQVETRRAGERLGWAVQCQEPLTMMALHIPEENRCMDILELSERLDLQRFHSHTLRLYRAVCALGNNRVAHALCSHVDQAQLLHALEDAHLPGPLRAGYYDLLISIHLESACRSRRSMLSEYIVPLTPETRAITLFPPGRSTENGHPRHGLPGVGVTTSLRPPHHFSPPCFVAALPAAGAAEAPARLSPAIPLEALRDKALRMLGEAVRDGGQHARDPVGGSVEFQFVPVLKLVSTLLVMGIFGDEDVKQILKMIEPEVFTEEEEEEDEEEEGEEEDEEEKEEDEEETAQEKEDEEKEEEEAAEGEKEEGLEEGLLQMKLPESVKLQMCHLLEYFCDQELQHRVESLAAFAERYVDKLQANQRSRYGLLIKAFSMTAAETARRTREFRSPPQEQINMLLQFKDGTDEEDCPLPEEIRQDLLDFHQDLLAHCGIQLDGEEEEPEEETTLGSRLMSLLEKVRLVKKKEEKPEEERSAEESKPRSLQELVSHMVVRWAQEDFVQSPELVRAMFSLLHRQYDGLGELLRALPRAYTISPSSVEDTMSLLECLGQIRSLLIVQMGPQEENLMIQSIGNIMNNKVFYQHPNLMRALGMHETVMEVMVNVLGGGESKEIRFPKMVTSCCRFLCYFCRISRQNQRSMFDHLSYLLENSGIGLGMQGSTPLDVAAASVIDNNELALALQEQDLEKVVSYLAGCGLQSCPMLVAKGYPDIGWNPCGGERYLDFLRFAVFVNGESVEENANVVVRLLIRKPECFGPALRGEGGSGLLAAIEEAIRISEDPARDGPGIRRDRRREHFGEEPPEENRVHLGHAIMSFYAALIDLLGRCAPEMHLIQAGKGEALRIRAILRSLVPLEDLVGIISLPLQIPTLGKDGALVQPKMSASFVPDHKASMVLFLDRVYGIENQDFLLHVLDVGFLPDMRAAASLDTATFSTTEMALALNRYLCLAVLPLITKCAPLFAGTEHRAIMVDSMLHTVYRLSRGRSLTKAQRDVIEDCLMSLCRYIRPSMLQHLLRRLVFDVPILNEFAKMPLKLLTNHYERCWKYYCLPTGWANFGVTSEEELHLTRKLFWGIFDSLAHKKYDPELYRMAMPCLCAIAGALPPDYVDASYSSKAEKKATVDAEGNFDPRPVETLNVIIPEKLDSFINKFAEYTHEKWAFDKIQNNWSYGENIDEELKTHPMLRPYKTFSEKDKEIYRWPIKESLKAMIAWEWTIEKAREGEEEKTEKKKTRKISQSAQTYDPREGYNPQPPDLSAVTLSRELQAMAEQLAENYHNTWGRKKKQELEAKGGGTHPLLVPYDTLTAKEKARDREKAQELLKFLQMNGYAVTRGLKDMELDSSSIEKRFAFGFLQQLLRWMDISQEFIAHLEAVVSSGRVEKSPHEQEIKFFAKILLPLINQYFTNHCLYFLSTPAKVLGSGGHASNKEKEMITSLFCKLAALVRHRVSLFGTDAPAVVNCLHILARSLDARTVMKSGPEIVKAGLRSFFESASEDIEKMVENLRLGKVSQARTQVKGVGQNLTYTTVALLPVLTTLFQHIAQHQFGDDVILDDVQVSCYRTLCSIYSLGTTKNTYVEKLRPALGECLARLAAAMPVAFLEPQLNEYNACSVYTTKSPRERAILGLPNSVEEMCPDIPVLERLMADIGGLAESGARYTEMPHVIEITLPMLCSYLPRWWERGPEAPPSALPAGAPPPCTAVTSDHLNSLLGNILRIIVNNLGIDEASWMKRLAVFAQPIVSRARPELLQSHFIPTIGRLRKRAGKVVSEEEQLRLEAKAEAQEGELLVRDEFSVLCRDLYALYPLLIRYVDNNRAQWLTEPNPSAEELFRMVGEIFIYWSKSHNFKREEQNFVVQNEINNMSFLTADNKSKMAKAGDIQSGGSDQERTKKKRRGDRYSVQTSLIVATLKKMLPIGLNMCAPTDQDLITLAKTRYALKDTDEEVREFLHNNLHLQGKVEGSPSLRWQMALYRGVPGREEDADDPEKIVRRVQEVSAVLYYLDQTEHPYKSKKAVWHKLLSKQRRRAVVACFRMTPLYNLPTHRACNMFLESYKAAWILTEDHSFEDRMIDDLSKAGEQEEEEEEVEEKKPDPLHQLVLHFSRTALTEKSKLDEDYLYMAYADIMAKSCHLEEGGENGEAEEEVEVSFEEKQMEKQRLLYQQARLHTRGAAEMVLQMISACKGETGAMVSSTLKLGISILNGGNAEVQQKMLDYLKDKKEVGFFQSIQALMQTCSVLDLNAFERQNKAEGLGMVNEDGTVINRQNGEKVMADDEFTQDLFRFLQLLCEGHNNDFQNYLRTQTGNTTTINIIICTVDYLLRLQESISDFYWYYSGKDVIEEQGKRNFSKAMSVAKQVFNSLTEYIQGPCTGNQQSLAHSRLWDAVVGFLHVFAHMMMKLAQDSSQIELLKELLDLQKDMVVMLLSLLEGNVVNGMIARQMVDMLVESSSNVEMILKFFDMFLKLKDIVGSEAFQDYVTDPRGLISKKDFQKAMDSQKQFSGPEIQFLLSCSEADENEMINCEEFANRFQEPARDIGFNVAVLLTNLSEHVPHDPRLHNFLELAESILEYFRPYLGRIEIMGASRRIERIYFEISETNRAQWEMPQVKESKRQFIFDVVNEGGEAEKMELFVSFCEDTIFEMQIAAQISEPEGEPETDEDEGAGAAEAGAEGAEEGAAGLEGTAATAAAGATARVVAAAGRALRGLSYRSLRRRVRRLRRLTAREAATAVAALLWAAVTRAGAAGAGAAAGALGLLWGSLFGGGLVEGAKKVTVTELLAGMPDPTSDEVHGEQPAGPGGDADGEGASEGAGDAAEGAGDEEEAVHEAGPGGADGAVAVTDGGPFRPEGAGGLGDMGDTTPAEPPTPEGSPILKRKLGVDGVEEELPPEPEPEPEPELEPEKADAENGEKEEVPEPTPEPPKKQAPPSPPPKKEEAGGEFWGELEVQRVKFLNYLSRNFYTLRFLALFLAFAINFILLFYKVSDSPPGEDDMEGSAAGDVSGAGSGGSSGWGLGAGEEAEGDEDENMVYYFLEESTGYMEPALRCLSLLHTLVAFLCIIGYNCLKVPLVIFKREKELARKLEFDGLYITEQPEDDDVKGQWDRLVLNTPSFPSNYWDKFVKRKVLDKHGDIYGRERIAELLGMDLATLEITAHNERKPNPPPGLLTWLMSIDVKYQIWKFGVIFTDNSFLYLGWYMVMSLLGHYNNFFFAAHLLDIAMGVKTLRTILSSVTHNGKQLVMTVGLLAVVVYLYTVVAFNFFRKFYNKSEDEDEPDMKCDDMMTCYLFHMYVGVRAGGGIGDEIEDPAGDEYELYRVVFDITFFFFVIVILLAIIQGLIIDAFGELRDQQEQVKEDMETKCFICGIGSDYFDTTPHGFETHTLEEHNLANYMFFLMYLINKDETEHTGQESYVWKMYQERCWDFFPAGDCFRKQYEDQLS	5038	P21817	V	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [1490], 'DISULFID_gain': [], 'DISULFID_loss_score': array([-0.00095022]), 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
479	NM_000540.2(RYR1):c.742G>C (p.Gly248Arg)	133203	CA024799	NM_000540.2:c.742G>C, NC_000019.10:g.38446710G>C, CM000681.2:g.38446710G>C, NC_000019.9:g.38937350G>C, CM000681.1:g.38937350G>C, NC_000019.8:g.43629190G>C, NG_008866.1:g.18011G>C, LRG_766:g.18011G>C, ENST00000599547.6:n.742G>C, ENST00000359596.8:c.742G>C, ENST00000355481.8:c.742G>C, ENST00000359596.7:n.742G>C, ENST00000360985.7:c.742G>C, LRG_766t1:c.742G>C, NM_001042723.1:c.742G>C, XM_006723317.1:c.742G>C, XM_006723319.1:c.742G>C, XM_011527204.1:c.742G>C, XM_011527205.1:c.742G>C, XM_006723317.2:c.742G>C, XM_006723319.2:c.742G>C, XM_011527205.2:c.742G>C, XR_001753735.1:n.825G>C, NM_000540.3:c.742G>C, NM_001042723.2:c.742G>C, NM_000540.3(RYR1):c.742G>C (p.Gly248Arg), NM_000540.2(RYR1):c.742G>C (p.Gly248Arg)	RYR1	malignant hyperthermia, susceptibility to, 1	MONDO:0007783	Autosomal dominant inheritance	Pathogenic	PP1_Moderate, PS1, PS4_Moderate, PM1_Supporting, PS3_Moderate, PP3_Moderate	BA1, BS1, BS3	This pathogenicity assessment is relevant only for malignant hyperthermia susceptibility (MHS) inherited in an autosomal dominant pattern. Variants in RYR1 can also cause other myopathies inherited in an autosomal dominant pattern or in an autosomal recessive pattern. Some of these disorders may predispose individuals to malignant hyperthermia. RYR1 variants may also contribute to a malignant hyperthermia reaction in combination with other genetic and non-genetic factors and the clinician needs to consider such factors in making management decisions.This sequence variant predicts a substitution of glycine with arginine at codon 248 of the RYR1 protein c.742G>C; p.(Gly248Arg). The maximum allele frequency for this variant among the six major gnomAD populations  is EAS: 0.00005), a frequency consistent with pathogenicity for MHS. This variant has been reported in four unrelated individuals who have a personal or family history of a malignant hyperthermia reaction and a positive in vitro contracture test (IVCT) or caffeine halothane contracture test (CHCT) result (when the proband was unavailable for testing a positive diagnostic test result in a mutation positive relative was counted), PS4_Moderate (PMID:30236257, PMID:19346234). This variant segregates with MHS in five individuals/families, PP1_Moderate (PMID:30236257, PMID:19346234, PMID:18564801). Functional studies in HEK293 cells show an increased sensitivity to RYR1 agonists, PS3_Moderate (PMID:26115329, PMID:27857962).  Another variant assessed as pathogenic occurs at this codon, c.742G>A; p.(Gly248Arg), PS1. This variant resides in a region of RYR1 considered to be a hotspot for pathogenic variants that contribute to MHS, use PM1_Supporting to avoid overweighting with PS1 (PMID: 21118704).A REVEL score > 0.85  supports pathogenicity, PP3_Moderate. This variant has been classified as Pathogenic. Criteria implemented: PS4_Moderate, PS3_Moderate, PM1_Supporting, PS1, PP1_Moderate, PP3_Moderate.	26115329, 27857962	Malignant Hyperthermia Susceptibility VCEP	https://clinicalgenome.org/docs/clingen-malignant-hyperthermia-susceptibility-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-for/	2022-09-08	2022-09-08	False	https://erepo.genome.network/evrepo/ui/classification/CA024799/MONDO:0007783/012	401b6e54-e8fe-4a87-99c9-105d6bf96366	p.Gly248Arg	Gly	248	Arg	MGDAEGEDEVQFLRTDDEVVLQCSATVLKEQLKLCLAAEGFGNRLCFLEPTSNAQNVPPDLAICCFVLEQSLSVRALQEMLANTVEAGVESSQGGGHRTLLYGHAILLRHAHSRMYLSCLTTSRSMTDKLAFDVGLQEDATGEACWWTMHPASKQRSEGEKVRVGDDIILVSVSSERYLHLSTASGELQVDASFMQTLWNMNPICSRCEEGFVTGGHVLRLFHGHMDECLTISPADSDDQRRLVYYEGGAVCTHARSLWRLEPLRISWSGSHLRWGQPLRVRHVTTGQYLALTEDQGLVVVDASKAHTKATSFCFRISKEKLDVAPKRDVEGMGPPEIKYGESLCFVQHVASGLWLTYAAPDPKALRLGVLKKKAMLHQEGHMDDALSLTRCQQEESQAARMIHSTNGLYNQFIKSLDSFSGKPRGSGPPAGTALPIEGVILSLQDLIIYFEPPSEDLQHEEKQSKLRSLRNRQSLFQEEGMLSMVLNCIDRLNVYTTAAHFAEFAGEEAAESWKEIVNLLYELLASLIRGNRSNCALFSTNLDWLVSKLDRLEASSGILEVLYCVLIESPEVLNIIQENHIKSIISLLDKHGRNHKVLDVLCSLCVCNGVAVRSNQDLITENLLPGRELLLQTNLINYVTSIRPNIFVGRAEGTTQYSKWYFEVMVDEVTPFLTAQATHLRVGWALTEGYTPYPGAGEGWGGNGVGDDLYSYGFDGLHLWTGHVARPVTSPGQHLLAPEDVISCCLDLSVPSISFRINGCPVQGVFESFNLDGLFFPVVSFSAGVKVRFLLGGRHGEFKFLPPPGYAPCHEAVLPRERLHLEPIKEYRREGPRGPHLVGPSRCLSHTDFVPCPVDTVQIVLPPHLERIREKLAENIHELWALTRIEQGWTYGPVRDDNKRLHPCLVDFHSLPEPERNYNLQMSGETLKTLLALGCHVGMADEKAEDNLKKTKLPKTYMMSNGYKPAPLDLSHVRLTPAQTTLVDRLAENGHNVWARDRVGQGWSYSAVQDIPARRNPRLVPYRLLDEATKRSNRDSLCQAVRTLLGYGYNIEPPDQEPSQVENQSRCDRVRIFRAEKSYTVQSGRWYFEFEAVTTGEMRVGWARPELRPDVELGADELAYVFNGHRGQRWHLGSEPFGRPWQPGDVVGCMIDLTENTIIFTLNGEVLMSDSGSETAFREIEIGDGFLPVCSLGPGQVGHLNLGQDVSSLRFFAICGLQEGFEPFAINMQRPVTTWFSKGLPQFEPVPLEHPHYEVSRVDGTVDTPPCLRLTHRTWGSQNSLVEMLFLRLSLPVQFHQHFRCTAGATPLAPPGLQPPAEDEARAAEPDPDYENLRRSAGGWSEAENGKEGTAKEGAPGGTPQAGGEAQPARAENEKDATTEKNKKRGFLFKAKKVAMMTQPPATPTLPRLPHDVVPADNRDDPEIILNTTTYYYSVRVFAGQEPSCVWAGWVTPDYHQHDMSFDLSKVRVVTVTMGDEQGNVHSSLKCSNCYMVWGGDFVSPGQQGRISHTDLVIGCLVDLATGLMTFTANGKESNTFFQVEPNTKLFPAVFVLPTHQNVIQFELGKQKNIMPLSAAMFQSERKNPAPQCPPRLEMQMLMPVSWSRMPNHFLQVETRRAGERLGWAVQCQEPLTMMALHIPEENRCMDILELSERLDLQRFHSHTLRLYRAVCALGNNRVAHALCSHVDQAQLLHALEDAHLPGPLRAGYYDLLISIHLESACRSRRSMLSEYIVPLTPETRAITLFPPGRSTENGHPRHGLPGVGVTTSLRPPHHFSPPCFVAALPAAGAAEAPARLSPAIPLEALRDKALRMLGEAVRDGGQHARDPVGGSVEFQFVPVLKLVSTLLVMGIFGDEDVKQILKMIEPEVFTEEEEEEDEEEEGEEEDEEEKEEDEEETAQEKEDEEKEEEEAAEGEKEEGLEEGLLQMKLPESVKLQMCHLLEYFCDQELQHRVESLAAFAERYVDKLQANQRSRYGLLIKAFSMTAAETARRTREFRSPPQEQINMLLQFKDGTDEEDCPLPEEIRQDLLDFHQDLLAHCGIQLDGEEEEPEEETTLGSRLMSLLEKVRLVKKKEEKPEEERSAEESKPRSLQELVSHMVVRWAQEDFVQSPELVRAMFSLLHRQYDGLGELLRALPRAYTISPSSVEDTMSLLECLGQIRSLLIVQMGPQEENLMIQSIGNIMNNKVFYQHPNLMRALGMHETVMEVMVNVLGGGESKEIRFPKMVTSCCRFLCYFCRISRQNQRSMFDHLSYLLENSGIGLGMQGSTPLDVAAASVIDNNELALALQEQDLEKVVSYLAGCGLQSCPMLVAKGYPDIGWNPCGGERYLDFLRFAVFVNGESVEENANVVVRLLIRKPECFGPALRGEGGSGLLAAIEEAIRISEDPARDGPGIRRDRRREHFGEEPPEENRVHLGHAIMSFYAALIDLLGRCAPEMHLIQAGKGEALRIRAILRSLVPLEDLVGIISLPLQIPTLGKDGALVQPKMSASFVPDHKASMVLFLDRVYGIENQDFLLHVLDVGFLPDMRAAASLDTATFSTTEMALALNRYLCLAVLPLITKCAPLFAGTEHRAIMVDSMLHTVYRLSRGRSLTKAQRDVIEDCLMSLCRYIRPSMLQHLLRRLVFDVPILNEFAKMPLKLLTNHYERCWKYYCLPTGWANFGVTSEEELHLTRKLFWGIFDSLAHKKYDPELYRMAMPCLCAIAGALPPDYVDASYSSKAEKKATVDAEGNFDPRPVETLNVIIPEKLDSFINKFAEYTHEKWAFDKIQNNWSYGENIDEELKTHPMLRPYKTFSEKDKEIYRWPIKESLKAMIAWEWTIEKAREGEEEKTEKKKTRKISQSAQTYDPREGYNPQPPDLSAVTLSRELQAMAEQLAENYHNTWGRKKKQELEAKGGGTHPLLVPYDTLTAKEKARDREKAQELLKFLQMNGYAVTRGLKDMELDSSSIEKRFAFGFLQQLLRWMDISQEFIAHLEAVVSSGRVEKSPHEQEIKFFAKILLPLINQYFTNHCLYFLSTPAKVLGSGGHASNKEKEMITSLFCKLAALVRHRVSLFGTDAPAVVNCLHILARSLDARTVMKSGPEIVKAGLRSFFESASEDIEKMVENLRLGKVSQARTQVKGVGQNLTYTTVALLPVLTTLFQHIAQHQFGDDVILDDVQVSCYRTLCSIYSLGTTKNTYVEKLRPALGECLARLAAAMPVAFLEPQLNEYNACSVYTTKSPRERAILGLPNSVEEMCPDIPVLERLMADIGGLAESGARYTEMPHVIEITLPMLCSYLPRWWERGPEAPPSALPAGAPPPCTAVTSDHLNSLLGNILRIIVNNLGIDEASWMKRLAVFAQPIVSRARPELLQSHFIPTIGRLRKRAGKVVSEEEQLRLEAKAEAQEGELLVRDEFSVLCRDLYALYPLLIRYVDNNRAQWLTEPNPSAEELFRMVGEIFIYWSKSHNFKREEQNFVVQNEINNMSFLTADNKSKMAKAGDIQSGGSDQERTKKKRRGDRYSVQTSLIVATLKKMLPIGLNMCAPTDQDLITLAKTRYALKDTDEEVREFLHNNLHLQGKVEGSPSLRWQMALYRGVPGREEDADDPEKIVRRVQEVSAVLYYLDQTEHPYKSKKAVWHKLLSKQRRRAVVACFRMTPLYNLPTHRACNMFLESYKAAWILTEDHSFEDRMIDDLSKAGEQEEEEEEVEEKKPDPLHQLVLHFSRTALTEKSKLDEDYLYMAYADIMAKSCHLEEGGENGEAEEEVEVSFEEKQMEKQRLLYQQARLHTRGAAEMVLQMISACKGETGAMVSSTLKLGISILNGGNAEVQQKMLDYLKDKKEVGFFQSIQALMQTCSVLDLNAFERQNKAEGLGMVNEDGTVINRQNGEKVMADDEFTQDLFRFLQLLCEGHNNDFQNYLRTQTGNTTTINIIICTVDYLLRLQESISDFYWYYSGKDVIEEQGKRNFSKAMSVAKQVFNSLTEYIQGPCTGNQQSLAHSRLWDAVVGFLHVFAHMMMKLAQDSSQIELLKELLDLQKDMVVMLLSLLEGNVVNGMIARQMVDMLVESSSNVEMILKFFDMFLKLKDIVGSEAFQDYVTDPRGLISKKDFQKAMDSQKQFSGPEIQFLLSCSEADENEMINCEEFANRFQEPARDIGFNVAVLLTNLSEHVPHDPRLHNFLELAESILEYFRPYLGRIEIMGASRRIERIYFEISETNRAQWEMPQVKESKRQFIFDVVNEGGEAEKMELFVSFCEDTIFEMQIAAQISEPEGEPETDEDEGAGAAEAGAEGAEEGAAGLEGTAATAAAGATARVVAAAGRALRGLSYRSLRRRVRRLRRLTAREAATAVAALLWAAVTRAGAAGAGAAAGALGLLWGSLFGGGLVEGAKKVTVTELLAGMPDPTSDEVHGEQPAGPGGDADGEGASEGAGDAAEGAGDEEEAVHEAGPGGADGAVAVTDGGPFRPEGAGGLGDMGDTTPAEPPTPEGSPILKRKLGVDGVEEELPPEPEPEPEPELEPEKADAENGEKEEVPEPTPEPPKKQAPPSPPPKKEEAGGEFWGELEVQRVKFLNYLSRNFYTLRFLALFLAFAINFILLFYKVSDSPPGEDDMEGSAAGDVSGAGSGGSSGWGLGAGEEAEGDEDENMVYYFLEESTGYMEPALRCLSLLHTLVAFLCIIGYNCLKVPLVIFKREKELARKLEFDGLYITEQPEDDDVKGQWDRLVLNTPSFPSNYWDKFVKRKVLDKHGDIYGRERIAELLGMDLATLEITAHNERKPNPPPGLLTWLMSIDVKYQIWKFGVIFTDNSFLYLGWYMVMSLLGHYNNFFFAAHLLDIAMGVKTLRTILSSVTHNGKQLVMTVGLLAVVVYLYTVVAFNFFRKFYNKSEDEDEPDMKCDDMMTCYLFHMYVGVRAGGGIGDEIEDPAGDEYELYRVVFDITFFFFVIVILLAIIQGLIIDAFGELRDQQEQVKEDMETKCFICGIGSDYFDTTPHGFETHTLEEHNLANYMFFLMYLINKDETEHTGQESYVWKMYQERCWDFFPAGDCFRKQYEDQLS	5038	P21817	R	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
480	NM_000152.5(GAA):c.953T>C (p.Met318Thr)	4021	CA116590	NM_000152.5:c.953T>C, NC_000017.11:g.80107894T>C, CM000679.2:g.80107894T>C, NC_000017.10:g.78081693T>C, CM000679.1:g.78081693T>C, NC_000017.9:g.75696288T>C, NG_009822.1:g.11339T>C, LRG_673:g.11339T>C, ENST00000302262.8:c.953T>C, ENST00000302262.7:c.953T>C, ENST00000390015.7:c.953T>C, NM_000152.3:c.953T>C, LRG_673t1:c.953T>C, NM_001079803.1:c.953T>C, NM_001079804.1:c.953T>C, XM_005257193.1:c.953T>C, XM_005257194.3:c.953T>C, NM_000152.4:c.953T>C, NM_001079803.2:c.953T>C, NM_001079804.2:c.953T>C, XM_005257193.2:c.953T>C, XM_005257194.4:c.953T>C, NM_001079803.3:c.953T>C, NM_001079804.3:c.953T>C, NM_000152.5(GAA):c.953T>C (p.Met318Thr)	GAA	glycogen storage disease II	MONDO:0009290	Autosomal recessive inheritance	Pathogenic	PS3_Supporting, PP4_Moderate, PP3, PM3_Very Strong, PM2_Supporting		The NM_000152.5:c.953T>C variant in GAA is a missense variant predicted to cause substitution of methionine by threonine at amino acid 318 (p.Met318Thr). Twelve probands with a diagnosis of Pompe disease were identified with this variant. At least 9 of them have GAA activity in the affected range in dried blood spots or <30% normal GAA activity in fibroblasts (PMIDs: 1652892, 19862843, 25139343, 30214072, 34357340, clinical laboratory data) with pseudodeficiency variants confirmed absent in three of these patients (clinical laboratory data) (PP4_Moderate). Of these patients, 10 are compound heterozygous for c.953T>C (p.Met318Thr) and a variant in GAA that has been classified as pathogenic by the ClinGen LSD VCEP; either c.2560C>T (p.Arg854Ter), confirmed in trans (PMID: 1652892, 19862843), c.1979G>A (p.Arg660His), confirmed in trans by parental testing (clinical diagnostic laboratory); c.-32-13T>G, phase unknown (PMIDs: 29122469, 31904026, 32317649, clinical diagnostic laboratory) (at least 5 patients, 1 confirmed in trans) c.2481+102_2646+31del (p.Gly828_Asn882del), phase unknown (clinical diagnostic laboratory), c.1292_1295dupTGCA, phase unknown (PMID: 30214072), or c.1082C>T (p.Pro361Leu), phase unknown (PMID: 25139343). One patient is homozygous for the variant (PMID: 34357340) (0.5 points) (PM3_Very Strong). Another patient is compound heterozygous for the variant and c.692+5G>T (PMID: 29181627) but the allelic data from this patient will be used in the classification of c.692+5G>T and is not included here to avoid circular logic. The highest population minor allele frequency in gnomAD v2.1.1 is 0.00009 in the African population, which is lower than the ClinGen LSD VCEP threshold (<0.001) for PM2_Suporting, and therefore meets this criterion (PM2_Supporting). Functional studies involving expression of the variant in cultured cells indicate that the variant impacts function, resulting in <2% GAA activity (PMID: 1652892, 19862843). The computational predictor REVEL gives a score of 0.89, which is above the threshold of 0.7, evidence that correlates with impact to GAA function (PP3). There is a ClinVar entry for this variant (Variation ID: 4021; 1 star review status) with 3 submitters classifying the variant as pathogenic, two as likley pathogenic and one as a variant of uncertain significance. With data from the published literature and a clinical laboratory, we find that the variant meets the criteria to be classified as pathogenic for Pompe disease. GAA-specific ACMG-AMP criteria met, as specified by the ClinGen LSD VCEP (Specifications Version 2.0): PM3_Very Strong, PP4_Moderate, PS3_Supporting, PM2_Supporting, PP3.Classification approved by the ClinGen LSD VCEP on Sept. 6, 2022.		Lysosomal Diseases VCEP	https://clinicalgenome.org/docs/clingen-lysosomal-storage-disorders-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-2/	2022-09-06	2022-09-19	False	https://erepo.genome.network/evrepo/ui/classification/CA116590/MONDO:0009290/010	de2308b1-77ef-4469-911a-9ac15ea1b98b	p.Met318Thr	Met	318	Thr	MGVRHPPCSHRLLAVCALVSLATAALLGHILLHDFLLVPRELSGSSPVLEETHPAHQQGASRPGPRDAQAHPGRPRAVPTQCDVPPNSRFDCAPDKAITQEQCEARGCCYIPAKQGLQGAQMGQPWCFFPPSYPSYKLENLSSSEMGYTATLTRTTPTFFPKDILTLRLDVMMETENRLHFTIKDPANRRYEVPLETPHVHSRAPSPLYSVEFSEEPFGVIVRRQLDGRVLLNTTVAPLFFADQFLQLSTSLPSQYITGLAEHLSPLMLSTSWTRITLWNRDLAPTPGANLYGSHPFYLALEDGGSAHGVFLLNSNAMDVVLQPSPALSWRSTGGILDVYIFLGPEPKSVVQQYLDVVGYPFMPPYWGLGFHLCRWGYSSTAITRQVVENMTRAHFPLDVQWNDLDYMDSRRDFTFNKDGFRDFPAMVQELHQGGRRYMMIVDPAISSSGPAGSYRPYDEGLRRGVFITNETGQPLIGKVWPGSTAFPDFTNPTALAWWEDMVAEFHDQVPFDGMWIDMNEPSNFIRGSEDGCPNNELENPPYVPGVVGGTLQAATICASSHQFLSTHYNLHNLYGLTEAIASHRALVKARGTRPFVISRSTFAGHGRYAGHWTGDVWSSWEQLASSVPEILQFNLLGVPLVGADVCGFLGNTSEELCVRWTQLGAFYPFMRNHNSLLSLPQEPYSFSEPAQQAMRKALTLRYALLPHLYTLFHQAHVAGETVARPLFLEFPKDSSTWTVDHQLLWGEALLITPVLQAGKAEVTGYFPLGTWYDLQTVPVEALGSLPPPPAAPREPAIHSEGQWVTLPAPLDTINVHLRAGYIIPLQGPGLTTTESRQQPMALAVALTKGGEARGELFWDDGESLEVLERGAYTQVIFLARNNTIVNELVRVTSEGAGLQLQKVTVLGVATAPQQVLSNGVPVSNFTYSPDTKVLDICVSLLMGEQFLVSWC	952	P10253	T	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [429, 658], 'DNA_BIND_gain_score': array([0.00193477, 0.0017972 ]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [666], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.00184155]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
481	NM_000018.4(ACADVL):c.128G>A (p.Gly43Asp)	21015	CA341517	NM_000018.4:c.128G>A, NC_000017.11:g.7220187G>A, CM000679.2:g.7220187G>A, NC_000017.10:g.7123506G>A, CM000679.1:g.7123506G>A, NC_000017.9:g.7064230G>A, NG_007975.1:g.5354G>A, NG_008391.2:g.4864C>T, ENST00000356839.10:c.128G>A, ENST00000322910.9:c.*83G>A, ENST00000350303.9:c.128G>A, ENST00000356839.9:c.128G>A, ENST00000543245.6:c.197G>A, ENST00000577191.5:n.205G>A, ENST00000577857.5:n.218G>A, ENST00000578269.5:n.235G>A, ENST00000578421.1:n.262G>A, ENST00000579286.5:n.235G>A, ENST00000579886.2:c.128G>A, ENST00000580263.5:n.218G>A, ENST00000581562.5:n.175G>A, ENST00000582056.5:n.218G>A, ENST00000582356.5:n.253G>A, ENST00000583312.5:c.128G>A, ENST00000584103.5:c.128G>A, NM_000018.3:c.128G>A, NM_001033859.2:c.128G>A, NM_001270447.1:c.197G>A, NM_001270448.1:c.-101G>A, XM_006721516.2:c.128G>A, XM_011523829.1:c.128G>A, XM_011523830.1:c.128G>A, XR_934021.1:n.235G>A, XR_934022.1:n.235G>A, XR_934023.1:n.235G>A, XM_006721516.3:c.128G>A, XM_011523829.2:c.128G>A, XM_011523830.2:c.128G>A, XM_024450741.1:c.128G>A, XR_934021.2:n.187G>A, XR_934022.2:n.187G>A, XR_934023.2:n.187G>A, NM_001033859.3:c.128G>A, NM_001270447.2:c.197G>A, NM_001270448.2:c.-101G>A, NM_000018.4(ACADVL):c.128G>A (p.Gly43Asp)	ACADVL	very long chain acyl-CoA dehydrogenase deficiency	MONDO:0008723	Autosomal recessive inheritance	Benign	BA1, BP4, BP2		The c.128G>A variant in ACADVL is well characterized as a benign polymorphism, being present in several VLCAD cases with alternate pathogenic variants (BP2; PMIDs: 11914034, 15210884, more in literature). The highest population minor allele frequency in gnomAD v2.1.1 is 0.17 in the East Asian population, which is higher than the ClinGen ACADVL Variant Curation Expert Panel threshold (≥0.007) for BA1, and therefore meets this criterion (BA1). The computational predictor REVEL gives a score of 0.259, which is below the threshold of 0.5, evidence that does not predict a damaging effect on ACADVL function (BP4). In summary, this variant meets criteria to be classified as benign for very long chain acyl-CoA dehydrogenase deficiency in an autosomal recessive manner. ACADVL-specific ACMG/AMP criteria applied: BA1; BP2; BP4		ACADVL VCEP	https://clinicalgenome.org/site/assets/files/7380/clingen_acadvl_acmg_specifications_v1.pdf	2022-09-22	2022-09-22	False	https://erepo.genome.network/evrepo/ui/classification/CA341517/MONDO:0008723/021	9f8832bb-a666-4dd7-b38a-df471b3b5691	p.Gly43Asp	Gly	43	Asp	MQAARMAASLGRQLLRLGGGSSRLTALLGQPRPGPARRPYAGGAAQLALDKSDSHPSDALTRKKPAKAESKSFAVGMFKGQLTTDQVFPYPSVLNEEQTQFLKELVEPVSRFFEEVNDPAKNDALEMVEETTWQGLKELGAFGLQVPSELGGVGLCNTQYARLVEIVGMHDLGVGITLGAHQSIGFKGILLFGTKAQKEKYLPKLASGETVAAFCLTEPSSGSDAASIRTSAVPSPCGKYYTLNGSKLWISNGGLADIFTVFAKTPVTDPATGAVKEKITAFVVERGFGGITHGPPEKKMGIKASNTAEVFFDGVRVPSENVLGEVGSGFKVAMHILNNGRFGMAAALAGTMRGIIAKAVDHATNRTQFGEKIHNFGLIQEKLARMVMLQYVTESMAYMVSANMDQGATDFQIEAAISKIFGSEAAWKVTDECIQIMGGMGFMKEPGVERVLRDLRIFRIFEGTNDILRLFVALQGCMDKGKELSGLGSALKNPFGNAGLLLGEAGKQLRRRAGLGSGLSLSGLVHPELSRSGELAVRALEQFATVVEAKLIKHKKGIVNEQFLLQRLADGAIDLYAMVVVLSRASRSLSEGHPTAQHEKMLCDTWCIEAAARIREGMAALQSDPWQQELYRNFKSISKALVERGGVVTSNPLGF	655	P49748	D	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [41, 42, 43, 44], 'TOPO_DOM_gain_score': array([0.23655343, 0.37405252, 0.3411938 , 0.31030405]), 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [41, 48], 'PROPEP_gain': [45], 'PROPEP_gain_score': array([0.01630437]), 'PROPEP_loss_score': array([-0.00661957, -0.01018596]), 'SIGNAL_loss': [], 'SIGNAL_gain': [22], 'SIGNAL_gain_score': array([0.09747344]), 'TRANSIT_loss': [40], 'TRANSIT_gain': [], 'TRANSIT_loss_score': array([-0.14575785]), 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [169, 337], 'HELIX_gain_score': array([0.00957352, 0.00263596]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [50, 51, 52], 'COMPBIAS_gain_score': array([0.20287585, 0.2194429 , 0.19490826]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [30, 31, 32, 34], 'REGION_gain_score': array([0.13991171, 0.14071125, 0.17274147, 0.20458829]), 'REPEAT_loss': [], 'REPEAT_gain': [382], 'REPEAT_gain_score': array([0.00187337]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
482	NM_000018.4(ACADVL):c.49C>T (p.Leu17Phe)	21022	CA341522	NM_000018.4:c.49C>T, NC_000017.11:g.7220033C>T, CM000679.2:g.7220033C>T, NC_000017.10:g.7123352C>T, CM000679.1:g.7123352C>T, NC_000017.9:g.7064076C>T, NG_007975.1:g.5200C>T, NG_008391.2:g.5018G>A, ENST00000356839.10:c.49C>T, ENST00000322910.9:c.49C>T, ENST00000350303.9:c.49C>T, ENST00000356839.9:c.49C>T, ENST00000543245.6:c.132-89C>T, ENST00000577191.5:n.126C>T, ENST00000577857.5:n.139C>T, ENST00000578269.5:n.156C>T, ENST00000578421.1:n.108C>T, ENST00000579286.5:n.156C>T, ENST00000579886.2:c.49C>T, ENST00000580263.5:n.139C>T, ENST00000581562.5:n.96C>T, ENST00000582056.5:n.139C>T, ENST00000582356.5:n.174C>T, ENST00000583312.5:c.49C>T, ENST00000584103.5:c.49C>T, NM_000018.3:c.49C>T, NM_001033859.2:c.49C>T, NM_001270447.1:c.132-89C>T, NM_001270448.1:c.-255C>T, NM_001365.3:c.-1184G>A, XM_006721516.2:c.49C>T, XM_011523829.1:c.49C>T, XM_011523830.1:c.49C>T, XR_934021.1:n.156C>T, XR_934022.1:n.156C>T, XR_934023.1:n.156C>T, NM_001321074.1:c.-1184G>A, NM_001365.4:c.-1184G>A, NR_135527.1:n.18G>A, XM_006721516.3:c.49C>T, XM_011523829.2:c.49C>T, XM_011523830.2:c.49C>T, XM_024450741.1:c.49C>T, XR_934021.2:n.108C>T, XR_934022.2:n.108C>T, XR_934023.2:n.108C>T, NM_001033859.3:c.49C>T, NM_001270447.2:c.132-89C>T, NM_001270448.2:c.-255C>T, NM_000018.4(ACADVL):c.49C>T (p.Leu17Phe)	ACADVL	very long chain acyl-CoA dehydrogenase deficiency	MONDO:0008723	Autosomal recessive inheritance	Benign	BA1, BP4	PP4, BS2, PM1	The c.49C>T variant in ACADVL has been reported as part of premature screening panels, however no probands have shown increased VLCAD activity or newborn screening (PMID: 23480858). The highest population minor allele frequency in gnomAD v2.1.1 is 0.06989 in the African population, which is higher than the ClinGen ACADVL Variant Curation Expert Panel threshold (≥0.007) for BA1, and therefore meets this criterion (BA1). The computational predictor REVEL gives a score of 0.236, which is below the threshold of 0.5, evidence that does not predict a damaging effect on ACADVL function (BP4). In summary, this variant meets criteria to be classified as benign for very long chain acyl-CoA dehydrogenase deficiency in an autosomal recessive manner. ACADVL-specific ACMG/AMP criteria applied: BA1; BP4		ACADVL VCEP	https://clinicalgenome.org/site/assets/files/7380/clingen_acadvl_acmg_specifications_v1.pdf	2022-09-22	2022-09-22	False	https://erepo.genome.network/evrepo/ui/classification/CA341522/MONDO:0008723/021	8cb4ff32-8a03-4e0b-a3f1-75c3222ef92b	p.Leu17Phe	Leu	17	Phe	MQAARMAASLGRQLLRLGGGSSRLTALLGQPRPGPARRPYAGGAAQLALDKSDSHPSDALTRKKPAKAESKSFAVGMFKGQLTTDQVFPYPSVLNEEQTQFLKELVEPVSRFFEEVNDPAKNDALEMVEETTWQGLKELGAFGLQVPSELGGVGLCNTQYARLVEIVGMHDLGVGITLGAHQSIGFKGILLFGTKAQKEKYLPKLASGETVAAFCLTEPSSGSDAASIRTSAVPSPCGKYYTLNGSKLWISNGGLADIFTVFAKTPVTDPATGAVKEKITAFVVERGFGGITHGPPEKKMGIKASNTAEVFFDGVRVPSENVLGEVGSGFKVAMHILNNGRFGMAAALAGTMRGIIAKAVDHATNRTQFGEKIHNFGLIQEKLARMVMLQYVTESMAYMVSANMDQGATDFQIEAAISKIFGSEAAWKVTDECIQIMGGMGFMKEPGVERVLRDLRIFRIFEGTNDILRLFVALQGCMDKGKELSGLGSALKNPFGNAGLLLGEAGKQLRRRAGLGSGLSLSGLVHPELSRSGELAVRALEQFATVVEAKLIKHKKGIVNEQFLLQRLADGAIDLYAMVVVLSRASRSLSEGHPTAQHEKMLCDTWCIEAAARIREGMAALQSDPWQQELYRNFKSISKALVERGGVVTSNPLGF	655	P49748	F	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [41, 46], 'PROPEP_gain': [], 'PROPEP_loss_score': array([-0.00591409, -0.00619739]), 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [337], 'HELIX_gain_score': array([0.00126827]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [33], 'REGION_gain': [], 'REGION_loss_score': array([-0.02752161]), 'REPEAT_loss': [], 'REPEAT_gain': [382], 'REPEAT_gain_score': array([0.00454175]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
483	NM_000156.6(GAMT):c.626C>T (p.Thr209Met)	21068	CA288884	NM_000156.6:c.626C>T, NC_000019.10:g.1397444G>A, CM000681.2:g.1397444G>A, NC_000019.9:g.1397443G>A, CM000681.1:g.1397443G>A, NC_000019.8:g.1348443G>A, NG_008283.1:g.18561G>A, NG_009785.1:g.9110C>T, ENST00000252288.8:c.626C>T, ENST00000640164.1:n.459C>T, ENST00000640762.1:c.557C>T, ENST00000252288.6:c.626C>T, NM_000156.5:c.626C>T, NM_000156.6(GAMT):c.626C>T (p.Thr209Met)	GAMT	guanidinoacetate methyltransferase deficiency	MONDO:0012999	Autosomal recessive inheritance	Benign	BS2, BA1, BP4		The NM_000156.6:c.626C>T variant in GAMT is a missense variant predicted to result in the substitution of threonine for methionine at amino acid 209 (p.Thr209Met). The highest continental population minor allele frequency in gnomAD v2.1.1 is 0.09656 (12354/ 127944 alleles) in the European non-Finnish population, which is higher than the ClinGen CCDS VCEP’s threshold for BA1 (>0.003), and therefore meets this criterion (BA1). There are 987 homozygotes in gnomAD v2.1.1. Given that GAMT deficiency has an early onset, this data supports that the variant does not cause the condition (BS2). The computational predictor REVEL gives a score of 0.313 which is below the threshold of 0.5, evidence that does not predict a damaging effect on GAMT function (BP4). It has been previously reported in a large Italian family (PMID: 12468279), where it did not segregate with AGAT deficiency, including being found in the homozygous state in the father, who was asymptomatic and had normal GAMT enzyme activity. It has also been found in presumed cis with the c.160G>C (p.Ala54Pro) variant in a patient with severe GAMT deficiency, as both parents were heterozygous for both the c.160G>C variant and c.626C>T variant and the patient was homozygous for both variants (PMID: 15108290). In this publication (PMID: 15108290), the c.626C>T was classified as a benign polymorphism due to its high frequency in a group of control individuals screened. It is noted in ClinVar (Variation ID: 21068). In summary, this variant meets the criteria to be classified as benign for GAMT deficiency. GAMT-specific ACMG/AMP codes met, as specified by the ClinGen Cerebral Creatine Deficiency Syndromes VCEP (Specifications Version 1.1.0): BA1, BS2, BP4.(Classification approved by the ClinGen CCDS VCEP on June 6, 2022).		Cerebral Creatine Deficiency Syndromes VCEP		2022-06-06	2022-10-07	False	https://erepo.genome.network/evrepo/ui/classification/CA288884/MONDO:0012999/026	9aa14816-bf8f-42a3-9555-5bb338d9c1c0	p.Thr209Met	Thr	209	Met	MSAPSATPIFAPGENCSPAWGAAPAAYDAADTHLRILGKPVMERWETPYMHALAAAASSKGGRVLEVGFGMAIAASKVQEAPIDEHWIIECNDGVFQRLRDWAPRQTHKVIPLKGLWEDVAPTLPDGHFDGILYDTYPLSEETWHTHQFNFIKNHAFRLLKPGGVLTYCNLTSWGELMKSKYSDITIMFEETQVPALLEAGFRRENIRTEVMALVPPADCRYYAFPQMITPLVTKG	236	Q14353	M	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [3, 4], 'TRANSIT_gain_score': array([0.01194108, 0.01116008]), 'STRAND_loss': [202], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.08532786]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
484	NM_005629.4(SLC6A8):c.544G>A (p.Val182Met)	465147	CA10549204	NM_005629.4:c.544G>A, NC_000023.11:g.153691453G>A, CM000685.2:g.153691453G>A, NC_000023.10:g.152956908G>A, CM000685.1:g.152956908G>A, NC_000023.9:g.152610102G>A, NG_012016.1:g.8157G>A, NG_012016.2:g.8157G>A, ENST00000253122.10:c.544G>A, ENST00000675713.1:n.298G>A, ENST00000253122.9:c.544G>A, ENST00000430077.6:c.199G>A, ENST00000466243.1:n.336G>A, ENST00000467402.1:n.91G>A, NM_001142805.1:c.544G>A, NM_001142806.1:c.199G>A, NM_005629.3:c.544G>A, NM_001142805.2:c.544G>A, NM_005629.4(SLC6A8):c.544G>A (p.Val182Met)	SLC6A8	creatine transporter deficiency	MONDO:0010305	X-linked inheritance	Benign	BS1, BS2, BP4		The NM_005629.4:c.544G>A variant in SLC6A8 is a missense variant predicted to cause substitution of valine by methionine at amino acid 182 (p.Val182Met). The highest population minor allele frequency in gnomAD v2.1.1 is 0.00084 (16/19086 alleles) in the African/African American population, meeting the CCDS VCEP’s allele frequency threshold for BS1 (>0.0002) (BS1). This variant is present in 5 or more hemizygotes in gnomAD v2.1.1 (BS2). Furthermore, the variant did not segregate with intellectual disability in multiple brothers, and the proband with the variant had normal urine creatine and normal cerebral creatine on 1H-magnetic resonance spectroscopy (PMID 16738945). The computational predictor REVEL gives a score of 0.184, evidence that does not predict a damaging effect on SLC6A8 function, and SpliceAI predicts no impact of the variant on splicing (BP4). There is a ClinVar entry for this variant (Variation ID: 465147). In summary, this variant meets the criteria to be classified as benign for creatine transporter deficiency. SLC6A8-specific ACMG/AMP codes met, as specified by the ClinGen CCDS VCEP (Specifications Version 1.1.0): BS1, BS2, BP4.(Classification approved by the ClinGen CCDS VCEP on June 6, 2022).		Cerebral Creatine Deficiency Syndromes VCEP		2022-06-06	2022-10-08	False	https://erepo.genome.network/evrepo/ui/classification/CA10549204/MONDO:0010305/027	91859ceb-d576-431c-b9fe-8e45c136f694	p.Val182Met	Val	182	Met	MAKKSAENGIYSVSGDEKKGPLIAPGPDGAPAKGDGPVGLGTPGGRLAVPPRETWTRQMDFIMSCVGFAVGLGNVWRFPYLCYKNGGGVFLIPYVLIALVGGIPIFFLEISLGQFMKAGSINVWNICPLFKGLGYASMVIVFYCNTYYIMVLAWGFYYLVKSFTTTLPWATCGHTWNTPDCVEIFRHEDCANASLANLTCDQLADRRSPVIEFWENKVLRLSGGLEVPGALNWEVTLCLLACWVLVYFCVWKGVKSTGKIVYFTATFPYVVLVVLLVRGVLLPGALDGIIYYLKPDWSKLGSPQVWIDAGTQIFFSYAIGLGALTALGSYNRFNNNCYKDAIILALINSGTSFFAGFVVFSILGFMAAEQGVHISKVAESGPGLAFIAYPRAVTLMPVAPLWAALFFFMLLLLGLDSQFVGVEGFITGLLDLLPASYYFRFQREISVALCCALCFVIDLSMVTDGGMYVFQLFDYYSASGTTLLWQAFWECVVVAWVYGADRFMDDIACMIGYRPCPWMKWCWSFFTPLVCMGIFIFNVVYYEPLVYNNTYVYPWWGEAMGWAFALSSMLCVPLHLLGCLLRAKGTMAERWQHLTQPIWGLHHLEYRAQDADVRGLTTLTPVSESSKVVVVESVM	635	P48029	M	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [131], 'DNA_BIND_gain': [], 'DNA_BIND_loss_score': array([-0.00598329]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [392], 'TRANSMEM_gain': [134], 'TRANSMEM_gain_score': array([0.00728291]), 'TRANSMEM_loss_score': array([-0.00212818]), 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [148], 'DOMAIN_gain': [340], 'DOMAIN_gain_score': array([0.00462168]), 'DOMAIN_loss_score': array([-0.01355016]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
485	NM_000152.5(GAA):c.1210G>A (p.Asp404Asn)	657348	CA8815234	NM_000152.5:c.1210G>A, NC_000017.11:g.80108712G>A, CM000679.2:g.80108712G>A, NC_000017.10:g.78082511G>A, CM000679.1:g.78082511G>A, NC_000017.9:g.75697106G>A, NG_009822.1:g.12157G>A, LRG_673:g.12157G>A, ENST00000302262.8:c.1210G>A, ENST00000302262.7:c.1210G>A, ENST00000390015.7:c.1210G>A, NM_000152.3:c.1210G>A, LRG_673t1:c.1210G>A, NM_001079803.1:c.1210G>A, NM_001079804.1:c.1210G>A, XM_005257193.1:c.1210G>A, XM_005257194.3:c.1210G>A, NM_000152.4:c.1210G>A, NM_001079803.2:c.1210G>A, NM_001079804.2:c.1210G>A, XM_005257193.2:c.1210G>A, XM_005257194.4:c.1210G>A, NM_001079803.3:c.1210G>A, NM_001079804.3:c.1210G>A, NM_000152.5(GAA):c.1210G>A (p.Asp404Asn)	GAA	glycogen storage disease II	MONDO:0009290	Autosomal recessive inheritance	Pathogenic	PM3_Strong, PS3_Supporting, PP4_Moderate, PP3, PM2_Supporting, PM1	PM5	The NM_000152.5:c.1210G>A variant in GAA is a missense variant predicted to cause substitution of aspartate by asparagine at amino acid 404 (p.Asp404Asn). At least 9 individuals with Pompe disease have been reported with this variant including individuals with documentation of deficient GAA activity and/or combination of clinical features of IOPD and on enzyme replacement therapy (PMID: 16433701, 22538254, 25687635, 26497565, 29205646) (PP4_Moderate). Four patients with Pompe disease are compound heterozygous for the variant, phase unknown, and a variant in GAA that has been classified as pathogenic by the ClinGen LSD VCEP, including c.1064T>C (p.Leu355Pro) (PMIDs 22658377, 23787031, 31193175), c.2481+102_2646+31del (PMID 22538254, 31086307), c.2227C>T (p.Gln743Ter) (PMID 25687635, 29205646), and c.2560C>T (p.Arg854Ter) (PMID 26497565) (0.5 points). In addition, the variant was found in a child in trans with c.2432delT, and his father in trans with c.-32-13T>G (PMID 16433701) (PM3_Strong).  The variant has also been reported in compound heterozygosity with c.1445C>T (p.Pro482Leu)(PMID 31086307), c.1979G>A (p.Arg660His) (PMID 31086307), and c.1924G>T (p.Val642Phe) (PMID 29122469). The allelic data from these patients will be used in the assessment of the second variant and is not included here to avoid circular logic. The highest population minor allele frequency in a continental population in gnomAD v2.1.1 is 0.00006 (1/15828 alleles) in the African population, which is lower than the ClinGen LSD VCEP’s threshold for PM2_Supporting (<0.001), meeting this criterion (PM2_Supporting). This variant alters amino acid Asp404, a residue that crystallography studies have shown to be important in the active site of GAA, and therefore has been defined as a critical residue by the ClinGen LSD VCEP (https://www.biorxiv.org/content/10.1101/212837v1.full.pdf, PMID: 29061980) (PM1). When expressed in COS or HEK293 cells, this variant resulted in normal intracellular amounts of 110 kDa precursor, 95 kDa intermediate and 76 kDa mature forms of GAA but <2% wild type activity of GAA indicating that this variant may impact protein function (PMID 19862843,  24384324)(PS3_Supporting). The computational predictor REVEL gives a score of 0.869 which is above the threshold of 0.7, evidence that correlates with impact to GAA function (PP3). Four different missense variants, c.1211A>G (p.Asp404Gly), c.1211A>C (p.Asp404Ala), c.1211A>T (p.Asp404Val), and c.1212C>G (p.Asp404Glu), in the same codon have been reported in patients with Pompe disease (see http://www.pompevariantdatabase.nl/). The data from this variant (c.1210G>A (p.Asp404Asn) will be used to support the classification of the other missense substitutions of Asp404 and is not included here to avoid circular logic. There is a ClinVar entry for this variant (Variation ID: 657348, 2 star review status) with five submitters classifying the variant as pathogenic and two as likely pathogenic. In summary, this variant meets the criteria to be classified as pathogenic for Pompe disease based on the ACMG/AMP criteria applied, as specified by the ClinGen Lysosomal Storage Disorder Variant Curation Expert Panel (Specifications Version 2.0): PM3_Strong, PM1, PP4_Moderate, PP3, PS3_Supporting, PM2_Supporting.(Classification approved by the ClinGen LSD VCEP on Sept 21, 2022).	24384324	Lysosomal Diseases VCEP	https://clinicalgenome.org/docs/clingen-lysosomal-storage-disorders-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-2/	2022-09-21	2022-10-21	False	https://erepo.genome.network/evrepo/ui/classification/CA8815234/MONDO:0009290/010	13d44d46-c6e9-4a49-af4b-41db6c72811b	p.Asp404Asn	Asp	404	Asn	MGVRHPPCSHRLLAVCALVSLATAALLGHILLHDFLLVPRELSGSSPVLEETHPAHQQGASRPGPRDAQAHPGRPRAVPTQCDVPPNSRFDCAPDKAITQEQCEARGCCYIPAKQGLQGAQMGQPWCFFPPSYPSYKLENLSSSEMGYTATLTRTTPTFFPKDILTLRLDVMMETENRLHFTIKDPANRRYEVPLETPHVHSRAPSPLYSVEFSEEPFGVIVRRQLDGRVLLNTTVAPLFFADQFLQLSTSLPSQYITGLAEHLSPLMLSTSWTRITLWNRDLAPTPGANLYGSHPFYLALEDGGSAHGVFLLNSNAMDVVLQPSPALSWRSTGGILDVYIFLGPEPKSVVQQYLDVVGYPFMPPYWGLGFHLCRWGYSSTAITRQVVENMTRAHFPLDVQWNDLDYMDSRRDFTFNKDGFRDFPAMVQELHQGGRRYMMIVDPAISSSGPAGSYRPYDEGLRRGVFITNETGQPLIGKVWPGSTAFPDFTNPTALAWWEDMVAEFHDQVPFDGMWIDMNEPSNFIRGSEDGCPNNELENPPYVPGVVGGTLQAATICASSHQFLSTHYNLHNLYGLTEAIASHRALVKARGTRPFVISRSTFAGHGRYAGHWTGDVWSSWEQLASSVPEILQFNLLGVPLVGADVCGFLGNTSEELCVRWTQLGAFYPFMRNHNSLLSLPQEPYSFSEPAQQAMRKALTLRYALLPHLYTLFHQAHVAGETVARPLFLEFPKDSSTWTVDHQLLWGEALLITPVLQAGKAEVTGYFPLGTWYDLQTVPVEALGSLPPPPAAPREPAIHSEGQWVTLPAPLDTINVHLRAGYIIPLQGPGLTTTESRQQPMALAVALTKGGEARGELFWDDGESLEVLERGAYTQVIFLARNNTIVNELVRVTSEGAGLQLQKVTVLGVATAPQQVLSNGVPVSNFTYSPDTKVLDICVSLLMGEQFLVSWC	952	P10253	N	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [375, 377, 420, 507, 508, 704, 714, 716], 'DNA_BIND_gain': [423, 429], 'DNA_BIND_gain_score': array([0.01703459, 0.00542885]), 'DNA_BIND_loss_score': array([-0.00174302, -0.01061517, -0.00240123, -0.00539708, -0.00550067,
       -0.0032872 , -0.0129205 , -0.00573105]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [208, 214, 233], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.07980186, -0.06322664, -0.10674131]), 'HELIX_loss': [453, 606], 'HELIX_gain': [364], 'HELIX_gain_score': array([0.0273996]), 'HELIX_loss_score': array([-0.04298055, -0.03608567]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [384, 386, 427, 433, 434, 505, 584, 623, 666, 710], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.02310002, -0.00779819, -0.01480943, -0.0179913 , -0.02211171,
       -0.00880289, -0.01489919, -0.01110405, -0.00227159, -0.01041001]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
486	NM_000152.3(GAA):c.307T>G (p.Cys103Gly)	92483	CA220404	NM_000152.3:c.307T>G, NC_000017.11:g.80104893T>G, CM000679.2:g.80104893T>G, NC_000017.10:g.78078692T>G, CM000679.1:g.78078692T>G, NC_000017.9:g.75693287T>G, NG_009822.1:g.8338T>G, LRG_673:g.8338T>G, ENST00000302262.8:c.307T>G, ENST00000302262.7:c.307T>G, ENST00000390015.7:c.307T>G, ENST00000570803.5:c.307T>G, ENST00000577106.5:c.307T>G, LRG_673t1:c.307T>G, NM_001079803.1:c.307T>G, NM_001079804.1:c.307T>G, XM_005257193.1:c.307T>G, XM_005257194.3:c.307T>G, NM_000152.4:c.307T>G, NM_001079803.2:c.307T>G, NM_001079804.2:c.307T>G, XM_005257193.2:c.307T>G, XM_005257194.4:c.307T>G, NM_000152.5:c.307T>G, NM_001079803.3:c.307T>G, NM_001079804.3:c.307T>G, NM_000152.5(GAA):c.307T>G (p.Cys103Gly), NM_000152.3(GAA):c.307T>G (p.Cys103Gly)	GAA	glycogen storage disease II	MONDO:0009290	Autosomal recessive inheritance	Pathogenic	PM3_Strong, PP4_Moderate, PP3, PM2_Supporting, PS3_Moderate	PM5	The NM_000152.5: c.307T>G variant in GAA is a missense variant predicted to cause substitution of cysteine by glycine at amino acid 103 (p.Cys103Gly). This variant has been reported in at least 12 patients who have been diagnosed with Pompe disease, including patients with documented GAA deficiency in the affected range in dried blood spot, leukocytes, and fibroblasts and <10% normal GAA activity in muscle (PMIDs: 16838077, 18285536, 21109266, 22676651, 24011652, 24158270, 29803406; Pediatr Pol 2021; 96 (3): 220–222; https://doi.org/10.5114/polp.2021.109310) and three on enzyme replacement therapy (PMID:  18607768, 29565424, 29803406, 23160972) (PP4_Moderate). Of note, in some of these patients, the variant was noted to be in cis with another variant (p.Asp91Asn) which can falsely lower GAA activity in in vitro assays when the substrate is glycogen, but not when the substrate is an artificial substrate, 4-MU. This was taken into account when utilizing GAA activity data. Of the reported patients, at least 11 patients compound heterozygous for the variant, phase unknown, and a known pathogenic variant in GAA including c.-32-13T>G (9 patients, PMID: 16838077, 18285536, 18607768, 21109266, 22676651, 23160972, 24011652, 24158270, 29803406;  Pediatr Pol 2021; 96 (3): 220–222; https://doi.org/10.5114/polp.2021.109310), c.525delT (PMID: 14695532) and c.2481+102_c.2646+31del (PMID: 29565424). In addition, one patient is compound heterozygous for the variant and c.1465G>A (p.Asp489Asn) (PMID: 18429042). The allelic data from this patient will be used in the assessment of p.Asp489Asn and is not included here to avoid circular logic. For another patient, the cDNA change for the variants was not provided and therefore the data was not included (PMID: 28196920). The highest population minor allele frequency in gnomAD is 0.00001 (1/126998 alleles) in the European non-Finnish population, which is lower than the ClinGen LSD VCEP threshold (<0.001) for PM2_Supporting, meeting this criterion (PM2_Supporting). When expressed in COS cells, the variant resulted in 1.5% normal activity, and evidence of abnormal GAA processing on Western blot (PMID: 14695532) (PS3_Moderate). The computational predictor REVEL gives a score of 0.985 which is above the threshold of 0.7, evidence that correlates with impact to GAA function (PP3). Two other amino acid substitutions at the same position have been reported in patients with Pompe disease - c.307T>C (p.Cys103Arg) (PMIDs 21984055, 22644586) and c.309C>G (p.Cys103Trp) (PMID 27142047); the classification of p.Cys103Gly will be used to support the classification of these other variants. Therefore, the data is not used here to avoid circular logic. There is a ClinVar entry for this variant (Variation ID: 92483, 2 star review status) with 8 submitters classifying the variant as pathogenic and one as likely pathogenic. In summary, this variant meets the criteria to be classified as pathogenic for Pompe disease. GAA-specific ACMG/AMP criteria applied, as specified by the ClinGen LSD VCEP: PM3_Strong, PS3_Moderate, PP4_Moderate, PP3, PM2_Supporting.(Approved by the ClinGen LSD VCEP on Sept. 21, 2022).		Lysosomal Diseases VCEP	https://clinicalgenome.org/docs/clingen-lysosomal-storage-disorders-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-2/	2022-09-21	2022-10-21	False	https://erepo.genome.network/evrepo/ui/classification/CA220404/MONDO:0009290/010	e5afb18d-a245-421a-9d32-466c06f390cf	p.Cys103Gly	Cys	103	Gly	MGVRHPPCSHRLLAVCALVSLATAALLGHILLHDFLLVPRELSGSSPVLEETHPAHQQGASRPGPRDAQAHPGRPRAVPTQCDVPPNSRFDCAPDKAITQEQCEARGCCYIPAKQGLQGAQMGQPWCFFPPSYPSYKLENLSSSEMGYTATLTRTTPTFFPKDILTLRLDVMMETENRLHFTIKDPANRRYEVPLETPHVHSRAPSPLYSVEFSEEPFGVIVRRQLDGRVLLNTTVAPLFFADQFLQLSTSLPSQYITGLAEHLSPLMLSTSWTRITLWNRDLAPTPGANLYGSHPFYLALEDGGSAHGVFLLNSNAMDVVLQPSPALSWRSTGGILDVYIFLGPEPKSVVQQYLDVVGYPFMPPYWGLGFHLCRWGYSSTAITRQVVENMTRAHFPLDVQWNDLDYMDSRRDFTFNKDGFRDFPAMVQELHQGGRRYMMIVDPAISSSGPAGSYRPYDEGLRRGVFITNETGQPLIGKVWPGSTAFPDFTNPTALAWWEDMVAEFHDQVPFDGMWIDMNEPSNFIRGSEDGCPNNELENPPYVPGVVGGTLQAATICASSHQFLSTHYNLHNLYGLTEAIASHRALVKARGTRPFVISRSTFAGHGRYAGHWTGDVWSSWEQLASSVPEILQFNLLGVPLVGADVCGFLGNTSEELCVRWTQLGAFYPFMRNHNSLLSLPQEPYSFSEPAQQAMRKALTLRYALLPHLYTLFHQAHVAGETVARPLFLEFPKDSSTWTVDHQLLWGEALLITPVLQAGKAEVTGYFPLGTWYDLQTVPVEALGSLPPPPAAPREPAIHSEGQWVTLPAPLDTINVHLRAGYIIPLQGPGLTTTESRQQPMALAVALTKGGEARGELFWDDGESLEVLERGAYTQVIFLARNNTIVNELVRVTSEGAGLQLQKVTVLGVATAPQQVLSNGVPVSNFTYSPDTKVLDICVSLLMGEQFLVSWC	952	P10253	G	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [420], 'DNA_BIND_gain': [707], 'DNA_BIND_gain_score': array([0.00078285]), 'DNA_BIND_loss_score': array([-0.0009923]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [91, 102, 107, 108], 'DISULFID_gain': [], 'DISULFID_loss_score': array([-0.10300106, -0.68251729, -0.08894509, -0.10770708]), 'PROPEP_loss': [], 'PROPEP_gain': [72, 73], 'PROPEP_gain_score': array([0.19186854, 0.26537174]), 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [22], 'TRANSIT_gain_score': array([0.02038777]), 'STRAND_loss': [109], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.44842625]), 'HELIX_loss': [99, 100, 101, 102, 103, 104], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.58207905, -0.44859791, -0.51396018, -0.5418368 , -0.64655721,
       -0.62066138]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.62789476, -0.70770097, -0.75453413, -0.84678066, -0.88802207,
       -0.82631081, -0.91321886, -0.90238738, -0.91826928, -0.93032748,
       -0.91981792, -0.89625448, -0.91046304, -0.85802794, -0.87925452,
       -0.88479984, -0.89217752, -0.91960937, -0.88865519, -0.9027127 ,
       -0.87581062, -0.87319916, -0.86313391, -0.82431924, -0.83187133,
       -0.84088397, -0.79457891, -0.83225048, -0.8504793 , -0.83449912,
       -0.81725013, -0.84787983, -0.8427161 , -0.8203041 , -0.90004754,
       -0.88724971, -0.91432559, -0.89226943, -0.93640351, -0.93739569,
       -0.9426468 , -0.96421361, -0.95383173, -0.95615757, -0.9629423 ,
       -0.96431512, -0.96384168, -0.96895659, -0.96645868, -0.97017443,
       -0.96926582, -0.97341299, -0.9558531 , -0.78087169, -0.62363428]), 'REGION_loss': [], 'REGION_gain': [80], 'REGION_gain_score': array([0.12399518]), 'REPEAT_loss': [386], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.00212187]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
487	NM_000152.4(GAA):c.1799G>A (p.Arg600His)	370130	CA8815482	NM_000152.4:c.1799G>A, NC_000017.11:g.80112622G>A, CM000679.2:g.80112622G>A, NC_000017.10:g.78086421G>A, CM000679.1:g.78086421G>A, NC_000017.9:g.75701016G>A, NG_009822.1:g.16067G>A, LRG_673:g.16067G>A, ENST00000302262.8:c.1799G>A, ENST00000302262.7:c.1799G>A, ENST00000390015.7:c.1799G>A, ENST00000570716.1:n.239G>A, ENST00000572080.1:n.187G>A, ENST00000572803.1:n.413G>A, NM_000152.3:c.1799G>A, LRG_673t1:c.1799G>A, NM_001079803.1:c.1799G>A, NM_001079804.1:c.1799G>A, XM_005257193.1:c.1799G>A, XM_005257194.3:c.1799G>A, NM_001079803.2:c.1799G>A, NM_001079804.2:c.1799G>A, XM_005257193.2:c.1799G>A, XM_005257194.4:c.1799G>A, NM_000152.5:c.1799G>A, NM_001079803.3:c.1799G>A, NM_001079804.3:c.1799G>A, NM_000152.5(GAA):c.1799G>A (p.Arg600His), NM_000152.4(GAA):c.1799G>A (p.Arg600His)	GAA	glycogen storage disease II	MONDO:0009290	Autosomal recessive inheritance	Pathogenic	PM3_Strong, PP4_Moderate, PP3, PS3_Moderate, PM2_Supporting, PM1	PM5	The NM_000152.5:c.1799G>A variant in GAA is a missense variant predicted to result in substitution of arginine by histidine at amino acid 600 (p.Arg600His).This variant has been reported in at least 7 patients including those with symptoms consistent with infantile onset Pompe disease, <10% GAA activity in muscle, and showing improvement on enzyme replacement therapy (PMID: 15121988, 24715333); one patient identified on newborn screen with confirmatory GAA activity testing and showing cardiac hypertrophy and arrythmia on cardiac evaluation (PMID: 33073007), three patients with features consistent with Pompe disease and GAA activity in the laboratory's affected range in dried blood spots or leukocytes (PMID: 2267665, 33741225) (PP4_Moderate). Four patients are compound heterozygous for the variant and another variant in GAA, phase unknown, that has been classified a pathogenic by the ClinGen LSD VCEP including c.-32-13T>G (2 independent probands, PMIDs: 21967859, 2267665), c.2481+110_2646+39del) (2 independent probands, PMID: 15121988, 24715333; PMID: 2267665), and one homozygote (PMID: 33073007) (PM3_Strong). In addition, two patients are compound heterozygous for the variant and another missense change, or c.1465G>A (p.Asp489Asn) (PMID: 22711147) or c.1751A>C (p.His584Pro) (PMID: 33741225). The allelic data from these patients will be used in the assessment of the other missense change and is not included here to avoid circular logic. The amino acid change was reported in additional patients but the cDNA changes were not provided and so the data is not included (PMID: 10338092, 20033296).The highest population minor allele frequency in gnomAD is 0.00003 (1.30606 alleles) in the South Asian population, which is lower than the ClinGen LSD VCEP threshold (<0.001) for PM2_Supporting, meeting this criterion (PM2_Supporting).This variant alters the arginine at amino acid 600, a residue that crystallography studies have shown to be important important in the active site architecture and substrate binding of GAA, and therefore has been defined as a critical residue by the ClinGen LSD VCEP (https://www.biorxiv.org/content/10.1101/212837v1.full.pdf, PMID: 29061980) (PM1).This variant results in <2% GAA activity when expressed in COS-7 and HEK 293 cells (PMID: 19862843, 24715333), and was shown to be abnormally processed by Western blot analysis, with production of very little of the active 76 kDa form, when expressed in HEK293 cells (PMID: 24715333). PS3_Moderate is applied based on two separate studies, one showing GAA deficiency and the other showing abnormal GAA processing (PS3_Moderate).The computational predictor REVEL gives a score of 0.967 which is above the threshold of 0.7, evidence that correlates with impact to GAA function (PP3).Three additional missense changes in the same codon have been reported in patients with Pompe disease. The classification of p.Arg600His will be used to to support the classification of the other variants c.1798C>T (p.Arg600Cys) (pathogenic based on classification by the ClinGen LSD VCEP), c.1799G>C (p.Arg600Pro) and c.1799G>T (p.Arg600Leu), and is not used here to avoid circular logic.There is a ClinVar entry for this variant (Variation ID: 370130) with 10 submitters  classifying the variant as pathogenic and two as likely pathogenic.In summary, this variant meets the criteria to be classified as pathogenic for Pompe disease. GAA-specific ACMG-AMP crteria applied, as specified by the ClinGen LSD VCEP (Specification Version 2.0): PM3_Strong, PM1, PS3_Moderate, PP4_Moderate, PP3, PM2_Supporting.Classification approved by the ClinGen LSD VCEP on Oct 18, 2022).		Lysosomal Diseases VCEP	https://clinicalgenome.org/docs/clingen-lysosomal-storage-disorders-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-2/	2022-10-18	2022-10-21	False	https://erepo.genome.network/evrepo/ui/classification/CA8815482/MONDO:0009290/010	692b25ea-7706-485c-b444-ebe61391e4b5	p.Arg600His	Arg	600	His	MGVRHPPCSHRLLAVCALVSLATAALLGHILLHDFLLVPRELSGSSPVLEETHPAHQQGASRPGPRDAQAHPGRPRAVPTQCDVPPNSRFDCAPDKAITQEQCEARGCCYIPAKQGLQGAQMGQPWCFFPPSYPSYKLENLSSSEMGYTATLTRTTPTFFPKDILTLRLDVMMETENRLHFTIKDPANRRYEVPLETPHVHSRAPSPLYSVEFSEEPFGVIVRRQLDGRVLLNTTVAPLFFADQFLQLSTSLPSQYITGLAEHLSPLMLSTSWTRITLWNRDLAPTPGANLYGSHPFYLALEDGGSAHGVFLLNSNAMDVVLQPSPALSWRSTGGILDVYIFLGPEPKSVVQQYLDVVGYPFMPPYWGLGFHLCRWGYSSTAITRQVVENMTRAHFPLDVQWNDLDYMDSRRDFTFNKDGFRDFPAMVQELHQGGRRYMMIVDPAISSSGPAGSYRPYDEGLRRGVFITNETGQPLIGKVWPGSTAFPDFTNPTALAWWEDMVAEFHDQVPFDGMWIDMNEPSNFIRGSEDGCPNNELENPPYVPGVVGGTLQAATICASSHQFLSTHYNLHNLYGLTEAIASHRALVKARGTRPFVISRSTFAGHGRYAGHWTGDVWSSWEQLASSVPEILQFNLLGVPLVGADVCGFLGNTSEELCVRWTQLGAFYPFMRNHNSLLSLPQEPYSFSEPAQQAMRKALTLRYALLPHLYTLFHQAHVAGETVARPLFLEFPKDSSTWTVDHQLLWGEALLITPVLQAGKAEVTGYFPLGTWYDLQTVPVEALGSLPPPPAAPREPAIHSEGQWVTLPAPLDTINVHLRAGYIIPLQGPGLTTTESRQQPMALAVALTKGGEARGELFWDDGESLEVLERGAYTQVIFLARNNTIVNELVRVTSEGAGLQLQKVTVLGVATAPQQVLSNGVPVSNFTYSPDTKVLDICVSLLMGEQFLVSWC	952	P10253	H	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [599], 'BINDING_gain': [], 'BINDING_loss_score': array([-0.34420604]), 'DNA_BIND_loss': [588, 614, 704], 'DNA_BIND_gain': [423, 429, 612, 658, 707], 'DNA_BIND_gain_score': array([0.00509405, 0.00395185, 0.01042736, 0.00994462, 0.00163251]), 'DNA_BIND_loss_score': array([-0.01185274, -0.00889564, -0.00071639]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [259, 595, 872, 884, 885, 913], 'STRAND_gain_score': array([0.00853676, 0.08261019, 0.01065671, 0.00723296, 0.01259768,
       0.01439154]), 'HELIX_loss': [], 'HELIX_gain': [729], 'HELIX_gain_score': array([0.02204919]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [584, 666, 710], 'REPEAT_gain': [598, 643, 764], 'REPEAT_gain_score': array([0.00694901, 0.00682014, 0.00652528]), 'REPEAT_loss_score': array([-0.0213083 , -0.00893486, -0.00597274]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
488	NM_000152.5(GAA):c.877G>A (p.Gly293Arg)	4036	CA116622	NM_000152.5:c.877G>A, NC_000017.11:g.80107818G>A, CM000679.2:g.80107818G>A, NC_000017.10:g.78081617G>A, CM000679.1:g.78081617G>A, NC_000017.9:g.75696212G>A, NG_009822.1:g.11263G>A, LRG_673:g.11263G>A, ENST00000302262.8:c.877G>A, ENST00000302262.7:c.877G>A, ENST00000390015.7:c.877G>A, NM_000152.3:c.877G>A, LRG_673t1:c.877G>A, NM_001079803.1:c.877G>A, NM_001079804.1:c.877G>A, XM_005257193.1:c.877G>A, XM_005257194.3:c.877G>A, NM_000152.4:c.877G>A, NM_001079803.2:c.877G>A, NM_001079804.2:c.877G>A, XM_005257193.2:c.877G>A, XM_005257194.4:c.877G>A, NM_001079803.3:c.877G>A, NM_001079804.3:c.877G>A, NM_000152.5(GAA):c.877G>A (p.Gly293Arg)	GAA	glycogen storage disease II	MONDO:0009290	Autosomal recessive inheritance	Pathogenic	PM3_Strong, PP4_Moderate, PP3, PS3_Moderate, PM2_Supporting		The NM_000152.5:c.877G>A variant in GAA is a missense variant that is predicted to result in the substitution of glycine by arginine at amino acid 293 (p.Gly293Arg). Patients with a diagnosis of Pompe disease reported with this variant include five individuals with documented laboratory values showing deficient GAA activity meeting the specifications of the ClinGen LSD VCEP (PMIDs: 23566438, 24590251, 26497565), one of whom also has features reported that are consistent with infantile onset Pompe disease (PMID: 31510962) and additional patients reported to be on enzyme replacement therapy but without documentation of residual GAA activity (PMID: 18607768, 21605996) (PP4_Moderate). At least 6 patients are compound heterozygous, phase unconfirmed, for the variant and another variant in GAA that has been classified as pathogenic by the ClinGen LSD VCEP including c.-32-13T>G (PMIDs: 18607768, 21605996, 23566438, 24590251, 25455803, 29181627, 31710733), c.2481+102_2646+31del (PMID: 18429042) and c.716del (p.Leu239fsTer28) (PMID: 14695532), and at least two individuals are homozygous for the variant (PMIDs: 31510962, 26497565) (2 x 0.5 points) (PM3_Strong). In addition, two patients are compound heterozygous for the variant and either c.719C>T (p.Phe240Ser; note that reference sequence has a T at position 719) (PMID: 25455803) or c.710C>T (p.Ala237Val) (PMIDs: 15668445, 17573812, 17643989. The allelic data from these patients will be used in the classification of p.Phe240Ser and is not included here to avoid circular logic. The highest population minor allele frequency in gnomAD v2.1.1. is 0.00006 (2/35062 alleles) in the Latino / Admixed American population, which is lower than the ClinGen LSD VCEP threshold (<0.001) for PM2_Supporting, meeting this criterion (PM2_Supporting). When expressed in COS cells, this variant results in <2% residual GAA activity in medium and cells (PMIDs 14695532, 19862843). No GAA protein was observed on Western blot of COS cells expressing the variant (PMID 14695532) (PS3_Moderate). The computational predictor REVEL gives a score of 0.931 which is above the threshold of 0.7, evidence that correlates with impact to GAA function, and SpliceAI predicts the creation of a cryptic splice site 2 nucleotides downstream from the variant (PP3). There is a ClinVar entry for this variant (Variation ID: 4036; 2 star review status) with 6 submitters classifying the variant as pathogenic. In summary, this variant meets the criteria to be classified as pathogenic for Pompe disease. GAA-specific ACMG/AMP criteria applied, as specified by the ClinGen LSD VCEP (Specification Version 2.0): PM3_Strong, PS3_Moderate, PP4_Moderate, PP3, PM2_Supporting. )Classification approved by the ClinGen LSD VCEP on Nov. 2, 2022)		Lysosomal Diseases VCEP	https://clinicalgenome.org/docs/clingen-lysosomal-storage-disorders-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-2/	2022-11-02	2022-11-18	False	https://erepo.genome.network/evrepo/ui/classification/CA116622/MONDO:0009290/010	0000332d-036c-4002-aea8-7c869781a384	p.Gly293Arg	Gly	293	Arg	MGVRHPPCSHRLLAVCALVSLATAALLGHILLHDFLLVPRELSGSSPVLEETHPAHQQGASRPGPRDAQAHPGRPRAVPTQCDVPPNSRFDCAPDKAITQEQCEARGCCYIPAKQGLQGAQMGQPWCFFPPSYPSYKLENLSSSEMGYTATLTRTTPTFFPKDILTLRLDVMMETENRLHFTIKDPANRRYEVPLETPHVHSRAPSPLYSVEFSEEPFGVIVRRQLDGRVLLNTTVAPLFFADQFLQLSTSLPSQYITGLAEHLSPLMLSTSWTRITLWNRDLAPTPGANLYGSHPFYLALEDGGSAHGVFLLNSNAMDVVLQPSPALSWRSTGGILDVYIFLGPEPKSVVQQYLDVVGYPFMPPYWGLGFHLCRWGYSSTAITRQVVENMTRAHFPLDVQWNDLDYMDSRRDFTFNKDGFRDFPAMVQELHQGGRRYMMIVDPAISSSGPAGSYRPYDEGLRRGVFITNETGQPLIGKVWPGSTAFPDFTNPTALAWWEDMVAEFHDQVPFDGMWIDMNEPSNFIRGSEDGCPNNELENPPYVPGVVGGTLQAATICASSHQFLSTHYNLHNLYGLTEAIASHRALVKARGTRPFVISRSTFAGHGRYAGHWTGDVWSSWEQLASSVPEILQFNLLGVPLVGADVCGFLGNTSEELCVRWTQLGAFYPFMRNHNSLLSLPQEPYSFSEPAQQAMRKALTLRYALLPHLYTLFHQAHVAGETVARPLFLEFPKDSSTWTVDHQLLWGEALLITPVLQAGKAEVTGYFPLGTWYDLQTVPVEALGSLPPPPAAPREPAIHSEGQWVTLPAPLDTINVHLRAGYIIPLQGPGLTTTESRQQPMALAVALTKGGEARGELFWDDGESLEVLERGAYTQVIFLARNNTIVNELVRVTSEGAGLQLQKVTVLGVATAPQQVLSNGVPVSNFTYSPDTKVLDICVSLLMGEQFLVSWC	952	P10253	R	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [375, 704], 'DNA_BIND_gain': [658], 'DNA_BIND_gain_score': array([0.0008918]), 'DNA_BIND_loss_score': array([-0.00060201, -0.00086898]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [277], 'STRAND_gain': [885, 913], 'STRAND_gain_score': array([0.00526518, 0.00852269]), 'STRAND_loss_score': array([-0.09390336]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [624], 'REPEAT_gain_score': array([0.00280356]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
489	NM_000152.5(GAA):c.1941C>G (p.Cys647Trp)	550327	CA8815554	NM_000152.5:c.1941C>G, NC_000017.11:g.80112928C>G, CM000679.2:g.80112928C>G, NC_000017.10:g.78086727C>G, CM000679.1:g.78086727C>G, NC_000017.9:g.75701322C>G, NG_009822.1:g.16373C>G, LRG_673:g.16373C>G, ENST00000302262.8:c.1941C>G, ENST00000302262.7:c.1941C>G, ENST00000390015.7:c.1941C>G, ENST00000570716.1:n.381C>G, ENST00000572080.1:n.360C>G, ENST00000572803.1:n.555C>G, NM_000152.3:c.1941C>G, LRG_673t1:c.1941C>G, NM_001079803.1:c.1941C>G, NM_001079804.1:c.1941C>G, XM_005257193.1:c.1941C>G, XM_005257194.3:c.1941C>G, NM_000152.4:c.1941C>G, NM_001079803.2:c.1941C>G, NM_001079804.2:c.1941C>G, XM_005257193.2:c.1941C>G, XM_005257194.4:c.1941C>G, NM_001079803.3:c.1941C>G, NM_001079804.3:c.1941C>G, NM_000152.5(GAA):c.1941C>G (p.Cys647Trp)	GAA	glycogen storage disease II	MONDO:0009290	Autosomal recessive inheritance	Pathogenic	PS3_Supporting, PP4_Moderate, PP3, PM2_Supporting, PM3_Very Strong		"The NM_000152.5:c.1941C>G variant in GAA is a missense variant that is predicted to result in substitution of cysteine by tryptophan at amino acid 647 (p.Cys647Trp). At least 10 patients with this variant have been reported to have Pompe disease including two with documented laboratory values showing deficiency of GAA, one of whom also had reported symptoms consistent with infantile onset Pompe disease (PMID: 7981676, 9535769, 17723315) (meeting PP4_Moderate), three patients with reported symptoms consistent with infantile onset Pompe disease (PMID: 7981676, 19588081, 22658377, 31510962), one patient on enzyme replacement therapy (PMID: 31086307) (all meeting PP4). Four patients are compound heterozygous for the variant and a variant in GAA that has been classified as pathogenic for Pompe disease including c.-32-13T>G (PMID: 25681614, 31931849; 2 patients), c.2481+110_2646+39del (exon 18 deletion, PMID: 7981676), and c.1655T>C (p.Leu552Pro) (PMID: 19588081), all phase unconfirmed. In another patient, the variant is confirmed in trans with an allele containing two pathogenic variants, c.1456_1468del (p.Ala486fsTer30) (confirmed de novo) and c.2238G>C (p.Trp746Cys) (PMID: 7981676), and two patients are homozygous for the variant (PMID: 9535769, 31510962) (PM3_Very Strong). In addition, two patients are compound heterozygous for the variant and either c.1846G>A (p.Asp616Asn) (PMID: 31086307) or c.1781G>C (p.Arg594Pro) (PMID: 19588081). The allelic data from these patients will be used in the classification of the second variant and is not included here to avoid circular logic.  In another patient, no second variant was found (PMID: 25681614). When expressed in GAA-deficient SV40 immortalized fibroblasts, the variant resulted in <1% GAA activity compared to the normal control ( PMID: 9535769) (PS3_Supporting).The computational predictor REVEL gives a score of 0.802 which is above the threshold of 0.7, evidence that correlates with impact to GAA function (PP3). The highest continental population minor allele frequency in gnomAD v2.1.1 is 0.00002 (3/124712 alleles) in the European non-Finnish population, which is lower than the ClinGen LSD VCEP’s threshold for PM2_Supporting (<0.001), meeting this criterion (PM2_Supporting). Of note, the highest population minor allele frequency in gnomAD v2.1.1 is in the """"""""""""""""other"""""""""""""""" population, 0.00014 (1/7006 alleles) which also meets the PM2_Supporting threshold. There is a ClinVar entry for this variant (Variation ID: 550327). In summary, this variant meets the criteria to be classified as pathogenic for Pompe disease. GAA-specific ACMG-AMP criteria met, as specified by the ClinGen Lysosomal Storage Disorders VCEP (Specifications Version 2.0): PM3_Very_Strong, PP4_Moderate, PP3, PS3_Supporting, PM2_Supporting.Classification approved by the ClinGen LSD VCEP on Nov. 15, 2022."		Lysosomal Diseases VCEP	https://clinicalgenome.org/docs/clingen-lysosomal-storage-disorders-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-2/	2022-11-15	2022-11-28	False	https://erepo.genome.network/evrepo/ui/classification/CA8815554/MONDO:0009290/010	a3c3a3a7-7ae4-469a-8ead-80c01b286ac7	p.Cys647Trp	Cys	647	Trp	MGVRHPPCSHRLLAVCALVSLATAALLGHILLHDFLLVPRELSGSSPVLEETHPAHQQGASRPGPRDAQAHPGRPRAVPTQCDVPPNSRFDCAPDKAITQEQCEARGCCYIPAKQGLQGAQMGQPWCFFPPSYPSYKLENLSSSEMGYTATLTRTTPTFFPKDILTLRLDVMMETENRLHFTIKDPANRRYEVPLETPHVHSRAPSPLYSVEFSEEPFGVIVRRQLDGRVLLNTTVAPLFFADQFLQLSTSLPSQYITGLAEHLSPLMLSTSWTRITLWNRDLAPTPGANLYGSHPFYLALEDGGSAHGVFLLNSNAMDVVLQPSPALSWRSTGGILDVYIFLGPEPKSVVQQYLDVVGYPFMPPYWGLGFHLCRWGYSSTAITRQVVENMTRAHFPLDVQWNDLDYMDSRRDFTFNKDGFRDFPAMVQELHQGGRRYMMIVDPAISSSGPAGSYRPYDEGLRRGVFITNETGQPLIGKVWPGSTAFPDFTNPTALAWWEDMVAEFHDQVPFDGMWIDMNEPSNFIRGSEDGCPNNELENPPYVPGVVGGTLQAATICASSHQFLSTHYNLHNLYGLTEAIASHRALVKARGTRPFVISRSTFAGHGRYAGHWTGDVWSSWEQLASSVPEILQFNLLGVPLVGADVCGFLGNTSEELCVRWTQLGAFYPFMRNHNSLLSLPQEPYSFSEPAQQAMRKALTLRYALLPHLYTLFHQAHVAGETVARPLFLEFPKDSSTWTVDHQLLWGEALLITPVLQAGKAEVTGYFPLGTWYDLQTVPVEALGSLPPPPAAPREPAIHSEGQWVTLPAPLDTINVHLRAGYIIPLQGPGLTTTESRQQPMALAVALTKGGEARGELFWDDGESLEVLERGAYTQVIFLARNNTIVNELVRVTSEGAGLQLQKVTVLGVATAPQQVLSNGVPVSNFTYSPDTKVLDICVSLLMGEQFLVSWC	952	P10253	W	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [599], 'BINDING_gain': [], 'BINDING_loss_score': array([-0.04721135]), 'DNA_BIND_loss': [420, 424, 663, 704, 714], 'DNA_BIND_gain': [601, 611], 'DNA_BIND_gain_score': array([0.00834799, 0.00378633]), 'DNA_BIND_loss_score': array([-0.00119346, -0.00144488, -0.00483435, -0.00093746, -0.01049012]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [646, 657], 'DISULFID_gain': [], 'DISULFID_loss_score': array([-0.61060685, -0.28133219]), 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [22], 'TRANSIT_gain_score': array([0.00921625]), 'STRAND_loss': [], 'STRAND_gain': [885, 893], 'STRAND_gain_score': array([0.00536221, 0.01138604]), 'HELIX_loss': [], 'HELIX_gain': [729], 'HELIX_gain_score': array([0.00990617]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [386, 623, 710], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.00276506, -0.00553954, -0.01198965]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
490	NM_000138.4(FBN1):c.4459G>A (p.Asp1487Asn)	549232	CA269554323	NM_000138.4:c.4459G>A, NC_000015.10:g.48470634C>T, CM000677.2:g.48470634C>T, NC_000015.9:g.48762831C>T, CM000677.1:g.48762831C>T, NC_000015.8:g.46550123C>T, NG_008805.2:g.180155G>A, LRG_778:g.180155G>A, ENST00000683268.1:n.426G>A, ENST00000684448.1:n.3133G>A, ENST00000316623.10:c.4459G>A, ENST00000316623.9:c.4459G>A, ENST00000537463.6:c.*222G>A, LRG_778t1:c.4459G>A, NM_000138.5:c.4459G>A, NM_000138.5(FBN1):c.4459G>A (p.Asp1487Asn), NM_000138.4(FBN1):c.4459G>A (p.Asp1487Asn)	FBN1	Marfan syndrome	MONDO:0007947	Autosomal dominant inheritance	Pathogenic	PS4, PM1, PP1_Strong, PP2, PP3, PP4, PM2_Supporting	PS1, PS3, PS2, PM5, PM3, PM4, BP5, BP7, BS1, BS3, BS4, BS2, PM6, PVS1, BA1, BP1, BP4, BP2, BP3	The NM_000138 c.4459G>A, is a missense variant in FBN1 predicted to cause a substitution of an Aspartic acid by Asparagine at amino acid 1487 p.(Asp1487Asn). This variant was found in four probands meeting the Ghent criteria (PP4, PS4_strong). The variant segregates with the disease in six affected family members of one proband and three affected family members of another proband (PP1_strong). This variant has been reported three times in ClinVar as likely pathogenic (Variation ID: 549232). It has been reported one time in the literature in a proband with classical Marfan syndrome (PMID: 19293843). This variant is not present in gnomAD v2.1.1 (PM2_sup; https://gnomad.broadinstitute.org/). This variant lies in a critical calcium binding site within a calcium binding EGF domain (PM1). Computational prediction tools and conservation analysis suggest that this variant may impact the protein structure (PP3). The constraint z-score for missense variants affecting FBN1 is 5.06 (PP2). In summary, this variant meets criteria to be classified as pathogenic for Marfan syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen FBN1 VCEP: PS4, PP1_strong, PM1, PP2, PP3, PP4, PM2_supporting		FBN1 VCEP	https://clinicalgenome.org/docs/clingen-fbn1-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2022-12-01	2022-12-01	False	https://erepo.genome.network/evrepo/ui/classification/CA269554323/MONDO:0007947/022	bcb32b50-f400-4bba-8030-d8f1e31ee6ac	p.Asp1487Asn	Asp	1487	Asn	MRRGRLLEIALGFTVLLASYTSHGADANLEAGNVKETRASRAKRRGGGGHDALKGPNVCGSRYNAYCCPGWKTLPGGNQCIVPICRHSCGDGFCSRPNMCTCPSGQIAPSCGSRSIQHCNIRCMNGGSCSDDHCLCQKGYIGTHCGQPVCESGCLNGGRCVAPNRCACTYGFTGPQCERDYRTGPCFTVISNQMCQGQLSGIVCTKTLCCATVGRAWGHPCEMCPAQPHPCRRGFIPNIRTGACQDVDECQAIPGLCQGGNCINTVGSFECKCPAGHKLNEVSQKCEDIDECSTIPGICEGGECTNTVSSYFCKCPPGFYTSPDGTRCIDVRPGYCYTALTNGRCSNQLPQSITKMQCCCDAGRCWSPGVTVAPEMCPIRATEDFNKLCSVPMVIPGRPEYPPPPLGPIPPVLPVPPGFPPGPQIPVPRPPVEYLYPSREPPRVLPVNVTDYCQLVRYLCQNGRCIPTPGSYRCECNKGFQLDLRGECIDVDECEKNPCAGGECINNQGSYTCQCRAGYQSTLTRTECRDIDECLQNGRICNNGRCINTDGSFHCVCNAGFHVTRDGKNCEDMDECSIRNMCLNGMCINEDGSFKCICKPGFQLASDGRYCKDINECETPGICMNGRCVNTDGSYRCECFPGLAVGLDGRVCVDTHMRSTCYGGYKRGQCIKPLFGAVTKSECCCASTEYAFGEPCQPCPAQNSAEYQALCSSGPGMTSAGSDINECALDPDICPNGICENLRGTYKCICNSGYEVDSTGKNCVDINECVLNSLLCDNGQCRNTPGSFVCTCPKGFIYKPDLKTCEDIDECESSPCINGVCKNSPGSFICECSSESTLDPTKTICIETIKGTCWQTVIDGRCEININGATLKSQCCSSLGAAWGSPCTLCQVDPICGKGYSRIKGTQCEDIDECEVFPGVCKNGLCVNTRGSFKCQCPSGMTLDATGRICLDIRLETCFLRYEDEECTLPIAGRHRMDACCCSVGAAWGTEECEECPMRNTPEYEELCPRGPGFATKEITNGKPFFKDINECKMIPSLCTHGKCRNTIGSFKCRCDSGFALDSEERNCTDIDECRISPDLCGRGQCVNTPGDFECKCDEGYESGFMMMKNCMDIDECQRDPLLCRGGVCHNTEGSYRCECPPGHQLSPNISACIDINECELSAHLCPNGRCVNLIGKYQCACNPGYHSTPDRLFCVDIDECSIMNGGCETFCTNSEGSYECSCQPGFALMPDQRSCTDIDECEDNPNICDGGQCTNIPGEYRCLCYDGFMASEDMKTCVDVNECDLNPNICLSGTCENTKGSFICHCDMGYSGKKGKTGCTDINECEIGAHNCGKHAVCTNTAGSFKCSCSPGWIGDGIKCTDLDECSNGTHMCSQHADCKNTMGSYRCLCKEGYTGDGFTCTDLDECSENLNLCGNGQCLNAPGGYRCECDMGFVPSADGKACEDIDECSLPNICVFGTCHNLPGLFRCECEIGYELDRSGGNCTDVNECLDPTTCISGNCVNTPGSYICDCPPDFELNPTRVGCVDTRSGNCYLDIRPRGDNGDTACSNEIGVGVSKASCCCSLGKAWGTPCEMCPAVNTSEYKILCPGGEGFRPNPITVILEDIDECQELPGLCQGGKCINTFGSFQCRCPTGYYLNEDTRVCDDVNECETPGICGPGTCYNTVGNYTCICPPDYMQVNGGNNCMDMRRSLCYRNYYADNQTCDGELLFNMTKKMCCCSYNIGRAWNKPCEQCPIPSTDEFATLCGSQRPGFVIDIYTGLPVDIDECREIPGVCENGVCINMVGSFRCECPVGFFYNDKLLVCEDIDECQNGPVCQRNAECINTAGSYRCDCKPGYRFTSTGQCNDRNECQEIPNICSHGQCIDTVGSFYCLCHTGFKTNDDQTMCLDINECERDACGNGTCRNTIGSFNCRCNHGFILSHNNDCIDVDECASGNGNLCRNGQCINTVGSFQCQCNEGYEVAPDGRTCVDINECLLEPRKCAPGTCQNLDGSYRCICPPGYSLQNEKCEDIDECVEEPEICALGTCSNTEGSFKCLCPEGFSLSSSGRRCQDLRMSYCYAKFEGGKCSSPKSRNHSKQECCCALKGEGWGDPCELCPTEPDEAFRQICPYGSGIIVGPDDSAVDMDECKEPDVCKHGQCINTDGSYRCECPFGYILAGNECVDTDECSVGNPCGNGTCKNVIGGFECTCEEGFEPGPMMTCEDINECAQNPLLCAFRCVNTYGSYECKCPVGYVLREDRRMCKDEDECEEGKHDCTEKQMECKNLIGTYMCICGPGYQRRPDGEGCVDENECQTKPGICENGRCLNTRGSYTCECNDGFTASPNQDECLDNREGYCFTEVLQNMCQIGSSNRNPVTKSECCCDGGRGWGPHCEICPFQGTVAFKKLCPHGRGFMTNGADIDECKVIHDVCRNGECVNDRGSYHCICKTGYTPDITGTSCVDLNECNQAPKPCNFICKNTEGSYQCSCPKGYILQEDGRSCKDLDECATKQHNCQFLCVNTIGGFTCKCPPGFTQHHTSCIDNNECTSDINLCGSKGICQNTPGSFTCECQRGFSLDQTGSSCEDVDECEGNHRCQHGCQNIIGGYRCSCPQGYLQHYQWNQCVDENECLSAHICGGASCHNTLGSYKCMCPAGFQYEQFSGGCQDINECGSAQAPCSYGCSNTEGGYLCGCPPGYFRIGQGHCVSGMGMGRGNPEPPVSGEMDDNSLSPEACYECKINGYPKRGRKRRSTNETDASNIEDQSETEANVSLASWDVEKTAIFAFNISHVSNKVRILELLPALTTLTNHNRYLIESGNEDGFFKINQKEGISYLHFTKKKPVAGTYSLQISSTPLYKKKELNQLEDKYDKDYLSGELGDNLKMKIQVLLH	2871	P35555	N	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [1471, 1476, 1509, 1511, 1513], 'DOMAIN_gain': [928, 2182], 'DOMAIN_gain_score': array([0.00779939, 0.0033083 ]), 'DOMAIN_loss_score': array([-0.05617201, -0.08386183, -0.07487893, -0.06058317, -0.09003377]), 'REGION_loss': [933, 976, 1670, 2074, 2112, 2120, 2146, 2184, 2195, 2199, 2207, 2210, 2216, 2225, 2536], 'REGION_gain': [], 'REGION_loss_score': array([-0.00122696, -0.00140005, -0.0020979 , -0.00288755, -0.00247836,
       -0.00284147, -0.00328588, -0.00291204, -0.00276935, -0.00300431,
       -0.0028826 , -0.00293356, -0.00290942, -0.00314444, -0.00275797]), 'REPEAT_loss': [282, 1031, 1480, 1517, 1685, 2480], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.01210153, -0.00146031, -0.05373645, -0.0043996 , -0.00554097,
       -0.00065243]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
491	NM_000138.5(FBN1):c.3422C>T (p.Pro1141Leu)	42334	CA014098	NM_000138.5:c.3422C>T, NC_000015.10:g.48487353G>A, CM000677.2:g.48487353G>A, NC_000015.9:g.48779550G>A, CM000677.1:g.48779550G>A, NC_000015.8:g.46566842G>A, NG_008805.2:g.163436C>T, LRG_778:g.163436C>T, ENST00000684448.1:n.2096C>T, ENST00000316623.10:c.3422C>T, ENST00000316623.9:c.3422C>T, ENST00000537463.6:c.637-12703C>T, NM_000138.4:c.3422C>T, LRG_778t1:c.3422C>T, NM_000138.5(FBN1):c.3422C>T (p.Pro1141Leu)	FBN1	Marfan syndrome	MONDO:0007947	Autosomal dominant inheritance	Benign	BS1, BS4	PS1, PS3, PS4, PS2, PM5, PM1, PM3, BP5, BS3, PP2, PP3, PP1, PP4, BS2, PM2, PM6, BP1, BP4, BP2, BA1	NM_00138 c.3422C>T is a missense variant in FBN1 predicted to cause a substitution of a Proline by Leucine at amino acid 1141 (p.Pro1141Leu). This variant has been reported in the literature in at least 3 individuals in association with thoracic aortic aneurysm and dissection (TAAD), MASS syndrome, and features possibly consistent with Marfan syndrome (PMID: 10533071; PMID: 24740214; PMID: 26188975). This variant was also identified in an internal proband with isolated TAAD with a family history highly specific for Marfan syndrome, however it does not segregate with disease in an affected family member (BS4) and therefore PP4 cannot be used. This variant has been previously reported in ClinVar as benign, likely benign, and uncertain significance (Variation ID: 42334). This variant has been identified in 0.026% of individuals of European origin (BS1; https://gnomad.broadinstitute.org/ version 2.1.1). Computational prediction tools and conservation analysis are unclear on the predicted impact on the protein. The constraint z-score for missense variants affecting FBN1 is 5.06, however due to the presence of two benign arguments PP2 cannot be used. In summary, this variant meets criteria to be classified as benign for Marfan syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen FBN1 VCEP: BS1, BS4		FBN1 VCEP	https://clinicalgenome.org/docs/clingen-fbn1-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2022-12-01	2022-12-01	False	https://erepo.genome.network/evrepo/ui/classification/CA014098/MONDO:0007947/022	33b1c05d-fe29-4995-a9e2-14529a6a0c8f	p.Pro1141Leu	Pro	1141	Leu	MRRGRLLEIALGFTVLLASYTSHGADANLEAGNVKETRASRAKRRGGGGHDALKGPNVCGSRYNAYCCPGWKTLPGGNQCIVPICRHSCGDGFCSRPNMCTCPSGQIAPSCGSRSIQHCNIRCMNGGSCSDDHCLCQKGYIGTHCGQPVCESGCLNGGRCVAPNRCACTYGFTGPQCERDYRTGPCFTVISNQMCQGQLSGIVCTKTLCCATVGRAWGHPCEMCPAQPHPCRRGFIPNIRTGACQDVDECQAIPGLCQGGNCINTVGSFECKCPAGHKLNEVSQKCEDIDECSTIPGICEGGECTNTVSSYFCKCPPGFYTSPDGTRCIDVRPGYCYTALTNGRCSNQLPQSITKMQCCCDAGRCWSPGVTVAPEMCPIRATEDFNKLCSVPMVIPGRPEYPPPPLGPIPPVLPVPPGFPPGPQIPVPRPPVEYLYPSREPPRVLPVNVTDYCQLVRYLCQNGRCIPTPGSYRCECNKGFQLDLRGECIDVDECEKNPCAGGECINNQGSYTCQCRAGYQSTLTRTECRDIDECLQNGRICNNGRCINTDGSFHCVCNAGFHVTRDGKNCEDMDECSIRNMCLNGMCINEDGSFKCICKPGFQLASDGRYCKDINECETPGICMNGRCVNTDGSYRCECFPGLAVGLDGRVCVDTHMRSTCYGGYKRGQCIKPLFGAVTKSECCCASTEYAFGEPCQPCPAQNSAEYQALCSSGPGMTSAGSDINECALDPDICPNGICENLRGTYKCICNSGYEVDSTGKNCVDINECVLNSLLCDNGQCRNTPGSFVCTCPKGFIYKPDLKTCEDIDECESSPCINGVCKNSPGSFICECSSESTLDPTKTICIETIKGTCWQTVIDGRCEININGATLKSQCCSSLGAAWGSPCTLCQVDPICGKGYSRIKGTQCEDIDECEVFPGVCKNGLCVNTRGSFKCQCPSGMTLDATGRICLDIRLETCFLRYEDEECTLPIAGRHRMDACCCSVGAAWGTEECEECPMRNTPEYEELCPRGPGFATKEITNGKPFFKDINECKMIPSLCTHGKCRNTIGSFKCRCDSGFALDSEERNCTDIDECRISPDLCGRGQCVNTPGDFECKCDEGYESGFMMMKNCMDIDECQRDPLLCRGGVCHNTEGSYRCECPPGHQLSPNISACIDINECELSAHLCPNGRCVNLIGKYQCACNPGYHSTPDRLFCVDIDECSIMNGGCETFCTNSEGSYECSCQPGFALMPDQRSCTDIDECEDNPNICDGGQCTNIPGEYRCLCYDGFMASEDMKTCVDVNECDLNPNICLSGTCENTKGSFICHCDMGYSGKKGKTGCTDINECEIGAHNCGKHAVCTNTAGSFKCSCSPGWIGDGIKCTDLDECSNGTHMCSQHADCKNTMGSYRCLCKEGYTGDGFTCTDLDECSENLNLCGNGQCLNAPGGYRCECDMGFVPSADGKACEDIDECSLPNICVFGTCHNLPGLFRCECEIGYELDRSGGNCTDVNECLDPTTCISGNCVNTPGSYICDCPPDFELNPTRVGCVDTRSGNCYLDIRPRGDNGDTACSNEIGVGVSKASCCCSLGKAWGTPCEMCPAVNTSEYKILCPGGEGFRPNPITVILEDIDECQELPGLCQGGKCINTFGSFQCRCPTGYYLNEDTRVCDDVNECETPGICGPGTCYNTVGNYTCICPPDYMQVNGGNNCMDMRRSLCYRNYYADNQTCDGELLFNMTKKMCCCSYNIGRAWNKPCEQCPIPSTDEFATLCGSQRPGFVIDIYTGLPVDIDECREIPGVCENGVCINMVGSFRCECPVGFFYNDKLLVCEDIDECQNGPVCQRNAECINTAGSYRCDCKPGYRFTSTGQCNDRNECQEIPNICSHGQCIDTVGSFYCLCHTGFKTNDDQTMCLDINECERDACGNGTCRNTIGSFNCRCNHGFILSHNNDCIDVDECASGNGNLCRNGQCINTVGSFQCQCNEGYEVAPDGRTCVDINECLLEPRKCAPGTCQNLDGSYRCICPPGYSLQNEKCEDIDECVEEPEICALGTCSNTEGSFKCLCPEGFSLSSSGRRCQDLRMSYCYAKFEGGKCSSPKSRNHSKQECCCALKGEGWGDPCELCPTEPDEAFRQICPYGSGIIVGPDDSAVDMDECKEPDVCKHGQCINTDGSYRCECPFGYILAGNECVDTDECSVGNPCGNGTCKNVIGGFECTCEEGFEPGPMMTCEDINECAQNPLLCAFRCVNTYGSYECKCPVGYVLREDRRMCKDEDECEEGKHDCTEKQMECKNLIGTYMCICGPGYQRRPDGEGCVDENECQTKPGICENGRCLNTRGSYTCECNDGFTASPNQDECLDNREGYCFTEVLQNMCQIGSSNRNPVTKSECCCDGGRGWGPHCEICPFQGTVAFKKLCPHGRGFMTNGADIDECKVIHDVCRNGECVNDRGSYHCICKTGYTPDITGTSCVDLNECNQAPKPCNFICKNTEGSYQCSCPKGYILQEDGRSCKDLDECATKQHNCQFLCVNTIGGFTCKCPPGFTQHHTSCIDNNECTSDINLCGSKGICQNTPGSFTCECQRGFSLDQTGSSCEDVDECEGNHRCQHGCQNIIGGYRCSCPQGYLQHYQWNQCVDENECLSAHICGGASCHNTLGSYKCMCPAGFQYEQFSGGCQDINECGSAQAPCSYGCSNTEGGYLCGCPPGYFRIGQGHCVSGMGMGRGNPEPPVSGEMDDNSLSPEACYECKINGYPKRGRKRRSTNETDASNIEDQSETEANVSLASWDVEKTAIFAFNISHVSNKVRILELLPALTTLTNHNRYLIESGNEDGFFKINQKEGISYLHFTKKKPVAGTYSLQISSTPLYKKKELNQLEDKYDKDYLSGELGDNLKMKIQVLLH	2871	P35555	L	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [1188, 2543], 'DOMAIN_gain': [1056], 'DOMAIN_gain_score': array([0.01419991]), 'DOMAIN_loss_score': array([-0.00849885, -0.01605016]), 'REGION_loss': [2074, 2112, 2146, 2184, 2195, 2210, 2216, 2536], 'REGION_gain': [], 'REGION_loss_score': array([-0.00091207, -0.00118887, -0.00171709, -0.00151736, -0.00115955,
       -0.00142151, -0.00137025, -0.0013873 ]), 'REPEAT_loss': [1517], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.00356239]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
492	NM_000545.8(HNF1A):c.1522G>A (p.Glu508Lys)	135665	CA289173	NM_000545.8:c.1522G>A, NC_000012.12:g.120999288G>A, CM000674.2:g.120999288G>A, NC_000012.11:g.121437091G>A, CM000674.1:g.121437091G>A, NC_000012.10:g.119921474G>A, NG_011731.2:g.25543G>A, LRG_522:g.25543G>A, ENST00000257555.11:c.1522G>A, ENST00000257555.10:c.1522G>A, ENST00000540108.1:c.*962G>A, ENST00000541395.5:c.1522G>A, ENST00000543427.5:c.985G>A, ENST00000544413.2:c.1522G>A, ENST00000560968.5:n.1339G>A, ENST00000615446.4:c.310G>A, ENST00000617366.4:c.639G>A, NM_000545.5:c.1522G>A, LRG_522t1:c.1522G>A, NM_000545.6:c.1522G>A, NM_001306179.1:c.1522G>A, XM_005253931.2:c.1522G>A, XM_024449168.1:c.1522G>A, NM_001306179.2:c.1522G>A, NM_000545.8(HNF1A):c.1522G>A (p.Glu508Lys)	HNF1A	monogenic diabetes	MONDO:0015967	Autosomal dominant inheritance	Benign	BA1	PS4, PS3	The c.1522G>A variant in the HNF1 homeobox A gene, HNF1A, causes an amino acid change of glutamic acid to lysine at codon 508 (p.(Glu508Lys)) of transcript NM_000545.8.  This variant has a Popmax Filtering allele frequency in gnomAD 2.1.1 of 0.002884, which is greater than the MDEP threshold for BA1 (greater than or equal to 0.0001) (BA1).  This variant has been found in many unrelated individuals who do not have autoimmune or absolute/near-absolute insulin-deficient diabetes (PMID: 24915262); however, PS4 cannot be applied because the variant MAF in gnomAD is above the ClinGen MDEP PM2_Supporting.  Functional studies demonstrated the p.Glu508Lys protein has transactivation activity between 40-80%, which is less severe than typical HNF1A-MODY-causing variants (below 40%) (PMID: 32910913, 27899486).  In summary, this variant meets the criteria to be classified as benign for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP: BA1 (specification version 1.2, approved 6/5/21).  However, this variant is an established risk allele for type 2 diabetes in individuals of Mexican ancestry (PMID: 24915262).  These individuals do not respond to treatment with sulfonylureas, unlike individuals with HNF1A-MODY (PMID: 29844095).		Monogenic Diabetes VCEP		2022-12-01	2022-12-01	False	https://erepo.genome.network/evrepo/ui/classification/CA289173/MONDO:0015967/017	0285392d-14d0-41c7-8b20-aabbdacbd554	p.Glu508Lys	Glu	508	Lys	MVSKLSQLQTELLAALLESGLSKEALIQALGEPGPYLLAGEGPLDKGESCGGGRGELAELPNGLGETRGSEDETDDDGEDFTPPILKELENLSPEEAAHQKAVVETLLQEDPWRVAKMVKSYLQQHNIPQREVVDTTGLNQSHLSQHLNKGTPMKTQKRAALYTWYVRKQREVAQQFTHAGQGGLIEEPTGDELPTKKGRRNRFKWGPASQQILFQAYERQKNPSKEERETLVEECNRAECIQRGVSPSQAQGLGSNLVTEVRVYNWFANRRKEEAFRHKLAMDTYSGPPPGPGPGPALPAHSSPGLPPPALSPSKVHGVRYGQPATSETAEVPSSSGGPLVTVSTPLHQVSPTGLEPSHSLLSTEAKLVSAAGGPLPPVSTLTALHSLEQTSPGLNQQPQNLIMASLPGVMTIGPGEPASLGPTFTNTGASTLVIGLASTQAQSVPVINSMGSSLTTLQPVQFSQPLHPSYQQPLMPPVQSHVTQSPFMATMAQLQSPHALYSHKPEVAQYTHTGLLPQTMLITDTTNLSALASLTPTKQVFTSDTEASSESGLHTPASQATTLHVPSQDPAGIQHLQPAHRLSASPTVSSSSLVLYQSSDSSNGQSHLLPSNHSVIETFISTQMASSSQ	631	P20823	K	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [580], 'REGION_gain': [], 'REGION_loss_score': array([-0.0182445]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
493	NM_001110792.2(MECP2):c.408G>C (p.Leu136Phe)	143549	CA270369	NM_001110792.2:c.408G>C, NC_000023.11:g.154032212C>G, CM000685.2:g.154032212C>G, NC_000023.10:g.153297663C>G, CM000685.1:g.153297663C>G, NC_000023.9:g.152950857C>G, NG_007107.2:g.109916G>C, NG_007107.3:g.109892G>C, ENST00000303391.11:c.372G>C, ENST00000453960.7:c.408G>C, ENST00000637917.1:n.5G>C, ENST00000303391.10:c.372G>C, ENST00000369957.5:c.*426G>C, ENST00000407218.5:c.408G>C, ENST00000453960.6:c.408G>C, ENST00000486506.5:n.2720G>C, ENST00000611468.1:c.360G>C, ENST00000619732.4:c.372G>C, ENST00000622433.4:c.360G>C, ENST00000628176.2:c.372G>C, NM_001110792.1:c.408G>C, NM_001316337.1:c.93G>C, NM_004992.3:c.372G>C, XM_005274681.3:c.372G>C, XM_005274682.3:c.93G>C, XM_005274683.3:c.93G>C, XM_006724819.2:c.-189G>C, XM_011531166.1:c.93G>C, XM_006724819.3:c.-189G>C, XM_011531166.2:c.93G>C, XM_024452383.1:c.93G>C, XM_024452384.1:c.93G>C, NM_001316337.2:c.93G>C, NM_001369391.2:c.93G>C, NM_001369392.2:c.93G>C, NM_001369393.2:c.93G>C, NM_001369394.1:c.93G>C, NM_001369394.2:c.93G>C, NM_001386137.1:c.-189G>C, NM_001386138.1:c.-189G>C, NM_001386139.1:c.-189G>C, NM_004992.4:c.372G>C, NM_001110792.2(MECP2):c.408G>C (p.Leu136Phe)	MECP2	Rett syndrome	MONDO:0010726	X-linked inheritance	Pathogenic	PM2_Supporting, PM6, PS1, PS3_Supporting, PM1		The c.372G>C (p.Leu124Phe) variant in MECP2 (NM_004992.3) occurs in the de novo state (biological parentage unconfirmed) in an individual with Rett syndrome (PMID 10991688) (PM6). The c.372G>C (p.Leu124Phe) variant occurs in the well-characterized methyl-DNA binding functional domain of the MECP2 gene (PM1). The c.372G>C (p.Leu124Phe) variant in MECP2 is absent from gnomAD (PM2_supporting). MECP2 heterochromatin binding assay and in vitro transcriptional repression assay have shown that this variant impacts protein function (PMID 12843318) (PS3_supporting). The c.372G>T variant in the MECP2 gene results in a p.Leu124Phe change that is a previously established pathogenic variant (internal database - Invitae) (PS1). In summary, the c.372G>C (p.Leu124Phe) variant in MECP2 is classified as Pathogenic for Rett syndrome based on the ACMG/AMP criteria (PS1, PM1, PM6, PM2_supporting, PS3_supporting).		Rett and Angelman-like Disorders VCEP	https://clinicalgenome.org/site/assets/files/7339/clingen_rettas_acmg_specifications_v2.pdf	2022-10-11	2022-12-02	False	https://erepo.genome.network/evrepo/ui/classification/CA270369/MONDO:0010726/016	40db135c-d0c1-40a2-bb59-8540e334e2d5	p.Leu136Phe	Leu	136	Phe	MVAGMLGLREEKSEDQDLQGLKDKPLKFKKVKKDKKEEKEGKHEPVQPSAHHSAEPAEAGKAETSEGSGSAPAVPEASASPKQRRSIIRDRGPMYDDPTLPEGWTRKLKQRKSGRSAGKYDVYLINPQGKAFRSKVELIAYFEKVGDTSLDPNDFDFTVTGRGSPSRREQKPPKKPKSPKAPGTGRGRGRPKGSGTTRPKAATSEGVQVKRVLEKSPGKLLVKMPFQTSPGGKAEGGGATTSTQVMVIKRPGRKRKAEADPQAIPKKRGRKPGSVVAAAAAEAKKKAVKESSIRSVQETVLPIKKRKTRETVSIEVKEVVKPLLVSTLGEKSGKGLKTCKSPGRKSKESSPKGRSSSASSPPKKEHHHHHHHSESPKAPVPLLPPLPPPPPEPESSEDPTSPPEPQDLSSSVCKEEKMPRGGSLESDGCPKEPAKTQPAVATAATAAEKYKHRGEGERKDIVSSSMPRPNREEPVDSRTPVTERVS	486	P51608	F	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [83, 84, 85, 164], 'DOMAIN_gain_score': array([0.1456278 , 0.14317048, 0.13973653, 0.10537153]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
494	NM_001110792.2(MECP2):c.408G>T (p.Leu136Phe)	143550	CA270371	NM_001110792.2:c.408G>T, NC_000023.11:g.154032212C>A, CM000685.2:g.154032212C>A, NC_000023.10:g.153297663C>A, CM000685.1:g.153297663C>A, NC_000023.9:g.152950857C>A, NG_007107.2:g.109916G>T, NG_007107.3:g.109892G>T, ENST00000303391.11:c.372G>T, ENST00000453960.7:c.408G>T, ENST00000637917.1:n.5G>T, ENST00000303391.10:c.372G>T, ENST00000369957.5:c.*426G>T, ENST00000407218.5:c.408G>T, ENST00000453960.6:c.408G>T, ENST00000486506.5:n.2720G>T, ENST00000611468.1:c.360G>T, ENST00000619732.4:c.372G>T, ENST00000622433.4:c.360G>T, ENST00000628176.2:c.372G>T, NM_001110792.1:c.408G>T, NM_001316337.1:c.93G>T, NM_004992.3:c.372G>T, XM_005274681.3:c.372G>T, XM_005274682.3:c.93G>T, XM_005274683.3:c.93G>T, XM_006724819.2:c.-189G>T, XM_011531166.1:c.93G>T, XM_006724819.3:c.-189G>T, XM_011531166.2:c.93G>T, XM_024452383.1:c.93G>T, XM_024452384.1:c.93G>T, NM_001316337.2:c.93G>T, NM_001369391.2:c.93G>T, NM_001369392.2:c.93G>T, NM_001369393.2:c.93G>T, NM_001369394.1:c.93G>T, NM_001369394.2:c.93G>T, NM_001386137.1:c.-189G>T, NM_001386138.1:c.-189G>T, NM_001386139.1:c.-189G>T, NM_004992.4:c.372G>T, NM_001110792.2(MECP2):c.408G>T (p.Leu136Phe)	MECP2	Rett syndrome	MONDO:0010726	X-linked inheritance	Pathogenic	PM2_Supporting, PS2, PS1, PM1	PP3, PP4, PS3	The c.372G>T (p.Leu124Phe) variant in MECP2 (NM_004992.3) occurs in the mosaic state in a male patient with a neurodevelopmental phenotype consistent with the MECP2 gene (internal database - Invitae) and therefore confirmed to be de novo (PS2). The c.372G>T (p.Leu124Phe) variant occurs in the well-characterized methyl-DNA binding functional domain of the MECP2 gene (PM1). The c.372G>T (p.Leu124Phe) variant in MECP2 is absent from gnomAD (PM2_supporting). The c.372G>C variant in the MECP2 gene results in a p.Leu124Phe change that is a previously established pathogenic variant (PMID 10991688, 12843318) (PS1). In summary, the c.372G>T (p.Leu124Phe) variant in MECP2 is classified as Pathogenic for Rett syndrome based on the ACMG/AMP criteria (PS1, PS2, PM1, PM2_supporting).		Rett and Angelman-like Disorders VCEP	https://clinicalgenome.org/site/assets/files/7339/clingen_rettas_acmg_specifications_v2.pdf	2022-10-11	2022-12-02	False	https://erepo.genome.network/evrepo/ui/classification/CA270371/MONDO:0010726/016	217fc1a3-cebb-449b-9d62-7b2a58d3f29b	p.Leu136Phe	Leu	136	Phe	MVAGMLGLREEKSEDQDLQGLKDKPLKFKKVKKDKKEEKEGKHEPVQPSAHHSAEPAEAGKAETSEGSGSAPAVPEASASPKQRRSIIRDRGPMYDDPTLPEGWTRKLKQRKSGRSAGKYDVYLINPQGKAFRSKVELIAYFEKVGDTSLDPNDFDFTVTGRGSPSRREQKPPKKPKSPKAPGTGRGRGRPKGSGTTRPKAATSEGVQVKRVLEKSPGKLLVKMPFQTSPGGKAEGGGATTSTQVMVIKRPGRKRKAEADPQAIPKKRGRKPGSVVAAAAAEAKKKAVKESSIRSVQETVLPIKKRKTRETVSIEVKEVVKPLLVSTLGEKSGKGLKTCKSPGRKSKESSPKGRSSSASSPPKKEHHHHHHHSESPKAPVPLLPPLPPPPPEPESSEDPTSPPEPQDLSSSVCKEEKMPRGGSLESDGCPKEPAKTQPAVATAATAAEKYKHRGEGERKDIVSSSMPRPNREEPVDSRTPVTERVS	486	P51608	F	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [83, 84, 85, 164], 'DOMAIN_gain_score': array([0.1456278 , 0.14317048, 0.13973653, 0.10537153]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
495	NM_001110792.2(MECP2):c.434G>T (p.Arg145Leu)	143560	CA270390	NM_001110792.2:c.434G>T, NC_000023.11:g.154031430C>A, CM000685.2:g.154031430C>A, NC_000023.10:g.153296881C>A, CM000685.1:g.153296881C>A, NC_000023.9:g.152950075C>A, NG_007107.2:g.110698G>T, NG_007107.3:g.110674G>T, ENST00000303391.11:c.398G>T, ENST00000453960.7:c.434G>T, ENST00000637917.1:n.31G>T, ENST00000303391.10:c.398G>T, ENST00000369957.5:c.*452G>T, ENST00000407218.5:c.434G>T, ENST00000453960.6:c.434G>T, ENST00000486506.5:n.2746G>T, ENST00000611468.1:c.386G>T, ENST00000619732.4:c.398G>T, ENST00000622433.4:c.386G>T, ENST00000628176.2:c.398G>T, NM_001110792.1:c.434G>T, NM_001316337.1:c.119G>T, NM_004992.3:c.398G>T, XM_005274681.3:c.398G>T, XM_005274682.3:c.119G>T, XM_005274683.3:c.119G>T, XM_006724819.2:c.-163G>T, XM_011531166.1:c.119G>T, XM_006724819.3:c.-163G>T, XM_011531166.2:c.119G>T, XM_024452383.1:c.119G>T, XM_024452384.1:c.119G>T, NM_001316337.2:c.119G>T, NM_001369391.2:c.119G>T, NM_001369392.2:c.119G>T, NM_001369393.2:c.119G>T, NM_001369394.1:c.119G>T, NM_001369394.2:c.119G>T, NM_001386137.1:c.-163G>T, NM_001386138.1:c.-163G>T, NM_001386139.1:c.-163G>T, NM_004992.4:c.398G>T, NM_001110792.2(MECP2):c.434G>T (p.Arg145Leu)	MECP2	Rett syndrome	MONDO:0010726	X-linked inheritance	Pathogenic	PP3, PP4, PM2_Supporting, PS4_Supporting, PM6, PM5_Strong, PS3_Supporting		The p.Arg133Leu variant in MECP2 (NM_004992.3) occurs in the de novo state (biological parentage unconfirmed) in an individual with classic Rett syndrome (PMID 10854091) (PM6). The p.Arg133Leu variant has been observed in at least 1 other individual with classic Rett syndrome (PMID 19722030) (PS4_supporting, PP4). Multiple pathogenic missense variants have been previously identified within this codon which indicates that this residue is critical to the function of the protein (PMID 30569584, 23421866, 11738879, 26418480, 16473305, 22368975; ClinVar) (PM5_strong). The p.Arg133Leu variant in MECP2 is absent from gnomAD (PM2_supporting). Computational prediction analysis tools suggests a deleterious impact; however, this information does not predict clinical significance on its own (PP3). MECP2 chromatin binding assays have shown that this variant impacts protein function (PMID 27929079, 22923521) (PS3_supporting). In summary, the p.Arg133Leu variant in MECP2 is classified as Pathogenic for Rett syndrome based on the ACMG/AMP criteria (PM5_strong,  PM6, PS3_supporting, PS4_supporting, PM2_supporting, PP3 + PP4).		Rett and Angelman-like Disorders VCEP	https://clinicalgenome.org/site/assets/files/7339/clingen_rettas_acmg_specifications_v2.pdf	2022-10-11	2022-12-02	False	https://erepo.genome.network/evrepo/ui/classification/CA270390/MONDO:0010726/016	65ae8c8f-de06-4f4f-b4b2-72936e46dca4	p.Arg145Leu	Arg	145	Leu	MVAGMLGLREEKSEDQDLQGLKDKPLKFKKVKKDKKEEKEGKHEPVQPSAHHSAEPAEAGKAETSEGSGSAPAVPEASASPKQRRSIIRDRGPMYDDPTLPEGWTRKLKQRKSGRSAGKYDVYLINPQGKAFRSKVELIAYFEKVGDTSLDPNDFDFTVTGRGSPSRREQKPPKKPKSPKAPGTGRGRGRPKGSGTTRPKAATSEGVQVKRVLEKSPGKLLVKMPFQTSPGGKAEGGGATTSTQVMVIKRPGRKRKAEADPQAIPKKRGRKPGSVVAAAAAEAKKKAVKESSIRSVQETVLPIKKRKTRETVSIEVKEVVKPLLVSTLGEKSGKGLKTCKSPGRKSKESSPKGRSSSASSPPKKEHHHHHHHSESPKAPVPLLPPLPPPPPEPESSEDPTSPPEPQDLSSSVCKEEKMPRGGSLESDGCPKEPAKTQPAVATAATAAEKYKHRGEGERKDIVSSSMPRPNREEPVDSRTPVTERVS	486	P51608	L	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
496	NM_001110792.2(MECP2):c.507C>G (p.Phe169Leu)	143589	CA270435	NM_001110792.2:c.507C>G, NC_000023.11:g.154031357G>C, CM000685.2:g.154031357G>C, NC_000023.10:g.153296808G>C, CM000685.1:g.153296808G>C, NC_000023.9:g.152950002G>C, NG_007107.2:g.110771C>G, NG_007107.3:g.110747C>G, ENST00000303391.11:c.471C>G, ENST00000453960.7:c.507C>G, ENST00000637917.1:n.65+39C>G, ENST00000303391.10:c.471C>G, ENST00000407218.5:c.468+39C>G, ENST00000453960.6:c.507C>G, ENST00000486506.5:n.2819C>G, ENST00000611468.1:c.459C>G, ENST00000619732.4:c.471C>G, ENST00000622433.4:c.459C>G, ENST00000628176.2:c.432+39C>G, NM_001110792.1:c.507C>G, NM_001316337.1:c.192C>G, NM_004992.3:c.471C>G, XM_005274681.3:c.471C>G, XM_005274682.3:c.192C>G, XM_005274683.3:c.192C>G, XM_006724819.2:c.-129+39C>G, XM_011531166.1:c.192C>G, XM_006724819.3:c.-129+39C>G, XM_011531166.2:c.192C>G, XM_024452383.1:c.192C>G, XM_024452384.1:c.192C>G, NM_001316337.2:c.192C>G, NM_001369391.2:c.192C>G, NM_001369392.2:c.192C>G, NM_001369393.2:c.192C>G, NM_001369394.1:c.192C>G, NM_001369394.2:c.192C>G, NM_001386137.1:c.-129+39C>G, NM_001386138.1:c.-129+39C>G, NM_001386139.1:c.-129+39C>G, NM_004992.4:c.471C>G, NM_001110792.2(MECP2):c.507C>G (p.Phe169Leu)	MECP2	Rett syndrome	MONDO:0010726	X-linked inheritance	Pathogenic	PP3, PP4, PM2_Supporting, PS4_Moderate, PS1, PM5, PM1		The c.471C>G (p.Phe157Leu) variant in MECP2 (NM_004992.3) has been reported in an individual with a clinical phenotype suggestive of Rett syndrome (PMID 15675358) (PP4). The p.Phe157Leu variant in MECP2 has been observed in 2 additional individuals with MECP2-related conditions (PMID 30536762, RettBASE) (PS4_moderate). The p.Phe157Leu variant occurs in the well-characterized methyl-DNA binding functional domain of the MECP2 gene (PM1). Computational prediction analysis tools suggests a deleterious impact; however, this information does not predict clinical significance on its own (PP3). The p.Phe169Leu variant in MECP2 is absent from gnomAD (PM2_supporting). The c.471C>A variant in the MECP2 gene results in a p.Phe157Leu change that is a previously established pathogenic variant (ClinVar, Invitae - internal database) (PS1). A pathogenic missense variant (p.Phe157Ile) has been previously identified within this codon which indicates that this residue is critical to the function of the protein (PMID 16832102, 27929079, RettBASE) (PM5). In summary, the c.471C>G (p.Phe157Leu) variant in MECP2 is classified as Pathogenic for Rett syndrome based on the ACMG/AMP criteria (PS1 + PM1 + PM5 + PS4_moderate + PM2_supporting + PP3 + PP4).		Rett and Angelman-like Disorders VCEP	https://clinicalgenome.org/site/assets/files/7339/clingen_rettas_acmg_specifications_v2.pdf	2022-10-11	2022-12-02	False	https://erepo.genome.network/evrepo/ui/classification/CA270435/MONDO:0010726/016	6c97e782-e936-4540-94ee-46205d786176	p.Phe169Leu	Phe	169	Leu	MVAGMLGLREEKSEDQDLQGLKDKPLKFKKVKKDKKEEKEGKHEPVQPSAHHSAEPAEAGKAETSEGSGSAPAVPEASASPKQRRSIIRDRGPMYDDPTLPEGWTRKLKQRKSGRSAGKYDVYLINPQGKAFRSKVELIAYFEKVGDTSLDPNDFDFTVTGRGSPSRREQKPPKKPKSPKAPGTGRGRGRPKGSGTTRPKAATSEGVQVKRVLEKSPGKLLVKMPFQTSPGGKAEGGGATTSTQVMVIKRPGRKRKAEADPQAIPKKRGRKPGSVVAAAAAEAKKKAVKESSIRSVQETVLPIKKRKTRETVSIEVKEVVKPLLVSTLGEKSGKGLKTCKSPGRKSKESSPKGRSSSASSPPKKEHHHHHHHSESPKAPVPLLPPLPPPPPEPESSEDPTSPPEPQDLSSSVCKEEKMPRGGSLESDGCPKEPAKTQPAVATAATAAEKYKHRGEGERKDIVSSSMPRPNREEPVDSRTPVTERVS	486	P51608	L	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [102], 'COMPBIAS_gain': [], 'COMPBIAS_loss_score': array([-0.03468978]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [300], 'REGION_gain': [], 'REGION_loss_score': array([-0.02543104]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
497	NM_001110792.2(MECP2):c.191A>G (p.His64Arg)	143494	CA170263	NM_001110792.2:c.191A>G, NC_000023.11:g.154032429T>C, CM000685.2:g.154032429T>C, NC_000023.10:g.153297880T>C, CM000685.1:g.153297880T>C, NC_000023.9:g.152951074T>C, NG_007107.2:g.109699A>G, NG_007107.3:g.109675A>G, ENST00000303391.11:c.155A>G, ENST00000453960.7:c.191A>G, ENST00000303391.10:c.155A>G, ENST00000369957.5:c.*209A>G, ENST00000407218.5:c.191A>G, ENST00000453960.6:c.191A>G, ENST00000486506.5:n.2503A>G, ENST00000496908.5:n.286A>G, ENST00000611468.1:c.143A>G, ENST00000619732.4:c.155A>G, ENST00000622433.4:c.143A>G, ENST00000628176.2:c.155A>G, ENST00000631210.1:n.434A>G, NM_001110792.1:c.191A>G, NM_001316337.1:c.-125A>G, NM_004992.3:c.155A>G, XM_005274681.3:c.155A>G, XM_005274682.3:c.-125A>G, XM_005274683.3:c.-125A>G, XM_011531166.1:c.-125A>G, XM_006724819.3:c.-406A>G, XM_011531166.2:c.-125A>G, XM_024452383.1:c.-125A>G, XM_024452384.1:c.-125A>G, NM_001316337.2:c.-125A>G, NM_001369391.2:c.-125A>G, NM_001369392.2:c.-125A>G, NM_001369393.2:c.-125A>G, NM_001369394.1:c.-125A>G, NM_001369394.2:c.-125A>G, NM_001386137.1:c.-406A>G, NM_001386138.1:c.-406A>G, NM_001386139.1:c.-406A>G, NM_004992.4:c.155A>G, NM_001110792.2(MECP2):c.191A>G (p.His64Arg)	MECP2	Rett syndrome	MONDO:0010726	X-linked inheritance	Benign	BA1	BP4, PM1	The allele frequency of the p.His52Arg variant in MECP2 (NM_004992.3) is 0.121% in the South Asian sub population in gnomAD, which is high enough to be classified as benign based on thresholds defined by the ClinGen Rett/Angelman-like Expert Panel for Rett/AS-like conditions (BA1). In summary, the p.His52Arg variant in MECP2 is classified as Benign based on the ACMG/AMP criteria (BA1).		Rett and Angelman-like Disorders VCEP	https://clinicalgenome.org/site/assets/files/7339/clingen_rettas_acmg_specifications_v2.pdf	2022-10-11	2022-12-02	False	https://erepo.genome.network/evrepo/ui/classification/CA170263/MONDO:0010726/016	6df1d753-4719-4799-9a41-de087cce3897	p.His64Arg	His	64	Arg	MVAGMLGLREEKSEDQDLQGLKDKPLKFKKVKKDKKEEKEGKHEPVQPSAHHSAEPAEAGKAETSEGSGSAPAVPEASASPKQRRSIIRDRGPMYDDPTLPEGWTRKLKQRKSGRSAGKYDVYLINPQGKAFRSKVELIAYFEKVGDTSLDPNDFDFTVTGRGSPSRREQKPPKKPKSPKAPGTGRGRGRPKGSGTTRPKAATSEGVQVKRVLEKSPGKLLVKMPFQTSPGGKAEGGGATTSTQVMVIKRPGRKRKAEADPQAIPKKRGRKPGSVVAAAAAEAKKKAVKESSIRSVQETVLPIKKRKTRETVSIEVKEVVKPLLVSTLGEKSGKGLKTCKSPGRKSKESSPKGRSSSASSPPKKEHHHHHHHSESPKAPVPLLPPLPPPPPEPESSEDPTSPPEPQDLSSSVCKEEKMPRGGSLESDGCPKEPAKTQPAVATAATAAEKYKHRGEGERKDIVSSSMPRPNREEPVDSRTPVTERVS	486	P51608	R	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
498	NM_001110792.2(MECP2):c.260C>T (p.Pro87Leu)	143504	CA170272	NM_001110792.2:c.260C>T, NC_000023.11:g.154032360G>A, CM000685.2:g.154032360G>A, NC_000023.10:g.153297811G>A, CM000685.1:g.153297811G>A, NC_000023.9:g.152951005G>A, NG_007107.2:g.109768C>T, NG_007107.3:g.109744C>T, ENST00000303391.11:c.224C>T, ENST00000453960.7:c.260C>T, ENST00000303391.10:c.224C>T, ENST00000369957.5:c.*278C>T, ENST00000407218.5:c.260C>T, ENST00000453960.6:c.260C>T, ENST00000486506.5:n.2572C>T, ENST00000611468.1:c.212C>T, ENST00000619732.4:c.224C>T, ENST00000622433.4:c.212C>T, ENST00000628176.2:c.224C>T, NM_001110792.1:c.260C>T, NM_001316337.1:c.-56C>T, NM_004992.3:c.224C>T, XM_005274681.3:c.224C>T, XM_005274682.3:c.-56C>T, XM_005274683.3:c.-56C>T, XM_011531166.1:c.-56C>T, XM_006724819.3:c.-337C>T, XM_011531166.2:c.-56C>T, XM_024452383.1:c.-56C>T, XM_024452384.1:c.-56C>T, NM_001316337.2:c.-56C>T, NM_001369391.2:c.-56C>T, NM_001369392.2:c.-56C>T, NM_001369393.2:c.-56C>T, NM_001369394.1:c.-56C>T, NM_001369394.2:c.-56C>T, NM_001386137.1:c.-337C>T, NM_001386138.1:c.-337C>T, NM_001386139.1:c.-337C>T, NM_004992.4:c.224C>T, NM_001110792.2(MECP2):c.260C>T (p.Pro87Leu)	MECP2	Rett syndrome	MONDO:0010726	X-linked inheritance	Benign	BA1	BP4, PM1	The allele frequency of the p.Pro75Leu variant in MECP2 (NM_004992.3) is 0.038% in the Other sub population in gnomAD, which is high enough to be classified as benign based on thresholds defined by the ClinGen Rett/Angelman-like Expert Panel for Rett/AS-like conditions (BA1). In summary, the p.Pro75Leu variant in MECP2 is classified as Benign based on the ACMG/AMP criteria (BA1).		Rett and Angelman-like Disorders VCEP	https://clinicalgenome.org/site/assets/files/7339/clingen_rettas_acmg_specifications_v2.pdf	2022-10-11	2022-12-02	False	https://erepo.genome.network/evrepo/ui/classification/CA170272/MONDO:0010726/016	ddb1c36d-ce11-4d3d-934c-55ce859dee8f	p.Pro87Leu	Pro	87	Leu	MVAGMLGLREEKSEDQDLQGLKDKPLKFKKVKKDKKEEKEGKHEPVQPSAHHSAEPAEAGKAETSEGSGSAPAVPEASASPKQRRSIIRDRGPMYDDPTLPEGWTRKLKQRKSGRSAGKYDVYLINPQGKAFRSKVELIAYFEKVGDTSLDPNDFDFTVTGRGSPSRREQKPPKKPKSPKAPGTGRGRGRPKGSGTTRPKAATSEGVQVKRVLEKSPGKLLVKMPFQTSPGGKAEGGGATTSTQVMVIKRPGRKRKAEADPQAIPKKRGRKPGSVVAAAAAEAKKKAVKESSIRSVQETVLPIKKRKTRETVSIEVKEVVKPLLVSTLGEKSGKGLKTCKSPGRKSKESSPKGRSSSASSPPKKEHHHHHHHSESPKAPVPLLPPLPPPPPEPESSEDPTSPPEPQDLSSSVCKEEKMPRGGSLESDGCPKEPAKTQPAVATAATAAEKYKHRGEGERKDIVSSSMPRPNREEPVDSRTPVTERVS	486	P51608	L	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [86], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.0595988]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
499	NM_001110792.2(MECP2):c.653G>C (p.Gly218Ala)	143638	CA170346	NM_001110792.2:c.653G>C, NC_000023.11:g.154031211C>G, CM000685.2:g.154031211C>G, NC_000023.10:g.153296662C>G, CM000685.1:g.153296662C>G, NC_000023.9:g.152949856C>G, NG_007107.2:g.110917G>C, NG_007107.3:g.110893G>C, ENST00000303391.11:c.617G>C, ENST00000453960.7:c.653G>C, ENST00000637917.1:n.65+185G>C, ENST00000303391.10:c.617G>C, ENST00000407218.5:c.544G>C, ENST00000453960.6:c.653G>C, ENST00000619732.4:c.617G>C, ENST00000622433.4:c.605G>C, ENST00000628176.2:c.508G>C, NM_001110792.1:c.653G>C, NM_001316337.1:c.338G>C, NM_004992.3:c.617G>C, XM_005274681.3:c.617G>C, XM_005274682.3:c.338G>C, XM_005274683.3:c.338G>C, XM_006724819.2:c.-53G>C, XM_011531166.1:c.338G>C, XM_006724819.3:c.-53G>C, XM_011531166.2:c.338G>C, XM_024452383.1:c.338G>C, XM_024452384.1:c.338G>C, NM_001316337.2:c.338G>C, NM_001369391.2:c.338G>C, NM_001369392.2:c.338G>C, NM_001369393.2:c.338G>C, NM_001369394.1:c.338G>C, NM_001369394.2:c.338G>C, NM_001386137.1:c.-53G>C, NM_001386138.1:c.-53G>C, NM_001386139.1:c.-53G>C, NM_004992.4:c.617G>C, NM_001110792.2(MECP2):c.653G>C (p.Gly218Ala)	MECP2	Rett syndrome	MONDO:0010726	X-linked inheritance	Benign	BS2, BS1, BP5_Strong	BP4, PM1	The allele frequency of the p.Gly206Ala variant in MECP2 (NM_004992.3) is 0.008% in the European (non-Finnish) sub population in gnomAD, which is high enough to meet the BS1 criteria based on thresholds defined by the ClinGen Rett/Angelman-like Expert Panel for Rett/AS-like conditions (BS1). The p.Gly206Ala variant in MECP2 is observed in at least 2 unaffected individuals (PMID 17427193, internal database - GeneDx) (BS2). The p.Gly206Ala variant is found in at least 3 patients with an alternate molecular basis of disease (internal database - GeneDx; internal database - Invitae) (BP5_strong). In summary, the p.Gly206Ala variant in MECP2 is classified as Benign based on the ACMG/AMP criteria (BS1, BS2, BP5_strong).		Rett and Angelman-like Disorders VCEP	https://clinicalgenome.org/site/assets/files/7339/clingen_rettas_acmg_specifications_v2.pdf	2022-10-11	2022-12-02	False	https://erepo.genome.network/evrepo/ui/classification/CA170346/MONDO:0010726/016	25d4eef7-f6df-4c31-a1ab-11f029f4c8d2	p.Gly218Ala	Gly	218	Ala	MVAGMLGLREEKSEDQDLQGLKDKPLKFKKVKKDKKEEKEGKHEPVQPSAHHSAEPAEAGKAETSEGSGSAPAVPEASASPKQRRSIIRDRGPMYDDPTLPEGWTRKLKQRKSGRSAGKYDVYLINPQGKAFRSKVELIAYFEKVGDTSLDPNDFDFTVTGRGSPSRREQKPPKKPKSPKAPGTGRGRGRPKGSGTTRPKAATSEGVQVKRVLEKSPGKLLVKMPFQTSPGGKAEGGGATTSTQVMVIKRPGRKRKAEADPQAIPKKRGRKPGSVVAAAAAEAKKKAVKESSIRSVQETVLPIKKRKTRETVSIEVKEVVKPLLVSTLGEKSGKGLKTCKSPGRKSKESSPKGRSSSASSPPKKEHHHHHHHSESPKAPVPLLPPLPPPPPEPESSEDPTSPPEPQDLSSSVCKEEKMPRGGSLESDGCPKEPAKTQPAVATAATAAEKYKHRGEGERKDIVSSSMPRPNREEPVDSRTPVTERVS	486	P51608	A	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [264], 'COMPBIAS_gain_score': array([0.00908703]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [300], 'REGION_gain': [], 'REGION_loss_score': array([-0.02073109]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
500	NM_001110792.2(MECP2):c.1363G>A (p.Ala455Thr)	36491	CA199489	NM_001110792.2:c.1363G>A, NC_000023.11:g.154030501C>T, CM000685.2:g.154030501C>T, NC_000023.10:g.153295952C>T, CM000685.1:g.153295952C>T, NC_000023.9:g.152949146C>T, NG_007107.2:g.111627G>A, NG_007107.3:g.111603G>A, ENST00000303391.11:c.1327G>A, ENST00000453960.7:c.1363G>A, ENST00000303391.10:c.1327G>A, ENST00000453960.6:c.1363G>A, ENST00000619732.4:c.1327G>A, ENST00000628176.2:c.*699G>A, NM_001110792.1:c.1363G>A, NM_001316337.1:c.1048G>A, NM_004992.3:c.1327G>A, XM_005274681.3:c.1327G>A, XM_005274682.3:c.1048G>A, XM_005274683.3:c.1048G>A, XM_006724819.2:c.658G>A, XM_011531166.1:c.1048G>A, XM_006724819.3:c.658G>A, XM_011531166.2:c.1048G>A, XM_024452383.1:c.1048G>A, XM_024452384.1:c.1048G>A, NM_001316337.2:c.1048G>A, NM_001369391.2:c.1048G>A, NM_001369392.2:c.1048G>A, NM_001369393.2:c.1048G>A, NM_001369394.1:c.1048G>A, NM_001369394.2:c.1048G>A, NM_001386137.1:c.658G>A, NM_001386138.1:c.658G>A, NM_001386139.1:c.658G>A, NM_004992.4:c.1327G>A, NM_001110792.2(MECP2):c.1363G>A (p.Ala455Thr)	MECP2	Rett syndrome	MONDO:0010726	X-linked inheritance	Benign	BS2, BS1	PS4	The allele frequency of the p.Ala443Thr variant in MECP2 (NM_004992.3) is 0.015% in Latino population and 0.014% in East Asian population in gnomAD, which is high enough to meet the BS1 criteria based on thresholds defined by the ClinGen Rett/Angelman-like Expert Panel for Rett/AS-like conditions (BS1). The p.Ala443Thr variant is observed in at least 2 unaffected individuals (RettBASE, PMID 22277191, GeneDx internal database, Invitae internal database) (BS2). In summary, the p.Ala443Thr variant in MECP2 is classified as benign based on the ACMG/AMP criteria (BS1, BS2).		Rett and Angelman-like Disorders VCEP	https://clinicalgenome.org/site/assets/files/7339/clingen_rettas_acmg_specifications_v2.pdf	2022-02-18	2022-12-02	False	https://erepo.genome.network/evrepo/ui/classification/CA199489/MONDO:0010726/016	94181559-64a8-47c9-8e46-171662a6bbfa	p.Ala455Thr	Ala	455	Thr	MVAGMLGLREEKSEDQDLQGLKDKPLKFKKVKKDKKEEKEGKHEPVQPSAHHSAEPAEAGKAETSEGSGSAPAVPEASASPKQRRSIIRDRGPMYDDPTLPEGWTRKLKQRKSGRSAGKYDVYLINPQGKAFRSKVELIAYFEKVGDTSLDPNDFDFTVTGRGSPSRREQKPPKKPKSPKAPGTGRGRGRPKGSGTTRPKAATSEGVQVKRVLEKSPGKLLVKMPFQTSPGGKAEGGGATTSTQVMVIKRPGRKRKAEADPQAIPKKRGRKPGSVVAAAAAEAKKKAVKESSIRSVQETVLPIKKRKTRETVSIEVKEVVKPLLVSTLGEKSGKGLKTCKSPGRKSKESSPKGRSSSASSPPKKEHHHHHHHSESPKAPVPLLPPLPPPPPEPESSEDPTSPPEPQDLSSSVCKEEKMPRGGSLESDGCPKEPAKTQPAVATAATAAEKYKHRGEGERKDIVSSSMPRPNREEPVDSRTPVTERVS	486	P51608	T	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [447, 448], 'COMPBIAS_gain': [374], 'COMPBIAS_gain_score': array([0.01629877]), 'COMPBIAS_loss_score': array([-0.35854298, -0.35206485]), 'DOMAIN_loss': [], 'DOMAIN_gain': [85], 'DOMAIN_gain_score': array([0.00793523]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
501	NM_000018.4(ACADVL):c.1322G>A (p.Gly441Asp)	21016	CA220193	NM_000018.4:c.1322G>A, NC_000017.11:g.7223865G>A, CM000679.2:g.7223865G>A, NC_000017.10:g.7127184G>A, CM000679.1:g.7127184G>A, NC_000017.9:g.7067908G>A, NG_007975.1:g.9032G>A, NG_008391.2:g.1186C>T, NG_033038.1:g.15680C>T, ENST00000356839.10:c.1322G>A, ENST00000322910.9:c.*1277G>A, ENST00000350303.9:c.1256G>A, ENST00000356839.9:c.1322G>A, ENST00000542255.6:n.180G>A, ENST00000543245.6:c.1391G>A, ENST00000578711.1:n.361G>A, ENST00000579425.5:n.346G>A, ENST00000579546.1:n.159G>A, ENST00000583074.5:n.41G>A, ENST00000583850.5:n.97G>A, ENST00000583858.5:n.351G>A, ENST00000585203.6:n.523+7G>A, NM_000018.3:c.1322G>A, NM_001033859.2:c.1256G>A, NM_001270447.1:c.1391G>A, NM_001270448.1:c.1094G>A, XM_006721516.2:c.1322G>A, XM_011523829.1:c.1322G>A, XM_011523830.1:c.1322G>A, XR_934021.1:n.1429G>A, XR_934022.1:n.1429G>A, XR_934023.1:n.1429G>A, XM_006721516.3:c.1322G>A, XM_011523829.2:c.1322G>A, XM_011523830.2:c.1322G>A, XM_024450741.1:c.1322G>A, XR_934021.2:n.1381G>A, XR_934022.2:n.1381G>A, XR_934023.2:n.1381G>A, NM_001033859.3:c.1256G>A, NM_001270447.2:c.1391G>A, NM_001270448.2:c.1094G>A, NM_000018.4(ACADVL):c.1322G>A (p.Gly441Asp)	ACADVL	very long chain acyl-CoA dehydrogenase deficiency	MONDO:0008723	Autosomal recessive inheritance	Pathogenic	PM2, PP4_Moderate, PP3, PM1, PM3_Strong	BP4	The c.1322G>A (p.Gly441Asp) variant in ACADVL is a missense variant predicted to cause substitution of glycine by aspartic acid at amino acid 441. At least two individuals with this variant displayed VLCAD enzyme activity <20% of normal, which is highly specific for very long chain acyl CoA dehydrogenase (VLCAD) deficiency (PP4_Moderate; PMID: 25834949). The variant has been described in the homozygous state in at least 4 affected individuals, confirmed in trans to a pathogenic variant in at least one individual, and in at least one individual with a distinct pathogenic variant without determination of phase of the variants (PM3_Strong; PMIDs: 1648817, 17999356, 24305961, 30194637, 32061778). The highest population minor allele frequency in gnomAD v2.1.1 is 0.00006 in the European (Non-Finnish) population, which is lower than the ClinGen ACADVL Variant Curation Expert Panel threshold (<0.001) for PM2_Supporting, meeting this criterion. This variant occurs adjacent to the FAD binding pocket and is located on a loop that contributes to dimer formation (PM1; PMID: 20060901). The computational predictor REVEL gives a score of 0.982, which is above the threshold of 0.75, evidence that correlates with impact to ACADVL function (PP3). In summary, this variant meets the criteria to be classified as pathogenic for autosomal recessive VLCAD deficiency based on the ACMG/AMP criteria applied, as specified by the ClinGen ACADVL Variant Curation Expert Panel: PP4_Moderate, PM3_Strong, PM2_Supporting, PP3 (ACADVL specifications version 1; approved November 8, 2021)		ACADVL VCEP	https://clinicalgenome.org/site/assets/files/7380/clingen_acadvl_acmg_specifications_v1.pdf	2022-12-14	2022-12-14	False	https://erepo.genome.network/evrepo/ui/classification/CA220193/MONDO:0008723/021	7632a574-ebef-41ce-8cb8-6a5028bf2de6	p.Gly441Asp	Gly	441	Asp	MQAARMAASLGRQLLRLGGGSSRLTALLGQPRPGPARRPYAGGAAQLALDKSDSHPSDALTRKKPAKAESKSFAVGMFKGQLTTDQVFPYPSVLNEEQTQFLKELVEPVSRFFEEVNDPAKNDALEMVEETTWQGLKELGAFGLQVPSELGGVGLCNTQYARLVEIVGMHDLGVGITLGAHQSIGFKGILLFGTKAQKEKYLPKLASGETVAAFCLTEPSSGSDAASIRTSAVPSPCGKYYTLNGSKLWISNGGLADIFTVFAKTPVTDPATGAVKEKITAFVVERGFGGITHGPPEKKMGIKASNTAEVFFDGVRVPSENVLGEVGSGFKVAMHILNNGRFGMAAALAGTMRGIIAKAVDHATNRTQFGEKIHNFGLIQEKLARMVMLQYVTESMAYMVSANMDQGATDFQIEAAISKIFGSEAAWKVTDECIQIMGGMGFMKEPGVERVLRDLRIFRIFEGTNDILRLFVALQGCMDKGKELSGLGSALKNPFGNAGLLLGEAGKQLRRRAGLGSGLSLSGLVHPELSRSGELAVRALEQFATVVEAKLIKHKKGIVNEQFLLQRLADGAIDLYAMVVVLSRASRSLSEGHPTAQHEKMLCDTWCIEAAARIREGMAALQSDPWQQELYRNFKSISKALVERGGVVTSNPLGF	655	P49748	D	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [523], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.01006687]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [382], 'REPEAT_gain_score': array([0.00254935]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
502	NM_000152.5(GAA):c.1735G>A (p.Glu579Lys)	495664	CA294895841	NM_000152.5:c.1735G>A, NC_000017.11:g.80112081G>A, CM000679.2:g.80112081G>A, NC_000017.10:g.78085880G>A, CM000679.1:g.78085880G>A, NC_000017.9:g.75700475G>A, NG_009822.1:g.15526G>A, LRG_673:g.15526G>A, ENST00000302262.8:c.1735G>A, ENST00000302262.7:c.1735G>A, ENST00000390015.7:c.1735G>A, ENST00000572080.1:n.123G>A, ENST00000572803.1:n.349G>A, NM_000152.3:c.1735G>A, LRG_673t1:c.1735G>A, NM_001079803.1:c.1735G>A, NM_001079804.1:c.1735G>A, XM_005257193.1:c.1735G>A, XM_005257194.3:c.1735G>A, NM_000152.4:c.1735G>A, NM_001079803.2:c.1735G>A, NM_001079804.2:c.1735G>A, XM_005257193.2:c.1735G>A, XM_005257194.4:c.1735G>A, NM_001079803.3:c.1735G>A, NM_001079804.3:c.1735G>A, NM_000152.5(GAA):c.1735G>A (p.Glu579Lys)	GAA	glycogen storage disease II	MONDO:0009290	Autosomal recessive inheritance	Pathogenic	PM3_Strong, PP4_Moderate, PP3, PS3_Moderate, PM2_Supporting		The NM_000152.:c.1735G>A variant in GAA is a missense variant predicted to result in the substitution of glutamate by lysine at amino acid 579 (p.Glu579Lys). Five patients with a diagnosis of Pompe disease and the variant have been reported, three with documented laboratory values showing deficiency of GAA activity (PMID: 21676566, 23601496, 29124014, 34357340), one with reported features consistent with infantile-onset Pompe disease (PMID: 24269976), and another reported to have Pompe disease (PMID: 14695532) (PP4_Moderate). Four of these patients are compound heterozygous for the variant and a variant in GAA that has been classified as pathogenic by the ClinGen LSD VCEP, all phase unknown, including c.-32-13T>G (PMID: 34357340) (0.5 points), c.525delT (PMID: 14695532) (0.5 points), c.2237G>A (p.Trp746Ter) (PMID: 24269976) (0.5 points), and c.655G>A (p.Gly219Arg) (PMIDs: 23601496, 31086307,31193175) (0.5 points). Total 2 points (PM3_Strong). Another patient is compound heterozygous for the variant and c.1857C>G (p.Ser619Arg) (PMIDs: 21676566, 29124014)  The allelic data from this patient will be used in the classification of p.Ser619Arg and is not included here to avoid circular logic. The highest population minor allele frequency in gnomAD v2.1.1 is 0.00002 (2/129092) in the European Non-Finnish population, which is lower than the ClinGen LSD VCEP threshold (<0.001) for PM2_Supporting, meeting this criterion (PM2_Supporting). When expressed in COS cells, this variant had <5% GAA activity in cells and <2% in medium, evidence of abnormal synthesis and processing on Western blot, and did not localize to the lysosomes (PMID: 14695532, 19862843) (PS3_Moderate). The computational predictor REVEL gives a score of 0.878 which is above the threshold of 0.7, evidence that correlates with impact to GAA function (PP3). There is a ClinVar entry for this variant (Variation ID: 495664). In summary this variant meets the criteria to be classified as pathogenic for Pompe disease. GAA-specific ACMG-AMP criteria met, as specified by the Clingen Lysosomal Storage Disorders VCEP (Specifications Version 2.0): PM3_Strong, PS3_Moderate, PP4_Moderate, PP3, PM2_Supporting.(Classification approved by the ClinGen LSD VCEP on December 6, 2022)	19862843	Lysosomal Diseases VCEP	https://clinicalgenome.org/docs/clingen-lysosomal-storage-disorders-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-2/	2022-12-06	2022-12-20	False	https://erepo.genome.network/evrepo/ui/classification/CA294895841/MONDO:0009290/010	751727f5-33d5-4e67-a898-c4ef9dba3fcc	p.Glu579Lys	Glu	579	Lys	MGVRHPPCSHRLLAVCALVSLATAALLGHILLHDFLLVPRELSGSSPVLEETHPAHQQGASRPGPRDAQAHPGRPRAVPTQCDVPPNSRFDCAPDKAITQEQCEARGCCYIPAKQGLQGAQMGQPWCFFPPSYPSYKLENLSSSEMGYTATLTRTTPTFFPKDILTLRLDVMMETENRLHFTIKDPANRRYEVPLETPHVHSRAPSPLYSVEFSEEPFGVIVRRQLDGRVLLNTTVAPLFFADQFLQLSTSLPSQYITGLAEHLSPLMLSTSWTRITLWNRDLAPTPGANLYGSHPFYLALEDGGSAHGVFLLNSNAMDVVLQPSPALSWRSTGGILDVYIFLGPEPKSVVQQYLDVVGYPFMPPYWGLGFHLCRWGYSSTAITRQVVENMTRAHFPLDVQWNDLDYMDSRRDFTFNKDGFRDFPAMVQELHQGGRRYMMIVDPAISSSGPAGSYRPYDEGLRRGVFITNETGQPLIGKVWPGSTAFPDFTNPTALAWWEDMVAEFHDQVPFDGMWIDMNEPSNFIRGSEDGCPNNELENPPYVPGVVGGTLQAATICASSHQFLSTHYNLHNLYGLTEAIASHRALVKARGTRPFVISRSTFAGHGRYAGHWTGDVWSSWEQLASSVPEILQFNLLGVPLVGADVCGFLGNTSEELCVRWTQLGAFYPFMRNHNSLLSLPQEPYSFSEPAQQAMRKALTLRYALLPHLYTLFHQAHVAGETVARPLFLEFPKDSSTWTVDHQLLWGEALLITPVLQAGKAEVTGYFPLGTWYDLQTVPVEALGSLPPPPAAPREPAIHSEGQWVTLPAPLDTINVHLRAGYIIPLQGPGLTTTESRQQPMALAVALTKGGEARGELFWDDGESLEVLERGAYTQVIFLARNNTIVNELVRVTSEGAGLQLQKVTVLGVATAPQQVLSNGVPVSNFTYSPDTKVLDICVSLLMGEQFLVSWC	952	P10253	K	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [704, 716], 'DNA_BIND_gain': [585, 611, 658], 'DNA_BIND_gain_score': array([0.01670629, 0.00495219, 0.0036338 ]), 'DNA_BIND_loss_score': array([-0.00113702, -0.00256991]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [259, 885], 'STRAND_gain_score': array([0.00899112, 0.00410616]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [386], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.00061816]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
503	NM_000152.5(GAA):c.1857C>G (p.Ser619Arg)	550825	CA401369658	NM_000152.5:c.1857C>G, NC_000017.11:g.80112680C>G, CM000679.2:g.80112680C>G, NC_000017.10:g.78086479C>G, CM000679.1:g.78086479C>G, NC_000017.9:g.75701074C>G, NG_009822.1:g.16125C>G, LRG_673:g.16125C>G, ENST00000302262.8:c.1857C>G, ENST00000302262.7:c.1857C>G, ENST00000390015.7:c.1857C>G, ENST00000570716.1:n.297C>G, ENST00000572080.1:n.245C>G, ENST00000572803.1:n.471C>G, NM_000152.3:c.1857C>G, LRG_673t1:c.1857C>G, NM_001079803.1:c.1857C>G, NM_001079804.1:c.1857C>G, XM_005257193.1:c.1857C>G, XM_005257194.3:c.1857C>G, NM_000152.4:c.1857C>G, NM_001079803.2:c.1857C>G, NM_001079804.2:c.1857C>G, XM_005257193.2:c.1857C>G, XM_005257194.4:c.1857C>G, NM_001079803.3:c.1857C>G, NM_001079804.3:c.1857C>G, NM_000152.5(GAA):c.1857C>G (p.Ser619Arg)	GAA	glycogen storage disease II	MONDO:0009290	Autosomal recessive inheritance	Pathogenic	PS3_Supporting, PP4_Moderate, PP3, PM2_Supporting, PM3_Very Strong		The NM_000152.5:c.1857C>G variant in GAA is predicted to result in the substitution of serine by arginine at amino acid 619 (p.Ser619Arg).This variant has been reported in at least 10 patients with features consistent with Pompe disease including individuals with clinical symptoms of Pompe disease and documented laboratory data showing GAA activity below the normal reference range or <10% in relevant tissues (PMID: 14643388, 17092519, 29124014, 21984055, 23884227), and additional patients without GAA activity reported but on enzyme replacement therapy (PMID: 25213570, 29869463) (PP4_Moderate). Five patients are compound heterozygous for the variant and another variant in GAA that has been classified as pathogenic by the ClinGen LSD VCEP including c.1579_1580del (p.Arg527GlyfsTer3), confirmed in trans (PMID: 29869463); c.1156C>T (p.Gln386Ter), phase unknown (PMID: 23884227); c.1309C>T (p.Arg437Cys), phase unknown (PMID: 29124014); c.1798C>T (p.Arg600Cys), phase unknown (PMID: 29124014); and c.1735G>A (p.Glu579Lys), phase unknown (PMID: 29124014); and at least three are homozygous for the variant (PMID: 14643388, 29124014) (maximum allowed = 2 x 0.5 points = 1 point). Additional patients have been reported who are compound heterozygous for the variant and either c.875A>G (p.Tyr292Cys) (PMID: 23884227, 25213570), or c.2015G>A (p.Arg672Gln) (PMID: 17092519). The allelic data from these patients will be used in the assessment of the second variant and is not included here to avoid circular logic. Finally, additional patients may also carry the variant but were not included because the cDNA change for the variant was not reported (PMID: 17805474, 18495398, 21676566) (PM3_Very Strong). When expressed in COS cells in two seprate function, studies, the variant results in <2% GAA activity compared to wild type (PMIDs: 14643388, 19862843) (PS3_Supporting). The computational predictor REVEL gives a score of 0.795 which is above the threshold of 0.7, evidence that correlates with impact to GAA function (PP3). This variant is absent in gnomAD v2.1.1 (PM2_Supporting). There is a ClinVar entry for this variant (Variation ID: 550825). In summary, this variant meets the criteria to be classified as pathogenic for Pompe disease. GAA-specific ACMG-AMP criteria met, as specified by the ClinGen Lysosomal Storage Disorders VCEP (Specifications Version 2.0): PM3_Very Strong, PP4_Moderate, PP3, PS3_Supporting, PM2_Supporting.(Classification approved by the ClinGen LSD VCEP on December 6, 2022)	19862843	Lysosomal Diseases VCEP	https://clinicalgenome.org/docs/clingen-lysosomal-storage-disorders-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-2/	2022-12-06	2022-12-20	False	https://erepo.genome.network/evrepo/ui/classification/CA401369658/MONDO:0009290/010	30e62ba1-3fee-4211-9163-9b346dedf038	p.Ser619Arg	Ser	619	Arg	MGVRHPPCSHRLLAVCALVSLATAALLGHILLHDFLLVPRELSGSSPVLEETHPAHQQGASRPGPRDAQAHPGRPRAVPTQCDVPPNSRFDCAPDKAITQEQCEARGCCYIPAKQGLQGAQMGQPWCFFPPSYPSYKLENLSSSEMGYTATLTRTTPTFFPKDILTLRLDVMMETENRLHFTIKDPANRRYEVPLETPHVHSRAPSPLYSVEFSEEPFGVIVRRQLDGRVLLNTTVAPLFFADQFLQLSTSLPSQYITGLAEHLSPLMLSTSWTRITLWNRDLAPTPGANLYGSHPFYLALEDGGSAHGVFLLNSNAMDVVLQPSPALSWRSTGGILDVYIFLGPEPKSVVQQYLDVVGYPFMPPYWGLGFHLCRWGYSSTAITRQVVENMTRAHFPLDVQWNDLDYMDSRRDFTFNKDGFRDFPAMVQELHQGGRRYMMIVDPAISSSGPAGSYRPYDEGLRRGVFITNETGQPLIGKVWPGSTAFPDFTNPTALAWWEDMVAEFHDQVPFDGMWIDMNEPSNFIRGSEDGCPNNELENPPYVPGVVGGTLQAATICASSHQFLSTHYNLHNLYGLTEAIASHRALVKARGTRPFVISRSTFAGHGRYAGHWTGDVWSSWEQLASSVPEILQFNLLGVPLVGADVCGFLGNTSEELCVRWTQLGAFYPFMRNHNSLLSLPQEPYSFSEPAQQAMRKALTLRYALLPHLYTLFHQAHVAGETVARPLFLEFPKDSSTWTVDHQLLWGEALLITPVLQAGKAEVTGYFPLGTWYDLQTVPVEALGSLPPPPAAPREPAIHSEGQWVTLPAPLDTINVHLRAGYIIPLQGPGLTTTESRQQPMALAVALTKGGEARGELFWDDGESLEVLERGAYTQVIFLARNNTIVNELVRVTSEGAGLQLQKVTVLGVATAPQQVLSNGVPVSNFTYSPDTKVLDICVSLLMGEQFLVSWC	952	P10253	R	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [599], 'BINDING_gain': [], 'BINDING_loss_score': array([-0.02203012]), 'DNA_BIND_loss': [375, 420], 'DNA_BIND_gain': [608, 611, 625, 628, 658, 707], 'DNA_BIND_gain_score': array([0.0092541 , 0.0041517 , 0.01585323, 0.00775641, 0.00355583,
       0.00050807]), 'DNA_BIND_loss_score': array([-0.00021279, -0.00057214]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [259], 'STRAND_gain_score': array([0.003667]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [624], 'REPEAT_gain_score': array([0.00479841]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
504	NM_001110792.2(MECP2):c.737C>G (p.Ala246Gly)	156670	CA294719	NM_001110792.2:c.737C>G, NC_000023.11:g.154031127G>C, CM000685.2:g.154031127G>C, NC_000023.10:g.153296578G>C, CM000685.1:g.153296578G>C, NC_000023.9:g.152949772G>C, NG_007107.2:g.111001C>G, NG_007107.3:g.110977C>G, ENST00000303391.11:c.701C>G, ENST00000453960.7:c.737C>G, ENST00000637917.1:n.66-191C>G, ENST00000303391.10:c.701C>G, ENST00000407218.5:c.*73C>G, ENST00000453960.6:c.737C>G, ENST00000619732.4:c.701C>G, ENST00000622433.4:c.689C>G, ENST00000628176.2:c.*73C>G, NM_001110792.1:c.737C>G, NM_001316337.1:c.422C>G, NM_004992.3:c.701C>G, XM_005274681.3:c.701C>G, XM_005274682.3:c.422C>G, XM_005274683.3:c.422C>G, XM_006724819.2:c.32C>G, XM_011531166.1:c.422C>G, XM_006724819.3:c.32C>G, XM_011531166.2:c.422C>G, XM_024452383.1:c.422C>G, XM_024452384.1:c.422C>G, NM_001316337.2:c.422C>G, NM_001369391.2:c.422C>G, NM_001369392.2:c.422C>G, NM_001369393.2:c.422C>G, NM_001369394.1:c.422C>G, NM_001369394.2:c.422C>G, NM_001386137.1:c.32C>G, NM_001386138.1:c.32C>G, NM_001386139.1:c.32C>G, NM_004992.4:c.701C>G, NM_001110792.2(MECP2):c.737C>G (p.Ala246Gly)	MECP2	Rett syndrome	MONDO:0010726	X-linked inheritance	Benign	BS2, BA1		The allele frequency of the p.Ala234Gly variant in MECP2 (NM_004992.3) is 0.26% in Ashkenazi Jewish sub population in gnomAD, which is high enough to be classified as benign based on thresholds defined by the ClinGen Rett/Angelman-like Expert Panel for Rett/AS-like conditions (BA1). The p.Ala234Gly variant is observed in at least 2 unaffected individuals (internal database) (BS2). In summary, the p.Ala234Gly variant in MECP2 is classified as Benign based on the ACMG/AMP criteria (BA1, BS2).		Rett and Angelman-like Disorders VCEP	https://clinicalgenome.org/site/assets/files/7339/clingen_rettas_acmg_specifications_v2.pdf	2022-12-08	2022-12-23	False	https://erepo.genome.network/evrepo/ui/classification/CA294719/MONDO:0010726/016	21681f8f-ca00-41a5-a493-384733758727	p.Ala246Gly	Ala	246	Gly	MVAGMLGLREEKSEDQDLQGLKDKPLKFKKVKKDKKEEKEGKHEPVQPSAHHSAEPAEAGKAETSEGSGSAPAVPEASASPKQRRSIIRDRGPMYDDPTLPEGWTRKLKQRKSGRSAGKYDVYLINPQGKAFRSKVELIAYFEKVGDTSLDPNDFDFTVTGRGSPSRREQKPPKKPKSPKAPGTGRGRGRPKGSGTTRPKAATSEGVQVKRVLEKSPGKLLVKMPFQTSPGGKAEGGGATTSTQVMVIKRPGRKRKAEADPQAIPKKRGRKPGSVVAAAAAEAKKKAVKESSIRSVQETVLPIKKRKTRETVSIEVKEVVKPLLVSTLGEKSGKGLKTCKSPGRKSKESSPKGRSSSASSPPKKEHHHHHHHSESPKAPVPLLPPLPPPPPEPESSEDPTSPPEPQDLSSSVCKEEKMPRGGSLESDGCPKEPAKTQPAVATAATAAEKYKHRGEGERKDIVSSSMPRPNREEPVDSRTPVTERVS	486	P51608	G	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [157], 'STRAND_gain_score': array([0.03657675]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [252], 'COMPBIAS_gain_score': array([0.02242416]), 'DOMAIN_loss': [163], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.04017961]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
505	NM_001110792.2(MECP2):c.1096C>T (p.Arg366Cys)	158880	CA206493	NM_001110792.2:c.1096C>T, NC_000023.11:g.154030768G>A, CM000685.2:g.154030768G>A, NC_000023.10:g.153296219G>A, CM000685.1:g.153296219G>A, NC_000023.9:g.152949413G>A, NG_007107.2:g.111360C>T, NG_007107.3:g.111336C>T, ENST00000303391.11:c.1060C>T, ENST00000453960.7:c.1096C>T, ENST00000303391.10:c.1060C>T, ENST00000407218.5:c.*432C>T, ENST00000453960.6:c.1096C>T, ENST00000619732.4:c.1060C>T, ENST00000628176.2:c.*432C>T, NM_001110792.1:c.1096C>T, NM_001316337.1:c.781C>T, NM_004992.3:c.1060C>T, XM_005274681.3:c.1060C>T, XM_005274682.3:c.781C>T, XM_005274683.3:c.781C>T, XM_006724819.2:c.391C>T, XM_011531166.1:c.781C>T, XM_006724819.3:c.391C>T, XM_011531166.2:c.781C>T, XM_024452383.1:c.781C>T, XM_024452384.1:c.781C>T, NM_001316337.2:c.781C>T, NM_001369391.2:c.781C>T, NM_001369392.2:c.781C>T, NM_001369393.2:c.781C>T, NM_001369394.1:c.781C>T, NM_001369394.2:c.781C>T, NM_001386137.1:c.391C>T, NM_001386138.1:c.391C>T, NM_001386139.1:c.391C>T, NM_004992.4:c.1060C>T, NM_001110792.2(MECP2):c.1096C>T (p.Arg366Cys)	MECP2	Rett syndrome	MONDO:0010726	X-linked inheritance	Benign	BS2, BS1		The allele frequency of the p.Arg354Cys variant in MECP2 (NM_004992.3) is 0.028% in East Asian sub population in gnomAD, which is high enough to meet the BS1 criteria based on thresholds defined by the ClinGen Rett/Angelman-like Expert Panel for Rett/AS-like conditions (BS1). The p.Arg354Cys variant is observed in at least 2 unaffected individuals (internal database) (BS2).  In summary, the p.Arg354Cys variant in MECP2 is classified as Benign based on the ACMG/AMP criteria (BS1, BS2).		Rett and Angelman-like Disorders VCEP	https://clinicalgenome.org/site/assets/files/7339/clingen_rettas_acmg_specifications_v2.pdf	2022-12-09	2022-12-23	False	https://erepo.genome.network/evrepo/ui/classification/CA206493/MONDO:0010726/016	9a0ddb9b-0b82-4d80-9cde-6793c04b5f7e	p.Arg366Cys	Arg	366	Cys	MVAGMLGLREEKSEDQDLQGLKDKPLKFKKVKKDKKEEKEGKHEPVQPSAHHSAEPAEAGKAETSEGSGSAPAVPEASASPKQRRSIIRDRGPMYDDPTLPEGWTRKLKQRKSGRSAGKYDVYLINPQGKAFRSKVELIAYFEKVGDTSLDPNDFDFTVTGRGSPSRREQKPPKKPKSPKAPGTGRGRGRPKGSGTTRPKAATSEGVQVKRVLEKSPGKLLVKMPFQTSPGGKAEGGGATTSTQVMVIKRPGRKRKAEADPQAIPKKRGRKPGSVVAAAAAEAKKKAVKESSIRSVQETVLPIKKRKTRETVSIEVKEVVKPLLVSTLGEKSGKGLKTCKSPGRKSKESSPKGRSSSASSPPKKEHHHHHHHSESPKAPVPLLPPLPPPPPEPESSEDPTSPPEPQDLSSSVCKEEKMPRGGSLESDGCPKEPAKTQPAVATAATAAEKYKHRGEGERKDIVSSSMPRPNREEPVDSRTPVTERVS	486	P51608	C	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [300, 301, 303, 324], 'REGION_gain': [], 'REGION_loss_score': array([-0.04015476, -0.03763115, -0.03563279, -0.04504526]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
506	NM_000527.5(LDLR):c.1301C>G (p.Thr434Arg)	251774	CA10585393	NM_000527.5:c.1301C>G, NC_000019.10:g.11113392C>G, CM000681.2:g.11113392C>G, NC_000019.9:g.11224068C>G, CM000681.1:g.11224068C>G, NC_000019.8:g.11085068C>G, NG_009060.1:g.29012C>G, LRG_274:g.29012C>G, ENST00000558518.6:c.1301C>G, ENST00000252444.9:n.1555C>G, ENST00000455727.6:c.797C>G, ENST00000535915.5:c.1178C>G, ENST00000545707.5:c.920C>G, ENST00000557933.5:c.1301C>G, ENST00000558013.5:c.1301C>G, ENST00000558518.5:c.1301C>G, ENST00000559340.1:n.22C>G, ENST00000560173.1:n.300C>G, ENST00000560467.1:n.781C>G, NM_000527.4:c.1301C>G, LRG_274t1:c.1301C>G, NM_001195798.1:c.1301C>G, NM_001195799.1:c.1178C>G, NM_001195800.1:c.797C>G, NM_001195803.1:c.920C>G, XM_011528010.1:c.1301C>G, XM_011528011.1:c.920C>G, XR_244074.2:n.1451C>G, XM_011528010.2:c.1301C>G, XR_001753685.2:n.1418C>G, XR_001753686.2:n.1418C>G, NM_001195798.2:c.1301C>G, NM_001195799.2:c.1178C>G, NM_001195800.2:c.797C>G, NM_001195803.2:c.920C>G, NM_000527.5(LDLR):c.1301C>G (p.Thr434Arg)	LDLR	hypercholesterolemia, familial	MONDO:0007750	Semidominant inheritance	Pathogenic	PS4, PP1_Strong, PM3, PM2, PP4	PS1, PS3, PS2, BS1, BS3, BS4, PM5, PM1, PM4, PVS1, PM6, BS2, PP3, BP4, BP3, BP2, BA1	The NM_000527.5(LDLR):c.1301C>G (p.Thr434Arg) variant is classified as Pathogenic for Familial Hypercholesterolemia by applying evidence codes PS4, PM2, PM3, PP1_Strong, and PP4 as defined by the ClinGen Familial Hypercholesterolemia Expert Panel LDLR-specific variant curation guidelines (https://doi.org/10.1016/j.gim.2021.09.012). The supporting evidence is as follows: PS4: Variant meets PM2 and is identified in 10 unrelated cases, as follows: 6 patients with DLCN >=6 and 2 patients with Simon-Broome criteria of possible FH from Centre de Genetique Moleculaire et Chromosomique, Unite de genetique de l'Obesite et des Dyslipidies; 1 case with MedPed criteria from PMID 21868016 (Garcia-Garcia et al., 2011); 1 case with DLCN>6 from PMID 10634824 (Deiana et al., 2000). So PS4 is met. PM2: This variant is absent from gnomAD (gnomAD v2.1.1), so PM2 is met.PM3: Variant meets PM2 and is identified in 2 siblings from PMID 29306853 with childhood total cholesterol levels >700 mg/dL and homozygous for this variant. So PM3 is met. PP1_Strong: Variant segregates with FH phenotype in >1 families, as follows: 6 affected family members from Centre de Genetique Moleculaire et Chromosomique, Unite de genetique de l'Obesite et des Dyslipidies; 10 affected members tested positive and 7 unaffected members tested negative in one family in 17 informative meiosis from PMID 21868016, so PP1_Strong is met.PP4: Variant meets PM2 and is identified in 10 unrelated index cases who fulfill clinical criteria for FH (see PS4 for details).		Familial Hypercholesterolemia VCEP	https://clinicalgenome.org/docs/clingen-familial-hypercholesterolemia-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1-2/	2022-10-28	2022-12-24	False	https://erepo.genome.network/evrepo/ui/classification/CA10585393/MONDO:0007750/013	e7fe2f7c-172d-4122-83bc-6fa3cc271b27	p.Thr434Arg	Thr	434	Arg	MGPWGWKLRWTVALLLAAAGTAVGDRCERNEFQCQDGKCISYKWVCDGSAECQDGSDESQETCLSVTCKSGDFSCGGRVNRCIPQFWRCDGQVDCDNGSDEQGCPPKTCSQDEFRCHDGKCISRQFVCDSDRDCLDGSDEASCPVLTCGPASFQCNSSTCIPQLWACDNDPDCEDGSDEWPQRCRGLYVFQGDSSPCSAFEFHCLSGECIHSSWRCDGGPDCKDKSDEENCAVATCRPDEFQCSDGNCIHGSRQCDREYDCKDMSDEVGCVNVTLCEGPNKFKCHSGECITLDKVCNMARDCRDWSDEPIKECGTNECLDNNGGCSHVCNDLKIGYECLCPDGFQLVAQRRCEDIDECQDPDTCSQLCVNLEGGYKCQCEEGFQLDPHTKACKAVGSIAYLFFTNRHEVRKMTLDRSEYTSLIPNLRNVVALDTEVASNRIYWSDLSQRMICSTQLDRAHGVSSYDTVISRDIQAPDGLAVDWIHSNIYWTDSVLGTVSVADTKGVKRKTLFRENGSKPRAIVVDPVHGFMYWTDWGTPAKIKKGGLNGVDIYSLVTENIQWPNGITLDLLSGRLYWVDSKLHSISSIDVNGGNRKTILEDEKRLAHPFSLAVFEDKVFWTDIINEAIFSANRLTGSDVNLLAENLLSPEDMVLFHNLTQPRGVNWCERTTLSNGGCQYLCLPAPQINPHSPKFTCACPDGMLLARDMRSCLTEAEAAVATQETSTVRLKVSSTAVRTQHTTTRPVPDTSRLPGATPGLTTVEIVTMSHQALGDVAGRGNEKKPSSVRALSIVLPIVLLVFLCLGVFLLWKNWRLKNINSINFDNPVYQKTTEDEVHICHNQDGYSYPSRQMVSLEDDVA	860	P01130	R	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [419], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.09843451]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
507	NM_000527.5(LDLR):c.81C>G (p.Cys27Trp)	226304	CA041664	NM_000527.5:c.81C>G, NC_000019.10:g.11100236C>G, CM000681.2:g.11100236C>G, NC_000019.9:g.11210912C>G, CM000681.1:g.11210912C>G, NC_000019.8:g.11071912C>G, NG_009060.1:g.15856C>G, LRG_274:g.15856C>G, ENST00000558518.6:c.81C>G, ENST00000252444.9:n.335C>G, ENST00000455727.6:c.81C>G, ENST00000535915.5:c.81C>G, ENST00000545707.5:c.81C>G, ENST00000557933.5:c.81C>G, ENST00000557958.1:n.167C>G, ENST00000558013.5:c.81C>G, ENST00000558518.5:c.81C>G, ENST00000560502.5:n.167C>G, NM_000527.4:c.81C>G, LRG_274t1:c.81C>G, NM_001195798.1:c.81C>G, NM_001195799.1:c.81C>G, NM_001195800.1:c.81C>G, NM_001195803.1:c.81C>G, XM_011528010.1:c.81C>G, XM_011528011.1:c.81C>G, XR_244074.2:n.231C>G, XM_011528010.2:c.81C>G, XR_001753685.2:n.198C>G, XR_001753686.2:n.198C>G, NM_001195798.2:c.81C>G, NM_001195799.2:c.81C>G, NM_001195800.2:c.81C>G, NM_001195803.2:c.81C>G, NM_000527.5(LDLR):c.81C>G (p.Cys27Trp)	LDLR	hypercholesterolemia, familial	MONDO:0007750	Semidominant inheritance	Pathogenic	PS4, PM1, PM2, PP3, PP4, PP1, PS3_Moderate		NM_000527.5(LDLR):c.81C>G (p.Cys27Trp) variant is classified as pathogenic for Familial Hypercholesterolemia by applying evidence code PM1, PM2, PS3_moderate, PS4, PP1, PP3 and PP4 as defined by the ClinGen Familial Hypercholesterolemia Expert Panel LDLR-specific variant curation guidelines (https://doi.org/10.1016/j.gim.2021.09.012). The supporting evidence is as follows:PM1: Variant meets PM2 and alters Cys27, one of the cysteine residues listed.PM2: PopMax MAF = 0.00003518 (0.004%) in European (non-Finnish) exomes (gnomAD v2.1.1).PS3_moderate: PMID:1301956 - Level 2 assay- study on hmz patient's fibroblast cell, LDLR activity value range: 15-30%.PS4: Variant meets PM2. Variant identified in >15 index cases - 1 case from Molecular Genetics Laboratory (Centre for Cardiovascular Surgery and Transplantation) with Simon Broome possible- 1 case from Cardiovascular Genetics Laboratory (PathWest Laboratory Medicine WA) with Dutch lipid clinic network >=6- 2 cases from Robarts Research Institute with Dutch lipid clinic network >=6- 2 cases from Research Lab of Molecular Genetics of Lipid Metabolism - Prof. M.Arca with Dutch lipid clinic network >=6-as well as >10 cases from (PMID: 1301956, 9259195, 11317361, 11668627, 14974088, 16250003, 23375686, 25463123, 27497240, 27824480, 31345425) PP1: Variant segregates with FH phenotype in at least 2 informative meiosis (minimum 2) from 2 families from different labs (Research Lab of Molecular Genetics of Lipid Metabolism - Prof. M.Arca, and Laboratory of Genetics and Molecular Cardiology)PP3: REVEL = 0.759PP4: Variant meets PM2 and is identified in several index case who fulfil SB/DLCN>6/MedPed/other criteria for FH from different labs (see PS4), after alternative causes of high cholesterol were excluded.		Familial Hypercholesterolemia VCEP	https://clinicalgenome.org/docs/clingen-familial-hypercholesterolemia-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1-2/	2022-05-06	2022-12-24	False	https://erepo.genome.network/evrepo/ui/classification/CA041664/MONDO:0007750/013	1b6349ea-5843-44ac-bd0b-6dbe58fb0da4	p.Cys27Trp	Cys	27	Trp	MGPWGWKLRWTVALLLAAAGTAVGDRCERNEFQCQDGKCISYKWVCDGSAECQDGSDESQETCLSVTCKSGDFSCGGRVNRCIPQFWRCDGQVDCDNGSDEQGCPPKTCSQDEFRCHDGKCISRQFVCDSDRDCLDGSDEASCPVLTCGPASFQCNSSTCIPQLWACDNDPDCEDGSDEWPQRCRGLYVFQGDSSPCSAFEFHCLSGECIHSSWRCDGGPDCKDKSDEENCAVATCRPDEFQCSDGNCIHGSRQCDREYDCKDMSDEVGCVNVTLCEGPNKFKCHSGECITLDKVCNMARDCRDWSDEPIKECGTNECLDNNGGCSHVCNDLKIGYECLCPDGFQLVAQRRCEDIDECQDPDTCSQLCVNLEGGYKCQCEEGFQLDPHTKACKAVGSIAYLFFTNRHEVRKMTLDRSEYTSLIPNLRNVVALDTEVASNRIYWSDLSQRMICSTQLDRAHGVSSYDTVISRDIQAPDGLAVDWIHSNIYWTDSVLGTVSVADTKGVKRKTLFRENGSKPRAIVVDPVHGFMYWTDWGTPAKIKKGGLNGVDIYSLVTENIQWPNGITLDLLSGRLYWVDSKLHSISSIDVNGGNRKTILEDEKRLAHPFSLAVFEDKVFWTDIINEAIFSANRLTGSDVNLLAENLLSPEDMVLFHNLTQPRGVNWCERTTLSNGGCQYLCLPAPQINPHSPKFTCACPDGMLLARDMRSCLTEAEAAVATQETSTVRLKVSSTAVRTQHTTTRPVPDTSRLPGATPGLTTVEIVTMSHQALGDVAGRGNEKKPSSVRALSIVLPIVLLVFLCLGVFLLWKNWRLKNINSINFDNPVYQKTTEDEVHICHNQDGYSYPSRQMVSLEDDVA	860	P01130	W	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [26], 'DISULFID_gain': [], 'DISULFID_loss_score': array([-0.75027382]), 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [401], 'STRAND_gain_score': array([0.02767605]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [735], 'COMPBIAS_gain': [], 'COMPBIAS_loss_score': array([-0.01238817]), 'DOMAIN_loss': [24, 25], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.44309521, -0.64615065]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [661], 'REPEAT_gain_score': array([0.00742882]), 'ZN_FING_loss': [30, 31, 33, 45, 97, 100, 110, 181], 'ZN_FING_gain': [], 'ZN_FING_loss_score': array([-0.08350486, -0.09295923, -0.06258726, -0.02032375, -0.01227093,
       -0.00658596, -0.00687432, -0.00277203])}"
508	NM_000527.5(LDLR):c.2177C>T (p.Thr726Ile)	36461	CA023649	NM_000527.5:c.2177C>T, NC_000019.10:g.11123210C>T, CM000681.2:g.11123210C>T, NC_000019.9:g.11233886C>T, CM000681.1:g.11233886C>T, NC_000019.8:g.11094886C>T, NG_009060.1:g.38830C>T, LRG_274:g.38830C>T, ENST00000558518.6:c.2177C>T, ENST00000252444.9:n.2431C>T, ENST00000455727.6:c.1673C>T, ENST00000535915.5:c.2054C>T, ENST00000545707.5:c.1643C>T, ENST00000557933.5:c.2177C>T, ENST00000558013.5:c.2177C>T, ENST00000558518.5:c.2177C>T, NM_000527.4:c.2177C>T, LRG_274t1:c.2177C>T, NM_001195798.1:c.2177C>T, NM_001195799.1:c.2054C>T, NM_001195800.1:c.1673C>T, NM_001195803.1:c.1643C>T, XM_011528010.1:c.2177C>T, XM_011528011.1:c.1796C>T, XR_244074.2:n.2187C>T, XM_011528010.2:c.2177C>T, XR_001753685.2:n.2511C>T, XR_001753686.2:n.2154C>T, NM_001195798.2:c.2177C>T, NM_001195799.2:c.2054C>T, NM_001195800.2:c.1673C>T, NM_001195803.2:c.1643C>T, NM_000527.5(LDLR):c.2177C>T (p.Thr726Ile)	LDLR	hypercholesterolemia, familial	MONDO:0007750	Semidominant inheritance	Benign	BP4, BA1	PS4, PS3, PS1, PS2, BP7, BS1, BS3, BS4, PM5, PM4, PM3, PM1, PVS1, PM2, PM6, BS2, PP4, PP1, PP3, BP2	The NM_000527.5(LDLR):c.2177C>T (p.Thr726Ile) variant is classified as Benign for Familial Hypercholesterolemia by applying evidence codes BA1 and BP4 as defined by the ClinGen Familial Hypercholesterolemia Expert Panel LDLR-specific variant curation guidelines (https://doi.org/10.1016/j.gim.2021.09.012). The supporting evidence is as follows:BA1 - FAF = 0.008138 (0.8138%) in European (non-Finnish) exomes (gnomAD v2.1.1), so BA1 is Met.BP4 - REVEL = 0.454, it is below 0.50, so splicing evaluation is required.Functional data on splicing not available.A) variant not on limitsB) does not create AGC) variant is exonic and there 1 an AG nearby    MES scores: variant cryptic = -1.90, wt cryptic = -1.77, canonical acceptor = 8.76.    Ratio variant cryptic/wt cryptic: -1.90/-1.77 = 1.07 --- it is not above 1.1    Ratio variant cryptic/canonical acceptor: -1.90/8.76 --- it is not above 0.9--- BP4 is Met.		Familial Hypercholesterolemia VCEP	https://clinicalgenome.org/docs/clingen-familial-hypercholesterolemia-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1-2/	2022-05-24	2022-12-24	False	https://erepo.genome.network/evrepo/ui/classification/CA023649/MONDO:0007750/013	cf5aea83-78f5-4c3c-8aaa-fb5df3b65938	p.Thr726Ile	Thr	726	Ile	MGPWGWKLRWTVALLLAAAGTAVGDRCERNEFQCQDGKCISYKWVCDGSAECQDGSDESQETCLSVTCKSGDFSCGGRVNRCIPQFWRCDGQVDCDNGSDEQGCPPKTCSQDEFRCHDGKCISRQFVCDSDRDCLDGSDEASCPVLTCGPASFQCNSSTCIPQLWACDNDPDCEDGSDEWPQRCRGLYVFQGDSSPCSAFEFHCLSGECIHSSWRCDGGPDCKDKSDEENCAVATCRPDEFQCSDGNCIHGSRQCDREYDCKDMSDEVGCVNVTLCEGPNKFKCHSGECITLDKVCNMARDCRDWSDEPIKECGTNECLDNNGGCSHVCNDLKIGYECLCPDGFQLVAQRRCEDIDECQDPDTCSQLCVNLEGGYKCQCEEGFQLDPHTKACKAVGSIAYLFFTNRHEVRKMTLDRSEYTSLIPNLRNVVALDTEVASNRIYWSDLSQRMICSTQLDRAHGVSSYDTVISRDIQAPDGLAVDWIHSNIYWTDSVLGTVSVADTKGVKRKTLFRENGSKPRAIVVDPVHGFMYWTDWGTPAKIKKGGLNGVDIYSLVTENIQWPNGITLDLLSGRLYWVDSKLHSISSIDVNGGNRKTILEDEKRLAHPFSLAVFEDKVFWTDIINEAIFSANRLTGSDVNLLAENLLSPEDMVLFHNLTQPRGVNWCERTTLSNGGCQYLCLPAPQINPHSPKFTCACPDGMLLARDMRSCLTEAEAAVATQETSTVRLKVSSTAVRTQHTTTRPVPDTSRLPGATPGLTTVEIVTMSHQALGDVAGRGNEKKPSSVRALSIVLPIVLLVFLCLGVFLLWKNWRLKNINSINFDNPVYQKTTEDEVHICHNQDGYSYPSRQMVSLEDDVA	860	P01130	I	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [735, 736, 737], 'COMPBIAS_gain': [], 'COMPBIAS_loss_score': array([-0.30950779, -0.22861916, -0.17770213]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [735], 'REGION_gain': [], 'REGION_loss_score': array([-0.17495573]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': [268], 'ZN_FING_gain_score': array([0.00212765])}
509	NM_001110792.2(MECP2):c.338C>G (p.Pro113Arg)	143526	CA274626	NM_001110792.2:c.338C>G, NC_000023.11:g.154032282G>C, CM000685.2:g.154032282G>C, NC_000023.10:g.153297733G>C, CM000685.1:g.153297733G>C, NC_000023.9:g.152950927G>C, NG_007107.2:g.109846C>G, NG_007107.3:g.109822C>G, ENST00000303391.11:c.302C>G, ENST00000453960.7:c.338C>G, ENST00000303391.10:c.302C>G, ENST00000369957.5:c.*356C>G, ENST00000407218.5:c.338C>G, ENST00000453960.6:c.338C>G, ENST00000486506.5:n.2650C>G, ENST00000611468.1:c.290C>G, ENST00000619732.4:c.302C>G, ENST00000622433.4:c.290C>G, ENST00000628176.2:c.302C>G, NM_001110792.1:c.338C>G, NM_001316337.1:c.23C>G, NM_004992.3:c.302C>G, XM_005274681.3:c.302C>G, XM_005274682.3:c.23C>G, XM_005274683.3:c.23C>G, XM_011531166.1:c.23C>G, XM_006724819.3:c.-259C>G, XM_011531166.2:c.23C>G, XM_024452383.1:c.23C>G, XM_024452384.1:c.23C>G, NM_001316337.2:c.23C>G, NM_001369391.2:c.23C>G, NM_001369392.2:c.23C>G, NM_001369393.2:c.23C>G, NM_001369394.1:c.23C>G, NM_001369394.2:c.23C>G, NM_001386137.1:c.-259C>G, NM_001386138.1:c.-259C>G, NM_001386139.1:c.-259C>G, NM_004992.4:c.302C>G, NM_001110792.2(MECP2):c.338C>G (p.Pro113Arg)	MECP2	Rett syndrome	MONDO:0010726	X-linked inheritance	Pathogenic	PP3, PM2_Supporting, PM5_Strong, PS4		The p.Pro101Arg variant in MECP2 (NM_004992.4) has been observed in 4 other individuals with Rett Syndrome (PMID 10991689, RettBASE proband ID: 4426, 6597, 6598) and another individual with Angelman syndrome-like phenotype (PMID 11283202) (PS4). Multiple pathogenic missense variants (p.Pro101His, p.Pro101Leu, p.Pro101Thr, p.Pro101Ser) have been previously identified within this codon which indicates that this residue is critical to the function of the protein (PMID 11269512, RettBASE)(PM5_Strong). The p.Pro101Arg variant in MECP2 is absent from gnomAD (PM2_supporting). Computational prediction analysis tools suggests a deleterious impact; however, this information does not predict clinical significance on its own (PP3). In summary the p.Pro101Arg variant in MECP2 is classified as Pathogenic for Rett Syndrome based on the ACMG/AMP criteria (PS4, PM5_Strong, PM2_supporting, PP3).		Rett and Angelman-like Disorders VCEP	https://clinicalgenome.org/site/assets/files/7339/clingen_rettas_acmg_specifications_v2.pdf	2022-04-28	2023-01-04	False	https://erepo.genome.network/evrepo/ui/classification/CA274626/MONDO:0010726/016	f3b3ee49-05e1-4b1b-9eac-caaee4fc5588	p.Pro113Arg	Pro	113	Arg	MVAGMLGLREEKSEDQDLQGLKDKPLKFKKVKKDKKEEKEGKHEPVQPSAHHSAEPAEAGKAETSEGSGSAPAVPEASASPKQRRSIIRDRGPMYDDPTLPEGWTRKLKQRKSGRSAGKYDVYLINPQGKAFRSKVELIAYFEKVGDTSLDPNDFDFTVTGRGSPSRREQKPPKKPKSPKAPGTGRGRGRPKGSGTTRPKAATSEGVQVKRVLEKSPGKLLVKMPFQTSPGGKAEGGGATTSTQVMVIKRPGRKRKAEADPQAIPKKRGRKPGSVVAAAAAEAKKKAVKESSIRSVQETVLPIKKRKTRETVSIEVKEVVKPLLVSTLGEKSGKGLKTCKSPGRKSKESSPKGRSSSASSPPKKEHHHHHHHSESPKAPVPLLPPLPPPPPEPESSEDPTSPPEPQDLSSSVCKEEKMPRGGSLESDGCPKEPAKTQPAVATAATAAEKYKHRGEGERKDIVSSSMPRPNREEPVDSRTPVTERVS	486	P51608	R	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [108], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.09924114]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
510	NM_000138.4(FBN1):c.8363C>T (p.Thr2788Met)	263832	CA059963	NM_000138.4:c.8363C>T, NC_000015.10:g.48411243G>A, CM000677.2:g.48411243G>A, NC_000015.9:g.48703440G>A, CM000677.1:g.48703440G>A, NC_000015.8:g.46490732G>A, NG_008805.2:g.239546C>T, LRG_778:g.239546C>T, ENST00000682158.1:n.1744C>T, ENST00000682170.1:n.2544C>T, ENST00000682767.1:n.1660C>T, ENST00000316623.10:c.8363C>T, ENST00000674301.1:n.3529C>T, ENST00000316623.9:c.8363C>T, ENST00000559133.5:n.3732C>T, ENST00000561429.1:n.618C>T, LRG_778t1:c.8363C>T, NM_000138.5:c.8363C>T, NM_000138.5(FBN1):c.8363C>T (p.Thr2788Met), NM_000138.4(FBN1):c.8363C>T (p.Thr2788Met)	FBN1	Marfan syndrome	MONDO:0007947	Autosomal dominant inheritance	Benign	BA1	PS1, PS3, PS4, PS2, PM5, PM4, PM1, PM3, BP7, BP5, BS1, BS3, BS4, BS2, PP2, PP3, PP1, PP4, PVS1, PM2, PM6, BP1, BP4, BP3, BP2	The NM_00138 c.8363C>T, is a missense variant in FBN1 predicted to cause a substitution of a threonine by methionine at amino acid 2788 (p.Thr2788Met). The variant in FBN1 has been reported 13 times in ClinVar: 12 times as likely benign and once as benign (Variation ID: 263832). This variant has been identified in 44 individuals of African origin (gnomAD version 3.1.1, MAF: 0.1%, one homozygous) (BA1; https://gnomad.broadinstitute.org/). Computational prediction tools and conservation analysis are unclear on the predicted impact on the protein (REVEL: 0.356). The constraint z-score for missense variants affecting FBN1 is 5.06, however due to the presence of benign arguments PP2 cannot be used. In summary, this variant meets criteria to be classified as benign for Marfan syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen FBN1 VCEP: BA1.		FBN1 VCEP	https://clinicalgenome.org/docs/clingen-fbn1-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2023-02-01	2023-02-01	False	https://erepo.genome.network/evrepo/ui/classification/CA059963/MONDO:0007947/022	a1d82f83-e29b-4022-a4ae-7d95a9d27888	p.Thr2788Met	Thr	2788	Met	MRRGRLLEIALGFTVLLASYTSHGADANLEAGNVKETRASRAKRRGGGGHDALKGPNVCGSRYNAYCCPGWKTLPGGNQCIVPICRHSCGDGFCSRPNMCTCPSGQIAPSCGSRSIQHCNIRCMNGGSCSDDHCLCQKGYIGTHCGQPVCESGCLNGGRCVAPNRCACTYGFTGPQCERDYRTGPCFTVISNQMCQGQLSGIVCTKTLCCATVGRAWGHPCEMCPAQPHPCRRGFIPNIRTGACQDVDECQAIPGLCQGGNCINTVGSFECKCPAGHKLNEVSQKCEDIDECSTIPGICEGGECTNTVSSYFCKCPPGFYTSPDGTRCIDVRPGYCYTALTNGRCSNQLPQSITKMQCCCDAGRCWSPGVTVAPEMCPIRATEDFNKLCSVPMVIPGRPEYPPPPLGPIPPVLPVPPGFPPGPQIPVPRPPVEYLYPSREPPRVLPVNVTDYCQLVRYLCQNGRCIPTPGSYRCECNKGFQLDLRGECIDVDECEKNPCAGGECINNQGSYTCQCRAGYQSTLTRTECRDIDECLQNGRICNNGRCINTDGSFHCVCNAGFHVTRDGKNCEDMDECSIRNMCLNGMCINEDGSFKCICKPGFQLASDGRYCKDINECETPGICMNGRCVNTDGSYRCECFPGLAVGLDGRVCVDTHMRSTCYGGYKRGQCIKPLFGAVTKSECCCASTEYAFGEPCQPCPAQNSAEYQALCSSGPGMTSAGSDINECALDPDICPNGICENLRGTYKCICNSGYEVDSTGKNCVDINECVLNSLLCDNGQCRNTPGSFVCTCPKGFIYKPDLKTCEDIDECESSPCINGVCKNSPGSFICECSSESTLDPTKTICIETIKGTCWQTVIDGRCEININGATLKSQCCSSLGAAWGSPCTLCQVDPICGKGYSRIKGTQCEDIDECEVFPGVCKNGLCVNTRGSFKCQCPSGMTLDATGRICLDIRLETCFLRYEDEECTLPIAGRHRMDACCCSVGAAWGTEECEECPMRNTPEYEELCPRGPGFATKEITNGKPFFKDINECKMIPSLCTHGKCRNTIGSFKCRCDSGFALDSEERNCTDIDECRISPDLCGRGQCVNTPGDFECKCDEGYESGFMMMKNCMDIDECQRDPLLCRGGVCHNTEGSYRCECPPGHQLSPNISACIDINECELSAHLCPNGRCVNLIGKYQCACNPGYHSTPDRLFCVDIDECSIMNGGCETFCTNSEGSYECSCQPGFALMPDQRSCTDIDECEDNPNICDGGQCTNIPGEYRCLCYDGFMASEDMKTCVDVNECDLNPNICLSGTCENTKGSFICHCDMGYSGKKGKTGCTDINECEIGAHNCGKHAVCTNTAGSFKCSCSPGWIGDGIKCTDLDECSNGTHMCSQHADCKNTMGSYRCLCKEGYTGDGFTCTDLDECSENLNLCGNGQCLNAPGGYRCECDMGFVPSADGKACEDIDECSLPNICVFGTCHNLPGLFRCECEIGYELDRSGGNCTDVNECLDPTTCISGNCVNTPGSYICDCPPDFELNPTRVGCVDTRSGNCYLDIRPRGDNGDTACSNEIGVGVSKASCCCSLGKAWGTPCEMCPAVNTSEYKILCPGGEGFRPNPITVILEDIDECQELPGLCQGGKCINTFGSFQCRCPTGYYLNEDTRVCDDVNECETPGICGPGTCYNTVGNYTCICPPDYMQVNGGNNCMDMRRSLCYRNYYADNQTCDGELLFNMTKKMCCCSYNIGRAWNKPCEQCPIPSTDEFATLCGSQRPGFVIDIYTGLPVDIDECREIPGVCENGVCINMVGSFRCECPVGFFYNDKLLVCEDIDECQNGPVCQRNAECINTAGSYRCDCKPGYRFTSTGQCNDRNECQEIPNICSHGQCIDTVGSFYCLCHTGFKTNDDQTMCLDINECERDACGNGTCRNTIGSFNCRCNHGFILSHNNDCIDVDECASGNGNLCRNGQCINTVGSFQCQCNEGYEVAPDGRTCVDINECLLEPRKCAPGTCQNLDGSYRCICPPGYSLQNEKCEDIDECVEEPEICALGTCSNTEGSFKCLCPEGFSLSSSGRRCQDLRMSYCYAKFEGGKCSSPKSRNHSKQECCCALKGEGWGDPCELCPTEPDEAFRQICPYGSGIIVGPDDSAVDMDECKEPDVCKHGQCINTDGSYRCECPFGYILAGNECVDTDECSVGNPCGNGTCKNVIGGFECTCEEGFEPGPMMTCEDINECAQNPLLCAFRCVNTYGSYECKCPVGYVLREDRRMCKDEDECEEGKHDCTEKQMECKNLIGTYMCICGPGYQRRPDGEGCVDENECQTKPGICENGRCLNTRGSYTCECNDGFTASPNQDECLDNREGYCFTEVLQNMCQIGSSNRNPVTKSECCCDGGRGWGPHCEICPFQGTVAFKKLCPHGRGFMTNGADIDECKVIHDVCRNGECVNDRGSYHCICKTGYTPDITGTSCVDLNECNQAPKPCNFICKNTEGSYQCSCPKGYILQEDGRSCKDLDECATKQHNCQFLCVNTIGGFTCKCPPGFTQHHTSCIDNNECTSDINLCGSKGICQNTPGSFTCECQRGFSLDQTGSSCEDVDECEGNHRCQHGCQNIIGGYRCSCPQGYLQHYQWNQCVDENECLSAHICGGASCHNTLGSYKCMCPAGFQYEQFSGGCQDINECGSAQAPCSYGCSNTEGGYLCGCPPGYFRIGQGHCVSGMGMGRGNPEPPVSGEMDDNSLSPEACYECKINGYPKRGRKRRSTNETDASNIEDQSETEANVSLASWDVEKTAIFAFNISHVSNKVRILELLPALTTLTNHNRYLIESGNEDGFFKINQKEGISYLHFTKKKPVAGTYSLQISSTPLYKKKELNQLEDKYDKDYLSGELGDNLKMKIQVLLH	2871	P35555	M	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [611, 753, 1253, 2543], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.00080264, -0.00491327, -0.00632554, -0.02782458]), 'REGION_loss': [2146], 'REGION_gain': [432, 932, 1233, 1279, 2521, 2525, 2527, 2528], 'REGION_gain_score': array([0.00129569, 0.00032717, 0.00151736, 0.00148737, 0.00084174,
       0.00088751, 0.00095755, 0.00086659]), 'REGION_loss_score': array([-0.00027317]), 'REPEAT_loss': [2480, 2521, 2558], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.00106788, -0.00222713, -0.0022465 ]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
511	NM_000138.5(FBN1):c.3509G>A (p.Arg1170His)	16451	CA014215	NM_000138.5:c.3509G>A, NC_000015.10:g.48487155C>T, CM000677.2:g.48487155C>T, NC_000015.9:g.48779352C>T, CM000677.1:g.48779352C>T, NC_000015.8:g.46566644C>T, NG_008805.2:g.163634G>A, LRG_778:g.163634G>A, ENST00000684448.1:n.2183G>A, ENST00000316623.10:c.3509G>A, ENST00000316623.9:c.3509G>A, ENST00000537463.6:c.637-12505G>A, NM_000138.4:c.3509G>A, LRG_778t1:c.3509G>A, NM_000138.5(FBN1):c.3509G>A (p.Arg1170His)	FBN1	Marfan syndrome	MONDO:0007947	Autosomal dominant inheritance	Benign	BP5, BP2, BA1	PS1, PS3, PS4, PM5, PM1, BS1, BS3, PP2, PP3, PP1, PM2, BP1, BP4	The NM_00138 c.3509G>A, is a missense variant in FBN1 predicted to cause a substitution of an arginine acid by histidine at amino acid 1170 (p.Arg1170His). This variant has been previously reported in several apparently unrelated individuals with Marfan syndrome (PMID 26787436, internal data), incomplete Marfan syndrome, including with skeletal features and/or mitral valve prolapse (PMID 7870075, 9837823, 17418587, 17627385, 17657824), in individuals with isolated thoracic aortic aneurysm and/or dissection (internal data) and in other phenotypes like arterial dissection and venous bleeding (internal data). This variant was found to segregate with disease in seven affected individuals with incomplete Marfan syndrome from three families (PMID 7870075, 9837823, internal data). This variant has been found to co-occur with different pathogenic variants in FBN1 (BP2), TGFBR1, and TGFRB2 (BP5) (internal data). This variant has been identified in 286 individuals of European non-Finnish origin (MAF: 0.2%) (BA1; https://gnomad.broadinstitute.org/, version 2.1.1). The variant in FBN1 has been reported 21 times in ClinVar: 16 times as likely benign and 5 times as uncertain significance (Variation ID: 16451). Computational prediction tools and conservation analysis are unclear on the predicted impact on the protein (REVEL: 0.502). Functional studies, including in-vitro splicing analysis, found that this variant had no impact on splicing (PMID 21895641, 32123317). The constraint z-score for missense variants affecting FBN1 is 5.06, however due to the presence of benign arguments, PP2 cannot be used. In summary, this variant meets criteria to be classified as benign for Marfan syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen FBN1 VCEP: BA1, BP2, BP5.		FBN1 VCEP	https://clinicalgenome.org/docs/clingen-fbn1-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2023-02-01	2023-02-01	False	https://erepo.genome.network/evrepo/ui/classification/CA014215/MONDO:0007947/022	bbe2b789-1955-4672-a1a5-d8ee020aa9d6	p.Arg1170His	Arg	1170	His	MRRGRLLEIALGFTVLLASYTSHGADANLEAGNVKETRASRAKRRGGGGHDALKGPNVCGSRYNAYCCPGWKTLPGGNQCIVPICRHSCGDGFCSRPNMCTCPSGQIAPSCGSRSIQHCNIRCMNGGSCSDDHCLCQKGYIGTHCGQPVCESGCLNGGRCVAPNRCACTYGFTGPQCERDYRTGPCFTVISNQMCQGQLSGIVCTKTLCCATVGRAWGHPCEMCPAQPHPCRRGFIPNIRTGACQDVDECQAIPGLCQGGNCINTVGSFECKCPAGHKLNEVSQKCEDIDECSTIPGICEGGECTNTVSSYFCKCPPGFYTSPDGTRCIDVRPGYCYTALTNGRCSNQLPQSITKMQCCCDAGRCWSPGVTVAPEMCPIRATEDFNKLCSVPMVIPGRPEYPPPPLGPIPPVLPVPPGFPPGPQIPVPRPPVEYLYPSREPPRVLPVNVTDYCQLVRYLCQNGRCIPTPGSYRCECNKGFQLDLRGECIDVDECEKNPCAGGECINNQGSYTCQCRAGYQSTLTRTECRDIDECLQNGRICNNGRCINTDGSFHCVCNAGFHVTRDGKNCEDMDECSIRNMCLNGMCINEDGSFKCICKPGFQLASDGRYCKDINECETPGICMNGRCVNTDGSYRCECFPGLAVGLDGRVCVDTHMRSTCYGGYKRGQCIKPLFGAVTKSECCCASTEYAFGEPCQPCPAQNSAEYQALCSSGPGMTSAGSDINECALDPDICPNGICENLRGTYKCICNSGYEVDSTGKNCVDINECVLNSLLCDNGQCRNTPGSFVCTCPKGFIYKPDLKTCEDIDECESSPCINGVCKNSPGSFICECSSESTLDPTKTICIETIKGTCWQTVIDGRCEININGATLKSQCCSSLGAAWGSPCTLCQVDPICGKGYSRIKGTQCEDIDECEVFPGVCKNGLCVNTRGSFKCQCPSGMTLDATGRICLDIRLETCFLRYEDEECTLPIAGRHRMDACCCSVGAAWGTEECEECPMRNTPEYEELCPRGPGFATKEITNGKPFFKDINECKMIPSLCTHGKCRNTIGSFKCRCDSGFALDSEERNCTDIDECRISPDLCGRGQCVNTPGDFECKCDEGYESGFMMMKNCMDIDECQRDPLLCRGGVCHNTEGSYRCECPPGHQLSPNISACIDINECELSAHLCPNGRCVNLIGKYQCACNPGYHSTPDRLFCVDIDECSIMNGGCETFCTNSEGSYECSCQPGFALMPDQRSCTDIDECEDNPNICDGGQCTNIPGEYRCLCYDGFMASEDMKTCVDVNECDLNPNICLSGTCENTKGSFICHCDMGYSGKKGKTGCTDINECEIGAHNCGKHAVCTNTAGSFKCSCSPGWIGDGIKCTDLDECSNGTHMCSQHADCKNTMGSYRCLCKEGYTGDGFTCTDLDECSENLNLCGNGQCLNAPGGYRCECDMGFVPSADGKACEDIDECSLPNICVFGTCHNLPGLFRCECEIGYELDRSGGNCTDVNECLDPTTCISGNCVNTPGSYICDCPPDFELNPTRVGCVDTRSGNCYLDIRPRGDNGDTACSNEIGVGVSKASCCCSLGKAWGTPCEMCPAVNTSEYKILCPGGEGFRPNPITVILEDIDECQELPGLCQGGKCINTFGSFQCRCPTGYYLNEDTRVCDDVNECETPGICGPGTCYNTVGNYTCICPPDYMQVNGGNNCMDMRRSLCYRNYYADNQTCDGELLFNMTKKMCCCSYNIGRAWNKPCEQCPIPSTDEFATLCGSQRPGFVIDIYTGLPVDIDECREIPGVCENGVCINMVGSFRCECPVGFFYNDKLLVCEDIDECQNGPVCQRNAECINTAGSYRCDCKPGYRFTSTGQCNDRNECQEIPNICSHGQCIDTVGSFYCLCHTGFKTNDDQTMCLDINECERDACGNGTCRNTIGSFNCRCNHGFILSHNNDCIDVDECASGNGNLCRNGQCINTVGSFQCQCNEGYEVAPDGRTCVDINECLLEPRKCAPGTCQNLDGSYRCICPPGYSLQNEKCEDIDECVEEPEICALGTCSNTEGSFKCLCPEGFSLSSSGRRCQDLRMSYCYAKFEGGKCSSPKSRNHSKQECCCALKGEGWGDPCELCPTEPDEAFRQICPYGSGIIVGPDDSAVDMDECKEPDVCKHGQCINTDGSYRCECPFGYILAGNECVDTDECSVGNPCGNGTCKNVIGGFECTCEEGFEPGPMMTCEDINECAQNPLLCAFRCVNTYGSYECKCPVGYVLREDRRMCKDEDECEEGKHDCTEKQMECKNLIGTYMCICGPGYQRRPDGEGCVDENECQTKPGICENGRCLNTRGSYTCECNDGFTASPNQDECLDNREGYCFTEVLQNMCQIGSSNRNPVTKSECCCDGGRGWGPHCEICPFQGTVAFKKLCPHGRGFMTNGADIDECKVIHDVCRNGECVNDRGSYHCICKTGYTPDITGTSCVDLNECNQAPKPCNFICKNTEGSYQCSCPKGYILQEDGRSCKDLDECATKQHNCQFLCVNTIGGFTCKCPPGFTQHHTSCIDNNECTSDINLCGSKGICQNTPGSFTCECQRGFSLDQTGSSCEDVDECEGNHRCQHGCQNIIGGYRCSCPQGYLQHYQWNQCVDENECLSAHICGGASCHNTLGSYKCMCPAGFQYEQFSGGCQDINECGSAQAPCSYGCSNTEGGYLCGCPPGYFRIGQGHCVSGMGMGRGNPEPPVSGEMDDNSLSPEACYECKINGYPKRGRKRRSTNETDASNIEDQSETEANVSLASWDVEKTAIFAFNISHVSNKVRILELLPALTTLTNHNRYLIESGNEDGFFKINQKEGISYLHFTKKKPVAGTYSLQISSTPLYKKKELNQLEDKYDKDYLSGELGDNLKMKIQVLLH	2871	P35555	H	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [611, 753, 1188, 1253, 2543], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.0011273 , -0.00432456, -0.03187335, -0.01115662, -0.01330984]), 'REGION_loss': [], 'REGION_gain': [922, 932, 942, 969, 1233, 1279, 2176, 2521, 2525, 2527, 2528], 'REGION_gain_score': array([0.00180453, 0.00169611, 0.00191933, 0.00243312, 0.00357455,
       0.00193471, 0.00218433, 0.00267059, 0.00237828, 0.00247359,
       0.00230753]), 'REPEAT_loss': [1031, 1517], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.00028354, -0.00124985]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
512	NM_001110792.2(MECP2):c.535C>T (p.Arg179Trp)	143603	CA170308	NM_001110792.2:c.535C>T, NC_000023.11:g.154031329G>A, CM000685.2:g.154031329G>A, NC_000023.10:g.153296780G>A, CM000685.1:g.153296780G>A, NC_000023.9:g.152949974G>A, NG_007107.2:g.110799C>T, NG_007107.3:g.110775C>T, ENST00000303391.11:c.499C>T, ENST00000453960.7:c.535C>T, ENST00000637917.1:n.65+67C>T, ENST00000303391.10:c.499C>T, ENST00000407218.5:c.469-43C>T, ENST00000453960.6:c.535C>T, ENST00000486506.5:n.2847C>T, ENST00000611468.1:c.485C>T, ENST00000619732.4:c.499C>T, ENST00000622433.4:c.487C>T, ENST00000628176.2:c.433-43C>T, NM_001110792.1:c.535C>T, NM_001316337.1:c.220C>T, NM_004992.3:c.499C>T, XM_005274681.3:c.499C>T, XM_005274682.3:c.220C>T, XM_005274683.3:c.220C>T, XM_006724819.2:c.-128-43C>T, XM_011531166.1:c.220C>T, XM_006724819.3:c.-128-43C>T, XM_011531166.2:c.220C>T, XM_024452383.1:c.220C>T, XM_024452384.1:c.220C>T, NM_001316337.2:c.220C>T, NM_001369391.2:c.220C>T, NM_001369392.2:c.220C>T, NM_001369393.2:c.220C>T, NM_001369394.1:c.220C>T, NM_001369394.2:c.220C>T, NM_001386137.1:c.-128-43C>T, NM_001386138.1:c.-128-43C>T, NM_001386139.1:c.-128-43C>T, NM_004992.4:c.499C>T, NM_001110792.2(MECP2):c.535C>T (p.Arg179Trp)	MECP2	Rett syndrome	MONDO:0010726	X-linked inheritance	Pathogenic	PM2_Supporting, PS2_Very Strong, PP1_Strong		The p.Arg167Trp variant (NM_004992.3) in MECP2 has been reported as a de novo occurrence (biological parentage confirmed) in at least 2 individuals with MECP2-related disorders through testing completed at GeneDx (PS2_very strong). The variant has been reported to segregate in at least five informative meioses in published literature (Couvert et al., 2001) (PP1_strong). The p.Arg167Trp variant in MECP2 is absent from gnomAD (PM2_supporting). In summary, the p.Arg167Trp variant in MECP2 is classified as pathogenic for Rett syndrome based on the ACMG/AMP criteria (PS2_very strong, PP1_strong, PM2_supporting).		Rett and Angelman-like Disorders VCEP	https://clinicalgenome.org/site/assets/files/7339/clingen_rettas_acmg_specifications_v2.pdf	2021-12-13	2023-02-24	False	https://erepo.genome.network/evrepo/ui/classification/CA170308/MONDO:0010726/016	f50c6e2c-0485-4079-a589-cb0a7c521757	p.Arg179Trp	Arg	179	Trp	MVAGMLGLREEKSEDQDLQGLKDKPLKFKKVKKDKKEEKEGKHEPVQPSAHHSAEPAEAGKAETSEGSGSAPAVPEASASPKQRRSIIRDRGPMYDDPTLPEGWTRKLKQRKSGRSAGKYDVYLINPQGKAFRSKVELIAYFEKVGDTSLDPNDFDFTVTGRGSPSRREQKPPKKPKSPKAPGTGRGRGRPKGSGTTRPKAATSEGVQVKRVLEKSPGKLLVKMPFQTSPGGKAEGGGATTSTQVMVIKRPGRKRKAEADPQAIPKKRGRKPGSVVAAAAAEAKKKAVKESSIRSVQETVLPIKKRKTRETVSIEVKEVVKPLLVSTLGEKSGKGLKTCKSPGRKSKESSPKGRSSSASSPPKKEHHHHHHHSESPKAPVPLLPPLPPPPPEPESSEDPTSPPEPQDLSSSVCKEEKMPRGGSLESDGCPKEPAKTQPAVATAATAAEKYKHRGEGERKDIVSSSMPRPNREEPVDSRTPVTERVS	486	P51608	W	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [102], 'COMPBIAS_gain': [], 'COMPBIAS_loss_score': array([-0.04299319]), 'DOMAIN_loss': [163], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.03467488]), 'REGION_loss': [300, 301, 303], 'REGION_gain': [], 'REGION_loss_score': array([-0.03654629, -0.02960515, -0.0383184 ]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
513	NM_000152.5(GAA):c.1465G>A (p.Asp489Asn)	92465	CA220390	NM_000152.5:c.1465G>A, NC_000017.11:g.80110754G>A, CM000679.2:g.80110754G>A, NC_000017.10:g.78084553G>A, CM000679.1:g.78084553G>A, NC_000017.9:g.75699148G>A, NG_009822.1:g.14199G>A, LRG_673:g.14199G>A, ENST00000302262.8:c.1465G>A, ENST00000302262.7:c.1465G>A, ENST00000390015.7:c.1465G>A, NM_000152.3:c.1465G>A, LRG_673t1:c.1465G>A, NM_001079803.1:c.1465G>A, NM_001079804.1:c.1465G>A, XM_005257193.1:c.1465G>A, XM_005257194.3:c.1465G>A, NM_000152.4:c.1465G>A, NM_001079803.2:c.1465G>A, NM_001079804.2:c.1465G>A, XM_005257193.2:c.1465G>A, XM_005257194.4:c.1465G>A, NM_001079803.3:c.1465G>A, NM_001079804.3:c.1465G>A, NM_000152.5(GAA):c.1465G>A (p.Asp489Asn)	GAA	glycogen storage disease II	MONDO:0009290	Autosomal recessive inheritance	Pathogenic	PP4_Moderate, PP3, PM2_Supporting, PM3_Very Strong, PS3_Moderate		The NM_000152.5:c.1465G>A variant in GAA is a missense variant that is predicted to result in the substitution of aspartate by asparagine at amino acid 489 (p.Asp489Asn). This variant has been detected in at least 10 patients reported to have Pompe disease including 7 individuals with reported laboratory values demonstrating deficient GAA activity (PMID: 17151339, 22081099, 22658377, 24395639, 24844452, 24923245, 29422078, 31193175), and three for whom GAA activity was not reported but who were treated by enzyme replacement (PMIDs: 25626711, 28574618). Nine individuals were compound heterozygous, phase unknown, for the variant and a variant that has been classified as pathogenic by the ClinGen LSD VCEP including c.-32-13T>G  (PMIDs: 16917947, 2208109, 24395639, 24844452, 24923245, 28574618), c.40_47del8 (PMID: 29422078),  c.307T>G (p.Cys103Gly) (PMID: 18429042), c.1799G>A (p.Arg600His) (PMID: 22711147), c.2014C>T (p.Arg672Trp) (PMID: 16917947, 2208109), and another individual was compound heterozygous for the variant and c.2481+110_2646+39del (labeled as c.IVS17 + 102_IVS18 + 31 in the paper) confirmed in trans (PMID: 25626711). The variant was also detected in a parent of two affected children, now deceased, with c.1962_1964delAGA (p.Glu655del) in the other parent. However, as these variants were not confirmed to be present in the affected children, the data is not included (PMID: 22711147). Another individual was reported to have the variant but the cDNA sequence was not provided (PMID: 17616415 (PM3_VeryStrong). The highest population minor allele frequency in gnomAD is 0.00005 (1/21638) in the European Finnish population which is lower than the ClinGen LSD VCEP threshold (<0.001) for PM2_Supporting, meeting this criterion (PM2_Supporting). In two different studies, this variant results in <2% GAA activity when expressed in COS-7 cells or Ad5-SV40 immortalized human GAA-deficient fibroblasts and, on Western blot, most of the gene product remained as the 110 kDa inactive precursor (PMID: 17915575, 19862843) (PS3_Moderate). The computational predictor REVEL gives a score of 0.938 which is above the threshold of 0.7, evidence that correlates with impact to GAA function (PP3). There is a ClinVar entry for this variant (Variation ID: 92465). In summary, this variant meets the criteria to be classified as pathogenic for Pompe disease. GAA-specific ACMG/AMP criteria applied, as specified by the ClinGen LSD VCEP (specifications version 2.0): PM3_VeryStrong, PS3_Moderate, PP4_Moderate, PP3, PM2_Supporting.(Classification approved by the ClinGen LSD VCEP, February 7, 2023).		Lysosomal Diseases VCEP	https://clinicalgenome.org/docs/clingen-lysosomal-storage-disorders-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-2/	2023-02-07	2023-03-03	False	https://erepo.genome.network/evrepo/ui/classification/CA220390/MONDO:0009290/010	8f5d297d-fcfe-4bf7-ba17-fde165ab1525	p.Asp489Asn	Asp	489	Asn	MGVRHPPCSHRLLAVCALVSLATAALLGHILLHDFLLVPRELSGSSPVLEETHPAHQQGASRPGPRDAQAHPGRPRAVPTQCDVPPNSRFDCAPDKAITQEQCEARGCCYIPAKQGLQGAQMGQPWCFFPPSYPSYKLENLSSSEMGYTATLTRTTPTFFPKDILTLRLDVMMETENRLHFTIKDPANRRYEVPLETPHVHSRAPSPLYSVEFSEEPFGVIVRRQLDGRVLLNTTVAPLFFADQFLQLSTSLPSQYITGLAEHLSPLMLSTSWTRITLWNRDLAPTPGANLYGSHPFYLALEDGGSAHGVFLLNSNAMDVVLQPSPALSWRSTGGILDVYIFLGPEPKSVVQQYLDVVGYPFMPPYWGLGFHLCRWGYSSTAITRQVVENMTRAHFPLDVQWNDLDYMDSRRDFTFNKDGFRDFPAMVQELHQGGRRYMMIVDPAISSSGPAGSYRPYDEGLRRGVFITNETGQPLIGKVWPGSTAFPDFTNPTALAWWEDMVAEFHDQVPFDGMWIDMNEPSNFIRGSEDGCPNNELENPPYVPGVVGGTLQAATICASSHQFLSTHYNLHNLYGLTEAIASHRALVKARGTRPFVISRSTFAGHGRYAGHWTGDVWSSWEQLASSVPEILQFNLLGVPLVGADVCGFLGNTSEELCVRWTQLGAFYPFMRNHNSLLSLPQEPYSFSEPAQQAMRKALTLRYALLPHLYTLFHQAHVAGETVARPLFLEFPKDSSTWTVDHQLLWGEALLITPVLQAGKAEVTGYFPLGTWYDLQTVPVEALGSLPPPPAAPREPAIHSEGQWVTLPAPLDTINVHLRAGYIIPLQGPGLTTTESRQQPMALAVALTKGGEARGELFWDDGESLEVLERGAYTQVIFLARNNTIVNELVRVTSEGAGLQLQKVTVLGVATAPQQVLSNGVPVSNFTYSPDTKVLDICVSLLMGEQFLVSWC	952	P10253	N	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [367, 429], 'DNA_BIND_gain_score': array([0.00367767, 0.00272232]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [485], 'STRAND_gain': [478], 'STRAND_gain_score': array([0.01653934]), 'STRAND_loss_score': array([-0.04687059]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
514	NM_000152.5(GAA):c.271G>A (p.Asp91Asn)	4020	CA116586	NM_000152.5:c.271G>A, NC_000017.11:g.80104857G>A, CM000679.2:g.80104857G>A, NC_000017.10:g.78078656G>A, CM000679.1:g.78078656G>A, NC_000017.9:g.75693251G>A, NG_009822.1:g.8302G>A, LRG_673:g.8302G>A, ENST00000302262.8:c.271G>A, ENST00000302262.7:c.271G>A, ENST00000390015.7:c.271G>A, ENST00000570803.5:c.271G>A, ENST00000577106.5:c.271G>A, NM_000152.3:c.271G>A, LRG_673t1:c.271G>A, NM_001079803.1:c.271G>A, NM_001079804.1:c.271G>A, XM_005257193.1:c.271G>A, XM_005257194.3:c.271G>A, NM_000152.4:c.271G>A, NM_001079803.2:c.271G>A, NM_001079804.2:c.271G>A, XM_005257193.2:c.271G>A, XM_005257194.4:c.271G>A, NM_001079803.3:c.271G>A, NM_001079804.3:c.271G>A, NM_000152.5(GAA):c.271G>A (p.Asp91Asn)	GAA	glycogen storage disease II	MONDO:0009290	Autosomal recessive inheritance	Benign	BA1, BP4		The NM_000152.5:c.271G>A missense variant in GAA (p.Asp91Asn) has a highest population minor allele frequency in gnomAD v2.1.1 of 0.03291 (4183/127102 alleles; 70 homozygotes) in the European non-Finnish population, which is higher than the ClinGen LSD VCEP’s threshold for BA1 (>0.01), and therefore meets this criterion (BA1). The computational predictor REVEL gives a score of 0.396 which is below the threshold of 0.5, evidence that does not predict a damaging effect on GAA function. In addition, the computational splice predictors SpliceAI and varSEAK predict that the variant has no impact on splicing (BP4).  This variant is frequently described as a “pseudodeficiency” variant in the literature. It has been identified as the amino acid substitution responsible for the GAA*2 alloenzyme (also known as GAA2) (PMID: 2203258).  GAA*2 was identified by its faster migration  on starch gel electrophoresis compared to the GAA*1 alloenzyme (PMID: 2688539). In addition, compared to GAA*1, GAA*2 has a 10 fold higher Km for glycogen, but similar Km for maltose and 4-MUG (PMID: 2688539). No differences between the processing of GAA*2 and GAA*1 were noted on Western blot of protein from fibroblasts homozygous for either alloenzyme (PMID: 2688539). Furthermore, comparable amounts of glycogen were found in the lysosomes of the GAA*1 and GAA*2 homozygous cell lines, and there was no evidence of abnormal lysosomal glycogen storage in GAA*2 fibroblasts on electron microscopy (PMID: 2688539). When expressed in SV40-transformed GAA-deficient fibroblasts, c.271G>A (p.Asp91Asn) has similar GAA activity to wild type when 4-MUG is used as the substrate (PMID: 2203258).  Studies in cells from patients show a difference in GAA activity depending on the substrate used. In cells from individuals who are homozygous, or compound heterozygous for the variant and a known pathogenic GAA variant, false positives arose when glycogen was used as the substrate in the leukocyte assay, while the expected result was obtained when 4-MUG was used as the substrate in either the leukocyte or fibroblast assays (PMID: 19387865, 33162552). Evidence from the crystal structures of native and recombinant GAA indicate that Asp91 is involved in a sugar binding site, which could explain why this variant binds carbohydrate less effectively (PMID: 29061980; https://www.biorxiv.org/content/10.1101/212837v1 ). In addition, while the computational splice site predictors SpliceAI and varSEAK predict no impact on splicing, a mini-gene assay indicated that the variant results in exon 2 exclusion in about 30% of transcripts (PMID: 31301153). As an explanation for how the biochemical features of this variant result in no clinical features, substrate concentrations are usually far below that required for saturation of the enzyme. A reduction in enzyme activity brought about by decrease in Vmax, or increase in Km, would be compensated for by an increase in substrate concentration, restoring the normal turnover rate and establishing an equilibrium substrate concentration (PMID: 2688539).In patients with Pompe disease, c.271G>A has been found in cis with other variants that have been classified as pathogenic by the ClinGen LSD VCEP, p.Cys103Gly (PMID: 16838077, 33073003) and c.877G>A (p.Gly293Arg) (PMID: 27189384).There is a ClinVar entry for this variant (Variation ID: 4020) with eight submitters classifying the variant as benign, two as likely benign, and two as “other”. In summary, based on the evidence available to date, this variant meets the criteria to be classified as benign for Pompe disease. However, it is important to note that GAA activity may be in the patient range in individuals who are homozygous for the variant, or compound heterozygous for the variant and a pathogenic GAA variant, if glycogen is used as a substrate. Careful evaluation and use of 4-MUG as the substrate is necessary to provide accurate results. Therefore, this variant is classified as “other” to ensure that an explanation for deficient enzyme activity in the context of a clinically benign variant is highlighted.  GAA-specific ACMG-AMP criteria applied, as specified by the ClinGen LSD VCEP: BA1.		Lysosomal Diseases VCEP	https://clinicalgenome.org/docs/clingen-lysosomal-storage-disorders-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-2/	2023-03-03	2023-03-03	False	https://erepo.genome.network/evrepo/ui/classification/CA116586/MONDO:0009290/010	c57d6db1-c68b-48ee-b07d-9747ba7252e9	p.Asp91Asn	Asp	91	Asn	MGVRHPPCSHRLLAVCALVSLATAALLGHILLHDFLLVPRELSGSSPVLEETHPAHQQGASRPGPRDAQAHPGRPRAVPTQCDVPPNSRFDCAPDKAITQEQCEARGCCYIPAKQGLQGAQMGQPWCFFPPSYPSYKLENLSSSEMGYTATLTRTTPTFFPKDILTLRLDVMMETENRLHFTIKDPANRRYEVPLETPHVHSRAPSPLYSVEFSEEPFGVIVRRQLDGRVLLNTTVAPLFFADQFLQLSTSLPSQYITGLAEHLSPLMLSTSWTRITLWNRDLAPTPGANLYGSHPFYLALEDGGSAHGVFLLNSNAMDVVLQPSPALSWRSTGGILDVYIFLGPEPKSVVQQYLDVVGYPFMPPYWGLGFHLCRWGYSSTAITRQVVENMTRAHFPLDVQWNDLDYMDSRRDFTFNKDGFRDFPAMVQELHQGGRRYMMIVDPAISSSGPAGSYRPYDEGLRRGVFITNETGQPLIGKVWPGSTAFPDFTNPTALAWWEDMVAEFHDQVPFDGMWIDMNEPSNFIRGSEDGCPNNELENPPYVPGVVGGTLQAATICASSHQFLSTHYNLHNLYGLTEAIASHRALVKARGTRPFVISRSTFAGHGRYAGHWTGDVWSSWEQLASSVPEILQFNLLGVPLVGADVCGFLGNTSEELCVRWTQLGAFYPFMRNHNSLLSLPQEPYSFSEPAQQAMRKALTLRYALLPHLYTLFHQAHVAGETVARPLFLEFPKDSSTWTVDHQLLWGEALLITPVLQAGKAEVTGYFPLGTWYDLQTVPVEALGSLPPPPAAPREPAIHSEGQWVTLPAPLDTINVHLRAGYIIPLQGPGLTTTESRQQPMALAVALTKGGEARGELFWDDGESLEVLERGAYTQVIFLARNNTIVNELVRVTSEGAGLQLQKVTVLGVATAPQQVLSNGVPVSNFTYSPDTKVLDICVSLLMGEQFLVSWC	952	P10253	N	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [375, 420, 424, 663, 704, 716], 'DNA_BIND_gain': [], 'DNA_BIND_loss_score': array([-0.00017512, -0.00074977, -0.0010885 , -0.00504547, -0.00085276,
       -0.00199157]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [71], 'PROPEP_gain': [], 'PROPEP_loss_score': array([-0.01412433]), 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [259], 'STRAND_gain_score': array([0.00364566]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [386], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.00066054]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
515	NM_000156.6(GAMT):c.581T>C (p.Val194Ala)	205606	CA314855	NM_000156.6:c.581T>C, NC_000019.10:g.1397489A>G, CM000681.2:g.1397489A>G, NC_000019.9:g.1397488A>G, CM000681.1:g.1397488A>G, NC_000019.8:g.1348488A>G, NG_008283.1:g.18606A>G, NG_009785.1:g.9065T>C, ENST00000252288.8:c.581T>C, ENST00000640164.1:n.414T>C, ENST00000640762.1:c.512T>C, ENST00000252288.6:c.581T>C, NM_000156.5:c.581T>C, NM_000156.6(GAMT):c.581T>C (p.Val194Ala)	GAMT	guanidinoacetate methyltransferase deficiency	MONDO:0012999	Autosomal recessive inheritance	Benign	BA1, BP4	PM2, PP3, BS1	The NM_000156.6(GAMT):c.581T>C variant in GAMT is a missense variant predicted to cause substitution of valine by alanine at amino acid 194 (p.Val194Ala). Population allele frequency of this variant is higher than 0.3% in two populations in gnomAD v2.1.1 (BA1 met). In silico predictors predict no damaging effect (REVEL<0.5) and no effect on splicing (SpliceAI<0.05; varSEAK - class 1). To our knowledge, this variant has not been reported in the literature in any individuals with GAMT deficiency. In summary, this variant meets the criteria to be classified as Benign for GAMT deficiency based on the ACMG/AMP criteria applied, as specified by the ClinGen Cerebral Creatine Deficiency Syndromes Variant Curation Expert Panel (Specifications Version 1.0): BA1, BP4.		Cerebral Creatine Deficiency Syndromes VCEP		2023-01-30	2023-03-09	False	https://erepo.genome.network/evrepo/ui/classification/CA314855/MONDO:0012999/026	06cf0406-fa6d-4cb2-88a9-244a96a94089	p.Val194Ala	Val	194	Ala	MSAPSATPIFAPGENCSPAWGAAPAAYDAADTHLRILGKPVMERWETPYMHALAAAASSKGGRVLEVGFGMAIAASKVQEAPIDEHWIIECNDGVFQRLRDWAPRQTHKVIPLKGLWEDVAPTLPDGHFDGILYDTYPLSEETWHTHQFNFIKNHAFRLLKPGGVLTYCNLTSWGELMKSKYSDITIMFEETQVPALLEAGFRRENIRTEVMALVPPADCRYYAFPQMITPLVTKG	236	Q14353	A	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [115], 'DNA_BIND_gain_score': array([0.00185782]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [182], 'HELIX_gain_score': array([0.0370118]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [93, 164], 'REPEAT_gain_score': array([0.00441843, 0.00114274]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
516	NM_000156.6(GAMT):c.79T>C (p.Tyr27His)	167131	CA295620	NM_000156.6:c.79T>C, NC_000019.10:g.1401398A>G, CM000681.2:g.1401398A>G, NC_000019.9:g.1401397A>G, CM000681.1:g.1401397A>G, NC_000019.8:g.1352397A>G, NG_009785.1:g.5156T>C, ENST00000252288.8:c.79T>C, ENST00000447102.8:c.79T>C, ENST00000640762.1:c.79T>C, ENST00000252288.6:c.79T>C, ENST00000447102.7:c.79T>C, NM_000156.5:c.79T>C, NM_138924.2:c.79T>C, NM_138924.3:c.79T>C, NM_000156.6(GAMT):c.79T>C (p.Tyr27His)	GAMT	guanidinoacetate methyltransferase deficiency	MONDO:0012999	Autosomal recessive inheritance	Benign	BA1, BS3_Supporting	PP3	NM_000156.6:c.79T>C variant in GAMT is a missense variant that is predicted to result in the substitution of tyrosine by histidine at amino acid 27 (p.Tyr27His). This variant was identified in the homozygous state in an individual with normal GAMT enzyme activity in fibroblasts (PMID: 24415674). The variant is present in gnomAD v2.1.1. at a maximum population frequency of 0.00471 (>0.003, cutoff for BA1) and found in the homozygous state in 2 individuals in gnomAD v2.1.1 (BA1). In fibroblasts, overexpressing the GAMT c.79T>C (p.Tyr27His) variant, restored GAMT activity to similar levels as the wild-type GAMT transfection (PMID: 24415674)(BS3_Supporting). There is a ClinVar entry for this variant (Variation ID: 167131). In summary, this variant meets the criteria to be classified as benign for GAMT deficiency. GAMT-specific ACMG/AMP criteria met, based on the specifications of the ClinGen Cerebral Creatine Deficiencies VCEP (Specifications Version 1.1.0): BA1, BS3_Supporting.(Classification approved by the ClinGen CCDS VCEP on February 8, 2023).		Cerebral Creatine Deficiency Syndromes VCEP		2023-02-08	2023-03-09	False	https://erepo.genome.network/evrepo/ui/classification/CA295620/MONDO:0012999/026	7c04e605-50d3-4535-babc-261b76fc7eee	p.Tyr27His	Tyr	27	His	MSAPSATPIFAPGENCSPAWGAAPAAYDAADTHLRILGKPVMERWETPYMHALAAAASSKGGRVLEVGFGMAIAASKVQEAPIDEHWIIECNDGVFQRLRDWAPRQTHKVIPLKGLWEDVAPTLPDGHFDGILYDTYPLSEETWHTHQFNFIKNHAFRLLKPGGVLTYCNLTSWGELMKSKYSDITIMFEETQVPALLEAGFRRENIRTEVMALVPPADCRYYAFPQMITPLVTKG	236	Q14353	H	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [116, 133], 'DNA_BIND_gain': [], 'DNA_BIND_loss_score': array([-0.00375038, -0.0048418 ]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [9], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.06936592]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [164], 'REPEAT_gain_score': array([0.00509453]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
517	NM_000156.6(GAMT):c.224C>T (p.Ala75Val)	544251	CA402996954	NM_000156.6:c.224C>T, NC_000019.10:g.1399896G>A, CM000681.2:g.1399896G>A, NC_000019.9:g.1399895G>A, CM000681.1:g.1399895G>A, NC_000019.8:g.1350895G>A, NG_009785.1:g.6658C>T, ENST00000252288.8:c.224C>T, ENST00000447102.8:c.224C>T, ENST00000640762.1:c.155C>T, ENST00000252288.6:c.224C>T, ENST00000447102.7:c.224C>T, NM_000156.5:c.224C>T, NM_138924.2:c.224C>T, NM_138924.3:c.224C>T, NM_000156.6(GAMT):c.224C>T (p.Ala75Val)	GAMT	guanidinoacetate methyltransferase deficiency	MONDO:0012999	Autosomal recessive inheritance	Pathogenic	PP3, PM2_Supporting, PS3, PM3_Supporting, PP4_Strong		The NM_000156.6:c.224C>T variant in GAMT is a missense variant that is predicted to result in the substitution of alanine by valine at amino acid 75 (p.Ala75Val). One patient, with mild intellectual disability, anti-epileptic drug-responsive seizures, and stereotypic movements has been reported with creatine and guanidinoacetate peak absent on MRS, bilateral thalami increased on MRI, and urine guanidinoacetate levels between 1.1 and 12 times above the upper limit of reference range (PP4_Strong). This individual is homozygous for the variant (PM3_Supporting). The highest population minor allele frequency in gnomAD v2.1.1 is 0.00007 (1/15028 alleles) in the African population, which is lower than the ClinGen CCDS VCEP’s threshold for PM2_Supporting (<0.0004), meeting this criterion (PM2_Supporting). GAMT-deficient fibroblasts transfected with the variant showed <15% wild-type enzyme activity (PMID: 24415674). The computational predictor REVEL gives a score of 0.86 which is above the threshold of 0.75, evidence that correlates with impact to GAMT function (PP3). There is a ClinVar entry for this variant (Variation ID: 544251). In summary, this variant meets the criteria to be classified as pathogenic for GAMT deficiency based on the ACMG/AMP criteria applied, as specified by the ClinGen Cerebral Creatine Deficiency Syndromes Variant Curation Expert Panel (Specifications Version 1.1.0): PP4_Strong, PP3, PS3_Supporting, PM2_Supporting, PM3_Supporting.		Cerebral Creatine Deficiency Syndromes VCEP		2023-03-09	2023-03-29	False	https://erepo.genome.network/evrepo/ui/classification/CA402996954/MONDO:0012999/026	543d3f53-50b9-4b9a-a383-2302291c5f99	p.Ala75Val	Ala	75	Val	MSAPSATPIFAPGENCSPAWGAAPAAYDAADTHLRILGKPVMERWETPYMHALAAAASSKGGRVLEVGFGMAIAASKVQEAPIDEHWIIECNDGVFQRLRDWAPRQTHKVIPLKGLWEDVAPTLPDGHFDGILYDTYPLSEETWHTHQFNFIKNHAFRLLKPGGVLTYCNLTSWGELMKSKYSDITIMFEETQVPALLEAGFRRENIRTEVMALVPPADCRYYAFPQMITPLVTKG	236	Q14353	V	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [69], 'BINDING_gain': [], 'BINDING_loss_score': array([-0.02005267]), 'DNA_BIND_loss': [71, 74, 116, 133, 154], 'DNA_BIND_gain': [], 'DNA_BIND_loss_score': array([-0.01509899, -0.02899528, -0.00798267, -0.01126552, -0.00361741]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [3, 4], 'TRANSIT_gain_score': array([0.01088732, 0.01141334]), 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [9, 10, 11, 12, 13], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.12941539, -0.13001466, -0.13205481, -0.11908782, -0.11392683]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [80, 130], 'REPEAT_gain': [70], 'REPEAT_gain_score': array([0.02712929]), 'REPEAT_loss_score': array([-0.02951688, -0.01663566]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
518	NM_001323289.2(CDKL5):c.1768G>A (p.Glu590Lys)	680382	CA10360416	NM_001323289.2:c.1768G>A, NC_000023.11:g.18604692G>A, CM000685.2:g.18604692G>A, NC_000023.10:g.18622812G>A, CM000685.1:g.18622812G>A, NC_000023.9:g.18532733G>A, NG_008475.1:g.184088G>A, ENST00000623535.2:c.1768G>A, ENST00000635828.1:c.1768G>A, ENST00000674046.1:c.1768G>A, ENST00000379989.6:c.1768G>A, ENST00000379996.7:c.1768G>A, ENST00000463994.4:c.1768G>A, ENST00000623535.1:n.1768G>A, NM_001037343.1:c.1768G>A, NM_003159.2:c.1768G>A, XM_011545569.1:c.1717G>A, XM_011545570.1:c.1636G>A, XR_950484.1:n.2020G>A, NM_001323289.1:c.1768G>A, NM_001037343.2:c.1768G>A, NM_003159.3:c.1768G>A, NM_001323289.2(CDKL5):c.1768G>A (p.Glu590Lys)	CDKL5	CDKL5 disorder	MONDO:0100039	X-linked inheritance	Benign	BS2, BS1, BP5_Strong	PP3, BP4, PM1	The allele frequency of the p.Glu590Lys variant in CDKL5 is 0.015% in Latino sub population in gnomAD, which is high enough to be classified as likely benign based on thresholds defined by the ClinGen Rett/Angelman-like Expert Panel for Rett/AS-like conditions (BS1). Additionally, the p.Glu590Lys variant is observed in at least 14 unaffected individuals (internal database - GeneDx) (BS2) and at least 4 patients with an alternate molecular basis of disease (internal database - Invitae, internal database - GeneDx) (BP5_strong). In summary, the p.Glu590Lys variant in CDKL5 is classified as Benign for CDKL5-associated disorder based on the ACMG/AMP criteria (BS1, BS2, BP5_Strong).		Rett and Angelman-like Disorders VCEP	https://clinicalgenome.org/site/assets/files/7339/clingen_rettas_acmg_specifications_v2.pdf	2023-03-17	2023-03-31	False	https://erepo.genome.network/evrepo/ui/classification/CA10360416/MONDO:0100039/016	05067df3-3a57-4067-95be-a1f6bd26509f	p.Glu590Lys	Glu	590	Lys	MKIPNIGNVMNKFEILGVVGEGAYGVVLKCRHKETHEIVAIKKFKDSEENEEVKETTLRELKMLRTLKQENIVELKEAFRRRGKLYLVFEYVEKNMLELLEEMPNGVPPEKVKSYIYQLIKAIHWCHKNDIVHRDIKPENLLISHNDVLKLCDFGFARNLSEGNNANYTEYVATRWYRSPELLLGAPYGKSVDMWSVGCILGELSDGQPLFPGESEIDQLFTIQKVLGPLPSEQMKLFYSNPRFHGLRFPAVNHPQSLERRYLGILNSVLLDLMKNLLKLDPADRYLTEQCLNHPTFQTQRLLDRSPSRSAKRKPYHVESSTLSNRNQAGKSTALQSHHRSNSKDIQNLSVGLPRADEGLPANESFLNGNLAGASLSPLHTKTYQASSQPGSTSKDLTNNNIPHLLSPKEAKSKTEFDFNIDPKPSEGPGTKYLKSNSRSQQNRHSFMESSQSKAGTLQPNEKQSRHSYIDTIPQSSRSPSYRTKAKSHGALSDSKSVSNLSEARAQIAEPSTSRYFPSSCLDLNSPTSPTPTRHSDTRTLLSPSGRNNRNEGTLDSRRTTTRHSKTMEELKLPEHMDSSHSHSLSAPHESFSYGLGYTSPFSSQQRPHRHSMYVTRDKVRAKGLDGSLSIGQGMAARANSLQLLSPQPGEQLPPEMTVARSSVKETSREGTSSFHTRQKSEGGVYHDPHSDDGTAPKENRHLYNDPVPRRVGSFYRVPSPRPDNSFHENNVSTRVSSLPSESSSGTNHSKRQPAFDPWKSPENISHSEQLKEKEKQGFFRSMKKKKKKSQTVPNSDSPDLLTLQKSIHSASTPSSRPKEWRPEKISDLQTQSQPLKSLRKLLHLSSASNHPASSDPRFQPLTAQQTKNSFSEIRIHPLSQASGGSSNIRQEPAPKGRPALQLPGQMDPGWHVSSVTRSATEGPSYSEQLGAKSGPNGHPYNRTNRSRMPNLNDLKETAL	960	O76039	K	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [16], 'SIGNAL_gain': [], 'SIGNAL_loss_score': array([-0.00589085]), 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [241], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.00157326]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [340], 'COMPBIAS_gain': [578], 'COMPBIAS_gain_score': array([0.02263075]), 'COMPBIAS_loss_score': array([-0.00107437]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [584], 'REGION_gain_score': array([0.05595398]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
519	NM_001323289.2(CDKL5):c.1564T>G (p.Leu522Val)	434664	CA10360394	NM_001323289.2:c.1564T>G, NC_000023.11:g.18604488T>G, CM000685.2:g.18604488T>G, NC_000023.10:g.18622608T>G, CM000685.1:g.18622608T>G, NC_000023.9:g.18532529T>G, NG_008475.1:g.183884T>G, ENST00000623535.2:c.1564T>G, ENST00000635828.1:c.1564T>G, ENST00000674046.1:c.1564T>G, ENST00000379989.6:c.1564T>G, ENST00000379996.7:c.1564T>G, ENST00000463994.4:c.1564T>G, ENST00000623535.1:n.1564T>G, NM_001037343.1:c.1564T>G, NM_003159.2:c.1564T>G, XM_011545569.1:c.1513T>G, XM_011545570.1:c.1432T>G, XR_950484.1:n.1816T>G, NM_001323289.1:c.1564T>G, NM_001037343.2:c.1564T>G, NM_003159.3:c.1564T>G, NM_001323289.2(CDKL5):c.1564T>G (p.Leu522Val)	CDKL5	CDKL5 disorder	MONDO:0100039	X-linked inheritance	Benign	BS2, BP5, BS1	PP3, PM2, BP4, PS4, PM1	The allele frequency of the p.Leu522Val variant in CDKL5 is 0.011% in European Non-Finnish sub population in gnomAD, which is high enough to meet the BS1 criteria based on thresholds defined by the ClinGen Rett/Angelman-like Expert Panel for Rett/AS-like conditions (BS1). Additionally, the p.Leu522Val variant is observed in at least 2 unaffected individuals (internal database - GeneDx, internal database - Ambry Genetics) (BS2) and is found in a patient with an alternate molecular basis of disease (internal database - GeneDx) (BP5). In summary, the p.Leu522Val variant in CDKL5 is classified as Benign for CDKL5-associated disorder according to ACMG/AMP criteria (BS1, BS2, BP5).		Rett and Angelman-like Disorders VCEP	https://clinicalgenome.org/site/assets/files/7339/clingen_rettas_acmg_specifications_v2.pdf	2023-02-20	2023-03-31	False	https://erepo.genome.network/evrepo/ui/classification/CA10360394/MONDO:0100039/016	32174cab-38f2-4ca9-816b-e98c24809005	p.Leu522Val	Leu	522	Val	MKIPNIGNVMNKFEILGVVGEGAYGVVLKCRHKETHEIVAIKKFKDSEENEEVKETTLRELKMLRTLKQENIVELKEAFRRRGKLYLVFEYVEKNMLELLEEMPNGVPPEKVKSYIYQLIKAIHWCHKNDIVHRDIKPENLLISHNDVLKLCDFGFARNLSEGNNANYTEYVATRWYRSPELLLGAPYGKSVDMWSVGCILGELSDGQPLFPGESEIDQLFTIQKVLGPLPSEQMKLFYSNPRFHGLRFPAVNHPQSLERRYLGILNSVLLDLMKNLLKLDPADRYLTEQCLNHPTFQTQRLLDRSPSRSAKRKPYHVESSTLSNRNQAGKSTALQSHHRSNSKDIQNLSVGLPRADEGLPANESFLNGNLAGASLSPLHTKTYQASSQPGSTSKDLTNNNIPHLLSPKEAKSKTEFDFNIDPKPSEGPGTKYLKSNSRSQQNRHSFMESSQSKAGTLQPNEKQSRHSYIDTIPQSSRSPSYRTKAKSHGALSDSKSVSNLSEARAQIAEPSTSRYFPSSCLDLNSPTSPTPTRHSDTRTLLSPSGRNNRNEGTLDSRRTTTRHSKTMEELKLPEHMDSSHSHSLSAPHESFSYGLGYTSPFSSQQRPHRHSMYVTRDKVRAKGLDGSLSIGQGMAARANSLQLLSPQPGEQLPPEMTVARSSVKETSREGTSSFHTRQKSEGGVYHDPHSDDGTAPKENRHLYNDPVPRRVGSFYRVPSPRPDNSFHENNVSTRVSSLPSESSSGTNHSKRQPAFDPWKSPENISHSEQLKEKEKQGFFRSMKKKKKKSQTVPNSDSPDLLTLQKSIHSASTPSSRPKEWRPEKISDLQTQSQPLKSLRKLLHLSSASNHPASSDPRFQPLTAQQTKNSFSEIRIHPLSQASGGSSNIRQEPAPKGRPALQLPGQMDPGWHVSSVTRSATEGPSYSEQLGAKSGPNGHPYNRTNRSRMPNLNDLKETAL	960	O76039	V	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [16], 'SIGNAL_gain': [], 'SIGNAL_loss_score': array([-0.00422221]), 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [94], 'STRAND_gain_score': array([0.00105786]), 'HELIX_loss': [241], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.00211585]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [340], 'COMPBIAS_gain': [], 'COMPBIAS_loss_score': array([-0.00074667]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
520	NM_001323289.2(CDKL5):c.1064G>A (p.Arg355Gln)	423478	CA10360343	NM_001323289.2:c.1064G>A, NC_000023.11:g.18603988G>A, CM000685.2:g.18603988G>A, NC_000023.10:g.18622108G>A, CM000685.1:g.18622108G>A, NC_000023.9:g.18532029G>A, NG_008475.1:g.183384G>A, ENST00000623535.2:c.1064G>A, ENST00000635828.1:c.1064G>A, ENST00000637881.1:c.1064G>A, ENST00000674046.1:c.1064G>A, ENST00000379989.6:c.1064G>A, ENST00000379996.7:c.1064G>A, ENST00000463994.4:c.1064G>A, ENST00000623535.1:n.1064G>A, NM_001037343.1:c.1064G>A, NM_003159.2:c.1064G>A, XM_011545569.1:c.1013G>A, XM_011545570.1:c.932G>A, XR_950484.1:n.1316G>A, NM_001323289.1:c.1064G>A, NM_001037343.2:c.1064G>A, NM_003159.3:c.1064G>A, NM_001323289.2(CDKL5):c.1064G>A (p.Arg355Gln)	CDKL5	CDKL5 disorder	MONDO:0100039	X-linked inheritance	Benign	BS2, BS1, BP5	PM1	The allele frequency of the p.Arg355Gln variant in CDKL5 is 0.011% in African sub population in gnomAD, which is high enough to be classified as likely benign based on thresholds defined by the ClinGen Rett/Angelman-like Expert Panel for Rett/AS-like conditions (BS1). Additionally, the p.Arg355Gln variant is observed in at least 2 unaffected individuals (internal database - GeneDx, internal database - Invitae) (BS2) and the variant is found in at least 2 patients with an alternate molecular basis of disease (internal database - GeneDx, internal database - Invitae) (BP5).  In summary, the p.Arg355Gln variant in CDKL5 is classified as Benign for CDKL5-associated disorder based on the ACMG/AMP criteria (BS1, BS2, BP5).		Rett and Angelman-like Disorders VCEP	https://clinicalgenome.org/site/assets/files/7339/clingen_rettas_acmg_specifications_v2.pdf	2023-02-20	2023-03-31	False	https://erepo.genome.network/evrepo/ui/classification/CA10360343/MONDO:0100039/016	a7116a77-0031-4c0b-a786-be34fcc7373e	p.Arg355Gln	Arg	355	Gln	MKIPNIGNVMNKFEILGVVGEGAYGVVLKCRHKETHEIVAIKKFKDSEENEEVKETTLRELKMLRTLKQENIVELKEAFRRRGKLYLVFEYVEKNMLELLEEMPNGVPPEKVKSYIYQLIKAIHWCHKNDIVHRDIKPENLLISHNDVLKLCDFGFARNLSEGNNANYTEYVATRWYRSPELLLGAPYGKSVDMWSVGCILGELSDGQPLFPGESEIDQLFTIQKVLGPLPSEQMKLFYSNPRFHGLRFPAVNHPQSLERRYLGILNSVLLDLMKNLLKLDPADRYLTEQCLNHPTFQTQRLLDRSPSRSAKRKPYHVESSTLSNRNQAGKSTALQSHHRSNSKDIQNLSVGLPRADEGLPANESFLNGNLAGASLSPLHTKTYQASSQPGSTSKDLTNNNIPHLLSPKEAKSKTEFDFNIDPKPSEGPGTKYLKSNSRSQQNRHSFMESSQSKAGTLQPNEKQSRHSYIDTIPQSSRSPSYRTKAKSHGALSDSKSVSNLSEARAQIAEPSTSRYFPSSCLDLNSPTSPTPTRHSDTRTLLSPSGRNNRNEGTLDSRRTTTRHSKTMEELKLPEHMDSSHSHSLSAPHESFSYGLGYTSPFSSQQRPHRHSMYVTRDKVRAKGLDGSLSIGQGMAARANSLQLLSPQPGEQLPPEMTVARSSVKETSREGTSSFHTRQKSEGGVYHDPHSDDGTAPKENRHLYNDPVPRRVGSFYRVPSPRPDNSFHENNVSTRVSSLPSESSSGTNHSKRQPAFDPWKSPENISHSEQLKEKEKQGFFRSMKKKKKKSQTVPNSDSPDLLTLQKSIHSASTPSSRPKEWRPEKISDLQTQSQPLKSLRKLLHLSSASNHPASSDPRFQPLTAQQTKNSFSEIRIHPLSQASGGSSNIRQEPAPKGRPALQLPGQMDPGWHVSSVTRSATEGPSYSEQLGAKSGPNGHPYNRTNRSRMPNLNDLKETAL	960	O76039	Q	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [16], 'SIGNAL_gain': [], 'SIGNAL_loss_score': array([-0.02339822]), 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [340], 'COMPBIAS_gain': [], 'COMPBIAS_loss_score': array([-0.00762653]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
521	NM_001323289.2(CDKL5):c.2546C>T (p.Ser849Leu)	422765	CA16621285	NM_001323289.2:c.2546C>T, NC_000023.11:g.18628420C>T, CM000685.2:g.18628420C>T, NC_000023.10:g.18646540C>T, CM000685.1:g.18646540C>T, NC_000023.9:g.18556461C>T, NG_008475.1:g.207816C>T, ENST00000623535.2:c.2546C>T, ENST00000674046.1:c.2669C>T, ENST00000379989.6:c.2546C>T, ENST00000379996.7:c.2546C>T, ENST00000623535.1:n.2546C>T, NM_001037343.1:c.2546C>T, NM_003159.2:c.2546C>T, XM_011545569.1:c.2618C>T, XM_011545570.1:c.2537C>T, XR_950484.1:n.2921C>T, NM_001323289.1:c.2546C>T, NM_001037343.2:c.2546C>T, NM_003159.3:c.2546C>T, NM_001323289.2(CDKL5):c.2546C>T (p.Ser849Leu)	CDKL5	CDKL5 disorder	MONDO:0100039	X-linked inheritance	Benign	BS2, BS1	PP3, BA1, BP4	The allele frequency of the p.Ser849Leu variant in CDKL5 is 0.009217% in European (non-Finnish) sub population in gnomAD, which is high enough to meet the BS1 criteria based on thresholds defined by the ClinGen Rett/Angelman-like Expert Panel for Rett/AS-like conditions (BS1). The p.Ser849Leu variant is observed in at least 2 unaffected individuals (internal database-GeneDX) (BS2). In summary, the p.Ser849Leu variant in CDKL5 is classified as Benign based on the ACMG/AMP criteria (BS1, BS2).		Rett and Angelman-like Disorders VCEP	https://clinicalgenome.org/site/assets/files/7339/clingen_rettas_acmg_specifications_v2.pdf	2023-02-20	2023-03-31	False	https://erepo.genome.network/evrepo/ui/classification/CA16621285/MONDO:0100039/016	f4a3b72c-84d3-49d3-a412-459eecd460b0	p.Ser849Leu	Ser	849	Leu	MKIPNIGNVMNKFEILGVVGEGAYGVVLKCRHKETHEIVAIKKFKDSEENEEVKETTLRELKMLRTLKQENIVELKEAFRRRGKLYLVFEYVEKNMLELLEEMPNGVPPEKVKSYIYQLIKAIHWCHKNDIVHRDIKPENLLISHNDVLKLCDFGFARNLSEGNNANYTEYVATRWYRSPELLLGAPYGKSVDMWSVGCILGELSDGQPLFPGESEIDQLFTIQKVLGPLPSEQMKLFYSNPRFHGLRFPAVNHPQSLERRYLGILNSVLLDLMKNLLKLDPADRYLTEQCLNHPTFQTQRLLDRSPSRSAKRKPYHVESSTLSNRNQAGKSTALQSHHRSNSKDIQNLSVGLPRADEGLPANESFLNGNLAGASLSPLHTKTYQASSQPGSTSKDLTNNNIPHLLSPKEAKSKTEFDFNIDPKPSEGPGTKYLKSNSRSQQNRHSFMESSQSKAGTLQPNEKQSRHSYIDTIPQSSRSPSYRTKAKSHGALSDSKSVSNLSEARAQIAEPSTSRYFPSSCLDLNSPTSPTPTRHSDTRTLLSPSGRNNRNEGTLDSRRTTTRHSKTMEELKLPEHMDSSHSHSLSAPHESFSYGLGYTSPFSSQQRPHRHSMYVTRDKVRAKGLDGSLSIGQGMAARANSLQLLSPQPGEQLPPEMTVARSSVKETSREGTSSFHTRQKSEGGVYHDPHSDDGTAPKENRHLYNDPVPRRVGSFYRVPSPRPDNSFHENNVSTRVSSLPSESSSGTNHSKRQPAFDPWKSPENISHSEQLKEKEKQGFFRSMKKKKKKSQTVPNSDSPDLLTLQKSIHSASTPSSRPKEWRPEKISDLQTQSQPLKSLRKLLHLSSASNHPASSDPRFQPLTAQQTKNSFSEIRIHPLSQASGGSSNIRQEPAPKGRPALQLPGQMDPGWHVSSVTRSATEGPSYSEQLGAKSGPNGHPYNRTNRSRMPNLNDLKETAL	960	O76039	L	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [842, 843, 844, 845, 846, 847, 848], 'COMPBIAS_gain': [953], 'COMPBIAS_gain_score': array([0.02440298]), 'COMPBIAS_loss_score': array([-0.48958594, -0.66266632, -0.68603796, -0.72249562, -0.7605952 ,
       -0.65931922, -0.61074859]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [583, 835, 836, 837, 838, 839, 840, 841, 842, 843, 844, 845, 846, 847, 848], 'REGION_gain': [], 'REGION_loss_score': array([-0.00357318, -0.35705578, -0.38232952, -0.40525758, -0.50237787,
       -0.47638482, -0.51954752, -0.49602854, -0.53091216, -0.52707905,
       -0.58862805, -0.65253407, -0.59202957, -0.58895302, -0.50798458]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
522	NM_001323289.2(CDKL5):c.2243A>G (p.Asn748Ser)	194499	CA240506	NM_001323289.2:c.2243A>G, NC_000023.11:g.18613242A>G, CM000685.2:g.18613242A>G, NC_000023.10:g.18631362A>G, CM000685.1:g.18631362A>G, NC_000023.9:g.18541283A>G, NG_008475.1:g.192638A>G, ENST00000623535.2:c.2243A>G, ENST00000635828.1:c.2243A>G, ENST00000674046.1:c.2243A>G, ENST00000379989.6:c.2243A>G, ENST00000379996.7:c.2243A>G, ENST00000463994.4:c.2243A>G, ENST00000623535.1:n.2243A>G, NM_001037343.1:c.2243A>G, NM_003159.2:c.2243A>G, XM_011545569.1:c.2192A>G, XM_011545570.1:c.2111A>G, XR_950484.1:n.2495A>G, NM_001323289.1:c.2243A>G, NM_001037343.2:c.2243A>G, NM_003159.3:c.2243A>G, NM_001323289.2(CDKL5):c.2243A>G (p.Asn748Ser)	CDKL5	CDKL5 disorder	MONDO:0100039	X-linked inheritance (dominant (HP:0001423))	Benign	BA1, BS2_Supporting		The allele frequency of the p.Asn748Ser variant in CDKL5 is 0.03683% in African/African American sub population in gnomAD, which is high enough to be classified as benign based on thresholds defined by the ClinGen Rett/Angelman-like Expert Panel for Rett/AS-like conditions (BA1). The p.Asn748Ser variant is observed in at least 1 unaffected individual (PMID: 29264392) (BS2_supporting). In summary, the p.Asn748Ser variant in CDKL5 is classified as Benign based on the ACMG/AMP criteria (BA1, BA2_supporting).		Rett and Angelman-like Disorders VCEP	https://clinicalgenome.org/site/assets/files/7339/clingen_rettas_acmg_specifications_v2.pdf	2023-02-20	2023-03-31	False	https://erepo.genome.network/evrepo/ui/classification/CA240506/MONDO:0100039/016	7f8bf0db-1204-4240-937b-b8fb10254549	p.Asn748Ser	Asn	748	Ser	MKIPNIGNVMNKFEILGVVGEGAYGVVLKCRHKETHEIVAIKKFKDSEENEEVKETTLRELKMLRTLKQENIVELKEAFRRRGKLYLVFEYVEKNMLELLEEMPNGVPPEKVKSYIYQLIKAIHWCHKNDIVHRDIKPENLLISHNDVLKLCDFGFARNLSEGNNANYTEYVATRWYRSPELLLGAPYGKSVDMWSVGCILGELSDGQPLFPGESEIDQLFTIQKVLGPLPSEQMKLFYSNPRFHGLRFPAVNHPQSLERRYLGILNSVLLDLMKNLLKLDPADRYLTEQCLNHPTFQTQRLLDRSPSRSAKRKPYHVESSTLSNRNQAGKSTALQSHHRSNSKDIQNLSVGLPRADEGLPANESFLNGNLAGASLSPLHTKTYQASSQPGSTSKDLTNNNIPHLLSPKEAKSKTEFDFNIDPKPSEGPGTKYLKSNSRSQQNRHSFMESSQSKAGTLQPNEKQSRHSYIDTIPQSSRSPSYRTKAKSHGALSDSKSVSNLSEARAQIAEPSTSRYFPSSCLDLNSPTSPTPTRHSDTRTLLSPSGRNNRNEGTLDSRRTTTRHSKTMEELKLPEHMDSSHSHSLSAPHESFSYGLGYTSPFSSQQRPHRHSMYVTRDKVRAKGLDGSLSIGQGMAARANSLQLLSPQPGEQLPPEMTVARSSVKETSREGTSSFHTRQKSEGGVYHDPHSDDGTAPKENRHLYNDPVPRRVGSFYRVPSPRPDNSFHENNVSTRVSSLPSESSSGTNHSKRQPAFDPWKSPENISHSEQLKEKEKQGFFRSMKKKKKKSQTVPNSDSPDLLTLQKSIHSASTPSSRPKEWRPEKISDLQTQSQPLKSLRKLLHLSSASNHPASSDPRFQPLTAQQTKNSFSEIRIHPLSQASGGSSNIRQEPAPKGRPALQLPGQMDPGWHVSSVTRSATEGPSYSEQLGAKSGPNGHPYNRTNRSRMPNLNDLKETAL	960	O76039	S	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [16], 'SIGNAL_gain': [], 'SIGNAL_loss_score': array([-0.0032059]), 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
523	NM_000527.5(LDLR):c.2475C>A (p.Asn825Lys)	252341	CA040801	NM_000527.5:c.2475C>A, NC_000019.10:g.11129598C>A, CM000681.2:g.11129598C>A, NC_000019.9:g.11240274C>A, CM000681.1:g.11240274C>A, NC_000019.8:g.11101274C>A, NG_009060.1:g.45218C>A, LRG_274:g.45218C>A, ENST00000558518.6:c.2475C>A, ENST00000252444.9:n.2729C>A, ENST00000455727.6:c.1971C>A, ENST00000535915.5:c.2352C>A, ENST00000545707.5:c.1941C>A, ENST00000557933.5:c.2537C>A, ENST00000558013.5:c.2475C>A, ENST00000558518.5:c.2475C>A, ENST00000560628.1:n.108+1944C>A, NM_000527.4:c.2475C>A, LRG_274t1:c.2475C>A, NM_001195798.1:c.2475C>A, NM_001195799.1:c.2352C>A, NM_001195800.1:c.1971C>A, NM_001195803.1:c.1941C>A, XM_011528010.1:c.2397C>A, XM_011528011.1:c.2094C>A, XM_011528010.2:c.2397C>A, XR_001753685.2:n.2809C>A, XR_001753686.2:n.2452C>A, NM_001195798.2:c.2475C>A, NM_001195799.2:c.2352C>A, NM_001195800.2:c.1971C>A, NM_001195803.2:c.1941C>A, NM_000527.5(LDLR):c.2475C>A (p.Asn825Lys)	LDLR	hypercholesterolemia, familial	MONDO:0007750	Semidominant inheritance	Pathogenic	PS3, PS4, PP1_Strong, PM2, PP3, PP4	PS1, PM5	The NM_000527.5 (LDLR):c.2475C>A (p.Asn825Lys) variant is classified as Pathogenic for Familial Hypercholesterolemia by applying evidence codes (PM2, PP3, PS3, PP4, PS4, PP1_Strong) as defined by the ClinGen Familial Hypercholesterolemia Expert Panel LDLR-specific variant curation guidelines (https://doi.org/10.1016/j.gim.2021.09.012).The supporting evidence is as follows:PM2: PopMax MAF= 0.00001 in European (Non-Finnish) population (gnomAD v2.1.1).PP3: REVEL = 0.802.PS3: Level 1 experiment using heterologous cells (CHO), the experiments shown 50-60% LDL uptake, and normal LDL-LDLR binding (95%) and normal cell surface LDLR (95%), Etxebarria et al, 2015, Unidad de Biofísica (CSIC, UPV/EHU), Departamento de Bioquímica, Universidad del País Vasco, Spain, PMID25378237.PP4: Variant meets PM2 and is identified in >1 index cases who fulfil FH diagnostic criteria after alternative causes of high cholesterol were excluded.PS4: Variant meets PM2 and is identified in 22 unrelated index cases who fulfil FH diagnostic criteria. Four index cases from Centre de Génétique Moléculaire et Chromosomique, Unité de génétique de l'Obésité et des Dyslipidémies (APHP.Sorbonne Université, Hôpital de la Pitié-Salpêtrière), three of them had DLCN score ≥6, one met Simon Broome possible for FH. Three index cases with DLCN score ≥6, from Robarts Research Institute, Canada. One case fulfil criteria of TC and LDLc higher than the 95th percentile, with presence of tendon xanthomata, CAD in the proband or in a first degree relative, Chaves et al, 2001, Institute of cytological research and service of endocrinology and nutrition, University of  Valencia, Spain, PMID 11600564. Fourteen index cases fulfil 2 of 3 criteria of: 1) TC>8mmol/l, LDL>6mmol/l, TG<2.5mmol/l, 2) CAD before 60yr or family history of CAD, 3) presence of tendon xanthoma, Brusgaard et al, 2006, Department of clinical biochemistry and clinical genetics, Odense University hospital, Denmark, PMID 16542394.PP1_Strong: Variant segregates with FH phenotype in 16 informative meiosis from more than 3 families.  Two affected relatives, one each from 2 families tested positive for the variant from Robarts Research Institute, Canada. Fourteen affected relatives from unknown number of families tested positive for the variant, Brusgaard et al, 2006, Department of clinical biochemistry and clinical genetics, Odense University hospital, Denmark, PMID 16542394.PS1 not met: One other missense variant that leads to the same amino acid change at same codon, NM_000527.5 (LDLR):c.2475C>G (p.Asn825Lys), (ClinVarID 161265), is classified as Likely Pathogenic by these guidelines, therefore PS1 is not met. PM5 not met: One other missense variants in the same codon: NM_000527.5 (LDLR):c.2473A>G (p.Asn825Asp), (ClinVarID 252340) is classified as Likely Pathogenic by these guidelines, therefore PM5 not met.		Familial Hypercholesterolemia VCEP	https://clinicalgenome.org/docs/clingen-familial-hypercholesterolemia-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1-2/	2023-03-20	2023-03-31	False	https://erepo.genome.network/evrepo/ui/classification/CA040801/MONDO:0007750/013	1ae3ec5c-c9bd-4b0e-969b-7abf6e727dc1	p.Asn825Lys	Asn	825	Lys	MGPWGWKLRWTVALLLAAAGTAVGDRCERNEFQCQDGKCISYKWVCDGSAECQDGSDESQETCLSVTCKSGDFSCGGRVNRCIPQFWRCDGQVDCDNGSDEQGCPPKTCSQDEFRCHDGKCISRQFVCDSDRDCLDGSDEASCPVLTCGPASFQCNSSTCIPQLWACDNDPDCEDGSDEWPQRCRGLYVFQGDSSPCSAFEFHCLSGECIHSSWRCDGGPDCKDKSDEENCAVATCRPDEFQCSDGNCIHGSRQCDREYDCKDMSDEVGCVNVTLCEGPNKFKCHSGECITLDKVCNMARDCRDWSDEPIKECGTNECLDNNGGCSHVCNDLKIGYECLCPDGFQLVAQRRCEDIDECQDPDTCSQLCVNLEGGYKCQCEEGFQLDPHTKACKAVGSIAYLFFTNRHEVRKMTLDRSEYTSLIPNLRNVVALDTEVASNRIYWSDLSQRMICSTQLDRAHGVSSYDTVISRDIQAPDGLAVDWIHSNIYWTDSVLGTVSVADTKGVKRKTLFRENGSKPRAIVVDPVHGFMYWTDWGTPAKIKKGGLNGVDIYSLVTENIQWPNGITLDLLSGRLYWVDSKLHSISSIDVNGGNRKTILEDEKRLAHPFSLAVFEDKVFWTDIINEAIFSANRLTGSDVNLLAENLLSPEDMVLFHNLTQPRGVNWCERTTLSNGGCQYLCLPAPQINPHSPKFTCACPDGMLLARDMRSCLTEAEAAVATQETSTVRLKVSSTAVRTQHTTTRPVPDTSRLPGATPGLTTVEIVTMSHQALGDVAGRGNEKKPSSVRALSIVLPIVLLVFLCLGVFLLWKNWRLKNINSINFDNPVYQKTTEDEVHICHNQDGYSYPSRQMVSLEDDVA	860	P01130	K	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
524	NM_000527.5(LDLR):c.859G>T (p.Gly287Cys)	251489	CA10585162	NM_000527.5:c.859G>T, NC_000019.10:g.11107433G>T, CM000681.2:g.11107433G>T, NC_000019.9:g.11218109G>T, CM000681.1:g.11218109G>T, NC_000019.8:g.11079109G>T, NG_009060.1:g.23053G>T, LRG_274:g.23053G>T, ENST00000558518.6:c.859G>T, ENST00000252444.9:n.1113G>T, ENST00000455727.6:c.355G>T, ENST00000535915.5:c.736G>T, ENST00000545707.5:c.478G>T, ENST00000557933.5:c.859G>T, ENST00000558013.5:c.859G>T, ENST00000558518.5:c.859G>T, ENST00000558528.1:n.374G>T, ENST00000560467.1:n.459G>T, NM_000527.4:c.859G>T, LRG_274t1:c.859G>T, NM_001195798.1:c.859G>T, NM_001195799.1:c.736G>T, NM_001195800.1:c.355G>T, NM_001195803.1:c.478G>T, XM_011528010.1:c.859G>T, XM_011528011.1:c.478G>T, XR_244074.2:n.1009G>T, XM_011528010.2:c.859G>T, XR_001753685.2:n.976G>T, XR_001753686.2:n.976G>T, NM_001195798.2:c.859G>T, NM_001195799.2:c.736G>T, NM_001195800.2:c.355G>T, NM_001195803.2:c.478G>T, NM_000527.5(LDLR):c.859G>T (p.Gly287Cys)	LDLR	hypercholesterolemia, familial	MONDO:0007750	Semidominant inheritance	Pathogenic	PS4, PP1_Strong, PM2, PP3, PP4	PS3, PM5, PM3	The NM_000527.5 (LDLR):c.859G>T (p.Gly287Cys) variant is classified as Pathogenic for Familial Hypercholesterolemia by applying evidence codes (PM2, PP3, PP4, PS4, PP1_Strong) as defined by the ClinGen Familial Hypercholesterolemia Expert Panel LDLR-specific variant curation guidelines (https://doi.org/10.1016/j.gim.2021.09.012).The supporting evidence is as follows:PM2: This variant is absent from gnomAD (gnomAD v2.1.1).PP3: REVEL=0.928.PP4: Variant meets PM2 and is identified in ˃1 index cases who fulfil criteria for FH after alternative causes of high cholesterol were excluded.PS4: Variant meets PM2 and is identified in at least 11 unrelated index cases fulfil DLCN ≥ 6 reported in ClinGen VCI, PubMed and ClinVar: 7 cases reported in VCI, 6 of them from Service de Biochimie et de Biologie Moléculaire, Hospices Civils de Lyon, France, and 1 from Research Lab of Molecular Genetics of Lipid Metabolism-Prof. M.Arca; 3 cases reported from PubMed and at least 1 additional case reported in ClinVar from U4M-Lille University, France. From PubMed, 1 case reported In PMID 12730724 by El Messal et al, 2003, from Laboratoire de Biochimie, Faculte des Sciences Ain Chock, Casablanca, Morocco; 1 case reported in PMID 17196209 by Campagna et al, 2008, from University of Rome, Italy; 1 case reported in PMID 22669020 by El Aziz et al, 2012, from Ibn Rochd University Hospital, Casablanca, Morocco.PP1_Strong: Variant segregates with FH phenotype in 6 informative meiosis from 6 families reported from different laboratories: 4 affected relatives from 4 families tested positive for the variant, reported in VCI from Service de Biochimie et de Biologie Moléculaire, Hospices Civils de Lyon, Lyon, France; 2 affected relative is positive for the variant, reported in PMID 17196209 by Campagna et al, 2008, from University of Rome, Italy, and in PMID 22669020 by El Aziz et al, 2012, from Ibn Rochd University Hospital, Casablanca, Morocco.PS3 not met: Functional data is not available.PM5 not met: One other variant at same codon: NM_000527.5(LDLR):c.859G>A (p.Gly287Ser), ClinVar ID 161280, is classified as Uncertain significance by these guidelines, therefore PM5 is not met.PM3 not met: One case reported in VCI from Service de Biochimie et de Biologie Moléculaire, Hospices Civils de Lyon, Lyon, France. The subject is homozygous for the variant, however patient’s LDL-C is 5.32 mmol/l and no indication of lipid lowering medication. In PMID 22669020, two brothers of 21 and 18 years old are homozygous for the variant with untreated LDL-C at 12.8 mmol/l and 10.1 mmol/l respectively, which are just below 13 mmol/l threshold for HoFH phenotype. Additionally, one of 2 brothers (21 yrs with LDL-C 12.8 mmol/l) also had Type 1 diabetes.		Familial Hypercholesterolemia VCEP	https://clinicalgenome.org/docs/clingen-familial-hypercholesterolemia-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1-2/	2023-03-24	2023-04-01	False	https://erepo.genome.network/evrepo/ui/classification/CA10585162/MONDO:0007750/013	a146f460-92d1-4395-9894-8c05b643abb6	p.Gly287Cys	Gly	287	Cys	MGPWGWKLRWTVALLLAAAGTAVGDRCERNEFQCQDGKCISYKWVCDGSAECQDGSDESQETCLSVTCKSGDFSCGGRVNRCIPQFWRCDGQVDCDNGSDEQGCPPKTCSQDEFRCHDGKCISRQFVCDSDRDCLDGSDEASCPVLTCGPASFQCNSSTCIPQLWACDNDPDCEDGSDEWPQRCRGLYVFQGDSSPCSAFEFHCLSGECIHSSWRCDGGPDCKDKSDEENCAVATCRPDEFQCSDGNCIHGSRQCDREYDCKDMSDEVGCVNVTLCEGPNKFKCHSGECITLDKVCNMARDCRDWSDEPIKECGTNECLDNNGGCSHVCNDLKIGYECLCPDGFQLVAQRRCEDIDECQDPDTCSQLCVNLEGGYKCQCEEGFQLDPHTKACKAVGSIAYLFFTNRHEVRKMTLDRSEYTSLIPNLRNVVALDTEVASNRIYWSDLSQRMICSTQLDRAHGVSSYDTVISRDIQAPDGLAVDWIHSNIYWTDSVLGTVSVADTKGVKRKTLFRENGSKPRAIVVDPVHGFMYWTDWGTPAKIKKGGLNGVDIYSLVTENIQWPNGITLDLLSGRLYWVDSKLHSISSIDVNGGNRKTILEDEKRLAHPFSLAVFEDKVFWTDIINEAIFSANRLTGSDVNLLAENLLSPEDMVLFHNLTQPRGVNWCERTTLSNGGCQYLCLPAPQINPHSPKFTCACPDGMLLARDMRSCLTEAEAAVATQETSTVRLKVSSTAVRTQHTTTRPVPDTSRLPGATPGLTTVEIVTMSHQALGDVAGRGNEKKPSSVRALSIVLPIVLLVFLCLGVFLLWKNWRLKNINSINFDNPVYQKTTEDEVHICHNQDGYSYPSRQMVSLEDDVA	860	P01130	C	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [286], 'DISULFID_gain_score': array([0.7704761]), 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [368], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.0119406]), 'HELIX_loss': [291], 'HELIX_gain': [357], 'HELIX_gain_score': array([0.02043629]), 'HELIX_loss_score': array([-0.11508346]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [24, 271, 272, 274, 275, 276, 277, 278, 279, 280], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.01582885, -0.42278337, -0.33699125, -0.47593856, -0.49257529,
       -0.44892961, -0.5470944 , -0.6496492 , -0.72111613, -0.64153332]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [74, 100, 110, 168, 181, 228, 232, 233, 237, 261, 266, 280, 281, 282, 283], 'ZN_FING_gain': [295], 'ZN_FING_gain_score': array([0.01021671]), 'ZN_FING_loss_score': array([-0.0042432 , -0.0091629 , -0.01101875, -0.01111281, -0.01793879,
       -0.02930355, -0.01867592, -0.02304494, -0.03704184, -0.01853424,
       -0.04241848, -0.17877316, -0.16161424, -0.08957797, -0.12570107])}"
525	NM_024675.4(PALB2):c.2014G>C (p.Glu672Gln)	126630	CA151230	NM_024675.4:c.2014G>C, NC_000016.10:g.23630140C>G, CM000678.2:g.23630140C>G, NC_000016.9:g.23641461C>G, CM000678.1:g.23641461C>G, NC_000016.8:g.23548962C>G, NG_007406.1:g.16218G>C, LRG_308:g.16218G>C, ENST00000261584.9:c.2014G>C, ENST00000261584.8:c.2014G>C, ENST00000565038.1:n.87-865G>C, ENST00000568219.5:c.1129G>C, NM_024675.3:c.2014G>C, LRG_308t1:c.2014G>C, XM_011545946.1:c.2020G>C, XM_011545947.1:c.2020G>C, XM_011545948.1:c.1129G>C, XR_950851.1:n.2810G>C, XM_011545946.2:c.2020G>C, XM_011545947.2:c.2020G>C, XM_011545948.2:c.1129G>C, XM_017023671.1:c.2020G>C, XM_017023672.2:c.2014G>C, XM_017023673.2:c.2014G>C, NM_024675.4(PALB2):c.2014G>C (p.Glu672Gln)	PALB2	hereditary breast cancer	MONDO:0016419	Autosomal dominant inheritance	Benign	BA1, BP1	PM2, BS1, BS3, PP3, BP4	The c.2014G>C variant in PALB2 is a missense variant predicted to cause a substitution of a glutamic acid by glutamine at amino acid 672 (p.Glu672Gln). This variant has a gnomAD v2.1.1 filtering allele frequency of 0.02846 in non-Finnish European population, which is higher than the HBOP VCEP threshold (>0.001) for BA1, and therefore meets this criterion. This variant is functional in multiple protein assays (PMID: 31636395, PMID: 31757951, PMID: 33964450); however, due to a lack of known positive missense controls with known clinical impact, these assays do not meet the requirements for use by the HBOP VCEP. PALB2, in which the variant was identified, is defined by the HBOP VCEP as a gene for which primarily truncating variants are known to cause disease. In summary, this variant meets the criteria to be classified as benign for autosomal dominant hereditary breast and pancreatic cancer and autosomal recessive FANCN based on the ACMG/AMP criteria applied as specified by the HBOP VCEP. (BA1, BP1)	33964450, 31636395, 31757951	Hereditary Breast, Ovarian and Pancreatic Cancer VCEP		2023-04-05	2023-04-07	False	https://erepo.genome.network/evrepo/ui/classification/CA151230/MONDO:0016419/020	033fe989-5072-4c44-957b-9bd48b02178f	p.Glu672Gln	Glu	672	Gln	MDEPPGKPLSCEEKEKLKEKLAFLKREYSKTLARLQRAQRAEKIKHSIKKTVEEQDCLSQQDLSPQLKHSEPKNKICVYDKLHIKTHLDEETGEKTSITLDVGPESFNPGDGPGGLPIQRTDDTQEHFPHRVSDPSGEQKQKLPSRRKKQQKRTFISQERDCVFGTDSLRLSGKRLKEQEEISSKNPARSPVTEIRTHLLSLKSELPDSPEPVTEINEDSVLIPPTAQPEKGVDTFLRRPNFTRATTVPLQTLSDSGSSQHLEHIPPKGSSELTTHDLKNIRFTSPVSLEAQGKKMTVSTDNLLVNKAISKSGQLPTSSNLEANISCSLNELTYNNLPANENQNLKEQNQTEKSLKSPSDTLDGRNENLQESEILSQPKSLSLEATSPLSAEKHSCTVPEGLLFPAEYYVRTTRSMSNCQRKVAVEAVIQSHLDVKKKGFKNKNKDASKNLNLSNEETDQSEIRMSGTCTGQPSSRTSQKLLSLTKVSSPAGPTEDNDLSRKAVAQAPGRRYTGKRKSACTPASDHCEPLLPTSSLSIVNRSKEEVTSHKYQHEKLFIQVKGKKSRHQKEDSLSWSNSAYLSLDDDAFTAPFHRDGMLSLKQLLSFLSITDFQLPDEDFGPLKLEKVKSCSEKPVEPFESKMFGERHLKEGSCIFPEELSPKRMDTEMEDLEEDLIVLPGKSHPKRPNSQSQHTKTGLSSSILLYTPLNTVAPDDNDRPTTDMCSPAFPILGTTPAFGPQGSYEKASTEVAGRTCCTPQLAHLKDSVCLASDTKQFDSSGSPAKPHTTLQVSGRQGQPTCDCDSVPPGTPPPIESFTFKENQLCRNTCQELHKHSVEQTETAELPASDSINPGNLQLVSELKNPSGSCSVDVSAMFWERAGCKEPCIITACEDVVSLWKALDAWQWEKLYTWHFAEVPVLQIVPVPDVYNLVCVALGNLEIREIRALFCSSDDESEKQVLLKSGNIKAVLGLTKRRLVSSSGTLSDQQVEVMTFAEDGGGKENQFLMPPEETILTFAEVQGMQEALLGTTIMNNIVIWNLKTGQLLKKMHIDDSYQASVCHKAYSEMGLLFIVLSHPCAKESESLRSPVFQLIVINPKTTLSVGVMLYCLPPGQAGRFLEGDVKDHCAAAILTSGTIAIWDLLLGQCTALLPPVSDQHWSFVKWSGTDSHLLAGQKDGNIFVYHYS	1186	Q86YC2	Q	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
526	NM_024675.3(PALB2):c.3249G>C (p.Glu1083Asp)	126726	CA288472	NM_024675.3:c.3249G>C, NC_000016.10:g.23607965C>G, CM000678.2:g.23607965C>G, NC_000016.9:g.23619286C>G, CM000678.1:g.23619286C>G, NC_000016.8:g.23526787C>G, NG_007406.1:g.38393G>C, LRG_308:g.38393G>C, ENST00000261584.9:c.3249G>C, ENST00000261584.8:c.3249G>C, ENST00000566069.5:n.117-4296G>C, ENST00000568219.5:c.2364G>C, LRG_308t1:c.3249G>C, XM_011545946.1:c.3255G>C, XM_011545947.1:c.3208-4296G>C, XM_011545948.1:c.2364G>C, XR_950851.1:n.3957G>C, XM_011545946.2:c.3255G>C, XM_011545947.2:c.3208-4296G>C, XM_011545948.2:c.2364G>C, XM_017023671.1:c.3120-4296G>C, XM_017023672.2:c.3114-4296G>C, XM_017023673.2:c.3202-4296G>C, NM_024675.4:c.3249G>C, NM_024675.4(PALB2):c.3249G>C (p.Glu1083Asp), NM_024675.3(PALB2):c.3249G>C (p.Glu1083Asp)	PALB2	hereditary breast cancer	MONDO:0016419	Autosomal dominant inheritance	Benign	BA1	PM2, BS1, BS3, PP3, BS2, BP4	The c.3249G>C (p.Glu1083Asp) variant in PALB2 is a missense variant predicted to cause substitution of glutamic acid by aspartic acid at amino acid 1083 (p.Glu1083Asp). This variant has a gnomAD v2.1.1 filtering allele frequency of 0.001331 in the Latino/Admixed American population, which is higher than the HBOP VCEP threshold (>0.001) for BA1, and therefore meets this criterion. This variant is functional in multiple protein assays; however, due to a lack of positive missense controls with known clinical impact, these assays do not meet the requirements for use by the HBOP VCEP (PMID: 31636395).  PALB2, in which the variant was identified, is defined by the HBOP VCEP as a gene for which primarily truncating variants are known to cause disease. In summary, this variant meets the criteria to be classified as benign for autosomal dominant hereditary breast and pancreatic cancer and autosomal recessive FANCN based on the ACMG/AMP criteria applied as specified by the HBOP VCEP. (BA1, BP1)		Hereditary Breast, Ovarian and Pancreatic Cancer VCEP		2023-04-05	2023-04-07	False	https://erepo.genome.network/evrepo/ui/classification/CA288472/MONDO:0016419/020	27b045d7-68a2-4cb4-b7f9-e2837a29e462	p.Glu1083Asp	Glu	1083	Asp	MDEPPGKPLSCEEKEKLKEKLAFLKREYSKTLARLQRAQRAEKIKHSIKKTVEEQDCLSQQDLSPQLKHSEPKNKICVYDKLHIKTHLDEETGEKTSITLDVGPESFNPGDGPGGLPIQRTDDTQEHFPHRVSDPSGEQKQKLPSRRKKQQKRTFISQERDCVFGTDSLRLSGKRLKEQEEISSKNPARSPVTEIRTHLLSLKSELPDSPEPVTEINEDSVLIPPTAQPEKGVDTFLRRPNFTRATTVPLQTLSDSGSSQHLEHIPPKGSSELTTHDLKNIRFTSPVSLEAQGKKMTVSTDNLLVNKAISKSGQLPTSSNLEANISCSLNELTYNNLPANENQNLKEQNQTEKSLKSPSDTLDGRNENLQESEILSQPKSLSLEATSPLSAEKHSCTVPEGLLFPAEYYVRTTRSMSNCQRKVAVEAVIQSHLDVKKKGFKNKNKDASKNLNLSNEETDQSEIRMSGTCTGQPSSRTSQKLLSLTKVSSPAGPTEDNDLSRKAVAQAPGRRYTGKRKSACTPASDHCEPLLPTSSLSIVNRSKEEVTSHKYQHEKLFIQVKGKKSRHQKEDSLSWSNSAYLSLDDDAFTAPFHRDGMLSLKQLLSFLSITDFQLPDEDFGPLKLEKVKSCSEKPVEPFESKMFGERHLKEGSCIFPEELSPKRMDTEMEDLEEDLIVLPGKSHPKRPNSQSQHTKTGLSSSILLYTPLNTVAPDDNDRPTTDMCSPAFPILGTTPAFGPQGSYEKASTEVAGRTCCTPQLAHLKDSVCLASDTKQFDSSGSPAKPHTTLQVSGRQGQPTCDCDSVPPGTPPPIESFTFKENQLCRNTCQELHKHSVEQTETAELPASDSINPGNLQLVSELKNPSGSCSVDVSAMFWERAGCKEPCIITACEDVVSLWKALDAWQWEKLYTWHFAEVPVLQIVPVPDVYNLVCVALGNLEIREIRALFCSSDDESEKQVLLKSGNIKAVLGLTKRRLVSSSGTLSDQQVEVMTFAEDGGGKENQFLMPPEETILTFAEVQGMQEALLGTTIMNNIVIWNLKTGQLLKKMHIDDSYQASVCHKAYSEMGLLFIVLSHPCAKESESLRSPVFQLIVINPKTTLSVGVMLYCLPPGQAGRFLEGDVKDHCAAAILTSGTIAIWDLLLGQCTALLPPVSDQHWSFVKWSGTDSHLLAGQKDGNIFVYHYS	1186	Q86YC2	D	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [1103, 1116, 1123], 'REPEAT_gain_score': array([0.00582814, 0.00609684, 0.0065819 ]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
527	NM_024675.4(PALB2):c.3350G>A (p.Arg1117Lys)	232594	CA10579920	NM_024675.4:c.3350G>A, NC_000016.10:g.23607864C>T, CM000678.2:g.23607864C>T, NC_000016.9:g.23619185C>T, CM000678.1:g.23619185C>T, NC_000016.8:g.23526686C>T, NG_007406.1:g.38494G>A, LRG_308:g.38494G>A, ENST00000261584.9:c.3350G>A, ENST00000261584.8:c.3350G>A, ENST00000566069.5:n.117-4195G>A, ENST00000568219.5:c.2465G>A, NM_024675.3:c.3350G>A, LRG_308t1:c.3350G>A, XM_011545946.1:c.3356G>A, XM_011545947.1:c.3208-4195G>A, XM_011545948.1:c.2465G>A, XR_950851.1:n.4058G>A, XM_011545946.2:c.3356G>A, XM_011545947.2:c.3208-4195G>A, XM_011545948.2:c.2465G>A, XM_017023671.1:c.3120-4195G>A, XM_017023672.2:c.3114-4195G>A, XM_017023673.2:c.3202-4195G>A, NM_024675.4(PALB2):c.3350G>A (p.Arg1117Lys)	PALB2	hereditary breast cancer	MONDO:0016419	Autosomal dominant inheritance	Pathogenic	PM5_Supporting, PVS1, PM2_Supporting	BS1, PP3, BS2, BA1, BP4	The c.3350G>A variant in PALB2 is a missense variant predicted to cause substitution of arginine by lysine at amino acid 1117 (p.Arg1117Lys); however, RNA analysis demonstrated that the variant impacts splicing, leading to exon 12 skipping (r.3202_3350del149, p.Gly1068ValfsTer5) and a translational frameshift with 100% allele bias and no wild-type splice events harboring the variant (Ambry Genetics). The resulting mRNA is not predicted to undergo nonsense-mediated decay, but impacts the WD40 domain, which is a functionally important region. This variant is absent from gnomAD v2.1.1. This alteration results in a termination codon upstream of the most C-terminus pathogenic alteration (PALB2 p.Tyr1183*), as classified by the HBOP VCEP, and is expected to be more deleterious. This variant has been observed in combination with a PALB2 exon 11 duplication, which is classified as pathogenic, in at least four adult individuals without Fanconi Anemia (Ambry Genetics and Invitae). Although the phase of the variants was not confirmed, evidence from these individuals was not used to apply BS2 on the basis that multiple co-occurrences of this variant with the exon 11 duplication in unrelated individuals suggests these variants are more likely to be in cis. In summary, this variant meets the criteria to be classified as pathogenic for autosomal dominant hereditary breast and pancreatic cancer and autosomal recessive FANCN based on the ACMG/AMP criteria applied as specified by the HBOP VCEP. (PVS1(RNA), PM2_Supporting, PM5_Supporting)		Hereditary Breast, Ovarian and Pancreatic Cancer VCEP		2023-04-05	2023-04-07	False	https://erepo.genome.network/evrepo/ui/classification/CA10579920/MONDO:0016419/020	0c9dcd4f-ddc9-466a-8f90-103c078d7193	p.Arg1117Lys	Arg	1117	Lys	MDEPPGKPLSCEEKEKLKEKLAFLKREYSKTLARLQRAQRAEKIKHSIKKTVEEQDCLSQQDLSPQLKHSEPKNKICVYDKLHIKTHLDEETGEKTSITLDVGPESFNPGDGPGGLPIQRTDDTQEHFPHRVSDPSGEQKQKLPSRRKKQQKRTFISQERDCVFGTDSLRLSGKRLKEQEEISSKNPARSPVTEIRTHLLSLKSELPDSPEPVTEINEDSVLIPPTAQPEKGVDTFLRRPNFTRATTVPLQTLSDSGSSQHLEHIPPKGSSELTTHDLKNIRFTSPVSLEAQGKKMTVSTDNLLVNKAISKSGQLPTSSNLEANISCSLNELTYNNLPANENQNLKEQNQTEKSLKSPSDTLDGRNENLQESEILSQPKSLSLEATSPLSAEKHSCTVPEGLLFPAEYYVRTTRSMSNCQRKVAVEAVIQSHLDVKKKGFKNKNKDASKNLNLSNEETDQSEIRMSGTCTGQPSSRTSQKLLSLTKVSSPAGPTEDNDLSRKAVAQAPGRRYTGKRKSACTPASDHCEPLLPTSSLSIVNRSKEEVTSHKYQHEKLFIQVKGKKSRHQKEDSLSWSNSAYLSLDDDAFTAPFHRDGMLSLKQLLSFLSITDFQLPDEDFGPLKLEKVKSCSEKPVEPFESKMFGERHLKEGSCIFPEELSPKRMDTEMEDLEEDLIVLPGKSHPKRPNSQSQHTKTGLSSSILLYTPLNTVAPDDNDRPTTDMCSPAFPILGTTPAFGPQGSYEKASTEVAGRTCCTPQLAHLKDSVCLASDTKQFDSSGSPAKPHTTLQVSGRQGQPTCDCDSVPPGTPPPIESFTFKENQLCRNTCQELHKHSVEQTETAELPASDSINPGNLQLVSELKNPSGSCSVDVSAMFWERAGCKEPCIITACEDVVSLWKALDAWQWEKLYTWHFAEVPVLQIVPVPDVYNLVCVALGNLEIREIRALFCSSDDESEKQVLLKSGNIKAVLGLTKRRLVSSSGTLSDQQVEVMTFAEDGGGKENQFLMPPEETILTFAEVQGMQEALLGTTIMNNIVIWNLKTGQLLKKMHIDDSYQASVCHKAYSEMGLLFIVLSHPCAKESESLRSPVFQLIVINPKTTLSVGVMLYCLPPGQAGRFLEGDVKDHCAAAILTSGTIAIWDLLLGQCTALLPPVSDQHWSFVKWSGTDSHLLAGQKDGNIFVYHYS	1186	Q86YC2	K	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [1060], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.00344872]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [1117, 1119], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.02516216, -0.03848422]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
528	NM_024675.3(PALB2):c.2027T>C (p.Ile676Thr)	142310	CA294362	NM_024675.3:c.2027T>C, NC_000016.10:g.23630127A>G, CM000678.2:g.23630127A>G, NC_000016.9:g.23641448A>G, CM000678.1:g.23641448A>G, NC_000016.8:g.23548949A>G, NG_007406.1:g.16231T>C, LRG_308:g.16231T>C, ENST00000261584.9:c.2027T>C, ENST00000261584.8:c.2027T>C, ENST00000565038.1:n.87-852T>C, ENST00000568219.5:c.1142T>C, LRG_308t1:c.2027T>C, XM_011545946.1:c.2033T>C, XM_011545947.1:c.2033T>C, XM_011545948.1:c.1142T>C, XR_950851.1:n.2823T>C, XM_011545946.2:c.2033T>C, XM_011545947.2:c.2033T>C, XM_011545948.2:c.1142T>C, XM_017023671.1:c.2033T>C, XM_017023672.2:c.2027T>C, XM_017023673.2:c.2027T>C, NM_024675.4:c.2027T>C, NM_024675.4(PALB2):c.2027T>C (p.Ile676Thr), NM_024675.3(PALB2):c.2027T>C (p.Ile676Thr)	PALB2	hereditary breast cancer	MONDO:0016419	Autosomal dominant inheritance	Benign	BS2, BA1, BP1	PM3, PM2, BS3, PP3, BP4	The c.2027T>C variant in PALB2 is a missense variant predicted to cause a substitution of isoleucine by threonine at amino acid 676 (p.Ile676Thr). This variant has been observed in the homozygous state in multiple individuals without Fanconi Anemia (Ambry Genetics). This variant has a gnomAD v.2.1.1 filtering allele frequency of 0.005 in the Latino/Admixed American population, which is higher than the HBOP VCEP threshold (>0.001) for BA1, and therefore meets this criterion. This variant is functional in a protein assay (PMID 33964450); however due to a lack of positive missense controls with known clinical impact, these protein assays do not meet the requirements for use by the HBOP VCEP. PALB2, in which the variant was identified, is defined by the HBOP VCEP as a gene for which primarily truncating variants are known to cause disease. In summary, this variant meets the criteria to be classified as benign for autosomal dominant hereditary breast and pancreatic cancer and autosomal recessive FANCN based on the ACMG/AMP criteria applied, as specified by the HBOP VCEP. (BA1, BS2, BP1)	33964450	Hereditary Breast, Ovarian and Pancreatic Cancer VCEP		2023-04-05	2023-04-07	False	https://erepo.genome.network/evrepo/ui/classification/CA294362/MONDO:0016419/020	09e52437-a25c-47bf-bb56-3a3aeed7872d	p.Ile676Thr	Ile	676	Thr	MDEPPGKPLSCEEKEKLKEKLAFLKREYSKTLARLQRAQRAEKIKHSIKKTVEEQDCLSQQDLSPQLKHSEPKNKICVYDKLHIKTHLDEETGEKTSITLDVGPESFNPGDGPGGLPIQRTDDTQEHFPHRVSDPSGEQKQKLPSRRKKQQKRTFISQERDCVFGTDSLRLSGKRLKEQEEISSKNPARSPVTEIRTHLLSLKSELPDSPEPVTEINEDSVLIPPTAQPEKGVDTFLRRPNFTRATTVPLQTLSDSGSSQHLEHIPPKGSSELTTHDLKNIRFTSPVSLEAQGKKMTVSTDNLLVNKAISKSGQLPTSSNLEANISCSLNELTYNNLPANENQNLKEQNQTEKSLKSPSDTLDGRNENLQESEILSQPKSLSLEATSPLSAEKHSCTVPEGLLFPAEYYVRTTRSMSNCQRKVAVEAVIQSHLDVKKKGFKNKNKDASKNLNLSNEETDQSEIRMSGTCTGQPSSRTSQKLLSLTKVSSPAGPTEDNDLSRKAVAQAPGRRYTGKRKSACTPASDHCEPLLPTSSLSIVNRSKEEVTSHKYQHEKLFIQVKGKKSRHQKEDSLSWSNSAYLSLDDDAFTAPFHRDGMLSLKQLLSFLSITDFQLPDEDFGPLKLEKVKSCSEKPVEPFESKMFGERHLKEGSCIFPEELSPKRMDTEMEDLEEDLIVLPGKSHPKRPNSQSQHTKTGLSSSILLYTPLNTVAPDDNDRPTTDMCSPAFPILGTTPAFGPQGSYEKASTEVAGRTCCTPQLAHLKDSVCLASDTKQFDSSGSPAKPHTTLQVSGRQGQPTCDCDSVPPGTPPPIESFTFKENQLCRNTCQELHKHSVEQTETAELPASDSINPGNLQLVSELKNPSGSCSVDVSAMFWERAGCKEPCIITACEDVVSLWKALDAWQWEKLYTWHFAEVPVLQIVPVPDVYNLVCVALGNLEIREIRALFCSSDDESEKQVLLKSGNIKAVLGLTKRRLVSSSGTLSDQQVEVMTFAEDGGGKENQFLMPPEETILTFAEVQGMQEALLGTTIMNNIVIWNLKTGQLLKKMHIDDSYQASVCHKAYSEMGLLFIVLSHPCAKESESLRSPVFQLIVINPKTTLSVGVMLYCLPPGQAGRFLEGDVKDHCAAAILTSGTIAIWDLLLGQCTALLPPVSDQHWSFVKWSGTDSHLLAGQKDGNIFVYHYS	1186	Q86YC2	T	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [1060], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.00310689]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [451], 'COMPBIAS_gain_score': array([0.00684249]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [671, 672, 673, 674, 675, 676, 697], 'REGION_gain_score': array([0.48489368, 0.51778555, 0.54389614, 0.64921689, 0.61832625,
       0.5410037 , 0.21762121]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
529	NM_024675.3(PALB2):c.3054G>C (p.Glu1018Asp)	126708	CA294183	NM_024675.3:c.3054G>C, NC_000016.10:g.23621421C>G, CM000678.2:g.23621421C>G, NC_000016.9:g.23632742C>G, CM000678.1:g.23632742C>G, NC_000016.8:g.23540243C>G, NG_007406.1:g.24937G>C, LRG_308:g.24937G>C, ENST00000261584.9:c.3054G>C, ENST00000261584.8:c.3054G>C, ENST00000568219.5:c.2169G>C, LRG_308t1:c.3054G>C, XM_011545946.1:c.3060G>C, XM_011545947.1:c.3060G>C, XM_011545948.1:c.2169G>C, XR_950851.1:n.3850G>C, XM_011545946.2:c.3060G>C, XM_011545947.2:c.3060G>C, XM_011545948.2:c.2169G>C, XM_017023671.1:c.3060G>C, XM_017023672.2:c.3054G>C, XM_017023673.2:c.3054G>C, NM_024675.4:c.3054G>C, NM_024675.4(PALB2):c.3054G>C (p.Glu1018Asp), NM_024675.3(PALB2):c.3054G>C (p.Glu1018Asp)	PALB2	hereditary breast cancer	MONDO:0016419	Autosomal dominant inheritance	Benign	BS2, BA1, BP1	BS3, BP4	The c.3054G>C variant in PALB2 is a missense variant predicted to cause substitution of glutamate by aspartate at amino acid 1018 (p.Glu1018Asp). The filtering allele frequency in gnomAD v2.1.1 is 0.004 in the East Asian population, which is higher than the ClinGen HBOP threshold (>0.001) for BA1, and therefore meets this criterion. This variant has been observed in a homozygous state and phase unknown with numerous other PALB2 variants that are tentatively classified as likely pathogenic or pathogenic by the HBOP VCEP in individuals without Fanconi Anemia (GeneDx, Ambry Genetics, Invitae). This variant is functional in multiple different protein assays (PMID 31757951); however due to a lack of positive missense controls with known clinical impact, these protein assays do not meet the requirements for use by the HBOP VCEP. PALB2, in which the variant was identified, is defined by the HBOP VCEP as a gene for which primarily truncating variants are known to cause disease. In summary, this variant meets the criteria to be classified as benign for autosomal dominant hereditary breast and pancreatic cancer and autosomal recessive FANCN based on the ACMG/AMP criteria applied, as specified by the HBOP VCEP. (BA1, BP2_Moderate, BP1)		Hereditary Breast, Ovarian and Pancreatic Cancer VCEP		2023-04-05	2023-04-07	False	https://erepo.genome.network/evrepo/ui/classification/CA294183/MONDO:0016419/020	b9dcdd59-819e-404b-8621-7ddc360ccb68	p.Glu1018Asp	Glu	1018	Asp	MDEPPGKPLSCEEKEKLKEKLAFLKREYSKTLARLQRAQRAEKIKHSIKKTVEEQDCLSQQDLSPQLKHSEPKNKICVYDKLHIKTHLDEETGEKTSITLDVGPESFNPGDGPGGLPIQRTDDTQEHFPHRVSDPSGEQKQKLPSRRKKQQKRTFISQERDCVFGTDSLRLSGKRLKEQEEISSKNPARSPVTEIRTHLLSLKSELPDSPEPVTEINEDSVLIPPTAQPEKGVDTFLRRPNFTRATTVPLQTLSDSGSSQHLEHIPPKGSSELTTHDLKNIRFTSPVSLEAQGKKMTVSTDNLLVNKAISKSGQLPTSSNLEANISCSLNELTYNNLPANENQNLKEQNQTEKSLKSPSDTLDGRNENLQESEILSQPKSLSLEATSPLSAEKHSCTVPEGLLFPAEYYVRTTRSMSNCQRKVAVEAVIQSHLDVKKKGFKNKNKDASKNLNLSNEETDQSEIRMSGTCTGQPSSRTSQKLLSLTKVSSPAGPTEDNDLSRKAVAQAPGRRYTGKRKSACTPASDHCEPLLPTSSLSIVNRSKEEVTSHKYQHEKLFIQVKGKKSRHQKEDSLSWSNSAYLSLDDDAFTAPFHRDGMLSLKQLLSFLSITDFQLPDEDFGPLKLEKVKSCSEKPVEPFESKMFGERHLKEGSCIFPEELSPKRMDTEMEDLEEDLIVLPGKSHPKRPNSQSQHTKTGLSSSILLYTPLNTVAPDDNDRPTTDMCSPAFPILGTTPAFGPQGSYEKASTEVAGRTCCTPQLAHLKDSVCLASDTKQFDSSGSPAKPHTTLQVSGRQGQPTCDCDSVPPGTPPPIESFTFKENQLCRNTCQELHKHSVEQTETAELPASDSINPGNLQLVSELKNPSGSCSVDVSAMFWERAGCKEPCIITACEDVVSLWKALDAWQWEKLYTWHFAEVPVLQIVPVPDVYNLVCVALGNLEIREIRALFCSSDDESEKQVLLKSGNIKAVLGLTKRRLVSSSGTLSDQQVEVMTFAEDGGGKENQFLMPPEETILTFAEVQGMQEALLGTTIMNNIVIWNLKTGQLLKKMHIDDSYQASVCHKAYSEMGLLFIVLSHPCAKESESLRSPVFQLIVINPKTTLSVGVMLYCLPPGQAGRFLEGDVKDHCAAAILTSGTIAIWDLLLGQCTALLPPVSDQHWSFVKWSGTDSHLLAGQKDGNIFVYHYS	1186	Q86YC2	D	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [1023, 1029, 1038], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.10559756, -0.14233905, -0.063214  ]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [1026, 1103, 1116, 1123], 'REPEAT_gain_score': array([0.00972295, 0.00716984, 0.00377786, 0.00512153]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
530	NM_024675.3(PALB2):c.721A>G (p.Asn241Asp)	126765	CA151529	NM_024675.3:c.721A>G, NC_000016.10:g.23635825T>C, CM000678.2:g.23635825T>C, NC_000016.9:g.23647146T>C, CM000678.1:g.23647146T>C, NC_000016.8:g.23554647T>C, NG_007406.1:g.10533A>G, LRG_308:g.10533A>G, ENST00000261584.9:c.721A>G, ENST00000261584.8:c.721A>G, ENST00000565038.1:n.86+2025A>G, ENST00000568219.5:c.-165A>G, LRG_308t1:c.721A>G, XM_011545946.1:c.727A>G, XM_011545947.1:c.727A>G, XM_011545948.1:c.-165A>G, XR_950851.1:n.1517A>G, XM_011545946.2:c.727A>G, XM_011545947.2:c.727A>G, XM_011545948.2:c.-165A>G, XM_017023671.1:c.727A>G, XM_017023672.2:c.721A>G, XM_017023673.2:c.721A>G, NM_024675.4:c.721A>G, NM_024675.4(PALB2):c.721A>G (p.Asn241Asp), NM_024675.3(PALB2):c.721A>G (p.Asn241Asp)	PALB2	hereditary breast cancer	MONDO:0016419	Autosomal dominant inheritance	Benign	BP2_Strong, BS2, BA1, BP1	PM2, BS1	The c.721A>G variant in PALB2 is a missense variant predicted to predicted to cause substitution of asparagine by aspartic acid at amino acid 241 (p.Asn241Asp). This variant has been observed in three homozygous individuals with no features of FANCN, a condition with full penetrance at an early age (Ambry Genetics). The highest population minor filtering allele frequency in gnomAD v2.1.1 is 0.005509 in the African population, which is higher than the HBOP VCEP threshold (>0.001) for BA1, and therefore meets this criterion. PALB2, in which the variant was identified, is defined by the HBOP VCEP as a gene for which primarily truncating variants are known to cause disease. In summary, this variant meets the criteria to be classified as benign for autosomal dominant hereditary breast and pancreatic cancer and autosomal recessive FANCN based on the ACMG/AMP criteria applied, as specified by the HBOP VCEP (BA1, BS2, BP1)		Hereditary Breast, Ovarian and Pancreatic Cancer VCEP		2023-04-05	2023-04-07	False	https://erepo.genome.network/evrepo/ui/classification/CA151529/MONDO:0016419/020	f1d80ff5-d93c-41ed-8272-b137d5131076	p.Asn241Asp	Asn	241	Asp	MDEPPGKPLSCEEKEKLKEKLAFLKREYSKTLARLQRAQRAEKIKHSIKKTVEEQDCLSQQDLSPQLKHSEPKNKICVYDKLHIKTHLDEETGEKTSITLDVGPESFNPGDGPGGLPIQRTDDTQEHFPHRVSDPSGEQKQKLPSRRKKQQKRTFISQERDCVFGTDSLRLSGKRLKEQEEISSKNPARSPVTEIRTHLLSLKSELPDSPEPVTEINEDSVLIPPTAQPEKGVDTFLRRPNFTRATTVPLQTLSDSGSSQHLEHIPPKGSSELTTHDLKNIRFTSPVSLEAQGKKMTVSTDNLLVNKAISKSGQLPTSSNLEANISCSLNELTYNNLPANENQNLKEQNQTEKSLKSPSDTLDGRNENLQESEILSQPKSLSLEATSPLSAEKHSCTVPEGLLFPAEYYVRTTRSMSNCQRKVAVEAVIQSHLDVKKKGFKNKNKDASKNLNLSNEETDQSEIRMSGTCTGQPSSRTSQKLLSLTKVSSPAGPTEDNDLSRKAVAQAPGRRYTGKRKSACTPASDHCEPLLPTSSLSIVNRSKEEVTSHKYQHEKLFIQVKGKKSRHQKEDSLSWSNSAYLSLDDDAFTAPFHRDGMLSLKQLLSFLSITDFQLPDEDFGPLKLEKVKSCSEKPVEPFESKMFGERHLKEGSCIFPEELSPKRMDTEMEDLEEDLIVLPGKSHPKRPNSQSQHTKTGLSSSILLYTPLNTVAPDDNDRPTTDMCSPAFPILGTTPAFGPQGSYEKASTEVAGRTCCTPQLAHLKDSVCLASDTKQFDSSGSPAKPHTTLQVSGRQGQPTCDCDSVPPGTPPPIESFTFKENQLCRNTCQELHKHSVEQTETAELPASDSINPGNLQLVSELKNPSGSCSVDVSAMFWERAGCKEPCIITACEDVVSLWKALDAWQWEKLYTWHFAEVPVLQIVPVPDVYNLVCVALGNLEIREIRALFCSSDDESEKQVLLKSGNIKAVLGLTKRRLVSSSGTLSDQQVEVMTFAEDGGGKENQFLMPPEETILTFAEVQGMQEALLGTTIMNNIVIWNLKTGQLLKKMHIDDSYQASVCHKAYSEMGLLFIVLSHPCAKESESLRSPVFQLIVINPKTTLSVGVMLYCLPPGQAGRFLEGDVKDHCAAAILTSGTIAIWDLLLGQCTALLPPVSDQHWSFVKWSGTDSHLLAGQKDGNIFVYHYS	1186	Q86YC2	D	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [1060], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.00147021]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [451], 'COMPBIAS_gain_score': array([0.00349867]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [254], 'REGION_gain_score': array([0.01323646]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
531	NM_000527.5(LDLR):c.1729T>G (p.Trp577Gly)	252000	CA10585585	NM_000527.5:c.1729T>G, NC_000019.10:g.11116882T>G, CM000681.2:g.11116882T>G, NC_000019.9:g.11227558T>G, CM000681.1:g.11227558T>G, NC_000019.8:g.11088558T>G, NG_009060.1:g.32502T>G, LRG_274:g.32502T>G, ENST00000558518.6:c.1729T>G, ENST00000252444.9:n.1983T>G, ENST00000455727.6:c.1225T>G, ENST00000535915.5:c.1606T>G, ENST00000545707.5:c.1348T>G, ENST00000557933.5:c.1729T>G, ENST00000558013.5:c.1729T>G, ENST00000558518.5:c.1729T>G, ENST00000559340.1:n.426+670T>G, NM_000527.4:c.1729T>G, LRG_274t1:c.1729T>G, NM_001195798.1:c.1729T>G, NM_001195799.1:c.1606T>G, NM_001195800.1:c.1225T>G, NM_001195803.1:c.1348T>G, XM_011528010.1:c.1729T>G, XM_011528011.1:c.1348T>G, XR_244074.2:n.1855+670T>G, XM_011528010.2:c.1729T>G, XR_001753685.2:n.1846T>G, XR_001753686.2:n.1822+670T>G, NM_001195798.2:c.1729T>G, NM_001195799.2:c.1606T>G, NM_001195800.2:c.1225T>G, NM_001195803.2:c.1348T>G, NM_000527.5(LDLR):c.1729T>G (p.Trp577Gly)	LDLR	hypercholesterolemia, familial	MONDO:0007750	Semidominant inheritance	Pathogenic	PS3, PP1_Moderate, PM2, PP3, PP4, PS4_Supporting		The NM_000527.5(LDLR):c.1729T>G (p.Trp577Gly) variant is classified as Pathogenic for Familial Hypercholesterolemia by applying evidence codes PS3, PP1_moderate, PM2, PP3, PS4_supporting, PP4, as defined by the ClinGen Familial Hypercholesterolemia Expert Panel LDLR-specific variant curation guidelines (https://doi.org/10.1016/j.gim.2021.09.012). The supporting evidence is as follows: PS3:  Level 1 assays: PMID 25378237: Heterologous cells, FACS assays -10-15% LDL-LDLR binding; 5% LDL-LDLR uptake; 5% cell surface LDLR---- activity is below 70% of wild-type, so functional study is consistent with damaging effect.PP1_moderate: Variant segregates with FH phenotype in at least 4 informative meiosis from 1 family from Molecular Genetics Laboratory (Centre for Cardiovascular Surgery and Transplantation)PM2: This variant is absent from gnomAD (gnomAD v2.1.1).PP3: REVEL = 0.937.PS4_supporting: Variant meets PM2 and is identified in 2 index cases (1 case with DLCN criteria>=6 from Robarts Research Institute; 1 case with DLCN criteria>=6 from Molecular Genetics Laboratory (Centre for Cardiovascular Surgery and Transplantation))PP4: Variant meets PM2 and is identified in 2 index cases who fulfill clinical criteria for FH from several labs (see PS4 for details), after alternative causes of high cholesterol were excluded.		Familial Hypercholesterolemia VCEP	https://clinicalgenome.org/docs/clingen-familial-hypercholesterolemia-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1-2/	2023-04-28	2023-04-28	False	https://erepo.genome.network/evrepo/ui/classification/CA10585585/MONDO:0007750/013	adb0184f-0bcb-4ed0-a59a-783932dac98b	p.Trp577Gly	Trp	577	Gly	MGPWGWKLRWTVALLLAAAGTAVGDRCERNEFQCQDGKCISYKWVCDGSAECQDGSDESQETCLSVTCKSGDFSCGGRVNRCIPQFWRCDGQVDCDNGSDEQGCPPKTCSQDEFRCHDGKCISRQFVCDSDRDCLDGSDEASCPVLTCGPASFQCNSSTCIPQLWACDNDPDCEDGSDEWPQRCRGLYVFQGDSSPCSAFEFHCLSGECIHSSWRCDGGPDCKDKSDEENCAVATCRPDEFQCSDGNCIHGSRQCDREYDCKDMSDEVGCVNVTLCEGPNKFKCHSGECITLDKVCNMARDCRDWSDEPIKECGTNECLDNNGGCSHVCNDLKIGYECLCPDGFQLVAQRRCEDIDECQDPDTCSQLCVNLEGGYKCQCEEGFQLDPHTKACKAVGSIAYLFFTNRHEVRKMTLDRSEYTSLIPNLRNVVALDTEVASNRIYWSDLSQRMICSTQLDRAHGVSSYDTVISRDIQAPDGLAVDWIHSNIYWTDSVLGTVSVADTKGVKRKTLFRENGSKPRAIVVDPVHGFMYWTDWGTPAKIKKGGLNGVDIYSLVTENIQWPNGITLDLLSGRLYWVDSKLHSISSIDVNGGNRKTILEDEKRLAHPFSLAVFEDKVFWTDIINEAIFSANRLTGSDVNLLAENLLSPEDMVLFHNLTQPRGVNWCERTTLSNGGCQYLCLPAPQINPHSPKFTCACPDGMLLARDMRSCLTEAEAAVATQETSTVRLKVSSTAVRTQHTTTRPVPDTSRLPGATPGLTTVEIVTMSHQALGDVAGRGNEKKPSSVRALSIVLPIVLLVFLCLGVFLLWKNWRLKNINSINFDNPVYQKTTEDEVHICHNQDGYSYPSRQMVSLEDDVA	860	P01130	G	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [577], 'STRAND_gain_score': array([0.07450098]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [735], 'COMPBIAS_gain': [], 'COMPBIAS_loss_score': array([-0.01845676]), 'DOMAIN_loss': [24], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.00490385]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [661], 'REPEAT_gain_score': array([0.0270384]), 'ZN_FING_loss': [], 'ZN_FING_gain': [698], 'ZN_FING_gain_score': array([0.01318443])}
532	NM_000527.5(LDLR):c.1027G>A (p.Gly343Ser)	183106	CA023406	NM_000527.5:c.1027G>A, NC_000019.10:g.11110738G>A, CM000681.2:g.11110738G>A, NC_000019.9:g.11221414G>A, CM000681.1:g.11221414G>A, NC_000019.8:g.11082414G>A, NG_009060.1:g.26358G>A, LRG_274:g.26358G>A, ENST00000558518.6:c.1027G>A, ENST00000252444.9:n.1281G>A, ENST00000455727.6:c.523G>A, ENST00000535915.5:c.904G>A, ENST00000545707.5:c.646G>A, ENST00000557933.5:c.1027G>A, ENST00000558013.5:c.1027G>A, ENST00000558518.5:c.1027G>A, ENST00000560173.1:n.26G>A, ENST00000560467.1:n.541-776G>A, NM_000527.4:c.1027G>A, LRG_274t1:c.1027G>A, NM_001195798.1:c.1027G>A, NM_001195799.1:c.904G>A, NM_001195800.1:c.523G>A, NM_001195803.1:c.646G>A, XM_011528010.1:c.1027G>A, XM_011528011.1:c.646G>A, XR_244074.2:n.1177G>A, XM_011528010.2:c.1027G>A, XR_001753685.2:n.1144G>A, XR_001753686.2:n.1144G>A, NM_001195798.2:c.1027G>A, NM_001195799.2:c.904G>A, NM_001195800.2:c.523G>A, NM_001195803.2:c.646G>A, NM_000527.5(LDLR):c.1027G>A (p.Gly343Ser)	LDLR	hypercholesterolemia, familial	MONDO:0007750	Semidominant inheritance	Pathogenic	PS3, PS4, PP1_Strong, BS4, PM5, PM3, PM2, PP3, PP4		The NM_000527.5 (LDLR):c.1027G>A (p.Gly343Ser) variant is classified as Pathogenic (modified) for Familial Hypercholesterolemia by applying evidence codes (PM2, PP3, PS3, PP4, PS4, PP1_Strong, PM5, PM3, BS4) as defined by the ClinGen Familial Hypercholesterolemia Expert Panel LDLR-specific variant curation guidelines (https://doi.org/10.1016/j.gim.2021.09.012).The supporting evidence is as follows:PM2: PopMaxMAF=0.00005 in East Asian population from gnomAD (gnomAD v2.1.1).PP3: REVEL=0.929, it is above 0.75.PS3: Level 1 assays: PMID 15100232. Heterologous cells (CHO) were used in WB, FACS and NMR Spectroscopy. The experiments shown <60% cell surface LDLR expression (Fig 5C), and >80% expressed receptor bind and release LDL upon low pH condition (Fig 6B), the amount of LDL bound to the mutant receptor correlates tightly with cell-surface LDLR expression, NMR indicates misfolding defects of the receptor. Functional data is consistent with damaging effect. This study is reported by Boswell et al, 2004, from Department of Biochemistry, Division of Structural Biology, University of Oxford, UK. PP4: Variant meets PM2 and is identified in at least ˃1 index cases who fulfil criteria for FH after alternative causes of high cholesterol were excluded.PS4: Variant meets PM2 and is identified in at least 26 index cases reported in VCI and PubMed. There are 14 unrelated index case reported in VCI who fulfil criteria for FH diagnosis: Twelve cases fulfil DLCN criteria, 7 reported from Service de Biochimie et de Biologie Moléculaire, Hospices Civils de Lyon, Lyon, France, 1 from Cardiovascular Genetics Laboratory (PathWest Laboratory Medicine WA), 2 from Research Lab of Molecular Genetics of Lipid Metabolism; and 2 from Robarts Research Institute, Canada; two cases fulfil Simon Broome possible criteria, reported from Cardiovascular Research Group, Instituto Nacional de Saude Doutor Ricardo Jorge. Variant is reported in PubMed in at least 12 index cases fulfil criteria for FH diagnosis: 8 cases fulfil DLCN probable/definite FH criteria in PMID 11040093, 11810272, 32977124, 30270055, 27784735; 1 case fulfil Simon Broome possible FH criteria in PMID 26748104; 3 cases fulfil MedPed criteria in PMID 8882879, 27824480. PP1_Strong: Variant segregates with FH phenotype in 18 informative meiosis from 6 families reported from 4 different labs in VCI: 11 affected carries and 7 unaffected non-carriers reported from Cardiovascular Genetics Laboratory (PathWest Laboratory Medicine WA), Cardiovascular Research Group, Instituto Nacional de Saude Doutor Ricardo Jorge, Laboratory of Genetics and Molecular Cardiology, and Research Lab of Molecular Genetics of Lipid Metabolism. PM5: Three other variants at the same codon: NM_000527.5(LDLR):c.1028G>T (p.Gly343Val)(ClinVarID 440618) classified as Likely Pathogenic, NM_000527.5(LDLR):c.1028G>A (p.Gly343Asp)(ClinVarID 251606) is classified as Likely Pathogenic,  NM_000527.5(LDLR):c.1027G>T (p.Gly343Cys)(ClinVarID 251605) is classified as Pathogenic, by these guidelines, therefore PM5 is met.PM3: Variant meets PM2 and is identified in an index case with homozygous FH phenotype (untreated LDL-C > 500mg/dL, or LDL-C > 300 mmol/dL on high-intensive lipid-lowering therapy and the presence of tendon xanthomas before 10 year of age), reported by Sanchez-Hernandez et al, 2016, Universitario Insular Materno Infantil de Gran Canaria, Spain, PMID 27784735. This variant met enough pathogenic criteria toward Pathogenic classification by these guidelines before PM3 code applied.BS4: Variant does not segregate with FH phenotype in total of 6 informative meiosis reported in VCI. Five affected relatives without the variant and had LDL-C>75th percentile, 2 cases from Cardiovascular Genetics Laboratory (PathWest Laboratory Medicine WA), 1 case each from Cardiovascular Research Group, Instituto Nacional de Saude Doutor Ricardo Jorge, Laboratory of Genetics and Molecular Cardiology, and Research Lab of Molecular Genetics of Lipid Metabolism. There is 1 instance reported from 1 laboratory, where an unaffected family member had LDL-C<50th percentile and carries the variant, reported in VCI from Laboratory of Genetics and Molecular Cardiology, GTR LabID 505581.Variant has 3 Strong, 3 Moderate and 2 Supporting evidence codes toward Pathogenic, enough to classify as Pathogenic, and only 1 Strong evidence code towards Benign. The Pathogenic criteria overwhelms the Benign criteria, so we are confident in classifying this variant as Pathogenic.		Familial Hypercholesterolemia VCEP	https://clinicalgenome.org/docs/clingen-familial-hypercholesterolemia-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1-2/	2023-04-28	2023-05-01	False	https://erepo.genome.network/evrepo/ui/classification/CA023406/MONDO:0007750/013	2fc03ee7-785f-44c9-bac0-10c93ad52227	p.Gly343Ser	Gly	343	Ser	MGPWGWKLRWTVALLLAAAGTAVGDRCERNEFQCQDGKCISYKWVCDGSAECQDGSDESQETCLSVTCKSGDFSCGGRVNRCIPQFWRCDGQVDCDNGSDEQGCPPKTCSQDEFRCHDGKCISRQFVCDSDRDCLDGSDEASCPVLTCGPASFQCNSSTCIPQLWACDNDPDCEDGSDEWPQRCRGLYVFQGDSSPCSAFEFHCLSGECIHSSWRCDGGPDCKDKSDEENCAVATCRPDEFQCSDGNCIHGSRQCDREYDCKDMSDEVGCVNVTLCEGPNKFKCHSGECITLDKVCNMARDCRDWSDEPIKECGTNECLDNNGGCSHVCNDLKIGYECLCPDGFQLVAQRRCEDIDECQDPDTCSQLCVNLEGGYKCQCEEGFQLDPHTKACKAVGSIAYLFFTNRHEVRKMTLDRSEYTSLIPNLRNVVALDTEVASNRIYWSDLSQRMICSTQLDRAHGVSSYDTVISRDIQAPDGLAVDWIHSNIYWTDSVLGTVSVADTKGVKRKTLFRENGSKPRAIVVDPVHGFMYWTDWGTPAKIKKGGLNGVDIYSLVTENIQWPNGITLDLLSGRLYWVDSKLHSISSIDVNGGNRKTILEDEKRLAHPFSLAVFEDKVFWTDIINEAIFSANRLTGSDVNLLAENLLSPEDMVLFHNLTQPRGVNWCERTTLSNGGCQYLCLPAPQINPHSPKFTCACPDGMLLARDMRSCLTEAEAAVATQETSTVRLKVSSTAVRTQHTTTRPVPDTSRLPGATPGLTTVEIVTMSHQALGDVAGRGNEKKPSSVRALSIVLPIVLLVFLCLGVFLLWKNWRLKNINSINFDNPVYQKTTEDEVHICHNQDGYSYPSRQMVSLEDDVA	860	P01130	S	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [344, 345], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.07244575, -0.02280027]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [354], 'ZN_FING_gain': [], 'ZN_FING_loss_score': array([-0.01906258])}
533	NM_000527.5(LDLR):c.1027G>T (p.Gly343Cys)	251605	CA10585257	NM_000527.5:c.1027G>T, NC_000019.10:g.11110738G>T, CM000681.2:g.11110738G>T, NC_000019.9:g.11221414G>T, CM000681.1:g.11221414G>T, NC_000019.8:g.11082414G>T, NG_009060.1:g.26358G>T, LRG_274:g.26358G>T, ENST00000558518.6:c.1027G>T, ENST00000252444.9:n.1281G>T, ENST00000455727.6:c.523G>T, ENST00000535915.5:c.904G>T, ENST00000545707.5:c.646G>T, ENST00000557933.5:c.1027G>T, ENST00000558013.5:c.1027G>T, ENST00000558518.5:c.1027G>T, ENST00000560173.1:n.26G>T, ENST00000560467.1:n.541-776G>T, NM_000527.4:c.1027G>T, LRG_274t1:c.1027G>T, NM_001195798.1:c.1027G>T, NM_001195799.1:c.904G>T, NM_001195800.1:c.523G>T, NM_001195803.1:c.646G>T, XM_011528010.1:c.1027G>T, XM_011528011.1:c.646G>T, XR_244074.2:n.1177G>T, XM_011528010.2:c.1027G>T, XR_001753685.2:n.1144G>T, XR_001753686.2:n.1144G>T, NM_001195798.2:c.1027G>T, NM_001195799.2:c.904G>T, NM_001195800.2:c.523G>T, NM_001195803.2:c.646G>T, NM_000527.5(LDLR):c.1027G>T (p.Gly343Cys)	LDLR	hypercholesterolemia, familial	MONDO:0007750	Semidominant inheritance	Pathogenic	PP1_Strong, PM5, PM3, PM2, PP3, PP4	PS3	The NM_000527.5 (LDLR):c.1027G>T (p.Gly343Cys) variant is classified as Pathogenic for Familial Hypercholesterolemia by applying evidence codes (PM2, PP3, PP4, PP1_Strong, PM5, PM3) as defined by the ClinGen Familial Hypercholesterolemia Expert Panel LDLR-specific variant curation guidelines (https://doi.org/10.1016/j.gim.2021.09.012).The supporting evidence is as follows:PM2: This variant is absent in gnomAD (gnomAD v2.1.1).PP3: REVEL=0.92, it is above 0.75.PP4: Variant meets PM2 and is identified in 1 index case who fulfil criteria for FH after alternative causes of high cholesterol were excluded. The patient had LDL-C level of 16.62 mmol/L with xanthomas and CHD, reported by Jelassi et al, 2009 and 2010, from Research Unit of Genetic and Biologic Factors of Atherosclerosis, Faculty of Medicine, Monastir, Tunisia, PMID 18757057 and 20144596. PP1_Strong: Variant segregates with FH phenotype in 6 informative meiosis from 1 family: 5 affected relatives were positive, 1 unaffected relative was negative for the variant, reported by Jelassi et al, PMID 18757057 and 20144596.PM5: Three other variants at the same codon: NM_000527.5(LDLR):c.1028G>T (p.Gly343Val)(ClinVarID 440618) classified as Likely Pathogenic, NM_000527.5(LDLR):c.1028G>A (p.Gly343Asp)(ClinVarID 251606) is classified as Likely Pathogenic, NM_000527.5(LDLR):c.1027G>A (p.Gly343Ser)(ClinVarID 183106) is classified as Pathogenic by these guidelines, therefore PM5 is met.PM3: Variant meets PM2 and is identified in an index case with homozygous FH phenotype with plasma LDL-C 16.62 mmol/L, reported by Jelassi et al, PMID 18757057. This variant met enough pathogenic criteria toward Pathogenic classification by these guidelines before PM3 code applied.PS4 not met: Variant meets PM2 and is reported in 1 index case fulfil FH criteria and with homozygous FH phenotype, by Jelassi et al, PMID 18757057 and 20144596.PS3 not met: Functional data is not available.		Familial Hypercholesterolemia VCEP	https://clinicalgenome.org/docs/clingen-familial-hypercholesterolemia-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1-2/	2023-04-28	2023-05-01	False	https://erepo.genome.network/evrepo/ui/classification/CA10585257/MONDO:0007750/013	e65fb077-97df-4afc-b5c3-c4ffbb0958de	p.Gly343Cys	Gly	343	Cys	MGPWGWKLRWTVALLLAAAGTAVGDRCERNEFQCQDGKCISYKWVCDGSAECQDGSDESQETCLSVTCKSGDFSCGGRVNRCIPQFWRCDGQVDCDNGSDEQGCPPKTCSQDEFRCHDGKCISRQFVCDSDRDCLDGSDEASCPVLTCGPASFQCNSSTCIPQLWACDNDPDCEDGSDEWPQRCRGLYVFQGDSSPCSAFEFHCLSGECIHSSWRCDGGPDCKDKSDEENCAVATCRPDEFQCSDGNCIHGSRQCDREYDCKDMSDEVGCVNVTLCEGPNKFKCHSGECITLDKVCNMARDCRDWSDEPIKECGTNECLDNNGGCSHVCNDLKIGYECLCPDGFQLVAQRRCEDIDECQDPDTCSQLCVNLEGGYKCQCEEGFQLDPHTKACKAVGSIAYLFFTNRHEVRKMTLDRSEYTSLIPNLRNVVALDTEVASNRIYWSDLSQRMICSTQLDRAHGVSSYDTVISRDIQAPDGLAVDWIHSNIYWTDSVLGTVSVADTKGVKRKTLFRENGSKPRAIVVDPVHGFMYWTDWGTPAKIKKGGLNGVDIYSLVTENIQWPNGITLDLLSGRLYWVDSKLHSISSIDVNGGNRKTILEDEKRLAHPFSLAVFEDKVFWTDIINEAIFSANRLTGSDVNLLAENLLSPEDMVLFHNLTQPRGVNWCERTTLSNGGCQYLCLPAPQINPHSPKFTCACPDGMLLARDMRSCLTEAEAAVATQETSTVRLKVSSTAVRTQHTTTRPVPDTSRLPGATPGLTTVEIVTMSHQALGDVAGRGNEKKPSSVRALSIVLPIVLLVFLCLGVFLLWKNWRLKNINSINFDNPVYQKTTEDEVHICHNQDGYSYPSRQMVSLEDDVA	860	P01130	C	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [342], 'DISULFID_gain_score': array([0.66464233]), 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [368], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.02637744]), 'HELIX_loss': [317], 'HELIX_gain': [357], 'HELIX_gain_score': array([0.06145757]), 'HELIX_loss_score': array([-0.03035086]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [181, 318], 'ZN_FING_gain': [698], 'ZN_FING_gain_score': array([0.00993782]), 'ZN_FING_loss_score': array([-0.00354773, -0.02691495])}
534	NM_000162.5(GCK):c.566T>C (p.Ile189Thr)	431972	CA367401550	NM_000162.5:c.566T>C, NC_000007.14:g.44149982A>G, CM000669.2:g.44149982A>G, NC_000007.13:g.44189581A>G, CM000669.1:g.44189581A>G, NC_000007.12:g.44156106A>G, NG_008847.1:g.44442T>C, NG_008847.2:g.53189T>C, ENST00000395796.8:c.*564T>C, ENST00000616242.5:c.566T>C, ENST00000682635.1:n.1052T>C, ENST00000345378.7:c.569T>C, ENST00000403799.8:c.566T>C, ENST00000671824.1:c.566T>C, ENST00000673284.1:c.566T>C, ENST00000345378.6:c.569T>C, ENST00000395796.7:c.563T>C, ENST00000403799.7:c.566T>C, ENST00000437084.1:c.515T>C, ENST00000616242.4:n.563T>C, NM_000162.3:c.566T>C, NM_033507.1:c.569T>C, NM_033508.1:c.563T>C, NM_000162.4:c.566T>C, NM_001354800.1:c.566T>C, NM_033507.2:c.569T>C, NM_033508.2:c.563T>C, NM_033507.3:c.569T>C, NM_033508.3:c.563T>C, NM_000162.5(GCK):c.566T>C (p.Ile189Thr)	GCK	monogenic diabetes	MONDO:0015967	Semidominant inheritance	Pathogenic	PS4, PP1_Strong, PP2, PP3, PP4, PM2_Supporting	PM1	The c.566T>C variant in the glucokinase gene, GCK, causes an amino acid change of isoleucine to threonine at codon 189 (p.Ile189Thr) of NM_000162.5. This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.969, which is greater than the MDEP VCEP threshold of 0.70 (PP3) and is absent from gnomAD v2.1.1 (PM2_Supporting). GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2). This variant was identified in 7 unrelated individuals with non- autoimmune and non-absolute/near-absolute insulin-deficient diabetes (PS4; internal lab contributors). Additionally, this variant was identified in at least one individual with a clinical history highly specific for GCK-MODY (fasting glucose = 125 mg/dl and HbA1c = 6.5%) (PP4, internal lab contributors).  Lastly, this variant segregated with diabetes, with five informative meioses in two families with MODY (PP1_Strong; internal lab contributors). In summary, c.566T>C meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.1.0, approved 3/23/2023): PM2_Supporting, PP3, PP2, PP4, PP1_Strong, PS4.		Monogenic Diabetes VCEP		2023-05-08	2023-05-08	False	https://erepo.genome.network/evrepo/ui/classification/CA367401550/MONDO:0015967/086	7e0e63cf-14f1-40ba-9af0-8f9179fc282a	p.Ile189Thr	Ile	189	Thr	MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQ	465	P35557	T	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [408], 'BINDING_gain': [], 'BINDING_loss_score': array([-0.0185408]), 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [164, 203], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.05297172, -0.07014889]), 'HELIX_loss': [4], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.02247047]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [83], 'DOMAIN_gain_score': array([0.03889585]), 'REGION_loss': [73, 74, 79, 82], 'REGION_gain': [], 'REGION_loss_score': array([-0.0197714 , -0.02051425, -0.02003604, -0.01823401]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
535	NM_000156.6(GAMT):c.59G>C (p.Trp20Ser)	8303	CA340769	NM_000156.6:c.59G>C, NC_000019.10:g.1401418C>G, CM000681.2:g.1401418C>G, NC_000019.9:g.1401417C>G, CM000681.1:g.1401417C>G, NC_000019.8:g.1352417C>G, NG_009785.1:g.5136G>C, ENST00000252288.8:c.59G>C, ENST00000447102.8:c.59G>C, ENST00000640762.1:c.59G>C, ENST00000252288.6:c.59G>C, ENST00000447102.7:c.59G>C, NM_000156.5:c.59G>C, NM_138924.2:c.59G>C, NM_138924.3:c.59G>C, NM_000156.6(GAMT):c.59G>C (p.Trp20Ser)	GAMT	guanidinoacetate methyltransferase deficiency	MONDO:0012999	Autosomal recessive inheritance	Pathogenic	PS3_Supporting, PP3, PM3_Strong, PP4_Strong	PM2, PP1, PM5	The NM_000156.6:c.59G>C variant in GAMT is a missense variant predicted to cause substitution of tryptophan by serine at amino acid 20 (p.Trp20Ser). This variant has been detected in at least 9 unrelated individuals with GAMT deficiency (PMID: 15651030, PMID: 16855203, PMID: 15108290). Of those individuals, one was compound heterozygous for the variant and a pathogenic variant, c.521G>A (p.Trp174*, in trans (PMID: 16855203) and eight individuals were homozygous for the variant (PMID: 15651030, PMID: 16855203, PMID: 15108290) (2 points total) (PM3_Strong). These individuals showed elevated plasma GAA and urine GAA (PMID: 15651030, PMID: 16855203, PMID: 15108290), three also showed deficient (<5% wild-type) GAMT enzyme activity in lymphoblasts (PMID: 15651030), and one also showed deficient (<5% wild-type) GAMT enzyme activity in fibroblasts and reduced creatine signal on brain MRS (PMID: 16855203, PMID: 21140503) (PP4_Strong). Expression of the variant in HeLa cells resulted in 3% wild type GAMT activity indicating that this variant may impact protein function (PMID: 17336114)(PS3_Supporting). The highest population minor allele frequency in gnomAD v2.1.1 is 0.0001 (3/27420 alleles) in the European (non-Finnish) population, which is lower than the ClinGen CCDS VCEP’s threshold for PM2_Supporting (<0.0004); however, as this variant is covered in <50% of individuals in gnomAD v2.1.1, allele frequency estimates may not be reliable and thus PM2_Supporting is not met. The computational predictor REVEL gives a score of 0.94 which is above the threshold of 0.75, evidence that correlates with impact to GAMT function (PP3). There is a ClinVar entry for this variant (Variation ID: 8303, 2 star review status) with 9 submitters classifying the variant as pathogenic and 1 submitter classifying the variant as likely pathogenic. In summary, this variant meets the criteria to be classified as pathogenic for GAMT deficiency based on the ACMG/AMP criteria applied, as specified by the ClinGen Cerebral Creatine Deficiency Syndromes Variant Curation Expert Panel (Specifications Version 1.1.0): PS3_Supporting, PM3_Strong, PP3, PP4_Strong.(Classification approved by the ClinGen Cerebral Creatine Deficiency Syndromes Variant Curation Expert Panel on May 25, 2023)		Cerebral Creatine Deficiency Syndromes VCEP		2023-05-25	2023-05-25	False	https://erepo.genome.network/evrepo/ui/classification/CA340769/MONDO:0012999/026	dc790a08-e798-46d6-ad31-772c3482c12b	p.Trp20Ser	Trp	20	Ser	MSAPSATPIFAPGENCSPAWGAAPAAYDAADTHLRILGKPVMERWETPYMHALAAAASSKGGRVLEVGFGMAIAASKVQEAPIDEHWIIECNDGVFQRLRDWAPRQTHKVIPLKGLWEDVAPTLPDGHFDGILYDTYPLSEETWHTHQFNFIKNHAFRLLKPGGVLTYCNLTSWGELMKSKYSDITIMFEETQVPALLEAGFRRENIRTEVMALVPPADCRYYAFPQMITPLVTKG	236	Q14353	S	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [75, 115], 'DNA_BIND_gain_score': array([0.0051567 , 0.00475597]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [19], 'SIGNAL_gain': [], 'SIGNAL_loss_score': array([-0.0884707]), 'TRANSIT_loss': [], 'TRANSIT_gain': [3, 4], 'TRANSIT_gain_score': array([0.03581297, 0.03517276]), 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [43, 58], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.1328041 , -0.08058155]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [0, 1, 2, 3, 4, 5, 7, 8, 10, 11], 'COMPBIAS_gain_score': array([0.50478655, 0.58024204, 0.58847159, 0.57951111, 0.51038438,
       0.51581031, 0.54642361, 0.5447281 , 0.53240389, 0.55587906]), 'DOMAIN_loss': [9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 21], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.27426434, -0.29668838, -0.30427885, -0.28404182, -0.31705415,
       -0.27049762, -0.30085957, -0.28273547, -0.33413005, -0.31927383,
       -0.30728471, -0.27969086]), 'REGION_loss': [], 'REGION_gain': [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16], 'REGION_gain_score': array([0.50027144, 0.56921613, 0.60341632, 0.59978735, 0.66634625,
       0.65452743, 0.60035008, 0.61925668, 0.67728049, 0.6809113 ,
       0.7489444 , 0.65696245, 0.67641211, 0.59293216, 0.63487232,
       0.51414669, 0.53341019]), 'REPEAT_loss': [130], 'REPEAT_gain': [164], 'REPEAT_gain_score': array([0.00701863]), 'REPEAT_loss_score': array([-0.00815678]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
536	NM_005629.4(SLC6A8):c.1169C>T (p.Pro390Leu)	1361089	CA415086230	NM_005629.4:c.1169C>T, NC_000023.11:g.153693932C>T, CM000685.2:g.153693932C>T, NC_000023.10:g.152959387C>T, CM000685.1:g.152959387C>T, NC_000023.9:g.152612581C>T, NG_012016.1:g.10636C>T, NG_012016.2:g.10636C>T, ENST00000253122.10:c.1169C>T, ENST00000253122.9:c.1169C>T, ENST00000413787.1:n.258-272C>T, ENST00000430077.6:c.824C>T, ENST00000442457.1:n.223C>T, ENST00000457723.1:n.153C>T, ENST00000467402.1:n.268C>T, ENST00000485324.1:n.1202C>T, NM_001142805.1:c.1139C>T, NM_001142806.1:c.824C>T, NM_005629.3:c.1169C>T, NM_001142805.2:c.1139C>T, NM_005629.4(SLC6A8):c.1169C>T (p.Pro390Leu)	SLC6A8	creatine transporter deficiency	MONDO:0010305	X-linked inheritance	Pathogenic	PM2_Supporting, PP4_Strong, PP1_Strong, PP3	PS3, PS4	"The NM_005629.4:c.1169C>T variant in SLC6A8 is a missense variant that is predicted to result in the substitution of proline by leucine at amino acid 390 (p.Pro390Leu). The variant was shown to segregate in a family from a heterozygous mother with mild intellectual disability, to two affected sons and an affected daughter. A clinically unaffected daughter did not carry the variant (PMID: 28065824) (PP1_Strong, PP4_Strong). In addition, two unrelated males with intellectual disability, and an affected brother of one of these individuals, are hemizygous for the variant (PMID: 15154114, 21267006. Fibroblasts from a patient with this variant were shown to be """"""""""""""""deficient in creatine uptake"""""""""""""""" (PMID: 17465020), but further details were not provided, other than the patient is unrelated to the patient reported in PMID: 15154114. The variant is absent in gnomAD v2.1.1. (PM2_Supporting). When transiently expressed in SLC6A8-deficient fibroblasts, the variant resulted in reduced creatine transport. However, the study does not meet the specifications of the CCDS VCEP (must be done with <125 mM creatine while the study used 500 uM). The computational predictor REVEL gives a score of 0.942 which is above the threshold of 0.75, evidence that correlates with impact to SLC6A8 function (PP3). In summary, this variant meets the criteria to be classified as pathogenic for creatine transporter deficiency. SLC6A8-specific criteria applied, as specified by the ClinGen CCDS VCEP (Specifications Version 1.1.0): PP1_Strong, PP4_Strong, PP3, PM2_Supporting.(Classification approved by the ClinGen Cerebral Creatine Deficiency Syndromes Variant Curation Expert Panel on May 11, 2023)"		Cerebral Creatine Deficiency Syndromes VCEP		2023-05-11	2023-05-25	False	https://erepo.genome.network/evrepo/ui/classification/CA415086230/MONDO:0010305/027	b427252d-51e0-4eaf-a14c-2f989ff1a43e	p.Pro390Leu	Pro	390	Leu	MAKKSAENGIYSVSGDEKKGPLIAPGPDGAPAKGDGPVGLGTPGGRLAVPPRETWTRQMDFIMSCVGFAVGLGNVWRFPYLCYKNGGGVFLIPYVLIALVGGIPIFFLEISLGQFMKAGSINVWNICPLFKGLGYASMVIVFYCNTYYIMVLAWGFYYLVKSFTTTLPWATCGHTWNTPDCVEIFRHEDCANASLANLTCDQLADRRSPVIEFWENKVLRLSGGLEVPGALNWEVTLCLLACWVLVYFCVWKGVKSTGKIVYFTATFPYVVLVVLLVRGVLLPGALDGIIYYLKPDWSKLGSPQVWIDAGTQIFFSYAIGLGALTALGSYNRFNNNCYKDAIILALINSGTSFFAGFVVFSILGFMAAEQGVHISKVAESGPGLAFIAYPRAVTLMPVAPLWAALFFFMLLLLGLDSQFVGVEGFITGLLDLLPASYYFRFQREISVALCCALCFVIDLSMVTDGGMYVFQLFDYYSASGTTLLWQAFWECVVVAWVYGADRFMDDIACMIGYRPCPWMKWCWSFFTPLVCMGIFIFNVVYYEPLVYNNTYVYPWWGEAMGWAFALSSMLCVPLHLLGCLLRAKGTMAERWQHLTQPIWGLHHLEYRAQDADVRGLTTLTPVSESSKVVVVESVM	635	P48029	L	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [131, 309, 352], 'DNA_BIND_gain': [312], 'DNA_BIND_gain_score': array([0.00365096]), 'DNA_BIND_loss_score': array([-0.00810277, -0.00510633, -0.0011847 ]), 'TOPO_DOM_loss': [389, 501], 'TOPO_DOM_gain': [], 'TOPO_DOM_loss_score': array([-0.08517724, -0.01342243]), 'TRANSMEM_loss': [328, 392], 'TRANSMEM_gain': [], 'TRANSMEM_loss_score': array([-0.02730697, -0.1152395 ]), 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [411], 'DOMAIN_gain': [265, 340, 343], 'DOMAIN_gain_score': array([0.02537268, 0.03977644, 0.04639989]), 'DOMAIN_loss_score': array([-0.02734393]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
537	NM_175914.5(HNF4A):c.1177G>A (p.Gly393Arg)	435440	CA9870495	NM_175914.5:c.1177G>A, NC_000020.11:g.44428448G>A, CM000682.2:g.44428448G>A, NC_000020.10:g.43057088G>A, CM000682.1:g.43057088G>A, NC_000020.9:g.42490502G>A, NG_009818.1:g.77648G>A, LRG_483:g.77648G>A, ENST00000316099.10:c.1243G>A, ENST00000316099.9:c.1243G>A, ENST00000316099.8:c.1243G>A, ENST00000316673.8:c.1177G>A, ENST00000372920.1:c.*1010G>A, ENST00000415691.2:c.1243G>A, ENST00000457232.5:c.1177G>A, ENST00000619550.4:c.1168G>A, NM_000457.4:c.1243G>A, LRG_483t2:c.1243G>A, NM_001030003.2:c.1177G>A, NM_001258355.1:c.1222G>A, NM_001287182.1:c.1168G>A, NM_001287183.1:c.1168G>A, LRG_483t3:c.1168G>A, NM_175914.4:c.1177G>A, LRG_483t1:c.1177G>A, NM_178849.2:c.1243G>A, XM_005260407.2:c.1360G>A, XM_011528797.1:c.1291G>A, XM_011528798.1:c.1291G>A, XM_005260407.4:c.1360G>A, NM_001030003.3:c.1177G>A, NM_001258355.2:c.1222G>A, NM_001287182.2:c.1168G>A, NM_178849.3:c.1243G>A, NM_000457.5:c.1243G>A, NM_000457.6:c.1243G>A, NM_001287183.2:c.1168G>A, NM_175914.5(HNF4A):c.1177G>A (p.Gly393Arg)	HNF4A	monogenic diabetes	MONDO:0015967	Autosomal dominant inheritance	Benign	BS2, BS1	PM5, PM1, PP3, PP4, BP4, PS4	The c.1177G>A in the HNF4A gene causes an amino acid change of glycine to arginine at codon 393 (p.Gly393Arg) of NM_15914.4. The nucleotide change c.1177G>C, which causes the same amino acid change, has been reported in a patient with monogenic diabetes; however, the c.1177G>C variant has not met the criteria to be classified as pathogenic for monogenic diabetes by the ClinGen MDEP. This variant was identified in three unrelated individuals with non-autoimmune and non-absolute/near-absolute insulin-deficient diabetes; however, PS4_Moderate cannot be applied because this number is below the ClinGen MDEP threshold (internal lab contributors). This variant is outside of the region defined as critical for the protein’s function by the ClinGen MDEP (codons 37-113, 180-220 and 300-350). This variant has a Popmax Filtering allele frequency in gnomAD 2.1.1 of 0.0000751, which is greater than the MDEP threshold for BS1 (greater than or equal to 0.000033) (BS1). This variant was identified in a normoglycemic individual >70 years old, and the expected penetrance for HNF4A-MODY is 95% by age 70 (internal lab contributor) (BS2). This variant has a REVEL score of 0.451, which is between the ClinGen MDEP thresholds, predicting neither a damaging nor benign impact on protein function. This variant was identified in individuals with diabetes; however, the MODY probability is unable to be calculated due to age of diagnosis over 35 and lack of clinical information (internal lab contributors). In summary, c.1177G>A meets the criteria to be classified as benign for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.0.0, approved 11/16/2022): BS1, BS2.		Monogenic Diabetes VCEP		2023-05-27	2023-05-27	False	https://erepo.genome.network/evrepo/ui/classification/CA9870495/MONDO:0015967/085	4d775106-7b61-4d80-b19c-a4156dc7c7fa	p.Gly393Arg	Gly	393	Arg	MRLSKTLVDMDMADYSAALDPAYTTLEFENVQVLTMGNDTSPSEGTNLNAPNSLGVSALCAICGDRATGKHYGASSCDGCKGFFRRSVRKNHMYSCRFSRQCVVDKDKRNQCRYCRLKKCFRAGMKKEAVQNERDRISTRRSSYEDSSLPSINALLQAEVLSRQITSPVSGINGDIRAKKIASIADVCESMKEQLLVLVEWAKYIPAFCELPLDDQVALLRAHAGEHLLLGATKRSMVFKDVLLLGNDYIVPRHCPELAEMSRVSIRILDELVLPFQELQIDDNEYAYLKAIIFFDPDAKGLSDPGKIKRLRSQVQVSLEDYINDRQYDSRGRFGELLLLLPTLQSITWQMIEQIQFIKLFGMAKIDNLLQEMLLGGSPSDAPHAHHPLHPHLMQEHMGTNVIVANTMPTHLSNGQMCEWPRPRGQAATPETPQPSPPGGSGSEPYKLLPGAVATIVKPLSAIPQPTITKQEVI	474	P41235	R	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [351], 'TRANSMEM_gain_score': array([0.00345951]), 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [330], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.01334095]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [152], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.00586754]), 'REGION_loss': [], 'REGION_gain': [417], 'REGION_gain_score': array([0.03218085]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
538	NM_175914.5(HNF4A):c.1321A>G (p.Ile441Val)	36345	CA213913	NM_175914.5:c.1321A>G, NC_000020.11:g.44429627A>G, CM000682.2:g.44429627A>G, NC_000020.10:g.43058267A>G, CM000682.1:g.43058267A>G, NC_000020.9:g.42491681A>G, NG_009818.1:g.78827A>G, LRG_483:g.78827A>G, ENST00000316099.10:c.1387A>G, ENST00000316099.9:c.1387A>G, ENST00000316099.8:c.1387A>G, ENST00000316673.8:c.1321A>G, ENST00000372920.1:c.*1154A>G, ENST00000415691.2:c.1357A>G, ENST00000457232.5:c.1291A>G, ENST00000619550.4:c.1312A>G, NM_000457.4:c.1387A>G, LRG_483t2:c.1387A>G, NM_001030003.2:c.1291A>G, NM_001258355.1:c.1366A>G, NM_001287182.1:c.1282A>G, NM_001287183.1:c.1312A>G, LRG_483t3:c.1312A>G, NM_175914.4:c.1321A>G, LRG_483t1:c.1321A>G, NM_178849.2:c.1357A>G, XM_005260407.2:c.1504A>G, XM_011528797.1:c.1405A>G, XM_011528798.1:c.1435A>G, XM_005260407.4:c.1504A>G, NM_001030003.3:c.1291A>G, NM_001258355.2:c.1366A>G, NM_001287182.2:c.1282A>G, NM_178849.3:c.1357A>G, NM_000457.5:c.1387A>G, NM_000457.6:c.1387A>G, NM_001287183.2:c.1312A>G, NM_175914.5(HNF4A):c.1321A>G (p.Ile441Val)	HNF4A	monogenic diabetes	MONDO:0015967	Autosomal dominant inheritance	Benign	BS3_Supporting, BA1, BS4, BP5, PP4_Moderate	PM1, PP3, BP4, PS4	The c.1321A>G p.(Ile441Val) variant in the hepatocyte nuclear factor 4-alpha gene, HNF4A, has a Popmax Filtering allele frequency in gnomAD 2.1.1 of 0.0005025, which is greater than the MDEP threshold for BA1 (BA1). This variant was identified in an individual with a clinical history highly specific for HNF4A-MODY (MODY probability calculator result >50%, negative genetic testing for HNF1A, and GAD negative) (PP4_Moderate, internal contributors). There is evidence in vitro that this variant has identical transactivation activity to wildtype, indicating that this variant does not impact protein function (BS3_Supporting, PMID: 30191603). This variant does not segregate with diabetes in three families (BS4; internal lab contributors, PMIDs: 25905084, 10227563, 33324081). This variant was identified in a patient with an alternate molecular basis for disease (BP5; internal lab contributors). In summary, c.1321A>G p.(Ile441Val) meets the criteria to be classified as benign for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP VCEP (specification version 1.0.0, approved 11/16/2022): BA1, PP4_Moderate, BS3_Supporting, BS4, BP5.		Monogenic Diabetes VCEP		2023-05-27	2023-05-27	False	https://erepo.genome.network/evrepo/ui/classification/CA213913/MONDO:0015967/085	a2587a88-8193-4949-94fa-a8203f614da4	p.Ile441Val	Ile	441	Val	MRLSKTLVDMDMADYSAALDPAYTTLEFENVQVLTMGNDTSPSEGTNLNAPNSLGVSALCAICGDRATGKHYGASSCDGCKGFFRRSVRKNHMYSCRFSRQCVVDKDKRNQCRYCRLKKCFRAGMKKEAVQNERDRISTRRSSYEDSSLPSINALLQAEVLSRQITSPVSGINGDIRAKKIASIADVCESMKEQLLVLVEWAKYIPAFCELPLDDQVALLRAHAGEHLLLGATKRSMVFKDVLLLGNDYIVPRHCPELAEMSRVSIRILDELVLPFQELQIDDNEYAYLKAIIFFDPDAKGLSDPGKIKRLRSQVQVSLEDYINDRQYDSRGRFGELLLLLPTLQSITWQMIEQIQFIKLFGMAKIDNLLQEMLLGGSPSDAPHAHHPLHPHLMQEHMGTNVIVANTMPTHLSNGQMCEWPRPRGQAATPETPQPSPPGGSGSEPYKLLPGAVATIVKPLSAIPQPTITKQEVI	474	P41235	V	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [351], 'TRANSMEM_gain_score': array([0.00891566]), 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [330], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.00965315]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [445, 446, 447], 'REGION_gain': [], 'REGION_loss_score': array([-0.29267842, -0.20280272, -0.19045365]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
539	NM_000156.6(GAMT):c.403G>A (p.Asp135Asn)	573140	CA9043671	NM_000156.6:c.403G>A, NC_000019.10:g.1399184C>T, CM000681.2:g.1399184C>T, NC_000019.9:g.1399183C>T, CM000681.1:g.1399183C>T, NC_000019.8:g.1350183C>T, NG_009785.1:g.7370G>A, ENST00000252288.8:c.403G>A, ENST00000447102.8:c.403G>A, ENST00000591788.3:n.86G>A, ENST00000640164.1:n.236G>A, ENST00000640762.1:c.334G>A, ENST00000252288.6:c.403G>A, ENST00000447102.7:c.403G>A, ENST00000591788.2:n.88G>A, NM_000156.5:c.403G>A, NM_138924.2:c.403G>A, NM_138924.3:c.403G>A, NM_000156.6(GAMT):c.403G>A (p.Asp135Asn)	GAMT	guanidinoacetate methyltransferase deficiency	MONDO:0012999	Autosomal recessive inheritance	Pathogenic	PS3_Supporting, PM5_Supporting, PP3, PM2_Supporting, PM3, PP4_Strong		The NM_000156.6(GAMT):c.403G>A variant in GAMT is predicted to result in the substitution of aspartate by asparagine at amino acid 135 (p.Asp135Asn). Four probands and one affected sibling have been reported with this variant, all with clinical symptoms consistent with GAMT deficiency, evidence of elevated guanidinoacetate and low creatine in plasma and/or urine, and reduced creatine on brain MRS with guanidinoacetate peak also noted for two patients. In addition, one proband was shown to have deficient GAMT activity in fibroblasts (PMID: 19027335, 19388150, 24071436, 24268530, 24415674) (PP4_Strong). Each of these individuals is compound heterozygous for the variant and another variant in GAMT that has been classified as pathogenic or likely pathogenic by the ClinGen CCDS VCEP including c.327G>A (2 patients; PMID: 24071436, 24268530, 24415674), c.299dup13 (a.k.a. c.299_311dup) (PMID: 19388150), and c.507_521dup15 (p.Cys169_Ser173dup) (PMID: 19027335)(PM3). The highest population minor allele frequency in gnomAD v2.1.1 is 0.00011 (2/18390 alleles) in the East Asian population, which is lower than the ClinGen CCDS VCEP’s threshold for PM2_Supporting (<0.0004), meeting this criterion (PM2_Supporting). When the variant was expressed in GAMT-deficient fibroblasts, GAMT enzyme activity was undetectable (PMID: 24415674). The computational predictor REVEL gives a score of 0.856 which is above the threshold of 0.75, evidence that correlates with impact to GAMT function (PP3). Another variant at the same amino acid position, c.403G>T (p.Asp135Tyr), has been classified as likely pathogenic by the ClinGen CCDS VCEP (and would be likely pathogenic even without the use of PM5, therefore avoiding circular logic) (PM5_Supporting). There is a ClinVar entry for this variant (Variation ID: 573140). In summary, this variant meets the criteria to be classified as pathogenic for GAMT deficiency. GAMT-specific ACMG/AMP criteria applied, as specified by the ClinGen Cerebral Creatine Deficiency Syndromes Variant Curation Expert Panel (Specifications Version 1.1.0); PP4_Strong, PM3, PP3, PS3_Supporting, PM2_Supporting, PM5_Supporting.(Classification approved by the ClinGen CCDS VCEP on June 8, 2023)		Cerebral Creatine Deficiency Syndromes VCEP		2023-06-08	2023-06-08	False	https://erepo.genome.network/evrepo/ui/classification/CA9043671/MONDO:0012999/026	8a818f12-30b9-40f0-9411-9be1e355f21b	p.Asp135Asn	Asp	135	Asn	MSAPSATPIFAPGENCSPAWGAAPAAYDAADTHLRILGKPVMERWETPYMHALAAAASSKGGRVLEVGFGMAIAASKVQEAPIDEHWIIECNDGVFQRLRDWAPRQTHKVIPLKGLWEDVAPTLPDGHFDGILYDTYPLSEETWHTHQFNFIKNHAFRLLKPGGVLTYCNLTSWGELMKSKYSDITIMFEETQVPALLEAGFRRENIRTEVMALVPPADCRYYAFPQMITPLVTKG	236	Q14353	N	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [72], 'BINDING_gain': [], 'BINDING_loss_score': array([-0.0507381]), 'DNA_BIND_loss': [68, 71, 73, 116, 133, 139, 142, 144, 174], 'DNA_BIND_gain': [115, 163], 'DNA_BIND_gain_score': array([0.00953937, 0.00590253]), 'DNA_BIND_loss_score': array([-0.04688948, -0.03440648, -0.02061731, -0.04945338, -0.0809623 ,
       -0.05059451, -0.02544039, -0.03864187, -0.02485514]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [186, 187, 227, 228, 229, 230, 231, 232], 'STRAND_gain_score': array([0.37515539, 0.35976404, 0.35908151, 0.39699095, 0.41665828,
       0.45791966, 0.37286621, 0.3441416 ]), 'HELIX_loss': [43, 44, 45, 78, 173, 174, 176], 'HELIX_gain': [25, 28, 31, 32, 33, 34, 35, 140, 141, 142, 182], 'HELIX_gain_score': array([0.48081785, 0.48123431, 0.45343769, 0.48416567, 0.53619331,
       0.63303763, 0.5545305 , 0.18126768, 0.27097809, 0.3136586 ,
       0.23093581]), 'HELIX_loss_score': array([-0.20958143, -0.39591479, -0.36363631, -0.24000847, -0.22709316,
       -0.36191273, -0.22915351]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 235], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.46424967, -0.53401613, -0.53043818, -0.5354178 , -0.55603993,
       -0.57227212, -0.55598301, -0.63281041, -0.65791905, -0.6625194 ,
       -0.64631975, -0.736637  , -0.70809376, -0.66767436, -0.66864818,
       -0.68617058, -0.71813852, -0.68360186, -0.67949992, -0.67099178,
       -0.63782376, -0.63757062, -0.61494297, -0.48975456, -0.52023125,
       -0.3788954 , -0.48245126, -0.5051325 , -0.45101887, -0.41505253,
       -0.44108057, -0.37960458, -0.33818769, -0.11459965]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [62, 63, 72, 78, 79, 80, 81, 82, 85, 92, 114, 115, 126, 127, 128, 130, 131, 132, 163], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.08301735, -0.04802793, -0.06479603, -0.06826973, -0.09031218,
       -0.06098974, -0.06535435, -0.05722475, -0.02296364, -0.06540525,
       -0.08242327, -0.04227799, -0.10810781, -0.08963609, -0.06574941,
       -0.05366963, -0.0462172 , -0.05834508, -0.04900217]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
540	NM_000138.5(FBN1):c.4640C>T (p.Thr1547Ile)	42367	CA015264	NM_000138.5:c.4640C>T, NC_000015.10:g.48468045G>A, CM000677.2:g.48468045G>A, NC_000015.9:g.48760242G>A, CM000677.1:g.48760242G>A, NC_000015.8:g.46547534G>A, NG_008805.2:g.182744C>T, LRG_778:g.182744C>T, ENST00000684448.1:n.3314C>T, ENST00000316623.10:c.4640C>T, ENST00000316623.9:c.4640C>T, ENST00000537463.6:c.*403C>T, NM_000138.4:c.4640C>T, LRG_778t1:c.4640C>T, NM_000138.5(FBN1):c.4640C>T (p.Thr1547Ile)	FBN1	Marfan syndrome	MONDO:0007947	Autosomal dominant inheritance	Benign	BA1	PS4, PS2, PS3, PM1, BP5, BS1, BS4, BS3, PP2, PP3, PP4, PP1, PM2, PM6, BP4, BP2	The NM_00138 c.4640C>T, is a missense variant in FBN1 predicted to cause a substitution of a threonine by isoleucine at amino acid 1547 (p.Thr1547Ile). This variant was found one proband with Marfan syndrome (PMID 24793577) and in three apparently unrelated probands with features of Marfan syndrome (PMID 24793577, internal data). In one of these individuals with features of Marfan syndrome, this variant was also detected in the proband’s mother and sister, both of whom had a systemic score of 9, however relatedness of these individuals was not confirmed (internal data). This variant was also identified in an individual with features of Marfan syndrome but no diagnosis who also carried a pathogenic variant in FBN1, c.3193delG p.Glu1065Lysfs*23 (PMID 29543232). The variant in FBN1 has been reported 17 times in ClinVar: 6 times as uncertain significance and 11 times as likely benign (Variation ID: 42367). This variant has been identified in 37 individuals of Latino/Admixed American origin in gnomAD v3.1.2 (MAF: 0.24%) (BA1; https://gnomad.broadinstitute.org/). Computational prediction tools and conservation analysis are unclear on the predicted impact on the protein (REVEL: 0.375). The constraint z-score for missense variants affecting FBN1 is 5.06, however due to the presence of benign arguments PP2 cannot be used. In summary, this variant meets criteria to be classified as benign for Marfan syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen FBN1 VCEP: BA1.		FBN1 VCEP	https://clinicalgenome.org/docs/clingen-fbn1-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2023-06-15	2023-06-15	False	https://erepo.genome.network/evrepo/ui/classification/CA015264/MONDO:0007947/022	d2dbabeb-c2f7-48bd-bc81-757034edd0e6	p.Thr1547Ile	Thr	1547	Ile	MRRGRLLEIALGFTVLLASYTSHGADANLEAGNVKETRASRAKRRGGGGHDALKGPNVCGSRYNAYCCPGWKTLPGGNQCIVPICRHSCGDGFCSRPNMCTCPSGQIAPSCGSRSIQHCNIRCMNGGSCSDDHCLCQKGYIGTHCGQPVCESGCLNGGRCVAPNRCACTYGFTGPQCERDYRTGPCFTVISNQMCQGQLSGIVCTKTLCCATVGRAWGHPCEMCPAQPHPCRRGFIPNIRTGACQDVDECQAIPGLCQGGNCINTVGSFECKCPAGHKLNEVSQKCEDIDECSTIPGICEGGECTNTVSSYFCKCPPGFYTSPDGTRCIDVRPGYCYTALTNGRCSNQLPQSITKMQCCCDAGRCWSPGVTVAPEMCPIRATEDFNKLCSVPMVIPGRPEYPPPPLGPIPPVLPVPPGFPPGPQIPVPRPPVEYLYPSREPPRVLPVNVTDYCQLVRYLCQNGRCIPTPGSYRCECNKGFQLDLRGECIDVDECEKNPCAGGECINNQGSYTCQCRAGYQSTLTRTECRDIDECLQNGRICNNGRCINTDGSFHCVCNAGFHVTRDGKNCEDMDECSIRNMCLNGMCINEDGSFKCICKPGFQLASDGRYCKDINECETPGICMNGRCVNTDGSYRCECFPGLAVGLDGRVCVDTHMRSTCYGGYKRGQCIKPLFGAVTKSECCCASTEYAFGEPCQPCPAQNSAEYQALCSSGPGMTSAGSDINECALDPDICPNGICENLRGTYKCICNSGYEVDSTGKNCVDINECVLNSLLCDNGQCRNTPGSFVCTCPKGFIYKPDLKTCEDIDECESSPCINGVCKNSPGSFICECSSESTLDPTKTICIETIKGTCWQTVIDGRCEININGATLKSQCCSSLGAAWGSPCTLCQVDPICGKGYSRIKGTQCEDIDECEVFPGVCKNGLCVNTRGSFKCQCPSGMTLDATGRICLDIRLETCFLRYEDEECTLPIAGRHRMDACCCSVGAAWGTEECEECPMRNTPEYEELCPRGPGFATKEITNGKPFFKDINECKMIPSLCTHGKCRNTIGSFKCRCDSGFALDSEERNCTDIDECRISPDLCGRGQCVNTPGDFECKCDEGYESGFMMMKNCMDIDECQRDPLLCRGGVCHNTEGSYRCECPPGHQLSPNISACIDINECELSAHLCPNGRCVNLIGKYQCACNPGYHSTPDRLFCVDIDECSIMNGGCETFCTNSEGSYECSCQPGFALMPDQRSCTDIDECEDNPNICDGGQCTNIPGEYRCLCYDGFMASEDMKTCVDVNECDLNPNICLSGTCENTKGSFICHCDMGYSGKKGKTGCTDINECEIGAHNCGKHAVCTNTAGSFKCSCSPGWIGDGIKCTDLDECSNGTHMCSQHADCKNTMGSYRCLCKEGYTGDGFTCTDLDECSENLNLCGNGQCLNAPGGYRCECDMGFVPSADGKACEDIDECSLPNICVFGTCHNLPGLFRCECEIGYELDRSGGNCTDVNECLDPTTCISGNCVNTPGSYICDCPPDFELNPTRVGCVDTRSGNCYLDIRPRGDNGDTACSNEIGVGVSKASCCCSLGKAWGTPCEMCPAVNTSEYKILCPGGEGFRPNPITVILEDIDECQELPGLCQGGKCINTFGSFQCRCPTGYYLNEDTRVCDDVNECETPGICGPGTCYNTVGNYTCICPPDYMQVNGGNNCMDMRRSLCYRNYYADNQTCDGELLFNMTKKMCCCSYNIGRAWNKPCEQCPIPSTDEFATLCGSQRPGFVIDIYTGLPVDIDECREIPGVCENGVCINMVGSFRCECPVGFFYNDKLLVCEDIDECQNGPVCQRNAECINTAGSYRCDCKPGYRFTSTGQCNDRNECQEIPNICSHGQCIDTVGSFYCLCHTGFKTNDDQTMCLDINECERDACGNGTCRNTIGSFNCRCNHGFILSHNNDCIDVDECASGNGNLCRNGQCINTVGSFQCQCNEGYEVAPDGRTCVDINECLLEPRKCAPGTCQNLDGSYRCICPPGYSLQNEKCEDIDECVEEPEICALGTCSNTEGSFKCLCPEGFSLSSSGRRCQDLRMSYCYAKFEGGKCSSPKSRNHSKQECCCALKGEGWGDPCELCPTEPDEAFRQICPYGSGIIVGPDDSAVDMDECKEPDVCKHGQCINTDGSYRCECPFGYILAGNECVDTDECSVGNPCGNGTCKNVIGGFECTCEEGFEPGPMMTCEDINECAQNPLLCAFRCVNTYGSYECKCPVGYVLREDRRMCKDEDECEEGKHDCTEKQMECKNLIGTYMCICGPGYQRRPDGEGCVDENECQTKPGICENGRCLNTRGSYTCECNDGFTASPNQDECLDNREGYCFTEVLQNMCQIGSSNRNPVTKSECCCDGGRGWGPHCEICPFQGTVAFKKLCPHGRGFMTNGADIDECKVIHDVCRNGECVNDRGSYHCICKTGYTPDITGTSCVDLNECNQAPKPCNFICKNTEGSYQCSCPKGYILQEDGRSCKDLDECATKQHNCQFLCVNTIGGFTCKCPPGFTQHHTSCIDNNECTSDINLCGSKGICQNTPGSFTCECQRGFSLDQTGSSCEDVDECEGNHRCQHGCQNIIGGYRCSCPQGYLQHYQWNQCVDENECLSAHICGGASCHNTLGSYKCMCPAGFQYEQFSGGCQDINECGSAQAPCSYGCSNTEGGYLCGCPPGYFRIGQGHCVSGMGMGRGNPEPPVSGEMDDNSLSPEACYECKINGYPKRGRKRRSTNETDASNIEDQSETEANVSLASWDVEKTAIFAFNISHVSNKVRILELLPALTTLTNHNRYLIESGNEDGFFKINQKEGISYLHFTKKKPVAGTYSLQISSTPLYKKKELNQLEDKYDKDYLSGELGDNLKMKIQVLLH	2871	P35555	I	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [611, 753, 1253, 2543], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.00099051, -0.00286841, -0.00901616, -0.00397956]), 'REGION_loss': [], 'REGION_gain': [432, 435, 855, 909, 922, 927, 932, 941, 942, 969, 972, 1229, 1232, 1233, 1252, 1260, 1265, 1279, 2072, 2073, 2084, 2085, 2097, 2101, 2104, 2110, 2111, 2117, 2157, 2172, 2176, 2197, 2201, 2204, 2214, 2514, 2517, 2521, 2523, 2525, 2526, 2527, 2528, 2537], 'REGION_gain_score': array([0.00460535, 0.0045104 , 0.00343043, 0.00493491, 0.00487339,
       0.0053134 , 0.00442553, 0.0048061 , 0.00479513, 0.00468707,
       0.00460583, 0.00761825, 0.0075047 , 0.0076893 , 0.00770402,
       0.00745326, 0.00776279, 0.00827032, 0.0100047 , 0.01028359,
       0.00997359, 0.0105831 , 0.00957733, 0.01008695, 0.00968957,
       0.00998139, 0.01008576, 0.00993341, 0.00930005, 0.0092082 ,
       0.00893652, 0.00940818, 0.00918055, 0.00892466, 0.00794303,
       0.01141983, 0.01231986, 0.01192498, 0.01217312, 0.0113374 ,
       0.01107031, 0.01128584, 0.01086885, 0.01079345]), 'REPEAT_loss': [1031, 1517, 2480, 2558], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.00165302, -0.00489777, -0.00063902, -0.00069994]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
541	NM_001323289.2(CDKL5):c.2555C>T (p.Pro852Leu)	156690	CA294764	NM_001323289.2:c.2555C>T, NC_000023.11:g.18628429C>T, CM000685.2:g.18628429C>T, NC_000023.10:g.18646549C>T, CM000685.1:g.18646549C>T, NC_000023.9:g.18556470C>T, NG_008475.1:g.207825C>T, ENST00000623535.2:c.2555C>T, ENST00000674046.1:c.2678C>T, ENST00000379989.6:c.2555C>T, ENST00000379996.7:c.2555C>T, ENST00000623535.1:n.2555C>T, NM_001037343.1:c.2555C>T, NM_003159.2:c.2555C>T, XM_011545569.1:c.2627C>T, XM_011545570.1:c.2546C>T, XR_950484.1:n.2930C>T, NM_001323289.1:c.2555C>T, NM_001037343.2:c.2555C>T, NM_003159.3:c.2555C>T, NM_001323289.2(CDKL5):c.2555C>T (p.Pro852Leu)	CDKL5	CDKL5 disorder	MONDO:0100039	X-linked inheritance	Benign	BA1		The allele frequency of the p.Pro852Leu variant in CDKL5 is 0.031% in African sub population in gnomAD, which is high enough to be classified as benign based on thresholds defined by the ClinGen Rett/Angelman-like Expert Panel for Rett/AS-like conditions (BA1). In summary, the p.Pro852Leu variant in CDKL5 is classified as benign based on the ACMG/AMP criteria (BA1).		Rett and Angelman-like Disorders VCEP		2023-04-14	2023-06-16	False	https://erepo.genome.network/evrepo/ui/classification/CA294764/MONDO:0100039/033	8068e478-0128-4e9e-ba26-c670045b3859	p.Pro852Leu	Pro	852	Leu	MKIPNIGNVMNKFEILGVVGEGAYGVVLKCRHKETHEIVAIKKFKDSEENEEVKETTLRELKMLRTLKQENIVELKEAFRRRGKLYLVFEYVEKNMLELLEEMPNGVPPEKVKSYIYQLIKAIHWCHKNDIVHRDIKPENLLISHNDVLKLCDFGFARNLSEGNNANYTEYVATRWYRSPELLLGAPYGKSVDMWSVGCILGELSDGQPLFPGESEIDQLFTIQKVLGPLPSEQMKLFYSNPRFHGLRFPAVNHPQSLERRYLGILNSVLLDLMKNLLKLDPADRYLTEQCLNHPTFQTQRLLDRSPSRSAKRKPYHVESSTLSNRNQAGKSTALQSHHRSNSKDIQNLSVGLPRADEGLPANESFLNGNLAGASLSPLHTKTYQASSQPGSTSKDLTNNNIPHLLSPKEAKSKTEFDFNIDPKPSEGPGTKYLKSNSRSQQNRHSFMESSQSKAGTLQPNEKQSRHSYIDTIPQSSRSPSYRTKAKSHGALSDSKSVSNLSEARAQIAEPSTSRYFPSSCLDLNSPTSPTPTRHSDTRTLLSPSGRNNRNEGTLDSRRTTTRHSKTMEELKLPEHMDSSHSHSLSAPHESFSYGLGYTSPFSSQQRPHRHSMYVTRDKVRAKGLDGSLSIGQGMAARANSLQLLSPQPGEQLPPEMTVARSSVKETSREGTSSFHTRQKSEGGVYHDPHSDDGTAPKENRHLYNDPVPRRVGSFYRVPSPRPDNSFHENNVSTRVSSLPSESSSGTNHSKRQPAFDPWKSPENISHSEQLKEKEKQGFFRSMKKKKKKSQTVPNSDSPDLLTLQKSIHSASTPSSRPKEWRPEKISDLQTQSQPLKSLRKLLHLSSASNHPASSDPRFQPLTAQQTKNSFSEIRIHPLSQASGGSSNIRQEPAPKGRPALQLPGQMDPGWHVSSVTRSATEGPSYSEQLGAKSGPNGHPYNRTNRSRMPNLNDLKETAL	960	O76039	L	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [842, 843, 844, 845], 'COMPBIAS_gain': [953], 'COMPBIAS_gain_score': array([0.01985997]), 'COMPBIAS_loss_score': array([-0.36855835, -0.47051305, -0.44750303, -0.45184869]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [583, 835, 836, 837, 838, 839, 840, 841, 842, 843, 844, 845, 846, 847, 848, 849, 850, 852], 'REGION_gain': [], 'REGION_loss_score': array([-0.00586051, -0.39708358, -0.4272058 , -0.43110693, -0.50201267,
       -0.48470926, -0.5163182 , -0.48903871, -0.53225034, -0.5131759 ,
       -0.5800091 , -0.66073167, -0.66696835, -0.64911968, -0.62434673,
       -0.52850246, -0.50088573, -0.4909035 ]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
542	NM_000162.5(GCK):c.835G>C (p.Glu279Gln)	211076	CA208420	NM_000162.5:c.835G>C, NC_000007.14:g.44147678C>G, CM000669.2:g.44147678C>G, NC_000007.13:g.44187277C>G, CM000669.1:g.44187277C>G, NC_000007.12:g.44153802C>G, NG_008847.1:g.46746G>C, NG_008847.2:g.55493G>C, ENST00000395796.8:c.*833G>C, ENST00000616242.5:c.835G>C, ENST00000345378.7:c.838G>C, ENST00000403799.8:c.835G>C, ENST00000671824.1:c.835G>C, ENST00000673284.1:c.835G>C, ENST00000345378.6:c.838G>C, ENST00000395796.7:c.832G>C, ENST00000403799.7:c.835G>C, ENST00000437084.1:c.784G>C, ENST00000616242.4:n.832G>C, NM_000162.3:c.835G>C, NM_033507.1:c.838G>C, NM_033508.1:c.832G>C, XR_927223.1:n.12C>G, NM_000162.4:c.835G>C, NM_001354800.1:c.835G>C, NM_033507.2:c.838G>C, NM_033508.2:c.832G>C, XR_927223.2:n.12C>G, NM_033507.3:c.838G>C, NM_033508.3:c.832G>C, NM_000162.5(GCK):c.835G>C (p.Glu279Gln)	GCK	monogenic diabetes	MONDO:0015967	Semidominant inheritance	Benign	BA1, PP2	PS3, PS4, PP3	The c.835G>C variant in the glucokinase gene, GCK, causes an amino acid change of glutamic acid to glutamine at codon 279 (p.(Glu279Gln)) of NM_000162.5. GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2). This variant has a Popmax Filtering allele frequency in gnomAD 2.1.1 of 0.000112, which is greater than the MDEP threshold for BA1 (≥0.0001) (BA1). This variant was identified in at least 4 unrelated individuals with non-autoimmune and non-absolute/near-absolute insulin-deficient diabetes; however, PS4 cannot be applied because the variant MAF in gnomAD is above the ClinGen MDEP PM2_Supporting cutoff (PMID 8446612, PMID 24097065, PMID 30245511, internal lab contributor). This variant has a REVEL score of 0.698, which is between the ClinGen MDEP thresholds predicting neither a damaging nor benign impact on GCK function. While functional studies exploring the effect of this mutation on the gene have been assessed, these studies do not meet the criteria set forth by the MDEP for application of PS3 or BS3 (PMID: 8446612). In summary, c.835G>C meets the criteria to be classified as benign for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.2.0, approved 6/7/2023): BA1, PP2.		Monogenic Diabetes VCEP		2023-06-21	2023-06-21	False	https://erepo.genome.network/evrepo/ui/classification/CA208420/MONDO:0015967/086	74d8f360-8f66-4226-92b9-8c48395cfbff	p.Glu279Gln	Glu	279	Gln	MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQ	465	P35557	Q	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [203], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.0068056]), 'HELIX_loss': [278], 'HELIX_gain': [283], 'HELIX_gain_score': array([0.09962201]), 'HELIX_loss_score': array([-0.16550595]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [11, 21, 71, 80], 'REGION_gain_score': array([0.00537962, 0.00406891, 0.00759172, 0.0082792 ]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
543	NM_000162.5(GCK):c.1322C>G (p.Ser441Trp)	1320655	CA367397017	NM_000162.5:c.1322C>G, NC_000007.14:g.44145212G>C, CM000669.2:g.44145212G>C, NC_000007.13:g.44184811G>C, CM000669.1:g.44184811G>C, NC_000007.12:g.44151336G>C, NG_008847.1:g.49212C>G, NG_008847.2:g.57959C>G, ENST00000395796.8:c.*1320C>G, ENST00000616242.5:c.*442C>G, ENST00000683378.1:n.548C>G, ENST00000336642.9:c.356C>G, ENST00000345378.7:c.1325C>G, ENST00000403799.8:c.1322C>G, ENST00000671824.1:c.1385C>G, ENST00000672743.1:n.334C>G, ENST00000673284.1:c.1322C>G, ENST00000336642.8:n.374C>G, ENST00000345378.6:c.1325C>G, ENST00000395796.7:c.1319C>G, ENST00000403799.7:c.1322C>G, ENST00000437084.1:c.1271C>G, ENST00000459642.1:n.702C>G, ENST00000616242.4:n.1319C>G, NM_000162.3:c.1322C>G, NM_033507.1:c.1325C>G, NM_033508.1:c.1319C>G, NM_000162.4:c.1322C>G, NM_001354800.1:c.1322C>G, NM_001354801.1:c.311C>G, NM_001354802.1:c.182C>G, NM_001354803.1:c.356C>G, NM_033507.2:c.1325C>G, NM_033508.2:c.1319C>G, XM_024446707.1:c.182C>G, NM_033507.3:c.1325C>G, NM_033508.3:c.1319C>G, NM_001354803.2:c.356C>G, NM_000162.5(GCK):c.1322C>G (p.Ser441Trp)	GCK	monogenic diabetes	MONDO:0015967	Semidominant inheritance	Pathogenic	PS4, PP4_Moderate, PP2, PP3, PS3_Moderate, PM2_Supporting		The c.1322C>G variant in the glucokinase gene, GCK, causes an amino acid change of glycine to asparagine at codon 441 (p.(Ser441Trp)) of NM_000162.5.  This variant is absent from gnomAD v2.1.1 (PM2_Supporting). GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2). This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.967, which is greater than the MDEP VCEP threshold of 0.70 (PP3). This variant was identified in an individual with a clinical history highly specific for GCK-MODY (FBG 5.5-8 mmol/L and HbA1c 5.6 - 7.6% and OGTT increment < 3.0 mmol/L) (PP4_Moderate; PMID: 25665835).  A kinetic analysis of recombinant wild-type (WT) and mutant glucokinase demonstrated that the wild-type kinetic parameters pass the quality control, the wild-type ATP Km is between 0.4-0.65, and the p.Ser441Trp has RAI=0.11, which is less than the MDEP VCEP threshold of 0.50 (PS3_Moderate; PMID 19884385). This variant was identified in 8 unrelated individuals with non-autoimmune and non-absolute/near-absolute insulin-deficient diabetes (PS4; PMID: 27420379, 25665835, 19884385, 17573900, 16965331, 11508276, internal lab contributors). In summary, 1322C>G meets the criteria to be classified as likely pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.2.0, approved 6/7/2023): PM2_Supporting, PP2, PP3, PP4_Moderate, PS3, PS4.		Monogenic Diabetes VCEP		2023-06-25	2023-06-25	False	https://erepo.genome.network/evrepo/ui/classification/CA367397017/MONDO:0015967/086	5a5a400f-b924-4261-a797-30b4d0f80434	p.Ser441Trp	Ser	441	Trp	MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQ	465	P35557	W	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [414], 'BINDING_gain': [], 'BINDING_loss_score': array([-0.0244453]), 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [203], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.01709062]), 'HELIX_loss': [444], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.12668926]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [73, 74, 82], 'REGION_gain': [11], 'REGION_gain_score': array([0.00359976]), 'REGION_loss_score': array([-0.0173074 , -0.02032167, -0.01728863]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
544	NM_000162.5(GCK):c.1240A>G (p.Lys414Glu)	36188	CA213739	NM_000162.5:c.1240A>G, NC_000007.14:g.44145510T>C, CM000669.2:g.44145510T>C, NC_000007.13:g.44185109T>C, CM000669.1:g.44185109T>C, NC_000007.12:g.44151634T>C, NG_008847.1:g.48914A>G, NG_008847.2:g.57661A>G, ENST00000395796.8:c.*1238A>G, ENST00000616242.5:c.*360A>G, ENST00000683378.1:n.466A>G, ENST00000336642.9:c.274A>G, ENST00000345378.7:c.1243A>G, ENST00000403799.8:c.1240A>G, ENST00000671824.1:c.1303A>G, ENST00000672743.1:n.252A>G, ENST00000673284.1:c.1240A>G, ENST00000336642.8:n.292A>G, ENST00000345378.6:c.1243A>G, ENST00000395796.7:c.1237A>G, ENST00000403799.7:c.1240A>G, ENST00000437084.1:c.1189A>G, ENST00000459642.1:n.620A>G, ENST00000616242.4:n.1237A>G, NM_000162.3:c.1240A>G, NM_033507.1:c.1243A>G, NM_033508.1:c.1237A>G, NM_000162.4:c.1240A>G, NM_001354800.1:c.1240A>G, NM_001354801.1:c.229A>G, NM_001354802.1:c.100A>G, NM_001354803.1:c.274A>G, NM_033507.2:c.1243A>G, NM_033508.2:c.1237A>G, XM_024446707.1:c.100A>G, NM_033507.3:c.1243A>G, NM_033508.3:c.1237A>G, NM_001354803.2:c.274A>G, NM_000162.5(GCK):c.1240A>G (p.Lys414Glu)	GCK	monogenic diabetes	MONDO:0015967	Semidominant inheritance	Pathogenic	PS4, PP1_Strong, PP2, PP3, PP4, PM1, PM2_Supporting	PS3	The c.1240A>G variant in the glucokinase gene, GCK, causes an amino acid change of lysine to glutamic acid at codon 414 (p.(Lys414Glu)) of NM_000162.5. GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2). This variant resides in an amino acid that directly binds ATP, which is defined as critical for the protein’s function by the ClinGen MDEP (PM1), and is predicted to be deleterious by computational evidence, with a REVEL score of 0.9279, which is greater than the MDEP VCEP threshold of 0.70 (PP3). This variant is absent from gnomAD v2.1.1 (PM2_Supporting), and was identified in seven unrelated individuals with non- autoimmune and non-absolute/near-absolute insulin-deficient diabetes (PS4; ClinVar ID 36188, PMID 18411240, internal lab contributors). The variant segregated with diabetes, with 5 informative meioses in three families with MODY (PP1_Strong; internal lab contributors). Additionally, one of these individuals has a clinical history highly specific for GCK-MODY (FBG 5.5-8 mmol/L and HbA1c 5.6 - 7.6%) (PP4; internal lab contributor).  In summary, c.1240A>G meets the criteria to be classified as pathogenic by the ClinGen MDEP (specification version 1.2.0, approved 6/7/2023): PP1_Strong, PS4, PP4, PM1, PP2, PP3, PM2_Supporting.		Monogenic Diabetes VCEP		2023-06-26	2023-06-26	False	https://erepo.genome.network/evrepo/ui/classification/CA213739/MONDO:0015967/086	887ffb3c-717c-4c08-8aa1-5319b0be7b76	p.Lys414Glu	Lys	414	Glu	MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQ	465	P35557	E	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [408, 414], 'BINDING_gain': [], 'BINDING_loss_score': array([-0.03667551, -0.05901903]), 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [83], 'DOMAIN_gain_score': array([0.00551558]), 'REGION_loss': [73], 'REGION_gain': [], 'REGION_loss_score': array([-0.00510675]), 'REPEAT_loss': [], 'REPEAT_gain': [75], 'REPEAT_gain_score': array([0.00277263]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
545	NM_022124.6(CDH23):c.6085C>T (p.Arg2029Trp)	446446	CA5545996	NM_022124.6:c.6085C>T, NC_000010.11:g.71791167C>T, CM000672.2:g.71791167C>T, NC_000010.10:g.73550924C>T, CM000672.1:g.73550924C>T, NC_000010.9:g.73220930C>T, NG_008835.1:g.399221C>T, ENST00000224721.12:c.6085C>T, ENST00000224721.10:c.6100C>T, ENST00000622827.4:c.6085C>T, NM_022124.5:c.6085C>T, XM_006717940.2:c.6280C>T, XM_006717942.2:c.6214C>T, XM_011540039.1:c.6277C>T, XM_011540040.1:c.6274C>T, XM_011540041.1:c.6220C>T, XM_011540042.1:c.6280C>T, XM_011540043.1:c.6280C>T, XM_011540044.1:c.6145C>T, XM_011540045.1:c.6280C>T, XM_011540046.1:c.5740C>T, XM_011540047.1:c.5098C>T, XM_011540048.1:c.6280C>T, XM_011540049.1:c.6280C>T, XM_011540050.1:c.6280C>T, XM_011540051.1:c.6280C>T, XM_011540052.1:c.2608C>T, XR_945796.1:n.6523C>T, NM_022124.6(CDH23):c.6085C>T (p.Arg2029Trp)	CDH23	nonsyndromic genetic deafness	MONDO:0019497	Autosomal recessive inheritance	Pathogenic	PP3, PP1, PM3_Very Strong	PM2	The c.6085C>T variant in CDH23 is a missense variant predicted to cause substitution of arginine by tryptophan at amino acid 2029 (p.Arg2029Trp). The highest population minor allele frequency in gnomAD v2.1.1 is 0.02% (3/17816 alleles) in the East Asian population. (PM2_Supporting, BS1, and BA1 are not met). The computational predictor REVEL gives a score of 0.7, evidence that correlates with impact to CDH23 function (PP3). This variant has been detected in many individuals with hearing loss or deafness, without any reported vision loss or evidence of retinopathy. Of those individuals, over 10 were homozygous or compound heterozygous for the variant and a pathogenic or likely pathogenic and many of those were confirmed in trans (6.75 PM3_Very Strong points, PMID: 35020051, 25963016, 22899989, 17850630). The variant has been reported to segregate with hearing loss in 1 affected family member from 1 family (PP1_Supporting; PMID: 22899989, 17850630). In summary, this variant meets the criteria to be classified as Pathogenic for autosomal recessive hearing loss based on the ACMG/AMP criteria applied, as specified by the ClinGen Hearing Loss VCEP: PM3_VeryStrong, PP3, PP1. (VCEP specifications version 2; 06.26.2023).		Hearing Loss VCEP	https://clinicalgenome.org/site/assets/files/7814/clingen_hl_acmg_specifications_cdh23_coch_gjb2_kcnq4_myo6_myo7a_slc26a4_tecta_ush2a_v2.pdf	2023-06-26	2023-06-30	False	https://erepo.genome.network/evrepo/ui/classification/CA5545996/MONDO:0019497/005	e333b58d-b3ca-4e2b-b958-09402de4c847	p.Arg2029Trp	Arg	2029	Trp	MGRHVATSCHVAWLLVLISGCWGQVNRLPFFTNHFFDTYLLISEDTPVGSSVTQLLAQDMDNDPLVFGVSGEEASRFFAVEPDTGVVWLRQPLDRETKSEFTVEFSVSDHQGVITRKVNIQVGDVNDNAPTFHNQPYSVRIPENTPVGTPIFIVNATDPDLGAGGSVLYSFQPPSQFFAIDSARGIVTVIRELDYETTQAYQLTVNATDQDKTRPLSTLANLAIIITDVQDMDPIFINLPYSTNIYEHSPPGTTVRIITAIDQDKGRPRGIGYTIVSGNTNSIFALDYISGVLTLNGLLDRENPLYSHGFILTVKGTELNDDRTPSDATVTTTFNILVIDINDNAPEFNSSEYSVAITELAQVGFALPLFIQVVDKDENLGLNSMFEVYLVGNNSHHFIISPTSVQGKADIRIRVAIPLDYETVDRYDFDLFANESVPDHVGYAKVKITLINENDNRPIFSQPLYNISLYENVTVGTSVLTVLATDNDAGTFGEVSYFFSDDPDRFSLDKDTGLIMLIARLDYELIQRFTLTIIARDGGGEETTGRVRINVLDVNDNVPTFQKDAYVGALRENEPSVTQLVRLRATDEDSPPNNQITYSIVSASAFGSYFDISLYEGYGVISVSRPLDYEQISNGLIYLTVMAMDAGNPPLNSTVPVTIEVFDENDNPPTFSKPAYFVSVVENIMAGATVLFLNATDLDRSREYGQESIIYSLEGSTQFRINARSGEITTTSLLDRETKSEYILIVRAVDGGVGHNQKTGIATVNITLLDINDNHPTWKDAPYYINLVEMTPPDSDVTTVVAVDPDLGENGTLVYSIQPPNKFYSLNSTTGKIRTTHAMLDRENPDPHEAELMRKIVVSVTDCGRPPLKATSSATVFVNLLDLNDNDPTFQNLPFVAEVLEGIPAGVSIYQVVAIDLDEGLNGLVSYRMPVGMPRMDFLINSSSGVVVTTTELDRERIAEYQLRVVASDAGTPTKSSTSTLTIHVLDVNDETPTFFPAVYNVSVSEDVPREFRVVWLNCTDNDVGLNAELSYFITGGNVDGKFSVGYRDAVVRTVVGLDRETTAAYMLILEAIDNGPVGKRHTGTATVFVTVLDVNDNRPIFLQSSYEASVPEDIPEGHSILQLKATDADEGEFGRVWYRILHGNHGNNFRIHVSNGLLMRGPRPLDRERNSSHVLIVEAYNHDLGPMRSSVRVIVYVEDINDEAPVFTQQQYSRLGLRETAGIGTSVIVVQATDRDSGDGGLVNYRILSGAEGKFEIDESTGLIITVNYLDYETKTSYMMNVSATDQAPPFNQGFCSVYITLLNELDEAVQFSNASYEAAILENLALGTEIVRVQAYSIDNLNQITYRFNAYTSTQAKALFKIDAITGVITVQGLVDREKGDFYTLTVVADDGGPKVDSTVKVYITVLDENDNSPRFDFTSDSAVSIPEDCPVGQRVATVKAWDPDAGSNGQVVFSLASGNIAGAFEIVTTNDSIGEVFVARPLDREELDHYILQVVASDRGTPPRKKDHILQVTILDINDNPPVIESPFGYNVSVNENVGGGTAVVQVRATDRDIGINSVLSYYITEGNKDMAFRMDRISGEIATRPAPPDRERQSFYHLVATVEDEGTPTLSATTHVYVTIVDENDNAPMFQQPHYEVLLDEGPDTLNTSLITIQALDLDEGPNGTVTYAIVAGNIVNTFRIDRHMGVITAAKELDYEISHGRYTLIVTATDQCPILSHRLTSTTTVLVNVNDINDNVPTFPRDYEGPFEVTEGQPGPRVWTFLAHDRDSGPNGQVEYSIMDGDPLGEFVISPVEGVLRVRKDVELDRETIAFYNLTICARDRGMPPLSSTMLVGIRVLDINDNDPVLLNLPMNITISENSPVSSFVAHVLASDADSGCNARLTFNITAGNRERAFFINATTGIVTVNRPLDRERIPEYKLTISVKDNPENPRIARRDYDLLLIFLSDENDNHPLFTKSTYQAEVMENSPAGTPLTVLNGPILALDADQDIYAVVTYQLLGAQSGLFDINSSTGVVTVRSGVIIDREAFSPPILELLLLAEDIGLLNSTAHLLITILDDNDNRPTFSPATLTVHLLENCPPGFSVLQVTATDEDSGLNGELVYRIEAGAQDRFLIHLVTGVIRVGNATIDREEQESYRLTVVATDRGTVPLSGTAIVTILIDDINDSRPEFLNPIQTVSVLESAEPGTVIANITAIDHDLNPKLEYHIVGIVAKDDTDRLVPNQEDAFAVNINTGSVMVKSPMNRELVATYEVTLSVIDNASDLPERSVSVPNAKLTVNVLDVNDNTPQFKPFGITYYMERILEGATPGTTLIAVAAVDPDKGLNGLVTYTLLDLVPPGYVQLEDSSAGKVIANRTVDYEEVHWLNFTVRASDNGSPPRAAEIPVYLEIVDINDNNPIFDQPSYQEAVFEDVPVGTIILTVTATDADSGNFALIEYSLGDGESKFAINPTTGDIYVLSSLDREKKDHYILTALAKDNPGDVASNRRENSVQVVIQVLDVNDCRPQFSKPQFSTSVYENEPAGTSVITMMATDQDEGPNGELTYSLEGPGVEAFHVDMDSGLVTTQRPLQSYEKFSLTVVATDGGEPPLWGTTMLLVEVIDVNDNRPVFVRPPNGTILHIREEIPLRSNVYEVYATDKDEGLNGAVRYSFLKTAGNRDWEFFIIDPISGLIQTAQRLDRESQAVYSLILVASDLGQPVPYETMQPLQVALEDIDDNEPLFVRPPKGSPQYQLLTVPEHSPRGTLVGNVTGAVDADEGPNAIVYYFIAAGNEEKNFHLQPDGCLLVLRDLDREREAIFSFIVKASSNRSWTPPRGPSPTLDLVADLTLQEVRVVLEDINDQPPRFTKAEYTAGVATDAKVGSELIQVLALDADIGNNSLVFYSILAIHYFRALANDSEDVGQVFTMGSMDGILRTFDLFMAYSPGYFVVDIVARDLAGHNDTAIIGIYILRDDQRVKIVINEIPDRVRGFEEEFIHLLSNITGAIVNTDNVQFHVDKKGRVNFAQTELLIHVVNRDTNRILDVDRVIQMIDENKEQLRNLFRNYNVLDVQPAISVRLPDDMSALQMAIIVLAILLFLAAMLFVLMNWYYRTVHKRKLKAIVAGSAGNRGFIDIMDMPNTNKYSFDGANPVWLDPFCRNLELAAQAEHEDDLPENLSEIADLWNSPTRTHGTFGREPAAVKPDDDRYLRAAIQEYDNIAKLGQIIREGPIKGSLLKVVLEDYLRLKKLFAQRMVQKASSCHSSISELIQTELDEEPGDHSPGQGSLRFRHKPPVELKGPDGIHVVHGSTGTLLATDLNSLPEEDQKGLGRSLETLTAAEATAFERNARTESAKSTPLHKLRDVIMETPLEITEL	3354	Q9H251	W	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [2296, 2352], 'STRAND_gain_score': array([0.00096405, 0.00095582]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [251, 2023, 2032, 2789], 'DOMAIN_gain': [1822, 1823, 2028, 3275, 3340, 3342], 'DOMAIN_gain_score': array([0.01450485, 0.01567447, 0.06763136, 0.02379501, 0.03256047,
       0.03704524]), 'DOMAIN_loss_score': array([-0.02503574, -0.02732223, -0.04678059, -0.01502544]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
546	NM_000162.5(GCK):c.1190G>T (p.Arg397Leu)	21077	CA341587	NM_000162.5:c.1190G>T, NC_000007.14:g.44145560C>A, CM000669.2:g.44145560C>A, NC_000007.13:g.44185159C>A, CM000669.1:g.44185159C>A, NC_000007.12:g.44151684C>A, NG_008847.1:g.48864G>T, NG_008847.2:g.57611G>T, ENST00000395796.8:c.*1188G>T, ENST00000616242.5:c.*310G>T, ENST00000683378.1:n.416G>T, ENST00000336642.9:c.224G>T, ENST00000345378.7:c.1193G>T, ENST00000403799.8:c.1190G>T, ENST00000671824.1:c.1253G>T, ENST00000672743.1:n.202G>T, ENST00000673284.1:c.1190G>T, ENST00000336642.8:n.242G>T, ENST00000345378.6:c.1193G>T, ENST00000395796.7:c.1187G>T, ENST00000403799.7:c.1190G>T, ENST00000437084.1:c.1139G>T, ENST00000459642.1:n.570G>T, ENST00000616242.4:n.1187G>T, NM_000162.3:c.1190G>T, NM_033507.1:c.1193G>T, NM_033508.1:c.1187G>T, NM_000162.4:c.1190G>T, NM_001354800.1:c.1190G>T, NM_001354801.1:c.179G>T, NM_001354802.1:c.50G>T, NM_001354803.1:c.224G>T, NM_033507.2:c.1193G>T, NM_033508.2:c.1187G>T, XM_024446707.1:c.50G>T, NM_033507.3:c.1193G>T, NM_033508.3:c.1187G>T, NM_001354803.2:c.224G>T, NM_000162.5(GCK):c.1190G>T (p.Arg397Leu)	GCK	monogenic diabetes	MONDO:0015967	Semidominant inheritance	Pathogenic	PS4, PP1_Strong, PP4_Moderate, PP2, PP3, PM3, PS3_Moderate, PM2_Supporting		The c.1190G>T variant in the glucokinase gene, GCK, causes an amino acid change of Arg to Leu at codon 397 (p.(Arg397Leu)) of NM_000162.5. This variant is absent from gnomAD v2.1.1 (PM2_Supporting). GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2). This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.925 which is greater than the MDEP VCEP threshold of 0.70 (PP3). This variant was identified in 21 unrelated individuals with non- autoimmune and non-absolute/near-absolute insulin-deficient diabetes (PS4; PMID:17186219 , internal lab contributors). This variant segregated with diabetes, with at least 7 informative meioses in 14 families with MODY (PP1_Strong; internal lab contributors). This variant was identified in an individual with a clinical history highly specific for GCK-MODY (FBG 5.5-8 mmol/L, HbA1c 5.6 - 7.6%, and OGTT increment < 3 mmol/L) (PP4_Moderate; PMID:17186219).  A kinetic analysis of recombinant wild-type (WT) and mutant glucokinase demonstrated that the wild-type kinetic parameters pass the quality control, the wild-type ATP Km is between 0.4-0.65, and the p.Arg397Leu has RAI=0.72, which is less than the MDEP VCEP threshold of 0.50 (PS3_Moderate; PMID 17186219). This variant has been detected in the homozygous state in at least 5 individuals with neonatal diabetes (PM3; internal lab contributors). In summary, c.1190G>T meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.2.0, approved 6/7/2023): PM2_Supporting, PP2, PP3, PS4, PP1_Strong, PP4_Moderate, PS3_Supporting, PM3.		Monogenic Diabetes VCEP		2023-07-16	2023-07-16	False	https://erepo.genome.network/evrepo/ui/classification/CA341587/MONDO:0015967/086	ca025555-c2e2-4b53-9af7-3bdcb6aa5da7	p.Arg397Leu	Arg	397	Leu	MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQ	465	P35557	L	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [414], 'BINDING_gain': [], 'BINDING_loss_score': array([-0.01857972]), 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [227], 'STRAND_gain_score': array([0.01774216]), 'HELIX_loss': [323], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.01997882]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [221], 'DOMAIN_gain_score': array([0.04647714]), 'REGION_loss': [73], 'REGION_gain': [21], 'REGION_gain_score': array([0.00029105]), 'REGION_loss_score': array([-0.00315422]), 'REPEAT_loss': [], 'REPEAT_gain': [75], 'REPEAT_gain_score': array([0.00580108]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
547	NM_000162.5(GCK):c.1174C>T (p.Arg392Cys)	585909	CA367398622	NM_000162.5:c.1174C>T, NC_000007.14:g.44145576G>A, CM000669.2:g.44145576G>A, NC_000007.13:g.44185175G>A, CM000669.1:g.44185175G>A, NC_000007.12:g.44151700G>A, NG_008847.1:g.48848C>T, NG_008847.2:g.57595C>T, ENST00000395796.8:c.*1172C>T, ENST00000616242.5:c.*294C>T, ENST00000683378.1:n.400C>T, ENST00000336642.9:c.208C>T, ENST00000345378.7:c.1177C>T, ENST00000403799.8:c.1174C>T, ENST00000671824.1:c.1237C>T, ENST00000672743.1:n.186C>T, ENST00000673284.1:c.1174C>T, ENST00000336642.8:n.226C>T, ENST00000345378.6:c.1177C>T, ENST00000395796.7:c.1171C>T, ENST00000403799.7:c.1174C>T, ENST00000437084.1:c.1123C>T, ENST00000459642.1:n.554C>T, ENST00000616242.4:n.1171C>T, NM_000162.3:c.1174C>T, NM_033507.1:c.1177C>T, NM_033508.1:c.1171C>T, NM_000162.4:c.1174C>T, NM_001354800.1:c.1174C>T, NM_001354801.1:c.163C>T, NM_001354802.1:c.34C>T, NM_001354803.1:c.208C>T, NM_033507.2:c.1177C>T, NM_033508.2:c.1171C>T, XM_024446707.1:c.34C>T, NM_033507.3:c.1177C>T, NM_033508.3:c.1171C>T, NM_001354803.2:c.208C>T, NM_000162.5(GCK):c.1174C>T (p.Arg392Cys)	GCK	monogenic diabetes	MONDO:0015967	Semidominant inheritance	Pathogenic	PS4, PP1_Strong, PP2, PP3, PP4, PM2_Supporting		The c.1174C>T variant in the glucokinase gene, GCK, causes an amino acid change of Arg to Cys at codon 392 (p.(Arg392Cys)) of NM_000162.5. This variant is absent from gnomAD v2.1.1 (PM2_Supporting). GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2). This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.911 which is greater than the MDEP VCEP threshold of 0.70 (PP3). This variant was identified in an individual with a clinical history highly specific for GCK-MODY (FBG 5.5-8 mmol/L and HbA1c 5.6 - 7.6%) (PP4;  internal lab contributors). This variant was identified in 15 unrelated individuals with non- autoimmune and non-absolute/near-absolute insulin-deficient diabetes (PS4; PMID:29758564 , internal lab contributors). This variant segregated with diabetes/hyperglycemia, with at least 19 informative meioses in 10 families with MODY (PP1_Strong; internal lab contributors). In summary, c.1174C>T meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.2.0, approved 6/7/2023): PM2_Supporting, PP2, PP3, PP4, PS4, PP1_Strong.		Monogenic Diabetes VCEP		2023-07-16	2023-07-16	False	https://erepo.genome.network/evrepo/ui/classification/CA367398622/MONDO:0015967/086	0e01d1e0-cdee-4782-ab8d-766899ffa48f	p.Arg392Cys	Arg	392	Cys	MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQ	465	P35557	C	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [395], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.14074326]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [11, 21, 71], 'REGION_gain_score': array([0.00529402, 0.00237191, 0.00464976]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
548	NM_000162.5(GCK):c.1145G>A (p.Cys382Tyr)	1256304	CA367398751	NM_000162.5:c.1145G>A, NC_000007.14:g.44145605C>T, CM000669.2:g.44145605C>T, NC_000007.13:g.44185204C>T, CM000669.1:g.44185204C>T, NC_000007.12:g.44151729C>T, NG_008847.1:g.48819G>A, NG_008847.2:g.57566G>A, ENST00000395796.8:c.*1143G>A, ENST00000616242.5:c.*265G>A, ENST00000683378.1:n.371G>A, ENST00000336642.9:c.179G>A, ENST00000345378.7:c.1148G>A, ENST00000403799.8:c.1145G>A, ENST00000671824.1:c.1208G>A, ENST00000672743.1:n.157G>A, ENST00000673284.1:c.1145G>A, ENST00000336642.8:n.197G>A, ENST00000345378.6:c.1148G>A, ENST00000395796.7:c.1142G>A, ENST00000403799.7:c.1145G>A, ENST00000437084.1:c.1094G>A, ENST00000459642.1:n.525G>A, ENST00000616242.4:n.1142G>A, NM_000162.3:c.1145G>A, NM_033507.1:c.1148G>A, NM_033508.1:c.1142G>A, NM_000162.4:c.1145G>A, NM_001354800.1:c.1145G>A, NM_001354801.1:c.134G>A, NM_001354802.1:c.5G>A, NM_001354803.1:c.179G>A, NM_033507.2:c.1148G>A, NM_033508.2:c.1142G>A, XM_024446707.1:c.5G>A, NM_033507.3:c.1148G>A, NM_033508.3:c.1142G>A, NM_001354803.2:c.179G>A, NM_000162.5(GCK):c.1145G>A (p.Cys382Tyr)	GCK	monogenic diabetes	MONDO:0015967	Semidominant inheritance	Pathogenic	PS4, PP1, PP2, PP3, PP4, PM2_Supporting, PM5		The c.1145G>A variant in the glucokinase gene, GCK, causes an amino acid change of cysteine to tyrosine at codon 382 (p.(Cys382Tyr)) of NM_000162.5. This variant is absent from gnomAD v2.1.1 (PM2_Supporting). GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2). This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.922 which is greater than the MDEP VCEP threshold of 0.70 (PP3).  This variant was identified in the homozygous state in three individuals with neonatal diabetes and negative testing for ABCC8, KCNJ11, and INS (internal lab contributors). This variant segregated with diabetes, with 3 informative meioses in 1 family with MODY (PP1; internal lab contributors). Another missense variant, c.1144T>C p.Cys382Arg, has been interpreted as pathogenic by the ClinGen MDEP, and p.Cys382Tyr has a greater Grantham distance (PM5). This variant was identified in 7 unrelated individuals with non- autoimmune and non-absolute/near-absolute insulin-deficient diabetes (PS4; Zubkova N.A et al, World J PM. 2017;1(1):40-48, https://doi.org/10.14341/WJPM9298, internal lab contributors). In summary, c.1145G>A meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.2.0 approved 6/7/2023): PP1, PP2, PP3, PM2_Supporting, PM5, PP4, PS4.		Monogenic Diabetes VCEP		2023-07-16	2023-07-16	False	https://erepo.genome.network/evrepo/ui/classification/CA367398751/MONDO:0015967/086	b17e0692-a2da-4e76-9e2b-b28ed6772784	p.Cys382Tyr	Cys	382	Tyr	MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQ	465	P35557	Y	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [414], 'BINDING_gain': [], 'BINDING_loss_score': array([-0.03629237]), 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [2], 'SIGNAL_gain_score': array([0.04560053]), 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [8, 73], 'REGION_gain': [], 'REGION_loss_score': array([-0.00968009, -0.00300872]), 'REPEAT_loss': [], 'REPEAT_gain': [75], 'REPEAT_gain_score': array([0.00511473]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
549	NM_000162.5(GCK):c.1144T>C (p.Cys382Arg)	447384	CA367398754	NM_000162.5:c.1144T>C, NC_000007.14:g.44145606A>G, CM000669.2:g.44145606A>G, NC_000007.13:g.44185205A>G, CM000669.1:g.44185205A>G, NC_000007.12:g.44151730A>G, NG_008847.1:g.48818T>C, NG_008847.2:g.57565T>C, ENST00000395796.8:c.*1142T>C, ENST00000616242.5:c.*264T>C, ENST00000683378.1:n.370T>C, ENST00000336642.9:c.178T>C, ENST00000345378.7:c.1147T>C, ENST00000403799.8:c.1144T>C, ENST00000671824.1:c.1207T>C, ENST00000672743.1:n.156T>C, ENST00000673284.1:c.1144T>C, ENST00000336642.8:n.196T>C, ENST00000345378.6:c.1147T>C, ENST00000395796.7:c.1141T>C, ENST00000403799.7:c.1144T>C, ENST00000437084.1:c.1093T>C, ENST00000459642.1:n.524T>C, ENST00000616242.4:n.1141T>C, NM_000162.3:c.1144T>C, NM_033507.1:c.1147T>C, NM_033508.1:c.1141T>C, NM_000162.4:c.1144T>C, NM_001354800.1:c.1144T>C, NM_001354801.1:c.133T>C, NM_001354802.1:c.4T>C, NM_001354803.1:c.178T>C, NM_033507.2:c.1147T>C, NM_033508.2:c.1141T>C, XM_024446707.1:c.4T>C, NM_033507.3:c.1147T>C, NM_033508.3:c.1141T>C, NM_001354803.2:c.178T>C, NM_000162.5(GCK):c.1144T>C (p.Cys382Arg)	GCK	monogenic diabetes	MONDO:0015967	Semidominant inheritance	Pathogenic	PS4, PM5_Supporting, PP4_Moderate, PP2, PP3, PM2_Supporting		The c.1144T>C variant in the glucokinase gene, GCK, causes an amino acid change of Cys to Arg at codon 382 (p.(Cys382Arg)) of NM_000162.5. This variant is absent from gnomAD v2.1.1 (PM2_Supporting). GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2). This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.967 which is greater than the MDEP VCEP threshold of 0.70 (PP3). Another missense variant, c.1144T>G p.Cys382Gly, has been classified as likely pathogenic by the ClinGen MDEP (PM5_Supporting). This variant was identified in an individual with a clinical history highly specific for GCK-MODY (FBG 5.5-8 mmol/L and HbA1c 5.6 - 7.6% and 3 generation family history of diabetes) (PP4_Moderate; internal lab contributors). This variant was identified in 7 unrelated individuals with non- autoimmune and non-absolute/near-absolute insulin-deficient diabetes (PS4; PMID:24804978, Zubkova N.A et al, World J PM. 2017;1(1):40-48. https://doi.org/10.14341/WJPM9298, internal lab contributors).  In summary, c.1144T>C meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.2.0, approved 6/7/2023): PP2, PP3, PM2_Supporting, PM5_Supporting, PP4_Moderate, PS4.		Monogenic Diabetes VCEP		2023-07-16	2023-07-16	False	https://erepo.genome.network/evrepo/ui/classification/CA367398754/MONDO:0015967/086	e7a5686b-f48c-44b4-b009-039d4f87746f	p.Cys382Arg	Cys	382	Arg	MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQ	465	P35557	R	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [203], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.02777523]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [21, 71, 75, 80, 81, 86], 'REGION_gain_score': array([0.00338364, 0.02176577, 0.03233713, 0.03069228, 0.02760929,
       0.02182519]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
550	NM_000162.5(GCK):c.622G>A (p.Ala208Thr)	804344	CA367401322	NM_000162.5:c.622G>A, NC_000007.14:g.44149817C>T, CM000669.2:g.44149817C>T, NC_000007.13:g.44189416C>T, CM000669.1:g.44189416C>T, NC_000007.12:g.44155941C>T, NG_008847.1:g.44607G>A, NG_008847.2:g.53354G>A, ENST00000395796.8:c.*620G>A, ENST00000616242.5:c.622G>A, ENST00000682635.1:n.1108G>A, ENST00000345378.7:c.625G>A, ENST00000403799.8:c.622G>A, ENST00000671824.1:c.622G>A, ENST00000673284.1:c.622G>A, ENST00000345378.6:c.625G>A, ENST00000395796.7:c.619G>A, ENST00000403799.7:c.622G>A, ENST00000437084.1:c.571G>A, ENST00000616242.4:n.619G>A, NM_000162.3:c.622G>A, NM_033507.1:c.625G>A, NM_033508.1:c.619G>A, NM_000162.4:c.622G>A, NM_001354800.1:c.622G>A, NM_033507.2:c.625G>A, NM_033508.2:c.619G>A, NM_033507.3:c.625G>A, NM_033508.3:c.619G>A, NM_000162.5(GCK):c.622G>A (p.Ala208Thr)	GCK	monogenic diabetes	MONDO:0015967	Semidominant inheritance	Pathogenic	PS4, PP1_Strong, PM5_Supporting, PP4_Moderate, PP2, PP3, PM2_Supporting, PS3_Moderate		The c.622G>A variant in the glucokinase gene, GCK causes an amino acid change of Ala to Thr at codon 210 (p.(Ala208Thr)) of NM_000162.5. GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2). This variant is also predicted to be deleterious by computational evidence, with a REVEL score of 0.905, which is greater than the MDEP VCEP threshold of 0.70 (PP3). This variant has an uncomputable Popmax filtering allele frequency in the gnomAD v2.1.1 due to only one copy in the European non-Finnish population and no copies in another subpopulation (PM2_Supporting).  This variant was identified in 7 unrelated individuals with diabetes (PS4; PMID: 25015100, internal lab contributors). This variant was identified in an individual with a clinical history highly specific for GCK-MODY (FBG 5.5-8 mmol/L and HbA1c 5.6 - 7.6% and OGTT increment < 3.0 mmol/L) (PP4_Moderate; internal lab contributors).  This variant segregated with diabetes with 4 informative meioses in 4 families with diabetes (PP1_Strong; internal lab contributors). A kinetic analysis of recombinant wild-type (WT) and mutant glucokinase demonstrated that the wild-type kinetic parameters passed the quality control, the wild-type ATP Km is between 0.4-0.65, and the p.Ala208Thr has RAI<0.50 (PS3_Moderate; PMID: 25015100). Another missense variant, c.623C>T p.Ala208Val, has been classified as pathogenic by the ClinGen MDEP VCEP but has a greater Grantham distance than p.Ala208Thr (PM5_Supporting). In summary, this variant meets the criteria to be classified as Pathogenic for GCK-MODY. ACMG/AMP criteria applied, as specified by the ClinGen MDEP VCEP (specification version 1.2, approved 6/7/2023) PP3, PP2, PM2_Supporting, PP4_Moderate, PM5_Supporting, PS4, PP1_Strong, PS3_Moderate.		Monogenic Diabetes VCEP		2023-07-23	2023-07-23	False	https://erepo.genome.network/evrepo/ui/classification/CA367401322/MONDO:0015967/086	7be4b009-9f38-4314-9c03-e3d5facd3f2d	p.Ala208Thr	Ala	208	Thr	MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQ	465	P35557	T	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [204], 'BINDING_gain': [], 'BINDING_loss_score': array([-0.20384473]), 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [203], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.03862423]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [11, 21, 71, 80], 'REGION_gain_score': array([0.00527006, 0.00362146, 0.01132226, 0.01360804]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
551	NM_000162.5(GCK):c.571C>T (p.Arg191Trp)	426122	CA367401530	NM_000162.5:c.571C>T, NC_000007.14:g.44149977G>A, CM000669.2:g.44149977G>A, NC_000007.13:g.44189576G>A, CM000669.1:g.44189576G>A, NC_000007.12:g.44156101G>A, NG_008847.1:g.44447C>T, NG_008847.2:g.53194C>T, ENST00000395796.8:c.*569C>T, ENST00000616242.5:c.571C>T, ENST00000682635.1:n.1057C>T, ENST00000345378.7:c.574C>T, ENST00000403799.8:c.571C>T, ENST00000671824.1:c.571C>T, ENST00000673284.1:c.571C>T, ENST00000345378.6:c.574C>T, ENST00000395796.7:c.568C>T, ENST00000403799.7:c.571C>T, ENST00000437084.1:c.520C>T, ENST00000616242.4:n.568C>T, NM_000162.3:c.571C>T, NM_033507.1:c.574C>T, NM_033508.1:c.568C>T, NM_000162.4:c.571C>T, NM_001354800.1:c.571C>T, NM_033507.2:c.574C>T, NM_033508.2:c.568C>T, NM_033507.3:c.574C>T, NM_033508.3:c.568C>T, NM_000162.5(GCK):c.571C>T (p.Arg191Trp)	GCK	monogenic diabetes	MONDO:0015967	Semidominant inheritance	Pathogenic	PS4, PP1_Strong, PP4_Moderate, PP2, PP3, PM2_Supporting, PS2_Moderate	PS3	The c.571C>T variant in the glucokinase gene, GCK causes an amino acid change of Arg to Trp at codon 191 (p.(Arg191Trp)) of NM_000162.5. GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2). This variant is also predicted to be deleterious by computational evidence, with a REVEL score of 0.936, which is greater than the MDEP VCEP threshold of 0.70 (PP3). This variant has an incomputable Popmax filtering allele frequency in gnomAD v2.1 due to only one copy in European non-Finnish population and one copy in another subpopulation, which is less than the MDEP threshold for PM2_Supporting (Popmax filtering FAF <= 0.000003 and <= 2 copies in ENF and ≤1 copy in any other subpopulation) (PM2_Supporting).  This variant was identified in more than 100 unrelated individuals with diabetes/hyperglycemia (PS4; PMIDs: 10753050, 22060211, 23295292, 28170077, internal lab contributors). This variant segregated with diabetes with at least 72 informative meioses from 51 families with MODY (PP1_Strong; internal lab contributors).  This variant was identified in an individual with a clinical history highly specific for GCK-MODY (FBG 5.5-8 mmol/L and HbA1c 5.6 - 7.6% and negative antibodies) (PP4_Moderate; PMID:  23295292).  This variant was found de novo in an individual with a phenotype highly specific for GCK-MODY with unconfirmed parental relationships (PS2_Moderate; internal lab contributor).  Functional studies demonstrated the p.Arg191Trp protein has RAI<0.5; however, the wild-type kinetic parameters didn’t pass the quality control, and the PS3 cannot be applied (PMID: 30592380). In summary, this variant meets the criteria to be classified as Pathogenic for GCK-MODY. ACMG/AMP criteria applied, as specified by the ClinGen MDEP VCEP (specification version 1.2, approved 6/7/2023): PS4, PP1_Strong, PS2_Moderate, PP4_Moderate, PM2_Supporting, PP2, PP3.		Monogenic Diabetes VCEP		2023-07-23	2023-07-23	False	https://erepo.genome.network/evrepo/ui/classification/CA367401530/MONDO:0015967/086	c6d46289-9537-46e1-99aa-e854f39affb2	p.Arg191Trp	Arg	191	Trp	MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQ	465	P35557	W	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [408, 414], 'BINDING_gain': [], 'BINDING_loss_score': array([-0.01759326, -0.01685578]), 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [203], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.05167872]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [73, 82], 'REGION_gain': [11, 21], 'REGION_gain_score': array([0.00911355, 0.00185478]), 'REGION_loss_score': array([-0.01288223, -0.02338427]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
552	NM_000162.5(GCK):c.629T>A (p.Met210Lys)	16141	CA204367	NM_000162.5:c.629T>A, NC_000007.14:g.44149810A>T, CM000669.2:g.44149810A>T, NC_000007.13:g.44189409A>T, CM000669.1:g.44189409A>T, NC_000007.12:g.44155934A>T, NG_008847.1:g.44614T>A, NG_008847.2:g.53361T>A, ENST00000395796.8:c.*627T>A, ENST00000616242.5:c.629T>A, ENST00000682635.1:n.1115T>A, ENST00000345378.7:c.632T>A, ENST00000403799.8:c.629T>A, ENST00000671824.1:c.629T>A, ENST00000673284.1:c.629T>A, ENST00000345378.6:c.632T>A, ENST00000395796.7:c.626T>A, ENST00000403799.7:c.629T>A, ENST00000437084.1:c.578T>A, ENST00000616242.4:n.626T>A, NM_000162.3:c.629T>A, NM_033507.1:c.632T>A, NM_033508.1:c.626T>A, NM_000162.4:c.629T>A, NM_001354800.1:c.629T>A, NM_033507.2:c.632T>A, NM_033508.2:c.626T>A, NM_033507.3:c.632T>A, NM_033508.3:c.626T>A, NM_000162.5(GCK):c.629T>A (p.Met210Lys)	GCK	monogenic diabetes	MONDO:0015967	Semidominant inheritance	Pathogenic	PM3_Supporting, PP1_Strong, PP4_Moderate, PP2, PP3, PS3_Moderate, PM2_Supporting, PM5	PS4, BA1, BS1	The c.629T>A variant in the glucokinase gene, GCK, causes an amino acid change of methionine to lysine at codon 210 (p.(Met210Lys)) of NM_000162.5. GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2). This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.979, which is greater than the MDEP threshold of 0.70 (PP3), and functional studies suggest that this variant alters glucokinase kinetic parameters, with an RAI less than 0.5 (wild-type QC parameters met including ATP Km between 0.4 and 0.65) (PS3_Moderate; PMIDs: 16731834,14517946). This variant was identified in two unrelated families with non-autoimmune and non-absolute/near-absolute insulin-deficient diabetes; however, PS4_Moderate cannot be applied because this number is below the ClinGen MDEP threshold (PMIDs:18399931, 11372010, 27913849, internal lab contributor). At least one individual individual had a clinical history highly specific for GCK-MODY (FBG 5.5-8 mmol/L and HbA1c 5.6 - 7.6% persisting over time) (PP4_Moderate; internal lab contributors).  This variant segregated with diabetes, with at least 10 informative meioses in a family with MODY (PP1_Strong; PMIDs: 18399931, 11372010). This variant has also been detected in at least one family with neonatal diabetes. One individual in this family was homozygous and experienced permanent neonatal diabetes mellitus, and variants were were confirmed in trans (PM3_Supporting; PMIDs:18399931, 11372010). Additionally, another missense variant, c.629T>C (p.Met210Thr) has been interpreted as pathogenic by the ClinGen MDEP, and p.Met210Lyshas a greater Grantham distance (PM5). In summary, c.629T>A meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.2.0, approved 6/7/2023): PP1_Strong, PM5, PP4_Moderate, PS3_Moderate, PP2, PP3, PM2_Supporting, PM3_Supporting.		Monogenic Diabetes VCEP		2023-07-30	2023-07-30	False	https://erepo.genome.network/evrepo/ui/classification/CA204367/MONDO:0015967/086	7277513a-d176-41fb-8fee-d6d0a2da162e	p.Met210Lys	Met	210	Lys	MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQ	465	P35557	K	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [203], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.06624573]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [83], 'DOMAIN_gain_score': array([0.00504434]), 'REGION_loss': [], 'REGION_gain': [21], 'REGION_gain_score': array([0.00151867]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
553	NM_000162.5(GCK):c.630G>T (p.Met210Ile)	36236	CA213814	NM_000162.5:c.630G>T, NC_000007.14:g.44149809C>A, CM000669.2:g.44149809C>A, NC_000007.13:g.44189408C>A, CM000669.1:g.44189408C>A, NC_000007.12:g.44155933C>A, NG_008847.1:g.44615G>T, NG_008847.2:g.53362G>T, ENST00000395796.8:c.*628G>T, ENST00000616242.5:c.630G>T, ENST00000682635.1:n.1116G>T, ENST00000345378.7:c.633G>T, ENST00000403799.8:c.630G>T, ENST00000671824.1:c.630G>T, ENST00000673284.1:c.630G>T, ENST00000345378.6:c.633G>T, ENST00000395796.7:c.627G>T, ENST00000403799.7:c.630G>T, ENST00000437084.1:c.579G>T, ENST00000616242.4:c.627G>T, NM_000162.3:c.630G>T, NM_033507.1:c.633G>T, NM_033508.1:c.627G>T, NM_000162.4:c.630G>T, NM_001354800.1:c.630G>T, NM_033507.2:c.633G>T, NM_033508.2:c.627G>T, NM_033507.3:c.633G>T, NM_033508.3:c.627G>T, NM_000162.5(GCK):c.630G>T (p.Met210Ile)	GCK	monogenic diabetes	MONDO:0015967	Semidominant inheritance	Pathogenic	PS1, PM5_Strong, PP2, PP3, PM2_Supporting	PS4, PP4	The c.630G>T variant in the glucokinase gene, GCK, causes an amino acid change of methionine to isoleucine at codon 210 (p.(Met210Ile)) of NM_000162.5. GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2). This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.9399, which is greater than the MDEP VCEP threshold of 0.70 (PP3). This variant is absent in gnomAD v2.1.1 (PM2_Supporting), and was identified in an individual with diabetes; however, PP4 is unable to be evaluated due to lack of clinical information (ClinVar ID 36236). Two other missense variants, c.629T>A (p.Met210Lys) and c.629T>C (p.Met210Thr), have been classified as pathogenic by the ClinGen MDEP (PM5_Strong). The nucleotide change c.630G>A, which causes the same amino acid change, has been classified as pathogenic for monogenic diabetes by the ClinGen MDEP (PS1). Taken together, the c.630G>T meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.3.0, approved 8/11/2023): PM5_Strong, PS1, PP2, PP3, PM2_Supporting.		Monogenic Diabetes VCEP		2024-01-22	2024-01-22	False	https://erepo.genome.network/evrepo/ui/classification/CA213814/MONDO:0015967/086	d17187f9-d65a-4117-af07-cfcb9e907236	p.Met210Ile	Met	210	Ile	MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQ	465	P35557	I	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [21, 71, 75, 80], 'REGION_gain_score': array([0.00361401, 0.02063322, 0.02120012, 0.02040976]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
554	NM_000162.5(GCK):c.523G>A (p.Gly175Arg)	129143	CA231137	NM_000162.5:c.523G>A, NC_000007.14:g.44150025C>T, CM000669.2:g.44150025C>T, NC_000007.13:g.44189624C>T, CM000669.1:g.44189624C>T, NC_000007.12:g.44156149C>T, NG_008847.1:g.44399G>A, NG_008847.2:g.53146G>A, ENST00000395796.8:c.*521G>A, ENST00000616242.5:c.523G>A, ENST00000682635.1:n.1009G>A, ENST00000345378.7:c.526G>A, ENST00000403799.8:c.523G>A, ENST00000671824.1:c.523G>A, ENST00000673284.1:c.523G>A, ENST00000345378.6:c.526G>A, ENST00000395796.7:c.520G>A, ENST00000403799.7:c.523G>A, ENST00000437084.1:c.472G>A, ENST00000616242.4:n.520G>A, NM_000162.3:c.523G>A, NM_033507.1:c.526G>A, NM_033508.1:c.520G>A, NM_000162.4:c.523G>A, NM_001354800.1:c.523G>A, NM_033507.2:c.526G>A, NM_033508.2:c.520G>A, NM_033507.3:c.526G>A, NM_033508.3:c.520G>A, NM_000162.5(GCK):c.523G>A (p.Gly175Arg)	GCK	monogenic diabetes	MONDO:0015967	Semidominant inheritance	Pathogenic	PS4, PS1, PP1_Strong, PS3_Supporting, PP4_Moderate, PP2, PP3, PM2_Supporting		The c.523G>A variant in the glucokinase gene, GCK causes an amino acid change of Gly to Arg at codon 210 (p.(Gly175Arg)) of NM_000162.5. GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2). This variant is also predicted to be deleterious by computational evidence, with a REVEL score of 0.965, which is greater than the MDEP VCEP threshold of 0.70 (PP3). This variant is absent from gnomAD v2.1.1 (PM2_Supporting). This variant was identified in 8 unrelated individuals with diabetes (PS4; PMID: 29944009, 20337973, 26552609, internal lab contributors). This variant was identified in an individual with a clinical history highly specific for GCK-hyperglycemia (FBG 5.5-8 mmol/L and HbA1c 5.6 - 7.6% and three-generation, dominant family history of diabetes/hyperglycemia) (PP4_Moderate; internal lab contributors).  This variant segregated with diabetes with 5 informative meioses in 4 families with diabetes (PP1_Strong; internal lab contributors). A kinetic analysis of recombinant wild-type (WT) and mutant glucokinase demonstrated that the wild-type kinetic parameters pass the quality control, but the wild-type ATP Km is not between 0.4-0.65, and the p.Gly175Arg variant has Kcat/S0.5<0.5 (PS3_Supporting; PMID 10525657). The nucleotide change c.523G>C, which causes the same amino acid change, has been classified as pathogenic for MODY by the ClinGen MDEP (PS1). In summary, this variant meets the criteria to be classified as Pathogenic for GCK-MODY. ACMG/AMP criteria applied, as specified by the ClinGen MDEP VCEP (specification version 1.2.0, approved 6/7/2023) : PS4, PP1_Strong, PP4_Moderate, PS3_Supporting, PM2_Supporting, PP2, PP3, PS1.		Monogenic Diabetes VCEP		2023-07-30	2023-07-30	False	https://erepo.genome.network/evrepo/ui/classification/CA231137/MONDO:0015967/086	4b2ceaad-8826-45d2-bf5d-9ff4c035568d	p.Gly175Arg	Gly	175	Arg	MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQ	465	P35557	R	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [83], 'DOMAIN_gain_score': array([0.00300568]), 'REGION_loss': [73], 'REGION_gain': [21], 'REGION_gain_score': array([0.00180703]), 'REGION_loss_score': array([-0.00355893]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
555	NM_000162.5(GCK):c.608T>C (p.Val203Ala)	585923	CA367401366	NM_000162.5:c.608T>C, NC_000007.14:g.44149831A>G, CM000669.2:g.44149831A>G, NC_000007.13:g.44189430A>G, CM000669.1:g.44189430A>G, NC_000007.12:g.44155955A>G, NG_008847.1:g.44593T>C, NG_008847.2:g.53340T>C, ENST00000395796.8:c.*606T>C, ENST00000616242.5:c.608T>C, ENST00000682635.1:n.1094T>C, ENST00000345378.7:c.611T>C, ENST00000403799.8:c.608T>C, ENST00000671824.1:c.608T>C, ENST00000673284.1:c.608T>C, ENST00000345378.6:c.611T>C, ENST00000395796.7:c.605T>C, ENST00000403799.7:c.608T>C, ENST00000437084.1:c.557T>C, ENST00000616242.4:n.605T>C, NM_000162.3:c.608T>C, NM_033507.1:c.611T>C, NM_033508.1:c.605T>C, NM_000162.4:c.608T>C, NM_001354800.1:c.608T>C, NM_033507.2:c.611T>C, NM_033508.2:c.605T>C, NM_033507.3:c.611T>C, NM_033508.3:c.605T>C, NM_000162.5(GCK):c.608T>C (p.Val203Ala)	GCK	monogenic diabetes	MONDO:0015967	Semidominant inheritance	Pathogenic	PS4, PP1_Strong, PP4_Moderate, PP2, PP3, PS3_Moderate, PM2_Supporting	PM1	The c.608T>C variant in the glucokinase gene, GCK, causes an amino acid change of valine to alanine at codon 203 (p.(Val203Ala)) of NM_000162.5. GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2). This variant is absent from gnomAD v2.1.1 (PM2_Supporting), and has been identified in at least 15 unrelated individuals with non-autoimmune and non-absolute/near-absolute insulin-deficient diabetes (PS4; ClinVar ID: 585923, PMIDs: 9075802, 9000695, 8433729, 15841481,19790256). At least one of these individuals has a clinical history highly specific for GCK-MODY (FBG 5.5-8 mmol/L and HbA1c 5.6-7.6%, antibody negative, and three-generation dominant family history of diabetes or hyperglycemia) (PP4_Moderate; PMID 15841481). This variant segregated with diabetes, with at least six informative meioses in five families with MODY (PP1_Strong; PMID:9075802, PMID:16059790). This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.946, which is greater than the MDEP VCEP threshold of 0.70 (PP3). Additionally, functional studies have determined that the c.608C>T variant has decreased catalytic activity as measured by a relative activity index (RAI) < 0.5 (PS3_Moderate; https://doi.org/10.1159/000079009). In summary, c.608C>T meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.1, approved 3/23/2023): PP1_Strong, PS4, PP4_Moderate, PS3_Moderate, PP2, PP3, PM2_Supporting).		Monogenic Diabetes VCEP		2023-07-31	2023-07-31	False	https://erepo.genome.network/evrepo/ui/classification/CA367401366/MONDO:0015967/086	7305dd73-b842-458c-b7f8-5d8dd9f9cd7a	p.Val203Ala	Val	203	Ala	MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQ	465	P35557	A	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [203], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.14368004]), 'HELIX_loss': [], 'HELIX_gain': [203], 'HELIX_gain_score': array([0.31287998]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [83, 221], 'DOMAIN_gain_score': array([0.0126363 , 0.02727532]), 'REGION_loss': [73, 74], 'REGION_gain': [], 'REGION_loss_score': array([-0.01785004, -0.01832128]), 'REPEAT_loss': [], 'REPEAT_gain': [75], 'REPEAT_gain_score': array([0.00271094]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
556	NM_004360.5(CDH1):c.1565C>T (p.Thr522Ile)	216588	CA337526	NM_004360.5:c.1565C>T, NC_000016.10:g.68815759C>T, CM000678.2:g.68815759C>T, NC_000016.9:g.68849662C>T, CM000678.1:g.68849662C>T, NC_000016.8:g.67407163C>T, NG_008021.1:g.83468C>T, LRG_301:g.83468C>T, ENST00000261769.10:c.1565C>T, ENST00000261769.9:c.1565C>T, ENST00000422392.6:c.1382C>T, ENST00000562836.5:n.1636C>T, ENST00000566510.5:c.*231C>T, ENST00000566612.5:c.1565C>T, ENST00000611625.4:c.1628C>T, ENST00000612417.4:c.1565C>T, ENST00000621016.4:c.1565C>T, NM_004360.3:c.1565C>T, LRG_301t1:c.1565C>T, XM_011523488.1:c.830C>T, XM_011523489.1:c.830C>T, NM_001317184.1:c.1382C>T, NM_001317185.1:c.17C>T, NM_001317186.1:c.-255C>T, NM_004360.4:c.1565C>T, NM_001317184.2:c.1382C>T, NM_001317185.2:c.17C>T, NM_001317186.2:c.-255C>T, NM_004360.5(CDH1):c.1565C>T (p.Thr522Ile)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0100488	Autosomal dominant inheritance	Benign	BS2, BP2_Strong	PS4, BA1, BS1, PM2	The NM_004360.5(CDH1): c.1565C>T (p.Thr522Ile) variant has been observed in >10 individuals without a diagnosis of diffuse gastric cancer, signet ring tumor or lobular breast cancer and whose family histories do not suggest HDGC (BS2; internal laboratory contributors). This variant was observed in the homozygous state in 1 individual without personal and/or family history of DGC, LBC, or SRC tumors (BP2_strong; internal laboratory contributors). This variant is known in one family with HDGC criteria (ERN_GENTURIS). In summary, the clinical significance of this variant is classified as benign based on BS2 and BP2_strong. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel: BS2, BP2_strong. (CDH1 VCEP specifications version 3.1; 06/26/2023)		CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-03	2023-08-03	False	https://erepo.genome.network/evrepo/ui/classification/CA337526/MONDO:0100488/007	bfceaed6-bdd0-41f8-857a-4ee3c6a14e03	p.Thr522Ile	Thr	522	Ile	MGPWSRSLSALLLLLQVSSWLCQEPEPCHPGFDAESYTFTVPRRHLERGRVLGRVNFEDCTGRQRTAYFSLDTRFKVGTDGVITVKRPLRFHNPQIHFLVYAWDSTYRKFSTKVTLNTVGHHHRPPPHQASVSGIQAELLTFPNSSPGLRRQKRDWVIPPISCPENEKGPFPKNLVQIKSNKDKEGKVFYSITGQGADTPPVGVFIIERETGWLKVTEPLDRERIATYTLFSHAVSSNGNAVEDPMEILITVTDQNDNKPEFTQEVFKGSVMEGALPGTSVMEVTATDADDDVNTYNAAIAYTILSQDPELPDKNMFTINRNTGVISVVTTGLDRESFPTYTLVVQAADLQGEGLSTTATAVITVTDTNDNPPIFNPTTYKGQVPENEANVVITTLKVTDADAPNTPAWEAVYTILNDDGGQFVVTTNPVNNDGILKTAKGLDFEAKQQYILHVAVTNVVPFEVSLTTSTATVTVDVLDVNEAPIFVPPEKRVEVSEDFGVGQEITSYTAQEPDTFMEQKITYRIWRDTANWLEINPDTGAISTRAELDREDFEHVKNSTYTALIIATDNGSPVATGTGTLLLILSDVNDNAPIPEPRTIFFCERNPKPQVINIIDADLPPNTSPFTAELTHGASANWTIQYNDPTQESIILKPKMALEVGDYKINLKLMDNQNKDQVTTLEVSVCDCEGAAGVCRKAQPVEAGLQIPAILGILGGILALLILILLLLLFLRRRAVVKEPLLPPEDDTRDNVYYYDEEGGGEEDQDFDLSQLHRGLDARPEVTRNDVAPTLMSVPRYLPRPANPDEIGNFIDENLKAADTDPTAPPYDSLLVFDYEGSGSEAASLSSLNSSESDKDQDYDYLNEWGNRFKKLADMYGGGEDD	882	P12830	I	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [503], 'STRAND_gain': [175, 485, 678], 'STRAND_gain_score': array([0.00190634, 0.00932437, 0.00222427]), 'STRAND_loss_score': array([-0.00364614]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
557	NM_004360.5(CDH1):c.1568A>G (p.Tyr523Cys)	141014	CA090925	NM_004360.5:c.1568A>G, NC_000016.10:g.68819282A>G, CM000678.2:g.68819282A>G, NC_000016.9:g.68853185A>G, CM000678.1:g.68853185A>G, NC_000016.8:g.67410686A>G, NG_008021.1:g.86991A>G, LRG_301:g.86991A>G, ENST00000261769.10:c.1568A>G, ENST00000261769.9:c.1568A>G, ENST00000422392.6:c.1385A>G, ENST00000562836.5:n.1639A>G, ENST00000566510.5:c.*234A>G, ENST00000566612.5:c.1566-2719A>G, ENST00000611625.4:c.1631A>G, ENST00000612417.4:c.1568A>G, ENST00000621016.4:c.1568A>G, NM_004360.3:c.1568A>G, LRG_301t1:c.1568A>G, XM_011523488.1:c.833A>G, XM_011523489.1:c.833A>G, NM_001317184.1:c.1385A>G, NM_001317185.1:c.20A>G, NM_001317186.1:c.-254-2719A>G, NM_004360.4:c.1568A>G, NM_001317184.2:c.1385A>G, NM_001317185.2:c.20A>G, NM_001317186.2:c.-254-2719A>G, NM_004360.5(CDH1):c.1568A>G (p.Tyr523Cys)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0100488	Autosomal dominant inheritance	Benign	BS2, BP2_Strong, BS1	BA1, PM2	The filtering allele frequency of the c.1568A>G (p.Tyr523Cys) variant in the CDH1 gene is 0.15% for Latino/Admixed American chromosomes in gnomAD (95% CI of 23/15282), which meets the allele frequency threshold defined by the ClinGen CDH1 Variant Curation Expert Panel for considering strong evidence against pathogenicity for autosomal dominant hereditary diffuse gastric cancer variants (BS1). This variant has been observed in >10 individuals without a diagnosis of diffuse gastric cancer, signet ring tumor or lobular breast cancer and whose family histories do not suggest HDGC (BS2; internal laboratory contributors). This variant was observed in the homozygous state in 9 individuals without personal and/or family history of DGC, LBC, or SRC tumors (BP2_strong; internal laboratory contributors). In summary, the clinical significance of this variant is classified as benign. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel: BS1, BS2, BP2_strong. (CDH1 VCEP specifications version 3.1; 06/26/2023)		CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-03	2023-08-03	False	https://erepo.genome.network/evrepo/ui/classification/CA090925/MONDO:0100488/007	19eabdee-a252-43c4-a1f4-f09d37e205e2	p.Tyr523Cys	Tyr	523	Cys	MGPWSRSLSALLLLLQVSSWLCQEPEPCHPGFDAESYTFTVPRRHLERGRVLGRVNFEDCTGRQRTAYFSLDTRFKVGTDGVITVKRPLRFHNPQIHFLVYAWDSTYRKFSTKVTLNTVGHHHRPPPHQASVSGIQAELLTFPNSSPGLRRQKRDWVIPPISCPENEKGPFPKNLVQIKSNKDKEGKVFYSITGQGADTPPVGVFIIERETGWLKVTEPLDRERIATYTLFSHAVSSNGNAVEDPMEILITVTDQNDNKPEFTQEVFKGSVMEGALPGTSVMEVTATDADDDVNTYNAAIAYTILSQDPELPDKNMFTINRNTGVISVVTTGLDRESFPTYTLVVQAADLQGEGLSTTATAVITVTDTNDNPPIFNPTTYKGQVPENEANVVITTLKVTDADAPNTPAWEAVYTILNDDGGQFVVTTNPVNNDGILKTAKGLDFEAKQQYILHVAVTNVVPFEVSLTTSTATVTVDVLDVNEAPIFVPPEKRVEVSEDFGVGQEITSYTAQEPDTFMEQKITYRIWRDTANWLEINPDTGAISTRAELDREDFEHVKNSTYTALIIATDNGSPVATGTGTLLLILSDVNDNAPIPEPRTIFFCERNPKPQVINIIDADLPPNTSPFTAELTHGASANWTIQYNDPTQESIILKPKMALEVGDYKINLKLMDNQNKDQVTTLEVSVCDCEGAAGVCRKAQPVEAGLQIPAILGILGGILALLILILLLLLFLRRRAVVKEPLLPPEDDTRDNVYYYDEEGGGEEDQDFDLSQLHRGLDARPEVTRNDVAPTLMSVPRYLPRPANPDEIGNFIDENLKAADTDPTAPPYDSLLVFDYEGSGSEAASLSSLNSSESDKDQDYDYLNEWGNRFKKLADMYGGGEDD	882	P12830	C	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [485, 522], 'STRAND_gain_score': array([0.02877027, 0.08028173]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
558	NM_000162.5(GCK):c.1133C>T (p.Ala378Val)	21076	CA341585	NM_000162.5:c.1133C>T, NC_000007.14:g.44145617G>A, CM000669.2:g.44145617G>A, NC_000007.13:g.44185216G>A, CM000669.1:g.44185216G>A, NC_000007.12:g.44151741G>A, NG_008847.1:g.48807C>T, NG_008847.2:g.57554C>T, ENST00000395796.8:c.*1131C>T, ENST00000616242.5:c.*253C>T, ENST00000683378.1:n.359C>T, ENST00000336642.9:c.167C>T, ENST00000345378.7:c.1136C>T, ENST00000403799.8:c.1133C>T, ENST00000671824.1:c.1196C>T, ENST00000672743.1:n.145C>T, ENST00000673284.1:c.1133C>T, ENST00000336642.8:c.185C>T, ENST00000345378.6:c.1136C>T, ENST00000395796.7:c.1130C>T, ENST00000403799.7:c.1133C>T, ENST00000437084.1:c.1082C>T, ENST00000459642.1:n.513C>T, ENST00000616242.4:c.1130C>T, NM_000162.3:c.1133C>T, NM_033507.1:c.1136C>T, NM_033508.1:c.1130C>T, NM_000162.4:c.1133C>T, NM_001354800.1:c.1133C>T, NM_001354801.1:c.122C>T, NM_001354802.1:c.-8C>T, NM_001354803.1:c.167C>T, NM_033507.2:c.1136C>T, NM_033508.2:c.1130C>T, XM_024446707.1:c.-8C>T, NM_033507.3:c.1136C>T, NM_033508.3:c.1130C>T, NM_001354803.2:c.167C>T, NM_000162.5(GCK):c.1133C>T (p.Ala378Val)	GCK	monogenic diabetes	MONDO:0015967	Semidominant inheritance	Pathogenic	PS4, PP1_Strong, PM3_Supporting, PP2, PP3, PP4, PM5, PM2_Supporting	PM1	The  variant in the glucokinase gene, GCK, causes an amino acid change of alanine to valine at codon 378 (p.(Ala378Val)) of NM_000162.5. GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2). This variant is also predicted to be deleterious by computational evidence, with a REVEL score of 0.967, which is greater than the MDEP VCEP threshold of 0.70 (PP3). This variant is absent in gnomAD v2.1.1 (PM2_Supporting), and was identified in 9 unrelated individuals with non-autoimmune and non-absolute/near-absolute insulin-deficient diabetes (PS4; PMIDs: 14578306, 25935773, internal lab contributors). One of these individuals has a clinical history highly specific for GCK-hyperglycemia (FBG 5.5-8 mmol/L and HbA1c 5.6 - 7.6%) (internal lab contributors).  It has also been detected in an individual with neonatal diabetes who was homozygous for this variant and had antibody-negative diabetes (PM3_Supporting, PMID: 14578306). This variant also segregated with diabetes, with at least 4 informative meioses in 4 families with MODY (PP1_Strong; internal lab contributors). Additionally, another missense variant, c.1132G>A (p.Ala378Thr) has been interpreted as pathogenic by the ClinGen MDEP and p.Ala378Val has a greater Grantham distance (PM5). In summary, c.1133C>T meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.2.0, approved 6/7/2023): PP1_Strong, PP4, PS4, PM5, PP2, PP3, PM2_Supporting, PM3_Supporting.		Monogenic Diabetes VCEP		2023-08-08	2023-08-08	False	https://erepo.genome.network/evrepo/ui/classification/CA341585/MONDO:0015967/086	ee600241-27a2-46f8-8e47-92684c9a911a	p.Ala378Val	Ala	378	Val	MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQ	465	P35557	V	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [21], 'REGION_gain_score': array([0.00229716]), 'REPEAT_loss': [], 'REPEAT_gain': [75], 'REPEAT_gain_score': array([0.00383621]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
559	NM_000162.5(GCK):c.1132G>A (p.Ala378Thr)	16145	CA126216	NM_000162.5:c.1132G>A, NC_000007.14:g.44145618C>T, CM000669.2:g.44145618C>T, NC_000007.13:g.44185217C>T, CM000669.1:g.44185217C>T, NC_000007.12:g.44151742C>T, NG_008847.1:g.48806G>A, NG_008847.2:g.57553G>A, ENST00000395796.8:c.*1130G>A, ENST00000616242.5:c.*252G>A, ENST00000683378.1:n.358G>A, ENST00000336642.9:c.166G>A, ENST00000345378.7:c.1135G>A, ENST00000403799.8:c.1132G>A, ENST00000671824.1:c.1195G>A, ENST00000672743.1:n.144G>A, ENST00000673284.1:c.1132G>A, ENST00000336642.8:c.184G>A, ENST00000345378.6:c.1135G>A, ENST00000395796.7:c.1129G>A, ENST00000403799.7:c.1132G>A, ENST00000437084.1:c.1081G>A, ENST00000459642.1:n.512G>A, ENST00000616242.4:c.1129G>A, NM_000162.3:c.1132G>A, NM_033507.1:c.1135G>A, NM_033508.1:c.1129G>A, NM_000162.4:c.1132G>A, NM_001354800.1:c.1132G>A, NM_001354801.1:c.121G>A, NM_001354802.1:c.-9G>A, NM_001354803.1:c.166G>A, NM_033507.2:c.1135G>A, NM_033508.2:c.1129G>A, XM_024446707.1:c.-9G>A, NM_033507.3:c.1135G>A, NM_033508.3:c.1129G>A, NM_001354803.2:c.166G>A, NM_000162.5(GCK):c.1132G>A (p.Ala378Thr)	GCK	monogenic diabetes	MONDO:0015967	Semidominant inheritance	Pathogenic	PS4, PP1_Strong, PM5_Supporting, PP4_Moderate, PP2, PP3, PM2_Supporting		The c.1132G>A variant in the glucokinase gene, GCK, causes an amino acid change of alanine to threonine at codon 378 (p.(Ala378Thr) of NM_000162.5. This variant failed quality control check in gnomAD 2.1.1; however, it is absent in multiple large population cohorts (UKBiobank, BioMe, Geisinger, internal lab contributors) and therefore the ClinGen MDEP has approved the application of PM2_Supporting for this variant (PM2_Supporting). This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.921, which is greater than the MDEP VCEP threshold of 0.70 (PP3). Another missense variant, c.1133C>T (p.(Ala378Val)), has been classified as pathogenic by the ClinGen MDEP VCEP but has a greater Grantham distance than p.Ala378Thr (PM5_Supporting). Additionally, GCK is defined by the ClinGen MDEP VCEP as a gene that has a low rate of benign missense variation and where pathogenic missense variants are a common mechanism of disease (PP2). This variant has been identified in over 30 unrelated individuals with non-autoimmune/insulin-dependent diabetes (PS4; PMID 18248649, PMID 16965331, internal lab contributors). This variant segregates with diabetes in 15 informative meioses in a large extended family with diabetes (PP1_Strong; internal lab contributor). This variant was identified in an individual with a clinical history highly specific for GCK-hyperglycemia (FBG 5.5-8 mmol/L and HbA1c 5.6 - 7.6% and negative antibodies) (PP4_Moderate;  internal lab contributors).  In summary, c.1132G>A meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.2.0, approved 6/7/2023):  PM2_Supporting, PP3, PM5_Supporting, PP2, PS4, PP1_Strong, PP4_moderate.		Monogenic Diabetes VCEP		2023-08-07	2023-08-07	False	https://erepo.genome.network/evrepo/ui/classification/CA126216/MONDO:0015967/086	842ba46d-dc6f-44fd-8d92-daf3ce162363	p.Ala378Thr	Ala	378	Thr	MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQ	465	P35557	T	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [203], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.01186258]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [11, 21, 80], 'REGION_gain_score': array([0.00510639, 0.00256509, 0.00812888]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
560	NM_000162.5(GCK):c.1129C>T (p.Arg377Cys)	585908	CA367398826	NM_000162.5:c.1129C>T, NC_000007.14:g.44145621G>A, CM000669.2:g.44145621G>A, NC_000007.13:g.44185220G>A, CM000669.1:g.44185220G>A, NC_000007.12:g.44151745G>A, NG_008847.1:g.48803C>T, NG_008847.2:g.57550C>T, ENST00000395796.8:c.*1127C>T, ENST00000616242.5:c.*249C>T, ENST00000683378.1:n.355C>T, ENST00000336642.9:c.163C>T, ENST00000345378.7:c.1132C>T, ENST00000403799.8:c.1129C>T, ENST00000671824.1:c.1192C>T, ENST00000672743.1:n.141C>T, ENST00000673284.1:c.1129C>T, ENST00000336642.8:c.181C>T, ENST00000345378.6:c.1132C>T, ENST00000395796.7:c.1126C>T, ENST00000403799.7:c.1129C>T, ENST00000437084.1:c.1078C>T, ENST00000459642.1:n.509C>T, ENST00000616242.4:c.1126C>T, NM_000162.3:c.1129C>T, NM_033507.1:c.1132C>T, NM_033508.1:c.1126C>T, NM_000162.4:c.1129C>T, NM_001354800.1:c.1129C>T, NM_001354801.1:c.118C>T, NM_001354802.1:c.-12C>T, NM_001354803.1:c.163C>T, NM_033507.2:c.1132C>T, NM_033508.2:c.1126C>T, XM_024446707.1:c.-12C>T, NM_033507.3:c.1132C>T, NM_033508.3:c.1126C>T, NM_001354803.2:c.163C>T, NM_000162.5(GCK):c.1129C>T (p.Arg377Cys)	GCK	monogenic diabetes	MONDO:0015967	Semidominant inheritance	Pathogenic	PS4, PP4, PP2, PP3, PM2_Supporting, PS3_Moderate	PP1	The c.1129C>T variant in the glucokinase gene, GCK, causes an amino acid change of arginine to cysteine at codon 377 (p.(Arg377Cys)) of NM_000162.5. GCK is defined by the ClinGen MDEP VCEP as a gene that has a low rate of benign missense variation and where pathogenic missense variants are a common mechanism of disease (PP2). This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.992, which is greater than the MDEP VCEP threshold of 0.70 (PP3). This variant is absent from gnomAD v2.1.1 (PM2_Supporting). This variant was identified in at least 7 unrelated individuals with hyperglycemia (PS4; PMID 16731834, 20337973, internal lab contributors). This variant was identified in an individual with a clinical history highly specific for GCK-hyperglycemia (FBG 5.5-8 mmol/L and HbA1c 5.6 - 7.6%) (PP4; PMID: 20337973).  This variant segregated with hyperglycemia with two informative meioses in a single family with diabetes, however, this does not meet the thresholds for PP1 set by the ClinGen MDEP VCEP (PMID: 27236918, internal lab contributors). A kinetic analysis of recombinant wild-type (WT) and mutant glucokinase demonstrated that the wild-type kinetic parameters pass the quality control, the wild-type ATP Km is between 0.4-0.65, and the p.Arg377Cys has RAI=0.01, which is less than the MDEP VCEP threshold of 0.50 (PS3_Moderate, PMID: 16731834). In summary, this variant meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP VCEP (specification version 1.2.0, approved 6/7/2023) : PP2, PP3, PM2_Supporting, PS4, PS3_Moderate, PP4.		Monogenic Diabetes VCEP		2023-08-08	2023-08-08	False	https://erepo.genome.network/evrepo/ui/classification/CA367398826/MONDO:0015967/086	55dc1eb2-246e-4c40-81d9-6d7af9e62fc4	p.Arg377Cys	Arg	377	Cys	MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQ	465	P35557	C	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [203], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.00816846]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [11, 21, 71, 80], 'REGION_gain_score': array([0.00792748, 0.00531876, 0.0146423 , 0.01234305]), 'REPEAT_loss': [], 'REPEAT_gain': [75], 'REPEAT_gain_score': array([0.00225359]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
561	NM_000162.5(GCK):c.911T>C (p.Leu304Pro)	447425	CA367400043	NM_000162.5:c.911T>C, NC_000007.14:g.44146571A>G, CM000669.2:g.44146571A>G, NC_000007.13:g.44186170A>G, CM000669.1:g.44186170A>G, NC_000007.12:g.44152695A>G, NG_008847.1:g.47853T>C, NG_008847.2:g.56600T>C, ENST00000395796.8:c.*909T>C, ENST00000616242.5:c.*31T>C, ENST00000683378.1:n.137T>C, ENST00000345378.7:c.914T>C, ENST00000403799.8:c.911T>C, ENST00000671824.1:c.974T>C, ENST00000673284.1:c.911T>C, ENST00000345378.6:c.914T>C, ENST00000395796.7:c.908T>C, ENST00000403799.7:c.911T>C, ENST00000437084.1:c.860T>C, ENST00000473353.1:n.209T>C, ENST00000616242.4:n.908T>C, NM_000162.3:c.911T>C, NM_033507.1:c.914T>C, NM_033508.1:c.908T>C, NM_000162.4:c.911T>C, NM_001354800.1:c.911T>C, NM_001354801.1:c.8+48T>C, NM_033507.2:c.914T>C, NM_033508.2:c.908T>C, NM_033507.3:c.914T>C, NM_033508.3:c.908T>C, NM_000162.5(GCK):c.911T>C (p.Leu304Pro)	GCK	monogenic diabetes	MONDO:0015967	Semidominant inheritance	Pathogenic	PS4, PP1_Strong, PP2, PP3, PP4, PM2_Supporting, PS3_Moderate		The c.911T>C variant in the glucokinase gene, GCK, causes an amino acid change of leucine to proline at codon 304 (p.(Leu304Pro)) of NM_000162.5. GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2). This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.874, which is greater than the MDEP threshold of 0.70 (PP3). This  variant has an incomputable gnomAD v2.1.1  Popmax minor filtering allele frequency due to 1 copy in the European non-Finnish subpopulation and 0 copies in any other subpopulation, thereby meeting the ClinGen MDEP threshold criteria for PM2_Supporting (ENF Popmax FAF less than or equal to 0.000003 and <= 2 copies in ENF and <=1 copy in any other subpopulation) (PM2_Supporting).  This variant was identified in 13 unrelated individuals with hyperglycemia (PS4; PMID 29207974, 11942313, internal lab contributors). This variant segregated with diabetes with 4 informative meioses in 3 families with diabetes/hyperglycemia (PP1_Strong; internal lab contributors). This variant was identified in an individual with a clinical history highly specific for GCK-hyperglycemia (FBG 5.5-8 mmol/L and HbA1c 5.6 - 7.6%) (PP4; internal lab contributors).  A kinetic analysis of recombinant wild-type (WT) and mutant glucokinase demonstrated that the wild-type kinetic parameters pass the quality control, the wild-type ATP Km is between 0.4-0.65, and the p.Leu304Pro variant has RAI=0.19, which is less than the MDEP VCEP threshold of 0.50. (PMIDs: 29704611, 26208450).  In summary, this variant meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP VCEP (specification version 1.2.0, approved 6/7/2023): PM2_Supporting, PP3, PP2, PP4, PS4, PP1_Strong, PS3_Supporting.		Monogenic Diabetes VCEP		2023-08-09	2023-08-10	False	https://erepo.genome.network/evrepo/ui/classification/CA367400043/MONDO:0015967/086	b5ed44bd-0988-4dfa-b8cb-386b405459c5	p.Leu304Pro	Leu	304	Pro	MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQ	465	P35557	P	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [295, 316], 'BINDING_gain_score': array([0.03538871, 0.19121408]), 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [196], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.0450632]), 'HELIX_loss': [297], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.493689]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [73], 'REGION_gain': [], 'REGION_loss_score': array([-0.00159413]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
562	NM_000162.5(GCK):c.1099G>A (p.Val367Met)	381598	CA16605802	NM_000162.5:c.1099G>A, NC_000007.14:g.44145651C>T, CM000669.2:g.44145651C>T, NC_000007.13:g.44185250C>T, CM000669.1:g.44185250C>T, NC_000007.12:g.44151775C>T, NG_008847.1:g.48773G>A, NG_008847.2:g.57520G>A, ENST00000395796.8:c.*1097G>A, ENST00000616242.5:c.*219G>A, ENST00000683378.1:n.325G>A, ENST00000336642.9:c.133G>A, ENST00000345378.7:c.1102G>A, ENST00000403799.8:c.1099G>A, ENST00000671824.1:c.1162G>A, ENST00000672743.1:n.111G>A, ENST00000673284.1:c.1099G>A, ENST00000336642.8:n.151G>A, ENST00000345378.6:c.1102G>A, ENST00000395796.7:c.1096G>A, ENST00000403799.7:c.1099G>A, ENST00000437084.1:c.1048G>A, ENST00000459642.1:n.479G>A, ENST00000473353.1:n.397G>A, ENST00000616242.4:n.1096G>A, NM_000162.3:c.1099G>A, NM_033507.1:c.1102G>A, NM_033508.1:c.1096G>A, NM_000162.4:c.1099G>A, NM_001354800.1:c.1099G>A, NM_001354801.1:c.88G>A, NM_001354802.1:c.-42G>A, NM_001354803.1:c.133G>A, NM_033507.2:c.1102G>A, NM_033508.2:c.1096G>A, XM_024446707.1:c.-42G>A, NM_033507.3:c.1102G>A, NM_033508.3:c.1096G>A, NM_001354803.2:c.133G>A, NM_000162.5(GCK):c.1099G>A (p.Val367Met)	GCK	monogenic diabetes	MONDO:0015967	Semidominant inheritance	Pathogenic	PS4, PP1_Strong, PP4, PP2, PP3, PM2_Supporting		The c.1099G>A variant in the glucokinase gene, GCK, causes an amino acid change of valine to methionine at codon 367 (p.(Val367Met)) of NM_000162.5. GCK is defined by the ClinGen MDEP VCEP as a gene that has a low rate of benign missense variation and where pathogenic missense variants are a common mechanism of disease (PP2). This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.929, which is greater than the MDEP VCEP threshold of 0.70 (PP3). This variant is absent from gnomAD v2.1.1 (PM2_Supporting). This variant was identified in 7 unrelated individuals with diabetes/hyperglycemia (PS4; PMID 27256595, 31968686, 9049484, internal lab contributors). This variant segregated with diabetes with 4 informative meioses in 3 families with diabetes/hyperglycemia (PP1_Strong; PMID 27256595, 9049484, internal lab contributors). This variant was identified in an individual with a clinical history highly specific for GCK-hyperglycemia (FBG 5.5-8 mmol/L and HbA1c 5.6 - 7.6%) (PP4; PMID 27256595 ).  In summary, this variant meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP VCEP (specification version 1.2.0, approved 6/7/2023): PP2, PP3, PM2_Supporting, PS4, PP4, PP1_Strong.		Monogenic Diabetes VCEP		2023-08-09	2023-08-10	False	https://erepo.genome.network/evrepo/ui/classification/CA16605802/MONDO:0015967/086	e7250528-78fc-4419-81da-e7b6d944fc80	p.Val367Met	Val	367	Met	MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQ	465	P35557	M	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [408, 414], 'BINDING_gain': [], 'BINDING_loss_score': array([-0.01704067, -0.01689553]), 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [83], 'DOMAIN_gain_score': array([0.00628752]), 'REGION_loss': [73], 'REGION_gain': [], 'REGION_loss_score': array([-0.00735945]), 'REPEAT_loss': [], 'REPEAT_gain': [75], 'REPEAT_gain_score': array([0.00381017]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
563	NM_000162.5(GCK):c.1112G>T (p.Cys371Phe)	129140	CA152950	NM_000162.5:c.1112G>T, NC_000007.14:g.44145638C>A, CM000669.2:g.44145638C>A, NC_000007.13:g.44185237C>A, CM000669.1:g.44185237C>A, NC_000007.12:g.44151762C>A, NG_008847.1:g.48786G>T, NG_008847.2:g.57533G>T, ENST00000395796.8:c.*1110G>T, ENST00000616242.5:c.*232G>T, ENST00000683378.1:n.338G>T, ENST00000336642.9:c.146G>T, ENST00000345378.7:c.1115G>T, ENST00000403799.8:c.1112G>T, ENST00000671824.1:c.1175G>T, ENST00000672743.1:n.124G>T, ENST00000673284.1:c.1112G>T, ENST00000336642.8:n.164G>T, ENST00000345378.6:c.1115G>T, ENST00000395796.7:c.1109G>T, ENST00000403799.7:c.1112G>T, ENST00000437084.1:c.1061G>T, ENST00000459642.1:n.492G>T, ENST00000616242.4:n.1109G>T, NM_000162.3:c.1112G>T, NM_033507.1:c.1115G>T, NM_033508.1:c.1109G>T, NM_000162.4:c.1112G>T, NM_001354800.1:c.1112G>T, NM_001354801.1:c.101G>T, NM_001354802.1:c.-29G>T, NM_001354803.1:c.146G>T, NM_033507.2:c.1115G>T, NM_033508.2:c.1109G>T, XM_024446707.1:c.-29G>T, NM_033507.3:c.1115G>T, NM_033508.3:c.1109G>T, NM_001354803.2:c.146G>T, NM_000162.5(GCK):c.1112G>T (p.Cys371Phe)	GCK	monogenic diabetes	MONDO:0015967	Semidominant inheritance	Pathogenic	PS4, PP1_Strong, PP4_Moderate, PP2, PP3, PM2_Supporting		The c.1112G>T variant in the glucokinase gene, GCK, causes an amino acid change of cysteine to phenylalanine at codon 371 (p.(Cys371Phe)) of NM_000162.5. GCK is defined by the ClinGen MDEP VCEP as a gene that has a low rate of benign missense variation and where pathogenic missense variants are a common mechanism of disease (PP2). This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.931, which is greater than the MDEP VCEP threshold of 0.70 (PP3). This variant is absent from gnomAD v2.1.1 (PM2_Supporting). This variant was hyperglycemia (PS4; PMID 24735133, internal lab contributors). This variant segregated with hyperglycemia with 12 informative meioses in 3 families with MODY (PP1_Strong; internal lab contributors). This variant was identified in at least two individuals with a clinical history highly specific for GCK-hyperglycemia (FBG 5.5-8 mmol/L and HbA1c 5.6 - 7.6% as well as either OGTT increment < 3 mmol/L or negative antibodies) (PP4_Moderate; internal lab contributors).  In summary, this variant meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP VCEP (specification version 1.2.0, approved 6/7/2023) : PP2, PP3, PM2_Supporting, PP1_Strong, PS4, PP4_Moderate .		Monogenic Diabetes VCEP		2023-08-09	2023-08-10	False	https://erepo.genome.network/evrepo/ui/classification/CA152950/MONDO:0015967/086	9eb4e0f9-20ec-4efb-bf65-c18791943812	p.Cys371Phe	Cys	371	Phe	MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQ	465	P35557	F	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [414], 'BINDING_gain': [], 'BINDING_loss_score': array([-0.01776028]), 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [2], 'SIGNAL_gain_score': array([0.02697933]), 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [73], 'REGION_gain': [], 'REGION_loss_score': array([-0.00777858]), 'REPEAT_loss': [], 'REPEAT_gain': [75], 'REPEAT_gain_score': array([0.00358438]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
564	NM_000162.5(GCK):c.781G>A (p.Gly261Arg)	16135	CA126211	NM_000162.5:c.781G>A, NC_000007.14:g.44147732C>T, CM000669.2:g.44147732C>T, NC_000007.13:g.44187331C>T, CM000669.1:g.44187331C>T, NC_000007.12:g.44153856C>T, NG_008847.1:g.46692G>A, NG_008847.2:g.55439G>A, ENST00000395796.8:c.*779G>A, ENST00000616242.5:c.781G>A, ENST00000345378.7:c.784G>A, ENST00000403799.8:c.781G>A, ENST00000671824.1:c.781G>A, ENST00000673284.1:c.781G>A, ENST00000345378.6:c.784G>A, ENST00000395796.7:c.778G>A, ENST00000403799.7:c.781G>A, ENST00000437084.1:c.730G>A, ENST00000616242.4:n.778G>A, NM_000162.3:c.781G>A, NM_033507.1:c.784G>A, NM_033508.1:c.778G>A, XR_927223.1:n.66C>T, NM_000162.4:c.781G>A, NM_001354800.1:c.781G>A, NM_033507.2:c.784G>A, NM_033508.2:c.778G>A, XR_927223.2:n.66C>T, NM_033507.3:c.784G>A, NM_033508.3:c.778G>A, NM_000162.5(GCK):c.781G>A (p.Gly261Arg)	GCK	monogenic diabetes	MONDO:0015967	Semidominant inheritance	Pathogenic	PS4, PS2, PP1_Strong, PP4_Moderate, PP2, PP3, PS3_Moderate, PM2_Supporting, PM3	PM1	"The c.781G>A variant in the glucokinase gene, GCK, causes an amino acid change of glycine to arginine at codon 261 (p.(Gly261Arg)) of NM_000162.5. GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2). This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.914, which is greater than the MDEP threshold of 0.70 (PP3). This variant has an incomputable gnomAD v2.1.1  Popmax minor filtering allele frequency due to 0 copies in the European non-Finnish subpopulation and 1 copy in the """"""""""""""""Other"""""""""""""""" subpopulation, thereby meeting the ClinGen MDEP threshold criteria for PM2_Supporting (ENF Popmax FAF less than or equal to 0.000003 and <= 2 copies in ENF and <=1 copy in any other subpopulation) (PM2_Supporting).  This variant was identified in more than 38 unrelated individuals with diabetes (PS4; PMIDs: 29417725, 33324081, 21518409, 25015100, 22611063, 17573900, internal lab contributors). This variant was identified in at least two individuals with a clinical history highly specific for GCK-hyperglycemia (FBG 5.5-8 mmol/L and HbA1c 5.6 - 7.6% and negative antibodies) (PP4_Moderate, internal lab contributors).  This variant segregated with diabetes/hyperglycemia with 30 informative meioses in 18 families  (PP1_Strong; PMID 33324081, 21518409, internal lab contributors). This variant was identified as a de novo occurrence with confirmed parental relationships in one individual with a clinical picture consistent with GCK-hyperglycemia (PS2; internal lab contributors). This variant has been detected in at least 2 individuals with neonatal diabetes who were both homozygous for the variant, confirmed in trans (PM3: PMID 33324081, 25015100, internal lab contributors).  A kinetic analysis of recombinant wild-type (WT) and mutant glucokinase demonstrated that the wild-type kinetic parameters pass the quality control, the wild-type ATP Km is between 0.4-0.65, and the p.Gly261Arg variant has a relative activity index (RAI) of 0.02, which is less than the MDEP VCEP threshold of 0.50 (PMID: 19903754). In summary, this variant meets the criteria to be classified as pathogenic for monogenic diabetews. ACMG/AMP criteria applied, as specified by the ClinGen MDEP VCEP (specification version 1.3.0, approved 8/11/2023): PM2_Supporting, PP2, PP3, PP4_Moderate, PS3_Moderate, PM3, PP1_Strong, PS4, PS2."		Monogenic Diabetes VCEP		2023-08-12	2023-08-12	False	https://erepo.genome.network/evrepo/ui/classification/CA126211/MONDO:0015967/086	30f3b683-bd18-46bf-808d-e9059fa45ccb	p.Gly261Arg	Gly	261	Arg	MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQ	465	P35557	R	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [323], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.05079621]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
565	NM_000162.5(GCK):c.781G>C (p.Gly261Arg)	447418	CA367400571	NM_000162.5:c.781G>C, NC_000007.14:g.44147732C>G, CM000669.2:g.44147732C>G, NC_000007.13:g.44187331C>G, CM000669.1:g.44187331C>G, NC_000007.12:g.44153856C>G, NG_008847.1:g.46692G>C, NG_008847.2:g.55439G>C, ENST00000395796.8:c.*779G>C, ENST00000616242.5:c.781G>C, ENST00000345378.7:c.784G>C, ENST00000403799.8:c.781G>C, ENST00000671824.1:c.781G>C, ENST00000673284.1:c.781G>C, ENST00000345378.6:c.784G>C, ENST00000395796.7:c.778G>C, ENST00000403799.7:c.781G>C, ENST00000437084.1:c.730G>C, ENST00000616242.4:n.778G>C, NM_000162.3:c.781G>C, NM_033507.1:c.784G>C, NM_033508.1:c.778G>C, XR_927223.1:n.66C>G, NM_000162.4:c.781G>C, NM_001354800.1:c.781G>C, NM_033507.2:c.784G>C, NM_033508.2:c.778G>C, XR_927223.2:n.66C>G, NM_033507.3:c.784G>C, NM_033508.3:c.778G>C, NM_000162.5(GCK):c.781G>C (p.Gly261Arg)	GCK	monogenic diabetes	MONDO:0015967	Semidominant inheritance	Pathogenic	PS1, PS4_Moderate, PP4_Moderate, PP2, PP3, PM2_Supporting, PS3_Moderate	PP1, PM1	The c.781G>C variant in the glucokinase gene, GCK, causes an amino acid change of glycine to arginine at codon 261 (p.(Gly261Arg)) of NM_000162.5. GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2). This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.914, which is greater than the MDEP threshold of 0.70 (PP3). This variant was identified in an individual with a clinical history highly specific for GCK-hyperglycemia (FBG 5.5-8 mmol/L and HbA1c 5.6 - 7.6% and negative antibodies) (PP4_Moderate;  internal lab contributors).  This variant segregated with hyperglycemia with one informative meioses in a single family; however, this does not meet the thresholds for PP1 set by the ClinGen MDEP (PMID: 27236918, internal lab contributors).  This variant was identified in 5 unrelated individuals with hyperglycemia (PS4_Moderate; internal lab contributors). The nucleotide change c.781G>A, which causes the same amino acid change, has been classified as pathogenic by the ClinGen MDEP (PS1). A kinetic analysis of recombinant wild-type (WT) and mutant glucokinase demonstrated that the wild-type kinetic parameters pass the quality control, the wild-type ATP Km is between 0.4-0.65, and the p.Gly261Arg variant has a relative activity index (RAI) of 0.02, which is less than the MDEP VCEP threshold of 0.50 (PMID: 19903754). In summary, the c.781G>C variant meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP VCEP (specification version 1.3.0, approved 8/11/2023): PM2_Supporting, PP2, PP3, PS3_Moderate, PS1, PS4_Moderate, PP4_Moderate.		Monogenic Diabetes VCEP		2023-08-12	2023-08-12	False	https://erepo.genome.network/evrepo/ui/classification/CA367400571/MONDO:0015967/086	fb522608-bab6-43d3-9eb8-e195b15539cd	p.Gly261Arg	Gly	261	Arg	MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQ	465	P35557	R	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [323], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.05079621]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
566	NM_000162.5(GCK):c.775G>A (p.Ala259Thr)	435302	CA367400584	NM_000162.5:c.775G>A, NC_000007.14:g.44147738C>T, CM000669.2:g.44147738C>T, NC_000007.13:g.44187337C>T, CM000669.1:g.44187337C>T, NC_000007.12:g.44153862C>T, NG_008847.1:g.46686G>A, NG_008847.2:g.55433G>A, ENST00000395796.8:c.*773G>A, ENST00000616242.5:c.775G>A, ENST00000345378.7:c.778G>A, ENST00000403799.8:c.775G>A, ENST00000671824.1:c.775G>A, ENST00000673284.1:c.775G>A, ENST00000345378.6:c.778G>A, ENST00000395796.7:c.772G>A, ENST00000403799.7:c.775G>A, ENST00000437084.1:c.724G>A, ENST00000616242.4:n.772G>A, NM_000162.3:c.775G>A, NM_033507.1:c.778G>A, NM_033508.1:c.772G>A, XR_927223.1:n.72C>T, NM_000162.4:c.775G>A, NM_001354800.1:c.775G>A, NM_033507.2:c.778G>A, NM_033508.2:c.772G>A, XR_927223.2:n.72C>T, NM_033507.3:c.778G>A, NM_033508.3:c.772G>A, NM_000162.5(GCK):c.775G>A (p.Ala259Thr)	GCK	monogenic diabetes	MONDO:0015967	Semidominant inheritance	Pathogenic	PS4, PP1_Strong, PM5_Supporting, PP4_Moderate, PP2, PP3, PM2_Supporting	PM1	The c.775G>A variant in the glucokinase gene, GCK, causes an amino acid change of alanine to threonine at codon 259 (p.(Ala259Thr)) of NM_000162.5.  This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.948, which is greater than the MDEP VCEP threshold of 0.70 (PP3) and is absent from gnomAD v2.1.1 (PM2_Supporting). GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2). Another missense variant, c.776C>T, p.Ala259Val, has been classified as pathogenic by the ClinGen MDEP but has a greater Grantham distance than p.Ala259Thr (PM5_Supporting). This variant was identified in 12 unrelated individuals with hyperglycemia (PS4; internal lab contributors). Additionally, this variant segregated with diabetes/hyperglycemia, with 7 informative meioses in 6 families (PP1_Strong; internal lab contributors). This variant was identified in an individual with a clinical history highly specific for GCK-hyperglycemia (FBG 5.5-8 mmol/L and HbA1c 5.6 - 7.6% and a 3-generation family history of diabetes) (PP4_Moderate; internal lab contributors).  In summary, c.775G>A meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.3.0, approved 8/11/2023): PP3, PP2, PM5_Supporting, PS4, PP1_Strong, PP4_Moderate, PM2_Supporting.		Monogenic Diabetes VCEP		2023-08-12	2023-08-12	False	https://erepo.genome.network/evrepo/ui/classification/CA367400584/MONDO:0015967/086	7c9a6580-e9be-4685-b711-9d54c57cf1f2	p.Ala259Thr	Ala	259	Thr	MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQ	465	P35557	T	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [11, 21, 71], 'REGION_gain_score': array([0.00503463, 0.00370532, 0.00780106]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
567	NM_000162.5(GCK):c.776C>T (p.Ala259Val)	447417	CA367400579	NM_000162.5:c.776C>T, NC_000007.14:g.44147737G>A, CM000669.2:g.44147737G>A, NC_000007.13:g.44187336G>A, CM000669.1:g.44187336G>A, NC_000007.12:g.44153861G>A, NG_008847.1:g.46687C>T, NG_008847.2:g.55434C>T, ENST00000395796.8:c.*774C>T, ENST00000616242.5:c.776C>T, ENST00000345378.7:c.779C>T, ENST00000403799.8:c.776C>T, ENST00000671824.1:c.776C>T, ENST00000673284.1:c.776C>T, ENST00000345378.6:c.779C>T, ENST00000395796.7:c.773C>T, ENST00000403799.7:c.776C>T, ENST00000437084.1:c.725C>T, ENST00000616242.4:n.773C>T, NM_000162.3:c.776C>T, NM_033507.1:c.779C>T, NM_033508.1:c.773C>T, XR_927223.1:n.71G>A, NM_000162.4:c.776C>T, NM_001354800.1:c.776C>T, NM_033507.2:c.779C>T, NM_033508.2:c.773C>T, XR_927223.2:n.71G>A, NM_033507.3:c.779C>T, NM_033508.3:c.773C>T, NM_000162.5(GCK):c.776C>T (p.Ala259Val)	GCK	monogenic diabetes	MONDO:0015967	Semidominant inheritance	Pathogenic	PS4, PP1_Strong, PP4_Moderate, PP2, PP3, PM5, PM2_Supporting		The c.776C>T variant in the glucokinase gene, GCK, causes an amino acid change of alanine to valine at codon 259 (p.(Ala259Val)) of NM_000162.5.  This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.948, which is greater than the MDEP VCEP threshold of 0.70 (PP3) and is absent from gnomAD v2.1.1 (PM2_Supporting). Additionally, this variant was identified in 15 unrelated individuals with hyperglycemia (PS4; PMID:22035297, internal lab contributors). This variant segregated with diabetes/hyperglycemia, with 16 informative meioses in 5 families (PP1_Strong; PMID: 22035297, internal lab contributors). GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2). Another missense variant, c.775G>A, p.Ala259Thr has been interpreted as pathogenic by the ClinGen MDEP, and p.Ala259Val has a greater Grantham distance (PM5). Lastly, this variant was identified in two individuals with a clinical history highly specific for GCK-hyperglycemia (FBG 5.5-8 mmol/L and HbA1c 5.6 - 7.6% and OGTT increment < 3 mmol/L) (PP4_Moderate; internal lab contributors).  In summary, c. 776C>T meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.3.0, approved 8/11/2023):  PP3, PM2_Supporting, PS4, PP1_Strong, PP2, PM5, PP4_Moderate.		Monogenic Diabetes VCEP		2023-08-12	2023-08-12	False	https://erepo.genome.network/evrepo/ui/classification/CA367400579/MONDO:0015967/086	82a2ea94-5ac2-4707-9095-99789b4b0229	p.Ala259Val	Ala	259	Val	MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQ	465	P35557	V	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [11, 21, 71, 80], 'REGION_gain_score': array([0.00490236, 0.00309741, 0.00769687, 0.00785679]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
568	NM_000162.5(GCK):c.676G>A (p.Val226Met)	36243	CA213827	NM_000162.5:c.676G>A, NC_000007.14:g.44149763C>T, CM000669.2:g.44149763C>T, NC_000007.13:g.44189362C>T, CM000669.1:g.44189362C>T, NC_000007.12:g.44155887C>T, NG_008847.1:g.44661G>A, NG_008847.2:g.53408G>A, ENST00000395796.8:c.*674G>A, ENST00000616242.5:c.676G>A, ENST00000682635.1:n.1162G>A, ENST00000345378.7:c.679G>A, ENST00000403799.8:c.676G>A, ENST00000671824.1:c.676G>A, ENST00000673284.1:c.676G>A, ENST00000345378.6:c.679G>A, ENST00000395796.7:c.673G>A, ENST00000403799.7:c.676G>A, ENST00000437084.1:c.625G>A, ENST00000616242.4:n.673G>A, NM_000162.3:c.676G>A, NM_033507.1:c.679G>A, NM_033508.1:c.673G>A, XR_927223.1:n.278C>T, NM_000162.4:c.676G>A, NM_001354800.1:c.676G>A, NM_033507.2:c.679G>A, NM_033508.2:c.673G>A, XR_927223.2:n.278C>T, NM_033507.3:c.679G>A, NM_033508.3:c.673G>A, NM_000162.5(GCK):c.676G>A (p.Val226Met)	GCK	monogenic diabetes	MONDO:0015967	Semidominant inheritance	Pathogenic	PS4, PP1_Strong, PP4_Moderate, PP2, PP3, PM1, PS3_Moderate, PM2_Supporting		The c.676G>A variant in the glucokinase gene, GCK, causes an amino acid change of valine to methionine at codon 261 (p.(Val226Met)) of NM_000162.5. GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2). This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.789, which is greater than the MDEP threshold of 0.70 (PP3). This variant has a gnomAD v2.1.1  Popmax filtering allele frequency of 0.000002920 (below the MDEP threshold of 0.000003) and ≤ 2 copies observed in the European non-Finnish population and ≤ 1 copy in any other subpopulation, thereby meeting the ClinGen MDEP criteria for PM2_Supporting (PM2_Supporting).  This variant was identified in more than 70 unrelated individuals with hyperglycemia (PS4; internal lab contributors). This variant was identified in an individual with a clinical history highly specific for GCK-hyperglycemia (FBG 5.5-8 mmol/L and HbA1c 5.6 - 7.6% and negative antibodies) (PP4_Moderate; internal lab contributors).  This variant segregated with diabetes/hyperglycemia with more than 20 informative meioses in more than 30 families (PP1_Strong; internal lab contributors). This variant resides in an amino acid that directly binds glucose, which is defined as critical for the protein’s function by the ClinGen MDEP (PM1).  A kinetic analysis of recombinant wild-type (WT) and mutant glucokinase demonstrated that the wild-type kinetic parameters pass the quality control, the wild-type ATP Km is between 0.4-0.65, and the p.Val226Met variant has a relative activity index (RAI) of 0.009 to 0.198, which is less than the MDEP VCEP threshold of 0.50 (PS3_Moderate; PMID: 10525657, 25015100, https://doi.org/10.1159/isbn.978-3-318-01080-0​).   In summary, this variant meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP VCEP (specification version 1.3.0, approved 8/11/2023): PS4, PP1_Strong, PS3_Moderate, PM2_Supporting, PP2, PP4_Moderate, PP3, PM1.		Monogenic Diabetes VCEP		2023-08-13	2023-08-13	False	https://erepo.genome.network/evrepo/ui/classification/CA213827/MONDO:0015967/086	a3bc2935-1bf2-4171-b759-ca1cfb249eb6	p.Val226Met	Val	226	Met	MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQ	465	P35557	M	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [414], 'BINDING_gain': [], 'BINDING_loss_score': array([-0.0255906]), 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [83, 221, 224, 225, 230, 231], 'DOMAIN_gain_score': array([0.02799994, 0.10604304, 0.06706321, 0.07501417, 0.10462064,
       0.10370177]), 'REGION_loss': [8, 73, 82], 'REGION_gain': [], 'REGION_loss_score': array([-0.00875717, -0.01031649, -0.0184713 ]), 'REPEAT_loss': [], 'REPEAT_gain': [75], 'REPEAT_gain_score': array([0.01047122]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
569	NM_000162.5(GCK):c.649G>A (p.Asp217Asn)	911631	CA4239564	NM_000162.5:c.649G>A, NC_000007.14:g.44149790C>T, CM000669.2:g.44149790C>T, NC_000007.13:g.44189389C>T, CM000669.1:g.44189389C>T, NC_000007.12:g.44155914C>T, NG_008847.1:g.44634G>A, NG_008847.2:g.53381G>A, ENST00000395796.8:c.*647G>A, ENST00000616242.5:c.649G>A, ENST00000682635.1:n.1135G>A, ENST00000345378.7:c.652G>A, ENST00000403799.8:c.649G>A, ENST00000671824.1:c.649G>A, ENST00000673284.1:c.649G>A, ENST00000345378.6:c.652G>A, ENST00000395796.7:c.646G>A, ENST00000403799.7:c.649G>A, ENST00000437084.1:c.598G>A, ENST00000616242.4:n.646G>A, NM_000162.3:c.649G>A, NM_033507.1:c.652G>A, NM_033508.1:c.646G>A, NM_000162.4:c.649G>A, NM_001354800.1:c.649G>A, NM_033507.2:c.652G>A, NM_033508.2:c.646G>A, NM_033507.3:c.652G>A, NM_033508.3:c.646G>A, NM_000162.5(GCK):c.649G>A (p.Asp217Asn)	GCK	monogenic diabetes	MONDO:0015967	Semidominant inheritance	Benign	BP2, BS1, BS2, PP2	PS3, PS4	The c.649G>A variant in the glucokinase gene, GCK, causes an amino acid change of aspartic acid to asparagine at codon 217 (p.(Asp217Asn)) of [transcript, e.g. NM_000545.8]. NM_000162.5. GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2). This variant has a Popmax Filtering allele frequency in gnomAD 2.1.1 of 0.00005377, which is greater than the MDEP threshold for BS1 (≥0.0.00004) (BS1). This variant was identified in four unrelated individuals with non-autoimmune and non-absolute/near-absolute insulin-deficient diabetes; however, PS4 cannot be applied because the variant MAF in gnomAD is above the ClinGen MDEP PM2_Supporting cutoff (internal lab contributors). Additionally, this variant was identified in an individual with a normal fasting glucose (BS2) (internal lab contributor). This variant has been observed in cis with the variant GCK c.781G>A (p.Gly261Arg) (PMID:22611063), which is classified as pathogenic by the ClinGen MDEP (BP2). Lastly, functional studies suggest that the p.Asp217Asn protein has increased activity (RAI=2.0); however, the thermostability and protein interactions were not analyzed and therefore neither PS3 or BS3 can be applied (PMID 22611063). In summary, c.649G>A meets the criteria to be classified as benign for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.3.0, approved 8/11/2023): BS1, BS2, BP2, PP2.		Monogenic Diabetes VCEP		2023-08-13	2023-08-13	False	https://erepo.genome.network/evrepo/ui/classification/CA4239564/MONDO:0015967/086	074db8ad-1490-4c1f-a15b-103a2b17ef3f	p.Asp217Asn	Asp	217	Asn	MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQ	465	P35557	N	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [204], 'BINDING_gain': [], 'BINDING_loss_score': array([-0.11149967]), 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [214], 'HELIX_gain_score': array([0.16163671]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [83, 221], 'DOMAIN_gain_score': array([0.0141623 , 0.03728515]), 'REGION_loss': [73], 'REGION_gain': [21], 'REGION_gain_score': array([0.00220191]), 'REGION_loss_score': array([-0.00235379]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
570	NM_000162.5(GCK):c.437T>C (p.Leu146Pro)	2428681	CA367401978	NM_000162.5:c.437T>C, NC_000007.14:g.44151002A>G, CM000669.2:g.44151002A>G, NC_000007.13:g.44190601A>G, CM000669.1:g.44190601A>G, NC_000007.12:g.44157126A>G, NG_008847.1:g.43422T>C, NG_008847.2:g.52169T>C, ENST00000395796.8:c.*435T>C, ENST00000616242.5:c.437T>C, ENST00000682635.1:n.923T>C, ENST00000345378.7:c.440T>C, ENST00000403799.8:c.437T>C, ENST00000671824.1:c.437T>C, ENST00000673284.1:c.437T>C, ENST00000345378.6:c.440T>C, ENST00000395796.7:c.434T>C, ENST00000403799.7:c.437T>C, ENST00000437084.1:c.386T>C, ENST00000616242.4:n.434T>C, NM_000162.3:c.437T>C, NM_033507.1:c.440T>C, NM_033508.1:c.434T>C, NM_000162.4:c.437T>C, NM_001354800.1:c.437T>C, NM_033507.2:c.440T>C, NM_033508.2:c.434T>C, NM_033507.3:c.440T>C, NM_033508.3:c.434T>C, NM_000162.5(GCK):c.437T>C (p.Leu146Pro)	GCK	monogenic diabetes	MONDO:0015967	Semidominant inheritance	Pathogenic	PS4_Moderate, PP2, PP3, PP4, PP1, PM3, PM2_Supporting, PS3_Moderate		The c.437T>C variant in the glucokinase gene, GCK causes an amino acid change of leucine to proline at codon 146 (p.(Leu146Pro)) of NM_000162.5. GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2). This variant is also predicted to be deleterious by computational evidence, with a REVEL score of 0.983, which is greater than the MDEP VCEP threshold of 0.70 (PP3). This variant is absent from gnomAD v2.1.1 (PM2_Supporting). This variant was identified in 4 unrelated individuals with diabetes/hyperglycemia (PS4_Moderate; PMID: 25015100, 31441606, internal lab contributors).  This variant segregated with diabetes/hyperglycemia with 3 informative meioses in 1 family (PP1; internal lab contributors). This variant has been detected in the homozygous state in at least 3 individuals with permanent neonatal diabetes (PP4 and PM3; PMIDs: 25015100, 31441606, internal lab contributor).  A kinetic analysis of recombinant wild-type (WT) and mutant glucokinase demonstrated that the wild-type kinetic parameters pass the quality control, the wild-type ATP Km is between 0.4-0.65, and the p.Leu146Pro variant has a relative activity index (RAI) <0.50 (PS3_Moderate; PMID: 25015100).  In summary, the c.437T>C variant meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP VCEP (specification version 1.3.0, approved 8/11/2023): PS4_Moderate, PM3, PP4, PP1, PM2_Supporting, PP2, PP3, PS3_Moderate.		Monogenic Diabetes VCEP		2023-08-13	2023-08-13	False	https://erepo.genome.network/evrepo/ui/classification/CA367401978/MONDO:0015967/086	d4e06e06-f5e0-4a8d-82bb-81e4dbeb6520	p.Leu146Pro	Leu	146	Pro	MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQ	465	P35557	P	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [144, 162, 163, 164, 236], 'STRAND_gain': [171, 227], 'STRAND_gain_score': array([0.0877893 , 0.04926103]), 'STRAND_loss_score': array([-0.42409784, -0.2112596 , -0.26759166, -0.26989532, -0.05786407]), 'HELIX_loss': [], 'HELIX_gain': [115], 'HELIX_gain_score': array([0.2558338]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [83, 150, 221, 223, 224, 225, 229, 230, 231], 'DOMAIN_gain_score': array([0.02472025, 0.10219866, 0.1963315 , 0.15027332, 0.14309877,
       0.09752351, 0.1374827 , 0.08009464, 0.0942359 ]), 'REGION_loss': [], 'REGION_gain': [5, 6, 7, 10, 11, 13, 16, 17, 21, 22, 23, 27, 30, 31, 34, 35, 38, 39, 41, 42, 43, 45, 46, 50, 55, 56, 58, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 75, 76, 78, 80, 81, 83, 84, 85, 86, 87, 89, 92, 93, 96, 99, 128, 130, 131, 135, 136, 137], 'REGION_gain_score': array([0.02827215, 0.03013027, 0.026963  , 0.03324211, 0.0272187 ,
       0.02627909, 0.03351551, 0.03426957, 0.0296523 , 0.03582036,
       0.03613877, 0.03163016, 0.03782034, 0.03564739, 0.03578097,
       0.03887087, 0.03573173, 0.04020262, 0.04599208, 0.04692668,
       0.0588457 , 0.05587912, 0.06290329, 0.06908941, 0.08318758,
       0.08940184, 0.08645934, 0.11072797, 0.11704296, 0.12680584,
       0.12771678, 0.1268    , 0.12691343, 0.1439054 , 0.1316033 ,
       0.15462583, 0.17395914, 0.143242  , 0.14400625, 0.17073637,
       0.12401146, 0.14045   , 0.15367603, 0.15828252, 0.1582703 ,
       0.15766805, 0.14515752, 0.10023552, 0.10647613, 0.11405581,
       0.10242504, 0.10697979, 0.07921112, 0.06401962, 0.12866777,
       0.16976887, 0.19242567, 0.2656672 , 0.22757792, 0.26721811]), 'REPEAT_loss': [77], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.04475176]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
571	NM_000162.5(GCK):c.214G>A (p.Gly72Arg)	36209	CA213771	NM_000162.5:c.214G>A, NC_000007.14:g.44152420C>T, CM000669.2:g.44152420C>T, NC_000007.13:g.44192019C>T, CM000669.1:g.44192019C>T, NC_000007.12:g.44158544C>T, NG_008847.1:g.42004G>A, NG_008847.2:g.50751G>A, ENST00000395796.8:c.*212G>A, ENST00000616242.5:c.214G>A, ENST00000682635.1:n.700G>A, ENST00000345378.7:c.217G>A, ENST00000403799.8:c.214G>A, ENST00000671824.1:c.214G>A, ENST00000673284.1:c.214G>A, ENST00000345378.6:c.217G>A, ENST00000395796.7:c.211G>A, ENST00000403799.7:c.214G>A, ENST00000437084.1:c.214G>A, ENST00000616242.4:n.211G>A, NM_000162.3:c.214G>A, NM_033507.1:c.217G>A, NM_033508.1:c.211G>A, NM_000162.4:c.214G>A, NM_001354800.1:c.214G>A, NM_033507.2:c.217G>A, NM_033508.2:c.211G>A, NM_033507.3:c.217G>A, NM_033508.3:c.211G>A, NM_000162.5(GCK):c.214G>A (p.Gly72Arg)	GCK	monogenic diabetes	MONDO:0015967	Semidominant inheritance	Pathogenic	PS4, PP1_Strong, PS3_Supporting, PP4_Moderate, PP2, PP3, PM2_Supporting	PM1	The c.214G>A variant in the glucokinase gene, GCK causes an amino acid change of glycine to arginine at codon 72 (p.(Gly72Arg)) of NM_000162.5. GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2). This variant is also predicted to be deleterious by computational evidence, with a REVEL score of 0.994, which is greater than the MDEP VCEP threshold of 0.70 (PP3). This variant has an incomputable gnomAD v2.1.1  Popmax minor filtering allele frequency due to 0 copies in the European non-Finnish subpopulation and 1 copies in the African/African American subpopulation, thereby meeting the ClinGen MDEP threshold criteria for PM2_Supporting (ENF Popmax FAF <= 0.000003 and <= 2 copies in ENF and <=1 copy in any other subpopulation) (PM2_Supporting).  This variant was identified in 48 unrelated individuals with diabetes/hyperglycemia (PS4; internal lab contributors).  This variant was identified in an individual with a clinical history highly specific for GCK-hyperglycemia (FBG 5.5-8 mmol/L and HbA1c 5.6 - 7.6% and OGTT increment < 3 mmol/L) (PP4_Moderate, internal lab contributors).  This variant segregated with diabetes/hyperglycemia with 23 informative meioses in multiple families (PP1_Strong; internal lab contributors). A kinetic analysis of recombinant wild-type (WT) and mutant glucokinase demonstrated that the wild-type kinetic parameters passed the quality control, the wild-type ATP Km was between 0.4-0.65, the p.Gly72Arg had a relative activity index (RAI) > 0.5 and a relative stability index (RSI) <=0.5 (PS3_Supporting; PMID: 25015100).  In summary, c.214G>A meets the criteria to be classified as Pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP VCEP (specification version 1.2.0, approved 8/11/2023):  PS4, PP1_Strong, PP4_Moderate, PS3_Supporting, PM2_Supporting, PP3, PP2.		Monogenic Diabetes VCEP		2023-08-13	2023-08-13	False	https://erepo.genome.network/evrepo/ui/classification/CA213771/MONDO:0015967/086	f7b1c7c0-e94c-4adc-9ff1-69192f1f5cd3	p.Gly72Arg	Gly	72	Arg	MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQ	465	P35557	R	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [8, 73], 'REGION_gain': [], 'REGION_loss_score': array([-0.00748485, -0.02350837]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
572	NM_000162.5(GCK):c.127C>T (p.Arg43Cys)	585911	CA367403451	NM_000162.5:c.127C>T, NC_000007.14:g.44153382G>A, CM000669.2:g.44153382G>A, NC_000007.13:g.44192981G>A, CM000669.1:g.44192981G>A, NC_000007.12:g.44159506G>A, NG_008847.1:g.41042C>T, NG_008847.2:g.49789C>T, ENST00000395796.8:c.*125C>T, ENST00000616242.5:c.127C>T, ENST00000682635.1:n.613C>T, ENST00000345378.7:c.130C>T, ENST00000403799.8:c.127C>T, ENST00000671824.1:c.127C>T, ENST00000673284.1:c.127C>T, ENST00000345378.6:c.130C>T, ENST00000395796.7:c.124C>T, ENST00000403799.7:c.127C>T, ENST00000437084.1:c.127C>T, ENST00000616242.4:n.124C>T, NM_000162.3:c.127C>T, NM_033507.1:c.130C>T, NM_033508.1:c.124C>T, NM_000162.4:c.127C>T, NM_001354800.1:c.127C>T, NM_033507.2:c.130C>T, NM_033508.2:c.124C>T, NM_033507.3:c.130C>T, NM_033508.3:c.124C>T, NM_000162.5(GCK):c.127C>T (p.Arg43Cys)	GCK	monogenic diabetes	MONDO:0015967	Semidominant inheritance	Pathogenic	PS4, PP1_Strong, PP2, PP3, PP4, PM2_Supporting, PS3_Moderate, PM5		The c.127C>T variant in the glucokinase gene, GCK, causes an amino acid change of arginine to cysteine at codon 43 (p.(Arg43Cys)) of NM_000162.5. GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2). This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.924, which is greater than the MDEP VCEP threshold of 0.70 (PP3). Additionally, established functional studies demonstrated the p.Arg43Cys protein has a relative activity index (RAI) < 0.5, indicating that this variant impacts protein function (PS3_Moderate; PMID: 25015100). This variant is absent in gnomAD v2.1.1 (PM2_Supporting), and was identified in at least eight unrelated individuals with hyperglycemia/diabetes (PS4; PMIDs: 30592380, 21348868, PMID 23771172, 25015100). One of these individuals was homozygous for c.127C>T and had permanent neonatal diabetes mellitus (PNDM) and negative testing for ABCC8, KCNJ11, INS and EIF2AK3 (PP4; PMID 25015100). This variant also segregated with diabetes/hyperglycemia, with 5 informative meioses in one family  (PP1_Strong; PMID 21348868). Another missense variant, c.128G>A (p.Arg43His), has been interpreted as pathogenic by the ClinGen MDEP and p.Arg43Cys has a greater Grantham distance (PM5). Taken together, this evidence supports the classification of this variant as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.3.0, approved 8/11/2023): PP1_Strong, PS4, PM5, PP2, PP3, PP4, PM2_Supporting, PS3_Moderate.		Monogenic Diabetes VCEP		2023-08-13	2023-08-13	False	https://erepo.genome.network/evrepo/ui/classification/CA367403451/MONDO:0015967/086	8eefadd2-11eb-46d6-88b2-35a21909f993	p.Arg43Cys	Arg	43	Cys	MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQ	465	P35557	C	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [1], 'SIGNAL_gain': [], 'SIGNAL_loss_score': array([-0.06571424]), 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [40], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.19186962]), 'COILED_loss': [44, 45], 'COILED_gain': [], 'COILED_loss_score': array([-0.30646878, -0.29179239]), 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [83], 'DOMAIN_gain_score': array([0.01910424]), 'REGION_loss': [], 'REGION_gain': [11, 13, 21, 71, 75, 80, 81, 86], 'REGION_gain_score': array([0.01414269, 0.01887769, 0.01126623, 0.04052001, 0.03953254,
       0.03814262, 0.03446025, 0.03255612]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
573	NM_175914.5(HNF4A):c.322G>A (p.Val108Ile)	994902	CA9870225	NM_175914.5:c.322G>A, NC_000020.11:g.44413696G>A, CM000682.2:g.44413696G>A, NC_000020.10:g.43042336G>A, CM000682.1:g.43042336G>A, NC_000020.9:g.42475750G>A, NG_009818.1:g.62896G>A, LRG_483:g.62896G>A, ENST00000316099.10:c.388G>A, ENST00000619550.5:n.362G>A, ENST00000683148.1:n.364G>A, ENST00000683657.1:n.1512G>A, ENST00000316099.9:c.388G>A, ENST00000316099.8:c.388G>A, ENST00000316673.8:c.322G>A, ENST00000372920.1:c.*155G>A, ENST00000415691.2:c.388G>A, ENST00000443598.6:c.388G>A, ENST00000457232.5:c.322G>A, ENST00000609795.5:c.322G>A, ENST00000619550.4:c.313G>A, NM_000457.4:c.388G>A, LRG_483t2:c.388G>A, NM_001030003.2:c.322G>A, NM_001030004.2:c.322G>A, NM_001258355.1:c.367G>A, NM_001287182.1:c.313G>A, NM_001287183.1:c.313G>A, LRG_483t3:c.313G>A, NM_001287184.1:c.313G>A, NM_175914.4:c.322G>A, LRG_483t1:c.322G>A, NM_178849.2:c.388G>A, NM_178850.2:c.388G>A, XM_005260407.2:c.505G>A, XM_011528797.1:c.436G>A, XM_011528798.1:c.436G>A, XM_005260407.4:c.505G>A, NM_001030003.3:c.322G>A, NM_001030004.3:c.322G>A, NM_001258355.2:c.367G>A, NM_001287182.2:c.313G>A, NM_001287184.2:c.313G>A, NM_178849.3:c.388G>A, NM_178850.3:c.388G>A, NM_000457.5:c.388G>A, NM_000457.6:c.388G>A, NM_001287183.2:c.313G>A, NM_175914.5(HNF4A):c.322G>A (p.Val108Ile)	HNF4A	monogenic diabetes	MONDO:0015967	Autosomal dominant inheritance	Pathogenic	PP3, PP4, PM2_Supporting, PM1_Supporting, PS4, PP1_Strong		The c.322G>A variant in the HNF4 homeobox A gene, HNF4A, causes an amino acid change of valine to isoleucine at codon 108 (p.(Val108Ile)) of NM_175914.5. This variant is located within the DNA binding domain (codons 80-110) of HNF4A, which is defined as critical for the protein's function by the ClinGen MDEP (PM1_Supporting). This variant has an incomputable gnomAD v2.1.1  Popmax filtering allele frequency due to 1 copy in the European non-Finnish subpopulation and 1 copy in the East Asian subpopoulation, thereby meeting the ClinGen MDEP threshold criteria for PM2_Supporting (ENF Popmax FAF <= 0.000003 and <= 2 copies in ENF and <=1 copy in any other subpopulation) (PM2_Supporting).  This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.804, which is greater than the MDEP VCEP threshold of 0.70 (PP3). This variant was identified in 16 unrelated individuals with non-autoimmune/insulin-dependent diabetes (PS4; PMID 12203996, PMID 12627330, PMID 28701371, internal lab contributors). This variant segregated with diabetes with 18 informative meioses in 3 families (PP1_Strong; PMID 12203996, internal lab contributors). This variant was identified in an individual with a clinical history highly specific for HNF4A-MODY (MODY probability calculator result >50% and negative genetic testing for HNF1A) (PP4; internal lab contributors). In summary, this evidence supports the classification of this variant as pathogenic for HNF4A-MODY. ACMG/AMP criteria applied, as specified by the ClinGen MDEP VCEP (specification version 1.1.0, approved 8/11/2023):  PM1_Supporting, PM2_Supporting, PP3, PS4, PP1_Strong, PP4.		Monogenic Diabetes VCEP		2023-08-13	2023-08-13	False	https://erepo.genome.network/evrepo/ui/classification/CA9870225/MONDO:0015967/085	1553851e-2f0a-4a90-9490-d6bae857656d	p.Val108Ile	Val	108	Ile	MRLSKTLVDMDMADYSAALDPAYTTLEFENVQVLTMGNDTSPSEGTNLNAPNSLGVSALCAICGDRATGKHYGASSCDGCKGFFRRSVRKNHMYSCRFSRQCVVDKDKRNQCRYCRLKKCFRAGMKKEAVQNERDRISTRRSSYEDSSLPSINALLQAEVLSRQITSPVSGINGDIRAKKIASIADVCESMKEQLLVLVEWAKYIPAFCELPLDDQVALLRAHAGEHLLLGATKRSMVFKDVLLLGNDYIVPRHCPELAEMSRVSIRILDELVLPFQELQIDDNEYAYLKAIIFFDPDAKGLSDPGKIKRLRSQVQVSLEDYINDRQYDSRGRFGELLLLLPTLQSITWQMIEQIQFIKLFGMAKIDNLLQEMLLGGSPSDAPHAHHPLHPHLMQEHMGTNVIVANTMPTHLSNGQMCEWPRPRGQAATPETPQPSPPGGSGSEPYKLLPGAVATIVKPLSAIPQPTITKQEVI	474	P41235	I	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [330], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.03652412]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [152], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.00946808]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
574	NM_000545.8(HNF1A):c.1136C>G (p.Pro379Arg)	1675516	CA244534392	NM_000545.8:c.1136C>G, NC_000012.12:g.120996569C>G, CM000674.2:g.120996569C>G, NC_000012.11:g.121434372C>G, CM000674.1:g.121434372C>G, NC_000012.10:g.119918755C>G, NG_011731.2:g.22824C>G, LRG_522:g.22824C>G, ENST00000257555.11:c.1136C>G, ENST00000257555.10:c.1136C>G, ENST00000400024.6:c.1136C>G, ENST00000402929.5:n.1271C>G, ENST00000535955.5:n.43-922C>G, ENST00000538626.2:n.191-922C>G, ENST00000538646.5:c.*112C>G, ENST00000540108.1:c.*576C>G, ENST00000541395.5:c.1136C>G, ENST00000541924.5:c.*150C>G, ENST00000543255.1:n.180C>G, ENST00000543427.5:c.634-35C>G, ENST00000544413.2:c.1136C>G, ENST00000544574.5:c.73-48C>G, ENST00000560968.5:n.953C>G, ENST00000615446.4:c.-77C>G, ENST00000617366.4:c.587-1065C>G, NM_000545.5:c.1136C>G, LRG_522t1:c.1136C>G, NM_000545.6:c.1136C>G, NM_001306179.1:c.1136C>G, XM_005253931.2:c.1136C>G, XM_024449168.1:c.1136C>G, NM_001306179.2:c.1136C>G, NM_000545.8(HNF1A):c.1136C>G (p.Pro379Arg)	HNF1A	monogenic diabetes	MONDO:0015967	Autosomal dominant inheritance	Pathogenic	PS4, PP1_Strong, PP4_Moderate, PP3, PM2_Supporting	PM1, PS3, BS3	The c.1136C>G variant in the HNF1 homeobox A gene, HNF1A, causes an amino acid change of proline to arginine at codon 379 (p.(Pro379Arg)) of NM_000545.8. This variant has an incomputable gnomAD v2.1.1  Popmax filtering allele frequency due to 1 copy in the European non-Finnish subpopulation and 0 copies in any other subpopulation, thereby meeting the ClinGen MDEP threshold criteria for PM2_Supporting (ENF Popmax FAF <= 0.000003 and <= 2 copies in ENF and <=1 copy in any other subpopulation) (PM2_Supporting).  This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.961, which is greater than the MDEP threshold of 0.70 (PP3). This variant was identified in an individual with a MODY probability calculator result >50%, negative genetic testing for HNF4A, and antibody negative (PP4_Moderate; internal lab contributors). This variant was identified in 8 unrelated individuals with non- autoimmune and non-absolute/near-absolute insulin-deficient diabetes (PS4; PMID: 21170474, PMID: 15657605, internal lab contributors). This variant segregated with diabetes, with at least 4 informative meioses in 3 families with MODY (PP1_Strong; PMID: 15657605, internal lab contributors). In summary, this variant meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 2.1.0, approved 8/11/2023): PM2_Supporting, PP3, PP4_Moderate, PS4, PP1_Strong.		Monogenic Diabetes VCEP		2023-08-14	2023-08-14	False	https://erepo.genome.network/evrepo/ui/classification/CA244534392/MONDO:0015967/017	bc82f8ab-c82c-4497-b59a-b899a6ac82e7	p.Pro379Arg	Pro	379	Arg	MVSKLSQLQTELLAALLESGLSKEALIQALGEPGPYLLAGEGPLDKGESCGGGRGELAELPNGLGETRGSEDETDDDGEDFTPPILKELENLSPEEAAHQKAVVETLLQEDPWRVAKMVKSYLQQHNIPQREVVDTTGLNQSHLSQHLNKGTPMKTQKRAALYTWYVRKQREVAQQFTHAGQGGLIEEPTGDELPTKKGRRNRFKWGPASQQILFQAYERQKNPSKEERETLVEECNRAECIQRGVSPSQAQGLGSNLVTEVRVYNWFANRRKEEAFRHKLAMDTYSGPPPGPGPGPALPAHSSPGLPPPALSPSKVHGVRYGQPATSETAEVPSSSGGPLVTVSTPLHQVSPTGLEPSHSLLSTEAKLVSAAGGPLPPVSTLTALHSLEQTSPGLNQQPQNLIMASLPGVMTIGPGEPASLGPTFTNTGASTLVIGLASTQAQSVPVINSMGSSLTTLQPVQFSQPLHPSYQQPLMPPVQSHVTQSPFMATMAQLQSPHALYSHKPEVAQYTHTGLLPQTMLITDTTNLSALASLTPTKQVFTSDTEASSESGLHTPASQATTLHVPSQDPAGIQHLQPAHRLSASPTVSSSSLVLYQSSDSSNGQSHLLPSNHSVIETFISTQMASSSQ	631	P20823	R	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [97], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.00295335]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [345], 'COMPBIAS_gain': [69, 73], 'COMPBIAS_gain_score': array([0.01716596, 0.01615149]), 'COMPBIAS_loss_score': array([-0.04341877]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
575	NM_000162.5(GCK):c.128G>A (p.Arg43His)	393453	CA4239718	NM_000162.5:c.128G>A, NC_000007.14:g.44153381C>T, CM000669.2:g.44153381C>T, NC_000007.13:g.44192980C>T, CM000669.1:g.44192980C>T, NC_000007.12:g.44159505C>T, NG_008847.1:g.41043G>A, NG_008847.2:g.49790G>A, ENST00000395796.8:c.*126G>A, ENST00000616242.5:c.128G>A, ENST00000682635.1:n.614G>A, ENST00000345378.7:c.131G>A, ENST00000403799.8:c.128G>A, ENST00000671824.1:c.128G>A, ENST00000673284.1:c.128G>A, ENST00000345378.6:c.131G>A, ENST00000395796.7:c.125G>A, ENST00000403799.7:c.128G>A, ENST00000437084.1:c.128G>A, ENST00000616242.4:n.125G>A, NM_000162.3:c.128G>A, NM_033507.1:c.131G>A, NM_033508.1:c.125G>A, NM_000162.4:c.128G>A, NM_001354800.1:c.128G>A, NM_033507.2:c.131G>A, NM_033508.2:c.125G>A, NM_033507.3:c.131G>A, NM_033508.3:c.125G>A, NM_000162.5(GCK):c.128G>A (p.Arg43His)	GCK	monogenic diabetes	MONDO:0015967	Semidominant inheritance	Pathogenic	PS4, PP1_Moderate, PM5_Supporting, PP4_Moderate, PP2, PP3, PM2_Supporting	PS3	The c.128G>A variant in the glucokinase gene, GCK, causes an amino acid change of arginine to histidine at codon 43 (p.(Arg43His)) of NM_000162.5. GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2). This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.8159, which is greater than the MDEP VCEP threshold of 0.70 (PP3). Functional studies demonstrated that the p.Arg43His variant has normal relative activity index (RAI>0.5) and normal GKA/GKRP interaction; however the relative stability index (RSI) was not calculated and therefore neither PS3 or BS3 can be applied (PMID: 22611063). This variant has an incomputable gnomAD v2.1.1 Popmax filtering allele frequency due to 0 copies in the European non-Finnish subpopulation and 1 copy in the Latino/Admixed American subpopulation, thereby meeting the ClinGen MDEP threshold criteria for PM2_Supporting (ENF Popmax FAF <= 0.000003 and <= 2 copies in ENF and <=1 copy in any other subpopulation) (PM2_Supporting).  This variant was identified in eight unrelated individuals with hyperglycemia (PS4; PMIDs: 11942313, 22611063, 27106716, 25015100, 22493702, 30245511, 31638168, 33046911).  This variant was identified in an individual with a clinical history highly specific for GCK-hyperglycemia (FBG 5.5-8 mmol/L and HbA1c 5.6 - 7.6% and OGTT increment < 3 mmol/L) (PP4_Moderate; PMID: 30245511).  This variant segregated with diabetes/hyperglycemia, with three informative meioses in two families (PP1_Moderate; PMIDs: 22611063, 22493702). Another missense variant, c.127C>T (p.Arg43Cys), has been classified as pathogenic by the ClinGen MDEP but has a greater Grantham distance than p.Arg43His (PM5_Supporting). In summary, the c.128G>A variant meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified for by the GlinGen MDEP (specification version 1.3.0, approved 8/11/2023): PS4, PP4_Moderate, PP1_Moderate, PP2, PP3, PM2_Supporting, PM5_Supporting.		Monogenic Diabetes VCEP		2023-08-25	2023-08-25	False	https://erepo.genome.network/evrepo/ui/classification/CA4239718/MONDO:0015967/086	dd64642b-fad9-40c9-a9ea-0b3de810cdff	p.Arg43His	Arg	43	His	MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQ	465	P35557	H	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [44, 45], 'COILED_gain': [], 'COILED_loss_score': array([-0.16265702, -0.17325443]), 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [83], 'DOMAIN_gain_score': array([0.00415373]), 'REGION_loss': [], 'REGION_gain': [7, 11, 21, 42, 71, 75, 80, 86], 'REGION_gain_score': array([0.00878668, 0.01009512, 0.00543255, 0.02395773, 0.03284466,
       0.02931726, 0.02890551, 0.02536494]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
576	NM_000162.5(GCK):c.184G>A (p.Val62Met)	419624	CA16618472	NM_000162.5:c.184G>A, NC_000007.14:g.44153325C>T, CM000669.2:g.44153325C>T, NC_000007.13:g.44192924C>T, CM000669.1:g.44192924C>T, NC_000007.12:g.44159449C>T, NG_008847.1:g.41099G>A, NG_008847.2:g.49846G>A, ENST00000395796.8:c.*182G>A, ENST00000616242.5:c.184G>A, ENST00000682635.1:n.670G>A, ENST00000345378.7:c.187G>A, ENST00000403799.8:c.184G>A, ENST00000671824.1:c.184G>A, ENST00000673284.1:c.184G>A, ENST00000345378.6:c.187G>A, ENST00000395796.7:c.181G>A, ENST00000403799.7:c.184G>A, ENST00000437084.1:c.184G>A, ENST00000616242.4:n.181G>A, NM_000162.3:c.184G>A, NM_033507.1:c.187G>A, NM_033508.1:c.181G>A, NM_000162.4:c.184G>A, NM_001354800.1:c.184G>A, NM_033507.2:c.187G>A, NM_033508.2:c.181G>A, NM_033507.3:c.187G>A, NM_033508.3:c.181G>A, NM_000162.5(GCK):c.184G>A (p.Val62Met)	GCK	monogenic diabetes	MONDO:0015967	Semidominant inheritance	Pathogenic	PS4_Moderate, PP1_Strong, PS3_Supporting, PP4_Moderate, PP2, PP3, PM2_Supporting		The c.184G>A variant in the glucokinase gene, GCK, causes an amino acid change of valine to methionine at codon 62 (p.(Val62Met)) of NM_000162.5. GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2). This variant is also predicted to be deleterious by computational evidence, with a REVEL score of 0.972, which is greater than the MDEP VCEP threshold of 0.70 (PP3). While p.Val62Met did not have reduction in enzyme activity or stability, its activity was unresponsive to GKRP (PS3_Supporting; PMID 15677479). This variant is absent in gnomAD v2.1.1 (PM2_Supporting), and was identified in six unrelated individuals with non- autoimmune and non-absolute/near-absolute insulin-deficient diabetes (PS4_Moderate; PMID:15677479, PMID: 28726111, ClinVar ID: 419624, internal lab contributors). At least two of these individuals had a clinical history highly specific for for GCK-hyperglycemia (FBG 5.5-8 mmol/L and HbA1c 5.6 - 7.6% and OGTT increment < 3 mmol/L) (PP4_Moderate; PMID:15677479). This variant segregated with diabetes, with six informative meioses in two families with MODY (PP1_Strong; PMID: 15677479). In summary, c.184G>A meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.3.0, approved 8/11/2023): PP1_strong, PP4_moderate, PS4_moderate, PP2, PP3, PM2_Supporting, PS3_Supporting.		Monogenic Diabetes VCEP		2023-08-25	2023-08-25	False	https://erepo.genome.network/evrepo/ui/classification/CA16618472/MONDO:0015967/086	1f57faf8-0f13-448a-a462-a8cde367a841	p.Val62Met	Val	62	Met	MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQ	465	P35557	M	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [83], 'DOMAIN_gain_score': array([0.00380927]), 'REGION_loss': [], 'REGION_gain': [71, 75, 80, 81, 86], 'REGION_gain_score': array([0.04010999, 0.03510702, 0.03269506, 0.03184867, 0.02579445]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
577	NM_000545.8(HNF1A):c.1135C>G (p.Pro379Ala)	431970	CA6831955	NM_000545.8:c.1135C>G, NC_000012.12:g.120996568C>G, CM000674.2:g.120996568C>G, NC_000012.11:g.121434371C>G, CM000674.1:g.121434371C>G, NC_000012.10:g.119918754C>G, NG_011731.2:g.22823C>G, LRG_522:g.22823C>G, ENST00000257555.11:c.1135C>G, ENST00000257555.10:c.1135C>G, ENST00000400024.6:c.1135C>G, ENST00000402929.5:n.1270C>G, ENST00000535955.5:n.43-923C>G, ENST00000538626.2:n.191-923C>G, ENST00000538646.5:c.*111C>G, ENST00000540108.1:c.*575C>G, ENST00000541395.5:c.1135C>G, ENST00000541924.5:c.*149C>G, ENST00000543255.1:n.179C>G, ENST00000543427.5:c.634-36C>G, ENST00000544413.2:c.1135C>G, ENST00000544574.5:c.73-49C>G, ENST00000560968.5:n.952C>G, ENST00000615446.4:c.-78C>G, ENST00000617366.4:c.587-1066C>G, NM_000545.5:c.1135C>G, LRG_522t1:c.1135C>G, NM_000545.6:c.1135C>G, NM_001306179.1:c.1135C>G, XM_005253931.2:c.1135C>G, XM_024449168.1:c.1135C>G, NM_001306179.2:c.1135C>G, NM_000545.8(HNF1A):c.1135C>G (p.Pro379Ala)	HNF1A	monogenic diabetes	MONDO:0015967	Autosomal dominant inheritance	Benign	PP3, BA1	PM1, PS4, BP5, PM2	The c.1135C>G variant in the HNF1 homeobox A gene, HNF1A, causes an amino acid change of proline to alanine at codon 379 (p.(Pro379Ala)) of NM_000545.8. This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.9639, which is greater than the MDEP VCEP threshold of 0.70 (PP3). While this variant has been identified in >20 unrelated individuals with diabetes in the literature (ClinVar ID 431970, PMID:18003757, PMID: 23348805, PMID: 29207974, PMID: 21761282, PMID: 23607861), it has a Popmax Filtering allele frequency in gnomAD 2.1.1 of 0.0005091, which is greater than the MDEP threshold for BA1 (greater than 0.0001) (BA1). Therefore, PS4 cannot be applied. While another variant at this codon, c.1136C>G (p.(Pro379Arg)), is classified as Pathogenic by the MDEP, the c.1135C>G meets the criteria to be classified as benign for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 2.1.1, approved 8/11/2023): BA1, PP3.  It may, however, confer an increased risk of type 2 diabetes (OR = 11.8, p = 0.0007324 at type2diabetesgenetics.org).		Monogenic Diabetes VCEP		2023-09-06	2023-09-06	False	https://erepo.genome.network/evrepo/ui/classification/CA6831955/MONDO:0015967/017	2e13c2de-6b67-4738-b89f-f88858c71a3b	p.Pro379Ala	Pro	379	Ala	MVSKLSQLQTELLAALLESGLSKEALIQALGEPGPYLLAGEGPLDKGESCGGGRGELAELPNGLGETRGSEDETDDDGEDFTPPILKELENLSPEEAAHQKAVVETLLQEDPWRVAKMVKSYLQQHNIPQREVVDTTGLNQSHLSQHLNKGTPMKTQKRAALYTWYVRKQREVAQQFTHAGQGGLIEEPTGDELPTKKGRRNRFKWGPASQQILFQAYERQKNPSKEERETLVEECNRAECIQRGVSPSQAQGLGSNLVTEVRVYNWFANRRKEEAFRHKLAMDTYSGPPPGPGPGPALPAHSSPGLPPPALSPSKVHGVRYGQPATSETAEVPSSSGGPLVTVSTPLHQVSPTGLEPSHSLLSTEAKLVSAAGGPLPPVSTLTALHSLEQTSPGLNQQPQNLIMASLPGVMTIGPGEPASLGPTFTNTGASTLVIGLASTQAQSVPVINSMGSSLTTLQPVQFSQPLHPSYQQPLMPPVQSHVTQSPFMATMAQLQSPHALYSHKPEVAQYTHTGLLPQTMLITDTTNLSALASLTPTKQVFTSDTEASSESGLHTPASQATTLHVPSQDPAGIQHLQPAHRLSASPTVSSSSLVLYQSSDSSNGQSHLLPSNHSVIETFISTQMASSSQ	631	P20823	A	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [345, 346], 'COMPBIAS_gain': [69, 73], 'COMPBIAS_gain_score': array([0.02223498, 0.02011001]), 'COMPBIAS_loss_score': array([-0.06331843, -0.063389  ]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
578	NM_000162.5(GCK):c.1139A>C (p.His380Pro)	1098819	CA367398780	NM_000162.5:c.1139A>C, NC_000007.14:g.44145611T>G, CM000669.2:g.44145611T>G, NC_000007.13:g.44185210T>G, CM000669.1:g.44185210T>G, NC_000007.12:g.44151735T>G, NG_008847.1:g.48813A>C, NG_008847.2:g.57560A>C, ENST00000395796.8:c.*1137A>C, ENST00000616242.5:c.*259A>C, ENST00000683378.1:n.365A>C, ENST00000336642.9:c.173A>C, ENST00000345378.7:c.1142A>C, ENST00000403799.8:c.1139A>C, ENST00000671824.1:c.1202A>C, ENST00000672743.1:n.151A>C, ENST00000673284.1:c.1139A>C, ENST00000336642.8:c.191A>C, ENST00000345378.6:c.1142A>C, ENST00000395796.7:c.1136A>C, ENST00000403799.7:c.1139A>C, ENST00000437084.1:c.1088A>C, ENST00000459642.1:n.519A>C, ENST00000616242.4:c.1136A>C, NM_000162.3:c.1139A>C, NM_033507.1:c.1142A>C, NM_033508.1:c.1136A>C, NM_000162.4:c.1139A>C, NM_001354800.1:c.1139A>C, NM_001354801.1:c.128A>C, NM_001354802.1:c.-2A>C, NM_001354803.1:c.173A>C, NM_033507.2:c.1142A>C, NM_033508.2:c.1136A>C, XM_024446707.1:c.-2A>C, NM_033507.3:c.1142A>C, NM_033508.3:c.1136A>C, NM_001354803.2:c.173A>C, NM_000162.5(GCK):c.1139A>C (p.His380Pro)	GCK	monogenic diabetes	MONDO:0015967	Semidominant inheritance	Pathogenic	PS4, PP1_Strong, PP4_Moderate, PP2, PP3, PM2_Supporting	PM1	The c.1139A>C variant in the glucokinase gene, GCK, causes an amino acid change of histidine to proline at codon 380 (p.(His380Pro)) of NM_000162.5. GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2).  This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.789, which is greater than the MDEP VCEP threshold of 0.70 (PP3). This variant is absent from gnomAD v2.1.1 (PM2_Supporting).  This variant was identified in nine unrelated individuals with hyperglycemia (PS4; PMIDs: 34440516, 19790256, internal lab contributors).  At least two of these individuals had a clinical history highly specific for GCK-hyperglycemia (FBG 5.5-8 mmol/L and HbA1c 5.6 - 7.6% and 2 hour OGTT increment < 3 mmol/L or negative antibodies) (PP4_Moderate, PMID: 34440516, internal lab contributor).  This variant segregated with hyperglycemia, with at least eight informative meioses in six families (PP1_Strong; PMID: 34440516, internal lab contributor).  In summary, c.1139A>C meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.3, approved 8/11/2023): PP4_Moderate, PS4, PP2, PP3, PM2_Supporting, PP1_Strong.		Monogenic Diabetes VCEP		2023-09-19	2023-09-19	False	https://erepo.genome.network/evrepo/ui/classification/CA367398780/MONDO:0015967/086	25b05c55-bdc8-4ab4-827f-8ae499b52ff9	p.His380Pro	His	380	Pro	MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQ	465	P35557	P	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [203], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.03096902]), 'HELIX_loss': [457], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.08137882]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [11, 21, 71, 80], 'REGION_gain_score': array([0.00587338, 0.00417966, 0.00992715, 0.01415724]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
579	NM_000162.5(GCK):c.823C>T (p.Arg275Cys)	585927	CA4239519	NM_000162.5:c.823C>T, NC_000007.14:g.44147690G>A, CM000669.2:g.44147690G>A, NC_000007.13:g.44187289G>A, CM000669.1:g.44187289G>A, NC_000007.12:g.44153814G>A, NG_008847.1:g.46734C>T, NG_008847.2:g.55481C>T, ENST00000395796.8:c.*821C>T, ENST00000616242.5:c.823C>T, ENST00000345378.7:c.826C>T, ENST00000403799.8:c.823C>T, ENST00000671824.1:c.823C>T, ENST00000673284.1:c.823C>T, ENST00000345378.6:c.826C>T, ENST00000395796.7:c.820C>T, ENST00000403799.7:c.823C>T, ENST00000437084.1:c.772C>T, ENST00000616242.4:c.820C>T, NM_000162.3:c.823C>T, NM_033507.1:c.826C>T, NM_033508.1:c.820C>T, XR_927223.1:n.24G>A, NM_000162.4:c.823C>T, NM_001354800.1:c.823C>T, NM_033507.2:c.826C>T, NM_033508.2:c.820C>T, XR_927223.2:n.24G>A, NM_033507.3:c.826C>T, NM_033508.3:c.820C>T, NM_000162.5(GCK):c.823C>T (p.Arg275Cys)	GCK	monogenic diabetes	MONDO:0015967	Semidominant inheritance	Pathogenic	PS4, PP4_Moderate, PP2, PP3, PP1, PM2_Supporting	PS3	The c.823C>T variant in the glucokinase gene, GCK, causes an amino acid change of arginine to cysteine at codon 275 (p.(Arg275Cys)) of NM_000162.5.  This variant was identified in 7 unrelated individuals with hyperglycemia (PS4; PMID: 24001579, internal lab contributors).  This variant was identified in two individuals with a clinical history highly specific for GCK-hyperglycemia (FBG 5.5-8 mmol/L and HbA1c 5.6 - 7.6% and OGTT increment < 3 mmol/L) (internal lab contributors).  This variant segregated with diabetes/hyperglycemia, with 3 informative meioses in 1 family (PP1; PMID: 24001579).  GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2).  This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.901, which is greater than the MDEP VCEP threshold of 0.70 (PP3). While a study exploring the effect of this variant on protein function has been performed and suggests a possible impact on stability and dimerization, the study does not meet the criteria set forth by the MDEP for the application of PS3 or BS3 (PMID: 24001579).  This variant has an incomputable gnomAD v2.1.1  Popmax minor filtering allele frequency due to 1 copy in the European non-Finnish subpopulation, 1 copy in the African/African American subpopulation, and 1 copy in the South Asian subpopulation, thereby meeting the ClinGen MDEP threshold criteria for PM2_Supporting (ENF Popmax FAF less than or equal to 0.000003 and <= 2 copies in ENF and <=1 copy in any other subpopulation) (PM2_Supporting).  In summary, 823C>T meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.3.0, approved 8/11/2023): PS4, PP4_Moderate, PP1, PP2, PP3, PM2_Supporting.		Monogenic Diabetes VCEP		2023-09-20	2023-09-20	False	https://erepo.genome.network/evrepo/ui/classification/CA4239519/MONDO:0015967/086	10a41ed2-a058-4df3-b3ec-335ec9c2b90e	p.Arg275Cys	Arg	275	Cys	MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQ	465	P35557	C	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [203], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.0113157]), 'HELIX_loss': [272, 273, 274, 275, 276, 277, 278], 'HELIX_gain': [283], 'HELIX_gain_score': array([0.13338268]), 'HELIX_loss_score': array([-0.53068566, -0.61596513, -0.59859496, -0.69134104, -0.65817457,
       -0.55838478, -0.16402704]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [83], 'DOMAIN_gain_score': array([0.01107633]), 'REGION_loss': [73, 82], 'REGION_gain': [11, 21], 'REGION_gain_score': array([0.00851721, 0.00535589]), 'REGION_loss_score': array([-0.01142114, -0.02003878]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
580	NM_004360.5(CDH1):c.2638G>A (p.Glu880Lys)	184838	CA190198	NM_004360.5:c.2638G>A, NC_000016.10:g.68833488G>A, CM000678.2:g.68833488G>A, NC_000016.9:g.68867391G>A, CM000678.1:g.68867391G>A, NC_000016.8:g.67424892G>A, NG_008021.1:g.101197G>A, LRG_301:g.101197G>A, ENST00000261769.10:c.2638G>A, ENST00000261769.9:c.2638G>A, ENST00000422392.6:c.2455G>A, ENST00000562118.1:n.856G>A, ENST00000562836.5:n.2709G>A, ENST00000566510.5:c.*1304G>A, ENST00000566612.5:c.*878G>A, ENST00000611625.4:c.2701G>A, ENST00000612417.4:c.1854-703G>A, ENST00000621016.4:c.1866-715G>A, NM_004360.3:c.2638G>A, LRG_301t1:c.2638G>A, XM_011523488.1:c.1903G>A, XM_011523489.1:c.1903G>A, NM_001317184.1:c.2455G>A, NM_001317185.1:c.1090G>A, NM_001317186.1:c.673G>A, NM_004360.4:c.2638G>A, NM_001317184.2:c.2455G>A, NM_001317185.2:c.1090G>A, NM_001317186.2:c.673G>A, NM_004360.5(CDH1):c.2638G>A (p.Glu880Lys)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0100488	Autosomal dominant inheritance	Benign	BS2, BS1	BA1, PM2	The c.2638G>A (p.Glu880Lys) variant results in a missense change in the last exon of CDH1. This variant has been reported in at least five individuals meeting criteria for HDGC (PMID: 28522256, 32426482, 34537906, 32241597). However, this variant is present at a maximum frequency of 0.001153 (6 of 5,204 alleles) in the East Asian subpopulation in gnomAD, which is greater than expected for CDH1-related diffuse gastric and lobular breast cancer (BS1). This variant has also been observed in 112 individuals without DGC, LBC or SRC tumours and whose families do not suggest HDGC (BS2; internal laboratory contributors). In summary, this variant is classified as benign based on ACMG/AMP criteria applied as specified by the CDH1 Variant Curation Expert Panel: BS1, BS2.		CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-09-25	2023-09-27	False	https://erepo.genome.network/evrepo/ui/classification/CA190198/MONDO:0100488/007	776e37b6-c807-4cd8-99c7-ad18dd7a6391	p.Glu880Lys	Glu	880	Lys	MGPWSRSLSALLLLLQVSSWLCQEPEPCHPGFDAESYTFTVPRRHLERGRVLGRVNFEDCTGRQRTAYFSLDTRFKVGTDGVITVKRPLRFHNPQIHFLVYAWDSTYRKFSTKVTLNTVGHHHRPPPHQASVSGIQAELLTFPNSSPGLRRQKRDWVIPPISCPENEKGPFPKNLVQIKSNKDKEGKVFYSITGQGADTPPVGVFIIERETGWLKVTEPLDRERIATYTLFSHAVSSNGNAVEDPMEILITVTDQNDNKPEFTQEVFKGSVMEGALPGTSVMEVTATDADDDVNTYNAAIAYTILSQDPELPDKNMFTINRNTGVISVVTTGLDRESFPTYTLVVQAADLQGEGLSTTATAVITVTDTNDNPPIFNPTTYKGQVPENEANVVITTLKVTDADAPNTPAWEAVYTILNDDGGQFVVTTNPVNNDGILKTAKGLDFEAKQQYILHVAVTNVVPFEVSLTTSTATVTVDVLDVNEAPIFVPPEKRVEVSEDFGVGQEITSYTAQEPDTFMEQKITYRIWRDTANWLEINPDTGAISTRAELDREDFEHVKNSTYTALIIATDNGSPVATGTGTLLLILSDVNDNAPIPEPRTIFFCERNPKPQVINIIDADLPPNTSPFTAELTHGASANWTIQYNDPTQESIILKPKMALEVGDYKINLKLMDNQNKDQVTTLEVSVCDCEGAAGVCRKAQPVEAGLQIPAILGILGGILALLILILLLLLFLRRRAVVKEPLLPPEDDTRDNVYYYDEEGGGEEDQDFDLSQLHRGLDARPEVTRNDVAPTLMSVPRYLPRPANPDEIGNFIDENLKAADTDPTAPPYDSLLVFDYEGSGSEAASLSSLNSSESDKDQDYDYLNEWGNRFKKLADMYGGGEDD	882	P12830	K	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [503], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.00280166]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
581	NM_004360.5(CDH1):c.1178T>A (p.Ile393Asn)	141828	CA294202	NM_004360.5:c.1178T>A, NC_000016.10:g.68813353T>A, CM000678.2:g.68813353T>A, NC_000016.9:g.68847256T>A, CM000678.1:g.68847256T>A, NC_000016.8:g.67404757T>A, NG_008021.1:g.81062T>A, LRG_301:g.81062T>A, ENST00000261769.10:c.1178T>A, ENST00000261769.9:c.1178T>A, ENST00000422392.6:c.1137+1090T>A, ENST00000562836.5:n.1249T>A, ENST00000565810.1:n.222T>A, ENST00000566510.5:c.1022T>A, ENST00000566612.5:c.1178T>A, ENST00000611625.4:c.1178T>A, ENST00000612417.4:c.1178T>A, ENST00000621016.4:c.1178T>A, NM_004360.3:c.1178T>A, LRG_301t1:c.1178T>A, XM_011523488.1:c.443T>A, XM_011523489.1:c.443T>A, NM_001317184.1:c.1137+1090T>A, NM_001317185.1:c.-438T>A, NM_001317186.1:c.-642T>A, NM_004360.4:c.1178T>A, NM_001317184.2:c.1137+1090T>A, NM_001317185.2:c.-438T>A, NM_001317186.2:c.-642T>A, NM_004360.5(CDH1):c.1178T>A (p.Ile393Asn)	CDH1	CDH1-related diffuse gastric and lobular breast cancer	MONDO:0100488	Autosomal dominant inheritance	Benign	BP2_Strong, BS2	PP2, PP3, PS1, PS4, BP1, BP4, BP3, BA1, PM1, PM3, PM4, PVS1, PM2, BP7, BS1	The NM_004360.5(CDH1):c.1178T>A (p.Ile393Asn) variant has been observed in more than 10 (85) individuals without a diagnosis of diffuse gastric cancer, signet ring tumor or lobular breast cancer and whose family histories do not suggest HDGC (BS2; internal laboratory contributors). This variant co-occurs in trans with a pathogenic CDH1 deletion in a carrier with a congenital malformation of the palate and family history of GC (BP2_Strong; internal laboratory contributors). This variant is known in one family with HDGC criteria (internal laboratory contributors). In summary, the clinical significance of this variant is classified as benign based on BS2 and BP2_Strong. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): BS2, BP2_Strong.		CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2023-08-28	2023-09-27	False	https://erepo.genome.network/evrepo/ui/classification/CA294202/MONDO:0100488/007	002de39a-37d7-42dc-aa7b-2f386c531abf	p.Ile393Asn	Ile	393	Asn	MGPWSRSLSALLLLLQVSSWLCQEPEPCHPGFDAESYTFTVPRRHLERGRVLGRVNFEDCTGRQRTAYFSLDTRFKVGTDGVITVKRPLRFHNPQIHFLVYAWDSTYRKFSTKVTLNTVGHHHRPPPHQASVSGIQAELLTFPNSSPGLRRQKRDWVIPPISCPENEKGPFPKNLVQIKSNKDKEGKVFYSITGQGADTPPVGVFIIERETGWLKVTEPLDRERIATYTLFSHAVSSNGNAVEDPMEILITVTDQNDNKPEFTQEVFKGSVMEGALPGTSVMEVTATDADDDVNTYNAAIAYTILSQDPELPDKNMFTINRNTGVISVVTTGLDRESFPTYTLVVQAADLQGEGLSTTATAVITVTDTNDNPPIFNPTTYKGQVPENEANVVITTLKVTDADAPNTPAWEAVYTILNDDGGQFVVTTNPVNNDGILKTAKGLDFEAKQQYILHVAVTNVVPFEVSLTTSTATVTVDVLDVNEAPIFVPPEKRVEVSEDFGVGQEITSYTAQEPDTFMEQKITYRIWRDTANWLEINPDTGAISTRAELDREDFEHVKNSTYTALIIATDNGSPVATGTGTLLLILSDVNDNAPIPEPRTIFFCERNPKPQVINIIDADLPPNTSPFTAELTHGASANWTIQYNDPTQESIILKPKMALEVGDYKINLKLMDNQNKDQVTTLEVSVCDCEGAAGVCRKAQPVEAGLQIPAILGILGGILALLILILLLLLFLRRRAVVKEPLLPPEDDTRDNVYYYDEEGGGEEDQDFDLSQLHRGLDARPEVTRNDVAPTLMSVPRYLPRPANPDEIGNFIDENLKAADTDPTAPPYDSLLVFDYEGSGSEAASLSSLNSSESDKDQDYDYLNEWGNRFKKLADMYGGGEDD	882	P12830	N	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [5], 'TRANSIT_gain': [], 'TRANSIT_loss_score': array([-0.01187247]), 'STRAND_loss': [503], 'STRAND_gain': [175, 260, 485, 678], 'STRAND_gain_score': array([0.00394851, 0.00591189, 0.00323629, 0.0035376 ]), 'STRAND_loss_score': array([-0.00106591]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
582	NM_175914.5(HNF4A):c.335G>A (p.Arg112Gln)	427034	CA409105430	NM_175914.5:c.335G>A, NC_000020.11:g.44413709G>A, CM000682.2:g.44413709G>A, NC_000020.10:g.43042349G>A, CM000682.1:g.43042349G>A, NC_000020.9:g.42475763G>A, NG_009818.1:g.62909G>A, LRG_483:g.62909G>A, ENST00000316099.10:c.401G>A, ENST00000619550.5:c.375G>A, ENST00000683148.1:n.377G>A, ENST00000683657.1:n.1525G>A, ENST00000316099.9:c.401G>A, ENST00000316099.8:c.401G>A, ENST00000316673.8:c.335G>A, ENST00000372920.1:c.*168G>A, ENST00000415691.2:c.401G>A, ENST00000443598.6:c.401G>A, ENST00000457232.5:c.335G>A, ENST00000609795.5:c.335G>A, ENST00000619550.4:c.326G>A, NM_000457.4:c.401G>A, LRG_483t2:c.401G>A, NM_001030003.2:c.335G>A, NM_001030004.2:c.335G>A, NM_001258355.1:c.380G>A, NM_001287182.1:c.326G>A, NM_001287183.1:c.326G>A, LRG_483t3:c.326G>A, NM_001287184.1:c.326G>A, NM_175914.4:c.335G>A, LRG_483t1:c.335G>A, NM_178849.2:c.401G>A, NM_178850.2:c.401G>A, XM_005260407.2:c.518G>A, XM_011528797.1:c.449G>A, XM_011528798.1:c.449G>A, XM_005260407.4:c.518G>A, NM_001030003.3:c.335G>A, NM_001030004.3:c.335G>A, NM_001258355.2:c.380G>A, NM_001287182.2:c.326G>A, NM_001287184.2:c.326G>A, NM_178849.3:c.401G>A, NM_178850.3:c.401G>A, NM_000457.5:c.401G>A, NM_000457.6:c.401G>A, NM_001287183.2:c.326G>A, NM_175914.5(HNF4A):c.335G>A (p.Arg112Gln)	HNF4A	monogenic diabetes	MONDO:0015967	Autosomal dominant inheritance	Pathogenic	PP3, PM1, PM2_Supporting, PS4, PP1_Strong, PM5_Supporting, PP4_Moderate		The c.335G>A variant in the hepatic nuclear factor 4-alpha gene, HNF4A, causes an amino acid change of arginine to glutamine at codon 112 (p.(Arg112Gln)) of NM_175914.5. This variant resides in an amino acid within the HNF4A DNA binding domain that directly binds DNA, which is defined as critical for the protein’s function by the ClinGen MDEP (PM1).  This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.959, which is greater than the MDEP VCEP threshold of 0.70 (PP3).  This variant is absent from gnomAD v2.1.1 (PM2_Supporting). This variant was identified in at least 17 unrelated individuals with non-autoimmune and non-absolute/near-absolute insulin-deficient diabetes (PS4; PMIDs: 36257325, 25306193, 26552609, 18356407, internal lab contributors).  At least one of these individuals had a clinical history highly specific for HNF4A-MODY (MODY probability calculator result >50%, negative genetic testing for HNF1A, and sulfonylurea-responsive) (PP4_Moderate; internal lab contributors).  This variant segregated with diabetes, with 12 informative meioses in 11 families (PP1_Strong; PMID: 18356407, internal lab contributors). Another missense variant, c.334C>T p.Arg112Trp, has been classified as pathogenic by the ClinGen MDEP but has a greater Grantham distance than p.Arg112Gln (PM5_Supporting). In summary, c.335A>G meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.1.0, approved 8/11/2023): PS4, PP1_Strong, PM1, PP4_Moderate, PP3, PM2_Supporting, PM5_Supporting.		Monogenic Diabetes VCEP		2023-09-29	2023-09-29	False	https://erepo.genome.network/evrepo/ui/classification/CA409105430/MONDO:0015967/085	9374a449-3776-451d-b6e1-4eb50bcbc616	p.Arg112Gln	Arg	112	Gln	MRLSKTLVDMDMADYSAALDPAYTTLEFENVQVLTMGNDTSPSEGTNLNAPNSLGVSALCAICGDRATGKHYGASSCDGCKGFFRRSVRKNHMYSCRFSRQCVVDKDKRNQCRYCRLKKCFRAGMKKEAVQNERDRISTRRSSYEDSSLPSINALLQAEVLSRQITSPVSGINGDIRAKKIASIADVCESMKEQLLVLVEWAKYIPAFCELPLDDQVALLRAHAGEHLLLGATKRSMVFKDVLLLGNDYIVPRHCPELAEMSRVSIRILDELVLPFQELQIDDNEYAYLKAIIFFDPDAKGLSDPGKIKRLRSQVQVSLEDYINDRQYDSRGRFGELLLLLPTLQSITWQMIEQIQFIKLFGMAKIDNLLQEMLLGGSPSDAPHAHHPLHPHLMQEHMGTNVIVANTMPTHLSNGQMCEWPRPRGQAATPETPQPSPPGGSGSEPYKLLPGAVATIVKPLSAIPQPTITKQEVI	474	P41235	Q	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [58, 60], 'DNA_BIND_gain': [], 'DNA_BIND_loss_score': array([-0.49677837, -0.28617358]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [351], 'TRANSMEM_gain_score': array([0.05618906]), 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [242, 243, 248, 249], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.14510429, -0.12149823, -0.09953707, -0.11122411]), 'HELIX_loss': [229, 230, 231, 232, 330], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.20707715, -0.29484981, -0.2086277 , -0.21813333, -0.05141485]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [437], 'COMPBIAS_gain_score': array([0.01017219]), 'DOMAIN_loss': [152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 374, 375], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.48016506, -0.55092025, -0.56612074, -0.61418837, -0.68009496,
       -0.70891589, -0.7480278 , -0.75145888, -0.79559141, -0.78133303,
       -0.84855902, -0.84354854, -0.86275643, -0.85626668, -0.86971098,
       -0.85755402, -0.86208999, -0.86475891, -0.84960985, -0.87815565,
       -0.84446853, -0.80475283, -0.73185349, -0.62569797, -0.59514815,
       -0.18834376, -0.28443021]), 'REGION_loss': [447], 'REGION_gain': [], 'REGION_loss_score': array([-0.0537982]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [119], 'ZN_FING_gain': [80, 93, 94], 'ZN_FING_gain_score': array([0.21974248, 0.44184637, 0.3657102 ]), 'ZN_FING_loss_score': array([-0.43591851])}"
583	NM_000488.4(SERPINC1):c.1274G>A (p.Arg425His)	18019	CA210766	NM_000488.4:c.1274G>A, NC_000001.11:g.173904010C>T, CM000663.2:g.173904010C>T, NC_000001.10:g.173873148C>T, CM000663.1:g.173873148C>T, NC_000001.9:g.172139771C>T, NG_012462.1:g.18369G>A, LRG_577:g.18369G>A, ENST00000367698.4:c.1274G>A, ENST00000367698.3:c.1274G>A, ENST00000617423.4:c.659G>A, NM_000488.3:c.1274G>A, LRG_577t1:c.1274G>A, XM_005245198.2:c.1130G>A, NM_001365052.1:c.1130G>A, NM_001365052.2:c.1130G>A, NM_001386302.1:c.1397G>A, NM_001386303.1:c.1355G>A, NM_001386304.1:c.1253G>A, NM_001386305.1:c.1217G>A, NM_001386306.1:c.1058G>A, NM_000488.4(SERPINC1):c.1274G>A (p.Arg425His)	SERPINC1	antithrombin III deficiency	MONDO:0013144	Autosomal dominant inheritance	Pathogenic	PS4, PP1_Moderate, PP3, PP4, PM2_Supporting	PVS1, PM5	The c.1274G>A (NM_000488.3) variant in SERPINC1 is a missense variant predicted to cause substitution of arginine by histidine at amino acid 425 (p.Arg425His; legacy nomenclature p.R393H aka Antithrombin Glasgow).  The computational predictor REVEL gives a score of 0.806, which is above the threshold of >0.6 and provides evidence that correlates with impact to SERPINC1 function, meeting criteria for PP3.  This variant is at extremely low frequency (Total: 0.000003979, European (non-Finnish): 0.000008798) in gnomAD v2.1.1 with good coverage across both genomes and exomes, meeting criteria for PM2_supporting (MAF <2.0 X 10-5). This variant has been reported in at least 16 probands in the literature with AT deficiency meeting PP4 and PS4_VeryStrong (PMID: 26134363; 27766527; 28607330; 28300866; 3179448). Additionally, this variant has been report in at least 4 meioses across 14 families meeting PP1_Moderate. In summary, based on the evidence available at this time, the clinical significance of this variant is pathogenic. ACMG/AMP criteria applied, as specified by the Thrombosis Variant Curation Expert Panel for SERPINC1: PS4_Very Strong, PP1_Moderate, PP3, PP4, PM2_Supporting.		Thrombosis VCEP		2023-09-21	2023-09-29	False	https://erepo.genome.network/evrepo/ui/classification/CA210766/MONDO:0013144/084	90b0cc6b-fac4-4e73-a309-1759d8a91ed3	p.Arg425His	Arg	425	His	MYSNVIGTVTSGKRKVYLLSLLLIGFWDCVTCHGSPVDICTAKPRDIPMNPMCIYRSPEKKATEDEGSEQKIPEATNRRVWELSKANSRFATTFYQHLADSKNDNDNIFLSPLSISTAFAMTKLGACNDTLQQLMEVFKFDTISEKTSDQIHFFFAKLNCRLYRKANKSSKLVSANRLFGDKSLTFNETYQDISELVYGAKLQPLDFKENAEQSRAAINKWVSNKTEGRITDVIPSEAINELTVLVLVNTIYFKGLWKSKFSPENTRKELFYKADGESCSASMMYQEGKFRYRRVAEGTQVLELPFKGDDITMVLILPKPEKSLAKVEKELTPEVLQEWLDELEEMMLVVHMPRFRIEDGFSLKEQLQDMGLVDLFSPEKSKLPGIVAEGRDDLYVSDAFHKAFLEVNEEGSEAAASTAVVIAGRSLNPNRVTFKANRPFLVFIREVPLNTIIFMGRVANPCVK	464	P01008	H	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [161], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.01659584]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [426], 'REGION_gain': [], 'REGION_loss_score': array([-0.01432151]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
584	NM_000488.3(SERPINC1):c.1315C>A (p.Pro439Thr)	627228	CA343772370	NM_000488.3:c.1315C>A, NC_000001.11:g.173903969G>T, CM000663.2:g.173903969G>T, NC_000001.10:g.173873107G>T, CM000663.1:g.173873107G>T, NC_000001.9:g.172139730G>T, NG_012462.1:g.18410C>A, LRG_577:g.18410C>A, ENST00000367698.4:c.1315C>A, ENST00000367698.3:c.1315C>A, ENST00000617423.4:c.700C>A, LRG_577t1:c.1315C>A, XM_005245198.2:c.1171C>A, NM_001365052.1:c.1171C>A, NM_000488.4:c.1315C>A, NM_001365052.2:c.1171C>A, NM_001386302.1:c.1438C>A, NM_001386303.1:c.1396C>A, NM_001386304.1:c.1294C>A, NM_001386305.1:c.1258C>A, NM_001386306.1:c.1099C>A, NM_000488.4(SERPINC1):c.1315C>A (p.Pro439Thr), NM_000488.3(SERPINC1):c.1315C>A (p.Pro439Thr)	SERPINC1	antithrombin III deficiency	MONDO:0013144	Autosomal dominant inheritance	Pathogenic	PS4, PP1_Moderate, PS3_Supporting, PP3, PP4, PM2_Supporting	PM5	The c.1315C>A (p.Pro439Thr) variant is reported at an MAF of (FAF not available), 1/68048 alleles in the non-Finnish European population in gnomAD v3.1.1 and meets criteria for PM2_Supporting (threshold <0.00002). It has a REVEL score of 0.88 and meets criteria for PP3. Several probands can be counted across the literature, who meet phenotype criteria for AT deficiency with a mix of repeat sampling, meeting PP4 and PS4. Four segregations are counted across two families meeting criteria for PP1_Moderate. Expression of mutant AT, 439Thr-AT, in HEK293 cells described in PMID: 18480576 revealed decrease in AT secretion, meeting criteria for PS3_Supporting. In summary, the variant meets criteria to be classified as pathogenic. ACMG/AMP criteria applied, as specified by the Thrombosis Variant Curation Expert Panel for SERPINC1: PS4, PP1_Moderate, PP3, PP4, PM2_Supporting, PS3_Supporting.		Thrombosis VCEP		2023-09-21	2023-09-29	False	https://erepo.genome.network/evrepo/ui/classification/CA343772370/MONDO:0013144/084	1030c18a-bb25-4557-a2d7-449ce81e8f9d	p.Pro439Thr	Pro	439	Thr	MYSNVIGTVTSGKRKVYLLSLLLIGFWDCVTCHGSPVDICTAKPRDIPMNPMCIYRSPEKKATEDEGSEQKIPEATNRRVWELSKANSRFATTFYQHLADSKNDNDNIFLSPLSISTAFAMTKLGACNDTLQQLMEVFKFDTISEKTSDQIHFFFAKLNCRLYRKANKSSKLVSANRLFGDKSLTFNETYQDISELVYGAKLQPLDFKENAEQSRAAINKWVSNKTEGRITDVIPSEAINELTVLVLVNTIYFKGLWKSKFSPENTRKELFYKADGESCSASMMYQEGKFRYRRVAEGTQVLELPFKGDDITMVLILPKPEKSLAKVEKELTPEVLQEWLDELEEMMLVVHMPRFRIEDGFSLKEQLQDMGLVDLFSPEKSKLPGIVAEGRDDLYVSDAFHKAFLEVNEEGSEAAASTAVVIAGRSLNPNRVTFKANRPFLVFIREVPLNTIIFMGRVANPCVK	464	P01008	T	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [43, 46, 48, 49, 51, 55, 57, 59, 64], 'PROPEP_gain_score': array([0.04159856, 0.04808652, 0.05473655, 0.05446851, 0.0476023 ,
       0.04593408, 0.04345608, 0.03827947, 0.0318988 ]), 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [160], 'STRAND_gain_score': array([0.03236562]), 'HELIX_loss': [99], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.04893464]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [446], 'DOMAIN_gain': [113, 122, 123, 220, 224], 'DOMAIN_gain_score': array([0.04629117, 0.02341682, 0.03696704, 0.06627947, 0.10066658]), 'DOMAIN_loss_score': array([-0.10063952]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
585	NM_000488.4(SERPINC1):c.655A>G (p.Asn219Asp)	18042	CA210798	NM_000488.4:c.655A>G, NC_000001.11:g.173910861T>C, CM000663.2:g.173910861T>C, NC_000001.10:g.173879999T>C, CM000663.1:g.173879999T>C, NC_000001.9:g.172146622T>C, NG_012462.1:g.11518A>G, LRG_577:g.11518A>G, ENST00000367698.4:c.655A>G, ENST00000367698.3:c.655A>G, ENST00000487183.1:n.330-24A>G, ENST00000617423.4:c.559+1003A>G, NM_000488.3:c.655A>G, LRG_577t1:c.655A>G, XM_005245198.2:c.511A>G, NM_001365052.1:c.511A>G, NM_001365052.2:c.511A>G, NM_001386302.1:c.655A>G, NM_001386303.1:c.736A>G, NM_001386304.1:c.655A>G, NM_001386305.1:c.655A>G, NM_001386306.1:c.439A>G, NM_000488.4(SERPINC1):c.655A>G (p.Asn219Asp)	SERPINC1	antithrombin III deficiency	MONDO:0013144	Autosomal dominant inheritance	Pathogenic	PS4, PP1_Strong, PP3, PP4, PM2_Supporting	PM5	The NM_000488.4(SERPINC1):c.655A>G (p.Asn219Asp) missense variant is reported at a Popmax FAF of 0.00000488 (non-Finnish European) in gnomAD v3.1.2 and a frequency of 0.000008792 (1/113744) in gnomAD v2.1.1, meeting criteria for PM2_Supporting. It has a REVEL score of 0.898 (PP3 is >0.6). One proband from PMID: 28300866 (family of four affected individuals), 2 probands from PMID: 15630491, 1 proband from PMID: 7989582, and 1 proband from PMID: 7795154 meet phenotype criteria for PS4, PP4 and PP1_Strong. Of note, PMID: 30005274 reports that the Asn219Asp variant associated with Type II RS is hardly detected by the different anti-FXa or anti-FIIa assay methods. In summary, the variant meets criteria to be classified as pathogenic. ACMG/AMP criteria applied, as specified by the Thrombosis Variant Curation Expert Panel for SERPINC1: PS4, PP1_Strong, PP3, PP4, PM2_Supporting.		Thrombosis VCEP		2023-09-21	2023-09-29	False	https://erepo.genome.network/evrepo/ui/classification/CA210798/MONDO:0013144/084	9482d4bb-1f00-4a9d-b00d-13d6a0fdea2c	p.Asn219Asp	Asn	219	Asp	MYSNVIGTVTSGKRKVYLLSLLLIGFWDCVTCHGSPVDICTAKPRDIPMNPMCIYRSPEKKATEDEGSEQKIPEATNRRVWELSKANSRFATTFYQHLADSKNDNDNIFLSPLSISTAFAMTKLGACNDTLQQLMEVFKFDTISEKTSDQIHFFFAKLNCRLYRKANKSSKLVSANRLFGDKSLTFNETYQDISELVYGAKLQPLDFKENAEQSRAAINKWVSNKTEGRITDVIPSEAINELTVLVLVNTIYFKGLWKSKFSPENTRKELFYKADGESCSASMMYQEGKFRYRRVAEGTQVLELPFKGDDITMVLILPKPEKSLAKVEKELTPEVLQEWLDELEEMMLVVHMPRFRIEDGFSLKEQLQDMGLVDLFSPEKSKLPGIVAEGRDDLYVSDAFHKAFLEVNEEGSEAAASTAVVIAGRSLNPNRVTFKANRPFLVFIREVPLNTIIFMGRVANPCVK	464	P01008	D	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [42, 47], 'PROPEP_gain': [], 'PROPEP_loss_score': array([-0.00735903, -0.00903809]), 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [26], 'TRANSIT_gain_score': array([0.00932688]), 'STRAND_loss': [200], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.02462637]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
586	NM_000488.3(SERPINC1):c.236G>A (p.Arg79His)	18014	CA210758	NM_000488.3:c.236G>A, NC_000001.11:g.173914725C>T, CM000663.2:g.173914725C>T, NC_000001.10:g.173883863C>T, CM000663.1:g.173883863C>T, NC_000001.9:g.172150486C>T, NG_012462.1:g.7654G>A, LRG_577:g.7654G>A, ENST00000367698.4:c.236G>A, ENST00000367698.3:c.236G>A, ENST00000494024.1:n.462G>A, ENST00000617423.4:c.236G>A, LRG_577t1:c.236G>A, XM_005245198.2:c.92G>A, NM_001365052.1:c.92G>A, NM_000488.4:c.236G>A, NM_001365052.2:c.92G>A, NM_001386302.1:c.236G>A, NM_001386303.1:c.317G>A, NM_001386304.1:c.236G>A, NM_001386305.1:c.236G>A, NM_001386306.1:c.236G>A, NM_000488.4(SERPINC1):c.236G>A (p.Arg79His), NM_000488.3(SERPINC1):c.236G>A (p.Arg79His)	SERPINC1	antithrombin III deficiency	MONDO:0013144	Autosomal dominant inheritance	Pathogenic	PS4, PP1_Strong, PM1, PP3, PP4	BS1, PM2, PM5, BS2	The c.236G>A (p.Arg79His) variant is reported at an FAF of 0.0002303 and MAF of 0.0003380 (23/68044 alleles) in the non-Finnish European population in gnomAD v3.1.1 meeting BS1 criteria of MAF >0.0002. However, this variant is an established founder variant known as AT Padua I making it ineligible for the BS1 rule application. It has a REVEL score of 0.702, and meets PP3. At least 23 individuals with AT deficiency meeting the SERPINC1 phenotype criteria (other cases are reported but do not meet criteria) are reported in the literature meeting PS4_Very Strong and PP4. Additionally, 9 meioses have been reported across 16 families meeting PP1_Strong. In summary, this variant reaches a classification of pathogenic. ACMG/AMP criteria applied, as specified by the Thrombosis Variant Curation Expert Panel for SERPINC1: PS4_Very Strong, PP1_Strong, PM1, PP3, PP4.	2615648	Thrombosis VCEP		2023-09-21	2023-09-29	False	https://erepo.genome.network/evrepo/ui/classification/CA210758/MONDO:0013144/084	43e159f4-6a9d-4030-8321-d7a5462a898f	p.Arg79His	Arg	79	His	MYSNVIGTVTSGKRKVYLLSLLLIGFWDCVTCHGSPVDICTAKPRDIPMNPMCIYRSPEKKATEDEGSEQKIPEATNRRVWELSKANSRFATTFYQHLADSKNDNDNIFLSPLSISTAFAMTKLGACNDTLQQLMEVFKFDTISEKTSDQIHFFFAKLNCRLYRKANKSSKLVSANRLFGDKSLTFNETYQDISELVYGAKLQPLDFKENAEQSRAAINKWVSNKTEGRITDVIPSEAINELTVLVLVNTIYFKGLWKSKFSPENTRKELFYKADGESCSASMMYQEGKFRYRRVAEGTQVLELPFKGDDITMVLILPKPEKSLAKVEKELTPEVLQEWLDELEEMMLVVHMPRFRIEDGFSLKEQLQDMGLVDLFSPEKSKLPGIVAEGRDDLYVSDAFHKAFLEVNEEGSEAAASTAVVIAGRSLNPNRVTFKANRPFLVFIREVPLNTIIFMGRVANPCVK	464	P01008	H	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [41, 42, 47, 53, 60, 62, 65, 66, 67], 'PROPEP_gain': [], 'PROPEP_loss_score': array([-0.01133651, -0.01238346, -0.01418054, -0.02356064, -0.02533329,
       -0.02324623, -0.02927607, -0.03432512, -0.03943968]), 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [57], 'COMPBIAS_gain': [], 'COMPBIAS_loss_score': array([-0.05690753]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [426], 'REGION_gain': [], 'REGION_loss_score': array([-0.00380808]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
587	NM_000488.3(SERPINC1):c.391C>T (p.Leu131Phe)	18034	CA210787	NM_000488.3:c.391C>T, NC_000001.11:g.173914570G>A, CM000663.2:g.173914570G>A, NC_000001.10:g.173883708G>A, CM000663.1:g.173883708G>A, NC_000001.9:g.172150331G>A, NG_012462.1:g.7809C>T, LRG_577:g.7809C>T, ENST00000367698.4:c.391C>T, ENST00000367698.3:c.391C>T, ENST00000487183.1:n.96C>T, ENST00000494024.1:n.617C>T, ENST00000617423.4:c.391C>T, LRG_577t1:c.391C>T, XM_005245198.2:c.247C>T, NM_001365052.1:c.247C>T, NM_000488.4:c.391C>T, NM_001365052.2:c.247C>T, NM_001386302.1:c.391C>T, NM_001386303.1:c.472C>T, NM_001386304.1:c.391C>T, NM_001386305.1:c.391C>T, NM_001386306.1:c.391C>T, NM_000488.4(SERPINC1):c.391C>T (p.Leu131Phe), NM_000488.3(SERPINC1):c.391C>T (p.Leu131Phe)	SERPINC1	antithrombin III deficiency	MONDO:0013144	Autosomal dominant inheritance	Pathogenic	PS4, PP1_Strong, PP3	PM2	The c.391C>T (NM_000488.3) variant in SERPINC1 is a missense variant predicted to cause substitution of leucine by phenylalanine at amino acid 131 (p.Leu131Phe; legacy nomenclature p.Leu99Phe, Antithrombin Budapest 3 (ATBp3)).  The highest population minor allele frequency in gnomAD v2.1.1 is 0.00003516 (4/113752 alleles) in the non-Finnish European population, which does not meet criteria for PM2_Supporting (MAF =< 2.0 X 10-5 in gnomAD).  The computational predictor REVEL gives a score of 0.853, which is above the threshold of >0.6 and provides evidence that correlates with impact to SERPINC1 function (PP3).  The variant has been reported to segregate with AT deficiency in at least 11 affected family members from 2 families (PP1_Strong; PMIDs: 32686144, 24072242).  This variant has been reported in at least 100 probands with AT deficiency and is a founder variant in the Hugarian population. Further studies of the Hungarian cohort demonstrated that homozygosity was associated with thrombosis at a younger age and led to a high thrombotic risk while the heterozygous carriers also had venous and/or arterial thrombosis, as well as pregnancy complications. This variant was also reported in internal laboratory data (PS4_Very Strong; PMIDs: 26748602, 1555650, 32686144).  In summary, this variant meets criteria to be classified as pathogenic. ACMG/AMP criteria applied, as specified by the Thrombosis Variant Curation Expert Panel for SERPINC1: PP1_strong, PP3, PS4_Very Strong		Thrombosis VCEP		2023-09-21	2023-09-29	False	https://erepo.genome.network/evrepo/ui/classification/CA210787/MONDO:0013144/084	79c443a1-cbfc-43e9-8bed-9b6b5bc302be	p.Leu131Phe	Leu	131	Phe	MYSNVIGTVTSGKRKVYLLSLLLIGFWDCVTCHGSPVDICTAKPRDIPMNPMCIYRSPEKKATEDEGSEQKIPEATNRRVWELSKANSRFATTFYQHLADSKNDNDNIFLSPLSISTAFAMTKLGACNDTLQQLMEVFKFDTISEKTSDQIHFFFAKLNCRLYRKANKSSKLVSANRLFGDKSLTFNETYQDISELVYGAKLQPLDFKENAEQSRAAINKWVSNKTEGRITDVIPSEAINELTVLVLVNTIYFKGLWKSKFSPENTRKELFYKADGESCSASMMYQEGKFRYRRVAEGTQVLELPFKGDDITMVLILPKPEKSLAKVEKELTPEVLQEWLDELEEMMLVVHMPRFRIEDGFSLKEQLQDMGLVDLFSPEKSKLPGIVAEGRDDLYVSDAFHKAFLEVNEEGSEAAASTAVVIAGRSLNPNRVTFKANRPFLVFIREVPLNTIIFMGRVANPCVK	464	P01008	F	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [124], 'HELIX_gain_score': array([0.0504142]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [426], 'REGION_gain': [], 'REGION_loss_score': array([-0.00350821]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
588	NM_000488.4(SERPINC1):c.953C>T (p.Pro318Leu)	627161	CA343774114	NM_000488.4:c.953C>T, NC_000001.11:g.173909752G>A, CM000663.2:g.173909752G>A, NC_000001.10:g.173878890G>A, CM000663.1:g.173878890G>A, NC_000001.9:g.172145513G>A, NG_012462.1:g.12627C>T, LRG_577:g.12627C>T, ENST00000367698.4:c.953C>T, ENST00000367698.3:c.953C>T, ENST00000487183.1:n.604C>T, ENST00000617423.4:c.559+2112C>T, NM_000488.3:c.953C>T, LRG_577t1:c.953C>T, XM_005245198.2:c.809C>T, NM_001365052.1:c.809C>T, NM_001365052.2:c.809C>T, NM_001386302.1:c.1076C>T, NM_001386303.1:c.1034C>T, NM_001386304.1:c.932C>T, NM_001386305.1:c.896C>T, NM_001386306.1:c.737C>T, NM_000488.4(SERPINC1):c.953C>T (p.Pro318Leu)	SERPINC1	antithrombin III deficiency	MONDO:0013144	Autosomal dominant inheritance	Pathogenic	PS4, PP3, PP4, PM2_Supporting		The NM_000488.4(SERPINC1):c.953C>T variant predicts a Pro318Leu missense change. It is absent from gnomAD v2.1.1 and v3.1.2, meeting criteria for PM2_Supporting. It has a REVEL score of 0.956 and meets PP3 (threshold >0.6). At least 2 probands with AT deficiency (and repeat sampling) are reported in the literature (PP4) and 8 probands with AT deficiency and a positive family history are noted from internal VCEP data, meeting criteria for PS4_Very Strong. In summary, this variant meets criteria to be classified as pathogenic. ACMG/AMP criteria applied, as specified by the Thrombosis Variant Curation Expert Panel for SERPINC1: PS4_Very Strong, PP3, PP4, PM2_Supporting.		Thrombosis VCEP		2023-09-21	2023-09-29	False	https://erepo.genome.network/evrepo/ui/classification/CA343774114/MONDO:0013144/084	e12cc661-43a5-4e98-a4b1-600aab2e3f6e	p.Pro318Leu	Pro	318	Leu	MYSNVIGTVTSGKRKVYLLSLLLIGFWDCVTCHGSPVDICTAKPRDIPMNPMCIYRSPEKKATEDEGSEQKIPEATNRRVWELSKANSRFATTFYQHLADSKNDNDNIFLSPLSISTAFAMTKLGACNDTLQQLMEVFKFDTISEKTSDQIHFFFAKLNCRLYRKANKSSKLVSANRLFGDKSLTFNETYQDISELVYGAKLQPLDFKENAEQSRAAINKWVSNKTEGRITDVIPSEAINELTVLVLVNTIYFKGLWKSKFSPENTRKELFYKADGESCSASMMYQEGKFRYRRVAEGTQVLELPFKGDDITMVLILPKPEKSLAKVEKELTPEVLQEWLDELEEMMLVVHMPRFRIEDGFSLKEQLQDMGLVDLFSPEKSKLPGIVAEGRDDLYVSDAFHKAFLEVNEEGSEAAASTAVVIAGRSLNPNRVTFKANRPFLVFIREVPLNTIIFMGRVANPCVK	464	P01008	L	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [295], 'STRAND_gain_score': array([0.06911814]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [217, 323, 324], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.08274013, -0.1034047 , -0.09142387]), 'REGION_loss': [426], 'REGION_gain': [], 'REGION_loss_score': array([-0.00972396]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
589	NM_000488.3(SERPINC1):c.218C>T (p.Pro73Leu)	18011	CA210756	NM_000488.3:c.218C>T, NC_000001.11:g.173914743G>A, CM000663.2:g.173914743G>A, NC_000001.10:g.173883881G>A, CM000663.1:g.173883881G>A, NC_000001.9:g.172150504G>A, NG_012462.1:g.7636C>T, LRG_577:g.7636C>T, ENST00000367698.4:c.218C>T, ENST00000367698.3:c.218C>T, ENST00000494024.1:n.444C>T, ENST00000617423.4:c.218C>T, LRG_577t1:c.218C>T, XM_005245198.2:c.74C>T, NM_001365052.1:c.74C>T, NM_000488.4:c.218C>T, NM_001365052.2:c.74C>T, NM_001386302.1:c.218C>T, NM_001386303.1:c.299C>T, NM_001386304.1:c.218C>T, NM_001386305.1:c.218C>T, NM_001386306.1:c.218C>T, NM_000488.4(SERPINC1):c.218C>T (p.Pro73Leu), NM_000488.3(SERPINC1):c.218C>T (p.Pro73Leu)	SERPINC1	antithrombin III deficiency	MONDO:0013144	Autosomal dominant inheritance	Pathogenic	PS4, PP1_Strong, PM1, PP3, PP4	PS3, PM2	The c.218C>T (p.Pro73Leu) variant is reported at a POPMAX FAF of 0.0007473 in exomes in gnomAD v2.1.1 and at an FAF of 0.0006639 in genomes in gnomAD v3.1.1 in the non-Finnish European population. The frequency does not meet the threshold for PM2_Supporting. At least 30 probands with AT deficiency and several others from internal laboratory data are reported with AT tests on 2 independent samples, meeting criteria for PS4_VeryStrong and PP4. There at least 17 meioses out of 35 families meeting PP1_Strong (PMID:28300866). This missense variant has a REVEL score of 0.658 (threshold >0.6), meeting criteria for PP3, and is within a heparin binding site, meeting PM1. In summary, this variant meets criteria to be classified as pathogenic. ACMG/AMP criteria applied, as specified by the Thrombosis Variant Curation Expert Panel for SERPINC1: PS4_VeryStrong, PP1_Strong, PM1, PP3, PP4.		Thrombosis VCEP		2023-09-21	2023-09-29	False	https://erepo.genome.network/evrepo/ui/classification/CA210756/MONDO:0013144/084	b7a99380-d40e-4611-81d1-d60401803a33	p.Pro73Leu	Pro	73	Leu	MYSNVIGTVTSGKRKVYLLSLLLIGFWDCVTCHGSPVDICTAKPRDIPMNPMCIYRSPEKKATEDEGSEQKIPEATNRRVWELSKANSRFATTFYQHLADSKNDNDNIFLSPLSISTAFAMTKLGACNDTLQQLMEVFKFDTISEKTSDQIHFFFAKLNCRLYRKANKSSKLVSANRLFGDKSLTFNETYQDISELVYGAKLQPLDFKENAEQSRAAINKWVSNKTEGRITDVIPSEAINELTVLVLVNTIYFKGLWKSKFSPENTRKELFYKADGESCSASMMYQEGKFRYRRVAEGTQVLELPFKGDDITMVLILPKPEKSLAKVEKELTPEVLQEWLDELEEMMLVVHMPRFRIEDGFSLKEQLQDMGLVDLFSPEKSKLPGIVAEGRDDLYVSDAFHKAFLEVNEEGSEAAASTAVVIAGRSLNPNRVTFKANRPFLVFIREVPLNTIIFMGRVANPCVK	464	P01008	L	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [32], 'TRANSMEM_gain': [], 'TRANSMEM_loss_score': array([-0.02002496]), 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [35, 38, 39, 40, 41, 42, 44, 45, 47, 53, 58, 60, 61, 62, 63, 65, 66, 67], 'PROPEP_gain': [], 'PROPEP_loss_score': array([-0.07416487, -0.08644271, -0.08158803, -0.08084285, -0.0999347 ,
       -0.11476475, -0.09666687, -0.12488097, -0.12225336, -0.12517089,
       -0.13163149, -0.13408846, -0.1577726 , -0.1535157 , -0.15444034,
       -0.15987539, -0.18990982, -0.20454818]), 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [161], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.04517645]), 'HELIX_loss': [79], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.18899119]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70], 'COMPBIAS_gain': [], 'COMPBIAS_loss_score': array([-0.50904143, -0.68547624, -0.74450576, -0.74118304, -0.76143527,
       -0.79354888, -0.80450475, -0.77538127, -0.78406709, -0.79909623,
       -0.80422592, -0.75402421, -0.69036722, -0.62975425]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
590	NM_000488.3(SERPINC1):c.914C>A (p.Pro305His)	597303	CA1251311	NM_000488.3:c.914C>A, NC_000001.11:g.173909791G>T, CM000663.2:g.173909791G>T, NC_000001.10:g.173878929G>T, CM000663.1:g.173878929G>T, NC_000001.9:g.172145552G>T, NG_012462.1:g.12588C>A, LRG_577:g.12588C>A, ENST00000367698.4:c.914C>A, ENST00000367698.3:c.914C>A, ENST00000487183.1:n.565C>A, ENST00000617423.4:c.559+2073C>A, LRG_577t1:c.914C>A, XM_005245198.2:c.770C>A, NM_001365052.1:c.770C>A, NM_000488.4:c.914C>A, NM_001365052.2:c.770C>A, NM_001386302.1:c.1037C>A, NM_001386303.1:c.995C>A, NM_001386304.1:c.893C>A, NM_001386305.1:c.857C>A, NM_001386306.1:c.698C>A, NM_000488.4(SERPINC1):c.914C>A (p.Pro305His), NM_000488.3(SERPINC1):c.914C>A (p.Pro305His)	SERPINC1	antithrombin III deficiency	MONDO:0013144	Autosomal dominant inheritance	Benign	BA1, BS2		The c.914C>A (NM_000488.3) variant in SERPINC1 is a missense variant predicted to cause substitution of proline by histidine at amino acid 305 (p.Pro305His).  The highest population minor allele frequency in gnomAD v2.1.1 is 0.008133 (249/30616 alleles) in the South Asian population, which is higher than the ClinGen SERPINC1 threshold ([>0.002]) for BA1, and therefore meets this criterion (BA1).  This variant has been observed in nine individuals, of Indian heritage, with normal normal antithrombin levels, five of which showed normal levels with repeat testing (BS2; PMID: 27161325).  In summary, this variant meets criteria to be classified as benign.  ACMG/AMP criteria applied, as specified by the Thrombosis Variant Curation Expert Panel for SERPINC1: BA1, BS2.		Thrombosis VCEP		2023-07-25	2023-09-29	False	https://erepo.genome.network/evrepo/ui/classification/CA1251311/MONDO:0013144/084	cbdbee38-f5df-4dea-a641-e7961a17dd29	p.Pro305His	Pro	305	His	MYSNVIGTVTSGKRKVYLLSLLLIGFWDCVTCHGSPVDICTAKPRDIPMNPMCIYRSPEKKATEDEGSEQKIPEATNRRVWELSKANSRFATTFYQHLADSKNDNDNIFLSPLSISTAFAMTKLGACNDTLQQLMEVFKFDTISEKTSDQIHFFFAKLNCRLYRKANKSSKLVSANRLFGDKSLTFNETYQDISELVYGAKLQPLDFKENAEQSRAAINKWVSNKTEGRITDVIPSEAINELTVLVLVNTIYFKGLWKSKFSPENTRKELFYKADGESCSASMMYQEGKFRYRRVAEGTQVLELPFKGDDITMVLILPKPEKSLAKVEKELTPEVLQEWLDELEEMMLVVHMPRFRIEDGFSLKEQLQDMGLVDLFSPEKSKLPGIVAEGRDDLYVSDAFHKAFLEVNEEGSEAAASTAVVIAGRSLNPNRVTFKANRPFLVFIREVPLNTIIFMGRVANPCVK	464	P01008	H	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [51], 'PROPEP_gain_score': array([0.00859129]), 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [422], 'STRAND_gain': [295], 'STRAND_gain_score': array([0.06082445]), 'STRAND_loss_score': array([-0.01488858]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [323, 324], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.05121136, -0.07586211]), 'REGION_loss': [426], 'REGION_gain': [], 'REGION_loss_score': array([-0.0032267]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
591	NM_000488.4(SERPINC1):c.719A>G (p.Asn240Ser)	1094336	CA1251357	NM_000488.4:c.719A>G, NC_000001.11:g.173910797T>C, CM000663.2:g.173910797T>C, NC_000001.10:g.173879935T>C, CM000663.1:g.173879935T>C, NC_000001.9:g.172146558T>C, NG_012462.1:g.11582A>G, LRG_577:g.11582A>G, ENST00000367698.4:c.719A>G, ENST00000367698.3:c.719A>G, ENST00000487183.1:n.370A>G, ENST00000617423.4:c.559+1067A>G, NM_000488.3:c.719A>G, LRG_577t1:c.719A>G, XM_005245198.2:c.575A>G, NM_001365052.1:c.575A>G, NM_001365052.2:c.575A>G, NM_001386302.1:c.719A>G, NM_001386303.1:c.800A>G, NM_001386304.1:c.719A>G, NM_001386305.1:c.719A>G, NM_001386306.1:c.503A>G, NM_000488.4(SERPINC1):c.719A>G (p.Asn240Ser)	SERPINC1	antithrombin III deficiency	MONDO:0013144	Autosomal dominant inheritance	Benign	BS3_Supporting, BS1, PP3	PS4, PM2	The NM_000488.4(SERPINC1):c.719A>G variant predicts a missense change at position 240, from Asparagine to Serine. This variant is present gnomAD (v2.1.1 and v3.1.1) with a MAF of 0.0208% and no homozygotes. Functional testing of HEK293 cells transfected with c.719A>G (p.Asn240Ser) revealed AT antigen levels of 88.8± 4.5%, AT specific activity of 105.4± 2.0%, and Anti-FXa total activity of 95.7± 2.7%. This missense variant has a REVEL score of 0.732, meeting criteria for PP3. In summary, the variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the Thrombosis Variant Curation Expert Panel for SERPINC1: BS1, BS3, PM2_Supporting. While the variant meets conflicting pathogenic (PP3) and benign (BS1, BS3) codes, the overall score based on the Bayesian framework is -7 (PMID: 32720330), resulting in a benign classification.		Thrombosis VCEP		2023-07-25	2023-09-29	False	https://erepo.genome.network/evrepo/ui/classification/CA1251357/MONDO:0013144/084	6922ea7e-e071-45e0-931c-fab73ba16f83	p.Asn240Ser	Asn	240	Ser	MYSNVIGTVTSGKRKVYLLSLLLIGFWDCVTCHGSPVDICTAKPRDIPMNPMCIYRSPEKKATEDEGSEQKIPEATNRRVWELSKANSRFATTFYQHLADSKNDNDNIFLSPLSISTAFAMTKLGACNDTLQQLMEVFKFDTISEKTSDQIHFFFAKLNCRLYRKANKSSKLVSANRLFGDKSLTFNETYQDISELVYGAKLQPLDFKENAEQSRAAINKWVSNKTEGRITDVIPSEAINELTVLVLVNTIYFKGLWKSKFSPENTRKELFYKADGESCSASMMYQEGKFRYRRVAEGTQVLELPFKGDDITMVLILPKPEKSLAKVEKELTPEVLQEWLDELEEMMLVVHMPRFRIEDGFSLKEQLQDMGLVDLFSPEKSKLPGIVAEGRDDLYVSDAFHKAFLEVNEEGSEAAASTAVVIAGRSLNPNRVTFKANRPFLVFIREVPLNTIIFMGRVANPCVK	464	P01008	S	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [42], 'PROPEP_gain': [], 'PROPEP_loss_score': array([-0.00440192]), 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [161, 180, 182], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.01346517, -0.01864803, -0.02157706]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [426], 'REGION_gain': [], 'REGION_loss_score': array([-0.00449824]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
592	NM_000162.5(GCK):c.802G>A (p.Glu268Lys)	447420	CA367400529	NM_000162.5:c.802G>A, NC_000007.14:g.44147711C>T, CM000669.2:g.44147711C>T, NC_000007.13:g.44187310C>T, CM000669.1:g.44187310C>T, NC_000007.12:g.44153835C>T, NG_008847.1:g.46713G>A, NG_008847.2:g.55460G>A, ENST00000395796.8:c.*800G>A, ENST00000616242.5:c.802G>A, ENST00000345378.7:c.805G>A, ENST00000403799.8:c.802G>A, ENST00000671824.1:c.802G>A, ENST00000673284.1:c.802G>A, ENST00000345378.6:c.805G>A, ENST00000395796.7:c.799G>A, ENST00000403799.7:c.802G>A, ENST00000437084.1:c.751G>A, ENST00000616242.4:c.799G>A, NM_000162.3:c.802G>A, NM_033507.1:c.805G>A, NM_033508.1:c.799G>A, XR_927223.1:n.45C>T, NM_000162.4:c.802G>A, NM_001354800.1:c.802G>A, NM_033507.2:c.805G>A, NM_033508.2:c.799G>A, XR_927223.2:n.45C>T, NM_033507.3:c.805G>A, NM_033508.3:c.799G>A, NM_000162.5(GCK):c.802G>A (p.Glu268Lys)	GCK	monogenic diabetes	MONDO:0015967	Semidominant inheritance	Pathogenic	PS4, PP1_Strong, PP4_Moderate, PP2, PP3, PM2_Supporting	PM1	The c.802G>A variant in the glucokinase gene, GCK, causes an amino acid change of glutamic acid to lysine at codon 268 (p.(Glu268Lys)) of NM_000162.5.  This variant segregated with diabetes/hyperglycemia, with four informative meioses in two families (PP1_Strong; internal lab contributors).  This variant is absent from gnomAD v2.1.1 (PM2_Supporting).  This variant was identified in eight unrelated individuals with hyperglycemia (PS4; internal lab contributors).  This variant was identified in an individual with a clinical history highly specific for GCK-hyperglycemia (FBG 5.5-8 mmol/L and HbA1c 5.6 - 7.6% and negative antibodies) (PP4_Moderate; internal lab contributors).  GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2).   This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.727, which is greater than the MDEP VCEP threshold of 0.70 (PP3).  In summary, c.802G>A meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.3.0, approved 8/11/2023): PP1_Strong, PS4, PP4_Moderate, PP2, PP3, PM2_Supporting.		Monogenic Diabetes VCEP		2023-10-05	2023-10-05	False	https://erepo.genome.network/evrepo/ui/classification/CA367400529/MONDO:0015967/086	93ccf57a-26e5-4877-90ce-0e0474dc8231	p.Glu268Lys	Glu	268	Lys	MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQ	465	P35557	K	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [203], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.00673056]), 'HELIX_loss': [], 'HELIX_gain': [264], 'HELIX_gain_score': array([0.25675178]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [221], 'DOMAIN_gain_score': array([0.03186595]), 'REGION_loss': [], 'REGION_gain': [21], 'REGION_gain_score': array([0.00083137]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
593	NM_000059.4(BRCA2):c.7879A>T (p.Ile2627Phe)	52430	CA025321	NM_000059.4:c.7879A>T, NC_000013.11:g.32362596A>T, CM000675.2:g.32362596A>T, NC_000013.10:g.32936733A>T, CM000675.1:g.32936733A>T, NC_000013.9:g.31834733A>T, NG_012772.3:g.52117A>T, LRG_293:g.52117A>T, ENST00000470094.2:c.7879A>T, ENST00000528762.2:c.7879A>T, ENST00000530893.7:c.7510A>T, ENST00000665585.2:c.7879A>T, ENST00000666593.2:c.7879A>T, ENST00000700202.2:c.7879A>T, ENST00000700202.1:c.346A>T, ENST00000380152.8:c.7879A>T, ENST00000544455.6:c.7879A>T, ENST00000614259.2:c.7887A>T, ENST00000665585.1:c.444A>T, ENST00000680887.1:c.7879A>T, ENST00000380152.7:c.7879A>T, ENST00000544455.5:c.7879A>T, ENST00000614259.1:n.7887A>T, NM_000059.3:c.7879A>T, LRG_293t1:c.7879A>T, XM_011535203.1:c.7879A>T, XM_011535204.1:c.7783A>T, XM_011535205.1:c.7879A>T, NM_000059.4(BRCA2):c.7879A>T (p.Ile2627Phe)	BRCA2	breast-ovarian cancer, familial, susceptibility to, 2	MONDO:0012933	Autosomal dominant inheritance	Pathogenic	PS3, PP4_Strong, PM2_Supporting	BP1, BP4, PP3	The c.7879A>T variant in BRCA2 is a missense variant predicted to cause substitution of Isoleucine by Phenylalanine at amino acid 2627 (p.Ile2627Phe). This variant is absent from gnomAD v2.1 (exomes only, non-cancer subset, read depth ≥25) and gnomAD v3.1 (non-cancer subset, read depth ≥25) (PM2_Supporting met). This BRCA2 missense variant is within a key functional domain and the computational predictor BayesDel (noAF) gives a score of 0.25 indicating that impact on BRCA2 function via protein change is unclear (score range 0.18-0.30). SpliceAI predictor score of 0.00 suggests that the variant has no impact on splicing (score threshold <0.10) (no bioinformatic code is applied). Reported by three calibrated studies to exhibit protein function similar to pathogenic control variants (PMIDs: 29988080, 33609447, 32444794) (PS3 met). Multifactorial likelihood ratio analysis using clinically calibrated data produced a combined LR for this variant of 406 (based on Cosegregation LR=1.88; Co-occurrence LR=1.28; Family History LR=168.6), above the threshold for Very strong evidence towards pathogenicity (LR >350) (PP4_Very strong met; PMID: 17924331, 31853058).In summary, this variant meets the criteria to be classified as a Pathogenic variant for BRCA2-related cancer predisposition based on the ACMG/AMP criteria applied as specified by the ENIGMA BRCA1/2 VCEP (PM2_Supporting, PP4_Very strong, PS3).		ENIGMA BRCA1 and BRCA2 VCEP		2024-04-23	2024-04-23	False	https://erepo.genome.network/evrepo/ui/classification/CA025321/MONDO:0012933/097	fba08ba8-3664-4d8a-ba08-13e7495a93a0	p.Ile2627Phe	Ile	2627	Phe	MPIGSKERPTFFEIFKTRCNKADLGPISLNWFEELSSEAPPYNSEPAEESEHKNNNYEPNLFKTPQRKPSYNQLASTPIIFKEQGLTLPLYQSPVKELDKFKLDLGRNVPNSRHKSLRTVKTKMDQADDVSCPLLNSCLSESPVVLQCTHVTPQRDKSVVCGSLFHTPKFVKGRQTPKHISESLGAEVDPDMSWSSSLATPPTLSSTVLIVRNEEASETVFPHDTTANVKSYFSNHDESLKKNDRFIASVTDSENTNQREAASHGFGKTSGNSFKVNSCKDHIGKSMPNVLEDEVYETVVDTSEEDSFSLCFSKCRTKNLQKVRTSKTRKKIFHEANADECEKSKNQVKEKYSFVSEVEPNDTDPLDSNVANQKPFESGSDKISKEVVPSLACEWSQLTLSGLNGAQMEKIPLLHISSCDQNISEKDLLDTENKRKKDFLTSENSLPRISSLPKSEKPLNEETVVNKRDEEQHLESHTDCILAVKQAISGTSPVASSFQGIKKSIFRIRESPKETFNASFSGHMTDPNFKKETEASESGLEIHTVCSQKEDSLCPNLIDNGSWPATTTQNSVALKNAGLISTLKKKTNKFIYAIHDETSYKGKKIPKDQKSELINCSAQFEANAFEAPLTFANADSGLLHSSVKRSCSQNDSEEPTLSLTSSFGTILRKCSRNETCSNNTVISQDLDYKEAKCNKEKLQLFITPEADSLSCLQEGQCENDPKSKKVSDIKEEVLAAACHPVQHSKVEYSDTDFQSQKSLLYDHENASTLILTPTSKDVLSNLVMISRGKESYKMSDKLKGNNYESDVELTKNIPMEKNQDVCALNENYKNVELLPPEKYMRVASPSRKVQFNQNTNLRVIQKNQEETTSISKITVNPDSEELFSDNENNFVFQVANERNNLALGNTKELHETDLTCVNEPIFKNSTMVLYGDTGDKQATQVSIKKDLVYVLAEENKNSVKQHIKMTLGQDLKSDISLNIDKIPEKNNDYMNKWAGLLGPISNHSFGGSFRTASNKEIKLSEHNIKKSKMFFKDIEEQYPTSLACVEIVNTLALDNQKKLSKPQSINTVSAHLQSSVVVSDCKNSHITPQMLFSKQDFNSNHNLTPSQKAEITELSTILEESGSQFEFTQFRKPSYILQKSTFEVPENQMTILKTTSEECRDADLHVIMNAPSIGQVDSSKQFEGTVEIKRKFAGLLKNDCNKSASGYLTDENEVGFRGFYSAHGTKLNVSTEALQKAVKLFSDIENISEETSAEVHPISLSSSKCHDSVVSMFKIENHNDKTVSEKNNKCQLILQNNIEMTTGTFVEEITENYKRNTENEDNKYTAASRNSHNLEFDGSDSSKNDTVCIHKDETDLLFTDQHNICLKLSGQFMKEGNTQIKEDLSDLTFLEVAKAQEACHGNTSNKEQLTATKTEQNIKDFETSDTFFQTASGKNISVAKESFNKIVNFFDQKPEELHNFSLNSELHSDIRKNKMDILSYEETDIVKHKILKESVPVGTGNQLVTFQGQPERDEKIKEPTLLGFHTASGKKVKIAKESLDKVKNLFDEKEQGTSEITSFSHQWAKTLKYREACKDLELACETIEITAAPKCKEMQNSLNNDKNLVSIETVVPPKLLSDNLCRQTENLKTSKSIFLKVKVHENVEKETAKSPATCYTNQSPYSVIENSALAFYTSCSRKTSVSQTSLLEAKKWLREGIFDGQPERINTADYVGNYLYENNSNSTIAENDKNHLSEKQDTYLSNSSMSNSYSYHSDEVYNDSGYLSKNKLDSGIEPVLKNVEDQKNTSFSKVISNVKDANAYPQTVNEDICVEELVTSSSPCKNKNAAIKLSISNSNNFEVGPPAFRIASGKIVCVSHETIKKVKDIFTDSFSKVIKENNENKSKICQTKIMAGCYEALDDSEDILHNSLDNDECSTHSHKVFADIQSEEILQHNQNMSGLEKVSKISPCDVSLETSDICKCSIGKLHKSVSSANTCGIFSTASGKSVQVSDASLQNARQVFSEIEDSTKQVFSKVLFKSNEHSDQLTREENTAIRTPEHLISQKGFSYNVVNSSAFSGFSTASGKQVSILESSLHKVKGVLEEFDLIRTEHSLHYSPTSRQNVSKILPRVDKRNPEHCVNSEMEKTCSKEFKLSNNLNVEGGSSENNHSIKVSPYLSQFQQDKQQLVLGTKVSLVENIHVLGKEQASPKNVKMEIGKTETFSDVPVKTNIEVCSTYSKDSENYFETEAVEIAKAFMEDDELTDSKLPSHATHSLFTCPENEEMVLSNSRIGKRRGEPLILVGEPSIKRNLLNEFDRIIENQEKSLKASKSTPDGTIKDRRLFMHHVSLEPITCVPFRTTKERQEIQNPNFTAPGQEFLSKSHLYEHLTLEKSSSNLAVSGHPFYQVSATRNEKMRHLITTGRPTKVFVPPFKTKSHFHRVEQCVRNINLEENRQKQNIDGHGSDDSKNKINDNEIHQFNKNNSNQAVAVTFTKCEEEPLDLITSLQNARDIQDMRIKKKQRQRVFPQPGSLYLAKTSTLPRISLKAAVGGQVPSACSHKQLYTYGVSKHCIKINSKNAESFQFHTEDYFGKESLWTGKGIQLADGGWLIPSNDGKAGKEEFYRALCDTPGVDPKLISRIWVYNHYRWIIWKLAAMECAFPKEFANRCLSPERVLLQLKYRYDTEIDRSRRSAIKKIMERDDTAAKTLVLCVSDIISLSANISETSSNKTSSADTQKVAIIELTDGWYAVKAQLDPPLLAVLKNGRLTVGQKIILHGAELVGSPDACTPLEAPESLMLKISANSTRPARWYTKLGFFPDPRPFPLPLSSLFSDGGNVGCVDVIIQRAYPIQWMEKTSSGLYIFRNEREEEKEAAKYVEAQQKRLEALFTKIQEEFEEHEENTTKPYLPSRALTRQQVRALQDGAELYEAVKNAADPAYLEGYFSEEQLRALNNHRQMLNDKKQAQIQLEIRKAMESAEQKEQGLSRDVTTVWKLRIVSYSKKEKDSVILSIWRPSSDLYSLLTEGKRYRIYHLATSKSKSKSERANIQLAATKKTQYQQLPVSDEILFQIYQPREPLHFSKFLDPDFQPSCSEVDLIGFVVSVVKKTGLAPFVYLSDECYNLLAIKFWIDLNEDIIKPHMLIAASNLQWRPESKSGLLTLFAGDFSVFSASPKEGHFQETFNKMKNTVENIDILCNEAENKLMHILHANDPKWSTPTKDCTSGPYTAQIIPGTGNKLLMSSPNCEIYYQSPLSLCMAKRKSVSTPVSAQMTSKSCKGEKEIDDQKNCKKRRALDFLSRLPLPPPVSPICTFVSPAAQKAFQPPRSCGTKYETPIKKKELNSPQMTPFKKFNEISLLESNSIADEELALINTQALLSGSTGEKQFISVSESTRTAPTSSEDYLRLKRRCTTSLIKEQESSQASTEECEKNKQDTITTKKYI	3418	P51587	F	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
594	NM_000059.4(BRCA2):c.831T>G (p.Asn277Lys)	38152	CA025568	NM_000059.4:c.831T>G, NC_000013.11:g.32332309T>G, CM000675.2:g.32332309T>G, NC_000013.10:g.32906446T>G, CM000675.1:g.32906446T>G, NC_000013.9:g.31804446T>G, NG_012772.3:g.21830T>G, LRG_293:g.21830T>G, ENST00000380152.8:c.831T>G, ENST00000544455.6:c.831T>G, ENST00000614259.2:c.831T>G, ENST00000680887.1:c.831T>G, ENST00000380152.7:c.831T>G, ENST00000530893.6:n.1029T>G, ENST00000544455.5:c.831T>G, ENST00000614259.1:n.831T>G, NM_000059.3:c.831T>G, LRG_293t1:c.831T>G, XM_011535203.1:c.831T>G, XM_011535204.1:c.831T>G, XM_011535205.1:c.831T>G, NM_000059.4(BRCA2):c.831T>G (p.Asn277Lys)	BRCA2	breast-ovarian cancer, familial, susceptibility to, 2	MONDO:0012933	Autosomal dominant inheritance	Benign	BS1_Supporting, BP1_Strong, BP5, BS3		The c.831T>G variant in BRCA2 is a missense variant predicted to cause substitution of Asparagine by Lysine at amino acid 277 (p.Asn277Lys). The highest non-cancer, non-founder population filter allele frequency in gnomAD v2.1 (exomes only, non-cancer subset, read depth ≥20) or gnomAD v3.1 (non-cancer subset, read depth ≥20) is 0.00008331 in the European (non-Finnish) population, which is within the ENIGMA BRCA1/2 VCEP threshold (>0.00002 to ≤ 0.0001) for BS1_Supporting (BS1_Supporting met). This missense variant is located outside of a key functional domain and was not predicted to alter mRNA splicing using the SpliceAI predictor (score 0, score threshold <0.1) (BP1_Strong met). Reported by one calibrated study to exhibit protein function similar to benign control variants (PMID: 33293522) (BS3 met). Multifactorial likelihood ratio analysis using clinically calibrated data produced a combined LR for this variant of 0.06 (based on Cosegregation LR=0.3; Pathology LR=1.27; Co-occurrence LR=1.88; Family History LR=0.0888), within the thresholds for Moderate benign evidence (LR ≥0.05 & <0.23) (BP5_Moderate met; PMID: 31131967). In summary, this variant meets the criteria to be classified as a Benign variant for BRCA2-related cancer predisposition based on the ACMG/AMP criteria applied as specified by the ENIGMA BRCA1/2 VCEP (BS1_Supporting, BP1_Strong, BS3, BP5_Moderate).	33293522	ENIGMA BRCA1 and BRCA2 VCEP		2023-10-08	2023-10-08	False	https://erepo.genome.network/evrepo/ui/classification/CA025568/MONDO:0012933/097	faec2530-d561-4e92-b253-ec7d7166e8a4	p.Asn277Lys	Asn	277	Lys	MPIGSKERPTFFEIFKTRCNKADLGPISLNWFEELSSEAPPYNSEPAEESEHKNNNYEPNLFKTPQRKPSYNQLASTPIIFKEQGLTLPLYQSPVKELDKFKLDLGRNVPNSRHKSLRTVKTKMDQADDVSCPLLNSCLSESPVVLQCTHVTPQRDKSVVCGSLFHTPKFVKGRQTPKHISESLGAEVDPDMSWSSSLATPPTLSSTVLIVRNEEASETVFPHDTTANVKSYFSNHDESLKKNDRFIASVTDSENTNQREAASHGFGKTSGNSFKVNSCKDHIGKSMPNVLEDEVYETVVDTSEEDSFSLCFSKCRTKNLQKVRTSKTRKKIFHEANADECEKSKNQVKEKYSFVSEVEPNDTDPLDSNVANQKPFESGSDKISKEVVPSLACEWSQLTLSGLNGAQMEKIPLLHISSCDQNISEKDLLDTENKRKKDFLTSENSLPRISSLPKSEKPLNEETVVNKRDEEQHLESHTDCILAVKQAISGTSPVASSFQGIKKSIFRIRESPKETFNASFSGHMTDPNFKKETEASESGLEIHTVCSQKEDSLCPNLIDNGSWPATTTQNSVALKNAGLISTLKKKTNKFIYAIHDETSYKGKKIPKDQKSELINCSAQFEANAFEAPLTFANADSGLLHSSVKRSCSQNDSEEPTLSLTSSFGTILRKCSRNETCSNNTVISQDLDYKEAKCNKEKLQLFITPEADSLSCLQEGQCENDPKSKKVSDIKEEVLAAACHPVQHSKVEYSDTDFQSQKSLLYDHENASTLILTPTSKDVLSNLVMISRGKESYKMSDKLKGNNYESDVELTKNIPMEKNQDVCALNENYKNVELLPPEKYMRVASPSRKVQFNQNTNLRVIQKNQEETTSISKITVNPDSEELFSDNENNFVFQVANERNNLALGNTKELHETDLTCVNEPIFKNSTMVLYGDTGDKQATQVSIKKDLVYVLAEENKNSVKQHIKMTLGQDLKSDISLNIDKIPEKNNDYMNKWAGLLGPISNHSFGGSFRTASNKEIKLSEHNIKKSKMFFKDIEEQYPTSLACVEIVNTLALDNQKKLSKPQSINTVSAHLQSSVVVSDCKNSHITPQMLFSKQDFNSNHNLTPSQKAEITELSTILEESGSQFEFTQFRKPSYILQKSTFEVPENQMTILKTTSEECRDADLHVIMNAPSIGQVDSSKQFEGTVEIKRKFAGLLKNDCNKSASGYLTDENEVGFRGFYSAHGTKLNVSTEALQKAVKLFSDIENISEETSAEVHPISLSSSKCHDSVVSMFKIENHNDKTVSEKNNKCQLILQNNIEMTTGTFVEEITENYKRNTENEDNKYTAASRNSHNLEFDGSDSSKNDTVCIHKDETDLLFTDQHNICLKLSGQFMKEGNTQIKEDLSDLTFLEVAKAQEACHGNTSNKEQLTATKTEQNIKDFETSDTFFQTASGKNISVAKESFNKIVNFFDQKPEELHNFSLNSELHSDIRKNKMDILSYEETDIVKHKILKESVPVGTGNQLVTFQGQPERDEKIKEPTLLGFHTASGKKVKIAKESLDKVKNLFDEKEQGTSEITSFSHQWAKTLKYREACKDLELACETIEITAAPKCKEMQNSLNNDKNLVSIETVVPPKLLSDNLCRQTENLKTSKSIFLKVKVHENVEKETAKSPATCYTNQSPYSVIENSALAFYTSCSRKTSVSQTSLLEAKKWLREGIFDGQPERINTADYVGNYLYENNSNSTIAENDKNHLSEKQDTYLSNSSMSNSYSYHSDEVYNDSGYLSKNKLDSGIEPVLKNVEDQKNTSFSKVISNVKDANAYPQTVNEDICVEELVTSSSPCKNKNAAIKLSISNSNNFEVGPPAFRIASGKIVCVSHETIKKVKDIFTDSFSKVIKENNENKSKICQTKIMAGCYEALDDSEDILHNSLDNDECSTHSHKVFADIQSEEILQHNQNMSGLEKVSKISPCDVSLETSDICKCSIGKLHKSVSSANTCGIFSTASGKSVQVSDASLQNARQVFSEIEDSTKQVFSKVLFKSNEHSDQLTREENTAIRTPEHLISQKGFSYNVVNSSAFSGFSTASGKQVSILESSLHKVKGVLEEFDLIRTEHSLHYSPTSRQNVSKILPRVDKRNPEHCVNSEMEKTCSKEFKLSNNLNVEGGSSENNHSIKVSPYLSQFQQDKQQLVLGTKVSLVENIHVLGKEQASPKNVKMEIGKTETFSDVPVKTNIEVCSTYSKDSENYFETEAVEIAKAFMEDDELTDSKLPSHATHSLFTCPENEEMVLSNSRIGKRRGEPLILVGEPSIKRNLLNEFDRIIENQEKSLKASKSTPDGTIKDRRLFMHHVSLEPITCVPFRTTKERQEIQNPNFTAPGQEFLSKSHLYEHLTLEKSSSNLAVSGHPFYQVSATRNEKMRHLITTGRPTKVFVPPFKTKSHFHRVEQCVRNINLEENRQKQNIDGHGSDDSKNKINDNEIHQFNKNNSNQAVAVTFTKCEEEPLDLITSLQNARDIQDMRIKKKQRQRVFPQPGSLYLAKTSTLPRISLKAAVGGQVPSACSHKQLYTYGVSKHCIKINSKNAESFQFHTEDYFGKESLWTGKGIQLADGGWLIPSNDGKAGKEEFYRALCDTPGVDPKLISRIWVYNHYRWIIWKLAAMECAFPKEFANRCLSPERVLLQLKYRYDTEIDRSRRSAIKKIMERDDTAAKTLVLCVSDIISLSANISETSSNKTSSADTQKVAIIELTDGWYAVKAQLDPPLLAVLKNGRLTVGQKIILHGAELVGSPDACTPLEAPESLMLKISANSTRPARWYTKLGFFPDPRPFPLPLSSLFSDGGNVGCVDVIIQRAYPIQWMEKTSSGLYIFRNEREEEKEAAKYVEAQQKRLEALFTKIQEEFEEHEENTTKPYLPSRALTRQQVRALQDGAELYEAVKNAADPAYLEGYFSEEQLRALNNHRQMLNDKKQAQIQLEIRKAMESAEQKEQGLSRDVTTVWKLRIVSYSKKEKDSVILSIWRPSSDLYSLLTEGKRYRIYHLATSKSKSKSERANIQLAATKKTQYQQLPVSDEILFQIYQPREPLHFSKFLDPDFQPSCSEVDLIGFVVSVVKKTGLAPFVYLSDECYNLLAIKFWIDLNEDIIKPHMLIAASNLQWRPESKSGLLTLFAGDFSVFSASPKEGHFQETFNKMKNTVENIDILCNEAENKLMHILHANDPKWSTPTKDCTSGPYTAQIIPGTGNKLLMSSPNCEIYYQSPLSLCMAKRKSVSTPVSAQMTSKSCKGEKEIDDQKNCKKRRALDFLSRLPLPPPVSPICTFVSPAAQKAFQPPRSCGTKYETPIKKKELNSPQMTPFKKFNEISLLESNSIADEELALINTQALLSGSTGEKQFISVSESTRTAPTSSEDYLRLKRRCTTSLIKEQESSQASTEECEKNKQDTITTKKYI	3418	P51587	K	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
595	NM_007294.4(BRCA1):c.1233T>G (p.Asp411Glu)	41804	CA000811	NM_007294.4:c.1233T>G, NC_000017.11:g.43094298A>C, CM000679.2:g.43094298A>C, NC_000017.10:g.41246315A>C, CM000679.1:g.41246315A>C, NC_000017.9:g.38499841A>C, NG_005905.2:g.123686T>G, LRG_292:g.123686T>G, ENST00000357654.9:c.1233T>G, ENST00000471181.7:c.1233T>G, ENST00000652672.1:c.1092T>G, ENST00000352993.7:c.670+1548T>G, ENST00000354071.7:c.1233T>G, ENST00000357654.7:c.1233T>G, ENST00000412061.3:c.584T>G, ENST00000461221.5:c.*1016T>G, ENST00000468300.5:c.787+446T>G, ENST00000470026.5:c.1233T>G, ENST00000471181.6:c.1233T>G, ENST00000473961.5:c.830T>G, ENST00000477152.5:c.1155T>G, ENST00000478531.5:c.784+446T>G, ENST00000484087.5:c.409+446T>G, ENST00000487825.5:c.412+446T>G, ENST00000491747.6:c.787+446T>G, ENST00000492859.5:c.*1169T>G, ENST00000493795.5:c.1092T>G, ENST00000493919.5:c.646+446T>G, ENST00000494123.5:c.1233T>G, ENST00000497488.1:c.345T>G, ENST00000586385.5:c.5-30347T>G, ENST00000591534.5:c.-43-19777T>G, ENST00000591849.5:c.-99+30973T>G, ENST00000634433.1:c.1110T>G, NM_007294.3:c.1233T>G, LRG_292t1:c.1233T>G, NM_007297.3:c.1092T>G, NM_007298.3:c.787+446T>G, NM_007299.3:c.787+446T>G, NM_007300.3:c.1233T>G, NR_027676.1:n.1369T>G, NM_007297.4:c.1092T>G, NM_007299.4:c.787+446T>G, NM_007300.4:c.1233T>G, NR_027676.2:n.1410T>G, NM_007294.4(BRCA1):c.1233T>G (p.Asp411Glu)	BRCA1	breast-ovarian cancer, familial, susceptibility to, 1	MONDO:0011450	Autosomal dominant inheritance	Benign	BS1, BS3, BP1_Strong		The c.1233T>G variant in BRCA1 is a missense variant predicted to cause substitution of Aspartic acid by Glutamic acid at amino acid 411 (p.Asp411Glu). The highest non-cancer, non-founder population filter allele frequency in gnomAD v2.1 (exomes only, non-cancer subset, read depth ≥20) or gnomAD v3.1 (non-cancer subset, read depth ≥20) is 0.0002413 in the African/African American population, which is above the ENIGMA BRCA1/2 VCEP threshold (>0.0001) for BS1, and below the BA1 threshold (>0.001) (BS1 met). This missense variant is located outside of a key functional domain and was not predicted to alter mRNA splicing using the SpliceAI predictor (score 0.07, score threshold <0.1) (BP1_Strong met). Reported by one calibrated study to exhibit protein function similar to benign control variants (PMID: 32546644) (BS3 met).In summary, this variant meets the criteria to be classified as a Benign variant for BRCA1-related cancer predisposition based on the ACMG/AMP criteria applied as specified by the ENIGMA BRCA1/2 VCEP (BS1, BP1_Strong, BS3).	32546644	ENIGMA BRCA1 and BRCA2 VCEP		2023-10-08	2023-10-08	False	https://erepo.genome.network/evrepo/ui/classification/CA000811/MONDO:0011450/092	b565abfc-a0e8-4a5b-91dc-fd4ddbc6cc87	p.Asp411Glu	Asp	411	Glu	MDLSALRVEEVQNVINAMQKILECPICLELIKEPVSTKCDHIFCKFCMLKLLNQKKGPSQCPLCKNDITKRSLQESTRFSQLVEELLKIICAFQLDTGLEYANSYNFAKKENNSPEHLKDEVSIIQSMGYRNRAKRLLQSEPENPSLQETSLSVQLSNLGTVRTLRTKQRIQPQKTSVYIELGSDSSEDTVNKATYCSVGDQELLQITPQGTRDEISLDSAKKAACEFSETDVTNTEHHQPSNNDLNTTEKRAAERHPEKYQGSSVSNLHVEPCGTNTHASSLQHENSSLLLTKDRMNVEKAEFCNKSKQPGLARSQHNRWAGSKETCNDRRTPSTEKKVDLNADPLCERKEWNKQKLPCSENPRDTEDVPWITLNSSIQKVNEWFSRSDELLGSDDSHDGESESNAKVADVLDVLNEVDEYSGSSEKIDLLASDPHEALICKSERVHSKSVESNIEDKIFGKTYRKKASLPNLSHVTENLIIGAFVTEPQIIQERPLTNKLKRKRRPTSGLHPEDFIKKADLAVQKTPEMINQGTNQTEQNGQVMNITNSGHENKTKGDSIQNEKNPNPIESLEKESAFKTKAEPISSSISNMELELNIHNSKAPKKNRLRRKSSTRHIHALELVVSRNLSPPNCTELQIDSCSSSEEIKKKKYNQMPVRHSRNLQLMEGKEPATGAKKSNKPNEQTSKRHDSDTFPELKLTNAPGSFTKCSNTSELKEFVNPSLPREEKEEKLETVKVSNNAEDPKDLMLSGERVLQTERSVESSSISLVPGTDYGTQESISLLEVSTLGKAKTEPNKCVSQCAAFENPKGLIHGCSKDNRNDTEGFKYPLGHEVNHSRETSIEMEESELDAQYLQNTFKVSKRQSFAPFSNPGNAEEECATFSAHSGSLKKQSPKVTFECEQKEENQGKNESNIKPVQTVNITAGFPVVGQKDKPVDNAKCSIKGGSRFCLSSQFRGNETGLITPNKHGLLQNPYRIPPLFPIKSFVKTKCKKNLLEENFEEHSMSPEREMGNENIPSTVSTISRNNIRENVFKEASSSNINEVGSSTNEVGSSINEIGSSDENIQAELGRNRGPKLNAMLRLGVLQPEVYKQSLPGSNCKHPEIKKQEYEEVVQTVNTDFSPYLISDNLEQPMGSSHASQVCSETPDDLLDDGEIKEDTSFAENDIKESSAVFSKSVQKGELSRSPSPFTHTHLAQGYRRGAKKLESSEENLSSEDEELPCFQHLLFGKVNNIPSQSTRHSTVATECLSKNTEENLLSLKNSLNDCSNQVILAKASQEHHLSEETKCSASLFSSQCSELEDLTANTNTQDPFLIGSSKQMRHQSESQGVGLSDKELVSDDEERGTGLEENNQEEQSMDSNLGEAASGCESETSVSEDCSGLSSQSDILTTQQRDTMQHNLIKLQQEMAELEAVLEQHGSQPSNSYPSIISDSSALEDLRNPEQSTSEKAVLTSQKSSEYPISQNPEGLSADKFEVSADSSTSKNKEPGVERSSPSKCPSLDDRWYMHSCSGSLQNRNYPSQEELIKVVDVEEQQLEESGPHDLTETSYLPRQDLEGTPYLESGISLFSDDPESDPSEDRAPESARVGNIPSSTSALKVPQLKVAESAQSPAAAHTTDTAGYNAMEESVSREKPELTASTERVNKRMSMVVSGLTPEEFMLVYKFARKHHITLTNLITEETTHVVMKTDAEFVCERTLKYFLGIAGGKWVVSYFWVTQSIKERKMLNEHDFEVRGDVVNGRNHQGPKRARESQDRKIFRGLEICCYGPFTNMPTDQLEWMVQLCGASVVKELSSFTLGTGVHPIVVVQPDAWTEDNGFHAIGQMCEAPVVTREWVLDSVALYQCQELDTYLIPQIPHSHY	1863	P38398	E	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [1440], 'REGION_gain_score': array([0.00234973]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
596	NM_000059.4(BRCA2):c.8023A>G (p.Ile2675Val)	52475	CA025410	NM_000059.4:c.8023A>G, NC_000013.11:g.32363225A>G, CM000675.2:g.32363225A>G, NC_000013.10:g.32937362A>G, CM000675.1:g.32937362A>G, NC_000013.9:g.31835362A>G, NG_012772.3:g.52746A>G, LRG_293:g.52746A>G, ENST00000470094.2:c.8023A>G, ENST00000528762.2:c.8023A>G, ENST00000530893.7:c.7654A>G, ENST00000665585.2:c.8023A>G, ENST00000666593.2:c.8023A>G, ENST00000700202.2:c.8023A>G, ENST00000700202.1:c.490A>G, ENST00000380152.8:c.8023A>G, ENST00000544455.6:c.8023A>G, ENST00000614259.2:c.8031A>G, ENST00000665585.1:c.588A>G, ENST00000680887.1:c.8023A>G, ENST00000380152.7:c.8023A>G, ENST00000544455.5:c.8023A>G, NM_000059.3:c.8023A>G, LRG_293t1:c.8023A>G, XM_011535203.1:c.8023A>G, XM_011535204.1:c.7927A>G, XM_011535205.1:c.8023A>G, NM_000059.4(BRCA2):c.8023A>G (p.Ile2675Val)	BRCA2	breast-ovarian cancer, familial, susceptibility to, 2	MONDO:0012933	Autosomal dominant inheritance	Pathogenic	PP4_Strong, PVS1	BA1, BS1, PM2	The c.8023A>G variant in BRCA2 is a missense variant predicted to cause substitution of Isoleucine by Valine at amino acid 2675 (p.Ile2675Val). This variant is present in gnomAD v2.1 (exomes only, non-cancer subset) or gnomAD v3.1 (non-cancer subset) but is below the ENIGMA BRCA1/2 VCEP threshold >0.00002 for BS1_Supporting (PM2_Supporting, BS1, and BA1 are not met). This variant is reported to result in aberrant mRNA splicing. RT-PCR and mini-gene assays demonstrated that the variant impacts splicing by creation of a donor site, resulting in skipping of 309nt of exon 18 (PMIDs: 18424508, 22505045, 28339459). All studies report no wild-type transcript from the variant allele. Appropriate code strength determined by comparison of results to PVS1 decision tree (PVS1 (RNA) met). Multifactorial likelihood ratio analysis using clinically calibrated data produced a combined LR for this variant of 1612 (based on Cosegregation LR=605.1; Pathology LR=0.88; Co-occurrence LR=1.05; Family History LR=2.88), above the threshold for Very strong evidence towards pathogenicity (LR >350) (PP4_Very strong met; PMID: 31131967). In summary, this variant meets the criteria to be classified as a Pathogenic variant for BRCA2-related cancer predisposition based on the ACMG/AMP criteria applied as specified by the ENIGMA BRCA1/2 VCEP (PVS1 (RNA), PP4_Very strong).		ENIGMA BRCA1 and BRCA2 VCEP		2024-04-23	2024-04-23	False	https://erepo.genome.network/evrepo/ui/classification/CA025410/MONDO:0012933/097	a635e51b-a3d1-4c44-b83f-c8e9bad4ccaf	p.Ile2675Val	Ile	2675	Val	MPIGSKERPTFFEIFKTRCNKADLGPISLNWFEELSSEAPPYNSEPAEESEHKNNNYEPNLFKTPQRKPSYNQLASTPIIFKEQGLTLPLYQSPVKELDKFKLDLGRNVPNSRHKSLRTVKTKMDQADDVSCPLLNSCLSESPVVLQCTHVTPQRDKSVVCGSLFHTPKFVKGRQTPKHISESLGAEVDPDMSWSSSLATPPTLSSTVLIVRNEEASETVFPHDTTANVKSYFSNHDESLKKNDRFIASVTDSENTNQREAASHGFGKTSGNSFKVNSCKDHIGKSMPNVLEDEVYETVVDTSEEDSFSLCFSKCRTKNLQKVRTSKTRKKIFHEANADECEKSKNQVKEKYSFVSEVEPNDTDPLDSNVANQKPFESGSDKISKEVVPSLACEWSQLTLSGLNGAQMEKIPLLHISSCDQNISEKDLLDTENKRKKDFLTSENSLPRISSLPKSEKPLNEETVVNKRDEEQHLESHTDCILAVKQAISGTSPVASSFQGIKKSIFRIRESPKETFNASFSGHMTDPNFKKETEASESGLEIHTVCSQKEDSLCPNLIDNGSWPATTTQNSVALKNAGLISTLKKKTNKFIYAIHDETSYKGKKIPKDQKSELINCSAQFEANAFEAPLTFANADSGLLHSSVKRSCSQNDSEEPTLSLTSSFGTILRKCSRNETCSNNTVISQDLDYKEAKCNKEKLQLFITPEADSLSCLQEGQCENDPKSKKVSDIKEEVLAAACHPVQHSKVEYSDTDFQSQKSLLYDHENASTLILTPTSKDVLSNLVMISRGKESYKMSDKLKGNNYESDVELTKNIPMEKNQDVCALNENYKNVELLPPEKYMRVASPSRKVQFNQNTNLRVIQKNQEETTSISKITVNPDSEELFSDNENNFVFQVANERNNLALGNTKELHETDLTCVNEPIFKNSTMVLYGDTGDKQATQVSIKKDLVYVLAEENKNSVKQHIKMTLGQDLKSDISLNIDKIPEKNNDYMNKWAGLLGPISNHSFGGSFRTASNKEIKLSEHNIKKSKMFFKDIEEQYPTSLACVEIVNTLALDNQKKLSKPQSINTVSAHLQSSVVVSDCKNSHITPQMLFSKQDFNSNHNLTPSQKAEITELSTILEESGSQFEFTQFRKPSYILQKSTFEVPENQMTILKTTSEECRDADLHVIMNAPSIGQVDSSKQFEGTVEIKRKFAGLLKNDCNKSASGYLTDENEVGFRGFYSAHGTKLNVSTEALQKAVKLFSDIENISEETSAEVHPISLSSSKCHDSVVSMFKIENHNDKTVSEKNNKCQLILQNNIEMTTGTFVEEITENYKRNTENEDNKYTAASRNSHNLEFDGSDSSKNDTVCIHKDETDLLFTDQHNICLKLSGQFMKEGNTQIKEDLSDLTFLEVAKAQEACHGNTSNKEQLTATKTEQNIKDFETSDTFFQTASGKNISVAKESFNKIVNFFDQKPEELHNFSLNSELHSDIRKNKMDILSYEETDIVKHKILKESVPVGTGNQLVTFQGQPERDEKIKEPTLLGFHTASGKKVKIAKESLDKVKNLFDEKEQGTSEITSFSHQWAKTLKYREACKDLELACETIEITAAPKCKEMQNSLNNDKNLVSIETVVPPKLLSDNLCRQTENLKTSKSIFLKVKVHENVEKETAKSPATCYTNQSPYSVIENSALAFYTSCSRKTSVSQTSLLEAKKWLREGIFDGQPERINTADYVGNYLYENNSNSTIAENDKNHLSEKQDTYLSNSSMSNSYSYHSDEVYNDSGYLSKNKLDSGIEPVLKNVEDQKNTSFSKVISNVKDANAYPQTVNEDICVEELVTSSSPCKNKNAAIKLSISNSNNFEVGPPAFRIASGKIVCVSHETIKKVKDIFTDSFSKVIKENNENKSKICQTKIMAGCYEALDDSEDILHNSLDNDECSTHSHKVFADIQSEEILQHNQNMSGLEKVSKISPCDVSLETSDICKCSIGKLHKSVSSANTCGIFSTASGKSVQVSDASLQNARQVFSEIEDSTKQVFSKVLFKSNEHSDQLTREENTAIRTPEHLISQKGFSYNVVNSSAFSGFSTASGKQVSILESSLHKVKGVLEEFDLIRTEHSLHYSPTSRQNVSKILPRVDKRNPEHCVNSEMEKTCSKEFKLSNNLNVEGGSSENNHSIKVSPYLSQFQQDKQQLVLGTKVSLVENIHVLGKEQASPKNVKMEIGKTETFSDVPVKTNIEVCSTYSKDSENYFETEAVEIAKAFMEDDELTDSKLPSHATHSLFTCPENEEMVLSNSRIGKRRGEPLILVGEPSIKRNLLNEFDRIIENQEKSLKASKSTPDGTIKDRRLFMHHVSLEPITCVPFRTTKERQEIQNPNFTAPGQEFLSKSHLYEHLTLEKSSSNLAVSGHPFYQVSATRNEKMRHLITTGRPTKVFVPPFKTKSHFHRVEQCVRNINLEENRQKQNIDGHGSDDSKNKINDNEIHQFNKNNSNQAVAVTFTKCEEEPLDLITSLQNARDIQDMRIKKKQRQRVFPQPGSLYLAKTSTLPRISLKAAVGGQVPSACSHKQLYTYGVSKHCIKINSKNAESFQFHTEDYFGKESLWTGKGIQLADGGWLIPSNDGKAGKEEFYRALCDTPGVDPKLISRIWVYNHYRWIIWKLAAMECAFPKEFANRCLSPERVLLQLKYRYDTEIDRSRRSAIKKIMERDDTAAKTLVLCVSDIISLSANISETSSNKTSSADTQKVAIIELTDGWYAVKAQLDPPLLAVLKNGRLTVGQKIILHGAELVGSPDACTPLEAPESLMLKISANSTRPARWYTKLGFFPDPRPFPLPLSSLFSDGGNVGCVDVIIQRAYPIQWMEKTSSGLYIFRNEREEEKEAAKYVEAQQKRLEALFTKIQEEFEEHEENTTKPYLPSRALTRQQVRALQDGAELYEAVKNAADPAYLEGYFSEEQLRALNNHRQMLNDKKQAQIQLEIRKAMESAEQKEQGLSRDVTTVWKLRIVSYSKKEKDSVILSIWRPSSDLYSLLTEGKRYRIYHLATSKSKSKSERANIQLAATKKTQYQQLPVSDEILFQIYQPREPLHFSKFLDPDFQPSCSEVDLIGFVVSVVKKTGLAPFVYLSDECYNLLAIKFWIDLNEDIIKPHMLIAASNLQWRPESKSGLLTLFAGDFSVFSASPKEGHFQETFNKMKNTVENIDILCNEAENKLMHILHANDPKWSTPTKDCTSGPYTAQIIPGTGNKLLMSSPNCEIYYQSPLSLCMAKRKSVSTPVSAQMTSKSCKGEKEIDDQKNCKKRRALDFLSRLPLPPPVSPICTFVSPAAQKAFQPPRSCGTKYETPIKKKELNSPQMTPFKKFNEISLLESNSIADEELALINTQALLSGSTGEKQFISVSESTRTAPTSSEDYLRLKRRCTTSLIKEQESSQASTEECEKNKQDTITTKKYI	3418	P51587	V	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
597	NM_007294.4(BRCA1):c.191G>A (p.Cys64Tyr)	54400	CA001262	NM_007294.4:c.191G>A, NC_000017.11:g.43106477C>T, CM000679.2:g.43106477C>T, NC_000017.10:g.41258494C>T, CM000679.1:g.41258494C>T, NC_000017.9:g.38512020C>T, NG_005905.2:g.111507G>A, LRG_292:g.111507G>A, ENST00000354071.8:n.255G>A, ENST00000461574.2:c.191G>A, ENST00000470026.6:c.191G>A, ENST00000473961.6:c.191G>A, ENST00000476777.6:c.191G>A, ENST00000477152.6:c.135-1521G>A, ENST00000478531.6:c.191G>A, ENST00000489037.2:c.135-1521G>A, ENST00000493919.6:c.50G>A, ENST00000494123.6:c.191G>A, ENST00000497488.2:c.-218-11617G>A, ENST00000618469.2:c.191G>A, ENST00000634433.2:c.191G>A, ENST00000644379.2:c.191G>A, ENST00000644555.2:c.50G>A, ENST00000652672.2:c.50G>A, ENST00000484087.6:c.191G>A, ENST00000700182.1:c.135-1521G>A, ENST00000700183.1:c.*126+1G>A, ENST00000700184.1:n.434G>A, ENST00000357654.9:c.191G>A, ENST00000471181.7:c.191G>A, ENST00000642945.1:c.*65G>A, ENST00000644555.1:c.50G>A, ENST00000652672.1:c.50G>A, ENST00000352993.7:c.191G>A, ENST00000354071.7:c.191G>A, ENST00000357654.7:c.191G>A, ENST00000461221.5:c.190+1G>A, ENST00000461798.5:c.190+1G>A, ENST00000468300.5:c.191G>A, ENST00000470026.5:c.191G>A, ENST00000471181.6:c.191G>A, ENST00000476777.5:c.191G>A, ENST00000477152.5:c.135-1521G>A, ENST00000478531.5:c.191G>A, ENST00000489037.1:c.135-1521G>A, ENST00000491747.6:c.191G>A, ENST00000492859.5:c.*127G>A, ENST00000493795.5:c.50G>A, ENST00000493919.5:c.50G>A, ENST00000494123.5:c.191G>A, ENST00000497488.1:c.-218-11617G>A, ENST00000586385.5:c.4+18705G>A, ENST00000591534.5:c.-44+18794G>A, ENST00000591849.5:c.-99+18794G>A, ENST00000634433.1:c.191G>A, NM_007294.3:c.191G>A, LRG_292t1:c.191G>A, NM_007297.3:c.50G>A, NM_007298.3:c.191G>A, NM_007299.3:c.191G>A, NM_007300.3:c.191G>A, NR_027676.1:n.351+1G>A, NM_007297.4:c.50G>A, NM_007299.4:c.191G>A, NM_007300.4:c.191G>A, NR_027676.2:n.392+1G>A, NM_007294.4(BRCA1):c.191G>A (p.Cys64Tyr)	BRCA1	breast-ovarian cancer, familial, susceptibility to, 1	MONDO:0011450	Autosomal dominant inheritance	Pathogenic	PM2_Supporting, PP4_Strong, PS3, PP3		The c.191G>A variant in BRCA1 is a missense variant predicted to cause substitution of Cysteine by Tyrosine at amino acid 64 (p.Cys64Tyr). This variant is absent from gnomAD v2.1 (exomes only, non-cancer subset, read depth ≥25) and gnomAD v3.1 (non-cancer subset, read depth ≥25) (PM2_Supporting met). This BRCA1 missense variant is within a key functional domain and the computational predictor BayesDel (noAF) gives a score of 0.557, above the recommended threshold of 0.28 for prediction of impact on BRCA1 function via protein change. SpliceAI predictor score of 0.00 suggests that the variant has no impact on splicing (score threshold <0.10) (PP3 met). Reported by one calibrated study to exhibit protein function similar to pathogenic control variants (PMID: 30209399) (PS3 met). Multifactorial likelihood ratio analysis using clinically calibrated data produced a combined LR for this variant of 17239845573264 (based on Cosegregation LR=5300394; Pathology LR=189; Family History LR=17201), above the threshold for Very strong evidence towards pathogenicity (>350) (PP4_Very strong met; PMID: 31131967, 31853058).In summary, this variant meets the criteria to be classified as a Pathogenic variant for BRCA1-related cancer predisposition based on the ACMG/AMP criteria applied as specified by the ENIGMA BRCA1/2 VCEP (PM2_Supporting, PP3, PS3, PP4_Very strong).	30209399	ENIGMA BRCA1 and BRCA2 VCEP		2024-04-23	2024-04-23	False	https://erepo.genome.network/evrepo/ui/classification/CA001262/MONDO:0011450/092	aed4706a-e502-48b4-8417-bb5c3aa01461	p.Cys64Tyr	Cys	64	Tyr	MDLSALRVEEVQNVINAMQKILECPICLELIKEPVSTKCDHIFCKFCMLKLLNQKKGPSQCPLCKNDITKRSLQESTRFSQLVEELLKIICAFQLDTGLEYANSYNFAKKENNSPEHLKDEVSIIQSMGYRNRAKRLLQSEPENPSLQETSLSVQLSNLGTVRTLRTKQRIQPQKTSVYIELGSDSSEDTVNKATYCSVGDQELLQITPQGTRDEISLDSAKKAACEFSETDVTNTEHHQPSNNDLNTTEKRAAERHPEKYQGSSVSNLHVEPCGTNTHASSLQHENSSLLLTKDRMNVEKAEFCNKSKQPGLARSQHNRWAGSKETCNDRRTPSTEKKVDLNADPLCERKEWNKQKLPCSENPRDTEDVPWITLNSSIQKVNEWFSRSDELLGSDDSHDGESESNAKVADVLDVLNEVDEYSGSSEKIDLLASDPHEALICKSERVHSKSVESNIEDKIFGKTYRKKASLPNLSHVTENLIIGAFVTEPQIIQERPLTNKLKRKRRPTSGLHPEDFIKKADLAVQKTPEMINQGTNQTEQNGQVMNITNSGHENKTKGDSIQNEKNPNPIESLEKESAFKTKAEPISSSISNMELELNIHNSKAPKKNRLRRKSSTRHIHALELVVSRNLSPPNCTELQIDSCSSSEEIKKKKYNQMPVRHSRNLQLMEGKEPATGAKKSNKPNEQTSKRHDSDTFPELKLTNAPGSFTKCSNTSELKEFVNPSLPREEKEEKLETVKVSNNAEDPKDLMLSGERVLQTERSVESSSISLVPGTDYGTQESISLLEVSTLGKAKTEPNKCVSQCAAFENPKGLIHGCSKDNRNDTEGFKYPLGHEVNHSRETSIEMEESELDAQYLQNTFKVSKRQSFAPFSNPGNAEEECATFSAHSGSLKKQSPKVTFECEQKEENQGKNESNIKPVQTVNITAGFPVVGQKDKPVDNAKCSIKGGSRFCLSSQFRGNETGLITPNKHGLLQNPYRIPPLFPIKSFVKTKCKKNLLEENFEEHSMSPEREMGNENIPSTVSTISRNNIRENVFKEASSSNINEVGSSTNEVGSSINEIGSSDENIQAELGRNRGPKLNAMLRLGVLQPEVYKQSLPGSNCKHPEIKKQEYEEVVQTVNTDFSPYLISDNLEQPMGSSHASQVCSETPDDLLDDGEIKEDTSFAENDIKESSAVFSKSVQKGELSRSPSPFTHTHLAQGYRRGAKKLESSEENLSSEDEELPCFQHLLFGKVNNIPSQSTRHSTVATECLSKNTEENLLSLKNSLNDCSNQVILAKASQEHHLSEETKCSASLFSSQCSELEDLTANTNTQDPFLIGSSKQMRHQSESQGVGLSDKELVSDDEERGTGLEENNQEEQSMDSNLGEAASGCESETSVSEDCSGLSSQSDILTTQQRDTMQHNLIKLQQEMAELEAVLEQHGSQPSNSYPSIISDSSALEDLRNPEQSTSEKAVLTSQKSSEYPISQNPEGLSADKFEVSADSSTSKNKEPGVERSSPSKCPSLDDRWYMHSCSGSLQNRNYPSQEELIKVVDVEEQQLEESGPHDLTETSYLPRQDLEGTPYLESGISLFSDDPESDPSEDRAPESARVGNIPSSTSALKVPQLKVAESAQSPAAAHTTDTAGYNAMEESVSREKPELTASTERVNKRMSMVVSGLTPEEFMLVYKFARKHHITLTNLITEETTHVVMKTDAEFVCERTLKYFLGIAGGKWVVSYFWVTQSIKERKMLNEHDFEVRGDVVNGRNHQGPKRARESQDRKIFRGLEICCYGPFTNMPTDQLEWMVQLCGASVVKELSSFTLGTGVHPIVVVQPDAWTEDNGFHAIGQMCEAPVVTREWVLDSVALYQCQELDTYLIPQIPHSHY	1863	P38398	Y	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [60, 63], 'BINDING_gain': [23, 43], 'BINDING_gain_score': array([0.19692934, 0.3247537 ]), 'BINDING_loss_score': array([-0.52819139, -0.67578751]), 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [1347, 1350, 1359, 1361, 1440], 'REGION_gain_score': array([0.01613212, 0.0136075 , 0.01227683, 0.01217061, 0.00866866]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
598	NM_007294.4(BRCA1):c.2155A>G (p.Lys719Glu)	37452	CA001442	NM_007294.4:c.2155A>G, NC_000017.11:g.43093376T>C, CM000679.2:g.43093376T>C, NC_000017.10:g.41245393T>C, CM000679.1:g.41245393T>C, NC_000017.9:g.38498919T>C, NG_005905.2:g.124608A>G, LRG_292:g.124608A>G, ENST00000354071.8:n.2219A>G, ENST00000461574.2:c.2155A>G, ENST00000470026.6:c.2155A>G, ENST00000473961.6:c.2029A>G, ENST00000476777.6:c.2152A>G, ENST00000477152.6:c.2077A>G, ENST00000478531.6:c.784+1368A>G, ENST00000489037.2:c.2077A>G, ENST00000493919.6:c.646+1368A>G, ENST00000494123.6:c.2155A>G, ENST00000497488.2:c.1267A>G, ENST00000618469.2:c.2155A>G, ENST00000634433.2:c.2032A>G, ENST00000644379.2:c.2155A>G, ENST00000644555.2:c.646+1368A>G, ENST00000652672.2:c.2014A>G, ENST00000484087.6:c.664+1368A>G, ENST00000700182.1:c.706+1368A>G, ENST00000357654.9:c.2155A>G, ENST00000471181.7:c.2155A>G, ENST00000352993.7:c.671-2344A>G, ENST00000354071.7:c.2155A>G, ENST00000357654.7:c.2155A>G, ENST00000461221.5:c.*1938A>G, ENST00000468300.5:c.787+1368A>G, ENST00000471181.6:c.2155A>G, ENST00000478531.5:c.784+1368A>G, ENST00000484087.5:c.409+1368A>G, ENST00000487825.5:c.412+1368A>G, ENST00000491747.6:c.787+1368A>G, ENST00000493795.5:c.2014A>G, ENST00000493919.5:c.646+1368A>G, ENST00000586385.5:c.5-29425A>G, ENST00000591534.5:c.-43-18855A>G, ENST00000591849.5:c.-99+31895A>G, ENST00000634433.1:c.2032A>G, NM_007294.3:c.2155A>G, LRG_292t1:c.2155A>G, NM_007297.3:c.2014A>G, NM_007298.3:c.787+1368A>G, NM_007299.3:c.787+1368A>G, NM_007300.3:c.2155A>G, NR_027676.1:n.2291A>G, NM_007297.4:c.2014A>G, NM_007299.4:c.787+1368A>G, NM_007300.4:c.2155A>G, NR_027676.2:n.2332A>G, NM_007294.4(BRCA1):c.2155A>G (p.Lys719Glu)	BRCA1	breast-ovarian cancer, familial, susceptibility to, 1	MONDO:0011450	Autosomal dominant inheritance	Benign	BS1, BP5_Strong, BP1_Strong		The c.2155A>G variant in BRCA1 is a missense variant predicted to cause substitution of Lysine by Glutamic acid at amino acid 719 (p.Lys719Glu). The highest non-cancer, non-founder population filter allele frequency in gnomAD v2.1 (exomes only, non-cancer subset, read depth ≥20) or gnomAD v3.1 (non-cancer subset, read depth  ≥20) is 0.0003 in the African/African American population, which is above the ENIGMA BRCA1/2 VCEP threshold (>0.0001) for BS1, and below the BA1 threshold (>0.001) (BS1 met). This missense variant is located outside of a key functional domain and was not predicted to alter mRNA splicing using the SpliceAI predictor (score 0.01, score threshold <0.1) (BP1_Strong met). Multifactorial likelihood ratio analysis using clinically calibrated data produced a combined LR for this variant of 0.0000515 (based on Family History LR= 0.0000515), below the thresholds for very strong benign evidence (LR <0.00285) (BP5_Very strong met; PMID: 31853058).  In summary, this variant meets the criteria to be classified as a Benign variant for BRCA1-related cancer predisposition based on the ACMG/AMP criteria applied as specified by the ENIGMA BRCA1/2 VCEP (BS1, BP1_Strong, BP5_Very strong).		ENIGMA BRCA1 and BRCA2 VCEP		2024-04-23	2024-04-23	False	https://erepo.genome.network/evrepo/ui/classification/CA001442/MONDO:0011450/092	fd4bcbc3-5cf5-46ae-b827-465fec09e761	p.Lys719Glu	Lys	719	Glu	MDLSALRVEEVQNVINAMQKILECPICLELIKEPVSTKCDHIFCKFCMLKLLNQKKGPSQCPLCKNDITKRSLQESTRFSQLVEELLKIICAFQLDTGLEYANSYNFAKKENNSPEHLKDEVSIIQSMGYRNRAKRLLQSEPENPSLQETSLSVQLSNLGTVRTLRTKQRIQPQKTSVYIELGSDSSEDTVNKATYCSVGDQELLQITPQGTRDEISLDSAKKAACEFSETDVTNTEHHQPSNNDLNTTEKRAAERHPEKYQGSSVSNLHVEPCGTNTHASSLQHENSSLLLTKDRMNVEKAEFCNKSKQPGLARSQHNRWAGSKETCNDRRTPSTEKKVDLNADPLCERKEWNKQKLPCSENPRDTEDVPWITLNSSIQKVNEWFSRSDELLGSDDSHDGESESNAKVADVLDVLNEVDEYSGSSEKIDLLASDPHEALICKSERVHSKSVESNIEDKIFGKTYRKKASLPNLSHVTENLIIGAFVTEPQIIQERPLTNKLKRKRRPTSGLHPEDFIKKADLAVQKTPEMINQGTNQTEQNGQVMNITNSGHENKTKGDSIQNEKNPNPIESLEKESAFKTKAEPISSSISNMELELNIHNSKAPKKNRLRRKSSTRHIHALELVVSRNLSPPNCTELQIDSCSSSEEIKKKKYNQMPVRHSRNLQLMEGKEPATGAKKSNKPNEQTSKRHDSDTFPELKLTNAPGSFTKCSNTSELKEFVNPSLPREEKEEKLETVKVSNNAEDPKDLMLSGERVLQTERSVESSSISLVPGTDYGTQESISLLEVSTLGKAKTEPNKCVSQCAAFENPKGLIHGCSKDNRNDTEGFKYPLGHEVNHSRETSIEMEESELDAQYLQNTFKVSKRQSFAPFSNPGNAEEECATFSAHSGSLKKQSPKVTFECEQKEENQGKNESNIKPVQTVNITAGFPVVGQKDKPVDNAKCSIKGGSRFCLSSQFRGNETGLITPNKHGLLQNPYRIPPLFPIKSFVKTKCKKNLLEENFEEHSMSPEREMGNENIPSTVSTISRNNIRENVFKEASSSNINEVGSSTNEVGSSINEIGSSDENIQAELGRNRGPKLNAMLRLGVLQPEVYKQSLPGSNCKHPEIKKQEYEEVVQTVNTDFSPYLISDNLEQPMGSSHASQVCSETPDDLLDDGEIKEDTSFAENDIKESSAVFSKSVQKGELSRSPSPFTHTHLAQGYRRGAKKLESSEENLSSEDEELPCFQHLLFGKVNNIPSQSTRHSTVATECLSKNTEENLLSLKNSLNDCSNQVILAKASQEHHLSEETKCSASLFSSQCSELEDLTANTNTQDPFLIGSSKQMRHQSESQGVGLSDKELVSDDEERGTGLEENNQEEQSMDSNLGEAASGCESETSVSEDCSGLSSQSDILTTQQRDTMQHNLIKLQQEMAELEAVLEQHGSQPSNSYPSIISDSSALEDLRNPEQSTSEKAVLTSQKSSEYPISQNPEGLSADKFEVSADSSTSKNKEPGVERSSPSKCPSLDDRWYMHSCSGSLQNRNYPSQEELIKVVDVEEQQLEESGPHDLTETSYLPRQDLEGTPYLESGISLFSDDPESDPSEDRAPESARVGNIPSSTSALKVPQLKVAESAQSPAAAHTTDTAGYNAMEESVSREKPELTASTERVNKRMSMVVSGLTPEEFMLVYKFARKHHITLTNLITEETTHVVMKTDAEFVCERTLKYFLGIAGGKWVVSYFWVTQSIKERKMLNEHDFEVRGDVVNGRNHQGPKRARESQDRKIFRGLEICCYGPFTNMPTDQLEWMVQLCGASVVKELSSFTLGTGVHPIVVVQPDAWTEDNGFHAIGQMCEAPVVTREWVLDSVALYQCQELDTYLIPQIPHSHY	1863	P38398	E	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [692], 'COMPBIAS_gain': [], 'COMPBIAS_loss_score': array([-0.00918233]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [1440], 'REGION_gain_score': array([0.00201821]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
599	NM_007294.4(BRCA1):c.305C>G (p.Ala102Gly)	37505	CA002009	NM_007294.4:c.305C>G, NC_000017.11:g.43104258G>C, CM000679.2:g.43104258G>C, NC_000017.10:g.41256275G>C, CM000679.1:g.41256275G>C, NC_000017.9:g.38509801G>C, NG_005905.2:g.113726C>G, LRG_292:g.113726C>G, ENST00000354071.8:n.369C>G, ENST00000461574.2:c.305C>G, ENST00000470026.6:c.305C>G, ENST00000473961.6:c.305C>G, ENST00000476777.6:c.305C>G, ENST00000477152.6:c.227C>G, ENST00000478531.6:c.305C>G, ENST00000489037.2:c.227C>G, ENST00000493919.6:c.164C>G, ENST00000494123.6:c.305C>G, ENST00000497488.2:c.-218-9398C>G, ENST00000618469.2:c.305C>G, ENST00000634433.2:c.305C>G, ENST00000644379.2:c.305C>G, ENST00000644555.2:c.164C>G, ENST00000652672.2:c.164C>G, ENST00000484087.6:c.305C>G, ENST00000700083.1:n.1276C>G, ENST00000700182.1:c.227C>G, ENST00000700183.1:c.*219C>G, ENST00000700184.1:n.548C>G, ENST00000357654.9:c.305C>G, ENST00000471181.7:c.305C>G, ENST00000642945.1:c.*179C>G, ENST00000644555.1:c.164C>G, ENST00000652672.1:c.164C>G, ENST00000352993.7:c.305C>G, ENST00000354071.7:c.305C>G, ENST00000357654.7:c.305C>G, ENST00000461221.5:c.*91C>G, ENST00000461798.5:c.*91C>G, ENST00000468300.5:c.305C>G, ENST00000470026.5:c.305C>G, ENST00000471181.6:c.305C>G, ENST00000473961.5:c.28C>G, ENST00000476777.5:c.305C>G, ENST00000477152.5:c.227C>G, ENST00000478531.5:c.305C>G, ENST00000484087.5:c.53C>G, ENST00000487825.5:c.53C>G, ENST00000489037.1:c.227C>G, ENST00000491747.6:c.305C>G, ENST00000492859.5:c.*241C>G, ENST00000493795.5:c.164C>G, ENST00000493919.5:c.164C>G, ENST00000494123.5:c.305C>G, ENST00000497488.1:c.-218-9398C>G, ENST00000586385.5:c.4+20924C>G, ENST00000591534.5:c.-44+21013C>G, ENST00000591849.5:c.-99+21013C>G, ENST00000634433.1:c.305C>G, NM_007294.3:c.305C>G, LRG_292t1:c.305C>G, NM_007297.3:c.164C>G, NM_007298.3:c.305C>G, NM_007299.3:c.305C>G, NM_007300.3:c.305C>G, NR_027676.1:n.444C>G, NM_007297.4:c.164C>G, NM_007299.4:c.305C>G, NM_007300.4:c.305C>G, NR_027676.2:n.485C>G, NM_007294.4(BRCA1):c.305C>G (p.Ala102Gly)	BRCA1	breast-ovarian cancer, familial, susceptibility to, 1	MONDO:0011450	Autosomal dominant inheritance	Benign	PM2_Supporting, BP1_Strong, BS3, BP5_Strong		The c.305C>G variant in BRCA1 is a missense variant predicted to cause substitution of Alanine by Glycine at amino acid 102 (p.Ala102Gly). This variant is absent from gnomAD v2.1 (exomes only, non-cancer subset, read depth ≥25) and gnomAD v3.1 (non-cancer subset, read depth ≥25) (PM2_Supporting met). This missense variant is located outside of a key functional domain and was not predicted to alter mRNA splicing using the SpliceAI predictor (score 0.00, score threshold <0.1) (BP1_Strong met). Reported by one calibrated study to exhibit protein function similar to benign control variants (PMID: 30219179) (BS3 met). Multifactorial likelihood ratio analysis using clinically calibrated data produced a combined LR for this variant of 0.015 (based on Co-occurrence LR=1.177; Family History LR=0.0127), below the threshold for strong benign evidence (LR <0.05) (BP5_Strong met; PMID: 31131967, 31853058). In summary, this variant meets the criteria to be classified as a Benign variant for BRCA1-related cancer predisposition based on the ACMG/AMP criteria applied as specified by the ENIGMA BRCA1/2 VCEP (PM2_Supporting, BP1_Strong, BS3, BP5_Strong).	30219179	ENIGMA BRCA1 and BRCA2 VCEP		2024-04-23	2024-04-23	False	https://erepo.genome.network/evrepo/ui/classification/CA002009/MONDO:0011450/092	de5081dd-8e3e-444d-9826-44632cbee0f3	p.Ala102Gly	Ala	102	Gly	MDLSALRVEEVQNVINAMQKILECPICLELIKEPVSTKCDHIFCKFCMLKLLNQKKGPSQCPLCKNDITKRSLQESTRFSQLVEELLKIICAFQLDTGLEYANSYNFAKKENNSPEHLKDEVSIIQSMGYRNRAKRLLQSEPENPSLQETSLSVQLSNLGTVRTLRTKQRIQPQKTSVYIELGSDSSEDTVNKATYCSVGDQELLQITPQGTRDEISLDSAKKAACEFSETDVTNTEHHQPSNNDLNTTEKRAAERHPEKYQGSSVSNLHVEPCGTNTHASSLQHENSSLLLTKDRMNVEKAEFCNKSKQPGLARSQHNRWAGSKETCNDRRTPSTEKKVDLNADPLCERKEWNKQKLPCSENPRDTEDVPWITLNSSIQKVNEWFSRSDELLGSDDSHDGESESNAKVADVLDVLNEVDEYSGSSEKIDLLASDPHEALICKSERVHSKSVESNIEDKIFGKTYRKKASLPNLSHVTENLIIGAFVTEPQIIQERPLTNKLKRKRRPTSGLHPEDFIKKADLAVQKTPEMINQGTNQTEQNGQVMNITNSGHENKTKGDSIQNEKNPNPIESLEKESAFKTKAEPISSSISNMELELNIHNSKAPKKNRLRRKSSTRHIHALELVVSRNLSPPNCTELQIDSCSSSEEIKKKKYNQMPVRHSRNLQLMEGKEPATGAKKSNKPNEQTSKRHDSDTFPELKLTNAPGSFTKCSNTSELKEFVNPSLPREEKEEKLETVKVSNNAEDPKDLMLSGERVLQTERSVESSSISLVPGTDYGTQESISLLEVSTLGKAKTEPNKCVSQCAAFENPKGLIHGCSKDNRNDTEGFKYPLGHEVNHSRETSIEMEESELDAQYLQNTFKVSKRQSFAPFSNPGNAEEECATFSAHSGSLKKQSPKVTFECEQKEENQGKNESNIKPVQTVNITAGFPVVGQKDKPVDNAKCSIKGGSRFCLSSQFRGNETGLITPNKHGLLQNPYRIPPLFPIKSFVKTKCKKNLLEENFEEHSMSPEREMGNENIPSTVSTISRNNIRENVFKEASSSNINEVGSSTNEVGSSINEIGSSDENIQAELGRNRGPKLNAMLRLGVLQPEVYKQSLPGSNCKHPEIKKQEYEEVVQTVNTDFSPYLISDNLEQPMGSSHASQVCSETPDDLLDDGEIKEDTSFAENDIKESSAVFSKSVQKGELSRSPSPFTHTHLAQGYRRGAKKLESSEENLSSEDEELPCFQHLLFGKVNNIPSQSTRHSTVATECLSKNTEENLLSLKNSLNDCSNQVILAKASQEHHLSEETKCSASLFSSQCSELEDLTANTNTQDPFLIGSSKQMRHQSESQGVGLSDKELVSDDEERGTGLEENNQEEQSMDSNLGEAASGCESETSVSEDCSGLSSQSDILTTQQRDTMQHNLIKLQQEMAELEAVLEQHGSQPSNSYPSIISDSSALEDLRNPEQSTSEKAVLTSQKSSEYPISQNPEGLSADKFEVSADSSTSKNKEPGVERSSPSKCPSLDDRWYMHSCSGSLQNRNYPSQEELIKVVDVEEQQLEESGPHDLTETSYLPRQDLEGTPYLESGISLFSDDPESDPSEDRAPESARVGNIPSSTSALKVPQLKVAESAQSPAAAHTTDTAGYNAMEESVSREKPELTASTERVNKRMSMVVSGLTPEEFMLVYKFARKHHITLTNLITEETTHVVMKTDAEFVCERTLKYFLGIAGGKWVVSYFWVTQSIKERKMLNEHDFEVRGDVVNGRNHQGPKRARESQDRKIFRGLEICCYGPFTNMPTDQLEWMVQLCGASVVKELSSFTLGTGVHPIVVVQPDAWTEDNGFHAIGQMCEAPVVTREWVLDSVALYQCQELDTYLIPQIPHSHY	1863	P38398	G	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [1347, 1350, 1359, 1361, 1440], 'REGION_gain_score': array([0.0247758 , 0.02130175, 0.02212846, 0.02196294, 0.00482792]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
600	NM_007294.4(BRCA1):c.3082C>T (p.Arg1028Cys)	37506	CA002019	NM_007294.4:c.3082C>T, NC_000017.11:g.43092449G>A, CM000679.2:g.43092449G>A, NC_000017.10:g.41244466G>A, CM000679.1:g.41244466G>A, NC_000017.9:g.38497992G>A, NG_005905.2:g.125535C>T, LRG_292:g.125535C>T, ENST00000357654.9:c.3082C>T, ENST00000471181.7:c.3082C>T, ENST00000352993.7:c.671-1417C>T, ENST00000354071.7:c.3082C>T, ENST00000357654.7:c.3082C>T, ENST00000461221.5:c.*2865C>T, ENST00000468300.5:c.788-1417C>T, ENST00000471181.6:c.3082C>T, ENST00000478531.5:c.785-1417C>T, ENST00000484087.5:c.410-1417C>T, ENST00000487825.5:c.413-1417C>T, ENST00000491747.6:c.788-1417C>T, ENST00000493795.5:c.2941C>T, ENST00000493919.5:c.647-1417C>T, ENST00000586385.5:c.5-28498C>T, ENST00000591534.5:c.-43-17928C>T, ENST00000591849.5:c.-99+32822C>T, NM_007294.3:c.3082C>T, LRG_292t1:c.3082C>T, NM_007297.3:c.2941C>T, NM_007298.3:c.788-1417C>T, NM_007299.3:c.788-1417C>T, NM_007300.3:c.3082C>T, NR_027676.1:n.3218C>T, NM_007297.4:c.2941C>T, NM_007299.4:c.788-1417C>T, NM_007300.4:c.3082C>T, NR_027676.2:n.3259C>T, NM_007294.4(BRCA1):c.3082C>T (p.Arg1028Cys)	BRCA1	breast-ovarian cancer, familial, susceptibility to, 1	MONDO:0011450	Autosomal dominant inheritance	Benign	BP1_Strong, BS2_Supporting, BS3, BP5_Strong	BA1, BS1, PM2	The c.3082C>T variant in BRCA1 is a missense variant predicted to cause substitution of Arginine by Cysteine at amino acid 1028 (p.Arg1028Cys). This variant is present in gnomAD v2.1 (exomes only, non-cancer subset) or gnomAD v3.1 (non-cancer subset) but is below the ENIGMA BRCA1/2 VCEP threshold >0.00002 for BS1_Supporting (PM2_Supporting, BS1, and BA1 are not met). This missense variant is located outside of a key functional domain and was not predicted to alter mRNA splicing using the SpliceAI predictor (score 0.01, score threshold < 0.1) (BP1_Strong met). Reported by one calibrated study to exhibit protein function similar to benign control variants (PMID: 32546644) (BS3 met). This variant has been observed in one individual with features considered inconsistent with an FA-associated phenotype, variant is homozygous (total score 1 point) (BS2_Supporting met; PMID: 29435075). Multifactorial likelihood ratio analysis using clinically calibrated data produced a combined LR for this variant of 0.0009 (based on Cosegregation LR=0.131; Pathology LR=0.056; Co-occurrence LR= 1.527; Family History LR= 0.081), below the thresholds for very strong benign evidence (LR <0.00285) (BP5_Very strong met; PMID: 31131967). In summary, this variant meets the criteria to be classified as a Benign variant for BRCA1-related cancer predisposition based on the ACMG/AMP criteria applied as specified by the ENIGMA BRCA1/2 VCEP (BP1_Strong, BS3, BS2_Supporting, BP5_Very strong).		ENIGMA BRCA1 and BRCA2 VCEP		2023-10-10	2023-10-10	False	https://erepo.genome.network/evrepo/ui/classification/CA002019/MONDO:0011450/092	2061883d-ba9a-4fc8-92c5-d24655eaf5b3	p.Arg1028Cys	Arg	1028	Cys	MDLSALRVEEVQNVINAMQKILECPICLELIKEPVSTKCDHIFCKFCMLKLLNQKKGPSQCPLCKNDITKRSLQESTRFSQLVEELLKIICAFQLDTGLEYANSYNFAKKENNSPEHLKDEVSIIQSMGYRNRAKRLLQSEPENPSLQETSLSVQLSNLGTVRTLRTKQRIQPQKTSVYIELGSDSSEDTVNKATYCSVGDQELLQITPQGTRDEISLDSAKKAACEFSETDVTNTEHHQPSNNDLNTTEKRAAERHPEKYQGSSVSNLHVEPCGTNTHASSLQHENSSLLLTKDRMNVEKAEFCNKSKQPGLARSQHNRWAGSKETCNDRRTPSTEKKVDLNADPLCERKEWNKQKLPCSENPRDTEDVPWITLNSSIQKVNEWFSRSDELLGSDDSHDGESESNAKVADVLDVLNEVDEYSGSSEKIDLLASDPHEALICKSERVHSKSVESNIEDKIFGKTYRKKASLPNLSHVTENLIIGAFVTEPQIIQERPLTNKLKRKRRPTSGLHPEDFIKKADLAVQKTPEMINQGTNQTEQNGQVMNITNSGHENKTKGDSIQNEKNPNPIESLEKESAFKTKAEPISSSISNMELELNIHNSKAPKKNRLRRKSSTRHIHALELVVSRNLSPPNCTELQIDSCSSSEEIKKKKYNQMPVRHSRNLQLMEGKEPATGAKKSNKPNEQTSKRHDSDTFPELKLTNAPGSFTKCSNTSELKEFVNPSLPREEKEEKLETVKVSNNAEDPKDLMLSGERVLQTERSVESSSISLVPGTDYGTQESISLLEVSTLGKAKTEPNKCVSQCAAFENPKGLIHGCSKDNRNDTEGFKYPLGHEVNHSRETSIEMEESELDAQYLQNTFKVSKRQSFAPFSNPGNAEEECATFSAHSGSLKKQSPKVTFECEQKEENQGKNESNIKPVQTVNITAGFPVVGQKDKPVDNAKCSIKGGSRFCLSSQFRGNETGLITPNKHGLLQNPYRIPPLFPIKSFVKTKCKKNLLEENFEEHSMSPEREMGNENIPSTVSTISRNNIRENVFKEASSSNINEVGSSTNEVGSSINEIGSSDENIQAELGRNRGPKLNAMLRLGVLQPEVYKQSLPGSNCKHPEIKKQEYEEVVQTVNTDFSPYLISDNLEQPMGSSHASQVCSETPDDLLDDGEIKEDTSFAENDIKESSAVFSKSVQKGELSRSPSPFTHTHLAQGYRRGAKKLESSEENLSSEDEELPCFQHLLFGKVNNIPSQSTRHSTVATECLSKNTEENLLSLKNSLNDCSNQVILAKASQEHHLSEETKCSASLFSSQCSELEDLTANTNTQDPFLIGSSKQMRHQSESQGVGLSDKELVSDDEERGTGLEENNQEEQSMDSNLGEAASGCESETSVSEDCSGLSSQSDILTTQQRDTMQHNLIKLQQEMAELEAVLEQHGSQPSNSYPSIISDSSALEDLRNPEQSTSEKAVLTSQKSSEYPISQNPEGLSADKFEVSADSSTSKNKEPGVERSSPSKCPSLDDRWYMHSCSGSLQNRNYPSQEELIKVVDVEEQQLEESGPHDLTETSYLPRQDLEGTPYLESGISLFSDDPESDPSEDRAPESARVGNIPSSTSALKVPQLKVAESAQSPAAAHTTDTAGYNAMEESVSREKPELTASTERVNKRMSMVVSGLTPEEFMLVYKFARKHHITLTNLITEETTHVVMKTDAEFVCERTLKYFLGIAGGKWVVSYFWVTQSIKERKMLNEHDFEVRGDVVNGRNHQGPKRARESQDRKIFRGLEICCYGPFTNMPTDQLEWMVQLCGASVVKELSSFTLGTGVHPIVVVQPDAWTEDNGFHAIGQMCEAPVVTREWVLDSVALYQCQELDTYLIPQIPHSHY	1863	P38398	C	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [1044, 1045, 1046, 1047, 1048, 1049, 1050, 1051, 1052, 1053, 1054, 1055, 1056, 1057, 1058, 1059, 1060, 1061, 1062], 'REGION_gain': [1347, 1350, 1359, 1361, 1440], 'REGION_gain_score': array([0.01733404, 0.01604587, 0.01612103, 0.01711285, 0.00524974]), 'REGION_loss_score': array([-0.37452906, -0.29055709, -0.25988501, -0.28761709, -0.24985611,
       -0.23797363, -0.24901974, -0.25586408, -0.27482897, -0.22651315,
       -0.24347907, -0.24735415, -0.23415065, -0.23896295, -0.24077904,
       -0.22689241, -0.19993544, -0.22701681, -0.2419377 ]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
601	NM_007294.4(BRCA1):c.3418A>G (p.Ser1140Gly)	41817	CA002212	NM_007294.4:c.3418A>G, NC_000017.11:g.43092113T>C, CM000679.2:g.43092113T>C, NC_000017.10:g.41244130T>C, CM000679.1:g.41244130T>C, NC_000017.9:g.38497656T>C, NG_005905.2:g.125871A>G, LRG_292:g.125871A>G, ENST00000357654.9:c.3418A>G, ENST00000471181.7:c.3418A>G, ENST00000352993.7:c.671-1081A>G, ENST00000354071.7:c.3418A>G, ENST00000357654.7:c.3418A>G, ENST00000461221.5:c.*3201A>G, ENST00000468300.5:c.788-1081A>G, ENST00000471181.6:c.3418A>G, ENST00000478531.5:c.785-1081A>G, ENST00000484087.5:c.410-1081A>G, ENST00000487825.5:c.413-1081A>G, ENST00000491747.6:c.788-1081A>G, ENST00000493795.5:c.3277A>G, ENST00000493919.5:c.647-1081A>G, ENST00000586385.5:c.5-28162A>G, ENST00000591534.5:c.-43-17592A>G, ENST00000591849.5:c.-99+33158A>G, NM_007294.3:c.3418A>G, LRG_292t1:c.3418A>G, NM_007297.3:c.3277A>G, NM_007298.3:c.788-1081A>G, NM_007299.3:c.788-1081A>G, NM_007300.3:c.3418A>G, NR_027676.1:n.3554A>G, NM_007297.4:c.3277A>G, NM_007299.4:c.788-1081A>G, NM_007300.4:c.3418A>G, NR_027676.2:n.3595A>G, NM_007294.4(BRCA1):c.3418A>G (p.Ser1140Gly)	BRCA1	breast-ovarian cancer, familial, susceptibility to, 1	MONDO:0011450	Autosomal dominant inheritance	Benign	BA1, BP5_Strong, BS3, BP1_Strong, BS2		The c.3418A>G variant in BRCA1 is a missense variant predicted to cause substitution of Serine by Glycine at amino acid 1140 (p.Ser1140Gly). The highest non-cancer, non-founder population filter allele frequency in gnomAD v2.1 (exomes only, non-cancer subset, read depth ≥20) or gnomAD v3.1 (non-cancer subset, read depth ≥20) is 0.03171 in the African/African-American population, which is above the ENIGMA BRCA1/2 VCEP threshold (>0.001) for BA1 (BA1 met). This missense variant is located outside of a key functional domain and was not predicted to alter mRNA splicing using the SpliceAI predictor (score 0.06, score threshold <0.1) (BP1_Strong met). Reported by one calibrated study to exhibit protein function similar to benign control variants (PMID: 32546644) (BS3 met). This variant has been observed in more than 10 individuals with features considered inconsistent with an FA-associated phenotype, and (Likely) Pathogenic variant seen in trans or variant is homozygous (total score 4 points) (BS2 met; Invitae internal contributor). Multifactorial likelihood ratio analysis using clinically calibrated data produced a combined LR for this variant of 0.00029 (based on Co-occurrence LR=0.00029), below the threshold for Very strong benign evidence (LR <0.00285) (BP5_Very strong met; PMID: 16014699). In summary, this variant meets the criteria to be classified as a Benign variant for BRCA1-related cancer predisposition based on the ACMG/AMP criteria applied as specified by the ENIGMA BRCA1/2 VCEP (BA1, BP1_Strong, BS3, BS2, BP5_Very strong).		ENIGMA BRCA1 and BRCA2 VCEP		2023-10-10	2023-10-10	False	https://erepo.genome.network/evrepo/ui/classification/CA002212/MONDO:0011450/092	911b8df3-87b8-4dad-b9b9-792bc57a5295	p.Ser1140Gly	Ser	1140	Gly	MDLSALRVEEVQNVINAMQKILECPICLELIKEPVSTKCDHIFCKFCMLKLLNQKKGPSQCPLCKNDITKRSLQESTRFSQLVEELLKIICAFQLDTGLEYANSYNFAKKENNSPEHLKDEVSIIQSMGYRNRAKRLLQSEPENPSLQETSLSVQLSNLGTVRTLRTKQRIQPQKTSVYIELGSDSSEDTVNKATYCSVGDQELLQITPQGTRDEISLDSAKKAACEFSETDVTNTEHHQPSNNDLNTTEKRAAERHPEKYQGSSVSNLHVEPCGTNTHASSLQHENSSLLLTKDRMNVEKAEFCNKSKQPGLARSQHNRWAGSKETCNDRRTPSTEKKVDLNADPLCERKEWNKQKLPCSENPRDTEDVPWITLNSSIQKVNEWFSRSDELLGSDDSHDGESESNAKVADVLDVLNEVDEYSGSSEKIDLLASDPHEALICKSERVHSKSVESNIEDKIFGKTYRKKASLPNLSHVTENLIIGAFVTEPQIIQERPLTNKLKRKRRPTSGLHPEDFIKKADLAVQKTPEMINQGTNQTEQNGQVMNITNSGHENKTKGDSIQNEKNPNPIESLEKESAFKTKAEPISSSISNMELELNIHNSKAPKKNRLRRKSSTRHIHALELVVSRNLSPPNCTELQIDSCSSSEEIKKKKYNQMPVRHSRNLQLMEGKEPATGAKKSNKPNEQTSKRHDSDTFPELKLTNAPGSFTKCSNTSELKEFVNPSLPREEKEEKLETVKVSNNAEDPKDLMLSGERVLQTERSVESSSISLVPGTDYGTQESISLLEVSTLGKAKTEPNKCVSQCAAFENPKGLIHGCSKDNRNDTEGFKYPLGHEVNHSRETSIEMEESELDAQYLQNTFKVSKRQSFAPFSNPGNAEEECATFSAHSGSLKKQSPKVTFECEQKEENQGKNESNIKPVQTVNITAGFPVVGQKDKPVDNAKCSIKGGSRFCLSSQFRGNETGLITPNKHGLLQNPYRIPPLFPIKSFVKTKCKKNLLEENFEEHSMSPEREMGNENIPSTVSTISRNNIRENVFKEASSSNINEVGSSTNEVGSSINEIGSSDENIQAELGRNRGPKLNAMLRLGVLQPEVYKQSLPGSNCKHPEIKKQEYEEVVQTVNTDFSPYLISDNLEQPMGSSHASQVCSETPDDLLDDGEIKEDTSFAENDIKESSAVFSKSVQKGELSRSPSPFTHTHLAQGYRRGAKKLESSEENLSSEDEELPCFQHLLFGKVNNIPSQSTRHSTVATECLSKNTEENLLSLKNSLNDCSNQVILAKASQEHHLSEETKCSASLFSSQCSELEDLTANTNTQDPFLIGSSKQMRHQSESQGVGLSDKELVSDDEERGTGLEENNQEEQSMDSNLGEAASGCESETSVSEDCSGLSSQSDILTTQQRDTMQHNLIKLQQEMAELEAVLEQHGSQPSNSYPSIISDSSALEDLRNPEQSTSEKAVLTSQKSSEYPISQNPEGLSADKFEVSADSSTSKNKEPGVERSSPSKCPSLDDRWYMHSCSGSLQNRNYPSQEELIKVVDVEEQQLEESGPHDLTETSYLPRQDLEGTPYLESGISLFSDDPESDPSEDRAPESARVGNIPSSTSALKVPQLKVAESAQSPAAAHTTDTAGYNAMEESVSREKPELTASTERVNKRMSMVVSGLTPEEFMLVYKFARKHHITLTNLITEETTHVVMKTDAEFVCERTLKYFLGIAGGKWVVSYFWVTQSIKERKMLNEHDFEVRGDVVNGRNHQGPKRARESQDRKIFRGLEICCYGPFTNMPTDQLEWMVQLCGASVVKELSSFTLGTGVHPIVVVQPDAWTEDNGFHAIGQMCEAPVVTREWVLDSVALYQCQELDTYLIPQIPHSHY	1863	P38398	G	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
602	NM_007294.4(BRCA1):c.5089T>C (p.Cys1697Arg)	55392	CA003228	NM_007294.4:c.5089T>C, NC_000017.11:g.43063937A>G, CM000679.2:g.43063937A>G, NC_000017.10:g.41215954A>G, CM000679.1:g.41215954A>G, NC_000017.9:g.38469480A>G, NG_005905.2:g.154047T>C, LRG_292:g.154047T>C, ENST00000461574.2:c.5086T>C, ENST00000470026.6:c.5089T>C, ENST00000473961.6:c.4963T>C, ENST00000476777.6:c.5083T>C, ENST00000477152.6:c.5011T>C, ENST00000478531.6:c.1777T>C, ENST00000489037.2:c.5011T>C, ENST00000493919.6:c.1639T>C, ENST00000494123.6:c.5089T>C, ENST00000497488.2:c.4201T>C, ENST00000618469.2:c.5089T>C, ENST00000634433.2:c.4966T>C, ENST00000644379.2:c.5155T>C, ENST00000644555.2:c.1639T>C, ENST00000652672.2:c.4948T>C, ENST00000484087.6:c.1651T>C, ENST00000357654.9:c.5089T>C, ENST00000471181.7:c.5152T>C, ENST00000644379.1:c.1476T>C, ENST00000352993.7:c.1663T>C, ENST00000357654.7:c.5089T>C, ENST00000461221.5:c.*4872T>C, ENST00000468300.5:c.1777T>C, ENST00000471181.6:c.5152T>C, ENST00000478531.5:c.1777T>C, ENST00000484087.5:c.1402T>C, ENST00000491747.6:c.1777T>C, ENST00000493795.5:c.4948T>C, ENST00000493919.5:c.1639T>C, ENST00000586385.5:c.19T>C, ENST00000591534.5:c.562T>C, ENST00000591849.5:c.-98-13747T>C, NM_007294.3:c.5089T>C, LRG_292t1:c.5089T>C, NM_007297.3:c.4948T>C, NM_007298.3:c.1777T>C, NM_007299.3:c.1777T>C, NM_007300.3:c.5152T>C, NR_027676.1:n.5225T>C, NM_007297.4:c.4948T>C, NM_007299.4:c.1777T>C, NM_007300.4:c.5152T>C, NR_027676.2:n.5266T>C, NM_007294.4(BRCA1):c.5089T>C (p.Cys1697Arg)	BRCA1	breast-ovarian cancer, familial, susceptibility to, 1	MONDO:0011450	Autosomal dominant inheritance	Pathogenic	PM2_Supporting, PP4_Strong, PS3, PP1_Moderate, PP3		The c.5089T>C variant in BRCA1 is a missense variant predicted to cause substitution of Cysteine by Arginine at amino acid 1697 (p.Cys1697Arg). This variant is absent from gnomAD v2.1 (exomes only, non-cancer subset, read depth ≥25) and gnomAD v3.1 (non-cancer subset, read depth ≥25) (PM2_Supporting met). This BRCA1 missense variant is within a key functional domain and the computational predictor BayesDel (noAF) gives a score of 0.40, above the recommended threshold of 0.28 for prediction of impact on BRCA1 function via protein change. SpliceAI predictor score of 0.05 suggests that the variant has no impact on splicing (score threshold <0.10) (PP3 met). Reported by three calibrated studies to exhibit protein function similar to pathogenic control variants (PMIDs: 30209399, 30257991, 30765603) (PS3 met). Cosegregation analysis of family(ies) carrying this variant provided evidence towards pathogenicity, and has a Bayes Score of 5.24, within the thresholds for moderate pathogenic evidence (LR >4.3 & ≤18.7) (PP1_Moderate met; internal lab contributor). Multifactorial likelihood ratio analysis using clinically calibrated data produced a combined LR for this variant of 2735.2 (based on Cosegregation LR=730.6; Pathology LR=2.41; Family History LR=1.56), above the thresholds for Very strong evidence towards pathogenicity (LR>350) (PP4_Very strong met; PMID: 31131967, 31853058).In summary, this variant meets the criteria to be classified as a Pathogenic variant for BRCA1-related cancer predisposition based on the ACMG/AMP criteria applied as specified by the ENIGMA BRCA1/2 VCEP (PM2_Supporting, PP3, PS3, PP1_Moderate, PP4_Very strong).	30765603, 30257991, 30209399	ENIGMA BRCA1 and BRCA2 VCEP		2024-04-23	2024-04-23	False	https://erepo.genome.network/evrepo/ui/classification/CA003228/MONDO:0011450/092	f967f72f-9e0d-4402-8841-91c26c03b30f	p.Cys1697Arg	Cys	1697	Arg	MDLSALRVEEVQNVINAMQKILECPICLELIKEPVSTKCDHIFCKFCMLKLLNQKKGPSQCPLCKNDITKRSLQESTRFSQLVEELLKIICAFQLDTGLEYANSYNFAKKENNSPEHLKDEVSIIQSMGYRNRAKRLLQSEPENPSLQETSLSVQLSNLGTVRTLRTKQRIQPQKTSVYIELGSDSSEDTVNKATYCSVGDQELLQITPQGTRDEISLDSAKKAACEFSETDVTNTEHHQPSNNDLNTTEKRAAERHPEKYQGSSVSNLHVEPCGTNTHASSLQHENSSLLLTKDRMNVEKAEFCNKSKQPGLARSQHNRWAGSKETCNDRRTPSTEKKVDLNADPLCERKEWNKQKLPCSENPRDTEDVPWITLNSSIQKVNEWFSRSDELLGSDDSHDGESESNAKVADVLDVLNEVDEYSGSSEKIDLLASDPHEALICKSERVHSKSVESNIEDKIFGKTYRKKASLPNLSHVTENLIIGAFVTEPQIIQERPLTNKLKRKRRPTSGLHPEDFIKKADLAVQKTPEMINQGTNQTEQNGQVMNITNSGHENKTKGDSIQNEKNPNPIESLEKESAFKTKAEPISSSISNMELELNIHNSKAPKKNRLRRKSSTRHIHALELVVSRNLSPPNCTELQIDSCSSSEEIKKKKYNQMPVRHSRNLQLMEGKEPATGAKKSNKPNEQTSKRHDSDTFPELKLTNAPGSFTKCSNTSELKEFVNPSLPREEKEEKLETVKVSNNAEDPKDLMLSGERVLQTERSVESSSISLVPGTDYGTQESISLLEVSTLGKAKTEPNKCVSQCAAFENPKGLIHGCSKDNRNDTEGFKYPLGHEVNHSRETSIEMEESELDAQYLQNTFKVSKRQSFAPFSNPGNAEEECATFSAHSGSLKKQSPKVTFECEQKEENQGKNESNIKPVQTVNITAGFPVVGQKDKPVDNAKCSIKGGSRFCLSSQFRGNETGLITPNKHGLLQNPYRIPPLFPIKSFVKTKCKKNLLEENFEEHSMSPEREMGNENIPSTVSTISRNNIRENVFKEASSSNINEVGSSTNEVGSSINEIGSSDENIQAELGRNRGPKLNAMLRLGVLQPEVYKQSLPGSNCKHPEIKKQEYEEVVQTVNTDFSPYLISDNLEQPMGSSHASQVCSETPDDLLDDGEIKEDTSFAENDIKESSAVFSKSVQKGELSRSPSPFTHTHLAQGYRRGAKKLESSEENLSSEDEELPCFQHLLFGKVNNIPSQSTRHSTVATECLSKNTEENLLSLKNSLNDCSNQVILAKASQEHHLSEETKCSASLFSSQCSELEDLTANTNTQDPFLIGSSKQMRHQSESQGVGLSDKELVSDDEERGTGLEENNQEEQSMDSNLGEAASGCESETSVSEDCSGLSSQSDILTTQQRDTMQHNLIKLQQEMAELEAVLEQHGSQPSNSYPSIISDSSALEDLRNPEQSTSEKAVLTSQKSSEYPISQNPEGLSADKFEVSADSSTSKNKEPGVERSSPSKCPSLDDRWYMHSCSGSLQNRNYPSQEELIKVVDVEEQQLEESGPHDLTETSYLPRQDLEGTPYLESGISLFSDDPESDPSEDRAPESARVGNIPSSTSALKVPQLKVAESAQSPAAAHTTDTAGYNAMEESVSREKPELTASTERVNKRMSMVVSGLTPEEFMLVYKFARKHHITLTNLITEETTHVVMKTDAEFVCERTLKYFLGIAGGKWVVSYFWVTQSIKERKMLNEHDFEVRGDVVNGRNHQGPKRARESQDRKIFRGLEICCYGPFTNMPTDQLEWMVQLCGASVVKELSSFTLGTGVHPIVVVQPDAWTEDNGFHAIGQMCEAPVVTREWVLDSVALYQCQELDTYLIPQIPHSHY	1863	P38398	R	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
603	NM_007294.4(BRCA1):c.5509T>G (p.Trp1837Gly)	55607	CA003681	NM_007294.4:c.5509T>G, NC_000017.11:g.43045761A>C, CM000679.2:g.43045761A>C, NC_000017.10:g.41197778A>C, CM000679.1:g.41197778A>C, NC_000017.9:g.38451304A>C, NG_005905.2:g.172223T>G, LRG_292:g.172223T>G, ENST00000357654.9:c.5509T>G, ENST00000471181.7:c.5572T>G, ENST00000644379.1:c.1896T>G, ENST00000352993.7:c.2083T>G, ENST00000357654.7:c.5509T>G, ENST00000461221.5:c.*5292T>G, ENST00000468300.5:c.*23T>G, ENST00000471181.6:c.5572T>G, ENST00000491747.6:c.2197T>G, ENST00000493795.5:c.5368T>G, ENST00000586385.5:c.439T>G, ENST00000591534.5:c.982T>G, ENST00000591849.5:c.208T>G, NM_007294.3:c.5509T>G, LRG_292t1:c.5509T>G, NM_007297.3:c.5368T>G, NM_007298.3:c.2197T>G, NM_007299.3:c.*23T>G, NM_007300.3:c.5572T>G, NR_027676.1:n.5645T>G, NM_007297.4:c.5368T>G, NM_007299.4:c.*23T>G, NM_007300.4:c.5572T>G, NR_027676.2:n.5686T>G, NM_007294.4(BRCA1):c.5509T>G (p.Trp1837Gly)	BRCA1	breast-ovarian cancer, familial, susceptibility to, 1	MONDO:0011450	Autosomal dominant inheritance	Pathogenic	PP4_Strong, PM2_Supporting, PP3	PS3, BS3	The c.5509T>G variant in BRCA1 is a missense variant predicted to cause substitution of Tryptophan by Glycine at amino acid 1837 (p.Trp1837Gly). This variant is absent from gnomAD v2.1 (exomes only, non-cancer subset, read depth ≥25) and gnomAD v3.1 (non-cancer subset, read depth ≥25) (PM2_Supporting met). This BRCA1 missense variant is within a key functional domain and the computational predictor BayesDel (noAF) gives a score of 0.533, above the recommended threshold of 0.28 for prediction of impact on BRCA1 function via protein change. SpliceAI predictor score of 0.00 suggests that the variant has no impact on splicing (score threshold <0.10) (PP3 met). Reported by three calibrated studies with discordant results. Exhibits protein function similar to pathogenic control variants (PMIDs: 30209399, 30765603) and between what was observed for benign and pathogenic control variants (PMID: 30257991) (PS3 and BS3 not met). Multifactorial likelihood ratio analysis using clinically calibrated data produced a combined LR for this variant of 2004.67 (based on Co-occurrence LR=1.067; Family History LR=1878.3), above the threshold for very strong evidence towards pathogenicity (>350) (PP4_Very strong met; PMIDs: 17924331, 31853058).In summary, this variant meets the criteria to be classified as a Pathogenic variant for BRCA1-related cancer predisposition based on the ACMG/AMP criteria applied as specified by the ENIGMA BRCA1/2 VCEP (PM2_Supporting, PP3, PP4_Very strong).		ENIGMA BRCA1 and BRCA2 VCEP		2023-10-10	2023-10-10	False	https://erepo.genome.network/evrepo/ui/classification/CA003681/MONDO:0011450/092	03c35580-6129-4df7-b7b4-8055d39efda1	p.Trp1837Gly	Trp	1837	Gly	MDLSALRVEEVQNVINAMQKILECPICLELIKEPVSTKCDHIFCKFCMLKLLNQKKGPSQCPLCKNDITKRSLQESTRFSQLVEELLKIICAFQLDTGLEYANSYNFAKKENNSPEHLKDEVSIIQSMGYRNRAKRLLQSEPENPSLQETSLSVQLSNLGTVRTLRTKQRIQPQKTSVYIELGSDSSEDTVNKATYCSVGDQELLQITPQGTRDEISLDSAKKAACEFSETDVTNTEHHQPSNNDLNTTEKRAAERHPEKYQGSSVSNLHVEPCGTNTHASSLQHENSSLLLTKDRMNVEKAEFCNKSKQPGLARSQHNRWAGSKETCNDRRTPSTEKKVDLNADPLCERKEWNKQKLPCSENPRDTEDVPWITLNSSIQKVNEWFSRSDELLGSDDSHDGESESNAKVADVLDVLNEVDEYSGSSEKIDLLASDPHEALICKSERVHSKSVESNIEDKIFGKTYRKKASLPNLSHVTENLIIGAFVTEPQIIQERPLTNKLKRKRRPTSGLHPEDFIKKADLAVQKTPEMINQGTNQTEQNGQVMNITNSGHENKTKGDSIQNEKNPNPIESLEKESAFKTKAEPISSSISNMELELNIHNSKAPKKNRLRRKSSTRHIHALELVVSRNLSPPNCTELQIDSCSSSEEIKKKKYNQMPVRHSRNLQLMEGKEPATGAKKSNKPNEQTSKRHDSDTFPELKLTNAPGSFTKCSNTSELKEFVNPSLPREEKEEKLETVKVSNNAEDPKDLMLSGERVLQTERSVESSSISLVPGTDYGTQESISLLEVSTLGKAKTEPNKCVSQCAAFENPKGLIHGCSKDNRNDTEGFKYPLGHEVNHSRETSIEMEESELDAQYLQNTFKVSKRQSFAPFSNPGNAEEECATFSAHSGSLKKQSPKVTFECEQKEENQGKNESNIKPVQTVNITAGFPVVGQKDKPVDNAKCSIKGGSRFCLSSQFRGNETGLITPNKHGLLQNPYRIPPLFPIKSFVKTKCKKNLLEENFEEHSMSPEREMGNENIPSTVSTISRNNIRENVFKEASSSNINEVGSSTNEVGSSINEIGSSDENIQAELGRNRGPKLNAMLRLGVLQPEVYKQSLPGSNCKHPEIKKQEYEEVVQTVNTDFSPYLISDNLEQPMGSSHASQVCSETPDDLLDDGEIKEDTSFAENDIKESSAVFSKSVQKGELSRSPSPFTHTHLAQGYRRGAKKLESSEENLSSEDEELPCFQHLLFGKVNNIPSQSTRHSTVATECLSKNTEENLLSLKNSLNDCSNQVILAKASQEHHLSEETKCSASLFSSQCSELEDLTANTNTQDPFLIGSSKQMRHQSESQGVGLSDKELVSDDEERGTGLEENNQEEQSMDSNLGEAASGCESETSVSEDCSGLSSQSDILTTQQRDTMQHNLIKLQQEMAELEAVLEQHGSQPSNSYPSIISDSSALEDLRNPEQSTSEKAVLTSQKSSEYPISQNPEGLSADKFEVSADSSTSKNKEPGVERSSPSKCPSLDDRWYMHSCSGSLQNRNYPSQEELIKVVDVEEQQLEESGPHDLTETSYLPRQDLEGTPYLESGISLFSDDPESDPSEDRAPESARVGNIPSSTSALKVPQLKVAESAQSPAAAHTTDTAGYNAMEESVSREKPELTASTERVNKRMSMVVSGLTPEEFMLVYKFARKHHITLTNLITEETTHVVMKTDAEFVCERTLKYFLGIAGGKWVVSYFWVTQSIKERKMLNEHDFEVRGDVVNGRNHQGPKRARESQDRKIFRGLEICCYGPFTNMPTDQLEWMVQLCGASVVKELSSFTLGTGVHPIVVVQPDAWTEDNGFHAIGQMCEAPVVTREWVLDSVALYQCQELDTYLIPQIPHSHY	1863	P38398	G	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [668], 'REGION_gain': [1350, 1359, 1440], 'REGION_gain_score': array([0.0082894 , 0.00807649, 0.00655907]), 'REGION_loss_score': array([-0.0154295]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
604	NM_000059.4(BRCA2):c.8149G>T (p.Ala2717Ser)	41564	CA025471	NM_000059.4:c.8149G>T, NC_000013.11:g.32363351G>T, CM000675.2:g.32363351G>T, NC_000013.10:g.32937488G>T, CM000675.1:g.32937488G>T, NC_000013.9:g.31835488G>T, NG_012772.3:g.52872G>T, LRG_293:g.52872G>T, ENST00000470094.2:c.8149G>T, ENST00000528762.2:c.8149G>T, ENST00000530893.7:c.7780G>T, ENST00000665585.2:c.8149G>T, ENST00000666593.2:c.8149G>T, ENST00000700202.2:c.8149G>T, ENST00000700202.1:c.616G>T, ENST00000380152.8:c.8149G>T, ENST00000544455.6:c.8149G>T, ENST00000614259.2:c.8157G>T, ENST00000665585.1:c.714G>T, ENST00000680887.1:c.8149G>T, ENST00000380152.7:c.8149G>T, ENST00000544455.5:c.8149G>T, NM_000059.3:c.8149G>T, LRG_293t1:c.8149G>T, XM_011535203.1:c.8149G>T, XM_011535204.1:c.8053G>T, XM_011535205.1:c.8149G>T, NM_000059.4(BRCA2):c.8149G>T (p.Ala2717Ser)	BRCA2	breast-ovarian cancer, familial, susceptibility to, 2	MONDO:0012933	Autosomal dominant inheritance	Benign	BP4, BA1, BP5_Strong, BS3, BS2		The c.8149G>T variant in BRCA2 is a missense variant predicted to cause substitution of Alanine by Serine at amino acid 2717 (p.Ala2717Ser). The highest non-cancer, non-founder population filter allele frequency in gnomAD v2.1 (exomes only, non-cancer subset, read depth ≥20) or gnomAD v3.1 (non-cancer subset, read depth ≥20) is 0.001751 in the Latino/Admixed American population, which is above the ENIGMA BRCA1/2 VCEP threshold (>0.001) for BA1 (BA1 met). This BRCA2 missense variant is within a key functional domain and the computational predictor BayesDel (noAF) gives a score of -0.0816, which is below the recommended threshold of 0.18 for predicting no impact on BRCA2 via protein change. SpliceAI predictor score of 0.03 suggests that the variant has no impact on splicing (score threshold <0.10) (BP4 met). Reported by 3 calibrated studies to exhibit protein function similar to benign control variants (PMIDs: 29988080, 33609447, 32444794) (BS3 met). This variant has been observed in 2 individuals with features considered inconsistent with an FA-associated phenotype, and (Likely) Pathogenic variant seen in trans or variant is homozygous (total score 4 points) (BS2 met; Invitae internal contributor). Multifactorial likelihood ratio analysis using clinically calibrated data produced a combined LR for this variant of 2.288E-117 (based on Cosegregation LR=4.52E-08; Pathology LR=5.249E-08; Family History LR=1.995E-19; Case-Control LR=4.83E-84), below the threshold for Very strong benign evidence (LR <0.00285) (BP5_Very strong met; PMID: Internal lab contributors).In summary, this variant meets the criteria to be classified as a Benign variant for BRCA2-related cancer predisposition based on the ACMG/AMP criteria applied as specified by the ENIGMA BRCA1/2 VCEP (BA1, BP4, BS3, BS2, BP5_Very strong).		ENIGMA BRCA1 and BRCA2 VCEP		2024-04-24	2024-04-24	False	https://erepo.genome.network/evrepo/ui/classification/CA025471/MONDO:0012933/097	85356a31-9019-465e-a963-2b1162997a9e	p.Ala2717Ser	Ala	2717	Ser	MPIGSKERPTFFEIFKTRCNKADLGPISLNWFEELSSEAPPYNSEPAEESEHKNNNYEPNLFKTPQRKPSYNQLASTPIIFKEQGLTLPLYQSPVKELDKFKLDLGRNVPNSRHKSLRTVKTKMDQADDVSCPLLNSCLSESPVVLQCTHVTPQRDKSVVCGSLFHTPKFVKGRQTPKHISESLGAEVDPDMSWSSSLATPPTLSSTVLIVRNEEASETVFPHDTTANVKSYFSNHDESLKKNDRFIASVTDSENTNQREAASHGFGKTSGNSFKVNSCKDHIGKSMPNVLEDEVYETVVDTSEEDSFSLCFSKCRTKNLQKVRTSKTRKKIFHEANADECEKSKNQVKEKYSFVSEVEPNDTDPLDSNVANQKPFESGSDKISKEVVPSLACEWSQLTLSGLNGAQMEKIPLLHISSCDQNISEKDLLDTENKRKKDFLTSENSLPRISSLPKSEKPLNEETVVNKRDEEQHLESHTDCILAVKQAISGTSPVASSFQGIKKSIFRIRESPKETFNASFSGHMTDPNFKKETEASESGLEIHTVCSQKEDSLCPNLIDNGSWPATTTQNSVALKNAGLISTLKKKTNKFIYAIHDETSYKGKKIPKDQKSELINCSAQFEANAFEAPLTFANADSGLLHSSVKRSCSQNDSEEPTLSLTSSFGTILRKCSRNETCSNNTVISQDLDYKEAKCNKEKLQLFITPEADSLSCLQEGQCENDPKSKKVSDIKEEVLAAACHPVQHSKVEYSDTDFQSQKSLLYDHENASTLILTPTSKDVLSNLVMISRGKESYKMSDKLKGNNYESDVELTKNIPMEKNQDVCALNENYKNVELLPPEKYMRVASPSRKVQFNQNTNLRVIQKNQEETTSISKITVNPDSEELFSDNENNFVFQVANERNNLALGNTKELHETDLTCVNEPIFKNSTMVLYGDTGDKQATQVSIKKDLVYVLAEENKNSVKQHIKMTLGQDLKSDISLNIDKIPEKNNDYMNKWAGLLGPISNHSFGGSFRTASNKEIKLSEHNIKKSKMFFKDIEEQYPTSLACVEIVNTLALDNQKKLSKPQSINTVSAHLQSSVVVSDCKNSHITPQMLFSKQDFNSNHNLTPSQKAEITELSTILEESGSQFEFTQFRKPSYILQKSTFEVPENQMTILKTTSEECRDADLHVIMNAPSIGQVDSSKQFEGTVEIKRKFAGLLKNDCNKSASGYLTDENEVGFRGFYSAHGTKLNVSTEALQKAVKLFSDIENISEETSAEVHPISLSSSKCHDSVVSMFKIENHNDKTVSEKNNKCQLILQNNIEMTTGTFVEEITENYKRNTENEDNKYTAASRNSHNLEFDGSDSSKNDTVCIHKDETDLLFTDQHNICLKLSGQFMKEGNTQIKEDLSDLTFLEVAKAQEACHGNTSNKEQLTATKTEQNIKDFETSDTFFQTASGKNISVAKESFNKIVNFFDQKPEELHNFSLNSELHSDIRKNKMDILSYEETDIVKHKILKESVPVGTGNQLVTFQGQPERDEKIKEPTLLGFHTASGKKVKIAKESLDKVKNLFDEKEQGTSEITSFSHQWAKTLKYREACKDLELACETIEITAAPKCKEMQNSLNNDKNLVSIETVVPPKLLSDNLCRQTENLKTSKSIFLKVKVHENVEKETAKSPATCYTNQSPYSVIENSALAFYTSCSRKTSVSQTSLLEAKKWLREGIFDGQPERINTADYVGNYLYENNSNSTIAENDKNHLSEKQDTYLSNSSMSNSYSYHSDEVYNDSGYLSKNKLDSGIEPVLKNVEDQKNTSFSKVISNVKDANAYPQTVNEDICVEELVTSSSPCKNKNAAIKLSISNSNNFEVGPPAFRIASGKIVCVSHETIKKVKDIFTDSFSKVIKENNENKSKICQTKIMAGCYEALDDSEDILHNSLDNDECSTHSHKVFADIQSEEILQHNQNMSGLEKVSKISPCDVSLETSDICKCSIGKLHKSVSSANTCGIFSTASGKSVQVSDASLQNARQVFSEIEDSTKQVFSKVLFKSNEHSDQLTREENTAIRTPEHLISQKGFSYNVVNSSAFSGFSTASGKQVSILESSLHKVKGVLEEFDLIRTEHSLHYSPTSRQNVSKILPRVDKRNPEHCVNSEMEKTCSKEFKLSNNLNVEGGSSENNHSIKVSPYLSQFQQDKQQLVLGTKVSLVENIHVLGKEQASPKNVKMEIGKTETFSDVPVKTNIEVCSTYSKDSENYFETEAVEIAKAFMEDDELTDSKLPSHATHSLFTCPENEEMVLSNSRIGKRRGEPLILVGEPSIKRNLLNEFDRIIENQEKSLKASKSTPDGTIKDRRLFMHHVSLEPITCVPFRTTKERQEIQNPNFTAPGQEFLSKSHLYEHLTLEKSSSNLAVSGHPFYQVSATRNEKMRHLITTGRPTKVFVPPFKTKSHFHRVEQCVRNINLEENRQKQNIDGHGSDDSKNKINDNEIHQFNKNNSNQAVAVTFTKCEEEPLDLITSLQNARDIQDMRIKKKQRQRVFPQPGSLYLAKTSTLPRISLKAAVGGQVPSACSHKQLYTYGVSKHCIKINSKNAESFQFHTEDYFGKESLWTGKGIQLADGGWLIPSNDGKAGKEEFYRALCDTPGVDPKLISRIWVYNHYRWIIWKLAAMECAFPKEFANRCLSPERVLLQLKYRYDTEIDRSRRSAIKKIMERDDTAAKTLVLCVSDIISLSANISETSSNKTSSADTQKVAIIELTDGWYAVKAQLDPPLLAVLKNGRLTVGQKIILHGAELVGSPDACTPLEAPESLMLKISANSTRPARWYTKLGFFPDPRPFPLPLSSLFSDGGNVGCVDVIIQRAYPIQWMEKTSSGLYIFRNEREEEKEAAKYVEAQQKRLEALFTKIQEEFEEHEENTTKPYLPSRALTRQQVRALQDGAELYEAVKNAADPAYLEGYFSEEQLRALNNHRQMLNDKKQAQIQLEIRKAMESAEQKEQGLSRDVTTVWKLRIVSYSKKEKDSVILSIWRPSSDLYSLLTEGKRYRIYHLATSKSKSKSERANIQLAATKKTQYQQLPVSDEILFQIYQPREPLHFSKFLDPDFQPSCSEVDLIGFVVSVVKKTGLAPFVYLSDECYNLLAIKFWIDLNEDIIKPHMLIAASNLQWRPESKSGLLTLFAGDFSVFSASPKEGHFQETFNKMKNTVENIDILCNEAENKLMHILHANDPKWSTPTKDCTSGPYTAQIIPGTGNKLLMSSPNCEIYYQSPLSLCMAKRKSVSTPVSAQMTSKSCKGEKEIDDQKNCKKRRALDFLSRLPLPPPVSPICTFVSPAAQKAFQPPRSCGTKYETPIKKKELNSPQMTPFKKFNEISLLESNSIADEELALINTQALLSGSTGEKQFISVSESTRTAPTSSEDYLRLKRRCTTSLIKEQESSQASTEECEKNKQDTITTKKYI	3418	P51587	S	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [839], 'REPEAT_gain_score': array([0.00074112]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
605	NM_000059.4(BRCA2):c.8168A>C (p.Asp2723Ala)	52516	CA025483	NM_000059.4:c.8168A>C, NC_000013.11:g.32363370A>C, CM000675.2:g.32363370A>C, NC_000013.10:g.32937507A>C, CM000675.1:g.32937507A>C, NC_000013.9:g.31835507A>C, NG_012772.3:g.52891A>C, LRG_293:g.52891A>C, ENST00000470094.2:c.8168A>C, ENST00000528762.2:c.8168A>C, ENST00000530893.7:c.7799A>C, ENST00000665585.2:c.8168A>C, ENST00000666593.2:c.8168A>C, ENST00000700202.2:c.8168A>C, ENST00000700202.1:c.635A>C, ENST00000380152.8:c.8168A>C, ENST00000544455.6:c.8168A>C, ENST00000614259.2:c.8176A>C, ENST00000665585.1:c.733A>C, ENST00000680887.1:c.8168A>C, ENST00000380152.7:c.8168A>C, ENST00000544455.5:c.8168A>C, NM_000059.3:c.8168A>C, LRG_293t1:c.8168A>C, XM_011535203.1:c.8168A>C, XM_011535204.1:c.8072A>C, XM_011535205.1:c.8168A>C, NM_000059.4(BRCA2):c.8168A>C (p.Asp2723Ala)	BRCA2	breast-ovarian cancer, familial, susceptibility to, 2	MONDO:0012933	Autosomal dominant inheritance	Pathogenic	PS3, PP1_Strong, PP3	BA1, BP5, BS1, PM2, PP4	The c.8168A>C variant in BRCA2 is a missense variant predicted to cause substitution of Aspartic acid by Alanine at amino acid 2723 (p.Asp2723Ala). This variant is present in gnomAD v2.1 (exomes only, non-cancer subset) or gnomAD v3.1 (non-cancer subset) but is below the ENIGMA BRCA1/2 VCEP threshold >0.00002 for BS1_Supporting (PM2_Supporting, BS1, and BA1 are not met). This BRCA2 missense variant is within a key functional domain and the computational predictor BayesDel (noAF) gives a score of 0.576, above the recommended threshold of 0.30 for prediction of impact on BRCA2 function via protein change. SpliceAI predictor score of 0.00 suggests that the variant has no impact on splicing (score threshold <0.10) (PP3 met). Reported by two calibrated studies to exhibit protein function similar to pathogenic control variants (PMIDs: 33609447, 33293522) (PS3 met). Multifactorial likelihood ratio analysis using clinically calibrated data produced a combined LR for this variant of 0.557 (based on Pathology LR=0.214; Co-occurrence LR=1.102; Family History LR=2.36), which is above the ENIGMA BRCA1/2 VCEP threshold for BP5 (>0.48) and below PP4 (<2.08) (BP5 and PP4 not met; 31853058, Internal lab contributors). Cosegregation analysis of family(ies) carrying this variant provided evidence towards pathogenicity, and has a Bayes Score of 74321.3, above the thresholds for Very strong pathogenic evidence (LR >350) (PP1_Very strong; Internal lab contributors).In summary, this variant meets the criteria to be classified as a Pathogenic variant variant for BRCA2-related cancer predisposition based on the ACMG/AMP criteria applied as specified by the ENIGMA BRCA1/2 VCEP (PP3, PS3, PP1_Very strong).	33293522, 33609447	ENIGMA BRCA1 and BRCA2 VCEP		2024-04-24	2024-04-24	False	https://erepo.genome.network/evrepo/ui/classification/CA025483/MONDO:0012933/097	4ba6ceec-f98a-4a5b-8b20-b69a86adda01	p.Asp2723Ala	Asp	2723	Ala	MPIGSKERPTFFEIFKTRCNKADLGPISLNWFEELSSEAPPYNSEPAEESEHKNNNYEPNLFKTPQRKPSYNQLASTPIIFKEQGLTLPLYQSPVKELDKFKLDLGRNVPNSRHKSLRTVKTKMDQADDVSCPLLNSCLSESPVVLQCTHVTPQRDKSVVCGSLFHTPKFVKGRQTPKHISESLGAEVDPDMSWSSSLATPPTLSSTVLIVRNEEASETVFPHDTTANVKSYFSNHDESLKKNDRFIASVTDSENTNQREAASHGFGKTSGNSFKVNSCKDHIGKSMPNVLEDEVYETVVDTSEEDSFSLCFSKCRTKNLQKVRTSKTRKKIFHEANADECEKSKNQVKEKYSFVSEVEPNDTDPLDSNVANQKPFESGSDKISKEVVPSLACEWSQLTLSGLNGAQMEKIPLLHISSCDQNISEKDLLDTENKRKKDFLTSENSLPRISSLPKSEKPLNEETVVNKRDEEQHLESHTDCILAVKQAISGTSPVASSFQGIKKSIFRIRESPKETFNASFSGHMTDPNFKKETEASESGLEIHTVCSQKEDSLCPNLIDNGSWPATTTQNSVALKNAGLISTLKKKTNKFIYAIHDETSYKGKKIPKDQKSELINCSAQFEANAFEAPLTFANADSGLLHSSVKRSCSQNDSEEPTLSLTSSFGTILRKCSRNETCSNNTVISQDLDYKEAKCNKEKLQLFITPEADSLSCLQEGQCENDPKSKKVSDIKEEVLAAACHPVQHSKVEYSDTDFQSQKSLLYDHENASTLILTPTSKDVLSNLVMISRGKESYKMSDKLKGNNYESDVELTKNIPMEKNQDVCALNENYKNVELLPPEKYMRVASPSRKVQFNQNTNLRVIQKNQEETTSISKITVNPDSEELFSDNENNFVFQVANERNNLALGNTKELHETDLTCVNEPIFKNSTMVLYGDTGDKQATQVSIKKDLVYVLAEENKNSVKQHIKMTLGQDLKSDISLNIDKIPEKNNDYMNKWAGLLGPISNHSFGGSFRTASNKEIKLSEHNIKKSKMFFKDIEEQYPTSLACVEIVNTLALDNQKKLSKPQSINTVSAHLQSSVVVSDCKNSHITPQMLFSKQDFNSNHNLTPSQKAEITELSTILEESGSQFEFTQFRKPSYILQKSTFEVPENQMTILKTTSEECRDADLHVIMNAPSIGQVDSSKQFEGTVEIKRKFAGLLKNDCNKSASGYLTDENEVGFRGFYSAHGTKLNVSTEALQKAVKLFSDIENISEETSAEVHPISLSSSKCHDSVVSMFKIENHNDKTVSEKNNKCQLILQNNIEMTTGTFVEEITENYKRNTENEDNKYTAASRNSHNLEFDGSDSSKNDTVCIHKDETDLLFTDQHNICLKLSGQFMKEGNTQIKEDLSDLTFLEVAKAQEACHGNTSNKEQLTATKTEQNIKDFETSDTFFQTASGKNISVAKESFNKIVNFFDQKPEELHNFSLNSELHSDIRKNKMDILSYEETDIVKHKILKESVPVGTGNQLVTFQGQPERDEKIKEPTLLGFHTASGKKVKIAKESLDKVKNLFDEKEQGTSEITSFSHQWAKTLKYREACKDLELACETIEITAAPKCKEMQNSLNNDKNLVSIETVVPPKLLSDNLCRQTENLKTSKSIFLKVKVHENVEKETAKSPATCYTNQSPYSVIENSALAFYTSCSRKTSVSQTSLLEAKKWLREGIFDGQPERINTADYVGNYLYENNSNSTIAENDKNHLSEKQDTYLSNSSMSNSYSYHSDEVYNDSGYLSKNKLDSGIEPVLKNVEDQKNTSFSKVISNVKDANAYPQTVNEDICVEELVTSSSPCKNKNAAIKLSISNSNNFEVGPPAFRIASGKIVCVSHETIKKVKDIFTDSFSKVIKENNENKSKICQTKIMAGCYEALDDSEDILHNSLDNDECSTHSHKVFADIQSEEILQHNQNMSGLEKVSKISPCDVSLETSDICKCSIGKLHKSVSSANTCGIFSTASGKSVQVSDASLQNARQVFSEIEDSTKQVFSKVLFKSNEHSDQLTREENTAIRTPEHLISQKGFSYNVVNSSAFSGFSTASGKQVSILESSLHKVKGVLEEFDLIRTEHSLHYSPTSRQNVSKILPRVDKRNPEHCVNSEMEKTCSKEFKLSNNLNVEGGSSENNHSIKVSPYLSQFQQDKQQLVLGTKVSLVENIHVLGKEQASPKNVKMEIGKTETFSDVPVKTNIEVCSTYSKDSENYFETEAVEIAKAFMEDDELTDSKLPSHATHSLFTCPENEEMVLSNSRIGKRRGEPLILVGEPSIKRNLLNEFDRIIENQEKSLKASKSTPDGTIKDRRLFMHHVSLEPITCVPFRTTKERQEIQNPNFTAPGQEFLSKSHLYEHLTLEKSSSNLAVSGHPFYQVSATRNEKMRHLITTGRPTKVFVPPFKTKSHFHRVEQCVRNINLEENRQKQNIDGHGSDDSKNKINDNEIHQFNKNNSNQAVAVTFTKCEEEPLDLITSLQNARDIQDMRIKKKQRQRVFPQPGSLYLAKTSTLPRISLKAAVGGQVPSACSHKQLYTYGVSKHCIKINSKNAESFQFHTEDYFGKESLWTGKGIQLADGGWLIPSNDGKAGKEEFYRALCDTPGVDPKLISRIWVYNHYRWIIWKLAAMECAFPKEFANRCLSPERVLLQLKYRYDTEIDRSRRSAIKKIMERDDTAAKTLVLCVSDIISLSANISETSSNKTSSADTQKVAIIELTDGWYAVKAQLDPPLLAVLKNGRLTVGQKIILHGAELVGSPDACTPLEAPESLMLKISANSTRPARWYTKLGFFPDPRPFPLPLSSLFSDGGNVGCVDVIIQRAYPIQWMEKTSSGLYIFRNEREEEKEAAKYVEAQQKRLEALFTKIQEEFEEHEENTTKPYLPSRALTRQQVRALQDGAELYEAVKNAADPAYLEGYFSEEQLRALNNHRQMLNDKKQAQIQLEIRKAMESAEQKEQGLSRDVTTVWKLRIVSYSKKEKDSVILSIWRPSSDLYSLLTEGKRYRIYHLATSKSKSKSERANIQLAATKKTQYQQLPVSDEILFQIYQPREPLHFSKFLDPDFQPSCSEVDLIGFVVSVVKKTGLAPFVYLSDECYNLLAIKFWIDLNEDIIKPHMLIAASNLQWRPESKSGLLTLFAGDFSVFSASPKEGHFQETFNKMKNTVENIDILCNEAENKLMHILHANDPKWSTPTKDCTSGPYTAQIIPGTGNKLLMSSPNCEIYYQSPLSLCMAKRKSVSTPVSAQMTSKSCKGEKEIDDQKNCKKRRALDFLSRLPLPPPVSPICTFVSPAAQKAFQPPRSCGTKYETPIKKKELNSPQMTPFKKFNEISLLESNSIADEELALINTQALLSGSTGEKQFISVSESTRTAPTSSEDYLRLKRRCTTSLIKEQESSQASTEECEKNKQDTITTKKYI	3418	P51587	A	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [839], 'REPEAT_gain_score': array([0.00069797]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
606	NM_000059.4(BRCA2):c.9227G>T (p.Gly3076Val)	126203	CA026041	NM_000059.4:c.9227G>T, NC_000013.11:g.32380116G>T, CM000675.2:g.32380116G>T, NC_000013.10:g.32954253G>T, CM000675.1:g.32954253G>T, NC_000013.9:g.31852253G>T, NG_012772.3:g.69637G>T, LRG_293:g.69637G>T, ENST00000470094.2:c.9227G>T, ENST00000528762.2:c.*594G>T, ENST00000530893.7:c.8858G>T, ENST00000665585.2:c.*789G>T, ENST00000666593.2:c.9227G>T, ENST00000700202.2:c.9176G>T, ENST00000700202.1:c.1643G>T, ENST00000700203.1:n.1354G>T, ENST00000380152.8:c.9227G>T, ENST00000544455.6:c.9227G>T, ENST00000614259.2:c.9235G>T, ENST00000665585.1:c.2105G>T, ENST00000666593.1:c.110G>T, ENST00000680887.1:c.9227G>T, ENST00000380152.7:c.9227G>T, ENST00000470094.1:c.184G>T, ENST00000544455.5:c.9227G>T, NM_000059.3:c.9227G>T, LRG_293t1:c.9227G>T, XM_011535203.1:c.9227G>T, XM_011535204.1:c.9131G>T, NM_000059.4(BRCA2):c.9227G>T (p.Gly3076Val)	BRCA2	breast-ovarian cancer, familial, susceptibility to, 2	MONDO:0012933	Autosomal dominant inheritance	Pathogenic	PS3, PP4_Strong, PP3, PM2_Supporting		The variant c.9227G>T in BRCA2 is a missense variant predicted to cause substitution of Glycine by Valine at amino acid 3076 (p.Gly3076Val). This variant is absent from gnomAD v2.1 (exomes only, non-cancer subset, read depth ≥25) and gnomAD v3.1 (non-cancer subset, read depth ≥25) (PM2_Supporting met). This BRCA2 missense variant is within a key functional domain and the computational predictor BayesDel (noAF) gives a score of 0.398, above the recommended threshold of 0.30 for prediction of impact on BRCA2 function via protein change. SpliceAI predictor score of 0.01 suggests that the variant has no impact on splicing (score threshold <0.10) (PP3 met). Reported by one calibrated study to exhibit protein function similar to pathogenic control variants (PMID: 33609447) (PS3 met). Multifactorial likelihood ratio analysis using clinically calibrated data produced a combined LR for this variant of 3104.98 (based on Cosegregation LR=770.85; Pathology LR=1.89; Co-occurrence LR=1.08; Family History LR=1.98), above the threshold for Very strong evidence towards pathogenicity (LR >350) (PP4_Very strong met; PMID: 31853058, Internal lab contributors).In summary, this variant meets the criteria to be classified as a Pathogenic variant for BRCA2-related cancer predisposition based on the ACMG/AMP criteria applied as specified by the ENIGMA BRCA1/2 VCEP (PM2_Supporting, PP3, PS3, PP4_Very strong).	33609447	ENIGMA BRCA1 and BRCA2 VCEP		2024-04-24	2024-04-24	False	https://erepo.genome.network/evrepo/ui/classification/CA026041/MONDO:0012933/097	99aead68-b6f2-4ef5-9fc4-2e8ea5567bf1	p.Gly3076Val	Gly	3076	Val	MPIGSKERPTFFEIFKTRCNKADLGPISLNWFEELSSEAPPYNSEPAEESEHKNNNYEPNLFKTPQRKPSYNQLASTPIIFKEQGLTLPLYQSPVKELDKFKLDLGRNVPNSRHKSLRTVKTKMDQADDVSCPLLNSCLSESPVVLQCTHVTPQRDKSVVCGSLFHTPKFVKGRQTPKHISESLGAEVDPDMSWSSSLATPPTLSSTVLIVRNEEASETVFPHDTTANVKSYFSNHDESLKKNDRFIASVTDSENTNQREAASHGFGKTSGNSFKVNSCKDHIGKSMPNVLEDEVYETVVDTSEEDSFSLCFSKCRTKNLQKVRTSKTRKKIFHEANADECEKSKNQVKEKYSFVSEVEPNDTDPLDSNVANQKPFESGSDKISKEVVPSLACEWSQLTLSGLNGAQMEKIPLLHISSCDQNISEKDLLDTENKRKKDFLTSENSLPRISSLPKSEKPLNEETVVNKRDEEQHLESHTDCILAVKQAISGTSPVASSFQGIKKSIFRIRESPKETFNASFSGHMTDPNFKKETEASESGLEIHTVCSQKEDSLCPNLIDNGSWPATTTQNSVALKNAGLISTLKKKTNKFIYAIHDETSYKGKKIPKDQKSELINCSAQFEANAFEAPLTFANADSGLLHSSVKRSCSQNDSEEPTLSLTSSFGTILRKCSRNETCSNNTVISQDLDYKEAKCNKEKLQLFITPEADSLSCLQEGQCENDPKSKKVSDIKEEVLAAACHPVQHSKVEYSDTDFQSQKSLLYDHENASTLILTPTSKDVLSNLVMISRGKESYKMSDKLKGNNYESDVELTKNIPMEKNQDVCALNENYKNVELLPPEKYMRVASPSRKVQFNQNTNLRVIQKNQEETTSISKITVNPDSEELFSDNENNFVFQVANERNNLALGNTKELHETDLTCVNEPIFKNSTMVLYGDTGDKQATQVSIKKDLVYVLAEENKNSVKQHIKMTLGQDLKSDISLNIDKIPEKNNDYMNKWAGLLGPISNHSFGGSFRTASNKEIKLSEHNIKKSKMFFKDIEEQYPTSLACVEIVNTLALDNQKKLSKPQSINTVSAHLQSSVVVSDCKNSHITPQMLFSKQDFNSNHNLTPSQKAEITELSTILEESGSQFEFTQFRKPSYILQKSTFEVPENQMTILKTTSEECRDADLHVIMNAPSIGQVDSSKQFEGTVEIKRKFAGLLKNDCNKSASGYLTDENEVGFRGFYSAHGTKLNVSTEALQKAVKLFSDIENISEETSAEVHPISLSSSKCHDSVVSMFKIENHNDKTVSEKNNKCQLILQNNIEMTTGTFVEEITENYKRNTENEDNKYTAASRNSHNLEFDGSDSSKNDTVCIHKDETDLLFTDQHNICLKLSGQFMKEGNTQIKEDLSDLTFLEVAKAQEACHGNTSNKEQLTATKTEQNIKDFETSDTFFQTASGKNISVAKESFNKIVNFFDQKPEELHNFSLNSELHSDIRKNKMDILSYEETDIVKHKILKESVPVGTGNQLVTFQGQPERDEKIKEPTLLGFHTASGKKVKIAKESLDKVKNLFDEKEQGTSEITSFSHQWAKTLKYREACKDLELACETIEITAAPKCKEMQNSLNNDKNLVSIETVVPPKLLSDNLCRQTENLKTSKSIFLKVKVHENVEKETAKSPATCYTNQSPYSVIENSALAFYTSCSRKTSVSQTSLLEAKKWLREGIFDGQPERINTADYVGNYLYENNSNSTIAENDKNHLSEKQDTYLSNSSMSNSYSYHSDEVYNDSGYLSKNKLDSGIEPVLKNVEDQKNTSFSKVISNVKDANAYPQTVNEDICVEELVTSSSPCKNKNAAIKLSISNSNNFEVGPPAFRIASGKIVCVSHETIKKVKDIFTDSFSKVIKENNENKSKICQTKIMAGCYEALDDSEDILHNSLDNDECSTHSHKVFADIQSEEILQHNQNMSGLEKVSKISPCDVSLETSDICKCSIGKLHKSVSSANTCGIFSTASGKSVQVSDASLQNARQVFSEIEDSTKQVFSKVLFKSNEHSDQLTREENTAIRTPEHLISQKGFSYNVVNSSAFSGFSTASGKQVSILESSLHKVKGVLEEFDLIRTEHSLHYSPTSRQNVSKILPRVDKRNPEHCVNSEMEKTCSKEFKLSNNLNVEGGSSENNHSIKVSPYLSQFQQDKQQLVLGTKVSLVENIHVLGKEQASPKNVKMEIGKTETFSDVPVKTNIEVCSTYSKDSENYFETEAVEIAKAFMEDDELTDSKLPSHATHSLFTCPENEEMVLSNSRIGKRRGEPLILVGEPSIKRNLLNEFDRIIENQEKSLKASKSTPDGTIKDRRLFMHHVSLEPITCVPFRTTKERQEIQNPNFTAPGQEFLSKSHLYEHLTLEKSSSNLAVSGHPFYQVSATRNEKMRHLITTGRPTKVFVPPFKTKSHFHRVEQCVRNINLEENRQKQNIDGHGSDDSKNKINDNEIHQFNKNNSNQAVAVTFTKCEEEPLDLITSLQNARDIQDMRIKKKQRQRVFPQPGSLYLAKTSTLPRISLKAAVGGQVPSACSHKQLYTYGVSKHCIKINSKNAESFQFHTEDYFGKESLWTGKGIQLADGGWLIPSNDGKAGKEEFYRALCDTPGVDPKLISRIWVYNHYRWIIWKLAAMECAFPKEFANRCLSPERVLLQLKYRYDTEIDRSRRSAIKKIMERDDTAAKTLVLCVSDIISLSANISETSSNKTSSADTQKVAIIELTDGWYAVKAQLDPPLLAVLKNGRLTVGQKIILHGAELVGSPDACTPLEAPESLMLKISANSTRPARWYTKLGFFPDPRPFPLPLSSLFSDGGNVGCVDVIIQRAYPIQWMEKTSSGLYIFRNEREEEKEAAKYVEAQQKRLEALFTKIQEEFEEHEENTTKPYLPSRALTRQQVRALQDGAELYEAVKNAADPAYLEGYFSEEQLRALNNHRQMLNDKKQAQIQLEIRKAMESAEQKEQGLSRDVTTVWKLRIVSYSKKEKDSVILSIWRPSSDLYSLLTEGKRYRIYHLATSKSKSKSERANIQLAATKKTQYQQLPVSDEILFQIYQPREPLHFSKFLDPDFQPSCSEVDLIGFVVSVVKKTGLAPFVYLSDECYNLLAIKFWIDLNEDIIKPHMLIAASNLQWRPESKSGLLTLFAGDFSVFSASPKEGHFQETFNKMKNTVENIDILCNEAENKLMHILHANDPKWSTPTKDCTSGPYTAQIIPGTGNKLLMSSPNCEIYYQSPLSLCMAKRKSVSTPVSAQMTSKSCKGEKEIDDQKNCKKRRALDFLSRLPLPPPVSPICTFVSPAAQKAFQPPRSCGTKYETPIKKKELNSPQMTPFKKFNEISLLESNSIADEELALINTQALLSGSTGEKQFISVSESTRTAPTSSEDYLRLKRRCTTSLIKEQESSQASTEECEKNKQDTITTKKYI	3418	P51587	V	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [839], 'REPEAT_gain_score': array([0.00097066]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
607	NM_000162.5(GCK):c.790G>A (p.Gly264Ser)	21078	CA341589	NM_000162.5:c.790G>A, NC_000007.14:g.44147723C>T, CM000669.2:g.44147723C>T, NC_000007.13:g.44187322C>T, CM000669.1:g.44187322C>T, NC_000007.12:g.44153847C>T, NG_008847.1:g.46701G>A, NG_008847.2:g.55448G>A, ENST00000395796.8:c.*788G>A, ENST00000616242.5:c.790G>A, ENST00000345378.7:c.793G>A, ENST00000403799.8:c.790G>A, ENST00000671824.1:c.790G>A, ENST00000673284.1:c.790G>A, ENST00000345378.6:c.793G>A, ENST00000395796.7:c.787G>A, ENST00000403799.7:c.790G>A, ENST00000437084.1:c.739G>A, ENST00000616242.4:c.787G>A, NM_000162.3:c.790G>A, NM_033507.1:c.793G>A, NM_033508.1:c.787G>A, XR_927223.1:n.57C>T, NM_000162.4:c.790G>A, NM_001354800.1:c.790G>A, NM_033507.2:c.793G>A, NM_033508.2:c.787G>A, XR_927223.2:n.57C>T, NM_033507.3:c.793G>A, NM_033508.3:c.787G>A, NM_000162.5(GCK):c.790G>A (p.Gly264Ser)	GCK	monogenic diabetes	MONDO:0015967	Semidominant inheritance	Pathogenic	PS4, PM3_Strong, PP1_Strong, PP4_Moderate, PP2, PP3, PM2_Supporting	PS3, PM1	The c.790G>A variant in the glucokinase gene, GCK, causes an amino acid change of glycine to serine at codon 264 (p.(Gly264Ser)) of NM_000162.5.  This variant is absent from gnomAD v2.1.1 (PM2_Supporting).  This variant was identified in 7  unrelated individuals with hyperglycemia (PS4; PMID: 11508276, internal lab contributors).  This variant was identified in an individual with a clinical history highly specific for GCK-hyperglycemia (FBG 5.5-8 mmol/L and HbA1c 5.6 - 7.6% and negative antibodies) (PP4_Moderate, internal lab contributors).  This variant segregated with diabetes/hyperglycemia, with 4 informative meioses in 2 families (PP1_Strong; PMID: 16026363s, internal lab contributors). This variant has been detected in two individuals with neonatal diabetes. Both were compound heterozygous (confirmed in trans) for this variant and another variant classified as pathogenic by ClinGen MDEP (PM3_Strong; PMIDs:  14578306, 16026363, internal lab contributors).  GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2).  This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.847, which is greater than the MDEP VCEP threshold of 0.70 (PP3).   The Relative Activity Index (RAI) of this variant was found to be above the MDEP cutoff (0.5) for PS3_Moderate.  While the p.Gly264Ser variant has been reported to cause protein misfolding, this is not considered to meet criteria for applying PS3_Supporting by the ClinGen MDEP (PMIDs: 22820548, 14578306, 16731834, https://doi.org/10.1159/000079009).  In summary, c.790G>A meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.3.0, approved 8/11/2023): PP1_Strong, PS4, PP4_Moderate, PM3_Strong, PP2, PP3, PM2_Supporting.		Monogenic Diabetes VCEP		2023-11-02	2023-11-02	False	https://erepo.genome.network/evrepo/ui/classification/CA341589/MONDO:0015967/086	a0bd4d0f-fd6d-43b1-b64a-12ff1f71245d	p.Gly264Ser	Gly	264	Ser	MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQ	465	P35557	S	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [264], 'HELIX_gain_score': array([0.27950859]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [11, 21], 'REGION_gain_score': array([0.00434393, 0.00340641]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
608	NM_000419.5(ITGA2B):c.2511G>C (p.Gln837His)	323545	CA8602661	NM_000419.5:c.2511G>C, NC_000017.11:g.44375923C>G, CM000679.2:g.44375923C>G, NC_000017.10:g.42453291C>G, CM000679.1:g.42453291C>G, NC_000017.9:g.39808817C>G, NG_008331.1:g.18583G>C, LRG_479:g.18583G>C, ENST00000262407.6:c.2511G>C, ENST00000648408.1:c.1942G>C, ENST00000262407.5:c.2511G>C, ENST00000587295.5:c.163G>C, ENST00000592462.5:n.1306G>C, NM_000419.3:c.2511G>C, LRG_479t1:c.2511G>C, XM_011524749.1:c.2511G>C, XM_011524750.1:c.2511G>C, NM_000419.4:c.2511G>C, NM_000419.5(ITGA2B):c.2511G>C (p.Gln837His)	ITGA2B	Glanzmann thrombasthenia	MONDO:0100326	Autosomal recessive inheritance	Benign	BA1, BP4		The c.2511G>C variant in ITGA2B is a missense variant predicted to cause substitution of Glutamine by Histidine at amino acid 837 (p.Gln837His). The highest population minor allele frequency in gnomAD v2.1.1 is 0.01740 (530/30456 alleles) in the South Asian population, which is higher than the ClinGen PD VCEP threshold (>0.0024) for BA1, and therefore meets this criterion (BA1). The computational predictor REVEL gives a score of 0.197, which is below the ClinGen PD VCEP threshold of <0.25 and predicts no damaging effect on ITGA2B function (BP4). In summary, this variant meets the criteria to be classified as Benign for autosomal recessive Glanzmann Thrombasthenia based on the ACMG/AMP criteria applied, as specified by the ClinGen PD VCEP: BA1 and BP4 (VCEP specifications version 2).		Platelet Disorders VCEP	https://clinicalgenome.org/docs/clingen-platelet-disorders-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-2.1/	2023-10-17	2023-10-17	False	https://erepo.genome.network/evrepo/ui/classification/CA8602661/MONDO:0100326/011	30381c7f-905f-4666-9898-4cec7195fb7d	p.Gln837His	Gln	837	His	MARALCPLQALWLLEWVLLLLGPCAAPPAWALNLDPVQLTFYAGPNGSQFGFSLDFHKDSHGRVAIVVGAPRTLGPSQEETGGVFLCPWRAEGGQCPSLLFDLRDETRNVGSQTLQTFKARQGLGASVVSWSDVIVACAPWQHWNVLEKTEEAEKTPVGSCFLAQPESGRRAEYSPCRGNTLSRIYVENDFSWDKRYCEAGFSSVVTQAGELVLGAPGGYYFLGLLAQAPVADIFSSYRPGILLWHVSSQSLSFDSSNPEYFDGYWGYSVAVGEFDGDLNTTEYVVGAPTWSWTLGAVEILDSYYQRLHRLRGEQMASYFGHSVAVTDVNGDGRHDLLVGAPLYMESRADRKLAEVGRVYLFLQPRGPHALGAPSLLLTGTQLYGRFGSAIAPLGDLDRDGYNDIAVAAPYGGPSGRGQVLVFLGQSEGLRSRPSQVLDSPFPTGSAFGFSLRGAVDIDDNGYPDLIVGAYGANQVAVYRAQPVVKASVQLLVQDSLNPAVKSCVLPQTKTPVSCFNIQMCVGATGHNIPQKLSLNAELQLDRQKPRQGRRVLLLGSQQAGTTLNLDLGGKHSPICHTTMAFLRDEADFRDKLSPIVLSLNVSLPPTEAGMAPAVVLHGDTHVQEQTRIVLDCGEDDVCVPQLQLTASVTGSPLLVGADNVLELQMDAANEGEGAYEAELAVHLPQGAHYMRALSNVEGFERLICNQKKENETRVVLCELGNPMKKNAQIGIAMLVSVGNLEEAGESVSFQLQIRSKNSQNPNSKIVLLDVPVRAEAQVELRGNSFPASLVVAAEEGEREQNSLDSWGPKVEHTYELHNNGPGTVNGLHLSIHLPGQSQPSDLLYILDIQPQGGLQCFPQPPVNPLKVDWGLPIPSPSPIHPAHHKRDRRQIFLPEPEQPSRLQDPVLVSCDSAPCTVVQCDLQEMARGQRAMVTVLAFLWLPSLYQRPLDQFVLQSHAWFNVSSLPYAVPPLSLPRGEAQVWTQLLRALEERAIPIWWVLVGVLGGLLLLTILVLAMWKVGFFKRNRPPLEEDDEEGE	1039	P08514	H	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [842], 'STRAND_gain_score': array([0.05405015]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [785], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.00585949]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
609	NM_000162.5(GCK):c.748C>T (p.Arg250Cys)	393451	CA16609268	NM_000162.5:c.748C>T, NC_000007.14:g.44147765G>A, CM000669.2:g.44147765G>A, NC_000007.13:g.44187364G>A, CM000669.1:g.44187364G>A, NC_000007.12:g.44153889G>A, NG_008847.1:g.46659C>T, NG_008847.2:g.55406C>T, ENST00000395796.8:c.*746C>T, ENST00000616242.5:c.748C>T, ENST00000345378.7:c.751C>T, ENST00000403799.8:c.748C>T, ENST00000671824.1:c.748C>T, ENST00000673284.1:c.748C>T, ENST00000345378.6:c.751C>T, ENST00000395796.7:c.745C>T, ENST00000403799.7:c.748C>T, ENST00000437084.1:c.697C>T, ENST00000616242.4:c.745C>T, NM_000162.3:c.748C>T, NM_033507.1:c.751C>T, NM_033508.1:c.745C>T, XR_927223.1:n.82+17G>A, NM_000162.4:c.748C>T, NM_001354800.1:c.748C>T, NM_033507.2:c.751C>T, NM_033508.2:c.745C>T, XR_927223.2:n.82+17G>A, NM_033507.3:c.751C>T, NM_033508.3:c.745C>T, NM_000162.5(GCK):c.748C>T (p.Arg250Cys)	GCK	monogenic diabetes	MONDO:0015967	Semidominant inheritance	Pathogenic	PS4, PP1_Strong, PP4_Moderate, PP2, PP3, PM2_Supporting		The c.748C>T variant in the glucokinase gene, GCK, causes an amino acid change of arginine to cysteine at codon 250 (p.(Arg250Cys)) of NM_000162.5.  This variant is absent from gnomAD v2.1.1 (PM2_Supporting).  GCK: This variant was identified in 11  unrelated individuals with hyperglycemia (PS4; PMIDs: 30245511, 17204055, 19069349, internal lab contributors).  This variant was identified in an individual with a clinical history highly specific for GCK-hyperglycemia (FBG 5.5-8 mmol/L and HbA1c 5.6 - 7.6% and OGTT increment < 3 mmol/L and 3 generation family history of diabetes/hyperglycemia (PP4_Moderate; internal lab contributors).  This variant segregated with diabetes/hyperglycemia, with 5 informative meioses in 2 families (PP1_Strong; PMID: 30245511, internal lab contributors).  GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2).  This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.944 which is greater than the MDEP VCEP threshold of 0.70 (PP3).  In summary, c.748C>T meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.3.0, approved 8/11/2023): PM2_Supporting, PS4, PP4_Moderate, PP1_Strong, PP2, PP3.		Monogenic Diabetes VCEP		2023-10-25	2023-10-25	False	https://erepo.genome.network/evrepo/ui/classification/CA16609268/MONDO:0015967/086	5d160251-b40f-4a9f-8f75-1363fc23633c	p.Arg250Cys	Arg	250	Cys	MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQ	465	P35557	C	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [408], 'BINDING_gain': [], 'BINDING_loss_score': array([-0.023987]), 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [236], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.04648054]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [83], 'DOMAIN_gain_score': array([0.00537574]), 'REGION_loss': [], 'REGION_gain': [11, 21], 'REGION_gain_score': array([0.00720525, 0.005391  ]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
610	NM_000162.5(GCK):c.370G>A (p.Asp124Asn)	211073	CA206547	NM_000162.5:c.370G>A, NC_000007.14:g.44151069C>T, CM000669.2:g.44151069C>T, NC_000007.13:g.44190668C>T, CM000669.1:g.44190668C>T, NC_000007.12:g.44157193C>T, NG_008847.1:g.43355G>A, NG_008847.2:g.52102G>A, ENST00000395796.8:c.*368G>A, ENST00000616242.5:c.370G>A, ENST00000682635.1:n.856G>A, ENST00000345378.7:c.373G>A, ENST00000403799.8:c.370G>A, ENST00000671824.1:c.370G>A, ENST00000673284.1:c.370G>A, ENST00000345378.6:c.373G>A, ENST00000395796.7:c.367G>A, ENST00000403799.7:c.370G>A, ENST00000437084.1:c.364-45G>A, ENST00000616242.4:c.367G>A, NM_000162.3:c.370G>A, NM_033507.1:c.373G>A, NM_033508.1:c.367G>A, NM_000162.4:c.370G>A, NM_001354800.1:c.370G>A, NM_033507.2:c.373G>A, NM_033508.2:c.367G>A, NM_033507.3:c.373G>A, NM_033508.3:c.367G>A, NM_000162.5(GCK):c.370G>A (p.Asp124Asn)	GCK	monogenic diabetes	MONDO:0015967	Semidominant inheritance	Pathogenic	PS4, PP1_Strong, PP4_Moderate, PP2, PP3, PM2_Supporting	PM1	The c.370G>A variant in the glucokinase gene, GCK, causes an amino acid change of aspartic acid to asparagine at codon 124 (p.(Asp124Asn)) of NM_000162.5.  GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2). This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.817, which is greater than the MDEP VCEP threshold of 0.70 (PP3). This variant has an incomputable gnomAD v2.1.1  Popmax filtering allele frequency due to one copy in the European non-Finnish subpopulation and one copy in the Latino/Admixed American subpopulation, thereby meeting the ClinGen MDEP threshold criteria for PM2_Supporting (ENF Popmax FAF <= 0.000003 and <= 2 copies in ENF and <=1 copy in any other subpopulation) (PM2_Supporting). This variant was identified in 14 unrelated individuals with hyperglycemia (PS4; PMIDs: 20337973, 22773699, internal lab contributors).  This variant was identified in a at least three individuals with a clinical history highly specific for GCK-hyperglycemia (FBG 5.5-8 mmol/L and HbA1c 5.6 - 7.6% and OGTT increment < 3 mmol/L) (PP4_Moderate; internal lab contributors).  This variant segregated with diabetes/hyperglycemia, with seven informative meioses in five families (PP1_Strong; internal lab contributors).  In summary, c.379G>A meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.3.0, approved 8/11/2023): PP1_Strong, PS4, PP4_Moderate, PP2, PP3, PM2_Supporting.		Monogenic Diabetes VCEP		2023-11-02	2023-11-02	False	https://erepo.genome.network/evrepo/ui/classification/CA206547/MONDO:0015967/086	e92e139f-6994-4774-beb3-99278185204a	p.Asp124Asn	Asp	124	Asn	MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQ	465	P35557	N	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [164], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.01896417]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [83], 'DOMAIN_gain_score': array([0.00882143]), 'REGION_loss': [], 'REGION_gain': [11, 21], 'REGION_gain_score': array([0.0089739 , 0.00584286]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
611	NM_000152.5(GAA):c.2173C>T (p.Arg725Trp)	4024	CA116598	NM_000152.5(GAA):c.2173C>T, NM_000152.5:c.2173C>T, NC_000017.11:g.80113350C>T, CM000679.2:g.80113350C>T, NC_000017.10:g.78087149C>T, CM000679.1:g.78087149C>T, NC_000017.9:g.75701744C>T, NG_009822.1:g.16795C>T, LRG_673:g.16795C>T, ENST00000302262.8:c.2173C>T, ENST00000302262.7:c.2173C>T, ENST00000390015.7:c.2173C>T, ENST00000572080.1:c.592C>T, NM_000152.3:c.2173C>T, LRG_673t1:c.2173C>T, NM_001079803.1:c.2173C>T, NM_001079804.1:c.2173C>T, XM_005257193.1:c.2173C>T, XM_005257194.3:c.2173C>T, NM_000152.4:c.2173C>T, NM_001079803.2:c.2173C>T, NM_001079804.2:c.2173C>T, XM_005257193.2:c.2173C>T, XM_005257194.4:c.2173C>T, NM_001079803.3:c.2173C>T, NM_001079804.3:c.2173C>T, NM_000152.5(GAA):c.2173C>T (p.Arg725Trp)	GAA	glycogen storage disease II	MONDO:0009290	Autosomal recessive inheritance	Pathogenic	PS3_Supporting, PP4_Moderate, PP3, PM3_Very Strong, PM2_Supporting		The NM_000152.5:c.2173C>T variant in GAA is a missense variant predicted to cause substitution of Arg by Trp at amino acid 725 (p.Arg725Trp). This variant is present in gnomAD V2.1.1 with the highest population minor allele frequency of 0.00077 (7/9058 alleles) in the Ashkenazi Jewish population, which is lower than the ClinGen LSD VCEP's threshold for PM2_Supporting (<0.001), meeting this criterion (PM2_Supporting). The computational predictor REVEL gives a score of 0.909 which is above the thresholds predicting a damaging (>0.7) impact on GAA function. Thus met PP3 criteria. This variant results in 6.5% GAA activity when expressed in COS cells (PMID: 8401535), meeting the ClinGen LSD VCEP specifications for PS3. This variant has been detected in at least 12 individuals with Pompe disease. Of those individuals, 10 were compound heterozygous for the variant and a pathogenic or likely pathogenic variant including 2 with c.573C>A-pathogenic (PMID: 30155607), 1 with ex18 deletion-pathogenic (PMID: 28648663), 3 with c.-32-13T>G-pathogenic (PMID: 27711114, 17616415), 1 with c.-32-3C>A-likely pathogenic (PMID: 19588081), 2 with c.1076-1G>C pathogenic variants (PMID: 17616415). 1 individual was homozygous for the variant (PMID: 27711114). A total of 4.25 points were awarded. Thus meets PM3-Very Strong. At least 4 individuals have been reported with this variant and GAA activity <10% normal in leukocytes/muscle samples or <30% normal in cultured fibroblasts. Patient 5 (PMID: 21550241) has 0.2% normal GAA activity in fibroblast. Patient 3 has 1.1% normal GAA activity in fibroblasts, patient 15 has 5.2% normal GAA activity in fibroblasts (PMID: 17616415). Patient 1 (PMID: 3865697) has GAA activity in affected range in muscle, cultured fibroblasts, and leucocytes when compared to the laboratory’s control range. This meets the criteria for PP4. There is a ClinVar entry for this variant (Variation ID: 4024; 2 star review status) with 9 submitters classifying the variant as pathogenic with no conflict.  In summary, this variant meets the criteria to be classified as Pathogenic for Pompe disease based on the ACMG/AMP criteria applied, as specified by the ClinGen Lysosomal Storage Disorders Variant Curation Expert panel (Specifications Version 2.0): PS3-supporting, PM2-supporting, PM3-very strong, PP3, and PP4-moderate.(Classification approved by the ClinGen Lysosomal Diseases VCEP on Oct. 3, 2023)		Lysosomal Diseases VCEP	https://clinicalgenome.org/docs/clingen-lysosomal-storage-disorders-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-2/	2023-10-03	2023-11-03	False	https://erepo.genome.network/evrepo/ui/classification/CA116598/MONDO:0009290/010	e11bf381-2b73-4d3a-bcba-22ea27d1ea55	p.Arg725Trp	Arg	725	Trp	MGVRHPPCSHRLLAVCALVSLATAALLGHILLHDFLLVPRELSGSSPVLEETHPAHQQGASRPGPRDAQAHPGRPRAVPTQCDVPPNSRFDCAPDKAITQEQCEARGCCYIPAKQGLQGAQMGQPWCFFPPSYPSYKLENLSSSEMGYTATLTRTTPTFFPKDILTLRLDVMMETENRLHFTIKDPANRRYEVPLETPHVHSRAPSPLYSVEFSEEPFGVIVRRQLDGRVLLNTTVAPLFFADQFLQLSTSLPSQYITGLAEHLSPLMLSTSWTRITLWNRDLAPTPGANLYGSHPFYLALEDGGSAHGVFLLNSNAMDVVLQPSPALSWRSTGGILDVYIFLGPEPKSVVQQYLDVVGYPFMPPYWGLGFHLCRWGYSSTAITRQVVENMTRAHFPLDVQWNDLDYMDSRRDFTFNKDGFRDFPAMVQELHQGGRRYMMIVDPAISSSGPAGSYRPYDEGLRRGVFITNETGQPLIGKVWPGSTAFPDFTNPTALAWWEDMVAEFHDQVPFDGMWIDMNEPSNFIRGSEDGCPNNELENPPYVPGVVGGTLQAATICASSHQFLSTHYNLHNLYGLTEAIASHRALVKARGTRPFVISRSTFAGHGRYAGHWTGDVWSSWEQLASSVPEILQFNLLGVPLVGADVCGFLGNTSEELCVRWTQLGAFYPFMRNHNSLLSLPQEPYSFSEPAQQAMRKALTLRYALLPHLYTLFHQAHVAGETVARPLFLEFPKDSSTWTVDHQLLWGEALLITPVLQAGKAEVTGYFPLGTWYDLQTVPVEALGSLPPPPAAPREPAIHSEGQWVTLPAPLDTINVHLRAGYIIPLQGPGLTTTESRQQPMALAVALTKGGEARGELFWDDGESLEVLERGAYTQVIFLARNNTIVNELVRVTSEGAGLQLQKVTVLGVATAPQQVLSNGVPVSNFTYSPDTKVLDICVSLLMGEQFLVSWC	952	P10253	W	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [420, 663, 704, 714, 716], 'DNA_BIND_gain': [], 'DNA_BIND_loss_score': array([-0.00078648, -0.00684643, -0.00481355, -0.0105328 , -0.00585395]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [893, 913], 'STRAND_gain_score': array([0.01142287, 0.00799984]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [386, 666, 710], 'REPEAT_gain': [764], 'REPEAT_gain_score': array([0.00654596]), 'REPEAT_loss_score': array([-0.00094676, -0.00513339, -0.00365275]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
612	NM_000152.5(GAA):c.1441T>C (p.Trp481Arg)	189007	CA274247	NM_000152.5:c.1441T>C, NC_000017.11:g.80110730T>C, CM000679.2:g.80110730T>C, NC_000017.10:g.78084529T>C, CM000679.1:g.78084529T>C, NC_000017.9:g.75699124T>C, NG_009822.1:g.14175T>C, LRG_673:g.14175T>C, ENST00000302262.8:c.1441T>C, ENST00000302262.7:c.1441T>C, ENST00000390015.7:c.1441T>C, NM_000152.3:c.1441T>C, LRG_673t1:c.1441T>C, NM_001079803.1:c.1441T>C, NM_001079804.1:c.1441T>C, XM_005257193.1:c.1441T>C, XM_005257194.3:c.1441T>C, NM_000152.4:c.1441T>C, NM_001079803.2:c.1441T>C, NM_001079804.2:c.1441T>C, XM_005257193.2:c.1441T>C, XM_005257194.4:c.1441T>C, NM_001079803.3:c.1441T>C, NM_001079804.3:c.1441T>C, NM_000152.5(GAA):c.1441T>C (p.Trp481Arg)	GAA	glycogen storage disease II	MONDO:0009290	Autosomal recessive inheritance	Pathogenic	PM3_Strong, PS3_Supporting, PP4_Moderate, PP3, PM2_Supporting, PM1		The NM_000152.5:c.1441T>C variant in GAA is predicted to result in the missense substitution of tryptophan by arginine at amino acid 481 (p.Trp481Arg). The variant has been reported in at least 6 individuals with Pompe disease in compound heterozygosity with another variant in GAA that has been classified as pathogenic by the ClinGen Lysosomal Diseases VCEP. It was confirmed in trans with c.1326+1G>A (PMIDs: 10189220, 9862843), and was found in unconfirmed phase with c.-32-13T>G (PMID: 14695532, 18757064, 22676651, 27189384, 29556838, 34357340); c.2560C>T (p.Arg854Ter) (PMIDs: 31086307, 35787971), c.1979G>A (p.Arg660His) (PMID: 31086307), and c.2481+102_c.2646+31del (PMID: 26497565, 28657663). Another patient is compound heterozygous for the variant and c.1556T>C (p.Met519Thr) (PMID: 31086307); the allelic data from this patient will be used in the assessment of the other variant and is not included here to avoid circular logic (PM3_Strong). This variant has been reported in individuals with specific phenotypic features of Pompe disease including documented laboratory values revealing GAA deficiency, individuals on enzyme replacement therapy, patients with documented symptoms of infantile onset Pompe disease, and elevated urine Hex4 (PMID: 26497565, 28657663, 31086307, 34357340) (PP4_Moderate). Trp481 is a residue that crystallography studies have shown to be important in the architecture of the active site and substrate binding of GAA; this residues has, therefore, has been defined as a critical residue by the ClinGen Lysosomal Diseases VCEP (https://www.biorxiv.org/content/10.1101/212837v1.full.pdf, PMID: 29061980) (PM1). In two independent studies, expression of the variant in COS cells results in <2% GAA activity compared to normal, but also a significant amount of mature GAA protein, suggesting that the variant impacts catalysis rather than protein production or stability (PMID: 14695532, 19862843). The computational predictor REVEL gives a score of 0.967 which is above the threshold of 0.7, evidence that correlates with impact to GAA function (PP3). There is a ClinVar entry for this variant (Variation ID: ). In summary, this variant meets the criteria to be classified as pathogenic for Pompe disease. GAA-specific ACMG/AMP criteria met, as specified by the ClinGen Lysosomal Diseases Variant Curation Expert Panel (Specifications Version 2.0): PM3_Strong, PM1, PP4_Moderate, PP3, PS3_Supporting, PM2_Supporting, (Classification approved by the ClinGen Lysosomal Diseases VCEP on Oct. 1, 2023)		Lysosomal Diseases VCEP	https://clinicalgenome.org/docs/clingen-lysosomal-storage-disorders-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-2/	2023-10-01	2023-11-03	False	https://erepo.genome.network/evrepo/ui/classification/CA274247/MONDO:0009290/010	2f9f62d1-d280-478e-9aed-b8a1c5c4d838	p.Trp481Arg	Trp	481	Arg	MGVRHPPCSHRLLAVCALVSLATAALLGHILLHDFLLVPRELSGSSPVLEETHPAHQQGASRPGPRDAQAHPGRPRAVPTQCDVPPNSRFDCAPDKAITQEQCEARGCCYIPAKQGLQGAQMGQPWCFFPPSYPSYKLENLSSSEMGYTATLTRTTPTFFPKDILTLRLDVMMETENRLHFTIKDPANRRYEVPLETPHVHSRAPSPLYSVEFSEEPFGVIVRRQLDGRVLLNTTVAPLFFADQFLQLSTSLPSQYITGLAEHLSPLMLSTSWTRITLWNRDLAPTPGANLYGSHPFYLALEDGGSAHGVFLLNSNAMDVVLQPSPALSWRSTGGILDVYIFLGPEPKSVVQQYLDVVGYPFMPPYWGLGFHLCRWGYSSTAITRQVVENMTRAHFPLDVQWNDLDYMDSRRDFTFNKDGFRDFPAMVQELHQGGRRYMMIVDPAISSSGPAGSYRPYDEGLRRGVFITNETGQPLIGKVWPGSTAFPDFTNPTALAWWEDMVAEFHDQVPFDGMWIDMNEPSNFIRGSEDGCPNNELENPPYVPGVVGGTLQAATICASSHQFLSTHYNLHNLYGLTEAIASHRALVKARGTRPFVISRSTFAGHGRYAGHWTGDVWSSWEQLASSVPEILQFNLLGVPLVGADVCGFLGNTSEELCVRWTQLGAFYPFMRNHNSLLSLPQEPYSFSEPAQQAMRKALTLRYALLPHLYTLFHQAHVAGETVARPLFLEFPKDSSTWTVDHQLLWGEALLITPVLQAGKAEVTGYFPLGTWYDLQTVPVEALGSLPPPPAAPREPAIHSEGQWVTLPAPLDTINVHLRAGYIIPLQGPGLTTTESRQQPMALAVALTKGGEARGELFWDDGESLEVLERGAYTQVIFLARNNTIVNELVRVTSEGAGLQLQKVTVLGVATAPQQVLSNGVPVSNFTYSPDTKVLDICVSLLMGEQFLVSWC	952	P10253	R	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [599], 'BINDING_gain': [], 'BINDING_loss_score': array([-0.03193939]), 'DNA_BIND_loss': [375, 663], 'DNA_BIND_gain': [], 'DNA_BIND_loss_score': array([-0.0005132, -0.0070098]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [22], 'TRANSIT_gain_score': array([0.01004016]), 'STRAND_loss': [], 'STRAND_gain': [259, 478, 913], 'STRAND_gain_score': array([0.00677395, 0.09360808, 0.00709873]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [666], 'REPEAT_gain': [494, 643], 'REPEAT_gain_score': array([0.00500995, 0.00121963]), 'REPEAT_loss_score': array([-0.00351304]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
613	NM_000162.5(GCK):c.605T>C (p.Met202Thr)	36233	CA213810	NM_000162.5:c.605T>C, NC_000007.14:g.44149834A>G, CM000669.2:g.44149834A>G, NC_000007.13:g.44189433A>G, CM000669.1:g.44189433A>G, NC_000007.12:g.44155958A>G, NG_008847.1:g.44590T>C, NG_008847.2:g.53337T>C, ENST00000395796.8:c.*603T>C, ENST00000616242.5:c.605T>C, ENST00000682635.1:n.1091T>C, ENST00000345378.7:c.608T>C, ENST00000403799.8:c.605T>C, ENST00000671824.1:c.605T>C, ENST00000673284.1:c.605T>C, ENST00000345378.6:c.608T>C, ENST00000395796.7:c.602T>C, ENST00000403799.7:c.605T>C, ENST00000437084.1:c.554T>C, ENST00000616242.4:c.602T>C, NM_000162.3:c.605T>C, NM_033507.1:c.608T>C, NM_033508.1:c.602T>C, NM_000162.4:c.605T>C, NM_001354800.1:c.605T>C, NM_033507.2:c.608T>C, NM_033508.2:c.602T>C, NM_033507.3:c.608T>C, NM_033508.3:c.602T>C, NM_000162.5(GCK):c.605T>C (p.Met202Thr)	GCK	monogenic diabetes	MONDO:0015967	Semidominant inheritance	Pathogenic	PS4, PP1_Strong, PP4_Moderate, PP2, PP3, PM2_Supporting	PM1	The c.605C>T variant in the glucokinase gene, GCK, causes an amino acid change of methionine to threonine at codon 202 (p.(Met202Thr)) of NM_000162.5. This variant segregated with diabetes/hyperglycemia, with 6 informative meioses in 4 families  (PP1_Strong; internal lab contributors).  This variant was identified in 12 unrelated individuals with hyperglycemia (PS4; PMID: 17573000, internal lab contributors).  This variant was identified in two individuals with a clinical history highly specific for GCK-hyperglycemia (FBG 5.5-8 mmol/L and HbA1c 5.6 - 7.6% and negative antibodies) (PP4_Moderate; internal lab contributors). GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2).  This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.917, which is greater than the MDEP VCEP threshold of 0.70 (PP3).  This variant has a gnomAD v2.1.1  Popmax filtering allele frequency of 0.000002920 (below the MDEP threshold of 0.000003) and 2 copies observed in the European non-Finnish population and 0 copies in any other subpopulation, thereby meeting the ClinGen MDEP criteria for PM2_Supporting (PM2_Supporting).  In summary, c.605C>T meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.3.0, approved 8/11/2023): PP1_Strong, PS4, PP4_Moderate, PP2, PP3, PM2_Supporting.		Monogenic Diabetes VCEP		2023-12-01	2023-12-01	False	https://erepo.genome.network/evrepo/ui/classification/CA213810/MONDO:0015967/086	0d897a5d-9b10-4f8b-8c76-5fb7e538d5b0	p.Met202Thr	Met	202	Thr	MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQ	465	P35557	T	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [205], 'BINDING_gain_score': array([0.16142505]), 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [164, 196, 203], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.02845812, -0.05849993, -0.16312444]), 'HELIX_loss': [], 'HELIX_gain': [203], 'HELIX_gain_score': array([0.28486919]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [11, 21, 71, 80, 86], 'REGION_gain_score': array([0.00364631, 0.00359845, 0.0208075 , 0.01839906, 0.01913202]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
614	NM_000162.5(GCK):c.503C>T (p.Thr168Ile)	1490297	CA367401750	NM_000162.5:c.503C>T, NC_000007.14:g.44150045G>A, CM000669.2:g.44150045G>A, NC_000007.13:g.44189644G>A, CM000669.1:g.44189644G>A, NC_000007.12:g.44156169G>A, NG_008847.1:g.44379C>T, NG_008847.2:g.53126C>T, ENST00000395796.8:c.*501C>T, ENST00000616242.5:c.503C>T, ENST00000682635.1:n.989C>T, ENST00000345378.7:c.506C>T, ENST00000403799.8:c.503C>T, ENST00000671824.1:c.503C>T, ENST00000673284.1:c.503C>T, ENST00000345378.6:c.506C>T, ENST00000395796.7:c.500C>T, ENST00000403799.7:c.503C>T, ENST00000437084.1:c.452C>T, ENST00000616242.4:c.500C>T, NM_000162.3:c.503C>T, NM_033507.1:c.506C>T, NM_033508.1:c.500C>T, NM_000162.4:c.503C>T, NM_001354800.1:c.503C>T, NM_033507.2:c.506C>T, NM_033508.2:c.500C>T, NM_033507.3:c.506C>T, NM_033508.3:c.500C>T, NM_000162.5(GCK):c.503C>T (p.Thr168Ile)	GCK	monogenic diabetes	MONDO:0015967	Semidominant inheritance	Pathogenic	PM5_Strong, PS4_Moderate, PP2, PP3, PP4, PM1, PM2_Supporting		The c.503C>T variant in the glucokinase gene, GCK, causes an amino acid change of threonine to isoleucine at codon 168 (p.(Thr168Ile)) of NM_000162.5.  This variant is absent from gnomAD v2.1.1 (PM2_Supporting). GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2).  This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.997 which is greater than the MDEP VCEP threshold of 0.70 (PP3). This variant resides in an amino acid that directly binds glucose, which is defined as critical for the protein’s function by the ClinGen MDEP (PM1). This variant was identified in an individual with a clinical history highly specific for GCK-hyperglycemia (FBG 5.5-8 mmol/L and HbA1c 5.6 - 7.6%) (PP4; internal lab contributors). This variant was identified in 4 unrelated individuals with hyperglycemia (PS4_Moderate; internal lab contributors).  Two other missense variants, c.502A>G p.Thr168Ala and c.503C>A p.Thr168Asn, have been interpreted as pathogenic by the ClinGen MDEP, and p.Thr168Ile has a greater Grantham distance than p.Thr168Ala and p.Thr168Asn (PM5_Strong).  In summary, c.503C>T meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.3.0, approved 8/11/2023): PM2_Supporting, PP2, PP3, PM1, PP4, PS4_Moderate, PM5_Strong.		Monogenic Diabetes VCEP		2023-12-01	2023-12-01	False	https://erepo.genome.network/evrepo/ui/classification/CA367401750/MONDO:0015967/086	013ccb72-f009-4e24-af55-2fef3fc8abde	p.Thr168Ile	Thr	168	Ile	MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQ	465	P35557	I	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [151], 'BINDING_gain_score': array([0.06342429]), 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [162, 163, 164, 203], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.2915135 , -0.36390114, -0.33995795, -0.03082442]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [83], 'DOMAIN_gain_score': array([0.00881928]), 'REGION_loss': [73, 74, 79, 82], 'REGION_gain': [], 'REGION_loss_score': array([-0.03137517, -0.02912712, -0.03580368, -0.03881073]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
615	NM_000162.5(GCK):c.736G>A (p.Gly246Arg)	995372	CA367400665	NM_000162.5:c.736G>A, NC_000007.14:g.44147777C>T, CM000669.2:g.44147777C>T, NC_000007.13:g.44187376C>T, CM000669.1:g.44187376C>T, NC_000007.12:g.44153901C>T, NG_008847.1:g.46647G>A, NG_008847.2:g.55394G>A, ENST00000395796.8:c.*734G>A, ENST00000616242.5:c.736G>A, ENST00000345378.7:c.739G>A, ENST00000403799.8:c.736G>A, ENST00000671824.1:c.736G>A, ENST00000673284.1:c.736G>A, ENST00000345378.6:c.739G>A, ENST00000395796.7:c.733G>A, ENST00000403799.7:c.736G>A, ENST00000437084.1:c.685G>A, ENST00000616242.4:c.733G>A, NM_000162.3:c.736G>A, NM_033507.1:c.739G>A, NM_033508.1:c.733G>A, XR_927223.1:n.82+29C>T, NM_000162.4:c.736G>A, NM_001354800.1:c.736G>A, NM_033507.2:c.739G>A, NM_033508.2:c.733G>A, XR_927223.2:n.82+29C>T, NM_033507.3:c.739G>A, NM_033508.3:c.733G>A, NM_000162.5(GCK):c.736G>A (p.Gly246Arg)	GCK	monogenic diabetes	MONDO:0015967	Semidominant inheritance	Pathogenic	PS4, PP1_Strong, PP2, PP3, PP4, PM2_Supporting		The c.736G>A variant in the glucokinase gene, GCK, causes an amino acid change of glycine to arginine at codon 246 (p.(Gly246Arg)) of NM_000162.5.  This variant segregated with diabetes/hyperglycemia, with 6 informative meioses in 3 families (PP1_Strong; internal lab contributors).  GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2).  This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.905, which is greater than the MDEP VCEP threshold of 0.70 (PP3).  This variant is absent from gnomAD v2.1.1 (PM2_Supporting).  This variant was identified in 7 unrelated individuals with hyperglycemia (PS4; PMIDs: 33852230, 34469064, internal lab contributors).  One of these individuals had a clinical history highly specific for GCK-hyperglycemia (FBG 5.5-8 mmol/L and HbA1c 5.6 - 7.6% and negative antibodies and OGTT increment < 3 mmol/L) (PP4_Moderate; internal lab contributors).  This variant segregated with diabetes/hyperglycemia, with 6 informative meioses in 3 families (PP1_Strong; internal lab contributors).  In summary, c.736G>A meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.3.0, approved 8/11/2023): PP1_Strong, PS4, PP2, PP3, PP4_Moderate, PM2_Supporting.		Monogenic Diabetes VCEP		2023-12-02	2023-12-02	False	https://erepo.genome.network/evrepo/ui/classification/CA367400665/MONDO:0015967/086	be8a66cd-d3c2-4aec-8da9-876f201fc473	p.Gly246Arg	Gly	246	Arg	MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQ	465	P35557	R	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [203, 239, 250], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.01989317, -0.07391334, -0.23345703]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [21], 'REGION_gain_score': array([0.00070035]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
616	NM_000162.5(GCK):c.1163G>A (p.Gly388Asp)	995101	CA367398670	NM_000162.5:c.1163G>A, NC_000007.14:g.44145587C>T, CM000669.2:g.44145587C>T, NC_000007.13:g.44185186C>T, CM000669.1:g.44185186C>T, NC_000007.12:g.44151711C>T, NG_008847.1:g.48837G>A, NG_008847.2:g.57584G>A, ENST00000395796.8:c.*1161G>A, ENST00000616242.5:c.*283G>A, ENST00000683378.1:n.389G>A, ENST00000336642.9:c.197G>A, ENST00000345378.7:c.1166G>A, ENST00000403799.8:c.1163G>A, ENST00000671824.1:c.1226G>A, ENST00000672743.1:n.175G>A, ENST00000673284.1:c.1163G>A, ENST00000336642.8:c.215G>A, ENST00000345378.6:c.1166G>A, ENST00000395796.7:c.1160G>A, ENST00000403799.7:c.1163G>A, ENST00000437084.1:c.1112G>A, ENST00000459642.1:n.543G>A, ENST00000616242.4:c.1160G>A, NM_000162.3:c.1163G>A, NM_033507.1:c.1166G>A, NM_033508.1:c.1160G>A, NM_000162.4:c.1163G>A, NM_001354800.1:c.1163G>A, NM_001354801.1:c.152G>A, NM_001354802.1:c.23G>A, NM_001354803.1:c.197G>A, NM_033507.2:c.1166G>A, NM_033508.2:c.1160G>A, XM_024446707.1:c.23G>A, NM_033507.3:c.1166G>A, NM_033508.3:c.1160G>A, NM_001354803.2:c.197G>A, NM_000162.5(GCK):c.1163G>A (p.Gly388Asp)	GCK	monogenic diabetes	MONDO:0015967	Semidominant inheritance	Pathogenic	PS4, PP1_Moderate, PP4_Moderate, PP2, PP3, PM2_Supporting, PS2_Moderate	PM1	The c.1163G>A variant in the glucokinase gene, GCK, causes an amino acid change of glycine to aspartic acid at codon 388 (p.(Gly388Asp)) of NM_000162.5.  GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2).  This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.871, which is greater than the MDEP VCEP threshold of 0.70 (PP3).  This variant is absent from gnomAD v2.1.1 (PM2_Supporting).  This variant was identified in 8  unrelated individuals with hyperglycemia (PS4; PMID:35737141, internal lab contributors).  One of these individuals had a clinical history highly specific for GCK-hyperglycemia (FBG 5.5-8 mmol/L and HbA1c 5.6 - 7.6% and negative antibodies) (PP4_Moderate, internal lab contributors).  Another one of these individuals was identified as a de novo occurrence with confirmed parental relationships whose clinical picture was consistent with but not highly specific for GCK-hyperglycemia (PS2_Moderate;  internal lab contributors).  This variant segregated with hyperglycemia, with 3 informative meioses in 3 families (PP1_Moderate; internal lab contributors). In summary, c.1163G>A meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.3, approved 8/11/2023): PS4, PP1_Moderate, PP4_Moderate, PS2_Moderate, PP2, PP3, PM2_Supporting.		Monogenic Diabetes VCEP		2023-12-02	2023-12-02	False	https://erepo.genome.network/evrepo/ui/classification/CA367398670/MONDO:0015967/086	e2b51e72-7014-4bfd-aa41-30e5318337fe	p.Gly388Asp	Gly	388	Asp	MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQ	465	P35557	D	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [408], 'BINDING_gain': [], 'BINDING_loss_score': array([-0.03423077]), 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [11, 21, 38, 71, 75, 80], 'REGION_gain_score': array([0.00770813, 0.00912035, 0.00961238, 0.02467072, 0.02612346,
       0.02177042]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
617	NM_000545.8(HNF1A):c.1136C>A (p.Pro379His)	1471754	CA6831958	NM_000545.8:c.1136C>A, NC_000012.12:g.120996569C>A, CM000674.2:g.120996569C>A, NC_000012.11:g.121434372C>A, CM000674.1:g.121434372C>A, NC_000012.10:g.119918755C>A, NG_011731.2:g.22824C>A, LRG_522:g.22824C>A, ENST00000257555.11:c.1136C>A, ENST00000257555.10:c.1136C>A, ENST00000400024.6:c.1136C>A, ENST00000402929.5:n.1271C>A, ENST00000535955.5:n.43-922C>A, ENST00000538626.2:n.191-922C>A, ENST00000538646.5:c.*112C>A, ENST00000540108.1:c.*576C>A, ENST00000541395.5:c.1136C>A, ENST00000541924.5:c.*150C>A, ENST00000543255.1:n.180C>A, ENST00000543427.5:c.634-35C>A, ENST00000544413.2:c.1136C>A, ENST00000544574.5:c.73-48C>A, ENST00000560968.5:c.953C>A, ENST00000615446.4:c.-77C>A, ENST00000617366.4:c.587-1065C>A, NM_000545.5:c.1136C>A, LRG_522t1:c.1136C>A, NM_000545.6:c.1136C>A, NM_001306179.1:c.1136C>A, XM_005253931.2:c.1136C>A, XM_024449168.1:c.1136C>A, NM_001306179.2:c.1136C>A, NM_000545.8(HNF1A):c.1136C>A (p.Pro379His)	HNF1A	monogenic diabetes	MONDO:0015967	Autosomal dominant inheritance	Benign	PP3, BA1, PM5_Supporting, PP4_Moderate	PP1, PM1, PS3, PS4, BS3	The c.1136C>A variant in the HNF1 homeobox A gene, HNF1A causes an amino acid change of proline to histidine at codon 379 (p.(Pro379His)) of NM_000545.8.  This variant has a Popmax Filtering allele frequency in gnomAD 2.1.1 of 0.0001567, which is greater than the MDEP threshold for BA1 (0.0001)(BA1).  This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.969, which is greater than the MDEP VCEP threshold of 0.70 (PP3).  Functional studies demonstrated the p.Pro379His protein has transcriptional activity on insulin promoter 62% of WT in RINm5f cells and 78% of WT in HeLA cells (PMID 15883474).  While one cell line is greater than the MDEP BS3 cutoff of 75%, one is between the ClinGen MDEP cutoffs for PS3 (<=40%) and BS3, and therefore neither PS3 nor BS3 is applied. This variant was identified in one family and segregated with diabetes with two informative meioses; however, this does not meet the thresholds for PP1 or PS4 set by the ClinGen MDEP (PMIDs: 27236918, 15883474).  An individual in this family had a clinical history highly specific for HNF1A-monogenic diabetes (MODY probability calculator result >50%, negative genetic testing for HNF4A, and antibody negative) (PP4_Moderate; PMID 15883474).  Another missense variant, c.1136C>G (p.Pro379Arg), has been classified as pathogenic by the ClinGen MDEP but has a greater Grantham distance than p.Pro379His (PM5_Supporting).  In summary, c.1136C>A meets the criteria to be classified as benign for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 2.1.0, approved 8/11/2023): BA1, PM5_Supporting, PP4_Moderate, PP3.		Monogenic Diabetes VCEP		2023-12-10	2023-12-10	False	https://erepo.genome.network/evrepo/ui/classification/CA6831958/MONDO:0015967/085	b58c9783-3b46-44d4-9278-dd3ce929703c	p.Pro379His	Pro	379	His	MVSKLSQLQTELLAALLESGLSKEALIQALGEPGPYLLAGEGPLDKGESCGGGRGELAELPNGLGETRGSEDETDDDGEDFTPPILKELENLSPEEAAHQKAVVETLLQEDPWRVAKMVKSYLQQHNIPQREVVDTTGLNQSHLSQHLNKGTPMKTQKRAALYTWYVRKQREVAQQFTHAGQGGLIEEPTGDELPTKKGRRNRFKWGPASQQILFQAYERQKNPSKEERETLVEECNRAECIQRGVSPSQAQGLGSNLVTEVRVYNWFANRRKEEAFRHKLAMDTYSGPPPGPGPGPALPAHSSPGLPPPALSPSKVHGVRYGQPATSETAEVPSSSGGPLVTVSTPLHQVSPTGLEPSHSLLSTEAKLVSAAGGPLPPVSTLTALHSLEQTSPGLNQQPQNLIMASLPGVMTIGPGEPASLGPTFTNTGASTLVIGLASTQAQSVPVINSMGSSLTTLQPVQFSQPLHPSYQQPLMPPVQSHVTQSPFMATMAQLQSPHALYSHKPEVAQYTHTGLLPQTMLITDTTNLSALASLTPTKQVFTSDTEASSESGLHTPASQATTLHVPSQDPAGIQHLQPAHRLSASPTVSSSSLVLYQSSDSSNGQSHLLPSNHSVIETFISTQMASSSQ	631	P20823	H	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [102], 'HELIX_gain_score': array([0.00410271]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [345, 346], 'COMPBIAS_gain': [69], 'COMPBIAS_gain_score': array([0.01558793]), 'COMPBIAS_loss_score': array([-0.06504822, -0.06167185]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
618	NM_000162.5(GCK):c.322T>C (p.Tyr108His)	585918	CA367402690	NM_000162.5:c.322T>C, NC_000007.14:g.44152312A>G, CM000669.2:g.44152312A>G, NC_000007.13:g.44191911A>G, CM000669.1:g.44191911A>G, NC_000007.12:g.44158436A>G, NG_008847.1:g.42112T>C, NG_008847.2:g.50859T>C, ENST00000395796.8:c.*320T>C, ENST00000616242.5:c.322T>C, ENST00000682635.1:n.808T>C, ENST00000345378.7:c.325T>C, ENST00000403799.8:c.322T>C, ENST00000671824.1:c.322T>C, ENST00000673284.1:c.322T>C, ENST00000345378.6:c.325T>C, ENST00000395796.7:c.319T>C, ENST00000403799.7:c.322T>C, ENST00000437084.1:c.322T>C, ENST00000616242.4:c.319T>C, NM_000162.3:c.322T>C, NM_033507.1:c.325T>C, NM_033508.1:c.319T>C, NM_000162.4:c.322T>C, NM_001354800.1:c.322T>C, NM_033507.2:c.325T>C, NM_033508.2:c.319T>C, NM_033507.3:c.325T>C, NM_033508.3:c.319T>C, NM_000162.5(GCK):c.322T>C (p.Tyr108His)	GCK	monogenic diabetes	MONDO:0015967	Semidominant inheritance	Pathogenic	PS4, PP1_Strong, PP2, PP3, PP4, PM2_Supporting		The c.322T>C variant in the glucokinase gene, GCK, causes an amino acid change of tyrosine to histidine at codon 108 (p.(Tyr108His)) of NM_000162.5.  GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2). This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.949, which is [greater than/equal to] the MDEP VCEP threshold of 0.70 (PP3).  This variant is absent from gnomAD v2.1.1 (PM2_Supporting).  This variant was identified in 14 unrelated individuals with hyperglycemia (PS4; PMIDs: 17573900, 19564454, ClinVar ID: 585918, internal lab contributors), including an individual with a clinical history highly specific for GCK-hyperglycemia (FBG 5.5-8 mmol/L and HbA1c 5.6 - 7.6%) (PP4;  internal lab contributors).  This variant segregated with diabetes/hyperglycemia, with 5 informative meioses in multiple families (internal lab contributors).  In summary, c.322T>C meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.3.0, approved 8/11/2023): PP1_Strong, PS4, PP2, PP3, PP4, PM2_Supporting.		Monogenic Diabetes VCEP		2023-12-15	2023-12-15	False	https://erepo.genome.network/evrepo/ui/classification/CA367402690/MONDO:0015967/086	527e5735-ecaf-41ad-bbb3-476fcfa5b7d5	p.Tyr108His	Tyr	108	His	MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQ	465	P35557	H	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [7, 11, 21, 71, 80, 86], 'REGION_gain_score': array([0.00983447, 0.01255435, 0.00838685, 0.01861566, 0.01550025,
       0.02560002]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
619	NM_000162.5(GCK):c.113A>C (p.Gln38Pro)	420070	CA16618475	NM_000162.5:c.113A>C, NC_000007.14:g.44153396T>G, CM000669.2:g.44153396T>G, NC_000007.13:g.44192995T>G, CM000669.1:g.44192995T>G, NC_000007.12:g.44159520T>G, NG_008847.1:g.41028A>C, NG_008847.2:g.49775A>C, ENST00000395796.8:c.*111A>C, ENST00000616242.5:c.113A>C, ENST00000682635.1:n.599A>C, ENST00000345378.7:c.116A>C, ENST00000403799.8:c.113A>C, ENST00000671824.1:c.113A>C, ENST00000673284.1:c.113A>C, ENST00000345378.6:c.116A>C, ENST00000395796.7:c.110A>C, ENST00000403799.7:c.113A>C, ENST00000437084.1:c.113A>C, ENST00000476008.1:n.548A>C, ENST00000616242.4:c.110A>C, NM_000162.3:c.113A>C, NM_033507.1:c.116A>C, NM_033508.1:c.110A>C, NM_000162.4:c.113A>C, NM_001354800.1:c.113A>C, NM_033507.2:c.116A>C, NM_033508.2:c.110A>C, NM_033507.3:c.116A>C, NM_033508.3:c.110A>C, NM_000162.5(GCK):c.113A>C (p.Gln38Pro)	GCK	monogenic diabetes	MONDO:0015967	Semidominant inheritance	Pathogenic	PS4, PP1_Strong, PP4_Moderate, PP2, PP3, PM2_Supporting		The c.113A>C variant in the glucokinase gene, GCK, causes an amino acid change of glutamine to proline at codon 38 (p.(Gln38Pro)) of NM_000162.5. GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2). This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.887, which is greater than the MDEP VCEP threshold of 0.70 (PP3).  This variant is absent from gnomAD v2.1.1 (PM2_Supporting).  This variant was identified in 7  unrelated individuals with hyperglycemia (PS4; PMID: 1508276, 11079754, internal lab contributors).  One of these individuals had a clinical history highly specific for GCK-hyperglycemia (FBG 5.5-8 mmol/L and HbA1c 5.6 - 7.6% and OGTT 2 hour glucose < 3 mmol/L)(PP4_Moderate; internal lab contributor).  This variant segregated with diabetes/hyperglycemia, with 4 informative meioses in 3 families (PP1_Strong; PMID: 11508276, internal lab contributors).  In summary, c.113A>C meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.3.0, approved 8/11/2023): PP1_Strong, PS4, PP4_Moderate, PP2, PP3, PM2_Supporting.		Monogenic Diabetes VCEP		2024-03-19	2024-03-19	False	https://erepo.genome.network/evrepo/ui/classification/CA16618475/MONDO:0015967/086	48a7d27c-294c-4c83-89df-d899b89e63fe	p.Gln38Pro	Gln	38	Pro	MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQ	465	P35557	P	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [2], 'SIGNAL_gain_score': array([0.03143978]), 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [35, 36, 37, 38, 39, 40], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.52817047, -0.80792475, -0.5905329 , -0.3458491 , -0.33669138,
       -0.24438441]), 'COILED_loss': [37, 38, 39, 40, 41, 42, 43, 44, 45], 'COILED_gain': [0], 'COILED_gain_score': array([0.09247559]), 'COILED_loss_score': array([-0.53570461, -0.680233  , -0.74138087, -0.83076417, -0.79125673,
       -0.75091833, -0.72777373, -0.56663871, -0.51206201]), 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [83], 'DOMAIN_gain_score': array([0.01905721]), 'REGION_loss': [8, 9, 12], 'REGION_gain': [71, 75, 80, 81, 86], 'REGION_gain_score': array([0.04571867, 0.03421432, 0.04392362, 0.04181981, 0.04325181]), 'REGION_loss_score': array([-0.03381407, -0.04091972, -0.04109246]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
620	NM_000162.5(GCK):c.449T>A (p.Phe150Tyr)	129142	CA231135	NM_000162.5:c.449T>A, NC_000007.14:g.44150990A>T, CM000669.2:g.44150990A>T, NC_000007.13:g.44190589A>T, CM000669.1:g.44190589A>T, NC_000007.12:g.44157114A>T, NG_008847.1:g.43434T>A, NG_008847.2:g.52181T>A, ENST00000395796.8:c.*447T>A, ENST00000616242.5:c.449T>A, ENST00000682635.1:n.935T>A, ENST00000345378.7:c.452T>A, ENST00000403799.8:c.449T>A, ENST00000671824.1:c.449T>A, ENST00000673284.1:c.449T>A, ENST00000345378.6:c.452T>A, ENST00000395796.7:c.446T>A, ENST00000403799.7:c.449T>A, ENST00000437084.1:c.398T>A, ENST00000616242.4:c.446T>A, NM_000162.3:c.449T>A, NM_033507.1:c.452T>A, NM_033508.1:c.446T>A, NM_000162.4:c.449T>A, NM_001354800.1:c.449T>A, NM_033507.2:c.452T>A, NM_033508.2:c.446T>A, NM_033507.3:c.452T>A, NM_033508.3:c.446T>A, NM_000162.5(GCK):c.449T>A (p.Phe150Tyr)	GCK	monogenic diabetes	MONDO:0015967	Semidominant inheritance	Pathogenic	PS4, PP1_Moderate, PP4_Moderate, PP2, PP3, PS3_Moderate, PM2_Supporting	PM1	The c.449T>A variant in the glucokinase gene, GCK, causes an amino acid change of phenylalanine to tyrosine at codon 150 (p.(Phe150Tyr)) of NM_000162.5.  GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2).  This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.962, which is greater than the MDEP VCEP threshold of 0.70 (PP3).  This variant is absent from gnomAD v2.1.1 (PM2_Supporting).  This variant was identified in 10  unrelated individuals with hyperglycemia (PS4; PMIDs: 25306193, 19564454, 32086287, 30663027, 28726111, 22761713, internal lab contributors).  One of these individuals had a clinical history highly specific for GCK-hyperglycemia (FBG 5.5-8 mmol/L and HbA1c 5.6 - 7.6% and negative antibodies) (PP4_Moderate; PMID: 28726111).  This variant segregated with hyperglycemia, with 3 informative meioses in 2 families (PP1_Moderate; internal lab contributors).  MDEP wild type quality control measures were met, and the relative activity Index (RAI) of this variant was found to be 0.014, which is below the MDEP cutoff (<0.5) (PS3_Moderate, PMID: 22761713).  In summary, c.449T>A meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.3.0, approved 8/11/2023): PS4, PP1_Moderate, PP4_Moderate, PS3_Moderate, PP2, PP3, PM2_Supporting.	22761713	Monogenic Diabetes VCEP		2024-01-06	2024-01-06	False	https://erepo.genome.network/evrepo/ui/classification/CA231135/MONDO:0015967/086	8f461c2d-5648-4776-a76a-bec2564f0ba7	p.Phe150Tyr	Phe	150	Tyr	MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQ	465	P35557	Y	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [2], 'SIGNAL_gain_score': array([0.03202903]), 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [83, 221, 224], 'DOMAIN_gain_score': array([0.00297499, 0.06612521, 0.03079617]), 'REGION_loss': [], 'REGION_gain': [71, 75, 80], 'REGION_gain_score': array([0.02364063, 0.02430558, 0.0257228 ]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
621	NM_000138.5(FBN1):c.79G>A (p.Ala27Thr)	163486	CA017499	NM_000138.5:c.79G>A, NC_000015.10:g.48644691C>T, CM000677.2:g.48644691C>T, NC_000015.9:g.48936888C>T, CM000677.1:g.48936888C>T, NC_000015.8:g.46724180C>T, NG_008805.2:g.6098G>A, LRG_778:g.6098G>A, ENST00000316623.10:c.79G>A, ENST00000316623.9:c.79G>A, ENST00000537463.6:c.79G>A, ENST00000558230.1:n.142G>A, ENST00000560355.1:c.79G>A, NM_000138.4:c.79G>A, LRG_778t1:c.79G>A, NM_000138.5(FBN1):c.79G>A (p.Ala27Thr)	FBN1	Marfan syndrome	MONDO:0007947	Autosomal dominant inheritance	Benign	BA1, BP4	BP2	The NM_000138.5 c.79G>A, is a missense variant in FBN1 predicted to cause a substitution of a alanine acid by threonine at amino acid 27 (p.Ala27Thr). This variant has been previously reported in ClinVar as likely benign and benign (Variation ID: 163486). This variant has been identified in 129/19954 (0.65%) of individuals of East Asian origin (MAF: 0.65%) (BA1; https://gnomad.broadinstitute.org/ version 2.1.1). It has been reported in individuals with thoracic aortic aneurysm and/or dissection, and in individuals with clinical features of Marfan syndrome, however it was considered to be a polymorphism (PMID 26272055, 19839986, 16835936). Computational prediction tools and conservation analysis suggests no impact on the protein (REVEL: 0.097) (BP4). The constraint z-score for missense variants affecting FBN1 is 5.06, however due to the presence of two benign arguments, PP2 cannot be used. In summary, this variant meets criteria to be classified as benign for Marfan syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGenFBN1 VCEP: BA1, BP4.		FBN1 VCEP	https://clinicalgenome.org/docs/clingen-fbn1-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2023-09-28	2023-09-28	False	https://erepo.genome.network/evrepo/ui/classification/CA017499/MONDO:0007947/022	06981afe-9f52-4bdc-b6e0-b30bad5cda4d	p.Ala27Thr	Ala	27	Thr	MRRGRLLEIALGFTVLLASYTSHGADANLEAGNVKETRASRAKRRGGGGHDALKGPNVCGSRYNAYCCPGWKTLPGGNQCIVPICRHSCGDGFCSRPNMCTCPSGQIAPSCGSRSIQHCNIRCMNGGSCSDDHCLCQKGYIGTHCGQPVCESGCLNGGRCVAPNRCACTYGFTGPQCERDYRTGPCFTVISNQMCQGQLSGIVCTKTLCCATVGRAWGHPCEMCPAQPHPCRRGFIPNIRTGACQDVDECQAIPGLCQGGNCINTVGSFECKCPAGHKLNEVSQKCEDIDECSTIPGICEGGECTNTVSSYFCKCPPGFYTSPDGTRCIDVRPGYCYTALTNGRCSNQLPQSITKMQCCCDAGRCWSPGVTVAPEMCPIRATEDFNKLCSVPMVIPGRPEYPPPPLGPIPPVLPVPPGFPPGPQIPVPRPPVEYLYPSREPPRVLPVNVTDYCQLVRYLCQNGRCIPTPGSYRCECNKGFQLDLRGECIDVDECEKNPCAGGECINNQGSYTCQCRAGYQSTLTRTECRDIDECLQNGRICNNGRCINTDGSFHCVCNAGFHVTRDGKNCEDMDECSIRNMCLNGMCINEDGSFKCICKPGFQLASDGRYCKDINECETPGICMNGRCVNTDGSYRCECFPGLAVGLDGRVCVDTHMRSTCYGGYKRGQCIKPLFGAVTKSECCCASTEYAFGEPCQPCPAQNSAEYQALCSSGPGMTSAGSDINECALDPDICPNGICENLRGTYKCICNSGYEVDSTGKNCVDINECVLNSLLCDNGQCRNTPGSFVCTCPKGFIYKPDLKTCEDIDECESSPCINGVCKNSPGSFICECSSESTLDPTKTICIETIKGTCWQTVIDGRCEININGATLKSQCCSSLGAAWGSPCTLCQVDPICGKGYSRIKGTQCEDIDECEVFPGVCKNGLCVNTRGSFKCQCPSGMTLDATGRICLDIRLETCFLRYEDEECTLPIAGRHRMDACCCSVGAAWGTEECEECPMRNTPEYEELCPRGPGFATKEITNGKPFFKDINECKMIPSLCTHGKCRNTIGSFKCRCDSGFALDSEERNCTDIDECRISPDLCGRGQCVNTPGDFECKCDEGYESGFMMMKNCMDIDECQRDPLLCRGGVCHNTEGSYRCECPPGHQLSPNISACIDINECELSAHLCPNGRCVNLIGKYQCACNPGYHSTPDRLFCVDIDECSIMNGGCETFCTNSEGSYECSCQPGFALMPDQRSCTDIDECEDNPNICDGGQCTNIPGEYRCLCYDGFMASEDMKTCVDVNECDLNPNICLSGTCENTKGSFICHCDMGYSGKKGKTGCTDINECEIGAHNCGKHAVCTNTAGSFKCSCSPGWIGDGIKCTDLDECSNGTHMCSQHADCKNTMGSYRCLCKEGYTGDGFTCTDLDECSENLNLCGNGQCLNAPGGYRCECDMGFVPSADGKACEDIDECSLPNICVFGTCHNLPGLFRCECEIGYELDRSGGNCTDVNECLDPTTCISGNCVNTPGSYICDCPPDFELNPTRVGCVDTRSGNCYLDIRPRGDNGDTACSNEIGVGVSKASCCCSLGKAWGTPCEMCPAVNTSEYKILCPGGEGFRPNPITVILEDIDECQELPGLCQGGKCINTFGSFQCRCPTGYYLNEDTRVCDDVNECETPGICGPGTCYNTVGNYTCICPPDYMQVNGGNNCMDMRRSLCYRNYYADNQTCDGELLFNMTKKMCCCSYNIGRAWNKPCEQCPIPSTDEFATLCGSQRPGFVIDIYTGLPVDIDECREIPGVCENGVCINMVGSFRCECPVGFFYNDKLLVCEDIDECQNGPVCQRNAECINTAGSYRCDCKPGYRFTSTGQCNDRNECQEIPNICSHGQCIDTVGSFYCLCHTGFKTNDDQTMCLDINECERDACGNGTCRNTIGSFNCRCNHGFILSHNNDCIDVDECASGNGNLCRNGQCINTVGSFQCQCNEGYEVAPDGRTCVDINECLLEPRKCAPGTCQNLDGSYRCICPPGYSLQNEKCEDIDECVEEPEICALGTCSNTEGSFKCLCPEGFSLSSSGRRCQDLRMSYCYAKFEGGKCSSPKSRNHSKQECCCALKGEGWGDPCELCPTEPDEAFRQICPYGSGIIVGPDDSAVDMDECKEPDVCKHGQCINTDGSYRCECPFGYILAGNECVDTDECSVGNPCGNGTCKNVIGGFECTCEEGFEPGPMMTCEDINECAQNPLLCAFRCVNTYGSYECKCPVGYVLREDRRMCKDEDECEEGKHDCTEKQMECKNLIGTYMCICGPGYQRRPDGEGCVDENECQTKPGICENGRCLNTRGSYTCECNDGFTASPNQDECLDNREGYCFTEVLQNMCQIGSSNRNPVTKSECCCDGGRGWGPHCEICPFQGTVAFKKLCPHGRGFMTNGADIDECKVIHDVCRNGECVNDRGSYHCICKTGYTPDITGTSCVDLNECNQAPKPCNFICKNTEGSYQCSCPKGYILQEDGRSCKDLDECATKQHNCQFLCVNTIGGFTCKCPPGFTQHHTSCIDNNECTSDINLCGSKGICQNTPGSFTCECQRGFSLDQTGSSCEDVDECEGNHRCQHGCQNIIGGYRCSCPQGYLQHYQWNQCVDENECLSAHICGGASCHNTLGSYKCMCPAGFQYEQFSGGCQDINECGSAQAPCSYGCSNTEGGYLCGCPPGYFRIGQGHCVSGMGMGRGNPEPPVSGEMDDNSLSPEACYECKINGYPKRGRKRRSTNETDASNIEDQSETEANVSLASWDVEKTAIFAFNISHVSNKVRILELLPALTTLTNHNRYLIESGNEDGFFKINQKEGISYLHFTKKKPVAGTYSLQISSTPLYKKKELNQLEDKYDKDYLSGELGDNLKMKIQVLLH	2871	P35555	T	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [2458], 'DOMAIN_gain_score': array([0.00703681]), 'REGION_loss': [933, 976, 1235, 1255, 1273, 2074, 2146, 2184, 2195, 2210, 2216, 2536], 'REGION_gain': [], 'REGION_loss_score': array([-0.00185311, -0.00199044, -0.0037508 , -0.00422937, -0.00340271,
       -0.00099009, -0.00152326, -0.00138652, -0.00129104, -0.00146443,
       -0.00140399, -0.00273371]), 'REPEAT_loss': [1031], 'REPEAT_gain': [2547], 'REPEAT_gain_score': array([0.00378734]), 'REPEAT_loss_score': array([-0.00099939]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
622	NM_005249.5(FOXG1):c.455G>C (p.Gly152Ala)	538817	CA389475129	NM_005249.5:c.455G>C, NC_000014.9:g.28767734G>C, CM000676.2:g.28767734G>C, NC_000014.8:g.29236940G>C, CM000676.1:g.29236940G>C, NC_000014.7:g.28306691G>C, NG_009367.1:g.5654G>C, ENST00000313071.7:c.455G>C, ENST00000313071.6:c.455G>C, NM_005249.4:c.455G>C, NM_005249.5(FOXG1):c.455G>C (p.Gly152Ala)	FOXG1	FOXG1 disorder	MONDO:0100040	Autosomal dominant inheritance	Benign	BP5_Strong, BS1, BS2, BP4		The allele frequency of the p.Gly152Ala variant in FOXG1 is 0.008% in Latino sub population in gnomAD, which is high enough to meet the BS1 criteria based on thresholds defined by the ClinGen Rett/Angelman-like Expert Panel for Rett/AS-like conditions (BS1). The p.Gly152Ala variant is observed in at least 20 unaffected individuals (internal database - GeneDx; internal database - Invitae) (BS2).The p.Gly152Ala variant is found in at least 4 patients with an alternate molecular basis of disease (internal database - GeneDx; internal database - Invitae) (BP5_strong). Computational analysis prediction tools suggest that the p.Gly152Ala variant does not have a deleterious impact; however this information does not predict clinical significance on its own (BP4). In summary, the p.Gly152Ala variant in FOXG1 is classified as Benign based on the ACMG/AMP criteria (BS1, BS2, BP5_strong, BP4).		Rett and Angelman-like Disorders VCEP		2023-10-13	2023-12-08	False	https://erepo.genome.network/evrepo/ui/classification/CA389475129/MONDO:0100040/035	2b929ff0-8b7d-4641-bbea-2611b4ad2ad3	p.Gly152Ala	Gly	152	Ala	MLDMGDRKEVKMIPKSSFSINSLVPEAVQNDNHHASHGHHNSHHPQHHHHHHHHHHHPPPPAPQPPPPPQQQQPPPPPPPAPQPPQTRGAPAADDDKGPQQLLLPPPPPPPPAAALDGAKADGLGGKGEPGGGPGELAPVGPDEKEKGAGAGGEEKKGAGEGGKDGEGGKEGEKKNGKYEKPPFSYNALIMMAIRQSPEKRLTLNGIYEFIMKNFPYYRENKQGWQNSIRHNLSLNKCFVKVPRHYDDPGKGNYWMLDPSSDDVFIGGTTGKLRRRSTTSRAKLAFKRGARLTSTGLTFMDRAGSLYWPMSPFLSLHHPRASSTLSYNGTTSAYPSHPMPYSSVLTQNSLGNNHSFSTANGLSVDRLVNGEIPYATHHLTAAALAASVPCGLSVPCSGTYSLNPCSVNLLAGQTSYFFPHVPHPSMTSQSSTSMSARAASSSTSPQAPSTLPCESLRPSLPSFTTGLSGGLSDYFTHQNQGSSSNPLIH	489	P55316	A	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
623	NM_001110792.2(MECP2):c.877G>A (p.Ala293Thr)	386725	CA10558543	NM_001110792.2:c.877G>A, NC_000023.11:g.154030987C>T, CM000685.2:g.154030987C>T, NC_000023.10:g.153296438C>T, CM000685.1:g.153296438C>T, NC_000023.9:g.152949632C>T, NG_007107.2:g.111141G>A, NG_007107.3:g.111117G>A, ENST00000303391.11:c.841G>A, ENST00000453960.7:c.877G>A, ENST00000637917.1:c.66-51G>A, ENST00000303391.10:c.841G>A, ENST00000407218.5:c.*213G>A, ENST00000453960.6:c.877G>A, ENST00000619732.4:c.841G>A, ENST00000622433.4:c.829G>A, ENST00000628176.2:c.*213G>A, NM_001110792.1:c.877G>A, NM_001316337.1:c.562G>A, NM_004992.3:c.841G>A, XM_005274681.3:c.841G>A, XM_005274682.3:c.562G>A, XM_005274683.3:c.562G>A, XM_006724819.2:c.172G>A, XM_011531166.1:c.562G>A, XM_006724819.3:c.172G>A, XM_011531166.2:c.562G>A, XM_024452383.1:c.562G>A, XM_024452384.1:c.562G>A, NM_001316337.2:c.562G>A, NM_001369391.2:c.562G>A, NM_001369392.2:c.562G>A, NM_001369393.2:c.562G>A, NM_001369394.1:c.562G>A, NM_001369394.2:c.562G>A, NM_001386137.1:c.172G>A, NM_001386138.1:c.172G>A, NM_001386139.1:c.172G>A, NM_004992.4:c.841G>A, NM_001110792.2(MECP2):c.877G>A (p.Ala293Thr)	MECP2	Rett syndrome	MONDO:0010726	X-linked inheritance	Benign	BA1, BS2	BP4	The allele frequency of the p.Ala281Thr variant in MECP2 (NM_004992.3) is 0.037% in the South Asian sub population in gnomAD, which is high enough to be classified as benign based on thresholds defined by the ClinGen Rett/Angelman-like Expert Panel for Rett/AS-like conditions (BA1). The p.Ala281Thr variant is observed in at least 8 unaffected individuals (internal database - Invitae) (BS2). In summary, the p.Ala281Thr variant in MECP2 is classified as Benign based on the ACMG/AMP criteria (BA1, BS2).		Rett and Angelman-like Disorders VCEP		2023-10-13	2023-12-08	False	https://erepo.genome.network/evrepo/ui/classification/CA10558543/MONDO:0010726/036	2f74986e-d5ce-493c-b0bb-09d790cb4c9f	p.Ala293Thr	Ala	293	Thr	MVAGMLGLREEKSEDQDLQGLKDKPLKFKKVKKDKKEEKEGKHEPVQPSAHHSAEPAEAGKAETSEGSGSAPAVPEASASPKQRRSIIRDRGPMYDDPTLPEGWTRKLKQRKSGRSAGKYDVYLINPQGKAFRSKVELIAYFEKVGDTSLDPNDFDFTVTGRGSPSRREQKPPKKPKSPKAPGTGRGRGRPKGSGTTRPKAATSEGVQVKRVLEKSPGKLLVKMPFQTSPGGKAEGGGATTSTQVMVIKRPGRKRKAEADPQAIPKKRGRKPGSVVAAAAAEAKKKAVKESSIRSVQETVLPIKKRKTRETVSIEVKEVVKPLLVSTLGEKSGKGLKTCKSPGRKSKESSPKGRSSSASSPPKKEHHHHHHHSESPKAPVPLLPPLPPPPPEPESSEDPTSPPEPQDLSSSVCKEEKMPRGGSLESDGCPKEPAKTQPAVATAATAAEKYKHRGEGERKDIVSSSMPRPNREEPVDSRTPVTERVS	486	P51608	T	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [288, 302], 'COMPBIAS_gain_score': array([0.26115388, 0.20529586]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [302, 304, 305, 306, 307, 308, 309, 310, 311, 323], 'REGION_gain_score': array([0.43620467, 0.36187017, 0.36724502, 0.34798759, 0.3868829 ,
       0.3110736 , 0.31462079, 0.26479089, 0.22644109, 0.15210378]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
624	NM_000156.6(GAMT):c.133T>A (p.Trp45Arg)	328352	CA10651554	NM_000156.6:c.133T>A, NC_000019.10:g.1401344A>T, CM000681.2:g.1401344A>T, NC_000019.9:g.1401343A>T, CM000681.1:g.1401343A>T, NC_000019.8:g.1352343A>T, NG_009785.1:g.5210T>A, ENST00000252288.8:c.133T>A, ENST00000447102.8:c.133T>A, ENST00000640762.1:c.112+21T>A, ENST00000252288.6:c.133T>A, ENST00000447102.7:c.133T>A, NM_000156.5:c.133T>A, NM_138924.2:c.133T>A, NM_138924.3:c.133T>A, NM_000156.6(GAMT):c.133T>A (p.Trp45Arg)	GAMT	guanidinoacetate methyltransferase deficiency	MONDO:0012999	Autosomal recessive inheritance	Pathogenic	PS3_Supporting, PP3, PM2_Supporting, PM3_Strong, PP4_Strong		The NM_000156.6:c.133T>A variant in GAMT is a missense variant predicted to cause substitution of tryptophan by arginine at amino acid 45 (p.Trp45Arg). This variant has been detected in 4 unrelated individuals with GAMT deficiency (PMID: 24415674, PMID: 29506905, PMID: 23660394, PMID: 24268530). Of those individuals, one was homozygous for the variant (PMID: 29506905), two were compound heterozygous for the variant and a pathogenic variant, c.327G>A, in trans (phase confirmed by parental testing) (PMID: 24415674, PMID: 23660394), and two were compound heterozygous for the variant and a pathogenic variant, c.327G>A, with phase unknown (PMID: 24268530) (3pts total, PM3_Strong). One of these individuals had an absent creatine peak and present GAA peak on brain MRS and elevated GAA in urine (PMID: 24415674) (PP4_Strong). The highest population minor allele frequency in gnomAD v2.1.1 is 0.00005 in the European (non-Finnish) population, which is lower than the ClinGen CCDS VCEP's threshold for PM2_Supporting (<0.0004), meeting this criterion (PM2_Supporting). Expression of the variant in GAMT-deficient fibroblasts resulted in undetectable GAMT activity indicating that this variant may impact protein function (PMID: 24415674)(PS3_Supporting). The computational predictor REVEL gives a score of 0.95 which is above the threshold of 0.75, evidence that correlates with impact to GAMT function (PP3). There is a ClinVar entry for this variant (Variation ID: 328352). In summary, this variant meets the criteria to be classified as pathogenic for GAMT deficiency based on the ACMG/AMP criteria applied, as specified by the ClinGen Cerebral Creatine Deficiency Syndromes Variant Curation Expert Panel (Specifications Version 1.1.0): PS3_Supporting, PM2_Supporting, PM3_Strong, PP3, PP4_Strong.(Classification approved by the ClinGen CCDS VCEP on Sept. 14, 2023)		Cerebral Creatine Deficiency Syndromes VCEP		2023-11-08	2023-11-08	False	https://erepo.genome.network/evrepo/ui/classification/CA10651554/MONDO:0012999/026	32560924-6d9e-4d50-86f9-cc09a65e4c56	p.Trp45Arg	Trp	45	Arg	MSAPSATPIFAPGENCSPAWGAAPAAYDAADTHLRILGKPVMERWETPYMHALAAAASSKGGRVLEVGFGMAIAASKVQEAPIDEHWIIECNDGVFQRLRDWAPRQTHKVIPLKGLWEDVAPTLPDGHFDGILYDTYPLSEETWHTHQFNFIKNHAFRLLKPGGVLTYCNLTSWGELMKSKYSDITIMFEETQVPALLEAGFRRENIRTEVMALVPPADCRYYAFPQMITPLVTKG	236	Q14353	R	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [133, 142], 'DNA_BIND_gain': [], 'DNA_BIND_loss_score': array([-0.00537735, -0.00257766]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [3, 4], 'TRANSIT_gain_score': array([0.01772922, 0.01889789]), 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [58], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.11134297]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [7], 'DOMAIN_gain_score': array([0.01789421]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [164], 'REPEAT_gain_score': array([0.00533736]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
625	NM_000138.5(FBN1):c.1453C>T (p.Arg485Cys)	16466	CA012160	NM_000138.5:c.1453C>T, NC_000015.10:g.48515402G>A, CM000677.2:g.48515402G>A, NC_000015.9:g.48807599G>A, CM000677.1:g.48807599G>A, NC_000015.8:g.46594891G>A, NG_008805.2:g.135387C>T, LRG_778:g.135387C>T, ENST00000684448.1:n.127C>T, ENST00000316623.10:c.1453C>T, ENST00000316623.9:c.1453C>T, ENST00000537463.6:c.636+22309C>T, NM_000138.4:c.1453C>T, LRG_778t1:c.1453C>T, NM_000138.5(FBN1):c.1453C>T (p.Arg485Cys)	FBN1	Marfan syndrome	MONDO:0007947	Autosomal dominant inheritance	Pathogenic	PS4, PM1, PS2_Supporting, PP1_Strong, PP2, PM2_Supporting	PS3, PS1, PM3, PM4, PM5, BP7, BS1, BS4, BS3, BS2, PP3, PP4, PM6, PVS1, BP2, BP1, BP4, BP3, BA1	NM_00138 c.1453C>T is a missense variant in FBN1 predicted to cause a substitution of an arginine by cysteine at amino acid 485 (p.Arg484Cys). This variant has been identified in the literature in at least seven probands with features consistent with or suggestive of Marfan syndrome including thoracic aortic aneurysm and dissection (TAAD) with or without additional features (PS4; PMIDs: 16342915, 19293843, 24793577, 30485715). It was found in the homozygous state in two cousins with bilateral ectopia lentis (EL) and additional features of Marfan syndrome; of note, in both instances the variant was inherited from mildly affected or apparently unaffected heterozygous parents (PMID: 17568394). It was identified in trans with a different FBN1 pathogenic variant in three siblings with isolated EL (Bichat internal data); clinical information for the heterozygous parents was not available. The variant has also been identified in the heterozygous state in 5 additional internal probands diagnosed with TAAD with or without systemic features (UZG, Johns Hopkins University, Bichat, & University of Tokyo internal data). It has been found to segregate in the heterozygous state with features of Marfan syndrome in at least 19 individuals among five different families (PP1_strong; PMID: 30485715; Johns Hopkins & Bichat internal data). It has been identified as de novo once with confirmed maternity/paternity in an internal proband with a non-specific phenotype (PS2_supporting; PMID: 19293843; UZG internal data). It is not present in gnomAD (PM2_supporting; https://gnomad.broadinstitute.org/). This variant introduces a novel cysteine residue which may impede the normal formation of critical disulfide bridges (PM1). Computational prediction tools and conservation analysis are unclear about the variant’s predicted impact on the protein’s structure or function. The constraint z-score for missense variants affecting FBN1 is 5.06 (PP2). In summary, this variant meets criteria to be classified as pathogenic for Marfan syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen FBN1 VCEP: PS4, PP1_strong, PM1, PS2_supporting, PM2_supporting, PP2.		FBN1 VCEP	https://clinicalgenome.org/docs/clingen-fbn1-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2023-11-16	2023-11-16	False	https://erepo.genome.network/evrepo/ui/classification/CA012160/MONDO:0007947/022	326c25fb-e8bf-44cd-83e0-6f57e005411d	p.Arg485Cys	Arg	485	Cys	MRRGRLLEIALGFTVLLASYTSHGADANLEAGNVKETRASRAKRRGGGGHDALKGPNVCGSRYNAYCCPGWKTLPGGNQCIVPICRHSCGDGFCSRPNMCTCPSGQIAPSCGSRSIQHCNIRCMNGGSCSDDHCLCQKGYIGTHCGQPVCESGCLNGGRCVAPNRCACTYGFTGPQCERDYRTGPCFTVISNQMCQGQLSGIVCTKTLCCATVGRAWGHPCEMCPAQPHPCRRGFIPNIRTGACQDVDECQAIPGLCQGGNCINTVGSFECKCPAGHKLNEVSQKCEDIDECSTIPGICEGGECTNTVSSYFCKCPPGFYTSPDGTRCIDVRPGYCYTALTNGRCSNQLPQSITKMQCCCDAGRCWSPGVTVAPEMCPIRATEDFNKLCSVPMVIPGRPEYPPPPLGPIPPVLPVPPGFPPGPQIPVPRPPVEYLYPSREPPRVLPVNVTDYCQLVRYLCQNGRCIPTPGSYRCECNKGFQLDLRGECIDVDECEKNPCAGGECINNQGSYTCQCRAGYQSTLTRTECRDIDECLQNGRICNNGRCINTDGSFHCVCNAGFHVTRDGKNCEDMDECSIRNMCLNGMCINEDGSFKCICKPGFQLASDGRYCKDINECETPGICMNGRCVNTDGSYRCECFPGLAVGLDGRVCVDTHMRSTCYGGYKRGQCIKPLFGAVTKSECCCASTEYAFGEPCQPCPAQNSAEYQALCSSGPGMTSAGSDINECALDPDICPNGICENLRGTYKCICNSGYEVDSTGKNCVDINECVLNSLLCDNGQCRNTPGSFVCTCPKGFIYKPDLKTCEDIDECESSPCINGVCKNSPGSFICECSSESTLDPTKTICIETIKGTCWQTVIDGRCEININGATLKSQCCSSLGAAWGSPCTLCQVDPICGKGYSRIKGTQCEDIDECEVFPGVCKNGLCVNTRGSFKCQCPSGMTLDATGRICLDIRLETCFLRYEDEECTLPIAGRHRMDACCCSVGAAWGTEECEECPMRNTPEYEELCPRGPGFATKEITNGKPFFKDINECKMIPSLCTHGKCRNTIGSFKCRCDSGFALDSEERNCTDIDECRISPDLCGRGQCVNTPGDFECKCDEGYESGFMMMKNCMDIDECQRDPLLCRGGVCHNTEGSYRCECPPGHQLSPNISACIDINECELSAHLCPNGRCVNLIGKYQCACNPGYHSTPDRLFCVDIDECSIMNGGCETFCTNSEGSYECSCQPGFALMPDQRSCTDIDECEDNPNICDGGQCTNIPGEYRCLCYDGFMASEDMKTCVDVNECDLNPNICLSGTCENTKGSFICHCDMGYSGKKGKTGCTDINECEIGAHNCGKHAVCTNTAGSFKCSCSPGWIGDGIKCTDLDECSNGTHMCSQHADCKNTMGSYRCLCKEGYTGDGFTCTDLDECSENLNLCGNGQCLNAPGGYRCECDMGFVPSADGKACEDIDECSLPNICVFGTCHNLPGLFRCECEIGYELDRSGGNCTDVNECLDPTTCISGNCVNTPGSYICDCPPDFELNPTRVGCVDTRSGNCYLDIRPRGDNGDTACSNEIGVGVSKASCCCSLGKAWGTPCEMCPAVNTSEYKILCPGGEGFRPNPITVILEDIDECQELPGLCQGGKCINTFGSFQCRCPTGYYLNEDTRVCDDVNECETPGICGPGTCYNTVGNYTCICPPDYMQVNGGNNCMDMRRSLCYRNYYADNQTCDGELLFNMTKKMCCCSYNIGRAWNKPCEQCPIPSTDEFATLCGSQRPGFVIDIYTGLPVDIDECREIPGVCENGVCINMVGSFRCECPVGFFYNDKLLVCEDIDECQNGPVCQRNAECINTAGSYRCDCKPGYRFTSTGQCNDRNECQEIPNICSHGQCIDTVGSFYCLCHTGFKTNDDQTMCLDINECERDACGNGTCRNTIGSFNCRCNHGFILSHNNDCIDVDECASGNGNLCRNGQCINTVGSFQCQCNEGYEVAPDGRTCVDINECLLEPRKCAPGTCQNLDGSYRCICPPGYSLQNEKCEDIDECVEEPEICALGTCSNTEGSFKCLCPEGFSLSSSGRRCQDLRMSYCYAKFEGGKCSSPKSRNHSKQECCCALKGEGWGDPCELCPTEPDEAFRQICPYGSGIIVGPDDSAVDMDECKEPDVCKHGQCINTDGSYRCECPFGYILAGNECVDTDECSVGNPCGNGTCKNVIGGFECTCEEGFEPGPMMTCEDINECAQNPLLCAFRCVNTYGSYECKCPVGYVLREDRRMCKDEDECEEGKHDCTEKQMECKNLIGTYMCICGPGYQRRPDGEGCVDENECQTKPGICENGRCLNTRGSYTCECNDGFTASPNQDECLDNREGYCFTEVLQNMCQIGSSNRNPVTKSECCCDGGRGWGPHCEICPFQGTVAFKKLCPHGRGFMTNGADIDECKVIHDVCRNGECVNDRGSYHCICKTGYTPDITGTSCVDLNECNQAPKPCNFICKNTEGSYQCSCPKGYILQEDGRSCKDLDECATKQHNCQFLCVNTIGGFTCKCPPGFTQHHTSCIDNNECTSDINLCGSKGICQNTPGSFTCECQRGFSLDQTGSSCEDVDECEGNHRCQHGCQNIIGGYRCSCPQGYLQHYQWNQCVDENECLSAHICGGASCHNTLGSYKCMCPAGFQYEQFSGGCQDINECGSAQAPCSYGCSNTEGGYLCGCPPGYFRIGQGHCVSGMGMGRGNPEPPVSGEMDDNSLSPEACYECKINGYPKRGRKRRSTNETDASNIEDQSETEANVSLASWDVEKTAIFAFNISHVSNKVRILELLPALTTLTNHNRYLIESGNEDGFFKINQKEGISYLHFTKKKPVAGTYSLQISSTPLYKKKELNQLEDKYDKDYLSGELGDNLKMKIQVLLH	2871	P35555	C	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [480], 'STRAND_gain': [1948], 'STRAND_gain_score': array([0.00539321]), 'STRAND_loss_score': array([-0.04419941]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [471, 473, 476, 478, 482], 'DOMAIN_gain': [484, 1806, 1842, 1913, 2182, 2458, 2493, 2503, 2504], 'DOMAIN_gain_score': array([0.07170659, 0.02766269, 0.03568035, 0.02722764, 0.01859158,
       0.01855248, 0.0268895 , 0.02586973, 0.02160394]), 'DOMAIN_loss_score': array([-0.12011498, -0.14543104, -0.14394587, -0.11181974, -0.1347639 ]), 'REGION_loss': [933, 976, 2536], 'REGION_gain': [432, 435, 438, 439, 440, 445, 1672, 1673, 1674, 1675], 'REGION_gain_score': array([0.02249402, 0.02251792, 0.02874184, 0.02807909, 0.02832973,
       0.0343594 , 0.04422861, 0.04298359, 0.04584181, 0.04460245]), 'REGION_loss_score': array([-0.00185597, -0.00109762, -0.00137287]), 'REPEAT_loss': [485], 'REPEAT_gain': [247, 283, 909, 912, 1518, 2547], 'REPEAT_gain_score': array([0.00744212, 0.015504  , 0.01164705, 0.0106827 , 0.01205033,
       0.004704  ]), 'REPEAT_loss_score': array([-0.02415425]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
626	NM_000138.5(FBN1):c.1708T>C (p.Cys570Arg)	956400	CA269554328	NM_000138.5:c.1708T>C, NC_000015.10:g.48510050A>G, CM000677.2:g.48510050A>G, NC_000015.9:g.48802247A>G, CM000677.1:g.48802247A>G, NC_000015.8:g.46589539A>G, NG_008805.2:g.140739T>C, LRG_778:g.140739T>C, ENST00000684448.1:n.382T>C, ENST00000316623.10:c.1708T>C, ENST00000316623.9:c.1708T>C, ENST00000537463.6:c.636+27661T>C, NM_000138.4:c.1708T>C, LRG_778t1:c.1708T>C, NM_000138.5(FBN1):c.1708T>C (p.Cys570Arg)	FBN1	Marfan syndrome	MONDO:0007947	Autosomal dominant inheritance	Pathogenic	PS4_Moderate, PS3_Supporting, PM1_Strong, PP4, PP2, PP3, PM2_Supporting	PS1, PS2, PM5, PM4, PM3, BS1, BS3, BS4, BP5, BS2, PP1, PVS1, PM6, BA1, BP4, BP3, BP2	NM_00138 c.1708T>C is a missense variant in FBN1 predicted to cause a substitution of a cysteine by arginine at amino acid 570 (p.Cys570Arg). This variant has been found in two probands with ectopia lentis (EL), one of whom was also reported to have numerous systemic features of Marfan syndrome without thoracic aortic aneurysm and dissection (TAAD), as well as a proband with isolated TAAD (PS4_moderate; PMID: 10486319; 3billion & Invitae internal data, ClinVar Variation ID: 956400). An additional proband with a severe Marfan syndrome phenotype including EL, TAAD, and major skeletal involvement (PP4; Bichat internal data). Functional studies performed on patient fibroblasts with this variant demonstrated reduced fibrillin synthesis and secretion (50% and 28% of controls, respectively) (PS3_supporting; PMID: 10486319). This variant is not present in gnomAD (PM2_supporting; https://gnomad.broadinstitute.org/). This variant affects a cysteine residue in a calcium binding EGF domain; cysteine residues are believed to be involved in the formation of disulfide bridges which are essential for the protein structure (PM1_strong). Several other variants affecting this codon have been reported in association with Marfan syndrome (p.Cys570Gly, p.Cys570SerSer, p.Cys570Trp, p.Cys570Tyr). Computational prediction tools and conservation analysis support that this variant may impact the protein’s structure or function (PP3). The constraint z-score for missense variants affecting FBN1 is 5.06 (PP2). In summary, this variant meets criteria to be classified as pathogenic for Marfan syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen FBN1 VCEP: PM1_strong, PS4_moderate, PS3_supporting, PM2_supporting, PP2, PP3, PP4.	10486319	FBN1 VCEP	https://clinicalgenome.org/docs/clingen-fbn1-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2023-11-16	2023-11-16	False	https://erepo.genome.network/evrepo/ui/classification/CA269554328/MONDO:0007947/022	38d36d10-5c7c-455c-9338-0706c4a6f7f9	p.Cys570Arg	Cys	570	Arg	MRRGRLLEIALGFTVLLASYTSHGADANLEAGNVKETRASRAKRRGGGGHDALKGPNVCGSRYNAYCCPGWKTLPGGNQCIVPICRHSCGDGFCSRPNMCTCPSGQIAPSCGSRSIQHCNIRCMNGGSCSDDHCLCQKGYIGTHCGQPVCESGCLNGGRCVAPNRCACTYGFTGPQCERDYRTGPCFTVISNQMCQGQLSGIVCTKTLCCATVGRAWGHPCEMCPAQPHPCRRGFIPNIRTGACQDVDECQAIPGLCQGGNCINTVGSFECKCPAGHKLNEVSQKCEDIDECSTIPGICEGGECTNTVSSYFCKCPPGFYTSPDGTRCIDVRPGYCYTALTNGRCSNQLPQSITKMQCCCDAGRCWSPGVTVAPEMCPIRATEDFNKLCSVPMVIPGRPEYPPPPLGPIPPVLPVPPGFPPGPQIPVPRPPVEYLYPSREPPRVLPVNVTDYCQLVRYLCQNGRCIPTPGSYRCECNKGFQLDLRGECIDVDECEKNPCAGGECINNQGSYTCQCRAGYQSTLTRTECRDIDECLQNGRICNNGRCINTDGSFHCVCNAGFHVTRDGKNCEDMDECSIRNMCLNGMCINEDGSFKCICKPGFQLASDGRYCKDINECETPGICMNGRCVNTDGSYRCECFPGLAVGLDGRVCVDTHMRSTCYGGYKRGQCIKPLFGAVTKSECCCASTEYAFGEPCQPCPAQNSAEYQALCSSGPGMTSAGSDINECALDPDICPNGICENLRGTYKCICNSGYEVDSTGKNCVDINECVLNSLLCDNGQCRNTPGSFVCTCPKGFIYKPDLKTCEDIDECESSPCINGVCKNSPGSFICECSSESTLDPTKTICIETIKGTCWQTVIDGRCEININGATLKSQCCSSLGAAWGSPCTLCQVDPICGKGYSRIKGTQCEDIDECEVFPGVCKNGLCVNTRGSFKCQCPSGMTLDATGRICLDIRLETCFLRYEDEECTLPIAGRHRMDACCCSVGAAWGTEECEECPMRNTPEYEELCPRGPGFATKEITNGKPFFKDINECKMIPSLCTHGKCRNTIGSFKCRCDSGFALDSEERNCTDIDECRISPDLCGRGQCVNTPGDFECKCDEGYESGFMMMKNCMDIDECQRDPLLCRGGVCHNTEGSYRCECPPGHQLSPNISACIDINECELSAHLCPNGRCVNLIGKYQCACNPGYHSTPDRLFCVDIDECSIMNGGCETFCTNSEGSYECSCQPGFALMPDQRSCTDIDECEDNPNICDGGQCTNIPGEYRCLCYDGFMASEDMKTCVDVNECDLNPNICLSGTCENTKGSFICHCDMGYSGKKGKTGCTDINECEIGAHNCGKHAVCTNTAGSFKCSCSPGWIGDGIKCTDLDECSNGTHMCSQHADCKNTMGSYRCLCKEGYTGDGFTCTDLDECSENLNLCGNGQCLNAPGGYRCECDMGFVPSADGKACEDIDECSLPNICVFGTCHNLPGLFRCECEIGYELDRSGGNCTDVNECLDPTTCISGNCVNTPGSYICDCPPDFELNPTRVGCVDTRSGNCYLDIRPRGDNGDTACSNEIGVGVSKASCCCSLGKAWGTPCEMCPAVNTSEYKILCPGGEGFRPNPITVILEDIDECQELPGLCQGGKCINTFGSFQCRCPTGYYLNEDTRVCDDVNECETPGICGPGTCYNTVGNYTCICPPDYMQVNGGNNCMDMRRSLCYRNYYADNQTCDGELLFNMTKKMCCCSYNIGRAWNKPCEQCPIPSTDEFATLCGSQRPGFVIDIYTGLPVDIDECREIPGVCENGVCINMVGSFRCECPVGFFYNDKLLVCEDIDECQNGPVCQRNAECINTAGSYRCDCKPGYRFTSTGQCNDRNECQEIPNICSHGQCIDTVGSFYCLCHTGFKTNDDQTMCLDINECERDACGNGTCRNTIGSFNCRCNHGFILSHNNDCIDVDECASGNGNLCRNGQCINTVGSFQCQCNEGYEVAPDGRTCVDINECLLEPRKCAPGTCQNLDGSYRCICPPGYSLQNEKCEDIDECVEEPEICALGTCSNTEGSFKCLCPEGFSLSSSGRRCQDLRMSYCYAKFEGGKCSSPKSRNHSKQECCCALKGEGWGDPCELCPTEPDEAFRQICPYGSGIIVGPDDSAVDMDECKEPDVCKHGQCINTDGSYRCECPFGYILAGNECVDTDECSVGNPCGNGTCKNVIGGFECTCEEGFEPGPMMTCEDINECAQNPLLCAFRCVNTYGSYECKCPVGYVLREDRRMCKDEDECEEGKHDCTEKQMECKNLIGTYMCICGPGYQRRPDGEGCVDENECQTKPGICENGRCLNTRGSYTCECNDGFTASPNQDECLDNREGYCFTEVLQNMCQIGSSNRNPVTKSECCCDGGRGWGPHCEICPFQGTVAFKKLCPHGRGFMTNGADIDECKVIHDVCRNGECVNDRGSYHCICKTGYTPDITGTSCVDLNECNQAPKPCNFICKNTEGSYQCSCPKGYILQEDGRSCKDLDECATKQHNCQFLCVNTIGGFTCKCPPGFTQHHTSCIDNNECTSDINLCGSKGICQNTPGSFTCECQRGFSLDQTGSSCEDVDECEGNHRCQHGCQNIIGGYRCSCPQGYLQHYQWNQCVDENECLSAHICGGASCHNTLGSYKCMCPAGFQYEQFSGGCQDINECGSAQAPCSYGCSNTEGGYLCGCPPGYFRIGQGHCVSGMGMGRGNPEPPVSGEMDDNSLSPEACYECKINGYPKRGRKRRSTNETDASNIEDQSETEANVSLASWDVEKTAIFAFNISHVSNKVRILELLPALTTLTNHNRYLIESGNEDGFFKINQKEGISYLHFTKKKPVAGTYSLQISSTPLYKKKELNQLEDKYDKDYLSGELGDNLKMKIQVLLH	2871	P35555	R	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [1948], 'STRAND_gain_score': array([0.01280075]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [482, 527, 529, 567, 568, 569, 570], 'DOMAIN_gain': [1806], 'DOMAIN_gain_score': array([0.023678]), 'DOMAIN_loss_score': array([-0.02164716, -0.07399249, -0.05314428, -0.26232898, -0.24363166,
       -0.33574784, -0.21204686]), 'REGION_loss': [933, 976, 1670, 2074, 2112, 2146, 2184, 2195, 2210, 2536], 'REGION_gain': [432], 'REGION_gain_score': array([0.00067919]), 'REGION_loss_score': array([-0.00075829, -0.00095558, -0.00319624, -0.00286669, -0.00168103,
       -0.0013817 , -0.00108296, -0.00098795, -0.00132436, -0.0007171 ]), 'REPEAT_loss': [567, 568, 1031], 'REPEAT_gain': [134, 169, 2547], 'REPEAT_gain_score': array([0.0064106 , 0.0055238 , 0.00347847]), 'REPEAT_loss_score': array([-0.12389988, -0.23568606, -0.00186664]), 'ZN_FING_loss': [585], 'ZN_FING_gain': [1820], 'ZN_FING_gain_score': array([0.00466359]), 'ZN_FING_loss_score': array([-0.03462487])}"
627	NM_005249.5(FOXG1):c.218A>C (p.Gln73Pro)	193306	CA238810	NM_005249.5:c.218A>C, NC_000014.9:g.28767497A>C, CM000676.2:g.28767497A>C, NC_000014.8:g.29236703A>C, CM000676.1:g.29236703A>C, NC_000014.7:g.28306454A>C, NG_009367.1:g.5417A>C, ENST00000313071.7:c.218A>C, ENST00000313071.6:c.218A>C, NM_005249.4:c.218A>C, NM_005249.5(FOXG1):c.218A>C (p.Gln73Pro)	FOXG1	FOXG1 disorder	MONDO:0100040	Autosomal dominant inheritance	Benign	BS1, BP5_Strong, BS2, BP4		The allele frequency of the p.Gln73Pro variant in FOXG1 is 0.027% in the European (non-Finnish) sub population in gnomAD, which is high enough to meet the BS1 criteria based on thresholds defined by the ClinGen Rett/Angelman-like Expert Panel for Rett/AS-like conditions (BS1). The p.Gln73Pro variant is observed in at least 50 unaffected individuals (internal database - GeneDx) (BS2). The p.Gln73Pro variant is found in at least 8 individuals with an alternate molecular basis of disease (internal database - Invitae, internal database - GeneDx) (BP5_Strong). Computational analysis prediction tools suggest that the p.Gln73Pro variant does not have a deleterious impact; however this information does not predict clinical significance on its own (BP4). In summary, the p.Gln73Pro variant in FOXG1  is classified as Benign based on the ACMG/AMP criteria (BS1, BS2, BP5_Strong, BP4).		Rett and Angelman-like Disorders VCEP		2023-10-13	2023-12-08	False	https://erepo.genome.network/evrepo/ui/classification/CA238810/MONDO:0100040/035	3f0124ab-b79d-45ed-90e7-a56317665c70	p.Gln73Pro	Gln	73	Pro	MLDMGDRKEVKMIPKSSFSINSLVPEAVQNDNHHASHGHHNSHHPQHHHHHHHHHHHPPPPAPQPPPPPQQQQPPPPPPPAPQPPQTRGAPAADDDKGPQQLLLPPPPPPPPAAALDGAKADGLGGKGEPGGGPGELAPVGPDEKEKGAGAGGEEKKGAGEGGKDGEGGKEGEKKNGKYEKPPFSYNALIMMAIRQSPEKRLTLNGIYEFIMKNFPYYRENKQGWQNSIRHNLSLNKCFVKVPRHYDDPGKGNYWMLDPSSDDVFIGGTTGKLRRRSTTSRAKLAFKRGARLTSTGLTFMDRAGSLYWPMSPFLSLHHPRASSTLSYNGTTSAYPSHPMPYSSVLTQNSLGNNHSFSTANGLSVDRLVNGEIPYATHHLTAAALAASVPCGLSVPCSGTYSLNPCSVNLLAGQTSYFFPHVPHPSMTSQSSTSMSARAASSSTSPQAPSTLPCESLRPSLPSFTTGLSGGLSDYFTHQNQGSSSNPLIH	489	P55316	P	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [33], 'COMPBIAS_gain': [], 'COMPBIAS_loss_score': array([-0.01812488]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
628	NM_001110792.2(MECP2):c.1455G>C (p.Glu485Asp)	431908	CA10558429	NM_001110792.2:c.1455G>C, NC_000023.11:g.154030409C>G, CM000685.2:g.154030409C>G, NC_000023.10:g.153295860C>G, CM000685.1:g.153295860C>G, NC_000023.9:g.152949054C>G, NG_007107.2:g.111719G>C, NG_007107.3:g.111695G>C, ENST00000303391.11:c.1419G>C, ENST00000453960.7:c.1455G>C, ENST00000303391.10:c.1419G>C, ENST00000453960.6:c.1455G>C, ENST00000619732.4:c.1419G>C, ENST00000628176.2:c.*791G>C, NM_001110792.1:c.1455G>C, NM_001316337.1:c.1140G>C, NM_004992.3:c.1419G>C, XM_005274681.3:c.1419G>C, XM_005274682.3:c.1140G>C, XM_005274683.3:c.1140G>C, XM_006724819.2:c.750G>C, XM_011531166.1:c.1140G>C, XM_006724819.3:c.750G>C, XM_011531166.2:c.1140G>C, XM_024452383.1:c.1140G>C, XM_024452384.1:c.1140G>C, NM_001316337.2:c.1140G>C, NM_001369391.2:c.1140G>C, NM_001369392.2:c.1140G>C, NM_001369393.2:c.1140G>C, NM_001369394.1:c.1140G>C, NM_001369394.2:c.1140G>C, NM_001386137.1:c.750G>C, NM_001386138.1:c.750G>C, NM_001386139.1:c.750G>C, NM_004992.4:c.1419G>C, NM_001110792.2(MECP2):c.1455G>C (p.Glu485Asp)	MECP2	Rett syndrome	MONDO:0010726	X-linked inheritance	Benign	BP5, BS1, BS2		The allele frequency of the p.Glu473Asp variant in MECP2 (NM_004992.3) is 0.019% in Other sub population in gnomAD, which is high enough to meet the BS1 criteria based on thresholds defined by the ClinGen Rett/Angelman-like Expert Panel for Rett/AS-like conditions (BS1). The p.Glu473Asp variant is observed in at least 4 unaffected individuals (internal database - Invitae) (BS2). The p.Glu473Asp variant is found in an individual with an alternate molecular basis of disease (internal database - Invitae) (BP5). In summary, the p.Glu473Asp variant in MECP2 is classified as Benign based on the ACMG/AMP criteria (BS1, BS2, BP5).		Rett and Angelman-like Disorders VCEP		2023-10-13	2023-12-08	False	https://erepo.genome.network/evrepo/ui/classification/CA10558429/MONDO:0010726/036	447cc8f6-ee34-4553-86fe-ba1983558606	p.Glu485Asp	Glu	485	Asp	MVAGMLGLREEKSEDQDLQGLKDKPLKFKKVKKDKKEEKEGKHEPVQPSAHHSAEPAEAGKAETSEGSGSAPAVPEASASPKQRRSIIRDRGPMYDDPTLPEGWTRKLKQRKSGRSAGKYDVYLINPQGKAFRSKVELIAYFEKVGDTSLDPNDFDFTVTGRGSPSRREQKPPKKPKSPKAPGTGRGRGRPKGSGTTRPKAATSEGVQVKRVLEKSPGKLLVKMPFQTSPGGKAEGGGATTSTQVMVIKRPGRKRKAEADPQAIPKKRGRKPGSVVAAAAAEAKKKAVKESSIRSVQETVLPIKKRKTRETVSIEVKEVVKPLLVSTLGEKSGKGLKTCKSPGRKSKESSPKGRSSSASSPPKKEHHHHHHHSESPKAPVPLLPPLPPPPPEPESSEDPTSPPEPQDLSSSVCKEEKMPRGGSLESDGCPKEPAKTQPAVATAATAAEKYKHRGEGERKDIVSSSMPRPNREEPVDSRTPVTERVS	486	P51608	D	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [485], 'COMPBIAS_gain_score': array([0.34992331]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
629	NM_001323289.2(CDKL5):c.761A>G (p.His254Arg)	1051353	CA412354904	NM_001323289.2:c.761A>G, NC_000023.11:g.18595364A>G, CM000685.2:g.18595364A>G, NC_000023.10:g.18613484A>G, CM000685.1:g.18613484A>G, NC_000023.9:g.18523405A>G, NG_008475.1:g.174760A>G, ENST00000623535.2:c.761A>G, ENST00000635828.1:c.761A>G, ENST00000637881.1:c.761A>G, ENST00000674046.1:c.761A>G, ENST00000379989.6:c.761A>G, ENST00000379996.7:c.761A>G, ENST00000463994.4:c.761A>G, ENST00000623535.1:c.761A>G, NM_001037343.1:c.761A>G, NM_003159.2:c.761A>G, XM_011545569.1:c.761A>G, XM_011545570.1:c.629A>G, XR_950484.1:n.1013A>G, NM_001323289.1:c.761A>G, NM_001037343.2:c.761A>G, NM_003159.3:c.761A>G, NM_001323289.2(CDKL5):c.761A>G (p.His254Arg)	CDKL5	CDKL5 disorder	MONDO:0100039	X-linked inheritance	Benign	BP5_Strong, BS2	PM1, BS1, BP4, PP3	The c.761A>G p.His254Arg variant in CDKL5 (NM_001323289.2) is present in 1 XX and 2 XY individuals in gnomAD (0.0036% in the Latino/Admixed American sub population) (not sufficient to meet BS1 criteria). The p.His254Arg variant is observed in at least 2 unaffected individuals (GeneDx internal data) (BS2). The p.His254Arg variant is found in at least 3 patients with an alternate molecular basis of disease (GeneDx internal data) (BP5_Strong). Computational prediction analysis tools are inconclusive for this variant (no criteria met). In summary, the c.761A>G p.His254Arg variant in CDKL5 is classified as Benign based on the ACMG/AMP criteria (BS2, BP5_Strong).		Rett and Angelman-like Disorders VCEP		2023-06-20	2023-12-08	False	https://erepo.genome.network/evrepo/ui/classification/CA412354904/MONDO:0100039/034	5ab6409c-fae4-4493-9951-0b6fc13e7ea7	p.His254Arg	His	254	Arg	MKIPNIGNVMNKFEILGVVGEGAYGVVLKCRHKETHEIVAIKKFKDSEENEEVKETTLRELKMLRTLKQENIVELKEAFRRRGKLYLVFEYVEKNMLELLEEMPNGVPPEKVKSYIYQLIKAIHWCHKNDIVHRDIKPENLLISHNDVLKLCDFGFARNLSEGNNANYTEYVATRWYRSPELLLGAPYGKSVDMWSVGCILGELSDGQPLFPGESEIDQLFTIQKVLGPLPSEQMKLFYSNPRFHGLRFPAVNHPQSLERRYLGILNSVLLDLMKNLLKLDPADRYLTEQCLNHPTFQTQRLLDRSPSRSAKRKPYHVESSTLSNRNQAGKSTALQSHHRSNSKDIQNLSVGLPRADEGLPANESFLNGNLAGASLSPLHTKTYQASSQPGSTSKDLTNNNIPHLLSPKEAKSKTEFDFNIDPKPSEGPGTKYLKSNSRSQQNRHSFMESSQSKAGTLQPNEKQSRHSYIDTIPQSSRSPSYRTKAKSHGALSDSKSVSNLSEARAQIAEPSTSRYFPSSCLDLNSPTSPTPTRHSDTRTLLSPSGRNNRNEGTLDSRRTTTRHSKTMEELKLPEHMDSSHSHSLSAPHESFSYGLGYTSPFSSQQRPHRHSMYVTRDKVRAKGLDGSLSIGQGMAARANSLQLLSPQPGEQLPPEMTVARSSVKETSREGTSSFHTRQKSEGGVYHDPHSDDGTAPKENRHLYNDPVPRRVGSFYRVPSPRPDNSFHENNVSTRVSSLPSESSSGTNHSKRQPAFDPWKSPENISHSEQLKEKEKQGFFRSMKKKKKKSQTVPNSDSPDLLTLQKSIHSASTPSSRPKEWRPEKISDLQTQSQPLKSLRKLLHLSSASNHPASSDPRFQPLTAQQTKNSFSEIRIHPLSQASGGSSNIRQEPAPKGRPALQLPGQMDPGWHVSSVTRSATEGPSYSEQLGAKSGPNGHPYNRTNRSRMPNLNDLKETAL	960	O76039	R	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [94], 'STRAND_gain_score': array([0.00171101]), 'HELIX_loss': [255], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.27724612]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
630	NM_000138.5(FBN1):c.1850G>A (p.Cys617Tyr)	495563	CA392339186	NM_000138.5:c.1850G>A, NC_000015.10:g.48505135C>T, CM000677.2:g.48505135C>T, NC_000015.9:g.48797332C>T, CM000677.1:g.48797332C>T, NC_000015.8:g.46584624C>T, NG_008805.2:g.145654G>A, LRG_778:g.145654G>A, ENST00000684448.1:n.524G>A, ENST00000316623.10:c.1850G>A, ENST00000316623.9:c.1850G>A, ENST00000537463.6:c.637-30485G>A, NM_000138.4:c.1850G>A, LRG_778t1:c.1850G>A, NM_000138.5(FBN1):c.1850G>A (p.Cys617Tyr)	FBN1	Marfan syndrome	MONDO:0007947	Autosomal dominant inheritance	Pathogenic	PS4_Moderate, PS2_Supporting, PM1_Strong, PP4, PP2, PP3, PM2_Supporting	PS1, PM5, BP4	NM_00138 c.1850G>A is a missense variant in FBN1 predicted to cause a substitution of a cysteine by tyrosine at amino acid 617 (p.Cys617Tyr). This variant was found in a proband with ectopia lentis, thoracic aortic aneurysm and dissection, and skeletal features (PP4; Bichat internal data). It has also been reported in the literature in two probands, one meeting revised Ghent criteria for Marfan syndrome and one with EL and a systemic score of 7 (PS4_moderate; PMIDs: 27906200, 33483584). This variant was found to be de novo with confirmation of maternity and paternity in an individual with Marfan syndrome, without specific phenotypic features available (PS2_supporting; deCODE genetics internal data, ClinVar Variation ID: 495563). It is not present in gnomAD (PM2_supporting; https://gnomad.broadinstitute.org/). This variant affects a cysteine residue in a calcium binding EGF domain; cysteine residues are believed to be involved in the formation of disulfide bridges which are essential for the protein structure (PM1_strong). Several other variants affecting this codon have been reported in association with Marfan syndrome (p.Cys617Arg, p.Cys617Gly, p.Cys617Ser). Computational prediction tools and conservation analysis suggest that this variant may impact the protein (PP3). The constraint z-score for missense variants affecting FBN1 is 5.06 (PP2). In summary, this variant meets criteria to be classified as pathogenic for Marfan syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen FBN1 VCEP: PM1_strong, PS4_moderate, PM2_supporting, PS2_supporting, PP2, PP3, PP4.		FBN1 VCEP	https://clinicalgenome.org/docs/clingen-fbn1-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2023-11-16	2023-11-16	False	https://erepo.genome.network/evrepo/ui/classification/CA392339186/MONDO:0007947/022	6728ee68-bbe8-4097-a92d-9ce209abb025	p.Cys617Tyr	Cys	617	Tyr	MRRGRLLEIALGFTVLLASYTSHGADANLEAGNVKETRASRAKRRGGGGHDALKGPNVCGSRYNAYCCPGWKTLPGGNQCIVPICRHSCGDGFCSRPNMCTCPSGQIAPSCGSRSIQHCNIRCMNGGSCSDDHCLCQKGYIGTHCGQPVCESGCLNGGRCVAPNRCACTYGFTGPQCERDYRTGPCFTVISNQMCQGQLSGIVCTKTLCCATVGRAWGHPCEMCPAQPHPCRRGFIPNIRTGACQDVDECQAIPGLCQGGNCINTVGSFECKCPAGHKLNEVSQKCEDIDECSTIPGICEGGECTNTVSSYFCKCPPGFYTSPDGTRCIDVRPGYCYTALTNGRCSNQLPQSITKMQCCCDAGRCWSPGVTVAPEMCPIRATEDFNKLCSVPMVIPGRPEYPPPPLGPIPPVLPVPPGFPPGPQIPVPRPPVEYLYPSREPPRVLPVNVTDYCQLVRYLCQNGRCIPTPGSYRCECNKGFQLDLRGECIDVDECEKNPCAGGECINNQGSYTCQCRAGYQSTLTRTECRDIDECLQNGRICNNGRCINTDGSFHCVCNAGFHVTRDGKNCEDMDECSIRNMCLNGMCINEDGSFKCICKPGFQLASDGRYCKDINECETPGICMNGRCVNTDGSYRCECFPGLAVGLDGRVCVDTHMRSTCYGGYKRGQCIKPLFGAVTKSECCCASTEYAFGEPCQPCPAQNSAEYQALCSSGPGMTSAGSDINECALDPDICPNGICENLRGTYKCICNSGYEVDSTGKNCVDINECVLNSLLCDNGQCRNTPGSFVCTCPKGFIYKPDLKTCEDIDECESSPCINGVCKNSPGSFICECSSESTLDPTKTICIETIKGTCWQTVIDGRCEININGATLKSQCCSSLGAAWGSPCTLCQVDPICGKGYSRIKGTQCEDIDECEVFPGVCKNGLCVNTRGSFKCQCPSGMTLDATGRICLDIRLETCFLRYEDEECTLPIAGRHRMDACCCSVGAAWGTEECEECPMRNTPEYEELCPRGPGFATKEITNGKPFFKDINECKMIPSLCTHGKCRNTIGSFKCRCDSGFALDSEERNCTDIDECRISPDLCGRGQCVNTPGDFECKCDEGYESGFMMMKNCMDIDECQRDPLLCRGGVCHNTEGSYRCECPPGHQLSPNISACIDINECELSAHLCPNGRCVNLIGKYQCACNPGYHSTPDRLFCVDIDECSIMNGGCETFCTNSEGSYECSCQPGFALMPDQRSCTDIDECEDNPNICDGGQCTNIPGEYRCLCYDGFMASEDMKTCVDVNECDLNPNICLSGTCENTKGSFICHCDMGYSGKKGKTGCTDINECEIGAHNCGKHAVCTNTAGSFKCSCSPGWIGDGIKCTDLDECSNGTHMCSQHADCKNTMGSYRCLCKEGYTGDGFTCTDLDECSENLNLCGNGQCLNAPGGYRCECDMGFVPSADGKACEDIDECSLPNICVFGTCHNLPGLFRCECEIGYELDRSGGNCTDVNECLDPTTCISGNCVNTPGSYICDCPPDFELNPTRVGCVDTRSGNCYLDIRPRGDNGDTACSNEIGVGVSKASCCCSLGKAWGTPCEMCPAVNTSEYKILCPGGEGFRPNPITVILEDIDECQELPGLCQGGKCINTFGSFQCRCPTGYYLNEDTRVCDDVNECETPGICGPGTCYNTVGNYTCICPPDYMQVNGGNNCMDMRRSLCYRNYYADNQTCDGELLFNMTKKMCCCSYNIGRAWNKPCEQCPIPSTDEFATLCGSQRPGFVIDIYTGLPVDIDECREIPGVCENGVCINMVGSFRCECPVGFFYNDKLLVCEDIDECQNGPVCQRNAECINTAGSYRCDCKPGYRFTSTGQCNDRNECQEIPNICSHGQCIDTVGSFYCLCHTGFKTNDDQTMCLDINECERDACGNGTCRNTIGSFNCRCNHGFILSHNNDCIDVDECASGNGNLCRNGQCINTVGSFQCQCNEGYEVAPDGRTCVDINECLLEPRKCAPGTCQNLDGSYRCICPPGYSLQNEKCEDIDECVEEPEICALGTCSNTEGSFKCLCPEGFSLSSSGRRCQDLRMSYCYAKFEGGKCSSPKSRNHSKQECCCALKGEGWGDPCELCPTEPDEAFRQICPYGSGIIVGPDDSAVDMDECKEPDVCKHGQCINTDGSYRCECPFGYILAGNECVDTDECSVGNPCGNGTCKNVIGGFECTCEEGFEPGPMMTCEDINECAQNPLLCAFRCVNTYGSYECKCPVGYVLREDRRMCKDEDECEEGKHDCTEKQMECKNLIGTYMCICGPGYQRRPDGEGCVDENECQTKPGICENGRCLNTRGSYTCECNDGFTASPNQDECLDNREGYCFTEVLQNMCQIGSSNRNPVTKSECCCDGGRGWGPHCEICPFQGTVAFKKLCPHGRGFMTNGADIDECKVIHDVCRNGECVNDRGSYHCICKTGYTPDITGTSCVDLNECNQAPKPCNFICKNTEGSYQCSCPKGYILQEDGRSCKDLDECATKQHNCQFLCVNTIGGFTCKCPPGFTQHHTSCIDNNECTSDINLCGSKGICQNTPGSFTCECQRGFSLDQTGSSCEDVDECEGNHRCQHGCQNIIGGYRCSCPQGYLQHYQWNQCVDENECLSAHICGGASCHNTLGSYKCMCPAGFQYEQFSGGCQDINECGSAQAPCSYGCSNTEGGYLCGCPPGYFRIGQGHCVSGMGMGRGNPEPPVSGEMDDNSLSPEACYECKINGYPKRGRKRRSTNETDASNIEDQSETEANVSLASWDVEKTAIFAFNISHVSNKVRILELLPALTTLTNHNRYLIESGNEDGFFKINQKEGISYLHFTKKKPVAGTYSLQISSTPLYKKKELNQLEDKYDKDYLSGELGDNLKMKIQVLLH	2871	P35555	Y	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [1948], 'STRAND_gain_score': array([0.00847089]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [611, 615, 616, 638, 640, 641, 642, 1836, 1837, 1840, 1857], 'DOMAIN_gain': [1913, 1938, 2458], 'DOMAIN_gain_score': array([0.03575784, 0.02111328, 0.01592559]), 'DOMAIN_loss_score': array([-0.1151877 , -0.3162064 , -0.47402042, -0.276838  , -0.30634969,
       -0.2935881 , -0.38931173, -0.17816567, -0.17132074, -0.14833164,
       -0.02719736]), 'REGION_loss': [976, 1670, 2074, 2146, 2184, 2195, 2210, 2216, 2536], 'REGION_gain': [432, 435], 'REGION_gain_score': array([0.00733691, 0.00728106]), 'REGION_loss_score': array([-0.00030893, -0.00129062, -0.00050181, -0.00045907, -0.00055951,
       -0.00067329, -0.00133252, -0.00132257, -0.00171202]), 'REPEAT_loss': [618], 'REPEAT_gain': [134, 168, 169, 456, 1764, 1816, 1843], 'REPEAT_gain_score': array([0.00636703, 0.00720406, 0.00583678, 0.02864999, 0.02092665,
       0.00623786, 0.03557539]), 'REPEAT_loss_score': array([-0.15395635]), 'ZN_FING_loss': [625], 'ZN_FING_gain': [], 'ZN_FING_loss_score': array([-0.16953743])}"
631	NM_000138.5(FBN1):c.1556A>G (p.Tyr519Cys)	549024	CA392342185	NM_000138.5:c.1556A>G, NC_000015.10:g.48513581T>C, CM000677.2:g.48513581T>C, NC_000015.9:g.48805778T>C, CM000677.1:g.48805778T>C, NC_000015.8:g.46593070T>C, NG_008805.2:g.137208A>G, LRG_778:g.137208A>G, ENST00000684448.1:n.230A>G, ENST00000316623.10:c.1556A>G, ENST00000316623.9:c.1556A>G, ENST00000537463.6:c.636+24130A>G, NM_000138.4:c.1556A>G, LRG_778t1:c.1556A>G, NM_000138.5(FBN1):c.1556A>G (p.Tyr519Cys)	FBN1	Marfan syndrome	MONDO:0007947	Autosomal dominant inheritance	Pathogenic	PS4, PM1, PS2_Supporting, PP2, PP3, PP1, PM2_Supporting	PS1, PS3, PM5, PM3, PM4, BP7, BP5, BS1, BS3, PP4, BS2, PM6, PVS1, BP4, BP2, BP3, BA1	The NM_00138 c.1556A>G, is a missense variant in FBN1 predicted to cause a substitution of a tyrosine by cysteine at amino acid 519 (p.Tyr519Cys). This variant was found in at least 7 probands with features consistent with or suggestive of Marfan syndrome including the following: one proband who met the original Ghent criteria with cardiovascular, skeletal, and skin involvement; one proband with bilateral ectopia lentis (EL) and systemic features; one proband with thoracic aortic aneurysm and dissection (TAAD); one proband with EL and systemic features; one proband with isolated EL; one proband with TAAD and systemic features; and once as de novo with confirmed maternity/paternity with bilateral EL, TAAD, and systemic features, a phenotype highly specific for Marfan syndrome (PS2_supporting, PS4; PMID: 15241795; University of Tokyo, UZG, Invitae, & Ambry internal data; ClinVar Variation ID: 5490254). The variant also segregates with features of Marfan syndrome in at least two affected family members (PP1; Invitae internal data). It is not present in gnomAD (PM2_supporting; https://gnomad.broadinstitute.org/). This variant introduces a novel cysteine residue which may impede the normal formation of critical disulfide bridges (PM1). Computational prediction tools and conservation analysis suggest that this variant may impact the protein’s structure or function (PP3). The constraint z-score for missense variants affecting FBN1 is 5.06 (PP2). In summary, this variant meets criteria to be classified as pathogenic for Marfan syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen FBN1 VCEP: PS4, PM1, PS2_supporting, PM2_supporting, PP1, PP2, PP3.		FBN1 VCEP	https://clinicalgenome.org/docs/clingen-fbn1-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2023-11-16	2023-11-16	False	https://erepo.genome.network/evrepo/ui/classification/CA392342185/MONDO:0007947/022	70862165-bdcf-4d1f-ae67-bae146408176	p.Tyr519Cys	Tyr	519	Cys	MRRGRLLEIALGFTVLLASYTSHGADANLEAGNVKETRASRAKRRGGGGHDALKGPNVCGSRYNAYCCPGWKTLPGGNQCIVPICRHSCGDGFCSRPNMCTCPSGQIAPSCGSRSIQHCNIRCMNGGSCSDDHCLCQKGYIGTHCGQPVCESGCLNGGRCVAPNRCACTYGFTGPQCERDYRTGPCFTVISNQMCQGQLSGIVCTKTLCCATVGRAWGHPCEMCPAQPHPCRRGFIPNIRTGACQDVDECQAIPGLCQGGNCINTVGSFECKCPAGHKLNEVSQKCEDIDECSTIPGICEGGECTNTVSSYFCKCPPGFYTSPDGTRCIDVRPGYCYTALTNGRCSNQLPQSITKMQCCCDAGRCWSPGVTVAPEMCPIRATEDFNKLCSVPMVIPGRPEYPPPPLGPIPPVLPVPPGFPPGPQIPVPRPPVEYLYPSREPPRVLPVNVTDYCQLVRYLCQNGRCIPTPGSYRCECNKGFQLDLRGECIDVDECEKNPCAGGECINNQGSYTCQCRAGYQSTLTRTECRDIDECLQNGRICNNGRCINTDGSFHCVCNAGFHVTRDGKNCEDMDECSIRNMCLNGMCINEDGSFKCICKPGFQLASDGRYCKDINECETPGICMNGRCVNTDGSYRCECFPGLAVGLDGRVCVDTHMRSTCYGGYKRGQCIKPLFGAVTKSECCCASTEYAFGEPCQPCPAQNSAEYQALCSSGPGMTSAGSDINECALDPDICPNGICENLRGTYKCICNSGYEVDSTGKNCVDINECVLNSLLCDNGQCRNTPGSFVCTCPKGFIYKPDLKTCEDIDECESSPCINGVCKNSPGSFICECSSESTLDPTKTICIETIKGTCWQTVIDGRCEININGATLKSQCCSSLGAAWGSPCTLCQVDPICGKGYSRIKGTQCEDIDECEVFPGVCKNGLCVNTRGSFKCQCPSGMTLDATGRICLDIRLETCFLRYEDEECTLPIAGRHRMDACCCSVGAAWGTEECEECPMRNTPEYEELCPRGPGFATKEITNGKPFFKDINECKMIPSLCTHGKCRNTIGSFKCRCDSGFALDSEERNCTDIDECRISPDLCGRGQCVNTPGDFECKCDEGYESGFMMMKNCMDIDECQRDPLLCRGGVCHNTEGSYRCECPPGHQLSPNISACIDINECELSAHLCPNGRCVNLIGKYQCACNPGYHSTPDRLFCVDIDECSIMNGGCETFCTNSEGSYECSCQPGFALMPDQRSCTDIDECEDNPNICDGGQCTNIPGEYRCLCYDGFMASEDMKTCVDVNECDLNPNICLSGTCENTKGSFICHCDMGYSGKKGKTGCTDINECEIGAHNCGKHAVCTNTAGSFKCSCSPGWIGDGIKCTDLDECSNGTHMCSQHADCKNTMGSYRCLCKEGYTGDGFTCTDLDECSENLNLCGNGQCLNAPGGYRCECDMGFVPSADGKACEDIDECSLPNICVFGTCHNLPGLFRCECEIGYELDRSGGNCTDVNECLDPTTCISGNCVNTPGSYICDCPPDFELNPTRVGCVDTRSGNCYLDIRPRGDNGDTACSNEIGVGVSKASCCCSLGKAWGTPCEMCPAVNTSEYKILCPGGEGFRPNPITVILEDIDECQELPGLCQGGKCINTFGSFQCRCPTGYYLNEDTRVCDDVNECETPGICGPGTCYNTVGNYTCICPPDYMQVNGGNNCMDMRRSLCYRNYYADNQTCDGELLFNMTKKMCCCSYNIGRAWNKPCEQCPIPSTDEFATLCGSQRPGFVIDIYTGLPVDIDECREIPGVCENGVCINMVGSFRCECPVGFFYNDKLLVCEDIDECQNGPVCQRNAECINTAGSYRCDCKPGYRFTSTGQCNDRNECQEIPNICSHGQCIDTVGSFYCLCHTGFKTNDDQTMCLDINECERDACGNGTCRNTIGSFNCRCNHGFILSHNNDCIDVDECASGNGNLCRNGQCINTVGSFQCQCNEGYEVAPDGRTCVDINECLLEPRKCAPGTCQNLDGSYRCICPPGYSLQNEKCEDIDECVEEPEICALGTCSNTEGSFKCLCPEGFSLSSSGRRCQDLRMSYCYAKFEGGKCSSPKSRNHSKQECCCALKGEGWGDPCELCPTEPDEAFRQICPYGSGIIVGPDDSAVDMDECKEPDVCKHGQCINTDGSYRCECPFGYILAGNECVDTDECSVGNPCGNGTCKNVIGGFECTCEEGFEPGPMMTCEDINECAQNPLLCAFRCVNTYGSYECKCPVGYVLREDRRMCKDEDECEEGKHDCTEKQMECKNLIGTYMCICGPGYQRRPDGEGCVDENECQTKPGICENGRCLNTRGSYTCECNDGFTASPNQDECLDNREGYCFTEVLQNMCQIGSSNRNPVTKSECCCDGGRGWGPHCEICPFQGTVAFKKLCPHGRGFMTNGADIDECKVIHDVCRNGECVNDRGSYHCICKTGYTPDITGTSCVDLNECNQAPKPCNFICKNTEGSYQCSCPKGYILQEDGRSCKDLDECATKQHNCQFLCVNTIGGFTCKCPPGFTQHHTSCIDNNECTSDINLCGSKGICQNTPGSFTCECQRGFSLDQTGSSCEDVDECEGNHRCQHGCQNIIGGYRCSCPQGYLQHYQWNQCVDENECLSAHICGGASCHNTLGSYKCMCPAGFQYEQFSGGCQDINECGSAQAPCSYGCSNTEGGYLCGCPPGYFRIGQGHCVSGMGMGRGNPEPPVSGEMDDNSLSPEACYECKINGYPKRGRKRRSTNETDASNIEDQSETEANVSLASWDVEKTAIFAFNISHVSNKVRILELLPALTTLTNHNRYLIESGNEDGFFKINQKEGISYLHFTKKKPVAGTYSLQISSTPLYKKKELNQLEDKYDKDYLSGELGDNLKMKIQVLLH	2871	P35555	C	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [1948], 'STRAND_gain_score': array([0.00622398]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [473, 478, 482, 518, 519, 520, 522, 523, 524, 525, 527, 529, 611, 774, 1035], 'DOMAIN_gain': [928, 1806, 1913, 1916, 1938, 1953, 2182, 2458], 'DOMAIN_gain_score': array([0.00811988, 0.03401065, 0.0619238 , 0.06000447, 0.0323655 ,
       0.04352629, 0.02085418, 0.01381809]), 'DOMAIN_loss_score': array([-0.08929425, -0.1211459 , -0.09473807, -0.46845126, -0.40945345,
       -0.4120912 , -0.2307319 , -0.26284719, -0.21623683, -0.24922132,
       -0.21841413, -0.13583034, -0.01408035, -0.0141536 , -0.0099358 ]), 'REGION_loss': [933, 976], 'REGION_gain': [432, 435, 438, 1672, 1673, 1674, 1675, 1676, 2521, 2525, 2527], 'REGION_gain_score': array([0.01435971, 0.01412845, 0.01786107, 0.04288989, 0.03948987,
       0.04678965, 0.0463087 , 0.05008751, 0.00054771, 0.00069255,
       0.00062817]), 'REGION_loss_score': array([-0.0009321 , -0.00116813]), 'REPEAT_loss': [521, 522], 'REPEAT_gain': [134, 168, 169, 247, 248, 456, 528, 1518, 1764, 2547], 'REPEAT_gain_score': array([0.00441486, 0.00634617, 0.00675124, 0.00959581, 0.00863469,
       0.02639484, 0.01516759, 0.01736218, 0.03265101, 0.00652683]), 'REPEAT_loss_score': array([-0.02928054, -0.01660335]), 'ZN_FING_loss': [], 'ZN_FING_gain': [1820], 'ZN_FING_gain_score': array([0.00563735])}"
632	NM_005249.5(FOXG1):c.251C>A (p.Pro84His)	380242	CA16606972	NM_005249.5:c.251C>A, NC_000014.9:g.28767530C>A, CM000676.2:g.28767530C>A, NC_000014.8:g.29236736C>A, CM000676.1:g.29236736C>A, NC_000014.7:g.28306487C>A, NG_009367.1:g.5450C>A, ENST00000313071.7:c.251C>A, ENST00000313071.6:c.251C>A, NM_005249.4:c.251C>A, NM_005249.5(FOXG1):c.251C>A (p.Pro84His)	FOXG1	FOXG1 disorder	MONDO:0100040	Autosomal dominant inheritance	Benign	BP5_Strong, BS2, BP4	BS1	The p.Pro84His variant in FOXG1 is present in 1 individual in gnomAD (0.0039%) (not sufficient to meet BS1 criteria). The p.Pro84His variant is observed in at least 20 unaffected individuals (internal database - GeneDx; internal database - Invitae) (BS2). The p.Pro84His variant is found in at least 4 patients with an alternate molecular basis of disease (internal database - Invitae; internal database - GeneDx) (BP5_strong). Computational analysis prediction tools suggest that the p.Pro84His variant does not have a deleterious impact; however this information does not predict clinical significance on its own (BP4). In summary, the p.Pro84His variant in FOXG1 is classified as Benign based on the ACMG/AMP criteria (BS2, BP5_strong, BP4).		Rett and Angelman-like Disorders VCEP		2023-10-13	2023-12-08	False	https://erepo.genome.network/evrepo/ui/classification/CA16606972/MONDO:0100040/035	730af61e-30b2-4069-a5ff-815ecda50686	p.Pro84His	Pro	84	His	MLDMGDRKEVKMIPKSSFSINSLVPEAVQNDNHHASHGHHNSHHPQHHHHHHHHHHHPPPPAPQPPPPPQQQQPPPPPPPAPQPPQTRGAPAADDDKGPQQLLLPPPPPPPPAAALDGAKADGLGGKGEPGGGPGELAPVGPDEKEKGAGAGGEEKKGAGEGGKDGEGGKEGEKKNGKYEKPPFSYNALIMMAIRQSPEKRLTLNGIYEFIMKNFPYYRENKQGWQNSIRHNLSLNKCFVKVPRHYDDPGKGNYWMLDPSSDDVFIGGTTGKLRRRSTTSRAKLAFKRGARLTSTGLTFMDRAGSLYWPMSPFLSLHHPRASSTLSYNGTTSAYPSHPMPYSSVLTQNSLGNNHSFSTANGLSVDRLVNGEIPYATHHLTAAALAASVPCGLSVPCSGTYSLNPCSVNLLAGQTSYFFPHVPHPSMTSQSSTSMSARAASSSTSPQAPSTLPCESLRPSLPSFTTGLSGGLSDYFTHQNQGSSSNPLIH	489	P55316	H	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [85], 'COMPBIAS_gain': [], 'COMPBIAS_loss_score': array([-0.41511869]), 'DOMAIN_loss': [224], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.00860643]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
633	NM_177438.3(DICER1):c.1124C>G (p.Pro375Arg)	242032	CA7331526	NM_177438.3:c.1124C>G, NC_000014.9:g.95124448G>C, CM000676.2:g.95124448G>C, NC_000014.8:g.95590785G>C, CM000676.1:g.95590785G>C, NC_000014.7:g.94660538G>C, NG_016311.1:g.37975C>G, LRG_492:g.37975C>G, ENST00000343455.8:c.1124C>G, ENST00000393063.6:c.1124C>G, ENST00000526495.6:c.1124C>G, ENST00000532939.3:c.1124C>G, ENST00000556045.6:c.1124C>G, ENST00000674628.1:c.1124C>G, ENST00000675995.1:c.1124C>G, ENST00000343455.7:c.1124C>G, ENST00000393063.5:c.1124C>G, ENST00000526495.5:c.1124C>G, ENST00000527414.5:c.1124C>G, ENST00000541352.5:c.1124C>G, NM_001195573.1:c.1124C>G, NM_001271282.2:c.1124C>G, NM_001291628.1:c.1124C>G, NM_030621.4:c.1124C>G, NM_177438.2:c.1124C>G, LRG_492t1:c.1124C>G, XM_011536599.1:c.1124C>G, XM_011536600.1:c.1124C>G, XM_011536601.1:c.1124C>G, XM_011536602.1:c.1124C>G, XM_011536603.1:c.1124C>G, XM_011536604.1:c.719C>G, XM_011536599.2:c.1124C>G, XM_011536600.3:c.1124C>G, XM_011536601.3:c.1124C>G, XM_011536602.3:c.1124C>G, XM_011536604.2:c.719C>G, XM_017021120.2:c.1124C>G, XM_017021121.2:c.1124C>G, XM_017021122.2:c.719C>G, XM_017021123.2:c.719C>G, NM_001271282.3:c.1124C>G, NM_001291628.2:c.1124C>G, NM_001395677.1:c.1124C>G, NM_001395678.1:c.1124C>G, NM_001395679.1:c.1124C>G, NM_001395680.1:c.1124C>G, NM_001395682.1:c.1124C>G, NM_001395683.1:c.1124C>G, NM_001395684.1:c.1124C>G, NM_001395685.1:c.1124C>G, NM_001395686.1:c.842C>G, NM_001395687.1:c.719C>G, NM_001395688.1:c.719C>G, NM_001395689.1:c.719C>G, NM_001395690.1:c.719C>G, NM_001395691.1:c.557C>G, NM_001395692.1:c.1124C>G, NM_001395693.1:c.1124C>G, NM_001395694.1:c.1124C>G, NM_001395695.1:c.1124C>G, NM_001395696.1:c.719C>G, NM_001395697.1:c.-445C>G, NM_001395698.1:c.719C>G, NM_001395699.1:c.1124C>G, NM_001395700.1:c.1124C>G, NR_172715.1:n.1338C>G, NR_172716.1:n.1469C>G, NR_172717.1:n.1636C>G, NR_172718.1:n.1636C>G, NR_172719.1:n.1469C>G, NR_172720.1:n.1469C>G, NM_177438.3(DICER1):c.1124C>G (p.Pro375Arg)	DICER1	DICER1-related tumor predisposition	MONDO:0100216	Autosomal dominant inheritance	Benign	BS2, BS1	PM2, PVS1, PM6, PP3, PP4, BP2, BP3, BP4, BA1, PS3, PS2, PS4, PS1, PM1, PM4, PM5, BP7, BP5, BS3	The NM_177438.2:c.1124C>G variant in DICER1 is a missense variant predicted to cause substitution of Proline by Arginine at amino acid 375 (p.Pro375Arg). This variant has been seen in 40 or more unrelated females without tumors through age 50 in at least one testing laboratory (BS2; Internal lab contributors, PMIDs 29641532, 33630087). The highest population minor allele frequency in gnomAD v2.1.1 (non-cancer) is 0.0004911 (58/118098 alleles) in the European (non-Finnish) population, which is higher than the ClinGen DICER1 VCEP threshold (>0.0003) for BS1, and therefore meets this criterion (BS1). This variant does not reside within a region of the RNAse IIIb domain that is defined as a mutational hotspot or critical functional domain by the ClinGen DICER1 VCEP (PM1 not met). The computational predictor REVEL gives a score of 0.578, which is neither above nor below the thresholds predicting a damaging or benign impact on DICER1 function (PP3 and BP4 not met). In summary, this variant meets the criteria to be classified as benign for DICER1 syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen DICER1 VCEP: BS1, BS2. (Bayesian Points: -8; VCEP specifications version 1.2.0; 08/22/23).		DICER1 and miRNA-Processing Gene VCEP		2023-08-22	2023-09-01	False	https://erepo.genome.network/evrepo/ui/classification/CA7331526/MONDO:0100216/024	776daba8-46ba-4339-8fc1-22f854ce32fb	p.Pro375Arg	Pro	375	Arg	MKSPALQPLSMAGLQLMTPASSPMGPFFGLPWQQEAIHDNIYTPRKYQVELLEAALDHNTIVCLNTGSGKTFIAVLLTKELSYQIRGDFSRNGKRTVFLVNSANQVAQQVSAVRTHSDLKVGEYSNLEVNASWTKERWNQEFTKHQVLIMTCYVALNVLKNGYLSLSDINLLVFDECHLAILDHPYREIMKLCENCPSCPRILGLTASILNGKCDPEELEEKIQKLEKILKSNAETATDLVVLDRYTSQPCEIVVDCGPFTDRSGLYERLLMELEEALNFINDCNISVHSKERDSTLISKQILSDCRAVLVVLGPWCADKVAGMMVRELQKYIKHEQEELHRKFLLFTDTFLRKIHALCEEHFSPASLDLKFVTPKVIKLLEILRKYKPYERQQFESVEWYNNRNQDNYVSWSDSEDDDEDEEIEEKEKPETNFPSPFTNILCGIIFVERRYTAVVLNRLIKEAGKQDPELAYISSNFITGHGIGKNQPRNKQMEAEFRKQEEVLRKFRAHETNLLIATSIVEEGVDIPKCNLVVRFDLPTEYRSYVQSKGRARAPISNYIMLADTDKIKSFEEDLKTYKAIEKILRNKCSKSVDTGETDIDPVMDDDDVFPPYVLRPDDGGPRVTINTAIGHINRYCARLPSDPFTHLAPKCRTRELPDGTFYSTLYLPINSPLRASIVGPPMSCVRLAERVVALICCEKLHKIGELDDHLMPVGKETVKYEEELDLHDEEETSVPGRPGSTKRRQCYPKAIPECLRDSYPRPDQPCYLYVIGMVLTTPLPDELNFRRRKLYPPEDTTRCFGILTAKPIPQIPHFPVYTRSGEVTISIELKKSGFMLSLQMLELITRLHQYIFSHILRLEKPALEFKPTDADSAYCVLPLNVVNDSSTLDIDFKFMEDIEKSEARIGIPSTKYTKETPFVFKLEDYQDAVIIPRYRNFDQPHRFYVADVYTDLTPLSKFPSPEYETFAEYYKTKYNLDLTNLNQPLLDVDHTSSRLNLLTPRHLNQKGKALPLSSAEKRKAKWESLQNKQILVPELCAIHPIPASLWRKAVCLPSILYRLHCLLTAEELRAQTASDAGVGVRSLPADFRYPNLDFGWKKSIDSKSFISISNSSSAENDNYCKHSTIVPENAAHQGANRTSSLENHDQMSVNCRTLLSESPGKLHVEVSADLTAINGLSYNQNLANGSYDLANRDFCQGNQLNYYKQEIPVQPTTSYSIQNLYSYENQPQPSDECTLLSNKYLDGNANKSTSDGSPVMAVMPGTTDTIQVLKGRMDSEQSPSIGYSSRTLGPNPGLILQALTLSNASDGFNLERLEMLGDSFLKHAITTYLFCTYPDAHEGRLSYMRSKKVSNCNLYRLGKKKGLPSRMVVSIFDPPVNWLPPGYVVNQDKSNTDKWEKDEMTKDCMLANGKLDEDYEEEDEEEESLMWRAPKEEADYEDDFLEYDQEHIRFIDNMLMGSGAFVKKISLSPFSTTDSAYEWKMPKKSSLGSMPFSSDFEDFDYSSWDAMCYLDPSKAVEEDDFVVGFWNPSEENCGVDTGKQSISYDLHTEQCIADKSIADCVEALLGCYLTSCGERAAQLFLCSLGLKVLPVIKRTDREKALCPTRENFNSQQKNLSVSCAAASVASSRSSVLKDSEYGCLKIPPRCMFDHPDADKTLNHLISGFENFEKKINYRFKNKAYLLQAFTHASYHYNTITDCYQRLEFLGDAILDYLITKHLYEDPRQHSPGVLTDLRSALVNNTIFASLAVKYDYHKYFKAVSPELFHVIDDFVQFQLEKNEMQGMDSELRRSEEDEEKEEDIEVPKAMGDIFESLAGAIYMDSGMSLETVWQVYYPMMRPLIEKFSANVPRSPVRELLEMEPETAKFSPAERTYDGKVRVTVEVVGKGKFKGVGRSYRIAKSAAARRALRSLKANQPQVPNS	1922	Q9UPY3	R	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [308, 309], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.06695741, -0.06564862]), 'HELIX_loss': [634], 'HELIX_gain': [1704], 'HELIX_gain_score': array([0.00568569]), 'HELIX_loss_score': array([-0.00460589]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
634	NM_175914.5(HNF4A):c.733C>T (p.Arg245Cys)	804917	CA409107447	NM_175914.5:c.733C>T, NC_000020.11:g.44419783C>T, CM000682.2:g.44419783C>T, NC_000020.10:g.43048423C>T, CM000682.1:g.43048423C>T, NC_000020.9:g.42481837C>T, NG_009818.1:g.68983C>T, LRG_483:g.68983C>T, ENST00000316099.10:c.799C>T, ENST00000619550.5:c.773C>T, ENST00000683148.1:n.775C>T, ENST00000683657.1:n.1923C>T, ENST00000316099.9:c.799C>T, ENST00000316099.8:c.799C>T, ENST00000316673.8:c.733C>T, ENST00000372920.1:c.*566C>T, ENST00000415691.2:c.799C>T, ENST00000443598.6:c.799C>T, ENST00000457232.5:c.733C>T, ENST00000609795.5:c.733C>T, ENST00000619550.4:c.724C>T, NM_000457.4:c.799C>T, LRG_483t2:c.799C>T, NM_001030003.2:c.733C>T, NM_001030004.2:c.733C>T, NM_001258355.1:c.778C>T, NM_001287182.1:c.724C>T, NM_001287183.1:c.724C>T, LRG_483t3:c.724C>T, NM_001287184.1:c.724C>T, NM_175914.4:c.733C>T, LRG_483t1:c.733C>T, NM_178849.2:c.799C>T, NM_178850.2:c.799C>T, XM_005260407.2:c.916C>T, XM_011528797.1:c.847C>T, XM_011528798.1:c.847C>T, XM_005260407.4:c.916C>T, NM_001030003.3:c.733C>T, NM_001030004.3:c.733C>T, NM_001258355.2:c.778C>T, NM_001287182.2:c.724C>T, NM_001287184.2:c.724C>T, NM_178849.3:c.799C>T, NM_178850.3:c.799C>T, NM_000457.5:c.799C>T, NM_000457.6:c.799C>T, NM_001287183.2:c.724C>T, NM_175914.5(HNF4A):c.733C>T (p.Arg245Cys)	HNF4A	monogenic diabetes	MONDO:0015967	Autosomal dominant inheritance	Pathogenic	PP3, PS2_Moderate, PS4, PP4_Moderate, PM2	PM1	The c.733C>T variant in the hepatocyte nuclear factor-4-alpha gene, HNF4A, causes an amino acid change of arginine to cysteine at codon 245 (p.(Arg245Cys)) of NM_175914.5. This variant was identified in at least 8 unrelated individuals with non-autoimmune and non-absolute/near-absolute insulin-deficient diabetes (PS4; internal lab collaborators; PMIDs: 23348805, 31957151, 30026763). This variant is found in only one individual in gnomAD (PM2_Supporting). This variant segregated with diabetes, with at least 4 informative meioses in 2 families with MODY (PP1_Strong; internal lab collaborators). This variant was identified as a de novo occurrence with unconfirmed parental relationships in an individual with a clinical picture consistent with HNF4A-MODY (MODY probability calculator result >50% and negative genetic testing for HNF1A) (PS2_Moderate; PMID: 31957151).This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.898, which is greater than the MDEP VCEP threshold of 0.70 (PP3). This variant was identified in an individual with a clinical history highly specific for HNF4A-MODY (MODY probability calculator result >50%, negative genetic testing for HNF1A, antibody negative, and sulfonylurea-responsive) (PP4_Moderate; internal lab collaborators). In summary, c.733C>T meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.1.0, approved 8/11/2023): PS4, PM2_Supporting, PP1_Strong, PS2_Moderate, PP3, PP4_Moderate.		Monogenic Diabetes VCEP		2023-09-15	2023-09-15	False	https://erepo.genome.network/evrepo/ui/classification/CA409107447/MONDO:0015967/085	799d516d-6710-4c9c-a350-1d09b2121933	p.Arg245Cys	Arg	245	Cys	MRLSKTLVDMDMADYSAALDPAYTTLEFENVQVLTMGNDTSPSEGTNLNAPNSLGVSALCAICGDRATGKHYGASSCDGCKGFFRRSVRKNHMYSCRFSRQCVVDKDKRNQCRYCRLKKCFRAGMKKEAVQNERDRISTRRSSYEDSSLPSINALLQAEVLSRQITSPVSGINGDIRAKKIASIADVCESMKEQLLVLVEWAKYIPAFCELPLDDQVALLRAHAGEHLLLGATKRSMVFKDVLLLGNDYIVPRHCPELAEMSRVSIRILDELVLPFQELQIDDNEYAYLKAIIFFDPDAKGLSDPGKIKRLRSQVQVSLEDYINDRQYDSRGRFGELLLLLPTLQSITWQMIEQIQFIKLFGMAKIDNLLQEMLLGGSPSDAPHAHHPLHPHLMQEHMGTNVIVANTMPTHLSNGQMCEWPRPRGQAATPETPQPSPPGGSGSEPYKLLPGAVATIVKPLSAIPQPTITKQEVI	474	P41235	C	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [351], 'TRANSMEM_gain_score': array([0.0066334]), 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [237, 244, 247], 'STRAND_gain_score': array([0.29772168, 0.02580816, 0.07227933]), 'HELIX_loss': [330], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.01691186]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [437], 'COMPBIAS_gain_score': array([0.00710237]), 'DOMAIN_loss': [152], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.00808209]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
635	NM_177438.3(DICER1):c.5425G>A (p.Gly1809Arg)	661301	CA390864683	NM_177438.3:c.5425G>A, NC_000014.9:g.95091305C>T, CM000676.2:g.95091305C>T, NC_000014.8:g.95557642C>T, CM000676.1:g.95557642C>T, NC_000014.7:g.94627395C>T, NG_016311.1:g.71118G>A, LRG_492:g.71118G>A, ENST00000343455.8:c.5425G>A, ENST00000393063.6:c.5425G>A, ENST00000526495.6:c.5425G>A, ENST00000556045.6:c.*142G>A, ENST00000675540.1:c.3170G>A, ENST00000675995.1:c.*3741G>A, ENST00000343455.7:c.5425G>A, ENST00000393063.5:c.5425G>A, ENST00000526495.5:c.5425G>A, ENST00000527414.5:c.5425G>A, ENST00000527416.2:n.18G>A, ENST00000527554.2:n.118G>A, ENST00000541352.5:c.5365-196G>A, ENST00000556045.5:c.2119G>A, NM_001195573.1:c.5365-196G>A, NM_001271282.2:c.5425G>A, NM_001291628.1:c.5425G>A, NM_030621.4:c.5425G>A, NM_177438.2:c.5425G>A, LRG_492t1:c.5425G>A, XM_011536599.1:c.5425G>A, XM_011536600.1:c.5425G>A, XM_011536601.1:c.5425G>A, XM_011536602.1:c.5425G>A, XM_011536603.1:c.5425G>A, XM_011536604.1:c.5020G>A, XM_011536605.1:c.3946G>A, XM_011536599.2:c.5425G>A, XM_011536600.3:c.5425G>A, XM_011536601.3:c.5425G>A, XM_011536602.3:c.5425G>A, XM_011536604.2:c.5020G>A, XM_011536605.2:c.3946G>A, XM_017021120.2:c.5425G>A, XM_017021121.2:c.5425G>A, XM_017021122.2:c.5020G>A, XM_017021123.2:c.5020G>A, NM_001271282.3:c.5425G>A, NM_001291628.2:c.5425G>A, NM_001395677.1:c.5425G>A, NM_001395678.1:c.5425G>A, NM_001395679.1:c.5425G>A, NM_001395680.1:c.5425G>A, NM_001395682.1:c.5425G>A, NM_001395683.1:c.5425G>A, NM_001395684.1:c.5425G>A, NM_001395685.1:c.5425G>A, NM_001395686.1:c.5143G>A, NM_001395687.1:c.5020G>A, NM_001395688.1:c.5020G>A, NM_001395689.1:c.5020G>A, NM_001395690.1:c.5020G>A, NM_001395691.1:c.4858G>A, NM_001395697.1:c.3742G>A, NR_172715.1:n.5843G>A, NR_172716.1:n.6027G>A, NR_172717.1:n.5937G>A, NR_172718.1:n.5860G>A, NR_172719.1:n.5693G>A, NR_172720.1:n.5896G>A, NM_177438.3(DICER1):c.5425G>A (p.Gly1809Arg)	DICER1	DICER1-related tumor predisposition	MONDO:0100216	Autosomal dominant inheritance	Pathogenic	PS3_Supporting, PP3, PM2_Supporting, PS4_Supporting, PS2, PM1	PM6, PP1, PP4, BS2, BP4, BP2, BA1, PS1, BS1, BS3, BS4	The NM_177438.2:c.5425G>A variant in DICER1 is a missense variant predicted to cause substitution of glycine by arginine at amino acid 1809 (p.Gly1809Arg). This variant has been identified as a de novo occurrence with constitutional mosaicism in 1 individual with lung cysts, pleuropulmonary blastoma, and multinodular goiter (PS2, PS4_Supporting; PMID: 26475046, 34544839). This variant is absent from gnomAD v2.1.1 and v3.1.1 (non-cancer) (PM2_Supporting). In vitro cleavage assay showed that this variant reduces the capacity of the protein to produce 5p microRNAs from a pre-miRNA, indicating that this variant impacts protein function (PS3_Supporting, PMID: 25190313, 26033159). The computational predictor REVEL gives a score of 0.852, which is above the threshold of 0.75, evidence that correlates with impact to DICER1 function (PP3). This variant resides in the p.G1809 metal ion-binding residues located in the RNase IIIb domain of DICER1, that is defined as a mutational hotspot and critical functional domain by the ClinGen DICER1 VCEP (PM1, PMID: 31342592). In summary, this variant meets the criteria to be classified as Pathogenic for DICER1 syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen DICER1 VCEP: PS2, PS4_Supporting, PM2_Supporting, PS3_Supporting, PP3, PM1. (Bayesian Points: 10; VCEP specifications version 1.2.0; 8/22/23)		DICER1 and miRNA-Processing Gene VCEP		2023-08-22	2023-09-01	False	https://erepo.genome.network/evrepo/ui/classification/CA390864683/MONDO:0100216/024	820f8c3e-ff4e-425e-8802-101705afb56b	p.Gly1809Arg	Gly	1809	Arg	MKSPALQPLSMAGLQLMTPASSPMGPFFGLPWQQEAIHDNIYTPRKYQVELLEAALDHNTIVCLNTGSGKTFIAVLLTKELSYQIRGDFSRNGKRTVFLVNSANQVAQQVSAVRTHSDLKVGEYSNLEVNASWTKERWNQEFTKHQVLIMTCYVALNVLKNGYLSLSDINLLVFDECHLAILDHPYREIMKLCENCPSCPRILGLTASILNGKCDPEELEEKIQKLEKILKSNAETATDLVVLDRYTSQPCEIVVDCGPFTDRSGLYERLLMELEEALNFINDCNISVHSKERDSTLISKQILSDCRAVLVVLGPWCADKVAGMMVRELQKYIKHEQEELHRKFLLFTDTFLRKIHALCEEHFSPASLDLKFVTPKVIKLLEILRKYKPYERQQFESVEWYNNRNQDNYVSWSDSEDDDEDEEIEEKEKPETNFPSPFTNILCGIIFVERRYTAVVLNRLIKEAGKQDPELAYISSNFITGHGIGKNQPRNKQMEAEFRKQEEVLRKFRAHETNLLIATSIVEEGVDIPKCNLVVRFDLPTEYRSYVQSKGRARAPISNYIMLADTDKIKSFEEDLKTYKAIEKILRNKCSKSVDTGETDIDPVMDDDDVFPPYVLRPDDGGPRVTINTAIGHINRYCARLPSDPFTHLAPKCRTRELPDGTFYSTLYLPINSPLRASIVGPPMSCVRLAERVVALICCEKLHKIGELDDHLMPVGKETVKYEEELDLHDEEETSVPGRPGSTKRRQCYPKAIPECLRDSYPRPDQPCYLYVIGMVLTTPLPDELNFRRRKLYPPEDTTRCFGILTAKPIPQIPHFPVYTRSGEVTISIELKKSGFMLSLQMLELITRLHQYIFSHILRLEKPALEFKPTDADSAYCVLPLNVVNDSSTLDIDFKFMEDIEKSEARIGIPSTKYTKETPFVFKLEDYQDAVIIPRYRNFDQPHRFYVADVYTDLTPLSKFPSPEYETFAEYYKTKYNLDLTNLNQPLLDVDHTSSRLNLLTPRHLNQKGKALPLSSAEKRKAKWESLQNKQILVPELCAIHPIPASLWRKAVCLPSILYRLHCLLTAEELRAQTASDAGVGVRSLPADFRYPNLDFGWKKSIDSKSFISISNSSSAENDNYCKHSTIVPENAAHQGANRTSSLENHDQMSVNCRTLLSESPGKLHVEVSADLTAINGLSYNQNLANGSYDLANRDFCQGNQLNYYKQEIPVQPTTSYSIQNLYSYENQPQPSDECTLLSNKYLDGNANKSTSDGSPVMAVMPGTTDTIQVLKGRMDSEQSPSIGYSSRTLGPNPGLILQALTLSNASDGFNLERLEMLGDSFLKHAITTYLFCTYPDAHEGRLSYMRSKKVSNCNLYRLGKKKGLPSRMVVSIFDPPVNWLPPGYVVNQDKSNTDKWEKDEMTKDCMLANGKLDEDYEEEDEEEESLMWRAPKEEADYEDDFLEYDQEHIRFIDNMLMGSGAFVKKISLSPFSTTDSAYEWKMPKKSSLGSMPFSSDFEDFDYSSWDAMCYLDPSKAVEEDDFVVGFWNPSEENCGVDTGKQSISYDLHTEQCIADKSIADCVEALLGCYLTSCGERAAQLFLCSLGLKVLPVIKRTDREKALCPTRENFNSQQKNLSVSCAAASVASSRSSVLKDSEYGCLKIPPRCMFDHPDADKTLNHLISGFENFEKKINYRFKNKAYLLQAFTHASYHYNTITDCYQRLEFLGDAILDYLITKHLYEDPRQHSPGVLTDLRSALVNNTIFASLAVKYDYHKYFKAVSPELFHVIDDFVQFQLEKNEMQGMDSELRRSEEDEEKEEDIEVPKAMGDIFESLAGAIYMDSGMSLETVWQVYYPMMRPLIEKFSANVPRSPVRELLEMEPETAKFSPAERTYDGKVRVTVEVVGKGKFKGVGRSYRIAKSAAARRALRSLKANQPQVPNS	1922	Q9UPY3	R	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [309], 'STRAND_gain': [123], 'STRAND_gain_score': array([0.0066852]), 'STRAND_loss_score': array([-0.01015568]), 'HELIX_loss': [548, 634], 'HELIX_gain': [1328], 'HELIX_gain_score': array([0.00431705]), 'HELIX_loss_score': array([-0.01882291, -0.00515401]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [575, 576, 579, 588], 'DOMAIN_gain_score': array([0.05668896, 0.05975783, 0.06587249, 0.06570601]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
636	NM_000138.5(FBN1):c.7540G>A (p.Gly2514Arg)	178034	CA017250	NM_000138.5:c.7540G>A, NC_000015.10:g.48421982C>T, CM000677.2:g.48421982C>T, NC_000015.9:g.48714179C>T, CM000677.1:g.48714179C>T, NC_000015.8:g.46501471C>T, NG_008805.2:g.228807G>A, LRG_778:g.228807G>A, ENST00000682170.1:n.1721G>A, ENST00000682767.1:n.837G>A, ENST00000316623.10:c.7540G>A, ENST00000674301.1:c.2706G>A, ENST00000316623.9:c.7540G>A, ENST00000559133.5:c.2909G>A, NM_000138.4:c.7540G>A, LRG_778t1:c.7540G>A, NM_000138.5(FBN1):c.7540G>A (p.Gly2514Arg)	FBN1	Marfan syndrome	MONDO:0007947	Autosomal dominant inheritance	Pathogenic	PS4, PP1_Strong, PP4, PP2, PM2_Supporting	PP3	The NM_000138.5 c.7540G>A is a missense variant in FBN1 predicted to cause a substitution of a glycine acid by arginine at amino acid 2514 (p.Gly2514Arg), located within a calcium binding EGF-like (cbEGF) domain of the protein. This variant was found in a proband with thoracic aortic aneurysm and ectopia lentis which is a highly specific phenotype for Marfan syndrome (internal data-Bichat) (PP4). This variant has been reported in at least 4 individuals with thoracic aortic aneurysm and/or clinical features of Marfan syndrome (PMID 26272055, 19720936, 11875032, Laboratory for Molecular Medicine ClinVarentry), and in at least 3 individuals clinically diagnosed with Marfan syndrome (PMID 33483584, 28468757, Rurali et al. 2019) (PS4). It was also found to segregate with the disease in at least 5 affected family members from multiple families (Rurali et al. 2019, Laboratory for Molecular Medicine ClinVar entry, internal data) (PP1_Strong). This variant is not present in gnomAD (PM2_sup; https://gnomad.broadinstitute.org/ version 2.1.1). Computational prediction tools and conservation analysis suggest that this variant may impact the protein (REVEL: 0.945) (PP3). The constraint z-score for missense variants affecting FBN1 is 5.06 (PP2). In summary, this variant meets criteria to be classified as pathogenic for Marfan syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen FBN1 VCEP: PS4, PP1_Strong, PM2_Sup, PP2, PP3, PP4		FBN1 VCEP	https://clinicalgenome.org/docs/clingen-fbn1-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2023-09-28	2023-09-28	False	https://erepo.genome.network/evrepo/ui/classification/CA017250/MONDO:0007947/022	b03fd0bc-a7b0-4309-afa3-e4e8a053be65	p.Gly2514Arg	Gly	2514	Arg	MRRGRLLEIALGFTVLLASYTSHGADANLEAGNVKETRASRAKRRGGGGHDALKGPNVCGSRYNAYCCPGWKTLPGGNQCIVPICRHSCGDGFCSRPNMCTCPSGQIAPSCGSRSIQHCNIRCMNGGSCSDDHCLCQKGYIGTHCGQPVCESGCLNGGRCVAPNRCACTYGFTGPQCERDYRTGPCFTVISNQMCQGQLSGIVCTKTLCCATVGRAWGHPCEMCPAQPHPCRRGFIPNIRTGACQDVDECQAIPGLCQGGNCINTVGSFECKCPAGHKLNEVSQKCEDIDECSTIPGICEGGECTNTVSSYFCKCPPGFYTSPDGTRCIDVRPGYCYTALTNGRCSNQLPQSITKMQCCCDAGRCWSPGVTVAPEMCPIRATEDFNKLCSVPMVIPGRPEYPPPPLGPIPPVLPVPPGFPPGPQIPVPRPPVEYLYPSREPPRVLPVNVTDYCQLVRYLCQNGRCIPTPGSYRCECNKGFQLDLRGECIDVDECEKNPCAGGECINNQGSYTCQCRAGYQSTLTRTECRDIDECLQNGRICNNGRCINTDGSFHCVCNAGFHVTRDGKNCEDMDECSIRNMCLNGMCINEDGSFKCICKPGFQLASDGRYCKDINECETPGICMNGRCVNTDGSYRCECFPGLAVGLDGRVCVDTHMRSTCYGGYKRGQCIKPLFGAVTKSECCCASTEYAFGEPCQPCPAQNSAEYQALCSSGPGMTSAGSDINECALDPDICPNGICENLRGTYKCICNSGYEVDSTGKNCVDINECVLNSLLCDNGQCRNTPGSFVCTCPKGFIYKPDLKTCEDIDECESSPCINGVCKNSPGSFICECSSESTLDPTKTICIETIKGTCWQTVIDGRCEININGATLKSQCCSSLGAAWGSPCTLCQVDPICGKGYSRIKGTQCEDIDECEVFPGVCKNGLCVNTRGSFKCQCPSGMTLDATGRICLDIRLETCFLRYEDEECTLPIAGRHRMDACCCSVGAAWGTEECEECPMRNTPEYEELCPRGPGFATKEITNGKPFFKDINECKMIPSLCTHGKCRNTIGSFKCRCDSGFALDSEERNCTDIDECRISPDLCGRGQCVNTPGDFECKCDEGYESGFMMMKNCMDIDECQRDPLLCRGGVCHNTEGSYRCECPPGHQLSPNISACIDINECELSAHLCPNGRCVNLIGKYQCACNPGYHSTPDRLFCVDIDECSIMNGGCETFCTNSEGSYECSCQPGFALMPDQRSCTDIDECEDNPNICDGGQCTNIPGEYRCLCYDGFMASEDMKTCVDVNECDLNPNICLSGTCENTKGSFICHCDMGYSGKKGKTGCTDINECEIGAHNCGKHAVCTNTAGSFKCSCSPGWIGDGIKCTDLDECSNGTHMCSQHADCKNTMGSYRCLCKEGYTGDGFTCTDLDECSENLNLCGNGQCLNAPGGYRCECDMGFVPSADGKACEDIDECSLPNICVFGTCHNLPGLFRCECEIGYELDRSGGNCTDVNECLDPTTCISGNCVNTPGSYICDCPPDFELNPTRVGCVDTRSGNCYLDIRPRGDNGDTACSNEIGVGVSKASCCCSLGKAWGTPCEMCPAVNTSEYKILCPGGEGFRPNPITVILEDIDECQELPGLCQGGKCINTFGSFQCRCPTGYYLNEDTRVCDDVNECETPGICGPGTCYNTVGNYTCICPPDYMQVNGGNNCMDMRRSLCYRNYYADNQTCDGELLFNMTKKMCCCSYNIGRAWNKPCEQCPIPSTDEFATLCGSQRPGFVIDIYTGLPVDIDECREIPGVCENGVCINMVGSFRCECPVGFFYNDKLLVCEDIDECQNGPVCQRNAECINTAGSYRCDCKPGYRFTSTGQCNDRNECQEIPNICSHGQCIDTVGSFYCLCHTGFKTNDDQTMCLDINECERDACGNGTCRNTIGSFNCRCNHGFILSHNNDCIDVDECASGNGNLCRNGQCINTVGSFQCQCNEGYEVAPDGRTCVDINECLLEPRKCAPGTCQNLDGSYRCICPPGYSLQNEKCEDIDECVEEPEICALGTCSNTEGSFKCLCPEGFSLSSSGRRCQDLRMSYCYAKFEGGKCSSPKSRNHSKQECCCALKGEGWGDPCELCPTEPDEAFRQICPYGSGIIVGPDDSAVDMDECKEPDVCKHGQCINTDGSYRCECPFGYILAGNECVDTDECSVGNPCGNGTCKNVIGGFECTCEEGFEPGPMMTCEDINECAQNPLLCAFRCVNTYGSYECKCPVGYVLREDRRMCKDEDECEEGKHDCTEKQMECKNLIGTYMCICGPGYQRRPDGEGCVDENECQTKPGICENGRCLNTRGSYTCECNDGFTASPNQDECLDNREGYCFTEVLQNMCQIGSSNRNPVTKSECCCDGGRGWGPHCEICPFQGTVAFKKLCPHGRGFMTNGADIDECKVIHDVCRNGECVNDRGSYHCICKTGYTPDITGTSCVDLNECNQAPKPCNFICKNTEGSYQCSCPKGYILQEDGRSCKDLDECATKQHNCQFLCVNTIGGFTCKCPPGFTQHHTSCIDNNECTSDINLCGSKGICQNTPGSFTCECQRGFSLDQTGSSCEDVDECEGNHRCQHGCQNIIGGYRCSCPQGYLQHYQWNQCVDENECLSAHICGGASCHNTLGSYKCMCPAGFQYEQFSGGCQDINECGSAQAPCSYGCSNTEGGYLCGCPPGYFRIGQGHCVSGMGMGRGNPEPPVSGEMDDNSLSPEACYECKINGYPKRGRKRRSTNETDASNIEDQSETEANVSLASWDVEKTAIFAFNISHVSNKVRILELLPALTTLTNHNRYLIESGNEDGFFKINQKEGISYLHFTKKKPVAGTYSLQISSTPLYKKKELNQLEDKYDKDYLSGELGDNLKMKIQVLLH	2871	P35555	R	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [2515], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.06447202]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [611, 1035, 1253, 2488, 2492, 2494, 2505, 2540, 2542, 2543], 'DOMAIN_gain': [1303, 1304, 1328], 'DOMAIN_gain_score': array([0.04015499, 0.05584472, 0.02242982]), 'DOMAIN_loss_score': array([-0.00148624, -0.01142627, -0.01013601, -0.11507177, -0.12724149,
       -0.16021514, -0.15341246, -0.09012377, -0.1262114 , -0.12302023]), 'REGION_loss': [2513, 2536], 'REGION_gain': [922, 932, 942, 969, 1233, 2521], 'REGION_gain_score': array([0.00170994, 0.00180787, 0.00205958, 0.00239718, 0.00126874,
       0.00205064]), 'REGION_loss_score': array([-0.02031171, -0.0011633 ]), 'REPEAT_loss': [2480, 2516, 2517, 2518, 2521, 2542, 2557, 2558], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.01407015, -0.17858243, -0.16234714, -0.16477269, -0.11633962,
       -0.03435618, -0.03617096, -0.02787656]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
637	NM_000156.6(GAMT):c.407C>T (p.Thr136Met)	544257	CA9043669	NM_000156.6:c.407C>T, NC_000019.10:g.1399180G>A, CM000681.2:g.1399180G>A, NC_000019.9:g.1399179G>A, CM000681.1:g.1399179G>A, NC_000019.8:g.1350179G>A, NG_009785.1:g.7374C>T, ENST00000252288.8:c.407C>T, ENST00000447102.8:c.407C>T, ENST00000591788.3:c.90C>T, ENST00000640164.1:n.240C>T, ENST00000640762.1:c.338C>T, ENST00000252288.6:c.407C>T, ENST00000447102.7:c.407C>T, ENST00000591788.2:c.92C>T, NM_000156.5:c.407C>T, NM_138924.2:c.407C>T, NM_138924.3:c.407C>T, NM_000156.6(GAMT):c.407C>T (p.Thr136Met)	GAMT	guanidinoacetate methyltransferase deficiency	MONDO:0012999	Autosomal recessive inheritance	Pathogenic	PS3_Supporting, PM2_Supporting, PP3_Moderate, PP4_Strong, PM3		The NM_000156.6:c.407C>T variant in GAMT is a missense variant predicted to cause substitution of threonine by methionine at amino acid 136 (p.Thr136Met). This variant has been detected in 3 unrelated individuals with GAMT deficiency (PMID: 24415674, PMID: 21140503, ClinVar SCV001428825.1). Of those individuals, two were compound heterozygous for the variant and a pathogenic variant, c.316C>T (p.Q106*) in unknown phase (PMID: 24415674, PMID: 21140503) and 1 was homozygous for the variant (ClinVar SCV001428825.1) (1.5pts total, PM3). One of these individuals had elevated GAA in plasma, deficient GAMT enzyme activity (<5% wild-type enzyme) in fibroblasts, and significantly reduced creatine peak on brain MRS (PMID: 21140503) and one individual had an absent creatine peak with visible GAA peak on brain MRS (PMID: 24415674) (PP4_Strong). Expression of the variant in GAMT-deficient fibroblasts resulted in <5% wild type GAMT activity indicating that this variant may impact protein function (PMID: 24415674)(PS3_Supporting). The highest population minor allele frequency in gnomAD v2.1.1 is 0.000009 (1/113420 alleles) in the European (non-Finnish) population, which is lower than the ClinGen CCDS VCEP’s threshold for PM2_Supporting (<0.0004), meeting this criterion (PM2_Supporting). The computational predictor REVEL gives a score of 0.976 which is above the threshold of 0.75, evidence that correlates with impact to GAMT function (PP3_Moderate). There is a ClinVar entry for this variant (Variation ID: 544257). In summary, this variant meets the criteria to be classified as pathogenic for GAMT deficiency based on the ACMG/AMP criteria applied, as specified by the ClinGen Cerebral Creatine Deficiency Syndromes Variant Curation Expert Panel (Specifications Version 1.1.0): PP4_Strong, PM3, PP3_Moderate, PS3_Supporting, PM2_Supporting.(Classification approved by the ClinGen CCDS VCEP on Oct. 2026, 2023)	24415674	Cerebral Creatine Deficiency Syndromes VCEP		2023-10-26	2023-11-08	False	https://erepo.genome.network/evrepo/ui/classification/CA9043669/MONDO:0012999/026	b1540be4-deab-4ef4-b3d1-260e5e246046	p.Thr136Met	Thr	136	Met	MSAPSATPIFAPGENCSPAWGAAPAAYDAADTHLRILGKPVMERWETPYMHALAAAASSKGGRVLEVGFGMAIAASKVQEAPIDEHWIIECNDGVFQRLRDWAPRQTHKVIPLKGLWEDVAPTLPDGHFDGILYDTYPLSEETWHTHQFNFIKNHAFRLLKPGGVLTYCNLTSWGELMKSKYSDITIMFEETQVPALLEAGFRRENIRTEVMALVPPADCRYYAFPQMITPLVTKG	236	Q14353	M	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [94, 95, 115, 153, 163, 172, 173], 'DNA_BIND_gain_score': array([0.01054406, 0.01100636, 0.01022911, 0.00381124, 0.00381935,
       0.01699334, 0.01432478]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [214], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.05137813]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [235], 'DOMAIN_gain': [7, 8], 'DOMAIN_gain_score': array([0.0565024 , 0.05993837]), 'DOMAIN_loss_score': array([-0.03564942]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [61, 93, 98, 111, 164], 'REPEAT_gain_score': array([0.01272237, 0.01479924, 0.03138357, 0.02555984, 0.01247609]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
638	NM_000138.5(FBN1):c.4414T>C (p.Cys1472Arg)	549229	CA392354459	NM_000138.5:c.4414T>C, NC_000015.10:g.48470679A>G, CM000677.2:g.48470679A>G, NC_000015.9:g.48762876A>G, CM000677.1:g.48762876A>G, NC_000015.8:g.46550168A>G, NG_008805.2:g.180110T>C, LRG_778:g.180110T>C, ENST00000683268.1:n.381T>C, ENST00000684448.1:n.3088T>C, ENST00000316623.10:c.4414T>C, ENST00000316623.9:c.4414T>C, ENST00000537463.6:c.*177T>C, NM_000138.4:c.4414T>C, LRG_778t1:c.4414T>C, NM_000138.5(FBN1):c.4414T>C (p.Cys1472Arg)	FBN1	Marfan syndrome	MONDO:0007947	Autosomal dominant inheritance	Pathogenic	PS4, PM1_Strong, PP2, PP3, PP4, PM2_Supporting	PS1, PS3, PM5, BS1, BS3, BS2, BA1, BP1, BP4	The NM_00138 c.4414T>C is a missense variant in FBN1 predicted to cause a substitution of a cysteine by arginine at amino acid 1472 (p.Cys1472Arg). This variant was found in a proband with thoracic aortic aneurysm and/or dissection, ectopia lentis, and a systemic score of 7, which is a highly specific phenotype for Marfan syndrome (internal data-Ghent University Hospital) (PP4). This variant has been reported 3 times in ClinVar, once as pathogenic and twice as likely pathogenic (Variation ID: 549229). 6 other probands with a clinical diagnosis of Marfan syndrome or clinical features of Marfan syndrome carry the same variant (PMID 33087052, InvitaeClinVarentry, University of Antwerp ClinVar entry, internal data, PS4). This variant is not present in gnomAD (PM2_sup; https://gnomad.broadinstitute.org/ version 2.1.1). This variant affects a cysteine residue in a calcium binding EGF domain. Cysteine residues are believed to be involved in the formation of disulfide bridges which are essential for the protein structure (PM1_strong). Computational prediction tools and conservation analysis suggest that this variant may impact the protein (REVEL: 0.979) (PP3). The constraint z-score for missense variants affecting FBN1 is 5.06 (PP2). In summary, this variant meets criteria to be classified as pathogenic for Marfan syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen FBN1 VCEP: PS4, PM1_Strong, PP2, PP3, PP4		FBN1 VCEP	https://clinicalgenome.org/docs/clingen-fbn1-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2023-09-28	2023-09-28	False	https://erepo.genome.network/evrepo/ui/classification/CA392354459/MONDO:0007947/022	baa4831c-99de-48eb-a54d-88dcc423a770	p.Cys1472Arg	Cys	1472	Arg	MRRGRLLEIALGFTVLLASYTSHGADANLEAGNVKETRASRAKRRGGGGHDALKGPNVCGSRYNAYCCPGWKTLPGGNQCIVPICRHSCGDGFCSRPNMCTCPSGQIAPSCGSRSIQHCNIRCMNGGSCSDDHCLCQKGYIGTHCGQPVCESGCLNGGRCVAPNRCACTYGFTGPQCERDYRTGPCFTVISNQMCQGQLSGIVCTKTLCCATVGRAWGHPCEMCPAQPHPCRRGFIPNIRTGACQDVDECQAIPGLCQGGNCINTVGSFECKCPAGHKLNEVSQKCEDIDECSTIPGICEGGECTNTVSSYFCKCPPGFYTSPDGTRCIDVRPGYCYTALTNGRCSNQLPQSITKMQCCCDAGRCWSPGVTVAPEMCPIRATEDFNKLCSVPMVIPGRPEYPPPPLGPIPPVLPVPPGFPPGPQIPVPRPPVEYLYPSREPPRVLPVNVTDYCQLVRYLCQNGRCIPTPGSYRCECNKGFQLDLRGECIDVDECEKNPCAGGECINNQGSYTCQCRAGYQSTLTRTECRDIDECLQNGRICNNGRCINTDGSFHCVCNAGFHVTRDGKNCEDMDECSIRNMCLNGMCINEDGSFKCICKPGFQLASDGRYCKDINECETPGICMNGRCVNTDGSYRCECFPGLAVGLDGRVCVDTHMRSTCYGGYKRGQCIKPLFGAVTKSECCCASTEYAFGEPCQPCPAQNSAEYQALCSSGPGMTSAGSDINECALDPDICPNGICENLRGTYKCICNSGYEVDSTGKNCVDINECVLNSLLCDNGQCRNTPGSFVCTCPKGFIYKPDLKTCEDIDECESSPCINGVCKNSPGSFICECSSESTLDPTKTICIETIKGTCWQTVIDGRCEININGATLKSQCCSSLGAAWGSPCTLCQVDPICGKGYSRIKGTQCEDIDECEVFPGVCKNGLCVNTRGSFKCQCPSGMTLDATGRICLDIRLETCFLRYEDEECTLPIAGRHRMDACCCSVGAAWGTEECEECPMRNTPEYEELCPRGPGFATKEITNGKPFFKDINECKMIPSLCTHGKCRNTIGSFKCRCDSGFALDSEERNCTDIDECRISPDLCGRGQCVNTPGDFECKCDEGYESGFMMMKNCMDIDECQRDPLLCRGGVCHNTEGSYRCECPPGHQLSPNISACIDINECELSAHLCPNGRCVNLIGKYQCACNPGYHSTPDRLFCVDIDECSIMNGGCETFCTNSEGSYECSCQPGFALMPDQRSCTDIDECEDNPNICDGGQCTNIPGEYRCLCYDGFMASEDMKTCVDVNECDLNPNICLSGTCENTKGSFICHCDMGYSGKKGKTGCTDINECEIGAHNCGKHAVCTNTAGSFKCSCSPGWIGDGIKCTDLDECSNGTHMCSQHADCKNTMGSYRCLCKEGYTGDGFTCTDLDECSENLNLCGNGQCLNAPGGYRCECDMGFVPSADGKACEDIDECSLPNICVFGTCHNLPGLFRCECEIGYELDRSGGNCTDVNECLDPTTCISGNCVNTPGSYICDCPPDFELNPTRVGCVDTRSGNCYLDIRPRGDNGDTACSNEIGVGVSKASCCCSLGKAWGTPCEMCPAVNTSEYKILCPGGEGFRPNPITVILEDIDECQELPGLCQGGKCINTFGSFQCRCPTGYYLNEDTRVCDDVNECETPGICGPGTCYNTVGNYTCICPPDYMQVNGGNNCMDMRRSLCYRNYYADNQTCDGELLFNMTKKMCCCSYNIGRAWNKPCEQCPIPSTDEFATLCGSQRPGFVIDIYTGLPVDIDECREIPGVCENGVCINMVGSFRCECPVGFFYNDKLLVCEDIDECQNGPVCQRNAECINTAGSYRCDCKPGYRFTSTGQCNDRNECQEIPNICSHGQCIDTVGSFYCLCHTGFKTNDDQTMCLDINECERDACGNGTCRNTIGSFNCRCNHGFILSHNNDCIDVDECASGNGNLCRNGQCINTVGSFQCQCNEGYEVAPDGRTCVDINECLLEPRKCAPGTCQNLDGSYRCICPPGYSLQNEKCEDIDECVEEPEICALGTCSNTEGSFKCLCPEGFSLSSSGRRCQDLRMSYCYAKFEGGKCSSPKSRNHSKQECCCALKGEGWGDPCELCPTEPDEAFRQICPYGSGIIVGPDDSAVDMDECKEPDVCKHGQCINTDGSYRCECPFGYILAGNECVDTDECSVGNPCGNGTCKNVIGGFECTCEEGFEPGPMMTCEDINECAQNPLLCAFRCVNTYGSYECKCPVGYVLREDRRMCKDEDECEEGKHDCTEKQMECKNLIGTYMCICGPGYQRRPDGEGCVDENECQTKPGICENGRCLNTRGSYTCECNDGFTASPNQDECLDNREGYCFTEVLQNMCQIGSSNRNPVTKSECCCDGGRGWGPHCEICPFQGTVAFKKLCPHGRGFMTNGADIDECKVIHDVCRNGECVNDRGSYHCICKTGYTPDITGTSCVDLNECNQAPKPCNFICKNTEGSYQCSCPKGYILQEDGRSCKDLDECATKQHNCQFLCVNTIGGFTCKCPPGFTQHHTSCIDNNECTSDINLCGSKGICQNTPGSFTCECQRGFSLDQTGSSCEDVDECEGNHRCQHGCQNIIGGYRCSCPQGYLQHYQWNQCVDENECLSAHICGGASCHNTLGSYKCMCPAGFQYEQFSGGCQDINECGSAQAPCSYGCSNTEGGYLCGCPPGYFRIGQGHCVSGMGMGRGNPEPPVSGEMDDNSLSPEACYECKINGYPKRGRKRRSTNETDASNIEDQSETEANVSLASWDVEKTAIFAFNISHVSNKVRILELLPALTTLTNHNRYLIESGNEDGFFKINQKEGISYLHFTKKKPVAGTYSLQISSTPLYKKKELNQLEDKYDKDYLSGELGDNLKMKIQVLLH	2871	P35555	R	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [250, 272, 277, 280, 281, 282, 611, 1330, 1386, 1410, 1412, 1426, 1427, 1428, 1431, 1433, 1434, 1449, 1450, 1451, 1452, 1453, 1454, 1455, 1456, 1457, 1458, 1459, 1460, 1461, 1462, 1463, 1464, 1465, 1466, 1467, 1468, 1469, 1470, 1471, 1472, 1473, 1474, 1475, 1476, 1491, 1506, 1507, 1508, 1509, 1511, 1513], 'DOMAIN_gain': [2182, 2458, 2493, 2503, 2504, 2538], 'DOMAIN_gain_score': array([0.02016687, 0.03744   , 0.04406756, 0.0511685 , 0.04273564,
       0.06693274]), 'DOMAIN_loss_score': array([-0.09027201, -0.1753301 , -0.12932229, -0.12786144, -0.10917836,
       -0.03658289, -0.00109202, -0.01622552, -0.06900448, -0.12362957,
       -0.12147069, -0.22883564, -0.24895018, -0.28303427, -0.2740097 ,
       -0.51867157, -0.38358635, -0.76326889, -0.70926291, -0.81423861,
       -0.79261142, -0.85131812, -0.89740068, -0.93399256, -0.92310447,
       -0.92660922, -0.89928895, -0.88991272, -0.77052933, -0.90263253,
       -0.89096504, -0.89162147, -0.87274337, -0.82543349, -0.86264127,
       -0.80956864, -0.76818609, -0.80961776, -0.64743131, -0.477992  ,
       -0.61830753, -0.5673846 , -0.79172963, -0.59794086, -0.5427832 ,
       -0.35585964, -0.31290859, -0.36138844, -0.41324502, -0.30682558,
       -0.30035692, -0.24187016]), 'REGION_loss': [976, 1670, 2074, 2112, 2146, 2184, 2195, 2199, 2207, 2210, 2216, 2225, 2536], 'REGION_gain': [922, 932], 'REGION_gain_score': array([0.00055343, 0.00036067]), 'REGION_loss_score': array([-0.00139266, -0.00295991, -0.00174499, -0.00168753, -0.0021919 ,
       -0.0028615 , -0.00268495, -0.00286859, -0.00278407, -0.00300097,
       -0.00290436, -0.00296938, -0.00162399]), 'REPEAT_loss': [282, 1479, 1480, 1517], 'REPEAT_gain': [134, 136, 140, 168, 169, 247, 248, 1030, 2524, 2547, 2564, 2870], 'REPEAT_gain_score': array([0.02037454, 0.01876497, 0.0210405 , 0.02442485, 0.0319109 ,
       0.0205344 , 0.00931036, 0.01212394, 0.01214314, 0.0091728 ,
       0.00810158, 0.04501796]), 'REPEAT_loss_score': array([-0.02874178, -0.16654223, -0.14154434, -0.00140917]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
639	NM_130839.5(UBE3A):c.2096A>C (p.Lys699Thr)	156144	CA206151	NM_130839.5:c.2096A>C, NC_000015.10:g.25355920T>G, CM000677.2:g.25355920T>G, NC_000015.9:g.25601067T>G, CM000677.1:g.25601067T>G, NC_000015.8:g.23152160T>G, NG_009268.1:g.88062A>C, LRG_15:g.88062A>C, ENST00000438097.6:c.2036A>C, ENST00000625778.3:c.2036A>C, ENST00000635914.1:c.2036A>C, ENST00000637886.1:c.2096A>C, ENST00000638011.1:c.2036A>C, ENST00000638155.1:c.2036A>C, ENST00000648336.2:c.2096A>C, ENST00000649550.1:c.2036A>C, ENST00000650110.1:c.2105A>C, ENST00000675177.1:c.1919A>C, ENST00000675593.1:n.4792A>C, ENST00000232165.7:c.2036A>C, ENST00000397954.6:c.2105A>C, ENST00000428984.6:c.2036A>C, ENST00000438097.5:c.2036A>C, ENST00000566215.5:c.2036A>C, ENST00000604860.3:c.75+771A>C, ENST00000614096.4:c.2096A>C, ENST00000625778.2:c.2036A>C, ENST00000626176.2:c.63A>C, ENST00000630424.2:c.2036A>C, ENST00000631247.1:n.585A>C, NM_000462.3:c.2105A>C, NM_130838.1:c.2036A>C, LRG_15t1:c.2036A>C, NM_130839.2:c.2096A>C, XM_005268267.3:c.2036A>C, XM_005268268.3:c.2036A>C, XM_005268269.3:c.2036A>C, XM_005268270.3:c.2036A>C, XM_005268271.3:c.2036A>C, XM_006720673.2:c.2096A>C, XM_006720674.2:c.2096A>C, XM_006720675.2:c.2036A>C, XM_006720676.2:c.2036A>C, XM_011521994.1:c.2105A>C, XM_011521995.1:c.2105A>C, XM_011521996.1:c.2036A>C, NM_000462.5:c.2105A>C, NM_001354505.1:c.2096A>C, NM_001354506.1:c.2036A>C, NM_001354507.1:c.2036A>C, NM_001354508.1:c.2036A>C, NM_001354509.1:c.2036A>C, NM_001354511.1:c.2036A>C, NM_001354512.1:c.2036A>C, NM_001354513.1:c.2036A>C, NM_001354523.1:c.2036A>C, NM_001354526.1:c.2036A>C, NM_001354538.1:c.2096A>C, NM_001354539.1:c.2036A>C, NM_001354540.1:c.2036A>C, NM_001354541.1:c.2036A>C, NM_001354542.1:c.2036A>C, NM_001354543.1:c.2036A>C, NM_001354544.1:c.2036A>C, NM_001354545.1:c.2096A>C, NM_001354546.1:c.1919A>C, NM_001354547.1:c.2036A>C, NM_001354548.1:c.2036A>C, NM_001354549.1:c.1899+771A>C, NM_001354550.1:c.845A>C, NM_001354551.1:c.785A>C, NM_130838.3:c.2036A>C, NM_130839.4:c.2096A>C, NR_146177.1:n.18393-35676T>G, NR_148916.1:n.2640A>C, XM_011521995.3:c.2105A>C, XM_017022547.2:c.2096A>C, XM_017022548.2:c.2096A>C, XM_017022550.2:c.2096A>C, XM_017022556.2:c.2105A>C, XM_024450043.1:c.2105A>C, XM_024450044.1:c.2036A>C, NM_001354506.2:c.2036A>C, NM_001354507.2:c.2036A>C, NM_001354508.2:c.2036A>C, NM_001354509.2:c.2036A>C, NM_001354511.2:c.2036A>C, NM_001354512.2:c.2036A>C, NM_001354513.2:c.2036A>C, NM_001354523.2:c.2036A>C, NM_001354538.2:c.2096A>C, NM_001354539.2:c.2036A>C, NM_001354540.2:c.2036A>C, NM_001354541.2:c.2036A>C, NM_001354542.2:c.2036A>C, NM_001354543.2:c.2036A>C, NM_001354544.2:c.2036A>C, NM_001354545.2:c.2096A>C, NM_001354546.2:c.1919A>C, NM_001354547.2:c.2036A>C, NM_001354548.2:c.2036A>C, NM_001354549.2:c.1899+771A>C, NM_001354550.2:c.845A>C, NM_001354551.2:c.785A>C, NM_001374461.1:c.2036A>C, NM_130838.4:c.2036A>C, NR_148916.2:n.2608A>C, NM_130839.5(UBE3A):c.2096A>C (p.Lys699Thr)	UBE3A	Angelman syndrome	MONDO:0007113	Autosomal dominant inheritance	Benign	BA1, BP5	BS2	The allele frequency of The p.Lys679Thr variant in UBE3A (NM_130838.2) is 0.03187% in European (non-Finnish) sub population in gnomAD v4, which is high enough to be classified as benign based on thresholds defined by the ClinGen Rett/Angelman-like Expert Panel for Rett/AS-like conditions (BA1). The p.Lys679Thr variant is found in a patient with an alternate molecular basis of disease (internal database - Baylor) (BP5). In summary, the p.Lys679Thr variant in UBE3A (NM_130838.2) is classified as benign based on the ACMG/AMP criteria (BA1, BP5).		Rett and Angelman-like Disorders VCEP		2023-12-06	2023-12-11	False	https://erepo.genome.network/evrepo/ui/classification/CA206151/MONDO:0007113/037	d19ee94f-a011-463d-bbf0-0fa8dc6e5da9	p.Lys699Thr	Lys	699	Thr	MEKLHQCYWKSGEPQSDDIEASRMKRAAAKHLIERYYHQLTEGCGNEACTNEFCASCPTFLRMDNNAAAIKALELYKINAKLCDPHPSKKGASSAYLENSKGAPNNSCSEIKMNKKGARIDFKDVTYLTEEKVYEILELCREREDYSPLIRVIGRVFSSAEALVQSFRKVKQHTKEELKSLQAKDEDKDEDEKEKAACSAAAMEEDSEASSSRIGDSSQGDNNLQKLGPDDVSVDIDAIRRVYTRLLSNEKIETAFLNALVYLSPNVECDLTYHNVYSRDPNYLNLFIIVMENRNLHSPEYLEMALPLFCKAMSKLPLAAQGKLIRLWSKYNADQIRRMMETFQQLITYKVISNEFNSRNLVNDDDAIVAASKCLKMVYYANVVGGEVDTNHNEEDDEEPIPESSELTLQELLGEERRNKKGPRVDPLETELGVKTLDCRKPLIPFEEFINEPLNEVLEMDKDYTFFKVETENKFSFMTCPFILNAVTKNLGLYYDNRIRMYSERRITVLYSLVQGQQLNPYLRLKVRRDHIIDDALVRLEMIAMENPADLKKQLYVEFEGEQGVDEGGVSKEFFQLVVEEIFNPDIGMFTYDESTKLFWFNPSSFETEGQFTLIGIVLGLAIYNNCILDVHFPMVVYRKLMGKKGTFRDLGDSHPVLYQSLKDLLEYEGNVEDDMMITFQISQTDLFGNPMMYDLKENGDKIPITNENRKEFVNLYSDYILNKSVEKQFKAFRRGFHMVTNESPLKYLFRPEEIELLICGSRNLDFQALEETTEYDGGYTRDSVLIREFWEIVHSFTDEQKRLFLQFTTGTDRAPVGGLGKLKMIIAKNGPDTERLPTSHTCFNVLLLPEYSSKEKLKERLLKAITYAKGFGML	875	Q05086	T	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [13], 'SIGNAL_gain': [], 'SIGNAL_loss_score': array([-0.0034169]), 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [693], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.07085514]), 'HELIX_loss': [174, 378, 744, 755], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.00429171, -0.00625026, -0.01817656, -0.05416101]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [735, 741, 745, 864], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.04566377, -0.03665197, -0.03199708, -0.05078393]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
640	NM_005249.5(FOXG1):c.268G>T (p.Ala90Ser)	390253	CA16607631	NM_005249.5:c.268G>T, NC_000014.9:g.28767547G>T, CM000676.2:g.28767547G>T, NC_000014.8:g.29236753G>T, CM000676.1:g.29236753G>T, NC_000014.7:g.28306504G>T, NG_009367.1:g.5467G>T, ENST00000313071.7:c.268G>T, ENST00000313071.6:c.268G>T, NM_005249.4:c.268G>T, NM_005249.5(FOXG1):c.268G>T (p.Ala90Ser)	FOXG1	FOXG1 disorder	MONDO:0100040	Autosomal dominant inheritance	Benign	BS1, BS2, BP4	PM2, BA1	The allele frequency of the p.Ala90Ser variant in FOXG1 is 0.01457% in Admixed American sub population in gnomAD, which is high enough to meet the BS1 criteria based on thresholds defined by the ClinGen Rett/Angelman-like Expert Panel for Rett/AS-like conditions (BS1). The p.Ala90Ser variant is observed in 10 unaffected individuals (internal database - GeneDx) (BS2). Computational analysis prediction tools suggest that the p.Ala90Ser variant does not have a deleterious impact; however this information does not predict clinical significance on its own (BP4). In summary, the p.Ala90Ser variant in FOXG1 is classified as Benign based on the ACMG/AMP criteria (BS1, BS2, BP4).		Rett and Angelman-like Disorders VCEP		2023-12-06	2023-12-11	False	https://erepo.genome.network/evrepo/ui/classification/CA16607631/MONDO:0100040/035	d9c130a5-bda0-4c59-9d9c-a90bf6550834	p.Ala90Ser	Ala	90	Ser	MLDMGDRKEVKMIPKSSFSINSLVPEAVQNDNHHASHGHHNSHHPQHHHHHHHHHHHPPPPAPQPPPPPQQQQPPPPPPPAPQPPQTRGAPAADDDKGPQQLLLPPPPPPPPAAALDGAKADGLGGKGEPGGGPGELAPVGPDEKEKGAGAGGEEKKGAGEGGKDGEGGKEGEKKNGKYEKPPFSYNALIMMAIRQSPEKRLTLNGIYEFIMKNFPYYRENKQGWQNSIRHNLSLNKCFVKVPRHYDDPGKGNYWMLDPSSDDVFIGGTTGKLRRRSTTSRAKLAFKRGARLTSTGLTFMDRAGSLYWPMSPFLSLHHPRASSTLSYNGTTSAYPSHPMPYSSVLTQNSLGNNHSFSTANGLSVDRLVNGEIPYATHHLTAAALAASVPCGLSVPCSGTYSLNPCSVNLLAGQTSYFFPHVPHPSMTSQSSTSMSARAASSSTSPQAPSTLPCESLRPSLPSFTTGLSGGLSDYFTHQNQGSSSNPLIH	489	P55316	S	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [0], 'SIGNAL_gain_score': array([0.02635092]), 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
641	NM_177438.3(DICER1):c.3553G>A (p.Ala1185Thr)	133970	CA158273	NM_177438.3:c.3553G>A, NC_000014.9:g.95103843C>T, CM000676.2:g.95103843C>T, NC_000014.8:g.95570180C>T, CM000676.1:g.95570180C>T, NC_000014.7:g.94639933C>T, NG_016311.1:g.58580G>A, LRG_492:g.58580G>A, ENST00000343455.8:c.3553G>A, ENST00000393063.6:c.3553G>A, ENST00000526495.6:c.3553G>A, ENST00000532939.3:c.3553G>A, ENST00000556045.6:c.3553G>A, ENST00000675540.1:c.1298G>A, ENST00000675995.1:c.*1869G>A, ENST00000343455.7:c.3553G>A, ENST00000393063.5:c.3553G>A, ENST00000526495.5:c.3553G>A, ENST00000527414.5:c.3553G>A, ENST00000541352.5:c.3553G>A, ENST00000554367.1:n.762G>A, ENST00000556045.5:c.247G>A, NM_001195573.1:c.3553G>A, NM_001271282.2:c.3553G>A, NM_001291628.1:c.3553G>A, NM_030621.4:c.3553G>A, NM_177438.2:c.3553G>A, LRG_492t1:c.3553G>A, XM_011536599.1:c.3553G>A, XM_011536600.1:c.3553G>A, XM_011536601.1:c.3553G>A, XM_011536602.1:c.3553G>A, XM_011536603.1:c.3553G>A, XM_011536604.1:c.3148G>A, XM_011536605.1:c.2074G>A, XM_011536599.2:c.3553G>A, XM_011536600.3:c.3553G>A, XM_011536601.3:c.3553G>A, XM_011536602.3:c.3553G>A, XM_011536604.2:c.3148G>A, XM_011536605.2:c.2074G>A, XM_017021120.2:c.3553G>A, XM_017021121.2:c.3553G>A, XM_017021122.2:c.3148G>A, XM_017021123.2:c.3148G>A, NM_001271282.3:c.3553G>A, NM_001291628.2:c.3553G>A, NM_001395677.1:c.3553G>A, NM_001395678.1:c.3553G>A, NM_001395679.1:c.3553G>A, NM_001395680.1:c.3553G>A, NM_001395682.1:c.3553G>A, NM_001395683.1:c.3553G>A, NM_001395684.1:c.3553G>A, NM_001395685.1:c.3553G>A, NM_001395686.1:c.3271G>A, NM_001395687.1:c.3148G>A, NM_001395688.1:c.3148G>A, NM_001395689.1:c.3148G>A, NM_001395690.1:c.3148G>A, NM_001395691.1:c.2986G>A, NM_001395692.1:c.3553G>A, NM_001395693.1:c.3553G>A, NM_001395694.1:c.3553G>A, NM_001395695.1:c.3553G>A, NM_001395696.1:c.3148G>A, NM_001395697.1:c.1870G>A, NR_172715.1:n.3971G>A, NR_172716.1:n.4155G>A, NR_172717.1:n.4065G>A, NR_172718.1:n.3988G>A, NR_172719.1:n.3821G>A, NR_172720.1:n.3898G>A, NM_177438.3(DICER1):c.3553G>A (p.Ala1185Thr)	DICER1	DICER1-related tumor predisposition	MONDO:0100216	Autosomal dominant inheritance	Benign	BS2, BP4, BS1	PM2, PVS1, PM6, PP2, PP3, PP1, PP4, BP1, BP3, BP2, BA1, PS2, PS3, PS4, PS1, BP7, BP5, BS4, BS3, PM4, PM1, PM3, PM5	The NM_177438.2:c.3553G>A variant in DICER1 is a missense variant predicted to cause substitution of alanine by threonine at amino acid 1185 (p.Ala1185Thr). This variant has been seen in 40 or more unrelated females without tumors through age 50 in at least one testing laboratory (BS2; ClinVar SCV: SCV000661803.4, SCV000291663.10; PMIDs: 24728327). The highest population minor allele frequency in gnomAD v3.1.2 is 0.002 (45/15,076 alleles) in Latino/Admixed American populations, which is higher than the ClinGen DICER1 VCEP threshold (>0.0003) for BS1, and therefore meets this criterion (BS1). In silico tools predict no damaging impact of the variant on protein function (REVEL: 0.048; MaxEntScan and SpliceAI: no effect on splicing (BP4). In summary, this variant meets the criteria to be classified as Benign for DICER1 syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen DICER1 VCEP: BS1, BS2, BP4. (Bayesian Points: -9; VCEP specifications version 1.2.0; 08/22/23)		DICER1 and miRNA-Processing Gene VCEP		2023-08-22	2023-09-01	False	https://erepo.genome.network/evrepo/ui/classification/CA158273/MONDO:0100216/024	f9b0da96-b8bc-4ebc-9b7f-1bba9acb1e97	p.Ala1185Thr	Ala	1185	Thr	MKSPALQPLSMAGLQLMTPASSPMGPFFGLPWQQEAIHDNIYTPRKYQVELLEAALDHNTIVCLNTGSGKTFIAVLLTKELSYQIRGDFSRNGKRTVFLVNSANQVAQQVSAVRTHSDLKVGEYSNLEVNASWTKERWNQEFTKHQVLIMTCYVALNVLKNGYLSLSDINLLVFDECHLAILDHPYREIMKLCENCPSCPRILGLTASILNGKCDPEELEEKIQKLEKILKSNAETATDLVVLDRYTSQPCEIVVDCGPFTDRSGLYERLLMELEEALNFINDCNISVHSKERDSTLISKQILSDCRAVLVVLGPWCADKVAGMMVRELQKYIKHEQEELHRKFLLFTDTFLRKIHALCEEHFSPASLDLKFVTPKVIKLLEILRKYKPYERQQFESVEWYNNRNQDNYVSWSDSEDDDEDEEIEEKEKPETNFPSPFTNILCGIIFVERRYTAVVLNRLIKEAGKQDPELAYISSNFITGHGIGKNQPRNKQMEAEFRKQEEVLRKFRAHETNLLIATSIVEEGVDIPKCNLVVRFDLPTEYRSYVQSKGRARAPISNYIMLADTDKIKSFEEDLKTYKAIEKILRNKCSKSVDTGETDIDPVMDDDDVFPPYVLRPDDGGPRVTINTAIGHINRYCARLPSDPFTHLAPKCRTRELPDGTFYSTLYLPINSPLRASIVGPPMSCVRLAERVVALICCEKLHKIGELDDHLMPVGKETVKYEEELDLHDEEETSVPGRPGSTKRRQCYPKAIPECLRDSYPRPDQPCYLYVIGMVLTTPLPDELNFRRRKLYPPEDTTRCFGILTAKPIPQIPHFPVYTRSGEVTISIELKKSGFMLSLQMLELITRLHQYIFSHILRLEKPALEFKPTDADSAYCVLPLNVVNDSSTLDIDFKFMEDIEKSEARIGIPSTKYTKETPFVFKLEDYQDAVIIPRYRNFDQPHRFYVADVYTDLTPLSKFPSPEYETFAEYYKTKYNLDLTNLNQPLLDVDHTSSRLNLLTPRHLNQKGKALPLSSAEKRKAKWESLQNKQILVPELCAIHPIPASLWRKAVCLPSILYRLHCLLTAEELRAQTASDAGVGVRSLPADFRYPNLDFGWKKSIDSKSFISISNSSSAENDNYCKHSTIVPENAAHQGANRTSSLENHDQMSVNCRTLLSESPGKLHVEVSADLTAINGLSYNQNLANGSYDLANRDFCQGNQLNYYKQEIPVQPTTSYSIQNLYSYENQPQPSDECTLLSNKYLDGNANKSTSDGSPVMAVMPGTTDTIQVLKGRMDSEQSPSIGYSSRTLGPNPGLILQALTLSNASDGFNLERLEMLGDSFLKHAITTYLFCTYPDAHEGRLSYMRSKKVSNCNLYRLGKKKGLPSRMVVSIFDPPVNWLPPGYVVNQDKSNTDKWEKDEMTKDCMLANGKLDEDYEEEDEEEESLMWRAPKEEADYEDDFLEYDQEHIRFIDNMLMGSGAFVKKISLSPFSTTDSAYEWKMPKKSSLGSMPFSSDFEDFDYSSWDAMCYLDPSKAVEEDDFVVGFWNPSEENCGVDTGKQSISYDLHTEQCIADKSIADCVEALLGCYLTSCGERAAQLFLCSLGLKVLPVIKRTDREKALCPTRENFNSQQKNLSVSCAAASVASSRSSVLKDSEYGCLKIPPRCMFDHPDADKTLNHLISGFENFEKKINYRFKNKAYLLQAFTHASYHYNTITDCYQRLEFLGDAILDYLITKHLYEDPRQHSPGVLTDLRSALVNNTIFASLAVKYDYHKYFKAVSPELFHVIDDFVQFQLEKNEMQGMDSELRRSEEDEEKEEDIEVPKAMGDIFESLAGAIYMDSGMSLETVWQVYYPMMRPLIEKFSANVPRSPVRELLEMEPETAKFSPAERTYDGKVRVTVEVVGKGKFKGVGRSYRIAKSAAARRALRSLKANQPQVPNS	1922	Q9UPY3	T	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [45], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.00576794]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
642	NM_000138.5(FBN1):c.4409G>A (p.Cys1470Tyr)	1325422	CA392354488	NM_000138.5:c.4409G>A, NC_000015.10:g.48470684C>T, CM000677.2:g.48470684C>T, NC_000015.9:g.48762881C>T, CM000677.1:g.48762881C>T, NC_000015.8:g.46550173C>T, NG_008805.2:g.180105G>A, LRG_778:g.180105G>A, ENST00000683268.1:n.376G>A, ENST00000684448.1:n.3083G>A, ENST00000316623.10:c.4409G>A, ENST00000316623.9:c.4409G>A, ENST00000537463.6:c.*172G>A, NM_000138.4:c.4409G>A, LRG_778t1:c.4409G>A, NM_000138.5(FBN1):c.4409G>A (p.Cys1470Tyr)	FBN1	Marfan syndrome	MONDO:0007947	Autosomal dominant inheritance	Pathogenic	PS4_Moderate, PM1_Strong, PP4, PP2, PP3, PM2_Supporting	PS1, PS3, PS2, PM5, PM3, PM4, BP7, BP5, BS1, BS3, BS4, PP1, BS2, PVS1, PM6, BP1, BP4, BP2, BP3, BA1	NM_000138.5 c.4409G>A is a missense variant in FBN1 predicted to cause a substitution of a cysteine by tyrosine at amino acid 1470 (p.Cys1470Tyr). This variant has been identified in at least three individuals with clinical diagnoses of Marfan syndrome (PS4_moderate, PP4; PMIDs: 35058154, 11933199; Bichat, & CHEO internal data). It is absent from gnomAD (PM2_supporting; https://gnomad.broadinstitute.org/ v2.1.1 & v3.1.2). This variant affects a cysteine residue in a calcium-binding EGF-like domain; cysteine residues are involved in the formation of disulfide bridges which are essential for the protein structure (PM1_strong). Computational prediction tools and conservation analysis support that this variant is likely to impact the protein (PP3; REVEL = 0.976). The constraint z-score for missense variants affecting FBN1 is 5.06 (PP2). In summary, this variant meets criteria to be classified as pathogenic for Marfan syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen FBN1 VCEP: PM1_strong, PS4_moderate, PP2, PP3, PP4, PM2_supporting.		FBN1 VCEP	https://clinicalgenome.org/docs/clingen-fbn1-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2023-12-29	2023-12-29	False	https://erepo.genome.network/evrepo/ui/classification/CA392354488/MONDO:0007947/022	3bb0c419-ebfe-49c4-9329-d99371d562a7	p.Cys1470Tyr	Cys	1470	Tyr	MRRGRLLEIALGFTVLLASYTSHGADANLEAGNVKETRASRAKRRGGGGHDALKGPNVCGSRYNAYCCPGWKTLPGGNQCIVPICRHSCGDGFCSRPNMCTCPSGQIAPSCGSRSIQHCNIRCMNGGSCSDDHCLCQKGYIGTHCGQPVCESGCLNGGRCVAPNRCACTYGFTGPQCERDYRTGPCFTVISNQMCQGQLSGIVCTKTLCCATVGRAWGHPCEMCPAQPHPCRRGFIPNIRTGACQDVDECQAIPGLCQGGNCINTVGSFECKCPAGHKLNEVSQKCEDIDECSTIPGICEGGECTNTVSSYFCKCPPGFYTSPDGTRCIDVRPGYCYTALTNGRCSNQLPQSITKMQCCCDAGRCWSPGVTVAPEMCPIRATEDFNKLCSVPMVIPGRPEYPPPPLGPIPPVLPVPPGFPPGPQIPVPRPPVEYLYPSREPPRVLPVNVTDYCQLVRYLCQNGRCIPTPGSYRCECNKGFQLDLRGECIDVDECEKNPCAGGECINNQGSYTCQCRAGYQSTLTRTECRDIDECLQNGRICNNGRCINTDGSFHCVCNAGFHVTRDGKNCEDMDECSIRNMCLNGMCINEDGSFKCICKPGFQLASDGRYCKDINECETPGICMNGRCVNTDGSYRCECFPGLAVGLDGRVCVDTHMRSTCYGGYKRGQCIKPLFGAVTKSECCCASTEYAFGEPCQPCPAQNSAEYQALCSSGPGMTSAGSDINECALDPDICPNGICENLRGTYKCICNSGYEVDSTGKNCVDINECVLNSLLCDNGQCRNTPGSFVCTCPKGFIYKPDLKTCEDIDECESSPCINGVCKNSPGSFICECSSESTLDPTKTICIETIKGTCWQTVIDGRCEININGATLKSQCCSSLGAAWGSPCTLCQVDPICGKGYSRIKGTQCEDIDECEVFPGVCKNGLCVNTRGSFKCQCPSGMTLDATGRICLDIRLETCFLRYEDEECTLPIAGRHRMDACCCSVGAAWGTEECEECPMRNTPEYEELCPRGPGFATKEITNGKPFFKDINECKMIPSLCTHGKCRNTIGSFKCRCDSGFALDSEERNCTDIDECRISPDLCGRGQCVNTPGDFECKCDEGYESGFMMMKNCMDIDECQRDPLLCRGGVCHNTEGSYRCECPPGHQLSPNISACIDINECELSAHLCPNGRCVNLIGKYQCACNPGYHSTPDRLFCVDIDECSIMNGGCETFCTNSEGSYECSCQPGFALMPDQRSCTDIDECEDNPNICDGGQCTNIPGEYRCLCYDGFMASEDMKTCVDVNECDLNPNICLSGTCENTKGSFICHCDMGYSGKKGKTGCTDINECEIGAHNCGKHAVCTNTAGSFKCSCSPGWIGDGIKCTDLDECSNGTHMCSQHADCKNTMGSYRCLCKEGYTGDGFTCTDLDECSENLNLCGNGQCLNAPGGYRCECDMGFVPSADGKACEDIDECSLPNICVFGTCHNLPGLFRCECEIGYELDRSGGNCTDVNECLDPTTCISGNCVNTPGSYICDCPPDFELNPTRVGCVDTRSGNCYLDIRPRGDNGDTACSNEIGVGVSKASCCCSLGKAWGTPCEMCPAVNTSEYKILCPGGEGFRPNPITVILEDIDECQELPGLCQGGKCINTFGSFQCRCPTGYYLNEDTRVCDDVNECETPGICGPGTCYNTVGNYTCICPPDYMQVNGGNNCMDMRRSLCYRNYYADNQTCDGELLFNMTKKMCCCSYNIGRAWNKPCEQCPIPSTDEFATLCGSQRPGFVIDIYTGLPVDIDECREIPGVCENGVCINMVGSFRCECPVGFFYNDKLLVCEDIDECQNGPVCQRNAECINTAGSYRCDCKPGYRFTSTGQCNDRNECQEIPNICSHGQCIDTVGSFYCLCHTGFKTNDDQTMCLDINECERDACGNGTCRNTIGSFNCRCNHGFILSHNNDCIDVDECASGNGNLCRNGQCINTVGSFQCQCNEGYEVAPDGRTCVDINECLLEPRKCAPGTCQNLDGSYRCICPPGYSLQNEKCEDIDECVEEPEICALGTCSNTEGSFKCLCPEGFSLSSSGRRCQDLRMSYCYAKFEGGKCSSPKSRNHSKQECCCALKGEGWGDPCELCPTEPDEAFRQICPYGSGIIVGPDDSAVDMDECKEPDVCKHGQCINTDGSYRCECPFGYILAGNECVDTDECSVGNPCGNGTCKNVIGGFECTCEEGFEPGPMMTCEDINECAQNPLLCAFRCVNTYGSYECKCPVGYVLREDRRMCKDEDECEEGKHDCTEKQMECKNLIGTYMCICGPGYQRRPDGEGCVDENECQTKPGICENGRCLNTRGSYTCECNDGFTASPNQDECLDNREGYCFTEVLQNMCQIGSSNRNPVTKSECCCDGGRGWGPHCEICPFQGTVAFKKLCPHGRGFMTNGADIDECKVIHDVCRNGECVNDRGSYHCICKTGYTPDITGTSCVDLNECNQAPKPCNFICKNTEGSYQCSCPKGYILQEDGRSCKDLDECATKQHNCQFLCVNTIGGFTCKCPPGFTQHHTSCIDNNECTSDINLCGSKGICQNTPGSFTCECQRGFSLDQTGSSCEDVDECEGNHRCQHGCQNIIGGYRCSCPQGYLQHYQWNQCVDENECLSAHICGGASCHNTLGSYKCMCPAGFQYEQFSGGCQDINECGSAQAPCSYGCSNTEGGYLCGCPPGYFRIGQGHCVSGMGMGRGNPEPPVSGEMDDNSLSPEACYECKINGYPKRGRKRRSTNETDASNIEDQSETEANVSLASWDVEKTAIFAFNISHVSNKVRILELLPALTTLTNHNRYLIESGNEDGFFKINQKEGISYLHFTKKKPVAGTYSLQISSTPLYKKKELNQLEDKYDKDYLSGELGDNLKMKIQVLLH	2871	P35555	Y	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [250, 272, 277, 280, 281, 282, 314, 1253, 1386, 1410, 1412, 1426, 1427, 1428, 1431, 1433, 1434, 1449, 1450, 1451, 1452, 1453, 1454, 1455, 1456, 1457, 1458, 1459, 1460, 1461, 1462, 1463, 1464, 1465, 1466, 1467, 1468, 1469, 1470, 1471, 1472, 1473, 1474, 1475, 1476, 1491, 1506, 1507, 1508, 1509, 1511, 1513], 'DOMAIN_gain': [928, 1056, 2182, 2458, 2493, 2503, 2504], 'DOMAIN_gain_score': array([0.0274474 , 0.00858647, 0.01959342, 0.02656871, 0.02686805,
       0.0305261 , 0.02390349]), 'DOMAIN_loss_score': array([-0.12076485, -0.18595624, -0.1383878 , -0.16307127, -0.1283915 ,
       -0.08142883, -0.02517223, -0.00353092, -0.06341892, -0.13823837,
       -0.1272068 , -0.22276545, -0.25719875, -0.29597348, -0.29365075,
       -0.5110485 , -0.38401157, -0.75784528, -0.70595866, -0.80878907,
       -0.78973347, -0.84589815, -0.89266551, -0.9135322 , -0.91633278,
       -0.91708446, -0.86283618, -0.87043524, -0.6749562 , -0.88231373,
       -0.80361944, -0.85957682, -0.85025489, -0.8227061 , -0.85289204,
       -0.80474532, -0.77063346, -0.80222291, -0.64542645, -0.48627967,
       -0.62098479, -0.56937402, -0.79299206, -0.60218161, -0.54246628,
       -0.34563106, -0.29263538, -0.34255981, -0.39475334, -0.30058187,
       -0.30746436, -0.25609034]), 'REGION_loss': [933, 976, 1670, 2112, 2146, 2184, 2195, 2207, 2210, 2216], 'REGION_gain': [1233, 1260, 1279, 2521, 2525, 2527, 2528], 'REGION_gain_score': array([0.00509274, 0.00402999, 0.00437641, 0.00115031, 0.00133514,
       0.0013662 , 0.00137591]), 'REGION_loss_score': array([-0.00064635, -0.00123674, -0.00176793, -0.00117213, -0.00153953,
       -0.00182766, -0.00161761, -0.00173318, -0.00194061, -0.00187534]), 'REPEAT_loss': [1480], 'REPEAT_gain': [134, 136, 168, 169, 247, 248, 2547, 2564, 2635], 'REPEAT_gain_score': array([0.01865649, 0.01556534, 0.01718819, 0.02480209, 0.0318439 ,
       0.02044499, 0.00802326, 0.00775921, 0.01407522]), 'REPEAT_loss_score': array([-0.05268157]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
643	NM_000138.5(FBN1):c.4330T>A (p.Cys1444Ser)	222604	CA353655	NM_000138.5:c.4330T>A, NC_000015.10:g.48472557A>T, CM000677.2:g.48472557A>T, NC_000015.9:g.48764754A>T, CM000677.1:g.48764754A>T, NC_000015.8:g.46552046A>T, NG_008805.2:g.178232T>A, LRG_778:g.178232T>A, ENST00000683268.1:n.297T>A, ENST00000684448.1:n.3004T>A, ENST00000316623.10:c.4330T>A, ENST00000316623.9:c.4330T>A, ENST00000537463.6:c.*93T>A, NM_000138.4:c.4330T>A, LRG_778t1:c.4330T>A, NM_000138.5(FBN1):c.4330T>A (p.Cys1444Ser)	FBN1	Marfan syndrome	MONDO:0007947	Autosomal dominant inheritance	Pathogenic	PS4_Moderate, PM1_Strong, PP2, PP3, PP4, PM2_Supporting	PS1, PS3, PS2, PM4, PM3, PM5, BP7, BP5, BS1, BS3, BS4, PP1, BS2, PVS1, PM6, BP1, BP4, BP3, BP2, BA1	NM_000138.5 c.4330T>A is a missense variant in FBN1 predicted to cause a substitution of a cysteine by serine at amino acid 1444 (p.Cys1444Ser). This variant has been identified in an adult patient with Marfan syndrome with bilateral ectopia lentis (EL), borderline thoracic aortic aneurysm and dissection (TAAD), and systemic features (PP4; Invitae internal data). A different nucleotide substitution (c.4331G>C) resulting in the same amino acid change has been identified in three individuals with clinical diagnoses of Marfan syndrome, all of whom were noted to have have EL in addition to other features of Marfan syndrome (PS4_moderate; University of Tokyo, Bichat, & Invitae internal data); in one family, c.4331G>C was found to segregate with annuloaortic ectasia and arachnodactyly in an infant child (University of Tokyo internal data). Of note, there is no predicted difference in splicing patterns between the two nucleotide substitutions. The c.4330T>A variant is absent from gnomAD (PM2_supporting; https://gnomad.broadinstitute.org, v2.1.1 & v3.1.2). It affects a cysteine residue in a calcium-binding EGF-like domain; cysteine residues are involved in the formation of disulfide bridges which are essential for the protein structure (PM1_strong). Computational prediction tools and conservation analysis further support that this variant is likely to impact the protein (PP3; REVEL = 0.949). The constraint z-score for missense variants affecting FBN1 is 5.06 (PP2). In summary, c.4330T>A (p.Cys1444Ser) meets criteria to be classified as pathogenic for Marfan syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen FBN1 VCEP: PM1_strong, PS4_moderate, PP2, PP3, PP4, PM2_supporting.		FBN1 VCEP	https://clinicalgenome.org/docs/clingen-fbn1-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2023-12-29	2023-12-29	False	https://erepo.genome.network/evrepo/ui/classification/CA353655/MONDO:0007947/022	3ae64fc8-99d1-4681-b0cf-6ece56643d71	p.Cys1444Ser	Cys	1444	Ser	MRRGRLLEIALGFTVLLASYTSHGADANLEAGNVKETRASRAKRRGGGGHDALKGPNVCGSRYNAYCCPGWKTLPGGNQCIVPICRHSCGDGFCSRPNMCTCPSGQIAPSCGSRSIQHCNIRCMNGGSCSDDHCLCQKGYIGTHCGQPVCESGCLNGGRCVAPNRCACTYGFTGPQCERDYRTGPCFTVISNQMCQGQLSGIVCTKTLCCATVGRAWGHPCEMCPAQPHPCRRGFIPNIRTGACQDVDECQAIPGLCQGGNCINTVGSFECKCPAGHKLNEVSQKCEDIDECSTIPGICEGGECTNTVSSYFCKCPPGFYTSPDGTRCIDVRPGYCYTALTNGRCSNQLPQSITKMQCCCDAGRCWSPGVTVAPEMCPIRATEDFNKLCSVPMVIPGRPEYPPPPLGPIPPVLPVPPGFPPGPQIPVPRPPVEYLYPSREPPRVLPVNVTDYCQLVRYLCQNGRCIPTPGSYRCECNKGFQLDLRGECIDVDECEKNPCAGGECINNQGSYTCQCRAGYQSTLTRTECRDIDECLQNGRICNNGRCINTDGSFHCVCNAGFHVTRDGKNCEDMDECSIRNMCLNGMCINEDGSFKCICKPGFQLASDGRYCKDINECETPGICMNGRCVNTDGSYRCECFPGLAVGLDGRVCVDTHMRSTCYGGYKRGQCIKPLFGAVTKSECCCASTEYAFGEPCQPCPAQNSAEYQALCSSGPGMTSAGSDINECALDPDICPNGICENLRGTYKCICNSGYEVDSTGKNCVDINECVLNSLLCDNGQCRNTPGSFVCTCPKGFIYKPDLKTCEDIDECESSPCINGVCKNSPGSFICECSSESTLDPTKTICIETIKGTCWQTVIDGRCEININGATLKSQCCSSLGAAWGSPCTLCQVDPICGKGYSRIKGTQCEDIDECEVFPGVCKNGLCVNTRGSFKCQCPSGMTLDATGRICLDIRLETCFLRYEDEECTLPIAGRHRMDACCCSVGAAWGTEECEECPMRNTPEYEELCPRGPGFATKEITNGKPFFKDINECKMIPSLCTHGKCRNTIGSFKCRCDSGFALDSEERNCTDIDECRISPDLCGRGQCVNTPGDFECKCDEGYESGFMMMKNCMDIDECQRDPLLCRGGVCHNTEGSYRCECPPGHQLSPNISACIDINECELSAHLCPNGRCVNLIGKYQCACNPGYHSTPDRLFCVDIDECSIMNGGCETFCTNSEGSYECSCQPGFALMPDQRSCTDIDECEDNPNICDGGQCTNIPGEYRCLCYDGFMASEDMKTCVDVNECDLNPNICLSGTCENTKGSFICHCDMGYSGKKGKTGCTDINECEIGAHNCGKHAVCTNTAGSFKCSCSPGWIGDGIKCTDLDECSNGTHMCSQHADCKNTMGSYRCLCKEGYTGDGFTCTDLDECSENLNLCGNGQCLNAPGGYRCECDMGFVPSADGKACEDIDECSLPNICVFGTCHNLPGLFRCECEIGYELDRSGGNCTDVNECLDPTTCISGNCVNTPGSYICDCPPDFELNPTRVGCVDTRSGNCYLDIRPRGDNGDTACSNEIGVGVSKASCCCSLGKAWGTPCEMCPAVNTSEYKILCPGGEGFRPNPITVILEDIDECQELPGLCQGGKCINTFGSFQCRCPTGYYLNEDTRVCDDVNECETPGICGPGTCYNTVGNYTCICPPDYMQVNGGNNCMDMRRSLCYRNYYADNQTCDGELLFNMTKKMCCCSYNIGRAWNKPCEQCPIPSTDEFATLCGSQRPGFVIDIYTGLPVDIDECREIPGVCENGVCINMVGSFRCECPVGFFYNDKLLVCEDIDECQNGPVCQRNAECINTAGSYRCDCKPGYRFTSTGQCNDRNECQEIPNICSHGQCIDTVGSFYCLCHTGFKTNDDQTMCLDINECERDACGNGTCRNTIGSFNCRCNHGFILSHNNDCIDVDECASGNGNLCRNGQCINTVGSFQCQCNEGYEVAPDGRTCVDINECLLEPRKCAPGTCQNLDGSYRCICPPGYSLQNEKCEDIDECVEEPEICALGTCSNTEGSFKCLCPEGFSLSSSGRRCQDLRMSYCYAKFEGGKCSSPKSRNHSKQECCCALKGEGWGDPCELCPTEPDEAFRQICPYGSGIIVGPDDSAVDMDECKEPDVCKHGQCINTDGSYRCECPFGYILAGNECVDTDECSVGNPCGNGTCKNVIGGFECTCEEGFEPGPMMTCEDINECAQNPLLCAFRCVNTYGSYECKCPVGYVLREDRRMCKDEDECEEGKHDCTEKQMECKNLIGTYMCICGPGYQRRPDGEGCVDENECQTKPGICENGRCLNTRGSYTCECNDGFTASPNQDECLDNREGYCFTEVLQNMCQIGSSNRNPVTKSECCCDGGRGWGPHCEICPFQGTVAFKKLCPHGRGFMTNGADIDECKVIHDVCRNGECVNDRGSYHCICKTGYTPDITGTSCVDLNECNQAPKPCNFICKNTEGSYQCSCPKGYILQEDGRSCKDLDECATKQHNCQFLCVNTIGGFTCKCPPGFTQHHTSCIDNNECTSDINLCGSKGICQNTPGSFTCECQRGFSLDQTGSSCEDVDECEGNHRCQHGCQNIIGGYRCSCPQGYLQHYQWNQCVDENECLSAHICGGASCHNTLGSYKCMCPAGFQYEQFSGGCQDINECGSAQAPCSYGCSNTEGGYLCGCPPGYFRIGQGHCVSGMGMGRGNPEPPVSGEMDDNSLSPEACYECKINGYPKRGRKRRSTNETDASNIEDQSETEANVSLASWDVEKTAIFAFNISHVSNKVRILELLPALTTLTNHNRYLIESGNEDGFFKINQKEGISYLHFTKKKPVAGTYSLQISSTPLYKKKELNQLEDKYDKDYLSGELGDNLKMKIQVLLH	2871	P35555	S	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [250, 1410, 1412, 1413, 1431, 1434, 1471], 'DOMAIN_gain': [2182, 2458], 'DOMAIN_gain_score': array([0.01289815, 0.01024407]), 'DOMAIN_loss_score': array([-0.09314787, -0.15209126, -0.16342419, -0.1537599 , -0.0987373 ,
       -0.18696219, -0.01650017]), 'REGION_loss': [433, 933, 976, 1670, 2074, 2112, 2146, 2184, 2195, 2210, 2216], 'REGION_gain': [1229, 1232, 1233, 1260, 1279, 2521, 2523, 2525, 2526, 2527, 2528, 2537], 'REGION_gain_score': array([0.00587511, 0.00595236, 0.00596702, 0.0055021 , 0.00534242,
       0.00479203, 0.00542736, 0.00520259, 0.00494474, 0.00524908,
       0.00540447, 0.00649053]), 'REGION_loss_score': array([-0.00339657, -0.0013628 , -0.00123703, -0.00367242, -0.00150657,
       -0.0012874 , -0.00161922, -0.00128919, -0.00117022, -0.00130433,
       -0.00128055]), 'REPEAT_loss': [], 'REPEAT_gain': [134, 136, 140, 168, 169, 283, 284, 1518, 2547, 2564, 2632, 2635], 'REPEAT_gain_score': array([0.02240461, 0.02335346, 0.02560467, 0.02474743, 0.02895856,
       0.0209806 , 0.02211893, 0.03888261, 0.01818627, 0.01189309,
       0.02005875, 0.01905823]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
644	NM_000138.5(FBN1):c.3707G>A (p.Cys1236Tyr)	495599	CA392324303	NM_000138.5:c.3707G>A, NC_000015.10:g.48485379C>T, CM000677.2:g.48485379C>T, NC_000015.9:g.48777576C>T, CM000677.1:g.48777576C>T, NC_000015.8:g.46564868C>T, NG_008805.2:g.165410G>A, LRG_778:g.165410G>A, ENST00000684448.1:n.2381G>A, ENST00000316623.10:c.3707G>A, ENST00000316623.9:c.3707G>A, ENST00000537463.6:c.637-10729G>A, NM_000138.4:c.3707G>A, LRG_778t1:c.3707G>A, NM_000138.5(FBN1):c.3707G>A (p.Cys1236Tyr)	FBN1	Marfan syndrome	MONDO:0007947	Autosomal dominant inheritance	Pathogenic	PS4_Moderate, PM1_Strong, PP2, PP3, PP4, PM2_Supporting	PS1, PS3, PS2, PM3, PM4, PM5, BP7, BP5, BS1, BS3, BS4, PP1, BS2, PVS1, PM6, BP1, BP4, BP2, BP3, BA1	NM_000138.5 c.3707G>A is a missense variant in FBN1 predicted to cause a substitution of a cysteine by tyrosine at amino acid 1236 (p.Cys1236Tyr). This variant has been identified in at least three individuals including two probands with clinical diagnoses of Marfan syndrome, with neonatal onset in one case, and one proband with a highly specific Marfan syndrome phenotype including thoracic aortic aneurysm and dissection (TAAD), ectopia lentis, and systemic features of Marfan syndrome (PS4_moderate, PP4; UZG, Mayo, & Bichat internal data). It is not present in gnomAD (PM2_supporting; https://gnomad.broadinstitute.org/ v2.1.1 & v3.1.2). This variant affects a cysteine residue in a calcium-binding EGF-like domain; cysteine residues are involved in the formation of disulfide bridges which are essential for the protein structure (PM1_strong). Computational prediction tools and conservation analysis support that this variant is likely to impact the protein (PP3; REVEL = 0.960). The constraint z-score for missense variants affecting FBN1 is 5.06 (PP2). In summary, this variant meets criteria to be classified as pathogenic for Marfan syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen FBN1 VCEP: PM1_strong, PS4_moderate, PP2, PP3, PP4, PM2_supporting.		FBN1 VCEP	https://clinicalgenome.org/docs/clingen-fbn1-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2023-12-29	2023-12-29	False	https://erepo.genome.network/evrepo/ui/classification/CA392324303/MONDO:0007947/022	5ec31f85-0600-444a-80bc-517d8d4448fa	p.Cys1236Tyr	Cys	1236	Tyr	MRRGRLLEIALGFTVLLASYTSHGADANLEAGNVKETRASRAKRRGGGGHDALKGPNVCGSRYNAYCCPGWKTLPGGNQCIVPICRHSCGDGFCSRPNMCTCPSGQIAPSCGSRSIQHCNIRCMNGGSCSDDHCLCQKGYIGTHCGQPVCESGCLNGGRCVAPNRCACTYGFTGPQCERDYRTGPCFTVISNQMCQGQLSGIVCTKTLCCATVGRAWGHPCEMCPAQPHPCRRGFIPNIRTGACQDVDECQAIPGLCQGGNCINTVGSFECKCPAGHKLNEVSQKCEDIDECSTIPGICEGGECTNTVSSYFCKCPPGFYTSPDGTRCIDVRPGYCYTALTNGRCSNQLPQSITKMQCCCDAGRCWSPGVTVAPEMCPIRATEDFNKLCSVPMVIPGRPEYPPPPLGPIPPVLPVPPGFPPGPQIPVPRPPVEYLYPSREPPRVLPVNVTDYCQLVRYLCQNGRCIPTPGSYRCECNKGFQLDLRGECIDVDECEKNPCAGGECINNQGSYTCQCRAGYQSTLTRTECRDIDECLQNGRICNNGRCINTDGSFHCVCNAGFHVTRDGKNCEDMDECSIRNMCLNGMCINEDGSFKCICKPGFQLASDGRYCKDINECETPGICMNGRCVNTDGSYRCECFPGLAVGLDGRVCVDTHMRSTCYGGYKRGQCIKPLFGAVTKSECCCASTEYAFGEPCQPCPAQNSAEYQALCSSGPGMTSAGSDINECALDPDICPNGICENLRGTYKCICNSGYEVDSTGKNCVDINECVLNSLLCDNGQCRNTPGSFVCTCPKGFIYKPDLKTCEDIDECESSPCINGVCKNSPGSFICECSSESTLDPTKTICIETIKGTCWQTVIDGRCEININGATLKSQCCSSLGAAWGSPCTLCQVDPICGKGYSRIKGTQCEDIDECEVFPGVCKNGLCVNTRGSFKCQCPSGMTLDATGRICLDIRLETCFLRYEDEECTLPIAGRHRMDACCCSVGAAWGTEECEECPMRNTPEYEELCPRGPGFATKEITNGKPFFKDINECKMIPSLCTHGKCRNTIGSFKCRCDSGFALDSEERNCTDIDECRISPDLCGRGQCVNTPGDFECKCDEGYESGFMMMKNCMDIDECQRDPLLCRGGVCHNTEGSYRCECPPGHQLSPNISACIDINECELSAHLCPNGRCVNLIGKYQCACNPGYHSTPDRLFCVDIDECSIMNGGCETFCTNSEGSYECSCQPGFALMPDQRSCTDIDECEDNPNICDGGQCTNIPGEYRCLCYDGFMASEDMKTCVDVNECDLNPNICLSGTCENTKGSFICHCDMGYSGKKGKTGCTDINECEIGAHNCGKHAVCTNTAGSFKCSCSPGWIGDGIKCTDLDECSNGTHMCSQHADCKNTMGSYRCLCKEGYTGDGFTCTDLDECSENLNLCGNGQCLNAPGGYRCECDMGFVPSADGKACEDIDECSLPNICVFGTCHNLPGLFRCECEIGYELDRSGGNCTDVNECLDPTTCISGNCVNTPGSYICDCPPDFELNPTRVGCVDTRSGNCYLDIRPRGDNGDTACSNEIGVGVSKASCCCSLGKAWGTPCEMCPAVNTSEYKILCPGGEGFRPNPITVILEDIDECQELPGLCQGGKCINTFGSFQCRCPTGYYLNEDTRVCDDVNECETPGICGPGTCYNTVGNYTCICPPDYMQVNGGNNCMDMRRSLCYRNYYADNQTCDGELLFNMTKKMCCCSYNIGRAWNKPCEQCPIPSTDEFATLCGSQRPGFVIDIYTGLPVDIDECREIPGVCENGVCINMVGSFRCECPVGFFYNDKLLVCEDIDECQNGPVCQRNAECINTAGSYRCDCKPGYRFTSTGQCNDRNECQEIPNICSHGQCIDTVGSFYCLCHTGFKTNDDQTMCLDINECERDACGNGTCRNTIGSFNCRCNHGFILSHNNDCIDVDECASGNGNLCRNGQCINTVGSFQCQCNEGYEVAPDGRTCVDINECLLEPRKCAPGTCQNLDGSYRCICPPGYSLQNEKCEDIDECVEEPEICALGTCSNTEGSFKCLCPEGFSLSSSGRRCQDLRMSYCYAKFEGGKCSSPKSRNHSKQECCCALKGEGWGDPCELCPTEPDEAFRQICPYGSGIIVGPDDSAVDMDECKEPDVCKHGQCINTDGSYRCECPFGYILAGNECVDTDECSVGNPCGNGTCKNVIGGFECTCEEGFEPGPMMTCEDINECAQNPLLCAFRCVNTYGSYECKCPVGYVLREDRRMCKDEDECEEGKHDCTEKQMECKNLIGTYMCICGPGYQRRPDGEGCVDENECQTKPGICENGRCLNTRGSYTCECNDGFTASPNQDECLDNREGYCFTEVLQNMCQIGSSNRNPVTKSECCCDGGRGWGPHCEICPFQGTVAFKKLCPHGRGFMTNGADIDECKVIHDVCRNGECVNDRGSYHCICKTGYTPDITGTSCVDLNECNQAPKPCNFICKNTEGSYQCSCPKGYILQEDGRSCKDLDECATKQHNCQFLCVNTIGGFTCKCPPGFTQHHTSCIDNNECTSDINLCGSKGICQNTPGSFTCECQRGFSLDQTGSSCEDVDECEGNHRCQHGCQNIIGGYRCSCPQGYLQHYQWNQCVDENECLSAHICGGASCHNTLGSYKCMCPAGFQYEQFSGGCQDINECGSAQAPCSYGCSNTEGGYLCGCPPGYFRIGQGHCVSGMGMGRGNPEPPVSGEMDDNSLSPEACYECKINGYPKRGRKRRSTNETDASNIEDQSETEANVSLASWDVEKTAIFAFNISHVSNKVRILELLPALTTLTNHNRYLIESGNEDGFFKINQKEGISYLHFTKKKPVAGTYSLQISSTPLYKKKELNQLEDKYDKDYLSGELGDNLKMKIQVLLH	2871	P35555	Y	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [1062, 1188, 1253], 'DOMAIN_gain': [2182, 2458, 2493, 2503, 2504, 2538], 'DOMAIN_gain_score': array([0.01055235, 0.03091079, 0.05429077, 0.05566508, 0.04609275,
       0.06522548]), 'DOMAIN_loss_score': array([-0.00512272, -0.01477849, -0.01108629]), 'REGION_loss': [933, 976, 1241, 1243, 1244, 1255, 1256, 1273, 2074, 2146, 2184, 2195, 2207, 2210, 2216, 2505, 2513, 2522, 2524, 2536], 'REGION_gain': [1229, 1233], 'REGION_gain_score': array([0.0071584 , 0.00469261]), 'REGION_loss_score': array([-0.00233954, -0.00418347, -0.0099237 , -0.014678  , -0.01925778,
       -0.0094586 , -0.00906491, -0.00592196, -0.00061882, -0.00173891,
       -0.00213057, -0.00206542, -0.00219071, -0.00240153, -0.00189954,
       -0.00865757, -0.00848055, -0.00780714, -0.00772995, -0.00680876]), 'REPEAT_loss': [], 'REPEAT_gain': [1028, 1030, 1518, 2524, 2547, 2564], 'REPEAT_gain_score': array([0.05253267, 0.03760463, 0.01203448, 0.0125981 , 0.01010561,
       0.01045448]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
645	NM_000138.5(FBN1):c.3557A>G (p.Tyr1186Cys)	495594	CA392324980	NM_000138.5:c.3557A>G, NC_000015.10:g.48487107T>C, CM000677.2:g.48487107T>C, NC_000015.9:g.48779304T>C, CM000677.1:g.48779304T>C, NC_000015.8:g.46566596T>C, NG_008805.2:g.163682A>G, LRG_778:g.163682A>G, ENST00000684448.1:n.2231A>G, ENST00000316623.10:c.3557A>G, ENST00000316623.9:c.3557A>G, ENST00000537463.6:c.637-12457A>G, NM_000138.4:c.3557A>G, LRG_778t1:c.3557A>G, NM_000138.5(FBN1):c.3557A>G (p.Tyr1186Cys)	FBN1	Marfan syndrome	MONDO:0007947	Autosomal dominant inheritance	Pathogenic	PS4, PM1, PP2, PP3, PP1, PM2_Supporting	PS1, PS3, PS2, PM3, PM4, PM5, BP7, BP5, BS1, BS3, BS4, BS2, PP4, PVS1, PM6, BP1, BP4, BP2, BP3, BA1	NM_000138.5 c.3557A>G is a missense variant in FBN1 predicted to cause a substitution of a tyrosine by a cysteine at amino acid 1186 (p.Tyr1186Cys). It has been identified in at least five individuals with diagnoses or suspicion of Marfan syndrome including the following: a pediatric patient with bilateral ectopia lentis (EL), severe thoracic aortic aneurysm and dissection (TAAD), and a systemic score of 9; an adult patient with EL and a systemic score of 6; a patient with bilateral EL, TAAD, and systemic features; an individual reported to have Marfan syndrome without specific details provided; and an individual with bilateral EL, TAAD, retinal detachment, and systemic features (PS4; PMIDs: 31061752, 11933199; UZG, Bichat, & Invitae internal data). It was also found to segregate with Marfan syndrome in two other members of an aforementioned family (PP1; Bichat internal data). It is absent from gnomAD (PM2_supporting; https://gnomad.broadinstitute.org/, v2.1.1 & v3.1.2). This variant introduces a novel cysteine residue which may impede the normal formation of critical disulfide bridges (PM1). Computational prediction tools and conservation analysis support that this variant is likely to impact the protein (PP3; REVEL = 0.974). The constraint z-score for missense variants affecting FBN1 is 5.06 (PP2). In summary, this variant meets criteria to be classified as pathogenic for Marfan syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen FBN1 VCEP: PS4, PM1, PP1, PP2, PP3, PM2_supporting.		FBN1 VCEP	https://clinicalgenome.org/docs/clingen-fbn1-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2023-12-29	2023-12-29	False	https://erepo.genome.network/evrepo/ui/classification/CA392324980/MONDO:0007947/022	40d44fc6-1e1f-408a-8694-a304f4acafde	p.Tyr1186Cys	Tyr	1186	Cys	MRRGRLLEIALGFTVLLASYTSHGADANLEAGNVKETRASRAKRRGGGGHDALKGPNVCGSRYNAYCCPGWKTLPGGNQCIVPICRHSCGDGFCSRPNMCTCPSGQIAPSCGSRSIQHCNIRCMNGGSCSDDHCLCQKGYIGTHCGQPVCESGCLNGGRCVAPNRCACTYGFTGPQCERDYRTGPCFTVISNQMCQGQLSGIVCTKTLCCATVGRAWGHPCEMCPAQPHPCRRGFIPNIRTGACQDVDECQAIPGLCQGGNCINTVGSFECKCPAGHKLNEVSQKCEDIDECSTIPGICEGGECTNTVSSYFCKCPPGFYTSPDGTRCIDVRPGYCYTALTNGRCSNQLPQSITKMQCCCDAGRCWSPGVTVAPEMCPIRATEDFNKLCSVPMVIPGRPEYPPPPLGPIPPVLPVPPGFPPGPQIPVPRPPVEYLYPSREPPRVLPVNVTDYCQLVRYLCQNGRCIPTPGSYRCECNKGFQLDLRGECIDVDECEKNPCAGGECINNQGSYTCQCRAGYQSTLTRTECRDIDECLQNGRICNNGRCINTDGSFHCVCNAGFHVTRDGKNCEDMDECSIRNMCLNGMCINEDGSFKCICKPGFQLASDGRYCKDINECETPGICMNGRCVNTDGSYRCECFPGLAVGLDGRVCVDTHMRSTCYGGYKRGQCIKPLFGAVTKSECCCASTEYAFGEPCQPCPAQNSAEYQALCSSGPGMTSAGSDINECALDPDICPNGICENLRGTYKCICNSGYEVDSTGKNCVDINECVLNSLLCDNGQCRNTPGSFVCTCPKGFIYKPDLKTCEDIDECESSPCINGVCKNSPGSFICECSSESTLDPTKTICIETIKGTCWQTVIDGRCEININGATLKSQCCSSLGAAWGSPCTLCQVDPICGKGYSRIKGTQCEDIDECEVFPGVCKNGLCVNTRGSFKCQCPSGMTLDATGRICLDIRLETCFLRYEDEECTLPIAGRHRMDACCCSVGAAWGTEECEECPMRNTPEYEELCPRGPGFATKEITNGKPFFKDINECKMIPSLCTHGKCRNTIGSFKCRCDSGFALDSEERNCTDIDECRISPDLCGRGQCVNTPGDFECKCDEGYESGFMMMKNCMDIDECQRDPLLCRGGVCHNTEGSYRCECPPGHQLSPNISACIDINECELSAHLCPNGRCVNLIGKYQCACNPGYHSTPDRLFCVDIDECSIMNGGCETFCTNSEGSYECSCQPGFALMPDQRSCTDIDECEDNPNICDGGQCTNIPGEYRCLCYDGFMASEDMKTCVDVNECDLNPNICLSGTCENTKGSFICHCDMGYSGKKGKTGCTDINECEIGAHNCGKHAVCTNTAGSFKCSCSPGWIGDGIKCTDLDECSNGTHMCSQHADCKNTMGSYRCLCKEGYTGDGFTCTDLDECSENLNLCGNGQCLNAPGGYRCECDMGFVPSADGKACEDIDECSLPNICVFGTCHNLPGLFRCECEIGYELDRSGGNCTDVNECLDPTTCISGNCVNTPGSYICDCPPDFELNPTRVGCVDTRSGNCYLDIRPRGDNGDTACSNEIGVGVSKASCCCSLGKAWGTPCEMCPAVNTSEYKILCPGGEGFRPNPITVILEDIDECQELPGLCQGGKCINTFGSFQCRCPTGYYLNEDTRVCDDVNECETPGICGPGTCYNTVGNYTCICPPDYMQVNGGNNCMDMRRSLCYRNYYADNQTCDGELLFNMTKKMCCCSYNIGRAWNKPCEQCPIPSTDEFATLCGSQRPGFVIDIYTGLPVDIDECREIPGVCENGVCINMVGSFRCECPVGFFYNDKLLVCEDIDECQNGPVCQRNAECINTAGSYRCDCKPGYRFTSTGQCNDRNECQEIPNICSHGQCIDTVGSFYCLCHTGFKTNDDQTMCLDINECERDACGNGTCRNTIGSFNCRCNHGFILSHNNDCIDVDECASGNGNLCRNGQCINTVGSFQCQCNEGYEVAPDGRTCVDINECLLEPRKCAPGTCQNLDGSYRCICPPGYSLQNEKCEDIDECVEEPEICALGTCSNTEGSFKCLCPEGFSLSSSGRRCQDLRMSYCYAKFEGGKCSSPKSRNHSKQECCCALKGEGWGDPCELCPTEPDEAFRQICPYGSGIIVGPDDSAVDMDECKEPDVCKHGQCINTDGSYRCECPFGYILAGNECVDTDECSVGNPCGNGTCKNVIGGFECTCEEGFEPGPMMTCEDINECAQNPLLCAFRCVNTYGSYECKCPVGYVLREDRRMCKDEDECEEGKHDCTEKQMECKNLIGTYMCICGPGYQRRPDGEGCVDENECQTKPGICENGRCLNTRGSYTCECNDGFTASPNQDECLDNREGYCFTEVLQNMCQIGSSNRNPVTKSECCCDGGRGWGPHCEICPFQGTVAFKKLCPHGRGFMTNGADIDECKVIHDVCRNGECVNDRGSYHCICKTGYTPDITGTSCVDLNECNQAPKPCNFICKNTEGSYQCSCPKGYILQEDGRSCKDLDECATKQHNCQFLCVNTIGGFTCKCPPGFTQHHTSCIDNNECTSDINLCGSKGICQNTPGSFTCECQRGFSLDQTGSSCEDVDECEGNHRCQHGCQNIIGGYRCSCPQGYLQHYQWNQCVDENECLSAHICGGASCHNTLGSYKCMCPAGFQYEQFSGGCQDINECGSAQAPCSYGCSNTEGGYLCGCPPGYFRIGQGHCVSGMGMGRGNPEPPVSGEMDDNSLSPEACYECKINGYPKRGRKRRSTNETDASNIEDQSETEANVSLASWDVEKTAIFAFNISHVSNKVRILELLPALTTLTNHNRYLIESGNEDGFFKINQKEGISYLHFTKKKPVAGTYSLQISSTPLYKKKELNQLEDKYDKDYLSGELGDNLKMKIQVLLH	2871	P35555	C	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [753, 1185, 1187, 1188, 1189, 1253, 2488, 2492, 2505, 2542, 2543], 'DOMAIN_gain': [928], 'DOMAIN_gain_score': array([0.01355183]), 'DOMAIN_loss_score': array([-0.00416178, -0.35346037, -0.16163462, -0.0901159 , -0.14095539,
       -0.04001272, -0.04485488, -0.05298162, -0.06331837, -0.06116384,
       -0.0673902 ]), 'REGION_loss': [], 'REGION_gain': [432, 855, 909, 922, 927, 932, 941, 942, 963, 969, 972, 1009, 1011, 1014, 1204, 1219, 1220, 1224, 1226, 1227, 1228, 1229, 1231, 1232, 1233, 1236, 1237, 1239, 1240, 1242, 1252, 1253, 1254, 1260, 1263, 1265, 1276, 1279, 2084, 2172, 2176, 2197, 2214, 2431, 2438, 2472, 2508, 2514, 2517, 2519, 2521, 2523, 2525, 2526, 2527, 2528, 2537], 'REGION_gain_score': array([0.00133169, 0.00295436, 0.00499082, 0.0058651 , 0.00605148,
       0.00516027, 0.00586575, 0.00577062, 0.00714606, 0.00698942,
       0.00734818, 0.01154059, 0.01046854, 0.01162082, 0.03945076,
       0.03661799, 0.03575957, 0.03396654, 0.03148097, 0.0342111 ,
       0.03041726, 0.0302844 , 0.02907479, 0.02942187, 0.0314008 ,
       0.02938932, 0.0294047 , 0.02815121, 0.02783757, 0.02725303,
       0.02441275, 0.02725977, 0.02555251, 0.02210313, 0.02300185,
       0.02072817, 0.01989836, 0.01955336, 0.00280678, 0.0059346 ,
       0.00591683, 0.00666767, 0.00683457, 0.04008055, 0.03650147,
       0.02995348, 0.02267981, 0.02052557, 0.02016872, 0.01977074,
       0.02172923, 0.02080935, 0.01995862, 0.01963681, 0.02010208,
       0.01844823, 0.02088475]), 'REPEAT_loss': [], 'REPEAT_gain': [134, 136, 168, 169, 247, 909, 912, 916, 1028, 1030, 1518, 1816, 2323, 2524, 2547, 2564], 'REPEAT_gain_score': array([0.0092386 , 0.00660044, 0.00921124, 0.00903505, 0.00656885,
       0.01093423, 0.0120486 , 0.01327509, 0.02293223, 0.01484805,
       0.01254517, 0.0072338 , 0.01292443, 0.01906109, 0.01088053,
       0.01042151]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
646	NM_000138.5(FBN1):c.3290G>A (p.Cys1097Tyr)	549150	CA392327231	NM_000138.5:c.3290G>A, NC_000015.10:g.48488160C>T, CM000677.2:g.48488160C>T, NC_000015.9:g.48780357C>T, CM000677.1:g.48780357C>T, NC_000015.8:g.46567649C>T, NG_008805.2:g.162629G>A, LRG_778:g.162629G>A, ENST00000684448.1:n.1964G>A, ENST00000316623.10:c.3290G>A, ENST00000316623.9:c.3290G>A, ENST00000537463.6:c.637-13510G>A, NM_000138.4:c.3290G>A, LRG_778t1:c.3290G>A, NM_000138.5(FBN1):c.3290G>A (p.Cys1097Tyr)	FBN1	Marfan syndrome	MONDO:0007947	Autosomal dominant inheritance	Pathogenic	PS4_Moderate, PM1_Strong, PP4, PP2, PP3, PM2_Supporting, PM6		The NM_00138 c.3290G>A, is a missense variant in FBN1 predicted to cause a substitution of a cysteine by tyrosine at amino acid 1097 (p.Cys1097Tyr). This variant was found in a proband with a neonatal onset of Marfan syndrome (internal data, PP4). This variant has been reported four times in ClinVar: once as pathogenic, twice as likely pathogenic, and once as uncertain significance (Variation ID: 549150). This variant has been reported in the literature in individuals with clinical diagnosis of Marfan syndrome and/or features of Marfan syndrome (PMID 37684520, 29357934, Invitae ClinVar entry, internal data; PS4_Mod), and was observed de novo without parental confirmation in one individual with a highly specific phenotype (PMID 37684520; PM6). This variant is not present in gnomAD (PM2_sup; https://gnomad.broadinstitute.org/ v2.1.1). This variant affects a cysteine residue in a calcium binding EGF domain. Cysteine residues are believed to be involved in the formation of disulfide bridges which are essential for the protein structure (PM1_strong). Computational prediction tools and conservation analysis suggest that this variant may impact the protein (REVEL: 0.979, PP3). The constraint z-score for missense variants affecting FBN1 is 5.06 (PP2). In summary, this variant meets criteria to be classified as pathogenic for Marfan syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen FBN1 VCEP: PM1_Strong, PS4_moderate, PM6, PM2_Sup, PP2, PP3, PP4.		FBN1 VCEP	https://clinicalgenome.org/docs/clingen-fbn1-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2023-12-29	2023-12-29	False	https://erepo.genome.network/evrepo/ui/classification/CA392327231/MONDO:0007947/022	84fff3f2-562a-42df-95a6-8a4ba7e43b29	p.Cys1097Tyr	Cys	1097	Tyr	MRRGRLLEIALGFTVLLASYTSHGADANLEAGNVKETRASRAKRRGGGGHDALKGPNVCGSRYNAYCCPGWKTLPGGNQCIVPICRHSCGDGFCSRPNMCTCPSGQIAPSCGSRSIQHCNIRCMNGGSCSDDHCLCQKGYIGTHCGQPVCESGCLNGGRCVAPNRCACTYGFTGPQCERDYRTGPCFTVISNQMCQGQLSGIVCTKTLCCATVGRAWGHPCEMCPAQPHPCRRGFIPNIRTGACQDVDECQAIPGLCQGGNCINTVGSFECKCPAGHKLNEVSQKCEDIDECSTIPGICEGGECTNTVSSYFCKCPPGFYTSPDGTRCIDVRPGYCYTALTNGRCSNQLPQSITKMQCCCDAGRCWSPGVTVAPEMCPIRATEDFNKLCSVPMVIPGRPEYPPPPLGPIPPVLPVPPGFPPGPQIPVPRPPVEYLYPSREPPRVLPVNVTDYCQLVRYLCQNGRCIPTPGSYRCECNKGFQLDLRGECIDVDECEKNPCAGGECINNQGSYTCQCRAGYQSTLTRTECRDIDECLQNGRICNNGRCINTDGSFHCVCNAGFHVTRDGKNCEDMDECSIRNMCLNGMCINEDGSFKCICKPGFQLASDGRYCKDINECETPGICMNGRCVNTDGSYRCECFPGLAVGLDGRVCVDTHMRSTCYGGYKRGQCIKPLFGAVTKSECCCASTEYAFGEPCQPCPAQNSAEYQALCSSGPGMTSAGSDINECALDPDICPNGICENLRGTYKCICNSGYEVDSTGKNCVDINECVLNSLLCDNGQCRNTPGSFVCTCPKGFIYKPDLKTCEDIDECESSPCINGVCKNSPGSFICECSSESTLDPTKTICIETIKGTCWQTVIDGRCEININGATLKSQCCSSLGAAWGSPCTLCQVDPICGKGYSRIKGTQCEDIDECEVFPGVCKNGLCVNTRGSFKCQCPSGMTLDATGRICLDIRLETCFLRYEDEECTLPIAGRHRMDACCCSVGAAWGTEECEECPMRNTPEYEELCPRGPGFATKEITNGKPFFKDINECKMIPSLCTHGKCRNTIGSFKCRCDSGFALDSEERNCTDIDECRISPDLCGRGQCVNTPGDFECKCDEGYESGFMMMKNCMDIDECQRDPLLCRGGVCHNTEGSYRCECPPGHQLSPNISACIDINECELSAHLCPNGRCVNLIGKYQCACNPGYHSTPDRLFCVDIDECSIMNGGCETFCTNSEGSYECSCQPGFALMPDQRSCTDIDECEDNPNICDGGQCTNIPGEYRCLCYDGFMASEDMKTCVDVNECDLNPNICLSGTCENTKGSFICHCDMGYSGKKGKTGCTDINECEIGAHNCGKHAVCTNTAGSFKCSCSPGWIGDGIKCTDLDECSNGTHMCSQHADCKNTMGSYRCLCKEGYTGDGFTCTDLDECSENLNLCGNGQCLNAPGGYRCECDMGFVPSADGKACEDIDECSLPNICVFGTCHNLPGLFRCECEIGYELDRSGGNCTDVNECLDPTTCISGNCVNTPGSYICDCPPDFELNPTRVGCVDTRSGNCYLDIRPRGDNGDTACSNEIGVGVSKASCCCSLGKAWGTPCEMCPAVNTSEYKILCPGGEGFRPNPITVILEDIDECQELPGLCQGGKCINTFGSFQCRCPTGYYLNEDTRVCDDVNECETPGICGPGTCYNTVGNYTCICPPDYMQVNGGNNCMDMRRSLCYRNYYADNQTCDGELLFNMTKKMCCCSYNIGRAWNKPCEQCPIPSTDEFATLCGSQRPGFVIDIYTGLPVDIDECREIPGVCENGVCINMVGSFRCECPVGFFYNDKLLVCEDIDECQNGPVCQRNAECINTAGSYRCDCKPGYRFTSTGQCNDRNECQEIPNICSHGQCIDTVGSFYCLCHTGFKTNDDQTMCLDINECERDACGNGTCRNTIGSFNCRCNHGFILSHNNDCIDVDECASGNGNLCRNGQCINTVGSFQCQCNEGYEVAPDGRTCVDINECLLEPRKCAPGTCQNLDGSYRCICPPGYSLQNEKCEDIDECVEEPEICALGTCSNTEGSFKCLCPEGFSLSSSGRRCQDLRMSYCYAKFEGGKCSSPKSRNHSKQECCCALKGEGWGDPCELCPTEPDEAFRQICPYGSGIIVGPDDSAVDMDECKEPDVCKHGQCINTDGSYRCECPFGYILAGNECVDTDECSVGNPCGNGTCKNVIGGFECTCEEGFEPGPMMTCEDINECAQNPLLCAFRCVNTYGSYECKCPVGYVLREDRRMCKDEDECEEGKHDCTEKQMECKNLIGTYMCICGPGYQRRPDGEGCVDENECQTKPGICENGRCLNTRGSYTCECNDGFTASPNQDECLDNREGYCFTEVLQNMCQIGSSNRNPVTKSECCCDGGRGWGPHCEICPFQGTVAFKKLCPHGRGFMTNGADIDECKVIHDVCRNGECVNDRGSYHCICKTGYTPDITGTSCVDLNECNQAPKPCNFICKNTEGSYQCSCPKGYILQEDGRSCKDLDECATKQHNCQFLCVNTIGGFTCKCPPGFTQHHTSCIDNNECTSDINLCGSKGICQNTPGSFTCECQRGFSLDQTGSSCEDVDECEGNHRCQHGCQNIIGGYRCSCPQGYLQHYQWNQCVDENECLSAHICGGASCHNTLGSYKCMCPAGFQYEQFSGGCQDINECGSAQAPCSYGCSNTEGGYLCGCPPGYFRIGQGHCVSGMGMGRGNPEPPVSGEMDDNSLSPEACYECKINGYPKRGRKRRSTNETDASNIEDQSETEANVSLASWDVEKTAIFAFNISHVSNKVRILELLPALTTLTNHNRYLIESGNEDGFFKINQKEGISYLHFTKKKPVAGTYSLQISSTPLYKKKELNQLEDKYDKDYLSGELGDNLKMKIQVLLH	2871	P35555	Y	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [2460], 'STRAND_gain_score': array([0.03080994]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [527, 774, 1035, 1051, 1052, 1053, 1057, 1058, 1062, 1073, 1074, 1075, 1076, 1077, 1078, 1079, 1080, 1081, 1082, 1083, 1084, 1085, 1086, 1087, 1088, 1089, 1090, 1091, 1092, 1093, 1094, 1095, 1096, 1097, 1098, 1099, 1100, 1101], 'DOMAIN_gain': [928, 2182, 2458, 2491, 2493, 2503, 2504], 'DOMAIN_gain_score': array([0.02535325, 0.04492557, 0.04224145, 0.07147026, 0.07683325,
       0.0849241 , 0.05815566]), 'DOMAIN_loss_score': array([-0.02580684, -0.00720942, -0.11999398, -0.23875237, -0.33776462,
       -0.27799618, -0.31655526, -0.35761005, -0.30608755, -0.66285729,
       -0.63449806, -0.75843698, -0.84545124, -0.75810719, -0.86137605,
       -0.89865631, -0.942379  , -0.93669224, -0.93691903, -0.94030517,
       -0.90341216, -0.86136544, -0.90751863, -0.91716379, -0.91326672,
       -0.90782011, -0.88314301, -0.91855669, -0.85273522, -0.80542886,
       -0.80884761, -0.69123363, -0.6468212 , -0.84453946, -0.72731727,
       -0.7291224 , -0.67998415, -0.56112301]), 'REGION_loss': [2536], 'REGION_gain': [840, 855, 909, 922, 927, 932, 941, 942, 969, 972, 1011, 2172, 2176, 2197, 2214, 2215, 2224], 'REGION_gain_score': array([0.00574905, 0.00539464, 0.00616491, 0.00625265, 0.00601089,
       0.00475115, 0.00475925, 0.00467342, 0.00387776, 0.0037145 ,
       0.00656939, 0.0026837 , 0.00311989, 0.00610095, 0.00926024,
       0.00964749, 0.01287514]), 'REGION_loss_score': array([-0.0004046]), 'REPEAT_loss': [], 'REPEAT_gain': [909, 912, 916, 1028, 1029, 1030, 1816, 2256, 2259, 2261, 2265, 2323, 2418, 2524, 2547, 2564], 'REPEAT_gain_score': array([0.02621287, 0.0160951 , 0.01260495, 0.05305934, 0.06073582,
       0.04239494, 0.00445682, 0.02982253, 0.04825491, 0.05449635,
       0.06114656, 0.09349823, 0.04039156, 0.03192729, 0.02123147,
       0.01772523]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
647	NM_000138.5(FBN1):c.2287T>G (p.Cys763Gly)	549070	CA392335588	NM_000138.5:c.2287T>G, NC_000015.10:g.48497272A>C, CM000677.2:g.48497272A>C, NC_000015.9:g.48789469A>C, CM000677.1:g.48789469A>C, NC_000015.8:g.46576761A>C, NG_008805.2:g.153517T>G, LRG_778:g.153517T>G, ENST00000684448.1:n.961T>G, ENST00000316623.10:c.2287T>G, ENST00000316623.9:c.2287T>G, ENST00000537463.6:c.637-22622T>G, NM_000138.4:c.2287T>G, LRG_778t1:c.2287T>G, NM_000138.5(FBN1):c.2287T>G (p.Cys763Gly)	FBN1	Marfan syndrome	MONDO:0007947	Autosomal dominant inheritance	Pathogenic	PM1_Strong, PP4, PP2, PP3, PM2_Supporting, PS4_Supporting, PM6		The NM_00138 c.2287T>G is a missense variant in FBN1 predicted to cause a substitution of a cysteine by glycine at amino acid 763 (p.Cys763Gly). This variant was found in two probands with a clinical diagnosis of Marfan syndrome (internal data, PP4, PS4_Supporting). In one of these probands the variant was found de novo with assumed paternity and maternity (PM6). This variant has been reported 3 times in ClinVar, once as pathogenic, once as likely pathogenic and once as uncertain significance (Variation ID: 549070). To our knowledge, this variant has not previously been reported in individuals affected with Marfan syndrome in the literature. This variant is not present in gnomAD (PM2_sup; https://gnomad.broadinstitute.org/ version 2.1.1). This variant affects a cysteine residue in a calcium binding EGF domain. Cysteine residues are believed to be involved in the formation of disulfide bridges which are essential for the protein structure (PM1_strong). Computational prediction tools and conservation analysis suggest that this variant may impact the protein (REVEL: 0.98) (PP3). The constraint z-score for missense variants affecting FBN1 is 5.06 (PP2). In summary, this variant meets criteria to be classified as pathogenic for Marfan syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen FBN1 VCEP: PM1_Strong, PM6, PS4_Supporting, PM2_Sup, PP2, PP3, PP4.		FBN1 VCEP	https://clinicalgenome.org/docs/clingen-fbn1-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2023-12-29	2023-12-29	False	https://erepo.genome.network/evrepo/ui/classification/CA392335588/MONDO:0007947/022	c6e31e31-fd57-4bb1-af09-e057b9a6ccda	p.Cys763Gly	Cys	763	Gly	MRRGRLLEIALGFTVLLASYTSHGADANLEAGNVKETRASRAKRRGGGGHDALKGPNVCGSRYNAYCCPGWKTLPGGNQCIVPICRHSCGDGFCSRPNMCTCPSGQIAPSCGSRSIQHCNIRCMNGGSCSDDHCLCQKGYIGTHCGQPVCESGCLNGGRCVAPNRCACTYGFTGPQCERDYRTGPCFTVISNQMCQGQLSGIVCTKTLCCATVGRAWGHPCEMCPAQPHPCRRGFIPNIRTGACQDVDECQAIPGLCQGGNCINTVGSFECKCPAGHKLNEVSQKCEDIDECSTIPGICEGGECTNTVSSYFCKCPPGFYTSPDGTRCIDVRPGYCYTALTNGRCSNQLPQSITKMQCCCDAGRCWSPGVTVAPEMCPIRATEDFNKLCSVPMVIPGRPEYPPPPLGPIPPVLPVPPGFPPGPQIPVPRPPVEYLYPSREPPRVLPVNVTDYCQLVRYLCQNGRCIPTPGSYRCECNKGFQLDLRGECIDVDECEKNPCAGGECINNQGSYTCQCRAGYQSTLTRTECRDIDECLQNGRICNNGRCINTDGSFHCVCNAGFHVTRDGKNCEDMDECSIRNMCLNGMCINEDGSFKCICKPGFQLASDGRYCKDINECETPGICMNGRCVNTDGSYRCECFPGLAVGLDGRVCVDTHMRSTCYGGYKRGQCIKPLFGAVTKSECCCASTEYAFGEPCQPCPAQNSAEYQALCSSGPGMTSAGSDINECALDPDICPNGICENLRGTYKCICNSGYEVDSTGKNCVDINECVLNSLLCDNGQCRNTPGSFVCTCPKGFIYKPDLKTCEDIDECESSPCINGVCKNSPGSFICECSSESTLDPTKTICIETIKGTCWQTVIDGRCEININGATLKSQCCSSLGAAWGSPCTLCQVDPICGKGYSRIKGTQCEDIDECEVFPGVCKNGLCVNTRGSFKCQCPSGMTLDATGRICLDIRLETCFLRYEDEECTLPIAGRHRMDACCCSVGAAWGTEECEECPMRNTPEYEELCPRGPGFATKEITNGKPFFKDINECKMIPSLCTHGKCRNTIGSFKCRCDSGFALDSEERNCTDIDECRISPDLCGRGQCVNTPGDFECKCDEGYESGFMMMKNCMDIDECQRDPLLCRGGVCHNTEGSYRCECPPGHQLSPNISACIDINECELSAHLCPNGRCVNLIGKYQCACNPGYHSTPDRLFCVDIDECSIMNGGCETFCTNSEGSYECSCQPGFALMPDQRSCTDIDECEDNPNICDGGQCTNIPGEYRCLCYDGFMASEDMKTCVDVNECDLNPNICLSGTCENTKGSFICHCDMGYSGKKGKTGCTDINECEIGAHNCGKHAVCTNTAGSFKCSCSPGWIGDGIKCTDLDECSNGTHMCSQHADCKNTMGSYRCLCKEGYTGDGFTCTDLDECSENLNLCGNGQCLNAPGGYRCECDMGFVPSADGKACEDIDECSLPNICVFGTCHNLPGLFRCECEIGYELDRSGGNCTDVNECLDPTTCISGNCVNTPGSYICDCPPDFELNPTRVGCVDTRSGNCYLDIRPRGDNGDTACSNEIGVGVSKASCCCSLGKAWGTPCEMCPAVNTSEYKILCPGGEGFRPNPITVILEDIDECQELPGLCQGGKCINTFGSFQCRCPTGYYLNEDTRVCDDVNECETPGICGPGTCYNTVGNYTCICPPDYMQVNGGNNCMDMRRSLCYRNYYADNQTCDGELLFNMTKKMCCCSYNIGRAWNKPCEQCPIPSTDEFATLCGSQRPGFVIDIYTGLPVDIDECREIPGVCENGVCINMVGSFRCECPVGFFYNDKLLVCEDIDECQNGPVCQRNAECINTAGSYRCDCKPGYRFTSTGQCNDRNECQEIPNICSHGQCIDTVGSFYCLCHTGFKTNDDQTMCLDINECERDACGNGTCRNTIGSFNCRCNHGFILSHNNDCIDVDECASGNGNLCRNGQCINTVGSFQCQCNEGYEVAPDGRTCVDINECLLEPRKCAPGTCQNLDGSYRCICPPGYSLQNEKCEDIDECVEEPEICALGTCSNTEGSFKCLCPEGFSLSSSGRRCQDLRMSYCYAKFEGGKCSSPKSRNHSKQECCCALKGEGWGDPCELCPTEPDEAFRQICPYGSGIIVGPDDSAVDMDECKEPDVCKHGQCINTDGSYRCECPFGYILAGNECVDTDECSVGNPCGNGTCKNVIGGFECTCEEGFEPGPMMTCEDINECAQNPLLCAFRCVNTYGSYECKCPVGYVLREDRRMCKDEDECEEGKHDCTEKQMECKNLIGTYMCICGPGYQRRPDGEGCVDENECQTKPGICENGRCLNTRGSYTCECNDGFTASPNQDECLDNREGYCFTEVLQNMCQIGSSNRNPVTKSECCCDGGRGWGPHCEICPFQGTVAFKKLCPHGRGFMTNGADIDECKVIHDVCRNGECVNDRGSYHCICKTGYTPDITGTSCVDLNECNQAPKPCNFICKNTEGSYQCSCPKGYILQEDGRSCKDLDECATKQHNCQFLCVNTIGGFTCKCPPGFTQHHTSCIDNNECTSDINLCGSKGICQNTPGSFTCECQRGFSLDQTGSSCEDVDECEGNHRCQHGCQNIIGGYRCSCPQGYLQHYQWNQCVDENECLSAHICGGASCHNTLGSYKCMCPAGFQYEQFSGGCQDINECGSAQAPCSYGCSNTEGGYLCGCPPGYFRIGQGHCVSGMGMGRGNPEPPVSGEMDDNSLSPEACYECKINGYPKRGRKRRSTNETDASNIEDQSETEANVSLASWDVEKTAIFAFNISHVSNKVRILELLPALTTLTNHNRYLIESGNEDGFFKINQKEGISYLHFTKKKPVAGTYSLQISSTPLYKKKELNQLEDKYDKDYLSGELGDNLKMKIQVLLH	2871	P35555	G	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [734, 742, 743, 745, 746, 753, 774, 779, 2543], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.17215902, -0.1350112 , -0.14429283, -0.14968026, -0.14436853,
       -0.10294819, -0.09553808, -0.05447984, -0.00717998]), 'REGION_loss': [837, 841, 844, 845, 848, 849, 906, 908, 920, 933, 976, 1235, 2074, 2078, 2080, 2083, 2100, 2103, 2108, 2112, 2116, 2120, 2146, 2184, 2195, 2199, 2207, 2210, 2212, 2216, 2225, 2536], 'REGION_gain': [], 'REGION_loss_score': array([-0.01208586, -0.01331091, -0.0119217 , -0.01225001, -0.01146883,
       -0.01176172, -0.00623041, -0.00578403, -0.00545263, -0.00536799,
       -0.00383091, -0.00303656, -0.01003933, -0.008636  , -0.00921375,
       -0.00907296, -0.00735992, -0.00810057, -0.00748223, -0.0074169 ,
       -0.00846881, -0.00812781, -0.00759047, -0.00653249, -0.00556117,
       -0.00626856, -0.00619203, -0.00614154, -0.00621432, -0.0063225 ,
       -0.00618905, -0.00211418]), 'REPEAT_loss': [485, 521, 522, 757, 758, 760, 761, 762, 763, 764, 765, 766, 768, 769, 770, 771, 772, 1031], 'REPEAT_gain': [2547], 'REPEAT_gain_score': array([0.00429797]), 'REPEAT_loss_score': array([-0.01043087, -0.01865506, -0.01747257, -0.21332264, -0.19999897,
       -0.25045896, -0.35060573, -0.2988351 , -0.32142144, -0.36823308,
       -0.34153247, -0.36552274, -0.32082337, -0.2815361 , -0.24409413,
       -0.18295681, -0.16746265, -0.01367623]), 'ZN_FING_loss': [778, 1906], 'ZN_FING_gain': [], 'ZN_FING_loss_score': array([-0.04049253, -0.00380683])}"
648	NM_000329.3(RPE65):c.1301C>T (p.Ala434Val)	98836	CA226501	NM_000329.3:c.1301C>T, NC_000001.11:g.68431319G>A, CM000663.2:g.68431319G>A, NC_000001.10:g.68897002G>A, CM000663.1:g.68897002G>A, NC_000001.9:g.68669590G>A, NG_008472.1:g.23641C>T, NG_008472.2:g.23641C>T, ENST00000262340.6:c.1301C>T, ENST00000262340.5:c.1301C>T, NM_000329.2:c.1301C>T, XM_017002027.1:c.1025C>T, NM_000329.3(RPE65):c.1301C>T (p.Ala434Val)	RPE65	RPE65-related recessive retinopathy	MONDO:0100368	Autosomal recessive inheritance	Benign	BS2, BA1, BS3_Supporting	PP3, BP4, PS3	The NM_000329.3(RPE65):c.1301C>T (p.Ala434Val) missense variant that is present in gnomAD v.2.1.1 at a GrpMax allele frequency of 0.07646, with 1976 alleles / 24962 total alleles in the African / African-American population with 72 homozygotes, which is higher than the ClinGen LCA / eoRD VCEP BA1 threshold of >0.008 (BA1). The variant has been reported in at least one patient with retinal dystrophy, however the phenotype is not specific to RPE65 and no second variant was described in trans (PMID: 9501220). Three separate publications on families who carry this variant have reported unaffected individuals who harbor it in homozygous state (PMID: 19431183, PMID: 9501220, PMID: 19920137, BS2). The computational predictor REVEL gives a score of 0.418, which is below the ClinGen LCA / eoRD VCEP threshold of ≥ 0.7 and does not predict a damaging effect on RPE65 function. Additionally, the splicing impact predictor SpliceAI gives a score of 0.14, which is below the ClinGen LCA / eoRD VCEP recommended threshold of  ≥0.2 and does not strongly predict an impact on splicing. The variant exhibited 110% or 55% enzymatic activity in two retinoid isomerase assays relative to the wild-type control, which are higher than the ClinGen LCA / eoRD BS3_Supporting threshold of >50% activity, indicating that it largely preserves normal protein function (PMID: 19431183, PMID: 16150724, BS3_Supporting). In summary, this variant meets the criteria to be classified as Benign for RPE65-related recessive retinopathy based on the ACMG/AMP criteria applied, as specified by the ClinGen LCA/eoRD VCEP: BA1, BS2, BS3_supporting. (VCEP specifications version 1.0.0; date of approval 09/21/2023).	16150724	Leber Congenital Amaurosis/early onset Retinal Dystrophy VCEP		2023-12-22	2023-12-22	False	https://erepo.genome.network/evrepo/ui/classification/CA226501/MONDO:0100368/120	f70f8917-2432-426c-8fea-58947fe136be	p.Ala434Val	Ala	434	Val	MSIQVEHPAGGYKKLFETVEELSSPLTAHVTGRIPLWLTGSLLRCGPGLFEVGSEPFYHLFDGQALLHKFDFKEGHVTYHRRFIRTDAYVRAMTEKRIVITEFGTCAFPDPCKNIFSRFFSYFRGVEVTDNALVNVYPVGEDYYACTETNFITKINPETLETIKQVDLCNYVSVNGATAHPHIENDGTVYNIGNCFGKNFSIAYNIVKIPPLQADKEDPISKSEIVVQFPCSDRFKPSYVHSFGLTPNYIVFVETPVKINLFKFLSSWSLWGANYMDCFESNETMGVWLHIADKKRKKYLNNKYRTSPFNLFHHINTYEDNGFLIVDLCCWKGFEFVYNYLYLANLRENWEEVKKNARKAPQPEVRRYVLPLNIDKADTGKNLVTLPNTTATAILCSDETIWLEPEVLFSGPRQAFEFPQINYQKYCGKPYTYAYGLGLNHFVPDRLCKLNVKTKETWVWQEPDSYPSEPIFVSHPDALEEDDGVVLSVVVSPGAGQKPAYLLILNAKDLSEVARAEVEINIPVTFHGLFKKS	533	Q16518	V	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [251, 261, 286], 'DNA_BIND_gain': [], 'DNA_BIND_loss_score': array([-0.00429308, -0.00457424, -0.00294334]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [409], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.01434362]), 'HELIX_loss': [264], 'HELIX_gain': [18], 'HELIX_gain_score': array([0.01930463]), 'HELIX_loss_score': array([-0.00772429]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [92], 'DOMAIN_gain': [376, 378, 503], 'DOMAIN_gain_score': array([0.01772076, 0.01597017, 0.02592629]), 'DOMAIN_loss_score': array([-0.0121938]), 'REGION_loss': [316, 326], 'REGION_gain': [], 'REGION_loss_score': array([-0.01637679, -0.01295966]), 'REPEAT_loss': [497], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.00159556]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
649	NM_000329.3(RPE65):c.963T>G (p.Asn321Lys)	92860	CA146044	NM_000329.3:c.963T>G, NC_000001.11:g.68438977A>C, CM000663.2:g.68438977A>C, NC_000001.10:g.68904660A>C, CM000663.1:g.68904660A>C, NC_000001.9:g.68677248A>C, NG_008472.1:g.15983T>G, NG_008472.2:g.15983T>G, ENST00000262340.6:c.963T>G, ENST00000262340.5:c.963T>G, NM_000329.2:c.963T>G, XM_017002027.1:c.687T>G, NM_000329.3(RPE65):c.963T>G (p.Asn321Lys)	RPE65	RPE65-related recessive retinopathy	MONDO:0100368	Autosomal recessive inheritance	Benign	BS3_Supporting, BP4, BA1		The NM_000329.3(RPE65):c.963T>G (p.Asn321Lys) missense variant is present in gnomAD v.2.1.1 at a GrpMax allele frequency of 0.03299, with 1063 alleles / 30614 total alleles in the South Asian population with 29 homozygotes, which is higher than the ClinGen LCA / eoRD VCEP BA1 threshold of >0.008 (BA1). This variant has been reported in at least one LCA patient, however the phenotype is not sufficiently specific to RPE65 and no second variant was described in trans, instead two CRB1 variants were identified (PMID: 18055816). The computational predictor REVEL gives a score of 0.215, which is below the  ClinGen LCA/eoRD VCEP threshold of <0.3 and predicts no damaging effect on RPE65 function. Additionally, the splicing impact predictor SpliceAI gives a delta score of 0.00, which is below the ClinGen X-linked IRD VCEP recommended threshold of <0.1 and does not predict an impact on splicing (BP4). The variant exhibited 127% enzymatic activity in an isomerohydrolase assay relative to the wild-type control, which is higher than the ClinGen LCA / eoRD BS3_Supporting threshold of >50% activity, indicating that it preserves normal protein function (PMID: 19431183, BS3). In summary, this variant meets the criteria to be classified as benign for RPE65-related recessive retinopathy based on the ACMG/AMP criteria applied, as specified by the ClinGen LCA/eoRD VCEP: BA1, BS3_Supporting, BP4. (VCEP specifications version 1.0.0; date of approval 09/21/2023).	19431183	Leber Congenital Amaurosis/early onset Retinal Dystrophy VCEP		2023-12-22	2023-12-22	False	https://erepo.genome.network/evrepo/ui/classification/CA146044/MONDO:0100368/120	8c0c6342-b407-4413-be30-35e48105188f	p.Asn321Lys	Asn	321	Lys	MSIQVEHPAGGYKKLFETVEELSSPLTAHVTGRIPLWLTGSLLRCGPGLFEVGSEPFYHLFDGQALLHKFDFKEGHVTYHRRFIRTDAYVRAMTEKRIVITEFGTCAFPDPCKNIFSRFFSYFRGVEVTDNALVNVYPVGEDYYACTETNFITKINPETLETIKQVDLCNYVSVNGATAHPHIENDGTVYNIGNCFGKNFSIAYNIVKIPPLQADKEDPISKSEIVVQFPCSDRFKPSYVHSFGLTPNYIVFVETPVKINLFKFLSSWSLWGANYMDCFESNETMGVWLHIADKKRKKYLNNKYRTSPFNLFHHINTYEDNGFLIVDLCCWKGFEFVYNYLYLANLRENWEEVKKNARKAPQPEVRRYVLPLNIDKADTGKNLVTLPNTTATAILCSDETIWLEPEVLFSGPRQAFEFPQINYQKYCGKPYTYAYGLGLNHFVPDRLCKLNVKTKETWVWQEPDSYPSEPIFVSHPDALEEDDGVVLSVVVSPGAGQKPAYLLILNAKDLSEVARAEVEINIPVTFHGLFKKS	533	Q16518	K	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [312], 'BINDING_gain': [], 'BINDING_loss_score': array([-0.17324525]), 'DNA_BIND_loss': [286], 'DNA_BIND_gain': [], 'DNA_BIND_loss_score': array([-0.0015797]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [285], 'STRAND_gain': [103], 'STRAND_gain_score': array([0.04003245]), 'STRAND_loss_score': array([-0.03733581]), 'HELIX_loss': [87, 277], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.02115828, -0.0114702 ]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [326], 'REGION_gain': [], 'REGION_loss_score': array([-0.00994152]), 'REPEAT_loss': [497], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.0023436]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
650	NM_000329.3(RPE65):c.394G>A (p.Ala132Thr)	13119	CA226547	NM_000329.3:c.394G>A, NC_000001.11:g.68444632C>T, CM000663.2:g.68444632C>T, NC_000001.10:g.68910315C>T, CM000663.1:g.68910315C>T, NC_000001.9:g.68682903C>T, NG_008472.1:g.10328G>A, NG_008472.2:g.10328G>A, ENST00000262340.6:c.394G>A, ENST00000262340.5:c.394G>A, NM_000329.2:c.394G>A, XM_017002027.1:c.118G>A, NM_000329.3(RPE65):c.394G>A (p.Ala132Thr)	RPE65	RPE65-related recessive retinopathy	MONDO:0100368	Autosomal recessive inheritance	Benign	BS3_Supporting, BA1	BP4	NM_000329.3(RPE65):c.394G>A is a missense variant that replaces alanine with threonine at codon 132. This variant is present in gnomAD v.2.1.1 at a GrpMax allele frequency of 0.01113, with 372 alleles / 30614 total alleles in the South Asian population (with 6 homozygotes), which is higher than the ClinGen LCA / eoRD VCEP BA1 threshold of >0.008 (BA1). The computational predictor REVEL gives a score of 0.548, which is above the ClinGen LCA / eoRD VCEP threshold of <0.3 and does not strongly predict a non-damaging effect on RPE65 function. The splicing impact predictor SpliceAI gives a score of 0.03 for splice acceptor loss, which is below the ClinGen LCA / eoRD VCEP recommended threshold of  ≥0.2 and does not strongly predict an impact on splicing. The variant exhibited 50% enzymatic activity in an isomerohydrolase assay relative to the wild-type control, which is higher than the ClinGen LCA / eoRD BS3_Supporting threshold of >50% activity, indicating that it largely preserves] normal protein function (PMID: 16150724, BS3_Supporting). In summary, this variant meets the criteria to be classified as benign for RPE65-related recessive retinopathy based on the ACMG/AMP criteria applied, as specified by the ClinGen LCA/eoRD VCEP: BA1, BS3_Supporting. (VCEP specifications version 1.0.0; date of approval 09/21/2023).	16150724	Leber Congenital Amaurosis/early onset Retinal Dystrophy VCEP		2023-12-22	2023-12-22	False	https://erepo.genome.network/evrepo/ui/classification/CA226547/MONDO:0100368/120	c96cbaae-09fb-4a90-9c7a-dcd5435fd7ff	p.Ala132Thr	Ala	132	Thr	MSIQVEHPAGGYKKLFETVEELSSPLTAHVTGRIPLWLTGSLLRCGPGLFEVGSEPFYHLFDGQALLHKFDFKEGHVTYHRRFIRTDAYVRAMTEKRIVITEFGTCAFPDPCKNIFSRFFSYFRGVEVTDNALVNVYPVGEDYYACTETNFITKINPETLETIKQVDLCNYVSVNGATAHPHIENDGTVYNIGNCFGKNFSIAYNIVKIPPLQADKEDPISKSEIVVQFPCSDRFKPSYVHSFGLTPNYIVFVETPVKINLFKFLSSWSLWGANYMDCFESNETMGVWLHIADKKRKKYLNNKYRTSPFNLFHHINTYEDNGFLIVDLCCWKGFEFVYNYLYLANLRENWEEVKKNARKAPQPEVRRYVLPLNIDKADTGKNLVTLPNTTATAILCSDETIWLEPEVLFSGPRQAFEFPQINYQKYCGKPYTYAYGLGLNHFVPDRLCKLNVKTKETWVWQEPDSYPSEPIFVSHPDALEEDDGVVLSVVVSPGAGQKPAYLLILNAKDLSEVARAEVEINIPVTFHGLFKKS	533	Q16518	T	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [12, 30], 'PROPEP_gain_score': array([0.00612694, 0.01031709]), 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [98], 'STRAND_gain': [107], 'STRAND_gain_score': array([0.007002]), 'STRAND_loss_score': array([-0.01997942]), 'HELIX_loss': [87], 'HELIX_gain': [18], 'HELIX_gain_score': array([0.02273792]), 'HELIX_loss_score': array([-0.03478003]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [497], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.00191319]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
651	NM_000329.3(RPE65):c.1087C>A (p.Pro363Thr)	13117	CA256730	NM_000329.3:c.1087C>A, NC_000001.11:g.68438228G>T, CM000663.2:g.68438228G>T, NC_000001.10:g.68903911G>T, CM000663.1:g.68903911G>T, NC_000001.9:g.68676499G>T, NG_008472.1:g.16732C>A, NG_008472.2:g.16732C>A, ENST00000262340.6:c.1087C>A, ENST00000262340.5:c.1087C>A, NM_000329.2:c.1087C>A, XM_017002027.1:c.811C>A, NM_000329.3(RPE65):c.1087C>A (p.Pro363Thr)	RPE65	RPE65-related recessive retinopathy	MONDO:0100368	Autosomal recessive inheritance	Pathogenic	PP3, PM2_Supporting, PP1_Strong, PM3, PS3_Supporting, PP4_Moderate		The NM_000329.3(RPE65):c.1087C>A (p.Pro363Thr) variant is reported in the literature in a homozygous state in at least two probands affected with Leber congenital amaurosis or early onset severe retinal dystrophy (1 point, PM3, PMID: 9326941, PMID: 26352687). At least one patient harboring the variant exhibited reduced or nondetectable rod ERG (required, 0.5 pts), decreased central visual acuity (1 pt), symptomatic onset between birth and age 5 years (1 pt), evidence of cone involvement on ERG (1 pt), light staring (1 pt), nyctalopia (0.5 pts), and positive response to RPE65 gene therapy (8 pts), which together are specific for RPE65-related recessive retinopathy (13 pts total, VCEP member-provided data, PP4_Moderate). The variant has been reported to segregate with childhood-onset severe retinal dystrophy in multiple families with at least 3 members (PP1_strong, PMID:9326941, PMID: 26352687). This variant is reported in ClinVar (Variation ID: 13117), and its Popmax Filtering AF in gnomAD v.2.1.1 is 0.00004443 (4/30608 alleles) in the South Asian population, which is lower than the ClinGen LCA / eoRD VCEP threshold (<0.0002) (PM2_Supporting). The meta-predictor REVEL gives a score of 0.702, which is above the ClinGen LCA/eoRD VCEP PP3 threshold of >0.644 and predicts a damaging effect on RPE65 function (PP3). An in vitro isomerohydrolase activity assay performed in adenovirus-infected 293A-LRAT cells showed that the p.Pro363Thr mutant exhibits complete loss of 11-cis-retinol production relative to the wild-type RPE65 control, confirming that this variant has a damaging effect on protein function (PMID: 16828753, PS3_supporting). In summary, this variant meets the criteria to be classified as Pathogenic for RPE65-related recessive retinopathy based on the ACMG/AMP criteria applied, as specified by the ClinGen LCA/eoRD VCEP: PP1_Strong, PM3, PP4_Moderate, PS3_Supporting, PM2_Supporting, PP3. (VCEP specifications version 1.0.0; date of approval 09/21/2023).		Leber Congenital Amaurosis/early onset Retinal Dystrophy VCEP		2023-12-22	2023-12-22	False	https://erepo.genome.network/evrepo/ui/classification/CA256730/MONDO:0100368/120	2a06ba5b-9a33-453f-9155-c4652c7b97b3	p.Pro363Thr	Pro	363	Thr	MSIQVEHPAGGYKKLFETVEELSSPLTAHVTGRIPLWLTGSLLRCGPGLFEVGSEPFYHLFDGQALLHKFDFKEGHVTYHRRFIRTDAYVRAMTEKRIVITEFGTCAFPDPCKNIFSRFFSYFRGVEVTDNALVNVYPVGEDYYACTETNFITKINPETLETIKQVDLCNYVSVNGATAHPHIENDGTVYNIGNCFGKNFSIAYNIVKIPPLQADKEDPISKSEIVVQFPCSDRFKPSYVHSFGLTPNYIVFVETPVKINLFKFLSSWSLWGANYMDCFESNETMGVWLHIADKKRKKYLNNKYRTSPFNLFHHINTYEDNGFLIVDLCCWKGFEFVYNYLYLANLRENWEEVKKNARKAPQPEVRRYVLPLNIDKADTGKNLVTLPNTTATAILCSDETIWLEPEVLFSGPRQAFEFPQINYQKYCGKPYTYAYGLGLNHFVPDRLCKLNVKTKETWVWQEPDSYPSEPIFVSHPDALEEDDGVVLSVVVSPGAGQKPAYLLILNAKDLSEVARAEVEINIPVTFHGLFKKS	533	Q16518	T	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [15, 22], 'PROPEP_gain': [], 'PROPEP_loss_score': array([-0.00531107, -0.00512135]), 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [388], 'STRAND_gain': [107], 'STRAND_gain_score': array([0.00843704]), 'STRAND_loss_score': array([-0.04625022]), 'HELIX_loss': [333], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.02000117]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [469], 'REPEAT_gain_score': array([0.0018326]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
652	NM_000022.4(ADA):c.425G>A (p.Arg142Gln)	68262	CA266009	NM_000022.4:c.425G>A, NC_000020.11:g.44625622C>T, CM000682.2:g.44625622C>T, NC_000020.10:g.43254263C>T, CM000682.1:g.43254263C>T, NC_000020.9:g.42687677C>T, NG_007385.1:g.31114G>A, LRG_16:g.31114G>A, ENST00000372874.9:c.425G>A, ENST00000372874.8:c.425G>A, ENST00000464097.5:n.99G>A, ENST00000492931.5:n.509G>A, ENST00000536532.5:c.425G>A, ENST00000537820.1:c.425G>A, ENST00000539235.5:c.219-2544G>A, NM_000022.2:c.425G>A, LRG_16t1:c.425G>A, XM_005260236.2:c.425G>A, XM_011528478.1:c.73+834G>A, XM_011528479.1:c.73+834G>A, XR_244129.1:n.479G>A, NM_000022.3:c.425G>A, NM_001322050.1:c.73+834G>A, NM_001322051.1:c.425G>A, NR_136160.1:n.576G>A, NM_001322050.2:c.73+834G>A, NM_001322051.2:c.425G>A, NR_136160.2:n.517G>A, NM_000022.4(ADA):c.425G>A (p.Arg142Gln)	ADA	adenosine deaminase deficiency	MONDO:0007064	Autosomal recessive inheritance	Benign	BS2_Supporting, BA1		NM_000022.4(ADA):c.425G>A  is a missense variant predicted to cause substitution of Arginine by Glutamine at amino acid 142 (p.Arg142Gln). The filtering allele frequency (the upper threshold of the 95% CI of 975/74574 alleles) of the c.425G>A variant in ADA is 0.01222 for African/African American chromosomes by gnomAD v.4, which is higher than the ClinGen SCID VCEP threshold (>0.00721) for BA1 and therefore meets this criterion (BA1).This variant has been observed in 6 homozygous individuals in gnomAD v.4, a condition with full penetrance at an early age (BS2_Supporting). In summary, this variant meets the criteria to be classified as Benign for autosomal recessive SCID. ACMG/AMP criteria applied, as specified by the ClinGen SCID-VCEP: BA1 and BS2_Supporting. (VCEP specifications version 1).		Severe Combined Immunodeficiency Disease  VCEP		2024-01-10	2024-01-10	False	https://erepo.genome.network/evrepo/ui/classification/CA266009/MONDO:0007064/114	0bf86526-9d24-4027-b0fa-f37b88888f3c	p.Arg142Gln	Arg	142	Gln	MAQTPAFDKPKVELHVHLDGSIKPETILYYGRRRGIALPANTAEGLLNVIGMDKPLTLPDFLAKFDYYMPAIAGCREAIKRIAYEFVEMKAKEGVVYVEVRYSPHLLANSKVEPIPWNQAEGDLTPDEVVALVGQGLQEGERDFGVKARSILCCMRHQPNWSPKVVELCKKYQQQTVVAIDLAGDETIPGSSLLPGHVQAYQEAVKSGIHRTVHAGEVGSAEVVKEAVDILKTERLGHGYHTLEDQALYNRLRQENMHFEICPWSSYLTGAWKPDTEHAVIRLKNDQANYSLNTDDPLIFKSTLDTDYQMTKRDMGFTEEEFKRLNINAAKSSFLPEDEKRELLDLLYKAYGMPPSASAGQNL	363	P00813	Q	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [106], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.0068661]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [219], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.00303304]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
653	NM_000022.4(ADA):c.632G>A (p.Arg211His)	1957	CA252000	NM_000022.4:c.632G>A, NC_000020.11:g.44623053C>T, CM000682.2:g.44623053C>T, NC_000020.10:g.43251694C>T, CM000682.1:g.43251694C>T, NC_000020.9:g.42685108C>T, NG_007385.1:g.33683G>A, LRG_16:g.33683G>A, ENST00000372874.9:c.632G>A, ENST00000372874.8:c.632G>A, ENST00000372887.5:c.152-880C>T, ENST00000464097.5:n.306G>A, ENST00000492931.5:n.716G>A, ENST00000536532.5:c.632G>A, ENST00000537820.1:c.607-123G>A, ENST00000539235.5:c.*16G>A, NM_000022.2:c.632G>A, LRG_16t1:c.632G>A, XM_005260236.2:c.607-123G>A, XM_011528478.1:c.227G>A, XM_011528479.1:c.227G>A, XR_244129.1:n.686G>A, NM_000022.3:c.632G>A, NM_001322050.1:c.227G>A, NM_001322051.1:c.607-123G>A, NR_136160.1:n.783G>A, NM_001322050.2:c.227G>A, NM_001322051.2:c.607-123G>A, NR_136160.2:n.724G>A, NM_000022.4(ADA):c.632G>A (p.Arg211His)	ADA	adenosine deaminase deficiency	MONDO:0007064	Autosomal recessive inheritance	Pathogenic	PP4_Moderate, PM2, PS3_Moderate, PM3_Strong, PP1_Strong	PS1	The NM_000022.4:c.632G>A variant in ADA is a missense variant predicted to cause substitution of arginine by histidine at amino acid 211 (p.Arg211His).The filtering allele frequency (the upper threshold of the 95% CI of 10/35432) of the c.632G>A variant in ADA is 0.0001565 for Latino/Admixed American chromosomes by gnomAD v.2.1.1, which is lower than the ClinGen SCID VCEP threshold (<0.0001742) and therefore meets this criterion (PM2_Supporting). Total Expressed ADA Activity in SØ3834 in E. coli showed the values: Mean +- SD = 30.4 +- 35.8 (3.0–134.2)[nmol/h/mg protein] and the following percent of Wild Type (Range) = 0.012 - 0.014 (0.001–0.051), belonging to group I of Arredondo-Vega classification, indicating that this variant impacts protein function (PMID: 9758612, PS3_moderate). This variant has been detected in 22 individuals with SCID. Of those individuals, one was a heterozygous compound with c.95+1G>A (variant classified pathogenic according to the SCID VCEP specifications). The trans phase of the variants was confirmed by parental testing (1pt; PMID 9414266). Four individuals were with this variant, and a variant that has not been curated by the SCID VCEP (p.A179D, PMID 26684479; p.R101Q, PMID 16973956; p.Y201*, PMID 26255240, patient #46; p.L107P, PMID 19179314, patient #2) (0pt - These variants will not be curated now because the pathogenic level was already reached). Seventeen individuals were homozygous for the variant (maximum 1pt; PMID 27129325, 20460637, 26376800, 19179314, 16276484, 9758612). 2pts in total, PM3_Strong is met.At least one patient with this variant displayed: Diagnostic criteria for SCID/Leaky SCID/Omenn syndrome (0.5pt) + Reduced ADA enzyme activity in patient cells (1pt) + Increased dAdo nucleotides (dATP or dAXP) in pretreatment erythrocytes (2pt) + ADA-SCID phenotype corrected by ADA gene therapy (1pt), in a total of 4.5 points, which is highly specific for SCID (PP4_Moderate; PMID: 9414266). The variant has been reported to segregate with SCID in 4 affected family members from 2 families (LOD score 2.41; PP1_Strong; PMID 20460637, 26376800). In summary, this variant meets the criteria to be classified as pathogenic for SCID. ACMG/AMP criteria applied, as specified by the ClinGen SCID-VCEP: PP4_Moderate, PM3_Strong, PP1_Strong, PM2_Supporting, PS3_Moderate. (VCEP specifications version 1).		Severe Combined Immunodeficiency Disease  VCEP		2024-01-17	2024-01-17	False	https://erepo.genome.network/evrepo/ui/classification/CA252000/MONDO:0007064/114	4c664ec8-5d63-46a5-a3d1-142655c6aa1c	p.Arg211His	Arg	211	His	MAQTPAFDKPKVELHVHLDGSIKPETILYYGRRRGIALPANTAEGLLNVIGMDKPLTLPDFLAKFDYYMPAIAGCREAIKRIAYEFVEMKAKEGVVYVEVRYSPHLLANSKVEPIPWNQAEGDLTPDEVVALVGQGLQEGERDFGVKARSILCCMRHQPNWSPKVVELCKKYQQQTVVAIDLAGDETIPGSSLLPGHVQAYQEAVKSGIHRTVHAGEVGSAEVVKEAVDILKTERLGHGYHTLEDQALYNRLRQENMHFEICPWSSYLTGAWKPDTEHAVIRLKNDQANYSLNTDDPLIFKSTLDTDYQMTKRDMGFTEEEFKRLNINAAKSSFLPEDEKRELLDLLYKAYGMPPSASAGQNL	363	P00813	H	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [216], 'BINDING_gain': [], 'BINDING_loss_score': array([-0.02718979]), 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [38, 208], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.0503279 , -0.13846171]), 'HELIX_loss': [191], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.07286257]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [42, 337], 'DOMAIN_gain_score': array([0.02021039, 0.03352046]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [179, 180, 185, 219, 292], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.02833629, -0.01080626, -0.02570373, -0.00499737, -0.0041005 ]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
654	NM_001033855.3(DCLRE1C):c.959C>G (p.Ser320Cys)	137073	CA290573	NM_001033855.3:c.959C>G, NC_000010.11:g.14926856G>C, CM000672.2:g.14926856G>C, NC_000010.10:g.14968855G>C, CM000672.1:g.14968855G>C, NC_000010.9:g.15008861G>C, NG_007276.1:g.32240C>G, LRG_54:g.32240C>G, ENST00000378278.7:c.959C>G, ENST00000357717.6:c.614C>G, ENST00000378246.6:c.614C>G, ENST00000378249.5:c.614C>G, ENST00000378254.5:c.599C>G, ENST00000378255.5:c.599C>G, ENST00000378258.5:c.599C>G, ENST00000378278.6:c.959C>G, ENST00000378289.8:c.959C>G, ENST00000396817.6:c.599C>G, ENST00000489161.1:n.47+1160C>G, ENST00000492201.5:n.109C>G, NM_001033855.2:c.959C>G, NM_001033857.2:c.599C>G, NM_001033858.2:c.599C>G, NM_001289076.1:c.614C>G, NM_001289077.1:c.599C>G, NM_001289078.1:c.614C>G, NM_001289079.1:c.599C>G, NM_022487.3:c.614C>G, NR_110297.1:n.1593C>G, XM_006717491.2:c.614C>G, XM_011519616.1:c.614C>G, XM_011519617.1:c.614C>G, XM_011519618.1:c.614C>G, XM_011519619.1:c.599C>G, XM_011519620.1:c.959C>G, XM_011519621.1:c.917+1160C>G, XR_242702.2:n.1056C>G, XR_930514.1:n.1014+1160C>G, XR_930515.1:n.1014+1160C>G, NM_001350965.1:c.959C>G, NM_001350966.1:c.614C>G, NM_001350967.1:c.599C>G, NR_146960.1:n.1339+1160C>G, NR_146961.1:n.1410C>G, NR_146962.1:n.1381C>G, XM_006717491.4:c.614C>G, XM_011519620.3:c.959C>G, XM_011519621.2:c.917+1160C>G, XM_017016557.1:c.614C>G, XM_017016558.1:c.599C>G, XM_024448134.1:c.599C>G, XM_024448135.1:c.614C>G, XR_001747185.2:n.1261+1160C>G, XR_001747187.1:n.939C>G, XR_930515.2:n.1261+1160C>G, NM_001033857.3:c.599C>G, NM_001033858.3:c.599C>G, NM_001289076.2:c.614C>G, NM_001289077.2:c.599C>G, NM_001289078.2:c.614C>G, NM_001289079.2:c.599C>G, NM_001350965.2:c.959C>G, NM_001350966.2:c.614C>G, NM_001350967.2:c.599C>G, NM_022487.4:c.614C>G, NR_110297.2:n.1257C>G, NR_146961.2:n.1074C>G, NM_001033855.3(DCLRE1C):c.959C>G (p.Ser320Cys)	DCLRE1C	severe combined immunodeficiency due to DCLRE1C deficiency	MONDO:0011225	Autosomal recessive inheritance	Benign	BA1, BS2_Supporting		The NM_001033855.3:c.959C>G variant in DCLRE1C is a missense variant predicted to cause substitution of serine by cysteine at amino acid 320 (p.Ser320Cys). This variant has an allele frequency of 0.03553 in the African / African American population in gnomAD, which is above the threshold for BA1 set by the ClinGen SCID VCEP for DCLRE1C (>0.00346). In addition, 16 adult homozygous individuals with this variant are present in gnomAD v2.1.1 (in African/African American population)(BS2_Supporting).In summary, this variant meets the criteria to be classified as Benign for autosomal recessive SCID based on the ACMG criteria applied: BA1 and BS2_Supporting as specified by the ClinGen SCID VCEP (VCEP specifications version 1).		Severe Combined Immunodeficiency Disease  VCEP		2024-01-17	2024-01-17	False	https://erepo.genome.network/evrepo/ui/classification/CA290573/MONDO:0011225/116	1e415979-5d92-452e-a666-3a4ecd34b44e	p.Ser320Cys	Ser	320	Cys	MSSFEGQMAEYPTISIDRFDRENLRARAYFLSHCHKDHMKGLRAPTLKRRLECSLKVYLYCSPVTKELLLTSPKYRFWKKRIISIEIETPTQISLVDEASGEKEEIVVTLLPAGHCPGSVMFLFQGNNGTVLYTGDFRLAQGEAARMELLHSGGRVKDIQSVYLDTTFCDPRFYQIPSREECLSGVLELVRSWITRSPYHVVWLNCKAAYGYEYLFTNLSEELGVQVHVNKLDMFRNMPEILHHLTTDRNTQIHACRHPKAEEYFQWSKLPCGITSRNRIPLHIISIKPSTMWFGERSRKTNVIVRTGESSYRACFSFHSSYSEIKDFLSYLCPVNAYPNVIPVGTTMDKVVEILKPLCRSSQSTEPKYKPLGKLKRARTVHRDSEEEDDYLFDDPLPIPLRHKVPYPETFHPEVFSMTAVSEKQPEKLRQTPGCCRAECMQSSRFTNFVDCEESNSESEEEVGIPASLQGDLGSVLHLQKADGDVPQWEVFFKRNDEITDESLENFPSSTVAGGSQSPKLFSDSDGESTHISSQNSSQSTHITEQGSQGWDSQSDTVLLSSQERNSGDITSLDKADYRPTIKENIPASLMEQNVICPKDTYSDLKSRDKDVTIVPSTGEPTTLSSETHIPEEKSLLNLSTNADSQSSSDFEVPSTPEAELPKREHLQYLYEKLATGESIAVKKRKCSLLDT	692	Q96SD1	C	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [347], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.03319615]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [148, 152, 190, 307, 320], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.0215013 , -0.01803732, -0.04038864, -0.05527508, -0.00477087]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
655	NM_001033855.3(DCLRE1C):c.512C>G (p.Pro171Arg)	35999	CA213684	NM_001033855.3:c.512C>G, NC_000010.11:g.14934728G>C, CM000672.2:g.14934728G>C, NC_000010.10:g.14976727G>C, CM000672.1:g.14976727G>C, NC_000010.9:g.15016733G>C, NG_007276.1:g.24368C>G, LRG_54:g.24368C>G, ENST00000378278.7:c.512C>G, ENST00000357717.6:c.167C>G, ENST00000378241.5:c.152C>G, ENST00000378246.6:c.167C>G, ENST00000378249.5:c.167C>G, ENST00000378254.5:c.152C>G, ENST00000378255.5:c.152C>G, ENST00000378258.5:c.152C>G, ENST00000378278.6:c.512C>G, ENST00000378289.8:c.512C>G, ENST00000396817.6:c.152C>G, ENST00000418843.5:c.74C>G, ENST00000456122.1:c.167C>G, NM_001033855.2:c.512C>G, NM_001033857.2:c.152C>G, NM_001033858.2:c.152C>G, NM_001289076.1:c.167C>G, NM_001289077.1:c.152C>G, NM_001289078.1:c.167C>G, NM_001289079.1:c.152C>G, NM_022487.3:c.167C>G, NR_110297.1:n.1146C>G, XM_006717491.2:c.167C>G, XM_011519616.1:c.167C>G, XM_011519617.1:c.167C>G, XM_011519618.1:c.167C>G, XM_011519619.1:c.152C>G, XM_011519620.1:c.512C>G, XM_011519621.1:c.512C>G, XR_242702.2:n.609C>G, XR_930514.1:n.609C>G, XR_930515.1:n.609C>G, NM_001350965.1:c.512C>G, NM_001350966.1:c.167C>G, NM_001350967.1:c.152C>G, NR_146960.1:n.934C>G, NR_146961.1:n.963C>G, NR_146962.1:n.934C>G, XM_006717491.4:c.167C>G, XM_011519620.3:c.512C>G, XM_011519621.2:c.512C>G, XM_017016557.1:c.167C>G, XM_017016558.1:c.152C>G, XM_024448134.1:c.152C>G, XM_024448135.1:c.167C>G, XR_001747185.2:n.856C>G, XR_001747187.1:n.492C>G, XR_930515.2:n.856C>G, NM_001033857.3:c.152C>G, NM_001033858.3:c.152C>G, NM_001289076.2:c.167C>G, NM_001289077.2:c.152C>G, NM_001289078.2:c.167C>G, NM_001289079.2:c.152C>G, NM_001350965.2:c.512C>G, NM_001350966.2:c.167C>G, NM_001350967.2:c.152C>G, NM_022487.4:c.167C>G, NR_110297.2:n.810C>G, NR_146961.2:n.627C>G, NM_001033855.3(DCLRE1C):c.512C>G (p.Pro171Arg)	DCLRE1C	severe combined immunodeficiency due to DCLRE1C deficiency	MONDO:0011225	Autosomal recessive inheritance	Benign	BA1, BS2_Supporting		The NM_001033855.3:c.512C>G variant in DCLRE1C is a missense variant predicted to cause the substitution of proline by arginine at amino acid 171 (p.Pro171Arg). This variant has an allele frequency of 0.19422 in the East Asian population in gnomAD, which is above the threshold for BA1 set by the ClinGen SCID VCEP for DCLRE1C (>0.00346). In addition, this variant is present 1394 adult homozygous individuals in gnomADv2.1.1 (distributed in all gnomAD populations)(BS2_Supporting). In summary, this variant meets the criteria to be classified as Benign for autosomal recessive SCID based on the ACMG criteria applied: BA1 and BS2_Supporting, as specified by the ClinGen SCID VCEP (VCEP specifications version 1).		Severe Combined Immunodeficiency Disease  VCEP		2024-01-17	2024-01-17	False	https://erepo.genome.network/evrepo/ui/classification/CA213684/MONDO:0011225/116	b82ebffe-f888-4104-91bf-516686f3b479	p.Pro171Arg	Pro	171	Arg	MSSFEGQMAEYPTISIDRFDRENLRARAYFLSHCHKDHMKGLRAPTLKRRLECSLKVYLYCSPVTKELLLTSPKYRFWKKRIISIEIETPTQISLVDEASGEKEEIVVTLLPAGHCPGSVMFLFQGNNGTVLYTGDFRLAQGEAARMELLHSGGRVKDIQSVYLDTTFCDPRFYQIPSREECLSGVLELVRSWITRSPYHVVWLNCKAAYGYEYLFTNLSEELGVQVHVNKLDMFRNMPEILHHLTTDRNTQIHACRHPKAEEYFQWSKLPCGITSRNRIPLHIISIKPSTMWFGERSRKTNVIVRTGESSYRACFSFHSSYSEIKDFLSYLCPVNAYPNVIPVGTTMDKVVEILKPLCRSSQSTEPKYKPLGKLKRARTVHRDSEEEDDYLFDDPLPIPLRHKVPYPETFHPEVFSMTAVSEKQPEKLRQTPGCCRAECMQSSRFTNFVDCEESNSESEEEVGIPASLQGDLGSVLHLQKADGDVPQWEVFFKRNDEITDESLENFPSSTVAGGSQSPKLFSDSDGESTHISSQNSSQSTHITEQGSQGWDSQSDTVLLSSQERNSGDITSLDKADYRPTIKENIPASLMEQNVICPKDTYSDLKSRDKDVTIVPSTGEPTTLSSETHIPEEKSLLNLSTNADSQSSSDFEVPSTPEAELPKREHLQYLYEKLATGESIAVKKRKCSLLDT	692	Q96SD1	R	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [142], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.03891462]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [320], 'DOMAIN_gain': [149, 151, 155, 160, 188, 189, 192, 212], 'DOMAIN_gain_score': array([0.04783404, 0.09502023, 0.06181449, 0.02976775, 0.08660352,
       0.08572388, 0.09016079, 0.08823675]), 'DOMAIN_loss_score': array([-0.00959325]), 'REGION_loss': [617, 619, 632], 'REGION_gain': [], 'REGION_loss_score': array([-0.00502884, -0.00582623, -0.00623924]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
656	NM_001033855.3(DCLRE1C):c.457G>A (p.Gly153Arg)	35998	CA213680	NM_001033855.3:c.457G>A, NC_000010.11:g.14935470C>T, CM000672.2:g.14935470C>T, NC_000010.10:g.14977469C>T, CM000672.1:g.14977469C>T, NC_000010.9:g.15017475C>T, NG_007276.1:g.23626G>A, LRG_54:g.23626G>A, ENST00000378278.7:c.457G>A, ENST00000357717.6:c.112G>A, ENST00000378241.5:c.97G>A, ENST00000378246.6:c.112G>A, ENST00000378249.5:c.112G>A, ENST00000378254.5:c.97G>A, ENST00000378255.5:c.97G>A, ENST00000378258.5:c.97G>A, ENST00000378278.6:c.457G>A, ENST00000378289.8:c.457G>A, ENST00000396817.6:c.97G>A, ENST00000418843.5:c.19G>A, ENST00000456122.1:c.112G>A, NM_001033855.2:c.457G>A, NM_001033857.2:c.97G>A, NM_001033858.2:c.97G>A, NM_001289076.1:c.112G>A, NM_001289077.1:c.97G>A, NM_001289078.1:c.112G>A, NM_001289079.1:c.97G>A, NM_022487.3:c.112G>A, NR_110297.1:n.1091G>A, XM_006717491.2:c.112G>A, XM_011519616.1:c.112G>A, XM_011519617.1:c.112G>A, XM_011519618.1:c.112G>A, XM_011519619.1:c.97G>A, XM_011519620.1:c.457G>A, XM_011519621.1:c.457G>A, XR_242702.2:n.554G>A, XR_930514.1:n.554G>A, XR_930515.1:n.554G>A, NM_001350965.1:c.457G>A, NM_001350966.1:c.112G>A, NM_001350967.1:c.97G>A, NR_146960.1:n.879G>A, NR_146961.1:n.908G>A, NR_146962.1:n.879G>A, XM_006717491.4:c.112G>A, XM_011519620.3:c.457G>A, XM_011519621.2:c.457G>A, XM_017016557.1:c.112G>A, XM_017016558.1:c.97G>A, XM_024448134.1:c.97G>A, XM_024448135.1:c.112G>A, XR_001747185.2:n.801G>A, XR_001747187.1:n.437G>A, XR_930515.2:n.801G>A, NM_001033857.3:c.97G>A, NM_001033858.3:c.97G>A, NM_001289076.2:c.112G>A, NM_001289077.2:c.97G>A, NM_001289078.2:c.112G>A, NM_001289079.2:c.97G>A, NM_001350965.2:c.457G>A, NM_001350966.2:c.112G>A, NM_001350967.2:c.97G>A, NM_022487.4:c.112G>A, NR_110297.2:n.755G>A, NR_146961.2:n.572G>A, NM_001033855.3(DCLRE1C):c.457G>A (p.Gly153Arg)	DCLRE1C	severe combined immunodeficiency due to DCLRE1C deficiency	MONDO:0011225	Autosomal recessive inheritance	Benign	BA1, BS2_Supporting	PS3	The c.457G>A (NM_001033855.3) variant in DCLRE1C is a missense variant predicted to cause the substitution of Glycine by Arginine at amino acid 153 (p.Gly153Arg).The filtering allele frequency (the lower threshold of the 95% CI of 2195/129158) of the c.457G>A variant in DCLRE1C is 0.01641 for  European (non-Finnish) chromosomes by gnomAD v2.1.1, which is higher than the ClinGen SCID VCEP threshold  >0.00346 for BA1, and therefore meets this criterion (BA1). Also, nineteen (19) adult homozygous individuals with this variant are present in gnomADv2.1.1 (European non-Finnish n=15, European (Finnish) n=1, Latino/Admixed American n=1, South Asian n=2)(BS2_Supporting).Additionally, a functional study showed non-dysfunction of V(D)J recombination and DNA repair (around 100% compared to wild type), and we do not find this variant described in patients with SCID due to DCLRE1C deficiency after a comprehensive literature search.In summary, this variant meets the criteria to be classified as Benign for autosomal recessive SCID based on the ACMG/AMP criteria applied, BA1 and BS2_Supporting, as specified by the ClinGen SCID VCEP (VCEP specifications version 1).	25917813	Severe Combined Immunodeficiency Disease  VCEP		2024-01-17	2024-01-17	False	https://erepo.genome.network/evrepo/ui/classification/CA213680/MONDO:0011225/116	a85e5f2e-f699-4ccb-b9a9-96bc25475fc4	p.Gly153Arg	Gly	153	Arg	MSSFEGQMAEYPTISIDRFDRENLRARAYFLSHCHKDHMKGLRAPTLKRRLECSLKVYLYCSPVTKELLLTSPKYRFWKKRIISIEIETPTQISLVDEASGEKEEIVVTLLPAGHCPGSVMFLFQGNNGTVLYTGDFRLAQGEAARMELLHSGGRVKDIQSVYLDTTFCDPRFYQIPSREECLSGVLELVRSWITRSPYHVVWLNCKAAYGYEYLFTNLSEELGVQVHVNKLDMFRNMPEILHHLTTDRNTQIHACRHPKAEEYFQWSKLPCGITSRNRIPLHIISIKPSTMWFGERSRKTNVIVRTGESSYRACFSFHSSYSEIKDFLSYLCPVNAYPNVIPVGTTMDKVVEILKPLCRSSQSTEPKYKPLGKLKRARTVHRDSEEEDDYLFDDPLPIPLRHKVPYPETFHPEVFSMTAVSEKQPEKLRQTPGCCRAECMQSSRFTNFVDCEESNSESEEEVGIPASLQGDLGSVLHLQKADGDVPQWEVFFKRNDEITDESLENFPSSTVAGGSQSPKLFSDSDGESTHISSQNSSQSTHITEQGSQGWDSQSDTVLLSSQERNSGDITSLDKADYRPTIKENIPASLMEQNVICPKDTYSDLKSRDKDVTIVPSTGEPTTLSSETHIPEEKSLLNLSTNADSQSSSDFEVPSTPEAELPKREHLQYLYEKLATGESIAVKKRKCSLLDT	692	Q96SD1	R	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [146], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.11961144]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [150, 152], 'DOMAIN_gain': [128, 189, 192], 'DOMAIN_gain_score': array([0.01222092, 0.04780072, 0.04569489]), 'DOMAIN_loss_score': array([-0.08639115, -0.13101435]), 'REGION_loss': [], 'REGION_gain': [616], 'REGION_gain_score': array([0.00230348]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
657	NM_001033855.3(DCLRE1C):c.194C>T (p.Thr65Ile)	254217	CA10586373	NM_001033855.3:c.194C>T, NC_000010.11:g.14945157G>A, CM000672.2:g.14945157G>A, NC_000010.10:g.14987156G>A, CM000672.1:g.14987156G>A, NC_000010.9:g.15027162G>A, NG_007276.1:g.13939C>T, LRG_54:g.13939C>T, ENST00000378278.7:c.194C>T, ENST00000357717.6:c.-44+3879C>T, ENST00000378241.5:c.-294C>T, ENST00000378246.6:c.-96C>T, ENST00000378249.5:c.-96C>T, ENST00000378254.5:c.-167C>T, ENST00000378255.5:c.-489C>T, ENST00000378258.5:c.-167C>T, ENST00000378278.6:c.194C>T, ENST00000378289.8:c.194C>T, ENST00000396817.6:c.-489C>T, ENST00000418843.5:c.-204C>T, ENST00000456122.1:c.-418C>T, NM_001033855.2:c.194C>T, NM_001033857.2:c.-167C>T, NM_001033858.2:c.-489C>T, NM_001289076.1:c.-44+3879C>T, NM_001289077.1:c.-167C>T, NM_001289078.1:c.-96C>T, NM_001289079.1:c.-489C>T, NM_022487.3:c.-96C>T, NR_110297.1:n.701C>T, XM_006717491.2:c.-96C>T, XM_011519616.1:c.-96C>T, XM_011519617.1:c.-96C>T, XM_011519618.1:c.-223C>T, XM_011519619.1:c.-167C>T, XM_011519620.1:c.194C>T, XM_011519621.1:c.194C>T, XR_242702.2:n.291C>T, XR_930514.1:n.291C>T, XR_930515.1:n.291C>T, NM_001350965.1:c.194C>T, NM_001350966.1:c.-96C>T, NM_001350967.1:c.-167C>T, NR_146960.1:n.616C>T, NR_146961.1:n.701C>T, NR_146962.1:n.616C>T, XM_006717491.4:c.-96C>T, XM_011519620.3:c.194C>T, XM_011519621.2:c.194C>T, XM_017016557.1:c.-223C>T, XM_017016558.1:c.-294C>T, XM_024448134.1:c.-167C>T, XM_024448135.1:c.-96C>T, XR_001747185.2:n.538C>T, XR_001747187.1:n.230C>T, XR_930515.2:n.538C>T, NM_001033857.3:c.-167C>T, NM_001033858.3:c.-489C>T, NM_001289076.2:c.-44+3879C>T, NM_001289077.2:c.-167C>T, NM_001289078.2:c.-96C>T, NM_001289079.2:c.-489C>T, NM_001350965.2:c.194C>T, NM_001350966.2:c.-96C>T, NM_001350967.2:c.-167C>T, NM_022487.4:c.-96C>T, NR_110297.2:n.365C>T, NR_146961.2:n.365C>T, NM_001033855.3(DCLRE1C):c.194C>T (p.Thr65Ile)	DCLRE1C	severe combined immunodeficiency due to DCLRE1C deficiency	MONDO:0011225	Autosomal recessive inheritance	Pathogenic	PP4_Moderate, PM2_Supporting, PM3_Strong, PP1_Strong	PS3	The c.194C>T(NM_001033855.3) variant in DCLRE1C is a missense variant predicted to cause substitution of Threonine by Isoleucine at amino acid 65 p.Thr65Ile.This variant is absent from gnomAD v2.1.1 (PM2_Supporting).This variant has been detected in at least 13 individuals with SCID/Lealy SCID/Omen. Of those individuals, 2 were compound heterozygous for the variant p.T577Nfs*21 (Likely Pathogenic according to the SCID VCEP specifications - confirmed in trans by family testing (PMID: 26476407, 2 pts). 10 individuals were homozygous for the variant (1 point limit was reached - PMID: 26476407) (PM3_moderate); For 1 individual (PMID: 25917813), the second allele information wasn't available. The variant has been reported to segregate with SCID in 7 affected family members from 3 families (Family A: Proband + 4; Family D: Proband + 2; Family E: Proband + 1 = 7 segregations, LOD: 4.21); PP1_Strong; PMID: 26476407). At least one patient with this variant displayed Vector-based complementation corrected increased cellular radiosensitivity and/or decreased V(D)J recombination (P1, 2 and 5, 2 pts, PMID:26476407, PP4_moderate).In summary, this variant meets the criteria to be classified as pathogenic for autosomal recessive SCID based on the ACMG/AMP criteria applied, PP4_Moderate, PP1_Strong, PM3_Strong, PM2_Supporting, as specified by the ClinGen SCID VCEP (VCEP specifications version 1).		Severe Combined Immunodeficiency Disease  VCEP		2024-01-17	2024-01-17	False	https://erepo.genome.network/evrepo/ui/classification/CA10586373/MONDO:0011225/116	3fe92f1e-0ee4-4f50-aaa3-923da18fc227	p.Thr65Ile	Thr	65	Ile	MSSFEGQMAEYPTISIDRFDRENLRARAYFLSHCHKDHMKGLRAPTLKRRLECSLKVYLYCSPVTKELLLTSPKYRFWKKRIISIEIETPTQISLVDEASGEKEEIVVTLLPAGHCPGSVMFLFQGNNGTVLYTGDFRLAQGEAARMELLHSGGRVKDIQSVYLDTTFCDPRFYQIPSREECLSGVLELVRSWITRSPYHVVWLNCKAAYGYEYLFTNLSEELGVQVHVNKLDMFRNMPEILHHLTTDRNTQIHACRHPKAEEYFQWSKLPCGITSRNRIPLHIISIKPSTMWFGERSRKTNVIVRTGESSYRACFSFHSSYSEIKDFLSYLCPVNAYPNVIPVGTTMDKVVEILKPLCRSSQSTEPKYKPLGKLKRARTVHRDSEEEDDYLFDDPLPIPLRHKVPYPETFHPEVFSMTAVSEKQPEKLRQTPGCCRAECMQSSRFTNFVDCEESNSESEEEVGIPASLQGDLGSVLHLQKADGDVPQWEVFFKRNDEITDESLENFPSSTVAGGSQSPKLFSDSDGESTHISSQNSSQSTHITEQGSQGWDSQSDTVLLSSQERNSGDITSLDKADYRPTIKENIPASLMEQNVICPKDTYSDLKSRDKDVTIVPSTGEPTTLSSETHIPEEKSLLNLSTNADSQSSSDFEVPSTPEAELPKREHLQYLYEKLATGESIAVKKRKCSLLDT	692	Q96SD1	I	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [50], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.05476511]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [5, 53, 66, 68, 117, 128, 149, 155, 160], 'DOMAIN_gain_score': array([0.04540968, 0.08492416, 0.08986074, 0.12638432, 0.04583633,
       0.04113215, 0.05376923, 0.0381766 , 0.03910971]), 'REGION_loss': [617, 619], 'REGION_gain': [], 'REGION_loss_score': array([-0.00248188, -0.00358748]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
658	NM_002185.5(IL7R):c.1241C>T (p.Thr414Met)	134536	CA160123	NM_002185.5:c.1241C>T, NC_000005.10:g.35876347C>T, CM000667.2:g.35876347C>T, NC_000005.9:g.35876449C>T, CM000667.1:g.35876449C>T, NC_000005.8:g.35912206C>T, NG_009567.1:g.24459C>T, LRG_74:g.24459C>T, ENST00000303115.8:c.1241C>T, ENST00000303115.7:c.1241C>T, ENST00000505093.1:c.556C>T, ENST00000505875.1:n.539C>T, ENST00000514217.5:c.*435C>T, NM_002185.3:c.1241C>T, NR_120485.1:n.1081C>T, NM_002185.4:c.1241C>T, NR_120485.2:n.1107C>T, XM_005248299.4:c.*358C>T, NR_120485.3:n.1065C>T, NM_002185.5(IL7R):c.1241C>T (p.Thr414Met)	IL7R	severe combined immunodeficiency, autosomal recessive, T cell-negative, B cell-positive, NK cell-positive	MONDO:0012163	Autosomal recessive inheritance	Benign	BA1, BS2_Supporting		The NM_002185.5(IL7R):c.1241C>T (p.Thr414Met) missense variant occurs at a frequency too high for the disease. The filtering allele frequency based on the South Asian population (upper bound of 95% CI of 1076/30502 observed alleles) is 0.03353 in gnomAD v2.1.1, which is above the SCID-VCEP BA1 threshold (>0.00566). Also, 46 adult homozygous individuals with this variant are present in gnomAD v2.1.1 (BS2_Supporting). In summary, this variant meets the criteria to be classified as Benign for autosomal recessive SCID based on the ACMG/AMP criteria applied, as specified by the ClinGen SCID VCEP. Criteria applied: BA1 and BS2_Supporting (SCID VCEP specifications version 1.0).		Severe Combined Immunodeficiency Disease  VCEP		2024-01-17	2024-01-17	False	https://erepo.genome.network/evrepo/ui/classification/CA160123/MONDO:0012163/119	d5b9112d-d56d-4e07-8713-01a5d04b0d59	p.Thr414Met	Thr	414	Met	MTILGTTFGMVFSLLQVVSGESGYAQNGDLEDAELDDYSFSCYSQLEVNGSQHSLTCAFEDPDVNITNLEFEICGALVEVKCLNFRKLQEIYFIETKKFLLIGKSNICVKVGEKSLTCKKIDLTTIVKPEAPFDLSVVYREGANDFVVTFNTSHLQKKYVKVLMHDVAYRQEKDENKWTHVNLSSTKLTLLQRKLQPAAMYEIKVRSIPDHYFKGFWSEWSPSYYFRTPEINNSSGEMDPILLTISILSFFSVALLVILACVLWKKRIKPIVWPSLPDHKKTLEHLCKKPRKNLNVSFNPESFLDCQIHRVDDIQARDEVEGFLQDTFPQQLEESEKQRLGGDVQSPNCPSEDVVITPESFGRDSSLTCLAGNVSACDAPILSSSRSLDCRESGKNGPHVYQDLLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQPILTSLGSNQEEAYVTMSSFYQNQ	459	P16871	M	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
659	NM_002185.5(IL7R):c.353G>A (p.Cys118Tyr)	36392	CA214043	NM_002185.5:c.353G>A, NC_000005.10:g.35867437G>A, CM000667.2:g.35867437G>A, NC_000005.9:g.35867539G>A, CM000667.1:g.35867539G>A, NC_000005.8:g.35903296G>A, NG_009567.1:g.15549G>A, LRG_74:g.15549G>A, ENST00000303115.8:c.353G>A, ENST00000303115.7:c.353G>A, ENST00000506850.5:c.353G>A, ENST00000511031.1:n.487G>A, ENST00000511982.1:c.353G>A, ENST00000514217.5:c.353G>A, NM_002185.3:c.353G>A, NR_120485.1:n.456G>A, XM_005248299.2:c.353G>A, XM_005248300.1:c.353G>A, XM_011514037.1:c.353G>A, NM_002185.4:c.353G>A, NR_120485.2:n.482G>A, XM_005248299.4:c.353G>A, NR_120485.3:n.440G>A, NM_002185.5(IL7R):c.353G>A (p.Cys118Tyr)	IL7R	severe combined immunodeficiency, autosomal recessive, T cell-negative, B cell-positive, NK cell-positive	MONDO:0012163	Autosomal recessive inheritance	Pathogenic	PP1, PM3_Very Strong, PM2_Supporting, PP4_Moderate		The missense variant NM_002185.5(IL7R):c.353G>A (p.Cys118Tyr) occurs at a low filtering allele frequency of 0.000009610 in gnomAD v2.1.1 (<0.00004129; PM2_Supporting). At least 14 SCID or Omenn syndrome patients have been reported with this variant in 10 publications (PMIDs: 35503492, 34573280, 27593400, 24759676, 16492442,15661025, 34153518, 17827065, 24578017, 27833609). Several have highly specific phenotypes which meet criteria for PP4 (PMIDs: 35503492, 24759676) and one patient (PMID: 27833609) had sufficient information to meet PP4_moderate; this patient fulfilled clinical and immunological parameters for severe combined immunodeficiency (SCID), with at T-B+NK+ subtype, absence of CD127 expression, and reduced f IL-7 induced pSTAT5 (Y694) in T-cells, which together are highly specific for IL7R-related SCID (PP4_moderate). Additionally, the variant has been reported to segregate with SCID in 2 affected family members from family 2 in PMID: 15661025 (PP1). Of the 14 patients, eight patients have been reported homozygous for this variant (PMIDs: 35503492, 34573280, 27593400, 24759676, 16492442,15661025; PM3) and six compound heterozygous; second variants were reported in P19 (PMID: 35503492) and the SCID patient reported in Zago CA et al. (PMID: 24759676) both harboring c.361dup without confirmation of trans phase (classified Pathogenic by the SCID VCEP; 0.5+0.5pt), the patients reported by Tsilifis C et al. (PMID: 34153518) and Butte MJ et al. (PMID: 17827065) both harbor c.379+288G>A confirmed in trans (provisionally classified by the SCID VCEP as VUS; 0.25+0.25pt), Case 1 (PMID: 24578017) has c.83-2A>T without confirmation of trans phase (provisionally classified as Pathogenic by the SCID VCEP; 0.5pt), and the patient reported by Gallego-Bustos F et al. (PMID: 27833609) has c.333T>A confirmed in trans (provisionally classified Likely Pathogenic by the SCID VCEP; 1pt), Total=4pts (PM3_VeryStrong). In summary, this variant meets the criteria to be classified as Pathogenic for autosomal recessive SCID based on the ACMG/AMP criteria applied, as specified by the ClinGen SCID VCEP. Criteria applied: PM2_supporting, PM3_VeryStrong, PP1, PP4_moderate. (SCID VCEP specifications version 1.0).		Severe Combined Immunodeficiency Disease  VCEP		2024-01-17	2024-01-17	False	https://erepo.genome.network/evrepo/ui/classification/CA214043/MONDO:0012163/119	27622bc8-a3f6-4be1-8586-efaffc7e60b2	p.Cys118Tyr	Cys	118	Tyr	MTILGTTFGMVFSLLQVVSGESGYAQNGDLEDAELDDYSFSCYSQLEVNGSQHSLTCAFEDPDVNITNLEFEICGALVEVKCLNFRKLQEIYFIETKKFLLIGKSNICVKVGEKSLTCKKIDLTTIVKPEAPFDLSVVYREGANDFVVTFNTSHLQKKYVKVLMHDVAYRQEKDENKWTHVNLSSTKLTLLQRKLQPAAMYEIKVRSIPDHYFKGFWSEWSPSYYFRTPEINNSSGEMDPILLTISILSFFSVALLVILACVLWKKRIKPIVWPSLPDHKKTLEHLCKKPRKNLNVSFNPESFLDCQIHRVDDIQARDEVEGFLQDTFPQQLEESEKQRLGGDVQSPNCPSEDVVITPESFGRDSSLTCLAGNVSACDAPILSSSRSLDCRESGKNGPHVYQDLLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQPILTSLGSNQEEAYVTMSSFYQNQ	459	P16871	Y	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [107, 117], 'DISULFID_gain': [], 'DISULFID_loss_score': array([-0.1483776, -0.5921008]), 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [114], 'STRAND_gain': [66, 124], 'STRAND_gain_score': array([0.02215779, 0.06402433]), 'STRAND_loss_score': array([-0.0298692]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
660	NM_000448.3(RAG1):c.577G>A (p.Glu193Lys)	304495	CA5950009	NM_000448.3:c.577G>A, NC_000011.10:g.36573881G>A, CM000673.2:g.36573881G>A, NC_000011.9:g.36595431G>A, CM000673.1:g.36595431G>A, NC_000011.8:g.36552007G>A, NG_007528.1:g.10869G>A, LRG_98:g.10869G>A, ENST00000299440.6:c.577G>A, ENST00000299440.5:c.577G>A, ENST00000534663.1:c.577G>A, NM_000448.2:c.577G>A, LRG_98t1:c.577G>A, XM_005253041.3:c.577G>A, XM_011520250.1:c.577G>A, XM_011520251.1:c.577G>A, XM_005253041.4:c.577G>A, XM_011520250.2:c.577G>A, NM_001377277.1:c.577G>A, NM_001377278.1:c.577G>A, NM_001377279.1:c.577G>A, NM_001377280.1:c.577G>A, NM_000448.3(RAG1):c.577G>A (p.Glu193Lys)	RAG1	recombinase activating gene 1 deficiency	MONDO:0000572	Autosomal recessive inheritance	Benign	BS2_Supporting, BA1		The c.577G>A (NM_000448.3) variant in RAG1 is a missense variant predicted to cause the substitution of Glutamic Acid by Lysine at amino acid 193 (p.Glu193Lys).The filtering allele frequency (the lower threshold of the 95% CI of 772/30614) of the c.577G>A variant in RAG1 is 0.02374 for South Asian chromosomes by gnomAD v2.1.1, which is higher than the ClinGen SCID VCEP threshold (>0.00872) for BA1, and therefore meets this criterion (BA1). 12 adult homozygous reported on GnomAD v2.1.1, BS2_Supporting is Met.In summary, this variant meets the criteria to be classified as Benign for autosomal recessive SCID based on the ACMG/AMP criteria applied, BA1 and BS2_Supporting, as specified by the ClinGen SCID VCEP (VCEP specifications version 1).		Severe Combined Immunodeficiency Disease  VCEP		2024-01-17	2024-01-17	False	https://erepo.genome.network/evrepo/ui/classification/CA5950009/MONDO:0000572/123	cb12f728-a219-4fd7-978f-b87b9a154e56	p.Glu193Lys	Glu	193	Lys	MAASFPPTLGLSSAPDEIQHPHIKFSEWKFKLFRVRSFEKTPEEAQKEKKDSFEGKPSLEQSPAVLDKADGQKPVPTQPLLKAHPKFSKKFHDNEKARGKAIHQANLRHLCRICGNSFRADEHNRRYPVHGPVDGKTLGLLRKKEKRATSWPDLIAKVFRIDVKADVDSIHPTEFCHNCWSIMHRKFSSAPCEVYFPRNVTMEWHPHTPSCDICNTARRGLKRKSLQPNLQLSKKLKTVLDQARQARQHKRRAQARISSKDVMKKIANCSKIHLSTKLLAVDFPEHFVKSISCQICEHILADPVETNCKHVFCRVCILRCLKVMGSYCPSCRYPCFPTDLESPVKSFLSVLNSLMVKCPAKECNEEVSLEKYNHHISSHKESKEIFVHINKGGRPRQHLLSLTRRAQKHRLRELKLQVKAFADKEEGGDVKSVCMTLFLLALRARNEHRQADELEAIMQGKGSGLQPAVCLAIRVNTFLSCSQYHKMYRTVKAITGRQIFQPLHALRNAEKVLLPGYHHFEWQPPLKNVSSSTDVGIIDGLSGLSSSVDDYPVDTIAKRFRYDSALVSALMDMEEDILEGMRSQDLDDYLNGPFTVVVKESCDGMGDVSEKHGSGPVVPEKAVRFSFTIMKITIAHSSQNVKVFEEAKPNSELCCKPLCLMLADESDHETLTAILSPLIAEREAMKSSELMLELGGILRTFKFIFRGTGYDEKLVREVEGLEASGSVYICTLCDATRLEASQNLVFHSITRSHAENLERYEVWRSNPYHESVEELRDRVKGVSAKPFIETVPSIDALHCDIGNAAEFYKIFQLEIGEVYKNPNASKEERKRWQATLDKHLRKKMNLKPIMRMNGNFARKLMTKETVDAVCELIPSEERHEALRELMDLYLKMKPVWRSSCPAKECPESLCQYSFNSQRFAELLSTKFKYRYEGKITNYFHKTLAHVPEIIERDGSIGAWASEGNESGNKLFRRFRKMNARQSKCYEMEDVLKHHWLYTSKYLQKFMNAHNALKTSGFTMNPQASLGDPLGIEDSLESQDSMEF	1043	P15918	K	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [4], 'TRANSIT_gain': [], 'TRANSIT_loss_score': array([-0.00604486]), 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [632], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.00266051]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
661	NM_000448.3(RAG1):c.906C>A (p.Asp302Glu)	36715	CA214206	NM_000448.3:c.906C>A, NC_000011.10:g.36574210C>A, CM000673.2:g.36574210C>A, NC_000011.9:g.36595760C>A, CM000673.1:g.36595760C>A, NC_000011.8:g.36552336C>A, NG_007528.1:g.11198C>A, LRG_98:g.11198C>A, ENST00000299440.6:c.906C>A, ENST00000299440.5:c.906C>A, ENST00000534663.1:c.906C>A, NM_000448.2:c.906C>A, LRG_98t1:c.906C>A, XM_005253041.3:c.906C>A, XM_011520250.1:c.906C>A, XM_011520251.1:c.906C>A, XM_005253041.4:c.906C>A, XM_011520250.2:c.906C>A, NM_001377277.1:c.906C>A, NM_001377278.1:c.906C>A, NM_001377279.1:c.906C>A, NM_001377280.1:c.906C>A, NM_000448.3(RAG1):c.906C>A (p.Asp302Glu)	RAG1	recombinase activating gene 1 deficiency	MONDO:0000572	Autosomal recessive inheritance	Benign	BA1		The c.906C>A (NM_000448.3) variant in RAG1 is a missense variant predicted to cause substitution of Aspartic Acid by Glutamic Acid at amino acid 302 (p.Asp302Glu).The filtering allele frequency (the lower threshold of the 95% CI of 1968/24958) of the c.906C>A variant in RAG1 is 0.07684 for African/African American chromosomes by gnomAD v2.1.1, which is higher than the ClinGen SCID VCEP threshold (>0.00872) for BA1, and therefore meets this criterion (BA1).In summary, this variant meets the criteria to be classified as Benign for autosomal recessive SCID based on the ACMG/AMP criteria applied, BA1, as specified by the ClinGen SCID VCEP (VCEP specifications version 1).		Severe Combined Immunodeficiency Disease  VCEP		2024-01-17	2024-01-17	False	https://erepo.genome.network/evrepo/ui/classification/CA214206/MONDO:0000572/123	81a9682b-1815-4c02-ac77-a69b610f573b	p.Asp302Glu	Asp	302	Glu	MAASFPPTLGLSSAPDEIQHPHIKFSEWKFKLFRVRSFEKTPEEAQKEKKDSFEGKPSLEQSPAVLDKADGQKPVPTQPLLKAHPKFSKKFHDNEKARGKAIHQANLRHLCRICGNSFRADEHNRRYPVHGPVDGKTLGLLRKKEKRATSWPDLIAKVFRIDVKADVDSIHPTEFCHNCWSIMHRKFSSAPCEVYFPRNVTMEWHPHTPSCDICNTARRGLKRKSLQPNLQLSKKLKTVLDQARQARQHKRRAQARISSKDVMKKIANCSKIHLSTKLLAVDFPEHFVKSISCQICEHILADPVETNCKHVFCRVCILRCLKVMGSYCPSCRYPCFPTDLESPVKSFLSVLNSLMVKCPAKECNEEVSLEKYNHHISSHKESKEIFVHINKGGRPRQHLLSLTRRAQKHRLRELKLQVKAFADKEEGGDVKSVCMTLFLLALRARNEHRQADELEAIMQGKGSGLQPAVCLAIRVNTFLSCSQYHKMYRTVKAITGRQIFQPLHALRNAEKVLLPGYHHFEWQPPLKNVSSSTDVGIIDGLSGLSSSVDDYPVDTIAKRFRYDSALVSALMDMEEDILEGMRSQDLDDYLNGPFTVVVKESCDGMGDVSEKHGSGPVVPEKAVRFSFTIMKITIAHSSQNVKVFEEAKPNSELCCKPLCLMLADESDHETLTAILSPLIAEREAMKSSELMLELGGILRTFKFIFRGTGYDEKLVREVEGLEASGSVYICTLCDATRLEASQNLVFHSITRSHAENLERYEVWRSNPYHESVEELRDRVKGVSAKPFIETVPSIDALHCDIGNAAEFYKIFQLEIGEVYKNPNASKEERKRWQATLDKHLRKKMNLKPIMRMNGNFARKLMTKETVDAVCELIPSEERHEALRELMDLYLKMKPVWRSSCPAKECPESLCQYSFNSQRFAELLSTKFKYRYEGKITNYFHKTLAHVPEIIERDGSIGAWASEGNESGNKLFRRFRKMNARQSKCYEMEDVLKHHWLYTSKYLQKFMNAHNALKTSGFTMNPQASLGDPLGIEDSLESQDSMEF	1043	P15918	E	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [433], 'TRANSMEM_gain': [], 'TRANSMEM_loss_score': array([-0.00410616]), 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [284, 913], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.00865543, -0.00510019]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [781], 'DOMAIN_gain_score': array([0.00430799]), 'REGION_loss': [], 'REGION_gain': [80], 'REGION_gain_score': array([0.00257337]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
662	NM_000448.3(RAG1):c.1331C>T (p.Ala444Val)	68681	CA219800	NM_000448.3:c.1331C>T, NC_000011.10:g.36574635C>T, CM000673.2:g.36574635C>T, NC_000011.9:g.36596185C>T, CM000673.1:g.36596185C>T, NC_000011.8:g.36552761C>T, NG_007528.1:g.11623C>T, LRG_98:g.11623C>T, ENST00000299440.6:c.1331C>T, ENST00000299440.5:c.1331C>T, ENST00000534663.1:c.1331C>T, NM_000448.2:c.1331C>T, LRG_98t1:c.1331C>T, XM_005253041.3:c.1331C>T, XM_011520250.1:c.1331C>T, XM_011520251.1:c.1331C>T, XM_005253041.4:c.1331C>T, XM_011520250.2:c.1331C>T, NM_001377277.1:c.1331C>T, NM_001377278.1:c.1331C>T, NM_001377279.1:c.1331C>T, NM_001377280.1:c.1331C>T, NM_000448.3(RAG1):c.1331C>T (p.Ala444Val)	RAG1	recombinase activating gene 1 deficiency	MONDO:0000572	Autosomal recessive inheritance	Pathogenic	PM3_Strong, PP4, PM2_Supporting, PS3_Moderate, PM1		The NM_000448.3(RAG1):c.1331C>T (p.Ala444Val) missense variant occurs in the NBD domain (amino acids 394-460), which is defined as a critical functional domain by the ClinGen SCID VCEP (PMID: 26996199; PM1). The popmax allele frequency is 0.00003266 (1/30614 alleles) in the South Asisan population, which is below the SCID VCEP established threshold of <0.000102 (PM2_supporting). At least 11 patients have been reported with this variant (PMIDs: 26596586, 24290284, 23085344, 17572155, 11133745, 36596882, 29410113), including patient 11 of PMID: 26596586 whom meets diagnostic criteria for SCID with a T-B-NK+ lymphocyte subset profile which is specific to recombinase activating gene 1 deficiency (PP4). Six patients are homozygous for this variant (PMIDs: 24290284, 17572155,11133745; 1pt maximum) and five are compound heterozygous (PMIDs: 26596586, 23085344, 11133745, 36596882, 29410113), harboring this variant as well as c.256_257 (provisionally classified Pathogenic by the SCID VCEP; 1+0.5pt), Val433Met, Lys992Glu, or c.2018_2025del. Total 2.5pt (PM3_Strong).  Functional studies have shown a deleterious effect of this variant, significantly reducing function of the V(D)J recombination activity; mean recombination activity for Ala444Val was 1.4% of wild type +/- 0.2 (PMID: 24290284; PS3_moderate). In summary, this variant meets the criteria to be classified as pathogenic for recombinase activating gene 1 deficiency based on the ACMG/AMP criteria applied, as specified by the ClinGen SCID VCEP. Criteria applied: PM1, PM2_supporting, PP4, PM3_Strong, PS3_Moderate. (VCEP specifications version 1).		Severe Combined Immunodeficiency Disease  VCEP		2024-01-17	2024-01-17	False	https://erepo.genome.network/evrepo/ui/classification/CA219800/MONDO:0000572/123	4c48f76d-1958-49ce-9365-ac8fe43b0175	p.Ala444Val	Ala	444	Val	MAASFPPTLGLSSAPDEIQHPHIKFSEWKFKLFRVRSFEKTPEEAQKEKKDSFEGKPSLEQSPAVLDKADGQKPVPTQPLLKAHPKFSKKFHDNEKARGKAIHQANLRHLCRICGNSFRADEHNRRYPVHGPVDGKTLGLLRKKEKRATSWPDLIAKVFRIDVKADVDSIHPTEFCHNCWSIMHRKFSSAPCEVYFPRNVTMEWHPHTPSCDICNTARRGLKRKSLQPNLQLSKKLKTVLDQARQARQHKRRAQARISSKDVMKKIANCSKIHLSTKLLAVDFPEHFVKSISCQICEHILADPVETNCKHVFCRVCILRCLKVMGSYCPSCRYPCFPTDLESPVKSFLSVLNSLMVKCPAKECNEEVSLEKYNHHISSHKESKEIFVHINKGGRPRQHLLSLTRRAQKHRLRELKLQVKAFADKEEGGDVKSVCMTLFLLALRARNEHRQADELEAIMQGKGSGLQPAVCLAIRVNTFLSCSQYHKMYRTVKAITGRQIFQPLHALRNAEKVLLPGYHHFEWQPPLKNVSSSTDVGIIDGLSGLSSSVDDYPVDTIAKRFRYDSALVSALMDMEEDILEGMRSQDLDDYLNGPFTVVVKESCDGMGDVSEKHGSGPVVPEKAVRFSFTIMKITIAHSSQNVKVFEEAKPNSELCCKPLCLMLADESDHETLTAILSPLIAEREAMKSSELMLELGGILRTFKFIFRGTGYDEKLVREVEGLEASGSVYICTLCDATRLEASQNLVFHSITRSHAENLERYEVWRSNPYHESVEELRDRVKGVSAKPFIETVPSIDALHCDIGNAAEFYKIFQLEIGEVYKNPNASKEERKRWQATLDKHLRKKMNLKPIMRMNGNFARKLMTKETVDAVCELIPSEERHEALRELMDLYLKMKPVWRSSCPAKECPESLCQYSFNSQRFAELLSTKFKYRYEGKITNYFHKTLAHVPEIIERDGSIGAWASEGNESGNKLFRRFRKMNARQSKCYEMEDVLKHHWLYTSKYLQKFMNAHNALKTSGFTMNPQASLGDPLGIEDSLESQDSMEF	1043	P15918	V	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [426, 427, 428, 429, 430, 431, 432, 435, 440, 441], 'TRANSMEM_gain_score': array([0.11409867, 0.11248016, 0.11580092, 0.12298417, 0.13244236,
       0.12749797, 0.12586218, 0.1262725 , 0.07428002, 0.08959103]), 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [4], 'TRANSIT_gain': [], 'TRANSIT_loss_score': array([-0.00421405]), 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [575], 'HELIX_gain_score': array([0.00770015]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [632, 725], 'DOMAIN_gain': [178], 'DOMAIN_gain_score': array([0.02046198]), 'DOMAIN_loss_score': array([-0.00673306, -0.01112384]), 'REGION_loss': [], 'REGION_gain': [80], 'REGION_gain_score': array([0.0030238]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
663	NM_000536.4(RAG2):c.686G>A (p.Arg229Gln)	13130	CA122854	NM_000536.4:c.686G>A, NC_000011.10:g.36593483C>T, CM000673.2:g.36593483C>T, NC_000011.9:g.36615033C>T, CM000673.1:g.36615033C>T, NC_000011.8:g.36571609C>T, NG_007573.1:g.9754G>A, LRG_99:g.9754G>A, NG_033154.1:g.3991C>T, ENST00000311485.8:c.686G>A, ENST00000311485.7:c.686G>A, ENST00000524423.1:n.131+4619G>A, ENST00000618712.4:c.686G>A, NM_000536.3:c.686G>A, NM_001243785.1:c.686G>A, NM_001243786.1:c.686G>A, NM_001243785.2:c.686G>A, NM_001243786.2:c.686G>A, NM_000536.4(RAG2):c.686G>A (p.Arg229Gln)	RAG2	recombinase activating gene 2 deficiency	MONDO:0000573	Autosomal recessive inheritance	Pathogenic	PM1_Supporting, PS3, PM3, PP4, PP1, PM2_Supporting		The c.686G>A (NM_000536.4) variant in RAG2 is a missense variant predicted to cause the substitution of arginine by glycine at amino acid 229 (p.Arg229Gln). The filtering allele frequency (the upper threshold of the 95% CI of 2/113660) of the c.686G>A variant in RAG2 is 0.000002920 for European (non-Finnish) chromosomes by gnomAD v2.1.1, which is lower than the ClinGen SCID VCEP threshold (<0.0000588) for PM2_Supporting, and therefore meets this criterion (PM2_Supporting). This variant resides within a region, amino acids 1-383, of RAG2 that is defined as a critical functional domain by the ClinGen SCID VCEP (PMID: 26996199) (PM1_Supporting). At least one patient with this variant displayed: Diagnostic criteria for SCID/Leaky SCID/Omenn syndrome met (0.5pt) + T-B-NK+ lymphocyte subset profile (0.5pt) total 1 pt, which is highly specific for SCID (PP4, PMID: 30307608). The variant showed disrupted V(D)J recombination activity at 8.9% of WT-RAG2 (PMID: 29772310). Additionally, an animal model homozygous for the variant recapitulates most phenotypes associated with OS (PMID: 17476358) (PS3). The variant has been reported to segregate with SCID in 02 affected siblings from one family (Proband + one) (PP1_Supporting; PMID: 30307608). Five patients (14–18) were homozygous for the variant (reaching the maximum 1 pt) PM3_Moderate (PMID: 30307608).In summary, this variant meets the criteria to be classified as pathogenic for AR  SCID. ACMG/AMP criteria applied, as specified by the ClinGen SCID VCEP: PM2_Supporting, PP4, PM3_Moderate, PS3, PP1, and PM1_Supporting. (VCEP specifications version  1).	17476358	Severe Combined Immunodeficiency Disease  VCEP		2024-01-17	2024-01-17	False	https://erepo.genome.network/evrepo/ui/classification/CA122854/MONDO:0000573/124	fd98b152-9eb9-4af8-805c-30689fa24066	p.Arg229Gln	Arg	229	Gln	MSLQMVTVSNNIALIQPGFSLMNFDGQVFFFGQKGWPKRSCPTGVFHLDVKHNHVKLKPTIFSKDSCYLPPLRYPATCTFKGSLESEKHQYIIHGGKTPNNEVSDKIYVMSIVCKNNKKVTFRCTEKDLVGDVPEARYGHSINVVYSRGKSMGVLFGGRSYMPSTHRTTEKWNSVADCLPCVFLVDFEFGCATSYILPELQDGLSFHVSIAKNDTIYILGGHSLANNIRPANLYRIRVDLPLGSPAVNCTVLPGGISVSSAILTQTNNDEFVIVGGYQLENQKRMICNIISLEDNKIEIREMETPDWTPDIKHSKIWFGSNMGNGTVFLGIPGDNKQVVSEGFYFYMLKCAEDDTNEEQTTFTNSQTSTEDPGDSTPFEDSEEFCFSAEANSFDGDDEFDTYNEDDEEDESETGYWITCCPTCDVDINTWVPFYSTELNKPAMIYCSHGDGHWVHAQCMDLAERTLIHLSAGSNKYYCNEHVEIARALHTPQRVLPLKKPPMKSLRKKGSGKILTPAKKSFLRRLFD	527	P55895	Q	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
664	NM_000536.4(RAG2):c.1158C>A (p.Phe386Leu)	138887	CA293061	NM_000536.4:c.1158C>A, NC_000011.10:g.36593011G>T, CM000673.2:g.36593011G>T, NC_000011.9:g.36614561G>T, CM000673.1:g.36614561G>T, NC_000011.8:g.36571137G>T, NG_007573.1:g.10226C>A, LRG_99:g.10226C>A, NG_033154.1:g.3519G>T, ENST00000311485.8:c.1158C>A, ENST00000311485.7:c.1158C>A, ENST00000524423.1:n.131+5091C>A, ENST00000534663.1:c.*130G>T, ENST00000618712.4:c.1158C>A, NM_000536.3:c.1158C>A, NM_001243785.1:c.1158C>A, NM_001243786.1:c.1158C>A, NM_001243785.2:c.1158C>A, NM_001243786.2:c.1158C>A, NM_000536.4(RAG2):c.1158C>A (p.Phe386Leu)	RAG2	recombinase activating gene 2 deficiency	MONDO:0000573	Autosomal recessive inheritance	Benign	BA1, BS2_Supporting		The NM_000536.4:c.1158C>A variant in RAG2 is a missense variant predicted to cause substitution of phenylalanine by leucine at amino acid 386 (p.Phe386Leu). This variant has a population max filtering allele frequency of 0.01649 in the European (non-Finnish) population in gnomAD, which is above the threshold for BA1 set by the ClinGen SCID VCEP for RAG2 (>0.00872). In addition, this variant is present in 23 homozygotes in gnomAD (BS2_Supporting). In summary, this variant meets the criteria to be classified as Benign for autosomal recessive SCID based on the ACMG criteria applied: BA1 and BS2_Supporting as specified by the ClinGen SCID VCEP (VCEP specifications version 1).		Severe Combined Immunodeficiency Disease  VCEP		2024-01-17	2024-01-17	False	https://erepo.genome.network/evrepo/ui/classification/CA293061/MONDO:0000573/124	85a75daf-5427-494d-a55d-98c8fa7e91d5	p.Phe386Leu	Phe	386	Leu	MSLQMVTVSNNIALIQPGFSLMNFDGQVFFFGQKGWPKRSCPTGVFHLDVKHNHVKLKPTIFSKDSCYLPPLRYPATCTFKGSLESEKHQYIIHGGKTPNNEVSDKIYVMSIVCKNNKKVTFRCTEKDLVGDVPEARYGHSINVVYSRGKSMGVLFGGRSYMPSTHRTTEKWNSVADCLPCVFLVDFEFGCATSYILPELQDGLSFHVSIAKNDTIYILGGHSLANNIRPANLYRIRVDLPLGSPAVNCTVLPGGISVSSAILTQTNNDEFVIVGGYQLENQKRMICNIISLEDNKIEIREMETPDWTPDIKHSKIWFGSNMGNGTVFLGIPGDNKQVVSEGFYFYMLKCAEDDTNEEQTTFTNSQTSTEDPGDSTPFEDSEEFCFSAEANSFDGDDEFDTYNEDDEEDESETGYWITCCPTCDVDINTWVPFYSTELNKPAMIYCSHGDGHWVHAQCMDLAERTLIHLSAGSNKYYCNEHVEIARALHTPQRVLPLKKPPMKSLRKKGSGKILTPAKKSFLRRLFD	527	P55895	L	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [21], 'TOPO_DOM_gain_score': array([0.00774628]), 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [88], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.00328577]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [54, 63, 143], 'REPEAT_gain_score': array([0.00631267, 0.00946832, 0.00684577]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
665	NM_000536.4(RAG2):c.1352G>C (p.Gly451Ala)	13138	CA122872	NM_000536.4:c.1352G>C, NC_000011.10:g.36592817C>G, CM000673.2:g.36592817C>G, NC_000011.9:g.36614367C>G, CM000673.1:g.36614367C>G, NC_000011.8:g.36570943C>G, NG_007573.1:g.10420G>C, LRG_99:g.10420G>C, NG_033154.1:g.3325C>G, ENST00000311485.8:c.1352G>C, ENST00000311485.7:c.1352G>C, ENST00000524423.1:n.131+5285G>C, ENST00000534663.1:c.*86-150C>G, ENST00000618712.4:c.1352G>C, NM_000536.3:c.1352G>C, NM_001243785.1:c.1352G>C, NM_001243786.1:c.1352G>C, NM_001243785.2:c.1352G>C, NM_001243786.2:c.1352G>C, NM_000536.4(RAG2):c.1352G>C (p.Gly451Ala)	RAG2	recombinase activating gene 2 deficiency	MONDO:0000573	Autosomal recessive inheritance	Pathogenic	PP1_Strong, PS3_Supporting, PM1, PM3, PP4, PM2_Supporting	BS2	The NM_000536.4:c.1352G>C variant in RAG2 is a missense variant predicted to cause the substitution of glycine by alanine at amino acid 451 (p.Gly451Ala). The variant has been identified in at least 8 individuals. Three individuals described by Dr. Jolan were homozygous for this variant (reaching the maximum of 1 pt for homozygous occurrence). One individual with Omenn Syndrome was heterozygous for this variant and a p.R229Q variant, which is classified as pathogenic according to the SCID VCEP specifications. The trans phase was not confirmed (0.5 points, PMID 32655540). One individual with CID was heterozygous for this variant, and p.M459L, a likely pathogenic variant classified by the SCID VCEP. The trans phase was not confirmed (0.25pt, PMID 26457731). Three other individuals were heterozygous for this variant and a VUS (p.I210T, PMID 31334206; p.G32E, PMID 26457731; p.T77N, PMID 18463379, 24331380, 26457731, 29772310). 1.75 points in total, PM3 is met.These three homozygous individuals described by Dr. Jolan are from the same family: 3 affected segregations, LOD score 1.81, PP1_Strong. The filtering allele frequency (the upper threshold of the 95% CI of 9/129174 alleles) of this variant in gnomAD v.2.1.1 is 0.00003418 for European (non-Finnish) chromosomes, which is lower than the ClinGen SCID VCEP threshold (<0.0000588) for PM2_Supporting, and therefore meets this criterion (PM2_Supporting)This variant resides within the PHD domain region, amino acids 414-487, of RAG2, defined as a critical functional domain by the ClinGen SCID VCEP (PM1). In one study (PMID 29772310), a recombination activity assay shows that the relevant activity of the p.G451A variant to wildtype RAG2 is 66.3%, which is higher than the SCID VCEP threshold (<60%) for PS3_supporting. However, in two other studies (PMID 18463379, 24331380), the relevant activity of the variant is shown to be 30% and 27.6%, respectively, which falls in the SCID VCEP threshold (>25% and <60%) for PS3_supporting (PS3_Supporting). Diagnostic criteria for SCID/Leaky SCID/Omenn syndrome met 0.5pts + SCID gene panel or exome/genome sequencing conducted 0.5pts; the total is 1 point, PP4 is met (PMID: 32655540).In summary, this variant meets the criteria to be classified as Pathogenic for SCID due to recombinase activating gene 2 deficiency. ACMG/AMP criteria applied, as specified by the ClinGen SCID-VCEP: PM3, PM2_Supporting, PM1, PS3_Supporting, PP4, and PP1_Strong. (VCEP specifications version 1.0).	18463379	Severe Combined Immunodeficiency Disease  VCEP		2024-01-17	2024-01-17	False	https://erepo.genome.network/evrepo/ui/classification/CA122872/MONDO:0000573/124	94790ef3-57d4-4eb4-9217-50749c0f1d36	p.Gly451Ala	Gly	451	Ala	MSLQMVTVSNNIALIQPGFSLMNFDGQVFFFGQKGWPKRSCPTGVFHLDVKHNHVKLKPTIFSKDSCYLPPLRYPATCTFKGSLESEKHQYIIHGGKTPNNEVSDKIYVMSIVCKNNKKVTFRCTEKDLVGDVPEARYGHSINVVYSRGKSMGVLFGGRSYMPSTHRTTEKWNSVADCLPCVFLVDFEFGCATSYILPELQDGLSFHVSIAKNDTIYILGGHSLANNIRPANLYRIRVDLPLGSPAVNCTVLPGGISVSSAILTQTNNDEFVIVGGYQLENQKRMICNIISLEDNKIEIREMETPDWTPDIKHSKIWFGSNMGNGTVFLGIPGDNKQVVSEGFYFYMLKCAEDDTNEEQTTFTNSQTSTEDPGDSTPFEDSEEFCFSAEANSFDGDDEFDTYNEDDEEDESETGYWITCCPTCDVDINTWVPFYSTELNKPAMIYCSHGDGHWVHAQCMDLAERTLIHLSAGSNKYYCNEHVEIARALHTPQRVLPLKKPPMKSLRKKGSGKILTPAKKSFLRRLFD	527	P55895	A	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [21], 'TOPO_DOM_gain_score': array([0.00565845]), 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [88], 'STRAND_gain': [444], 'STRAND_gain_score': array([0.08449858]), 'STRAND_loss_score': array([-0.00531769]), 'HELIX_loss': [479], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.03522778]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [54, 63, 65, 140, 143], 'REPEAT_gain_score': array([0.01150787, 0.01803768, 0.01677275, 0.01235843, 0.01163131]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
666	NM_000206.3(IL2RG):c.325G>A (p.Glu109Lys)	368619	CA10443889	NM_000206.3:c.325G>A, NC_000023.11:g.71110633C>T, CM000685.2:g.71110633C>T, NC_000023.10:g.70330483C>T, CM000685.1:g.70330483C>T, NC_000023.9:g.70247208C>T, NG_009088.1:g.5921G>A, LRG_150:g.5921G>A, NG_021141.1:g.1156G>A, ENST00000374202.7:c.325G>A, ENST00000642473.1:n.689G>A, ENST00000644022.1:n.731G>A, ENST00000644708.1:n.731G>A, ENST00000644911.1:n.731G>A, ENST00000645266.1:c.325G>A, ENST00000645518.1:c.325G>A, ENST00000646106.1:c.325G>A, ENST00000646505.1:c.325G>A, ENST00000647492.1:c.325G>A, ENST00000276110.6:n.710G>A, ENST00000374188.7:c.-392G>A, ENST00000374202.6:c.325G>A, ENST00000456850.6:c.24+792G>A, ENST00000464642.5:c.193G>A, ENST00000473378.1:c.262G>A, ENST00000487883.1:c.289G>A, ENST00000512747.3:n.392G>A, NM_000206.2:c.325G>A, LRG_150t1:c.325G>A, NM_000206.3(IL2RG):c.325G>A (p.Glu109Lys)	IL2RG	T-B+ severe combined immunodeficiency due to gamma chain deficiency	MONDO:0010315	X-linked inheritance (recessive (HP:0001419))	Benign	BS1, BS2	PM2, BP4	The NM_000206.3(IL2RG):c.325G>A (p.Glu109Lys) is a missense variant that has been reported in ClinVar, without patient information, however it has not been reported in the literature to our knowledge. It occurs at an intermediate allele frequency, with a popmax filtering allele frequency in gnomAD v2.1.1 of  0.0006719 (based on 74/92629 alleles in the non-Finnish European population) which is below the SCID VCEP established threshold of >0.00249 for BS1 and above the PM2 threshold of <0.000124. However, the highest MAF is in the Finnish population at 0.004561 (85/18638 alleles, 28 hemizygotes and 1 homozygote) which is above the SCID VCEP established threshold of >0.00249. As this population is not known to have a higher prevalence of this is considered to meet BS1. Sixty-two adult hemizygous males with this variant are present in the gnomADv2.1.1 dataset as well as a homozygous female (BS2). In summary, this variant is classified as Benign. Criteria applied: BS1, BS2 (VCEP specifications version 1).		Severe Combined Immunodeficiency Disease  VCEP		2024-01-17	2024-01-17	False	https://erepo.genome.network/evrepo/ui/classification/CA10443889/MONDO:0010315/129	665bca67-f957-4531-87d1-b052b7e0f034	p.Glu109Lys	Glu	109	Lys	MLKPSLPFTSLLFLQLPLLGVGLNTTILTPNGNEDTTADFFLTTMPTDSLSVSTLPLPEVQCFVFNVEYMNCTWNSSSEPQPTNLTLHYWYKNSDNDKVQKCSHYLFSEEITSGCQLQKKEIHLYQTFVVQLQDPREPRRQATQMLKLQNLVIPWAPENLTLHKLSESQLELNWNNRFLNHCLEHLVQYRTDWDHSWTEQSVDYRHKFSLPSVDGQKRYTFRVRSRFNPLCGSAQHWSEWSHPIHWGSNTSKENPFLFALEAVVISVGSMGLIISLLCVYFWLERTMPRIPTLKNLEDLVTEYHGNFSAWSGVSKGLAESLQPDYSERLCLVSEIPPKGGALGEGPGASPCNQHSPYWAPPCYTLKPET	369	P31785	K	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
667	NM_000206.3(IL2RG):c.676C>T (p.Arg226Cys)	225195	CA358784	NM_000206.3:c.676C>T, NC_000023.11:g.71109309G>A, CM000685.2:g.71109309G>A, NC_000023.10:g.70329159G>A, CM000685.1:g.70329159G>A, NC_000023.9:g.70245884G>A, NG_009088.1:g.7245C>T, LRG_150:g.7245C>T, NG_021141.1:g.2480C>T, ENST00000374202.7:c.676C>T, ENST00000642473.1:n.1040C>T, ENST00000644022.1:n.942C>T, ENST00000644708.1:n.1082C>T, ENST00000644911.1:n.1082C>T, ENST00000645266.1:c.676C>T, ENST00000645518.1:c.676C>T, ENST00000646106.1:c.676C>T, ENST00000646505.1:c.676C>T, ENST00000647492.1:c.676C>T, ENST00000276110.6:n.1269C>T, ENST00000374188.7:c.-41C>T, ENST00000374202.6:c.676C>T, ENST00000456850.6:c.106C>T, ENST00000464642.5:c.544C>T, ENST00000482750.5:c.89C>T, ENST00000512747.3:n.603C>T, NM_000206.2:c.676C>T, LRG_150t1:c.676C>T, NM_000206.3(IL2RG):c.676C>T (p.Arg226Cys)	IL2RG	T-B+ severe combined immunodeficiency due to gamma chain deficiency	MONDO:0010315	X-linked inheritance (recessive (HP:0001419))	Pathogenic	PS3_Supporting, PM6, PP4, PM2_Supporting, PS4, PM1_Strong	PP3, PM5	The NM_000206.3(IL2RG):c.676C>T (p.Arg226Cys) missense variant resides within a CpG dinucleotide region, cDNA 676-677 encoding amino acid R226, of IL2RG that is defined as a mutational hotspot (PMID: 7668284; PM1_Strong). This variant is absent from gnomAD v2.1.1 (PM2_Supporting). The male (0.5pt) patient of PMID: 14966353 has a T-B+NK- lymphocyte subset profile (0.5pt) [CD3: 2.5%; CD19: 95.4%; CD16/CD56: 0.5%] which is specific for SCID due to gamma chain deficiency (1pt; PP4). In a second case, the R226C variant arose de novo as a somatic mutation early in embryogenesis in the mother of the patient, 1 pt, PM6_Moderate (PMID: 23683512).At least eight additional male X-SCID patients have been reported (PMIDs: 9058718, 11129345, 22936741, 7668284) with this hemizygous variant (total 4.5pt; PS4). PMID: 7632950 Examined the mutant 7 chain distribution by confocal microscopy in transiently transfected COS-7 cells, comparing it with the wild-type 7 chain distribution. The mutant 7 chain could not be detected by an antihuman IL-2 receptor 7 chain monoclonal antibody, TUGh4, on the cell surface of the transfected COS-7 cells. This result was in sharp contrast to that obtained with the wild-type γ chain, which was clearly stained by TUGh4 on the transfected cells. PS3_Supporting is met.In summary, this variant meets the criteria to be classified as Pathogenic for X-linked T-B+ severe combined immunodeficiency due to gamma chain deficiency based on the ACMG/AMP criteria applied, as specified by the ClinGen SCID VCEP. Criteria applied: PS4, PM1_Strong, PM6_Moderate, PM2_Supporting, PS3_Supporting, and PP4. (VCEP specifications version 1).	7632950	Severe Combined Immunodeficiency Disease  VCEP		2024-01-17	2024-01-17	False	https://erepo.genome.network/evrepo/ui/classification/CA358784/MONDO:0010315/129	23b8665a-973b-4fee-9486-bd8769d320c9	p.Arg226Cys	Arg	226	Cys	MLKPSLPFTSLLFLQLPLLGVGLNTTILTPNGNEDTTADFFLTTMPTDSLSVSTLPLPEVQCFVFNVEYMNCTWNSSSEPQPTNLTLHYWYKNSDNDKVQKCSHYLFSEEITSGCQLQKKEIHLYQTFVVQLQDPREPRRQATQMLKLQNLVIPWAPENLTLHKLSESQLELNWNNRFLNHCLEHLVQYRTDWDHSWTEQSVDYRHKFSLPSVDGQKRYTFRVRSRFNPLCGSAQHWSEWSHPIHWGSNTSKENPFLFALEAVVISVGSMGLIISLLCVYFWLERTMPRIPTLKNLEDLVTEYHGNFSAWSGVSKGLAESLQPDYSERLCLVSEIPPKGGALGEGPGASPCNQHSPYWAPPCYTLKPET	369	P31785	C	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [280], 'TOPO_DOM_gain_score': array([0.03251755]), 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
668	NM_000206.3(IL2RG):c.664C>T (p.Arg222Cys)	10027	CA120885	NM_000206.3:c.664C>T, NC_000023.11:g.71109321G>A, CM000685.2:g.71109321G>A, NC_000023.10:g.70329171G>A, CM000685.1:g.70329171G>A, NC_000023.9:g.70245896G>A, NG_009088.1:g.7233C>T, LRG_150:g.7233C>T, NG_021141.1:g.2468C>T, ENST00000374202.7:c.664C>T, ENST00000642473.1:n.1028C>T, ENST00000644022.1:n.930C>T, ENST00000644708.1:n.1070C>T, ENST00000644911.1:n.1070C>T, ENST00000645266.1:c.664C>T, ENST00000645518.1:c.664C>T, ENST00000646106.1:c.664C>T, ENST00000646505.1:c.664C>T, ENST00000647492.1:c.664C>T, ENST00000276110.6:n.1257C>T, ENST00000374188.7:c.-53C>T, ENST00000374202.6:c.664C>T, ENST00000456850.6:c.94C>T, ENST00000464642.5:c.532C>T, ENST00000482750.5:c.77C>T, ENST00000512747.3:n.591C>T, NM_000206.2:c.664C>T, LRG_150t1:c.664C>T, NM_000206.3(IL2RG):c.664C>T (p.Arg222Cys)	IL2RG	T-B+ severe combined immunodeficiency due to gamma chain deficiency	MONDO:0010315	X-linked inheritance (recessive (HP:0001419))	Pathogenic	PP4_Moderate, PM2_Supporting, PS4, PP1_Strong	PP3, PS3	The NM_000206.3(IL2RG):c.664C>T (p.Arg222Cys) missense variant has been reported in several (atypical) SCID cases, including male (0.5pt) patient P1 (PMID: 29948574) in whom the variant was detected by WES (1pt) and there was a family history of SCID (first-degree male relatives from the maternal side with suspected primary immune deficiency, who were not available for this study; 0.5pt), additionally STAT5 phosphorylation after exposure to IL-2 was virtually absent in CD4 and CD8 T cells (1pt); together these are highly specific for SCID due to gamma chain deficiency (3pt; PP4_moderate). There are 5 genotype/phenotype positive individuals in the pedigree through 11 segregations of this variant (PMID: 29948574); P1 plus four second cousins are all hemizygous for this variant and affected with atypical SCID and an additional great uncle was also affected but not available for genotyping (5+ segregations; PP1_Strong). At least 15 additional male X-SCID patients have been reported (PMIDs: 25042067, 16227049, 10794431, 7557965) with this hemizygous variant (total 11pt; PS4) and this variant is absent from gnomADv2.1.1 (PM2_Supporting). In summary, this variant meets the criteria to be classified as pathogenic for X-linked T-B+ severe combined immunodeficiency due to gamma chain deficiency based on the ACMG/AMP criteria applied, as specified by the ClinGen SCID VCEP. Criteria applied: PS4, Pp1_Strong, PP4_Moderate and PM2_supporting. (VCEP specifications version 1).		Severe Combined Immunodeficiency Disease  VCEP		2024-01-17	2024-01-17	False	https://erepo.genome.network/evrepo/ui/classification/CA120885/MONDO:0010315/129	3f6af4f7-f617-4684-bd64-58811dc750eb	p.Arg222Cys	Arg	222	Cys	MLKPSLPFTSLLFLQLPLLGVGLNTTILTPNGNEDTTADFFLTTMPTDSLSVSTLPLPEVQCFVFNVEYMNCTWNSSSEPQPTNLTLHYWYKNSDNDKVQKCSHYLFSEEITSGCQLQKKEIHLYQTFVVQLQDPREPRRQATQMLKLQNLVIPWAPENLTLHKLSESQLELNWNNRFLNHCLEHLVQYRTDWDHSWTEQSVDYRHKFSLPSVDGQKRYTFRVRSRFNPLCGSAQHWSEWSHPIHWGSNTSKENPFLFALEAVVISVGSMGLIISLLCVYFWLERTMPRIPTLKNLEDLVTEYHGNFSAWSGVSKGLAESLQPDYSERLCLVSEIPPKGGALGEGPGASPCNQHSPYWAPPCYTLKPET	369	P31785	C	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [280], 'TOPO_DOM_gain_score': array([0.03201234]), 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [221], 'DISULFID_gain_score': array([0.59575307]), 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [133], 'STRAND_gain_score': array([0.02817595]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
669	NM_177438.3(DICER1):c.5113G>A (p.Glu1705Lys)	932987	CA390865421	NM_177438.3:c.5113G>A, NC_000014.9:g.95094139C>T, CM000676.2:g.95094139C>T, NC_000014.8:g.95560476C>T, CM000676.1:g.95560476C>T, NC_000014.7:g.94630229C>T, NG_016311.1:g.68284G>A, LRG_492:g.68284G>A, ENST00000343455.8:c.5113G>A, ENST00000393063.6:c.5113G>A, ENST00000526495.6:c.5113G>A, ENST00000556045.6:c.5113G>A, ENST00000675540.1:c.2858G>A, ENST00000675995.1:c.*3429G>A, ENST00000343455.7:c.5113G>A, ENST00000393063.5:c.5113G>A, ENST00000526495.5:c.5113G>A, ENST00000527414.5:c.5113G>A, ENST00000541352.5:c.5113G>A, ENST00000556045.5:c.1807G>A, NM_001195573.1:c.5113G>A, NM_001271282.2:c.5113G>A, NM_001291628.1:c.5113G>A, NM_030621.4:c.5113G>A, NM_177438.2:c.5113G>A, LRG_492t1:c.5113G>A, XM_011536599.1:c.5113G>A, XM_011536600.1:c.5113G>A, XM_011536601.1:c.5113G>A, XM_011536602.1:c.5113G>A, XM_011536603.1:c.5113G>A, XM_011536604.1:c.4708G>A, XM_011536605.1:c.3634G>A, XM_011536599.2:c.5113G>A, XM_011536600.3:c.5113G>A, XM_011536601.3:c.5113G>A, XM_011536602.3:c.5113G>A, XM_011536604.2:c.4708G>A, XM_011536605.2:c.3634G>A, XM_017021120.2:c.5113G>A, XM_017021121.2:c.5113G>A, XM_017021122.2:c.4708G>A, XM_017021123.2:c.4708G>A, NM_001271282.3:c.5113G>A, NM_001291628.2:c.5113G>A, NM_001395677.1:c.5113G>A, NM_001395678.1:c.5113G>A, NM_001395679.1:c.5113G>A, NM_001395680.1:c.5113G>A, NM_001395682.1:c.5113G>A, NM_001395683.1:c.5113G>A, NM_001395684.1:c.5113G>A, NM_001395685.1:c.5113G>A, NM_001395686.1:c.4831G>A, NM_001395687.1:c.4708G>A, NM_001395688.1:c.4708G>A, NM_001395689.1:c.4708G>A, NM_001395690.1:c.4708G>A, NM_001395691.1:c.4546G>A, NM_001395697.1:c.3430G>A, NR_172715.1:n.5531G>A, NR_172716.1:n.5715G>A, NR_172717.1:n.5625G>A, NR_172718.1:n.5548G>A, NR_172719.1:n.5381G>A, NR_172720.1:n.5458G>A, NM_177438.3(DICER1):c.5113G>A (p.Glu1705Lys)	DICER1	DICER1-related tumor predisposition	MONDO:0100216	Autosomal dominant inheritance	Pathogenic	PS3_Supporting, PP3, PM2_Supporting, PS4_Supporting, PS2, PM1	BS2, PP4, BA1, BP4, PM5, BS1, BS3	The NM_177438.2:c.5113G>A variant in DICER1 is a missense variant predicted to cause substitution of glutamic acid by lysine at amino acid 1705 (p.Glu1705Lys). This variant has been identified as a de novo occurrence with constitutional mosaicism in one individual with pleuropulmonary blastoma type I and cystic nephroma (PS2; PS4_supporting; 26925222). This variant is absent from gnomAD v2.1.1 and v3.1.2 (non-cancer) (PM2_Supporting). In vitro cleavage assays performed in different cell lines have demonstrated that this variant fails to produce 5p microRNAs from a pre-miRNA, indicating that this variant impacts protein function (PS3_Supporting; 22187960, 23132766, 28862265). In silico tools predict damaging impact of the variant on protein function (REVEL: 0.925) (PP3). This variant resides in the p.E1705 metal ion-binding residue located in the RNase IIIb domain of DICER1, that is defined as a mutational hotspot and critical functional domain by the ClinGen DICER1 VCEP (PM1; PMID: 31342592). In summary, this variant meets the criteria to be classified as Pathogenic for DICER1-related tumor predisposition based on the ACMG/AMP criteria applied, as specified by the ClinGen DICER1 VCEP: PS2, PM2_Supporting, PS4_supporting, PS3_Supporting, PP3, PM1. (Bayesian Points: 10; VCEP specifications version 1.2.0; 01/09/2024).		DICER1 and miRNA-Processing Gene VCEP		2024-01-09	2024-01-17	False	https://erepo.genome.network/evrepo/ui/classification/CA390865421/MONDO:0100216/024	f086a53b-4033-4d0b-8cc9-b5f0fd9cbc34	p.Glu1705Lys	Glu	1705	Lys	MKSPALQPLSMAGLQLMTPASSPMGPFFGLPWQQEAIHDNIYTPRKYQVELLEAALDHNTIVCLNTGSGKTFIAVLLTKELSYQIRGDFSRNGKRTVFLVNSANQVAQQVSAVRTHSDLKVGEYSNLEVNASWTKERWNQEFTKHQVLIMTCYVALNVLKNGYLSLSDINLLVFDECHLAILDHPYREIMKLCENCPSCPRILGLTASILNGKCDPEELEEKIQKLEKILKSNAETATDLVVLDRYTSQPCEIVVDCGPFTDRSGLYERLLMELEEALNFINDCNISVHSKERDSTLISKQILSDCRAVLVVLGPWCADKVAGMMVRELQKYIKHEQEELHRKFLLFTDTFLRKIHALCEEHFSPASLDLKFVTPKVIKLLEILRKYKPYERQQFESVEWYNNRNQDNYVSWSDSEDDDEDEEIEEKEKPETNFPSPFTNILCGIIFVERRYTAVVLNRLIKEAGKQDPELAYISSNFITGHGIGKNQPRNKQMEAEFRKQEEVLRKFRAHETNLLIATSIVEEGVDIPKCNLVVRFDLPTEYRSYVQSKGRARAPISNYIMLADTDKIKSFEEDLKTYKAIEKILRNKCSKSVDTGETDIDPVMDDDDVFPPYVLRPDDGGPRVTINTAIGHINRYCARLPSDPFTHLAPKCRTRELPDGTFYSTLYLPINSPLRASIVGPPMSCVRLAERVVALICCEKLHKIGELDDHLMPVGKETVKYEEELDLHDEEETSVPGRPGSTKRRQCYPKAIPECLRDSYPRPDQPCYLYVIGMVLTTPLPDELNFRRRKLYPPEDTTRCFGILTAKPIPQIPHFPVYTRSGEVTISIELKKSGFMLSLQMLELITRLHQYIFSHILRLEKPALEFKPTDADSAYCVLPLNVVNDSSTLDIDFKFMEDIEKSEARIGIPSTKYTKETPFVFKLEDYQDAVIIPRYRNFDQPHRFYVADVYTDLTPLSKFPSPEYETFAEYYKTKYNLDLTNLNQPLLDVDHTSSRLNLLTPRHLNQKGKALPLSSAEKRKAKWESLQNKQILVPELCAIHPIPASLWRKAVCLPSILYRLHCLLTAEELRAQTASDAGVGVRSLPADFRYPNLDFGWKKSIDSKSFISISNSSSAENDNYCKHSTIVPENAAHQGANRTSSLENHDQMSVNCRTLLSESPGKLHVEVSADLTAINGLSYNQNLANGSYDLANRDFCQGNQLNYYKQEIPVQPTTSYSIQNLYSYENQPQPSDECTLLSNKYLDGNANKSTSDGSPVMAVMPGTTDTIQVLKGRMDSEQSPSIGYSSRTLGPNPGLILQALTLSNASDGFNLERLEMLGDSFLKHAITTYLFCTYPDAHEGRLSYMRSKKVSNCNLYRLGKKKGLPSRMVVSIFDPPVNWLPPGYVVNQDKSNTDKWEKDEMTKDCMLANGKLDEDYEEEDEEEESLMWRAPKEEADYEDDFLEYDQEHIRFIDNMLMGSGAFVKKISLSPFSTTDSAYEWKMPKKSSLGSMPFSSDFEDFDYSSWDAMCYLDPSKAVEEDDFVVGFWNPSEENCGVDTGKQSISYDLHTEQCIADKSIADCVEALLGCYLTSCGERAAQLFLCSLGLKVLPVIKRTDREKALCPTRENFNSQQKNLSVSCAAASVASSRSSVLKDSEYGCLKIPPRCMFDHPDADKTLNHLISGFENFEKKINYRFKNKAYLLQAFTHASYHYNTITDCYQRLEFLGDAILDYLITKHLYEDPRQHSPGVLTDLRSALVNNTIFASLAVKYDYHKYFKAVSPELFHVIDDFVQFQLEKNEMQGMDSELRRSEEDEEKEEDIEVPKAMGDIFESLAGAIYMDSGMSLETVWQVYYPMMRPLIEKFSANVPRSPVRELLEMEPETAKFSPAERTYDGKVRVTVEVVGKGKFKGVGRSYRIAKSAAARRALRSLKANQPQVPNS	1922	Q9UPY3	K	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [1695, 1696], 'BINDING_gain': [], 'BINDING_loss_score': array([-0.12065583, -0.09221447]), 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [563], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.00729358]), 'HELIX_loss': [45, 548, 571, 574, 577, 578, 1325, 1709, 1710, 1763, 1764], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.00499785, -0.26556361, -0.03747642, -0.03693295, -0.02894121,
       -0.02950573, -0.0400703 , -0.40669763, -0.36639565, -0.19829518,
       -0.20858693]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [558, 559, 560, 1685, 1686, 1687, 1688, 1689, 1690, 1691, 1692, 1693, 1694, 1695, 1696, 1697, 1698, 1699, 1700, 1701, 1702, 1703, 1704, 1705, 1706, 1707, 1741, 1742, 1743, 1746, 1747, 1748, 1749, 1750, 1751, 1752, 1753, 1754, 1755, 1756, 1757, 1758, 1759, 1762], 'DOMAIN_gain': [449, 450, 453, 454, 455, 463, 464, 466, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 561, 562, 564, 565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578, 579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, 1771], 'DOMAIN_gain_score': array([0.48504269, 0.51127374, 0.57453442, 0.64375842, 0.6025483 ,
       0.47217077, 0.51005709, 0.4632929 , 0.48847556, 0.58689672,
       0.53103918, 0.55331057, 0.62266511, 0.67536181, 0.72873318,
       0.77792561, 0.85636902, 0.83308047, 0.86532521, 0.849617  ,
       0.8557055 , 0.83714616, 0.85719097, 0.81806362, 0.86352277,
       0.78712177, 0.79419756, 0.77871227, 0.80718368, 0.76497936,
       0.78700143, 0.77584106, 0.7869308 , 0.78090727, 0.78252977,
       0.74470538, 0.54297423, 0.63131249, 0.68116176, 0.69881558,
       0.50416619, 0.17883623, 0.30123794, 0.36523235, 0.46244133,
       0.40648794, 0.47598505, 0.47665155, 0.45995247, 0.52817678,
       0.43888634, 0.41284782, 0.46316457, 0.45821613, 0.4024635 ,
       0.41624206, 0.497971  , 0.48802817, 0.47535652, 0.58570868,
       0.55097479, 0.49397528, 0.58953345, 0.56732219, 0.51234657,
       0.53766179, 0.54165411, 0.47213012, 0.56411552, 0.60404092,
       0.58082902, 0.50834692, 0.50403494, 0.42707652, 0.41877908,
       0.26806647]), 'DOMAIN_loss_score': array([-0.35240835, -0.1616478 , -0.12534457, -0.70265448, -0.73991573,
       -0.76757723, -0.69685036, -0.73341799, -0.84168404, -0.85516942,
       -0.82678372, -0.86360669, -0.87439662, -0.84072524, -0.80229789,
       -0.90667248, -0.88777304, -0.77346861, -0.70783818, -0.80271548,
       -0.75578684, -0.65661114, -0.49290425, -0.75354379, -0.61528647,
       -0.46166182, -0.48340303, -0.64838207, -0.75496644, -0.61475635,
       -0.50351167, -0.63231087, -0.65009165, -0.60178572, -0.45134217,
       -0.56076044, -0.44213098, -0.41404384, -0.27174979, -0.2910527 ,
       -0.38218218, -0.26753861, -0.16210818, -0.04119611]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
670	NM_000162.5(GCK):c.623C>T (p.Ala208Val)	447411	CA4239569	NM_000162.5:c.623C>T, NC_000007.14:g.44149816G>A, CM000669.2:g.44149816G>A, NC_000007.13:g.44189415G>A, CM000669.1:g.44189415G>A, NC_000007.12:g.44155940G>A, NG_008847.1:g.44608C>T, NG_008847.2:g.53355C>T, ENST00000395796.8:c.*621C>T, ENST00000616242.5:c.623C>T, ENST00000682635.1:n.1109C>T, ENST00000345378.7:c.626C>T, ENST00000403799.8:c.623C>T, ENST00000671824.1:c.623C>T, ENST00000673284.1:c.623C>T, ENST00000345378.6:c.626C>T, ENST00000395796.7:c.620C>T, ENST00000403799.7:c.623C>T, ENST00000437084.1:c.572C>T, ENST00000616242.4:c.620C>T, NM_000162.3:c.623C>T, NM_033507.1:c.626C>T, NM_033508.1:c.620C>T, NM_000162.4:c.623C>T, NM_001354800.1:c.623C>T, NM_033507.2:c.626C>T, NM_033508.2:c.620C>T, NM_033507.3:c.626C>T, NM_033508.3:c.620C>T, NM_000162.5(GCK):c.623C>T (p.Ala208Val)	GCK	monogenic diabetes	MONDO:0015967	Semidominant inheritance	Pathogenic	PS4, PP1_Strong, PP4_Moderate, PP2, PP3, PM2_Supporting		The c.623C>T variant in the glucokinase gene, GCK, causes an amino acid change of alanine to valine at codon 208 (p.(Ala208Val)) of NM_000162.5.  This variant segregated with diabetes/hyperglycemia, with 9 informative meioses in 6 families (PP1_Strong; internal lab contributors).  This variant was identified in 16 unrelated individuals with hyperglycemia (PS4; internal lab contributors).  This variant was identified in an individual with a clinical history highly specific for GCK-hyperglycemia (FBG 5.5-8 mmol/L and HbA1c 5.6 - 7.6% and a 5 generation family history of diabetes) (PP4_Moderate; internal lab contributors).  GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2).  This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.851, which is greater than the MDEP VCEP threshold of 0.70 (PP3).  This variant has an incomputable gnomAD v2.1.1  Popmax minor filtering allele frequency due to 1 copy in the European non-Finnish subpopulation and 0 copies in any other subpopulation, thereby meeting the ClinGen MDEP threshold criteria for PM2_Supporting (ENF Popmax FAF <= 0.000003 and <= 2 copies in ENF and <=1 copy in any other subpopulation) (PM2_Supporting).  In summary, c.623C>T meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.3.0 approved 8/11/2023): PP1_Strong, PS4, PP4_Moderate, PP2, PP3, PM2_Supporting.		Monogenic Diabetes VCEP		2024-01-18	2024-01-18	False	https://erepo.genome.network/evrepo/ui/classification/CA4239569/MONDO:0015967/086	6769e16e-1976-4b67-bf42-cbeb1e4c072b	p.Ala208Val	Ala	208	Val	MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQ	465	P35557	V	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [196, 203], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.07643056, -0.0602113 ]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [73], 'REGION_gain': [11, 21], 'REGION_gain_score': array([0.0084638 , 0.00577885]), 'REGION_loss_score': array([-0.00124735]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
671	NM_000162.5(GCK):c.629T>C (p.Met210Thr)	804852	CA367401300	NM_000162.5:c.629T>C, NC_000007.14:g.44149810A>G, CM000669.2:g.44149810A>G, NC_000007.13:g.44189409A>G, CM000669.1:g.44189409A>G, NC_000007.12:g.44155934A>G, NG_008847.1:g.44614T>C, NG_008847.2:g.53361T>C, ENST00000395796.8:c.*627T>C, ENST00000616242.5:c.629T>C, ENST00000682635.1:n.1115T>C, ENST00000345378.7:c.632T>C, ENST00000403799.8:c.629T>C, ENST00000671824.1:c.629T>C, ENST00000673284.1:c.629T>C, ENST00000345378.6:c.632T>C, ENST00000395796.7:c.626T>C, ENST00000403799.7:c.629T>C, ENST00000437084.1:c.578T>C, ENST00000616242.4:c.626T>C, NM_000162.3:c.629T>C, NM_033507.1:c.632T>C, NM_033508.1:c.626T>C, NM_000162.4:c.629T>C, NM_001354800.1:c.629T>C, NM_033507.2:c.632T>C, NM_033508.2:c.626T>C, NM_033507.3:c.632T>C, NM_033508.3:c.626T>C, NM_000162.5(GCK):c.629T>C (p.Met210Thr)	GCK	monogenic diabetes	MONDO:0015967	Semidominant inheritance	Pathogenic	PS4, PP1_Strong, PS3_Supporting, PP2, PP3, PM2_Supporting	PP4	The c.629T>C variant in the glucokinase gene, GCK, causes an amino acid change of methionine to threonine at codon 210 (p.(Met210Thr)) of NM_000162.5. GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2). This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.982, which is greater than the MDEP threshold of 0.70 (PP3). A kinetic analysis of recombinant wild-type (WT) and mutant glucokinase demonstrated that the wild-type kinetic parameters pass the quality control, but the wild-type ATP Km is not between 0.4-0.65, and the p.Met210Thr has Kcat/S0.5<0.5 (PS3_Supporting; PMID: 14517946, DOI:10.1007/s001250051289).  This variant has an incomputable gnomAD v2.1.1 Popmax filtering allele frequency of due to 0 copies observed in the European non-Finnish population and only 1 copy in another subpopulation (Latino/admixed), thereby meeting the ClinGen MDEP criteria for PM2_Supporting (PM2_Supporting).  This variant was identified in 11 unrelated individuals with non-autoimmune and non-absolute/near-absolute insulin-deficient diabetes (PS4; PMIDs: 25555642, 9049484, ClinVar ID: 804852, internal lab contributor). This variant was identified in an individual with a phenotype suggestive of GCK-hyperglycemia; however, PP4 is unable to be evaluated due to insufficient clinical information (internal lab contributor). This variant segregated with diabetes, with 5 informative meioses in 2 families with MODY (PP1_Strong; internal lab contributors). Taken together, the evidence supports the classification of c.629T>C as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.2.0, approved 6/7/2023): PP1_Strong, PS4, PS3_Moderate, PP2, PP3, PM2_Supporting.		Monogenic Diabetes VCEP		2024-01-18	2024-01-18	False	https://erepo.genome.network/evrepo/ui/classification/CA367401300/MONDO:0015967/086	36ad32f3-6b33-4dae-8175-4a5daf06b61c	p.Met210Thr	Met	210	Thr	MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQ	465	P35557	T	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [196], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.05019313]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [21], 'REGION_gain_score': array([0.00103658]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
672	NM_000022.4(ADA):c.239A>G (p.Lys80Arg)	1954	CA251993	NM_000022.4:c.239A>G, NC_000020.11:g.44626579T>C, CM000682.2:g.44626579T>C, NC_000020.10:g.43255220T>C, CM000682.1:g.43255220T>C, NC_000020.9:g.42688634T>C, NG_007385.1:g.30157A>G, LRG_16:g.30157A>G, ENST00000372874.9:c.239A>G, ENST00000372874.8:c.239A>G, ENST00000492931.5:n.323A>G, ENST00000536076.1:n.419A>G, ENST00000536532.5:c.239A>G, ENST00000537820.1:c.239A>G, ENST00000539235.5:c.218+2468A>G, ENST00000545776.5:n.293A>G, NM_000022.2:c.239A>G, LRG_16t1:c.239A>G, XM_005260236.2:c.239A>G, XM_011528478.1:c.-51A>G, XM_011528479.1:c.-51A>G, XR_244129.1:n.293A>G, NM_000022.3:c.239A>G, NM_001322051.1:c.239A>G, NM_001322050.2:c.-51A>G, NM_001322051.2:c.239A>G, NR_136160.2:n.331A>G, NM_000022.4(ADA):c.239A>G (p.Lys80Arg)	ADA	adenosine deaminase deficiency	MONDO:0007064	Autosomal recessive inheritance	Benign	BS2_Supporting, BA1		The NM_000022.4:c.239A>G variant in ADA is a missense variant predicted to cause substitution of lysine by arginine at amino acid 80 (p.Lys80Arg). The Popmax filtering allele frequency of this variant in the gnomAD v2.1.1 database is 0.06430, which is higher than the ClinGen SCID VCEP threshold (>0.00721) for BA1 (BA1). This variant has been observed in 551 homozygous individuals with no feature of SCID, a condition with full penetrance at an early age (BS2_Supporting). In summary, this variant meets the criteria to be classified as benign for SCID. ACMG/AMP criteria applied, as specified by the ClinGen SCID-VCEP: BA1 and BS2_Supporting. (VCEP specifications version 1).		Severe Combined Immunodeficiency Disease  VCEP		2024-01-23	2024-01-23	False	https://erepo.genome.network/evrepo/ui/classification/CA251993/MONDO:0007064/114	5adcbc29-0bdb-463d-ae7a-c6fb29411314	p.Lys80Arg	Lys	80	Arg	MAQTPAFDKPKVELHVHLDGSIKPETILYYGRRRGIALPANTAEGLLNVIGMDKPLTLPDFLAKFDYYMPAIAGCREAIKRIAYEFVEMKAKEGVVYVEVRYSPHLLANSKVEPIPWNQAEGDLTPDEVVALVGQGLQEGERDFGVKARSILCCMRHQPNWSPKVVELCKKYQQQTVVAIDLAGDETIPGSSLLPGHVQAYQEAVKSGIHRTVHAGEVGSAEVVKEAVDILKTERLGHGYHTLEDQALYNRLRQENMHFEICPWSSYLTGAWKPDTEHAVIRLKNDQANYSLNTDDPLIFKSTLDTDYQMTKRDMGFTEEEFKRLNINAAKSSFLPEDEKRELLDLLYKAYGMPPSASAGQNL	363	P00813	R	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [181, 196, 208, 210, 231], 'REPEAT_gain_score': array([0.00745302, 0.00327176, 0.00876129, 0.00651109, 0.00315452]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
673	NM_000022.4(ADA):c.845G>A (p.Arg282Gln)	402341	CA9871496	NM_000022.4:c.845G>A, NC_000020.11:g.44622588C>T, CM000682.2:g.44622588C>T, NC_000020.10:g.43251229C>T, CM000682.1:g.43251229C>T, NC_000020.9:g.42684643C>T, NG_007385.1:g.34148G>A, LRG_16:g.34148G>A, ENST00000372874.9:c.845G>A, ENST00000372874.8:c.845G>A, ENST00000372887.5:c.152-1345C>T, ENST00000464097.5:n.595G>A, ENST00000492931.5:n.1005G>A, ENST00000536532.5:c.780+241G>A, ENST00000537820.1:c.773G>A, ENST00000539235.5:c.*229G>A, NM_000022.2:c.845G>A, LRG_16t1:c.845G>A, XM_005260236.2:c.773G>A, XM_011528478.1:c.440G>A, XM_011528479.1:c.440G>A, XR_244129.1:n.834+241G>A, NM_000022.3:c.845G>A, NM_001322050.1:c.440G>A, NM_001322051.1:c.773G>A, NR_136160.1:n.931+241G>A, NM_001322050.2:c.440G>A, NM_001322051.2:c.773G>A, NR_136160.2:n.872+241G>A, NM_000022.4(ADA):c.845G>A (p.Arg282Gln)	ADA	adenosine deaminase deficiency	MONDO:0007064	Autosomal recessive inheritance	Pathogenic	PP4_Moderate, PM2_Supporting, PM3_Strong, PVS1_Strong	PM5	The c.845G>A (NM_000022.4) variant in ADA is a missense variant predicted to cause substitution of Arginine by Glutamine at amino acid 282 (p.Arg282Gln). This variant is considered in the PVS1 criteria based on experimental evidence indicating that it has the effect of affecting the splicing site. In line with the predictions of splicing algorithms, experimental validation (from Dr. Mike Hershfield - Internal Communication) has established that the variant occurs at the splice junction between exon 9 and intron 10 and has been shown to cause aberrant splicing in peripheral blood leukocytes (PBL) of a female Arab patient with ADA-SCID. Based on this, we classify PVS1 at a Strong level, as it results in the loss of more than 10% of the protein, and other pathogenic variants have already been described downstream (e.g., NM_000022.4(ADA):c.870C>A (p.Tyr290Ter), Pathogenic according to SCID VCEP specifications).The highest population minor allele frequency in gnomAD v4 is 0.000005310 (12/1180048 alleles) in European (non-Finnish) population, which is lower than the ClinGen SCID VCEP threshold (<0.0001742) for PM2_Supporting, meeting this criterion (PM2_Supporting). PMID: 19830125: 14-month-old Arab boy: Family history of SCID 0.5pts + T-B-NK- profile 0.5pts + Diagnostic criteria for SCID/Leaky SCID/Omenn syndrome met 0.5pts + Reduced ADA enzyme activity 1pt, total=2.5 pts, PP4_Moderate. PMID: 32307643, Patients 3 and 25, both are homozygous, reaching the maximum of 1 point for homozygous occurrence. From the same report, patient 2: Compound heterozygous,c.221G>T, p.G74V, Likely Pathogenic according to SCID VCEP specifications; 1 point. Total 2 points, PM3_Strong.In summary, this variant meets the criteria to be classified as Pathogenic for SCID based on the ACMG/AMP criteria applied, as specified by the ClinGen SCID VCEP. Criteria applied: PVS1_Strong, PM2_Supporting, PP4_Moderate, and PM3_Strong.  (VCEP specifications version 1.0).		Severe Combined Immunodeficiency Disease  VCEP		2024-01-23	2024-01-23	False	https://erepo.genome.network/evrepo/ui/classification/CA9871496/MONDO:0007064/114	c2cf447a-486b-46db-9aec-0c3e8f56633d	p.Arg282Gln	Arg	282	Gln	MAQTPAFDKPKVELHVHLDGSIKPETILYYGRRRGIALPANTAEGLLNVIGMDKPLTLPDFLAKFDYYMPAIAGCREAIKRIAYEFVEMKAKEGVVYVEVRYSPHLLANSKVEPIPWNQAEGDLTPDEVVALVGQGLQEGERDFGVKARSILCCMRHQPNWSPKVVELCKKYQQQTVVAIDLAGDETIPGSSLLPGHVQAYQEAVKSGIHRTVHAGEVGSAEVVKEAVDILKTERLGHGYHTLEDQALYNRLRQENMHFEICPWSSYLTGAWKPDTEHAVIRLKNDQANYSLNTDDPLIFKSTLDTDYQMTKRDMGFTEEEFKRLNINAAKSSFLPEDEKRELLDLLYKAYGMPPSASAGQNL	363	P00813	Q	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [275], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.01829749]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [42], 'DOMAIN_gain_score': array([0.02300113]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [179, 180, 219, 292], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.01427567, -0.00479835, -0.00535375, -0.00359172]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
674	NM_001033855.3(DCLRE1C):c.227G>C (p.Arg76Thr)	379076	CA5416971	NM_001033855.3:c.227G>C, NC_000010.11:g.14945124C>G, CM000672.2:g.14945124C>G, NC_000010.10:g.14987123C>G, CM000672.1:g.14987123C>G, NC_000010.9:g.15027129C>G, NG_007276.1:g.13972G>C, LRG_54:g.13972G>C, ENST00000378278.7:c.227G>C, ENST00000357717.6:c.-44+3912G>C, ENST00000378241.5:c.-261G>C, ENST00000378246.6:c.-63G>C, ENST00000378249.5:c.-63G>C, ENST00000378254.5:c.-134G>C, ENST00000378255.5:c.-456G>C, ENST00000378258.5:c.-134G>C, ENST00000378278.6:c.227G>C, ENST00000378289.8:c.227G>C, ENST00000396817.6:c.-456G>C, ENST00000418843.5:c.-171G>C, ENST00000456122.1:c.-385G>C, NM_001033855.2:c.227G>C, NM_001033857.2:c.-134G>C, NM_001033858.2:c.-456G>C, NM_001289076.1:c.-44+3912G>C, NM_001289077.1:c.-134G>C, NM_001289078.1:c.-63G>C, NM_001289079.1:c.-456G>C, NM_022487.3:c.-63G>C, NR_110297.1:n.734G>C, XM_006717491.2:c.-63G>C, XM_011519616.1:c.-63G>C, XM_011519617.1:c.-63G>C, XM_011519618.1:c.-190G>C, XM_011519619.1:c.-134G>C, XM_011519620.1:c.227G>C, XM_011519621.1:c.227G>C, XR_242702.2:n.324G>C, XR_930514.1:n.324G>C, XR_930515.1:n.324G>C, NM_001350965.1:c.227G>C, NM_001350966.1:c.-63G>C, NM_001350967.1:c.-134G>C, NR_146960.1:n.649G>C, NR_146961.1:n.734G>C, NR_146962.1:n.649G>C, XM_006717491.4:c.-63G>C, XM_011519620.3:c.227G>C, XM_011519621.2:c.227G>C, XM_017016557.1:c.-190G>C, XM_017016558.1:c.-261G>C, XM_024448134.1:c.-134G>C, XM_024448135.1:c.-63G>C, XR_001747185.2:n.571G>C, XR_001747187.1:n.263G>C, XR_930515.2:n.571G>C, NM_001033857.3:c.-134G>C, NM_001033858.3:c.-456G>C, NM_001289076.2:c.-44+3912G>C, NM_001289077.2:c.-134G>C, NM_001289078.2:c.-63G>C, NM_001289079.2:c.-456G>C, NM_001350965.2:c.227G>C, NM_001350966.2:c.-63G>C, NM_001350967.2:c.-134G>C, NM_022487.4:c.-63G>C, NR_110297.2:n.398G>C, NR_146961.2:n.398G>C, NM_001033855.3(DCLRE1C):c.227G>C (p.Arg76Thr)	DCLRE1C	severe combined immunodeficiency due to DCLRE1C deficiency	MONDO:0011225	Autosomal recessive inheritance	Benign	BA1		The c.227G>C (NM_001033855.3) variant in DCLRE1C is a missense variant predicted to cause substitution of Arginine by Threonine at amino acid 76 p.Arg76Thr.The filtering allele frequency (the lower threshold of the 95% CI of 713/24912) of the c.227G>C variant in DCLRE1C is 0.02613 for African/African American chromosomes by gnomAD v2.1.1, which is higher than the ClinGen SCID VCEP threshold (>0.00346) for BA1, and therefore meets this criterion (BA1). Additionally, there have been descriptions of 11 homozygous individuals.In summary, this variant meets the criteria to be classified as Benign for autosomal recessive severe combined immunodeficiency due to DCLRE1C deficiency based on the ACMG/AMP criteria applied, as specified by the ClinGen SCID VCEP:  BA1. (VCEP specifications version 1).		Severe Combined Immunodeficiency Disease  VCEP		2024-01-23	2024-01-23	False	https://erepo.genome.network/evrepo/ui/classification/CA5416971/MONDO:0011225/116	d4696620-30cd-4692-9933-4e11fc4e5158	p.Arg76Thr	Arg	76	Thr	MSSFEGQMAEYPTISIDRFDRENLRARAYFLSHCHKDHMKGLRAPTLKRRLECSLKVYLYCSPVTKELLLTSPKYRFWKKRIISIEIETPTQISLVDEASGEKEEIVVTLLPAGHCPGSVMFLFQGNNGTVLYTGDFRLAQGEAARMELLHSGGRVKDIQSVYLDTTFCDPRFYQIPSREECLSGVLELVRSWITRSPYHVVWLNCKAAYGYEYLFTNLSEELGVQVHVNKLDMFRNMPEILHHLTTDRNTQIHACRHPKAEEYFQWSKLPCGITSRNRIPLHIISIKPSTMWFGERSRKTNVIVRTGESSYRACFSFHSSYSEIKDFLSYLCPVNAYPNVIPVGTTMDKVVEILKPLCRSSQSTEPKYKPLGKLKRARTVHRDSEEEDDYLFDDPLPIPLRHKVPYPETFHPEVFSMTAVSEKQPEKLRQTPGCCRAECMQSSRFTNFVDCEESNSESEEEVGIPASLQGDLGSVLHLQKADGDVPQWEVFFKRNDEITDESLENFPSSTVAGGSQSPKLFSDSDGESTHISSQNSSQSTHITEQGSQGWDSQSDTVLLSSQERNSGDITSLDKADYRPTIKENIPASLMEQNVICPKDTYSDLKSRDKDVTIVPSTGEPTTLSSETHIPEEKSLLNLSTNADSQSSSDFEVPSTPEAELPKREHLQYLYEKLATGESIAVKKRKCSLLDT	692	Q96SD1	T	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [148, 190, 320], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.01829427, -0.02303088, -0.00553   ]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
675	NM_001033855.3(DCLRE1C):c.103C>G (p.His35Asp)	4674	CA117007	NM_001033855.3:c.103C>G, NC_000010.11:g.14953908G>C, CM000672.2:g.14953908G>C, NC_000010.10:g.14995907G>C, CM000672.1:g.14995907G>C, NC_000010.9:g.15035913G>C, NG_007276.1:g.5188C>G, LRG_54:g.5188C>G, ENST00000378278.7:c.103C>G, ENST00000357717.6:c.-102C>G, ENST00000378241.5:c.-470C>G, ENST00000378246.6:c.-187C>G, ENST00000378249.5:c.-135C>G, ENST00000378254.5:c.-389C>G, ENST00000378255.5:c.-711C>G, ENST00000378258.5:c.-343C>G, ENST00000378278.6:c.103C>G, ENST00000378289.8:c.103C>G, ENST00000396817.6:c.-665C>G, ENST00000418843.5:c.-426C>G, ENST00000456122.1:c.-594C>G, NM_001033855.2:c.103C>G, NM_001033857.2:c.-343C>G, NM_001033858.2:c.-665C>G, NM_001289076.1:c.-102C>G, NM_001289077.1:c.-389C>G, NM_001289078.1:c.-135C>G, NM_001289079.1:c.-711C>G, NM_022487.3:c.-187C>G, NR_110297.1:n.525C>G, XM_006717491.2:c.-318C>G, XM_011519616.1:c.-272C>G, XM_011519617.1:c.-403C>G, XM_011519618.1:c.-530C>G, XM_011519619.1:c.-474C>G, XM_011519620.1:c.103C>G, XM_011519621.1:c.103C>G, XR_242702.2:n.200C>G, XR_930514.1:n.200C>G, XR_930515.1:n.200C>G, NM_001350965.1:c.103C>G, NM_001350966.1:c.-135C>G, NM_001350967.1:c.-343C>G, NR_146960.1:n.525C>G, NR_146961.1:n.525C>G, NR_146962.1:n.525C>G, XM_006717491.4:c.-318C>G, XM_011519620.3:c.103C>G, XM_011519621.2:c.103C>G, XM_017016557.1:c.-314C>G, XM_017016558.1:c.-385C>G, XM_024448134.1:c.-206C>G, XM_024448135.1:c.-187C>G, XR_001747185.2:n.447C>G, XR_001747187.1:n.139C>G, XR_930515.2:n.447C>G, NM_001033857.3:c.-343C>G, NM_001033858.3:c.-665C>G, NM_001289076.2:c.-102C>G, NM_001289077.2:c.-389C>G, NM_001289078.2:c.-135C>G, NM_001289079.2:c.-711C>G, NM_001350965.2:c.103C>G, NM_001350966.2:c.-135C>G, NM_001350967.2:c.-343C>G, NM_022487.4:c.-187C>G, NR_110297.2:n.189C>G, NR_146961.2:n.189C>G, NM_001033855.3(DCLRE1C):c.103C>G (p.His35Asp)	DCLRE1C	severe combined immunodeficiency due to DCLRE1C deficiency	MONDO:0011225	Autosomal recessive inheritance	Pathogenic	PP4_Moderate, PP1, PM2_Supporting, PS3_Moderate, PM3_Strong	PP3, BS2	The c.103C>G (NM_001033855.3) variant in DCLRE1C is a missense variant predicted to cause the substitution of Histidine by  Aspartic Acid at amino acid 35 (p.His35Asp).The highest population minor allele frequency in gnomAD v4 is 0.000003100 (8/1111884 alleles) in the European (non-Finnish) population, which is lower than the ClinGen SCID VCEP threshold (<0.00003266) for PM2_Supporting, meeting this criterion (PM2_Supporting). No homozygotes have been observed in gnomAD.Activity levels in % of WT activity = Recombination: Mean (SD): 0 (0.3) and DNA repair (36h after IR): Mean (SD): 27.29 (16.57). PS3 is Met at a moderate level (PMID: 25917813).This variant has been detected in at least 4 individuals with SCID. Of those individuals, 02 were compound heterozygous for the variants: c.2T>C (p.Met1Thr) VUS according to SCID VCEP, 0.25pts AND p.L187*; Pathogenic according to the SCID VCEP specifications, 1 point. 02 individuals were homozygous for the variants (1 point). The total is 2.25 points, PM3_Strong. (PMIDs: 24481607, 15731174, and 32441320).At least one patient with this variant displayed T-B-NK+ (0.5 pts) + Diagnostic criteria for SCID/Leaky SCID/Omenn syndrome met (0.5 pts) + Family history of SCID (0.5 pts) + SCID gene panel or exome/genome sequencing conducted (0.5 pts), totaling 2 points, which is highly specific for SCID (PP4_Moderate, PMID: 24481607).In summary, this variant is classified as a Pathogenic for autosomal recessive SCID based on ACMG/AMP criteria applied, as specified by the ClinGen SCID VCEP (specification version 1.0): PM3_Strong, PS3_Moderate, PP1_Supporting, PP4_Moderate, and PM2_Supporting.		Severe Combined Immunodeficiency Disease  VCEP		2024-01-23	2024-01-23	False	https://erepo.genome.network/evrepo/ui/classification/CA117007/MONDO:0011225/116	50baf4df-88c8-469b-a6eb-3b8a7fecc340	p.His35Asp	His	35	Asp	MSSFEGQMAEYPTISIDRFDRENLRARAYFLSHCHKDHMKGLRAPTLKRRLECSLKVYLYCSPVTKELLLTSPKYRFWKKRIISIEIETPTQISLVDEASGEKEEIVVTLLPAGHCPGSVMFLFQGNNGTVLYTGDFRLAQGEAARMELLHSGGRVKDIQSVYLDTTFCDPRFYQIPSREECLSGVLELVRSWITRSPYHVVWLNCKAAYGYEYLFTNLSEELGVQVHVNKLDMFRNMPEILHHLTTDRNTQIHACRHPKAEEYFQWSKLPCGITSRNRIPLHIISIKPSTMWFGERSRKTNVIVRTGESSYRACFSFHSSYSEIKDFLSYLCPVNAYPNVIPVGTTMDKVVEILKPLCRSSQSTEPKYKPLGKLKRARTVHRDSEEEDDYLFDDPLPIPLRHKVPYPETFHPEVFSMTAVSEKQPEKLRQTPGCCRAECMQSSRFTNFVDCEESNSESEEEVGIPASLQGDLGSVLHLQKADGDVPQWEVFFKRNDEITDESLENFPSSTVAGGSQSPKLFSDSDGESTHISSQNSSQSTHITEQGSQGWDSQSDTVLLSSQERNSGDITSLDKADYRPTIKENIPASLMEQNVICPKDTYSDLKSRDKDVTIVPSTGEPTTLSSETHIPEEKSLLNLSTNADSQSSSDFEVPSTPEAELPKREHLQYLYEKLATGESIAVKKRKCSLLDT	692	Q96SD1	D	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [7, 8, 9, 90], 'STRAND_gain_score': array([0.0394305 , 0.04225302, 0.02859056, 0.01293069]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [7, 46, 114, 116, 119, 121, 129, 132, 143, 144, 147, 148, 150, 152, 162, 190, 307, 310, 312, 320], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.07047445, -0.1033498 , -0.09619182, -0.09165114, -0.07907575,
       -0.08008778, -0.09045541, -0.07745373, -0.1280297 , -0.13415402,
       -0.15942186, -0.14775771, -0.17045116, -0.11954731, -0.08820659,
       -0.09335411, -0.06445098, -0.05910343, -0.06775868, -0.0362395 ]), 'REGION_loss': [], 'REGION_gain': [616], 'REGION_gain_score': array([0.01732439]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
676	NM_002185.5(IL7R):c.197T>C (p.Ile66Thr)	14839	CA124390	NM_002185.5:c.197T>C, NC_000005.10:g.35860966T>C, CM000667.2:g.35860966T>C, NC_000005.9:g.35861068T>C, CM000667.1:g.35861068T>C, NC_000005.8:g.35896825T>C, NG_009567.1:g.9078T>C, LRG_74:g.9078T>C, ENST00000303115.8:c.197T>C, ENST00000303115.7:c.197T>C, ENST00000506850.5:c.197T>C, ENST00000511031.1:n.331T>C, ENST00000511982.1:c.197T>C, ENST00000514217.5:c.197T>C, NM_002185.3:c.197T>C, NR_120485.1:n.300T>C, XM_005248299.2:c.197T>C, XM_005248300.1:c.197T>C, XM_011514037.1:c.197T>C, NM_002185.4:c.197T>C, NR_120485.2:n.326T>C, XM_005248299.4:c.197T>C, NR_120485.3:n.284T>C, NM_002185.5(IL7R):c.197T>C (p.Ile66Thr)	IL7R	severe combined immunodeficiency, autosomal recessive, T cell-negative, B cell-positive, NK cell-positive	MONDO:0012163	Autosomal recessive inheritance	Benign	BA1		NM_002185.5(IL7R):c.197T>C is a missense variant predicted to cause substitution of Isoleucine by Threonine at amino acid 66 (p.Ile66Thr). The filtering allele frequency (the lower threshold of the 95% CI of 56371/74906 alleles) of the c.197T>C variant in IL7R is 0.7458 for African/African American chromosomes by gnomAD v.4, which is higher than the ClinGen SCID VCEP threshold (>0.00566) for BA1, and therefore meets this criterion (BA1). Additionally, 353136 homozygotes have been described.In summary, this variant meets the criteria to be classified as  Benign for autosomal recessive SCID, based on the ACMG/AMP criteria applied, as specified by the ClinGen SCID VCEP. Criteria applied: BA1 (VCEP specifications version 1).		Severe Combined Immunodeficiency Disease  VCEP		2024-01-23	2024-01-23	False	https://erepo.genome.network/evrepo/ui/classification/CA124390/MONDO:0012163/119	c8cc977c-3f8e-47b1-91a6-280d5a93d09b	p.Ile66Thr	Ile	66	Thr	MTILGTTFGMVFSLLQVVSGESGYAQNGDLEDAELDDYSFSCYSQLEVNGSQHSLTCAFEDPDVNITNLEFEICGALVEVKCLNFRKLQEIYFIETKKFLLIGKSNICVKVGEKSLTCKKIDLTTIVKPEAPFDLSVVYREGANDFVVTFNTSHLQKKYVKVLMHDVAYRQEKDENKWTHVNLSSTKLTLLQRKLQPAAMYEIKVRSIPDHYFKGFWSEWSPSYYFRTPEINNSSGEMDPILLTISILSFFSVALLVILACVLWKKRIKPIVWPSLPDHKKTLEHLCKKPRKNLNVSFNPESFLDCQIHRVDDIQARDEVEGFLQDTFPQQLEESEKQRLGGDVQSPNCPSEDVVITPESFGRDSSLTCLAGNVSACDAPILSSSRSLDCRESGKNGPHVYQDLLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQPILTSLGSNQEEAYVTMSSFYQNQ	459	P16871	T	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [78], 'STRAND_gain': [88], 'STRAND_gain_score': array([0.03055465]), 'STRAND_loss_score': array([-0.05690211]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
677	NM_002185.5(IL7R):c.412G>A (p.Val138Ile)	14840	CA124393	NM_002185.5:c.412G>A, NC_000005.10:g.35871088G>A, CM000667.2:g.35871088G>A, NC_000005.9:g.35871190G>A, CM000667.1:g.35871190G>A, NC_000005.8:g.35906947G>A, NG_009567.1:g.19200G>A, LRG_74:g.19200G>A, ENST00000303115.8:c.412G>A, ENST00000303115.7:c.412G>A, ENST00000506850.5:c.412G>A, ENST00000514217.5:c.412G>A, NM_002185.3:c.412G>A, NR_120485.1:n.515G>A, XM_005248299.2:c.412G>A, XM_005248300.1:c.412G>A, XM_011514037.1:c.412G>A, NM_002185.4:c.412G>A, NR_120485.2:n.541G>A, XM_005248299.4:c.412G>A, NR_120485.3:n.499G>A, NM_002185.5(IL7R):c.412G>A (p.Val138Ile)	IL7R	severe combined immunodeficiency, autosomal recessive, T cell-negative, B cell-positive, NK cell-positive	MONDO:0012163	Autosomal recessive inheritance	Benign	BA1		NM_002185.5(IL7R):c.412G>A is a missense variant predicted to cause substitution of Valine by Isoleucine at amino acid 138 (p.Val138Ile). The filtering allele frequency (the lower threshold of the 95% CI of 65661/74940 alleles) of the c.412G>A variant in IL7R is 0.8743 for African/African American chromosomes by gnomAD v.4, which is higher than the ClinGen SCID VCEP threshold (>0.00566) for BA1 and therefore meets this criterion (BA1). Additionally, 367924 homozygous have been described.In summary, this variant meets the criteria to be classified as Benign for autosomal recessive SCID, based on the ACMG/AMP criteria applied, as specified by the ClinGen SCID VCEP. Criteria applied: BA1 (VCEP specifications version 1).		Severe Combined Immunodeficiency Disease  VCEP		2024-01-23	2024-01-23	False	https://erepo.genome.network/evrepo/ui/classification/CA124393/MONDO:0012163/119	08ce9006-62e7-4115-8b9f-3378119517cb	p.Val138Ile	Val	138	Ile	MTILGTTFGMVFSLLQVVSGESGYAQNGDLEDAELDDYSFSCYSQLEVNGSQHSLTCAFEDPDVNITNLEFEICGALVEVKCLNFRKLQEIYFIETKKFLLIGKSNICVKVGEKSLTCKKIDLTTIVKPEAPFDLSVVYREGANDFVVTFNTSHLQKKYVKVLMHDVAYRQEKDENKWTHVNLSSTKLTLLQRKLQPAAMYEIKVRSIPDHYFKGFWSEWSPSYYFRTPEINNSSGEMDPILLTISILSFFSVALLVILACVLWKKRIKPIVWPSLPDHKKTLEHLCKKPRKNLNVSFNPESFLDCQIHRVDDIQARDEVEGFLQDTFPQQLEESEKQRLGGDVQSPNCPSEDVVITPESFGRDSSLTCLAGNVSACDAPILSSSRSLDCRESGKNGPHVYQDLLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQPILTSLGSNQEEAYVTMSSFYQNQ	459	P16871	I	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
678	NM_002185.5(IL7R):c.731C>T (p.Thr244Ile)	134530	CA160105	NM_002185.5:c.731C>T, NC_000005.10:g.35874473C>T, CM000667.2:g.35874473C>T, NC_000005.9:g.35874575C>T, CM000667.1:g.35874575C>T, NC_000005.8:g.35910332C>T, NG_009567.1:g.22585C>T, LRG_74:g.22585C>T, ENST00000303115.8:c.731C>T, ENST00000303115.7:c.731C>T, ENST00000505093.1:c.115+825C>T, ENST00000506850.5:c.706+825C>T, ENST00000509668.1:n.473C>T, ENST00000514217.5:c.538-1039C>T, NM_002185.3:c.731C>T, NR_120485.1:n.641-1039C>T, XM_005248299.2:c.706+825C>T, XM_005248300.1:c.706+825C>T, XM_011514037.1:c.731C>T, NM_002185.4:c.731C>T, NR_120485.2:n.667-1039C>T, XM_005248299.4:c.706+825C>T, NR_120485.3:n.625-1039C>T, NM_002185.5(IL7R):c.731C>T (p.Thr244Ile)	IL7R	severe combined immunodeficiency, autosomal recessive, T cell-negative, B cell-positive, NK cell-positive	MONDO:0012163	Autosomal recessive inheritance	Benign	BA1, BS2_Supporting		The c.731C>T (NM_002185.5) variant in IL7R is a missense variant predicted to cause substitution of Threonine by Isoleucine at amino acid 244 (p.Thr244Ile).The filtering allele frequency (the lower threshold of the 95% CI of 21695/63972 alleles) of the c.731C>T variant in IL7R is 0.2678 for European (non-Finnish) chromosomes by gnomAD v4, which is higher than the ClinGen SCID VCEP threshold (>0.00566) for BA1, and therefore meets this criterion (BA1). Additionally, 53760 homozygous adults are reported in gnomAD v.4. BS2_Supporting is Met. In summary, this variant meets the criteria to be classified as Benign for Autosomal Recessive SCID based on the ACMG/AMP criteria applied, as specified by the ClinGen SCID-VCEP: BA1 and BS2_Supporting. (VCEP specifications version 1).		Severe Combined Immunodeficiency Disease  VCEP		2024-01-23	2024-01-23	False	https://erepo.genome.network/evrepo/ui/classification/CA160105/MONDO:0012163/119	2276fa62-1e5a-4e37-82d0-ca41c4b6b94d	p.Thr244Ile	Thr	244	Ile	MTILGTTFGMVFSLLQVVSGESGYAQNGDLEDAELDDYSFSCYSQLEVNGSQHSLTCAFEDPDVNITNLEFEICGALVEVKCLNFRKLQEIYFIETKKFLLIGKSNICVKVGEKSLTCKKIDLTTIVKPEAPFDLSVVYREGANDFVVTFNTSHLQKKYVKVLMHDVAYRQEKDENKWTHVNLSSTKLTLLQRKLQPAAMYEIKVRSIPDHYFKGFWSEWSPSYYFRTPEINNSSGEMDPILLTISILSFFSVALLVILACVLWKKRIKPIVWPSLPDHKKTLEHLCKKPRKNLNVSFNPESFLDCQIHRVDDIQARDEVEGFLQDTFPQQLEESEKQRLGGDVQSPNCPSEDVVITPESFGRDSSLTCLAGNVSACDAPILSSSRSLDCRESGKNGPHVYQDLLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQPILTSLGSNQEEAYVTMSSFYQNQ	459	P16871	I	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [262], 'TRANSMEM_gain': [], 'TRANSMEM_loss_score': array([-0.11941314]), 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
679	NM_000448.3(RAG1):c.251A>G (p.His84Arg)	378467	CA5949933	NM_000448.3:c.251A>G, NC_000011.10:g.36573555A>G, CM000673.2:g.36573555A>G, NC_000011.9:g.36595105A>G, CM000673.1:g.36595105A>G, NC_000011.8:g.36551681A>G, NG_007528.1:g.10543A>G, LRG_98:g.10543A>G, ENST00000299440.6:c.251A>G, ENST00000299440.5:c.251A>G, ENST00000534663.1:c.251A>G, NM_000448.2:c.251A>G, LRG_98t1:c.251A>G, XM_005253041.3:c.251A>G, XM_011520250.1:c.251A>G, XM_011520251.1:c.251A>G, XM_005253041.4:c.251A>G, XM_011520250.2:c.251A>G, NM_001377277.1:c.251A>G, NM_001377278.1:c.251A>G, NM_001377279.1:c.251A>G, NM_001377280.1:c.251A>G, NM_000448.3(RAG1):c.251A>G (p.His84Arg)	RAG1	recombinase activating gene 1 deficiency	MONDO:0000572	Autosomal recessive inheritance	Benign	BS2_Supporting, BA1		The NM_000448.3:c.251A>G variant in RAG1 is a missense variant predicted to cause the substitution of Histidine by Arginine at amino acid 249 (p.His84Arg). The Popmax Filtering allele frequency (95% CI) of the c.251A>G variant in RAG1 is 0.01622 in gnomAD v.4, which is higher than the ClinGen SCID VCEP threshold (>0.00872) for BA1. Therefore, BA1 is met. Additionally, 19 homozygous adults are reported on GnomAD v.4, BS2_Supporting is Met.In summary, this variant meets the criteria to be classified as Benign for autosomal recessive SCID. ACMG/AMP criteria applied, as specified by the ClinGen SCID-VCEP: BA1 and BS2_Supporting. (VCEP specifications version 1).		Severe Combined Immunodeficiency Disease  VCEP		2024-01-23	2024-01-23	False	https://erepo.genome.network/evrepo/ui/classification/CA5949933/MONDO:0000572/123	3b035dd6-9008-48f6-993a-b85715aecd8c	p.His84Arg	His	84	Arg	MAASFPPTLGLSSAPDEIQHPHIKFSEWKFKLFRVRSFEKTPEEAQKEKKDSFEGKPSLEQSPAVLDKADGQKPVPTQPLLKAHPKFSKKFHDNEKARGKAIHQANLRHLCRICGNSFRADEHNRRYPVHGPVDGKTLGLLRKKEKRATSWPDLIAKVFRIDVKADVDSIHPTEFCHNCWSIMHRKFSSAPCEVYFPRNVTMEWHPHTPSCDICNTARRGLKRKSLQPNLQLSKKLKTVLDQARQARQHKRRAQARISSKDVMKKIANCSKIHLSTKLLAVDFPEHFVKSISCQICEHILADPVETNCKHVFCRVCILRCLKVMGSYCPSCRYPCFPTDLESPVKSFLSVLNSLMVKCPAKECNEEVSLEKYNHHISSHKESKEIFVHINKGGRPRQHLLSLTRRAQKHRLRELKLQVKAFADKEEGGDVKSVCMTLFLLALRARNEHRQADELEAIMQGKGSGLQPAVCLAIRVNTFLSCSQYHKMYRTVKAITGRQIFQPLHALRNAEKVLLPGYHHFEWQPPLKNVSSSTDVGIIDGLSGLSSSVDDYPVDTIAKRFRYDSALVSALMDMEEDILEGMRSQDLDDYLNGPFTVVVKESCDGMGDVSEKHGSGPVVPEKAVRFSFTIMKITIAHSSQNVKVFEEAKPNSELCCKPLCLMLADESDHETLTAILSPLIAEREAMKSSELMLELGGILRTFKFIFRGTGYDEKLVREVEGLEASGSVYICTLCDATRLEASQNLVFHSITRSHAENLERYEVWRSNPYHESVEELRDRVKGVSAKPFIETVPSIDALHCDIGNAAEFYKIFQLEIGEVYKNPNASKEERKRWQATLDKHLRKKMNLKPIMRMNGNFARKLMTKETVDAVCELIPSEERHEALRELMDLYLKMKPVWRSSCPAKECPESLCQYSFNSQRFAELLSTKFKYRYEGKITNYFHKTLAHVPEIIERDGSIGAWASEGNESGNKLFRRFRKMNARQSKCYEMEDVLKHHWLYTSKYLQKFMNAHNALKTSGFTMNPQASLGDPLGIEDSLESQDSMEF	1043	P15918	R	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [4], 'TRANSIT_gain': [], 'TRANSIT_loss_score': array([-0.00311571]), 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [913], 'HELIX_gain': [153, 157, 575, 863, 950], 'HELIX_gain_score': array([0.03020072, 0.02381498, 0.00624609, 0.00408828, 0.00464696]), 'HELIX_loss_score': array([-0.0049907]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [38], 'COMPBIAS_gain_score': array([0.01450777]), 'DOMAIN_loss': [], 'DOMAIN_gain': [178, 179, 781], 'DOMAIN_gain_score': array([0.07425529, 0.04847467, 0.00182962]), 'REGION_loss': [], 'REGION_gain': [80, 81], 'REGION_gain_score': array([0.17532057, 0.13017398]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
680	NM_000448.3(RAG1):c.746A>G (p.His249Arg)	403361	CA5950043	NM_000448.3:c.746A>G, NC_000011.10:g.36574050A>G, CM000673.2:g.36574050A>G, NC_000011.9:g.36595600A>G, CM000673.1:g.36595600A>G, NC_000011.8:g.36552176A>G, ENST00000299440.6:c.746A>G, ENST00000299440.5:c.746A>G, ENST00000534663.1:c.746A>G, XM_005253041.3:c.746A>G, XM_011520250.1:c.746A>G, XM_011520251.1:c.746A>G, XM_005253041.4:c.746A>G, XM_011520250.2:c.746A>G, NM_001377277.1:c.746A>G, NM_001377278.1:c.746A>G, NM_001377279.1:c.746A>G, NM_001377280.1:c.746A>G, NM_000448.3(RAG1):c.746A>G (p.His249Arg)	RAG1	recombinase activating gene 1 deficiency	MONDO:0000572	Autosomal recessive inheritance	Benign	BS2_Supporting, BA1		The NM_000448.3:c.746A>G variant in RAG1 is a missense variant predicted to cause the substitution of Histidine by Arginine at amino acid 249 (p.His249Arg). The filtering allele frequency (the lower threshold of the 95% CI of 34582/44854) of the c.746A>G variant in RAG1 is 0.7646 for East Asian chromosomes by gnomAD v.4, which is higher than the ClinGen SCID VCEP threshold (>0.00872) for BA1, and therefore meets this criterion (BA1). Additionally, 127763 homozygous adults are reported in gnomAD v.4. BS2_Supporting is Met. In summary, this variant meets the criteria to be classified as Benign for  Autosomal Recessive SCID. ACMG/AMP criteria applied, as specified by the ClinGen SCID-VCEP: BA1 and BS2_Supporting. (VCEP specifications version 1).		Severe Combined Immunodeficiency Disease  VCEP		2024-01-23	2024-01-23	False	https://erepo.genome.network/evrepo/ui/classification/CA5950043/MONDO:0000572/123	0ae93900-298a-45d9-809a-8e738c2880c3	p.His249Arg	His	249	Arg	MAASFPPTLGLSSAPDEIQHPHIKFSEWKFKLFRVRSFEKTPEEAQKEKKDSFEGKPSLEQSPAVLDKADGQKPVPTQPLLKAHPKFSKKFHDNEKARGKAIHQANLRHLCRICGNSFRADEHNRRYPVHGPVDGKTLGLLRKKEKRATSWPDLIAKVFRIDVKADVDSIHPTEFCHNCWSIMHRKFSSAPCEVYFPRNVTMEWHPHTPSCDICNTARRGLKRKSLQPNLQLSKKLKTVLDQARQARQHKRRAQARISSKDVMKKIANCSKIHLSTKLLAVDFPEHFVKSISCQICEHILADPVETNCKHVFCRVCILRCLKVMGSYCPSCRYPCFPTDLESPVKSFLSVLNSLMVKCPAKECNEEVSLEKYNHHISSHKESKEIFVHINKGGRPRQHLLSLTRRAQKHRLRELKLQVKAFADKEEGGDVKSVCMTLFLLALRARNEHRQADELEAIMQGKGSGLQPAVCLAIRVNTFLSCSQYHKMYRTVKAITGRQIFQPLHALRNAEKVLLPGYHHFEWQPPLKNVSSSTDVGIIDGLSGLSSSVDDYPVDTIAKRFRYDSALVSALMDMEEDILEGMRSQDLDDYLNGPFTVVVKESCDGMGDVSEKHGSGPVVPEKAVRFSFTIMKITIAHSSQNVKVFEEAKPNSELCCKPLCLMLADESDHETLTAILSPLIAEREAMKSSELMLELGGILRTFKFIFRGTGYDEKLVREVEGLEASGSVYICTLCDATRLEASQNLVFHSITRSHAENLERYEVWRSNPYHESVEELRDRVKGVSAKPFIETVPSIDALHCDIGNAAEFYKIFQLEIGEVYKNPNASKEERKRWQATLDKHLRKKMNLKPIMRMNGNFARKLMTKETVDAVCELIPSEERHEALRELMDLYLKMKPVWRSSCPAKECPESLCQYSFNSQRFAELLSTKFKYRYEGKITNYFHKTLAHVPEIIERDGSIGAWASEGNESGNKLFRRFRKMNARQSKCYEMEDVLKHHWLYTSKYLQKFMNAHNALKTSGFTMNPQASLGDPLGIEDSLESQDSMEF	1043	P15918	R	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [913], 'HELIX_gain': [575], 'HELIX_gain_score': array([0.00252599]), 'HELIX_loss_score': array([-0.00515038]), 'COILED_loss': [], 'COILED_gain': [261], 'COILED_gain_score': array([0.10610098]), 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [632], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.00825834]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
681	NM_000448.3(RAG1):c.1346G>A (p.Arg449Lys)	256188	CA5950130	NM_000448.3:c.1346G>A, NC_000011.10:g.36574650G>A, CM000673.2:g.36574650G>A, NC_000011.9:g.36596200G>A, CM000673.1:g.36596200G>A, NC_000011.8:g.36552776G>A, NG_007528.1:g.11638G>A, LRG_98:g.11638G>A, ENST00000299440.6:c.1346G>A, ENST00000299440.5:c.1346G>A, ENST00000534663.1:c.1346G>A, NM_000448.2:c.1346G>A, LRG_98t1:c.1346G>A, XM_005253041.3:c.1346G>A, XM_011520250.1:c.1346G>A, XM_011520251.1:c.1346G>A, XM_005253041.4:c.1346G>A, XM_011520250.2:c.1346G>A, NM_001377277.1:c.1346G>A, NM_001377278.1:c.1346G>A, NM_001377279.1:c.1346G>A, NM_001377280.1:c.1346G>A, NM_000448.3(RAG1):c.1346G>A (p.Arg449Lys)	RAG1	recombinase activating gene 1 deficiency	MONDO:0000572	Autosomal recessive inheritance	Benign	BS2_Supporting, BA1		The NM_000448.3:c.1346G>A variant in RAG1 is a missense variant predicted to cause the substitution of Arginine by Lysine at amino acid 449 (p.Arg449Lys). The filtering allele frequency (the lower threshold of the 95% CI of 21803/1180030) of the c.1346G>A variant in RAG1 is 0.01837 for European (non-Finnish) chromosomes by gnomAD v.4, which is higher than the ClinGen SCID VCEP threshold (>0.00872) for BA1 and, therefore, meets this criterion (BA1). Additionally, 207 homozygous adults are reported on gnomAD v.4 (BS2_Supporting). In summary, this variant meets the criteria to be classified as Benign for autosomal recessive SCID. ACMG/AMP criteria applied, as specified by the ClinGen SCID-VCEP: BA1 and BS2_Supporting. (VCEP specifications version 1).		Severe Combined Immunodeficiency Disease  VCEP		2024-01-23	2024-01-23	False	https://erepo.genome.network/evrepo/ui/classification/CA5950130/MONDO:0000572/123	9a1a1479-2183-4e3d-bff7-3898c6865d3a	p.Arg449Lys	Arg	449	Lys	MAASFPPTLGLSSAPDEIQHPHIKFSEWKFKLFRVRSFEKTPEEAQKEKKDSFEGKPSLEQSPAVLDKADGQKPVPTQPLLKAHPKFSKKFHDNEKARGKAIHQANLRHLCRICGNSFRADEHNRRYPVHGPVDGKTLGLLRKKEKRATSWPDLIAKVFRIDVKADVDSIHPTEFCHNCWSIMHRKFSSAPCEVYFPRNVTMEWHPHTPSCDICNTARRGLKRKSLQPNLQLSKKLKTVLDQARQARQHKRRAQARISSKDVMKKIANCSKIHLSTKLLAVDFPEHFVKSISCQICEHILADPVETNCKHVFCRVCILRCLKVMGSYCPSCRYPCFPTDLESPVKSFLSVLNSLMVKCPAKECNEEVSLEKYNHHISSHKESKEIFVHINKGGRPRQHLLSLTRRAQKHRLRELKLQVKAFADKEEGGDVKSVCMTLFLLALRARNEHRQADELEAIMQGKGSGLQPAVCLAIRVNTFLSCSQYHKMYRTVKAITGRQIFQPLHALRNAEKVLLPGYHHFEWQPPLKNVSSSTDVGIIDGLSGLSSSVDDYPVDTIAKRFRYDSALVSALMDMEEDILEGMRSQDLDDYLNGPFTVVVKESCDGMGDVSEKHGSGPVVPEKAVRFSFTIMKITIAHSSQNVKVFEEAKPNSELCCKPLCLMLADESDHETLTAILSPLIAEREAMKSSELMLELGGILRTFKFIFRGTGYDEKLVREVEGLEASGSVYICTLCDATRLEASQNLVFHSITRSHAENLERYEVWRSNPYHESVEELRDRVKGVSAKPFIETVPSIDALHCDIGNAAEFYKIFQLEIGEVYKNPNASKEERKRWQATLDKHLRKKMNLKPIMRMNGNFARKLMTKETVDAVCELIPSEERHEALRELMDLYLKMKPVWRSSCPAKECPESLCQYSFNSQRFAELLSTKFKYRYEGKITNYFHKTLAHVPEIIERDGSIGAWASEGNESGNKLFRRFRKMNARQSKCYEMEDVLKHHWLYTSKYLQKFMNAHNALKTSGFTMNPQASLGDPLGIEDSLESQDSMEF	1043	P15918	K	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [913], 'HELIX_gain': [435, 436, 437, 438, 439, 440, 441, 442, 554, 575], 'HELIX_gain_score': array([0.11083215, 0.12576765, 0.13031602, 0.14433503, 0.14162731,
       0.14930844, 0.14459461, 0.17097902, 0.0131458 , 0.00439787]), 'HELIX_loss_score': array([-0.0087319]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
682	NM_000448.3(RAG1):c.1573C>T (p.Pro525Ser)	785784	CA5950156	NM_000448.3:c.1573C>T, NC_000011.10:g.36574877C>T, CM000673.2:g.36574877C>T, NC_000011.9:g.36596427C>T, CM000673.1:g.36596427C>T, NC_000011.8:g.36553003C>T, NG_007528.1:g.11865C>T, LRG_98:g.11865C>T, ENST00000299440.6:c.1573C>T, ENST00000299440.5:c.1573C>T, ENST00000534663.1:c.1573C>T, NM_000448.2:c.1573C>T, LRG_98t1:c.1573C>T, XM_005253041.3:c.1573C>T, XM_011520250.1:c.1573C>T, XM_011520251.1:c.1573C>T, XM_005253041.4:c.1573C>T, XM_011520250.2:c.1573C>T, NM_001377277.1:c.1573C>T, NM_001377278.1:c.1573C>T, NM_001377279.1:c.1573C>T, NM_001377280.1:c.1573C>T, NM_000448.3(RAG1):c.1573C>T (p.Pro525Ser)	RAG1	recombinase activating gene 1 deficiency	MONDO:0000572	Autosomal recessive inheritance	Benign	BS2_Supporting, BA1		The NM_000448.3:c.1573C>T variant in RAG1 is a missense variant predicted to cause the substitution of Proline by Serine at amino acid 525 (p.Pro525Ser). The filtering allele frequency (the lower threshold of the 95% CI of 1571/91080) of the c.1573C>T variant in RAG1 is 0.01663 for South Asian chromosomes by gnomAD v.4, which is higher than the ClinGen SCID VCEP threshold (>0.00872) for BA1, and therefore meets this criterion (BA1). Additionally, 24 homozygous adults are reported on gnomAD v.4, BS2_Supporting is Met.In summary, this variant meets the criteria to be classified as Benign for autosomal recessive SCID, based on the ACMG/AMP criteria applied, as specified by the ClinGen SCID-VCEP: BA1 and BS2_Supporting. (VCEP specifications version 1).		Severe Combined Immunodeficiency Disease  VCEP		2024-01-23	2024-01-23	False	https://erepo.genome.network/evrepo/ui/classification/CA5950156/MONDO:0000572/123	ff322d40-0d85-45cd-838f-9837973d10a6	p.Pro525Ser	Pro	525	Ser	MAASFPPTLGLSSAPDEIQHPHIKFSEWKFKLFRVRSFEKTPEEAQKEKKDSFEGKPSLEQSPAVLDKADGQKPVPTQPLLKAHPKFSKKFHDNEKARGKAIHQANLRHLCRICGNSFRADEHNRRYPVHGPVDGKTLGLLRKKEKRATSWPDLIAKVFRIDVKADVDSIHPTEFCHNCWSIMHRKFSSAPCEVYFPRNVTMEWHPHTPSCDICNTARRGLKRKSLQPNLQLSKKLKTVLDQARQARQHKRRAQARISSKDVMKKIANCSKIHLSTKLLAVDFPEHFVKSISCQICEHILADPVETNCKHVFCRVCILRCLKVMGSYCPSCRYPCFPTDLESPVKSFLSVLNSLMVKCPAKECNEEVSLEKYNHHISSHKESKEIFVHINKGGRPRQHLLSLTRRAQKHRLRELKLQVKAFADKEEGGDVKSVCMTLFLLALRARNEHRQADELEAIMQGKGSGLQPAVCLAIRVNTFLSCSQYHKMYRTVKAITGRQIFQPLHALRNAEKVLLPGYHHFEWQPPLKNVSSSTDVGIIDGLSGLSSSVDDYPVDTIAKRFRYDSALVSALMDMEEDILEGMRSQDLDDYLNGPFTVVVKESCDGMGDVSEKHGSGPVVPEKAVRFSFTIMKITIAHSSQNVKVFEEAKPNSELCCKPLCLMLADESDHETLTAILSPLIAEREAMKSSELMLELGGILRTFKFIFRGTGYDEKLVREVEGLEASGSVYICTLCDATRLEASQNLVFHSITRSHAENLERYEVWRSNPYHESVEELRDRVKGVSAKPFIETVPSIDALHCDIGNAAEFYKIFQLEIGEVYKNPNASKEERKRWQATLDKHLRKKMNLKPIMRMNGNFARKLMTKETVDAVCELIPSEERHEALRELMDLYLKMKPVWRSSCPAKECPESLCQYSFNSQRFAELLSTKFKYRYEGKITNYFHKTLAHVPEIIERDGSIGAWASEGNESGNKLFRRFRKMNARQSKCYEMEDVLKHHWLYTSKYLQKFMNAHNALKTSGFTMNPQASLGDPLGIEDSLESQDSMEF	1043	P15918	S	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [5], 'TRANSIT_gain_score': array([0.00931686]), 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [554], 'HELIX_gain_score': array([0.01386315]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [725], 'DOMAIN_gain': [178, 179], 'DOMAIN_gain_score': array([0.0283941 , 0.02742857]), 'DOMAIN_loss_score': array([-0.01490825]), 'REGION_loss': [], 'REGION_gain': [80], 'REGION_gain_score': array([0.00374401]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
683	NM_000448.3(RAG1):c.2459A>G (p.Lys820Arg)	256189	CA5950267	NM_000448.3:c.2459A>G, NC_000011.10:g.36575763A>G, CM000673.2:g.36575763A>G, NC_000011.9:g.36597313A>G, CM000673.1:g.36597313A>G, NC_000011.8:g.36553889A>G, NG_007528.1:g.12751A>G, LRG_98:g.12751A>G, ENST00000299440.6:c.2459A>G, ENST00000299440.5:c.2459A>G, ENST00000524423.1:n.340T>C, ENST00000534663.1:c.2459A>G, NM_000448.2:c.2459A>G, LRG_98t1:c.2459A>G, XM_005253041.3:c.2459A>G, XM_011520250.1:c.2459A>G, XM_011520251.1:c.2459A>G, XM_005253041.4:c.2459A>G, XM_011520250.2:c.2459A>G, NM_001377277.1:c.2459A>G, NM_001377278.1:c.2459A>G, NM_001377279.1:c.2459A>G, NM_001377280.1:c.2459A>G, NM_000448.3(RAG1):c.2459A>G (p.Lys820Arg)	RAG1	recombinase activating gene 1 deficiency	MONDO:0000572	Autosomal recessive inheritance	Benign	BS2_Supporting, BA1		The NM_000448.3:c.2459A>G variant in RAG1 is a missense variant predicted to cause the substitution of Lysine by Arginine at amino acid 820 (p.Lys820Arg). The filtering allele frequency (the lower threshold of the 95% CI of 26338/44862) of the c.2459A>G variant in RAG1 is 0.5818 for East Asian chromosomes by gnomAD v.4, which is higher than the ClinGen SCID VCEP threshold (>0.00872) for BA1, and therefore meets this criterion (BA1). Additionally, 22786 homozygous adults are reported on gnomAD v.4, BS2_Supporting is Met.In summary, this variant meets the criteria to be classified as Benign for autosomal recessive SCID. ACMG/AMP criteria applied, as specified by the ClinGen SCID-VCEP: BA1 and BS2_Supporting. (VCEP specifications version 1).		Severe Combined Immunodeficiency Disease  VCEP		2024-01-23	2024-01-23	False	https://erepo.genome.network/evrepo/ui/classification/CA5950267/MONDO:0000572/123	6cf7f377-1194-41d6-bf55-408745e22428	p.Lys820Arg	Lys	820	Arg	MAASFPPTLGLSSAPDEIQHPHIKFSEWKFKLFRVRSFEKTPEEAQKEKKDSFEGKPSLEQSPAVLDKADGQKPVPTQPLLKAHPKFSKKFHDNEKARGKAIHQANLRHLCRICGNSFRADEHNRRYPVHGPVDGKTLGLLRKKEKRATSWPDLIAKVFRIDVKADVDSIHPTEFCHNCWSIMHRKFSSAPCEVYFPRNVTMEWHPHTPSCDICNTARRGLKRKSLQPNLQLSKKLKTVLDQARQARQHKRRAQARISSKDVMKKIANCSKIHLSTKLLAVDFPEHFVKSISCQICEHILADPVETNCKHVFCRVCILRCLKVMGSYCPSCRYPCFPTDLESPVKSFLSVLNSLMVKCPAKECNEEVSLEKYNHHISSHKESKEIFVHINKGGRPRQHLLSLTRRAQKHRLRELKLQVKAFADKEEGGDVKSVCMTLFLLALRARNEHRQADELEAIMQGKGSGLQPAVCLAIRVNTFLSCSQYHKMYRTVKAITGRQIFQPLHALRNAEKVLLPGYHHFEWQPPLKNVSSSTDVGIIDGLSGLSSSVDDYPVDTIAKRFRYDSALVSALMDMEEDILEGMRSQDLDDYLNGPFTVVVKESCDGMGDVSEKHGSGPVVPEKAVRFSFTIMKITIAHSSQNVKVFEEAKPNSELCCKPLCLMLADESDHETLTAILSPLIAEREAMKSSELMLELGGILRTFKFIFRGTGYDEKLVREVEGLEASGSVYICTLCDATRLEASQNLVFHSITRSHAENLERYEVWRSNPYHESVEELRDRVKGVSAKPFIETVPSIDALHCDIGNAAEFYKIFQLEIGEVYKNPNASKEERKRWQATLDKHLRKKMNLKPIMRMNGNFARKLMTKETVDAVCELIPSEERHEALRELMDLYLKMKPVWRSSCPAKECPESLCQYSFNSQRFAELLSTKFKYRYEGKITNYFHKTLAHVPEIIERDGSIGAWASEGNESGNKLFRRFRKMNARQSKCYEMEDVLKHHWLYTSKYLQKFMNAHNALKTSGFTMNPQASLGDPLGIEDSLESQDSMEF	1043	P15918	R	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [834, 913, 915], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.0160166 , -0.01981062, -0.02123541]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [632], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.00203353]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
684	NM_000448.3(RAG1):c.2638G>A (p.Glu880Lys)	138884	CA293052	NM_000448.3:c.2638G>A, NC_000011.10:g.36575942G>A, CM000673.2:g.36575942G>A, NC_000011.9:g.36597492G>A, CM000673.1:g.36597492G>A, NC_000011.8:g.36554068G>A, NG_007528.1:g.12930G>A, LRG_98:g.12930G>A, ENST00000299440.6:c.2638G>A, ENST00000299440.5:c.2638G>A, ENST00000524423.1:n.161C>T, ENST00000534663.1:c.2638G>A, NM_000448.2:c.2638G>A, LRG_98t1:c.2638G>A, XM_005253041.3:c.2638G>A, XM_011520250.1:c.2638G>A, XM_011520251.1:c.2638G>A, XM_005253041.4:c.2638G>A, XM_011520250.2:c.2638G>A, NM_001377277.1:c.2638G>A, NM_001377278.1:c.2638G>A, NM_001377279.1:c.2638G>A, NM_001377280.1:c.2638G>A, NM_000448.3(RAG1):c.2638G>A (p.Glu880Lys)	RAG1	recombinase activating gene 1 deficiency	MONDO:0000572	Autosomal recessive inheritance	Benign	BS2_Supporting, BA1		The NM_000448.3:c.2638G>A variant in RAG1 is a missense variant predicted to cause the substitution of Glutamic Acid by Lysine at amino acid 880 (p.Glu880Lys). The filtering allele frequency (the lower threshold of the 95% CI of 3496/75044) of the c.2638G>A variant in RAG1 is 0.04730 for African/African American chromosomes by gnomAD v.4, which is higher than the ClinGen SCID VCEP threshold (>0.00872) for BA1, and therefore meets this criterion (BA1). Additionally, 84 homozygous adults are reported on gnomAD v.4 (BS2_Supporting). In summary, this variant meets the criteria to be classified as Benign for autosomal recessive SCID based on the ACMG/AMP criteria applied, as specified by the ClinGen SCID-VCEP: BA1 and BS2_Supporting. (VCEP specifications version 1).		Severe Combined Immunodeficiency Disease  VCEP		2024-01-23	2024-01-23	False	https://erepo.genome.network/evrepo/ui/classification/CA293052/MONDO:0000572/123	02968afa-1298-4a0c-aea4-61ca4fa8fc1a	p.Glu880Lys	Glu	880	Lys	MAASFPPTLGLSSAPDEIQHPHIKFSEWKFKLFRVRSFEKTPEEAQKEKKDSFEGKPSLEQSPAVLDKADGQKPVPTQPLLKAHPKFSKKFHDNEKARGKAIHQANLRHLCRICGNSFRADEHNRRYPVHGPVDGKTLGLLRKKEKRATSWPDLIAKVFRIDVKADVDSIHPTEFCHNCWSIMHRKFSSAPCEVYFPRNVTMEWHPHTPSCDICNTARRGLKRKSLQPNLQLSKKLKTVLDQARQARQHKRRAQARISSKDVMKKIANCSKIHLSTKLLAVDFPEHFVKSISCQICEHILADPVETNCKHVFCRVCILRCLKVMGSYCPSCRYPCFPTDLESPVKSFLSVLNSLMVKCPAKECNEEVSLEKYNHHISSHKESKEIFVHINKGGRPRQHLLSLTRRAQKHRLRELKLQVKAFADKEEGGDVKSVCMTLFLLALRARNEHRQADELEAIMQGKGSGLQPAVCLAIRVNTFLSCSQYHKMYRTVKAITGRQIFQPLHALRNAEKVLLPGYHHFEWQPPLKNVSSSTDVGIIDGLSGLSSSVDDYPVDTIAKRFRYDSALVSALMDMEEDILEGMRSQDLDDYLNGPFTVVVKESCDGMGDVSEKHGSGPVVPEKAVRFSFTIMKITIAHSSQNVKVFEEAKPNSELCCKPLCLMLADESDHETLTAILSPLIAEREAMKSSELMLELGGILRTFKFIFRGTGYDEKLVREVEGLEASGSVYICTLCDATRLEASQNLVFHSITRSHAENLERYEVWRSNPYHESVEELRDRVKGVSAKPFIETVPSIDALHCDIGNAAEFYKIFQLEIGEVYKNPNASKEERKRWQATLDKHLRKKMNLKPIMRMNGNFARKLMTKETVDAVCELIPSEERHEALRELMDLYLKMKPVWRSSCPAKECPESLCQYSFNSQRFAELLSTKFKYRYEGKITNYFHKTLAHVPEIIERDGSIGAWASEGNESGNKLFRRFRKMNARQSKCYEMEDVLKHHWLYTSKYLQKFMNAHNALKTSGFTMNPQASLGDPLGIEDSLESQDSMEF	1043	P15918	K	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [433], 'TRANSMEM_gain': [], 'TRANSMEM_loss_score': array([-0.00316912]), 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [4], 'TRANSIT_gain': [], 'TRANSIT_loss_score': array([-0.0042426]), 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [913, 915], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.02544677, -0.02670854]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [632], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.00406456]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
685	NM_000536.4(RAG2):c.644C>T (p.Thr215Ile)	13135	CA122864	NM_000536.4:c.644C>T, NC_000011.10:g.36593525G>A, CM000673.2:g.36593525G>A, NC_000011.9:g.36615075G>A, CM000673.1:g.36615075G>A, NC_000011.8:g.36571651G>A, NG_007573.1:g.9712C>T, LRG_99:g.9712C>T, NG_033154.1:g.4033G>A, ENST00000311485.8:c.644C>T, ENST00000311485.7:c.644C>T, ENST00000524423.1:n.131+4577C>T, ENST00000618712.4:c.644C>T, NM_000536.3:c.644C>T, NM_001243785.1:c.644C>T, NM_001243786.1:c.644C>T, NM_001243785.2:c.644C>T, NM_001243786.2:c.644C>T, NM_000536.4(RAG2):c.644C>T (p.Thr215Ile)	RAG2	recombinase activating gene 2 deficiency	MONDO:0000573	Autosomal recessive inheritance	Benign	BA1, BS2_Supporting		"The c.644C>T (NM_000536.4) variant in RAG2 is a missense variant predicted to cause substitution of Threonine by Isoleucine at amino acid 215 (p.Thr215Ile).The filtering allele frequency (the lower threshold of the 95% CI of 2177/91084 alleles) of the c.644C>T variant in RAG2 is 0.02308 for South Asian chromosomes by gnomAD v.4, which is higher than the ClinGen SCID VCEP threshold (>0.00872) for BA1, and therefore meets this criterion (BA1). Additionally, 42 homozygous individuals have been described (40 and 2 individuals in South Asian and """"""""""""""""Remaining"""""""""""""""" populations, respectively (BS2_Supporting).In summary, this variant meets the criteria to be classified as Benign for autosomal recessive recombinase activating gene 2 deficiency based on the ACMG/AMP criteria applied, as specified by the ClinGen SCID VCEP. Criteria applied: BA1 and BS2_Supporting (VCEP specifications version 1.0)."		Severe Combined Immunodeficiency Disease  VCEP		2024-01-23	2024-01-23	False	https://erepo.genome.network/evrepo/ui/classification/CA122864/MONDO:0000573/124	76b80f29-618c-4760-a6d1-807615561d42	p.Thr215Ile	Thr	215	Ile	MSLQMVTVSNNIALIQPGFSLMNFDGQVFFFGQKGWPKRSCPTGVFHLDVKHNHVKLKPTIFSKDSCYLPPLRYPATCTFKGSLESEKHQYIIHGGKTPNNEVSDKIYVMSIVCKNNKKVTFRCTEKDLVGDVPEARYGHSINVVYSRGKSMGVLFGGRSYMPSTHRTTEKWNSVADCLPCVFLVDFEFGCATSYILPELQDGLSFHVSIAKNDTIYILGGHSLANNIRPANLYRIRVDLPLGSPAVNCTVLPGGISVSSAILTQTNNDEFVIVGGYQLENQKRMICNIISLEDNKIEIREMETPDWTPDIKHSKIWFGSNMGNGTVFLGIPGDNKQVVSEGFYFYMLKCAEDDTNEEQTTFTNSQTSTEDPGDSTPFEDSEEFCFSAEANSFDGDDEFDTYNEDDEEDESETGYWITCCPTCDVDINTWVPFYSTELNKPAMIYCSHGDGHWVHAQCMDLAERTLIHLSAGSNKYYCNEHVEIARALHTPQRVLPLKKPPMKSLRKKGSGKILTPAKKSFLRRLFD	527	P55895	I	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [21], 'TOPO_DOM_gain_score': array([0.01055717]), 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [64, 76, 77, 142, 163, 166], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.02834839, -0.02643055, -0.01911348, -0.0243631 , -0.01939851,
       -0.00854337]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
686	NM_001033855.3(DCLRE1C):c.1894G>A (p.Glu632Lys)	598004	CA5416379	NM_001033855.3:c.1894G>A, NC_000010.11:g.14908593C>T, CM000672.2:g.14908593C>T, NC_000010.10:g.14950592C>T, CM000672.1:g.14950592C>T, NC_000010.9:g.14990598C>T, NG_007276.1:g.50503G>A, LRG_54:g.50503G>A, ENST00000378278.7:c.1894G>A, ENST00000357717.6:c.1549G>A, ENST00000378242.1:c.853G>A, ENST00000378246.6:c.1549G>A, ENST00000378249.5:c.1549G>A, ENST00000378254.5:c.1534G>A, ENST00000378255.5:c.1534G>A, ENST00000378258.5:c.1534G>A, ENST00000378278.6:c.1894G>A, ENST00000378289.8:c.1157-9281G>A, ENST00000396817.6:c.1534G>A, NM_001033855.2:c.1894G>A, NM_001033857.2:c.1534G>A, NM_001033858.2:c.1534G>A, NM_001289076.1:c.1549G>A, NM_001289077.1:c.1534G>A, NM_001289078.1:c.1549G>A, NM_001289079.1:c.1534G>A, NM_022487.3:c.1549G>A, NR_110297.1:n.2669G>A, XM_006717491.2:c.1549G>A, XM_011519616.1:c.1549G>A, XM_011519617.1:c.1549G>A, XM_011519618.1:c.1549G>A, XM_011519619.1:c.1534G>A, NM_001350965.1:c.1782+112G>A, NM_001350966.1:c.1437+112G>A, NM_001350967.1:c.1422+112G>A, NR_146960.1:n.2149+112G>A, NR_146961.1:n.2410G>A, NR_146962.1:n.2381G>A, XM_006717491.4:c.1549G>A, XM_017016557.1:c.1549G>A, XM_017016558.1:c.1534G>A, XM_024448134.1:c.1534G>A, XM_024448135.1:c.1437+112G>A, XR_001747185.2:n.2183G>A, XR_001747187.1:n.2015G>A, NM_001033857.3:c.1534G>A, NM_001033858.3:c.1534G>A, NM_001289076.2:c.1549G>A, NM_001289077.2:c.1534G>A, NM_001289078.2:c.1549G>A, NM_001289079.2:c.1534G>A, NM_001350965.2:c.1782+112G>A, NM_001350966.2:c.1437+112G>A, NM_001350967.2:c.1422+112G>A, NM_022487.4:c.1549G>A, NR_110297.2:n.2333G>A, NR_146961.2:n.2074G>A, NM_001033855.3(DCLRE1C):c.1894G>A (p.Glu632Lys)	DCLRE1C	severe combined immunodeficiency due to DCLRE1C deficiency	MONDO:0011225	Autosomal recessive inheritance	Benign	BA1, BS2_Supporting		The c.1894G>A (NM_001033855.3) variant in DCLRE1C is a missense variant predicted to cause substitution of Glutamic Acid by Lysine at amino acid 632 (p.Glu632Lys).The filtering allele frequency (the lower threshold of the 95% CI of 431/91076) of the c.1894G>A variant in DCLRE1C is 0.004306 for South Asian chromosomes by gnomAD v4, which is higher than the ClinGen SCID VCEP threshold (>0.00346) for BA1, and therefore meets this criterion (BA1). Additionally, 6 adult homozygous have been reported in the same population (BS2_Supporting).In summary, this variant meets the criteria to be classified as Benign for autosomal recessive severe combined immunodeficiency due to DCLRE1C deficiency, based on the ACMG/AMP criteria applied, as specified by the ClinGen SCID VCEP. Criteria applied: BA1 and BS2_Supporting (VCEP specifications version 1).		Severe Combined Immunodeficiency Disease  VCEP		2024-01-23	2024-01-23	False	https://erepo.genome.network/evrepo/ui/classification/CA5416379/MONDO:0011225/116	ce865125-3527-4e3a-b583-b842605ccb62	p.Glu632Lys	Glu	632	Lys	MSSFEGQMAEYPTISIDRFDRENLRARAYFLSHCHKDHMKGLRAPTLKRRLECSLKVYLYCSPVTKELLLTSPKYRFWKKRIISIEIETPTQISLVDEASGEKEEIVVTLLPAGHCPGSVMFLFQGNNGTVLYTGDFRLAQGEAARMELLHSGGRVKDIQSVYLDTTFCDPRFYQIPSREECLSGVLELVRSWITRSPYHVVWLNCKAAYGYEYLFTNLSEELGVQVHVNKLDMFRNMPEILHHLTTDRNTQIHACRHPKAEEYFQWSKLPCGITSRNRIPLHIISIKPSTMWFGERSRKTNVIVRTGESSYRACFSFHSSYSEIKDFLSYLCPVNAYPNVIPVGTTMDKVVEILKPLCRSSQSTEPKYKPLGKLKRARTVHRDSEEEDDYLFDDPLPIPLRHKVPYPETFHPEVFSMTAVSEKQPEKLRQTPGCCRAECMQSSRFTNFVDCEESNSESEEEVGIPASLQGDLGSVLHLQKADGDVPQWEVFFKRNDEITDESLENFPSSTVAGGSQSPKLFSDSDGESTHISSQNSSQSTHITEQGSQGWDSQSDTVLLSSQERNSGDITSLDKADYRPTIKENIPASLMEQNVICPKDTYSDLKSRDKDVTIVPSTGEPTTLSSETHIPEEKSLLNLSTNADSQSSSDFEVPSTPEAELPKREHLQYLYEKLATGESIAVKKRKCSLLDT	692	Q96SD1	K	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [634, 636], 'COMPBIAS_gain': [617], 'COMPBIAS_gain_score': array([0.03311646]), 'COMPBIAS_loss_score': array([-0.07423818, -0.07315898]), 'DOMAIN_loss': [], 'DOMAIN_gain': [128, 149], 'DOMAIN_gain_score': array([0.00728637, 0.01231217]), 'REGION_loss': [], 'REGION_gain': [616], 'REGION_gain_score': array([0.03013301]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
687	NM_001033855.3(DCLRE1C):c.728A>G (p.His243Arg)	257180	CA5416704	NM_001033855.3:c.728A>G, NC_000010.11:g.14932906T>C, CM000672.2:g.14932906T>C, NC_000010.10:g.14974905T>C, CM000672.1:g.14974905T>C, NC_000010.9:g.15014911T>C, NG_007276.1:g.26190A>G, LRG_54:g.26190A>G, ENST00000378278.7:c.728A>G, ENST00000357717.6:c.383A>G, ENST00000378246.6:c.383A>G, ENST00000378249.5:c.383A>G, ENST00000378254.5:c.368A>G, ENST00000378255.5:c.368A>G, ENST00000378258.5:c.368A>G, ENST00000378278.6:c.728A>G, ENST00000378289.8:c.728A>G, ENST00000396817.6:c.368A>G, ENST00000418843.5:c.290A>G, NM_001033855.2:c.728A>G, NM_001033857.2:c.368A>G, NM_001033858.2:c.368A>G, NM_001289076.1:c.383A>G, NM_001289077.1:c.368A>G, NM_001289078.1:c.383A>G, NM_001289079.1:c.368A>G, NM_022487.3:c.383A>G, NR_110297.1:n.1362A>G, XM_006717491.2:c.383A>G, XM_011519616.1:c.383A>G, XM_011519617.1:c.383A>G, XM_011519618.1:c.383A>G, XM_011519619.1:c.368A>G, XM_011519620.1:c.728A>G, XM_011519621.1:c.728A>G, XR_242702.2:n.825A>G, XR_930514.1:n.825A>G, XR_930515.1:n.825A>G, NM_001350965.1:c.728A>G, NM_001350966.1:c.383A>G, NM_001350967.1:c.368A>G, NR_146960.1:n.1150A>G, NR_146961.1:n.1179A>G, NR_146962.1:n.1150A>G, XM_006717491.4:c.383A>G, XM_011519620.3:c.728A>G, XM_011519621.2:c.728A>G, XM_017016557.1:c.383A>G, XM_017016558.1:c.368A>G, XM_024448134.1:c.368A>G, XM_024448135.1:c.383A>G, XR_001747185.2:n.1072A>G, XR_001747187.1:n.708A>G, XR_930515.2:n.1072A>G, NM_001033857.3:c.368A>G, NM_001033858.3:c.368A>G, NM_001289076.2:c.383A>G, NM_001289077.2:c.368A>G, NM_001289078.2:c.383A>G, NM_001289079.2:c.368A>G, NM_001350965.2:c.728A>G, NM_001350966.2:c.383A>G, NM_001350967.2:c.368A>G, NM_022487.4:c.383A>G, NR_110297.2:n.1026A>G, NR_146961.2:n.843A>G, NM_001033855.3(DCLRE1C):c.728A>G (p.His243Arg)	DCLRE1C	severe combined immunodeficiency due to DCLRE1C deficiency	MONDO:0011225	Autosomal recessive inheritance	Benign	BA1, BS2_Supporting		The c.728A>G (NM_001033855.3) variant in DCLRE1C is a missense variant predicted to cause substitution of Histidine by Arginine at amino acid 243 (p.His243Arg).The filtering allele frequency (the lower threshold of the 95% CI of 13221/60002) of the c.728A>G variant in DCLRE1C is 0.2249 for Admixed American chromosomes by gnomAD v4, which is higher than the ClinGen SCID VCEP threshold (>0.00346) for BA1, and therefore meets this criterion (BA1). Additionally, 23214 adult homozygous have been reported (BS2_Supporting).In summary, this variant meets the criteria to be classified as Benign for autosomal recessive severe combined immunodeficiency due to DCLRE1C deficiency, based on the ACMG/AMP criteria applied, as specified by the ClinGen SCID VCEP. Criteria applied: BA1 and BS2_Supporting (VCEP specifications version 1).		Severe Combined Immunodeficiency Disease  VCEP		2024-01-23	2024-01-23	False	https://erepo.genome.network/evrepo/ui/classification/CA5416704/MONDO:0011225/116	7e71d964-bb7a-40e1-9385-3393a4499ac5	p.His243Arg	His	243	Arg	MSSFEGQMAEYPTISIDRFDRENLRARAYFLSHCHKDHMKGLRAPTLKRRLECSLKVYLYCSPVTKELLLTSPKYRFWKKRIISIEIETPTQISLVDEASGEKEEIVVTLLPAGHCPGSVMFLFQGNNGTVLYTGDFRLAQGEAARMELLHSGGRVKDIQSVYLDTTFCDPRFYQIPSREECLSGVLELVRSWITRSPYHVVWLNCKAAYGYEYLFTNLSEELGVQVHVNKLDMFRNMPEILHHLTTDRNTQIHACRHPKAEEYFQWSKLPCGITSRNRIPLHIISIKPSTMWFGERSRKTNVIVRTGESSYRACFSFHSSYSEIKDFLSYLCPVNAYPNVIPVGTTMDKVVEILKPLCRSSQSTEPKYKPLGKLKRARTVHRDSEEEDDYLFDDPLPIPLRHKVPYPETFHPEVFSMTAVSEKQPEKLRQTPGCCRAECMQSSRFTNFVDCEESNSESEEEVGIPASLQGDLGSVLHLQKADGDVPQWEVFFKRNDEITDESLENFPSSTVAGGSQSPKLFSDSDGESTHISSQNSSQSTHITEQGSQGWDSQSDTVLLSSQERNSGDITSLDKADYRPTIKENIPASLMEQNVICPKDTYSDLKSRDKDVTIVPSTGEPTTLSSETHIPEEKSLLNLSTNADSQSSSDFEVPSTPEAELPKREHLQYLYEKLATGESIAVKKRKCSLLDT	692	Q96SD1	R	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [244], 'HELIX_gain_score': array([0.03455812]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [190], 'DOMAIN_gain': [128, 149], 'DOMAIN_gain_score': array([0.00788403, 0.01695949]), 'DOMAIN_loss_score': array([-0.02961481]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
688	NM_000022.4(ADA):c.646G>A (p.Gly216Arg)	1968	CA252008	NM_000022.4:c.646G>A, NC_000020.11:g.44623039C>T, CM000682.2:g.44623039C>T, NC_000020.10:g.43251680C>T, CM000682.1:g.43251680C>T, NC_000020.9:g.42685094C>T, NG_007385.1:g.33697G>A, LRG_16:g.33697G>A, ENST00000372874.9:c.646G>A, ENST00000372874.8:c.646G>A, ENST00000372887.5:c.152-894C>T, ENST00000464097.5:n.320G>A, ENST00000492931.5:n.730G>A, ENST00000536532.5:c.646G>A, ENST00000537820.1:c.607-109G>A, ENST00000539235.5:c.*30G>A, NM_000022.2:c.646G>A, LRG_16t1:c.646G>A, XM_005260236.2:c.607-109G>A, XM_011528478.1:c.241G>A, XM_011528479.1:c.241G>A, XR_244129.1:n.700G>A, NM_000022.3:c.646G>A, NM_001322050.1:c.241G>A, NM_001322051.1:c.607-109G>A, NR_136160.1:n.797G>A, NM_001322050.2:c.241G>A, NM_001322051.2:c.607-109G>A, NR_136160.2:n.738G>A, NM_000022.4(ADA):c.646G>A (p.Gly216Arg)	ADA	adenosine deaminase deficiency	MONDO:0007064	Autosomal recessive inheritance	Pathogenic	PP4_Moderate, PM2_Supporting, PS3_Moderate, PM3_Strong, PP1_Strong	PM1, PP2, PP3, BP1, BP4, PS4	NM_000022.4 :c.646G>A is a missense variant predicted to cause substitution of  Glycine by Arginine at amino acid 216 (p.Gly216Arg). The filtering allele frequency (the upper threshold of the 95% CI of 46/1180026) of the c.646G>A variant in ADA is 0.00002743 for European Non-Finnish chromosomes by gnomAD v4, which is lower than the ClinGen SCID VCEP threshold (<0.0001742) for PM2_Supporting, and therefore meets this criterion (PM2_Supporting).The variant has been reported to segregate with SCID in 4 affected family members from 2 families (PP1_strong; PMID : 26255240). This variant has been detected in 15 individuals with ADA deficient SCID. Of those individuals, 3 were compound heterozygous for the variant and a pathogenic variant (Glu319Glyfs*320 ,confirmed in trans ,1pt.). 12 individuals were homozygous for the variant (1 pt.) (total: 2 pts; PM3_Strong ,PMID : 26255240). Male patient with SCID (0.5 pt.), genome sequencing conducted (0.5 pt.), reduced ADA enzyme activity in patient cells (1 pt),SCID phenotype corrected by exogenous ADA supplementation (1 pt.),Increased dATP in pretreatment erythrocytes (2 pts.). (PP4_Moderate (5 pts.), PMID: 1680289). ADA activity in SØ3834 was 30.4 nmol/h/mg protein which is .012 % of wild type ADA activity indicating that this variant impacts protein function (PMID : 9758612, PS3_Moderate). Based on the above evidence, the variant may be classified as pathogenic for autosomal recessive severe combined immunodeficiency due to ADA deficiency based on the ACMG/AMP criteria applied, as specified by the ClinGen SCID VCEP: PP1_strong,PM2_supporting,PM3_strong,PP4_moderate,PS3_moderate (VCEP specifications version 1).		Severe Combined Immunodeficiency Disease  VCEP		2024-01-24	2024-01-24	False	https://erepo.genome.network/evrepo/ui/classification/CA252008/MONDO:0007064/114	a0ddb75c-ba0b-4900-89fd-00d467cb01d7	p.Gly216Arg	Gly	216	Arg	MAQTPAFDKPKVELHVHLDGSIKPETILYYGRRRGIALPANTAEGLLNVIGMDKPLTLPDFLAKFDYYMPAIAGCREAIKRIAYEFVEMKAKEGVVYVEVRYSPHLLANSKVEPIPWNQAEGDLTPDEVVALVGQGLQEGERDFGVKARSILCCMRHQPNWSPKVVELCKKYQQQTVVAIDLAGDETIPGSSLLPGHVQAYQEAVKSGIHRTVHAGEVGSAEVVKEAVDILKTERLGHGYHTLEDQALYNRLRQENMHFEICPWSSYLTGAWKPDTEHAVIRLKNDQANYSLNTDDPLIFKSTLDTDYQMTKRDMGFTEEEFKRLNINAAKSSFLPEDEKRELLDLLYKAYGMPPSASAGQNL	363	P00813	R	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [216], 'BINDING_gain': [], 'BINDING_loss_score': array([-0.22782886]), 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [208], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.06204891]), 'HELIX_loss': [191, 356], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.01688159, -0.02451706]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [143], 'DOMAIN_gain_score': array([0.06380165]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [179, 180, 185, 219, 220, 268, 292, 300], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.0368492 , -0.01050752, -0.02216995, -0.01331091, -0.02684444,
       -0.03627139, -0.0178979 , -0.01916075]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
689	NM_000206.3(IL2RG):c.202G>A (p.Glu68Lys)	379561	CA16608976	NM_000206.3:c.202G>A, NC_000023.11:g.71110964C>T, CM000685.2:g.71110964C>T, NC_000023.10:g.70330814C>T, CM000685.1:g.70330814C>T, NC_000023.9:g.70247539C>T, NG_009088.1:g.5590G>A, LRG_150:g.5590G>A, NG_021141.1:g.825G>A, ENST00000374202.7:c.202G>A, ENST00000642473.1:n.566G>A, ENST00000644022.1:n.608G>A, ENST00000644708.1:n.608G>A, ENST00000644911.1:n.608G>A, ENST00000645266.1:c.202G>A, ENST00000645518.1:c.202G>A, ENST00000646106.1:c.202G>A, ENST00000646505.1:c.202G>A, ENST00000647492.1:c.202G>A, ENST00000276110.6:n.587G>A, ENST00000374188.7:c.-515G>A, ENST00000374202.6:c.202G>A, ENST00000456850.6:c.24+461G>A, ENST00000464642.5:c.70G>A, ENST00000473378.1:c.139G>A, ENST00000487883.1:c.166G>A, ENST00000512747.3:n.269G>A, NM_000206.2:c.202G>A, LRG_150t1:c.202G>A, NM_000206.3(IL2RG):c.202G>A (p.Glu68Lys)	IL2RG	T-B+ severe combined immunodeficiency due to gamma chain deficiency	MONDO:0010315	X-linked inheritance	Pathogenic	PP4_Moderate, PM2_Supporting, PS4		NM_000206.3(IL2RG):c.202G>A  is a missense variant predicted to cause substitution of Glutamic Acid by Lysine at amino acid 68 (p.Glu68Lys). The variant is absent in gnomAD v4 (PM2_supporting). Male patient (0.5 pt.) with SCID (0.5 pt.), genome sequencing conducted (1 pt.), Absent CD132 expression (1 pt.), T-B+NK- lymphocyte subset profile (0.5 pt.); total :3.5 pts  PMID: 30778343 (PP4_moderate). This variant is found in multiple unrelated affected probands (total pts. >16) (PS4_very strong) (PMIDs: 9058718, 24534054,11129345, 32477911,31456805, 27484032,31031743,30778343).As per the SCID VCEP specifications and the Bayesian interpretation of the ACMG/AMP combining rules, 1 Very Strong,1 Moderate and 1 Supporting criteria results in a Pathogenic classification. In summary, this variant meets the criteria to be classified as Pathogenic for X-linked severe combined immunodeficiency due to IL2RG deficiency based on the ACMG/AMP criteria applied, as specified by the ClinGen SCID VCEP: PM2_supporting,PP4_moderate,PS4_very strong (VCEP specifications version 1).		Severe Combined Immunodeficiency Disease  VCEP		2024-01-31	2024-01-31	False	https://erepo.genome.network/evrepo/ui/classification/CA16608976/MONDO:0010315/129	2777e3d3-64d9-471a-a3d8-c36d5f50889d	p.Glu68Lys	Glu	68	Lys	MLKPSLPFTSLLFLQLPLLGVGLNTTILTPNGNEDTTADFFLTTMPTDSLSVSTLPLPEVQCFVFNVEYMNCTWNSSSEPQPTNLTLHYWYKNSDNDKVQKCSHYLFSEEITSGCQLQKKEIHLYQTFVVQLQDPREPRRQATQMLKLQNLVIPWAPENLTLHKLSESQLELNWNNRFLNHCLEHLVQYRTDWDHSWTEQSVDYRHKFSLPSVDGQKRYTFRVRSRFNPLCGSAQHWSEWSHPIHWGSNTSKENPFLFALEAVVISVGSMGLIISLLCVYFWLERTMPRIPTLKNLEDLVTEYHGNFSAWSGVSKGLAESLQPDYSERLCLVSEIPPKGGALGEGPGASPCNQHSPYWAPPCYTLKPET	369	P31785	K	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [106], 'STRAND_gain_score': array([0.01627856]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
690	NM_002185.5(IL7R):c.379G>A (p.Val127Ile)	1339483	CA359428682	NM_002185.5:c.379G>A, NC_000005.10:g.35867463G>A, CM000667.2:g.35867463G>A, NC_000005.9:g.35867565G>A, CM000667.1:g.35867565G>A, NC_000005.8:g.35903322G>A, NG_009567.1:g.15575G>A, LRG_74:g.15575G>A, ENST00000303115.8:c.379G>A, ENST00000303115.7:c.379G>A, ENST00000506850.5:c.379G>A, ENST00000511031.1:n.513G>A, ENST00000511982.1:c.379G>A, ENST00000514217.5:c.379G>A, NM_002185.3:c.379G>A, NR_120485.1:n.482G>A, XM_005248299.2:c.379G>A, XM_005248300.1:c.379G>A, XM_011514037.1:c.379G>A, NM_002185.4:c.379G>A, NR_120485.2:n.508G>A, XM_005248299.4:c.379G>A, NR_120485.3:n.466G>A, NM_002185.5(IL7R):c.379G>A (p.Val127Ile)	IL7R	severe combined immunodeficiency, autosomal recessive, T cell-negative, B cell-positive, NK cell-positive	MONDO:0012163	Autosomal recessive inheritance	Pathogenic	PP4, PM2_Supporting, PM3_Supporting, PVS1		NM_002185.5(IL7R):c.379G>A is a missense variant predicted to cause substitution of Valine by Isoleucine at amino acid 127  (p.Val127Ile). The highest population minor allele frequency in gnomAD v4 is 0.00002991 (1/33436) in African/African American population which is lower than the ClinGen SCID VCEP threshold (<0.00004129) for PM2_Supporting, meeting this criterion (PM2_Supporting). c.379G>A mutation in IL7R abolishes splicing of exons 3-4 and replaces it with splicing of exons 2-4, which introduces a STOP site resulting in premature termination of IL-7Ra translation (Nonsense mediated decay) (PVS1) PMID: 35418989.Female patient with SCID (0.5 pt.), reduced CD127 expression demonstrated by flow cytometry (1 pt.),T-B+NK+ lymphocyte subset profile (0.25 pt.) Total :1.75 pts. (PP4_met ; PMID: 35418989).The patient (PMID: 35418989) was found homozygous for the mutation (0.5 pt.) (PM3_supporting).In summary, this variant meets the criteria to be classified as a Pathogenic variant for autosomal recessive severe combined immunodeficiency due to IL7R deficiency based on the ACMG/AMP criteria applied, as specified by the ClinGen SCID VCEP: PM2_supporting,PVS1, PP4_met,PM3_supporting (VCEP specifications version 1).		Severe Combined Immunodeficiency Disease  VCEP		2024-02-01	2024-02-01	False	https://erepo.genome.network/evrepo/ui/classification/CA359428682/MONDO:0012163/119	577ca02a-d27e-42e8-86e0-4f997bb220da	p.Val127Ile	Val	127	Ile	MTILGTTFGMVFSLLQVVSGESGYAQNGDLEDAELDDYSFSCYSQLEVNGSQHSLTCAFEDPDVNITNLEFEICGALVEVKCLNFRKLQEIYFIETKKFLLIGKSNICVKVGEKSLTCKKIDLTTIVKPEAPFDLSVVYREGANDFVVTFNTSHLQKKYVKVLMHDVAYRQEKDENKWTHVNLSSTKLTLLQRKLQPAAMYEIKVRSIPDHYFKGFWSEWSPSYYFRTPEINNSSGEMDPILLTISILSFFSVALLVILACVLWKKRIKPIVWPSLPDHKKTLEHLCKKPRKNLNVSFNPESFLDCQIHRVDDIQARDEVEGFLQDTFPQQLEESEKQRLGGDVQSPNCPSEDVVITPESFGRDSSLTCLAGNVSACDAPILSSSRSLDCRESGKNGPHVYQDLLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQPILTSLGSNQEEAYVTMSSFYQNQ	459	P16871	I	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [124], 'HELIX_gain_score': array([0.09820175]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
691	NM_000162.5(GCK):c.1024A>C (p.Thr342Pro)	908615	CA157913750	NM_000162.5:c.1024A>C, NC_000007.14:g.44145726T>G, CM000669.2:g.44145726T>G, NC_000007.13:g.44185325T>G, CM000669.1:g.44185325T>G, NC_000007.12:g.44151850T>G, NG_008847.1:g.48698A>C, NG_008847.2:g.57445A>C, ENST00000395796.8:c.*1022A>C, ENST00000616242.5:c.*144A>C, ENST00000683378.1:n.250A>C, ENST00000336642.9:c.58A>C, ENST00000345378.7:c.1027A>C, ENST00000403799.8:c.1024A>C, ENST00000671824.1:c.1087A>C, ENST00000672743.1:n.36A>C, ENST00000673284.1:c.1024A>C, ENST00000336642.8:c.76A>C, ENST00000345378.6:c.1027A>C, ENST00000395796.7:c.1021A>C, ENST00000403799.7:c.1024A>C, ENST00000437084.1:c.973A>C, ENST00000459642.1:n.404A>C, ENST00000473353.1:n.322A>C, ENST00000616242.4:c.1021A>C, NM_000162.3:c.1024A>C, NM_033507.1:c.1027A>C, NM_033508.1:c.1021A>C, NM_000162.4:c.1024A>C, NM_001354800.1:c.1024A>C, NM_001354801.1:c.13A>C, NM_001354802.1:c.-117A>C, NM_001354803.1:c.58A>C, NM_033507.2:c.1027A>C, NM_033508.2:c.1021A>C, XM_024446707.1:c.-117A>C, NM_033507.3:c.1027A>C, NM_033508.3:c.1021A>C, NM_001354803.2:c.58A>C, NM_000162.5(GCK):c.1024A>C (p.Thr342Pro)	GCK	monogenic diabetes	MONDO:0015967	Semidominant inheritance	Benign	BS4, PP2, BS2	PS4, PM2, BS1, BS3, PP3, PM5	The c.1024A>C variant in the glucokinase gene, GCK, causes an amino acid change of threonine to proline at codon 342 (p.(Thr342Pro)) of NM_000162.5. GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2). This variant has a Popmax filtering allele frequency of 0.000004789, which is between the MDEP thresholds for PM2_Supporting and BS1. This variant was identified in two unrelated individuals with non-autoimmune and non-absolute/near-absolute insulin-deficient diabetes; however, PS4_Moderate cannot be applied because this number is below the ClinGen MDEP threshold (PMID: 21604084, PMID: 33046911). However, this variant was identified in multiple individuals with a normal fasting glucose (BS2; PMID: 23799006, PMID 21604084). Additionally, this variant does not segregate with diabetes in one family in the literature (BS4; PMID: 21604084). This variant has a REVEL score of 0.296, which is between the ClinGen MDEP thresholds predicting neither a damaging nor benign impact on GCK function. Additionally, functional studies are inconclusive on whether the p.Thr342Pro variant impacts glucokinase function (normal RAI (>0.5) + normal RSI (>0.5) but no studies investigating GKRP/GKA interaction) (PMID 25015100). Two other missense variants, c.1024A>T (p.Thr342Ser) and c.1025C>T p.Thr342Met have been classified as a VUS by the ClinGen MDEP; therefore, PM5 will not be applied. Taken together, the c.1024A>C variant meets the criteria to be classified as benign for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.3.0, approved 8/11/2023): BS2, BS4, PP2.		Monogenic Diabetes VCEP		2024-02-02	2024-02-02	False	https://erepo.genome.network/evrepo/ui/classification/CA157913750/MONDO:0015967/086	29f5347b-abc0-44ae-bbf6-c5464d91d0b5	p.Thr342Pro	Thr	342	Pro	MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQ	465	P35557	P	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [203], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.00948453]), 'HELIX_loss': [323, 338], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.04333937, -0.26358092]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [11, 21], 'REGION_gain_score': array([0.00542396, 0.00317103]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
692	NM_001033855.3(DCLRE1C):c.1284A>C (p.Lys428Asn)	287735	CA5416508	NM_001033855.3:c.1284A>C, NC_000010.11:g.14909203T>G, CM000672.2:g.14909203T>G, NC_000010.10:g.14951202T>G, CM000672.1:g.14951202T>G, NC_000010.9:g.14991208T>G, NG_007276.1:g.49893A>C, LRG_54:g.49893A>C, ENST00000378278.7:c.1284A>C, ENST00000357717.6:c.939A>C, ENST00000378242.1:c.243A>C, ENST00000378246.6:c.939A>C, ENST00000378249.5:c.939A>C, ENST00000378254.5:c.924A>C, ENST00000378255.5:c.924A>C, ENST00000378258.5:c.924A>C, ENST00000378278.6:c.1284A>C, ENST00000378289.8:c.1157-9891A>C, ENST00000396817.6:c.924A>C, ENST00000489845.1:n.261A>C, ENST00000492201.5:n.499A>C, NM_001033855.2:c.1284A>C, NM_001033857.2:c.924A>C, NM_001033858.2:c.924A>C, NM_001289076.1:c.939A>C, NM_001289077.1:c.924A>C, NM_001289078.1:c.939A>C, NM_001289079.1:c.924A>C, NM_022487.3:c.939A>C, NR_110297.1:n.2059A>C, XM_006717491.2:c.939A>C, XM_011519616.1:c.939A>C, XM_011519617.1:c.939A>C, XM_011519618.1:c.939A>C, XM_011519619.1:c.924A>C, NM_001350965.1:c.1284A>C, NM_001350966.1:c.939A>C, NM_001350967.1:c.924A>C, NR_146960.1:n.1651A>C, NR_146961.1:n.1800A>C, NR_146962.1:n.1771A>C, XM_006717491.4:c.939A>C, XM_017016557.1:c.939A>C, XM_017016558.1:c.924A>C, XM_024448134.1:c.924A>C, XM_024448135.1:c.939A>C, XR_001747185.2:n.1573A>C, XR_001747187.1:n.1405A>C, NM_001033857.3:c.924A>C, NM_001033858.3:c.924A>C, NM_001289076.2:c.939A>C, NM_001289077.2:c.924A>C, NM_001289078.2:c.939A>C, NM_001289079.2:c.924A>C, NM_001350965.2:c.1284A>C, NM_001350966.2:c.939A>C, NM_001350967.2:c.924A>C, NM_022487.4:c.939A>C, NR_110297.2:n.1723A>C, NR_146961.2:n.1464A>C, NM_001033855.3(DCLRE1C):c.1284A>C (p.Lys428Asn)	DCLRE1C	severe combined immunodeficiency due to DCLRE1C deficiency	MONDO:0011225	Autosomal recessive inheritance	Benign	BA1, BS2_Supporting		NM_001033855.3(DCLRE1C):c.1284A>C  is a missense variant predicted to cause substitution of Lysine by Asparagine at amino acid 428 (p.Lys428Asn).The filtering allele frequency (the lower threshold of the 95% CI of 501/75018) of the c.1284A>C variant in DCLRE1C is 0.005719 for African/African American chromosomes by gnomAD v4, which is higher than the ClinGen SCID VCEP threshold (>0.00346) for BA1, and therefore meets this criterion (BA1). Additionally, 2 homozygous adults are reported in gnomAD v.4 in the same population. BS2_Supporting is Met.In summary, this variant meets the criteria to be classified as Benign for autosomal recessive severe combined immunodeficiency due to DCLRE1C deficiency based on the ACMG/AMP criteria applied, as specified by the ClinGen SCID-VCEP: BA1 and BS2_Supporting. (VCEP specifications version 1).		Severe Combined Immunodeficiency Disease  VCEP		2024-02-05	2024-02-05	False	https://erepo.genome.network/evrepo/ui/classification/CA5416508/MONDO:0011225/116	a53b7359-07f9-40fc-b931-3c4d33611762	p.Lys428Asn	Lys	428	Asn	MSSFEGQMAEYPTISIDRFDRENLRARAYFLSHCHKDHMKGLRAPTLKRRLECSLKVYLYCSPVTKELLLTSPKYRFWKKRIISIEIETPTQISLVDEASGEKEEIVVTLLPAGHCPGSVMFLFQGNNGTVLYTGDFRLAQGEAARMELLHSGGRVKDIQSVYLDTTFCDPRFYQIPSREECLSGVLELVRSWITRSPYHVVWLNCKAAYGYEYLFTNLSEELGVQVHVNKLDMFRNMPEILHHLTTDRNTQIHACRHPKAEEYFQWSKLPCGITSRNRIPLHIISIKPSTMWFGERSRKTNVIVRTGESSYRACFSFHSSYSEIKDFLSYLCPVNAYPNVIPVGTTMDKVVEILKPLCRSSQSTEPKYKPLGKLKRARTVHRDSEEEDDYLFDDPLPIPLRHKVPYPETFHPEVFSMTAVSEKQPEKLRQTPGCCRAECMQSSRFTNFVDCEESNSESEEEVGIPASLQGDLGSVLHLQKADGDVPQWEVFFKRNDEITDESLENFPSSTVAGGSQSPKLFSDSDGESTHISSQNSSQSTHITEQGSQGWDSQSDTVLLSSQERNSGDITSLDKADYRPTIKENIPASLMEQNVICPKDTYSDLKSRDKDVTIVPSTGEPTTLSSETHIPEEKSLLNLSTNADSQSSSDFEVPSTPEAELPKREHLQYLYEKLATGESIAVKKRKCSLLDT	692	Q96SD1	N	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [148], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.00914145]), 'REGION_loss': [617], 'REGION_gain': [], 'REGION_loss_score': array([-0.00098628]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
693	NM_005629.4(SLC6A8):c.1162G>A (p.Ala388Thr)	436771	CA10549443	NM_005629.4:c.1162G>A, NC_000023.11:g.153693925G>A, CM000685.2:g.153693925G>A, NC_000023.10:g.152959380G>A, CM000685.1:g.152959380G>A, NC_000023.9:g.152612574G>A, NG_012016.1:g.10629G>A, NG_012016.2:g.10629G>A, ENST00000253122.10:c.1162G>A, ENST00000253122.9:c.1162G>A, ENST00000413787.1:c.258-279G>A, ENST00000430077.6:c.817G>A, ENST00000442457.1:c.216G>A, ENST00000457723.1:c.146G>A, ENST00000467402.1:n.261G>A, ENST00000485324.1:n.1195G>A, NM_001142805.1:c.1132G>A, NM_001142806.1:c.817G>A, NM_005629.3:c.1162G>A, NM_001142805.2:c.1132G>A, NM_005629.4(SLC6A8):c.1162G>A (p.Ala388Thr)	SLC6A8	creatine transporter deficiency	MONDO:0010305	X-linked inheritance	Benign	BA1		The NM_005629.4(SLC6A8):c.1162G>A (p.Ala388Thr) variant in SLC6A8 is a missense variant predicted to cause substitution of Threonine for Alanine at amino acid 338 (p.Ala338Thr). There is a ClinVar entry for this variant (Variation ID:436771). This variant is found with an allele frequency of 0.003854 in gnomADv2.1.1 with 17 hemizygotes present in that population database.  Given the presence of >10 hemizygotes in gnomADv2.1.1 and an allele frequency >0.002, the stand alone benign criteria BA1 is applicable for this variant.  In summary, this variant meets the criteria to be classified as Benign for Creatine Transporter Deficiency based on the ACMG/AMP criteria applied, as specified by the ClinGen Cerebral Creatine Deficiency Syndromes Variant Curation Expert Panel (Specifications Version 1.1.0; ; classification approved Feb 23, 2023): BA1		Cerebral Creatine Deficiency Syndromes VCEP		2023-02-23	2024-02-11	False	https://erepo.genome.network/evrepo/ui/classification/CA10549443/MONDO:0010305/027	79b7be5f-ce88-4161-a6df-707def707253	p.Ala388Thr	Ala	388	Thr	MAKKSAENGIYSVSGDEKKGPLIAPGPDGAPAKGDGPVGLGTPGGRLAVPPRETWTRQMDFIMSCVGFAVGLGNVWRFPYLCYKNGGGVFLIPYVLIALVGGIPIFFLEISLGQFMKAGSINVWNICPLFKGLGYASMVIVFYCNTYYIMVLAWGFYYLVKSFTTTLPWATCGHTWNTPDCVEIFRHEDCANASLANLTCDQLADRRSPVIEFWENKVLRLSGGLEVPGALNWEVTLCLLACWVLVYFCVWKGVKSTGKIVYFTATFPYVVLVVLLVRGVLLPGALDGIIYYLKPDWSKLGSPQVWIDAGTQIFFSYAIGLGALTALGSYNRFNNNCYKDAIILALINSGTSFFAGFVVFSILGFMAAEQGVHISKVAESGPGLAFIAYPRAVTLMPVAPLWAALFFFMLLLLGLDSQFVGVEGFITGLLDLLPASYYFRFQREISVALCCALCFVIDLSMVTDGGMYVFQLFDYYSASGTTLLWQAFWECVVVAWVYGADRFMDDIACMIGYRPCPWMKWCWSFFTPLVCMGIFIFNVVYYEPLVYNNTYVYPWWGEAMGWAFALSSMLCVPLHLLGCLLRAKGTMAERWQHLTQPIWGLHHLEYRAQDADVRGLTTLTPVSESSKVVVVESVM	635	P48029	T	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [312], 'DNA_BIND_gain_score': array([0.00155663]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
694	NM_000051.4(ATM):c.5236G>A (p.Gly1746Arg)	407510	CA16613442	NM_000051.4:c.5236G>A, NC_000011.10:g.108301706G>A, CM000673.2:g.108301706G>A, NC_000011.9:g.108172433G>A, CM000673.1:g.108172433G>A, NC_000011.8:g.107677643G>A, NG_009830.1:g.83875G>A, LRG_135:g.83875G>A, ENST00000452508.7:c.5236G>A, ENST00000713593.1:c.*4707G>A, ENST00000278616.9:c.5236G>A, ENST00000683174.1:n.6720G>A, ENST00000683524.1:n.460G>A, ENST00000684152.1:n.950G>A, ENST00000527805.6:c.*300G>A, ENST00000675595.1:c.*300G>A, ENST00000675843.1:c.5236G>A, ENST00000278616.8:c.5236G>A, ENST00000452508.6:c.5236G>A, ENST00000524792.5:n.1451G>A, ENST00000533690.5:n.640G>A, ENST00000534625.1:n.465G>A, NM_000051.3:c.5236G>A, LRG_135t1:c.5236G>A, XM_005271561.3:c.5236G>A, XM_005271562.3:c.5236G>A, XM_006718843.2:c.5236G>A, XM_006718845.1:c.1192G>A, XM_011542840.1:c.5236G>A, XM_011542841.1:c.5236G>A, XM_011542842.1:c.5071G>A, XM_011542843.1:c.5236G>A, XM_011542844.1:c.4192G>A, XM_011542845.1:c.3928G>A, XM_011542846.1:c.5236G>A, XM_011542847.1:c.307G>A, NM_001351834.1:c.5236G>A, XM_005271562.5:c.5236G>A, XM_006718843.4:c.5236G>A, XM_006718845.2:c.1192G>A, XM_011542840.3:c.5236G>A, XM_011542842.3:c.5071G>A, XM_011542843.2:c.5236G>A, XM_011542844.3:c.4192G>A, XM_011542845.2:c.3928G>A, XM_017017789.2:c.5236G>A, XM_017017790.2:c.5236G>A, XM_017017791.1:c.5236G>A, XM_017017792.2:c.5236G>A, XR_002957150.1:n.5836G>A, NM_001351834.2:c.5236G>A, NM_000051.4(ATM):c.5236G>A (p.Gly1746Arg)	ATM	hereditary breast cancer	MONDO:0016419	Autosomal dominant inheritance	Pathogenic	PM5_Supporting, PVS1, PM2_Supporting, PM3_Supporting	PP3	The c.5236G>A (p.Gly1746Arg) variant in ATM has been demonstrated to cause aberrant splicing, resulting in a frameshift leading to nonsense mediated decay in a gene in which loss-of-function is an established disease mechanism (Ambry internal data). This alteration results in a termination codon upstream of the most C-terminus pathogenic alteration (ATM p.Arg3047*), as classified by the HBOP VCEP, and is expected to be more deleterious. This variant was observed in an individual with Ataxia-Telangiectasia (PMID:26896183), and is absent from gnomAD v2.1.1. In summary, this variant meets criteria to be classified as pathogenic for autosomal dominant hereditary breast cancer and autosomal recessive Ataxia-Telangiectasia based on the ACMG/AMP criteria applied, as specified by the HBOP VCEP (PVS1(RNA), PM2_Supporting, PM3_Supporting, PM5_Supporting).		Hereditary Breast, Ovarian and Pancreatic Cancer VCEP		2024-01-25	2024-02-14	False	https://erepo.genome.network/evrepo/ui/classification/CA16613442/MONDO:0016419/020	4f737153-e8dd-4e1e-9a3f-07bad4253908	p.Gly1746Arg	Gly	1746	Arg	MSLVLNDLLICCRQLEHDRATERKKEVEKFKRLIRDPETIKHLDRHSDSKQGKYLNWDAVFRFLQKYIQKETECLRIAKPNVSASTQASRQKKMQEISSLVKYFIKCANRRAPRLKCQELLNYIMDTVKDSSNGAIYGADCSNILLKDILSVRKYWCEISQQQWLELFSVYFRLYLKPSQDVHRVLVARIIHAVTKGCCSQTDGLNSKFLDFFSKAIQCARQEKSSSGLNHILAALTIFLKTLAVNFRIRVCELGDEILPTLLYIWTQHRLNDSLKEVIIELFQLQIYIHHPKGAKTQEKGAYESTKWRSILYNLYDLLVNEISHIGSRGKYSSGFRNIAVKENLIELMADICHQVFNEDTRSLEISQSYTTTQRESSDYSVPCKRKKIELGWEVIKDHLQKSQNDFDLVPWLQIATQLISKYPASLPNCELSPLLMILSQLLPQQRHGERTPYVLRCLTEVALCQDKRSNLESSQKSDLLKLWNKIWCITFRGISSEQIQAENFGLLGAIIQGSLVEVDREFWKLFTGSACRPSCPAVCCLTLALTTSIVPGTVKMGIEQNMCEVNRSFSLKESIMKWLLFYQLEGDLENSTEVPPILHSNFPHLVLEKILVSLTMKNCKAAMNFFQSVPECEHHQKDKEELSFSEVEELFLQTTFDKMDFLTIVRECGIEKHQSSIGFSVHQNLKESLDRCLLGLSEQLLNNYSSEITNSETLVRCSRLLVGVLGCYCYMGVIAEEEAYKSELFQKAKSLMQCAGESITLFKNKTNEEFRIGSLRNMMQLCTRCLSNCTKKSPNKIASGFFLRLLTSKLMNDIADICKSLASFIKKPFDRGEVESMEDDTNGNLMEVEDQSSMNLFNDYPDSSVSDANEPGESQSTIGAINPLAEEYLSKQDLLFLDMLKFLCLCVTTAQTNTVSFRAADIRRKLLMLIDSSTLEPTKSLHLHMYLMLLKELPGEEYPLPMEDVLELLKPLSNVCSLYRRDQDVCKTILNHVLHVVKNLGQSNMDSENTRDAQGQFLTVIGAFWHLTKERKYIFSVRMALVNCLKTLLEADPYSKWAILNVMGKDFPVNEVFTQFLADNHHQVRMLAAESINRLFQDTKGDSSRLLKALPLKLQQTAFENAYLKAQEGMREMSHSAENPETLDEIYNRKSVLLTLIAVVLSCSPICEKQALFALCKSVKENGLEPHLVKKVLEKVSETFGYRRLEDFMASHLDYLVLEWLNLQDTEYNLSSFPFILLNYTNIEDFYRSCYKVLIPHLVIRSHFDEVKSIANQIQEDWKSLLTDCFPKILVNILPYFAYEGTRDSGMAQQRETATKVYDMLKSENLLGKQIDHLFISNLPEIVVELLMTLHEPANSSASQSTDLCDFSGDLDPAPNPPHFPSHVIKATFAYISNCHKTKLKSILEILSKSPDSYQKILLAICEQAAETNNVYKKHRILKIYHLFVSLLLKDIKSGLGGAWAFVLRDVIYTLIHYINQRPSCIMDVSLRSFSLCCDLLSQVCQTAVTYCKDALENHLHVIVGTLIPLVYEQVEVQKQVLDLLKYLVIDNKDNENLYITIKLLDPFPDHVVFKDLRITQQKIKYSRGPFSLLEEINHFLSVSVYDALPLTRLEGLKDLRRQLELHKDQMVDIMRASQDNPQDGIMVKLVVNLLQLSKMAINHTGEKEVLEAVGSCLGEVGPIDFSTIAIQHSKDASYTKALKLFEDKELQWTFIMLTYLNNTLVEDCVKVRSAAVTCLKNILATKTGHSFWEIYKMTTDPMLAYLQPFRTSRKKFLEVPRFDKENPFEGLDDINLWIPLSENHDIWIKTLTCAFLDSGGTKCEILQLLKPMCEVKTDFCQTVLPYLIHDILLQDTNESWRNLLSTHVQGFFTSCLRHFSQTSRSTTPANLDSESEHFFRCCLDKKSQRTMLAVVDYMRRQKRPSSGTIFNDAFWLDLNYLEVAKVAQSCAAHFTALLYAEIYADKKSMDDQEKRSLAFEEGSQSTTISSLSEKSKEETGISLQDLLLEIYRSIGEPDSLYGCGGGKMLQPITRLRTYEHEAMWGKALVTYDLETAIPSSTRQAGIIQALQNLGLCHILSVYLKGLDYENKDWCPELEELHYQAAWRNMQWDHCTSVSKEVEGTSYHESLYNALQSLRDREFSTFYESLKYARVKEVEEMCKRSLESVYSLYPTLSRLQAIGELESIGELFSRSVTHRQLSEVYIKWQKHSQLLKDSDFSFQEPIMALRTVILEILMEKEMDNSQRECIKDILTKHLVELSILARTFKNTQLPERAIFQIKQYNSVSCGVSEWQLEEAQVFWAKKEQSLALSILKQMIKKLDASCAANNPSLKLTYTECLRVCGNWLAETCLENPAVIMQTYLEKAVEVAGNYDGESSDELRNGKMKAFLSLARFSDTQYQRIENYMKSSEFENKQALLKRAKEEVGLLREHKIQTNRYTVKVQRELELDELALRALKEDRKRFLCKAVENYINCLLSGEEHDMWVFRLCSLWLENSGVSEVNGMMKRDGMKIPTYKFLPLMYQLAARMGTKMMGGLGFHEVLNNLISRISMDHPHHTLFIILALANANRDEFLTKPEVARRSRITKNVPKQSSQLDEDRTEAANRIICTIRSRRPQMVRSVEALCDAYIILANLDATQWKTQRKGINIPADQPITKLKNLEDVVVPTMEIKVDHTGEYGNLVTIQSFKAEFRLAGGVNLPKIIDCVGSDGKERRQLVKGRDDLRQDAVMQQVFQMCNTLLQRNTETRKRKLTICTYKVVPLSQRSGVLEWCTGTVPIGEFLVNNEDGAHKRYRPNDFSAFQCQKKMMEVQKKSFEEKYEVFMDVCQNFQPVFRYFCMEKFLDPAIWFEKRLAYTRSVATSSIVGYILGLGDRHVQNILINEQSAELVHIDLGVAFEQGKILPTPETVPFRLTRDIVDGMGITGVEGVFRRCCEKTMEVMRNSQETLLTIVEVLLYDPLFDWTMNPLKALYLQQRPEDETELHPTLNADDQECKRNLSDIDQSFNKVAERVLMRLQEKLKGVEEGTVLSVGGQVNLLIQQAIDPKNLSRLFPGWKAWV	3056	Q13315	R	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [2886], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.00872689]), 'HELIX_loss': [623, 1587, 1824, 1859, 2196, 2945], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.00302446, -0.0060097 , -0.00253958, -0.00306755, -0.001077  ,
       -0.00670153]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [400, 1734], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.00974524, -0.00790977]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [2088], 'REPEAT_gain_score': array([0.00069529]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
695	NM_000329.3(RPE65):c.331C>T (p.Pro111Ser)	281715	CA10603953	NM_000329.3:c.331C>T, NC_000001.11:g.68444798G>A, CM000663.2:g.68444798G>A, NC_000001.10:g.68910481G>A, CM000663.1:g.68910481G>A, NC_000001.9:g.68683069G>A, NG_008472.1:g.10162C>T, NG_008472.2:g.10162C>T, ENST00000262340.6:c.331C>T, ENST00000262340.5:c.331C>T, NM_000329.2:c.331C>T, XM_017002027.1:c.55C>T, NM_000329.3(RPE65):c.331C>T (p.Pro111Ser)	RPE65	RPE65-related recessive retinopathy	MONDO:0100368	Autosomal recessive inheritance	Pathogenic	PP4, PP1, PM2_Supporting, PM3_Strong, PP3_Moderate, PM1		NM_000329.3(RPE65):c.331C>T is a missense variant causing substitution of proline with serine at position 111. This variant is present in gnomAD v.2.1.1 at a GrpMax allele frequency of 0.00003249, with 4 alleles / 41440 total alleles in the African/African American population, which is lower than the ClinGen LCA / eoRD VCEP PM2_Supporting threshold of <0.0002 (PM2_Supporting). The computational predictor REVEL gives a score of 0.911, which is above the ClinGen LCA / eoRD VCEP threshold of ≥ 0.773 and predicts a damaging effect on RPE65 function (PP3_Moderate). This variant is located within a well-established functional domain (residues 107-125, PMID: 36265895) required for proper localization of the RPE65 protein to the ER membrane (PM1). This variant has been reported in at least 1 proband with early-onset severe retinal dystrophy who was homozygous for the variant (0.5, PMID: 34492281). This variant has also been reported in at least 2 probands with early-onset severe retinal dystrophy who were compound heterozygous with either the NM_000329.2:c.11+5G>A or NM_000329.2:c.1451G>A (p.Gly484Asp) variants confirmed in trans (2 pts, PMIDs: 34492281), which were previously classified as pathogenic or likely pathogenic by the ClinGen LCA / eoRD VCEP (2.5 total points, PM3_Strong). At least one proband harboring this variant exhibits a phenotype including diagnosis with Leber congenital amaurosis (0.5 pts) with onset before age 1 year (1 pt), reduced ERG responses from rods (0.5 pts) and cones (1 pt), salt and pepper pigmentation of the fundus (0.5 pts), visual fields decreased (1 pt), visual acuity reduced (1 pt), and night blindness (0.5 pts), which together are specific for RPE65-related recessive retinopathy (6 points, PMID: 34492281, PP4). The variant has been reported to segregate with childhood-onset severe retinal dystrophy through the proband plus 1 similarly affected relative, with the variant present in the homozygous state (PP1; PMID: 34492281). In summary, this variant meets the criteria to be classified as pathogenic for RPE65-related recessive retinopathy based on the ACMG/AMP criteria applied, as specified by the ClinGen LCA / eoRD VCEP: PM1, PM2_Supporting, PM3_Strong, PP1, PP3_Moderate, and PP4. (VCEP specifications version 1.0.0; date of approval 09/21/2023).		Leber Congenital Amaurosis/early onset Retinal Dystrophy VCEP		2024-02-18	2024-02-18	False	https://erepo.genome.network/evrepo/ui/classification/CA10603953/MONDO:0100368/120	a2cc1491-a345-4251-b323-da56d95e7cab	p.Pro111Ser	Pro	111	Ser	MSIQVEHPAGGYKKLFETVEELSSPLTAHVTGRIPLWLTGSLLRCGPGLFEVGSEPFYHLFDGQALLHKFDFKEGHVTYHRRFIRTDAYVRAMTEKRIVITEFGTCAFPDPCKNIFSRFFSYFRGVEVTDNALVNVYPVGEDYYACTETNFITKINPETLETIKQVDLCNYVSVNGATAHPHIENDGTVYNIGNCFGKNFSIAYNIVKIPPLQADKEDPISKSEIVVQFPCSDRFKPSYVHSFGLTPNYIVFVETPVKINLFKFLSSWSLWGANYMDCFESNETMGVWLHIADKKRKKYLNNKYRTSPFNLFHHINTYEDNGFLIVDLCCWKGFEFVYNYLYLANLRENWEEVKKNARKAPQPEVRRYVLPLNIDKADTGKNLVTLPNTTATAILCSDETIWLEPEVLFSGPRQAFEFPQINYQKYCGKPYTYAYGLGLNHFVPDRLCKLNVKTKETWVWQEPDSYPSEPIFVSHPDALEEDDGVVLSVVVSPGAGQKPAYLLILNAKDLSEVARAEVEINIPVTFHGLFKKS	533	Q16518	S	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [111], 'DISULFID_gain': [], 'DISULFID_loss_score': array([-0.11995196]), 'PROPEP_loss': [5, 15, 16, 22, 31], 'PROPEP_gain': [], 'PROPEP_loss_score': array([-0.01317626, -0.01205051, -0.01270062, -0.0111807 , -0.01047993]), 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [131, 409], 'STRAND_gain': [96, 103], 'STRAND_gain_score': array([0.0593133 , 0.13000357]), 'STRAND_loss_score': array([-0.01079583, -0.01189464]), 'HELIX_loss': [333], 'HELIX_gain': [109, 110, 111, 112, 113], 'HELIX_gain_score': array([0.4976083 , 0.31645828, 0.34044451, 0.33020991, 0.39222538]), 'HELIX_loss_score': array([-0.00645977]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [15], 'DOMAIN_gain_score': array([0.01181465]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [497], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.00219858]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
696	NM_000329.3(RPE65):c.715T>G (p.Tyr239Asp)	98889	CA226579	NM_000329.3:c.715T>G, NC_000001.11:g.68439571A>C, CM000663.2:g.68439571A>C, NC_000001.10:g.68905254A>C, CM000663.1:g.68905254A>C, NC_000001.9:g.68677842A>C, NG_008472.1:g.15389T>G, NG_008472.2:g.15389T>G, ENST00000262340.6:c.715T>G, ENST00000262340.5:c.715T>G, NM_000329.2:c.715T>G, XM_017002027.1:c.439T>G, NM_000329.3(RPE65):c.715T>G (p.Tyr239Asp)	RPE65	RPE65-related recessive retinopathy	MONDO:0100368	Autosomal recessive inheritance	Pathogenic	PM2_Supporting, PM3_Strong, PP3_Moderate, PS3_Supporting, PP4_Moderate		NM_000329.3(RPE65):c.715T>G is a predicted missense variant substituting tyrosine by aspartic acid at position 239. The computational predictor REVEL gives a score of 0.987, which is above the ClinGen LCA / eoRD VCEP threshold of ≥ 0.773 and predicts a damaging effect on RPE65 function (PP3_Moderate). The splicing impact predictor SpliceAI also gives a score of 0.34 for splice acceptor gain, which is above the ClinGen LCA / eoRD VCEP recommended threshold of  ≥0.2 and predicts a damaging impact on splicing. This variant is present in gnomAD v.2.1.1 at a GrpMax allele frequency of 0.00002, with 3/129118 total alleles in the European (Non-Finnish) population, which is lower than the ClinGen LCA / eoRD VCEP PM2_Supporting threshold of <0.0002 (PM2_Supporting). This variant has been reported in at least 3 unrelated probands with early-onset severe retinal dystrophy who were homozygous for the variant (1 point, PMID: 32032261). This variant has also been reported in at least 1 proband with early-onset severe retinal dystrophy who was compound heterozygous with the NM_000329.3(RPE65):c.1102T>C (p.Tyr368His) variant confirmed in trans (1 point, PMID: 26626312), which was previously classified pathogenic by the ClinGen LCA / eoRD VCEP (2 total points, PM3_Strong). At least one proband harboring this variant exhibits a phenotype including clinical diagnosis of Leber congenital amaurosis (0.5 pt) and significant, documented improvement of blue full-field stimulus testing after treatment with RPE65 gene therapy (8 pts), which together are highly specific for RPE65-related recessive retinopathy (8.5 points, PMID: 21911650, PP4_Moderate). The variant exhibited between 1% (PMID: 24849605) and 5% (PMID: 19431183) enzymatic activity in retinoid isomerase assays relative to the wild-type control, which is lower than the ClinGen LCA / eoRD PS3_Supporting threshold of <10% activity, indicating that it triggers a severe defect in protein function (PS3_Supporting). In summary, this variant meets the criteria to be classified as pathogenic for RPE65-related recessive retinopathy based on the ACMG/AMP criteria applied, as specified by the ClinGen LCA / eoRD VCEP: PS3_Supporting, PM2_Supporting, PM3_Strong, PP3_Moderate, and PP4_Moderate. (VCEP specifications version 1.0.0; date of approval 09/21/2023).		Leber Congenital Amaurosis/early onset Retinal Dystrophy VCEP		2024-02-18	2024-02-18	False	https://erepo.genome.network/evrepo/ui/classification/CA226579/MONDO:0100368/120	862029ef-cc5c-4b10-b102-f9a252e48910	p.Tyr239Asp	Tyr	239	Asp	MSIQVEHPAGGYKKLFETVEELSSPLTAHVTGRIPLWLTGSLLRCGPGLFEVGSEPFYHLFDGQALLHKFDFKEGHVTYHRRFIRTDAYVRAMTEKRIVITEFGTCAFPDPCKNIFSRFFSYFRGVEVTDNALVNVYPVGEDYYACTETNFITKINPETLETIKQVDLCNYVSVNGATAHPHIENDGTVYNIGNCFGKNFSIAYNIVKIPPLQADKEDPISKSEIVVQFPCSDRFKPSYVHSFGLTPNYIVFVETPVKINLFKFLSSWSLWGANYMDCFESNETMGVWLHIADKKRKKYLNNKYRTSPFNLFHHINTYEDNGFLIVDLCCWKGFEFVYNYLYLANLRENWEEVKKNARKAPQPEVRRYVLPLNIDKADTGKNLVTLPNTTATAILCSDETIWLEPEVLFSGPRQAFEFPQINYQKYCGKPYTYAYGLGLNHFVPDRLCKLNVKTKETWVWQEPDSYPSEPIFVSHPDALEEDDGVVLSVVVSPGAGQKPAYLLILNAKDLSEVARAEVEINIPVTFHGLFKKS	533	Q16518	D	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [243, 251, 261, 286], 'DNA_BIND_gain': [], 'DNA_BIND_loss_score': array([-0.02014297, -0.02848583, -0.02957517, -0.01427925]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [30], 'PROPEP_gain_score': array([0.00629616]), 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [230, 409], 'STRAND_gain': [103], 'STRAND_gain_score': array([0.01825726]), 'STRAND_loss_score': array([-0.02403349, -0.00042212]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [268, 271, 361], 'DOMAIN_gain': [118, 329, 376, 378], 'DOMAIN_gain_score': array([0.02613682, 0.05877906, 0.02885407, 0.02717692]), 'DOMAIN_loss_score': array([-0.08767331, -0.09556198, -0.02547085]), 'REGION_loss': [], 'REGION_gain': [261], 'REGION_gain_score': array([0.0492382]), 'REPEAT_loss': [193, 239, 497], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.01763546, -0.05949122, -0.0033949 ]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
697	NM_000329.3(RPE65):c.1399C>G (p.Pro467Ala)	1069898	CA340741972	NM_000329.3:c.1399C>G, NC_000001.11:g.68431116G>C, CM000663.2:g.68431116G>C, NC_000001.10:g.68896799G>C, CM000663.1:g.68896799G>C, NC_000001.9:g.68669387G>C, NG_008472.1:g.23844C>G, NG_008472.2:g.23844C>G, ENST00000262340.6:c.1399C>G, ENST00000262340.5:c.1399C>G, NM_000329.2:c.1399C>G, XM_017002027.1:c.1123C>G, NM_000329.3(RPE65):c.1399C>G (p.Pro467Ala)	RPE65	RPE65-related recessive retinopathy	MONDO:0100368	Autosomal recessive inheritance	Pathogenic	PP4, PP1, PM2_Supporting, PM3_Strong, PP3_Moderate, PS3_Supporting	BS1	NM_000329.3(RPE65):c.1399C>G is a missense variant causing substitution of proline by alanine at position 467. This variant is present in gnomAD v.2.1.1 at a GrpMax allele frequency of 0.00001898, with 2 alleles / 18384 total alleles in the East Asian population, which is lower than the ClinGen LCA / eoRD VCEP PM2_Supporting threshold of <0.0002 (PM2_Supporting). This variant has been reported in at least 2 probands with early-onset severe retinal dystrophy who were compound heterozygous with the NM_000329.3(RPE65):c.998+1G>A or NM_000329.3(RPE65):c.130C>T (p.Arg44Ter) variants confirmed in trans (PMID: 31273949, PMID: 30996589), which were previously classified pathogenic by the ClinGen LCA / eoRD VCEP (2 total points, PM3_Strong). At least one proband harboring this variant exhibits a phenotype including grey-white fundus albipunctatus‐like changes (2 pts), genotyping by exome sequencing that did not provide an alternative explanation for visual impairment (2 pts), night blindness with onset before age 5 years (1 pt), extinguished rod ERG responses (0.5 pts), and severely reduced cone ERG responses (1 pt), which together are specific for RPE65-related recessive retinopathy (6.5 total points, PMID: 31273949, PP4). Two other probands also meet the PP4 criteria including extinguished ERG, night blindness with onset in early childhood as well as additional consistent features such as white dot deposits in the mid-peripheral retina, and reduced visual acuity (PP4; PMID: 31273949). The variant has been reported to segregate with childhood-onset severe retinal dystrophy through the proband plus 1 similarly affected relative in 2 different families, with the variant present in the compound heterozygous state (PP1; PMID: 31273949). The computational predictor REVEL gives a score of 0.891, which is above the ClinGen LCA/eoRD VCEP threshold of >0.773 and predicts a damaging effect on RPE65 function (PP3_Moderate). The variant exhibited 0% enzymatic activity in a retinoid isomerase assay relative to the wild-type control, which is lower than the ClinGen LCA / eoRD PS3_Supporting threshold of <10% activity, indicating that it triggers a severe defect in protein function (PS3_Supporting, PMID: 31580392). In summary, this variant meets the criteria to be classified as pathogenic for RPE65-related recessive retinopathy based on the ACMG/AMP criteria applied, as specified by the ClinGen LCA / eoRD VCEP: PS3_Supporting, PM2_Supporting, PM3_Strong, PP1, PP3_Moderate, and PP4. (VCEP specifications version 1.0.0; date of approval 09/21/2023).	31580392	Leber Congenital Amaurosis/early onset Retinal Dystrophy VCEP		2024-02-18	2024-02-18	False	https://erepo.genome.network/evrepo/ui/classification/CA340741972/MONDO:0100368/120	0bdf3eff-3307-4deb-b922-a33e0a747fba	p.Pro467Ala	Pro	467	Ala	MSIQVEHPAGGYKKLFETVEELSSPLTAHVTGRIPLWLTGSLLRCGPGLFEVGSEPFYHLFDGQALLHKFDFKEGHVTYHRRFIRTDAYVRAMTEKRIVITEFGTCAFPDPCKNIFSRFFSYFRGVEVTDNALVNVYPVGEDYYACTETNFITKINPETLETIKQVDLCNYVSVNGATAHPHIENDGTVYNIGNCFGKNFSIAYNIVKIPPLQADKEDPISKSEIVVQFPCSDRFKPSYVHSFGLTPNYIVFVETPVKINLFKFLSSWSLWGANYMDCFESNETMGVWLHIADKKRKKYLNNKYRTSPFNLFHHINTYEDNGFLIVDLCCWKGFEFVYNYLYLANLRENWEEVKKNARKAPQPEVRRYVLPLNIDKADTGKNLVTLPNTTATAILCSDETIWLEPEVLFSGPRQAFEFPQINYQKYCGKPYTYAYGLGLNHFVPDRLCKLNVKTKETWVWQEPDSYPSEPIFVSHPDALEEDDGVVLSVVVSPGAGQKPAYLLILNAKDLSEVARAEVEINIPVTFHGLFKKS	533	Q16518	A	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [253, 285, 491], 'DNA_BIND_gain_score': array([0.00481296, 0.00652909, 0.02705306]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [15, 22], 'PROPEP_gain': [], 'PROPEP_loss_score': array([-0.00659347, -0.00913906]), 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [98, 409, 490], 'STRAND_gain': [107], 'STRAND_gain_score': array([0.0044232]), 'STRAND_loss_score': array([-0.01425809, -0.00876498, -0.02405792]), 'HELIX_loss': [333], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.00568235]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [215], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.03792644]), 'REGION_loss': [326], 'REGION_gain': [], 'REGION_loss_score': array([-0.01368779]), 'REPEAT_loss': [], 'REPEAT_gain': [190, 241, 464, 469, 494, 526, 528], 'REPEAT_gain_score': array([0.00474954, 0.00670588, 0.03948116, 0.00345057, 0.00746554,
       0.01576495, 0.01647156]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
698	NM_000488.4(SERPINC1):c.235C>T (p.Arg79Cys)	18004	CA210748	NM_000488.4:c.235C>T, NC_000001.11:g.173914726G>A, CM000663.2:g.173914726G>A, NC_000001.10:g.173883864G>A, CM000663.1:g.173883864G>A, NC_000001.9:g.172150487G>A, NG_012462.1:g.7653C>T, LRG_577:g.7653C>T, ENST00000367698.4:c.235C>T, ENST00000367698.3:c.235C>T, ENST00000494024.1:n.461C>T, ENST00000617423.4:c.235C>T, NM_000488.3:c.235C>T, LRG_577t1:c.235C>T, XM_005245198.2:c.91C>T, NM_001365052.1:c.91C>T, NM_001365052.2:c.91C>T, NM_001386302.1:c.235C>T, NM_001386303.1:c.316C>T, NM_001386304.1:c.235C>T, NM_001386305.1:c.235C>T, NM_001386306.1:c.235C>T, NM_000488.4(SERPINC1):c.235C>T (p.Arg79Cys)	SERPINC1	antithrombin III deficiency	MONDO:0013144	Autosomal dominant inheritance	Pathogenic	PS4, PP1_Strong, PM1, PM5, PP3, PP4	PM2	The c.235C>T (NM_000488.4) variant in SERPINC1 is a missense variant predicted to cause substitution of arginine by cysteine at amino acid 79 (p.Arg79Cys). This variant has been reported in at least 31 probands meeting an antithrombin activity level of <0.8 IU/mL and several more are reported in the literature (PS4_Very Strong; PMID:28300866). The variant has been reported to segregate with autosomal dominant hereditary antithrombin deficiency in 18 affected family meioses from 32 families (PP1_Strong; 28300866). One of 50 individuals within 45 families who had a mean AT activity of 53% and AT antigen level of 106%, which is highly specific for hereditary antithrombin deficiencies. The curators confirmed with lead author that most individuals AT levels were confirmed with at least two samples since this is not specified in the publication. The ClinGen Thrombosis VCEP members have agreed that all probands in this paper can be counted at full strength for PP4 (PP4_Supporting; PMID:28300866). The computational predictor REVEL gives a score of 0.743, which is above the threshold of 0.6, evidence that correlates with impact to SERPINC1 function (PP3). This variant resides within a region, Arg79, of SERPINC1  that would impact heparin binding site residues and is defined as a critical functional domain by the ClinGen Thrombosis VCEP (PMID:2615648; PM1). Another missense variant c.236G>A (p.Arg79His) (ClinVarID:18014) in the same codon has been classified as pathogenic for autosomal dominant hereditary antithrombin deficiency by the ClinGen Thrombosis VCEP (PM5). In summary, this variant meets the criteria to be classified as pathogenic for autosomal dominant hereditary antithrombin deficiency based on the ACMG/AMP criteria applied, as specified by the ClinGen Thrombosis VCEP: PP1, PS4_Very strong, PM1, PM5, PP3, PP4. (ClinGen Thrombosis Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for SERPINC1 Version 1.0.0; date of approval)	2615648	Thrombosis VCEP		2024-02-19	2024-02-19	False	https://erepo.genome.network/evrepo/ui/classification/CA210748/MONDO:0013144/084	1a0f0b66-2f20-4764-92d2-7612eccb97c1	p.Arg79Cys	Arg	79	Cys	MYSNVIGTVTSGKRKVYLLSLLLIGFWDCVTCHGSPVDICTAKPRDIPMNPMCIYRSPEKKATEDEGSEQKIPEATNRRVWELSKANSRFATTFYQHLADSKNDNDNIFLSPLSISTAFAMTKLGACNDTLQQLMEVFKFDTISEKTSDQIHFFFAKLNCRLYRKANKSSKLVSANRLFGDKSLTFNETYQDISELVYGAKLQPLDFKENAEQSRAAINKWVSNKTEGRITDVIPSEAINELTVLVLVNTIYFKGLWKSKFSPENTRKELFYKADGESCSASMMYQEGKFRYRRVAEGTQVLELPFKGDDITMVLILPKPEKSLAKVEKELTPEVLQEWLDELEEMMLVVHMPRFRIEDGFSLKEQLQDMGLVDLFSPEKSKLPGIVAEGRDDLYVSDAFHKAFLEVNEEGSEAAASTAVVIAGRSLNPNRVTFKANRPFLVFIREVPLNTIIFMGRVANPCVK	464	P01008	C	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [33], 'TOPO_DOM_gain_score': array([0.09024554]), 'TRANSMEM_loss': [19, 30, 31, 32], 'TRANSMEM_gain': [], 'TRANSMEM_loss_score': array([-0.08609408, -0.08787405, -0.09587932, -0.09835678]), 'DISULFID_loss': [], 'DISULFID_gain': [78], 'DISULFID_gain_score': array([0.7953968]), 'PROPEP_loss': [38, 39, 40, 41, 42, 44, 45, 47, 53, 58, 60, 61, 62, 63, 65, 66, 67], 'PROPEP_gain': [], 'PROPEP_loss_score': array([-0.08065867, -0.06687629, -0.08299202, -0.10528886, -0.11569428,
       -0.09492022, -0.13351876, -0.13479823, -0.15804237, -0.18211174,
       -0.18136442, -0.19816875, -0.20019877, -0.2066468 , -0.23078293,
       -0.25197643, -0.2753213 ]), 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [79], 'HELIX_gain': [124], 'HELIX_gain_score': array([0.03674716]), 'HELIX_loss_score': array([-0.152233]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70], 'COMPBIAS_gain': [], 'COMPBIAS_loss_score': array([-0.38916397, -0.44362658, -0.47640675, -0.44898915, -0.44696277,
       -0.47437978, -0.42759949, -0.42778963, -0.43605947, -0.47207958,
       -0.48810786, -0.4821378 , -0.47853333, -0.49827743]), 'DOMAIN_loss': [], 'DOMAIN_gain': [122], 'DOMAIN_gain_score': array([0.01662481]), 'REGION_loss': [426], 'REGION_gain': [], 'REGION_loss_score': array([-0.00076336]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
699	NM_000329.3(RPE65):c.1022T>C (p.Leu341Ser)	13118	CA226472	NM_000329.3:c.1022T>C, NC_000001.11:g.68438293A>G, CM000663.2:g.68438293A>G, NC_000001.10:g.68903976A>G, CM000663.1:g.68903976A>G, NC_000001.9:g.68676564A>G, NG_008472.1:g.16667T>C, NG_008472.2:g.16667T>C, ENST00000262340.6:c.1022T>C, ENST00000262340.5:c.1022T>C, NM_000329.2:c.1022T>C, XM_017002027.1:c.746T>C, NM_000329.3(RPE65):c.1022T>C (p.Leu341Ser)	RPE65	RPE65-related recessive retinopathy	MONDO:0100368	Autosomal recessive inheritance	Pathogenic	PM2_Supporting, PM3_Strong, PP1_Strong, PP3_Moderate, PP4_Moderate		The NM_000329.3(RPE65):c.1022T>C (p.Leu341Ser) missense variant replaces the leucine at position 341 with serine and has been reported in several patients. At least one patient (analyzed on a 100+ retinal dystrophy gene panel testing (2 pt) in PMID: 23847139) who displayed a non-detectable ERG (2 pt), visual acuity 20/400 OD and OS (1 pt), visual field of central island only (1 pt), nystagmus (1 pt), nyctalopia (1 pt), and no pigment in peripheral retina, which is highly specific for RPE65 retinopathy (PP4_Moderate). One patient was compound heterozygous for this variant and a pathogenic pathogenic variant (c.1205_1206insCCTG classified Pathogenic by the LCA/eoRD VCEP) confirmed in trans by parental testing (PMID: 9501220) and two probands were homozygous for the variant (PMID: 9501220, PMID: 15837919) (PM3_strong). The variant has been reported to segregate with RPE65 retinopathy (confirmed by absent or severely decreased rod electroretinogram response) in the proband plus 3 affected family members, all with the compound heterozygous genotype of Leu341Ser and c.1205_1206insCCTG variants. (PP1_strong; PMID: 9501220). The computational predictor REVEL gives a score of 0.988 and predicts a damaging effect on RPE65 function (PP3_Moderate). This variant is absent from gnomAD v2.1.1 and has a Grpmax Filtering AF of 0.00005290 in gnomAD v.3.1.2 (PM2_Supporting). In summary, this variant meets the criteria to be classified as pathogenic for RPE65-related recessive retinopathy based on the ACMG/AMP criteria applied, as specified by the ClinGen LCA/eoRD VCEP: PP1_strong, PM3_strong, PP3_Moderate, PP4_Moderate, PM2_supporting.  (VCEP specifications version 1.0.0; date of approval 09/21/2023).		Leber Congenital Amaurosis/early onset Retinal Dystrophy VCEP		2024-02-20	2024-02-20	False	https://erepo.genome.network/evrepo/ui/classification/CA226472/MONDO:0100368/120	a12475a1-7bae-4034-b8bc-f41373cc8110	p.Leu341Ser	Leu	341	Ser	MSIQVEHPAGGYKKLFETVEELSSPLTAHVTGRIPLWLTGSLLRCGPGLFEVGSEPFYHLFDGQALLHKFDFKEGHVTYHRRFIRTDAYVRAMTEKRIVITEFGTCAFPDPCKNIFSRFFSYFRGVEVTDNALVNVYPVGEDYYACTETNFITKINPETLETIKQVDLCNYVSVNGATAHPHIENDGTVYNIGNCFGKNFSIAYNIVKIPPLQADKEDPISKSEIVVQFPCSDRFKPSYVHSFGLTPNYIVFVETPVKINLFKFLSSWSLWGANYMDCFESNETMGVWLHIADKKRKKYLNNKYRTSPFNLFHHINTYEDNGFLIVDLCCWKGFEFVYNYLYLANLRENWEEVKKNARKAPQPEVRRYVLPLNIDKADTGKNLVTLPNTTATAILCSDETIWLEPEVLFSGPRQAFEFPQINYQKYCGKPYTYAYGLGLNHFVPDRLCKLNVKTKETWVWQEPDSYPSEPIFVSHPDALEEDDGVVLSVVVSPGAGQKPAYLLILNAKDLSEVARAEVEINIPVTFHGLFKKS	533	Q16518	S	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [312], 'BINDING_gain': [], 'BINDING_loss_score': array([-0.05294353]), 'DNA_BIND_loss': [], 'DNA_BIND_gain': [253], 'DNA_BIND_gain_score': array([0.00413662]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [6, 7, 11, 12, 18, 30], 'PROPEP_gain_score': array([0.01660049, 0.01609272, 0.01515388, 0.01795071, 0.01515561,
       0.010607  ]), 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [98, 409], 'STRAND_gain': [107], 'STRAND_gain_score': array([0.00747454]), 'STRAND_loss_score': array([-0.02638561, -0.00076789]), 'HELIX_loss': [333, 335, 336, 337, 338], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.04793417, -0.17217582, -0.43761826, -0.41254413, -0.47939974]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [118], 'DOMAIN_gain_score': array([0.00741053]), 'REGION_loss': [], 'REGION_gain': [323], 'REGION_gain_score': array([0.01698232]), 'REPEAT_loss': [], 'REPEAT_gain': [190, 241, 464, 469], 'REPEAT_gain_score': array([0.00594103, 0.00345176, 0.00552237, 0.00375825]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
700	NM_000329.3(RPE65):c.1338G>T (p.Arg446Ser)	427864	CA340742354	NM_000329.3:c.1338G>T, NC_000001.11:g.68431282C>A, CM000663.2:g.68431282C>A, NC_000001.10:g.68896965C>A, CM000663.1:g.68896965C>A, NC_000001.9:g.68669553C>A, NG_008472.1:g.23678G>T, NG_008472.2:g.23678G>T, ENST00000262340.6:c.1338G>T, ENST00000262340.5:c.1338G>T, NM_000329.2:c.1338G>T, XM_017002027.1:c.1062G>T, NM_000329.3(RPE65):c.1338G>T (p.Arg446Ser)	RPE65	RPE65-related recessive retinopathy	MONDO:0100368	Autosomal recessive inheritance	Pathogenic	PP1, PM2_Supporting, PM3_Strong, PP4_Moderate, PVS1	PP3, PS3	NM_000329.3(RPE65):c.1338G>T is a missense variant that substitutes arginine with serine at position 446. The variant is found in multiple probands affected with early-onset severe retinal dystrophy. At least one patient genotyped by whole exome sequencing (2 pts) has a diagnosis of Leber congenital amaurosis (0.5 pts) with infantile onset (1 pt), reduced visual acuity (1 pt), nyctalopia (required, 0.5 pts), light gazing (1 pt), nystagmus (1 pt), RPE mottling (0.5 pt), attenuated retinal vessels (0.5 pt), and flat rod (0.5 pts) and cone (1 pt) ERG responses, which together are highly specific for RPE65-related recessive retinopathy (9.5 pts, PMID: 30870047, PP4_Moderate). At least 3 reported probands harbor the variant in the homozygous state, while an additional proband harbors this maternal variant in compound heterozygosity with a paternal c.361dup (p.Ser121Phefs*10 variant (previously classified pathogenic by the ClinGen LCA/eoRD VCEP)(PMID: 30870047, PM3_Strong). Three pairs of siblings have been reported (PMID: 30870047) harboring the variant in either the homozygous or compound heterozygous state (PP1). This variant has a Grpmax Filtering AF of 0.000009610 (2/34488, with no homozygotes) in the Latino/Admixed American population in gnomAD v2.1.1 which is lower than the ClinGen LCA/eoRD VCEP PM2_Supporting threshold of <0.0002. Although the meta-predictor REVEL gives a score of 0.571, which is below the ClinGen LCA/eoRD VCEP PP3 threshold of >0.7, the computational splicing predictor SpliceAI indicates that the variant triggers the loss of a splice donor site, with a change score of 0.45. The variant was confirmed to exhibit a complete splicing defect in two minigene assays relative to the wild-type control, showing skipping of the 95-bp exon 12, indicating that it triggers nonsense-mediated decay (PMID: 30996589, PMID: 28714225, PVS1). In summary, this variant meets the criteria to be classified as Pathogenic for RPE65-related recessive retinopathy based on the ACMG/AMP criteria applied, as specified by the ClinGen LCA/eoRD VCEP: PVS1, PM2_Supporting, PM3_Strong, PP1, PP4_Moderate. (VCEP specifications version 1.0.0; date of approval 09/21/2023)		Leber Congenital Amaurosis/early onset Retinal Dystrophy VCEP		2024-02-20	2024-02-20	False	https://erepo.genome.network/evrepo/ui/classification/CA340742354/MONDO:0100368/120	79b802a8-f024-4536-a8a2-3e73fddaa67c	p.Arg446Ser	Arg	446	Ser	MSIQVEHPAGGYKKLFETVEELSSPLTAHVTGRIPLWLTGSLLRCGPGLFEVGSEPFYHLFDGQALLHKFDFKEGHVTYHRRFIRTDAYVRAMTEKRIVITEFGTCAFPDPCKNIFSRFFSYFRGVEVTDNALVNVYPVGEDYYACTETNFITKINPETLETIKQVDLCNYVSVNGATAHPHIENDGTVYNIGNCFGKNFSIAYNIVKIPPLQADKEDPISKSEIVVQFPCSDRFKPSYVHSFGLTPNYIVFVETPVKINLFKFLSSWSLWGANYMDCFESNETMGVWLHIADKKRKKYLNNKYRTSPFNLFHHINTYEDNGFLIVDLCCWKGFEFVYNYLYLANLRENWEEVKKNARKAPQPEVRRYVLPLNIDKADTGKNLVTLPNTTATAILCSDETIWLEPEVLFSGPRQAFEFPQINYQKYCGKPYTYAYGLGLNHFVPDRLCKLNVKTKETWVWQEPDSYPSEPIFVSHPDALEEDDGVVLSVVVSPGAGQKPAYLLILNAKDLSEVARAEVEINIPVTFHGLFKKS	533	Q16518	S	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [251, 286, 489, 490], 'DNA_BIND_gain': [], 'DNA_BIND_loss_score': array([-0.00457144, -0.00190502, -0.02700979, -0.03620344]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [12, 30], 'PROPEP_gain_score': array([0.01079571, 0.01098782]), 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [98], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.01866978]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [118], 'DOMAIN_gain_score': array([0.02506381]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [497], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.00570214]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
701	NM_000329.3(RPE65):c.1102T>C (p.Tyr368His)	29870	CA226484	NM_000329.3:c.1102T>C, NC_000001.11:g.68438213A>G, CM000663.2:g.68438213A>G, NC_000001.10:g.68903896A>G, CM000663.1:g.68903896A>G, NC_000001.9:g.68676484A>G, NG_008472.1:g.16747T>C, NG_008472.2:g.16747T>C, ENST00000262340.6:c.1102T>C, ENST00000262340.5:c.1102T>C, NM_000329.2:c.1102T>C, XM_017002027.1:c.826T>C, NM_000329.3(RPE65):c.1102T>C (p.Tyr368His)	RPE65	RPE65-related recessive retinopathy	MONDO:0100368	Autosomal recessive inheritance	Pathogenic	PP1, PM3_Very Strong, PM2_Supporting, PP3_Moderate	PP4	NM_000329.3(RPE65):c.1102T>C (p.Tyr368His) is a missense variant that replaces the tyrosine at position 368 with histidine. It has been reported in the literature in at least 2 unrelated probands with early-onset severe retinal dystrophy who were homozygous for the variant (1 point, PMID: 12960219, PMID: 25257057). The variant has also been reported in at least 3 probands with early-onset severe retinal dystrophy who were compound heterozygous with either the c.11+5G>A, c.292_311del p.Ile98Hisfs*26, or p.Arg44Ter variant confirmed in trans (3 points, PMIDs: 11786058, PMID: 34492281). All of these variants were previously classified pathogenic by the ClinGen LCA/eoRD VCEP (4 total points, PM3_VeryStrong). The variant has also been reported to segregate with childhood-onset severe retinal dystrophy through at least 1 affected meiosis from 1 family (PP1; PMID:11786058). The variant is present in gnomAD v.2.1.1 at a Grpmax allele frequency of 0.00009488, with 19/129116 in the European (Non-Finnish) population, which is lower than the ClinGen LCA/eoRD VCEP PM2_Supporting threshold of <0.0002 (PM2_Supporting). The computational predictor REVEL gives a score of 0.969, which is above the ClinGen LCA/eoRD VCEP threshold of ≥ 0.773 and predicts a damaging effect on RPE65 function (PP3_Moderate). In summary, this variant meets the criteria to be classified as Pathogenic for RPE65-related recessive retinopathy based on the ACMG/AMP criteria applied, as specified by the ClinGen LCA/eoRD VCEP: PM3_VeryStrong, PP1, PM2_Supporting, PP3_Moderate. (VCEP specifications version 1.0.0; date of approval 09/21/2023).		Leber Congenital Amaurosis/early onset Retinal Dystrophy VCEP		2024-02-20	2024-02-20	False	https://erepo.genome.network/evrepo/ui/classification/CA226484/MONDO:0100368/120	86ff5b9c-88b5-4ac3-adc8-f384a6332bcf	p.Tyr368His	Tyr	368	His	MSIQVEHPAGGYKKLFETVEELSSPLTAHVTGRIPLWLTGSLLRCGPGLFEVGSEPFYHLFDGQALLHKFDFKEGHVTYHRRFIRTDAYVRAMTEKRIVITEFGTCAFPDPCKNIFSRFFSYFRGVEVTDNALVNVYPVGEDYYACTETNFITKINPETLETIKQVDLCNYVSVNGATAHPHIENDGTVYNIGNCFGKNFSIAYNIVKIPPLQADKEDPISKSEIVVQFPCSDRFKPSYVHSFGLTPNYIVFVETPVKINLFKFLSSWSLWGANYMDCFESNETMGVWLHIADKKRKKYLNNKYRTSPFNLFHHINTYEDNGFLIVDLCCWKGFEFVYNYLYLANLRENWEEVKKNARKAPQPEVRRYVLPLNIDKADTGKNLVTLPNTTATAILCSDETIWLEPEVLFSGPRQAFEFPQINYQKYCGKPYTYAYGLGLNHFVPDRLCKLNVKTKETWVWQEPDSYPSEPIFVSHPDALEEDDGVVLSVVVSPGAGQKPAYLLILNAKDLSEVARAEVEINIPVTFHGLFKKS	533	Q16518	H	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [409], 'STRAND_gain': [402], 'STRAND_gain_score': array([0.01990122]), 'STRAND_loss_score': array([-0.01332563]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [328, 361], 'DOMAIN_gain': [376], 'DOMAIN_gain_score': array([0.01373875]), 'DOMAIN_loss_score': array([-0.05468941, -0.14989012]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [497], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.00747079]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
702	NM_000329.3(RPE65):c.560G>A (p.Gly187Glu)	801497	CA902468	NM_000329.3:c.560G>A, NC_000001.11:g.68440936C>T, CM000663.2:g.68440936C>T, NC_000001.10:g.68906619C>T, CM000663.1:g.68906619C>T, NC_000001.9:g.68679207C>T, NG_008472.1:g.14024G>A, NG_008472.2:g.14024G>A, ENST00000262340.6:c.560G>A, ENST00000262340.5:c.560G>A, NM_000329.2:c.560G>A, XM_017002027.1:c.284G>A, NM_000329.3(RPE65):c.560G>A (p.Gly187Glu)	RPE65	RPE65-related recessive retinopathy	MONDO:0100368	Autosomal recessive inheritance	Pathogenic	PP4, PM2_Supporting, PP3_Moderate, PP1_Strong, PM3	BA1, BS1	NM_000329.3(RPE65):c.560G>A is a missense variant that causes substitution of glycine with glutamic acid at position 187. This variant is present in gnomAD v.2.1.1 at a GrpMax allele frequency of 0.000009590, with 2 alleles / 34536 total alleles in the Admixed American population, which is lower than the ClinGen LCA / eoRD VCEP PM2_Supporting threshold of <0.0002 (PM2_Supporting). At least one proband harboring this variant exhibits a phenotype including diagnosis of retinitis pigmentosa with onset at age 2 years (1 pt), night blindness (0.5 pts), visual field reduction (1 pt), bone spicule pigmentation (0.5 pts), loss of central vision (1 pt), and undetectable electroretinogram responses from rods (0.5 pts) and cones (1 pt), which together are specific for RPE65-related recessive retinopathy (5.5 pts, PMID: 34492281, PP4). This variant has been reported in at least 3 unrelated probands with early-onset severe retinal dystrophy who were homozygous for the variant (1 pt, PMID: 31878136, PM3). The variant has been reported to segregate with childhood-onset severe retinal dystrophy through three probands plus 4 similarly affected relatives, with the variant present in the homozygous state (PP1_Strong; PMID: 31878136). The computational predictor REVEL gives a score of 0.939, which is above the ClinGen LCA / eoRD VCEP threshold of ≥ 0.774 and predicts a damaging effect on RPE65 function (PP3_Moderate). In summary, this variant meets the criteria to be classified as pathogenic for RPE65-related recessive retinopathy based on the ACMG/AMP criteria applied, as specified by the ClinGen LCA / eoRD VCEP: PM2_Supporting, PM3, PP1_Strong, PP3_Moderate, and PP4. (VCEP specifications version 1.0.0; date of approval 09/21/2023).		Leber Congenital Amaurosis/early onset Retinal Dystrophy VCEP		2024-02-20	2024-02-20	False	https://erepo.genome.network/evrepo/ui/classification/CA902468/MONDO:0100368/120	031673ea-5fc6-4c5d-b847-707253e40d30	p.Gly187Glu	Gly	187	Glu	MSIQVEHPAGGYKKLFETVEELSSPLTAHVTGRIPLWLTGSLLRCGPGLFEVGSEPFYHLFDGQALLHKFDFKEGHVTYHRRFIRTDAYVRAMTEKRIVITEFGTCAFPDPCKNIFSRFFSYFRGVEVTDNALVNVYPVGEDYYACTETNFITKINPETLETIKQVDLCNYVSVNGATAHPHIENDGTVYNIGNCFGKNFSIAYNIVKIPPLQADKEDPISKSEIVVQFPCSDRFKPSYVHSFGLTPNYIVFVETPVKINLFKFLSSWSLWGANYMDCFESNETMGVWLHIADKKRKKYLNNKYRTSPFNLFHHINTYEDNGFLIVDLCCWKGFEFVYNYLYLANLRENWEEVKKNARKAPQPEVRRYVLPLNIDKADTGKNLVTLPNTTATAILCSDETIWLEPEVLFSGPRQAFEFPQINYQKYCGKPYTYAYGLGLNHFVPDRLCKLNVKTKETWVWQEPDSYPSEPIFVSHPDALEEDDGVVLSVVVSPGAGQKPAYLLILNAKDLSEVARAEVEINIPVTFHGLFKKS	533	Q16518	E	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [251, 261, 286, 489, 490], 'DNA_BIND_gain': [], 'DNA_BIND_loss_score': array([-0.00536484, -0.01032925, -0.00490934, -0.00962198, -0.01258641]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [5, 15, 16, 22, 31], 'PROPEP_gain': [], 'PROPEP_loss_score': array([-0.01151758, -0.01025963, -0.01378524, -0.01309854, -0.01414728]), 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [409], 'STRAND_gain': [103, 107, 237], 'STRAND_gain_score': array([0.05798525, 0.01764846, 0.02557039]), 'STRAND_loss_score': array([-0.00044948]), 'HELIX_loss': [264], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.00869197]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [328, 361], 'DOMAIN_gain': [118], 'DOMAIN_gain_score': array([0.0206005]), 'DOMAIN_loss_score': array([-0.02387619, -0.02442825]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [191, 193], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.07026482, -0.06154668]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
703	NM_000329.3(RPE65):c.1543C>T (p.Arg515Trp)	13120	CA226519	NM_000329.3:c.1543C>T, NC_000001.11:g.68429835G>A, CM000663.2:g.68429835G>A, NC_000001.10:g.68895518G>A, CM000663.1:g.68895518G>A, NC_000001.9:g.68668106G>A, NG_008472.1:g.25125C>T, NG_008472.2:g.25125C>T, ENST00000262340.6:c.1543C>T, ENST00000262340.5:c.1543C>T, NM_000329.2:c.1543C>T, XM_017002027.1:c.1267C>T, NM_000329.3(RPE65):c.1543C>T (p.Arg515Trp)	RPE65	RPE65-related recessive retinopathy	MONDO:0100368	Autosomal recessive inheritance	Pathogenic	PM2_Supporting, PM3_Strong, PP3_Moderate, PS3_Supporting, PP4_Moderate		NM_000329.3(RPE65):c.1543C>T is a missense variant predicted to replace arginine with tryptophan at position 515. This variant is present in gnomAD v.2.1.1 at a GrpMax allele frequency of 0.000002980, with 2 alleles / 126782 total alleles in the European (non-Finnish population), which is lower than the ClinGen LCA / eoRD VCEP PM2_Supporting threshold of <0.0002 (PM2_Supporting). This variant has been reported in at least 1 proband with early-onset severe retinal dystrophy who was homozygous for the variant (0.5 pts, PMID: 25495949). This variant has also been reported in at least 4 probands with early-onset severe retinal dystrophy who were compound heterozygous with either the NM_000329.3(RPE65):c.1022T>C (p.Leu341Ser) (PMID: 34492281)), NM_000329.3(RPE65):c.1102T>C (p.Tyr368His) (PMID: 32032261), NM_000329.3(RPE65):c.1067dup (p.Asn356fs) (PMID: 35129589), or NM_000329.3(RPE65):c.130C>T (p.Arg44Ter) variant (PMID: 30025081) variants suspected in trans (2 pts), which were all previously classified pathogenic by the ClinGen LCA / eoRD VCEP (2.5 total points, PM3_Strong). At least one proband harboring this variant exhibits a phenotype including diagnosis of Leber congenital amaurosis (0.5 pts) based on exome sequencing-based genotyping that did not provide an alternative explanation for visual impairment (2 pts), night blindness (0.5 pts) with onset during the first year of life (1 pt), attenuated retinal vessels (0.5 pts), macular atrophy (0.5 pts), bone spicule pigmentation (0.5 pts), non-recordable electroretinogram pattern in rod (0.5 pts) and cone (1 pt) responses, and decreased central visual acuity (1 pt), which together are highly specific for RPE65-related recessive retinopathy (8 total pts, PMID: 25495949, PP4_Moderate). The computational predictor REVEL gives a score of 0.935, which is above the ClinGen LCA / eoRD VCEP threshold of ≥0.773 and predicts a damaging effect on RPE65 function (PP3_Moderate). The variant exhibited less than 10% enzymatic activity in a retinoid isomerase assay relative to the wild-type control, which is lower than the ClinGen LCA / eoRD PS3_Supporting threshold of <10% activity, indicating that it triggers a severe defect in protein function (PMID: 25752820, PS3_Supporting). In summary, this variant meets the criteria to be classified as pathogenic for RPE65-related recessive retinopathy based on the ACMG/AMP criteria applied, as specified by the ClinGen LCA / eoRD VCEP: PS3_Supporting, PM2_Supporting, PM3_Strong, PP3_Moderate, and PP4_Moderate. (VCEP specifications version 1.0.0; date of approval 09/21/2023).		Leber Congenital Amaurosis/early onset Retinal Dystrophy VCEP		2024-02-20	2024-02-20	False	https://erepo.genome.network/evrepo/ui/classification/CA226519/MONDO:0100368/120	62e2905f-cba8-449d-85c5-7f56947cd41a	p.Arg515Trp	Arg	515	Trp	MSIQVEHPAGGYKKLFETVEELSSPLTAHVTGRIPLWLTGSLLRCGPGLFEVGSEPFYHLFDGQALLHKFDFKEGHVTYHRRFIRTDAYVRAMTEKRIVITEFGTCAFPDPCKNIFSRFFSYFRGVEVTDNALVNVYPVGEDYYACTETNFITKINPETLETIKQVDLCNYVSVNGATAHPHIENDGTVYNIGNCFGKNFSIAYNIVKIPPLQADKEDPISKSEIVVQFPCSDRFKPSYVHSFGLTPNYIVFVETPVKINLFKFLSSWSLWGANYMDCFESNETMGVWLHIADKKRKKYLNNKYRTSPFNLFHHINTYEDNGFLIVDLCCWKGFEFVYNYLYLANLRENWEEVKKNARKAPQPEVRRYVLPLNIDKADTGKNLVTLPNTTATAILCSDETIWLEPEVLFSGPRQAFEFPQINYQKYCGKPYTYAYGLGLNHFVPDRLCKLNVKTKETWVWQEPDSYPSEPIFVSHPDALEEDDGVVLSVVVSPGAGQKPAYLLILNAKDLSEVARAEVEINIPVTFHGLFKKS	533	Q16518	W	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [285, 491], 'DNA_BIND_gain_score': array([0.00648779, 0.0150966 ]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [5, 15, 16, 22], 'PROPEP_gain': [], 'PROPEP_loss_score': array([-0.00894505, -0.01029491, -0.013273  , -0.0095886 ]), 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [98], 'STRAND_gain': [402, 518], 'STRAND_gain_score': array([0.01382124, 0.08148891]), 'STRAND_loss_score': array([-0.03375143]), 'HELIX_loss': [87], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.02198941]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [376, 378, 503, 512, 514], 'DOMAIN_gain_score': array([0.02366185, 0.02312785, 0.01965773, 0.04001623, 0.17919725]), 'REGION_loss': [], 'REGION_gain': [323], 'REGION_gain_score': array([0.01659518]), 'REPEAT_loss': [], 'REPEAT_gain': [241, 469], 'REPEAT_gain_score': array([0.00305557, 0.00271797]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
704	NM_000329.3(RPE65):c.272G>A (p.Arg91Gln)	98857	CA226533	NM_000329.3:c.272G>A, NC_000001.11:g.68444857C>T, CM000663.2:g.68444857C>T, NC_000001.10:g.68910540C>T, CM000663.1:g.68910540C>T, NC_000001.9:g.68683128C>T, NG_008472.1:g.10103G>A, NG_008472.2:g.10103G>A, ENST00000262340.6:c.272G>A, ENST00000262340.5:c.272G>A, NM_000329.2:c.272G>A, XM_017002027.1:c.-5G>A, NM_000329.3(RPE65):c.272G>A (p.Arg91Gln)	RPE65	RPE65-related recessive retinopathy	MONDO:0100368	Autosomal recessive inheritance	Pathogenic	PP1, PP3, PM2_Supporting, PM3_Strong, PS3_Supporting, PP4_Moderate	PM5	NM_000329.3(RPE65):c.272G>A (p.Arg91Gln) is a missense variant that replaces arginine with glutamine at position 91 in RPE65. At least one proband harboring this variant has been genotyped by next-generation sequencing analysis of 586 candidate genes without an alternative explanation for visual impairment (2 pts), with phenotypes including congenital onset (1 pt), abnormal best corrected visual acuity test (1 pt), extinguished scotopic (0.5 pts) and photopic (1 pt) electroretinogram responses, bone spicule pigmentation (0.5 pts), white or yellow dots in the fundus (2 pts), and nystagmus (1 pt), which together are highly specific for RPE65-related recessive retinopathy (9 points, PP4_Moderate). This variant has also been reported in at least 2 probands with early-onset severe retinal dystrophy who were compound heterozygous with either the c.1022T>C (p.Leu341Ser) variant or the c.370C>T (p.Arg124Ter) variant suspected in trans (1 point, PMID: 32865313, PMID: 27102010), both of which were previously classified pathogenic by the ClinGen LCA / eoRD VCEP. This variant has also been reported in the homozygous state in at least 2 probands with early-onset severe retinal dystrophy (1 point, PMID: 32865313, PMID: 34492281; 2 total points, PM3_Strong). The variant has been reported to segregate with childhood-onset severe retinal dystrophy through a proband plus 1 similarly affected relative, both of whom harbor the variant present in the compound heterozygous state with the c.725+4A>G variant confirmed in trans (PP1; PMID: 11462243). This variant is present in gnomAD v.2.1.1 at a Grpmax allele frequency of 0.0001609, with 8 alleles / 24940 total alleles in the African / African-American population, which is lower than the ClinGen LCA / eoRD VCEP PM2_Supporting threshold of <0.0002 (PM2_Supporting). The computational predictor REVEL gives a score of 0.659, which is above the ClinGen LCA / eoRD VCEP threshold of ≥ 0.644 and predicts a damaging effect on RPE65 function (PP3). The variant also exhibited 1.33% enzymatic activity in a retinoid isomerase assay relative to the wild-type control, which is lower than the ClinGen LCA / eoRD PS3_Supporting threshold of <10% activity, indicating that it triggers a severe defect in protein function (PS3_Supporting, Table 2, PMID: 19431183). Two other missense variants encoding different amino acid substitutions at the same codon have been reported in association with RPE65-related recessive retinopathy (PMID: 17724218, PMID: 9501220). However, c.271C>T (p.Arg91Trp) and c.272G>C (p.Arg91Pro) have not yet been classified by the ClinGen LCA / eoRD VCEP, and PM5 was not considered to avoid circularity. In summary, this variant meets the criteria to be classified as pathogenic for RPE65-related recessive retinopathy based on the ACMG/AMP criteria applied, as specified by the ClinGen LCA/eoRD VCEP: PS3_Supporting, PM2_Supporting, PM3_Strong, PP1, PP3, PP4_Moderate (VCEP specifications version 1.0.0; date of approval 09/21/2023).		Leber Congenital Amaurosis/early onset Retinal Dystrophy VCEP		2024-02-20	2024-02-20	False	https://erepo.genome.network/evrepo/ui/classification/CA226533/MONDO:0100368/120	56991886-2f75-46fa-809b-e3cfde70721f	p.Arg91Gln	Arg	91	Gln	MSIQVEHPAGGYKKLFETVEELSSPLTAHVTGRIPLWLTGSLLRCGPGLFEVGSEPFYHLFDGQALLHKFDFKEGHVTYHRRFIRTDAYVRAMTEKRIVITEFGTCAFPDPCKNIFSRFFSYFRGVEVTDNALVNVYPVGEDYYACTETNFITKINPETLETIKQVDLCNYVSVNGATAHPHIENDGTVYNIGNCFGKNFSIAYNIVKIPPLQADKEDPISKSEIVVQFPCSDRFKPSYVHSFGLTPNYIVFVETPVKINLFKFLSSWSLWGANYMDCFESNETMGVWLHIADKKRKKYLNNKYRTSPFNLFHHINTYEDNGFLIVDLCCWKGFEFVYNYLYLANLRENWEEVKKNARKAPQPEVRRYVLPLNIDKADTGKNLVTLPNTTATAILCSDETIWLEPEVLFSGPRQAFEFPQINYQKYCGKPYTYAYGLGLNHFVPDRLCKLNVKTKETWVWQEPDSYPSEPIFVSHPDALEEDDGVVLSVVVSPGAGQKPAYLLILNAKDLSEVARAEVEINIPVTFHGLFKKS	533	Q16518	Q	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [253], 'DNA_BIND_gain_score': array([0.00128359]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [190, 241], 'REPEAT_gain_score': array([0.00462031, 0.00191146]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
705	NM_000329.3(RPE65):c.200T>G (p.Leu67Arg)	1068757	CA340749010	NM_000329.3:c.200T>G, NC_000001.11:g.68446755A>C, CM000663.2:g.68446755A>C, NC_000001.10:g.68912438A>C, CM000663.1:g.68912438A>C, NC_000001.9:g.68685026A>C, NG_008472.1:g.8205T>G, NG_008472.2:g.8205T>G, ENST00000262340.6:c.200T>G, ENST00000262340.5:c.200T>G, NM_000329.2:c.200T>G, XM_017002027.1:c.-32+1869T>G, NM_000329.3(RPE65):c.200T>G (p.Leu67Arg)	RPE65	RPE65-related recessive retinopathy	MONDO:0100368	Autosomal recessive inheritance	Pathogenic	PP1, PM2_Supporting, PM3_Strong, PP3_Moderate, PP4_Moderate		NM_000329.3(RPE65):c.200T>G is a missense variant that causes substitution of leucine with arginine at position 67. This variant is present in gnomAD v.2.1.1 at a maximum allele frequency of 0.00005437, with 1 allele / 18392 total alleles in the East Asian population, which is lower than the ClinGen LCA / eoRD VCEP PM2_Supporting threshold of <0.0002 (PM2_Supporting). This variant has been reported in at least 2 unrelated probands with early-onset severe retinal dystrophy who were compound heterozygous with either the NM_000329.3(RPE65):c.596dup (p.Asn199LysfsTer?) or NM_000329.3(RPE65):c.893del (Lys298Asnfs*27) variant confirmed in trans, which were previously classified pathogenic by the ClinGen LCA / eoRD VCEP (2 total pts, PMID: 34830511, PM3_Strong). At least one proband harboring this variant exhibits a phenotype including diagnosis of Leber congenital amaurosis (0.5 pts) with genotyping by targeted exome sequencing finding no alternative cause of disease among 188 known inherited retinal degeneration genes (2 pts), onset before the age of 5 years (1 pt), reduced central visual acuity (1 pt), nystagmus (1 pt), hypo-autofluorescence (2 pts), and extinguished electroretinogram responses from rods (0.5 pts) and cones (1 pt), which together are highly specific for RPE65-related recessive retinopathy (9 pts, PMID: 34830511, PP4_Moderate). The variant has been reported to segregate with childhood-onset severe retinal dystrophy through the proband plus 1 similarly affected relative in two different families, with the variant present in the compound heterozygous state in both instances (PMID: 22509104, PMID: 23661369, PP1). The computational predictor REVEL gives a score of 0.98, which is above the ClinGen LCA / eoRD VCEP threshold of ≥0.773 and predicts a damaging effect on RPE65 function (PP3_Moderate). In summary, this variant meets the criteria to be classified as pathogenic for RPE65-related recessive retinopathy based on the ACMG/AMP criteria applied, as specified by the ClinGen LCA / eoRD VCEP: PM2_Supporting, PM3_Strong, PP1, PP3_Moderate, and PP4_Moderate. (VCEP specifications version 1.0.0; date of approval 09/21/2023).		Leber Congenital Amaurosis/early onset Retinal Dystrophy VCEP		2024-02-20	2024-02-20	False	https://erepo.genome.network/evrepo/ui/classification/CA340749010/MONDO:0100368/120	4d66b49c-5789-488a-9be7-7312b3695d19	p.Leu67Arg	Leu	67	Arg	MSIQVEHPAGGYKKLFETVEELSSPLTAHVTGRIPLWLTGSLLRCGPGLFEVGSEPFYHLFDGQALLHKFDFKEGHVTYHRRFIRTDAYVRAMTEKRIVITEFGTCAFPDPCKNIFSRFFSYFRGVEVTDNALVNVYPVGEDYYACTETNFITKINPETLETIKQVDLCNYVSVNGATAHPHIENDGTVYNIGNCFGKNFSIAYNIVKIPPLQADKEDPISKSEIVVQFPCSDRFKPSYVHSFGLTPNYIVFVETPVKINLFKFLSSWSLWGANYMDCFESNETMGVWLHIADKKRKKYLNNKYRTSPFNLFHHINTYEDNGFLIVDLCCWKGFEFVYNYLYLANLRENWEEVKKNARKAPQPEVRRYVLPLNIDKADTGKNLVTLPNTTATAILCSDETIWLEPEVLFSGPRQAFEFPQINYQKYCGKPYTYAYGLGLNHFVPDRLCKLNVKTKETWVWQEPDSYPSEPIFVSHPDALEEDDGVVLSVVVSPGAGQKPAYLLILNAKDLSEVARAEVEINIPVTFHGLFKKS	533	Q16518	R	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [286], 'DNA_BIND_gain': [], 'DNA_BIND_loss_score': array([-0.00126898]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [15, 22], 'PROPEP_gain': [], 'PROPEP_loss_score': array([-0.0061236 , -0.00487441]), 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [56, 57, 60], 'STRAND_gain': [42, 72, 99, 101, 103, 107], 'STRAND_gain_score': array([0.12898564, 0.10114408, 0.33551151, 0.24801463, 0.15721303,
       0.00251389]), 'STRAND_loss_score': array([-0.58851039, -0.46576858, -0.35480022]), 'HELIX_loss': [87, 88, 90, 91, 333], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.12613672, -0.11569417, -0.2496503 , -0.25483495, -0.00867146]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [89, 91, 92, 93, 328], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.04873401, -0.05873132, -0.03363401, -0.05269736, -0.02947241]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [497], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.00277585]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
706	NM_000138.5(FBN1):c.5558G>A (p.Cys1853Tyr)	632819	CA392342530	NM_000138.5:c.5558G>A, NC_000015.10:g.48448881C>T, CM000677.2:g.48448881C>T, NC_000015.9:g.48741078C>T, CM000677.1:g.48741078C>T, NC_000015.8:g.46528370C>T, NG_008805.2:g.201908G>A, LRG_778:g.201908G>A, ENST00000559133.6:c.5558G>A, ENST00000674301.2:c.5558G>A, ENST00000684448.1:n.4232G>A, ENST00000316623.10:c.5558G>A, ENST00000674301.1:c.557G>A, ENST00000316623.9:c.5558G>A, ENST00000537463.6:c.*1321G>A, ENST00000559133.5:c.865G>A, NM_000138.4:c.5558G>A, LRG_778t1:c.5558G>A, NM_000138.5(FBN1):c.5558G>A (p.Cys1853Tyr)	FBN1	Marfan syndrome	MONDO:0007947	Autosomal dominant inheritance	Pathogenic	PS4_Moderate, PM1_Strong, PP4, PP2, PP3, PM2_Supporting	PM5	The NM_00138 c.5558G>A, is a missense variant in FBN1 predicted to cause a substitution of a cysteine by tyrosine at amino acid 1853 (p.Cys1853Tyr). This variant was found in a proband with aortic aneurysm and dissection and skeletal features who met revised Ghent criteria, which is a highly specific phenotype for Marfan syndrome (Internal lab data, PP4). This variant has been reported twice in ClinVar: once as likely pathogenic, and once as uncertain significance (Variation ID: 632189). This variant has also been identified in individuals with clinical diagnosis of Marfan syndrome and/or features of Marfan syndrome (Invitae ClinVar entry, internal data; PS4_Mod). This variant is not present in gnomAD (PM2_sup; https://gnomad.broadinstitute.org/v2.1.1). This variant affects a cysteine residue in a calcium binding EGF-like domain. Cysteine residues in these domains are believed to be involved in the formation of disulfide bridges which are essential for the protein structure (PM1_strong). Computational prediction tools and conservation analysis suggest that this variant may impact the protein (REVEL: 0.992, PP3). The constraint z-score for missense variants affecting FBN1 is 5.06 (PP2). In summary, this variant meets criteria to be classified as pathogenic for Marfan syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen FBN1 VCEP: PM1_Strong, PS4_Mod, PM2_Sup, PP2, PP3, PP4.		FBN1 VCEP	https://clinicalgenome.org/docs/clingen-fbn1-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2024-02-22	2024-02-22	False	https://erepo.genome.network/evrepo/ui/classification/CA392342530/MONDO:0007947/022	4dcb95f6-9507-4207-9507-74c17d761569	p.Cys1853Tyr	Cys	1853	Tyr	MRRGRLLEIALGFTVLLASYTSHGADANLEAGNVKETRASRAKRRGGGGHDALKGPNVCGSRYNAYCCPGWKTLPGGNQCIVPICRHSCGDGFCSRPNMCTCPSGQIAPSCGSRSIQHCNIRCMNGGSCSDDHCLCQKGYIGTHCGQPVCESGCLNGGRCVAPNRCACTYGFTGPQCERDYRTGPCFTVISNQMCQGQLSGIVCTKTLCCATVGRAWGHPCEMCPAQPHPCRRGFIPNIRTGACQDVDECQAIPGLCQGGNCINTVGSFECKCPAGHKLNEVSQKCEDIDECSTIPGICEGGECTNTVSSYFCKCPPGFYTSPDGTRCIDVRPGYCYTALTNGRCSNQLPQSITKMQCCCDAGRCWSPGVTVAPEMCPIRATEDFNKLCSVPMVIPGRPEYPPPPLGPIPPVLPVPPGFPPGPQIPVPRPPVEYLYPSREPPRVLPVNVTDYCQLVRYLCQNGRCIPTPGSYRCECNKGFQLDLRGECIDVDECEKNPCAGGECINNQGSYTCQCRAGYQSTLTRTECRDIDECLQNGRICNNGRCINTDGSFHCVCNAGFHVTRDGKNCEDMDECSIRNMCLNGMCINEDGSFKCICKPGFQLASDGRYCKDINECETPGICMNGRCVNTDGSYRCECFPGLAVGLDGRVCVDTHMRSTCYGGYKRGQCIKPLFGAVTKSECCCASTEYAFGEPCQPCPAQNSAEYQALCSSGPGMTSAGSDINECALDPDICPNGICENLRGTYKCICNSGYEVDSTGKNCVDINECVLNSLLCDNGQCRNTPGSFVCTCPKGFIYKPDLKTCEDIDECESSPCINGVCKNSPGSFICECSSESTLDPTKTICIETIKGTCWQTVIDGRCEININGATLKSQCCSSLGAAWGSPCTLCQVDPICGKGYSRIKGTQCEDIDECEVFPGVCKNGLCVNTRGSFKCQCPSGMTLDATGRICLDIRLETCFLRYEDEECTLPIAGRHRMDACCCSVGAAWGTEECEECPMRNTPEYEELCPRGPGFATKEITNGKPFFKDINECKMIPSLCTHGKCRNTIGSFKCRCDSGFALDSEERNCTDIDECRISPDLCGRGQCVNTPGDFECKCDEGYESGFMMMKNCMDIDECQRDPLLCRGGVCHNTEGSYRCECPPGHQLSPNISACIDINECELSAHLCPNGRCVNLIGKYQCACNPGYHSTPDRLFCVDIDECSIMNGGCETFCTNSEGSYECSCQPGFALMPDQRSCTDIDECEDNPNICDGGQCTNIPGEYRCLCYDGFMASEDMKTCVDVNECDLNPNICLSGTCENTKGSFICHCDMGYSGKKGKTGCTDINECEIGAHNCGKHAVCTNTAGSFKCSCSPGWIGDGIKCTDLDECSNGTHMCSQHADCKNTMGSYRCLCKEGYTGDGFTCTDLDECSENLNLCGNGQCLNAPGGYRCECDMGFVPSADGKACEDIDECSLPNICVFGTCHNLPGLFRCECEIGYELDRSGGNCTDVNECLDPTTCISGNCVNTPGSYICDCPPDFELNPTRVGCVDTRSGNCYLDIRPRGDNGDTACSNEIGVGVSKASCCCSLGKAWGTPCEMCPAVNTSEYKILCPGGEGFRPNPITVILEDIDECQELPGLCQGGKCINTFGSFQCRCPTGYYLNEDTRVCDDVNECETPGICGPGTCYNTVGNYTCICPPDYMQVNGGNNCMDMRRSLCYRNYYADNQTCDGELLFNMTKKMCCCSYNIGRAWNKPCEQCPIPSTDEFATLCGSQRPGFVIDIYTGLPVDIDECREIPGVCENGVCINMVGSFRCECPVGFFYNDKLLVCEDIDECQNGPVCQRNAECINTAGSYRCDCKPGYRFTSTGQCNDRNECQEIPNICSHGQCIDTVGSFYCLCHTGFKTNDDQTMCLDINECERDACGNGTCRNTIGSFNCRCNHGFILSHNNDCIDVDECASGNGNLCRNGQCINTVGSFQCQCNEGYEVAPDGRTCVDINECLLEPRKCAPGTCQNLDGSYRCICPPGYSLQNEKCEDIDECVEEPEICALGTCSNTEGSFKCLCPEGFSLSSSGRRCQDLRMSYCYAKFEGGKCSSPKSRNHSKQECCCALKGEGWGDPCELCPTEPDEAFRQICPYGSGIIVGPDDSAVDMDECKEPDVCKHGQCINTDGSYRCECPFGYILAGNECVDTDECSVGNPCGNGTCKNVIGGFECTCEEGFEPGPMMTCEDINECAQNPLLCAFRCVNTYGSYECKCPVGYVLREDRRMCKDEDECEEGKHDCTEKQMECKNLIGTYMCICGPGYQRRPDGEGCVDENECQTKPGICENGRCLNTRGSYTCECNDGFTASPNQDECLDNREGYCFTEVLQNMCQIGSSNRNPVTKSECCCDGGRGWGPHCEICPFQGTVAFKKLCPHGRGFMTNGADIDECKVIHDVCRNGECVNDRGSYHCICKTGYTPDITGTSCVDLNECNQAPKPCNFICKNTEGSYQCSCPKGYILQEDGRSCKDLDECATKQHNCQFLCVNTIGGFTCKCPPGFTQHHTSCIDNNECTSDINLCGSKGICQNTPGSFTCECQRGFSLDQTGSSCEDVDECEGNHRCQHGCQNIIGGYRCSCPQGYLQHYQWNQCVDENECLSAHICGGASCHNTLGSYKCMCPAGFQYEQFSGGCQDINECGSAQAPCSYGCSNTEGGYLCGCPPGYFRIGQGHCVSGMGMGRGNPEPPVSGEMDDNSLSPEACYECKINGYPKRGRKRRSTNETDASNIEDQSETEANVSLASWDVEKTAIFAFNISHVSNKVRILELLPALTTLTNHNRYLIESGNEDGFFKINQKEGISYLHFTKKKPVAGTYSLQISSTPLYKKKELNQLEDKYDKDYLSGELGDNLKMKIQVLLH	2871	P35555	Y	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [1839], 'STRAND_gain': [1948], 'STRAND_gain_score': array([0.00922561]), 'STRAND_loss_score': array([-0.02921522]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [473, 476, 482, 641, 753, 774, 1837, 1840, 1857, 1858, 1859, 1860, 1867, 1869, 1870], 'DOMAIN_gain': [1150], 'DOMAIN_gain_score': array([0.00389081]), 'DOMAIN_loss_score': array([-0.03774244, -0.04108578, -0.0322727 , -0.039536  , -0.00591391,
       -0.00853586, -0.05003601, -0.1091935 , -0.34838694, -0.41109967,
       -0.32482052, -0.4043116 , -0.25399256, -0.21996236, -0.19865578]), 'REGION_loss': [374, 433, 436, 1670], 'REGION_gain': [922, 932, 942, 969, 1233, 1279, 2521, 2527], 'REGION_gain_score': array([0.00184304, 0.00186104, 0.00202847, 0.00219804, 0.00192624,
       0.00084484, 0.0006054 , 0.00053275]), 'REGION_loss_score': array([-0.0044207 , -0.00674081, -0.00897139, -0.003905  ]), 'REPEAT_loss': [1841, 1844, 1845, 1846, 1850, 1851, 1852, 1853, 1854, 1855, 1856], 'REPEAT_gain': [134, 136, 168, 169, 247, 248, 2547], 'REPEAT_gain_score': array([0.00615913, 0.0070883 , 0.00590849, 0.00561595, 0.00676978,
       0.00656337, 0.00440097]), 'REPEAT_loss_score': array([-0.07884616, -0.0884465 , -0.09590411, -0.18451315, -0.23718178,
       -0.26055199, -0.17133808, -0.17969149, -0.20013279, -0.23748422,
       -0.20263159]), 'ZN_FING_loss': [1862, 1906], 'ZN_FING_gain': [], 'ZN_FING_loss_score': array([-0.30006331, -0.02848494])}"
707	NM_000138.5(FBN1):c.5743C>T (p.Arg1915Cys)	495629	CA392341191	NM_000138.5:c.5743C>T, NC_000015.10:g.48446751G>A, CM000677.2:g.48446751G>A, NC_000015.9:g.48738948G>A, CM000677.1:g.48738948G>A, NC_000015.8:g.46526240G>A, NG_008805.2:g.204038C>T, LRG_778:g.204038C>T, ENST00000559133.6:c.5743C>T, ENST00000674301.2:c.5743C>T, ENST00000684448.1:n.4417C>T, ENST00000316623.10:c.5743C>T, ENST00000674301.1:c.742C>T, ENST00000316623.9:c.5743C>T, ENST00000537463.6:c.*1506C>T, ENST00000559133.5:c.1050C>T, NM_000138.4:c.5743C>T, LRG_778t1:c.5743C>T, NM_000138.5(FBN1):c.5743C>T (p.Arg1915Cys)	FBN1	Marfan syndrome	MONDO:0007947	Autosomal dominant inheritance	Pathogenic	PS4, PM1, PP1, PP2, PP4, PM2_Supporting	PS2, PS1, PS3, PM5, BP5, BS1, BS4, BS3, PP3, PM6, PVS1, BP2, BP1, BP4, BA1	The NM_00138 c.5743C>T is a missense variant in FBN1 predicted to cause a substitution of an arginine by cysteine at amino acid 1915 (p.Arg1915Cys) within a calcium binding EGF-like domain of the protein (PM1). This variant was found in a proband with classical Marfan syndrome (MFS) (Internal lab data, PP4). This variant has been reported 6 times in ClinVar: once as pathogenic, 4 times as likely pathogenic, and once as uncertain significance (Variation ID: 495629). This variant has also been identified in at least 7 individuals with clinical diagnosis of MFS as well as in individuals with clinical features of MFS (PMID 27234404, 35916808, 33174221, 27906200, internal data; PS4). In two families with MFS, the variant was found to segregate with disease in three affected relatives (Internal lab data, PP1). Different missense variants at this position, c.5744G>A p.(Arg1915His) and c.5743C>A p.(Arg1915Ser), have previously been reported in individuals with MFS and/or MFS-related features (PMID 11700157, 31830381), however these variants have not yet been reviewed by the FBN1 Variant Curation Expert Panel. This variant is not present in gnomAD (PM2_sup; https://gnomad.broadinstitute.org/v2.1.1). Computational prediction tools and conservation analysis are inconclusive with regards to a possible impact on this variant's protein function and structure (REVEL: 0.62). The constraint z-score for missense variants affecting FBN1 is 5.06 (PP2). In summary, this variant meets criteria to be classified as pathogenic for Marfan syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen FBN1 VCEP: PS4, PM1, PP1, PM2_Sup, PP2, PP4.		FBN1 VCEP	https://clinicalgenome.org/docs/clingen-fbn1-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2024-02-22	2024-02-22	False	https://erepo.genome.network/evrepo/ui/classification/CA392341191/MONDO:0007947/022	2a7d7c4d-0a6e-4c19-b14a-9928b8c3e8ed	p.Arg1915Cys	Arg	1915	Cys	MRRGRLLEIALGFTVLLASYTSHGADANLEAGNVKETRASRAKRRGGGGHDALKGPNVCGSRYNAYCCPGWKTLPGGNQCIVPICRHSCGDGFCSRPNMCTCPSGQIAPSCGSRSIQHCNIRCMNGGSCSDDHCLCQKGYIGTHCGQPVCESGCLNGGRCVAPNRCACTYGFTGPQCERDYRTGPCFTVISNQMCQGQLSGIVCTKTLCCATVGRAWGHPCEMCPAQPHPCRRGFIPNIRTGACQDVDECQAIPGLCQGGNCINTVGSFECKCPAGHKLNEVSQKCEDIDECSTIPGICEGGECTNTVSSYFCKCPPGFYTSPDGTRCIDVRPGYCYTALTNGRCSNQLPQSITKMQCCCDAGRCWSPGVTVAPEMCPIRATEDFNKLCSVPMVIPGRPEYPPPPLGPIPPVLPVPPGFPPGPQIPVPRPPVEYLYPSREPPRVLPVNVTDYCQLVRYLCQNGRCIPTPGSYRCECNKGFQLDLRGECIDVDECEKNPCAGGECINNQGSYTCQCRAGYQSTLTRTECRDIDECLQNGRICNNGRCINTDGSFHCVCNAGFHVTRDGKNCEDMDECSIRNMCLNGMCINEDGSFKCICKPGFQLASDGRYCKDINECETPGICMNGRCVNTDGSYRCECFPGLAVGLDGRVCVDTHMRSTCYGGYKRGQCIKPLFGAVTKSECCCASTEYAFGEPCQPCPAQNSAEYQALCSSGPGMTSAGSDINECALDPDICPNGICENLRGTYKCICNSGYEVDSTGKNCVDINECVLNSLLCDNGQCRNTPGSFVCTCPKGFIYKPDLKTCEDIDECESSPCINGVCKNSPGSFICECSSESTLDPTKTICIETIKGTCWQTVIDGRCEININGATLKSQCCSSLGAAWGSPCTLCQVDPICGKGYSRIKGTQCEDIDECEVFPGVCKNGLCVNTRGSFKCQCPSGMTLDATGRICLDIRLETCFLRYEDEECTLPIAGRHRMDACCCSVGAAWGTEECEECPMRNTPEYEELCPRGPGFATKEITNGKPFFKDINECKMIPSLCTHGKCRNTIGSFKCRCDSGFALDSEERNCTDIDECRISPDLCGRGQCVNTPGDFECKCDEGYESGFMMMKNCMDIDECQRDPLLCRGGVCHNTEGSYRCECPPGHQLSPNISACIDINECELSAHLCPNGRCVNLIGKYQCACNPGYHSTPDRLFCVDIDECSIMNGGCETFCTNSEGSYECSCQPGFALMPDQRSCTDIDECEDNPNICDGGQCTNIPGEYRCLCYDGFMASEDMKTCVDVNECDLNPNICLSGTCENTKGSFICHCDMGYSGKKGKTGCTDINECEIGAHNCGKHAVCTNTAGSFKCSCSPGWIGDGIKCTDLDECSNGTHMCSQHADCKNTMGSYRCLCKEGYTGDGFTCTDLDECSENLNLCGNGQCLNAPGGYRCECDMGFVPSADGKACEDIDECSLPNICVFGTCHNLPGLFRCECEIGYELDRSGGNCTDVNECLDPTTCISGNCVNTPGSYICDCPPDFELNPTRVGCVDTRSGNCYLDIRPRGDNGDTACSNEIGVGVSKASCCCSLGKAWGTPCEMCPAVNTSEYKILCPGGEGFRPNPITVILEDIDECQELPGLCQGGKCINTFGSFQCRCPTGYYLNEDTRVCDDVNECETPGICGPGTCYNTVGNYTCICPPDYMQVNGGNNCMDMRRSLCYRNYYADNQTCDGELLFNMTKKMCCCSYNIGRAWNKPCEQCPIPSTDEFATLCGSQRPGFVIDIYTGLPVDIDECREIPGVCENGVCINMVGSFRCECPVGFFYNDKLLVCEDIDECQNGPVCQRNAECINTAGSYRCDCKPGYRFTSTGQCNDRNECQEIPNICSHGQCIDTVGSFYCLCHTGFKTNDDQTMCLDINECERDACGNGTCRNTIGSFNCRCNHGFILSHNNDCIDVDECASGNGNLCRNGQCINTVGSFQCQCNEGYEVAPDGRTCVDINECLLEPRKCAPGTCQNLDGSYRCICPPGYSLQNEKCEDIDECVEEPEICALGTCSNTEGSFKCLCPEGFSLSSSGRRCQDLRMSYCYAKFEGGKCSSPKSRNHSKQECCCALKGEGWGDPCELCPTEPDEAFRQICPYGSGIIVGPDDSAVDMDECKEPDVCKHGQCINTDGSYRCECPFGYILAGNECVDTDECSVGNPCGNGTCKNVIGGFECTCEEGFEPGPMMTCEDINECAQNPLLCAFRCVNTYGSYECKCPVGYVLREDRRMCKDEDECEEGKHDCTEKQMECKNLIGTYMCICGPGYQRRPDGEGCVDENECQTKPGICENGRCLNTRGSYTCECNDGFTASPNQDECLDNREGYCFTEVLQNMCQIGSSNRNPVTKSECCCDGGRGWGPHCEICPFQGTVAFKKLCPHGRGFMTNGADIDECKVIHDVCRNGECVNDRGSYHCICKTGYTPDITGTSCVDLNECNQAPKPCNFICKNTEGSYQCSCPKGYILQEDGRSCKDLDECATKQHNCQFLCVNTIGGFTCKCPPGFTQHHTSCIDNNECTSDINLCGSKGICQNTPGSFTCECQRGFSLDQTGSSCEDVDECEGNHRCQHGCQNIIGGYRCSCPQGYLQHYQWNQCVDENECLSAHICGGASCHNTLGSYKCMCPAGFQYEQFSGGCQDINECGSAQAPCSYGCSNTEGGYLCGCPPGYFRIGQGHCVSGMGMGRGNPEPPVSGEMDDNSLSPEACYECKINGYPKRGRKRRSTNETDASNIEDQSETEANVSLASWDVEKTAIFAFNISHVSNKVRILELLPALTTLTNHNRYLIESGNEDGFFKINQKEGISYLHFTKKKPVAGTYSLQISSTPLYKKKELNQLEDKYDKDYLSGELGDNLKMKIQVLLH	2871	P35555	C	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [611, 641, 746, 753, 1857, 1858, 1869, 1870, 1897, 1898, 1911, 1912, 1918, 1919, 1940, 1942, 1950, 1952], 'DOMAIN_gain': [2458], 'DOMAIN_gain_score': array([0.01010841]), 'DOMAIN_loss_score': array([-0.00391316, -0.01792783, -0.00573248, -0.01824862, -0.06670642,
       -0.07675481, -0.08265156, -0.09613395, -0.21313959, -0.22377467,
       -0.23130465, -0.23792154, -0.22932988, -0.31308168, -0.14708185,
       -0.1670894 , -0.12203562, -0.11387646]), 'REGION_loss': [], 'REGION_gain': [432, 435, 922, 932, 942, 2072, 2084, 2176, 2521, 2525, 2527, 2528], 'REGION_gain_score': array([0.0081318 , 0.0088343 , 0.00166744, 0.00158346, 0.00162053,
       0.00379747, 0.00274432, 0.00247276, 0.00113279, 0.00113517,
       0.00107849, 0.00110942]), 'REPEAT_loss': [1517], 'REPEAT_gain': [2547], 'REPEAT_gain_score': array([0.00194442]), 'REPEAT_loss_score': array([-0.00175273]), 'ZN_FING_loss': [1862, 1906], 'ZN_FING_gain': [], 'ZN_FING_loss_score': array([-0.02241939, -0.05069911])}"
708	NM_000138.5(FBN1):c.5966G>T (p.Cys1989Phe)	638559	CA392339801	NM_000138.5:c.5966G>T, NC_000015.10:g.48444612C>A, CM000677.2:g.48444612C>A, NC_000015.9:g.48736809C>A, CM000677.1:g.48736809C>A, NC_000015.8:g.46524101C>A, NG_008805.2:g.206177G>T, LRG_778:g.206177G>T, ENST00000559133.6:c.5966G>T, ENST00000674301.2:c.5966G>T, ENST00000684448.1:n.4640G>T, ENST00000316623.10:c.5966G>T, ENST00000674301.1:c.965G>T, ENST00000316623.9:c.5966G>T, ENST00000537463.6:c.*1729G>T, ENST00000559133.5:c.1273G>T, ENST00000560820.1:n.86G>T, NM_000138.4:c.5966G>T, LRG_778t1:c.5966G>T, NM_000138.5(FBN1):c.5966G>T (p.Cys1989Phe)	FBN1	Marfan syndrome	MONDO:0007947	Autosomal dominant inheritance	Pathogenic	PS4_Moderate, PM1_Strong, PP4, PP2, PP3, PM2_Supporting, PM6	PM5	The NM_00138 c.5966G>T, is a missense variant in FBN1 predicted to cause a substitution of a cysteine by phenylalanine at amino acid 1989 (p.Cys1989Phe). This variant was found in a proband diagnosed with typical Marfan syndrome (internal lab data, PP4); in this family, the variant was found to be de novo in the proband’s symptomatic mother (internal lab data, PM6). This variant has been reported three times in ClinVar: once as pathogenic, once as likely pathogenic, and once as uncertain significance (Variation ID: 638559). At least three other probands with Marfan syndrome and/or clinical features of Marfan syndrome carry the same variant (PMID 29848614, Petrovsky National Research Centre of Surgery ClinVar entry, Cologne University ClinVar entry, PS4_Mod). This variant is not present in gnomAD (PM2_sup; https://gnomad.broadinstitute.org/v2.1.1). This variant affects a cysteine residue in a calcium binding EGF-like domain. Cysteine residues in these domains are believed to be involved in the formation of disulfide bridges which are essential for the protein structure (PM1_strong). Computational prediction tools and conservation analysis suggest that this variant may impact the protein (REVEL: 0.947, PP3). The constraint z-score for missense variants affecting FBN1 is 5.06 (PP2). In summary, this variant meets criteria to be classified as pathogenic for Marfan syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen FBN1 VCEP: PM1_Strong, PS4_Mod, PM2_Sup, PP2, PP3, PP4.		FBN1 VCEP	https://clinicalgenome.org/docs/clingen-fbn1-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/	2024-02-22	2024-02-22	False	https://erepo.genome.network/evrepo/ui/classification/CA392339801/MONDO:0007947/022	04d959ce-14d0-4ae4-b998-caa24dcb60f5	p.Cys1989Phe	Cys	1989	Phe	MRRGRLLEIALGFTVLLASYTSHGADANLEAGNVKETRASRAKRRGGGGHDALKGPNVCGSRYNAYCCPGWKTLPGGNQCIVPICRHSCGDGFCSRPNMCTCPSGQIAPSCGSRSIQHCNIRCMNGGSCSDDHCLCQKGYIGTHCGQPVCESGCLNGGRCVAPNRCACTYGFTGPQCERDYRTGPCFTVISNQMCQGQLSGIVCTKTLCCATVGRAWGHPCEMCPAQPHPCRRGFIPNIRTGACQDVDECQAIPGLCQGGNCINTVGSFECKCPAGHKLNEVSQKCEDIDECSTIPGICEGGECTNTVSSYFCKCPPGFYTSPDGTRCIDVRPGYCYTALTNGRCSNQLPQSITKMQCCCDAGRCWSPGVTVAPEMCPIRATEDFNKLCSVPMVIPGRPEYPPPPLGPIPPVLPVPPGFPPGPQIPVPRPPVEYLYPSREPPRVLPVNVTDYCQLVRYLCQNGRCIPTPGSYRCECNKGFQLDLRGECIDVDECEKNPCAGGECINNQGSYTCQCRAGYQSTLTRTECRDIDECLQNGRICNNGRCINTDGSFHCVCNAGFHVTRDGKNCEDMDECSIRNMCLNGMCINEDGSFKCICKPGFQLASDGRYCKDINECETPGICMNGRCVNTDGSYRCECFPGLAVGLDGRVCVDTHMRSTCYGGYKRGQCIKPLFGAVTKSECCCASTEYAFGEPCQPCPAQNSAEYQALCSSGPGMTSAGSDINECALDPDICPNGICENLRGTYKCICNSGYEVDSTGKNCVDINECVLNSLLCDNGQCRNTPGSFVCTCPKGFIYKPDLKTCEDIDECESSPCINGVCKNSPGSFICECSSESTLDPTKTICIETIKGTCWQTVIDGRCEININGATLKSQCCSSLGAAWGSPCTLCQVDPICGKGYSRIKGTQCEDIDECEVFPGVCKNGLCVNTRGSFKCQCPSGMTLDATGRICLDIRLETCFLRYEDEECTLPIAGRHRMDACCCSVGAAWGTEECEECPMRNTPEYEELCPRGPGFATKEITNGKPFFKDINECKMIPSLCTHGKCRNTIGSFKCRCDSGFALDSEERNCTDIDECRISPDLCGRGQCVNTPGDFECKCDEGYESGFMMMKNCMDIDECQRDPLLCRGGVCHNTEGSYRCECPPGHQLSPNISACIDINECELSAHLCPNGRCVNLIGKYQCACNPGYHSTPDRLFCVDIDECSIMNGGCETFCTNSEGSYECSCQPGFALMPDQRSCTDIDECEDNPNICDGGQCTNIPGEYRCLCYDGFMASEDMKTCVDVNECDLNPNICLSGTCENTKGSFICHCDMGYSGKKGKTGCTDINECEIGAHNCGKHAVCTNTAGSFKCSCSPGWIGDGIKCTDLDECSNGTHMCSQHADCKNTMGSYRCLCKEGYTGDGFTCTDLDECSENLNLCGNGQCLNAPGGYRCECDMGFVPSADGKACEDIDECSLPNICVFGTCHNLPGLFRCECEIGYELDRSGGNCTDVNECLDPTTCISGNCVNTPGSYICDCPPDFELNPTRVGCVDTRSGNCYLDIRPRGDNGDTACSNEIGVGVSKASCCCSLGKAWGTPCEMCPAVNTSEYKILCPGGEGFRPNPITVILEDIDECQELPGLCQGGKCINTFGSFQCRCPTGYYLNEDTRVCDDVNECETPGICGPGTCYNTVGNYTCICPPDYMQVNGGNNCMDMRRSLCYRNYYADNQTCDGELLFNMTKKMCCCSYNIGRAWNKPCEQCPIPSTDEFATLCGSQRPGFVIDIYTGLPVDIDECREIPGVCENGVCINMVGSFRCECPVGFFYNDKLLVCEDIDECQNGPVCQRNAECINTAGSYRCDCKPGYRFTSTGQCNDRNECQEIPNICSHGQCIDTVGSFYCLCHTGFKTNDDQTMCLDINECERDACGNGTCRNTIGSFNCRCNHGFILSHNNDCIDVDECASGNGNLCRNGQCINTVGSFQCQCNEGYEVAPDGRTCVDINECLLEPRKCAPGTCQNLDGSYRCICPPGYSLQNEKCEDIDECVEEPEICALGTCSNTEGSFKCLCPEGFSLSSSGRRCQDLRMSYCYAKFEGGKCSSPKSRNHSKQECCCALKGEGWGDPCELCPTEPDEAFRQICPYGSGIIVGPDDSAVDMDECKEPDVCKHGQCINTDGSYRCECPFGYILAGNECVDTDECSVGNPCGNGTCKNVIGGFECTCEEGFEPGPMMTCEDINECAQNPLLCAFRCVNTYGSYECKCPVGYVLREDRRMCKDEDECEEGKHDCTEKQMECKNLIGTYMCICGPGYQRRPDGEGCVDENECQTKPGICENGRCLNTRGSYTCECNDGFTASPNQDECLDNREGYCFTEVLQNMCQIGSSNRNPVTKSECCCDGGRGWGPHCEICPFQGTVAFKKLCPHGRGFMTNGADIDECKVIHDVCRNGECVNDRGSYHCICKTGYTPDITGTSCVDLNECNQAPKPCNFICKNTEGSYQCSCPKGYILQEDGRSCKDLDECATKQHNCQFLCVNTIGGFTCKCPPGFTQHHTSCIDNNECTSDINLCGSKGICQNTPGSFTCECQRGFSLDQTGSSCEDVDECEGNHRCQHGCQNIIGGYRCSCPQGYLQHYQWNQCVDENECLSAHICGGASCHNTLGSYKCMCPAGFQYEQFSGGCQDINECGSAQAPCSYGCSNTEGGYLCGCPPGYFRIGQGHCVSGMGMGRGNPEPPVSGEMDDNSLSPEACYECKINGYPKRGRKRRSTNETDASNIEDQSETEANVSLASWDVEKTAIFAFNISHVSNKVRILELLPALTTLTNHNRYLIESGNEDGFFKINQKEGISYLHFTKKKPVAGTYSLQISSTPLYKKKELNQLEDKYDKDYLSGELGDNLKMKIQVLLH	2871	P35555	F	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [482, 611, 1035, 1062, 1253, 1837, 1840, 1857, 1869, 1870, 1912], 'DOMAIN_gain': [748, 752, 768, 769, 770, 771, 772, 773, 781, 783, 784, 785, 786, 787, 788, 789, 1938, 1953], 'DOMAIN_gain_score': array([0.08564132, 0.15137047, 0.31221265, 0.40589076, 0.39445126,
       0.38276196, 0.39923173, 0.40544021, 0.340891  , 0.33564317,
       0.40669513, 0.38682306, 0.34987164, 0.39577305, 0.34299624,
       0.32903802, 0.03009868, 0.04047567]), 'DOMAIN_loss_score': array([-0.01892763, -0.01348311, -0.00956047, -0.00689554, -0.00520021,
       -0.02855229, -0.02437615, -0.03647369, -0.05079985, -0.05227911,
       -0.04594177]), 'REGION_loss': [933, 976, 2074, 2112, 2120, 2146, 2184, 2195, 2216, 2536], 'REGION_gain': [1233, 1279], 'REGION_gain_score': array([0.00130355, 0.00087589]), 'REGION_loss_score': array([-0.00098556, -0.00044018, -0.00402528, -0.00349045, -0.0041427 ,
       -0.00402701, -0.00227177, -0.00200021, -0.00121367, -0.00065428]), 'REPEAT_loss': [2137, 2558], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.03925669, -0.00060678]), 'ZN_FING_loss': [778, 1862, 1906], 'ZN_FING_gain': [], 'ZN_FING_loss_score': array([-0.02480704, -0.01336932, -0.0097605 ])}"
709	NM_000162.5(GCK):c.601G>T (p.Ala201Ser)	198050	CA246541	NM_000162.5:c.601G>T, NC_000007.14:g.44149838C>A, CM000669.2:g.44149838C>A, NC_000007.13:g.44189437C>A, CM000669.1:g.44189437C>A, NC_000007.12:g.44155962C>A, NG_008847.1:g.44586G>T, NG_008847.2:g.53333G>T, ENST00000395796.8:c.*599G>T, ENST00000616242.5:c.601G>T, ENST00000682635.1:n.1087G>T, ENST00000345378.7:c.604G>T, ENST00000403799.8:c.601G>T, ENST00000671824.1:c.601G>T, ENST00000673284.1:c.601G>T, ENST00000345378.6:c.604G>T, ENST00000395796.7:c.598G>T, ENST00000403799.7:c.601G>T, ENST00000437084.1:c.550G>T, ENST00000616242.4:c.598G>T, NM_000162.3:c.601G>T, NM_033507.1:c.604G>T, NM_033508.1:c.598G>T, NM_000162.4:c.601G>T, NM_001354800.1:c.601G>T, NM_033507.2:c.604G>T, NM_033508.2:c.598G>T, NM_033507.3:c.604G>T, NM_033508.3:c.598G>T, NM_000162.5(GCK):c.601G>T (p.Ala201Ser)	GCK	monogenic diabetes	MONDO:0015967	Semidominant inheritance	Pathogenic	PS4_Moderate, PP1_Strong, PP4_Moderate, PP2, PM2_Supporting		The c.601G>T variant in the glucokinase gene, GCK, causes an amino acid change of alanine to serine at codon 201 (p.(Ala201Ser)) of NM_000162.5. GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2). This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.929, which is greater than the MDEP VCEP threshold of 0.70 (PP3). This variant is absent from gnomAD v2.1.1 (PM2_Supporting). This variant was identified in four unrelated individuals with hyperglycemia (PS4_Moderate; internal lab contributors). This variant was identified in an individual with a clinical history highly specific for GCK-hyperglycemia (FBG 5.5-8 mmol/L and HbA1c 5.6 - 7.6% and antibody negative) (PP4_Moderate; internal lab contributors). This variant segregated with diabetes/hyperglycemia, with seven informative meioses in one family (PP1_Strong; internal lab contributors). In summary, c.605T>G meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.3.0, approved 8/11/2023): PM2_Supporting, PP2, PP3, PS4_Moderate, PP1_Strong, PP4_Moderate.		Monogenic Diabetes VCEP		2024-02-23	2024-02-23	False	https://erepo.genome.network/evrepo/ui/classification/CA246541/MONDO:0015967/086	e88a1f47-bc1b-4f78-bda7-6d240f568d62	p.Ala201Ser	Ala	201	Ser	MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQ	465	P35557	S	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [83, 221], 'DOMAIN_gain_score': array([0.00705683, 0.03376192]), 'REGION_loss': [], 'REGION_gain': [11, 21, 71, 75, 80], 'REGION_gain_score': array([0.00473619, 0.00441474, 0.02089441, 0.0221473 , 0.01933789]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
710	NM_000536.4(RAG2):c.115A>G (p.Arg39Gly)	13136	CA122867	NM_000536.4:c.115A>G, NC_000011.10:g.36594054T>C, CM000673.2:g.36594054T>C, NC_000011.9:g.36615604T>C, CM000673.1:g.36615604T>C, NC_000011.8:g.36572180T>C, NG_007573.1:g.9183A>G, LRG_99:g.9183A>G, NG_033154.1:g.4562T>C, ENST00000527033.6:c.115A>G, ENST00000529083.2:c.115A>G, ENST00000532616.2:c.115A>G, ENST00000311485.8:c.115A>G, ENST00000311485.7:c.115A>G, ENST00000524423.1:n.131+4048A>G, ENST00000527033.5:c.115A>G, ENST00000529083.1:c.115A>G, ENST00000618712.4:c.115A>G, NM_000536.3:c.115A>G, NM_001243785.1:c.115A>G, NM_001243786.1:c.115A>G, NM_001243785.2:c.115A>G, NM_001243786.2:c.115A>G, NM_000536.4(RAG2):c.115A>G (p.Arg39Gly)	RAG2	recombinase activating gene 2 deficiency	MONDO:0000573	Autosomal recessive inheritance	Pathogenic	PM3_Strong, PM1_Supporting, PP1_Moderate, PP4, PS3_Moderate, PM2_Supporting		NM_000536.4(RAG2):c.115A>G  is a missense variant predicted to cause substitution of Arginine by Glycine at amino acid 39 (p.Arg39Gly).This missense variant is located in the core domain (amino acids 1-383) (PM1_supporting).The variant is absent in gnomAD v4 (PM2_supporting). Patient with SCID (0.5 pt.), genome sequencing conducted (0.5 pt.),T-B-NK+ lymphocyte subset profile (0.5 pt.) :Total :1.5 pts. PP4 met (PMID: 11313270). This variant was found to segregate in 2 affected siblings from one family (PP1_moderate) (PMID: 11313270).Two patients (PMID: 11313270) were found compound heterozygous for  R39G and R229Q (pathogenic variant) ;total : 2pts. (PM3_strong).This variant showed <25 % of wild type activity in In vitro V(D)J recombination assay (PS3_moderate) (PMID: 11313270).In summary, this variant meets the criteria to be classified as a Pathogenic variant for autosomal recessive severe combined immunodeficiency due to RAG2 deficiency based on the ACMG/AMP criteria applied, as specified by the ClinGen SCID VCEP:  PM1_supporting,PM2_supporting,PP4 met,PP1_moderate,PM3_strong,PS3_moderate(VCEP specifications version 1).	11313270	Severe Combined Immunodeficiency Disease  VCEP		2024-02-26	2024-02-26	False	https://erepo.genome.network/evrepo/ui/classification/CA122867/MONDO:0000573/124	418ca304-b22e-4a9e-a014-7abfa82d833c	p.Arg39Gly	Arg	39	Gly	MSLQMVTVSNNIALIQPGFSLMNFDGQVFFFGQKGWPKRSCPTGVFHLDVKHNHVKLKPTIFSKDSCYLPPLRYPATCTFKGSLESEKHQYIIHGGKTPNNEVSDKIYVMSIVCKNNKKVTFRCTEKDLVGDVPEARYGHSINVVYSRGKSMGVLFGGRSYMPSTHRTTEKWNSVADCLPCVFLVDFEFGCATSYILPELQDGLSFHVSIAKNDTIYILGGHSLANNIRPANLYRIRVDLPLGSPAVNCTVLPGGISVSSAILTQTNNDEFVIVGGYQLENQKRMICNIISLEDNKIEIREMETPDWTPDIKHSKIWFGSNMGNGTVFLGIPGDNKQVVSEGFYFYMLKCAEDDTNEEQTTFTNSQTSTEDPGDSTPFEDSEEFCFSAEANSFDGDDEFDTYNEDDEEDESETGYWITCCPTCDVDINTWVPFYSTELNKPAMIYCSHGDGHWVHAQCMDLAERTLIHLSAGSNKYYCNEHVEIARALHTPQRVLPLKKPPMKSLRKKGSGKILTPAKKSFLRRLFD	527	P55895	G	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [16, 19, 20, 21], 'TOPO_DOM_gain_score': array([0.08608049, 0.07905149, 0.0993219 , 0.10400772]), 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [10, 11], 'TRANSIT_gain': [], 'TRANSIT_loss_score': array([-0.02962726, -0.02855355]), 'STRAND_loss': [43], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.0281831]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [53, 54, 55, 57, 58, 60, 62, 63, 65, 140], 'REPEAT_gain_score': array([0.07564139, 0.08654982, 0.1096642 , 0.0965609 , 0.06351674,
       0.08276391, 0.05392909, 0.04872817, 0.0479427 , 0.01304328]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
711	NM_000162.5(GCK):c.1160C>T (p.Ala387Val)	36182	CA213727	NM_000162.5:c.1160C>T, NC_000007.14:g.44145590G>A, CM000669.2:g.44145590G>A, NC_000007.13:g.44185189G>A, CM000669.1:g.44185189G>A, NC_000007.12:g.44151714G>A, NG_008847.1:g.48834C>T, NG_008847.2:g.57581C>T, ENST00000395796.8:c.*1158C>T, ENST00000616242.5:c.*280C>T, ENST00000683378.1:n.386C>T, ENST00000336642.9:c.194C>T, ENST00000345378.7:c.1163C>T, ENST00000403799.8:c.1160C>T, ENST00000671824.1:c.1223C>T, ENST00000672743.1:n.172C>T, ENST00000673284.1:c.1160C>T, ENST00000336642.8:c.212C>T, ENST00000345378.6:c.1163C>T, ENST00000395796.7:c.1157C>T, ENST00000403799.7:c.1160C>T, ENST00000437084.1:c.1109C>T, ENST00000459642.1:n.540C>T, ENST00000616242.4:c.1157C>T, NM_000162.3:c.1160C>T, NM_033507.1:c.1163C>T, NM_033508.1:c.1157C>T, NM_000162.4:c.1160C>T, NM_001354800.1:c.1160C>T, NM_001354801.1:c.149C>T, NM_001354802.1:c.20C>T, NM_001354803.1:c.194C>T, NM_033507.2:c.1163C>T, NM_033508.2:c.1157C>T, XM_024446707.1:c.20C>T, NM_033507.3:c.1163C>T, NM_033508.3:c.1157C>T, NM_001354803.2:c.194C>T, NM_000162.5(GCK):c.1160C>T (p.Ala387Val)	GCK	monogenic diabetes	MONDO:0015967	Semidominant inheritance	Pathogenic	PS4_Moderate, PP1_Strong, PP4_Moderate, PP2, PP3, PM5, PM2_Supporting	PM1	The c.1160C>T variant in the glucokinase gene, GCK, causes an amino acid change of alanine to valine at codon 387 (p. (Ala387Val)) of NM_000162.5.  This variant has an incomputable gnomAD v2.1.1  Popmax filtering allele frequency due to no copies in the European non-Finnish subpopulation and one copy in any other subpopulation, thereby meeting the ClinGen MDEP threshold criteria for PM2_Supporting (ENF Popmax FAF <= 0.000003 and <= 2 copies in ENF and <=1 copy in any other subpopulation) (PM2_Supporting).   GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2).  This variant is located in the larger hexokinase domain of the GCK gene (PMID: 31638168) but this variant does not reside in an amino acid that directly binds glucose or ATP, which is defined as critical for the protein’s function by the ClinGen MDEP, so it does not meet PM1.  This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.871 which is greater than the MDEP VCEP threshold of 0.70 (PP3). Another missense variant, c.1159G>A p.(Ala387Thr) has been interpreted as pathogenic by the ClinGen MDEP, and p.Ala387Glu has a greater Grantham distance (PM5). This variant was identified in four unrelated individuals with hyperglycemia (PS4_Moderate; PMID: 34421822, Internal lab contributors).  One of these individuals had a clinical history highly specific for GCK-hyperglycemia (FBG 5.5-8 mmol/L and HbA1c 5.6 - 7.6% and negative antibodies) (PP4_Moderate; PMID: 34421822).  This variant segregated with hyperglycemia, with five informative meioses in three families (PP1_Strong; PMID: 34421822, Internal lab contributor).  In summary, c.1160C>T meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP VCEP (VCEP specifications version v1.3.0; approved 8/11/2023): PP2, PP3, PM2_Supporting, PP1_Strong, PM5, PS4_Moderate, PP4_Moderate.		Monogenic Diabetes VCEP		2024-02-28	2024-02-28	False	https://erepo.genome.network/evrepo/ui/classification/CA213727/MONDO:0015967/086	73712264-65e3-4f09-bf55-c8058854d12f	p.Ala387Val	Ala	387	Val	MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQ	465	P35557	V	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [11, 21], 'REGION_gain_score': array([0.00371677, 0.00218475]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
712	NM_000162.5(GCK):c.1148C>T (p.Ser383Leu)	236014	CA10581499	NM_000162.5:c.1148C>T, NC_000007.14:g.44145602G>A, CM000669.2:g.44145602G>A, NC_000007.13:g.44185201G>A, CM000669.1:g.44185201G>A, NC_000007.12:g.44151726G>A, NG_008847.1:g.48822C>T, NG_008847.2:g.57569C>T, ENST00000395796.8:c.*1146C>T, ENST00000616242.5:c.*268C>T, ENST00000683378.1:n.374C>T, ENST00000336642.9:c.182C>T, ENST00000345378.7:c.1151C>T, ENST00000403799.8:c.1148C>T, ENST00000671824.1:c.1211C>T, ENST00000672743.1:n.160C>T, ENST00000673284.1:c.1148C>T, ENST00000336642.8:c.200C>T, ENST00000345378.6:c.1151C>T, ENST00000395796.7:c.1145C>T, ENST00000403799.7:c.1148C>T, ENST00000437084.1:c.1097C>T, ENST00000459642.1:n.528C>T, ENST00000616242.4:c.1145C>T, NM_000162.3:c.1148C>T, NM_033507.1:c.1151C>T, NM_033508.1:c.1145C>T, NM_000162.4:c.1148C>T, NM_001354800.1:c.1148C>T, NM_001354801.1:c.137C>T, NM_001354802.1:c.8C>T, NM_001354803.1:c.182C>T, NM_033507.2:c.1151C>T, NM_033508.2:c.1145C>T, XM_024446707.1:c.8C>T, NM_033507.3:c.1151C>T, NM_033508.3:c.1145C>T, NM_001354803.2:c.182C>T, NM_000162.5(GCK):c.1148C>T (p.Ser383Leu)	GCK	monogenic diabetes	MONDO:0015967	Semidominant inheritance	Pathogenic	PS4, PP1_Strong, PP4_Moderate, PP2, PP3, PM2_Supporting, PS3_Moderate	PM1	The c.1148C>T variant in the glucokinase gene, GCK, causes an amino acid change of serine to leucine at codon 383 (p. (Ser383Leu)) of NM_000162.5. This variant is absent from gnomAD v2.1.1 (PM2_Supporting). GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2)  This variant is located in the larger hexokinase domain of the GCK gene (PMID: 31638168) but this variant does not reside in an amino acid that directly binds glucose or ATP, which is defined as critical for the protein’s function by the ClinGen MDEP, so it does not meet PM1.  This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.831 which is greater than the MDEP VCEP threshold of 0.70 (PP3). MDEP wild type quality control measures were met, and the relative activity Index (RAI) of this variant was found to be 0.20, which is below the MDEP cutoff (<0.5) (Matschinsky FM, Magnuson MA (eds): Glucokinase and Glycemic Disease: From Basics to Novel Therapeutics. Front. Diabetes. Basel, Karger, 2004, vol 16, pp 92–109).  This variant has been identified in at least 53 unrelated individuals with hyperglycemia and segregated with the phenotype, with 30 informative meioses in 49 families  (PS4, PP1_Strong; PMID: 28555465, 30663027, 34462253, 34746319, internal lab contributors). At least of of these patients had a clinical history highly specific for GCK-hyperglycemia (FBG 5.5-8 mmol/L and HbA1c 5.6 - 7.6%, negative GAD-65 (PP4_Moderate; PMID: 28555465). In summary, c.1148C>T meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP VCEP (VCEP specifications version v1.3.0; approved 8/11/2023): PP3, PS4, PP4_Moderate, PP2, PP1_Strong, PM2_Supporting		Monogenic Diabetes VCEP		2024-02-28	2024-02-28	False	https://erepo.genome.network/evrepo/ui/classification/CA10581499/MONDO:0015967/086	585d0bc1-7940-4c9b-aa3c-faf9a98a90a8	p.Ser383Leu	Ser	383	Leu	MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQ	465	P35557	L	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [196], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.02515244]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [21, 71], 'REGION_gain_score': array([0.0027042 , 0.00459468]), 'REPEAT_loss': [], 'REPEAT_gain': [75], 'REPEAT_gain_score': array([0.00309718]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
713	NM_000162.5(GCK):c.683C>T (p.Thr228Met)	16134	CA260620	NM_000162.5:c.683C>T, NC_000007.14:g.44147830G>A, CM000669.2:g.44147830G>A, NC_000007.13:g.44187429G>A, CM000669.1:g.44187429G>A, NC_000007.12:g.44153954G>A, NG_008847.1:g.46594C>T, NG_008847.2:g.55341C>T, ENST00000395796.8:c.*681C>T, ENST00000616242.5:c.683C>T, ENST00000345378.7:c.686C>T, ENST00000403799.8:c.683C>T, ENST00000671824.1:c.683C>T, ENST00000673284.1:c.683C>T, ENST00000345378.6:c.686C>T, ENST00000395796.7:c.680C>T, ENST00000403799.7:c.683C>T, ENST00000437084.1:c.632C>T, ENST00000616242.4:c.680C>T, NM_000162.3:c.683C>T, NM_033507.1:c.686C>T, NM_033508.1:c.680C>T, XR_927223.1:n.82+82G>A, NM_000162.4:c.683C>T, NM_001354800.1:c.683C>T, NM_033507.2:c.686C>T, NM_033508.2:c.680C>T, XR_927223.2:n.82+82G>A, NM_033507.3:c.686C>T, NM_033508.3:c.680C>T, NM_000162.5(GCK):c.683C>T (p.Thr228Met)	GCK	monogenic diabetes	MONDO:0015967	Semidominant inheritance	Pathogenic	PS4, PS2, PM3_Supporting, PP1_Strong, PS3_Supporting, PP4_Moderate, PP2, PP3, PM1, PM2_Supporting		The c.683C>T variant in the glucokinase gene, GCK, causes an amino acid change of threonine to methionine at codon 228 (p.(Thr228Met)) of NM_000162.5. GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2). This variant resides in an amino acid that directly binds glucose and ATP, which is defined as critical for the protein’s function by the ClinGen MDEP (PM1). This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.966 which is greater than the MDEP VCEP threshold of 0.70 (PP3). In an assay in which the ATPkm was above the MDEP threshold for evaluation of relative activity index (RAI), the Kcat/S0.5 ratio of the Thr228Met variant was 0.0001, which is less than 0.5 of wild type (PS3_Supporting; PMID: 11372010).  This variant has an incomputable gnomAD v2.1.1  Grpmax filtering allele frequency due to 0 copies in the European non-Finnish subpopulation and 1 copy in the Latino/Admixed American subpopulation, thereby meeting the ClinGen MDEP threshold criteria for PM2_Supporting (ENF Popmax FAF <= 0.000003 and <= 2 copies in ENF and <=1 copy in any other subpopulation) (PM2_Supporting). This variant was identified in at least 26 unrelated individuals with hyperglycemia (PS4; PMIDs: 21720051, 2721189, 36836406, 36723869, 32741144, 34756319, 11372010, 1502186, 31639168, 24323243, internal lab contributors).  At least 2 of these individuals had a clinical history highly specific for GCK-hyperglycemia (FBG 5.5-8 mmol/L and HbA1c 5.6 - 7.6% and negative antibodies) (PP4_Moderate; PMID: 36723869).  This variant was identified as a de novo occurrence with confirmed parental relationships in an individual with a clinical picture highly specific for GCK-hyperglycemia (FBG 5.5-8 mmol/L and HbA1c 5.6-7.6 and negative antibodies) (PS2; PMID: 24323243).  This variant has been detected in one individual with neonatal diabetes who was found to be homozygous for the c.683C>T variant (PM3_Supporting; PMID: 11372010).  In summary, c.683C>T meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.3, approved 8/11/2023): PS4, PS2, PP4_Moderate, PM1, PP2, PP3, PM2_Supporting, PM3_Supporting, PS3_Supporting.		Monogenic Diabetes VCEP		2024-02-28	2024-02-28	False	https://erepo.genome.network/evrepo/ui/classification/CA260620/MONDO:0015967/086	5ffe0ec7-6736-4676-bf37-412af923d449	p.Thr228Met	Thr	228	Met	MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQ	465	P35557	M	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [414], 'BINDING_gain': [], 'BINDING_loss_score': array([-0.02792728]), 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [196, 228], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.05163074, -0.08240157]), 'HELIX_loss': [114, 323], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.06634676, -0.05763501]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [226, 232, 233], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.09562123, -0.17154509, -0.24367177]), 'REGION_loss': [], 'REGION_gain': [7, 11, 21, 71, 75, 80], 'REGION_gain_score': array([0.00788999, 0.01414347, 0.00776893, 0.02886826, 0.02942371,
       0.02611393]), 'REPEAT_loss': [226], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.09970921]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
714	NM_000162.5(GCK):c.1016A>G (p.Glu339Gly)	393450	CA16609267	NM_000162.5:c.1016A>G, NC_000007.14:g.44146466T>C, CM000669.2:g.44146466T>C, NC_000007.13:g.44186065T>C, CM000669.1:g.44186065T>C, NC_000007.12:g.44152590T>C, NG_008847.1:g.47958A>G, NG_008847.2:g.56705A>G, ENST00000395796.8:c.*1014A>G, ENST00000616242.5:c.*136A>G, ENST00000683378.1:n.242A>G, ENST00000345378.7:c.1019A>G, ENST00000403799.8:c.1016A>G, ENST00000671824.1:c.1079A>G, ENST00000673284.1:c.1016A>G, ENST00000345378.6:c.1019A>G, ENST00000395796.7:c.1013A>G, ENST00000403799.7:c.1016A>G, ENST00000437084.1:c.965A>G, ENST00000473353.1:n.314A>G, ENST00000616242.4:c.1013A>G, NM_000162.3:c.1016A>G, NM_033507.1:c.1019A>G, NM_033508.1:c.1013A>G, NM_000162.4:c.1016A>G, NM_001354800.1:c.1016A>G, NM_001354801.1:c.8+153A>G, NM_033507.2:c.1019A>G, NM_033508.2:c.1013A>G, NM_033507.3:c.1019A>G, NM_033508.3:c.1013A>G, NM_000162.5(GCK):c.1016A>G (p.Glu339Gly)	GCK	monogenic diabetes	MONDO:0015967	Semidominant inheritance	Pathogenic	PS4, PM5_Supporting, PP2, PP3, PP1, PS3_Moderate, PM2_Supporting	PM1	The c.1016A>G variant in the glucokinase gene, GCK, causes an amino acid change of glutamic acid to glycine at codon 339 (p.(Glu339Gly)) of NM_000162.5.  GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2).  This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.993, which is greater than the MDEP VCEP threshold of 0.70 (PP3).  This variant is absent from gnomAD v2.1.1 (PM2_Supporting).  This variant was identified in 8 unrelated individuals with hyperglycemia (PS4; ClinVar:  393450, PMIDs: 18399931, 16731834, internal lab contributors).  This variant segregated with hyperglycemia, with 3 informative meioses in 1 family (PP1; internal lab contributors). MDEP wild type quality control measures were met, and the relative activity Index (RAI) of this variant was found to be 0.06, which is below the MDEP cutoff (<0.5) (PS3_Moderate; PMID: 16731834).  Another missense variant, c.1015G>A p.Glu339Lys, has been classified as likely pathogenic by the ClinGen MDEP (PM5_Supporting).  In summary, c.1016A>G meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.3.0, approved 8/11/2023): PS4, PS3_Moderate, PP2, PP3, PM2_Supporting, PM5_Supporting, PP1.		Monogenic Diabetes VCEP		2024-02-28	2024-02-28	False	https://erepo.genome.network/evrepo/ui/classification/CA16609267/MONDO:0015967/086	2af9f012-c414-4f5b-83ed-96420fa85e07	p.Glu339Gly	Glu	339	Gly	MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQ	465	P35557	G	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [323, 331, 334, 335, 336, 337, 338], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.04628533, -0.2824465 , -0.39863992, -0.4399429 , -0.43899548,
       -0.5051837 , -0.57524121]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [73], 'REGION_gain': [21], 'REGION_gain_score': array([0.00104916]), 'REGION_loss_score': array([-0.00405782]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
715	NM_000162.5(GCK):c.682A>G (p.Thr228Ala)	447413	CA367400790	NM_000162.5:c.682A>G, NC_000007.14:g.44147831T>C, CM000669.2:g.44147831T>C, NC_000007.13:g.44187430T>C, CM000669.1:g.44187430T>C, NC_000007.12:g.44153955T>C, NG_008847.1:g.46593A>G, NG_008847.2:g.55340A>G, ENST00000395796.8:c.*680A>G, ENST00000616242.5:c.682A>G, ENST00000345378.7:c.685A>G, ENST00000403799.8:c.682A>G, ENST00000671824.1:c.682A>G, ENST00000673284.1:c.682A>G, ENST00000345378.6:c.685A>G, ENST00000395796.7:c.679A>G, ENST00000403799.7:c.682A>G, ENST00000437084.1:c.631A>G, ENST00000616242.4:c.679A>G, NM_000162.3:c.682A>G, NM_033507.1:c.685A>G, NM_033508.1:c.679A>G, XR_927223.1:n.82+83T>C, NM_000162.4:c.682A>G, NM_001354800.1:c.682A>G, NM_033507.2:c.685A>G, NM_033508.2:c.679A>G, XR_927223.2:n.82+83T>C, NM_033507.3:c.685A>G, NM_033508.3:c.679A>G, NM_000162.5(GCK):c.682A>G (p.Thr228Ala)	GCK	monogenic diabetes	MONDO:0015967	Semidominant inheritance	Pathogenic	PS4, PM5_Supporting, PP2, PP3, PM1, PM2_Supporting	PS3	The c.682A>G variant in the glucokinase gene, GCK, causes an amino acid change of threonine to alanine at codon 228 (p.(Thr228Ala)) of NM_000162.5. GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2).  This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.931 which is greater than the MDEP VCEP threshold of 0.70 (PP3).  This variant resides in an amino acid that directly binds ATP, which is defined as critical for the protein’s function by the ClinGen MDEP (PM1).  This variant has an incomputable gnomAD v2.1.1  Grpmax filtering allele frequency due to 1 copy in the East Asian subpopulation and no copies in any other subpopulation, thereby meeting the ClinGen MDEP threshold criteria for PM2_Supporting (ENF Popmax FAF <= 0.000003 and <= 2 copies in ENF and <=1 copy in any other subpopulation) (PM2_Supporting).  This variant was identified in 7 unrelated individuals with hyperglycemia (PS4, PMIDs: 31638168, 12955723, internal lab contributors).  Another missense variant, c.683C>T p.Thr228Met, has been classified as pathogenic by the ClinGen MDEP but has a greater Grantham distance than p.Thr228Ala (PM5_Supporting).  In summary, c.682A>G meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.3, approved 8/11/2023): PM1, PP2, PP3, PM2_Supporting, PM5_Supporting, PS4.		Monogenic Diabetes VCEP		2024-02-28	2024-02-28	False	https://erepo.genome.network/evrepo/ui/classification/CA367400790/MONDO:0015967/086	58958324-9a8b-470d-aece-e0dc19575634	p.Thr228Ala	Thr	228	Ala	MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQ	465	P35557	A	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [414], 'BINDING_gain': [205], 'BINDING_gain_score': array([0.12763238]), 'BINDING_loss_score': array([-0.04629809]), 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [323], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.01932693]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [149, 226, 232, 233], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.04002964, -0.09090751, -0.12567037, -0.14904493]), 'REGION_loss': [], 'REGION_gain': [11, 21, 71, 75, 80], 'REGION_gain_score': array([0.00921595, 0.00512725, 0.0275991 , 0.02813488, 0.02649599]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
716	NM_000162.5(GCK):c.661G>A (p.Glu221Lys)	36241	CA213824	NM_000162.5:c.661G>A, NC_000007.14:g.44149778C>T, CM000669.2:g.44149778C>T, NC_000007.13:g.44189377C>T, CM000669.1:g.44189377C>T, NC_000007.12:g.44155902C>T, NG_008847.1:g.44646G>A, NG_008847.2:g.53393G>A, ENST00000395796.8:c.*659G>A, ENST00000616242.5:c.661G>A, ENST00000682635.1:n.1147G>A, ENST00000345378.7:c.664G>A, ENST00000403799.8:c.661G>A, ENST00000671824.1:c.661G>A, ENST00000673284.1:c.661G>A, ENST00000345378.6:c.664G>A, ENST00000395796.7:c.658G>A, ENST00000403799.7:c.661G>A, ENST00000437084.1:c.610G>A, ENST00000616242.4:c.658G>A, NM_000162.3:c.661G>A, NM_033507.1:c.664G>A, NM_033508.1:c.658G>A, NM_000162.4:c.661G>A, NM_001354800.1:c.661G>A, NM_033507.2:c.664G>A, NM_033508.2:c.658G>A, NM_033507.3:c.664G>A, NM_033508.3:c.658G>A, NM_000162.5(GCK):c.661G>A (p.Glu221Lys)	GCK	monogenic diabetes	MONDO:0015967	Semidominant inheritance	Pathogenic	PS4, PP1_Strong, PP4_Moderate, PP2, PP3, PM2_Supporting	PS3, PM1	The c.661A>G variant in the glucokinase gene, GCK, causes an amino acid change of glutamic acid to lysine at codon 221 (p.(Glu221Lys)) of NM_000162.5.  GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2).  This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.789, which is greater than the MDEP VCEP threshold of 0.70 (PP3).  This variant is absent from gnomAD v2.1.1 (PM2_Supporting). This variant is located in the larger hexokinase domain of the GCK gene (PMID: 31638168) but this variant does not reside in an amino acid that directly binds glucose or ATP, which is defined as critical for the protein’s function by the ClinGen MDEP.  This variant was identified in 4 unelated individuals with a clinical history highly specific for GCK-hyperglycemia (FBG 5.5-8 mmol/L and HbA1c 5.6 - 7.6% and negative antibodies or 2 hour OGTT glucose increment < 3 mmol/L) (PP4_Moderate; PMID: 23295292, internal lab contributors). This variant has been identified in 25 unrelated individuals with hyperglycemia and segregated with the phenotype, with 17 informative meioses in at least 7 families (PS4, PP1_Strong; PMIDs: 10694920, 12955723, 31658956, 34462253, 35592779, 35733065, 23295292, and 30592380).  A relative activity index (RAI) was calculated for this variant but the wild type parameters are outside of MDEP's recommendations; therefore, this data cannot be used towards PS3 (PMID: 30592380).  In summary, c.661A>G meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.3, approved 8/11/2023): PS4, PP1_Strong, PP4_Moderate, PP2, PP3, PM2_Supporting.		Monogenic Diabetes VCEP		2024-02-28	2024-02-28	False	https://erepo.genome.network/evrepo/ui/classification/CA213824/MONDO:0015967/086	bcac1d6c-8f3c-4870-ae6e-44213e7b972a	p.Glu221Lys	Glu	221	Lys	MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQ	465	P35557	K	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [408], 'BINDING_gain': [], 'BINDING_loss_score': array([-0.02527803]), 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [221, 225], 'DOMAIN_gain_score': array([0.06867057, 0.03501159]), 'REGION_loss': [73], 'REGION_gain': [], 'REGION_loss_score': array([-0.00834864]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
717	NM_000206.3(IL2RG):c.677G>A (p.Arg226His)	225196	CA358793	NM_000206.3:c.677G>A, NC_000023.11:g.71109308C>T, CM000685.2:g.71109308C>T, NC_000023.10:g.70329158C>T, CM000685.1:g.70329158C>T, NC_000023.9:g.70245883C>T, NG_009088.1:g.7246G>A, LRG_150:g.7246G>A, NG_021141.1:g.2481G>A, ENST00000482750.6:c.677G>A, ENST00000696903.1:n.728G>A, ENST00000374202.7:c.677G>A, ENST00000642473.1:n.1041G>A, ENST00000644022.1:n.943G>A, ENST00000644708.1:n.1083G>A, ENST00000644911.1:n.1083G>A, ENST00000645266.1:c.677G>A, ENST00000645518.1:c.677G>A, ENST00000646106.1:c.677G>A, ENST00000646505.1:c.677G>A, ENST00000647492.1:c.677G>A, ENST00000276110.6:n.1270G>A, ENST00000374188.7:c.-40G>A, ENST00000374202.6:c.677G>A, ENST00000456850.6:c.107G>A, ENST00000464642.5:c.545G>A, ENST00000482750.5:c.90G>A, ENST00000512747.3:n.604G>A, NM_000206.2:c.677G>A, LRG_150t1:c.677G>A, NM_000206.3(IL2RG):c.677G>A (p.Arg226His)	IL2RG	T-B+ severe combined immunodeficiency due to gamma chain deficiency	MONDO:0010315	X-linked inheritance	Pathogenic	PS3_Supporting, PP4_Moderate, PM2_Supporting, PM5, PS4, PM1_Strong		The NM_000206.3:c.677G>A variant in IL2RG is a missense variant predicted to cause substitution of arginine by histidine at amino acid 226 (p.Arg226His). The variant has been observed in at least 9 probands with SCID/Ommen Syndrome (PMIDs 7668284, 9058718, 17598841, 21184155) (PS4). Among these probands, one presented with symptoms reminiscent of Omenn syndrome. The proband exhibited a T-B-NK+ lymphocyte profile. CD132 was absent in every lymphocyte subpopulation, and the NK cells isolated from the patient did not respond to IL-2 stimulation (PMID 17598841) (PP4). The variant is absent from gnomAD v4.0 (PM2_Supporting). The variant affects CpG dinucleotides at c.677G, which is defined as a mutational hotspot by the ClinGen SCID VCEP (PMID 7668284) (PM1_Strong). Surface expression of the IL-2 receptor gamma chain in patient B cells showed that the variant causes decreased surface localization of the protein, indicating that this variant impacts protein function (PMID 9058718)(PS3_Supporting). In addition, another missense variant c.676C>T, p.Arg226Cys (ClinVar Variation ID 225195) in the same codon has been classified as pathogenic for SCID by the ClinGen SCID VCEP (PM5). In summary, this variant meets the criteria to be classified as pathogenic for SCID. ACMG/AMP criteria applied, as specified by the ClinGen SCID-VCEP: PM1_Strong, PS4_Strong, PM5, PP4_Moderate, PM2_Supporting, PS3_Supporting. (VCEP specifications version 1.0)		Severe Combined Immunodeficiency Disease  VCEP		2024-03-08	2024-03-08	False	https://erepo.genome.network/evrepo/ui/classification/CA358793/MONDO:0010315/129	df49371f-60da-48d8-9c4d-d677e3afed13	p.Arg226His	Arg	226	His	MLKPSLPFTSLLFLQLPLLGVGLNTTILTPNGNEDTTADFFLTTMPTDSLSVSTLPLPEVQCFVFNVEYMNCTWNSSSEPQPTNLTLHYWYKNSDNDKVQKCSHYLFSEEITSGCQLQKKEIHLYQTFVVQLQDPREPRRQATQMLKLQNLVIPWAPENLTLHKLSESQLELNWNNRFLNHCLEHLVQYRTDWDHSWTEQSVDYRHKFSLPSVDGQKRYTFRVRSRFNPLCGSAQHWSEWSHPIHWGSNTSKENPFLFALEAVVISVGSMGLIISLLCVYFWLERTMPRIPTLKNLEDLVTEYHGNFSAWSGVSKGLAESLQPDYSERLCLVSEIPPKGGALGEGPGASPCNQHSPYWAPPCYTLKPET	369	P31785	H	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
718	NM_000206.3(IL2RG):c.670C>T (p.Arg224Trp)	225194	CA358778	NM_000206.3:c.670C>T, NC_000023.11:g.71109315G>A, CM000685.2:g.71109315G>A, NC_000023.10:g.70329165G>A, CM000685.1:g.70329165G>A, NC_000023.9:g.70245890G>A, NG_009088.1:g.7239C>T, LRG_150:g.7239C>T, NG_021141.1:g.2474C>T, ENST00000482750.6:c.670C>T, ENST00000696903.1:n.721C>T, ENST00000374202.7:c.670C>T, ENST00000642473.1:n.1034C>T, ENST00000644022.1:n.936C>T, ENST00000644708.1:n.1076C>T, ENST00000644911.1:n.1076C>T, ENST00000645266.1:c.670C>T, ENST00000645518.1:c.670C>T, ENST00000646106.1:c.670C>T, ENST00000646505.1:c.670C>T, ENST00000647492.1:c.670C>T, ENST00000276110.6:n.1263C>T, ENST00000374188.7:c.-47C>T, ENST00000374202.6:c.670C>T, ENST00000456850.6:c.100C>T, ENST00000464642.5:c.538C>T, ENST00000482750.5:c.83C>T, ENST00000512747.3:n.597C>T, NM_000206.2:c.670C>T, LRG_150t1:c.670C>T, NM_000206.3(IL2RG):c.670C>T (p.Arg224Trp)	IL2RG	T-B+ severe combined immunodeficiency due to gamma chain deficiency	MONDO:0010315	X-linked inheritance	Pathogenic	PS3_Supporting, PP4, PM2_Supporting, PS4, PM1_Strong		The NM_000206.3:c.670C>T variant in IL2RG is a missense variant predicted to cause substitution of arginine by tryptophan at amino acid 224 (p.Arg226Trp). The variant has been observed in at least 10 male probands with SCID (PMIDs 28747913, 21184155, 10792291, 9633906, 9058718, 9049783) (PS4). Among these probands, one proband hemizygous for this variant was diagnosed with SCID and presented a T-B+NK- lymphocyte profile (PMID 9049783) (PP4). The variant is absent from gnomAD v4.0 (PM2_Supporting). The variant affects CpG dinucleotides at c.670C, which is defined as a mutational hotspot by the ClinGen SCID VCEP (PMID 7668284) (PM1_Strong). Surface expression of the IL-2 receptor gamma chain in patient B cells showed that the variant causes decreased surface localization of the protein, indicating that this variant impacts protein function (PMID 9058718)(PS3_Supporting). In summary, this variant meets the criteria to be classified as pathogenic for SCID. ACMG/AMP criteria applied, as specified by the ClinGen SCID-VCEP: PM1_Strong, PS4, PP4_Supporting, PM2_Supporting, PS3_Supporting. (VCEP specifications version 1.0)		Severe Combined Immunodeficiency Disease  VCEP		2024-03-08	2024-03-08	False	https://erepo.genome.network/evrepo/ui/classification/CA358778/MONDO:0010315/129	20eae169-0d74-4c7c-ab5c-ece464898a11	p.Arg224Trp	Arg	224	Trp	MLKPSLPFTSLLFLQLPLLGVGLNTTILTPNGNEDTTADFFLTTMPTDSLSVSTLPLPEVQCFVFNVEYMNCTWNSSSEPQPTNLTLHYWYKNSDNDKVQKCSHYLFSEEITSGCQLQKKEIHLYQTFVVQLQDPREPRRQATQMLKLQNLVIPWAPENLTLHKLSESQLELNWNNRFLNHCLEHLVQYRTDWDHSWTEQSVDYRHKFSLPSVDGQKRYTFRVRSRFNPLCGSAQHWSEWSHPIHWGSNTSKENPFLFALEAVVISVGSMGLIISLLCVYFWLERTMPRIPTLKNLEDLVTEYHGNFSAWSGVSKGLAESLQPDYSERLCLVSEIPPKGGALGEGPGASPCNQHSPYWAPPCYTLKPET	369	P31785	W	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
719	NM_001110792.2(MECP2):c.1351G>T (p.Ala451Ser)	95190	CA222801	NM_001110792.2:c.1351G>T, NC_000023.11:g.154030513C>A, CM000685.2:g.154030513C>A, NC_000023.10:g.153295964C>A, CM000685.1:g.153295964C>A, NC_000023.9:g.152949158C>A, NG_007107.2:g.111615G>T, NG_007107.3:g.111591G>T, ENST00000303391.11:c.1315G>T, ENST00000453960.7:c.1351G>T, ENST00000303391.10:c.1315G>T, ENST00000453960.6:c.1351G>T, ENST00000619732.4:c.1315G>T, ENST00000628176.2:c.*687G>T, NM_001110792.1:c.1351G>T, NM_001316337.1:c.1036G>T, NM_004992.3:c.1315G>T, XM_005274681.3:c.1315G>T, XM_005274682.3:c.1036G>T, XM_005274683.3:c.1036G>T, XM_006724819.2:c.646G>T, XM_011531166.1:c.1036G>T, XM_006724819.3:c.646G>T, XM_011531166.2:c.1036G>T, XM_024452383.1:c.1036G>T, XM_024452384.1:c.1036G>T, NM_001316337.2:c.1036G>T, NM_001369391.2:c.1036G>T, NM_001369392.2:c.1036G>T, NM_001369393.2:c.1036G>T, NM_001369394.1:c.1036G>T, NM_001369394.2:c.1036G>T, NM_001386137.1:c.646G>T, NM_001386138.1:c.646G>T, NM_001386139.1:c.646G>T, NM_004992.4:c.1315G>T, NM_001110792.2(MECP2):c.1351G>T (p.Ala451Ser)	MECP2	Rett syndrome	MONDO:0010726	X-linked inheritance	Benign	BA1	BP4, PM1	The allele frequency of the p.Ala439Ser variant in MECP2 (NM_004992.3) is 0.04208% in the African/African-American sub population in gnomAD, which is high enough to be classified as benign based on thresholds defined by the ClinGen Rett/Angelman-like Expert Panel for Rett/AS-like conditions (BA1). In summary, the p.Ala439Ser variant in MECP2 is classified as Benign based on the ACMG/AMP criteria (BA1).		Rett and Angelman-like Disorders VCEP		2022-10-11	2024-03-13	False	https://erepo.genome.network/evrepo/ui/classification/CA222801/MONDO:0010726/036	59bf97c6-4a96-4fae-84d2-0bd8b32390ba	p.Ala451Ser	Ala	451	Ser	MVAGMLGLREEKSEDQDLQGLKDKPLKFKKVKKDKKEEKEGKHEPVQPSAHHSAEPAEAGKAETSEGSGSAPAVPEASASPKQRRSIIRDRGPMYDDPTLPEGWTRKLKQRKSGRSAGKYDVYLINPQGKAFRSKVELIAYFEKVGDTSLDPNDFDFTVTGRGSPSRREQKPPKKPKSPKAPGTGRGRGRPKGSGTTRPKAATSEGVQVKRVLEKSPGKLLVKMPFQTSPGGKAEGGGATTSTQVMVIKRPGRKRKAEADPQAIPKKRGRKPGSVVAAAAAEAKKKAVKESSIRSVQETVLPIKKRKTRETVSIEVKEVVKPLLVSTLGEKSGKGLKTCKSPGRKSKESSPKGRSSSASSPPKKEHHHHHHHSESPKAPVPLLPPLPPPPPEPESSEDPTSPPEPQDLSSSVCKEEKMPRGGSLESDGCPKEPAKTQPAVATAATAAEKYKHRGEGERKDIVSSSMPRPNREEPVDSRTPVTERVS	486	P51608	S	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [447, 448], 'COMPBIAS_gain': [374], 'COMPBIAS_gain_score': array([0.01994509]), 'COMPBIAS_loss_score': array([-0.49212307, -0.28260887]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
720	NM_001110792.2(MECP2):c.968C>T (p.Thr323Met)	36496	CA170409	NM_001110792.2:c.968C>T, NC_000023.11:g.154030896G>A, CM000685.2:g.154030896G>A, NC_000023.10:g.153296347G>A, CM000685.1:g.153296347G>A, NC_000023.9:g.152949541G>A, NG_007107.2:g.111232C>T, NG_007107.3:g.111208C>T, ENST00000303391.11:c.932C>T, ENST00000453960.7:c.968C>T, ENST00000637917.1:c.106C>T, ENST00000303391.10:c.932C>T, ENST00000407218.5:c.*304C>T, ENST00000453960.6:c.968C>T, ENST00000619732.4:c.932C>T, ENST00000622433.4:c.918C>T, ENST00000628176.2:c.*304C>T, NM_001110792.1:c.968C>T, NM_001316337.1:c.653C>T, NM_004992.3:c.932C>T, XM_005274681.3:c.932C>T, XM_005274682.3:c.653C>T, XM_005274683.3:c.653C>T, XM_006724819.2:c.263C>T, XM_011531166.1:c.653C>T, XM_006724819.3:c.263C>T, XM_011531166.2:c.653C>T, XM_024452383.1:c.653C>T, XM_024452384.1:c.653C>T, NM_001316337.2:c.653C>T, NM_001369391.2:c.653C>T, NM_001369392.2:c.653C>T, NM_001369393.2:c.653C>T, NM_001369394.1:c.653C>T, NM_001369394.2:c.653C>T, NM_001386137.1:c.263C>T, NM_001386138.1:c.263C>T, NM_001386139.1:c.263C>T, NM_004992.4:c.932C>T, NM_001110792.2(MECP2):c.968C>T (p.Thr323Met)	MECP2	Rett syndrome	MONDO:0010726	X-linked inheritance	Benign	BP5, BS1, BS2, PP3		"The allele frequency of the p.Thr311Met variant in MECP2 (NM_004992.3) is 0.022% and 0.01% in """"""""""""""""Other"""""""""""""""" and South Asian sub population in gnomAD, which is high enough to meet the BS1 criteria based on thresholds defined by the ClinGen Rett/Angelman-like Expert Panel for Rett/AS-like conditions (BS1). The p.Thr311Met variant is observed in at least 2 unaffected individuals (GeneDx internal database) (BS2) and found in 2 patients with an alternate molecular basis of disease (Baylor Genetics internal database, Invitae internal database) (BP5). Computational prediction analysis tools suggests a deleterious impact; however, this information does not predict clinical significance on its own (PP3). As this variant meets 2 strong and 1 supporting benign criteria it can be classified as benign even though in silico predictions meet PP3. In summary, the p.Thr311Met variant in MECP2 is classified as benign for Rett syndrome based on the ACMG/AMP criteria (BS1, BS2, BP5)."		Rett and Angelman-like Disorders VCEP		2022-02-18	2024-03-13	False	https://erepo.genome.network/evrepo/ui/classification/CA170409/MONDO:0010726/036	cf504ba2-3f8d-472c-88e2-1bf8fcf65ee5	p.Thr323Met	Thr	323	Met	MVAGMLGLREEKSEDQDLQGLKDKPLKFKKVKKDKKEEKEGKHEPVQPSAHHSAEPAEAGKAETSEGSGSAPAVPEASASPKQRRSIIRDRGPMYDDPTLPEGWTRKLKQRKSGRSAGKYDVYLINPQGKAFRSKVELIAYFEKVGDTSLDPNDFDFTVTGRGSPSRREQKPPKKPKSPKAPGTGRGRGRPKGSGTTRPKAATSEGVQVKRVLEKSPGKLLVKMPFQTSPGGKAEGGGATTSTQVMVIKRPGRKRKAEADPQAIPKKRGRKPGSVVAAAAAEAKKKAVKESSIRSVQETVLPIKKRKTRETVSIEVKEVVKPLLVSTLGEKSGKGLKTCKSPGRKSKESSPKGRSSSASSPPKKEHHHHHHHSESPKAPVPLLPPLPPPPPEPESSEDPTSPPEPQDLSSSVCKEEKMPRGGSLESDGCPKEPAKTQPAVATAATAAEKYKHRGEGERKDIVSSSMPRPNREEPVDSRTPVTERVS	486	P51608	M	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [302, 304, 323], 'REGION_gain_score': array([0.04803985, 0.03318495, 0.18763405]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
721	NM_000162.5(GCK):c.370G>C (p.Asp124His)	447397	CA367402212	NM_000162.5:c.370G>C, NC_000007.14:g.44151069C>G, CM000669.2:g.44151069C>G, NC_000007.13:g.44190668C>G, CM000669.1:g.44190668C>G, NC_000007.12:g.44157193C>G, NG_008847.1:g.43355G>C, NG_008847.2:g.52102G>C, ENST00000395796.8:c.*368G>C, ENST00000616242.5:c.370G>C, ENST00000682635.1:n.856G>C, ENST00000345378.7:c.373G>C, ENST00000403799.8:c.370G>C, ENST00000671824.1:c.370G>C, ENST00000673284.1:c.370G>C, ENST00000345378.6:c.373G>C, ENST00000395796.7:c.367G>C, ENST00000403799.7:c.370G>C, ENST00000437084.1:c.364-45G>C, ENST00000616242.4:c.367G>C, NM_000162.3:c.370G>C, NM_033507.1:c.373G>C, NM_033508.1:c.367G>C, NM_000162.4:c.370G>C, NM_001354800.1:c.370G>C, NM_033507.2:c.373G>C, NM_033508.2:c.367G>C, NM_033507.3:c.373G>C, NM_033508.3:c.367G>C, NM_000162.5(GCK):c.370G>C (p.Asp124His)	GCK	monogenic diabetes	MONDO:0015967	Semidominant inheritance	Pathogenic	PS4, PP1_Moderate, PP2, PP3, PP4, PM2_Supporting		The c.370G>C variant in the glucokinase gene, GCK, causes an amino acid change of aspartate to histidine at codon 124 (p.(Asp124His)) of NM_000162.5. GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2). This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.985, which is greater than the MDEP VCEP threshold of 0.70 (PP3). This variant is absent in gnomAD v2.1.1 (PM2_Supporting). This variant was identified in eight unrelated individuals with hyperglycemia (PS4; internal lab contributors). This variant segregated with hyperglycemia, with three informative meioses in three families (PP1_Moderate; internal lab contributors). This variant was identified in an individual with a clinical history highly specific for GCK-hyperglycemia (FBG 5.5-8 mmol/L and HbA1c 5.6 - 7.6%) (PP4; internal lab contributors). Taken together, this evidence supports the classification of c.370G>C as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.3.0, approved 8/11/2023): PS4, PP1_Moderate, PP2, PP3, PP4, PM2_Supporting.		Monogenic Diabetes VCEP		2024-03-14	2024-03-14	False	https://erepo.genome.network/evrepo/ui/classification/CA367402212/MONDO:0015967/086	fca2d2ea-e409-4de3-b300-eb9f0e6105d9	p.Asp124His	Asp	124	His	MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQ	465	P35557	H	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [73], 'REGION_gain': [11, 21], 'REGION_gain_score': array([0.01056528, 0.00412422]), 'REGION_loss_score': array([-0.00249666]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
722	NM_001114753.3(ENG):c.991G>A (p.Gly331Ser)	407115	CA16612528	NM_001114753.3:c.991G>A, NC_000009.12:g.127824800C>T, CM000671.2:g.127824800C>T, NC_000009.11:g.130587079C>T, CM000671.1:g.130587079C>T, NC_000009.10:g.129626900C>T, NG_009551.1:g.34969G>A, LRG_589:g.34969G>A, ENST00000480266.6:c.445G>A, ENST00000373203.9:c.991G>A, ENST00000344849.4:c.991G>A, ENST00000373203.8:c.991G>A, ENST00000480266.5:c.445G>A, NM_000118.3:c.991G>A, LRG_589t1:c.991G>A, NM_001114753.2:c.991G>A, LRG_589t2:c.991G>A, NM_001278138.1:c.445G>A, NM_001278138.2:c.445G>A, NM_001114753.3(ENG):c.991G>A (p.Gly331Ser)	ENG	telangiectasia, hereditary hemorrhagic, type 1	MONDO:0008535	Autosomal dominant inheritance	Pathogenic	PP4_Moderate, PP1, PM2_Supporting, PS4, PS3	PP3	The NM_001114753.3: c.991G>A variant in ENG is a missense variant predicted to cause substitution of glycine by serine at amino acid 331 (p.Gly331Ser). This variant is absent from gnomAD v2.1.1 (PM2_Supporting). This variant has been reported in >10 probands with a phenotype consistent with HHT (PS4; PMID: 19767588, 34872578, 16690726, 34880085, 15517393, 25970827, 29171923, 32573726, 21158752, Internal lab contributors). At least one patient's phenotype meets Curacao Criteria for HHT, and sequencing and large deletion/duplication analysis was performed for ENG and ACVRL1, which is highly specific for HHT (PP4_Moderate; PMID: 19767588, 21158752). The variant has been reported to segregate with HHT in 3 affected meioses from 2 families (PP1; PMID: 19767588, 34872578). The computational predictor REVEL gives a score of 0.202, which is neither above nor below the thresholds predicting a damaging or benign impact on ENG function. However, RT-PCR analysis of cDNA demonstrated that the variant impacts splicing by leading to exon 7 skipping (PS3; PMID: 16690726). In summary, this variant meets the criteria to be classified as pathogenic for autosomal dominant hereditary hemorrhagic telangiectasia based on the ACMG/AMP criteria applied, as specified by the ClinGen Hereditary Hemorrhagic Telangiectasia Variant Curation Expert Panel: PS3, PS4, PP4_Moderate, PP1, PM2_Supporting (specification version 1.0.0; 1/4/2024).		Hereditary Hemorrhagic Telangiectasia VCEP		2024-03-15	2024-03-15	False	https://erepo.genome.network/evrepo/ui/classification/CA16612528/MONDO:0008535/136	3ce6893b-d576-45bb-b69c-edf517fe12d9	p.Gly331Ser	Gly	331	Ser	MDRGTLPLAVALLLASCSLSPTSLAETVHCDLQPVGPERGEVTYTTSQVSKGCVAQAPNAILEVHVLFLEFPTGPSQLELTLQASKQNGTWPREVLLVLSVNSSVFLHLQALGIPLHLAYNSSLVTFQEPPGVNTTELPSFPKTQILEWAAERGPITSAAELNDPQSILLRLGQAQGSLSFCMLEASQDMGRTLEWRPRTPALVRGCHLEGVAGHKEAHILRVLPGHSAGPRTVTVKVELSCAPGDLDAVLILQGPPYVSWLIDANHNMQIWTTGEYSFKIFPEKNIRGFKLPDTPQGLLGEARMLNASIVASFVELPLASIVSLHASSCGGRLQTSPAPIQTTPPKDTCSPELLMSLIQTKCADDAMTLVLKKELVAHLKCTITGLTFWDPSCEAEDRGDKFVLRSAYSSCGMQVSASMISNEAVVNILSSSSPQRKKVHCLNMDSLSFQLGLYLSPHFLQASNTIEPGQQSFVQVRVSPSVSEFLLQLDSCHLDLGPEGGTVELIQGRAAKGNCVSLLSPSPEGDPRFSFLLHFYTVPIPKTGTLSCTVALRPKTGSQDQEVHRTVFMRLNIISPDLSGCTSKGLVLPAVLGITFGAFLIGALLTAALWYIYSHTRSPSKREPVVAVAAPASSESSSTNHSIGSTQSTPCSTSSMA	658	P17813	S	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [329], 'DISULFID_gain': [], 'DISULFID_loss_score': array([-0.09081459]), 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [321], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.08250242]), 'HELIX_loss': [], 'HELIX_gain': [353], 'HELIX_gain_score': array([0.01853395]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
723	NM_001114753.3(ENG):c.572G>A (p.Gly191Asp)	213200	CA325327	NM_001114753.3:c.572G>A, NC_000009.12:g.127825812C>T, CM000671.2:g.127825812C>T, NC_000009.11:g.130588091C>T, CM000671.1:g.130588091C>T, NC_000009.10:g.129627912C>T, NG_009551.1:g.33957G>A, LRG_589:g.33957G>A, ENST00000480266.6:c.26G>A, ENST00000373203.9:c.572G>A, ENST00000344849.4:c.572G>A, ENST00000373203.8:c.572G>A, ENST00000462196.1:n.472G>A, ENST00000480266.5:c.26G>A, NM_000118.3:c.572G>A, LRG_589t1:c.572G>A, NM_001114753.2:c.572G>A, LRG_589t2:c.572G>A, NM_001278138.1:c.26G>A, XR_001746952.2:n.82+354C>T, NM_001278138.2:c.26G>A, NM_001114753.3(ENG):c.572G>A (p.Gly191Asp)	ENG	telangiectasia, hereditary hemorrhagic, type 1	MONDO:0008535	Autosomal dominant inheritance	Benign	BP5, BA1	PP3	The NM_001114753.3: c.572G>A variant in ENG is a missense variant predicted to cause substitution of glycine by aspartic acid at amino acid 191 (p.Gly191Asp). The filtering allele frequency (the lower threshold of the 95% CI of 1725/109328) of the c.572G>A variant in ENG is 0.01669 for European (non-Finnish) chromosomes by gnomAD v2.1.1, which is higher than the ClinGen Hereditary Hemorrhagic Telangiectasia Variant Curation Expert Panel threshold (>0.01) for BA1, and therefore meets this criterion (BA1). This variant has been observed in at least 2 patients with an alternate molecular basis for disease (patients also carry likely pathogenic/pathogenic ACVRL1 variant) (BP5; PMID: 32573726, Internal lab contributors). The computational predictor REVEL gives a score of 0.275, which is neither above nor below the thresholds predicting a damaging or benign impact on ENG function. In summary, this variant meets the criteria to be classified as benign for autosomal dominant hereditary hemorrhagic telangiectasia based on the ACMG/AMP criteria applied, as specified by the ClinGen Hereditary Hemorrhagic Telangiectasia Variant Curation Expert Panel: BA1, BP5 (specification version 1.0.0; 1/4/2024).		Hereditary Hemorrhagic Telangiectasia VCEP		2024-03-15	2024-03-15	False	https://erepo.genome.network/evrepo/ui/classification/CA325327/MONDO:0008535/136	5e64b35b-3660-45cd-bc60-6e2be0e909ee	p.Gly191Asp	Gly	191	Asp	MDRGTLPLAVALLLASCSLSPTSLAETVHCDLQPVGPERGEVTYTTSQVSKGCVAQAPNAILEVHVLFLEFPTGPSQLELTLQASKQNGTWPREVLLVLSVNSSVFLHLQALGIPLHLAYNSSLVTFQEPPGVNTTELPSFPKTQILEWAAERGPITSAAELNDPQSILLRLGQAQGSLSFCMLEASQDMGRTLEWRPRTPALVRGCHLEGVAGHKEAHILRVLPGHSAGPRTVTVKVELSCAPGDLDAVLILQGPPYVSWLIDANHNMQIWTTGEYSFKIFPEKNIRGFKLPDTPQGLLGEARMLNASIVASFVELPLASIVSLHASSCGGRLQTSPAPIQTTPPKDTCSPELLMSLIQTKCADDAMTLVLKKELVAHLKCTITGLTFWDPSCEAEDRGDKFVLRSAYSSCGMQVSASMISNEAVVNILSSSSPQRKKVHCLNMDSLSFQLGLYLSPHFLQASNTIEPGQQSFVQVRVSPSVSEFLLQLDSCHLDLGPEGGTVELIQGRAAKGNCVSLLSPSPEGDPRFSFLLHFYTVPIPKTGTLSCTVALRPKTGSQDQEVHRTVFMRLNIISPDLSGCTSKGLVLPAVLGITFGAFLIGALLTAALWYIYSHTRSPSKREPVVAVAAPASSESSSTNHSIGSTQSTPCSTSSMA	658	P17813	D	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [492], 'DISULFID_gain_score': array([0.00370342]), 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [48, 101, 147, 172, 186, 321], 'STRAND_gain': [454], 'STRAND_gain_score': array([0.02484065]), 'STRAND_loss_score': array([-0.01842248, -0.00946879, -0.02863836, -0.03628594, -0.13894379,
       -0.02711505]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
724	NM_001114753.3(ENG):c.392C>T (p.Pro131Leu)	161232	CA202695	NM_001114753.3:c.392C>T, NC_000009.12:g.127826641G>A, CM000671.2:g.127826641G>A, NC_000009.11:g.130588920G>A, CM000671.1:g.130588920G>A, NC_000009.10:g.129628741G>A, NG_009551.1:g.33128C>T, LRG_589:g.33128C>T, ENST00000480266.6:c.-155C>T, ENST00000373203.9:c.392C>T, ENST00000344849.4:c.392C>T, ENST00000373203.8:c.392C>T, ENST00000462196.1:n.292C>T, ENST00000480266.5:c.-155C>T, NM_000118.3:c.392C>T, LRG_589t1:c.392C>T, NM_001114753.2:c.392C>T, LRG_589t2:c.392C>T, NM_001278138.1:c.-155C>T, XR_001746952.2:n.82+1183G>A, NM_001278138.2:c.-155C>T, NM_001114753.3(ENG):c.392C>T (p.Pro131Leu)	ENG	telangiectasia, hereditary hemorrhagic, type 1	MONDO:0008535	Autosomal dominant inheritance	Benign	BA1	PP3	The NM_001114753.3: c.392C>T variant in ENG is a missense variant predicted to cause substitution of proline by leucine at amino acid 131 (p.Pro131Leu). The filtering allele frequency (the lower threshold of the 95% CI of 762/30612) of the c.392C>T variant in ENG is 0.02343 for South Asian chromosomes by gnomAD v2.1.1, which is higher than the ClinGen Hereditary Hemorrhagic Telangiectasia Variant Curation Expert Panel threshold (>0.01) for BA1, and therefore meets this criterion (BA1). The computational predictor REVEL gives a score of 0.315, which is neither above nor below the thresholds predicting a damaging or benign impact on ENG function. In summary, this variant meets the criteria to be classified as benign for autosomal dominant hereditary hemorrhagic telangiectasia based on the ACMG/AMP criteria applied, as specified by the ClinGen Hereditary Hemorrhagic Telangiectasia Variant Curation Expert Panel: BA1 (specification version 1.0.0; 1/4/2024).		Hereditary Hemorrhagic Telangiectasia VCEP		2024-03-15	2024-03-15	False	https://erepo.genome.network/evrepo/ui/classification/CA202695/MONDO:0008535/136	007c246a-5626-4580-b6dc-c5817c428f04	p.Pro131Leu	Pro	131	Leu	MDRGTLPLAVALLLASCSLSPTSLAETVHCDLQPVGPERGEVTYTTSQVSKGCVAQAPNAILEVHVLFLEFPTGPSQLELTLQASKQNGTWPREVLLVLSVNSSVFLHLQALGIPLHLAYNSSLVTFQEPPGVNTTELPSFPKTQILEWAAERGPITSAAELNDPQSILLRLGQAQGSLSFCMLEASQDMGRTLEWRPRTPALVRGCHLEGVAGHKEAHILRVLPGHSAGPRTVTVKVELSCAPGDLDAVLILQGPPYVSWLIDANHNMQIWTTGEYSFKIFPEKNIRGFKLPDTPQGLLGEARMLNASIVASFVELPLASIVSLHASSCGGRLQTSPAPIQTTPPKDTCSPELLMSLIQTKCADDAMTLVLKKELVAHLKCTITGLTFWDPSCEAEDRGDKFVLRSAYSSCGMQVSASMISNEAVVNILSSSSPQRKKVHCLNMDSLSFQLGLYLSPHFLQASNTIEPGQQSFVQVRVSPSVSEFLLQLDSCHLDLGPEGGTVELIQGRAAKGNCVSLLSPSPEGDPRFSFLLHFYTVPIPKTGTLSCTVALRPKTGSQDQEVHRTVFMRLNIISPDLSGCTSKGLVLPAVLGITFGAFLIGALLTAALWYIYSHTRSPSKREPVVAVAAPASSESSSTNHSIGSTQSTPCSTSSMA	658	P17813	L	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [101, 147], 'STRAND_gain': [75, 210, 223, 454], 'STRAND_gain_score': array([0.01451325, 0.0101456 , 0.02469075, 0.0232504 ]), 'STRAND_loss_score': array([-0.00504255, -0.05859512]), 'HELIX_loss': [], 'HELIX_gain': [353], 'HELIX_gain_score': array([0.0003655]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
725	NM_001114753.3(ENG):c.2T>G (p.Met1Arg)	458346	CA374989708	NM_001114753.3:c.2T>G, NC_000009.12:g.127854354A>C, CM000671.2:g.127854354A>C, NC_000009.11:g.130616633A>C, CM000671.1:g.130616633A>C, NC_000009.10:g.129656454A>C, NG_009551.1:g.5415T>G, LRG_589:g.5415T>G, ENST00000373203.9:c.2T>G, ENST00000344849.4:c.2T>G, ENST00000373203.8:c.2T>G, NM_000118.3:c.2T>G, LRG_589t1:c.2T>G, NM_001114753.2:c.2T>G, LRG_589t2:c.2T>G, NM_001114753.3(ENG):c.2T>G (p.Met1Arg)	ENG	telangiectasia, hereditary hemorrhagic, type 1	MONDO:0008535	Autosomal dominant inheritance	Pathogenic	PVS1_Strong, PP4_Moderate, PM2_Supporting, PS4, PM5_Strong		The NM_001114753.3: c.2T>G variant in ENG may cause a truncated or absent protein by altering the start codon of the coding sequence and is predicted to lead to the omission of a critical region of the protein (PVS1_Strong). This variant is absent from gnomAD v2.1.1 (PM2_Supporting). This variant has been reported in >4 probands with a phenotype consistent with HHT (PS4; PMID:12920067, 32300199, 15024723, ClinVar, Internal lab contributors). At least one patient's phenotype meets Curacao Criteria for HHT, and sequencing and large deletion/duplication analysis was performed for ENG and ACVRL1, which is highly specific for HHT (PP4_Moderate; Internal lab contributors). Four different missense variants, c.3G>A, c.1A>T, c.2T>C, c.1A>G, in the same codon have been classified as pathogenic/likely pathogenic for autosomal dominant hereditary hemorrhagic telangiectasia by the ClinGen Hereditary Hemorrhagic Telangiectasia Variant Curation Expert Panel (PM5_Strong). In summary, this variant meets the criteria to be classified as pathogenic for autosomal dominant hereditary hemorrhagic telangiectasia based on the ACMG/AMP criteria applied, as specified by the ClinGen Hereditary Hemorrhagic Telangiectasia Variant Curation Expert Panel: PM2_Supporting, PVS1_Strong, PS4, PP4_Moderate, PM5_Strong (specification version 1.0.0; 1/4/2024).		Hereditary Hemorrhagic Telangiectasia VCEP		2024-03-15	2024-03-15	False	https://erepo.genome.network/evrepo/ui/classification/CA374989708/MONDO:0008535/136	9c37e4fd-9165-4c38-b2bb-afc7e9587d13	p.Met1Arg	Met	1	Arg	MDRGTLPLAVALLLASCSLSPTSLAETVHCDLQPVGPERGEVTYTTSQVSKGCVAQAPNAILEVHVLFLEFPTGPSQLELTLQASKQNGTWPREVLLVLSVNSSVFLHLQALGIPLHLAYNSSLVTFQEPPGVNTTELPSFPKTQILEWAAERGPITSAAELNDPQSILLRLGQAQGSLSFCMLEASQDMGRTLEWRPRTPALVRGCHLEGVAGHKEAHILRVLPGHSAGPRTVTVKVELSCAPGDLDAVLILQGPPYVSWLIDANHNMQIWTTGEYSFKIFPEKNIRGFKLPDTPQGLLGEARMLNASIVASFVELPLASIVSLHASSCGGRLQTSPAPIQTTPPKDTCSPELLMSLIQTKCADDAMTLVLKKELVAHLKCTITGLTFWDPSCEAEDRGDKFVLRSAYSSCGMQVSASMISNEAVVNILSSSSPQRKKVHCLNMDSLSFQLGLYLSPHFLQASNTIEPGQQSFVQVRVSPSVSEFLLQLDSCHLDLGPEGGTVELIQGRAAKGNCVSLLSPSPEGDPRFSFLLHFYTVPIPKTGTLSCTVALRPKTGSQDQEVHRTVFMRLNIISPDLSGCTSKGLVLPAVLGITFGAFLIGALLTAALWYIYSHTRSPSKREPVVAVAAPASSESSSTNHSIGSTQSTPCSTSSMA	658	P17813	R	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [321], 'STRAND_gain': [75, 105, 196, 384], 'STRAND_gain_score': array([0.01806384, 0.02186316, 0.01143408, 0.00756049]), 'STRAND_loss_score': array([-0.0192793]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [351, 547, 553, 555, 556, 557], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.04935879, -0.08597034, -0.07856077, -0.05541706, -0.05516446,
       -0.05498606]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
726	NM_001114753.3(ENG):c.447G>C (p.Trp149Cys)	237027	CA10582615	NM_001114753.3:c.447G>C, NC_000009.12:g.127826586C>G, CM000671.2:g.127826586C>G, NC_000009.11:g.130588865C>G, CM000671.1:g.130588865C>G, NC_000009.10:g.129628686C>G, NG_009551.1:g.33183G>C, LRG_589:g.33183G>C, ENST00000480266.6:c.-100G>C, ENST00000373203.9:c.447G>C, ENST00000344849.4:c.447G>C, ENST00000373203.8:c.447G>C, ENST00000462196.1:n.347G>C, ENST00000480266.5:c.-100G>C, NM_000118.3:c.447G>C, LRG_589t1:c.447G>C, NM_001114753.2:c.447G>C, LRG_589t2:c.447G>C, NM_001278138.1:c.-100G>C, XR_001746952.2:n.82+1128C>G, NM_001278138.2:c.-100G>C, NM_001114753.3(ENG):c.447G>C (p.Trp149Cys)	ENG	telangiectasia, hereditary hemorrhagic, type 1	MONDO:0008535	Autosomal dominant inheritance	Pathogenic	PS3_Supporting, PP4_Moderate, PP3, PP1, PM2_Supporting, PS4		The NM_001114753.3: c.447G>C variant in ENG is a missense variant predicted to cause substitution of tryptophan by cysteine at amino acid 149 (p.Trp149Cys). This variant is absent from gnomAD v2.1.1 (PM2_Supporting). This variant has been reported in >4 probands with a phenotype consistent with HHT (PS4; PMID: 9554745, 22022569, 22991266, 32300199, Internal lab contributors). At least one patient's phenotype meets Curacao Criteria for HHT, and sequencing and large deletion/duplication analysis was performed for ENG and ACVRL1, which is highly specific for HHT (PP4_Moderate; Internal lab contributors). The variant has been reported to segregate with HHT in 3 affected individuals of a family (4 generations) (PP1; PMID: 10545596). The computational predictor REVEL gives a score of 0.762, which is above the threshold of ≥0.644, evidence that correlates with impact to ENG function (PP3). Additionally, expression studies in endoglin-deficient mice, human umbilical vein endothelial cells (HUVECs) and peripheral blood activated monocytes showed reduced expression of fully processed normal endoglin indicating that this variant impacts protein function (PS3_Supporting; PMID: 10545596, 11343967, 10749981). In summary, this variant meets the criteria to be classified as pathogenic for autosomal dominant hereditary hemorrhagic telangiectasia based on the ACMG/AMP criteria applied, as specified by the ClinGen Hereditary Hemorrhagic Telangiectasia Variant Curation Expert Panel: PM2_Supporting, PP3, PP4_Moderate, PS4, PS3_Supporting, PP1 (specification version 1.0.0; 1/4/2024).		Hereditary Hemorrhagic Telangiectasia VCEP		2024-03-15	2024-03-15	False	https://erepo.genome.network/evrepo/ui/classification/CA10582615/MONDO:0008535/136	81eb6b2e-96ac-4bf0-bfce-6ca2da09ea81	p.Trp149Cys	Trp	149	Cys	MDRGTLPLAVALLLASCSLSPTSLAETVHCDLQPVGPERGEVTYTTSQVSKGCVAQAPNAILEVHVLFLEFPTGPSQLELTLQASKQNGTWPREVLLVLSVNSSVFLHLQALGIPLHLAYNSSLVTFQEPPGVNTTELPSFPKTQILEWAAERGPITSAAELNDPQSILLRLGQAQGSLSFCMLEASQDMGRTLEWRPRTPALVRGCHLEGVAGHKEAHILRVLPGHSAGPRTVTVKVELSCAPGDLDAVLILQGPPYVSWLIDANHNMQIWTTGEYSFKIFPEKNIRGFKLPDTPQGLLGEARMLNASIVASFVELPLASIVSLHASSCGGRLQTSPAPIQTTPPKDTCSPELLMSLIQTKCADDAMTLVLKKELVAHLKCTITGLTFWDPSCEAEDRGDKFVLRSAYSSCGMQVSASMISNEAVVNILSSSSPQRKKVHCLNMDSLSFQLGLYLSPHFLQASNTIEPGQQSFVQVRVSPSVSEFLLQLDSCHLDLGPEGGTVELIQGRAAKGNCVSLLSPSPEGDPRFSFLLHFYTVPIPKTGTLSCTVALRPKTGSQDQEVHRTVFMRLNIISPDLSGCTSKGLVLPAVLGITFGAFLIGALLTAALWYIYSHTRSPSKREPVVAVAAPASSESSSTNHSIGSTQSTPCSTSSMA	658	P17813	C	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [148], 'DISULFID_gain_score': array([0.51446217]), 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [48, 104, 106, 147, 172, 257, 276, 280, 395, 448], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.04121548, -0.04093248, -0.09505022, -0.03374249, -0.10572577,
       -0.0176217 , -0.01531661, -0.03681546, -0.0366562 , -0.03653038]), 'HELIX_loss': [], 'HELIX_gain': [353], 'HELIX_gain_score': array([0.00085324]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [350, 558], 'DOMAIN_gain_score': array([0.04490161, 0.03046679]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
727	NM_000162.5(GCK):c.449T>C (p.Phe150Ser)	36218	CA213784	NM_000162.5:c.449T>C, NC_000007.14:g.44150990A>G, CM000669.2:g.44150990A>G, NC_000007.13:g.44190589A>G, CM000669.1:g.44190589A>G, NC_000007.12:g.44157114A>G, NG_008847.1:g.43434T>C, NG_008847.2:g.52181T>C, ENST00000395796.8:c.*447T>C, ENST00000616242.5:c.449T>C, ENST00000682635.1:n.935T>C, ENST00000345378.7:c.452T>C, ENST00000403799.8:c.449T>C, ENST00000671824.1:c.449T>C, ENST00000673284.1:c.449T>C, ENST00000345378.6:c.452T>C, ENST00000395796.7:c.446T>C, ENST00000403799.7:c.449T>C, ENST00000437084.1:c.398T>C, ENST00000616242.4:c.446T>C, NM_000162.3:c.449T>C, NM_033507.1:c.452T>C, NM_033508.1:c.446T>C, NM_000162.4:c.449T>C, NM_001354800.1:c.449T>C, NM_033507.2:c.452T>C, NM_033508.2:c.446T>C, NM_033507.3:c.452T>C, NM_033508.3:c.446T>C, NM_000162.5(GCK):c.449T>C (p.Phe150Ser)	GCK	monogenic diabetes	MONDO:0015967	Semidominant inheritance	Pathogenic	PS4, PP1_Strong, PP2, PP3, PM5, PM2_Supporting		The c.449T>C variant in the glucokinase gene, GCK, causes an amino acid change of phenylalanine to serine at codon 150 (p.(Phe150Ser)) of NM_000162.5. GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2).  This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.983, which is greater than the MDEP VCEP threshold of 0.70 (PP3). This variant has a gnomAD v4.0.0  Popmax filtering allele frequency of 0 (below the MDEP threshold of 0.000003), and ≤ 2 copies observed in the European non-Finnish population and any other subpopulation, thereby meeting the ClinGen MDEP criteria for PM2_Supporting (PM2_Supporting). This variant was identified in at least 28 unrelated individuals with hyperglycemia (PS4; PMIDs: 15305805, 30191644, internal lab contributors). This variant segregated with hyperglycemia, with at least 19 informative meioses in multiple families (PP1_Strong; internal lab contributors). Another missense variant, c.449T>A p.Phe150Tyr has been interpreted as pathogenic by the ClinGen MDEP, and p.Phe150Ser has a greater Grantham distance (PM5).  In summary, c.449T>C meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.3.0 approved 8/11/2023): PS4, PP1_Strong, PM2_Supporting, PP3, PP2, PM5.		Monogenic Diabetes VCEP		2024-03-22	2024-03-22	False	https://erepo.genome.network/evrepo/ui/classification/CA213784/MONDO:0015967/086	2f1f3c66-5829-44e1-a27b-080c80bfdb5f	p.Phe150Ser	Phe	150	Ser	MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQ	465	P35557	S	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [408], 'BINDING_gain': [], 'BINDING_loss_score': array([-0.02677077]), 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [196, 203, 236], 'STRAND_gain': [227], 'STRAND_gain_score': array([0.03334045]), 'STRAND_loss_score': array([-0.0408901 , -0.03073335, -0.0523926 ]), 'HELIX_loss': [], 'HELIX_gain': [156, 157, 158], 'HELIX_gain_score': array([0.23140997, 0.22302312, 0.12580669]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [83, 150, 221, 224, 225, 229, 230], 'DOMAIN_gain_score': array([0.00882554, 0.1020999 , 0.12505507, 0.10495472, 0.05847323,
       0.12730622, 0.06028688]), 'REGION_loss': [], 'REGION_gain': [6, 7, 11, 13, 21, 22, 27, 31, 38, 42, 43, 71, 75, 80, 81, 84, 86], 'REGION_gain_score': array([0.01245576, 0.01136702, 0.01231074, 0.01139265, 0.013201  ,
       0.01916319, 0.01560843, 0.01631814, 0.01410878, 0.02004331,
       0.0234409 , 0.05276388, 0.06807321, 0.06223065, 0.05841911,
       0.06699771, 0.02921575]), 'REPEAT_loss': [], 'REPEAT_gain': [75], 'REPEAT_gain_score': array([0.02684504]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
728	NM_000152.5(GAA):c.2105G>A (p.Arg702His)	426278	CA8815610	NM_000152.5:c.2105G>A, NC_000017.11:g.80113282G>A, CM000679.2:g.80113282G>A, NC_000017.10:g.78087081G>A, CM000679.1:g.78087081G>A, NC_000017.9:g.75701676G>A, NG_009822.1:g.16727G>A, LRG_673:g.16727G>A, ENST00000570803.6:c.2105G>A, ENST00000572080.2:c.*243G>A, ENST00000577106.6:c.2105G>A, ENST00000302262.8:c.2105G>A, ENST00000302262.7:c.2105G>A, ENST00000390015.7:c.2105G>A, ENST00000572080.1:c.524G>A, NM_000152.3:c.2105G>A, LRG_673t1:c.2105G>A, NM_001079803.1:c.2105G>A, NM_001079804.1:c.2105G>A, XM_005257193.1:c.2105G>A, XM_005257194.3:c.2105G>A, NM_000152.4:c.2105G>A, NM_001079803.2:c.2105G>A, NM_001079804.2:c.2105G>A, XM_005257193.2:c.2105G>A, XM_005257194.4:c.2105G>A, NM_001079803.3:c.2105G>A, NM_001079804.3:c.2105G>A, NM_000152.5(GAA):c.2105G>A (p.Arg702His)	GAA	glycogen storage disease II	MONDO:0009290	Autosomal recessive inheritance	Pathogenic	PM3_Strong, PS3_Supporting, PP4_Moderate, PP3, PM2_Supporting, PM5		The NM_000152.5:c.2105G>A variant in GAA is a missense variant predicted to cause substitution of arginine by histidine at amino acid 702 (p.Arg702His). At least 3 unrelated patients were noted to have deficient GAA activity but results were not provided (PMID: 26310554, 30897595, 28394184). Two patients are described as having IOPD with clinical symptoms consistent with IOPD reported in one (PMID: 26310554). One patient is described as having juvenile-onset Pompe disease with deficient GAA (value not provided) (PMID: 18211760). Another patient is reported to have deficient GAA and late-onset Pompe disease (PMID: 30897595) (PP4_Moderate). At least one patient is described as having this variant in trans with a variant classified as likely pathogenic by the ClinGen Lysosomal Diseases (LD) VCEP (c.796C>T, p.Pro266Ser; ClinVar Variation ID Variation ID: 556117; SCV002540664.1) (PMID: 18211760). At least two patients have been reported with this variant in compound heterozygosity with another variant that has been classified as pathogenic by the ClinGen LD VCEP (c.2297A>C, p.Tyr766Ser, ClinVar Variation ID: Variation ID: 420102, SCV002540647.1, and c.2238G>C, p.Trp746Cys, ClinVar Variation ID: Variation ID: 265160, SCV002032122.1), phase unconfirmed for both (PMID: 28394184 and 30897595) (PM3_Strong). This variant is absent in gnomAD v2.1.1. (PM2_Supporting). The computational predictor REVEL gives a score of 0.985, which is above the threshold of 0.7, evidence that correlates with impact to GAA function (PP3). Expression of the variant in COS-7 cells resulted in 5% wild type GAA activity in medium and 13% residual activity in cells with evidence of abnormal synthesizing and processing (PMID: 18425781) leading the variant to be described as Class D “potentially mild” indicating that this variant may impact protein function (PS3_supporting). Another missense variant (c.2105G>T, p.Arg702Leu) in the same codon has been classified as pathogenic for Pompe disease by the ClinGen LD VCEP (ClinVar Variation ID: Variation ID: 92472)(PM5). There is a ClinVar entry for this variant (Variation ID: 426278). In summary, this variant meets the criteria to be classified as pathogenic for Pompe disease based on the GAA-specific ACMG/AMP criteria applied, as specified by the ClinGen Lysosomal Diseases Variant Curation Expert Panel (Specifications Version 2.0): PM3_strong, PM5, PP4_moderate, PM2_supporting, PP3, PS3_supporting.		Lysosomal Diseases VCEP	https://clinicalgenome.org/docs/clingen-lysosomal-storage-disorders-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-2/	2024-03-05	2024-03-26	False	https://erepo.genome.network/evrepo/ui/classification/CA8815610/MONDO:0009290/010	15c8deda-d3b2-4e03-a4c6-3c97f3b96012	p.Arg702His	Arg	702	His	MGVRHPPCSHRLLAVCALVSLATAALLGHILLHDFLLVPRELSGSSPVLEETHPAHQQGASRPGPRDAQAHPGRPRAVPTQCDVPPNSRFDCAPDKAITQEQCEARGCCYIPAKQGLQGAQMGQPWCFFPPSYPSYKLENLSSSEMGYTATLTRTTPTFFPKDILTLRLDVMMETENRLHFTIKDPANRRYEVPLETPHVHSRAPSPLYSVEFSEEPFGVIVRRQLDGRVLLNTTVAPLFFADQFLQLSTSLPSQYITGLAEHLSPLMLSTSWTRITLWNRDLAPTPGANLYGSHPFYLALEDGGSAHGVFLLNSNAMDVVLQPSPALSWRSTGGILDVYIFLGPEPKSVVQQYLDVVGYPFMPPYWGLGFHLCRWGYSSTAITRQVVENMTRAHFPLDVQWNDLDYMDSRRDFTFNKDGFRDFPAMVQELHQGGRRYMMIVDPAISSSGPAGSYRPYDEGLRRGVFITNETGQPLIGKVWPGSTAFPDFTNPTALAWWEDMVAEFHDQVPFDGMWIDMNEPSNFIRGSEDGCPNNELENPPYVPGVVGGTLQAATICASSHQFLSTHYNLHNLYGLTEAIASHRALVKARGTRPFVISRSTFAGHGRYAGHWTGDVWSSWEQLASSVPEILQFNLLGVPLVGADVCGFLGNTSEELCVRWTQLGAFYPFMRNHNSLLSLPQEPYSFSEPAQQAMRKALTLRYALLPHLYTLFHQAHVAGETVARPLFLEFPKDSSTWTVDHQLLWGEALLITPVLQAGKAEVTGYFPLGTWYDLQTVPVEALGSLPPPPAAPREPAIHSEGQWVTLPAPLDTINVHLRAGYIIPLQGPGLTTTESRQQPMALAVALTKGGEARGELFWDDGESLEVLERGAYTQVIFLARNNTIVNELVRVTSEGAGLQLQKVTVLGVATAPQQVLSNGVPVSNFTYSPDTKVLDICVSLLMGEQFLVSWC	952	P10253	H	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [659, 663, 714, 716], 'DNA_BIND_gain': [701, 705, 707], 'DNA_BIND_gain_score': array([0.02600473, 0.01976508, 0.01361966]), 'DNA_BIND_loss_score': array([-0.0111928 , -0.00817072, -0.04192311, -0.00769103]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [872], 'STRAND_gain_score': array([0.01074404]), 'HELIX_loss': [], 'HELIX_gain': [729], 'HELIX_gain_score': array([0.05110162]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [386, 710], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.00060821, -0.00386363]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
729	NM_000152.5(GAA):c.2105G>T (p.Arg702Leu)	92472	CA220396	NM_000152.5:c.2105G>T, NC_000017.11:g.80113282G>T, CM000679.2:g.80113282G>T, NC_000017.10:g.78087081G>T, CM000679.1:g.78087081G>T, NC_000017.9:g.75701676G>T, NG_009822.1:g.16727G>T, LRG_673:g.16727G>T, ENST00000570803.6:c.2105G>T, ENST00000572080.2:c.*243G>T, ENST00000577106.6:c.2105G>T, ENST00000302262.8:c.2105G>T, ENST00000302262.7:c.2105G>T, ENST00000390015.7:c.2105G>T, ENST00000572080.1:c.524G>T, NM_000152.3:c.2105G>T, LRG_673t1:c.2105G>T, NM_001079803.1:c.2105G>T, NM_001079804.1:c.2105G>T, XM_005257193.1:c.2105G>T, XM_005257194.3:c.2105G>T, NM_000152.4:c.2105G>T, NM_001079803.2:c.2105G>T, NM_001079804.2:c.2105G>T, XM_005257193.2:c.2105G>T, XM_005257194.4:c.2105G>T, NM_001079803.3:c.2105G>T, NM_001079804.3:c.2105G>T, NM_000152.5(GAA):c.2105G>T (p.Arg702Leu)	GAA	glycogen storage disease II	MONDO:0009290	Autosomal recessive inheritance	Pathogenic	PM3_Strong, PP4_Moderate, PP3, PS3_Moderate, PM2_Supporting		The NM_000152.5:c.2105G>T variant in GAA is a missense variant predicted tocause substitution of arginine by leucine at amino acid 702 (p.Arg702Leu). It has been reported in at least two unrelated patients with infantile-onset Pompe disease with documented GAA deficiency and receiving enzyme replacement therapy, and in one patient identified via newborn screening with deficient confirmatory enzyme in blood and clinical symptoms (Clinical diagnostic laboratory) described has having late-onset Pompe disease, meeting criteria for PP4_moderate (PMID: 26497565, 27344650, 26167453).  Of those individuals, a a proband and full sibling were compound heterozygous for the variant and variant that has been classified as pathogenic by the ClinGen LD VCEP, c.2512C>T (p.Gln838Ter) (ClinVar Variation ID: Variation ID: 92479, SCV001371718.1), confirmed in trans by parental testing (PMID: 26167453) (1 point). Another patient was compound heterozygous for the variant and variant classified as pathogenic by the ClinGen LD VCEP,  c.1798C>T (p.Arg600Cys) (Variation ID: 640911; SCV002032136.1), phase unknown (PMID: 26497565, 27344650). The variant has also been reported in trans with a pathogenic variant (c.-32-13T>G; ClinVar Variation ID: 4027) in one individual identified on newborn screening with deficient confirmatory GAA and clinical symptoms with deficient confirmatory GAA in DBS (Clinical diagnostic laboratory) (PM3_Strong).It has also been reported in one individual with a positive newborn screen for Pompe disease and deficient confirmatory GAA activity, but no reported phenotype (PMID: 33202836). It is absent from large population databases (gnomAD v2.1.1.) meeting PM2_Supporting. Expression of the variant in COS-7 and HEK293T cells resulted in 0.4% GAA activity in cells and 1.3% in medium and evidence of abnormal GAA synthesis and processing – leading the variant to be classified as Class B (“potentially less severe”), indicating that this variant may impact protein function (PMID:22644586), meeting PS3_moderate. The computational predictor REVEL gives a score of 0.972 which is above the threshold of 0.7, evidence that correlates with impact to GAA function (PP3). There is a ClinVar entry for this variant (Variation ID: 92472). In summary, this variant meets the criteria to be classified as pathogenic for Pompe disease based on the GAA-specific ACMG/AMP criteria applied, as specified by the ClinGen Lysosomal Diseases Variant Curation Expert panel (Specifications Version 2.0): (PM3_strong, PP4_moderate, PS3_moderate, PM2_supporting, PP3).(Classification approved by the ClinGen Lysosomal Diseases Variant Curation Expert Panel on March 5, 2024).		Lysosomal Diseases VCEP	https://clinicalgenome.org/docs/clingen-lysosomal-storage-disorders-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-2/	2024-03-05	2024-03-26	False	https://erepo.genome.network/evrepo/ui/classification/CA220396/MONDO:0009290/010	3e7bd67d-b563-4ca2-a3cb-daf3018e5942	p.Arg702Leu	Arg	702	Leu	MGVRHPPCSHRLLAVCALVSLATAALLGHILLHDFLLVPRELSGSSPVLEETHPAHQQGASRPGPRDAQAHPGRPRAVPTQCDVPPNSRFDCAPDKAITQEQCEARGCCYIPAKQGLQGAQMGQPWCFFPPSYPSYKLENLSSSEMGYTATLTRTTPTFFPKDILTLRLDVMMETENRLHFTIKDPANRRYEVPLETPHVHSRAPSPLYSVEFSEEPFGVIVRRQLDGRVLLNTTVAPLFFADQFLQLSTSLPSQYITGLAEHLSPLMLSTSWTRITLWNRDLAPTPGANLYGSHPFYLALEDGGSAHGVFLLNSNAMDVVLQPSPALSWRSTGGILDVYIFLGPEPKSVVQQYLDVVGYPFMPPYWGLGFHLCRWGYSSTAITRQVVENMTRAHFPLDVQWNDLDYMDSRRDFTFNKDGFRDFPAMVQELHQGGRRYMMIVDPAISSSGPAGSYRPYDEGLRRGVFITNETGQPLIGKVWPGSTAFPDFTNPTALAWWEDMVAEFHDQVPFDGMWIDMNEPSNFIRGSEDGCPNNELENPPYVPGVVGGTLQAATICASSHQFLSTHYNLHNLYGLTEAIASHRALVKARGTRPFVISRSTFAGHGRYAGHWTGDVWSSWEQLASSVPEILQFNLLGVPLVGADVCGFLGNTSEELCVRWTQLGAFYPFMRNHNSLLSLPQEPYSFSEPAQQAMRKALTLRYALLPHLYTLFHQAHVAGETVARPLFLEFPKDSSTWTVDHQLLWGEALLITPVLQAGKAEVTGYFPLGTWYDLQTVPVEALGSLPPPPAAPREPAIHSEGQWVTLPAPLDTINVHLRAGYIIPLQGPGLTTTESRQQPMALAVALTKGGEARGELFWDDGESLEVLERGAYTQVIFLARNNTIVNELVRVTSEGAGLQLQKVTVLGVATAPQQVLSNGVPVSNFTYSPDTKVLDICVSLLMGEQFLVSWC	952	P10253	L	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [599], 'BINDING_gain': [], 'BINDING_loss_score': array([-0.03778255]), 'DNA_BIND_loss': [420, 424, 507, 508, 584, 588, 659, 663, 714, 716], 'DNA_BIND_gain': [707], 'DNA_BIND_gain_score': array([0.02227348]), 'DNA_BIND_loss_score': array([-0.00260746, -0.00274521, -0.00854504, -0.00770169, -0.01328355,
       -0.01759893, -0.0165363 , -0.00371444, -0.08251184, -0.03047675]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [722, 723], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.17228276, -0.20255625]), 'HELIX_loss': [], 'HELIX_gain': [729], 'HELIX_gain_score': array([0.07722491]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [386, 505, 623, 710, 711], 'REPEAT_gain': [670], 'REPEAT_gain_score': array([0.01607162]), 'REPEAT_loss_score': array([-0.00320333, -0.00297236, -0.00583684, -0.02799183, -0.02539098]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
730	NM_000152.5(GAA):c.2668G>C (p.Val890Leu)	255361	CA8815831	NM_000152.5:c.2668G>C, NC_000017.11:g.80118674G>C, CM000679.2:g.80118674G>C, NC_000017.10:g.78092473G>C, CM000679.1:g.78092473G>C, NC_000017.9:g.75707068G>C, NG_009822.1:g.22119G>C, LRG_673:g.22119G>C, ENST00000570803.6:c.2668G>C, ENST00000572080.2:c.*806G>C, ENST00000577106.6:c.2668G>C, ENST00000302262.8:c.2668G>C, ENST00000302262.7:c.2668G>C, ENST00000390015.7:c.2668G>C, ENST00000573556.1:n.621G>C, NM_000152.3:c.2668G>C, LRG_673t1:c.2668G>C, NM_001079803.1:c.2668G>C, NM_001079804.1:c.2668G>C, XM_005257193.1:c.2668G>C, XM_005257194.3:c.2668G>C, NM_000152.4:c.2668G>C, NM_001079803.2:c.2668G>C, NM_001079804.2:c.2668G>C, XM_005257193.2:c.2668G>C, XM_005257194.4:c.2668G>C, NM_001079803.3:c.2668G>C, NM_001079804.3:c.2668G>C, NM_000152.5(GAA):c.2668G>C (p.Val890Leu)	GAA	glycogen storage disease II	MONDO:0009290	Autosomal recessive inheritance	Benign	BA1		The NM_000152.5:c.2668G>C variant in GAA is predicted to result in the missense substitution of valine by leucine at amino acid position 890. The highest population minor allele frequency in gnomAD v2.1.1 is 0.02652 (812/30616 alleles with 13 homozygotes) in the South Asian population, which is higher than the ClinGen LSD VCEP’s threshold for BA1 (>0.01), and therefore meets this criterion (BA1). There is a ClinVar entry for this variant (Variation ID: 255361). In summary, this variant meets the criteria to be classified as benign for Pompe disease. GAA-specific ACMG/AMP criteria met, as specified by the ClinGen Lysosomal Diseases VCEP (Specifications Version 2.0): BA1.(Classified approved by the ClinGen Lysosomal Diseases Variant Curation Expert Panel on October 1, 2023).		Lysosomal Diseases VCEP	https://clinicalgenome.org/docs/clingen-lysosomal-storage-disorders-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-2/	2023-10-01	2024-03-26	False	https://erepo.genome.network/evrepo/ui/classification/CA8815831/MONDO:0009290/010	0fe52acc-430a-4aaf-9a32-84fe84fbaa02	p.Val890Leu	Val	890	Leu	MGVRHPPCSHRLLAVCALVSLATAALLGHILLHDFLLVPRELSGSSPVLEETHPAHQQGASRPGPRDAQAHPGRPRAVPTQCDVPPNSRFDCAPDKAITQEQCEARGCCYIPAKQGLQGAQMGQPWCFFPPSYPSYKLENLSSSEMGYTATLTRTTPTFFPKDILTLRLDVMMETENRLHFTIKDPANRRYEVPLETPHVHSRAPSPLYSVEFSEEPFGVIVRRQLDGRVLLNTTVAPLFFADQFLQLSTSLPSQYITGLAEHLSPLMLSTSWTRITLWNRDLAPTPGANLYGSHPFYLALEDGGSAHGVFLLNSNAMDVVLQPSPALSWRSTGGILDVYIFLGPEPKSVVQQYLDVVGYPFMPPYWGLGFHLCRWGYSSTAITRQVVENMTRAHFPLDVQWNDLDYMDSRRDFTFNKDGFRDFPAMVQELHQGGRRYMMIVDPAISSSGPAGSYRPYDEGLRRGVFITNETGQPLIGKVWPGSTAFPDFTNPTALAWWEDMVAEFHDQVPFDGMWIDMNEPSNFIRGSEDGCPNNELENPPYVPGVVGGTLQAATICASSHQFLSTHYNLHNLYGLTEAIASHRALVKARGTRPFVISRSTFAGHGRYAGHWTGDVWSSWEQLASSVPEILQFNLLGVPLVGADVCGFLGNTSEELCVRWTQLGAFYPFMRNHNSLLSLPQEPYSFSEPAQQAMRKALTLRYALLPHLYTLFHQAHVAGETVARPLFLEFPKDSSTWTVDHQLLWGEALLITPVLQAGKAEVTGYFPLGTWYDLQTVPVEALGSLPPPPAAPREPAIHSEGQWVTLPAPLDTINVHLRAGYIIPLQGPGLTTTESRQQPMALAVALTKGGEARGELFWDDGESLEVLERGAYTQVIFLARNNTIVNELVRVTSEGAGLQLQKVTVLGVATAPQQVLSNGVPVSNFTYSPDTKVLDICVSLLMGEQFLVSWC	952	P10253	L	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [704, 716], 'DNA_BIND_gain': [], 'DNA_BIND_loss_score': array([-0.00078028, -0.00189507]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [893], 'STRAND_gain_score': array([0.0253942]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [386], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.00090742]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
731	NM_000152.5(GAA):c.1564C>G (p.Pro522Ala)	371277	CA16041893	NM_000152.5:c.1564C>G, NC_000017.11:g.80110953C>G, CM000679.2:g.80110953C>G, NC_000017.10:g.78084752C>G, CM000679.1:g.78084752C>G, NC_000017.9:g.75699347C>G, NG_009822.1:g.14398C>G, LRG_673:g.14398C>G, ENST00000570803.6:c.1564C>G, ENST00000572080.2:c.1564C>G, ENST00000577106.6:c.1564C>G, ENST00000302262.8:c.1564C>G, ENST00000302262.7:c.1564C>G, ENST00000390015.7:c.1564C>G, NM_000152.3:c.1564C>G, LRG_673t1:c.1564C>G, NM_001079803.1:c.1564C>G, NM_001079804.1:c.1564C>G, XM_005257193.1:c.1564C>G, XM_005257194.3:c.1564C>G, NM_000152.4:c.1564C>G, NM_001079803.2:c.1564C>G, NM_001079804.2:c.1564C>G, XM_005257193.2:c.1564C>G, XM_005257194.4:c.1564C>G, NM_001079803.3:c.1564C>G, NM_001079804.3:c.1564C>G, NM_000152.5(GAA):c.1564C>G (p.Pro522Ala)	GAA	glycogen storage disease II	MONDO:0009290	Autosomal recessive inheritance	Pathogenic	PM3_Strong, PM5_Supporting, PS3_Supporting, PP4_Moderate, PP3, PM2_Supporting		The NM_000152.5:c.1564C>G variant in GAA is a missense variant predicted to cause substitution of proline by alanine at amino acid 522 (p.Pro522Ala). This variant has been detected in at least 7 unrelated patients reported to have Pompe disease including four individuals with reported laboratory values demonstrating deficient GAA activity (PMID: 26800218, 33301762, 34072668, Duke University), and three for whom GAA activity was not reported (PMID: 18429042, 37087815) (PP4_Moderate). Of those individuals, 6 were compound heterozygous for the variant and a variant classified as pathogenic by the ClinGen LD VCEP: c.784G>A (p.Glu262Lys) (ClinVar Variation ID: 188806, SCV002032128.1) (PMID: 18429042), c.1933G>A (p.Asp645Asn) (ClinVar Variation ID: 188728, SCV001371736.1) (PMID: 18429042), c.1465G>A (p.Asp489Asn) (ClinVar Variation ID: 92465, SCV003852732.1) (PMID: 34072668), and c.-32-13T>G (ClinVar Variation ID: 4027) (PMID: 26800218, 37087815, Clinical Diagnostic Laboratory; at least 3 unrelated patients). The phase is not confirmed for any of these individuals. One individual was homozygous for this variant (PMID: 33301762) (PM3_Strong). Another missense variant, c.1564C>T, p.Pro522Ser (ClinVar Variation ID: 972746) in the same codon has been classified as likely pathogenic for Pompe disease by the ClinGen Lysosomal Diseases VCEP (PM5_Supporting). This variant is absent in gnomAD v2.1.1 (PM2_Supporting). Expression of the variant in Ad5-SV40 immortalized human GAA-deficient fibroblast cell line resulted in 0% wild type GAA activity when measured using fluorogenic substrate 4-methylumbelliferyl-α-D glucopyranoside. This was further supported via Western blot analysis demonstrating deficient GAA protein expression (PMID: 18429042) (PS3_Supporting). The computational predictor REVEL gives a score of 0.883 which is above the threshold predicting a damaging (>0.7) impact on GAA function. There is a ClinVar entry for this variant (Variation ID: 371277). In summary, this variant meets the criteria to be classified as Pathogenic for Pompe disease. GAA-specific ACMG/AMP criteria met, based on the specifications of the ClinGen Lysosomal Diseases VCEP (Specifications Version 2.0): PM3_Strong, PP4_Moderate, PM2_Supporting, PM5_Supporting PS3_Supporting.(Classification approved by the ClinGen Lysosomal Diseases Variant Curation Expert Panel on March 19, 2024).		Lysosomal Diseases VCEP	https://clinicalgenome.org/docs/clingen-lysosomal-storage-disorders-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-2/	2024-03-19	2024-03-26	False	https://erepo.genome.network/evrepo/ui/classification/CA16041893/MONDO:0009290/010	14e28913-369c-46e3-8235-50bb31d98411	p.Pro522Ala	Pro	522	Ala	MGVRHPPCSHRLLAVCALVSLATAALLGHILLHDFLLVPRELSGSSPVLEETHPAHQQGASRPGPRDAQAHPGRPRAVPTQCDVPPNSRFDCAPDKAITQEQCEARGCCYIPAKQGLQGAQMGQPWCFFPPSYPSYKLENLSSSEMGYTATLTRTTPTFFPKDILTLRLDVMMETENRLHFTIKDPANRRYEVPLETPHVHSRAPSPLYSVEFSEEPFGVIVRRQLDGRVLLNTTVAPLFFADQFLQLSTSLPSQYITGLAEHLSPLMLSTSWTRITLWNRDLAPTPGANLYGSHPFYLALEDGGSAHGVFLLNSNAMDVVLQPSPALSWRSTGGILDVYIFLGPEPKSVVQQYLDVVGYPFMPPYWGLGFHLCRWGYSSTAITRQVVENMTRAHFPLDVQWNDLDYMDSRRDFTFNKDGFRDFPAMVQELHQGGRRYMMIVDPAISSSGPAGSYRPYDEGLRRGVFITNETGQPLIGKVWPGSTAFPDFTNPTALAWWEDMVAEFHDQVPFDGMWIDMNEPSNFIRGSEDGCPNNELENPPYVPGVVGGTLQAATICASSHQFLSTHYNLHNLYGLTEAIASHRALVKARGTRPFVISRSTFAGHGRYAGHWTGDVWSSWEQLASSVPEILQFNLLGVPLVGADVCGFLGNTSEELCVRWTQLGAFYPFMRNHNSLLSLPQEPYSFSEPAQQAMRKALTLRYALLPHLYTLFHQAHVAGETVARPLFLEFPKDSSTWTVDHQLLWGEALLITPVLQAGKAEVTGYFPLGTWYDLQTVPVEALGSLPPPPAAPREPAIHSEGQWVTLPAPLDTINVHLRAGYIIPLQGPGLTTTESRQQPMALAVALTKGGEARGELFWDDGESLEVLERGAYTQVIFLARNNTIVNELVRVTSEGAGLQLQKVTVLGVATAPQQVLSNGVPVSNFTYSPDTKVLDICVSLLMGEQFLVSWC	952	P10253	A	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [663], 'DNA_BIND_gain': [518, 601, 608, 611, 707], 'DNA_BIND_gain_score': array([0.01657087, 0.00566512, 0.00334132, 0.00288194, 0.00207359]), 'DNA_BIND_loss_score': array([-0.00789434]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [468], 'STRAND_gain': [913], 'STRAND_gain_score': array([0.00289756]), 'STRAND_loss_score': array([-0.01587135]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [666], 'REPEAT_gain': [494, 579, 624, 643], 'REPEAT_gain_score': array([0.01238972, 0.00832015, 0.00976366, 0.00353694]), 'REPEAT_loss_score': array([-0.00560445]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
732	NM_004360.5(CDH1):c.2336G>A (p.Arg779Gln)	140840	CA293940	NM_004360.5:c.2336G>A, NC_000016.10:g.68829694G>A, CM000678.2:g.68829694G>A, NC_000016.9:g.68863597G>A, CM000678.1:g.68863597G>A, NC_000016.8:g.67421098G>A, NG_008021.1:g.97403G>A, LRG_301:g.97403G>A, ENST00000261769.10:c.2336G>A, ENST00000261769.9:c.2336G>A, ENST00000422392.6:c.2153G>A, ENST00000562118.1:n.554G>A, ENST00000562836.5:n.2407G>A, ENST00000566510.5:c.*1002G>A, ENST00000566612.5:c.*576G>A, ENST00000611625.4:c.2399G>A, ENST00000612417.4:c.1853+3140G>A, ENST00000621016.4:c.1866-4509G>A, NM_004360.3:c.2336G>A, LRG_301t1:c.2336G>A, XM_011523488.1:c.1601G>A, XM_011523489.1:c.1601G>A, NM_001317184.1:c.2153G>A, NM_001317185.1:c.788G>A, NM_001317186.1:c.371G>A, NM_004360.4:c.2336G>A, NM_001317184.2:c.2153G>A, NM_001317185.2:c.788G>A, NM_001317186.2:c.371G>A, NM_004360.5(CDH1):c.2336G>A (p.Arg779Gln)	CDH1	hereditary diffuse gastric adenocarcinoma	MONDO:0007648	Autosomal dominant inheritance	Benign	BP2_Strong, BS2	PM2, BS1	The c.2336G>A (NM_004360.5) variant in CDH1 is a missense variant predicted to cause substitution of arginine by glutamine at amino acid 779 (p.Arg779Gln). This variant was observed in the homozygous state in an individual without a personal and/or family history of diffuse gastric cancer, lobular breast cancer (BP2_Strong; internal clinical data). This variant has been observed in more than 10 (134) individuals without a diagnosis of diffuse gastric cancer, signet ring tumor or lobular breast cancer and whose family histories do not suggest HDGC. (BS2; PMID: 29522266, 36436516; ClinVar SCVs: SCV000172951.7, SCV000288462.10, SCV000210875.16; internal lab contributors). In summary, this variant meets the criteria to be classified as benign for hereditary diffuse gastric cancer based on the ACMG/AMP criteria applied, as specified by the ClinGen CDH1 variant curation expert panel (Variant Interpretation Guidelines Version 3.1): BS2, BP2_S.		CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf	2024-03-25	2024-03-27	False	https://erepo.genome.network/evrepo/ui/classification/CA293940/MONDO:0007648/007	0339a717-77e2-4a43-8a0e-d945828d8cdb	p.Arg779Gln	Arg	779	Gln	MGPWSRSLSALLLLLQVSSWLCQEPEPCHPGFDAESYTFTVPRRHLERGRVLGRVNFEDCTGRQRTAYFSLDTRFKVGTDGVITVKRPLRFHNPQIHFLVYAWDSTYRKFSTKVTLNTVGHHHRPPPHQASVSGIQAELLTFPNSSPGLRRQKRDWVIPPISCPENEKGPFPKNLVQIKSNKDKEGKVFYSITGQGADTPPVGVFIIERETGWLKVTEPLDRERIATYTLFSHAVSSNGNAVEDPMEILITVTDQNDNKPEFTQEVFKGSVMEGALPGTSVMEVTATDADDDVNTYNAAIAYTILSQDPELPDKNMFTINRNTGVISVVTTGLDRESFPTYTLVVQAADLQGEGLSTTATAVITVTDTNDNPPIFNPTTYKGQVPENEANVVITTLKVTDADAPNTPAWEAVYTILNDDGGQFVVTTNPVNNDGILKTAKGLDFEAKQQYILHVAVTNVVPFEVSLTTSTATVTVDVLDVNEAPIFVPPEKRVEVSEDFGVGQEITSYTAQEPDTFMEQKITYRIWRDTANWLEINPDTGAISTRAELDREDFEHVKNSTYTALIIATDNGSPVATGTGTLLLILSDVNDNAPIPEPRTIFFCERNPKPQVINIIDADLPPNTSPFTAELTHGASANWTIQYNDPTQESIILKPKMALEVGDYKINLKLMDNQNKDQVTTLEVSVCDCEGAAGVCRKAQPVEAGLQIPAILGILGGILALLILILLLLLFLRRRAVVKEPLLPPEDDTRDNVYYYDEEGGGEEDQDFDLSQLHRGLDARPEVTRNDVAPTLMSVPRYLPRPANPDEIGNFIDENLKAADTDPTAPPYDSLLVFDYEGSGSEAASLSSLNSSESDKDQDYDYLNEWGNRFKKLADMYGGGEDD	882	P12830	Q	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [503], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.00113308]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
733	NM_005629.4(SLC6A8):c.1141G>C (p.Gly381Arg)	11697	CA256011	NM_005629.4:c.1141G>C, NC_000023.11:g.153693586G>C, CM000685.2:g.153693586G>C, NC_000023.10:g.152959041G>C, CM000685.1:g.152959041G>C, NC_000023.9:g.152612235G>C, NG_012016.1:g.10290G>C, NG_012016.2:g.10290G>C, ENST00000253122.10:c.1141G>C, ENST00000253122.9:c.1141G>C, ENST00000413787.1:c.257G>C, ENST00000430077.6:c.796G>C, ENST00000442457.1:c.195G>C, ENST00000457723.1:c.125G>C, ENST00000467402.1:n.240G>C, ENST00000485324.1:n.1174G>C, NM_001142805.1:c.1111G>C, NM_001142806.1:c.796G>C, NM_005629.3:c.1141G>C, NM_001142805.2:c.1111G>C, NM_005629.4(SLC6A8):c.1141G>C (p.Gly381Arg)	SLC6A8	creatine transporter deficiency	MONDO:0010305	X-linked inheritance	Pathogenic	PM2_Supporting, PP4_Strong, PP1_Strong, PP3, PS3_Supporting		The NM_005629.4:c.1141G>C variant in SLC6A8 is a missense variant that is predicted to lead to the substitution of a glycine for an arginine at amino acid 381 (p.Gly381Arg). This variant has been previously reported in one family with 5 affected males with elevated urinary creatine/creatinine and deficient creatine uptake in cultured fibroblasts (PP4_Strong) and segregated with disease in this family (PP1_Strong) (PMID: 11898126). This variant was reported to result in reduced (<10% of wild-type) creatine transport activity in SLC6A8 deficient fibroblasts (PMID: 22281021) (PS3_Supporting). In addition, the variant was shown to result in altered splicing via RT-PCR analysis (PMID: 11898126). The variant is absent in gnomAD v2.1.1. (PM2_Supporting). The computational predictor REVEL gives a score of 0.923 which is above the threshold of 0.75, evidence that correlates with impact to SLC6A8 function (PP3). There is a ClinVar entry for this variant (Variation ID 11697, zero-star review status), with one submitter classifying the variant as pathogenic.  In summary, this variant meets criteria to be classified as pathogenic for creatine transporter deficiency. SLC6A8-specific criteria applied, as specified by the ClinGen CCDS VCEP (Specifications Version 1.1.0): PS3_Supporting, PM2_Supporting, PP3, PP1_Strong, PP4_Strong.(Classification approved by the ClinGen Cerebral Creatine Deficiency Syndromes Variant Curation Expert Panel on March 28, 2024).		Cerebral Creatine Deficiency Syndromes VCEP		2024-03-28	2024-03-28	False	https://erepo.genome.network/evrepo/ui/classification/CA256011/MONDO:0010305/027	c1a4361d-9e35-418a-a3f0-64f450c5c95a	p.Gly381Arg	Gly	381	Arg	MAKKSAENGIYSVSGDEKKGPLIAPGPDGAPAKGDGPVGLGTPGGRLAVPPRETWTRQMDFIMSCVGFAVGLGNVWRFPYLCYKNGGGVFLIPYVLIALVGGIPIFFLEISLGQFMKAGSINVWNICPLFKGLGYASMVIVFYCNTYYIMVLAWGFYYLVKSFTTTLPWATCGHTWNTPDCVEIFRHEDCANASLANLTCDQLADRRSPVIEFWENKVLRLSGGLEVPGALNWEVTLCLLACWVLVYFCVWKGVKSTGKIVYFTATFPYVVLVVLLVRGVLLPGALDGIIYYLKPDWSKLGSPQVWIDAGTQIFFSYAIGLGALTALGSYNRFNNNCYKDAIILALINSGTSFFAGFVVFSILGFMAAEQGVHISKVAESGPGLAFIAYPRAVTLMPVAPLWAALFFFMLLLLGLDSQFVGVEGFITGLLDLLPASYYFRFQREISVALCCALCFVIDLSMVTDGGMYVFQLFDYYSASGTTLLWQAFWECVVVAWVYGADRFMDDIACMIGYRPCPWMKWCWSFFTPLVCMGIFIFNVVYYEPLVYNNTYVYPWWGEAMGWAFALSSMLCVPLHLLGCLLRAKGTMAERWQHLTQPIWGLHHLEYRAQDADVRGLTTLTPVSESSKVVVVESVM	635	P48029	R	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [312], 'DNA_BIND_gain_score': array([0.00310928]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [443, 548, 549], 'TOPO_DOM_gain_score': array([0.01218098, 0.01471204, 0.01781905]), 'TRANSMEM_loss': [392], 'TRANSMEM_gain': [419, 420, 421, 422, 424, 425, 426, 427, 428, 431, 432, 433], 'TRANSMEM_gain_score': array([0.19762444, 0.29331881, 0.25911617, 0.29995799, 0.32539105,
       0.29758978, 0.29945451, 0.27380472, 0.27252126, 0.20596159,
       0.19924206, 0.22584683]), 'TRANSMEM_loss_score': array([-0.03985488]), 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [437, 438], 'HELIX_gain': [378, 394, 463, 465], 'HELIX_gain_score': array([0.17395139, 0.10864317, 0.01896119, 0.05379862]), 'HELIX_loss_score': array([-0.13053906, -0.08984804]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [103, 154, 289, 311], 'DOMAIN_gain_score': array([0.01185304, 0.01955974, 0.01517063, 0.03358728]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
734	NM_000536.4(RAG2):c.685C>T (p.Arg229Trp)	496624	CA5950542	NM_000536.4:c.685C>T, NC_000011.10:g.36593484G>A, CM000673.2:g.36593484G>A, NC_000011.9:g.36615034G>A, CM000673.1:g.36615034G>A, NC_000011.8:g.36571610G>A, NG_007573.1:g.9753C>T, LRG_99:g.9753C>T, NG_033154.1:g.3992G>A, ENST00000527033.6:c.685C>T, ENST00000529083.2:c.685C>T, ENST00000532616.2:c.685C>T, ENST00000311485.8:c.685C>T, ENST00000311485.7:c.685C>T, ENST00000524423.1:n.131+4618C>T, ENST00000618712.4:c.685C>T, NM_000536.3:c.685C>T, NM_001243785.1:c.685C>T, NM_001243786.1:c.685C>T, NM_001243785.2:c.685C>T, NM_001243786.2:c.685C>T, NM_000536.4(RAG2):c.685C>T (p.Arg229Trp)	RAG2	recombinase activating gene 2 deficiency	MONDO:0000573	Autosomal recessive inheritance	Pathogenic	PM3_Strong, PM1_Supporting, PP1, PP4, PS3_Moderate, PM2_Supporting	PM5, BS2	The c.685C>T (NM_000536.4) variant in RAG2 is a missense variant predicted to cause the substitution of Arginine by Tryptophan at amino acid 229 (p.Arg229Trp).The filtering allele frequency (the upper threshold of the 95% CI of (11/1180024 alleles) is 0.000005000 in gnomad v4 for the European (non-Finnish) population, which is lower than the ClinGen SCID VCEP threshold (<0.0000588) for PM2_Supporting, meeting this criterion (PM2_Supporting). No homozygous has been described.This variant is located in the core domain, amino acids 1-383 of RAG2, which is defined as a critical functional domain by the ClinGen SCID VCEP (PMID: 26996199); PM1_Supporting.The recombination activity assay showed activity of this variant compared to wildtype RAG2 is 10.5% (SEM 0.5), which is lower than the SCID VCEP threshold (<25%) for PS3_Moderate, meeting this criterion (PS3_Moderate, PMID 29772310).The variant has been reported to segregate in two affected family members (Proband + 1) (PP1); (Proband 30a and 30b, PMID: 11133745).At least 9 probands were reported in the literature carrying this variant. 8 of them were homozygous, reaching the maximum of 1 point for homozygous occurrence. Also, 1 proband is compound heterozygous for paternal Arg229Trp and maternal Gly95Arg, which is likely pathogenic according to SCID VCEP specifications, as phase is confirmed; 1 point—a total of 2 points, PM3_Strong.Proband 24 presents: *Diagnostic criteria for SCID/Leaky SCID/Omenn syndrome met 0.5pts + *T-B-NK+ lymphocyte subset profile 0.5pts; total 1pt, PP4 is met (PMID: 11133745).In summary, this variant meets the criteria to be classified as Pathogenic for autosomal recessive recombinase activating gene 2 deficiency based on the ACMG/AMP criteria applied, as specified by the ClinGen SCID VCEP. Criteria applied: PM2_Supporting, PM1_Supporting, PS3_Moderate, PP1, PM3_Strong, and PP4 (VCEP specifications version 1.0).		Severe Combined Immunodeficiency Disease  VCEP		2024-04-01	2024-04-01	False	https://erepo.genome.network/evrepo/ui/classification/CA5950542/MONDO:0000573/124	425dc324-2478-4987-b039-5a6755df655e	p.Arg229Trp	Arg	229	Trp	MSLQMVTVSNNIALIQPGFSLMNFDGQVFFFGQKGWPKRSCPTGVFHLDVKHNHVKLKPTIFSKDSCYLPPLRYPATCTFKGSLESEKHQYIIHGGKTPNNEVSDKIYVMSIVCKNNKKVTFRCTEKDLVGDVPEARYGHSINVVYSRGKSMGVLFGGRSYMPSTHRTTEKWNSVADCLPCVFLVDFEFGCATSYILPELQDGLSFHVSIAKNDTIYILGGHSLANNIRPANLYRIRVDLPLGSPAVNCTVLPGGISVSSAILTQTNNDEFVIVGGYQLENQKRMICNIISLEDNKIEIREMETPDWTPDIKHSKIWFGSNMGNGTVFLGIPGDNKQVVSEGFYFYMLKCAEDDTNEEQTTFTNSQTSTEDPGDSTPFEDSEEFCFSAEANSFDGDDEFDTYNEDDEEDESETGYWITCCPTCDVDINTWVPFYSTELNKPAMIYCSHGDGHWVHAQCMDLAERTLIHLSAGSNKYYCNEHVEIARALHTPQRVLPLKKPPMKSLRKKGSGKILTPAKKSFLRRLFD	527	P55895	W	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [21], 'TOPO_DOM_gain_score': array([0.01711142]), 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [10], 'TRANSIT_gain': [], 'TRANSIT_loss_score': array([-0.00879312]), 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [54, 58, 63, 65, 140, 141, 143], 'REPEAT_gain_score': array([0.03308296, 0.03047645, 0.02782863, 0.03174084, 0.03918535,
       0.04053104, 0.01871246]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
735	NM_002185.5(IL7R):c.1043A>C (p.Asn348Thr)	134532	CA160111	NM_002185.5:c.1043A>C, NC_000005.10:g.35876149A>C, CM000667.2:g.35876149A>C, NC_000005.9:g.35876251A>C, CM000667.1:g.35876251A>C, NC_000005.8:g.35912008A>C, NG_009567.1:g.24261A>C, LRG_74:g.24261A>C, ENST00000303115.8:c.1043A>C, ENST00000303115.7:c.1043A>C, ENST00000505093.1:c.358A>C, ENST00000505875.1:n.341A>C, ENST00000514217.5:c.*237A>C, NM_002185.3:c.1043A>C, NR_120485.1:n.883A>C, XM_005248299.2:c.*160A>C, NM_002185.4:c.1043A>C, NR_120485.2:n.909A>C, XM_005248299.4:c.*160A>C, NR_120485.3:n.867A>C, NM_002185.5(IL7R):c.1043A>C (p.Asn348Thr)	IL7R	severe combined immunodeficiency, autosomal recessive, T cell-negative, B cell-positive, NK cell-positive	MONDO:0012163	Autosomal recessive inheritance	Benign	BA1, BS2_Supporting		The c.1043A>C (NM_002185.5) variant in IL7R is a missense variant predicted to cause substitution of Asparagine by Threonine at amino acid 348 (p.Asn348Thr).The filtering allele frequency (the lower threshold of the 95% CI of 20801/1179968 alleles) of the c.1043A>C variant in IL7R is 0.01743 for European (non-Finnish) chromosomes by gnomAD v4, which is higher than the ClinGen SCID VCEP threshold (>0.00566) for BA1, and therefore meets this criterion (BA1). Additionally, 215 adult homozygous occurrences are described in gnomAD (BS2_Supporting).In summary, this variant meets the criteria to be classified as Benign for autosomal recessive SCID based on the ACMG/AMP criteria applied, as specified by the ClinGen SCID VCEP: BA1 and BS2_Supporting. (VCEP specifications version 1)		Severe Combined Immunodeficiency Disease  VCEP		2024-04-03	2024-04-03	False	https://erepo.genome.network/evrepo/ui/classification/CA160111/MONDO:0012163/119	d6943a2d-65f3-453d-8466-d14040885cb4	p.Asn348Thr	Asn	348	Thr	MTILGTTFGMVFSLLQVVSGESGYAQNGDLEDAELDDYSFSCYSQLEVNGSQHSLTCAFEDPDVNITNLEFEICGALVEVKCLNFRKLQEIYFIETKKFLLIGKSNICVKVGEKSLTCKKIDLTTIVKPEAPFDLSVVYREGANDFVVTFNTSHLQKKYVKVLMHDVAYRQEKDENKWTHVNLSSTKLTLLQRKLQPAAMYEIKVRSIPDHYFKGFWSEWSPSYYFRTPEINNSSGEMDPILLTISILSFFSVALLVILACVLWKKRIKPIVWPSLPDHKKTLEHLCKKPRKNLNVSFNPESFLDCQIHRVDDIQARDEVEGFLQDTFPQQLEESEKQRLGGDVQSPNCPSEDVVITPESFGRDSSLTCLAGNVSACDAPILSSSRSLDCRESGKNGPHVYQDLLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQPILTSLGSNQEEAYVTMSSFYQNQ	459	P16871	T	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
736	NM_002185.5(IL7R):c.1066A>G (p.Ile356Val)	134533	CA160114	NM_002185.5:c.1066A>G, NC_000005.10:g.35876172A>G, CM000667.2:g.35876172A>G, NC_000005.9:g.35876274A>G, CM000667.1:g.35876274A>G, NC_000005.8:g.35912031A>G, NG_009567.1:g.24284A>G, LRG_74:g.24284A>G, ENST00000303115.8:c.1066A>G, ENST00000303115.7:c.1066A>G, ENST00000505093.1:c.381A>G, ENST00000505875.1:n.364A>G, ENST00000514217.5:c.*260A>G, NM_002185.3:c.1066A>G, NR_120485.1:n.906A>G, NM_002185.4:c.1066A>G, NR_120485.2:n.932A>G, XM_005248299.4:c.*183A>G, NR_120485.3:n.890A>G, NM_002185.5(IL7R):c.1066A>G (p.Ile356Val)	IL7R	severe combined immunodeficiency, autosomal recessive, T cell-negative, B cell-positive, NK cell-positive	MONDO:0012163	Autosomal recessive inheritance	Benign	BA1, BS2_Supporting		The c.1066A>G (NM_002185.5) variant in IL7R is a missense variant predicted to cause substitution of Isoleucine by Valine at amino acid 356 (p.Ile356Val).The filtering allele frequency (the lower threshold of the 95% CI of 25619/74900 alleles) of the c.1066A>G variant in IL7R is 0.3385 for African/African American chromosomes by gnomAD v4, which is higher than the ClinGen SCID VCEP threshold (>0.00566) for BA1, and therefore meets this criterion (BA1). Additionally, 55069 adult homozygous occurrences are described in gnomAD (BS2_Supporting).In summary, this variant meets the criteria to be classified as Benign for autosomal recessive SCID based on the ACMG/AMP criteria applied, as specified by the ClinGen SCID VCEP: BA1 and BS2_Supporting. (VCEP specifications version 1)		Severe Combined Immunodeficiency Disease  VCEP		2024-04-03	2024-04-03	False	https://erepo.genome.network/evrepo/ui/classification/CA160114/MONDO:0012163/119	3d11b85f-1934-4263-8542-1a44854f60d0	p.Ile356Val	Ile	356	Val	MTILGTTFGMVFSLLQVVSGESGYAQNGDLEDAELDDYSFSCYSQLEVNGSQHSLTCAFEDPDVNITNLEFEICGALVEVKCLNFRKLQEIYFIETKKFLLIGKSNICVKVGEKSLTCKKIDLTTIVKPEAPFDLSVVYREGANDFVVTFNTSHLQKKYVKVLMHDVAYRQEKDENKWTHVNLSSTKLTLLQRKLQPAAMYEIKVRSIPDHYFKGFWSEWSPSYYFRTPEINNSSGEMDPILLTISILSFFSVALLVILACVLWKKRIKPIVWPSLPDHKKTLEHLCKKPRKNLNVSFNPESFLDCQIHRVDDIQARDEVEGFLQDTFPQQLEESEKQRLGGDVQSPNCPSEDVVITPESFGRDSSLTCLAGNVSACDAPILSSSRSLDCRESGKNGPHVYQDLLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQPILTSLGSNQEEAYVTMSSFYQNQ	459	P16871	V	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
737	NM_002185.5(IL7R):c.1092T>G (p.Asp364Glu)	134538	CA160129	NM_002185.5:c.1092T>G, NC_000005.10:g.35876198T>G, CM000667.2:g.35876198T>G, NC_000005.9:g.35876300T>G, CM000667.1:g.35876300T>G, NC_000005.8:g.35912057T>G, NG_009567.1:g.24310T>G, LRG_74:g.24310T>G, ENST00000303115.8:c.1092T>G, ENST00000303115.7:c.1092T>G, ENST00000505093.1:c.407T>G, ENST00000505875.1:n.390T>G, ENST00000514217.5:c.*286T>G, NM_002185.3:c.1092T>G, NR_120485.1:n.932T>G, NM_002185.4:c.1092T>G, NR_120485.2:n.958T>G, XM_005248299.4:c.*209T>G, NR_120485.3:n.916T>G, NM_002185.5(IL7R):c.1092T>G (p.Asp364Glu)	IL7R	severe combined immunodeficiency, autosomal recessive, T cell-negative, B cell-positive, NK cell-positive	MONDO:0012163	Autosomal recessive inheritance	Benign	BA1, BS2_Supporting		The c.1092T>G (NM_002185.5) variant in IL7R is a missense variant predicted to cause the substitution of Aspartic Acid by Glutamic Acid at amino acid 364 (p.Asp364Glu).The filtering allele frequency (the lower threshold of the 95% CI of 1584/91068 alleles) of the c.1092T>G variant in IL7R is 0.01668 for South Asian chromosomes by gnomAD v4, which is higher than the ClinGen SCID VCEP threshold (>0.00566) for BA1, and therefore meets this criterion (BA1). Additionally, 35 adult homozygous occurrences are described in gnomAD (BS2_Supporting).In summary, this variant meets the criteria to be classified as Benign for autosomal recessive SCID based on the ACMG/AMP criteria applied, as specified by the ClinGen SCID VCEP: BA1 and BS2_Supporting. (VCEP specifications version 1)		Severe Combined Immunodeficiency Disease  VCEP		2024-04-03	2024-04-03	False	https://erepo.genome.network/evrepo/ui/classification/CA160129/MONDO:0012163/119	03413dd6-5c0a-4120-a288-5a615a7d1ab0	p.Asp364Glu	Asp	364	Glu	MTILGTTFGMVFSLLQVVSGESGYAQNGDLEDAELDDYSFSCYSQLEVNGSQHSLTCAFEDPDVNITNLEFEICGALVEVKCLNFRKLQEIYFIETKKFLLIGKSNICVKVGEKSLTCKKIDLTTIVKPEAPFDLSVVYREGANDFVVTFNTSHLQKKYVKVLMHDVAYRQEKDENKWTHVNLSSTKLTLLQRKLQPAAMYEIKVRSIPDHYFKGFWSEWSPSYYFRTPEINNSSGEMDPILLTISILSFFSVALLVILACVLWKKRIKPIVWPSLPDHKKTLEHLCKKPRKNLNVSFNPESFLDCQIHRVDDIQARDEVEGFLQDTFPQQLEESEKQRLGGDVQSPNCPSEDVVITPESFGRDSSLTCLAGNVSACDAPILSSSRSLDCRESGKNGPHVYQDLLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQPILTSLGSNQEEAYVTMSSFYQNQ	459	P16871	E	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
738	NM_000536.4(RAG2):c.878A>G (p.Glu293Gly)	256378	CA5950510	NM_000536.4:c.878A>G, NC_000011.10:g.36593291T>C, CM000673.2:g.36593291T>C, NC_000011.9:g.36614841T>C, CM000673.1:g.36614841T>C, NC_000011.8:g.36571417T>C, NG_007573.1:g.9946A>G, LRG_99:g.9946A>G, NG_033154.1:g.3799T>C, ENST00000527033.6:c.878A>G, ENST00000529083.2:c.878A>G, ENST00000532616.2:c.878A>G, ENST00000311485.8:c.878A>G, ENST00000311485.7:c.878A>G, ENST00000524423.1:n.131+4811A>G, ENST00000618712.4:c.878A>G, NM_000536.3:c.878A>G, NM_001243785.1:c.878A>G, NM_001243786.1:c.878A>G, NM_001243785.2:c.878A>G, NM_001243786.2:c.878A>G, NM_000536.4(RAG2):c.878A>G (p.Glu293Gly)	RAG2	recombinase activating gene 2 deficiency	MONDO:0000573	Autosomal recessive inheritance	Benign	BA1, BS2_Supporting		The c.878A>G (NM_000536.4) variant in RAG2 is a missense variant predicted to cause the substitution of Glutamic Acid by Glycine at amino acid 293 (p.Glu293Gly).The filtering allele frequency (the lower threshold of the 95% CI of 7999/75012 alleles) of the c.878A>G variant in RAG2 is 0.1047 for African/African American chromosomes by gnomAD v4, which is higher than the ClinGen SCID VCEP threshold (>0.00872) for BA1, and therefore meets this criterion (BA1).Additionally, 437 adult homozygous occurrences are reported in gnomAD v4 (BS2_Supporting)In summary, this variant meets the criteria to be classified as Benign for autosomal recessive recombinase activating gene 2 deficiency based on the ACMG/AMP criteria applied, as specified by the ClinGen SCID VCEP: BA1 and BS2_Supporting. (VCEP specifications version 1)		Severe Combined Immunodeficiency Disease  VCEP		2024-04-03	2024-04-03	False	https://erepo.genome.network/evrepo/ui/classification/CA5950510/MONDO:0000573/124	6911fcf3-20bc-4fc2-99cd-a3df948f8de8	p.Glu293Gly	Glu	293	Gly	MSLQMVTVSNNIALIQPGFSLMNFDGQVFFFGQKGWPKRSCPTGVFHLDVKHNHVKLKPTIFSKDSCYLPPLRYPATCTFKGSLESEKHQYIIHGGKTPNNEVSDKIYVMSIVCKNNKKVTFRCTEKDLVGDVPEARYGHSINVVYSRGKSMGVLFGGRSYMPSTHRTTEKWNSVADCLPCVFLVDFEFGCATSYILPELQDGLSFHVSIAKNDTIYILGGHSLANNIRPANLYRIRVDLPLGSPAVNCTVLPGGISVSSAILTQTNNDEFVIVGGYQLENQKRMICNIISLEDNKIEIREMETPDWTPDIKHSKIWFGSNMGNGTVFLGIPGDNKQVVSEGFYFYMLKCAEDDTNEEQTTFTNSQTSTEDPGDSTPFEDSEEFCFSAEANSFDGDDEFDTYNEDDEEDESETGYWITCCPTCDVDINTWVPFYSTELNKPAMIYCSHGDGHWVHAQCMDLAERTLIHLSAGSNKYYCNEHVEIARALHTPQRVLPLKKPPMKSLRKKGSGKILTPAKKSFLRRLFD	527	P55895	G	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [10], 'TRANSIT_gain': [], 'TRANSIT_loss_score': array([-0.01249838]), 'STRAND_loss': [343], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.01737285]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [54, 58, 62, 63, 65, 78, 140, 141, 143], 'REPEAT_gain_score': array([0.03942925, 0.04791731, 0.04559052, 0.04841858, 0.04957128,
       0.04169476, 0.02642483, 0.02928913, 0.02276826]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
739	NM_175914.5(HNF4A):c.187C>T (p.Arg63Trp)	156152	CA170773	NM_175914.5:c.187C>T, NC_000020.11:g.44406195C>T, CM000682.2:g.44406195C>T, NC_000020.10:g.43034835C>T, CM000682.1:g.43034835C>T, NC_000020.9:g.42468249C>T, NG_009818.1:g.55395C>T, LRG_483:g.55395C>T, ENST00000316673.9:c.187C>T, ENST00000316099.10:c.253C>T, ENST00000619550.5:c.227C>T, ENST00000681977.1:c.229C>T, ENST00000682169.1:c.206C>T, ENST00000683148.1:n.229C>T, ENST00000683657.1:n.229C>T, ENST00000684046.1:c.229C>T, ENST00000684136.1:c.229C>T, ENST00000684476.1:c.210C>T, ENST00000316099.9:c.253C>T, ENST00000316099.8:c.253C>T, ENST00000316673.8:c.187C>T, ENST00000372920.1:c.*20C>T, ENST00000415691.2:c.253C>T, ENST00000443598.6:c.253C>T, ENST00000457232.5:c.187C>T, ENST00000609262.5:c.178C>T, ENST00000609795.5:c.187C>T, ENST00000619550.4:c.178C>T, NM_000457.4:c.253C>T, LRG_483t2:c.253C>T, NM_001030003.2:c.187C>T, NM_001030004.2:c.187C>T, NM_001258355.1:c.232C>T, NM_001287182.1:c.178C>T, NM_001287183.1:c.178C>T, LRG_483t3:c.178C>T, NM_001287184.1:c.178C>T, NM_175914.4:c.187C>T, LRG_483t1:c.187C>T, NM_178849.2:c.253C>T, NM_178850.2:c.253C>T, XM_005260407.2:c.370C>T, XM_011528797.1:c.301C>T, XM_011528798.1:c.301C>T, XM_005260407.4:c.370C>T, NM_001030003.3:c.187C>T, NM_001030004.3:c.187C>T, NM_001258355.2:c.232C>T, NM_001287182.2:c.178C>T, NM_001287184.2:c.178C>T, NM_178849.3:c.253C>T, NM_178850.3:c.253C>T, NM_000457.5:c.253C>T, NM_000457.6:c.253C>T, NM_001287183.2:c.178C>T, NM_175914.5(HNF4A):c.187C>T (p.Arg63Trp)	HNF4A	monogenic diabetes	MONDO:0015967	Autosomal dominant inheritance	Pathogenic	PP3, PM5, PM1, PM2_Supporting, PS4, PP1_Strong, PS2_Very Strong, PP4_Moderate		The c.187C>T variant in the hepatocyte nuclear factor 4-alpha gene, HNF4A, causes an amino acid change of arginine to tryptophan at codon 63 (p.(Arg63Trp) of NM_175914.5. This variant is absent in gnomAD v2.1.1 (PM2_Supporting), and was identified in 21 unrelated individuals with non- autoimmune and non-absolute/near-absolute insulin-deficient diabetes (PS4; PMID: 24285859, 25819479, 28693455, internal lab contributors). This variant segregated with diabetes, with at least 7 meioses in 4 families (PP1_Strong, PMID: 24285859, 28693455, internal lab contributors). At least 6 individuals have a clinical history highly specific for HNF4A-MODY (MODY probability calculator result >50%, negative genetic testing for HNF1A, and Fanconi phenotype) (PP4_Moderate; internal lab contributors). Additionally, this variant was identified as a de novo occurrence with both confirmed and unconfirmed parental relationships in 5 individual(s) with a clinical picture consistent with HNF4A-MODY (MODY probability calculator result >50% and negative genetic testing for HNF1A) (PS2_Very Strong; internal lab contributor, PMID: 24285859, 25819479). This variant resides in an amino acid within the HNF4α DNA binding domain that directly binds DNA, which is defined as critical for the protein’s function by the ClinGen MDEP (PM1). It is also predicted to be deleterious by computational evidence, with a REVEL score of 0.949, which is greater than the MDEP VCEP threshold of 0.70 (PP3). Lastly, another missense variant, c.188G>A (p.Arg63Gln), has been interpreted as pathogenic by the ClinGen MDEP, and p.Arg63Trp has a greater Grantham distance (PM5). In summary, c.187C>T meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 2.0.0, approved 10/11/2023): PS2_Very strong, PP1_Strong, PS4, PP4_Moderate, PM1, PP3, PM2_Supporting, PM5_Supporting.		Monogenic Diabetes VCEP		2024-04-06	2024-04-06	False	https://erepo.genome.network/evrepo/ui/classification/CA170773/MONDO:0015967/085	35127f40-c453-4957-ab23-eb682d17599f	p.Arg63Trp	Arg	63	Trp	MRLSKTLVDMDMADYSAALDPAYTTLEFENVQVLTMGNDTSPSEGTNLNAPNSLGVSALCAICGDRATGKHYGASSCDGCKGFFRRSVRKNHMYSCRFSRQCVVDKDKRNQCRYCRLKKCFRAGMKKEAVQNERDRISTRRSSYEDSSLPSINALLQAEVLSRQITSPVSGINGDIRAKKIASIADVCESMKEQLLVLVEWAKYIPAFCELPLDDQVALLRAHAGEHLLLGATKRSMVFKDVLLLGNDYIVPRHCPELAEMSRVSIRILDELVLPFQELQIDDNEYAYLKAIIFFDPDAKGLSDPGKIKRLRSQVQVSLEDYINDRQYDSRGRFGELLLLLPTLQSITWQMIEQIQFIKLFGMAKIDNLLQEMLLGGSPSDAPHAHHPLHPHLMQEHMGTNVIVANTMPTHLSNGQMCEWPRPRGQAATPETPQPSPPGGSGSEPYKLLPGAVATIVKPLSAIPQPTITKQEVI	474	P41235	W	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [79, 114], 'BINDING_gain_score': array([0.35022479, 0.30018884]), 'DNA_BIND_loss': [58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68], 'DNA_BIND_gain': [], 'DNA_BIND_loss_score': array([-0.57567447, -0.62797326, -0.72046506, -0.7427972 , -0.32020265,
       -0.59112936, -0.54971355, -0.5961256 , -0.47843784, -0.50669217,
       -0.3618654 ]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [351], 'TRANSMEM_gain_score': array([0.01998144]), 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [229, 230, 330], 'HELIX_gain': [244], 'HELIX_gain_score': array([0.09107322]), 'HELIX_loss_score': array([-0.07932293, -0.09667063, -0.00897342]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [152, 153, 154], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.09966433, -0.11869216, -0.13278443]), 'REGION_loss': [447], 'REGION_gain': [], 'REGION_loss_score': array([-0.02013719]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [59, 60], 'ZN_FING_gain': [], 'ZN_FING_loss_score': array([-0.42269129, -0.36244535])}"
740	NM_175914.5(HNF4A):c.188G>A (p.Arg63Gln)	372382	CA16043128	NM_175914.5:c.188G>A, NC_000020.11:g.44406196G>A, CM000682.2:g.44406196G>A, NC_000020.10:g.43034836G>A, CM000682.1:g.43034836G>A, NC_000020.9:g.42468250G>A, NG_009818.1:g.55396G>A, LRG_483:g.55396G>A, ENST00000316673.9:c.188G>A, ENST00000316099.10:c.254G>A, ENST00000619550.5:c.228G>A, ENST00000681977.1:c.230G>A, ENST00000682169.1:c.207G>A, ENST00000683148.1:n.230G>A, ENST00000683657.1:n.230G>A, ENST00000684046.1:c.230G>A, ENST00000684136.1:c.230G>A, ENST00000684476.1:c.211G>A, ENST00000316099.9:c.254G>A, ENST00000316099.8:c.254G>A, ENST00000316673.8:c.188G>A, ENST00000372920.1:c.*21G>A, ENST00000415691.2:c.254G>A, ENST00000443598.6:c.254G>A, ENST00000457232.5:c.188G>A, ENST00000609262.5:c.179G>A, ENST00000609795.5:c.188G>A, ENST00000619550.4:c.179G>A, NM_000457.4:c.254G>A, LRG_483t2:c.254G>A, NM_001030003.2:c.188G>A, NM_001030004.2:c.188G>A, NM_001258355.1:c.233G>A, NM_001287182.1:c.179G>A, NM_001287183.1:c.179G>A, LRG_483t3:c.179G>A, NM_001287184.1:c.179G>A, NM_175914.4:c.188G>A, LRG_483t1:c.188G>A, NM_178849.2:c.254G>A, NM_178850.2:c.254G>A, XM_005260407.2:c.371G>A, XM_011528797.1:c.302G>A, XM_011528798.1:c.302G>A, XM_005260407.4:c.371G>A, NM_001030003.3:c.188G>A, NM_001030004.3:c.188G>A, NM_001258355.2:c.233G>A, NM_001287182.2:c.179G>A, NM_001287184.2:c.179G>A, NM_178849.3:c.254G>A, NM_178850.3:c.254G>A, NM_000457.5:c.254G>A, NM_000457.6:c.254G>A, NM_001287183.2:c.179G>A, NM_175914.5(HNF4A):c.188G>A (p.Arg63Gln)	HNF4A	monogenic diabetes	MONDO:0015967	Autosomal dominant inheritance	Pathogenic	PP3, PP1, PM1, PM2_Supporting, PS2, PS4_Moderate, PP4_Moderate		The c.188G>A variant in the hepatocyte nuclear factor 4-alpha gene, HNF4A, causes an amino acid change of arginine to glutamine at codon 63 (p.(Arg63Gln)) of NM_175914.5.  This variant is absent in gnomAD v2.1.1 (PM2_Supporting), and was identified in at least 6 unrelated individuals with non- autoimmune and non-absolute/near-absolute insulin-deficient diabetes (PS4_Moderate; internal lab contributors). One of these individuals has a clinical history highly specific for HNF4A-MODY (MODY probability calculator result >50%, negative genetic testing for HNF1A, and sulfonylurea sensitive) (PP4_Moderate; internal lab contributor). This variant segregated with diabetes, with two informative meioses in two families with MODY (PP1; internal lab contributors). It was also identified as a de novo occurrence with confirmed parental relationships in an individual with a clinical picture consistent with HNF4A-MODY (persistent neonatal hypoglycemia and negative testing for ABCC8 and KCNJ11) (PS2; internal lab contributor). Additionally, this variant resides in an amino acid within the HNF4α DNA binding domain that directly binds DNA, which is defined as critical for the protein’s function by the ClinGen MDEP (PM1). It is also predicted to be deleterious by computational evidence, with a REVEL score of 0.921, which is greater than the MDEP VCEP threshold of 0.70 (PP3). In summary, c.188G>A meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 2.0.0, approved 10/11/2023): PS2, PP4_Moderate, PM1, PS4_Moderate, PP1, PP3, PM2_Supporting.		Monogenic Diabetes VCEP		2024-04-06	2024-04-06	False	https://erepo.genome.network/evrepo/ui/classification/CA16043128/MONDO:0015967/085	b3f02629-63c0-4004-ae89-406467301f00	p.Arg63Gln	Arg	63	Gln	MRLSKTLVDMDMADYSAALDPAYTTLEFENVQVLTMGNDTSPSEGTNLNAPNSLGVSALCAICGDRATGKHYGASSCDGCKGFFRRSVRKNHMYSCRFSRQCVVDKDKRNQCRYCRLKKCFRAGMKKEAVQNERDRISTRRSSYEDSSLPSINALLQAEVLSRQITSPVSGINGDIRAKKIASIADVCESMKEQLLVLVEWAKYIPAFCELPLDDQVALLRAHAGEHLLLGATKRSMVFKDVLLLGNDYIVPRHCPELAEMSRVSIRILDELVLPFQELQIDDNEYAYLKAIIFFDPDAKGLSDPGKIKRLRSQVQVSLEDYINDRQYDSRGRFGELLLLLPTLQSITWQMIEQIQFIKLFGMAKIDNLLQEMLLGGSPSDAPHAHHPLHPHLMQEHMGTNVIVANTMPTHLSNGQMCEWPRPRGQAATPETPQPSPPGGSGSEPYKLLPGAVATIVKPLSAIPQPTITKQEVI	474	P41235	Q	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [79, 114], 'BINDING_gain_score': array([0.34367228, 0.3377471 ]), 'DNA_BIND_loss': [58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69], 'DNA_BIND_gain': [], 'DNA_BIND_loss_score': array([-0.58816415, -0.71117622, -0.74871266, -0.80473787, -0.72620332,
       -0.74213898, -0.74904078, -0.71759683, -0.71487159, -0.65218204,
       -0.54625106, -0.51101094]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [230], 'HELIX_gain': [361], 'HELIX_gain_score': array([0.0824008]), 'HELIX_loss_score': array([-0.0496248]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [152], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.03871787]), 'REGION_loss': [447], 'REGION_gain': [], 'REGION_loss_score': array([-0.01486868]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [59, 60], 'ZN_FING_gain': [], 'ZN_FING_loss_score': array([-0.54777086, -0.55052364])}"
741	NM_175914.5(HNF4A):c.200G>A (p.Arg67Gln)	435436	CA409103974	NM_175914.5:c.200G>A, NC_000020.11:g.44406208G>A, CM000682.2:g.44406208G>A, NC_000020.10:g.43034848G>A, CM000682.1:g.43034848G>A, NC_000020.9:g.42468262G>A, NG_009818.1:g.55408G>A, LRG_483:g.55408G>A, ENST00000316673.9:c.200G>A, ENST00000316099.10:c.266G>A, ENST00000619550.5:c.240G>A, ENST00000681977.1:c.242G>A, ENST00000682169.1:c.219G>A, ENST00000683148.1:n.242G>A, ENST00000683657.1:n.242G>A, ENST00000684046.1:c.242G>A, ENST00000684136.1:c.242G>A, ENST00000684476.1:c.223G>A, ENST00000316099.9:c.266G>A, ENST00000316099.8:c.266G>A, ENST00000316673.8:c.200G>A, ENST00000372920.1:c.*33G>A, ENST00000415691.2:c.266G>A, ENST00000443598.6:c.266G>A, ENST00000457232.5:c.200G>A, ENST00000609262.5:c.191G>A, ENST00000609795.5:c.200G>A, ENST00000619550.4:c.191G>A, NM_000457.4:c.266G>A, LRG_483t2:c.266G>A, NM_001030003.2:c.200G>A, NM_001030004.2:c.200G>A, NM_001258355.1:c.245G>A, NM_001287182.1:c.191G>A, NM_001287183.1:c.191G>A, LRG_483t3:c.191G>A, NM_001287184.1:c.191G>A, NM_175914.4:c.200G>A, LRG_483t1:c.200G>A, NM_178849.2:c.266G>A, NM_178850.2:c.266G>A, XM_005260407.2:c.383G>A, XM_011528797.1:c.314G>A, XM_011528798.1:c.314G>A, XM_005260407.4:c.383G>A, NM_001030003.3:c.200G>A, NM_001030004.3:c.200G>A, NM_001258355.2:c.245G>A, NM_001287182.2:c.191G>A, NM_001287184.2:c.191G>A, NM_178849.3:c.266G>A, NM_178850.3:c.266G>A, NM_000457.5:c.266G>A, NM_000457.6:c.266G>A, NM_001287183.2:c.191G>A, NM_175914.5(HNF4A):c.200G>A (p.Arg67Gln)	HNF4A	monogenic diabetes	MONDO:0015967	Autosomal dominant inheritance	Pathogenic	PP3, PM2_Supporting, PS4, PP1_Strong, PM5_Supporting, PP4_Moderate		The c.200G>A variant in the hepatocyte nuclear factor 4-alpha gene, HNF4A, causes an amino acid change of arginine to glutamine at codon 67 (p.(Arg67Gln)) of NM_175914.5. This variant has poor data quality in gnomAD v2.1.1 exomes but is absent in gnomAD genomes v3.0 and therefore at the discretion of the ClinGen MDEP PM2_Supporting will be applied (PM2_Supporting). This variant was identified in 17 unrelated individuals with non- autoimmune and non-absolute/near-absolute insulin-deficient diabetes (PS4; PMID:31523701, 20705777, 21353246, 29493090, internal lab contributors). At least 3 of these individuals has a clinical history highly specific for HNF4A-MODY (MODY probability calculator result >50%, negative genetic testing for HNF1A, and negative antibodies) (PP4_Moderate; PMID:20705777, internal lab contributors). This variant segregated with diabetes/hyperglycemia, with at least 10 informative meioses in five families (PP1_Strong; PMID:20705777, internal lab contributor). This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.943, which is greater than the MDEP VCEP threshold of 0.70 (PP3). It resides in an amino acid within the HNF4α DNA binding domain that directly binds DNA, which is defined as critical for the protein’s function by the ClinGen MDEP (PM1). Another missense variant, c.199C>T (p.(Arg67Trp)), has been classified as pathogenic by the ClinGen MDEP but has a greater Grantham distance than p.(Arg67Gln)​ (PM5_Supporting). In summary, the c.200G>A variant meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 2.0.0, approved 10/11/2023): PP1_Strong, PS4, PP4_Moderate, PM1, PP3, PM2_Supporting, PM5_Supporting.		Monogenic Diabetes VCEP		2024-04-06	2024-04-06	False	https://erepo.genome.network/evrepo/ui/classification/CA409103974/MONDO:0015967/085	52fc616a-f4a7-4bab-8217-946ff8373ccc	p.Arg67Gln	Arg	67	Gln	MRLSKTLVDMDMADYSAALDPAYTTLEFENVQVLTMGNDTSPSEGTNLNAPNSLGVSALCAICGDRATGKHYGASSCDGCKGFFRRSVRKNHMYSCRFSRQCVVDKDKRNQCRYCRLKKCFRAGMKKEAVQNERDRISTRRSSYEDSSLPSINALLQAEVLSRQITSPVSGINGDIRAKKIASIADVCESMKEQLLVLVEWAKYIPAFCELPLDDQVALLRAHAGEHLLLGATKRSMVFKDVLLLGNDYIVPRHCPELAEMSRVSIRILDELVLPFQELQIDDNEYAYLKAIIFFDPDAKGLSDPGKIKRLRSQVQVSLEDYINDRQYDSRGRFGELLLLLPTLQSITWQMIEQIQFIKLFGMAKIDNLLQEMLLGGSPSDAPHAHHPLHPHLMQEHMGTNVIVANTMPTHLSNGQMCEWPRPRGQAATPETPQPSPPGGSGSEPYKLLPGAVATIVKPLSAIPQPTITKQEVI	474	P41235	Q	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [336], 'TRANSMEM_gain': [], 'TRANSMEM_loss_score': array([-0.01684254]), 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
742	NM_175914.5(HNF4A):c.334C>T (p.Arg112Trp)	995121	CA9870226	NM_175914.5:c.334C>T, NC_000020.11:g.44413708C>T, CM000682.2:g.44413708C>T, NC_000020.10:g.43042348C>T, CM000682.1:g.43042348C>T, NC_000020.9:g.42475762C>T, NG_009818.1:g.62908C>T, LRG_483:g.62908C>T, ENST00000316673.9:c.334C>T, ENST00000316099.10:c.400C>T, ENST00000619550.5:c.374C>T, ENST00000683148.1:n.376C>T, ENST00000683657.1:n.1524C>T, ENST00000316099.9:c.400C>T, ENST00000316099.8:c.400C>T, ENST00000316673.8:c.334C>T, ENST00000372920.1:c.*167C>T, ENST00000415691.2:c.400C>T, ENST00000443598.6:c.400C>T, ENST00000457232.5:c.334C>T, ENST00000609795.5:c.334C>T, ENST00000619550.4:c.325C>T, NM_000457.4:c.400C>T, LRG_483t2:c.400C>T, NM_001030003.2:c.334C>T, NM_001030004.2:c.334C>T, NM_001258355.1:c.379C>T, NM_001287182.1:c.325C>T, NM_001287183.1:c.325C>T, LRG_483t3:c.325C>T, NM_001287184.1:c.325C>T, NM_175914.4:c.334C>T, LRG_483t1:c.334C>T, NM_178849.2:c.400C>T, NM_178850.2:c.400C>T, XM_005260407.2:c.517C>T, XM_011528797.1:c.448C>T, XM_011528798.1:c.448C>T, XM_005260407.4:c.517C>T, NM_001030003.3:c.334C>T, NM_001030004.3:c.334C>T, NM_001258355.2:c.379C>T, NM_001287182.2:c.325C>T, NM_001287184.2:c.325C>T, NM_178849.3:c.400C>T, NM_178850.3:c.400C>T, NM_000457.5:c.400C>T, NM_000457.6:c.400C>T, NM_001287183.2:c.325C>T, NM_175914.5(HNF4A):c.334C>T (p.Arg112Trp)	HNF4A	monogenic diabetes	MONDO:0015967	Autosomal dominant inheritance	Pathogenic	PP3, PM5, PM1, PM2_Supporting, PS4, PP1_Strong, PP4_Moderate		The c.334C>T variant in the hepatocyte nuclear factor 4-alpha gene, HNF4A, causes an amino acid change of arginine to tryptophan at codon 112 (p.Arg112Trp)) of NM_175914.5. This variant has an incomputable gnomAD v2.1.1  Popmax filtering allele frequency due to zero copies in the European non-Finnish subpopulation and one copy in the Latino subpopulation, thereby meeting the ClinGen MDEP threshold criteria for PM2_Supporting (ENF Popmax FAF <= 0.000003 and <= 2 copies in ENF and <=1 copy in any other subpopulation) (PM2_Supporting). It was identified in 8 unrelated individuals with non- autoimmune and non-absolute/near-absolute insulin-deficient diabetes (PS4; PMID:29207974, 12627330, internal lab contributors). At least two of these individuals have a clinical history highly specific for HNF4A-MODY (MODY probability calculator result >50%, negative genetic testing for HNF1A, and responsive to low-dose sulfonylureas) (PP4_Moderate; internal lab contributor). Additionally, this variant segregated with diabetes, with 7 informative meioses in two families (PP1_Strong; PMID:12627330, internal lab contributor). This variant resides in an amino acid within the HNF4α DNA binding domain that directly binds DNA, which is defined as critical for the protein’s function by the ClinGen MDEP (PM1). It is also predicted to be deleterious by computational evidence, with a REVEL score of 0.95, which is greater than the MDEP VCEP threshold of 0.70 (PP3). Another missense variant, c.335G>A (p.Arg112Gln) has been interpreted as pathogenic by the ClinGen MDEP, and p.Arg112Trp has a greater Grantham distance (PM5). In summary, c.334C>T meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 2.0.0, approved 10/11/23): PP1_strong, PS4, PP4_Moderate, PM1, PM5, PP3, PM2_Supporting.		Monogenic Diabetes VCEP		2024-04-06	2024-04-06	False	https://erepo.genome.network/evrepo/ui/classification/CA9870226/MONDO:0015967/085	4cf5740f-27ec-496d-ae49-2dfa3e110ba0	p.Arg112Trp	Arg	112	Trp	MRLSKTLVDMDMADYSAALDPAYTTLEFENVQVLTMGNDTSPSEGTNLNAPNSLGVSALCAICGDRATGKHYGASSCDGCKGFFRRSVRKNHMYSCRFSRQCVVDKDKRNQCRYCRLKKCFRAGMKKEAVQNERDRISTRRSSYEDSSLPSINALLQAEVLSRQITSPVSGINGDIRAKKIASIADVCESMKEQLLVLVEWAKYIPAFCELPLDDQVALLRAHAGEHLLLGATKRSMVFKDVLLLGNDYIVPRHCPELAEMSRVSIRILDELVLPFQELQIDDNEYAYLKAIIFFDPDAKGLSDPGKIKRLRSQVQVSLEDYINDRQYDSRGRFGELLLLLPTLQSITWQMIEQIQFIKLFGMAKIDNLLQEMLLGGSPSDAPHAHHPLHPHLMQEHMGTNVIVANTMPTHLSNGQMCEWPRPRGQAATPETPQPSPPGGSGSEPYKLLPGAVATIVKPLSAIPQPTITKQEVI	474	P41235	W	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [58, 128], 'DNA_BIND_gain': [], 'DNA_BIND_loss_score': array([-0.26215076, -0.23660314]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [351], 'TRANSMEM_gain_score': array([0.03384084]), 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [242, 243, 248, 249], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.15267384, -0.12177628, -0.09736848, -0.10396576]), 'HELIX_loss': [206, 229, 230, 231, 232, 330], 'HELIX_gain': [87], 'HELIX_gain_score': array([0.17025769]), 'HELIX_loss_score': array([-0.05383372, -0.24866623, -0.28705364, -0.20585728, -0.22463441,
       -0.07661563]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 374, 375], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.47732264, -0.54188508, -0.5614993 , -0.60637355, -0.68335378,
       -0.70641458, -0.74963862, -0.73985636, -0.77922899, -0.76845968,
       -0.84637392, -0.83460253, -0.85233355, -0.84795296, -0.86193579,
       -0.85002697, -0.85980213, -0.86708957, -0.85796589, -0.87296218,
       -0.83958811, -0.73774242, -0.75161481, -0.78725892, -0.53748798,
       -0.12617499, -0.20596039]), 'REGION_loss': [447], 'REGION_gain': [], 'REGION_loss_score': array([-0.02017391]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [119], 'ZN_FING_gain': [80], 'ZN_FING_gain_score': array([0.15684456]), 'ZN_FING_loss_score': array([-0.50282305])}"
743	NM_175914.5(HNF4A):c.925C>T (p.Arg309Cys)	36364	CA207744	NM_175914.5:c.925C>T, NC_000020.11:g.44424116C>T, CM000682.2:g.44424116C>T, NC_000020.10:g.43052756C>T, CM000682.1:g.43052756C>T, NC_000020.9:g.42486170C>T, NG_009818.1:g.73316C>T, LRG_483:g.73316C>T, ENST00000316673.9:c.925C>T, ENST00000316099.10:c.991C>T, ENST00000619550.5:c.965C>T, ENST00000316099.9:c.991C>T, ENST00000316099.8:c.991C>T, ENST00000316673.8:c.925C>T, ENST00000372920.1:c.*758C>T, ENST00000415691.2:c.991C>T, ENST00000443598.6:c.991C>T, ENST00000457232.5:c.925C>T, ENST00000609795.5:c.925C>T, ENST00000619550.4:c.916C>T, NM_000457.4:c.991C>T, LRG_483t2:c.991C>T, NM_001030003.2:c.925C>T, NM_001030004.2:c.925C>T, NM_001258355.1:c.970C>T, NM_001287182.1:c.916C>T, NM_001287183.1:c.916C>T, LRG_483t3:c.916C>T, NM_001287184.1:c.916C>T, NM_175914.4:c.925C>T, LRG_483t1:c.925C>T, NM_178849.2:c.991C>T, NM_178850.2:c.991C>T, XM_005260407.2:c.1108C>T, XM_011528797.1:c.1039C>T, XM_011528798.1:c.1039C>T, XM_005260407.4:c.1108C>T, NM_001030003.3:c.925C>T, NM_001030004.3:c.925C>T, NM_001258355.2:c.970C>T, NM_001287182.2:c.916C>T, NM_001287184.2:c.916C>T, NM_178849.3:c.991C>T, NM_178850.3:c.991C>T, NM_000457.5:c.991C>T, NM_000457.6:c.991C>T, NM_001287183.2:c.916C>T, NM_175914.5(HNF4A):c.925C>T (p.Arg309Cys)	HNF4A	monogenic diabetes	MONDO:0015967	Autosomal dominant inheritance	Pathogenic	PP3, PM2_Supporting, PS4, PM1_Supporting, PP1_Moderate, PP4_Moderate		The c.925C>T variant in the Hepatocyte Nuclear Factor 4 Alpha gene, HNF4A, causes an amino acid change of Arginine to Cysteine at codon 309 (p.(Arg309Cys)) of NM_175914.5. This variant was identified in at least 10 unrelated individuals with non-autoimmune and non-absolute/near-absolute insulin-deficient diabetes (PS4; Internal lab contributors). This variant is located within the ligand-binding domain of HNF4A, which is defined as critical for the protein’s function by the ClinGen MDEP (PM1_Supporting). This variant has a gnomAD v2.1.1  Grpmax filtering allele frequency of 0.000002970 (below the MDEP threshold of 0.000003) and ≤ 2 copies observed in the European non-Finnish population and ≤ 1 copy in any other subpopulation, thereby meeting the ClinGen MDEP criteria for PM2_Supporting (PM2_Supporting). This variant segregated with diabetes, with 1 informative meiosis in each of 3 families with MODY (PP1_moderate; Internal lab contributors). This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.787, which is greater than to the MDEP VCEP threshold of 0.70 (PP3). This variant was identified in several individuals with a clinical history highly specific for HNF4A-MODY (MODY probability calculator result >50%, negative genetic testing for HNF1A, responsiveness to sulfonylureas, and 1 family member with persistent neonatal hypoglycemia) (PP4_Moderate; Internal lab contributors). In summary, c.925C>T meets the criteria to be classified as Pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 2.0.0, approved 10/11/2023): PS4, PM1_Supporting, PM2_Supporting, PP1_Moderate, PP3, PP4_Moderate.		Monogenic Diabetes VCEP		2024-04-06	2024-04-06	False	https://erepo.genome.network/evrepo/ui/classification/CA207744/MONDO:0015967/085	09205e51-4a3a-4e2d-a6a3-bb1f8159b636	p.Arg309Cys	Arg	309	Cys	MRLSKTLVDMDMADYSAALDPAYTTLEFENVQVLTMGNDTSPSEGTNLNAPNSLGVSALCAICGDRATGKHYGASSCDGCKGFFRRSVRKNHMYSCRFSRQCVVDKDKRNQCRYCRLKKCFRAGMKKEAVQNERDRISTRRSSYEDSSLPSINALLQAEVLSRQITSPVSGINGDIRAKKIASIADVCESMKEQLLVLVEWAKYIPAFCELPLDDQVALLRAHAGEHLLLGATKRSMVFKDVLLLGNDYIVPRHCPELAEMSRVSIRILDELVLPFQELQIDDNEYAYLKAIIFFDPDAKGLSDPGKIKRLRSQVQVSLEDYINDRQYDSRGRFGELLLLLPTLQSITWQMIEQIQFIKLFGMAKIDNLLQEMLLGGSPSDAPHAHHPLHPHLMQEHMGTNVIVANTMPTHLSNGQMCEWPRPRGQAATPETPQPSPPGGSGSEPYKLLPGAVATIVKPLSAIPQPTITKQEVI	474	P41235	C	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [351], 'TRANSMEM_gain_score': array([0.03980368]), 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [244], 'STRAND_gain_score': array([0.02487314]), 'HELIX_loss': [326, 330], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.05162507, -0.07458085]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
744	NM_175914.5(HNF4A):c.868C>T (p.Arg290Cys)	447524	CA409108070	NM_175914.5:c.868C>T, NC_000020.11:g.44424059C>T, CM000682.2:g.44424059C>T, NC_000020.10:g.43052699C>T, CM000682.1:g.43052699C>T, NC_000020.9:g.42486113C>T, NG_009818.1:g.73259C>T, LRG_483:g.73259C>T, ENST00000316673.9:c.868C>T, ENST00000316099.10:c.934C>T, ENST00000619550.5:c.908C>T, ENST00000316099.9:c.934C>T, ENST00000316099.8:c.934C>T, ENST00000316673.8:c.868C>T, ENST00000372920.1:c.*701C>T, ENST00000415691.2:c.934C>T, ENST00000443598.6:c.934C>T, ENST00000457232.5:c.868C>T, ENST00000609795.5:c.868C>T, ENST00000619550.4:c.859C>T, NM_000457.4:c.934C>T, LRG_483t2:c.934C>T, NM_001030003.2:c.868C>T, NM_001030004.2:c.868C>T, NM_001258355.1:c.913C>T, NM_001287182.1:c.859C>T, NM_001287183.1:c.859C>T, LRG_483t3:c.859C>T, NM_001287184.1:c.859C>T, NM_175914.4:c.868C>T, LRG_483t1:c.868C>T, NM_178849.2:c.934C>T, NM_178850.2:c.934C>T, XM_005260407.2:c.1051C>T, XM_011528797.1:c.982C>T, XM_011528798.1:c.982C>T, XM_005260407.4:c.1051C>T, NM_001030003.3:c.868C>T, NM_001030004.3:c.868C>T, NM_001258355.2:c.913C>T, NM_001287182.2:c.859C>T, NM_001287184.2:c.859C>T, NM_178849.3:c.934C>T, NM_178850.3:c.934C>T, NM_000457.5:c.934C>T, NM_000457.6:c.934C>T, NM_001287183.2:c.859C>T, NM_175914.5(HNF4A):c.868C>T (p.Arg290Cys)	HNF4A	monogenic diabetes	MONDO:0015967	Autosomal dominant inheritance	Pathogenic	PP3, PM5, PM2_Supporting, PS4, PP1_Strong, PP4_Moderate	PM1, BP4	The c.868C>T variant in the hepatic nuclear factor 4-alpha gene, HNF4A, causes an amino acid change of arginine to cysteine at codon 290 (p.(Arg290Cys)) of NM_175914.5.  This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.92, which is greater than the MDEP VCEP threshold of 0.70 (PP3).  This variant is absent from gnomAD v2.1.1 (PM2_Supporting).  This variant was identified in at least 10 unrelated individuals with non- autoimmune and non-absolute/near-absolute insulin-deficient diabetes (PS4; PMIDs: 32533152, 21683639, internal lab contributors).  One of these individuals had a clinical history highly specific for HNF4A-monogenic diabetes (MODY probability calculator result >50%, negative genetic testing for HNF1A, and a family member with the variant with diazoxide-responsive neonatal hyperinsulinemic hypoglycemia) (PP4_Moderate; internal lab contributors).  This variant segregated with diabetes, with 20 informative meioses in 8 families (PP1_Strong;  internal lab contributors).  Another missense variant, c.869G>A p.Arg290His, has been interpreted as pathogenic by the ClinGen MDEP, and p.Arg290Cys has a greater Grantham distance (PM5).  In summary, c.868C>T meets the criteria to be classified as Pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 2.0.0, approved 10/11/2023): PP1_Strong, PS4, PP4_Moderate, PM5, PP3, PM2_Supporting.		Monogenic Diabetes VCEP		2024-04-06	2024-04-06	False	https://erepo.genome.network/evrepo/ui/classification/CA409108070/MONDO:0015967/085	f865092a-203c-4229-8cf1-4453409017d7	p.Arg290Cys	Arg	290	Cys	MRLSKTLVDMDMADYSAALDPAYTTLEFENVQVLTMGNDTSPSEGTNLNAPNSLGVSALCAICGDRATGKHYGASSCDGCKGFFRRSVRKNHMYSCRFSRQCVVDKDKRNQCRYCRLKKCFRAGMKKEAVQNERDRISTRRSSYEDSSLPSINALLQAEVLSRQITSPVSGINGDIRAKKIASIADVCESMKEQLLVLVEWAKYIPAFCELPLDDQVALLRAHAGEHLLLGATKRSMVFKDVLLLGNDYIVPRHCPELAEMSRVSIRILDELVLPFQELQIDDNEYAYLKAIIFFDPDAKGLSDPGKIKRLRSQVQVSLEDYINDRQYDSRGRFGELLLLLPTLQSITWQMIEQIQFIKLFGMAKIDNLLQEMLLGGSPSDAPHAHHPLHPHLMQEHMGTNVIVANTMPTHLSNGQMCEWPRPRGQAATPETPQPSPPGGSGSEPYKLLPGAVATIVKPLSAIPQPTITKQEVI	474	P41235	C	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [336, 337, 342, 344, 348, 349, 350], 'TRANSMEM_gain': [], 'TRANSMEM_loss_score': array([-0.07440305, -0.07089972, -0.07280672, -0.07712632, -0.05625343,
       -0.0582087 , -0.0522275 ]), 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [206, 229, 230, 252, 325, 326], 'HELIX_gain': [294], 'HELIX_gain_score': array([0.18597823]), 'HELIX_loss_score': array([-0.04659885, -0.03566349, -0.06259745, -0.04949987, -0.11374062,
       -0.11214399]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [152, 374], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.04751182, -0.07245052]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
745	NM_175914.5(HNF4A):c.869G>A (p.Arg290His)	804918	CA409108072	NM_175914.5:c.869G>A, NC_000020.11:g.44424060G>A, CM000682.2:g.44424060G>A, NC_000020.10:g.43052700G>A, CM000682.1:g.43052700G>A, NC_000020.9:g.42486114G>A, NG_009818.1:g.73260G>A, LRG_483:g.73260G>A, ENST00000316673.9:c.869G>A, ENST00000316099.10:c.935G>A, ENST00000619550.5:c.909G>A, ENST00000316099.9:c.935G>A, ENST00000316099.8:c.935G>A, ENST00000316673.8:c.869G>A, ENST00000372920.1:c.*702G>A, ENST00000415691.2:c.935G>A, ENST00000443598.6:c.935G>A, ENST00000457232.5:c.869G>A, ENST00000609795.5:c.869G>A, ENST00000619550.4:c.860G>A, NM_000457.4:c.935G>A, LRG_483t2:c.935G>A, NM_001030003.2:c.869G>A, NM_001030004.2:c.869G>A, NM_001258355.1:c.914G>A, NM_001287182.1:c.860G>A, NM_001287183.1:c.860G>A, LRG_483t3:c.860G>A, NM_001287184.1:c.860G>A, NM_175914.4:c.869G>A, LRG_483t1:c.869G>A, NM_178849.2:c.935G>A, NM_178850.2:c.935G>A, XM_005260407.2:c.1052G>A, XM_011528797.1:c.983G>A, XM_011528798.1:c.983G>A, XM_005260407.4:c.1052G>A, NM_001030003.3:c.869G>A, NM_001030004.3:c.869G>A, NM_001258355.2:c.914G>A, NM_001287182.2:c.860G>A, NM_001287184.2:c.860G>A, NM_178849.3:c.935G>A, NM_178850.3:c.935G>A, NM_000457.5:c.935G>A, NM_000457.6:c.935G>A, NM_001287183.2:c.860G>A, NM_175914.5(HNF4A):c.869G>A (p.Arg290His)	HNF4A	monogenic diabetes	MONDO:0015967	Autosomal dominant inheritance	Pathogenic	PP3, PM2_Supporting, PS4, PP1_Strong, PP4_Moderate	PM1, BP4, BA1, BS1	The c.869G>A variant in the hepatocyte nuclear factor 4-alpha gene, HNF4A, causes an amino acid change of arginine to histidine at codon 290 (p.(Arg290His)) of NM_175914.5.  This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.919, which is greater than the MDEP VCEP threshold of 0.70 (PP3).  This variant has an incomputable gnomAD v2.1.1  Grpmax filtering allele frequency due to 1 copy in the European non-Finnish subpopulation and 0 copies in any other subpopulation, thereby meeting the ClinGen MDEP threshold criteria for PM2_Supporting (ENF Grpmax FAF <= 0.000003 and <= 2 copies in ENF and <=1 copy in any other subpopulation) (PM2_Supporting).  This variant was identified in 14 unrelated individuals with non- autoimmune and non-absolute/near-absolute insulin-deficient diabetes (PS4; internal lab contributors).  Two of these individuals had a clinical history highly specific for HNF4A-monogenic diabetes (MODY probability calculator result >50%, negative genetic testing for HNF1A, and sufonylurea-sensitive) (PP4_Moderate; internal lab contributors).  This variant segregated with diabetes, with 14 informative meioses in 6 families (PP1_Strong, internal lab contributors).  In summary, c.869G>A meets the criteria to be classified as Pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 2.0.0, approved 10/11/2023): PP1_Strong, PS4, PP4_Moderate, PP3, PM2_Supporting.		Monogenic Diabetes VCEP		2024-04-06	2024-04-06	False	https://erepo.genome.network/evrepo/ui/classification/CA409108072/MONDO:0015967/085	c0ea2cde-0642-4dcb-acf2-a4b234a5f4a9	p.Arg290His	Arg	290	His	MRLSKTLVDMDMADYSAALDPAYTTLEFENVQVLTMGNDTSPSEGTNLNAPNSLGVSALCAICGDRATGKHYGASSCDGCKGFFRRSVRKNHMYSCRFSRQCVVDKDKRNQCRYCRLKKCFRAGMKKEAVQNERDRISTRRSSYEDSSLPSINALLQAEVLSRQITSPVSGINGDIRAKKIASIADVCESMKEQLLVLVEWAKYIPAFCELPLDDQVALLRAHAGEHLLLGATKRSMVFKDVLLLGNDYIVPRHCPELAEMSRVSIRILDELVLPFQELQIDDNEYAYLKAIIFFDPDAKGLSDPGKIKRLRSQVQVSLEDYINDRQYDSRGRFGELLLLLPTLQSITWQMIEQIQFIKLFGMAKIDNLLQEMLLGGSPSDAPHAHHPLHPHLMQEHMGTNVIVANTMPTHLSNGQMCEWPRPRGQAATPETPQPSPPGGSGSEPYKLLPGAVATIVKPLSAIPQPTITKQEVI	474	P41235	H	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [336], 'TRANSMEM_gain': [], 'TRANSMEM_loss_score': array([-0.02082467]), 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [244, 247], 'STRAND_gain_score': array([0.05639386, 0.05385613]), 'HELIX_loss': [326, 330], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.05204058, -0.01616323]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [152], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.03916264]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
746	NM_000419.5(ITGA2B):c.1374C>G (p.Ile458Met)	1684814	CA8603157	NM_000419.5:c.1374C>G, NC_000017.11:g.44380898G>C, CM000679.2:g.44380898G>C, NC_000017.10:g.42458266G>C, CM000679.1:g.42458266G>C, NC_000017.9:g.39813792G>C, NG_008331.1:g.13608C>G, LRG_479:g.13608C>G, ENST00000262407.6:c.1374C>G, ENST00000648408.1:c.805C>G, ENST00000262407.5:c.1374C>G, ENST00000592226.5:n.614C>G, ENST00000592462.5:n.169C>G, NM_000419.3:c.1374C>G, LRG_479t1:c.1374C>G, XM_011524749.1:c.1374C>G, XM_011524750.1:c.1374C>G, NM_000419.4:c.1374C>G, NM_000419.5(ITGA2B):c.1374C>G (p.Ile458Met)	ITGA2B	Glanzmann thrombasthenia	MONDO:0100326	Autosomal recessive inheritance	Benign	BA1	BP4, PM3, PP3, PP4	The NM_000419.5(ITGA2B):c.1374C>G (p.Ile458Met) missense variant has been reported in at least one patient (Patient 6 in PMID:19172520/GT database record 163), however it occurs at a high allele frequency with the highest population minor allele frequency in gnomAD v4.0.0 is 0.003502 (319/91084 alleles with 3 homozygotes) in the South Asian population, which is higher than the ClinGen PD VCEP threshold (>0.0024), and therefore meets this criterion (BA1).  In summary, this variant meets the criteria to be classified as Benign, for autosomal recessive Glanzmann Thrombasthenia based on the ACMG/AMP criteria applied, as specified by the ClinGen PD VCEP: BA1 (VCEP specifications version 2.1).		Platelet Disorders VCEP	https://clinicalgenome.org/docs/clingen-platelet-disorders-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-2.1/	2024-04-16	2024-04-16	False	https://erepo.genome.network/evrepo/ui/classification/CA8603157/MONDO:0100326/011	cb9b7f41-55db-45f4-b91d-c5d6c8ad3a72	p.Ile458Met	Ile	458	Met	MARALCPLQALWLLEWVLLLLGPCAAPPAWALNLDPVQLTFYAGPNGSQFGFSLDFHKDSHGRVAIVVGAPRTLGPSQEETGGVFLCPWRAEGGQCPSLLFDLRDETRNVGSQTLQTFKARQGLGASVVSWSDVIVACAPWQHWNVLEKTEEAEKTPVGSCFLAQPESGRRAEYSPCRGNTLSRIYVENDFSWDKRYCEAGFSSVVTQAGELVLGAPGGYYFLGLLAQAPVADIFSSYRPGILLWHVSSQSLSFDSSNPEYFDGYWGYSVAVGEFDGDLNTTEYVVGAPTWSWTLGAVEILDSYYQRLHRLRGEQMASYFGHSVAVTDVNGDGRHDLLVGAPLYMESRADRKLAEVGRVYLFLQPRGPHALGAPSLLLTGTQLYGRFGSAIAPLGDLDRDGYNDIAVAAPYGGPSGRGQVLVFLGQSEGLRSRPSQVLDSPFPTGSAFGFSLRGAVDIDDNGYPDLIVGAYGANQVAVYRAQPVVKASVQLLVQDSLNPAVKSCVLPQTKTPVSCFNIQMCVGATGHNIPQKLSLNAELQLDRQKPRQGRRVLLLGSQQAGTTLNLDLGGKHSPICHTTMAFLRDEADFRDKLSPIVLSLNVSLPPTEAGMAPAVVLHGDTHVQEQTRIVLDCGEDDVCVPQLQLTASVTGSPLLVGADNVLELQMDAANEGEGAYEAELAVHLPQGAHYMRALSNVEGFERLICNQKKENETRVVLCELGNPMKKNAQIGIAMLVSVGNLEEAGESVSFQLQIRSKNSQNPNSKIVLLDVPVRAEAQVELRGNSFPASLVVAAEEGEREQNSLDSWGPKVEHTYELHNNGPGTVNGLHLSIHLPGQSQPSDLLYILDIQPQGGLQCFPQPPVNPLKVDWGLPIPSPSPIHPAHHKRDRRQIFLPEPEQPSRLQDPVLVSCDSAPCTVVQCDLQEMARGQRAMVTVLAFLWLPSLYQRPLDQFVLQSHAWFNVSSLPYAVPPLSLPRGEAQVWTQLLRALEERAIPIWWVLVGVLGGLLLLTILVLAMWKVGFFKRNRPPLEEDDEEGE	1039	P08514	M	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [453], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.0157429]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [893], 'COMPBIAS_gain': [], 'COMPBIAS_loss_score': array([-0.00742888]), 'DOMAIN_loss': [], 'DOMAIN_gain': [563], 'DOMAIN_gain_score': array([0.01350033]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [126], 'REPEAT_gain_score': array([0.00263208]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
747	NM_000419.5(ITGA2B):c.1772A>C (p.Asp591Ala)	627020	CA8602942	NM_000419.5:c.1772A>C, NC_000017.11:g.44379795T>G, CM000679.2:g.44379795T>G, NC_000017.10:g.42457163T>G, CM000679.1:g.42457163T>G, NC_000017.9:g.39812689T>G, NG_008331.1:g.14711A>C, LRG_479:g.14711A>C, ENST00000262407.6:c.1772A>C, ENST00000648408.1:c.1203A>C, ENST00000262407.5:c.1772A>C, ENST00000592462.5:n.567A>C, NM_000419.3:c.1772A>C, LRG_479t1:c.1772A>C, XM_011524749.1:c.1772A>C, XM_011524750.1:c.1772A>C, NM_000419.4:c.1772A>C, NM_000419.5(ITGA2B):c.1772A>C (p.Asp591Ala)	ITGA2B	Glanzmann thrombasthenia	MONDO:0100326	Autosomal recessive inheritance	Pathogenic	PM3_Strong, PP4_Strong, PP3, PM2_Supporting	PS3	The NM_000419.5(ITGA2B):c.1772A>C (p.Asp591Ala) missense variant has been reported in at least six patients, including at least one patient (P13 in PMID: 34275420) who displayed mucocutaneous bleeding and impaired aggregation with all agonists except ristocetin, which is highly specific for Glanzmann thrombasthenia. Additionally, αIIbβ3 surface expression was reduced to <5%, as measured by flow cytometry (PP4_strong). At least four patients have been reported homozygous for this variant  (PMIDs: 34275420, 29385657, ClinVar SCV004013075.1). Two additional compound heterozygous patients have been reported (PMID: 34355501), the first patient had Pro176Ala confirmed in trans (classified Pathogenic by the PD-EP, score 1pt) and the second patient had c.1440-13_1440-1del assumed in trans (PM3_strong).The highest population minor allele frequency in gnomAD v4.0.0 is 0.000005932 (7/1180006alleles) in the European (non-Finnish) population, which is lower than the ClinGen PD VCEP threshold (<0.0001; PM2_Supporting). The computational predictor REVEL gives a score of 0.755, which is above the  ClinGen PD VCEP threshold of >0.7 and predicts a damaging effect on function (PP3). In summary, this variant meets criteria to be classified as Pathogenic for autosomal recessive Glanzmann thrombasthenia. GT-specific criteria applied: PM2_supporting, PM3_strong, PP4_strong and PP3.		Platelet Disorders VCEP	https://clinicalgenome.org/docs/clingen-platelet-disorders-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-2.1/	2024-04-16	2024-04-16	False	https://erepo.genome.network/evrepo/ui/classification/CA8602942/MONDO:0100326/011	0573a051-dc7f-431c-a4f5-8d38b0d16bb5	p.Asp591Ala	Asp	591	Ala	MARALCPLQALWLLEWVLLLLGPCAAPPAWALNLDPVQLTFYAGPNGSQFGFSLDFHKDSHGRVAIVVGAPRTLGPSQEETGGVFLCPWRAEGGQCPSLLFDLRDETRNVGSQTLQTFKARQGLGASVVSWSDVIVACAPWQHWNVLEKTEEAEKTPVGSCFLAQPESGRRAEYSPCRGNTLSRIYVENDFSWDKRYCEAGFSSVVTQAGELVLGAPGGYYFLGLLAQAPVADIFSSYRPGILLWHVSSQSLSFDSSNPEYFDGYWGYSVAVGEFDGDLNTTEYVVGAPTWSWTLGAVEILDSYYQRLHRLRGEQMASYFGHSVAVTDVNGDGRHDLLVGAPLYMESRADRKLAEVGRVYLFLQPRGPHALGAPSLLLTGTQLYGRFGSAIAPLGDLDRDGYNDIAVAAPYGGPSGRGQVLVFLGQSEGLRSRPSQVLDSPFPTGSAFGFSLRGAVDIDDNGYPDLIVGAYGANQVAVYRAQPVVKASVQLLVQDSLNPAVKSCVLPQTKTPVSCFNIQMCVGATGHNIPQKLSLNAELQLDRQKPRQGRRVLLLGSQQAGTTLNLDLGGKHSPICHTTMAFLRDEADFRDKLSPIVLSLNVSLPPTEAGMAPAVVLHGDTHVQEQTRIVLDCGEDDVCVPQLQLTASVTGSPLLVGADNVLELQMDAANEGEGAYEAELAVHLPQGAHYMRALSNVEGFERLICNQKKENETRVVLCELGNPMKKNAQIGIAMLVSVGNLEEAGESVSFQLQIRSKNSQNPNSKIVLLDVPVRAEAQVELRGNSFPASLVVAAEEGEREQNSLDSWGPKVEHTYELHNNGPGTVNGLHLSIHLPGQSQPSDLLYILDIQPQGGLQCFPQPPVNPLKVDWGLPIPSPSPIHPAHHKRDRRQIFLPEPEQPSRLQDPVLVSCDSAPCTVVQCDLQEMARGQRAMVTVLAFLWLPSLYQRPLDQFVLQSHAWFNVSSLPYAVPPLSLPRGEAQVWTQLLRALEERAIPIWWVLVGVLGGLLLLTILVLAMWKVGFFKRNRPPLEEDDEEGE	1039	P08514	A	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [450, 453, 524, 582, 619, 910], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.0065307 , -0.01247913, -0.01677275, -0.08328038, -0.02900958,
       -0.00455809]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [478, 492, 493, 552, 554, 561, 565, 566, 567, 573, 596, 601, 746, 761, 785], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.01866186, -0.02703077, -0.03718501, -0.1193397 , -0.1093533 ,
       -0.10502416, -0.14010882, -0.11947101, -0.14001799, -0.15785956,
       -0.10997528, -0.13172489, -0.0222559 , -0.01289958, -0.02183533]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [126], 'REPEAT_gain_score': array([0.00737578]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
748	NM_000162.5(GCK):c.454T>C (p.Phe152Leu)	995370	CA367401929	NM_000162.5:c.454T>C, NC_000007.14:g.44150985A>G, CM000669.2:g.44150985A>G, NC_000007.13:g.44190584A>G, CM000669.1:g.44190584A>G, NC_000007.12:g.44157109A>G, NG_008847.1:g.43439T>C, NG_008847.2:g.52186T>C, ENST00000395796.8:c.*452T>C, ENST00000616242.5:c.454T>C, ENST00000682635.1:n.940T>C, ENST00000345378.7:c.457T>C, ENST00000403799.8:c.454T>C, ENST00000671824.1:c.454T>C, ENST00000673284.1:c.454T>C, ENST00000345378.6:c.457T>C, ENST00000395796.7:c.451T>C, ENST00000403799.7:c.454T>C, ENST00000437084.1:c.403T>C, ENST00000616242.4:c.451T>C, NM_000162.3:c.454T>C, NM_033507.1:c.457T>C, NM_033508.1:c.451T>C, NM_000162.4:c.454T>C, NM_001354800.1:c.454T>C, NM_033507.2:c.457T>C, NM_033508.2:c.451T>C, NM_033507.3:c.457T>C, NM_033508.3:c.451T>C, NM_000162.5(GCK):c.454T>C (p.Phe152Leu)	GCK	monogenic diabetes	MONDO:0015967	Semidominant inheritance	Pathogenic	PS4, PP1_Strong, PP4_Moderate, PP2, PP3, PM2_Supporting		The c.454T>C variant in the glucokinase gene, GCK, causes an amino acid change of phenylalanine to leucine at codon 152 (p.(Phe152Leu)) of NM_000162.5.  GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2).  This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.992, which is greater than the MDEP VCEP threshold of 0.70 (PP3).  This variant is absent from gnomAD v2.1.1 (PM2_Supporting). This variant was identified in seven unrelated individuals with hyperglycemia (PS4; PMID: 16965331, internal lab contributors]). This variant segregated with diabetes/hyperglycemia, with at least four informative meioses in two families (PP1_Strong; internal lab contributors). This variant was identified in an individual with a clinical history highly specific for GCK-hyperglycemia (FBG 5.5-8 mmol/L and HbA1c 5.6 - 7.6% and negative antibody) (PP4_Moderate; internal lab contributors]). In summary, c.454T>C meets the criteria to be classified as a variant of pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.3.0, approved 8/11/2023): PP4_Moderate, PS4, PM2_Supporting, PP3, PP2, PP1_Strong.		Monogenic Diabetes VCEP		2024-04-18	2024-04-18	False	https://erepo.genome.network/evrepo/ui/classification/CA367401929/MONDO:0015967/086	c45f79b0-c0a7-429f-8d11-0f0b09338025	p.Phe152Leu	Phe	152	Leu	MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQ	465	P35557	L	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [151], 'BINDING_gain_score': array([0.10381144]), 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [83, 221, 224], 'DOMAIN_gain_score': array([0.01520044, 0.05164272, 0.02733815]), 'REGION_loss': [], 'REGION_gain': [21], 'REGION_gain_score': array([0.00215477]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
749	NM_000162.5(GCK):c.455T>C (p.Phe152Ser)	1741488	CA367401925	NM_000162.5:c.455T>C, NC_000007.14:g.44150984A>G, CM000669.2:g.44150984A>G, NC_000007.13:g.44190583A>G, CM000669.1:g.44190583A>G, NC_000007.12:g.44157108A>G, NG_008847.1:g.43440T>C, NG_008847.2:g.52187T>C, ENST00000395796.8:c.*453T>C, ENST00000616242.5:c.455T>C, ENST00000682635.1:n.941T>C, ENST00000345378.7:c.458T>C, ENST00000403799.8:c.455T>C, ENST00000671824.1:c.455T>C, ENST00000673284.1:c.455T>C, ENST00000345378.6:c.458T>C, ENST00000395796.7:c.452T>C, ENST00000403799.7:c.455T>C, ENST00000437084.1:c.404T>C, ENST00000616242.4:c.452T>C, NM_000162.3:c.455T>C, NM_033507.1:c.458T>C, NM_033508.1:c.452T>C, NM_000162.4:c.455T>C, NM_001354800.1:c.455T>C, NM_033507.2:c.458T>C, NM_033508.2:c.452T>C, NM_033507.3:c.458T>C, NM_033508.3:c.452T>C, NM_000162.5(GCK):c.455T>C (p.Phe152Ser)	GCK	monogenic diabetes	MONDO:0015967	Semidominant inheritance	Pathogenic	PP1_Strong, PP4_Moderate, PP2, PP3, PM2_Supporting, PM5		The c.455T>C variant in the glucokinase gene, GCK, causes an amino acid change of phenylalanine to serine at codon 152 (p.(Phe152Ser)) of NM_000162.5.  GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2).  This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.981, which is greater than the MDEP VCEP threshold of 0.70 (PP3).  This variant is absent from gnomAD v2.1.1 (PM2_Supporting).  This variant was identified in an individual with a clinical history highly specific for GCK-hyperglycemia (FBG 5.5-8 mmol/L and HbA1c 5.6 - 7.6% and negative antibody) (PP4_Moderate; PMID: 21978167).  This variant segregated with diabetes/hyperglycemia, with four informative meioses in two families (PP1_Strong; PMID: 21978167, internal lab contributors]). Another missense variant, c.454T>C p.(Phe152Leu)​ has been interpreted as pathogenic by the ClinGen MDEP, and p.(Phe152Ser)​ has an equal or greater Grantham distance (PM5). In summary, c.455T>C meets the criteria to be classified as a variant of pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.3.0, approved 8/11/2023): PM2_Supporting, PP3, PP2, PM5, PP4_Moderate, PP1_Strong.		Monogenic Diabetes VCEP		2024-04-18	2024-04-18	False	https://erepo.genome.network/evrepo/ui/classification/CA367401925/MONDO:0015967/086	b8a8c2fb-7517-4e9e-a2e5-a4a95d0a14cb	p.Phe152Ser	Phe	152	Ser	MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQ	465	P35557	S	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [408], 'BINDING_gain': [151, 295], 'BINDING_gain_score': array([0.19176477, 0.02449787]), 'BINDING_loss_score': array([-0.03603834]), 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [227], 'STRAND_gain_score': array([0.01557672]), 'HELIX_loss': [114], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.10162932]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [83, 221, 224, 225, 230], 'DOMAIN_gain_score': array([0.0547576 , 0.1079455 , 0.05138338, 0.03894025, 0.08085078]), 'REGION_loss': [], 'REGION_gain': [7, 11, 21, 71, 75, 80, 81, 86], 'REGION_gain_score': array([0.0082165 , 0.00679189, 0.00564969, 0.02284455, 0.03253269,
       0.02943575, 0.03460616, 0.03291029]), 'REPEAT_loss': [], 'REPEAT_gain': [75], 'REPEAT_gain_score': array([0.02043629]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
750	NM_000162.5(GCK):c.572G>A (p.Arg191Gln)	283358	CA10604473	NM_000162.5:c.572G>A, NC_000007.14:g.44149976C>T, CM000669.2:g.44149976C>T, NC_000007.13:g.44189575C>T, CM000669.1:g.44189575C>T, NC_000007.12:g.44156100C>T, NG_008847.1:g.44448G>A, NG_008847.2:g.53195G>A, ENST00000395796.8:c.*570G>A, ENST00000616242.5:c.572G>A, ENST00000682635.1:n.1058G>A, ENST00000345378.7:c.575G>A, ENST00000403799.8:c.572G>A, ENST00000671824.1:c.572G>A, ENST00000673284.1:c.572G>A, ENST00000345378.6:c.575G>A, ENST00000395796.7:c.569G>A, ENST00000403799.7:c.572G>A, ENST00000437084.1:c.521G>A, ENST00000616242.4:c.569G>A, NM_000162.3:c.572G>A, NM_033507.1:c.575G>A, NM_033508.1:c.569G>A, NM_000162.4:c.572G>A, NM_001354800.1:c.572G>A, NM_033507.2:c.575G>A, NM_033508.2:c.569G>A, NM_033507.3:c.575G>A, NM_033508.3:c.569G>A, NM_000162.5(GCK):c.572G>A (p.Arg191Gln)	GCK	monogenic diabetes	MONDO:0015967	Semidominant inheritance	Pathogenic	PS4, PP1_Strong, PM5_Supporting, PP4_Moderate, PP2, PP3, PM2_Supporting	PM3	The c.605T>G variant in the glucokinase gene, GCK, causes an amino acid change of methionine to arginine at codon 202 (p.(Met202Arg)) of NM_000162.5. GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2). This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.873, which is greater than the MDEP VCEP threshold of 0.70 (PP3). This variant is absent from gnomAD v2.1.1 (PM2_Supporting). This variant was identified in 39 unrelated individuals with hyperglycemia (PS4; PMID: 30259503, 29927023, 29510678, 29207974, 29056535, 27256595, 25953829, 25555642, 24918535, 20337973, 19309449, 11508276, internal lab contributors). This variant was identified in an individual with a clinical history highly specific for GCK-hyperglycemia (FBG 5.5-8 mmol/L and HbA1c 5.6 - 7.6% and three-generation, dominant family history of diabetes or hyperglycemia in a family not used for PP1) (PP4_Moderate; internal lab contributors). This variant segregated with diabetes/hyperglycemia, with 13 informative meioses in one family with MODY (PP1_Strong; internal lab contributors). Another missense variant, c.571C>T p.(Arg191Trp), has been classified as pathogenic by the ClinGen MDEP but has a greater Grantham distance than p.(Arg191Gln) (PM5_Supporting). In summary, c.572G>A meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.3.0, approved 8/11/2023): PP3, PP2, PM2_Supporting, PS4, PP1_Strong, PP4_Moderate, PM5_Supporting.		Monogenic Diabetes VCEP		2024-04-19	2024-04-19	False	https://erepo.genome.network/evrepo/ui/classification/CA10604473/MONDO:0015967/086	572070cd-f397-46ce-86c0-08a594ad4b36	p.Arg191Gln	Arg	191	Gln	MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQ	465	P35557	Q	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [203], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.02395952]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [83], 'DOMAIN_gain_score': array([0.00712234]), 'REGION_loss': [], 'REGION_gain': [11, 21, 71, 80], 'REGION_gain_score': array([0.00345337, 0.00348878, 0.00701004, 0.00738674]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
751	NM_000329.3(RPE65):c.118G>A (p.Gly40Ser)	98830	CA226491	NM_000329.3:c.118G>A, NC_000001.11:g.68446837C>T, CM000663.2:g.68446837C>T, NC_000001.10:g.68912520C>T, CM000663.1:g.68912520C>T, NC_000001.9:g.68685108C>T, NG_008472.1:g.8123G>A, NG_008472.2:g.8123G>A, ENST00000262340.6:c.118G>A, ENST00000262340.5:c.118G>A, NM_000329.2:c.118G>A, XM_017002027.1:c.-32+1787G>A, NM_000329.3(RPE65):c.118G>A (p.Gly40Ser)	RPE65	RPE65-related recessive retinopathy	MONDO:0100368	Autosomal recessive inheritance	Pathogenic	PP1, PM2_Supporting, PM3_Strong, PP3_Moderate, PS3_Supporting, PP4_Moderate		NM_000329.3(RPE65):c.118G>A is a missense variant predicted to replace glycine with serine at position 40. This variant is present in gnomAD v.2.1.1 at a GrpMax allele frequency of 0.00006, with 2 alleles/24966 total alleles in the African/African-American population, which is lower than the ClinGen LCA / eoRD VCEP PM2_Supporting threshold of <0.0002 (PM2_Supporting). The computational predictor REVEL gives a score of 0.984, which is above the ClinGen LCA / eoRD VCEP threshold of ≥ 0.773 and predicts a damaging effect on RPE65 function (PP3_Moderate). The variant exhibited <2 % enzymatic activity in a retinoid isomerase assay relative to the wild-type control, which is lower than the ClinGen LCA / eoRD VCEP PS3_Supporting threshold of <10% activity, indicating that it triggers a severe defect in protein function (PS3_Supporting, PMID: 16150724 ). This variant has been reported in at least 2 unrelated probands with early-onset severe retinal dystrophy who were homozygous for the variant (1 pt, PMID: 25257057, PMID: 33608557). This variant has also been reported in at least 3 probands with early-onset severe retinal dystrophy who were compound heterozygous with either the NM_000329.3(RPE65):c.544C>T (p.His182Tyr) variant confirmed in trans (1 pt, PMID: 9501220, PMID: 11462243), the c.11+5G>A variant suspected in trans (0.5 pts, PMID: 18441371), or the p.Arg91Gln variant suspected in trans (0.5 pts, PMID: 19117922), all of which were previously classified pathogenic by the ClinGen LCA / eoRD VCEP (total 3 pts, PM3_Strong). The variant has been reported to segregate with childhood-onset severe retinal dystrophy through the proband plus 1 similarly affected relative, with the variant present in the compound heterozygous state (PMID: 9501220, PP1). At least one proband harboring this variant exhibits a phenotype including diagnosis of Leber congenital amaurosis (0.5 pts), absent or severely reduced rod ERG (0.5 pts), decreased central visual acuity (1 pt), and significant improvement of visual function by FST after gene-specific gene therapy (8 pts), which together are highly specific for RPE65-related recessive retinopathy (total 10 pts, PMID: 21911650, PP4_Moderate). In summary, this variant meets the criteria to be classified as pathogenic for RPE65-related recessive retinopathy based on the ACMG/AMP criteria applied, as specified by the ClinGen LCA / eoRD VCEP: PS3_Supporting, PM2_Supporting, PM3_Strong, PP1, PP3_Moderate, and PP4_Moderate. (VCEP specifications version 1.0.0; date of approval 09/21/2023).		Leber Congenital Amaurosis/early onset Retinal Dystrophy VCEP		2024-04-22	2024-04-22	False	https://erepo.genome.network/evrepo/ui/classification/CA226491/MONDO:0100368/120	193dec7c-8db4-4918-9b66-bc72bde8e064	p.Gly40Ser	Gly	40	Ser	MSIQVEHPAGGYKKLFETVEELSSPLTAHVTGRIPLWLTGSLLRCGPGLFEVGSEPFYHLFDGQALLHKFDFKEGHVTYHRRFIRTDAYVRAMTEKRIVITEFGTCAFPDPCKNIFSRFFSYFRGVEVTDNALVNVYPVGEDYYACTETNFITKINPETLETIKQVDLCNYVSVNGATAHPHIENDGTVYNIGNCFGKNFSIAYNIVKIPPLQADKEDPISKSEIVVQFPCSDRFKPSYVHSFGLTPNYIVFVETPVKINLFKFLSSWSLWGANYMDCFESNETMGVWLHIADKKRKKYLNNKYRTSPFNLFHHINTYEDNGFLIVDLCCWKGFEFVYNYLYLANLRENWEEVKKNARKAPQPEVRRYVLPLNIDKADTGKNLVTLPNTTATAILCSDETIWLEPEVLFSGPRQAFEFPQINYQKYCGKPYTYAYGLGLNHFVPDRLCKLNVKTKETWVWQEPDSYPSEPIFVSHPDALEEDDGVVLSVVVSPGAGQKPAYLLILNAKDLSEVARAEVEINIPVTFHGLFKKS	533	Q16518	S	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [2, 4, 6, 7, 11, 12, 18, 26, 30], 'PROPEP_gain_score': array([0.04577988, 0.03904951, 0.03984565, 0.0324254 , 0.03114957,
       0.03607768, 0.02827203, 0.01777202, 0.01470596]), 'SIGNAL_loss': [], 'SIGNAL_gain': [7, 8, 9, 10, 19, 26], 'SIGNAL_gain_score': array([0.06555742, 0.07207388, 0.07606995, 0.07772017, 0.12271416,
       0.17195082]), 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [43], 'STRAND_gain': [103, 107], 'STRAND_gain_score': array([0.04706097, 0.01816189]), 'STRAND_loss_score': array([-0.36048663]), 'HELIX_loss': [], 'HELIX_gain': [24], 'HELIX_gain_score': array([0.0626334]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [497], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.00130194]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
752	NM_000329.3(RPE65):c.1451G>T (p.Gly484Val)	813222	CA902151	NM_000329.3:c.1451G>T, NC_000001.11:g.68429927C>A, CM000663.2:g.68429927C>A, NC_000001.10:g.68895610C>A, CM000663.1:g.68895610C>A, NC_000001.9:g.68668198C>A, NG_008472.1:g.25033G>T, NG_008472.2:g.25033G>T, ENST00000262340.6:c.1451G>T, ENST00000262340.5:c.1451G>T, NM_000329.2:c.1451G>T, XM_017002027.1:c.1175G>T, NM_000329.3(RPE65):c.1451G>T (p.Gly484Val)	RPE65	RPE65-related recessive retinopathy	MONDO:0100368	Autosomal recessive inheritance	Pathogenic	PP4, PM2_Supporting, PM3_Strong, PP3_Moderate, PS1_Moderate, PP1_Moderate	PM5	NM_000329.3(RPE65):c.1451G>T (p.Gly484Val) is a putative missense variant located in the first nucleotide of exon 14 that is predicted to cause the replacement of glycine with valine at codon 484. The computational predictor REVEL gives a score of 0.991, which is above the ClinGen LCA / eoRD VCEP threshold of ≥0.773 and predicts a damaging effect on RPE65 function. Additionally, the splicing impact predictor SpliceAI gives a score of 0.56, which is above the ClinGen LCA/eoRD VCEP recommended threshold of ≥0.2 and predicts a damaging impact on splicing (PP3_Moderate). Another missense variant at the same nucleotide, NM_000329.3(RPE65):c.1451G>A (p.Gly484Asp), has been classified as likely pathogenic for RPE65-related recessive retinopathy by the ClinGen LCA / eoRD VCEP and has a SpliceAI score of 0.23 for acceptor loss, indicating that both variants are predicted to have a damaging impact on splicing (PMID: 30025081, PMID: 34492281, PS1_Moderate). This variant is present in gnomAD v2.1.1 at a GrpMax allele frequency of 0.000002990, with 2 alleles / 111,040 total alleles in the European (Non-Finnish) population, which is lower than the ClinGen LCA/eoRD VCEP PM2_Supporting threshold of <0.0002 (PM2_Supporting). This variant has been reported in at least 3 unrelated probands with early-onset severe retinal dystrophy who are homozygous for the variant (1 pt, PMID: 33308271, PMID: 32531858, PMID: 33472769). The variant has also been reported in at least 1 proband with early-onset severe retinal dystrophy who was compound heterozygous with the NM_000329.3(RPE65):c.272G>A (p.Arg91Gln) variant confirmed in trans (1 pt, PMID: 38002999), which was previously classified pathogenic or likely pathogenic by the ClinGen LCA / eoRD VCEP (2 total pts, PM3_Strong). The variant has been reported to segregate with childhood-onset severe retinal dystrophy through the proband plus 2 similarly affected relatives, with the variant present in the homozygous state (PMID: 33308271, PP1_Moderate). At least one proband harboring this variant exhibits a phenotype including clinical diagnosis of Leber congenital amaurosis (0.5 pts), symptomatic onset at age 3 months (1 pt), extinguished ERG responses from rods (0.5 pts) and cones, optic nerve pallor (0.5 pts), macular atrophy (0.5 pts), decreased peripheral vision (1 pt), abnormal color vision (1 pt), decreased central visual acuity (1 pt), nystagmus (1 pt), which together are specific for RPE65-related recessive retinopathy (total 7 pts, PMID: 33308271, PP4). In summary, this variant meets the criteria to be classified as pathogenic for RPE65-related recessive retinopathy based on the ACMG/AMP criteria applied, as specified by the ClinGen LCA / eoRD VCEP: PS1_moderate, PM2_supporting, PM3_strong, PP1_moderate, PP3, and PP4. (VCEP specifications version 1.0.0; date of approval 09/21/2023).		Leber Congenital Amaurosis/early onset Retinal Dystrophy VCEP		2024-04-22	2024-04-22	False	https://erepo.genome.network/evrepo/ui/classification/CA902151/MONDO:0100368/120	28d19f3d-84d3-41a4-961e-ce9e607a350c	p.Gly484Val	Gly	484	Val	MSIQVEHPAGGYKKLFETVEELSSPLTAHVTGRIPLWLTGSLLRCGPGLFEVGSEPFYHLFDGQALLHKFDFKEGHVTYHRRFIRTDAYVRAMTEKRIVITEFGTCAFPDPCKNIFSRFFSYFRGVEVTDNALVNVYPVGEDYYACTETNFITKINPETLETIKQVDLCNYVSVNGATAHPHIENDGTVYNIGNCFGKNFSIAYNIVKIPPLQADKEDPISKSEIVVQFPCSDRFKPSYVHSFGLTPNYIVFVETPVKINLFKFLSSWSLWGANYMDCFESNETMGVWLHIADKKRKKYLNNKYRTSPFNLFHHINTYEDNGFLIVDLCCWKGFEFVYNYLYLANLRENWEEVKKNARKAPQPEVRRYVLPLNIDKADTGKNLVTLPNTTATAILCSDETIWLEPEVLFSGPRQAFEFPQINYQKYCGKPYTYAYGLGLNHFVPDRLCKLNVKTKETWVWQEPDSYPSEPIFVSHPDALEEDDGVVLSVVVSPGAGQKPAYLLILNAKDLSEVARAEVEINIPVTFHGLFKKS	533	Q16518	V	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [312], 'BINDING_gain': [], 'BINDING_loss_score': array([-0.1469931]), 'DNA_BIND_loss': [243, 251, 261, 286, 489, 490], 'DNA_BIND_gain': [], 'DNA_BIND_loss_score': array([-0.02870327, -0.03062004, -0.05143726, -0.02090472, -0.07943767,
       -0.12761879]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [5, 8, 9, 10, 15, 16, 19, 20, 22, 23, 31], 'PROPEP_gain': [], 'PROPEP_loss_score': array([-0.06677204, -0.07796693, -0.06545287, -0.06374383, -0.04484516,
       -0.05873287, -0.04114193, -0.03276241, -0.03288215, -0.03093982,
       -0.03543907]), 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [131, 230], 'STRAND_gain': [528], 'STRAND_gain_score': array([0.0718627]), 'STRAND_loss_score': array([-0.01527381, -0.02811044]), 'HELIX_loss': [277], 'HELIX_gain': [18, 20, 408], 'HELIX_gain_score': array([0.04151005, 0.05008006, 0.08585912]), 'HELIX_loss_score': array([-0.03565449]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [119], 'DOMAIN_gain': [13, 14, 15, 94, 329, 330, 331, 332, 334, 356, 357, 358, 359, 360, 376, 378, 503, 509, 511, 512, 514, 515, 516, 517, 518, 519], 'DOMAIN_gain_score': array([0.04761118, 0.04802728, 0.04888058, 0.03194505, 0.29616392,
       0.30506468, 0.23234296, 0.33055985, 0.25389642, 0.20226014,
       0.17467105, 0.22701651, 0.29019493, 0.41607273, 0.24295229,
       0.19596756, 0.31496125, 0.22070032, 0.238814  , 0.22980976,
       0.31454104, 0.33609951, 0.38909262, 0.43123215, 0.33624947,
       0.42103595]), 'DOMAIN_loss_score': array([-0.03141719]), 'REGION_loss': [], 'REGION_gain': [236, 237, 238, 239, 240, 241, 243, 244, 250, 256, 257, 258, 259, 260, 261, 262, 323, 324, 325, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355], 'REGION_gain_score': array([0.10259128, 0.12134671, 0.10928792, 0.15751326, 0.14230454,
       0.14557612, 0.17381364, 0.15361571, 0.14276224, 0.19768226,
       0.19755298, 0.19020212, 0.19102526, 0.17527562, 0.1594165 ,
       0.1713028 , 0.15435797, 0.15904671, 0.1509999 , 0.16508162,
       0.15794498, 0.1639365 , 0.17015308, 0.16730493, 0.16305029,
       0.16508412, 0.16521919, 0.16369742, 0.1613729 , 0.14995795,
       0.16415584, 0.14937979, 0.15211207, 0.14670032, 0.15272397,
       0.15573001, 0.14916384, 0.14028436, 0.15131265, 0.15033495,
       0.13156277, 0.13977444, 0.14883208, 0.14583623, 0.13373685,
       0.15074688, 0.14647925, 0.14193636]), 'REPEAT_loss': [191, 193, 238, 240, 492, 495, 497], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.04248703, -0.04191786, -0.03411746, -0.02201772, -0.04405117,
       -0.02685541, -0.02872837]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
753	NM_000329.3(RPE65):c.242G>T (p.Arg81Ile)	559523	CA340748885	NM_000329.3:c.242G>T, NC_000001.11:g.68446713C>A, CM000663.2:g.68446713C>A, NC_000001.10:g.68912396C>A, CM000663.1:g.68912396C>A, NC_000001.9:g.68684984C>A, NG_008472.1:g.8247G>T, NG_008472.2:g.8247G>T, ENST00000262340.6:c.242G>T, ENST00000262340.5:c.242G>T, NM_000329.2:c.242G>T, XM_017002027.1:c.-31-1830G>T, NM_000329.3(RPE65):c.242G>T (p.Arg81Ile)	RPE65	RPE65-related recessive retinopathy	MONDO:0100368	Autosomal recessive inheritance	Pathogenic	PP1, PM2_Supporting, PM3_Strong, PP3_Moderate, PP4_Moderate		NM_000329.3(RPE65):c.242G>T is a missense variant causing substitution of arginine by isoleucine at position 81. This variant is present in gnomAD v.4.0.0 at a GrpMax allele frequency of 0.0001576, with 24 alleles / 59020 total alleles in the Admixed American population, which is lower than the ClinGen LCA / eoRD VCEP PM2_Supporting threshold of <0.0002 (PM2_Supporting). This variant has been reported in at least 2 unrelated probands with early-onset severe retinal dystrophy who were homozygous for the variant (1 pt, PMID: 30870047). This variant has also been reported in at least 1 proband with early-onset severe retinal dystrophy who was compound heterozygous with the NM_000329.2(RPE65):c.292_311del (p.Ile98Hisfs) variant confirmed in trans (1 pt, PMID: 30870047), which was previously classified pathogenic by the ClinGen LCA / eoRD VCEP (2 total points, PM3_Strong). At least one proband harboring this variant exhibits a phenotype including a diagnosis of Leber congenital amaurosis (0.5 pts), onset at 1 month of age (1 pt), undetectable ERG responses from rods (0.5 pts) and cones (1 pt), nyctalopia (0.5 pts), reduced visual acuity (1 pt), light gazing (1 pt), RPE mottling (0.5 pts), optic nerve pallor (0.5 pt), nystagmus (1 pt), and pigmentary retinopathy with attenuated vessels (0.5 pt), which together are highly specific for RPE65-related recessive retinopathy (8 total points, PMID: 30870047, PP4_Moderate). The variant has been reported to segregate with childhood-onset severe retinal dystrophy through the proband plus 1 similarly affected relative, with the variant present in the homozygous state (PMID: 30870047, PP1). The computational predictor REVEL gives a score of 0.849, which is above the ClinGen LCA / eoRD VCEP threshold of ≥ 0.773 and predicts a damaging effect on RPE65 function (PP3_Moderate). In summary, this variant meets the criteria to be classified as pathogenic for RPE65-related recessive retinopathy based on the ACMG/AMP criteria applied, as specified by the ClinGen LCA / eoRD VCEP: PM2_supporting, PM3_Strong, PP1, PP3_Moderate, and PP4_Moderate. (VCEP specifications version 1.0.0; date of approval 09/21/2023).		Leber Congenital Amaurosis/early onset Retinal Dystrophy VCEP		2024-04-22	2024-04-22	False	https://erepo.genome.network/evrepo/ui/classification/CA340748885/MONDO:0100368/120	03c7302f-425c-4d5b-a848-1afc29d90381	p.Arg81Ile	Arg	81	Ile	MSIQVEHPAGGYKKLFETVEELSSPLTAHVTGRIPLWLTGSLLRCGPGLFEVGSEPFYHLFDGQALLHKFDFKEGHVTYHRRFIRTDAYVRAMTEKRIVITEFGTCAFPDPCKNIFSRFFSYFRGVEVTDNALVNVYPVGEDYYACTETNFITKINPETLETIKQVDLCNYVSVNGATAHPHIENDGTVYNIGNCFGKNFSIAYNIVKIPPLQADKEDPISKSEIVVQFPCSDRFKPSYVHSFGLTPNYIVFVETPVKINLFKFLSSWSLWGANYMDCFESNETMGVWLHIADKKRKKYLNNKYRTSPFNLFHHINTYEDNGFLIVDLCCWKGFEFVYNYLYLANLRENWEEVKKNARKAPQPEVRRYVLPLNIDKADTGKNLVTLPNTTATAILCSDETIWLEPEVLFSGPRQAFEFPQINYQKYCGKPYTYAYGLGLNHFVPDRLCKLNVKTKETWVWQEPDSYPSEPIFVSHPDALEEDDGVVLSVVVSPGAGQKPAYLLILNAKDLSEVARAEVEINIPVTFHGLFKKS	533	Q16518	I	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [286], 'DNA_BIND_gain': [], 'DNA_BIND_loss_score': array([-0.00257325]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [2, 4, 6, 7, 11, 12, 18, 26, 30], 'PROPEP_gain_score': array([0.03563833, 0.03108001, 0.03451461, 0.03046995, 0.02378845,
       0.02549672, 0.02286881, 0.01443398, 0.0127489 ]), 'SIGNAL_loss': [2, 4, 5], 'SIGNAL_gain': [], 'SIGNAL_loss_score': array([-0.07671452, -0.08100778, -0.09361935]), 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [43, 51, 98, 409], 'STRAND_gain': [72, 83], 'STRAND_gain_score': array([0.1328271 , 0.40297407]), 'STRAND_loss_score': array([-0.19570667, -0.15544498, -0.12862664, -0.01304632]), 'HELIX_loss': [333], 'HELIX_gain': [18], 'HELIX_gain_score': array([0.02618569]), 'HELIX_loss_score': array([-0.01123732]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [18, 85, 88, 89, 90, 91, 92, 93, 119, 121, 122, 271, 513], 'DOMAIN_gain': [329], 'DOMAIN_gain_score': array([0.06387651]), 'DOMAIN_loss_score': array([-0.02815497, -0.07054335, -0.07008123, -0.10719812, -0.08862072,
       -0.09061641, -0.05511618, -0.0995689 , -0.04505467, -0.03213352,
       -0.03587055, -0.04934365, -0.01937729]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
754	NM_000329.3(RPE65):c.544C>T (p.His182Tyr)	98875	CA226559	NM_000329.3:c.544C>T, NC_000001.11:g.68440952G>A, CM000663.2:g.68440952G>A, NC_000001.10:g.68906635G>A, CM000663.1:g.68906635G>A, NC_000001.9:g.68679223G>A, NG_008472.1:g.14008C>T, NG_008472.2:g.14008C>T, ENST00000262340.6:c.544C>T, ENST00000262340.5:c.544C>T, NM_000329.2:c.544C>T, XM_017002027.1:c.268C>T, NM_000329.3(RPE65):c.544C>T (p.His182Tyr)	RPE65	RPE65-related recessive retinopathy	MONDO:0100368	Autosomal recessive inheritance	Pathogenic	PM2_Supporting, PM3_Strong, PP3_Moderate, PM1, PS3_Supporting, PP1_Moderate	PM5	The NM_000329.3(RPE65):c.544C>T (p.His182Tyr) variant in RPE65 is a missense variant resulting in a substitution of histidine by tyrosine at codon 182. This variant is absent from gnomAD v2.1.1 (PM2_Supporting). This variant has been reported in at least 1 unrelated proband with early-onset severe retinal dystrophy who was homozygous for the variant (0.5 point, PMID: 27874104). This variant has also been reported in 2 unrelated probands with early-onset severe retinal dystrophy who were compound heterozygous with the NM_000329.3(RPE65):c.118G>A (p.Gly40Ser) confirmed in trans (2 points, PMID: 9501220,  PMID: 27102010), which was previously classified as pathogenic by the ClinGen LCA / eoRD VCEP (2.5 total points, PM3_Strong). The variant has been reported to segregate with childhood-onset severe retinal dystrophy  through the proband plus 2 similarly affected relatives, with the variant present in the  homozygous state (PP1_Moderate; PMID: 27874104).This variant is a missense substitution at p.His182, which is located within the active site, a well-characterized functional domain required for enzymatic activity (PM1, PMID: 34492281). The variant exhibited approximately 10% enzymatic activity in a retinoid isomerase assay relative to the wildtype control, which meets the ClinGen LCA / eoRD PS3_Supporting threshold of ≤10% activity, indicating that it triggers a severe defect in protein function (PS3_Supporting, PMID: 16150724). The computational predictor REVEL gives a score of 0.912, which is above the ClinGen LCA / eoRD VCEP threshold of ≥ 0.773 and predicts a damaging effect on RPE65 function (PP3_Moderate). In summary, this variant meets the criteria to be classified as pathogenic for RPE65-related recessive retinopathy based on the ACMG/AMP criteria applied, as specified by the ClinGen LCA/eoRD VCEP: PM2_Supporting, PM3_Strong, PP1_Moderate, PM1, PS3_Supporting, PP3_Moderate. (VCEP specifications version 1.0.0; date of approval 09/21/2023).		Leber Congenital Amaurosis/early onset Retinal Dystrophy VCEP		2024-04-22	2024-04-22	False	https://erepo.genome.network/evrepo/ui/classification/CA226559/MONDO:0100368/120	08f5d49e-8b51-4825-a7cf-652155a5682d	p.His182Tyr	His	182	Tyr	MSIQVEHPAGGYKKLFETVEELSSPLTAHVTGRIPLWLTGSLLRCGPGLFEVGSEPFYHLFDGQALLHKFDFKEGHVTYHRRFIRTDAYVRAMTEKRIVITEFGTCAFPDPCKNIFSRFFSYFRGVEVTDNALVNVYPVGEDYYACTETNFITKINPETLETIKQVDLCNYVSVNGATAHPHIENDGTVYNIGNCFGKNFSIAYNIVKIPPLQADKEDPISKSEIVVQFPCSDRFKPSYVHSFGLTPNYIVFVETPVKINLFKFLSSWSLWGANYMDCFESNETMGVWLHIADKKRKKYLNNKYRTSPFNLFHHINTYEDNGFLIVDLCCWKGFEFVYNYLYLANLRENWEEVKKNARKAPQPEVRRYVLPLNIDKADTGKNLVTLPNTTATAILCSDETIWLEPEVLFSGPRQAFEFPQINYQKYCGKPYTYAYGLGLNHFVPDRLCKLNVKTKETWVWQEPDSYPSEPIFVSHPDALEEDDGVVLSVVVSPGAGQKPAYLLILNAKDLSEVARAEVEINIPVTFHGLFKKS	533	Q16518	Y	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [253], 'DNA_BIND_gain_score': array([0.00122482]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [12, 30], 'PROPEP_gain_score': array([0.00765908, 0.01228315]), 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [98, 409], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.04930794, -0.00349075]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [193], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.01625419]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
755	NM_000329.3(RPE65):c.545A>G (p.His182Arg)	1074826	CA340747132	NM_000329.3:c.545A>G, NC_000001.11:g.68440951T>C, CM000663.2:g.68440951T>C, NC_000001.10:g.68906634T>C, CM000663.1:g.68906634T>C, NC_000001.9:g.68679222T>C, NG_008472.1:g.14009A>G, NG_008472.2:g.14009A>G, ENST00000262340.6:c.545A>G, ENST00000262340.5:c.545A>G, NM_000329.2:c.545A>G, XM_017002027.1:c.269A>G, NM_000329.3(RPE65):c.545A>G (p.His182Arg)	RPE65	RPE65-related recessive retinopathy	MONDO:0100368	Autosomal recessive inheritance	Pathogenic	PM2_Supporting, PM3_Strong, PP3_Moderate, PM1, PM5		The NM_000329.3(RPE65):c.545A>G (p.His182Arg) variant in RPE65 is a missense variant resulting in a substitution of histidine by arginine at codon 182 . This variant is absent from gnomAD v2.1.1 (PM2_Supporting). This variant has been reported in at least 2 probands with early-onset severe retinal dystrophy who were homozygous for the variant (1 point, PMIDs: 19117922, 27102010). This variant has also been reported in at least 1 proband with early-onset severe retinal dystrophy who was compound heterozygous with the NM_000329.3(RPE65):c.271C>T (p.Arg91Trp) variant confirmed in trans (1 point, PMID: 31273949), which was previously classified pathogenic by the ClinGen LCA / eoRD VCEP (2 total points, PM3_Strong).  This variant is a missense substitution at  p.His182, which is located within the active site, a well-characterized functional domain required for enzymatic activity (PM1, PMID: 34492281). The computational predictor REVEL gives a score of 0.900, which is above the ClinGen LCA / eoRD VCEP threshold of ≥ 0.773 and predicts a damaging effect on RPE65 function (PP3_Moderate). Another missense variant in the same codon (NM_000329.3(RPE65):c.544C>T (p.His182Tyr) has been classified as Pathogenic for RPE65-related recessive retinopathy by the ClinGen LCA / eoRD VCEP (PM5, ClinVar Variation ID: 98875). Splicing prediction using SpliceAI did not strongly predict an effect on splicing due to either of these variants. In summary, this variant meets the criteria to be classified as pathogenic for RPE65-related recessive retinopathy based on the ACMG/AMP criteria applied, as specified by the ClinGen LCA/eoRD VCEP: PM2_Supporting, PM3_Strong, PM1, PP3_Moderate, PM5. (VCEP specifications version 1.0.0; date of approval 09/21/2023).		Leber Congenital Amaurosis/early onset Retinal Dystrophy VCEP		2024-04-22	2024-04-22	False	https://erepo.genome.network/evrepo/ui/classification/CA340747132/MONDO:0100368/120	eb14df3e-1b46-45fe-b28d-df938719c5cf	p.His182Arg	His	182	Arg	MSIQVEHPAGGYKKLFETVEELSSPLTAHVTGRIPLWLTGSLLRCGPGLFEVGSEPFYHLFDGQALLHKFDFKEGHVTYHRRFIRTDAYVRAMTEKRIVITEFGTCAFPDPCKNIFSRFFSYFRGVEVTDNALVNVYPVGEDYYACTETNFITKINPETLETIKQVDLCNYVSVNGATAHPHIENDGTVYNIGNCFGKNFSIAYNIVKIPPLQADKEDPISKSEIVVQFPCSDRFKPSYVHSFGLTPNYIVFVETPVKINLFKFLSSWSLWGANYMDCFESNETMGVWLHIADKKRKKYLNNKYRTSPFNLFHHINTYEDNGFLIVDLCCWKGFEFVYNYLYLANLRENWEEVKKNARKAPQPEVRRYVLPLNIDKADTGKNLVTLPNTTATAILCSDETIWLEPEVLFSGPRQAFEFPQINYQKYCGKPYTYAYGLGLNHFVPDRLCKLNVKTKETWVWQEPDSYPSEPIFVSHPDALEEDDGVVLSVVVSPGAGQKPAYLLILNAKDLSEVARAEVEINIPVTFHGLFKKS	533	Q16518	R	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [98], 'STRAND_gain': [107], 'STRAND_gain_score': array([0.01387346]), 'STRAND_loss_score': array([-0.02127606]), 'HELIX_loss': [264], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.00761092]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [193], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.01483452]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
756	NM_000329.3(RPE65):c.74C>T (p.Pro25Leu)	437985	CA902628	NM_000329.3:c.74C>T, NC_000001.11:g.68448644G>A, CM000663.2:g.68448644G>A, NC_000001.10:g.68914327G>A, CM000663.1:g.68914327G>A, NC_000001.9:g.68686915G>A, NG_008472.1:g.6316C>T, NG_008472.2:g.6316C>T, ENST00000262340.6:c.74C>T, ENST00000262340.5:c.74C>T, NM_000329.2:c.74C>T, XM_017002027.1:c.-52C>T, NM_000329.3(RPE65):c.74C>T (p.Pro25Leu)	RPE65	RPE65-related recessive retinopathy	MONDO:0100368	Autosomal recessive inheritance	Pathogenic	PM2_Supporting, PM3_Strong, PP3_Moderate, PS3_Supporting, PP4_Moderate		NM_000329.3(RPE65):c.74C>T is a missense variant predicted to replace proline with leucine at position 25 in exon 2 of RPE65. This variant has been reported in at least 1 proband with early-onset severe retinal dystrophy who was homozygous for the variant (0.5 points, PMIDs: 18599565). This variant has also been reported in at least 3 probands with early-onset severe retinal dystrophy who were either compound heterozygous with the c.893del p.Lys298fs variant confirmed in trans (1 pt), with the Arg515Trp variant suspected in trans (0.5 pts), or with the c.11+5G>A variant suspected in trans (0.5 pts), PMIDs: 35001204, 36672611, 30025081), which were all previously classified as pathogenic by the ClinGen LCA / eoRD VCEP (2.5 total points, PM3_Strong).  This variant has also been reported in additional probands in the compound heterozygous state with the Ala434Glu or Tyr79His variants, but these cases were not considered to avoid circularity in the application of the PM3 code or due to insufficient phenotype data (PMIDs 29033008, 32581362, 22807296). At least one proband harboring this variant exhibits a phenotype including significant, documented improvement of dark-adapted vision after treatment with RPE65 gene therapy (8 pt), congenital night blindness (0.5 pt), nystagmus (1 pt), decreased central visual acuity (1 pt), and onset between birth and age five years (1 pt), which together are highly specific for RPE65-related recessive retinopathy (11.5 points, PMID: 36672611, PP4_Moderate). The variant exhibited 7.75% enzymatic activity in a retinoid isomerase assay relative to the wild-type control, which is lower than the ClinGen LCA / eoRD PS3_Supporting threshold of <10% activity, indicating that it triggers a severe defect in protein function (PS3_Supporting, PMID: 18599565). The computational predictor REVEL gives a score of 0.898, which is above the ClinGen LCA / eoRD VCEP threshold of ≥ 0.773 and predicts a damaging effect on RPE65 function (PP3_Moderate). This variant is present in gnomAD v.2.1.1 at a GrpMax allele frequency of 0.0001, with 1/30582 total alleles in the South Asian population, which is lower than the ClinGen LCA / eoRD VCEP PM2_Supporting threshold of <0.0002 (PM2_Supporting). In summary, this variant meets the criteria to be classified as Pathogenic for RPE65-related recessive retinopathy based on the ACMG/AMP criteria applied, as specified by the ClinGen LCA/eoRD VCEP: PM3_Strong, PP3_Moderate, PP4_Moderate, PS3_Supporting, PM3_Supporting (VCEP specifications version 1.0.0; date of approval 09/21/2023).		Leber Congenital Amaurosis/early onset Retinal Dystrophy VCEP		2024-04-22	2024-04-22	False	https://erepo.genome.network/evrepo/ui/classification/CA902628/MONDO:0100368/120	9ffc6fee-a8f4-44ab-b142-5c93b283144f	p.Pro25Leu	Pro	25	Leu	MSIQVEHPAGGYKKLFETVEELSSPLTAHVTGRIPLWLTGSLLRCGPGLFEVGSEPFYHLFDGQALLHKFDFKEGHVTYHRRFIRTDAYVRAMTEKRIVITEFGTCAFPDPCKNIFSRFFSYFRGVEVTDNALVNVYPVGEDYYACTETNFITKINPETLETIKQVDLCNYVSVNGATAHPHIENDGTVYNIGNCFGKNFSIAYNIVKIPPLQADKEDPISKSEIVVQFPCSDRFKPSYVHSFGLTPNYIVFVETPVKINLFKFLSSWSLWGANYMDCFESNETMGVWLHIADKKRKKYLNNKYRTSPFNLFHHINTYEDNGFLIVDLCCWKGFEFVYNYLYLANLRENWEEVKKNARKAPQPEVRRYVLPLNIDKADTGKNLVTLPNTTATAILCSDETIWLEPEVLFSGPRQAFEFPQINYQKYCGKPYTYAYGLGLNHFVPDRLCKLNVKTKETWVWQEPDSYPSEPIFVSHPDALEEDDGVVLSVVVSPGAGQKPAYLLILNAKDLSEVARAEVEINIPVTFHGLFKKS	533	Q16518	L	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [251, 261, 286], 'DNA_BIND_gain': [], 'DNA_BIND_loss_score': array([-0.00481045, -0.00709593, -0.00347733]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [17, 18, 26, 27, 30, 32, 33, 34, 36], 'PROPEP_gain_score': array([0.03018177, 0.03538942, 0.05977917, 0.05969298, 0.04882485,
       0.06099916, 0.07223189, 0.07322824, 0.06173551]), 'SIGNAL_loss': [], 'SIGNAL_gain': [6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32], 'SIGNAL_gain_score': array([0.32578635, 0.30131155, 0.32508194, 0.33546484, 0.3583312 ,
       0.44064891, 0.45803559, 0.50558537, 0.49947083, 0.50187159,
       0.4560014 , 0.48437518, 0.48765844, 0.45119363, 0.47318518,
       0.48022574, 0.49146301, 0.52752984, 0.49802381, 0.51524067,
       0.43065363, 0.54512352, 0.48515344, 0.49003226, 0.50863183,
       0.43121618, 0.35573637]), 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [43, 48, 131, 409], 'STRAND_gain': [103, 107, 528], 'STRAND_gain_score': array([0.07385403, 0.03324676, 0.01938897]), 'STRAND_loss_score': array([-0.38405305, -0.23841953, -0.03411132, -0.02119917]), 'HELIX_loss': [264], 'HELIX_gain': [18, 20, 21, 22, 23, 24, 26, 27, 28], 'HELIX_gain_score': array([0.03583705, 0.18768346, 0.25985909, 0.52031952, 0.59431511,
       0.25845486, 0.11927104, 0.20545322, 0.19821054]), 'HELIX_loss_score': array([-0.01276296]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [10, 11, 12, 13, 14, 15, 94, 96, 118, 376, 503], 'DOMAIN_gain_score': array([0.06196266, 0.06445873, 0.0673269 , 0.07496738, 0.07460618,
       0.06992573, 0.02962238, 0.03157872, 0.03893119, 0.01257896,
       0.01662457]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [497], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.00051856]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
757	NM_000329.3(RPE65):c.938A>G (p.His313Arg)	1679125	CA340744821	NM_000329.3:c.938A>G, NC_000001.11:g.68439002T>C, CM000663.2:g.68439002T>C, NC_000001.10:g.68904685T>C, CM000663.1:g.68904685T>C, NC_000001.9:g.68677273T>C, NG_008472.1:g.15958A>G, NG_008472.2:g.15958A>G, ENST00000262340.6:c.938A>G, ENST00000262340.5:c.938A>G, NM_000329.2:c.938A>G, XM_017002027.1:c.662A>G, NM_000329.3(RPE65):c.938A>G (p.His313Arg)	RPE65	RPE65-related recessive retinopathy	MONDO:0100368	Autosomal recessive inheritance	Pathogenic	PM2_Supporting, PP3_Moderate, PM1, PM3, PS3_Supporting, PP4_Moderate	PM5	The NM_000329.3(RPE65):c.938A>G (p.His313Arg) variant is a missense substitution at His313, which is located within the active site, a well-characterized functional domain required for enzymatic activity (PM1, PMID: 34492281).The computational predictor REVEL gives a score of 0.964 which is above the ClinGen LCA/eoRD VCEP threshold of ≥ 0.773 and predicts a damaging effect on RPE65 function (PP3_Moderate). The variant exhibited 0% enzymatic activity in a retinoid isomerase assay relative to the wild-type control, which is lower than the ClinGen LCA/eoRD VCEP PS3_Supporting threshold of <10% activity, indicating that it triggers a severe defect in protein function (PS3_Supporting, PMID: 24849605). At least one proband harboring this variant exhibits a phenotype including diagnosis of LCA (0.5 points), absent ERG (0.5 points), nystagmus (0.5 points) and decreased visual acuity (1 point). This patient showed significant improvement in several measures of dark-adapted vision after gene therapy treatment (8 points). Together these are highly specific for RPE65-related recessive retinopathy (10.5 points, PMID: 19854499, PP4_Moderate). This variant has been reported in at least 1 proband with early-onset severe retinal dystrophy who was  homozygous for the variant (0.5 points, PMIDs: 35129589). This variant has also been reported in at least 1 proband with early-onset severe retinal dystrophy who was compound heterozygous with the c.292_311del(p.Ile98Hisfs*26) variant suspected in trans (0.5 points) and at least 1 proband with early-onset severe retinal dystrophy who was compound heterozygous with the p.Tyr386 variant suspected in trans (0.5 points) (PMID: 35129589), which were both previously classified pathogenic by the ClinGen LCA/eoRD VCEP.  (1.5 total points, PM3).This variant is present in gnomAD v.4.0.0 at a GrpMax allele frequency of 0.000002280, with 4 alleles/418086 total alleles in the European (Non-Finnish) population, which is lower than the ClinGen LCA/eoRD VCEP PM2_Supporting threshold of <0.0002 (PM2_Supporting). In summary, this variant meets the criteria to be classified as Pathogenic for RPE65-related recessive retinopathy based on the ACMG/AMP criteria applied, as specified by the ClinGen LCA/eoRD VCEP: PP3_Moderate, PP4_Moderate, PM1, PM3, PM2_Supporting, PS3_Supporting. (VCEP specifications version 1.0.0; date of approval 09/21/2023)		Leber Congenital Amaurosis/early onset Retinal Dystrophy VCEP		2024-04-22	2024-04-22	False	https://erepo.genome.network/evrepo/ui/classification/CA340744821/MONDO:0100368/120	4595da62-656a-482d-b84c-f4d607fb808c	p.His313Arg	His	313	Arg	MSIQVEHPAGGYKKLFETVEELSSPLTAHVTGRIPLWLTGSLLRCGPGLFEVGSEPFYHLFDGQALLHKFDFKEGHVTYHRRFIRTDAYVRAMTEKRIVITEFGTCAFPDPCKNIFSRFFSYFRGVEVTDNALVNVYPVGEDYYACTETNFITKINPETLETIKQVDLCNYVSVNGATAHPHIENDGTVYNIGNCFGKNFSIAYNIVKIPPLQADKEDPISKSEIVVQFPCSDRFKPSYVHSFGLTPNYIVFVETPVKINLFKFLSSWSLWGANYMDCFESNETMGVWLHIADKKRKKYLNNKYRTSPFNLFHHINTYEDNGFLIVDLCCWKGFEFVYNYLYLANLRENWEEVKKNARKAPQPEVRRYVLPLNIDKADTGKNLVTLPNTTATAILCSDETIWLEPEVLFSGPRQAFEFPQINYQKYCGKPYTYAYGLGLNHFVPDRLCKLNVKTKETWVWQEPDSYPSEPIFVSHPDALEEDDGVVLSVVVSPGAGQKPAYLLILNAKDLSEVARAEVEINIPVTFHGLFKKS	533	Q16518	R	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [312], 'BINDING_gain': [], 'BINDING_loss_score': array([-0.36878896]), 'DNA_BIND_loss': [286], 'DNA_BIND_gain': [], 'DNA_BIND_loss_score': array([-0.00349951]), 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [409], 'STRAND_gain': [103, 107], 'STRAND_gain_score': array([0.02510226, 0.00858086]), 'STRAND_loss_score': array([-0.00148177]), 'HELIX_loss': [277, 333], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.01911795, -0.0167262 ]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [92, 271], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.01085228, -0.03239423]), 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [497], 'REPEAT_gain': [], 'REPEAT_loss_score': array([-0.0020799]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}
758	NM_000162.5(GCK):c.1345G>A (p.Ala449Thr)	36199	CA213758	NM_000162.5:c.1345G>A, NC_000007.14:g.44145189C>T, CM000669.2:g.44145189C>T, NC_000007.13:g.44184788C>T, CM000669.1:g.44184788C>T, NC_000007.12:g.44151313C>T, NG_008847.1:g.49235G>A, NG_008847.2:g.57982G>A, ENST00000395796.8:c.*1343G>A, ENST00000616242.5:c.*465G>A, ENST00000683378.1:n.571G>A, ENST00000336642.9:c.379G>A, ENST00000345378.7:c.1348G>A, ENST00000403799.8:c.1345G>A, ENST00000671824.1:c.1408G>A, ENST00000672743.1:n.357G>A, ENST00000673284.1:c.1345G>A, ENST00000336642.8:c.397G>A, ENST00000345378.6:c.1348G>A, ENST00000395796.7:c.1342G>A, ENST00000403799.7:c.1345G>A, ENST00000437084.1:c.1294G>A, ENST00000459642.1:n.725G>A, ENST00000616242.4:c.1342G>A, NM_000162.3:c.1345G>A, NM_033507.1:c.1348G>A, NM_033508.1:c.1342G>A, NM_000162.4:c.1345G>A, NM_001354800.1:c.1345G>A, NM_001354801.1:c.334G>A, NM_001354802.1:c.205G>A, NM_001354803.1:c.379G>A, NM_033507.2:c.1348G>A, NM_033508.2:c.1342G>A, XM_024446707.1:c.205G>A, NM_033507.3:c.1348G>A, NM_033508.3:c.1342G>A, NM_001354803.2:c.379G>A, NM_000162.5(GCK):c.1345G>A (p.Ala449Thr)	GCK	monogenic diabetes	MONDO:0015967	Semidominant inheritance	Pathogenic	PS4_Moderate, PP1_Strong, PS3_Supporting, PP2, PP3, PP4, PM3, PM2_Supporting	PM1	The c.1345G>A variant in the glucokinase gene, GCK, causes an amino acid change of alanine to threonine at codon 449 (p.(Ala449Thr)) of NM_000162.5.  GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2).  This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.89, which is greater than the MDEP VCEP threshold of 0.70 (PP3).  While the relative activity index (RAI) of this variant was above the MDEP cutoff of 0.5, the relative stability index was below the MDEP cutoff of 0.5 (PS3_Supporting; PMID: 25015100).  This variant is absent from gnomAD v2.1.1 (PM2_Supporting).  This variant was identified in 4 unrelated individuals with hyperglycemia (PS4_Moderate; PMID: 25015100, internal lab contributors).  This variant has been detected in the homozygous state in 3 individuals with permanent neonatal diabetes (PNDM) and negative testing for ABCC8, KCNJ11, and INS (PM3).  This variant segregated in the homozygous state with permanent neonatal diabetes and the in the heterozygous state with hyperglycemia, with 6 informative meioses in 2 families (PP1_Strong; internal lab contributors).  In summary, c.1345G>A meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.3.0, approved 8/11/2023): PP1_Strong, PM3, PS4_Moderate, PP2, PP3, PP4, PM2_Moderate, PS3_Supporting.		Monogenic Diabetes VCEP		2024-04-27	2024-04-27	False	https://erepo.genome.network/evrepo/ui/classification/CA213758/MONDO:0015967/086	cacf5183-a9c7-4f46-b4f0-96850253a67d	p.Ala449Thr	Ala	449	Thr	MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQ	465	P35557	T	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [203], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.01618558]), 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [73], 'REGION_gain': [], 'REGION_loss_score': array([-0.00457829]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
759	NM_000162.5(GCK):c.1307T>A (p.Ile436Asn)	36195	CA213751	NM_000162.5:c.1307T>A, NC_000007.14:g.44145227A>T, CM000669.2:g.44145227A>T, NC_000007.13:g.44184826A>T, CM000669.1:g.44184826A>T, NC_000007.12:g.44151351A>T, NG_008847.1:g.49197T>A, NG_008847.2:g.57944T>A, ENST00000395796.8:c.*1305T>A, ENST00000616242.5:c.*427T>A, ENST00000683378.1:n.533T>A, ENST00000336642.9:c.341T>A, ENST00000345378.7:c.1310T>A, ENST00000403799.8:c.1307T>A, ENST00000671824.1:c.1370T>A, ENST00000672743.1:n.319T>A, ENST00000673284.1:c.1307T>A, ENST00000336642.8:c.359T>A, ENST00000345378.6:c.1310T>A, ENST00000395796.7:c.1304T>A, ENST00000403799.7:c.1307T>A, ENST00000437084.1:c.1256T>A, ENST00000459642.1:n.687T>A, ENST00000616242.4:c.1304T>A, NM_000162.3:c.1307T>A, NM_033507.1:c.1310T>A, NM_033508.1:c.1304T>A, NM_000162.4:c.1307T>A, NM_001354800.1:c.1307T>A, NM_001354801.1:c.296T>A, NM_001354802.1:c.167T>A, NM_001354803.1:c.341T>A, NM_033507.2:c.1310T>A, NM_033508.2:c.1304T>A, XM_024446707.1:c.167T>A, NM_033507.3:c.1310T>A, NM_033508.3:c.1304T>A, NM_001354803.2:c.341T>A, NM_000162.5(GCK):c.1307T>A (p.Ile436Asn)	GCK	monogenic diabetes	MONDO:0015967	Semidominant inheritance	Pathogenic	PS4_Moderate, PP1_Strong, PS3_Supporting, PM5_Supporting, PP4_Moderate, PP2, PP3, PM2_Supporting		The c.1307T>A variant in the glucokinase gene, GCK, causes an amino acid change of isoleucine to asparagine at codon 436 (p.(Ile436Asn)) of NM_000162.5. GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2). This variant is also predicted to be deleterious by computational evidence, with a REVEL score of 0.957, which is greater than the MDEP VCEP threshold of 0.70 (PP3). This variant is absent in gnomAD v2.1.1 (PM2_Supporting), and was identified in at least 5 unrelated individuals with hyperglycemia (PS4_Moderate; PMID 17204055, PMID 20337973, PMID 22493702, internal lab contributors). At least 2 of these individuals have a clinical history highly specific for GCK-hyperglycemia (FBG 5.5-8 mmol/L and HbA1c 5.6 - 7.6% and negative antibodies +/- 2 hour oral glucose tolerance test increment <3 mmol/L) (PP4_Moderate; internal lab contributors). This variant also segregated with diabetes/hyperglycemia, with 4 informative meioses in 2 families (PP1_Strong; internal lab contributors). Another missense variant, c.1306A>T p.Ile436Phe has been interpreted as likely pathogenic by the ClinGen MDEP (PM5_Supporting). While the RAI of this variant was 0.975, this variant results in decreased inhibition by GKRP (PS3_Supporting; PMID: 22493702).  In summary, this evidence supports the classification of c.1307T>A as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.3.0, approved 8/11/2023): PP1_Strong, PS4_Moderate, PP4_Moderate, PM5_Supporting, PP2, PP3, PM2_Supporting.		Monogenic Diabetes VCEP		2024-04-27	2024-04-27	False	https://erepo.genome.network/evrepo/ui/classification/CA213751/MONDO:0015967/086	848bb6b5-a99b-41c3-a9b8-413c2dce18db	p.Ile436Asn	Ile	436	Asn	MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQ	465	P35557	N	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [434], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.38051456]), 'HELIX_loss': [457, 458], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.18900526, -0.15815723]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [149], 'DOMAIN_gain': [221], 'DOMAIN_gain_score': array([0.03290159]), 'DOMAIN_loss_score': array([-0.02527523]), 'REGION_loss': [], 'REGION_gain': [11, 13, 21, 22, 38, 71, 75, 80], 'REGION_gain_score': array([0.01571548, 0.01037395, 0.01065576, 0.01769203, 0.00953764,
       0.01845062, 0.03231031, 0.02646512]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
760	NM_000162.5(GCK):c.1268T>A (p.Phe423Tyr)	36189	CA213740	NM_000162.5:c.1268T>A, NC_000007.14:g.44145266A>T, CM000669.2:g.44145266A>T, NC_000007.13:g.44184865A>T, CM000669.1:g.44184865A>T, NC_000007.12:g.44151390A>T, NG_008847.1:g.49158T>A, NG_008847.2:g.57905T>A, ENST00000395796.8:c.*1266T>A, ENST00000616242.5:c.*388T>A, ENST00000683378.1:n.494T>A, ENST00000336642.9:c.302T>A, ENST00000345378.7:c.1271T>A, ENST00000403799.8:c.1268T>A, ENST00000671824.1:c.1331T>A, ENST00000672743.1:n.280T>A, ENST00000673284.1:c.1268T>A, ENST00000336642.8:c.320T>A, ENST00000345378.6:c.1271T>A, ENST00000395796.7:c.1265T>A, ENST00000403799.7:c.1268T>A, ENST00000437084.1:c.1217T>A, ENST00000459642.1:n.648T>A, ENST00000616242.4:c.1265T>A, NM_000162.3:c.1268T>A, NM_033507.1:c.1271T>A, NM_033508.1:c.1265T>A, NM_000162.4:c.1268T>A, NM_001354800.1:c.1268T>A, NM_001354801.1:c.257T>A, NM_001354802.1:c.128T>A, NM_001354803.1:c.302T>A, NM_033507.2:c.1271T>A, NM_033508.2:c.1265T>A, XM_024446707.1:c.128T>A, NM_033507.3:c.1271T>A, NM_033508.3:c.1265T>A, NM_001354803.2:c.302T>A, NM_000162.5(GCK):c.1268T>A (p.Phe423Tyr)	GCK	monogenic diabetes	MONDO:0015967	Semidominant inheritance	Pathogenic	PS4, PP1_Moderate, PP4_Moderate, PP2, PP3, PM2_Supporting	BA1, BP1, BP4, BS1	The c.1268T>A variant in the glucokinase gene, GCK, causes an amino acid change of phenylalanine to tyrosine at codon 423 (p.(Phe423Tyr)) of NM_000162.5. GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2). This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.801, which is greater than the MDEP VCEP threshold of 0.70 (PP3). This variant is absent from gnomAD v2.1.1 (PM2_Supporting). This variant was identified in eight unrelated individuals with hyperglycemia (PS4; PMIDs: 23843579, 31968686, internal lab contributors). This variant segregated with hyperglycemia, with three informative meioses in two families (PP1_Moderate; PMIDs: 28012402, 23843579). This variant was identified in an individual with a clinical history highly specific for GCK-hyperglycemia (FBG 5.5-8 mmol/L and HbA1c 5.6-7.6% and OGTT with minimal increment <3 mmol/l) (PP4_Moderate; PMID: 23843579). In summary, c.1268T>A meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.3.0, approved 8/11/2023): PS4, PP4_Moderate, PP1_Moderate, PM2_supporting, PP2, PP3.		Monogenic Diabetes VCEP		2024-04-27	2024-04-27	False	https://erepo.genome.network/evrepo/ui/classification/CA213740/MONDO:0015967/086	fa69a74e-6d24-423d-a24e-3ea3241ed013	p.Phe423Tyr	Phe	423	Tyr	MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQ	465	P35557	Y	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [2], 'SIGNAL_gain_score': array([0.02662337]), 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [203], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.00842535]), 'HELIX_loss': [457, 458], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.09123635, -0.09346145]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [83], 'DOMAIN_gain_score': array([0.0055356]), 'REGION_loss': [], 'REGION_gain': [71, 80], 'REGION_gain_score': array([0.01365501, 0.01808822]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
761	NM_000162.5(GCK):c.1235T>G (p.Val412Gly)	447387	CA367398280	NM_000162.5:c.1235T>G, NC_000007.14:g.44145515A>C, CM000669.2:g.44145515A>C, NC_000007.13:g.44185114A>C, CM000669.1:g.44185114A>C, NC_000007.12:g.44151639A>C, NG_008847.1:g.48909T>G, NG_008847.2:g.57656T>G, ENST00000395796.8:c.*1233T>G, ENST00000616242.5:c.*355T>G, ENST00000683378.1:n.461T>G, ENST00000336642.9:c.269T>G, ENST00000345378.7:c.1238T>G, ENST00000403799.8:c.1235T>G, ENST00000671824.1:c.1298T>G, ENST00000672743.1:n.247T>G, ENST00000673284.1:c.1235T>G, ENST00000336642.8:c.287T>G, ENST00000345378.6:c.1238T>G, ENST00000395796.7:c.1232T>G, ENST00000403799.7:c.1235T>G, ENST00000437084.1:c.1184T>G, ENST00000459642.1:n.615T>G, ENST00000616242.4:c.1232T>G, NM_000162.3:c.1235T>G, NM_033507.1:c.1238T>G, NM_033508.1:c.1232T>G, NM_000162.4:c.1235T>G, NM_001354800.1:c.1235T>G, NM_001354801.1:c.224T>G, NM_001354802.1:c.95T>G, NM_001354803.1:c.269T>G, NM_033507.2:c.1238T>G, NM_033508.2:c.1232T>G, XM_024446707.1:c.95T>G, NM_033507.3:c.1238T>G, NM_033508.3:c.1232T>G, NM_001354803.2:c.269T>G, NM_000162.5(GCK):c.1235T>G (p.Val412Gly)	GCK	monogenic diabetes	MONDO:0015967	Semidominant inheritance	Pathogenic	PS4_Moderate, PM5_Strong, PP4_Moderate, PP2, PP3, PM1, PM2_Supporting		The c.1235T>G variant in the glucokinase gene, GCK, causes an amino acid change of valine to glycine at codon 412 (p.(Val412Gly)) of NM_000162.5.  GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2).  This variant resides in an amino acid that directly binds ATP, which is defined as critical for the protein’s function by the ClinGen MDEP (PM1). This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.99, which is greater than the MDEP VCEP threshold of 0.70 (PP3).  This variant is absent from gnomAD v2.1.1 (PM2_Supporting).  This variant was identified in 4 unrelated individuals with hyperglycemia (PS4_Moderate; PMIDs: 34362814, 36939643, internal lab contributors).  One of these individuals had a clinical history highly specific for GCK-hyperglycemia (FBG 5.5-8 mmol/L and HbA1c 5.6 - 7.6% and negative antibodies) (PP4_Moderate; internal lab contributors).  Two other missense variants, c.1235T>C p.Val412Ala and p.1235T>A p.Val412Glu, have been interpreted as pathogenic by the ClinGen MDEP, and p.Val412Gly has a greater Grantham distance than p.Val412Ala (PM5_Strong). In summary, c.1235T>G meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.3, approved 8/11/2023): PM5_Strong, PM1, PP2, PP3, PP4_Moderate, PS4_Moderate, PM2_Supporting.		Monogenic Diabetes VCEP		2024-04-27	2024-04-27	False	https://erepo.genome.network/evrepo/ui/classification/CA367398280/MONDO:0015967/086	bebc77b2-ec6d-4a20-8b26-a8fb9cdb636f	p.Val412Gly	Val	412	Gly	MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQ	465	P35557	G	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [408, 414], 'BINDING_gain': [295], 'BINDING_gain_score': array([0.0235517]), 'BINDING_loss_score': array([-0.09429735, -0.13653862]), 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [457, 458], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.27035618, -0.21318698]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [226], 'DOMAIN_gain': [], 'DOMAIN_loss_score': array([-0.04893941]), 'REGION_loss': [8, 9, 12, 73, 74, 79, 82], 'REGION_gain': [], 'REGION_loss_score': array([-0.01406318, -0.01638103, -0.01985824, -0.02981877, -0.02801514,
       -0.03248149, -0.02918273]), 'REPEAT_loss': [], 'REPEAT_gain': [75], 'REPEAT_gain_score': array([0.00741613]), 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
762	NM_000162.5(GCK):c.1229G>A (p.Gly410Asp)	447386	CA367398309	NM_000162.5:c.1229G>A, NC_000007.14:g.44145521C>T, CM000669.2:g.44145521C>T, NC_000007.13:g.44185120C>T, CM000669.1:g.44185120C>T, NC_000007.12:g.44151645C>T, NG_008847.1:g.48903G>A, NG_008847.2:g.57650G>A, ENST00000395796.8:c.*1227G>A, ENST00000616242.5:c.*349G>A, ENST00000683378.1:n.455G>A, ENST00000336642.9:c.263G>A, ENST00000345378.7:c.1232G>A, ENST00000403799.8:c.1229G>A, ENST00000671824.1:c.1292G>A, ENST00000672743.1:n.241G>A, ENST00000673284.1:c.1229G>A, ENST00000336642.8:c.281G>A, ENST00000345378.6:c.1232G>A, ENST00000395796.7:c.1226G>A, ENST00000403799.7:c.1229G>A, ENST00000437084.1:c.1178G>A, ENST00000459642.1:n.609G>A, ENST00000616242.4:c.1226G>A, NM_000162.3:c.1229G>A, NM_033507.1:c.1232G>A, NM_033508.1:c.1226G>A, NM_000162.4:c.1229G>A, NM_001354800.1:c.1229G>A, NM_001354801.1:c.218G>A, NM_001354802.1:c.89G>A, NM_001354803.1:c.263G>A, NM_033507.2:c.1232G>A, NM_033508.2:c.1226G>A, XM_024446707.1:c.89G>A, NM_033507.3:c.1232G>A, NM_033508.3:c.1226G>A, NM_001354803.2:c.263G>A, NM_000162.5(GCK):c.1229G>A (p.Gly410Asp)	GCK	monogenic diabetes	MONDO:0015967	Semidominant inheritance	Pathogenic	PM2, PP4_Moderate, PP2, PP3, PP1, PM1, PM5	PS4	The c.1229G>A variant in the glucokinase gene, GCK, causes an amino acid change of glycine to aspartate at codon 410 (p.(Gly410Asp)) of NM_000162.5. GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2). This variant resides in an amino acid that directly binds ATP, which is defined as critical for the protein’s function by the ClinGen MDEP (PM1). This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.991, which is greater than the MDEP VCEP threshold of 0.70 (PP3). This variant is absent from gnomAD v2.1.1 (PM2_Supporting). This variant segregated with hyperglycemia, with 2 informative meioses in 2 families (PP1; internal lab contributors). This variant was identified in an individual with a clinical history highly specific for GCK-hyperglycemia (FBG 5.5-8 mmol/L and HbA1c 5.6 - 7.6% and antibody negative) (PP4_Moderate; internal lab contributors). This variant was identified in three unrelated individuals with hyperglycemia; however, PS4_Moderate cannot be applied because this number is below the ClinGen MDEP threshold (internal lab contributors). Another missense variant, c.1228G>A p.Gly410Ser, has been interpreted as pathogenic by the ClinGen MDEP, and p.Gly410Asp has a greater Grantham distance (PM5). In summary, c.1229G>A meets the criteria to be classified as likely pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.3.0, approved 8/11/2023): PM1, PP2, PP3, PM2_Supporting, PM5, PP1, PP4_moderate.		Monogenic Diabetes VCEP		2024-04-28	2024-04-28	False	https://erepo.genome.network/evrepo/ui/classification/CA367398309/MONDO:0015967/086	d064c5c8-3236-4805-ad04-ceb6948d456d	p.Gly410Asp	Gly	410	Asp	MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQ	465	P35557	D	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [295], 'BINDING_gain_score': array([0.02310795]), 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [203], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.01327652]), 'HELIX_loss': [323, 457], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.03789163, -0.08424693]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [83], 'DOMAIN_gain_score': array([0.00891131]), 'REGION_loss': [], 'REGION_gain': [11, 21, 71, 75, 80], 'REGION_gain_score': array([0.00658202, 0.00533539, 0.01170462, 0.03356892, 0.02593946]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
763	NM_000162.5(GCK):c.1228G>C (p.Gly410Arg)	1472875	CA367398313	NM_000162.5:c.1228G>C, NC_000007.14:g.44145522C>G, CM000669.2:g.44145522C>G, NC_000007.13:g.44185121C>G, CM000669.1:g.44185121C>G, NC_000007.12:g.44151646C>G, NG_008847.1:g.48902G>C, NG_008847.2:g.57649G>C, ENST00000395796.8:c.*1226G>C, ENST00000616242.5:c.*348G>C, ENST00000683378.1:n.454G>C, ENST00000336642.9:c.262G>C, ENST00000345378.7:c.1231G>C, ENST00000403799.8:c.1228G>C, ENST00000671824.1:c.1291G>C, ENST00000672743.1:n.240G>C, ENST00000673284.1:c.1228G>C, ENST00000336642.8:c.280G>C, ENST00000345378.6:c.1231G>C, ENST00000395796.7:c.1225G>C, ENST00000403799.7:c.1228G>C, ENST00000437084.1:c.1177G>C, ENST00000459642.1:n.608G>C, ENST00000616242.4:c.1225G>C, NM_000162.3:c.1228G>C, NM_033507.1:c.1231G>C, NM_033508.1:c.1225G>C, NM_000162.4:c.1228G>C, NM_001354800.1:c.1228G>C, NM_001354801.1:c.217G>C, NM_001354802.1:c.88G>C, NM_001354803.1:c.262G>C, NM_033507.2:c.1231G>C, NM_033508.2:c.1225G>C, XM_024446707.1:c.88G>C, NM_033507.3:c.1231G>C, NM_033508.3:c.1225G>C, NM_001354803.2:c.262G>C, NM_000162.5(GCK):c.1228G>C (p.Gly410Arg)	GCK	monogenic diabetes	MONDO:0015967	Semidominant inheritance	Pathogenic	PM5_Strong, PP4_Moderate, PP2, PP3, PM1, PM2_Supporting		The c.1228G>C variant in the glucokinase gene, GCK, causes an amino acid change of glycine to arginine at codon 410 (p.(Gly410Arg)) of NM_000162.5.  GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2).  This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.989, which is greater than the MDEP VCEP threshold of 0.70 (PP3).  This variant resides in an amino acid that directly binds ATP, which is defined as critical for the protein’s function by the ClinGen MDEP (PM1).  This variant is absent from gnomAD v2.1.1 (PM2_Supporting).  This variant was identified in an individual with a clinical history highly specific for GCK-hyperglycemia (FBG 5.5-8 mmol/L and HbA1c 5.6 - 7.6% and negative antibodies) (PP4_Moderate; internal lab contributors).  Two other missense variants, c.1229G>A p.Gly410Asp and c.1228G>A p.Gly410Ser, have been interpreted as pathogenic by the ClinGen MDEP, and p.Gly410Arg has a greater Grantham distance than p.Gly410Asp and p.Gly410Ser (PM5_Strong).  In summary, c.1228G>C meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.3.0, approved 8/11/2023): PP4_Moderate, PM1, PP2, PP3, PM2_Supporting, PM5_Strong.		Monogenic Diabetes VCEP		2024-04-28	2024-04-28	False	https://erepo.genome.network/evrepo/ui/classification/CA367398313/MONDO:0015967/086	f41e9d0e-df64-4721-97fd-a52fdf30869e	p.Gly410Arg	Gly	410	Arg	MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQ	465	P35557	R	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [414], 'BINDING_gain': [], 'BINDING_loss_score': array([-0.10182327]), 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [408], 'STRAND_gain_score': array([0.05537486]), 'HELIX_loss': [323], 'HELIX_gain': [409], 'HELIX_gain_score': array([0.19448191]), 'HELIX_loss_score': array([-0.07381958]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [11, 21, 71, 75, 80], 'REGION_gain_score': array([0.0094077 , 0.00622481, 0.00500965, 0.02190053, 0.01417768]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
764	NM_000162.5(GCK):c.1157T>C (p.Leu386Pro)	36180	CA213723	NM_000162.5:c.1157T>C, NC_000007.14:g.44145593A>G, CM000669.2:g.44145593A>G, NC_000007.13:g.44185192A>G, CM000669.1:g.44185192A>G, NC_000007.12:g.44151717A>G, NG_008847.1:g.48831T>C, NG_008847.2:g.57578T>C, ENST00000395796.8:c.*1155T>C, ENST00000616242.5:c.*277T>C, ENST00000683378.1:n.383T>C, ENST00000336642.9:c.191T>C, ENST00000345378.7:c.1160T>C, ENST00000403799.8:c.1157T>C, ENST00000671824.1:c.1220T>C, ENST00000672743.1:n.169T>C, ENST00000673284.1:c.1157T>C, ENST00000336642.8:c.209T>C, ENST00000345378.6:c.1160T>C, ENST00000395796.7:c.1154T>C, ENST00000403799.7:c.1157T>C, ENST00000437084.1:c.1106T>C, ENST00000459642.1:n.537T>C, ENST00000616242.4:c.1154T>C, NM_000162.3:c.1157T>C, NM_033507.1:c.1160T>C, NM_033508.1:c.1154T>C, NM_000162.4:c.1157T>C, NM_001354800.1:c.1157T>C, NM_001354801.1:c.146T>C, NM_001354802.1:c.17T>C, NM_001354803.1:c.191T>C, NM_033507.2:c.1160T>C, NM_033508.2:c.1154T>C, XM_024446707.1:c.17T>C, NM_033507.3:c.1160T>C, NM_033508.3:c.1154T>C, NM_001354803.2:c.191T>C, NM_000162.5(GCK):c.1157T>C (p.Leu386Pro)	GCK	monogenic diabetes	MONDO:0015967	Semidominant inheritance	Pathogenic	PS2, PP4_Moderate, PP2, PP3, PM2_Supporting, PM5		The c.1157T>C variant in the glucokinase gene, GCK, causes an amino acid change of leucine to proline at codon 286 (p.(Leu386Pro)) of NM_000162.5. GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2). This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.984, which is greater than the MDEP VCEP threshold of 0.70 (PP3). This variant is absent from gnomAD v2.1.1 (PM2_Supporting). This variant was identified as a de novo occurrence with confirmed parental relationships in 1 individual with a clinical picture highly specific for GCK-hyperglycemia (FBG 5.5-8 mmol/L and HbA1c 5.6-7.6 and negative antibodies) (PP4_Moderate, PS2; internal lab contributors).  Another missense variant, c.1156C>G, p.(Leu386Val) has been interpreted as pathogenic by the ClinGen MDEP, and p.(Leu386Pro) has a greater Grantham distance (PM5).  In summary, c.1157T>C meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.3.0, approved 8/11/2023): PS2, PP4_Moderate, PM2_supporting, PP2, PP3, PM5.		Monogenic Diabetes VCEP		2024-04-28	2024-04-28	False	https://erepo.genome.network/evrepo/ui/classification/CA213723/MONDO:0015967/086	c4a62d4d-a903-4909-823c-f2774bc16754	p.Leu386Pro	Leu	386	Pro	MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQ	465	P35557	P	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [408], 'BINDING_gain': [], 'BINDING_loss_score': array([-0.03035742]), 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [203], 'STRAND_gain': [], 'STRAND_loss_score': array([-0.03942209]), 'HELIX_loss': [], 'HELIX_gain': [355], 'HELIX_gain_score': array([0.26438129]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [11, 21, 71, 75, 80], 'REGION_gain_score': array([0.01084024, 0.00684166, 0.01545632, 0.02296001, 0.02099872]), 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
765	NM_000162.5(GCK):c.1156C>G (p.Leu386Val)	804837	CA367398705	NM_000162.5:c.1156C>G, NC_000007.14:g.44145594G>C, CM000669.2:g.44145594G>C, NC_000007.13:g.44185193G>C, CM000669.1:g.44185193G>C, NC_000007.12:g.44151718G>C, NG_008847.1:g.48830C>G, NG_008847.2:g.57577C>G, ENST00000395796.8:c.*1154C>G, ENST00000616242.5:c.*276C>G, ENST00000683378.1:n.382C>G, ENST00000336642.9:c.190C>G, ENST00000345378.7:c.1159C>G, ENST00000403799.8:c.1156C>G, ENST00000671824.1:c.1219C>G, ENST00000672743.1:n.168C>G, ENST00000673284.1:c.1156C>G, ENST00000336642.8:c.208C>G, ENST00000345378.6:c.1159C>G, ENST00000395796.7:c.1153C>G, ENST00000403799.7:c.1156C>G, ENST00000437084.1:c.1105C>G, ENST00000459642.1:n.536C>G, ENST00000616242.4:c.1153C>G, NM_000162.3:c.1156C>G, NM_033507.1:c.1159C>G, NM_033508.1:c.1153C>G, NM_000162.4:c.1156C>G, NM_001354800.1:c.1156C>G, NM_001354801.1:c.145C>G, NM_001354802.1:c.16C>G, NM_001354803.1:c.190C>G, NM_033507.2:c.1159C>G, NM_033508.2:c.1153C>G, XM_024446707.1:c.16C>G, NM_033507.3:c.1159C>G, NM_033508.3:c.1153C>G, NM_001354803.2:c.190C>G, NM_000162.5(GCK):c.1156C>G (p.Leu386Val)	GCK	monogenic diabetes	MONDO:0015967	Semidominant inheritance	Pathogenic	PS4, PP1_Strong, PP2, PP3, PM2_Supporting		The c.1156C>G variant in the glucokinase gene, GCK, causes an amino acid change of leucine to valine at codon 386 (p.(Leu386Val)) of NM_000162.5.  GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2).  This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.745, which is greater than the MDEP VCEP threshold of 0.70 (PP3).  This variant is absent from gnomAD v2.1.1 (PM2_Supporting).  This variant was identified in at least 13 unrelated individuals with hyperglycemia (PS4; PMID: 19790256, internal lab contributors).  This variant segregated with hyperglycemia, with at least 5 informative meioses in multiple families (PP1_Strong; internal lab contributors).  In summary, c.1156C>G meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.3.0, approved 8/11/2023): PP1_Strong, PS4, PP2, PP3, PM2_Supporting.		Monogenic Diabetes VCEP		2024-04-28	2024-04-28	False	https://erepo.genome.network/evrepo/ui/classification/CA367398705/MONDO:0015967/086	9fe505f4-9287-4671-ac7c-48bfe0745003	p.Leu386Val	Leu	386	Val	MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQ	465	P35557	V	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [], 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
766	NM_001204.7(BMPR2):c.251G>A (p.Cys84Tyr)	812796	CA350399510	NM_001204.7:c.251G>A, NC_000002.12:g.202467522G>A, CM000664.2:g.202467522G>A, NC_000002.11:g.203332245G>A, CM000664.1:g.203332245G>A, NC_000002.10:g.203040490G>A, NG_009363.1:g.96196G>A, LRG_712:g.96196G>A, ENST00000374580.10:c.251G>A, ENST00000638587.1:c.182G>A, ENST00000374574.2:c.251G>A, ENST00000374580.8:c.251G>A, ENST00000479069.1:n.158G>A, NM_001204.6:c.251G>A, LRG_712t1:c.251G>A, XM_011511687.1:c.251G>A, XM_011511688.1:c.251G>A, NM_001204.7(BMPR2):c.251G>A (p.Cys84Tyr)	BMPR2	pulmonary arterial hypertension	MONDO:0015924	Autosomal dominant inheritance	Pathogenic	PP3, PM2_Supporting, PS4_Moderate, PM1_Strong, PM5	PP2, BP1, BA1	NM_001204.7 (BMPR2):c.251G>A (p.Cys84Tyr)The BMPR2 c.251G>A variant is a missense variant predicted to cause a cysteine to tyrosine substitution at amino acid 84 (p.Cys84Tyr).The variant is absent from gnomAD controls v.2.1.1 and gnomAD v4.0.0 (PM2_supporting). Four unrelated pulmonary arterial hypertension probands were identified with this variant (PMID: 31727138, PMID: 29650961 and 2 identified in the internal ClinGen Pulmonary Hypertension VCEP database) (PS4_moderate). BMPR2 p.Cys84Tyr is located within the conserved extracellular domain and is a Cys residue critical for protein function (PMID: 16429395, PMID: 9886286) (PM1_strong). A different amino acid change at the same position (p.Cys84Phe) was classified as pathogenic (PMID: 21737554, PMID: 28507310) (PM5). Two more amino acid changes, p.Cys84Arg and p.Cys84Gly, were reported to be pathogenic (PMID: 19555857). In silico prediction (REVEL =0.951) is consistent with a pathogenic effect for this variant (PP3). In summary, the variant meets the criteria to be classified as pathogenic for pulmonary arterial hypertension based on the ACMG/AMP criteria applied, as specified by the ClinGen Pulmonary Hypertension VCEP: PM2_sup, PS4_mod, PM1_strong, PM5, PP3 (VCEP specification version 1.1, 1/18/2024).		Pulmonary Hypertension VCEP		2024-05-01	2024-05-01	False	https://erepo.genome.network/evrepo/ui/classification/CA350399510/MONDO:0015924/125	4db4a74b-0bdd-48e9-9e2a-3e8c5939e77c	p.Cys84Tyr	Cys	84	Tyr	MTSSLQRPWRVPWLPWTILLVSTAAASQNQERLCAFKDPYQQDLGIGESRISHENGTILCSKGSTCYGLWEKSKGDINLVKQGCWSHIGDPQECHYEECVVTTTPPSIQNGTYRFCCCSTDLCNVNFTENFPPPDTTPLSPPHSFNRDETIIIALASVSVLAVLIVALCFGYRMLTGDRKQGLHSMNMMEAAASEPSLDLDNLKLLELIGRGRYGAVYKGSLDERPVAVKVFSFANRQNFINEKNIYRVPLMEHDNIARFIVGDERVTADGRMEYLLVMEYYPNGSLCKYLSLHTSDWVSSCRLAHSVTRGLAYLHTELPRGDHYKPAISHRDLNSRNVLVKNDGTCVISDFGLSMRLTGNRLVRPGEEDNAAISEVGTIRYMAPEVLEGAVNLRDCESALKQVDMYALGLIYWEIFMRCTDLFPGESVPEYQMAFQTEVGNHPTFEDMQVLVSREKQRPKFPEAWKENSLAVRSLKETIEDCWDQDAEARLTAQCAEERMAELMMIWERNKSVSPTVNPMSTAMQNERNLSHNRRVPKIGPYPDYSSSSYIEDSIHHTDSIVKNISSEHSMSSTPLTIGEKNRNSINYERQQAQARIPSPETSVTSLSTNTTTTNTTGLTPSTGMTTISEMPYPDETNLHTTNVAQSIGPTPVCLQLTEEDLETNKLDPKEVDKNLKESSDENLMEHSLKQFSGPDPLSSTSSSLLYPLIKLAVEATGQQDFTQTANGQACLIPDVLPTQIYPLPKQQNLPKRPTSLPLNTKNSTKEPRLKFGSKHKSNLKQVETGVAKMNTINAAEPHVVTVTMNGVAGRNHSVNSHAATTQYANGTVLSGQTTNIVTHRAQEMLQNQFIGEDTRLNINSSPDEHEPLLRREQQAGHDEGVLDRLVDRRERPLEGGRTNSNNNNSNPCSEQDVLAQGVPSTAADPGPSKPRRAQRPNSLDLSATNVLDGSSIQIGESTQDGKSGSGEKIKKRVKTPYSLKRWRPSTWVISTESLDCEVNNNGSNRAVHSKSSTAVYLAEGGTATTMVSKDIGMNCL	1038	Q13873	Y	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [83], 'DISULFID_gain': [], 'DISULFID_loss_score': array([-0.87950253]), 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [48, 49, 50], 'STRAND_gain': [35, 60, 76, 87, 91, 92, 93, 94, 99, 100], 'STRAND_gain_score': array([0.07472354, 0.14338166, 0.09556818, 0.02316314, 0.2980085 ,
       0.28908575, 0.31582987, 0.18170464, 0.10741103, 0.09524077]), 'STRAND_loss_score': array([-0.04998404, -0.05397338, -0.058074  ]), 'HELIX_loss': [], 'HELIX_gain': [299], 'HELIX_gain_score': array([0.01152474]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
767	NM_001204.7(BMPR2):c.354T>G (p.Cys118Trp)	8799	CA278075	NM_001204.7:c.354T>G, NC_000002.12:g.202467625T>G, CM000664.2:g.202467625T>G, NC_000002.11:g.203332348T>G, CM000664.1:g.203332348T>G, NC_000002.10:g.203040593T>G, NG_009363.1:g.96299T>G, LRG_712:g.96299T>G, ENST00000374580.10:c.354T>G, ENST00000638587.1:c.285T>G, ENST00000374574.2:c.354T>G, ENST00000374580.8:c.354T>G, ENST00000479069.1:n.261T>G, NM_001204.6:c.354T>G, LRG_712t1:c.354T>G, XM_011511687.1:c.354T>G, XM_011511688.1:c.354T>G, NM_001204.7(BMPR2):c.354T>G (p.Cys118Trp)	BMPR2	pulmonary arterial hypertension	MONDO:0015924	Autosomal dominant inheritance	Pathogenic	PP1, PP3, PM2_Supporting, PS3, PS4, PM1_Strong, PM5_Supporting		The BMPR2 c.354T>C variant is a missense variant predicted to cause a cysteine to tryptophan substitution at amino acid position 118 (p.Cys118Trp). The variant is absent from gnomAD exomes v.2.1.1 controls and gnomAD genomes v3.0 (PM2_supporting). More than 4 unrelated pulmonary arterial hypertension probands were identified with this variant (PMID: 10973254, PMID: 32255665, PMID: 33007923, and PMID: 31727138) (PS4). In one multigenerational family, the variant segregated with PAH in at least 3 family members (PMID: 10973254) (PP1). BMPR2 p.Cys118Trp is located within the conserved extracellular domain and is a Cys residue critical for protein function (PMID: 9886286, PMID: 12221115, PMID: 12045205, PMID: 16429395) (PM1_strong). Several well-controlled in vitro functional assays provided variant-specific evidence of protein loss of function (PMID: 25688877, PMID: 12221115, and PMID: 32255665) (PS3). In silico prediction (REVEL =0.9279) is consistent with a pathogenic effect for this variant (PP3). Additionally, another variant in the same codon, BMPR2 (NM_001204.7):c.353G>A:(p.Cys118Tyr), was classified as likely pathogenic (PM5_supporting). In summary, the variant meets the criteria to be classified as pathogenic for pulmonary arterial hypertension based on the ACMG/AMP criteria applied, as specified by theClinGen Pulmonary Hypertension VCEP: PS3, PS4, PM1_strong, PM2_supporting, PM5_supporting, PP3, PP1 (VCEP specification version v 1.1, 1/18/2024).		Pulmonary Hypertension VCEP		2024-05-03	2024-05-03	False	https://erepo.genome.network/evrepo/ui/classification/CA278075/MONDO:0015924/125	82e7b757-e5df-4ae4-b47e-2d132ddd21cf	p.Cys118Trp	Cys	118	Trp	MTSSLQRPWRVPWLPWTILLVSTAAASQNQERLCAFKDPYQQDLGIGESRISHENGTILCSKGSTCYGLWEKSKGDINLVKQGCWSHIGDPQECHYEECVVTTTPPSIQNGTYRFCCCSTDLCNVNFTENFPPPDTTPLSPPHSFNRDETIIIALASVSVLAVLIVALCFGYRMLTGDRKQGLHSMNMMEAAASEPSLDLDNLKLLELIGRGRYGAVYKGSLDERPVAVKVFSFANRQNFINEKNIYRVPLMEHDNIARFIVGDERVTADGRMEYLLVMEYYPNGSLCKYLSLHTSDWVSSCRLAHSVTRGLAYLHTELPRGDHYKPAISHRDLNSRNVLVKNDGTCVISDFGLSMRLTGNRLVRPGEEDNAAISEVGTIRYMAPEVLEGAVNLRDCESALKQVDMYALGLIYWEIFMRCTDLFPGESVPEYQMAFQTEVGNHPTFEDMQVLVSREKQRPKFPEAWKENSLAVRSLKETIEDCWDQDAEARLTAQCAEERMAELMMIWERNKSVSPTVNPMSTAMQNERNLSHNRRVPKIGPYPDYSSSSYIEDSIHHTDSIVKNISSEHSMSSTPLTIGEKNRNSINYERQQAQARIPSPETSVTSLSTNTTTTNTTGLTPSTGMTTISEMPYPDETNLHTTNVAQSIGPTPVCLQLTEEDLETNKLDPKEVDKNLKESSDENLMEHSLKQFSGPDPLSSTSSSLLYPLIKLAVEATGQQDFTQTANGQACLIPDVLPTQIYPLPKQQNLPKRPTSLPLNTKNSTKEPRLKFGSKHKSNLKQVETGVAKMNTINAAEPHVVTVTMNGVAGRNHSVNSHAATTQYANGTVLSGQTTNIVTHRAQEMLQNQFIGEDTRLNINSSPDEHEPLLRREQQAGHDEGVLDRLVDRRERPLEGGRTNSNNNNSNPCSEQDVLAQGVPSTAADPGPSKPRRAQRPNSLDLSATNVLDGSSIQIGESTQDGKSGSGEKIKKRVKTPYSLKRWRPSTWVISTESLDCEVNNNGSNRAVHSKSSTAVYLAEGGTATTMVSKDIGMNCL	1038	Q13873	W	"{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [117], 'DISULFID_gain': [], 'DISULFID_loss_score': array([-0.89767617]), 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [35, 51, 60, 99, 100, 101, 102], 'STRAND_gain_score': array([0.08018857, 0.100941  , 0.12665093, 0.2657665 , 0.31145221,
       0.30986077, 0.25589424]), 'HELIX_loss': [], 'HELIX_gain': [245, 299, 467], 'HELIX_gain_score': array([0.01089364, 0.03449637, 0.00688142]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}"
768	NM_001204.7(BMPR2):c.2618G>A (p.Arg873Gln)	425999	CA2061553	NM_001204.7:c.2618G>A, NC_000002.12:g.202556283G>A, CM000664.2:g.202556283G>A, NC_000002.11:g.203421006G>A, CM000664.1:g.203421006G>A, NC_000002.10:g.203129251G>A, NG_009363.1:g.184957G>A, LRG_712:g.184957G>A, ENST00000374580.10:c.2618G>A, ENST00000638587.1:c.2549G>A, ENST00000374574.2:c.1586+3395G>A, ENST00000374580.8:c.2618G>A, NM_001204.6:c.2618G>A, LRG_712t1:c.2618G>A, XM_011511687.1:c.2618G>A, XM_011511688.1:c.1586+3395G>A, NM_001204.7(BMPR2):c.2618G>A (p.Arg873Gln)	BMPR2	pulmonary arterial hypertension	MONDO:0015924	Autosomal dominant inheritance	Benign	BS3_Supporting, BS1, BS4	PP3, BS2, BA1, BP4, PS4, PM2, PM1	The c.2618G>A variant (NM_001204.7) in BMPR2 is a missense variant predicted to cause substitution of arginine by glutamine at amino acid 873 (p.Arg873Gln). This variant has been reported not to segregate with pulmonary arterial hypertension in one affected family member from one family (BS4; Internal lab contributor). The highest population minor allele frequency in gnomAD v2.2.1 controls is 0.001595 in Other East Asian population, which is higher than the ClinGen Pulmonary Hypertension VCEP threshold (≥0.001) for BS1, and therefore meets this criterion (BS1). In vitro reporter system assay in mouse embryonic endothelial cells showed that the c.2618 G>A variant activate BRE-Luc (specific reporter gene for Smad1/5 activation) in response to BMP4 treatment in a similar way as the wild-type BMPR2 reporter gene. However the impairment of another function through an alternative signaling pathway of BMPRII could not be excluded (PMID 25429696)(BS3_Supporting). In summary, this variant meets the criteria to be classified as benign for pulmonary arterial hypertension based on the ACMG/AMP criteria applied, as specified by the ClinGen Pulmonary Hypertension VCEP (specification version 1.1, 1/18/2024): BS4, BS1, BS3_Supporting.		Pulmonary Hypertension VCEP		2024-05-03	2024-05-03	False	https://erepo.genome.network/evrepo/ui/classification/CA2061553/MONDO:0015924/125	1b0344d0-aad2-4412-a6e0-ab7c3c719261	p.Arg873Gln	Arg	873	Gln	MTSSLQRPWRVPWLPWTILLVSTAAASQNQERLCAFKDPYQQDLGIGESRISHENGTILCSKGSTCYGLWEKSKGDINLVKQGCWSHIGDPQECHYEECVVTTTPPSIQNGTYRFCCCSTDLCNVNFTENFPPPDTTPLSPPHSFNRDETIIIALASVSVLAVLIVALCFGYRMLTGDRKQGLHSMNMMEAAASEPSLDLDNLKLLELIGRGRYGAVYKGSLDERPVAVKVFSFANRQNFINEKNIYRVPLMEHDNIARFIVGDERVTADGRMEYLLVMEYYPNGSLCKYLSLHTSDWVSSCRLAHSVTRGLAYLHTELPRGDHYKPAISHRDLNSRNVLVKNDGTCVISDFGLSMRLTGNRLVRPGEEDNAAISEVGTIRYMAPEVLEGAVNLRDCESALKQVDMYALGLIYWEIFMRCTDLFPGESVPEYQMAFQTEVGNHPTFEDMQVLVSREKQRPKFPEAWKENSLAVRSLKETIEDCWDQDAEARLTAQCAEERMAELMMIWERNKSVSPTVNPMSTAMQNERNLSHNRRVPKIGPYPDYSSSSYIEDSIHHTDSIVKNISSEHSMSSTPLTIGEKNRNSINYERQQAQARIPSPETSVTSLSTNTTTTNTTGLTPSTGMTTISEMPYPDETNLHTTNVAQSIGPTPVCLQLTEEDLETNKLDPKEVDKNLKESSDENLMEHSLKQFSGPDPLSSTSSSLLYPLIKLAVEATGQQDFTQTANGQACLIPDVLPTQIYPLPKQQNLPKRPTSLPLNTKNSTKEPRLKFGSKHKSNLKQVETGVAKMNTINAAEPHVVTVTMNGVAGRNHSVNSHAATTQYANGTVLSGQTTNIVTHRAQEMLQNQFIGEDTRLNINSSPDEHEPLLRREQQAGHDEGVLDRLVDRRERPLEGGRTNSNNNNSNPCSEQDVLAQGVPSTAADPGPSKPRRAQRPNSLDLSATNVLDGSSIQIGESTQDGKSGSGEKIKKRVKTPYSLKRWRPSTWVISTESLDCEVNNNGSNRAVHSKSSTAVYLAEGGTATTMVSKDIGMNCL	1038	Q13873	Q	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [], 'HELIX_gain': [467], 'HELIX_gain_score': array([0.00210387]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [866, 867, 868], 'COMPBIAS_gain': [], 'COMPBIAS_loss_score': array([-0.21366584, -0.24060011, -0.24685436]), 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
769	NM_001204.7(BMPR2):c.1472G>A (p.Arg491Gln)	8806	CA278089	NM_001204.7:c.1472G>A, NC_000002.12:g.202552774G>A, CM000664.2:g.202552774G>A, NC_000002.11:g.203417497G>A, CM000664.1:g.203417497G>A, NC_000002.10:g.203125742G>A, NG_009363.1:g.181448G>A, LRG_712:g.181448G>A, ENST00000374580.10:c.1472G>A, ENST00000638587.1:c.1403G>A, ENST00000374574.2:c.1472G>A, ENST00000374580.8:c.1472G>A, NM_001204.6:c.1472G>A, LRG_712t1:c.1472G>A, XM_011511687.1:c.1472G>A, XM_011511688.1:c.1472G>A, NM_001204.7(BMPR2):c.1472G>A (p.Arg491Gln)	BMPR2	pulmonary arterial hypertension	MONDO:0015924	Autosomal dominant inheritance	Pathogenic	PP1, PP3, PM2_Supporting, PS4, PS2, PM1_Strong, PS3_Supporting, PM5	PP2, BA1, BP1, BP4, BP3, PS1, BP7, BS3, BS1, PM4	The NM_001204.7(BMPR2):c.1472G>A (p.Arg491Gln) variant is a missense variant predicted to cause an arginine to glutamine substitution at amino acid position 491. The variant is absent from gnomAD v2.1.1 and v3.1.2 controls (PM2_supporting). The variant co-segregated with PAH in a large Iberian family with at least four confirmed meioses (PP1; PMID: 30894412), is recurrent in more than four unrelated PAH patients (PS4; PMID: 20534176 and PMID: 29023671) and confirmed de novo in at least two probands with unaffected parents (PS2; PMID: 10903931 and PMID: 23298310). c.1472G>A resides in the conserved kinase domain of BMPR-II and changes an invariant and critical arginine residue at position 491 (PM1_Strong; PMID: 7768349, PMID: 34400635), likely impairing interaction with other BMP receptors. The functional assay evidence for a role in BMP receptor interactions was based on a PH VCEP approved luciferase activity assay but lacked known pathogenic and benign variant controls, so PS3 was scored at the supporting level (PS3_supporting; PMID: 18321866). A different amino acid change at the same position (p.Arg491Trp) was classified as pathogenic (PM5). PP3 was met based on a REVEL score of 0.962. In summary, this variant meets the criteria to be classified as pathogenic for pulmonary arterial hypertension based on ACMG/AMP criteria applied, as specified by the ClinGen Pulmonary Hypertension VCEP: PS2, PS3_supporting, PS4, PM1_strong, PM2_supporting, PM5, PP1, PP3 (VCEP specification version v 1.1, 1/18/2024).	31797984, 34400635	Pulmonary Hypertension VCEP		2024-05-03	2024-05-03	False	https://erepo.genome.network/evrepo/ui/classification/CA278089/MONDO:0015924/125	2649bacd-6839-4dbf-bad0-fa4462173e43	p.Arg491Gln	Arg	491	Gln	MTSSLQRPWRVPWLPWTILLVSTAAASQNQERLCAFKDPYQQDLGIGESRISHENGTILCSKGSTCYGLWEKSKGDINLVKQGCWSHIGDPQECHYEECVVTTTPPSIQNGTYRFCCCSTDLCNVNFTENFPPPDTTPLSPPHSFNRDETIIIALASVSVLAVLIVALCFGYRMLTGDRKQGLHSMNMMEAAASEPSLDLDNLKLLELIGRGRYGAVYKGSLDERPVAVKVFSFANRQNFINEKNIYRVPLMEHDNIARFIVGDERVTADGRMEYLLVMEYYPNGSLCKYLSLHTSDWVSSCRLAHSVTRGLAYLHTELPRGDHYKPAISHRDLNSRNVLVKNDGTCVISDFGLSMRLTGNRLVRPGEEDNAAISEVGTIRYMAPEVLEGAVNLRDCESALKQVDMYALGLIYWEIFMRCTDLFPGESVPEYQMAFQTEVGNHPTFEDMQVLVSREKQRPKFPEAWKENSLAVRSLKETIEDCWDQDAEARLTAQCAEERMAELMMIWERNKSVSPTVNPMSTAMQNERNLSHNRRVPKIGPYPDYSSSSYIEDSIHHTDSIVKNISSEHSMSSTPLTIGEKNRNSINYERQQAQARIPSPETSVTSLSTNTTTTNTTGLTPSTGMTTISEMPYPDETNLHTTNVAQSIGPTPVCLQLTEEDLETNKLDPKEVDKNLKESSDENLMEHSLKQFSGPDPLSSTSSSLLYPLIKLAVEATGQQDFTQTANGQACLIPDVLPTQIYPLPKQQNLPKRPTSLPLNTKNSTKEPRLKFGSKHKSNLKQVETGVAKMNTINAAEPHVVTVTMNGVAGRNHSVNSHAATTQYANGTVLSGQTTNIVTHRAQEMLQNQFIGEDTRLNINSSPDEHEPLLRREQQAGHDEGVLDRLVDRRERPLEGGRTNSNNNNSNPCSEQDVLAQGVPSTAADPGPSKPRRAQRPNSLDLSATNVLDGSSIQIGESTQDGKSGSGEKIKKRVKTPYSLKRWRPSTWVISTESLDCEVNNNGSNRAVHSKSSTAVYLAEGGTATTMVSKDIGMNCL	1038	Q13873	Q	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [381, 453, 454, 455, 471], 'HELIX_gain': [463], 'HELIX_gain_score': array([0.03067929]), 'HELIX_loss_score': array([-0.03095537, -0.13420314, -0.14128184, -0.07050645, -0.08638227]), 'COILED_loss': [], 'COILED_gain': [485], 'COILED_gain_score': array([0.08267099]), 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
770	NM_001204.7(BMPR2):c.901T>C (p.Ser301Pro)	228460	CA10576586	NM_001204.7:c.901T>C, NC_000002.12:g.202520135T>C, CM000664.2:g.202520135T>C, NC_000002.11:g.203384858T>C, CM000664.1:g.203384858T>C, NC_000002.10:g.203093103T>C, NG_009363.1:g.148809T>C, LRG_712:g.148809T>C, ENST00000374580.10:c.901T>C, ENST00000638587.1:c.832T>C, ENST00000374574.2:c.901T>C, ENST00000374580.8:c.901T>C, NM_001204.6:c.901T>C, LRG_712t1:c.901T>C, XM_011511687.1:c.901T>C, XM_011511688.1:c.901T>C, NM_001204.7(BMPR2):c.901T>C (p.Ser301Pro)	BMPR2	pulmonary arterial hypertension	MONDO:0015924	Autosomal dominant inheritance	Pathogenic	PM2_Supporting, PS3, PS4, PM6, PM1	PP3, BS2, BA1, BP4, BS1	The c.901T>C variant (NM_001204.7) in BMPR2 is a missense variant predicted to cause substitution of serine by proline at amino acid 301 (p.Ser301Pro). The variant is absent from gnomAD v2.1.1 and v3.1.2 controls (PM2_supporting).The variant has been identified in 5 probands, meeting the PH VCEP threshold for PS4 (>4 pro bands; PMIDs 16429395, 18356561, 25917481, 29743074, and PH VCEP internal lab contributors). The variant has been identified as a de novo occurrence in one individual with pulmonary arterial hypertension and unconfirmed parental relationships  (PM6; PMID 29743074). Immunostaining in Hela cells transfected with a FLAG-tagged c.901C>T BMPR2 expression construct demonstrated impaired subcellular trafficking of BMPRII (PMID: 25688877) and Western-blot analysis of pulmonary artery smooth muscle cells isolated from a patient with the c.901C>T variant showed no BMP4-induced phosphorylation of Smad1/5/8 (PMID: 19324947), indicating an effect on protein function (PS3). This variant resides in a conserved kinase domain (amino acids 203 – 504) but is not defined as a critical residue by the ClinGen PH VCEP (PM1_moderate). In summary, this variant meets the criteria to be classified as pathogenic for pulmonary arterial hypertension based on the ACMG/AMP criteria applied, as specified by the ClinGen Pulmonary Hypertension VCEP (specification version 1.0): PS4, PM6, PM2_Supporting, PS3, PM1_moderate).		Pulmonary Hypertension VCEP		2024-05-03	2024-05-03	False	https://erepo.genome.network/evrepo/ui/classification/CA10576586/MONDO:0015924/125	35456c4e-ef26-4ca0-902b-0d0270033b01	p.Ser301Pro	Ser	301	Pro	MTSSLQRPWRVPWLPWTILLVSTAAASQNQERLCAFKDPYQQDLGIGESRISHENGTILCSKGSTCYGLWEKSKGDINLVKQGCWSHIGDPQECHYEECVVTTTPPSIQNGTYRFCCCSTDLCNVNFTENFPPPDTTPLSPPHSFNRDETIIIALASVSVLAVLIVALCFGYRMLTGDRKQGLHSMNMMEAAASEPSLDLDNLKLLELIGRGRYGAVYKGSLDERPVAVKVFSFANRQNFINEKNIYRVPLMEHDNIARFIVGDERVTADGRMEYLLVMEYYPNGSLCKYLSLHTSDWVSSCRLAHSVTRGLAYLHTELPRGDHYKPAISHRDLNSRNVLVKNDGTCVISDFGLSMRLTGNRLVRPGEEDNAAISEVGTIRYMAPEVLEGAVNLRDCESALKQVDMYALGLIYWEIFMRCTDLFPGESVPEYQMAFQTEVGNHPTFEDMQVLVSREKQRPKFPEAWKENSLAVRSLKETIEDCWDQDAEARLTAQCAEERMAELMMIWERNKSVSPTVNPMSTAMQNERNLSHNRRVPKIGPYPDYSSSSYIEDSIHHTDSIVKNISSEHSMSSTPLTIGEKNRNSINYERQQAQARIPSPETSVTSLSTNTTTTNTTGLTPSTGMTTISEMPYPDETNLHTTNVAQSIGPTPVCLQLTEEDLETNKLDPKEVDKNLKESSDENLMEHSLKQFSGPDPLSSTSSSLLYPLIKLAVEATGQQDFTQTANGQACLIPDVLPTQIYPLPKQQNLPKRPTSLPLNTKNSTKEPRLKFGSKHKSNLKQVETGVAKMNTINAAEPHVVTVTMNGVAGRNHSVNSHAATTQYANGTVLSGQTTNIVTHRAQEMLQNQFIGEDTRLNINSSPDEHEPLLRREQQAGHDEGVLDRLVDRRERPLEGGRTNSNNNNSNPCSEQDVLAQGVPSTAADPGPSKPRRAQRPNSLDLSATNVLDGSSIQIGESTQDGKSGSGEKIKKRVKTPYSLKRWRPSTWVISTESLDCEVNNNGSNRAVHSKSSTAVYLAEGGTATTMVSKDIGMNCL	1038	Q13873	P	{'ACT_SITE_loss': [], 'ACT_SITE_gain': [], 'BINDING_loss': [], 'BINDING_gain': [], 'DNA_BIND_loss': [], 'DNA_BIND_gain': [], 'TOPO_DOM_loss': [], 'TOPO_DOM_gain': [], 'TRANSMEM_loss': [], 'TRANSMEM_gain': [], 'DISULFID_loss': [], 'DISULFID_gain': [], 'PROPEP_loss': [], 'PROPEP_gain': [], 'SIGNAL_loss': [], 'SIGNAL_gain': [], 'TRANSIT_loss': [], 'TRANSIT_gain': [], 'STRAND_loss': [], 'STRAND_gain': [], 'HELIX_loss': [297, 298], 'HELIX_gain': [], 'HELIX_loss_score': array([-0.47075582, -0.62242401]), 'COILED_loss': [], 'COILED_gain': [], 'COMPBIAS_loss': [], 'COMPBIAS_gain': [], 'DOMAIN_loss': [], 'DOMAIN_gain': [], 'REGION_loss': [], 'REGION_gain': [], 'REPEAT_loss': [], 'REPEAT_gain': [], 'ZN_FING_loss': [], 'ZN_FING_gain': []}
